category	mir	disease	pmid	root_name	doid	icd10cm	mesh	omim	hpo	description
circulation_biomarker_diagnosis_down	hsa-mir-210	Acute Cerebral Infarction	25476086	cardiovascular system disease	DOID:3526	I63	D002544			The serum level of miR-210 in ACI was significantly lower than that in normal healthy persons, and it may be an important new serological marker in screening and diagnosis of ACI.
circulation_biomarker_diagnosis_down	hsa-mir-126	Acute Heart Failure	26580972			I50				Levels of miR-126  and miR-423-5p were lower in AHF and in non-AHF patients compared to stable CHF patients (both p<0.001).
circulation_biomarker_diagnosis_down	hsa-mir-27a	Acute Heart Failure	26569364			I50				The increase in creatinine during the first 3 days of hospitalization was significantly associated with lower levels of miR-199a-3p, miR-27a-3p, miR-652-3p, miR-423-5p, and miR-let-7i-5p
circulation_biomarker_diagnosis_down	hsa-mir-335	Acute Ischemic Stroke	27856935	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Decreased plasma miR-335 expression in patients with acute ischemic stroke and its association with calmodulin expression.
circulation_biomarker_diagnosis_down	hsa-mir-214	Acute Myocardial Infarction	25931214	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	The circulating level of miR-214 was significantly decreased in the AMI group, which might be correlated with the extent of the coronary lesion.Circulating miR-214 may be a promising biomarker for the diagnosis and prognosis of severe AMI.
circulation_biomarker_diagnosis_down	hsa-mir-181a	Allergic Rhinitis	27199509	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	The OPN protein and miR-181a levels may serve as predictors of disease severity in childhood AR and appear to be promising targets for modulating AR.
circulation_biomarker_diagnosis_down	hsa-let-7f	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-1285	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-107	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-103a	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-26b	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-26a	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-532	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-143	Alzheimer Disease	26078483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Alzheimer Disease	26078483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-31	Alzheimer Disease	26078483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-590	Alzheimer Disease	21548758	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Decreased relative expression levels of hsa-miR-590-3p in blood cells was observed in patients with AD versus controls. hnRNP-A1 and its transcription regulatory factor miR-590-3p are disregulated in patients with AD, and the hnRNP-A1 rs7967622 C/C genotype is likely a risk factor for FTLD in male populations.
circulation_biomarker_diagnosis_down	hsa-mir-93	Alzheimer Disease	26078483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-4505	Anxiety Disorders	27423364	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Results showed that the level of miR-4505 and miR-663 was negatively correlated with the  total HAMA scores in GAD patients (r=0.2228, r=0.264 P<0.05).
circulation_biomarker_diagnosis_down	hsa-mir-663	Anxiety Disorders	27423364	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	esults showed that the level of miR-4505 and miR-663 was negatively correlated with the  total HAMA scores in GAD patients (r=0.2228, r=0.264 P<0.05).
circulation_biomarker_diagnosis_down	hsa-mir-106a	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-148a	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-204	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-211	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-30a	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-31	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-424	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-204	Aortic Valve Disease	28377507	cardiovascular system disease	DOID:62			PS109730		miR-486 inhibits Smurf2 expression to augment the miR-204 down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-1	Arrhythmia	25625292			I49.9	D001145	600919	HP:0011675	patients with SVT had lower miR-1 expression levels while those with VT had higher miR-133 expression levels.
circulation_biomarker_diagnosis_down	hsa-mir-148a	Asthma	17847008	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del.
circulation_biomarker_diagnosis_down	hsa-mir-148b	Asthma	17847008	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del.
circulation_biomarker_diagnosis_down	hsa-mir-152	Asthma	17847008	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del.
circulation_biomarker_diagnosis_down	hsa-mir-126	Atherosclerosis	25975504	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-126 and miR-223 platelets were reduced in the rabbit atherosclerotic plaque model group
circulation_biomarker_diagnosis_down	hsa-mir-145	Atherosclerosis	19744308	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-181b	Atherosclerosis	26420120	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The serum miR-181b level was significantly reduced in patients with atherosclerosis. miR-181b may function as an atherosclerosis suppressor by interupting the NF-κB pathway in endothelial cells and inhibiting the proliferation and migration of vascular smooth muscle cells.
circulation_biomarker_diagnosis_down	hsa-mir-181b	Atherosclerosis	25896908	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Hyperlipidemia reduced the expression of miR-181b and increased  NT and N/M ratio.
circulation_biomarker_diagnosis_down	hsa-mir-182	Atherosclerosis	27199451	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Atherosclerotic lesions from patients with high asymmetrical dimethylarginine plasma levels exhibited decreased miR-182-3p expression levels and elevated MYADM expression levels.
circulation_biomarker_diagnosis_down	hsa-mir-30	Atherosclerosis	27379414	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	circulating miR-30 might be used as a biomarker for atherosclerosis
circulation_biomarker_diagnosis_down	hsa-mir-181b	Autism Spectrum Disorder	25126405	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	MiR-151a-3p, miR-181b-5p, miR-320a, miR-328, miR-433, miR-489, miR-572, and miR-663a were downregulated, while miR-101-3p, miR-106b-5p, miR-130a-3p, miR-195-5p, and miR-19b-3p were upregulated.
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Autistic Disorder	20868653	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-181b:deregulated
circulation_biomarker_diagnosis_down	hsa-mir-363	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-363: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-486	Autistic Disorder	20868653	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-486:deregulated
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-92a-1: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-92a-2	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-92a-2: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-1	Bladder Neoplasms	25015192			C67	D001749	109800	HP:0009725	Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer.
circulation_biomarker_diagnosis_down	hsa-mir-107	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-10b	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-125b-1	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-125b-2	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-143	Breast Neoplasms	17940623	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines.
circulation_biomarker_diagnosis_down	hsa-mir-145	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-145	Breast Neoplasms	16885332	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Reduced expression in breast cancers
circulation_biomarker_diagnosis_down	hsa-mir-145	Breast Neoplasms	17940623	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines.
circulation_biomarker_diagnosis_down	hsa-mir-1469	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-1471	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-17	Breast Neoplasms	17442096	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In breast cancer cells, mir-17-5p expression is decreased.
circulation_biomarker_diagnosis_down	hsa-mir-17	Breast Neoplasms	17965831	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-17-5p was down-regulated in breast cancer cells, and enhanced expression decreased tumour cell proliferation.
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Breast Neoplasms	22692639	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Decreased serum miR-181a is a potential new tool for breast cancer screening.
circulation_biomarker_diagnosis_down	hsa-mir-182	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-1915	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-193a	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-193a-3p is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-195	Breast Neoplasms	25103018	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.
circulation_biomarker_diagnosis_down	hsa-mir-200c	Breast Neoplasms	27197674	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas  miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed.
circulation_biomarker_diagnosis_down	hsa-mir-21	Breast Neoplasms	23052693	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer
circulation_biomarker_diagnosis_down	hsa-mir-210	Breast Neoplasms	27197674	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas  miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed.
circulation_biomarker_diagnosis_down	hsa-mir-222	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-222: decreased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_down	hsa-mir-2355	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-24-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-24-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-30a	Breast Neoplasms	23389917	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	plasma; plasma miRNA-30a decreased in patients with BC and has great potential to use as novel biomarkers for BC diagnosis
circulation_biomarker_diagnosis_down	hsa-mir-3130-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-3130-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-3186	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-526a-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-526a-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-625	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-625* is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-718	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-874	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Breast Neoplasms	23052693	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer
circulation_biomarker_diagnosis_down	hsa-mir-92a-2	Breast Neoplasms	23052693	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer
circulation_biomarker_diagnosis_down	hsa-mir-100	Carcinoma, Adrenocortical	21472710	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors.
circulation_biomarker_diagnosis_down	hsa-mir-218	Carcinoma, Esophageal	25812647	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The serum expression of miR-218 is downregulated in esophageal cancer patients and is correlated with tumor differentiation, stage, and lymph node metastasis. Serum miR-218 may be a potential biomarker for early detection and clinical evaluation in patient with esophageal cancer.
circulation_biomarker_diagnosis_down	hsa-let-7e	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|ив, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes.
circulation_biomarker_diagnosis_down	hsa-mir-125a	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|ив, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes.
circulation_biomarker_diagnosis_down	hsa-mir-127	Carcinoma, Hepatocellular	18942116	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-127: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Carcinoma, Hepatocellular	21278583	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-16-2	Carcinoma, Hepatocellular	21278583	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-199a-1	Carcinoma, Hepatocellular	21278583	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-199a-2	Carcinoma, Hepatocellular	21278583	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-200b	Carcinoma, Hepatocellular	18942116	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-200b: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet
circulation_biomarker_diagnosis_down	hsa-mir-21	Carcinoma, Hepatocellular	21749846	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In the 10-patient group, plasma microRNA-21 levels significantly diminished after surgery compared with the pre-operative values (p=0.0125). Plasma microRNA-21 level in the 126 patients with hepatocellular carcinoma was significantly higher than in patients with chronic hepatitis and healthy volunteers (p<0.0001, p<0.0001, respectively). ROC analysis of plasma microRNA-21 yielded an AUC of 0.773 with 61.1% sensitivity and 83.3% specificity when differentiating hepatocellular carcinoma from chronic hepatitis, and an AUC of 0.953 with 87.3% sensitivity and 92.0% specificity when differentiating hepatocellular carcinoma from healthy volunteers.
circulation_biomarker_diagnosis_down	hsa-mir-34a	Carcinoma, Hepatocellular	18942116	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-34a: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet
circulation_biomarker_diagnosis_down	hsa-mir-99b	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|ив, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes.
circulation_biomarker_diagnosis_down	hsa-mir-125b	Carcinoma, Hepatocellular, HBV-Related	27152955							The levels of plasma miR-125b were remarkably decreased in HBV-HCC patients compared to healthy controls
circulation_biomarker_diagnosis_down	hsa-mir-106a	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-146b	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-223	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	Reduced plasma expression of let-7b was modestly associated with worse cancer-specific mortality in all patients and reduced serum expression of miR-223 was modestly associated with cancer-specific mortality in stage IA/B patients.
circulation_biomarker_diagnosis_down	hsa-mir-27a	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-361	Carcinoma, Lung, Non-Small-Cell	22675530			C34.90	D002289		HP:0030358	Low levels of cell-free circulating miR-361-3p and miR-625* could be blood-based markers for discriminating malignant from benign lung tumors.
circulation_biomarker_diagnosis_down	hsa-mir-625	Carcinoma, Lung, Non-Small-Cell	22675530			C34.90	D002289		HP:0030358	Low levels of cell-free circulating miR-361-3p and miR-625* could be blood-based markers for discriminating malignant from benign lung tumors.
circulation_biomarker_diagnosis_down	hsa-let-7a-1	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7a-1	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7a-2	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7a-2	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7b	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7c	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7d	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7e	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7f-1	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7f-1	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7f-2	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7f-2	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7g	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7i	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-141	Carcinoma, Renal Cell	18925646	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-141: down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-142	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-142-5p: Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-150	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-19a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-200c	Carcinoma, Renal Cell	18925646	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-200c: down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-219	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-219-5p: Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-26a-1	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-26a-2	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-302b	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-302c	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-30c-1	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-30c-2	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-367	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-381	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-451a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-508	Carcinoma, Renal Cell	22369946	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro.
circulation_biomarker_diagnosis_down	hsa-mir-509-1	Carcinoma, Renal Cell	22369946	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro.
circulation_biomarker_diagnosis_down	hsa-mir-509-2	Carcinoma, Renal Cell	22369946	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro.
circulation_biomarker_diagnosis_down	hsa-mir-509-3	Carcinoma, Renal Cell	22369946	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro.
circulation_biomarker_diagnosis_down	hsa-mir-1-1	Cardiomyopathy, Hypertrophic	17234972	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Significantly,the muscle-specific microRNA-1 (miR-1) was singularly downregulatedas early as day 1, persisting through day7, after aortic constriction Cinduced hypertrophy in a mouse model.
circulation_biomarker_diagnosis_down	hsa-mir-1-1	Cardiomyopathy, Hypertrophic	17468766	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-1-1	Cardiomyopathy, Hypertrophic	17479098	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue.
circulation_biomarker_diagnosis_down	hsa-mir-1-2	Cardiomyopathy, Hypertrophic	17234972	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Significantly,the muscle-specific microRNA-1 (miR-1) was singularly downregulatedas early as day 1, persisting through day7, after aortic constriction Cinduced hypertrophy in a mouse model.
circulation_biomarker_diagnosis_down	hsa-mir-1-2	Cardiomyopathy, Hypertrophic	17468766	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-1-2	Cardiomyopathy, Hypertrophic	17479098	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue.
circulation_biomarker_diagnosis_down	hsa-mir-133a-1	Cardiomyopathy, Hypertrophic	17468766	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-133a-1	Cardiomyopathy, Hypertrophic	17479098	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue.
circulation_biomarker_diagnosis_down	hsa-mir-133a-2	Cardiomyopathy, Hypertrophic	17468766	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-133a-2	Cardiomyopathy, Hypertrophic	17479098	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue.
circulation_biomarker_diagnosis_down	hsa-mir-126	Cardiovascular Diseases [unspecific]	28065883				D002318			Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy.
circulation_biomarker_diagnosis_down	hsa-mir-132	Cardiovascular Diseases [unspecific]	28065883				D002318			Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy.
circulation_biomarker_diagnosis_down	hsa-mir-320b	Carotid Artery Diseases	27460454			G45.1	D002340	147820	HP:0005344	Low serum miR-320b expression as a novel indicator of carotid atherosclerosis.
circulation_biomarker_diagnosis_down	hsa-mir-106b	Child Development Disorders, Pervasive	20374639			F84.9	D002659			down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-106a	Cholangiocarcinoma	26534789	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Together, reduced expression of serum miR-106a is a powerful prognostic indicator for CCA patients. The dismal outcome of these CCA patients might correlate with a higher risk of lymph node metastasis.
circulation_biomarker_diagnosis_down	hsa-mir-150	Cholangiocarcinoma	27658773	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
circulation_biomarker_diagnosis_down	hsa-mir-194	Cholangiocarcinoma	26864161	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-483-5p and miR-194 showed deregulated expression in CC compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-483	Cholangiocarcinoma	26864161	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	whereas miR-483-5p and miR-194 showed deregulated expression in CC compared with controls
circulation_biomarker_diagnosis_down	hsa-mir-199b	Choriocarcinoma	19900756	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	miR-199b:Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma
circulation_biomarker_diagnosis_down	hsa-mir-155	Chronic Hepatitis B	27110261			B18.0-.1	D019694	610424		In the HBV-infected patients, the miR-155 levels were significantly lower than in the healthy controls
circulation_biomarker_diagnosis_down	hsa-mir-143	Colon Neoplasms	16195701			D12.6	D003110		HP:0100273	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-143	Colon Neoplasms	16885332			D12.6	D003110		HP:0100273	miR-143 and miR-145 expression is reduced.
circulation_biomarker_diagnosis_down	hsa-mir-143	Colon Neoplasms	16940181			D12.6	D003110		HP:0100273	Downregulation of Mir-143 and Mir-145 has been observed in colorectal cancer.
circulation_biomarker_diagnosis_down	hsa-mir-143	Colon Neoplasms	17940623			D12.6	D003110		HP:0100273	Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines.
circulation_biomarker_diagnosis_down	hsa-mir-145	Colon Neoplasms	16195701			D12.6	D003110		HP:0100273	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-145	Colon Neoplasms	16940181			D12.6	D003110		HP:0100273	Downregulation of Mir-143 and Mir-145 has beenobserved in colorectal cancer.
circulation_biomarker_diagnosis_down	hsa-mir-145	Colon Neoplasms	17940623			D12.6	D003110		HP:0100273	Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines.
circulation_biomarker_diagnosis_down	hsa-mir-221	Colorectal Carcinoma	29630521	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Following the overexpression of GAS5, the GAS5expressions was up-regulated and miR-221 expression was down-regulated; the rate  of cell proliferation, migration and invasion were decreased
circulation_biomarker_diagnosis_down	hsa-mir-143	Colorectal Carcinoma	16847880	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		reduced
circulation_biomarker_diagnosis_down	hsa-mir-143	Colorectal Carcinoma	19242066	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-143: only down-regulated in colon cancer but not in rectal cancer
circulation_biomarker_diagnosis_down	hsa-mir-145	Colorectal Carcinoma	16847880	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		reduced
circulation_biomarker_diagnosis_down	hsa-mir-145	Colorectal Carcinoma	19242066	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-145: down-regulated in both colon and rectal cancer
circulation_biomarker_diagnosis_down	hsa-mir-34a	Colorectal Carcinoma	22648208	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-34a levels are reduced in colorectal cancer.
circulation_biomarker_diagnosis_down	hsa-mir-126	Coronary Artery Disease	29062343	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-126 expression was significantly down-regulated in the circulation of CAD patients compared with control subjects
circulation_biomarker_diagnosis_down	hsa-mir-126	Coronary Artery Disease	27321479	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-126 strongly associated with T2D and CAD
circulation_biomarker_diagnosis_down	hsa-mir-145	Coronary Artery Disease	25938589	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Lower plasma levels of miRNA-145 were significantly associated with the presence as well as severity of CAD. As a potential biomarker for CAD, plasma miRNA-145 may be useful in predicting CAD and its severity in patients presenting with chest pain.
circulation_biomarker_diagnosis_down	hsa-let-7b	Crohn Disease	24910152	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD.
circulation_biomarker_diagnosis_down	hsa-mir-378	Dengue Virus Infection	26166761	disease by infectious agent	DOID:12205	A90	D003715	614371		This study found that miR-27a*, miR-30e, and miR-378 were down-regulated in DENV-infected patients
circulation_biomarker_diagnosis_down	hsa-mir-107	Diabetes Mellitus	24908639	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients.
circulation_biomarker_diagnosis_down	hsa-mir-126	Diabetes Mellitus	26299579	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Diabetes mellitus
circulation_biomarker_diagnosis_down	hsa-mir-126	Diabetes Mellitus	27005938	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Among those, miR-126 and miR-26a were significantly reduced in diabetic patients compared to non-diabetic patients.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Diabetes Mellitus	24908639	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients.
circulation_biomarker_diagnosis_down	hsa-mir-155	Diabetes Mellitus	26188366	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Downregulated microRNA-155 expression in peripheral blood mononuclear cells of type 2 diabetic patients is not correlated with increased inflammatory cytokine production.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Diabetes Mellitus	26460159	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	These results demonstrated that peripheral blood miR-15a expression levels were significantly lower in patients with T2D and IFG/IGT individuals, compared with healthy individuals. Thus, miR-15a in peripheral whole blood may serve as a potential biomarker for T2D and pre-diabetes.
circulation_biomarker_diagnosis_down	hsa-mir-223	Diabetes Mellitus	24908639	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients.
circulation_biomarker_diagnosis_down	hsa-mir-375	Diabetes Mellitus	27383196	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	lower circulating levels of miR-192 and miR-375 compared to CD period
circulation_biomarker_diagnosis_down	hsa-mir-495	Diabetes Mellitus	24908639	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients.
circulation_biomarker_diagnosis_down	hsa-mir-503	Diabetes Mellitus	21220732	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Deregulation of microRNA-503 Contributes to Diabetes Mellitus-Induced Impairment of Endothelial Function and Reparative Angiogenesis After Limb Ischemia.
circulation_biomarker_diagnosis_down	hsa-mir-146	Diabetes Mellitus, Type 1	24796653	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Decreased miR-146 expression in peripheral blood mononuclear cells is correlated  with ongoing islet autoimmunity in type 1 diabetes patients 1miR-146.
circulation_biomarker_diagnosis_down	hsa-mir-126	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-126	Diabetes Mellitus, Type 2	27321479	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	expression levels of circulating miR-126, determined by quantitative real time PCR, were decrease in peripheral blood of T2D patients and T2D with CAD compared  with healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Diabetes Mellitus, Type 2	25500583	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased serum anti-inflammatory miR-146a, increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair factor) as discriminating markers of failure of glucose control occurring on the  background of obesity and dyslipidemia.
circulation_biomarker_diagnosis_down	hsa-mir-155	Diabetes Mellitus, Type 2	25500583	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased serum anti-inflammatory miR-146a, increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair factor) as discriminating markers of failure of glucose control occurring on the  background of obesity and dyslipidemia.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-191	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-197	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-20b	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-21	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-223	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-24-1	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-24-2	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-320a	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-486	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-517a	Ectopic Pregnancy	22395025	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%).
circulation_biomarker_diagnosis_down	hsa-mir-519d	Ectopic Pregnancy	22395025	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%).
circulation_biomarker_diagnosis_down	hsa-mir-525	Ectopic Pregnancy	22395025	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%).
circulation_biomarker_diagnosis_down	hsa-mir-17	Endometriosis	23203215	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis
circulation_biomarker_diagnosis_down	hsa-mir-20a	Endometriosis	23203215	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis
circulation_biomarker_diagnosis_down	hsa-mir-20a	Endometriosis	27049094	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	For recurred cases, miR-199 showed a remarkably high expression and miR-17-5p and miR-20a expressed significantly low.
circulation_biomarker_diagnosis_down	hsa-mir-22	Endometriosis	23203215	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis
circulation_biomarker_diagnosis_down	hsa-let-7c	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-144	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-144*: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-193a	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-193a-5p and miR-193a-3p: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-193b	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-203	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-210	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-211	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-30a	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-30a-3p: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-365a	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-375	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		The most downregulated miRNA, which strongly correlated with esophageal eosinophil levels.
circulation_biomarker_diagnosis_down	hsa-let-7d	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_down	hsa-mir-107	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_down	hsa-mir-148b	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_down	hsa-mir-146b	Fatty Liver, Non-Alcoholic	25232454	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miR-181d, miR-99a, miR-197 and miR-146b were significantly lower in biopsy-proven NAFLD patients than in the healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-155	Fatty Liver, Non-Alcoholic	27832630	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity.
circulation_biomarker_diagnosis_down	hsa-mir-29a	Fatty Liver, Non-Alcoholic	25232454	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miR-181d, miR-99a, miR-197 and miR-146b were significantly lower in biopsy-proven NAFLD patients than in the healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-203	Gastric Neoplasms	26233325	disease of cellular proliferation	DOID:10534	C16	D013274	137215		serum miR-203 levels were significantly lower in stage IV than stage I-III GC patients.
circulation_biomarker_diagnosis_down	hsa-mir-218-1	Gastric Neoplasms	22860003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-218-2	Gastric Neoplasms	22860003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-421	Gastric Neoplasms	22926798	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Gastric juice microRNA-421 is a new biomarker for screening gastric cancer.
circulation_biomarker_diagnosis_down	hsa-mir-101-1	Glioblastoma	21321380				D005909		HP:0100843	miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.
circulation_biomarker_diagnosis_down	hsa-mir-101-2	Glioblastoma	21321380				D005909		HP:0100843	miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.
circulation_biomarker_diagnosis_down	hsa-mir-342	Glioblastoma	21561454				D005909		HP:0100843	miR-342-3p: downregulated in the peripheral blood of glioblastoma patients.
circulation_biomarker_diagnosis_down	hsa-mir-205	Glioma	26230475	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
circulation_biomarker_diagnosis_down	hsa-mir-200a	Glomerulonephritis	20364043	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-200b	Glomerulonephritis	20364043	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-429	Glomerulonephritis	20364043	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-154	Graves Disease	22456620	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission.
circulation_biomarker_diagnosis_down	hsa-mir-376b	Graves Disease	22456620	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission.
circulation_biomarker_diagnosis_down	hsa-mir-431	Graves Disease	22456620	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission.
circulation_biomarker_diagnosis_down	hsa-mir-126	Heart Failure	21157109			I50	D006331		HP:0001635	The plasma concentration of miR-126 was negatively correlated with age and NYHA class, and could be a useful biomarker for heart failure
circulation_biomarker_diagnosis_down	hsa-mir-130b	Heart Failure	26211628			I50	D006331		HP:0001635	MiR-130b levels were reduced in obese HF patients compared with HF lean (P=0.036) and controls (P=0.025).
circulation_biomarker_diagnosis_down	hsa-mir-133	Heart Failure	23711953			I50	D006331		HP:0001635	In surgical CAD patients, a decreased miR-133 expression is associated with variables characteristic of heart failure.
circulation_biomarker_diagnosis_down	hsa-mir-16	Heart Failure	25033200			I50	D006331		HP:0001635	We provide evidence that miR-16 decreases in the circulation of end-stage HF patients and increases with a LVAD. Modeling studies suggest that miR-16 binds to and decreases expression of VPS4a. Overexpression of VPS4a decreases cell number. Together, these experiments suggest that miR-16 and VPS4a expression are altered in end-stage HF and in response to unloading with a LVAD. This signaling pathway may lead to reduced circulating cell number in HF.
circulation_biomarker_diagnosis_down	hsa-mir-27a	Heart Failure	28293796			I50	D006331		HP:0001635	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations.
circulation_biomarker_diagnosis_down	hsa-mir-424	Hemangioma	21179471	disease of cellular proliferation	DOID:255	D18.0	D006391	602089		Down-Regulation of mir-424 Contributes to the Abnormal Angiogenesis via MEK1 and Cyclin E1 in Senile Hemangioma: Its Implications to Therapy.
circulation_biomarker_diagnosis_down	hsa-mir-155	Hepatitis C Virus Infection	22846613	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection.
circulation_biomarker_diagnosis_down	hsa-mir-106b	Human Immunodeficiency Virus Infection	26755399			B20	D015658	609423		we found that the miRNAs miR-106b and miR-20a that target p21  were specifically downregulated in HIV-1 infected CD4+ T cells.
circulation_biomarker_diagnosis_down	hsa-mir-125b-1	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-125b-2	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-150	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-181a	Human Immunodeficiency Virus Infection	27171002			B20	D015658	609423		hsa-miR-155 and hsa-miR-181a were downregulated in VP whereas in the other groups, either an upregulation or no differences were observed after stimulation, respectively.
circulation_biomarker_diagnosis_down	hsa-mir-20a	Human Immunodeficiency Virus Infection	26755399			B20	D015658	609423		we found that the miRNAs miR-106b and miR-20a that target p21  were specifically downregulated in HIV-1 infected CD4+ T cells.
circulation_biomarker_diagnosis_down	hsa-mir-28	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-382	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-133b	Hypertension	21924071	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples.
circulation_biomarker_diagnosis_down	hsa-mir-296	Hypertension	21924071	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples.
circulation_biomarker_diagnosis_down	hsa-mir-1-1	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_down	hsa-mir-1-2	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_down	hsa-mir-133a-1	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_down	hsa-mir-133a-2	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_down	hsa-mir-374a	Hypoxic-Ischemic Encephalopathy	26001314			P91.60	D020925			We have shown a significant step-wise downregulation of hsa-miR-374a expression in cord blood of infants with perinatal asphyxia and subsequent HIE.
circulation_biomarker_diagnosis_down	hsa-mir-200b	Kideny Transplant Rejection	27521993			T86.11	D006084			our findings indicated that the aberrant urinary miR-21 and miR-200b expression levels were accompanied with renal allograft dysfunction and IFTA.
circulation_biomarker_diagnosis_down	hsa-mir-106	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-10a	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-10b	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-126	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-17	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-181a*: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-199b	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-199b: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-20	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-21	Leukemia	24141112			C95	D007938	613065	HP:0001909	Moreover, the down-regulated expression of microRNA-21 in DF-1 chicken fibroblast cells infected with subgroup J avian leukemia virus (ALVs) was confirmed by the developed method, indicating that microRNA-21 might be a new biomarker for avian leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-27a	Leukemia	21070600			C95	D007938	613065	HP:0001909	Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.
circulation_biomarker_diagnosis_down	hsa-mir-331	Leukemia	21070600			C95	D007938	613065	HP:0001909	Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.
circulation_biomarker_diagnosis_down	hsa-mir-378a	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-378: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-454	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-454-3p: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-575	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-575: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-663	Leukemia	27535859			C95	D007938	613065	HP:0001909	The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL.
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Lymphoblastic	18056805	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML.
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Lymphoblastic	27535859	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL.
circulation_biomarker_diagnosis_down	hsa-mir-18a	Leukemia, Lymphoblastic, Acute	29068867	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Low Expression of miR-18a as a Characteristic of Pediatric Acute Lymphoblastic Leukemia.
circulation_biomarker_diagnosis_down	hsa-let-7f	Leukemia, Lymphoblastic, Acute, Childhood	28910942	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were  significantly lower than those of the controls
circulation_biomarker_diagnosis_down	hsa-mir-25	Leukemia, Lymphoblastic, Acute, Childhood	28910942	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were  significantly lower than those of the controls
circulation_biomarker_diagnosis_down	hsa-mir-5100	Leukemia, Lymphoblastic, Acute, Childhood	28910942	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were  significantly lower than those of the controls
circulation_biomarker_diagnosis_down	hsa-mir-103a-1	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-103a-2	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	26908869	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	18362358	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	lost or downregulated
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	26908869	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	18362358	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	lost or downregulated
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181b:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	21636858	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MiR-181b is a biomarker of disease progression in chronic lymphocytic leukemia
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181b:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	21636858	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MiR-181b is a biomarker of disease progression in chronic lymphocytic leukemia
circulation_biomarker_diagnosis_down	hsa-mir-181c	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-22	Leukemia, Lymphocytic, Chronic, B-Cell	19144983	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-22: downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-29b-1	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-29b-2	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-29b-2	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	19144983	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-29c: downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification
circulation_biomarker_diagnosis_down	hsa-mir-146b	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	28407516	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	15737576	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Some human miRNAs are linked to leukemias: the miR-15a/miR-16 locus is frequently deleted or down-regulated in patients with B-cell chronic lymphocytic  leukemia and miR-142 is at a translocation site found in a case of aggressive B-cell leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_down	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	15737576	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Some human miRNAs are linked to leukemias: the miR-15a/miR-16 locus is frequently deleted or down-regulated in patients with B-cell chronic lymphocytic  leukemia and miR-142 is at a translocation site found in a case of aggressive B-cell leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_down	hsa-mir-186	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-19a	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-20a	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-324	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-484	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-660	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-let-7b	Leukemia, Myeloid, Acute	18056805	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML.
circulation_biomarker_diagnosis_down	hsa-mir-143	Leukemia, Myeloid, Acute	21678057	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29a and miR-142-3p show downregulation and diagnostic implication in human acute myeloid leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-148a	Leukemia, Myeloid, Acute	25924238	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	whilst anti-oncogenic microRNAsincluding miR-148a and miR-193a were down-regulated in MAPKBP1high patients with CN-AML
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-181c	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-181d	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-199b	Leukemia, Myeloid, Acute	26848406	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Low miR-199b in AML patients correlates with worse overall survival and has prognostic significance for FAB-M5 subtype.
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Myeloid, Acute	25793640	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MIR233 is genetically or epigenetically silenced in a subset of acute myeloid leukemia (AML).
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Myeloid, Acute	21678057	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29a and miR-142-3p show downregulation and diagnostic implication in human acute myeloid leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Myeloid, Acute	21818844	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Lower miR-29a expression was mainly observed in MLL-rearranged pediatric acute myeloid leukemia, specifically in cases carrying t(10;11).
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Myeloid, Acute	22981932	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our data indicate for the first time that the down-regulation of miR-29a was associated with advanced clinical features and poor prognosis of pediatric AML patients, suggesting that miR-29a down-regulation may be used as an unfavorable prognostic marker in pediatric AML.
circulation_biomarker_diagnosis_down	hsa-mir-96	Leukemia, Myeloid, Acute	24678958	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might become a potential biomarker of prognosis and monitoring in AML.
circulation_biomarker_diagnosis_down	hsa-mir-34b	Leukemia, Myeloid, Acute, Pediatric	26861642			C92.0				miR鈥?4b levels in leukemia cell lines and primary leukemic cells were significantly lower than those in normal cells.
circulation_biomarker_diagnosis_down	hsa-mir-181a	Leukemia, Myeloid, Chronic	26722250	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression levels of miR-181a were significantly reduced in the patient with CML  and in the CML K562 cell line.
circulation_biomarker_diagnosis_down	hsa-mir-199b	Leukemia, Myeloid, Chronic	24680705	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
circulation_biomarker_diagnosis_down	hsa-mir-451a	Leukemia, Myeloid, Chronic	21511335	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-10a	Leukemia, Myeloid, Chronic-Phase	19074828			C92.1	D015466			miR-10a: Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia, Promyelocytic, Acute	16847880	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells.
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Promyelocytic, Acute	16847880	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells.
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Promyelocytic, Acute	16847880	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells.
circulation_biomarker_diagnosis_down	hsa-mir-181d	Leukemia, Promyelocytic, Acute	16847880	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells.
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Leukemia-Lymphoma, Adult T-Cell	21441948			C91.51	D015459		HP:0005517	Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-kB activity and miR-16-1(*).
circulation_biomarker_diagnosis_down	hsa-mir-373	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-373*: down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-451a	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-451: down-regulated
circulation_biomarker_diagnosis_down	hsa-let-7b	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_down	hsa-mir-19a	Lung Fibrosis	27312312	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-19a in peripheral blood leukocyte could be used as an effective biomarker for silicosis
circulation_biomarker_diagnosis_down	hsa-let-7a-1	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7a-1	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7a-2	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7a-2	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7b	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7b	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7c	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7c	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7c	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-let-7d	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7d	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7d	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-let-7e	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7e	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7e	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-let-7f-1	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7f-1	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7f-2	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7f-2	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7g	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7g	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7g	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-let-7i	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7i	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-mir-126	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-mir-145	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-mir-198	Lung Neoplasms	23354517	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Circulating;Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion
circulation_biomarker_diagnosis_down	hsa-mir-21	Lung Neoplasms	22782668	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation.
circulation_biomarker_diagnosis_down	hsa-mir-24	Lung Neoplasms	22782668	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation.
circulation_biomarker_diagnosis_down	hsa-mir-98	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-mir-150	Lupus Vulgaris	18998140			A18.4	D008177			miR-150: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-210	Lupus Vulgaris	18998140			A18.4	D008177			miR-210: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-223	Lupus Vulgaris	18998140			A18.4	D008177			miR-223: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-296	Lupus Vulgaris	18998140			A18.4	D008177			miR-296: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-30d	Lupus Vulgaris	18998140			A18.4	D008177			miR-30d: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-324	Lupus Vulgaris	18998140			A18.4	D008177			miR-324-3p: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-346	Lupus Vulgaris	18998140			A18.4	D008177			miR-346: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-365a	Lupus Vulgaris	18998140			A18.4	D008177			miR-365: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-365b	Lupus Vulgaris	18998140			A18.4	D008177			miR-365: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-423	Lupus Vulgaris	18998140			A18.4	D008177			miR-423: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-484	Lupus Vulgaris	18998140			A18.4	D008177			miR-484: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-486	Lupus Vulgaris	18998140			A18.4	D008177			miR-486: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-500a	Lupus Vulgaris	18998140			A18.4	D008177			miR-500: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-518b	Lupus Vulgaris	18998140			A18.4	D008177			miR-518b: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-557	Lupus Vulgaris	18998140			A18.4	D008177			miR-557: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-596	Lupus Vulgaris	18998140			A18.4	D008177			miR-596: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-602	Lupus Vulgaris	18998140			A18.4	D008177			miR-602: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-611	Lupus Vulgaris	18998140			A18.4	D008177			miR-611: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-615	Lupus Vulgaris	18998140			A18.4	D008177			miR-615: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-629	Lupus Vulgaris	18998140			A18.4	D008177			miR-629: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-637	Lupus Vulgaris	18998140			A18.4	D008177			miR-637: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-642a	Lupus Vulgaris	18998140			A18.4	D008177			miR-642: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-654	Lupus Vulgaris	18998140			A18.4	D008177			miR-654: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-663a	Lupus Vulgaris	18998140			A18.4	D008177			miR-663: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-769	Lupus Vulgaris	18998140			A18.4	D008177			miR-769-3p: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-99a	Lupus Vulgaris	18998140			A18.4	D008177			miR-99a: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-17	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-17-5p: Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-19a	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-19b-1	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-19b-2	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal cani   ne peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-203	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-218-1	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-218-2	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Lymphoma	21383985	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma.
circulation_biomarker_diagnosis_down	hsa-mir-92a-2	Lymphoma	21383985	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma.
circulation_biomarker_diagnosis_down	hsa-mir-143	Lymphoma, B-Cell	17892514	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Downregulation of microRNAs-143 and -145 in B-cell malignancies.
circulation_biomarker_diagnosis_down	hsa-mir-17	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-17: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-18a	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-18a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-19a	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-19a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-19b-1	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-19b: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-19b-2	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-19b: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-20a	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-20a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-92a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-92a-2	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-92a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-128-1	Lymphoma, Hodgkin	18089852	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-128-2	Lymphoma, Hodgkin	18089852	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-96	Lymphoma, Hodgkin	18089852	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-101-1	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-101:miR-101 was down-regulated in all ALCL model systems
circulation_biomarker_diagnosis_down	hsa-mir-101-2	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-101:miR-101 was down-regulated in all ALCL model systems
circulation_biomarker_diagnosis_down	hsa-mir-150	Marek Disease	19297609				D008380			miR-150: down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-223	Marek Disease	19297609				D008380			miR-223: down-regulated
circulation_biomarker_diagnosis_down	hsa-let-7i	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7i*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-106b	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-106b:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-107	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-107:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-125b	Melanoma	24878024	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Exosomes can provide a suitable material to measure circulating miRNA in melanoma, and miR-16 can be used as an endogenous normalizer. Lower levels of miR-125b in exosomes obtained from serum are associated with advanced melanoma disease, probably reflecting the tumoral cell dysregulation.
circulation_biomarker_diagnosis_down	hsa-mir-16	Melanoma	24878024	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Exosomes can provide a suitable material to measure circulating miRNA in melanoma, and miR-16 can be used as an endogenous normalizer. Lower levels of miR-125b in exosomes obtained from serum are associated with advanced melanoma disease, probably reflecting the tumoral cell dysregulation.
circulation_biomarker_diagnosis_down	hsa-mir-17	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-17:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-20a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-20a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-20b	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-20b:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-214	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-214:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-216a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-216a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-217	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-217:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-221	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-221*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-330	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-330-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-452	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-452:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-509-3	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-509-3-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-517a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-517*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-518e	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-518e*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-519b	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-519b-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-593	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-593*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-621	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-621:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-646	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-646:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-767	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-767-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-126	Mesothelioma	21483773	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Levels of miR-126 in serum, and its levels in patients' serum in association with a specific marker of MPM, SMRPs, correlate with subjects at high risk to develop malignant pleural mesothelioma (MPM).
circulation_biomarker_diagnosis_down	hsa-mir-126	Mesothelioma	22374169	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Kaplan-Meier analysis revealed that low level of circulating miR-126 in MM patients was strongly associated with worse prognosis.
circulation_biomarker_diagnosis_down	hsa-mir-9-1	Methylmalonic Acidemia	24927441	disease of metabolism	DOID:14749	E71.120	C537358	309541		Plasma miR-9-1 is significantly down-regulated in MMA patients, but it is significantly up-regulated after vitamin B12 treatment, suggesting that miR-9-1 may act as a biomarker in monitoring the progression of MMA.
circulation_biomarker_diagnosis_down	hsa-mir-33b	Multiple Myeloma	25975752	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma.
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Multiple Myeloma	22829237	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.
circulation_biomarker_diagnosis_down	hsa-mir-15b	Multiple Sclerosis	24277735	nervous system disease	DOID:2377	G35	D009103	PS126200		Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
circulation_biomarker_diagnosis_down	hsa-mir-223	Multiple Sclerosis	24277735	nervous system disease	DOID:2377	G35	D009103	PS126200		Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
circulation_biomarker_diagnosis_down	hsa-mir-23a	Multiple Sclerosis	24277735	nervous system disease	DOID:2377	G35	D009103	PS126200		Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
circulation_biomarker_diagnosis_down	hsa-mir-320a	Multiple Sclerosis	25468268	nervous system disease	DOID:2377	G35	D009103	PS126200		expression of miR-320a is decreased in B cells of MS patients and may contribute to increased blood-brain barrier permeability and neurological disability.
circulation_biomarker_diagnosis_down	hsa-mir-145	Myasthenia Gravis	24043548	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.
circulation_biomarker_diagnosis_down	hsa-mir-181c	Myasthenia Gravis	25962782	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis.
circulation_biomarker_diagnosis_down	hsa-mir-125b-1	Myelodysplastic Syndromes	18936236	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-125b-1: Myeloid cell differentiation arrest by miR-125b-1
circulation_biomarker_diagnosis_down	hsa-mir-671	Myelodysplastic Syndromes	21649547	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-671-5p: down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-126	Myocardial Infarction	22719221	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found.
circulation_biomarker_diagnosis_down	hsa-mir-133a	Myocardial Infarction	29324314	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Down-regulation of miR-133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation
circulation_biomarker_diagnosis_down	hsa-mir-133b	Myocardial Infarction	29324314	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Down-regulation of miR-133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation
circulation_biomarker_diagnosis_down	hsa-mir-155	Myocardial Infarction	28618412	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Failed Downregulation of Circulating MicroRNA-155 in the Early Phase after ST Elevation Myocardial Infarction Is Associated with Adverse Left Ventricular Remodeling.
circulation_biomarker_diagnosis_down	hsa-mir-29c	Nasopharyngeal Neoplasms	18390668			C11.9	D009303	607107	HP:0100630	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-155	Neoplasms [unspecific]	16885332			C80.1	D009369			High expression of precursor miR-155/BIC in pediatric BL, but lack of BIC and miR-155 expression in adult BL
circulation_biomarker_diagnosis_down	hsa-mir-199a-1	Neoplasms [unspecific]	18430245			C80.1	D009369			decreased
circulation_biomarker_diagnosis_down	hsa-mir-337	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-337-3p: down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-338	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-338-3p: down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-143	Obesity	26223376	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Circulating miR-335 (P鈥?鈥?.001), miR-143 (P鈥?鈥?.001) and miR-758 (P鈥?鈥?.006) in obese children were significantly lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-335	Obesity	26223376	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Circulating miR-335 (P鈥?鈥?.001), miR-143 (P鈥?鈥?.001) and miR-758 (P鈥?鈥?.006) in obese children were significantly lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Ovarian Neoplasms	17974952	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	decreased
circulation_biomarker_diagnosis_down	hsa-let-7e	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	let-7e: deregulated
circulation_biomarker_diagnosis_down	hsa-let-7d	Pancreatic Neoplasms	21139804	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-146a	Pancreatic Neoplasms	21139804	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-29a	Parkinson Disease	24648008	nervous system disease	DOID:14330	G20	D010300	PS168600		We found four statistically significant miRNAs that were downregulated in either LRRK2 or IPD (miR-29a, miR-29c, miR-19a, and miR-19b).
circulation_biomarker_diagnosis_down	hsa-mir-15a	Pituitary Neoplasms	17028302	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas.
circulation_biomarker_diagnosis_down	hsa-mir-15b	Pituitary Neoplasms	17028302	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas.
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Pituitary Neoplasms	17028302	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas.
circulation_biomarker_diagnosis_down	hsa-mir-16-2	Pituitary Neoplasms	17028302	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas.
circulation_biomarker_diagnosis_down	hsa-mir-16	Plasmodium vivax Infection	25913668	disease by infectious agent	DOID:12978	B51	D016780	248310		Downregulation of plasma miR-451 and miR-16 in Plasmodium vivax infection.
circulation_biomarker_diagnosis_down	hsa-mir-451	Plasmodium vivax Infection	25913668	disease by infectious agent	DOID:12978	B51	D016780	248310		Downregulation of plasma miR-451 and miR-16 in Plasmodium vivax infection.
circulation_biomarker_diagnosis_down	hsa-mir-1	Polycystic Kidney Disease	24489795			Q61.19	D007690	PS173900	HP:0000113	We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis.
circulation_biomarker_diagnosis_down	hsa-mir-199b	Polycystic Ovarian Syndrome	26860517	syndrome	DOID:11612	E28.2	D011085	184700		whereas that of miR-199b-5p was down-regulated.
circulation_biomarker_diagnosis_down	hsa-let-7a	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_down	hsa-mir-150	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_down	hsa-mir-150	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_down	hsa-mir-155	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_down	hsa-mir-221	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_down	hsa-mir-30b	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_down	hsa-mir-30c	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_down	hsa-mir-152	Preeclampsia	22095477	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Serum expression level of mir-152 was down-regulated in preeclampsia patients.
circulation_biomarker_diagnosis_down	hsa-mir-222	Preeclampsia	29381395	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	serum miR-222 expression levels showed a significant decrease in PE compared to GH and normotensive groups
circulation_biomarker_diagnosis_down	hsa-mir-22	Premature Ovarian Failure	25585503	endocrine system disease	DOID:5426	E28.3	D016649	PS311360		Mir-22-3p showed a lower expression level in POF and was modestly effective in distinguishing POF from control subjects. The decreased expression of miR-22-3p in plasma of POF may reflect the diminished ovarian reserve and be a consequence of the pathologic process of POF.
circulation_biomarker_diagnosis_down	hsa-mir-197	Primary Biliary Cirrhosis	23776611	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	Our results indicate that sera from patients with PBC have a unique mirNA expression profile and that the down-regulated expression of mir-505-3p and mir-197-3p can serve as clinical biomarkers of PBC.
circulation_biomarker_diagnosis_down	hsa-mir-505	Primary Biliary Cirrhosis	23776611	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	Our results indicate that sera from patients with PBC have a unique mirNA expression profile and that the down-regulated expression of mir-505-3p and mir-197-3p can serve as clinical biomarkers of PBC.
circulation_biomarker_diagnosis_down	hsa-let-7b	Prostate Neoplasms	22719071	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulated in prostate cancer stem/progenitor cell.
circulation_biomarker_diagnosis_down	hsa-mir-125b	Prostate Neoplasms	22892455	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Prostate Neoplasms	22892455	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B.
circulation_biomarker_diagnosis_down	hsa-mir-221	Prostate Neoplasms	26831660	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH.
circulation_biomarker_diagnosis_down	hsa-mir-409	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_down	hsa-mir-708	Prostate Neoplasms	26831660	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH.
circulation_biomarker_diagnosis_down	hsa-mir-182	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-182: decreased expression
circulation_biomarker_diagnosis_down	hsa-mir-183	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-183: decreased expression
circulation_biomarker_diagnosis_down	hsa-mir-96	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-96: decreased expression
circulation_biomarker_diagnosis_down	hsa-let-7e	Retinoblastoma	24748987	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Plasma miRNA (miR)-320, miR-let-7e and miR-21 levels were downregulated in the patient samples
circulation_biomarker_diagnosis_down	hsa-mir-21	Rheumatoid Arthritis	25164131	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis.
circulation_biomarker_diagnosis_down	hsa-mir-22	Rheumatoid Arthritis	25939484	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiRNAs with a P-value <0.05 using three different normalizations were included in a multivariate model.After backwards elimination, the combination of low expression of miR-22 and high expression of miR-886.3p was associated with EULAR good response. Future studies to assess the utility of these miRNAs as predictive biomarkers are needed.
circulation_biomarker_diagnosis_down	hsa-mir-346	Schizophrenia	19264453	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-346: Expression of both miR-346 and GRID1 is lower in SZ patients than that in normal controls
circulation_biomarker_diagnosis_down	hsa-mir-146a	Sepsis	20188071			A41.9	D018805		HP:0100806	Serum miR-146a and miR-223 as potential new biomarkers for sepsis
circulation_biomarker_diagnosis_down	hsa-mir-150	Sepsis	19823581			A41.9	D018805		HP:0100806	miR-150 as a plasma prognostic marker in patients with sepsis
circulation_biomarker_diagnosis_down	hsa-mir-150	Sepsis	23372743			A41.9	D018805		HP:0100806	Circulating;Circulating MicroRNA-150 Serum Levels Predict Survival in Patients with Critical Illness and Sepsis
circulation_biomarker_diagnosis_down	hsa-mir-150	Sepsis	25394245			A41.9	D018805		HP:0100806	The expression of two miRNAs, that is, let-7a (P < 0.001) and miR-150 (P < 0.001), were confirmed to be significantly downregulated in GNB urosepsis patients compared with healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-223	Sepsis	20188071			A41.9	D018805		HP:0100806	Serum miR-146a and miR-223 as potential new biomarkers for sepsis
circulation_biomarker_diagnosis_down	hsa-mir-155	Sjogren Syndrome	24931100	immune system disease	DOID:12894	M35.00	D012859	270150		Our results demonstrated miR-146a overexpression and miR-155 underexpression in the peripheral mononuclear blood cells of the patients with pSS. Furthermore, the expression levels of these miRNAs correlated with the patients' clinical features. Our data suggest that miR-146a and miR-155 might play important roles in the pathogenesis of pSS and that their expression levels may be useful for diagnosing pSS and for predicting disease activity and therapeutic responses.
circulation_biomarker_diagnosis_down	hsa-mir-130a	Spinal Cord Injuries	25973054			S34.139A	D013119			Increased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries.
circulation_biomarker_diagnosis_down	hsa-mir-335	Spinal Muscular Atrophy	27483257	nervous system disease	DOID:12377	G12.9	D009134	253300	HP:0007269	The expression of miR-335-5p; already identified to control self-renewal or differentiation of mouse embryonic stem cells (mESCs); resulted to be reduced during the early steps of differentiation of SMA hiPSCs compared to wild type cells.
circulation_biomarker_diagnosis_down	hsa-mir-150	Spondylarthritis	26689798			M45-M49	D025241			miR-150 was downregulated in all of the samples
circulation_biomarker_diagnosis_down	hsa-mir-1297	Squamous Cell Carcinoma, Esophageal	27152453	disease of cellular proliferation	DOID:3748		C562729			It was statistically decreased in ESCC patients  compared with healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Squamous Cell Carcinoma, Esophageal	26794279	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-146a is significantly reduced in cancerous tissue and serum samples of ESCC patients. It is an ideal biomarker for the prognosis and diagnosis of ESCC.
circulation_biomarker_diagnosis_down	hsa-mir-375	Squamous Cell Carcinoma, Esophageal	21673684	disease of cellular proliferation	DOID:3748		C562729			the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164).
circulation_biomarker_diagnosis_down	hsa-mir-122	Stroke	26661204			I64	D020521	601367	HP:0001297	our recent studies have demonstrated that miR-122 decreased in whole blood of patients and in whole blood of rats following ischemic stroke
circulation_biomarker_diagnosis_down	hsa-mir-124	Stroke	25257664			I64	D020521	601367	HP:0001297	serum miR-124 was significantly decreased within 24 hours after stroke onset and serum miR-9 was decreased in patients with larger stroke.
circulation_biomarker_diagnosis_down	hsa-mir-9	Stroke	25257664			I64	D020521	601367	HP:0001297	serum miR-124 was significantly decreased within 24 hours after stroke onset and serum miR-9 was decreased in patients with larger stroke.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Stroke, Ischemic	26044809			I63.9			HP:0002140	miR-146a and miR-185 were present with quite low abundance in ISA compared with healthy individuals
circulation_biomarker_diagnosis_down	hsa-mir-106a	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-141	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-145	Systemic Lupus Erythematosus	23199328	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis
circulation_biomarker_diagnosis_down	hsa-mir-17	Systemic Lupus Erythematosus	23129428	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Dual downregulation of microRNA 17-5p and E2F1 transcriptional factor in pediatric systemic lupus erythematosus patients
circulation_biomarker_diagnosis_down	hsa-mir-17	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-192	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-200a	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-200b	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-200c	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-203	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-205	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-20a	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-31	Systemic Lupus Erythematosus	27510529	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The results revealed that miR-31 was lower expressed, while miR-21 was  high expressed in SLE patients compared to their first-degree relatives and controls.
circulation_biomarker_diagnosis_down	hsa-mir-429	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-92a	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-127	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144.
circulation_biomarker_diagnosis_down	hsa-mir-130a	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144.
circulation_biomarker_diagnosis_down	hsa-mir-144	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144.
circulation_biomarker_diagnosis_down	hsa-mir-218-1	Urinary Bladder Cancer	22237456	urinary system disease	DOID:11054	C67	D001749	109800		Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion.
circulation_biomarker_diagnosis_down	hsa-mir-218-2	Urinary Bladder Cancer	22237456	urinary system disease	DOID:11054	C67	D001749	109800		Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion.
circulation_biomarker_diagnosis_down	hsa-mir-133a	Vascular Hypertrophy	28772031							Local microRNA-133a downregulation is associated with hypertrophy in the dyssynchronous heart.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Acute Cerebral Infarction	27846323	cardiovascular system disease	DOID:3526	I63	D002544			Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Acute Cerebral Infarction	24841240	cardiovascular system disease	DOID:3526	I63	D002544			Identification of miRNA-21 and miRNA-24 in plasma as potential early stage markers of acute cerebral infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Acute Cerebral Infarction	24841240	cardiovascular system disease	DOID:3526	I63	D002544			Identification of miRNA-21 and miRNA-24 in plasma as potential early stage markers of acute cerebral infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Acute Cerebral Ischemia	21622133			I67.82			HP:0002637	MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Acute Coronary Syndrome	29350392			I24.9	D054058			although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events
circulation_biomarker_diagnosis_ns	hsa-mir-100	Acute Coronary Syndrome	25744750			I24.9	D054058			Plasma microRNA-100 as a biomarker of coronary plaque vulnerability – a new generation of biomarker for developing acute coronary syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Acute Coronary Syndrome	25933289			I24.9	D054058			Plasma miR-122, -140-3p, -720, -2861, and -3149 were associated with and potentially novel biomarkers for ACS.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Acute Coronary Syndrome	29350392			I24.9	D054058			although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Acute Coronary Syndrome	29350392			I24.9	D054058			although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events
circulation_biomarker_diagnosis_ns	hsa-mir-21	Acute Coronary Syndrome	27590242			I24.9	D054058			The role of serum levels of microRNA-21 and matrix metalloproteinase-9 in patients with acute coronary syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-3149	Acute Coronary Syndrome	25933289			I24.9	D054058			Plasma miR-122, -140-3p, -720, -2861, and -3149 were associated with and potentially novel biomarkers for ACS.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Acute Coronary Syndrome	29350392			I24.9	D054058			although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Acute Heart Failure	26345695			I50				Fifteen miRNAs found in the discovery phase to differ most significantly between healthy controls and patients with AHF
circulation_biomarker_diagnosis_ns	hsa-mir-145	Acute Ischemic Stroke	26096228	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Circulating miR-145 is associated with plasma high-sensitivity C-reactive protein in acute ischemic stroke patients.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Acute Kidney Failure	21700819	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	Circulating miR-210 predicts survival in critically ill patients with acute kidney injury.
circulation_biomarker_diagnosis_ns	hsa-mir-494	Acute Kidney Failure	23160513	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	In conclusion, upregulation of microRNA-494 contributes to inflammatory or adhesion molecule-induced kidney injury after ischemia/reperfusion by inhibiting expression of ATF3. Furthermore, microRNA-494 may be a specific and noninvasive biomarker for AKI.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-194	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-216a	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-216b	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-217	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-449a	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Acute Myocardial Infarction	24253456	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Acute Myocardial Infarction	26526403	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Acute Myocardial Infarction	27593229	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-124	Acute Myocardial Infarction	28338188	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Implication of peripheral blood miRNA-124 in predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Acute Myocardial Infarction	24053180	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-133a may be a new biomarker for AMI and as a potential diagnostic tool. And increased miR-133a level may be used to predict both the presence and severity of coronary lesions in CHD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Acute Myocardial Infarction	27593229	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Acute Myocardial Infarction	20886220	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In addition, we show that miR-30c and miR-145 levels correlate with infarct sizes estimated by Troponin T release. The here presented study shows that single miRNAs and especially miRNA signatures derived from peripheral blood, could be valuable novel biomarkers for cardiovascular diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Acute Myocardial Infarction	28051023	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating MicroRNA-145 is Associated with Acute Myocardial Infarction and Heart Failure.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Acute Myocardial Infarction	27997916	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-181a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Acute Myocardial Infarction	25383678	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating microRNA-19a as a potential novel biomarker for diagnosis of acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Acute Myocardial Infarction	29085838	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	The miRNA Expression Profile in Acute Myocardial Infarct Using Sheep Model with Left Ventricular Assist Device Unloading.
circulation_biomarker_diagnosis_ns	hsa-mir-208	Acute Myocardial Infarction	26526403	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Acute Myocardial Infarction	28272696	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	A meta-analysis of the relations between blood microRNA-208b detection and acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Acute Myocardial Infarction	26875904	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Plasma miR-21 may be a novel biomarker for the diagnosis of AMI. Our study may also provide implications for the development of new biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Acute Myocardial Infarction	20886220	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In addition, we show that miR-30c and miR-145 levels correlate with infarct sizes estimated by Troponin T release. The here presented study shows that single miRNAs and especially miRNA signatures derived from peripheral blood, could be valuable novel biomarkers for cardiovascular diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Acute Myocardial Infarction	26526403	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Acute Myocardial Infarction	26547429	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	favorable sensitivity and selectivity,thus provides an alternative for the detection of miRNA. Most importantly, this effort may promote miRNA to work as an effective biomarker in the diagnosis of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-99a	Acute Myocardial Infarction	28051249	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	The clinical value of circulating miR-99a in plasma of patients with acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-126a	Acute Pancreatitis	26094040	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	Serum levels of unique miR-551-5p and endothelial-specific miR-126a-5p allow discrimination of patients in the early phase of acute pancreatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-551	Acute Pancreatitis	26094040	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	Serum levels of unique miR-551-5p and endothelial-specific miR-126a-6p allow discrimination of patients in the early phase of acute pancreatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Acute Respiratory Distress Syndrome	28856588	respiratory system disease	DOID:11394	J80	D012128			miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker
circulation_biomarker_diagnosis_ns	hsa-mir-424	Acute Respiratory Distress Syndrome	28856588	respiratory system disease	DOID:11394	J80	D012128			miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Acute Respiratory Distress Syndrome	28856588	respiratory system disease	DOID:11394	J80	D012128			miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker
circulation_biomarker_diagnosis_ns	hsa-mir-195	Adenocarcinoma, Lung	24282590	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Plasma levels of miR-195 and miR-122 expression were also associated with overall survival in the patients, especially in those with advanced stage (HR=0.23, 95%CI:0.07-0.84; and HR=0.22, 95%CI:0.06-0.77) and EGFR mutation (HR=0.27, 95%CI:0.08-0.96; and HR=0.23, 95%CI=0.06-0.81).
circulation_biomarker_diagnosis_ns	hsa-mir-21	Adenocarcinoma, Lung	29103767	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Adenocarcinoma, Lung	28123597	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Adenocarcinoma, Lung	28123597	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-339	Adenocarcinoma, Lung	29103767	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Adenocarcinoma, Lung	28449331	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Adenocarcinoma, Pancreatic Ductal	20614181	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Serum miR-196a could be a potential noninvasive marker for PDAC prognosis and selection of laparotomy.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26262588	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Serum miR-21 and miR-34a are potentially useful diagnostic biomarkers of PDAC. In addition, our results suggest that these miRNAs are not differentially expressed in saliva, making them unsuitable for use as noninvasive biomarkers for diagnostic purposes.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Adenocarcinoma, Pancreatic Ductal	26262588	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Serum miR-21 and miR-34a are potentially useful diagnostic biomarkers of PDAC. In addition, our results suggest that these miRNAs are not differentially expressed in saliva, making them unsuitable for use as noninvasive biomarkers for diagnostic purposes.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Adrenal Cortex Neoplasms	24336071	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	In contrast, of the selected eight miRNAs reported in the literature as differentially expressed in ACT tissues, five (hsa-miR-100, hsa-miR-181b, hsa-miR-184, hsa-miR-210 and hsa-miR-483-5p) showed a statistically significant overexpression in adrenocortical cancer vs adenoma when normalized on hsa-miR-16  as a reference gene.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Adrenal Cortex Neoplasms	24336071	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	In contrast, of the selected eight miRNAs reported in the literature as differentially expressed in ACT tissues, five (hsa-miR-100, hsa-miR-181b, hsa-miR-184, hsa-miR-210 and hsa-miR-483-5p) showed a statistically significant overexpression in adrenocortical cancer vs adenoma when normalized on hsa-miR-16  as a reference gene.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Adrenal Cortex Neoplasms	29029450	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	we demonstrated that miR483-5p absolute plasma levels in ACC patients are powerful molecular markers that may help in the follow-up of patients after surgery and chemotherapy, and contribute to more accurately classify and predict tumor progression.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Age-Related Macular Degeneration	27658786	nervous system disease	DOID:10871	H35.30	D008268	PS603075		mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae
circulation_biomarker_diagnosis_ns	hsa-mir-155	Age-Related Macular Degeneration	27658786	nervous system disease	DOID:10871	H35.30	D008268	PS603075		mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae
circulation_biomarker_diagnosis_ns	hsa-mir-17	Age-Related Macular Degeneration	27658786	nervous system disease	DOID:10871	H35.30	D008268	PS603075		mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae
circulation_biomarker_diagnosis_ns	hsa-mir-21	Allergic Asthma	25707810	immune system disease	DOID:9415	J45.909	C564133	600807		Serum MicroRNA-21 as a Biomarker for Allergic Inflammatory Disease in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Allergic Rhinitis	25675113	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Serum hsa-miR-223 was significantly up-regulated in postseason compared with preseason  samples.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Alzheimer Disease	24139697	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Our results indicate that serum miR-125b may serve as a useful noninvasive biomarker for AD.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Alzheimer Disease	26899870	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-136	Alzheimer Disease	26899870	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-137	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-137	Alzheimer Disease	26899870	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Alzheimer Disease	25119742	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's  disease.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-1	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-1	Alzheimer Disease	23435408	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	blood;Expression of the Transcription Factor Sp1 and its Regulatory hsa-miR-29b in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease
circulation_biomarker_diagnosis_ns	hsa-mir-29b-2	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-2	Alzheimer Disease	23435408	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	blood;Expression of the Transcription Factor Sp1 and its Regulatory hsa-miR-29b in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease
circulation_biomarker_diagnosis_ns	hsa-mir-301a	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-545	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-9-1	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-9-2	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-9-3	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-98	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-124a	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-206	Amyotrophic Lateral Sclerosis	24586506	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-638	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-9	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-126	Angiosarcoma	26512652	disease of cellular proliferation	DOID:0001816	C49.9	D006394		HP:0200058	Our findings suggest that these malignant endothelial proliferative diseases over-secreted miR-214 and miR-126, thus suggesting that these miRNAs have potential as diagnostic biomarkers for malignant endothelial proliferative diseases in canine and possible in human angiosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-214	Angiosarcoma	26512652	disease of cellular proliferation	DOID:0001816	C49.9	D006394		HP:0200058	Our findings suggest that these malignant endothelial proliferative diseases over-secreted miR-214 and miR-126, thus suggesting that these miRNAs have potential as diagnostic biomarkers for malignant endothelial proliferative diseases in canine and possible in human angiosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Aortic Aneurysm, Abdominal	28425970	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Aneurysm-Specific miR-221 and miR-146a Participates in Human Thoracic and Abdominal Aortic Aneurysms.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Aortic Aneurysm, Abdominal	28425970	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Aneurysm-Specific miR-221 and miR-146a Participates in Human Thoracic and Abdominal Aortic Aneurysms.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Aortic Stenosis	23948643	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Preoperative plasma levels of miR-133a reflect their myocardial pression and predict the regression potential of LV hypertrophy after AVR. The value of this bedside information for the surgical timing, particularly in asymptomatic aortic stenosis patients, deserves confirmation in further clinical studies.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Aplastic Anemia	27658437	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	A plasma microRNA signature as a biomarker for acquired aplastic anemia.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Aplastic Anemia	27658437	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	A plasma microRNA signature as a biomarker for acquired aplastic anemia.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Aplastic Anemia	27658437	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	A plasma microRNA signature as a biomarker for acquired aplastic anemia.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Arteriosclerosis Obliterans	27900989	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-126	Atherosclerosis	28785651	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Circulating level of microRNA-126 may be a potential biomarker for recovery from smoking-related vascular damage in middle-aged habitual smokers.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Atherosclerosis	29531852	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-4p
circulation_biomarker_diagnosis_ns	hsa-mir-127	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-145	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-21	Atherosclerosis	27785570	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Atherosclerosis	29531852	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-3p
circulation_biomarker_diagnosis_ns	hsa-mir-210	Atherosclerosis	20888330	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The serum levels of miR-130a, miR-27b and miR-210 may serve as potential biomarkers for early stage ASO.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Atherosclerosis	28301500	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Atherosclerosis	20888330	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The serum levels of miR-130a, miR-27b and miR-210 may serve as potential biomarkers for early stage ASO.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Atherosclerosis	28301500	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Atherosclerosis	29531852	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-5p
circulation_biomarker_diagnosis_ns	hsa-mir-222	Atherosclerosis	20888330	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The serum levels of miR-130a, miR-27b and miR-210 may serve as potential biomarkers for early stage ASO.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Atherosclerosis	28301500	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Atherosclerosis	27997904	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The Relationship of Plasma miR-29a and Oxidized Low Density Lipoprotein with Atherosclerosis.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-30	Atherosclerosis	29531852	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-3p
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-33a	Atherosclerosis	27664032	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Aberrant expression of plasma microRNA-33a in an atherosclerosis-risk group.
circulation_biomarker_diagnosis_ns	hsa-mir-1266	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-3149	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-3171	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-4279	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-4666a	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-892a	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-103a	Autism Spectrum Disorder	26061495	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	this study provides the first global miRNA expression profile of ASD in China. The differentially expressed miR-34b may potentially explain the higher percentage of male ASD patients, and the aberrantly expressed miR-103a-3p may contribute to the abnormal ubiquitin-mediated proteolysis observed in ASD.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Autism Spectrum Disorder	26061495	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	this study provides the first global miRNA expression profile of ASD in China. The differentially expressed miR-34b may potentially explain the higher percentage of male ASD patients, and the aberrantly expressed miR-103a-3p may contribute to the abnormal ubiquitin-mediated proteolysis observed in ASD.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Autoimmune Lymphoproliferative Syndrome	27060458	immune system disease	DOID:6688	D89.82	D056735	PS308240		miR-21-3p was over-expressed significantly (P = 0路0313) in the son, with no significant change in the expression of miR-146a, miR-146a-3p and miR-21.
circulation_biomarker_diagnosis_ns	hsa-mir-139	Behcet Disease	26486198	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		miR199-3p and miR720 deserve further confirmation as biomarkers of BD in larger studies. PBMCs from active BD displayed a unique signature of microRNAs which may be implicated in regulation of innate immunity activation and T-cell function.
circulation_biomarker_diagnosis_ns	hsa-mir-720	Behcet Disease	26486198	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		miR199-3p and miR720 deserve further confirmation as biomarkers of BD in larger studies. PBMCs from active BD displayed a unique signature of microRNAs which may be implicated in regulation of innate immunity activation and T-cell function.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Biliary Tract Neoplasms	24118467	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	Plasma miR-21 is a novel diagnostic biomarker for BTC, and may be useful in distinguishing between BTC and BBD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Bladder Neoplasms	26489968			C67	D001749	109800	HP:0009725	MiRNAs detected in urine and serum/plasma will demonstrate their potentiality to describe the variegated scenario of BC and to become relevant clinical markers.
circulation_biomarker_diagnosis_ns	hsa-mir-152	Bladder Neoplasms	24961907			C67	D001749	109800	HP:0009725	expression level of serum miR-152 could provide information on the recurrence risk of NMIBC.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Bladder Neoplasms	26252880			C67	D001749	109800	HP:0009725	Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-497	Bladder Neoplasms	26014226			C67	D001749	109800	HP:0009725	Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-663a	Bladder Neoplasms	26014226			C67	D001749	109800	HP:0009725	Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Bladder Neoplasms	26489968			C67	D001749	109800	HP:0009725	MiRNAs detected in urine and serum/plasma will demonstrate their potentiality to describe the variegated scenario of BC and to become relevant clinical markers.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-32	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-744	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-886	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Breast Neoplasms	29683112	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-10	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Breast Neoplasms	25722304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.
circulation_biomarker_diagnosis_ns	hsa-mir-105	Breast Neoplasms	24735924	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-105 can be detected in the circulation at the premetastatic stage, and its levels in the blood and tumor are associated with ZO-1 expression and metastatic progression in early-stage breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Breast Neoplasms	26033453	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Breast Neoplasms	25004125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Breast Neoplasms	23238818	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-122	Breast Neoplasms	22400902	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Breast Neoplasms	26056355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-127	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1307	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Breast Neoplasms	26033453	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-140	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Breast Neoplasms	26124344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-146	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Breast Neoplasms	26033453	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Breast Neoplasms	25004125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-148b	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Breast Neoplasms	23071695	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum microRNA-155 as a potential biomarker to track disease in breast cancer
circulation_biomarker_diagnosis_ns	hsa-mir-155	Breast Neoplasms	23748853	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Breast Neoplasms	29683112	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Breast Neoplasms	26033453	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Breast Neoplasms	23748853	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Breast Neoplasms	26124344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Breast Neoplasms	20576643	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A combination of three circulating miRNAs, including miR-195, further enhanced the discriminative power of this test for breast cancer to 94%.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Breast Neoplasms	26476723	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	25516467	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 is a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, and its clinical application warrants further investigation
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	26056355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	26063582	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, our findings demonstrate that serum miR-21 expression profile may serve as a potential non-invasive diagnostic and prognostic biomarker for breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	27311114	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-21 (miR-21) is a promising diagnostic biomarker for breast cancer screening and disease progression
circulation_biomarker_diagnosis_ns	hsa-mir-210	Breast Neoplasms	22370716	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-215	Breast Neoplasms	22353773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-221	Breast Neoplasms	22156446	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression level of miR-221 was significantly associated with hormone receptor (HR) status (p = 0.008). Patients with higher plasma miR-221 levels tended to be HR-negative. Patients with different miR-221 levels had significant differences in the overall response rate (p = 0.044) but not in the pathologic complete response rate (p = 0.477).
circulation_biomarker_diagnosis_ns	hsa-mir-222	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Breast Neoplasms	25004125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-299	Breast Neoplasms	22353773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Breast Neoplasms	26476723	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-301a	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-324	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-338	Breast Neoplasms	25004125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Breast Neoplasms	23748853	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression.
circulation_biomarker_diagnosis_ns	hsa-mir-373	Breast Neoplasms	23238818	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-373	Breast Neoplasms	23748853	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Breast Neoplasms	22400902	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients.
circulation_biomarker_diagnosis_ns	hsa-mir-376a	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-409	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-411	Breast Neoplasms	22353773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-423	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-424	Breast Neoplasms	26476723	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-451	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Breast Neoplasms	26124344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-452	Breast Neoplasms	22353773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-4634	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Breast Neoplasms	26056355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-520h	Breast Neoplasms	25982274	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-520h is crucial for DAPK2 regulation and breast cancer progression.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Breast Neoplasms	29683112	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-6861	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-6875	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-708	Breast Neoplasms	26124344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-801	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-92	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Breast Neoplasms	26056355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Bronchopulmonary Dysplasia	26291337			P27.1	D001997			Our data are the first to demonstrate altered expression of the miR-17-92 cluster in bronchopulmonary dysplasia. The consistency between our autopsy and plasma findings further support our working hypothesis that the miR-17-92 cluster contributes to the molecular pathogenesis of bronchopulmonary dysplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Carcinoma, Adrenocortical	23756429	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Carcinoma, Adrenocortical	24238045	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	We show that dysregulated miRNAs in ACC are detectable in human serum samples. MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Adrenocortical	23756429	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Adrenocortical	24238045	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	We show that dysregulated miRNAs in ACC are detectable in human serum samples. MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-4294	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-4476	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-4530	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-6075	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-6799	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-6836	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-6880	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Carcinoma, Bladder	28239818	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Identification of miR-146b-5p in tissues as a novel biomarker for prognosis of gallbladder carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Carcinoma, Breast	28058628			D05	D001943	114480	HP:0003002	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Breast	25431259			D05	D001943	114480	HP:0003002	MiR-21 has a relatively high diagnostic value for detecting breast cancer, and miR-21 assays based on plasma, serum, and tissue achieved relatively higher accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Breast	28058628			D05	D001943	114480	HP:0003002	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Carcinoma, Breast	28058628			D05	D001943	114480	HP:0003002	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Carcinoma, Breast	28178621			D05	D001943	114480	HP:0003002	Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-374b	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-942	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Breast, Triple Negative	28078851				D064726			Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-127	Carcinoma, Cervical	25701838	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Plasma miR-127 and miR-218 Might Serve as Potential Biomarkers for Cervical Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Carcinoma, Cervical	26656154	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Carcinoma, Cervical	26656154	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Carcinoma, Cervical	26782446	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-218	Carcinoma, Cervical	25701838	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Plasma miR-127 and miR-218 Might Serve as Potential Biomarkers for Cervical Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-2861	Carcinoma, Cervical	26656154	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-497	Carcinoma, Cervical	26656154	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Carcinoma, Colon	27485599	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Carcinoma, Colon	27798914	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Carcinoma, Colon	27872469	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Preoperative Serum MicroRNA-155 Expression Independently Predicts Postoperative Cognitive Dysfunction After Laparoscopic Surgery for Colon Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Colon	27798914	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Colon	27910062	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Plasma and saliva miR-21 expression in colorectal cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Colon	28376502	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Colon	27798914	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Carcinoma, Colon	27485599	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922).
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Carcinoma, Colon	27485599	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922).
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Carcinoma, Colon	25894979	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Carcinoma, Colon	25894979	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Carcinoma, Colon	27485599	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922).
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Esophageal	24968850	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Both salivary and plasmatic miR-21 can be sensitive biomarkers for EC, and salivary miR-21 detection has the potential to replace plasma detection for EC diagnosis.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-187	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-202	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Carcinoma, Gastric	27909811	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Carcinoma, Gastric	27909811	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-125	Carcinoma, Gastric	27986464	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-194	Carcinoma, Gastric	27909811	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Carcinoma, Gastric	27614739	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Gastric	28121346	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-21 can be used for the diagnosis of gastric cancer and prognosis of lymph node metastasis in gastric cancer
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Gastric	28641313	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331.
circulation_biomarker_diagnosis_ns	hsa-mir-331	Carcinoma, Gastric	28641313	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331.
circulation_biomarker_diagnosis_ns	hsa-mir-383	Carcinoma, Gastric	28243881	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The Value of MiR-383, an Intronic MiRNA, as a Diagnostic and Prognostic Biomarker in Intestinal-Type Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-let-7f	Carcinoma, Hepatocellular	24697119	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Carcinoma, Hepatocellular	23810247	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data indicate that serum miR-1 is a new independent parameter of OS in HCC patients and may therefore improve the predictive value of classical HCC staging scores.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Carcinoma, Hepatocellular	25894380	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We found that plasma miR-106b has clinical value in the detection of HCC from healthy people and CLD patients. Further large-scale study may be needed to validate our findings.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Carcinoma, Hepatocellular	29312570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA signatures and metabolomics have high diagnostic value in hepatocellular carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-107	Carcinoma, Hepatocellular	28079796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Carcinoma, Hepatocellular	28049231	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	23723713	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	23810247	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data indicate that serum miR-1 is a new independent parameter of OS in HCC patients and may therefore improve the predictive value of classical HCC staging scores.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	26133725	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-16 could be used as potential indicators of the progress of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	28750770	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-199a can help to differentiate HCC from CHC and LC
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Carcinoma, Hepatocellular	26637228	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A combination of serum miR-125b, miR-223, miR-27a, and miR-26a as a second-line tests could help detect  HCC in AFP (-) subjects.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Carcinoma, Hepatocellular	26756996	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-139	Carcinoma, Hepatocellular	27633066	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Reanalysis of microRNA expression profiles identifies novel biomarkers for hepatocellular carcinoma prognosis.
circulation_biomarker_diagnosis_ns	hsa-mir-139	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-200a can help to differentiate HCC from CHC and LC
circulation_biomarker_diagnosis_ns	hsa-mir-143	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-201a can help to differentiate HCC from CHC and LC
circulation_biomarker_diagnosis_ns	hsa-mir-155	Carcinoma, Hepatocellular	27751368	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Relationship Between Serum microRNA155 and Telomerase Expression in Hepatocellular Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Carcinoma, Hepatocellular	26119771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Hepatocellular	24697119	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Hepatocellular	26133725	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-18 could be used as potential indicators of the progress of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Hepatocellular	28079796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-8p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Carcinoma, Hepatocellular	29312570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA signatures and metabolomics have high diagnostic value in hepatocellular carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-183	Carcinoma, Hepatocellular	26278140	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Sensitivity and specificity of miR-183 as a diagnostic marker of HCC were 57.9% and 76.2% in serum, and 78.9% and 81.0% in plasma
circulation_biomarker_diagnosis_ns	hsa-mir-192	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Hepatocellular	25618599	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	circulating miR-199a-3p showed better predictive value in patients with long-term drinking. Our data suggested that circulating miR-375 and miR-199a-3p could be a novel serum biomarker for HCC. Nevertheless, further validating and improving study with larger sample should be conducted to confirm our results.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Hepatocellular	26133725	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-17 could be used as potential indicators of the progress of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	using miRNA panel of miR-22 and miR-199a-3p with AFP provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-202a can help to differentiate HCC from CHC and LC
circulation_biomarker_diagnosis_ns	hsa-mir-200	Carcinoma, Hepatocellular	26447841	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating microRNA-200 family members are significantly deregulated in patients with HCC and liver cirrhosis. Further studies are necessary to confirm the diagnostic value of the microRNA-200 family as accurate serum marker for cirrhosis-associated HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-9p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	24697119	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	24963487	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	26114756	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our current findings suggested that circulating miR-21 can serve as a potential co-biomarker for early-stage HCC diagnosis. Thorough large-scale studies are needed to confirm the generalizability of our findings.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	25973032	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC):clinical analyses of patients and an HCC rat model.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	29215815	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC
circulation_biomarker_diagnosis_ns	hsa-mir-22	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	using miRNA panel of miR-22 and miR-199a-3p with AFP provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	using miRNA panel of miR-122, miR-885-5p, miR-221, and miR-22 with AFP provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-223	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-6p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Carcinoma, Hepatocellular	26776075	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-30e and miR-224 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Carcinoma, Hepatocellular	28878865	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA 23a can be used as a screening test for early detection of HCC
circulation_biomarker_diagnosis_ns	hsa-mir-24	Carcinoma, Hepatocellular	25129312	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Carcinoma, Hepatocellular	29215815	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC
circulation_biomarker_diagnosis_ns	hsa-mir-26a-1	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-26a-2	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Carcinoma, Hepatocellular	29215815	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-302c	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-7p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Carcinoma, Hepatocellular	26776075	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-3126	Carcinoma, Hepatocellular	28079796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-338	Carcinoma, Hepatocellular	26119771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Carcinoma, Hepatocellular	27893432	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Carcinoma, Hepatocellular	25618599	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	circulating miR-199a-3p showed better predictive value in patients with long-term drinking. Our data suggested that circulating miR-375 and miR-199a-3p could be a novel serum biomarker for HCC. Nevertheless, further validating and improving study with larger sample should be conducted to confirm our results.
circulation_biomarker_diagnosis_ns	hsa-mir-494	Carcinoma, Hepatocellular	26509672	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-519d	Carcinoma, Hepatocellular	26509672	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment.
circulation_biomarker_diagnosis_ns	hsa-mir-595	Carcinoma, Hepatocellular	26509672	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment.
circulation_biomarker_diagnosis_ns	hsa-mir-764	Carcinoma, Hepatocellular	26119771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-92	Carcinoma, Hepatocellular	28079796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-939	Carcinoma, Hepatocellular	26509672	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Carcinoma, Hepatocellular, HBV-Related	25814782							These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Carcinoma, Hepatocellular, HBV-Related	25519019							only in the HCC group, miR-18a, miR-100, miR-145 and miR-223 were up-regulated 3.48-, 2.95-, 2.12- and 3.91-fold, respectively, and miR-200a and miR-222 were down-regulated 2.56- and 2.00-fold, respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-374a	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-542	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Carcinoma, Hepatocellular, HCV-Related	26272105							This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Hepatocellular, HCV-Related	26272105							This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular, HCV-Related	26272105							This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Carcinoma, Hepatocellular, HCV-Related	26272105							This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Carcinoma, Lung	27768748	disease of cellular proliferation	DOID:3905	C34.90	D008175			Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Carcinoma, Lung	26146958	disease of cellular proliferation	DOID:3905	C34.90	D008175			The assessment of miRs-19b-3p and -29b-3p miRNAs may provide a new diagnostic approach for the early detection of non-small cell lung cancer
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Carcinoma, Lung	27768748	disease of cellular proliferation	DOID:3905	C34.90	D008175			Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung	24865991	disease of cellular proliferation	DOID:3905	C34.90	D008175			The current evidence suggests that serum miR-21 can be rapidly measured in lung carcinoma patients and has potential diagnostic value with moderate sensitivity and specificity. Further prospective studies to assess the early stage diagnostic value are needed in the future.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Carcinoma, Lung, Non-Small-Cell	28055956			C34.90	D002289		HP:0030358	Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	28253725			C34.90	D002289		HP:0030358	Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	28002496			C34.90	D002289		HP:0030358	a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Lung, Non-Small-Cell	28634901			C34.90	D002289		HP:0030358	Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Carcinoma, Lung, Non-Small-Cell	27733164			C34.90	D002289		HP:0030358	Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Lung, Non-Small-Cell	23342174			C34.90	D002289		HP:0030358	a three-miRNA plasma panel (high miR-20a-5p, low miR-152-3p, and low miR-199a-5p) significantly predicted survival of squamous cell carcinoma patients. In conclusion, we identified two plasma miRNA expression profiles that may be useful for predicting the outcome of patients with resectable NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	28634901			C34.90	D002289		HP:0030358	Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	28002496			C34.90	D002289		HP:0030358	a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Carcinoma, Lung, Non-Small-Cell	26672767			C34.90	D002289		HP:0030358	Among the top markers that were concordant between both studies we found hsa-miR-20b-5p, hsa-miR-20a-5p, hsa-miR-17-5p, and hsa-miR-106a-5p.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	28055956			C34.90	D002289		HP:0030358	Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	28002496			C34.90	D002289		HP:0030358	a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC
circulation_biomarker_diagnosis_ns	hsa-mir-22	Carcinoma, Lung, Non-Small-Cell	28253725			C34.90	D002289		HP:0030358	Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-23b	Carcinoma, Lung, Non-Small-Cell	28055956			C34.90	D002289		HP:0030358	Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-372	Carcinoma, Lung, Non-Small-Cell	27122989			C34.90	D002289		HP:0030358	A sputum mir-21, mir-210, and mir-372 expression profile might provide a sensitive and highly specific means for detecting nsclc.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Carcinoma, Lung, Non-Small-Cell	25755772			C34.90	D002289		HP:0030358	These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	22009180			C34.90	D002289		HP:0030358	There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-141	Carcinoma, Lung, Non-Small-Cell	26202143			C34.90	D002289		HP:0030358	we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	25755772			C34.90	D002289		HP:0030358	These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Carcinoma, Lung, Non-Small-Cell	25755772			C34.90	D002289		HP:0030358	These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-148	Carcinoma, Lung, Non-Small-Cell	25904302			C34.90	D002289		HP:0030358	The results of present study suggest that the expression levels of circulating miR-148/152 family may serve as biomarkers for NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-152	Carcinoma, Lung, Non-Small-Cell	25904302			C34.90	D002289		HP:0030358	The results of present study suggest that the expression levels of circulating miR-148/152 family may serve as biomarkers for NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Carcinoma, Lung, Non-Small-Cell	22009180			C34.90	D002289		HP:0030358	There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Carcinoma, Lung, Non-Small-Cell	26202143			C34.90	D002289		HP:0030358	we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Carcinoma, Lung, Non-Small-Cell	26202143			C34.90	D002289		HP:0030358	we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	23881177			C34.90	D002289		HP:0030358	Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23881177			C34.90	D002289		HP:0030358	Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	24065453			C34.90	D002289		HP:0030358	These findings suggest that serum miR-210 levels might be a novel diagnostic and prognostic marker of NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-214	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-222	Carcinoma, Lung, Non-Small-Cell	22009180			C34.90	D002289		HP:0030358	There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-301	Carcinoma, Lung, Non-Small-Cell	26202143			C34.90	D002289		HP:0030358	we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-451b	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-486	Carcinoma, Lung, Non-Small-Cell	26237047			C34.90	D002289		HP:0030358	The results suggest that miR-486 and miR-150 could be potential blood-based biomarkers for early diagnosis of NSCLC. Monitoring change of miR-486 expression in plasma might be an effective and non-invasive method for recurrence prediction of early-staged NSCLC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Carcinoma, Lung, Non-Small-Cell	24549225			C34.90	D002289		HP:0030358	Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Carcinoma, Lung, Small-Cell	28106539			C34.90	D055752	182280	HP:0030357	Plasma miR-92a-2 as a biomarker for small cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Nasopharyngeal	24025417	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	plasma miRNA expression is a useful biomarker for NPC diagnosis but not for its prognosis. More importantly, it is simple, effective, and non-invasive. Combination of several plasma miRNAs can increase both NPC diagnostic sensitivity and specificity. miR-329,hsa-mir-487b,hsa-mir-494,hsa-mir-495
circulation_biomarker_diagnosis_ns	hsa-mir-24	Carcinoma, Nasopharyngeal	26018275	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Plasma miR-24 may serve as a novel molecular biomarker for early diagnosis and prognosis of NPC.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Nasopharyngeal	24874644	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-548q	Carcinoma, Nasopharyngeal	24874644	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Carcinoma, Nasopharyngeal	24327016	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our study reports that plasma miR-9 may serve as a useful biomarker to predict NPC metastasis and to monitor tumour dynamics.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Carcinoma, Oral	22902387	gastrointestinal system disease	DOID:0050610					miR-27b-regulated TCTP as a novel plasma biomarker for oral cancer: From quantitative proteomics to post-transcriptional study.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Carcinoma, Ovarian	27092777	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Carcinoma, Ovarian	27062783	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Carcinoma, Ovarian, Serous	28017893	endocrine system disease	DOID:0050933					Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-191	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Carcinoma, Pancreatic	27631726			C25.3	C562463	260350	HP:0002894	Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-25	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-25	Carcinoma, Pancreatic	27639768			C25.3	C562463	260350	HP:0002894	Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-323	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-345	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-642b	Carcinoma, Pancreatic	27631726			C25.3	C562463	260350	HP:0002894	Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Carcinoma, Pancreatic	27631726			C25.3	C562463	260350	HP:0002894	Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Carcinoma, Prostate	28091918	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-297	Carcinoma, Prostate	28091918	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Rectal	20880178	disease of cellular proliferation	DOID:1993	C20	D012004			The direct amplification of plasma miR-221 can be used as a potential noninvasive molecular marker for diagnosis and prognosis of CRC and is correlated with p53 expression.
circulation_biomarker_diagnosis_ns	hsa-mir-106a	Carcinoma, Renal Cell	27814278	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-1233	Carcinoma, Renal Cell	29262564	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Renal Cell	27814278	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Renal Cell	23064048	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Renal Cell	26426010	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Renal Cell	29262564	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Renal Cell	25909813	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Renal Cell	29262564	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-222	Carcinoma, Renal Cell	25909813	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Carcinoma, Renal Cell	26426010	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Carcinoma, Renal Cell	25909813	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Renal Cell, Clear-Cell	24212760	disease of cellular proliferation	DOID:4467				HP:0006770	Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-148b	Carcinoma, Thyroid, Follicular	27473101	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	The best two-miRNA classifier (miR-484/miR-148b-3p) identified thyroid malignancy with a sensitivity of 89鈥? and a specificity of 87鈥?.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Carcinoma, Thyroid, Papillary	26341226	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Carcinoma, Thyroid, Papillary	26341226	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Carcinoma, Thyroid, Papillary	28288173	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Microarray profiling of circular RNAs in human papillary thyroid carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Carcinoma, Thyroid, Papillary	26341226	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	24301304	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This study demonstrated that tumor levels of miR-222 and miR-146b are associated with PTC recurrence and that miR-222 and miR-146b levels in the circulation correspond to the presence of PTC. The potential of these miRNAs as tumor biomarkers to improve patient stratification according to the risk of recurrence and as circulating biomarkers for PTC surveillance warrants further study.
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Carcinoma, Thyroid, Papillary	26341226	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Carcinoma, Thyroid, Papillary	28288173	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Microarray profiling of circular RNAs in human papillary thyroid carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Thyroid, Papillary	28061868	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Carcinoma, Thyroid, Papillary	24301304	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This study demonstrated that tumor levels of miR-222 and miR-146b are associated with PTC recurrence and that miR-222 and miR-146b levels in the circulation correspond to the presence of PTC. The potential of these miRNAs as tumor biomarkers to improve patient stratification according to the risk of recurrence and as circulating biomarkers for PTC surveillance warrants further study.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Carcinoma, Thyroid, Papillary	26168287	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Carcinoma, Thyroid, Papillary	26168287	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-let-7c	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-let-7f	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-1244	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-135	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-33b	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-429	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-431	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-520b	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-664a	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-133	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-29	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Cardiomyopathy, Dilated	25840506	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
circulation_biomarker_diagnosis_ns	hsa-mir-636	Cardiomyopathy, Dilated	25840506	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
circulation_biomarker_diagnosis_ns	hsa-mir-639	Cardiomyopathy, Dilated	25840506	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
circulation_biomarker_diagnosis_ns	hsa-mir-646	Cardiomyopathy, Dilated	25840506	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Cardiovascular Diseases [unspecific]	27924211				D002318			Circulating miR-126 and miR-499 reflect progression of cardiovascular disease; correlations with uric acid and ejection fraction.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-151	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Cardiovascular Diseases [unspecific]	24573468				D002318			Smoking alters circulating plasma microvesicle pattern and microRNA signatures.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Cardiovascular Diseases [unspecific]	27725938				D002318			Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-26	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Cardiovascular Diseases [unspecific]	24573468				D002318			Smoking alters circulating plasma microvesicle pattern and microRNA signatures.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-33	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Cardiovascular Diseases [unspecific]	27725938				D002318			Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-503	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-645	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-758	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-449a	Celiac Disease	28878141	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	Intestinal and Circulating MicroRNAs in Coeliac Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-150	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-205	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-215	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-467a	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-486	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-155	Cervical Neoplasms	28934937	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer
circulation_biomarker_diagnosis_ns	hsa-mir-21	Cervical Neoplasms	28934937	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer
circulation_biomarker_diagnosis_ns	hsa-mir-9	Cervical Neoplasms	28934937	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Chagas Disease	29559958	disease by infectious agent	DOID:12140	B57	D014355			Circulating Plasma MicroRNA-208a as Potential Biomarker of Chronic Indeterminate Phase of Chagas Disease
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Cholangiocarcinoma	26864161	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-200c was found to be expressed differentially in PSC versus controls
circulation_biomarker_diagnosis_ns	hsa-mir-21	Cholangiocarcinoma	27685844	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Cholangiocarcinoma	27685844	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Cholangiocarcinoma	26864161	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	a difference in the expression of miR-222 and miR-483-5p in CC versus PSC
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Cholangiocarcinoma	26087181	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Choriocarcinoma	25202432	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Normalization of miR-98 expression levels to those of U6 snRNA, miR-192 or a combination of these  genes enabled the detection of a significant difference between BPE and LA-MPE samples.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Chronic Hepatitis	28368488			K75.9	D006521		HP:0200123	Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Hepatitis B	24643113			B18.0-.1	D019694	610424		Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C.
circulation_biomarker_diagnosis_ns	hsa-mir-124	Chronic Hepatitis B	25131617			B18.0-.1	D019694	610424		Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Chronic Hepatitis B	26131144			B18.0-.1	D019694	610424		Positive correlation was found between the levels of hsa- miR-146a and ALT
circulation_biomarker_diagnosis_ns	hsa-mir-182	Chronic Hepatitis B	28562750			B18.0-.1	D019694	610424		Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Chronic Hepatitis B	26319884			B18.0-.1	D019694	610424		Serum miR-210 can be used as an indicator of HBV replication and translation, and a potential marker of necroinflammation in patients with CHB.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-29	Chronic Hepatitis B	25138057			B18.0-.1	D019694	610424		Serum miR-29 levels are negatively correlated with liver fibrotic stages and necroinflammation grades in patients with chronic HBV infection. miR-29 appears to be a novel biomarkers for predicting disease progression in these patients.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-511	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-98	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Hepatitis C	24643113			B18.2	D019698	609532		Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Hepatitis C	28211229			B18.2	D019698	609532		Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Chronic Hepatitis C	25877355			B18.2	D019698	609532		Involvement of TLR2-MyD88 in abnormal expression of miR-146a in peripheral blood monocytes of patients with chronic hepatitis C.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-mir-196	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Chronic Hepatitis C	25738504			B18.2	D019698	609532		Circulating microRNA-196a as a candidate diagnostic biomarker for chronic hepatitis C.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-mir-296	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-30	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-324	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-126	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-1281	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Chronic Kidney Disease	22512691	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Reduced Circulating miR-15b Is Correlated with Phosphate Metabolism in Patients with End-Stage Renal Disease on Maintenance Hemodialysis.
circulation_biomarker_diagnosis_ns	hsa-mir-1825	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-21	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Obstructive Pulmonary Disease	23814167	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Plasma levels of individual myomiRs are altered in patients with COPD but alone do not predict muscle fibre size or proportion. Our findings are consistent with an increase in muscle wasting and turnover associated with the development of skeletal muscle dysfunction and fibre-type shift in patients with stable COPD.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Chronic Obstructive Pulmonary Disease	23814167	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Plasma levels of individual myomiRs are altered in patients with COPD but alone do not predict muscle fibre size or proportion. Our findings are consistent with an increase in muscle wasting and turnover associated with the development of skeletal muscle dysfunction and fibre-type shift in patients with stable COPD.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-4732	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-491	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-644b	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Colon Neoplasms	28415718			D12.6	D003110		HP:0100273	Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Colon Neoplasms	28415718			D12.6	D003110		HP:0100273	Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Colorectal Adenocarcinoma	25115394	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Colorectal Carcinoma	26134152	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Colorectal Carcinoma	27632639	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1229	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-135a	Colorectal Carcinoma	27998467	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Expression and significance of serum microRNA-135a-5p level in colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-135b	Colorectal Carcinoma	24691020	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Stool-based miR-135b can be used as a noninvasive biomarker for the detection of CRC and advanced adenoma. 
circulation_biomarker_diagnosis_ns	hsa-mir-139	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Colorectal Carcinoma	25269744	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Colorectal Carcinoma	28177881	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A panel of microRNA signature in serum for colorectal cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-200	Colorectal Carcinoma	27632639	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-202	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-203	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	24586105	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Re: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	25524942	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-21 may be a suitable diagnostic biomarker for CRC with moderate sensitivity and specificity. Further studies should evaluate the diagnostic value of miR-21 for CRC in the future.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	25683351	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	28177881	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A panel of microRNA signature in serum for colorectal cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Colorectal Carcinoma	23840538	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miRNA-29c shows anti-tumorigenesis activity, and preoperative circulating miRNA-29c levels can be used to predict postoperative early relapse of CRC.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Colorectal Carcinoma	24573638	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Colorectal Carcinoma	24573638	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Colorectal Carcinoma	24573638	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Colorectal Carcinoma	24423916	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma levels of miR-378 could be used to discriminate CRC patients from healthy individuals, irrespective of the level of haemoglobin of plasma samples.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Colorectal Carcinoma	25807655	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Colorectal Carcinoma	28177881	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A panel of microRNA signature in serum for colorectal cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-431	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-451	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-484	Colorectal Carcinoma	25807655	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-532	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-532	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-652	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-720	Colorectal Carcinoma	26134152	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Colorectal Carcinoma	25736690	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		All 3 miRNAs studied were positively inter-correlated.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Colorectal Carcinoma	25405754	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Colorectal Carcinoma	26038573	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Colorectal Carcinoma	24646542	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-15b and miR-17 Are Tumor-derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Colorectal Carcinoma	25405754	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Colorectal Carcinoma	24646542	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-15b and miR-17 Are Tumor-derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Colorectal Carcinoma	23673725	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-18a and miR-29a could be promising biomarkers for the screening and monitoring of CRC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	25405754	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	26038573	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	25405754	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	26038573	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	19876917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-29a:plasma miR-29a and miR-92a have significant diagnostic value for advanced neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	22018950	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	23673725	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-18a and miR-29a could be promising biomarkers for the screening and monitoring of CRC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-92a-1	Colorectal Carcinoma	19876917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-92a:plasma miR-29a and miR-92a have significant diagnostic value for advanced neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-92a-2	Colorectal Carcinoma	19876917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-92a:plasma miR-29a and miR-92a have significant diagnostic value for advanced neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-126	Coronary Artery Disease	25327597	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Plasma miR-126 level is positively correlated to the CCC formation and is an independent predictor of CCC development in patients with severely narrowed coronary arteries, suggesting that plasma miR-126 might be a useful new, stable blood biomarker for predicting CCC formation in patients with severely narrowed coronary arteries.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Coronary Artery Disease	20595655	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Consistent with the data obtained by the profile, circulating levels of miR-126, miR-17, miR-92a, and the inflammation-associated miR-155 were significantly reduced in patients with coronary artery disease compared with healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Coronary Artery Disease	25349183	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		In contrast, increased expression of miR-126 and miR-199a in circulating MVs was significantly associated with a lower major adverse CV event rate.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Coronary Artery Disease	28628920	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Coronary Artery Disease	28205634	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Coronary Artery Disease	29357324	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circulating MiR-146a May be a Potential Biomarker of Coronary Heart Disease in Patients with Subclinical Hypothyroidism.
circulation_biomarker_diagnosis_ns	hsa-mir-149	Coronary Artery Disease	25664324	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circulating miR-765 and miR-149: potential noninvasive diagnostic biomarkers for geriatric coronary artery disease patients.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Coronary Artery Disease	29411649	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		serum miR-155 content may serve as a novel biomarker for evaluating severity of CHD
circulation_biomarker_diagnosis_ns	hsa-mir-155	Coronary Artery Disease	28628920	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Coronary Artery Disease	20595655	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Consistent with the data obtained by the profile, circulating levels of miR-126, miR-17, miR-92a, and the inflammation-associated miR-155 were significantly reduced in patients with coronary artery disease compared with healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Coronary Artery Disease	27602213	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Coronary Artery Disease	28628920	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China.
circulation_biomarker_diagnosis_ns	hsa-mir-370	Coronary Artery Disease	27602213	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease.
circulation_biomarker_diagnosis_ns	hsa-mir-765	Coronary Artery Disease	25664324	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circulating miR-765 and miR-149: potential noninvasive diagnostic biomarkers for geriatric coronary artery disease patients.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Coronary Artery Disease	20595655	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Consistent with the data obtained by the profile, circulating levels of miR-126, miR-17, miR-92a, and the inflammation-associated miR-155 were significantly reduced in patients with coronary artery disease compared with healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Coronary Atherosclerosis	26159918			I25.1	D003324		HP:0004929	miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation.
circulation_biomarker_diagnosis_ns	hsa-mir-1273	Coronary Atherosclerosis	26159918			I25.1	D003324		HP:0004929	miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Coronary Atherosclerosis	26159918			I25.1	D003324		HP:0004929	miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Coronary Atherosclerosis	26159918			I25.1	D003324		HP:0004929	miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation.
circulation_biomarker_diagnosis_ns	hsa-mir-598	Crohn Colitis	29272478	gastrointestinal system disease	DOID:0060192	K50.1	D003424			Two miRNAs (miR-598, miR-642) were consistently different between the patient groups
circulation_biomarker_diagnosis_ns	hsa-mir-642	Crohn Colitis	29272478	gastrointestinal system disease	DOID:0060192	K50.1	D003424			Two miRNAs (miR-598, miR-642) were consistently different between the patient groups
circulation_biomarker_diagnosis_ns	hsa-mir-19	Crohn Disease	25985247	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	These data identify miR-19-3p as a potential circulating marker of stricturing CD. Our data show that microRNAs have utility as noninvasive biomarkers of stricturing CD. Further longitudinal studies are required to determine the prognostic value of miR-19-3p at diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-149	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-524	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Dementia	29559383	disease of mental health	DOID:1307	F03	D003704	127750	HP:0000726	Serum Exosomal miR-223 Serves as a Potential Diagnostic and Prognostic Biomarker for Dementia
circulation_biomarker_diagnosis_ns	hsa-let-7e	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-132	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-155	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-184	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus	26498351	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells:relationship with type 2 diabetes complications.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus	24927146	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus	29452547	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Plasma miR-126 and miR-210 levels may be biomarkers for diabetes with or without CAD
circulation_biomarker_diagnosis_ns	hsa-mir-21	Diabetes Mellitus	26498351	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells:relationship with type 2 diabetes complications.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Diabetes Mellitus	25120598	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Compared with the miR-375 levels in patients with normal glucose tolerance (NGT; n=53), the samples from patients with IGT (n=44) exhibited downregulation of miR-375, while those from patients with T2DM (n=54) exhibited upregulation of miR-375 in the plasma.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-1275	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-150	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-21	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-210	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-24	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-342	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-375	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-103	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus, Type 2	23144172	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	AngiomiR-126 expression and secretion from circulating CD34+ and CD14+ PBMCs:role for proangiogenic effects and alterations in type 2 diabetics
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus, Type 2	24455723	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-138	Diabetes Mellitus, Type 2	24204780	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Diabetes Mellitus, Type 2	18633110	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-146: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-148	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Diabetes Mellitus, Type 2	24204780	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Diabetes Mellitus, Type 2	25530976	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-182 can be a biomarker in diagnosis of the potential T2D that has benefits for medical purpose.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Diabetes Mellitus, Type 2	24981880	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-320d	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Diabetes Mellitus, Type 2	29373500	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus
circulation_biomarker_diagnosis_ns	hsa-mir-376a	Diabetes Mellitus, Type 2	24204780	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-3960	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-409	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-4534	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-454	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-455	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-503	Diabetes Mellitus, Type 2	24204780	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-572	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-665	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-766	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Diabetic Cardiomyopathies	29044172				D058065			Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Diabetic Cardiomyopathies	29044172				D058065			Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-130b	Diabetic Nephropathy	25952368			E10-11.21	D003928			Our findings suggest that serum miR-130b may be a new biomarker for the early diagnosis of DN in T2DM. Circulating miR-130b may possibly be involved  in the pathological mechanism of DN, such as lipid metabolic disorders, oxidative stress, extracellular matrix deposition and renal fibrosis.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Digestive System Neoplasms	26683919			D49.0	D004067			Potential Role of Circulating MiR-21 in the Diagnosis and Prognosis of Digestive System Cancer: A Systematic Review and Meta-Analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-139	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-365	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-484	Early-Stage Breast Carcinoma	24641801			D05.10	D001943	114480		In this study, we found that miR-484 is significantly differentially expressed in serum of early breast cancer patients compared to healthy volunteers. We did not however find any correlation between miR-484 levels with histopathological parameters of the breast cancers. With further studies, miR-484 may prove useful as an adjunct to mammography for detection of early breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-2392	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-3162	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-4484	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-451	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Early-Stage Lung Carcinoma	24553369					211980		4-(Methylnitrosamino)-1-(3-pyridyl) -1-butanone induces circulating microRNA deregulation in early lung carcinogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Early-Stage Lung Carcinoma	24553369					211980		4-(Methylnitrosamino)-1-(3-pyridyl) -1-butanone induces circulating microRNA deregulation in early lung carcinogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Early-Stage Non-Small-Cell Lung Carcinoma	27093275			C34.90	D002289	211980		Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Early-Stage Non-Small-Cell Lung Carcinoma	27093275			C34.90	D002289	211980		Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Early-Stage Non-Small-Cell Lung Carcinoma	27093275			C34.90	D002289	211980		Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Early-Stage Non-Small-Cell Lung Carcinoma	27093275			C34.90	D002289	211980		Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Early-Stage Non-Small-Cell Lung Carcinoma	24523873			C34.90	D002289	211980		The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-429	Early-Stage Non-Small-Cell Lung Carcinoma	24523873			C34.90	D002289	211980		The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Early-Stage Non-Small-Cell Lung Carcinoma	24523873			C34.90	D002289	211980		The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-873	Ectopic Pregnancy	28472791	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	MicroRNA-873 is a Potential Serum Biomarker for the Detection of Ectopic Pregnancy.
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Endometrial Neoplasms	22920721	reproductive system disease	DOID:1380	C54.1	D016889	608089		Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-99a	Endometrial Neoplasms	22920721	reproductive system disease	DOID:1380	C54.1	D016889	608089		Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Endometriosis	19692421	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-145	Endometriosis	29308623	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis
circulation_biomarker_diagnosis_ns	hsa-mir-145	Endometriosis	29633787	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis
circulation_biomarker_diagnosis_ns	hsa-mir-200	Endometriosis	26206343	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Circulating miR-200-family micro-RNAs have altered plasma levels in patients with endometriosis and vary with blood collection time.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Endometriosis	29308623	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis
circulation_biomarker_diagnosis_ns	hsa-mir-31	Endometriosis	29633787	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis
circulation_biomarker_diagnosis_ns	hsa-mir-29	Endomyocardial Fibrosis	25457410	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	Reply: MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Epilepsy	27840934	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Epilepsy	27840934	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure.
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-194	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Epilepsy	27840934	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Epilepsy	27840934	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure.
circulation_biomarker_diagnosis_ns	hsa-mir-9a	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Esophageal Neoplasms	23361059			C15.9	D004938	133239	HP:0100751	Serum;Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-155	Esophageal Neoplasms	22891887			C15.9	D004938	133239	HP:0100751	The relative expressions of miR-155, miR-183, and miR-20a in esophageal tissue were found to be significantly associated with increased risk for esophageal cancer. Circulating miR-155 showed significantly higher risk for esophageal cancer when adjusted by smoking status and alcohol use. Circulating miR-155 was found to have significant diagnostic value for esophageal cancer as evidenced by a receiver operating characteristic curve area of 66%.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-361	Essential Hypertension	28445253	cardiovascular system disease	DOID:10825	I10	C562386	145500		micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-362	Essential Hypertension	28445253	cardiovascular system disease	DOID:10825	I10	C562386	145500		micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-34	Ewing Sarcoma	26659003	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MicroRNA expression profiling may have some potential for prediction of disease progression and survival in Ewing sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Fatty Liver, Non-Alcoholic	24313922	disease of metabolism	DOID:0080208	K75.81	D065626	613282		We found that the hepatic and serum miR-122 levels were associated with hepatic steatosis and fibrosis. The serum miR-122 level can be a useful predictive marker of liver fibrosis in patients with NAFLD.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Fatty Liver, Non-Alcoholic	27077736	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Fatty Liver, Non-Alcoholic	27955628	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Fatty Liver, Non-Alcoholic	27077736	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Fatty Liver, Non-Alcoholic	27956809	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-1225	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-186	Focal Segmental Glomerulosclerosis	25218681	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Plasma miR-186 may be a biomarker for FSGS with nephrotic proteinuria.
circulation_biomarker_diagnosis_ns	hsa-mir-1915	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Focal Segmental Glomerulosclerosis	28246603	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-663	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Foot-and-Mouth Disease	28388926				D005536			Proof-of-concept study: profile of circulating microRNAs in Bovine serum harvested during acute and persistent FMDV infection.
circulation_biomarker_diagnosis_ns	hsa-mir-424	Fragile X Syndrome	23790110	genetic disease	DOID:14261	Q99.2	D005600	300624		MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Fragile X Syndrome	23790110	genetic disease	DOID:14261	Q99.2	D005600	300624		MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-130b	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-142	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-151a	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-323a	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-330	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-625	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-let-7a	Gastric Neoplasms	23519840	disease of cellular proliferation	DOID:10534	C16	D013274	137215		High CCR7 protein expression may be caused by the loss of Dicer 1 protein expression and reduced let-7a miRNA level in gastric cancer. The serum let-7a level might be a marker for the diagnosis of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-106a	Gastric Neoplasms	20349219	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106a:detection of miRNA in peripheral blood may be a novel tool for monitoring circulating tumor cells in patients with gastric cancers
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Gastric Neoplasms	25218271	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Gastric Neoplasms	24481716	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-129-1	Gastric Neoplasms	23307240	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Gastric juice miR-129 as a potential biomarker for screening gastric cancer
circulation_biomarker_diagnosis_ns	hsa-mir-129-2	Gastric Neoplasms	23307240	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Gastric juice miR-129 as a potential biomarker for screening gastric cancer
circulation_biomarker_diagnosis_ns	hsa-mir-140	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Gastric Neoplasms	20349219	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-17:detection of miRNA in peripheral blood may be a novel tool for monitoring circulating tumor cells in patients with gastric cancers
circulation_biomarker_diagnosis_ns	hsa-mir-185	Gastric Neoplasms	26059512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Gastric Neoplasms	24626859	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating miR-18a could be a useful biomarker for screening GC and monitoring tumor dynamics.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Gastric Neoplasms	24481716	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Gastric Neoplasms	29535809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		circulating miRNA-196a is a novel biomarker for detection of early gastric cancer and its precursor
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-199a-1	Gastric Neoplasms	23733518	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiRNA-199a-3p: A Potential Circulating Diagnostic Biomarker for Early Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-199a-2	Gastric Neoplasms	23733518	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiRNA-199a-3p: A Potential Circulating Diagnostic Biomarker for Early Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Gastric Neoplasms	24947260	disease of cellular proliferation	DOID:10534	C16	D013274	137215		GDF15 and MMP7 serum levels have diagnostic value for GC. The combination marker formed by GDF15, MMP7 and miR-200c is indicative of adverse evolution in GC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Gastric Neoplasms	26059512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Gastric Neoplasms	23521833	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The levels of serum miR-20a-5p, let-7a and miR-320a were positively correlated with PGA/PGC, which may indirectly reflect the functional status of the gastric mucosa.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Gastric Neoplasms	28413641	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Serum miR-20a is a promising biomarker for gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Gastric Neoplasms	26509997	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In summary, we verified the diagnostic and prognostic value of tissue hsa-miR-21hsa-miR-21 and hsa-miR-29 in GC. Both of them can be potentially applied as novel and non-invasive biomarkers for GC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Gastric Neoplasms	26720919	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Two-stage cyclic enzymatic amplification method for ultrasensitive electrochemical assay of microRNA-21 in the blood serum of gastric cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Gastric Neoplasms	26059512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Gastric Neoplasms	22432036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three serum miRNAs (miR-221, miR-744, and miR-376c) as potential biomarkers for GC detection
circulation_biomarker_diagnosis_ns	hsa-mir-222	Gastric Neoplasms	25129310	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Gastric Neoplasms	27010210	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-29	Gastric Neoplasms	26509997	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In summary, we verified the diagnostic and prognostic value of tissue hsa-miR-21hsa-miR-21 and hsa-miR-29 in GC. Both of them can be potentially applied as novel and non-invasive biomarkers for GC.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Gastric Neoplasms	23521833	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The levels of serum miR-20a-5p, let-7a and miR-320a were positively correlated with PGA/PGC, which may indirectly reflect the functional status of the gastric mucosa.
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Gastric Neoplasms	22432036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three serum miRNAs (miR-221, miR-744, and miR-376c) as potential biomarkers for GC detection
circulation_biomarker_diagnosis_ns	hsa-mir-421	Gastric Neoplasms	22263628	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Gastric Neoplasms	24603541	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, our results revealed the oncogenic roles of miR-191 and miR-425 in gastric carcinogenesis, and indicated the potential use of serum miR-191 as a novel and stable biomarker for GC diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-433	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-627	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-629	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-744	Gastric Neoplasms	22432036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three serum miRNAs (miR-221, miR-744, and miR-376c) as potential biomarkers for GC detection
circulation_biomarker_diagnosis_ns	hsa-mir-92b	Gastric Neoplasms	26059512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Gastrointestinal Neoplasms	22198701			D37.9	D005770			The algorithms revealed miR-16 and miR-93 were the most stably expressed reference genes, with stability values of 1.778 and 2.213, respectively, for serum microRNA analysis across all the patients and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Gastrointestinal Neoplasms	22198701			D37.9	D005770			The algorithms revealed miR-16 and miR-93 were the most stably expressed reference genes, with stability values of 1.778 and 2.213, respectively, for serum microRNA analysis across all the patients and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-367	Germ Cell Tumor	26671749	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Germ Cell Tumor	25187505	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Germ Cell Tumor	26671749	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
circulation_biomarker_diagnosis_ns	hsa-mir-372	Germ Cell Tumor	26671749	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
circulation_biomarker_diagnosis_ns	hsa-mir-373	Germ Cell Tumor	26671749	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
circulation_biomarker_diagnosis_ns	hsa-mir-224	Giant Cell Tumor of Bone	22326282	disease of cellular proliferation	DOID:4305		D018212		HP:0011847	altered expression
circulation_biomarker_diagnosis_ns	hsa-mir-144	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-184	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-202	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-3074	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-4448	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Glioblastoma	23174013				D005909		HP:0100843	The plasma levels of miR-21, miR-128 and miR-342-3p were significantly altered in GBM patients compared to normal controls and could discriminate glioma from healthy controls with high specificity and sensitivity
circulation_biomarker_diagnosis_ns	hsa-mir-21	Glioblastoma	23174013				D005909		HP:0100843	The plasma levels of miR-21, miR-128 and miR-342-3p were significantly altered in GBM patients compared to normal controls and could discriminate glioma from healthy controls with high specificity and sensitivity
circulation_biomarker_diagnosis_ns	hsa-mir-221	Glioblastoma	28381184				D005909		HP:0100843	microRNA expression levels was built, which has the potential to be used in clinics and thus to improve the survival status of glioblastoma multiforme patients
circulation_biomarker_diagnosis_ns	hsa-mir-222	Glioblastoma	28381184				D005909		HP:0100843	microRNA expression levels was built, which has the potential to be used in clinics and thus to improve the survival status of glioblastoma multiforme patients
circulation_biomarker_diagnosis_ns	hsa-mir-342	Glioblastoma	23174013				D005909		HP:0100843	The plasma levels of miR-21, miR-128 and miR-342-3p were significantly altered in GBM patients compared to normal controls and could discriminate glioma from healthy controls with high specificity and sensitivity
circulation_biomarker_diagnosis_ns	hsa-let-7g	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-124	Glioma	23936026	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These results suggest that miR-124 may function as anti-migration and anti-invasion influence in glioma and provides a potential approach for developing miR-124-based therapeutic strategies for malignant glioma therapy.
circulation_biomarker_diagnosis_ns	hsa-mir-1825	Glioma	28475008	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A novel serum microRNA-based identification and classification biomarker of human glioma.
circulation_biomarker_diagnosis_ns	hsa-mir-185	Glioma	26458593	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These findings suggest that plasma miR-185 has become potential biomarkers for glioma and may be useful in clinical management for glioma patients.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Glioma	27981547	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Circulating miR-199a-3p in plasma and its potential diagnostic and prognostic value in glioma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Glioma	26284486	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Therefore, we concluded that the exosomal miR-21 levels could be demonstrated as a promising indicator for glioma diagnosis and prognosis, particularly with values to predict tumor recurrence or metastasis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Glioma	25756397	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Serum miR-210 is a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
circulation_biomarker_diagnosis_ns	hsa-mir-29	Glioma	25367878	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Identification and Evaluation of Serum MicroRNA-29 Family for Glioma Screening.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Glioma	26620922	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-29b and VEGFA in blood were significantly different compared with the control group
circulation_biomarker_diagnosis_ns	hsa-mir-320	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-340	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-454	Glioma	28815332	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls
circulation_biomarker_diagnosis_ns	hsa-mir-576	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-590	Glioma	28815332	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls
circulation_biomarker_diagnosis_ns	hsa-mir-626	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Glioma	28815332	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls
circulation_biomarker_diagnosis_ns	hsa-mir-21	Glomerulonephritis	25468389	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	Furthermore, the glomerular and serum levels of miR-21, a putative microRNA ligand of TLR8, were higher in BXSB-Yaa mice than in BXSB mice.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-374a	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-377	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-411	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-489	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-586	Graft-Versus-Host Disease	26051902			D89.813	D006086	614395		Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-671	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Head And Neck Neoplasms	19043531	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	mir-205: a marker of metastatic
circulation_biomarker_diagnosis_ns	hsa-let-7b	Heart Failure	25763857			I50	D006331		HP:0001635	Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells.
circulation_biomarker_diagnosis_ns	hsa-let-7i	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Heart Failure	26498537			I50	D006331		HP:0001635	Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Heart Failure	28052002			I50	D006331		HP:0001635	Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Heart Failure	23696613			I50	D006331		HP:0001635	Four microRNAs, miR-103, miR-142-3p, miR-30b, and miR-342-3p, were differentially expressed between HF and controls
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Heart Failure	23247724			I50	D006331		HP:0001635	We identified new circulating miRNAs (miR-454, miR-500, miR-1246, miR-142-3p) which showed distinct patterns of expression in patients with diastolic dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Heart Failure	25619197			I50	D006331		HP:0001635	Of these, miR-1233, -183-3p, -190a, -193b-3p, -193b-5p, -211-5p, -494, and -671-5p distinguished HF from controls.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-129	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Heart Failure	28666417			I50	D006331		HP:0001635	Identifying differential miR and gene consensus patterns in peripheral blood of patients with cardiovascular diseases from literature data.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Heart Failure	23247724			I50	D006331		HP:0001635	We identified new circulating miRNAs (miR-454, miR-500, miR-1246, miR-142-3p) which showed distinct patterns of expression in patients with diastolic dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Heart Failure	23696613			I50	D006331		HP:0001635	Four microRNAs, miR-103, miR-142-3p, miR-30b, and miR-342-3p, were differentially expressed between HF and controls
circulation_biomarker_diagnosis_ns	hsa-mir-145	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Heart Failure	29258606			I50	D006331		HP:0001635	Inflammation-associated microRNA changes in circulating exosomes of heart failure patients
circulation_biomarker_diagnosis_ns	hsa-mir-155	Heart Failure	22939041			I50	D006331		HP:0001635	Angiotensin Receptor Type 1 Single Nucleotide Polymorphism 1166A/C is Associated With Malignant Arrhythmias and Altered Circulating miR-155 Levels in Patients With Chronic Heart Failure.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Heart Failure	29258606			I50	D006331		HP:0001635	Inflammation-associated microRNA changes in circulating exosomes of heart failure patients
circulation_biomarker_diagnosis_ns	hsa-mir-182	Heart Failure	25985726			I50	D006331		HP:0001635	miR-182 (p = 0.04), miR-200a* (p = 0.019), and miR-568 (p = 0.023) were found to be inversely  correlated with LVM index (LVMI), while miR-155 (p = 0.019) and miR-595 (p = 0.04) were determined to be positively correlated with LVMI.
circulation_biomarker_diagnosis_ns	hsa-mir-199	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-208	Heart Failure	23676496			I50	D006331		HP:0001635	Gain-of-function and loss-of-function strategies in mice, together with assessment of muscle biopsies from humans, demonstrated that type I muscle fiber proportion is increased via the stimulatory actions of ERRγ on the expression of miR-499 and miR-208b.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Heart Failure	26498537			I50	D006331		HP:0001635	Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Heart Failure	26498537			I50	D006331		HP:0001635	Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Heart Failure	26211628			I50	D006331		HP:0001635	MiR-21 levels were not different among the groups.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-211	Heart Failure	25619197			I50	D006331		HP:0001635	Of these, miR-1233, -183-3p, -190a, -193b-3p, -193b-5p, -211-5p, -494, and -671-5p distinguished HF from controls.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Heart Failure	25364765			I50	D006331		HP:0001635	miR-24 and miR-214 are bi-functional cardio-miRs.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Heart Failure	29499204			I50	D006331		HP:0001635	miR-25 expression during different stages of heart disease, offers a new perspective for the role of miR-25 function in heart failure
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Heart Failure	28475616			I50	D006331		HP:0001635	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Heart Failure	23696613			I50	D006331		HP:0001635	Four microRNAs, miR-103, miR-142-3p, miR-30b, and miR-342-3p, were differentially expressed between HF and controls
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Heart Failure	25995320			I50	D006331		HP:0001635	Baseline plasma miR-30d level is associated with response to CRT in HFDYS in this translational pilot study. MiR-30d increase in cardiomyocytes correlates with areas of increased wall stress in HFDYS and is protective against deleterious tumor necrosis factor signaling.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-328	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Heart Failure	23696613			I50	D006331		HP:0001635	Four microRNAs, miR-103, miR-142-3p, miR-30b, and miR-342-3p, were differentially expressed between HF and controls
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-375	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-454	Heart Failure	23247724			I50	D006331		HP:0001635	We identified new circulating miRNAs (miR-454, miR-500, miR-1246, miR-142-3p) which showed distinct patterns of expression in patients with diastolic dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Heart Failure	23676496			I50	D006331		HP:0001635	Gain-of-function and loss-of-function strategies in mice, together with assessment of muscle biopsies from humans, demonstrated that type I muscle fiber proportion is increased via the stimulatory actions of ERRγ on the expression of miR-499 and miR-208b.
circulation_biomarker_diagnosis_ns	hsa-mir-500	Heart Failure	23247724			I50	D006331		HP:0001635	We identified new circulating miRNAs (miR-454, miR-500, miR-1246, miR-142-3p) which showed distinct patterns of expression in patients with diastolic dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-92a-1	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-92a-2	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-122	HELLP Syndrome	24304191	cardiovascular system disease	DOID:13133	O14.2	D017359	614985		In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	HELLP Syndrome	24304191	cardiovascular system disease	DOID:13133	O14.2	D017359	614985		In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease.
circulation_biomarker_diagnosis_ns	hsa-mir-758	HELLP Syndrome	24304191	cardiovascular system disease	DOID:13133	O14.2	D017359	614985		In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hematologic Neoplasms	27761889	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	EV miR155 may serve as an attractive new, non-invasive diagnostic biomarker in human hematologic malignancies
circulation_biomarker_diagnosis_ns	hsa-let-7c	Hepatitis B Virus Infection	22392036	disease by infectious agent	DOID:2043	B16/18	D006509	610424		After screening 13 previously identified HBV-specific serum miRNAs, we obtained four miRNAs, let-7c, miR-23b, miR-122, and miR-150, which are differentially expressed in OBI sera compared to healthy control sera. This 4-serum miRNA signature shows a high level of accuracy in discriminating both OBI (AUC = 0.999) and HBV (AUC = 0.989) cases from the non-infected controls.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis B Virus Infection	22239527	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum miR-122 levels are strongly correlated with HBs antigen.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis B Virus Infection	22392036	disease by infectious agent	DOID:2043	B16/18	D006509	610424		After screening 13 previously identified HBV-specific serum miRNAs, we obtained four miRNAs, let-7c, miR-23b, miR-122, and miR-150, which are differentially expressed in OBI sera compared to healthy control sera. This 4-serum miRNA signature shows a high level of accuracy in discriminating both OBI (AUC = 0.999) and HBV (AUC = 0.989) cases from the non-infected controls.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis B Virus Infection	21606975	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The serum level of miR-122 strongly correlates with serum ALT activity and with necroinflammatory activity in patients with CHC and elevated ALT levels, but not with fibrosis stage and functional capacity of the liver
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Hepatitis B Virus Infection	24595450	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-1275	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Hepatitis B Virus Infection	22392036	disease by infectious agent	DOID:2043	B16/18	D006509	610424		After screening 13 previously identified HBV-specific serum miRNAs, we obtained four miRNAs, let-7c, miR-23b, miR-122, and miR-150, which are differentially expressed in OBI sera compared to healthy control sera. This 4-serum miRNA signature shows a high level of accuracy in discriminating both OBI (AUC = 0.999) and HBV (AUC = 0.989) cases from the non-infected controls.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Hepatitis B Virus Infection	25976622	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum miR-181b is correlated with liver and serum HBV DNA levels as well as disease progression in CHB.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Hepatitis B Virus Infection	24595450	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-23b	Hepatitis B Virus Infection	22392036	disease by infectious agent	DOID:2043	B16/18	D006509	610424		After screening 13 previously identified HBV-specific serum miRNAs, we obtained four miRNAs, let-7c, miR-23b, miR-122, and miR-150, which are differentially expressed in OBI sera compared to healthy control sera. This 4-serum miRNA signature shows a high level of accuracy in discriminating both OBI (AUC = 0.999) and HBV (AUC = 0.989) cases from the non-infected controls.
circulation_biomarker_diagnosis_ns	hsa-mir-583	Hepatitis B Virus Infection	23554832	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Circulating miR-583 and miR-663 Refer to ZHENG Differentiation in Chronic Hepatitis B
circulation_biomarker_diagnosis_ns	hsa-mir-663	Hepatitis B Virus Infection	23554832	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Circulating miR-583 and miR-663 Refer to ZHENG Differentiation in Chronic Hepatitis B
circulation_biomarker_diagnosis_ns	hsa-mir-720	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-99a	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	27239848	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Evaluation of miR-122 level in the plasma of chronically HCV infected patients.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	23085648	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	23383654	disease by infectious agent	DOID:1883	B19.2	D006526	609532		circulating;Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	26283876	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	25065618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, miR-126, miR-136 and miR-181a have been  shown to be involved in HCV infection with different genotypes. Their expression  has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	28232800	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Circulating ECV-Associated miRNAs as Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Hepatitis C Virus Infection	25065618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, miR-126, miR-136 and miR-181a have been  shown to be involved in HCV infection with different genotypes. Their expression  has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Hepatitis C Virus Infection	26283876	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-136	Hepatitis C Virus Infection	25065618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, miR-126, miR-136 and miR-181a have been  shown to be involved in HCV infection with different genotypes. Their expression  has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-16	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Hepatitis C Virus Infection	25065618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, miR-126, miR-136 and miR-181a have been  shown to be involved in HCV infection with different genotypes. Their expression  has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Hepatitis C Virus Infection	28232800	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Circulating ECV-Associated miRNAs as Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Hepatitis C Virus Infection	23390075	disease by infectious agent	DOID:1883	B19.2	D006526	609532		circulating;The circulating miR-20a may serve as a potential for predictive biomarker in HCV mediated fibrosis
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hepatitis C Virus Infection	22066022	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The serum miR-21 level is a marker for necroinflammatory activity, but does not differ between patients with HCV and HCV-induced HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-424	Hepatitis C Virus Infection	26283876	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-629	Hepatitis C Virus Infection	26283876	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hepatoblastoma	27601233	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Diagnostic and prognostic values of serum exosomal microRNA-21 in children with hepatoblastoma: a Chinese population-based study.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Hereditary Breast Carcinoma	24129975			D05	D001943	114480		miR-4417 and miR-423-3p expressions differentiated 70.1 % of hereditary and non-hereditary BCs. Array miR expression profiles can differentiate the four study groups using FFPE BC.
circulation_biomarker_diagnosis_ns	hsa-mir-4417	Hereditary Breast Carcinoma	24129975			D05	D001943	114480		miR-4417 and miR-423-3p expressions differentiated 70.1 % of hereditary and non-hereditary BCs. Array miR expression profiles can differentiate the four study groups using FFPE BC.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-369	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-429	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-638	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-938	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Human Immunodeficiency Virus Infection	25997625			B20	D015658	609423		We show for the first time a joint miRNA and mRNA expression profile related to a HIV-1 latency phenotype, outline a dynamic network of potential regulators involving in HIV-1 latency or replication state, and gain new insights into the source messages for affecting HIV-1 latency.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Human Immunodeficiency Virus Infection	28955339			B20	D015658	609423		Deregulated MicroRNA-21 Expression in Monocytes from HIV-Infected Patients Contributes to Elevated IP-10 Secretion in HIV Infection.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Huntington Disease	25889241	nervous system disease	DOID:12858	G10	D006816	143100		These results demonstrate that miRNA expression in cortical BA9 provides insight into striatal involvement and support a role for these miRNAs,particularly miR-10b-5p, in HD pathogenicity. The miRNAs identified in our studies of postmortem brain tissue may be detectable in peripheral fluids and thus warrant consideration as accessible biomarkers for disease stage, rate of progression, and other important clinical characteristics of HD.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Hyperactivity Disorder	25724585	disease of mental health	DOID:1094	F90	D001289	143465	HP:0007018	Circulating MicroRNA Let-7d in Attention-Deficit/Hyperactivity Disorder.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Hyperhomocysteinemia	28633641				D020138			Expression levels of atherosclerosis-associated miR-143 and miR-145 in the plasma of patients with hyperhomocysteinaemia.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Hyperhomocysteinemia	28633641				D020138			Expression levels of atherosclerosis-associated miR-143 and miR-145 in the plasma of patients with hyperhomocysteinaemia.
circulation_biomarker_diagnosis_ns	hsa-mir-33a	Hyperlipoproteinemia Type III	28811385	disease of metabolism	DOID:3145		D006952	617347	HP:0010980	Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism.
circulation_biomarker_diagnosis_ns	hsa-mir-33b	Hyperlipoproteinemia Type III	28811385	disease of metabolism	DOID:3145		D006952	617347	HP:0010980	Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism.
circulation_biomarker_diagnosis_ns	hsa-mir-1-1	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-1: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-1-2	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-1: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-126	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-126	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-154 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Hypertension	26984682	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miRNA-208b and miRNA-133a show distinct profiling in peripheral blood cells isolated from untreated patients
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-133a: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-133a: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-143	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-145	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-145	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-155 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-156 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-155: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hypertension	29057982	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Characterization of serum miRNAs as molecular biomarkers for acute Stanford type A aortic dissection diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-157	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-157 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-17	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-150 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-208: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Hypertension	26984682	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miRNA-208b and miRNA-133a show distinct profiling in peripheral blood cells isolated from untreated patients
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hypertension	26114349	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The decreased levels of NOx and eNOS found in this study indicate the co-existence of endothelial dysfunction and hypertension once more. In the absence of microalbuminuria, the increased miR-21 expression in patients with iCIMT made us conclude that this miRNA might be involved in the early stages of atherosclerotic process in hypertensive patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-151 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-221	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-223	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-152 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-505	Hypertension	25449503	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	hsa-mir-505 is a novel circulating signature of hypertension, which may play a role in angiogenesis. Our results provide mechanistic insights into hypertension-associated pathogenesis and point 
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-153 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-122	Idiopathic Asthenospermia	27264812			R86.9			HP:0012207	Seminal plasma miR-122-3p and miR-141-5p stability and its diagnosis value for idiopathic asthenospermia.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Idiopathic Asthenospermia	27264812			R86.9			HP:0012207	Seminal plasma miR-122-3p and miR-141-5p stability and its diagnosis value for idiopathic asthenospermia.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-302a	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-302c	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-3620	Immune Thrombocytopenic Purpura	24851893	immune system disease	DOID:8924	D69.3	D016553	188030		The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-378i	Immune Thrombocytopenic Purpura	24851893	immune system disease	DOID:8924	D69.3	D016553	188030		The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-410	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-4721	Immune Thrombocytopenic Purpura	24851893	immune system disease	DOID:8924	D69.3	D016553	188030		The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-544a	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-597	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Inflammation	26083362				D007249			The expression profile of microRNAs/mRNAs in monocytes of T2D patients indicates an altered adhesion, differentiation, and shape change potential. Monocyte inflammatory activation was only found in patients with normal serum lipids. Abnormal lipid values coincided with a reduced monocyte inflammatory state.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Influenza	24699363	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Influenza	24699363	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Influenza	24699363	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-3663	Inherited Hemoglobin Disease	26837891							Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume.
circulation_biomarker_diagnosis_ns	hsa-mir-4726	Inherited Hemoglobin Disease	26837891							Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume.
circulation_biomarker_diagnosis_ns	hsa-mir-7109	Inherited Hemoglobin Disease	26837891							Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume.
circulation_biomarker_diagnosis_ns	hsa-mir-940	Inherited Hemoglobin Disease	26837891							Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume.
circulation_biomarker_diagnosis_ns	hsa-mir-125b-1	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-125b-2	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-128-1	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-128-2	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-20b	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Intestinal Schistosomiasis	26230095	disease by infectious agent	DOID:0050597	B65.1	D012554	181460		The inconsistent levels of the host circulating miRNAs, miR-122, miR-21 and miR-34a in serum were confirmed in the two murine models during infection
circulation_biomarker_diagnosis_ns	hsa-mir-1275	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Intrahepatic Cholangiocarcinoma	25482320	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		combination of these two markers improved the power of screening ICC. Moreover, on the basis of the plasma miR-150 level, 15 ICC patients were divided into a low or high expression group. We found that plasma miR-150 is a potential diagnostic biomarker for ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-874	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Irritable Bowel Syndrome	24768587	syndrome	DOID:9778	K58	D043183			This preliminary study reports the association of two miRNAs,detected in whole blood, with IBS. These miRNAs link to pain and inflammatory pathways both of which are thought to be dysregulated in IBS. Larger sample sizes are needed to confirm their importance and potential as biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Irritable Bowel Syndrome	24768587	syndrome	DOID:9778	K58	D043183			This preliminary study reports the association of two miRNAs,detected in whole blood, with IBS. These miRNAs link to pain and inflammatory pathways both of which are thought to be dysregulated in IBS. Larger sample sizes are needed to confirm their importance and potential as biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Ischemia-Reperfusion Injury	27760486				D015427			Micro RNA-320 as a novel potential biomarker in renal ischemia reperfusion.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Ischemia-Reperfusion Injury	27979484				D015427			MicroRNA-125b as a new potential biomarker on diagnosis of renal ischemia-reperfusion injury.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-142	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Kidney Diseases [unspecific]	28522697			N18.9	D007674			Circulating MicroRNA-125b Predicts the Presence and Progression of Uremic Vascular Calcification.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Kidney Diseases [unspecific]	23070235			N18.9	D007674			Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease
circulation_biomarker_diagnosis_ns	hsa-mir-192	Kidney Injury	28056546			S37.0	D058186			Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Kidney Injury	28056546			S37.0	D058186			Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Kidney Neoplasms	22429968	disease of cellular proliferation	DOID:263	C64	D007680			MicroRNA 15a, Inversely Correlated to PKC, Is a Potential Marker to Differentiate between Benign and Malignant Renal Tumors in Biopsy and Urine Samples.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Leukemia	22431542			C95	D007938	613065	HP:0001909	Analyzed retrospectively, miR-15a levels differ among the del(13q) groups.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Leukemia	21176349			C95	D007938	613065	HP:0001909	The results showed that the expression levels of miRNA-17-19b in K562 cells and white blood cells of peripheral blood from CML patients were higher than those in mobilized white blood cells of peripheral blood from normal person.
circulation_biomarker_diagnosis_ns	hsa-mir-18	Leukemia	21176349			C95	D007938	613065	HP:0001909	The results showed that the expression levels of miRNA-17-19b in K562 cells and white blood cells of peripheral blood from CML patients were higher than those in mobilized white blood cells of peripheral blood from normal person.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Leukemia	23998571			C95	D007938	613065	HP:0001909	MicroRNA-193b expression in newly diagnosed leukemia patients and its significance.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Leukemia	21176349			C95	D007938	613065	HP:0001909	The results showed that the expression levels of miRNA-17-19b in K562 cells and white blood cells of peripheral blood from CML patients were higher than those in mobilized white blood cells of peripheral blood from normal person.
circulation_biomarker_diagnosis_ns	hsa-mir-19b-1	Leukemia	21176349			C95	D007938	613065	HP:0001909	The results showed that the expression levels of miRNA-17-19b in K562 cells and white blood cells of peripheral blood from CML patients were higher than those in mobilized white blood cells of peripheral blood from normal person.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Leukemia	24153013			C95	D007938	613065	HP:0001909	Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells.
circulation_biomarker_diagnosis_ns	hsa-mir-365	Leukemia	24153013			C95	D007938	613065	HP:0001909	Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells.
circulation_biomarker_diagnosis_ns	hsa-mir-638	Leukemia	19440243			C95	D007938	613065	HP:0001909	The ratio of miR-92a/miR-638 in plasma has strong potential for clinical application as a novel biomarker for detection of leukemia.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Leukemia	19440243			C95	D007938	613065	HP:0001909	The ratio of miR-92a/miR-638 in plasma has strong potential for clinical application as a novel biomarker for detection of leukemia.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-128-1	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-101-2	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	As for the most differentially expressed miRNAs, they included 8 upregulated and 14 downregulated miRNAs, of which miR-148a at 7p15.2, miR-22 at 17p13.3, miR-223 at Xq12, as well as miR-101-2 at 9p24.1 exhibited recurrent CNAs or CNN LOH.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Leukemia, Lymphoblastic, Acute	24955371	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	As for the most differentially expressed miRNAs, they included 8 upregulated and 14 downregulated miRNAs, of which miR-148a at 7p15.2, miR-22 at 17p13.3, miR-223 at Xq12, as well as miR-101-2 at 9p24.1 exhibited recurrent CNAs or CNN LOH.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Lymphoblastic, Acute	24955371	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Leukemia, Lymphoblastic, Acute	24955371	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	As for the most differentially expressed miRNAs, they included 8 upregulated and 14 downregulated miRNAs, of which miR-148a at 7p15.2, miR-22 at 17p13.3, miR-223 at Xq12, as well as miR-101-2 at 9p24.1 exhibited recurrent CNAs or CNN LOH.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	As for the most differentially expressed miRNAs, they included 8 upregulated and 14 downregulated miRNAs, of which miR-148a at 7p15.2, miR-22 at 17p13.3, miR-223 at Xq12, as well as miR-101-2 at 9p24.1 exhibited recurrent CNAs or CNN LOH.
circulation_biomarker_diagnosis_ns	hsa-mir-708	Leukemia, Lymphoblastic, Acute, Childhood	25214155	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		MiR-708-5p is differentially expressed in childhood acute lymphoblastic leukemia but not strongly associated to clinical features.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-92	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-155:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_ns	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	22350310	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181b is a biomarker for the progression of this disease from indolent to aggressive.
circulation_biomarker_diagnosis_ns	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	22350310	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181b is a biomarker for the progression of this disease from indolent to aggressive.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Leukemia, Lymphocytic, Chronic, B-Cell	21460253	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	circulating miR-20a correlates reliably with diagnosis-to-treatment time.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-34a:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_ns	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_ns	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Leukemia, Lymphocytic, Chronic, B-Cell	28830603	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-92	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Leukemia, Myeloid, Acute	26067326	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose development of serum exosome miRNA as a platform for a novel,sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Leukemia, Myeloid, Acute	24477595	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
circulation_biomarker_diagnosis_ns	hsa-mir-127	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-135a	Leukemia, Myeloid, Acute	24072101	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Leukemia, Myeloid, Acute	28890884	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-150	Leukemia, Myeloid, Acute	23391324	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	plasma;Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-154	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Myeloid, Acute	26067326	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose development of serum exosome miRNA as a platform for a novel,sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-181a-2	Leukemia, Myeloid, Acute	18450603	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Leukemia, Myeloid, Acute	18450603	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-181d	Leukemia, Myeloid, Acute	18450603	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-196b	Leukemia, Myeloid, Acute	24072101	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
circulation_biomarker_diagnosis_ns	hsa-mir-196b	Leukemia, Myeloid, Acute	26317787	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	These results suggest that microRNA-155 is a potential diagnostic biomarker for all subgroups of paediatric AML, whereas microRNA-196b is specific for subgroups M4-M5.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Leukemia, Myeloid, Acute	28987820	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo.
circulation_biomarker_diagnosis_ns	hsa-mir-299	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-3151	Leukemia, Myeloid, Acute	26430723	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
circulation_biomarker_diagnosis_ns	hsa-mir-323a	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-335	Leukemia, Myeloid, Acute	25301405	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our data offer the convincing evidence for the first time that serum miR-335 level may be markedly and consistently increased in pediatric AML patients. Serum miR-335 may serve as a promising marker for monitoring the progression and predicting the clinical outcome of patients with this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Leukemia, Myeloid, Acute	23391324	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	plasma;Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-342	Leukemia, Myeloid, Acute	28890884	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-370	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-377	Leukemia, Myeloid, Acute	25502508	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	a miRNA signature in human cord blood stem and progenitor cells with a potential role in hematopoietic stemness properties and possibly in leukemogenesis of specific AML subtypes.
circulation_biomarker_diagnosis_ns	hsa-mir-409	Leukemia, Myeloid, Acute	24072101	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
circulation_biomarker_diagnosis_ns	hsa-mir-4739	Leukemia, Myeloid, Acute	25502508	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	a miRNA signature in human cord blood stem and progenitor cells with a potential role in hematopoietic stemness properties and possibly in leukemogenesis of specific AML subtypes.
circulation_biomarker_diagnosis_ns	hsa-mir-644	Leukemia, Myeloid, Acute	24072101	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Leukemia, Myeloid, Acute	28890884	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-103	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-1827	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-1973	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-298	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-299	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3201	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3611	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3646	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3686	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3915	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-4268	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-4279	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-4290	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-498	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-518b	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-525	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-612	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-665	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-711	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-943	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	24598659	disease of cellular proliferation	DOID:5599	C83.5	D054218			Expression of miR-16 in patients with T lymphoblastic lymphoma/acute lymphoblastic leukemia.
circulation_biomarker_diagnosis_ns	hsa-mir-3613	Liposarcoma	29689704	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	Whole blood miRNA expression analysis reveals miR-3613-3p as a potential biomarker for dedifferentiated liposarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-513a-1	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-513a-2	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-513b	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-513c	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-571	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-let-7f	Liver Diseases [unspecific]	27639178			K76.9	D008107			Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Diseases [unspecific]	22427142			K76.9	D008107			The results showed a positive correlation between serum miR-122 and alanine aminotransferase, a clinical biomarker for liver function.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Diseases [unspecific]	28070111			K76.9	D008107			circulating liver-specific miR-122 and miR-192 levels also increased 24 hr or later compared with ALT, suggesting that circulating miR-122 and miR-192 may serve as potential biomarkers to detect hepatotoxicity in cynomolgus monkeys
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Diseases [unspecific]	29636028			K76.9	D008107			Comprehensive analysis of blood cells and plasma identifies tissue-specific miRNAs as potential novel circulating biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Liver Diseases [unspecific]	25815788			K76.9	D008107			Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Liver Diseases [unspecific]	23886700			K76.9	D008107			Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Liver Diseases [unspecific]	28070111			K76.9	D008107			circulating liver-specific miR-122 and miR-192 levels also increased 24 hr or later compared with ALT, suggesting that circulating miR-122 and miR-192 may serve as potential biomarkers to detect hepatotoxicity in cynomolgus monkeys
circulation_biomarker_diagnosis_ns	hsa-mir-223	Liver Diseases [unspecific]	23886700			K76.9	D008107			Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Liver Diseases [unspecific]	27639178			K76.9	D008107			Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.
circulation_biomarker_diagnosis_ns	hsa-mir-340	Liver Diseases [unspecific]	27639178			K76.9	D008107			Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Injury	24086271			S36.11	D056486			serum miR-122 has strong potential as a novel, specific and noninvasive biomarker for diagnosis of cholestasis-induced liver injury.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Injury	24287929			S36.11	D056486			Plasma miR-122 expression is correlated with hepatectomy-induced liver injury in patients with HCC. Increase in miR-122 expression could be used as an index of such injury before and after hepatectomy in these patients.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-451	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-146	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-212	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-340	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Lung Disease [unspecific]	23338559	respiratory system disease	DOID:850	J98.4	D008171	606963		plasma;Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease
circulation_biomarker_diagnosis_ns	hsa-let-7f	Lung Neoplasms	20595154	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	NSCLC patients and healthy controls differ in vesicle-related miRNAs in plasma. Levels of let-7f and miR-30e-3p in NSCLC patients are associated with poor outcome.
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Lung Neoplasms	25639977	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Lung Neoplasms	25639977	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Lung Neoplasms	23337359	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	serum;Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
circulation_biomarker_diagnosis_ns	hsa-mir-142	Lung Neoplasms	23410826	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Serum: miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Lung Neoplasms	25501703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results.
circulation_biomarker_diagnosis_ns	hsa-mir-148b	Lung Neoplasms	25501703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results.
circulation_biomarker_diagnosis_ns	hsa-mir-152	Lung Neoplasms	25501703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Lung Neoplasms	23337359	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	serum;Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lung Neoplasms	25501703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lung Neoplasms	26109362	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-21 expression levels in whole blood and peripheral blood cells did not show significant differences between lung cancer patients and healthy controls, and it might be ineffective to measure miR-21 expression to achieve an  early diagnosis of lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Lung Neoplasms	25639977	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Lung Neoplasms	20595154	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	NSCLC patients and healthy controls differ in vesicle-related miRNAs in plasma. Levels of let-7f and miR-30e-3p in NSCLC patients are associated with poor outcome.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Lung Neoplasms	25765717	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-31 may be a molecular marker for the diagnostic and prognostic evaluation of primary lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-3662	Lung Neoplasms	26079400	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-944	Lung Neoplasms	26079400	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1224	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-1224-3P:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-371-5P:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-423	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-423-5P:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-638	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-638:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-663a	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-663:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Lymphoma, Burkitt	27991481	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lymphoma, Burkitt	27991481	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Lymphoma, Burkitt	27991481	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-18	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-19b-1	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lymphoma, Large B-Cell, Diffuse	24400911	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-92-1	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Lymphoma, Non-Hodgkin	24675587	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Altered serum levels of miR-21, miR-122, and miR-223 are seen in HIV-infected individuals.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Machado-Joseph Disease	23879331	nervous system disease	DOID:1440	G11.1	D017827	109150		MicroRNA profiling in the serums of SCA3/MJD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Machado-Joseph Disease	23879331	nervous system disease	DOID:1440	G11.1	D017827	109150		MicroRNA profiling in the serums of SCA3/MJD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Machado-Joseph Disease	23879331	nervous system disease	DOID:1440	G11.1	D017827	109150		MicroRNA profiling in the serums of SCA3/MJD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Machado-Joseph Disease	23879331	nervous system disease	DOID:1440	G11.1	D017827	109150		MicroRNA profiling in the serums of SCA3/MJD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Macroglobulinemia	25428891	disease of metabolism	DOID:9080	Q38.2	D008258	153600		Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia.
circulation_biomarker_diagnosis_ns	hsa-mir-320b	Macroglobulinemia	25428891	disease of metabolism	DOID:9080	Q38.2	D008258	153600		Combination of serum microRNA-320a and microRNA-321b as a marker for Waldenström macroglobulinemia.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Major Depressive Disorder	26807671	disease of mental health	DOID:1470	F32	D003865	608520		Differentially Notch-associated miRNAs expressions in peripheral blood might be involved in MDD, and the miR-34b-5p and miR-34c-5p levels in peripheral blood leukocytes are closely related to MDD, suicide idea and cognitive function, further studies with large sample size are warranted to test the feasibility of these miRNAs serving as biomarkers for MDD.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Major Depressive Disorder	26807671	disease of mental health	DOID:1470	F32	D003865	608520		Differentially Notch-associated miRNAs expressions in peripheral blood might be involved in MDD, and the miR-34b-5p and miR-34c-5p levels in peripheral blood leukocytes are closely related to MDD, suicide idea and cognitive function, further studies with large sample size are warranted to test the feasibility of these miRNAs serving as biomarkers for MDD.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Male Infertility	25740880	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Serum miR-155 as a potential biomarker of male fertility.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Melanoma	26039581	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A profile of 2 miRNAs (miR-1246 and miR-185) significantly associated with metastatic melanoma with a sensitivity of 90.5% and a specificity of 89.1% was identified. This plasma miRNA profile may become an accurate non-invasive biomarker for melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-155	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-185	Melanoma	26039581	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A profile of 2 miRNAs (miR-1246 and miR-185) significantly associated with metastatic melanoma with a sensitivity of 90.5% and a specificity of 89.1% was identified. This plasma miRNA profile may become an accurate non-invasive biomarker for melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-203	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Melanoma	26045823	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our results offer the convincing evidence that miR-206 may be implicated in aggressive progression of melanoma. More importantly, the serum level of miR-206 may be a noninvasive prognostic biomarker for the patients with melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-211	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-33a	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-373	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-424	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-4487	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-4706	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-4731	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-506	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-509	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-514	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-514a	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-520c	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Mesial Temporal Lobe Epilepsy	28384161			G40.209	D004833	608096		MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-365a	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-532	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-663b	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Mesothelioma	28321148	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.
circulation_biomarker_diagnosis_ns	hsa-mir-1207	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Metabolic Syndrome	23922812	disease of metabolism	DOID:14221	E88.81	D024821	605552		These findings cast new light on the regulation of miR-33a and miR-122 in a dyslipidemic model of obese rats and the way these miRNAs are modulated by dietary components in the liver and in PBMCs.
circulation_biomarker_diagnosis_ns	hsa-mir-1237	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-1288	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-129-1	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-129-2	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-130b	Metabolic Syndrome	23868745	disease of metabolism	DOID:14221	E88.81	D024821	605552		Circulating miR-130b reflects the degree of obesity and could serve as a potential biomarker for hypertriacylglycerolaemia and metabolic syndrome. Circulating miR-130b could function as a metabolic mediator for adipose muscle crosstalk and might be involved in the pathogenesis of obesity associated metabolic diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-331	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-33a	Metabolic Syndrome	23922812	disease of metabolism	DOID:14221	E88.81	D024821	605552		These findings cast new light on the regulation of miR-33a and miR-122 in a dyslipidemic model of obese rats and the way these miRNAs are modulated by dietary components in the liver and in PBMCs.
circulation_biomarker_diagnosis_ns	hsa-mir-484	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-625	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-323	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-370	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-382	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-491	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-874	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-let-7c	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Multiple Myeloma	26516702	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Therefore, our data suggest that the expression patterns of miR-15a/16-1 are different in MM patients, and miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Multiple Myeloma	28446295	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Circulating Serum MicroRNA as Diagnostic Biomarkers for Multiple Myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Multiple Myeloma	26516702	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Therefore, our data suggest that the expression patterns of miR-15a/16-1 are different in MM patients, and miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-331	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Multiple Myeloma	18700954	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-335: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-342	Multiple Myeloma	18700954	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-342: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-449	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-561	Multiple Myeloma	18700954	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-561: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-660	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Multiple Sclerosis	22108567	nervous system disease	DOID:2377	G35	D009103	PS126200		deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-128	Multiple Sclerosis	29527713	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Multiple Sclerosis	23773985	nervous system disease	DOID:2377	G35	D009103	PS126200		RRMS patients in remission had altered expression of mirNAs. We validated mir-145 as a potential diagnostic biomarker for the diagnosis of MS in blood, plasma and serum.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Multiple Sclerosis	29246612	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-150	Multiple Sclerosis	22108567	nervous system disease	DOID:2377	G35	D009103	PS126200		deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-191	Multiple Sclerosis	29527713	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Multiple Sclerosis	29246612	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-24	Multiple Sclerosis	29527713	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Multiple Sclerosis	27606352	nervous system disease	DOID:2377	G35	D009103	PS126200		Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis.
circulation_biomarker_diagnosis_ns	hsa-mir-326	Multiple Sclerosis	21949733	nervous system disease	DOID:2377	G35	D009103	PS126200		Four miRNAs (miR-326, miR-155, miR-146a, miR-142-3p) were aberrantly expressed in peripheral blood mononuclear cells from RRMS (relapsing remitting multiple sclerosis) patients compared to healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-326	Multiple Sclerosis	25642434	nervous system disease	DOID:2377	G35	D009103	PS126200		Our longitudinal analysis revealed that miR-18a, miR-20b, miR-29a, and miR-103 were upregulated and predominantly expressed by CD4(+) T cells, whereas miR-326 was downregulated upon natalizumab treatment.
circulation_biomarker_diagnosis_ns	hsa-mir-326	Multiple Sclerosis	29246612	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Multiple Sclerosis	29527713	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-572	Multiple Sclerosis	25947625	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of miR-572 may serve as a non-invasive biomarker for remyelination.
circulation_biomarker_diagnosis_ns	hsa-let-7c	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-let-7e	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-let-7i	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-100	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-103a-1	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-103a-2	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-107	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-126	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-132	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-140	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-143	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-145	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-151a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-154	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-155	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-195	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-199a-1	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-199a-2	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-19b-1	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-19b-2	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-21	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-210	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-214	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-22	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-221	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-222	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-223	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-28	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-299	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-335	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-362	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-379	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-381	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-432	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-452	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-487b	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-495	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-497	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-501	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-99b	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-1	Muscle Diseases [unspecific]	25146754			M63.80	D009135			These miRNAs are potential biomarkers of muscle damage or adaptation to exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Muscular Dystrophy	27529242			G71.0	D009136	310200	HP:0003560	miR-206 has  potential as a "liquid biopsy" for carrier detection and genetic counseling in DMD.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Muscular Dystrophy, Duchenne	25150707	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Muscular Dystrophy, Duchenne	24460924	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
circulation_biomarker_diagnosis_ns	hsa-mir-1-1	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-1-2	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-133	Muscular Dystrophy, Duchenne	24460924	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Muscular Dystrophy, Duchenne	25150707	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-206	Muscular Dystrophy, Duchenne	25150707	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Muscular Dystrophy, Duchenne	24460924	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-140	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-185	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-20b	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-101	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-140	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-296	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-485	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-let-7a-1	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-let-7a-2	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-let-7a-3	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-194	Myelodysplastic Syndromes	25975751	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myelodysplastic Syndromes	24503739	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Myeloma	25216866			C90.0	D009101	254500		Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Myeloproliferative Neoplasms	18773208	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-10a: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-126	Myeloproliferative Neoplasms	18773208	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-126: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-155	Myeloproliferative Neoplasms	18299402	disease of cellular proliferation	DOID:2226	D47.1		616871		Sustained expression
circulation_biomarker_diagnosis_ns	hsa-mir-17	Myeloproliferative Neoplasms	18773208	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-17-5p: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Myeloproliferative Neoplasms	18773208	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-20a: deregulation
circulation_biomarker_diagnosis_ns	hsa-let-7b	Myocardial Infarction	24284400	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The circulating let-7b is suspected to be the biomarker of acute MI and let-7i, the biomarker of DCM.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Infarction	23630629	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	the levels of miR-1 in serum and urine from patients after open-heart surgeries and CPB were significant increased at all observed time points.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Infarction	28663047	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Infarction	29030746	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Platelet microRNA for predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-106a	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-1-1	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-1-2	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Myocardial Infarction	22813605	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-126 showed a positive association , whereas miR-223 and miR-197 were inversely associated with disease risk.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Myocardial Infarction	29030746	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Platelet microRNA for predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Myocardial Infarction	23347612	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating;Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Myocardial Infarction	26337652	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-146a and miR-21 may be novel biomarkers predictive of LVR after acute MI. Their combination may better predict LVR than either alone.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Myocardial Infarction	29030746	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Platelet microRNA for predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-186	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-186	Myocardial Infarction	24727883	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In a validation phase, a miRNA panel including miR-132, miR-150, and miR-186 showed the highest discriminatory power
circulation_biomarker_diagnosis_ns	hsa-mir-195	Myocardial Infarction	23236408	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our results imply that the plasma concentration of miR-30a, miR-195 and let-7b can be potential indicators for AMI
circulation_biomarker_diagnosis_ns	hsa-mir-197	Myocardial Infarction	22813605	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-126 showed a positive association , whereas miR-223 and miR-197 were inversely associated with disease risk.
circulation_biomarker_diagnosis_ns	hsa-mir-208	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Myocardial Infarction	23168198	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Serum miR-208a may be a new biomarker the early diagnosis of STEAMI patients.
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Myocardial Infarction	28164501	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-208b: A Potentially Sensitive and Reliable Biomarker for the Diagnosis and Prognosis of Acute Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Myocardial Infarction	29475914	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	plasma levels of circulating miR-208b and miR-499 could serve as potential AMI biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Myocardial Infarction	21949348	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	deregulated between blood of patients with Unstable Angina and patients with Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myocardial Infarction	26337652	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-146a and miR-21 may be novel biomarkers predictive of LVR after acute MI. Their combination may better predict LVR than either alone.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myocardial Infarction	29030746	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Platelet microRNA for predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myocardial Infarction	29188800	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients
circulation_biomarker_diagnosis_ns	hsa-mir-223	Myocardial Infarction	22813605	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-126 showed a positive association , whereas miR-223 and miR-197 were inversely associated with disease risk.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-424-5p and miR-26a-5p were associated exclusively with risk in men and women
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Myocardial Infarction	28663047	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Myocardial Infarction	23236408	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our results imply that the plasma concentration of miR-30a, miR-195 and let-7b can be potential indicators for AMI
circulation_biomarker_diagnosis_ns	hsa-mir-423	Myocardial Infarction	23347612	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating;Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction
circulation_biomarker_diagnosis_ns	hsa-mir-424	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	24533109	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiRNAs, especially miR-499 and miR-133a, may be suitable for use as diagnostic biomarkers of myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	28614255	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	 miRNA-499 had better diagnostic accuracy over other miRNAs
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	29188800	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	29475914	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	plasma levels of circulating miR-208b and miR-500 could serve as potential AMI biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-499a	Myocardial Infarction	22252325	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Serum miR-499 and hs-cTnT provided comparable diagnostic value with areas under the ROC curves of 0.97. The reclassification index of miR-499 to a clinical model including several risk factors and hs-cTnT was not significant (P = 0.15).
circulation_biomarker_diagnosis_ns	hsa-mir-660	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Ischemic-Reperfusion Injury	25791720				D015428			A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Myocardial Ischemic-Reperfusion Injury	25791720				D015428			A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Myocardial Ischemic-Reperfusion Injury	20395621				D015428			miR-208:plasma miR-208 is a biomarker of myocardial injury
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myocardial Ischemic-Reperfusion Injury	25791720				D015428			A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Ischemic-Reperfusion Injury	25791720				D015428			A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Myotonic Dystrophy Type 1	26919350	musculoskeletal system disease	DOID:11722	G71.11	D009223	PS160900		a selection of six candidate miRNAs, miR-103, miR-107, miR-21, miR-29a, miR-30c, and miR-652 all failed to show consistent differences in serum expression in subsequent validation experiments.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Myotonic Dystrophy Type 1	26919350	musculoskeletal system disease	DOID:11722	G71.11	D009223	PS160900		a selection of six candidate miRNAs, miR-103, miR-107, miR-21, miR-29a, miR-30c, and miR-652 all failed to show consistent differences in serum expression in subsequent validation experiments.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Nasopharyngeal Neoplasms	23056289			C11.9	D009303	607107	HP:0100630	Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Nasopharyngeal Neoplasms	23056289			C11.9	D009303	607107	HP:0100630	Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-223	Nasopharyngeal Neoplasms	23056289			C11.9	D009303	607107	HP:0100630	Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Nasopharyngeal Neoplasms	23056289			C11.9	D009303	607107	HP:0100630	Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma
circulation_biomarker_diagnosis_ns	hsa-let-7	Neoplasms [unspecific]	25856466			C80.1	D009369			Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected].
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Neoplasms [unspecific]	26522916			C80.1	D009369			Heterogeneity of miR-10b expression in circulating tumor cells.
circulation_biomarker_diagnosis_ns	hsa-mir-124	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-140	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1538	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Neoplasms [unspecific]	26765436			C80.1	D009369			Appraising MicroRNA-155 as a Noninvasive Diagnostic Biomarker for Cancer Detection: A Meta-Analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-185	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Neoplasms [unspecific]	24815829			C80.1	D009369			Circulating miR-18a: a sensitive cancer screening biomarker in human cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Neoplasms [unspecific]	26035744			C80.1	D009369			in clinicopathology analysis,miR-200c expression in blood was significantly associated with TNM stage, lymph node metastasis and distant metastasis. MiR-200c may have the potential to become a new blood biomarker to monitor cancer prognosis and progression.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Neoplasms [unspecific]	25907045			C80.1	D009369			we selectively detected cancer cell-derived exosomal miRNA-21 among heterogeneous exosome mixtures and in human serum. The method developed in the article is simple, fast, and sensitive, so it will offer great opportunities for the high-throughput diagnosis and prognosis of diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Neoplasms [unspecific]	25777797			C80.1	D009369			Finally, the protocol was applied to monitor miRNA-21 expression in epithelial to mesenchymal transition (EMT)-induced MCF-7 cells, an epithelial tumor cell line. CK expression was lost in these cells,whereas miRNA-21 was still expressed, suggesting that miRNA-21 might be a good marker for detecting CTCs with an EMT phenotype.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Neoplasms [unspecific]	25431259			C80.1	D009369			MiR-21 has a relatively high diagnostic value for detecting breast cancer, and miR-21 assays based on plasma, serum, and tissue achieved relatively higher accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-21	Neoplasms [unspecific]	25527152			C80.1	D009369			the circulating miR-21 may be a potential biomarker as diagnostic tool for early-stage cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-218	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Neoplasms [unspecific]	27859748			C80.1	D009369			Use of Serum MicroRNAs as Biomarker for Hepatobiliary Diseases in Dogs.
circulation_biomarker_diagnosis_ns	hsa-mir-302a	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-302b	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-302c	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-302d	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-367	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-367	Neoplasms [unspecific]	26306513			C80.1	D009369			Targeted miRNA-based blood tests for miR-371-3 and miR-367 clusters are currently under development and hold a great promise for the future.
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-372	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-373	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Neoplasms [unspecific]	28638226			C80.1	D009369			Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-490	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-520d	Neoplasms [unspecific]	26094174			C80.1	D009369			Among HKGs that were expressed in all samples, we suggest that RNU6 and miR-520d-5p were the best candidates for HKGs for studies of plasma miRNA because of the consistent and high Ct in all samples and a very narrow,reproducible SD.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-586	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-942	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-127	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-892b	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Obesity	21367929	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Expression of two miRNAs (miR-17-5p and miR-132) differed significantly between obese and nonobese omental fat (P = 0.048 and P = 0.016).
circulation_biomarker_diagnosis_ns	hsa-mir-143	Obesity	25637573	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Obesity leads to alterations in miRNA expressions and miRNA-143 and -223s can be used as biomarkers for the metabolic changes in obesity.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-150	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-17	Obesity	21367929	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Expression of two miRNAs (miR-17-5p and miR-132) differed significantly between obese and nonobese omental fat (P = 0.048 and P = 0.016).
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-221	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Obesity	25637573	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Obesity leads to alterations in miRNA expressions and miRNA-143 and -223s can be used as biomarkers for the metabolic changes in obesity.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-324	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-340	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-375	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-99b	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Oral Neoplasms	25485932			C06.9	D009062		HP:0100649	Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-196b	Oral Neoplasms	25485932			C06.9	D009062		HP:0100649	Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Osteoarthritis	28647559	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miRNA-146a, miRNA-155 and JNK expression levels in peripheral blood mononuclear cells according to grade of knee osteoarthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Osteoarthritis	28647559	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miRNA-146a, miRNA-155 and JNK expression levels in peripheral blood mononuclear cells according to grade of knee osteoarthritis.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Osteoporosis	26026730	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	In total 6 miRNAs, miR-10a-5p, miR-10b-5p, miR-133b, miR-22-3p, miR-328-3p, and let-7g-5p exhibited  significantly different serum levels in response to fracture
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Osteoporosis	22506038	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-133a in circulating monocytes is a potential biomarker for postmenopausal osteoporosis.
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Osteoporosis	22506038	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-133a in circulating monocytes is a potential biomarker for postmenopausal osteoporosis.
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Osteosarcoma	25185654	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Osteosarcoma	25775010	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Osteosarcoma	25775010	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Osteosarcoma	26069101	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Identification of miR-199a-5p in serum as noninvasive biomarkers for detecting and monitoring osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Osteosarcoma	27922432	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-21 predicts poor prognosis in patients with osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Osteosarcoma	28742209	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Osteosarcoma	26377680	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy.Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Osteosarcoma	25960240	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-27a expression may be elevated in sera of osteosarcoma patients and in turn contributes to aggressive progression of this malignancy. Detection of serum miR-27a levels may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Osteosarcoma	26377680	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy.Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Osteosarcoma	25775010	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-374a	Osteosarcoma	25775010	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-497	Osteosarcoma	27735043	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-497 as a potential serum biomarker for the diagnosis and prognosis of osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Ovarian Neoplasms	23542579	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum miR-132, miR-26a, let-7b, and miR-145 could be considered aspotential candidates as novel biomarkers in serous ovarian cancer. 
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Ovarian Neoplasms	24641401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-125b-1	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-125b: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-125b-2	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-125b: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-130a: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-132	Ovarian Neoplasms	23542579	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum miR-132, miR-26a, let-7b, and miR-145 could be considered aspotential candidates as novel biomarkers in serous ovarian cancer. 
circulation_biomarker_diagnosis_ns	hsa-mir-138	Ovarian Neoplasms	24911418	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	our study suggests that detecting these ovarian cancer specific miRNAs in plasma might serve as novel non-invasive biomarkers for ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Ovarian Neoplasms	25722112	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum microRNA-145 as a novel biomarker in human ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Ovarian Neoplasms	23542579	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum miR-132, miR-26a, let-7b, and miR-145 could be considered aspotential candidates as novel biomarkers in serous ovarian cancer. 
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-203	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-214	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Ovarian Neoplasms	24641401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Ovarian Neoplasms	18442408	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	dysregulated
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Ovarian Neoplasms	23542579	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum miR-132, miR-26a, let-7b, and miR-145 could be considered aspotential candidates as novel biomarkers in serous ovarian cancer. 
circulation_biomarker_diagnosis_ns	hsa-mir-30c-1	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-30c: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-30c-2	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-30c: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-335	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-335: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-339	Ovarian Neoplasms	26485143	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	10 miRNAs (miR-193a-5p, miR-375, miR-339-3p, miR-340-5p, miR-532-3p, miR-133a-3p, miR-25-3p, miR-10a-5p, miR-616-5p, and miR-148b-5p) displayed fold changes in concentration ranging from -2.9 to 4 (p<0.05), in recurrent platinum resistant ovarian cancer patients
circulation_biomarker_diagnosis_ns	hsa-mir-451	Ovarian Neoplasms	24641401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Ovarian Neoplasms	24641401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-92	Ovary Mixed Epithelial Carcinoma	23963852	endocrine system disease	DOID:6898					The detection of miR-92 levels in the serum might serve as a new tumour biomarker in the diagnosis and assessment of prognosis of EOC.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				miR-155 has recently been identified as a candidate biomarker of early pancreatic neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Pancreatic Adenocarcinoma	28466015	disease of cellular proliferation	DOID:4074	C25.3				Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-204	Pancreatic Adenocarcinoma	26807325	disease of cellular proliferation	DOID:4074	C25.3				miR-223 and miR-204 were able to distinguish patients with early stage cancer from patients with CP
circulation_biomarker_diagnosis_ns	hsa-mir-21	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				profiled four miRNAs, miR-21, miR-210, miR-155, and miR-196a, all implicated in the development of pancreatic cancer with either proven or predicted target genes involved in critical cancer-associated cellular pathways.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				profiled four miRNAs, miR-21, miR-210, miR-155, and miR-196a, all implicated in the development of pancreatic cancer with either proven or predicted target genes involved in critical cancer-associated cellular pathways.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Pancreatic Adenocarcinoma	28466015	disease of cellular proliferation	DOID:4074	C25.3				Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Pancreatic Neoplasms	23834149	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Pancreatic Neoplasms	29100367	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Pancreatic Neoplasms	19106647	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-155: miR-155 is a biomarker of early pancreatic neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-182	Pancreatic Neoplasms	25326859	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1825	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Pancreatic Neoplasms	27380024	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b).
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Pancreatic Neoplasms	29100367	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-211	Pancreatic Neoplasms	23329235	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer
circulation_biomarker_diagnosis_ns	hsa-mir-221	Pancreatic Neoplasms	27539232	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Pancreatic Neoplasms	25819175	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma miR-223 might be a clinically useful biomarker for screening PCa, and predicting malignant potential of IPMN and the invasiveness of PCa.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Pancreatic Neoplasms	25030590	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma miR-21, miR-155, miR-25, miR-210 have diagnostic value for pancreatic cancer, and deserve further study.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Pancreatic Neoplasms	23430754	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		blood;Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Pancreatic Neoplasms	23782250	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Pancreatic Neoplasms	27380024	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b).
circulation_biomarker_diagnosis_ns	hsa-mir-378	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-484	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-628	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-636	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Pancreatic Neoplasms	27380024	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b).
circulation_biomarker_diagnosis_ns	hsa-mir-744	Pancreatic Neoplasms	26505678	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma miR-744 might be useful biomarker for screening PCa,monitoring, and predicting poor prognosis and chemoresistance in PCa patients.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Pancreatic Neoplasms	27539232	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1-1	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-1-2	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-126*: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-147a	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-147: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-151a	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-151-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-199a-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-199a-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-19b-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-19b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-19b-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-19b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Parkinson Disease	27748571	nervous system disease	DOID:14330	G20	D010300	PS168600		Serum miR-221 serves as a biomarker for Parkinson's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-26a-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-26a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-26a-2	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-26a-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-26a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-28-5p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-1	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-29b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-2	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-29b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-29c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-301a	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-301a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-30b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-30c-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-30c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-30c-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-30c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-335: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-374a	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-374a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-374b	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-374b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Peripheral Nervous System Diseases	28870579	nervous system disease	DOID:574	G64	D010523			Aberrant microRNA expression in patients with painful peripheral neuropathies.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Peripheral Nervous System Diseases	28870579	nervous system disease	DOID:574	G64	D010523			Aberrant microRNA expression in patients with painful peripheral neuropathies.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Peripheral Nervous System Diseases	28870579	nervous system disease	DOID:574	G64	D010523			Aberrant microRNA expression in patients with painful peripheral neuropathies.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Peripheral Vascular Disease	24129591	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Peripheral Vascular Disease	24129591	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values
circulation_biomarker_diagnosis_ns	hsa-mir-16	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-181a-2	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-20b	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-363	Peripheral Vascular Disease	24129591	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values
circulation_biomarker_diagnosis_ns	hsa-mir-363	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Polycystic Ovarian Syndrome	28193283	syndrome	DOID:11612	E28.2	D011085	184700		Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-23b	Polycystic Ovarian Syndrome	28193283	syndrome	DOID:11612	E28.2	D011085	184700		Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-125	Polycythemia Vera	26011312	hematopoietic system disease	DOID:8997	D45	D011087	263300		In conclusion, our data indicate that other factors such as aberrant miR-125 expression may influence on the disease phenotype in patients with PV and ET.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Prediabetes	26164754	disease of metabolism	DOID:11716	R73.03	D011236			Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Prediabetes	26164754	disease of metabolism	DOID:11716	R73.03	D011236			Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Prediabetes	25532038	disease of metabolism	DOID:11716	R73.03	D011236			the pattern of circulating miRNAs is modified by defects in glucose metabolism in a similar manner in mice and humans. This circulating miRNA signature for prediabetes could be used as a new diagnostic tool, as well as to monitor response to intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Prediabetes	25532038	disease of metabolism	DOID:11716	R73.03	D011236			the pattern of circulating miRNAs is modified by defects in glucose metabolism in a similar manner in mice and humans. This circulating miRNA signature for prediabetes could be used as a new diagnostic tool, as well as to monitor response to intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-1301	Preeclampsia	25064070	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-135b	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-149	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Preeclampsia	28700503	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies.
circulation_biomarker_diagnosis_ns	hsa-mir-188	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-18b	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-203	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Preeclampsia	24035613	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Hence, we conclude that aberrant expression of miR-210 may contribute to trophoblast function and that miR-210 is a novel predictive serum biomarker for preeclampsia that can help in identifying at-risk women for monitoring and treatment.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Preeclampsia	28700503	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Preeclampsia	25064070	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy.
circulation_biomarker_diagnosis_ns	hsa-mir-224	Preeclampsia	25064070	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy.
circulation_biomarker_diagnosis_ns	hsa-mir-224	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-296	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-301a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-517c	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-518	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-518e	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-519d	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-98	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-1179	Proliferative Diabetic Retinopathy	25427542	nervous system disease	DOID:13207	E11.3599				serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR.
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Proliferative Diabetic Retinopathy	25427542	nervous system disease	DOID:13207	E11.3599				serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Proliferative Diabetic Retinopathy	25427542	nervous system disease	DOID:13207	E11.3599				serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR.
circulation_biomarker_diagnosis_ns	hsa-mir-106a	Proliferative Glomerulonephritis	29748623	urinary system disease	DOID:4778				HP:0000793	Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis.
circulation_biomarker_diagnosis_ns	hsa-let-7c	Prostate Neoplasms	25521481	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Prostate Neoplasms	24583788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Prostate Neoplasms	24583788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Prostate Neoplasms	25521481	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Prostate Neoplasms	22240788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating miR-141 and miR-375 have association with metastatic prostate cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-19	Prostate Neoplasms	24893170	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Prostate Neoplasms	23574937	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Prostate Neoplasms	24583788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Prostate Neoplasms	25521481	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
circulation_biomarker_diagnosis_ns	hsa-mir-345	Prostate Neoplasms	24893170	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Prostate Neoplasms	18668526	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-34c: Significant changes in Radiation modulation
circulation_biomarker_diagnosis_ns	hsa-mir-375	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Prostate Neoplasms	25521481	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Prostate Neoplasms	25754273	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Prostate Neoplasms	22240788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating miR-141 and miR-375 have association with metastatic prostate cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-519c	Prostate Neoplasms	24893170	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.
circulation_biomarker_diagnosis_ns	hsa-mir-521-1	Prostate Neoplasms	18668526	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-521: Significant changes in Radiation modulation
circulation_biomarker_diagnosis_ns	hsa-mir-521-2	Prostate Neoplasms	18668526	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-521: Significant changes in Radiation modulation
circulation_biomarker_diagnosis_ns	hsa-mir-628	Prostate Neoplasms	24477576	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results demonstrate that the three miRNAs, particularly miR-628-5p, may be further developed as a biomarker, which can serve as novel noninvasive biomarker for PCa diagnosis and prognosis.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Psoriasis	24909097	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Psoriasis	24909097	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.
circulation_biomarker_diagnosis_ns	hsa-mir-33	Psoriasis	24656994	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	In psoriasis patients plasma levels of lipid and glucose metabolism-related miRNA-33 are increased and correlated with insulin. The study of circulating miRNA-33 in psoriasis may provide new insights about the associated systemic inflammatory abnormalities.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Pulmonary Hypertension	28554172	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	The Circulating MicroRNA-206 Level Predicts the Severity of Pulmonary Hypertension in Patients with Left Heart Diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-18b	Rectal Neoplasms	25990502	disease of cellular proliferation	DOID:1984		D012004			MicroRNA expression in patient plasma changes during preoperative CRT. The alteration is not continuous and the meaning requires additional analysis on a larger patient cohort. The co-occurrence of reduced miR-18b and miR-20a expression with lymph node negativity after preoperative CRT could help to stratify the surgical procedure with respect to total mesorectal excision and LR if validated prospectively.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Rectal Neoplasms	25990502	disease of cellular proliferation	DOID:1984		D012004			MicroRNA expression in patient plasma changes during preoperative CRT. The alteration is not continuous and the meaning requires additional analysis on a larger patient cohort. The co-occurrence of reduced miR-18b and miR-20a expression with lymph node negativity after preoperative CRT could help to stratify the surgical procedure with respect to total mesorectal excision and LR if validated prospectively.
circulation_biomarker_diagnosis_ns	hsa-mir-1183	Rheumatic Heart Diseases	26539505	cardiovascular system disease	DOID:0050827	I09.9	D012214			Detection of Differentially Expressed MicroRNAs in Rheumatic Heart Disease:miR-1183 and miR-1299 as Potential Diagnostic Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1299	Rheumatic Heart Diseases	26539505	cardiovascular system disease	DOID:0050827	I09.9	D012214			Detection of Differentially Expressed MicroRNAs in Rheumatic Heart Disease:miR-1183 and miR-1299 as Potential Diagnostic Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Rheumatoid Arthritis	23874885	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Rheumatoid Arthritis	28782994	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Rheumatoid Arthritis	28560518	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Rheumatoid Arthritis	28782994	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-219-2	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Rheumatoid Arthritis	23874885	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-3925	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-3926	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-4634	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-4764	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-103a-1	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-103a-2	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-103b-1	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-103b-2	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Schizophrenia	25985888	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-137	Schizophrenia	29684772	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia
circulation_biomarker_diagnosis_ns	hsa-mir-17	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-181b-1	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-181b-2	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-212	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-212	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-219-2	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Schizophrenia	29684772	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-346	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-346	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-346	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-346	Schizophrenia	29127368	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Schizophrenia	21738743	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	peripheral blood miR-34a was differentially expressed between cases and controls in both the learning and the testing set.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-432	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-432	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Schizophrenia	28877483	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Dysregulation of miRNA-9 in a Subset of Schizophrenia Patient-Derived Neural Progenitor Cells.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Schizophrenia	29684772	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia
circulation_biomarker_diagnosis_ns	hsa-mir-92a-1	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Scleroderma, Localized	25152444	musculoskeletal system disease	DOID:8472	L94.0	D012594			Down-regulation of miR-196a and subsequent overexpression of type 1 collagen in dermal fibroblasts may play a key role in the pathogenesis of LSc. The serum levels of miR-196a may be useful as a diagnostic marker of LSc.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Scleroderma, Localized	21129921	musculoskeletal system disease	DOID:8472	L94.0	D012594			Circulating miR-29a levels in patients with scleroderma spectrum disorder
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Scleroderma, Systemic	21129921	musculoskeletal system disease	DOID:418	M34	D012595	181750		Circulating miR-29a levels in patients with scleroderma spectrum disorder
circulation_biomarker_diagnosis_ns	hsa-mir-122	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Sepsis	24421215			A41.9	D018805		HP:0100806	Serum miR-122 levels are related to coagulation disorders in sepsis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Sepsis	24413579			A41.9	D018805		HP:0100806	Levels of circulating miR-133a are elevated in sepsis and predict mortality in critically ill patients.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Sepsis	25086335			A41.9	D018805		HP:0100806	So far, miR-223, miR-146a and miR-150 have been identified to have promising prognostic and diagnostic value to sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Sepsis	25265569			A41.9	D018805		HP:0100806	miR-182, miR-143, miR-145, miR-146a, miR-150, and miR-155 were dysregulated in sepsis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Sepsis	28164567			A41.9	D018805		HP:0100806	The Prognostic Value of Plasma MicroRNA-155 and MicroRNA-146a Level in Severe Sepsis and Sepsis-Induced Acute Lung Injury Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Sepsis	28552958			A41.9	D018805		HP:0100806	Characterization of basal and lipopolysaccharide-induced microRNA expression in equine peripheral blood mononuclear cells using Next-Generation Sequencing.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Sepsis	24146790			A41.9	D018805		HP:0100806	microRNA miR-150 and miR-4772-5p-iso were able to discriminate between patients who have systemic inflammatory response syndrome and patients with sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Sepsis	25086335			A41.9	D018805		HP:0100806	So far, miR-223, miR-146a and miR-150 have been identified to have promising prognostic and diagnostic value to sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Sepsis	28164567			A41.9	D018805		HP:0100806	The Prognostic Value of Plasma MicroRNA-155 and MicroRNA-146a Level in Severe Sepsis and Sepsis-Induced Acute Lung Injury Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Sepsis	28552958			A41.9	D018805		HP:0100806	Characterization of basal and lipopolysaccharide-induced microRNA expression in equine peripheral blood mononuclear cells using Next-Generation Sequencing.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Sepsis	19823581			A41.9	D018805		HP:0100806	we found that miR-150, miR-182, miR-342-5p, and miR-486 expression profiles differentiated sepsis patients from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Sepsis	25810564			A41.9	D018805		HP:0100806	Recent reports on alterations in miR-223 serum levels during sepsis revealed contradictory results, preventing a potential use of this miRNA in clinical routine. We clearly show that miR-223 serum levels do not reflect the presence of sepsis neither in mouse models nor in a large cohort of ICU patients and do not indicate clinical outcome of critically ill patients. Thus miR-223 serum levels should not be used as a biomarker in this setting.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Sepsis	23026916			A41.9	D018805		HP:0100806	only miR-223 (p = 0.035) and miR-499-5p (p < 0.001) were significantly different between patients with mild sepsis and patients with severe sepsis and septic shock.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-297	Sepsis	22344312			A41.9	D018805		HP:0100806	Microarray analysis showed that serum miR-297 and miR-574-5p were differentially expressed in sepsis survivors and nonsurvivors. Upon validation with 118 sepsis patients' samples, these two miRNA expressions were significantly different, with P < 0.001. miR-297 was more closely associated with survival from sepsis, whereas miR-574-5p was associated with death from sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-297	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Sepsis	19823581			A41.9	D018805		HP:0100806	we found that miR-150, miR-182, miR-342-5p, and miR-486 expression profiles differentiated sepsis patients from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-4772	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Sepsis	19823581			A41.9	D018805		HP:0100806	we found that miR-150, miR-182, miR-342-5p, and miR-486 expression profiles differentiated sepsis patients from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-499	Sepsis	23026916			A41.9	D018805		HP:0100806	only miR-223 (p = 0.035) and miR-499-5p (p < 0.001) were significantly different between patients with mild sepsis and patients with severe sepsis and septic shock.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Sepsis	22344312			A41.9	D018805		HP:0100806	Microarray analysis showed that serum miR-297 and miR-574-5p were differentially expressed in sepsis survivors and nonsurvivors. Upon validation with 118 sepsis patients' samples, these two miRNA expressions were significantly different, with P < 0.001. miR-297 was more closely associated with survival from sepsis, whereas miR-574-5p was associated with death from sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Spinal Muscular Atrophy	27377135	nervous system disease	DOID:12377	G12.9	D009134	253300	HP:0007269	confirmed a significant alteration of miR-9 and miR-132 level in serum samples from SMA patients.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Spondylarthritis	26689798			M45-M49	D025241			The most repressed miRNA was miR-16 and is predicted to regulate the expression of activin A receptor
circulation_biomarker_diagnosis_ns	hsa-let-7a	Squamous Cell Carcinoma, Esophageal	25914476	disease of cellular proliferation	DOID:3748		C562729			Plasma miR-20a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Squamous Cell Carcinoma, Esophageal	26554762	disease of cellular proliferation	DOID:3748		C562729			Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Squamous Cell Carcinoma, Esophageal	27802201	disease of cellular proliferation	DOID:3748		C562729			Serum microRNA-15a level acts as a potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-185	Squamous Cell Carcinoma, Esophageal	26316588	disease of cellular proliferation	DOID:3748		C562729			In conclusion, our findings shed novel light on the role of miR-185/RAGE in ESCC metastasis, and plasma miR-185 has potential as a novel diagnostic biomarker in ESCC.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Squamous Cell Carcinoma, Esophageal	23579215	disease of cellular proliferation	DOID:3748		C562729			Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Squamous Cell Carcinoma, Esophageal	28095062	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-196a as a Potential Diagnostic Biomarker for Esophageal Squamous Cell Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Squamous Cell Carcinoma, Esophageal	26554762	disease of cellular proliferation	DOID:3748		C562729			Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Squamous Cell Carcinoma, Esophageal	25914476	disease of cellular proliferation	DOID:3748		C562729			Plasma miR-20a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Squamous Cell Carcinoma, Esophageal	27566562	disease of cellular proliferation	DOID:3748		C562729			Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Squamous Cell Carcinoma, Esophageal	25117812	disease of cellular proliferation	DOID:3748		C562729			Plasma miR-25 might be a clinically useful biomarker for cancer detection and the monitoring of tumour dynamics in ESCC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Squamous Cell Carcinoma, Esophageal	26554762	disease of cellular proliferation	DOID:3748		C562729			Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	22094257	disease of cellular proliferation	DOID:5520	C76.0	C535575			Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	25099764	disease of cellular proliferation	DOID:2876					Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	28051256	disease of cellular proliferation	DOID:2876					Expression of serum microRNA-378 and its clinical significance in laryngeal squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Squamous Cell Carcinoma, Oral	25858373	disease of cellular proliferation	DOID:0050866					Due to the satisfactory diagnostic performance, plasma miR-125b can  be used as a promising biomarker in OSCC.
circulation_biomarker_diagnosis_ns	hsa-mir-186	Squamous Cell Carcinoma, Oral	24452363	disease of cellular proliferation	DOID:0050866					miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Squamous Cell Carcinoma, Oral	25174622	disease of cellular proliferation	DOID:0050866					Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are promising novel biomarkers for detection of oral squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Squamous Cell Carcinoma, Oral	20233326	disease of cellular proliferation	DOID:0050866					plasma miR-31 could be validated a marker of OSCC for diagnostic uses
circulation_biomarker_diagnosis_ns	hsa-mir-3651	Squamous Cell Carcinoma, Oral	24452363	disease of cellular proliferation	DOID:0050866					miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Squamous Cell Carcinoma, Oral	28030794	disease of cellular proliferation	DOID:0050866					Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-494	Squamous Cell Carcinoma, Oral	24452363	disease of cellular proliferation	DOID:0050866					miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Stroke	26806865			I64	D020521	601367	HP:0001297	These results indicated that there was a substantial correlation between serum miR-132 expression and post-stroke cognitive functionality,suggesting that miR-132 may be a risk marker for PSCI. Because of the limitations of this study, the results should be treated with caution. cel-mir-39
circulation_biomarker_diagnosis_ns	hsa-mir-145	Stroke	23860376			I64	D020521	601367	HP:0001297	Serum miR-145 was not detected in over 50% of the patients and it may not be an ideal marker to predict stroke. MiR-21 and miR-221 are novel biomarkers for atherosclerosis and stroke.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Stroke	19724284			I64	D020521	601367	HP:0001297	correlate(upregulated or downregulated)
circulation_biomarker_diagnosis_ns	hsa-mir-22	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Stroke	23860376			I64	D020521	601367	HP:0001297	Serum miR-145 was not detected in over 50% of the patients and it may not be an ideal marker to predict stroke. MiR-21 and miR-221 are novel biomarkers for atherosclerosis and stroke.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-298	Stroke	19724284			I64	D020521	601367	HP:0001297	correlate(upregulated or downregulated)
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-362	Stroke	19724284			I64	D020521	601367	HP:0001297	miR-362-3p correlate(pregulated or downregulated)
circulation_biomarker_diagnosis_ns	hsa-let-7b	Stroke, Ischemic	24237608			I63.9			HP:0002140	These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans.
circulation_biomarker_diagnosis_ns	hsa-let-7e	Stroke, Ischemic	26415639			I63.9			HP:0002140	MicroRNA let-7e Is a Potential Circulating Biomarker of Acute Stage Ischemic Stroke.
circulation_biomarker_diagnosis_ns	hsa-let-7e	Stroke, Ischemic	27776139			I63.9			HP:0002140	Identification of Blood Let-7e-5p as a Biomarker for Ischemic Stroke.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Stroke, Ischemic	27151415			I63.9			HP:0002140	Two miRNAs (miR-145 and miR-122) may represent potential biomarkers in ischemic stroke
circulation_biomarker_diagnosis_ns	hsa-mir-126	Stroke, Ischemic	24237608			I63.9			HP:0002140	These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Stroke, Ischemic	24237608			I63.9			HP:0002140	These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-148b	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-500b	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-99a	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-let-7e	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Systemic Lupus Erythematosus	29246612	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-150	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Systemic Lupus Erythematosus	25253569	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Systemic Lupus Erythematosus	27816459	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-18b	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Systemic Lupus Erythematosus	27816459	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Systemic Lupus Erythematosus	27816459	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Systemic Lupus Erythematosus	28560518	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Systemic Lupus Erythematosus	29246612	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-3074	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-324	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-326	Systemic Lupus Erythematosus	29246612	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-328	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-345	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-362	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-365	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-380	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-494	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-532	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-556	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-579	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-629	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-638	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-744	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-758	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Testicular Neoplasms	23059743	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours
circulation_biomarker_diagnosis_ns	hsa-mir-141	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	A unique miRNA expression signature differentiated between PTC cell lines with BRAF mutations and a normal thyroid cell line. 15 miRNAs were found to be upregulated and 23 miRNAs were downregulated.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Thyroid Neoplasms	25456009	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b and miR-155 helped to discriminate between benign and malignant lesions. Circulating miRNA is likely a useful alternate serological marker for PTC. This preliminary study suggested that circulating miRNAs may be useful as follow-up tools as well as diagnostic tools.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Thyroid Neoplasms	25456009	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b and miR-155 helped to discriminate between benign and malignant lesions. Circulating miRNA is likely a useful alternate serological marker for PTC. This preliminary study suggested that circulating miRNAs may be useful as follow-up tools as well as diagnostic tools.
circulation_biomarker_diagnosis_ns	hsa-mir-181a-1	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Another miRNA these two groups found to be upregulated albeit less significantly was miR-213, our study also found miR-213 to be upregulated in BRAF mutated cell lines [25 fold].
circulation_biomarker_diagnosis_ns	hsa-mir-16	Transitional Cell Carcinoma	29141625	disease of cellular proliferation	DOID:2671		D002295			MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Transitional Cell Carcinoma	29141625	disease of cellular proliferation	DOID:2671		D002295			MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Traumatic Brain Injury	28117263			S06.2	D000070642			Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Traumatic Brain Injury	28117263			S06.2	D000070642			Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Tuberculosis	25753045	disease by infectious agent	DOID:399	A15-A19	D014376			Identification of miR-93 as a suitable miR for normalizing miRNA in plasma of tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-204	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Tuberculosis, Pulmonary	21998423	disease by infectious agent	DOID:2957	A15	D014397			Circulating miR-29a might have great potential to serve as a marker for detection of active pulmonary tuberculosis infection.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Tuberculosis, Pulmonary	26681217	disease by infectious agent	DOID:2957	A15	D014397			Therefore, miR-31 has the potential to be a diagnostic marker in pediatric TB patients.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Unstable Angina	25704294	cardiovascular system disease	DOID:8805	I20.0	D000789			Our findings suggest that circulating miR-28-5p, involved in LXRα-ABCA1 pathway, may be a potential biomarker for diagnosis and prognosis of unstable angina.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Urinary Bladder Cancer	18799331	urinary system disease	DOID:11054	C67	D001749	109800		miR-205: miR-21/miR-205 expression ratio that has the ability to distinguish between invasive and noninvasive bladder tumors
circulation_biomarker_diagnosis_ns	hsa-mir-21	Urinary Bladder Cancer	18799331	urinary system disease	DOID:11054	C67	D001749	109800		miR-21: miR-21/miR-205 expression ratio that has the ability to distinguish between invasive and noninvasive bladder tumors
circulation_biomarker_diagnosis_ns	hsa-mir-93	Uterine Cancer	29844841	disease of cellular proliferation	DOID:363	C55	D014594			Expression of serum Hsa-miR-93 in uterine cancer and its clinical significance.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Uveal Melanoma	25951497				C536494	155720	HP:0007716	Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Uveal Melanoma	25951497				C536494	155720	HP:0007716	Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Uveal Melanoma	25951497				C536494	155720	HP:0007716	Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Vascular Disease [unspecific]	23386708	cardiovascular system disease	DOID:178	I72.9	D000783			plasma;Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-142	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-383	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_up	hsa-mir-124-1	Acute Cerebral Infarction	21551949	cardiovascular system disease	DOID:3526	I63	D002544			Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction.
circulation_biomarker_diagnosis_up	hsa-mir-124-2	Acute Cerebral Infarction	21551949	cardiovascular system disease	DOID:3526	I63	D002544			Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction.
circulation_biomarker_diagnosis_up	hsa-mir-124-3	Acute Cerebral Infarction	21551949	cardiovascular system disease	DOID:3526	I63	D002544			Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction.
circulation_biomarker_diagnosis_up	hsa-mir-210	Acute Cerebral Infarction	29434712	cardiovascular system disease	DOID:3526	I63	D002544			miR-210 is upregulated in the serum of patients with ACI, and miR-210 may be involved in the pathogenesis of ACI through regulating the proliferation and apoptosis of endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-122	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-125a	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-223	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-323	Acute Coronary Syndrome	25124998			I24.9	D054058			Our study identifies miR-652 as a novel candidate biomarker for post-ACS prognosis beyond existing biomarkers of LVEF and NT-proBNP. Moreover circulating miR-323-3p was markedly elevated in patients for at least a year post-ACS and may be a stable biomarker for ACS.
circulation_biomarker_diagnosis_up	hsa-mir-486	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-499	Acute Coronary Syndrome	27346801			I24.9	D054058			miRNA-499 and miRNA-210 expression levels were significantly increased
circulation_biomarker_diagnosis_up	hsa-mir-652	Acute Coronary Syndrome	25124998			I24.9	D054058			Our study identifies miR-652 as a novel candidate biomarker for post-ACS prognosis beyond existing biomarkers of LVEF and NT-proBNP. Moreover circulating miR-323-3p was markedly elevated in patients for at least a year post-ACS and may be a stable biomarker for ACS.
circulation_biomarker_diagnosis_up	hsa-mir-92a	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Acute Kidney Failure	27400799	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	The results showed that in acute kidney injury induced by cisplatin, miR-146b in serum increased more quickly than did the usual indexes of kidney injury and decreased with restoration of MSCs.
circulation_biomarker_diagnosis_up	hsa-mir-133a	Acute Myocardial Infarction	27124025	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	circulating miR-133a is upregulated in AMI patients,
circulation_biomarker_diagnosis_up	hsa-mir-208a	Acute Myocardial Infarction	24253456	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis.
circulation_biomarker_diagnosis_up	hsa-mir-221	Acute Myocardial Infarction	27374153	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-221-3p as a novel marker for early prediction of acute myocardial infarction.
circulation_biomarker_diagnosis_up	hsa-mir-30d	Acute Myocardial Infarction	27176713	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	miR-125b-5p and miR-30d-5p presented a diagnostic value for early diagnosis of AMI, and miR鈥?0d鈥?p may have a higher diagnostic value than cTnI.
circulation_biomarker_diagnosis_up	hsa-mir-423	Acute Myocardial Infarction	24253456	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis.
circulation_biomarker_diagnosis_up	hsa-mir-499	Acute Myocardial Infarction	26101645	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	miR-499 expression levels were significantly higher in the 53 AMI patients
circulation_biomarker_diagnosis_up	hsa-mir-499	Acute Myocardial Infarction	27162785	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	the circulating levels of miRNA-499 was increased in AMI patients.
circulation_biomarker_diagnosis_up	hsa-mir-122	Acute Pancreatitis	27477940	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	In mice, we found that LPS-induced inflammation increases blood levels of MIR122, which reduces expression of Epo in the kidney;
circulation_biomarker_diagnosis_up	hsa-mir-155	Adenocarcinoma, Lung	24190459	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	endogenous miR-155 stably existed in patient serum and could be sensitively and specifically measured. Overexpression of miR-155 in serum specimens could constitute a diagnostic marker for the early detection of lung adenocarcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-155	Adenocarcinoma, Pancreatic Ductal	22513294	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC
circulation_biomarker_diagnosis_up	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	22513294	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC
circulation_biomarker_diagnosis_up	hsa-mir-210	Adenocarcinoma, Pancreatic Ductal	22513294	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC
circulation_biomarker_diagnosis_up	hsa-mir-375	Adenocarcinoma, Pancreatic Ductal	24048453	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		In the plasma-miRNA population, we find miRNA-375, which is selectively expressed in the endocrine pancreas under normal conditions, increased in PDAC cases compared with patients with other pancreatic or gastrointestinal diseases. The miRNA-375 does not outperform CA-19-9 diagnostically in the present cohort.
circulation_biomarker_diagnosis_up	hsa-mir-19a	Allergic Rhinitis	27491928	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants.
circulation_biomarker_diagnosis_up	hsa-mir-151a	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-mir-161	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-let-7d	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-mir-5010	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-mir-112	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-mir-338	Amyotrophic Lateral Sclerosis	25130371	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients.
circulation_biomarker_diagnosis_up	hsa-mir-21	Ankylosing Spondylitis	24786924	musculoskeletal system disease	DOID:7147	M45.9	D013167			Higher expression of whole blood microRNA-21 in patients with ankylosing spondylitis associated with programmed cell death 4 mRNA expression and collagen cross-linked C-telopeptide concentration.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Ankylosing Spondylitis	24593209	musculoskeletal system disease	DOID:7147	M45.9	D013167			We report for the first time elevated miR-29a expression in PBMCs of patients with ankylosing spondylitis, and miR-29a might be used as a useful diagnostic marker in new bone formation but cannot reflect disease activity.
circulation_biomarker_diagnosis_up	hsa-mir-21	Aortic Stenosis	22882958	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	The myocardial and plasma levels of miR-21 were significantly higher in the AS patients compared with the controls and correlated directly with the echocardiographic mean transvalvular gradients.
circulation_biomarker_diagnosis_up	hsa-mir-30c	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_up	hsa-mir-133	Arrhythmia	25625292			I49.9	D001145	600919	HP:0011675	patients with SVT had lower miR-1 expression levels while those with VT had higher miR-133 expression levels.
circulation_biomarker_diagnosis_up	hsa-mir-126	Arteriosclerosis Obliterans	27766047	cardiovascular system disease	DOID:5160		D001162		HP:0002634	In smokers who completely attained smoking cessation, both RH-PAT index and plasma miR-126 values were increased
circulation_biomarker_diagnosis_up	hsa-mir-126	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-126:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-126	Atherosclerosis	25697638	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	and the levels of miR-126 had positive correlation with cerebral atherosclerosis
circulation_biomarker_diagnosis_up	hsa-mir-146a	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Atherosclerosis	27502756	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In monocytes, miR124a and -125a were low, while miR-146a and miR-155 appeared elevated.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-17	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-17-5p:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-17	Atherosclerosis	25697638	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	he levels of miR-17 were significantly increased in acute stroke patients
circulation_biomarker_diagnosis_up	hsa-mir-21	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-21	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-21	Atherosclerosis	24848278	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In atherosclerosis, miR-21, 122, 130a, and 211 were significantly increased whereas miR-92a, 126, and 222 were markedly decreased.
circulation_biomarker_diagnosis_up	hsa-mir-210	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-210:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-210	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-221	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-221:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-222	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-222:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-296	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-296:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-29a	Atherosclerosis	28250354	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Elevated Plasma miR-29a Levels Are Associated with Increased Carotid Intima-Media Thickness in Atherosclerosis Patients.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-203	Atopic Dermatitis	25531302	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	miR-203 and miR-483-5p were significantly up-regulated in serum of children with AD compared with healthy children.
circulation_biomarker_diagnosis_up	hsa-mir-328	Atrial Fibrillation	26987792	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Plasma levels of miR-328 were higher in patients with AF than in control subjects.
circulation_biomarker_diagnosis_up	hsa-mir-132	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-132: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-146a	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-146a: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-146b	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		mir-146b: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-23a	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-23a: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-23b	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-23b: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-663a	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-663: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-301a	Autoimmune Diseases [unspecific]	26338824				D001327	607836	HP:0002960	Our data reveal a novel mechanism in which the elevated miR-301a in  PBMC and inflamed mucosa of IBD promotes Th17 cell differentiation through downregulation of SNIP1.
circulation_biomarker_diagnosis_up	hsa-mir-21	Autoimmune Lymphoproliferative Syndrome	27060458	immune system disease	DOID:6688	D89.82	D056735	PS308240		miR-21-3p was over-expressed significantly (P = 0路0313) in the son, with no significant change in the expression of miR-146a, miR-146a-3p and miR-21.
circulation_biomarker_diagnosis_up	hsa-mir-21	Brain Neoplasms	16466964	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	overexpressed
circulation_biomarker_diagnosis_up	hsa-let-7a-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a* is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-let-7a-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a* is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-let-7a-3	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a* is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-let-7b	Breast Neoplasms	22821209	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours.
circulation_biomarker_diagnosis_up	hsa-let-7g	Breast Neoplasms	22821209	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours.
circulation_biomarker_diagnosis_up	hsa-mir-103a-1	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-103a-1	Breast Neoplasms	22588912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05).
circulation_biomarker_diagnosis_up	hsa-mir-103a-2	Breast Neoplasms	22588912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05).
circulation_biomarker_diagnosis_up	hsa-mir-103b-1	Breast Neoplasms	22588912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05).
circulation_biomarker_diagnosis_up	hsa-mir-103b-2	Breast Neoplasms	22588912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05).
circulation_biomarker_diagnosis_up	hsa-mir-106b	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-10b	Breast Neoplasms	22906258	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum Overexpression of MicroRNA-10b in Patients with Bone Metastatic Primary Breast Cancer.
circulation_biomarker_diagnosis_up	hsa-mir-127	Breast Neoplasms	16766263	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	upregulation
circulation_biomarker_diagnosis_up	hsa-mir-132	Breast Neoplasms	17447837	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-1323	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-141	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-146a	Breast Neoplasms	23898484	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Breast Neoplasms	27197674	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas  miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed.
circulation_biomarker_diagnosis_up	hsa-mir-148b	Breast Neoplasms	22927033	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-155	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-155	Breast Neoplasms	16885332	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression in breast cancers
circulation_biomarker_diagnosis_up	hsa-mir-155	Breast Neoplasms	23372341	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	serum;miR-205 was down-regulated and miR-155 was up-regulated in BC patient serum
circulation_biomarker_diagnosis_up	hsa-mir-18b	Breast Neoplasms	22821209	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours.
circulation_biomarker_diagnosis_up	hsa-mir-197	Breast Neoplasms	25644077	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression level of miR-29b-2, -155, -197 and -205 was significantly increased in the serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-200a	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-200b	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-200c	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-202	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-203	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-205	Breast Neoplasms	23372341	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	serum;miR-205 was down-regulated and miR-155 was up-regulated in BC patient serum
circulation_biomarker_diagnosis_up	hsa-mir-20a	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-20a: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-20a	Breast Neoplasms	22350790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-20b	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-20b: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	23898484	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	16885332	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression in breast cancers
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	22350790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	26827795	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the serum levels of miR-21 and miR-221 were significantly overexpressed in breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	27197674	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas  miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed.
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	29679553	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters
circulation_biomarker_diagnosis_up	hsa-mir-210	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-214	Breast Neoplasms	22350790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-221	Breast Neoplasms	26827795	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the serum levels of miR-21 and miR-221 were significantly overexpressed in breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-222	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-222	Breast Neoplasms	29679553	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters
circulation_biomarker_diagnosis_up	hsa-mir-23a	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-23b	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-24-1	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-25	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-335	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-373	Breast Neoplasms	25333260	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-373	Breast Neoplasms	29679553	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters
circulation_biomarker_diagnosis_up	hsa-mir-375	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-376c	Breast Neoplasms	22927033	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-409	Breast Neoplasms	22927033	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-4257	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-4306	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-497	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-516b-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-516b-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-9-1	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-9-2	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-922	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-9-3	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-127	Carcinoma, Breast	27983524			D05	D001943	114480	HP:0003002	Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.
circulation_biomarker_diagnosis_up	hsa-mir-372	Carcinoma, Embryonal	19057917	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	miR-372: highly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-373	Carcinoma, Embryonal	19057917	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	miR-373: highly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-122	Carcinoma, Hepatocellular	21229610	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC.
circulation_biomarker_diagnosis_up	hsa-mir-130b	Carcinoma, Hepatocellular	22403344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity).
circulation_biomarker_diagnosis_up	hsa-mir-15b	Carcinoma, Hepatocellular	22403344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity).
circulation_biomarker_diagnosis_up	hsa-mir-17	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-17: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-182	Carcinoma, Hepatocellular	25903466	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our present study indicates that serum miR-182 and miR-331-3p, upregulated in HCC, can provide positive diagnostic and prognostic values for HCC
circulation_biomarker_diagnosis_up	hsa-mir-183	Carcinoma, Hepatocellular	22403344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity).
circulation_biomarker_diagnosis_up	hsa-mir-18a	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-18a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-18a	Carcinoma, Hepatocellular	22865399	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-18a was significantly higher in HBV patients with HCC than healthy controls (p < 0.01).
circulation_biomarker_diagnosis_up	hsa-mir-19a	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-19a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-19b: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-19b: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-20a	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-20a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Hepatocellular	18223217	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	increased
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-21: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Hepatocellular	21229610	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC.
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Hepatocellular	22403344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity).
circulation_biomarker_diagnosis_up	hsa-mir-210	Carcinoma, Hepatocellular	22387901	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro.
circulation_biomarker_diagnosis_up	hsa-mir-222	Carcinoma, Hepatocellular	26380927	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The serum levels of exosomal miR-18a, miR-221, miR-222 and miR-224 were significantly higher in patients with HCC
circulation_biomarker_diagnosis_up	hsa-mir-223	Carcinoma, Hepatocellular	21229610	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC.
circulation_biomarker_diagnosis_up	hsa-mir-331	Carcinoma, Hepatocellular	25903466	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-96	Carcinoma, Hepatocellular	26770453	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-96 levels in the HCC patients were remarkably higher than in the other groups
circulation_biomarker_diagnosis_up	hsa-mir-100	Carcinoma, Lung, Non-Small-Cell	22937028			C34.90	D002289		HP:0030358	High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort.
circulation_biomarker_diagnosis_up	hsa-mir-10b	Carcinoma, Lung, Non-Small-Cell	25869877			C34.90	D002289		HP:0030358	Prognostic value of microRNA-10b overexpression in peripheral blood mononuclear cells of nonsmall-cell lung cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-1254-1	Carcinoma, Lung, Non-Small-Cell	21258252			C34.90	D002289		HP:0030358	miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls.  The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation.
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	21627863			C34.90	D002289		HP:0030358	Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	21721011			C34.90	D002289		HP:0030358	serum miR-21 expression was an independent prognostic factor for NSCLC patients.
circulation_biomarker_diagnosis_up	hsa-mir-29c	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_up	hsa-mir-574	Carcinoma, Lung, Non-Small-Cell	21258252			C34.90	D002289		HP:0030358	miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls.  The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation.
circulation_biomarker_diagnosis_up	hsa-mir-200b	Carcinoma, Ovarian	26416421	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Plasma miR-200b proved to have a greater average concentration in OvCa samples
circulation_biomarker_diagnosis_up	hsa-mir-106b	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-1233-1	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-1233-2	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-126	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-126*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-1290	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-134	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-144	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-144*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-151a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-151-30: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-151b	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-151-30: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-203	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-210	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-26b	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-26b*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-29c	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-29c*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-320a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-320b-1	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-320b-2	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-339	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-339-3p: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-365a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-365b	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-378a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-378a	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378b	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378c	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378d-1	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378d-2	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378e	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378f	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378g	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378h	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378i	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-425	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-425*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-454	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-454*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-571	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-625	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-625*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-629	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-655	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-7-1	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-760	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-93	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Cardiac Allograft Vasculopathy	26198441			T86.290	D014652			Median plasma levels of miR-210-5p, miR-92a-3p, miR-126-3p, and miR-126-5p were higher in patients with CAV than in patients without CAV.
circulation_biomarker_diagnosis_up	hsa-mir-208	Cardiomegaly	26622415			I51.7	D006332		HP:0001640	miR-208 expression levels are increased in the peripheral blood of patients with cardiac hypertrophy.
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Cardiomyopathy, Hypertrophic	17965831	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue.
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Cardiomyopathy, Hypertrophic	17965831	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue.
circulation_biomarker_diagnosis_up	hsa-mir-195	Cardiomyopathy, Hypertrophic	17786230	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Cardiac-specific overexpression of miRNA-195 (miR-195), which is consistently upregulated in rodent and human hypertrophic hearts, for example, results in dilated cardiomyopathy and heart failure in mice as early as two weeks of age, implying that upregulation of miR-195 during cardiac hypertrophy actively contributes to the disease process.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Cardiomyopathy, Hypertrophic	24161319	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	cardiac remodeling associated with HCM determines a significant release of miRNAs into the bloodstream: the circulating levels of both cardiac- and non-cardiac-specific miRNAs are significantly increased in the plasma of HCM patients. However, correlation with left ventricular hypertrophy parameters holds true for only a few miRNAs (i.e.,miR-199a-5p, -27a, and -29a), whereas only miR-29a is significantly associated with both hypertrophy and fibrosis, identifying it as a potential biomarker for myocardial remodeling assessment in HCM.
circulation_biomarker_diagnosis_up	hsa-mir-1	Cardiovascular Diseases [unspecific]	22135162				D002318			miR-1 and miR-133 are highly expressed in cardiomyocytes and their precursors and regulate cardiomyogenesis. 
circulation_biomarker_diagnosis_up	hsa-mir-1	Cardiovascular Diseases [unspecific]	29506853				D002318			Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery
circulation_biomarker_diagnosis_up	hsa-mir-133	Cardiovascular Diseases [unspecific]	22135162				D002318			miR-1 and miR-133 are highly expressed in cardiomyocytes and their precursors and regulate cardiomyogenesis. 
circulation_biomarker_diagnosis_up	hsa-mir-133a	Cardiovascular Diseases [unspecific]	29506853				D002318			Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery
circulation_biomarker_diagnosis_up	hsa-mir-208a	Cardiovascular Diseases [unspecific]	29506853				D002318			Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery
circulation_biomarker_diagnosis_up	hsa-mir-423	Cardiovascular Diseases [unspecific]	26562412				D002318			Our results suggested that miR-423-5p is enriched in PF, and serum miR-423-5p may be associate with uAP. Its expression pattern was different to that of muscle- and vascular-enriched miRNAs, miR-133a, miR-126, and miR-92a.
circulation_biomarker_diagnosis_up	hsa-mir-372	Cerebellum Cancer	19057917	nervous system disease	DOID:4205	C71.6	D002528			miR-372: highly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-373	Cerebellum Cancer	19057917	nervous system disease	DOID:4205	C71.6	D002528			miR-373: highly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-145	Cerebral Ischemia	22370881	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	Circulatory microRNA-145 expression is increased in cerebral ischemia.
circulation_biomarker_diagnosis_up	hsa-mir-200a	Cervical Neoplasms	26171195	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The Solexa sequencing results revealed 12 markedly upregulated serum miRNAs in cervical cancer patients compared with controls
circulation_biomarker_diagnosis_up	hsa-mir-23a	Child Development Disorders, Pervasive	20374639			F84.9	D002659			up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-141	Cholangiocarcinoma	17355635	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-192	Cholangiocarcinoma	26456596	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	We found that miR-192 was significantly higher in O. viverrini infected, PDF and also CCA groups (p<0.05) than in healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-200b	Cholangiocarcinoma	17355635	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-21	Cholangiocarcinoma	26456596	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-21 was significantly higher in PDF and CCA groups (p<0.05) than in healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-21	Cholangiocarcinoma	29516989	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	serum miR-21 was a promising biomarker for diagnosing the late stage CCA and would have potential to be a useful prognostic biomarker of CCA
circulation_biomarker_diagnosis_up	hsa-mir-21	Cholesteatoma	28224282	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-10b	Choriocarcinoma	23933230	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	we observed that miR-21 was significantly overexpressed in PDAC, and miR-10b was highly expressed in PanIN II-III.
circulation_biomarker_diagnosis_up	hsa-mir-223	Choriocarcinoma	26807325	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Three miRNAs (miR-143, miR-223, and  miR-30e) were significantly over-expressed in patients with Stage I cancer when compared with age-matched healthy individuals
circulation_biomarker_diagnosis_up	hsa-mir-99b	Chronic Fatigue Syndrome	26967895	syndrome	DOID:8544	G93.3	D015673		HP:0012432	Microarray analysis identified differential expression of 34 miRNA, all  of which were up-regulated.
circulation_biomarker_diagnosis_up	hsa-mir-125b	Chronic Hepatitis B	26802212			B18.0-.1	D019694	610424		serum miRNA-125b was positively correlated with the  serum HBV DNA level.
circulation_biomarker_diagnosis_up	hsa-mir-122	Chronic Hepatitis C	25461662			B18.2	D019698	609532		serum microRNA-122 was elevated in acute and chronic hepatitis patients. However, this biomarker for acute liver injury did not reflect the liver inflammation activity in CHC patients.
circulation_biomarker_diagnosis_up	hsa-mir-122	Chronic Hepatitis C	26812693			B18.2	D019698	609532		serum levels of miR-122 and miR-222 were significantly elevated in HCV patients
circulation_biomarker_diagnosis_up	hsa-mir-222	Chronic Hepatitis C	26812693			B18.2	D019698	609532		the serum levels of miR-122 and miR-222 were significantly elevated in HCV patients
circulation_biomarker_diagnosis_up	hsa-mir-296	Chronic Hepatitis C	25790297			B18.2	D019698	609532		Serum miR-34a, miR-130a, miR-19a, miR-192, miR-195, and miR-296 were upregulated, whereas serum miR-146a was downregulated in CHC compared to controls.
circulation_biomarker_diagnosis_up	hsa-mir-21	Chronic Obstructive Pulmonary Disease	24556821	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	An increased ratio of serum miR-21 to miR-181a levels is associated with the early pathogenic process of chronic obstructive pulmonary disease in asymptomatic heavy smokers.
circulation_biomarker_diagnosis_up	hsa-mir-106a	Colon Neoplasms	17442096			D12.6	D003110		HP:0100273	Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors.
circulation_biomarker_diagnosis_up	hsa-mir-132	Colon Neoplasms	17447837			D12.6	D003110		HP:0100273	miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-141	Colon Neoplasms	17355635			D12.6	D003110		HP:0100273	These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-145	Colon Neoplasms	16885332			D12.6	D003110		HP:0100273	Reduced accumulation in colon adenomas and carcinomas
circulation_biomarker_diagnosis_up	hsa-mir-200b	Colon Neoplasms	17355635			D12.6	D003110		HP:0100273	These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-96	Colorectal Adenocarcinoma	27044381	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-96 is significantly upregulated in colorectal adenocarcinoma specimens compared to their non-cancerous counterparts
circulation_biomarker_diagnosis_up	hsa-mir-135a	Colorectal Carcinoma	27126269	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-135a-5p expression in colorectal cancer patients was higher than that in patients with colorectal polyps and healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-21	Colorectal Carcinoma	25178939	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Elevated level of microRNA-21 in the serum of patients with colorectal cancer.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Colorectal Carcinoma	25736690	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Significant upregulation of miR-29a in CRC was reported when compared to normal
circulation_biomarker_diagnosis_up	hsa-mir-145	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-145: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-181b-1	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-181b: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-203	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-203: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-20a	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-21	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-21	Colorectal Carcinoma	22868372	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In the plasma group, miR-21 differentiated CRC patients from controls with 90% specificity and sensitivity.
circulation_biomarker_diagnosis_up	hsa-mir-31	Colorectal Carcinoma	19242066	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-31: up-regulated compared with normal control
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Coronary Artery Disease	17919180	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		elevated expression
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Coronary Artery Disease	17965831	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue.
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Coronary Artery Disease	17919180	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		elevated expression
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Coronary Artery Disease	17965831	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue.
circulation_biomarker_diagnosis_up	hsa-mir-122	Coronary Artery Disease	22587332	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-126	Coronary Artery Disease	28751542	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress
circulation_biomarker_diagnosis_up	hsa-mir-206	Coronary Artery Disease	26685009	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-21	Coronary Artery Disease	26248417	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA-21 was significantly elevated in acute myocardial infarction subgroup than the control group. The level of miRNA-21 associates with the degree of coronary artery stenosis, and might be a potential marker for the diagnosis of acute myocardial infarction. miRNA-21 may play an important role in protecting myocardium from ischemia/reperfusion injury.
circulation_biomarker_diagnosis_up	hsa-mir-21	Coronary Artery Disease	28751542	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress
circulation_biomarker_diagnosis_up	hsa-mir-222	Coronary Artery Disease	28751542	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress
circulation_biomarker_diagnosis_up	hsa-mir-370	Coronary Artery Disease	22587332	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-574	Coronary Artery Disease	26685009	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-106a	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-107	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-126	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-191	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-199a-1	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-199a-2	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-200c	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-23a	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-362	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-532	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-124	Depression Disorder	27078210	disease of mental health	DOID:1596	F32.9	D003866			expression levels of miR-124 from PBMCs in MDD patients were significantly higher than those in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-147	Diabetes Mellitus	27518498	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Analysis for serum microRNAs expression showed the distinctive and synergistic upregulation of miR-147 with periodontitis-induced effects in rats
circulation_biomarker_diagnosis_up	hsa-mir-326	Diabetes Mellitus, Type 1	22069274	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity.
circulation_biomarker_diagnosis_up	hsa-mir-101	Diabetes Mellitus, Type 2	25726255	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes.
circulation_biomarker_diagnosis_up	hsa-mir-143	Diabetes Mellitus, Type 2	24927876	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function.
circulation_biomarker_diagnosis_up	hsa-mir-145	Diabetes Mellitus, Type 2	24927876	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Diabetes Mellitus, Type 2	24023848	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	circulating miRNA-146a levels were significantly elevated in new-T2DM patients compared with healthy controls. Whether expression of circulating miRNA-146a holds predictive value for T2DM warrants further investigations.
circulation_biomarker_diagnosis_up	hsa-mir-217	Diabetes Mellitus, Type 2	27522360	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Compared with control, serum microRNA-217 levels were significantly increased in type 2 diabetes patients
circulation_biomarker_diagnosis_up	hsa-mir-33b	Diabetes Mellitus, Type 2	27301461	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	plasma miRNA33b may be useful as a new metabolic biomarker of dyslipidemia in patients with T2DM
circulation_biomarker_diagnosis_up	hsa-mir-375	Diabetes Mellitus, Type 2	25726255	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes.
circulation_biomarker_diagnosis_up	hsa-mir-802	Diabetes Mellitus, Type 2	25726255	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes.
circulation_biomarker_diagnosis_up	hsa-mir-30	Diabetic Nephropathy	27470555			E10-11.21	D003928			We found urinary exosomalmiR-133b, miR-342, and miR-30a were expressed at significantly elevated levels in T2DN patients (P<0.001) compared to normal.
circulation_biomarker_diagnosis_up	hsa-mir-342	Diabetic Nephropathy	27470555			E10-11.21	D003928			We found urinary exosomalmiR-133b, miR-342, and miR-30a were expressed at significantly elevated levels in T2DN patients (P<0.001) compared to normal.
circulation_biomarker_diagnosis_up	hsa-mir-377	Diabetic Nephropathy	18716028			E10-11.21	D003928			miR-377: MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy
circulation_biomarker_diagnosis_up	hsa-mir-27b	Diabetic Retinopathy	26395742	nervous system disease	DOID:8947	E10-11.31	D003930			miR-27b and miR-320a, were associated with incidence and with progression of retinopathy
circulation_biomarker_diagnosis_up	hsa-let-7c	Down Syndrome	27323694	genetic disease	DOID:14250	Q90	D004314	190685		Seven miRNAs were verified as upregulated in DS placentas (miR-99a, miR-542-5p, miR-10b, miR-125b, miR-615, let-7c and miR-654)
circulation_biomarker_diagnosis_up	hsa-mir-323a	Ectopic Pregnancy	22395025	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%).
circulation_biomarker_diagnosis_up	hsa-mir-146a	Eczema Herpeticum	18419608	disease by infectious agent	DOID:9123	B00.0	D007617			upregulation
circulation_biomarker_diagnosis_up	hsa-mir-106b	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-106b*: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-132	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-142	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-146a	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Plasma analysis of the most upregulated esophageal miRNAs identified miR-146a, miR-146b, and miR-223 as the most differentially expressed miRNAs in the plasma.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Plasma analysis of the most upregulated esophageal miRNAs identified miR-146a, miR-146b, and miR-223 as the most differentially expressed miRNAs in the plasma.
circulation_biomarker_diagnosis_up	hsa-mir-21	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		One of the most upregulated miRNA, which strongly correlated with esophageal eosinophil levels.
circulation_biomarker_diagnosis_up	hsa-mir-212	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-222	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-222*: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-223	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		One of the most upregulated miRNA, which strongly correlated with esophageal eosinophil levels. And miR-223 is one of the most differentially expressed miRNAs in the plasma.
circulation_biomarker_diagnosis_up	hsa-mir-29b-1	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-29b-2	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-339	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-339-5p: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-592	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-7-1	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-7-2	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-7-3	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-92a-1*: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-21	Esophageal Neoplasms	22354855			C15.9	D004938	133239	HP:0100751	Serum concentration of miRNA-21 in ESCC patients was significantly higher than that in healthy controls (P<0.001). A significant reduction in the serum miR-21 levels was observed in the postoperative samples versus the preoperative samples (P=0.003). Furthermore, miRNA-21 levels were significantly reduced in ESCC patients who responded to chemotherapy (P=0.003), whereas no significant change was observed in the non-responders.
circulation_biomarker_diagnosis_up	hsa-mir-21	Esophageal Neoplasms	22799367			C15.9	D004938	133239	HP:0100751	Serum miR-21 expression in ESCC samples was significantly higher than in paired cancer-free samples (P <0.05). Metastasis was associated with mir-21 expression in serum (P <0.05), ESCC patients with metastasis having 8.4-fold higher serum miR-21 concentrations than healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-21	Esophageal Neoplasms	23224754			C15.9	D004938	133239	HP:0100751	Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma
circulation_biomarker_diagnosis_up	hsa-mir-1	Essential Hypertension	24284386	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertensive patients showed lower miR-143, miR-145 and miR-133 and higher miR-21 and miR-1 expression levels compared with controls
circulation_biomarker_diagnosis_up	hsa-mir-144	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_up	hsa-mir-21	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_up	hsa-mir-4454	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_up	hsa-mir-451a	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_up	hsa-mir-15b	Fatty Liver [unspecific]	23287814	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease
circulation_biomarker_diagnosis_up	hsa-mir-122	Fatty Liver, Alcoholic	21886843			K70.0	D005235			Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Fatty Liver, Alcoholic	21886843			K70.0	D005235			Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Fatty Liver, Alcoholic	21886843			K70.0	D005235			Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Fatty Liver, Alcoholic	21886843			K70.0	D005235			Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
circulation_biomarker_diagnosis_up	hsa-mir-122	Fatty Liver, Non-Alcoholic	23727030	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis.
circulation_biomarker_diagnosis_up	hsa-mir-21	Fatty Liver, Non-Alcoholic	23727030	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Fatty Liver, Non-Alcoholic	23727030	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis.
circulation_biomarker_diagnosis_up	hsa-mir-451	Fatty Liver, Non-Alcoholic	23727030	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis.
circulation_biomarker_diagnosis_up	hsa-mir-21	Focal Epithelial Hyperplasia	17478730	disease by infectious agent	DOID:5362	K13.29	D017573	229045		We found that miR-21 was one of the most upregulated miRNAs in the vascular wall after balloon injury. Our results strongly indicate that miR-21 is an important regulator for neointimal hyperplasia.
circulation_biomarker_diagnosis_up	hsa-mir-107	Gastric Neoplasms	26406411	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The overexpression of miR-107 in tumors and serum of gastric cancer patients and its correlation with HIF-1α expression in tumor tissues was indicated that miR-107 may have a potential to use as a biomarker for detection of gastric cancer patients and hypoxia in gastric cancer tumor.
circulation_biomarker_diagnosis_up	hsa-mir-132	Gastric Neoplasms	17447837	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-151a	Gastric Neoplasms	22956063	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-151b	Gastric Neoplasms	22956063	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-199a-1	Gastric Neoplasms	22956063	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-199a-2	Gastric Neoplasms	22956063	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-200c	Gastric Neoplasms	22954417	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The miR-200c blood expression levels in GC patients were significantly higher than in normal controls (p = 0.018). increased miR-200c levels are detected in the blood of gastric cancer patients. MiR-200c has the potential to be a predictor of progression and survival.
circulation_biomarker_diagnosis_up	hsa-mir-21	Gastric Neoplasms	22860003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-223	Gastric Neoplasms	22860003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-421	Gastric Neoplasms	25510566	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-421 increased significantly in GC patients than in controls. miR-421 in either serum or PBMCs had higher sensitivity and specificity than CEA and CA-125 in GC diagnosis.
circulation_biomarker_diagnosis_up	hsa-mir-92a	Gastric Neoplasms	26790436	disease of cellular proliferation	DOID:10534	C16	D013274	137215		High expression of miR-92a compared with adjacent normal tissues was associated with shorter OS.
circulation_biomarker_diagnosis_up	hsa-mir-128-1	Glioblastoma	21561454				D005909		HP:0100843	upregulated in the peripheral blood of glioblastoma patients.
circulation_biomarker_diagnosis_up	hsa-mir-128-2	Glioblastoma	21561454				D005909		HP:0100843	upregulated in the peripheral blood of glioblastoma patients.
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	16466964				D005909		HP:0100843	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	16885332				D005909		HP:0100843	Elevated levels in glioblastoma primary tumors and cell lines
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	17028302				D005909		HP:0100843	miR-21 is strongly overexpressed in this highly malignant brain tumor type, while knockdown of miR-21 in glioblastoma cells by an antisense-oligonucleotide triggered activation of caspases and led to increased apoptotic cell death, suggesting that miR-21 overexpression may contribute to the malignant phenotype by suppressing critical apoptosis-related genes.
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	22891879				D005909		HP:0100843	Plasma MicroRNA-21 in glioblastoma was significantly higher than controls (p = .02) and decreased significantly in 9 patients (p = .05). One patient with increasing microRNA-21 developed a histopathologically proven recurrence after the second sample collection.
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	27047250				D005909		HP:0100843	we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas
circulation_biomarker_diagnosis_up	hsa-mir-15b	Glioma	27047250	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas
circulation_biomarker_diagnosis_up	hsa-mir-16	Glioma	27047250	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas
circulation_biomarker_diagnosis_up	hsa-mir-182	Glioma	26978735	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our findings showed that the level of circulating miR-182 in glioma patients was higher than that in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioma	27047250	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioma	27166186	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	CSF-based miR-21 might serve as a potential biomarker for  diagnosing brain cancer
circulation_biomarker_diagnosis_up	hsa-mir-146a	Glomerulonephritis	21694443	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	The expression levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy were elevated.
circulation_biomarker_diagnosis_up	hsa-mir-155	Glomerulonephritis	21694443	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	The expression levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy were elevated.
circulation_biomarker_diagnosis_up	hsa-mir-199a	Graft-Versus-Host Disease	27342518			D89.813	D006086	614395		The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD.
circulation_biomarker_diagnosis_up	hsa-mir-423	Graft-Versus-Host Disease	27342518			D89.813	D006086	614395		The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD.
circulation_biomarker_diagnosis_up	hsa-mir-93	Graft-Versus-Host Disease	27342518			D89.813	D006086	614395		The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD.
circulation_biomarker_diagnosis_up	hsa-mir-22	Graves Disease	24533739	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	Further analysis consistently showed that serum levels of miR-22, miR-375 and miR-451 were increased in patients with HT. On the other hand, the serum levels of miR-16, miR-22, miR-375 and miR-451 were increased in patients with GD compared with healthy subjects.
circulation_biomarker_diagnosis_up	hsa-mir-16	Hearing Loss	28224282			H91.93	D034381			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-185	Hearing Loss	28224282			H91.93	D034381			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-24	Hearing Loss	28224282			H91.93	D034381			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-451a	Hearing Loss	28224282			H91.93	D034381			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-106b	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-155	Heart Failure	28319523			I50	D006331		HP:0001635	Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support.
circulation_biomarker_diagnosis_up	hsa-mir-16	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-182	Heart Failure	25643195			I50	D006331		HP:0001635	Microarray profiling revealed an increase in the expression of miR-21, miR-650, miR-744, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 miR-122, miR-3148 and miR-518e and a decrease in the expression of miR-129-3p, miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star and miR-502-5p in sera of CHF patients.
circulation_biomarker_diagnosis_up	hsa-mir-192	Heart Failure	23743335			I50	D006331		HP:0001635	Among the 377 examined microRNAs, the serum level of only miR-192 was significantly upregulated in AMI patients with development of ischemic HF
circulation_biomarker_diagnosis_up	hsa-mir-195	Heart Failure	25364765			I50	D006331		HP:0001635	Circulating miR-195 is elevated in acute myocardial infarction, breast cancer, prostate cancer and colorectal adenoma.
circulation_biomarker_diagnosis_up	hsa-mir-208a	Heart Failure	17379774			I50	D006331		HP:0001635	upregulation
circulation_biomarker_diagnosis_up	hsa-mir-208a	Heart Failure	29559958			I50	D006331		HP:0001635	miR-208a, a microRNA that is a key factor in promoting cardiovascular dysfunction during cardiac hypertrophy processes of heart failure, has its circulating levels increased during chronic indeterminate  phase when compared to cardiac (CARD) clinical forms in patients with Chagas disease
circulation_biomarker_diagnosis_up	hsa-mir-20b	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-22	Heart Failure	22120965			I50	D006331		HP:0001635	significantly increased serum level
circulation_biomarker_diagnosis_up	hsa-mir-223	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-299	Heart Failure	25643195			I50	D006331		HP:0001635	Microarray profiling revealed an increase in the expression of miR-21, miR-650, miR-744, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 miR-122, miR-3148 and miR-518e and a decrease in the expression of miR-129-3p, miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star and miR-502-5p in sera of CHF patients.
circulation_biomarker_diagnosis_up	hsa-mir-320a	Heart Failure	22120965			I50	D006331		HP:0001635	significantly increased serum level
circulation_biomarker_diagnosis_up	hsa-mir-423	Heart Failure	20185794			I50	D006331		HP:0001635	MiR423-5p as a circulating biomarker for heart failure
circulation_biomarker_diagnosis_up	hsa-mir-423	Heart Failure	22120965			I50	D006331		HP:0001635	miR-423-5p: significantly increased serum level
circulation_biomarker_diagnosis_up	hsa-mir-423	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-423-5p	Heart Failure	23438607			I50	D006331		HP:0001635	Patients with DCM have elevated plasma miR-423-5p levels. The plasma concentration of miR-423-5p was positively correlated with the level of NT-proBNP. Circulating levels of miR-423-5p could be served as a diagnostic biomarker for heart failure caused by DCM. 
circulation_biomarker_diagnosis_up	hsa-mir-499	Heart Failure	27162785			I50	D006331		HP:0001635	the circulating levels of miRNA-499 was increased in AMI patients.
circulation_biomarker_diagnosis_up	hsa-mir-499a	Heart Failure	20921333			I50	D006331		HP:0001635	miR-499 was significantly elevated
circulation_biomarker_diagnosis_up	hsa-mir-92b	Heart Failure	22120965			I50	D006331		HP:0001635	significantly increased serum level
circulation_biomarker_diagnosis_up	hsa-mir-93	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-122	Hepatitis C Virus Infection	21886843	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection.
circulation_biomarker_diagnosis_up	hsa-mir-122	Hepatitis C Virus Infection	26157120	disease by infectious agent	DOID:1883	B19.2	D006526	609532		During acute HCV infection, increases in miR-122 (P < 0.01) and miR-885-5p (Pcorrected < 0.05) and a decrease in miR-494 (Pcorrected <  0.05) were observed at the earliest time points after virus detection.
circulation_biomarker_diagnosis_up	hsa-mir-155	Hepatitis C Virus Infection	29528577	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-155 is a relatively reliable marker for HCC detection
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Hepatitis C Virus Infection	21886843	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection.
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Hepatitis C Virus Infection	21886843	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection.
circulation_biomarker_diagnosis_up	hsa-mir-221	Hepatitis C Virus Infection	25433287	disease by infectious agent	DOID:1883	B19.2	D006526	609532		HCVcc infection could upregulate the expression of miR-221 in NF-κB dependent manner.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Hepatitis C Virus Infection	21886843	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection.
circulation_biomarker_diagnosis_up	hsa-mir-155	Human Immunodeficiency Virus Infection	28627655			B20	D015658	609423		Elevated expression of miR-155 is associated with the differentiation of CD8+ T cells in patients with HIV-1.
circulation_biomarker_diagnosis_up	hsa-mir-21	Human Immunodeficiency Virus Infection	28968466			B20	D015658	609423		upregulation of hsa-miR-21 and hsa-miR-222 by Tat may contribute to protect against apoptosis and to anergy observed in HIV-infected CD4+ T cells
circulation_biomarker_diagnosis_up	hsa-mir-222	Human Immunodeficiency Virus Infection	28968466			B20	D015658	609423		upregulation of hsa-miR-21 and hsa-miR-222 by Tat may contribute to protect against apoptosis and to anergy observed in HIV-infected CD4+ T cells
circulation_biomarker_diagnosis_up	hsa-mir-34b	Huntington Disease	21421997	nervous system disease	DOID:12858	G10	D006816	143100		Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.
circulation_biomarker_diagnosis_up	hsa-mir-33a	Hypercholesterolaemia	26229086			E78.3	D006937	143890		Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age.
circulation_biomarker_diagnosis_up	hsa-mir-33b	Hypercholesterolaemia	26229086			E78.3	D006937	143890		Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age.
circulation_biomarker_diagnosis_up	hsa-mir-122	Hyperlipidemia	22587332			E78.4	D006949		HP:0003077	Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-370	Hyperlipidemia	22587332			E78.4	D006949		HP:0003077	Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-let-7e	Hypertension	21924071	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples.
circulation_biomarker_diagnosis_up	hsa-mir-122	Hypertension	25837765	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-122 and miR-637 expressions were also significantly upregulated in the WCH group compared with the NT group
circulation_biomarker_diagnosis_up	hsa-mir-132	Hypertension	23712358	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The miR-132 and miR-212 are highly increased in the heart, aortic wall and kidney of rats with hypertension (159 ± 12 mm Hg) and cardiac hypertrophy following chronic AngII infusion.
circulation_biomarker_diagnosis_up	hsa-mir-145	Hypertension	23339529	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients
circulation_biomarker_diagnosis_up	hsa-mir-212	Hypertension	23712358	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The miR-132 and miR-212 are highly increased in the heart, aortic wall and kidney of rats with hypertension (159 ± 12 mm Hg) and cardiac hypertrophy following chronic AngII infusion.
circulation_biomarker_diagnosis_up	hsa-mir-21	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_up	hsa-mir-185	Idiopathic Short Stature	24342208			R62.56	C565805	300582		plasma miR-185 expression was significantly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-132	Inflammation	23264652				D007249			In peptidoglycan (PGN)/TLR2-stimulated THP-1 monocytes, PBMCs, and primary macrophages showed rapid and dramatic miR-132 and miR-212 (miR-132/-212) upregulation.
circulation_biomarker_diagnosis_up	hsa-mir-212	Inflammation	23264652				D007249			In peptidoglycan (PGN)/TLR2-stimulated THP-1 monocytes, PBMCs, and primary macrophages showed rapid and dramatic miR-132 and miR-212 (miR-132/-212) upregulation.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Intrahepatic Cholangiocarcinoma	29095255	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		Both plasma and tumor tissue miR-146a high expression correlates with prolonged overall survival of surgical patients with intrahepatic cholangiocarcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-16	Ischemia-Reperfusion Injury	27297958				D015427			urinary miR-16 was 100-fold higher in AKI patients.
circulation_biomarker_diagnosis_up	hsa-mir-192	Ischemia-Reperfusion Injury	24553149				D015427			However, miR-10a, miR-192, and miR-194 were significantly increased in plasma of rats with renal ischemia-reperfusion injury, among which miR-10a was elevated within 1 h after reperfusion, whereas miR-192 and miR-194 were elevated at 6 h after injury.
circulation_biomarker_diagnosis_up	hsa-mir-194	Ischemia-Reperfusion Injury	24553149				D015427			However, miR-10a, miR-192, and miR-194 were significantly increased in plasma of rats with renal ischemia-reperfusion injury, among which miR-10a was elevated within 1 h after reperfusion, whereas miR-192 and miR-194 were elevated at 6 h after injury.
circulation_biomarker_diagnosis_up	hsa-mir-210	Ischemic Diseases [unspecific]	21360638				D007511	601367		High levels of miR-210 have been linked to an in vivo hypoxic signature and associated with adverse prognosis in cancer patients. A wide spectrum of miR-210 targets have been identified, with roles in mitochondrial metabolism, angiogenesis, DNA repair, and cell survival.
circulation_biomarker_diagnosis_up	hsa-mir-200c	Kawasaki Syndrome	24259014	immune system disease	DOID:13378	M30.3	D009080	611775		Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease.
circulation_biomarker_diagnosis_up	hsa-mir-371	Kawasaki Syndrome	24259014	immune system disease	DOID:13378	M30.3	D009080	611775		Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease.
circulation_biomarker_diagnosis_up	hsa-mir-142	Kideny Transplant Rejection	28380212			T86.11	D006084			Upregulation of microRNA 142-3p in the peripheral blood and urinary cells of kidney transplant recipients with post-transplant graft dysfunction.
circulation_biomarker_diagnosis_up	hsa-mir-21	Kideny Transplant Rejection	27521993			T86.11	D006084			our findings indicated that the aberrant urinary miR-21 and miR-200b expression levels were accompanied with renal allograft dysfunction and IFTA.
circulation_biomarker_diagnosis_up	hsa-mir-126	Kidney Diseases [unspecific]	23070235			N18.9	D007674			Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease
circulation_biomarker_diagnosis_up	hsa-mir-204	Kidney Injury	24641951			S37.0	D058186			Our findings indicate that miR-204/miR-211 downregulation accounts at least partially for the Hmx1 upregulation and the miR-204/miR-211-Hmx1 signaling axis may contribute to immune-suppression in the host thereby the Candidemia-induced kidney dysfunction.
circulation_biomarker_diagnosis_up	hsa-mir-211	Kidney Injury	24641951			S37.0	D058186			Our findings indicate that miR-204/miR-211 downregulation accounts at least partially for the Hmx1 upregulation and the miR-204/miR-211-Hmx1 signaling axis may contribute to immune-suppression in the host thereby the Candidemia-induced kidney dysfunction.
circulation_biomarker_diagnosis_up	hsa-mir-125a	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-125a: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia	27619068			C95	D007938	613065	HP:0001909	MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia	18923441			C95	D007938	613065	HP:0001909	the expression of miR-196b was 500-fold higher in MLL-rearranged and 800-fold higher in 5 of 15 T-ALL cases as compared with the expression level in the remaining precursor B-ALL cases (P<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-339	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-339: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_up	hsa-mir-660	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-660: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_up	hsa-mir-663a	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-663: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_up	hsa-mir-126	Leukemia, B-Cell	27300437			C91.31	D015448	151430		miRNA-126 is highly expressed in a subset of human B-ALL
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, B-Cell	16466964			C91.31	D015448	151430		overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, B-Cell	17940623			C91.31	D015448	151430		miR-155 is encoded by nucleotides 241-262 of BIC, which was originally identified as a transcript derived from an integration site for the avian leucosis virus and found to be overexpressed in B-cell lymphomas. The role of miR-155 is not restricted to B cell lymphomas, however. Recent studies have reported that miR-155 is upregulated in breast, lung, colon, and thyroid cancers.
circulation_biomarker_diagnosis_up	hsa-mir-17	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-17	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-18a	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-18a	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-19a	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-19a	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-20a	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-20a	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-125b	Leukemia, Lymphoblastic	22335948	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-126	Leukemia, Lymphoblastic	22335948	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-128a	Leukemia, Lymphoblastic	18056805	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML.
circulation_biomarker_diagnosis_up	hsa-mir-128b	Leukemia, Lymphoblastic	18056805	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML.
circulation_biomarker_diagnosis_up	hsa-mir-181c	Leukemia, Lymphoblastic	27535859	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL.
circulation_biomarker_diagnosis_up	hsa-mir-335	Leukemia, Lymphoblastic	22335948	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-128b	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-15a	Leukemia, Lymphoblastic, Acute	26434860	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The results of our study indicate that resveratrol induces apoptosis in a time and dose-dependent manner in CCRF-CEM cells. Also, increased expression level of miR 16-1 and miR 15a by means of resveratrol in CCRF-CEM
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Leukemia, Lymphoblastic, Acute	26434860	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The results of our study indicate that resveratrol induces apoptosis in a time and dose- dependent manner in CCRF-CEM cells. Also, increased expression level of miR 16-1 and miR 15a by means of resveratrol in CCRF-CEM
circulation_biomarker_diagnosis_up	hsa-mir-17	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-18	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-181b-1	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-19a	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-204	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-20a	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-218	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-29b	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	BCR-ABL1 positive cases, in contrast to negative ones, were characterized by slightly, but still significantly, higher expression levels of miR-29b.
circulation_biomarker_diagnosis_up	hsa-mir-331	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-92-1	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-146b	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-148a	Leukemia, Lymphocytic, Chronic, B-Cell	20504344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-148a:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	upregulation
circulation_biomarker_diagnosis_up	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	high expression
circulation_biomarker_diagnosis_up	hsa-mir-195	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-21	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
circulation_biomarker_diagnosis_up	hsa-mir-21	Leukemia, Lymphocytic, Chronic, B-Cell	20504344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-21:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients
circulation_biomarker_diagnosis_up	hsa-mir-221	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-222	Leukemia, Lymphocytic, Chronic, B-Cell	20504344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-222:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients
circulation_biomarker_diagnosis_up	hsa-mir-23b	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-24-1	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-342	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-342-3p upregulation
circulation_biomarker_diagnosis_up	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	upregulation
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	28407516	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_up	hsa-mir-195	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-21	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_up	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-331	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-92a	Leukemia, Lymphocytic, Chronic, B-Cell	28407516	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
circulation_biomarker_diagnosis_up	hsa-mir-125b-1	Leukemia, Myeloid	20660734	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-125b:Overexpression of the most advantageous miRNA, miR-125b, caused a dose-dependent myeloproliferative disorder that progressed to a lethal myeloid leukemia in mice
circulation_biomarker_diagnosis_up	hsa-mir-125b-2	Leukemia, Myeloid	20660734	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-125b:Overexpression of the most advantageous miRNA, miR-125b, caused a dose-dependent myeloproliferative disorder that progressed to a lethal myeloid leukemia in mice
circulation_biomarker_diagnosis_up	hsa-mir-17	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-17: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-18a	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-18a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19a	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-19a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-19b: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-19b: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-20a	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-20a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-92a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-92a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-10a	Leukemia, Myeloid, Acute	25687041	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The high expression of miR-10a may be closely related to over-proliferation of promyelocyte and drug resistance of acute myeloid leukemia cells, except M3.
circulation_biomarker_diagnosis_up	hsa-mir-10a	Leukemia, Myeloid, Acute	21784052	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation  in intermediate-risk acute myeloid leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-196a-1	Leukemia, Myeloid, Acute	21818844	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes.
circulation_biomarker_diagnosis_up	hsa-mir-196a-2	Leukemia, Myeloid, Acute	21818844	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes.
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia, Myeloid, Acute	21818844	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes.
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia, Myeloid, Acute	26744876	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The expression level of miR-155 was significantly higher in AML patients than in controls.
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia, Myeloid, Acute	28507466	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome.
circulation_biomarker_diagnosis_up	hsa-mir-19b	Leukemia, Myeloid, Acute	29032147	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-210	Leukemia, Myeloid, Acute	26549593	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MiR-210 up-regulation was associated with poor prognosis in AML and it might be useful as a marker for predicting the clinical outcome of AML patients.
circulation_biomarker_diagnosis_up	hsa-mir-221	Leukemia, Myeloid, Acute	23895238	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Overexpression of primary microRNA 221/222 in acute myeloid leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-222	Leukemia, Myeloid, Acute	23895238	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Overexpression of primary microRNA 221/222 in acute myeloid leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-140	Leukemia, Myeloid, Chronic	28197964	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.
circulation_biomarker_diagnosis_up	hsa-mir-18a	Leukemia, Myeloid, Chronic	26458312	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	up-regulated expression of oncogenic miRNAs (miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155)
circulation_biomarker_diagnosis_up	hsa-let-7a-3	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-let-7c	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-let-7d	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-107	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-15a	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-15b	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-223	Leukemia, Promyelocytic, Acute	22053279	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-223	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-342	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia-Lymphoma, Adult T-Cell	22884882			C91.51	D015459		HP:0005517	The high and low plasma levels of miR-155 and miR-126 changed with ATL stage.
circulation_biomarker_diagnosis_up	hsa-mir-125b	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	28415578	disease of cellular proliferation	DOID:7061	C83.5	D015452			High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-142	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-142-3p: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-222	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-222: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-339	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-339: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-100	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_up	hsa-mir-100	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22099053	disease of cellular proliferation	DOID:5599	C83.5	D054218			A significant association was observed between higher expression levels of miR-196b and T-ALL, miR-100 and patients with low white blood cell count at diagnosis and t(12;21) positive ALL.
circulation_biomarker_diagnosis_up	hsa-mir-125b-1	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_up	hsa-mir-125b-2	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22099053	disease of cellular proliferation	DOID:5599	C83.5	D054218			A significant association was observed between higher expression levels of miR-196b and T-ALL, miR-100 and patients with low white blood cell count at diagnosis and t(12;21) positive ALL.
circulation_biomarker_diagnosis_up	hsa-mir-223	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	20418243	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-223:over-expression of miR-223
circulation_biomarker_diagnosis_up	hsa-mir-99a	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_up	hsa-mir-29a	Liver Cirrhosis	21946200	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis.
circulation_biomarker_diagnosis_up	hsa-mir-29b-1	Liver Cirrhosis	21946200	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis.
circulation_biomarker_diagnosis_up	hsa-mir-29b-2	Liver Cirrhosis	21946200	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis.
circulation_biomarker_diagnosis_up	hsa-mir-29c	Liver Cirrhosis	21946200	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis.
circulation_biomarker_diagnosis_up	hsa-mir-212	Liver Diseases [unspecific]	18162065			K76.9	D008107			increased
circulation_biomarker_diagnosis_up	hsa-mir-192	Liver Injury	22045675			S36.11	D056486			Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients.
circulation_biomarker_diagnosis_up	hsa-mir-122	Liver Neoplasms	21154767	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	in serum, miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-223	Liver Neoplasms	21154767	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	in serum, miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-128-2	Lung Neoplasms	18304967	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	increased
circulation_biomarker_diagnosis_up	hsa-mir-132	Lung Neoplasms	17447837	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-155	Lung Neoplasms	21904633	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-155	Lung Neoplasms	26867772	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Two miRNAs, miR-21 and miR-155, were found to be significantly upregulated in recurrent tumors compared  to primary tumors.
circulation_biomarker_diagnosis_up	hsa-mir-17	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-17	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-17	Lung Neoplasms	17442096	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The mir-17 cluster is also overexpressed in human lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-182	Lung Neoplasms	21904633	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-197	Lung Neoplasms	21904633	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-21	Lung Neoplasms	26867772	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Two miRNAs, miR-21 and miR-155, were found to be significantly upregulated in recurrent tumors compared  to primary tumors.
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-125a	Lupus Nephritis	27215082	urinary system disease	DOID:0080162	M32.14	D008181			Elevated Serum Inflammatory Cytokines in Lupus Nephritis Patients, in Association with Promoted hsa-miR-125a.
circulation_biomarker_diagnosis_up	hsa-let-7a-1	Lupus Vulgaris	18998140			A18.4	D008177			let-7a: upregulation
circulation_biomarker_diagnosis_up	hsa-let-7a-2	Lupus Vulgaris	18998140			A18.4	D008177			let-7a: upregulation
circulation_biomarker_diagnosis_up	hsa-let-7a-3	Lupus Vulgaris	18998140			A18.4	D008177			let-7a: upregulation
circulation_biomarker_diagnosis_up	hsa-let-7e	Lupus Vulgaris	18998140			A18.4	D008177			let-7e: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-130b	Lupus Vulgaris	18998140			A18.4	D008177			miR-130b: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-134	Lupus Vulgaris	18998140			A18.4	D008177			miR-134: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-142	Lupus Vulgaris	18998140			A18.4	D008177			miR-142-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-184	Lupus Vulgaris	18998140			A18.4	D008177			miR-184: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-185	Lupus Vulgaris	18998140			A18.4	D008177			miR-185: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-195	Lupus Vulgaris	18998140			A18.4	D008177			miR-195: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-197	Lupus Vulgaris	18998140			A18.4	D008177			miR-197: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-198	Lupus Vulgaris	18998140			A18.4	D008177			miR-198: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-200c	Lupus Vulgaris	18998140			A18.4	D008177			miR-200c: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-208b	Lupus Vulgaris	18998140			A18.4	D008177			miR-208: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-23a	Lupus Vulgaris	18998140			A18.4	D008177			miR-23a: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-30a	Lupus Vulgaris	18998140			A18.4	D008177			miR-30a-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-433	Lupus Vulgaris	18998140			A18.4	D008177			miR-433: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-494	Lupus Vulgaris	18998140			A18.4	D008177			miR-494: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-516a-1	Lupus Vulgaris	18998140			A18.4	D008177			miR-516-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-516a-2	Lupus Vulgaris	18998140			A18.4	D008177			miR-516-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-516b-1	Lupus Vulgaris	18998140			A18.4	D008177			miR-516-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-516b-2	Lupus Vulgaris	18998140			A18.4	D008177			miR-516-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-518c	Lupus Vulgaris	18998140			A18.4	D008177			miR-518c*: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-575	Lupus Vulgaris	18998140			A18.4	D008177			miR-575: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-583	Lupus Vulgaris	18998140			A18.4	D008177			miR-583: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-600	Lupus Vulgaris	18998140			A18.4	D008177			miR-600: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-601	Lupus Vulgaris	18998140			A18.4	D008177			miR-601: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-608	Lupus Vulgaris	18998140			A18.4	D008177			miR-608: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-612	Lupus Vulgaris	18998140			A18.4	D008177			miR-612: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-622	Lupus Vulgaris	18998140			A18.4	D008177			miR-622: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-638	Lupus Vulgaris	18998140			A18.4	D008177			miR-638: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-657	Lupus Vulgaris	18998140			A18.4	D008177			miR-657: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-658	Lupus Vulgaris	18998140			A18.4	D008177			miR-658: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-662	Lupus Vulgaris	18998140			A18.4	D008177			miR-662: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-150	Lymphoma	18348159	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. 
circulation_biomarker_diagnosis_up	hsa-mir-16	Lymphoma	18348159	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. 
circulation_biomarker_diagnosis_up	hsa-mir-17	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-21	Lymphoma	18348159	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. 
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, B-Cell	15738415	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-181a	Lymphoma, B-Cell	27535859	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL.
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Burkitt	14695998	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Burkitt	16195701	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Burkitt	16466964	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Burkitt	16940181	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Increased expression of the precursor of Mir-155has been detected in pediatric Burkitt lymphoma.
circulation_biomarker_diagnosis_up	hsa-let-7a-1	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	let-7a: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-let-7a-2	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	let-7a: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-let-7a-3	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	let-7a: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Hodgkin	16466964	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-155: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-16: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-16: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-17	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-17: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-18a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-19a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-19b: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-19b: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-20a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-21	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-21: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-24-1	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-24: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-24-2	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-24: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-9-1	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-9: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-mir-9-2	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-9: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-92a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-92a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-9-3	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-9: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	17487835	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells.
circulation_biomarker_diagnosis_up	hsa-mir-21	Lymphoma, Large B-Cell, Diffuse	17487835	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells.
circulation_biomarker_diagnosis_up	hsa-mir-221	Lymphoma, Large B-Cell, Diffuse	17487835	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells.
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-155:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-17	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-17:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-18a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-19a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-19b:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-19b:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-20a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-92a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-92a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-21	Lymphoma, Non-Hodgkin	22487708	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-92a	Lymphoma, Non-Hodgkin	25236768	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	MiR-92a was decreased exclusively in HBV-/HCV- B-NHLs, while miR-30b was increased in HBV+ and HCV+ samples, though only the HCV+ achieved full statistical significance.
circulation_biomarker_diagnosis_up	hsa-mir-148a	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-182	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-183	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-193a	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-193b	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-224	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-452	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-96	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-let-7d	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7d:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-1249	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-1249:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-125a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-125a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-1280	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-1280:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-142	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-145	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-145:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-146a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-146a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-146a	Melanoma	27895580	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Increased Levels of miRNA-146a in Serum and Histologic Samples of Patients with Uveal Melanoma.
circulation_biomarker_diagnosis_up	hsa-mir-151a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-151-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-181a-2*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-183	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-183*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-186	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-186:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-18a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-18a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-199a-1	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-199a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-199a-2	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-199a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-22	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-22*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-221	Melanoma	21273047	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Malignant melanoma patients had significantly higher miR-221 levels than healthy controls in serum.
circulation_biomarker_diagnosis_up	hsa-mir-30a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-30a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-30e	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-30e*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-328	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-328:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-342	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-342-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-361	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-361-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-362	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-362-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-365a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-365:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-365b	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-365:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-378a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-378*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-422a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-422a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-501	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-501-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-550a-1	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-550*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-550a-2	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-550*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-584	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-584:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-625	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-625:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-664	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-664:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-99a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-99a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-103a-1	Mesothelioma	22253921	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR-103 was identified as a potential biomarker for malignant mesothelioma
circulation_biomarker_diagnosis_up	hsa-mir-103a-2	Mesothelioma	22253921	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR-103 was identified as a potential biomarker for malignant mesothelioma
circulation_biomarker_diagnosis_up	hsa-mir-625	Mesothelioma	22617246	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Increased circulating miR-625-3p is a potential biomarker for patients with malignant pleural mesothelioma.
circulation_biomarker_diagnosis_up	hsa-mir-132	Mild Cognitive Impairment	25589731			G31.84	D060825	614306		circulating miR-206 and miR-132 as novel miRNAs upregulated in MCI patient were potential biomarkers for diagnosis of MCI.
circulation_biomarker_diagnosis_up	hsa-mir-206	Mild Cognitive Impairment	25589731			G31.84	D060825	614306		circulating miR-206 and miR-132 as novel miRNAs upregulated in MCI patient were potential biomarkers for diagnosis of MCI.
circulation_biomarker_diagnosis_up	hsa-mir-451	Mountain Sickness	25948209			T70.29	D000532	616182		There is a certain level of microRNA-451 in healthy people, the expression of microRNA-451 in CMS patients is significantly higher than that in healthy people. MicroRNA-451 may play an important role in the process of chronic mountain sickness.
circulation_biomarker_diagnosis_up	hsa-mir-130a	Moyamoya Disease	25093848	cardiovascular system disease	DOID:13099	I67.5	D009072	PS252350	HP:0011834	In  an independent MMD cohort, real-time PCR confirmed that miR-106b, miR-130a and miR-126 were significantly upregulated while miR-125a-3p was significantly downregulated in serum.
circulation_biomarker_diagnosis_up	hsa-mir-148a	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.High levels of miR-20a and miR-148a were related to shorter relapse-free survival.
circulation_biomarker_diagnosis_up	hsa-mir-181a-1	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-202	Multiple Myeloma	24048721	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The relative expression of serum miR-202 in MM patients was significantly higher than that in healthy controls, and therefore it may prove to be useful in the auxiliary diagnosis of MM.
circulation_biomarker_diagnosis_up	hsa-mir-20a	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-21	Multiple Myeloma	26909911	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	We found that the expression level of serum mir-21  in the MM group was significantly higher than the MGUS group and the NC group
circulation_biomarker_diagnosis_up	hsa-mir-221	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.High levels of miR-20a and miR-148a were related to shorter relapse-free survival.
circulation_biomarker_diagnosis_up	hsa-mir-4449	Multiple Myeloma	27155004	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The expression levels of serum miR-4449 in MM patients were significantly higher than in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-625	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-99b	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-126	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-146a	Multiple Sclerosis	21875645	nervous system disease	DOID:2377	G35	D009103	PS126200		In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Multiple Sclerosis	21875645	nervous system disease	DOID:2377	G35	D009103	PS126200		In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-155	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-196a	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-21	Multiple Sclerosis	21875645	nervous system disease	DOID:2377	G35	D009103	PS126200		In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls.
circulation_biomarker_diagnosis_up	hsa-mir-21	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-22	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-223	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-326	Multiple Sclerosis	21151203	nervous system disease	DOID:2377	G35	D009103	PS126200		The expression of miRNA-326 in blood cells has been reported to increase during relapses.
circulation_biomarker_diagnosis_up	hsa-mir-326	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-379	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-422a	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-572	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-614	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-648	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-206	Muscular Dystrophy	18827405			G71.0	D009136	310200	HP:0003560	miR-206: miR-206 high expression for muscle regeneration and maturation
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-mir-133a-1	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-mir-133a-2	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-mir-206	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-let-7	Myasthenia Gravis	26943954	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.
circulation_biomarker_diagnosis_up	hsa-mir-21	Myelodysplastic Syndromes	21649547	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-720	Myelodysplastic Syndromes	21649547	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-1	Myocardial Infarction	25225581	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	the expression of plasma miR-1 was significantly increased in the AMI patients compared with the healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-1	Myocardial Infarction	29150941	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	significantly elevated levels of miRNA-1 in post-MI old heart could be predictive of cardiac injury in older mice as the high risk biomarker for MI in older individuals
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Myocardial Infarction	19245789	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1: Upregulated expression in a rat model
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Myocardial Infarction	21642241	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage.
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Myocardial Infarction	22719221	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found.
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Myocardial Infarction	19245789	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1: Upregulated expression in a rat model
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Myocardial Infarction	21642241	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage.
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Myocardial Infarction	22719221	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found.
circulation_biomarker_diagnosis_up	hsa-mir-125b	Myocardial Infarction	27176713	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-125b-5p and miR-30d-5p presented a diagnostic value for early diagnosis of AMI, and miR鈥?0d鈥?p may have a higher diagnostic value than cTnI.
circulation_biomarker_diagnosis_up	hsa-mir-133a-1	Myocardial Infarction	21642241	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage.
circulation_biomarker_diagnosis_up	hsa-mir-133a-1	Myocardial Infarction	21881276	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples.
circulation_biomarker_diagnosis_up	hsa-mir-133a-2	Myocardial Infarction	21642241	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage.
circulation_biomarker_diagnosis_up	hsa-mir-133a-2	Myocardial Infarction	21881276	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples.
circulation_biomarker_diagnosis_up	hsa-mir-133b	Myocardial Infarction	21881276	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples.
circulation_biomarker_diagnosis_up	hsa-mir-133b	Myocardial Infarction	26198874	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The level of miR-133a, miR-133b and miR-499-5p were significantly higher in both STEMI and NSTEMI patients compared to healthy volunteers
circulation_biomarker_diagnosis_up	hsa-mir-206	Myocardial Infarction	19245789	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-206: Upregulated expression in a rat model
circulation_biomarker_diagnosis_up	hsa-mir-208a	Myocardial Infarction	20159880	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Elevated cardiac-specific miR-208a in plasma may be a novel biomarker for early detection of myocardial injury in humans
circulation_biomarker_diagnosis_up	hsa-mir-208a	Myocardial Infarction	24482699	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Serum miR-208a was increased by 36-fold and 51-fold while miR-499 was elevated by 103-fold and 95-fold at 4 h and 24 h after AMI.
circulation_biomarker_diagnosis_up	hsa-mir-208a	Myocardial Infarction	26528525	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRNA-208a was increased in STEMI patients at the time of admission and  nearly undetectable in CAD patients and controls.
circulation_biomarker_diagnosis_up	hsa-mir-208b	Myocardial Infarction	20921333	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRs-208b and -499 were highly elevated in acute myocardial infarction plasma
circulation_biomarker_diagnosis_up	hsa-mir-21	Myocardial Infarction	29197221	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Expression of miRNA-21 was upregulated in the serum of elderly patients with AMI, which inhibited TNF-a induced apoptosis in HCM by activating the JNK/p38/caspase-3 signaling pathway
circulation_biomarker_diagnosis_up	hsa-mir-210	Myocardial Infarction	27346801	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRNA-499 and miRNA-210 expression levels were significantly increased
circulation_biomarker_diagnosis_up	hsa-mir-22	Myocardial Infarction	27484208	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Subsequent validation in an independent patient group confirmed that miR鈥?33b and miR鈥?2鈥?p were significantly up鈥憆egulated in the serum of patients with AMI.
circulation_biomarker_diagnosis_up	hsa-mir-328	Myocardial Infarction	21881276	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-328 levels in plasma and whole blood of AMI patients were markedly increased by 10.9-fold and 16.1-fold, respectively, compared to those in control subjects (p=0.033 and p<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-499	Myocardial Infarction	24482699	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Serum miR-208a was increased by 36-fold and 51-fold while miR-499 was elevated by 103-fold and 95-fold at 4 h and 24 h after AMI.
circulation_biomarker_diagnosis_up	hsa-mir-499	Myocardial Infarction	25922707	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-499 was shown to substantially increase the diagnostic accuracy  of CK-MB and cTnI in the diagnosis of AMI
circulation_biomarker_diagnosis_up	hsa-mir-499	Myocardial Infarction	25966174	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	the expression  of microRNA-499 in serum of patients with AMI was significantly higher than in controls
circulation_biomarker_diagnosis_up	hsa-mir-499	Myocardial Infarction	27346801	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRNA-499 and miRNA-210 expression levels were significantly increased
circulation_biomarker_diagnosis_up	hsa-mir-499a	Myocardial Infarction	20395621	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Plasma microRNA 499 as a biomarker of acute myocardial infarction
circulation_biomarker_diagnosis_up	hsa-mir-499a	Myocardial Infarction	20921333	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRs-208b and -499 were highly elevated in acute myocardial infarction plasma
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Myocardial Infarction	22153007	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In STEMI (ST-segment elevation myocardial infarction) patients, the expression of circulating miR-92a is up-regulated. PCI therapy may suppress such up-regulation. Survival rate is higher in patients showing down-regulation of miR-92a. Our data suggest that miR-92a might have potential for diagnosis and therapeutic application in the prevention and treatment of STEMI.
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Myocardial Infarction	22153007	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In STEMI (ST-segment elevation myocardial infarction) patients, the expression of circulating miR-92a is up-regulated. PCI therapy may suppress such up-regulation. Survival rate is higher in patients showing down-regulation of miR-92a. Our data suggest that miR-92a might have potential for diagnosis and therapeutic application in the prevention and treatment of STEMI.
circulation_biomarker_diagnosis_up	hsa-mir-106a	Neoplasms [unspecific]	20234369			C80.1	D009369			the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls
circulation_biomarker_diagnosis_up	hsa-mir-17	Neoplasms [unspecific]	17060945			C80.1	D009369			overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-17	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-17	Neoplasms [unspecific]	20234369			C80.1	D009369			the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls
circulation_biomarker_diagnosis_up	hsa-mir-184	Neoplasms [unspecific]	26525105			C80.1	D009369			The increase of plasma miR-146a, miR-184 and miR-372 was detectable early in the induction, and it was particularly eminent at the most advanced lesion state.
circulation_biomarker_diagnosis_up	hsa-mir-18a	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-18b	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-191	Neoplasms [unspecific]	17060945			C80.1	D009369			overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19a	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-20a	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-20b	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-21	Neoplasms [unspecific]	25098165			C80.1	D009369			Over-expression of mir-21, especially in cancerous tissue, was effectively predictive of worse prognosis in various carcinomas. Non-invasive circulating mir-21, however, exhibited modest ability to discriminate outcomes.Major concerns about mir-21 assay standardization and selection of specimen need to be fully addressed before its practical implementation in management of cancer.
circulation_biomarker_diagnosis_up	hsa-mir-21	Neoplasms [unspecific]	20234369			C80.1	D009369			the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls
circulation_biomarker_diagnosis_up	hsa-mir-210	Neoplasms [unspecific]	29187235			C80.1	D009369			miR-210 was > sixfold higher in the TCC group compared to the control group
circulation_biomarker_diagnosis_up	hsa-mir-31	Neoplasms [unspecific]	26525105			C80.1	D009369			A progressive increase of miR-21, miR-31 and miR-146a in both saliva  and plasma samples was also noted.
circulation_biomarker_diagnosis_up	hsa-mir-372	Neoplasms [unspecific]	26525105			C80.1	D009369			The increase of plasma miR-146a, miR-184 and miR-372 was detectable early in the induction
circulation_biomarker_diagnosis_up	hsa-mir-21	Neurilemmoma	28224282	disease of cellular proliferation	DOID:3192	D36.10	D009442			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-let-7b	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	let-7b: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-139	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-139-5p: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-146a	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-146a: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-328	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-328: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-342	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-342-3p: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-370	Obesity	26223376	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	circulating miR-27 (P鈥?鈥?.032), miR-378 (P鈥?鈥?.001) and miR-370 (P鈥?鈥?.045) in obese children were significantly higher
circulation_biomarker_diagnosis_up	hsa-mir-378	Obesity	26223376	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	circulating miR-27 (P鈥?鈥?.032), miR-378 (P鈥?鈥?.001) and miR-370 (P鈥?鈥?.045) in obese children were significantly higher
circulation_biomarker_diagnosis_up	hsa-mir-146a	Oral Lichen Planus	25779071			L43.9	D017676		HP:0031453	The expressions of PBMC and plasma miRNA-155 and miRNA-146a are higher in OLP patients. The expressions of plasma miRNA-155 and miRNA-146a are associated with OLP severity. The over expression of miRNA-155 and miRNA-146a in OLP may play a role in the pathogenesis of OLP.
circulation_biomarker_diagnosis_up	hsa-mir-155	Oral Lichen Planus	25779071			L43.9	D017676		HP:0031453	The expressions of PBMC and plasma miRNA-155 and miRNA-146a are higher in OLP patients. The expressions of plasma miRNA-155 and miRNA-146a are associated with OLP severity. The over expression of miRNA-155 and miRNA-146a in OLP may play a role in the pathogenesis of OLP.
circulation_biomarker_diagnosis_up	hsa-mir-184	Oral Neoplasms	25784212			C06.9	D009062		HP:0100649	There was a highly significant increase in salivary miRNA-21 and miRNA-184 in OSCC and PMD
circulation_biomarker_diagnosis_up	hsa-mir-223	Oral Neoplasms	27441818			C06.9	D009062		HP:0100649	circulating miR-223 levels were significantly higher (~2-fold, P< 0.05) in patients with oral cancer (n = 31) than in those without cancer (n = 31).
circulation_biomarker_diagnosis_up	hsa-mir-140	Osteoarthritis	22143896	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	the expression of both miR-140-5p and miR-455-3p was increased in OA cartilage.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Osteoarthritis	28785809	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA
circulation_biomarker_diagnosis_up	hsa-mir-155	Osteoarthritis	28785809	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA
circulation_biomarker_diagnosis_up	hsa-mir-181a	Osteoarthritis	28785809	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA
circulation_biomarker_diagnosis_up	hsa-mir-223	Osteoarthritis	28785809	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA
circulation_biomarker_diagnosis_up	hsa-mir-455	Osteoarthritis	22143896	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	the expression of both miR-140-5p and miR-455-3p was increased in OA cartilage.
circulation_biomarker_diagnosis_up	hsa-mir-191	Osteosarcoma	26406942	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data provide new insights for the involvement of miR-191 in osteosarcoma and suggest that the increased expression of miR-191 may be associated with aggressive tumor progression and adverse outcome. Of note, serum miR-191 quantification may be a promising biomarker for the diagnosis and prognosis in osteosarcoma.
circulation_biomarker_diagnosis_up	hsa-mir-200a	Ovarian Neoplasms	23272653	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer
circulation_biomarker_diagnosis_up	hsa-mir-200b	Ovarian Neoplasms	23272653	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer
circulation_biomarker_diagnosis_up	hsa-mir-200c	Ovarian Neoplasms	23272653	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer
circulation_biomarker_diagnosis_up	hsa-mir-21	Ovarian Neoplasms	29373877	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-21 may be used as a diagnostic biomarker for human ovarian cancer
circulation_biomarker_diagnosis_up	hsa-mir-143	Pancreatic Adenocarcinoma	26807325	disease of cellular proliferation	DOID:4074	C25.3				Three miRNAs (miR-143, miR-223, and  miR-30e) were significantly over-expressed in patients with Stage I cancer when compared with age-matched healthy individuals
circulation_biomarker_diagnosis_up	hsa-mir-196a-1	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				uperegulated
circulation_biomarker_diagnosis_up	hsa-mir-196a-2	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				uperegulated
circulation_biomarker_diagnosis_up	hsa-mir-193b	Pancreatic Endocrine Carcinoma	24778027	disease of cellular proliferation	DOID:1798	C25.4	D018273			Evaluation of microRNAs appears to be promising in the assessment of pNEN. In particular, miR-193b, which is also increased in serum, may be a potential new biomarker of pNEN.
circulation_biomarker_diagnosis_up	hsa-mir-106a	Pancreatic Neoplasms	17442096	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors.
circulation_biomarker_diagnosis_up	hsa-mir-132	Pancreatic Neoplasms	17447837	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-18a	Pancreatic Neoplasms	22045190	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of miR-18a was significantly higher in pancreatic cancer tissues (P=0.012) and pancreatic cancer cell lines (P=0.015) than in normal tissues and fibroblasts. Plasma concentrations of miR-18a were significantly higher in pancreatic cancer patients than in controls (P<0.0001). The value of the area under the receiver-operating characteristic curve (AUC) was 0.9369. Plasma levels of miR-18a were significantly lower in postoperative samples than in preoperative samples (P=0.0077).
circulation_biomarker_diagnosis_up	hsa-mir-191	Pancreatic Neoplasms	29385987	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker
circulation_biomarker_diagnosis_up	hsa-mir-192	Pancreatic Neoplasms	25894267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our data shows that miR-21, miR-192 and miR-200 could be used as new  diagnostic markers for pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-196a	Pancreatic Neoplasms	24956938	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Serum levels of miR-196a and -196b were significantly higher in mice with PanIN2/3 lesions (n = 10) or PC (n = 8) as compared to control mice (n = 10) or mice with PanIN1 lesions (n = 10; P = .01).
circulation_biomarker_diagnosis_up	hsa-mir-200	Pancreatic Neoplasms	25894267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our data shows that miR-21, miR-192 and miR-200 could be used as new  diagnostic markers for pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-205	Pancreatic Neoplasms	25258651	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A marked difference in the profiles of four circulating miRNAs (miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from patients with PDAC and those without  pancreatic disease.
circulation_biomarker_diagnosis_up	hsa-mir-21	Pancreatic Neoplasms	25384963	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-21	Pancreatic Neoplasms	25894267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our data shows that miR-21, miR-192 and miR-200 could be used as new  diagnostic markers for pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-21	Pancreatic Neoplasms	29385987	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker
circulation_biomarker_diagnosis_up	hsa-mir-210	Pancreatic Neoplasms	20360935	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer
circulation_biomarker_diagnosis_up	hsa-mir-210	Pancreatic Neoplasms	25258651	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A marked difference in the profiles of four circulating miRNAs (miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from patients with PDAC and those without  pancreatic disease.
circulation_biomarker_diagnosis_up	hsa-mir-25	Pancreatic Neoplasms	25991015	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A combination of six serum miRNAs (miR-483-5p, miR-19a, miR-29a,  miR-20a, miR-24, miR-25) was selected by qRT-PCR as a biomarker for PaC-DM.
circulation_biomarker_diagnosis_up	hsa-mir-451a	Pancreatic Neoplasms	29385987	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker
circulation_biomarker_diagnosis_up	hsa-mir-483	Pancreatic Neoplasms	25384963	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-195	Parkinson Disease	26631952	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-195 was up-regulated, and miR-185, miR-15b, miR-221 and miR-181a were down-regulated.
circulation_biomarker_diagnosis_up	hsa-mir-122	Polycystic Ovarian Syndrome	26860517	syndrome	DOID:11612	E28.2	D011085	184700		relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients
circulation_biomarker_diagnosis_up	hsa-mir-193b	Polycystic Ovarian Syndrome	26860517	syndrome	DOID:11612	E28.2	D011085	184700		relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients
circulation_biomarker_diagnosis_up	hsa-mir-194	Polycystic Ovarian Syndrome	26860517	syndrome	DOID:11612	E28.2	D011085	184700		relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients
circulation_biomarker_diagnosis_up	hsa-mir-223	Polycystic Ovarian Syndrome	26582398	syndrome	DOID:11612	E28.2	D011085	184700		In conclusion, circulating miRNA-93 and miRNA-223 were higher in women with PCOS compared to age and weight matched controls independent of insulin resistance and testosterone levels, and miR-93 may represent a novel diagnostic biomarker for PCOS.
circulation_biomarker_diagnosis_up	hsa-mir-93	Polycystic Ovarian Syndrome	26582398	syndrome	DOID:11612	E28.2	D011085	184700		In conclusion, circulating miRNA-93 and miRNA-223 were higher in women with PCOS compared to age and weight matched controls independent of insulin resistance and testosterone levels, and miR-93 may represent a novel diagnostic biomarker for PCOS.
circulation_biomarker_diagnosis_up	hsa-mir-143	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-145	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-182	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-21	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-223	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-26b	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-26b	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-451a	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-103a-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-103a-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-103b-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-103b-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-130b	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-181a-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-210	Preeclampsia	22095477	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Serum expression level of miR-210 was up-regulated in preeclampsia patients.
circulation_biomarker_diagnosis_up	hsa-mir-24-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-24-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-26a-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-26a-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-342	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-574	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-885	Preeclampsia	26853698	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-885-5p is increased in plasma from pre-eclampsia compared with healthy pregnant women, and it is released into circulation mainly inside exosomes.
circulation_biomarker_diagnosis_up	hsa-mir-342	Prion Diseases	19712440	nervous system disease	DOID:649	A81.9	D017096			upregulated
circulation_biomarker_diagnosis_up	hsa-mir-494	Prion Diseases	19712440	nervous system disease	DOID:649	A81.9	D017096			upregulated
circulation_biomarker_diagnosis_up	hsa-mir-106a	Prostate Neoplasms	17442096	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors.
circulation_biomarker_diagnosis_up	hsa-mir-132	Prostate Neoplasms	17447837	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-141	Prostate Neoplasms	21274675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the miRNA levels in patient blood were higher than that of the controls
circulation_biomarker_diagnosis_up	hsa-mir-141	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-141	Prostate Neoplasms	23377530	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	serum;An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions
circulation_biomarker_diagnosis_up	hsa-mir-21	Prostate Neoplasms	21274675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the miRNA levels in patient blood were higher than that of the controls
circulation_biomarker_diagnosis_up	hsa-mir-21	Prostate Neoplasms	27434290	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression levels of miR-21 in PCa group were increased compared to  BPH and control group
circulation_biomarker_diagnosis_up	hsa-mir-221	Prostate Neoplasms	21274675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the miRNA levels in patient blood were higher than that of the controls
circulation_biomarker_diagnosis_up	hsa-mir-223	Prostate Neoplasms	22892455	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B.
circulation_biomarker_diagnosis_up	hsa-mir-375	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378a	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378b	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378c	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378d-1	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378d-2	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378e	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378f	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378g	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378h	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378i	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-1266	Psoriasis	22133505	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Increased serum levels of miR-1266 in patients with psoriasis vulgaris.
circulation_biomarker_diagnosis_up	hsa-mir-1266	Psoriasis	27371164	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Psoriasis	17965831	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-146 is also expressed highly in the skin of psoriasis patients.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Psoriasis	27535005	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Psoriasis	17965831	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-146 is also expressed highly in the skin of psoriasis patients.
circulation_biomarker_diagnosis_up	hsa-mir-155	Psoriasis	27535005	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma.
circulation_biomarker_diagnosis_up	hsa-mir-21	Psoriasis	27535005	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma.
circulation_biomarker_diagnosis_up	hsa-mir-223	Psoriasis	27535005	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma.
circulation_biomarker_diagnosis_up	hsa-mir-369	Psoriasis	24135466	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	The expression of miR-369-3p is increased in both serum samples and skin tissues from psoriasis patients, and its level in the skin positively correlates with disease severity. Further studies are needed to clarify the role of miR-369-3p in the pathogenesis of psoriasis.
circulation_biomarker_diagnosis_up	hsa-mir-134	Pulmonary Embolism	21943159	cardiovascular system disease	DOID:9477	I26	D011655			Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.833 (95% confidence interval, 0.737 to 0.929; P<0.001). The findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of APE.
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-1: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-1: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-133b	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-133: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-142	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-142: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-206	Rhabdomyosarcoma	20696132	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-206:miR-206, as landmark biomarkers for RMS
circulation_biomarker_diagnosis_up	hsa-mir-125b	Rheumatoid Arthritis	28738524	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Elevated microRNA-125b promotes inflammation in rheumatoid arthritis by activation of NF-κB pathway.
circulation_biomarker_diagnosis_up	hsa-mir-139	Rheumatoid Arthritis	29191214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The expression levels of  miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents
circulation_biomarker_diagnosis_up	hsa-mir-146a	Rheumatoid Arthritis	24120842	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Elevated expression of specific microRNAs (miRNA) in peripheral blood-derived mononuclear cells (PBMC), particularly miR-146a and miR-155, is associated with rheumatoid arthritis (RA).
circulation_biomarker_diagnosis_up	hsa-mir-155	Rheumatoid Arthritis	24120842	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Elevated expression of specific microRNAs (miRNA) in peripheral blood-derived mononuclear cells (PBMC), particularly miR-146a and miR-155, is associated with rheumatoid arthritis (RA).
circulation_biomarker_diagnosis_up	hsa-mir-204	Rheumatoid Arthritis	29191214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The expression levels of  miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents
circulation_biomarker_diagnosis_up	hsa-mir-214	Rheumatoid Arthritis	29191214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The expression levels of  miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents
circulation_biomarker_diagnosis_up	hsa-mir-223	Rheumatoid Arthritis	26164649	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiR-16, miR-146a/b, miR-150, miR-155, and miR-223 described here were shown to be overexpressed at the systemic level: in both the periphery  and RA joints.
circulation_biomarker_diagnosis_up	hsa-mir-760	Rheumatoid Arthritis	29191214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The expression levels of  miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents
circulation_biomarker_diagnosis_up	hsa-mir-106b	Schizophrenia	27489379	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Schizophrenia patients showed statistically significant upregulation of  five microRNAs: miR9-5p (p=0.002), miR29a-3p (p锛?.001), miR106b-5p (p=0.002), miR125a-3p (p锛?.001), and miR125b-3p (p=0.018).
circulation_biomarker_diagnosis_up	hsa-mir-130b	Schizophrenia	26183697	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The up-regulation of miR-130b and miR-193a-3p is a state-independent biomarker for schizophrenia, and these two miRNAs could be used to develop a diagnostic tool for schizophrenia.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Schizophrenia	26173148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p).
circulation_biomarker_diagnosis_up	hsa-mir-15a	Schizophrenia	19721432	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-15b	Schizophrenia	19721432	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-193a	Schizophrenia	26183697	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The up-regulation of miR-130b and miR-193a-3p is a state-independent biomarker for schizophrenia, and these two miRNAs could be used to develop a diagnostic tool for schizophrenia.
circulation_biomarker_diagnosis_up	hsa-mir-23a	Schizophrenia	26173148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p).
circulation_biomarker_diagnosis_up	hsa-mir-29a	Schizophrenia	27489379	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Schizophrenia patients showed statistically significant upregulation of  five microRNAs: miR9-5p (p=0.002), miR29a-3p (p锛?.001), miR106b-5p (p=0.002), miR125a-3p (p锛?.001), and miR125b-3p (p=0.018).
circulation_biomarker_diagnosis_up	hsa-mir-34	Schizophrenia	26173148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p).
circulation_biomarker_diagnosis_up	hsa-mir-4449	Schizophrenia	26173148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p).
circulation_biomarker_diagnosis_up	hsa-mir-142	Scleroderma, Systemic	21883400	musculoskeletal system disease	DOID:418	M34	D012595	181750		Serum miR-142-3p levels in patients with SSc (systemic sclerosis) were significantly higher than in patients with SSD (scleroderma spectrum disorder), SLE (systemic lupus erythematosus) or DM (dermatomyositis), and healthy control groups. Patients with increased miR-142-3p levels tended to have a short sublingual frenulum.
circulation_biomarker_diagnosis_up	hsa-mir-133a	Sepsis	27434558			A41.9	D018805		HP:0100806	The mRNA expressions of serum miR-155-5p and miR-133a-3p were gradually increased with the aggravation of sepsis.
circulation_biomarker_diagnosis_up	hsa-mir-143	Sepsis	27225861			A41.9	D018805		HP:0100806	Serum miR-143 levels were significantly higher in patients with sepsis
circulation_biomarker_diagnosis_up	hsa-mir-146a	Sepsis	24680405			A41.9	D018805		HP:0100806	The expression levels of miR-146a and miR-223 in plasma in pediatric patients with sepsis was significantly upregulated, and had a positive correlation with IL-10 and IL-10/TNF-α, which may be used as early diagnostic markers and can reflect the severity of condition to a certain degree.
circulation_biomarker_diagnosis_up	hsa-mir-155	Sepsis	27434558			A41.9	D018805		HP:0100806	The mRNA expressions of serum miR-155-5p and miR-133a-3p were gradually increased with the aggravation of sepsis.
circulation_biomarker_diagnosis_up	hsa-mir-223	Sepsis	24680405			A41.9	D018805		HP:0100806	The expression levels of miR-146a and miR-223 in plasma in pediatric patients with sepsis was significantly upregulated, and had a positive correlation with IL-10 and IL-10/TNF-α, which may be used as early diagnostic markers and can reflect the severity of condition to a certain degree.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Sjogren Syndrome	24931100	immune system disease	DOID:12894	M35.00	D012859	270150		Our results demonstrated miR-146a overexpression and miR-155 underexpression in the peripheral mononuclear blood cells of the patients with pSS. Furthermore, the expression levels of these miRNAs correlated with the patients' clinical features. Our data suggest that miR-146a and miR-155 might play important roles in the pathogenesis of pSS and that their expression levels may be useful for diagnosing pSS and for predicting disease activity and therapeutic responses.
circulation_biomarker_diagnosis_up	hsa-mir-181a	Sjogren Syndrome	25128511	immune system disease	DOID:12894	M35.00	D012859	270150		Together, these observations suggested that an elevated miRNA-181a level is a general phenomenon  in Chinese patients with pSS.
circulation_biomarker_diagnosis_up	hsa-mir-100	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-16	Squamous Cell Carcinoma, Esophageal	26221263	disease of cellular proliferation	DOID:3748		C562729			Levels of four of the selected miRNAs were found to be significantly higher in ESCC patients than in controls; namely, miR-16, miR-21, miR-185, and miR-375 (P < 0.050).
circulation_biomarker_diagnosis_up	hsa-mir-193	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-194	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	21673684	disease of cellular proliferation	DOID:3748		C562729			the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164).
circulation_biomarker_diagnosis_up	hsa-mir-223	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-25	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-337	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-483	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-210	Squamous Cell Carcinoma, Head and Neck	20187102	disease of cellular proliferation	DOID:5520	C76.0	C535575			Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis
circulation_biomarker_diagnosis_up	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27067271	disease of cellular proliferation	DOID:2876					Compared with controls, miR-21 levels in tissue and plasma were significantly higher for both PLL and LSCC groups
circulation_biomarker_diagnosis_up	hsa-mir-181a-1	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181b-1	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181b-2	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181c	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181d	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-122	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity: illustrated liver and muscle toxicity
circulation_biomarker_diagnosis_up	hsa-mir-124-1	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity:illustrated injuries in liver, muscle, and brain
circulation_biomarker_diagnosis_up	hsa-mir-124-2	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity:illustrated injuries in liver, muscle, and brain
circulation_biomarker_diagnosis_up	hsa-mir-124-3	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity:illustrated injuries in liver, muscle, and brain
circulation_biomarker_diagnosis_up	hsa-mir-133a-1	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity: illustrated liver and muscle toxicity
circulation_biomarker_diagnosis_up	hsa-mir-133a-2	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity: illustrated liver and muscle toxicity
circulation_biomarker_diagnosis_up	hsa-mir-146b	Stroke	29402769			I64	D020521	601367	HP:0001297	upregulated serum miR-146b in acute ischemic stroke might be a potential biomarker for AIS evaluation
circulation_biomarker_diagnosis_up	hsa-mir-21	Stroke	27288814			I64	D020521	601367	HP:0001297	The stroke with SAI group had significantly higher miRNA-21 expression
circulation_biomarker_diagnosis_up	hsa-mir-144	Stroke, Ischemic	26175178			I63.9			HP:0002140	In conclusion, hyperglycemia may activate platelets through miR-144 and miR-223 to downregulate IRS-1 and upregulate P2Y12 expression in the platelets of T2DM patients through an IRS-1-PI3K-Akt signaling.
circulation_biomarker_diagnosis_up	hsa-mir-223	Stroke, Ischemic	26175178			I63.9			HP:0002140	In conclusion, hyperglycemia may activate platelets through miR-144 and miR-223 to downregulate IRS-1 and upregulate P2Y12 expression in the platelets of T2DM patients through an IRS-1-PI3K-Akt signaling.
circulation_biomarker_diagnosis_up	hsa-let-7e	Synovial Sarcoma	21140508	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-125a	Synovial Sarcoma	21140508	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	miR-125a-3p: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-99b	Synovial Sarcoma	21140508	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-126	Systemic Lupus Erythematosus	22683424	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-126 was specifically enriched only in the blood of the SLE patients
circulation_biomarker_diagnosis_up	hsa-mir-142	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_up	hsa-mir-146a	Systemic Lupus Erythematosus	21529448	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Increased Expression in Peripheral Blood Mononuclear Cells in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_up	hsa-mir-181	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_up	hsa-mir-21	Systemic Lupus Erythematosus	24659142	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Plasma miR-21 in SLE patients from Central China is overexpressed.Since circulating miR-21 is aberrantly expressed in many diseases, the applying of it as a disease biomarker should be considered carefully.
circulation_biomarker_diagnosis_up	hsa-mir-21	Systemic Lupus Erythematosus	27510529	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-21 was  high expressed in SLE patients compared to their first-degree relatives and controls.
circulation_biomarker_diagnosis_up	hsa-mir-224	Systemic Lupus Erythematosus	23199328	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis
circulation_biomarker_diagnosis_up	hsa-mir-516a	Systemic Lupus Erythematosus, With Pericarditis	24687380			M32.12				High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus.
circulation_biomarker_diagnosis_up	hsa-mir-525	Systemic Lupus Erythematosus, With Pericarditis	24687380			M32.12				High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus.
circulation_biomarker_diagnosis_up	hsa-mir-629	Systemic Lupus Erythematosus, With Pericarditis	24687380			M32.12				High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus.
circulation_biomarker_diagnosis_up	hsa-mir-372	Testicular Neoplasms	17189674	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	The relevance to human tumorigenesis was shown when it was found that these miRNAs are hyper-expressed in Testicular Germ Cell Tumors, a tumor type characterized by its prevalence of wild type p53.
circulation_biomarker_diagnosis_up	hsa-mir-373	Testicular Neoplasms	17189674	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	The relevance to human tumorigenesis was shown when it was found that these miRNAs are hyper-expressed in Testicular Germ Cell Tumors, a tumor type characterized by its prevalence of wild type p53.
circulation_biomarker_diagnosis_up	hsa-let-7e	Thyroid Neoplasms	22472564	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Thyroid Neoplasms	16885332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-146a	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Thyroid Neoplasms	17965831	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Thyroid Neoplasms	16885332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-146b	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Thyroid Neoplasms	17965831	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation.
circulation_biomarker_diagnosis_up	hsa-mir-151a	Thyroid Neoplasms	22472564	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage.
circulation_biomarker_diagnosis_up	hsa-mir-151b	Thyroid Neoplasms	22472564	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage.
circulation_biomarker_diagnosis_up	hsa-mir-200a	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Three of these upregulated miRNAs showed significantly higher fold change than the other upregulated miRNAs, these are mir-200a, mir-200b and mir-141.
circulation_biomarker_diagnosis_up	hsa-mir-200b	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Three of these upregulated miRNAs showed significantly higher fold change than the other upregulated miRNAs, these are mir-200a, mir-200b and mir-141.
circulation_biomarker_diagnosis_up	hsa-mir-22	Thyroid Neoplasms	17965831	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation.
circulation_biomarker_diagnosis_up	hsa-mir-221	Thyroid Neoplasms	16885332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	It was shown that miR-221, highly overexpressed in papillary thyroid tumors, is also overexpressed in normal thyroid tissue adjacent to tumors but not in normal thyroid tissues from individuals without clinical thyroid disease.
circulation_biomarker_diagnosis_up	hsa-mir-221	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146.
circulation_biomarker_diagnosis_up	hsa-mir-221	Thyroid Neoplasms	17965831	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation.
circulation_biomarker_diagnosis_up	hsa-mir-222	Thyroid Neoplasms	16885332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-222	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146.
circulation_biomarker_diagnosis_up	hsa-mir-222	Thyroid Neoplasms	22472564	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage.
circulation_biomarker_diagnosis_up	hsa-mir-184	Tongue Neoplasms	19219377	gastrointestinal system disease	DOID:8649	C01	D014062		HP:0100648	miR-184: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-191	Traumatic Brain Injury	26756543			S06.2	D000070642			Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury.
circulation_biomarker_diagnosis_up	hsa-mir-499	Traumatic Brain Injury	26756543			S06.2	D000070642			Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury.
circulation_biomarker_diagnosis_up	hsa-mir-93	Traumatic Brain Injury	26756543			S06.2	D000070642			Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury.
circulation_biomarker_diagnosis_up	hsa-mir-223	Tuberculosis	26316141	disease by infectious agent	DOID:399	A15-A19	D014376			Leukocyte recruitment, measured as the expression of microRNA-223 was increased in pulmonary TB patients compared to LTBI
circulation_biomarker_diagnosis_up	hsa-mir-155	Tuberculosis, Pulmonary	22037148	disease by infectious agent	DOID:2957	A15	D014397			Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis.
circulation_biomarker_diagnosis_up	hsa-mir-183	Urinary Bladder Cancer	21166959	urinary system disease	DOID:11054	C67	D001749	109800		MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology.
circulation_biomarker_diagnosis_up	hsa-mir-96	Urinary Bladder Cancer	21166959	urinary system disease	DOID:11054	C67	D001749	109800		MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology.
circulation_biomarker_diagnosis_up	hsa-mir-21	Vascular Disease [unspecific]	28464406	cardiovascular system disease	DOID:178	I72.9	D000783			miR-21 and miR-92 levels increased, but did not reach the level of significance
circulation_biomarker_diagnosis_up	hsa-mir-92	Vascular Disease [unspecific]	28464406	cardiovascular system disease	DOID:178	I72.9	D000783			miR-21 and miR-92 levels increased, but did not reach the level of significance
circulation_biomarker_diagnosis_up	hsa-mir-223	Viral Infectious Disease	27226534	disease by infectious agent	DOID:934	A94	D001102			vesicular stomatitis virus (VSV) infection induced significant up-regulation of miR-223 in murine macrophages.
circulation_biomarker_diagnosis_up	hsa-mir-208b	Viral Myocarditis	20921333			B33.2	D009205			a milder but significant elevation of miRs-208b and -499 were highly elevated in Viral Myocarditis plasma
circulation_biomarker_diagnosis_up	hsa-mir-499a	Viral Myocarditis	20921333			B33.2	D009205			a milder but significant elevation of miRs-208b and -499 were highly elevated in Viral Myocarditis plasma
circulation_biomarker_diagnosis_up	hsa-mir-9-1	Wounds and Injuries [unspecific]	21538484				D014947			Upregulated in in serum
circulation_biomarker_diagnosis_up	hsa-mir-9-2	Wounds and Injuries [unspecific]	21538484				D014947			Upregulated in in serum
circulation_biomarker_diagnosis_up	hsa-mir-9-3	Wounds and Injuries [unspecific]	21538484				D014947			Upregulated in in serum
circulation_biomarker_prognosis_down	hsa-mir-1	Acute Heart Failure	26580972			I50				admission levels of miR-1 were lower in AHF and stable CHF patients compared to non-AHF patients
circulation_biomarker_prognosis_down	hsa-mir-34a	Adenocarcinoma, Pancreatic Ductal	27458977	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A loss of expression of miR-34a, but not of miR-150, is associated with disease progression and poor prognosis in PDAC patients, and may be involved in the chemoresistance of PDAC cells.
circulation_biomarker_prognosis_down	hsa-mir-126	Arteriosclerosis Obliterans	27497911	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score.
circulation_biomarker_prognosis_down	hsa-mir-21	Atrial Fibrillation	29676832	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF
circulation_biomarker_prognosis_down	hsa-mir-100	Bladder Neoplasms	26662386			C67	D001749	109800	HP:0009725	The present study demonstrated that the downregulation of miR-100 was associated with advanced clinical features and poor prognosis for bladder cancer patients, suggesting that miR-100 downregulation may be used as an unfavorable prognostic biomarker in bladder cancer.
circulation_biomarker_prognosis_down	hsa-mir-195	Breast Neoplasms	20134314	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	circulating levels of miR-195 and let-7a decreased in cancer patients postoperatively
circulation_biomarker_prognosis_down	hsa-mir-19a	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_down	hsa-mir-19b	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_down	hsa-mir-99a	Carcinoma, Breast	27706621			D05	D001943	114480	HP:0003002	Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
circulation_biomarker_prognosis_down	hsa-mir-1300	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Low expression of miR-1300 and miR-939 was significantly correlated with shorter distant metastasis-free survival (DMFS) in Cox univariate analysis (p.adjusted = 0.049).
circulation_biomarker_prognosis_down	hsa-mir-939	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Low expression of miR-1300 and miR-939 was significantly correlated with shorter distant metastasis-free survival (DMFS) in Cox univariate analysis (p.adjusted = 0.049).
circulation_biomarker_prognosis_down	hsa-mir-145	Carcinoma, Gastric	27460730	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-145-5p is down-expressed in GC, and can be used as a marker of poor prognosis in GC patients.
circulation_biomarker_prognosis_down	hsa-mir-1	Carcinoma, Hepatocellular	26554254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Low miR-1 expression is associated with shortened survival time.MiR-1 may act as a potential prognostic biomarker for HCC patients.
circulation_biomarker_prognosis_down	hsa-mir-100	Carcinoma, Hepatocellular	23842624	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma.
circulation_biomarker_prognosis_down	hsa-mir-218	Carcinoma, Hepatocellular	26586116	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Consequently, our findings revealed that serum miR-218 levels were remarkably underexpressed in HCC patients as compared to BLD patients and healthy controls.
circulation_biomarker_prognosis_down	hsa-mir-29c	Carcinoma, Hepatocellular	27525839	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate that miR-29c expression is significantly downregulated in HCC patients and that miR-29c can act as an independent predictor of unfavorable clinical outcome.
circulation_biomarker_prognosis_down	hsa-mir-135a	Carcinoma, Lung, Non-Small-Cell	27525941			C34.90	D002289		HP:0030358	the serum miR-135a level was downregulated in NSCLC patients, and was associated with poor prognosis.
circulation_biomarker_prognosis_down	hsa-mir-30c	Carcinoma, Lung, Non-Small-Cell	27506865			C34.90	D002289		HP:0030358	MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer.
circulation_biomarker_prognosis_down	hsa-mir-153	Carcinoma, Lung, Non-Small-Cell	26339455			C34.90	D002289		HP:0030358	Decreased expression of miR-153 might be a potential unfavorable prognostic factor for patients with NSCLC, and further studies would be needed to prove our findings.
circulation_biomarker_prognosis_down	hsa-mir-204	Carcinoma, Lung, Non-Small-Cell	26497897			C34.90	D002289		HP:0030358	Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
circulation_biomarker_prognosis_down	hsa-mir-200a	Choriocarcinoma	27081702	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Eleven miRNAs were significantly different between R and NR (miR-154, miR-409-3p, miR-127-3p, miR-214*, miR-299-5p and miR-125b overexpressed in NR; miR-33a, miR-30e, miR-338-3p, miR-200a and miR-378 decreased).
circulation_biomarker_prognosis_down	hsa-mir-296	Colon Neoplasms	22892953			D12.6	D003110		HP:0100273	Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
circulation_biomarker_prognosis_down	hsa-mir-16	Colorectal Carcinoma	26934556	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-16 levels were significantly lower in the high blood glucose patients
circulation_biomarker_prognosis_down	hsa-mir-126	Coronary Artery Disease	27497911	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score.
circulation_biomarker_prognosis_down	hsa-mir-146a	Coronary Artery Disease	28050558	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease.
circulation_biomarker_prognosis_down	hsa-mir-148a	Gastric Neoplasms	27529338	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-regulation of miR-26a and miR-148a was significantly associated with shorter OS of GC patients
circulation_biomarker_prognosis_down	hsa-mir-26a	Gastric Neoplasms	27529338	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-regulation of miR-26a and miR-148a was significantly associated with shorter OS of GC patients
circulation_biomarker_prognosis_down	hsa-mir-34a	Gastric Neoplasms	24232982	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Decreased miR-34a expression and increased FOXP1, p53, and BCL2 coexpression to predict a poor OS for MALT lymphoma and DLBCL patients could become very important prognostic markers in daily clinical work. Further investigation of these changes may be of prognostic significance in clinical practice.
circulation_biomarker_prognosis_down	hsa-mir-30c	Human Papilloma Virus Infection	27506865			B97.7	D027383			MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer.
circulation_biomarker_prognosis_down	hsa-mir-150	Hypertension	23220912	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Reduced miR-150 is Associated with Poor Survival in Pulmonary Arterial Hypertension
circulation_biomarker_prognosis_down	hsa-mir-124-1	Leukemia, Myeloid, Acute	24135052	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	These findings suggest that miR-124-1 underexpression is a common event and might have a favorable impact on prognosis in AML.
circulation_biomarker_prognosis_down	hsa-mir-204	Leukemia, Myeloid, Acute	26126974	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We showed low miR-204 expression in AML and found it to be an independent prognostic factor in this patient population.
circulation_biomarker_prognosis_down	hsa-mir-215	Leukemia, Myeloid, Acute	26802165	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our study demonstrates that reduced microRNA-215 expression is a common event and is associated with poor clinical outcome in acute myeloid leukemia.
circulation_biomarker_prognosis_down	hsa-mir-328	Leukemia, Myeloid, Acute	26185105	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
circulation_biomarker_prognosis_down	hsa-let-7i	Leukemia, Myeloid, Chronic	28512058	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression.
circulation_biomarker_prognosis_down	hsa-mir-224	Leukemia, Myeloid, Chronic	28512058	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression.
circulation_biomarker_prognosis_down	hsa-mir-451	Leukemia, Myeloid, Chronic	27825294	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance.
circulation_biomarker_prognosis_down	hsa-let-7a-1	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7a-2	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7a-3	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7b	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7c	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7d	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7e	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7f-1	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7f-2	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7g	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7i	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-mir-129-1	Lymphoma, Large B-Cell, Diffuse	23463124	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)
circulation_biomarker_prognosis_down	hsa-mir-129-2	Lymphoma, Large B-Cell, Diffuse	23463124	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)
circulation_biomarker_prognosis_down	hsa-mir-146b	Lymphoma, Large B-Cell, Diffuse	24931464	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine,and prednisone.
circulation_biomarker_prognosis_down	hsa-mir-320d	Lymphoma, Large B-Cell, Diffuse	24931464	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine,and prednisone.
circulation_biomarker_prognosis_down	hsa-mir-19a	Myeloma	25220540			C90.0	D009101	254500		Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.
circulation_biomarker_prognosis_down	hsa-mir-126	Myocardial Infarction	27497911	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score.
circulation_biomarker_prognosis_down	hsa-mir-150	Myocardial Infarction	23967079	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	We enrolled 150 patients after AMI. Blood samples were obtained at discharge for determination of N-terminal pro-brain natriuretic peptide (Nt-proBNP) and levels of miR-16, miR-27a, miR-101 and miR-150.
circulation_biomarker_prognosis_down	hsa-mir-218	Neoplasms [unspecific]	27631228			C80.1	D009369			Prognostic significance of low microRNA-218 expression in patients with different types of cancer: Evidence from published studies.
circulation_biomarker_prognosis_down	hsa-mir-199a	Ovarian Neoplasms	26951510	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of miR-199a was found to be significantly downregulated in comparison with matched normal controls.
circulation_biomarker_prognosis_down	hsa-mir-17	Preeclampsia	26339600	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	ur data indicate that short-term exposure of 3A villous first trimester trophoblasts to H2O2 significantly alters miRNA profile and mRNA expression of genes implicated in defective placental development. Our data, which indicate that oxidative stress alters miRNAs and RNAs expression, could partially explain some of the early changes in gene expression profiles and miRNA observed in PE.
circulation_biomarker_prognosis_down	hsa-mir-128	Prostate Neoplasms	26339409	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that the decreased expression of miR-128 in both tissue and serum samples of PCa patients may be associated with tumor malignant progression and BCR-free survival. Particularly, serum miR-128 may be developed as a novel noninvasive biomarker for PCa diagnosis and prognosis.
circulation_biomarker_prognosis_down	hsa-let-7g	Squamous Cell Carcinoma, Head and Neck	25677760	disease of cellular proliferation	DOID:5520	C76.0	C535575			decreased expressions of miR-153, miR-200c, miR-363, miR-203, miR-17, miR-205, miR-Let-7d, Let-7g, miR-34a, miR-126a, miR-375, miR-491-p5, miR 218, miR-451 and miR-125b were associated with poor prognosis.
circulation_biomarker_prognosis_down	hsa-mir-100	Urinary Bladder Cancer	23173870	urinary system disease	DOID:11054	C67	D001749	109800		Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer
circulation_biomarker_prognosis_down	hsa-mir-9-1	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-9*: decreased expression
circulation_biomarker_prognosis_down	hsa-mir-9-2	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-9*: decreased expression
circulation_biomarker_prognosis_down	hsa-mir-9-3	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-9*: decreased expression
circulation_biomarker_prognosis_ns	hsa-mir-29a	Acquired Immunodeficiency Syndrome	27232693	disease by infectious agent	DOID:635	B20	D000163	609423		the expression level of miR-29a was found to be inversely correlated with HIV viral load
circulation_biomarker_prognosis_ns	hsa-mir-145	Adenocarcinoma, Lung	25192889	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miRNA-145 is strongly associated with overall survival
circulation_biomarker_prognosis_ns	hsa-mir-210	Adenocarcinoma, Lung	25733977	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Significant correlations were found between miR-210 expression and lymph node metastasis, late disease stages, and poor prognosis in patients with adenocarcinoma.
circulation_biomarker_prognosis_ns	hsa-mir-31	Adenocarcinoma, Pancreatic Ductal	24289824	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		In a cohort of 70 patients, the high expression of miR-21 (p=0.018, HR=2.610; 95% CI=1.179-5.777) and miR-31 (p=0.039, HR=2.735; 95% CI=1.317-6.426), the low expression of miR-375 (p=0.022, HR=2.337; 95% CI=1.431-5.066) were associated with poor overall survival following resection, independent of clinical covariates.
circulation_biomarker_prognosis_ns	hsa-mir-1	Atrial Fibrillation	28422282	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery.
circulation_biomarker_prognosis_ns	hsa-mir-23a	Atrial Fibrillation	28422282	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery.
circulation_biomarker_prognosis_ns	hsa-mir-26a	Atrial Fibrillation	28422282	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery.
circulation_biomarker_prognosis_ns	hsa-mir-122	Autoimmune Hepatitis	26575387	immune system disease	DOID:2048	K75.4	D019693			Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH.
circulation_biomarker_prognosis_ns	hsa-mir-21	Autoimmune Hepatitis	26575387	immune system disease	DOID:2048	K75.4	D019693			Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH.
circulation_biomarker_prognosis_ns	hsa-let-7c	Breast Neoplasms	24866763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
circulation_biomarker_prognosis_ns	hsa-mir-106b	Breast Neoplasms	25619461	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-106b was found to be associated with a high risk of recurrence of breast cancer, and miR-106b is a putative plasma marker for risk assessment in patients with breast cancer.
circulation_biomarker_prognosis_ns	hsa-mir-10b	Breast Neoplasms	25369070	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Moreover, miR-10b, miR-21 and miR-182 were significantly associated to lymph node metastases occurrence in triple negative breast carcinoma while only miR-10b was associated with grade III in non triple negative breast cancer cases.
circulation_biomarker_prognosis_ns	hsa-mir-139	Breast Neoplasms	24866763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
circulation_biomarker_prognosis_ns	hsa-mir-141	Breast Neoplasms	25885099	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miR-200c and miR-141 were deregulated in BC comparing with controls. Furthermore, miR-200c and miR-141 were independent prognostic factors and associated with distinct outcomes of BC patients.
circulation_biomarker_prognosis_ns	hsa-mir-182	Breast Neoplasms	25369070	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Moreover, miR-10b, miR-21 and miR-182 were significantly associated to lymph node metastases occurrence in triple negative breast carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-19a	Breast Neoplasms	25137071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Breast Neoplasms	25885099	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miR-200c and miR-141 were deregulated in BC comparing with controls. Furthermore, miR-200c and miR-141 were independent prognostic factors and associated with distinct outcomes of BC patients.
circulation_biomarker_prognosis_ns	hsa-mir-202	Breast Neoplasms	24983365	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Based on their cancer-specific increase in breast cancer patients,circulating MAGE-A and BORIS mRNAs may be further explored for early detection of breast cancer and monitoring of MAGE-directed immunotherapies. Moreover, serum miR-202 is associated with prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-205	Breast Neoplasms	25137071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-208a	Breast Neoplasms	26046768	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
circulation_biomarker_prognosis_ns	hsa-mir-21	Breast Neoplasms	25086636	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy
circulation_biomarker_prognosis_ns	hsa-mir-210	Breast Neoplasms	25086636	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy
circulation_biomarker_prognosis_ns	hsa-mir-320d	Breast Neoplasms	24866763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
circulation_biomarker_prognosis_ns	hsa-mir-373	Breast Neoplasms	25086636	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy
circulation_biomarker_prognosis_ns	hsa-mir-4728	Breast Neoplasms	26406406	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-4728-3p had better ability in distinguishing patients with different status of HER2 than miR-4728-5p. And plasma miR-4728-3p might act as a non-invasive biomarker in predicting HER2 status.
circulation_biomarker_prognosis_ns	hsa-mir-516a	Breast Neoplasms	27528030	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Finally, we show that a combination of 2 miRNAs (miR-190b and miR-516a-5p) exhibiting altered expression in TamR cell lines were predictive of  treatment outcome in a cohort of ER+ breast cancer patients receiving adjuvant tamoxifen mono-therapy.
circulation_biomarker_prognosis_ns	hsa-mir-567	Breast Neoplasms	24866763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
circulation_biomarker_prognosis_ns	hsa-let-7i	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-103a	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-140	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-21	Carcinoma, Breast	27696295			D05	D001943	114480	HP:0003002	Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.
circulation_biomarker_prognosis_ns	hsa-mir-21	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-25	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-30a	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-30c	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-320a	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-34a	Carcinoma, Breast	27561942			D05	D001943	114480	HP:0003002	Human serum miR-34a as an indicator of exposure to ionizing radiation.
circulation_biomarker_prognosis_ns	hsa-mir-361	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-374b	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-651	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-1296	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS
circulation_biomarker_prognosis_ns	hsa-mir-135b	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS.
circulation_biomarker_prognosis_ns	hsa-mir-185	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS.
circulation_biomarker_prognosis_ns	hsa-mir-539	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS.
circulation_biomarker_prognosis_ns	hsa-mir-572	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS.
circulation_biomarker_prognosis_ns	hsa-mir-592	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of miR-592 was significantly associated with the MMR status (p.adjusted <0.01).
circulation_biomarker_prognosis_ns	hsa-mir-6826	Carcinoma, Colon	27878288	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.
circulation_biomarker_prognosis_ns	hsa-mir-6875	Carcinoma, Colon	27878288	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Carcinoma, Esophageal	23838916	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The serum level of miR-200c can be useful for predicting the response to chemotherapy and the prognosis of patients with esophageal cancer who receive neoadjuvant chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	27074850	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HCC and/or histological components of NASH affected serum miR-122 levels, independently.
circulation_biomarker_prognosis_ns	hsa-mir-125b	Carcinoma, Hepatocellular	28814883	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-125b	Carcinoma, Hepatocellular	27267832	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	serum miR-125b can serve as a biomarker to reliably predict microvascular invasion
circulation_biomarker_prognosis_ns	hsa-mir-128-2	Carcinoma, Hepatocellular	25642945	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma.
circulation_biomarker_prognosis_ns	hsa-mir-148a	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-16	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-192	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-210	Carcinoma, Hepatocellular	24935355	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-210 may represent a novel biomarker for predicting efficacy of transarterial chemoembolization and overall survival for patients with HCC.
circulation_biomarker_prognosis_ns	hsa-mir-221	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-224	Carcinoma, Hepatocellular	25688365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-224 might be BCLC stage dependent. It can reflect the status of tumor and liver damage. It was an independent predictor for the survival of HCC patients.
circulation_biomarker_prognosis_ns	hsa-mir-224	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-34a	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-718	Carcinoma, Hepatocellular	25584485	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating miRs in serum exosomes have potential as novel biomarkers for predicting HCC recurrence.
circulation_biomarker_prognosis_ns	hsa-mir-16-1	Carcinoma, Lung, Non-Small-Cell	23774211			C34.90	D002289		HP:0030358	MiR-16 exhibited the most statistically significant association: high expression of miR-16 was associated with a significantly better survival
circulation_biomarker_prognosis_ns	hsa-mir-29a	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Ten miRNA's were significantly associated with OS, with hsa-miR-29a being the strongest prognostic marker (HR=6.44, 95%-CI 2.39-17.33).
circulation_biomarker_prognosis_ns	hsa-mir-33a	Carcinoma, Lung, Non-Small-Cell	28141816			C34.90	D002289		HP:0030358	Association of microRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis after Chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-376a	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-424	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-500a	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-502	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-542	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-125b-1	Carcinoma, Lung, Non-Small-Cell	22806310			C34.90	D002289		HP:0030358	Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-125b-2	Carcinoma, Lung, Non-Small-Cell	22806310			C34.90	D002289		HP:0030358	Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-146a	Carcinoma, Lung, Non-Small-Cell	24531034			C34.90	D002289		HP:0030358	Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-19b	Carcinoma, Lung, Non-Small-Cell	24531034			C34.90	D002289		HP:0030358	Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-22	Carcinoma, Lung, Non-Small-Cell	23794259			C34.90	D002289		HP:0030358	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-24	Carcinoma, Lung, Non-Small-Cell	23794259			C34.90	D002289		HP:0030358	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	23794259			C34.90	D002289		HP:0030358	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-103	Carcinoma, Nasopharyngeal	24563490	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients.
circulation_biomarker_prognosis_ns	hsa-mir-29a	Carcinoma, Nasopharyngeal	24563490	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients.
circulation_biomarker_prognosis_ns	hsa-mir-483	Carcinoma, Nasopharyngeal	24563490	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients.
circulation_biomarker_prognosis_ns	hsa-mir-1274a	Carcinoma, Ovarian	28293063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
circulation_biomarker_prognosis_ns	hsa-mir-141	Carcinoma, Ovarian	28293063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
circulation_biomarker_prognosis_ns	hsa-mir-200b	Carcinoma, Ovarian	28293063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Carcinoma, Ovarian	28293063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
circulation_biomarker_prognosis_ns	hsa-mir-192	Carcinoma, Periampullary	28351309	disease of cellular proliferation	DOID:8110					Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma.
circulation_biomarker_prognosis_ns	hsa-mir-484	Carcinoma, Thyroid, Follicular	27473101	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	The best two-miRNA classifier (miR-484/miR-148b-3p) identified thyroid malignancy with a sensitivity of 89鈥? and a specificity of 87鈥?.
circulation_biomarker_prognosis_ns	hsa-mir-192	Carcinoma, Urothelial	28928837	disease of cellular proliferation	DOID:4006				HP:0030409	hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-518b	Carcinoma, Urothelial	28928837	disease of cellular proliferation	DOID:4006				HP:0030409	hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-7705	Carcinoma, Urothelial	28928837	disease of cellular proliferation	DOID:4006				HP:0030409	hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-126	Cardiovascular Diseases [unspecific]	23391580				D002318			Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra.
circulation_biomarker_prognosis_ns	hsa-mir-21	Central Nervous System Embryonal Tumor	23832112			C72.9	D009373			Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma.
circulation_biomarker_prognosis_ns	hsa-let-7	Chronic Hepatitis C	27227815			B18.2	D019698	609532		reduced levels of let-7a/7c/7d-5p (let-7s) in plasma were correlated with advanced histological hepatic fibrosis stage
circulation_biomarker_prognosis_ns	hsa-mir-122	Chronic Hepatitis C	28401565			B18.2	D019698	609532		Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
circulation_biomarker_prognosis_ns	hsa-mir-199a	Chronic Hepatitis C	28401565			B18.2	D019698	609532		Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
circulation_biomarker_prognosis_ns	hsa-let-7i	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-106a	Colorectal Carcinoma	26250939	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC.
circulation_biomarker_prognosis_ns	hsa-mir-10b	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-130	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-143	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-145	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-145	Colorectal Carcinoma	26250939	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC.
circulation_biomarker_prognosis_ns	hsa-mir-155	Colorectal Carcinoma	25528214	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the detection of miR-155 levels in the serum might serve as a new tumor biomarker in the diagnosis and assessment of prognosis of CRC.
circulation_biomarker_prognosis_ns	hsa-mir-17	Colorectal Carcinoma	26250939	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC.
circulation_biomarker_prognosis_ns	hsa-mir-19a	Colorectal Carcinoma	24460313	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Colorectal Carcinoma	23982750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
circulation_biomarker_prognosis_ns	hsa-mir-20a	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-21	Colorectal Carcinoma	23970420	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggest that circulating serum miR-21 is a promising prognostic tumour marker, and they highlight the potential clinical utility of miR-21 expression as a prognostic marker for CRC prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-216	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-221	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-320a	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-324	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-345	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-34a	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-372	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-628	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-885	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-886	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-197	Coronary Artery Disease	26720041	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Serum-derived circulating miRNA-197 and miRNA-223 were identified as predictors for cardiovascular death in a large patient cohort with CAD. These results reinforce the assumption that circulating miRNAs are promising biomarkers with prognostic value with respect to future cardiovascular events.
circulation_biomarker_prognosis_ns	hsa-mir-223	Coronary Artery Disease	26720041	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Serum-derived circulating miRNA-197 and miRNA-223 were identified as predictors for cardiovascular death in a large patient cohort with CAD. These results reinforce the assumption that circulating miRNAs are promising biomarkers with prognostic value with respect to future cardiovascular events.
circulation_biomarker_prognosis_ns	hsa-let-7a	Diabetes Mellitus	24937531	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Treatment-naïve, poorly controlled diabetic patients show a significant dysregulation of miRNAs involved in the regulation of the adiponectin pathway, a phenomenon that may be reversed, at least in part, by improved glycemic control.
circulation_biomarker_prognosis_ns	hsa-mir-106b	Ependymoma	27390862	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	Three miRNAs were shown to efficiently differentiate between grade II and III ependymomas: miR-17-5p, miR-19a-3p, and miR-106b-5p.
circulation_biomarker_prognosis_ns	hsa-mir-21	Esophageal Neoplasms	22519435			C15.9	D004938	133239	HP:0100751	Circulating miR-21 and miR-375 could be reliable prognostic markers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-375	Esophageal Neoplasms	22519435			C15.9	D004938	133239	HP:0100751	Circulating miR-21 and miR-375 could be reliable prognostic markers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-34a	Fatty Liver, Non-Alcoholic	28853202	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Potentially pro-apoptotic miR-34a was reduced in the vesicle-free fraction in serum but not in liver after UDCA treatment
circulation_biomarker_prognosis_ns	hsa-mir-100	Gastric Neoplasms	23975664	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
circulation_biomarker_prognosis_ns	hsa-mir-17	Gastric Neoplasms	22406928	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The concentrations of plasma miR-17-5p/20a were significantly associated with the differentiation status and TNM stages of gastric cancer. Kaplan-Meier curve analysis revealed that high expression levels of miR-17-5p/20a were significantly correlated with poor overall survival. Cox regression analysis demonstrated that the level of plasma miR-20a was an independent risk predictor for prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-196a	Gastric Neoplasms	27420607	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, we propose that circulating miR-196a/b  serve as a more sensitive and specific novel biomarker than carbohydrate antigen  19-9 for GC monitor, diagnosis and prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-196b	Gastric Neoplasms	27420607	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, we propose that circulating miR-196a/b  serve as a more sensitive and specific novel biomarker than carbohydrate antigen  19-9 for GC monitor, diagnosis and prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Gastric Neoplasms	26662382	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Serum miR-200c expression level as a prognostic biomarker for gastric cancer.
circulation_biomarker_prognosis_ns	hsa-mir-20a	Gastric Neoplasms	22406928	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The concentrations of plasma miR-17-5p/20a were significantly associated with the differentiation status and TNM stages of gastric cancer. Kaplan-Meier curve analysis revealed that high expression levels of miR-17-5p/20a were significantly correlated with poor overall survival. Cox regression analysis demonstrated that the level of plasma miR-20a was an independent risk predictor for prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-21	Gastric Neoplasms	24460332	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma post-operative miR-21 expression in the prognosis of gastric cancers.
circulation_biomarker_prognosis_ns	hsa-mir-21	Gastric Neoplasms	26063956	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer.
circulation_biomarker_prognosis_ns	hsa-mir-218	Gastric Neoplasms	24944481	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-218 is deregulated in gastric cancer patients and is strongly correlated with tumor stage, grade and metastasis. Serum expression of miR-218 may be a prognostic marker.
circulation_biomarker_prognosis_ns	hsa-mir-106a	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-145	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-182	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-20a	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-222	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-15a	Glioma	25575767	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	the expression of miR-15a is significantly correlated with prognosis in glioma patients, suggesting that the miR-15a may serve as independent prognostic marker.
circulation_biomarker_prognosis_ns	hsa-mir-21	Glioma	25279461	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Moreover, in the GBM dataset miR-21 and miR-210 were predictors  of worse prognosis in both univariable and multivariable Cox regression analyses
circulation_biomarker_prognosis_ns	hsa-mir-454	Glioma	25190548	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Plasma miR-454-3p as a potential prognostic indicator in human glioma.
circulation_biomarker_prognosis_ns	hsa-mir-224	Graves Ophthalmopathy	25588771			E05.00	D049970			baseline serum miR-224-5p was associated with GC sensitivity in GO and in vitro overexpression of miR-224-5p restored GC sensitivity in a resistant cell model. A parameter combined serum miR-224-5p and TRAb could effectively predict GC ensitivity in GO patients.
circulation_biomarker_prognosis_ns	hsa-mir-30d	Heart Failure	28214846			I50	D006331		HP:0001635	Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure.
circulation_biomarker_prognosis_ns	hsa-mir-101	Heart Transplant Rejection	28125729			T86.31				Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation.
circulation_biomarker_prognosis_ns	hsa-mir-142	Heart Transplant Rejection	28125729			T86.31				Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation.
circulation_biomarker_prognosis_ns	hsa-mir-122	Hepatitis C Virus Infection	25811198	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The expression levels of miR-21 and miR-122 were significantly different between the SVR and NR groups.
circulation_biomarker_prognosis_ns	hsa-mir-29a	Human Immunodeficiency Virus Infection	27232693			B20	D015658	609423		the expression level of miR-29a was found to be inversely correlated with HIV viral load
circulation_biomarker_prognosis_ns	hsa-mir-155	Idiopathic Pulmonary Fibrosis	23822889	respiratory system disease	DOID:0050156	J84.112	D054990	178500		These findings suggest that serum miR-21 is associated with IPF and the degree of damage indicated by FVC and radiologic examinations could correlate with miR-21 and miR-155 expression in serum. From another perspective, our study confirmed serum miRNA can be stable and detectable in serum of patients with IPF,which could prove useful as it could be considered as a new biomarker in serum for diagnosis and assessment of prognosis of IPF in the future.
circulation_biomarker_prognosis_ns	hsa-mir-21	Idiopathic Pulmonary Fibrosis	23822889	respiratory system disease	DOID:0050156	J84.112	D054990	178500		These findings suggest that serum miR-21 is associated with IPF and the degree of damage indicated by FVC and radiologic examinations could correlate with miR-21 and miR-155 expression in serum. From another perspective, our study confirmed serum miRNA can be stable and detectable in serum of patients with IPF,which could prove useful as it could be considered as a new biomarker in serum for diagnosis and assessment of prognosis of IPF in the future.
circulation_biomarker_prognosis_ns	hsa-mir-126	Intermittent Claudication	26116711	cardiovascular system disease	DOID:3669	I73.9	D007383		HP:0004417	Whole blood expression of pro-angiogenic microRNA-126 increased after maximal exercise in the PLA session, but treatment with NAC prevented this response.
circulation_biomarker_prognosis_ns	hsa-mir-223	Intestinal Schistosomiasis	24330517	disease by infectious agent	DOID:0050597	B65.1	D012554	181460		This study suggested that the circulating miR-223 could serve as a potential new biomarker for the detection of schistosome infection and the assessment of the response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-15a	Ischemia	23233752	cardiovascular system disease	DOID:326		D007511	601367		MicroRNA-15a and MicroRNA-16 Impair Human Circulating Proangiogenic Cell Functions and Are Increased in the Proangiogenic Cells and Serum of Patients With Critical Limb Ischemia
circulation_biomarker_prognosis_ns	hsa-mir-155	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_prognosis_ns	hsa-mir-16	Leukemia	19195700			C95	D007938	613065	HP:0001909	Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation.
circulation_biomarker_prognosis_ns	hsa-mir-181a	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_prognosis_ns	hsa-mir-92a-1	Leukemia	21182798			C95	D007938	613065	HP:0001909	The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients
circulation_biomarker_prognosis_ns	hsa-mir-92a-2	Leukemia	21182798			C95	D007938	613065	HP:0001909	The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients
circulation_biomarker_prognosis_ns	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	25584781	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Cellular and serum levels of miR-150 are associated with opposite clinical prognoses and could be used to molecularly monitor disease evolution as a new prognostic factor in CLL.
circulation_biomarker_prognosis_ns	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	20487546	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181a:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment
circulation_biomarker_prognosis_ns	hsa-mir-221	Leukemia, Lymphocytic, Chronic, B-Cell	20487546	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-221:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment
circulation_biomarker_prognosis_ns	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	20487546	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-29a:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment
circulation_biomarker_prognosis_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	28599250	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
circulation_biomarker_prognosis_ns	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	28599250	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
circulation_biomarker_prognosis_ns	hsa-mir-10	Leukemia, Myeloid, Acute	26134365	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia.
circulation_biomarker_prognosis_ns	hsa-mir-181a	Leukemia, Myeloid, Acute	29166738	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Expression characteristics and prognosis significance of miRNA-181a in acute myeloid leukemia with normal karyotype
circulation_biomarker_prognosis_ns	hsa-mir-146a	Leukemia, Promyelocytic, Acute	25161335	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	These findings indicated that miR-146a played an important role in the development of APL in part through the repression on Smad4 protein expression. miR-146a functioned as an oncogene and may be a novel prognostic biomarker in APL.
circulation_biomarker_prognosis_ns	hsa-mir-16-1	Leukemia-Lymphoma, Adult T-Cell	23260326			C91.51	D015459		HP:0005517	Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia
circulation_biomarker_prognosis_ns	hsa-mir-16-2	Leukemia-Lymphoma, Adult T-Cell	23260326			C91.51	D015459		HP:0005517	Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia
circulation_biomarker_prognosis_ns	hsa-let-7	Lung Neoplasms	27133539	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Patients with a high level of baseline serum let-7 expression level had significantly better overall survival
circulation_biomarker_prognosis_ns	hsa-let-7a-1	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7a-2	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7a-3	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7b	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7c	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7d	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7e	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7f-1	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7f-2	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7g	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7i	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-mir-197	Lung Neoplasms	26078336	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Especially hsa-miR-197 could be validated by qRT-PCR as prognostic marker.
circulation_biomarker_prognosis_ns	hsa-mir-16	Lymphoma	24447552	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Significance of microRNA-16 and bcl-2 expression in T lymphoblastic lymphoma/leukemia and its relation with prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-221	Lymphoma	25430553	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	serum miR-221 expression level has prognostic value in patients with CMM.
circulation_biomarker_prognosis_ns	hsa-mir-224	Lymphoma	26301883	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-224 expression level is implicated as a prognostic marker for DLBCL patients treated with R-CHOP.
circulation_biomarker_prognosis_ns	hsa-mir-150	Lymphoma, B-Cell	22936066	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-155 and miR-150 expression levels were associated with progression-free survival .
circulation_biomarker_prognosis_ns	hsa-mir-155	Lymphoma, B-Cell	22936066	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-155 and miR-150 expression levels were associated with progression-free survival .
circulation_biomarker_prognosis_ns	hsa-mir-122	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-144	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-212	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-23b	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-510	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-1236	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-214	Lymphoma, Large B-Cell, Diffuse	25723320	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
circulation_biomarker_prognosis_ns	hsa-mir-223	Lymphoma, Large B-Cell, Diffuse	22932402	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		As a potential prognostic biomarker, overexpression of miR-223 correlates with a longer OS of patients with DLBCL (diffuse large B cell lymphoma).
circulation_biomarker_prognosis_ns	hsa-mir-224	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-224	Lymphoma, Large B-Cell, Diffuse	25052605	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-224 expression may play an important role in the development and progression of DLBCL and could be prognostic significance.
circulation_biomarker_prognosis_ns	hsa-mir-28	Lymphoma, Large B-Cell, Diffuse	25723320	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
circulation_biomarker_prognosis_ns	hsa-mir-339	Lymphoma, Large B-Cell, Diffuse	25723320	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
circulation_biomarker_prognosis_ns	hsa-mir-33a	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-455	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-520d	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-5586	Lymphoma, Large B-Cell, Diffuse	25723320	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
circulation_biomarker_prognosis_ns	hsa-mir-200c	Malignant Neoplasms [unspecific]	26556949			C80.1	D009369			Our findings indicated that, compared to their tissue counterparts, the expression level of miR-200c and miR-141 in peripheral blood may be more effective for monitoring cancer prognosis. High miR-141 expression was better at predicting tumor progression than survival for malignant tumors.
circulation_biomarker_prognosis_ns	hsa-mir-210	Melanoma	25749524	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
circulation_biomarker_prognosis_ns	hsa-let-7b	Multiple Myeloma	28213378	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Prognostic role of circulating exosomal miRNAs in multiple myeloma.
circulation_biomarker_prognosis_ns	hsa-mir-18a	Multiple Myeloma	28213378	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Prognostic role of circulating exosomal miRNAs in multiple myeloma.
circulation_biomarker_prognosis_ns	hsa-mir-15b	Multiple Sclerosis	27725128	nervous system disease	DOID:2377	G35	D009103	PS126200		Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
circulation_biomarker_prognosis_ns	hsa-mir-223	Multiple Sclerosis	27725128	nervous system disease	DOID:2377	G35	D009103	PS126200		Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
circulation_biomarker_prognosis_ns	hsa-mir-23a	Multiple Sclerosis	27725128	nervous system disease	DOID:2377	G35	D009103	PS126200		Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
circulation_biomarker_prognosis_ns	hsa-let-7a-1	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7a-2	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7a-3	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7b	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7c	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7d	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7e	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7f-1	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7f-2	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7g	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7i	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181a-1	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181a-2	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181b-2	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181c	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181d	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-133a-1	Myocardial Infarction	23137501	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction
circulation_biomarker_prognosis_ns	hsa-mir-133a-2	Myocardial Infarction	23137501	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction
circulation_biomarker_prognosis_ns	hsa-mir-499	Myocardial Infarction	24461971	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction.
circulation_biomarker_prognosis_ns	hsa-mir-149	Neoplasms [unspecific]	24180461			C80.1	D009369			The regression analysis identified tumour stage and miR-31 and miR-149 expression as independently associated with tumour progression and tumour stage and miR-149 expression as independently associated with cancer-specific survival.
circulation_biomarker_prognosis_ns	hsa-mir-200	Neoplasms [unspecific]	28321402			C80.1	D009369			Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis.
circulation_biomarker_prognosis_ns	hsa-mir-21	Neoplasms [unspecific]	24076132			C80.1	D009369			Our findings suggest that circulating miR-21 may not suitable to be a diagnostic biomarker, but it has a prognostic value in patients with cancer.
circulation_biomarker_prognosis_ns	hsa-mir-21	Neoplasms [unspecific]	24664585			C80.1	D009369			The present meta-analysis suggests that circulating miR-21 expression is associated with poor survival in patients with cancer and could be a prognostic biomarker for those patients.
circulation_biomarker_prognosis_ns	hsa-mir-221	Neoplasms [unspecific]	24319365			C80.1	D009369			Lack of significant association between plasma/serum miR-221 expression and poor survival of carcinoma: a meta analysis.
circulation_biomarker_prognosis_ns	hsa-mir-133b	Osteosarcoma	25120799	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma.
circulation_biomarker_prognosis_ns	hsa-mir-206	Osteosarcoma	25120799	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma.
circulation_biomarker_prognosis_ns	hsa-mir-21	Osteosarcoma	23321165	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Identification of Serum MicroRNA-21 as a Biomarker for Chemosensitivity and Prognosis in Human Osteosarcoma
circulation_biomarker_prognosis_ns	hsa-let-7a-1	Ovarian Neoplasms	21571355	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	let-7a is a potential marker for selection of paclitaxel in ovarian cancer management.
circulation_biomarker_prognosis_ns	hsa-let-7f	Ovarian Neoplasms	24223734	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings indicate that plasma miR-205 and let-7f are biomarkers for ovarian cancer detection that complement CA-125; let-7f may be predictive of ovarian cancer prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-141	Ovarian Neoplasms	25636451	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200c and miR-141 may be predictive biomarkers for ovarian cancer prognosis. Further large-scale studies are still needed to confirm our findings.
circulation_biomarker_prognosis_ns	hsa-mir-200a	Ovarian Neoplasms	26063644	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients.
circulation_biomarker_prognosis_ns	hsa-mir-200b	Ovarian Neoplasms	26063644	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Ovarian Neoplasms	25636451	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200c and miR-141 may be predictive biomarkers for ovarian cancer prognosis. Further large-scale studies are still needed to confirm our findings.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Ovarian Neoplasms	26063644	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients.
circulation_biomarker_prognosis_ns	hsa-mir-181d	Pancreatic Neoplasms	27380024	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		serum miR-181d was significantly associated with the presence of metastasis in patients with PDA
circulation_biomarker_prognosis_ns	hsa-mir-105	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-132	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-135a	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-142	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-147	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-155	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-223	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-298	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-299a	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-325	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-410	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-101	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-191	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-223	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-25	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-26b	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-29a	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-335	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-433	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-516	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-21	Preeclampsia	28694210	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Circulating microRNA expression as predictor of preeclampsia and its severity.
circulation_biomarker_prognosis_ns	hsa-let-7	Prostate Neoplasms	23798998	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
circulation_biomarker_prognosis_ns	hsa-mir-18a	Retinoblastoma	27574784	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Downregulation of inhibitor of apoptosis proteins, tumor miRNA-18a, altered serum cytokines, and serum miRNA-18a levels were observed upon NCL-APT treatment
circulation_biomarker_prognosis_ns	hsa-mir-122	Sepsis	25672224			A41.9	D018805		HP:0100806	Serum miR-122 correlates with short-term mortality in sepsis patients.
circulation_biomarker_prognosis_ns	hsa-mir-15a	Sepsis	26683209			A41.9	D018805		HP:0100806	The plasma levels of miRNA are altered in patients with severe sepsis complicated by shock and may offer prognostic value as well as insights into the mechanisms of endothelial dysfunction in sepsis.
circulation_biomarker_prognosis_ns	hsa-mir-27a	Sepsis	26683209			A41.9	D018805		HP:0100806	The plasma levels of miRNA are altered in patients with severe sepsis complicated by shock and may offer prognostic value as well as insights into the mechanisms of endothelial dysfunction in sepsis.
circulation_biomarker_prognosis_ns	hsa-mir-16	Squamous Cell Carcinoma, Esophageal	26692950	disease of cellular proliferation	DOID:3748		C562729			the level of miR-16 in the patients with good outcome was significantly higher than that in the patients with poor outcome
circulation_biomarker_prognosis_ns	hsa-mir-223	Squamous Cell Carcinoma, Esophageal	24390317	disease of cellular proliferation	DOID:3748		C562729			miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-25	Squamous Cell Carcinoma, Esophageal	24390317	disease of cellular proliferation	DOID:3748		C562729			miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-375	Squamous Cell Carcinoma, Esophageal	24390317	disease of cellular proliferation	DOID:3748		C562729			miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-455	Squamous Cell Carcinoma, Head and Neck	27109697	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-193b-3p and miR-455-5p were positively associated with survival, and miR-92a-3p and miR-497-5p were negatively associated with survival in OPSCC.
circulation_biomarker_prognosis_ns	hsa-mir-124	Toxic Epidermal Necrolysis	26394757	disease by infectious agent	DOID:9063	L51.2	D013206	608579		The serum miR-124 concentration can be used as a disease activity marker for severe drug eruptions, reflecting the severity of keratinocyte apoptosis.
circulation_biomarker_prognosis_up	hsa-mir-155	Acute Myocardial Infarction	22995291	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Real-time RT-PCR confirmed that the serum levels of miR-155 and miR-380* were approximately 4- and 3-fold higher, respectively, in patients who experienced cardiac death within 1 year after discharge.
circulation_biomarker_prognosis_up	hsa-mir-380	Acute Myocardial Infarction	22995291	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Real-time RT-PCR confirmed that the serum levels of miR-155 and miR-380* were approximately 4- and 3-fold higher, respectively, in patients who experienced cardiac death within 1 year after discharge.
circulation_biomarker_prognosis_up	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26705427	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Upregulation of these microRNAs was associated with a significantly shorter overall survival and recurrence-free survival
circulation_biomarker_prognosis_up	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26969625	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our meta-analysis indicated that elevated miR-21 expression level can predict poor prognosis in patients with PDAC.
circulation_biomarker_prognosis_up	hsa-mir-210	Adenocarcinoma, Pancreatic Ductal	26705427	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Upregulation of these microRNAs was associated with a significantly shorter overall survival and recurrence-free survival
circulation_biomarker_prognosis_up	hsa-mir-483	Adenocarcinoma, Pancreatic Ductal	26124009	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
circulation_biomarker_prognosis_up	hsa-mir-210	Aortic Stenosis	24626394	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Circulating miR-210 levels are increased in patients with AS and provide independent prognostic information to established risk indices.Analytical characteristics were also excellent supporting the potential of micro-RNAs as novel CV biomarkers.
circulation_biomarker_prognosis_up	hsa-mir-133b	Atrial Fibrillation	29676832	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF
circulation_biomarker_prognosis_up	hsa-mir-328	Atrial Fibrillation	29676832	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF
circulation_biomarker_prognosis_up	hsa-mir-499	Atrial Fibrillation	29676832	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF
circulation_biomarker_prognosis_up	hsa-mir-21	B-cell Childhood Acute Lymphoblastic Leukemia	28253825	disease of cellular proliferation	DOID:0080146					Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia.
circulation_biomarker_prognosis_up	hsa-mir-155	Bladder Neoplasms	25918190			C67	D001749	109800	HP:0009725	We found that elevated expression of miR-155 is correlated with a poor outcome for patients with bladder cancer; this suggests that miR-155 is a potential biomarker for bladder cancer prognosis.
circulation_biomarker_prognosis_up	hsa-mir-21	Brain Neoplasms	25790954	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	microRNA-21 is associated with the prognosis of patients with brain tumors,  and high expression of microRNA-21 can predict poor prognosis in patients with brain tumors.
circulation_biomarker_prognosis_up	hsa-mir-10b	Breast Neoplasms	24416156	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC.
circulation_biomarker_prognosis_up	hsa-mir-146b	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-155	Breast Neoplasms	25503185	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer.
circulation_biomarker_prognosis_up	hsa-mir-15a	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-16	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-181b	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-195	Breast Neoplasms	25503185	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer.
circulation_biomarker_prognosis_up	hsa-mir-19a	Breast Neoplasms	24416156	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC.
circulation_biomarker_prognosis_up	hsa-mir-203	Breast Neoplasms	28351024	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer
circulation_biomarker_prognosis_up	hsa-mir-21	Breast Neoplasms	24416156	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC.
circulation_biomarker_prognosis_up	hsa-mir-21	Breast Neoplasms	25503185	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer.
circulation_biomarker_prognosis_up	hsa-mir-21	Breast Neoplasms	18812439	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21: miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis
circulation_biomarker_prognosis_up	hsa-mir-21	Breast Neoplasms	25277099	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Women with metastatic breast cancer, especially CSII, presented up-regulated levels of miR-183, miR-494 and miR-21, which were associated with a  poor prognosis.
circulation_biomarker_prognosis_up	hsa-mir-34a	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-18b	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-302a	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-423	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-523	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-582	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-888	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-101	Carcinoma, Hepatocellular	27498785	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High miR-101 expression, vascular invasion, tumor  size 鈮? cm and late pathological stage were the risk factors of recurrence-free survival rate.
circulation_biomarker_prognosis_up	hsa-mir-122	Carcinoma, Hepatocellular	25636448	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	high serum miR-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients, and it is a good biomarker of better prognosis in patients with hepatocellular carcinoma.
circulation_biomarker_prognosis_up	hsa-mir-122	Carcinoma, Hepatocellular	26129878	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High plasma microRNA-122 expression was associated with poor OS in patients with HBV-related hepatocellular carcinoma who underwent RFA.
circulation_biomarker_prognosis_up	hsa-mir-17	Carcinoma, Hepatocellular	23108086	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma
circulation_biomarker_prognosis_up	hsa-mir-221	Carcinoma, Hepatocellular	21295551	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-221, upregulated in HCC, can provide predictive significance for prognosis of HCC patients.
circulation_biomarker_prognosis_up	hsa-mir-522	Carcinoma, Hepatocellular	27466991	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulation of miR-522 is associated with poor outcome of hepatocellular carcinoma.
circulation_biomarker_prognosis_up	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	25466375			C34.90	D002289		HP:0030358	High serum miR-155 and miR-221 during the first 2 weeks of CRT were  associated with the development of severe RIET
circulation_biomarker_prognosis_up	hsa-mir-211	Carcinoma, Oral	18946016	gastrointestinal system disease	DOID:0050610					miR-211: Association between high miR-211 microRNA expression and the poor prognosis
circulation_biomarker_prognosis_up	hsa-mir-221	Carcinoma, Renal Cell	24379138	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients.
circulation_biomarker_prognosis_up	hsa-mir-21	Carcinoma, Urothelial	27383043	disease of cellular proliferation	DOID:4006				HP:0030409	miR-21 may be a prognostic marker for cancer progression.
circulation_biomarker_prognosis_up	hsa-mir-21	Cervical Neoplasms	27101583	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Increased circulating miR-21 expression in serum is associated with lymph node metastasis in patients with cervical cancer.
circulation_biomarker_prognosis_up	hsa-mir-181c	Cholangiocarcinoma	27533020	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Down-regulation of NDRG2 and overexpression of miR-181c or LIF are significantly associated with a poorer overall survival (OS) in CCA patients.
circulation_biomarker_prognosis_up	hsa-mir-1260b	Colorectal Carcinoma	27399918	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The high expression level of miR-1260b is an independent prognostic biomarker that indicates a worse prognosis for patients with CRC.
circulation_biomarker_prognosis_up	hsa-mir-183	Colorectal Carcinoma	25629978	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the elevated miR-183 in the plasma could be a promising biomarker for predicting the risk of tumor recurrence and poor survival in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-203	Colorectal Carcinoma	26701878	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-203 levels were significantly upregulated in a stage-dependent manner, and high miR-203 expression was associated with poor survival in patients with CRC in both patient cohorts.
circulation_biomarker_prognosis_up	hsa-mir-203	Colorectal Carcinoma	28351024	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer
circulation_biomarker_prognosis_up	hsa-mir-141	Colorectal Carcinoma	21445232	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High levels of plasma miR-141 predicted poor survival in both cohorts and that miR-141 was an independent prognostic factor for advanced colon cancer.
circulation_biomarker_prognosis_up	hsa-mir-17	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-18	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-19a	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-19b-1	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-20a	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-92-1	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-126	Diabetic Foot	27623390			E10-11.621	D017719			Increasing the miR-126 expression in the peripheral blood of patients with diabetic foot ulcers treated with maggot debridement therapy.
circulation_biomarker_prognosis_up	hsa-mir-29c	Diabetic Nephropathy	27279796			E10-11.21	D003928			miR-21, miR-29a/b/c and miR-192 could reflect DN pathogenesis
circulation_biomarker_prognosis_up	hsa-let-7d	Glioblastoma	22722712				D005909		HP:0100843	miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract).
circulation_biomarker_prognosis_up	hsa-mir-21	Glioblastoma	27531352				D005909		HP:0100843	Further subgroup analysis indicated that increased expression of miRNA-21 was also associated with OS in GBM patients.
circulation_biomarker_prognosis_up	hsa-mir-21	Glioma	27531352	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our analysis  revealed that the high expression of miRNA-21 is associated with the worse OS in  gliomas.
circulation_biomarker_prognosis_up	hsa-mir-1	Heart Failure	23079087			I50	D006331		HP:0001635	Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction.
circulation_biomarker_prognosis_up	hsa-mir-133a	Hypertension	27514547	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The hypertensive ocean seamen had significantly higher expression levels of microRNA21 and MicroRNA133a than the healthy ocean seamen.
circulation_biomarker_prognosis_up	hsa-mir-21	Hypertension	27514547	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The hypertensive ocean seamen had significantly higher expression levels of microRNA21 and MicroRNA133a than the healthy ocean seamen.
circulation_biomarker_prognosis_up	hsa-mir-183	Kidney Neoplasms	26091793	disease of cellular proliferation	DOID:263	C64	D007680			High serum miR-183 level is associated with poor responsiveness of renal cancer to natural killer cells.
circulation_biomarker_prognosis_up	hsa-mir-24	Leukemia, Acute	25672522	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia.
circulation_biomarker_prognosis_up	hsa-mir-221	Leukemia, Lymphoblastic, Acute	23566596	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia
circulation_biomarker_prognosis_up	hsa-mir-100	Leukemia, Myeloid, Acute	23055746	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia
circulation_biomarker_prognosis_up	hsa-mir-126	Leukemia, Myeloid, Acute	25759982	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The results of the present study demonstrated that higher expression levels of miR-126-5p/3p in patients with AML resulted in a poorer prognosis. Furthermore, miR-126-5p elevated the phosphorylation of Akt.
circulation_biomarker_prognosis_up	hsa-mir-146b	Leukemia, Myeloid, Acute	28473658	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	high expression of  hsa-miR-146b was independent poor prognostic factor
circulation_biomarker_prognosis_up	hsa-mir-155	Leukemia, Myeloid, Acute	27511899	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High miR-155 expression is an adverse prognostic factor in pediatric NK-AML patients.
circulation_biomarker_prognosis_up	hsa-mir-155	Leukemia, Myeloid, Acute	27531760	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The high expression of miR-155 is an poor prognostic  factor for patients with AML.
circulation_biomarker_prognosis_up	hsa-mir-181c	Leukemia, Myeloid, Acute	28473658	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	high expression of hsa-miR-181c and hsa-miR-4786 appeared to be favorable factors
circulation_biomarker_prognosis_up	hsa-mir-375	Leukemia, Myeloid, Acute	23864342	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia.
circulation_biomarker_prognosis_up	hsa-mir-551b	Leukemia, Myeloid, Acute	26108690	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia.
circulation_biomarker_prognosis_up	hsa-mir-663a	Leukemia, Myeloid, Acute	21518431	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663
circulation_biomarker_prognosis_up	hsa-mir-155	Lung Neoplasms	17028302	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A high expression of miR-155 has been suggested to be significantly associated with unfavorable prognosis in lung adenocarcinoma patients.
circulation_biomarker_prognosis_up	hsa-mir-155	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	High mir-155 associated with poor prognosis in lung cancer (Yanaihara et al., 2006).
circulation_biomarker_prognosis_up	hsa-mir-183	Lung Neoplasms	21920043	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher than that of their normal counterparts. The miR-96 expression in tumors was positively associated with its expression in sera. Log-rank and Cox regression analyses demonstrated that high expression of tumor and serum miRNAs of the miR-183 family were associated with overall poor survival in patients with lung cancer.
circulation_biomarker_prognosis_up	hsa-mir-200c	Lung Neoplasms	21516486	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer
circulation_biomarker_prognosis_up	hsa-mir-21	Lung Neoplasms	21516486	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer
circulation_biomarker_prognosis_up	hsa-mir-96	Lung Neoplasms	21920043	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher than that of their normal counterparts. The miR-96 expression in tumors was positively associated with its expression in sera. Log-rank and Cox regression analyses demonstrated that high expression of tumor and serum miRNAs of the miR-183 family were associated with overall poor survival in patients with lung cancer.
circulation_biomarker_prognosis_up	hsa-mir-18b	Lymphoma	25736311	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
circulation_biomarker_prognosis_up	hsa-mir-21	Lymphoma	22541087	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The expression of miR-21 in plasma of lymphoma patient group significantly correlated with their serum LDH level. The expressions of miR-21 and miR-210 in plasma of previously untreated lymphoma patient group were higher than those of the patients treated for 6 or more courses
circulation_biomarker_prognosis_up	hsa-mir-210	Lymphoma	22541087	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The expression of miR-21 in plasma of lymphoma patient group significantly correlated with their serum LDH level. The expressions of miR-21 and miR-210 in plasma of previously untreated lymphoma patient group were higher than those of the patients treated for 6 or more courses
circulation_biomarker_prognosis_up	hsa-mir-34a	Lymphoma, B-Cell	26854484	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
circulation_biomarker_prognosis_up	hsa-mir-17	Lymphoma, Burkitt	27044389	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis.
circulation_biomarker_prognosis_up	hsa-mir-20a	Lymphoma, Burkitt	27044389	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We  found that upregulated expression of miR-17 and miR-20a correlates with lack of pro-apoptotic Bim expression.
circulation_biomarker_prognosis_up	hsa-mir-125b	Lymphoma, Large B-Cell	26870228			C83.3	D016403	109565		high miR-125b indicated poor prognosis
circulation_biomarker_prognosis_up	hsa-mir-200c	Lymphoma, Large B-Cell, Diffuse	23232598	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma
circulation_biomarker_prognosis_up	hsa-mir-141	Malignant Neoplasms [unspecific]	26556949			C80.1	D009369			Our findings indicated that, compared to their tissue counterparts, the expression level of miR-200c and miR-141 in peripheral blood may be more effective for monitoring cancer prognosis. High miR-141 expression was better at predicting tumor progression than survival for malignant tumors.
circulation_biomarker_prognosis_up	hsa-mir-15b	Melanoma	25155861	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Serum miR-15b levels significantly increased over time in recurrent patients
circulation_biomarker_prognosis_up	hsa-mir-206	Myotonic Muscular Dystrophy	25915631			G71.11	D009223	160900		Specifically, miR-1, miR-133a, miR133b and miR-206 serum levels were found elevated in DM1 patients with progressive muscle wasting compared to disease stable DM1 patients.
circulation_biomarker_prognosis_up	hsa-mir-200c	Neoplasms [unspecific]	24870778			C80.1	D009369			Low expression of microRNA 200c in tumor tissue and high expression of microRNA 200c in serum are associated with worse survival in solid tumors. Further study is needed to elucidate this contradiction.
circulation_biomarker_prognosis_up	hsa-mir-27a	Neoplasms [unspecific]	24122958			C80.1	D009369			miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.
circulation_biomarker_prognosis_up	hsa-mir-10b	Pancreatic Adenocarcinoma	27456015	disease of cellular proliferation	DOID:4074	C25.3				We conclude that elevated miRNA-10b levels in station 8 lymph nodes could be utilized to assess risk for early disease progression in patients with periampullary tumors.
circulation_biomarker_prognosis_up	hsa-mir-21	Pancreatic Neoplasms	21139804	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		upregulated and correlated with worse survival
circulation_biomarker_prognosis_up	hsa-mir-146b	Prostate Neoplasms	23846169	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Multivariate analysis revealed that miR-146b-3p possessed prognostic information beyond standard clinicopathological parameters. 
circulation_biomarker_prognosis_up	hsa-mir-194	Prostate Neoplasms	23846169	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Analysis of tissue cohorts revealed that miR-194 was robustly expressed in the prostate, elevated in metastases, and its expression in primary tumours was associated with a poor prognosis.
circulation_biomarker_prognosis_up	hsa-mir-21	Prostate Neoplasms	26247873	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our study demonstrates that high miR-21 expression levels in PBMCs were correlated with the presence, recurrence, and metastasis of PCa and that this may be a useful biomarker for screening PCa and monitoring the risk of Pca recurrence and metastasis.
circulation_biomarker_prognosis_up	hsa-mir-221	Prostate Neoplasms	24760272	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies.
circulation_biomarker_prognosis_up	hsa-mir-7	Prostate Neoplasms	24760272	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies.
circulation_biomarker_prognosis_up	hsa-mir-125b-1	Rectal Neoplasms	18695884	disease of cellular proliferation	DOID:1984		D012004			miR-125b: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer
circulation_biomarker_prognosis_up	hsa-mir-125b-2	Rectal Neoplasms	18695884	disease of cellular proliferation	DOID:1984		D012004			miR-125b: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer
circulation_biomarker_prognosis_up	hsa-mir-137	Rectal Neoplasms	18695884	disease of cellular proliferation	DOID:1984		D012004			miR-137: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer
circulation_biomarker_prognosis_up	hsa-mir-125b	Rectum Adenocarcinoma	27081702	disease of cellular proliferation	DOID:1996	C20				High miR-125b expression in tissue and serum were associated with a poor treatment response in LARC patients
circulation_biomarker_prognosis_up	hsa-mir-206	Rhabdomyosarcoma	28834127	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Serum microRNA-206 levels were elevated and remained high after three cycles of vincristine, dactinomycin, and cyclophosphamide (VAC)
circulation_biomarker_prognosis_up	hsa-mir-18a	Squamous Cell Carcinoma, Head and Neck	25677760	disease of cellular proliferation	DOID:5520	C76.0	C535575			significant elevated expressions of  miR-21, miR-18a, miR-134a, miR-210, miR-181a, miR-19a, and miR-155 were associated with poor survival in human HNSCC.
circulation_biomarker_prognosis_up	hsa-mir-183	Tuberculosis	25755759	disease by infectious agent	DOID:399	A15-A19	D014376			High serum miR-183 level is associated with the bioactivity of macrophage derived from tuberculosis patients.
circulation_biomarker_prognosis_up	hsa-mir-155	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-155: increased expression
circulation_biomarker_prognosis_up	hsa-mir-184	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-184: increased expression
circulation_biomarker_prognosis_up	hsa-mir-206	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-206: increased expression
circulation_biomarker_prognosis_up	hsa-mir-363	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-363*: increased expression
circulation_biomarker_prognosis_up	hsa-mir-494	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-494: increased expression
circulation_biomarker_prognosis_up	hsa-mir-542	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-542-3p: increased expression
epigenetics	hsa-mir-31	Adenocarcinoma, Colon	24752710	disease of cellular proliferation	DOID:234	C18			HP:0040276	MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.
epigenetics	hsa-mir-106b	Adenocarcinoma, Esophageal	28049580	disease of cellular proliferation	DOID:4914		C562730	133239		Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma.
epigenetics	hsa-mir-193b	Adenocarcinoma, Esophageal	27176876	disease of cellular proliferation	DOID:4914		C562730	133239		Aberrant methylation of microRNA-193b in human Barrett's esophagus and esophageal adenocarcinoma
epigenetics	hsa-mir-145	Adenocarcinoma, Lung	26582602	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Taken together, DNA hyper-methylation in the miR-145 promoter region reduced its expression in LAC and miR-145 expression level might serve as a novel prognostic biomarker.
epigenetics	hsa-mir-615	Adenocarcinoma, Pancreatic Ductal	24769899	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma.
epigenetics	hsa-mir-10a	Atherosclerosis	26148682	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Methylation-specific PCR (MSP) confirmed differential CpG methylation of HOXA genes, the ER stress gene ATF4, inflammatory regulator microRNA-10a and ARHGAP25 that encodes a negative regulator of Rho GTPases involved in cytoskeleton remodeling.
epigenetics	hsa-mir-10b	Atherosclerosis	28601079	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Variability of Methylation Profiles of CpG Sites in microrNA Genes in Leukocytes and Vascular Tissues of Patients with Atherosclerosis.
epigenetics	hsa-mir-152	Atherosclerosis	22295098	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-152 mediates DNMT1-regulated DNA methylation in the estrogen receptor α gene.
epigenetics	hsa-mir-29b-1	Atherosclerosis	21266537	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases.
epigenetics	hsa-mir-29b-2	Atherosclerosis	21266537	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases.
epigenetics	hsa-mir-10a	Bladder Neoplasms	23867826			C67	D001749	109800	HP:0009725	Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers.
epigenetics	hsa-mir-124	Bladder Neoplasms	23200812			C67	D001749	109800	HP:0009725	Among them, miR-137,miR-124-2, miR-124-3, and miR-9-3 were frequently and tumor-specifically methylated in primary cancers
epigenetics	hsa-mir-137	Bladder Neoplasms	23200812			C67	D001749	109800	HP:0009725	Among them, miR-137,miR-124-2, miR-124-3, and miR-9-3 were frequently and tumor-specifically methylated in primary cancers
epigenetics	hsa-mir-152	Bladder Neoplasms	23867826			C67	D001749	109800	HP:0009725	Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers.
epigenetics	hsa-mir-193a	Bladder Neoplasms	25188512			C67	D001749	109800	HP:0009725	The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression.
epigenetics	hsa-mir-200b	Bladder Neoplasms	23867826			C67	D001749	109800	HP:0009725	Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers.
epigenetics	hsa-mir-34a	Bladder Neoplasms	24423412			C67	D001749	109800	HP:0009725	Cisplatin-based chemotherapy induced demethylation of miR-34a promoter and increased miR-34a expression, which in turn sensitized MIBC cells to cisplatin and decreased the tumorigenicity and proliferation of cancer cells that by reducing the production of CD44.
epigenetics	hsa-mir-34b	Bladder Neoplasms	27557899			C67	D001749	109800	HP:0009725	MicroRNA epigenetic signatures in human disease.
epigenetics	hsa-mir-9	Bladder Neoplasms	23200812			C67	D001749	109800	HP:0009725	Among them, miR-137,miR-124-2, miR-124-3, and miR-9-3 were frequently and tumor-specifically methylated in primary cancers
epigenetics	hsa-let-7e	Breast Neoplasms	21969366	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Jumonji/Arid1 B (JARID1B) promotes breast tumor cell cycle progression through epigenetic repression of micro RNA let-7e.
epigenetics	hsa-mir-124a-1	Breast Neoplasms	24375250	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease.
epigenetics	hsa-mir-124a-2	Breast Neoplasms	24375250	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease.
epigenetics	hsa-mir-124a-3	Breast Neoplasms	24375250	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease.
epigenetics	hsa-mir-125b-1	Breast Neoplasms	22277129	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We observed a significant reduction on the expression of miR-125b1 in cancer cells in comparison with controls, suggesting that DNA methylation at the CpG island might reduce miR-125b1 expression.
epigenetics	hsa-mir-129-2	Breast Neoplasms	26519551	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the obtained data indicate the involvement of methylation in the down-regulation of the studied coding and miRNA genes and suggest the involvement of miR-129-2 in the deregulation of RASSF1(A) via a direct interaction or/and mediators in common pathways (according to KEGG, Gene Ontology (FDR < 0.01), and GeneCards data) in the examined gynecological tumors.
epigenetics	hsa-mir-143	Breast Neoplasms	24218337	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells.
epigenetics	hsa-mir-148a	Breast Neoplasms	25980823	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Glabridin inhibits cancer stem cell-like properties of human breast cancer cells:An epigenetic regulation of miR-148a/SMAd2 signaling.
epigenetics	hsa-mir-148b	Breast Neoplasms	24257477	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer.
epigenetics	hsa-mir-149	Breast Neoplasms	25156775	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.
epigenetics	hsa-mir-151a	Breast Neoplasms	24257477	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer.
epigenetics	hsa-mir-199a-1	Breast Neoplasms	21317930	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-199a-2	Breast Neoplasms	21317930	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-199b	Breast Neoplasms	21317930	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-19a	Breast Neoplasms	27445062	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CAP treatment of MCF-7 induced hypermethylation at the promoter CpG sites and downregulation of miR-19a, which was known as an oncomiR.
epigenetics	hsa-mir-200	Breast Neoplasms	24918286	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SUMOylation of FOXM1B alters its transcriptional activity on regulation of MiR-200 family and JNK1 in MCF7 human breast cancer cells.
epigenetics	hsa-mir-200	Breast Neoplasms	23525011	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem cell-like state
epigenetics	hsa-mir-200a	Breast Neoplasms	23112837	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer
epigenetics	hsa-mir-200b	Breast Neoplasms	22231446	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Methylation of functional promoters of the Hsa-mir-200b is associated with metastasis or hormone receptor status in advanced breast cancer.
epigenetics	hsa-mir-200b	Breast Neoplasms	23112837	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer
epigenetics	hsa-mir-200c	Breast Neoplasms	24729530	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells.
epigenetics	hsa-mir-200c	Breast Neoplasms	23112837	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer
epigenetics	hsa-mir-200c	Breast Neoplasms	28724364	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
epigenetics	hsa-mir-203	Breast Neoplasms	22393463	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells.
epigenetics	hsa-mir-21	Breast Neoplasms	24257477	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer.
epigenetics	hsa-mir-218-1	Breast Neoplasms	22705304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
epigenetics	hsa-mir-218-2	Breast Neoplasms	22705304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
epigenetics	hsa-mir-219	Breast Neoplasms	23813567	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant DNA methylation of miR-219 promoter in long-term night shiftworkers.
epigenetics	hsa-mir-221	Breast Neoplasms	21673316	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.
epigenetics	hsa-mir-27b	Breast Neoplasms	27363334	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells
epigenetics	hsa-mir-29c	Breast Neoplasms	24297604	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer.
epigenetics	hsa-mir-29c	Breast Neoplasms	26539832	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
epigenetics	hsa-mir-31	Breast Neoplasms	22289355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.
epigenetics	hsa-mir-320a	Breast Neoplasms	25159093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.
epigenetics	hsa-mir-328	Breast Neoplasms	23991164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Methylation patterns in the miR-328 5'-flanking region are involved in the inter-individual difference in BCRP levels in human placenta
epigenetics	hsa-mir-335	Breast Neoplasms	21289068	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer.
epigenetics	hsa-mir-34a	Breast Neoplasms	21225432	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34a	Breast Neoplasms	21317930	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-34a	Breast Neoplasms	23292869	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis
epigenetics	hsa-mir-34b	Breast Neoplasms	25398683	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	long-term shiftwork may increase the risk of breast cancer via methylation-based suppression of miR-34b and a consequent reduction in immunomediated anti-tumor capacity and support our previous findings that LAN may induce epigenetic alteration of cancer-relevant microRNAs.
epigenetics	hsa-mir-34b	Breast Neoplasms	21225432	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34c	Breast Neoplasms	21225432	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34c	Breast Neoplasms	22074923	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-34c down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells.
epigenetics	hsa-mir-375	Breast Neoplasms	20978187	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells.
epigenetics	hsa-mir-7-1	Breast Neoplasms	22705304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
epigenetics	hsa-mir-7-2	Breast Neoplasms	22705304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
epigenetics	hsa-mir-7-3	Breast Neoplasms	22705304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
epigenetics	hsa-mir-9-1	Breast Neoplasms	26519551	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the obtained data indicate the involvement of methylation in the down-regulation of the studied coding and miRNA genes and suggest the involvement of miR-129-2 in the deregulation of RASSF1(A) via a direct interaction or/and mediators in common pathways (according to KEGG, Gene Ontology (FDR < 0.01), and GeneCards data) in the examined gynecological tumors.
epigenetics	hsa-mir-17	Bronchopulmonary Dysplasia	27694474			P27.1	D001997			our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD
epigenetics	hsa-mir-18	Bronchopulmonary Dysplasia	27694474			P27.1	D001997			our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD
epigenetics	hsa-mir-19a	Bronchopulmonary Dysplasia	27694474			P27.1	D001997			our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD
epigenetics	hsa-mir-19b-1	Bronchopulmonary Dysplasia	27694474			P27.1	D001997			our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD
epigenetics	hsa-mir-20a	Bronchopulmonary Dysplasia	27694474			P27.1	D001997			our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD
epigenetics	hsa-mir-92-1	Bronchopulmonary Dysplasia	27694474			P27.1	D001997			our data support a plausible role for epigenetically altered miR-17/92 cluster in the pathogenesis of severe BPD
epigenetics	hsa-mir-34a	Carcinoma, Bladder	27557899	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MicroRNA epigenetic signatures in human disease.
epigenetics	hsa-mir-34c	Carcinoma, Bladder	27557899	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MicroRNA epigenetic signatures in human disease.
epigenetics	hsa-mir-107	Carcinoma, Breast	27830681			D05	D001943	114480	HP:0003002	Novel miRNA genes hypermethylated in breast cancer.
epigenetics	hsa-mir-124	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-1258	Carcinoma, Breast	27830681			D05	D001943	114480	HP:0003002	Novel miRNA genes hypermethylated in breast cancer.
epigenetics	hsa-mir-125b	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-127	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-130b	Carcinoma, Breast	27830681			D05	D001943	114480	HP:0003002	Novel miRNA genes hypermethylated in breast cancer.
epigenetics	hsa-mir-132	Carcinoma, Breast	27830681			D05	D001943	114480	HP:0003002	Novel miRNA genes hypermethylated in breast cancer.
epigenetics	hsa-mir-132	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-137	Carcinoma, Breast	27830681			D05	D001943	114480	HP:0003002	Novel miRNA genes hypermethylated in breast cancer.
epigenetics	hsa-mir-137	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-148a	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-152	Carcinoma, Breast	27475839			D05	D001943	114480	HP:0003002	DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop.
epigenetics	hsa-mir-191	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-193a	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-200c	Carcinoma, Breast	27717206			D05	D001943	114480	HP:0003002	Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.
epigenetics	hsa-mir-203	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-212	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-34b	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-375	Carcinoma, Breast	24571711			D05	D001943	114480	HP:0003002	Epigenetic silencing of miR-375 causes the upregulation of IGF1R,which at least partially underlies trastuzumab resistance of breast cancer cells.Our study has implications for miR-375 as a potential target in combination with trastuzumab for treating HER2-positive breast cancers.
epigenetics	hsa-mir-375	Carcinoma, Breast	27466996			D05	D001943	114480	HP:0003002	MiR-375 is downregulated in MCF-7/ADM and MCF-7/PTX cells, and its downregulation is a result of promoter methylation.
epigenetics	hsa-mir-375	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-mir-9	Carcinoma, Breast	27998789			D05	D001943	114480	HP:0003002	DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
epigenetics	hsa-let-7b	Carcinoma, Colon	27525719	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	G9a binds with and stabilizes RelB, thereby recruiting DNA methyltransferase 3 on the Let-7b promoter and repressing its expression.
epigenetics	hsa-mir-155	Carcinoma, Colon	25502084	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-200c/141 was downregulated by CpG island methylation and TGF-β signaling, which decreased ZEB1/2 expression and increased E-cadherin expression to inhibit migration and invasion of gastric cancer cells and provides powerful evidence for the application of decitabine in gastric cancer treatment.
epigenetics	hsa-mir-203	Carcinoma, Endometrial	24530564	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Hypermethylation of miR-203 is a frequent event in endometrial carcinomas and is strongly associated with microsatellite instability and MLH1 methylation status. Thus, miR-203 methylation level might represent a marker for patients with endometrioid and clear endometrial sub-cancers.
epigenetics	hsa-mir-200	Carcinoma, Endometrioid Endometrial	28088687			C54.1	D018269			Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma.
epigenetics	hsa-mir-218	Carcinoma, Esophageal	26610476	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	In conclusion, our results support that aberrant CpG hypermethylation at least partly accounts for miR-218 silencing in ESCC, which impairs its tumor-suppressive function.
epigenetics	hsa-mir-490	Carcinoma, Gastric	25503559	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	hypermethylation-mediated silencing of miR-490-3p reactivates SMARCD1 to confer malignant phenotypes, mechanistically linking H. pylori, chromatin remodeling, and gastric carcinogenesis.
epigenetics	hsa-let-7c	Carcinoma, Hepatocellular	22370893	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
epigenetics	hsa-mir-101-1	Carcinoma, Hepatocellular	22370893	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
epigenetics	hsa-mir-106b	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-122	Carcinoma, Hepatocellular	24085423	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The expression of miRNA-122 is regulated by DNA methylation and correlated with apoptosis of liver cancer cells. Methylation regulation of miRNA-122 expression might be involved in the development of hepatocellular carcinoma.
epigenetics	hsa-mir-124-1	Carcinoma, Hepatocellular	19843643	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-124:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
epigenetics	hsa-mir-124-2	Carcinoma, Hepatocellular	19843643	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-124:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
epigenetics	hsa-mir-124-3	Carcinoma, Hepatocellular	19843643	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-124:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
epigenetics	hsa-mir-125b-1	Carcinoma, Hepatocellular	22370893	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
epigenetics	hsa-mir-125b-2	Carcinoma, Hepatocellular	22370893	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
epigenetics	hsa-mir-126	Carcinoma, Hepatocellular	27774652	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6 -methyladenosine-dependent primary MicroRNA processing.
epigenetics	hsa-mir-129-1	Carcinoma, Hepatocellular	23580407	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma
epigenetics	hsa-mir-129-2	Carcinoma, Hepatocellular	23402613	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC
epigenetics	hsa-mir-129-2	Carcinoma, Hepatocellular	23580407	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma
epigenetics	hsa-mir-139	Carcinoma, Hepatocellular	22370893	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
epigenetics	hsa-mir-142	Carcinoma, Hepatocellular	28963738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Loss-of-function of miR-142 by hypermethylation promotes TGF-β-mediated tumour growth and metastasis in hepatocellular carcinoma.
epigenetics	hsa-mir-148a	Carcinoma, Hepatocellular	24714841	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis.
epigenetics	hsa-mir-148a	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-152	Carcinoma, Hepatocellular	20578129	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-152:a tumor-suppressive role of miR-152 in the epigenetic aberration of HBV-related HCC
epigenetics	hsa-mir-181a-2	Carcinoma, Hepatocellular	21464043	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
epigenetics	hsa-mir-181b-1	Carcinoma, Hepatocellular	21464043	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
epigenetics	hsa-mir-181b-2	Carcinoma, Hepatocellular	21464043	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
epigenetics	hsa-mir-181c	Carcinoma, Hepatocellular	21464043	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
epigenetics	hsa-mir-181d	Carcinoma, Hepatocellular	21464043	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBx promotes stemness by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
epigenetics	hsa-mir-183	Carcinoma, Hepatocellular	28321157	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-183 is frequently methylated and related to poor survival in human hepatocellular carcinoma.
epigenetics	hsa-mir-191	Carcinoma, Hepatocellular	21969817	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hypomethylation of the hsa-miR-191 Locus Causes High Expression of hsa-miR-191 and Promotes the Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma.
epigenetics	hsa-mir-193a	Carcinoma, Hepatocellular	22117060	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via SRSF2.
epigenetics	hsa-mir-195	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-195 expression is decreased in HCC compared to nontumor liver [59], and is also deleted in lung cancer [65], suggesting it is tumor related. miRNA-195 alters the expression of methyl-CpG binding protein 2 (which alters DNA methylation), the SKI oncogene, and a Bcl-2 like protein [59], suggesting miRNA-195 may act as a tumor suppressor in HCC.
epigenetics	hsa-mir-195	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-196a-2	Carcinoma, Hepatocellular	21692953	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The CC genotype of the miR-196a-2 rs11614913 polymorphism is associated with increased risk of HCC development in this Turkish population.
epigenetics	hsa-mir-200a	Carcinoma, Hepatocellular	21837748	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The histone deacetylase 4/Sp1/miR-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma.
epigenetics	hsa-mir-200a	Carcinoma, Hepatocellular	23222811	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma
epigenetics	hsa-mir-200b	Carcinoma, Hepatocellular	22370893	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
epigenetics	hsa-mir-200b	Carcinoma, Hepatocellular	23222811	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma
epigenetics	hsa-mir-200c	Carcinoma, Hepatocellular	23222811	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma
epigenetics	hsa-mir-203	Carcinoma, Hepatocellular	19843643	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-203:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
epigenetics	hsa-mir-223	Carcinoma, Hepatocellular	24333181	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of miR-223 in HCC is associated with the epigenetic regulation by highly expressed sulfatide and involved in tumor metastasis.
epigenetics	hsa-mir-224	Carcinoma, Hepatocellular	22459148	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms.
epigenetics	hsa-mir-23a	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-25	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-27a	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-29a	Carcinoma, Hepatocellular	23789939	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-29a could regulate TGF-β-induced EMT by affecting DNA methylation via the suppression of DNMT.
epigenetics	hsa-mir-302	Carcinoma, Hepatocellular	24740829	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-302-mediated iPSC technology reprogrammed HCC cells and improved drug sensitivity through AOF2 down-regulation, which caused H3K4 methylation and c-Myc repression.
epigenetics	hsa-mir-335	Carcinoma, Hepatocellular	23229728	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma
epigenetics	hsa-mir-34b	Carcinoma, Hepatocellular	24704024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer.
epigenetics	hsa-mir-375	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-378	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-429	Carcinoma, Hepatocellular	24572141	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Epigenetic modification of miR-429 can manipulate liver T-ICs by targeting the RBBP4/E2F1/OCT4 axis. This miRNA might be targeted to inactivate T-ICs, thus providing a novel strategy for HCC prevention and treatment.
epigenetics	hsa-mir-497	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-519d	Carcinoma, Hepatocellular	22262409	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In hepatocellular carcinoma miR-519d is upregulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.
epigenetics	hsa-mir-615	Carcinoma, Hepatocellular	27487123	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In conclusion, our findings characterize miR-615-5p as an important epigenetically silenced miRNA involved in the Rab-Ras pathway in hepatocellular carcinoma and expand our understanding of the molecular mechanism  underlying hepatocarcinogenesis and metastasis.
epigenetics	hsa-mir-93	Carcinoma, Hepatocellular	25424171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	DNA methylation plays an important and complex role in the regulation of miRNA expression in HCC, which may provide insights into the pathogenesis of HCC and thus may be used for diagnosis and intervention.
epigenetics	hsa-mir-137	Carcinoma, Lung, Non-Small-Cell	28223039			C34.90	D002289		HP:0030358	Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer.
epigenetics	hsa-mir-124-2	Carcinoma, Lung, Non-Small-Cell	21917081			C34.90	D002289		HP:0030358	The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit.
epigenetics	hsa-mir-124-3	Carcinoma, Lung, Non-Small-Cell	21917081			C34.90	D002289		HP:0030358	The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit.
epigenetics	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	21702040			C34.90	D002289		HP:0030358	mir-34b and mir-126 were silenced by DNA methylation.
epigenetics	hsa-mir-139	Carcinoma, Lung, Non-Small-Cell	26256448			C34.90	D002289		HP:0030358	Histone methylation-mediated silencing of miR-139 enhances invasion of non-small-cell lung cancer.
epigenetics	hsa-mir-15a	Carcinoma, Lung, Non-Small-Cell	23867991			C34.90	D002289		HP:0030358	Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
epigenetics	hsa-mir-16-1	Carcinoma, Lung, Non-Small-Cell	23867991			C34.90	D002289		HP:0030358	Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
epigenetics	hsa-mir-193a	Carcinoma, Lung, Non-Small-Cell	22282464			C34.90	D002289		HP:0030358	Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non-Small Cell Lung Cancers.
epigenetics	hsa-mir-199a-1	Carcinoma, Lung, Non-Small-Cell	21317930			C34.90	D002289		HP:0030358	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-199a-2	Carcinoma, Lung, Non-Small-Cell	21317930			C34.90	D002289		HP:0030358	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-199b	Carcinoma, Lung, Non-Small-Cell	21317930			C34.90	D002289		HP:0030358	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-212	Carcinoma, Lung, Non-Small-Cell	22110741			C34.90	D002289		HP:0030358	We identified histone modifications rather than DNA hypermethylation as epigenetic events that regulate miR-212 levels in NSCLC. Moreover, we found that miR-212 silencing in vivo is closely associated with the severity of the disease.
epigenetics	hsa-mir-29	Carcinoma, Lung, Non-Small-Cell	23939044			C34.90	D002289		HP:0030358	Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer.
epigenetics	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	21317930			C34.90	D002289		HP:0030358	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-34b	Carcinoma, Lung, Non-Small-Cell	21383543			C34.90	D002289		HP:0030358	DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer.
epigenetics	hsa-mir-34b	Carcinoma, Lung, Non-Small-Cell	21702040			C34.90	D002289		HP:0030358	mir-34b and mir-126 were silenced by DNA methylation.
epigenetics	hsa-mir-34c	Carcinoma, Lung, Non-Small-Cell	21383543			C34.90	D002289		HP:0030358	DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer.
epigenetics	hsa-mir-9-3	Carcinoma, Lung, Non-Small-Cell	21917081			C34.90	D002289		HP:0030358	The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit.
epigenetics	hsa-mir-9-3	Carcinoma, Lung, Non-Small-Cell	22282464			C34.90	D002289		HP:0030358	Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non-Small Cell Lung Cancers.
epigenetics	hsa-mir-34b	Carcinoma, Lung, Small-Cell	22047961			C34.90	D055752	182280	HP:0030357	Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.
epigenetics	hsa-mir-34c	Carcinoma, Lung, Small-Cell	22047961			C34.90	D055752	182280	HP:0030357	Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.
epigenetics	hsa-mir-148a	Carcinoma, Nasopharyngeal	25277193	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Silencing of miRNA-148a by hypermethylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma.
epigenetics	hsa-mir-24	Carcinoma, Nasopharyngeal	25319395	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation.
epigenetics	hsa-mir-127	Carcinoma, Oral	22132151	gastrointestinal system disease	DOID:0050610					MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
epigenetics	hsa-mir-137	Carcinoma, Oral	22132151	gastrointestinal system disease	DOID:0050610					MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
epigenetics	hsa-mir-141	Carcinoma, Oral	22132151	gastrointestinal system disease	DOID:0050610					MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
epigenetics	hsa-mir-200a	Carcinoma, Oral	22132151	gastrointestinal system disease	DOID:0050610					MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
epigenetics	hsa-mir-200c	Carcinoma, Oral	22132151	gastrointestinal system disease	DOID:0050610					MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
epigenetics	hsa-mir-375	Carcinoma, Oral	22132151	gastrointestinal system disease	DOID:0050610					MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
epigenetics	hsa-mir-375	Carcinoma, Ovarian	29631007	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis
epigenetics	hsa-mir-124-1	Carcinoma, Renal Cell	23321515	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma
epigenetics	hsa-mir-124-2	Carcinoma, Renal Cell	23321515	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma
epigenetics	hsa-mir-124-3	Carcinoma, Renal Cell	23321515	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma
epigenetics	hsa-mir-124a-2	Carcinoma, Renal Cell	23755536	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
epigenetics	hsa-mir-124a-3	Carcinoma, Renal Cell	23755536	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
epigenetics	hsa-mir-129-2	Carcinoma, Renal Cell	23755536	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
epigenetics	hsa-mir-34a	Carcinoma, Renal Cell	21225432	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Carcinoma, Renal Cell	21225432	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Carcinoma, Renal Cell	23755536	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
epigenetics	hsa-mir-34c	Carcinoma, Renal Cell	21225432	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34c	Carcinoma, Renal Cell	23755536	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
epigenetics	hsa-mir-9-1	Carcinoma, Renal Cell	23755536	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
epigenetics	hsa-mir-9-3	Carcinoma, Renal Cell	23755536	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
epigenetics	hsa-mir-129	Carcinoma, Urothelial	28081549	disease of cellular proliferation	DOID:4006				HP:0030409	MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma.
epigenetics	hsa-mir-663a	Carcinoma, Urothelial	28081549	disease of cellular proliferation	DOID:4006				HP:0030409	MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma.
epigenetics	hsa-mir-1	Cardiomegaly	18539123			I51.7	D006332		HP:0001640	Microinjecting fragments of either the coding region or the related microRNA miR-1 led to high levels of expression of homologous RNA, resulting in an epigenetic defect, cardiac hypertrophy, whose efficient hereditary transmission correlated with the presence of miR-1 in the sperm nucleus.
epigenetics	hsa-mir-133a	Cardiomegaly	26830171			I51.7	D006332		HP:0001640	Phe exposure led to methylation of CpG sites within the miR-133a locus and reduced miR-133a expression in H9C2 cells
epigenetics	hsa-let-7c	Cardiomyopathy	24365598	cardiovascular system disease	DOID:0050700	I42	D009202			Cardiomyogenesis is controlled by the miR-99a/let-7c cluster and epigenetic modifications.
epigenetics	hsa-mir-99a	Cardiomyopathy	24365598	cardiovascular system disease	DOID:0050700	I42	D009202			Cardiomyogenesis is controlled by the miR-99a/let-7c cluster and epigenetic modifications.
epigenetics	hsa-mir-210	Cardiovascular Diseases [unspecific]	26254226				D002318			Oxidized low-density lipoprotein is a common risk factor for cardiovascular diseases and gastroenterological cancers via epigenomical regulation of microRNA-210.
epigenetics	hsa-mir-29b	Cardiovascular Diseases [unspecific]	22226905				D002318			This article is part of a Special Issue entitled OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: Novel mechanisms for cardiovascular diseases.
epigenetics	hsa-mir-124	Cervical Neoplasms	27765948	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124.
epigenetics	hsa-mir-200b	Cervical Neoplasms	27272214	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b
epigenetics	hsa-mir-200b	Cervical Neoplasms	29077234	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	DNA methylation regulated microRNAs in human cervical cancer.
epigenetics	hsa-mir-124-1	Cholangiocarcinoma	22819820	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
epigenetics	hsa-mir-124-2	Cholangiocarcinoma	22819820	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
epigenetics	hsa-mir-34a	Cholangiocarcinoma	28923203	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
epigenetics	hsa-mir-370	Cholangiocarcinoma	28545228	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma.
epigenetics	hsa-mir-373	Cholangiocarcinoma	21165562	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar Cholangiocarcinoma.
epigenetics	hsa-mir-429	Cholangiocarcinoma	27593557	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.
epigenetics	hsa-mir-125b	Chondrosarcoma	27576314	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma.
epigenetics	hsa-mir-145	Chondrosarcoma	25145279	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	The epigenetic regulation of SOX9 by miR-145 in human chondrosarcoma.
epigenetics	hsa-mir-302c	Chondrosarcoma	26094604	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1.
epigenetics	hsa-mir-219	Chronic Inflammatory Pain	25031391							methylation-mediated epigenetic modification of spinal miR-219 expression regulates chronic inflammatory pain by targeting CaMKIIγ.
epigenetics	hsa-mir-199a	Chronic Obstructive Pulmonary Disease	24299514	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	miR-199a-5p is a key regulator of the unfolded protein response in AAT-deficient monocytes, and epigenetic silencing of its expression regulates this process in chronic obstructive pulmonary disease.
epigenetics	hsa-mir-24	Colon Adenoma	26559563	disease of cellular proliferation	DOID:0050912					Butyrate and partial TSA reduced the expression of miR-135a, miR-135b, miR-24 and miR-let-7a (~0.5-fold, 24 h) and miR-24, miR-106b and miR-let-7a (~0.5-0.7-fold, 48 h) in LT97 cells.
epigenetics	hsa-mir-127	Colon Neoplasms	17355635			D12.6	D003110		HP:0100273	Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene.
epigenetics	hsa-mir-34a	Colon Neoplasms	23243217			D12.6	D003110		HP:0100273	Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and beta-Catenin Predicts Distant Metastasis of Colon Cancer
epigenetics	hsa-mir-124a	Colorectal Carcinoma	22870149	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The results showed that the methylation of miR-124a and miR-34b/c occured early in colorectal carcinogenesis and certain CRCs may arise from a field defect defined by the epigenetic inactivation of miRs.
epigenetics	hsa-mir-125a	Colorectal Carcinoma	26693202	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggest that DNA hypermethylation may be involved in the inactivation of miR-125a and miR-125b in CRC, and hypermethylation of miR-125 is a potential biomarker for clinical outcome.
epigenetics	hsa-mir-125b	Colorectal Carcinoma	26693202	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggest that DNA hypermethylation may be involved in the inactivation of miR-125a and miR-125b in CRC, and hypermethylation of miR-125 is a potential biomarker for clinical outcome.
epigenetics	hsa-mir-126	Colorectal Carcinoma	23900443	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer.
epigenetics	hsa-mir-21	Colorectal Carcinoma	26787105	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		This study suggests a high frequency of miR-21 overexpression and aberrant promoter methylation in down-regulation of PTEN expression in colorectal carcinoma. Loss of PTEN may be a prognostic factor for patients with CRC.
epigenetics	hsa-mir-210	Colorectal Carcinoma	28364795	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The significance of DNA methylation profile in metastasis-related genes for the progression of colorectal cancer.
epigenetics	hsa-mir-34	Colorectal Carcinoma	28364795	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The significance of DNA methylation profile in metastasis-related genes for the progression of colorectal cancer.
epigenetics	hsa-mir-34a	Colorectal Carcinoma	25422210	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miRNA-34a-5p may play a role as a tumor suppressor gene in colorectal cancer, with involvement of DNA methylation.
epigenetics	hsa-mir-34b	Colorectal Carcinoma	18519671	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC.
epigenetics	hsa-mir-34b	Colorectal Carcinoma	22870149	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The results showed that the methylation of miR-124a and miR-34b/c occured early in colorectal carcinogenesis and certain CRCs may arise from a field defect defined by the epigenetic inactivation of miRs.
epigenetics	hsa-mir-34c	Colorectal Carcinoma	26704889	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In conclusion, our results suggested the existence of E2F1-miR-34c-SCF negative feedback loop which was interrupted by the hyper-methylation of miR-34c promoter in CRC cells and increased cell proliferation.
epigenetics	hsa-mir-34c	Colorectal Carcinoma	18519671	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggest that miR-34b/c and BTG4 are novel tumor suppressors in CRC and that the miR-34b/c CpG island, which bidirectionally regulates miR-34b/c and BTG4, is a frequent target of epigenetic silencing in CRC.
epigenetics	hsa-mir-34c	Colorectal Carcinoma	22870149	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The results showed that the methylation of miR-124a and miR-34b/c occured early in colorectal carcinogenesis and certain CRCs may arise from a field defect defined by the epigenetic inactivation of miRs.
epigenetics	hsa-mir-484	Colorectal Carcinoma	25727216	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L.
epigenetics	hsa-mir-9	Colorectal Carcinoma	28364795	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The significance of DNA methylation profile in metastasis-related genes for the progression of colorectal cancer.
epigenetics	hsa-mir-1-1	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-1-1	Colorectal Carcinoma	22766685	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer.
epigenetics	hsa-mir-124-1	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-124-2	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-124-3	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-133a-1	Colorectal Carcinoma	22766685	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer.
epigenetics	hsa-mir-133a-2	Colorectal Carcinoma	22766685	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer.
epigenetics	hsa-mir-148a	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-149	Colorectal Carcinoma	22821729	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer.
epigenetics	hsa-mir-149	Colorectal Carcinoma	23115050	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer
epigenetics	hsa-mir-152	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-17	Colorectal Carcinoma	22308110	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
epigenetics	hsa-mir-18a	Colorectal Carcinoma	22308110	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
epigenetics	hsa-mir-18b	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-199a-1	Colorectal Carcinoma	21317930	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-199a-2	Colorectal Carcinoma	21317930	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-199b	Colorectal Carcinoma	21317930	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-19a	Colorectal Carcinoma	22308110	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
epigenetics	hsa-mir-19b-1	Colorectal Carcinoma	22308110	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
epigenetics	hsa-mir-200a	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-208a	Colorectal Carcinoma	21327300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-20a	Colorectal Carcinoma	22308110	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
epigenetics	hsa-mir-345	Colorectal Carcinoma	21665895	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer.
epigenetics	hsa-mir-34a	Colorectal Carcinoma	21225432	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34a	Colorectal Carcinoma	21317930	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells
epigenetics	hsa-mir-34b	Colorectal Carcinoma	21225432	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Colorectal Carcinoma	21610744	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer.
epigenetics	hsa-mir-34c	Colorectal Carcinoma	21225432	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34c	Colorectal Carcinoma	21610744	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer.
epigenetics	hsa-mir-373	Colorectal Carcinoma	21785829	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Epigenetic silencing of microRNA-373 plays an important role in regulating cell proliferation in colon cancer.
epigenetics	hsa-mir-92a-1	Colorectal Carcinoma	22308110	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
epigenetics	hsa-mir-375	Diabetes Mellitus, Type 2	24366165	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Expression and DNA methylation status of microRNA-375 in patients with type 2 diabetes mellitus.
epigenetics	hsa-mir-375	Diabetes Mellitus, Type 2	24741571	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Ethnic differences in microRNA-375 expression level and DNA methylation status in type 2 diabetes of Han and Kazak populations.
epigenetics	hsa-mir-34b	Early-Stage Lung Adenocarcinoma	24130071			C34.90	C538231	211980		Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in  early-stage lung adenocarcinoma.
epigenetics	hsa-mir-34c	Early-Stage Lung Adenocarcinoma	24130071			C34.90	C538231	211980		Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in  early-stage lung adenocarcinoma.
epigenetics	hsa-mir-1-1	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-124-1	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-124-2	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-124-3	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-148a	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-152	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-152	Endometrial Neoplasms	21868754	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer.
epigenetics	hsa-mir-18b	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-200a	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-208a	Endometrial Neoplasms	21327300	reproductive system disease	DOID:1380	C54.1	D016889	608089		Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-675	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		EoE remission induced a single miRNA (miR-675) likely to be involved in DNA methylation.
epigenetics	hsa-mir-129-2	Esophageal Neoplasms	21547903			C15.9	D004938	133239	HP:0100751	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
epigenetics	hsa-mir-141	Esophageal Neoplasms	22921431			C15.9	D004938	133239	HP:0100751	Inhibition of SOX17 by MicroRNA-141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer.
epigenetics	hsa-mir-34a	Esophageal Neoplasms	21547903			C15.9	D004938	133239	HP:0100751	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
epigenetics	hsa-mir-34b	Esophageal Neoplasms	21547903			C15.9	D004938	133239	HP:0100751	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
epigenetics	hsa-mir-34c	Esophageal Neoplasms	21547903			C15.9	D004938	133239	HP:0100751	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
epigenetics	hsa-mir-375	Esophageal Neoplasms	21533613			C15.9	D004938	133239	HP:0100751	Epigenetic Silencing of MicroRNA-375 Regulates PDK1 Expression in Esophageal Cancer
epigenetics	hsa-mir-22	Ewing Sarcoma	24362521	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
epigenetics	hsa-mir-10b	Gastric Neoplasms	24481854	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, these findings suggest that miR-10b may function as a novel tumor suppressor and is partially silenced by DNA hypermethylation in GC.
epigenetics	hsa-mir-10b	Gastric Neoplasms	21562367	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-10b methylation may be a useful molecular biomarker for assessing the risk of gastric cancer development, and modulation of miR-10b may represent a therapeutic approach for treating gastric cancer.
epigenetics	hsa-mir-124-1	Gastric Neoplasms	21365509	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Significant associations were found between hypermethylation of hsa-miR-124a and tumor size, differentiation, lymphatic metastasis, and invasion depth(P<0.01).
epigenetics	hsa-mir-124-1	Gastric Neoplasms	21914401	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma.
epigenetics	hsa-mir-124-2	Gastric Neoplasms	21365509	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Significant associations were found between hypermethylation of hsa-miR-124a and tumor size, differentiation, lymphatic metastasis, and invasion depth(P<0.01).
epigenetics	hsa-mir-124-3	Gastric Neoplasms	21365509	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Significant associations were found between hypermethylation of hsa-miR-124a and tumor size, differentiation, lymphatic metastasis, and invasion depth(P<0.01).
epigenetics	hsa-mir-129	Gastric Neoplasms	25344911	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters.
epigenetics	hsa-mir-129-2	Gastric Neoplasms	21213213	disease of cellular proliferation	DOID:10534	C16	D013274	137215		upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared with adjacent normal tissues, and their methylation status correlated inversely with their expression patterns.
epigenetics	hsa-mir-129-2	Gastric Neoplasms	21960261	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The methylation-silenced expression of the miRNA could be reactivated in gastric cancer cells by treatment with demethylating drugs in a time-dependent manner.Analysis of the methylation status of these miRNAs showed that the upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared to adjacent normal tissues, and their methylation status correlated inversely with their expression patterns. The expression of miR-34b and miR-129-3p was downregulated by DNA hypermethylation in primary gastric cancers, and the low expression was associated with poor clinicopathological features.
epigenetics	hsa-mir-137	Gastric Neoplasms	22703336	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis
epigenetics	hsa-mir-139	Gastric Neoplasms	21925125	disease of cellular proliferation	DOID:10534	C16	D013274	137215		HER2 Interacts with CD44 to Upregulate CXCR4 via Epigenetic Silencing of microRNA-139 in Gastric Cancer Cells.
epigenetics	hsa-mir-141	Gastric Neoplasms	25502084	disease of cellular proliferation	DOID:10534	C16	D013274	137215		sion of miR-200c/141 induced by TGF-β in SGC-7901 cells. Our study revealed that miR-200c/141 was downregulated by CpG  island methylation and TGF-β signaling, which decreased ZEB1/2 expression and increased E-cadherin expression to inhibit migration and invasion of gastric cancer cells and provides powerful evidence for the application of decitabine in  gastric cancer treatment.
epigenetics	hsa-mir-148a	Gastric Neoplasms	22167392	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer.
epigenetics	hsa-mir-181c	Gastric Neoplasms	20080834	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-181c:Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis.
epigenetics	hsa-mir-195	Gastric Neoplasms	23333942	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer
epigenetics	hsa-mir-200	Gastric Neoplasms	25502084	disease of cellular proliferation	DOID:10534	C16	D013274	137215		sion of miR-200c/141 induced by TGF-β in SGC-7901 cells. Our study revealed that miR-200c/141 was downregulated by CpG  island methylation and TGF-β signaling, which decreased ZEB1/2 expression and increased E-cadherin expression to inhibit migration and invasion of gastric cancer cells and provides powerful evidence for the application of decitabine in  gastric cancer treatment.
epigenetics	hsa-mir-210	Gastric Neoplasms	22703336	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis
epigenetics	hsa-mir-212	Gastric Neoplasms	20020497	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-212:miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer
epigenetics	hsa-mir-29b	Gastric Neoplasms	25874772	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Deregulation between miR-29b/c and DNMT3A is associated with epigenetic silencing of the CDH1 gene, affecting cell migration and invasion in gastric cancer.
epigenetics	hsa-mir-29c	Gastric Neoplasms	25874772	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Deregulation between miR-29b/c and DNMT3A is associated with epigenetic silencing of the CDH1 gene, affecting cell migration and invasion in gastric cancer.
epigenetics	hsa-mir-30b	Gastric Neoplasms	24913034	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Decreased miR-30b-5p expression by DNMT1 methylation regulation involved in gastric cancer metastasis.
epigenetics	hsa-mir-34a	Gastric Neoplasms	25860861	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a.
epigenetics	hsa-mir-34b	Gastric Neoplasms	23942619	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results suggest that methylation of miR-34b/c in the mucosa of the noncancerous gastric body may be a useful biomarker for predicting the risk of metachronous GC.
epigenetics	hsa-mir-34b	Gastric Neoplasms	21213213	disease of cellular proliferation	DOID:10534	C16	D013274	137215		upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared with adjacent normal tissues, and their methylation status correlated inversely with their expression patterns.
epigenetics	hsa-mir-34b	Gastric Neoplasms	21914401	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma.
epigenetics	hsa-mir-34b	Gastric Neoplasms	21960261	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The methylation-silenced expression of the miRNA could be reactivated in gastric cancer cells by treatment with demethylating drugs in a time-dependent manner.Analysis of the methylation status of these miRNAs showed that the upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared to adjacent normal tissues, and their methylation status correlated inversely with their expression patterns. The expression of miR-34b and miR-129-3p was downregulated by DNA hypermethylation in primary gastric cancers, and the low expression was associated with poor clinicopathological features.
epigenetics	hsa-mir-34b	Gastric Neoplasms	20924086	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These results suggest that miR-34b and miR-34c are novel tumor suppressors frequently silenced by DNA methylation in GC, that methylation of miR-34b/c is involved in an epigenetic field defect and that the methylation might be a predictive marker of GC risk.
epigenetics	hsa-mir-34b	Gastric Neoplasms	22703336	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis
epigenetics	hsa-mir-34c	Gastric Neoplasms	23942619	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results suggest that methylation of miR-34b/c in the mucosa of the noncancerous gastric body may be a useful biomarker for predicting the risk of metachronous GC.
epigenetics	hsa-mir-34c	Gastric Neoplasms	21914401	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma.
epigenetics	hsa-mir-378a	Gastric Neoplasms	23333942	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer
epigenetics	hsa-mir-449a	Gastric Neoplasms	24810364	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a.
epigenetics	hsa-mir-512	Gastric Neoplasms	19503096	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.
epigenetics	hsa-mir-9	Gastric Neoplasms	25270964	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Epigenetic silencing of miRNA-9 is correlated with promoter-proximal CpG island hypermethylation in gastric cancer in vitro and in vivo.
epigenetics	hsa-mir-9-1	Gastric Neoplasms	21931274	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment.
epigenetics	hsa-mir-9-1	Gastric Neoplasms	22703336	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis
epigenetics	hsa-mir-9-2	Gastric Neoplasms	21931274	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment.
epigenetics	hsa-mir-9-3	Gastric Neoplasms	21931274	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment.
epigenetics	hsa-mir-9-3	Gastric Neoplasms	22703336	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis
epigenetics	hsa-mir-99a	Gastric Neoplasms	24810364	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a.
epigenetics	hsa-mir-1-1	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-124-1	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-124-2	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-124-3	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-148a	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-152	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-18b	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-200a	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-208a	Gastrointestinal Neoplasms	21327300			D37.9	D005770			Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
epigenetics	hsa-mir-212	Gastrointestinal Neoplasms	21053104			D37.9	D005770			The conclusion could be deduced from the study that decreased expression of miR-212 may be due to hypermethylation of CPI in gastric cancer cells, and miR-212 might act on the progression of gastric cancer through the potential target gene Myc.
epigenetics	hsa-mir-34c	Gastrointestinal Neoplasms	20924086			D37.9	D005770			These results suggest that miR-34b and miR-34c are novel tumor suppressors frequently silenced by DNA methylation in GC, that methylation of miR-34b/c is involved in an epigenetic field defect and that the methylation might be a predictive marker of GC risk.
epigenetics	hsa-mir-122	Germ Cell Tumor	26497383	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology.
epigenetics	hsa-mir-302a	Germ Cell Tumor	26497383	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology.
epigenetics	hsa-mir-302d	Germ Cell Tumor	26497383	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology.
epigenetics	hsa-mir-371	Germ Cell Tumor	26497383	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology.
epigenetics	hsa-mir-373	Germ Cell Tumor	26497383	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology.
epigenetics	hsa-mir-101	Glioblastoma	29251856				D005909		HP:0100843	Studies of intragenic and distant intergenic alterations in DNA methylation will help elucidate the nature of epigenetic deregulation in glioblastoma
epigenetics	hsa-mir-137	Glioblastoma	26187071				D005909		HP:0100843	Direct transfection of miR-137 mimics is more effective than DNA demethylation of miR-137 promoter to augment anti-tumor mechanisms of delphinidin in human glioblastoma U87MG and LN18 cells.
epigenetics	hsa-mir-149	Glioblastoma	27783537				D005909		HP:0100843	MicroRNA-149 is epigenetically silenced tumor-suppressive microRNA, involved in cell proliferation and downregulation of AKT1 and cyclin D1 in human glioblastoma multiforme.
epigenetics	hsa-mir-153	Glioblastoma	27215075				D005909		HP:0100843	MiR-153 as a Tumor Suppressor in Glioblastoma Multiforme is Downregulated by DNA Methylation.
epigenetics	hsa-mir-181c	Glioblastoma	26983574				D005909		HP:0100843	Epigenetic silencing of miR-181c by DNA methylation in glioblastoma cell lines.
epigenetics	hsa-mir-296	Glioblastoma	26898758				D005909		HP:0100843	We show that miR-296-5p expression is repressed in a DNA methylation-dependent manner under conditions that promote GBM cell stemness
epigenetics	hsa-let-7	Glioma	26463235	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	epigenetic modification is a crucial mechanism for controlling the expression of  miR-126 in glioma.
epigenetics	hsa-mir-101	Glioma	25829251	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells.
epigenetics	hsa-mir-129-2	Glioma	25772485	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation.
epigenetics	hsa-mir-185	Glioma	21962230	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma.
epigenetics	hsa-mir-20a	Glioma	26337869	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In summary, DNMT1 mediated chemosensitivity by reducing methylation of the microRNA-20a promoter in glioma cells.
epigenetics	hsa-mir-211	Glioma	23183822	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Epigenetic Regulation of miRNA-211 by MMP-9 Governs Glioma Cell Apoptosis,Chemosensitivity and Radiosensitivity
epigenetics	hsa-mir-1	Heart Diseases [unspecific]	28209718			I51.9	D006333			Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo.
epigenetics	hsa-mir-133	Heart Diseases [unspecific]	28209718			I51.9	D006333			Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo.
epigenetics	hsa-mir-208	Heart Diseases [unspecific]	28209718			I51.9	D006333			Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo.
epigenetics	hsa-mir-499	Heart Diseases [unspecific]	28209718			I51.9	D006333			Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo.
epigenetics	hsa-mir-210	Helicobacter pylori Infection	25187177			B96.81	D016480	600263	HP:0005202	Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection.
epigenetics	hsa-mir-148	Hematologic Neoplasms	26314468	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	This article summarizes the expression of miR-148/152 family in hematological malignancies, aiming at expounding the signicance of relationship between DNA methylation modification and microRNA.
epigenetics	hsa-mir-149	Hematologic Neoplasms	28035377	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines.
epigenetics	hsa-mir-152	Hematologic Neoplasms	26314468	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	This article summarizes the expression of miR-148/152 family in hematological malignancies, aiming at expounding the signicance of relationship between DNA methylation modification and microRNA.
epigenetics	hsa-mir-497	Hematologic Neoplasms	27075177	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Strikingly, low-dose  decitabine was able to augment chemosensitivity in cancer stem cells, likely by the upregulation of miRNA-497
epigenetics	hsa-mir-520c	Hematologic Neoplasms	28035377	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines.
epigenetics	hsa-mir-101-1	Hepatitis B Virus Infection	23124077	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A
epigenetics	hsa-mir-101-2	Hepatitis B Virus Infection	23124077	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A
epigenetics	hsa-mir-205	Hepatitis B Virus Infection	24339740	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis.
epigenetics	hsa-mir-200	Hepatoblastoma	24122292	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	The strong correlation between expression and DNA methylation suggests a major role for this epigenetic mark in the regulation of the miR-141-200c locus.
epigenetics	hsa-mir-205	Hepatoblastoma	24122292	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	The strong correlation between expression and DNA methylation suggests a major role for this epigenetic mark in the regulation of the miR-141-200c locus.
epigenetics	hsa-mir-1286	Human Papilloma Virus Infection	23732000			B97.7	D027383			We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
epigenetics	hsa-mir-1287	Human Papilloma Virus Infection	23732000			B97.7	D027383			We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
epigenetics	hsa-mir-1290	Human Papilloma Virus Infection	23732000			B97.7	D027383			We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
epigenetics	hsa-mir-432	Human Papilloma Virus Infection	23732000			B97.7	D027383			We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
epigenetics	hsa-mir-641	Human Papilloma Virus Infection	23732000			B97.7	D027383			We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
epigenetics	hsa-mir-95	Human Papilloma Virus Infection	23732000			B97.7	D027383			We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
epigenetics	hsa-mir-181b-1	Inflammation	20797623				D007249			miR-181b-1:STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer
epigenetics	hsa-mir-21	Inflammation	20797623				D007249			miR-21:STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer
epigenetics	hsa-mir-29a	Influenza	22072783	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Epigenetic Changes Mediated by miR29 Activate Cyclooxygenase-2 and Interferon Production during Viral Infection.
epigenetics	hsa-mir-34b	Leukemia	26524015			C95	D007938	613065	HP:0001909	CpG island methylation of miR-34b promoter region in leukemia cell lines can decrease the expression levels of miR-34b, which is also the reason why miR-34b can reduce the inhibition of cell proliferation, thus miR-34b might be a tumor suppressor gene involved in the regulation of leukemia.
epigenetics	hsa-mir-34b	Leukemia	25582471			C95	D007938	613065	HP:0001909	The hypermethylation of promoter leads to decrease in the expression levels of miR-34b in leukemia cell lines, which attenuate mechanism of proliferative inhibition may be one of the reasons of occurrence or development of childhood leukemia.
epigenetics	hsa-mir-22	Leukemia, Lymphoblastic, Acute	19807731	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Thus, accumulation of H3K27triM independent of promoter DNA methylation may be a novel epigenetic mechanism for MIR22 silencing in ALL.
epigenetics	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
epigenetics	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
epigenetics	hsa-mir-16-2	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
epigenetics	hsa-mir-214	Leukemia, Lymphocytic, Chronic, B-Cell	25361012	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.
epigenetics	hsa-mir-26a	Leukemia, Lymphocytic, Chronic, B-Cell	25361012	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.
epigenetics	hsa-mir-29b-1	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
epigenetics	hsa-mir-29b-2	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
epigenetics	hsa-mir-34	Leukemia, Lymphocytic, Chronic, B-Cell	24686393	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.
epigenetics	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	24559316	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study.
epigenetics	hsa-mir-34b	Leukemia, Lymphocytic, Chronic, B-Cell	24559316	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study.
epigenetics	hsa-mir-34b	Leukemia, Lymphocytic, Chronic, B-Cell	24686393	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.
epigenetics	hsa-mir-34c	Leukemia, Lymphocytic, Chronic, B-Cell	24686393	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.
epigenetics	hsa-mir-34c	Leukemia, Lymphocytic, Chronic, B-Cell	24559316	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study.
epigenetics	hsa-mir-9	Leukemia, Lymphocytic, Chronic, B-Cell	24373626	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Of the miR-9 family, miR-9-3 is a tumor suppressor miRNA relatively frequently methylated, and hence silenced in CLL; whereas miR-9-1 methylation is rare in CLL. The role of miR-9-3 methylation in the constitutive activation of NFκB signaling pathway in CLL warrants further study.
epigenetics	hsa-let-7a-3	Leukemia, Myeloid, Acute	24703161	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia.
epigenetics	hsa-mir-15a	Leukemia, Myeloid, Acute	24885794	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The DLEU2 locus and embedded miRNA cluster miR-15a/16-1 is commonly deleted in adult cancers and shown to induce leukaemogenesis, however in paediatric AML we found the region to be transcriptionally repressed. In combination, our data highlights the utility of interrogating DNA methylation and microRNA in combination with underlying genetic status to provide novel insights into AML biology.
epigenetics	hsa-mir-16-1	Leukemia, Myeloid, Acute	24885794	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The DLEU2 locus and embedded miRNA cluster miR-15a/16-1 is commonly deleted in adult cancers and shown to induce leukaemogenesis, however in paediatric AML we found the region to be transcriptionally repressed. In combination, our data highlights the utility of interrogating DNA methylation and microRNA in combination with underlying genetic status to provide novel insights into AML biology.
epigenetics	hsa-mir-17	Leukemia, Myeloid, Acute	21897363	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states.
epigenetics	hsa-mir-18	Leukemia, Myeloid, Acute	21897363	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states.
epigenetics	hsa-mir-193a	Leukemia, Myeloid, Acute	21399664	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.
epigenetics	hsa-mir-193a	Leukemia, Myeloid, Acute	23223432	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21)acute myeloid leukemia by activating the PTEN/PI3K signal pathway
epigenetics	hsa-mir-19a	Leukemia, Myeloid, Acute	21897363	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states.
epigenetics	hsa-mir-19b-1	Leukemia, Myeloid, Acute	21897363	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states.
epigenetics	hsa-mir-200	Leukemia, Myeloid, Acute	27756750	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	epigenetic silencing of the miR-200 family microRNAs affects ZEB2 expression
epigenetics	hsa-mir-203	Leukemia, Myeloid, Acute	21323860	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The frequent hsa-miR-203 methylation in lymphoid malignancies suggested a pathogenetic role of hsa-miR-203 methylation.
epigenetics	hsa-mir-20a	Leukemia, Myeloid, Acute	21897363	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states.
epigenetics	hsa-mir-24-1	Leukemia, Myeloid, Acute	21544199	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-124-1 is epigenetically inactivated in Haematological Malignancies.
epigenetics	hsa-mir-29b-1	Leukemia, Myeloid, Acute	19211935	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29b: induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
epigenetics	hsa-mir-29b-1	Leukemia, Myeloid, Acute	23178755	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
epigenetics	hsa-mir-29b-2	Leukemia, Myeloid, Acute	19211935	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29b: induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
epigenetics	hsa-mir-29b-2	Leukemia, Myeloid, Acute	23178755	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
epigenetics	hsa-mir-663	Leukemia, Myeloid, Acute	23870168	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Expression of miR-663 was significantly lower in pediatric AML cells compared to NBM controls; furthermore, a high frequency of miR-663 promoter hypermethylation was observed in both AML cell lines and pediatric AML samples.Inactivation of miR-663 by promoter hypermethylation could be affected by 5-Aza demethylation. These findings suggest that hypermethylation of the miR-663 promoter may be an early event in the development of pediatric AML.
epigenetics	hsa-mir-720	Leukemia, Myeloid, Acute	25417880	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The expression of miR-720 in AML patients reduced significantly, and DNA methylation-mediated epigenetic silencing of miR-720 contributed to maintain the malignant characteristics of AML.
epigenetics	hsa-mir-92-1	Leukemia, Myeloid, Acute	21897363	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose that upon macrophage differentiation PU.1 represses the miR-17-92 cluster promoter by an Egr-2/Jarid1b-mediated H3K4 demethylation mechanism whose deregulation may contribute to leukaemic states.
epigenetics	hsa-mir-203	Leukemia, Myeloid, Acute, Pediatric	24103876			C92.0				miR-203 may not be regulated with methylation mechanism in pediatric acute leukemia. miR- 203 may be a protooncogene involved in the formation of pediatric acute leukemia and ALL. Further analyses indicated that high expression of miR-203 may be associated with poor prognosis of pediatric ALL and acute leukemia.
epigenetics	hsa-mir-21	Leukemia, Myeloid, Chronic	25575817	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	RBP2 epigenetically downregulated miR-21 in blast transformation of CML.
epigenetics	hsa-mir-369	Leukemia, Myeloid, Chronic	22089542	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation.
epigenetics	hsa-mir-378	Leukemia, Myeloid, Chronic	26913395	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Methylation of miR-378 in Chronic Myeloid Leukemia.
epigenetics	hsa-mir-410	Leukemia, Myeloid, Chronic	22089542	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation.
epigenetics	hsa-mir-615	Leukemia, Myeloid, Chronic	22089542	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation.
epigenetics	hsa-mir-663a	Leukemia, Myeloid, Chronic	22089542	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation.
epigenetics	hsa-mir-34a	Leukemia, Promyelocytic, Acute	24811488	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia.
epigenetics	hsa-mir-34b	Leukemia, Promyelocytic, Acute	24811488	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia.
epigenetics	hsa-mir-34c	Leukemia, Promyelocytic, Acute	24811488	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia.
epigenetics	hsa-mir-128a	Leukemia, T-Cell	24316133	disease of cellular proliferation	DOID:715	C91.5	D015458			Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD).
epigenetics	hsa-mir-143	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21706045	disease of cellular proliferation	DOID:5599	C83.5	D054218			Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression.
epigenetics	hsa-mir-378a	Liver Cirrhosis	27855367	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	The Epigenetically-Regulated microRNA-378a Targets TGF-β2 in TGF-β1-Treated Hepatic Stellate Cells.
epigenetics	hsa-mir-29b	Liver Fibrosis	24138392			K74	D008103			Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation--a novel mechanism suppressing liver fibrosis.
epigenetics	hsa-mir-373	Liver Neoplasms	21706058	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Thus, histone deacetylation of CDH1 and downregulation of miR-373, together with the previously demonstrated hypermethylation of CDH1 by HBx, may be important for the understanding of HBV-related carcinogenesis.
epigenetics	hsa-let-7b	Liver Neoplasms	22683924	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
epigenetics	hsa-mir-491	Liver Neoplasms	24680928	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491.
epigenetics	hsa-mir-214	Lung Fibrosis	24122720	respiratory system disease	DOID:3770	J84.10	D011658	178500		Stable decreases in miR-124 expression contribute to an epigenetically reprogrammed, highly proliferative, migratory, and inflammatory phenotype of hypertensive pulmonary adventitial fibroblasts. Thus, therapies directed at restoring miR-124 function, including histone deacetylase inhibitors,should be investigated.
epigenetics	hsa-mir-101	Lung Neoplasms	25210796	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation.
epigenetics	hsa-mir-1258	Lung Neoplasms	24450160	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel miRNA genes methylated in lung tumors.
epigenetics	hsa-mir-127	Lung Neoplasms	24665010	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Epigenetic analysis of microRNA genes in tumors from surgically resected lung cancer patients and association with survival.
epigenetics	hsa-mir-129-2	Lung Neoplasms	26081366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Epigenetic regulation of miR-129-2 and its effects on the proliferation and invasion in lung cancer cells.
epigenetics	hsa-mir-137	Lung Neoplasms	24450160	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel miRNA genes methylated in lung tumors.
epigenetics	hsa-mir-148a	Lung Neoplasms	20431052	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-148a:The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis
epigenetics	hsa-mir-182	Lung Neoplasms	25975295	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	DNA methylation occurs in the miR-182 promoter region in lung cancer cell lines. This methylation can regulate the expression level of miR-182.Further study must be conducted to explore the function of miR-182 promoter methylation in lung cancer occurrence and development.
epigenetics	hsa-mir-200	Lung Neoplasms	28698146	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
epigenetics	hsa-mir-29a	Lung Neoplasms	17890317	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
epigenetics	hsa-mir-29b	Lung Neoplasms	17890317	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
epigenetics	hsa-mir-29b-1	Lung Neoplasms	17890317	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
epigenetics	hsa-mir-29c	Lung Neoplasms	17890317	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
epigenetics	hsa-mir-375	Lung Neoplasms	24450160	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel miRNA genes methylated in lung tumors.
epigenetics	hsa-mir-155	Lymphoma	27110708	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	DNA methylation regulates miR-155 expression.
epigenetics	hsa-mir-203	Lymphoma	21454413	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis.
epigenetics	hsa-mir-24-1	Lymphoma	21544199	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-124-1 is epigenetically inactivated in Haematological Malignancies.
epigenetics	hsa-mir-146a	Lymphoma, Burkitt	23528241	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We concluded that similarly to the promoters of protein coding genes, both DNA methylation and histone modifications contribute to the host cell dependent expression of miR-146a.
epigenetics	hsa-mir-29a	Lymphoma, Burkitt	29318382	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	methylation-mediated miR-29 epigenetic silencing may occur during BL development
epigenetics	hsa-mir-155	Lymphoma, Non-Hodgkin	25211095	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas.
epigenetics	hsa-mir-142	Lymphoma, T-Cell	25405321	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients.
epigenetics	hsa-mir-146a	Lymphoma, T-Cell	25405321	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients.
epigenetics	hsa-mir-155	Lymphoma, T-Cell	25405321	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients.
epigenetics	hsa-mir-181b	Lymphoma, T-Cell	25405321	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients.
epigenetics	hsa-mir-21	Lymphoma, T-Cell	25405321	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	These results reveal a subgroup-specific epigenetically regulated microRNA signatures for MFt and CD30+ cALCL patients.
epigenetics	hsa-mir-199b	Medulloblastoma	22411914	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma.
epigenetics	hsa-mir-9	Medulloblastoma	24346283	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	microRNA-9 is a methylation-silenced tumour suppressor that could be a potential candidate predictive marker for poor prognosis of medulloblastoma.
epigenetics	hsa-mir-124a	Melanoma	24303550	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Epigenetic regulation of melanoma tumor suppressor miRNA-124a.
epigenetics	hsa-mir-125b	Melanoma	24118912	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	the reduction in miR-125b expression in pigmented cells was at least partially due to the hypermethylation of the MIR125B-1 promoter, and miR-125b expression was regulated by intracellular cAMP levels.
epigenetics	hsa-mir-203	Melanoma	26225581	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells.
epigenetics	hsa-mir-211	Melanoma	27237979	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	DNMT1 mediated promoter methylation is a mechanism of miRNA suppression in melanoma
epigenetics	hsa-mir-31	Melanoma	22948084	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma.
epigenetics	hsa-mir-34b	Mesothelioma	21673066	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma.
epigenetics	hsa-mir-34c	Mesothelioma	21673066	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma.
epigenetics	hsa-mir-155	Multiple Myeloma	25497370	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	DNA methylation contributes to miR-155 expression in myeloma cells. Interestingly, the survival data showed an association between miR-155 expression and outcome of MM.
epigenetics	hsa-mir-203	Multiple Myeloma	21707582	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MIR203 is epigeneticlly silenced in multiple myeloma.
epigenetics	hsa-mir-24-1	Multiple Myeloma	21544199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-124-1 is epigenetically inactivated in Haematological Malignancies.
epigenetics	hsa-mir-29b-1	Multiple Myeloma	23100393	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma
epigenetics	hsa-mir-29b-2	Multiple Myeloma	23100393	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma
epigenetics	hsa-mir-342	Multiple Myeloma	29242101	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Epigenetic silencing of EVL/miR-342 in multiple myeloma
epigenetics	hsa-mir-9-1	Multiple Myeloma	25855800	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Hypermethylation of miR-9-3 and miR-9-1 is tumour-specific in MM,leading to reversible miRNA silencing. Frequent methylation of miR-9-3 and miR-9-1 in cell lines, but not in primary samples, may be acquired during in vitro culture, and indicates an unimportant role of miR-9 methylation in myelomagenesis.
epigenetics	hsa-mir-9-3	Multiple Myeloma	25855800	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Hypermethylation of miR-9-3 and miR-9-1 is tumour-specific in MM,leading to reversible miRNA silencing. Frequent methylation of miR-9-3 and miR-9-1 in cell lines, but not in primary samples, may be acquired during in vitro culture, and indicates an unimportant role of miR-9 methylation in myelomagenesis.
epigenetics	hsa-mir-124-1	Myelodysplastic Syndromes	20448201	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome
epigenetics	hsa-mir-124-2	Myelodysplastic Syndromes	20448201	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome
epigenetics	hsa-mir-124-3	Myelodysplastic Syndromes	20448201	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome
epigenetics	hsa-mir-126	Myeloma	24875904			C90.0	D009101	254500		TNFα in the marrow microenvironment led to RANKL demethylation and re-expression in myeloma cells through DNMT1 repression and upregulation of miR-126-3p and miR-140, both known to repress DNMT1 translation.
epigenetics	hsa-mir-140	Myeloma	24875904			C90.0	D009101	254500		TNFα in the marrow microenvironment led to RANKL demethylation and re-expression in myeloma cells through DNMT1 repression and upregulation of miR-126-3p and miR-140, both known to repress DNMT1 translation.
epigenetics	hsa-mir-375	Myeloproliferative Neoplasms	25666256	disease of cellular proliferation	DOID:2226	D47.1		616871		Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
epigenetics	hsa-let-7	Neoplasms [unspecific]	26303212			C80.1	D009369			Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
epigenetics	hsa-let-7a-3	Neoplasms [unspecific]	24423609			C80.1	D009369			Reduction of let-7a3/let-7b miRNA may be one of mechanisms leading to overexpression of HMGA2 in AT/RT tissues.
epigenetics	hsa-mir-105	Neoplasms [unspecific]	25089631			C80.1	D009369			A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors.
epigenetics	hsa-mir-106a	Neoplasms [unspecific]	26303212			C80.1	D009369			Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
epigenetics	hsa-mir-106b	Neoplasms [unspecific]	26303212			C80.1	D009369			Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
epigenetics	hsa-mir-125b	Neoplasms [unspecific]	26354435			C80.1	D009369			Taken together, our results demonstrated that miR-125b mediates PAR2-induced cancer cell migration by targeting Gab2 and that NSun2-dependent RNA methylation contributes to the down-regulation of miR-125b by PAR2 signaling. 
epigenetics	hsa-mir-126	Neoplasms [unspecific]	19116145			C80.1	D009369			miR-126: a tumor supressor: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7
epigenetics	hsa-mir-137	Neoplasms [unspecific]	26066330			C80.1	D009369			We also found that miR-137 and its host gene are epigenetically silenced in human cancer specimens and cell lines.These results support the development and testing of microRNA-based therapies (in particular based on restoring miR-137 levels) for targeting the oncogenic family of p160 SRCs in cancer.
epigenetics	hsa-mir-15a	Neoplasms [unspecific]	26303212			C80.1	D009369			Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
epigenetics	hsa-mir-16	Neoplasms [unspecific]	26303212			C80.1	D009369			Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
epigenetics	hsa-mir-17	Neoplasms [unspecific]	26303212			C80.1	D009369			Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
epigenetics	hsa-mir-181b-1	Neoplasms [unspecific]	20797623			C80.1	D009369			miR-181b-1:STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer
epigenetics	hsa-mir-19b	Neoplasms [unspecific]	26303212			C80.1	D009369			Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
epigenetics	hsa-mir-200	Neoplasms [unspecific]	25178837			C80.1	D009369			Zeb1 and Snail1 engage miR-200f transcriptional and epigenetic regulation during EMT.
epigenetics	hsa-mir-200b	Neoplasms [unspecific]	21292642			C80.1	D009369			Depletion of miR-200 in arsenite-transformed cells involved induction of the EMT-inducing transcription factors ZEB1 (zinc-finger E-box-binding homeobox factor 1) and ZEB2 and increased methylation of miR-200 promoters.
epigenetics	hsa-mir-21	Neoplasms [unspecific]	20797623			C80.1	D009369			miR-21:STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer
epigenetics	hsa-mir-24-2	Neoplasms [unspecific]	25943634			C80.1	D009369			The conclusion drawn of hsa-miR-24-2 targeting the genes of cell survival correlated with the methylation profile and resultant transcription factor binding site gain or loss in support of absence of cell survival.
epigenetics	hsa-mir-29	Neoplasms [unspecific]	24096364			C80.1	D009369			The miR-29 family recurrently regulates active DNA demethylation pathway members TET1 and TDG.
epigenetics	hsa-mir-34a	Neoplasms [unspecific]	18719384			C80.1	D009369			miR-34a: inactivation, Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
epigenetics	hsa-mir-34b	Neoplasms [unspecific]	18768788			C80.1	D009369			miR-34b: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
epigenetics	hsa-mir-34b	Neoplasms [unspecific]	22082000			C80.1	D009369			miR-34b/c were homozygously methylated in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with miR silencing, and 5-aza-2'-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was methylated in one patient and none had methylation of miR-124-1.
epigenetics	hsa-mir-34b	Neoplasms [unspecific]	25979762			C80.1	D009369			although results obtained by the different DNA methylation analysis techniques are largely comparable, an appropriate correction may be necessary for stringent comparison.
epigenetics	hsa-mir-34c	Neoplasms [unspecific]	18768788			C80.1	D009369			miR-34c: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
epigenetics	hsa-mir-34c	Neoplasms [unspecific]	22082000			C80.1	D009369			miR-34b/c were homozygously methylated in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with miR silencing, and 5-aza-2'-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was methylated in one patient and none had methylation of miR-124-1.
epigenetics	hsa-mir-34c	Neoplasms [unspecific]	25979762			C80.1	D009369			although results obtained by the different DNA methylation analysis techniques are largely comparable, an appropriate correction may be necessary for stringent comparison.
epigenetics	hsa-mir-767	Neoplasms [unspecific]	25089631			C80.1	D009369			A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors.
epigenetics	hsa-mir-9-1	Neoplasms [unspecific]	18768788			C80.1	D009369			miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
epigenetics	hsa-mir-9-2	Neoplasms [unspecific]	18768788			C80.1	D009369			miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
epigenetics	hsa-mir-9-3	Neoplasms [unspecific]	18768788			C80.1	D009369			miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
epigenetics	hsa-mir-21	Nervous System Diseases [unspecific]	28903050			C72.9	D009422			Changes in the Coding and Non-coding Transcriptome and DNA Methylome that Define the Schwann Cell Repair Phenotype after Nerve Injury.
epigenetics	hsa-mir-137	Neuroblastoma	25505154	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	an epigenetic mechanism involving miR-137-mediated EZH2 repression in RSV-induced apoptosis and tumor suppression of neuroblastoma, which would provide a key potential therapeutic target in neuroblastoma treatment.
epigenetics	hsa-mir-340	Neuroblastoma	22797059	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-340 is upregulated by demethylation of an upstream genomic region that occurs during the process of neuroblastoma cell differentiation induced by all-trans retinoic acid (ATRA).
epigenetics	hsa-mir-181a	Neurodegenerative Diseases [unspecific]	27789312				D019636		HP:0002180	PPARβ/δ activation protects against corticosterone-induced ER stress in astrocytes by inhibiting the CpG hypermethylation of microRNA-181a.
epigenetics	hsa-mir-140	Osteoarthritis	26723856	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Some miRNA have also been identified and more extensively characterized, such as delineation of the role played by miR-140 in chondrogenesis, followed by the discovery of numerous miRNA potentially involved  in the epigenetic regulation of osteoarthritic disease.
epigenetics	hsa-mir-148a	Osteoporosis	27900532	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	MiR-148a the epigenetic regulator of bone homeostasis is increased in plasma of osteoporotic postmenopausal women.
epigenetics	hsa-mir-127	Osteosarcoma	22957032	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma.
epigenetics	hsa-mir-328	Osteosarcoma	25605016	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	the role of RESV-induced molecular and epigenetic regulation in suppressing tumor metastasis.
epigenetics	hsa-mir-411	Osteosarcoma	22957032	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma.
epigenetics	hsa-mir-431	Osteosarcoma	22957032	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma.
epigenetics	hsa-mir-432	Osteosarcoma	22957032	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Treatment with 4-phenylbutyrate increased acetylation of histones associated with 14q32 miRNAs, but interestingly, robust restoration of 14q32 miRNA expression, attenuation of cMYC expression, and induction of apoptosis required concomitant treatment with 5-Azacytidine, an inhibitor of DNA methylation. combination of these chromatin-modifying drugs may be a useful adjuvant in the treatment of rapidly progressive osteosarcoma.
epigenetics	hsa-mir-570	Osteosarcoma	29795113	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma.
epigenetics	hsa-mir-129-2	Ovarian Neoplasms	26519551	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In summary, the obtained data indicate the involvement of methylation in the down-regulation of the studied coding and miRNA genes and suggest the involvement of miR-129-2 in the deregulation of RASSF1(A) via a direct interaction or/and mediators in common pathways (according to KEGG, Gene Ontology (FDR < 0.01), and GeneCards data) in the examined gynecological tumors.
epigenetics	hsa-mir-199b	Ovarian Neoplasms	24659709	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
epigenetics	hsa-mir-29b-1	Ovarian Neoplasms	23179556	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation
epigenetics	hsa-mir-29b-2	Ovarian Neoplasms	23179556	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation
epigenetics	hsa-mir-30d	Ovarian Neoplasms	27141829	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	TET3 inhibits TGF-尾1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells
epigenetics	hsa-mir-34a	Ovarian Neoplasms	26879132	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer.
epigenetics	hsa-mir-34a	Ovarian Neoplasms	21225432	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Ovarian Neoplasms	21225432	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34c	Ovarian Neoplasms	21225432	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-9-1	Ovarian Neoplasms	26519551	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In summary, the obtained data indicate the involvement of methylation in the down-regulation of the studied coding and miRNA genes and suggest the involvement of miR-129-2 in the deregulation of RASSF1(A) via a direct interaction or/and mediators in common pathways (according to KEGG, Gene Ontology (FDR < 0.01), and GeneCards data) in the examined gynecological tumors.
epigenetics	hsa-mir-200	Ovarian Serous Cystadenocarcinoma	27746113	disease of cellular proliferation	DOID:5746		D018284			DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis.
epigenetics	hsa-mir-107	Pancreatic Neoplasms	19407485	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer.
epigenetics	hsa-mir-124-1	Pancreatic Neoplasms	23334332	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1
epigenetics	hsa-mir-124-2	Pancreatic Neoplasms	23334332	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1
epigenetics	hsa-mir-124-3	Pancreatic Neoplasms	23334332	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1
epigenetics	hsa-mir-132	Pancreatic Neoplasms	21665894	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development.
epigenetics	hsa-mir-21	Pancreatic Neoplasms	24460329	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-21 upregulation induced by histone acetylation in the promoter zone is associated with chemoresistance to gemcitabine and enhanced malignant potential in pancreatic cancer cells.
epigenetics	hsa-mir-27a	Pancreatic Neoplasms	20488920	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		microRNA-27a:Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a
epigenetics	hsa-mir-34a	Pancreatic Neoplasms	21225432	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Pancreatic Neoplasms	21225432	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34c	Pancreatic Neoplasms	21225432	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Pleural Mesothelioma	24168922	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Our digital MSP assay can quantify miR-34b/c methylation in serum-circulating DNA. The degree of miR-34b/c methylation in serum-circulating DNA is associated with MPM, suggesting that this approach might be useful for the establishment of a new detection system for MPM.
epigenetics	hsa-mir-34c	Pleural Mesothelioma	24168922	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Our digital MSP assay can quantify miR-34b/c methylation in serum-circulating DNA. The degree of miR-34b/c methylation in serum-circulating DNA is associated with MPM, suggesting that this approach might be useful for the establishment of a new detection system for MPM.
epigenetics	hsa-mir-106b	Polycystic Ovarian Syndrome	25243570	syndrome	DOID:11612	E28.2	D011085	184700		Our data suggest that the expression of MCM7 and miR-93/25 is PCOSand IR related, whereas that of miR-106b is related to IR only. In 3T3-L1 adipocytes, neither hyperglycemia nor hyperinsulinemia altered the expression of miR-93 or miR-25, although increasing glucose levels down-regulated MCM7 and paradoxically increased that of miR-106b expression. The expression of the miR-25/93/106b family may be regulated through mechanisms distinct from its host gene, MCM7. Finally, our studies suggest potential epigenetic mechanisms for both IR and PCOS.
epigenetics	hsa-mir-25	Polycystic Ovarian Syndrome	25243570	syndrome	DOID:11612	E28.2	D011085	184700		Our data suggest that the expression of MCM7 and miR-93/25 is PCOSand IR related, whereas that of miR-106b is related to IR only. In 3T3-L1 adipocytes, neither hyperglycemia nor hyperinsulinemia altered the expression of miR-93 or miR-25, although increasing glucose levels down-regulated MCM7 and paradoxically increased that of miR-106b expression. The expression of the miR-25/93/106b family may be regulated through mechanisms distinct from its host gene, MCM7. Finally, our studies suggest potential epigenetic mechanisms for both IR and PCOS.
epigenetics	hsa-mir-93	Polycystic Ovarian Syndrome	25243570	syndrome	DOID:11612	E28.2	D011085	184700		Our data suggest that the expression of MCM7 and miR-93/25 is PCOSand IR related, whereas that of miR-106b is related to IR only. In 3T3-L1 adipocytes, neither hyperglycemia nor hyperinsulinemia altered the expression of miR-93 or miR-25, although increasing glucose levels down-regulated MCM7 and paradoxically increased that of miR-106b expression. The expression of the miR-25/93/106b family may be regulated through mechanisms distinct from its host gene, MCM7. Finally, our studies suggest potential epigenetic mechanisms for both IR and PCOS.
epigenetics	hsa-mir-34a	Preeclampsia	29557690	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Hypomethylation of the miRNA-34a gene promoter is associated with Severe Preeclampsia
epigenetics	hsa-mir-124	Prostate Neoplasms	25860954	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
epigenetics	hsa-mir-1256	Prostate Neoplasms	22805767	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.
epigenetics	hsa-mir-125b-2	Prostate Neoplasms	25728837	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our work underlined the importance of histone demethylation and DNA oxidation/repairing machinery in androgen-dependent transcription. The present finds have implications for research into new druggable targets for prostate cancer relying on the cascade of AR activity regulation.
epigenetics	hsa-mir-1260b	Prostate Neoplasms	24504368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that genistein exerts its anti-tumour effect via downregulation of miR-1260b that targeted sRRP1 and Smad4 genes in prostate cancer cells. The expression of sFRP1 and Smad4 was also modulated by genistein via DNA methylation or histone modifications in PC cell lines.
epigenetics	hsa-mir-127	Prostate Neoplasms	17355635	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene.
epigenetics	hsa-mir-132	Prostate Neoplasms	22310291	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	DNA methylation silences miR-132 in prostate cancer.
epigenetics	hsa-mir-133b	Prostate Neoplasms	25728837	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our work underlined the importance of histone demethylation and DNA oxidation/repairing machinery in androgen-dependent transcription. The present finds have implications for research into new druggable targets for prostate cancer relying on the cascade of AR activity regulation.
epigenetics	hsa-mir-141	Prostate Neoplasms	27198154	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-200c and miR-141 are under epigenetic regulation in PCa cells.
epigenetics	hsa-mir-145	Prostate Neoplasms	25749421	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	A feedback regulation between miR-145 and DNA methyltransferase 3b in prostate cancer cell and their responses to irradiation.
epigenetics	hsa-mir-145	Prostate Neoplasms	21349819	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	this is the first report documenting that downregulation of miR-145 is through DNA methylation and p53 mutation pathways in prostate cancer.
epigenetics	hsa-mir-146a	Prostate Neoplasms	24885368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Up-regulating miR-146a expression via the hypomethylation of the miR-146a promoter by 5-Aza-CdR was correlated with delayed progression of castration-resistant prostate cancers. Moreover, site-specific DNA methylation may play an important role in miR-146a expression in androgen-dependent prostate cancer progression to androgen-independent prostate cancer and therefore provides a potentially useful biomarker for assessing drug efficacy in prostate cancer.
epigenetics	hsa-mir-148a	Prostate Neoplasms	29596883	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-148a is silenced by DNA methylation and ectopic expression of miR-148a suppresses DNMT1 expression and induced apoptotic genes expression in hormone-refractory prostate cancer cells
epigenetics	hsa-mir-193b	Prostate Neoplasms	20073067	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-193b:miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer
epigenetics	hsa-mir-193b	Prostate Neoplasms	28143614	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.
epigenetics	hsa-mir-196b	Prostate Neoplasms	21255435	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We find miR-205, miR-21, and miR-196b to be epigenetically repressed, and miR-615 epigenetically activated in prostate cancer cells.
epigenetics	hsa-mir-200c	Prostate Neoplasms	27198154	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-200c and miR-141 are under epigenetic regulation in PCa cells.
epigenetics	hsa-mir-205	Prostate Neoplasms	21255435	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We find miR-205, miR-21, and miR-196b to be epigenetically repressed, and miR-615 epigenetically activated in prostate cancer cells.
epigenetics	hsa-mir-205	Prostate Neoplasms	22869146	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer.
epigenetics	hsa-mir-21	Prostate Neoplasms	21255435	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We find miR-205, miR-21, and miR-196b to be epigenetically repressed, and miR-615 epigenetically activated in prostate cancer cells.
epigenetics	hsa-mir-224	Prostate Neoplasms	24737792	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The GABRE-miR-452-miR-224 locus is downregulated and hypermethylated in prostate cancer and is a new promising epigenetic candidate biomarker for prostate cancer diagnosis and prognosis. Tumor-suppressive functions of the intronic miR-224 and miR-452 were demonstrated in two prostate cancer cell lines,suggesting that epigenetic silencing of GABRE/miR-452/miR-224 may be selected for in prostate cancer.
epigenetics	hsa-mir-23b	Prostate Neoplasms	23074286	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-23b Represses Proto-oncogene Src Kinase and Functions as Methylation-Silenced Tumor Suppressor with Diagnostic and Prognostic Significance in Prostate Cancer
epigenetics	hsa-mir-29a	Prostate Neoplasms	22805767	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.
epigenetics	hsa-mir-31	Prostate Neoplasms	23233736	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression
epigenetics	hsa-mir-34a	Prostate Neoplasms	22347519	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
epigenetics	hsa-mir-34b	Prostate Neoplasms	23147995	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways
epigenetics	hsa-mir-375	Prostate Neoplasms	24173286	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen receptor is negatively correlated with the methylation-mediated transcriptional repression of miR-375 in human prostate cancer cells.
epigenetics	hsa-mir-452	Prostate Neoplasms	24737792	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The GABRE-miR-452-miR-224 locus is downregulated and hypermethylated in prostate cancer and is a new promising epigenetic candidate biomarker for prostate cancer diagnosis and prognosis. Tumor-suppressive functions of the intronic miR-224 and miR-452 were demonstrated in two prostate cancer cell lines,suggesting that epigenetic silencing of GABRE/miR-452/miR-224 may be selected for in prostate cancer.
epigenetics	hsa-mir-124	Pulmonary Hypertension	24385500	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Deacetylation of MicroRNA-124 in fibroblasts: role in pulmonary hypertension.
epigenetics	hsa-mir-203	Rhabdomyosarcoma	24247238	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.
epigenetics	hsa-mir-214	Rhabdomyosarcoma	24811402	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis.
epigenetics	hsa-mir-124a	Rheumatoid Arthritis	24223605	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The methylation status of miR-124a seen in this study concurs with that reported in tumor cells, indicating epigenetic dysregulation constituents, a mechanism in the development of rheumatoid arthritis.
epigenetics	hsa-mir-124a	Rheumatoid Arthritis	27824863	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Demethylation of MicroRNA-124a Genes Attenuated Proliferation of Rheumatoid Arthritis Derived Fibroblast-Like Synoviocytes and Synthesis of Tumor Necrosis Factor-α.
epigenetics	hsa-mir-126	Rheumatoid Arthritis	26464634	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Correlation between miR-126 expression and DNA hypomethylation of CD4+ T cells in rheumatoid arthritis patients.
epigenetics	hsa-mir-34a	Sarcoma [unspecific]	21225432	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Sarcoma [unspecific]	21225432	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34c	Sarcoma [unspecific]	21225432	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Sarcomatoid Mesothelioma	26870271	disease of cellular proliferation	DOID:4488					miR-34b/c was heavily methylated in 2/4 established MPM cell lines
epigenetics	hsa-mir-34c	Sarcomatoid Mesothelioma	26870271	disease of cellular proliferation	DOID:4488					miR-34b/c was heavily methylated in 2/4 established MPM cell lines
epigenetics	hsa-mir-148a	Skin Neoplasms	26638007	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	Taken together, the expression of miR-148a was regulated by DNA methylation and targeted by TGIF2.Its methylation may be a potential prognostic indicator in skin cancer.
epigenetics	hsa-mir-34b	Soft Tissue Sarcoma	25773680			C49.9	D012509		HP:0030448	Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas.
epigenetics	hsa-mir-34c	Soft Tissue Sarcoma	25773680			C49.9	D012509		HP:0030448	Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas.
epigenetics	hsa-mir-10b	Squamous Cell Carcinoma	25312779	disease of cellular proliferation	DOID:1749		D002294			Reduction of TIP30 in esophageal squamous cell carcinoma cells involves promoter methylation and microRNA-10b.
epigenetics	hsa-mir-297	Squamous Cell Carcinoma	24394434	disease of cellular proliferation	DOID:1749		D002294			Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas.
epigenetics	hsa-mir-485	Squamous Cell Carcinoma	24394434	disease of cellular proliferation	DOID:1749		D002294			Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas.
epigenetics	hsa-mir-92b	Squamous Cell Carcinoma	24394434	disease of cellular proliferation	DOID:1749		D002294			Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas.
epigenetics	hsa-mir-129-2	Squamous Cell Carcinoma, Esophageal	21547903	disease of cellular proliferation	DOID:3748		C562729			The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
epigenetics	hsa-mir-145	Squamous Cell Carcinoma, Esophageal	26254350	disease of cellular proliferation	DOID:3748		C562729			Suppressor microRNA-145 Is Epigenetically Regulated by Promoter Hypermethylation in Esophageal Squamous Cell Carcinoma.
epigenetics	hsa-mir-34a	Squamous Cell Carcinoma, Esophageal	21547903	disease of cellular proliferation	DOID:3748		C562729			The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
epigenetics	hsa-mir-34b	Squamous Cell Carcinoma, Esophageal	21547903	disease of cellular proliferation	DOID:3748		C562729			The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
epigenetics	hsa-mir-34c	Squamous Cell Carcinoma, Esophageal	21547903	disease of cellular proliferation	DOID:3748		C562729			The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
epigenetics	hsa-mir-10b	Squamous Cell Carcinoma, Head and Neck	27002147	disease of cellular proliferation	DOID:5520	C76.0	C535575			DOT1L-associated  epigenetic changes induced by HA play pivotal roles in miR-10 production leading  to up-regulation of RhoGTPase and survival proteins.
epigenetics	hsa-mir-137	Squamous Cell Carcinoma, Head and Neck	21425146	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck.
epigenetics	hsa-mir-34a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27450916	disease of cellular proliferation	DOID:2876					Our study revealed that miR-34a promoter hypermethylation was a risk factor for LSCC, played a critical role in the disease progression and metastasis, and could serve as a poor prognostic factor for LSCC.
epigenetics	hsa-mir-137	Squamous Cell Carcinoma, Oral	20197299	disease of cellular proliferation	DOID:0050866					miR-137:MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index
epigenetics	hsa-mir-137	Squamous Cell Carcinoma, Oral	23121285	disease of cellular proliferation	DOID:0050866					MicroRNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma
epigenetics	hsa-mir-9-1	Squamous Cell Carcinoma, Oral	22133638	disease of cellular proliferation	DOID:0050866					Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas.
epigenetics	hsa-mir-9-3	Squamous Cell Carcinoma, Oral	22133638	disease of cellular proliferation	DOID:0050866					Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas.
epigenetics	hsa-mir-126	Systemic Lupus Erythematosus	21165896	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-126 regulates DNA methylation in CD4(+) T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1.
epigenetics	hsa-mir-126	Systemic Lupus Erythematosus	21538319	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1.
epigenetics	hsa-mir-126	Systemic Lupus Erythematosus	23981988	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The upregulation of miR-126 and its host gene EGFL7 expression in CD4+ T cells from SLE is associated with the hypomethylation of the EGFL7 promoter.
epigenetics	hsa-mir-142	Systemic Lupus Erythematosus	25661834	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Data from this study suggest that MPA activates miR-142 and miR-146a expression through histone modification at the promoter region, which may partially explain the pharmacological mechanisms of MPA for SLE.
epigenetics	hsa-mir-146a	Systemic Lupus Erythematosus	25661834	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Data from this study suggest that MPA activates miR-142 and miR-146a expression through histone modification at the promoter region, which may partially explain the pharmacological mechanisms of MPA for SLE.
epigenetics	hsa-mir-29b-1	Systemic Lupus Erythematosus	23142053	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1
epigenetics	hsa-mir-29b-2	Systemic Lupus Erythematosus	23142053	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1
epigenetics	hsa-mir-371	Testicular Germ Cell Tumor	28199193	disease of cellular proliferation	DOID:5557		C563236	273300		Epigenetic and risk factors of testicular germ cell tumors: a brief review.
epigenetics	hsa-mir-373	Testicular Germ Cell Tumor	28199193	disease of cellular proliferation	DOID:5557		C563236	273300		Epigenetic and risk factors of testicular germ cell tumors: a brief review.
epigenetics	hsa-mir-199a	Testicular Neoplasms	23959088	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	microRNA-199a-3p, DNMT3A, and aberrant DNA methylation in testicular cancer.
epigenetics	hsa-mir-199a-1	Testicular Neoplasms	21383689	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	PODXL is a downstream effector mediating the action of miR199a-5p. This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy.
epigenetics	hsa-mir-199a-2	Testicular Neoplasms	21383689	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	PODXL is a downstream effector mediating the action of miR199a-5p. This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy.
epigenetics	hsa-mir-129-1	Thyroid Neoplasms	21946411	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Two HDACi, Trichostatin A and vorinostat, induced miR-129-5p overexpression, histone acetylation and cell death. In addition, miR-129-5p alone was sufficient to induce cell death and knockdown experiments showed that expression of this miRNA was required for HDACi-induced cell death. Moreover, miR-129-5p was also able to improve the anti-proliferative effects of other cancer drugs such as etoposide or HAMLET (human alpha lactalbumin made letal for tumor cells). Taken together, the data show that miR-129-5p is involved in the antitumor activity of HDACi and highlight that miRNA-driven cell death may be an efficient approach to cancer treatment.
epigenetics	hsa-mir-129-2	Thyroid Neoplasms	21946411	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Two HDACi, Trichostatin A and vorinostat, induced miR-129-5p overexpression, histone acetylation and cell death. In addition, miR-129-5p alone was sufficient to induce cell death and knockdown experiments showed that expression of this miRNA was required for HDACi-induced cell death. Moreover, miR-129-5p was also able to improve the anti-proliferative effects of other cancer drugs such as etoposide or HAMLET (human alpha lactalbumin made letal for tumor cells). Taken together, the data show that miR-129-5p is involved in the antitumor activity of HDACi and highlight that miRNA-driven cell death may be an efficient approach to cancer treatment.
epigenetics	hsa-mir-1224	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-1227	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-1229	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-127	Urinary Bladder Cancer	17355635	urinary system disease	DOID:11054	C67	D001749	109800		Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene.
epigenetics	hsa-mir-149	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-203	Urinary Bladder Cancer	21461574	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation of miR-124a and miR-203 in the precursor lesions compared to the control samples
epigenetics	hsa-mir-210	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-212	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-328	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-34a	Urinary Bladder Cancer	21225432	urinary system disease	DOID:11054	C67	D001749	109800		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34b	Urinary Bladder Cancer	21225432	urinary system disease	DOID:11054	C67	D001749	109800		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-34c	Urinary Bladder Cancer	21225432	urinary system disease	DOID:11054	C67	D001749	109800		Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
epigenetics	hsa-mir-503	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-9-1	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-9-2	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-9-3	Urinary Bladder Cancer	21138856	urinary system disease	DOID:11054	C67	D001749	109800		hypermethylation was more frequent and dense in CpG shores than islands
epigenetics	hsa-mir-143	Vascular Disease [unspecific]	26573388	cardiovascular system disease	DOID:178	I72.9	D000783			Taken together, these findings suggest that DNMT3a is a direct target of miR-143, and that the upregulation of DNMT3 is responsible for the hypermethylation of miR-143 in Hcy-induced VSMC proliferation.
epigenetics	hsa-mir-206	Waldenstrom Macroglobulinemia	20519629			C88.0	D008258	153600	HP:0005508	miR-206:Waldenström macroglobulinemia (WM) cells present with increased expression of microRNA-206 (miRNA-206) and reduced expression of miRNA-9
epigenetics	hsa-mir-9-1	Waldenstrom Macroglobulinemia	20519629			C88.0	D008258	153600	HP:0005508	miR-9:Waldenström macroglobulinemia (WM) cells present with increased expression of microRNA-206 (miRNA-206) and reduced expression of miRNA-9
epigenetics	hsa-mir-9-2	Waldenstrom Macroglobulinemia	20519629			C88.0	D008258	153600	HP:0005508	miR-9:Waldenström macroglobulinemia (WM) cells present with increased expression of microRNA-206 (miRNA-206) and reduced expression of miRNA-9
epigenetics	hsa-mir-34b	Wilms Tumor	25625843			C64.2	D009396	PS194070	HP:0002667	Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
genetics_GWAS	hsa-mir-146a	Acute Cerebral Infarction	23202363	cardiovascular system disease	DOID:3526	I63	D002544			Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk
genetics_GWAS	hsa-mir-149	Acute Cerebral Infarction	23202363	cardiovascular system disease	DOID:3526	I63	D002544			Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk
genetics_GWAS	hsa-mir-196a-1	Acute Cerebral Infarction	23202363	cardiovascular system disease	DOID:3526	I63	D002544			Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk
genetics_GWAS	hsa-mir-196a-2	Acute Cerebral Infarction	23202363	cardiovascular system disease	DOID:3526	I63	D002544			Association of the miR-146a, miR-149, miR-196a2, and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk
genetics_GWAS	hsa-mir-146a	Acute Coronary Syndrome	26537765			I24.9	D054058			These findings indicate that miR-146a rs2910164 may act as a novel molecular marker for ACS susceptibility.
genetics_GWAS	hsa-mir-107	Adenocarcinoma, Gastric	25771723	disease of cellular proliferation	DOID:3717	D37.1	D013274			miR-107 is dysregulated in GAC pathogenesis and the SNP rs2296616 may play a role in the process.
genetics_GWAS	hsa-mir-199a	Adenocarcinoma, Pancreatic Ductal	26872370	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		our study demonstrates that host genetic variants could disturb the regulation of the miR-199a/HIF1A regulatory loop and alter PDAC risk and poor prognosis.
genetics_GWAS	hsa-mir-146a	Alcohol Use Disorder	24630744	disease of mental health	DOID:1574	F10.1	D000437			This is the first genetic association study to explore the relationship of miRNA polymorphisms with AUDs and to show an association of the miR-146a C>G rs2910164 allelic variant with this disease.
genetics_GWAS	hsa-mir-149	Allergic Rhinitis	28181414	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	A functional variant of miRNA-149 confers risk for allergic rhinitis and comorbid asthma in Chinese children.
genetics_GWAS	hsa-mir-146a	Alzheimer Disease	24586483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A functional polymorphism in the promoter region of microRNA-146a is associated with the risk of Alzheimer disease and the rate of cognitive decline in patients.
genetics_GWAS	hsa-mir-146a	Alzheimer Disease	26095531	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A single nucleotide polymorphism in primary-microRNA-146a reduces the expression of mature microRNA-146a in patients with Alzheimer's disease and is associated with the pathogenesis of Alzheimer's disease.
genetics_GWAS	hsa-mir-146a	Ankylosing Spondylitis	25836258	musculoskeletal system disease	DOID:7147	M45.9	D013167			Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms.
genetics_GWAS	hsa-mir-499	Ankylosing Spondylitis	25836258	musculoskeletal system disease	DOID:7147	M45.9	D013167			Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms.
genetics_GWAS	hsa-mir-128	Anxiety Disorders	19370765	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
genetics_GWAS	hsa-mir-148a	Anxiety Disorders	19370765	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
genetics_GWAS	hsa-mir-148b	Anxiety Disorders	19370765	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
genetics_GWAS	hsa-mir-152	Anxiety Disorders	19370765	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
genetics_GWAS	hsa-mir-485	Anxiety Disorders	19370765	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
genetics_GWAS	hsa-mir-509	Anxiety Disorders	19370765	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
genetics_GWAS	hsa-mir-765	Anxiety Disorders	19370765	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
genetics_GWAS	hsa-mir-146a	Arthritis	25269878	musculoskeletal system disease	DOID:848	M19.90	D001168			This meta-analysis suggests that the miR-499 rs374644 and IRAKI rs3027898 polymorphisms are associated with susceptibility to inflammatory arthritis.
genetics_GWAS	hsa-mir-499	Arthritis	25269878	musculoskeletal system disease	DOID:848	M19.90	D001168			This meta-analysis suggests that the miR-499 rs374644 and IRAKI rs3027898 polymorphisms are associated with susceptibility to inflammatory arthritis.
genetics_GWAS	hsa-mir-146a	Asthma	22823586	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MiR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients.
genetics_GWAS	hsa-mir-146a	Asthma	27431205	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	The miR鈥?46a rs2910164 polymorphism CC genotype was identified to be significantly associated with a decreased risk of BHR in response to intubation when compared with the GG or GC genotype (odds ratio, 0.38; confidence interval, 0.18鈥?.78).
genetics_GWAS	hsa-mir-152	Asthma	27383317	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Single nucleotide polymorphisms in the promoter region of mir-133a-1 and in pre-mir-152 rs1707 may contribute to the risk of asthma in a Chinese Han population.
genetics_GWAS	hsa-mir-196a2	Asthma	27487239	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	microRNA-196a2 rs11614913 polymorphism might be associated with asthma severity in our sample of the Egyptian population.
genetics_GWAS	hsa-mir-146a	Atherosclerosis	26875519	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Apolipoprotein E Epsilon 4 Enhances the Association between the rs2910164 Polymorphism of miR-146a and Risk of Atherosclerotic Cerebral Infarction.
genetics_GWAS	hsa-mir-146a	Atherosclerosis	28674224	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Association of NFKB1A and microRNAs variations and the susceptibility to atherosclerosis.
genetics_GWAS	hsa-mir-196a2	Atrial Fibrillation	26554236	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Our data support that the pre-miR-196a2 polymorphism is associated with AF, and the C allele is a risk factor for AF.
genetics_GWAS	hsa-mir-4436b-1	Autism Spectrum Disorder	24667286	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	Assessing the impact of copy number variants on miRNA genes in autism by Monte Carlo simulation.
genetics_GWAS	hsa-mir-4436b-2	Autism Spectrum Disorder	24667286	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	Assessing the impact of copy number variants on miRNA genes in autism by Monte Carlo simulation.
genetics_GWAS	hsa-mir-146a	Autoimmune Diseases [unspecific]	25830862				D001327	607836	HP:0002960	MiR-146a rs2910164 G>C polymorphism was associated with the susceptibility of ADs.
genetics_GWAS	hsa-mir-125a	Autoimmune Thyroiditis	24990808	immune system disease	DOID:7188	E06.3	D013967	109100		Associations of single nucleotide polymorphisms in precursor-microRNA (miR)-125a and the expression of mature miR-125a with the development and prognosis of autoimmune thyroid diseases.
genetics_GWAS	hsa-mir-146a	Behcet Disease	23268366	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome
genetics_GWAS	hsa-mir-146a	Behcet Disease	26053525	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		Association of Pre-miRNA-499 rs3746444 and Pre-miRNA-146a rs2910164 Polymorphisms and Susceptibility to Behcet's Disease.
genetics_GWAS	hsa-mir-182	Behcet Disease	24801147	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		Predisposition to Behcet's disease and VKH syndrome by genetic variants of miR-182.
genetics_GWAS	hsa-mir-499	Behcet Disease	26053525	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		Association of Pre-miRNA-499 rs3746444 and Pre-miRNA-146a rs2910164 Polymorphisms and Susceptibility to Behcet's Disease.
genetics_GWAS	hsa-mir-140	Bladder Neoplasms	26695686			C67	D001749	109800	HP:0009725	Together, these results suggest that rs35592567 in TP63 may be a novel causal variant contributing to the susceptibility to bladder cancer, which provides additional insight into the pathogenesis of bladder carcinogenesis.
genetics_GWAS	hsa-mir-143	Bladder Neoplasms	27438131			C67	D001749	109800	HP:0009725	These findings suggest that the functional rs353293 polymorphism may  be a useful biomarker to predict the risk of bladder cancer.
genetics_GWAS	hsa-mir-145	Bladder Neoplasms	27438131			C67	D001749	109800	HP:0009725	These findings suggest that the functional rs353293 polymorphism may  be a useful biomarker to predict the risk of bladder cancer.
genetics_GWAS	hsa-mir-146a	Bladder Neoplasms	29491365			C67	D001749	109800	HP:0009725	miR-146a rs2910164 polymorphism is a risk factor for urological neoplasms, particularly for bladder cancer
genetics_GWAS	hsa-mir-21	Bladder Neoplasms	24078506			C67	D001749	109800	HP:0009725	In accordance to the observed similarity between TGF-β variants and miR-21 gene expression alterations in bladder tumors, treating 5637 bladder cancer cell line with TGF-β recombinant protein caused a significant upregulation of miR-21. The later finding further confirmed a correlated expression of TGF-βand miR-21 in bladder tumors.
genetics_GWAS	hsa-mir-27b	Bladder Neoplasms	24312312			C67	D001749	109800	HP:0009725	Taken together, these findings suggested that DROSHA rs10719T>C polymorphism may be associated with bladder cancer risk in a Chinese population, and hsa-miR-27b can influence the expression of DROSHA protein by binding with 3'UTR.
genetics_GWAS	hsa-mir-101-1	Breast Neoplasms	24475105	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Genetic variations in the flanking regions of miR-101-2 are associated with increased risk of breast cancer.
genetics_GWAS	hsa-mir-101-2	Breast Neoplasms	24475105	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Genetic variations in the flanking regions of miR-101-2 are associated with increased risk of breast cancer.
genetics_GWAS	hsa-mir-103a-2	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-106b	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-1-1	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-124-1	Breast Neoplasms	21318219	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.
genetics_GWAS	hsa-mir-124-2	Breast Neoplasms	21318219	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.
genetics_GWAS	hsa-mir-124-3	Breast Neoplasms	21318219	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.
genetics_GWAS	hsa-mir-125a	Breast Neoplasms	23420759	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	rs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients
genetics_GWAS	hsa-mir-125b	Breast Neoplasms	26190157	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Evaluation the susceptibility of five polymorphisms in microRNA-binding sites to female breast cancer risk in Chinese population.
genetics_GWAS	hsa-mir-125b	Breast Neoplasms	19738052	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.
genetics_GWAS	hsa-mir-133a-2	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-135b	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-145	Breast Neoplasms	26577090	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our study is the first to report an association between a miR-SNP in MIR145 and breast cancer risk in individuals of Caucasian background. This finding requires further validation through genotyping of larger cohorts or in individuals of different ethnicities to determine the potential significance of this finding as well as studies aimed to determine functional significance.
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	24039706	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This meta-analysis demonstrates the compelling evidence that the rs11614913 CC genotype in miR-196a2 increases breast cancer risk, which provides useful information for the early diagnosis and prevention of breast cancer.
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	26476291	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The microRNA miR146a has a potential role in the development of breast cancer and the effects of its SNPs require further inquiry to determine the nature of their influence on breast tissue and cancer.
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	18634034	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-146: rs2910164 were associated with increased risk of breast cancer in Chinese women
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	18660546	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-146a: A functional polymorphism (rs2910164) in the miR-146a gene and age of familial breast/ovarian cancer diagnosis
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	22363415	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The authors found that hs-miR-196a2 in premenopausal patients, and hs-miR-499, hs-miR-146a and hs-miR-196a2 in postmenopausal patients, may discriminate breast cancer patients from healthy individuals. In addition, we found a significant association between two microRNA polymorphisms (hs-miR-196a2 and hs-miR-499) and breast cancer risk.
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	22363684	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased Risk of Breast Cancer Associated with CC Genotype of Has-miR-146a Rs2910164 Polymorphism in Europeans.
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	26785832	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	e identified one rare variant in MIR146A, four in MIR146B, five in BRCA1 3'-UTR and one in BRCA2 3'-UTR in 716 index cases and 619  controls.
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	27434289	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Logistic regression data represented the C allele of rs2910164 (OR = 4.00, p= 0.0037) as the risk allele and associated with Her2-positive phenotype.
genetics_GWAS	hsa-mir-146a	Breast Neoplasms	29521182	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Effects of miR-27a, miR-196a2 and miR-146a polymorphisms on the risk of breast cancer
genetics_GWAS	hsa-mir-146b	Breast Neoplasms	18634034	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-146: rs2910164 were associated with increased risk of breast cancer in Chinese women
genetics_GWAS	hsa-mir-146b	Breast Neoplasms	26785832	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified one rare variant in MIR146A, four in MIR146B, five in BRCA1 3'-UTR and one in BRCA2 3'-UTR in 716 index cases and 619  controls.
genetics_GWAS	hsa-mir-149	Breast Neoplasms	18634034	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-149: rs2292832 were associated with increased risk of breast cancer in Chinese women
genetics_GWAS	hsa-mir-151a	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-153-2	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-17	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-17	Breast Neoplasms	19048628	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-17: mutations
genetics_GWAS	hsa-mir-17	Breast Neoplasms	21140207	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SNP (rs3739008) located at 3'UTR of NPAS2 and the C to T changing of the SNP may disrupt the binding of microRNA- (miR-)17-5p and miR-519e to the 3'UTR of NPAS2
genetics_GWAS	hsa-mir-17	Breast Neoplasms	25680407	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer.
genetics_GWAS	hsa-mir-18	Breast Neoplasms	25680407	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer.
genetics_GWAS	hsa-mir-18a	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-194-1	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-196a	Breast Neoplasms	24039706	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This meta-analysis demonstrates the compelling evidence that the rs11614913 CC genotype in miR-196a2 increases breast cancer risk, which provides useful information for the early diagnosis and prevention of breast cancer.
genetics_GWAS	hsa-mir-196a	Breast Neoplasms	24922658	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The current study provides evidence that the miR-196a rs11614913T>C polymorphisms are possible prognostic biomarker for patients with hormone receptor-expressing early breast cancer.
genetics_GWAS	hsa-mir-196a-1	Breast Neoplasms	23228090	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Evaluation of single nucleotide polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	26125831	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results suggested that miR-146a rs2910164 G>C and miR-196a2 rs11614913 T>C may be biomarkers for predicting breast cancer risk in the Chinese population.
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	23982873	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the current meta-analysis supports that the miR-196a-2 rs11614913*T, miR-499 rs3746444*T, miR-605 rs2043556*A, and miR-27a rs895919*C alleles might be protective factors for breast cancer
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	26710106	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Somatic Mutation of the SNP rs11614913 and Its Association with Increased MIR 196A2 Expression in Breast Cancer.
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	18634034	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-196a-2: rs11614913 were associated with increased risk of breast cancer in Chinese women
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	21483822	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	rs11614913 polymorphism:Overall, individuals with the TC/CC genotypes were associated with higher cancer risk than those with the TT genotype (OR=1.18, 95% CI=1.03-1.34, P<0.001 for heterogeneity test). In the stratified analyses, we observed that the CC genotype might modulate breast cancer risk (OR=1.11, 95%CI=1.01-1.23, P(heterogeneity)=0.210) and lung cancer risk (OR=1.25, 95%CI=1.06-1.46, P(heterogeneity)=0.958), comparing with the TC/TT genotype. Moreover, a significantly increased risk was found among Asian populations in a dominant model (TC/CC versus TT, OR=1.24, 95% CI=1.07-1.43, P(heterogeneity)=0.006).
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	22074121	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The Chinese women with menarche age less than 16 years had increased breast cancer risk (OR = 2.10, 95% CI: 1.23-3.60). Marginally significant association between rs11614913 (hsa-miR-196a-2) CT/CC genotypes and reduced breast cancer risk was observed (OR = 0.65, 95% CI: 0.40-1.06),
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	22363415	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The authors found that hs-miR-196a2 in premenopausal patients, and hs-miR-499, hs-miR-146a and hs-miR-196a2 in postmenopausal patients, may discriminate breast cancer patients from healthy individuals. In addition, we found a significant association between two microRNA polymorphisms (hs-miR-196a2 and hs-miR-499) and breast cancer risk.
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	23228090	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Evaluation of single nucleotide polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer
genetics_GWAS	hsa-mir-196a-2	Breast Neoplasms	29521182	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Effects of miR-27a, miR-196a2 and miR-148a polymorphisms on the risk of breast cancer
genetics_GWAS	hsa-mir-199a-2	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-19a	Breast Neoplasms	25680407	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer.
genetics_GWAS	hsa-mir-19a	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-19b-1	Breast Neoplasms	25680407	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer.
genetics_GWAS	hsa-mir-19b-1	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-200a	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-200b	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-20a	Breast Neoplasms	25680407	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer.
genetics_GWAS	hsa-mir-20a	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-214	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-215	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-218-1	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-219-1	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-25	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-27a	Breast Neoplasms	23982873	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the current meta-analysis supports that the miR-196a-2 rs11614913*T, miR-499 rs3746444*T, miR-605 rs2043556*A, and miR-27a rs895919*C alleles might be protective factors for breast cancer
genetics_GWAS	hsa-mir-27a	Breast Neoplasms	25556434	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	an association between pre-miR-27a polymorphism rs895819 and cancer risk in Caucasians. The protective effect of rs895819 [G] allele in younger breast cancer and in the group of unilateral breast cancer patients await further confirmation since the included studies in this meta-analysis were limited.
genetics_GWAS	hsa-mir-27a	Breast Neoplasms	23954879	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A genetic variant in pre-miR-27a is associated with a reduced breast cancer risk  in younger Chinese population.
genetics_GWAS	hsa-mir-27a	Breast Neoplasms	29521182	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Effects of miR-27a, miR-196a2 and miR-147a polymorphisms on the risk of breast cancer
genetics_GWAS	hsa-mir-296	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-302a	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-302b	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-302c	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-302d	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-30b	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-30c-1	Breast Neoplasms	19048628	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-30c-1: mutations
genetics_GWAS	hsa-mir-30d	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-320	Breast Neoplasms	26190157	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Evaluation the susceptibility of five polymorphisms in microRNA-binding sites to female breast cancer risk in Chinese population.
genetics_GWAS	hsa-mir-320a	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-338	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-339	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-367	Breast Neoplasms	26190157	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Evaluation the susceptibility of five polymorphisms in microRNA-binding sites to female breast cancer risk in Chinese population.
genetics_GWAS	hsa-mir-367	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-367	Breast Neoplasms	21810988	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Functional SNP (rs1044129, is present in binding region) in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification.
genetics_GWAS	hsa-mir-383	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number loss
genetics_GWAS	hsa-mir-423	Breast Neoplasms	22593246	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A genetic variant (rs6505162:A>C) located in miR-423 is associated with reduced breast cancer risk.
genetics_GWAS	hsa-mir-429	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-485	Breast Neoplasms	25003827	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk.
genetics_GWAS	hsa-mir-488	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-499	Breast Neoplasms	23982873	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the current meta-analysis supports that the miR-196a-2 rs11614913*T, miR-499 rs3746444*T, miR-605 rs2043556*A, and miR-27a rs895919*C alleles might be protective factors for breast cancer
genetics_GWAS	hsa-mir-499	Breast Neoplasms	24039706	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This meta-analysis demonstrates the compelling evidence that the rs11614913 CC genotype in miR-196a2 increases breast cancer risk, which provides useful information for the early diagnosis and prevention of breast cancer.
genetics_GWAS	hsa-mir-499	Breast Neoplasms	24521023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our findings demonstrated that the hsa-mir-499 rs3746444 polymorphism is associated with higher risk of developing breast cancer in our population.
genetics_GWAS	hsa-mir-499	Breast Neoplasms	19847796	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Recently, the SNPs rs11614913 in hsa-mir-196a2 and rs3746444 in hsa-mir-499 were reported to be associated with increased breast cancer risk, and the SNP rs2910164 in hsa-mir-146a was shown to have an effect on age of breast cancer diagnosis.
genetics_GWAS	hsa-mir-499	Breast Neoplasms	23053947	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, this meta-analysis suggests that the miR-499 rs3746444 polymorphism (A>G) is a low-penetrant risk factor for cancer development among Asians and may contribute to breast cancer susceptibility.
genetics_GWAS	hsa-mir-499a	Breast Neoplasms	18634034	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-499: rs3746444 were associated with increased risk of breast cancer in Chinese women
genetics_GWAS	hsa-mir-499a	Breast Neoplasms	22363415	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The authors found that hs-miR-196a2 in premenopausal patients, and hs-miR-499, hs-miR-146a and hs-miR-196a2 in postmenopausal patients, may discriminate breast cancer patients from healthy individuals. In addition, we found a significant association between two microRNA polymorphisms (hs-miR-196a2 and hs-miR-499) and breast cancer risk.
genetics_GWAS	hsa-mir-519e	Breast Neoplasms	21140207	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SNP (rs3739008) located at 3'UTR of NPAS2 and the C to T changing of the SNP may disrupt the binding of microRNA- (miR-)17-5p and miR-519e to the 3'UTR of NPAS2
genetics_GWAS	hsa-mir-603	Breast Neoplasms	26718432	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion,the findings indicated that Mir603 rs11014002 T allele might contribute to decrease the risk of BC in a sample of Iranian population. Further studies with larger sample sizes and different ethnicities are warranted to confirm our findings.
genetics_GWAS	hsa-mir-605	Breast Neoplasms	23982873	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the current meta-analysis supports that the miR-196a-2 rs11614913*T, miR-499 rs3746444*T, miR-605 rs2043556*A, and miR-27a rs895919*C alleles might be protective factors for breast cancer
genetics_GWAS	hsa-mir-608	Breast Neoplasms	22586447	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes.
genetics_GWAS	hsa-mir-6826	Breast Neoplasms	27380242	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We systematically put together a list of 822 and 10,468 genetic variants among primary miRNA sequences and 38 genes in the miRNA biogenesis pathway
genetics_GWAS	hsa-mir-9-1	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-92-1	Breast Neoplasms	25680407	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Association of microRNA 17-92 cluster host gene (MIR17HG) polymorphisms with breast cancer.
genetics_GWAS	hsa-mir-92a	Breast Neoplasms	26471763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MDM4 SNP34091 status to be associated with reduced risk of breast cancer, in particular in individuals carrying the MDM2 SNP309GG genotype, but not to be associated with either lung-, colon- or prostate cancer.
genetics_GWAS	hsa-mir-93	Breast Neoplasms	16754881	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	copy number gain
genetics_GWAS	hsa-mir-200b	Carcinoma, Breast	27609814			D05	D001943	114480	HP:0003002	Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 3'UTR activity
genetics_GWAS	hsa-mir-200c	Carcinoma, Breast	27609814			D05	D001943	114480	HP:0003002	Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 3'UTR activity
genetics_GWAS	hsa-mir-205	Carcinoma, Breast	27885248			D05	D001943	114480	HP:0003002	Rs3842530 Polymorphism in MicroRNA-205 Host Gene in Lung and Breast Cancer Patients.
genetics_GWAS	hsa-mir-29a	Carcinoma, Breast	27609814			D05	D001943	114480	HP:0003002	Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 4'UTR activity
genetics_GWAS	hsa-mir-29b	Carcinoma, Breast	27609814			D05	D001943	114480	HP:0003002	Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 5'UTR activity
genetics_GWAS	hsa-mir-374a	Carcinoma, Breast	27609814			D05	D001943	114480	HP:0003002	Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 6'UTR activity
genetics_GWAS	hsa-mir-374b	Carcinoma, Breast	27609814			D05	D001943	114480	HP:0003002	Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 7'UTR activity
genetics_GWAS	hsa-mir-488	Carcinoma, Breast	27609814			D05	D001943	114480	HP:0003002	Mutation of putative miRNA-binding sites (miR-374a/b, miR-200b/c, miR-29a/b/c, miR-488) in these regions did not have significant impact on 8'UTR activity
genetics_GWAS	hsa-mir-561	Carcinoma, Breast	24166930			D05	D001943	114480	HP:0003002	Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years.
genetics_GWAS	hsa-mir-627	Carcinoma, Breast	27807724			D05	D001943	114480	HP:0003002	rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility.
genetics_GWAS	hsa-mir-124	Carcinoma, Cervical	24589598	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-124 rs531564 polymorphism may play a role in cervical cancer susceptibility in Chinese Han women, and G allele is associated with a reduced risk of cervical cancer.
genetics_GWAS	hsa-mir-135b	Carcinoma, Cervical	24465869	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Genetic variants in microRNA target sites of 37 selected cancer-related genes and the risk of cervical cancer.
genetics_GWAS	hsa-mir-146a	Carcinoma, Cervical	26464690	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The miR-146a (rs2910164) polymorphism is significantly correlated to ethnic factor and tumor diameters. miR-146a has differential expression in cervical tissues. Allele G of miR-146a (rs2910164) is related to the high expression of miR-146a, and the progression of cervical cancer.
genetics_GWAS	hsa-mir-21	Carcinoma, Cervical	25987069	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	E6D25E of the HPV16As variant differed from the E6 prototype in its activities on epigenetic modulation and immune surveillance and this might be a key factor for the important role of this variant in cervical cancer progression.
genetics_GWAS	hsa-mir-27a	Carcinoma, Cervical	24380734	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	A genetic variant in pre-miR-27a is associated with a reduced cervical cancer risk in southern Chinese women.
genetics_GWAS	hsa-mir-502	Carcinoma, Cervical	25169478	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	These data suggest that there are significant associations between the miR-502-binding site SNP in the 3'-UTR of SET8 and the TP53 codon 72 polymorphism with cervical cancer in Chinese, and there is a gene-gene interaction.
genetics_GWAS	hsa-let-7	Carcinoma, Colon	24727325	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	In the largest association study investigating the LCS6 polymorphism in colon cancers, the germline LCS6 genotype was not associated with KRAS mutation status or with clinical outcome in patients with stage III tumors.
genetics_GWAS	hsa-let-7a	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-143	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-145	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-146a	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-146a	Carcinoma, Colon	27706637	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA variants and colorectal cancer risk: a meta-analysis.
genetics_GWAS	hsa-mir-146a	Carcinoma, Colon	27824903	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-146a Polymorphism (rs2910164) Predicts Colorectal Cancer Patients' Susceptibility to Liver Metastasis.
genetics_GWAS	hsa-mir-149	Carcinoma, Colon	27706637	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA variants and colorectal cancer risk: a meta-analysis.
genetics_GWAS	hsa-mir-196a	Carcinoma, Colon	27706637	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA variants and colorectal cancer risk: a meta-analysis.
genetics_GWAS	hsa-mir-19a	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-19b	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-214	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-25	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-27a	Carcinoma, Colon	27706637	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA variants and colorectal cancer risk: a meta-analysis.
genetics_GWAS	hsa-mir-27a	Carcinoma, Colon	27751356	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Association between microRNA-27a rs895819 polymorphism and risk of colorectal cancer: A meta-analysis.
genetics_GWAS	hsa-mir-499	Carcinoma, Colon	27706637	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA variants and colorectal cancer risk: a meta-analysis.
genetics_GWAS	hsa-mir-525	Carcinoma, Colon	26630397	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Of the 327 SNPs identified in the literature as being important because of their potential regulation of miRNA expression levels, 12.5% had statistically significantly associations with miRNA expression. However, only two of these SNPs were significantly associated with colon cancer.
genetics_GWAS	hsa-mir-608	Carcinoma, Colon	28653886	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on type.
genetics_GWAS	hsa-mir-34b	Carcinoma, Esophageal	24260422	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population.
genetics_GWAS	hsa-mir-34c	Carcinoma, Esophageal	24260422	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population.
genetics_GWAS	hsa-mir-423	Carcinoma, Esophageal	24260422	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population.
genetics_GWAS	hsa-mir-218	Carcinoma, Gastric	28298809	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis.
genetics_GWAS	hsa-mir-219	Carcinoma, Gastric	28298809	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis.
genetics_GWAS	hsa-mir-27b	Carcinoma, Gastric	28214904	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	rs10719 Polymorphism Located within DROSHA 3'-Untranslated Region is Responsible for Development of Primary Hypertension by Disrupting Binding with microRNA-27b.
genetics_GWAS	hsa-mir-34b	Carcinoma, Gastric	28298809	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis.
genetics_GWAS	hsa-mir-34c	Carcinoma, Gastric	28298809	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis.
genetics_GWAS	hsa-mir-526b	Carcinoma, Gastric	24595048	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The has-miR-526b binding-site rs8506G>a polymorphism in the lincRNA-NR_024015 exon identified by GWASs predispose to non-cardia gastric cancer risk.
genetics_GWAS	hsa-mir-938	Carcinoma, Gastric	28298809	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Predictive Value of MiR-219-1, MiR-938, MiR-34b/c, and MiR-218 Polymorphisms for Gastric Cancer Susceptibility and Prognosis.
genetics_GWAS	hsa-mir-101	Carcinoma, Hepatocellular	28366737	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-101-1	Carcinoma, Hepatocellular	26434859	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results revealed no significant association between miR-149 (rs2292832) and miR-101-1 (rs7536540) and the risk of HCC in our Thai population.However, this research is the first study of miR-149 (rs2292832) and miR-101-1 (rs7536541) in HCC in Thai populations and the results need to be confirmed with a larger population.
genetics_GWAS	hsa-mir-106b	Carcinoma, Hepatocellular	22393390	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A Genetic Variant (rs999885) in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma.Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67-0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers (adjusted OR=1.25, 95% CIs=1.06-1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues.
genetics_GWAS	hsa-mir-106b	Carcinoma, Hepatocellular	24416400	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese.
genetics_GWAS	hsa-mir-122	Carcinoma, Hepatocellular	24995424	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A genetic variant in microRNA-122 regulatory region confers risk for chronic hepatitis B virus infection and hepatocellular carcinoma in Han Chinese.
genetics_GWAS	hsa-mir-122	Carcinoma, Hepatocellular	28512857	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Interest of variations in microRNA-152 and -122 in a series of hepatocellular carcinomas related to hepatitis C virus infection.
genetics_GWAS	hsa-mir-1231	Carcinoma, Hepatocellular	22824466	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A miR-1231 binding site polymorphism (rs17875871) in the 3'UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility.
genetics_GWAS	hsa-mir-125a	Carcinoma, Hepatocellular	27814341	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer.
genetics_GWAS	hsa-mir-1269a	Carcinoma, Hepatocellular	28081866	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A single nucleotide variant in microRNA-1269a promotes the occurrence and process of hepatocellular carcinoma by targeting to oncogenes SPATS2L and LRP6.
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	18711148	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-146a: A functional polymorphism (rs2910164) in the miR-146a gene is associated with the risk for hepatocellular carcinoma
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	24377574	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate that miR-196a4 CC genotype and C allele have an important role in HCC risk in Chinese, especially in patients with HBV infection.
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	24587132	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggest that a significant association exists between miRNA499 SNPs and hepatocellular carcinoma. Gene-environment interactions of miRNA499 polymorphisms, smoking, and alcohol consumption might alter hepatocellular carcinoma susceptibility.
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	24615520	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-146a G>C polymorphisms and risk of hepatocellular carcinoma in a Chinese population.
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	24816919	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population.
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	25546664	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the miR-146a rs2910164 polymorphism contributes to increased HCC susceptibility, especially in Asian populations. Further large and well-designed studies are required to validate this association.
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	27706712	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	27886162	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-146a rs2910164 and hepatocellular carcinoma: a meta-analysis.
genetics_GWAS	hsa-mir-146a	Carcinoma, Hepatocellular	28188097	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings supported the proposition that the polymorphisms of miR-146a rs2910164, miR-196a2 rs11614913, and miR-196a2 rs11614913 may contribute to the susceptibility of HCC
genetics_GWAS	hsa-mir-149	Carcinoma, Hepatocellular	24587132	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggest that a significant association exists between miRNA499 SNPs and hepatocellular carcinoma. Gene-environment interactions of miRNA499 polymorphisms, smoking, and alcohol consumption might alter hepatocellular carcinoma susceptibility.
genetics_GWAS	hsa-mir-149	Carcinoma, Hepatocellular	25061729	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Association of miR-149C>T and miR-500A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population.
genetics_GWAS	hsa-mir-149	Carcinoma, Hepatocellular	26434859	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results revealed no significant association between miR-149 (rs2292832) and miR-101-1 (rs7536540) and the risk of HCC in our Thai population.However, this research is the first study of miR-149 (rs2292832) and miR-101-1 (rs7536540) in HCC in Thai populations and the results need to be confirmed with a larger population.
genetics_GWAS	hsa-mir-149	Carcinoma, Hepatocellular	24040059	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Results of this meta-analysis suggest that the hsa-miR-149 rs2292832 polymorphism is not associated with cancer risk in spite of the potentially protective role of C allele in hepatocellular carcinoma and male gastric cancer.
genetics_GWAS	hsa-mir-149	Carcinoma, Hepatocellular	26823863	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-149	Carcinoma, Hepatocellular	27141902	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A meta-analysis of microRNA-149, microRNA-499 gene polymorphism and susceptibility to hepatocellular carcinoma
genetics_GWAS	hsa-mir-149	Carcinoma, Hepatocellular	27348444	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MIR-149 gene rs2292832 polymorphism contributed to the risk of HCC
genetics_GWAS	hsa-mir-149	Carcinoma, Hepatocellular	25222224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Role of miR-149C>T polymorphisms on the risk of hepatocellular carcinoma in a Chinese population.
genetics_GWAS	hsa-mir-196	Carcinoma, Hepatocellular	24587132	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggest that a significant association exists between miRNA499 SNPs and hepatocellular carcinoma. Gene-environment interactions of miRNA499 polymorphisms, smoking, and alcohol consumption might alter hepatocellular carcinoma susceptibility.
genetics_GWAS	hsa-mir-196a	Carcinoma, Hepatocellular	24377574	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate that miR-196a2 CC genotype and C allele have an important role in HCC risk in Chinese, especially in patients with HBV infection.
genetics_GWAS	hsa-mir-196a	Carcinoma, Hepatocellular	27706712	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-196a	Carcinoma, Hepatocellular	28188097	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings supported the proposition that the polymorphisms of miR-146a rs2910164, miR-196a2 rs11614913, and miR-196a2 rs11614913 may contribute to the susceptibility of HCC
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Hepatocellular	26464719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In conclusion, miR-196a2 rs11614913 polymorphism may contribute to identifying individuals, especially in HBV-infected subjects, who are at high risk for HCC.
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Hepatocellular	20188135	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-196a2:MIR196A2 polymorphism was associated with susceptibility to HBV-related HCC in a maleChinese population.
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Hepatocellular	23791656	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: a systematic review and meta-analysis. 
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Hepatocellular	24816919	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population.
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Hepatocellular	26365437	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In conclusion,the donor miR-196a-2 rs11614913 polymorphism is associated with HCC recurrence after LT and improves the predictive value of clinical models. The overexpression of miR-196a in the liver might provide a tumor-favorable environment for the development of HCC.
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Hepatocellular	25546664	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the miR-146a rs2910165 polymorphism contributes to increased HCC susceptibility, especially in Asian populations. Further large and well-designed studies are required to validate this association.
genetics_GWAS	hsa-mir-214	Carcinoma, Hepatocellular	27619679	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	U/G SNP rs111904020 in 3'UTR of STAT3 regulated by miR-214 promotes hepatocellular carcinoma development in Chinese population.
genetics_GWAS	hsa-mir-218	Carcinoma, Hepatocellular	24118778	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	rs11134527 may be a novel genetic risk factor of HCC in HBV-exposed subjects, can facilitate HBV preS deletion generation and predispose the host to the effect of T1674C/G and preS1 start codon mutation in hepatocarcinogenesis.
genetics_GWAS	hsa-mir-218-1	Carcinoma, Hepatocellular	22011248	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The AG genotype of pri-miR-218 rs11134527 A/G was associated with family history (p=0.018, odds ratio [OR]=2.96, 95% confidence interval [CI]: 1.16-7.56) and elevated serum alpha-fetoprotein (serum alpha-fetoprotein [AFP]) levels (≥20 ng/mL; p=0.009, OR=1.92, 95% CI: 1.17-3.14) in HCC patients. These findings suggested that the AG genotype of pri-miR-218 rs11134527 might relate to genetic predisposition and be involved in regulating the expression of AFP in Chinese HCC patients.
genetics_GWAS	hsa-mir-218-2	Carcinoma, Hepatocellular	22011248	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The AG genotype of pri-miR-218 rs11134527 A/G was associated with family history (p=0.018, odds ratio [OR]=2.96, 95% confidence interval [CI]: 1.16-7.56) and elevated serum alpha-fetoprotein (serum alpha-fetoprotein [AFP]) levels (≥20 ng/mL; p=0.009, OR=1.92, 95% CI: 1.17-3.14) in HCC patients. These findings suggested that the AG genotype of pri-miR-218 rs11134527 might relate to genetic predisposition and be involved in regulating the expression of AFP in Chinese HCC patients.
genetics_GWAS	hsa-mir-221	Carcinoma, Hepatocellular	28366737	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-25	Carcinoma, Hepatocellular	22393390	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A Genetic Variant (rs999885) in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma.Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67-0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers (adjusted OR=1.25, 95% CIs=1.06-1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues.
genetics_GWAS	hsa-mir-3131	Carcinoma, Hepatocellular	28034876	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma.
genetics_GWAS	hsa-mir-34a	Carcinoma, Hepatocellular	25179842	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A functional variant at miR-34a binding site in toll-like receptor 4 gene alters susceptibility to hepatocellular carcinoma in a Chinese Han population.
genetics_GWAS	hsa-mir-34b	Carcinoma, Hepatocellular	23935875	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Lack of association of MiR-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis.
genetics_GWAS	hsa-mir-34b	Carcinoma, Hepatocellular	27808368	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-34c	Carcinoma, Hepatocellular	27808368	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-378	Carcinoma, Hepatocellular	24751683	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings indicate that rs1076064 may be a biomarker for HCC susceptibility and prognosis through altering pri-miR-378 transcription.
genetics_GWAS	hsa-mir-492	Carcinoma, Hepatocellular	26753964	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-492G>C polymorphism (rs2289030) is associated with overall survival of hepatocellular carcinoma patients.
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	23791656	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: a systematic review and meta-analysis. 
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	24301908	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-499A>G rs3746444 and miR-146aG>C expression and hepatocellular carcinoma risk in the Chinese population.
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	24377574	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate that miR-196a3 CC genotype and C allele have an important role in HCC risk in Chinese, especially in patients with HBV infection.
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	24587132	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggest that a significant association exists between miRNA499 SNPs and hepatocellular carcinoma. Gene-environment interactions of miRNA499 polymorphisms, smoking, and alcohol consumption might alter hepatocellular carcinoma susceptibility.
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	24816919	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population.
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	24854593	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-499 rs3746444 may contribute to the risk and prognosis of HCC, indicating that this SNP could be developed as a biomarker for HCC prediction.
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	25867338	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	subjects carrying the miR-499 A allele showed a greatly increased risk of HCC in subjects infected with HBV compared with subjects carrying the miR-499 A allele, with an adjusted odds ratio (95% confidence interval) of 1.53 (1.34-2.41). In conclusion, the miR-146aG>C and miR-499A>G polymorphisms do not have a role in the genetic susceptibility to HCC.
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	27706712	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-499	Carcinoma, Hepatocellular	27453271	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-499 rs3746444 was significantly associated with an increased the risk of HCC.
genetics_GWAS	hsa-mir-499a	Carcinoma, Hepatocellular	25061729	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Association of miR-149C>T and miR-499A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population.
genetics_GWAS	hsa-mir-501	Carcinoma, Hepatocellular	27310251	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a novel SNP located in miR-501 acting as an important  factor of the HCC susceptibility
genetics_GWAS	hsa-mir-502	Carcinoma, Hepatocellular	22095217	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We analysed a single nucleotide polymorphism (rs16917496) within the miR-502 microRNA seed region for the 3' UTR of SET8 in Chinese hepatocellular carcinoma (HCC) patients. The SET8 CC genotype was independently associated with longer post-operative survival in HCC patients by multivariate analysis (relative risk, 0.175; 95% CI, 0.053 - 0.577; p = 0.004). The SET8 CC genotype was associated with reduced SET8 protein levels based on the immunostaining of 51 HCC tissue samples. We also found the low SET8 levels was associated with longer HCC survival. Our data suggest that SET8 modifies HCC outcome by altering its expression, which depends, at least in part, on its binding affinity with miR502.
genetics_GWAS	hsa-mir-604	Carcinoma, Hepatocellular	25408584	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The T allele at miR-604 rs2368392 may be a risk allele for the chronicity of HBV infection, but may be a protective allele for the progression to HCC in chronic HBV carriers.
genetics_GWAS	hsa-mir-608	Carcinoma, Hepatocellular	26815502	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma.
genetics_GWAS	hsa-mir-646	Carcinoma, Hepatocellular	25177719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings support the view that the miR-646 SNP rs6513497 may contribute to the susceptibility of HCC.
genetics_GWAS	hsa-mir-146a	Carcinoma, Lung	24246082	disease of cellular proliferation	DOID:3905	C34.90	D008175			The rs2910164 C allele in pre-miR-146a and rs11614913 C allele in pre-miR-196a2 were associated with increased genetic damage levels in coke oven workers
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Lung	24246082	disease of cellular proliferation	DOID:3905	C34.90	D008175			The rs2910164 C allele in pre-miR-146a and rs11614913 C allele in pre-miR-196a2 were associated with increased genetic damage levels in coke oven workers
genetics_GWAS	hsa-mir-429	Carcinoma, Lung, Non-Small-Cell	27374108			C34.90	D002289		HP:0030358	rs9660710 in miR-200b/200a/429 cluster and rs763354 in miR-30a might modify the susceptibility to NSCLC.
genetics_GWAS	hsa-mir-4293	Carcinoma, Lung, Non-Small-Cell	28410417			C34.90	D002289		HP:0030358	Genetic variant of miR-4293 rs12220909 is associated with susceptibility to non-small cell lung cancer in a Chinese Han population.
genetics_GWAS	hsa-let-7a	Carcinoma, Lung, Non-Small-Cell	18922928			C34.90	D002289		HP:0030358	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
genetics_GWAS	hsa-let-7a-1	Carcinoma, Lung, Non-Small-Cell	18922928			C34.90	D002289		HP:0030358	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
genetics_GWAS	hsa-let-7a-2	Carcinoma, Lung, Non-Small-Cell	18922928			C34.90	D002289		HP:0030358	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
genetics_GWAS	hsa-let-7a-3	Carcinoma, Lung, Non-Small-Cell	18922928			C34.90	D002289		HP:0030358	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
genetics_GWAS	hsa-let-7b	Carcinoma, Lung, Non-Small-Cell	18922928			C34.90	D002289		HP:0030358	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
genetics_GWAS	hsa-let-7d	Carcinoma, Lung, Non-Small-Cell	18922928			C34.90	D002289		HP:0030358	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
genetics_GWAS	hsa-let-7g	Carcinoma, Lung, Non-Small-Cell	18922928			C34.90	D002289		HP:0030358	A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
genetics_GWAS	hsa-mir-146a	Carcinoma, Lung, Non-Small-Cell	21902575			C34.90	D002289		HP:0030358	CG genotype of miR-146a(rs2910164 C-G) appeared associated to an increased risk for NSCLC (p=0.042 and 1.77 OR).
genetics_GWAS	hsa-mir-146b	Carcinoma, Lung, Non-Small-Cell	21902575			C34.90	D002289		HP:0030358	CG genotype of miR-146a(rs2910164 C-G) appeared associated to an increased risk for NSCLC (p=0.042 and 1.77 OR).
genetics_GWAS	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	25716425			C34.90	D002289		HP:0030358	The rs3660G>C affects KRT81 expression and thus influences survival in early-stage NSCLC. The analysis of the rs3660G>C polymorphism may be useful to identify patients at high risk of a poor disease outcome.
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Lung, Non-Small-Cell	21617338			C34.90	D002289		HP:0030358	MicroRNA196a2 rs11614913 Genotypes are associated with the Risk of Non-Small Cell Lung Cancer in Korean Population.
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Lung, Non-Small-Cell	21902575			C34.90	D002289		HP:0030358	The authors clearly detected a significant increase (p<0.001) of miR-196a2 expression in NSCLC. In particular the authors found a significant association between miR-196a2 (rs11614913 C-T) CC genotype and high expression, whereas TT genotype showed a very low expression in comparison to both CT (p<0.005) and CC patients (p<0.01).
genetics_GWAS	hsa-mir-196a-2	Carcinoma, Lung, Non-Small-Cell	24853117			C34.90	D002289		HP:0030358	Importantly, this method can be further applied to analyze the point mutation of  mir-196a2 in the lung tissues of non small-cell lung cancer patients.
genetics_GWAS	hsa-mir-20b	Carcinoma, Lung, Non-Small-Cell	25716425			C34.90	D002289		HP:0030358	The rs3660G>C affects KRT81 expression and thus influences survival in early-stage NSCLC. The analysis of the rs3660G>C polymorphism may be useful to identify patients at high risk of a poor disease outcome.
genetics_GWAS	hsa-mir-27a	Carcinoma, Lung, Non-Small-Cell	24223174			C34.90	D002289		HP:0030358	Our results suggest that the pre-miR-27a rs895819 polymorphism may influence NSCLC patients' clinical outcome. Further large sample studies should be used to validate our findings.
genetics_GWAS	hsa-mir-502	Carcinoma, Lung, Non-Small-Cell	24146953			C34.90	D002289		HP:0030358	Our data suggested that the rs16917496 T>C located at miR-502 binding site contributes to NSCLC survival by altering SET8 expression through modulating miRNA-target interaction.
genetics_GWAS	hsa-mir-502	Carcinoma, Lung, Non-Small-Cell	24374662			C34.90	D002289		HP:0030358	Association of miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population.
genetics_GWAS	hsa-mir-1827	Carcinoma, Lung, Small-Cell	21676885			C34.90	D055752	182280	HP:0030357	Genetic Variation in an miRNA-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung Cancer. The rs3134615T allele was associated with a significantly increased risk of SCLC, with the OR for carrying the GT or TT genotype being 2.08 (95% confidence interval, 1.39-3.21; P = 0.0004) compared with the GG genotype.
genetics_GWAS	hsa-mir-608	Carcinoma, Nasopharyngeal	23796562	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma.
genetics_GWAS	hsa-mir-608	Carcinoma, Nasopharyngeal	25861865	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Polymorphism in mature microRNA-608 sequence is associated with an increased risk of nasopharyngeal carcinoma.
genetics_GWAS	hsa-mir-1269b	Carcinoma, Oral	27525378	gastrointestinal system disease	DOID:0050610					Genetic variants in microRNA-146a (C>G) and microRNA-1269b (G>C) are associated with the decreased risk of oral premalignant lesions, oral cancer, and pharyngeal cancer.
genetics_GWAS	hsa-mir-146a	Carcinoma, Oral	27525378	gastrointestinal system disease	DOID:0050610					Genetic variants in microRNA-146a (C>G) and microRNA-1269b (G>C) are associated with the decreased risk of oral premalignant lesions, oral cancer, and pharyngeal cancer.
genetics_GWAS	hsa-mir-101	Carcinoma, Ovarian	21765906	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210  and miR-301a.
genetics_GWAS	hsa-mir-146a	Carcinoma, Ovarian	27706635	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-146a and miR-196a2 polymorphisms in ovarian cancer risk.
genetics_GWAS	hsa-mir-196a2	Carcinoma, Ovarian	27706635	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-146a and miR-196a2 polymorphisms in ovarian cancer risk.
genetics_GWAS	hsa-mir-21	Carcinoma, Ovarian	21765906	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210  and miR-301a.
genetics_GWAS	hsa-mir-210	Carcinoma, Ovarian	21765906	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210  and miR-301a.
genetics_GWAS	hsa-mir-301a	Carcinoma, Ovarian	21765906	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210  and miR-301a.
genetics_GWAS	hsa-mir-34b	Carcinoma, Prostate	27983526	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer.
genetics_GWAS	hsa-mir-34c	Carcinoma, Prostate	27983526	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer.
genetics_GWAS	hsa-mir-146a	Carcinoma, Renal Cell	26323945	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	the observed association between the GG and GC genotype and poorer survival rate  of RCC was at least partially mediated by the decreased expression of miR-146a.
genetics_GWAS	hsa-mir-149	Carcinoma, Renal Cell	24681820	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We genotyped four common miRNA SNPs (i.e. miR-146a rs2910164, miR-149 rs2292832, miR-196a2 rs11614913 and miR-499 rs3746444) to assess their associations with RCC risk in a two-stage case-control study (355 cases and 362 controls in discovery set, meanwhile 647 cases and 660 controls in validation set), as well as RCC survival  in 311 patients.
genetics_GWAS	hsa-mir-27a	Carcinoma, Renal Cell	23118855	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A genetic variant in pre-miR-27a is associated with a reduced renal cell cancer risk in a Chinese population
genetics_GWAS	hsa-mir-34b	Carcinoma, Renal Cell	24503183	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population.
genetics_GWAS	hsa-mir-34c	Carcinoma, Renal Cell	24503183	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population.
genetics_GWAS	hsa-mir-502	Carcinoma, Renal Cell, Clear-Cell	27346408	disease of cellular proliferation	DOID:4467				HP:0006770	Polymorphism at the miR-502 binding site in the 3' untranslated region of SET8 gene is associated with the risk of clear cell renal cell carcinoma
genetics_GWAS	hsa-mir-146a	Carcinoma, Thyroid, Papillary	26722556	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Our study indicated that the miR-146a polymorphism was significantly associated with PTC risk. In contrast, meta-analysis revealed no evidence of association between miR-146a variants and PTC risk. Further studies are required to elucidate the role of miR-146a in the etiology of PTC.
genetics_GWAS	hsa-mir-34b	Carcinoma, Thyroid, Papillary	26402809	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	These findings indicate that the miR-34b/c rs4938723 and TP-53 Arg72Pro polymorphisms may contribute to the susceptibility of PTC.
genetics_GWAS	hsa-mir-34c	Carcinoma, Thyroid, Papillary	26402809	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	These findings indicate that the miR-34b/c rs4938723 and TP-53 Arg72Pro polymorphisms may contribute to the susceptibility of PTC.
genetics_GWAS	hsa-mir-320e	Cardiometabolic Disorders	25814643							We provide evidence for a model in which polymorphisms in miRNA-binding sites can both positively and negatively affect miRNA-mediated regulation of cardiometabolic genes.
genetics_GWAS	hsa-mir-196a-2	Cardiomyopathy, Dilated	20488170	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	mir-196a2:Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy
genetics_GWAS	hsa-mir-499a	Cardiomyopathy, Dilated	20488170	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	mir-499:Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy
genetics_GWAS	hsa-mir-208b	Cardiomyopathy, Hypertrophic	25633875	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Sequence variants in miRNAs of patients with HCM are not frequent and the contribution of these variants to the development of this disease was not demonstrated.
genetics_GWAS	hsa-mir-367	Cardiomyopathy, Hypertrophic	25633875	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Sequence variants in miRNAs of patients with HCM are not frequent and the contribution of these variants to the development of this disease was not demonstrated.
genetics_GWAS	hsa-mir-146a	Cardiovascular Diseases [unspecific]	25865299				D002318			Association of miR-146a rs2910164 polymorphism with cardio-cerebrovascular diseases: A systematic review and meta-analysis.
genetics_GWAS	hsa-mir-146a	Carotid Atherosclerosis	26505665			I65.29	D002340			The miR-146a rs2910164 polymorphism might be associated with carotid vulnerable plaque risk in Chinese type 2 diabetes mellitus patients, particularly in older patients, females, those with diabetes duration of more than 10 years and those with hypertension. The transcriptional coactivator p300 rs20551 polymorphism may not be a risk factor for the development or progression of atherosclerosis in type 2 diabetes mellitus.
genetics_GWAS	hsa-mir-125b	Cataract	27431420	nervous system disease	DOID:83	H26.9	D002386	PS116200	HP:0000518	rs78378222 polymorphism in the 3'-untranslated region of TP53 contributes to development of age-associated cataracts by modifying microRNA-125b-induced apoptosis of lens epithelial cells.
genetics_GWAS	hsa-mir-184	Cataract	24138095	nervous system disease	DOID:83	H26.9	D002386	PS116200	HP:0000518	C.57 C > T Mutation in MIR 184 is Responsible for Congenital Cataracts and Corneal Abnormalities in a Five-generation Family from Galicia, Spain.
genetics_GWAS	hsa-mir-149	Charcot-Marie-Tooth Disease Type 1A	29729827	musculoskeletal system disease	DOID:0110148	G60.0	D002607	118220		Association of miR-149 polymorphism with onset age and severity in Charcot-Marie-Tooth disease type 1A.
genetics_GWAS	hsa-mir-196a-2	Chronic Hepatitis B	24248733			B18.0-.1	D019694	610424		MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B.
genetics_GWAS	hsa-mir-122	Chronic Hepatitis C	28082397			B18.2	D019698	609532		Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3΄ variants.
genetics_GWAS	hsa-mir-146a	Chronic Obstructive Pulmonary Disease	25767384	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	the rs2910164 CC and GC genotype was found to be associated with an improved lung function and milder disease stages, at least partially, mediated by its ability to increase in COX2 expression and PGE2 production.
genetics_GWAS	hsa-mir-196a-2	Chronic Obstructive Pulmonary Disease	21565178	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	The TT genotype and T allele of miR-196a2 rs11614913 were significantly associated with a decreased risk for COPD (Chronic obstructive pulmonary disease), compared with the CC genotype and C allele. Similarly, the GG genotype and G allele of miR-499 rs3746444 were associated with a decreased risk for COPD, compared with the AA genotype and A allele.
genetics_GWAS	hsa-mir-499a	Chronic Obstructive Pulmonary Disease	21565178	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	The TT genotype and T allele of miR-196a2 rs11614913 were significantly associated with a decreased risk for COPD (Chronic obstructive pulmonary disease), compared with the CC genotype and C allele. Similarly, the GG genotype and G allele of miR-499 rs3746444 were associated with a decreased risk for COPD, compared with the AA genotype and A allele.
genetics_GWAS	hsa-mir-196a	Colitis, Ulcerative	28301487	gastrointestinal system disease	DOID:8577	K51	D003093			Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs.
genetics_GWAS	hsa-mir-499	Colitis, Ulcerative	28301487	gastrointestinal system disease	DOID:8577	K51	D003093			Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs.
genetics_GWAS	hsa-let-7	Colorectal Carcinoma	27234654	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		rs868 is associated with lower TGFBR1 expression thereby increasing CRC risk.
genetics_GWAS	hsa-mir-145	Colorectal Carcinoma	27444415	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings indicate that the rs353292 polymorphism is functional and may be a risk factor for the development of CRC.
genetics_GWAS	hsa-mir-146	Colorectal Carcinoma	23898084	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The current study provides evidence that the miR-146a rs2690164 polymorphism, as the dominant model of the G allele, is associated with the susceptibility and prognosis of CRC.
genetics_GWAS	hsa-mir-146a	Colorectal Carcinoma	24136745	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Association between microRNA genetic variants and susceptibility to colorectal cancer in Chinese population.
genetics_GWAS	hsa-mir-146a	Colorectal Carcinoma	24399071	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis.
genetics_GWAS	hsa-mir-146a	Colorectal Carcinoma	24568449	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC.
genetics_GWAS	hsa-mir-146a	Colorectal Carcinoma	24740563	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Association of a genetic variant in microRNA-146a with risk of colorectal cancer: a population-based case-control study.
genetics_GWAS	hsa-mir-146a	Colorectal Carcinoma	25103961	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer.
genetics_GWAS	hsa-mir-146a	Colorectal Carcinoma	25283877	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Effect of a common genetic variant microRNA-146a rs2910164 on colorectal cancer: a meta-analysis.
genetics_GWAS	hsa-mir-146a	Colorectal Carcinoma	26813595	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		SNPs in the miRNA genes are important for tumorigenesis. The changes by hsa-mir-146a rs1052918 C>G may result in loss of Wnt, constant activation of the Wnt signaling pathway, and uncontrolled cell proliferation and tumor progression.
genetics_GWAS	hsa-mir-149	Colorectal Carcinoma	24568449	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC.
genetics_GWAS	hsa-mir-196a	Colorectal Carcinoma	24568449	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC.
genetics_GWAS	hsa-mir-196a-2	Colorectal Carcinoma	24399071	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis.
genetics_GWAS	hsa-mir-196a-2	Colorectal Carcinoma	25103961	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer.
genetics_GWAS	hsa-mir-27a	Colorectal Carcinoma	25078482	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Association between miR-27a genetic variants and susceptibility to colorectal cancer.
genetics_GWAS	hsa-mir-27a	Colorectal Carcinoma	25103961	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer.
genetics_GWAS	hsa-mir-27a	Colorectal Carcinoma	25222241	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Association between a functional variant in microRNA-27a and susceptibility to colorectal cancer in a Chinese Han population.
genetics_GWAS	hsa-mir-27a	Colorectal Carcinoma	25976406	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-27a rs895819 polymorphism was associated with increased risk of colorectal cancer in Chinese population.
genetics_GWAS	hsa-mir-27a	Colorectal Carcinoma	26302683	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Genotype GG of rs895819 Functional Polymorphism Within miR-27a Might Increase Genetic Susceptibility to Colorectal Cancer in Han Chinese Population
genetics_GWAS	hsa-mir-34b	Colorectal Carcinoma	24337371	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer.
genetics_GWAS	hsa-mir-34b	Colorectal Carcinoma	25475831	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		rs4938723 was a susceptible locus only for hepatocellular cancer and colorectal cancer.
genetics_GWAS	hsa-mir-34c	Colorectal Carcinoma	24337371	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Polymorphisms of the pri-miR-34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer.
genetics_GWAS	hsa-mir-34c	Colorectal Carcinoma	25475831	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		rs4938723 was a susceptible locus only for hepatocellular cancer and colorectal cancer.
genetics_GWAS	hsa-mir-3622a	Colorectal Carcinoma	26147304	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results indicate variations in RAN rs14035, DICER1 rs3742330, XPO5 rs11077, and DROSHA rs10719 of Korean patients are significantly associated with their risk of CRC.
genetics_GWAS	hsa-mir-370	Colorectal Carcinoma	27354594	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		rs2279398G>A may affect the expression of DOK3 by altering the miRNA binding efficiency at the miRNA-binding sites of the 3'-UTR in DOK3, thereby impacting CRC tumorigenesis.
genetics_GWAS	hsa-mir-423	Colorectal Carcinoma	29419695	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Association of microRNA-423 rs6505162 C>A polymorphism with susceptibility and metastasis of colorectal carcinoma.
genetics_GWAS	hsa-mir-499	Colorectal Carcinoma	24568449	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings supported that the miR-196a2 rs11614913 and miR-149 rs2292832 polymorphisms may contribute to susceptibility to CRC.
genetics_GWAS	hsa-mir-509	Colorectal Carcinoma	26010608	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings suggest that the rs13347C/T in microRNA binding site may be potential biomarkers for genetic susceptibility to CRC.
genetics_GWAS	hsa-mir-520a	Colorectal Carcinoma	25834816	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A functional variant at miR-520a binding site in PIK3CA alters susceptibility to colorectal cancer in a Chinese Han population.
genetics_GWAS	hsa-mir-5582	Colorectal Carcinoma	26147304	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results indicate variations in RAN rs14035, DICER1 rs3742330, XPO5 rs11077, and DROSHA rs10719 of Korean patients are significantly associated with their risk of CRC.
genetics_GWAS	hsa-mir-603	Colorectal Carcinoma	24934365	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our data suggest that hsa-miR-603 may be involved in colorectal tumorigenesis, and the genetic polymorphism in hsa-miR-603 is associated with CRC susceptibility.
genetics_GWAS	hsa-let-7	Colorectal Carcinoma	24890702	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
genetics_GWAS	hsa-mir-1273c	Colorectal Carcinoma	22348132	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		hsa-mir-1273c, hsa-mir-1303 and hsa-mir-567, with frequent and sometimes bi-allelic mutations in MSI tumors.
genetics_GWAS	hsa-mir-1303	Colorectal Carcinoma	22348132	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		hsa-mir-1273c, hsa-mir-1303 and hsa-mir-567, with frequent and sometimes bi-allelic mutations in MSI tumors.
genetics_GWAS	hsa-mir-146a	Colorectal Carcinoma	23306950	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A genetic variant in miR-146a modifies colorectal cancer susceptibility in a chinese population
genetics_GWAS	hsa-mir-196a-2	Colorectal Carcinoma	21241442	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A variant ( rs11614913 ) in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese.
genetics_GWAS	hsa-mir-196a-2	Colorectal Carcinoma	21565628	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Functional Variant in MicroRNA-196a2 (rs11614913 SNP) Is Associated with Susceptibility of Colorectal Cancer in a Chinese Population.
genetics_GWAS	hsa-mir-196a-2	Colorectal Carcinoma	21815818	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Functional Polymorphism (rs11614913 (T>C)) in miRNA-196a2 Is Associated with Colorectal Cancer Risk in a Chinese Population.
genetics_GWAS	hsa-mir-196a-2	Colorectal Carcinoma	22161766	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The authors found a significantly increased colorectal cancer risk with the miR-196a2CC (rs11614913) genotype compared with the TT/CT genotype (AOR=1.50; 95% CI=1.11-2.04; P=0.01; FDR-P=0.04) in Korean population.
genetics_GWAS	hsa-mir-219-1	Colorectal Carcinoma	22661538	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The mir219-1:rs213210 showed consistent association with death in the training set, the replication set, and combined data set
genetics_GWAS	hsa-mir-367	Colorectal Carcinoma	23393343	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the functional variant (rs1044129) in the miR-367 binding site of RYR3 may be a potential marker for prognosis in patients following curative surgery for CRC
genetics_GWAS	hsa-mir-423	Colorectal Carcinoma	22028396	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Two SNPs were identified to be significantly associated with recurrence-free survival and overall survival of the patients. The most significant SNP was rs6505162 in pre-miR-423. Compared to the homozygous wild-type genotype, the variant-containing genotypes of this SNP were significantly associated with both the overall survival (HR=2.12, 95% CI1.34--3.34, P=0.001) and the recurrence-free survival (HR=1.59, 95% CI1.08--2.36, P=0.019). Another SNP, rs4919510 in pre-miR-608, was also associated with altered recurrence-free survival (HR=0.61, 95% CI 0.41-0.92, P=0.017). These effects were evident only in patients receiving chemotherapy but not in those without chemotherapy. In addition, the combined analysis of the two SNPs conferred a 2.84-fold (95% CI 1.50-5.37, P=0.001) increased risk of recurrence and/or death. Similarly, this effect was only prominent in those receiving chemotherapy (P<0.001) but not in those without chemotherapy (P=0.999).
genetics_GWAS	hsa-mir-483	Colorectal Carcinoma	26235181	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Both the single nucleotide polymorphism variants showed a positive association toward risk of lung cancer.
genetics_GWAS	hsa-mir-491	Colorectal Carcinoma	21128281	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deleted
genetics_GWAS	hsa-mir-492	Colorectal Carcinoma	20044760	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		mir-492:In a univariate analysis, the progression-free survival of the patients with the combined mir492 C/G and G/G genotype was significantly worse than that of the patients with the mir492 C/C genotype (rs2289030) (P value = 0.0426)
genetics_GWAS	hsa-mir-520a	Colorectal Carcinoma	22553375	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A  3' untranslated region (UTR) mutation was also shown to be associated with increased sensitivity to saracatinib and have a reduced affinity for miR-520a and miR-525a.
genetics_GWAS	hsa-mir-542	Colorectal Carcinoma	21822307	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A common single-nucleotide polymorphism (T8473CA) in cyclooxygenase-2 disrupts microRNA (miR-542-3p)-mediated regulation.
genetics_GWAS	hsa-mir-551a	Colorectal Carcinoma	26235181	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Both the single nucleotide polymorphism variants showed a positive association toward risk of lung cancer.
genetics_GWAS	hsa-mir-567	Colorectal Carcinoma	22348132	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		hsa-mir-1273c, hsa-mir-1303 and hsa-mir-567, with frequent and sometimes bi-allelic mutations in MSI tumors.
genetics_GWAS	hsa-mir-608	Colorectal Carcinoma	22028396	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Two SNPs were identified to be significantly associated with recurrence-free survival and overall survival of the patients. The most significant SNP was rs6505162 in pre-miR-423. Compared to the homozygous wild-type genotype, the variant-containing genotypes of this SNP were significantly associated with both the overall survival (HR=2.12, 95% CI1.34--3.34, P=0.001) and the recurrence-free survival (HR=1.59, 95% CI1.08--2.36, P=0.019). Another SNP, rs4919510 in pre-miR-608, was also associated with altered recurrence-free survival (HR=0.61, 95% CI 0.41-0.92, P=0.017). These effects were evident only in patients receiving chemotherapy but not in those without chemotherapy. In addition, the combined analysis of the two SNPs conferred a 2.84-fold (95% CI 1.50-5.37, P=0.001) increased risk of recurrence and/or death. Similarly, this effect was only prominent in those receiving chemotherapy (P<0.001) but not in those without chemotherapy (P=0.999).
genetics_GWAS	hsa-mir-608	Colorectal Carcinoma	22606253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer.
genetics_GWAS	hsa-mir-608	Colorectal Carcinoma	22661538	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In patients with stage III disease, mir608: rs4919510 was associated with increased risk for both recurrence and death.
genetics_GWAS	hsa-mir-646	Colorectal Carcinoma	21128281	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deleted
genetics_GWAS	hsa-mir-143	Congenital Heart Diseases	24752771	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	No association of pri-miR-143 rs41291957 polymorphism with the risk of congenital heart disease in a Chinese population.
genetics_GWAS	hsa-mir-196a2	Congenital Heart Diseases	27813602	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	Association of miR-196a2, miR-27a, and miR-499 polymorphisms with isolated congenital heart disease in a Chinese population.
genetics_GWAS	hsa-mir-27a	Congenital Heart Diseases	27813602	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	Association of miR-196a2, miR-27a, and miR-499 polymorphisms with isolated congenital heart disease in a Chinese population.
genetics_GWAS	hsa-mir-499	Congenital Heart Diseases	27813602	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	Association of miR-196a2, miR-27a, and miR-499 polymorphisms with isolated congenital heart disease in a Chinese population.
genetics_GWAS	hsa-mir-1	Coronary Artery Disease	25197382	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Polymorphism in miRNA-1 target site and circulating miRNA-1 phenotype are associated with the decreased risk and prognosis of coronary artery disease.
genetics_GWAS	hsa-mir-146	Coronary Artery Disease	24447667	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression.
genetics_GWAS	hsa-mir-146a	Coronary Artery Disease	23794009	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-146a polymorphism influences levels of miR-146a, IRAK-1, and TRAF-6 in young patients with coronary artery disease.
genetics_GWAS	hsa-mir-146a	Coronary Artery Disease	26909569	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Our data provide the first evidence for the association of miR-146a  rs2910164 and TCF21 rs12190287 with CAD in an Iranian population, encouraging further research to elucidate the disease-related effects of miR-146a rs2910164.
genetics_GWAS	hsa-mir-146a	Coronary Artery Disease	27430349	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA polymorphisms (miR鈥?46a, miR鈥?49, miR鈥?96a2 and miR鈥?99) are associated with the risk of coronary artery disease.
genetics_GWAS	hsa-mir-149	Coronary Artery Disease	27430349	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA polymorphisms (miR鈥?46a, miR鈥?49, miR鈥?96a2 and miR鈥?99) are associated with the risk of coronary artery disease.
genetics_GWAS	hsa-mir-196a2	Coronary Artery Disease	27430349	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA polymorphisms (miR鈥?46a, miR鈥?49, miR鈥?96a2 and miR鈥?99) are associated with the risk of coronary artery disease.
genetics_GWAS	hsa-mir-196a-2	Coronary Artery Disease	22159951	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		The variant genotypes CC/CT of hsa-mir-196a2 rs11614913 T → C were not associated with a significantly increased risk of CAD (adjusted OR = 1.02, 95% CI = 0.76-1.38), compared with wide genotype TT, but CC and CC/CT genotypes were associated with 34 and 35% increased risks of serious prognosis of CAD (adjusted HR = 1.34, 95% CI = 1.02-1.75 for CC; adjusted HR = 1.35, 95% CI = 1.03-1.75 for CC/CT). In the variant of hsa-mir-499 rs3746444A → G, GG was associated with the 223% increased risk of CAD (adjusted OR = 3.23, 95% CI = 1.56-6.67). Cox regression analysis showed that age, smoking status, numbers of pathological changes in coronary arteries, rs11614913 T → C, and diabetes mellitus were associated with serious prognosis of CAD.
genetics_GWAS	hsa-mir-224	Coronary Artery Disease	24676100	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Coronary heart disease-associated variation in TCF21 disrupts a miR-224 binding site and miRNA-mediated regulation.
genetics_GWAS	hsa-mir-320b	Coronary Artery Disease	25573129	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		The common SNP (rs10916581) in the promoter region of pre-miR-320b-2 might have little contribution to the CHD predisposition in Chinese Han population, and it might not affect circulating miR-320b level. Conventional CHD  risk factors (BMI, TC/HDL-C, hypertension and diabetes) might have effects on its circulating level.
genetics_GWAS	hsa-mir-4513	Coronary Artery Disease	25256095	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		A genetic variant in the seed region of miR-4513 shows pleiotropic effects on lipid and glucose homeostasis, blood pressure, and coronary artery disease.
genetics_GWAS	hsa-mir-499	Coronary Artery Disease	27430349	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA polymorphisms (miR鈥?46a, miR鈥?49, miR鈥?96a2 and miR鈥?99) are associated with the risk of coronary artery disease.
genetics_GWAS	hsa-mir-499a	Coronary Artery Disease	22159951	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		The variant genotypes CC/CT of hsa-mir-196a2 rs11614913 T → C were not associated with a significantly increased risk of CAD (adjusted OR = 1.02, 95% CI = 0.76-1.38), compared with wide genotype TT, but CC and CC/CT genotypes were associated with 34 and 35% increased risks of serious prognosis of CAD (adjusted HR = 1.34, 95% CI = 1.02-1.75 for CC; adjusted HR = 1.35, 95% CI = 1.03-1.75 for CC/CT). In the variant of hsa-mir-499 rs3746444A → G, GG was associated with the 223% increased risk of CAD (adjusted OR = 3.23, 95% CI = 1.56-6.67). Cox regression analysis showed that age, smoking status, numbers of pathological changes in coronary arteries, rs11614913 T → C, and diabetes mellitus were associated with serious prognosis of CAD.
genetics_GWAS	hsa-mir-146a	Coronary Restenosis	25053223	cardiovascular system disease	DOID:4247		D023903		HP:0004761	we found a negative association for the G/C (P = 0.007) and a positive association for the C/C genotype with the risk of restenosis
genetics_GWAS	hsa-mir-146a	Creutzfeldt-Jakob Disease	29216791	nervous system disease	DOID:11949	A81.0	D007562	123400		The associations of two SNPs in miRNA-146a and one SNP in ZBTB38-RASA2 with the disease susceptibility and the clinical features of the Chinese patients of sCJD and FFI.
genetics_GWAS	hsa-let-7e	Crohn Disease	22262659	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the variant allele.
genetics_GWAS	hsa-let-7f-1	Crohn Disease	22262659	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the variant allele.
genetics_GWAS	hsa-let-7f-2	Crohn Disease	22262659	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The rs10889677 variant in the 3'-untranslated region of the IL-23R gene displays enhanced levels of both mRNA and protein production of IL-23R. This can be attributed to a loss of binding capacity for the microRNAs (miRNAs) Let-7e and Let-7f by the variant allele.
genetics_GWAS	hsa-mir-196a	Crohn Disease	29152405	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease
genetics_GWAS	hsa-mir-196a-1	Crohn Disease	21278745	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The common exonic synonymous SNP (c.313C>T) in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease.
genetics_GWAS	hsa-mir-196a-2	Crohn Disease	21278745	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The common exonic synonymous SNP (c.313C>T) in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease.
genetics_GWAS	hsa-mir-196b	Crohn Disease	21278745	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The common exonic synonymous SNP (c.313C>T) in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease.
genetics_GWAS	hsa-mir-659	Dementia	18723524	disease of mental health	DOID:1307	F03	D003704	127750	HP:0000726	miR-659: Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia
genetics_GWAS	hsa-mir-146a	Dermatomyositis	24716199	integumentary system disease	DOID:10223	M33	D003882			MIRSNP rs2910164 of miR-146a is associated with the muscle involvement in polymyositis/dermatomyositis.
genetics_GWAS	hsa-mir-214	Diabetes Mellitus	26329304	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	We have detected the interactions of hsa-miR-214-5p/hsa-miR-550a-5p and the 3'UTR SNP of the HNF1B gene by in vitro luciferase reporter assays, and propose that the binding of such miRNAs regulates the expression of the HNF1B gene and the susceptibility of T2DM.
genetics_GWAS	hsa-mir-550a	Diabetes Mellitus	26329304	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	We have detected the interactions of hsa-miR-214-5p/hsa-miR-550a-5p and the 3'UTR SNP of the HNF1B gene by in vitro luciferase reporter assays, and propose that the binding of such miRNAs regulates the expression of the HNF1B gene and the susceptibility of T2DM.
genetics_GWAS	hsa-mir-124a	Diabetes Mellitus, Type 2	25673459	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Affection of single-nucleotide polymorphisms in miR-27a, miR-124a, and miR-146a on susceptibility to type 2 diabetes mellitus in Chinese Han people.
genetics_GWAS	hsa-mir-146a	Diabetes Mellitus, Type 2	25673459	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Affection of single-nucleotide polymorphisms in miR-27a, miR-124a, and miR-146a on susceptibility to type 2 diabetes mellitus in Chinese Han people.
genetics_GWAS	hsa-mir-146a	Diabetes Mellitus, Type 2	28101643	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus.
genetics_GWAS	hsa-mir-155	Diabetes Mellitus, Type 2	28101643	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus.
genetics_GWAS	hsa-mir-196a-2	Diabetes Mellitus, Type 2	24972764	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Our findings suggest that miRNA-196a2 T/C polymorphism (rs11614913) is associated with an increased risk of CVD in type 2 diabetes patients. This provides further insights on pathogenesis of cardiovascular disease in type 2 diabetes patients.
genetics_GWAS	hsa-mir-27a	Diabetes Mellitus, Type 2	25673459	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Affection of single-nucleotide polymorphisms in miR-27a, miR-124a, and miR-146a on susceptibility to type 2 diabetes mellitus in Chinese Han people.
genetics_GWAS	hsa-mir-27a	Diabetes Mellitus, Type 2	27300034	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The pre-mir-27a variant rs895819 may contribute to type 2 diabetes mellitus susceptibility
genetics_GWAS	hsa-mir-125	Diabetic Nephropathy	26563755			E10-11.21	D003928			We identified miR-125a as a direct regulator of IL-6R, and the genotype of rs12976445 might be a novel predictor of the development of DN in DM.
genetics_GWAS	hsa-mir-146a	Diabetic Nephropathy	26997512			E10-11.21	D003928			Rs2910164 is significantly associated with microvascular complications DN in patients with T1DM and DME in patients with T2DM.
genetics_GWAS	hsa-mir-146a	Diabetic Retinopathy	26997512	nervous system disease	DOID:8947	E10-11.31	D003930			Rs2910164 is significantly associated with microvascular complications DN in patients with T1DM and DME in patients with T2DM.
genetics_GWAS	hsa-mir-146a	Digestive System Neoplasms	25555557			D49.0	D004067			digestive tract neoplasms might associate with miR-146a variants, but not miR-196a2 variants
genetics_GWAS	hsa-mir-146a	Digestive System Neoplasms	24247819			D49.0	D004067			miR-146a gene polymorphism rs2910164 and the risk of digestive tumors: A meta-analysis of 21 case-control studies.
genetics_GWAS	hsa-mir-196a	Digestive System Neoplasms	25555557			D49.0	D004067			digestive tract neoplasms might associate with miR-146a variants, but not miR-196a2 variants
genetics_GWAS	hsa-mir-34b	Digestive System Neoplasms	26320502			D49.0	D004067			The current evidence supports the conclusion that the miR-34b/c rs4938723 polymorphism decreases an individual's susceptibility to digestive cancers.
genetics_GWAS	hsa-mir-325	Dyspepsia	22438098	gastrointestinal system disease	DOID:2321	K30	D004415			Genetic polymorphism ( rs5981521 (C>T)) of pri-microRNA 325, targeting SLC6A4 3'-UTR, is closely associated with the risk of functional dyspepsia in Japan.
genetics_GWAS	hsa-mir-146a	Endometrial Neoplasms	26008204	reproductive system disease	DOID:1380	C54.1	D016889	608089		Association of SNPs in miR-146a, miR-196a2, and miR-499 with the risk of endometrial/ovarian cancer.
genetics_GWAS	hsa-mir-196a-2	Endometrial Neoplasms	26008204	reproductive system disease	DOID:1380	C54.1	D016889	608089		Association of SNPs in miR-146a, miR-196a2, and miR-499 with the risk of endometrial/ovarian cancer.
genetics_GWAS	hsa-mir-200b	Endometrial Neoplasms	22194984	reproductive system disease	DOID:1380	C54.1	D016889	608089		Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2alpha gene and negatively regulated the expression of endogenous AP-2alpha proteins. SNP rs1045385 A>C variation enhanced AP-2alpha.
genetics_GWAS	hsa-mir-200c	Endometrial Neoplasms	22194984	reproductive system disease	DOID:1380	C54.1	D016889	608089		Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2 alpha gene and negatively regulated the expression of endogenous AP-2 alpha proteins. SNP rs1045385 A>C variation enhanced AP-2 alpha expression.
genetics_GWAS	hsa-mir-429	Endometrial Neoplasms	22194984	reproductive system disease	DOID:1380	C54.1	D016889	608089		Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3' UTR of AP-2 alpha gene and negatively regulated the expression of endogenous AP-2 alpha proteins. SNP rs1045385 A>C variation enhanced AP-2 alpha expression.
genetics_GWAS	hsa-mir-499	Endometrial Neoplasms	26008204	reproductive system disease	DOID:1380	C54.1	D016889	608089		Association of SNPs in miR-146a, miR-196a2, and miR-499 with the risk of endometrial/ovarian cancer.
genetics_GWAS	hsa-let-7a-1	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7a-2	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7a-3	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7b	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7c	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7d	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7e	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7f-1	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7f-2	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7g	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-let-7i	Endometriosis	22307873	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The authors detected a KRAS variant allele in 31% of women with endometriosis as opposed to 5% of a large diverse control population.
genetics_GWAS	hsa-mir-125b	Endometriosis	24339876	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Genetic variation at the miR-125b binding site may play functional roles to protect against endometriosis progression.
genetics_GWAS	hsa-mir-126	Endometriosis	28277133	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	mir-126 rs4636297 and TGFβRI rs334348 functional gene variants are associated with susceptibility to endometriosis and its severity.
genetics_GWAS	hsa-mir-520a	Endometriosis	23364396	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women
genetics_GWAS	hsa-mir-520b	Endometriosis	23364396	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women
genetics_GWAS	hsa-mir-520c	Endometriosis	23364396	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women
genetics_GWAS	hsa-mir-520d	Endometriosis	23364396	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women
genetics_GWAS	hsa-mir-520e	Endometriosis	23364396	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women
genetics_GWAS	hsa-mir-520f	Endometriosis	23364396	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women
genetics_GWAS	hsa-mir-520g	Endometriosis	23364396	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women
genetics_GWAS	hsa-mir-520h	Endometriosis	23364396	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	A microRNA-520 mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women
genetics_GWAS	hsa-mir-146a	Epilepsy	25891929	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Our data indicate that the rs57095329 polymorphism in the promoter region of miR-146a is involved in the genetic susceptibility to DRE and the seizures frequency.
genetics_GWAS	hsa-mir-155	Epilepsy	26425555	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This study first demonstrates the association of MIR155HG/miR-155 tag SNPs with epilepsy and shows that rare CNVs were found exclusively in epileptic patients, clarifying the genetic role of miR-155 in epilepsy.
genetics_GWAS	hsa-mir-146a	Esophageal Neoplasms	21319225			C15.9	D004938	133239	HP:0100751	SNP (rs2910164 G/C): Significantly increased CSCC risks were found to be associated with G allele of rs2910164
genetics_GWAS	hsa-mir-196a-1	Esophageal Neoplasms	22859270			C15.9	D004938	133239	HP:0100751	MiR-196a binding-site SNP (rs6573) regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis.
genetics_GWAS	hsa-mir-196a-2	Esophageal Neoplasms	22859270			C15.9	D004938	133239	HP:0100751	MiR-196a binding-site SNP (rs6573) regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis.
genetics_GWAS	hsa-mir-499a	Esophageal Neoplasms	21319225			C15.9	D004938	133239	HP:0100751	SNP (rs3746444 A/G): Significantly increased CSCC risks were found to be associated with G allele of rs3746444
genetics_GWAS	hsa-let-7c	Essential Hypertension	26274321	cardiovascular system disease	DOID:10825	I10	C562386	145500		In conclusion, our experimental results provide evidence that the T allele of rs17168525 in the 3'-UTR of myotrophin might influence the level of myotrophin protein by interfering with let-7/miR-98 binding.
genetics_GWAS	hsa-mir-503	Essential Hypertension	26274321	cardiovascular system disease	DOID:10825	I10	C562386	145500		In conclusion, our experimental results provide evidence that the T allele of rs17168525 in the 3'-UTR of myotrophin might influence the level of myotrophin protein by interfering with let-7/miR-98 binding.
genetics_GWAS	hsa-mir-98	Essential Hypertension	26274321	cardiovascular system disease	DOID:10825	I10	C562386	145500		In conclusion, our experimental results provide evidence that the T allele of rs17168525 in the 3'-UTR of myotrophin might influence the level of myotrophin protein by interfering with let-7/miR-98 binding.
genetics_GWAS	hsa-let-7a	Gastric Neoplasms	24760009	disease of cellular proliferation	DOID:10534	C16	D013274	137215		pri-let-7a-2 rs629367 CC genotype could increase the risks of gastric cancer as well as atrophic gastritis and was also associated with poor survival of gastric cancer, which possibly by affecting the mature let-7a expression, and could serve as a predicting biomarker for high-risk and poor prognosis of gastric cancer.
genetics_GWAS	hsa-mir-125a	Gastric Neoplasms	25109760	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In this study, we found that a germline mutation in the miR-125a coding region is associated with human gastric cancer.
genetics_GWAS	hsa-mir-132	Gastric Neoplasms	24981235	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	24379078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	24528016	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A genetic variant in MiR-146a modifies digestive system cancer risk: a meta-analysis.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	25326754	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The present meta-analysis suggests an increased risk between miR-146a rs2910164 GG genotype and gastric cancer susceptibility in Chinese based on published literatures.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	25386093	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The miR-146a rs2910164 polymorphism is associated with increased gastric cancer risk, particularly evident in high quality studies with small sample sized Caucasian populations.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	25455160	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-146a rs2910164 polymorphism was associated with the susceptibility to gastric cancer, especially in Asian population.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	25795117	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	26345764	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	26345790	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In summary, the results suggested that the miR-146a rs2910164 polymorphism was related to gastric cancer risk in Asians but not in Caucasians, and no distinct correlation seemed to exist between the miR-196a-2 rs11614913 polymorphism and the risk of gastric cancer.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	23975664	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	21632853	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-146a levels in cancer tissues were significantly lower than those in the corresponding noncancerous tissue. Lower levels of miR-146a were associated with lymph node metastasis and venous invasion. Moreover, a lower level of miR-146a was an independent prognostic factor for overall survival.Ectopic expression of miR-146a inhibited migration and invasion and downregulated EGFR and IRAK1 expression in gastric cancer cells. In addition, G/C SNP within the pre-miR-146a seed sequence significantly reduced miR-146a levels in the GG genotype compared with the CC genotype.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	22455393	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A Functional Polymorphism (rs2910164) in Pre-miR-146a Is Associated with Susceptibility to Gastric Cancer in a Chinese Population.
genetics_GWAS	hsa-mir-146a	Gastric Neoplasms	27267319	disease of cellular proliferation	DOID:10534	C16	D013274	137215		rs2910164 of miR-146a is associated with GC
genetics_GWAS	hsa-mir-148a	Gastric Neoplasms	25399950	disease of cellular proliferation	DOID:10534	C16	D013274	137215		the SCRN1 rs6976789 polymorphism may play an important role in the GC development and progression.
genetics_GWAS	hsa-mir-149	Gastric Neoplasms	24379078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population.
genetics_GWAS	hsa-mir-149	Gastric Neoplasms	25795117	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk.
genetics_GWAS	hsa-mir-149	Gastric Neoplasms	21976437	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Marginally significant associations were found both for hsa-miR-149 rs2292832 with gastric cancer risk (TC+CC vs. TT, OR=0.68, 95% CI: 0.44-1.04) and for hsa-miR-605 rs2043556 with colorectal cancer risk (AG+GG vs. AA, OR=0.70, 95% CI: 0.48-1.02) in males.
genetics_GWAS	hsa-mir-149	Gastric Neoplasms	26345764	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility.
genetics_GWAS	hsa-mir-149	Gastric Neoplasms	28523307	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-149 rs2292832 C>T polymorphism and risk of gastric cancer.
genetics_GWAS	hsa-mir-184	Gastric Neoplasms	23724109	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The miR-184 Binding-Site rs8126 T>C Polymorphism in TNFAIP2 Is Associated with Risk of Gastric Cancer.
genetics_GWAS	hsa-mir-196a-2	Gastric Neoplasms	24379078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population.
genetics_GWAS	hsa-mir-196a-2	Gastric Neoplasms	25795117	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk.
genetics_GWAS	hsa-mir-196a-2	Gastric Neoplasms	26406571	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our studies suggested that the miR-146a rs2910164 polymorphism might marginally contribute to a decreased risk of gastric cancer, especially in Caucasians, whereas the miR-196a2 rs11614913 polymorphism might not be associated with susceptibility to GC.
genetics_GWAS	hsa-mir-196a-2	Gastric Neoplasms	26345764	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility.
genetics_GWAS	hsa-mir-196a-2	Gastric Neoplasms	26345790	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In summary, the results suggested that the miR-146a rs2910164 polymorphism was related to gastric cancer risk in Asians but not in Caucasians, and no distinct correlation seemed to exist between the miR-196a-2 rs11614913 polymorphism and the risk of gastric cancer.
genetics_GWAS	hsa-mir-196a-2	Gastric Neoplasms	19834808	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-196a-2:Association of microRNA-196a-2 gene polymorphism with gastric cancer risk
genetics_GWAS	hsa-mir-196a-2	Gastric Neoplasms	23975664	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
genetics_GWAS	hsa-mir-200c	Gastric Neoplasms	23065816	disease of cellular proliferation	DOID:10534	C16	D013274	137215		G-A variant in miR-200c binding site of EFNA1 alters susceptibility to gastric cancer
genetics_GWAS	hsa-mir-212	Gastric Neoplasms	24981235	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population.
genetics_GWAS	hsa-mir-214	Gastric Neoplasms	25998065	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our data suggested that rs114673809, which is located at the miR-214 binding site in the 3'-UTR of MTHFR, may play an important role in the development of gastric cancer in a Chinese Han population.
genetics_GWAS	hsa-mir-219-1	Gastric Neoplasms	23975664	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
genetics_GWAS	hsa-mir-26a-1	Gastric Neoplasms	23975664	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
genetics_GWAS	hsa-mir-27a	Gastric Neoplasms	25399405	disease of cellular proliferation	DOID:10534	C16	D013274	137215		rs895819 and rs11671784 inversely affect gastric cancer risk and the influence was closely related to their effects on miR-27a expression.
genetics_GWAS	hsa-mir-27a	Gastric Neoplasms	25795117	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk.
genetics_GWAS	hsa-mir-27a	Gastric Neoplasms	26345764	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility.
genetics_GWAS	hsa-mir-27a	Gastric Neoplasms	23975664	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
genetics_GWAS	hsa-mir-27a	Gastric Neoplasms	20666778	disease of cellular proliferation	DOID:10534	C16	D013274	137215		mir-27a:mir-27a genetic variant contributes to gastric cancer susceptibility
genetics_GWAS	hsa-mir-27a	Gastric Neoplasms	22350505	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The SNP rs895819 in the miR-27a gene with the minor allele C presented significantly reduced risk to gastric cancer in Chinese population.
genetics_GWAS	hsa-mir-27a	Gastric Neoplasms	23246964	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility
genetics_GWAS	hsa-mir-29c	Gastric Neoplasms	25661340	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miR-29c binding site genetic variant in the 3'-untranslated region of LAMTOR3 gene is associated with gastric cancer risk.
genetics_GWAS	hsa-mir-30c-1	Gastric Neoplasms	22108846	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The genotype frequencies of pre-miR-30c A/G (Polymorphism rs928508 in pre-miR-30c) in gastric cancer patients were obviously different from those in the controls (P = 0.022). AA genotype carriers were associated with an increased risk of gastric cancer compared with GG genotype (adjusted odds ratio (OR) = 1.83, 95% confidence interval (CI): 1.07-3.15, P = 0.029). Moreover, the gastric cancer risk especially elevated in older individuals (aged >60 years), males, nonsmokers, and Helicobacter pylori (H. pylori)-infected individuals (adjusted OR = 2.66, 95% CI: 1.38-5.13, P = 0.004; adjusted OR = 1.90, 95% CI: 1.10-3.27, P = 0.022; adjusted OR = 1.94, 95% CI: 1.12-3.35, P = 0.018; adjusted OR = 1.83, 95% CI: 1.08-3.10, P = 0.024, respectively). Further stratified analysis indicated that AA genotype facilitated developing of gastric cancer with lymph node metastasis (adjusted OR = 2.23, 95% CI: 1.07-4.64, P = 0.032). Expression analysis detected that rs928508 AA showed a significantly increased level of mature miR-30c compared with GG or AG/GG genotype (P = 0.011 or P = 0.013). Patients with AA genotype were associated with unfavorable outcome in overall survival compared with AG/GG genotype (Log rank 5.848, P = 0.016). This study demonstrates that pre-miR-30c A/G polymorphism may be associated with an increased risk of gastric cancer in a Chinese population through altering mature miR-30c expression.
genetics_GWAS	hsa-mir-30c-2	Gastric Neoplasms	22108846	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The genotype frequencies of pre-miR-30c A/G (Polymorphism rs928508 in pre-miR-30c) in gastric cancer patients were obviously different from those in the controls (P = 0.022). AA genotype carriers were associated with an increased risk of gastric cancer compared with GG genotype (adjusted odds ratio (OR) = 1.83, 95% confidence interval (CI): 1.07-3.15, P = 0.029). Moreover, the gastric cancer risk especially elevated in older individuals (aged >60 years), males, nonsmokers, and Helicobacter pylori (H. pylori)-infected individuals (adjusted OR = 2.66, 95% CI: 1.38-5.13, P = 0.004; adjusted OR = 1.90, 95% CI: 1.10-3.27, P = 0.022; adjusted OR = 1.94, 95% CI: 1.12-3.35, P = 0.018; adjusted OR = 1.83, 95% CI: 1.08-3.10, P = 0.024, respectively). Further stratified analysis indicated that AA genotype facilitated developing of gastric cancer with lymph node metastasis (adjusted OR = 2.23, 95% CI: 1.07-4.64, P = 0.032). Expression analysis detected that rs928508 AA showed a significantly increased level of mature miR-30c compared with GG or AG/GG genotype (P = 0.011 or P = 0.013). Patients with AA genotype were associated with unfavorable outcome in overall survival compared with AG/GG genotype (Log rank 5.848, P = 0.016). This study demonstrates that pre-miR-30c A/G polymorphism may be associated with an increased risk of gastric cancer in a Chinese population through altering mature miR-30c expression.
genetics_GWAS	hsa-mir-34b	Gastric Neoplasms	25190020	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population.
genetics_GWAS	hsa-mir-34b	Gastric Neoplasms	25658980	disease of cellular proliferation	DOID:10534	C16	D013274	137215		rs4938723 polymorphism is associated with a decreased risk of gastric cancer.
genetics_GWAS	hsa-mir-34c	Gastric Neoplasms	25190020	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population.
genetics_GWAS	hsa-mir-34c	Gastric Neoplasms	25658980	disease of cellular proliferation	DOID:10534	C16	D013274	137215		rs4938723 polymorphism is associated with a decreased risk of gastric cancer.
genetics_GWAS	hsa-mir-361	Gastric Neoplasms	24981235	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A functional variant at miR-132-3p, miR-212-3p, and miR-361-5p binding site in CD80 gene alters susceptibility to gastric cancer in a Chinese Han population.
genetics_GWAS	hsa-mir-423	Gastric Neoplasms	23975664	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
genetics_GWAS	hsa-mir-449a	Gastric Neoplasms	26722545	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, our findings suggest that miR-449a rs112310158 is a genetic risk factor for GC.
genetics_GWAS	hsa-mir-499	Gastric Neoplasms	24107911	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The rs3746444 (A>G) SNP is not associated with susceptibility to GC in the Chinese population.
genetics_GWAS	hsa-mir-499	Gastric Neoplasms	25795117	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27a rs895819 and miR-149 rs2292832 are of potential forewarning ability for gastric cancer risk.
genetics_GWAS	hsa-mir-499	Gastric Neoplasms	26345764	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overall, this meta-analysis failed to detect an association between five common miR-146a gene polymorphisms and GC susceptibility. However, this does not necessarily completely rule out a correlation between miRNA polymorphisms and GC susceptibility.
genetics_GWAS	hsa-mir-499	Gastric Neoplasms	26597478	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The present study indicated that miR-499 rs3746444 might contribute to GC risk and this SNP could be developed as a biomarker for GC prediction.
genetics_GWAS	hsa-mir-505	Gastric Neoplasms	26394032	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The PSMD10 rs111638916 SNP is highly associated with an increased risk of GC in Chinese patients, and could serve as a novel biomarker for this disease.
genetics_GWAS	hsa-mir-570	Gastric Neoplasms	22190470	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A guanine-to-cytosine mutation at the 3'-UTR of CD274 mRNA led to CD274 over-expression by disrupting the miR-570 binding. A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding.
genetics_GWAS	hsa-mir-605	Gastric Neoplasms	21976437	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Marginally significant associations were found both for hsa-miR-149 rs2292832 with gastric cancer risk (TC+CC vs. TT, OR=0.68, 95% CI: 0.44-1.04) and for hsa-miR-605 rs2043556 with colorectal cancer risk (AG+GG vs. AA, OR=0.70, 95% CI: 0.48-1.02) in males.
genetics_GWAS	hsa-mir-624	Gastric Neoplasms	24568522	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Bioinformatic prediction of SNPs within miRNA binding sites of inflammatory genes associated with gastric cancer.
genetics_GWAS	hsa-mir-938	Gastric Neoplasms	22537748	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genetic polymorphisms of IL17A ((rs2275913 (-197 G > A), rs3748067 (*1249 C > T)) and pri-microRNA-938 (pri-miR-938, rs2505901 (T > C).), targeting IL17A 3'-UTR, influence susceptibility to gastric cancer.
genetics_GWAS	hsa-mir-146a	Gastrointestinal Neoplasms	25693929			D37.9	D005770			No significant association between miR-146a rs2910164G/C polymorphism and gastrointestinal cancer susceptibility was found in this meta-analysis. But for homozygous model, people with GG genotype may have increased risk of developing colorectal cancer.
genetics_GWAS	hsa-mir-146a	Gastrointestinal Neoplasms	20653068			D37.9	D005770			Pre-miR-146a C/G polymorphism might be associated with an elevatedrisk of gastric cancer in Chinese population.
genetics_GWAS	hsa-mir-146a	Gastrointestinal Neoplasms	20721625			D37.9	D005770			This study revealed the combined effect of miR-146a rs2910164 G/G and TLR4 +3725 C allele on the increased risk of severe gastric atrophy among the H. pylori-infected Japanese subjects.
genetics_GWAS	hsa-mir-146a	Gastrointestinal Neoplasms	21073609			D37.9	D005770			The rs2910164 (G>C) SNP in the miR-146a is associated with susceptibility to GC.
genetics_GWAS	hsa-mir-146a	Generalized Epilepsy with Febrile Seizures Plus	25319229	nervous system disease	DOID:0060170	G40.3	C565808	604233		Association of genetic polymorphism of pre-microRNA-146a rs2910164 and serum high-mobility group box 1 with febrile seizures in Egyptian children.
genetics_GWAS	hsa-mir-182	Glaucoma	27537254	nervous system disease	DOID:1686	H40	D005901	137750		A Common Variant in MIR182 Is Associated With Primary Open-Angle Glaucoma in the NEIGHBORHOOD Consortium.
genetics_GWAS	hsa-mir-5481	Glaucoma	25809640	nervous system disease	DOID:1686	H40	D005901	137750		These data support the role of hsa-miR-548l as a regulator of FOXC1 translation and provide evidence for the c.*734A>T variant as a modifier factor for the activity of coding glaucoma-associated FOXC1 mutations.
genetics_GWAS	hsa-mir-146a	Glioblastoma	21744077				D005909		HP:0100843	A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. An increased glioma risk was observed among rs2910164 minor allele (C) carriers (per allele OR (95%CI)=1.22 (1.01-1.46, p (trend)=0.039)). The association was stronger among older subjects carrying at least one copy of the C allele (OR (95% CI)=1.38 (1.04-1.83, P=0.026). Mortality was increased among minor allele carriers (HR(95% CI)=1.33 (1.03-1.72, P=0.029)), with the association largely restricted to females (HR (95% CI)=2.02 (1.28-3.17, P=0.002)).
genetics_GWAS	hsa-mir-196a-1	Glioma	20229273	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population
genetics_GWAS	hsa-mir-196a2	Glioma	27796868	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Effect of rs11614913 Polymorphism on Mature miR196a2 Expression and its Target Gene HOXC8 Expression in Human Glioma.
genetics_GWAS	hsa-mir-196a-2	Glioma	20229273	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population
genetics_GWAS	hsa-mir-1207	Glomerulonephritis	22319602	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	A miR-1207-5p binding site polymorphism (C1936T, rs13385) abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy.
genetics_GWAS	hsa-mir-519a-1	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-519a-2	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-519b	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-519c	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-519d	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-519e	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-520a	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-520b	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-520d	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-520e	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-520f	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-520g	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-520h	Gout	21558165	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	There was a clear link between the rs1333049 genotypic and allelic frequencies between gout cases and controls. There was a significantly increased risk of gout in carriers of the CC genotype.This SNP is homologous to miR-519 and miR-520.
genetics_GWAS	hsa-mir-146a	Graft-Versus-Host Disease	27156151			D89.813	D006086	614395		expression levels of miR-146aC>G, miR-196a2T>C and putative gene-gene interaction between miR-146a, miR-196a2, miR-149 may be involved in RIF development in Korean women.
genetics_GWAS	hsa-mir-149	Graft-Versus-Host Disease	27156151			D89.813	D006086	614395		expression levels of miR-146aC>G, miR-196a2T>C and putative gene-gene interaction between miR-146a, miR-196a2, miR-149 may be involved in RIF development in Korean women.
genetics_GWAS	hsa-mir-196a2	Graft-Versus-Host Disease	27156151			D89.813	D006086	614395		expression levels of miR-146aC>G, miR-196a2T>C and putative gene-gene interaction between miR-146a, miR-196a2, miR-149 may be involved in RIF development in Korean women.
genetics_GWAS	hsa-mir-499a	Graft-Versus-Host Disease	27156151			D89.813	D006086	614395		expression levels of miR-146aC>G, miR-196a2T>C and putative gene-gene interaction between miR-146a, miR-196a2, miR-149 may be involved in RIF development in Korean women.
genetics_GWAS	hsa-mir-125a	Habitual Abortion	21788734			N96	D000026			Two common SNPs (rs41275794, rs12976445) in pri-miR-125a alter the mature miRNA expression and associate with Abortion, Habitual in a Han-Chinese population.
genetics_GWAS	hsa-mir-196a-2	Habitual Abortion	22222140			N96	D000026			RSA(recurrent spontaneous abortion) patients exhibited significantly different frequencies of the miR-196a2CC (TT+TC vs. CC; adjusted odds ratio [AOR], 1.587; 95% confidence interval [CI], 1.042-2.417) and miR-499AG+GG genotypes (AOR, 1.671; 95% CI, 1.054-2.651) compared with the control group.
genetics_GWAS	hsa-mir-499a	Habitual Abortion	22222140			N96	D000026			RSA(recurrent spontaneous abortion) patients exhibited significantly different frequencies of the miR-196a2CC (TT+TC vs. CC; adjusted odds ratio [AOR], 1.587; 95% confidence interval [CI], 1.042-2.417) and miR-499AG+GG genotypes (AOR, 1.671; 95% CI, 1.054-2.651) compared with the control group.
genetics_GWAS	hsa-mir-146a	Head And Neck Neoplasms	26277865	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis.
genetics_GWAS	hsa-mir-149	Head And Neck Neoplasms	26277865	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis.
genetics_GWAS	hsa-mir-196a-2	Head And Neck Neoplasms	26277865	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis.
genetics_GWAS	hsa-mir-499	Head And Neck Neoplasms	26277865	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Significant association between functional microRNA polymorphisms and head and neck cancer susceptibility: a comprehensive meta-analysis.
genetics_GWAS	hsa-mir-885	Head And Neck Neoplasms	23271051	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer
genetics_GWAS	hsa-mir-22	Heart Failure	23372812			I50	D006331		HP:0001635	Common variation neighbouring micro-RNA 22 is associated with increased left ventricular mass.
genetics_GWAS	hsa-mir-499a	Heart Failure	22374132			I50	D006331		HP:0001635	A naturally occurring miR-499 mutation(u17c in the 3' end) outside the critical seed sequence modifies mRNA targeting and end-organ function.
genetics_GWAS	hsa-let-7	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-146	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-150	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-155	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-15a	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-16-1	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-21	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-221	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-222	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-29	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-34	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-372	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-373	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-mir-708	Hematologic Neoplasms	26520014	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	our compiled results will be valuable for researchers interested in determining the role of target-SNPs in the development of hematological malignancies.
genetics_GWAS	hsa-let-7	Hepatitis B Virus Infection	24729511	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association of a functional RAD52 genetic variant locating in a miRNA binding site with risk of HBV-related hepatocellular carcinoma.
genetics_GWAS	hsa-let-7c	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-106b	Hepatitis B Virus Infection	22393390	disease by infectious agent	DOID:2043	B16/18	D006509	610424		A Genetic Variant (rs999885) in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma.Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67-0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers (adjusted OR=1.25, 95% CIs=1.06-1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues.
genetics_GWAS	hsa-mir-106b	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-122	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-124	Hepatitis B Virus Infection	23807362	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine.
genetics_GWAS	hsa-mir-146a	Hepatitis B Virus Infection	23292505	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association of a single-nucleotide polymorphism within the miR-146a gene with susceptibility for acute-on-chronic hepatitis B liver failure
genetics_GWAS	hsa-mir-146a	Hepatitis B Virus Infection	23807362	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine.
genetics_GWAS	hsa-mir-146a	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-149	Hepatitis B Virus Infection	23807362	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine.
genetics_GWAS	hsa-mir-149	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-196a-1	Hepatitis B Virus Infection	23516510	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Associations of pri-miR-34b/c and pre-miR-196a2 Polymorphisms and Their Multiplicative Interactions with Hepatitis B Virus Mutations with Hepatocellular Carcinoma Risk
genetics_GWAS	hsa-mir-196a-2	Hepatitis B Virus Infection	23807362	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine.
genetics_GWAS	hsa-mir-196a-2	Hepatitis B Virus Infection	23516510	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Associations of pri-miR-34b/c and pre-miR-196a2 Polymorphisms and Their Multiplicative Interactions with Hepatitis B Virus Mutations with Hepatocellular Carcinoma Risk
genetics_GWAS	hsa-mir-196a-2	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-218	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-25	Hepatitis B Virus Infection	22393390	disease by infectious agent	DOID:2043	B16/18	D006509	610424		A Genetic Variant (rs999885) in the Promoter Region of miR-106b-25 Cluster and Risk of HBV Infection and Hepatocellular Carcinoma.Compared with the HBV natural clearance subjects carrying rs999885 AA genotype, those with AG/GG genotypes had a decreased risk of chronic HBV infection with an adjusted odds ratio (OR) of 0.79 [95% confidence intervals (CIs)=0.67-0.93]. However, the AG/GG genotypes were significantly associated with an increased HCC risk in HBV persistent carriers (adjusted OR=1.25, 95% CIs=1.06-1.47). Expression analysis revealed that the expression level of miR-106b-25 cluster was significantly higher in AG/GG carriers than those in AA carriers in non-tumor liver tissues.
genetics_GWAS	hsa-mir-26a-1	Hepatitis B Virus Infection	23807362	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine.
genetics_GWAS	hsa-mir-27a	Hepatitis B Virus Infection	23807362	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association between microRNA polymorphisms and humoral immunity to hepatitis B vaccine.
genetics_GWAS	hsa-mir-34b	Hepatitis B Virus Infection	23516510	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Associations of pri-miR-34b/c and pre-miR-196a2 Polymorphisms and Their Multiplicative Interactions with Hepatitis B Virus Mutations with Hepatocellular Carcinoma Risk
genetics_GWAS	hsa-mir-34b	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-34c	Hepatitis B Virus Infection	23516510	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Associations of pri-miR-34b/c and pre-miR-196a2 Polymorphisms and Their Multiplicative Interactions with Hepatitis B Virus Mutations with Hepatocellular Carcinoma Risk
genetics_GWAS	hsa-mir-34c	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-499	Hepatitis B Virus Infection	25966251	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The meta-analysis results indicated that the miR-196a-2*T,miR-122*del, miR-106b-25*A, and miR-let-7c*del alleles/carriers increase the risk of hepatitis B among the Asian population. However, the miR-146a, miR- 499,miR-149, miR-218, and miR-34b/c polymorphisms may not be linked with the risk of hepatitis B. Further investigations are warranted to determine the exact associations between microRNA mutations and hepatitis B susceptibility.
genetics_GWAS	hsa-mir-196a-2	Hepatitis C Virus Infection	21604580	disease by infectious agent	DOID:1883	B19.2	D006526	609532		SNP rs11614913 on miR196a-2 gene is associated with  the antiviral therapy efficacy of hepatitis C patients.The TT genotype or T alleles be associated with the SVR while the CC genotype or C allele could be related to the NVR or recurrence.
genetics_GWAS	hsa-mir-146a	Hirschsprung Disease	25445498	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	the polymorphism rs2910164 in pre-miR-146a might alter the production of mature miR-146a and then down-regulate the target gene ROBO1, which plays an important role in pathogenesis of HSCR.
genetics_GWAS	hsa-mir-27a	Human Immunodeficiency Virus Infection	27919232			B20	D015658	609423		microRNA-27a rs895819 is associated with obesity in HIV infected preeclamptic Black South African women on HAART.
genetics_GWAS	hsa-mir-182	Hyperactivity Disorder	23906647	disease of mental health	DOID:1094	F90	D001289	143465	HP:0007018	Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs).
genetics_GWAS	hsa-mir-183	Hyperactivity Disorder	23906647	disease of mental health	DOID:1094	F90	D001289	143465	HP:0007018	Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs).
genetics_GWAS	hsa-mir-96	Hyperactivity Disorder	23906647	disease of mental health	DOID:1094	F90	D001289	143465	HP:0007018	Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs).
genetics_GWAS	hsa-mir-33b	Hyperglycemia	24825092	disease of metabolism	DOID:4195	E78.1	D006943		HP:0003074	Association of rs8066560 variant in the sterol regulatory element-binding protein 1 (SREBP-1) and miR-33b genes with hyperglycemia and insulin resistance.
genetics_GWAS	hsa-mir-485	Hyperglycemia	24387992	disease of metabolism	DOID:4195	E78.1	D006943		HP:0003074	An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site.
genetics_GWAS	hsa-mir-122	Hypertension	19067360	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	a polymorphism of the 3'UTR of the SLC7A1 gene affects the binding with miR-122
genetics_GWAS	hsa-mir-146a	Hypertension	27379568	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	This study suggests that the variant of miR-146aC>G polymorphism and  allelic combinations, at least in Koreans, affect susceptibility to hypertension.
genetics_GWAS	hsa-mir-155	Hypertension	20966899	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The interplay between miR-155 expression, +1166C polymorphism, and AT1R protein expression may have a role in the regulation of blood pressure.
genetics_GWAS	hsa-mir-31	Hypertension	23943853	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding.
genetics_GWAS	hsa-mir-518	Hypertension	24687999	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Our results suggest that TGFBR2 and miR-518 harbor variants that increase the risk of EH and affect blood pressure homeostasis as well as efficacy of antihypertensive agents.
genetics_GWAS	hsa-mir-584	Hypertension	23943853	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding.
genetics_GWAS	hsa-mir-637	Hypertension	21558123	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	A common genetic variant (rs938671) in the 3'-UTR of Vacuolar H+-ATPase ATP6V0A1 creates a micro-RNA (hsa-miR-637) motif to alter Chromogranin A (CHGA) processing and hypertension risk.
genetics_GWAS	hsa-mir-637	Hypertension	21846868	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	ATP6V0A1 Polymorphism and MicroRNA-637 may have A Pathogenetic Role for MicroRNAs in Essential Hypertension.
genetics_GWAS	hsa-mir-155	Hypertrophy	21771600				D006984			the C allele of rs5186 was associated with a significant increase in SWT (p=0.003) and LVM (p=0.001). This functional polymorphism increases expression of AGTR1 by altering the binding site for miR-155
genetics_GWAS	hsa-mir-146a	IgA Nephropathy	24781267	urinary system disease	DOID:2986	N02.8	D005922	161950	HP:0000794	These results indicated that rs2910164 may affect the susceptibility and severity of pediatric IgAN. Further studies are needed to validate these findings.
genetics_GWAS	hsa-mir-146a	Immune Thrombocytopenic Purpura	24502829	immune system disease	DOID:8924	D69.3	D016553	188030		hsa-mir-146a rs2910164 polymorphism and risk of immune thrombocytopenia.
genetics_GWAS	hsa-mir-146a	Intracranial Aneurysm	26214448	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		Association between the hsa-miR-146a rs2910164 functional polymorphism with susceptibility to intracranial aneurysm.
genetics_GWAS	hsa-mir-34b	Intracranial Aneurysm	22844323	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		The CC genotype of miR-34b/c rs4938723 was significantly associated with a decreased risk of IA compared with the TT genotype. Moreover, a significant gene interaction of the carriers with the combined genotypes of miR-34b/c rs4938723CC and TP53 Arg72Pro CG/CC/GG had a decreased risk of IA, compared with those carrying miR-34b/c rs4938723CT/TT+TP53 Arg72Pro GG/CG/CC combined genotypes.
genetics_GWAS	hsa-mir-34c	Intracranial Aneurysm	22844323	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		The CC genotype of miR-34b/c rs4938723 was significantly associated with a decreased risk of IA compared with the TT genotype. Moreover, a significant gene interaction of the carriers with the combined genotypes of miR-34b/c rs4938723CC and TP53 Arg72Pro CG/CC/GG had a decreased risk of IA, compared with those carrying miR-34b/c rs4938723CT/TT+TP53 Arg72Pro GG/CG/CC combined genotypes.
genetics_GWAS	hsa-mir-510	Irritable Bowel Syndrome	18614545	syndrome	DOID:9778	K58	D043183			First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor type 3E gene with diarrhea predominant irritable bowel syndrome.
genetics_GWAS	hsa-mir-146a	Kaposi Sarcoma	27819716	disease of cellular proliferation	DOID:8632	C46	D012514			Association of genetic variations in miR-146a rs2910164 and miR-149 rs11614913 with the development of classic Kaposi sarcoma.
genetics_GWAS	hsa-mir-149	Kaposi Sarcoma	27819716	disease of cellular proliferation	DOID:8632	C46	D012514			Association of genetic variations in miR-146a rs2910164 and miR-149 rs11614913 with the development of classic Kaposi sarcoma.
genetics_GWAS	hsa-mir-146a	Kidney Diseases [unspecific]	26426696			N18.9	D007674			There was no association of rs2910164 with susceptibility to IgAN in adults from a Chinese Han population. However, rs2910164 was correlated with the age of onset of IgAN in adult patients.
genetics_GWAS	hsa-mir-146a	Leprosy	25187983	disease by infectious agent	DOID:1024	A30.9	D007918	609888		Pre-miR-146a (rs2910164 G>C) single nucleotide polymorphism is genetically and functionally associated with leprosy.
genetics_GWAS	hsa-mir-142	Leukemia	15737576			C95	D007938	613065	HP:0001909	Some human miRNAs are linked to leukemias: the miR-15a/miR-16 locus is frequently deleted or down-regulated in patients with B-cell chronic lymphocytic  leukemia and miR-142 is at a translocation site found in a case of aggressive B-cell leukemia.
genetics_GWAS	hsa-mir-125b-1	Leukemia, Biphenotypic, Acute	20485370	disease of cellular proliferation	DOID:9953	C95.0	D015456		HP:0005531	miR-125b-1:A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia
genetics_GWAS	hsa-mir-499	Leukemia, Lymphoblastic, Acute	24618566	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	We found 11 SNPs significantly associated with ALL susceptibility. These included three SNPs present in miRNA genes (miR-612, miR-499, and miR-449b) and eight SNPs present in six miRNA biogenesis pathway genes (TNRC6B, DROSHA, DGCR8,  EIF2C1, CNOT1, and CNOT6).
genetics_GWAS	hsa-mir-34b	Leukemia, Lymphoblastic, Acute, Childhood	27886674	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		Pri-miR-34b/c rs4938723 polymorphism is associated with the risk of childhood acute lymphoblastic leukemia.
genetics_GWAS	hsa-mir-34c	Leukemia, Lymphoblastic, Acute, Childhood	27886674	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		Pri-miR-34b/c rs4938723 polymorphism is associated with the risk of childhood acute lymphoblastic leukemia.
genetics_GWAS	hsa-mir-1206	Leukemia, Lymphocytic, Chronic, B-Cell	25793711	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	These findings suggest that polymorphisms in genes involved in miRNAs biogenesis pathway as well as in pre-miRNAs contribute to the risk of CLL. Large-scale studies are needed to validate the current findings.
genetics_GWAS	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	mutation
genetics_GWAS	hsa-mir-187	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	mutation
genetics_GWAS	hsa-mir-196a-2	Leukemia, Lymphocytic, Chronic, B-Cell	25793711	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	These findings suggest that polymorphisms in genes involved in miRNAs biogenesis pathway as well as in pre-miRNAs contribute to the risk of CLL. Large-scale studies are needed to validate the current findings.
genetics_GWAS	hsa-mir-206	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	mutation
genetics_GWAS	hsa-mir-27b	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	mutation
genetics_GWAS	hsa-mir-29b-1	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	mutation
genetics_GWAS	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	26959643	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	mutations in the mir-15a/16-1 loci are responsible for decreased expression
genetics_GWAS	hsa-mir-34c	Leukemia, Myeloid	24886876	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	Our study implicates that microRNA-binding site polymorphisms modulate leukemia risk by interfering with the miRNA-mediated regulation. Our findings underscore the significance of variability in 3' untranslated regions in leukemia.
genetics_GWAS	hsa-mir-449b	Leukemia, Myeloid	24886876	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	Our study implicates that microRNA-binding site polymorphisms modulate leukemia risk by interfering with the miRNA-mediated regulation. Our findings underscore the significance of variability in 3' untranslated regions in leukemia.
genetics_GWAS	hsa-mir-125b-1	Leukemia, Myeloid, Acute	22843432	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m))-induced myeloid leukemia.
genetics_GWAS	hsa-mir-142	Leukemia, Myeloid, Acute	24724784	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Absence of miR-142 mutation in Chinese patients with acute myeloid leukemia.
genetics_GWAS	hsa-mir-337	Leukemia, Myeloid, Acute	23065518	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia
genetics_GWAS	hsa-mir-370	Leukemia, Myeloid, Acute	23077663	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia
genetics_GWAS	hsa-mir-126	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	20621067	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-126:Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126
genetics_GWAS	hsa-mir-128-2	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	20237425	disease of cellular proliferation	DOID:5599	C83.5	D054218			A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells.
genetics_GWAS	hsa-mir-605	Li-Fraumeni Syndrome	25683625	genetic disease	DOID:3012	Z15.01	D016864	151623		A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome.
genetics_GWAS	hsa-let-7	Liver Cirrhosis	27992614	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men.
genetics_GWAS	hsa-mir-196a-2	Liver Cirrhosis	26529280	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	In summary, rs12304647 is associated with a reduced risk of progression to HCC in patients with chronic HBV infection.
genetics_GWAS	hsa-mir-196a-2	Liver Neoplasms	24633889	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Quantitative assessment of the association between miR-196a2 rs11614913 polymorphism and cancer risk: evidence based on 45,816 subjects.
genetics_GWAS	hsa-let-7a-1	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7a-2	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7a-3	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7b	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7b: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7c	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7c: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7d	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7d: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7e	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7e: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7f-1	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7f: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7f-2	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7f: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7g	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7g: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-let-7i	Lung Neoplasms	18922928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7i: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk
genetics_GWAS	hsa-mir-146a	Lung Neoplasms	25077922	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk.
genetics_GWAS	hsa-mir-146a	Lung Neoplasms	25154761	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-146a rs2910164 polymorphism is associated with susceptibility to non-small cell lung cancer in the Chinese population.
genetics_GWAS	hsa-mir-146a	Lung Neoplasms	25524943	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-196a2 SNP influences the susceptibility of lung cancer. Mir-146a and mir-149 SNP do not play a role in lung cancer risk. These findings need more validation by larger studies.
genetics_GWAS	hsa-mir-146a	Lung Neoplasms	26083623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant.
genetics_GWAS	hsa-mir-146a	Lung Neoplasms	26926727	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population.
genetics_GWAS	hsa-mir-146a	Lung Neoplasms	24144839	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These findings suggest that the rs2910164C>G in pre-miR-146a may contribute to genetic susceptibility to lung cancer, and that miR-146a might be involved in lung cancer development.
genetics_GWAS	hsa-mir-146a	Lung Neoplasms	22818121	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our findings suggest that polymorphisms in the rs2910164 of miR-146a and the rs11614913 of miR-196a2 are associated with prognosis in patients with completely resected NSCLC.
genetics_GWAS	hsa-mir-149	Lung Neoplasms	25077922	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk.
genetics_GWAS	hsa-mir-149	Lung Neoplasms	25524943	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-196a2 SNP influences the susceptibility of lung cancer. Mir-146a and mir-149 SNP do not play a role in lung cancer risk. These findings need more validation by larger studies.
genetics_GWAS	hsa-mir-149	Lung Neoplasms	27685326	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-149 rs2292832 polymorphism may not be associated with lung cancer risk in Chinese non-smoking female
genetics_GWAS	hsa-mir-196a	Lung Neoplasms	22818121	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our findings suggest that polymorphisms in the rs2910164 of miR-146a and the rs11614913 of miR-196a2 are associated with prognosis in patients with completely resected NSCLC.
genetics_GWAS	hsa-mir-196a-1	Lung Neoplasms	23143626	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population
genetics_GWAS	hsa-mir-196a-2	Lung Neoplasms	26083623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant.
genetics_GWAS	hsa-mir-196a-2	Lung Neoplasms	26926727	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population.
genetics_GWAS	hsa-mir-196a-2	Lung Neoplasms	25077922	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk.
genetics_GWAS	hsa-mir-196a-2	Lung Neoplasms	25524943	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-196a2 SNP influences the susceptibility of lung cancer. Mir-146a and mir-149 SNP do not play a role in lung cancer risk. These findings need more validation by larger studies.
genetics_GWAS	hsa-mir-196a-2	Lung Neoplasms	21483822	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	rs11614913 polymorphism:Overall, individuals with the TC/CC genotypes were associated with higher cancer risk than those with the TT genotype (OR=1.18, 95% CI=1.03-1.34, P<0.001 for heterogeneity test). In the stratified analyses, we observed that the CC genotype might modulate breast cancer risk (OR=1.11, 95%CI=1.01-1.23, P(heterogeneity)=0.210) and lung cancer risk (OR=1.25, 95%CI=1.06-1.46, P(heterogeneity)=0.958), comparing with the TC/TT genotype. Moreover, a significantly increased risk was found among Asian populations in a dominant model (TC/CC versus TT, OR=1.24, 95% CI=1.07-1.43, P(heterogeneity)=0.006).
genetics_GWAS	hsa-mir-196a-2	Lung Neoplasms	23143626	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population
genetics_GWAS	hsa-mir-196a-2	Lung Neoplasms	18521189	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Therefore, the rs11614913 SNP in hsa-mir-196a2 may be a prognostic biomarker for NSCLC.
genetics_GWAS	hsa-mir-25	Lung Neoplasms	22349819	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	REV3L 3'UTR 460 T>C polymorphism in microRNA(miR-25/32) target sites contributes to lung cancer susceptibility.
genetics_GWAS	hsa-mir-26a-1	Lung Neoplasms	26926727	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population.
genetics_GWAS	hsa-mir-27a	Lung Neoplasms	26083623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant.
genetics_GWAS	hsa-mir-27a	Lung Neoplasms	26926727	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population.
genetics_GWAS	hsa-mir-300	Lung Neoplasms	26926727	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Rs11614913, rs12894467 and rs2910164 polymorphism were potentially associated with primary lung cancer in Fujian Han population.
genetics_GWAS	hsa-mir-30c-1	Lung Neoplasms	23159078	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Single nucleotide polymorphism in flanking region of miR-30c influences the maturing process of miR-30c in lung carcinoma
genetics_GWAS	hsa-mir-30c-2	Lung Neoplasms	23159078	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Single nucleotide polymorphism in flanking region of miR-30c influences the maturing process of miR-30c in lung carcinoma
genetics_GWAS	hsa-mir-32	Lung Neoplasms	22349819	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	REV3L 3'UTR 460 T>C polymorphism in microRNA(miR-25/32) target sites contributes to lung cancer susceptibility.
genetics_GWAS	hsa-mir-423	Lung Neoplasms	26083623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant.
genetics_GWAS	hsa-mir-423	Lung Neoplasms	26973201	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These findings suggest that miR-146a rs2910164C>G and miR-423 rs6505162C>A polymorphisms may contribute to genetic susceptibility to lung cancer and lung adenocarcinoma in Chinese non-smoking females.
genetics_GWAS	hsa-mir-499	Lung Neoplasms	25614447	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the rs3746444T>C polymorphism in mature miR-499 sequence could contribute to poor prognosis by modulating cancer-related genes' expression and thus involve tumorigenesis and anti-chemotherapy, which may be a useful biomarker to predict lung cancer patients' prognosis.
genetics_GWAS	hsa-mir-499b	Lung Neoplasms	25077922	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk.
genetics_GWAS	hsa-mir-608	Lung Neoplasms	26083623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The interactions between miRNA SNPs and cooking oil fume exposure suggested by ORs of different combination were not statistically significant.
genetics_GWAS	hsa-mir-629	Lung Neoplasms	22114071	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The rs2735383CC (NBS1 gene) genotype had a significantly increased risk of lung cancer under a recessive genetic model in the total 1559 cases versus 1679 controls (OR = 1.40, 95% C.I. = 1.18-1.66, P = 0.0001) when compared with GG or GC genotypes; the rs2735383CC genotype carriers had lower mRNA and protein expression levels in tumor tissues than those of other genotypes as qPCR and western blot shown. Luciferase assay revealed that the rs2735383C allele had a lower transcription activity than G allele; and the hsa-miR-629 but not hsa-miR-499-5P had effect on modulation of NBS1 gene in vitro. We further observed that the X-ray radiation induced more chromatid breaks in lymphocyte cells from the carriers of rs2735383CC homozygote than those from the subjects with other genotypes (P = 0.0008). Our data suggested that the rs2735383G>C variation contributes to an increased risk of lung cancer by diminishing gene's expression through binding of microRNA-629 to the polymorphic site in the 3'-UTR of NBS1 gene.
genetics_GWAS	hsa-mir-6720	Lymphedema	29511529	immune system disease	DOID:4977	I89.0	D008209	PS153100	HP:0001004	rs121909106 and rs121909107 were predicted to have the most harmful effects, while hsa-miR-6886-5p, hsa-miR-6886-5p and hsa-miR-6720-3p were predicted to be the most important miRNAs affected
genetics_GWAS	hsa-mir-6886	Lymphedema	29511529	immune system disease	DOID:4977	I89.0	D008209	PS153100	HP:0001004	rs121909106 and rs121909107 were predicted to have the most harmful effects, while hsa-miR-6886-5p, hsa-miR-6886-5p and hsa-miR-6720-3p were predicted to be the most important miRNAs affected
genetics_GWAS	hsa-mir-146a	Lymphoma, B-Cell	25370733	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population.
genetics_GWAS	hsa-mir-142	Lymphoma, Follicular	27389057	disease of cellular proliferation	DOID:0050873	C82	D008224	613024		We found recurrent mutations of miR-142, which has not been previously been reported to be mutated in FL/tFL.
genetics_GWAS	hsa-mir-142	Lymphoma, Large B-Cell, Diffuse	27390358	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Additionally, we detected recurrent mutations of hsa-miR-142 in diffuse large B-cell lymphomas and follicular lymphomas, and editing of the hsa-miR-376 cluster, providing evidence for microRNA editing in lymphomagenesis.
genetics_GWAS	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	25677902	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		the miRs expression in B-NHLs[11q] provides a new suggestion, in addition to pathomorphological and clinical similarities between classical, i.e.,MYC translocation-positive BL, and B-NHLs[11q], to recognize the B-NHLs[11q] subgroup of DLBCL/BL category as a MYC translocation-negative variant of BL in most cases, and points to the potential utility of miR-155/BIC/miR-21/miR-26a for the differential diagnosis of a heterogeneous category of DLBCL/BL.
genetics_GWAS	hsa-mir-21	Lymphoma, Large B-Cell, Diffuse	25677902	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		the miRs expression in B-NHLs[11q] provides a new suggestion, in addition to pathomorphological and clinical similarities between classical, i.e.,MYC translocation-positive BL, and B-NHLs[11q], to recognize the B-NHLs[11q] subgroup of DLBCL/BL category as a MYC translocation-negative variant of BL in most cases, and points to the potential utility of miR-155/BIC/miR-21/miR-26a for the differential diagnosis of a heterogeneous category of DLBCL/BL.
genetics_GWAS	hsa-mir-26a	Lymphoma, Large B-Cell, Diffuse	25677902	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		the miRs expression in B-NHLs[11q] provides a new suggestion, in addition to pathomorphological and clinical similarities between classical, i.e.,MYC translocation-positive BL, and B-NHLs[11q], to recognize the B-NHLs[11q] subgroup of DLBCL/BL category as a MYC translocation-negative variant of BL in most cases, and points to the potential utility of miR-155/BIC/miR-21/miR-26a for the differential diagnosis of a heterogeneous category of DLBCL/BL.
genetics_GWAS	hsa-mir-376	Lymphoma, Large B-Cell, Diffuse	27390358	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		we detected recurrent mutations of hsa-miR-142 in diffuse large B-cell lymphomas and follicular lymphomas, and editing of the hsa-miR-376 cluster, providing evidence for microRNA editing in lymphomagenesis.
genetics_GWAS	hsa-mir-155	Lymphoma, Non-Hodgkin	22347493	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Variant rs928883, near miR-155, showed an association (OR per A-allele: 2.80 [95% CI: 1.63-4.82]; p(F)=0.027) with marginal zone lymphoma that is significant after correction for multiple testing.
genetics_GWAS	hsa-mir-196a	Lymphoma, Non-Hodgkin	25501512	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	the miR-196a2 polymorphism may increase the risk of NHL by  altering the expression of mature miR-196a.
genetics_GWAS	hsa-mir-502	Lymphoma, Non-Hodgkin	25343552	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	the SNP in the miRNA binding site of the SET8 3'-untranslated region seems to influence survival of NHL. It may have possible prognostic and survival value in the clinic.
genetics_GWAS	hsa-let-7	Macular Degeneration	28343170	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD).
genetics_GWAS	hsa-let-7a	Macular Degeneration	28343170	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD).
genetics_GWAS	hsa-let-7b	Macular Degeneration	28343170	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD).
genetics_GWAS	hsa-let-7d	Macular Degeneration	28343170	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD).
genetics_GWAS	hsa-mir-146a	Macular Degeneration	28343170	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD).
genetics_GWAS	hsa-mir-155	Macular Degeneration	28343170	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD).
genetics_GWAS	hsa-mir-1302-1	Male Infertility	21601192	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro.
genetics_GWAS	hsa-mir-1302-2	Male Infertility	21601192	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro.
genetics_GWAS	hsa-mir-1302-3	Male Infertility	21601192	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro.
genetics_GWAS	hsa-mir-1302-4	Male Infertility	21601192	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro.
genetics_GWAS	hsa-mir-1302-5	Male Infertility	21601192	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro.
genetics_GWAS	hsa-mir-1302-6	Male Infertility	21601192	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro.
genetics_GWAS	hsa-mir-1302-7	Male Infertility	21601192	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro.
genetics_GWAS	hsa-mir-1302-8	Male Infertility	21601192	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Two SNPs from two genes (rs6631 of CGA and rs2303846 of CPEB1)(binding sites of miR-1302) were found to be associated with idiopathic male infertility. Functionally, the substitution of A by T in rs6631 results in decreased binding affinity of miR-1302 and overexpression of CGA in vitro.
genetics_GWAS	hsa-mir-34b	Male Infertility	26505368	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Our results indicated that the MTHFR 3'-UTR rs55763075 polymorphism might modify the susceptibility to male infertility with idiopathic azoospermia.
genetics_GWAS	hsa-mir-103a-2	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-106b	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-1-1	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-133a-2	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-135b	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-137	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-137 under expression was significantly associated with melanomas with the KRAS-variant.
genetics_GWAS	hsa-mir-146a	Melanoma	23222547	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The rs2910164 G>C polymorphism in microRNA-146a is associated with the incidence  of malignant melanoma
genetics_GWAS	hsa-mir-146a	Melanoma	26122011	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Association of microRNA 146a polymorphism rs2910164 and the risk of melanoma in an Italian population.
genetics_GWAS	hsa-mir-146a	Melanoma	28654546	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.
genetics_GWAS	hsa-mir-151a	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-153-2	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-155	Melanoma	26068396	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Polymorphisms in 3'UTR of TYRP1 mRNA can affect TYRP1 mRNA regulation by miR-155 and its subsequent translation into protein. These SNPs can render TYRP1 mRNA and protein expression nonsusceptible to miR-155 activity and disclose a prognostic value for TYRP1 protein in a subgroup of melanoma patients. These data support the interest in the prognostic value of melanogenic markers and propose TYRP1 to refine prognosis in patients with advanced disease.
genetics_GWAS	hsa-mir-17	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-182	Melanoma	22752337	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells.
genetics_GWAS	hsa-mir-18a	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-194-1	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-199a-2	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-19a	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-19b-1	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-200a	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-200b	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-20a	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-214	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-215	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-218-1	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-219-1	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-221	Melanoma	21119596	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This KIT variant results in a mismatch in the seed region of a miR-221 complementary site and reporter data suggests that this mismatch can result in increased expression ofthe KIT oncogene.
genetics_GWAS	hsa-mir-25	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-296	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-302a	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-302b	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-302c	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-302d	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-30b	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-30d	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-320a	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-338	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-339	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-367	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-383	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number loss
genetics_GWAS	hsa-mir-429	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-488	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-9-1	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-93	Melanoma	16754881	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	copy number gain
genetics_GWAS	hsa-mir-124	Mesial Temporal Lobe Epilepsy	27188998			G40.209	D004833	608096		In this study, the effect of the SNP of one neuronal miRNA, miR-124, on susceptibility to MTLE was investigated using a case control study.
genetics_GWAS	hsa-mir-146a	Metabolic Syndrome	25958310	disease of metabolism	DOID:14221	E88.81	D024821	605552		The C allele of miRNA-146a rs2910164 showed positive association with increased susceptibility to metabolic syndrome and its phenotypes in the study population.
genetics_GWAS	hsa-mir-146a	Moyamoya Disease	22659075	cardiovascular system disease	DOID:13099	I67.5	D009072	PS252350	HP:0011834	Association of the miR-146aC>G, miR-196a2C>T, and miR-499A>G polymorphisms with moyamoya disease in the Korean population.
genetics_GWAS	hsa-mir-196a-2	Moyamoya Disease	22659075	cardiovascular system disease	DOID:13099	I67.5	D009072	PS252350	HP:0011834	Association of the miR-146aC>G, miR-196a2C>T, and miR-499A>G polymorphisms with moyamoya disease in the Korean population.
genetics_GWAS	hsa-mir-15a	Multiple Myeloma	20031211	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-15a:Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma
genetics_GWAS	hsa-mir-16-1	Multiple Myeloma	20031211	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-16:Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma
genetics_GWAS	hsa-mir-16-2	Multiple Myeloma	20031211	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-16:Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma
genetics_GWAS	hsa-mir-146a	Multiple Sclerosis	25591770	nervous system disease	DOID:2377	G35	D009103	PS126200		rs2910164 may play a role in MS susceptibility in females. The rs2910164 G>C variation may affect the expression of miR-146a and the release of proinflammatory cytokines.
genetics_GWAS	hsa-mir-2278	Multiple Sclerosis	24638856	nervous system disease	DOID:2377	G35	D009103	PS126200		Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis.
genetics_GWAS	hsa-mir-411	Multiple Sclerosis	24638856	nervous system disease	DOID:2377	G35	D009103	PS126200		Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis.
genetics_GWAS	hsa-mir-548ac	Multiple Sclerosis	25795118	nervous system disease	DOID:2377	G35	D009103	PS126200		Susceptibility variants in the CD58 gene locus point to a role of microRNA-548ac  in the pathogenesis of multiple sclerosis.
genetics_GWAS	hsa-mir-424	Myelodysplastic Syndromes	24674452	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
genetics_GWAS	hsa-mir-126	Myocardial Infarction	29304813	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The association between pre-miR-27a rs895819 polymorphism and myocardial infarction risk in a Chinese Han population
genetics_GWAS	hsa-mir-146a	Myocardial Infarction	24850191	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population.
genetics_GWAS	hsa-mir-149	Myocardial Infarction	24850191	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population.
genetics_GWAS	hsa-mir-196a-2	Myocardial Infarction	24850191	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population.
genetics_GWAS	hsa-mir-218	Myocardial Infarction	24850191	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population.
genetics_GWAS	hsa-mir-499	Myocardial Infarction	24850191	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Association of microRNA polymorphisms with the risk of myocardial infarction in a Chinese population.
genetics_GWAS	hsa-mir-328	Myopia	21421876	nervous system disease	DOID:11830	H52.1	D009216	PS160700		SNPs rs644242 and rs662702 had marginal significance (p=0.063) and further analyses showed that these SNPs were associated with extreme myopia. The OR for extreme myopia was 2.1 (empirical p=0.007) for the CC genotype at SNP rs662702 at 3' UTR. The functional assay for SNP rs662702 demonstrated that the C allele had a significantly lower expression level than the T allele (P=0.0001). SNP rs662702 was predicted to be located in the microRNA-328 binding site, which may explain the differential allelic effect on gene expression.
genetics_GWAS	hsa-mir-146a	Nasopharyngeal Neoplasms	22711332			C11.9	D009303	607107	HP:0100630	A single nucleotide polymorphism (rs2910164) in microRNA-146a is associated with the risk for nasopharyngeal carcinoma.
genetics_GWAS	hsa-mir-151a	Nasopharyngeal Neoplasms	23416081			C11.9	D009303	607107	HP:0100630	A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma
genetics_GWAS	hsa-mir-151b	Nasopharyngeal Neoplasms	23416081			C11.9	D009303	607107	HP:0100630	A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma
genetics_GWAS	hsa-mir-34b	Nasopharyngeal Neoplasms	23504554			C11.9	D009303	607107	HP:0100630	Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma
genetics_GWAS	hsa-mir-34c	Nasopharyngeal Neoplasms	23504554			C11.9	D009303	607107	HP:0100630	Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma
genetics_GWAS	hsa-mir-124	Neoplasms [unspecific]	26625819			C80.1	D009369			This meta-analysis suggests that the miR-124 rs531564 C > G polymorphism is an important risk factor for cancers among the Chinese population.
genetics_GWAS	hsa-mir-146a	Neoplasms [unspecific]	24278149			C80.1	D009369			Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies.
genetics_GWAS	hsa-mir-146a	Neoplasms [unspecific]	24716941			C80.1	D009369			Association analysis of single nucleotide polymorphisms in miR-146a and miR-196a2 on the prevalence of cancer in elderly Japanese: a case-control study.
genetics_GWAS	hsa-mir-146a	Neoplasms [unspecific]	26337564			C80.1	D009369			We conclude that rs2910164 may represent a valuable biomarker associated with the risk of developing specific types of cancer.
genetics_GWAS	hsa-mir-149	Neoplasms [unspecific]	24278149			C80.1	D009369			Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies.
genetics_GWAS	hsa-mir-155	Neoplasms [unspecific]	27531892			C80.1	D009369			Our findings suggested that miR-155 and its functional variant rs767649 might contribute to the increased risk and poor prognosis of HCC
genetics_GWAS	hsa-mir-196a	Neoplasms [unspecific]	23691458			C80.1	D009369			The meta-analysis demonstrated that the miR-196a-2 polymorphism is associated with cancer susceptibility, especially lung cancer, colorectal cancer, and breast cancer among Asian populations.
genetics_GWAS	hsa-mir-196a-2	Neoplasms [unspecific]	24278149			C80.1	D009369			Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies.
genetics_GWAS	hsa-mir-196a-2	Neoplasms [unspecific]	24716941			C80.1	D009369			Association analysis of single nucleotide polymorphisms in miR-146a and miR-196a2 on the prevalence of cancer in elderly Japanese: a case-control study.
genetics_GWAS	hsa-mir-204	Neoplasms [unspecific]	20439436			C80.1	D009369			miR-204:hsa-miR-30 and hsa-miR-204, were found to be physically altered at the DNA copy number level as well
genetics_GWAS	hsa-mir-20a	Neoplasms [unspecific]	20439436			C80.1	D009369			mir-20a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_GWAS	hsa-mir-218	Neoplasms [unspecific]	24761857			C80.1	D009369			The findings suggest that pre-miR-218 rs11134527 polymorphism may have some relation to cancer development in Chinese. However, well-designed studies with larger sample size and more detailed data are needed to confirm these conclusions.
genetics_GWAS	hsa-mir-30a	Neoplasms [unspecific]	20439436			C80.1	D009369			miR-30:hsa-miR-103/106 were downgraded in cancer, whereas hsa-miR-30 became most prominent
genetics_GWAS	hsa-mir-34b	Neoplasms [unspecific]	25190019			C80.1	D009369			The genetic association between pri-miR-34b/c polymorphism (rs4938723 T>C) and susceptibility to cancers: evidence from published studies.
genetics_GWAS	hsa-mir-34c	Neoplasms [unspecific]	25190019			C80.1	D009369			The genetic association between pri-miR-34b/c polymorphism (rs4938723 T>C) and susceptibility to cancers: evidence from published studies.
genetics_GWAS	hsa-mir-423	Neoplasms [unspecific]	28430524			C80.1	D009369			miRNA-Related Polymorphisms in miR-423 (rs6505162) and PEX6 (rs1129186) and Risk of Esophageal Squamous Cell Carcinoma in an Iranian Cohort.
genetics_GWAS	hsa-mir-499	Neoplasms [unspecific]	24085457			C80.1	D009369			The miR-499 rs3746444 polymorphism is associated with an increased cancer risk.
genetics_GWAS	hsa-mir-499	Neoplasms [unspecific]	24278149			C80.1	D009369			Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies.
genetics_GWAS	hsa-mir-499	Neoplasms [unspecific]	25433484			C80.1	D009369			hsa-mir-499 rs3746444 T > C polymorphism is associated with the risk of cancer in Asians, mainly in Iranian and Chinese population. However, rs3746444 T > C polymorphism is negatively associated with the risk of esophageal cancer.
genetics_GWAS	hsa-mir-499	Neoplasms [unspecific]	25640376			C80.1	D009369			hsa-mir-499 rs3746444 A>G polymorphism is not associated with risk of cancer based on current evidence.
genetics_GWAS	hsa-mir-499	Neoplasms [unspecific]	24258110			C80.1	D009369			Quantitative assessment of the association between microRNA-499 rs3746444 A/G polymorphism and cancer risk.
genetics_GWAS	hsa-mir-34a	Neuroblastoma	27805929	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Genetic variant rs3750625 in the 3'UTR of ADRA2A affects stress-dependent acute pain severity after trauma and alters a microRNA-34a regulatory site.
genetics_GWAS	hsa-mir-26a	Neurodegenerative Diseases [unspecific]	25074322				D019636		HP:0002180	A functional SNP catalog of overlapping miRNA-binding sites in genes implicated in prion disease and other neurodegenerative disorders.
genetics_GWAS	hsa-mir-181a	Neuroinflammation	28769921							MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation
genetics_GWAS	hsa-mir-181b	Neuroinflammation	28769921							MicroRNA-181 Variants Regulate T Cell Phenotype in the Context of Autoimmune Neuroinflammation.
genetics_GWAS	hsa-mir-124-1	Neuropsychiatric Disorders [unspecific]	25841663				C537163			We showed for the first time the association of a functional polymorphism in MIR124-1 and aggressiveness. Known targets of miR-124 (such as BDNF and DRD4 genes) could explain the effect of this miRNA on behavior. A future analysis of additional novel functional polymorphisms in other brain expressed miRNAs could be useful for a deeper understanding of aggression in humans.
genetics_GWAS	hsa-mir-365	Neuropsychiatric Disorders [unspecific]	27074815				C537163			single nucleotide polymorphism (SNP) rs2235749 (in high linkage disequilibrium with rs910080) modifies striatal PDYN expression via impaired binding of miR-365
genetics_GWAS	hsa-mir-3649	Non-Syndromic Orofacial Clefts	24603642					PS119530		Taken together, these findings indicate that SNPs in the miRNA-binding sites might play an important role in the development of NSOCs. Furthermore, if confirmed in subsequent studies, the polymorphisms may be considered as additional markers for the evaluation of infants' risk of NSOCs.
genetics_GWAS	hsa-mir-26b	Obesity	24807789	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Expression of microRNA-26b, an obesity-related microRNA, is regulated by free fatty acids, glucose, dexamethasone and growth hormone in human adipocytes.
genetics_GWAS	hsa-mir-27a	Obesity	27537871	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	MicroRNAs and Drinking: Association between the Pre-miR-27a rs895819 Polymorphism and Alcohol Consumption in a Mediterranean Population.
genetics_GWAS	hsa-mir-122	Oral Neoplasms	25981582			C06.9	D009062		HP:0100649	These results suggest that IL-1α 3' UTR rs3783553 polymorphism may be functional and influence susceptibility to HPV16-associated OSCC, particularly for SCCOP. Validation of our findings is warranted.
genetics_GWAS	hsa-mir-29a	Oral Neoplasms	24885463			C06.9	D009062		HP:0100649	Variations in microRNAs and their processing genes modulated risk of precancer but further in-depth study is needed to understand mechanism of disease process.
genetics_GWAS	hsa-mir-34b	Oral Neoplasms	24297336			C06.9	D009062		HP:0100649	Genetic variations at microRNA and processing genes and risk of oral cancer.
genetics_GWAS	hsa-mir-34b	Oral Neoplasms	24885463			C06.9	D009062		HP:0100649	Variations in microRNAs and their processing genes modulated risk of precancer but further in-depth study is needed to understand mechanism of disease process.
genetics_GWAS	hsa-mir-423	Oral Neoplasms	24885463			C06.9	D009062		HP:0100649	Variations in microRNAs and their processing genes modulated risk of precancer but further in-depth study is needed to understand mechanism of disease process.
genetics_GWAS	hsa-mir-146a	Ossification of Posterior Longitudinal Ligament	27454313	musculoskeletal system disease	DOID:0060887	M48.8	D017887	602475		The miR-146a/-149/-196a2/-499 allele combinations may be a genetic risk factor for cervical OPLL in the Korean population.
genetics_GWAS	hsa-mir-149	Ossification of Posterior Longitudinal Ligament	27454313	musculoskeletal system disease	DOID:0060887	M48.8	D017887	602475		The miR-146a/-149/-196a2/-499 allele combinations may be a genetic risk factor for cervical OPLL in the Korean population.
genetics_GWAS	hsa-mir-196a2	Ossification of Posterior Longitudinal Ligament	27454313	musculoskeletal system disease	DOID:0060887	M48.8	D017887	602475		The miR-146a/-149/-196a2/-499 allele combinations may be a genetic risk factor for cervical OPLL in the Korean population.
genetics_GWAS	hsa-mir-499	Ossification of Posterior Longitudinal Ligament	27454313	musculoskeletal system disease	DOID:0060887	M48.8	D017887	602475		The results indicate that GG genotype of miR-499 is associated with significantly higher risks of OPLL in the segmental OPLL group.
genetics_GWAS	hsa-mir-34b	Osteoporosis	27227383	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	The present findings indicate that pri-miR-34b/c rs4938723 and TP53  Arg72Pro polymorphisms may contribute to the risk of OP.
genetics_GWAS	hsa-mir-34c	Osteoporosis	27227383	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	The present findings indicate that pri-miR-34b/c rs4938723 and TP53  Arg72Pro polymorphisms may contribute to the risk of OP.
genetics_GWAS	hsa-mir-98	Osteoporosis	29307778	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	Computational and functional characterization of four SNPs in the SOST locus associated with osteoporosis
genetics_GWAS	hsa-let-7a	Osteosarcoma	27430246	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, the findings of the present study demonstrated that the KRAS 3'-UTR rs61764370 polymorphism interfered with miRNA/mRNA interaction, and showed that the minor allele was associated with an elevated risk of developing metastatic disease in OS.
genetics_GWAS	hsa-mir-124a	Osteosarcoma	27540978	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.
genetics_GWAS	hsa-mir-17	Osteosarcoma	25663449	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1.
genetics_GWAS	hsa-mir-18	Osteosarcoma	25663449	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1.
genetics_GWAS	hsa-mir-19a	Osteosarcoma	25663449	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1.
genetics_GWAS	hsa-mir-19b-1	Osteosarcoma	25663449	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1.
genetics_GWAS	hsa-mir-20a	Osteosarcoma	25663449	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1.
genetics_GWAS	hsa-mir-92-1	Osteosarcoma	25663449	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This study suggests that SNPs in RISC complex genes may be involved in osteosarcoma susceptibility, especially rs11866002 in CNOT1.
genetics_GWAS	hsa-let-7a-1	Ovarian Neoplasms	21482675	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	rs12194974 (G>A), a SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR=0.90, 95% CI: 0.82-0.98; P=0.015). LIN28B LIN28B over-expression in epithelial ovarian cancer (EOC) contributes to tumorigenesis by repressing tumor suppressor let-7 expression.
genetics_GWAS	hsa-let-7a-2	Ovarian Neoplasms	21482675	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	rs12194974 (G>A), a SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR=0.90, 95% CI: 0.82-0.98; P=0.015). LIN28B LIN28B over-expression in epithelial ovarian cancer (EOC) contributes to tumorigenesis by repressing tumor suppressor let-7 expression.
genetics_GWAS	hsa-let-7a-2	Ovarian Neoplasms	22970210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found that there was a reduction in the copy number of let-7 genes in a cancer-type specific manner. Importantly, focal deletion of four let-7 family members was found in three cancer types: medulloblastoma (let-7a-2 and let-7e), breast cancer (let-7a-2), and ovarian cancer (let-7a-3/let-7b).
genetics_GWAS	hsa-let-7a-3	Ovarian Neoplasms	21482675	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	rs12194974 (G>A), a SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR=0.90, 95% CI: 0.82-0.98; P=0.015). LIN28B LIN28B over-expression in epithelial ovarian cancer (EOC) contributes to tumorigenesis by repressing tumor suppressor let-7 expression.
genetics_GWAS	hsa-let-7e	Ovarian Neoplasms	22970210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found that there was a reduction in the copy number of let-7 genes in a cancer-type specific manner. Importantly, focal deletion of four let-7 family members was found in three cancer types: medulloblastoma (let-7a-2 and let-7e), breast cancer (let-7a-2), and ovarian cancer (let-7a-3/let-7b).
genetics_GWAS	hsa-mir-103a-2	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-106b	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-1-1	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-133a-2	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-135b	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-146a	Ovarian Neoplasms	18660546	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-146a: A functional polymorphism (rs2910164) in the miR-146a gene and age of familial breast/ovarian cancer diagnosis
genetics_GWAS	hsa-mir-146a	Ovarian Neoplasms	26785832	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	e identified one rare variant in MIR146A, four in MIR146B, five in BRCA1 3'-UTR and one in BRCA2 3'-UTR in 716 index cases and 619  controls.
genetics_GWAS	hsa-mir-146b	Ovarian Neoplasms	26785832	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	we identified one rare variant in MIR146A, four in MIR146B, five in BRCA1 3'-UTR and one in BRCA2 3'-UTR in 716 index cases and 619  controls.
genetics_GWAS	hsa-mir-151a	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-153-2	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-17	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-17	Ovarian Neoplasms	22235027	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113
genetics_GWAS	hsa-mir-18a	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-18a	Ovarian Neoplasms	22235027	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113
genetics_GWAS	hsa-mir-191	Ovarian Neoplasms	20167074	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Novel genetic variants in miR-191 gene and familial ovarian cancer
genetics_GWAS	hsa-mir-194-1	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-199a-2	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-19a	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-19a	Ovarian Neoplasms	22235027	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113
genetics_GWAS	hsa-mir-19b-1	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-19b-1	Ovarian Neoplasms	22235027	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113
genetics_GWAS	hsa-mir-200a	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-200b	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-20a	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-20a	Ovarian Neoplasms	22235027	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113
genetics_GWAS	hsa-mir-214	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-215	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-218-1	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-219-1	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-25	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-296	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-302a	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-302b	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-302c	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-302d	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-30b	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-30d	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-320a	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-338	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-339	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-367	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-383	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number loss
genetics_GWAS	hsa-mir-429	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-488	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-502	Ovarian Neoplasms	22867998	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	A polymorphism (rs16917496) at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer.
genetics_GWAS	hsa-mir-9-1	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-92a-1	Ovarian Neoplasms	22235027	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most notable cluster is the tumorigenic miR-17-92 cluster with five microRNAs, all of which are significantly associated with rs3814113
genetics_GWAS	hsa-mir-93	Ovarian Neoplasms	16754881	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	copy number gain
genetics_GWAS	hsa-mir-34a	Parkinson Disease	25541488	nervous system disease	DOID:14330	G20	D010300	PS168600		down-regulation of miR-34b and miR-34c in the brain, as well as an SNP in the 3'-UTR of α-syn can increase α-syn expression, possibly contributing to PD pathogenesis.
genetics_GWAS	hsa-mir-584	Pemphigus	27424220	integumentary system disease	DOID:9182	L10	D010392			Collectively, these results suggest that a disease-associated SNP located within  the 3'UTR of KLRG1 directly interferes with miR-584-5p binding, allowing for KLRG1 mRNA differential accumulation, which in turn may contribute to pathogenesis of autoimmune diseases, such as pemphigus.
genetics_GWAS	hsa-mir-611	Pleural Mesothelioma	25436799	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	MRP performance as diagnostic biomarker improved by considering the genotype rs1057147. This polymorphism most likely affects a binding site for miR-611.
genetics_GWAS	hsa-mir-146a	Polycystic Ovarian Syndrome	29637801	syndrome	DOID:11612	E28.2	D011085	184700		women with miR-146a variation are at a higher risk for developing PCOS, which can be due to up-regulation of miR-146a
genetics_GWAS	hsa-mir-518	Premature Ovarian Failure	25365407	endocrine system disease	DOID:5426	E28.3	D016649	PS311360		Association study of TGFBR2 and miR-518 gene polymorphisms with age at natural menopause, premature ovarian failure, and early menopause among Chinese Hanwomen.
genetics_GWAS	hsa-mir-125b-1	Prostate Neoplasms	21556765	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	rs1434536 in the 3'UTR of BMPR1B gene affects the binding ability of miR-125b to BMPR1B mRNA and contributes to the genetic hspredisposition to localized prostate cancer and patients aged >70years.
genetics_GWAS	hsa-mir-125b-2	Prostate Neoplasms	21556765	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	rs1434536 in the 3'UTR of BMPR1B gene affects the binding ability of miR-125b to BMPR1B mRNA and contributes to the genetic hspredisposition to localized prostate cancer and patients aged >70years.
genetics_GWAS	hsa-mir-143	Prostate Neoplasms	25354797	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	there is the significant association between the functional promoter variant rs4705342T>C in miR-143 and PCa risk
genetics_GWAS	hsa-mir-146a	Prostate Neoplasms	25084752	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Association between genetic variant in hsa-miR-146a gene and prostate cancer progression
genetics_GWAS	hsa-mir-146a	Prostate Neoplasms	19902466	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The natural genetic variation in pre-miR-146a affects the amount of mature miR-146a, contributes to the genetic predisposition to CaP.
genetics_GWAS	hsa-mir-196a-2	Prostate Neoplasms	26112096	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Assessment of association between genetic variants in microRNA genes hsa-miR-499,hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population.
genetics_GWAS	hsa-mir-27a	Prostate Neoplasms	26112096	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Assessment of association between genetic variants in microRNA genes hsa-miR-499,hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population.
genetics_GWAS	hsa-mir-3162	Prostate Neoplasms	25691096	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk.
genetics_GWAS	hsa-mir-370	Prostate Neoplasms	25691096	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk.
genetics_GWAS	hsa-mir-499	Prostate Neoplasms	26112096	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Assessment of association between genetic variants in microRNA genes hsa-miR-499,hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population.
genetics_GWAS	hsa-mir-146a	Psoriasis	25209759	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study.
genetics_GWAS	hsa-mir-146a	Psoriasis	27098222	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	The miR-146a SNPs rs2910164, rs57095329, rs2431697 are associated with susceptibility to certain autoimmune diseases.
genetics_GWAS	hsa-mir-146a	Psoriasis	29587639	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	A single nucleotide polymorphism in the miR-146a gene (rs2910164),  aberrantly alters its gene expression and linked with the pathogenesis of several disorders, including psoriasis and PsA
genetics_GWAS	hsa-mir-492	Psoriasis	21655935	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	The rs8259 T allele was associated with significantly decreased psoriasis susceptibility (OR=0.758, 95% CI 0.638-0.901, p=0.002) compared to A allele. the rs8259 polymorphism was located in a seed region for miR-492 binding.
genetics_GWAS	hsa-mir-146a	Psoriatic Arthritis	29587639	syndrome	DOID:9008	L40.5	D015535	607507		A single nucleotide polymorphism in the miR-146a gene (rs2910164),  aberrantly alters its gene expression and linked with the pathogenesis of several disorders, including psoriasis and PsA
genetics_GWAS	hsa-mir-137	Psychiatric Disorders	23786914				D001523	604363		Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex.
genetics_GWAS	hsa-mir-146b	Psychiatric Disorders	25771167				D001523	604363		Our findings highlight trans effects of common variants on microRNA-mediated gene expression as an integral part of the genetic architecture of complex disorders and traits.
genetics_GWAS	hsa-mir-330	Psychiatric Disorders	24436253				D001523	604363		The effects of a MAP2K5 microRNA target site SNP on risk for anxiety and depressive disorders.
genetics_GWAS	hsa-mir-146a	Pulmonary Hypertension	26202355	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	the results of this study demonstrate that the rs2910164 CC and GC genotype is associated with a decreased risk of pulmonary hypertension, which could be attributed to defective miRNA processing and compromised ability to inhibit production of COX-2 and PGI2.
genetics_GWAS	hsa-mir-608	Rectal Neoplasms	27381831	disease of cellular proliferation	DOID:1984		D012004			Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.
genetics_GWAS	hsa-mir-34b	Retinoblastoma	28106538	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma.
genetics_GWAS	hsa-mir-34c	Retinoblastoma	28106538	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma.
genetics_GWAS	hsa-mir-146a	Rheumatoid Arthritis	24824381	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Association of two polymorphisms rs2910164 in miRNA-146a and rs3746444 in miRNA-499 with rheumatoid arthritis: a meta-analysis.
genetics_GWAS	hsa-mir-146a	Rheumatoid Arthritis	27342690	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	12 single nucleotide polymorphisms
genetics_GWAS	hsa-mir-146a	Rheumatoid Arthritis	28083614	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Significance of Polymorphism and Expression of miR-146a and NFkB1 Genetic Variants in Patients with Rheumatoid Arthritis.
genetics_GWAS	hsa-mir-149	Rheumatoid Arthritis	26032077	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	SNP rs22928323 in miR-149 is correlated with RA in the east of Chinese Han population, whereas there is no correlation between miR-149 polymorphism and clinical characteristics in patients with RA.
genetics_GWAS	hsa-mir-499	Rheumatoid Arthritis	24327058	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	This study suggested that miR-499 polymorphisms were associated with a significantly increased risk of RA in Mediterranean populations.
genetics_GWAS	hsa-mir-499	Rheumatoid Arthritis	24824381	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Association of two polymorphisms rs2910164 in miRNA-146a and rs3746444 in miRNA-499 with rheumatoid arthritis: a meta-analysis.
genetics_GWAS	hsa-mir-499a	Rheumatoid Arthritis	22019503	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	There was a significant difference in the levels of CRP and ESR among different genotypes in rs3746444 (hsa-mir-499) (p = 0.031 and p = 0.047, respectively) in Chinese Han people. The heterozygote CT had significantly higher levels of CRP and ESR compared with homozygotes CC and TT.
genetics_GWAS	hsa-mir-137	Schizophrenia	25044277	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The miR-137 schizophrenia susceptibility variant rs1625579 does not predict variability in brain volume in a sample of schizophrenic patients and healthy individuals.
genetics_GWAS	hsa-mir-137	Schizophrenia	21926974	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	GWAS analysis revealed that rs1625579 within an intron of a putative primary transcript for MIR137 (microRNA 137), a known regulator of neuronal development was associated with schizophrenia.
genetics_GWAS	hsa-mir-137	Schizophrenia	24132022	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Impact of the genome-wide schizophrenia risk single nucleotide polymorphism (rs1625579) in miR-137 on brain structures in healthy individuals.
genetics_GWAS	hsa-mir-137	Schizophrenia	25921703	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The impact of genome wide supported microRNA-137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia.
genetics_GWAS	hsa-mir-137	Schizophrenia	26836412	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Polymorphisms in MIR137HG and microRNA-137-regulated genes influence gray matter structure in schizophrenia.
genetics_GWAS	hsa-mir-137	Schizophrenia	25241074	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Lack of association between microRNA-137 SNP rs1625579 and schizophrenia in a replication study of Han Chinese.
genetics_GWAS	hsa-mir-137	Schizophrenia	25434007	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	rare noncoding risk variants are associated with SZ and  BP at MIR137/MIR2682 locus, with risk alleles decreasing MIR137/MIR2682 expression.
genetics_GWAS	hsa-mir-137	Schizophrenia	26429811	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A GWAS SNP for Schizophrenia Is Linked to the Internal MIR137 Promoter and Supports Differential Allele-Specific Expression.
genetics_GWAS	hsa-mir-137	Schizophrenia	27096222	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A single nucleotide polymorphism rs1625579 in the miR-137 gene has  recently been reported to confer risk of schizophrenia
genetics_GWAS	hsa-mir-137	Schizophrenia	27525637	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Genome-wide association studies (GWAS) have identified a region at chromosome 1p21.3, containing the microRNA MIR137, to be among the most significant associations for schizophrenia.
genetics_GWAS	hsa-mir-198	Schizophrenia	17849003	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	SNP (rs1700) disease susceptibility
genetics_GWAS	hsa-mir-206	Schizophrenia	17849003	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	SNP (rs17578796) disease susceptibility
genetics_GWAS	hsa-mir-206	Schizophrenia	27424800	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our study therefore suggests that miR-206 may contribute to schizophrenia risk through allele-dependent regulation  of the genome-wide significant gene NT5C2.
genetics_GWAS	hsa-mir-219	Schizophrenia	26257337	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	These findings suggest that GRIN2B may be associated with schizophrenia and interaction effects of the polymorphisms in hsa-miR-219, CAKM2G, GRIN2B and GRIN3A may confer susceptibility to schizophrenia in the Chinese Han population.
genetics_GWAS	hsa-mir-2682	Schizophrenia	25434007	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	rare noncoding risk variants are associated with SZ and  BP at MIR137/MIR2682 locus, with risk alleles decreasing MIR137/MIR2682 expression.
genetics_GWAS	hsa-mir-30e	Schizophrenia	20347265	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-30e:mir-30e ss178077483 plays a role in schizophrenia susceptibility
genetics_GWAS	hsa-mir-30e	Schizophrenia	20579744	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our previous study revealed a strong association between the polymorphism ss178077483 in the miRNA-30e precursor (pre-miR-30e) and the risk of SCZ.
genetics_GWAS	hsa-mir-96	Sensorineural Hearing Loss	19363478	nervous system disease	DOID:10003	H90.5	D006313	304400		miR-96: An ENU-induced mutation
genetics_GWAS	hsa-mir-96	Sensorineural Hearing Loss	19363479	nervous system disease	DOID:10003	H90.5	D006313	304400		miR-96: Mutations in the seed region
genetics_GWAS	hsa-mir-146a	Sepsis	24701036			A41.9	D018805		HP:0100806	The functional polymorphisms of miR-146a are associated with susceptibility to severe sepsis in the Chinese population.
genetics_GWAS	hsa-mir-146a	Skin Neoplasms	24699816	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	we investigated the impact of MIR146A SNP rs2910164 on cancer risk, and interaction with a SNP in one of its putative targets (RNASEL, rs486907).
genetics_GWAS	hsa-mir-149	Squamous Cell Carcinoma	27050146	disease of cellular proliferation	DOID:1749		D002294			hsa-mir-149 rs2292832 and hsa-mir-499 rs3746444 polymorphisms play a significant role in the prognosis of SCCNOP
genetics_GWAS	hsa-let-7i	Squamous Cell Carcinoma, Cerevial	29154871	endocrine system disease	DOID:5531					Association between genetic polymorphisms in the promoters of let-7 and risk of cervical squamous cell carcinoma
genetics_GWAS	hsa-mir-122	Squamous Cell Carcinoma, Cerevial	25955681	endocrine system disease	DOID:5531					These findings indicate that the IL1A rs3783553 polymorphism may be associated with the etiology of CSCC.
genetics_GWAS	hsa-mir-146a	Squamous Cell Carcinoma, Cerevial	21319225	endocrine system disease	DOID:5531					SNP (rs2910164 G/C): Significantly increased CSCC risks were found to be associated with G allele of rs2910164
genetics_GWAS	hsa-mir-499a	Squamous Cell Carcinoma, Cerevial	21319225	endocrine system disease	DOID:5531					SNP (rs3746444 A/G): Significantly increased CSCC risks were found to be associated with G allele of rs3746444
genetics_GWAS	hsa-mir-100	Squamous Cell Carcinoma, Esophageal	26261633	disease of cellular proliferation	DOID:3748		C562729			Genetic variation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China.
genetics_GWAS	hsa-mir-100	Squamous Cell Carcinoma, Esophageal	24288122	disease of cellular proliferation	DOID:3748		C562729			Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy.
genetics_GWAS	hsa-mir-124	Squamous Cell Carcinoma, Esophageal	24945256	disease of cellular proliferation	DOID:3748		C562729			Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations.
genetics_GWAS	hsa-mir-125a	Squamous Cell Carcinoma, Esophageal	24288122	disease of cellular proliferation	DOID:3748		C562729			Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy.
genetics_GWAS	hsa-mir-146a	Squamous Cell Carcinoma, Esophageal	23792053	disease of cellular proliferation	DOID:3748		C562729			These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings.
genetics_GWAS	hsa-mir-146a	Squamous Cell Carcinoma, Esophageal	24288122	disease of cellular proliferation	DOID:3748		C562729			Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy.
genetics_GWAS	hsa-mir-184	Squamous Cell Carcinoma, Esophageal	25383966	disease of cellular proliferation	DOID:3748		C562729			Our data demonstrate that functional TNFAIP2 rs8126 genetic variant  is a ESCC susceptibility SNP.
genetics_GWAS	hsa-mir-196a-2	Squamous Cell Carcinoma, Esophageal	24320161	disease of cellular proliferation	DOID:3748		C562729			These results suggest that the miRNA-196a2 functional polymorphism rs11614913 might be an effective genetic marker for ESCC risk assessment in individuals younger than 60 years of age from a region of high ESCC incidence in northern China.
genetics_GWAS	hsa-mir-196a-2	Squamous Cell Carcinoma, Esophageal	24288122	disease of cellular proliferation	DOID:3748		C562729			Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy.
genetics_GWAS	hsa-mir-196a-2	Squamous Cell Carcinoma, Esophageal	23792053	disease of cellular proliferation	DOID:3748		C562729			These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings.
genetics_GWAS	hsa-mir-214	Squamous Cell Carcinoma, Esophageal	27323028	disease of cellular proliferation	DOID:3748		C562729			esophageal squamous cell carcinoma
genetics_GWAS	hsa-mir-218	Squamous Cell Carcinoma, Esophageal	25337271	disease of cellular proliferation	DOID:3748		C562729			The impact of pri-miR-218 rs11134527 on the risk and prognosis of patients with esophageal squamous cell carcinoma.
genetics_GWAS	hsa-mir-219-1	Squamous Cell Carcinoma, Esophageal	26379361	disease of cellular proliferation	DOID:3748		C562729			These findings indicated that functional polymorphisms miR-219-1 rs107822G > A might change individual susceptibility to Kazakh ESCC.
genetics_GWAS	hsa-mir-26a-1	Squamous Cell Carcinoma, Esophageal	24288122	disease of cellular proliferation	DOID:3748		C562729			Taken together, these findings indicate that miRNA polymorphisms may predict prognosis in advanced ESCC patients receiving platinum-based chemotherapy.
genetics_GWAS	hsa-mir-26a-1	Squamous Cell Carcinoma, Esophageal	23792053	disease of cellular proliferation	DOID:3748		C562729			These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings.
genetics_GWAS	hsa-mir-27a	Squamous Cell Carcinoma, Esophageal	23792053	disease of cellular proliferation	DOID:3748		C562729			These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings.
genetics_GWAS	hsa-mir-34b	Squamous Cell Carcinoma, Esophageal	24945256	disease of cellular proliferation	DOID:3748		C562729			Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations.
genetics_GWAS	hsa-mir-34c	Squamous Cell Carcinoma, Esophageal	24945256	disease of cellular proliferation	DOID:3748		C562729			Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations.
genetics_GWAS	hsa-mir-423	Squamous Cell Carcinoma, Esophageal	24205249	disease of cellular proliferation	DOID:3748		C562729			MicroRNA polymorphisms and environmental smoke exposure as risk factors for oesophageal squamous cell carcinoma.
genetics_GWAS	hsa-mir-423	Squamous Cell Carcinoma, Esophageal	26518769	disease of cellular proliferation	DOID:3748		C562729			Four SNPs including miR-196a2 rs11614913, miR-146a rs2910164, miR-499 rs3746444, and miR-423 rs6505162 were selected with comprehensive collection strategy and genotyped using the SNaPshot Multiplex System.
genetics_GWAS	hsa-mir-4293	Squamous Cell Carcinoma, Esophageal	26055141	disease of cellular proliferation	DOID:3748		C562729			miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population.
genetics_GWAS	hsa-mir-449b	Squamous Cell Carcinoma, Esophageal	26055141	disease of cellular proliferation	DOID:3748		C562729			miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population.
genetics_GWAS	hsa-mir-483	Squamous Cell Carcinoma, Esophageal	27420938	disease of cellular proliferation	DOID:3748		C562729			SNP at miR-483-5p-binding site in the 3'-untranslated region of the BSG gene is associated with susceptibility to esophageal cancer in a Chinese population.
genetics_GWAS	hsa-mir-499	Squamous Cell Carcinoma, Esophageal	23792053	disease of cellular proliferation	DOID:3748		C562729			These findings indicated that functional polymorphism miR-196a2 rs11614913 T > C might contribute to decreased ESCC risk among women patients and patients who never smoking or drinking. However, our results were obtained with a limited sample size. Future larger studies with other ethnic populations and tissue-specific biological characterization are required to confirm current findings.
genetics_GWAS	hsa-mir-526b	Squamous Cell Carcinoma, Esophageal	27583835	disease of cellular proliferation	DOID:3748		C562729			A genetic polymorphism at miR-526b binding-site in the lincRNA-NR_024015 exon confers risk of esophageal squamous cell carcinoma in a population of North China.
genetics_GWAS	hsa-mir-608	Squamous Cell Carcinoma, Esophageal	24770678	disease of cellular proliferation	DOID:3748		C562729			The hereditary genetic polymorphisms of mir-608, RAN, and GEMIN4 can serve as predictors for clinical outcome in ESCC patients treated with concurrent chemoradiotherapy.
genetics_GWAS	hsa-mir-149	Squamous Cell Carcinoma, Head and Neck	23272122	disease of cellular proliferation	DOID:5520	C76.0	C535575			The Association between Genetic Polymorphism and the Processing Efficiency of miR-149 Affects the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma
genetics_GWAS	hsa-mir-149	Squamous Cell Carcinoma, Head and Neck	27515039	disease of cellular proliferation	DOID:5520	C76.0	C535575			However, no significant association was detected between the other three SNPs (miR-149 rs2292832, miR-146a rs2910164, and miR-608 rs4919510) and HNSCC risk.
genetics_GWAS	hsa-mir-184	Squamous Cell Carcinoma, Head and Neck	21934093	disease of cellular proliferation	DOID:5520	C76.0	C535575			The authors found that, compared with the rs8126 TT (a SNP of miR-184 Binding Site in TNFAIP2) genotype, the variant C allele were associated with increased SCCHN risk in an allele-dose response manner (adjusted odds ratio=1.48 and 95% confidence interval=1.06-2.05 for CC, respectively; P(trend)=0.009).
genetics_GWAS	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	24327270	disease of cellular proliferation	DOID:5520	C76.0	C535575			CLU is a specific, functional target of oncogenic miRNA-21 in HNSCCs. CLU-1 isoform is the predominant growth-suppressive variant targeted by miRNA-21.
genetics_GWAS	hsa-mir-499	Squamous Cell Carcinoma, Head and Neck	20549817	disease of cellular proliferation	DOID:5520	C76.0	C535575			Of the 4 SNPs that were studied, the hsa-mir-499 AG and GG genotypes were associated with a reduced risk of SCCHN
genetics_GWAS	hsa-mir-146a	Squamous Cell Carcinoma, Oral	22182931	disease of cellular proliferation	DOID:0050866					This study identifies that areca nut extract, TNFalpha and TGFbeta up-regulates miR-146a in OSCC cells. The increased expression of miR-146a enhanced the oncogenicity of OSCC cells. In addition, a G to C polymorphism (rs2910164), which is located in the pre-miR-146a and has been associated with functional alterations in miR-146a, was significantly more prevalent among OSCC patients having more advanced nodal involvement. Our analysis also suggested a higher miR-146a expression in OSCC tissues of patients carrying C polymorphism. The present study concluded a higher prevalence of the pre-mir-146a C-variant was associated with OSCC progression in patients with this disease.
genetics_GWAS	hsa-mir-146a	Squamous Cell Carcinoma, Oral	26214637	disease of cellular proliferation	DOID:0050866					The miR-146a rs2910164 polymorphism is associated with increased risk for cervical and skin SCC. In contrast, rs2910164 in miR-146a is related to decreased risk for nasopharyngeal and oral SCC.
genetics_GWAS	hsa-mir-149	Squamous Cell Carcinoma, Oral	26625766	disease of cellular proliferation	DOID:0050866					Our study suggests that miR-196a2C>T and miR-149C>T polymorphisms may play crucial roles in the development of OSCC in South Indian subjects.
genetics_GWAS	hsa-mir-149	Squamous Cell Carcinoma, Oral	29103762	disease of cellular proliferation	DOID:0050866					miRNA genetic variants: As potential diagnostic biomarkers for oral cancer.
genetics_GWAS	hsa-mir-499a	Squamous Cell Carcinoma, Oral	22761899	disease of cellular proliferation	DOID:0050866					This study determined that a significant association of miRNA499 with CC genotype, as compared to the subjects with TT genotype, had a higher risk of oral squamous cell carcinoma.
genetics_GWAS	hsa-mir-499b	Squamous Cell Carcinoma, Oral	22761899	disease of cellular proliferation	DOID:0050866					This study determined that a significant association of miRNA499 with CC genotype, as compared to the subjects with TT genotype, had a higher risk of oral squamous cell carcinoma.
genetics_GWAS	hsa-mir-122	Stroke	29145255			I64	D020521	601367	HP:0001297	Functional polymorphism rs3783553 in the 3'-untranslated region of IL-1A increased the risk of ischemic stroke
genetics_GWAS	hsa-mir-410	Stroke	24990426			I64	D020521	601367	HP:0001297	We report a novel association between a microRNA target site variant and stroke incidence, which is modulated by diet in terms of decreasing triglycerides and possibly stroke risk in rs13702 C allele carriers after a high-unsaturated fat MedDiet intervention.
genetics_GWAS	hsa-let-7	Stroke, Ischemic	27530126			I63.9			HP:0002140	An rs13293512 polymorphism in the promoter of let-7 is associated with a reduced  risk of ischemic stroke.
genetics_GWAS	hsa-mir-1203	Stroke, Ischemic	28171870			I63.9			HP:0002140	Methylene Tetrahydrofolate Reductase (MTHFR) rs868014 Polymorphism Regulated by miR-1203 Associates with Risk and Short Term Outcome of Ischemic Stroke.
genetics_GWAS	hsa-mir-130a	Stroke, Ischemic	27246008			I63.9			HP:0002140	Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke
genetics_GWAS	hsa-mir-130b	Stroke, Ischemic	27603512			I63.9			HP:0002140	Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality.
genetics_GWAS	hsa-mir-146a	Stroke, Ischemic	24952884			I63.9			HP:0002140	miR-146a and miR-196a2 polymorphisms in patients with ischemic stroke in the northern Chinese Han population.
genetics_GWAS	hsa-mir-146a	Stroke, Ischemic	26608782			I63.9			HP:0002140	Although the 3 SNPs might be associated with IS, the association varied significantly in different countries.
genetics_GWAS	hsa-mir-150	Stroke, Ischemic	27246008			I63.9			HP:0002140	Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke
genetics_GWAS	hsa-mir-155	Stroke, Ischemic	27246008			I63.9			HP:0002140	Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke
genetics_GWAS	hsa-mir-196a-2	Stroke, Ischemic	26608782			I63.9			HP:0002140	Although the 3 SNPs might be associated with IS, the association varied significantly in different countries.
genetics_GWAS	hsa-mir-196a-2	Stroke, Ischemic	24952884			I63.9			HP:0002140	miR-146a and miR-196a2 polymorphisms in patients with ischemic stroke in the northern Chinese Han population.
genetics_GWAS	hsa-mir-199a	Stroke, Ischemic	28234972			I63.9			HP:0002140	the +936C/T variants significantly increased the risk of poorer stroke outcome by affecting the bindings of miR-199a and miR-199b to VEGF mRNA at the rs30250340 polymorphic site
genetics_GWAS	hsa-mir-199b	Stroke, Ischemic	28234972			I63.9			HP:0002140	the +936C/T variants significantly increased the risk of poorer stroke outcome by affecting the bindings of miR-199a and miR-199b to VEGF mRNA at the rs30250340 polymorphic site
genetics_GWAS	hsa-mir-200b	Stroke, Ischemic	27603512			I63.9			HP:0002140	Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality.
genetics_GWAS	hsa-mir-34a	Stroke, Ischemic	27246008			I63.9			HP:0002140	Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke
genetics_GWAS	hsa-mir-495	Stroke, Ischemic	27603512			I63.9			HP:0002140	Association of the Single Nucleotide Polymorphisms in microRNAs 130b, 200b, and 495 with Ischemic Stroke Susceptibility and Post-Stroke Mortality.
genetics_GWAS	hsa-mir-499	Stroke, Ischemic	26608782			I63.9			HP:0002140	Although the 3 SNPs might be associated with IS, the association varied significantly in different countries.
genetics_GWAS	hsa-mir-618	Stroke, Ischemic	27011381			I63.9			HP:0002140	Our findings suggest that miR-618 SNP rs2682818 may play an important role in the recurrence of ischemic stroke.
genetics_GWAS	hsa-mir-146a	Systemic Lupus Erythematosus	21738483	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus.
genetics_GWAS	hsa-mir-146a	Systemic Lupus Erythematosus	22218224	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The SNP (rs2431697) was associated with the microRNA-146a, where the risk allele correlates with lower expression of the miRNA.
genetics_GWAS	hsa-mir-146a	Systemic Lupus Erythematosus	24803388	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Association of miR-146a polymorphisms with systemic lupus erythematosus: a meta-analysis.
genetics_GWAS	hsa-mir-146a	Systemic Lupus Erythematosus	25218914	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The present meta-analysis suggests important roles for the mir-499 rs3746444 polymorphism in RA, especially in the Caucasian population and for miR-146a rs57095329 polymorphism in SLE.
genetics_GWAS	hsa-mir-569	Systemic Lupus Erythematosus	21162035	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Association of a functional polymorphism in the 3' untranslated region of SPI1 with systemic lupus erythematosus.
genetics_GWAS	hsa-mir-569	Systemic Lupus Erythematosus	21360505	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	rs1057233 alters a target sequence for microRNA hsa-miR-569 (miR-569).
genetics_GWAS	hsa-mir-146a	Thyroid Neoplasms	17468766	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3'UTR of the KIT oncogene in papillary thyroid carcinoma.
genetics_GWAS	hsa-mir-146a	Thyroid Neoplasms	19164563	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146a: SNP rs2910164 contribute to thyroid cancer
genetics_GWAS	hsa-mir-146a	Thyroid Neoplasms	23451063	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Association between the rs2910164 Polymorphism in Pre-Mir-146a Sequence and Thyroid Carcinogenesis
genetics_GWAS	hsa-mir-146a	Thyroid Neoplasms	28899898	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The rs2910164 variant in MIR146A is significantly associated with DTC
genetics_GWAS	hsa-mir-146a	Thyroid Neoplasms	18474871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Thus, our data suggest that a common polymorphism in pre-miR-146a affects the miR expression, contributes to the genetic predisposition to PTC, and plays a role in the tumorigenesis through somatic mutation.
genetics_GWAS	hsa-mir-146a	Thyroid Neoplasms	21978540	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Despite some limitations, this meta-analysis suggests that the miR-146a G allele is a low-penetrant risk factor for papillary thyroid carcinoma development.
genetics_GWAS	hsa-mir-146b	Thyroid Neoplasms	17468766	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3'UTR of the KIT oncogene in papillary thyroid carcinoma.
genetics_GWAS	hsa-mir-149	Thyroid Neoplasms	25405731	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Rs2292832 was possibly involved in the susceptibility and local progression of PTC in Chinese patients, by altering the expression level of mir-149-5p and its target genes.
genetics_GWAS	hsa-mir-221	Thyroid Neoplasms	17468766	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3'UTR of the KIT oncogene in papillary thyroid carcinoma.
genetics_GWAS	hsa-mir-222	Thyroid Neoplasms	17468766	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	somatic mutations altering binding sites for miR-221, miR-222 and miR-146 have been observed in the 3'UTR of the KIT oncogene in papillary thyroid carcinoma.
genetics_GWAS	hsa-mir-1273d	Tooth Agenesis	27362534	gastrointestinal system disease	DOID:0050591	K00.0	D000848	PS106600	HP:0001592	our findings indicate that rs15705 and rs317250 are associated with the susceptibility of non-syndromic tooth agenesis by possibly affecting miRNAs and mRNA interaction.
genetics_GWAS	hsa-mir-4639	Tooth Agenesis	27362534	gastrointestinal system disease	DOID:0050591	K00.0	D000848	PS106600	HP:0001592	rs15705 and rs317250 are associated with the susceptibility of non-syndromic tooth agenesis by possibly affecting miRNAs and mRNA interaction.
genetics_GWAS	hsa-mir-189	Tourette Syndrome	16224024	disease of mental health	DOID:11119	F95.2	D005879	137580		we identified a frameshift mutation and two independent occurrences of the identical variant in the binding site for microRNA hsa-miR-189
genetics_GWAS	hsa-mir-146a	Tuberculosis, Pulmonary	25650003	disease by infectious agent	DOID:2957	A15	D014397			Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations.
genetics_GWAS	hsa-mir-146a	Tuberculosis, Pulmonary	21524676	disease by infectious agent	DOID:2957	A15	D014397			A polymorphism (rs2910164 G>C, in miR-146a) indicated an association with PTB risk in both Tibetan (p = 0.031) and Han (p = 0.000) populations. However, the role of the G allele of rs2910164, like the C allele in rs3746444, differed in the Tibetan (OR = 1.509, p < 0.05) and Han (OR = 0.575, p < 0.05) groups.
genetics_GWAS	hsa-mir-149	Tuberculosis, Pulmonary	25650003	disease by infectious agent	DOID:2957	A15	D014397			Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations.
genetics_GWAS	hsa-mir-196a-2	Tuberculosis, Pulmonary	25650003	disease by infectious agent	DOID:2957	A15	D014397			Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations.
genetics_GWAS	hsa-mir-499	Tuberculosis, Pulmonary	25650003	disease by infectious agent	DOID:2957	A15	D014397			Association of the miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms with susceptibility to pulmonary tuberculosis in the Chinese Uygur, Kazak and Southern Han populations.
genetics_GWAS	hsa-mir-499a	Tuberculosis, Pulmonary	21524676	disease by infectious agent	DOID:2957	A15	D014397			There was no association between rs3746444 (in hsa-mir-499) and PTB risk (p = 0.118) in the Han population, but subjects carrying the C allele exhibited decreased PTB risk (odds ratio [OR] = 0.403 [95% confidence interval (95% CI) 0.278-0.583]). There was an association between rs3746444 and PTB in the Tibetan population, and individuals carrying the C allele exhibited increased PTB risk (OR = 1.870 [95% CI 1.218-2.871]).
genetics_GWAS	hsa-mir-146a	Urinary Bladder Cancer	22846912	urinary system disease	DOID:11054	C67	D001749	109800		miR-146a rs2910164 C allele inhibited cell proliferation and significantly downregulates expression of IRAK1 and TRAF6 in bladder cancer cells.
genetics_GWAS	hsa-mir-146a	Urinary Bladder Cancer	21529907	urinary system disease	DOID:11054	C67	D001749	109800		Polymorphism (rs2910164) of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population. The subjects carrying GG homozygote had a 1.496-foldincreased risk than those carrying CG/CC genotypes. The carriers of GG genotype had obviously more reduced miR-146a expression level compared with the carriers of CC genotype.
genetics_GWAS	hsa-mir-196a-2	Urinary Bladder Cancer	21345130	urinary system disease	DOID:11054	C67	D001749	109800		Our results showed that the heterozygous genotype of rs11614913 (hsa-mir-196a2 C>T rs11614913) was higher in cases than controls but the results were marginally significant (p=0.055; odds ratio, 1.44).
genetics_GWAS	hsa-mir-196b	Urinary Bladder Cancer	21345130	urinary system disease	DOID:11054	C67	D001749	109800		Our results showed that the heterozygous genotype of rs11614913 (hsa-mir-196a2 C>T rs11614913) was higher in cases than controls but the results were marginally significant (p=0.055; odds ratio, 1.44).
genetics_GWAS	hsa-mir-218-1	Urinary Bladder Cancer	20163849	urinary system disease	DOID:11054	C67	D001749	109800		miR-218:Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer
genetics_GWAS	hsa-mir-218-1	Urinary Bladder Cancer	23320911	urinary system disease	DOID:11054	C67	D001749	109800		The pri-miR-218 rs11134527 SNP was significantly associated with the risk of cervical carcinoma in Eastern Chinese women
genetics_GWAS	hsa-mir-218-2	Urinary Bladder Cancer	20163849	urinary system disease	DOID:11054	C67	D001749	109800		miR-218:Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer
genetics_GWAS	hsa-mir-218-2	Urinary Bladder Cancer	23320911	urinary system disease	DOID:11054	C67	D001749	109800		The pri-miR-218 rs11134527 SNP was significantly associated with the risk of cervical carcinoma in Eastern Chinese women
genetics_GWAS	hsa-mir-7-1	Urinary Bladder Cancer	22768238	urinary system disease	DOID:11054	C67	D001749	109800		A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer.
genetics_GWAS	hsa-mir-7-2	Urinary Bladder Cancer	22768238	urinary system disease	DOID:11054	C67	D001749	109800		A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer.
genetics_GWAS	hsa-mir-7-3	Urinary Bladder Cancer	22768238	urinary system disease	DOID:11054	C67	D001749	109800		A microRNA-7 binding site polymorphism (1010A/G) in HOXB5 leads to differential gene expression in bladder cancer.
genetics_GWAS	hsa-mir-146a	Uveitis	24658012	nervous system disease	DOID:13141	H20.9	D014605			This study shows that miR-146a and Ets-1 are both associated with pediatric uveitis in Han Chinese. SNP rs10893872 may affect the genetic predisposition to pediatric uveitis by modulating expression of Ets-1.
genetics_GWAS	hsa-mir-1	Vascular Hypertrophy	17381315							we have identified an A-to-G transition in the 3'UTR of the GDF8 gene that reveals an illegitimate target site for microRNAs miR-1 and miR-206 that are highly expressed in skeletal muscle.
genetics_GWAS	hsa-mir-206	Vascular Hypertrophy	17381315							we have identified an A-to-G transition in the 3'UTR of the GDF8 gene that reveals an illegitimate target site for microRNAs miR-1 and miR-206 that are highly expressed in skeletal muscle.
genetics_GWAS	hsa-mir-570	Viral Infectious Disease	26199425	disease by infectious agent	DOID:934	A94	D001102			it was demonstrated that human CYP2E1 was regulated by miR-570 in a genotype-dependent manner. This report describes the first proof that SNP in 3'-UTR of human P450 affects binding of miRNA to modulate the expression in the liver.
genetics_GWAS	hsa-mir-196a-2	Vitiligo	23433405	immune system disease	DOID:12306	L80	D014820		HP:0001045	A Single Nucleotide Polymorphism of miR-196a-2 and Vitiligo: An Association Study and Functional Analysis in a Han Chinese Population
genetics_GWAS	hsa-mir-196a-2	Vitiligo	25896941	immune system disease	DOID:12306	L80	D014820		HP:0001045	miR-196a-2 rs11614913 polymorphism is associated with vitiligo by affecting heterodimeric molecular complexes of Tyr and Tyrp1.
genetics_knock down_promote	hsa-mir-21	Acute Kidney Failure	25844699	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	Knockdown of  miR-21 upregulated its target effectors programmed cell death protein 4 and phosphatase and tensin homolog deleted on chromosome 10 expression, resulted in an increase in apoptosis, and exacerbated lipopolysaccharide-induced acute kidney injury.
genetics_knock down_promote	hsa-mir-29a	Alzheimer Disease	18434550	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	loss
genetics_knock down_promote	hsa-mir-29b-1	Alzheimer Disease	18434550	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	loss
genetics_knock down_promote	hsa-mir-206	Amyotrophic Lateral Sclerosis	24664281	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	in mutant mice lacking miR-206, reinnervation is impaired following nerve injury and loss of NMJs is accelerated  in a mouse model of amyotrophic lateral sclerosis (ALS).
genetics_knock down_promote	hsa-mir-17	Atrial Fibrillation	24927531	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility.
genetics_knock down_promote	hsa-mir-18	Atrial Fibrillation	24927531	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility.
genetics_knock down_promote	hsa-mir-19a	Atrial Fibrillation	24927531	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility.
genetics_knock down_promote	hsa-mir-19b-1	Atrial Fibrillation	24927531	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility.
genetics_knock down_promote	hsa-mir-20a	Atrial Fibrillation	24927531	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility.
genetics_knock down_promote	hsa-mir-92-1	Atrial Fibrillation	24927531	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility.
genetics_knock down_promote	hsa-mir-181	Autism Spectrum Disorder	27017280	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	this loss-of miR-181c function  resulted in enhanced neurite sprouting and reduced synaptogenesis
genetics_knock down_promote	hsa-mir-125b-1	Breast Neoplasms	14973191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	deletion
genetics_knock down_promote	hsa-mir-133a-1	Breast Neoplasms	22292984	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion.
genetics_knock down_promote	hsa-mir-133a-2	Breast Neoplasms	22292984	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion.
genetics_knock down_promote	hsa-mir-15a	Breast Neoplasms	17012848	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Later on, deletion of mir-16-1 and mir-15a deletion were also identified in epithelial tumors, such as pituitary adenomas, ovarian and breast cancer.
genetics_knock down_promote	hsa-mir-17	Breast Neoplasms	16940181	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The genomic location of Mir-17-5p also undergoesloss of heterozygosity in different types of cancer, including breast cancer.
genetics_knock down_promote	hsa-mir-200a	Breast Neoplasms	24280074	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Loss of microRNA-200a expression correlates with tumor progression in breast cancer.
genetics_knock down_promote	hsa-mir-218-1	Breast Neoplasms	22898079	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway.
genetics_knock down_promote	hsa-mir-218-2	Breast Neoplasms	22898079	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway.
genetics_knock down_promote	hsa-mir-7	Breast Neoplasms	25532106	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppression of miR-7 in the MCF-7 cell line resulted in enhanced colony formation activity but not cell migration
genetics_knock down_promote	hsa-mir-29c	Carcinoma, Embryonal	26848028	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	Inhibition of miR鈥?9c promoted proliferation, and suppressed the apoptosis and differentiation of P19 cells.
genetics_knock down_promote	hsa-mir-101	Carcinoma, Esophageal	25400732	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	decreased expression of miR-101 might promote metastasis of human ESCC by inducing accumulation of EZH2 protein.
genetics_knock down_promote	hsa-mir-100	Carcinoma, Hepatocellular	25361001	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis of hepatocellular carcinoma cells.
genetics_knock down_promote	hsa-mir-1-1	Carcinoma, Hepatocellular	18593903	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1: silenced
genetics_knock down_promote	hsa-mir-1-2	Carcinoma, Hepatocellular	18593903	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1: silenced
genetics_knock down_promote	hsa-mir-126	Carcinoma, Hepatocellular	28639884	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Loss of tumor suppressor miR-126 contributes to the development of hepatitis B virus-related hepatocellular carcinoma metastasis through the upregulation of ADAM9.
genetics_knock down_promote	hsa-mir-142	Carcinoma, Hepatocellular	28177895	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Over-expression of Thrombospondin 4 correlates with loss of miR-142 and contributes to migration and vascular invasion of advanced hepatocellular carcinoma.
genetics_knock down_promote	hsa-mir-145	Carcinoma, Hepatocellular	24690171	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrated that miR-145 could inhibit HCC through targeting IRS1 and its downstream signaling, implicating the loss of miR-145 regulation may be a potential molecular mechanism causing aberrant oncogenic signaling in HCC.
genetics_knock down_promote	hsa-mir-17	Carcinoma, Hepatocellular	15944709	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	loss of heterozygosity of this cluster
genetics_knock down_promote	hsa-mir-18a	Carcinoma, Hepatocellular	15944709	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	loss of heterozygosity of this cluster
genetics_knock down_promote	hsa-mir-199a-1	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This region encodes miRNA-199a-1 (19p13.2), whose expression levels are lower in HCC compared to nontumor liver [59] and is deleted in several other tumor types.
genetics_knock down_promote	hsa-mir-19a	Carcinoma, Hepatocellular	15944709	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	loss of heterozygosity of this cluster
genetics_knock down_promote	hsa-mir-19b-1	Carcinoma, Hepatocellular	15944709	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	loss of heterozygosity of this cluster
genetics_knock down_promote	hsa-mir-20a	Carcinoma, Hepatocellular	15944709	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	loss of heterozygosity of this cluster
genetics_knock down_promote	hsa-mir-21	Carcinoma, Hepatocellular	26282675	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-21 knockdown led to increased HBP1 and p53 and subsequently reduced lipogenesis and delayed G1/S transition, and the additional treatment of HBP1-siRNA antagonised the effect of microRNA-21-ASO, suggesting that HBP1 mediated the inhibitory effects of microRNA-21-ASO on both hepatic lipid accumulation and hepatocarcinogenesis.
genetics_knock down_promote	hsa-mir-320a	Carcinoma, Hepatocellular	28288874	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis.
genetics_knock down_promote	hsa-mir-505	Carcinoma, Hepatocellular	27259809	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the up-regulation of miR-505 suppressed, whereas the down-regulation of miR-505 promoted proliferation, invasion and epithelial-mesenchymal transition in MHCC97.
genetics_knock down_promote	hsa-mir-15a	Carcinoma, Lung, Non-Small-Cell	29551936			C34.90	D002289		HP:0030358	Knocking down MiR-15a expression promotes the occurrence and development and induces the EMT of NSCLC cells in vitro
genetics_knock down_promote	hsa-mir-424	Carcinoma, Lung, Non-Small-Cell	27500472			C34.90	D002289		HP:0030358	It was found that down-regulation of miR-424-3p was pronouncedly associated with NSCLC progression  and overall prognosis;
genetics_knock down_promote	hsa-mir-101-1	Carcinoma, Lung, Non-Small-Cell	21993632			C34.90	D002289		HP:0030358	Down-regulation of miR-101 was associated with overexpression of Mcl-1 mRNA in NSCLC tissue when compared with corresponding normal tissue, with a negative correlation (r = -0.724, P < 0.01). MiR-101 expression was significantly associated with pathological stage (P = 0.004) and lymph node involvement (P = 0.012). Overexpression of Mcl-1 was associated with pathological grade (P = 0.022) and lymph node involvement (P = 0.017). A comparison of survival curves of low versus high expressers of miR-101 and Mcl-1 revealed a highly significant difference in NSCLC (P < 0.05), which suggests that reduced expression of miR-101 versus overexpression of Mcl-1 is associated with a poorer prognosis.
genetics_knock down_promote	hsa-mir-101-2	Carcinoma, Lung, Non-Small-Cell	21993632			C34.90	D002289		HP:0030358	Down-regulation of miR-101 was associated with overexpression of Mcl-1 mRNA in NSCLC tissue when compared with corresponding normal tissue, with a negative correlation (r = -0.724, P < 0.01). MiR-101 expression was significantly associated with pathological stage (P = 0.004) and lymph node involvement (P = 0.012). Overexpression of Mcl-1 was associated with pathological grade (P = 0.022) and lymph node involvement (P = 0.017). A comparison of survival curves of low versus high expressers of miR-101 and Mcl-1 revealed a highly significant difference in NSCLC (P < 0.05), which suggests that reduced expression of miR-101 versus overexpression of Mcl-1 is associated with a poorer prognosis.
genetics_knock down_promote	hsa-mir-214	Carcinoma, Nasopharyngeal	24465927	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma.
genetics_knock down_promote	hsa-mir-29b	Carcinoma, Renal Cell	26823729	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Inhibition of miR-29b expression could promote apoptosis, and inhibit proliferation and invasion ability in SN12-PM6 cells.
genetics_knock down_promote	hsa-mir-146b	Carcinoma, Thyroid, Papillary	25819770	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	The results showed that PTC cells overexpress miR-146b and miR-222 in exosomes; and that factors released by both normal thyroid and PTC cells alter proliferation of other cells in a complex manner. The intercellular interactions were likely conferred in part by exosomal miRNA, which can potentially be developed as biomarkers of PTC recurrence.
genetics_knock down_promote	hsa-mir-222	Carcinoma, Thyroid, Papillary	25819770	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	The results showed that PTC cells overexpress miR-146b and miR-222 in exosomes; and that factors released by both normal thyroid and PTC cells alter proliferation of other cells in a complex manner. The intercellular interactions were likely conferred in part by exosomal miRNA, which can potentially be developed as biomarkers of PTC recurrence.
genetics_knock down_promote	hsa-mir-195	Cervical Neoplasms	26511972	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	reducing the endogenous miR-195 level by miR-195 inhibitor promoted the proliferation of cervical cancer cells.
genetics_knock down_promote	hsa-mir-370	Cholangiocarcinoma	23110045	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch
genetics_knock down_promote	hsa-mir-101-1	Colon Neoplasms	22930392			D12.6	D003110		HP:0100273	Loss of miR-101 Expression Promotes Wnt/beta-Catenin Signalling Pathway Activation and Malignancy in Colon Cancer Cells.
genetics_knock down_promote	hsa-mir-4282	Colorectal Carcinoma	27120047	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		It was found that miR-4282 inhibition promoted cell growth, migration and invasion (P<0.05) of HT29 and HCT116 colorectal carcinoma cells while miR-4282 overexpression suppressed cell growth and mobility (P<0.05).
genetics_knock down_promote	hsa-mir-622	Colorectal Carcinoma	26333174	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-622 inhibited tumor proliferation and migration in vitro.
genetics_knock down_promote	hsa-mir-34a	Diabetes Mellitus	25483877	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Knockdown of miR-34a slightly decreased proliferation, but as apoptosis and NO synthesis were highly reduced, miR-34a may be further investigated as a therapeutic target to reduce 尾-cell death and dysfunction.
genetics_knock down_promote	hsa-mir-150	Diabetic Retinopathy	27304911	nervous system disease	DOID:8947	E10-11.31	D003930			deletion of miR-150 significantly increased the retinal pathological angiogenesis
genetics_knock down_promote	hsa-mir-148a	Endometrial Neoplasms	22890324	reproductive system disease	DOID:1380	C54.1	D016889	608089		Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility.
genetics_knock down_promote	hsa-mir-101-1	Gastric Neoplasms	22450781	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 upregulation in intestinal gastric cancer.
genetics_knock down_promote	hsa-mir-486	Gastric Neoplasms	21415212	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Anti-apoptotic Factor in Gastric Cancer.
genetics_knock down_promote	hsa-mir-124	Glioblastoma	26993295				D005909		HP:0100843	inhibitor of miR-124 promoted the expression of STAT3 and cell proliferation.
genetics_knock down_promote	hsa-mir-124-1	Glioma	22253443	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Loss of brain-enriched miR-124 enhances the stem-like traits and invasiveness of glioma cells.
genetics_knock down_promote	hsa-mir-124-2	Glioma	22253443	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Loss of brain-enriched miR-124 enhances the stem-like traits and invasiveness of glioma cells.
genetics_knock down_promote	hsa-mir-124-3	Glioma	22253443	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Loss of brain-enriched miR-124 enhances the stem-like traits and invasiveness of glioma cells.
genetics_knock down_promote	hsa-mir-204	Glioma	23204229	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Loss of miR-204 Expression Enhances Glioma Migration and Stem Cell-like Phenotype
genetics_knock down_promote	hsa-mir-423	Glioma	28381178	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-423-5p knockdown enhances the sensitivity of glioma stem cells to apigenin through the mitochondrial pathway.
genetics_knock down_promote	hsa-mir-146a	Gout	29544526	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	miR-146a provides negative feedback regulation of gouty arthritis development and lack of miR-146a enhances gouty arthritis via upregulation of TRAK6, IRAK-1, and the NALP3 inflammasome function
genetics_knock down_promote	hsa-mir-126	Heart Failure	23136161			I50	D006331		HP:0001635	Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure: Role for Impaired In Vivo Neovascularization and Cardiac Repair Capacity
genetics_knock down_promote	hsa-mir-130a	Heart Failure	23136161			I50	D006331		HP:0001635	Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure: Role for Impaired In Vivo Neovascularization and Cardiac Repair Capacity
genetics_knock down_promote	hsa-mir-133a	Heart Failure	26064437			I50	D006331		HP:0001635	attenuation of miR-133a contributes to the exacerbation  of diabetes mediated cardiac autophagy and hypertrophy in heart failure
genetics_knock down_promote	hsa-mir-150	Heart Failure	25824147			I50	D006331		HP:0001635	we show that genetic deletion of miR-150 in mice causes abnormalities in cardiac structural and functional remodelling after MI.
genetics_knock down_promote	hsa-mir-92a-1	Hematologic Neoplasms	17011485	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	The miR-17-92 cluster is amplified in hematopoietic malignancies.
genetics_knock down_promote	hsa-mir-122	Hepatitis B Virus Infection	22105316	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Loss of MiR-122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1 modulated P53 activity.
genetics_knock down_promote	hsa-mir-424	Hepatoblastoma	24796297	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Furthermore, miR-424 or miR-503 depletion enhanced extravasation to the lungs of hepatocarcinoma cells injected in the tail vein of mice.
genetics_knock down_promote	hsa-mir-21	Hypertension	21920918	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Induction of miR-21 and miR-27a may be a critical component of BMP-induced growth suppression, loss of which likely contributes to vascular cell proliferation in HPAH (Heritable pulmonary arterial hypertension).
genetics_knock down_promote	hsa-mir-133a	Hypertrophy	26064437				D006984			attenuation of miR-133a contributes to the exacerbation  of diabetes mediated cardiac autophagy and hypertrophy in heart failure
genetics_knock down_promote	hsa-mir-7	Hypogonadotropic Hypogonadism	28218624	endocrine system disease	DOID:0090070	E23.0		PS147950		Loss of microRNA-7a2 induces hypogonadotropic hypogonadism and infertility.
genetics_knock down_promote	hsa-mir-23a	Idiopathic Pulmonary Hypertension	25815108			I27.20	D065627	178600		Finally we found that silencing of miR23a resulted in an increase of the expression of PGC1α, as well as in its well-known regulated genes CYC, SOD, NRF2,and HO1. The results point to the utility of circulating miRNA expression as a biomarker of disease progression.
genetics_knock down_promote	hsa-mir-132	Inflammation	26052826				D007249			Blockage of miR-132 using miR-132  inhibitor reversed the Ach action upon LPS-induced release of inflammatory mediators and reduction in AchE protein/activity.
genetics_knock down_promote	hsa-mir-146a	Ischemia-Reperfusion Injury	27444565				D015427			After unilateral IRI, miR-146a-/- mice exhibited more extensive tubular injury, inflammatory infiltrates, and fibrosis than wild-type mice.
genetics_knock down_promote	hsa-mir-146a	Ischemia-Reperfusion Injury	27250735				D015427			miR146a exerts a kidney protective effect through negative  regulation of acute inflammatory response
genetics_knock down_promote	hsa-mir-21	Ischemia-Reperfusion Injury	24098402				D015427			Our data clearly demonstrate that miR-21 is involved in IPost-mediated cardiac protection against I/R injury and dysfunction through the PTEN/Akt signaling pathway in vivo.
genetics_knock down_promote	hsa-mir-377	Ischemia-Reperfusion Injury	26564600				D015427			These findings indicate that HF increased miR-377 expression in the myocardium, which is detrimental to stem cell function, and transplantation of miR-377 knockdown hCD34(+) cells into ischemic myocardium promoted their angiogenic ability, attenuating left ventricular remodeling and cardiac fibrosis.
genetics_knock down_promote	hsa-let-7	Kaposi Sarcoma	27531260	disease of cellular proliferation	DOID:8632	C46	D012514			Let-7 silencing may activate the replication of KSHV, possibly through up-regulating MAP4K4 and its downstream molecules COX-2, MMP-13, and phosphorylation of ERK1/2, finally results in the progression of Kaposi sarcoma.
genetics_knock down_promote	hsa-mir-29a	Kidney Diseases [unspecific]	22095944			N18.9	D007674			Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis.
genetics_knock down_promote	hsa-mir-29b-1	Kidney Diseases [unspecific]	22095944			N18.9	D007674			Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis.
genetics_knock down_promote	hsa-mir-29b-2	Kidney Diseases [unspecific]	22095944			N18.9	D007674			Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis.
genetics_knock down_promote	hsa-mir-29c	Kidney Diseases [unspecific]	22095944			N18.9	D007674			Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis.
genetics_knock down_promote	hsa-mir-15a	Leukemia	12434020			C95	D007938	613065	HP:0001909	deletion or downregulation
genetics_knock down_promote	hsa-mir-15a	Leukemia	16166262			C95	D007938	613065	HP:0001909	the deletion or downregulation of mir-15a results in increased expression of BCL2.
genetics_knock down_promote	hsa-mir-15a	Leukemia	27533467			C95	D007938	613065	HP:0001909	both miR-15a deficient HSC and B1P cells are capable of repopulating irradiated recipients and produce higher numbers of B1 cells than sources with normal miR-15a/16 levels.
genetics_knock down_promote	hsa-mir-16-1	Leukemia	12434020			C95	D007938	613065	HP:0001909	deletion or downregulation
genetics_knock down_promote	hsa-mir-16-1	Leukemia	16166262			C95	D007938	613065	HP:0001909	the deletion or downregulation of mir-15a results in increased expression of BCL2.
genetics_knock down_promote	hsa-mir-125b	Leukemia, B-Cell	29555645			C91.31	D015448	151430		physiological silencing of miR-125b is required for normal B-cell development and also acts as a mechanism of cancer suppression
genetics_knock down_promote	hsa-mir-125b-1	Leukemia, B-Cell	16885332			C91.31	D015448	151430		In a precursor B-cell acute lymphoblastic leukemia, an insertion of miR-125b-1 into a rearranged immunoglobulin heavy chain locus was described.
genetics_knock down_promote	hsa-mir-125b-1	Leukemia, B-Cell	17028302			C91.31	D015448	151430		It is of note that insertion of miR-125b-1 into a rearranged immunoglobulin heavy chain gene locus was recently reported in a patient with precursor B-cell acute lymphoblastic leukemia, though the expression miR-125b-1 was not investigated.
genetics_knock down_promote	hsa-mir-142	Leukemia, B-Cell	16885332			C91.31	D015448	151430		It was shown later that miR-142 is located at the chromosome 17 breakpoint and that c-Myc was rearranged under the control of the promoter of miR-142 with consequent overexpression.
genetics_knock down_promote	hsa-mir-15a	Leukemia, B-Cell	16885332			C91.31	D015448	151430		Deleted and down-regulated in the majority of B-CLLs
genetics_knock down_promote	hsa-mir-16-1	Leukemia, B-Cell	16885332			C91.31	D015448	151430		Deleted and down-regulated in the majority of B-CLLs
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	24026141	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	There was a significantly decreased expression of both miRNAs in patients with biallelic deletion of the 13q14 region but only when deletions were present in 77% or more of cells, as detected by fluorescent in situ hybridization (FISH).
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	24732594	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	12434020	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	deletion or downregulation
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17012848	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	It was found that mir-16-1 and mir-15a at 13q14 are deleted in more than 50% patients, with concurrent reduced expression in ~65% patients. Further studies demonstrated that these two miRNAs suppress BCL2 expression and may serve as tumor suppressor genes in this disease.
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17028302	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Detailed analyses of deletion and expression status revealed these two miRNAs to be located within a 30 kb minimally deleted region in chronic lymphocytic leukemia (CLL) patients, both of which were deleted or downregulated in most CLL cases, suggesting that miR-15a and miR-16-1 may function as tumor suppressor genes.
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17234972	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	After years of futile attemptsto identify the gene(s) in the deleted 13q14 region that participatein the pathogenesis of chronic lymphocytic leukemia, Calin etal discovered that miR-15 and miR-16 are located within thissequence and that both are downregulated in  68% of cases.
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17531469	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The loss-of-function of miR-15a and miR-16-1 in CLL, and perhaps other cancers as well, may contribute to malignant transformation by upregulating Bcl2 thereby preventing apoptosis.
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17940623	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells.
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17965831	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a and miR-16 are often deleted from chromosome 13q14.2 in patients with B cell CLL, suggesting that these miRNAs may be involved in tumour suppression. Additionally, introduction of exogenous miR-16 into a malignant B-1 cell line resulted in increased apoptosis.
genetics_knock down_promote	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	21156224	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	often absent
genetics_knock down_promote	hsa-mir-15b	Leukemia, Lymphocytic, Chronic, B-Cell	17234972	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	After years of futile attemptsto identify the gene(s) in the deleted 13q14 region that participatein the pathogenesis of chronic lymphocytic leukemia, Calin etal discovered that miR-15 and miR-16 are located within thissequence and that both are downregulated in  68% of cases.
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	24026141	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	There was a significantly decreased expression of both miRNAs in patients with biallelic deletion of the 13q14 region but only when deletions were present in 77% or more of cells, as detected by fluorescent in situ hybridization (FISH).
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	24732594	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	12434020	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	deletion or downregulation
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	17012848	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	It was found that mir-16-1 and mir-15a at 13q14 are deleted in more than 50% patients, with concurrent reduced expression in ~65% patients. Further studies demonstrated that these two miRNAs suppress BCL2 expression and may serve as tumor suppressor genes in this disease.
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	17028302	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Detailed analyses of deletion and expression status revealed these two miRNAs to be located within a 30 kb minimally deleted region in chronic lymphocytic leukemia (CLL) patients, both of which were deleted or downregulated in most CLL cases, suggesting that miR-15a and miR-16-1 may function as tumor suppressor genes.
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	17234972	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	After years of futile attemptsto identify the gene(s) in the deleted 13q14 region that participatein the pathogenesis of chronic lymphocytic leukemia, Calin etal discovered that miR-15 and miR-16 are located within thissequence and that both are downregulated in  68% of cases.
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	17531469	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	the loss-of-function of miR-15a and miR-16-1 in CLL, and perhaps other cancers as well, may contribute to malignant transformation by upregulating Bcl2 thereby preventing apoptosis.
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	17940623	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells.
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	17965831	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a and miR-16 are often deleted from chromosome 13q14.2 in patients with B cell CLL, suggesting that these miRNAs may be involved in tumour suppression. Additionally, introduction of exogenous miR-16 into a malignant B-1 cell line resulted in increased apoptosis.
genetics_knock down_promote	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	21156224	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	often absent
genetics_knock down_promote	hsa-mir-16-2	Leukemia, Lymphocytic, Chronic, B-Cell	17234972	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	After years of futile attemptsto identify the gene(s) in the deleted 13q14 region that participatein the pathogenesis of chronic lymphocytic leukemia, Calin etal discovered that miR-15 and miR-16 are located within thissequence and that both are downregulated in  68% of cases.
genetics_knock down_promote	hsa-mir-16-2	Leukemia, Lymphocytic, Chronic, B-Cell	17965831	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a and miR-16 are often deleted from chromosome 13q14.2 in patients with B cell CLL, suggesting that these miRNAs may be involved in tumour suppression. Additionally, introduction of exogenous miR-16 into a malignant B-1 cell line resulted in increased apoptosis.
genetics_knock down_promote	hsa-mir-29a	Leukemia, Myeloid, Acute	20628397	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29a:The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML
genetics_knock down_promote	hsa-mir-29b-1	Leukemia, Myeloid, Acute	20628397	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29b1:The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML
genetics_knock down_promote	hsa-mir-125b-1	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	16151463	disease of cellular proliferation	DOID:7061	C83.5	D015452			an insertion of pre-miRNA into the immunoglobulin heavy-chain locus
genetics_knock down_promote	hsa-mir-101	Lung Neoplasms	25428391	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	particle can induce the secretion of interleukin-1β. Interleukin-1β subsequently induces the downregulation of mir-101, which may result in the upregulated level of EZH2, and occurrence of lung cancer. We for the first time proposed the role interleukin-1β-mir-101-EZH2 axes in the particle-induced lung cancer. Further study may be needed to decipher the detailed mechanism involved.
genetics_knock down_promote	hsa-mir-101-1	Lung Neoplasms	21849855	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-101 DNA Copy Loss is a Prominent Subtype Specific Event in Lung Cancer.
genetics_knock down_promote	hsa-mir-101-2	Lung Neoplasms	21849855	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-101 DNA Copy Loss is a Prominent Subtype Specific Event in Lung Cancer.
genetics_knock down_promote	hsa-mir-125b-1	Lung Neoplasms	14973191	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	deletion
genetics_knock down_promote	hsa-mir-301a	Lung Neoplasms	20470754	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-301:blocking of miR-301 in A549 cells leads to a decrease in the expression of the host gene, ska2
genetics_knock down_promote	hsa-mir-15a	Lymphoma	16166262	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	the deletion or downregulation of mir-15a results in increased expression of BCL2.
genetics_knock down_promote	hsa-mir-16-1	Lymphoma	16166262	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	the deletion or downregulation of mir-15a results in increased expression of BCL2.
genetics_knock down_promote	hsa-mir-377	Lymphoma	25889255	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Our results suggest that miR-377 is an important negative regulator of E2F and MAP3K7/NF-kB signaling pathway in melanoma cells; it is tempting to speculate that its silencing in melanoma promotes the tumorigenic and metastatic potential of the cells through activation of these pathways.
genetics_knock down_promote	hsa-mir-155	Lymphoma, B-Cell	25829072	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	A deficiency of miR-155 in the immune system causes attenuated immune functions. Clinically, several types of malignancy including diffuse large B-cell lymphoma have high miR-155 expression levels.
genetics_knock down_promote	hsa-mir-15a	Lymphoma, Mantle-Cell	17940623			C83.10	D020522			The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells.
genetics_knock down_promote	hsa-mir-16-1	Lymphoma, Mantle-Cell	17940623			C83.10	D020522			The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells.
genetics_knock down_promote	hsa-mir-135a-1	Medulloblastoma	21793975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	deletion
genetics_knock down_promote	hsa-mir-135a-2	Medulloblastoma	21793975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	deletion or amplification
genetics_knock down_promote	hsa-mir-135b	Medulloblastoma	21793975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	deletion or amplification
genetics_knock down_promote	hsa-mir-186	Medulloblastoma	21793975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	deletion
genetics_knock down_promote	hsa-mir-33b	Medulloblastoma	21793975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	deletion, amplification or a mutation at the precursor miRNA
genetics_knock down_promote	hsa-mir-512-2	Medulloblastoma	21793975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	deletion. Antisense-based knockdown of miR-512-5p (mature sequence of miR-512-2) resulted in significant upregulation of MYCC expression in HeLa and A549 cells, while forced overexpression of miR-512-2 in medulloblastoma/PNET cell lines DAOY, UW-228-2, PFSK resulted in downregulation of MYCC protein.
genetics_knock down_promote	hsa-mir-548d-1	Medulloblastoma	21793975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	deletion
genetics_knock down_promote	hsa-mir-548d-2	Medulloblastoma	21793975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	deletion
genetics_knock down_promote	hsa-let-7g	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
genetics_knock down_promote	hsa-mir-155	Melanoma	25143000	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our current study showed that both B16-F10 melanoma and Lewis lung carcinoma tumors grew much faster in bic/miR-155 knockout (miR-155(-/-) ) mice
genetics_knock down_promote	hsa-mir-200a	Melanoma	22956368	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.
genetics_knock down_promote	hsa-mir-200c	Melanoma	22956368	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.
genetics_knock down_promote	hsa-mir-203	Melanoma	22956368	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.
genetics_knock down_promote	hsa-mir-205	Melanoma	22525428	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Loss of microRNA-205 expression is associated with melanoma progression.
genetics_knock down_promote	hsa-mir-31	Mesothelioma	20463022	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR-31:Pro-tumorigenic effects of miR-31 loss in mesothelioma
genetics_knock down_promote	hsa-mir-15a	Multiple Myeloma	17940623	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells.
genetics_knock down_promote	hsa-mir-16-1	Multiple Myeloma	17940623	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells.
genetics_knock down_promote	hsa-mir-29a	Muscular Dystrophy, Duchenne	22434133	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis.
genetics_knock down_promote	hsa-mir-29b-1	Muscular Dystrophy, Duchenne	22434133	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis.
genetics_knock down_promote	hsa-mir-29b-2	Muscular Dystrophy, Duchenne	22434133	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis.
genetics_knock down_promote	hsa-mir-29c	Muscular Dystrophy, Duchenne	22434133	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis.
genetics_knock down_promote	hsa-mir-17	Musculoskeletal Abnormalities [unspecific]	21892160				D009139			Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans.
genetics_knock down_promote	hsa-mir-18a	Musculoskeletal Abnormalities [unspecific]	21892160				D009139			Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans.
genetics_knock down_promote	hsa-mir-19a	Musculoskeletal Abnormalities [unspecific]	21892160				D009139			Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans.
genetics_knock down_promote	hsa-mir-19b-1	Musculoskeletal Abnormalities [unspecific]	21892160				D009139			Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans.
genetics_knock down_promote	hsa-mir-20a	Musculoskeletal Abnormalities [unspecific]	21892160				D009139			Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans.
genetics_knock down_promote	hsa-mir-92a-1	Musculoskeletal Abnormalities [unspecific]	21892160				D009139			Germline deletion of the miR-17-92 cluster causes skeletal and growth defects in humans.
genetics_knock down_promote	hsa-mir-155	Mycobacterium tuberculosis Infection	25846955			A18	D014376	607948		Following infection, miR-155-deficient C57BL/6 mice died significantly earlier and had significantly higher numbers of CFU in lungs than wild-type mice.
genetics_knock down_promote	hsa-mir-145	Myelodysplastic Syndromes	21873545	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-145 affects megakaryocyte and erythroid differentiation.Patients with del(5q) MDS have decreased expression of miR-145 and increased expression of Fli-1. Combined loss of miR-145 and RPS14 cooperate to alter erythroid-megakaryocytic differentiation in a manner similar to the 5q- syndrome.
genetics_knock down_promote	hsa-mir-150	Myocardial Infarction	25824147	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we show that genetic deletion of miR-150 in mice causes abnormalities in cardiac structural and functional remodelling after MI.
genetics_knock down_promote	hsa-mir-1-1	Myotonic Muscular Dystrophy	21685920			G71.11	D009223	160900		As a consequence of miR-1 loss, expression of GJA1 (connexin 43) and CACNA1C (Cav1.2), which are targets of miR-1, is increased in both DM1- and DM2-affected hearts.
genetics_knock down_promote	hsa-mir-1-2	Myotonic Muscular Dystrophy	21685920			G71.11	D009223	160900		As a consequence of miR-1 loss, expression of GJA1 (connexin 43) and CACNA1C (Cav1.2), which are targets of miR-1, is increased in both DM1- and DM2-affected hearts.
genetics_knock down_promote	hsa-mir-101-1	Neoplasms [unspecific]	19008416			C80.1	D009369			miR-101: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer
genetics_knock down_promote	hsa-mir-101-2	Neoplasms [unspecific]	19008416			C80.1	D009369			miR-101: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer
genetics_knock down_promote	hsa-mir-10a	Neoplasms [unspecific]	24204315			C80.1	D009369			Loss of miR-10a activates lpo and collaborates with activated Wnt signaling in inducing intestinal neoplasia in female mice.
genetics_knock down_promote	hsa-mir-143	Neoplasms [unspecific]	20439436			C80.1	D009369			miR-143:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_knock down_promote	hsa-mir-145	Neoplasms [unspecific]	20439436			C80.1	D009369			miR-145:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_knock down_promote	hsa-mir-26a	Neoplasms [unspecific]	25668004			C80.1	D009369			Loss of tumour-suppressive miR-26a/b enhanced cancer cell migration and invasion in OSCC through direct regulation of TMEM184B. Our data describing pathways regulated by tumour-suppressive miR-26a/b provide new insights into the potential mechanisms of OSCC oncogenesis and metastasis.
genetics_knock down_promote	hsa-mir-26b	Neoplasms [unspecific]	25668004			C80.1	D009369			Loss of tumour-suppressive miR-26a/b enhanced cancer cell migration and invasion in OSCC through direct regulation of TMEM184B. Our data describing pathways regulated by tumour-suppressive miR-26a/b provide new insights into the potential mechanisms of OSCC oncogenesis and metastasis.
genetics_knock down_promote	hsa-mir-31	Neoplasms [unspecific]	20179198			C80.1	D009369			miR-31 is associated with defects in the p53 pathway and functions in serous ovarian cancer and other cancers
genetics_knock down_promote	hsa-mir-34a	Neoplasms [unspecific]	18834855			C80.1	D009369			miR-34a: reduced or lost
genetics_knock down_promote	hsa-mir-150	Obesity	26833392	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-150KO mice displayed exacerbated obesity-associated tissue inflammation and systemic insulin resistance
genetics_knock down_promote	hsa-mir-34a	Obesity	27377585	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-34a(-/-) mice are susceptible to diet-induced obesity.
genetics_knock down_promote	hsa-mir-132	Osteosarcoma	23801049	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma.
genetics_knock down_promote	hsa-mir-125b-1	Ovarian Neoplasms	14973191	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	deletion
genetics_knock down_promote	hsa-mir-145	Ovarian Neoplasms	22285623	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The loss of miR-145 can result in the activation of factors that promote oncogenesis and cellular pluripotency which in turn could lead to the development of ovarian cancer.
genetics_knock down_promote	hsa-mir-16-1	Ovarian Neoplasms	17012848	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Later on, deletion of mir-16-1 and mir-15a deletion were also identified in epithelial tumors, such as pituitary adenomas, ovarian and breast cancer.
genetics_knock down_promote	hsa-mir-31	Ovarian Neoplasms	20179198	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-31 is associated with defects in the p53 pathway and functions in serous ovarian cancer and other cancers
genetics_knock down_promote	hsa-mir-101-1	Pancreatic Neoplasms	21932133	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2.
genetics_knock down_promote	hsa-mir-101-2	Pancreatic Neoplasms	21932133	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2.
genetics_knock down_promote	hsa-mir-126	Pancreatic Neoplasms	22845403	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Loss of miR-126 is crucial to pancreatic cancer progression.
genetics_knock down_promote	hsa-mir-214	Parkinson Disease	26349993	nervous system disease	DOID:14330	G20	D010300	PS168600		The loss of miR-214 in PD resulted in the increase of α-synuclein expression, which was the potential mechanism underlying the neuroprotective effects of Resveratrol.
genetics_knock down_promote	hsa-mir-15a	Pituitary Neoplasms	16885332	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	a type of benign tumors displaying deletions at 13q14.3 and reduced expression of miR-16-1 and miR-15a
genetics_knock down_promote	hsa-mir-16-1	Pituitary Neoplasms	16885332	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	a type of benign tumors displaying deletions at 13q14.3 and reduced expression of miR-16-1 and miR-15a
genetics_knock down_promote	hsa-mir-16-1	Pituitary Neoplasms	17012848	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Later on, deletion of mir-16-1 and mir-15a deletion were also identified in epithelial tumors, such as pituitary adenomas, ovarian and breast cancer.
genetics_knock down_promote	hsa-mir-142	Primary Immunodeficiency Disease	25931583	immune system disease	DOID:612	D84.9	D007153	242850		miR-142 as an essential regulator of lymphopoiesis, and suggest that lesions in this miRNA gene may lead to primary immunodeficiency.
genetics_knock down_promote	hsa-mir-132	Progressive Supranuclear Palsy	21807765	nervous system disease	DOID:678	G23.1	D013494	601104		MicroRNA-132 loss is associated with tau exon 10 inclusion in Supranuclear Palsy, Progressive.
genetics_knock down_promote	hsa-let-7	Prostate Neoplasms	23977098	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MSCs co-evolve with prostate cancer cells in the tumor microenvironment, and the downregulation of let-7 by cancer-associated MSCs upregulates IL-6 expression.
genetics_knock down_promote	hsa-let-7c	Prostate Neoplasms	22479342	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA let-7c Is Downregulated in Prostate Cancer and Suppresses Prostate Cancer Growth.
genetics_knock down_promote	hsa-mir-1	Prostate Neoplasms	25802280	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data support the existence of an AR-miR-1-SRC regulatory network.We propose that loss of miR-1 is one mechanistic link between low canonical Androgen receptor (AR) output and SRC-promoted metastatic phenotypes.
genetics_knock down_promote	hsa-mir-100	Prostate Neoplasms	24805183	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2.
genetics_knock down_promote	hsa-mir-126	Prostate Neoplasms	24350576	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These findings suggest for the first time that the loss of miR-126 expression may play a positive role in the malignant progression of PCa. 
genetics_knock down_promote	hsa-mir-145	Prostate Neoplasms	27465939	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	ASC-derived conditioned medium (CM) significantly inhibited PC3M-luc2 cell proliferation, inducing apoptosis, but the effect was canceled by miR-145 knockdown in ASCs.
genetics_knock down_promote	hsa-mir-15a	Prostate Neoplasms	17940623	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells.
genetics_knock down_promote	hsa-mir-15a	Prostate Neoplasms	21472816	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers.
genetics_knock down_promote	hsa-mir-16-1	Prostate Neoplasms	17940623	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The common loss of miR-15a and miR-16-1 in CLL, as well as the loss of 13q14 in mantle cell lymphoma (50 percent of cases), multiple myeloma (16 to 40 percent) and prostate cancer (60 percent), strongly suggests that these two miRNAs act as tumor suppressor genes. While their full target complement is unknown, they appear to mediate their effects largely by down-regulating the anti-apoptotic protein BCL2. This protein is often found expressed at high levels in CLL and is thought to be important for the survival of the malignant cells.
genetics_knock down_promote	hsa-mir-16-1	Prostate Neoplasms	21472816	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers.
genetics_knock down_promote	hsa-mir-203	Prostate Neoplasms	24980827	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration.
genetics_knock down_promote	hsa-mir-204	Prostate Neoplasms	25630658	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	not only tumor suppressor micro-RNA loss, but also significant genome rearrangement-driven regulatory loop perturbations play a role in the advanced cancer progression, conferring better pro-survival and metastatic potential.
genetics_knock down_promote	hsa-mir-205	Prostate Neoplasms	26059417	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of tumor-suppressive microRNA-205 seems to enhance cancer cell migration and invasion in prostate cancer through direct regulation of centromere protein F. Our data describing pathways regulated by tumor-suppressive microRNA-205 provide new insights into the potential mechanisms of prostate cancer oncogenesis and metastasis.
genetics_knock down_promote	hsa-mir-34a	Prostate Neoplasms	25436980	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the bone metastasis and anti-apoptotic effects found in Ras signaling-activated prostate cancer cells require miR-34a deficiency, which in turn aids in cell survival by activating the WNT and anti-apoptotic signaling pathways thereby inducing TCF7 and BIRC5 expressions.
genetics_knock down_promote	hsa-mir-378	Prostate Neoplasms	25153390	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients.
genetics_knock down_promote	hsa-mir-122	Pterygium	27415790	nervous system disease	DOID:0002116	H11.0	D011625	178200		Decreased expression of miR-122 in pterygium might result in abnormal cell apoptosis via its regulation of the expression of Bcl-w, and subsequently contribute to the development of pterygium.
genetics_knock down_promote	hsa-mir-21	Pulmonary Hypertension	24732886	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	In vivo, genetic deletion of microRNA-21 in mice (miR-21(-/-)  mice) resulted in functional activation of the PDCD4/caspase-3 axis in the pulmonary tissues, leading to the onset of progressive PH.
genetics_knock down_promote	hsa-mir-196a	Renal Fibrosis	26940097	urinary system disease	DOID:0050855	N26.9			HP:0030760	depletion of renal miR-196a/b by miR-196a/b antagomirs substantially aggravated UUO-induced renal fibrosis.
genetics_knock down_promote	hsa-mir-196b	Renal Fibrosis	26940097	urinary system disease	DOID:0050855	N26.9			HP:0030760	depletion of renal miR-196a/b by miR-196a/b antagomirs substantially aggravated UUO-induced renal fibrosis.
genetics_knock down_promote	hsa-mir-206	Rhabdomyosarcoma	27277678	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Genetic deletion of miR-206 in a mouse model of FN-RMS accelerated and exacerbated tumor  development
genetics_knock down_promote	hsa-mir-27a	Rheumatoid Arthritis	27498552	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	However, miR-27a inhibition promoted the migration and invasion of FLS.
genetics_knock down_promote	hsa-mir-34a	Rheumatoid Arthritis	22161761	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Downregulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance.
genetics_knock down_promote	hsa-mir-126a	Sepsis	26968021			A41.9	D018805		HP:0100806	The down-regulation of miR-126a-3p in endothelial cells resulted in the increased apoptosis, and decreased proliferation and migration,
genetics_knock down_promote	hsa-mir-150	Sepsis	26743170			A41.9	D018805		HP:0100806	miR-150(-/-)  mice died rapidly after sepsis.
genetics_knock down_promote	hsa-mir-223	Sepsis	24486439			A41.9	D018805		HP:0100806	Taken together, these data indicate that loss of miR-223/-223* causes an aggravation of sepsis-induced inflammation, myocardial dysfunction and mortality.
genetics_knock down_promote	hsa-mir-200b	Squamous Cell Carcinoma, Esophageal	27496804	disease of cellular proliferation	DOID:3748		C562729			Correlating with the frequent loss of miR-200b in ESCC, both CDK2 and PAF levels  are significantly increased in ESCC tumors compared to case-matched normal tissues.
genetics_knock down_promote	hsa-mir-451a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24918822	disease of cellular proliferation	DOID:2876					Loss of tumour suppressive miR-451a enhanced cancer cell migration and invasion in HSCC through direct regulation of ESDN. Our miRNA signature and functional analysis of targets regulated by tumour suppressive miR-451a provide new insights into the potential mechanisms of HSCC oncogenesis and metastasis.
genetics_knock down_promote	hsa-mir-200a	Squamous Cell Carcinoma, Oral	29480379	disease of cellular proliferation	DOID:0050866					lack of significant alterations in miR-31 and miR-200a levels in saliva of OLP patients may be indicative for absence of malignant transformation
genetics_knock down_promote	hsa-mir-31	Squamous Cell Carcinoma, Oral	29480379	disease of cellular proliferation	DOID:0050866					lack of significant alterations in miR-31 and miR-200a levels in saliva of OLP patients may be indicative for absence of malignant transformation
genetics_knock down_promote	hsa-mir-144	Thyroid Neoplasms	22049245	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-199b-5p and miR-144 which were essentially lost in the carcinomas.
genetics_knock down_promote	hsa-mir-199b	Thyroid Neoplasms	22049245	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-199b-5p and miR-144 which were essentially lost in the carcinomas.
genetics_knock down_promote	hsa-mir-107	Urinary Bladder Cancer	21388952	urinary system disease	DOID:11054	C67	D001749	109800		Specific deletion of p53 in urothelial cells is associated with specific overexpression of miR-18a and miR-19a and down-regulation of miR-107.
genetics_knock down_promote	hsa-mir-125b-1	Urinary Bladder Cancer	14973191	urinary system disease	DOID:11054	C67	D001749	109800		deletion
genetics_knock down_promote	hsa-mir-181b-2	Urinary Bladder Cancer	17470785	urinary system disease	DOID:11054	C67	D001749	109800		mir-181b-2 and mir-199b are 3.3 Mb from the peak of the colon Scc2 locus on Chr 2; homologous human miRNAs are located inside a cancer-associated genomic region, which is a region commonly deleted in bladder cancer.
genetics_knock down_promote	hsa-mir-199b	Urinary Bladder Cancer	17470785	urinary system disease	DOID:11054	C67	D001749	109800		mir-181b-2 and mir-199b are 3.3 Mb from the peak of the colon Scc2 locus on Chr 2; homologous human miRNAs are located inside a cancer-associated genomic region, which is a region commonly deleted in bladder cancer.
genetics_knock down_promote	hsa-mir-218-1	Urinary Bladder Cancer	21519788	urinary system disease	DOID:11054	C67	D001749	109800		miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer.
genetics_knock down_promote	hsa-mir-218-2	Urinary Bladder Cancer	21519788	urinary system disease	DOID:11054	C67	D001749	109800		miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer.
genetics_knock down_suppress	hsa-mir-155	Acute Lung Injury	27371731			S27	D055371			miR-155 gene inactivation protected mice from LPS-induced ALI
genetics_knock down_suppress	hsa-mir-155	Acute Myocardial Infarction	26589288	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	We reveal that in vivo, miR-155 knockout improves left ventricular function, reduces infarct size, and attenuates collagen deposition, whereas overexpression of miR-155 produces the opposite effects.
genetics_knock down_suppress	hsa-mir-372	Adenocarcinoma, Gastric	26151747	disease of cellular proliferation	DOID:3717	D37.1	D013274			Subcutaneously delivered LNAs reduce tumor growth of AGS xenografts in mice, upon formation of a stable, specific heteroduplex with the targeted miR-372 and -373 and LATS2 upregulation.
genetics_knock down_suppress	hsa-mir-18a	Adenocarcinoma, Lung	27412935	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Downregulation of miR-18a or miR-328 can inhibit the invasion and migration abilities of A549 cells effectively.
genetics_knock down_suppress	hsa-mir-192	Adenocarcinoma, Lung	26550150	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-192 inhibitor treated tumor exhibits sensitivity to cisplatin and gemcitabine therapy.
genetics_knock down_suppress	hsa-mir-214	Adenocarcinoma, Lung	26299367	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	downregulation of miR-214 expression in CSLCs resulted in a significant decrease  in spheroid formation and the expression of the stem-cell markers Nanog, Oct-4, and Sox-2.
genetics_knock down_suppress	hsa-mir-328	Adenocarcinoma, Lung	27412935	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Downregulation of miR-18a or miR-328 can inhibit the invasion and migration abilities of A549 cells effectively.
genetics_knock down_suppress	hsa-mir-184	Adenocarcinoma, Pancreatic Ductal	26722418	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The transfection of inhibitor effectively suppressed the expression of miR-184, and further inhibited both cell proliferation and invasion abilities, in addition to the up-regulation of pro-apoptotic protein caspase 3 expression.
genetics_knock down_suppress	hsa-mir-125b	Amyotrophic Lateral Sclerosis	26794445	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	by restoring A20 levels, miR-125b inhibition then sustains motor neuron survival.
genetics_knock down_suppress	hsa-mir-126	Asthma	19843690	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Selective blockade of microRNA (miR)-126 suppressed the asthmatic phenotype
genetics_knock down_suppress	hsa-mir-21	Asthma	27448447	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Treatment with Ant-21, or the pan-PI3K inhibitor LY294002, reduced PI3K activity and restored HDAC2 levels. This led to  suppression of airway hyperresponsiveness and restored steroid sensitivity to allergic airway disease.
genetics_knock down_suppress	hsa-mir-145	Atherosclerosis	25008143	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Absence of miR-143/145 significantly reduced atherosclerotic plaque size and macrophage infiltration.
genetics_knock down_suppress	hsa-mir-96	Bladder Neoplasms	26582573			C67	D001749	109800	HP:0009725	the inhibition of miR-96 expression remarkably decreased cell proliferation and promoted cell apoptosis of BC cell lines
genetics_knock down_suppress	hsa-mir-200a	Breast Neoplasms	27433802	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We further showed that inhibition of miR-200a function, mimicking the effect of calorie restriction on this microRNA, inhibited proliferation in both rat (LA7) and human (MCF7) luminal mammary cancer cell lines.
genetics_knock down_suppress	hsa-mir-21	Breast Neoplasms	21219636	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In vitro assays showed that ERBB2 is a direct target of miR-125a-5p, which potently suppressed the proliferation of gastric cancer cells
genetics_knock down_suppress	hsa-mir-214	Breast Neoplasms	27328731	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Depleting miR-214 or elevating miR-148b blocked the dissemination  of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration.
genetics_knock down_suppress	hsa-mir-106b	Carcinoma, Breast	27519168			D05	D001943	114480	HP:0003002	down-regulation of miR-106b increased the expression of FUT6 and resulted in an obvious decrease of  cell migration, invasion, and proliferation in MDA-MB-231 cells.
genetics_knock down_suppress	hsa-mir-29a	Carcinoma, Breast	29021023			D05	D001943	114480	HP:0003002	Knockdown of microRNA-29a Changes the Expression of Heat Shock Proteins in Breast Carcinoma MCF-7 Cells.
genetics_knock down_suppress	hsa-mir-29a	Carcinoma, Breast	29435304			D05	D001943	114480	HP:0003002	Knockdown of microRNA-29a regulates the expression of apoptosis-related genes in MCF-7 breast carcinoma cells
genetics_knock down_suppress	hsa-mir-322	Carcinoma, Breast	28404630			D05	D001943	114480	HP:0003002	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy.
genetics_knock down_suppress	hsa-mir-424	Carcinoma, Breast	28404630			D05	D001943	114480	HP:0003002	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy.
genetics_knock down_suppress	hsa-mir-503	Carcinoma, Breast	28404630			D05	D001943	114480	HP:0003002	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy.
genetics_knock down_suppress	hsa-mir-182	Carcinoma, Breast, Triple Negative	27476169				D064726			Knockdown of miR-182 promotes apoptosis via regulating RIP1 deubiquitination in TNF-伪-treated triple-negative breast cancer cells.
genetics_knock down_suppress	hsa-mir-9	Carcinoma, Breast, Triple Negative	27402080				D064726			miR-9 and miR-200 promoted and inhibited, respectively, the formation of vascular-like structures in vitro
genetics_knock down_suppress	hsa-mir-155	Carcinoma, Cervical	27470551	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Moreover, knockdown of miR-155 was demonstrated to inhibit cell proliferation, migration, and invasion in vitro.
genetics_knock down_suppress	hsa-mir-181a	Carcinoma, Cervical	27534652	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway.
genetics_knock down_suppress	hsa-mir-19b	Carcinoma, Embryonal	25483911	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	The results demonstrated  that miR鈥?9b knockdown inhibited the proliferation and apoptosis of P19 cells.
genetics_knock down_suppress	hsa-mir-503	Carcinoma, Esophageal	26580839	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The specific inhibition of miR-503 expression remarkably suppressed proliferation and invasion of tumor cells.
genetics_knock down_suppress	hsa-mir-126	Carcinoma, Hepatocellular	27499630	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Inhibition of miR-126 expression increased Spred1 expression and decreased vascular endothelial growth  factor expression (P<0.01).
genetics_knock down_suppress	hsa-mir-130b	Carcinoma, Hepatocellular	26861561	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	knockdown or overexpression of miR-130b inhibited and promoted proliferation and metastasis of HCC cells
genetics_knock down_suppress	hsa-mir-150	Carcinoma, Hepatocellular	19617899	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	repressed in a subset of primary tumorscharacterized by poor prognosis; loss of miR-122 expression correlates with suppression of the hepatic phenotype and gain of metastatic properties; a diagnostic and prognostic marker
genetics_knock down_suppress	hsa-mir-181a	Carcinoma, Hepatocellular	27384977	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Exogenous miR-181a expression in HepG2 cells reduced apoptosis, whereas inhibition of miR-181a in Hpe3B cells increased apoptosis.
genetics_knock down_suppress	hsa-mir-221	Carcinoma, Hepatocellular	22009537	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-221 silencing blocks hepatocellular carcinoma and promotes survival.
genetics_knock down_suppress	hsa-mir-221	Carcinoma, Hepatocellular	24993451	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties.
genetics_knock down_suppress	hsa-mir-20a	Carcinoma, Lung, Non-Small-Cell	26356817			C34.90	D002289		HP:0030358	Stable knock  down of miR-20a increases T尾RII expression and inhibits tumorigenicity of lung cancer cells in vivo.
genetics_knock down_suppress	hsa-mir-27b	Carcinoma, Lung, Non-Small-Cell	27221512			C34.90	D002289		HP:0030358	introduction of miR鈥?7b inhibitors significantly induced apoptosis and inhibited the proliferation of A549 cells.
genetics_knock down_suppress	hsa-mir-454	Carcinoma, Lung, Non-Small-Cell	27261580			C34.90	D002289		HP:0030358	Down-regulation of miR-454 could significantly reduce NSCLC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while up-regulation of miR-454 showed opposite effects.
genetics_knock down_suppress	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	24804226			C34.90	D002289		HP:0030358	Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt.
genetics_knock down_suppress	hsa-mir-23b	Carcinoma, Nasopharyngeal	27150436	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	inhibition of miR鈥?3b could significantly suppress NPC cell proliferation, migration and invasion.
genetics_knock down_suppress	hsa-mir-346	Carcinoma, Nasopharyngeal	27501413	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Inhibition of miR-346 significantly attenuated the migration and invasion of NPC cells.
genetics_knock down_suppress	hsa-mir-106a	Carcinoma, Ovarian	27510094	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Downregulation of the expression of miR-106a inhibited cell growth and metastasis of ovarian cancer cells.
genetics_knock down_suppress	hsa-let-7i	Carcinoma, Renal Cell	22926558	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We also validated the prognostic value of miRNA let-7i in RCC. miR-138, located in chromosome 3p deletion, was also found to have suppressive effects on tumor proliferation and migration abilities.
genetics_knock down_suppress	hsa-mir-106b	Carcinoma, Renal Cell	26648244	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Downregulation of miR-106b with a synthesized inhibitor suppressed cell migration and proliferation and induced renal cancer cell apoptosis
genetics_knock down_suppress	hsa-mir-138-1	Carcinoma, Renal Cell	22926558	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We also validated the prognostic value of miRNA let-7i in RCC. miR-138, located in chromosome 3p deletion, was also found to have suppressive effects on tumor proliferation and migration abilities.
genetics_knock down_suppress	hsa-mir-138-2	Carcinoma, Renal Cell	22926558	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We also validated the prognostic value of miRNA let-7i in RCC. miR-138, located in chromosome 3p deletion, was also found to have suppressive effects on tumor proliferation and migration abilities.
genetics_knock down_suppress	hsa-mir-183	Carcinoma, Thyroid, Medullary	22024754	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	MiR-183 knockdown in an MTC cell line (TT cells) reduced cellular proliferation in association with elevated LC3B expression.
genetics_knock down_suppress	hsa-mir-146b	Carcinoma, Thyroid, Papillary	26883911	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-146b-5p positively regulates migration and invasion of thyroid normal and tumor follicular cells
genetics_knock down_suppress	hsa-mir-221	Carotid Artery Diseases	19150885			G45.1	D002340	147820	HP:0005344	miR-221: knockdown of miR-221 and miR-222 in rat carotid arteries suppressed VSMC proliferation in vivo and neointimal lesion formation after angioplasty. The results indicate that miR-221 and miR-222 are novel regulators for VSMC proliferation and neointimal hype
genetics_knock down_suppress	hsa-mir-222	Carotid Artery Diseases	19150885			G45.1	D002340	147820	HP:0005344	miR-222: knockdown of miR-221 and miR-222 in rat carotid arteries suppressed VSMC proliferation in vivo and neointimal lesion formation after angioplasty. The results indicate that miR-221 and miR-222 are novel regulators for VSMC proliferation and neointimal hype
genetics_knock down_suppress	hsa-mir-224	Cerebral Ischemia	27165196	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	miR-224 inhibitor reduced neuronal cell apoptosis
genetics_knock down_suppress	hsa-mir-93	Cervical Neoplasms	27279231	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Enforced miR-93 knockdown or RAB11FIP1 overexpression suppressed proliferation and promoted apoptosis
genetics_knock down_suppress	hsa-mir-21	Cholangiocarcinoma	25769721	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	anti-miR-21 treatment reduced liver tumor growth and prevented tumor development.
genetics_knock down_suppress	hsa-mir-34a	Cholangiocarcinoma	26923637	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	The inhibition of miR-34a decreased proliferation, migration and invasion in cholangiocarcinoma cells.
genetics_knock down_suppress	hsa-mir-25	Choriocarcinoma	27120728	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Inhibition of miR-25 by its sponge in AGS cells resulted in suppressed cell viability (P<0.01) and promoted cell apoptosis (P<0.01)
genetics_knock down_suppress	hsa-mir-1-2	Chronic Heart Failure	17397913	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	deletion
genetics_knock down_suppress	hsa-mir-21	Colitis	29608690	gastrointestinal system disease	DOID:0060180	K52.9	D003092	191390	HP:0002583	Loss of microRNA-21 Influences the Gut Microbiota Causing Reduced Susceptibility in a Murine Model of Colitis
genetics_knock down_suppress	hsa-let-7a-1	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7a-2	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7a-3	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7b	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7c	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7d	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7e	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7f-1	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7f-2	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7g	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7i	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-mir-21	Colorectal Adenocarcinoma	27364574	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a  colorectal adenocarcinoma cell line
genetics_knock down_suppress	hsa-mir-15b	Colorectal Carcinoma	26743779	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Inhibition of miR-15b  activity by adenovirus carrying antimiR-15b sequence significantly increased MTSS1 and Klotho protein expression and subsequently decreased colony formation ability, invasion, and migration of HCT116 cells in vitro and liver metastasis of HCT116 tumors in vivo.
genetics_knock down_suppress	hsa-mir-21	Colorectal Carcinoma	25994220	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21-knockout mice showed reduced expression of proinflammatory and procarcinogenic cytokines (interleukin  (IL) 6, IL-23, IL-17A and IL-21) and a decrease in the size and number of tumours compared with the control mouse group.
genetics_knock down_suppress	hsa-mir-27a	Colorectal Carcinoma	28423356	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Knockdown of miR-27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf-1-caspase-9 complex.
genetics_knock down_suppress	hsa-mir-544a	Colorectal Carcinoma	27165435	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-544a inhibitor and/or HOXA10 overexpression reduced lung metastases in HCT116 xenografts.
genetics_knock down_suppress	hsa-mir-592	Colorectal Carcinoma	27167185	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-592 inhibitor exhibited a significant reduction of migration, proliferation, and clonogenicity in CRC cells.
genetics_knock down_suppress	hsa-mir-195	Diabetic Cardiomyopathies	25994075				D058065			Therapeutic silencing of miR-195 reduces myocardial hypertrophy and improves coronary blood flow and myocardial function in diabetes
genetics_knock down_suppress	hsa-mir-155	Encephalomyelitis	24648472	nervous system disease	DOID:640	B01.11	D004679			MiR-155 (-/-) mice are highly resistant to experimental autoimmune encephalomyelitis (EAE)
genetics_knock down_suppress	hsa-mir-223	Encephalomyelitis	26783338	nervous system disease	DOID:640	B01.11	D004679			We demonstrate that miR-223-knockout mice display significantly reduced active and adoptive-transfer experimental autoimmune encephalomyelitis
genetics_knock down_suppress	hsa-mir-10b	Endometrial Neoplasms	27447302	reproductive system disease	DOID:1380	C54.1	D016889	608089		The silence of miR-10b resulted in significantly enhanced cell apoptosis, and remarkably reduced cell proliferation, migration, and invasion (p鈥?鈥?.05).
genetics_knock down_suppress	hsa-mir-210	Epilepsy	27471387	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Our data showed that morphological changes of hippocampal neurons and apoptosis triggered by epilepsy were mitigated by miR-210 inhibition.
genetics_knock down_suppress	hsa-mir-21	Esophageal Neoplasms	27188433			C15.9	D004938	133239	HP:0100751	the proliferation, migration, and invasion of TE11 cells were less active in Inhibition-miR21 group.
genetics_knock down_suppress	hsa-mir-21	Fatty Liver, Non-Alcoholic	26338827	disease of metabolism	DOID:0080208	K75.81	D065626	613282		MicroRNA-21 inhibition or suppression decreases liver injury, inflammation and fibrosis
genetics_knock down_suppress	hsa-mir-193	Gastric Neoplasms	26753960	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In AGS and MKN-45 cells, miR-193-3p downregulation reduced cancer proliferation, migration and 5-FU chemoresistance in vitro, and tumorigenicity in vivo.
genetics_knock down_suppress	hsa-mir-224	Gastric Neoplasms	27315344	disease of cellular proliferation	DOID:10534	C16	D013274	137215		inhibition of miR-224 significantly reduced the expression of mTOR and improved caspase-9/3 expression while decreased cyclin D1/2 levels, attenuating gastric cancer cell proliferation.
genetics_knock down_suppress	hsa-mir-154	Glioblastoma	27338789				D005909		HP:0100843	Knockdown of miR-154 remarkably suppressed proliferation and migration of CD133(+) GBM cells.
genetics_knock down_suppress	hsa-mir-21	Glioblastoma	23732394				D005909		HP:0100843	Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death.
genetics_knock down_suppress	hsa-mir-21	Glioblastoma	25991676				D005909		HP:0100843	Both MPS1 and miR-21 depletion suppressed GBM cell proliferation
genetics_knock down_suppress	hsa-mir-21	Glioma	23077620	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines
genetics_knock down_suppress	hsa-mir-155	Graft-Versus-Host Disease	27296836			D89.813	D006086	614395		miR-155-/- mice showed resistance to cardiac rejection along with weakened T-cell-mediated inflammation
genetics_knock down_suppress	hsa-mir-17	Graft-Versus-Host Disease	26138686			D89.813	D006086	614395		Furthermore, we evaluated a translational approach and found that systemic administration of antagomir to block miR-17 or miR-19b in this cluster significantly inhibited alloreactive T-cell expansion and interferon-纬 (IFN纬) production, and prolonged
genetics_knock down_suppress	hsa-mir-19b	Graft-Versus-Host Disease	26138686			D89.813	D006086	614395		systemic administration of antagomir to block miR-17 or miR-19b in this cluster significantly inhibited alloreactive T-cell expansion and interferon-纬 (IFN纬) production
genetics_knock down_suppress	hsa-let-7c	Heart Failure	25505600			I50	D006331		HP:0001635	Let-7c inhibitor prevented the deterioration of cardiac function postinfarction, as demonstrated by preserved LV ejection fraction and elevated cardiac output.
genetics_knock down_suppress	hsa-mir-21	Heart Failure	22923342			I50	D006331		HP:0001635	Atrial miR-21 knockdown suppresses atrial fibrosis and AF promotion, implicating miR-21 as an important signaling molecule for the AF substrate and pointing to miR-21 as a potential target for molecular interventions designed to prevent AF
genetics_knock down_suppress	hsa-mir-21	Heart Failure	24551276			I50	D006331		HP:0001635	After injection of miR-21 antagonist, the the cardiac atrophy and cardiac fibrosis were conspicuously ameliorated.
genetics_knock down_suppress	hsa-mir-122	Hepatitis C Virus Infection	22898980	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The use of an HSP90 inhibitor or knockdown of HSP90 decreased GW182 and miR-122 expression and significantly reduced HCV replication.
genetics_knock down_suppress	hsa-mir-122	Hepatitis C Virus Infection	25848473	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122 promotes HCV accumulation, inhibition of miR-122 has been shown as an effective therapy for the treatment of HCV infection in both chimpanzees and humans.
genetics_knock down_suppress	hsa-mir-18a	Immune System Disease [unspecific]	24131405	immune system disease	DOID:2914	D89.9	D007154			Treatment of cells with a microRNA-18a mimic in PCPS (PCPS/miR-18) knocked down 90% expression of the microRNA-18a target gene ATM.
genetics_knock down_suppress	hsa-mir-155	Infection [unspecific]	28804270				D007239			Knockdown of miR-155 protects microglia against LPS-induced inflammatory injury via targeting RACK1: a novel research for intracranial infection
genetics_knock down_suppress	hsa-mir-138	Intervertebral Disc Degeneration	27207584	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	inhibition of miR-138-5p downregulated PTEN protein expression and promoted activation of PI3K/AKT, and knockdown of either SIRT1 or the PI3K/Akt inhibitor (LY294002) abolished the effect of miR-138-5p on NP cell apoptosis.
genetics_knock down_suppress	hsa-mir-21	Ischemia-Reperfusion Injury	23681145				D015427			Knockdown of miR-21 induced significant up-regulation of programmed cell death protein 4 and phosphatase and tensin homolog deleted on chromosome 10, two proapoptotic target effectors of miR-21, and resulted in significant down-regulation of phosphorylated protein kinase B and increased tubular cell apoptosis.
genetics_knock down_suppress	hsa-mir-21	Ischemia-Reperfusion Injury	27030384				D015427			With downregulation of miR-21, the protection of delayed IPC was attenuated and PHD2 protein was increased.
genetics_knock down_suppress	hsa-mir-181a	Ischemic Diseases [unspecific]	26283227				D007511	601367		Delivery of anti-miR-181a, which neutralizes endogenous miR-181a, significantly attenuated H2O2-induced decrease of HKII expression and disruption of mitochondrial membrane potential, improving  the survival of MSCs exposed to H2O2.
genetics_knock down_suppress	hsa-mir-942	Kaposi Sarcoma	27440900	disease of cellular proliferation	DOID:8632	C46	D012514			Suppression of miR-942-5p relieved I魏B伪 expression and reduced Vpr inhibition of  KSHV replication, while overexpression of miR-942-5p enhanced Vpr inhibition of KSHV replication.
genetics_knock down_suppress	hsa-mir-150	Leukemia	23079661			C95	D007938	613065	HP:0001909	Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia
genetics_knock down_suppress	hsa-mir-21	Leukemia, Lymphoblastic, Acute	25451263	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Transient inhibition of miR-21 resulted in increased apoptosis, PTEN upregulation and AKT dephosphorylation, whereas ectopic overexpression of miR-21 further conferred imatinib resistance.
genetics_knock down_suppress	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	20129242	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a and miR-16-1 were the first microRNAs linked to cancer because their genes are commonly deleted in human chronic lymphocytic leukemia (CLL)
genetics_knock down_suppress	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	19744129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2. 
genetics_knock down_suppress	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	19744129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2. 
genetics_knock down_suppress	hsa-mir-17	Leukemia, Lymphocytic, Chronic, B-Cell	25339346	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	In-vitro administration of antagomiR17 effectively reduced miR-17 expression and the proliferation of CLL-like MEC-1 cells.
genetics_knock down_suppress	hsa-mir-196b	Leukemia, Myeloid, Acute	24334453	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Therapeutic inhibition of microRNA-21 and microRNA-196b inhibited in vitro leukemic colony forming activity and depleted in vivo leukemia-initiating cell activity of HOX-based leukemias, which  led to leukemia-free survival in a murine AML model and delayed disease onset in  xenograft models.
genetics_knock down_suppress	hsa-mir-21	Leukemia, Myeloid, Acute	24334453	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Therapeutic inhibition of microRNA-21 and microRNA-196b inhibited in vitro leukemic colony forming activity and depleted in vivo leukemia-initiating cell activity of HOX-based leukemias, which  led to leukemia-free survival in a murine AML model and delayed disease onset in  xenograft models.
genetics_knock down_suppress	hsa-mir-125b	Leukemia, Myeloid, Chronic	27158338	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	inhibition of miR-125b decreased the proliferation rates and promoted apoptosis with cell cycle arrest at the G0/G1 phase in both K562 and NB-4 cells
genetics_knock down_suppress	hsa-mir-17	Leukemia, Myeloid, Chronic	25647305	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Furthermore, overexpression of c-Myc or miR-17/20a alleviated NC induced differentiation and apoptosis in K562 cells.
genetics_knock down_suppress	hsa-mir-20a	Leukemia, Myeloid, Chronic	25647305	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Furthermore, overexpression of c-Myc or miR-17/20a alleviated NC induced differentiation and apoptosis in K562 cells.
genetics_knock down_suppress	hsa-mir-451	Leukemia, Myeloid, Chronic	27158338	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	inhibition of miR-125b decreased the proliferation rates and promoted apoptosis with cell cycle arrest at the G0/G1 phase in both K562 and NB-4 cells
genetics_knock down_suppress	hsa-mir-223	Leukemia, Promyelocytic, Acute	16325577	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	In line with this, both RNAi against NFI-A and ectopic expression of miR-223 in acute promyelocytic leukemia (APL) cells enhance differentiation, whereas miR-223 knockdown inhibits the differentiation response to RA.
genetics_knock down_suppress	hsa-mir-92a	Leukemia, Promyelocytic, Acute	24385779	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Down-regulation of miR-92a in APL cell line (HL-60) by LNA antagomir extensively decreased cell viability in APL.
genetics_knock down_suppress	hsa-mir-92a	Leukemia, Promyelocytic, Acute	24627869	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	The assessment of the apoptosis and necrosis indicates that miR-92a inhibition can decrease the viable HL-60 cells and this is at least partially due to induction of apoptosis.
genetics_knock down_suppress	hsa-mir-181b-1	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22916024	disease of cellular proliferation	DOID:5599	C83.5	D054218			Deletion of mir-181a-1/b-1 expression inhibits the development of Notch1 oncogene-induced T cell acute lymphoblastic leukemia (T-ALL). mir-181a-1/b-1 controls the strength and threshold of Notch activity in tumorigenesis in part by dampening multiple negative feedback regulators downstream of NOTCH and pre-T cell receptor (TCR) signaling pathways.
genetics_knock down_suppress	hsa-mir-146a	Listeriosis	29587465	disease by infectious agent	DOID:11573	A32	D008088			MicroRNA-146a Deficiency Protects against Listeria monocytogenes Infection by Modulating the Gut Microbiota
genetics_knock down_suppress	hsa-mir-21	Liver Cirrhosis	27226339	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Ad-TuD-21  administered to liver fibrosis rats could remarkably suppress profibrotic gene expression
genetics_knock down_suppress	hsa-mir-21	Liver Cirrhosis	27775690	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice.
genetics_knock down_suppress	hsa-mir-214	Liver Fibrosis	26122702			K74	D008103			Pdgf-c Tg mice treated with LNA-antimiR-214 showed a marked reduction in fibrosis and tumor incidence compared with saline or LNA-miR-control-injected control mice.
genetics_knock down_suppress	hsa-mir-150	Liver Injury	26196694			S36.11	D056486			miR-150 deficiency prevents Fas-induced hepatocyte apoptosis and liver injury through regulation of the Akt pathway.
genetics_knock down_suppress	hsa-mir-192	Liver Injury	27129188			S36.11	D056486			Functional experiments confirmed a protective effect of down-regulation of miR-192-5p in hepatocytes, suggesting a role of miR-192-5p in limiting liver injury.
genetics_knock down_suppress	hsa-let-7a-1	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7a-2	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7a-3	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7b	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7c	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7d	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7e	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7f-1	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7f-2	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7g	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-let-7i	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Furthermore, a reduction in the expression of let-7 was associated with lung cancers and in particular with reduced survival./ Mayr et al. demonstrated that a chromosomal translocation at 12q5 disrupts let-7 expression and consequently curtails inhibition of the oncogene High Mobility Group A2 (Hmga2). Let-7 has also been implicated in the development of colon cancers and the progression of colorectal cancers.
genetics_knock down_suppress	hsa-mir-21	Lung Neoplasms	25065740	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	PHF8 promotes miR-21 expression in human lung cancer, and miR-21 knockdown blocks the effects of PHF8 on proliferation and apoptosis of lung cancer cells.
genetics_knock down_suppress	hsa-mir-17	Lymphoma	27498867	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Loss of miR-17鈭?2 in Myc(+) tumor cells leads to a global decrease in tumor cell metabolism, affecting both glycolytic and mitochondrial metabolism, whereas increased miR-17鈭?2 expression is sufficient to drive increased nutrient usage by tumor cells.
genetics_knock down_suppress	hsa-mir-23a	Macular Degeneration	27411920	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	Inhibition of the H2O2-induced miR-23a by antagomiR protected the RPE cells from the oxidative stress-induced cell death.
genetics_knock down_suppress	hsa-mir-17	Medulloblastoma	24145352	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression.
genetics_knock down_suppress	hsa-mir-17	Medulloblastoma	24928431	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Remarkably, deletion of the miR-17鈭?2 cluster abolished the development of SHH-MB in Ptch1(+/-) mice.
genetics_knock down_suppress	hsa-mir-19a	Medulloblastoma	24145352	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression.
genetics_knock down_suppress	hsa-mir-125b	Melanoma	26968260	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	inhibition of miR-125b reduces migratory and invasive potentials without affecting cell proliferation in vitro.
genetics_knock down_suppress	hsa-mir-21	Melanoma	27533779	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-21 can promote the proliferation, migration, and inhibit the apoptosis of human melanoma A375 cells by inhibiting SPRY1, PDCD4, and PTEN via ERK/NF-kB signaling pathway.
genetics_knock down_suppress	hsa-mir-214	Melanoma	27328731	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Depleting miR-214 or elevating miR-148b blocked the dissemination  of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration.
genetics_knock down_suppress	hsa-mir-17	Multiple Sclerosis	24644282	nervous system disease	DOID:2377	G35	D009103	PS126200		T cell-specific miR-17-92 deficiency reduced TH17 differentiation and ameliorated experimental autoimmune encephalomyelitis (EAE) symptoms.
genetics_knock down_suppress	hsa-mir-223	Multiple Sclerosis	27083389	nervous system disease	DOID:2377	G35	D009103	PS126200		miR223 promotes EAE, probably through enhancing DC activation and subsequently the differentiation of naive T cells toward Th1 and Th17 effector cells.
genetics_knock down_suppress	hsa-mir-206	Mycobacterium tuberculosis Infection	27291149			A18	D014376	607948		Inhibition of miR-206 markedly suppressed inflammatory cytokine secretion
genetics_knock down_suppress	hsa-mir-10b	Myocardial Infarction	19595696	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Knockdown of microRNA-181 by lentivirus decreases the arrhythmogenic effect of skeletal myoblast transplantation in rat with myocardial infarction.
genetics_knock down_suppress	hsa-mir-126	Myocardial Infarction	26782549	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-126 is down-regulated in myocardial ischemia-reperfusion injury and that the inhibition of miR-126 may protect against myocardial cell apoptosis caused by ischemia-reperfusion.
genetics_knock down_suppress	hsa-mir-150	Myocardial Infarction	26109086	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-150 deletion in mice protects kidney from myocardial infarction-induced  acute kidney injury.
genetics_knock down_suppress	hsa-mir-208a	Myocardial Infarction	25936493	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Overexpression of antagomir-208a and pretreatment with atorvastatin and valsartan in the AMI group significantly decreased the area of myocardial fibrosis induced by infarction.
genetics_knock down_suppress	hsa-mir-208a	Myocardial Infarction	26688617	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Therapeutic inhibition of miR-208a decreased cardiac fibrosis, hypertrophy, and apoptosis and significantly improved cardiac function 28 days after MI.
genetics_knock down_suppress	hsa-mir-210	Myocardial Infarction	26807177	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Inhibition of miR-210 expression improved the survival and cardiac function of MI mice.
genetics_knock down_suppress	hsa-mir-31	Myocardial Infarction	25925791	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-31 downregulation alleviated myocardial infarct size in  vivo.
genetics_knock down_suppress	hsa-mir-34a	Myocardial Infarction	26082557	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	locked nucleic acid-based anti-miR-34a treatment diminished post-MI miR-34a upregulation in adult hearts and significantly improved post-MI remodeling.
genetics_knock down_suppress	hsa-mir-128	Myocardial Ischemic-Reperfusion Injury	27150726				D015428			miR鈥?28 antagomirs significantly reduced apoptosis in hearts subjected to I/R injury
genetics_knock down_suppress	hsa-mir-21	Myocardial Ischemic-Reperfusion Injury	26862785				D015428			recombinant HMGB1鈥堿-box treatment protects against I/R injury and the mechanisms may involve inhibition of miR-21 expression.
genetics_knock down_suppress	hsa-mir-92a	Myocardial Ischemic-Reperfusion Injury	24941323				D015428			Inhibiting miR-92a can attenuate myocardiocyte apoptosis induced by hypoxia/reoxygenation by targeting Smad7.
genetics_knock down_suppress	hsa-let-7	Neoplasms [unspecific]	26033159			C80.1	D009369			we found that expression of DICER1 hotspot mutants promoted cell proliferation, whereas wild-type (WT) DICER1 inhibited cell proliferation. Furthermore, targets of let-7 family miRNAs are enriched among the up-regulated genes, suggesting that loss of let-7 may be impacting downstream pathways. Our results reveal that DICER1 hotspot mutations are implicated in common malignancies and may constitute a unique oncogenic pathway.
genetics_knock down_suppress	hsa-let-7a-1	Neoplasms [unspecific]	20614490			C80.1	D009369			let-7a:Gastric carcinoma has relatively lower expression of let-7a
genetics_knock down_suppress	hsa-let-7a-2	Neoplasms [unspecific]	20614490			C80.1	D009369			let-7a:Gastric carcinoma has relatively lower expression of let-7a
genetics_knock down_suppress	hsa-let-7a-3	Neoplasms [unspecific]	20614490			C80.1	D009369			let-7a:Gastric carcinoma has relatively lower expression of let-7a
genetics_knock down_suppress	hsa-let-7b	Neoplasms [unspecific]	25682900			C80.1	D009369			our findings suggest that let-7b contributes to the fidelity of cell division via regulation of Aurora B. Moreover, the loss of let-7b in aggressive tumors may drive tumorigenesis by up-regulation of Aurora B and other targets of the miRNA, which further supports the role of let-7b in tumor suppression.
genetics_knock down_suppress	hsa-let-7b	Neoplasms [unspecific]	24423609			C80.1	D009369			Reduction of let-7a3/let-7b miRNA may be one of mechanisms leading to overexpression of HMGA2 in AT/RT tissues.
genetics_knock down_suppress	hsa-mir-143	Neoplasms [unspecific]	22330136			C80.1	D009369			Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop.
genetics_knock down_suppress	hsa-mir-145	Neoplasms [unspecific]	22330136			C80.1	D009369			Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop.
genetics_knock down_suppress	hsa-mir-155	Neoplasms [unspecific]	25598954			C80.1	D009369			the proper increase of miR-155 inhibitor concentration can inhibit miR-155 and consequently increase caspase-3 activity and induce apoptosis in the  Jurkat cells leading to cell death ultimately.
genetics_knock down_suppress	hsa-mir-200a	Neoplasms [unspecific]	20832727			C80.1	D009369			miR-200a:Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells
genetics_knock down_suppress	hsa-mir-200b	Neoplasms [unspecific]	20832727			C80.1	D009369			miR-200b:Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells
genetics_knock down_suppress	hsa-mir-200c	Neoplasms [unspecific]	20832727			C80.1	D009369			miR-200c:Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells
genetics_knock down_suppress	hsa-mir-204	Neoplasms [unspecific]	23285024			C80.1	D009369			Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization
genetics_knock down_suppress	hsa-mir-205	Neoplasms [unspecific]	26446417			C80.1	D009369			When HEC-50B cells and HEC-1-A cells were treated with anti-miR-205 inhibitor, the migration and invasion were decreased as compared with the negative control.
genetics_knock down_suppress	hsa-mir-21	Neoplasms [unspecific]	29540832			C80.1	D009369			miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy
genetics_knock down_suppress	hsa-mir-222	Neoplasms [unspecific]	26909602			C80.1	D009369			Anti-miR-222 inhibitor treatment decreased cell proliferation, migration, tube formation, and induced apoptosis.
genetics_knock down_suppress	hsa-mir-210	Nervous System Diseases [unspecific]	26708520			C72.9	D009422			Application of miR-210 inhibitor efficiently downregulated endogenous miR-210, protected apoptosis and neurite retraction in bupivacaine damaged DRG neurons.
genetics_knock down_suppress	hsa-mir-124-1	Neuroblastoma	22024478	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR.
genetics_knock down_suppress	hsa-mir-124-2	Neuroblastoma	22024478	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR.
genetics_knock down_suppress	hsa-mir-124-3	Neuroblastoma	22024478	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR.
genetics_knock down_suppress	hsa-mir-127	Obesity	27532680	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	On the other hand, locked nucleic acid inhibitor synthesized to target miR-127-5p significantly increased b-F1-ATPase translation efficiency in myotubes.
genetics_knock down_suppress	hsa-mir-21	Obesity	25141837	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	MiR-21 inhibition reduced body weight, as well as adipocyte size and serum triglycerides were significantly decreased.
genetics_knock down_suppress	hsa-mir-21	Osteosarcoma	27513462	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	microRNA-21 inhibition slowed proliferation and exogenously expressed microRNA-21 promoted this process.
genetics_knock down_suppress	hsa-mir-182	Ovarian Neoplasms	24825857	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	we found that anti-miR182 treatment can significantly reduce tumor burden (size), local invasion, and distant metastasis compared with its control in both models.
genetics_knock down_suppress	hsa-mir-630	Ovarian Neoplasms	26725326	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Treatment  with the combination of anti-miR-630 and anti-vascular endothelial growth factor  antibody in mice resulted in rescue of Dicer expression and significantly decreased tumor growth and metastasis.
genetics_knock down_suppress	hsa-mir-183	Pancreatic Adenocarcinoma	26870180	disease of cellular proliferation	DOID:4074	C25.3				miR-183 knockdown decreased cell growth and motility in pancreatic cancer cells and significantly increased the expression of SOCS-6.
genetics_knock down_suppress	hsa-mir-199a	Pancreatic Neoplasms	26918939	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Inhibition of miR-199a/-214 using hairpin inhibitors significantly inhibited TGF尾-induced differentiation markers (e.g. 伪-SMA, collagen, PDGF尾R), migration and proliferation.
genetics_knock down_suppress	hsa-mir-222	Pancreatic Neoplasms	26535064	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		we co-transfected miR-222 inhibitor and p57 si-RNA into Capan-2 cells, and found that proliferation-suppressing effects of miR-222 inhibitor on Capan-2 cells could be  partially reversed by silencing p57.
genetics_knock down_suppress	hsa-mir-106b	Pituitary Neoplasms	27465551	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Down-regulation of miR-106b or up-regulation of PTEN could suppress cell proliferation and invasion of AtT-20 cells, and PTEN expression plasmid could partially simulate the function of miR-106b.
genetics_knock down_suppress	hsa-mir-18a	Prostate Neoplasms	24752237	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Interestingly, miR-18a knockdown decreased cell growth in prostate cancer cells and significantly decreased prostate tumor growth in in vivo nude mice experiments through STK4-mediated dephosphorylation of AKT and thereby inducing apoptosis.
genetics_knock down_suppress	hsa-mir-9	Prostate Neoplasms	27447934	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Inhibition of miR-9 resulted in reduced migratory and invasive potential of the M12 cell line, and reduced tumour growth and metastases in male athymic nude mice.
genetics_knock down_suppress	hsa-mir-221	Rheumatoid Arthritis	25891943	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Downregulation of miR-221 significantly suppressed the expression of pro-inflammatory cytokines and the chemokine
genetics_knock down_suppress	hsa-mir-155	Spinal Cord Injuries	25651871			S34.139A	D013119			Mir-155 deficiency suppresses Th17 cell differentiation and improves locomotor recovery after SCI.
genetics_knock down_suppress	hsa-mir-31	Squamous Cell Carcinoma, Esophageal	26286729	disease of cellular proliferation	DOID:3748		C562729			anti-miR-31 reduced miR-31 overexpression (P = .002) and suppressed the esophageal preneoplasia in Zn-deficient rats.
genetics_knock down_suppress	hsa-mir-23a	Squamous Cell Carcinoma, Head and Neck	24317043	disease of cellular proliferation	DOID:5520	C76.0	C535575			Transfection with anti-miR-23a inhibited the proliferation of HN4 cells and induced cell apoptosis.
genetics_knock down_suppress	hsa-mir-24	Squamous Cell Carcinoma, Head and Neck	27513190	disease of cellular proliferation	DOID:5520	C76.0	C535575			Inhibition of miR-24-3p reduced cell proliferation, colony  formation efficiency and reversed chemoresistance in HNSCC cells.
genetics_knock down_suppress	hsa-mir-455	Squamous Cell Carcinoma, Oral	27235675	disease of cellular proliferation	DOID:0050866					MiR-455-5p knockdown reduced both the anchorage-independent growth and the proliferative ability of oral cancer cells
genetics_knock down_suppress	hsa-mir-24	Squamous Cell Carcinoma, Tongue	27350307	disease of cellular proliferation	DOID:0050865	C02.9				Inhibition of miR-24 significantly suppressed the proliferation, migration and invasion of TSCC cells in vitro.
genetics_knock down_suppress	hsa-mir-155	Stroke	26354913			I64	D020521	601367	HP:0001297	In Vivo Inhibition of miR-155 Promotes Recovery after Experimental Mouse Stroke.
genetics_knock down_suppress	hsa-mir-24-1	Tourette Syndrome	17462786	disease of mental health	DOID:11119	F95.2	D005879	137580		A mutation in the 3'UTR of the SLITRK1 gene which is associated with Tourette's syndrome was found to enhance repression of the SLITRK mRNA by miR-189, presumably preventing SLITRK1's promotion of dendritic growth.
genetics_knock down_suppress	hsa-mir-21	Vascular Disease [unspecific]	25360215	cardiovascular system disease	DOID:178	I72.9	D000783			Low expression of miR-21 significantly inhibited VSMC proliferation, invasion and migration.
genetics_knock down_suppress	hsa-mir-137	Vascular Injuries	27497953				D057772			Down-regulation of miR-137 ameliorates HG-induced injury in HUVECs by overexpression of AMPK伪1, leading to increasing cellular reductive reactions and  decreasing oxidative stress.
genetics_overexpression_promote	hsa-mir-19a	Acute Erythroid Leukemia	22451425			C94.0	D004915			overexpression of individual miRNAs from this locus, miR-19a or miR-92a, results in B-cell hyperplasia and erythroleukemia, respectively.
genetics_overexpression_promote	hsa-mir-92a	Acute Erythroid Leukemia	22451425			C94.0	D004915			overexpression of individual miRNAs from this locus, miR-19a or miR-92a, results in B-cell hyperplasia and erythroleukemia, respectively.
genetics_overexpression_promote	hsa-mir-92a	Acute Myocardial Infarction	27411964	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Further, it could be observed in cellular experiments that treatment of miR-92a mimics can further upregulate endothelial injury markers.
genetics_overexpression_promote	hsa-mir-449a	Adenocarcinoma, Lung	23614048	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Overexpression of miR-449a in CL1-0 cells effectively increased irradiation-induced DNA damage and apoptosis,altered the cell cycle distribution and eventually led to sensitization of CL1-0 to irradiation.
genetics_overexpression_promote	hsa-mir-212	Adenocarcinoma, Pancreatic Ductal	27814273	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma.
genetics_overexpression_promote	hsa-mir-221	Adenocarcinoma, Pancreatic Ductal	27230035	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Overexpressing miR-221 significantly increased cell vitality and promoted cell proliferation and G1-to-S phase transition of the cell cycle in Capan-2 cells
genetics_overexpression_promote	hsa-mir-146a	Alzheimer Disease	27241555	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Overexpression of miRNA-146a in SH-SY5Y cells significantly decreased Lrp2 expression, resulting in a reduction of Akt activation and induction of proapoptotic caspase-3, thereby increasing cell apoptosis.
genetics_overexpression_promote	hsa-mir-206	Alzheimer Disease	27277332	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR鈥?06 upregulation enhanced LPS鈥慽nduced inflammation and A尾 release in microglia
genetics_overexpression_promote	hsa-mir-21	Asthma	26651881	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	This study provides the first in vitro evidence that overexpression of miR-21 in HASM cells can trigger cell proliferation and migration, and the effects of miR-21 depend on the level of PTEN.
genetics_overexpression_promote	hsa-mir-181a	Atherosclerosis	27460740	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The exogenous overexpression of miR-181a accelerates the apoptosis rates of HUVECs in response to H2O2.
genetics_overexpression_promote	hsa-mir-29a	Atrial Fibrillation	27341015	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-29a-3p transfection in cardiomyocytes produced the effects on the ICa
genetics_overexpression_promote	hsa-mir-222	Bladder Neoplasms	26800397			C67	D001749	109800	HP:0009725	Overexpression of miR-222 attenuated cisplatin-induced cell death in bladder cancer cells.
genetics_overexpression_promote	hsa-mir-92b	Bladder Neoplasms	27430302			C67	D001749	109800	HP:0009725	In this study, we demonstrated that  miR-92b could uniquely promote cell migration and invasion of BCa cells, but had  no effect on cell proliferation.
genetics_overexpression_promote	hsa-mir-29c	Brain Disease [unspecific]	25678279	nervous system disease	DOID:936	G93.40	D001927	608033		over-expression of miR-29c effectively reduced Birc2 (also Bak1) mRNA and protein levels, increased infarct volume and apoptosis, and deteriorated neurological outcomes, whereas down-regulation played a neuroprotective role.
genetics_overexpression_promote	hsa-mir-141	Breast Neoplasms	27075851	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ectopic expression of miR-141 in nonexpressing MDA-MB-231 enhanced brain metastatic colonization (5/9 mice vs 0/10 mice,P= .02).
genetics_overexpression_promote	hsa-mir-146a	Breast Neoplasms	25123132	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status.
genetics_overexpression_promote	hsa-mir-200c	Breast Neoplasms	25329395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer.
genetics_overexpression_promote	hsa-mir-21	Breast Neoplasms	21917003	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer.
genetics_overexpression_promote	hsa-mir-21	Breast Neoplasms	22547075	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	DNA damage induces NF-kB-dependent microRNA-21 upregulation and promotes breast cancer cell invasion.
genetics_overexpression_promote	hsa-mir-214	Breast Neoplasms	26951965	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the overexpression of miR鈥?14 markedly increased cell viability and abrogated the apoptosis triggered by serum starvation
genetics_overexpression_promote	hsa-mir-221	Breast Neoplasms	27044817	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Enforced expression of miR-221/222 promoted breast cancer cell proliferation, migration and invasion via targeting PTEN/Akt pathway.
genetics_overexpression_promote	hsa-mir-222	Breast Neoplasms	27044817	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Enforced expression of miR-221/222 promoted breast cancer cell proliferation, migration and invasion via targeting PTEN/Akt pathway.
genetics_overexpression_promote	hsa-mir-23b	Breast Neoplasms	24966325	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ectopic expression of the miRNAs in the weakly metastatic mouse 4TO7 mammary tumor cell line had no effect on proliferation or morphology of tumor cells in vitro but was found to increase lung metastasis in a mouse model of breast cancer metastasis.
genetics_overexpression_promote	hsa-mir-24	Breast Neoplasms	24966325	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ectopic expression of the miRNAs in the weakly metastatic mouse 4TO7 mammary tumor cell line had no effect on proliferation or morphology of tumor cells in vitro but was found to increase lung metastasis in a mouse model of breast cancer metastasis.
genetics_overexpression_promote	hsa-mir-27b	Breast Neoplasms	24966325	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ectopic expression of the miRNAs in the weakly metastatic mouse 4TO7 mammary tumor cell line had no effect on proliferation or morphology of tumor cells in vitro but was found to increase lung metastasis in a mouse model of breast cancer metastasis.
genetics_overexpression_promote	hsa-mir-449a	Breast Neoplasms	26934316	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In vitro, miR-449a promoted breast cancer cell proliferation, clonogenic survival, migration, and invasion.
genetics_overexpression_promote	hsa-mir-183	Carcinoma, Breast	27476679			D05	D001943	114480	HP:0003002	Overexpression of miR-183-5p significantly enhanced the cell proliferation and inhibited cell apoptosis in MCF-7 and MDA-MB-231 cells.
genetics_overexpression_promote	hsa-mir-21	Carcinoma, Cervical	25963606	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Overexpression of miR-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN.
genetics_overexpression_promote	hsa-mir-21	Carcinoma, Cervical	26884851	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The overexpression of HPV E7 protein facilitated the expression of miR-21, which potentiated Hela cell proliferation and invasion.
genetics_overexpression_promote	hsa-mir-1	Carcinoma, Colon	27511117	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	overexpression of PIK3CA-premir1 in HCT116 and SW480 cells resulted in significant reduction of the sub-G1 cell distribution and apoptotic cell rate and resulted in increased cell proliferation.
genetics_overexpression_promote	hsa-mir-125b	Carcinoma, Gastric	27220320	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Overexpression of miR-125b promoted gastric cancer cell migration and invasion in vitro and metastasis in vivo.
genetics_overexpression_promote	hsa-mir-200c	Carcinoma, Gastric	27498672	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Finally, ectopic expression of miR-200c or knockdown of DNMT3a expression impeded GC cell growth, migration and invasion.
genetics_overexpression_promote	hsa-mir-483	Carcinoma, Gastric	27511210	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	overexpression of miR鈥?83鈥?p by transfection with miR鈥?83鈥?p mimics significantly increased cell proliferation and Annexin V鈥憄ropidium iodide staining indicated the suppression of cell apoptosis.
genetics_overexpression_promote	hsa-mir-93	Carcinoma, Gastric	27021515	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-93 promoted the development of gastric tumor growth in xenograft mice
genetics_overexpression_promote	hsa-let-7	Carcinoma, Hepatocellular	28796071	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma
genetics_overexpression_promote	hsa-let-7a	Carcinoma, Hepatocellular	28796071	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma
genetics_overexpression_promote	hsa-let-7e	Carcinoma, Hepatocellular	28796071	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma
genetics_overexpression_promote	hsa-mir-106b	Carcinoma, Hepatocellular	23483935	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Over-Expression of miR-106b Promotes Cell Migration and Metastasis in Hepatocellular Carcinoma by Activating Epithelial-Mesenchymal Transition Process
genetics_overexpression_promote	hsa-mir-122	Carcinoma, Hepatocellular	22140464	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122 expression is highly elevated in quiescent human primary hepatocytes (hPHs) but lost or attenuated in hESCs and HCCs, while an opposing expression pattern is observed for Pkm2. Depleting hESCs and HCCs of Pkm2, or overexpressing miR-122, leads to a common deficiency in self-renewal and proliferation.
genetics_overexpression_promote	hsa-mir-1269	Carcinoma, Hepatocellular	25472505	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	overexpression of miR-1269 promotes cell proliferation in HCC through directly suppressing FOXO1, and functions as an oncomiR in HCC.
genetics_overexpression_promote	hsa-mir-153	Carcinoma, Hepatocellular	25714700	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Over-expression of miR-153 down-regulated the activity of Etoposide and Paclitaxel on cell cycle arrest of HepG2 cells and the effect of Sorafenib on the invasion and migration of HepG2 cells.
genetics_overexpression_promote	hsa-mir-155	Carcinoma, Hepatocellular	22071603	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.
genetics_overexpression_promote	hsa-mir-15b	Carcinoma, Hepatocellular	27499071	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	It was observed that high expression of miR-15b promoted cell proliferation of the HCC cells, while low expression of miR-15b suppressed cell growth and induced the apoptosis of HepG2 cells.
genetics_overexpression_promote	hsa-mir-196a	Carcinoma, Hepatocellular	27108614	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HCV core protein increased the expression of miR鈥?96a, and that overexpression of miR鈥?96a in the HepG2 and Huh鈥? HCC cell lines promoted cell proliferation by inducing the G1鈥慡 transition.
genetics_overexpression_promote	hsa-mir-222	Carcinoma, Hepatocellular	24955159	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-222 overexpression induced an enhancement of HepG2 cell proliferation in vitro, paralleling with an altered cell cycle progression via increased cell population in S phase.
genetics_overexpression_promote	hsa-mir-522	Carcinoma, Hepatocellular	26960688	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-522 overexpression promoted cell proliferation, colony formation, and cell cycle progression, whereas knockdown of miR-522 reduced these effects.
genetics_overexpression_promote	hsa-mir-548a	Carcinoma, Hepatocellular	27340352	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	overexpression of miR-548a-5p in HCC cell lines promoted cell proliferation, increased colony forming ability and hampered cell apoptosis.
genetics_overexpression_promote	hsa-mir-615	Carcinoma, Hepatocellular	22819824	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma.
genetics_overexpression_promote	hsa-mir-92b	Carcinoma, Hepatocellular	27100897	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92b could promote cell proliferation and metastasis of HCC in vitro and in vivo.
genetics_overexpression_promote	hsa-mir-23a	Carcinoma, Laryngeal	26171041	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	Ectopic expression of miR-23a and knockdown of APAF-1 significantly promoted cell proliferation and colony formation, and inhibited early apoptosis in Hep2 cells.
genetics_overexpression_promote	hsa-let-7g	Carcinoma, Lung, Non-Small-Cell	18308936			C34.90	D002289		HP:0030358	we observed significant growth reduction of both murine and human non-small cell lung tumors when overexpression of let-7g was induced from lentiviral vectors
genetics_overexpression_promote	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	26131134			C34.90	D002289		HP:0030358	We found that miR-222 overexpression increased cell viability and proliferative rate in H460 cells while opposite effects were obtained by down-regulation of miR-222.
genetics_overexpression_promote	hsa-mir-92a	Carcinoma, Lung, Non-Small-Cell	26432332			C34.90	D002289		HP:0030358	upregulation of miR-92a in NSCLC cells promoted cell proliferation, migration, and invasion, decreased apoptosis and caspase-3 activity, and enhanced chemoresistance of NSCLC cells, whereas downregulation of  miR-92a showed the opposite effects.
genetics_overexpression_promote	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	22335905			C34.90	D002289		HP:0030358	Overexpression of miR-21 promotes proliferation and reduces apoptosis in non-small cell lung cancer].
genetics_overexpression_promote	hsa-mir-141	Carcinoma, Nasopharyngeal	27010857	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	ectopic expression of miR-141 can significantly promote cell proliferation and inhibit apoptosis in NPC
genetics_overexpression_promote	hsa-mir-200a	Carcinoma, Nasopharyngeal	26718506	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Overexpression of miR-200a  resulted in the proliferation of CNE2 cells.
genetics_overexpression_promote	hsa-mir-205	Carcinoma, Nasopharyngeal	26880795	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Overexpression of miR-205 increased the proliferation, migration and invasion of CNE2 cells
genetics_overexpression_promote	hsa-mir-92a	Carcinoma, Nasopharyngeal	27366095	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-92a overexpression potentiated the migration and invasion of 6-10B cells
genetics_overexpression_promote	hsa-mir-194	Carcinoma, Ovarian	27486333	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Overexpression of miR-194 in ovarian cancer cells promotes cell proliferation, migration, and invasion; in contrast, inhibition of the expression of miR-194 has the opposite effects.
genetics_overexpression_promote	hsa-mir-196b	Carcinoma, Ovarian	28387653	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
genetics_overexpression_promote	hsa-mir-760	Carcinoma, Ovarian	27726922	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression.
genetics_overexpression_promote	hsa-mir-940	Carcinoma, Pancreatic	27459115			C25.3	C562463	260350	HP:0002894	Over-expression of microRNA-940 promotes cell proliferation by targeting GSK3尾 and sFRP1 in human pancreatic carcinoma.
genetics_overexpression_promote	hsa-mir-96	Carcinoma, Prostate	27164937	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Overexpressing miR-96 led to increased proliferation and colony formation of normal prostate epithelial cells.
genetics_overexpression_promote	hsa-mir-100	Carcinoma, Renal Cell	23378187	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-100 overexpression strongly associates with advanced tumor progression and unfavorable clinical outcome of patients with RCC
genetics_overexpression_promote	hsa-mir-222	Carcinoma, Thyroid, Papillary	23023232	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	The overexpression of oncogenic miR-221 and miR-222 caused by HMGB1 is associated with an increase in malignancy scores, namely cell growth and motility.
genetics_overexpression_promote	hsa-mir-214	Cardiomegaly	25085702			I51.7	D006332		HP:0001640	Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo.
genetics_overexpression_promote	hsa-mir-206	Cardiomegaly	26333362			I51.7	D006332		HP:0001640	Cardiac-specific overexpression of miR-206 in mice induced hypertrophy and protected the heart from ischemia/reperfusion injury
genetics_overexpression_promote	hsa-mir-146a	Cerebral Ischemia	27449900	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	In conclusion, our study revealed that miR-146a contributes  to OGD/R injury in vitro.
genetics_overexpression_promote	hsa-mir-182	Cerebral Ischemia	27242323	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	miR-182 plays an aggressive role in the cerebral ischemia injury
genetics_overexpression_promote	hsa-mir-27b	Cervical Neoplasms	26706910	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Upregulation of miR-27b significantly accelerated the proliferation, cell cycle transition from G1 to S phase, migration and invasion of C33A cells
genetics_overexpression_promote	hsa-mir-27b	Cervical Neoplasms	26910911	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-27b, up-regulated by E7, promoted CaSki and SiHa cell proliferation and invasion, inhibit paclitaxel-induced apoptosis.
genetics_overexpression_promote	hsa-mir-21	Cholesteatoma	27376830	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	miR-21 promotes the proliferation and invasion of cholesteatoma keratinocytes.
genetics_overexpression_promote	hsa-mir-21	Choriocarcinoma	27922982	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	miR-21 Is Overexpressed in Hydatidiform Mole Tissues and Promotes Proliferation, Migration, and Invasion in Choriocarcinoma Cells.
genetics_overexpression_promote	hsa-mir-125a	Chronic Hepatitis B	25993287			B18.0-.1	D019694	610424		Conversely, the overexpression of miR-125a or knockdown of A20 mimicked HBx  to enhance TRAIL susceptibility in hepatocytes.
genetics_overexpression_promote	hsa-mir-146a	Chronic Hepatitis B	26996068			B18.0-.1	D019694	610424		Overexpression of miR-146a reduced NK cell-mediated cytotoxicity
genetics_overexpression_promote	hsa-mir-17	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-17	Colon Neoplasms	22065543			D12.6	D003110		HP:0100273	MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death.
genetics_overexpression_promote	hsa-mir-18a	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-18a	Colon Neoplasms	22065543			D12.6	D003110		HP:0100273	MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death.
genetics_overexpression_promote	hsa-mir-19a	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-19a	Colon Neoplasms	22065543			D12.6	D003110		HP:0100273	MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death.
genetics_overexpression_promote	hsa-mir-19b-1	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-19b-1	Colon Neoplasms	22065543			D12.6	D003110		HP:0100273	MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death.
genetics_overexpression_promote	hsa-mir-20a	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-20a	Colon Neoplasms	22065543			D12.6	D003110		HP:0100273	MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death.
genetics_overexpression_promote	hsa-mir-92a-1	Colon Neoplasms	17965831			D12.6	D003110		HP:0100273	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-92a-1	Colon Neoplasms	22065543			D12.6	D003110		HP:0100273	MiR-17-92 cluster and its paralogs were significantly overexpressed in colon tumor. No significant associations were found between the deregulation of certain miRNAs and the clinical and pathologic characteristics observed in patients. Kaplan-Meier curves demonstrated significantly reduced overall survival in patients expressing high levels of miR-17. In multivariate Cox models, miR-17 overexpression (HR 2.67; P=0.007) and TNM staging (HR 8.87; P=0.002) were significantly associated with a risk of death.
genetics_overexpression_promote	hsa-mir-34a	Colorectal Adenocarcinoma	28624481	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-34a overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value.
genetics_overexpression_promote	hsa-mir-10b	Colorectal Carcinoma	28345456	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-10b in colorectal cancer patients: Correlation with TWIST-1 and E-cadherin expression.
genetics_overexpression_promote	hsa-mir-183	Colorectal Carcinoma	26717041	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		over-expression of miR-183 resulted in the attenuation of rapamycin-  or starvation-induced autophagy in cancer cells, whereas inhibition of endogenous miR-183 stimulated autophagy and apoptosis.
genetics_overexpression_promote	hsa-mir-194	Colorectal Carcinoma	29109785	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer.
genetics_overexpression_promote	hsa-mir-205	Colorectal Carcinoma	27271572	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-205 and miR-373 may differentially contribute to the aggressive phenotype of MAC in CRC.
genetics_overexpression_promote	hsa-mir-21	Colorectal Carcinoma	24149370	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21 is a key player in oncogenic EMT, its overexpression is controlled by the cooperation of genetic and epigenetic alterations, and its levels, along with ITGβ4 and PDCD4 expression, could be exploited as a prognostic tool for CRC metastasis.
genetics_overexpression_promote	hsa-mir-223	Colorectal Carcinoma	25270282	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancer.
genetics_overexpression_promote	hsa-mir-32	Colorectal Carcinoma	24123284	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-32 overexpression was correlated with specific CRC clinicopathological features and may be a marker of poor prognosis in CRC patients. MiR-32 and PTEN expression were inversely correlated, and miR-32 may be associated with the development of CRC.
genetics_overexpression_promote	hsa-mir-373	Colorectal Carcinoma	27271572	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-205 and miR-373 may differentially contribute to the aggressive phenotype of MAC in CRC.
genetics_overexpression_promote	hsa-mir-410	Colorectal Carcinoma	27177325	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		overexpression of miR鈥?10 resulted in an increase in growth activity and decrease in the extent of apoptosis
genetics_overexpression_promote	hsa-mir-28	Colorectal Carcinoma	22240480	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-28-5p altered expression of CCND1 and HOXB3, whereas miR-28-3p bound NM23-H1. Overexpression of miR-28-5p reduced CRC cell proliferation, migration, and invasion in vitro, whereas miR-28-3p increased CRC cell migration and invasion in vitro.
genetics_overexpression_promote	hsa-mir-410	Colorectal Carcinoma	25272045	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-410 is overexpressed in liver and colorectal tumors and enhances tumor cell growth by silencing FHL1 via a direct/indirect mechanism.
genetics_overexpression_promote	hsa-mir-200b	Cytotoxicity Tests, Immunologic	27183614				D003601			Cells overexpressing miR-200b/c or miR-217 showed reduced sensitivity to CDC
genetics_overexpression_promote	hsa-mir-200c	Cytotoxicity Tests, Immunologic	27183614				D003601			Cells overexpressing miR-200b/c or miR-217 showed reduced sensitivity to CDC
genetics_overexpression_promote	hsa-mir-217	Cytotoxicity Tests, Immunologic	27183614				D003601			Cells overexpressing miR-200b/c or miR-217 showed reduced sensitivity to CDC
genetics_overexpression_promote	hsa-mir-375	Diabetes Mellitus	28017506	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Insulin producing cells generation by overexpression of miR-375 in adipose-derived mesenchymal stem cells from diabetic patients.
genetics_overexpression_promote	hsa-mir-429	Diabetes Mellitus	27299781	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	increased miR-429 could down-regulate the expression of Ocln by targeting the Ocln 3'-UTR, which impaired intestinal barrier function in DM mice.
genetics_overexpression_promote	hsa-mir-132	Diabetes Mellitus, Type 2	26218441	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Overexpression of miR-132 or miR-212 enhances glucose and GLP-1-stimulated insulin secretion.
genetics_overexpression_promote	hsa-mir-212	Diabetes Mellitus, Type 2	26218441	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Overexpression of miR-132 or miR-212 enhances glucose and GLP-1-stimulated insulin secretion.
genetics_overexpression_promote	hsa-mir-144	Diabetic Cardiomyopathies	26164195				D058065			The miR-144 mimics aggravated high glucose-induced ROS formation and apoptosis in cardiomyocytes
genetics_overexpression_promote	hsa-mir-205	Endometrial Neoplasms	28105153	reproductive system disease	DOID:1380	C54.1	D016889	608089		Overexpression of microRNA-205 predicts lymph node metastasis and indicates an unfavorable prognosis in endometrial cancer.
genetics_overexpression_promote	hsa-mir-302	Fanconi Anemia	26343459	hematopoietic system disease	DOID:13636	D61.09	D005199	PS227650		Taken together, our results suggest that overexpression of miR-302 plays a critical role in the regulation of FANCD2 monoubiquitination, resulting in characteristic defects in DNA repair within cells.
genetics_overexpression_promote	hsa-mir-106a	Gastric Neoplasms	27142596	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Abnormal over-expression of miR-106a significantly promoted gastric cancer cell proliferation, metastasis, inhibited the cell apoptosis.
genetics_overexpression_promote	hsa-mir-17	Gastric Neoplasms	25047501	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-17 in gastric cancer is correlated with proliferation-associated oncogene amplification.
genetics_overexpression_promote	hsa-mir-17	Gastric Neoplasms	23333058	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-17-5p/20a promoted gastric cancer cell cycle progression and inhibited cell apoptosis, whereas knockdown of miR-17-5p/20a resulted in cell cycle arrest and increased apoptosis.
genetics_overexpression_promote	hsa-mir-181b	Gastric Neoplasms	27383203	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-181b mimic induced an in vitro EMT-like change to a phenotype similar to that following TGF-尾 treatment alone and was reversed by miRNA-181b inhibitor.
genetics_overexpression_promote	hsa-mir-20a	Gastric Neoplasms	23333058	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-17-5p/20a promoted gastric cancer cell cycle progression and inhibited cell apoptosis, whereas knockdown of miR-17-5p/20a resulted in cell cycle arrest and increased apoptosis.
genetics_overexpression_promote	hsa-mir-20a	Gastric Neoplasms	26286834	disease of cellular proliferation	DOID:10534	C16	D013274	137215		ectopic expression of miR-20a dramatically decreased the expression of NFKBIB; increased  the expression of p65, livin, and survivin
genetics_overexpression_promote	hsa-mir-21	Gastric Neoplasms	25230738	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This meta-analysis indicates that miR-21 detection has a prognostic value in patients with gastric cancer. In addition, overexpression of miR-21 is associated with worse tumor differentiation, lymph node metastasis, and TNM stage.
genetics_overexpression_promote	hsa-mir-222	Gastric Neoplasms	27323780	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Gastrin-induced miR-222 overexpression resulted in reduced expression and cytoplasmic mislocalisation of p27kip1, which in turn caused actin remodelling and increased  migration in AGSGR cells.
genetics_overexpression_promote	hsa-mir-27a	Gastric Neoplasms	27409164	disease of cellular proliferation	DOID:10534	C16	D013274	137215		And overexpression of miR-27a-3p, but not miR-27a-5p, markedly promoted gastric cancer cell proliferation in vitro as well as tumor growth in vivo.
genetics_overexpression_promote	hsa-mir-340	Gastric Neoplasms	27374211	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Functionally, forced expression of miR-340 promoted cell viability, proliferation, colony formation and cell cycle progression in the SGC-7901 cells
genetics_overexpression_promote	hsa-mir-210	Gastrointestinal Stromal Tumor	24623741	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
genetics_overexpression_promote	hsa-mir-125b-2	Glioblastoma	21879257				D005909		HP:0100843	miR-125b-2 overexpression might confer glioblastoma stem cells resistance to TMZ.
genetics_overexpression_promote	hsa-mir-138	Glioblastoma	26887050				D005909		HP:0100843	Transient transfection of miR-138 mimics in glioma cells with low basal miR-138 expression increased glioma cell proliferation.
genetics_overexpression_promote	hsa-mir-223	Glioblastoma	28035389				D005909		HP:0100843	overexpression of miR-223 increases TMZ chemoresistance, while inhibition of miR-223 with antagomir markedly decreases TMZ chemoresistance in GBM cells
genetics_overexpression_promote	hsa-mir-26a	Glioblastoma	20080666				D005909		HP:0100843	Overexpression of miR-26a in PTEN-competent and PTEN-deficient glioblastoma cells promoted tumor growth in vivo, and it further increased growth in cells overexpressing CDK4 or CENTG1.
genetics_overexpression_promote	hsa-mir-9	Glioblastoma	27036038				D005909		HP:0100843	hsa-miR-9 overexpression leads to MAPKAP signaling inhibition, partially by interfering with the MAPK14/MAPKAP3 complex. Further, hsa-miR-9 overexpression initiates re-arrangement of actin filament
genetics_overexpression_promote	hsa-mir-183	Glioma	26879754	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Introduction of miR-183 mimics into U251 cells could promoted, while  its antisense oligos inhibited cell proliferation and invasion.
genetics_overexpression_promote	hsa-mir-19a	Glioma	27329239	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Overexpression of miR-19a by a miR-19a mimic promoted glioma cell proliferation and invasion.
genetics_overexpression_promote	hsa-mir-215	Glioma	26317904	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In summary, miR-215 is overexpressed in human glioma, is involved in TGF-β1-induced oncogenesis, and can be used as a marker of poor prognosis in glioma patients.
genetics_overexpression_promote	hsa-mir-363	Glioma	27495233	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Transfection of miR-363 induced cell survival, while inhibition of miR-363 significantly reduced glioma cell viability.
genetics_overexpression_promote	hsa-mir-96	Glioma	26846266	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In vivo, microRNA-96 overexpression inhibits the apoptosis and increases tumor growth.
genetics_overexpression_promote	hsa-mir-29b	Hearing Loss	27635430			H91.93	D034381			miR-29b overexpression induces cochlear hair cell apoptosis through the regulation of SIRT1/PGC-1α signaling: Implications for age-related hearing loss.
genetics_overexpression_promote	hsa-mir-132	Heart Failure	23011132			I50	D006331		HP:0001635	MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice.
genetics_overexpression_promote	hsa-mir-195	Heart Failure	25100012			I50	D006331		HP:0001635	Cardiac overexpression of miR-195 results in pathological cardiac growth and heart failure in transgenic mice.
genetics_overexpression_promote	hsa-mir-21	Heart Failure	26865549			I50	D006331		HP:0001635	Overexpression of miR-21 in this monocyte cell line activated a fibrotic gene programme and promoted monocyte-to-fibrocyte transition
genetics_overexpression_promote	hsa-mir-212	Heart Failure	23011132			I50	D006331		HP:0001635	MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice.
genetics_overexpression_promote	hsa-mir-22	Heart Failure	24086656			I50	D006331		HP:0001635	microRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription.
genetics_overexpression_promote	hsa-mir-30c	Heart Failure	24789369			I50	D006331		HP:0001635	Taken together these data indicate impaired mitochondrial function due to OXPHOS  protein depletion as a potential cause for the observed dilated cardiomyopathic phenotype in miRNA-30c transgenic mice.
genetics_overexpression_promote	hsa-mir-17	Hematologic Neoplasms	17011485	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	The miR-17-92 cluster is amplified in hematopoietic malignancies.
genetics_overexpression_promote	hsa-mir-17	Hematologic Neoplasms	25597017	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	overexpression of miR-17-92 in a limited number of hematopoietic cells is sufficient to cause B cell malignancies.
genetics_overexpression_promote	hsa-mir-18a	Hematologic Neoplasms	17011485	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	The miR-17-92 cluster is amplified in hematopoietic malignancies.
genetics_overexpression_promote	hsa-mir-19a	Hematologic Neoplasms	17011485	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	The miR-17-92 cluster is amplified in hematopoietic malignancies.
genetics_overexpression_promote	hsa-mir-19b-1	Hematologic Neoplasms	17011485	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	The miR-17-92 cluster is amplified in hematopoietic malignancies.
genetics_overexpression_promote	hsa-mir-20a	Hematologic Neoplasms	17011485	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	The miR-17-92 cluster is amplified in hematopoietic malignancies.
genetics_overexpression_promote	hsa-mir-449a	Hepatitis B Virus Infection	27138288	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Ectopic miR-449a expression in HCC cells strongly enhanced HBV replication, transcription, progeny virions secretion, and antigen expression in a dose-dependent manner.
genetics_overexpression_promote	hsa-mir-155	Hepatitis C Virus Infection	21750860	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells.
genetics_overexpression_promote	hsa-mir-196b	Hepatitis C Virus Infection	21750860	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells.
genetics_overexpression_promote	hsa-mir-21	Hypertrophic Scar	27207585			L91.0	D017439			overexpression of miR-21 promoted fibroproliferative expression in fibroblasts.
genetics_overexpression_promote	hsa-mir-146b	Inflammation	23813877				D007249			MicroRNA-146b improves intestinal injury in mouse colitis by activating nuclear factor-κB and improving epithelial barrier function.
genetics_overexpression_promote	hsa-mir-221	Inflammation	23023232				D007249			The overexpression of oncogenic miR-221 and miR-222 caused by HMGB1 is associated with an increase in malignancy scores, namely cell growth and motility.
genetics_overexpression_promote	hsa-mir-221	Inflammation	26549234				D007249			Enforced expression of miR-221 significantly increased the production of proinflammatory cytokines
genetics_overexpression_promote	hsa-mir-9	Influenza	27322373	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Overexpression of miR-9 enhanced viral gene expression and production of infectious progeny
genetics_overexpression_promote	hsa-mir-125a	Juvenile Rheumatoid Arthritis	27014994	musculoskeletal system disease	DOID:676	M08.4	D001171	604302		miR-125a-5p overexpression enhanced M2b polarization and altered other polarized populations
genetics_overexpression_promote	hsa-mir-210	Kidney Neoplasms	26985942	disease of cellular proliferation	DOID:263	C64	D007680			ACHN cell proliferation and invasion were significantly increased and apoptosis was significantly decreased (P < 0.05) when miR-210 was overexpressed.
genetics_overexpression_promote	hsa-mir-31	Leiomyosarcoma	19602040			C55	D007890		HP:0100243	overexpression; leads to HMGA2 overexpression; Disrupting the control of HMGA2 and let-7 pairs promotes ULMS cell growth in vitro.
genetics_overexpression_promote	hsa-mir-125b	Leukemia	21118985			C95	D007938	613065	HP:0001909	Thus, we show that overexpression of miR-125b is sufficient both to shorten the latency of BCR-ABL-induced leukemia and to independently induce leukemia in a mouse model.
genetics_overexpression_promote	hsa-mir-17	Leukemia	22451425			C95	D007938	613065	HP:0001909	In both murine and human leukemias, p53 inactivation contributed to the selective overexpression of oncogenic miR-92a and miR-19a, and down-regulation of tumor-suppressive miR-17.
genetics_overexpression_promote	hsa-mir-17	Leukemia	24145403			C95	D007938	613065	HP:0001909	The miR-17∼92 overexpression was driven by the Eµ-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression.
genetics_overexpression_promote	hsa-mir-9	Leukemia	23798388			C95	D007938	613065	HP:0001909	miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.
genetics_overexpression_promote	hsa-mir-18a	Leukemia, B-Cell	24145403			C91.31	D015448	151430		The miR-17∼92 overexpression was driven by the Eµ-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression.
genetics_overexpression_promote	hsa-mir-19a	Leukemia, B-Cell	24145403			C91.31	D015448	151430		The miR-17∼92 overexpression was driven by the Eµ-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression.
genetics_overexpression_promote	hsa-mir-19b	Leukemia, B-Cell	24145403			C91.31	D015448	151430		The miR-17∼92 overexpression was driven by the Eµ-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression.
genetics_overexpression_promote	hsa-mir-92a	Leukemia, B-Cell	24145403			C91.31	D015448	151430		The miR-17∼92 overexpression was driven by the Eµ-enhancer and Ig heavy-chain promoter, and a 3' GFP tag was added to the transgene to track the miR expression.
genetics_overexpression_promote	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	22145958	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	microRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in chronic lymphocytic leukemia patients.
genetics_overexpression_promote	hsa-mir-125b	Leukemia, Myeloid, Acute	22689670	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We previously described a t(2;11)(p21;q23) chromosomal translocation found in patients with myelodysplasia or acute myeloid leukemia that leads to over-expression of the microRNA miR-125b, and we showed that transplantation of mice with murine stem/progenitor cells overexpressing miR-125b is able to induce leukemia.
genetics_overexpression_promote	hsa-mir-130a	Leukemia, Myeloid, Acute	29493383	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death.
genetics_overexpression_promote	hsa-mir-155	Leukemia, Myeloid, Acute	29657293	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-155 overexpression plays a key pathogenic role in some lymphomas and acute myeloid leukemias has led to the development of an antagomir-based approach as a new promising therapeutic strategy
genetics_overexpression_promote	hsa-mir-181a	Leukemia, Myeloid, Acute	27531761	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Overexpression of miR-181a can promote AML cell proliferation.
genetics_overexpression_promote	hsa-mir-375	Liver Failure	27531059			K72	D017093	613070	HP:0001399	Thus miR-375 is identified as a novel repressor of UGT1A-mediated hepatic acetaminophen glucuronidation through reduced AhR expression, which could predispose some individuals to increased risk for acetaminophen-induced ALF
genetics_overexpression_promote	hsa-mir-182	Liver Injury	27196584			S36.11	D056486			miR-182, which is associated with disease severity and liver injury.
genetics_overexpression_promote	hsa-mir-19b	Lung Fibrosis	27508324	respiratory system disease	DOID:3770	J84.10	D011658	178500		Overexpression of miR-19b in small-airway epithelial cells promoted the mechanical stretch-induced EMT phenotypes, whereas inhibition of miR-19b attenuated it.
genetics_overexpression_promote	hsa-mir-17	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-18a	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-19a	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-19b-1	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-20a	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-301b	Lung Neoplasms	27352910	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	ectopic expression of miR-301b enhanced cell population growth, reduced apoptosis and reduced sensitivity of cells to chemotherapy.
genetics_overexpression_promote	hsa-mir-92a-1	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miRNA cluster miR-17-92 is located at 13q31.3 and has been associated with several types of cancer, including colorectal cancer and lung cancer, and is thought to be a potential oncogene [86, 87] that enhances cell proliferation.
genetics_overexpression_promote	hsa-mir-937	Lung Neoplasms	27179609	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpression of miR-937 in A549 promoted anchorage -dependent and -independent growth
genetics_overexpression_promote	hsa-mir-17	Lymphoma	16940181	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Mir-17-5p, also known as Mir-91,is located on chromosome 13q31; this gene is amplified in childhoodlymphoma.
genetics_overexpression_promote	hsa-mir-17	Lymphoma, Burkitt	21981616	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse.
genetics_overexpression_promote	hsa-mir-18a	Lymphoma, Burkitt	21981616	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse.
genetics_overexpression_promote	hsa-mir-19a	Lymphoma, Burkitt	21981616	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse.
genetics_overexpression_promote	hsa-mir-19b-1	Lymphoma, Burkitt	21981616	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse.
genetics_overexpression_promote	hsa-mir-20a	Lymphoma, Burkitt	21981616	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse.
genetics_overexpression_promote	hsa-mir-92a-1	Lymphoma, Burkitt	21981616	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	The minimum common amplified region on 13q was at 13q31 and included the MIR17HG (MIR17-92) locus. Samples with this gain had higher levels of MIR17 RNA and showed a tendency for early relapse.
genetics_overexpression_promote	hsa-mir-17	Macular Degeneration	27505139	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	Transfection of miR-17-3p mimic in ARPE-19 induced cell death and exacerbated oxidative lethality that was  alleviated by miR-17-3p inhibitor.
genetics_overexpression_promote	hsa-mir-769	Melanoma	27470346	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overexpression of miR-769 promoted cell proliferation in human melanoma cell line A375, whereas  miR-769-in reverses the function.
genetics_overexpression_promote	hsa-mir-146a	Multiple Myeloma	27102001	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	overexpressing miR-146a in MSC, secretion of several cytokines and chemokines including CXCL1, IL6, IL-8, IP-10,  MCP-1, and CCL-5 was elevated, resulting in the enhancement of MM cell viability  and migration.
genetics_overexpression_promote	hsa-mir-19a	Multiple Myeloma	29665917	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-19a is overexpressed significantly in Lp-1 and U266 multiple myeloma cells, and promots the proliferation and invasion of the myeloma cells, but inhibits their apoptosis
genetics_overexpression_promote	hsa-mir-125a	Myelodysplastic Syndromes	24690917	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest.
genetics_overexpression_promote	hsa-mir-196b	Myelodysplastic Syndromes	28224273	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome.
genetics_overexpression_promote	hsa-mir-205	Myelodysplastic Syndromes	27379838	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Our findings suggest that miR-205-5p upregulation contributes to MDS by suppressing PTEN and that miR-205-5p thus acts as an oncogene in hematopoietic cells.
genetics_overexpression_promote	hsa-mir-1	Myocardial Infarction	23615185	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Overexpression of MicroRNA-1 improves the efficacy of mesenchymal stem cell transplantation after myocardial infarction.
genetics_overexpression_promote	hsa-mir-1	Myocardial Infarction	28397788	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Over-expression of microRNA-1 causes arrhythmia by disturbing intracellular trafficking system.
genetics_overexpression_promote	hsa-mir-34a	Myocardial Infarction	22403243	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	IGF-1 significantly inhibited H(2)O(2)-induced miR-34a expression, and miR-34a overexpression abolished the anti-apoptotic effect of IGF-1.
genetics_overexpression_promote	hsa-mir-195	Myocardial Ischemic-Reperfusion Injury	27019437				D015428			miR-195 expression was upregulated in myocardial I/R injury, and miR-195 overexpression may promote cardiomyocyte apoptosis by targeting Bcl-2 and inducing mitochondrial apoptotic pathway.
genetics_overexpression_promote	hsa-mir-195	Myocardial Ischemic-Reperfusion Injury	27489501				D015428			Up-regulation of miR-195 in ischemic cardiomyocytes promotes ischemic apoptosis by targeting Bcl-2.
genetics_overexpression_promote	hsa-mir-30a	Nasopharyngeal Neoplasms	24812123			C11.9	D009303	607107	HP:0100630	Furthermore, over-expression of miR-30a transfected with precursor increased the ability of metastasis and invasion of NPC tumor cells in vivo and in vitro.
genetics_overexpression_promote	hsa-mir-10b	Neoplasms [unspecific]	29262659			C80.1	D009369			the overexpression of miR-10b was significantly correlated with metastasis status, and indicated the potential  clinical use of miR-10b as a molecular biomarker, particularly in assessing prognosis for patients with cancers
genetics_overexpression_promote	hsa-mir-15b	Neoplasms [unspecific]	27530410			C80.1	D009369			increased miR-15b and decreased RECK expression may contribute to the pathobiology of LYO.
genetics_overexpression_promote	hsa-mir-17	Neoplasms [unspecific]	20439436			C80.1	D009369			mir-17:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_overexpression_promote	hsa-mir-18a	Neoplasms [unspecific]	20439436			C80.1	D009369			mir-18a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_overexpression_promote	hsa-mir-19a	Neoplasms [unspecific]	20439436			C80.1	D009369			mir-19a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_overexpression_promote	hsa-mir-19b-1	Neoplasms [unspecific]	20439436			C80.1	D009369			mir-19b:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_overexpression_promote	hsa-mir-19b-2	Neoplasms [unspecific]	20439436			C80.1	D009369			mir-19b:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_overexpression_promote	hsa-mir-21	Neoplasms [unspecific]	25241894			C80.1	D009369			Ectopic expression of miR-21 and miR-29a promotes angiogenesis and tumor cell proliferation
genetics_overexpression_promote	hsa-mir-221	Neoplasms [unspecific]	25686829			C80.1	D009369			Over-expression of miR-221 stimulated stem-like cells in luminal type of cancer and the miR-221 level was correlated with clinical outcome in breast cancer patients.
genetics_overexpression_promote	hsa-mir-374a	Neoplasms [unspecific]	25299640			C80.1	D009369			The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression.
genetics_overexpression_promote	hsa-mir-545	Neoplasms [unspecific]	25299640			C80.1	D009369			The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression.
genetics_overexpression_promote	hsa-mir-92a-1	Neoplasms [unspecific]	20439436			C80.1	D009369			mir-92a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_overexpression_promote	hsa-mir-92a-2	Neoplasms [unspecific]	20439436			C80.1	D009369			mir-92a:We correctly identified hsa-miR-17/92 family as amplified and the hsa-miR-143/145 cluster as deleted
genetics_overexpression_promote	hsa-mir-126	Neovascularization, Pathologic	27203443				D009389			silencing of miR-126-3p repressed angiogenesis, while overexpression of miR-126-5p enhanced angiogenesis.
genetics_overexpression_promote	hsa-mir-124-1	Neuroblastoma	22123030	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Ectopic overexpression of miR-124 resulted in the downregulation of CDK6, decreased cellular proliferation, and induced cellular morphological changes.
genetics_overexpression_promote	hsa-mir-124-2	Neuroblastoma	22123030	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Ectopic overexpression of miR-124 resulted in the downregulation of CDK6, decreased cellular proliferation, and induced cellular morphological changes.
genetics_overexpression_promote	hsa-mir-124-3	Neuroblastoma	22123030	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Ectopic overexpression of miR-124 resulted in the downregulation of CDK6, decreased cellular proliferation, and induced cellular morphological changes.
genetics_overexpression_promote	hsa-mir-1303	Neuroblastoma	27434867	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-1303 overexpression promoted the proliferation of SH-SY5Y NB cell investigated by MTT assay, colony formation assay and anchorage-independent growth ability assay, while miR-1303 knockdown reduced this effect.
genetics_overexpression_promote	hsa-mir-21	Neuroblastoma	27285119	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Forced overexpression of miR-21 significantly increased NB cell proliferation, migration, and invasion.
genetics_overexpression_promote	hsa-mir-138	Obesity	27762728	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-138/miR-222 Overexpression Characterizes the miRNome of Amniotic Mesenchymal Stem Cells in Obesity.
genetics_overexpression_promote	hsa-mir-222	Obesity	27762728	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-138/miR-222 Overexpression Characterizes the miRNome of Amniotic Mesenchymal Stem Cells in Obesity.
genetics_overexpression_promote	hsa-mir-196a	Oral Neoplasms	25233933			C06.9	D009062		HP:0100649	Functionally, miR-196 actively promoted cell migration and invasion without affecting cell growth.
genetics_overexpression_promote	hsa-mir-34a	Osteoarthritis	27247228	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Overexpression of miR-34a promoted apoptosis and inhibited cell proliferation in human chondrocytes
genetics_overexpression_promote	hsa-mir-196a	Osteosarcoma	26045752	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, miR-196a should be an oncogene in osteosarcoma. The possible mechanism was that overexpression of miR-196a promoted proliferation of MG63 and U2OS cells by modulating the PTEN/PI3K/Akt signaling pathway.
genetics_overexpression_promote	hsa-mir-21	Osteosarcoma	26779632	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-21 overexpression in MG63 caused a significant raise in cell proliferation and invasion and a significant reduction in cell apoptosis.
genetics_overexpression_promote	hsa-mir-214	Osteosarcoma	28260089	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Overexpression of miR‑214 promotes the progression of human osteosarcoma by regulating the Wnt/β‑catenin signaling pathway.
genetics_overexpression_promote	hsa-mir-421	Osteosarcoma	26758431	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	overexpression of miR-421 promoted osteosarcoma cell line MG-63 proliferation, migration, and invasion.
genetics_overexpression_promote	hsa-mir-488	Osteosarcoma	27376839	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	We  also found that exogenous over-expression of microRNA-488 promotes the proliferation, reduces the apoptosis and decreases the sensitivity to chemotherapy (doxorubicin) of osteosarcoma cells
genetics_overexpression_promote	hsa-mir-664	Osteosarcoma	26515813	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Overexpression of miR-664 was associated with increased migration and invasive abilities of OS cells in vitro
genetics_overexpression_promote	hsa-mir-9	Osteosarcoma	24969351	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The findings of our study suggest that increased miR-9 expression has a strong correlation with the aggressive progression of osteosarcoma and its overexpression is a statistically significant risk factor affecting overall survival, suggesting that increased miR-9 expression could be a valuable marker of tumor progression and for prognosis of osteosarcoma.
genetics_overexpression_promote	hsa-mir-9	Osteosarcoma	27724924	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
genetics_overexpression_promote	hsa-mir-92a	Osteosarcoma	28069547	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Overexpression of miR-92a promotes the tumor growth of osteosarcoma by suppressing F-box and WD repeat-containing protein 7.
genetics_overexpression_promote	hsa-mir-1207	Ovarian Neoplasms	26337084	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway.
genetics_overexpression_promote	hsa-mir-125a	Ovarian Neoplasms	19881956	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of miR-125a induces conversion of highly invasive ovarian cancer cells
genetics_overexpression_promote	hsa-mir-130a	Ovarian Neoplasms	22455133	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The over expression of miR-130a is associated with cisplatin resistance of ovarian cancer. Inhibiting miR-130a expression may help reverse the cisplatin resistance of ovarian cancer.
genetics_overexpression_promote	hsa-mir-182	Ovarian Neoplasms	22322863	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-182 overexpression resulted in increased tumor transformation in vitro, and enhanced tumor invasiveness in vitro and metastasis in vivo. The oncogenic properties of miR-182 in ovarian cancer were mediated in part by its impaired repair of DNA double-strand breaks and negative regulation of breast cancer 1 (BRCA1) and metastasis suppressor 1 (MTSS1) expressions as well as its positive regulation of oncogene high-mobility group AT-hook 2 (HMGA2).
genetics_overexpression_promote	hsa-mir-221	Ovarian Neoplasms	28350128	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer.
genetics_overexpression_promote	hsa-mir-320	Ovarian Neoplasms	28338235	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of Hsa-miR-320 Is Associated With Invasion and Metastasis of Ovarian Cancer.
genetics_overexpression_promote	hsa-mir-429	Ovarian Neoplasms	24802724	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells.
genetics_overexpression_promote	hsa-mir-433	Ovarian Neoplasms	25684390	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.
genetics_overexpression_promote	hsa-mir-10b	Pancreatic Neoplasms	22018284	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis.
genetics_overexpression_promote	hsa-mir-203	Pancreatic Neoplasms	26719072	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-203 promotes proliferation,  migration and invasion in pancreatic cancer cells
genetics_overexpression_promote	hsa-mir-1301	Prostate Neoplasms	27261573	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-1301 promoted  cell proliferation of prostate cancer.
genetics_overexpression_promote	hsa-mir-200a	Prostate Neoplasms	22161972	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-200a overexpression reduced prostate cancer cell growth and may have potential, in combination with other markers, in stratifying prostate cancer patients for more intensive monitoring and therapy.
genetics_overexpression_promote	hsa-mir-221	Prostate Neoplasms	19107213	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice
genetics_overexpression_promote	hsa-mir-222	Prostate Neoplasms	19107213	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-222: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice
genetics_overexpression_promote	hsa-mir-296	Prostate Neoplasms	24263102	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Interestingly, ectopic expression of miR-296-3p in P69 increases the tolerance to NK cells whereas knockdown of miR-296-3p in M12 reduces the resistance to NK cells, which both phenotypes can be rescued by re-expression or silencing of ICAM-1 in P69 and M12, respectively.
genetics_overexpression_promote	hsa-mir-331	Prostate Neoplasms	26259043	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Overexpression of miR-331-3p upregulated mesenchymal markers such as vimentin, N-cadherin, and snail and downregulated epithelial markers such as E-cadherin and desmoplakin in the prostate cancer cell line PC3.
genetics_overexpression_promote	hsa-mir-9	Pulmonary Hypertension	24615545	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Knockdown of miR-9 followed by hypoxia exposure attenuated PASMCs proliferation and enhanced the expression of contractile genes in vascular smooth muscle cells (VSMCs), while overexpression of miR-9 in normoxia promoted a proliferative phenotype in PASMCs.
genetics_overexpression_promote	hsa-mir-125b	Retinoblastoma	27518550	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	overexpression of miR-125b apparently promotes RB cell proliferation and migration in vitro.
genetics_overexpression_promote	hsa-mir-449a	Retinoblastoma	24120948	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We are the first to confirm an inhibitory effect of miR-449a and -449b in retinoblastoma by demonstrating significantly impaired proliferation and increased apoptosis of tumor cells when these miRNAs are overexpressed.
genetics_overexpression_promote	hsa-mir-125b-1	Rhinosinusitis	22071331			B48.1				Overexpression of miR-125b, a Novel Regulator of Innate Immunity, in Eosinophilic Chronic Rhinosinusitis with Nasal Polyps.
genetics_overexpression_promote	hsa-mir-125b-2	Rhinosinusitis	22071331			B48.1				Overexpression of miR-125b, a Novel Regulator of Innate Immunity, in Eosinophilic Chronic Rhinosinusitis with Nasal Polyps.
genetics_overexpression_promote	hsa-mir-34a	Sensorineural Hearing Loss	25638533	nervous system disease	DOID:10003	H90.5	D006313	304400		In the inner ear HEI-OC1 cell line, miR-34a overexpression inhibited SIRT1, leading to an increase in p53 acetylation and apoptosis.
genetics_overexpression_promote	hsa-mir-146a	Sepsis	23638011			A41.9	D018805		HP:0100806	Overexpression of miR-146a induces a state analogous to tolerance in BLP-stimulated cells and therefore may represent a future target for exogenous modulation of tolerance during microbial infection and sepsis.
genetics_overexpression_promote	hsa-mir-195	Spinal Cord Injuries	26927342			S34.139A	D013119			In addition, Ad-miR-195 also obviously increased the number of apoptotic cells and decreased the neurological  recovery in the animals injected with Ad-miR-195.
genetics_overexpression_promote	hsa-mir-184	Squamous Cell Carcinoma	18451220	disease of cellular proliferation	DOID:1749		D002294			Overexpression of miR-184 might play an oncogenic role in the antiapoptotic and proliferative processes of tongue SCC. In addition, plasma miR-184 levels were associated with the presence of primary tumor. 
genetics_overexpression_promote	hsa-mir-1288	Squamous Cell Carcinoma, Esophageal	27658568	disease of cellular proliferation	DOID:3748		C562729			Overexpression of miR-1288 play a key role in thepathogenesis of ESCCs and its modulation may have potential therapeutic value in patients with ESCC
genetics_overexpression_promote	hsa-mir-18a	Squamous Cell Carcinoma, Esophageal	27291152	disease of cellular proliferation	DOID:3748		C562729			upregulation of miR-18a promoted cell proliferation by increasing cylin D1
genetics_overexpression_promote	hsa-mir-223	Squamous Cell Carcinoma, Esophageal	22108521	disease of cellular proliferation	DOID:3748		C562729			Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma.
genetics_overexpression_promote	hsa-mir-373	Squamous Cell Carcinoma, Esophageal	27073718	disease of cellular proliferation	DOID:3748		C562729			Overexpression of miR-373 in ECA109 cells enhanced proliferation, G1-phase cell proportion, migration, and invasion.
genetics_overexpression_promote	hsa-mir-93	Squamous Cell Carcinoma, Esophageal	26273410	disease of cellular proliferation	DOID:3748		C562729			The introduction of miR-93 significantly promotes cell proliferation,cell cycle progression, and the metastatic capability of EC109 cells. 
genetics_overexpression_promote	hsa-mir-182	Squamous Cell Carcinoma, Head and Neck	27744260	disease of cellular proliferation	DOID:5520	C76.0	C535575			Overexpression of TP53 mutation-associated microRNA-182 promotes tumor cell proliferation and migration in head and neck squamous cell carcinoma.
genetics_overexpression_promote	hsa-mir-184	Squamous Cell Carcinoma, Head and Neck	25351569	disease of cellular proliferation	DOID:5520	C76.0	C535575			Treatment with the precursors of these miRNAs increases the proliferation and migration of HNSCC cells.
genetics_overexpression_promote	hsa-mir-196a	Squamous Cell Carcinoma, Head and Neck	25860510	disease of cellular proliferation	DOID:5520	C76.0	C535575			These results show that miR-196a and HOXB9 are overexpressed,perhaps co-ordinately, as HNSCC develops and exert a pro-tumourigenic phenotype in HNSCC and OPM cells.
genetics_overexpression_promote	hsa-mir-31	Squamous Cell Carcinoma, Head and Neck	27528032	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-31 associated oncogenicities were rescued by ARID1A expression in HNSCC cells.
genetics_overexpression_promote	hsa-mir-451	Squamous Cell Carcinoma, Head and Neck	26506880	disease of cellular proliferation	DOID:5520	C76.0	C535575			And overexpression of miRNA-451 in cells with low endogenous expression of miRNA-451 accelerated proliferation.
genetics_overexpression_promote	hsa-mir-675	Squamous Cell Carcinoma, Head and Neck	27994496	disease of cellular proliferation	DOID:5520	C76.0	C535575			Overexpression of lncRNA H19/miR-675 promotes tumorigenesis in head and neck squamous cell carcinoma.
genetics_overexpression_promote	hsa-mir-211	Squamous Cell Carcinoma, Oral	27221705	disease of cellular proliferation	DOID:0050866					Induction of oral carcinogenesis in transgenic mice using 4-nitroquinoline 1-oxide (4NQO) resulted in more extensive and severe tongue tumorigenesis compared with control  animals.
genetics_overexpression_promote	hsa-let-7a	Systemic Lupus Erythematosus	24240124	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	our results suggest that overexpression of let-7a may contribute to hyperplasia and the proinflammatory response in SLE.
genetics_overexpression_promote	hsa-mir-221	Thyroid Neoplasms	22855362	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.
genetics_overexpression_promote	hsa-mir-18a	Toxic Epidermal Necrolysis	24184144	disease by infectious agent	DOID:9063	L51.2	D013206	608579		Our results indicated that downregulated BCL2L10 caused by miR-18a-5p overexpression mediates intrinsic keratinocyte apoptosis in patients with TEN. Serum miR-18a-5p levels can be a useful disease marker for drug eruptions.
genetics_overexpression_promote	hsa-mir-18a	Urinary Bladder Cancer	21388952	urinary system disease	DOID:11054	C67	D001749	109800		Specific deletion of p53 in urothelial cells is associated with specific overexpression of miR-18a and miR-19a and down-regulation of miR-107.
genetics_overexpression_promote	hsa-mir-19a	Urinary Bladder Cancer	21388952	urinary system disease	DOID:11054	C67	D001749	109800		Specific deletion of p53 in urothelial cells is associated with specific overexpression of miR-18a and miR-19a and down-regulation of miR-107.
genetics_overexpression_promote	hsa-mir-15b	Uterine Leiomyoma	27530410			D25.9	D007889	150699	HP:0000131	Our findings suggest that miR-15b negatively regulates RECK expression in LYO, and increased miR-15b and decreased RECK expression may contribute to the pathobiology of LYO.
genetics_overexpression_promote	hsa-mir-20a	Uveal Melanoma	27356499				C536494	155720	HP:0007716	miR鈥?0a mimics were transfected into UM cells, which led to increases in cell growth, migration and invasion activities.
genetics_overexpression_promote	hsa-mir-1908	Wound Healing	27256397				D014945		HP:0001058	miR-1908 had a positive role in scar formation
genetics_overexpression_suppress	hsa-mir-210	Acute Ischemic Stroke	27390218	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Lentivirus-mediated miR-210 overexpression enhanced the microvessel density and the number of neural  progenitor cells in the ischemic mouse brain (P < 0.05) and improved neurobehavioral outcomes in the ischemic mouse (P < 0.05).
genetics_overexpression_suppress	hsa-mir-16	Acute Lung Injury	22185353			S27	D055371			Accordingly, over-expression of miR-16 could significantly suppress the luciferase activity of reporter fusion with the binding sites of TNFα in its 3'UTR region, suggesting that miR-16 played its role in LPS-induced lung inflammation by a direct manner.
genetics_overexpression_suppress	hsa-mir-21	Acute Myocardial Infarction	26978580	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	combination of miR-21 and miR-146a has a greater protective effect against cardiac ischemia/hypoxia-induced apoptosis
genetics_overexpression_suppress	hsa-mir-449a	Adenocarcinoma, Gastric	24260067	disease of cellular proliferation	DOID:3717	D37.1	D013274			The overexpression of miR-449a inhibited gastric adenocarcinoma cell growth and promoted cell apoptosis in the MGC-803 and SGC-7901 gastric adenocarcinoma cell lines.
genetics_overexpression_suppress	hsa-mir-16	Adenocarcinoma, Lung	26064212	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	enforced expression of mir-16 lead to reduced A549 cell proliferation and promote apoptosis.
genetics_overexpression_suppress	hsa-mir-30a	Adenocarcinoma, Lung	26837415	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	overexpression of miR-30a in A549 cells inhibited migration and invasion but not cell proliferation and cell cycle progression
genetics_overexpression_suppress	hsa-mir-31	Adenocarcinoma, Lung	26299665	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	overexpression of miR-31 led to the inhibition of adenocarcinoma cell proliferation.
genetics_overexpression_suppress	hsa-mir-519d	Adenocarcinoma, Lung	28351305	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Overexpression of miR-519d in lung adenocarcinoma inhibits cell proliferation and invasion via the association of eIF4H.
genetics_overexpression_suppress	hsa-mir-95	Adenocarcinoma, Lung	25971210	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1.
genetics_overexpression_suppress	hsa-mir-192	Adenocarcinoma, Pancreatic Ductal	27216198	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		overexpression of miR-192 was sufficient to reduce cell proliferation and invasion.
genetics_overexpression_suppress	hsa-mir-193b	Adenovirus Infection	25854561			B34.0	D000257			The over-expression of miR-193b may suppress the proliferation of K562 cells.
genetics_overexpression_suppress	hsa-mir-194	Adenovirus Infection	28618953			B34.0	D000257			Overexpression of microRNA-194 suppresses the epithelial-mesenchymal transition in targeting stem cell transcription factor Sox3 in endometrial carcinoma stem cells.
genetics_overexpression_suppress	hsa-mir-7	Adrenal Cortex Neoplasms	26452132	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	microRNA-7-5p (miR-7) reduces cell proliferation in vitro and induces G1 cell cycle arrest.
genetics_overexpression_suppress	hsa-mir-126	Age-Related Macular Degeneration	27338342	nervous system disease	DOID:10871	H35.30	D008268	PS603075		overexpression effects of miR-126 were also proven on human microvascular endothelial cells
genetics_overexpression_suppress	hsa-mir-155	Allergy	27497617	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	miR-155 overexpression significantly suppressed IL-13-induced secretion  of CCL11 and CCL26.
genetics_overexpression_suppress	hsa-mir-16	Alzheimer Disease	26592823	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Overexpression and inhibition of miR-16 in the cellular AD model with primary hippocampal neurons decreased and increased apoptosis
genetics_overexpression_suppress	hsa-mir-34a	Alzheimer Disease	26459758	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Importantly, the overexpression of TAp73伪 and miR-34a reversed cell cycle-related neuronal apoptosis (CRNA).
genetics_overexpression_suppress	hsa-mir-155	Arthritis	24708712	musculoskeletal system disease	DOID:848	M19.90	D001168			Overexpression of miR-155 in the gouty SFMC leads to suppress SHIP-1 levels and enhance proinflammatory cytokines.
genetics_overexpression_suppress	hsa-mir-23b	Asthma	26748386	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Overexpression of miR-23b significantly inhibited TGF-尾1-induced ASMCs proliferation and promoted apoptosis.
genetics_overexpression_suppress	hsa-mir-221	Astrocytoma	26191177	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Overexpression of miR-221 inhibits proliferation and promotes apoptosis of human astrocytoma cells.
genetics_overexpression_suppress	hsa-mir-106b	Atherosclerosis	27270534	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Overexpression of miR-106b-5p with miR-106b-5p mimic inhibited PTEN expression and TNF-伪-induced apoptosis in HUVEC.
genetics_overexpression_suppress	hsa-mir-126	Atherosclerosis	27180261	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-126 up-regulation activates EPCs and ECs and contributes to vascular healing and neovessel formation
genetics_overexpression_suppress	hsa-mir-126	Atherosclerosis	27827458	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes.
genetics_overexpression_suppress	hsa-mir-146a	Atherosclerosis	21329689	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Over-expression of miR-146a may be useful in the prevention and treatment of atherosclerosis.
genetics_overexpression_suppress	hsa-mir-146a	Atherosclerosis	25904598	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	cellular enrichment of miR-146a through the systemic delivery of miR-146a mimetics in Apoe(-/-)Ldlr(-/-) and Ldlr(-/-) mice attenuated monocyte/macrophage activation and atherosclerosis in the absence of plasma lipid reduction.
genetics_overexpression_suppress	hsa-mir-150	Atherosclerosis	27216461	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The suppressive effects of miR-150 on macrophage foam cell formation are mediated through targeting of AdipoR2.
genetics_overexpression_suppress	hsa-mir-181b	Atherosclerosis	24084690	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	overexpression of miR-181b in the aortic intima of apolipoprotein E-deficient mice and suppressed NF-κB signaling revealed by bioluminescence imaging and reduced target gene expression in the aortic arch in apolipoprotein E-deficient/NF-κB-luciferase transgenic mice.
genetics_overexpression_suppress	hsa-mir-21	Atherosclerosis	24502419	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Further analysis confirmed that overexpression of miR-21 by transfection with miR-21 mimics notably attenuated lipid accumulation and lipid-laden foam cell formation in LPS-stimulated macrophages, which was reversely up-regulated when silencing miR-21 expression via anti-miR-21 inhibitor transfection, indicating a reverse regulator of miR-21 in LPS-induced foam cell formation.
genetics_overexpression_suppress	hsa-mir-140	Biliary Tract Neoplasms	27155525	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	Ectopic expression of miR-140-5p markedly decreased SEPT2 protein  concentration in BTC cells and suppressed cell proliferation and colony formation in vitro.
genetics_overexpression_suppress	hsa-mir-1180	Bladder Neoplasms	27112784			C67	D001749	109800	HP:0009725	miR-1180-5p also suppressed the tumor growth in vivo significantly
genetics_overexpression_suppress	hsa-mir-122	Bladder Neoplasms	27508026			C67	D001749	109800	HP:0009725	Furthermore, miR-122 over-expression decreases bladder cancer cell migration, invasion, colony formation in vitro and slow bladder cancer growth and angiogenesis in vivo.
genetics_overexpression_suppress	hsa-mir-125b	Bladder Neoplasms	26807182			C67	D001749	109800	HP:0009725	Overexpression of miR-125b inhibited cellular growth, suppressed cellular migration and caused an accumulation of cells in the  G1 phase of the cell cycle
genetics_overexpression_suppress	hsa-mir-139	Bladder Neoplasms	27355528			C67	D001749	109800	HP:0009725	Gain-of-function studies showed that miR-139-5p and miR-139-3p significantly inhibited cell migration and invasion by BC cells.
genetics_overexpression_suppress	hsa-mir-26b	Bladder Neoplasms	27310702			C67	D001749	109800	HP:0009725	Restoration of these miRNAs inhibited cell migration and invasion in BC.
genetics_overexpression_suppress	hsa-mir-335	Bladder Neoplasms	27356628			C67	D001749	109800	HP:0009725	Overexpression of miR鈥?35 in T24 cells inhibited cell proliferation and induced apoptosis
genetics_overexpression_suppress	hsa-mir-429	Bladder Neoplasms	27058893			C67	D001749	109800	HP:0009725	Exogenous mimic of miR-429 treatment dramatically inhibited the migratory ability of T24 cells.
genetics_overexpression_suppress	hsa-mir-99a	Bladder Neoplasms	24944696			C67	D001749	109800	HP:0009725	It was found that miRNA-99a inhibits cell proliferation, migration and invasion in T24 and EJ cells.
genetics_overexpression_suppress	hsa-mir-203	Brain Disease [unspecific]	25723469	nervous system disease	DOID:936	G93.40	D001927	608033		enforced expression of miR-203 or MyD88 siRNA silencing inhibits downstream NF-κβ signaling and microglia activation
genetics_overexpression_suppress	hsa-let-7a	Breast Neoplasms	25846193	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Cell proliferation, colony formation, migration and invasion were decreased after overexpression of let-7a in breast cancer cells and vice versa.
genetics_overexpression_suppress	hsa-mir-107	Breast Neoplasms	24482686	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of miR-107 suppressed MDA-MB-231 cell proliferation and migration, meanwhile the cells were  arrested at G0/G1 phase.
genetics_overexpression_suppress	hsa-mir-143	Breast Neoplasms	26618772	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Up-regulating miR-143 enhanced E-cadherin-mediated cell-cell adhesion ability, reduced mesenchymal markers, and decreased cell proliferation, migration, and invasion in vitro.
genetics_overexpression_suppress	hsa-mir-145	Breast Neoplasms	26715279	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of miR-145 in MCF-7 and BT-549 cell lines significantly inhibited  cell proliferation, migration, and invasion in vitro.
genetics_overexpression_suppress	hsa-mir-145	Breast Neoplasms	27508031	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Wound healing assay and transwell migration assay showed that ectopic expression of miR-145 significantly inhibited breast cancer cell migration.
genetics_overexpression_suppress	hsa-mir-145	Breast Neoplasms	29425746	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-145 overexpression triggers alteration of the whole transcriptome and inhibits breast cancer development
genetics_overexpression_suppress	hsa-mir-148a	Breast Neoplasms	26707142	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The ectopic miR-148a expression inhibited the migration and invasion of MCF-7 and MDA-MB-231 breast cancer cells.
genetics_overexpression_suppress	hsa-mir-148b	Breast Neoplasms	27328731	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Depleting miR-214 or elevating miR-148b blocked the dissemination  of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration.
genetics_overexpression_suppress	hsa-mir-16	Breast Neoplasms	25672252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of microRNA-16 declines cellular growth, proliferation and induces apoptosis in human breast cancer cells.
genetics_overexpression_suppress	hsa-mir-195	Breast Neoplasms	26632252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ectopic expression of hsa-miR-195 in MCF-7 and MDA-MB-231 cells not only altered cellular cholesterol and triglyceride levels significantly but also  resulted in reduced proliferation, invasion and migration.
genetics_overexpression_suppress	hsa-mir-199a	Breast Neoplasms	27094578	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of miR-199a-5p reduced the mRNA and protein levels of Ets-1 in MCF-7 and MDA-MB-231 cells, whereas anti-miR-199a-5p elevated Ets-1.
genetics_overexpression_suppress	hsa-mir-223	Breast Neoplasms	26876200	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	both RT-induced miR-223 and peri-operative inhibition of EGFR efficiently prevented BC cell growth and reduced recurrence formation in mouse models of BC.
genetics_overexpression_suppress	hsa-mir-302b	Breast Neoplasms	26623722	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-302b overexpression enhances sensitivity to cisplatin in breast cancer cell lines, reducing cell viability and proliferation  in response to the treatment.
genetics_overexpression_suppress	hsa-mir-340	Breast Neoplasms	26758430	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-340 could dramatically down-regulate metastasis by targeting Wnt signaling in breast cancer cells.
genetics_overexpression_suppress	hsa-mir-378	Breast Neoplasms	26749280	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ectopic expression  of miR-378 in MDA-MB-231 cells inhibited Runx1 and suppressed migration and invasion, while inhibition of miR-378 in MCF7 cells increased Runx1 levels and cell migration.
genetics_overexpression_suppress	hsa-mir-410	Breast Neoplasms	27221455	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-410-3p overexpression reduced cell growth, colony formation and the number of EdU-positive cells in the MDA-MB-231 cells.
genetics_overexpression_suppress	hsa-mir-411	Breast Neoplasms	27264952	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ectopic expression of miR-411-5p suppressed the breast cancer cell proliferation
genetics_overexpression_suppress	hsa-mir-486	Breast Neoplasms	24104550	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	in vitro functional screening of the downregulated miRNAs in non-malignant and breast cancer cell lines identified several possible tumor suppressor miRNAs, including miR-193b, miR-193a-3p, miR-126, miR-134, miR-132, miR-486-5p, miR-886-3p, miR-195 and miR-497, showing reduced growth when re-expressed in cancer cells
genetics_overexpression_suppress	hsa-mir-497	Breast Neoplasms	27303812	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Enforced miR-497 expression, accompanied with SMAD7 reduction, suppressed MDA-MB-231 and MCF-7 breast cancer cell growth
genetics_overexpression_suppress	hsa-mir-497	Breast Neoplasms	27456360	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Further, overexpression  of miR-497 not only inhibited ERR伪 expression but also reduced MIF level and MMP9 activity, which led to significant decreases in cell proliferation, migration, and invasion of ER伪 negative breast cancer.
genetics_overexpression_suppress	hsa-mir-502	Breast Neoplasms	27080302	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with miR-502 or downregulation of SET8 suppressed cell proliferation and cell cycle, and reduced cell migration, invasion and EMT.
genetics_overexpression_suppress	hsa-mir-506	Breast Neoplasms	26059632	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-506 over-expression significantly inhibits the proliferation,colony formation, and migration of breast cancer cells. miR-506 over-expression may thus be able to improve the malignant phenotype of breast cancer cells.
genetics_overexpression_suppress	hsa-mir-613	Breast Neoplasms	27449609	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-613 mimics significantly inhibited the migration and invasion of  breast cancer cells, whereas miR-613 inhibitors significantly increased cell migration and invasion.
genetics_overexpression_suppress	hsa-mir-101	Carcinoma, Bladder	27485165	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	In addition, plasmid鈥憁ediated overexpression of miR鈥?01 and small hairpin RNA鈥憁ediated inhibition of c鈥慒OS significantly inhibited the proliferation and invasive capacity of T24 cells.
genetics_overexpression_suppress	hsa-mir-106a	Carcinoma, Bladder	27513725	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Overexpression of mir-106a suppressed the proliferation of bladder cancer cell in EJ.
genetics_overexpression_suppress	hsa-mir-205	Carcinoma, Breast	27468619			D05	D001943	114480	HP:0003002	Knock-up of miR-205 expression by transfection with its mimics promoted MDA-MB-468 cells apoptosis (P=0.006 1).
genetics_overexpression_suppress	hsa-mir-26a	Carcinoma, Breast	27517917			D05	D001943	114480	HP:0003002	MiR-26a overexpression resulted in a reduction in cell viability that was partially recovered by inhibiting it.
genetics_overexpression_suppress	hsa-mir-34a	Carcinoma, Breast	27524218			D05	D001943	114480	HP:0003002	MiR-34a expression was remarkably down-regulated in BC tissues and cell  lines compared with normal tissues and cell lines.
genetics_overexpression_suppress	hsa-mir-365	Carcinoma, Breast	27906431			D05	D001943	114480	HP:0003002	Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4.
genetics_overexpression_suppress	hsa-mir-145	Carcinoma, Breast, Triple Negative	26733177				D064726			tumor necrosis factor-alpha (TNF-伪)-induced apoptosis was expanded by the transfection of miR-145 in MDA-MB-231 which belongs to the TNBC cell lines.
genetics_overexpression_suppress	hsa-mir-145	Carcinoma, Breast, Triple Negative	27364572				D064726			Upregulating miR-145 in HCC1937 cells dramatically suppressed cell proliferation and induced G1-phase arrest
genetics_overexpression_suppress	hsa-mir-18a	Carcinoma, Breast, Triple Negative	27338042				D064726			Enforced miR-18a overexpression directly led to  increased autophagy in MDA-MB-231 cells
genetics_overexpression_suppress	hsa-mir-200	Carcinoma, Breast, Triple Negative	27402080				D064726			miR-9 and miR-200 promoted and inhibited, respectively, the formation of vascular-like structures in vitro
genetics_overexpression_suppress	hsa-mir-206	Carcinoma, Breast, Triple Negative	27318091				D064726			The miR-206 mimics inhibited TNBC breast cell invasion and angiogenesis.
genetics_overexpression_suppress	hsa-mir-490	Carcinoma, Breast, Triple Negative	27506313				D064726			Gain-of-function studies revealed that miR-490-3p-3p overexpression inhibited cell growth and invasion in both MDA-MB-231 and MDA-MB-436 TNBC cells and impaired tumorigenesis of MDA-MB-231 cells in nude mice.
genetics_overexpression_suppress	hsa-mir-544	Carcinoma, Breast, Triple Negative	27186677				D064726			overexpression of miR-544 in triple negative breast cancer cells significantly down-regulated expressions of Bcl6 and Stat3, which in turn severely inhibited cancer cell proliferation, migration and invasion in vitro.
genetics_overexpression_suppress	hsa-mir-139	Carcinoma, Cervical	27505862	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Overexpression of miR-139-3p significantly suppressed HeLa cell proliferation, migration and invasion and induced cell apoptosis.
genetics_overexpression_suppress	hsa-mir-148b	Carcinoma, Cervical	27505047	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-148b mimics significantly decreased the cell proliferation ability and invasion ability, and statistically induced apoptosis.
genetics_overexpression_suppress	hsa-mir-200b	Carcinoma, Cervical	26935156	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR鈥?00b suppressed the migratory potential of cervical carcinoma cells
genetics_overexpression_suppress	hsa-mir-34a	Carcinoma, Cervical	27456356	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	While forced expression of miR-34a in CaCx and CRC cells inhibited HMGB1 mRNA and protein levels, proliferation, migration and invasion, inhibition of endogenous miR-34a enhanced these tumourigenic properties.
genetics_overexpression_suppress	hsa-let-7a	Carcinoma, Colon	27498032	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Further studies demonstrated that over-expressed let-7a could remarkably inhibit  HCT-116 and SW620 cell growth and metastasis by directly down-regulating Rhotekin (RTKN).
genetics_overexpression_suppress	hsa-mir-34a	Carcinoma, Colon	28035390	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	overexpression of miR-34a may inhibit the proliferation, invasion and metastasis of HCT116 cells
genetics_overexpression_suppress	hsa-mir-29c	Carcinoma, Embryonal	26484393	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	MicroRNA-29c overexpression inhibits proliferation and promotes apoptosis and differentiation in P19 embryonal carcinoma cells.
genetics_overexpression_suppress	hsa-mir-24	Carcinoma, Endometrial	27279639	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Up-regulation of miR-24 inhibited the cell proliferation
genetics_overexpression_suppress	hsa-mir-372	Carcinoma, Endometrial	26673619	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	miR-372 overexpression suppressed tumor growth
genetics_overexpression_suppress	hsa-mir-138	Carcinoma, Gallbladder	25962180	disease of cellular proliferation	DOID:4948	C23	D005706			Expression of miR-138 is frequently reduced in gallbladder carcinoma when compared to normal cells. Overexpression of miR-138 inhibited cell proliferation by directly suppressing the expression of Bag-1. These results suggest that miR-138 plays an important role in inhibiting the growth of gallbladder carcinoma.
genetics_overexpression_suppress	hsa-mir-137	Carcinoma, Gastric	27468717	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Over expression of miR-137 could inhibit the cell migration, proliferation, and promote cell cycle arrest in G0/G1 stage in BGC-823 and SGC-7901 cell lines.
genetics_overexpression_suppress	hsa-mir-148a	Carcinoma, Gastric	27518872	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Ectopic expression of miR-148a inhibited tumor cell proliferation and migration in vitro, and inhibited tumor formation in vivo.
genetics_overexpression_suppress	hsa-mir-18a	Carcinoma, Gastric	26622381	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The results showed that miR-18a overexpression was able to promote cell apoptosis and inhibit cell invasion.
genetics_overexpression_suppress	hsa-mir-3178	Carcinoma, Gastric	27493095	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The condition medium from miR-3178 mimic transfected GES-1  cells could inhibit proliferation and induce apoptosis of inflammation-related gastric cancer cells SGC7901 and MGC803 by decreasing the production of inflammatory cytokines TNF-伪 and IL-6, which were secreted by GES-1 cells.
genetics_overexpression_suppress	hsa-mir-34a	Carcinoma, Gastric	27513895	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Upregulation of miR-34a enhanced the DDP sensitivity of SGC7901/DDP cells to DDP through the inhibition of cell proliferation and induction of cell apoptosis.
genetics_overexpression_suppress	hsa-mir-370	Carcinoma, Gastric	27499479	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Upregulation of microRNA-370 promotes cell apoptosis and inhibits proliferation by targeting PTEN in human gastric cancer.
genetics_overexpression_suppress	hsa-mir-449a	Carcinoma, Gastric	25202363	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The level of MGC-803 cell proliferation was decreased and the apoptosis level was increased by the upregulation of miR-449a expression
genetics_overexpression_suppress	hsa-let-7g	Carcinoma, Hepatocellular	25435961	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the overexpression of let-7g/i significantly suppressed DNA replication, inhibited cell proliferation and promoted apoptosis of BEL-7402 hepatoma cells.
genetics_overexpression_suppress	hsa-let-7i	Carcinoma, Hepatocellular	25435961	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the overexpression of let-7g/i significantly suppressed DNA replication, inhibited cell proliferation and promoted apoptosis of BEL-7402 hepatoma cells.
genetics_overexpression_suppress	hsa-let-7i	Carcinoma, Hepatocellular	27126374	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Let-7i was downregulated in HCC tissues, and transfection of HuH-7 with let-7i inhibited malignant cell behaviors and decreased IGF2BPs transcripts.
genetics_overexpression_suppress	hsa-mir-1207	Carcinoma, Hepatocellular	27461404	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-1207-5p significantly suppressed the cell growth and invasion of HCC cells.
genetics_overexpression_suppress	hsa-mir-125b-1	Carcinoma, Hepatocellular	18649363	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-125b: overexpression of miR-125b in HCC cell line could obviously suppress the cell growth and phosporylation of Akt
genetics_overexpression_suppress	hsa-mir-125b-2	Carcinoma, Hepatocellular	18649363	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-125b: overexpression of miR-125b in HCC cell line could obviously suppress the cell growth and phosporylation of Akt
genetics_overexpression_suppress	hsa-mir-1299	Carcinoma, Hepatocellular	27490780	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1299 overexpression inhibited cell proliferation and arrested cell cycle in G0/G1 phase analyzed by MTT assay, soft agar assay, BrdU cell proliferation assay and cell cycle assay, while miR-1299 knockdown promoted cell proliferation and accelerated G1/S transition.
genetics_overexpression_suppress	hsa-mir-132	Carcinoma, Hepatocellular	27467251	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The tumor-suppressive role of miR-132 in HCC has been further confirmed by in vitro experiments.
genetics_overexpression_suppress	hsa-mir-137	Carcinoma, Hepatocellular	27492460	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-137 via adenoviral vector inhibited the proliferation and anchorage-independent growth of HCC cells, HepG2 and MHCC-97H.
genetics_overexpression_suppress	hsa-mir-141	Carcinoma, Hepatocellular	27412940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Over-expression of miR-141 inhibits the proliferation, invasion and migration of hepatocellular carcinoma MHCC-97H cells
genetics_overexpression_suppress	hsa-mir-142	Carcinoma, Hepatocellular	28081734	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-142-5p Overexpression Inhibits Cell Growth and Induces Apoptosis by Regulating FOXO in Hepatocellular Carcinoma Cells.
genetics_overexpression_suppress	hsa-mir-145	Carcinoma, Hepatocellular	26615424	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-145 in HCC cell lines significantly inhibited cell proliferation, migration, and invasion in vitro.
genetics_overexpression_suppress	hsa-mir-149	Carcinoma, Hepatocellular	27300349	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-149 or inhibition of PARP-2 expression could inhibit tumor growth but was more effective in sensitizing chemotherapy and radiotherapy in xenograft HCC animal models
genetics_overexpression_suppress	hsa-mir-150	Carcinoma, Hepatocellular	26871477	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-150 overexpression inhibited cell proliferation, migration and invasion in vitro and tumor growth and metastasis in vivo.
genetics_overexpression_suppress	hsa-mir-15a	Carcinoma, Hepatocellular	26581909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ectopic overexpression of miR-15a-5p suppressed cancer proliferation, induced cell cycle arrest in HepG2 or SNU-182 cells in vitro, and inhibited HCC tumor growth in vivo.
genetics_overexpression_suppress	hsa-mir-16	Carcinoma, Hepatocellular	26499886	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The results of this study suggest that the overexpression of miR-16 inhibits the proliferation, invasion and metastasis of HepG2 HCC cells, and that these effects are associated with the PI3K/Akt signaling pathway.
genetics_overexpression_suppress	hsa-mir-18a	Carcinoma, Hepatocellular	27421245	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We transfected HepG2.2.15 with miR-18a mimics and CTGF siRNA, finding that upregulated miR-18a and downregulated CTGF suppress the viability and cause cell cycle arrest.
genetics_overexpression_suppress	hsa-mir-192	Carcinoma, Hepatocellular	26684241	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-192 significantly suppressed metastasis of  HCC cells in vitro and in vivo.
genetics_overexpression_suppress	hsa-mir-199a-1	Carcinoma, Hepatocellular	21847633	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Lentivirus-Mediated Overexpression of MicroRNA-199a Inhibits Cell Proliferation of Human Hepatocellular Carcinoma.
genetics_overexpression_suppress	hsa-mir-199a-2	Carcinoma, Hepatocellular	21847633	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Lentivirus-Mediated Overexpression of MicroRNA-199a Inhibits Cell Proliferation of Human Hepatocellular Carcinoma.
genetics_overexpression_suppress	hsa-mir-200b	Carcinoma, Hepatocellular	26919246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Forced expression of microRNA-200b in HCC cells dramatically repressed proliferation, colony formation, cell cycle progression, and invasion.
genetics_overexpression_suppress	hsa-mir-200b	Carcinoma, Hepatocellular	26986232	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulated miR鈥?00b expression in HepG2 cells led to a decrease in DNMT3a expression levels, and an inhibition of cell proliferation.
genetics_overexpression_suppress	hsa-mir-206	Carcinoma, Hepatocellular	24919811	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-206 overexpression promotes apoptosis, induces cell cycle arrest and inhibits the migration of human hepatocellular carcinoma HepG2 cells.
genetics_overexpression_suppress	hsa-mir-20a	Carcinoma, Hepatocellular	27313460	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	growth of HepG2 cells in the miR-20a mimics group was significantly inhibited
genetics_overexpression_suppress	hsa-mir-21	Carcinoma, Hepatocellular	27793160	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of microRNA-21 strengthens stem cell-like characteristics in a hepatocellular carcinoma cell line.
genetics_overexpression_suppress	hsa-mir-214	Carcinoma, Hepatocellular	26498144	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-214 in HCC cells inhibited  proliferation by inducing G1-S checkpoint arrest.
genetics_overexpression_suppress	hsa-mir-214	Carcinoma, Hepatocellular	26788207	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	enhanced expression of miR-214 or silencing of E2F3 inhibited the proliferation of HCC SMMC-7721 cells.
genetics_overexpression_suppress	hsa-mir-214	Carcinoma, Hepatocellular	27129291	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-214 significantly attenuated cell proliferation.
genetics_overexpression_suppress	hsa-mir-218	Carcinoma, Hepatocellular	25374061	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET.
genetics_overexpression_suppress	hsa-mir-26b	Carcinoma, Hepatocellular	26891666	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-26b-5p inhibited HCC cell growth and impaired  the tube formation ability of the HCC cells
genetics_overexpression_suppress	hsa-mir-302b	Carcinoma, Hepatocellular	26254095	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-302b suppressed HCC cell invasion and metastasis.
genetics_overexpression_suppress	hsa-mir-30b	Carcinoma, Hepatocellular	27333771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Gain- and loss-of-function studies revealed that miR-30b could dramatically inhibit in vitro HCC cell migration and invasion.
genetics_overexpression_suppress	hsa-mir-449a	Carcinoma, Hepatocellular	27398144	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ectopic expression of miR-449a suppressed HCC cell proliferation, colony formation, migration and invasion.
genetics_overexpression_suppress	hsa-mir-451	Carcinoma, Hepatocellular	27461244	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In this study, overexpression of miR-451 clearly attenuated the promoting effects of HCC  cells on cell proliferation, migration and tube formation of human umbilical vein endothelial cells (HUVECs).
genetics_overexpression_suppress	hsa-mir-663a	Carcinoma, Hepatocellular	27261623	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-663a distinctly inhibited cell proliferation, migration and invasion.
genetics_overexpression_suppress	hsa-mir-7	Carcinoma, Hepatocellular	27391479	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of miR-7 inhibited the HCC cell proliferation and invasion. Overexpression of miR-7 could suppress the direct target gene CCNE1 and PIK3CD expression.
genetics_overexpression_suppress	hsa-mir-92a-1	Carcinoma, Hepatocellular	22587342	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma.
genetics_overexpression_suppress	hsa-mir-34c	Carcinoma, Hepatocellular, HBV-Related	26722295							The restoration of miR-34c in HepG2.2.15 cells suppressed TGIF2 expression, HBV replication and viral antigen synthesis; inhibited cell proliferation; and induced apoptosis.
genetics_overexpression_suppress	hsa-mir-30b	Carcinoma, Laryngeal	25356506	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	Overexpression of microRNA-30b improves adenovirus-mediated p53 cancer gene therapy for laryngeal carcinoma.
genetics_overexpression_suppress	hsa-mir-34a	Carcinoma, Laryngeal	27220728	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	expression of miR-34a inhibited cell proliferation and migration in laryngeal carcinoma cells.
genetics_overexpression_suppress	hsa-mir-107	Carcinoma, Lung	27498977	disease of cellular proliferation	DOID:3905	C34.90	D008175			Function assays showed that overexpression of miR-107 suppressed cell proliferation, migration and invasion in A549 cells in vitro, and inhibited NSCLC tumor growth in vivo.
genetics_overexpression_suppress	hsa-mir-124	Carcinoma, Lung	27251409	disease of cellular proliferation	DOID:3905	C34.90	D008175			overexpression of miR-124 in A549 cells suppressed cell migration and invasion activity
genetics_overexpression_suppress	hsa-mir-29a	Carcinoma, Lung	27488440	disease of cellular proliferation	DOID:3905	C34.90	D008175			Restoration of miR-29a suppressed cancer cell aggressiveness and fibroblast migration.
genetics_overexpression_suppress	hsa-mir-509	Carcinoma, Lung	27498003	disease of cellular proliferation	DOID:3905	C34.90	D008175			In addition, over-expression of  miR-509-3-5p markedly blocked A549 cell proliferation and sensitized the cells to CIS and ADR treatment.
genetics_overexpression_suppress	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	27073840			C34.90	D002289		HP:0030358	Overexpression of miR-124 apparently suppressed the proliferation and invasion of NSCLC cell lines in vitro.
genetics_overexpression_suppress	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	27376157			C34.90	D002289		HP:0030358	Overexpression of miR-124 significantly  suppresses tumor cell proliferation, colony formation, migration, and induction of apoptosis in H322 and A549 cells.
genetics_overexpression_suppress	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	27236384			C34.90	D002289		HP:0030358	Upregulation of miR-126 resulted in  the decrease of the proliferation, migration, and invasive abilities of A549 cells
genetics_overexpression_suppress	hsa-mir-134	Carcinoma, Lung, Non-Small-Cell	27241841			C34.90	D002289		HP:0030358	miR-134 suppressed tumour growth of A549 xenograft  in nude mice.
genetics_overexpression_suppress	hsa-mir-143	Carcinoma, Lung, Non-Small-Cell	29630116			C34.90	D002289		HP:0030358	overexpression of miR-143 downregulated cell proliferation, promoted the apoptosis, and suppressed the phosphorylation of EGFR, AKT and ERK1/2; thus, miR-143 may play a role in treatment of NSCLC to enhance therapeutic efficacy
genetics_overexpression_suppress	hsa-mir-186	Carcinoma, Lung, Non-Small-Cell	27498924			C34.90	D002289		HP:0030358	Furthermore, overexpression of miR-186 suppressed lung cancer cell proliferation, migration and invasion, and induced cell apoptosis.
genetics_overexpression_suppress	hsa-mir-187	Carcinoma, Lung, Non-Small-Cell	27495872			C34.90	D002289		HP:0030358	Overexpression of miR-187-5p inhibited the growth and metastasis of NSCLC cells.
genetics_overexpression_suppress	hsa-mir-191	Carcinoma, Lung, Non-Small-Cell	27178817			C34.90	D002289		HP:0030358	cell proliferation was notably reduced by the miR-1908 mimic transfection
genetics_overexpression_suppress	hsa-mir-200b	Carcinoma, Lung, Non-Small-Cell	27356635			C34.90	D002289		HP:0030358	Overexpression of miR鈥?00b significantly inhibited NSCLC cell migration and invasion.
genetics_overexpression_suppress	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	26935975			C34.90	D002289		HP:0030358	Overexpression of miR鈥?00c  significantly suppressed cell migration and invasion of A549 NSCLC cells.
genetics_overexpression_suppress	hsa-mir-204	Carcinoma, Lung, Non-Small-Cell	26935060			C34.90	D002289		HP:0030358	Transient over-expression of miR-204 by transfecting with miR-204 mimics suppressed NSCLC cell proliferation, migration,  and induced apoptosis and G1 arrest
genetics_overexpression_suppress	hsa-mir-206	Carcinoma, Lung, Non-Small-Cell	26309565			C34.90	D002289		HP:0030358	Forced overexpression of  miR-206 significantly inhibited cell proliferation, migration and invasion of NSCLC cells.
genetics_overexpression_suppress	hsa-mir-223	Carcinoma, Lung, Non-Small-Cell	27177336			C34.90	D002289		HP:0030358	The overexpression of miR鈥?23 may partially reverse the acquired resistance to epidermal growth factor receptor-TKIs, thus, providing a potential  therapeutic strategy for TKI-resistant NSCLC.
genetics_overexpression_suppress	hsa-mir-26a	Carcinoma, Lung, Non-Small-Cell	26492332			C34.90	D002289		HP:0030358	Overexpression of miR-26a in A549 cells inhibited G1-S transition, increased cell death in response to CDDP treatment, and decreased the colony formation of A549 cells.
genetics_overexpression_suppress	hsa-mir-27b	Carcinoma, Lung, Non-Small-Cell	28081743			C34.90	D002289		HP:0030358	Overexpression of MicroRNA-27b Inhibits Proliferation, Migration, and Invasion via Suppression of MET Expression.
genetics_overexpression_suppress	hsa-mir-320	Carcinoma, Lung, Non-Small-Cell	27277534			C34.90	D002289		HP:0030358	miR鈥?20 inhibited cell growth, migration and invasion in NSCLC cells.
genetics_overexpression_suppress	hsa-mir-338	Carcinoma, Lung, Non-Small-Cell	27453416			C34.90	D002289		HP:0030358	Forced expression of miR-338-3p in A549 cells led to the suppression of migration/invasion capacity and inhibition of epithelial markers.
genetics_overexpression_suppress	hsa-mir-452	Carcinoma, Lung, Non-Small-Cell	26718215			C34.90	D002289		HP:0030358	xpression of miR-452 via adenoviral (Ad) vector inhibits the proliferation, invasion, and migration of NSCLC cells A549 or H460.
genetics_overexpression_suppress	hsa-mir-541	Carcinoma, Lung, Non-Small-Cell	27448300			C34.90	D002289		HP:0030358	We found that expression of miR-541-3p was decreased obviously in NSCLC tissues and plasma. Down-regulation of miR-541-3p was associated with TNM stage and postoperative survival.
genetics_overexpression_suppress	hsa-mir-34b	Carcinoma, Lung, Non-Small-Cell	22593438			C34.90	D002289		HP:0030358	Overexpression of miR-34b significantly reduced cell survival at lower than 4 Gy radiation doses.
genetics_overexpression_suppress	hsa-let-7a	Carcinoma, Nasopharyngeal	25884389	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	synthetic let-7a mimics suppressed NPC cells migration, invasion and EMT process and knockdown of HMGA2 was consistent with the effects of let-7a in NPC cells.
genetics_overexpression_suppress	hsa-mir-156a	Carcinoma, Nasopharyngeal	27341697	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	synthetic miR156a mimic inhibited the EMT of NPC cells in vitro.
genetics_overexpression_suppress	hsa-mir-15a	Carcinoma, Nasopharyngeal	27458095	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	As a result, miR-15a overexpression significantly reduced cell proliferation (p鈥?鈥?.01 or p鈥?鈥?.001) and induced cell apoptosis (p鈥?鈥?.001), while miR-15a suppression got the opposite result for cell proliferation and apoptosis.
genetics_overexpression_suppress	hsa-mir-16	Carcinoma, Nasopharyngeal	26383521	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	we identified upregulation of tumor suppressor miR-16a, which inhibited cell cycle progression and sensitized NPC cells to chemotherapy.
genetics_overexpression_suppress	hsa-mir-16	Carcinoma, Nasopharyngeal	26655091	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Ectopic expression of miR-16 suppressed NPC cell proliferation, migration, and invasion in vitro and inhibited tumor growth and metastatic colonization in the lung in vivo.
genetics_overexpression_suppress	hsa-mir-183	Carcinoma, Nasopharyngeal	28631568	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-183 overexpression inhibits tumorigenesis and enhances DDP-induced cytotoxicity by targeting MTA1 in nasopharyngeal carcinoma.
genetics_overexpression_suppress	hsa-mir-183	Carcinoma, Nasopharyngeal	27431799	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Using transient or stable transfection, we showed that ectopic expression of miR-96 and miR-183 suppressed cell growth and tumor sphere formation in NPC.
genetics_overexpression_suppress	hsa-mir-24	Carcinoma, Nasopharyngeal	26922862	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	cell proliferation was  suppressed and radiosensitivity increased when miR-24 was ectopically expressed in NPC cells.
genetics_overexpression_suppress	hsa-mir-320b	Carcinoma, Nasopharyngeal	27428374	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Further studies showed that overexpression of miR-320b suppressed NPC cell proliferation and enhanced mitochondrial fragmentation and apoptosis both in vitro and in vivo, while silencing of miR-320b promoted tumor growth and suppressed apoptosis.
genetics_overexpression_suppress	hsa-mir-96	Carcinoma, Nasopharyngeal	27431799	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Using transient or stable transfection, we showed that ectopic expression of miR-96 and miR-183 suppressed cell growth and tumor sphere formation in NPC.
genetics_overexpression_suppress	hsa-mir-148a	Carcinoma, Ovarian	27470550	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Moreover, cell experiments confirmed that miR-148a could inhibit proliferation, migration and invasion of ovarian cancer cells.
genetics_overexpression_suppress	hsa-mir-17	Carcinoma, Ovarian	27499367	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Forced expression of miR-17 led to  markedly diminished adhesion and invasion of ovarian cancer cells in vitro, and notably reduced metastatic nodules inside the peritoneal cavity in in vivo SKOV3  xenografts model.
genetics_overexpression_suppress	hsa-mir-30a	Carcinoma, Ovarian	26675258	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Overexpression of miR-30a decreased Akt and mitogen activated protein kinase signaling pathway activation, cell proliferation, invasion, plasticity, EMT marker levels, and vascular endothelial growth factor release.
genetics_overexpression_suppress	hsa-mir-494	Carcinoma, Ovarian	26695144	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	overexpression of miR-494 in EOC cells  could remarkably inhibit proliferation, colony formation, migration, and invasion and induce cell apoptosis, G0/G1 phase arrest.
genetics_overexpression_suppress	hsa-mir-497	Carcinoma, Ovarian	27513319	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Overexpression of microRNA-497 suppresses cell proliferation and induces apoptosis through targeting paired box 2 in human ovarian cancer.
genetics_overexpression_suppress	hsa-mir-210	Carcinoma, Pancreatic	27940128			C25.3	C562463	260350	HP:0002894	microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer.
genetics_overexpression_suppress	hsa-mir-132	Carcinoma, Prostate	27527117	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Notably, overexpression of miR-132/212 could inhibit TGF-β (transforming growth factor-β)-induced EMT in Vcap and Lncap cells at both the mRNA and protein expression levels.
genetics_overexpression_suppress	hsa-mir-212	Carcinoma, Prostate	27527117	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Notably, overexpression of miR-132/212 could inhibit TGF-β (transforming growth factor-β)-induced EMT in Vcap and Lncap cells at both the mRNA and protein expression levels.
genetics_overexpression_suppress	hsa-let-7d	Carcinoma, Renal Cell	25193015	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Functional studies indicated that ectopic expression of let-7d significantly inhibited RCC cell proliferation, migration, and peripheral  blood monocyte (PBMC) recruitment in vitro, as well as tumor growth, metastasis,  and tumor macrophage infiltration in vivo.
genetics_overexpression_suppress	hsa-mir-184	Carcinoma, Renal Cell	25667660	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our studies revealed that miR-184 mimic significantly inhibits cell migration, suppresses cell proliferation and induces renal cancer cell apoptosis in vitro when compared with the negative control (P<0.05).
genetics_overexpression_suppress	hsa-mir-184	Carcinoma, Renal Cell	27431728	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Overexpression of pre-miR-184 changed the metabolic and proliferation features of ccRCC cells by reducing cell glucose consumption, lactate production and cell proliferation.
genetics_overexpression_suppress	hsa-mir-196a	Carcinoma, Renal Cell	27175581	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR鈥?96a suppressed cell proliferation, apoptosis and migration of the 786鈥慜 and ACHN RCC cell lines.
genetics_overexpression_suppress	hsa-mir-205	Carcinoma, Renal Cell	27498834	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	It  was revealed that miR鈥?05 promoted the apoptosis of RCC cells and suppressed their proliferation, metastasis and invasion compared with the negative control.
genetics_overexpression_suppress	hsa-mir-218	Carcinoma, Renal Cell	27314976	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	cell proliferation was suppressed in miR鈥?18 mimic鈥憈ransfected RCC cells compared with control cells
genetics_overexpression_suppress	hsa-mir-27a	Carcinoma, Renal Cell	27313769	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	upregulated miR-27a attenuated RCC tumor growth in the tumor xenograft animal model
genetics_overexpression_suppress	hsa-mir-34a	Carcinoma, Renal Cell	24765202	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The Cell Counting Kit-8 identified that transient forced expression of miR-34a inhibited cell growth and  resulted in cell cycle arrest, which was evaluated by flow cytometry.
genetics_overexpression_suppress	hsa-mir-451	Carcinoma, Renal Cell	26884830	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNA-451 inhibited proliferation, migration and invasion of renal cell carcinomas cells.
genetics_overexpression_suppress	hsa-mir-141	Carcinoma, Renal Cell, Clear-Cell	27336447	disease of cellular proliferation	DOID:4467				HP:0006770	a tumor suppressive effect of miR-141-3p and miR-145-5p by decreasing migration and invasion of RCC cells could be shown.
genetics_overexpression_suppress	hsa-mir-145	Carcinoma, Renal Cell, Clear-Cell	27336447	disease of cellular proliferation	DOID:4467				HP:0006770	a tumor suppressive effect of miR-141-3p and miR-145-5p by decreasing migration and invasion of RCC cells could be shown.
genetics_overexpression_suppress	hsa-mir-182	Carcinoma, Renal Cell, Clear-Cell	27468875	disease of cellular proliferation	DOID:4467				HP:0006770	Compared to the control group, cell viability, colony-forming ability, and numbers of migrated and invaded cells were significantly decreased by transfection with miR-182 mimic but were markedly increased by miR-182 inhibitor  (all P < 0.05).
genetics_overexpression_suppress	hsa-mir-206	Carcinoma, Renal Cell, Clear-Cell	26718123	disease of cellular proliferation	DOID:4467				HP:0006770	upregulation of miR-206 inhibited renal cancer cell proliferation, invasion and migration
genetics_overexpression_suppress	hsa-let-7	Carcinoma, Salivary Adenoid Cystic	27042128	disease of cellular proliferation	DOID:4866	C08.9	D003528			the overexpression of miR-98 in ACC-M cells inhibited cell proliferation, invasion, and migration in vitro.
genetics_overexpression_suppress	hsa-mir-205	Carcinoma, Skin	26527515	disease of cellular proliferation	DOID:3451	D04.9	D018280		HP:0008069	Ectopic expression of miR-205-5p in spindle cancer cells reduces Rap1a, mitigates cell invasiveness, decreases proliferation, and delays tumor onset.
genetics_overexpression_suppress	hsa-mir-29a	Carcinoma, Thyroid, Papillary	26482618	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	overexpression of miR-29a markedly suppressed PTC cell proliferation, migration, and invasion and promoted PTC apoptosis and cell cycle  arrest at G0/G1 phase.
genetics_overexpression_suppress	hsa-mir-30a	Carcinoma, Urothelial	26775686	disease of cellular proliferation	DOID:4006				HP:0030409	Both miR-30a and small interfering RNA Notch1 negatively  regulated cell proliferation
genetics_overexpression_suppress	hsa-mir-1	Cardiomegaly	26638879			I51.7	D006332		HP:0001640	miRNA-1 overexpression prevented cardiomyocyte hypertrophy.
genetics_overexpression_suppress	hsa-mir-181a	Cardiomegaly	27221738			I51.7	D006332		HP:0001640	Over-expression of miR-30c or miR-181a decreased expression of p53, p21, ANP, cardiomyocyte cell size, and apoptosis in HG-treated cardiomyocytes.
genetics_overexpression_suppress	hsa-mir-1	Cardiomyopathy, Hypertrophic	26699910	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-1 mimic, in parallel to CDK6 siRNA, could inhibit PE-induced hypertrophy of NRVCs, with decreases in cell size
genetics_overexpression_suppress	hsa-mir-133a	Cardiomyopathy, Hypertrophic	26403739	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-133a is an important regulator of phenylephrine-induced cardiomyocyte hypertrophy and negatively regulates this process.
genetics_overexpression_suppress	hsa-mir-218	Cardiomyopathy, Hypertrophic	27258257	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Overexpression of miR-218 is sufficient to reduce hypertrophy
genetics_overexpression_suppress	hsa-mir-200a	Cardiomyopathy, Ischemic	27573160			I25.5				Overexpression of miR-200a protects cardiomyocytes against hypoxia-induced apoptosis by modulating the kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 signaling axis.
genetics_overexpression_suppress	hsa-mir-124	Cardiovascular Diseases [unspecific]	28849090				D002318			Overexpressed microRNA-506 and microRNA-124 alleviate H2O2-induced human cardiomyocyte dysfunction by targeting krüppel-like factor 4/5.
genetics_overexpression_suppress	hsa-mir-138	Cardiovascular Diseases [unspecific]	26129883				D002318			over-expression of miR-138 significantly enhanced the cell growth and significantly attenuated the cell apoptosis in hypoxic conditions.
genetics_overexpression_suppress	hsa-mir-19b	Cardiovascular Diseases [unspecific]	23443808				D002318			Overexpression of miR-19b inhibited activation of the Wnt/β-catenin signaling pathway in P19 cells, which may regulate cardiomyocyte differentiation.
genetics_overexpression_suppress	hsa-mir-27b	Cardiovascular Diseases [unspecific]	26161255				D002318			miR-27b mimic had overall beneficial effects
genetics_overexpression_suppress	hsa-mir-506	Cardiovascular Diseases [unspecific]	28849090				D002318			Overexpressed microRNA-506 and microRNA-124 alleviate H2O2-induced human cardiomyocyte dysfunction by targeting krüppel-like factor 4/5.
genetics_overexpression_suppress	hsa-mir-99a	Cardiovascular Diseases [unspecific]	26914935				D002318			Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy.
genetics_overexpression_suppress	hsa-mir-210	Cerebral Ischemia	25783636	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	Rats treated with VNS showed increased miR-210 expression as well as decreased apoptosis and antioxidant stress responses compared with the I/R group
genetics_overexpression_suppress	hsa-mir-24	Cerebral Ischemia	27349868	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	miR-24 overexpression or silencing of neurocan shows an antihypoxic effect in SH-SY5Y cells.
genetics_overexpression_suppress	hsa-mir-155	Cerebral Malaria	25189739	disease by infectious agent	DOID:14069	B50.0	D016779			AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites.
genetics_overexpression_suppress	hsa-mir-10b	Cervical Neoplasms	27296950	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	overexpression of miR-10b in cervical cancer cells could inhibit the cell proliferation and invasion
genetics_overexpression_suppress	hsa-mir-146b	Cervical Neoplasms	25572123	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR鈥?46b鈥?p was able to inhibit the proliferative, invasive and adhesive potential and block the cell cycle progression of Caski human cervical cancer cells
genetics_overexpression_suppress	hsa-mir-152	Cervical Neoplasms	26515145	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Overexpression of miR-152 repressed WNT1 and ERBB3 expression and decreased proliferation of HeLa cells.
genetics_overexpression_suppress	hsa-mir-195	Cervical Neoplasms	26622903	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The expression of miR-195 mimics in the cervical cancer HeLa cell line significantly decreased the cell proliferation, migration and invasion capacities in vitro.
genetics_overexpression_suppress	hsa-mir-195	Cervical Neoplasms	26631043	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	overexpression of miR-195 played a suppressor role in the proliferation of HeLa and SiHa cells and promoted cell apoptosis.
genetics_overexpression_suppress	hsa-mir-320	Cervical Neoplasms	26753959	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR-320 induces apoptosis via down-regulation of Mcl-1 and activation of caspase-3 but inhibits cell proliferation, migration, invasion, and tumorigenesis in cervical cancer cells.
genetics_overexpression_suppress	hsa-mir-328	Cervical Neoplasms	27181358	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Enforced expression of miR-328 led to a decline in the expression of endogenous TCF7L2 in cervical cancer cells.
genetics_overexpression_suppress	hsa-mir-376c	Cervical Neoplasms	27345009	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Upregulation of miR-376c impaired cell proliferation, blocked G1/S checkpoint of cell cycle and suppressed cell invasion in vitro.
genetics_overexpression_suppress	hsa-mir-429	Cervical Neoplasms	27133071	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR-429 over-expression and inhibition on cell elongation, migration, stress fiber formation, and invasion.
genetics_overexpression_suppress	hsa-mir-634	Cervical Neoplasms	26367112	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR-634 inhibited cell proliferation, migration and invasiveness in cervical cancer cells and the block of miR-634 enhances the mTOR expression at both the mRNA and protein levels which regulated  the expression of mTOR negatively.
genetics_overexpression_suppress	hsa-mir-744	Cervical Neoplasms	27261616	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	up-regulation of miR-744 and down-regulation of Bcl-2 could stimulate Caspase-3 expression, promoting apoptosis of cervical cancer cells.
genetics_overexpression_suppress	hsa-mir-122	Cholangiocarcinoma	27472451	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-122 overexpression reduced cell invasion and migration ability, and inhibited cell apoptosis and p53 expression. Inhibiting miR-122 caused the opposite results.
genetics_overexpression_suppress	hsa-mir-125b	Cholangiocarcinoma	26455324	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	We also found that enforced expression of let-7c, miR-99a or miR-125b could reduce the activity of STAT3 and further suppress CCA tumorigenicity in vivo and inhibit the migration and invasion of CCA cells in vitro.
genetics_overexpression_suppress	hsa-mir-218	Chronic Obstructive Pulmonary Disease	27409149	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Perturbation experiments with a miR-218-5p mimic or inhibitor demonstrated a protective role of miR-218-5p in cigarette smoke-induced inflammation and COPD.
genetics_overexpression_suppress	hsa-mir-132	Chronic Pain	27349406			G89.29	D059350		HP:0012532	Spinal administration of miR-132-3p antagonists via intrathecal (i.t.)  catheters dose dependently reversed mechanical allodyina (p<0.001) and eliminated pain behavior
genetics_overexpression_suppress	hsa-mir-125a	Colon Neoplasms	26297542			D12.6	D003110		HP:0100273	overexpression of miR-125a-5p inhibited cell proliferation and induced cell apoptosis in colon cancer cells.
genetics_overexpression_suppress	hsa-mir-143	Colon Neoplasms	22362069			D12.6	D003110		HP:0100273	Overexpression of three miRNA (miR200c*, miR143*, and miR424*) significantly abrogated invasive potential.
genetics_overexpression_suppress	hsa-mir-195	Colon Neoplasms	27347317			D12.6	D003110		HP:0100273	Overexpression of miR-195-5p inhibited cellular growth, suppressed cellular migration and invasion, and led to cell cycle arrest at G1 phase in vitro.
genetics_overexpression_suppress	hsa-mir-200c	Colon Neoplasms	22362069			D12.6	D003110		HP:0100273	Overexpression of three miRNA (miR200c*, miR143*, and miR424*) significantly abrogated invasive potential.
genetics_overexpression_suppress	hsa-mir-205	Colon Neoplasms	27283988			D12.6	D003110		HP:0100273	miR-205 decreases cell proliferation and  decreases migratory and invasive potential of colon cancer cells
genetics_overexpression_suppress	hsa-mir-424	Colon Neoplasms	22362069			D12.6	D003110		HP:0100273	Overexpression of three miRNA (miR200c*, miR143*, and miR424*) significantly abrogated invasive potential.
genetics_overexpression_suppress	hsa-mir-1	Colorectal Carcinoma	26980745	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The ectopic expression of these miRs induced growth suppression and autophagic cell death
genetics_overexpression_suppress	hsa-mir-149	Colorectal Carcinoma	27415661	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Re-expression of miR-149 could enhance the 5-FU sensitivity of 5-FU-resistant CRC cells by increasing 5-FU-inducing apoptosis, while downregulation of miR-149 could decrease the 5-FU sensitivity of parental CRC cells by decreasing 5-FU-inducing apoptosis
genetics_overexpression_suppress	hsa-mir-152	Colorectal Carcinoma	26820128	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		restoring the expression of miR-152 in CRC cells dramatically reduced the cell proliferation and cell migration and invasion and promoted apoptosis
genetics_overexpression_suppress	hsa-mir-195	Colorectal Carcinoma	26064276	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		has-miR-195 can promote cell apoptosis and inhibit the invasion and metastasis by inhibiting the expression of Bcl-2.
genetics_overexpression_suppress	hsa-mir-199b	Colorectal Carcinoma	27145368	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		restoration of miR-199b considerably reduced cell invasion and migration in vitro and in vivo
genetics_overexpression_suppress	hsa-mir-19a	Colorectal Carcinoma	29207158	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression
genetics_overexpression_suppress	hsa-mir-210	Colorectal Carcinoma	27293381	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-210 mediated the induction of apoptosis
genetics_overexpression_suppress	hsa-mir-33b	Colorectal Carcinoma	26329295	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-33b inhibited tumor cell growth and induced cell cycle arrest.
genetics_overexpression_suppress	hsa-mir-34a	Colorectal Carcinoma	27456356	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While forced expression of miR-34a in CaCx and CRC cells inhibited HMGB1 mRNA and protein levels, proliferation, migration and invasion, inhibition of endogenous miR-34a enhanced these tumourigenic properties.
genetics_overexpression_suppress	hsa-mir-375	Colorectal Carcinoma	27222350	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-375 inhibited proliferation, invasion and migration in DLD1 and HCT8 cells.
genetics_overexpression_suppress	hsa-mir-382	Colorectal Carcinoma	26800338	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Transfection with miR-382 mimics impeded the growth, migration, and invasion of CRC cells.
genetics_overexpression_suppress	hsa-mir-486	Colorectal Carcinoma	27284245	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		overexpression of miR-486-5p inhibited the tumor growth and lymphangiogenesis in nude mice
genetics_overexpression_suppress	hsa-mir-490	Colorectal Carcinoma	27037061	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-490-3p suppresses cancer cell proliferation by inducing apoptosis
genetics_overexpression_suppress	hsa-mir-874	Colorectal Carcinoma	27221209	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		expression of miR-874 was downregulated in CRC tissues and cell lines
genetics_overexpression_suppress	hsa-let-7a-1	Colorectal Carcinoma	22584434	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
genetics_overexpression_suppress	hsa-let-7a-2	Colorectal Carcinoma	22584434	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
genetics_overexpression_suppress	hsa-let-7a-3	Colorectal Carcinoma	22584434	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
genetics_overexpression_suppress	hsa-mir-10a	Congenital Diaphragmatic Hernia	25563880	musculoskeletal system disease	DOID:3827	Q79.0	D006548	142340	HP:0000776	Human fetal hypoplastic CDH lungs have a specific miR-200/miR-10a signature. Survival after FETO is associated with increased miR-200 family expression. miR-200b overexpression in CDH lungs results in decreased TGF-β/SMAD  signaling.
genetics_overexpression_suppress	hsa-mir-200	Congenital Diaphragmatic Hernia	25563880	musculoskeletal system disease	DOID:3827	Q79.0	D006548	142340	HP:0000776	Human fetal hypoplastic CDH lungs have a specific miR-200/miR-10a signature. Survival after FETO is associated with increased miR-200 family expression. miR-200b overexpression in CDH lungs results in decreased TGF-β/SMAD  signaling.
genetics_overexpression_suppress	hsa-mir-200b	Congenital Diaphragmatic Hernia	25563880	musculoskeletal system disease	DOID:3827	Q79.0	D006548	142340	HP:0000776	Human fetal hypoplastic CDH lungs have a specific miR-200/miR-10a signature. Survival after FETO is associated with increased miR-200 family expression. miR-200b overexpression in CDH lungs results in decreased TGF-β/SMAD  signaling.
genetics_overexpression_suppress	hsa-mir-138	Coronary Artery Disease	28371277	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Overexpression of microRNA-138 alleviates human coronary artery endothelial cell injury and inflammatory response by inhibiting the PI3K/Akt/eNOS pathway.
genetics_overexpression_suppress	hsa-mir-330	Cutaneous Melanoma	27363653	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Enforced expression of miR-330-5p inhibits malignant CMM cells proliferation and migration and led to downregulation of the TYR and PDIA3 protein.
genetics_overexpression_suppress	hsa-mir-15a	Diabetes Mellitus	27531575	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-15a overexpression led to modulation toward nondiabetic levels, rather than complete inhibition of ASM and VEGF-A providing therapeutic effect without detrimental consequences of ASM and VEGF-A deficiencies
genetics_overexpression_suppress	hsa-mir-29a	Diabetes Mellitus	24578127	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Diabetic miR-29a transgenic mice had better nephrin levels, podocyte viability, and renal  function and less glomerular fibrosis and inflammation reaction compared with diabetic wild-type mice.
genetics_overexpression_suppress	hsa-let-7a	Diabetes Mellitus, Type 2	24105413	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Expression of microRNA let-7a and let-7d, which are direct translational repressors of the IL-13 gene, was increased in skeletal muscle from T2DM patients. 
genetics_overexpression_suppress	hsa-mir-26a	Diabetes Mellitus, Type 2	26208605	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Mir-26a suppresses autoimmune diabetes in NOD mice in part through promoted regulatory T cells (Tregs) expression.
genetics_overexpression_suppress	hsa-mir-34c	Diabetic Nephropathy	26191142			E10-11.21	D003928			miR-34c was downregulated and that overexpression of miR-34c inhibited HG-induced podocyte apoptosis.
genetics_overexpression_suppress	hsa-mir-15a	Diabetic Retinopathy	27531575	nervous system disease	DOID:8947	E10-11.31	D003930			Over-expression of miR-15a downregulated, and inhibition of miR-15a upregulated ASM and VEGF-A expression in retinal cells.
genetics_overexpression_suppress	hsa-mir-27a	Endometrial Neoplasms	26934121	reproductive system disease	DOID:1380	C54.1	D016889	608089		Enforced expression of miR-124 suppresses EC cell invasion and proliferation.
genetics_overexpression_suppress	hsa-let-7	Endometriosis	27320036	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	increased let-7f expression effectively reduced the migration of endometrial cells.
genetics_overexpression_suppress	hsa-let-7f	Endometriosis	27320036	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	increased let-7f expression effectively reduced the migration of endometrial cells.
genetics_overexpression_suppress	hsa-mir-200b	Endometriosis	26854065	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	up-regulation of miR-200b reverts EMT, emerging as a potential therapeutic approach to inhibit endometriotic cell motility and invasiveness.
genetics_overexpression_suppress	hsa-mir-29a	Endomyocardial Fibrosis	27060017	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	over-expression of miRNA-29a suppresses cardiac fibroblasts proliferation.
genetics_overexpression_suppress	hsa-let-7a-1	Esophageal Neoplasms	22363450			C15.9	D004938	133239	HP:0100751	Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA.
genetics_overexpression_suppress	hsa-let-7a-2	Esophageal Neoplasms	22363450			C15.9	D004938	133239	HP:0100751	Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA.
genetics_overexpression_suppress	hsa-let-7a-3	Esophageal Neoplasms	22363450			C15.9	D004938	133239	HP:0100751	Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA.
genetics_overexpression_suppress	hsa-let-7a	Ewing Sarcoma	24383407	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	Restored let-7a expression inhibited cell proliferation, migration, as well as invasion; arrested cell cycle progression; and induced cell apoptosis of both cell lines.
genetics_overexpression_suppress	hsa-mir-203	Fatty Liver, Alcoholic	29670525			K70.0	D005235			over-expression of miR-203 inhibited the liver lipids accumulation and the progression of AFL by targeting Lipin1
genetics_overexpression_suppress	hsa-mir-26a	Fatty Liver, Non-Alcoholic	27377869	disease of metabolism	DOID:0080208	K75.81	D065626	613282		LV-26a-infected mice were protected from glucose dysmetabolism and showed markedly decreased total liver weight
genetics_overexpression_suppress	hsa-let-7	Gastric Neoplasms	25549793	disease of cellular proliferation	DOID:10534	C16	D013274	137215		There were significant negative correlations between serum let-7c and its target gene PGC expression
genetics_overexpression_suppress	hsa-let-7	Gastric Neoplasms	26745603	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpression of miR-let-7a markedly suppressed the proliferation, migration, and invasion of GC cells by down-regulating the expression of PKM2.
genetics_overexpression_suppress	hsa-let-7b	Gastric Neoplasms	25510669	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Ectopic expression of let-7b suppressed the growth, migration, invasion, and tumorigenicity of GC cells, whereas let-7b knockdown promoted these phenotypes.
genetics_overexpression_suppress	hsa-mir-133b	Gastric Neoplasms	24443799	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells.
genetics_overexpression_suppress	hsa-mir-137	Gastric Neoplasms	26840256	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-9 and miR-137 downregulated the CUL4A-LATS1-Hippo signaling pathway and suppressed GC cell proliferation and invasion in vitro.
genetics_overexpression_suppress	hsa-mir-140	Gastric Neoplasms	27353653	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-140 overexpression inhibited HGC-27 cell viability and colony formation and resulted in G0/G1 arrest.
genetics_overexpression_suppress	hsa-mir-142	Gastric Neoplasms	23209550	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication
genetics_overexpression_suppress	hsa-mir-155	Gastric Neoplasms	23209550	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication
genetics_overexpression_suppress	hsa-mir-15a	Gastric Neoplasms	26894855	disease of cellular proliferation	DOID:10534	C16	D013274	137215		ectopic expression of miR-15a decreased Bmi-1 in gastric cancer cell lines with reduced proliferation and tumor invasion.
genetics_overexpression_suppress	hsa-mir-27b	Gastric Neoplasms	26780940	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27b overexpression significantly inhibited H. pylori infection-induced cell proliferation and WNT signaling pathway activation in gastric cancer cells.
genetics_overexpression_suppress	hsa-mir-30a	Gastric Neoplasms	27208176	disease of cellular proliferation	DOID:10534	C16	D013274	137215		forced miR-30a over-expression in cancer cells can be  a potential way to inhibit tumour development.
genetics_overexpression_suppress	hsa-mir-34a	Gastric Neoplasms	24068565	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-34a over-expression could improve the sensitivity of gastric cancer cells against cisplatin-based chemotherapies, with PI3K/AKT/survivin signaling pathway possibly involved in the mechanism.
genetics_overexpression_suppress	hsa-mir-372	Gastric Neoplasms	26928593	disease of cellular proliferation	DOID:10534	C16	D013274	137215		inhibit proliferations of adenocarcinoma gastric cancer (AGS) cells overexpressing these miRNAs
genetics_overexpression_suppress	hsa-mir-448	Gastric Neoplasms	26852749	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Ectopic expression of miR-448 suppressed GC cell proliferation, colony formation, and invasion.
genetics_overexpression_suppress	hsa-mir-455	Gastric Neoplasms	27451075	disease of cellular proliferation	DOID:10534	C16	D013274	137215		re-expression of miR-455-5p could inhibit human GC cell proliferation and invasion, overexpression of miR-455-5p could also promote GC cell apoptosis.
genetics_overexpression_suppress	hsa-mir-488	Gastric Neoplasms	26738864	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The ectopic expression of miR-488 suppressed the GC cell proliferation, cell cycle, colony information, and migration.
genetics_overexpression_suppress	hsa-mir-9	Gastric Neoplasms	26840256	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-9 and miR-137 downregulated the CUL4A-LATS1-Hippo signaling pathway and suppressed GC cell proliferation and invasion in vitro.
genetics_overexpression_suppress	hsa-mir-93	Glaucoma	27878244	nervous system disease	DOID:1686	H40	D005901	137750		MicroRNA‑93 is overexpressed and induces apoptosis in glaucoma trabecular meshwork cells.
genetics_overexpression_suppress	hsa-mir-128	Glioblastoma	21358821				D005909		HP:0100843	Our analysis predicted a significant association between miR-128 and the protein kinase WEE1, which we subsequently validated experimentally by showing that the over-expression of the naturally under-expressed miR-128 in glioma cells resulted in the inhibition of WEE1 in glioblastoma cells.
genetics_overexpression_suppress	hsa-mir-137	Glioblastoma	27328425				D005909		HP:0100843	overexpression of miR-137 in GBM cells also inhibited cell proliferation, migration, and invasion.
genetics_overexpression_suppress	hsa-mir-145	Glioblastoma	26374689				D005909		HP:0100843	CSCs expressed low levels of miR-145, and its introduction decreased self-renewal through reductions in AKT signaling and stem cell marker (SOX2, OCT4, and NANOG) expression
genetics_overexpression_suppress	hsa-mir-146a	Glioblastoma	26916895				D005909		HP:0100843	The upregulation of miR-146a  in glioma cells through miR-146a mimic transfection led to reduction of cell viability and to an increase in the percentage of apoptosis.
genetics_overexpression_suppress	hsa-mir-154	Glioblastoma	27013470				D005909		HP:0100843	overexpression of miR-154 suppressed cell migration and invasion of U87 and U251  cells.
genetics_overexpression_suppress	hsa-mir-155	Glioblastoma	24705102				D005909		HP:0100843	Over-expression of miR-136 and miR-634 miRNAs negatively affected proliferation, but not migration, while expression of miR-155 reduced migration but did not affect the proliferation of LN229 cells.
genetics_overexpression_suppress	hsa-mir-16	Glioblastoma	26373393				D005909		HP:0100843	Overexpression of microRNA- 16 in the A172 and U87 GBM cell lines inhibited the activities of co-cultured endothelial cells, including proliferation, migration, extension and tubule formation.
genetics_overexpression_suppress	hsa-mir-203	Glioblastoma	27467502				D005909		HP:0100843	Conversely reconstitution of miR-203 expression induced apoptosis and inhibited migratory property of glioma cells.
genetics_overexpression_suppress	hsa-mir-203	Glioblastoma	27484906				D005909		HP:0100843	MicroRNA-203 transfected GBM-SCs had reduced capacity for self-renewal in the cell sphere assay and increased expression of glial and neuronal differentiation markers.
genetics_overexpression_suppress	hsa-mir-29a	Glioblastoma	25625222				D005909		HP:0100843	Exogenous miR-29s substantially inhibited the proliferation, migration and invasion of U87MG cells, and promoted their apoptosis.
genetics_overexpression_suppress	hsa-mir-29a	Glioblastoma	28212562				D005909		HP:0100843	Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6.
genetics_overexpression_suppress	hsa-mir-7-1	Glioblastoma	26573275				D005909		HP:0100843	In conclusion, our results clearly demonstrated that overexpression of miR-7-1-3p augmented the anti-tumor activities of LUT and SIL to inhibit autophagy and induce apoptosis for controlling growth of different human glioblastomas in vivo.
genetics_overexpression_suppress	hsa-let-7b	Glioma	27520092	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	upregulation of Let-7b, a member of the Let-7 microRNA family, inhibited proliferation, migration, and invasion in glioma cell lines.
genetics_overexpression_suppress	hsa-let-7f	Glioma	25735962	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The enhanced  expression of Let-7f suppressed glioma cells proliferation, migration, and invasion via direct targeting perisotin oncogenic activity.
genetics_overexpression_suppress	hsa-let-7f	Glioma	26750768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	inhibiting the pro-migratory function of POSTN by the overexpression of miR-Let-7f significantly reduced the formation of VM.
genetics_overexpression_suppress	hsa-mir-133a	Glioma	27154818	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Transfection of miR-150-5p or miR-133a mimics into glioma cell lines reduced MT1-MMP expression and MMP-2 activation by  these cells, and cell proliferation and invasion/migration were also suppressed by it.
genetics_overexpression_suppress	hsa-mir-134	Glioma	27012554	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	upregulated miR-134 expression restrained the proliferation and invasion of U251  cells in vitro.
genetics_overexpression_suppress	hsa-mir-140	Glioma	27498787	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Restoration of miR-140 obviously suppressed glioma cell proliferation, migration and invasion.
genetics_overexpression_suppress	hsa-mir-150	Glioma	27154818	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Transfection of miR-150-5p or miR-133a mimics into glioma cell lines reduced MT1-MMP expression and MMP-2 activation by  these cells, and cell proliferation and invasion/migration were also suppressed by it.
genetics_overexpression_suppress	hsa-mir-153	Glioma	27295037	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Exogenous overexpression  of miR-153 downregulated Rictor (mRNA and protein) and decreased p-Akt Ser473 in  U87MG cells, leading to significant growth inhibition and apoptosis activation.
genetics_overexpression_suppress	hsa-mir-15b	Glioma	27082313	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Furthermore, miR鈥?5b inhibited proliferation and invasion,  and promoted apoptosis of glioma cells while downregulating the expression of MMP鈥? and MMP鈥?.
genetics_overexpression_suppress	hsa-mir-16	Glioma	25511497	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-16 can significantly inhibit the in vivo growth of U87MG glioma.
genetics_overexpression_suppress	hsa-mir-182	Glioma	26622652	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	overexpression of miR-182 affected cell cycle regulation and cell migration capacity in vitro, which may have been associated with the promotion of apoptosis by this molecule.
genetics_overexpression_suppress	hsa-mir-34a	Glioma	24944883	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Ectopic expression of miR-34a in glioma stem cell-lines HNGC-2 and NSG-K16 decreased the proliferative and migratory potential of these cells, induced cell cycle arrest and caused apoptosis.
genetics_overexpression_suppress	hsa-mir-34a	Glioma	27176117	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Overexpression of miR鈥?4a inhibited proliferation, and induced apoptosis of U87 cells.
genetics_overexpression_suppress	hsa-mir-370	Glioma	27138069	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Overexpression of miR-370-3p showed a significant inhibitory effect on cell proliferation and accompanied cell cycle G0/G1 arrest in U251 and U87-MG cells.
genetics_overexpression_suppress	hsa-mir-373	Glioma	26858153	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	although miR-373 does not affect cell growth of U251, it inhibits migration and invasion of U251.
genetics_overexpression_suppress	hsa-mir-451	Glioma	27476171	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	By targeting CAB 39, miRNA-451 likely triggers the LKB1/AMPK/PI3K/AKT pathway, which regulates GLUT1, to inhibit the glucose metabolism of, reduce the energy supply to, and inhibit the proliferation and invasion of glioma cells.
genetics_overexpression_suppress	hsa-mir-495	Glioma	27220777	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	restoration of hsa-miR-495 inhibited glioma cell proliferation and invasion in vitro.
genetics_overexpression_suppress	hsa-mir-508	Glioma	27003587	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	over-expression of miR-508-5p was found to decrease glioma  cell growth.
genetics_overexpression_suppress	hsa-mir-610	Glioma	27485527	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Furthermore, the present study revealed that miR鈥?10 inhibited cell growth, migration and invasion in glioma cells.
genetics_overexpression_suppress	hsa-mir-26a	Graft-Versus-Host Disease	25865461			D89.813	D006086	614395		The prolonged allograft survival induced by LV-Mir-26a was also completely abrogated by IL-6 overexpression.
genetics_overexpression_suppress	hsa-mir-29b	Granular Corneal Dystrophy	27490049	nervous system disease	DOID:12318	H18.53	D003317	121900	HP:0007802	Overexpression of miR-29b decreased ECM protein production in human  corneal endothelial cells.
genetics_overexpression_suppress	hsa-mir-363	Head And Neck Neoplasms	26545583	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	These findings demonstrate that the overexpression of miR-363 reduces cellular migration in head and neck cancer and reveal the biological relationship between miR-363, myosin 1b, and HPV-positive SCCHN.
genetics_overexpression_suppress	hsa-mir-1	Heart Diseases [unspecific]	27531746			I51.9	D006333			We also found that microRNAs (miRNAs) 1 and 21 bind PLN strongly and relieve PLN inhibition of SERCA to a greater extent than a similar length random sequence RNA mixture.
genetics_overexpression_suppress	hsa-mir-133a	Heart Diseases [unspecific]	27411382			I51.9	D006333			Our results revealed that miR-133a mimic treatment improved the contractility of the diabetic rat's heart concomitant with upregulation of TH, cardiac NE, 尾-AR, and downregulation of TAT  and plasma levels of NE.
genetics_overexpression_suppress	hsa-mir-21	Heart Diseases [unspecific]	27531746			I51.9	D006333			We also found that microRNAs (miRNAs) 1 and 21 bind PLN strongly and relieve PLN inhibition of SERCA to a greater extent than a similar length random sequence RNA mixture.
genetics_overexpression_suppress	hsa-mir-1	Heart Failure	28063219			I50	D006331		HP:0001635	MicroRNA-1 overexpression blunts cardiomyocyte hypertrophy elicited by thyroid hormone.
genetics_overexpression_suppress	hsa-mir-132	Heart Failure	29682535			I50	D006331		HP:0001635	Overexpression of microRNA-132 dramatically increased the antioxidant stress and antiapoptotic ability of H9C2 cells and decreased the expression of TGF-β1 and smad3
genetics_overexpression_suppress	hsa-mir-133a	Heart Failure	25658461			I50	D006331		HP:0001635	transfecting MSCs with miR-133a mimic improves survival of MSCs as determined by  the MTT assay.
genetics_overexpression_suppress	hsa-mir-133a	Heart Failure	25960234			I50	D006331		HP:0001635	The miR-133a mimic and miR-133a overexpression significantly caused a decrease in the fibrosis of heart in chronic heart failure rats.
genetics_overexpression_suppress	hsa-mir-24	Heart Failure	24454859			I50	D006331		HP:0001635	In vivo delivery of miR-24 into a mouse MI model suppressed cardiac cell death, attenuated infarct size, and rescued cardiac dysfunction.
genetics_overexpression_suppress	hsa-mir-499	Heart Failure	24646523			I50	D006331		HP:0001635	We report that cardiac-abundant miR-499 could protect neonatal rat cardiomyocytes against H 2O 2-induced apoptosis. Increased miR-499 level favored survival, while decreased miR-499 level favored apoptosis.
genetics_overexpression_suppress	hsa-mir-30a	Hepatitis B Virus Infection	25620738	disease by infectious agent	DOID:2043	B16/18	D006509	610424		HBx induces autophagosome formation via beclin-1 expression, whereas miRNA-30a overexpression could successfully inhibit the beclin-1 expression induced by HBx, thereby modulating autophagosome formation in hepatic cells.
genetics_overexpression_suppress	hsa-mir-133a	Hypertension	23460283	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	In vitro overexpression of miR-27a,-29a, and -133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. 
genetics_overexpression_suppress	hsa-mir-27a	Hypertension	23460283	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	In vitro overexpression of miR-27a,-29a, and -133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. 
genetics_overexpression_suppress	hsa-mir-29a	Hypertension	23460283	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	In vitro overexpression of miR-27a,-29a, and -133a inhibited cardiomyocyte hypertrophy and reduced collagen expression. 
genetics_overexpression_suppress	hsa-mir-200b	Hypertrophic Scar	25228082			L91.0	D017439			Overexpression of miR-200b inhibits the cell proliferation and promotes apoptosis of human hypertrophic scar fibroblasts in vitro.
genetics_overexpression_suppress	hsa-let-7a-1	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7a-2	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7a-3	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7b	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7c	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7d	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7e	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7f-1	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7f-2	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7g	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-let-7i	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-mir-98	Hypertrophy	21183740				D006984			Thioredoxin 1 Negatively Regulates Angiotensin II-Induced Cardiac Hypertrophy Through Upregulation of miR-98/let-7.
genetics_overexpression_suppress	hsa-mir-19a	Hypoxia	27220268				D000860			miR-19a overexpression clearly ameliorated hypoxia-induced cell death (necrosis and apoptosis)
genetics_overexpression_suppress	hsa-mir-210	Hypoxia	26780211				D000860			miR-210 upregulation exerted amelioration on the hypoxia-induced apoptosis
genetics_overexpression_suppress	hsa-mir-185	Idiopathic Pulmonary Fibrosis	27392970	respiratory system disease	DOID:0050156	J84.112	D054990	178500		Furthermore, mimics of miR-185 and miR-186 blocked transforming growth factor-尾-induced collagen V overexpression and alleviated transforming growth factor-尾-induced epithelial-mesenchymal transition in A549 cells and HCC827 cells.
genetics_overexpression_suppress	hsa-mir-186	Idiopathic Pulmonary Fibrosis	27392970	respiratory system disease	DOID:0050156	J84.112	D054990	178500		Our findings suggest that attenuated expression of miR-185 and miR-186 may be responsible for collagen V overexpression during idiopathic pulmonary fibrosis, and these miRNAs may serve as pathogenesis-related biomarkers and treatment targets.
genetics_overexpression_suppress	hsa-mir-29a	Idiopathic Pulmonary Fibrosis	27488440	respiratory system disease	DOID:0050156	J84.112	D054990	178500		Restoration of miR-29a suppressed cancer cell aggressiveness and fibroblast migration.
genetics_overexpression_suppress	hsa-mir-21	Immune System Disease [unspecific]	25688245	immune system disease	DOID:2914	D89.9	D007154			miR-21 has emerged as a key mediator of the anti-inflammatory response in macrophages.
genetics_overexpression_suppress	hsa-mir-223	Inflammation	27148749				D007249			The overexpression of miR-223 in both J774A.1 and peritoneal macrophages induced a phenotypic change from M1 to M2 state
genetics_overexpression_suppress	hsa-mir-9	Inflammation	26354749				D007249			miR-9 overexpression significantly repressed NF-魏B expression and, thereby, suppressed  inflammation but promoted LEC tube formation
genetics_overexpression_suppress	hsa-mir-210	Intervertebral Disc Degeneration	27284319	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	downregulation of miR-210 may promote Fas-mediated apoptosis in human IDD by regulating the expression of HOXA9.
genetics_overexpression_suppress	hsa-mir-497	Invasive Bladder Transitional Cell Carcinoma	27430325	disease of cellular proliferation	DOID:6477	C67.9			HP:0006740	We also found that overexpression of miR-497 inhibited the proliferation, migration  and invasion of bladder cancer cells by downregulating E2F3 (an miR-497 target gene) mRNA and protein and that siRNA against E2F3 inhibited cell proliferation,  migration and invasion, which was similar to the effect of miR-497 overexpression in the BTCC cells.
genetics_overexpression_suppress	hsa-mir-21	Ischemia	26841045	cardiovascular system disease	DOID:326		D007511	601367		over-expressing miR-21 in UCBMSCs could improve neovascularization in CLI
genetics_overexpression_suppress	hsa-mir-146a	Ischemia-Reperfusion Injury	24987958				D015427			Overexpression of miR-146a directly decreased IRAK1 and TRAF6 expression and attenuated the release of proinflammatory cytokines through the inactivation of NF-魏B P65 in hypoxia/reoxygenation (H/R)-induced macrophages, RAW264.7 cells.
genetics_overexpression_suppress	hsa-mir-150	Ischemia-Reperfusion Injury	29328381				D015427			Overexpressing microRNA-150 attenuates hypoxia-induced human cardiomyocyte cell apoptosis by targeting glucose-regulated protein-94
genetics_overexpression_suppress	hsa-mir-204	Ischemia-Reperfusion Injury	29421577				D015427			overexpression of miR-204 has a protective effect against myocardial I/R injury
genetics_overexpression_suppress	hsa-mir-21	Ischemia-Reperfusion Injury	25322693				D015427			miR-21 is endowed with anti-apoptotic properties by suppressing the  expression of PDCD4 gene and active caspase 3/8 fragments in the condition of renal IRI.
genetics_overexpression_suppress	hsa-mir-21	Ischemia-Reperfusion Injury	27593550				D015427			Overexpression of microRNA-21 protects spinal cords against transient ischemia.
genetics_overexpression_suppress	hsa-mir-214	Ischemia-Reperfusion Injury	25593579				D015427			Transfection of miR-214 mimic showed protective effects on OGD-induced injury to H9c2 cells by reducing apoptosis
genetics_overexpression_suppress	hsa-mir-214	Ischemia-Reperfusion Injury	26025394				D015427			214 may participate in the protective function of ischemic post conditioning by down regulating HIF1AN.
genetics_overexpression_suppress	hsa-mir-214	Ischemia-Reperfusion Injury	27288437				D015427			Overexpression of the two miRs in cardiomyocytes mimics the effects of carvedilol
genetics_overexpression_suppress	hsa-mir-221	Ischemia-Reperfusion Injury	26396139				D015427			Mimics of miRNA-221, -150, and -206 were protective in both H9c2 and NRVM.
genetics_overexpression_suppress	hsa-mir-223	Ischemia-Reperfusion Injury	27502281				D015427			Precursor miR-223 (pre-miR-223) transgenic mouse hearts exhibited better recovery of contractile performance over reperfusion period and lesser degree of myocardial necrosis than wild type hearts upon ex vivo and in vivo myocardial ischemia.
genetics_overexpression_suppress	hsa-mir-26a	Ischemia-Reperfusion Injury	26320674				D015427			Mir-26a overexpression results in attenuated cardiac IR injury and inhibited HMGB1 expression.
genetics_overexpression_suppress	hsa-mir-497	Ischemia-Reperfusion Injury	27261611				D015427			miR-497 could inhibit inflammation and apoptosis of spinal cord IR through its targets
genetics_overexpression_suppress	hsa-mir-613	Ischemia-Reperfusion Injury	27534371				D015427			miR-613 inhibits I/R-induced cardiomyocyte apoptosis by targeting PDCD10 by regulating the PI3K/AKT signaling pathway
genetics_overexpression_suppress	hsa-mir-182	Ischemic Diseases [unspecific]	27008992				D007511	601367		Both exogenous miR-182 and Kenpaullone  significantly suppressed hypoxia-induced cardiomyocyte death in vitro.
genetics_overexpression_suppress	hsa-mir-210	Ischemic Diseases [unspecific]	27530798				D007511	601367		Neonatal rats show down-regulated expression of miRNA-210 after HI,  suggesting that miRNA-210 may be involved in the development and progression of hypoxic-ischemic brain edema in neonatal rats.
genetics_overexpression_suppress	hsa-let-7c	Kidney Injury	27203438			S37.0	D058186			miR-let7c-MSC therapy attenuated kidney injury
genetics_overexpression_suppress	hsa-mir-214	Kidney Neoplasms	27226530	disease of cellular proliferation	DOID:263	C64	D007680			miR-214 significantly blocked  IGF-1R-forced renal cancer cell proliferation
genetics_overexpression_suppress	hsa-mir-24	Lacrimal Adenoid Cystic Carcinoma	27351203	nervous system disease	DOID:4870	C69.51				overexpression of miR-24-3p decreased its malignant phenotype.
genetics_overexpression_suppress	hsa-mir-138	Laryngeal Neoplasms	26499780			C32.3	D007822			miR-138 overexpression inhibited ZEB2-mediated cell invasiveness, while miR-138 depletion increased ZEB2-mediated cell invasiveness in LC cells.
genetics_overexpression_suppress	hsa-mir-143	Leukemia	24626955			C95	D007938	613065	HP:0001909	Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells.
genetics_overexpression_suppress	hsa-mir-143	Leukemia	27492780			C95	D007938	613065	HP:0001909	miRNA143 transfection inhibited K562 cell growth and induced its apoptosis.
genetics_overexpression_suppress	hsa-mir-181a	Leukemia	27517749			C95	D007938	613065	HP:0001909	NP-mediated upregulation of miR-181a led to reduced proliferation, impaired colony formation and increased sensitivity to chemotherapy.
genetics_overexpression_suppress	hsa-mir-34a	Leukemia	27424989			C95	D007938	613065	HP:0001909	Induced expression of miR-34a in TIM3 positive leukemia stem cells (LSC), inhibits the clonogenic expansion, tumor progression and metastasis of leukemia.
genetics_overexpression_suppress	hsa-mir-663	Leukemia	21518471			C95	D007938	613065	HP:0001909	miRNA-663 in K562 cells is up-regulated after 5-aza treatment. Over-expression of miR-663 can suppress the proliferation of K562 cells, which suggests that miR-663 may possesses suppressive effect for leukaemia.
genetics_overexpression_suppress	hsa-mir-150	Leukemia, Lymphoblastic, Acute	25687053	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	miR-150 may be a putative oncoprotein in T-ALL cells. Overexpression of miR-150 has noticeable effects on the proliferation inhibition and apoptosis induction of Jurkat cells, which may be mediated by the negative regulation of PI3K/Akt /NF-κB signaling pathway.
genetics_overexpression_suppress	hsa-mir-10a	Leukemia, Myeloid, Acute	22348345	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated Acute Myeloid Leukaemia and its suppression induces cell death.
genetics_overexpression_suppress	hsa-mir-125b	Leukemia, Myeloid, Acute	28478034	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Overexpression of microRNA-125b inhibits human acute myeloid leukemia cells invasion, proliferation and promotes cells apoptosis by targeting NF-κB signaling pathway.
genetics_overexpression_suppress	hsa-mir-34b	Leukemia, Myeloid, Acute	27296951	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	the miR-34b mimicked transfection-mediated restoration of miR-34b inhibited cell viability and promoted cell apoptosis of HL-60 and OCI-AML3 cell lines.
genetics_overexpression_suppress	hsa-mir-101	Leukemia, Myeloid, Chronic	27517565	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	These findings suggest that miR-101 acts as a tumor suppressor by downregulating Jak2 expression and sensitizing K562 cells to imatinib.
genetics_overexpression_suppress	hsa-mir-130a	Leukemia, Myeloid, Chronic	27158382	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	over-expression of miR-130a in A562 CML cells dramatically suppresses cell proliferation and induces cell apoptosis both in vitro and in vivo.
genetics_overexpression_suppress	hsa-let-7b	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22918121	disease of cellular proliferation	DOID:5599	C83.5	D054218			The enforced expression of let-7b in ALL cell lines with an MLL fusion gene inhibited their growth.
genetics_overexpression_suppress	hsa-mir-146a	Liver Cirrhosis	27399683	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Overexpression of miR-146a-5p inhibited LPS induced pro-inflammatory cytokines secretion through down-regulating the expression levels of TLR-4, IL-1 receptor-associated kinase 1 (IRAK1), TNF receptor associated factor-6 (TRAF6) and phosphorylation of nuclear factor-kappa  B (NF-魏B).
genetics_overexpression_suppress	hsa-mir-29b	Liver Cirrhosis	27273381	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-29b overexpression inhibited proliferation of  LX-2 cells 24鈥塰 after transfection.
genetics_overexpression_suppress	hsa-mir-20a	Liver Diseases [unspecific]	27019188			K76.9	D008107			miR-20a-5p mimic could reverse high glucose-induced impaired glycogenesis and AKT/GSK activation in NCTC1469 and Hep1-6 cells.
genetics_overexpression_suppress	hsa-mir-145	Liver Fibrosis	27289031			K74	D008103			over-expression of miR-145 inhibited TGF-尾1-induced the activation and proliferation of HSC-T6 cells in vitro.
genetics_overexpression_suppress	hsa-mir-674	Liver Injury	27313091			S36.11	D056486			miR-674-5p might be a negative regulator in 5-LO mediated autoimmune liver injury
genetics_overexpression_suppress	hsa-mir-122	Liver Neoplasms	25762642	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-107, mir-122, miR-29, miR-365 and miR-802 exhibited weak to moderate tumor suppressor potential.
genetics_overexpression_suppress	hsa-mir-15b	Liver Neoplasms	26884837	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MiR-15b mimic transfection promoted miR-15b overexpression and inhibited HepG2 cell proliferation significantly
genetics_overexpression_suppress	hsa-mir-194	Liver Neoplasms	20979124	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	The overexpression of miR-194 in liver mesenchymal-like cancer cells reduced the expression of the mesenchymal cell marker N-cadherin and suppressed invasion and migration of the mesenchymal-like cancer cells both in vitro and in vivo
genetics_overexpression_suppress	hsa-mir-449a	Liver Neoplasms	26375440	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Overexpression of miR-449a inhibited cell proliferation, induced G1 phase arrest and cell apoptosis in liver cancer.
genetics_overexpression_suppress	hsa-mir-7	Liver Neoplasms	24491049	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Over-expression of miR-7 could significantly inhibit the growth of human lung cancer cells in vivo and in vitro, which might be related to the down-regulated expression of tumor growth-associated protein CGGBP1.
genetics_overexpression_suppress	hsa-mir-19a	Lung Fibrosis	26873752	respiratory system disease	DOID:3770	J84.10	D011658	178500		intratracheal application of miR-19a, -19b, and 26b reduced the pulmonary fibrotic severity induced by bleomycin
genetics_overexpression_suppress	hsa-mir-19b	Lung Fibrosis	26873752	respiratory system disease	DOID:3770	J84.10	D011658	178500		intratracheal application of miR-19a, -19b, and 26b reduced the pulmonary fibrotic severity induced by bleomycin
genetics_overexpression_suppress	hsa-mir-221	Lung Fibrosis	27513632	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR鈥?21 targets HMGA2 to inhibit bleomycin鈥慽nduced pulmonary fibrosis by regulating TGF鈥懳?/Smad3-induced EMT.
genetics_overexpression_suppress	hsa-mir-26b	Lung Fibrosis	26873752	respiratory system disease	DOID:3770	J84.10	D011658	178500		intratracheal application of miR-19a, -19b, and 26b reduced the pulmonary fibrotic severity induced by bleomycin
genetics_overexpression_suppress	hsa-mir-449a	Lung Fibrosis	27351886	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-449a significantly reduced both the distribution and severity of lung lesions induced by silica.
genetics_overexpression_suppress	hsa-mir-142	Lung Neoplasms	19228723	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-142-5p: were repressed, overexpression can inhibitu lung cancer growth
genetics_overexpression_suppress	hsa-mir-145	Lung Neoplasms	19228723	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-145: were repressed, overexpression can inhibitu lung cancer growth
genetics_overexpression_suppress	hsa-mir-146b	Lung Neoplasms	21789255	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpression of the Lung Cancer-Prognostic miR-146b MicroRNAs Has a Minimal and Negative Effect on the Malignant Phenotype of A549 Lung Cancer Cells.
genetics_overexpression_suppress	hsa-mir-196b	Lung Neoplasms	27302168	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-196b reexpression also significantly reduced the growth of tumor xenografts.
genetics_overexpression_suppress	hsa-mir-200c	Lung Neoplasms	25277203	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type.
genetics_overexpression_suppress	hsa-mir-200c	Lung Neoplasms	27432063	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Over expression of miR-200c could significantly inhibit cell proliferation, induce G0/G1 cell cycle arrest and induce cell apoptosis.
genetics_overexpression_suppress	hsa-mir-338	Lung Neoplasms	27431198	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Regaining the expression of miR-338 in lung cancer cell lines significantly impaired cellular adhesion, migration, invasion and lung tumor formation in nude mice.
genetics_overexpression_suppress	hsa-mir-34a	Lung Neoplasms	27109632	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Systemic and local injection of ghR-form miR-34a (ghR-34a) suppressed tumor growth in a mouse model of RAS-induced lung cancer.
genetics_overexpression_suppress	hsa-mir-34c	Lung Neoplasms	19228723	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-34c: were repressed, overexpression can inhibitu lung cancer growth
genetics_overexpression_suppress	hsa-mir-450	Lung Neoplasms	27246609	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	transfection with lentivirus carrying miR鈥?50 upregulated miR鈥?50 expression and significantly attenuated lung cancer cell proliferation and invasion
genetics_overexpression_suppress	hsa-mir-7	Lung Neoplasms	25334070	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Restoration of miR-7 inhibited 3LL cell proliferation,  induced cell apoptosis in vitro and reduced tumorigenicity in vivo.
genetics_overexpression_suppress	hsa-mir-130b	Lupus Nephritis	27111096	urinary system disease	DOID:0080162	M32.14	D008181			overexpressing miR-130b suppressed signaling downstream from  the type I IFN pathway in RMCs by targeting IFN regulatory factor 1 (IRF-1).
genetics_overexpression_suppress	hsa-mir-520a	Lymphoma	27461820	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Our data indicated that the mimics of miR鈥?20a inhibited growth, proliferation of Raji cells and promoted its apoptosis, which was related to downregulation of AKT1, NF鈥懳築 and ER stress response mediated by PERK/eIF2伪 pathway.
genetics_overexpression_suppress	hsa-mir-520a	Lymphoma, Burkitt	27461820	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Our data indicated that the mimics of miR鈥?20a inhibited growth, proliferation of Raji cells and promoted its apoptosis, which was related to downregulation of AKT1, NF鈥懳築 and ER stress response mediated by PERK/eIF2伪 pathway.
genetics_overexpression_suppress	hsa-mir-24	Lymphoma, Hodgkin	28432871	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis.
genetics_overexpression_suppress	hsa-mir-520a	Lymphoma, Hodgkin	27461820	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Our data indicated that the mimics of miR鈥?20a inhibited growth, proliferation of Raji cells and promoted its apoptosis, which was related to downregulation of AKT1, NF鈥懳築 and ER stress response mediated by PERK/eIF2伪 pathway.
genetics_overexpression_suppress	hsa-mir-144	Lymphoma, Large B-Cell	26865454			C83.3	D016403	109565		forced expression of miR-144 significantly attenuated cell proliferation and invasion of OCI-Ly3 cells in vitro, and the tumor-suppressor effect of miR-144 was also confirmed using a xenograft mouse model in vivo Taken together
genetics_overexpression_suppress	hsa-mir-181a	Lymphoma, Large B-Cell	26941399			C83.3	D016403	109565		miR-181a decreases DLBCL tumor cell proliferation and survival, and anti-miR-181a abrogates these effects.
genetics_overexpression_suppress	hsa-mir-16	Lymphoma, Non-Hodgkin	26640145	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	The miR-16 transfection significantly decreased senescent cells and increased apoptotic cells
genetics_overexpression_suppress	hsa-mir-520a	Lymphoma, Non-Hodgkin	27461820	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Our data indicated that the mimics of miR鈥?20a inhibited growth, proliferation of Raji cells and promoted its apoptosis, which was related to downregulation of AKT1, NF鈥懳築 and ER stress response mediated by PERK/eIF2伪 pathway.
genetics_overexpression_suppress	hsa-mir-16	Lymphoma, T-Cell, Cutaneous	26640145	disease of cellular proliferation	DOID:0060061	C84.A0	D016410	608856	HP:0012192	The miR-16 transfection significantly decreased senescent cells and increased apoptotic cells
genetics_overexpression_suppress	hsa-mir-145	Malignant Neoplasms [unspecific]	25926306			C80.1	D009369			cell proliferation level of OS-732 with microRNA-145 overexpression was significantly decreased, and OS-732 cell invasion capacity was also significantly decreased
genetics_overexpression_suppress	hsa-mir-124	Medulloblastoma	23172372	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MiR-124 overexpression inhibits the proliferation of medulloblastoma cells, and this effect is mediated mostly through the action of miR-124 upon CDK6.
genetics_overexpression_suppress	hsa-mir-129	Medulloblastoma	24093088	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Overexpression of miR-129-5p using mimics decreased DAOY proliferation
genetics_overexpression_suppress	hsa-mir-135a	Medulloblastoma	25639612	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Remarkably, enforced  expression of miR-135a in HT CSCs strongly inhibited tumorigenesis by repressing  the miR-135a direct target gene Arhgef6.
genetics_overexpression_suppress	hsa-mir-206	Medulloblastoma	25859932	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells.
genetics_overexpression_suppress	hsa-mir-125b	Melanoma	26596831	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Restored expression of miR-125b in melanoma suppressed cell proliferation and invasion both in vitro and in vivo.
genetics_overexpression_suppress	hsa-mir-137	Melanoma	26186482	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	overexpression of miR-137 inhibited the proliferation of melanoma cells
genetics_overexpression_suppress	hsa-mir-137	Melanoma	27233613	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overexpression of miR-137 decreased cell proliferation and colony formation in vitro.
genetics_overexpression_suppress	hsa-mir-145	Melanoma	24248543	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line.
genetics_overexpression_suppress	hsa-mir-148b	Melanoma	27328731	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Depleting miR-214 or elevating miR-148b blocked the dissemination  of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration.
genetics_overexpression_suppress	hsa-mir-15a	Melanoma	27492455	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-15a displayed inhibitory effects on proliferation and invasiveness of several malignant melanoma cell lines.
genetics_overexpression_suppress	hsa-mir-17	Melanoma	25594054	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The melanoma tumors formed in mice overexpressing miR-17 were less than  that in wild type mice. In addition, the miR-17 tumors were less invasive and less angiogenic.
genetics_overexpression_suppress	hsa-mir-18b	Melanoma	27220837	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Ectopic expression of miR-18b decreased the proliferation of A375 and B16 cells
genetics_overexpression_suppress	hsa-mir-200c	Melanoma	24120113	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice.
genetics_overexpression_suppress	hsa-mir-34a	Melanoma	22969970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	These results suggest that overexpression of miR-34a and c suppresses invasive and generative potentials, respectively, in human malignant melanoma.
genetics_overexpression_suppress	hsa-mir-34c	Melanoma	22969970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	All four melanoma cell lines showed significant expression of miR-34s - A375: miR-34a 0.6176, miR-34b 0.7625, miR-34c 0.7877; 
genetics_overexpression_suppress	hsa-mir-542	Melanoma	27107696	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Exogenous expression of miR-542-3p resulted in marked inhibition of melanoma cell migration, invasion and epithelial-mesenchymal transition (EMT) in vitro and lung metastasis in vivo.
genetics_overexpression_suppress	hsa-mir-17	Mesothelioma	27245839	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Transfection of MPM cells with a miR-17-5p mimic or KCNMA1-specific siRNAs reduced mRNA expression of KCa1.1 and inhibited MPM cell migration.
genetics_overexpression_suppress	hsa-mir-202	Multiple Myeloma	25971527	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The growth rate of miR-202 mimics transfection cells was significantly lower than that of non-transfected cells.
genetics_overexpression_suppress	hsa-mir-29a	Multiple Myeloma	26771839	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	In addition, ectopic expression of miRNA-29a or exposure to PRIMA-1Met reduced cell proliferation and induced apoptosis in MM cells.
genetics_overexpression_suppress	hsa-mir-206	Muscle Atrophy	27054781			M62.5	D009133		HP:0100295	Injection of miR-206 (30 渭g/rat) attenuated  morphological and physiological deterioration of muscle characteristics
genetics_overexpression_suppress	hsa-mir-1	Myocardial Infarction	26380976	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1 and -21 jointly blocked hypoxia-induced cardiomyocytes apoptosis.
genetics_overexpression_suppress	hsa-mir-133a	Myocardial Infarction	25465869	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-133a overexpression protected CPCs  against cell death, targeting, among others, the proapoptotic genes Bim and Bmf.
genetics_overexpression_suppress	hsa-mir-150	Myocardial Infarction	25466411	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In vivo studies showed that overexpression of miR-150 in mice resulted in improved cardiac function, reduced myocardial infarction size, inhibition of apoptosis, and reduced inflammatory Ly-6C(high) monocyte invasion levels after AMI.
genetics_overexpression_suppress	hsa-mir-208b	Myocardial Infarction	27236543	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Overexpressing miR-208b improved myocardial functions
genetics_overexpression_suppress	hsa-mir-21	Myocardial Infarction	25809568	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In miR-21 group, myocardial infarct size reduced by 36.9% in comparison with LV-GFP  group.
genetics_overexpression_suppress	hsa-mir-21	Myocardial Infarction	26380976	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1 and -21 jointly blocked hypoxia-induced cardiomyocytes apoptosis.
genetics_overexpression_suppress	hsa-mir-499	Myocardial Infarction	24646523	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	We report that cardiac-abundant miR-499 could protect neonatal rat cardiomyocytes against H 2O 2-induced apoptosis. Increased miR-499 level favored survival, while decreased miR-499 level favored apoptosis.
genetics_overexpression_suppress	hsa-let-7b	Myocardial Ischemic-Reperfusion Injury	26542107				D015428			intramyocardial injection of let-7b-modified MSCs significantly enhanced ventricular function and facilitated myocardial repair by protecting transplanted cells from apoptosis and autophagy in the rat cardiac ischemia-reperfusion model.
genetics_overexpression_suppress	hsa-mir-19b	Myocardial Ischemic-Reperfusion Injury	26918829				D015428			we found that overexpression of miR-19b decreased H2O2-induced apoptosis and improved cell survival
genetics_overexpression_suppress	hsa-mir-613	Myocardial Ischemic-Reperfusion Injury	27534371				D015428			miR-613 inhibits I/R-induced cardiomyocyte apoptosis by targeting PDCD10 by regulating the PI3K/AKT signaling pathway.
genetics_overexpression_suppress	hsa-let-7	Neoplasms [unspecific]	25597880			C80.1	D009369			let-7 microRNA would be involved in over-expression of cofilin-1 mediated tumor suppression in vitro and in vivo.
genetics_overexpression_suppress	hsa-let-7	Neoplasms [unspecific]	27295554			C80.1	D009369			genetic rescue of Let-7 miRNA activity in Dicer1-deficient TAMs partly restored their M2-like phenotype and decreased tumour-infiltrating CTLs.
genetics_overexpression_suppress	hsa-let-7a	Neoplasms [unspecific]	24100239			C80.1	D009369			Human Argonaute-3 specifically enhances the passenger strand expression and activity of the tumor suppressor microRNA let-7a.
genetics_overexpression_suppress	hsa-mir-23b	Neoplasms [unspecific]	26198058			C80.1	D009369			miR-23b, miR-199a, and miR-15a displayed increased expression during early AVC development whereas others such as miR-130a and miR-200a display decreased expression levels
genetics_overexpression_suppress	hsa-mir-26a	Nervous System Diseases [unspecific]	25808510			C72.9	D009422			We found that miR-26a up-regulation promoted neurite outgrowth and reduced apoptosis in bupivacaine-injured DRG neurons.
genetics_overexpression_suppress	hsa-mir-138-1	Neuroblastoma	23562653	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-138 Overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo
genetics_overexpression_suppress	hsa-mir-138-2	Neuroblastoma	23562653	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-138 Overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo
genetics_overexpression_suppress	hsa-mir-141	Neuroblastoma	26936280	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	lentivirus-induced miR-141 upregulation inhibited cancer proliferation, cell cycle progression, migration and increased cisplatin chemosensitivity in vitro.
genetics_overexpression_suppress	hsa-mir-7	Neurodegenerative Diseases [unspecific]	25071443				D019636		HP:0002180	Overexpression of miR-7 or miR-153 by adenoviral transduction protected cortical neurons from MPP(+)-induced toxicity, restored neuronal viability and anti-apoptotic BCL-2 protein levels while attenuated activation of  caspase-3.
genetics_overexpression_suppress	hsa-mir-98	Neuroinflammation	26126865							Overexpression of let-7 and miR-98 in vitro and in vivo resulted in reduced leukocyte adhesion to and migration across  endothelium, diminished expression of pro-inflammatory cytokines, and increased BBB tightness, attenuating barrier 'leakiness' in neuroinflammation conditions.
genetics_overexpression_suppress	hsa-mir-183	Neuropathic Pain	24612023				D009437			Intrathecal administration of lentivirions expressing miR-183 downregulated SNL-induced increases in the expression of Nav1.3 and brain-derived neurotrophic factor (BDNF), which correlated with the significant attenuation of  SNL-induced mechanical allodynia.
genetics_overexpression_suppress	hsa-mir-221	Neuropathic Pain	27059231				D009437			Intrathecal injection of a miR-221 inhibitor attenuated CCI-induced mechanical allodynia and thermal hyperalgesia, and reduced proinflammatory cytokine expression
genetics_overexpression_suppress	hsa-mir-210	Osteoarthritis	26244598	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Transfection with miR-210 mimic inhibited LPS-induced pro-inflammatory cytokines production, cell viability reduction and cell apoptosis.
genetics_overexpression_suppress	hsa-mir-222	Osteoarthritis	26673737	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Over-expression of miR-222 significantly suppressed apoptotic death by down-regulating HDAC-4 and MMP-13 level.
genetics_overexpression_suppress	hsa-mir-23a	Osteoarthritis	27318087	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-23a-3p overexpression suppresses type II collagen and aggrecan expression
genetics_overexpression_suppress	hsa-let-7g	Osteosarcoma	25197332	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Functional investigation revealed both restoration of let-7g and silencing Aurora-B induce cell apoptosis and suppressed cell viability, migratory and invasive ability in OS cells.
genetics_overexpression_suppress	hsa-mir-100	Osteosarcoma	26018508	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3.
genetics_overexpression_suppress	hsa-mir-101	Osteosarcoma	27073439	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Independent inhibition of c-FOS and overexpression of miR-101 expression levels significantly suppressed U2OS cell proliferation, migration and invasion (P<0.01).
genetics_overexpression_suppress	hsa-mir-106a	Osteosarcoma	27383537	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Downregulation of miR-106a-5p was found in OS tissues, and upregulation of miR-106a-5p can inhibit the proliferation, migration, and invasion by targeting HMGA2 in OS cells.
genetics_overexpression_suppress	hsa-mir-124	Osteosarcoma	25667613	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	transfection of miR-124 mimic into MG63 cells was able to  reduce cell proliferation, invasion and migration, and promote cell apoptosis.
genetics_overexpression_suppress	hsa-mir-125b	Osteosarcoma	26744308	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	stable overexpression of miR-125b in osteosarcoma cell lines U2OS and MG-63 inhibited cell proliferation, migration, and invasion.
genetics_overexpression_suppress	hsa-mir-138	Osteosarcoma	27095063	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-138 inhibited cell proliferation and invasion, and promoted cell apoptosis of human osteosarcoma cells.
genetics_overexpression_suppress	hsa-mir-140	Osteosarcoma	26219893	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	relative miR-140 expression was increased, cell proliferation was inhibited, cell population in G0/G1 phase was increased, cell population in G2/M phase and S phases and proliferation index (PI), and cell migration distance were decreased in the miR-140 mimic group
genetics_overexpression_suppress	hsa-mir-140	Osteosarcoma	27624383	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Overexpression of miR-140 Inhibits Proliferation of Osteosarcoma Cells via Suppression of Histone Deacetylase 4.
genetics_overexpression_suppress	hsa-mir-143	Osteosarcoma	25576341	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Forced miR-143 expression significantly inhibited tumor growth in xenograft SAOS-2-Dox and U2OS-Dox animal models.
genetics_overexpression_suppress	hsa-mir-150	Osteosarcoma	26561465	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	restoration of miR-150 expression in OS cells could inhibit cell proliferation, migration, and invasion and induced apoptosis in vitro as well as suppressed tumor growth of OS in vivo.
genetics_overexpression_suppress	hsa-mir-182	Osteosarcoma	27123060	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	upregulation of miRNA-182 promotes cell apoptosis and inhibits cell viability, proliferation, invasion and migration.
genetics_overexpression_suppress	hsa-mir-224	Osteosarcoma	27222381	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	overexpression of miR-224 suppressed osteosarcoma cell proliferation, migration and invasion
genetics_overexpression_suppress	hsa-mir-26a	Osteosarcoma	27270422	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-26a overexpression inhibits the tumor cell growth both in vitro and in vivo.
genetics_overexpression_suppress	hsa-mir-26a	Osteosarcoma	27468358	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Using in vitro and in vivo assays, we confirmed that miR-26a could inhibit the abilities of in vitro proliferation and suppress in vivo tumor growth in mouse model.
genetics_overexpression_suppress	hsa-mir-329	Osteosarcoma	27487475	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-329 is able to inhibit osteosarcoma cell proliferation, promote apoptosis, and induce G0/G1 cell cycle arrest.
genetics_overexpression_suppress	hsa-mir-34b	Osteosarcoma	26924291	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Upregulation of miR-34b also induced apoptosis and increased the sensitivity of the cells to the anticancer drugs
genetics_overexpression_suppress	hsa-mir-422a	Osteosarcoma	27779704	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells.
genetics_overexpression_suppress	hsa-mir-497	Osteosarcoma	27176490	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	upregulation of miR鈥?97 inhibited cell proliferation, migration and invasion in osteosarcoma cell lines
genetics_overexpression_suppress	hsa-mir-503	Osteosarcoma	26768615	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-503 overexpression suppressed cell invasion and migration and inhibited epithelial-to-mesenchymal transition (EMT) of MG-63.
genetics_overexpression_suppress	hsa-let-7c	Ovarian Neoplasms	24507678	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	After application of let-7c, number of T29A2+ cell clones was decreased significantly, however, after the application of Anti-let-7, the number of clones restored, and there was no significant difference compared with the negative control group.
genetics_overexpression_suppress	hsa-mir-100	Ovarian Neoplasms	26607088	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The expression of miR-100 is downregulated in SKOV3/DDP cells.Overexpressing miR-100 may effectively increase the sensitivity to cisplatin of human ovarian epithelial cancer SKOV3/DDP cells and may reverse cisplatin-resistance of EOC (epithelial ovarian cancer).
genetics_overexpression_suppress	hsa-mir-100	Ovarian Neoplasms	20081105	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of mir-100 inhibited mTOR signaling and enhanced sensitivity to the rapamycin analog RAD001 (everolimus), confirming the key relationship between mir-100 and the mTOR pathway.
genetics_overexpression_suppress	hsa-mir-125b	Ovarian Neoplasms	27383536	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ectopic expression of miR-125b in EOC cells significantly inhibited tumor invasion.
genetics_overexpression_suppress	hsa-mir-130b	Ovarian Neoplasms	27048832	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	overexpression of  miR-130b reduced the expression of RUNX3 and inhibited cancer cell migration and  invasion of EOC cells
genetics_overexpression_suppress	hsa-mir-145	Ovarian Neoplasms	27191261	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Activating miR-145 suppresses ovarian tumor growth and metastasis
genetics_overexpression_suppress	hsa-mir-155	Ovarian Neoplasms	23523916	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	overexpression of miR-155 may prevent tumorigenesis in human ovarian cancer through downregulation of CLDN1.
genetics_overexpression_suppress	hsa-mir-206	Ovarian Neoplasms	24604205	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor α-positive ovarian cancer cells.
genetics_overexpression_suppress	hsa-mir-215	Ovarian Neoplasms	26676658	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Upregulation of miR-215 inhibited cell proliferation, promoted apoptosis and increased sensitivity to chemotherapy drugs in EOC cells.
genetics_overexpression_suppress	hsa-mir-22	Ovarian Neoplasms	20081105	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	overexpression of the putative tumor suppressor mir-22 repressed the EVI1 oncogene, which is known to suppress apoptosis by stimulating phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog 1 signaling.
genetics_overexpression_suppress	hsa-mir-26a	Ovarian Neoplasms	27158389	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	over-expression could significantly inhibit the proliferation of ovarian cancer cells and induce their apoptosis.
genetics_overexpression_suppress	hsa-mir-29a	Ovarian Neoplasms	22479643	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	over-expression of miR-29a in vitro repressed several anti-correlated genes (including DNMT3A and DNMT3B) and substantially decreased ovarian cancer cell viability.
genetics_overexpression_suppress	hsa-mir-338	Ovarian Neoplasms	27508048	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Restoration of miR-338-3p expression in ovarian cancer cells could inhibit cell proliferation, lactate production and lactate production of ovarian cancer cells.
genetics_overexpression_suppress	hsa-mir-381	Ovarian Neoplasms	26768613	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of miR-381 significantly inhibited EOC cell proliferation,  migration, and invasion.
genetics_overexpression_suppress	hsa-mir-494	Ovarian Neoplasms	27313773	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of miR-494 inhibited ovarian cancer cell proliferation by inducing apoptosis.
genetics_overexpression_suppress	hsa-let-7	Pancreatic Neoplasms	25017900	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition.
genetics_overexpression_suppress	hsa-mir-506	Pancreatic Neoplasms	27065335	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-506 inhibited cell proliferation, induced cell cycle arrest at the G1/S transition and enhanced apoptosis and chemosensitivity of pancreatic cancer cells.
genetics_overexpression_suppress	hsa-mir-548an	Pancreatic Neoplasms	27353169	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpression of miR-548an significantly inhibited the proliferation and invasion of pancreatic cancer cell
genetics_overexpression_suppress	hsa-mir-7	Parkinson Disease	27003614	nervous system disease	DOID:14330	G20	D010300	PS168600		The upregulation of miR-7 promoted cell viability and suppressed cell apoptosis in MPP(+)-treated SH-SY5Y cells.
genetics_overexpression_suppress	hsa-mir-132	Prostate Neoplasms	27527117	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Notably, overexpression of miR-132/212 could inhibit TGF-β (transforming growth factor-β)-induced EMT in Vcap and Lncap cells at both the mRNA and protein expression levels.
genetics_overexpression_suppress	hsa-mir-143	Prostate Neoplasms	26269764	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-143 has an inhibitory effect on cell  proliferation as evidenced by decreased cell viability, increased cell apoptosis  and cell cycle arrest at the G1/S transition.
genetics_overexpression_suppress	hsa-mir-143	Prostate Neoplasms	26721309	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-143 restoration decreased secreted MMP-2 and MMP-9 enzyme activities compared with scramble controls
genetics_overexpression_suppress	hsa-mir-145	Prostate Neoplasms	25951106	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression.
genetics_overexpression_suppress	hsa-mir-154	Prostate Neoplasms	27074041	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The forced expression of miR-154-5p or E2F5 knockdown significantly restrained cell growth, as well as the migratory and invasive capabilities.
genetics_overexpression_suppress	hsa-mir-195	Prostate Neoplasms	27175617	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-195 overexpression inhibited cell proliferation, cell cycle progression and tumorigenesis via directly targeting HMGA1.
genetics_overexpression_suppress	hsa-mir-23b	Prostate Neoplasms	26898757	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-23b/-27b expression in prostate cancer cells decreased seminal vesicle invasion and distant metastases
genetics_overexpression_suppress	hsa-mir-26a	Prostate Neoplasms	27449037	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	It was confirmed that miR-26a-5p was markedly downregulated in PC tissues compared with  normal controls whose reduced expression was significantly associated with metastasis and poor overall prognosis and found that miR-26a-5p was able to prevent proliferation and motility of PC cells in vitro.
genetics_overexpression_suppress	hsa-mir-27b	Prostate Neoplasms	26898757	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-23b/-27b expression in prostate cancer cells decreased seminal vesicle invasion and distant metastases
genetics_overexpression_suppress	hsa-mir-29a	Prostate Neoplasms	26131109	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	enforced expression of miR-29a in PC-3 and LNCaP cells inhibited proliferation, and induced apoptosis by repressing the expression of KDM5B.
genetics_overexpression_suppress	hsa-mir-29b	Prostate Neoplasms	25784815	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	forced expression of miR-29b inhibited cell proliferation and cell invasion and induced cell apoptosis in PCa.
genetics_overexpression_suppress	hsa-mir-30a	Prostate Neoplasms	27431942	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR鈥?0a overexpression resulted in a significant suppression of cell growth in vitro, and reduced tumorigenicity  in vivo.
genetics_overexpression_suppress	hsa-mir-320	Prostate Neoplasms	27216188	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	An miR-320a mimic suppressed AR protein expression together with growth suppression
genetics_overexpression_suppress	hsa-mir-320a	Prostate Neoplasms	27212625	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Restoration of mature miR鈥?20a in PCa cell lines showed that miR鈥?20a significantly inhibited cancer cell migration and invasion.
genetics_overexpression_suppress	hsa-mir-34a	Prostate Neoplasms	26722316	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The over-expression of miR-34a inhibited PC-3 cells growth and resulted in increased cell cycle arrest compared with the negative control (P<0.05).
genetics_overexpression_suppress	hsa-mir-34c	Prostate Neoplasms	27461446	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this study, we identified that miR-34C was under-expressed in the purified CD133+ PCSCs and enforced introduction of miR-34C attenuated the stemness of CD133+ PCSCs.
genetics_overexpression_suppress	hsa-mir-449a	Prostate Neoplasms	26520443	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Overexpression of miR-449a induces cell cycle arrest,  apoptosis, and senescence
genetics_overexpression_suppress	hsa-mir-34	Pulmonary Hypertension	27302634	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miR-34a overexpression down-regulated platelet-derived growth factor receptor alpha (PDGFRA) expression, which is a key factor in PAH development.
genetics_overexpression_suppress	hsa-mir-184	Retinal Neovascularization	25796186			H35.059	D015861		HP:0030666	miR-184 mimic inhibits Wnt signaling in the OIR retina
genetics_overexpression_suppress	hsa-mir-124	Retinoblastoma	27498908	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	The ectopic expression of miR-124 in the RB cell lines (Y79 and SO-RB50) suppresses cell proliferation, migration and invasion, induced  cell apoptosis in vitro.
genetics_overexpression_suppress	hsa-mir-125a	Retinoblastoma	27094723	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	The overexpression of miR-125a-5p significantly suppressed cell proliferation and tumor formation in retinoblastoma.
genetics_overexpression_suppress	hsa-mir-140	Rheumatoid Arthritis	26473405	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Overexpression of miRNAs 140-3p and 140-5p caused a reduction in expression, with correlated kinetic patterns, of their corresponding target molecules sirtuin 1 and stromal cell-derived factor 1 in the SFs and joints of mice.
genetics_overexpression_suppress	hsa-mir-17	Rheumatoid Arthritis	27534557	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MicroRNA-17 Suppresses TNF-B Signaling by Interfering with TRAF2 and cIAP2 Association in Rheumatoid Arthritis Synovial Fibroblasts.
genetics_overexpression_suppress	hsa-mir-223	Rheumatoid Arthritis	22903258	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Overexpression of microRNA-223 in rheumatoid arthritis synovium controls osteoclast differentiation.
genetics_overexpression_suppress	hsa-mir-451	Rheumatoid Arthritis	26823778	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-451 treatment significantly decreased cell proliferation ability
genetics_overexpression_suppress	hsa-mir-573	Rheumatoid Arthritis	26166764	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-573 overexpression suppressed the expression of interleukin 6 (IL-6) and cyclooxygenase 2 in RASFs
genetics_overexpression_suppress	hsa-mir-16	Sarcoma [unspecific]	26044957	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	miR-16, but not other downregulated miRNAs, was able to significantly suppress both migration and invasion in vitro
genetics_overexpression_suppress	hsa-mir-9	Schizophrenia	27117414	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Overexpression of miR-9 was sufficient to ameliorate a previously reported neural migration deficit in SZ NPCs, whereas knockdown partially phenocopied aberrant migration in control NPCs.
genetics_overexpression_suppress	hsa-mir-146a	Sepsis	26048146			A41.9	D018805		HP:0100806	In vivo transfection of LmiR-146a attenuated sepsis-induced cardiac dysfunction.
genetics_overexpression_suppress	hsa-mir-146a	Sepsis	26138422			A41.9	D018805		HP:0100806	Up-regulation of miR-146a inhibit the release of the inflammatory cytokine  TNF-伪 stimulated by sepsis, and alleviate inflammatory reaction and lung tissue injury in mice with sepsis-induced ALI.
genetics_overexpression_suppress	hsa-mir-126	Spinal Cord Injuries	25724143			S34.139A	D013119			increased levels of miR-126 promoted angiogenesis, and  inhibited leukocyte extravasation into the injured spinal cord
genetics_overexpression_suppress	hsa-mir-9	Spinal Cord Injuries	26359086			S34.139A	D013119			miR-9 overexpression promoted osteoblast differentiation and angiogenesis
genetics_overexpression_suppress	hsa-mir-1	Squamous Cell Carcinoma, Esophageal	25672418	disease of cellular proliferation	DOID:3748		C562729			Downregulation of microRNA-1 in esophageal squamous cell carcinoma correlates with an advanced clinical stage and its overexpression inhibits cell migration and invasion.
genetics_overexpression_suppress	hsa-mir-1	Squamous Cell Carcinoma, Esophageal	27247259	disease of cellular proliferation	DOID:3748		C562729			miR鈥? suppressed ESCC cell proliferation and increased apoptosis
genetics_overexpression_suppress	hsa-mir-143	Squamous Cell Carcinoma, Esophageal	26758433	disease of cellular proliferation	DOID:3748		C562729			miR-143 exerted a tumor-suppressing effect by inhibiting the proliferation, migration, and invasion and inducing G1/G0 phase arrest of ESCC cells via the negative regulation of FAM83F expression.
genetics_overexpression_suppress	hsa-mir-143	Squamous Cell Carcinoma, Esophageal	27358073	disease of cellular proliferation	DOID:3748		C562729			Ectopic expression of miR-143-3p also reduced the metastatic potential of cells by selectively regulating epithelial-mesenchymal transition regulatory proteins.
genetics_overexpression_suppress	hsa-mir-194	Squamous Cell Carcinoma, Esophageal	27480251	disease of cellular proliferation	DOID:3748		C562729			miR-194 was found to inhibit proliferation and invasion and promote apoptosis of  esophageal squamous cell carcinoma cells.
genetics_overexpression_suppress	hsa-mir-20a	Squamous Cell Carcinoma, Esophageal	27508097	disease of cellular proliferation	DOID:3748		C562729			Together, our findings demonstrate that miR-17/20a suppresses cell migration and invasion of ESCC by modulating TGF-尾/ITGB6 pathway.
genetics_overexpression_suppress	hsa-mir-622	Squamous Cell Carcinoma, Esophageal	27501502	disease of cellular proliferation	DOID:3748		C562729			Up-regulation of miR-622 could significantly reduce ESCC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while down-regulation of miR-622 showed opposite effects.
genetics_overexpression_suppress	hsa-mir-1	Squamous Cell Carcinoma, Head and Neck	27169691	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-1 and miR-206 significantly inhibited HNSCC cells' aggressiveness.
genetics_overexpression_suppress	hsa-mir-203	Squamous Cell Carcinoma, Head and Neck	26882562	disease of cellular proliferation	DOID:5520	C76.0	C535575			oreover, ectopic overexpression of miR-203 suppressed the invasion and induced mesenchymal-epithelial transition (MET) in HNSCC cells.
genetics_overexpression_suppress	hsa-mir-206	Squamous Cell Carcinoma, Head and Neck	27169691	disease of cellular proliferation	DOID:5520	C76.0	C535575			restoration of miR-1 and miR-206 significantly inhibited HNSCC cells' aggressiveness.
genetics_overexpression_suppress	hsa-mir-149	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27403438	disease of cellular proliferation	DOID:2876					In vitro studies revealed that the exogenous expression of miRNA-149  inhibits the proliferation of human Hep-2 cells and induces cell apoptosis.
genetics_overexpression_suppress	hsa-mir-34a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24482044	disease of cellular proliferation	DOID:2876					Ectopic expression of miR-34a and miR-34c in Hep-2 cells significantly induced the cell proliferation and migration ability in vitro.
genetics_overexpression_suppress	hsa-mir-34c	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24482044	disease of cellular proliferation	DOID:2876					Ectopic expression of miR-34a and miR-34c in Hep-2 cells significantly induced the cell proliferation and migration ability in vitro.
genetics_overexpression_suppress	hsa-mir-375	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27279635	disease of cellular proliferation	DOID:2876					Overexpression of miR-375 led to a decreased protein level of Kr眉ppel-like factor 4 (KLF4) and marked suppression of the proliferation and invasion, and induced apoptosis of LSCC cell line
genetics_overexpression_suppress	hsa-mir-181d	Squamous Cell Carcinoma, Oral	26693182	disease of cellular proliferation	DOID:0050866					Ectopic expression of miR-181a/d decreased anchorage independent growth and CSC phenotype of HPV16-transfected OSCC.
genetics_overexpression_suppress	hsa-mir-206	Squamous Cell Carcinoma, Oral	25246801	disease of cellular proliferation	DOID:0050866					upregulation of miR-206 in Tca8113 cells was able  to reduce cell proliferation, invasion, and migration and promote cell apoptosis  in vitro.
genetics_overexpression_suppress	hsa-mir-20a	Squamous Cell Carcinoma, Oral	26781875	disease of cellular proliferation	DOID:0050866					Upregulation of miR-20a by transfected plasmid HPV-16 E7 can significantly inhibit Cal27 cell proliferation, invasion, and migration.
genetics_overexpression_suppress	hsa-mir-27a	Squamous Cell Carcinoma, Oral	27432214	disease of cellular proliferation	DOID:0050866					Intriguingly, increased expression of miR-27a-3p could significantly decrease the expression level of YAP1 as well as several epithelial to mesenchymal transition (EMT)-related molecules in OSCC cell lines, including Twist and Snail.
genetics_overexpression_suppress	hsa-mir-448	Squamous Cell Carcinoma, Oral	27184799	disease of cellular proliferation	DOID:0050866					Knockdown of N4BP2L1 and upregulation of miR-448 significantly reduced the invasive potential of oral squamous cell carcinoma cells.
genetics_overexpression_suppress	hsa-mir-222	Squamous Cell Carcinoma, Tongue	26517090	disease of cellular proliferation	DOID:0050865	C02.9				Moreover, miR-222 mimics and ABCG2 siRNA inhibited tumor growth and lung metastasis in vivo.
genetics_overexpression_suppress	hsa-mir-410	Systemic Lupus Erythematosus	27351906	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	overexpression of miR-410 significantly reduced the expression levels of IL-10.
genetics_overexpression_suppress	hsa-mir-199a	Testicular Neoplasms	27432288	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	it was determined that overexpression of miR鈥?99a鈥?p in Ntera鈥? cells caused suppression of cell growth and migration.
genetics_overexpression_suppress	hsa-mir-126	Thyroid Neoplasms	27175968	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	upregulation of miR鈥?26 inhibited cell proliferation, migration and invasion in thyroid cancer cells.
genetics_overexpression_suppress	hsa-mir-195	Thyroid Neoplasms	26527888	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	exogenous overexpression of miR-195 significantly inhibits the protein expression of Raf1 and blocks the thyroid cancer cell proliferation.
genetics_overexpression_suppress	hsa-mir-211	Thyroid Neoplasms	28703321	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Overexpression miR-211-5p hinders the proliferation, migration, and invasion of thyroid tumor cells by downregulating SOX11.
genetics_overexpression_suppress	hsa-let-7b	Uveal Melanoma	25588203				C536494	155720	HP:0007716	We then confirmed that let-7b mimics could inhibit UM growth both in vitro and in vivo.
genetics_overexpression_suppress	hsa-mir-1	Vascular Hypertrophy	26253469							the administration of a miR-1 mimic attenuated cardiac hypertrophy by suppressing the transverse aortic constriction-induced increase in myocardin expression
genetics_overexpression_suppress	hsa-mir-133a	Vascular Hypertrophy	25995211							delivery of miR-1 and miR-133a suppressed inducible cAMP early repressor expression and prevented both electrical remodeling and hypertrophy.
genetics_overexpression_suppress	hsa-mir-26a	Vascular Hypertrophy	27485101							Taken together, the present study suggested an anti鈥慼ypertrophic role of miR鈥?6a in cardiac hypertrophy, possibly via inhibition of GATA4.
genetics_overexpression_suppress	hsa-mir-29b	Wound Healing	27477081				D014945		HP:0001058	Importantly, local delivery of miR-29b lentiviral particles inhibited HSP47 expression and collagen biosynthesis as well as suppressed angiogenesis, thus reducing scar formation in an excisional wound splinting model.
lncRNA target	hsa-mir-204	Acute Kidney Failure	29669307	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	Long non-coding RNA NEAT1 plays an important role in sepsis-induced acute kidney injury by targeting miR-204 and modulating the NF-κB pathway
lncRNA target	hsa-let-7c	Adenocarcinoma, Lung	27566568	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	the oncogenic function of CCAT1 in docetaxel-resistant LAD cells depended on the sponging of let-7c
lncRNA target	hsa-mir-145	Adenocarcinoma, Lung	28388536	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway.
lncRNA target	hsa-let-7	Adenocarcinoma, Pancreatic Ductal	28947981	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Lin28B, a Lin28 homologue, represses the biogenesis of let-7 microRNAs (miRNAs),  has a role in tumorigenesis, and is considered a potential therapeutic target for various human malignancies
lncRNA target	hsa-mir-193b	Adenocarcinoma, Pancreatic Ductal	26549028	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MIR31HG is negatively regulated by miR-193b.
lncRNA target	hsa-mir-17	Atherosclerosis	28676341	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The Circular RNA Interacts with STAT3, Increasing Its Nuclear Translocation and Wound Repair by Modulating Dnmt3a and miR-17 Function.
lncRNA target	hsa-mir-221	Atherosclerosis	23697773	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	We further discovered that an Ang II-regulated lncRNA functions as the host transcript for miR-221 and miR-222, 2 microRNAs implicated in cell proliferation. 
lncRNA target	hsa-mir-9	Atherosclerosis	26981838	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	HULC regulated  TNF-伪-induced apoptosis through regulation of miR-9 expression.
lncRNA target	hsa-let-7a-1	Breast Neoplasms	22081076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.
lncRNA target	hsa-let-7a-1	Breast Neoplasms	22808086	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells.
lncRNA target	hsa-let-7a-2	Breast Neoplasms	22081076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.
lncRNA target	hsa-let-7a-2	Breast Neoplasms	22808086	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells.
lncRNA target	hsa-let-7a-3	Breast Neoplasms	22081076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.
lncRNA target	hsa-let-7a-3	Breast Neoplasms	22808086	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells.
lncRNA target	hsa-let-7c	Breast Neoplasms	22081076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.
lncRNA target	hsa-let-7d	Breast Neoplasms	22081076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.
lncRNA target	hsa-let-7f-1	Breast Neoplasms	22081076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.
lncRNA target	hsa-let-7f-2	Breast Neoplasms	22081076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.
lncRNA target	hsa-mir-19b	Breast Neoplasms	28731027	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer
lncRNA target	hsa-mir-34a	Breast Neoplasms	29037220	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.
lncRNA target	hsa-mir-9	Breast Neoplasms	28053623	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LncRNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation by Inhibiting MicroRNA-9 in MCF-7 Cells.
lncRNA target	hsa-mir-101	Carcinoma, Bladder	27998761	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2.
lncRNA target	hsa-mir-196a	Carcinoma, Bladder	27591936	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
lncRNA target	hsa-mir-197	Carcinoma, Bladder	27631965	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	LINC00312 inhibits the migration and invasion of bladder cancer cells by targeting miR-197-3p.
lncRNA target	hsa-mir-300	Carcinoma, Bladder	28178615	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Long non-coding RNA TUG1 promotes cell proliferation and metastasis by negatively regulating miR-300 in gallbladder carcinoma.
lncRNA target	hsa-mir-101	Carcinoma, Breast	28034643			D05	D001943	114480	HP:0003002	The long non-coding RNA NEAT1 interacted with miR-101 modulates breast cancer growth by targeting EZH2.
lncRNA target	hsa-mir-18a	Carcinoma, Breast	27629141			D05	D001943	114480	HP:0003002	Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
lncRNA target	hsa-mir-200	Carcinoma, Breast	28187158			D05	D001943	114480	HP:0003002	Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer.
lncRNA target	hsa-mir-205	Carcinoma, Breast	28063065			D05	D001943	114480	HP:0003002	Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.
lncRNA target	hsa-mir-148a	Carcinoma, Cervical	27574106	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Long non-coding RNA HOTAIR modulates HLA-G expression by absorbing miR-148a in human cervical cancer.
lncRNA target	hsa-mir-196a	Carcinoma, Cervical	28671039	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205.
lncRNA target	hsa-mir-205	Carcinoma, Cervical	28671039	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205.
lncRNA target	hsa-mir-100	Carcinoma, Colon	28130225	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis.
lncRNA target	hsa-mir-101	Carcinoma, Colon	28720069	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Long non-coding RNA SPRY4-IT1 promotes proliferation and invasion by acting as a ceRNA of miR-101-3p in colorectal cancer cells.
lncRNA target	hsa-mir-125b	Carcinoma, Colon	28130225	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis.
lncRNA target	hsa-mir-138	Carcinoma, Colon	28358427	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	H19 promotes the migration and invasion of colon cancer by sponging miR-138 to upregulate the expression of HMGA1.
lncRNA target	hsa-mir-193a	Carcinoma, Colon	27633443	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	the involvement of competing endogenous RNAs mechanism in Linc00152/miR-193a-3p/ERBB4/AKT signaling axis may provide a novel choice in the investigation of drug resistance
lncRNA target	hsa-mir-211	Carcinoma, Colon	28214867	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The Novel Long Noncoding RNA TUSC7 Inhibits Proliferation by Sponging MiR-211 in Colorectal Cancer.
lncRNA target	hsa-mir-217	Carcinoma, Colon	28472810	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Progression by Competitively Binding miR-217 with TCF7L2 and Enhancing the Wnt/β-Catenin Signaling Pathway.
lncRNA target	hsa-mir-24	Carcinoma, Colon	28306719	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients.
lncRNA target	hsa-mir-490	Carcinoma, Colon	28381168	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression.
lncRNA target	hsa-mir-99a	Carcinoma, Colon	28130225	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis.
lncRNA target	hsa-mir-103	Carcinoma, Endometrial	26511107	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	In summary, we demonstrate that GAS5 acts as an tumor suppressor lncRNA in endometrial cancer. Through inhibiting the expression of miR-103, GAS5 significantly enhanced the expression of PTEN to promote cancer cell apoptosis,and, thus, could be an important mediator in the pathogenesis of endometrial cancer.
lncRNA target	hsa-mir-23b	Carcinoma, Endometrial	28653877	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b.
lncRNA target	hsa-mir-200c	Carcinoma, Endometrioid Endometrial	27693631			C54.1	D018269			Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma.
lncRNA target	hsa-mir-204	Carcinoma, Esophageal	27667646	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer.
lncRNA target	hsa-mir-9	Carcinoma, Esophageal	28539329	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Aberrant Methylation-Mediated Silencing of lncRNA MEG3 Functions as a ceRNA in Esophageal Cancer.
lncRNA target	hsa-mir-194	Carcinoma, Gallbladder	26803515	disease of cellular proliferation	DOID:4948	C23	D005706			overexpression of H19 in GBC-SD cells downregulated miR-194-5p and markedly increased AKT2 expression, and miR-194-5p mimic reversed these effects.
lncRNA target	hsa-mir-26a	Carcinoma, Gallbladder	27345740	disease of cellular proliferation	DOID:4948	C23	D005706			Upregulation of MINCR and enhancer of zeste homolog 2 (EZH2) in GBC coincided with the downregulation of miR-26a-5p in GBC.
lncRNA target	hsa-mir-1297	Carcinoma, Gastric	27651312	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	HOXA11-AS/miR-1297/EZH2 cross-talk serve as critical effectors in gastric cancer tumorigenesis and progression, suggesting new therapeutic directions in gastric cancer
lncRNA target	hsa-mir-145	Carcinoma, Gastric	28490034	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Long Noncoding RNA CRNDE Promotes Proliferation of Gastric Cancer Cells by Targeting miR-145.
lncRNA target	hsa-mir-186	Carcinoma, Gastric	28122299	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer.
lncRNA target	hsa-mir-27b	Carcinoma, Gastric	27694794	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b.
lncRNA target	hsa-mir-32	Carcinoma, Gastric	27871067	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4.
lncRNA target	hsa-mir-335	Carcinoma, Gastric	28618927	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Long non-coding RNA MSTO2P promotes the proliferation and colony formation in gastric cancer by indirectly regulating miR-335 expression.
lncRNA target	hsa-mir-10a	Carcinoma, Hepatocellular	27002617	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT  in hepatocellular carcinoma.
lncRNA target	hsa-mir-129	Carcinoma, Hepatocellular	28526689	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IκB.
lncRNA target	hsa-mir-139	Carcinoma, Hepatocellular	28231734	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long non-coding RNA XIST promotes cell growth by regulating miR-139-5p/PDK1/AKT axis in hepatocellular carcinoma.
lncRNA target	hsa-mir-140	Carcinoma, Hepatocellular	27597739	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long non-coding RNA Unigene56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells.
lncRNA target	hsa-mir-145	Carcinoma, Hepatocellular	29559320	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long non-coding RNA ROR promotes radioresistance in hepatocelluar carcinoma cells by acting as a ceRNA for microRNA-145 to regulate RAD18 expression
lncRNA target	hsa-mir-15a	Carcinoma, Hepatocellular	28035067	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of γ-synuclein in hepatocellular carcinoma cells.
lncRNA target	hsa-mir-186	Carcinoma, Hepatocellular	28656879	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long non-coding RNA PVT1 serves as a competing endogenous RNA for miR-186-5p to promote the tumorigenesis and metastasis of hepatocellular carcinoma.
lncRNA target	hsa-mir-195	Carcinoma, Hepatocellular	27932778	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of Long Non-Coding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) Exacerbates Hepatocellular Carcinoma Through Suppressing miR-195.
lncRNA target	hsa-mir-195	Carcinoma, Hepatocellular	28722813	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195.
lncRNA target	hsa-mir-19a	Carcinoma, Hepatocellular	28724429	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	its pro-metastatic phenotype can partially be attributed to the HOXD-AS1/miR19a/ARHGAP11A signaling axis
lncRNA target	hsa-mir-200a	Carcinoma, Hepatocellular	28403886	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation.
lncRNA target	hsa-mir-203	Carcinoma, Hepatocellular	28271214	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression.
lncRNA target	hsa-mir-204	Carcinoma, Hepatocellular	28720061	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1.
lncRNA target	hsa-mir-216b	Carcinoma, Hepatocellular	25760077	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway.
lncRNA target	hsa-mir-372	Carcinoma, Hepatocellular	28415780	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372.
lncRNA target	hsa-mir-374a	Carcinoma, Hepatocellular	27065331	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a.
lncRNA target	hsa-mir-494	Carcinoma, Hepatocellular	27689326	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
lncRNA target	hsa-mir-513c	Carcinoma, Hepatocellular	29574975	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma.
lncRNA target	hsa-mir-9	Carcinoma, Hepatocellular	28520103	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression.
lncRNA target	hsa-mir-200	Carcinoma, Lung	27852821	disease of cellular proliferation	DOID:3905	C34.90	D008175			MEG3 regulated the recruitment of JARID2 and EZH2 and histone H3 methylation on the regulatory regions of CDH1 and microRNA-200 family genes for transcriptional repression
lncRNA target	hsa-mir-206	Carcinoma, Lung	27906963	disease of cellular proliferation	DOID:3905	C34.90	D008175			RMRP acted as an oncogene LncRNA to promote the expression of KRAS, FMNL2 and SOX9 by inhibiting miR-206 expression in lung cancer
lncRNA target	hsa-mir-21	Carcinoma, Lung	29503447	disease of cellular proliferation	DOID:3905	C34.90	D008175			We found that LIN28B overexpression significantly increased the number of CD44+/CD326+ tumor cells, upregulated VEGF-A and miR-21 and promoted tumor angiogenesis and epithelial-to-mesenchymal transition (EMT) accompanied by enhanced AKT phosphorylation and nuclear translocation of c-MYC
lncRNA target	hsa-mir-101	Carcinoma, Lung, Non-Small-Cell	28147312			C34.90	D002289		HP:0030358	Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway.
lncRNA target	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	29034803			C34.90	D002289		HP:0030358	LncRNA HOXA11-AS promotes proliferation and invasion by targeting miR-124 in human non-small cell lung cancer cells.
lncRNA target	hsa-mir-138	Carcinoma, Lung, Non-Small-Cell	28872894			C34.90	D002289		HP:0030358	Knockdown of Long Noncoding RNA Small Nucleolar RNA Host Gene 12 Inhibits Cell Growth and Induces Apoptosis by Upregulating miR-138 in Nonsmall Cell Lung Cancer.
lncRNA target	hsa-mir-186	Carcinoma, Lung, Non-Small-Cell	28448993			C34.90	D002289		HP:0030358	The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p.
lncRNA target	hsa-mir-449a	Carcinoma, Lung, Non-Small-Cell	28248928			C34.90	D002289		HP:0030358	The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancerThis article has been corrected since Advanced Online Publication, and an erratum is also printed in this issue.
lncRNA target	hsa-let-7a	Carcinoma, Nasopharyngeal	28117929	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Downregulation of lncRNA ANRIL represses tumorigenicity and enhances cisplatin-induced cytotoxicity via regulating microRNA let-7a in nasopharyngeal carcinoma.
lncRNA target	hsa-mir-134	Carcinoma, Nasopharyngeal	28728844	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Long non-coding RNA PCAT7 regulates ELF2 signaling through inhibition of miR-134-5p in nasopharyngeal carcinoma.
lncRNA target	hsa-mir-181a	Carcinoma, Nasopharyngeal	28358263	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis.
lncRNA target	hsa-mir-204	Carcinoma, Nasopharyngeal	27020592	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	The long non-coding RNA NEAT1 regulates epithelial to mesenchymal transition and  radioresistance in through miR-204/ZEB1 axis in nasopharyngeal carcinoma.
lncRNA target	hsa-mir-214	Carcinoma, Nasopharyngeal	28245169	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Long Noncoding RNA LINC0086 Functions as a Tumor Suppressor in Nasopharyngeal Carcinoma by Targeting miR-214.
lncRNA target	hsa-mir-34a	Carcinoma, Nasopharyngeal	27461945	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Long non-coding RNA XIST exerts oncogenic functions in human nasopharyngeal carcinoma by targeting miR-34a-5p
lncRNA target	hsa-mir-145	Carcinoma, Oral	28443494	gastrointestinal system disease	DOID:0050610					Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer.
lncRNA target	hsa-mir-106b	Carcinoma, Ovarian	28864116	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	lncRNA PCA3 may coordinate EOC tumorigenesis through disrupting miR-106b regulated gene expression
lncRNA target	hsa-mir-373	Carcinoma, Ovarian	27484896	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer.
lncRNA target	hsa-mir-124	Carcinoma, Pancreatic	27785603			C25.3	C562463	260350	HP:0002894	Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis.
lncRNA target	hsa-mir-133	Carcinoma, Pancreatic	29772434			C25.3	C562463	260350	HP:0002894	The interaction of long non-coding RNA MIAT and miR-133 play a role in the proliferation and metastasis of pancreatic carcinoma.
lncRNA target	hsa-mir-214	Carcinoma, Pancreatic	28639886			C25.3	C562463	260350	HP:0002894	A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer.
lncRNA target	hsa-mir-429	Carcinoma, Pancreatic	28639886			C25.3	C562463	260350	HP:0002894	A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer.
lncRNA target	hsa-mir-506	Carcinoma, Pancreatic	27888106			C25.3	C562463	260350	HP:0002894	Long non-coding RNA NEAT1 facilitates pancreatic cancer progression through negative modulation of miR-506-3p.
lncRNA target	hsa-mir-199a	Carcinoma, Prostate	28400279	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer.
lncRNA target	hsa-mir-495	Carcinoma, Renal Cell	28466784	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495.
lncRNA target	hsa-mir-200a	Carcinoma, Renal Cell, Clear-Cell	26461224	disease of cellular proliferation	DOID:4467				HP:0006770	LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma.
lncRNA target	hsa-mir-200b	Carcinoma, Renal Cell, Clear-Cell	26461224	disease of cellular proliferation	DOID:4467				HP:0006770	LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma.
lncRNA target	hsa-mir-200c	Carcinoma, Renal Cell, Clear-Cell	26461224	disease of cellular proliferation	DOID:4467				HP:0006770	LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma.
lncRNA target	hsa-mir-141	Carcinoma, Renal Cell, Clear-Cell	26461224	disease of cellular proliferation	DOID:4467				HP:0006770	LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma.
lncRNA target	hsa-mir-429	Carcinoma, Renal Cell, Clear-Cell	26461224	disease of cellular proliferation	DOID:4467				HP:0006770	LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma.
lncRNA target	hsa-mir-181a	Carcinoma, Skin	29514220	disease of cellular proliferation	DOID:3451	D04.9	D018280		HP:0008069	Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a/PLXNC1 axis in melanoma.
lncRNA target	hsa-mir-214	Carcinoma, Thyroid	28000845	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214.
lncRNA target	hsa-mir-124	Carcinoma, Tounge	28260102							Long non-coding RNA MALAT1 interacts with miR-124 and modulates tongue cancer growth by targeting JAG1.
lncRNA target	hsa-mir-21	Cardiac Fibrosis	28526319							LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway.
lncRNA target	hsa-mir-124	Cardiovascular Diseases [unspecific]	29042195				D002318			Circular RNA WDR77 target FGF-2 to regulate vascular smooth muscle cells proliferation and migration by sponging miR-124.
lncRNA target	hsa-let-7a	Cervical Neoplasms	27487126	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells.
lncRNA target	hsa-mir-145	Cervical Neoplasms	26311052	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer  via sponging miR-145.
lncRNA target	hsa-mir-34a	Cervical Neoplasms	29218240	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The long noncoding RNA LINC00473, a target of microRNA 34a, promotes tumorigenesis by inhibiting ILF2 degradation in cervical cancer
lncRNA target	hsa-mir-31	Chordoma	28963737	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	Long non-coding RNA LOC554202 modulates chordoma cell proliferation and invasion by recruiting EZH2 and regulating miR-31 expression.
lncRNA target	hsa-mir-204	Choriocarcinoma	28059437	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Long Non-Coding RNA MALAT1 Interacts With miR-204 to Modulate Human Hilar Cholangiocarcinoma Proliferation, Migration, and Invasion by Targeting CXCR4.
lncRNA target	hsa-let-7	Colitis, Ulcerative	29621481	gastrointestinal system disease	DOID:8577	K51	D003093			H19 lncRNA bound to p53 and microRNAs that inhibit cell proliferation, including microRNA 34a and let-7; H19 lncRNA binding blocked their function, leading to increased expression of genes that promote regeneration of the epithelium
lncRNA target	hsa-mir-145	Colon Neoplasms	27071407			D12.6	D003110		HP:0100273	Knockdown of lincRNA-ROR restored the expression of miR-145, and had a significant influence on colon cancer cell proliferation, migration and invasion.
lncRNA target	hsa-mir-145	Colon Neoplasms	29690669			D12.6	D003110		HP:0100273	LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells
lncRNA target	hsa-mir-21	Colon Neoplasms	28954383			D12.6	D003110		HP:0100273	Long non-coding RNA CASC7 inhibits the proliferation and migration of colon cancer cells via inhibiting microRNA-21.
lncRNA target	hsa-mir-143	Colorectal Carcinoma	28619512	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		PART-1 functions as a competitive endogenous RNA for promoting tumor progression by sponging miR-143 in colorectal cancer.
lncRNA target	hsa-mir-181a	Colorectal Carcinoma	28086904	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling.
lncRNA target	hsa-mir-200a	Colorectal Carcinoma	28164117	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The lncRNA H19 Promotes Cell Proliferation by Competitively Binding to miR-200a and Derepressing β-Catenin Expression in Colorectal Cancer.
lncRNA target	hsa-mir-215	Colorectal Carcinoma	29187907	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression
lncRNA target	hsa-mir-218	Colorectal Carcinoma	28069878	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the interaction between lncRNA MALAT1 and miR-218 was observed, which further indicated its prognostic value in patients who received standard FOLFOX treatment
lncRNA target	hsa-mir-92a	Coronary Artery Disease	28760552	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		CDKN2B-AS may indirectly regulate coronary artery disease-associated genes via targeting miR-92a.
lncRNA target	hsa-mir-23c	Diabetic Nephropathy	27964927			E10-11.21	D003928			Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy.
lncRNA target	hsa-mir-27a	Diabetic Nephropathy	29334763			E10-11.21	D003928			Long Noncoding RNA LINC01619 Regulates MicroRNA-27a/Forkhead Box Protein O1 and Endoplasmic Reticulum Stress-Mediated Podocyte Injury in Diabetic Nephropathy
lncRNA target	hsa-mir-29b	Diabetic Retinopathy	28246353	nervous system disease	DOID:8947	E10-11.31	D003930			Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis.
lncRNA target	hsa-mir-320a	Embryonal Testis Carcinoma	26539909	disease of cellular proliferation	DOID:5680	C62.00	C104948	273300		The accumulation of NLC1-C in the nucleus repressed miR-320a and miR-383 transcript and promoted testicular embryonal carcinoma cell proliferation by binding to Nucleolin. Here, we define a novel mechanism by which lncRNAs modulate miRNA expression at the transcriptional level by binding to RNA-binding proteins to regulate human spermatogenesis.
lncRNA target	hsa-let-7b	Epilepsy	29795132	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Long non-coding RNA H19 contributes to apoptosis of hippocampal neurons by inhibiting let-7b in a rat model of temporal lobe epilepsy.
lncRNA target	hsa-mir-770	Gastric Cardia Adenocarcinoma	28345805	disease of cellular proliferation	DOID:6271					Promoter hypermethylation-mediated downregulation of miR-770 and its host gene MEG3, a long non-coding RNA, in the development of gastric cardia adenocarcinoma.
lncRNA target	hsa-mir-107	Gastric Neoplasms	26636340	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results suggest that the Lin28/miR-107 pathway could be one of many signaling pathways regulated by Lin28 and associated with gastric cancer chemo-resistance.
lncRNA target	hsa-mir-152	Gastric Neoplasms	26187665	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Long non-coding RNA HOTAIR promotes HLA-G expression via inhibiting miR-152 in gastric cancer cells.
lncRNA target	hsa-mir-200c	Gastric Neoplasms	25986864	disease of cellular proliferation	DOID:10534	C16	D013274	137215		LncRNA-ATB plays an important role in EMT to promote invasion and metastasis through the TGF-尾/miR-200s/ZEB axis
lncRNA target	hsa-mir-206	Gastric Neoplasms	27192121	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Acting as a miR-206 sponge, RMRP modulated cell cycle by regulating Cyclin D2 expression.
lncRNA target	hsa-mir-30a	Gastric Neoplasms	29761936	disease of cellular proliferation	DOID:10534	C16	D013274	137215		upregulated expression of linc00483 in gastric cancer acts as a sponge to absorb endogenous tumour suppressor miR-30a-3p
lncRNA target	hsa-mir-34a	Gastric Neoplasms	29080815	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
lncRNA target	hsa-mir-675	Gastric Neoplasms	24388988	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1.
lncRNA target	hsa-mir-7	Gastric Neoplasms	28608528	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of Circular RNA ciRS-7 Abrogates the Tumor Suppressive Effect of miR-7 on Gastric Cancer via PTEN/PI3K/AKT Signaling Pathway.
lncRNA target	hsa-mir-101	Glioblastoma	29479863				D005909		HP:0100843	Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma
lncRNA target	hsa-mir-10a	Glioblastoma	27270310				D005909		HP:0100843	Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
lncRNA target	hsa-mir-10a	Glioblastoma	29397407				D005909		HP:0100843	Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma
lncRNA target	hsa-mir-21	Glioblastoma	28423669				D005909		HP:0100843	The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells.
lncRNA target	hsa-mir-26a	Glioblastoma	28499919				D005909		HP:0100843	Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy.
lncRNA target	hsa-mir-299	Glioblastoma	27345398				D005909		HP:0100843	TUG1 enhances tumor-induced angiogenesis and VEGF expression through inhibiting miR-299.
lncRNA target	hsa-mir-107	Glioma	27878295	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Silencing of the long non-coding RNA NEAT1 suppresses glioma stem-like properties through modulation of the miR-107/CDK6 pathway.
lncRNA target	hsa-mir-124	Glioma	29412778	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	TP73-AS1 was specificallyupregulated in brain glioma cell lines and promoted glioma cell growth through targeting miR-124TP73-AS1 was specifically upregulated in brain glioma cell lines and promoted glioma cell growth through targeting miR-124
lncRNA target	hsa-mir-139	Glioma	27434586	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	HCP5 regulated the malignant behavior of glioma cells by binding to microRNA-139, which functions as a tumor suppressor.
lncRNA target	hsa-mir-140	Glioma	27693036	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The lncRNA H19 interacts with miR-140 to modulate glioma growth by targeting iASPP.
lncRNA target	hsa-mir-181a	Glioma	28121023	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
lncRNA target	hsa-mir-182	Glioma	28137422	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP.
lncRNA target	hsa-mir-26a	Glioma	27363339	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Long non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells
lncRNA target	hsa-mir-373	Glioma	29310118	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis
lncRNA target	hsa-mir-384	Glioma	27058823	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Moreover, CRNDE promoted cell malignant behavior by decreasing miR-384 expression.
lncRNA target	hsa-mir-410	Glioma	27765628	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Long non-coding RNA CCAT1 promotes glioma cell proliferation via inhibiting microRNA-410.
lncRNA target	hsa-mir-675	Glioma	24466011	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675.
lncRNA target	hsa-mir-675	Glioma	27981546	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	LncRNA H19 is overexpressed in glioma tissue, is negatively associated with patient survival, and promotes tumor growth through its derivative miR-675.
lncRNA target	hsa-mir-9	Glioma	29137410	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	LINC00461 knockdown decreased expression levels of microRNA miR-9 and flanking genes MEF2C and TMEM161B
lncRNA target	hsa-mir-125b	Hepatitis B Virus Infection	28267418	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B/let-7 axis.
lncRNA target	hsa-mir-200a	Hepatitis C Virus Infection	28302418	disease by infectious agent	DOID:1883	B19.2	D006526	609532		LncRNA-ATB/microRNA-200a/β-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis.
lncRNA target	hsa-mir-200b	Hepatitis C Virus Infection	28302418	disease by infectious agent	DOID:1883	B19.2	D006526	609532		LncRNA-ATB/microRNA-200a/β-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis.
lncRNA target	hsa-mir-23a	Hypoxic-Ischemic Encephalopathy	29428721			P91.60	D020925			GAS5 regulated hippocampal neuron function by sponging miR-23a
lncRNA target	hsa-mir-125a	Immune Thrombocytopenic Purpura	27522004	immune system disease	DOID:8924	D69.3	D016553	188030		Long non-coding RNA MEG3 inhibits microRNA-125a-5p expression and induces immune  imbalance of Treg/Th17 in immune thrombocytopenic purpura.
lncRNA target	hsa-mir-34c	Inflammatory Bowel Diseases	28153728	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	MiR-34c and PlncRNA1 mediated the function of intestinal epithelial barrier by regulating tight junction proteins in inflammatory bowel disease.
lncRNA target	hsa-mir-124	Invasive Bladder Transitional Cell Carcinoma	29736319	disease of cellular proliferation	DOID:6477	C67.9			HP:0006740	LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC).
lncRNA target	hsa-mir-125b	Leukemia	27740626			C95	D007938	613065	HP:0001909	HOTAIRM1 was revealed to act as a microRNA sponge in a pathway that included miR-20a/106b, miR-125b and their targets ULK1, E2F1 and DRAM2
lncRNA target	hsa-mir-16	Leukemia	27854515			C95	D007938	613065	HP:0001909	lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells.
lncRNA target	hsa-mir-21	Leukemia	28190319			C95	D007938	613065	HP:0001909	LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21.
lncRNA target	hsa-let-7	Leukemia, Myeloid, Acute	28693523	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	LIN28B/let-7/IGF2BP1, in leukemogenesis and provide a rationale to target this pathway as effective therapeutic strategy
lncRNA target	hsa-mir-125a	Leukemia, Myeloid, Acute	29663500	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway
lncRNA target	hsa-mir-193a	Leukemia, Myeloid, Acute	25979172	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia.
lncRNA target	hsa-mir-200a	Leukemia, Myeloid, Chronic	28069548	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	HULC could modulate c-Myc and Bcl-2 by miR-200a as an endogenous sponge
lncRNA target	hsa-mir-181b	Liver Cirrhosis	27610008	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Identification of a Novel lincRNA-p21-miR-181b-PTEN Signaling Cascade in Liver Fibrosis.
lncRNA target	hsa-mir-29b	Liver Cirrhosis	28129115	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	HOTAIR Epigenetically Modulates PTEN Expression via MicroRNA-29b: A Novel Mechanism in Regulation of Liver Fibrosis.
lncRNA target	hsa-mir-222	Liver Fibrosis	26446789			K74	D008103			GAS5 could directly bind to miR-222.
lncRNA target	hsa-mir-200c	Lung Fibrosis	29113749	respiratory system disease	DOID:3770	J84.10	D011658	178500		Long non-coding RNA-ATB promotes EMT during silica-induced pulmonary fibrosis by competitively binding miR-200c.
lncRNA target	hsa-mir-150	Lung Injury [unspecific]	28655711			S27.309D	D055370			Long noncoding RNA FOXD3-AS1 regulates oxidative stress-induced apoptosis via sponging microRNA-150.
lncRNA target	hsa-let-7g	Lung Neoplasms	19745602	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	increased with response to ionizing radiation when knockdown LIN28B
lncRNA target	hsa-mir-144	Lung Neoplasms	28762326	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Long Noncoding RNA Urothelial Carcinoma Associated 1 Promotes the Proliferation and Metastasis of Human Lung Tumor Cells by Regulating MicroRNA-144.
lncRNA target	hsa-mir-218	Lung Neoplasms	27212446	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-218 is negatively regulated by CCAT1 in HBE cells exposed to CSE.
lncRNA target	hsa-mir-873	Lung Neoplasms	29790668	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The effects of aberrant expression of LncRNA DGCR5/miR-873-5p/TUSC3 in lung cancer cell progression.
lncRNA target	hsa-let-7	Malignant Neoplasms [unspecific]	28076679			C80.1	D009369			Molecular Dynamics Simulations for Deciphering the Structural Basis of Recognition of Pre-let-7 miRNAs by LIN28.
lncRNA target	hsa-mir-19b	Medulloblastoma	28415684	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	The long noncoding RNA linc-NeD125 controls the expression of medulloblastoma driver genes by microRNA sponge activity.
lncRNA target	hsa-let-7	Melanoma	26071398	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we discovered that Lin28B, a well-characterized inhibitor of let-7 miRNA biogenesis, was a direct target of miR-125a-5p in melanoma.
lncRNA target	hsa-mir-183	Melanoma	27966454	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Deregulation of miR-183 promotes melanoma development via lncRNA MALAT1 regulation and ITGB1 signal activation.
lncRNA target	hsa-mir-200b	Melanoma	28487474	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429.
lncRNA target	hsa-mir-429	Melanoma	28487474	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429.
lncRNA target	hsa-mir-507	Melanoma	27389544	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	We found that miR-507 could directly bind to UCA1 at the miRNA recognition site, and that there was a negative correlation between miR-507 and UCA1.
lncRNA target	hsa-mir-21	Multiple Myeloma	28801664	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	we identified microRNA-21 as a STAT3 target gene with strong anti-apoptotic potential, suggesting that noncoding RNAs have an impact on the pathogenesis of human multiple myeloma
lncRNA target	hsa-mir-150	Myocardial Infarction	27649667	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150.
lncRNA target	hsa-mir-150	Myocardial Infarction	28295592	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Knockdown of Long Non-Coding RNA-ZFAS1 Protects Cardiomyocytes Against Acute Myocardial Infarction Via Anti-Apoptosis by Regulating miR-150/CRP.
lncRNA target	hsa-mir-150	Myocardial Infarction	28843520	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The long non-coding RNA MIAT regulates zinc finger E-box binding homeobox 1 expression by sponging miR-150 and promoteing cell invasion in non-small-cell lung cancer.
lncRNA target	hsa-let-7	Neoplasms [unspecific]	26440890			C80.1	D009369			These findings refine the current model of let-7 regulation by LIN28 proteins and have important implications for understanding the LIN28/let-7 axis in development and disease.
lncRNA target	hsa-let-7	Neoplasms [unspecific]	27548809			C80.1	D009369			We anticipate that much can be learned from the use of this first reported small molecule antagonist of Lin28, including the potential of the Lin28/let-7 interaction as a new drug target for selected cancers
lncRNA target	hsa-let-7	Neoplasms [unspecific]	28846452			C80.1	D009369			Concise Review: LIN28/let-7 Signaling, a Critical Double-Negative Feedback Loop During Pluripotency, Reprogramming, and Tumorigenicity.
lncRNA target	hsa-let-7a	Neoplasms [unspecific]	21045151			C80.1	D009369			Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells.
lncRNA target	hsa-let-7a-1	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7a-1	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7a-2	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7a-2	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7a-3	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7a: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7a-3	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7b	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7b: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7b	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7b	Neoplasms [unspecific]	21045151			C80.1	D009369			Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells.
lncRNA target	hsa-let-7c	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7c: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7c	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7c	Neoplasms [unspecific]	21045151			C80.1	D009369			Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells.
lncRNA target	hsa-let-7d	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7d: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7d	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7d	Neoplasms [unspecific]	21045151			C80.1	D009369			Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells.
lncRNA target	hsa-let-7e	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7e: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7e	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7e	Neoplasms [unspecific]	21045151			C80.1	D009369			Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells.
lncRNA target	hsa-let-7f	Neoplasms [unspecific]	21045151			C80.1	D009369			Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells.
lncRNA target	hsa-let-7f-1	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7f: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7f-1	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7f-2	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7f: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7f-2	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7g	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7g: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7g	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7g	Neoplasms [unspecific]	21045151			C80.1	D009369			Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells.
lncRNA target	hsa-let-7i	Neoplasms [unspecific]	19211792			C80.1	D009369			let-7i: Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
lncRNA target	hsa-let-7i	Neoplasms [unspecific]	20005451			C80.1	D009369			Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
lncRNA target	hsa-let-7i	Neoplasms [unspecific]	21045151			C80.1	D009369			Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells.
lncRNA target	hsa-mir-107	Neoplasms [unspecific]	26158177			C80.1	D009369			Lin28 could mediate cancer chemotherapy resistance via regulation of miR107 and Let-7 MiRNA.
lncRNA target	hsa-mir-205	Neoplasms [unspecific]	28825698			C80.1	D009369			Functionally the lncRNA-PNUTS serves as a competitive sponge for miR-205 during epithelial-mesenchymal transition (EMT)
lncRNA target	hsa-mir-20a	Neoplasms [unspecific]	28542387			C80.1	D009369			LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells.
lncRNA target	hsa-mir-143	Neuroblastoma	27263970	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Binding and release of miR-143-3p by LncND control the expression of Notch receptors.
lncRNA target	hsa-mir-17	Non-Traumatic Osteonecrosis	28207735			M90.5	D010020			Long non-coding RNA HOTAIR inhibits miR-17-5p to regulate osteogenic differentiation and proliferation in non-traumatic osteonecrosis of femoral head.
lncRNA target	hsa-mir-21	Osteoarthritis	25196583	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	A long non-coding RNA, GAS5, plays a critical role in the regulation of miR-21 during osteoarthritis.
lncRNA target	hsa-mir-34a	Osteoarthritis	27529373	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Furthermore, we found that UFC1 regulates survival of OA chondrocytes through physically association with miR-34a.
lncRNA target	hsa-mir-125b	Osteosarcoma	28695772	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Circular RNA GLI2 promotes osteosarcoma cell proliferation, migration, and invasion by targeting miR-125b-5p.
lncRNA target	hsa-mir-129	Osteosarcoma	28346809	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p.
lncRNA target	hsa-mir-142	Osteosarcoma	28346809	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p.
lncRNA target	hsa-mir-195	Osteosarcoma	27813492	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195.
lncRNA target	hsa-mir-21	Osteosarcoma	29323740	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Long non-coding RNA ASBEL promotes osteosarcoma cell proliferation, migration and invasion by regulating microRNA-21
lncRNA target	hsa-mir-210	Osteosarcoma	28415557	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	lncRNA CTA is an essential regulator in DOX-induced OS cell apoptosis, and the lncRNA CTA-miR-210 axis plays an important role in reducing OS chemoresistance
lncRNA target	hsa-mir-221	Osteosarcoma	28519068	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating the miR-221/ARHI Pathway.
lncRNA target	hsa-mir-29c	Osteosarcoma	28789596	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	WITHDRAWN: Circular RNA hsa_circ_0001564 facilitates tumorigenesis of osteosarcoma via sponging miR-29c-3p.
lncRNA target	hsa-mir-34c	Osteosarcoma	29654165	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Knockdown of the oncogene LncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma
lncRNA target	hsa-mir-645	Osteosarcoma	27609068	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.
lncRNA target	hsa-mir-9	Osteosarcoma	27658774	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression.
lncRNA target	hsa-mir-485	Ovarian Neoplasms	26867765	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	UCA1 could function as an endogenous sponge by directly binding to miR-485-5p.
lncRNA target	hsa-let-7	Pancreatic Neoplasms	28580169	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		linc-ROR functioned as a competing endogenous RNA (ceRNA) to several tumor suppressor microRNAs, particularly some members of let-7 family
lncRNA target	hsa-mir-145	Pancreatic Neoplasms	26636540	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer.
lncRNA target	hsa-mir-32	Pancreatic Neoplasms	29225772	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis
lncRNA target	hsa-let-7	Perlman Syndrome	23594738	syndrome	DOID:0060476		C536399	267000		A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway.
lncRNA target	hsa-mir-146a	Prostate Neoplasms	27794184	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a.
lncRNA target	hsa-let-7a	Retinal Degeneration	20935637	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals.
lncRNA target	hsa-let-7b	Retinal Degeneration	20935637	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals.
lncRNA target	hsa-let-7c	Retinal Degeneration	20935637	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals.
lncRNA target	hsa-let-7d	Retinal Degeneration	20935637	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals.
lncRNA target	hsa-let-7e	Retinal Degeneration	20935637	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals.
lncRNA target	hsa-let-7f	Retinal Degeneration	20935637	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals.
lncRNA target	hsa-let-7g	Retinal Degeneration	20935637	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals.
lncRNA target	hsa-let-7i	Retinal Degeneration	20935637	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	The opposing actions of Lin-28 and let-7 miRNAs on Müller glia differentiation and dedifferentiation are similar to that of embryonic stem cells and suggest novel targets for stimulating Müller glia dedifferentiation and retinal regeneration in mammals.
lncRNA target	hsa-mir-218	Retinoblastoma	28088735	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Long non-coding RNA CCAT1 promotes human retinoblastoma SO-RB50 and Y79 cells through negative regulation of miR-218-5p.
lncRNA target	hsa-mir-125b	Sepsis	29227823			A41.9	D018805		HP:0100806	MALAT1 aggravates cardiac inflammation and dysfunction in sepsis, which is achieved via interaction with miR-125b and p38 MAPK/NFκB
lncRNA target	hsa-let-7a	Squamous Cell Carcinoma, Esophageal	29393461	disease of cellular proliferation	DOID:3748		C562729			Lin28/microRNA-let-7a promotes metastasis under circumstances of hyperactive Wnt  signaling in esophageal squamous cell carcinoma
lncRNA target	hsa-mir-200b	Squamous Cell Carcinoma, Esophageal	28640252	disease of cellular proliferation	DOID:3748		C562729			Long non-coding RNA ATB promotes malignancy of esophageal squamous cell carcinoma by regulating miR-200b/Kindlin-2 axis.
lncRNA target	hsa-mir-218	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	28631575	disease of cellular proliferation	DOID:2876					Long non-coding RNA CCAT1/miR-218/ZFX axis modulates the progression of laryngeal squamous cell cancer.
lncRNA target	hsa-mir-125b	Squamous Cell Carcinoma, Oral	28926115	disease of cellular proliferation	DOID:0050866					Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis.
lncRNA target	hsa-mir-184	Squamous Cell Carcinoma, Oral	29125238	disease of cellular proliferation	DOID:0050866					LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
lncRNA target	hsa-mir-224	Squamous Cell Carcinoma, Oral	28093311	disease of cellular proliferation	DOID:0050866					Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression.
lncRNA target	hsa-mir-21	Stroke, Ischemic	29238035			I63.9			HP:0002140	our data uncovers a novel mechanism of lncRNA MEG3 as a ceRNA by targeting  miR-21/PDCD4 signaling pathway in regulating ischemic neuronal death, which may help develop new strategies for the therapeutic interventions in cerebral ischemic stroke
lncRNA target	hsa-mir-204	Uterine Corpus Endometrial Carcinoma	28280730	disease of cellular proliferation	DOID:0050939					Cancer-Related Triplets of mRNA-lncRNA-miRNA Revealed by Integrative Network in Uterine Corpus Endometrial Carcinoma.
lncRNA target	hsa-mir-320	Uterine Corpus Endometrial Carcinoma	28280730	disease of cellular proliferation	DOID:0050939					Cancer-Related Triplets of mRNA-lncRNA-miRNA Revealed by Integrative Network in Uterine Corpus Endometrial Carcinoma.
lncRNA target	hsa-mir-195	Wilms Tumor	29159834			C64.2	D009396	PS194070	HP:0002667	LINC00473 as an oncogene is up-regulated to participate into the molecular pathogenesis of Wilms tumour via miR-195/IKKα
other	hsa-mir-198	Acquired Immunodeficiency Syndrome	19148268	disease by infectious agent	DOID:635	B20	D000163	609423		miR-198: miR-198 inhibits HIV-1 gene expression and replication in monocytes
other	hsa-mir-29a	Acquired Immunodeficiency Syndrome	16236258	disease by infectious agent	DOID:635	B20	D000163	609423		miRNAs expressed in T-cells can repress nef function and thus influence disease progression.
other	hsa-mir-29a	Acquired Immunodeficiency Syndrome	19102781	disease by infectious agent	DOID:635	B20	D000163	609423		miR-29a: Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication
other	hsa-mir-29b-1	Acquired Immunodeficiency Syndrome	16236258	disease by infectious agent	DOID:635	B20	D000163	609423		miRNAs expressed in T-cells can repress nef function and thus influence disease progression.
other	hsa-mir-126	Acute Brucellosis	27824867	disease by infectious agent	DOID:11077	A23	D002006			MicroRNA Expression Patterns of CD8+ T Cells in Acute and Chronic Brucellosis.
other	hsa-mir-4753	Acute Brucellosis	27824867	disease by infectious agent	DOID:11077	A23	D002006			MicroRNA Expression Patterns of CD8+ T Cells in Acute and Chronic Brucellosis.
other	hsa-let-7e	Acute Coronary Syndrome	25903651			I24.9	D054058			These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology.
other	hsa-mir-107	Acute Coronary Syndrome	25903651			I24.9	D054058			These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology.
other	hsa-mir-1-1	Acute Coronary Syndrome	21806992			I24.9	D054058			The miRNA was independently associated with hsTnT levels.
other	hsa-mir-1-2	Acute Coronary Syndrome	21806992			I24.9	D054058			The miRNA was independently associated with hsTnT levels.
other	hsa-mir-133a-1	Acute Coronary Syndrome	21806992			I24.9	D054058			The miRNA was independently associated with hsTnT levels. Its level was significantly associated with the risk of death in univariate and age- and gender-adjusted analyses.
other	hsa-mir-133a-2	Acute Coronary Syndrome	21806992			I24.9	D054058			The miRNA was independently associated with hsTnT levels. Its level was significantly associated with the risk of death in univariate and age- and gender-adjusted analyses.
other	hsa-mir-133b	Acute Coronary Syndrome	21806992			I24.9	D054058			The miRNA was independently associated with hsTnT levels.
other	hsa-mir-146a	Acute Coronary Syndrome	20195282			I24.9	D054058			miR-146a in PBMCs modulates Th1 function in patients with acute coronary syndrome
other	hsa-mir-155	Acute Coronary Syndrome	21804579			I24.9	D054058			The altered expression of inflammation-related microRNAs with microRNA-155 expression correlates with Th17 differentiation in patients with acute coronary syndrome.
other	hsa-mir-15b	Acute Coronary Syndrome	25903651			I24.9	D054058			These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology.
other	hsa-mir-208b	Acute Coronary Syndrome	21806992			I24.9	D054058			The miRNA was independently associated with hsTnT levels. Its level was significantly associated with the risk of death in univariate and age- and gender-adjusted analyses.
other	hsa-mir-223	Acute Coronary Syndrome	24202700			I24.9	D054058			Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome.
other	hsa-mir-486	Acute Coronary Syndrome	25903651			I24.9	D054058			These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology.
other	hsa-mir-92b	Acute Coronary Syndrome	25903651			I24.9	D054058			These results demonstrate a significant reprogramming of the platelet miRNome during activation, with consequent significant changes in platelet proteome and provide for the first time substantial evidence that fine-tuning of resident mRNA translation by miRNAs is a key event in platelet pathophysiology.
other	hsa-let-7i	Acute Ischemic Stroke	24911610	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis.
other	hsa-let-7i	Acute Ischemic Stroke	27784773	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Leukocyte response is regulated by microRNA let7i in patients with acute ischemic stroke.
other	hsa-mir-1	Acute Kidney Failure	26400542	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	Ramipril reduced cardiac hypertrophy, attenuated the increase in microRNA-212 and microRNA-132, and significantly increased microRNA-133 and microRNA-1 expression.
other	hsa-mir-182	Acute Kidney Failure	27865759	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miRNA-Coordinated Networks as Promising Therapeutic Targets for Acute Kidney Injury.
other	hsa-mir-21	Acute Kidney Failure	27122240	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	In summary, we report noninvasive detection of AKI in humans by combining the sensitivity of KIM-1 along with mechanistic potentials of miR-21, -200c, and -423.
other	hsa-mir-34a	Acute Kidney Failure	20386864	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival.
other	hsa-mir-21	Acute Kidney Failure	24214874	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	MicroRNA-21 in the pathogenesis of acute kidney injury.
other	hsa-mir-125b	Acute Lung Injury	25004393			S27	D055371			Enforced expression of miR-125b attenuates LPS-induced acute lung injury.
other	hsa-mir-16	Acute Lung Injury	29484411			S27	D055371			miR-16 inhibits hyperoxia-induced cell apoptosis in human alveolar epithelial cells
other	hsa-mir-125b-2	Acute Megakaryoblastic Leukemia	20194440	disease of cellular proliferation	DOID:8761	C94.2	D007947	606078		we propose miR-125b-2 as a positive regulator of megakaryopoiesis and an oncomiR involved in the pathogenesis of trisomy 21-associated megakaryoblastic leukemia.
other	hsa-mir-1291	Acute Myocardial Infarction	24885383	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	This study demonstrated that the levels of miR-133, miR-1291 and miR-663b are associated with AMI. The potential of these miRNAs as biomarkers to improve patient stratification according to the risk of AMI and as circulating biomarkers for the AMI progonos warrants further study.
other	hsa-mir-133	Acute Myocardial Infarction	24885383	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	This study demonstrated that the levels of miR-133, miR-1291 and miR-663b are associated with AMI. The potential of these miRNAs as biomarkers to improve patient stratification according to the risk of AMI and as circulating biomarkers for the AMI progonos warrants further study.
other	hsa-mir-133	Acute Myocardial Infarction	29845217	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	By searching the mir2disease database, four miRNAs associated with AMI were identified, including hsa-miR-21, hsa-miR-133, hsa-miR-29 and hsa-miR-30c.
other	hsa-mir-134	Acute Myocardial Infarction	24833470	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction.
other	hsa-mir-145	Acute Myocardial Infarction	25465803	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-145 may be a novel biomarker for predicting long-term outcome after acute myocardial infarction.
other	hsa-mir-150	Acute Myocardial Infarction	26077801	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Results indicated that the levels of circulating miR-486 and miR-150 are associated with AMI. They may be novel and powerful biomarkers for AMI,especially for NSTEMI.
other	hsa-mir-191	Acute Myocardial Infarction	26044724	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	miR-208b was significantly increased in the AMI compared with healthy people, while miR-26a and miR-191 were decreased. miR-26a, miR-191, and miR-208b were potential indices of AMI, and miR-208b was more effective in patients with non-ST-elevation myocardial infarction.
other	hsa-mir-208b	Acute Myocardial Infarction	26044724	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	miR-208b was significantly increased in the AMI compared with healthy people, while miR-26a and miR-191 were decreased. miR-26a, miR-191, and miR-208b were potential indices of AMI, and miR-208b was more effective in patients with non-ST-elevation myocardial infarction.
other	hsa-mir-208b	Acute Myocardial Infarction	26712201	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	none
other	hsa-mir-21	Acute Myocardial Infarction	29845217	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	By searching the mir2disease database, four miRNAs associated with AMI were identified, including hsa-miR-21, hsa-miR-133, hsa-miR-29 and hsa-miR-30c.
other	hsa-mir-26a	Acute Myocardial Infarction	26044724	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	miR-208b was significantly increased in the AMI compared with healthy people, while miR-26a and miR-191 were decreased. miR-26a, miR-191, and miR-208b were potential indices of AMI, and miR-208b was more effective in patients with non-ST-elevation myocardial infarction.
other	hsa-mir-29	Acute Myocardial Infarction	29845217	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	By searching the mir2disease database, four miRNAs associated with AMI were identified, including hsa-miR-21, hsa-miR-133, hsa-miR-29 and hsa-miR-30c.
other	hsa-mir-30c	Acute Myocardial Infarction	29845217	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	By searching the mir2disease database, four miRNAs associated with AMI were identified, including hsa-miR-21, hsa-miR-133, hsa-miR-29 and hsa-miR-30c.
other	hsa-mir-328	Acute Myocardial Infarction	24833470	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction.
other	hsa-mir-486	Acute Myocardial Infarction	26077801	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Results indicated that the levels of circulating miR-486 and miR-150 are associated with AMI. They may be novel and powerful biomarkers for AMI,especially for NSTEMI.
other	hsa-mir-497	Acute Myocardial Infarction	25110754	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	High association between human circulating microRNA-497 and acute myocardial infarction.
other	hsa-mir-499	Acute Myocardial Infarction	23872321	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	We developed a novel reverse-transcription real-time PCR assay for human miR-499 quantification. The good reproducibility and wide linearity range may permit more use of it in the quantification of other human miRNAs in future.
other	hsa-mir-499	Acute Myocardial Infarction	23192357	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	The target miRNA is miRNA-499, a biomarker candidate of AMI with low abundance in biological samples. 
other	hsa-mir-663b	Acute Myocardial Infarction	24885383	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	This study demonstrated that the levels of miR-133, miR-1291 and miR-663b are associated with AMI. The potential of these miRNAs as biomarkers to improve patient stratification according to the risk of AMI and as circulating biomarkers for the AMI progonos warrants further study.
other	hsa-mir-92a	Acute Myocardial Infarction	25240056	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Early single intracoronary administration of encapsulated antagomir-92a in an adult pig model of reperfused AMI prevents left ventricular remodeling with no local or distant adverse effects
other	hsa-mir-216	Acute Pancreatitis	28183420	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	Circulating microRNA 216 as a Marker for the Early Identification of Severe Acute Pancreatitis.
other	hsa-mir-216a	Acute Pancreatitis	23995054	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	MiR-216a and miR-216b as markers for acute phased pancreatic injury.
other	hsa-mir-216b	Acute Pancreatitis	23995054	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	MiR-216a and miR-216b as markers for acute phased pancreatic injury.
other	hsa-mir-34a	Acute Pancreatitis	28592850	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	NAD+ augmentation ameliorates acute pancreatitis through regulation of inflammasome signalling.
other	hsa-mir-27a	Adenocarcinoma, Cervical	29531222	disease of cellular proliferation	DOID:3702					miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-βRI signaling pathway.
other	hsa-mir-9	Adenocarcinoma, Cervical	25809226	disease of cellular proliferation	DOID:3702					our results here present a tumor suppressor potential of miR-9 in cervical adenocarcinoma for the first time and suggest that miR-9 could repress tumorigenesis through inhibiting the activity of IL-6/Jak/STAT3 pathway.has-miR-146b-5p
other	hsa-mir-193a	Adenocarcinoma, Colon	21670079	disease of cellular proliferation	DOID:234	C18			HP:0040276	Finally, expression of miR-193a is inversely correlated with PLAU and K-Ras in human colon adenocarcinomas.
other	hsa-mir-194	Adenocarcinoma, Colon	24691499	disease of cellular proliferation	DOID:234	C18			HP:0040276	miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy.
other	hsa-mir-21	Adenocarcinoma, Colon	19737943	disease of cellular proliferation	DOID:234	C18			HP:0040276	predictors of prognosis
other	hsa-mir-30	Adenocarcinoma, Colon	27261459	disease of cellular proliferation	DOID:234	C18			HP:0040276	miR-30 family likely plays an important role in IEC homeostasis
other	hsa-mir-96	Adenocarcinoma, Colon	28742206	disease of cellular proliferation	DOID:234	C18			HP:0040276	Bioinformatics analysis of RNA-seq data revealed critical genes in colon adenocarcinoma
other	hsa-mir-34b	Adenocarcinoma, Endometrial	22052540	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma.
other	hsa-mir-126	Adenocarcinoma, Esophageal	20309880	disease of cellular proliferation	DOID:4914		C562730	133239		we found that miR-126 expression was associated with tumor cell de-differentiation and lymph node metastasis,
other	hsa-mir-145	Adenocarcinoma, Esophageal	25551563	disease of cellular proliferation	DOID:4914		C562730	133239		While expression of miR-145 in ESCC stopped proliferation and invasion, expression of miR-145 in EAC cells enhanced invasion and anoikis resistance. Although more work is required to understand how miR-145 conveys these effects, expression of miR-145 appears to promote EAC progression by enhancing invasion and protection against anoikis, which could in turn facilitate distant metastasis.
other	hsa-mir-16-2	Adenocarcinoma, Esophageal	20309880	disease of cellular proliferation	DOID:4914		C562730	133239		miR-16-2 was associated with lymph node metastasis
other	hsa-mir-195	Adenocarcinoma, Esophageal	20309880	disease of cellular proliferation	DOID:4914		C562730	133239		miR-195p was associated with higher pathologic disease stages in patients with esophageal adenocarcinoma
other	hsa-mir-330	Adenocarcinoma, Esophageal	26221725	disease of cellular proliferation	DOID:4914		C562730	133239		MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
other	hsa-mir-143	Adenocarcinoma, Gastric	23898078	disease of cellular proliferation	DOID:3717	D37.1	D013274			Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors.
other	hsa-mir-145	Adenocarcinoma, Gastric	25904219	disease of cellular proliferation	DOID:3717	D37.1	D013274			Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302,miR-145, and P21) in Gastric Adenocarcinoma.
other	hsa-mir-155	Adenocarcinoma, Gastric	20209161	disease of cellular proliferation	DOID:3717	D37.1	D013274			Taken together, our study describes, in the context of an H. pylori infection, a direct link between Foxp3 and miR-155 in human T cells and highlights the significance of cAMP in this miR-155 induction cascade.
other	hsa-mir-203	Adenocarcinoma, Gastric	23898078	disease of cellular proliferation	DOID:3717	D37.1	D013274			Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors.
other	hsa-mir-205	Adenocarcinoma, Gastric	23898078	disease of cellular proliferation	DOID:3717	D37.1	D013274			Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors.
other	hsa-mir-21	Adenocarcinoma, Gastric	23898078	disease of cellular proliferation	DOID:3717	D37.1	D013274			Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors.
other	hsa-mir-223	Adenocarcinoma, Gastric	23898078	disease of cellular proliferation	DOID:3717	D37.1	D013274			Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors.
other	hsa-mir-23a	Adenocarcinoma, Gastric	23688986	disease of cellular proliferation	DOID:3717	D37.1	D013274			Suppression of miR-23a with ASO-23a obviously inhibited cell growth, colony formation and invasiveness of MGC803 cells and significantly enhanced the cell apoptosis.
other	hsa-mir-302	Adenocarcinoma, Gastric	25904219	disease of cellular proliferation	DOID:3717	D37.1	D013274			Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302,miR-145, and P21) in Gastric Adenocarcinoma.
other	hsa-mir-320	Adenocarcinoma, Gastric	24136787	disease of cellular proliferation	DOID:3717	D37.1	D013274			Strain-specific suppression of microRNA-320 by carcinogenic Helicobacter pylori promotes expression of the antiapoptotic protein Mcl-1.
other	hsa-mir-34a	Adenocarcinoma, Gastric	23898078	disease of cellular proliferation	DOID:3717	D37.1	D013274			Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors.
other	hsa-mir-486	Adenocarcinoma, Gastric	25793394	disease of cellular proliferation	DOID:3717	D37.1	D013274			Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma.
other	hsa-mir-93	Adenocarcinoma, Gastric	23898078	disease of cellular proliferation	DOID:3717	D37.1	D013274			Differential miRNA expression patterns of gastric adenocarcinoma of the same histopathology from a small geographic region's population show homogenous correlations with the existence of common risk factors.
other	hsa-mir-34	Adenocarcinoma, Lung	28512015	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma.
other	hsa-let-7c	Adenocarcinoma, Lung	23562878	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Ectopic let-7c expression increased the in vitro and in vivo chemo- or radiosensitivity of DTX-resistant LAD cells through enhanced apoptosis, reversal of epithelial-to-mesenchymal phenotypes, and inhibition of in vivo metastatic potential via inactivation of Akt phosphorylation, whereas a let-7c inhibitor decreased the chemo- or radiosensitivity of parental cells
other	hsa-mir-127	Adenocarcinoma, Lung	24317514	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Upregulation of the microRNA cluster at the Dlk1-Dio3 locus in lung adenocarcinoma.
other	hsa-mir-138	Adenocarcinoma, Lung	26631041	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	we discovered that 伪-solanine could affect the expression of miR-138 and focal adhesion kinase
other	hsa-mir-140	Adenocarcinoma, Lung	28005074	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-206 and miR-140 also suppressed lung adenocarcinoma cell metastasis in vitro and in vivo by regulating EMT-related factors
other	hsa-mir-145	Adenocarcinoma, Lung	24026105	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-145 may have a cell type-specific function and play important roles in the process of BM from lung adenocarcinoma.
other	hsa-mir-145	Adenocarcinoma, Lung	28535533	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MALAT1 Modulates TGF-β1-Induced Endothelial-to-Mesenchymal Transition through Downregulation of miR-145.
other	hsa-mir-146a	Adenocarcinoma, Lung	26902276	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Effects of microRNA-146a on Fas-associated factor 2 and inflammatory factors in human lung adenocarcinoma A549 cells under the stimulation of cigarette smoke extract.
other	hsa-mir-146a	Adenocarcinoma, Lung	28299977	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach.
other	hsa-mir-150	Adenocarcinoma, Lung	28299977	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach.
other	hsa-mir-155	Adenocarcinoma, Lung	26899325	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Role of miR-155 in invasion and metastasis of lung adenocarcinoma A549 cells.
other	hsa-mir-155	Adenocarcinoma, Lung	27081085	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified a regulatory network including miR-15b and miR-155, and transcription factors with prognostic value in lung cancer.
other	hsa-mir-17	Adenocarcinoma, Lung	23036707	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Moreover, the expression pattern of miR-17, miR-21, and miR-200a in rBM 3-D culture correlated with the expression of their targets and acinar morphogenesis, a differentiation behavior of lung epithelial cells in rBM 3-D culture
other	hsa-mir-17	Adenocarcinoma, Lung	26402252	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of Biomarker and Co-Regulatory Motifs in Lung Adenocarcinoma Based on Differential Interactions.
other	hsa-mir-181b	Adenocarcinoma, Lung	29324442	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	ZEB1 initiates a miR-181b-regulated ceRNA network to drive metastasis
other	hsa-mir-181b	Adenocarcinoma, Lung	29434967	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Celastrol suppresses the proliferation of lung adenocarcinoma cells by regulating microRNA-24 and microRNA-181b
other	hsa-mir-183	Adenocarcinoma, Lung	28115792	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of Factors for the Preoperative Prediction of Tumour Subtype and Prognosis in Patients with T1 Lung Adenocarcinoma.
other	hsa-mir-200a	Adenocarcinoma, Lung	23036707	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Moreover, the expression pattern of miR-17, miR-21, and miR-200a in rBM 3-D culture correlated with the expression of their targets and acinar morphogenesis, a differentiation behavior of lung epithelial cells in rBM 3-D culture
other	hsa-mir-200b	Adenocarcinoma, Lung	26416454	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	These results provide new evidence for the mechanisms governing the microRNA (miRNA)-ATG12 network and their possible contribution to autophagy modulation and LAD chemoresistance.
other	hsa-mir-200b	Adenocarcinoma, Lung	27027446	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	the double-negative feedback loop between E2F3b and miR-200b regulates docetaxel chemosensitivity of human LAD cells
other	hsa-mir-205	Adenocarcinoma, Lung	23043084	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens.
other	hsa-mir-205	Adenocarcinoma, Lung	26068980	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Surprisingly, expression of classifier miR-205 was intermediate between that of classical adenocarcinoma and squamous cell carcinoma suggesting that adenosquamous carcinoma is a transitional stage between these tumor types.
other	hsa-mir-206	Adenocarcinoma, Lung	28005074	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-206 and miR-140 also suppressed lung adenocarcinoma cell metastasis in vitro and in vivo by regulating EMT-related factors
other	hsa-mir-21	Adenocarcinoma, Lung	28089356	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Insertions and Deletions Target Lineage-Defining Genes in Human Cancers.
other	hsa-mir-21	Adenocarcinoma, Lung	23036707	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Moreover, the expression pattern of miR-17, miR-21, and miR-200a in rBM 3-D culture correlated with the expression of their targets and acinar morphogenesis, a differentiation behavior of lung epithelial cells in rBM 3-D culture
other	hsa-mir-21	Adenocarcinoma, Lung	29730429	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Lung adenocarcinoma cell-derived exosomal miR-21 facilitates osteoclastogenesis.
other	hsa-mir-210	Adenocarcinoma, Lung	25263437	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.
other	hsa-mir-214	Adenocarcinoma, Lung	26462018	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Collectively, this study uncovers a previously unappreciated miR-214-Sufu pathway in controlling EMT and metastasis of LAD and suggests that interfering with miR-214 and Sufu could be a viable approach to treat late stage metastatic LAD patients.
other	hsa-mir-214	Adenocarcinoma, Lung	29288987	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Machine Learning Based Prediction of Brain Metastasis of Patients with IIIA-N2 Lung Adenocarcinoma by a Three-miRNA Signature
other	hsa-mir-23a	Adenocarcinoma, Lung	27492069	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	In addition, miR-23a was significantly enriched in the exosomes after mesenchymal transition.
other	hsa-mir-24	Adenocarcinoma, Lung	29434967	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Celastrol suppresses the proliferation of lung adenocarcinoma cells by regulating microRNA-24 and microRNA-181b
other	hsa-mir-25	Adenocarcinoma, Lung	28101226	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum.
other	hsa-mir-29a	Adenocarcinoma, Lung	27569280	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon-α receptor.
other	hsa-mir-31	Adenocarcinoma, Lung	29367106	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	down-regulation of MIR31HG had no effect on the expression of miR-31 in lung adenocarcinoma cells
other	hsa-mir-326	Adenocarcinoma, Lung	27460077	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Overexpression of miR-326 reversed cisplatin chemoresistance of LAD cells in vitro and in vivo.
other	hsa-mir-342	Adenocarcinoma, Lung	28299977	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach.
other	hsa-mir-34a	Adenocarcinoma, Lung	23043084	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens.
other	hsa-mir-373	Adenocarcinoma, Lung	26182868	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-373-3p Promotes Invasion and Metastasis of Lung Adenocarcinoma Cells
other	hsa-mir-375	Adenocarcinoma, Lung	28533502	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-375 is essential for the progression of LUAD
other	hsa-mir-376a	Adenocarcinoma, Lung	24317514	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Upregulation of the microRNA cluster at the Dlk1-Dio3 locus in lung adenocarcinoma.
other	hsa-mir-451	Adenocarcinoma, Lung	25026294	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling.
other	hsa-mir-494	Adenocarcinoma, Lung	27575252	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Discriminating between Terminal- and Non-Terminal Respiratory Unit-Type Lung Adenocarcinoma Based on MicroRNA Profiles.
other	hsa-mir-497	Adenocarcinoma, Lung	28057758	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Down-regulation of Claudin-2 Expression and Proliferation by Epigenetic Inhibitors in Human Lung Adenocarcinoma A549 Cells.
other	hsa-mir-511	Adenocarcinoma, Lung	24402374	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX.
other	hsa-mir-551b	Adenocarcinoma, Lung	27575252	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Discriminating between Terminal- and Non-Terminal Respiratory Unit-Type Lung Adenocarcinoma Based on MicroRNA Profiles.
other	hsa-mir-552	Adenocarcinoma, Lung	24778034	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA profiles predict the histology of primary lung carcinomas,and differentiate between primary lung adenocarcinomas and colorectal cancer metastases.
other	hsa-mir-592	Adenocarcinoma, Lung	24778034	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA profiles predict the histology of primary lung carcinomas,and differentiate between primary lung adenocarcinomas and colorectal cancer metastases.
other	hsa-mir-608	Adenocarcinoma, Lung	24339958	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells.
other	hsa-mir-9	Adenocarcinoma, Lung	29492899	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	differences in cell response (both miR-9 and proliferation) to dexamethasone in naïve and desialylated cells may point to non-genomic dexamethasone effects
other	hsa-mir-99a	Adenocarcinoma, Lung	23893385	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Clinic significance of microRNA-99a expression in human lung adenocarcinoma.
other	hsa-mir-141	Adenocarcinoma, Pancreatic Ductal	24242138	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma.
other	hsa-mir-145	Adenocarcinoma, Pancreatic Ductal	29137251	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.
other	hsa-mir-155	Adenocarcinoma, Pancreatic Ductal	25520858	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MiR-21, miR-155 and miR-216 in stool have the potential of becoming biomarkers for screening PDAC.
other	hsa-mir-155	Adenocarcinoma, Pancreatic Ductal	28198398	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
other	hsa-mir-181b	Adenocarcinoma, Pancreatic Ductal	28064436	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy.
other	hsa-mir-186	Adenocarcinoma, Pancreatic Ductal	25742499	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
other	hsa-mir-194	Adenocarcinoma, Pancreatic Ductal	24398877	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
other	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	20460539	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-21:miR-21 expression correlated with outcome in PDAC patients treated with gemcitabine
other	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	25061297	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		microRNAs miR-21, miR-221, miR-222, and miR-10 in PDCA cells, promoting an almost complete abolishment of microRNA expression. 
other	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	20093556	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our findings indicate that miR-21 warrants further investigation as a marker for early detection of PDAC.
other	hsa-mir-221	Adenocarcinoma, Pancreatic Ductal	25061297	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		microRNAs miR-21, miR-221, miR-222, and miR-10 in PDCA cells, promoting an almost complete abolishment of microRNA expression. 
other	hsa-mir-222	Adenocarcinoma, Pancreatic Ductal	25061297	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		microRNAs miR-21, miR-221, miR-222, and miR-10 in PDCA cells, promoting an almost complete abolishment of microRNA expression. 
other	hsa-mir-31	Adenocarcinoma, Pancreatic Ductal	29486633	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The AT-rich interactive domain 1A expression level in the cells was increased following microRNA-31 (miR-31) inhibitor transfection
other	hsa-mir-326	Adenocarcinoma, Pancreatic Ductal	25742499	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
other	hsa-mir-34a	Adenocarcinoma, Pancreatic Ductal	27594424	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
other	hsa-mir-375	Adenocarcinoma, Pancreatic Ductal	27862697	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma.
other	hsa-mir-375	Adenocarcinoma, Pancreatic Ductal	28122349	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.
other	hsa-mir-663	Adenocarcinoma, Pancreatic Ductal	26028359	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA-663 activates the canonical Wnt signaling through the adenomatous polyposis coli suppression.
other	hsa-mir-126	Adenocarcinoma, Prostate	28089917	disease of cellular proliferation	DOID:2526	C61	D011471	176807		microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma.
other	hsa-mir-141	Adenocarcinoma, Prostate	25252191	disease of cellular proliferation	DOID:2526	C61	D011471	176807		Based on this small pilot study, men with localized prostate cancers with lower miR-221 expression may have a greater risk for recurrence after surgery.
other	hsa-mir-154	Adenocarcinoma, Prostate	28089917	disease of cellular proliferation	DOID:2526	C61	D011471	176807		microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma.
other	hsa-mir-21	Adenocarcinoma, Prostate	25252191	disease of cellular proliferation	DOID:2526	C61	D011471	176807		Based on this small pilot study, men with localized prostate cancers with lower miR-221 expression may have a greater risk for recurrence after surgery.
other	hsa-mir-21	Adenocarcinoma, Prostate	28089917	disease of cellular proliferation	DOID:2526	C61	D011471	176807		microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma.
other	hsa-mir-221	Adenocarcinoma, Prostate	25252191	disease of cellular proliferation	DOID:2526	C61	D011471	176807		Based on this small pilot study, men with localized prostate cancers with lower miR-221 expression may have a greater risk for recurrence after surgery.
other	hsa-mir-372	Adenocarcinoma, Prostate	26662140	disease of cellular proliferation	DOID:2526	C61	D011471	176807		hsa-miR-372 and miR-373, we suggest that miR-ch21 down-regulation might be the result of specific silencing of miR genes mapped to chromosome 21
other	hsa-mir-148a	Adenovirus Infection	25714032			B34.0	D000257			Thus, miRNA-control of late proteins constitutes a novel strategy to provide selectivity to adenoviruses.
other	hsa-mir-155	Adenovirus Infection	27916071			B34.0	D000257			The effect of curcumin on the expression of miR-155 to apoptosis and invasion of extravillus trophoblast cells treated by lipopolysaccharide.
other	hsa-mir-26b	Adenovirus Infection	28114818			B34.0	D000257			Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells.
other	hsa-mir-30c	Adenovirus Infection	24239602			B34.0	D000257			Comparison of RNAi with CCN2-modulating microRNA (miR) vectors expressing miR-30c or miR-133b showed higher efficacy of RNAi.
other	hsa-mir-100	Adrenal Cortex Neoplasms	20484036	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	miR-100:differentially regulated in childhood adrenocortical tumors (ACT), including miR-99a and miR-100
other	hsa-mir-142	Adrenal Cortex Neoplasms	28110695	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	MEN1 and microRNAs: The link between sporadic pituitary, parathyroid and adrenocortical tumors
other	hsa-mir-24	Adrenal Cortex Neoplasms	28110695	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	MEN1 and microRNAs: The link between sporadic pituitary, parathyroid and adrenocortical tumors
other	hsa-mir-99a	Adrenal Cortex Neoplasms	20484036	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	miR-99a:differentially regulated in childhood adrenocortical tumors (ACT), including miR-99a and miR-100
other	hsa-mir-130a	Adrenal Cortex Neoplasms	19849700	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	miR-130a:miR-130a and miR-382 as putative diagnostic MMAD markers
other	hsa-mir-382	Adrenal Cortex Neoplasms	19849700	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	miR-382:miR-130a and miR-382 as putative diagnostic MMAD markers
other	hsa-mir-150	Age-Related Macular Degeneration	29618664	nervous system disease	DOID:10871	H35.30	D008268	PS603075		miR-150 as pathogenic in AMD and provide potentially novel molecular insights into diseases of aging
other	hsa-mir-184	Age-Related Macular Degeneration	29325388	nervous system disease	DOID:10871	H35.30	D008268	PS603075		miR-184 plays crucial regulatory roles in several ocular diseases, such as neovascularization, keratoconus, endothelial dystrophy, iris hypoplasia, congenital cataract, stromal thinning syndrome, corneal squamous cell carcinoma, age-related macular degeneration and cataract
other	hsa-mir-34a	Alcoholic Hepatitis	26403328	endocrine system disease	DOID:12351	K70.1	D006519			These results constitute a demonstration of the altered regulation of miR-34a and miR-483-3p in the livers of AH and mice fed DDC where MDBs formed, providing further insight into the mechanism of MDB formation mediated by miR-34a and miR-483-3p in AH.
other	hsa-mir-483	Alcoholic Hepatitis	26403328	endocrine system disease	DOID:12351	K70.1	D006519			These results constitute a demonstration of the altered regulation of miR-34a and miR-483-3p in the livers of AH and mice fed DDC where MDBs formed, providing further insight into the mechanism of MDB formation mediated by miR-34a and miR-483-3p in AH.
other	hsa-mir-144	Allergic Asthma	26646558	immune system disease	DOID:9415	J45.909	C564133	600807		Together, the pathogenesis of OVA-induced asthma is highly associated with oxidative stress,and DAS may be an effective supplement to alleviate this disease.
other	hsa-mir-155	Allergic Asthma	29104649	immune system disease	DOID:9415	J45.909	C564133	600807		Small interfering RNA directed against microRNA-155 delivered by a lentiviral vector attenuates asthmatic features in a mouse model of allergic asthma.
other	hsa-mir-34a	Allergic Asthma	26646558	immune system disease	DOID:9415	J45.909	C564133	600807		Together, the pathogenesis of OVA-induced asthma is highly associated with oxidative stress,and DAS may be an effective supplement to alleviate this disease.
other	hsa-mir-34b	Allergic Asthma	26646558	immune system disease	DOID:9415	J45.909	C564133	600807		Together, the pathogenesis of OVA-induced asthma is highly associated with oxidative stress,and DAS may be an effective supplement to alleviate this disease.
other	hsa-mir-155	Allergic Contact Dermatitis	29404871	immune system disease	DOID:3042	L23	D017449			Involvement of the Negative Feedback of IL-33 Signaling in the Anti-Inflammatory  Effect of Electro-acupuncture on Allergic Contact Dermatitis via Targeting MicroRNA-155 in Mast Cells
other	hsa-mir-21	Allergic Contact Dermatitis	29282578	immune system disease	DOID:3042	L23	D017449			MicroRNA-21-Mediated Inhibition of Mast Cell Degranulation Involved in the Protective Effect of Berberine on 2,4-Dinitrofluorobenzene-Induced Allergic Contact Dermatitis in Rats via p38 Pathway
other	hsa-mir-17	Allergic Rhinitis	27491928	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants.
other	hsa-mir-18a	Allergic Rhinitis	27491928	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants.
other	hsa-mir-19b	Allergic Rhinitis	27491928	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	circulation_biomarker_diagnosis_up
other	hsa-mir-20a	Allergic Rhinitis	27491928	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants.
other	hsa-mir-92a	Allergic Rhinitis	27491928	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants.
other	hsa-mir-126	Allergy	24063594	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization.
other	hsa-mir-155	Allergy	24063594	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization.
other	hsa-mir-17	Allergy	29122948	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	MicroRNA regulation of type 2 innate lymphoid cell homeostasis and function in allergic inflammation.
other	hsa-mir-21	Allergy	24063594	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization.
other	hsa-mir-210	Allergy	24063594	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization.
other	hsa-mir-22	Allergy	24063594	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization.
other	hsa-mir-27b	Allergy	24063594	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization.
other	hsa-mir-31	Allergy	24063594	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Expression kinetics of miRNA involved in dermal toluene 2,4-diisocyanate sensitization.
other	hsa-mir-106b	Alopecia	19821055	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	mir-106b:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB
other	hsa-mir-125b-1	Alopecia	19821055	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	miR-125b:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB
other	hsa-mir-125b-2	Alopecia	19821055	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	miR-125b:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB
other	hsa-mir-203	Alopecia	25939713	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	RBM28 contributes to HF growth regulation through modulation of miR-203 and p63 activity.
other	hsa-mir-221	Alopecia	19821055	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	miR-221:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB
other	hsa-mir-410	Alopecia	19821055	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	miR-410:four microRNAs (miR-221, miR-125b, miR-106b and miR-410) that could participate in pathogenesis of MPB
other	hsa-mir-221	Alveolar Rhabdomyosarcoma	29367756	disease of cellular proliferation	DOID:4051		D018232	268220	HP:0006779	PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
other	hsa-mir-29	Alveolar Rhabdomyosarcoma	28883017	disease of cellular proliferation	DOID:4051		D018232	268220	HP:0006779	the NFκB-YY1-miR-29 regulatory circuit is dysregulated, resulting in repression of miR-29 and loss of the associated tumor suppressor activity
other	hsa-mir-486	Alveolar Rhabdomyosarcoma	29367756	disease of cellular proliferation	DOID:4051		D018232	268220	HP:0006779	PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
other	hsa-let-7a	Alzheimer Disease	25759134	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-let-7b	Alzheimer Disease	29170128	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	let-7b has an important association with the pathology of AD and can be used as an adjunct to improve the diagnostic performance of traditional AD biomarkers
other	hsa-mir-101	Alzheimer Disease	24194717	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	we found microRNAs, including miR-20a, miR-17, miR-34a, miR-155, miR-18a, miR-22, miR-26a, miR-101, miR-106b, and miR-125b, that might regulate the expression of nodes in the sub-network.
other	hsa-mir-101-1	Alzheimer Disease	21172309	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-101 downregulates Alzheimer's amyloid-beta precursor protein levels in human cell cultures and is differentially expressed.
other	hsa-mir-106b	Alzheimer Disease	19110058	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-106b: endogenous regulators of APP expression
other	hsa-mir-106b	Alzheimer Disease	24194717	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	we found microRNAs, including miR-20a, miR-17, miR-34a, miR-155, miR-18a, miR-22, miR-26a, miR-101, miR-106b, and miR-125b, that might regulate the expression of nodes in the sub-network.
other	hsa-mir-107	Alzheimer Disease	20413881	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study.
other	hsa-mir-107	Alzheimer Disease	27143098	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	osthole plays a neuroprotective activity role in part through up-regulate miR-107 in AD.
other	hsa-mir-10a	Alzheimer Disease	29215712	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-10a restrains synapse remodeling and neuronal cell proliferation while promoting apoptosis in AD rats via inhibiting BDNF-TrkB signaling pathway
other	hsa-mir-124	Alzheimer Disease	28912710	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Aβ downregulated miR-155 and miR-124, and reduced the CD11b+ subpopulation in 2 DIV microglia
other	hsa-mir-125b	Alzheimer Disease	24293102	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer's disease (AD) and in primary human neuronal-glial (HNG) cells.
other	hsa-mir-125b	Alzheimer Disease	25001178	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease.
other	hsa-mir-125b	Alzheimer Disease	26694372	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features.
other	hsa-mir-132	Alzheimer Disease	26792551	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer's disease.
other	hsa-mir-132	Alzheimer Disease	28148775	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease.
other	hsa-mir-146a	Alzheimer Disease	26694372	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features.
other	hsa-mir-146a	Alzheimer Disease	27797173	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Dipeptidyl Vinyl Sulfone as a Novel Chemical Tool to Inhibit HMGB1/NLRP3-Inflammasome and Inflamma-miRs in Aβ-Mediated Microglial Inflammation.
other	hsa-mir-146a	Alzheimer Disease	29615954	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Microbiome-Mediated Upregulation of MicroRNA-146a in Sporadic Alzheimer's Disease
other	hsa-mir-148b	Alzheimer Disease	24352679	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease.
other	hsa-mir-155	Alzheimer Disease	26694372	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features.
other	hsa-mir-155	Alzheimer Disease	28912710	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Aβ downregulated miR-155 and miR-124, and reduced the CD11b+ subpopulation in 2 DIV microglia
other	hsa-mir-15a	Alzheimer Disease	24352679	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease.
other	hsa-mir-15b	Alzheimer Disease	29207665	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-15b play an important role in the cellular AD phenotype and might be involved in the pathogenesis of AD
other	hsa-mir-17	Alzheimer Disease	19110058	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-17-5p: endogenous regulators of APP expression
other	hsa-mir-17	Alzheimer Disease	24194717	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	we found microRNAs, including miR-20a, miR-17, miR-34a, miR-155, miR-18a, miR-22, miR-26a, miR-101, miR-106b, and miR-125b, that might regulate the expression of nodes in the sub-network.
other	hsa-mir-186	Alzheimer Disease	27029568	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-186 in Alzheimer's disease: a big hope for a small RNA
other	hsa-mir-195	Alzheimer Disease	27693395	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MiR-195 dependent roles of mitofusin2 in the mitochondrial dysfunction of hippocampal neurons in SAMP8 mice.
other	hsa-mir-200c	Alzheimer Disease	25759134	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-mir-20a	Alzheimer Disease	19110058	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-20a: endogenous regulators of APP expression
other	hsa-mir-20a	Alzheimer Disease	24194717	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	we found microRNAs, including miR-20a, miR-17, miR-34a, miR-155, miR-18a, miR-22, miR-26a, miR-101, miR-106b, and miR-125b, that might regulate the expression of nodes in the sub-network.
other	hsa-mir-20a	Alzheimer Disease	24423585	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results of microarray analysis showed that miR-329, miR-193b, miR-20a, miR-296, and miR-130b were all upregulated in H2O2-induced primary hippocampal neurons and different strains of  senescence accelerated mice.
other	hsa-mir-21	Alzheimer Disease	29635890	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-21 can exert protective roles in AD, which might be dependent on PDCD4/PI3K/AKT/GSK-3β signaling pathway in vitro
other	hsa-mir-27a	Alzheimer Disease	24212398	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Our pilot study highlights hsa-miR-27a-3p as a candidate biomarker for AD and provides the groundwork for further confirmation studies in larger cohorts and in other hospitals.
other	hsa-mir-323	Alzheimer Disease	24283221	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-323-3p with clinical potential in rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy.
other	hsa-mir-33	Alzheimer Disease	26936997	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Understanding the Role of miR-33 in Brain Lipid Metabolism: Implications for Alzheimer's Disease.
other	hsa-mir-342	Alzheimer Disease	24440716	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-342-5p decreases ankyrin G levels in Alzheimer's disease transgenic mouse models.
other	hsa-mir-34a	Alzheimer Disease	26694372	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features.
other	hsa-mir-34a	Alzheimer Disease	27378912	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Over-Expressed Pathogenic miRNAs in Alzheimer's Disease (AD) and Prion Disease (PrD) Drive Deficits in TREM2-Mediated Aβ42 Peptide Clearance.
other	hsa-mir-34a	Alzheimer Disease	28652929	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	TNF-α and Beyond: Rapid Mitochondrial Dysfunction Mediates TNF-α-Induced Neurotoxicity.
other	hsa-mir-532	Alzheimer Disease	26402772	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Although we could not consistently separate AD patients and controls in the whole group, we have found indications miRNA in CSF are able to reflect aging and perhaps also heterogeneity in AD. Further investigation requires optimizing RNA input, while maintaining strict age matching.
other	hsa-mir-663	Alzheimer Disease	25695604	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Our results indicate that AICD has a novel role in suppression of neuronal differentiation via transcriptional regulation of miR-663 in human neural stem cells.
other	hsa-mir-7	Alzheimer Disease	26694372	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features.
other	hsa-mir-7	Alzheimer Disease	28296235	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	the circular RNA circular  RNA sponge for miR-7 (ciRS-7) has an important role in regulating BACE1 and APP protein levels
other	hsa-mir-9	Alzheimer Disease	26694372	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features.
other	hsa-mir-9	Alzheimer Disease	27394443	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	These results demonstrated that osthole plays a neuroprotective activity role in part through upregulating miR-9 in AD.
other	hsa-mir-125b	Amyotrophic Lateral Sclerosis	28090150	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	M1 and M2 Functional Imprinting of Primary Microglia: Role of P2X7 Activation and miR-125b.
other	hsa-mir-146a	Amyotrophic Lateral Sclerosis	28612258	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at an Early Stage.
other	hsa-mir-155	Amyotrophic Lateral Sclerosis	28612258	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at an Early Stage.
other	hsa-mir-206	Amyotrophic Lateral Sclerosis	20007902	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice
other	hsa-mir-125a	Androgenetic Alopecia	25778683	integumentary system disease	DOID:0050801	L64.9	D000505	109200		These results demonstrated that the expression of miRNA was altered in the DHT-treated nHDPCs and suggest the potential mechanisms of DHT-induced cell growth repression, cell cycle arrest, cell death, senescence and induction of ROS.
other	hsa-mir-485	Androgenetic Alopecia	25778683	integumentary system disease	DOID:0050801	L64.9	D000505	109200		These results demonstrated that the expression of miRNA was altered in the DHT-treated nHDPCs and suggest the potential mechanisms of DHT-induced cell growth repression, cell cycle arrest, cell death, senescence and induction of ROS.
other	hsa-mir-7	Androgenetic Alopecia	25778683	integumentary system disease	DOID:0050801	L64.9	D000505	109200		These results demonstrated that the expression of miRNA was altered in the DHT-treated nHDPCs and suggest the potential mechanisms of DHT-induced cell growth repression, cell cycle arrest, cell death, senescence and induction of ROS.
other	hsa-mir-144	Anemia	29269522	hematopoietic system disease	DOID:2355	D64.9	D000740	300751		miR-144/451 represses the LKB1/AMPK/mTOR pathway to promote red cell precursor survival during recovery from acute anemia
other	hsa-mir-151a	Anemia	21921042	hematopoietic system disease	DOID:2355	D64.9	D000740	300751		Expression of miR-26b and miR-151-3p were both associated with HbF levels at MTD (maximum tolerated dose).
other	hsa-mir-26b	Anemia	21921042	hematopoietic system disease	DOID:2355	D64.9	D000740	300751		Expression of miR-26b and miR-151-3p were both associated with HbF levels at MTD (maximum tolerated dose).
other	hsa-mir-34a	Anemia	23222379	hematopoietic system disease	DOID:2355	D64.9	D000740	300751		Thus, in FA patients, increased apoptosis occurs in target epithelial cells of severe aGVHD, and this deleterious effect is linked to overexpression of miR-34a but not TP53.
other	hsa-mir-194	Aneurysm	26771601			I72.9	D000783	105800		Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology.
other	hsa-mir-19b-1	Aneurysm	26771601			I72.9	D000783	105800		Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology.
other	hsa-mir-21	Aneurysm	26771601			I72.9	D000783	105800		Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology.
other	hsa-mir-362	Aneurysm	26771601			I72.9	D000783	105800		Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology.
other	hsa-mir-550	Aneurysm	26771601			I72.9	D000783	105800		Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology.
other	hsa-mir-769	Aneurysm	26771601			I72.9	D000783	105800		Aneurysm miRNA Signature Differs, Depending on Disease Localization and Morphology.
other	hsa-mir-155	Ankylosing Spondylitis	27412942	musculoskeletal system disease	DOID:7147	M45.9	D013167			Conclusion XFC could effectively improve  hypercoagulative state in active AS patients. The potential mechanism may be associated with the inhibition of miR-155 and NF-魏B signal pathway.
other	hsa-mir-19b-1	Antiphospholipid Syndrome	21794077	immune system disease	DOID:2988	D68.61	D016736	107320		Down-regulation of miR-19b and miR-20a observed in patients with SLE and SAF could contribute to increase TF expression and thus provoke the hypercoagulable state characteristic of these patients.
other	hsa-mir-20a	Antiphospholipid Syndrome	21794077	immune system disease	DOID:2988	D68.61	D016736	107320		Down-regulation of miR-19b and miR-20a observed in patients with SLE and SAF could contribute to increase TF expression and thus provoke the hypercoagulable state characteristic of these patients.
other	hsa-mir-15b	Anus Neoplasm	22045185	disease of cellular proliferation	DOID:4551	C21.0	D001005			The expression of miR-15b was shown to be highly correlated with that of five selected E2F-induced genes (CCNA2, CCNB1, CCNB2, MSH6 and MCM7). A knockdown of HPV16 E7 resulted in decreased levels of miR-15b in Ca Ski cells.Conclusion:MiR-15b expression correlates with E2F-regulated genes in anal carcinoma and appears to be part of the E2F-regulatory network.
other	hsa-mir-143	Aortic Aneurysm	28167124	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	P38 MAPK Signaling Pathway Mediates Angiotensin II-Induced miR143/145 Gene Cluster Downregulation during Aortic Dissection Formation.
other	hsa-mir-145	Aortic Aneurysm	28167124	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	P38 MAPK Signaling Pathway Mediates Angiotensin II-Induced miR143/145 Gene Cluster Downregulation during Aortic Dissection Formation.
other	hsa-mir-195	Aortic Aneurysm	25201911	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	We provide the first evidence that miR-195 may contribute to the pathogenesis of aortic aneurysmal disease. Although inhibition of miR-29b proved more effective in preventing aneurysm formation in a preclinical model, miR-195represents a potent regulator of the aortic extracellular matrix. Notably, plasma levels of miR-195 were reduced in patients with abdominal aortic aneurysms suggesting that microRNAs might serve as a noninvasive biomarker of abdominal aortic aneurysms.
other	hsa-mir-29b	Aortic Aneurysm	25342766	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	Battle of the bulge: miR-195 versus miR-29b in aortic aneurysm.
other	hsa-mir-145	Aortic Aneurysm, Abdominal	27956160	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNA-145 Mediates the Formation of Angiotensin II-Induced Murine Abdominal Aortic Aneurysm.
other	hsa-mir-155	Aortic Aneurysm, Abdominal	24283299	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		microRNA profiling in patients with abdominal aortic aneurysms: the significance of miR-155.
other	hsa-mir-181b	Aortic Aneurysm, Abdominal	27756793	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNA-181b Controls Atherosclerosis and Aneurysms Through Regulation of TIMP-3 and Elastin.
other	hsa-mir-21	Aortic Aneurysm, Abdominal	22357537	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNA-21 Blocks Abdominal Aortic Aneurysm Development and Nicotine-Augmented Expansion.
other	hsa-mir-29b	Aortic Aneurysm, Abdominal	23871588	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNA-29b regulation of abdominal aortic aneurysm development.
other	hsa-mir-125b	Aortic Insufficiency	26203686	cardiovascular system disease	DOID:57	I35.1	D001022		HP:0001659	MicroRNA-125b and chemokine CCL4 expression are associated with calcific aortic valve disease.
other	hsa-mir-22	Aortic Stenosis	26304936	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Despite holding great promise, circulating miRNA profiling requires further refinement before translation into clinical use as a biomarker in aortic stenosis.
other	hsa-mir-24	Aortic Stenosis	26304936	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Despite holding great promise, circulating miRNA profiling requires further refinement before translation into clinical use as a biomarker in aortic stenosis.
other	hsa-mir-378	Aortic Stenosis	25157568	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Circulating levels of miR-1, miR-133 and miR-378 were decreased in AS patients, and miR-378 predicts LVH independent of the pressure gradient. Further prospective investigations are needed to elucidate whether these circulating miRs affect clinical outcome.
other	hsa-mir-382	Aortic Stenosis	26304936	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Despite holding great promise, circulating miRNA profiling requires further refinement before translation into clinical use as a biomarker in aortic stenosis.
other	hsa-mir-451a	Aortic Stenosis	26304936	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Despite holding great promise, circulating miRNA profiling requires further refinement before translation into clinical use as a biomarker in aortic stenosis.
other	hsa-mir-126	Aplastic Anemia	26354756	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	Identification of novel microRNA signatures linked to acquired aplastic anemia.
other	hsa-mir-145	Aplastic Anemia	26354756	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	Identification of novel microRNA signatures linked to acquired aplastic anemia.
other	hsa-mir-199a	Aplastic Anemia	26354756	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	Identification of novel microRNA signatures linked to acquired aplastic anemia.
other	hsa-mir-223	Aplastic Anemia	26354756	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	Identification of novel microRNA signatures linked to acquired aplastic anemia.
other	hsa-mir-1	Arrhythmia	24468403			I49.9	D001145	600919	HP:0011675	Down-regulation of miR-1 could relieve arrhythmogenesis by the anti-miR-1 antisense oligonucleotides (AMO-1).
other	hsa-mir-1-1	Arrhythmia	17401374			I49.9	D001145	600919	HP:0011675	These data strongly indicate that miR-1 is an arrhythmogenic or proarrhythmic factor that is detrimental to the ischemic heart. Delivery of miR-1 into healthy hearts was also arrhythmogenic.
other	hsa-mir-1-1	Arrhythmia	17786230			I49.9	D001145	600919	HP:0011675	the finding that increasing or decreasing miR-1 expression causes lethal cardiac arrhythmias highlights not only the exquisite sensitivity of the heart to the levels of expression of this miRNA but also poses significant hurdles to the possible therapeutic manipulation of miR-1 levels in the settings of cardiac conduction abnormalities or myocardial repair.
other	hsa-mir-1-2	Arrhythmia	17401374			I49.9	D001145	600919	HP:0011675	These data strongly indicate that miR-1 is an arrhythmogenic or proarrhythmic factor that is detrimental to the ischemic heart. Delivery of miR-1 into healthy hearts was also arrhythmogenic.
other	hsa-mir-1-2	Arrhythmia	17786230			I49.9	D001145	600919	HP:0011675	the finding that increasing or decreasing miR-1 expression causes lethal cardiac arrhythmias highlights not only the exquisite sensitivity of the heart to the levels of expression of this miRNA but also poses significant hurdles to the possible therapeutic manipulation of miR-1 levels in the settings of cardiac conduction abnormalities or myocardial repair.
other	hsa-mir-133a	Arrhythmia	23497314			I49.9	D001145	600919	HP:0011675	Multiple miR-133a isomiRs with potential different mRNA target profiles are present in the atrium in humans and mice.
other	hsa-mir-133a-1	Arrhythmia	17786230			I49.9	D001145	600919	HP:0011675	These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy. Xiao et al. reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-goбзCrelated gene (ERG), which encodes a key K+ channel (IKr) responsible for rapid delayed rectifier K+ current in cardiac cells.
other	hsa-mir-133a-2	Arrhythmia	17786230			I49.9	D001145	600919	HP:0011675	These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy. Xiao et al. reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-goбзCrelated gene (ERG), which encodes a key K+ channel (IKr) responsible for rapid delayed rectifier K+ current in cardiac cells.
other	hsa-mir-126	Arteriosclerosis Obliterans	21969012	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Muscle-enriched miR-499 and miR-133a are released from the heart into the coronary circulation on myocardial injury, whereas the vascular miR-126 is consumed during transcoronary passage. 
other	hsa-mir-126	Arteriosclerosis Obliterans	28143713	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Intercellular transfer of miR-126-3p by endothelial microparticles reduces vascular smooth muscle cell proliferation and limits neointima formation by inhibiting LRP6.
other	hsa-mir-133a	Arteriosclerosis Obliterans	25740337	cardiovascular system disease	DOID:5160		D001162		HP:0002634	MicroRNA-133a in the Development of Arteriosclerosis Obliterans.
other	hsa-mir-133a	Arteriosclerosis Obliterans	21969012	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Muscle-enriched miR-499 and miR-133a are released from the heart into the coronary circulation on myocardial injury, whereas the vascular miR-126 is consumed during transcoronary passage. 
other	hsa-mir-140	Arteriosclerosis Obliterans	20528768	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2x10-16).
other	hsa-mir-182	Arteriosclerosis Obliterans	20528768	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2x10-16).
other	hsa-mir-21	Arteriosclerosis Obliterans	29506703	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction
other	hsa-mir-499	Arteriosclerosis Obliterans	21969012	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Muscle-enriched miR-499 and miR-133a are released from the heart into the coronary circulation on myocardial injury, whereas the vascular miR-126 is consumed during transcoronary passage. 
other	hsa-mir-92a	Arteriosclerosis Obliterans	20528768	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2x10-16).
other	hsa-mir-92b	Arteriosclerosis Obliterans	20528768	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Global analysis of predicted miRNA targets found significantly reduced expression of genes with target regions compared with those without: hsa-miR-140-3p (P=0.002), hsa-miR-182 (P=0.001), hsa-miR-92a and hsa-miR-92b (P=2.2x10-16).
other	hsa-mir-140	Arthritis	27165343	musculoskeletal system disease	DOID:848	M19.90	D001168			estrogen acts via ER and miR-140 to inhibit the catabolic activity of proteases within the chondrocyte extracellular matrix.
other	hsa-mir-146a	Arthritis	28545737	musculoskeletal system disease	DOID:848	M19.90	D001168			MicroRNA-146a governs fibroblast activation and joint pathology in arthritis.
other	hsa-let-7a	Asthma	25759134	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-let-7a-1	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7a:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7a-2	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7a:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7a-3	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7a:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7b	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7b:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7c	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7c:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7d	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7d:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7e	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7e:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7f	Asthma	26242299	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	17β-E2+P4 increased IL-17A production from TH17 cells, providing a potential mechanism for the increased prevalence of severe asthma in women compared with men.
other	hsa-let-7f	Asthma	29455573	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	A CREB-mediated increase in miRNA let-7f during prolonged β-agonist exposure: a novel mechanism of β2-adrenergic receptor down-regulation in airway smooth muscle
other	hsa-let-7f-1	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7f:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7f-2	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7f:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7g	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7g:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-let-7i	Asthma	20630862	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	let-7i:Proinflammatory role for let-7 microRNAS in experimental asthma
other	hsa-mir-128	Asthma	29231896	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulated miR-128 and miR-744 supports a Th2/Th17 type immune response in severe equine asthma
other	hsa-mir-133a	Asthma	29191361	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	The relative expression of miRNA-133a increased in the low-dose anti-IgE, high-dose anti-IgE, fluticasone+anti-IgE and anti-TNF groups
other	hsa-mir-146a	Asthma	22580216	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These observations suggest that microRNA-181a, -146a and -146b are proinflammatory factors in asthma, and that down-regulation of miRNA-146a may partially account for the anti-inflammatory effect of dexamethasone.
other	hsa-mir-146a	Asthma	27463381	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines.
other	hsa-mir-146b	Asthma	21305051	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. 
other	hsa-mir-146b	Asthma	22580216	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These observations suggest that microRNA-181a, -146a and -146b are proinflammatory factors in asthma, and that down-regulation of miRNA-146a may partially account for the anti-inflammatory effect of dexamethasone.
other	hsa-mir-148b	Asthma	25266681	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	We report that statins upregulate mir-148b and 152, and affect HLA-G expression in an rs1063320-dependent fashion.
other	hsa-mir-152	Asthma	25266681	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	We report that statins upregulate mir-148b and 152, and affect HLA-G expression in an rs1063320-dependent fashion.
other	hsa-mir-155	Asthma	27463381	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines.
other	hsa-mir-181a	Asthma	22580216	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These observations suggest that microRNA-181a, -146a and -146b are proinflammatory factors in asthma, and that down-regulation of miRNA-146a may partially account for the anti-inflammatory effect of dexamethasone.
other	hsa-mir-19a	Asthma	28081849	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Constitutive high expression of protein arginine methyltransferase 1 in asthmatic airway smooth muscle cells is caused by reduced microRNA-19a expression and leads to enhanced remodeling.
other	hsa-mir-200c	Asthma	25759134	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-mir-21	Asthma	27463381	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines.
other	hsa-mir-21	Asthma	28379062	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inhibition of MicroRNA-21 by an antagomir ameliorates allergic inflammation in a mouse model of asthma.
other	hsa-mir-221	Asthma	22572970	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inhibition of miRNA-221 Suppresses the Airway Inflammation in Asthma.
other	hsa-mir-221	Asthma	23944957	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Airway smooth muscle hyperproliferation is regulated by microRNA-221 in severe asthma.
other	hsa-mir-221	Asthma	27113449	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	The degranulation was found to be significantly increased in miR-221 overexpressed cells while it was found to be significantly decreased in miR-221 downregulated cells.
other	hsa-mir-223	Asthma	21305051	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. 
other	hsa-mir-29b	Asthma	21305051	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. 
other	hsa-mir-29c	Asthma	21305051	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. 
other	hsa-mir-33b	Asthma	28785038	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inhibition of airway inflammation in a cockroach allergen model of asthma by agonists of miRNA-33b.
other	hsa-mir-34	Asthma	24313771	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Subtypes of asthma defined by epithelial cell expression of messenger RNA and microRNA.
other	hsa-mir-449	Asthma	24313771	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Subtypes of asthma defined by epithelial cell expression of messenger RNA and microRNA.
other	hsa-mir-483	Asthma	21305051	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. 
other	hsa-mir-574	Asthma	21305051	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. 
other	hsa-mir-672	Asthma	21305051	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. 
other	hsa-mir-690	Asthma	21305051	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Inverse correlation with the expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best candidates for an active implication in asthma pathogenesis. 
other	hsa-mir-744	Asthma	29231896	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulated miR-128 and miR-744 supports a Th2/Th17 type immune response in severe equine asthma
other	hsa-mir-21	Astrocytoma	27504157	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Our data showed that in 1321N1 cells, 尾-adrenergic-Epac pathway stimulation up and down-regulated Cx43 and miR-21 expression respectively.
other	hsa-mir-221	Astrocytoma	26454049	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Loss of  miR-221 function and cytotoxicity induced by the miR-221 DOXO MB provides combined therapeutic efficacy against cancers.
other	hsa-mir-335	Astrocytoma	21592405	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells.
other	hsa-mir-100	Atherosclerosis	24815336	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque.
other	hsa-mir-10a	Atherosclerosis	21952822	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Endothelial inflammation is critically regulated by miRNAs such as miR-126 and miR-10a in vitro and in vivo.
other	hsa-mir-125b	Atherosclerosis	27835742	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis.
other	hsa-mir-126	Atherosclerosis	19996457	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Administration of apoptotic bodies or miR-126 limited atherosclerosis
other	hsa-mir-126	Atherosclerosis	23324496	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	whereas the endothelial cell-specific miRNA-126 signals the need for endothelial repair through its transfer from apoptotic endothelial cells in microvesicles
other	hsa-mir-126	Atherosclerosis	23774505	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease.
other	hsa-mir-126	Atherosclerosis	24870014	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	These effects may explain the ability of pitavastatin to reduce the progression of atherosclerosis. The findings further suggest that inhibitory effect of pitavastatin on VCAM-1 is not related to miR-126 but depends on other ways.
other	hsa-mir-126	Atherosclerosis	21946298	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-126	Atherosclerosis	21952822	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Endothelial inflammation is critically regulated by miRNAs such as miR-126 and miR-10a in vitro and in vivo.
other	hsa-mir-126	Atherosclerosis	24022569	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Increased miR-146a and miR-126 and reduced miR-155 levels were observed in both treatment groups (all, P<0.001)
other	hsa-mir-126	Atherosclerosis	24833799	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-126 in atherosclerosis
other	hsa-mir-126	Atherosclerosis	24933211	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Furthermore, significantly increased aortic expression of miR-26a, miR-21, miR-126a, miR-132, miR-146 and miR-155 and decreased expression of miR-20a and miR-92a were observed in the vehicle-treated ApoE-/- mice. While NR1 treatment led to a significant reduction in the expression of miR-21, miR-26a, miR-126 and  increased expression of miR-20a.
other	hsa-mir-126	Atherosclerosis	25315114	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNAs (miRNAs) encapsulated within microparticles (MPs) are likely to have a  role in cell-to-cell signaling in a variety of diseases, including atherosclerosis.
other	hsa-mir-126	Atherosclerosis	26001902	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Conversely, CXCL12 expression can be induced by miR-126 in ECs through an auto-amplifying feedback loop to facilitate  endothelial regeneration, thus limiting atherosclerosis and mediating plaque stabilization.
other	hsa-mir-126	Atherosclerosis	26662986	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In particular, the specific roles of miR-126 and miR-143/145, master regulators of EC and VSMC function, respectively, are deeply  explored.
other	hsa-mir-126	Atherosclerosis	27748840	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Paeonol promotes microRNA-126 expression to inhibit monocyte adhesion to ox-LDL-injured vascular endothelial cells and block the activation of the PI3K/Akt/NF-κB pathway.
other	hsa-mir-126	Atherosclerosis	27870587	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	17β-Estradiol Enhances Vascular Endothelial Ets-1/miR-126-3p Expression: The Possible Mechanism for Attenuation of Atherosclerosis.
other	hsa-mir-126	Atherosclerosis	27923459	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNAs in lipid metabolism and atherosclerosis.
other	hsa-mir-126	Atherosclerosis	28678312	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Identification of miRNAs as atherosclerosis biomarkers and functional role of miR-126 in atherosclerosis progression through MAPK signalling pathway.
other	hsa-mir-126	Atherosclerosis	29203244	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-126 alleviates endothelial cells injury in atherosclerosis by restoring autophagic flux via inhibiting of PI3K/Akt/mTOR pathway
other	hsa-mir-1264	Atherosclerosis	26047583	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	This could be a causative epigenetic mechanism associated with TNF-α and IGF-1 induced smooth muscle cell proliferation involved in the pathogenesis of coronary artery hyperplasia and restenosis.
other	hsa-mir-127	Atherosclerosis	24815336	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque.
other	hsa-mir-133	Atherosclerosis	23774505	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease.
other	hsa-mir-143	Atherosclerosis	22373869	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Secreted miRNAs (miR-143/145) suppress atherogenesis.
other	hsa-mir-143	Atherosclerosis	27775792	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-143 is involved in endothelial cell dysfunction through suppression of glycolysis and correlated with atherosclerotic plaques formation.
other	hsa-mir-145	Atherosclerosis	22373869	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Secreted miRNAs (miR-143/145) suppress atherogenesis.
other	hsa-mir-145	Atherosclerosis	23324496	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Downregulation of miR-145, which controls differentiation of smooth muscle cells, promotes lesion formation
other	hsa-mir-145	Atherosclerosis	24815336	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque.
other	hsa-mir-146	Atherosclerosis	23774505	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease.
other	hsa-mir-146	Atherosclerosis	24815336	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque.
other	hsa-mir-146a	Atherosclerosis	20195282	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	this study also provided evidence that miR-146a treatment in vitro could induce the protein expression of TNF-alpha, MCP-1, NF-kappaB p65, which are key pro-inflammatory cytokines and critical transcription factor in AS
other	hsa-mir-146a	Atherosclerosis	28637783	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Paradoxical Suppression of Atherosclerosis in the Absence of microRNA-146a.
other	hsa-mir-146a	Atherosclerosis	28882869	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	EV-derived miRNAs from atherogenic macrophages, in particular miR-146a, may accelerate the development of atherosclerosis by decreasing cell migration and promoting macrophage entrapment in the vessel wall
other	hsa-mir-146a	Atherosclerosis	29449647	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	they express a remarkably high basal level of miR-146a, a microRNA known to negatively regulate the TLR pathway
other	hsa-mir-150	Atherosclerosis	28254813	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-150 Modulates Ischemia-Induced Neovascularization in Atherosclerotic Conditions.
other	hsa-mir-152	Atherosclerosis	22370758	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Co-expression in plaque tissue and classical monocytes.
other	hsa-mir-155	Atherosclerosis	23324496	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Elevated miR-155 levels are characteristic of proinflammatory macrophages and atherosclerotic lesions
other	hsa-mir-155	Atherosclerosis	23513069	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The microRNA-342-5p Fosters Inflammatory Macrophage Activation Through an Akt1-and microRNA-155-Dependent Pathway during Atherosclerosis
other	hsa-mir-155	Atherosclerosis	23827206	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-155 in the pathogenesis of atherosclerosis
other	hsa-mir-155	Atherosclerosis	24767942	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	We hypothesized that native LDL and oxidized LDL played a key role in modulating the effects of miR-155 on macrophages at different stages of atherosclerosis.
other	hsa-mir-155	Atherosclerosis	23774505	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease.
other	hsa-mir-155	Atherosclerosis	24815336	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque.
other	hsa-mir-155	Atherosclerosis	28407320	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Role of TLR4 and miR-155 in peripheral blood mononuclear cell-mediated inflammatory reaction in coronary slow flow and coronary arteriosclerosis patients.
other	hsa-mir-155	Atherosclerosis	21946298	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-155	Atherosclerosis	24933211	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Furthermore, significantly increased aortic expression of miR-26a, miR-21, miR-126a, miR-132, miR-146 and miR-155 and decreased expression of miR-20a and miR-92a were observed in the vehicle-treated ApoE-/- mice. While NR1 treatment led to a significant reduction in the expression of miR-21, miR-26a, miR-126 and  increased expression of miR-20a.
other	hsa-mir-155	Atherosclerosis	29465752	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	both the atherosclerosis inducer ox-LDL and atheroprotective factor KLF2 regulated inflammation-associated microRNA-155 (miR-155) expression in human umbilical vein endothelial cells (HUVECs)
other	hsa-mir-17	Atherosclerosis	21946298	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-185	Atherosclerosis	26523989	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	These findings reveal that miR-185 controls cholesterol homeostasis as a key posttranscriptional LDLR modulator in hepatic cells, providing novel insight into the regulatory mechanism for LDLR expression and the anti-atherosclerosis effect of miR-185-inhibitor.
other	hsa-mir-19b	Atherosclerosis	25765596	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The present study demonstrates that Dgn enhances ABCA1-dependent cholesterol efflux and inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression.
other	hsa-mir-20a	Atherosclerosis	24933211	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Furthermore, significantly increased aortic expression of miR-26a, miR-21, miR-126a, miR-132, miR-146 and miR-155 and decreased expression of miR-20a and miR-92a were observed in the vehicle-treated ApoE-/- mice. While NR1 treatment led to a significant reduction in the expression of miR-21, miR-26a, miR-126 and  increased expression of miR-20a.
other	hsa-mir-21	Atherosclerosis	21817107	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-21 Regulates Vascular Smooth Muscle Cell Function via Targeting Tropomyosin 1 in Arteriosclerosis Obliterans of Lower Extremities.
other	hsa-mir-21	Atherosclerosis	25882990	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In atherosclerosis, miR-21 is increased in the aorta and associated with vitamin D deficiency. Vitamin D deficiency may influence aberrant miR-21 expression in vasculature and bone contributing to the concurrent development of atherosclerosis and osteoporosis.
other	hsa-mir-21	Atherosclerosis	23774505	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease.
other	hsa-mir-21	Atherosclerosis	24562307	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In ox-LDL treated VECs, transfection with a miR-21 mimic significantly increased miR-21 expression  and inhibited PTEN expression, and attenuated the protective effects of paeonol pretreatment, whereas transfection with an miR-21 inhibitor significantly decreased miR-21 expression and increased PTEN expression, thus enhanced the protective effects of paeonol pretreatment.
other	hsa-mir-21	Atherosclerosis	25961718	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	resveratrol significantly reduced miR-21 expression
other	hsa-mir-21	Atherosclerosis	25981603	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21 is involved in ischemic stroke pathology  through atherosclerosis and provides neuroprotection by its anti-apoptotic features.
other	hsa-mir-21	Atherosclerosis	27107761	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	LaCM  decreased apoptosis, necrosis and inflammatory miR-155 and conversely increased anti-apoptotic miR-21 in Ec-LPS-treated HUVECs.
other	hsa-mir-21	Atherosclerosis	28674080	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Macrophage deficiency of miR-21 promotes apoptosis, plaque necrosis, and vascular inflammation during atherogenesis.
other	hsa-mir-21	Atherosclerosis	29503197	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Local Delivery of miR-21 Stabilizes Fibrous Caps in Vulnerable Atherosclerotic Lesions
other	hsa-mir-21	Atherosclerosis	29659130	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	its involvement in the complex development of atherosclerosis has yet to be ascertained
other	hsa-mir-210	Atherosclerosis	25981603	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-497 induces neuronal death and miR-210 is upregulated in hypoxic cells.
other	hsa-mir-210	Atherosclerosis	27895035	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-210 Enhances Fibrous Cap Stability in Advanced Atherosclerotic Lesions.
other	hsa-mir-210	Atherosclerosis	28367268	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Protection of Human Umbilical Vein Endothelial Cells against Oxidative Stress by MicroRNA-210.
other	hsa-mir-221	Atherosclerosis	26221589	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling.
other	hsa-mir-221	Atherosclerosis	26451018	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Atherosclerotic plaque rupture is accompanied by a loss of miR-221 and miR-222 and an increase in p27Kip1 mRNA expression in the plaque shoulder,suggesting an association between these miRNAs and atherosclerotic plaque stability.
other	hsa-mir-221	Atherosclerosis	24815336	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque.
other	hsa-mir-221	Atherosclerosis	21946298	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-221	Atherosclerosis	27644883	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Human aortic smooth muscle cell-derived exosomal miR-221/222 inhibits autophagy via a PTEN/Akt signaling pathway in human umbilical vein endothelial cells.
other	hsa-mir-222	Atherosclerosis	26221589	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling.
other	hsa-mir-222	Atherosclerosis	26451018	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Atherosclerotic plaque rupture is accompanied by a loss of miR-221 and miR-222 and an increase in p27Kip1 mRNA expression in the plaque shoulder,suggesting an association between these miRNAs and atherosclerotic plaque stability.
other	hsa-mir-222	Atherosclerosis	24815336	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque.
other	hsa-mir-222	Atherosclerosis	21946298	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-222	Atherosclerosis	27644883	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Human aortic smooth muscle cell-derived exosomal miR-221/222 inhibits autophagy via a PTEN/Akt signaling pathway in human umbilical vein endothelial cells.
other	hsa-mir-223	Atherosclerosis	25463083	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-223-mediated suppression of TF expression provides a novel molecular mechanism for the regulation of coagulation cascade, and suggests a clue against thrombogenesis during the process of atherosclerotic plaque rupture.
other	hsa-mir-23b	Atherosclerosis	22955103	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In addition, members of the miR-23-27-24 cluster are increased and specifically miR-23b blocks cell cycle progression, whereas miR-27b was shown to reduce endothelial cell repulsive signals.
other	hsa-mir-24	Atherosclerosis	24815336	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The co-inertia approach in identification of specific microRNA in early and advanced atherosclerosis plaque.
other	hsa-mir-27b	Atherosclerosis	22955103	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In addition, members of the miR-23-27-24 cluster are increased and specifically miR-23b blocks cell cycle progression, whereas miR-27b was shown to reduce endothelial cell repulsive signals.
other	hsa-mir-29	Atherosclerosis	23774505	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease.
other	hsa-mir-29	Atherosclerosis	26309238	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Transcriptional and posttranscriptional mechanisms contribute to the dysregulation of elastogenesis in Schimke immuno-osseous dysplasia.
other	hsa-mir-296	Atherosclerosis	20415654	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Tumor angiogenesis is additionally controlled by miR-296 and miR-378.
other	hsa-mir-29a	Atherosclerosis	28593745	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	ox-LDL increases microRNA-29a transcription through upregulating YY1 and STAT1 in macrophages.
other	hsa-mir-30a	Atherosclerosis	26176854	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	we here report the successful use of miRNA technology to silence a platelet protein in megakaryoblastic cells and demonstrate its usefulness in functional assays. Hence, we believe that artificial miRNAs are suitable tools to unravel the role of a protein of interest in stem cells, megakaryocytes and platelets, thereby expanding their application to novel fields of basic and translational research.
other	hsa-mir-30e	Atherosclerosis	28123167	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-30e in VSMCs exerted an anti-atherosclerosis effect via inhibiting proliferation and migration, and promoting apoptosis of VSMCs
other	hsa-mir-31	Atherosclerosis	21946298	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-33	Atherosclerosis	24086374	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	These results reveal a novel mechanism for the BA-mediated ABCA1 expression, which may provide new insights for developing strategies for modulating vascular inflammation and atherosclerosis.
other	hsa-mir-33	Atherosclerosis	24953492	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Taken together, these results reveal that C. pneumoniae may negatively regulate ABCA1 expression via TLR2-NF-κB and miR-33 pathways in THP-1 macrophage-derived foam cells, which may provide new insights for understandingthe effects of C. pneumoniae on the pathogenesis of atherosclerosis.
other	hsa-mir-33	Atherosclerosis	27905947	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions.
other	hsa-mir-33	Atherosclerosis	27920122	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-33 Controls Adaptive Fibrotic Response in the Remodeling Heart by Preserving Lipid Raft Cholesterol.
other	hsa-mir-33	Atherosclerosis	28296196	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	SIRT6 reduces macrophage foam cell formation by inducing autophagy and cholesterol efflux under ox-LDL condition.
other	hsa-mir-33	Atherosclerosis	28428217	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	microRNA-33 Regulates Macrophage Autophagy in Atherosclerosis.
other	hsa-mir-33a	Atherosclerosis	22274626	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	microRNA-33a and b (miR-33a/b) were discovered as key regulators of metabolic programs including cholesterol and fatty acid homeostasis.
other	hsa-mir-33a	Atherosclerosis	27923459	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNAs in lipid metabolism and atherosclerosis.
other	hsa-mir-33b	Atherosclerosis	22274626	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	microRNA-33a and b (miR-33a/b) were discovered as key regulators of metabolic programs including cholesterol and fatty acid homeostasis.
other	hsa-mir-342	Atherosclerosis	23513069	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The microRNA-342-5p Fosters Inflammatory Macrophage Activation Through an Akt1-and microRNA-155-Dependent Pathway during Atherosclerosis
other	hsa-mir-34a	Atherosclerosis	20627091	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-34a:MicroRNA-34a regulation of endothelial senescence
other	hsa-mir-34a	Atherosclerosis	25395581	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-34a is involved in the flow-dependent regulation of endothelial inflammation.
other	hsa-mir-422a	Atherosclerosis	22370758	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Co-expression in plaque tissue and non-classical monocytes.
other	hsa-mir-494	Atherosclerosis	26583674	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Treatment with GSO-494 results in smaller atherosclerotic lesions with increased plaque stability. Inhibition of miR-494 may decrease the risk of surgical complications or even avert endarterectomy surgery in some cases.
other	hsa-mir-497	Atherosclerosis	27918592	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-497 Induces Apoptosis and Suppresses Proliferation via the Bcl-2/Bax-Caspase9-Caspase3 Pathway and Cyclin D2 Protein in HUVECs.
other	hsa-mir-548p	Atherosclerosis	28336556	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis.
other	hsa-mir-712	Atherosclerosis	24346612	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis.
other	hsa-mir-92a	Atherosclerosis	27923459	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNAs in lipid metabolism and atherosclerosis.
other	hsa-mir-98	Atherosclerosis	25623956	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Coculturing ECs with sSMCs under static condition causes initial increases of 4 anti-inflammatory miRs (146a/708/451/98) in ECs followed by decreases below basal levels at 7 days;
other	hsa-mir-98	Atherosclerosis	28436142	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Cortisol is associated with low frequency of interleukin 10-producing B cells in patients with atherosclerosis.
other	hsa-mir-99b	Atherosclerosis	22370758	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Co-expression in plaque tissue and classical monocytes.
other	hsa-mir-155	Atopic Dermatitis	25761610	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	MicroRNA-155 may be involved in the pathogenesis of atopic dermatitis by modulating the differentiation and function of T helper type 17 (Th17) cells.
other	hsa-mir-155	Atopic Dermatitis	24521175	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	The presented concept offers a new option for the prevention of atopic diseases by the addition of physiological amounts of miR-155-enriched exosomes to infant formula for mothers incapable of breastfeeding.
other	hsa-mir-1	Atrial Fibrillation	26221584	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The results suggest that immediate-early miRNA remodeling coupled with deregulation of TF expression underlies the onset of AF.
other	hsa-mir-106b	Atrial Fibrillation	24927531	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-17-92 and miR-106b-25 directly repress genes, such as Shox2 and Tbx3, that are required for sinoatrial node development.Together, to our knowledge, these findings provide the first genetic evidence for an miR loss-of-function that increases atrial fibrillation susceptibility.
other	hsa-mir-10a	Atrial Fibrillation	26221584	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The results suggest that immediate-early miRNA remodeling coupled with deregulation of TF expression underlies the onset of AF.
other	hsa-mir-10b	Atrial Fibrillation	26221584	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The results suggest that immediate-early miRNA remodeling coupled with deregulation of TF expression underlies the onset of AF.
other	hsa-mir-124	Atrial Fibrillation	26567235	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model.
other	hsa-mir-126	Atrial Fibrillation	26313139	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Biological significance of miR-126 expression in atrial fibrillation and heart failure.
other	hsa-mir-133a-1	Atrial Fibrillation	22407060	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF
other	hsa-mir-133a-2	Atrial Fibrillation	22407060	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF
other	hsa-mir-133b	Atrial Fibrillation	22407060	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF
other	hsa-mir-146a	Atrial Fibrillation	29437577	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation
other	hsa-mir-146b	Atrial Fibrillation	25617731	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-146b-5p probably acts as an intracellular mediator in the maladaptive remodeling in atrial fibrosis in atrial fibrillation.
other	hsa-mir-150	Atrial Fibrillation	24462065	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in  patients with chronic systolic heart failure.
other	hsa-mir-183	Atrial Fibrillation	26567235	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model.
other	hsa-mir-192	Atrial Fibrillation	26567235	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model.
other	hsa-mir-199a	Atrial Fibrillation	25706326	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Our combined transcriptomic analysis and miRNA microarray study of atrial samples from pAF patients revealed novel pathways and miRNA-mRNA regulations that may be relevant in the development of pAF. Future studies are required to investigate the potential involvement of the gonadotropin releasing hormone receptor and p53 pathways in AF pathogenesis.
other	hsa-mir-208b	Atrial Fibrillation	27545043	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation.
other	hsa-mir-21	Atrial Fibrillation	26221584	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The results suggest that immediate-early miRNA remodeling coupled with deregulation of TF expression underlies the onset of AF.
other	hsa-mir-215	Atrial Fibrillation	26567235	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model.
other	hsa-mir-26b	Atrial Fibrillation	26567235	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model.
other	hsa-mir-29	Atrial Fibrillation	24085039	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	These new insights into mir29’s functions further support a role for the adaptive immune system in the immunopathogenesis of AF. We recommend that AF investigators team up with immunologists in search for pathogenic T cells.
other	hsa-mir-30a	Atrial Fibrillation	22407060	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF
other	hsa-mir-30b	Atrial Fibrillation	22407060	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF
other	hsa-mir-30c-1	Atrial Fibrillation	22407060	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF
other	hsa-mir-30c-2	Atrial Fibrillation	22407060	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF
other	hsa-mir-30d	Atrial Fibrillation	22407060	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	both miR-133 and miR-30 play an important role in controlling structural changes in chronic AF
other	hsa-mir-355p	Atrial Fibrillation	26567235	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model.
other	hsa-mir-518a	Atrioventricular Septal Defect	27396555	cardiovascular system disease	DOID:0050651	Q21.2	D004694	PS606215		Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96.
other	hsa-mir-518e	Atrioventricular Septal Defect	27396555	cardiovascular system disease	DOID:0050651	Q21.2	D004694	PS606215		Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96.
other	hsa-mir-518f	Atrioventricular Septal Defect	27396555	cardiovascular system disease	DOID:0050651	Q21.2	D004694	PS606215		Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96.
other	hsa-mir-528a	Atrioventricular Septal Defect	27396555	cardiovascular system disease	DOID:0050651	Q21.2	D004694	PS606215		Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96.
other	hsa-mir-96	Atrioventricular Septal Defect	27396555	cardiovascular system disease	DOID:0050651	Q21.2	D004694	PS606215		Furthermore, miRNA-DEG regulatory networks were constructed. IL1B was the hub-gene of PPI networks, and AUTS2 and KIAA2022 were predicted to be targeted by miR-518a, miR518e, miR-518f, miR-528a, and miR-96.IL1B, IL12RB2, AUTS2, and KIAA2022 might participate in AVSD in DS patients, and AUTS2 and KIAA2022 might be targeted by miR-518a, miR-518e, miR-518f, miR-528a, and miR-96.
other	hsa-mir-155	Atrophic Gastritis	21880981	gastrointestinal system disease	DOID:8929	K29.4	D005757			MicroRNA-155 Is Essential for the T Cell-Mediated Control of Helicobacter pylori Infection and for the Induction of Chronic Gastritis and Colitis.
other	hsa-let-7g	Atypical Teratoid Tumor	25638158	disease of cellular proliferation	DOID:2129			609322		LIN28A knockdown led to increased expression of let-7b and let-7g microRNAs and a down-regulation of KRAS mRNA.
other	hsa-mir-140	Autism Spectrum Disorder	28848387	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder.
other	hsa-mir-182	Autism Spectrum Disorder	28617945	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	microRNA cluster 106a~363 is involved in T helper 17 cell differentiation.
other	hsa-mir-184	Autism Spectrum Disorder	18203756	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	The restricted release of MeCP2 from the paternal allele results in paternal allele-specific expression of miR-184. Our finding provides a clue to the link between the microRNA and DNA methylation pathways.
other	hsa-mir-21	Autism Spectrum Disorder	27571009	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	Genome-wide, integrative analysis implicates microRNA dysregulation in autism spectrum disorder.
other	hsa-mir-212	Autism Spectrum Disorder	28617945	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	microRNA cluster 106a~363 is involved in T helper 17 cell differentiation.
other	hsa-mir-363	Autism Spectrum Disorder	28617945	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	microRNA cluster 106a~363 is involved in T helper 17 cell differentiation.
other	hsa-let-7a	Autoimmune Diseases [unspecific]	25759134				D001327	607836	HP:0002960	we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-mir-10a	Autoimmune Diseases [unspecific]	27687891				D001327	607836	HP:0002960	MicroRNAs such as miR-155, miR-126, and miR-10a also exert an important influence on the differentiation, development, and immunological functions of Tregs
other	hsa-mir-125a	Autoimmune Diseases [unspecific]	25963922				D001327	607836	HP:0002960	Using a chemically synthesized miR-125a analogue,we show potential to re-programme the immune homeostasis in EAE models. These findings point to miR-125a as a critical factor that controls autoimmune diseases by stabilizing Treg-mediated immune homeostasis.
other	hsa-mir-126	Autoimmune Diseases [unspecific]	27687891				D001327	607836	HP:0002960	MicroRNAs such as miR-155, miR-126, and miR-10a also exert an important influence on the differentiation, development, and immunological functions of Tregs
other	hsa-mir-142	Autoimmune Diseases [unspecific]	27943367				D001327	607836	HP:0002960	Analysis of miR-146a and miR-142-3p as Potential Markers of Freshly Isolated or In Vitro-Expanded Human Treg cells.
other	hsa-mir-146a	Autoimmune Diseases [unspecific]	24014244				D001327	607836	HP:0002960	Our data unravel the crucial immunomodulatory role of miR-146a in pDCs and may add to our understanding of aberrant responses in autoimmune diseases.
other	hsa-mir-146a	Autoimmune Diseases [unspecific]	27943367				D001327	607836	HP:0002960	Analysis of miR-146a and miR-142-3p as Potential Markers of Freshly Isolated or In Vitro-Expanded Human Treg cells.
other	hsa-mir-150	Autoimmune Diseases [unspecific]	26275076				D001327	607836	HP:0002960	dysregulated expression of miR-150 in immune cells might result in autoimmune diseases.
other	hsa-mir-155	Autoimmune Diseases [unspecific]	26674874				D001327	607836	HP:0002960	We have shown that mice in which the miR-155 host gene (MIR155HG) has been deactivated are resistant to EAE.
other	hsa-mir-155	Autoimmune Diseases [unspecific]	27687891				D001327	607836	HP:0002960	MicroRNAs such as miR-155, miR-126, and miR-10a also exert an important influence on the differentiation, development, and immunological functions of Tregs
other	hsa-mir-200c	Autoimmune Diseases [unspecific]	25759134				D001327	607836	HP:0002960	we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-mir-21	Autoimmune Diseases [unspecific]	27271606				D001327	607836	HP:0002960	miR-21 was found to be correlated with the pathogenesis of autoimmune diseases
other	hsa-mir-188	Azoospermia	27868267	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	Reduced microRNA-188-3p expression contributes to apoptosis of spermatogenic cells in patients with azoospermia.
other	hsa-mir-143	Barrett Esophagus	19190970	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-143: significantly higher
other	hsa-mir-31	Barrett Esophagus	22302717	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	The authors propose miR-31 and -375 as novel candidate microRNAs specifically associated with early- and late-stage malignant progression, respectively, in Barrett's esophagus.
other	hsa-mir-375	Barrett Esophagus	22302717	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	The authors propose miR-31 and -375 as novel candidate microRNAs specifically associated with early- and late-stage malignant progression, respectively, in Barrett's esophagus.
other	hsa-mir-34c	Becker Muscular Dystrophy	29703249	musculoskeletal system disease	DOID:9883	G71.0		300376		miR-708-5p and miR-34c-5p are involved in nNOS regulation in dystrophic context.
other	hsa-mir-708	Becker Muscular Dystrophy	29703249	musculoskeletal system disease	DOID:9883	G71.0		300376		miR-708-5p and miR-34c-5p are involved in nNOS regulation in dystrophic context.
other	hsa-mir-196a2	Behcet Disease	27993883	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		Association of Reduced Heme Oxygenase-1 with Decreased MicroRNA-196a2 Expression in Peripheral Blood Mononuclear Cells of Patients with Intestinal Behcet's Disease.
other	hsa-mir-129	Biliary Atresia	27706677	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		Effect of miR-29c and miR-129-5p on epithelial-mesenchymal transition in experimental biliary atresia mouse models.
other	hsa-mir-155	Biliary Atresia	27817193	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		Effect of microRNA-155 on the interferon-gamma signaling pathway in biliary atresia.
other	hsa-mir-29a	Biliary Atresia	22167021	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		MicroRNA Profiling Identifies miR-29 as a Regulator of Disease-Associated Pathways in Experimental Biliary Atresia.
other	hsa-mir-29b-1	Biliary Atresia	22167021	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		MicroRNA Profiling Identifies miR-29 as a Regulator of Disease-Associated Pathways in Experimental Biliary Atresia.
other	hsa-mir-29c	Biliary Atresia	27706677	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		Effect of miR-29c and miR-129-5p on epithelial-mesenchymal transition in experimental biliary atresia mouse models.
other	hsa-mir-103-1	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-124	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-132	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-138	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-206	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-218-1	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-34a	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-449a	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-708	Bipolar Disorder	27864917	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Genetic variation in the miR-708 gene and its binding targets in bipolar disorder.
other	hsa-mir-9-3	Bipolar Disorder	25817407	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-100	Bladder Neoplasms	23911686			C67	D001749	109800	HP:0009725	Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models.
other	hsa-mir-100	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
other	hsa-mir-101	Bladder Neoplasms	23911686			C67	D001749	109800	HP:0009725	Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models.
other	hsa-mir-101	Bladder Neoplasms	25109742			C67	D001749	109800	HP:0009725	Enforced expression of miR-101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase-2 pathway.
other	hsa-mir-101	Bladder Neoplasms	25658842			C67	D001749	109800	HP:0009725	miR-101 suppresses VEGF-C expression, inhibits cell migration and invasion, and increases cisplatin sensitivity in bladder cancer cells. 
other	hsa-mir-101	Bladder Neoplasms	22745731			C67	D001749	109800	HP:0009725	The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization.
other	hsa-mir-106b	Bladder Neoplasms	25168920			C67	D001749	109800	HP:0009725	Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer.
other	hsa-mir-10b	Bladder Neoplasms	25620614			C67	D001749	109800	HP:0009725	urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial.
other	hsa-mir-125a	Bladder Neoplasms	22745731			C67	D001749	109800	HP:0009725	The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization.
other	hsa-mir-125b	Bladder Neoplasms	20549700			C67	D001749	109800	HP:0009725	Taken together, miR-125b may act as a tumor suppressor in bladder urothelium, and downregulation of miR-125b may contribute to the tumorigenesis of bladder cancer.
other	hsa-mir-125b	Bladder Neoplasms	28938585			C67	D001749	109800	HP:0009725	The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer.
other	hsa-mir-129	Bladder Neoplasms	19487295			C67	D001749	109800	HP:0009725	We identified several miRNAs with prognostic potential for predicting disease progression (e.g., miR-129, miR-133b, and miR-518c*).
other	hsa-mir-133b	Bladder Neoplasms	19487295			C67	D001749	109800	HP:0009725	We identified several miRNAs with prognostic potential for predicting disease progression (e.g., miR-129, miR-133b, and miR-518c*).
other	hsa-mir-141	Bladder Neoplasms	25884322			C67	D001749	109800	HP:0009725	MiRNA-141 and miRNA-200b play important roles in the invasive ability and EMT phenotype of bladder cancer. Detection of miRNA-141 and miRNA-200b can help to identify patients undergoing cystectomy who are likely to have lymph node metastasis, and therefore those who may benefit from super-extended PLND.
other	hsa-mir-143	Bladder Neoplasms	26356996			C67	D001749	109800	HP:0009725	Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.
other	hsa-mir-143	Bladder Neoplasms	25804644			C67	D001749	109800	HP:0009725	The cancer-related miR-143, miR-145 and miR-224 were investigated for the first time in the clinical setting of BlCa, and miR-143/145 cluster constitutes a novel marker helpful for providing an enhanced prediction of oncologic outcome for BlCa patients.
other	hsa-mir-143	Bladder Neoplasms	28123579			C67	D001749	109800	HP:0009725	miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling.
other	hsa-mir-145	Bladder Neoplasms	23911686			C67	D001749	109800	HP:0009725	Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models.
other	hsa-mir-145	Bladder Neoplasms	26356996			C67	D001749	109800	HP:0009725	Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.
other	hsa-mir-145	Bladder Neoplasms	25804644			C67	D001749	109800	HP:0009725	The cancer-related miR-143, miR-145 and miR-224 were investigated for the first time in the clinical setting of BlCa, and miR-143/145 cluster constitutes a novel marker helpful for providing an enhanced prediction of oncologic outcome for BlCa patients.
other	hsa-mir-145	Bladder Neoplasms	26852750			C67	D001749	109800	HP:0009725	decreasing miR-145 expression reduced cisplatin sensitivity
other	hsa-mir-148a	Bladder Neoplasms	25865490			C67	D001749	109800	HP:0009725	miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1.
other	hsa-mir-148b	Bladder Neoplasms	22745731			C67	D001749	109800	HP:0009725	The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization.
other	hsa-mir-151	Bladder Neoplasms	22745731			C67	D001749	109800	HP:0009725	The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization.
other	hsa-mir-155	Bladder Neoplasms	25965824			C67	D001749	109800	HP:0009725	MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1.
other	hsa-mir-16	Bladder Neoplasms	23991964			C67	D001749	109800	HP:0009725	miR-16 is an important regulator in bladder cancer, which will contribute to better understanding of important mis-regulated miRNAs.
other	hsa-mir-16	Bladder Neoplasms	26373319			C67	D001749	109800	HP:0009725	Together, our results revealed that urothelial carcinoma-associated 1 regulated the expression of GLS2 through interfering with miR-16, and repressed ROS formation in bladder cancer cells.
other	hsa-mir-17	Bladder Neoplasms	29386015			C67	D001749	109800	HP:0009725	Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression
other	hsa-mir-181b	Bladder Neoplasms	22745731			C67	D001749	109800	HP:0009725	The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization.
other	hsa-mir-182	Bladder Neoplasms	26356996			C67	D001749	109800	HP:0009725	Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.
other	hsa-mir-183	Bladder Neoplasms	26356996			C67	D001749	109800	HP:0009725	Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.
other	hsa-mir-192	Bladder Neoplasms	25566965			C67	D001749	109800	HP:0009725	miR-192 may be a suppressor for bladder cancer cells by cell cycle regulation.
other	hsa-mir-200a	Bladder Neoplasms	20473948			C67	D001749	109800	HP:0009725	we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression.
other	hsa-mir-200b	Bladder Neoplasms	25884322			C67	D001749	109800	HP:0009725	MiRNA-141 and miRNA-200b play important roles in the invasive ability and EMT phenotype of bladder cancer. Detection of miRNA-141 and miRNA-200b can help to identify patients undergoing cystectomy who are likely to have lymph node metastasis, and therefore those who may benefit from super-extended PLND.
other	hsa-mir-200b	Bladder Neoplasms	20473948			C67	D001749	109800	HP:0009725	we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression.
other	hsa-mir-200c	Bladder Neoplasms	20473948			C67	D001749	109800	HP:0009725	we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression.
other	hsa-mir-205	Bladder Neoplasms	20473948			C67	D001749	109800	HP:0009725	we observe that the mesoderm transcription factor TWIST1 and miR-200 expression are inversely correlated in bladder tumor samples and cell lines. TWIST1 associates directly with the miR-200 and miR-205 promoters, and may act as a repressor of miR-200 and miR-205 expression.
other	hsa-mir-21	Bladder Neoplasms	23911686			C67	D001749	109800	HP:0009725	Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models.
other	hsa-mir-21	Bladder Neoplasms	25266796			C67	D001749	109800	HP:0009725	A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis.
other	hsa-mir-21	Bladder Neoplasms	22788411			C67	D001749	109800	HP:0009725	The effect of normalization was tested with miR-21 as the target gene, as this was previously suggested to be upregulated in cancer patients' serum.
other	hsa-mir-210	Bladder Neoplasms	25620614			C67	D001749	109800	HP:0009725	urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial.
other	hsa-mir-214	Bladder Neoplasms	25975233			C67	D001749	109800	HP:0009725	Urinary cell-free miR-214 is a hopeful biomarker for tumor stratification, early diagnosis and prognostic assessment of bladder cancer.
other	hsa-mir-221	Bladder Neoplasms	25620614			C67	D001749	109800	HP:0009725	urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial.
other	hsa-mir-221	Bladder Neoplasms	25585941			C67	D001749	109800	HP:0009725	The expression of MMP-2, MMP-9 and VEGF-C were reduced, resulting in reduced invasiveness and infiltration capability of bladder cancer cells, thereby inhibiting the immune evasion of bladder cancer cells.
other	hsa-mir-221	Bladder Neoplasms	28770966			C67	D001749	109800	HP:0009725	Inhibition of miR-221 influences bladder cancer cell proliferation and apoptosis.
other	hsa-mir-224	Bladder Neoplasms	25804644			C67	D001749	109800	HP:0009725	The cancer-related miR-143, miR-145 and miR-224 were investigated for the first time in the clinical setting of BlCa, and miR-143/145 cluster constitutes a novel marker helpful for providing an enhanced prediction of oncologic outcome for BlCa patients.
other	hsa-mir-224	Bladder Neoplasms	29386015			C67	D001749	109800	HP:0009725	Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression
other	hsa-mir-23a	Bladder Neoplasms	25620614			C67	D001749	109800	HP:0009725	urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial.
other	hsa-mir-23b	Bladder Neoplasms	25405368			C67	D001749	109800	HP:0009725	RNA networks regulated by tumor-suppressive miR-23b/27b provide new insights into the potential mechanisms of BC oncogenesis and metastasis.
other	hsa-mir-27b	Bladder Neoplasms	25405368			C67	D001749	109800	HP:0009725	RNA networks regulated by tumor-suppressive miR-23b/27b provide new insights into the potential mechanisms of BC oncogenesis and metastasis.
other	hsa-mir-29a	Bladder Neoplasms	28687357			C67	D001749	109800	HP:0009725	Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway.
other	hsa-mir-29b	Bladder Neoplasms	27322434			C67	D001749	109800	HP:0009725	miR-21 and miR-29b depression have been shown in Snail-1 suppressed group in EJ-138 cells in vitro.
other	hsa-mir-29c	Bladder Neoplasms	24952510			C67	D001749	109800	HP:0009725	Down-regulation of miR-29c in human bladder cancer and the inhibition of proliferation in T24 cell via PI3K-AKT pathway.
other	hsa-mir-29c	Bladder Neoplasms	25620614			C67	D001749	109800	HP:0009725	urine miR-210, miR-10b, and miR-29c are promising tumor markers for BC: bilharzial and nonbilharzial.
other	hsa-mir-34a	Bladder Neoplasms	25572695			C67	D001749	109800	HP:0009725	polyphenols in PRE can be potential molecular clusters to suppress bladder cancer cell EJ proliferation via p53/miR-34a axis.
other	hsa-mir-34a	Bladder Neoplasms	23720881			C67	D001749	109800	HP:0009725	These findings suggest that the relative low expression of miRNA-34a might be involved in the tumorigenesis of bladder cancer.
other	hsa-mir-373	Bladder Neoplasms	23911686			C67	D001749	109800	HP:0009725	Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models.
other	hsa-mir-449a	Bladder Neoplasms	29659560			C67	D001749	109800	HP:0009725	Androgen Receptor Is Inactivated and Degraded in Bladder Cancer Cells by Phenyl Glucosamine via miR-449a Restoration.
other	hsa-mir-451	Bladder Neoplasms	25550801			C67	D001749	109800	HP:0009725	miR451 should be a tumor-suppressing gene in bladder cancer. miR-451 could maintain the bladder tumor cells in epithelial phenotype, inhibit EMT process, thereby reducing the invasion and migration of tumor cells.
other	hsa-mir-503	Bladder Neoplasms	29169421			C67	D001749	109800	HP:0009725	miR-503-5p inhibits the proliferation of T24 and EJ bladder cancer cells by interfering with the Rb/E2F signaling pathway
other	hsa-mir-708	Bladder Neoplasms	23568547			C67	D001749	109800	HP:0009725	miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2
other	hsa-mir-874	Bladder Neoplasms	22745731			C67	D001749	109800	HP:0009725	The combination of four (miR-101, miR-125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization.
other	hsa-mir-96	Bladder Neoplasms	26356996			C67	D001749	109800	HP:0009725	Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.
other	hsa-mir-99a	Bladder Neoplasms	23911686			C67	D001749	109800	HP:0009725	Aberrations in miR expression identified between non-muscle invasive BC and muscle-invasive BC provide insight into the molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores theimportance of in vivo validation in a field that utilizes in silico miR target-prediction models.
other	hsa-mir-1	Bladder Outlet Obstruction	26612603	urinary system disease	DOID:13948	N32.0	D001748			We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO.
other	hsa-mir-132	Bladder Outlet Obstruction	26612603	urinary system disease	DOID:13948	N32.0	D001748			We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO.
other	hsa-mir-204	Bladder Outlet Obstruction	26612603	urinary system disease	DOID:13948	N32.0	D001748			We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO.
other	hsa-mir-212	Bladder Outlet Obstruction	26612603	urinary system disease	DOID:13948	N32.0	D001748			We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO.
other	hsa-mir-221	Bladder Outlet Obstruction	26612603	urinary system disease	DOID:13948	N32.0	D001748			We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO.
other	hsa-mir-29	Bladder Outlet Obstruction	24340017	urinary system disease	DOID:13948	N32.0	D001748			Mir-29 repression in bladder outlet obstruction contributes to matrix remodeling and altered stiffness.
other	hsa-mir-29	Bladder Outlet Obstruction	26612603	urinary system disease	DOID:13948	N32.0	D001748			We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO.
other	hsa-mir-30	Bladder Outlet Obstruction	26612603	urinary system disease	DOID:13948	N32.0	D001748			We discuss known and predicted functions of miR-1, miR-29, miR-30, miR-132/212, miR-204 and miR-221, all of which change in BOO.
other	hsa-mir-410	Blindness	27297412	nervous system disease	DOID:1432	H54			HP:0000618	antisense microRNA-410 (anti-miR-410) induces RPE differentiation from amniotic epithelial  stem cells.
other	hsa-mir-24	Blood Coagulation Disorders	28694557			D68.9	D001778			Overexpression of miR-24 Is Involved in the Formation of Hypocoagulation State after Severe Trauma by Inhibiting the Synthesis of Coagulation Factor X.
other	hsa-mir-34a	Bone Disease [unspecific]	28543623	musculoskeletal system disease	DOID:0080001	M89.9	D001847			Regulatory effect of microRNA-34a on osteogenesis and angiogenesis in glucocorticoid-induced osteonecrosis of the femoral head.
other	hsa-mir-34c	Bone Disease [unspecific]	27492554	musculoskeletal system disease	DOID:0080001	M89.9	D001847			Taken together, our studies suggested that Icariine restored LPS-induced bone loss by downregulating miR-34c level and suppressing JNKs, p38,  and NF-kB pathways, which highlighted the potential use of Icariine as a therapeutic agent in the treatment of bacteria-induced bone loss diseases.
other	hsa-mir-34c	Bone Disease [unspecific]	27156573	musculoskeletal system disease	DOID:0080001	M89.9	D001847			Vaspin regulates the osteogenic differentiation of MC3T3-E1 through the PI3K-Akt/miR-34c loop.
other	hsa-let-7	Brain Disease [unspecific]	29408500	nervous system disease	DOID:936	G93.40	D001927	608033		MicroRNA let-7c-5p improves neurological outcomes in a murine model of traumatic  brain injury by suppressing neuroinflammation and regulating microglial activation
other	hsa-mir-132	Brain Disease [unspecific]	25957996	nervous system disease	DOID:936	G93.40	D001927	608033		our findings demonstrate the novel role of TLR4-related microRNAs, especially miR-132, in the regulation of MRP8-induced astrocyte activation and highlight the importance of miR-132 in the modulation of innate immune response induced by endogenous ligands in neurological diseases.
other	hsa-mir-146a	Brain Disease [unspecific]	25957996	nervous system disease	DOID:936	G93.40	D001927	608033		our findings demonstrate the novel role of TLR4-related microRNAs, especially miR-132, in the regulation of MRP8-induced astrocyte activation and highlight the importance of miR-132 in the modulation of innate immune response induced by endogenous ligands in neurological diseases.
other	hsa-mir-155	Brain Disease [unspecific]	25957996	nervous system disease	DOID:936	G93.40	D001927	608033		our findings demonstrate the novel role of TLR4-related microRNAs, especially miR-132, in the regulation of MRP8-induced astrocyte activation and highlight the importance of miR-132 in the modulation of innate immune response induced by endogenous ligands in neurological diseases.
other	hsa-mir-21	Brain Disease [unspecific]	28452880	nervous system disease	DOID:936	G93.40	D001927	608033		Acute and subacute microRNA dysregulation is associated with cytokine responses in the rodent model of penetrating ballistic-like brain injury.
other	hsa-mir-27b	Brain Disease [unspecific]	29050310	nervous system disease	DOID:936	G93.40	D001927	608033		MicroRNA-27b inhibition promotes Nrf2/ARE pathway activation and alleviates intracerebral hemorrhage-induced brain injury
other	hsa-mir-29b	Brain Disease [unspecific]	29087603	nervous system disease	DOID:936	G93.40	D001927	608033		MiR-29b expression is associated with a dexmedetomidine-mediated protective effect against oxygen-glucose deprivation-induced injury to SK-N-SH cells in vitro.
other	hsa-mir-9	Brain Disease [unspecific]	20362537	nervous system disease	DOID:936	G93.40	D001927	608033		These results identify miR-9 as a novel regulator that coordinates the proliferation and migration of hNPCs.
other	hsa-mir-106b	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-17	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-18	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-181c	Brain Neoplasms	24867100	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt  phosphorylation in glioblastoma.
other	hsa-mir-19a	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-19b-1	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-20a	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-21	Brain Neoplasms	19175699	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	Since its identification 3 years ago as the miRNA most commonly and strongly up-regulated in human brain tumour glioblastoma [1], miR-21 has attracted the attention of researchers in various fields
other	hsa-mir-25	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-34a	Brain Neoplasms	20190569	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
other	hsa-mir-520g	Brain Neoplasms	26687818	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment.
other	hsa-mir-92-1	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-93	Brain Neoplasms	29547527	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors
other	hsa-mir-21	Breast Adenocarcinoma	28092843	thoracic disease	DOID:3458					Moreover siRNA transfection had effects on breast adenocarcinoma cells and inhibits the migration (p<0.0001), proliferation (p<0.0001), cell cycle arrest (p=0.03) and induces apoptosis (p<0.0001) and reduces the expression of miR-21 (P=0.0014)
other	hsa-mir-10b	Breast Ductal Carcinoma	29599829	thoracic disease	DOID:3007	D05.10	D044584			miR-10b-positive expression was correlated with the expression of ER-α, Her-2 and the molecular subtypes of early invasive ductal carcinoma of the breast
other	hsa-mir-10b	Breast Ductal Carcinoma	28512126	thoracic disease	DOID:3007	D05.10	D044584			Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGFβ signaling.
other	hsa-mir-21	Breast Malignant Phyllodes Tumor	24980553	thoracic disease	DOID:3016		D003557			miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors.
other	hsa-let-7	Breast Neoplasms	23774803	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas
other	hsa-let-7a	Breast Neoplasms	24104964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-let-7b	Breast Neoplasms	24104964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-let-7c	Breast Neoplasms	24104964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-let-7d	Breast Neoplasms	24104964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-let-7f	Breast Neoplasms	24104964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-let-7g	Breast Neoplasms	24104964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-let-7i	Breast Neoplasms	24104964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-let-7	Breast Neoplasms	26178901	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity.
other	hsa-let-7a	Breast Neoplasms	25722304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.
other	hsa-let-7a	Breast Neoplasms	26178901	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity.
other	hsa-let-7a	Breast Neoplasms	24942235	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations.
other	hsa-let-7a	Breast Neoplasms	26924493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Mir-206 and let-7 were up-regulated, and mir-21 expression was down-regulated in  the exercise training compared to tumor group.
other	hsa-let-7a-1	Breast Neoplasms	21368581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbeta-induced oncomiR miRNA-181a.
other	hsa-let-7a-2	Breast Neoplasms	21368581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbe-induced oncomiR miRNA-181a.
other	hsa-let-7a-3	Breast Neoplasms	21368581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbeta-induced oncomiR miRNA-181a.
other	hsa-let-7c	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
other	hsa-let-7e	Breast Neoplasms	24257477	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer.
other	hsa-let-7i	Breast Neoplasms	24662829	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In breast cancer patients, significantly decreased let-7i  levels were associated with missense mutations in p53.
other	hsa-mir-1	Breast Neoplasms	26275461	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our findings emphasized the potential role of miR-1 as tumor suppressive miRNA in breast cancer.
other	hsa-mir-1	Breast Neoplasms	26497855	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-1 down-regulates proliferation and migration of breast cancer stem cells by inhibiting the Wnt/β-catenin pathway.
other	hsa-mir-101	Breast Neoplasms	25059472	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2.
other	hsa-mir-101	Breast Neoplasms	26360780	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7.
other	hsa-mir-103	Breast Neoplasms	22753153	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.
other	hsa-mir-103	Breast Neoplasms	22908280	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b.
other	hsa-mir-103a	Breast Neoplasms	24865188	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients.
other	hsa-mir-106a	Breast Neoplasms	24164962	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2.
other	hsa-mir-106b	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-107	Breast Neoplasms	20348243	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.
other	hsa-mir-107	Breast Neoplasms	22908280	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b.
other	hsa-mir-10a	Breast Neoplasms	25934412	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The data presented supports a potential tumour suppressor role for miR-10a in breast cancer, and highlights retinoic acid as a positive regulator of the microRNA.
other	hsa-mir-10a	Breast Neoplasms	29113237	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway.
other	hsa-mir-10b	Breast Neoplasms	24457988	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Critical role of miR-10b in transforming growth factor-β1-induced epithelial-mesenchymal transition in breast cancer.
other	hsa-mir-10b	Breast Neoplasms	24897960	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results provide evidences that the addition of miR-10b RERs to the prognostic factors used in clinical routine could improve the prediction abilities for both overall mortality and disease progression in breast cancer patients.
other	hsa-mir-10b	Breast Neoplasms	22020939	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Cysteine rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2(WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1{alpha}-TWIST signaling networks in human breast cancer cells.
other	hsa-mir-122	Breast Neoplasms	25078559	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.
other	hsa-mir-122	Breast Neoplasms	25150312	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122.
other	hsa-mir-122	Breast Neoplasms	25621950	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	by modifying glucose utilization by recipient premetastatic niche cells, cancer-derived extracellular miR-122 is able to reprogram systemic energy metabolism to facilitate disease progression.
other	hsa-mir-1258	Breast Neoplasms	21266359	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppresses Breast Cancer Brain Metastasis by Targeting Heparanase.
other	hsa-mir-125a	Breast Neoplasms	26130254	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
other	hsa-mir-125a	Breast Neoplasms	23519125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
other	hsa-mir-125b	Breast Neoplasms	24098452	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression of ENPEP and CK2-α was inversely correlated with miR-125b expression in breast tumors,indicating the relevance of these potential oncogenic proteins in breast cancer patients. 
other	hsa-mir-125b	Breast Neoplasms	24165569	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together our results show a mechanism for EPO/EPOR and ERBB2 co-regulation in breast cancer and confirm the importance of miR-125b in controlling clinically-relevant cancer features.
other	hsa-mir-125b	Breast Neoplasms	25539763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	context-dependent roles are not clear in breast cancer, a diverse expression pattern of ALCAM mRNA was detected in a panel of breast cancer patient samples. Differentially expressed/regulated cancer-related genes upon miR-125b expression along with the significant increase of ALCAM are of future interest to understand how deregulated expression of miR-125b may have a tumor suppressor role in breast and other cancers.
other	hsa-mir-125b	Breast Neoplasms	25722304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.
other	hsa-mir-125b	Breast Neoplasms	26130254	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
other	hsa-mir-125b-1	Breast Neoplasms	23519125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
other	hsa-mir-125b-2	Breast Neoplasms	23519125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
other	hsa-mir-126	Breast Neoplasms	26926567	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42.
other	hsa-mir-126	Breast Neoplasms	23396050	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-126 and miR-126(*) repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis
other	hsa-mir-1266	Breast Neoplasms	25640367	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients.
other	hsa-mir-127	Breast Neoplasms	24155205	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-127 is downregulated by Tudor-SN protein and contributes to metastasis and proliferation in breast cancer cell line MDA-MB-231.
other	hsa-mir-1274b	Breast Neoplasms	25722304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.
other	hsa-mir-128	Breast Neoplasms	27322220	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-128 in exosomes negatively regulates the level of Bax in MCF-7 recipient cells and inhibits cell  proliferation.
other	hsa-mir-128a	Breast Neoplasms	20054641	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These data suggest that the hormone-responsive miR-128a can modulate TGFβ signaling and survival of the letrozole-resistant cell lines.
other	hsa-mir-128b	Breast Neoplasms	22908280	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b.
other	hsa-mir-133a	Breast Neoplasms	25051376	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	both miR-148b and miR-133a have potential use as biomarkers for breast cancer detection
other	hsa-mir-133a	Breast Neoplasms	26107945	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2.
other	hsa-mir-134	Breast Neoplasms	26416415	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
other	hsa-mir-135a	Breast Neoplasms	25680412	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer.
other	hsa-mir-137	Breast Neoplasms	26215676	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A contrasting function for miR-137 in embryonic mammogenesis and adult breast carcinogenesis.
other	hsa-mir-139	Breast Neoplasms	24158791	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-139-5p is a regulator of metastatic pathways in breast cancer.
other	hsa-mir-139	Breast Neoplasms	25680412	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer.
other	hsa-mir-139	Breast Neoplasms	23722663	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Some novel miRNAs without known association to breast cancer were also found, and the putative functions of their PINs were also elucidated. These include miR-139 and miR-383. 
other	hsa-mir-140	Breast Neoplasms	26378051	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the existence of common pathways driving breast carcinogenesis in both BRCA1 and BRCA2 germ-line mutation carriers.
other	hsa-mir-140	Breast Neoplasms	23752191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer.
other	hsa-mir-141	Breast Neoplasms	26164002	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-141 as potential suppressor of β-catenin in breast cancer.
other	hsa-mir-143	Breast Neoplasms	25961039	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In our integrated genomics analysis and experimental validation, a new frame to predict candidate biomarkers of breast cancer subtype is provided and offers assistance in order to understand the potential disease etiology of the breast cancer subtypes.
other	hsa-mir-143	Breast Neoplasms	26439035	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	UCA1 can directly interact with miR-143, lower its expression and affect its downstream regulation. Therefore, the UCA1-miR-143 axis constitutes a part of the oncogenic role of UCA1 in breast cancer.
other	hsa-mir-143	Breast Neoplasms	22260523	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells.
other	hsa-mir-143	Breast Neoplasms	28933584	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circular RNA hsa_circ_0001982 Promotes Breast Cancer Cell Carcinogenesis Through Decreasing miR-143.
other	hsa-mir-144	Breast Neoplasms	25465851	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	4 miRNAs that are generally dysregulated in human pathologies. Although these markers are not specific to certain diseases they may add to the diagnosis in combination with other markers, building a specific signature. Besides these dysregulated miRNAs, we propose a set of constant miRNAs that may be used as control markers.
other	hsa-mir-144	Breast Neoplasms	26252024	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation,migration and invasion of breast cancer cells.
other	hsa-mir-145	Breast Neoplasms	25961039	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In our integrated genomics analysis and experimental validation, a new frame to predict candidate biomarkers of breast cancer subtype is provided and offers assistance in order to understand the potential disease etiology of the breast cancer subtypes.
other	hsa-mir-145	Breast Neoplasms	26324407	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells.
other	hsa-mir-145	Breast Neoplasms	19996288	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these results suggest that as a tumor suppressor, miR-145 inhibits not only tumor growth but also cell invasion and metastasis.
other	hsa-mir-145	Breast Neoplasms	19730444	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells.
other	hsa-mir-145	Breast Neoplasms	20818426	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness.
other	hsa-mir-145	Breast Neoplasms	22908280	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b.
other	hsa-mir-146a	Breast Neoplasms	26095299	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our study provided new insights into the function of CXCR4 in breast cancer: it promotes tumor progression as both a protein-coding gene and a non-coding RNA, complicating the mechanism by which oncogenes promote tumor progression.
other	hsa-mir-146a	Breast Neoplasms	21472990	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.
other	hsa-mir-146a	Breast Neoplasms	22949171	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-146a suppresses metastatic activity in brain metastasis.
other	hsa-mir-146b	Breast Neoplasms	24498150	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Unraveling the hidden heterogeneities of breast cancer based on functional miRNA cluster.
other	hsa-mir-146b	Breast Neoplasms	21472990	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.
other	hsa-mir-148a	Breast Neoplasms	25063027	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our findings offer important new insights into the ability of estrogenic GPER signaling to trigger HLA-G expression through inhibiting miR-148a that supports immune evasion in breast cancer.
other	hsa-mir-148a	Breast Neoplasms	25928008	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Estradiol induces HOTAIR levels via GPER-mediated miR-148a inhibition in breast cancer.
other	hsa-mir-148a	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-148b	Breast Neoplasms	25051376	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	both miR-148b and miR-133a have potential use as biomarkers for breast cancer detection
other	hsa-mir-15	Breast Neoplasms	25594541	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the expression of the miR-15 family contributes to increased radiosensitivity of breast cancer cells by influencing G2/M checkpoint proteins.
other	hsa-mir-15	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-150	Breast Neoplasms	25907662	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA.
other	hsa-mir-153	Breast Neoplasms	23803066	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line.
other	hsa-mir-153	Breast Neoplasms	27012032	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-153 Regulates NRF2 Expression and is Associated with Breast Carcinogenesis.
other	hsa-mir-155	Breast Neoplasms	24840899	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis.
other	hsa-mir-155	Breast Neoplasms	25086633	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
other	hsa-mir-155	Breast Neoplasms	25484137	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a role of miR-155 in thiamine homeostasis and suggests a function of this oncogenic miRNA on breast cancer metabolism.
other	hsa-mir-155	Breast Neoplasms	25523096	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs.
other	hsa-mir-155	Breast Neoplasms	25744731	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Role of miR-155 in drug resistance of breast cancer.
other	hsa-mir-155	Breast Neoplasms	26795347	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
other	hsa-mir-155	Breast Neoplasms	21460854	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT.
other	hsa-mir-155	Breast Neoplasms	22245916	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Up-regulated miR-155 expression was associated with lymph node positivity (P=0.034), higher proliferation index (Ki-67 >10%) (P=0.019) and advanced breast cancer TNM clinical stage (P=0.002).
other	hsa-mir-155	Breast Neoplasms	23302487	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-155, as an oncomir, promotes lymph node involvement and vascular invasion and accompanies over-expressed HER-2 on breast cancer FFPE tissue
other	hsa-mir-155	Breast Neoplasms	29214365	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study
other	hsa-mir-15a	Breast Neoplasms	22335947	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression level of miR-15a in MCF-7 cells was lower than that in the MCF-10A cells (0.253:1, P < 0.0001). The expression of MiR-15a was significantly inhibited by Bcl-2 (P < 0.05).
other	hsa-mir-15a	Breast Neoplasms	28337296	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Tumor suppressor p53 induces miR-15a processing to inhibit neuronal apoptosis inhibitory protein (NAIP) in the apoptotic response DNA damage in breast cancer cell.
other	hsa-mir-15a	Breast Neoplasms	28509572	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line.
other	hsa-mir-15b	Breast Neoplasms	25907662	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA.
other	hsa-mir-15b	Breast Neoplasms	22908280	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b.
other	hsa-mir-16	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-16	Breast Neoplasms	22908280	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b.
other	hsa-mir-16-1	Breast Neoplasms	22260523	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells.
other	hsa-mir-16-2	Breast Neoplasms	22260523	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells.
other	hsa-mir-17	Breast Neoplasms	24287487	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer.
other	hsa-mir-17	Breast Neoplasms	24398324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
other	hsa-mir-17	Breast Neoplasms	24658544	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1.
other	hsa-mir-17	Breast Neoplasms	25001613	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer.
other	hsa-mir-17	Breast Neoplasms	26130254	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
other	hsa-mir-17	Breast Neoplasms	20406904	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling
other	hsa-mir-17	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-18	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-181a-2	Breast Neoplasms	23774803	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas
other	hsa-mir-181a-2	Breast Neoplasms	21368581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFbeta-induced oncomiR miRNA-181a.
other	hsa-mir-181a-2	Breast Neoplasms	23759567	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment.
other	hsa-mir-181b	Breast Neoplasms	22009755	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, miR-221/222 and -181b facilitate growth factor signaling in tamoxifen-resistant breast cancer by down-regulating TIMP3, and corresponding anti-miRs can be used to render these tumors responsive to tamoxifen.
other	hsa-mir-181b-1	Breast Neoplasms	23759567	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment.
other	hsa-mir-181b-2	Breast Neoplasms	23759567	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment.
other	hsa-mir-181c	Breast Neoplasms	25828099	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier.
other	hsa-mir-182	Breast Neoplasms	24398324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
other	hsa-mir-182	Breast Neoplasms	22086602	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We demonstrated that DDX5 regulated a subset of MicroRNAs including miR-21 and miR-182 in basal breast cancer cells.
other	hsa-mir-183	Breast Neoplasms	26400174	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion,our findings provide evidence that post-transcriptional studies of BRCA will benefit from transcending the one-locus-one-miRNA paradigm and taking into account all isoforms from each miRNA locus as well as the patient's race.
other	hsa-mir-184	Breast Neoplasms	26070602	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These studies elucidate a new layer of regulation in the PI3K/AKT/mTOR pathway with relevance to mammary development and tumour progression and identify miR-184 as a putative breast tumour suppressor.
other	hsa-mir-187	Breast Neoplasms	23060431	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro
other	hsa-mir-18a	Breast Neoplasms	21755340	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-18a expression was much higher in ERa-negative than in ERa-positive tumors (P < 0.0001), with the expression levels of miR-18a not differing in ERa-positive breast cancer as a function of ERa protein level.
other	hsa-mir-18b	Breast Neoplasms	19684618	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	inhibit Eralpha signaling
other	hsa-mir-18b	Breast Neoplasms	21755340	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Low miR-18b expression was significantly associated with improved survival in HER2-negative breast cancer, although miR-18b expression was not correlated with ERa protein expression.
other	hsa-mir-19	Breast Neoplasms	24831732	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation.
other	hsa-mir-191	Breast Neoplasms	25907662	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA.
other	hsa-mir-191	Breast Neoplasms	23505378	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status
other	hsa-mir-192	Breast Neoplasms	26642352	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-192-Mediated Positive Feedback Loop Controls the Robustness of Stress-Induced p53 Oscillations in Breast Cancer Cells.
other	hsa-mir-193b	Breast Neoplasms	25213330	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b.
other	hsa-mir-193b	Breast Neoplasms	25550792	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-193b as a novel tumor suppressor plays an important role in breast cancer progression, understanding the mechanisms could account for the aggressive behaviour of breast cancer.
other	hsa-mir-193b	Breast Neoplasms	19684618	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	inhibit Eralpha signaling
other	hsa-mir-193b	Breast Neoplasms	21755340	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression levels of miR-193b and miR-221 were significantly lower in ERa-negative than in ERa-positive tumors (P = 0.0015 and P = 0.0045, respectively), and the levels of these miRNAs gradually increased as ERa protein expression increased.
other	hsa-mir-193b	Breast Neoplasms	21512034	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we present here a proteomic screen to identify targets of miR-193b, and a systems biological approach to mimic its effects at the level of cellular phenotypes.
other	hsa-mir-194	Breast Neoplasms	23273170	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Manipulation of the miR-194 expression level using a synthetic inhibiting RNA produced a small but significant suppression of cell proliferation and upregulation in the expression of several genes that are thought to act as tumor suppressors in MCF-7 and T47D breast cancer cells.
other	hsa-mir-196a-1	Breast Neoplasms	23250869	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A MicroRNA196a2* and TP63 Circuit Regulated by Estrogen Receptor-alpha and ERK2 that Controls Breast Cancer Proliferation and Invasiveness Properties
other	hsa-mir-196a-2	Breast Neoplasms	26886638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The Associations of Single Nucleotide Polymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility: A STROBE-Compliant Observational Study.
other	hsa-mir-196a-2	Breast Neoplasms	23250869	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A MicroRNA196a2* and TP63 Circuit Regulated by Estrogen Receptor-alpha and ERK2 that Controls Breast Cancer Proliferation and Invasiveness Properties
other	hsa-mir-199a	Breast Neoplasms	26399456	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Thus, miR-199a/b-3p functions as a tumor suppressor and has an important role in breast cancer metastasis through PAK4/MEK/ERK signaling pathway.
other	hsa-mir-199a-1	Breast Neoplasms	23337876	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our data identify miR-199a-5p as a novel and unique regulator of autophagy, which plays an important role in cancer biology and cancer therapy
other	hsa-mir-199a-2	Breast Neoplasms	23337876	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our data identify miR-199a-5p as a novel and unique regulator of autophagy, which plays an important role in cancer biology and cancer therapy
other	hsa-mir-199b	Breast Neoplasms	26399456	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Thus, miR-199a/b-3p functions as a tumor suppressor and has an important role in breast cancer metastasis through PAK4/MEK/ERK signaling pathway.
other	hsa-mir-19a	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-19a	Breast Neoplasms	24398324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
other	hsa-mir-19b-1	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-20	Breast Neoplasms	24658544	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1.
other	hsa-mir-200	Breast Neoplasms	24037528	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.
other	hsa-mir-200	Breast Neoplasms	24518294	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer.
other	hsa-mir-200	Breast Neoplasms	24967704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The tetraindole SK228 reverses the epithelial-to-mesenchymal transition of breast cancer cells by up-regulating members of the miR-200 family.
other	hsa-mir-200	Breast Neoplasms	25086633	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
other	hsa-mir-200	Breast Neoplasms	25401471	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	metastatic capability can be transferred by the uptake of extracellular vesicles.
other	hsa-mir-200	Breast Neoplasms	27257068	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200 levels increase following hPMR1 knockdown, and changes in miR-200 family microRNAs were  matched by corresponding changes in miR-200 targets and reporter expression.
other	hsa-mir-200a	Breast Neoplasms	26088362	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene.
other	hsa-mir-200a	Breast Neoplasms	26283635	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of miR-200a as a novel suppressor of connexin 43 in breast cancer cells.
other	hsa-mir-200a	Breast Neoplasms	24086551	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-200b eRNA may be involved in the regulation of miR-200b~200a~429 gene expression and silencing. Taken together, these findings reveal the presence of a novel enhancer, which contributes to miR-200b~200a~429 transcriptional regulation in epithelial cells.
other	hsa-mir-200a	Breast Neoplasms	19839049	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200a:microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells
other	hsa-mir-200a	Breast Neoplasms	23318438	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells
other	hsa-mir-200b	Breast Neoplasms	24398324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
other	hsa-mir-200b	Breast Neoplasms	24086551	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-200b eRNA may be involved in the regulation of miR-200b~200a~429 gene expression and silencing. Taken together, these findings reveal the presence of a novel enhancer, which contributes to miR-200b~200a~429 transcriptional regulation in epithelial cells.
other	hsa-mir-200b	Breast Neoplasms	19839049	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200b:microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells
other	hsa-mir-200b	Breast Neoplasms	23318438	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells
other	hsa-mir-200c	Breast Neoplasms	24754877	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c.
other	hsa-mir-200c	Breast Neoplasms	25746005	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential.
other	hsa-mir-200c	Breast Neoplasms	25907662	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA.
other	hsa-mir-200c	Breast Neoplasms	19839049	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200c:microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells
other	hsa-mir-200c	Breast Neoplasms	21553120	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor.
other	hsa-mir-200c	Breast Neoplasms	22364742	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	IL6-Mediated Suppression of miR-200c Directs Constitutive Activation of Inflammatory Signaling Circuit Driving Transformation and Tumorigenesis.
other	hsa-mir-200c	Breast Neoplasms	23318438	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells
other	hsa-mir-200c	Breast Neoplasms	23546450	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling
other	hsa-mir-200c	Breast Neoplasms	26310899	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	selected miRNAs, such as miR-200c and miR-34a, may influence response to chemotherapy in several tumor types
other	hsa-mir-200c	Breast Neoplasms	29532351	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Bioluminescence Imaging for Monitoring miR-200c Expression in Breast Cancer Cells and its Effects on Epithelial-Mesenchymal Transition Progress in Living Animals
other	hsa-mir-200c	Breast Neoplasms	21336307	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study elucidates a role for p53 in regulating EMT-MET (mesenchymal-epithelial transition) and stemness or differentiation plasticity, and reveals a potential therapeutic implication to suppress EMT-associated cancer stem cells through activation of the p53-miR-200c pathway.
other	hsa-mir-200	Breast Neoplasms	26068592	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The upregulation of fibronectin and lysyl oxidase directly by miR-200 or indirectly through Fli-1 or TCF12 contributed to ECM remodeling, triggering the invasion and metastasis of breast cancer cells both in vitro and vivo
other	hsa-mir-203	Breast Neoplasms	26790955	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis.
other	hsa-mir-203	Breast Neoplasms	21553120	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor.
other	hsa-mir-203	Breast Neoplasms	22260523	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of a panel of miRNAs (miR-16, miR-143, miR-203) in MCF-7 cells.
other	hsa-mir-204	Breast Neoplasms	26436206	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway.
other	hsa-mir-204	Breast Neoplasms	22629385	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Gene expression analysis of miR-204 and miR-379-transfected cells indicated that these miRNAs downregulated the expression of several genes involved in TGF-β signaling, including prostaglandin-endoperoxide synthase 2 (PTGS2).
other	hsa-mir-205	Breast Neoplasms	25722304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.
other	hsa-mir-205	Breast Neoplasms	21553120	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor.
other	hsa-mir-205	Breast Neoplasms	21787752	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ErbB2 down-regulates microRNA-205 in breast cancer.
other	hsa-mir-205	Breast Neoplasms	22578566	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.
other	hsa-mir-205	Breast Neoplasms	23519125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
other	hsa-mir-205	Breast Neoplasms	23474752	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
other	hsa-mir-206	Breast Neoplasms	26130254	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
other	hsa-mir-206	Breast Neoplasms	19684618	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	inhibit Eralpha signaling
other	hsa-mir-206	Breast Neoplasms	21302623	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-206 may suppress invasion and migration of MDA-MB-231 cells in vitro partly via regulating actin cytoskeleton remodelling such as filopodia formation
other	hsa-mir-20a	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-20a	Breast Neoplasms	24287487	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer.
other	hsa-mir-20a	Breast Neoplasms	20406904	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling
other	hsa-mir-20a	Breast Neoplasms	22901144	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential Distribution of miR-20a and miR-20b may Underly Metastatic Heterogeneity of Breast Cancers.
other	hsa-mir-20b	Breast Neoplasms	20406904	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling
other	hsa-mir-21	Breast Neoplasms	26026077	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 is a potential biomarker for breast cancer prognosis.
other	hsa-mir-21	Breast Neoplasms	23851508	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21.
other	hsa-mir-21	Breast Neoplasms	24248894	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-21 in breast cancer: diagnostic and prognostic potential.
other	hsa-mir-21	Breast Neoplasms	24488617	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.
other	hsa-mir-21	Breast Neoplasms	25523096	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs.
other	hsa-mir-21	Breast Neoplasms	25706383	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results indicated that miR-21 can predict unfavorable prognoses in breast cancer patients, especially in Asians.
other	hsa-mir-21	Breast Neoplasms	25722304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.
other	hsa-mir-21	Breast Neoplasms	25735723	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-21 controls in situ expansion of CCR6 regulatory T cells through PTEN/AKT pathway in breast cancer.
other	hsa-mir-21	Breast Neoplasms	25880495	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
other	hsa-mir-21	Breast Neoplasms	25907662	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA.
other	hsa-mir-21	Breast Neoplasms	26106867	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Successful attempts were made in applying the approach to detect miR-21 in human cell lysate samples of breast cancer patients.
other	hsa-mir-21	Breast Neoplasms	26178901	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity.
other	hsa-mir-21	Breast Neoplasms	26270351	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Breast Cancer/Stromal Cells Coculture on Polyelectrolyte Films Emulates Tumor Stages and miRNA Profiles of Clinical Samples.
other	hsa-mir-21	Breast Neoplasms	26349663	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results indicate that miRNAs show promising associations with prognosis in breast cancer. Moreover, specific miRNAs such as miR-21 and miR-210  can predict poor survival rates in breast cancer patients.
other	hsa-mir-21	Breast Neoplasms	26411332	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-21-triggered self-assembly of DNA nanostructures can also serve as a remarkable signal amplification platform to achieve ultrasensitive detection of miR-21 from as low as 10 MCF-7 human breast cancer cells.
other	hsa-mir-21	Breast Neoplasms	26486006	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Advances in Research on miR-21 and Breast Cancer.
other	hsa-mir-21	Breast Neoplasms	25784176	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21.
other	hsa-mir-21	Breast Neoplasms	18932017	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21: High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1
other	hsa-mir-21	Breast Neoplasms	20082533	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells
other	hsa-mir-21	Breast Neoplasms	21131358	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Induction of MIR-21 by retinoic acid in estrogen-receptor-positive breast carcinoma cells: biological correlates and molecular targets
other	hsa-mir-21	Breast Neoplasms	21471222	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of MIR-21 mediates resistance to trastuzumab therapy for breast cancer.
other	hsa-mir-21	Breast Neoplasms	22187223	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells.
other	hsa-mir-21	Breast Neoplasms	22618231	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Regulatory interplay between miR-21, JAG1 and 17beta-estradiol (E2) in breast cancer cells.
other	hsa-mir-21	Breast Neoplasms	23052036	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Endocrine Disruptors Fludioxonil and Fenhexamid Stimulate miR-21 Expression in Breast Cancer Cells
other	hsa-mir-21	Breast Neoplasms	23216894	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells
other	hsa-mir-21	Breast Neoplasms	26790955	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis.
other	hsa-mir-21	Breast Neoplasms	22086602	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We demonstrated that DDX5 regulated a subset of MicroRNAs including miR-21 and miR-182 in basal breast cancer cells.
other	hsa-mir-21	Breast Neoplasms	26769851	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, a well-documented oncogenic miRNA for promoting tumor cell metastasis, was also found to be involved in inhibitory activity of SSA in breast tumor cell motility through the modulation of TGF尾 pathway.
other	hsa-mir-21	Breast Neoplasms	26924493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Mir-206 and let-7 were up-regulated, and mir-21 expression was down-regulated in  the exercise training compared to tumor group.
other	hsa-mir-21	Breast Neoplasms	27372573	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MCF-7 has a high level of miR-21, miR-375, and miR-27a as target miRNAs.
other	hsa-mir-21	Breast Neoplasms	28509572	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line.
other	hsa-mir-21	Breast Neoplasms	28628833	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Urtica dioica extract suppresses miR-21 and metastasis-related genes in breast cancer.
other	hsa-mir-210	Breast Neoplasms	24395300	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response.
other	hsa-mir-210	Breast Neoplasms	26349663	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results indicate that miRNAs show promising associations with prognosis in breast cancer. Moreover, specific miRNAs such as miR-21 and miR-210  can predict poor survival rates in breast cancer patients.
other	hsa-mir-210	Breast Neoplasms	24591754	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our studies suggested that microRNA-210 could predict the outcome of patients with varieties of tumors, especially in breast cancers.
other	hsa-mir-210	Breast Neoplasms	18755890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-210: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
other	hsa-mir-210	Breast Neoplasms	21738599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.
other	hsa-mir-216b	Breast Neoplasms	25078617	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Regulation of the P2X7R by microRNA-216b in human breast cancer.
other	hsa-mir-22	Breast Neoplasms	24398324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
other	hsa-mir-22	Breast Neoplasms	26512777	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results provide mechanistic insight into TIP60 regulation and evidence for the utility of the combination of TIP60 and miR-22 as prognostic indicator of breast cancer progression.
other	hsa-mir-221	Breast Neoplasms	24197133	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	14-3-3ζ orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation.
other	hsa-mir-221	Breast Neoplasms	24886939	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer.
other	hsa-mir-221	Breast Neoplasms	24905916	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer.
other	hsa-mir-221	Breast Neoplasms	25007959	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.
other	hsa-mir-221	Breast Neoplasms	25523096	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs.
other	hsa-mir-221	Breast Neoplasms	18790736	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer
other	hsa-mir-221	Breast Neoplasms	21553120	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor.
other	hsa-mir-221	Breast Neoplasms	21755340	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression levels of miR-193b and miR-221 were significantly lower in ERa-negative than in ERa-positive tumors (P = 0.0015 and P = 0.0045, respectively), and the levels of these miRNAs gradually increased as ERa protein expression increased.
other	hsa-mir-221	Breast Neoplasms	25447917	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221-3p may give crucial information about molecular mechanism of the disease  upon PAK1 activity or different mechanisms with respect to histopathology and severity of breast cancer.
other	hsa-mir-221	Breast Neoplasms	23529451	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221/222: promising biomarkers for breast cancer.
other	hsa-mir-221	Breast Neoplasms	23637992	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221 promotes tumorigenesis in human triple negative breast cancer cells.
other	hsa-mir-221	Breast Neoplasms	27031715	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	5-aza treatment caused an increase of miRNA-10b, -122, -200b levels in MCF-7/S cells, miRNA-34a, -10b, -122, -200b and -320a levels in MCF-7/Dox cells and miRNA-34a, -10b, -200b and -320a levels in MCF-7/DDP cells.
other	hsa-mir-221	Breast Neoplasms	27420990	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression of miR-221/222 in the serum of the patients with post-menopausal breast cancer was higher than that of T2DM patients (P < 0.05), but lower than that of the T2DM patients who were also positive for post-menopausal breast cancer (P < 0.05);
other	hsa-mir-221	Breast Neoplasms	22009755	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, miR-221/222 and -181b facilitate growth factor signaling in tamoxifen-resistant breast cancer by down-regulating TIMP3, and corresponding anti-miRs can be used to render these tumors responsive to tamoxifen.
other	hsa-mir-222	Breast Neoplasms	23994196	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
other	hsa-mir-222	Breast Neoplasms	24886939	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer.
other	hsa-mir-222	Breast Neoplasms	24923427	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overall, this study suggested that both celecoxib and aspirin could prevent breast cancer growth by regulating proteins in the cell cycle and apoptosis without blocking estrogen synthesis. Besides, celecoxib might affect miR expression in an undesirable fashion.
other	hsa-mir-222	Breast Neoplasms	25007959	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.
other	hsa-mir-222	Breast Neoplasms	25562151	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	β-elemene could influence MDR related miRNA expression and subsequently regulate the expression of the target genes PTEN and Pgp, which may lead to reduction of the viability of the chemo-resistant breast cancer cells.
other	hsa-mir-222	Breast Neoplasms	25735339	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer.
other	hsa-mir-222	Breast Neoplasms	18790736	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-222: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer
other	hsa-mir-222	Breast Neoplasms	21553120	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppression of miR-200c, miR-203, and miR-205 and increases in miR-222 and miR-221 are involved in the inducement of EMT and repression of the estrogen receptor.
other	hsa-mir-222	Breast Neoplasms	23529451	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221/222: promising biomarkers for breast cancer.
other	hsa-mir-222	Breast Neoplasms	26432333	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	exosomes transmit drug resistance through delivering miR-222.
other	hsa-mir-222	Breast Neoplasms	27420990	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression of miR-221/222 in the serum of the patients with post-menopausal breast cancer was higher than that of T2DM patients (P < 0.05), but lower than that of the T2DM patients who were also positive for post-menopausal breast cancer (P < 0.05)
other	hsa-mir-222	Breast Neoplasms	22009755	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, miR-221/222 and -181b facilitate growth factor signaling in tamoxifen-resistant breast cancer by down-regulating TIMP3, and corresponding anti-miRs can be used to render these tumors responsive to tamoxifen.
other	hsa-mir-223	Breast Neoplasms	24400121	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions.
other	hsa-mir-223	Breast Neoplasms	24727437	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner.
other	hsa-mir-23a	Breast Neoplasms	25445205	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The overall concordance rates between miR-23a with HRG and FOXM1 tissue RNAs were 91% and 79%, respectively. The median follow-up period was 49 months. mi-23a and HRG RNA were significant independent prognostic markers in relapse-free survival. miR-23a may have an oncogenic function and enhance BC progression by directly activating FOXM1 and HRG at RNA level.
other	hsa-mir-23b	Breast Neoplasms	26178901	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity.
other	hsa-mir-23b	Breast Neoplasms	24985346	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.
other	hsa-mir-23b	Breast Neoplasms	23338610	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Pro-oncogenic factors miR-23b- and miR-27b are regulated by Her2/Neu, EGF, and TNFa in breast cancer
other	hsa-mir-24	Breast Neoplasms	23774803	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas
other	hsa-mir-24	Breast Neoplasms	24398324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
other	hsa-mir-24	Breast Neoplasms	29103019	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway.
other	hsa-mir-25	Breast Neoplasms	24398324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
other	hsa-mir-25	Breast Neoplasms	25523096	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs.
other	hsa-mir-25	Breast Neoplasms	25907662	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA.
other	hsa-mir-25	Breast Neoplasms	29765562	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A myriad of roles of miR-25 in health and disease.
other	hsa-mir-26a	Breast Neoplasms	25434799	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-26a functions as a tumour suppressor in TNBC development and serves as a prognostic marker for breast cancer.
other	hsa-mir-26a-1	Breast Neoplasms	22094936	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
other	hsa-mir-26a-1	Breast Neoplasms	22384020	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells.
other	hsa-mir-26a-2	Breast Neoplasms	22094936	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
other	hsa-mir-26a-2	Breast Neoplasms	22384020	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells.
other	hsa-mir-27a	Breast Neoplasms	20382698	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-27a:MicroRNA-27a Indirectly Regulates Estrogen Receptor {alpha} Expression and Hormone Responsiveness in MCF-7 Breast Cancer Cells
other	hsa-mir-27a	Breast Neoplasms	23240057	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival
other	hsa-mir-27a	Breast Neoplasms	26178901	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity.
other	hsa-mir-27a	Breast Neoplasms	29393459	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression
other	hsa-mir-27a	Breast Neoplasms	26662313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	knockdown of miR-27a by the specific inhibitors significantly increased the sensitivity of T-47D cells to cisplatin (CDDP) treatment.
other	hsa-mir-27a	Breast Neoplasms	27372573	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MCF-7 has a high level of miR-21, miR-375, and miR-27a as target miRNAs.
other	hsa-mir-27a	Breast Neoplasms	19921425	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We hypothesize that the G-variant of rs895819 might impair the maturation of the oncogenic miR-27a and thus, is associated with familial breast cancer risk.
other	hsa-mir-27b	Breast Neoplasms	26178901	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity.
other	hsa-mir-27b	Breast Neoplasms	26065921	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1.
other	hsa-mir-27b	Breast Neoplasms	26130254	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
other	hsa-mir-27b	Breast Neoplasms	23240057	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival
other	hsa-mir-29	Breast Neoplasms	24289849	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The inhibitory role of Mir-29 in growth of breast cancer cells.
other	hsa-mir-29	Breast Neoplasms	25174825	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant miR-29 expression may account for reduced NMI expression in breast tumors and mesenchymal phenotype of cancer cells that promotes invasive growth. Reduction in NMI levels has a feed-forward impact on miR-29 levels.
other	hsa-mir-29a	Breast Neoplasms	23994196	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
other	hsa-mir-29a	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-29a	Breast Neoplasms	19247375	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-29a: miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. Therefore, miRNAs can act as either oncogenes or tumour suppressors, depending on the context
other	hsa-mir-29a	Breast Neoplasms	19567675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	potentially oncogenic role in breast tumorigenesis; significantly associated with decreased breast cancer risk; mutant precursors of miR-196a-2 into breast cancer cells led to less efficient processing of the miRNA precursor to its mature form as well as diminished capacity to regulate target genes, further showed that cell cycle response to mutagen challenge was significantly enhanced;
other	hsa-mir-29a	Breast Neoplasms	25562151	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	β-elemene could influence MDR related miRNA expression and subsequently regulate the expression of the target genes PTEN and Pgp, which may lead to reduction of the viability of the chemo-resistant breast cancer cells.
other	hsa-mir-29a	Breast Neoplasms	25735339	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer.
other	hsa-mir-29a	Breast Neoplasms	28701793	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells.
other	hsa-mir-29b-1	Breast Neoplasms	21359530	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-29b regulates migration of human breast cancer cells.
other	hsa-mir-29b-2	Breast Neoplasms	21359530	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-29b regulates migration of human breast cancer cells.
other	hsa-mir-29c	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-301a	Breast Neoplasms	21393507	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-301 as a crucial oncogene in human breast cancer that acts through multiple pathways and mechanisms to promote nodal or distant relapses.
other	hsa-mir-301b	Breast Neoplasms	21393507	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-301 as a crucial oncogene in human breast cancer that acts through multiple pathways and mechanisms to promote nodal or distant relapses.
other	hsa-mir-302a	Breast Neoplasms	23184229	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-302 Replacement Therapy Sensitizes Breast Cancer Cells to Ionizing Radiation
other	hsa-mir-302c	Breast Neoplasms	19684618	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	inhibit Eralpha signaling
other	hsa-mir-30a	Breast Neoplasms	20498642	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Mir-30:Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells
other	hsa-mir-30a	Breast Neoplasms	27302063	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	regulation of lumen formation by miR-342
other	hsa-mir-30a	Breast Neoplasms	28461244	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect.
other	hsa-mir-30b	Breast Neoplasms	22384020	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells.
other	hsa-mir-30e	Breast Neoplasms	25523096	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the miRNA and isomiR levels in BC, which indicates biological roles of isomiRs.
other	hsa-mir-30e	Breast Neoplasms	26057454	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We highlighted a relevant and subtype-specific role in breast cancer for miR-30e* and demonstrated that adding miRNA markers to gene signatures and clinico-pathological features can help for a better prognostication.
other	hsa-mir-30e	Breast Neoplasms	27012041	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Abnormal miRNA-30e Expression is Associated with Breast Cancer Progression.
other	hsa-mir-31	Breast Neoplasms	21406558	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Activation of miR-31 function in already-established metastases elicits metastatic regression.
other	hsa-mir-320b	Breast Neoplasms	26178901	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity.
other	hsa-mir-320c	Breast Neoplasms	26378051	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the existence of common pathways driving breast carcinogenesis in both BRCA1 and BRCA2 germ-line mutation carriers.
other	hsa-mir-324	Breast Neoplasms	26166821	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis.
other	hsa-mir-326	Breast Neoplasms	19883630	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1
other	hsa-mir-328	Breast Neoplasms	25824027	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells.
other	hsa-mir-335	Breast Neoplasms	26378051	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the existence of common pathways driving breast carcinogenesis in both BRCA1 and BRCA2 germ-line mutation carriers.
other	hsa-mir-335	Breast Neoplasms	22034498	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aryl Hydrocarbon Receptor (AHR) Agonists Induce MicroRNA-335 Expression and Inhibit Lung Metastasis of Estrogen Receptor Negative Breast Cancer Cells.
other	hsa-mir-335	Breast Neoplasms	24942235	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations.
other	hsa-mir-335	Breast Neoplasms	22908280	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b.
other	hsa-mir-339	Breast Neoplasms	20932331	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis.
other	hsa-mir-33a	Breast Neoplasms	26507842	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These findings identified miR-33a as a negative regulator of breast cancer cell proliferation and metastasis.
other	hsa-mir-342	Breast Neoplasms	23408138	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-342 is associated with estrogen receptor-ж┿expression and response to tamoxifen in breast cancer
other	hsa-mir-34a	Breast Neoplasms	25078559	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.
other	hsa-mir-34a	Breast Neoplasms	25562151	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	β-elemene could influence MDR related miRNA expression and subsequently regulate the expression of the target genes PTEN and Pgp, which may lead to reduction of the viability of the chemo-resistant breast cancer cells.
other	hsa-mir-34a	Breast Neoplasms	25735339	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer.
other	hsa-mir-34a	Breast Neoplasms	25789847	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.
other	hsa-mir-34a	Breast Neoplasms	26359358	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These data provide evidence for the leptin-antagonist potential of HNK and reveal the involvement of LKB1 and miR-34a.
other	hsa-mir-34a	Breast Neoplasms	26790955	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis.
other	hsa-mir-34a	Breast Neoplasms	25784176	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21.
other	hsa-mir-34a	Breast Neoplasms	21399894	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	increased expression of miR-34a in an acquired model of docetaxel resistance in breast cancer.
other	hsa-mir-34a	Breast Neoplasms	22102859	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer.
other	hsa-mir-34a	Breast Neoplasms	29226432	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the intracellular function of miR-34a delivered by the nanocomplex to upregulate active Caspase-3 was imaged in real-time
other	hsa-mir-34b	Breast Neoplasms	25647415	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer.
other	hsa-mir-34b	Breast Neoplasms	22439831	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.Expression levels of miR-34b significantly correlate with disease free survival (DFS) (p = 0.0020, log-rank test) and overall survival (OS) (p = 0.0008, log-rank test) of TNBC patients.
other	hsa-mir-34c	Breast Neoplasms	25064703	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Together, our results support the role of miR-34c as a tumor suppressor miRNA also in breast cancer.
other	hsa-mir-34c	Breast Neoplasms	25647415	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer.
other	hsa-mir-3646	Breast Neoplasms	27045586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3β/β-Catenin Signaling Pathway.
other	hsa-mir-373	Breast Neoplasms	26122224	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	INFLUENCE OF miR-373 ON THE INVASION AND MIGRATION OF BREAST CANCER AND THE EXPRESSION LEVEL OF TARGET GENES TXNIP.
other	hsa-mir-373	Breast Neoplasms	26258411	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer.
other	hsa-mir-373	Breast Neoplasms	28260305	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Effects of microRNA-373 on the proliferation and invasiveness of breast carcinoma and its mechanisms.
other	hsa-mir-374a	Breast Neoplasms	23321667	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis
other	hsa-mir-375	Breast Neoplasms	25663261	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study demonstrated that formononetin promoted ERα-positive cell proliferation through miR-375 activation and this mechanism is possibly involving in a miR-375 and ERα feedback loop.
other	hsa-mir-375	Breast Neoplasms	25680412	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer.
other	hsa-mir-375	Breast Neoplasms	26962366	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Hsa-miR-375 is a predictor of local control in early stage breast cancer.
other	hsa-mir-375	Breast Neoplasms	25613180	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	biochanin A promoted ERα-positive cell proliferation through miR-375 activation and this mechanism is possibly involving in a miR-375 and ERα feedback loop.
other	hsa-mir-375	Breast Neoplasms	22508479	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.
other	hsa-mir-375	Breast Neoplasms	27372573	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MCF-7 has a high level of miR-21, miR-375, and miR-27a as target miRNAs.
other	hsa-mir-376	Breast Neoplasms	26940843	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MIR376 as an important  microRNA family for cancer formation and progression
other	hsa-mir-379	Breast Neoplasms	22629385	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Gene expression analysis of miR-204 and miR-379-transfected cells indicated that these miRNAs downregulated the expression of several genes involved in TGF-β signaling, including prostaglandin-endoperoxide synthase 2 (PTGS2).
other	hsa-mir-383	Breast Neoplasms	23722663	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Some novel miRNAs without known association to breast cancer were also found, and the putative functions of their PINs were also elucidated. These include miR-139 and miR-383. 
other	hsa-mir-423	Breast Neoplasms	25663458	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Genetic analysis and preliminary function study of miR-423 in breast cancer.
other	hsa-mir-424	Breast Neoplasms	20348243	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.
other	hsa-mir-425	Breast Neoplasms	23505378	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status
other	hsa-mir-429	Breast Neoplasms	25405387	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our results offer an opportunity for further understanding of the recondite mechanisms underlying the bone metastasis of breast cancer.
other	hsa-mir-429	Breast Neoplasms	24086551	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-200b eRNA may be involved in the regulation of miR-200b~200a~429 gene expression and silencing. Taken together, these findings reveal the presence of a novel enhancer, which contributes to miR-200b~200a~429 transcriptional regulation in epithelial cells.
other	hsa-mir-449a	Breast Neoplasms	29431182	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis
other	hsa-mir-451a	Breast Neoplasms	26161389	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-451a Inhibited Cell Proliferation and Enhanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibitory Factor.
other	hsa-mir-451a	Breast Neoplasms	18645025	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-451: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
other	hsa-mir-452	Breast Neoplasms	24648265	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells.
other	hsa-mir-452	Breast Neoplasms	25562151	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	β-elemene could influence MDR related miRNA expression and subsequently regulate the expression of the target genes PTEN and Pgp, which may lead to reduction of the viability of the chemo-resistant breast cancer cells.
other	hsa-mir-453	Breast Neoplasms	19028706	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In contrast, the T allele attenuates the binding of miR-453, which might lead to a reduced miRNA-mediated ESR1 repression, in consequence higher ESR1 protein levels and an increased breast cancer risk.
other	hsa-mir-467	Breast Neoplasms	26018675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Inhibition of hyperglycemia-induced angiogenesis and breast cancer tumor growth by systemic injection of microRNA-467 antagonist.
other	hsa-mir-4728	Breast Neoplasms	24828673	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we present here an alternative mode of miRNA regulation and demonstrate this dual function of the HER2 locus, linking the two major biomarkers in breast cancer.
other	hsa-mir-484	Breast Neoplasms	25643696	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer.
other	hsa-mir-486	Breast Neoplasms	26378051	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the existence of common pathways driving breast carcinogenesis in both BRCA1 and BRCA2 germ-line mutation carriers.
other	hsa-mir-489	Breast Neoplasms	27171498	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-489 could reverse the chemoresistance of breast cancer via the PI3K-Akt pathway by targeting SPIN1.
other	hsa-mir-494	Breast Neoplasms	27216190	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Elevating Dicer expression increased levels of the AXL kinase targeting  miRNA miR-494
other	hsa-mir-496	Breast Neoplasms	24204564	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Methylated DNA binding domain protein 2 (MBD2) coordinately silences gene expression through activation of the microRNA hsa-mir-496 promoter in breast cancer cell line.
other	hsa-mir-499	Breast Neoplasms	26886638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The Associations of Single Nucleotide Polymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility: A STROBE-Compliant Observational Study.
other	hsa-mir-505	Breast Neoplasms	22051041	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-505 is a novel tumor suppressive miRNA and inhibits cell proliferation by inducing apoptosis. We also find that Akt3, correlate inversely with miR-505, modulates drug sensitivity in MCF7-ADR.
other	hsa-mir-509	Breast Neoplasms	25659578	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-α.
other	hsa-mir-515	Breast Neoplasms	23928990	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation.
other	hsa-mir-515-1	Breast Neoplasms	23549953	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers
other	hsa-mir-515-2	Breast Neoplasms	23549953	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers
other	hsa-mir-516a-1	Breast Neoplasms	18755890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-516-3p: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
other	hsa-mir-516a-2	Breast Neoplasms	18755890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-516-3p: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
other	hsa-mir-516b-1	Breast Neoplasms	18755890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-516-3p: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
other	hsa-mir-516b-2	Breast Neoplasms	18755890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-516-3p: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
other	hsa-mir-526b	Breast Neoplasms	25733698	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
other	hsa-mir-548c	Breast Neoplasms	25802200	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we showed that miR-548c-3p is implicated in doxorubicin-treated MCF-7 cell viability, suggesting a role for this miRNA in resistance.
other	hsa-mir-570	Breast Neoplasms	20348243	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.
other	hsa-mir-573	Breast Neoplasms	25333258	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.
other	hsa-mir-574	Breast Neoplasms	25560734	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	functional screening mediated by miRNA libraries can provide new insights into the genes essential for tamoxifen response in breast cancer.
other	hsa-mir-574	Breast Neoplasms	26416693	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
other	hsa-mir-578	Breast Neoplasms	25333258	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.
other	hsa-mir-584	Breast Neoplasms	23479725	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Micro-RNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1): New Signaling Route Through Which Transforming Growth Factor-Beta Mediates the Migration and Actin Dynamics of Breast Cancer Cells
other	hsa-mir-592	Breast Neoplasms	25680412	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer.
other	hsa-mir-608	Breast Neoplasms	26886638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The Associations of Single Nucleotide Polymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility: A STROBE-Compliant Observational Study.
other	hsa-mir-618	Breast Neoplasms	20348243	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.
other	hsa-mir-621	Breast Neoplasms	25867061	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.
other	hsa-mir-660	Breast Neoplasms	26416693	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
other	hsa-mir-7	Breast Neoplasms	25511742	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7-5p has a critical function through blocking REGγ in breast cancer cells.
other	hsa-mir-7	Breast Neoplasms	24707474	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.
other	hsa-mir-7	Breast Neoplasms	18922890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Finally, we show that miR-7 introduction inhibits the motility, invasiveness, anchorage-independent growth, and tumorigenic potential of highly invasive breast cancer cells.
other	hsa-mir-708	Breast Neoplasms	23328481	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our findings uncover a mechanistic role for miR-708 in metastasis and provide arationale for developing miR-708 as a therapeutic agent against metastatic breast cancer.
other	hsa-mir-7-1	Breast Neoplasms	18755890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
other	hsa-mir-7-1	Breast Neoplasms	23227519	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma
other	hsa-mir-7-2	Breast Neoplasms	18755890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
other	hsa-mir-7-2	Breast Neoplasms	23227519	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma
other	hsa-mir-720	Breast Neoplasms	25722304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.
other	hsa-mir-7-3	Breast Neoplasms	18755890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7: associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
other	hsa-mir-7-3	Breast Neoplasms	23227519	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma
other	hsa-mir-760	Breast Neoplasms	25661353	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
other	hsa-mir-760	Breast Neoplasms	20348243	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.
other	hsa-mir-892b	Breast Neoplasms	26747895	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-892b Silencing Activates NF-κB and Promotes Aggressiveness in Breast Cancer.
other	hsa-mir-9	Breast Neoplasms	25017439	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	FOXO1 3'UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity.
other	hsa-mir-9	Breast Neoplasms	25086633	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
other	hsa-mir-9	Breast Neoplasms	25680412	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study aimed to screen potential microRNAs (miRNAs) and genes related to human primary breast cancer.
other	hsa-mir-9	Breast Neoplasms	27468688	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts.
other	hsa-mir-9	Breast Neoplasms	20173743	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The microRNA miR-9 is induced by Myc in breast cancer cells where it targets the major epithelial adherens junction protein, E-cadherin.
other	hsa-mir-9	Breast Neoplasms	28345661	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients.
other	hsa-mir-92-1	Breast Neoplasms	26046581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations have been validated using an independent publicly available breast cancer dataset from The Cancer Genome Atlas.
other	hsa-mir-92a	Breast Neoplasms	22482439	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We found that miR-221 levels are prognostic in breast cancer illustrating the high-throughput method and confirming that miRNAs can be valuable biomarkers in cancer.
other	hsa-mir-92a-1	Breast Neoplasms	22563438	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration.
other	hsa-mir-92a-2	Breast Neoplasms	22563438	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration.
other	hsa-mir-93	Breast Neoplasms	25238878	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer.
other	hsa-mir-96	Breast Neoplasms	25907662	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results all indicated that when analyzing miRNAs in surgical pathology specimens of breast cancer as a biomarker, they should be examined as a cluster through miRNA profiling, rather than relying on the analysis of a single miRNA.
other	hsa-mir-144	Bronchiolitis Obliterans Syndrome	26874429	respiratory system disease	DOID:2799	J42	D001989		HP:0011946	MicroRNA-144 is unlikely to play a role in bronchiolitis obliterans syndrome.
other	hsa-mir-144	Bronchiolitis Obliterans Syndrome	27044533	respiratory system disease	DOID:2799	J42	D001989		HP:0011946	MicroRNA-144 is unlikely to play a role in bronchiolitis obliterans syndrome.
other	hsa-mir-21	Bronchiolitis Obliterans Syndrome	27564214	respiratory system disease	DOID:2799	J42	D001989		HP:0011946	Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study.
other	hsa-mir-34a	Bronchiolitis Obliterans Syndrome	27564214	respiratory system disease	DOID:2799	J42	D001989		HP:0011946	Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study.
other	hsa-mir-16	Bronchopulmonary Dysplasia	28381639			P27.1	D001997			Thus the intergenerational effects of gestational SS involve epigenetic regulation of HIF-1α through specific miRs contributing to increased incidence of AA and BPD in the progenies
other	hsa-mir-29b	Bronchopulmonary Dysplasia	28473324			P27.1	D001997			miR-29b supplementation decreases expression of matrix proteins and improves alveolarization in mice exposed to maternal inflammation and neonatal hyperoxia.
other	hsa-mir-125b	Carcinoma, Adrenocortical	24205079	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-125b, miRNA-200b, miR-122, miRNA-466b, miR-138,vmiRNA-214, miRNA-503 and miRNA27a were down-regulated in response to 17α-E2 treatment.
other	hsa-mir-132	Carcinoma, Adrenocortical	24205079	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	ACTH up-regulated the expression of miRNA-212, miRNA-182, miRNA-183, miRNA-132, and miRNA-96 and down-regulated the levels of miRNA-466b, miRNA-214, miRNA-503, and miRNA-27a.
other	hsa-mir-210	Carcinoma, Adrenocortical	27550961	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
other	hsa-mir-212	Carcinoma, Adrenocortical	24205079	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	The levels of miR-212,miRNA-183, miRNA-182, miRNA-132, miRNA-370, miRNA-377, and miRNA-96 were up-regulated, whereas miR-125b, miRNA-200b, miR-122, miRNA-466b, miR-138, miRNA-214, miRNA-503 and miRNA27a were down-regulated in response to 17α-E2 treatment.
other	hsa-mir-146a	Carcinoma, Basal Cell	20680470	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	These findings suggest that this functional SNP in pre-miR-146a could contribute to ESCC susceptibility and clinical outcome.
other	hsa-mir-1246	Carcinoma, Biliary Tract	27573701	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	miR‑1246 and miR‑4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer.
other	hsa-mir-200	Carcinoma, Biliary Tract	27941621	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients.
other	hsa-mir-205	Carcinoma, Biliary Tract	27941621	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients.
other	hsa-mir-4644	Carcinoma, Biliary Tract	27573701	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	miR‑1246 and miR‑4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer.
other	hsa-mir-100	Carcinoma, Bladder	28229968	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status.
other	hsa-mir-125b	Carcinoma, Bladder	28347246	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer.
other	hsa-mir-145	Carcinoma, Bladder	28106737	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	A Novel Combination RNAi toward Warburg Effect by Replacement with miR-145 and Silencing of PTBP1 Induces Apoptotic Cell Death in Bladder Cancer Cells.
other	hsa-mir-148a	Carcinoma, Bladder	27906180	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer.
other	hsa-mir-203	Carcinoma, Bladder	28229968	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status.
other	hsa-mir-21	Carcinoma, Bladder	28139790	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of miR-21 and PTEN.
other	hsa-mir-223	Carcinoma, Bladder	27744452	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Ginkgolide B Inhibits Human Bladder Cancer Cell Migration and Invasion Through MicroRNA-223-3p.
other	hsa-mir-223	Carcinoma, Bladder	28222670	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MicroRNA-223-3p inhibits human bladder cancer cell migration and invasion.
other	hsa-mir-3658	Carcinoma, Bladder	27820650	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Upregulation of miR-3658 in bladder cancer and tumor progression.
other	hsa-mir-489	Carcinoma, Bladder	28281959	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	miR-489 Suppresses Proliferation and Invasion of Human Bladder Cancer Cells.
other	hsa-mir-576	Carcinoma, Bladder	28338199	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MiR-576-3p is a novel marker correlated with poor clinical outcome in bladder cancer.
other	hsa-mir-892b	Carcinoma, Bladder	27573859	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MicroRNA-892b influences proliferation, migration and invasion of bladder cancer cells by mediating the p19ARF/cyclin D1/CDK6 and Sp-1/MMP-9 pathways.
other	hsa-let-7	Carcinoma, Breast	27574028			D05	D001943	114480	HP:0003002	Let‑7 miRNAs sensitize breast cancer stem cells to radiation‑induced repression through inhibition of the cyclin D1/Akt1/Wnt1 signaling pathway.
other	hsa-let-7a	Carcinoma, Breast	25669981			D05	D001943	114480	HP:0003002	Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.
other	hsa-mir-101	Carcinoma, Breast	28109909			D05	D001943	114480	HP:0003002	ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer.
other	hsa-mir-122	Carcinoma, Breast	23791885			D05	D001943	114480	HP:0003002	MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention.
other	hsa-mir-125a	Carcinoma, Breast	27651454			D05	D001943	114480	HP:0003002	Structural dynamics control the MicroRNA maturation pathway.
other	hsa-mir-126	Carcinoma, Breast	28125889			D05	D001943	114480	HP:0003002	Micro RNA-126 coordinates cell behavior and signaling cascades according to characteristics of breast cancer cells.
other	hsa-mir-127	Carcinoma, Breast	23791885			D05	D001943	114480	HP:0003002	MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention.
other	hsa-mir-139	Carcinoma, Breast	27864119			D05	D001943	114480	HP:0003002	Role of miR-139 as a surrogate marker for tumor aggression in breast cancer.
other	hsa-mir-155	Carcinoma, Breast	27470349			D05	D001943	114480	HP:0003002	Therefore, through the anti-glycolytic effect and breakage of the JAK/STAT3/SOCS1 feedback loop via miR-155-5p, 3B may potentially serve as a potential therapeutic agent against breast cancer.
other	hsa-mir-155	Carcinoma, Breast	28338193			D05	D001943	114480	HP:0003002	Oncogenic miR-155 down-regulated upon activation of antitumor cytotoxic T lymphocytes by the fusion of dendritic cells with breast carcinoma cells.
other	hsa-mir-17	Carcinoma, Breast	27811009			D05	D001943	114480	HP:0003002	Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors.
other	hsa-mir-17	Carcinoma, Breast	28178652			D05	D001943	114480	HP:0003002	STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells.
other	hsa-mir-182	Carcinoma, Breast	23791885			D05	D001943	114480	HP:0003002	MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention.
other	hsa-mir-183	Carcinoma, Breast	23791885			D05	D001943	114480	HP:0003002	MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention.
other	hsa-mir-184	Carcinoma, Breast	28335433			D05	D001943	114480	HP:0003002	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.
other	hsa-mir-18a	Carcinoma, Breast	24633304			D05	D001943	114480	HP:0003002	Our findings identify a mechanically regulated microRNA circuit that can promote malignancy and suggest potential prognostic roles for HOXA9 and miR-18a levels in stratifying patients with luminal breast cancers.
other	hsa-mir-200b	Carcinoma, Breast	28152297			D05	D001943	114480	HP:0003002	miR-200b and miR-217 negatively regulated the expression of autophagy marker proteins
other	hsa-mir-200c	Carcinoma, Breast	25967125			D05	D001943	114480	HP:0003002	our data suggests that expression of miR-200c-141 and ∆Np63 in D492M can reverse EMT resulting in luminal- and myoepithelial differentiation, respectively,demonstrating the importance of these molecules in epithelial integrity in the human breast.
other	hsa-mir-200c	Carcinoma, Breast	28003747			D05	D001943	114480	HP:0003002	MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell.
other	hsa-mir-200c	Carcinoma, Breast	28334634			D05	D001943	114480	HP:0003002	E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
other	hsa-mir-205	Carcinoma, Breast	28346474			D05	D001943	114480	HP:0003002	The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model.
other	hsa-mir-206	Carcinoma, Breast	23791885			D05	D001943	114480	HP:0003002	MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention.
other	hsa-mir-20a	Carcinoma, Breast	27811009			D05	D001943	114480	HP:0003002	Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors.
other	hsa-mir-21	Carcinoma, Breast	26008976			D05	D001943	114480	HP:0003002	Our data revealed tissue specific changes of extracellular circulating miRNAs that would be otherwise unraveled using blood samples.
other	hsa-mir-21	Carcinoma, Breast	27579604			D05	D001943	114480	HP:0003002	Distinct Small RNA Signatures in Extracellular Vesicles Derived from Breast Cancer Cell Lines.
other	hsa-mir-21	Carcinoma, Breast	27836600			D05	D001943	114480	HP:0003002	A novel method for sensitive microRNA detection: Electropolymerization based doping.
other	hsa-mir-21	Carcinoma, Breast	28115844			D05	D001943	114480	HP:0003002	Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
other	hsa-mir-214	Carcinoma, Breast	28051254			D05	D001943	114480	HP:0003002	MiR-214 negatively regulates proliferation and WNT/β-catenin signaling in breast cancer.
other	hsa-mir-217	Carcinoma, Breast	28152297			D05	D001943	114480	HP:0003002	miR-200b and miR-217 negatively regulated the expression of autophagy marker proteins
other	hsa-mir-221	Carcinoma, Breast	27686606			D05	D001943	114480	HP:0003002	A small RNA (miR-221) target was determined via the impedimetric measurement of the hybridization event in a label-free and PCR-free approach
other	hsa-mir-221	Carcinoma, Breast	27940575			D05	D001943	114480	HP:0003002	mda-7/IL-24 Mediates Cancer Cell-Specific Death via Regulation of miR-221 and the Beclin-1 Axis.
other	hsa-mir-221	Carcinoma, Breast	28191469			D05	D001943	114480	HP:0003002	RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site.
other	hsa-mir-221	Carcinoma, Breast	28202520			D05	D001943	114480	HP:0003002	Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.
other	hsa-mir-221	Carcinoma, Breast	28335433			D05	D001943	114480	HP:0003002	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.
other	hsa-mir-222	Carcinoma, Breast	27569215			D05	D001943	114480	HP:0003002	Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow.
other	hsa-mir-222	Carcinoma, Breast	27699665			D05	D001943	114480	HP:0003002	miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway.
other	hsa-mir-223	Carcinoma, Breast	27569215			D05	D001943	114480	HP:0003002	Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow.
other	hsa-mir-23a	Carcinoma, Breast	24806942			D05	D001943	114480	HP:0003002	Downregulation of SP1 and increased miR-23a levels in MSCs after contact with tumor cell medium as well as enhanced TGF尾1 expression were identified as potential molecular regulators of CXCL12 activity in MSCs.
other	hsa-mir-27a	Carcinoma, Breast	27779715			D05	D001943	114480	HP:0003002	miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7.
other	hsa-mir-27a	Carcinoma, Breast	27811009			D05	D001943	114480	HP:0003002	Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors.
other	hsa-mir-29a	Carcinoma, Breast	27523474			D05	D001943	114480	HP:0003002	miR-29a may be a potential target for the patients who acquired ADR-resistance during the treatment of breast cancer.
other	hsa-mir-29a	Carcinoma, Breast	27986463			D05	D001943	114480	HP:0003002	Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
other	hsa-mir-29a	Carcinoma, Breast	28186968			D05	D001943	114480	HP:0003002	XIAP 3'-untranslated region as a ceRNA promotes FSCN1 function in inducing the progression of breast cancer by binding endogenous miR-29a-5p.
other	hsa-mir-29a	Carcinoma, Breast	28335433			D05	D001943	114480	HP:0003002	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.
other	hsa-mir-29b	Carcinoma, Breast	27986463			D05	D001943	114480	HP:0003002	Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.
other	hsa-mir-29a	Carcinoma, Breast	25656908			D05	D001943	114480	HP:0003002	Epigenetic Regulation of miR-29s Affects the Lactation Activity of Dairy Cow Mammary Epithelial Cells.
other	hsa-mir-29b	Carcinoma, Breast	25656908			D05	D001943	114480	HP:0003002	Epigenetic Regulation of miR-29s Affects the Lactation Activity of Dairy Cow Mammary Epithelial Cells.
other	hsa-mir-29c	Carcinoma, Breast	25656908			D05	D001943	114480	HP:0003002	Epigenetic Regulation of miR-29s Affects the Lactation Activity of Dairy Cow Mammary Epithelial Cells.
other	hsa-mir-30	Carcinoma, Breast	28347244			D05	D001943	114480	HP:0003002	The miR-30 family: Versatile players in breast cancer.
other	hsa-mir-324	Carcinoma, Breast	27798879			D05	D001943	114480	HP:0003002	MicroRNA-324 in Human Cancer: miR-324-5p and miR-324-3p Have Distinct Biological Functions in Human Cancer.
other	hsa-mir-335	Carcinoma, Breast	28008602			D05	D001943	114480	HP:0003002	MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance.
other	hsa-mir-34a	Carcinoma, Breast	28334277			D05	D001943	114480	HP:0003002	In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas.
other	hsa-mir-363	Carcinoma, Breast	28335433			D05	D001943	114480	HP:0003002	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.
other	hsa-mir-375	Carcinoma, Breast	23791885			D05	D001943	114480	HP:0003002	MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention.
other	hsa-mir-375	Carcinoma, Breast	28300567			D05	D001943	114480	HP:0003002	9-cis Retinoic acid modulates myotrophin expression and its miR in physiological and pathophysiological cell models.
other	hsa-mir-375	Carcinoma, Breast	28335433			D05	D001943	114480	HP:0003002	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.
other	hsa-mir-4443	Carcinoma, Breast	27504971			D05	D001943	114480	HP:0003002	We revealed that miR-4443 induced malignancy of breast cancer mainly in chemo-resistance aspect for the very first time, providing a novel biomarker in breast cancer diagnosis and therapy.
other	hsa-mir-455	Carcinoma, Breast	28335433			D05	D001943	114480	HP:0003002	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.
other	hsa-mir-485	Carcinoma, Breast	23886178			D05	D001943	114480	HP:0003002	miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells.
other	hsa-mir-503	Carcinoma, Breast	27539783			D05	D001943	114480	HP:0003002	An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells.
other	hsa-mir-650	Carcinoma, Breast	28101578			D05	D001943	114480	HP:0003002	A 22q11.2 amplification in the region encoding microRNA-650 correlates with the epithelial to mesenchymal transition in breast cancer primary cultures of Mexican patients.
other	hsa-mir-660	Carcinoma, Breast	28252173			D05	D001943	114480	HP:0003002	Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer.
other	hsa-mir-7	Carcinoma, Breast	28571043			D05	D001943	114480	HP:0003002	MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells.
other	hsa-mir-760	Carcinoma, Breast	27981531			D05	D001943	114480	HP:0003002	miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells.
other	hsa-mir-765	Carcinoma, Breast	26398721			D05	D001943	114480	HP:0003002	These results provided novel insight into the regulatory mechanism of EMP3 in primary breast carcinoma.
other	hsa-mir-98	Carcinoma, Breast	28232182			D05	D001943	114480	HP:0003002	SNHG16 contributes to breast cancer cell migration by competitively binding miR-98 with E2F5.
other	hsa-mir-128	Carcinoma, Breast, Triple Negative	24485087				D064726			This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation.The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells.
other	hsa-mir-15a	Carcinoma, Breast, Triple Negative	24485087				D064726			This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation.The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells.
other	hsa-mir-15b	Carcinoma, Breast, Triple Negative	24485087				D064726			This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation.The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells.
other	hsa-mir-16	Carcinoma, Breast, Triple Negative	24485087				D064726			This study provides evidence of posttranscriptional downregulation of Smurf2 in triple-negative breast cancers, and demonstrates that the loss of RB function is involved in microRNA-mediated interference with Smurf2 translation.The new link from RB inactivation to Smurf2 downregulation is likely to play a role in malignant phenotypes of triple-negative breast cancer cells.
other	hsa-mir-190a	Carcinoma, Breast, Triple Negative	24865188				D064726			Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients.
other	hsa-mir-200b	Carcinoma, Breast, Triple Negative	24865188				D064726			Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients.
other	hsa-mir-200c	Carcinoma, Breast, Triple Negative	29666469				D064726			the new p53/miR-30a/ZEB2 axis controls tumor cell invasion and distal spreading and impinges upon miR-200c expression
other	hsa-mir-205	Carcinoma, Breast, Triple Negative	25792283				D064726			Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
other	hsa-mir-210	Carcinoma, Breast, Triple Negative	28402752				D064726			The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer.
other	hsa-mir-211	Carcinoma, Breast, Triple Negative	25680404				D064726			MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.
other	hsa-mir-34c	Carcinoma, Breast, Triple Negative	28069384				D064726			Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
other	hsa-mir-93	Carcinoma, Breast, Triple Negative	24865188				D064726			Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients.
other	hsa-mir-93	Carcinoma, Breast, Triple Negative	27840899				D064726			miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1.
other	hsa-mir-940	Carcinoma, Breast, Triple Negative	27731867				D064726			MiR-940 Inhibited Cell Growth and Migration in Triple-Negative Breast Cancer.
other	hsa-let-7a	Carcinoma, Cervical	26209160	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs.
other	hsa-let-7a	Carcinoma, Cervical	27748903	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Let‑7a suppresses cell proliferation via the TGF‑β/SMAD signaling pathway in cervical cancer.
other	hsa-mir-106b	Carcinoma, Cervical	26769181	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Our data suggest that the TGF-β1/miR-106b/DAB2 axis may be involved in the pathogenesis of cervical carcinoma.
other	hsa-mir-124	Carcinoma, Cervical	27806357	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention.
other	hsa-mir-125b	Carcinoma, Cervical	24402874	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNAs as biomarkers of cervical cancer development: a literature review on miR-125b and miR-34a.
other	hsa-mir-126	Carcinoma, Cervical	24377569	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin
other	hsa-mir-145	Carcinoma, Cervical	25666710	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells.
other	hsa-mir-145	Carcinoma, Cervical	28112371	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-145 inhibits tumorigenesis and invasion of cervical cancer stem cells.
other	hsa-mir-146a	Carcinoma, Cervical	24406730	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer.
other	hsa-mir-155	Carcinoma, Cervical	27717891	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The rs767649 polymorphism in the promoter of miR-155 contributes to the decreased risk for cervical cancer in a Chinese population.
other	hsa-mir-18a	Carcinoma, Cervical	25963391	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-18a enhances the radiosensitivity of cervical cancer cells by promoting radiation-induced apoptosis.
other	hsa-mir-205	Carcinoma, Cervical	28304186	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan.
other	hsa-mir-20a	Carcinoma, Cervical	23819812	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Our results suggested that the circulating miR-20a may be a potential biomarker for detecting the lymph node status of cervical cancer patients.
other	hsa-mir-20a	Carcinoma, Cervical	25803820	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiR-20a promotes cervical cancer proliferation and metastasis in vitro and in vivo.
other	hsa-mir-21	Carcinoma, Cervical	24406730	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer.
other	hsa-mir-21	Carcinoma, Cervical	26051842	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Overall, our study suggests that the microRNAs, miR-21 and let-7a function as clinically relevant integral components of STAT3 signaling and are responsible for maintaining activated state of STAT3 in HPV-infected cells during cervical carcinogenesis.
other	hsa-mir-218	Carcinoma, Cervical	24843318	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-218 enhances the radiosensitivity of human cervical cancer via promoting radiation induced apoptosis.
other	hsa-mir-223	Carcinoma, Cervical	26617846	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	In conclusion, miR-223 inhibited cell metastasis of human cervical cancer by modulating epithelial-mesenchymal transition.
other	hsa-mir-23b	Carcinoma, Cervical	28077801	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Human papillomavirus type 16 E6 suppresses microRNA-23b expression in human cervical cancer cells through DNA methylation of the host gene C9orf3.
other	hsa-mir-29b	Carcinoma, Cervical	28122338	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Chemotherapy-mediated miR-29b expression inhibits the invasion and angiogenesis of cervical cancer.
other	hsa-mir-31	Carcinoma, Cervical	25894339	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Our results suggested that miR-31 plays an oncogenetic role in the development and progression of cervical cancer.
other	hsa-mir-335	Carcinoma, Cervical	25712373	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-335 represents an independent prognostic marker in cervical cancer.
other	hsa-mir-34a	Carcinoma, Cervical	24402874	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNAs as biomarkers of cervical cancer development: a literature review on miR-125b and miR-34a.
other	hsa-mir-34a	Carcinoma, Cervical	26209160	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs.
other	hsa-mir-361	Carcinoma, Cervical	24158756	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-361-5p facilitates cervical cancer progression through mediation of epithelial-to-mesenchymal transition.
other	hsa-mir-375	Carcinoma, Cervical	25330011	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT.
other	hsa-mir-494	Carcinoma, Cervical	25877755	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiRNA-494 inhibits metastasis of cervical cancer through Pttg1.
other	hsa-mir-9	Carcinoma, Cervical	25344913	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Activation of miR-9 by human papillomavirus in cervical cancer.
other	hsa-mir-92a	Carcinoma, Cervical	28081742	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-92a Promotes Cell Proliferation in Cervical Cancer via Inhibiting p21 Expression and Promoting Cell Cycle Progression.
other	hsa-let-7	Carcinoma, Colon	27789274	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer.
other	hsa-mir-1	Carcinoma, Colon	28560697	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations.
other	hsa-mir-103a	Carcinoma, Colon	24239208	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease.
other	hsa-mir-106a	Carcinoma, Colon	26224446	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer.
other	hsa-mir-106b	Carcinoma, Colon	24239208	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease.
other	hsa-mir-122	Carcinoma, Colon	24898807	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo.
other	hsa-mir-126	Carcinoma, Colon	25199818	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The current population based study of patients operated for stage II colon cancer demonstrated correlations between several prognostic unfavourable characteristics and miRNA-126 and argues for a possible prognostic impact on overall survival. An influence on survival by the MVD estimate was not detected.
other	hsa-mir-135b	Carcinoma, Colon	24735923	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.
other	hsa-mir-139	Carcinoma, Colon	25550849	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-139-3p has potential as a prognostic biomarker for colon cancer. Further prospective studies are required to validate this result.
other	hsa-mir-141	Carcinoma, Colon	28739727	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-141 Inhibits Proliferation and Migration of Colorectal Cancer SW480 Cells.
other	hsa-mir-143	Carcinoma, Colon	24239208	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease.
other	hsa-mir-145	Carcinoma, Colon	28272349	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The Influence of Spirulina platensis Filtrates on Caco-2 Proliferative Activity and Expression of Apoptosis-Related microRNAs and mRNA.
other	hsa-mir-145	Carcinoma, Colon	29360852	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	We show that approximately 100 proteins are differentially expressed in HCT116 human colon cancer cells stably transduced with miR-143 or miR-145 compared to Empty control cells
other	hsa-mir-146	Carcinoma, Colon	28272349	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The Influence of Spirulina platensis Filtrates on Caco-2 Proliferative Activity and Expression of Apoptosis-Related microRNAs and mRNA.
other	hsa-mir-146a	Carcinoma, Colon	28466779	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells.
other	hsa-mir-155	Carcinoma, Colon	26744471	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer.
other	hsa-mir-155	Carcinoma, Colon	28259135	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.
other	hsa-mir-17	Carcinoma, Colon	28272349	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The Influence of Spirulina platensis Filtrates on Caco-2 Proliferative Activity and Expression of Apoptosis-Related microRNAs and mRNA.
other	hsa-mir-185	Carcinoma, Colon	25216407	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-185 suppresses growth and invasion of colon cancer cells through inhibition of the hypoxia-inducible factor-2α pathway in vitro and in vivo.
other	hsa-mir-186	Carcinoma, Colon	28302487	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis.
other	hsa-mir-192	Carcinoma, Colon	24213572	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-192 suppresses liver metastasis of colon cancer.
other	hsa-mir-192	Carcinoma, Colon	27793841	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells.
other	hsa-mir-199a	Carcinoma, Colon	28542779	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Downregulation of miR-199a/b-5p is associated with GCNT2 induction upon epithelial-mesenchymal transition in colon cancer.
other	hsa-mir-199b	Carcinoma, Colon	28542779	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Downregulation of miR-199a/b-5p is associated with GCNT2 induction upon epithelial-mesenchymal transition in colon cancer.
other	hsa-mir-200	Carcinoma, Colon	25832648	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro.
other	hsa-mir-200	Carcinoma, Colon	27460529	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family.
other	hsa-mir-200	Carcinoma, Colon	27666412	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Colorectal cancer cell-derived microRNA200 modulates the resistance of adjacent blood endothelial barriers in vitro.
other	hsa-mir-200	Carcinoma, Colon	28163188	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT).
other	hsa-mir-200b	Carcinoma, Colon	28163188	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT).
other	hsa-mir-200c	Carcinoma, Colon	28163188	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT).
other	hsa-mir-203	Carcinoma, Colon	27771718	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Sodium Butyrate Upregulates miR-203 Expression to Exert Anti-Proliferation Effect on Colorectal Cancer Cells.
other	hsa-mir-20a	Carcinoma, Colon	24239208	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease.
other	hsa-mir-20a	Carcinoma, Colon	26012475	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The Effects of miR-20a on p21: Two Mechanisms Blocking Growth Arrest in TGF-β-Responsive Colon Carcinoma.
other	hsa-mir-20b	Carcinoma, Colon	27878272	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer.
other	hsa-mir-21	Carcinoma, Colon	23827854	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression.
other	hsa-mir-21	Carcinoma, Colon	24239208	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease.
other	hsa-mir-21	Carcinoma, Colon	27798874	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer.
other	hsa-mir-21	Carcinoma, Colon	21956205	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	our findings identify direct transcriptional regulation of miR-21 by TCF4 and suggest a role for miR-21 in cancer cell proliferation and invasion upon activation of β-catenin/TCF4 signaling.
other	hsa-mir-21	Carcinoma, Colon	28560697	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations.
other	hsa-mir-214	Carcinoma, Colon	27537384	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells.
other	hsa-mir-215	Carcinoma, Colon	24239208	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer,and might be able to predict which patients benefit from adjuvant chemotherapy.It might facilitate patient counselling and individualise management of patients with this disease.
other	hsa-mir-29c	Carcinoma, Colon	28392396	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	p53 target miR-29c-3p suppresses colon cancer cell invasion and migration through inhibition of PHLDB2.
other	hsa-mir-301a	Carcinoma, Colon	28193514	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1.
other	hsa-mir-302a	Carcinoma, Colon	27840990	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells.
other	hsa-mir-30d	Carcinoma, Colon	28651493	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Mir-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis.
other	hsa-mir-31	Carcinoma, Colon	27630355	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
other	hsa-mir-34a	Carcinoma, Colon	25333573	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil.
other	hsa-mir-34a	Carcinoma, Colon	23991105	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation.
other	hsa-mir-4465	Carcinoma, Colon	27793841	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells.
other	hsa-mir-493	Carcinoma, Colon	24533778	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MKK7 mediates miR-493-dependent suppression of liver metastasis of colon cancer cells.
other	hsa-mir-506	Carcinoma, Colon	26452129	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Taking together, our study sheds light on the role of miR-506 as a suppressor for tumor growth and metastasis and raises the intriguing possibility that miR-506 may serve as a new potential marker for monitoring and treating colon cancer.
other	hsa-mir-582	Carcinoma, Colon	27595705	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-582-5P induces colorectal cancer cell proliferation by targeting adenomatous polyposis coli.
other	hsa-mir-590	Carcinoma, Colon	27878255	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Roles of mitochondrial transcription factor A and microRNA‑590‑3p in the development of colon cancer.
other	hsa-mir-598	Carcinoma, Colon	28161537	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-598 inhibits metastasis in colorectal cancer by suppressing JAG1/Notch2 pathway stimulating EMT.
other	hsa-mir-134	Carcinoma, Embryonal	25447206	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	FOXM1 is essential for human pluripotent stem cells and miR-134 attenuates its expression during differentiation.
other	hsa-mir-140	Carcinoma, Embryonal	26318829	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	Role of miR-140 in embryonic bone development and cancer.
other	hsa-let-7	Carcinoma, Endometrial	27775072	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Metformin acts by upregulating microRNA let-7 through AMPK activation, leading to degradation of H19 long noncoding RNA, which normally binds to and inactivates SAHH
other	hsa-let-7	Carcinoma, Endometrial	28381177	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Dicer1 dysfunction promotes stemness and aggression in endometrial carcinoma.
other	hsa-mir-125b	Carcinoma, Endometrial	28225751	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Proliferation and migration capability of endometrial carcinoma cells were detected after transfection of endometrial carcinoma cells with mir-125b mimic
other	hsa-mir-134	Carcinoma, Endometrial	25528443	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	endogenous miR-134 regulation in HuECSCs may suppress tumourigenesis in human endometrial carcinoma.
other	hsa-mir-143	Carcinoma, Endometrial	24071015	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
other	hsa-mir-145	Carcinoma, Endometrial	24589415	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Linc-RoR is a ceRNA and acts as a miR-145 sponge to inhibit mediation of the differentiation of ETs by miR-145. These results suggest that linc-RoR has an important role during endometrial carcinogenesis.
other	hsa-mir-145	Carcinoma, Endometrial	25634023	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	OCT4-pg5 can act as an RNA sponge to protect OCT4 transcripts from being inhibited by miR-145, providing novel insight into the control of OCT4 expression.
other	hsa-mir-145	Carcinoma, Endometrial	24071015	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
other	hsa-mir-152	Carcinoma, Endometrial	27263284	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Effect of Progesterone-induced MicroRNA-152 on the Proliferation of Endometrial Epithelial Cells.
other	hsa-mir-203	Carcinoma, Endometrial	29331043	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Role of miR-203 in estrogen receptor-mediated signaling in the rat uterus and endometrial carcinoma
other	hsa-mir-203	Carcinoma, Endometrial	21125666	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	In addition, miR-23b and miR-29c, which are involved in the inhibition of mesenchymal markers, and miR-203, which is involved in the inhibition of cell stemness
other	hsa-mir-205	Carcinoma, Endometrial	26817318	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	The role of miRNA in endometrial cancer in the context of miRNA 205
other	hsa-mir-22	Carcinoma, Endometrial	24715036	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	miR-22 inhibits proliferation and invasion in estrogen receptor α-positive endometrial endometrioid carcinomas cells.
other	hsa-mir-23b	Carcinoma, Endometrial	21125666	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	In addition, miR-23b and miR-29c, which are involved in the inhibition of mesenchymal markers, and miR-203, which is involved in the inhibition of cell stemness
other	hsa-mir-29c	Carcinoma, Endometrial	21125666	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	In addition, miR-23b and miR-29c, which are involved in the inhibition of mesenchymal markers, and miR-203, which is involved in the inhibition of cell stemness
other	hsa-mir-302	Carcinoma, Endometrial	24333727	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1.
other	hsa-mir-31	Carcinoma, Endometrial	24779718	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MIR31 functions as an oncogene in endometrial cancer by repressing the Hippo pathway. MIR31 is a potential new molecular marker for predicting the risk of recurrence and prognosis of endometrial cancer.
other	hsa-mir-93	Carcinoma, Endometrial	27829043	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MicroRNA-93 Promotes Epithelial-Mesenchymal Transition of Endometrial Carcinoma Cells.
other	hsa-mir-944	Carcinoma, Endometrial	28178620	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer.
other	hsa-mir-186	Carcinoma, Endometrioid Endometrial	23946815			C54.1	D018269			The qRT-PCR analysis further identified a profile of four serum miRNAs (miR-222, miR-223, miR-186 and miR-204) as a fingerprint for EEC detection.
other	hsa-mir-206	Carcinoma, Endometrioid Endometrial	21983130			C54.1	D018269			Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERж┿positive endometrioid adenocarcinoma.
other	hsa-let-7g	Carcinoma, Esophageal	26655271	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10.
other	hsa-let-7i	Carcinoma, Esophageal	26655271	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10.
other	hsa-mir-138	Carcinoma, Esophageal	27536892	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	α-Solanine Modulates the Radiosensitivity of Esophageal Cancer Cells by Inducing MicroRNA 138 Expression.
other	hsa-mir-144	Carcinoma, Esophageal	24369245	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miRNA-144 in the saliva is a genetic marker for early diagnosis of esophageal cancer
other	hsa-mir-144	Carcinoma, Esophageal	27572636	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Possible tumor suppressive role of the miR-144/451 cluster in esophageal carcinoma as determined by principal component regression analysis.
other	hsa-mir-145	Carcinoma, Esophageal	26156802	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The effect of recombinant lentiviral vector encoding miR-145 on human esophageal cancer cells.
other	hsa-mir-193b	Carcinoma, Esophageal	26878873	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	These results highlight the importance of miR-193b in determining oesophageal cancer cell viability and demonstrate an enhancement of chemotoxicity that is independent of apoptosis induction.
other	hsa-mir-196a	Carcinoma, Esophageal	27621035	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Inhibition of miR-196a affects esophageal cancer cell growth in vitro.
other	hsa-mir-200a	Carcinoma, Esophageal	28025999	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-200a-3p promotes the proliferation of human esophageal cancer cells by post-transcriptionally regulating cytoplasmic collapsin response mediator protein-1.
other	hsa-mir-203	Carcinoma, Esophageal	24219349	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1.
other	hsa-mir-203	Carcinoma, Esophageal	24154605	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells.
other	hsa-mir-20b	Carcinoma, Esophageal	27701465	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	MicroRNA-20b (miR-20b) Promotes the Proliferation, Migration, Invasion, and Tumorigenicity in Esophageal Cancer Cells via the Regulation of Phosphatase and Tensin Homologue Expression.
other	hsa-mir-21	Carcinoma, Esophageal	26125864	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Association of miR-21 with esophageal cancer prognosis: a meta-analysis.
other	hsa-mir-21	Carcinoma, Esophageal	26481465	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	In this study, miR-21 was identified as an independent prognostic biomarker for DSS in patients with EAC whereas miR-21 failed to show independent prognostic significance in ESCC. High miR-375 was not associated with enhanced survival in either histology.
other	hsa-mir-21	Carcinoma, Esophageal	27885434	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Evaluation of miR-21 and miR-375 as prognostic biomarkers in oesophageal cancer in high-risk areas in China.
other	hsa-mir-212	Carcinoma, Esophageal	25299094	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Overregulation of microRNA-212 in the poor prognosis of esophageal cancer patients.
other	hsa-mir-27	Carcinoma, Esophageal	26026166	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.
other	hsa-mir-30c	Carcinoma, Esophageal	26402921	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Factors such as core promoter-binding protein (CPBP), nuclear factor of activated T-cells 1 (NFAT-1), miR-30c-5p, were located  in the central hub of this network, highlighting their vital roles in esophageal  tumorigenesis.
other	hsa-mir-374a	Carcinoma, Esophageal	26252180	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	MicroRNA-374a promotes esophageal cancer cell proliferation via Axin2 suppression.
other	hsa-mir-375	Carcinoma, Esophageal	26481465	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	In this study, miR-21 was identified as an independent prognostic biomarker for DSS in patients with EAC whereas miR-21 failed to show independent prognostic significance in ESCC. High miR-375 was not associated with enhanced survival in either histology.
other	hsa-mir-375	Carcinoma, Esophageal	25404787	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The findings from this meta-analysis suggest that miR-375 expression is associated with OS of patients with malignant tumors and could be a useful clinical prognostic biomarker.
other	hsa-mir-375	Carcinoma, Esophageal	27885434	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Evaluation of miR-21 and miR-375 as prognostic biomarkers in oesophageal cancer in high-risk areas in China.
other	hsa-mir-451	Carcinoma, Esophageal	27572636	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Possible tumor suppressive role of the miR-144/451 cluster in esophageal carcinoma as determined by principal component regression analysis.
other	hsa-mir-491	Carcinoma, Esophageal	26279431	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-491 may play a critical role in EC.
other	hsa-mir-506	Carcinoma, Esophageal	26617801	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Taken together, our data identify a new role of miR-506 in esophageal cancer involving CREB1 suppression.
other	hsa-mir-93	Carcinoma, Esophageal	28434073	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Direct Downregulation of B-Cell Translocation Gene 3 by microRNA-93 Is Required for Desensitizing Esophageal Cancer to Radiotherapy.
other	hsa-mir-130a	Carcinoma, Gallbladder	24953832	disease of cellular proliferation	DOID:4948	C23	D005706			Together, these results suggest that HOTAIR is a c-Myc-activated driver of malignancy, which acts in part through repression of miRNA-130a.
other	hsa-mir-145	Carcinoma, Gallbladder	24966896	disease of cellular proliferation	DOID:4948	C23	D005706			miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer.
other	hsa-mir-19a	Carcinoma, Gallbladder	29575299	disease of cellular proliferation	DOID:4948	C23	D005706			The PLGF/c-MYC/miR-19a axis promotes metastasis and stemness in gallbladder cancer.
other	hsa-mir-218	Carcinoma, Gallbladder	25569100	disease of cellular proliferation	DOID:4948	C23	D005706			CCAT1 is a driver of malignancy, which acts in part through 'spongeing' miRNA-218-5p.
other	hsa-let-7a	Carcinoma, Gastric	20809749	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Lentiviral vector-mediated upregulation of let-7a inhibits gastric carcinoma cell growth in vitro and in vivo.
other	hsa-mir-100	Carcinoma, Gastric	28381156	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Characterization of exosomal RNAs derived from human gastric cancer cells by deep sequencing.
other	hsa-mir-1284	Carcinoma, Gastric	27627897	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-1284 inhibits proliferation and induces apoptosis in SGC-7901 human gastric cancer cells.
other	hsa-mir-133b	Carcinoma, Gastric	27696637	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle-splicer polypyrimidine tract-binding protein 1.
other	hsa-mir-137	Carcinoma, Gastric	25663388	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis.
other	hsa-mir-148a	Carcinoma, Gastric	28381156	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Characterization of exosomal RNAs derived from human gastric cancer cells by deep sequencing.
other	hsa-mir-152	Carcinoma, Gastric	28056089	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells.
other	hsa-mir-155	Carcinoma, Gastric	29675003	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Role of microRNAs and Exosomes in Helicobacter pylori and Epstein-Barr Virus Associated Gastric Cancers
other	hsa-mir-190b	Carcinoma, Gastric	28044223	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-190b confers radio-sensitivity through negative regulation of Bcl-2 in gastric cancer cells.
other	hsa-mir-19a	Carcinoma, Gastric	26239140	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-19a mediates gastric carcinoma cell proliferation through the activation of nuclear factor-κB.
other	hsa-mir-200b	Carcinoma, Gastric	28056089	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells.
other	hsa-mir-200c	Carcinoma, Gastric	25672630	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	DZNep raises miR-200c expression to delay the invasion and migration of MGC-803 gastric carcinoma cells
other	hsa-mir-200c	Carcinoma, Gastric	28113080	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells.
other	hsa-mir-204	Carcinoma, Gastric	28133610	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Histological and Pathological Assessment of miR-204 and SOX4 Levels in Gastric Cancer Patients.
other	hsa-mir-21	Carcinoma, Gastric	28381156	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Characterization of exosomal RNAs derived from human gastric cancer cells by deep sequencing.
other	hsa-mir-21	Carcinoma, Gastric	28407783	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.
other	hsa-mir-22	Carcinoma, Gastric	27662840	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines.
other	hsa-mir-24	Carcinoma, Gastric	27743162	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-24-3p Regulates Progression of Gastric Mucosal Lesions and Suppresses Proliferation and Invasiveness of N87 Via Peroxiredoxin 6.
other	hsa-mir-29a	Carcinoma, Gastric	27000664	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma.
other	hsa-mir-29b	Carcinoma, Gastric	27497248	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Taken together, our results suggested that RUNX3-mediated up-regulation of miR-29b inhibited the  proliferation and migration of gastric cancer cells by targeting KDM2A, representing a novel molecular mechanism for the tumor suppression action of RUNX3.
other	hsa-mir-29c	Carcinoma, Gastric	27000664	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma.
other	hsa-mir-30	Carcinoma, Gastric	27729002	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-30 functions as an oncomiR in gastric cancer cells through regulation of P53-mediated mitochondrial apoptotic pathway.
other	hsa-mir-30a	Carcinoma, Gastric	27876712	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells.
other	hsa-mir-30a	Carcinoma, Gastric	28381156	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Characterization of exosomal RNAs derived from human gastric cancer cells by deep sequencing.
other	hsa-mir-31	Carcinoma, Gastric	27904131	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-31 Regulates Rho-Associated Kinase-Myosin Light Chain (ROCK-MLC) Pathway and Inhibits Gastric Cancer Invasion
other	hsa-mir-328	Carcinoma, Gastric	27923017	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Expression of microRNA-328 Functions as a Biomarker for Recurrence of Early Gastric Cancer (EGC) After Endoscopic Submucosal Dissection (ESD) by Modulating CD44.
other	hsa-mir-340	Carcinoma, Gastric	28057912	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-340 Inhibits Proliferation and Induces Apoptosis in Gastric Cancer Cell Line SGC-7901, Possibly via the AKT Pathway.
other	hsa-mir-34a	Carcinoma, Gastric	24796666	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The RNA-binding protein PCBP2 facilitates gastric carcinoma growth by targeting miR-34a.
other	hsa-mir-34a	Carcinoma, Gastric	29577459	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	abnormal glycolysis was relieved by ASIV via regulation of the expressions of LDHA, p53, TIGAR, MCT1, MCT4, HIF-1α, CD147, and miRNA-34a
other	hsa-mir-423	Carcinoma, Gastric	28254439	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The microRNA-423-3p-Bim Axis Promotes Cancer Progression and Activates Oncogenic Autophagy in Gastric Cancer.
other	hsa-mir-429	Carcinoma, Gastric	26513239	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Our data suggest that miR-429 suppression in GC promotes Bcl-2-mediated cancer cell survival against chemotherapy-induced cell death.Re-expression of miR-429 levels in GC cells may enhance cancer apoptosis during chemotherapy.
other	hsa-mir-449c	Carcinoma, Gastric	26141986	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-449c inhibits gastric carcinoma growth.
other	hsa-mir-502	Carcinoma, Gastric	27866197	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Rs56288038 (C/G) in 3'UTR of IRF-1 Regulated by MiR-502-5p Promotes Gastric Cancer Development.
other	hsa-mir-520d	Carcinoma, Gastric	28011625	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Gastric Cancer Cell Proliferation and Survival Is Enabled by a Cyclophilin B/STAT3/miR-520d-5p Signaling Feedback Loop.
other	hsa-mir-574	Carcinoma, Gastric	28042090	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Upregulation of microRNA-574-3p in a human gastric cancer cell line AGS by TGF-β1.
other	hsa-mir-9	Carcinoma, Gastric	28476807	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer.
other	hsa-mir-141	Carcinoma, Gastrooesophageal	26885979							The miRNA profile predictive for sensitivity to cisplatin,epirubicine and capecitabine was shown to be  independently associated with OS and DSS in patients with gastrooesophageal cancer.
other	hsa-mir-200c	Carcinoma, Gastrooesophageal	26885979							The miRNA profile predictive for sensitivity to cisplatin,epirubicine and capecitabine was shown to be  independently associated with OS and DSS in patients with gastrooesophageal cancer.
other	hsa-mir-505	Carcinoma, Gastrooesophageal	26885979							The miRNA profile predictive for sensitivity to cisplatin,epirubicine and capecitabine was shown to be  independently associated with OS and DSS in patients with gastrooesophageal cancer.
other	hsa-mir-99b	Carcinoma, Gastrooesophageal	26885979							The miRNA profile predictive for sensitivity to cisplatin,epirubicine and capecitabine was shown to be  independently associated with OS and DSS in patients with gastrooesophageal cancer.
other	hsa-mir-214	Carcinoma, Gingival	28565877			D00.03				Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma.
other	hsa-let-7	Carcinoma, Hepatocellular	27821157	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway.
other	hsa-let-7a	Carcinoma, Hepatocellular	27693636	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma.
other	hsa-let-7a	Carcinoma, Hepatocellular	28691642	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	XIAP 3'-untranslated region serves as a competitor for HMGA2 by arresting endogenous let-7a-5p in human hepatocellular carcinoma.
other	hsa-let-7a	Carcinoma, Hepatocellular	28012864	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
other	hsa-let-7b	Carcinoma, Hepatocellular	22934260	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	TLR4 signaling induces the release of microparticles by tumor cells that regulate inflammatory cytokine IL-6 of macrophages via microRNA let-7b.
other	hsa-let-7b	Carcinoma, Hepatocellular	24297460	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma.
other	hsa-let-7c	Carcinoma, Hepatocellular	20018759	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC
other	hsa-let-7d	Carcinoma, Hepatocellular	23682578	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The MC recurrence-related miRNA included let-7d*, miR-328 and miR18a*, which potentially regulate K-ras gene expression. 
other	hsa-let-7e	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-let-7e	Carcinoma, Hepatocellular	23282077	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-16, miR-30a, Let-7e and miR-204 were identified as key miRNA regulators contributed to HCC metastasis.
other	hsa-let-7f-1	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-let-7f-2	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-let-7g	Carcinoma, Hepatocellular	24791593	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Let-7g microRNA sensitizes fluorouracil-resistant human hepatoma cells.
other	hsa-mir-1	Carcinoma, Hepatocellular	26019452	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-1 might be a potential tumor activator. Inhibiting its expression could decrease proliferation, induce apoptosis, and inhibit the migration and invasion of TECs of human HCC.
other	hsa-mir-100	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-100	Carcinoma, Hepatocellular	22249248	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.
other	hsa-mir-100	Carcinoma, Hepatocellular	27577856	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters.
other	hsa-mir-101	Carcinoma, Hepatocellular	24759835	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In human HCC, COX-2 mRNA but not COX-2 protein levels are associated with expression levels of angiogenic factors. MiR-21 levels are not associated with angiogenic molecules. MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels.
other	hsa-mir-101-1	Carcinoma, Hepatocellular	19155302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-101: a tumor suppressor
other	hsa-mir-101-1	Carcinoma, Hepatocellular	20444294	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-101:PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells
other	hsa-mir-101-1	Carcinoma, Hepatocellular	21876625	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	potential associated miRNA
other	hsa-mir-101-1	Carcinoma, Hepatocellular	22035408	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Benzothiazole based compounds exhibited effective cytotoxicity at 4 M concentration and have shown G1 cell cycle arrest with decrease in levels of G1 cell cycle proteins such as cyclin D1 and Skp2. Involvement of tumour suppressor proteins such as PTEN and p53 was studied. Interestingly these compounds displayed decrease in the phosphorylated forms of AKT, p38 MAPK and ERK1/2 which play a vital role in cell proliferation. Compounds have exhibited strong and significant effect on the expression of micro RNAs such as miR-195a & miR-101-1 which regulate hepatic cell proliferation.
other	hsa-mir-101-1	Carcinoma, Hepatocellular	23483142	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells
other	hsa-mir-101-2	Carcinoma, Hepatocellular	19155302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-101: a tumor suppressor
other	hsa-mir-101-2	Carcinoma, Hepatocellular	20444294	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-101:PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells
other	hsa-mir-101-2	Carcinoma, Hepatocellular	21876625	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	potential associated miRNA
other	hsa-mir-101-2	Carcinoma, Hepatocellular	23483142	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells
other	hsa-mir-103a-1	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-103a-2	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-105	Carcinoma, Hepatocellular	25280563	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma.
other	hsa-mir-106a	Carcinoma, Hepatocellular	21876625	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	potential associated miRNA
other	hsa-mir-106a	Carcinoma, Hepatocellular	25760076	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.
other	hsa-mir-106b	Carcinoma, Hepatocellular	21876625	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	potential associated miRNA
other	hsa-mir-106b	Carcinoma, Hepatocellular	25327652	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Effects of miR-106b expression on the proliferation of human hepatocellular carcinoma cells.
other	hsa-mir-106b	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-106b	Carcinoma, Hepatocellular	24876719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.
other	hsa-mir-107	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-107	Carcinoma, Hepatocellular	26296971	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-7/21/108 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin.
other	hsa-mir-107	Carcinoma, Hepatocellular	27571925	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway.
other	hsa-mir-10a	Carcinoma, Hepatocellular	28958640	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression
other	hsa-mir-10b	Carcinoma, Hepatocellular	24875649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed  Issue entitled: Rare Cancers.
other	hsa-mir-1180	Carcinoma, Hepatocellular	28468075	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatics on vascular invasion markers in hepatocellular carcinoma via Big-Data analysis.
other	hsa-mir-1202	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-122	Carcinoma, Hepatocellular	19296470	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122: a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma
other	hsa-mir-122	Carcinoma, Hepatocellular	20527935	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122:Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma
other	hsa-mir-122	Carcinoma, Hepatocellular	21917968	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HepG2 cells expressing miR-122 support the entire hepatitis C virus life cycle.
other	hsa-mir-122	Carcinoma, Hepatocellular	24130799	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The continued expression of miR-122 in HCV-associated HCC may signify an important role for HCV replication late in the progression to malignancy.
other	hsa-mir-122	Carcinoma, Hepatocellular	24531873	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Antitumor function of microRNA-122 against hepatocellular carcinoma.
other	hsa-mir-122	Carcinoma, Hepatocellular	25023326	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Baculovirus-mediated miRNA regulation to suppress hepatocellular carcinoma tumorigenicity and metastasis.
other	hsa-mir-122	Carcinoma, Hepatocellular	25823567	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of the oncogenic function of distal-less 4 by microRNA-122 in hepatocellular carcinoma.
other	hsa-mir-122	Carcinoma, Hepatocellular	25965999	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met induction.
other	hsa-mir-122	Carcinoma, Hepatocellular	26179591	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Single-Vehicular Delivery of Antagomir and Small Molecules to Inhibit miR-122 Function in Hepatocellular Carcinoma Cells by using Smart Mesoporous Silica Nanoparticles.
other	hsa-mir-122	Carcinoma, Hepatocellular	26514126	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The findings suggest that the export of miR-122 via AMSC exosomes represents a novel strategy to enhance HCC chemosensitivity.
other	hsa-mir-122	Carcinoma, Hepatocellular	26655273	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data imply that an intimate correlation between miR-122 and IGF-1R abnormal expression is a critical determinant of sorafenib tolerance.
other	hsa-mir-122	Carcinoma, Hepatocellular	25269820	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA sponge blocks the tumor-suppressing functions of microRNA-122 in human hepatoma and osteosarcoma cells.
other	hsa-mir-122	Carcinoma, Hepatocellular	27846390	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5.
other	hsa-mir-122	Carcinoma, Hepatocellular	27895094	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Crosstalk between microRNA-122 and FOX family genes in HepG2 cells.
other	hsa-mir-122	Carcinoma, Hepatocellular	27980102	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
other	hsa-mir-122	Carcinoma, Hepatocellular	28114997	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Targeted imaging and induction of apoptosis of drug-resistant hepatoma cells by miR-122-loaded graphene-InP nanocompounds.
other	hsa-mir-122	Carcinoma, Hepatocellular	22820284	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Knockout mice also displayed hepatic inflammation, fibrosis, and a high incidence of hepatocellular carcinoma, suggesting that miR-122 has a tumor suppressor role in hepatocytes.
other	hsa-mir-122	Carcinoma, Hepatocellular	27194671	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression levels of plasma miR-122 are associated with early TACE refractoriness in HCC patients treated with TACE.
other	hsa-mir-122	Carcinoma, Hepatocellular	27391076	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	we showed that the isomiR profiles of liver specific MiR122, and a few other miRNAs, correlated with MC-LR treatment.
other	hsa-mir-122	Carcinoma, Hepatocellular	27450327	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In this system, we developed a conditionally replicative adenovirus (CRAd) loaded on human umbilical cord-derived mesenchymal stem cells (HUMSCs), in which the CRAd contained an adenovirus E1A gene dual regulated by 伪-fetoprotein promoter and microRNA-122 target sequence.
other	hsa-mir-122	Carcinoma, Hepatocellular	28179291	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
other	hsa-mir-122	Carcinoma, Hepatocellular	28642869	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Detection of MicroRNA in Hepatic Cirrhosis and Hepatocellular Carcinoma in Hepatitis C Genotype-4 in Egyptian Patients.
other	hsa-mir-122	Carcinoma, Hepatocellular	29534065	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD134+ cells associated with different stages of hepatocarinogensis
other	hsa-mir-122a	Carcinoma, Hepatocellular	28686599	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Flux balance analysis predicts Warburg-like effects of mouse hepatocyte deficient in miR-122a.
other	hsa-mir-124	Carcinoma, Hepatocellular	26188282	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	PABPC1 interacts with AGO2 and is responsible for the microRNA mediated gene silencing in high grade hepatocellular carcinoma.
other	hsa-mir-1246	Carcinoma, Hepatocellular	24060847	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
other	hsa-mir-1246	Carcinoma, Hepatocellular	27639189	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells.
other	hsa-mir-1249	Carcinoma, Hepatocellular	28365245	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Induced MiR-1249 expression by aberrant activation of Hedegehog signaling pathway in hepatocellular carcinoma.
other	hsa-mir-125a	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-125a-5p recurence related
other	hsa-mir-125a	Carcinoma, Hepatocellular	27982429	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.
other	hsa-mir-125a	Carcinoma, Hepatocellular	29534065	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD136+ cells associated with different stages of hepatocarinogensis
other	hsa-mir-125b	Carcinoma, Hepatocellular	25889022	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This finding provides the novel evidence for GLPS on inhibition of HCC through miR-125b inhibiting Tregs accumulation and function.
other	hsa-mir-125b	Carcinoma, Hepatocellular	27577856	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters.
other	hsa-mir-125b	Carcinoma, Hepatocellular	28654261	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Astragalin Reduces Hexokinase 2 through Increasing miR-125b to Inhibit the Proliferation of Hepatocellular Carcinoma Cells in Vitro and in Vivo.
other	hsa-mir-125b	Carcinoma, Hepatocellular	22824797	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	downregulation of miR-125b was a frequent event in hepatocellular carcinoma (HCC) tissues, and the miR-125b level was positively associated with the rate of apoptosis in HCC tissues.
other	hsa-mir-125b	Carcinoma, Hepatocellular	28521446	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis.
other	hsa-mir-125b	Carcinoma, Hepatocellular	28958640	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression
other	hsa-mir-125b-1	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-125b-1	Carcinoma, Hepatocellular	21703189	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-125b regulates of placenta growth factor in hepatocellular cancer
other	hsa-mir-125b-1	Carcinoma, Hepatocellular	22942733	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-125b Functions as a Tumor Suppressor in Hepatocellular Carcinoma Cells.
other	hsa-mir-125b-2	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-125b-2	Carcinoma, Hepatocellular	21703189	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-125b regulates of placenta growth factor in hepatocellular cancer
other	hsa-mir-125b-2	Carcinoma, Hepatocellular	22942733	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-125b Functions as a Tumor Suppressor in Hepatocellular Carcinoma Cells.
other	hsa-mir-126	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-126* recurence related
other	hsa-mir-126	Carcinoma, Hepatocellular	22552153	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurrence-related in hepatocellular carcinoma
other	hsa-mir-126	Carcinoma, Hepatocellular	25345948	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of miR-126/miR-126* in hepatocelluar carcinoma and its correlation with clinical outcomes.
other	hsa-mir-1260b	Carcinoma, Hepatocellular	24060847	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
other	hsa-mir-1269a	Carcinoma, Hepatocellular	24875649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed  Issue entitled: Rare Cancers.
other	hsa-mir-127	Carcinoma, Hepatocellular	24854842	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-127 plays a tumor-suppressor role and can serve as a potential diagnostic biomarker for HCC.
other	hsa-mir-1274a	Carcinoma, Hepatocellular	24060847	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
other	hsa-mir-128	Carcinoma, Hepatocellular	25704921	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.
other	hsa-mir-1290	Carcinoma, Hepatocellular	24060847	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
other	hsa-mir-129-1	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-129-5p recurence related
other	hsa-mir-129-2	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-129-5p recurence related
other	hsa-mir-1301	Carcinoma, Hepatocellular	22159405	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-1301-mediated inhibition of tumorigenesis.
other	hsa-mir-130a	Carcinoma, Hepatocellular	21712254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The hepatitis B virus-associated estrogen receptor alpha (ER{alpha}) was regulated by microRNA-130a in HepG2.2.15 human hepatocellular carcinoma cells.
other	hsa-mir-130b	Carcinoma, Hepatocellular	25387077	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome  proliferator-activated receptor gamma in human hepatocellular carcinoma.
other	hsa-mir-133a	Carcinoma, Hepatocellular	25714665	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings for the first time demonstrated that the involvement of miR-133a and miR-326 in MDR is mediated by ABCC1 in hepatocellular carcinoma cell line HepG2 and suggested that miR-133a and miR-326 may be efficient agents for preventing and reversing ADM resistance in cancer cells.
other	hsa-mir-137	Carcinoma, Hepatocellular	26352279	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Inhibition of cell proliferation and metastasis of human hepatocellular carcinoma by miR-137 is regulated by CDC42.
other	hsa-mir-138	Carcinoma, Hepatocellular	28258280	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HCV core inhibits hepatocellular carcinoma cell replicative senescence through downregulating microRNA-138 expression.
other	hsa-mir-140	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-140-3p recurence related
other	hsa-mir-141	Carcinoma, Hepatocellular	20619223	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-141:Hsa-miR-141 and hsa-miR-200c, microRNAs that promote epithelial phenotypes, had significantly higher levels in non-hepatic epithelial tumors
other	hsa-mir-141	Carcinoma, Hepatocellular	24135722	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Simultaneous silencing of miR-200c and miR-141 was likely to be responsible for the development of HCC-BDTT via ZEB1-directed EMT activation and Sec24a-mediated secretome.
other	hsa-mir-141	Carcinoma, Hepatocellular	25425543	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-141 functions as a tumor suppressor in HCC cells through the inhibition of HNF-3β translation.
other	hsa-mir-142	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-142-3p recurence related
other	hsa-mir-142	Carcinoma, Hepatocellular	25292173	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This study reveals a novel role for propofol in the inhibition of HCC through MV-mediated transfer of miR-142-3p from macrophages to cancer cells in vivo.
other	hsa-mir-142	Carcinoma, Hepatocellular	28243631	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies.
other	hsa-mir-145	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-145	Carcinoma, Hepatocellular	22378186	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145.
other	hsa-mir-145	Carcinoma, Hepatocellular	22431718	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma.
other	hsa-mir-145	Carcinoma, Hepatocellular	24630966	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-145: a promising biomarker for hepatocellular carcinoma (HCC).
other	hsa-mir-146a	Carcinoma, Hepatocellular	21982769	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-146a suppresses the sensitivity to interferon-a in hepatocellular carcinoma cells.
other	hsa-mir-146a	Carcinoma, Hepatocellular	24314246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC.
other	hsa-mir-146a	Carcinoma, Hepatocellular	24895573	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.
other	hsa-mir-146b	Carcinoma, Hepatocellular	24314246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC.
other	hsa-mir-147a	Carcinoma, Hepatocellular	22552153	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurrence-related in hepatocellular carcinoma
other	hsa-mir-148a	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-148a	Carcinoma, Hepatocellular	23861222	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma.
other	hsa-mir-148a	Carcinoma, Hepatocellular	24806207	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells.
other	hsa-mir-148a	Carcinoma, Hepatocellular	28958640	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression
other	hsa-mir-149	Carcinoma, Hepatocellular	28468075	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatics on vascular invasion markers in hepatocellular carcinoma via Big-Data analysis.
other	hsa-mir-150	Carcinoma, Hepatocellular	26215970	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma.
other	hsa-mir-150	Carcinoma, Hepatocellular	25549355	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	re-expression of MMP14 in hepatoma cells partially reverses the effect of miR-150-5p in inhibiting cell invasion
other	hsa-mir-151	Carcinoma, Hepatocellular	20812359	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma.
other	hsa-mir-152	Carcinoma, Hepatocellular	28339081	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBx represses RIZ1 expression by DNA methyltransferase 1 involvement in decreased miR-152 in hepatocellular carcinoma.
other	hsa-mir-153	Carcinoma, Hepatocellular	25708809	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-153 promotes Wnt/β-catenin activation in hepatocellular carcinoma through suppression of WWOX.
other	hsa-mir-155	Carcinoma, Hepatocellular	23316018	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggest that S100A4 exerts its effects through the regulation of miR-155 expression in HCC cells
other	hsa-mir-155	Carcinoma, Hepatocellular	27913196	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	NF-kB-regulated exosomal miR-155 promotes the inflammation associated with arsenite carcinogenesis.
other	hsa-mir-155	Carcinoma, Hepatocellular	28670383	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-155 up-regulated by TGF-β promotes epithelial-mesenchymal transition, invasion and metastasis of human hepatocellular carcinoma cells in vitro.
other	hsa-mir-15a	Carcinoma, Hepatocellular	24314246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC.
other	hsa-mir-15a	Carcinoma, Hepatocellular	23649629	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes.
other	hsa-mir-15b	Carcinoma, Hepatocellular	26023735	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-15b-5p induces endoplasmic reticulum stress and apoptosis in human hepatocellular carcinoma, both in vitro and in vivo, by suppressing Rab1A.
other	hsa-mir-16	Carcinoma, Hepatocellular	24314246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC.
other	hsa-mir-16	Carcinoma, Hepatocellular	24759835	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In human HCC, COX-2 mRNA but not COX-2 protein levels are associated with expression levels of angiogenic factors. MiR-21 levels are not associated with angiogenic molecules. MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels.
other	hsa-mir-16	Carcinoma, Hepatocellular	23282077	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-16, miR-30a, Let-7e and miR-204 were identified as key miRNA regulators contributed to HCC metastasis.
other	hsa-mir-16	Carcinoma, Hepatocellular	28770611	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Clinical significance of miRNA-autophagy transcript expression in patients with hepatocellular carcinoma
other	hsa-mir-16	Carcinoma, Hepatocellular	29136911	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-155 expression, essential in NK cell activation, was elevated in Foxo3-/- NK cells while its inhibition led to diminished IFNγ production
other	hsa-mir-16	Carcinoma, Hepatocellular	29344256	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Pien Tze Huang inhibits the growth of hepatocellular carcinoma cells by upregulating miR-16 expression
other	hsa-mir-16-1	Carcinoma, Hepatocellular	21336967	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells.
other	hsa-mir-16-1	Carcinoma, Hepatocellular	23649629	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes.
other	hsa-mir-16-2	Carcinoma, Hepatocellular	21336967	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells.
other	hsa-mir-17	Carcinoma, Hepatocellular	24297460	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma.
other	hsa-mir-17	Carcinoma, Hepatocellular	23912452	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells.
other	hsa-mir-17	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-17	Carcinoma, Hepatocellular	24876719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.
other	hsa-mir-17	Carcinoma, Hepatocellular	26231474	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-95 cluster promotes hepatocarcinogenesis.
other	hsa-mir-17	Carcinoma, Hepatocellular	26232302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-94 cluster promotes hepatocarcinogenesis.
other	hsa-mir-17	Carcinoma, Hepatocellular	26233130	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-93 cluster promotes hepatocarcinogenesis.
other	hsa-mir-17	Carcinoma, Hepatocellular	26804174	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	SLU7 knockdown altered the splicing of the C13orf25 primary transcript, and markedly reduced the expression  of its miR-17, miR-20 and miR-92a constituents.
other	hsa-mir-17	Carcinoma, Hepatocellular	28904393	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
other	hsa-mir-18	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-18	Carcinoma, Hepatocellular	24876719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.
other	hsa-mir-18	Carcinoma, Hepatocellular	26231474	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-95 cluster promotes hepatocarcinogenesis.
other	hsa-mir-18	Carcinoma, Hepatocellular	26232302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-94 cluster promotes hepatocarcinogenesis.
other	hsa-mir-18	Carcinoma, Hepatocellular	26233130	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-93 cluster promotes hepatocarcinogenesis.
other	hsa-mir-18	Carcinoma, Hepatocellular	28904393	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
other	hsa-mir-181a-2	Carcinoma, Hepatocellular	20576283	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-181a:Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines
other	hsa-mir-181b	Carcinoma, Hepatocellular	29534065	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD135+ cells associated with different stages of hepatocarinogensis
other	hsa-mir-181d	Carcinoma, Hepatocellular	24314246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC.
other	hsa-mir-182	Carcinoma, Hepatocellular	25739014	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma.
other	hsa-mir-182	Carcinoma, Hepatocellular	26126858	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data showed that hypoxia regulated the expression of miR-182 and RASA1 to promote HCC angiogenesis.
other	hsa-mir-182	Carcinoma, Hepatocellular	27262453	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upon forcing miR-182 expression in the HCC NK-cells, upregulation of both receptors was observed.
other	hsa-mir-183	Carcinoma, Hepatocellular	24060847	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
other	hsa-mir-183	Carcinoma, Hepatocellular	24222732	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression and significance of microRNA-183 in hepatocellular carcinoma.
other	hsa-mir-183	Carcinoma, Hepatocellular	24875649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed  Issue entitled: Rare Cancers.
other	hsa-mir-183	Carcinoma, Hepatocellular	26188282	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	PABPC1 interacts with AGO2 and is responsible for the microRNA mediated gene silencing in high grade hepatocellular carcinoma.
other	hsa-mir-183	Carcinoma, Hepatocellular	26400524	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This study revealed a novel miR-21/miR-183-SOCS7 axis that might play an important role in modulating cell growth and invasion of HCC cells.
other	hsa-mir-184	Carcinoma, Hepatocellular	24183204	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC).
other	hsa-mir-185	Carcinoma, Hepatocellular	28240051	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-185 induces potent autophagy via AKT signaling in hepatocellular carcinoma.
other	hsa-mir-18a	Carcinoma, Hepatocellular	19027010	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-18a: prevents estrogen receptor-alpha expression, promoting proliferation
other	hsa-mir-18a	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-18a	Carcinoma, Hepatocellular	21876625	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	potential associated miRNA
other	hsa-mir-18a	Carcinoma, Hepatocellular	24975878	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-α in female hepatocellular carcinoma.
other	hsa-mir-18a	Carcinoma, Hepatocellular	28219903	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer.
other	hsa-mir-18a	Carcinoma, Hepatocellular	23682578	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The MC recurrence-related miRNA included let-7d*, miR-328 and miR18a*, which potentially regulate K-ras gene expression. 
other	hsa-mir-18a	Carcinoma, Hepatocellular	28302149	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.
other	hsa-mir-18b	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-18b	Carcinoma, Hepatocellular	21876625	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	potential associated miRNA
other	hsa-mir-190a	Carcinoma, Hepatocellular	26608035	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results reveal the involvement of miR-190a-treRNA axis in hepatoma progression and shed light on lncRNA-based cancer therapies for hepatoma patients at high risk of metastasis.
other	hsa-mir-190b	Carcinoma, Hepatocellular	24586785	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Increased expression of miR-190 may cause decreased IGF-1 in HCC development. Insulin resistance appears to be a part of the physiopathologic significance of decreased IGF-1 levels in HCC progression. This study provides a novel miRNA-mediated regulatory mechanism for controlling IGF-1 expression in HCC and elucidates the biological relevance of this interaction in HCC.
other	hsa-mir-191	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-191	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-192	Carcinoma, Hepatocellular	22433310	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBx gene down-regulates miR-192 expression and inhibits apoptosis of human hepatoma cell line HepG2.
other	hsa-mir-192	Carcinoma, Hepatocellular	28465351	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	An HNF4α-microRNA-194/192 signaling axis maintains hepatic cell function.
other	hsa-mir-192	Carcinoma, Hepatocellular	29534065	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a miRNA panel comprised of four miRNAs (miR-192, miR-122, miR-181b and miR-125a-5p) that may serve as a molecular tool for characterization of the CD133+ cells associated with different stages of hepatocarinogensis
other	hsa-mir-193a	Carcinoma, Hepatocellular	24330766	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
other	hsa-mir-193b	Carcinoma, Hepatocellular	25034398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Modulation of miRNAs expression might be a potential way to enhance response to sorafenib in HBV-associated HCC.
other	hsa-mir-193b	Carcinoma, Hepatocellular	25997995	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy.
other	hsa-mir-194	Carcinoma, Hepatocellular	24314246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC.
other	hsa-mir-194	Carcinoma, Hepatocellular	28465351	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	An HNF4α-microRNA-194/192 signaling axis maintains hepatic cell function.
other	hsa-mir-195	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-196a-1	Carcinoma, Hepatocellular	20127796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-196:MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression
other	hsa-mir-196a-2	Carcinoma, Hepatocellular	20127796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-196:MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression
other	hsa-mir-198	Carcinoma, Hepatocellular	23391410	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration
other	hsa-mir-199a	Carcinoma, Hepatocellular	24875649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed  Issue entitled: Rare Cancers.
other	hsa-mir-199a	Carcinoma, Hepatocellular	25714015	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents.
other	hsa-mir-199a	Carcinoma, Hepatocellular	28529584	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells.
other	hsa-mir-199a-1	Carcinoma, Hepatocellular	23742776	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression.
other	hsa-mir-199a-2	Carcinoma, Hepatocellular	23742776	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression.
other	hsa-mir-199b	Carcinoma, Hepatocellular	24875649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed  Issue entitled: Rare Cancers.
other	hsa-mir-19a	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-19a	Carcinoma, Hepatocellular	24876719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.
other	hsa-mir-19a	Carcinoma, Hepatocellular	26231474	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-95 cluster promotes hepatocarcinogenesis.
other	hsa-mir-19a	Carcinoma, Hepatocellular	26232302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-94 cluster promotes hepatocarcinogenesis.
other	hsa-mir-19a	Carcinoma, Hepatocellular	26233130	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-93 cluster promotes hepatocarcinogenesis.
other	hsa-mir-19a	Carcinoma, Hepatocellular	22552153	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurrence-related in hepatocellular carcinoma
other	hsa-mir-19a	Carcinoma, Hepatocellular	28904393	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
other	hsa-mir-19b-1	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-19b-1	Carcinoma, Hepatocellular	24876719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.
other	hsa-mir-19b-1	Carcinoma, Hepatocellular	26231474	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-95 cluster promotes hepatocarcinogenesis.
other	hsa-mir-19b-1	Carcinoma, Hepatocellular	26232302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-94 cluster promotes hepatocarcinogenesis.
other	hsa-mir-19b-1	Carcinoma, Hepatocellular	26233130	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-93 cluster promotes hepatocarcinogenesis.
other	hsa-mir-19b-1	Carcinoma, Hepatocellular	28904393	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
other	hsa-mir-200	Carcinoma, Hepatocellular	23857252	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC).
other	hsa-mir-200	Carcinoma, Hepatocellular	24135722	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Simultaneous silencing of miR-200c and miR-141 was likely to be responsible for the development of HCC-BDTT via ZEB1-directed EMT activation and Sec23a-mediated secretome.
other	hsa-mir-200a	Carcinoma, Hepatocellular	22868917	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-200a and -200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers.
other	hsa-mir-200a	Carcinoma, Hepatocellular	23760980	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells.
other	hsa-mir-200a	Carcinoma, Hepatocellular	25482402	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-200a may be recognized as a novel potential biomarker to predict the survival of patients with HCCs following liver transplantation.
other	hsa-mir-200a	Carcinoma, Hepatocellular	25797260	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-200a suppresses metastatic potential of side population cells in human hepatocellular carcinoma by decreasing ZEB2.
other	hsa-mir-200b	Carcinoma, Hepatocellular	22868917	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-200a and -200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers.
other	hsa-mir-200b	Carcinoma, Hepatocellular	23760980	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells.
other	hsa-mir-200c	Carcinoma, Hepatocellular	20619223	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-200c:Hsa-miR-141 and hsa-miR-200c, microRNAs that promote epithelial phenotypes, had significantly higher levels in non-hepatic epithelial tumors
other	hsa-mir-200c	Carcinoma, Hepatocellular	24135722	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Simultaneous silencing of miR-200c and miR-141 was likely to be responsible for the development of HCC-BDTT via ZEB1-directed EMT activation and Sec25a-mediated secretome.
other	hsa-mir-203	Carcinoma, Hepatocellular	21786180	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver.
other	hsa-mir-203	Carcinoma, Hepatocellular	28100026	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver.
other	hsa-mir-203a	Carcinoma, Hepatocellular	26210453	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of miRNA-30c and miR-204a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells.
other	hsa-mir-204	Carcinoma, Hepatocellular	23282077	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-16, miR-30a, Let-7e and miR-204 were identified as key miRNA regulators contributed to HCC metastasis.
other	hsa-mir-20a	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-20a	Carcinoma, Hepatocellular	24876719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.
other	hsa-mir-20a	Carcinoma, Hepatocellular	26231474	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-95 cluster promotes hepatocarcinogenesis.
other	hsa-mir-20a	Carcinoma, Hepatocellular	26232302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-94 cluster promotes hepatocarcinogenesis.
other	hsa-mir-20a	Carcinoma, Hepatocellular	26233130	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-93 cluster promotes hepatocarcinogenesis.
other	hsa-mir-20a	Carcinoma, Hepatocellular	28904393	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
other	hsa-mir-21	Carcinoma, Hepatocellular	20018759	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC
other	hsa-mir-21	Carcinoma, Hepatocellular	20447717	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-21:MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma
other	hsa-mir-21	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-21	Carcinoma, Hepatocellular	23442323	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma
other	hsa-mir-21	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-21	Carcinoma, Hepatocellular	24060847	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
other	hsa-mir-21	Carcinoma, Hepatocellular	24759835	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In human HCC, COX-2 mRNA but not COX-2 protein levels are associated with expression levels of angiogenic factors. MiR-21 levels are not associated with angiogenic molecules. MiR-16 and miR-101 levels do not correlate with COX-2 mRNA and protein levels.
other	hsa-mir-21	Carcinoma, Hepatocellular	24845419	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.
other	hsa-mir-21	Carcinoma, Hepatocellular	25447674	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	I3C could function as a miR-21 regulator, leading to repression of the PTEN/AKT pathway and opening a new avenue for eradication of drug-resistant cells, thus potentially helping to improve the therapeutic outcome in patients diagnosed with HCC.
other	hsa-mir-21	Carcinoma, Hepatocellular	25720799	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.
other	hsa-mir-21	Carcinoma, Hepatocellular	26296971	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-7/21/109 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin.
other	hsa-mir-21	Carcinoma, Hepatocellular	26400524	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This study revealed a novel miR-21/miR-183-SOCS6 axis that might play an important role in modulating cell growth and invasion of HCC cells.
other	hsa-mir-21	Carcinoma, Hepatocellular	24112539	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3.
other	hsa-mir-21	Carcinoma, Hepatocellular	26060089	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate that cisplatin inhibits the growth of HCC, possibly through the induction of G1 cell cycle arrest and apoptosis through the alteration of microRNA expression.
other	hsa-mir-21	Carcinoma, Hepatocellular	25969534	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells.
other	hsa-mir-21	Carcinoma, Hepatocellular	29538313	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our analysis identified novel miR-21 targets that are likely to play a causal role in hepatocarcinogenesis
other	hsa-mir-21	Carcinoma, Hepatocellular	28529584	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells.
other	hsa-mir-210	Carcinoma, Hepatocellular	27018975	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulation of TIMP2 by HIF-1伪/miR-210/HIF-3伪 regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma.
other	hsa-mir-214	Carcinoma, Hepatocellular	24875649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed  Issue entitled: Rare Cancers.
other	hsa-mir-214	Carcinoma, Hepatocellular	23962428	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of microRNA-214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis.
other	hsa-mir-214	Carcinoma, Hepatocellular	24719559	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Addition of NCTD to treat RAW264.7 or TAMs enhanced M1 polarization through increase of miR-214 expression. NCTD significantly inhibited 尾-catenin expression, which could be reversed by miR-214 inhibitor.
other	hsa-mir-215	Carcinoma, Hepatocellular	28958640	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression
other	hsa-mir-216	Carcinoma, Hepatocellular	20206398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We also found an inverse correlation between IGF activation and miR-100/miR-216 levels (FDR<0.05).
other	hsa-mir-216b	Carcinoma, Hepatocellular	25741595	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway.
other	hsa-mir-218	Carcinoma, Hepatocellular	25110121	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Prognostic significance of miR-218 in human hepatocellular carcinoma and its role in cell growth.
other	hsa-mir-218	Carcinoma, Hepatocellular	25120782	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-218 modulate hepatocellular carcinoma cell proliferation through PTEN/AKT/PI3K pathway and HoxA10.
other	hsa-mir-218	Carcinoma, Hepatocellular	26024833	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hotair silence activates P16(Ink4a) and P14(ARF) signaling by enhancing miR-218 expression and suppressing Bmi-1 expression, resulting in the suppression of tumorigenesis in HCC.
other	hsa-mir-22	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-22	Carcinoma, Hepatocellular	21750200	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-22 promotes HBV related hepatocellular carcinoma development in males.
other	hsa-mir-221	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-221	Carcinoma, Hepatocellular	25447674	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	I3C could function as a miR-19 regulator, leading to repression of the PTEN/AKT pathway and opening a new avenue for eradication of drug-resistant cells, thus potentially helping to improve the therapeutic outcome in patients diagnosed with HCC.
other	hsa-mir-221	Carcinoma, Hepatocellular	27904678	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-221 promotes growth and invasion of hepatocellular carcinoma cells by constitutive activation of NFκB.
other	hsa-mir-221	Carcinoma, Hepatocellular	27983537	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma.
other	hsa-mir-221	Carcinoma, Hepatocellular	28096271	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
other	hsa-mir-221	Carcinoma, Hepatocellular	28302149	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.
other	hsa-mir-221	Carcinoma, Hepatocellular	29322790	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-221 and miR-222 might affect the pathogenesis of HCC
other	hsa-mir-221	Carcinoma, Hepatocellular	28529584	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells.
other	hsa-mir-222	Carcinoma, Hepatocellular	20018759	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC
other	hsa-mir-222	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-222	Carcinoma, Hepatocellular	25447674	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	I3C could function as a miR-20 regulator, leading to repression of the PTEN/AKT pathway and opening a new avenue for eradication of drug-resistant cells, thus potentially helping to improve the therapeutic outcome in patients diagnosed with HCC.
other	hsa-mir-222	Carcinoma, Hepatocellular	29322790	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-221 and miR-223 might affect the pathogenesis of HCC
other	hsa-mir-223	Carcinoma, Hepatocellular	18555017	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-223: MicroRNA-223 is commonly reproessed in hepatocellular carcinoma and potentiates expression of Stathmin1
other	hsa-mir-223	Carcinoma, Hepatocellular	22552153	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurrence-related in hepatocellular carcinoma
other	hsa-mir-223	Carcinoma, Hepatocellular	27998765	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation.
other	hsa-mir-224	Carcinoma, Hepatocellular	23741247	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling.
other	hsa-mir-224	Carcinoma, Hepatocellular	23913306	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A noncanonical pathway links autophagy,miR-224, Smad4, and HBV-associated HCC. These findings open a new avenue for the treatment of HCC.
other	hsa-mir-23a	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-23a	Carcinoma, Hepatocellular	24417970	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Correlation between miR-23a and onset of hepatocellular carcinoma.
other	hsa-mir-23a	Carcinoma, Hepatocellular	26305257	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	up-regulating the expression of miR-23a may activate the positive regulatory network of p53 and miR-23a involved  in the mechanism underlying the anti-tumor effect of berberine in hepatocellular  carcinoma (HCC).
other	hsa-mir-23a	Carcinoma, Hepatocellular	18508316	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells.
other	hsa-mir-24	Carcinoma, Hepatocellular	24800232	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis.
other	hsa-mir-24	Carcinoma, Hepatocellular	18508316	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells.
other	hsa-mir-24-1	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-24-1	Carcinoma, Hepatocellular	22552153	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurrence-related in hepatocellular carcinoma
other	hsa-mir-24-2	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-24-2	Carcinoma, Hepatocellular	22552153	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurrence-related in hepatocellular carcinoma
other	hsa-mir-25	Carcinoma, Hepatocellular	27840896	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway.
other	hsa-mir-26	Carcinoma, Hepatocellular	23569435	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Development of a miR-26 Companion Diagnostic Test for Adjuvant Interferon-alpha Therapy in Hepatocellular Carcinoma
other	hsa-mir-26a	Carcinoma, Hepatocellular	24296580	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatocellular carcinoma: New insight into angiogenesis in hepatocellular carcinoma: involvement of microRNA-26a.
other	hsa-mir-26a	Carcinoma, Hepatocellular	27906498	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Sialyltransferase ST3GAL6 mediates the effect of microRNA-26a on cell growth, migration, and invasion in hepatocellular carcinoma through the protein kinase B/mammalian target of rapamycin pathway.
other	hsa-mir-26a	Carcinoma, Hepatocellular	28079894	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
other	hsa-mir-26a-1	Carcinoma, Hepatocellular	21610700	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Tumor-specific Expression of MicroRNA-26a Suppresses Human Hepatocellular Carcinoma Growth via Cyclin-dependent and -independent Pathways.
other	hsa-mir-26a-2	Carcinoma, Hepatocellular	21610700	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Tumor-specific Expression of MicroRNA-26a Suppresses Human Hepatocellular Carcinoma Growth via Cyclin-dependent and -independent Pathways.
other	hsa-mir-27a	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-27a	Carcinoma, Hepatocellular	18508316	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We also explore that miR-23a approximately 27a approximately 24 can function as an antiapoptotic and proliferation-promoting factor in liver cancer cells.
other	hsa-mir-27b	Carcinoma, Hepatocellular	24314246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC.
other	hsa-mir-27b	Carcinoma, Hepatocellular	24614526	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Fumonisin B modulates expression of human cytochrome P450 1b1 in human hepatoma  (Hepg2) cells by repressing Mir-27b.
other	hsa-mir-29	Carcinoma, Hepatocellular	24798303	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular  carcinoma epigenome.
other	hsa-mir-29	Carcinoma, Hepatocellular	25367851	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.
other	hsa-mir-29a	Carcinoma, Hepatocellular	23023935	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate that the expression of miR-29a is important in the regulation of the SPARC-AKT pathway and HCC growth.
other	hsa-mir-302c	Carcinoma, Hepatocellular	25027009	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-302c inhibits tumor growth of hepatocellular carcinoma by suppressing the endothelial-mesenchymal transition of endothelial cells.
other	hsa-mir-30a	Carcinoma, Hepatocellular	25654285	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Effect of miR-30a-5p on the proliferation, apoptosis, invasion and migration of  SMCC-7721 human hepatocellular carcinoma cells
other	hsa-mir-30a	Carcinoma, Hepatocellular	23282077	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-16, miR-30a, Let-7e and miR-204 were identified as key miRNA regulators contributed to HCC metastasis.
other	hsa-mir-30a	Carcinoma, Hepatocellular	28732393	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma
other	hsa-mir-30a	Carcinoma, Hepatocellular	29061507	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma.
other	hsa-mir-30b	Carcinoma, Hepatocellular	24314246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Drug-resistant HCC cells have abnormal expressed miRNAs, which may be explored to further investigate the association of miRNA expressions with multidrugs resistance in HCC.
other	hsa-mir-30b	Carcinoma, Hepatocellular	27894814	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Tanshinone IIA induced cell death via miR30b-p53-PTPN11/SHP2 signaling pathway in human hepatocellular carcinoma cells.
other	hsa-mir-30c	Carcinoma, Hepatocellular	26210453	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of miRNA-30c and miR-203a is associated with hepatitis C virus core protein-induced epithelial-mesenchymal transition in normal hepatocytes and hepatocellular carcinoma cells.
other	hsa-mir-30d	Carcinoma, Hepatocellular	27571925	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway.
other	hsa-mir-30e	Carcinoma, Hepatocellular	28958640	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our data showed potential role of miR-10a, miR-30e, miR-215, miR-125b and miR-148a as important mediators in HCC progression
other	hsa-mir-31	Carcinoma, Hepatocellular	27909734	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma.
other	hsa-mir-3144	Carcinoma, Hepatocellular	24875649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed  Issue entitled: Rare Cancers.
other	hsa-mir-3178	Carcinoma, Hepatocellular	26182877	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of tumorigenesis and metastasis of hepatocellular carcinoma tumor endothelial cells by microRNA-3178 and underlying mechanism.
other	hsa-mir-326	Carcinoma, Hepatocellular	25714665	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings for the first time demonstrated that the involvement of miR-133a and miR-326 in MDR is mediated by ABCC1 in hepatocellular carcinoma cell line HepG2 and suggested that miR-133a and miR-326 may be efficient agents for preventing and reversing ADM resistance in cancer cells.
other	hsa-mir-328	Carcinoma, Hepatocellular	23682578	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The MC recurrence-related miRNA included let-7d*, miR-328 and miR18a*, which potentially regulate K-ras gene expression. 
other	hsa-mir-331	Carcinoma, Hepatocellular	25750939	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This provided useful information in exploring the mechanism of HCC induced by HBV infection.
other	hsa-mir-338	Carcinoma, Hepatocellular	26315112	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma.
other	hsa-mir-338	Carcinoma, Hepatocellular	26060089	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate that cisplatin inhibits the growth of HCC, possibly through the induction of G1 cell cycle arrest and apoptosis through the alteration of microRNA expression.
other	hsa-mir-338	Carcinoma, Hepatocellular	27694002	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma.
other	hsa-mir-345	Carcinoma, Hepatocellular	23577194	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis C Virus Core Protein Down-Regulates p21(Waf1/Cip1) and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells
other	hsa-mir-34a	Carcinoma, Hepatocellular	19006648	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-34a: miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells
other	hsa-mir-34a	Carcinoma, Hepatocellular	20018759	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC
other	hsa-mir-34a	Carcinoma, Hepatocellular	25596083	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the expression of miR-34a in HCC biopsy specimens has an independent predictive value of early recurrence after RFA.
other	hsa-mir-34a	Carcinoma, Hepatocellular	26060089	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate that cisplatin inhibits the growth of HCC, possibly through the induction of G1 cell cycle arrest and apoptosis through the alteration of microRNA expression.
other	hsa-mir-34a	Carcinoma, Hepatocellular	27725225	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells.
other	hsa-mir-34a	Carcinoma, Hepatocellular	28356025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of Apoptosis by SYB in HepG2 Liver Cancer Cells is Mediated by the P53/Caspase 9 Axis.
other	hsa-mir-34a	Carcinoma, Hepatocellular	29128099	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of Cellular Senescence by miR-34a in Alcoholic Liver Injury.
other	hsa-mir-362	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-362-3p recurence related
other	hsa-mir-365	Carcinoma, Hepatocellular	25973057	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Prognostic significance and anti-proliferation effect of microRNA-365 in hepatocellular carcinoma.
other	hsa-mir-365	Carcinoma, Hepatocellular	28184920	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma.
other	hsa-mir-367	Carcinoma, Hepatocellular	27688096	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
other	hsa-mir-379	Carcinoma, Hepatocellular	28051262	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatic identification of IGF1 as a hub gene in hepatocellular carcinoma (HCC) and in-vitro analysis of the chemosensitizing effect of miR-379 via suppressing the IGF1/IGF1R signaling pathway.
other	hsa-mir-375	Carcinoma, Hepatocellular	28577837	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
other	hsa-mir-375	Carcinoma, Hepatocellular	28769563	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma
other	hsa-mir-375	Carcinoma, Hepatocellular	28915706	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The role of autophagy in hepatocellular carcinoma: friend or foe.
other	hsa-mir-375	Carcinoma, Hepatocellular	29555460	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-375/Sf-LCC NPs can deliver sorafenib and miR-375 into HCC cells and tumor tissues, increase drug retention time in tumor, significantly inhibit autophagy and produce enhanced anti-tumor effect
other	hsa-mir-376a-1	Carcinoma, Hepatocellular	22684007	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma.
other	hsa-mir-376a-2	Carcinoma, Hepatocellular	22684007	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma.
other	hsa-mir-378a	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-379	Carcinoma, Hepatocellular	27266355	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Effects of microRNA-379-5p on proliferation, migration and invasion of hepatocellular carcinoma cell line.
other	hsa-mir-421	Carcinoma, Hepatocellular	22446874	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of Human Farnesoid X Receptor by miR-421 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells.
other	hsa-mir-423	Carcinoma, Hepatocellular	26663009	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR423-5p contributed to the tumorigenesis and progression of HCC.It could be a new predictor in HCC patients beyond the Milan criteria and would help to improve patient outcomes and enlarge recipient pools of liver transplantation.
other	hsa-mir-424	Carcinoma, Hepatocellular	26315541	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma.
other	hsa-mir-425	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-429	Carcinoma, Hepatocellular	25931210	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our results here defined miR-429 as a key inducer for HCC pathogenesis and metastasis with potential utility for tumor intervention.
other	hsa-mir-432	Carcinoma, Hepatocellular	25797263	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation.
other	hsa-mir-451	Carcinoma, Hepatocellular	26164082	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
other	hsa-mir-451	Carcinoma, Hepatocellular	24841638	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-451: potential role as tumor suppressor of human hepatoma cell growth and invasion.
other	hsa-mir-483	Carcinoma, Hepatocellular	24127413	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Exploration of genome-wide circulating microRNA in hepatocellular carcinoma:MiR-483-5p as a potential biomarker.
other	hsa-mir-490	Carcinoma, Hepatocellular	24875649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the study reveals the comprehensive miRNome of hepatic tissue and provides new tools for investigation of microRNA dependent pathways in cirrhotic liver and hepatocellular carcinoma. This article is part of a Directed  Issue entitled: Rare Cancers.
other	hsa-mir-491	Carcinoma, Hepatocellular	23725476	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition.
other	hsa-mir-497	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-499a	Carcinoma, Hepatocellular	22641068	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells.
other	hsa-mir-499b	Carcinoma, Hepatocellular	22641068	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells.
other	hsa-mir-500	Carcinoma, Hepatocellular	19863192	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings reveal that diverse changes of miRNAs occur during liver development and, one of these, miR-500 is an oncofetal miRNA relevant to the diagnosis of human HCC.
other	hsa-mir-500a	Carcinoma, Hepatocellular	19737067	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	oncofetal miRNA relevant to the diagnosis
other	hsa-mir-502	Carcinoma, Hepatocellular	26163264	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-502 inhibits cell proliferation and tumor growth in hepatocellular carcinoma through suppressing phosphoinositide 3-kinase catalytic subunit gamma.
other	hsa-mir-503	Carcinoma, Hepatocellular	21495032	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-503 regulates metastatic function in hepatocellular cancer cell.
other	hsa-mir-503	Carcinoma, Hepatocellular	23967867	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data highlight an important role for miR-503 in cell cycle regulation and in the molecular etiology of HCC, and implicate the potential application of miR-503 in prognosis prediction and miRNA-based HCC therapy.
other	hsa-mir-508	Carcinoma, Hepatocellular	24060847	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
other	hsa-mir-520d	Carcinoma, Hepatocellular	24458129	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hsa-miR-520d induces hepatoma cells to form normal liver tissues via a stemness-mediated process.
other	hsa-mir-520e	Carcinoma, Hepatocellular	22212428	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatoma.
other	hsa-mir-539	Carcinoma, Hepatocellular	27717846	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
other	hsa-mir-573	Carcinoma, Hepatocellular	26201458	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The miR-573/apoM/Bcl2A1-dependent signal transduction pathway is essential for hepatocyte apoptosis and hepatocarcinogenesis.
other	hsa-mir-581	Carcinoma, Hepatocellular	24913918	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-581 during hepatocarcinogenesis may lead to a reduction in HBsAg expression and impede HCC development.
other	hsa-mir-612	Carcinoma, Hepatocellular	23478189	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma
other	hsa-mir-630	Carcinoma, Hepatocellular	25731670	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggest that miR-630 is associated with tumor progression of hepatocellular carcinoma and may be a potential prognosis indicator.
other	hsa-mir-637	Carcinoma, Hepatocellular	21809363	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Primate-specific miRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting stat3 signaling.
other	hsa-mir-675	Carcinoma, Hepatocellular	24939300	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	inhibition of LncRNAH19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3β/Cdc25A  signaling pathway.
other	hsa-mir-7	Carcinoma, Hepatocellular	24339204	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of miR-7 upregulates Cullin 5 (CUL5) to facilitate G1/S transition in human hepatocellular carcinoma cells.
other	hsa-mir-7	Carcinoma, Hepatocellular	26296971	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin.
other	hsa-mir-7	Carcinoma, Hepatocellular	27519414	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Suppression of MicroRNA-7 (miR-7) Biogenesis by Nuclear Factor 90-Nuclear Factor  45 Complex (NF90-NF45) Controls Cell Proliferation in Hepatocellular Carcinoma.
other	hsa-mir-7	Carcinoma, Hepatocellular	27614453	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma.
other	hsa-mir-7	Carcinoma, Hepatocellular	28459371	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Role of microRNA-7 and selenoprotein P in hepatocellular carcinoma.
other	hsa-mir-744	Carcinoma, Hepatocellular	28468075	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatics on vascular invasion markers in hepatocellular carcinoma via Big-Data analysis.
other	hsa-mir-877	Carcinoma, Hepatocellular	24060847	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
other	hsa-mir-9	Carcinoma, Hepatocellular	26206264	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	this study revealed the involvement of the miR-9/PPARA/CDH1 signaling pathway in HCC oncogenesis.
other	hsa-mir-9	Carcinoma, Hepatocellular	25552204	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the potential of miR-9 as a novel prognostic biomarker for HCC. Large well-designed studies with diverse populations and functional evaluations are warranted to confirm and extend our findings.
other	hsa-mir-9	Carcinoma, Hepatocellular	28062574	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma.
other	hsa-mir-92	Carcinoma, Hepatocellular	23546593	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression and significance of PTEN and miR-92 in hepatocellular carcinoma
other	hsa-mir-92-1	Carcinoma, Hepatocellular	24358224	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Global assessment of Antrodia cinnamomea-induced microRNA alterations in hepatocarcinoma cells.
other	hsa-mir-92-1	Carcinoma, Hepatocellular	24876719	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.
other	hsa-mir-92-1	Carcinoma, Hepatocellular	26231474	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-95 cluster promotes hepatocarcinogenesis.
other	hsa-mir-92-1	Carcinoma, Hepatocellular	26232302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-94 cluster promotes hepatocarcinogenesis.
other	hsa-mir-92-1	Carcinoma, Hepatocellular	26233130	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-17-93 cluster promotes hepatocarcinogenesis.
other	hsa-mir-92-1	Carcinoma, Hepatocellular	28904393	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
other	hsa-mir-92a	Carcinoma, Hepatocellular	26804174	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	SLU7 knockdown altered the splicing of the C13orf25 primary transcript, and markedly reduced the expression  of its miR-17, miR-20 and miR-92a constituents.
other	hsa-mir-93	Carcinoma, Hepatocellular	20018759	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC
other	hsa-mir-93	Carcinoma, Hepatocellular	22773266	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of MiR-93 Expression Reduces Cell Proliferation and Clonogenicity of HepG2 Cells.
other	hsa-mir-940	Carcinoma, Hepatocellular	25940592	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients.
other	hsa-mir-940	Carcinoma, Hepatocellular	28468075	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatics on vascular invasion markers in hepatocellular carcinoma via Big-Data analysis.
other	hsa-mir-941	Carcinoma, Hepatocellular	25049231	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-941 and KDM6B regulated the epithelial-mesenchymal transition process and affected cell migratory/invasive properties.
other	hsa-mir-95	Carcinoma, Hepatocellular	24530415	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma.
other	hsa-mir-96	Carcinoma, Hepatocellular	20018759	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC
other	hsa-mir-96	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-96	Carcinoma, Hepatocellular	22160187	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells.
other	hsa-mir-96	Carcinoma, Hepatocellular	23151657	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells
other	hsa-mir-99a	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-99a	Carcinoma, Hepatocellular	26060089	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate that cisplatin inhibits the growth of HCC, possibly through the induction of G1 cell cycle arrest and apoptosis through the alteration of microRNA expression.
other	hsa-mir-99b	Carcinoma, Hepatocellular	21298008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	recurence related
other	hsa-mir-101	Carcinoma, Hepatocellular, HBV-Related	24697700							Functional analysis of miR-101-3p and Rap1b involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis.
other	hsa-mir-122	Carcinoma, Hepatocellular, HBV-Related	24748463							Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk.
other	hsa-mir-429	Carcinoma, Hepatocellular, HBV-Related	25312821							miR-429 represses cell proliferation and induces apoptosis in HBV-related HCC.
other	hsa-mir-602	Carcinoma, Hepatocellular, HBV-Related	24398562							Arctiin induces an UVB protective effect in human dermal fibroblast cells through microRNA expression changes.
other	hsa-mir-122	Carcinoma, Hepatocellular, HCV-Related	24690114							Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma.
other	hsa-let-7	Carcinoma, Laryngeal	27874955	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	Expression and significances of MiRNA Let-7 and HMGA2 in laryngeal carcinoma.
other	hsa-mir-106b	Carcinoma, Laryngeal	23912048	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	MicroRNA-106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells.
other	hsa-mir-152	Carcinoma, Laryngeal	25095980	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	Expression and clinical significance of microRNA-152 in supragalottic laryngeal carcinoma.
other	hsa-mir-27a	Carcinoma, Laryngeal	28122350	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	Transcriptional suppression of microRNA-27a contributes to laryngeal cancer differentiation via GSK-3β-involved Wnt/β-catenin pathway.
other	hsa-mir-423	Carcinoma, Laryngeal	25337209	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma.
other	hsa-mir-1	Carcinoma, Lung	27541266	disease of cellular proliferation	DOID:3905	C34.90	D008175			Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling.
other	hsa-mir-127	Carcinoma, Lung	27869168	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop.
other	hsa-mir-129b	Carcinoma, Lung	27813559	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-129b suppresses cell proliferation in the human lung cancer cell lines A549 and H1299.
other	hsa-mir-146a	Carcinoma, Lung	27463381	disease of cellular proliferation	DOID:3905	C34.90	D008175			Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines.
other	hsa-mir-155	Carcinoma, Lung	27463381	disease of cellular proliferation	DOID:3905	C34.90	D008175			Chitin also induced the expression of  the key pattern recognition receptors TLR2 and TLR4. Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines.
other	hsa-mir-155	Carcinoma, Lung	28400205	disease of cellular proliferation	DOID:3905	C34.90	D008175			Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles.
other	hsa-mir-200	Carcinoma, Lung	27694892	disease of cellular proliferation	DOID:3905	C34.90	D008175			ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
other	hsa-mir-200	Carcinoma, Lung	27189341	disease of cellular proliferation	DOID:3905	C34.90	D008175			AKT2  can regulate miR-200a in a histology- or stage-specific manner
other	hsa-mir-200a	Carcinoma, Lung	27189341	disease of cellular proliferation	DOID:3905	C34.90	D008175			AKT2  can regulate miR-200a in a histology- or stage-specific manner and that
other	hsa-mir-203	Carcinoma, Lung	26132195	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-203 Inhibits Frizzled-2 Expression via CD82/KAI1 Expression in Human Lung Carcinoma Cells.
other	hsa-mir-206	Carcinoma, Lung	24189536	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-206 is capable of suppressing a known oncogene, it might be a true tumor suppressor gene and, as such, be deleted, modified, or directly repressed in human tumors.
other	hsa-mir-206	Carcinoma, Lung	27541266	disease of cellular proliferation	DOID:3905	C34.90	D008175			Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling.
other	hsa-mir-21	Carcinoma, Lung	24004609	disease of cellular proliferation	DOID:3905	C34.90	D008175			Arsenite evokes IL-6 secretion, autocrine regulation of STAT3 signaling, and miR-21 expression, processes involved in the EMT and malignant transformation of human bronchial epithelial cells.
other	hsa-mir-21	Carcinoma, Lung	27463381	disease of cellular proliferation	DOID:3905	C34.90	D008175			Chitin induced the expression of miR-155, miR-146a and miR-21, each of which is known to up-regulate the expression of pro-inflammatory cytokines.
other	hsa-mir-21	Carcinoma, Lung	28283413	disease of cellular proliferation	DOID:3905	C34.90	D008175			Solasodine inhibits invasion of human lung cancer cell through downregulation of miR-21 and MMPs expression.
other	hsa-mir-21	Carcinoma, Lung	28705115	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact.
other	hsa-mir-214	Carcinoma, Lung	27642589	disease of cellular proliferation	DOID:3905	C34.90	D008175			cir-ITCH acted as sponge of oncogenic miR-7 and miR-214 to enhance ITCH expression and thus suppressed the activation of Wnt/β-catenin signaling
other	hsa-mir-222	Carcinoma, Lung	27566197	disease of cellular proliferation	DOID:3905	C34.90	D008175			Panax notoginseng saponins attenuate lung cancer growth in part through modulating the level of Met/miR-222 axis.
other	hsa-mir-223	Carcinoma, Lung	28281961	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-223 Promotes Tumor Progression in Lung Cancer A549 Cells via Activation of the NF-κB Signaling Pathway.
other	hsa-mir-30a	Carcinoma, Lung	28400205	disease of cellular proliferation	DOID:3905	C34.90	D008175			Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles.
other	hsa-mir-31	Carcinoma, Lung	27541266	disease of cellular proliferation	DOID:3905	C34.90	D008175			Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling.
other	hsa-mir-34	Carcinoma, Lung	28705115	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact.
other	hsa-mir-495	Carcinoma, Lung	25286762	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-495 mimics delivery inhibits lung tumor progression.
other	hsa-mir-558	Carcinoma, Lung	27485693	disease of cellular proliferation	DOID:3905	C34.90	D008175			By contrast, in the cells exposed to 4, 6 or 8 Gy, the administration of miR鈥?58 mimics or AATK specific siRNA significantly promoted cell survival rate and overexpression of AATK reversed this effect.
other	hsa-mir-616	Carcinoma, Lung	27890917	disease of cellular proliferation	DOID:3905	C34.90	D008175			Sulforaphane suppresses EMT and metastasis in human lung cancer through miR-616-5p-mediated GSK3β/β-catenin signaling pathways.
other	hsa-mir-7	Carcinoma, Lung	27642589	disease of cellular proliferation	DOID:3905	C34.90	D008175			cir-ITCH acted as sponge of oncogenic miR-7 and miR-214 to enhance ITCH expression and thus suppressed the activation of Wnt/β-catenin signaling
other	hsa-let-7a	Carcinoma, Lung, Non-Small-Cell	23349018			C34.90	D002289		HP:0030358	Expression levels of hsa-let-7a (P = 0.005) and miR-16 (P = 0.003) miRNA were significantly higher in squamous cell carcinoma than in adenocarcinoma samples.
other	hsa-let-7c	Carcinoma, Lung, Non-Small-Cell	24400442			C34.90	D002289		HP:0030358	Modulation of let-7c altered the sensitivity of A549/DDP cells to DDP through regulating DDP-induced apopotis.
other	hsa-mir-1	Carcinoma, Lung, Non-Small-Cell	23617628			C34.90	D002289		HP:0030358	Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis.
other	hsa-mir-125a	Carcinoma, Lung, Non-Small-Cell	20719190			C34.90	D002289		HP:0030358	hsa-miR-125a-5p was poorly-expressed in lung cancer cells and it could enhance lung cancer cell invasion by up-regulating hsa-miR-125a-5p.
other	hsa-mir-143	Carcinoma, Lung, Non-Small-Cell	27602093			C34.90	D002289		HP:0030358	miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor.
other	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	28347234			C34.90	D002289		HP:0030358	Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data.
other	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	26780934			C34.90	D002289		HP:0030358	TP53 knockdown reduced the miRNA hsa-miR-145
other	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	29266356			C34.90	D002289		HP:0030358	Effect of microRNA-145 on proliferation and apoptosis of human non-small cell lung cancer A549 cells by regulating mTOR signaling pathway
other	hsa-mir-150	Carcinoma, Lung, Non-Small-Cell	23670238			C34.90	D002289		HP:0030358	These findings suggest that miR-150, p53 protein and relevant miRNAs are members of a regulatory network in NSCLC tumorigenesis.
other	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	21350005			C34.90	D002289		HP:0030358	Elevated miR-21 (HR 2.06, 1.13-3.75), miR-17 (HR 2.00, 1.10-3.61), and miR-155 (HR 2.37, 1.27-4.42) was associated with worse cancer-specific mortality in the Maryland cohort.
other	hsa-mir-15a	Carcinoma, Lung, Non-Small-Cell	19549910			C34.90	D002289		HP:0030358	miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer.
other	hsa-mir-15a	Carcinoma, Lung, Non-Small-Cell	26314859			C34.90	D002289		HP:0030358	We found that induced expression of hsa-miR-15a-3p via mimic transfection sensitised cisplatin-resistant cells to apoptosis and autophagy.
other	hsa-mir-16	Carcinoma, Lung, Non-Small-Cell	19549910			C34.90	D002289		HP:0030358	miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer.
other	hsa-mir-16	Carcinoma, Lung, Non-Small-Cell	23349018			C34.90	D002289		HP:0030358	Expression levels of hsa-let-7a (P = 0.005) and miR-16 (P = 0.003) miRNA were significantly higher in squamous cell carcinoma than in adenocarcinoma samples.
other	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	21350005			C34.90	D002289		HP:0030358	Elevated miR-21 (HR 2.06, 1.13-3.75), miR-17 (HR 2.00, 1.10-3.61), and miR-155 (HR 2.37, 1.27-4.42) was associated with worse cancer-specific mortality in the Maryland cohort.
other	hsa-mir-182	Carcinoma, Lung, Non-Small-Cell	27073334			C34.90	D002289		HP:0030358	MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin
other	hsa-mir-195	Carcinoma, Lung, Non-Small-Cell	28848163			C34.90	D002289		HP:0030358	Knockdown of Lncrna PVT1 Enhances Radiosensitivity in Non-Small Cell Lung Cancer by Sponging Mir-195.
other	hsa-mir-200a	Carcinoma, Lung, Non-Small-Cell	23708087			C34.90	D002289		HP:0030358	The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells.
other	hsa-mir-200a	Carcinoma, Lung, Non-Small-Cell	27396618			C34.90	D002289		HP:0030358	we show that down-regulating Zeb-1 by inducing miR-200a or 尾-Catenin siRNA can increase drug sensitivity of TKI-resistant cells.
other	hsa-mir-200b	Carcinoma, Lung, Non-Small-Cell	23708087			C34.90	D002289		HP:0030358	The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells.
other	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	21263248			C34.90	D002289		HP:0030358	In conclusion, the relative quantification of miR-205 and miR-21 seems to be a promising diagnostic tool
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	21263248			C34.90	D002289		HP:0030358	In conclusion, the relative quantification of miR-205 and miR-21 seems to be a promising diagnostic tool
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	21350005			C34.90	D002289		HP:0030358	Elevated miR-21 (HR 2.06, 1.13-3.75), miR-17 (HR 2.00, 1.10-3.61), and miR-155 (HR 2.37, 1.27-4.42) was associated with worse cancer-specific mortality in the Maryland cohort.
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	28096685			C34.90	D002289		HP:0030358	The role of microRNA-21 in predicting brain metastases from non-small cell lung cancer.
other	hsa-mir-216b	Carcinoma, Lung, Non-Small-Cell	26852748			C34.90	D002289		HP:0030358	microRNA (miR)-216b levels were significantly downregulated in paclitaxel-treated NSCLC cells.
other	hsa-mir-224	Carcinoma, Lung, Non-Small-Cell	29387235			C34.90	D002289		HP:0030358	Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy
other	hsa-mir-29b	Carcinoma, Lung, Non-Small-Cell	27199349			C34.90	D002289		HP:0030358	Overall, our results reveal  a complexity in cancer for miR-29b, which can act as either an oncogene or tumor  suppressor gene depending on signaling context.
other	hsa-mir-29b	Carcinoma, Lung, Non-Small-Cell	26776158			C34.90	D002289		HP:0030358	knockdown of ETS1 led to upregulation of eight microRNAs and downregulation of miR-29b in the immune-evasion subtype.
other	hsa-mir-29b	Carcinoma, Lung, Non-Small-Cell	27555773			C34.90	D002289		HP:0030358	Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins.
other	hsa-mir-30a	Carcinoma, Lung, Non-Small-Cell	28158983			C34.90	D002289		HP:0030358	CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer.
other	hsa-mir-342	Carcinoma, Lung, Non-Small-Cell	29387235			C34.90	D002289		HP:0030358	Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy
other	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	29387235			C34.90	D002289		HP:0030358	Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy
other	hsa-mir-361	Carcinoma, Lung, Non-Small-Cell	27779659			C34.90	D002289		HP:0030358	microRNA-361 targets Wilms' tumor 1 to inhibit the growth, migration and invasion of non-small-cell lung cancer cells.
other	hsa-mir-361	Carcinoma, Lung, Non-Small-Cell	28051257			C34.90	D002289		HP:0030358	Downregulation of miR-361-5p associates with aggressive clinicopathological features and unfavorable prognosis in non-small cell lung cancer.
other	hsa-mir-378	Carcinoma, Lung, Non-Small-Cell	23617628			C34.90	D002289		HP:0030358	Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis.
other	hsa-mir-381	Carcinoma, Lung, Non-Small-Cell	26640150			C34.90	D002289		HP:0030358	ADAR1 overexpression enhances the editing frequencies of  target transcripts such as NEIL1 and miR-381.
other	hsa-mir-383	Carcinoma, Lung, Non-Small-Cell	27551765			C34.90	D002289		HP:0030358	MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner.
other	hsa-mir-424	Carcinoma, Lung, Non-Small-Cell	27666545			C34.90	D002289		HP:0030358	Effects of miR-424 on Proliferation and Migration Abilities in Non-small Cell Lung Cancer A549 Cells and Its Molecular Mechanism.
other	hsa-mir-519d	Carcinoma, Lung, Non-Small-Cell	27447710			C34.90	D002289		HP:0030358	The aim of the study was to evaluate the expression levels of selected miRNAs: miR-26a, miR-29b and miR-519d, and their target gene, matrix metalloproteinase-2  (MMP-2) in patients with non-small cell lung cancer (NSCLC).
other	hsa-mir-635	Carcinoma, Lung, Non-Small-Cell	27810784			C34.90	D002289		HP:0030358	The microRNA-635 suppresses tumorigenesis in non-small cell lung cancer.
other	hsa-mir-661	Carcinoma, Lung, Non-Small-Cell	28716024			C34.90	D002289		HP:0030358	MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer
other	hsa-mir-7	Carcinoma, Lung, Non-Small-Cell	28229971			C34.90	D002289		HP:0030358	Breviscapine suppresses the growth of non-small cell lung cancer by enhancing microRNA-7 expression.
other	hsa-mir-7	Carcinoma, Lung, Non-Small-Cell	25289099			C34.90	D002289		HP:0030358	Upregulation of miR-7 enhanced the PTX-sensitivity of NSCLC  cells by suppressing cell proliferation and promoting cell apoptosis
other	hsa-mir-7	Carcinoma, Lung, Non-Small-Cell	26557760			C34.90	D002289		HP:0030358	We found that miR-7 significantly decreased the IC50 of gefitinib and inhibited cell growth
other	hsa-mir-92a	Carcinoma, Lung, Non-Small-Cell	28534966			C34.90	D002289		HP:0030358	MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
other	hsa-mir-92b	Carcinoma, Lung, Non-Small-Cell	27775799			C34.90	D002289		HP:0030358	Regulation of Twist in the metastasis of non-small cell lung cancer by miR-92b.
other	hsa-mir-9501	Carcinoma, Lung, Non-Small-Cell	27734264			C34.90	D002289		HP:0030358	The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer.
other	hsa-mir-96	Carcinoma, Lung, Non-Small-Cell	28656287			C34.90	D002289		HP:0030358	Identification and characterization of miR-96, a potential biomarker of NSCLC, through bioinformatic analysis.
other	hsa-let-7	Carcinoma, Lung, Non-Small-Cell	25714397			C34.90	D002289		HP:0030358	Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.
other	hsa-let-7g	Carcinoma, Lung, Non-Small-Cell	23820752			C34.90	D002289		HP:0030358	Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features
other	hsa-mir-101-1	Carcinoma, Lung, Non-Small-Cell	22014955			C34.90	D002289		HP:0030358	The endogenous miR-101 level was similar or lower in 13 NSCLC cell lines but was 11-fold higher in one cell line (H157) than in NL20 cells. Although ectopic miR-101 efficiently decreased the ATM and DNA-PKcs levels and increased the radiosensitization level in H1299, H1975, and A549 cells, it did not change the levels of the miR-101 targets or radiosensitivity in H157 cells.
other	hsa-mir-101-2	Carcinoma, Lung, Non-Small-Cell	22014955			C34.90	D002289		HP:0030358	The endogenous miR-101 level was similar or lower in 13 NSCLC cell lines but was 11-fold higher in one cell line (H157) than in NL20 cells. Although ectopic miR-101 efficiently decreased the ATM and DNA-PKcs levels and increased the radiosensitization level in H1299, H1975, and A549 cells, it did not change the levels of the miR-101 targets or radiosensitivity in H157 cells.
other	hsa-mir-106a	Carcinoma, Lung, Non-Small-Cell	22295063			C34.90	D002289		HP:0030358	The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001).
other	hsa-mir-10b	Carcinoma, Lung, Non-Small-Cell	25988292			C34.90	D002289		HP:0030358	microRNA miR-10b inhibition reduces cell proliferation and promotes apoptosis in non-small cell lung cancer (NSCLC) cells.
other	hsa-mir-10b	Carcinoma, Lung, Non-Small-Cell	24198203			C34.90	D002289		HP:0030358	microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
other	hsa-mir-1-1	Carcinoma, Lung, Non-Small-Cell	20194856			C34.90	D002289		HP:0030358	significantly associated with overal survival
other	hsa-mir-1-2	Carcinoma, Lung, Non-Small-Cell	20194856			C34.90	D002289		HP:0030358	significantly associated with overal survival
other	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	25641933			C34.90	D002289		HP:0030358	Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells.
other	hsa-mir-222	Carcinoma, Lung, Non-Small-Cell	25641933			C34.90	D002289		HP:0030358	Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells.
other	hsa-mir-122	Carcinoma, Lung, Non-Small-Cell	26389880			C34.90	D002289		HP:0030358	These results indicate that miR-122 would be a novel strategy for NSCLC radiation-therapy.
other	hsa-mir-124-1	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-1246	Carcinoma, Lung, Non-Small-Cell	26711929			C34.90	D002289		HP:0030358	Anti-miR-1246 and anti-miR-1290 suppressed proliferation, sphere-formation, colony formation and invasion of NSCLC.CSCs-associated miR-1246, or miR-1290 may be important in the invasion or metastasis of NSCLC.
other	hsa-mir-125b	Carcinoma, Lung, Non-Small-Cell	25772251			C34.90	D002289		HP:0030358	Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer.
other	hsa-mir-125b-1	Carcinoma, Lung, Non-Small-Cell	23718732			C34.90	D002289		HP:0030358	MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b.
other	hsa-mir-125b-2	Carcinoma, Lung, Non-Small-Cell	23718732			C34.90	D002289		HP:0030358	MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b.
other	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	22295063			C34.90	D002289		HP:0030358	The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001).
other	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	22900072			C34.90	D002289		HP:0030358	MicroRNA-126 Inhibits Tumor Cell Growth and Its Expression Level Correlates with Poor Survival in Non-Small Cell Lung Cancer Patients.
other	hsa-mir-1290	Carcinoma, Lung, Non-Small-Cell	26711929			C34.90	D002289		HP:0030358	Anti-miR-1246 and anti-miR-1290 suppressed proliferation, sphere-formation, colony formation and invasion of NSCLC.CSCs-associated miR-1246, or miR-1290 may be important in the invasion or metastasis of NSCLC.
other	hsa-mir-1290	Carcinoma, Lung, Non-Small-Cell	25016979			C34.90	D002289		HP:0030358	miR-1290 suppresses cell viability and cell cycle progression. These data provide insight into miR-1290-mediated cellular mechanisms in asiatic acid-treated A549 non-small cell lung carcinoma cells.
other	hsa-mir-133a	Carcinoma, Lung, Non-Small-Cell	24816813			C34.90	D002289		HP:0030358	MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma.
other	hsa-mir-135a-1	Carcinoma, Lung, Non-Small-Cell	21552288			C34.90	D002289		HP:0030358	miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.
other	hsa-mir-135a-1	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-135a-2	Carcinoma, Lung, Non-Small-Cell	21552288			C34.90	D002289		HP:0030358	miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.
other	hsa-mir-135a-2	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-135b	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-136	Carcinoma, Lung, Non-Small-Cell	23959478			C34.90	D002289		HP:0030358	miR-146a-5p circuitry uncouples cell proliferation and migration, but not differentiation, in human mesenchymal stem cells.
other	hsa-mir-138-1	Carcinoma, Lung, Non-Small-Cell	21787234			C34.90	D002289		HP:0030358	miR-138 could play an important role in the development of cisplatin resistance in non-small cell lung cancer (NSCLC)
other	hsa-mir-138-2	Carcinoma, Lung, Non-Small-Cell	21787234			C34.90	D002289		HP:0030358	miR-138 could play an important role in the development of cisplatin resistance in non-small cell lung cancer (NSCLC)
other	hsa-mir-144	Carcinoma, Lung, Non-Small-Cell	24066116			C34.90	D002289		HP:0030358	Our results for the first time showed mir-144-ZFX pathway is involved in the development of NSCLC, which sheds a light for further investigations on underlying mechanisms toward better understanding and management of NSCLC.
other	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	22331473			C34.90	D002289		HP:0030358	miR-145* inhibits cell invasion and metastasis, and is associated with brain metastasis.
other	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	25661374			C34.90	D002289		HP:0030358	Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer.
other	hsa-mir-148a	Carcinoma, Lung, Non-Small-Cell	23843100			C34.90	D002289		HP:0030358	Decreased miRNA-148a is associated with lymph node metastasis and poor clinical outcomes and functions as a suppressor of tumor metastasis in non-small cell lung cancer.
other	hsa-mir-148b	Carcinoma, Lung, Non-Small-Cell	26377406			C34.90	D002289		HP:0030358	Our findings demonstrated that miR-148b may play a role as independent prognostic factor for patients with NSCLC.
other	hsa-mir-149	Carcinoma, Lung, Non-Small-Cell	24007627			C34.90	D002289		HP:0030358	A two miRNA signature (miR-149 and miR-375) was found predictive for response and was also associated to progression-free survival (p = 0.05).
other	hsa-mir-152	Carcinoma, Lung, Non-Small-Cell	25190353			C34.90	D002289		HP:0030358	MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2.
other	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	21219656			C34.90	D002289		HP:0030358	The prognostic impact of miR-155 depends on histological subtype and nodal status in NSCLC.
other	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	22295063			C34.90	D002289		HP:0030358	The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001).
other	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	26322518			C34.90	D002289		HP:0030358	These results suggest that miR-155 expression is not significantly related to non-small cell lung cancer patients except in patients from Asian and America.
other	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	23817461			C34.90	D002289		HP:0030358	This meta-analysis provides evidence that miR-21 and miR-155 are predicting factors for non-small-cell lung cancer prognosis and lymphoid infiltration.
other	hsa-mir-15a	Carcinoma, Lung, Non-Small-Cell	21575235			C34.90	D002289		HP:0030358	miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.
other	hsa-mir-16-1	Carcinoma, Lung, Non-Small-Cell	21575235			C34.90	D002289		HP:0030358	miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.
other	hsa-mir-16-2	Carcinoma, Lung, Non-Small-Cell	21575235			C34.90	D002289		HP:0030358	miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.
other	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	24200043			C34.90	D002289		HP:0030358	This work will provide a framework for constructing miRNA-TF synergistic regulatory networks, function analysis in diseases, and identification of the main regulators and regulatory motifs, which will be useful for understanding the putative regulatory motifs involving miRNAs and TFs, and for predicting new targets for cancer studies.
other	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	26482648			C34.90	D002289		HP:0030358	Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC.
other	hsa-mir-182	Carcinoma, Lung, Non-Small-Cell	22295063			C34.90	D002289		HP:0030358	The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001).
other	hsa-mir-186	Carcinoma, Lung, Non-Small-Cell	23671127			C34.90	D002289		HP:0030358	PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186.
other	hsa-mir-18a	Carcinoma, Lung, Non-Small-Cell	25755757			C34.90	D002289		HP:0030358	Effect of miR-18a overexpression on the radiosensitivity of non-small cell lung cancer.
other	hsa-mir-193b	Carcinoma, Lung, Non-Small-Cell	22491710			C34.90	D002289		HP:0030358	MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells.
other	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	22045191			C34.90	D002289		HP:0030358	Ectopic expression of mir-200c alters expression of EMT proteins, sensitivity to erlotinib, and migration in lung cells.
other	hsa-mir-203	Carcinoma, Lung, Non-Small-Cell	26683818			C34.90	D002289		HP:0030358	Our results suggest that LASP-1, mediated by miR-203,has crucial functions in the proliferation, migration and invasion of NSCLC.
other	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	26311306			C34.90	D002289		HP:0030358	Validation for histology-driven diagnosis in non-small cell lung cancer using hsa-miR-205 and hsa-miR-21 expression by two different normalization strategies.
other	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	26001154			C34.90	D002289		HP:0030358	the MiR-205 can also increase in the case with severe inflammation and benign tumor.3 The possibility of false-positive because of noncancerous lesion has to be further studied.
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	20832755			C34.90	D002289		HP:0030358	miR-21:Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	22237007			C34.90	D002289		HP:0030358	Increased miR-21 expression significantly increased the resistance of A549 cell to platinum, whereas reduced miR-21 decreased the resistance of A549/CDDP cell.
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	22295063			C34.90	D002289		HP:0030358	The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001).
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23820752			C34.90	D002289		HP:0030358	Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	24452750			C34.90	D002289		HP:0030358	Expression of microRNA-21 in non-small cell lung cancer tissue increases with disease progression and is likely caused by growth conditional changes during malignant transformation.
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	26311306			C34.90	D002289		HP:0030358	Validation for histology-driven diagnosis in non-small cell lung cancer using hsa-miR-205 and hsa-miR-21 expression by two different normalization strategies.
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	26453197			C34.90	D002289		HP:0030358	Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23817461			C34.90	D002289		HP:0030358	This meta-analysis provides evidence that miR-21 and miR-155 are predicting factors for non-small-cell lung cancer prognosis and lymphoid infiltration.
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	24198203			C34.90	D002289		HP:0030358	microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
other	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	24906642			C34.90	D002289		HP:0030358	Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
other	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	22295063			C34.90	D002289		HP:0030358	The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001).
other	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	24305009			C34.90	D002289		HP:0030358	We show that miR-210 in stromal cells, and co-expressed in cancer cells and stromal cells mediates an independent prognostic impact. It is a candidate marker for prognostic stratification in NSCLC.
other	hsa-mir-214	Carcinoma, Lung, Non-Small-Cell	22502680			C34.90	D002289		HP:0030358	MicroRNA-214 Regulates the Acquired Resistance to Gefitinib via the PTEN/AKT Pathway in EGFR-mutant Cell Lines.
other	hsa-mir-222	Carcinoma, Lung, Non-Small-Cell	24955421			C34.90	D002289		HP:0030358	MicroRNA-222 expression and its prognostic potential in non-small cell lung cancer.
other	hsa-mir-23a	Carcinoma, Lung, Non-Small-Cell	24898878			C34.90	D002289		HP:0030358	There is an interaction between miR-23a and IRS-1 in the modulation  of the migration and invasion of NSCLC cells. IRS-1 is variably expressed in NSCLC patients and correlates with NSCLC patient survival.
other	hsa-mir-27a	Carcinoma, Lung, Non-Small-Cell	25773791			C34.90	D002289		HP:0030358	Rs895819 within miR-27a might be involved in development of non small cell lung cancer in the Chinese Han population.
other	hsa-mir-29b-1	Carcinoma, Lung, Non-Small-Cell	22399498			C34.90	D002289		HP:0030358	increased after necitumumab in combination with cisplatin/gemcitabine
other	hsa-mir-29b-2	Carcinoma, Lung, Non-Small-Cell	22399498			C34.90	D002289		HP:0030358	increased after necitumumab in combination with cisplatin/gemcitabine
other	hsa-mir-30b	Carcinoma, Lung, Non-Small-Cell	24286402			C34.90	D002289		HP:0030358	Our study identified miR-30b and miR-30c as useful prognostic predictors in NSCLC patients who underwent first line treatment with TKIs.
other	hsa-mir-30c	Carcinoma, Lung, Non-Small-Cell	24286402			C34.90	D002289		HP:0030358	Our study identified miR-30b and miR-30c as useful prognostic predictors in NSCLC patients who underwent first line treatment with TKIs.
other	hsa-mir-30d	Carcinoma, Lung, Non-Small-Cell	20194856			C34.90	D002289		HP:0030358	significantly associated with overal survival
other	hsa-mir-3127	Carcinoma, Lung, Non-Small-Cell	25284075			C34.90	D002289		HP:0030358	Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.
other	hsa-mir-328	Carcinoma, Lung, Non-Small-Cell	21448905			C34.90	D002289		HP:0030358	MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration.
other	hsa-mir-34	Carcinoma, Lung, Non-Small-Cell	25714397			C34.90	D002289		HP:0030358	Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.
other	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	21575235			C34.90	D002289		HP:0030358	miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.
other	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	24595209			C34.90	D002289		HP:0030358	The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells.
other	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	26406332			C34.90	D002289		HP:0030358	Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells.
other	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	24444609			C34.90	D002289		HP:0030358	Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells.
other	hsa-mir-3619	Carcinoma, Lung, Non-Small-Cell	26512718			C34.90	D002289		HP:0030358	Our data demonstrate a previously unappreciated role for miR-3619-5p,in suppression of β-catenin-mediated cancer growth and invasion in NSCLC cells,and highlight miR-3619-5p as a novel cancer suppressor in NSCLC.
other	hsa-mir-375	Carcinoma, Lung, Non-Small-Cell	24404590			C34.90	D002289		HP:0030358	Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer.
other	hsa-mir-378a	Carcinoma, Lung, Non-Small-Cell	22052152			C34.90	D002289		HP:0030358	MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis.
other	hsa-mir-424	Carcinoma, Lung, Non-Small-Cell	22295063			C34.90	D002289		HP:0030358	The significantly altered angiogenesis-related miRs of high interest were miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424. miR-155 correlated significantly with fibroblast growth factor 2 (FGF2) in the total cohort (r=0.17, P=0.002), though most prominent in the subgroup with nodal metastasis (r=0.34, P<0.001).
other	hsa-mir-449a	Carcinoma, Lung, Non-Small-Cell	25424357			C34.90	D002289		HP:0030358	The tumor suppression role of microRNA-449a could be due to its promotion of tumor cell proliferation and its inhibition of tumor cell apoptosis.
other	hsa-mir-451a	Carcinoma, Lung, Non-Small-Cell	21329503			C34.90	D002289		HP:0030358	Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549).
other	hsa-mir-485	Carcinoma, Lung, Non-Small-Cell	23734217			C34.90	D002289		HP:0030358	hsa-mir-485 Prostatic Neoplasms Prostatic Neoplasms Cytotoxic treatment of DU-145 cells enhanced the release of PCS-miRNAs with the exception of miR-485-3p which was retained by surviving cells.
other	hsa-mir-486	Carcinoma, Lung, Non-Small-Cell	20194856			C34.90	D002289		HP:0030358	significantly associated with overal survival
other	hsa-mir-494	Carcinoma, Lung, Non-Small-Cell	25861022			C34.90	D002289		HP:0030358	Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer.
other	hsa-mir-495	Carcinoma, Lung, Non-Small-Cell	24038379			C34.90	D002289		HP:0030358	miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
other	hsa-mir-497	Carcinoma, Lung, Non-Small-Cell	26485685			C34.90	D002289		HP:0030358	Together, our data demonstrate a previously unappreciated role for miR-497 in suppression of VEGF-A-mediated NSCLC cancer cell growth and invasion.
other	hsa-mir-499a	Carcinoma, Lung, Non-Small-Cell	20194856			C34.90	D002289		HP:0030358	significantly associated with overal survival
other	hsa-mir-512	Carcinoma, Lung, Non-Small-Cell	25687035			C34.90	D002289		HP:0030358	Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer.
other	hsa-mir-520a	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-520b	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-520c	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-520d	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-520e	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation.
other	hsa-mir-570	Carcinoma, Lung, Non-Small-Cell	24200043			C34.90	D002289		HP:0030358	This work will provide a framework for constructing miRNA-TF synergistic regulatory networks, function analysis in diseases, and identification of the main regulators and regulatory motifs, which will be useful for understanding the putative regulatory motifs involving miRNAs and TFs, and for predicting new targets for cancer studies.
other	hsa-mir-590	Carcinoma, Lung, Non-Small-Cell	24200043			C34.90	D002289		HP:0030358	This work will provide a framework for constructing miRNA-TF synergistic regulatory networks, function analysis in diseases, and identification of the main regulators and regulatory motifs, which will be useful for understanding the putative regulatory motifs involving miRNAs and TFs, and for predicting new targets for cancer studies.
other	hsa-mir-92a	Carcinoma, Lung, Non-Small-Cell	26482648			C34.90	D002289		HP:0030358	Our study indicates that miR-17 and miR-92 families play important roles in cisplatin resistance and can be used as potential biomarkers for better predicting the clinical response to platinum-based chemotherapy in NSCLC.
other	hsa-mir-92b	Carcinoma, Lung, Non-Small-Cell	24099768			C34.90	D002289		HP:0030358	The miR-92b play an oncogene roles by regulatescell growth, cisplatin chemosensitivity phenotype, and could serve as a novel potential maker for NSCLC therapy.
other	hsa-mir-99a	Carcinoma, Lung, Non-Small-Cell	25046358			C34.90	D002289		HP:0030358	A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling.
other	hsa-mir-26a	Carcinoma, Lung, Small-Cell	27644194			C34.90	D055752	182280	HP:0030357	KH-type splicing regulatory protein (KHSRP) contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancer.
other	hsa-mir-29a	Carcinoma, Lung, Small-Cell	23043084			C34.90	D055752	182280	HP:0030357	Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens.
other	hsa-mir-375	Carcinoma, Lung, Small-Cell	23043084			C34.90	D055752	182280	HP:0030357	Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens.
other	hsa-mir-375	Carcinoma, Merkel Cell	26877261	disease of cellular proliferation	DOID:3965	C4A.9	D015266		HP:0030447	Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel Cell Carcinoma.
other	hsa-mir-10b	Carcinoma, Nasopharyngeal	24175854	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-10b promotes migration and invasion in nasopharyngeal carcinoma cells.
other	hsa-mir-1204	Carcinoma, Nasopharyngeal	25756509	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo.
other	hsa-mir-125a	Carcinoma, Nasopharyngeal	24896104	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Curcumin exerts inhibitory effects on undifferentiated nasopharyngeal carcinoma by inhibiting the expression of miR-125a-5p.
other	hsa-mir-141	Carcinoma, Nasopharyngeal	20053927	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	We propose that miR-141- and tumor-related genes c-MYC, SPLUNC1, BRD3, UBAP1 and PTEN may constitute a gene-miRNA network to contribute to NPC development.
other	hsa-mir-142	Carcinoma, Nasopharyngeal	26183850	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-142-3p Suppresses SOCS6 Expression and Promotes Cell Proliferation in Nasopharyngeal Carcinoma.
other	hsa-mir-143	Carcinoma, Nasopharyngeal	25701793	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Identification of miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling.
other	hsa-mir-146a	Carcinoma, Nasopharyngeal	24430575	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Association of miR-146a gene polymorphism with risk of nasopharyngeal carcinoma in the central-southern Chinese population.
other	hsa-mir-152	Carcinoma, Nasopharyngeal	26135619	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our findings provide new insights into the metastasis of NPC regulated by EBV and advocate for developing clinical intervention strategies against NPC.
other	hsa-mir-152	Carcinoma, Nasopharyngeal	27840403	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA-152 Targets Phosphatase and Tensin Homolog to Inhibit Apoptosis and Promote Cell Migration of Nasopharyngeal Carcinoma Cells.
other	hsa-mir-155	Carcinoma, Nasopharyngeal	24241359	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-155 up-regulation by LMP1 DNA contributes to increased nasopharyngeal carcinoma cell proliferation and migration.
other	hsa-mir-195	Carcinoma, Nasopharyngeal	26135619	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our findings provide new insights into the metastasis of NPC regulated by EBV and advocate for developing clinical intervention strategies against NPC.
other	hsa-mir-200a	Carcinoma, Nasopharyngeal	20826811	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our findings reveal for the first time the function of miR-200a in shifting nasopharyngeal carcinoma cell states via a reversible process coined as epithelial-mesenchymal to stem-like transition through differential and specific mechanisms.
other	hsa-mir-203	Carcinoma, Nasopharyngeal	27589832	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	A directly negative interaction of miR-203 and ZEB2 modulates tumor stemness and chemotherapy resistance in nasopharyngeal carcinoma.
other	hsa-mir-204	Carcinoma, Nasopharyngeal	25752113	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Clinical significance of miRNA-204 in nasopharyngeal carcinoma.
other	hsa-mir-21	Carcinoma, Nasopharyngeal	26568302	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	LMP1 greatly increased expression of miR-21 and downregulated expression of the miR-21 target
other	hsa-mir-31	Carcinoma, Nasopharyngeal	28042945	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Minicircle-oriP-miR-31 as a Novel EBNA1-Specific miRNA Therapy Approach for Nasopharyngeal Carcinoma.
other	hsa-mir-324	Carcinoma, Nasopharyngeal	25735100	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	The loss of miRNA-324-3p and ectopic WNT2B might co-induce the initiation and progression of NPC.
other	hsa-mir-34a	Carcinoma, Nasopharyngeal	25231528	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Hypofractionated radiotherapy induces miR-34a expression and enhances apoptosis in human nasopharyngeal carcinoma cells.
other	hsa-mir-34c	Carcinoma, Nasopharyngeal	26795575	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our study presents the current knowledge of miRNA regulatory network in NPC with combination of bioinformatics analysis and literature research. The hypothesis of miR-34c regulatory pathway may be beneficial in guiding further studies on the molecular mechanism of NPC tumorigenesis.
other	hsa-mir-494	Carcinoma, Nasopharyngeal	25809707	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma.
other	hsa-mir-744	Carcinoma, Nasopharyngeal	25961434	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-744 functions as a proto-oncogene in nasopharyngeal carcinoma progression and metastasis via transcriptional control of ARHGAP5.
other	hsa-mir-25	Carcinoma, Neuroendocrine	25512615	disease of cellular proliferation	DOID:1800	C7A	D018278		HP:0100634	The pathogenesis of prostatic SCNC involves a p53 and Aurora Kinase A signaling mechanism, both potentially targetable pathways.
other	hsa-mir-124	Carcinoma, Oral	28077301	gastrointestinal system disease	DOID:0050610					MiR-124 down-regulation is critical for cancer associated fibroblasts-enhanced tumor growth of oral carcinoma.
other	hsa-mir-21	Carcinoma, Oral	22249446	gastrointestinal system disease	DOID:0050610					miR-21 inhibitor sensitizes human OSCC(oral squamous cell carcinoma) cells to cisplatin.
other	hsa-mir-21	Carcinoma, Oral	22761427	gastrointestinal system disease	DOID:0050610					Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer.
other	hsa-mir-27a	Carcinoma, Oral	23472065	gastrointestinal system disease	DOID:0050610					Primary Microcephaly Gene MCPH1 Shows Signatures of Tumor Suppressors and Is Regulated by miR-27a in Oral Squamous Cell Carcinoma
other	hsa-mir-7-1	Carcinoma, Oral	22761427	gastrointestinal system disease	DOID:0050610					Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer.
other	hsa-mir-7-2	Carcinoma, Oral	22761427	gastrointestinal system disease	DOID:0050610					Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer.
other	hsa-mir-7-3	Carcinoma, Oral	22761427	gastrointestinal system disease	DOID:0050610					Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) in Oral Cancer.
other	hsa-let-7a	Carcinoma, Ovarian	27419385	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
other	hsa-mir-100	Carcinoma, Ovarian	27748936	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
other	hsa-mir-101	Carcinoma, Ovarian	28601063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role
other	hsa-mir-103a	Carcinoma, Ovarian	27419385	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
other	hsa-mir-122	Carcinoma, Ovarian	25195148	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A polymorphism at miRNA-122-binding site in the IL-1α 3'UTR is associated with risk of epithelial ovarian cancer.
other	hsa-mir-1284	Carcinoma, Ovarian	28281963	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA-1284 Inhibits Cell Viability and Induces Apoptosis of Ovarian Cancer Cell Line OVCAR3.
other	hsa-mir-130a	Carcinoma, Ovarian	26043084	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
other	hsa-mir-132	Carcinoma, Ovarian	27673409	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA and long non-coding RNA have potential clinical utility in the diagnosis of ovarian cancer and predicting prognosis, metastasis, recurrence, and response to therapy
other	hsa-mir-137	Carcinoma, Ovarian	25955305	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA-137 suppresses tumor growth in epithelial ovarian cancer in vitro and in vivo.
other	hsa-mir-145	Carcinoma, Ovarian	28601063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role
other	hsa-mir-16	Carcinoma, Ovarian	28067383	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The functional consequences and prognostic value of dosage sensitivity in ovarian cancer.
other	hsa-mir-16	Carcinoma, Ovarian	27419385	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
other	hsa-mir-182	Carcinoma, Ovarian	27748882	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Downregulation of DNMT3a expression increases miR-182-induced apoptosis of ovarian cancer through caspase-3 and caspase-9-mediated apoptosis and DNA damage response.
other	hsa-mir-191	Carcinoma, Ovarian	27419385	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
other	hsa-mir-196a	Carcinoma, Ovarian	26097603	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	In conclusion, miR-196a may play an important role in the progression of ovarian carcinoma, and could be used as an independent prognostic biomarker for patients with ovarian carcinoma.
other	hsa-mir-199a	Carcinoma, Ovarian	25839163	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
other	hsa-mir-200	Carcinoma, Ovarian	26213923	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer.
other	hsa-mir-200	Carcinoma, Ovarian	28245631	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer.
other	hsa-mir-200	Carcinoma, Ovarian	28601063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role
other	hsa-mir-203	Carcinoma, Ovarian	27655286	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway.
other	hsa-mir-21	Carcinoma, Ovarian	27840916	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA‑21 and the suppression of the PI3K/Akt‑NF‑κB signaling pathway in an in vitro model of ovarian carcinoma.
other	hsa-mir-210	Carcinoma, Ovarian	24715221	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis.
other	hsa-mir-214	Carcinoma, Ovarian	28175963	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer.
other	hsa-mir-214	Carcinoma, Ovarian	28601063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role
other	hsa-mir-23b	Carcinoma, Ovarian	28245631	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer.
other	hsa-mir-25	Carcinoma, Ovarian	28601063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role
other	hsa-mir-26a	Carcinoma, Ovarian	27673409	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA and long non-coding RNA have potential clinical utility in the diagnosis of ovarian cancer and predicting prognosis, metastasis, recurrence, and response to therapy
other	hsa-mir-29b	Carcinoma, Ovarian	24767251	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma.
other	hsa-mir-29b	Carcinoma, Ovarian	27832631	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A Double-Negative Feedback Interaction between MicroRNA-29b and DNMT3A/3B Contributes to Ovarian Cancer Progression.
other	hsa-mir-30a	Carcinoma, Ovarian	28222434	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells.
other	hsa-mir-30c	Carcinoma, Ovarian	28222434	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells.
other	hsa-mir-31	Carcinoma, Ovarian	28601063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role
other	hsa-mir-335	Carcinoma, Ovarian	24515774	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Our results indicate that miR-335 relates to the prognosis of patients with EOC and is a promising predictor of EOC recurrence.
other	hsa-mir-34b	Carcinoma, Ovarian	17823410	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Importantly, miR-34b and miR-34c cooperate in suppressing proliferation and soft-agar colony formation of neoplastic epithelial ovarian cells, in agreement with the partially overlapping spectrum of their predicted targets.
other	hsa-mir-34c	Carcinoma, Ovarian	17823410	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Importantly, miR-34b and miR-34c cooperate in suppressing proliferation and soft-agar colony formation of neoplastic epithelial ovarian cells, in agreement with the partially overlapping spectrum of their predicted targets.
other	hsa-mir-372	Carcinoma, Ovarian	28456593	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The role of miR-372 in ovarian carcinoma cell proliferation.
other	hsa-mir-374a	Carcinoma, Ovarian	26043084	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
other	hsa-mir-376a	Carcinoma, Ovarian	27979415	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-376a promotion of proliferation and metastases in ovarian cancer
other	hsa-mir-383	Carcinoma, Ovarian	27567588	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Inhibition of microRNA-383 has tumor suppressive effect in human epithelial ovarian cancer through the action on caspase-2 gene.
other	hsa-mir-423	Carcinoma, Ovarian	27419385	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
other	hsa-mir-483	Carcinoma, Ovarian	27554045	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.
other	hsa-mir-491	Carcinoma, Ovarian	25299770	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.
other	hsa-mir-506	Carcinoma, Ovarian	28601063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Clusters of microRNAs (miR-145, miR-31, miR-506, miR-101) most essential for metastasis of ovarian cancer including the families of microRNAs (miR-200, miR-214, miR-25) with dual role
other	hsa-mir-519d	Carcinoma, Ovarian	28146423	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C.
other	hsa-mir-551a	Carcinoma, Ovarian	28345465	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growth via up-regulating miR-551a.
other	hsa-mir-6126	Carcinoma, Ovarian	27742688	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
other	hsa-mir-7	Carcinoma, Ovarian	28216373	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA.
other	hsa-mir-9	Carcinoma, Ovarian	25846738	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
other	hsa-mir-92a	Carcinoma, Ovarian	27419385	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
other	hsa-mir-93	Carcinoma, Ovarian	26087719	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The results suggested that berberine modulated the sensitivity of cisplatin through miR-93/PTEN/AKT signaling pathway in the ovarian cancer cells.
other	hsa-mir-98	Carcinoma, Ovarian	28067383	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The functional consequences and prognostic value of dosage sensitivity in ovarian cancer.
other	hsa-mir-21	Carcinoma, Ovarian, Clear Cell	25366985	endocrine system disease	DOID:0050934					MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
other	hsa-mir-182	Carcinoma, Ovarian, Serous	24077281	endocrine system disease	DOID:0050933					We describe several mechanisms responsible for FOXO3a inactivity, including chromosomal deletion (chromosome 6q21), upregulation of miRNA-182 and destabilization by activated PI3K and MEK.
other	hsa-mir-30a	Carcinoma, Ovarian, Serous	23787480	endocrine system disease	DOID:0050933					miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC.
other	hsa-mir-30a	Carcinoma, Ovarian, Serous	25962395	endocrine system disease	DOID:0050933					Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
other	hsa-mir-30e	Carcinoma, Ovarian, Serous	23787480	endocrine system disease	DOID:0050933					miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC.
other	hsa-mir-505	Carcinoma, Ovarian, Serous	23787480	endocrine system disease	DOID:0050933					miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC.
other	hsa-mir-101	Carcinoma, Pancreatic	27988337			C25.3	C562463	260350	HP:0002894	micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine.
other	hsa-mir-124	Carcinoma, Pancreatic	29255366			C25.3	C562463	260350	HP:0002894	circRNA_100782 regulates BxPC3 cell proliferation by acting as miR-124 sponge through the IL6-STAT3 pathway
other	hsa-mir-125a	Carcinoma, Pancreatic	28498896			C25.3	C562463	260350	HP:0002894	targeting the overexpression of PRDM14 suppresses cancer stem-like phenotypes, including liver  metastasis, via miRNA regulation and siRNA-based therapy targeting it shows promise as a treatment for patients with pancreatic cancer
other	hsa-mir-1291	Carcinoma, Pancreatic	25115443			C25.3	C562463	260350	HP:0002894	N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis.
other	hsa-mir-15b	Carcinoma, Pancreatic	24892299			C25.3	C562463	260350	HP:0002894	Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer.
other	hsa-mir-17	Carcinoma, Pancreatic	28280038			C25.3	C562463	260350	HP:0002894	The NOP14/mutp53 axis suppressed p21 expression at both the transcriptional and posttranscriptional levels via induction of miR-17-5p in PDAC cells
other	hsa-mir-196a	Carcinoma, Pancreatic	26683934			C25.3	C562463	260350	HP:0002894	MiRNA-196a level may be a promising prognostic marker of recurrence in resected PanNETs, although further experimental investigation would be required.
other	hsa-mir-215	Carcinoma, Pancreatic	26063036			C25.3	C562463	260350	HP:0002894	miR-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas.
other	hsa-mir-24	Carcinoma, Pancreatic	26517093			C25.3	C562463	260350	HP:0002894	The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma.
other	hsa-mir-29c	Carcinoma, Pancreatic	28088520			C25.3	C562463	260350	HP:0002894	Palmitic acid increases invasiveness of pancreatic cancer cells AsPC-1 through TLR4/ROS/NF-κB/MMP-9 signaling pathway.
other	hsa-mir-33a	Carcinoma, Pancreatic	26113407			C25.3	C562463	260350	HP:0002894	miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells.
other	hsa-mir-374	Carcinoma, Pancreatic	27665739			C25.3	C562463	260350	HP:0002894	MicroRNA miR-374, a potential radiosensitizer for carbon ion beam radiotherapy.
other	hsa-mir-4787	Carcinoma, Pancreatic	27624777			C25.3	C562463	260350	HP:0002894	Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.
other	hsa-mir-489	Carcinoma, Pancreatic	27793842			C25.3	C562463	260350	HP:0002894	KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis.
other	hsa-mir-601	Carcinoma, Pancreatic	27993677			C25.3	C562463	260350	HP:0002894	Identification of miR-601 as a novel regulator in the development of pancreatic cancer.
other	hsa-mir-663a	Carcinoma, Pancreatic	27624777			C25.3	C562463	260350	HP:0002894	Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.
other	hsa-mir-7	Carcinoma, Pancreatic	28450156			C25.3	C562463	260350	HP:0002894	microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression.
other	hsa-mir-148a	Carcinoma, Pancreatic Ductal	29660218	disease of cellular proliferation	DOID:3587	C25.3	D021441			Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation.
other	hsa-mir-1	Carcinoma, Prostate	28317618	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MiR-1, a Potential Predictive Biomarker for Recurrence in Prostate Cancer After Radical Prostatectomy.
other	hsa-mir-1	Carcinoma, Prostate	28320379	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miRNAs associated with prostate cancer risk and progression.
other	hsa-mir-101	Carcinoma, Prostate	28384067	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells.
other	hsa-mir-129	Carcinoma, Prostate	27779679	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
other	hsa-mir-135a	Carcinoma, Prostate	27524492	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Our data support a model in which hsa-miR-135-1 acts as a potential tumor suppressor in metastatic prostate cancer.
other	hsa-mir-139	Carcinoma, Prostate	27562849	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
other	hsa-mir-141	Carcinoma, Prostate	25921227	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	The work demonstrated here thus offers new opportunities for the construction of functional DNA nanostructures and for the application of these DNA nanostructures as an effective signal amplification means in the sensitive detection of nucleic acid biomarkers.
other	hsa-mir-141	Carcinoma, Prostate	27589398	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Sensitive detection of microRNA in complex biological samples by using two stages DSN-assisted target recycling signal amplification method.
other	hsa-mir-145	Carcinoma, Prostate	28320379	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miRNAs associated with prostate cancer risk and progression.
other	hsa-mir-146a	Carcinoma, Prostate	28101571	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer.
other	hsa-mir-181a	Carcinoma, Prostate	28485104	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
other	hsa-mir-181b	Carcinoma, Prostate	28184935	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
other	hsa-mir-205	Carcinoma, Prostate	28320379	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miRNAs associated with prostate cancer risk and progression.
other	hsa-mir-21	Carcinoma, Prostate	27725205	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21.
other	hsa-mir-21	Carcinoma, Prostate	28320379	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miRNAs associated with prostate cancer risk and progression.
other	hsa-mir-221	Carcinoma, Prostate	28320379	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miRNAs associated with prostate cancer risk and progression.
other	hsa-mir-24	Carcinoma, Prostate	28157714	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	The role of miR-24 as a race related genetic factor in prostate cancer.
other	hsa-mir-25	Carcinoma, Prostate	25858144	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of αv- and α6-Integrin Expression.
other	hsa-mir-30d	Carcinoma, Prostate	28241827	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
other	hsa-mir-371	Carcinoma, Prostate	28005952	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.
other	hsa-mir-372	Carcinoma, Prostate	27730751	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Repression of MicroRNA-372 by Arsenic Sulphide Inhibits Prostate Cancer Cell Proliferation and Migration through Regulation of large tumour suppressor kinase 2.
other	hsa-mir-375	Carcinoma, Prostate	28320379	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miRNAs associated with prostate cancer risk and progression.
other	hsa-mir-502	Carcinoma, Prostate	28578017	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene increased the risk of prostate cancer in a sample of Iranian population.
other	hsa-mir-512	Carcinoma, Prostate	28005952	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.
other	hsa-mir-663	Carcinoma, Prostate	28005952	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.
other	hsa-mir-665	Carcinoma, Prostate	28005952	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.
other	hsa-mir-671	Carcinoma, Prostate	28005952	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.
other	hsa-mir-100	Carcinoma, Rectal	26255374	disease of cellular proliferation	DOID:1993	C20	D012004			The proposed methodology effectively made use of literature data and was able to show novel,significant miRNA-transcription associations in CRC.
other	hsa-mir-141	Carcinoma, Rectal	18483486	disease of cellular proliferation	DOID:1993	C20	D012004			Here, we report that ZEB1 directly suppresses transcription of microRNA-200 family members miR-141 and miR-200c, which strongly activate epithelial differentiation in pancreatic, colorectal and breast cancer cells.
other	hsa-mir-183	Carcinoma, Rectal	19935649	disease of cellular proliferation	DOID:1993	C20	D012004			Moreover, miR-200c, miR-203 and miR-183 cooperate to suppress expression of stem cell factors in cancer cells and mouse embryonic stem (ES) cells, as demonstrated for the polycomb repressor Bmi1.
other	hsa-mir-196a	Carcinoma, Rectal	19418581	disease of cellular proliferation	DOID:1993	C20	D012004			miR-196a exerts a pro-oncogenic influence in colorectal cancer.
other	hsa-mir-200c	Carcinoma, Rectal	18483486	disease of cellular proliferation	DOID:1993	C20	D012004			Here, we report that ZEB1 directly suppresses transcription of microRNA-200 family members miR-141 and miR-200c, which strongly activate epithelial differentiation in pancreatic, colorectal and breast cancer cells.
other	hsa-mir-200c	Carcinoma, Rectal	19935649	disease of cellular proliferation	DOID:1993	C20	D012004			Moreover, miR-200c, miR-203 and miR-183 cooperate to suppress expression of stem cell factors in cancer cells and mouse embryonic stem (ES) cells, as demonstrated for the polycomb repressor Bmi1.
other	hsa-mir-203	Carcinoma, Rectal	19935649	disease of cellular proliferation	DOID:1993	C20	D012004			Moreover, miR-200c, miR-203 and miR-183 cooperate to suppress expression of stem cell factors in cancer cells and mouse embryonic stem (ES) cells, as demonstrated for the polycomb repressor Bmi1.
other	hsa-mir-203	Carcinoma, Rectal	21063914	disease of cellular proliferation	DOID:1993	C20	D012004			miR-203 may be related to the proliferation and invasion of gastric and colorectal cancers.
other	hsa-mir-34a	Carcinoma, Rectal	20734047	disease of cellular proliferation	DOID:1993	C20	D012004			Satraplatin treatment induces p53-related genes and its direct microRNA target of miR-34a independently.
other	hsa-mir-34a	Carcinoma, Rectal	28435028	disease of cellular proliferation	DOID:1993	C20	D012004			Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells.
other	hsa-mir-630	Carcinoma, Rectal	26255374	disease of cellular proliferation	DOID:1993	C20	D012004			The proposed methodology effectively made use of literature data and was able to show novel,significant miRNA-transcription associations in CRC.
other	hsa-mir-99a	Carcinoma, Rectal	26255374	disease of cellular proliferation	DOID:1993	C20	D012004			The proposed methodology effectively made use of literature data and was able to show novel,significant miRNA-transcription associations in CRC.
other	hsa-let-7f	Carcinoma, Renal Cell	20180642	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Transfection of miR-224 into HEK-293 cells resulted in decreased KLK1 protein levels. A luciferase assay demonstrated that hsa-let-7f can target KLK10 in the RCC cell line ACHN.
other	hsa-let-7i	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-125b	Carcinoma, Renal Cell	28599452	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis.
other	hsa-mir-126	Carcinoma, Renal Cell	25279769	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava.
other	hsa-mir-127	Carcinoma, Renal Cell	22492545	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-127-3p, miR-145, and miR-126 are significantly correlated with relapse-free survival of nonmetastatic RCC patients.
other	hsa-mir-133b	Carcinoma, Renal Cell	27710896	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miRNA-133b and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling pathway in human renal carcinoma cells.
other	hsa-mir-135a	Carcinoma, Renal Cell	27710896	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miRNA-133b and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling pathway in human renal carcinoma cells.
other	hsa-mir-138-1	Carcinoma, Renal Cell	21875287	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-138 Suppresses Expression of Hypoxia-inducible factor 1a (HIF-1a) in Clear Cell Renal Cell Carcinoma 786-O Cells.
other	hsa-mir-138-2	Carcinoma, Renal Cell	21875287	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-138 Suppresses Expression of Hypoxia-inducible factor 1a (HIF-1a) in Clear Cell Renal Cell Carcinoma 786-O Cells.
other	hsa-mir-141	Carcinoma, Renal Cell	24647573	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-141 serves as a potential biomarker for discriminating ccRCC from normal tissues and a crucial suppressor of ccRCC cell proliferation and metastasis by modulating the EphA2/p-FAK/p-AKT/MMPs signaling cascade.
other	hsa-mir-141	Carcinoma, Renal Cell	24810210	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling.
other	hsa-mir-141	Carcinoma, Renal Cell	25974855	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC.
other	hsa-mir-146a	Carcinoma, Renal Cell	21472233	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Carbamylated albumin stimulates microRNA-146, which is increased in human renal cell carcinoma.
other	hsa-mir-146b	Carcinoma, Renal Cell	21472233	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Carbamylated albumin stimulates microRNA-146, which is increased in human renal cell carcinoma.
other	hsa-mir-155	Carcinoma, Renal Cell	23050614	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma
other	hsa-mir-155	Carcinoma, Renal Cell	26064968	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.
other	hsa-mir-155	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-155	Carcinoma, Renal Cell	29056573	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms.
other	hsa-mir-15a	Carcinoma, Renal Cell	28098906	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR‑15a‑5p acts as an oncogene in renal cell carcinoma.
other	hsa-mir-16	Carcinoma, Renal Cell	25815587	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Upregulated microRNA-16 as an oncogene in renal cell carcinoma.
other	hsa-mir-17	Carcinoma, Renal Cell	25011053	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/tumor initiating cell properties.
other	hsa-mir-17	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-18	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-184	Carcinoma, Renal Cell	21253009	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development
other	hsa-mir-184	Carcinoma, Renal Cell	21844955	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-184 show abnormal expression in human renal carcinoma.
other	hsa-mir-193b	Carcinoma, Renal Cell	27802451	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma.
other	hsa-mir-195	Carcinoma, Renal Cell	28260025	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Identification of miR‑195‑3p as an oncogene in RCC.
other	hsa-mir-19a	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-19b-1	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-200	Carcinoma, Renal Cell	27580029	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Loss of fumarate hydratase is associated with suppression of miR-200 and the EMT signature in renal cancer and is associated with poor clinical outcome
other	hsa-mir-200a	Carcinoma, Renal Cell	22082152	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS.
other	hsa-mir-200c	Carcinoma, Renal Cell	23754305	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis.
other	hsa-mir-200c	Carcinoma, Renal Cell	25974855	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC.
other	hsa-mir-205	Carcinoma, Renal Cell	21330408	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer.
other	hsa-mir-205	Carcinoma, Renal Cell	25600645	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	how overexpression of MALAT1 confers an oncogenic function in RCC that may offer a novel theranostic marker in this disease.
other	hsa-mir-206	Carcinoma, Renal Cell	21253009	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development
other	hsa-mir-20a	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-20a	Carcinoma, Renal Cell	20022054	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Transfection of miR-20a inhibitor significantly decreased cell proliferation in a dose dependent manner.
other	hsa-mir-21	Carcinoma, Renal Cell	25279769	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava.
other	hsa-mir-21	Carcinoma, Renal Cell	25974855	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC.
other	hsa-mir-21	Carcinoma, Renal Cell	28714373	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma.
other	hsa-mir-21	Carcinoma, Renal Cell	29070781	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Cordycepin induces apoptotic cell death and inhibits cell migration in renal cell carcinoma via regulation of microRNA-21 and PTEN phosphatase.
other	hsa-mir-210	Carcinoma, Renal Cell	21253009	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development
other	hsa-mir-210	Carcinoma, Renal Cell	25974855	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC.
other	hsa-mir-210	Carcinoma, Renal Cell	23902947	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	VHL, involved in tumorigenesis of PGLs and clear cell renal cell carcinomas, may be an important player in the pathogenesis of sporadic HNPGLs via activation of an HIF-1α/miR-210 pHx pathway.
other	hsa-mir-210	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-221	Carcinoma, Renal Cell	26201448	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Gain of function experiments showed that miR-221 and miR-222 decreased angiogenesis and cellular proliferation in human umbilical vein endothelial cells (HUVEC) while increasing cellular proliferation in ACHN cells. miRNAs represent potential predictive markers for sunitinib response.
other	hsa-mir-221	Carcinoma, Renal Cell	25279769	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava.
other	hsa-mir-222	Carcinoma, Renal Cell	26201448	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Gain of function experiments showed that miR-221 and miR-222 decreased angiogenesis and cellular proliferation in human umbilical vein endothelial cells (HUVEC) while increasing cellular proliferation in ACHN cells. miRNAs represent potential predictive markers for sunitinib response.
other	hsa-mir-224	Carcinoma, Renal Cell	20180642	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Transfection of miR-224 into HEK-293 cells resulted in decreased KLK1 protein levels. A luciferase assay demonstrated that hsa-let-7f can target KLK10 in the RCC cell line ACHN.
other	hsa-mir-27a	Carcinoma, Renal Cell	25973137	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-27a promotes cell proliferation and metastasis in renal cell carcinoma.
other	hsa-mir-30a	Carcinoma, Renal Cell	25712526	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
other	hsa-mir-30b	Carcinoma, Renal Cell	28259953	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Identification of miR‑30b as an oncogene in renal cell carcinoma.
other	hsa-mir-34a	Carcinoma, Renal Cell	28045889	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Metformin Induces Growth Inhibition and Cell Cycle Arrest by Upregulating MicroRNA34a in Renal Cancer Cells.
other	hsa-mir-34a	Carcinoma, Renal Cell	29104726	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.
other	hsa-mir-429	Carcinoma, Renal Cell	25974855	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We also constructed a five-miRNAs-based classifier as a reliable prognostic and predictive tool for CSS in patients with RCC, especially in clear cell RCC (ccRCC) (HR: 5.46, 95% CI: 1.51-19.66). This method might facilitate patient counselling and individualise management of RCC.
other	hsa-mir-429	Carcinoma, Renal Cell	27619681	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition.
other	hsa-mir-484	Carcinoma, Renal Cell	26064968	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.
other	hsa-mir-7	Carcinoma, Renal Cell	23793934	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Identification of miR-7 as an oncogene in renal cell carcinoma.
other	hsa-mir-708	Carcinoma, Renal Cell	21852381	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells.
other	hsa-mir-9-1	Carcinoma, Renal Cell	22082152	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS.
other	hsa-mir-9-2	Carcinoma, Renal Cell	22082152	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS.
other	hsa-mir-92-1	Carcinoma, Renal Cell	20964835	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	This pattern of regulation was also seen in renal cancer tissue for several of these miRNAs (miR-210, miR-155, let-7i and members of the miR-17-92 cluster) when compared with normal tissue.
other	hsa-mir-9-3	Carcinoma, Renal Cell	22082152	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS.
other	hsa-mir-99a	Carcinoma, Renal Cell	23173671	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma
other	hsa-mir-99b	Carcinoma, Renal Cell	23173671	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma
other	hsa-mir-1	Carcinoma, Renal Cell, Clear-Cell	26036633	disease of cellular proliferation	DOID:4467				HP:0006770	MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis.
other	hsa-mir-10b	Carcinoma, Renal Cell, Clear-Cell	24793999	disease of cellular proliferation	DOID:4467				HP:0006770	The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
other	hsa-mir-10b	Carcinoma, Renal Cell, Clear-Cell	28360191	disease of cellular proliferation	DOID:4467				HP:0006770	miR-10b is a prognostic marker in clear cell renal cell carcinoma.
other	hsa-mir-10b	Carcinoma, Renal Cell, Clear-Cell	29672315	disease of cellular proliferation	DOID:4467				HP:0006770	MicroRNA-10b Promotes Apoptosis via JNK Pathway in Clear Cell Renal Cell Carcinoma
other	hsa-mir-125b	Carcinoma, Renal Cell, Clear-Cell	25155155	disease of cellular proliferation	DOID:4467				HP:0006770	Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
other	hsa-mir-143	Carcinoma, Renal Cell, Clear-Cell	25776476	disease of cellular proliferation	DOID:4467				HP:0006770	our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process.
other	hsa-mir-145	Carcinoma, Renal Cell, Clear-Cell	25776476	disease of cellular proliferation	DOID:4467				HP:0006770	our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process.
other	hsa-mir-15a	Carcinoma, Renal Cell, Clear-Cell	25776476	disease of cellular proliferation	DOID:4467				HP:0006770	our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process.
other	hsa-mir-16	Carcinoma, Renal Cell, Clear-Cell	25776476	disease of cellular proliferation	DOID:4467				HP:0006770	our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process.
other	hsa-mir-182	Carcinoma, Renal Cell, Clear-Cell	25776476	disease of cellular proliferation	DOID:4467				HP:0006770	our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process.
other	hsa-mir-183	Carcinoma, Renal Cell, Clear-Cell	25776476	disease of cellular proliferation	DOID:4467				HP:0006770	our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process.
other	hsa-mir-185	Carcinoma, Renal Cell, Clear-Cell	25700976	disease of cellular proliferation	DOID:4467				HP:0006770	Our results suggest that the miR-185, as a tumor suppressor, plays a pivotal role by inhibiting VEGFA in VHL-inactivated ccRCC.
other	hsa-mir-200c	Carcinoma, Renal Cell, Clear-Cell	27123083	disease of cellular proliferation	DOID:4467				HP:0006770	Aza-induced upregulation of miR-200c may inhibit migration, invasion and EMT in ccRCC cells.
other	hsa-mir-21	Carcinoma, Renal Cell, Clear-Cell	24793999	disease of cellular proliferation	DOID:4467				HP:0006770	The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
other	hsa-mir-21	Carcinoma, Renal Cell, Clear-Cell	26572589	disease of cellular proliferation	DOID:4467				HP:0006770	Thus, a single miRNA may have an impact on the formation of highly tumorigenic cancer spheres in kidney cancer.
other	hsa-mir-217	Carcinoma, Renal Cell, Clear-Cell	23790169	disease of cellular proliferation	DOID:4467				HP:0006770	miR-217 plays a tumor suppressor role in ccRCC.
other	hsa-mir-27a	Carcinoma, Renal Cell, Clear-Cell	26046464	disease of cellular proliferation	DOID:4467				HP:0006770	Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma.
other	hsa-mir-30a	Carcinoma, Renal Cell, Clear-Cell	24402943	disease of cellular proliferation	DOID:4467				HP:0006770	miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation.
other	hsa-mir-30c-2	Carcinoma, Renal Cell, Clear-Cell	24402943	disease of cellular proliferation	DOID:4467				HP:0006770	miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation.
other	hsa-mir-335	Carcinoma, Renal Cell, Clear-Cell	25846734	disease of cellular proliferation	DOID:4467				HP:0006770	miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W.
other	hsa-mir-429	Carcinoma, Renal Cell, Clear-Cell	27549611	disease of cellular proliferation	DOID:4467				HP:0006770	Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma.
other	hsa-mir-584	Carcinoma, Renal Cell, Clear-Cell	21119662	disease of cellular proliferation	DOID:4467				HP:0006770	Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma.
other	hsa-mir-96	Carcinoma, Renal Cell, Clear-Cell	25776476	disease of cellular proliferation	DOID:4467				HP:0006770	our data support the notion that sunitinib and everolimus are able to directly induce cell death in renal cancer cells and simultaneously affect the expression levels of their apoptosis-related microRNAs and BCL2 family members upon this process.
other	hsa-mir-200	Carcinoma, Skin	26527515	disease of cellular proliferation	DOID:3451	D04.9	D018280		HP:0008069	only a functionally coherent group consisting of the miR-200 family members and miR-205-5p displays a pattern of progressive co-downregulation from the early toward the most aggressive stages of carcinogenesis.
other	hsa-mir-34a	Carcinoma, Skin	24726431	disease of cellular proliferation	DOID:3451	D04.9	D018280		HP:0008069	Our results demonstrate that p53 mutations increase apoptotic resistance in keratinocytes by interfering with miR-34a-mediated regulation of SIRT1 expression.
other	hsa-mir-146a	Carcinoma, Thyroid	28103112	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Potassium Iodate Differently Regulates the Proliferation, Migration, and Invasion of Human Thyroid Cancer Cells via Modulating miR-146a.
other	hsa-mir-146b	Carcinoma, Thyroid	24946010	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression.
other	hsa-mir-21	Carcinoma, Thyroid	25316501	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	The PDCD4/miR-21 pathway in medullary thyroid carcinoma.
other	hsa-mir-27a	Carcinoma, Thyroid	28002594	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Effects of miR-27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis.
other	hsa-mir-449b	Carcinoma, Thyroid	26044563	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Regulation of MET-mediated proliferation of thyroid carcinoma cells by miR-449b.
other	hsa-mir-144	Carcinoma, Thyroid, Anaplastic	29504819			C73	D065646	188550	HP:0011779	Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation.
other	hsa-mir-146b	Carcinoma, Thyroid, Anaplastic	27602131			C73	D065646	188550	HP:0011779	p21 participates in the regulation of anaplastic thyroid cancer cell proliferation by miR-146b.
other	hsa-mir-17	Carcinoma, Thyroid, Follicular	25748447	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Sphingosine-1-phosphate induces the migration of thyroid follicular carcinoma cells through the microRNA-17/PTK6/ERK1/2 pathway.
other	hsa-mir-10a	Carcinoma, Thyroid, Medullary	23685355	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma.
other	hsa-mir-375	Carcinoma, Thyroid, Medullary	23685355	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma.
other	hsa-let-7	Carcinoma, Thyroid, Papillary	27314338	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	let-7 miRNA was found to reduce RAS levels, acting as a tumor suppressor gene.
other	hsa-let-7e	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
other	hsa-mir-146	Carcinoma, Thyroid, Papillary	27011326	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Family of microRNA-146 Regulates RARβ in Papillary Thyroid Carcinoma.
other	hsa-mir-155	Carcinoma, Thyroid, Papillary	27777199	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Expression of microRNA-155 in papillary thyroid carcinoma and its clinical significance.
other	hsa-mir-16	Carcinoma, Thyroid, Papillary	28085013	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC.
other	hsa-mir-181a	Carcinoma, Thyroid, Papillary	27164936	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MiRNA-21 and MiRNA-181a-5p were found to be expressed reciprocally in the exosomes of patients with papillary and follicular TC
other	hsa-mir-199a	Carcinoma, Thyroid, Papillary	24810336	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.
other	hsa-mir-21	Carcinoma, Thyroid, Papillary	26007293	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
other	hsa-mir-21	Carcinoma, Thyroid, Papillary	27164936	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MiRNA-21 and MiRNA-181a-5p were found to be expressed reciprocally in the exosomes of patients with papillary and follicular TC
other	hsa-mir-221	Carcinoma, Thyroid, Papillary	28297755	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features.
other	hsa-mir-9	Carcinoma, Thyroid, Papillary	26007293	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
other	hsa-mir-140	Carcinoma, Tounge	24530397							Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
other	hsa-mir-628	Cardiac Allograft Vasculopathy	27653298			T86.290	D014652			MicroRNA 628-5p as a Novel Biomarker for Cardiac Allograft Vasculopathy.
other	hsa-mir-21	Cardiac Fibrosis	22580345							we identify the protective transcriptome signature of enhanced PI3Kα signaling in the context of pathological hypertrophy, and demonstrate the regulation of TGF-β/miR-21 by which enhanced PI3Kα signaling protects against cardiac fibrosis.
other	hsa-mir-199a	Cardiac Myocyte Injury	28077443							Single-Dose Intracardiac Injection of Pro-Regenerative MicroRNAs Improves Cardiac Function After Myocardial Infarction.
other	hsa-mir-133a	Cardiomegaly	25313674			I51.7	D006332		HP:0001640	Our observations supplied the possibility that circulating miR-133a could be a surrogate biomarker of cardiac hypertrophy in MHD patients.
other	hsa-mir-133a-1	Cardiomegaly	19096030			I51.7	D006332		HP:0001640	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-133a-2	Cardiomegaly	19096030			I51.7	D006332		HP:0001640	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-133b	Cardiomegaly	19096030			I51.7	D006332		HP:0001640	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-15	Cardiomegaly	25103110			I51.7	D006332		HP:0001640	We identified the miR-15 family as a novel regulator of cardiac hypertrophy and fibrosis acting by inhibition of the TGFβ-pathway.
other	hsa-mir-21	Cardiomegaly	25644540			I51.7	D006332		HP:0001640	miR-21: a star player in cardiac hypertrophy.
other	hsa-mir-29a	Cardiomegaly	25145535			I51.7	D006332		HP:0001640	MicroRNA-29a is a friend or foe for cardiac hypertrophy
other	hsa-mir-30a	Cardiomegaly	19096030			I51.7	D006332		HP:0001640	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-30b	Cardiomegaly	19096030			I51.7	D006332		HP:0001640	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-1	Cardiomegaly	19933931			I51.7	D006332		HP:0001640	Our results reveal a critical role of miR-1 in mediating the effects of the IGF-1 pathway and demonstrate a feedback loop between miR-1 expression and the IGF-1 signal transduction cascade.
other	hsa-mir-1	Cardiomegaly	28985746			I51.7	D006332		HP:0001640	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension.
other	hsa-mir-126	Cardiomegaly	21946298			I51.7	D006332		HP:0001640	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-133a	Cardiomegaly	26845040			I51.7	D006332		HP:0001640	APN reversed miR-133a levels through AMPK activation
other	hsa-mir-155	Cardiomegaly	21946298			I51.7	D006332		HP:0001640	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-17	Cardiomegaly	21946298			I51.7	D006332		HP:0001640	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-199a-1	Cardiomegaly	20458739			I51.7	D006332		HP:0001640	miR-199a:miR-199a is essential for the maintenance of cell size in cardiomyocytes
other	hsa-mir-199a-2	Cardiomegaly	20458739			I51.7	D006332		HP:0001640	miR-199a:miR-199a is essential for the maintenance of cell size in cardiomyocytes
other	hsa-mir-208a	Cardiomegaly	23623871			I51.7	D006332		HP:0001640	MiRNA-208a and miRNA-208b are triggered in thyroid hormone-induced cardiac hypertrophy - role of type 1 Angiotensin II receptor (AT1R) on miRNA-208a/α-MHC modulation.
other	hsa-mir-208b	Cardiomegaly	23623871			I51.7	D006332		HP:0001640	MiRNA-208a and miRNA-208b are triggered in thyroid hormone-induced cardiac hypertrophy - role of type 1 Angiotensin II receptor (AT1R) on miRNA-208a/α-MHC modulation.
other	hsa-mir-21	Cardiomegaly	24743143			I51.7	D006332		HP:0001640	In particular, a passenger strand miR, miR-21*, was identified as a potent paracrine factor that induces cardiomyocyte hypertrophy when shuttled through exosomes.
other	hsa-mir-221	Cardiomegaly	21946298			I51.7	D006332		HP:0001640	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-222	Cardiomegaly	21946298			I51.7	D006332		HP:0001640	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-29a	Cardiomegaly	28985746			I51.7	D006332		HP:0001640	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension.
other	hsa-mir-31	Cardiomegaly	21946298			I51.7	D006332		HP:0001640	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-34a	Cardiomegaly	26508703			I51.7	D006332		HP:0001640	Neonatal HHR had higher cardiac telomerase activity and expression of Tert and miR-34a.
other	hsa-mir-378	Cardiomegaly	23625957			I51.7	D006332		HP:0001640	MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors.
other	hsa-mir-146	Cardiometabolic Disorders	26165231							Post-Transcriptional Regulation of Renalase Gene by miR-29 and miR-146 MicroRNAs:Implications for Cardiometabolic Disorders.
other	hsa-mir-29	Cardiometabolic Disorders	26165231							Post-Transcriptional Regulation of Renalase Gene by miR-29 and miR-146 MicroRNAs:Implications for Cardiometabolic Disorders.
other	hsa-let-7a	Cardiomyopathy	27475403	cardiovascular system disease	DOID:0050700	I42	D009202			Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p
other	hsa-mir-1295a	Cardiomyopathy	27475403	cardiovascular system disease	DOID:0050700	I42	D009202			Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p
other	hsa-mir-16-1	Cardiomyopathy	27475403	cardiovascular system disease	DOID:0050700	I42	D009202			Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p
other	hsa-mir-19b-1	Cardiomyopathy	27475403	cardiovascular system disease	DOID:0050700	I42	D009202			Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p
other	hsa-mir-21	Cardiomyopathy	19043405	cardiovascular system disease	DOID:0050700	I42	D009202			miR-21: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
other	hsa-mir-34b	Cardiomyopathy	27475403	cardiovascular system disease	DOID:0050700	I42	D009202			Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p
other	hsa-mir-371a	Cardiomyopathy	26512958	cardiovascular system disease	DOID:0050700	I42	D009202			In conclusion, the presence of a g2252c polymorphism in the BAG3 3'-UTR determines loss of miR-371a-5p binding and results in an altered response to epi, potentially representing a new molecular mechanism that contributes to TTC pathogenesis.
other	hsa-mir-99b	Cardiomyopathy	27475403	cardiovascular system disease	DOID:0050700	I42	D009202			Six miRNAs seem to be associated with these 2 pathways, which include hsa-miR-19b-1-5p, hsa-miR-1295a, hsa-let-7a-5p, hsa-miR-99b-3p, hsa-miR-16-1-3p, and hsa-miR-34b-3p
other	hsa-mir-1	Cardiomyopathy, Hypertrophic	21464712	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy.
other	hsa-mir-125b-1	Cardiomyopathy, Hypertrophic	20470752	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-125b:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth
other	hsa-mir-125b-2	Cardiomyopathy, Hypertrophic	20470752	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-125b:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth
other	hsa-mir-133	Cardiomyopathy, Hypertrophic	21464712	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy.
other	hsa-mir-133	Cardiomyopathy, Hypertrophic	28322824	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	MicroRNA-133 mediates cardiac diseases: Mechanisms and clinical implications.
other	hsa-mir-133a	Cardiomyopathy, Hypertrophic	21586423	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Logistic regression analysis identified microRNA-133a as a significant positive predictor of LVM normalisation, whereas β-myosin heavy chain and BMI constituted negative predictors.
other	hsa-mir-133a	Cardiomyopathy, Hypertrophic	23070543	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Consistent with these structural changes, the expression of molecular markers of cardiac hypertrophy were also increased [Nppb(BNP), Myh7-Myh6(βMHC-αMHC) (both P < 0.05) and mir-133a (P < 0.01)].
other	hsa-mir-133a	Cardiomyopathy, Hypertrophic	28382463	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children.
other	hsa-mir-133a-1	Cardiomyopathy, Hypertrophic	17786230	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy. Xiao et al. reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-goбзCrelated gene (ERG), which encodes a key K+ channel (IKr) responsible for rapid delayed rectifier K+ current in cardiac cells.
other	hsa-mir-133a-1	Cardiomyopathy, Hypertrophic	20013939	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR133a regulates cardiomyocyte hypertrophy in diabetes
other	hsa-mir-133a-2	Cardiomyopathy, Hypertrophic	17786230	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	These results suggest an active role for miR-133 in the inhibition of cardiac hypertrophy. Xiao et al. reported miR-133 to play a role in cardiac conductance abnormalities during diabetes by lowering the protein levels of ether-a-go-goбзCrelated gene (ERG), which encodes a key K+ channel (IKr) responsible for rapid delayed rectifier K+ current in cardiac cells.
other	hsa-mir-133a-2	Cardiomyopathy, Hypertrophic	20013939	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR133a regulates cardiomyocyte hypertrophy in diabetes
other	hsa-mir-16	Cardiomyopathy, Hypertrophic	25583328	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy.
other	hsa-mir-195	Cardiomyopathy, Hypertrophic	20470752	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-195:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth
other	hsa-mir-199b	Cardiomyopathy, Hypertrophic	21464712	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy.
other	hsa-mir-208	Cardiomyopathy, Hypertrophic	21464712	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy.
other	hsa-mir-208a	Cardiomyopathy, Hypertrophic	17965831	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-208 was recently shown to enhance stress-related cardiac muscle growth by up-regulating a contractile protein, bMHC, possibly by repressing translation of thyroid hormone receptor-associated protein 1 (THRAP1).
other	hsa-mir-21	Cardiomyopathy, Hypertrophic	17525252	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Modulating miR-21 expression via antisense-mediated depletion (knockdown) had a significant negative effect on cardiomyocyte hypertrophy.
other	hsa-mir-21	Cardiomyopathy, Hypertrophic	28382463	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children.
other	hsa-mir-23a	Cardiomyopathy, Hypertrophic	20470752	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-23a:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth
other	hsa-mir-23a	Cardiomyopathy, Hypertrophic	21464712	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The cardiac-enriched miRNAs, including miR-1, miR-133, and miR-208, as well as the ubiquitous miR-23a and miR-199b, play major roles in the development of cardiac hypertrophy.
other	hsa-mir-23b	Cardiomyopathy, Hypertrophic	28382463	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children.
other	hsa-mir-24	Cardiomyopathy, Hypertrophic	28382463	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children.
other	hsa-mir-27b	Cardiomyopathy, Hypertrophic	20470752	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-27b:miR-23a, miR-27b, miR-125b and miR-195 were induced during early hypertrophic growth
other	hsa-mir-9-1	Cardiomyopathy, Hypertrophic	20177053	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy
other	hsa-mir-9-2	Cardiomyopathy, Hypertrophic	20177053	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy
other	hsa-mir-9-3	Cardiomyopathy, Hypertrophic	20177053	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy
other	hsa-mir-126	Cardiomyopathy, Ischemic	27866054			I25.5				Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft.
other	hsa-mir-155	Cardiomyopathy, Ischemic	27866054			I25.5				Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft.
other	hsa-mir-21	Cardiomyopathy, Ischemic	27666568			I25.5				Trimetazidine protects against cardiac ischemia/reperfusion injury via effects on cardiac miRNA‑21 expression, Akt and the Bcl‑2/Bax pathway.
other	hsa-mir-499	Cardiomyopathy, Ischemic	27866054			I25.5				Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft.
other	hsa-let-7a	Cardiovascular Diseases [unspecific]	25759134				D002318			we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-let-7b	Cardiovascular Diseases [unspecific]	28159509				D002318			Human Pericardial Fluid Contains Exosomes Enriched with Cardiovascular-Expressed MicroRNAs and Promotes Therapeutic Angiogenesis.
other	hsa-mir-100	Cardiovascular Diseases [unspecific]	25857370				D002318			In endothelial cells, activation of PPAR-δ decreased VLDL receptor expression and VLDL uptake via the induction of miR-100. These results provided a novel mechanism for the vascular protective effect of PPAR-δ agonists.
other	hsa-mir-10b	Cardiovascular Diseases [unspecific]	27624142				D002318			Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients.
other	hsa-mir-126	Cardiovascular Diseases [unspecific]	25958013				D002318			This review describes our current understanding of extracellular vesicle miRNA transfer, demonstrating the roles of miR-126, miR-146a, miR-143, and other miRNAs being shuttled from endothelial cells, stem cells, fibroblasts and others into myocytes, endothelial cells, and smooth muscle cells to activate cellular changes and modulate disease phenotypes.
other	hsa-mir-126	Cardiovascular Diseases [unspecific]	23201405				D002318			Synergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac myocytes
other	hsa-mir-126	Cardiovascular Diseases [unspecific]	22215713				D002318			miRNA-126 levels were reduced in SHRs with an increase of 51% in phosphoinositol-3 kinase regulatory subunit 2 expression but normalized in SHR-Ts.
other	hsa-mir-126	Cardiovascular Diseases [unspecific]	24349482				D002318			miR-126 expression was depressed in the process of EPC EndMT.
other	hsa-mir-126	Cardiovascular Diseases [unspecific]	28253326				D002318			Prevention of neointimal formation using miRNA-126-containing nanoparticle-conjugated stents in a rabbit model.
other	hsa-mir-138	Cardiovascular Diseases [unspecific]	24486907				D002318			Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction.
other	hsa-mir-143	Cardiovascular Diseases [unspecific]	25958013				D002318			This review describes our current understanding of extracellular vesicle miRNA transfer, demonstrating the roles of miR-126, miR-146a, miR-143, and other miRNAs being shuttled from endothelial cells, stem cells, fibroblasts and others into myocytes, endothelial cells, and smooth muscle cells to activate cellular changes and modulate disease phenotypes.
other	hsa-mir-143	Cardiovascular Diseases [unspecific]	22135162				D002318			MicroRNAs are critical for vascular smooth muscle cell differentiation and phenotype regulation, and miR-143 and miR-145 play a particularly important role in this respect.
other	hsa-mir-144	Cardiovascular Diseases [unspecific]	24642088				D002318			7-Ketocholesterol inhibits isocitrate dehydrogenase 2 expression and impairs endothelial function via microRNA-144.
other	hsa-mir-145	Cardiovascular Diseases [unspecific]	26845891				D002318			THERAPEUTIC POTENTIAL OF MICRORNA IN THE FIELD OF CARDIOVASCULAR SURGERY.
other	hsa-mir-145	Cardiovascular Diseases [unspecific]	22135162				D002318			MicroRNAs are critical for vascular smooth muscle cell differentiation and phenotype regulation, and miR-143 and miR-145 play a particularly important role in this respect.
other	hsa-mir-146a	Cardiovascular Diseases [unspecific]	25958013				D002318			This review describes our current understanding of extracellular vesicle miRNA transfer, demonstrating the roles of miR-126, miR-146a, miR-143, and other miRNAs being shuttled from endothelial cells, stem cells, fibroblasts and others into myocytes, endothelial cells, and smooth muscle cells to activate cellular changes and modulate disease phenotypes.
other	hsa-mir-155	Cardiovascular Diseases [unspecific]	24475727				D002318			The role of miRNA-155 in cardiovascular diseases
other	hsa-mir-155	Cardiovascular Diseases [unspecific]	28018919				D002318			a recent clinical trial of Miravirsen targeting microRNA-122 sheds light on exploiting microRNA-155 as a novel target to develop effective therapeutic strategies for cardiovascular diseases in the near future
other	hsa-mir-17	Cardiovascular Diseases [unspecific]	24386440				D002318			These findings revealed the role of miRNAs in h-ERG trafficking, which may contribute to the cardiac electrical disturbances associated with oxidative stress.
other	hsa-mir-17	Cardiovascular Diseases [unspecific]	24212931				D002318			The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease.
other	hsa-mir-18	Cardiovascular Diseases [unspecific]	24212931				D002318			The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease.
other	hsa-mir-188	Cardiovascular Diseases [unspecific]	19669742				D002318			These findings suggest that dicer and miRNAs especially miR-188 are involved in Hcy-induced cardiac remodeling
other	hsa-mir-199a-1	Cardiovascular Diseases [unspecific]	20458739				D002318			miR-199a is essential for the maintenance of cell size in cardiomyocytes
other	hsa-mir-199a-2	Cardiovascular Diseases [unspecific]	20458739				D002318			miR-199a is essential for the maintenance of cell size in cardiomyocytes
other	hsa-mir-19a	Cardiovascular Diseases [unspecific]	24212931				D002318			The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease.
other	hsa-mir-19b-1	Cardiovascular Diseases [unspecific]	24212931				D002318			The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease.
other	hsa-mir-200c	Cardiovascular Diseases [unspecific]	25759134				D002318			we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-mir-20a	Cardiovascular Diseases [unspecific]	24212931				D002318			The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease.
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	25975660				D002318			miR-21 and cardiac fibrosis: another brick in the wall
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	19043405				D002318			MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	20404348				D002318			MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	24447911				D002318			Ang II induced  miR-21 expression in primary mouse cardiac fibroblasts (CFs) via ERK-dependent AP-1 and STAT3 activation, and while a miR-21 inhibitor reversed Ang II-induced RECK suppression, a miR-21 mimic inhibited both RECK expression and Ang II-induced CF migration.
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	28418864				D002318			Bone marrow-derived mesenchymal stem cells overexpressing MiR-21 efficiently repair myocardial damage in rats.
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	21712654				D002318			The small regulatory RNA microRNA-21 (miR-21) plays a crucial role in a plethora of biological functions and diseases including development, cancer, cardiovascular diseases and inflammation.
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	21909994				D002318			This review highlights the complex roles that miRNA-21 plays in cancer and cardiovascular diseases and its potential clinical applications.
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	23710745				D002318			MicroRNA-21 protects cardiomyocytes from tumor necrosis factor-α induced apoptosis in vitro via modulating PTEN/AKT/FOXO3a pathway
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	28465657				D002318			The MicroRNA-21 signaling pathway is involved in prorenin receptor (PRR) -induced VEGF expression in ARPE-19 cells under a hyperglycemic condition.
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	29456377				D002318			the stability of both DIM and pre-miR-21 was found to be inversely correlated to each other in binding condition
other	hsa-mir-21	Cardiovascular Diseases [unspecific]	29659130				D002318			MicroRNA-21 (miR-21) is a short, non-coding RNA that has been implicated in cardiovascular diseases including proliferative vascular disease and ischaemic heart disease
other	hsa-mir-210	Cardiovascular Diseases [unspecific]	27359286				D002318			miR-210 has also been shown to be associated with the development of different human diseases including various types of cancers, cardiovascular and cerebrovascular diseases, and immunological diseases.
other	hsa-mir-22	Cardiovascular Diseases [unspecific]	25218673				D002318			miR-22 in cardiac remodeling and disease.
other	hsa-mir-222	Cardiovascular Diseases [unspecific]	25863248				D002318			These studies implicate miR-222 as necessary for exercise-induced cardiomyocyte growth and proliferation in the adult mammalian heart and show that it is sufficient to protect the heart against adverse remodeling.
other	hsa-mir-222	Cardiovascular Diseases [unspecific]	28127557				D002318			MiR-222 in Cardiovascular Diseases: Physiology and Pathology.
other	hsa-mir-223	Cardiovascular Diseases [unspecific]	24657505				D002318			miR-223 is one of the growing number of RNA biomarkers of various human metabolic diseases and is thus of special interest to both researchers and clinicians in the cardiovascular field.
other	hsa-mir-26	Cardiovascular Diseases [unspecific]	25066487				D002318			An emerging role for the miR-26 family in cardiovascular disease.
other	hsa-mir-29	Cardiovascular Diseases [unspecific]	27932253				D002318			Regulation of cyclin D1 by arsenic and microRNA inhibits adipogenesis.
other	hsa-mir-29b	Cardiovascular Diseases [unspecific]	27932253				D002318			Regulation of cyclin D1 by arsenic and microRNA inhibits adipogenesis.
other	hsa-mir-30c	Cardiovascular Diseases [unspecific]	29483230				D002318			Cocaine Exposure Increases Blood Pressure and Aortic Stiffness via the miR-30c-5p-Malic Enzyme 1-Reactive Oxygen Species Pathway.
other	hsa-mir-32	Cardiovascular Diseases [unspecific]	28319142				D002318			MicroRNA-32 promotes calcification in vascular smooth muscle cells: Implications as a novel marker for coronary artery calcification.
other	hsa-mir-34	Cardiovascular Diseases [unspecific]	26559089				D002318			MicroRNA-34 Family and Its Role in Cardiovascular Disease.
other	hsa-mir-34a	Cardiovascular Diseases [unspecific]	24438466				D002318			MicroRNA-34a: role in cancer and cardiovascular disease.
other	hsa-mir-34a	Cardiovascular Diseases [unspecific]	20627091				D002318			MiR-34a:MicroRNA-34a regulation of endothelial senescence
other	hsa-mir-34a	Cardiovascular Diseases [unspecific]	22651868				D002318			Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease.
other	hsa-mir-34a	Cardiovascular Diseases [unspecific]	25887273				D002318			Also,  miR-125a-5p/-351, miR-200c/-429, miR-106b/-17, miR-363/-92b, miR-181b/-181d, miR-19a/-19b, let-7d/-7f, miR-18a/-18b, miR-128/-27b and miR-106a/-291a-3p pairs  exhibited significant synergy and their association to aging and/or cardiovascular diseases is supported in many cases by a disease database and previous studies.
other	hsa-mir-425	Cardiovascular Diseases [unspecific]	27132035				D002318			After NaAsO2 treatment, we found the expression of microRNA-425-5p (miR-425-5p) was reduced in vitro and in vivo
other	hsa-mir-92-1	Cardiovascular Diseases [unspecific]	24212931				D002318			The miR-17/92 cluster: a comprehensive update on its genomics, genetics,functions and increasingly important and numerous roles in health and disease.
other	hsa-mir-92a	Cardiovascular Diseases [unspecific]	28696247				D002318			MicroRNA-92a Mediates Endothelial Dysfunction in CKD.
other	hsa-mir-92a	Cardiovascular Diseases [unspecific]	27208561				D002318			PDW/miR-92a-score with  a specificity of 97.5% and a sensitivity of 80.0% in relation to detect aspirin resistance.
other	hsa-mir-92a	Cardiovascular Diseases [unspecific]	27936205				D002318			Hyperhomocysteinemia in ApoE-/- Mice Leads to Overexpression of Enhancer of Zeste Homolog 2 via miR-92a Regulation.
other	hsa-mir-184	Cataract	29325388	nervous system disease	DOID:83	H26.9	D002386	PS116200	HP:0000518	miR-184 plays crucial regulatory roles in several ocular diseases, such as neovascularization, keratoconus, endothelial dystrophy, iris hypoplasia, congenital cataract, stromal thinning syndrome, corneal squamous cell carcinoma, age-related macular degeneration and cataract
other	hsa-mir-1290	Celiac Disease	24063611	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
other	hsa-mir-17	Celiac Disease	28208686	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	Identification of Autophagy-Related Genes and Their Regulatory miRNAs Associated with Celiac Disease in Children.
other	hsa-mir-192	Celiac Disease	24063611	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
other	hsa-mir-194	Celiac Disease	24063611	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
other	hsa-mir-30a	Celiac Disease	28208686	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	Identification of Autophagy-Related Genes and Their Regulatory miRNAs Associated with Celiac Disease in Children.
other	hsa-mir-31	Celiac Disease	24063611	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
other	hsa-mir-551a	Celiac Disease	24063611	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
other	hsa-mir-551b	Celiac Disease	24063611	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
other	hsa-mir-638	Celiac Disease	24063611	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
other	hsa-mir-134	Central Nervous System Embryonal Tumor	20622856			C72.9	D009373			miR-134:A novel pathway regulates memory and plasticity via SIRT1 and miR-134
other	hsa-mir-221	Central Nervous System Embryonal Tumor	24832085			C72.9	D009373			Downregulation of SUN2, a novel tumor suppressor, mediates miR-221/222-induced malignancy in central nervous system embryonal tumors.
other	hsa-mir-222	Central Nervous System Embryonal Tumor	24832085			C72.9	D009373			Downregulation of SUN2, a novel tumor suppressor, mediates miR-221/222-induced malignancy in central nervous system embryonal tumors.
other	hsa-mir-29b	Cerebral Aneurysm	28214880	cardiovascular system disease	DOID:0060228	I67.1	D002532	PS105800	HP:0007029	MiR-29b Downregulation Induces Phenotypic Modulation of Vascular Smooth Muscle Cells: Implication for Intracranial Aneurysm Formation and Progression to Rupture.
other	hsa-let-7c	Cerebral Ischemia	25934573	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation.
other	hsa-mir-124-1	Cerebral Ischemia	23754622	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation.
other	hsa-mir-124-2	Cerebral Ischemia	23754622	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation.
other	hsa-mir-128	Cerebral Ischemia	27905005	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	MicroRNA-128-3p Protects Mouse Against Cerebral Ischemia Through Reducing p38α Mitogen-Activated Protein Kinase Activity.
other	hsa-mir-497	Cerebral Ischemia	27209189	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	amikacin inhibits miR-497 maturation and promotes ischemic neuronal survival by upregulating anti-apoptotic protein, bcl-2.
other	hsa-let-7a	Cervical Neoplasms	25539644	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	existence of a functional loop involving Let-7a, STAT3 and miR-21 which were found potentially regulated by viral oncoprotein E6.
other	hsa-mir-125b	Cervical Neoplasms	28102867	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Gene regulation of the DEGs also revealed important TFs and miRNAs such as ELF1, SRF, has-mir-125b-5p and has-mir-644a
other	hsa-mir-146a	Cervical Neoplasms	23189617	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a
other	hsa-mir-15b	Cervical Neoplasms	22920753	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16.
other	hsa-mir-16	Cervical Neoplasms	22920753	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	These data suggested that down-regulation of NDRG2 could enhance sensitivity of Hela cells to cisplatin through inhibiting Bcl-2 protein expression, which might be mediated by up-regulating miR-15b and miR-16.
other	hsa-mir-200a	Cervical Neoplasms	23679328	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-93 and miR-200a are associated with metastasis and invasion of cervical carcinoma.
other	hsa-mir-21	Cervical Neoplasms	25539644	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	existence of a functional loop involving Let-7a, STAT3 and miR-21 which were found potentially regulated by viral oncoprotein E6.
other	hsa-mir-21	Cervical Neoplasms	28447761	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells.
other	hsa-mir-218	Cervical Neoplasms	23189617	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a
other	hsa-mir-29a	Cervical Neoplasms	23189617	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a
other	hsa-mir-34a	Cervical Neoplasms	21128241	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	In summary, our study demonstrates an intimate connection among oncogenic HPV E6,p53, miR-34a and p18Ink4c and identifies p18Ink4c as a possible biomarker for cervical cancer.
other	hsa-mir-34a	Cervical Neoplasms	23189617	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a
other	hsa-mir-644a	Cervical Neoplasms	28102867	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Gene regulation of the DEGs also revealed important TFs and miRNAs such as ELF1, SRF, has-mir-125b-5p and has-mir-644a
other	hsa-mir-93	Cervical Neoplasms	23679328	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-93 and miR-200a are associated with metastasis and invasion of cervical carcinoma.
other	hsa-mir-21	Cervicitis	26010154	reproductive system disease	DOID:2568	N72	D002575			Up-Regulation of miR-21 Is Associated with Cervicitis and Human Papillomavirus Infection in Cervical Tissues.
other	hsa-mir-200a	Cervix Endometrial Stromal Tumor	24850415	disease of cellular proliferation	DOID:4521					MicroRNA-200a locally attenuates progesterone signaling in the cervix, preventing embryo implantation.
other	hsa-mir-503	Chikungunya Virus Infection	24278205	disease by infectious agent	DOID:0050012	A92.0	D065632			Combined miRNA and mRNA signature identifies key molecular players and pathways involved in chikungunya virus infection in human cells.
other	hsa-mir-638	Chikungunya Virus Infection	24278205	disease by infectious agent	DOID:0050012	A92.0	D065632			Combined miRNA and mRNA signature identifies key molecular players and pathways involved in chikungunya virus infection in human cells.
other	hsa-mir-744	Chikungunya Virus Infection	24278205	disease by infectious agent	DOID:0050012	A92.0	D065632			Combined miRNA and mRNA signature identifies key molecular players and pathways involved in chikungunya virus infection in human cells.
other	hsa-mir-320a	Childhood Leukemia	20807887	disease of cellular proliferation	DOID:7757					In summary our data suggest that TEL-AML1 might exert its antiapoptotic action at least in part by suppressing miRNA-494 and miRNA-320a, lowering their expression causing enhanced survivin expression.
other	hsa-mir-494	Childhood Leukemia	20807887	disease of cellular proliferation	DOID:7757					In summary our data suggest that TEL-AML1 might exert its antiapoptotic action at least in part by suppressing miRNA-494 and miRNA-320a, lowering their expression causing enhanced survivin expression.
other	hsa-mir-107	Childhood Obesity	24423308			E66.9	D063766	601665		Childhood obesity is associated with changes in immune cell frequency, inflammatory environment, and regulation of metabolic gene expression.These changes have been causally linked to the onset of metabolic disease in adulthood and suggest the future trajectory of obese children to the development of type 2 diabetes mellitus and premature cardiovascular disease.
other	hsa-mir-33	Childhood Obesity	24423308			E66.9	D063766	601665		Childhood obesity is associated with changes in immune cell frequency, inflammatory environment, and regulation of metabolic gene expression.These changes have been causally linked to the onset of metabolic disease in adulthood and suggest the future trajectory of obese children to the development of type 2 diabetes mellitus and premature cardiovascular disease.
other	hsa-mir-146a	Chlamydial Infection 	20011700	disease by infectious agent	DOID:11263	A74.9	D002690			microRNA-146a is a negative regulator of Tolllike receptor (TLR) signaling
other	hsa-mir-106b	Cholangiocarcinoma	29286255	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-106b-responsive gene landscape identifies regulation of Kruppel-like factor family
other	hsa-mir-138	Cholangiocarcinoma	23446431	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9.
other	hsa-mir-146a	Cholangiocarcinoma	24918778	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA.
other	hsa-mir-155	Cholangiocarcinoma	24918778	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA.
other	hsa-mir-192	Cholangiocarcinoma	25131257	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	This finding indicates that elevated levels of miR-192 may be involved in CCA genesis and have a potential utility as a noninvasive prognostic indicator for CCA patients.
other	hsa-mir-199	Cholangiocarcinoma	25217977	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	the cell proliferation and inhibition of tumor suppression mediated by these miRNAs is common to both cancerous and non-cancerous cells.
other	hsa-mir-200a	Cholangiocarcinoma	24918778	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA.
other	hsa-mir-200b	Cholangiocarcinoma	24169343	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Our study shows that miR-200b/c has a critical role in the regulation of the tumorigenic and metastatic capacity of cholangiocarcinoma and reveals the probable underlying mechanisms.
other	hsa-mir-200b	Cholangiocarcinoma	24918778	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA.
other	hsa-mir-200c	Cholangiocarcinoma	22707408	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Inactivation of miR-200c resulted in an induction of EMT, whereas activation of miR-200c led to a reduction of EMT including a reduced cell migration and invasion in ICC cells.
other	hsa-mir-200c	Cholangiocarcinoma	24169343	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Our study shows that miR-200b/c has a critical role in the regulation of the tumorigenic and metastatic capacity of cholangiocarcinoma and reveals the probable underlying mechanisms.
other	hsa-mir-21	Cholangiocarcinoma	24918778	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA.
other	hsa-mir-21	Cholangiocarcinoma	22213145	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Based on our data, we conclude that Ars2 is overexpressed in human CCA and may be a diagnostic marker. Ars2 depletion increases PTEN and PDCD4 protein levels via the reduction of miR-21.
other	hsa-mir-21	Cholangiocarcinoma	28197636	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-21 and KLF4 jointly augment epithelial‑mesenchymal transition via the Akt/ERK1/2 pathway.
other	hsa-mir-221	Cholangiocarcinoma	24918778	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Significant variability was observed in the temporal function of all six miRNAs, which may play an important role in the development of CCA.
other	hsa-mir-24	Cholangiocarcinoma	28087162	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.
other	hsa-mir-30e	Cholangiocarcinoma	29662654	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition
other	hsa-mir-494	Cholangiocarcinoma	22785131	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Coordinated effects of microRNA-494 induce G/M arrest in human cholangiocarcinoma.
other	hsa-mir-130b	Cholestasis	25802328	gastrointestinal system disease	DOID:13580	K83.1	D002779	PS243300		These data support miR-130b as a potential negative regulator of drug metabolism by directly and/or indirectly affecting the expression of several ADME genes. This may be of relevance in pathophysiologic conditions such as cholestasis and inflammation, which are associated with increased miR-130b expression.
other	hsa-let-7a	Cholesteatoma	25405753	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	reveal the crucial role of let-7a miRNA in the inhibition of growth and invasion of cholesteatoma keratinocytes.
other	hsa-mir-21	Cholesteatoma	25405753	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	reveal the crucial role of let-7a miRNA in the inhibition of growth and invasion of cholesteatoma keratinocytes.
other	hsa-mir-125b	Chondrosarcoma	24178909	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line
other	hsa-mir-129	Chondrosarcoma	28535514	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	MiR-129-5p Inhibits Proliferation and Invasion of Chondrosarcoma Cells by Regulating SOX4/Wnt/β-Catenin Signaling Pathway.
other	hsa-mir-186	Chondrosarcoma	29730230	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Resistin facilitates VEGF-C-associated lymphangiogenesis by inhibiting miR-186 in human chondrosarcoma cells.
other	hsa-mir-192	Chondrosarcoma	24178909	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line
other	hsa-mir-206	Chondrosarcoma	27826039	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Amphiregulin enhances VEGF-A production in human chondrosarcoma cells and promotes angiogenesis by inhibiting miR-206 via FAK/c-Src/PKCδ pathway.
other	hsa-mir-20a	Chondrosarcoma	24178909	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line
other	hsa-mir-27b	Chondrosarcoma	27252405	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Adiponectin promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-27b through a CaMKII/AMPK/p38 signaling pathway in human chondrosarcoma cells
other	hsa-mir-27b	Chondrosarcoma	27345723	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	expression of microRNA-27b was negatively regulated by leptin
other	hsa-mir-490	Chondrosarcoma	24178909	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line
other	hsa-mir-509	Chondrosarcoma	24178909	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line
other	hsa-mir-550	Chondrosarcoma	24178909	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line
other	hsa-mir-589	Chondrosarcoma	24178909	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	mTORC 1 inhibitor PRP-1 caused significant upregulation of tumor suppressors, such as miR20a, miR125b, and miR192; and downregulation of onco miRNAs, miR509-3p, miR589, miR490-3p, miR 550 in human chondrosarcoma JJ012 cell line
other	hsa-mir-1-1	Chordoma	20041488	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	miR-1:miRNA-1 may have a functional effect on chordoma tumor pathogenesis
other	hsa-mir-1-2	Chordoma	20041488	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	miR-1:miRNA-1 may have a functional effect on chordoma tumor pathogenesis
other	hsa-mir-140	Chordoma	27016303	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	This study uncovered the potential of miR-31, miR-140-3p, miR-148a, and miR-222-3p to be key molecules in the cell viability, cell cycle, and apoptosis in chordomas, as well as initiation,differentiation, and progression.
other	hsa-mir-148a	Chordoma	27016303	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	This study uncovered the potential of miR-31, miR-140-3p, miR-148a, and miR-222-3p to be key molecules in the cell viability, cell cycle, and apoptosis in chordomas, as well as initiation,differentiation, and progression.
other	hsa-mir-222	Chordoma	27016303	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	This study uncovered the potential of miR-31, miR-140-3p, miR-148a, and miR-222-3p to be key molecules in the cell viability, cell cycle, and apoptosis in chordomas, as well as initiation,differentiation, and progression.
other	hsa-mir-31	Chordoma	23912551	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas.
other	hsa-mir-10b	Choriocarcinoma	22682079	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	The role of miR-10b in metastatic pancreatic ductal adenocarcinoma.
other	hsa-mir-141	Choriocarcinoma	21726338	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Reduction in miR-141 is induced by leukemia inhibitory factor and inhibits proliferation in choriocarcinoma cell line JEG-3.
other	hsa-mir-182	Choriocarcinoma	24078156	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	 We have also shown the alterations in expressing profile of miR-31, miR-133a, miR-141, miR-145, miR-149, miR-182 and miR-194, which were observed even in the early stage of disease, and identified a set of genes, which take place in correct assigning of patients in dependence of CRC stage.
other	hsa-mir-194	Choriocarcinoma	24078156	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	 We have also shown the alterations in expressing profile of miR-31, miR-133a, miR-141, miR-145, miR-149, miR-182 and miR-194, which were observed even in the early stage of disease, and identified a set of genes, which take place in correct assigning of patients in dependence of CRC stage.
other	hsa-mir-203	Choriocarcinoma	25486432	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Besides EZH2, increases in miR-203 expression in the crypts at  days 6 and 12 post infection correlated with reduced levels of its target WIF1; overexpression of miR-203 in primary colonocytes decreased WIF1 mRNA and protein  levels.
other	hsa-mir-30d	Choriocarcinoma	27481218	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Following transient transfection of mir-30d mimic, the disrupted attachment and outgrowth of JAR spheroids was partially restored in the model.
other	hsa-mir-31	Choriocarcinoma	24078156	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	 We have also shown the alterations in expressing profile of miR-31, miR-133a, miR-141, miR-145, miR-149, miR-182 and miR-194, which were observed even in the early stage of disease, and identified a set of genes, which take place in correct assigning of patients in dependence of CRC stage.
other	hsa-mir-34a	Choriocarcinoma	23327670	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	MiR-34a was either inhibited or ectopically expressed transiently in two choriocarcinoma cell lines (BeWo and JEG-3) respectively.
other	hsa-mir-211	Chromosome 15q13.3 Microdeletion Syndrome	27459725	genetic disease	DOID:0060394	Q93.5	C567439	612001		The 15q13.3 microdeletion syndrome is caused by a 1.5-MB hemizygous microdeletion located on 15q13.3 affecting seven genes: FAN1; MTMR10; TRPM1; miR-211; KLF13; OTUD7A; and CHRNA7
other	hsa-mir-145	Chromosome 5q Deletion Syndrome	26075044	hematopoietic system disease	DOID:0090016	D46.7		153550		Loss of the microRNA genes miR-145 and miR-146a has been associated with the thrombocytosis observed in 5q- syndrome patients.
other	hsa-mir-146a	Chromosome 5q Deletion Syndrome	26075044	hematopoietic system disease	DOID:0090016	D46.7		153550		Loss of the microRNA genes miR-145 and miR-146a has been associated with the thrombocytosis observed in 5q- syndrome patients.
other	hsa-mir-126	Chronic Heart Failure	24958738	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression.
other	hsa-mir-133a-1	Chronic Heart Failure	19015276	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart
other	hsa-mir-133a-2	Chronic Heart Failure	19015276	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart
other	hsa-mir-21	Chronic Heart Failure	24958738	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression.
other	hsa-mir-214	Chronic Heart Failure	24958738	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression.
other	hsa-mir-221	Chronic Heart Failure	24958738	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression.
other	hsa-mir-222	Chronic Heart Failure	24958738	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	In conclusion, the present study shows that HDL isolated from CHF patients (NYHA-III) reduces the expression of pro-angiogenic miRs (i.e. miR-126 and miR-21), which may contribute to atherogenesis and endothelial dysfunction. However, exercise training was able to attenuate the HDL-induced reduction in pro-angiogenic miRs expression.
other	hsa-mir-122	Chronic Hepatitis B	25788377			B18.0-.1	D019694	610424		Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection.
other	hsa-mir-15a	Chronic Hepatitis B	28498453			B18.0-.1	D019694	610424		The inhibition of microRNA-15a suppresses hepatitis B virus-associated liver cancer cell growth through the Smad/TGF-β pathway.
other	hsa-mir-181a	Chronic Hepatitis B	28053323			B18.0-.1	D019694	610424		HBx promotes cell proliferation by disturbing the cross-talk between miR-181a and PTEN.
other	hsa-mir-210	Chronic Hepatitis B	24597695			B18.0-.1	D019694	610424		Studying the association of microRNA-210 level with chronic hepatitis B progression.
other	hsa-mir-224	Chronic Hepatitis B	27731343			B18.0-.1	D019694	610424		MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C.
other	hsa-mir-122	Chronic Hepatitis C	23808991			B18.2	D019698	609532		Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy.
other	hsa-mir-122	Chronic Hepatitis C	24270780			B18.2	D019698	609532		Reply to miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection.
other	hsa-mir-122	Chronic Hepatitis C	24270782			B18.2	D019698	609532		miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection.
other	hsa-mir-122	Chronic Hepatitis C	24672032			B18.2	D019698	609532		Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.
other	hsa-mir-122	Chronic Hepatitis C	26503793			B18.2	D019698	609532		We demonstrated a substantial and prolonged decrease in plasma miR-122 levels in patients dosed with miravirsen. Plasma levels of other miRNAs were not significantly affected by antagonising miR-122.
other	hsa-mir-122	Chronic Hepatitis C	24752012			B18.2	D019698	609532		HMOX1 and miR-122 play an important role in the pathogenesis of CHC in HCV mono-and HIV/HCV co-infected patients. Reduced expression of HMOX1 in patients with HIV/HCV co-infection may indicate a worse prognosis in this group. Our results do not support the importance of Bach-1 in repression of HMOX1 in patients with chronic hepatitis C.
other	hsa-mir-122	Chronic Hepatitis C	19085952			B18.2	D019698	609532		Moreover, CD56(+) T SN treatment inhibited the expression of HCV-supportive micro RNA (miRNA)-122 and enhanced the levels of anti-HCV miRNA-196a in human hepatocytes.
other	hsa-mir-122	Chronic Hepatitis C	27614072			B18.2	D019698	609532		TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus.
other	hsa-mir-122	Chronic Hepatitis C	27805315			B18.2	D019698	609532		Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion.
other	hsa-mir-122	Chronic Hepatitis C	28008821			B18.2	D019698	609532		Cooperative enhancement of translation by two adjacent microRNA-122/Argonaute 2 complexes binding to the 5' untranslated region of hepatitis C virus RNA.
other	hsa-mir-122	Chronic Hepatitis C	28067225			B18.2	D019698	609532		Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2.
other	hsa-mir-122	Chronic Hepatitis C	28087069			B18.2	D019698	609532		Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
other	hsa-mir-122	Chronic Hepatitis C	28295463			B18.2	D019698	609532		Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.
other	hsa-mir-122	Chronic Hepatitis C	28389707			B18.2	D019698	609532		The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.
other	hsa-mir-122	Chronic Hepatitis C	28442604			B18.2	D019698	609532		Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R.
other	hsa-mir-122	Chronic Hepatitis C	28456022			B18.2	D019698	609532		Cellular DEAD-box RNA helicase DDX6 modulates interaction of miR-122 with the 5' untranslated region of hepatitis C virus RNA.
other	hsa-mir-122	Chronic Hepatitis C	28494029			B18.2	D019698	609532		Characterization of miR-122-independent propagation of HCV.
other	hsa-mir-122	Chronic Hepatitis C	28642978			B18.2	D019698	609532		Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin.
other	hsa-mir-122	Chronic Hepatitis C	28844749			B18.2	D019698	609532		Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
other	hsa-mir-122	Chronic Hepatitis C	29084265			B18.2	D019698	609532		miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence.
other	hsa-mir-122	Chronic Hepatitis C	29327233			B18.2	D019698	609532		DCAF1 is involved in HCV replication through regulation of miR-122 and thus provides new insights into the interaction between HCV and the host cell
other	hsa-mir-122	Chronic Hepatitis C	29343570			B18.2	D019698	609532		the 5'-proximal EHcV-specific region enhances viral replication and RNA stability in a miR-122-independent manner
other	hsa-mir-122	Chronic Hepatitis C	29486652			B18.2	D019698	609532		Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges
other	hsa-mir-122	Chronic Hepatitis C	29672716			B18.2	D019698	609532		miR-122 does not impact recognition of the HCV genome by innate sensors of RNA but rather protects the 5' end from the cellular pyrophosphatases, DOM3Z and DUSP11
other	hsa-mir-155	Chronic Hepatitis C	27765085			B18.2	D019698	609532		Differential Expression of MicroRNAs in Hepatitis C Virus-Mediated Liver Disease Between African Americans and Caucasians: Implications for Racial Health Disparities.
other	hsa-mir-196a	Chronic Hepatitis C	19085952			B18.2	D019698	609532		Moreover, CD56(+) T SN treatment inhibited the expression of HCV-supportive micro RNA (miRNA)-122 and enhanced the levels of anti-HCV miRNA-196a in human hepatocytes.
other	hsa-mir-223	Chronic Hepatitis C	28864162			B18.2	D019698	609532		Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
other	hsa-mir-224	Chronic Hepatitis C	27731343			B18.2	D019698	609532		MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C.
other	hsa-mir-24	Chronic Hepatitis C	28864162			B18.2	D019698	609532		Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
other	hsa-mir-30a	Chronic Hepatitis C	27591428			B18.2	D019698	609532		miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models.
other	hsa-mir-99a	Chronic Hepatitis C	25844942			B18.2	D019698	609532		IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
other	hsa-mir-146a	Chronic Inflammation	23705069							MicroRNA-146a (miR-146a) is a critical negative regulator of inflammation
other	hsa-mir-148a	Chronic Inflammation	25486906							Twist1 and T-bet not only control the differentiation and function of Th1 cells,  but also their persistence in chronic inflammation.
other	hsa-mir-34a	Chronic Inflammation	29773953							miR-34a-mediated regulation of XIST in female cells under inflammation.
other	hsa-mir-21	Chronic Kidney Disease	27610006	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	TGF-β1/Smads and miR-21 in Renal Fibrosis and Inflammation.
other	hsa-mir-1	Chronic Obstructive Pulmonary Disease	28025995	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease.
other	hsa-mir-132	Chronic Obstructive Pulmonary Disease	26807508	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Ectopic expression of PKR or miR-132 antagomiR alone failed to restore IFN-尾 induction, whereas cotreatment increased antiviral stress granule formation, induction of p300, and IFN-尾 in COPD pBECs.
other	hsa-mir-149	Chronic Obstructive Pulmonary Disease	28260877	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Repression of Toll-like receptor-4 by microRNA-149-3p is associated with smoking-related COPD.
other	hsa-mir-15a	Chronic Obstructive Pulmonary Disease	28025995	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease.
other	hsa-mir-16	Chronic Obstructive Pulmonary Disease	28025995	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease.
other	hsa-mir-196a-2	Chronic Obstructive Pulmonary Disease	27043015	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Association of MicroRNA-196a2 Variant with Response to Short-Acting β2-Agonist in COPD: An Egyptian Pilot Study.
other	hsa-mir-21	Chronic Obstructive Pulmonary Disease	29543496	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	MicroRNA-21 aggravates chronic obstructive pulmonary disease by promoting autophagy
other	hsa-mir-23a	Chronic Obstructive Pulmonary Disease	28025995	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease.
other	hsa-mir-34	Chronic Obstructive Pulmonary Disease	26191210	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	These proofs suggest that resveratrol inhibited dysfunction of dendritic cells (DCs) from COPD patients through promoting miR-34.
other	hsa-mir-9	Chronic Obstructive Pulmonary Disease	28025995	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease.
other	hsa-mir-212	Cocaine Abuse	20613834	disease of mental health	DOID:809	F14.1	D019970			miR-212:miR-212 signalling has a key role in determining vulnerability to cocaine addiction
other	hsa-mir-212	Cocaine Abuse	20711185	disease of mental health	DOID:809	F14.1	D019970			miR-212:miR-212 in dorsal striatum may be important in regulating vulnerability to cocaine addiction
other	hsa-mir-146b	Colitis	23071818	gastrointestinal system disease	DOID:0060180	K52.9	D003092	191390	HP:0002583	our data indicates that miRNA-146b and PPARγ activation may be implicated in the regulation of Th17 responses and colitis in C. difficile-infected mice.
other	hsa-mir-155	Colitis	21880981	gastrointestinal system disease	DOID:0060180	K52.9	D003092	191390	HP:0002583	MicroRNA-155 Is Essential for the T Cell-Mediated Control of Helicobacter pylori Infection and for the Induction of Chronic Gastritis and Colitis.
other	hsa-mir-200b	Colitis	28370348	gastrointestinal system disease	DOID:0060180	K52.9	D003092	191390	HP:0002583	miR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition.
other	hsa-mir-124	Colitis, Ulcerative	24825593	gastrointestinal system disease	DOID:8577	K51	D003093			attenuation of ischemic and inflammatory injury in cardiomyocytes.
other	hsa-mir-126	Colitis, Ulcerative	27061150	gastrointestinal system disease	DOID:8577	K51	D003093			mango  polyphenols attenuated inflammatory response by modulating the PI3K/AKT/mTOR pathway at least in part through upregulation of miRNA-126 expression both in vitro and in vivo
other	hsa-mir-146a	Colitis, Ulcerative	26730791	gastrointestinal system disease	DOID:8577	K51	D003093			Our results suggest that microRNAs may serve as a novel regulator in function and homoeostasis of UC Treg cells, providing a key role for them in pathophysiology of UC.
other	hsa-mir-155	Colitis, Ulcerative	26730791	gastrointestinal system disease	DOID:8577	K51	D003093			Our results suggest that microRNAs may serve as a novel regulator in function and homoeostasis of UC Treg cells, providing a key role for them in pathophysiology of UC.
other	hsa-mir-16	Colitis, Ulcerative	26440311	gastrointestinal system disease	DOID:8577	K51	D003093			miR-16 suppression during the colitis-to-cancer sequence in colon epithelial cells, which was rescued by drinking Cl-amidine.
other	hsa-mir-200	Colitis, Ulcerative	28288169	gastrointestinal system disease	DOID:8577	K51	D003093			The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients.
other	hsa-mir-21	Colitis, Ulcerative	26730791	gastrointestinal system disease	DOID:8577	K51	D003093			Our results suggest that microRNAs may serve as a novel regulator in function and homoeostasis of UC Treg cells, providing a key role for them in pathophysiology of UC.
other	hsa-mir-21	Colitis, Ulcerative	27824649	gastrointestinal system disease	DOID:8577	K51	D003093			Downregulation of MicroRNA-21 in Colonic CD3+ T Cells in UC Remission.
other	hsa-mir-941-1	Colitis, Ulcerative	22359580	gastrointestinal system disease	DOID:8577	K51	D003093			UC susceptibility
other	hsa-mir-941-3	Colitis, Ulcerative	22359580	gastrointestinal system disease	DOID:8577	K51	D003093			UC susceptibility
other	hsa-mir-941-4	Colitis, Ulcerative	22359580	gastrointestinal system disease	DOID:8577	K51	D003093			UC susceptibility
other	hsa-mir-204	Coloboma	26056285	nervous system disease	DOID:12270	Q13.0	D003103	120200		MiR-204 is responsible for inherited retinal dystrophy associated with ocular coloboma.
other	hsa-let-7a	Colon Neoplasms	25330373			D12.6	D003110		HP:0100273	63 miRNA are selectively enriched in the EVs--miR-19a/b-3p, miR-378a/c/d, and miR-577 and members of the let-7 and miR-8 families being the most prominent.
other	hsa-let-7c	Colon Neoplasms	18188765			D12.6	D003110		HP:0100273	Let-7C was clearly present in lung, prostate, and colon cancers but undetectable in ovary and thyroid cancer samples
other	hsa-let-7f	Colon Neoplasms	25330373			D12.6	D003110		HP:0100273	63 miRNA are selectively enriched in the EVs--miR-19a/b-3p, miR-378a/c/d, and miR-577 and members of the let-7 and miR-8 families being the most prominent.
other	hsa-let-7g	Colon Neoplasms	18172508			D12.6	D003110		HP:0100273	Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer.
other	hsa-let-7i	Colon Neoplasms	29588449			D12.6	D003110		HP:0100273	Available gene expression data allowed us to associate miR-30b expression with axon guidance and let-7i expression with cell adhesion, migration, and motility
other	hsa-mir-101-1	Colon Neoplasms	19133256			D12.6	D003110		HP:0100273	miR-101: MiR-101 downregulation is involved in cyclooxygenase-2 overexpression
other	hsa-mir-101-1	Colon Neoplasms	22353936			D12.6	D003110		HP:0100273	MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers.
other	hsa-mir-101-2	Colon Neoplasms	19133256			D12.6	D003110		HP:0100273	miR-101: MiR-101 downregulation is involved in cyclooxygenase-2 overexpression
other	hsa-mir-101-2	Colon Neoplasms	22353936			D12.6	D003110		HP:0100273	MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers.
other	hsa-mir-106b	Colon Neoplasms	21283757			D12.6	D003110		HP:0100273	Butyrate-induced p21 protein expression was dampened by treatment with a miR-106b mimic.
other	hsa-mir-1-1	Colon Neoplasms	22179665			D12.6	D003110		HP:0100273	MIR-1 DOWNREGULATION COOPERATES WITH MACC1 IN PROMOTING MET OVEREXPRESSION IN HUMAN COLON CANCER.
other	hsa-mir-125a	Colon Neoplasms	23327190			D12.6	D003110		HP:0100273	miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer
other	hsa-mir-125b-1	Colon Neoplasms	23327190			D12.6	D003110		HP:0100273	miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer
other	hsa-mir-125b-2	Colon Neoplasms	23327190			D12.6	D003110		HP:0100273	miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer
other	hsa-mir-126	Colon Neoplasms	18663744			D12.6	D003110		HP:0100273	miR-126: miR-126 suppresses the growth of neoplastic cells
other	hsa-mir-1290	Colon Neoplasms	23142292			D12.6	D003110		HP:0100273	Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells
other	hsa-mir-130a	Colon Neoplasms	29225578			D12.6	D003110		HP:0100273	Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a
other	hsa-mir-140	Colon Neoplasms	19734943			D12.6	D003110		HP:0100273	high-throughput microRNA (miRNA) expression analysis revealed that the expression of miR-140 was associated with chemosensitivity in osteosarcoma tumor xenografts
other	hsa-mir-143	Colon Neoplasms	14573789			D12.6	D003110		HP:0100273	reduced miRNA levels
other	hsa-mir-143	Colon Neoplasms	21276449			D12.6	D003110		HP:0100273	The ecotropic viral integration site 1 oncoprotein (Evi1) is a transcriptional suppressor of the miRNA-143 gene.
other	hsa-mir-143	Colon Neoplasms	21653642			D12.6	D003110		HP:0100273	EGFR suppresses miR-143 and miR-145 in murine models of colon cancer. Furthermore, Western diet unmasks the tumor suppressor roles of these EGFR-regulated miRNAs.
other	hsa-mir-143	Colon Neoplasms	26025964			D12.6	D003110		HP:0100273	The data also showed that the restoration of hsa-miR-143 expression in SW480 leads to a significant translation repression of the introduced reporter and suicide genes.
other	hsa-mir-143	Colon Neoplasms	26824186			D12.6	D003110		HP:0100273	miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells
other	hsa-mir-143	Colon Neoplasms	29360852			D12.6	D003110		HP:0100273	miR-143 might circumvent resistance of colon cancer cells to oxaliplatin via increased oxidative stress in HCT116 human colon cancer cells
other	hsa-mir-145	Colon Neoplasms	14573789			D12.6	D003110		HP:0100273	reduced miRNA levels
other	hsa-mir-145	Colon Neoplasms	18676867			D12.6	D003110		HP:0100273	miR-145: miR-145 potently suppressed growth of three different colon carcinoma cell lines
other	hsa-mir-145	Colon Neoplasms	21653642			D12.6	D003110		HP:0100273	EGFR suppresses miR-143 and miR-145 in murine models of colon cancer. Furthermore, Western diet unmasks the tumor suppressor roles of these EGFR-regulated miRNAs.
other	hsa-mir-145	Colon Neoplasms	26824186			D12.6	D003110		HP:0100273	miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells
other	hsa-mir-155	Colon Neoplasms	23036199			D12.6	D003110		HP:0100273	Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155
other	hsa-mir-15a	Colon Neoplasms	22574716			D12.6	D003110		HP:0100273	Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo.
other	hsa-mir-15b	Colon Neoplasms	24892299			D12.6	D003110		HP:0100273	Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer.
other	hsa-mir-16-1	Colon Neoplasms	22574716			D12.6	D003110		HP:0100273	Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo.
other	hsa-mir-16-1	Colon Neoplasms	23308284			D12.6	D003110		HP:0100273	The Induction of microRNA-16 in Colon Cancer Cells by Protein Arginine Deiminase Inhibition Causes a p53-Dependent Cell Cycle Arrest
other	hsa-mir-16-2	Colon Neoplasms	23308284			D12.6	D003110		HP:0100273	The Induction of microRNA-16 in Colon Cancer Cells by Protein Arginine Deiminase Inhibition Causes a p53-Dependent Cell Cycle Arrest
other	hsa-mir-17	Colon Neoplasms	22677902			D12.6	D003110		HP:0100273	miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
other	hsa-mir-181b	Colon Neoplasms	18172508			D12.6	D003110		HP:0100273	Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer.
other	hsa-mir-1915	Colon Neoplasms	24814047			D12.6	D003110		HP:0100273	Tumor suppressor p53 induces miR-1915 processing to inhibit Bcl-2 in the apoptotic response to DNA damage.
other	hsa-mir-192	Colon Neoplasms	19074875			D12.6	D003110		HP:0100273	Hence, miR-192 and miR-215 can act as effectors as well as regulators of p53; they seem to suppress cancerogenesis through p21 accumulation and cell cycle arrest.
other	hsa-mir-19a	Colon Neoplasms	22677902			D12.6	D003110		HP:0100273	miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
other	hsa-mir-19a	Colon Neoplasms	23666757			D12.6	D003110		HP:0100273	MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion.
other	hsa-mir-203	Colon Neoplasms	28431272			D12.6	D003110		HP:0100273	Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6.
other	hsa-mir-21	Colon Neoplasms	21279518			D12.6	D003110		HP:0100273	PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis.
other	hsa-mir-21	Colon Neoplasms	22677902			D12.6	D003110		HP:0100273	miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
other	hsa-mir-21	Colon Neoplasms	23544170			D12.6	D003110		HP:0100273	Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens
other	hsa-mir-21	Colon Neoplasms	26853468			D12.6	D003110		HP:0100273	a DHA-enriched diet induced a decrease of  human miR-21 expression and an increase of human TNF伪 mRNA expression limiting tumor growth in a cancer cell-derived TNF伪 dependent manner.
other	hsa-mir-21	Colon Neoplasms	28176652			D12.6	D003110		HP:0100273	Mechanisms for the Inhibition of Colon Cancer Cells by Sulforaphane through Epigenetic Modulation of MicroRNA-21 and Human Telomerase Reverse Transcriptase (hTERT) Down-regulation.
other	hsa-mir-21	Colon Neoplasms	17702597			D12.6	D003110		HP:0100273	In colon cancer cells, at a clinically relevant concentration,the drug up-regulates or down-regulates in vitro the expression of 19 and 3 miR genes, respectively, by a factor of not less than two-fold. In some instances, 5-FU up-regulates miR genes that are already over-expressed in neoplastic tissues, including, for example, miR-21 that is associated with anti-apoptotic functions characterizing malignant cells. 
other	hsa-mir-215	Colon Neoplasms	19074875			D12.6	D003110		HP:0100273	Hence, miR-192 and miR-215 can act as effectors as well as regulators of p53; they seem to suppress cancerogenesis through p21 accumulation and cell cycle arrest.
other	hsa-mir-22	Colon Neoplasms	22328083			D12.6	D003110		HP:0100273	MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells.
other	hsa-mir-223	Colon Neoplasms	23584479			D12.6	D003110		HP:0100273	Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.
other	hsa-mir-23b	Colon Neoplasms	22109528			D12.6	D003110		HP:0100273	Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis.
other	hsa-mir-29b	Colon Neoplasms	29545333			D12.6	D003110		HP:0100273	A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
other	hsa-mir-302b	Colon Neoplasms	22384170			D12.6	D003110		HP:0100273	Ascl2 Knockdown Results in Tumor Growth Arrest by miRNA-302b-Related Inhibition of Colon Cancer Progenitor Cells.
other	hsa-mir-30b	Colon Neoplasms	29588449			D12.6	D003110		HP:0100273	Available gene expression data allowed us to associate miR-30b expression with axon guidance and let-7i expression with cell adhesion, migration, and motility
other	hsa-mir-31	Colon Neoplasms	21062447			D12.6	D003110		HP:0100273	Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells.
other	hsa-mir-31	Colon Neoplasms	27926494			D12.6	D003110		HP:0100273	p38 and JNK pathways control E-selectin-dependent extravasation of colon cancer cells by modulating miR-31 transcription.
other	hsa-mir-34a	Colon Neoplasms	20433755			D12.6	D003110		HP:0100273	For instance, miR-34a up-regulation corresponded with a down-regulation of BCL2 protein. Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU.
other	hsa-mir-449a	Colon Neoplasms	28878284			D12.6	D003110		HP:0100273	MicroRNA-449a deficiency promotes colon carcinogenesis.
other	hsa-mir-455	Colon Neoplasms	27861461			D12.6	D003110		HP:0100273	MicroRNA-455-3p Inhibits Tumor Cell Proliferation and Induces Apoptosis in HCT116 Human Colon Cancer Cells.
other	hsa-mir-493	Colon Neoplasms	22373578			D12.6	D003110		HP:0100273	miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver.
other	hsa-mir-498	Colon Neoplasms	18676867			D12.6	D003110		HP:0100273	miR-498: correlated with the probability of recurrence-free survival
other	hsa-mir-502	Colon Neoplasms	22580605			D12.6	D003110		HP:0100273	Inhibition of autophagy and tumor growth in colon cancer by miR-502.
other	hsa-mir-627	Colon Neoplasms	27458137			D12.6	D003110		HP:0100273	In addition, overexpression of miR-627 or  siRNA knockdown of CYP3A4 enhanced the efficacy of irinotecan in growth inhibition and apoptosis induction.
other	hsa-mir-92a-1	Colon Neoplasms	21883694			D12.6	D003110		HP:0100273	miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer
other	hsa-mir-126	Colorectal Adenocarcinoma	23996930	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrant crypt foci and inflammation: possible role of miR-126/VCAM-1 and miR-126/PI3K/AKT/mTOR.
other	hsa-mir-145	Colorectal Adenocarcinoma	24938624	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		This might be attributable to the fact that effects of miRNA activity may oscillate between gene product repression and activation.
other	hsa-mir-182	Colorectal Adenocarcinoma	24615484	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		The increased levels of the oncogene-like miR-182 increase the risk for disease progression and predict poor overall survival for colorectal adenocarcinoma patients.
other	hsa-mir-21	Colorectal Adenocarcinoma	24938624	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		This might be attributable to the fact that effects of miRNA activity may oscillate between gene product repression and activation.
other	hsa-mir-21	Colorectal Adenocarcinoma	29512659	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		An amplification-free electrochemical detection of exosomal miRNA-21 in serum samples
other	hsa-mir-15a	Colorectal Adenoma	26148070	disease of cellular proliferation	DOID:0050860					Oncogenic Role of miR-15a-3p in 13q Amplicon-Driven Colorectal Adenoma-to-Carcinoma Progression.
other	hsa-let-7b	Colorectal Carcinoma	25611389	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer.
other	hsa-mir-100	Colorectal Carcinoma	26132860	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings suggest that extracellular miRNAs can function in target cells and uncover a potential new mode of action for mutant KRAS in CRC.
other	hsa-mir-101	Colorectal Carcinoma	26071354	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells.
other	hsa-mir-106a	Colorectal Carcinoma	23950216	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Fecal miR-106a is a good molecular marker to identify colorectal cancer patients from among those with negative iFOBT results. FmiRT combined with iFOBT may improve the sensitivity to detect colorectal cancer.
other	hsa-mir-106a	Colorectal Carcinoma	28693239	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Biological effects and clinical characteristics of microRNA-106a in human colorectal cancer
other	hsa-mir-106b	Colorectal Carcinoma	26238857	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer.
other	hsa-mir-106b	Colorectal Carcinoma	26617763	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Taken together, these findings demonstrated that miR-106b knockdown could induce EMT which conferring cells migratory and invasive properties but could not accomplish distant metastatic colonization efficiently.
other	hsa-mir-107	Colorectal Carcinoma	25197016	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-107 and miR-99a-3p were validated as predictors of response to standard fluoropyrimidine-based chemotherapy in patients with mCRC.
other	hsa-mir-10b	Colorectal Carcinoma	25606801	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-10b is potentially involved in the invasion of colorectal cancer.
other	hsa-mir-124	Colorectal Carcinoma	24909917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		KITENIN-targeting microRNA-124 suppresses colorectal cancer cell motility and tumorigenesis.
other	hsa-mir-124	Colorectal Carcinoma	25818238	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.
other	hsa-mir-1288	Colorectal Carcinoma	24009195	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance.
other	hsa-mir-1292	Colorectal Carcinoma	28054337	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis.
other	hsa-mir-1307	Colorectal Carcinoma	25977444	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The polymorphic terminal-loop of pre-miR-1307 binding with MBNL1 contributes to colorectal carcinogenesis via interference with Dicer1 recruitment.
other	hsa-mir-130b	Colorectal Carcinoma	24027433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer.
other	hsa-mir-130b	Colorectal Carcinoma	24204200	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer.
other	hsa-mir-132	Colorectal Carcinoma	24914372	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study indicated that miR-132 plays an important role in the invasion and metastasis of CRC.
other	hsa-mir-133a	Colorectal Carcinoma	25104873	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The clinicopathological significance of miR-133a in colorectal cancer.
other	hsa-mir-133a	Colorectal Carcinoma	24464560	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		DSS-induced chronic inflammation downregulates miR-133a and miR-143/145, which is reportedly  associated with human colorectal cancer and PI3K/Akt activation.
other	hsa-mir-133b	Colorectal Carcinoma	28098895	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer.
other	hsa-mir-134	Colorectal Carcinoma	26897940	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Decreased Expression of MIR-134 and its Clinical Significance in Human Colorectal Cancer.
other	hsa-mir-138	Colorectal Carcinoma	26316117	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of miR-138 as a Contributing Mechanism to Lcn-2 Overexpression in Colorectal Cancer with Liver Metastasis.
other	hsa-mir-139	Colorectal Carcinoma	24942287	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Post-transcriptional regulation of the tumor suppressor miR-139-5p and a network of miR-139-5p-mediated mRNA interactions in colorectal cancer.
other	hsa-mir-139	Colorectal Carcinoma	25286864	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Gene module based regulator inference identifying miR-139 as a tumor suppressor in colorectal cancer.
other	hsa-mir-139	Colorectal Carcinoma	27173050	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1.
other	hsa-mir-140	Colorectal Carcinoma	25980495	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy.
other	hsa-mir-141	Colorectal Carcinoma	26179333	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells.
other	hsa-mir-143	Colorectal Carcinoma	25474488	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		a role of the miR-143/145 cluster as a tumor suppressor in colorectal cancer through the inhibition of IGF1R translation.
other	hsa-mir-143	Colorectal Carcinoma	26392389	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings warrant further studies to investigate the relationship between miR-143, FXYD3 and fluoropyrimidines, and the clinical utility of miR-143 as biomarker.
other	hsa-mir-143	Colorectal Carcinoma	19843160	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Collectively, the data obtained in the present study suggest anti-proliferative, chemosensitizer and putative pro-apoptotic roles for miR-143 in colon cancer.
other	hsa-mir-143	Colorectal Carcinoma	22751122	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These results establish a complex network of regulation through which the miR-143/145 cluster is able to modulate KRAS signaling in colorectal cancer.
other	hsa-mir-143	Colorectal Carcinoma	27629291	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		we showed the importance of interactions between TP53, miR-143, KRAS, BCL2, and PLK1 with respect to colorectal cancer using bioinformatics approach
other	hsa-mir-143	Colorectal Carcinoma	19843336	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In vitro functional studies indicated that miR-143 and miR-145 appear to function in opposing manners to either inhibit or augment cell proliferation in a metastatic CRC model.
other	hsa-mir-145	Colorectal Carcinoma	25474488	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		a role of the miR-143/145 cluster as a tumor suppressor in colorectal cancer through the inhibition of IGF1R translation.
other	hsa-mir-145	Colorectal Carcinoma	22751122	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These results establish a complex network of regulation through which the miR-143/145 cluster is able to modulate KRAS signaling in colorectal cancer.
other	hsa-mir-145	Colorectal Carcinoma	29404790	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the pattern of miRNA expression and its correlation with histological markers are potentially valuable to apply as diagnostic biomarkers for CRC
other	hsa-mir-145	Colorectal Carcinoma	19843336	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In vitro functional studies indicated that miR-143 and miR-145 appear to function in opposing manners to either inhibit or augment cell proliferation in a metastatic CRC model.
other	hsa-mir-146a	Colorectal Carcinoma	24576899	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A microRNA-operated switch of asymmetric-to-symmetric cancer stem cell divisions.
other	hsa-mir-146a	Colorectal Carcinoma	27580100	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Numb is involved in the non-random segregation of subcellular vesicles in colorectal cancer stem cells.
other	hsa-mir-146a	Colorectal Carcinoma	27769860	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-146a inhibits proliferation, migration and invasion of human cervical and colorectal cancer cells.
other	hsa-mir-148a	Colorectal Carcinoma	23933284	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical significance of microRNA-148a in patients with early relapse of stage II stage and III colorectal cancer after curative resection.
other	hsa-mir-148b	Colorectal Carcinoma	24632606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer.
other	hsa-mir-150	Colorectal Carcinoma	25924769	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups.
other	hsa-mir-152	Colorectal Carcinoma	28098901	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		after treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted
other	hsa-mir-153	Colorectal Carcinoma	23950211	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.
other	hsa-mir-155	Colorectal Carcinoma	27176480	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		S100A8 activated the NF-魏B pathway in the macrophages and promoted the expression of miR-155
other	hsa-mir-16	Colorectal Carcinoma	24895601	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results have laid down a solid foundation in exploration of novel CRC mechanisms, and identification of miRNA roles as oncomirs or tumor suppressor mirs in CRC.
other	hsa-mir-16	Colorectal Carcinoma	27055667	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Prodigiosin caused a significant increase in miRNA-16-1 expression
other	hsa-mir-17	Colorectal Carcinoma	26215320	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Calycosin induces apoptosis by the regulation of ERβ/miR-17 signaling pathway in human colorectal cancer cells.
other	hsa-mir-182	Colorectal Carcinoma	25755709	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Fentanyl also downregulated the expression of 尾-catenin and miR-182 in  both xenograft tumors and HCT116 cells
other	hsa-mir-18a	Colorectal Carcinoma	25379703	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells.
other	hsa-mir-19	Colorectal Carcinoma	25934693	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.
other	hsa-mir-194	Colorectal Carcinoma	28280361	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-194 modulates epithelial-mesenchymal transition in human colorectal cancer metastasis.
other	hsa-mir-195	Colorectal Carcinoma	28255246	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-195 enhances the radiosensitivity of colorectal cancer cells by suppressing CARM1.
other	hsa-mir-195	Colorectal Carcinoma	28356122	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer.
other	hsa-mir-196a-2	Colorectal Carcinoma	24107909	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Meta-analysis of the association between a polymorphism in microRNA-196a2 and susceptibility to colorectal cancer.
other	hsa-mir-199a	Colorectal Carcinoma	26065676	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		It was found that miR-199a would reduce the proliferation, migration and invasion. However, overexpression of miR-199a on the apoptosis rate and cell cycles showed no significant results. The potential functionary mechanism of miR-199a might through HIF-1α/VEGF pathway.
other	hsa-mir-19a	Colorectal Carcinoma	26302825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Collectively, miR-19a played an important role in mediating EMT and metastatic behavior in CRC. It may serve as a potential marker of lymph node metastasis.
other	hsa-mir-200	Colorectal Carcinoma	24376848	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The role of microRNA-200 in progression of human colorectal and breast cancer.
other	hsa-mir-200b	Colorectal Carcinoma	28899657	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		HIF-1α/Ascl2/miR-200b regulatory feedback circuit modulated the epithelial-mesenchymal transition (EMT) in colorectal cancer cells.
other	hsa-mir-200c	Colorectal Carcinoma	26179333	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells.
other	hsa-mir-200c	Colorectal Carcinoma	27918105	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Resveratrol Inhibits Proliferation, Invasion, and Epithelial-Mesenchymal Transition by Increasing miR-200c Expression in HCT-116 Colorectal Cancer Cells.
other	hsa-mir-200c	Colorectal Carcinoma	28745318	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
other	hsa-mir-200c	Colorectal Carcinoma	28567416	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Negative Correlation between miR-200c and Decorin Plays an Important Role in the Pathogenesis of Colorectal Carcinoma.
other	hsa-mir-203	Colorectal Carcinoma	27236538	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		overexpression of miR-203 sensitizes colon cancer cells
other	hsa-mir-204	Colorectal Carcinoma	25294901	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results demonstrate for the first time that miR-204-5p acts as a tumor suppressor in colorectal cancer through inhibiting RAB22A and reveal RAB22A to be a new oncogene and prognostic factor for colorectal cancer.
other	hsa-mir-204	Colorectal Carcinoma	27571956	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs.
other	hsa-mir-205	Colorectal Carcinoma	26183718	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the integration of multiple omics methods allowed the comprehensive identification of direct and indirect effectors of p53 that provide new insights and leads into the mechanisms of p53-mediated tumor suppression.
other	hsa-mir-20a	Colorectal Carcinoma	29404790	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the pattern of miRNA expression and its correlation with histological markers are potentially valuable to apply as diagnostic biomarkers for CRC
other	hsa-mir-21	Colorectal Carcinoma	22281474	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Aging and DMH are associated with increases in CSLC biomarkers and miR21, each of which have been linked to colorectal cancer.
other	hsa-mir-21	Colorectal Carcinoma	23788041	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression.
other	hsa-mir-21	Colorectal Carcinoma	23858763	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Construction of microRNA-21 and PTEN eukaryotic expression and short hairpin RNA expression vectors
other	hsa-mir-21	Colorectal Carcinoma	24780321	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Correlation of over-expressions of miR-21 and Notch-1 in human colorectal cancer with clinical stages.
other	hsa-mir-21	Colorectal Carcinoma	24832083	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		nuclear translocation of β-catenin increased by miR-21 promotes tumour malignancy and a poor outcome in APC-mutated patients but not in APC-wild-type colorectal cancer.
other	hsa-mir-21	Colorectal Carcinoma	25178983	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR21 level has potential value for colorectal cancer early detection, whereas high tissue miR21 level is associated with adverse colorectal cancer prognosis.
other	hsa-mir-21	Colorectal Carcinoma	26184038	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b.
other	hsa-mir-21	Colorectal Carcinoma	27349026	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma Expression Levels of Circulating miR-21 are not Useful for Diagnosing and Monitoring Colorectal Cancer.
other	hsa-mir-21	Colorectal Carcinoma	29404790	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the pattern of miRNA expression and its correlation with histological markers are potentially valuable to apply as diagnostic biomarkers for CRC
other	hsa-mir-21	Colorectal Carcinoma	28192117	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		NR2F2 inhibits Smad7 expression and promotes TGF-β-dependent epithelial-mesenchymal transition of CRC via transactivation of miR-21.
other	hsa-mir-21	Colorectal Carcinoma	28236743	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Direct binding of microRNA-21 pre-element with Regorafenib: An alternative mechanism for anti-colorectal cancer chemotherapy
other	hsa-mir-21	Colorectal Carcinoma	28401648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.
other	hsa-mir-21	Colorectal Carcinoma	29456985	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Evaluation of miR-21 Inhibition and its Impact on Cancer Susceptibility Candidate 2 Long Noncoding RNA in Colorectal Cancer Cell Line
other	hsa-mir-21	Colorectal Carcinoma	26712035	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21 followed by miR-34, miR-200 and miR-215 are the most reported miRNAs to have roles in colon CSC regulation.
other	hsa-mir-210	Colorectal Carcinoma	24632577	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer.
other	hsa-mir-211	Colorectal Carcinoma	26974151	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Long Non-Coding RNA ucoo2kmd.1 Regulates CD44-Dependent Cell Growth by Competing for miR-211-3p in Colorectal Cancer.
other	hsa-mir-214	Colorectal Carcinoma	24616020	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression.
other	hsa-mir-215	Colorectal Carcinoma	28006930	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Systemic administration of miRNA mimics by liposomal delivery system in animal model of colorectal carcinoma.
other	hsa-mir-215	Colorectal Carcinoma	26712035	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21 followed by miR-34, miR-200 and miR-215 are the most reported miRNAs to have roles in colon CSC regulation.
other	hsa-mir-221	Colorectal Carcinoma	23770133	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In metastatic CRC cells, reduced levels of mir-221* and mir-224 increase levels of MBD2, thereby decreasing expression of the metastasis suppressor maspin. Increased activities of mir-221* and mir-224 reduce growth and metastasis of CRC xenograft tumors in mice; these mirs might be developed as therapeutic reagents or biomarkers of CRC progression.
other	hsa-mir-223	Colorectal Carcinoma	24841830	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		fecal miR-223 and miR-451 hold promise in detecting CRC.
other	hsa-mir-223	Colorectal Carcinoma	24819398	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-223 functions as an oncogene in human colorectal cancer cells.
other	hsa-mir-224	Colorectal Carcinoma	23770133	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In metastatic CRC cells, reduced levels of mir-221* and mir-224 increase levels of MBD2, thereby decreasing expression of the metastasis suppressor maspin. Increased activities of mir-221* and mir-224 reduce growth and metastasis of CRC xenograft tumors in mice; these mirs might be developed as therapeutic reagents or biomarkers of CRC progression.
other	hsa-mir-224	Colorectal Carcinoma	25919696	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We describe a novel mechanism of KRAS regulation, and highlight the clinical utility of colorectal cancer-specific miRNAs as disease progression or clinical response biomarkers.
other	hsa-mir-224	Colorectal Carcinoma	26822534	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our research showed mechanistic links between miR-224 and Wnt/β-catenin in the pathogenesis of CRC through modulation of GSK3β and SFRP2.
other	hsa-mir-23a	Colorectal Carcinoma	24249161	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells.
other	hsa-mir-26a	Colorectal Carcinoma	26494299	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA.
other	hsa-mir-26b	Colorectal Carcinoma	26308439	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical Value of miR-26b Discriminating Ulcerative Colitis-associated Colorectal Cancer in the Subgroup of Patients with Metastatic Disease.
other	hsa-mir-27a	Colorectal Carcinoma	24909917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		KITENIN-targeting microRNA-124 suppresses colorectal cancer cell motility and tumorigenesis.
other	hsa-mir-27a	Colorectal Carcinoma	25712055	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer.
other	hsa-mir-29a	Colorectal Carcinoma	26782449	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis.
other	hsa-mir-29a	Colorectal Carcinoma	28098901	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		after treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted
other	hsa-mir-29b	Colorectal Carcinoma	26184038	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b.
other	hsa-mir-30b	Colorectal Carcinoma	24909917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		KITENIN-targeting microRNA-124 suppresses colorectal cancer cell motility and tumorigenesis.
other	hsa-mir-31	Colorectal Carcinoma	24242331	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.
other	hsa-mir-31	Colorectal Carcinoma	27082577	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
other	hsa-mir-31	Colorectal Carcinoma	25543122	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-31 and -182 in CRC  leads to more aggressive cancer.
other	hsa-mir-31	Colorectal Carcinoma	26871294	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In conclusion, an inverse association was identified between EZH2 and miR-31 in colorectal cancers.
other	hsa-mir-320a	Colorectal Carcinoma	25458952	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-320b may function in competing with microRNA-320a. Thus, our study has proposed one novel mechanism for controlling colorectal cancer proliferation and invasion through homologous competition between microRNAs. This mechanism may be important for colorectal cancer metastasis.
other	hsa-mir-320b	Colorectal Carcinoma	25458952	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-320b may function in competing with microRNA-320a. Thus, our study has proposed one novel mechanism for controlling colorectal cancer proliferation and invasion through homologous competition between microRNAs. This mechanism may be important for colorectal cancer metastasis.
other	hsa-mir-320e	Colorectal Carcinoma	26035698	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In two clinical trial cohorts, a systematic biomarker discovery and validation approach identified miR-320e to be a novel prognostic biomarker that is associated with adverse clinical outcome in stage III CRC patients treated with 5-FU-based adjuvant chemotherapy. These findings have important implications for the personalised management of CRC patients.
other	hsa-mir-34a	Colorectal Carcinoma	25362853	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
other	hsa-mir-34a	Colorectal Carcinoma	25712055	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer.
other	hsa-mir-34a	Colorectal Carcinoma	25924769	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups.
other	hsa-mir-34a	Colorectal Carcinoma	26183718	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the integration of multiple omics methods allowed the comprehensive identification of direct and indirect effectors of p53 that provide new insights and leads into the mechanisms of p53-mediated tumor suppression.
other	hsa-mir-34c	Colorectal Carcinoma	26674205	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Res suppressed CRC by specifically activating miR-34c-KITLG in vitro and in vivo; and the effect was strengthened in the presence of p53. Besides, Resexerted a synergistic effect with Oxa in a miR-34c dependent manner. We also suggested that Res-increased miR-34c could interfere IL-6-triggered CRC progression.
other	hsa-mir-362	Colorectal Carcinoma	27082577	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
other	hsa-mir-374b	Colorectal Carcinoma	26045793	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer.
other	hsa-mir-375	Colorectal Carcinoma	22535378	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In formalin-fixed paraffin-embedded surgical tissue samples, a combination of miR-375, miR-424 and miR-92a yielded an accuracy of 94% (AUC=0.968) in discriminating carcinomas from adenomas. 
other	hsa-mir-375	Colorectal Carcinoma	28186962	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways.
other	hsa-mir-375	Colorectal Carcinoma	29068474	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer.
other	hsa-mir-378	Colorectal Carcinoma	25328987	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-378 inhibits cell growth and enhances L-OHP-induced apoptosis in human colorectal cancer.
other	hsa-mir-378	Colorectal Carcinoma	26496897	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
other	hsa-mir-378a	Colorectal Carcinoma	24412052	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer.
other	hsa-mir-423	Colorectal Carcinoma	26402653	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In conclusion, our findings demonstrated a critical impact of miR-423-3p on CRC growth.
other	hsa-mir-424	Colorectal Carcinoma	22535378	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In formalin-fixed paraffin-embedded surgical tissue samples, a combination of miR-375, miR-424 and miR-92a yielded an accuracy of 94% (AUC=0.968) in discriminating carcinomas from adenomas. 
other	hsa-mir-424	Colorectal Carcinoma	28054337	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis.
other	hsa-mir-425	Colorectal Carcinoma	27082577	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
other	hsa-mir-429	Colorectal Carcinoma	24237355	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-429 identified by dynamic transcriptome analysis is a new candidate biomarker for colorectal cancer prognosis.
other	hsa-mir-429	Colorectal Carcinoma	24510588	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy.
other	hsa-mir-429	Colorectal Carcinoma	28098901	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		after treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted
other	hsa-mir-449b	Colorectal Carcinoma	23674142	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These data suggest that miR-449b plays a tumor-suppressive role in colon cancer stem cells
other	hsa-mir-451	Colorectal Carcinoma	24841830	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		fecal miR-223 and miR-451 hold promise in detecting CRC.
other	hsa-mir-455	Colorectal Carcinoma	27571956	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs.
other	hsa-mir-4775	Colorectal Carcinoma	28095858	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFβ-mediated epithelial to mesenchymal transition.
other	hsa-mir-486	Colorectal Carcinoma	26183718	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the integration of multiple omics methods allowed the comprehensive identification of direct and indirect effectors of p53 that provide new insights and leads into the mechanisms of p53-mediated tumor suppression.
other	hsa-mir-497	Colorectal Carcinoma	24375248	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis.
other	hsa-mir-497	Colorectal Carcinoma	25926384	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-497 promotes metastasis of colorectal cancer cells through Nrdp1 inhibition.
other	hsa-mir-497	Colorectal Carcinoma	25929865	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug.
other	hsa-mir-502	Colorectal Carcinoma	26086375	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets.
other	hsa-mir-503	Colorectal Carcinoma	28054337	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis.
other	hsa-mir-518a	Colorectal Carcinoma	25812680	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of miR-518a-3p activates the NIK-dependent NF-κB pathway in colorectal cancer.
other	hsa-mir-584	Colorectal Carcinoma	26494299	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA.
other	hsa-mir-592	Colorectal Carcinoma	25661360	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer.
other	hsa-mir-625	Colorectal Carcinoma	23861214	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggest that miR-625 may serve as an efficient clinical biomarker and a therapeutic tool for the inhibition of metastasis in CRC.
other	hsa-mir-630	Colorectal Carcinoma	24981248	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-630 is a prognostic marker for patients with colorectal cancer.
other	hsa-mir-650	Colorectal Carcinoma	26086375	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets.
other	hsa-mir-7	Colorectal Carcinoma	26086375	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets.
other	hsa-mir-7	Colorectal Carcinoma	27919977	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-7 Is Associated with Malignant Potential and Poor Prognosis in Human Colorectal Cancer.
other	hsa-mir-7	Colorectal Carcinoma	28929494	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.
other	hsa-mir-760	Colorectal Carcinoma	26086375	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets.
other	hsa-mir-877	Colorectal Carcinoma	27082577	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
other	hsa-mir-9	Colorectal Carcinoma	25940709	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Regulation of UHRF1 by microRNA-9 modulates colorectal cancer cell proliferation and apoptosis.
other	hsa-mir-92a	Colorectal Carcinoma	25515201	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-92a is involved in lymph node metastasis of CRC patients through PTEN-regulated PI3K/AKT signaling pathway.
other	hsa-mir-92a	Colorectal Carcinoma	22535378	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In formalin-fixed paraffin-embedded surgical tissue samples, a combination of miR-375, miR-424 and miR-92a yielded an accuracy of 94% (AUC=0.968) in discriminating carcinomas from adenomas. 
other	hsa-mir-92b	Colorectal Carcinoma	28693229	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX.
other	hsa-mir-93	Colorectal Carcinoma	25371073	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-93 suppress colorectal cancer development via Wnt/β-catenin pathway downregulating.
other	hsa-mir-93	Colorectal Carcinoma	26086375	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While the approach is here validated for CRC, the implementation of disease-specific miRNA target prediction algorithms can be easily adopted for other applications too. The identification of disease-specific miRNA target interactions may also facilitate the identification of potential drug targets.
other	hsa-mir-95	Colorectal Carcinoma	25671802	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Glargine Promotes Human Colorectal Cancer Cell Proliferation via Upregulation of miR-95.
other	hsa-mir-95	Colorectal Carcinoma	27393650	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In conclusion, calycosin exerts an inhibitory effect on proliferation of CRC cells in vivo and in vitro, through ER尾-mediated regulation of the IGF-1R, PI3K/Akt signaling pathways and of miR-95 expression.
other	hsa-mir-96	Colorectal Carcinoma	25256312	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients.
other	hsa-mir-99a	Colorectal Carcinoma	25197016	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-107 and miR-99a-3p were validated as predictors of response to standard fluoropyrimidine-based chemotherapy in patients with mCRC.
other	hsa-let-7b	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-1	Colorectal Carcinoma	25196260	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Tumor suppressor miR-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the MAPK and PI3K/AKT pathway.
other	hsa-mir-106a	Colorectal Carcinoma	22202009	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks.
other	hsa-mir-10b	Colorectal Carcinoma	22322955	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-10b is a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells.
other	hsa-mir-1-1	Colorectal Carcinoma	22343615	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation.
other	hsa-mir-124-1	Colorectal Carcinoma	22885837	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer.
other	hsa-mir-124-2	Colorectal Carcinoma	22885837	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer.
other	hsa-mir-1246	Colorectal Carcinoma	22479426	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors.
other	hsa-mir-125b-1	Colorectal Carcinoma	21399871	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-125b is directly involved in cancer progression and is associated with poor prognosis in human colorectal cancer. Our findings suggest that miR-125b could be an important prognostic indicator for colorectal cancer patients.
other	hsa-mir-125b-2	Colorectal Carcinoma	21399871	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-125b is directly involved in cancer progression and is associated with poor prognosis in human colorectal cancer. Our findings suggest that miR-125b could be an important prognostic indicator for colorectal cancer patients.
other	hsa-mir-126	Colorectal Carcinoma	22848274	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer.
other	hsa-mir-1275	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-1280	Colorectal Carcinoma	22479426	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors.
other	hsa-mir-129-1	Colorectal Carcinoma	23744359	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.
other	hsa-mir-129-2	Colorectal Carcinoma	23744359	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.
other	hsa-mir-133a	Colorectal Carcinoma	23968734	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-133a may play a key role in CRC genesis and metastasis, which suggests its potential role in the molecular therapy of cancer.
other	hsa-mir-135b	Colorectal Carcinoma	26178670	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-135b and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors.
other	hsa-mir-137	Colorectal Carcinoma	23275153	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer
other	hsa-mir-140	Colorectal Carcinoma	22479426	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors.
other	hsa-mir-141	Colorectal Carcinoma	19830559	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-141:miR-141 regulates SIP1 to inhibit migration and invasion of CRC cells
other	hsa-mir-142	Colorectal Carcinoma	23397547	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of anti-oncomirs miR-143/145 cluster occurs before APC gene aberration in the development of colorectal tumors
other	hsa-mir-143	Colorectal Carcinoma	23866094	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-143 blocks the TLR2 signalling pathway in human CRC cells. This knowledge may pave the way for new clinical applications utilising miR-143 mimics in the treatment of patients with CRC.
other	hsa-mir-143	Colorectal Carcinoma	20094072	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		anti-oncomirs
other	hsa-mir-143	Colorectal Carcinoma	20620599	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-143:MiR-21 and miR-143 expressions were quantified by using the quantitative reverse transcription polymerase chain reaction method
other	hsa-mir-143	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-143	Colorectal Carcinoma	23128394	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression
other	hsa-mir-143	Colorectal Carcinoma	23574723	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers
other	hsa-mir-144	Colorectal Carcinoma	21929751	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism.
other	hsa-mir-145	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-145	Colorectal Carcinoma	23128394	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression
other	hsa-mir-145	Colorectal Carcinoma	23397547	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of anti-oncomirs miR-143/145 cluster occurs before APC gene aberration in the development of colorectal tumors
other	hsa-mir-146b	Colorectal Carcinoma	20881268	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-146b-3p and miR-486-5p are more abundant in KRAS mutated samples after cetuximab treatment respect to wild-type ones
other	hsa-mir-146b	Colorectal Carcinoma	26178670	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-135b and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors.
other	hsa-mir-148a	Colorectal Carcinoma	23056401	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer
other	hsa-mir-150	Colorectal Carcinoma	22052060	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Only one miR-150 was found to show a decrease in expression levels in the three tissue groups (normal, adenoma and cancer tissue) in parallel with increasing carcinogenesis of the colorectal tissue. In both ISH and qRT-PCR analysis, tumour tissue had reduced levels of miR-150 expression compared with paired non-cancerous tissue, which indicated that the levels of miR-150 expression were associated with CRC. Moreover, patients whose tumours had low miR-150 expression had shorter survival and a worse response to adjuvant chemotherapy than patients whose tumours had high miRNA expression.
other	hsa-mir-155	Colorectal Carcinoma	21806946	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Neurotensin Signaling Activates MicroRNAs -21 and -155 and Akt, Promotes Tumor Growth in Mice, and is Increased in Human Colon Tumors.
other	hsa-mir-155	Colorectal Carcinoma	20351277	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Modulation of mismatch repair and genomic stability by miR-155
other	hsa-mir-16-1	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-16-2	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-181b-1	Colorectal Carcinoma	22202009	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks.
other	hsa-mir-181b-2	Colorectal Carcinoma	22202009	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks.
other	hsa-mir-18a	Colorectal Carcinoma	25233396	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Stool-based miR-221 can be used as a non-invasive biomarker for the detection of CRC.
other	hsa-mir-18a	Colorectal Carcinoma	23437304	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-18a Attenuates DNA Damage Repair through Suppressing the Expression of Ataxia Telangiectasia Mutated in Colorectal Cancer
other	hsa-mir-193a	Colorectal Carcinoma	23758639	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer.
other	hsa-mir-194-1	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-194-2	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-195	Colorectal Carcinoma	20727858	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-195:microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells
other	hsa-mir-195	Colorectal Carcinoma	22479426	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The driving miRNAs were miR-195, miR-1280, miR-140-3p and miR-1246 in colorectal tumors.
other	hsa-mir-19b-1	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-19b-1	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-19b-2	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-19b-2	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-200a	Colorectal Carcinoma	25422078	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		PZH can inhibit metastasis of colorectal cancer cells via modulating TGF-β1/ZEB/miR-200 signaling network, which might be one of the mechanisms whereby PZH exerts its anticancer function.
other	hsa-mir-200a	Colorectal Carcinoma	23441132	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-Regulation of the miRNA-200 Family at the Invasive Front of Colorectal Cancers with Degraded Basement Membrane Indicates EMT Is Involved in Cancer Progression
other	hsa-mir-200b	Colorectal Carcinoma	25422078	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		PZH can inhibit metastasis of colorectal cancer cells via modulating TGF-β1/ZEB/miR-200 signaling network, which might be one of the mechanisms whereby PZH exerts its anticancer function.
other	hsa-mir-200b	Colorectal Carcinoma	22804917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In KRAS mutated tumours increased miR-200b and decreased miR-143 expression were associated with a good progression-free survival .
other	hsa-mir-200b	Colorectal Carcinoma	23441132	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-Regulation of the miRNA-200 Family at the Invasive Front of Colorectal Cancers with Degraded Basement Membrane Indicates EMT Is Involved in Cancer Progression
other	hsa-mir-200c	Colorectal Carcinoma	25422078	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		PZH can inhibit metastasis of colorectal cancer cells via modulating TGF-β1/ZEB/miR-200 signaling network, which might be one of the mechanisms whereby PZH exerts its anticancer function.
other	hsa-mir-200c	Colorectal Carcinoma	21873159	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells.
other	hsa-mir-200c	Colorectal Carcinoma	22735571	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis.
other	hsa-mir-200c	Colorectal Carcinoma	23441132	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-Regulation of the miRNA-200 Family at the Invasive Front of Colorectal Cancers with Degraded Basement Membrane Indicates EMT Is Involved in Cancer Progression
other	hsa-mir-203	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-203	Colorectal Carcinoma	22202009	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks.
other	hsa-mir-20a	Colorectal Carcinoma	22202009	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks.
other	hsa-mir-21	Colorectal Carcinoma	20620599	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21:Our results support the hypothesis about oncogenic function of miR-21
other	hsa-mir-21	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-21	Colorectal Carcinoma	21806946	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Neurotensin Signaling Activates MicroRNAs -21 and -155 and Akt, Promotes Tumor Growth in Mice, and is Increased in Human Colon Tumors.
other	hsa-mir-21	Colorectal Carcinoma	22202009	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks.
other	hsa-mir-21	Colorectal Carcinoma	22553926	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		EGF/Ras efficiently induces the miR-21 primary transcript, but this does not rapidly and simply translate into higher mature miR-21 levels.
other	hsa-mir-215	Colorectal Carcinoma	23532818	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery
other	hsa-mir-22	Colorectal Carcinoma	21629773	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-22 regulates hypoxia signaling in colon cancer cells.
other	hsa-mir-221	Colorectal Carcinoma	25233396	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Stool-based miR-221 can be used as a non-invasive biomarker for the detection of CRC.
other	hsa-mir-221	Colorectal Carcinoma	21873159	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells.
other	hsa-mir-222	Colorectal Carcinoma	21873159	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells.
other	hsa-mir-23a	Colorectal Carcinoma	22628407	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-23a promotes the transition from indolent to invasive colorectal cancer.
other	hsa-mir-23a	Colorectal Carcinoma	22684455	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-23a, a critical regulator of migRation and metastasis in colorectal cancer.
other	hsa-mir-23a	Colorectal Carcinoma	23758639	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer.
other	hsa-mir-26b	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-27a	Colorectal Carcinoma	23530649	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Resveratrol and Quercetin in Combination Have Anticancer Activity in Colon Cancer Cells and Repress Oncogenic microRNA-27a
other	hsa-mir-27a	Colorectal Carcinoma	26178670	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-135b and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors.
other	hsa-mir-27b	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-32	Colorectal Carcinoma	26054686	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects.
other	hsa-mir-324	Colorectal Carcinoma	22202009	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a, miR-21, miR-106a, miR-181b, miR-203, and miR-324-5p were stable in colorectal cancer archival tissue blocks.
other	hsa-mir-338	Colorectal Carcinoma	24277750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-338-3p could inhibit colorectal carcinoma cell invasion and migration by inhibiting smoothened expression.
other	hsa-mir-338	Colorectal Carcinoma	23758639	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer.
other	hsa-mir-372	Colorectal Carcinoma	22456107	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-372 Is Associated with Poor Prognosis in Colorectal Cancer.
other	hsa-mir-451a	Colorectal Carcinoma	21948564	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Microrna-451 is Involved in the Self-Renewal, Tumorigenicity and Chemoresistance of Colorectal Cancer Stem Cells.
other	hsa-mir-486	Colorectal Carcinoma	20881268	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-146b-3p and miR-486-5p are more abundant in KRAS mutated samples after cetuximab treatment respect to wild-type ones
other	hsa-mir-552	Colorectal Carcinoma	24778034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA profiles predict the histology of primary lung carcinomas,and differentiate between primary lung adenocarcinomas and colorectal cancer metastases.
other	hsa-mir-592	Colorectal Carcinoma	24778034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA profiles predict the histology of primary lung carcinomas,and differentiate between primary lung adenocarcinomas and colorectal cancer metastases.
other	hsa-mir-638	Colorectal Carcinoma	21722265	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNA has a role in colorectal liver metastases.
other	hsa-mir-9	Colorectal Carcinoma	26178670	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-135b and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors.
other	hsa-mir-93	Colorectal Carcinoma	21406606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diet and carcinogen exposure modulated a number of microRNAs (miR-16, miR-19b, miR-21, miR26b, miR27b, miR-93 and miR-203) linked to canonical oncogenic signaling pathways.
other	hsa-mir-211	Cone Dystrophy	29209045	nervous system disease	DOID:0050795			602093	HP:0000548	MiR-211 is essential for adult cone photoreceptor maintenance and visual function.
other	hsa-mir-183	Congenital Deafness	21621863				C565195	124480		The quantitative real-time polymerase chain reaction result demonstrated that the miR-183 family exhibits cell-specific expression in cochlear progenitor cells compared with neural stem cells.
other	hsa-mir-96	Congenital Deafness	26490746				C565195	124480		Cx26-mediated intercellular communication is required for cochlear development and that deficiency of Cx26 can impair miRNA-mediated intercellular genetic communication in the cochlea, which may lead to cochlear developmental disorders and eventually congenital deafness as previously reported.
other	hsa-mir-27b	Congenital Heart Diseases	25847058	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	The current study revealed for the first time that microRNAs may be important regulators in pulmonary arterial hypertension secondary to congenital heart disease, and demonstrated the correlation between microRNA-27b and pulmonary arterial hypertension with the implication of NOTCH1.
other	hsa-mir-302f	Congenital Heart Diseases	27637763	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	Copy-number variant analysis of classic heterotaxy highlights the importance of body patterning pathways.
other	hsa-mir-184	Cornea Squamous Cell Carcinoma	29325388	nervous system disease	DOID:13538					miR-184 plays crucial regulatory roles in several ocular diseases, such as neovascularization, keratoconus, endothelial dystrophy, iris hypoplasia, congenital cataract, stromal thinning syndrome, corneal squamous cell carcinoma, age-related macular degeneration and cataract
other	hsa-mir-106b	Coronary Artery Disease	25415674	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		a relationship between the miR-17-92 family and lipid metabolism, which merits further study.
other	hsa-mir-122	Coronary Artery Disease	26490079	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MicroRNA Biomarkers for Coronary Artery Disease
other	hsa-mir-125b	Coronary Artery Disease	26446730	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		We found several synergistic effects between miR-125b and classical risk factors, such as age,sex, CR, FBG and HDL-C; the proportion of CHD attributable to the interaction of miR-125b and age was as high as 80%. Therefore, miR-125b was shown to play an important role in individual's susceptibility to developing CHD.
other	hsa-mir-126	Coronary Artery Disease	21195052	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Coronary Artery Disease
other	hsa-mir-126	Coronary Artery Disease	21946298	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-130a	Coronary Artery Disease	21195052	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Coronary Artery Disease
other	hsa-mir-130a	Coronary Artery Disease	28947970	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circular RNAs promote TRPM3 expression by inhibiting hsa-miR-130a-3p in coronary artery disease patients.
other	hsa-mir-133a	Coronary Artery Disease	28511772	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Transcoronary Concentration Gradient of microRNA-133a and Outcome in Patients With Coronary Artery Disease.
other	hsa-mir-134	Coronary Artery Disease	20230787	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		a cluster of three microRNAs including miR-134, miR-198, and miR-370, suggesting that the microRNA signatures can be used to identify patients at risk for acute coronary syndromes
other	hsa-mir-146a	Coronary Artery Disease	26114385	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Meta-Analysis of miR-146a Polymorphisms Association with Coronary Artery Diseases and Ischemic Stroke.
other	hsa-mir-155	Coronary Artery Disease	24525789	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-155 expression is associated inversely with complicated proatherogenic metabolic risk factors, and the severity of coronary stenotic lesions calculated by Gensini scores.
other	hsa-mir-155	Coronary Artery Disease	21946298	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-16	Coronary Artery Disease	29306454	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		HDLs are depleted of miR-16, miR-92a and miR-223 during the transcoronary passage in patients with ACS compared to patients with stable CAD
other	hsa-mir-17	Coronary Artery Disease	25415674	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		a relationship between the miR-17-93 family and lipid metabolism, which merits further study.
other	hsa-mir-17	Coronary Artery Disease	26134369	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-17-5p as circulating biomarkers for the severity of coronary atherosclerosis in coronary artery disease.
other	hsa-mir-17	Coronary Artery Disease	21946298	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-18a	Coronary Artery Disease	25415674	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		a relationship between the miR-17-94 family and lipid metabolism, which merits further study.
other	hsa-mir-198	Coronary Artery Disease	20230787	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		a cluster of three microRNAs including miR-134, miR-198, and miR-370, suggesting that the microRNA signatures can be used to identify patients at risk for acute coronary syndromes
other	hsa-mir-19b	Coronary Artery Disease	26459935	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Therefore our results indicate that miR-19b plays a key role in the attenuation of TNF-α-induced endothelial cell apoptosis and that this function is closely linked to the Apaf1/caspase-dependent pathway.
other	hsa-mir-206	Coronary Artery Disease	27994218	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-206 Suppresses the Progression of Coronary Artery Disease by Modulating Vascular Endothelial Growth Factor (VEGF) Expression.
other	hsa-mir-21	Coronary Artery Disease	20489163	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-21:We identified a novel miR-21-dependent mechanism of ADMA-mediated APC dysfunction
other	hsa-mir-21	Coronary Artery Disease	25656948	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort.
other	hsa-mir-21	Coronary Artery Disease	26310808	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Local anti-miR delivery: the latest in the arsenal of drug-eluting stents
other	hsa-mir-214	Coronary Artery Disease	25575606	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		increased miR-214 level may be used to predict the presence and severity of coronary lesions in CAD patients.
other	hsa-mir-221	Coronary Artery Disease	21195052	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Coronary Artery Disease
other	hsa-mir-221	Coronary Artery Disease	21946298	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-222	Coronary Artery Disease	21195052	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Coronary Artery Disease
other	hsa-mir-222	Coronary Artery Disease	21946298	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-223	Coronary Artery Disease	29306454	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		HDLs are depleted of miR-16, miR-92a and miR-223 during the transcoronary passage in patients with ACS compared to patients with stable CAD
other	hsa-mir-23a	Coronary Artery Disease	25656948	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study
other	hsa-mir-31	Coronary Artery Disease	21946298	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-340	Coronary Artery Disease	22022480	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*.
other	hsa-mir-34a	Coronary Artery Disease	25656948	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort.
other	hsa-mir-370	Coronary Artery Disease	20230787	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		a cluster of three microRNAs including miR-134, miR-198, and miR-370, suggesting that the microRNA signatures can be used to identify patients at risk for acute coronary syndromes
other	hsa-mir-486	Coronary Artery Disease	26485305	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-486 and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients.
other	hsa-mir-616	Coronary Artery Disease	27615006	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Relationship of microRNA 616 gene polymorphism with prognosis of patients with premature coronary artery disease.
other	hsa-mir-624	Coronary Artery Disease	22022480	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*.
other	hsa-mir-92a	Coronary Artery Disease	25415674	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		a relationship between the miR-17-95 family and lipid metabolism, which merits further study.
other	hsa-mir-92a	Coronary Artery Disease	26485305	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-486 and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients.
other	hsa-mir-92a	Coronary Artery Disease	29306454	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		HDLs are depleted of miR-16, miR-92a and miR-223 during the transcoronary passage in patients with ACS compared to patients with stable CAD
other	hsa-mir-92a-1	Coronary Artery Disease	21195052	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Coronary Artery Disease
other	hsa-mir-92a-2	Coronary Artery Disease	21195052	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Coronary Artery Disease
other	hsa-mir-100	Coronary Atherosclerosis	25519160			I25.1	D003324		HP:0004929	miR-100 might be released into the coronary circulation from vulnerable coronary plaques. This study provides insights into the role of miRNAs in coronary atherosclerotic disease.
other	hsa-mir-138	Costello Syndrome	26138095	genetic disease	DOID:0050469		D056685	218040		These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-206	Costello Syndrome	26138095	genetic disease	DOID:0050469		D056685	218040		These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-330	Costello Syndrome	26138095	genetic disease	DOID:0050469		D056685	218040		These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-342	Costello Syndrome	26138095	genetic disease	DOID:0050469		D056685	218040		These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-99b	Costello Syndrome	26138095	genetic disease	DOID:0050469		D056685	218040		These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-126	Coxsackievirus Infection	23811937			B97.11	D006223			MiR-126 promotes coxsackievirus replication by mediating cross-talk of ERK1/2 and Wnt/β-catenin signal pathways.
other	hsa-mir-142	Crohn Disease	25886994	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	A panel of miRNAs(miR-19a, miR-21, miR-31, miR-101, miR-146a, and miR-375) may be used as markers to identify and discriminate between CD and UC.
other	hsa-mir-149	Crohn Disease	28260036	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Comprehensive bioinformatics analyses of Crohn's disease.
other	hsa-mir-155	Crohn Disease	29263823	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	a small subset had inflammatory responses almost comparable to wild-type patients on both gene and miR-155 regulatory levels
other	hsa-mir-200b	Crohn Disease	22294131	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	miR-200b is involved in intestinal fibrosis of Crohn's disease.
other	hsa-mir-21	Crohn Disease	25886994	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	A panel of miRNAs(miR-19a, miR-21, miR-31, miR-101, miR-146a, and miR-375) may be used as markers to identify and discriminate between CD and UC.
other	hsa-mir-29	Crohn Disease	24054330	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release.
other	hsa-mir-29	Crohn Disease	24641356	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts.
other	hsa-mir-29b	Crohn Disease	28190086	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8.
other	hsa-mir-31	Crohn Disease	25886994	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	A panel of miRNAs(miR-19a, miR-21, miR-31, miR-101, miR-146a, and miR-375) may be used as markers to identify and discriminate between CD and UC.
other	hsa-mir-4447	Crohn Disease	28260036	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Comprehensive bioinformatics analyses of Crohn's disease.
other	hsa-let-7e	Cystic Fibrosis	25800681	genetic disease	DOID:1485	E84	D003550	219700		Ingenuity Pathway Analysis indicated that hsa-miR-99b and hsa-miR-125a could be associated with the phenotypes manifested by p.F508del patients. Here we provide novel elements in the mechanism of hsa-miR-99b and hsa-miR-125a biogenesis, and for the role of CFTR and DeltaF508-CFTR on the expression of this miRNA cluster. These findings augment existing data implicating miRNAs as putative CF modifiers.
other	hsa-mir-125a	Cystic Fibrosis	25800681	genetic disease	DOID:1485	E84	D003550	219700		Ingenuity Pathway Analysis indicated that hsa-miR-99b and hsa-miR-125a could be associated with the phenotypes manifested by p.F508del patients. Here we provide novel elements in the mechanism of hsa-miR-99b and hsa-miR-125a biogenesis, and for the role of CFTR and DeltaF508-CFTR on the expression of this miRNA cluster. These findings augment existing data implicating miRNAs as putative CF modifiers.
other	hsa-mir-146a	Cystic Fibrosis	27689251	genetic disease	DOID:1485	E84	D003550	219700		miR-146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs.
other	hsa-mir-155	Cystic Fibrosis	21282106	genetic disease	DOID:1485	E84	D003550	219700		Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyper-expression of interleukin-8.
other	hsa-mir-155	Cystic Fibrosis	27689251	genetic disease	DOID:1485	E84	D003550	219700		miR-146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs.
other	hsa-mir-181b	Cystic Fibrosis	29044225	genetic disease	DOID:1485	E84	D003550	219700		microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense.
other	hsa-mir-199a	Cystic Fibrosis	25665524	genetic disease	DOID:1485	E84	D003550	219700		Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation.
other	hsa-mir-200	Cystic Fibrosis	26292219	genetic disease	DOID:1485	E84	D003550	219700		Transcription Factor Hepatocyte Nuclear Factor-1β (HNF-1β) Regulates MicroRNA-200 Expression through a Long Noncoding RNA.
other	hsa-mir-21	Cystic Fibrosis	19997496	genetic disease	DOID:1485	E84	D003550	219700		mir-125b-1, mir-21, mir-30b, and mir-23b-27b-24-1 cluster genes were transactivated through promoter binding of the NF-kappaB p65 subunit following C. parvum infection
other	hsa-mir-23b	Cystic Fibrosis	19997496	genetic disease	DOID:1485	E84	D003550	219700		mir-125b-1, mir-21, mir-30b, and mir-23b-27b-24-1 cluster genes were transactivated through promoter binding of the NF-kappaB p65 subunit following C. parvum infection
other	hsa-mir-27b	Cystic Fibrosis	19997496	genetic disease	DOID:1485	E84	D003550	219700		mir-125b-1, mir-21, mir-30b, and mir-23b-27b-24-1 cluster genes were transactivated through promoter binding of the NF-kappaB p65 subunit following C. parvum infection
other	hsa-mir-30b	Cystic Fibrosis	19997496	genetic disease	DOID:1485	E84	D003550	219700		mir-125b-1, mir-21, mir-30b, and mir-23b-27b-24-1 cluster genes were transactivated through promoter binding of the NF-kappaB p65 subunit following C. parvum infection
other	hsa-mir-370	Cystic Fibrosis	27689251	genetic disease	DOID:1485	E84	D003550	219700		miR-146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs.
other	hsa-mir-509	Cystic Fibrosis	24829907	genetic disease	DOID:1485	E84	D003550	219700		Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression.
other	hsa-mir-708	Cystic Fibrosis	27689251	genetic disease	DOID:1485	E84	D003550	219700		miR-146a, miR-155, miR-370, and miR-708 Are CFTR-Dependent, Predicted FOXO1 Regulators and Change at Onset of CFRDs.
other	hsa-mir-99b	Cystic Fibrosis	25800681	genetic disease	DOID:1485	E84	D003550	219700		Ingenuity Pathway Analysis indicated that hsa-miR-99b and hsa-miR-125a could be associated with the phenotypes manifested by p.F508del patients. Here we provide novel elements in the mechanism of hsa-miR-99b and hsa-miR-125a biogenesis, and for the role of CFTR and DeltaF508-CFTR on the expression of this miRNA cluster. These findings augment existing data implicating miRNAs as putative CF modifiers.
other	hsa-mir-34a	Dementia	21956116	disease of mental health	DOID:1307	F03	D003704	127750	HP:0000726	miR-34a was among the most highly induced miRNAs in HIV-1 Tat-treated neurons.
other	hsa-mir-126	Dengue Virus Infection	27039024	disease by infectious agent	DOID:12205	A90	D003715	614371		GRP75 is involved in processing of host miRNA, hsa-mir-126, that down regulates dengue virus replication.
other	hsa-mir-30e	Dengue Virus Infection	25122182	disease by infectious agent	DOID:12205	A90	D003715	614371		MicroRNA-30e* suppresses dengue virus replication by promoting NF-κB-dependent IFN production.
other	hsa-mir-675	Dental Enamel Hypoplasia	28963438	gastrointestinal system disease	DOID:693		D003744		HP:0006297	DLX3 promotes bone marrow mesenchymal stem cell proliferation through H19/miR-675 axis.
other	hsa-mir-185	Depression Disorder	24213247	disease of mental health	DOID:1596	F32.9	D003866			The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p.
other	hsa-mir-491	Depression Disorder	24213247	disease of mental health	DOID:1596	F32.9	D003866			The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p.
other	hsa-mir-206	Dermatomyositis	24288551	integumentary system disease	DOID:10223	M33	D003882			Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis.
other	hsa-let-7a	Diabetes Mellitus	25759134	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-mir-103	Diabetes Mellitus	27137869	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Long-term treatment with 500鈥壩糓 CML during adipogenesis resulted in increases in miR-103 and miR-143  levels
other	hsa-mir-126	Diabetes Mellitus	21946298	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-126	Diabetes Mellitus	23713864	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Recent studies identified circulating microRNA-126 as a biomarker for myocardial injury and vascular damage in diabetes.
other	hsa-mir-126	Diabetes Mellitus	29477147	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	While both miRs have differential functions on endothelial VCAM expression, miR-19a and miR-126 cooperate to exhibit anti-thrombotic properties via regulating vascular TF expression
other	hsa-mir-130b	Diabetes Mellitus	28433632	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	inhibition of miR-130b-3p appears to improve mitochondrial biogenesis signaling and protect placental trophoblast cells from oxidative stress
other	hsa-mir-143	Diabetes Mellitus	27137869	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Long-term treatment with 500鈥壩糓 CML during adipogenesis resulted in increases in miR-103 and miR-143  levels
other	hsa-mir-145	Diabetes Mellitus	26636106	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	CRT may lead to left ventricular reverse remodeling, with LVEF, NYHA functional class, and 6MWT improvement in both diabetic and nondiabetic adult patients.These observations have been confirmed by other authors in a population of elderly diabetic patients, a part of 6MWT improvement, that is not CRT-induced in elderly diabetes.
other	hsa-mir-146a	Diabetes Mellitus	20086228	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Our data identify miR-21, miR-34a, and miR-146a as novel players in beta-cell failure elicited in vitro and in vivo by proinflammatory cytokines,notably during the development of peri-insulitis that precedes overt diabetes in NOD mice.
other	hsa-mir-155	Diabetes Mellitus	23250986	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Global Remodeling of the Vascular Stem Cell Niche in Bone Marrow of Diabetic Patients: Implication of the miR-155/FOXO3a Signaling Pathway
other	hsa-mir-155	Diabetes Mellitus	23560074	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Bone Marrow Progenitor Cell Therapy-Mediated Paracrine Regulation of Cardiac miRNA-155 Modulates Fibrotic Response in Diabetic Hearts
other	hsa-mir-155	Diabetes Mellitus	21946298	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-17	Diabetes Mellitus	21946298	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-17	Diabetes Mellitus	25249581	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Ask1 deletion suppressed diabetes-induced  IRE1伪 endoriboneclease activities, which led to X-box binding protein 1 mRNA cleavage, an ER stress marker, decreased expression of microRNAs, and increased expression of a miR-17 target
other	hsa-mir-17	Diabetes Mellitus	26660634	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-17 repression mediates the pro-apoptotic effect of high glucose
other	hsa-mir-186	Diabetes Mellitus	25059983	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Differentiation of human induced pluripotent stem cells into insulin-like cell clusters with miR-186 and miR-375 by using chemical transfection.
other	hsa-mir-19a	Diabetes Mellitus	29477147	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	While both miRs have differential functions on endothelial VCAM expression, miR-19a and miR-126 cooperate to exhibit anti-thrombotic properties via regulating vascular TF expression
other	hsa-mir-200c	Diabetes Mellitus	25759134	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-mir-204	Diabetes Mellitus	27438705	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Its pathological functions have been observed in a few diseases including pulmonary arterial hypertension, diabetes, and various types of cancers.
other	hsa-mir-21	Diabetes Mellitus	26826461	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Role of microRNA 21 in diabetes and associated/related diseases.
other	hsa-mir-21	Diabetes Mellitus	21613227	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	microRNA-21 orchestrates high glucose-induced signals to TORC1 for renal cell pathology in diabetes.
other	hsa-mir-21	Diabetes Mellitus	20086228	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Our data identify miR-21, miR-34a, and miR-146a as novel players in beta-cell failure elicited in vitro and in vivo by proinflammatory cytokines,notably during the development of peri-insulitis that precedes overt diabetes in NOD mice.
other	hsa-mir-221	Diabetes Mellitus	21946298	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-222	Diabetes Mellitus	21946298	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-223	Diabetes Mellitus	25944670	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Thus, calpain inhibition may be one means of normalizing platelet miRNA processing as well as platelet function in diabetes mellitus.
other	hsa-mir-26b	Diabetes Mellitus	26636106	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	CRT may lead to left ventricular reverse remodeling, with LVEF, NYHA functional class, and 6MWT improvement in both diabetic and nondiabetic adult patients.These observations have been confirmed by other authors in a population of elderly diabetic patients, a part of 6MWT improvement, that is not CRT-induced in elderly diabetes.
other	hsa-mir-29a	Diabetes Mellitus	26636106	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	CRT may lead to left ventricular reverse remodeling, with LVEF, NYHA functional class, and 6MWT improvement in both diabetic and nondiabetic adult patients.These observations have been confirmed by other authors in a population of elderly diabetic patients, a part of 6MWT improvement, that is not CRT-induced in elderly diabetes.
other	hsa-mir-29b-2	Diabetes Mellitus	25587719	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The pathogenic role of persistent milk signaling in mTORC1- and milk-microRNA-driven type 2 diabetes mellitus.
other	hsa-mir-301a	Diabetes Mellitus	23573265	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNA-301a Mediated Regulation of Kv4.2 in Diabetes: Identification of Key Modulators
other	hsa-mir-31	Diabetes Mellitus	26318001	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Comparative Genomic, MicroRNA, and Tissue Analyses Reveal Subtle Differences between Non-Diabetic and Diabetic Foot Skin.
other	hsa-mir-31	Diabetes Mellitus	21946298	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-320a	Diabetes Mellitus	22900199	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-320 Regulates Glucose-Induced Gene Expression in Diabetes.
other	hsa-mir-34a	Diabetes Mellitus	20086228	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Our data identify miR-21, miR-34a, and miR-146a as novel players in beta-cell failure elicited in vitro and in vivo by proinflammatory cytokines,notably during the development of peri-insulitis that precedes overt diabetes in NOD mice.
other	hsa-mir-375	Diabetes Mellitus	16195701	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	mir-375 was found to modulate glucose-stimulated insulin secretion and exocytosis.
other	hsa-mir-375	Diabetes Mellitus	17965831	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	For instance, miR-375 was shown to directly regulate insulin secretion from pancreatic islet cells. Overexpression of miR-375 led to an enhanced inhibition of insulin exocytosis, whereas anti-sense to miR-375 enhanced insulin secretion by blocking the effects of the miRNA.
other	hsa-mir-375	Diabetes Mellitus	25059983	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Differentiation of human induced pluripotent stem cells into insulin-like cell clusters with miR-186 and miR-375 by using chemical transfection.
other	hsa-mir-375	Diabetes Mellitus	19800254	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Recent studies, for example, implicate miR-375 in pancreatic islet cell viability and function, and removal or overexpression of miR-375 profoundly affects glucose metabolism. 
other	hsa-mir-375	Diabetes Mellitus	26311337	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	This review analyzes the role of miRNAs in obesity and insulin resistance, focusing on the miR-17/92, miR-143-145, miR-130, let-7, miR-221/222, miR-200, miR-223, miR-29 and miR-375 families, as well as miRNA changes by relevant tissue
other	hsa-mir-410	Diabetes Mellitus	26307561	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-410 enhanced hESC-derived pancreatic endoderm transplant to alleviate gestational diabetes mellitus.
other	hsa-mir-494	Diabetes Mellitus	24349514	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNA-494, upregulated by tumor necrosis factor-α, desensitizes insulin effect in C2C12 muscle cells.
other	hsa-mir-503	Diabetes Mellitus	29285014	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	microRNA-503 contribute to pancreatic beta cell dysfunction by targeting the mTOR pathway in gestational diabetes mellitus
other	hsa-mir-550a	Diabetes Mellitus	27935135	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Micro RNA-550a interferes with vitamin D metabolism in peripheral B cells of patients with diabetes.
other	hsa-mir-590	Diabetes Mellitus	26770982	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	In this study, we identified a LDHA-suppressing microRNA (hsa-miR-590-3p)and used it together with human embryonic stem cell (hESC) derived pancreatic endoderm (PE) transplantation into a high-fat diet induced T2D mouse model. The procedure significantly improved glucose metabolism and other symptoms of T2D.
other	hsa-mir-92a	Diabetes Mellitus	26283734	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-92a Corrects CD34+ Cell Dysfunction in Diabetes by Modulating Core Circadian  Genes Involved in Progenitor Differentiation.
other	hsa-mir-92a	Diabetes Mellitus	26636106	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	CRT may lead to left ventricular reverse remodeling, with LVEF, NYHA functional class, and 6MWT improvement in both diabetic and nondiabetic adult patients.These observations have been confirmed by other authors in a population of elderly diabetic patients, a part of 6MWT improvement, that is not CRT-induced in elderly diabetes.
other	hsa-let-7a	Diabetes Mellitus, Gestational	27562513	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA.
other	hsa-let-7g	Diabetes Mellitus, Gestational	27562513	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA.
other	hsa-mir-126	Diabetes Mellitus, Gestational	27562513	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA.
other	hsa-mir-130b	Diabetes Mellitus, Gestational	27562513	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA.
other	hsa-mir-137	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-137	Diabetes Mellitus, Gestational	29505767	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	High glucose induces dysfunction of human umbilical vein endothelial cells by upregulating miR-137 in gestational diabetes mellitus.
other	hsa-mir-148a	Diabetes Mellitus, Gestational	27562513	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA.
other	hsa-mir-27a	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-30c	Diabetes Mellitus, Gestational	27562513	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA.
other	hsa-mir-30d	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-33a	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-362	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-452	Diabetes Mellitus, Gestational	27562513	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA.
other	hsa-mir-502	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-508	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-9	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-92a	Diabetes Mellitus, Gestational	26302821	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
other	hsa-mir-34a	Diabetes Mellitus, Type 1	28185128	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Effects of TRPM7/miR-34a Gene Silencing on Spatial Cognitive Function and Hippocampal Neurogenesis in Mice with Type 1 Diabetes Mellitus.
other	hsa-let-7f	Diabetes Mellitus, Type 2	23723366	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	let-7f, a microRNA which has been related to endothelial angiogenic function, is found to play key role in TSP-2 increase, but let-7f did not directly interact with TSP-2 mRNA.
other	hsa-mir-1	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4). 
other	hsa-mir-103	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Insulin resistance, obesity, and hyperlipidemia (high lipid levels in the blood)  have a strong connection with T2D and several miRNAs influence these clinical outcomes such as miR-143, miR-103, and miR-107, miR-29a, and miR-27b.
other	hsa-mir-103a-1	Diabetes Mellitus, Type 2	21654750	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MicroRNAs 103 and 107 regulate insulin sensitivity.
other	hsa-mir-103a-2	Diabetes Mellitus, Type 2	21654750	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MicroRNAs 103 and 107 regulate insulin sensitivity.
other	hsa-mir-107	Diabetes Mellitus, Type 2	22645244	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-107: a Toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes.
other	hsa-mir-107	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Insulin resistance, obesity, and hyperlipidemia (high lipid levels in the blood)  have a strong connection with T2D and several miRNAs influence these clinical outcomes such as miR-143, miR-103, and miR-107, miR-29a, and miR-27b.
other	hsa-mir-122	Diabetes Mellitus, Type 2	27592052	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	HNF-4α regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-treated HepG2 cells.
other	hsa-mir-122	Diabetes Mellitus, Type 2	27899485	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes.
other	hsa-mir-122	Diabetes Mellitus, Type 2	22488426	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Recent studies have shown key roles for miR-33 and miR-122 in regulation of lipid metabolism, and further evidence implicates miR-370 in regulation of miR-122.
other	hsa-mir-124a	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-126	Diabetes Mellitus, Type 2	25986735	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals.
other	hsa-mir-126	Diabetes Mellitus, Type 2	27696070	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study.
other	hsa-mir-126	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4). 
other	hsa-mir-128a	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4). 
other	hsa-mir-133a	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-133b	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-143	Diabetes Mellitus, Type 2	28270439	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Comprehensive functional screening of miRNAs involved in fat cell insulin sensitivity among women.
other	hsa-mir-143	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-144	Diabetes Mellitus, Type 2	27906902	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose.
other	hsa-mir-145	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-146	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-146a	Diabetes Mellitus, Type 2	21249428	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes.
other	hsa-mir-155	Diabetes Mellitus, Type 2	27711113	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MiR-155 Enhances Insulin Sensitivity by Coordinated Regulation of Multiple Genes in Mice.
other	hsa-mir-15a	Diabetes Mellitus, Type 2	28289072	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Down-regulation of miR-15a/b accelerates fibrotic remodelling in the Type 2 diabetic human and mouse heart.
other	hsa-mir-15a	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-15b	Diabetes Mellitus, Type 2	28289072	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Down-regulation of miR-15a/b accelerates fibrotic remodelling in the Type 2 diabetic human and mouse heart.
other	hsa-mir-15b	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-181b	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-192	Diabetes Mellitus, Type 2	27906902	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose.
other	hsa-mir-192	Diabetes Mellitus, Type 2	29040025	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Lower concentrations of miR-192 and miR-375 were also found, which correlated positively with HOMA-IR
other	hsa-mir-195	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-200	Diabetes Mellitus, Type 2	26032109	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Preventing β-cell apoptosis and T2DM with microRNAs--a role for miR-200
other	hsa-mir-200a	Diabetes Mellitus, Type 2	24812635	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-448, let-7b, miR-540, miR-296, miR-880, miR-200a, miR-500, miR-10b, miR-336, miR-30d, miR-208, let-7e, miR-142-5p, miR-874, miR-375, miR-879, miR-501, and miR-188 were upregulated, while miR-301b, miR-134, and miR-652 were  downregulated in TMH group.
other	hsa-mir-21	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-221	Diabetes Mellitus, Type 2	27420990	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The expression of miR-221/222 in the serum of the patients with post-menopausal breast cancer was higher than that of T2DM patients (P < 0.05), but lower than that of the T2DM patients who were also positive for post-menopausal breast cancer (P < 0.05)
other	hsa-mir-222	Diabetes Mellitus, Type 2	27420990	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The expression of miR-221/222 in the serum of the patients with post-menopausal breast cancer was higher than that of T2DM patients (P < 0.05), but lower than that of the T2DM patients who were also positive for post-menopausal breast cancer (P < 0.05)
other	hsa-mir-223	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-24	Diabetes Mellitus, Type 2	25737017	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis.
other	hsa-mir-27b	Diabetes Mellitus, Type 2	28698281	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MiR-27b augments bone marrow progenitor cell survival via suppressing the mitochondrial apoptotic pathway in Type 2 diabetes.
other	hsa-mir-27b	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Insulin resistance, obesity, and hyperlipidemia (high lipid levels in the blood)  have a strong connection with T2D and several miRNAs influence these clinical outcomes such as miR-143, miR-103, and miR-107, miR-29a, and miR-27b
other	hsa-mir-29	Diabetes Mellitus, Type 2	24349318	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Urinary miR-29a correlated with albuminuria while urinary miR-29b correlated with carotid intima-media thickness (cIMT) in patients with type 2 diabetes. Therefore, they may have the potential to serve as alternative biomarker for diabetic nephropathy and atherosclerosis in type 2 diabetes.
other	hsa-mir-29	Diabetes Mellitus, Type 2	28404597	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered miR-29 Expression in Type 2 Diabetes Influences Glucose and Lipid Metabolism in Skeletal Muscle.
other	hsa-mir-29	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-29a	Diabetes Mellitus, Type 2	27906902	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Comparison of Transcriptome Between Type 2 Diabetes Mellitus and Impaired Fasting Glucose.
other	hsa-mir-29a	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-30a	Diabetes Mellitus, Type 2	27758866	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Mitochondrial Activity in Human White Adipocytes Is Regulated by the Ubiquitin Carrier Protein 9/microRNA-30a Axis.
other	hsa-mir-320	Diabetes Mellitus, Type 2	24825548	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells.
other	hsa-mir-320	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-33	Diabetes Mellitus, Type 2	22488426	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Recent studies have shown key roles for miR-33 and miR-122 in regulation of lipid metabolism, and further evidence implicates miR-370 in regulation of miR-122.
other	hsa-mir-33a	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-33b	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-34a	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-370	Diabetes Mellitus, Type 2	26948318	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	salidroside can directly decrease the expression  of miR-370 in type 2 diabetic mice
other	hsa-mir-370	Diabetes Mellitus, Type 2	22488426	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Recent studies have shown key roles for miR-33 and miR-122 in regulation of lipid metabolism, and further evidence implicates miR-370 in regulation of miR-122.
other	hsa-mir-375	Diabetes Mellitus, Type 2	24812635	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Through target gene analysis and real-time PCR verification, we found that these miRNAs, especially miR-375 and miR-30d, can stimulate insulin secretion in islet.
other	hsa-mir-375	Diabetes Mellitus, Type 2	29040025	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Lower concentrations of miR-192 and miR-375 were also found, which correlated positively with HOMA-IR
other	hsa-mir-376	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-383	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-384	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Here, we highlight the role of miRNAs in different significant protein cascades within the insulin signaling pathway such as miR-320, miR-383, miR-181b with IGF-1, and its  receptor (IGF1R); miR-128a, miR-96, miR-126 with insulin receptor substrate (IRS) proteins; miR-29, miR-384-5p, miR-1 with phosphatidylinositol 3-kinase (PI3K); miR-143, miR-145, miR-29, miR-383, miR-33a/b miR-21 with AKT/protein kinase B (PKB) and miR-133a/b, miR-223, miR-143 with glucose transporter 4 (GLUT4).
other	hsa-mir-423	Diabetes Mellitus, Type 2	28411267	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.
other	hsa-mir-4687	Diabetes Mellitus, Type 2	27597954	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Role of miRNAs in Epicardial Adipose Tissue in CAD Patients with T2DM.
other	hsa-mir-652	Diabetes Mellitus, Type 2	28270439	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Comprehensive functional screening of miRNAs involved in fat cell insulin sensitivity among women.
other	hsa-mir-7	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-9	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-92a	Diabetes Mellitus, Type 2	24379347	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The updated subnetwork predicted that miR-126/-193b/-92a control CCL2 production by several TFs, including v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) (ETS1), MYC-associated factor X (MAX), and specificity protein 12 (SP1).
other	hsa-mir-96	Diabetes Mellitus, Type 2	24944010	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The influence of miRNAs (miR-7, miR-124a, miR-9,  miR-96, miR-15a/b, miR-34a, miR-195, miR-376, miR-103, miR-107, and miR-146) in insulin secretion and beta (尾) cell development has been well discussed.
other	hsa-mir-99a	Diabetes Mellitus, Type 2	23762265	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Insulin Promotes Glucose Consumption via Regulation of miR-99a/mTOR/PKM2 Pathway.
other	hsa-mir-384	Diabetic Encephalopathy	29511445	nervous system disease	DOID:0050850					Control of macrophage autophagy by miR-384-5p in the development of diabetic encephalopathy.
other	hsa-mir-124	Diabetic Nephropathy	24556741			E10-11.21	D003928			These results provide a novel idea that curcumin prevents against podocytic adhesive capacity damage under mechanical stress by inhibitting miR-124
other	hsa-mir-192	Diabetic Nephropathy	22223877			E10-11.21	D003928			Inhibiting MicroRNA-192 Ameliorates Renal Fibrosis in Diabetic Nephropathy
other	hsa-mir-21	Diabetic Nephropathy	24370587			E10-11.21	D003928			Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy.
other	hsa-mir-23b	Diabetic Nephropathy	26898629			E10-11.21	D003928			Diabetic nephropathy: MiR-23b protects against fibrosis in diabetic nephropathy.
other	hsa-mir-27a	Diabetic Nephropathy	28277542			E10-11.21	D003928			MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy.
other	hsa-mir-30c	Diabetic Nephropathy	28127848			E10-11.21	D003928			MiR-30c protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition in db/db mice.
other	hsa-mir-34a	Diabetic Nephropathy	27858840			E10-11.21	D003928			Regulation of podocyte lesions in diabetic nephropathy via miR-34a in the Notch signaling pathway.
other	hsa-let-7i	Diabetic Polyneuropathy	29533535	nervous system disease	DOID:12785		D003929			let-7i is widely expressed in sensory neurons, supports their growth and is depleted in experimental DPN
other	hsa-mir-126	Diabetic Retinopathy	27225425	nervous system disease	DOID:8947	E10-11.31	D003930			MicroRNA-126 (miR-126) plays a potential role in the pathogenesis in DR
other	hsa-mir-1273g	Diabetic Retinopathy	29197896	nervous system disease	DOID:8947	E10-11.31	D003930			miRNA-1273g-3p Involvement in Development of Diabetic Retinopathy by Modulating the Autophagy-Lysosome Pathway.
other	hsa-mir-146b	Diabetic Retinopathy	28170537	nervous system disease	DOID:8947	E10-11.31	D003930			Adenosine Deaminase-2-Induced Hyperpermeability in Human Retinal Vascular Endothelial Cells Is Suppressed by MicroRNA-146b-3p.
other	hsa-mir-200b	Diabetic Retinopathy	21357793	nervous system disease	DOID:8947	E10-11.31	D003930			MicroRNA-200b Regulates Vascular Endothelial Growth Factor-Mediated Alterations in Diabetic Retinopathy.
other	hsa-mir-21	Diabetic Retinopathy	28270521	nervous system disease	DOID:8947	E10-11.31	D003930			Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARα.
other	hsa-mir-34a	Diabetic Retinopathy	27977785	nervous system disease	DOID:8947	E10-11.31	D003930			LGR4 Is a Direct Target of MicroRNA-34a and Modulates the Proliferation and Migration of Retinal Pigment Epithelial ARPE-19 Cells.
other	hsa-mir-15a	Diabetic Vasculopathy	24397367	cardiovascular system disease	DOID:11713		D003925			Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment.
other	hsa-mir-181c	Diabetic Vasculopathy	24397367	cardiovascular system disease	DOID:11713		D003925			Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment.
other	hsa-mir-20b	Diabetic Vasculopathy	24397367	cardiovascular system disease	DOID:11713		D003925			Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment.
other	hsa-let-7	Diffuse Lipomatosis	22642449	integumentary system disease	DOID:3923					First description of inhibition of let-7 microRNA expression and HMGA2 overexpression in a case of deep-seated diffuse lipomatosis.
other	hsa-let-7a	Digeorge Syndrome	26202964	genetic disease	DOID:11198	D82.1	D004062	188400		Collectively, our data suggest a novel mechanism that SUMOylation of DGCR8 controls direct functions of pri-miRNAs in gene silencing.
other	hsa-mir-223	Disease of Metabolism	26512640	disease of metabolism	DOID:0014667	E88.9	D008659			the roles of miR-223 during the processes of osteoclast and osteoblast  differentiation, as well as the potential clinical applications of miR-223 in bone metabolism disorders.
other	hsa-mir-1-1	Distal Myopathy	20619221			G72.9	D049310	160500		miR-1:have a profound influence on multiple myopathies
other	hsa-mir-1-2	Distal Myopathy	20619221			G72.9	D049310	160500		miR-1:have a profound influence on multiple myopathies
other	hsa-mir-133a-1	Distal Myopathy	20619221			G72.9	D049310	160500		miR-133:have a profound influence on multiple myopathies
other	hsa-mir-133a-2	Distal Myopathy	20619221			G72.9	D049310	160500		miR-133:have a profound influence on multiple myopathies
other	hsa-mir-206	Distal Myopathy	20619221			G72.9	D049310	160500		miR-206:have a profound influence on multiple myopathies
other	hsa-mir-1246	Down Syndrome	21637297	genetic disease	DOID:14250	Q90	D004314	190685		p53 downregulates Down syndrome-associated DYRK1A through miR-1246.
other	hsa-mir-155	Down Syndrome	17468766	genetic disease	DOID:14250	Q90	D004314	190685		Because miR-155 maps to chromosome 21, Setupathy et al. speculate that miR-155 overexpression in trisomics'a which they confirmed experimentally a accounts for the lower levels of diastolic and systolic blood pressure associated with Down syndrome.
other	hsa-mir-155	Down Syndrome	24938108	genetic disease	DOID:14250	Q90	D004314	190685		Analysis of mtDNA, miR-155 and BACH1 expression in hearts from donors with and without Down syndrome.
other	hsa-mir-155	Down Syndrome	26546125	genetic disease	DOID:14250	Q90	D004314	190685		The lentiviral miRNA-sponge strategy demonstrated the genome-wide regulatory effects of miR-155 and miR-802. Furthermore, the analysis combining predicted candidates and experimental transcriptomic data proved to retrieve genes with potential significance in DS-hippocampal phenotype bridging with DS other neurological-associated diseases such as Alzheimer's disease.
other	hsa-mir-802	Down Syndrome	26546125	genetic disease	DOID:14250	Q90	D004314	190685		The lentiviral miRNA-sponge strategy demonstrated the genome-wide regulatory effects of miR-155 and miR-802. Furthermore, the analysis combining predicted candidates and experimental transcriptomic data proved to retrieve genes with potential significance in DS-hippocampal phenotype bridging with DS other neurological-associated diseases such as Alzheimer's disease.
other	hsa-mir-424	Early-Stage Colon Adenocarcinoma	28714374			C18.9				Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing.
other	hsa-mir-548am	Early-Stage Colon Adenocarcinoma	28714374			C18.9				Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing.
other	hsa-mir-548c	Early-Stage Colon Adenocarcinoma	28714374			C18.9				Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing.
other	hsa-mir-548i	Early-Stage Colon Adenocarcinoma	28714374			C18.9				Screening key genes and miRNAs in early-stage colon adenocarcinoma by RNA-sequencing.
other	hsa-mir-31	Early-Stage Colon Carcinoma	26173758			C18.9				The potential role of microRNA-31 expression in early colorectal cancer.
other	hsa-mir-150	Early-Stage Small-Cell Lung Carcinoma	24637927			C34.90	D055752	211980		A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy.
other	hsa-mir-886	Early-Stage Small-Cell Lung Carcinoma	24637927			C34.90	D055752	211980		A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy.
other	hsa-mir-1246	Ebola Hemorrhagic Fever	25218824	disease by infectious agent	DOID:4325	A98.4	D019142			Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro.
other	hsa-mir-22	Emphysema	26482970			J43	D004646	130700	HP:0002097	MicroRNA miR-22 drives T(H)17 responses in emphysema.
other	hsa-mir-155	Encephalitis	24516198	disease by infectious agent	DOID:9588	G04.90	D004660		HP:0002383	Critical role of microRNA-155 in herpes simplex encephalitis. miR-H2
other	hsa-mir-132	Encephalomyelitis	23780851	nervous system disease	DOID:640	B01.11	D004679			MicroRNA-132 suppresses autoimmune encephalomyelitis by inducing cholinergic anti-inflammation: a new Ahr-based exploration.
other	hsa-mir-155	Encephalomyelitis	24332164	nervous system disease	DOID:640	B01.11	D004679			MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis.
other	hsa-mir-155	Encephalomyelitis	21788439	nervous system disease	DOID:640	B01.11	D004679			Silencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis.
other	hsa-mir-155	Endometrial Neoplasms	21176560	reproductive system disease	DOID:1380	C54.1	D016889	608089		Hsa-miR-155 may play an important role in the proliferation, and metastasis of endometrial cancer, which may be a indicator in the diagnosis and prognosis of endometrial cancer and may be used as a predictive biomarker.
other	hsa-mir-181	Endometrial Neoplasms	22911744	reproductive system disease	DOID:1380	C54.1	D016889	608089		Three miRNAs families, miR-181, miR-183 and miR-200, are down-regulated during the decidualization process.
other	hsa-mir-182	Endometrial Neoplasms	22766795	reproductive system disease	DOID:1380	C54.1	D016889	608089		In distinguishing endometrial endometrial carcinoma from complex atypical hyperplasia, the composite panel of four miRNAs (miR-182, 183, 200a, 200c) produced 95% sensitivity and 91% specificity.
other	hsa-mir-183	Endometrial Neoplasms	22766795	reproductive system disease	DOID:1380	C54.1	D016889	608089		In distinguishing endometrial endometrial carcinoma from complex atypical hyperplasia, the composite panel of four miRNAs (miR-182, 183, 200a, 200c) produced 95% sensitivity and 91% specificity.
other	hsa-mir-183	Endometrial Neoplasms	22911744	reproductive system disease	DOID:1380	C54.1	D016889	608089		Three miRNAs families, miR-181, miR-183 and miR-200, are down-regulated during the decidualization process.
other	hsa-mir-200	Endometrial Neoplasms	22911744	reproductive system disease	DOID:1380	C54.1	D016889	608089		Three miRNAs families, miR-181, miR-183 and miR-200, are down-regulated during the decidualization process.
other	hsa-mir-200a	Endometrial Neoplasms	22766795	reproductive system disease	DOID:1380	C54.1	D016889	608089		In distinguishing endometrial endometrial carcinoma from complex atypical hyperplasia, the composite panel of four miRNAs (miR-182, 183, 200a, 200c) produced 95% sensitivity and 91% specificity.
other	hsa-mir-200a	Endometrial Neoplasms	23295740	reproductive system disease	DOID:1380	C54.1	D016889	608089		Tamoxifen Represses miR-200 MicroRNAs and Promotes Epithelial-to-Mesenchymal Transition by Up-Regulating c-Myc in Endometrial Carcinoma Cell Lines
other	hsa-mir-200a	Endometrial Neoplasms	23743934	reproductive system disease	DOID:1380	C54.1	D016889	608089		ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.
other	hsa-mir-200b	Endometrial Neoplasms	23295740	reproductive system disease	DOID:1380	C54.1	D016889	608089		Tamoxifen Represses miR-200 MicroRNAs and Promotes Epithelial-to-Mesenchymal Transition by Up-Regulating c-Myc in Endometrial Carcinoma Cell Lines
other	hsa-mir-200b	Endometrial Neoplasms	23743934	reproductive system disease	DOID:1380	C54.1	D016889	608089		ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.
other	hsa-mir-200c	Endometrial Neoplasms	22766795	reproductive system disease	DOID:1380	C54.1	D016889	608089		In distinguishing endometrial endometrial carcinoma from complex atypical hyperplasia, the composite panel of four miRNAs (miR-182, 183, 200a, 200c) produced 95% sensitivity and 91% specificity.
other	hsa-mir-200c	Endometrial Neoplasms	23295740	reproductive system disease	DOID:1380	C54.1	D016889	608089		Tamoxifen Represses miR-200 MicroRNAs and Promotes Epithelial-to-Mesenchymal Transition by Up-Regulating c-Myc in Endometrial Carcinoma Cell Lines
other	hsa-mir-200c	Endometrial Neoplasms	23743934	reproductive system disease	DOID:1380	C54.1	D016889	608089		ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.
other	hsa-mir-204	Endometrial Neoplasms	27438705	reproductive system disease	DOID:1380	C54.1	D016889	608089		It is believed that miR-204 acts as a tumor-suppressor via promoting apoptosis, conferring the resistance of cancer cells to chemotherapy, and suppressing the self-renewal of cancer stem cells (CSCs) and the epithelial to mesenchymal transition (EMT).
other	hsa-mir-205	Endometrial Neoplasms	27655663	reproductive system disease	DOID:1380	C54.1	D016889	608089		Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.
other	hsa-mir-30c-1	Endometrial Neoplasms	22139444	reproductive system disease	DOID:1380	C54.1	D016889	608089		Endometrial Neoplasms
other	hsa-mir-30c-2	Endometrial Neoplasms	22139444	reproductive system disease	DOID:1380	C54.1	D016889	608089		Endometrial Neoplasms
other	hsa-mir-142	Endometrial Stromal Sarcoma	25754227	reproductive system disease	DOID:4226	Z85.42	D018203			miR-142-3p is a novel regulator of cell viability and proinflammatory signalling in endometrial stroma cells.
other	hsa-mir-143	Endometriosis	29463003	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis
other	hsa-mir-145	Endometriosis	29463003	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis
other	hsa-mir-17	Endometriosis	29463003	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis
other	hsa-mir-183	Endometriosis	24173391	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Downregulation of miR-183 inhibits apoptosis and enhances the invasive potential of endometrial stromal cells in endometriosis.
other	hsa-mir-199a	Endometriosis	29463003	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis
other	hsa-mir-200	Endometriosis	29463003	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis
other	hsa-mir-20a	Endometriosis	22648654	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Hypoxia-induced microRNA-20a expression increases ERK phosphorylation and angiogenic gene expression in endometriotic stromal cells.
other	hsa-mir-20a	Endometriosis	29463003	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-17-5p/20a, miR-200, miR-199a, miR-143, and miR-145 were explored for their pivotal role in the aetiopathogenesis of endometriosis
other	hsa-mir-210	Endometriosis	25516558	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (no. 13237327 to K.N., no. 25861500 to Y.K. and no. 23592407 to H.N.). There are no conflicts of interest to declare.
other	hsa-mir-27b	Endometriosis	29247225	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Rg3 effectively altered fibrotic properties of HESCs from patients with endometriosis, which is likely associated with miR-27b-3p modulation
other	hsa-mir-29c	Endometriosis	27778641	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Progesterone Resistance in Endometriosis Is Modulated by the Altered Expression of MicroRNA-29c and FKBP4.
other	hsa-mir-33b	Endometriosis	28537685	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MiR-33b can mediate cell apoptosis, alter VEGF and MMP-9 expression and affect proliferation and apoptosis of uterus endometrial cells, thus participating endometriosis formation
other	hsa-mir-101-1	Endomyocardial Fibrosis	22811578	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor Pathway.
other	hsa-mir-101-2	Endomyocardial Fibrosis	22811578	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-ж┿ Pathway.
other	hsa-mir-18a	Endomyocardial Fibrosis	28733035	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	MiR-18a-5p inhibits endothelial-mesenchymal transition and cardiac fibrosis through the Notch2 pathway.
other	hsa-mir-208a	Endomyocardial Fibrosis	17786230	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	Clearly, miR-208 is also essential for expression of the genes involved in cardiac fibrosis and hypertrophic growth.
other	hsa-mir-21	Endomyocardial Fibrosis	25903305	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	Downregulation of miR-21 and p-ERK/ERK were observed in myocardial fibroblasts treated with UA in a dose-dependent manner compared with the control group both in vitro and in vivo.
other	hsa-mir-25	Endomyocardial Fibrosis	19919989	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	both miR-25 and miR-29a were sufficient to decrease collagen gene expression
other	hsa-mir-29a	Endomyocardial Fibrosis	19919989	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	both miR-25 and miR-29a were sufficient to decrease collagen gene expression
other	hsa-mir-146a	Enterovirus Infection	24561744			B97.10	D004769			Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon.
other	hsa-mir-146a	Enterovirus Infection	25469565			B97.10	D004769			EV71-induced cell apoptosis is partly governed by altered miRNAs.
other	hsa-mir-370	Enterovirus Infection	25469565			B97.10	D004769			EV71-induced cell apoptosis is partly governed by altered miRNAs.
other	hsa-let-7d	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	Three miRNAs (let-7d, miR-596 and miR-367) strongly correlate to overall survival.
other	hsa-mir-203	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	miR-203 is an independent marker for relapse compared to the parameters that are currently used.
other	hsa-mir-367	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	Three miRNAs (let-7d, miR-596 and miR-367) strongly correlate to overall survival.
other	hsa-mir-596	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	Three miRNAs (let-7d, miR-596 and miR-367) strongly correlate to overall survival.
other	hsa-let-7d	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-106b	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-130a	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-132	Epilepsy	24553459	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	miRNA represents a potentially important mechanism controlling protein levels in epilepsy. As such, miRNAs might be targeted to prevent or disrupt epilepsy as well as serve as diagnostic biomarkers of epileptogenesis.
other	hsa-mir-132	Epilepsy	23485811	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Functional studies employing antagomirs have identified contributions from miR-34a and miR-132 to seizure-induced neuronal death whereas silencing miR-134 potently reduced status epilepticus, seizure-damage and the later occurrence of spontaneous seizures.
other	hsa-mir-132	Epilepsy	24282394	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Targeting miR-34a, miR-132 and miR-184 has been reported  to alter seizure-induced neuronal death, whereas targeting miR-134 was neuroprotective, reduced seizure severity during status epilepticus and reduced the later emergence of recurrent spontaneous seizures.
other	hsa-mir-146a	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-146a	Epilepsy	24553459	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	miRNA represents a potentially important mechanism controlling protein levels in epilepsy. As such, miRNAs might be targeted to prevent or disrupt epilepsy as well as serve as diagnostic biomarkers of epileptogenesis.
other	hsa-mir-155	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-15a	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-184	Epilepsy	24282394	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Targeting miR-34a, miR-132 and miR-184 has been reported  to alter seizure-induced neuronal death, whereas targeting miR-134 was neuroprotective, reduced seizure severity during status epilepticus and reduced the later emergence of recurrent spontaneous seizures.
other	hsa-mir-194	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-21	Epilepsy	27725160	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Increased precursor microRNA-21 following status epilepticus can compete with mature microRNA-21 to alter translation.
other	hsa-mir-221	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-222	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-223	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-23a	Epilepsy	24553459	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	miRNA represents a potentially important mechanism controlling protein levels in epilepsy. As such, miRNAs might be targeted to prevent or disrupt epilepsy as well as serve as diagnostic biomarkers of epileptogenesis.
other	hsa-mir-301a	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-30b	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-342	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-mir-34a	Epilepsy	24553459	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	miRNA represents a potentially important mechanism controlling protein levels in epilepsy. As such, miRNAs might be targeted to prevent or disrupt epilepsy as well as serve as diagnostic biomarkers of epileptogenesis.
other	hsa-mir-34a	Epilepsy	23485811	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Functional studies employing antagomirs have identified contributions from miR-34a and miR-132 to seizure-induced neuronal death whereas silencing miR-134 potently reduced status epilepticus, seizure-damage and the later occurrence of spontaneous seizures.
other	hsa-mir-4446	Epilepsy	26506013	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	This review highlights the immunological features underlying the pathogenesis of epileptic seizures and the possible miRNA mediated approaches for drug resistant epilepsies that modulate the immune-mediated pathogenesis.
other	hsa-let-7	Epstein-Barr Virus Infection	25031339			B27.90	D020031	300853		Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.
other	hsa-mir-10b	Esophageal Neoplasms	20075075			C15.9	D004938	133239	HP:0100751	MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines.
other	hsa-mir-1286	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-143	Esophageal Neoplasms	23276710			C15.9	D004938	133239	HP:0100751	miR-143 may act as a tumor suppressor in ESCC
other	hsa-mir-148a	Esophageal Neoplasms	21246413			C15.9	D004938	133239	HP:0100751	Mir-148a Improves Response to Chemotherapy in Sensitive and Resistant Oesophageal Adenocarcinoma and Squamous Cell Carcinoma Cells.
other	hsa-mir-193a	Esophageal Neoplasms	21420070			C15.9	D004938	133239	HP:0100751	The expression of three miRNAs (miR-99b and miR-199a_3p and _5p) was associated with the presence of lymph node metastasis.
other	hsa-mir-199a-1	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-199a-2	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-200a	Esophageal Neoplasms	28635228			C15.9	D004938	133239	HP:0100751	MALAT1 functions as a competing endogenous RNA to regulate the expressions of ZEB1 and ZEB2 by sponging miR-200a and promotes invasion and migration of esophageal cancer cells through inducing epithelial-mesenchymal transition
other	hsa-mir-200c	Esophageal Neoplasms	21248297			C15.9	D004938	133239	HP:0100751	Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.
other	hsa-mir-21	Esophageal Neoplasms	22689922			C15.9	D004938	133239	HP:0100751	Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer.
other	hsa-mir-22	Esophageal Neoplasms	23188185			C15.9	D004938	133239	HP:0100751	Increased miRNA-22 expression sensitizes esophageal squamous cell carcinoma to irradiation
other	hsa-mir-25	Esophageal Neoplasms	22450326			C15.9	D004938	133239	HP:0100751	MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma.
other	hsa-mir-296	Esophageal Neoplasms	22939244			C15.9	D004938	133239	HP:0100751	differentially regulated
other	hsa-mir-302a	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-302f	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-31	Esophageal Neoplasms	22689922			C15.9	D004938	133239	HP:0100751	Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer.
other	hsa-mir-31	Esophageal Neoplasms	22706599			C15.9	D004938	133239	HP:0100751	MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma.
other	hsa-mir-342	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-425	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-451	Esophageal Neoplasms	27896643			C15.9	D004938	133239	HP:0100751	A novel signaling role for miR-451 in esophageal tumor microenvironment and its contribution to tumor progression.
other	hsa-mir-451a	Esophageal Neoplasms	23053883			C15.9	D004938	133239	HP:0100751	Effect of miR-451 on the Biological Behavior of the Esophageal Carcinoma Cell Line EC9706
other	hsa-mir-455	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-486	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-519c	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-548d-1	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-548d-2	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-617	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-758	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-766	Esophageal Neoplasms	21743970			C15.9	D004938	133239	HP:0100751	Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment by Chemotherapy.
other	hsa-mir-92a-1	Esophageal Neoplasms	21148309			C15.9	D004938	133239	HP:0100751	microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin.
other	hsa-mir-92a-2	Esophageal Neoplasms	21148309			C15.9	D004938	133239	HP:0100751	microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin.
other	hsa-mir-99b	Esophageal Neoplasms	21420070			C15.9	D004938	133239	HP:0100751	The expression of three miRNAs (miR-99b and miR-199a_3p and _5p) was associated with the presence of lymph node metastasis.
other	hsa-mir-126	Essential Hypertension	24794206	cardiovascular system disease	DOID:10825	I10	C562386	145500		MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage.
other	hsa-mir-9	Essential Hypertension	24794206	cardiovascular system disease	DOID:10825	I10	C562386	145500		MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage.
other	hsa-mir-124	Ewing Sarcoma	28055964	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	miR-124 represses the mesenchymal features and suppresses metastasis in Ewing sarcoma.
other	hsa-mir-125b	Ewing Sarcoma	26782555	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	Circulating miR-125b as a biomarker of Ewing's sarcoma in Chinese children.
other	hsa-mir-145	Ewing Sarcoma	21217773	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
other	hsa-mir-145	Ewing Sarcoma	20382729	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.
other	hsa-mir-34a	Ewing Sarcoma	25015333	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	By demonstrating its relationship with clinical outcome, we propose evaluation of miR-34a at diagnosis of EWS patients to allow early risk stratification. Validation of these results would nonetheless ultimately need a prospective assessment.
other	hsa-mir-34a	Ewing Sarcoma	21960059	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	miR-34a and miR490-3p achieved sufficient statistical power to predict prognosis.Patients with the highest expression of miR-34a did not experience adverse events in 5 years; in contrast, patients with the lowest expression recurred within two years.
other	hsa-mir-34a	Ewing Sarcoma	26616853	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	CD99 counteracts EWS-FLI1 in controlling NF-κB signaling through the miR-34a
other	hsa-mir-490	Ewing Sarcoma	21960059	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	miR-34a and miR490-3p achieved sufficient statistical power to predict prognosis.
other	hsa-mir-181c	Fanconi Anemia	22310912	hematopoietic system disease	DOID:13636	D61.09	D005199	PS227650		Downregulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNFж┿regulation and proliferation of hematopoietic progenitor cells.
other	hsa-mir-130a	Fatty Liver [unspecific]	24677715	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	A novel function of microRNA 130a-3p in hepatic insulin sensitivity and liver steatosis.
other	hsa-mir-29a	Fatty Liver [unspecific]	28167804	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	miR-29a modulates SCD expression and is regulated in response to a saturated fatty acid diet in juvenile genetically improved farmed tilapia (Oreochromis niloticus).
other	hsa-mir-122	Fatty Liver, Non-Alcoholic	24973316	disease of metabolism	DOID:0080208	K75.81	D065626	613282		miR-122 plays a role of physiological significance in the biology of NAFLD; circulating miRNAs mirror the histological and molecular events occurring in the liver. NAFLD has a distinguishing circulating miRNA profile associated with a global dysmetabolic disease state and cardiovascular risk.
other	hsa-mir-122	Fatty Liver, Non-Alcoholic	25117675	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
other	hsa-mir-122	Fatty Liver, Non-Alcoholic	25470250	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Finally, the liver appears to be an important source of circulating EVs in NAFLD animals as evidenced by the enrichment in blood with miR-122 and 192--two microRNAs previously described in chronic liver diseases, coupled with a corresponding decrease in expression of these microRNAs in the liver.
other	hsa-mir-122	Fatty Liver, Non-Alcoholic	27669236	disease of metabolism	DOID:0080208	K75.81	D065626	613282		miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
other	hsa-mir-33a	Fatty Liver, Non-Alcoholic	27669236	disease of metabolism	DOID:0080208	K75.81	D065626	613282		miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
other	hsa-mir-33b	Fatty Liver, Non-Alcoholic	27669236	disease of metabolism	DOID:0080208	K75.81	D065626	613282		miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
other	hsa-mir-17	Feingold Syndrome	23495052	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2.
other	hsa-mir-17	Feingold Syndrome	24511118	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		MicroRNA-17~92 is required for nephrogenesis and renal function.
other	hsa-mir-17	Feingold Syndrome	26026879	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		respectively, of miR-17-92∆/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission
other	hsa-mir-17	Feingold Syndrome	29636449	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.
other	hsa-mir-18	Feingold Syndrome	23495052	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2.
other	hsa-mir-18	Feingold Syndrome	24511118	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		MicroRNA-17~92 is required for nephrogenesis and renal function.
other	hsa-mir-18	Feingold Syndrome	26026879	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		respectively, of miR-17-92∆/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission
other	hsa-mir-18	Feingold Syndrome	29636449	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.
other	hsa-mir-19a	Feingold Syndrome	23495052	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2.
other	hsa-mir-19a	Feingold Syndrome	24511118	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		MicroRNA-17~92 is required for nephrogenesis and renal function.
other	hsa-mir-19a	Feingold Syndrome	26026879	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		respectively, of miR-17-92∆/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission
other	hsa-mir-19a	Feingold Syndrome	29636449	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.
other	hsa-mir-19b-1	Feingold Syndrome	23495052	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2.
other	hsa-mir-19b-1	Feingold Syndrome	24511118	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		MicroRNA-17~92 is required for nephrogenesis and renal function.
other	hsa-mir-19b-1	Feingold Syndrome	26026879	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		respectively, of miR-17-92∆/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission
other	hsa-mir-19b-1	Feingold Syndrome	29636449	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.
other	hsa-mir-20a	Feingold Syndrome	23495052	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2.
other	hsa-mir-20a	Feingold Syndrome	24511118	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		MicroRNA-17~92 is required for nephrogenesis and renal function.
other	hsa-mir-20a	Feingold Syndrome	26026879	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		respectively, of miR-17-92∆/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission
other	hsa-mir-20a	Feingold Syndrome	29636449	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.
other	hsa-mir-92-1	Feingold Syndrome	23495052	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		De novo 13q31.1-q32.1 interstitial deletion encompassing the miR-17-92 cluster in a patient with Feingold syndrome-2.
other	hsa-mir-92-1	Feingold Syndrome	24511118	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		MicroRNA-17~92 is required for nephrogenesis and renal function.
other	hsa-mir-92-1	Feingold Syndrome	26026879	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		respectively, of miR-17-92∆/+ in comparison with WT mice, thus suggesting a possible link between cognitive deficits and altered brain neurotransmission
other	hsa-mir-92-1	Feingold Syndrome	29636449	genetic disease	DOID:0060464	Q87.8	C537734	PS164280		Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.
other	hsa-mir-153	Fetal Alcohol Spectrum Disorder	24313161	disease of mental health	DOID:0050696		D063647			Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders.
other	hsa-mir-21	Fetal Alcohol Spectrum Disorder	24313161	disease of mental health	DOID:0050696		D063647			Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders.
other	hsa-mir-335	Fetal Alcohol Spectrum Disorder	24313161	disease of mental health	DOID:0050696		D063647			Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders.
other	hsa-mir-9	Fetal Alcohol Spectrum Disorder	24313161	disease of mental health	DOID:0050696		D063647			Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders.
other	hsa-mir-196a	Focal Segmental Glomerulosclerosis	25107948	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	The levels of urinary miR-196a, miR-30a-5p, and miR-490 are associated with FSGS disease activity.
other	hsa-mir-30a	Focal Segmental Glomerulosclerosis	25107948	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	The levels of urinary miR-196a, miR-30a-5p, and miR-490 are associated with FSGS disease activity.
other	hsa-mir-490	Focal Segmental Glomerulosclerosis	25107948	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	The levels of urinary miR-196a, miR-30a-5p, and miR-490 are associated with FSGS disease activity.
other	hsa-mir-29	Fuchs Endothelial Dystrophy	24334445	nervous system disease	DOID:11555	H18.51	D005642	136800		Decreased endothelial expression of miR-29 family members may be associated with increased subendothelial extracellular matrix accumulation in FECD.
other	hsa-mir-210	Gallstones	25639987			K80.20	D042882	600803	HP:0001081	An integrated analysis of differential miRNA and mRNA expressions in human gallstones.
other	hsa-mir-203a	Gastric Cardia Adenocarcinoma	27791400	disease of cellular proliferation	DOID:6271					Downregulation of Potential Tumor Suppressor miR-203a by Promoter Methylation Contributes to the Invasiveness of Gastric Cardia Adenocarcinoma.
other	hsa-let-7g	Gastric Neoplasms	19948396	disease of cellular proliferation	DOID:10534	C16	D013274	137215		different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1
other	hsa-mir-1	Gastric Neoplasms	27349337	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-1, -133 and -206 family in GC
other	hsa-mir-1	Gastric Neoplasms	28493075	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer.
other	hsa-mir-100	Gastric Neoplasms	25703026	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The role of miR-100-mediated Notch pathway in apoptosis of gastric tumor cells.
other	hsa-mir-100	Gastric Neoplasms	20022810	disease of cellular proliferation	DOID:10534	C16	D013274	137215		progression-related signature, miR-125b, miR-199a, and miR-100 were the most important microRNAs involved
other	hsa-mir-101-2	Gastric Neoplasms	26458815	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our expression analyses and in vitro functional assays suggest that miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in primary GCs as well as in GC-derived AGS cells.
other	hsa-mir-106	Gastric Neoplasms	24643999	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study.
other	hsa-mir-106a	Gastric Neoplasms	26722506	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Diagnostic significance of miR-106a in gastric cancer.
other	hsa-mir-106a	Gastric Neoplasms	18996190	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106a: oncogenic activity
other	hsa-mir-10a	Gastric Neoplasms	22969895	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miRNA expression profile in primary gastric cancers and paired lymph node metastases indicates that miR-10a plays a role in metastasis from primary gastric cancer to lymph nodes.
other	hsa-mir-10b	Gastric Neoplasms	26311318	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-10b promotes migration and invasion through Hoxd10 in human gastric cancer cell lines and may play an important role in tumorigenesis,progression, and prognosis.
other	hsa-mir-1228	Gastric Neoplasms	23554909	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Restoration of miR-1228* Expression Suppresses Epithelial-Mesenchymal Transition in Gastric Cancer
other	hsa-mir-1234	Gastric Neoplasms	25861021	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data provide a theoretical basis for the potential interaction between miRNA and the β-catenin signaling pathway in GC.
other	hsa-mir-125a	Gastric Neoplasms	22322911	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Low expression levels of miR-125a-3p were associated with indicators of enhanced malignant potential such as tumor size (p=0.0002), tumor invasion (p=0.0149), lymph node metastasis (p=0.018), liver metastasis (p=0.016), peritoneal dissemination (p=0.03), advanced clinical stage (p=0.0037) and poor prognosis (p=0.0083).
other	hsa-mir-125b-1	Gastric Neoplasms	23128435	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells
other	hsa-mir-125b-2	Gastric Neoplasms	26458815	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our expression analyses and in vitro functional assays suggest that miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in primary GCs as well as in GC-derived AGS cells.
other	hsa-mir-125b-2	Gastric Neoplasms	23128435	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells
other	hsa-mir-126	Gastric Neoplasms	20619534	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-126:miR-126 functions as a tumour suppressor in human gastric cancer
other	hsa-mir-127	Gastric Neoplasms	23880861	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The Tumor Suppressor Roles of miR-433 and miR-127 in Gastric Cancer.
other	hsa-mir-129	Gastric Neoplasms	24055727	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Growth inhibitory effects of three miR-129 family members on gastric cancer.
other	hsa-mir-129-2	Gastric Neoplasms	20331975	disease of cellular proliferation	DOID:10534	C16	D013274	137215		We also found that inactivation of SOX4 by siRNA and restoration of miR-129-2 induced apoptosis in gastric cancer cells.
other	hsa-mir-133	Gastric Neoplasms	27349337	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-1, -133 and -206 family in GC
other	hsa-mir-133a	Gastric Neoplasms	25780292	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.
other	hsa-mir-135a	Gastric Neoplasms	25322930	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p.
other	hsa-mir-135b	Gastric Neoplasms	25861021	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data provide a theoretical basis for the potential interaction between miRNA and the β-catenin signaling pathway in GC.
other	hsa-mir-135b	Gastric Neoplasms	23328512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Quantitative real-time PCR was used to validate the reliability of microarray and detect miR-135b expression in the above clinical samples, as well as cell lines GES-1, BGC-823 and SGC-7901.
other	hsa-mir-143	Gastric Neoplasms	25656032	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Expression of miR-143 and miR-145 and their functional study in gastric carcinoma.
other	hsa-mir-145	Gastric Neoplasms	26010149	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Reverse Correlation between MicroRNA-145 and FSCN1 Affecting Gastric Cancer Migration and Invasion.
other	hsa-mir-145	Gastric Neoplasms	25656032	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Expression of miR-143 and miR-145 and their functional study in gastric carcinoma.
other	hsa-mir-146a	Gastric Neoplasms	25081668	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-146a enhances Helicobacter pylori induced cell apoptosis in human gastric cancer epithelial cells.
other	hsa-mir-146a	Gastric Neoplasms	21947847	disease of cellular proliferation	DOID:10534	C16	D013274	137215		H. pylori related proinflammatory cytokines contribute to the induction of miR-146a in human gastric epithelial cells.
other	hsa-mir-146a	Gastric Neoplasms	28987948	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-146a functions as a small silent player in gastric cancer.
other	hsa-mir-148	Gastric Neoplasms	25261463	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Polymorphisms and haplotypes of the miR-148/152 family are associated with the risk and clinicopathological features of gastric cancer in a Northern Chinese population.
other	hsa-mir-148a	Gastric Neoplasms	23869555	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Quantitative proteomics reveals diverse roles of miR-148a from gastric cancer progression to neurological development.
other	hsa-mir-148a	Gastric Neoplasms	23873106	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-148a suppresses human gastric cancer cell metastasis by reversing epithelial-to-mesenchymal transition.
other	hsa-mir-152	Gastric Neoplasms	25261463	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Polymorphisms and haplotypes of the miR-148/152 family are associated with the risk and clinicopathological features of gastric cancer in a Northern Chinese population.
other	hsa-mir-155	Gastric Neoplasms	19702585	disease of cellular proliferation	DOID:10534	C16	D013274	137215		possible role in the intimate relationship
other	hsa-mir-155	Gastric Neoplasms	29675003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Role of microRNAs and Exosomes in Helicobacter pylori and Epstein-Barr Virus Associated Gastric Cancers
other	hsa-mir-16	Gastric Neoplasms	25897338	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer.
other	hsa-mir-16	Gastric Neoplasms	21081469	disease of cellular proliferation	DOID:10534	C16	D013274	137215		NF-κB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors.
other	hsa-mir-16	Gastric Neoplasms	27157613	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and  gastric cancer via its novel targets CCNJ and FUBP1.
other	hsa-mir-181b	Gastric Neoplasms	19948396	disease of cellular proliferation	DOID:10534	C16	D013274	137215		different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1
other	hsa-mir-181c	Gastric Neoplasms	23425811	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-181c expression level was significantly related to several clinicopathological features of gastric cancer
other	hsa-mir-185	Gastric Neoplasms	24352663	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer.
other	hsa-mir-18a	Gastric Neoplasms	26772615	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line  by chrysin-loaded PLGA-PEG nanoparticles.
other	hsa-mir-194-1	Gastric Neoplasms	21845495	disease of cellular proliferation	DOID:10534	C16	D013274	137215		There is an inverse Association between miR-194 Expression and Tumor Invasion in Gastric Cancer.
other	hsa-mir-194-2	Gastric Neoplasms	21845495	disease of cellular proliferation	DOID:10534	C16	D013274	137215		There is an inverse Association between miR-194 Expression and Tumor Invasion in Gastric Cancer.
other	hsa-mir-196b	Gastric Neoplasms	24222951	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Co-activation of miR-196b and HOXA10 characterized a poor-prognosis subgroup of patients with gastric cancer. Elucidation of the biologic function of miR-196b and HOXA10 is warranted.
other	hsa-mir-197	Gastric Neoplasms	26632693	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Associations of Il-1 Family-Related Polymorphisms With Gastric Cancer Risk and the Role of Mir-197 In Il-1f5 Expression.
other	hsa-mir-19b	Gastric Neoplasms	25897338	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer.
other	hsa-mir-200	Gastric Neoplasms	24352645	disease of cellular proliferation	DOID:10534	C16	D013274	137215		We have uncovered a key microRNA regulatory network that defines the mesenchymal gastric cancer subtype significantly associated with poor overall survival in gastric cancer
other	hsa-mir-200	Gastric Neoplasms	25270520	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-200 family members and ZEB2 are associated with brain metastasis in gastric adenocarcinoma.
other	hsa-mir-202	Gastric Neoplasms	23936094	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer.
other	hsa-mir-203	Gastric Neoplasms	27142767	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203.
other	hsa-mir-206	Gastric Neoplasms	25653235	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis.
other	hsa-mir-206	Gastric Neoplasms	26186594	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-206: Effective Inhibition of Gastric Cancer Progression through the c-Met Pathway.
other	hsa-mir-206	Gastric Neoplasms	27349337	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-1, -133 and -206 family in GC
other	hsa-mir-20a	Gastric Neoplasms	25861021	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data provide a theoretical basis for the potential interaction between miRNA and the β-catenin signaling pathway in GC.
other	hsa-mir-21	Gastric Neoplasms	24434352	disease of cellular proliferation	DOID:10534	C16	D013274	137215		the effect of celastrol on apoptosis was due to miR-21 inhibiting the PI3K/Akt-dependent NF-κB pathway.
other	hsa-mir-21	Gastric Neoplasms	26265521	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-21: Mechanisms of Oncogenesis and its Application in Diagnosis and Prognosis of Gastric Cancer.
other	hsa-mir-21	Gastric Neoplasms	18794849	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21: miR-21 plays a pivotal role in gastric cancer pathogenesis and progression
other	hsa-mir-21	Gastric Neoplasms	19702585	disease of cellular proliferation	DOID:10534	C16	D013274	137215		possible role in the intimate relationship
other	hsa-mir-21	Gastric Neoplasms	21081469	disease of cellular proliferation	DOID:10534	C16	D013274	137215		NF-κB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors.
other	hsa-mir-21	Gastric Neoplasms	26772615	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line  by chrysin-loaded PLGA-PEG nanoparticles.
other	hsa-mir-21	Gastric Neoplasms	29185784	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway
other	hsa-mir-21	Gastric Neoplasms	29422082	disease of cellular proliferation	DOID:10534	C16	D013274	137215		CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways
other	hsa-mir-210	Gastric Neoplasms	25861021	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data provide a theoretical basis for the potential interaction between miRNA and the β-catenin signaling pathway in GC.
other	hsa-mir-210	Gastric Neoplasms	25618442	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MIR210 is often highly overexpressed in gastric cancer
other	hsa-mir-214	Gastric Neoplasms	24614175	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Clinicopathological significance of microRNA-214 in gastric cancer and its effect on cell biological behaviour.
other	hsa-mir-214	Gastric Neoplasms	29129783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Hypoxia-induced miR-214 expression promotes tumour cell proliferation and migration by enhancing the Warburg effect in gastric carcinoma cells.
other	hsa-mir-214	Gastric Neoplasms	29456019	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer
other	hsa-mir-22	Gastric Neoplasms	23786758	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis..
other	hsa-mir-221	Gastric Neoplasms	24317477	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
other	hsa-mir-221	Gastric Neoplasms	26364844	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The miR-221/miR-222-RECK axis might be an important path modulating H. pylori infection-related gastric cancer development.
other	hsa-mir-221	Gastric Neoplasms	19702585	disease of cellular proliferation	DOID:10534	C16	D013274	137215		possible role in the intimate relationship
other	hsa-mir-221	Gastric Neoplasms	26772615	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line  by chrysin-loaded PLGA-PEG nanoparticles.
other	hsa-mir-222	Gastric Neoplasms	26364844	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The miR-221/miR-222-RECK axis might be an important path modulating H. pylori infection-related gastric cancer development.
other	hsa-mir-222	Gastric Neoplasms	19702585	disease of cellular proliferation	DOID:10534	C16	D013274	137215		possible role in the intimate relationship
other	hsa-mir-222	Gastric Neoplasms	29098549	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The GAS5/miR-222 Axis Regulates Proliferation of Gastric Cancer Cells Through the PTEN/Akt/mTOR Pathway.
other	hsa-mir-223	Gastric Neoplasms	25036956	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Increased microRNA-223 in Helicobacter pylori-associated gastric cancer contributed to cancer cell proliferation and migration.
other	hsa-mir-224	Gastric Neoplasms	24796455	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Effect of antisense miR-224 on gastric cancer cell proliferation and apoptosis.
other	hsa-mir-23b	Gastric Neoplasms	25765901	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Reciprocal repression between TUSC7 and miR-23b in gastric cancer.
other	hsa-mir-23b	Gastric Neoplasms	25861021	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data provide a theoretical basis for the potential interaction between miRNA and the β-catenin signaling pathway in GC.
other	hsa-mir-24	Gastric Neoplasms	26045155	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These results suggest that the measurement of miR-24 expression from formalin-fixed paraffin-embedded (FFPE) samples is useful to identify radiation-associated GC.
other	hsa-mir-25	Gastric Neoplasms	24643999	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study.
other	hsa-mir-27a	Gastric Neoplasms	18789835	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27a: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin
other	hsa-mir-27a	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27a: There was a correlation between mir-27a and lymph node metastasis
other	hsa-mir-27a	Gastric Neoplasms	19702585	disease of cellular proliferation	DOID:10534	C16	D013274	137215		possible role in the intimate relationship
other	hsa-mir-27a	Gastric Neoplasms	21569481	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells.
other	hsa-mir-27a	Gastric Neoplasms	22018270	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition.
other	hsa-mir-27a	Gastric Neoplasms	23175237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells
other	hsa-mir-27b	Gastric Neoplasms	22018270	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition.
other	hsa-mir-29	Gastric Neoplasms	24643999	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study.
other	hsa-mir-29	Gastric Neoplasms	25634213	disease of cellular proliferation	DOID:10534	C16	D013274	137215		a global mechanism for understanding the efficacious effects of cytotoxic chemotherapy in gastric cancer.
other	hsa-mir-29c	Gastric Neoplasms	23001726	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.
other	hsa-mir-30b	Gastric Neoplasms	26309359	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our findings describe a link between miR-30b and EIF5A2, which plays an important role in mediating epithelial-mesenchymal transition.
other	hsa-mir-31	Gastric Neoplasms	22212233	disease of cellular proliferation	DOID:10534	C16	D013274	137215		PDCD4 expression inversely correlated with miR-21 levels in gastric cancers.
other	hsa-mir-335	Gastric Neoplasms	22802949	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A high frequency recurrence and poor survival were observed in GC cases with high level of hsa-miR-335 (P<0.001).
other	hsa-mir-337	Gastric Neoplasms	24422944	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings indicate that hsa-miR-337-3p plays a role in the reduction of gastric cancer cell invasion capacity, and further studies on the mechanism of hsa-miR-337-3p in gastric cancer metastasis are warranted.
other	hsa-mir-33b	Gastric Neoplasms	27456358	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Curcumin inhibits cell growth and induces cell apoptosis through upregulation of  miR-33b in gastric cancer.
other	hsa-mir-340	Gastric Neoplasms	26722508	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Effect of miR-340 on gastric cancer cell proliferation and apoptosis.
other	hsa-mir-34a	Gastric Neoplasms	24981249	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer.
other	hsa-mir-34a	Gastric Neoplasms	24988056	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Luteolin Induces Apoptosis by Up-regulating miR-34a in Human Gastric Cancer Cells.
other	hsa-mir-34a	Gastric Neoplasms	26745070	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our study demonstrates chrysin loaded PLGA-PEG promises a natural and efficient system for anticancer drug delivery to fight gastric cancer.
other	hsa-mir-34a	Gastric Neoplasms	18803879	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-34: tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
other	hsa-mir-34b	Gastric Neoplasms	18803879	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-34: tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
other	hsa-mir-34c	Gastric Neoplasms	18803879	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-34: tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
other	hsa-mir-375	Gastric Neoplasms	24718681	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2-STAT3 signaling.
other	hsa-mir-376c	Gastric Neoplasms	27965982	disease of cellular proliferation	DOID:10534	C16	D013274	137215		hsa-miR-376c-3p Regulates Gastric Tumor Growth Both In Vitro and In Vivo.
other	hsa-mir-422a	Gastric Neoplasms	24317477	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
other	hsa-mir-423	Gastric Neoplasms	25861021	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data provide a theoretical basis for the potential interaction between miRNA and the β-catenin signaling pathway in GC.
other	hsa-mir-429	Gastric Neoplasms	21684154	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-429 Modulates the expression of c-myc in human gastric carcinoma cells.
other	hsa-mir-433	Gastric Neoplasms	23880861	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The Tumor Suppressor Roles of miR-433 and miR-127 in Gastric Cancer.
other	hsa-mir-4496	Gastric Neoplasms	27265143	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Here, we show that rebamipide suppresses H. pylori CagA-induced 尾-catenin and its target cancer-initiating cells (C-IC) marker gene expression via upregulation of miRNA-320a and -4496.
other	hsa-mir-451	Gastric Neoplasms	27173190	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Propofol effectively inhibited proliferation and induced apoptosis in gastric cancer cells, which was partly owing to the downregulation of MMP-2 expression by miR-451.
other	hsa-mir-451a	Gastric Neoplasms	26458815	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our expression analyses and in vitro functional assays suggest that miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in primary GCs as well as in GC-derived AGS cells.
other	hsa-mir-455	Gastric Neoplasms	25861021	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data provide a theoretical basis for the potential interaction between miRNA and the β-catenin signaling pathway in GC.
other	hsa-mir-4697	Gastric Neoplasms	26531872	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The expression of TM4SF5, CTD-2354A18.1 and miR-4697-3P is in balance at physiological conditions, however, the balance is disrupted by some situations, which may contribute to gastric cancer. GO analysis and Pathway analysis also showed TM4SF5 played an important role in proliferation,differentiation and apoptosis. Therefore, TM4SF5-miR-4697-3P- CTD-2354A18.1 may play a key role in the pathogenesis of gastric cancer (Tab. 2, Fig. 4, Ref. 30).
other	hsa-mir-4732	Gastric Neoplasms	24317477	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
other	hsa-mir-4739	Gastric Neoplasms	25861021	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data provide a theoretical basis for the potential interaction between miRNA and the β-catenin signaling pathway in GC.
other	hsa-mir-4758	Gastric Neoplasms	24317477	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
other	hsa-mir-494	Gastric Neoplasms	24606447	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Cinobufacin suppresses cell proliferation via miR-494 in BGC- 823 gastric cancer cells.
other	hsa-mir-497	Gastric Neoplasms	24845562	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The putative tumor suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by repressing eIF4E.
other	hsa-mir-500	Gastric Neoplasms	25595906	disease of cellular proliferation	DOID:10534	C16	D013274	137215		we report the uncovering of a novel mechanism for constitutive NF-κB activation, indicating the potentially pivotal role of miR-500 in the progression of gastric cancer.
other	hsa-mir-551b	Gastric Neoplasms	25623763	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Expression of miR-551b-3p in gastric cancer cell lines and tissues and its clinical significance.
other	hsa-mir-610	Gastric Neoplasms	22189055	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-610 inhibits the migration and invasion of gastric cancer cells by suppressing the expression of vasodilator-stimulated phosphoprotein.
other	hsa-mir-650	Gastric Neoplasms	20381459	disease of cellular proliferation	DOID:10534	C16	D013274	137215		we show that miR-650 is involved in lymphatic and distant metastasis in human gastric cancer
other	hsa-mir-7	Gastric Neoplasms	24573489	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression.
other	hsa-mir-7-1	Gastric Neoplasms	22139078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells.
other	hsa-mir-7-2	Gastric Neoplasms	22139078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells.
other	hsa-mir-7-3	Gastric Neoplasms	22139078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells.
other	hsa-mir-9	Gastric Neoplasms	25395097	disease of cellular proliferation	DOID:10534	C16	D013274	137215		membranous ALCAM expression and high serum sALCAM levels are independent prognostic markers of poor survival for patients with GC, and that the overexpression of ALCAM may be due to the downregulation of miR-9.
other	hsa-mir-92b	Gastric Neoplasms	24317477	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
other	hsa-mir-92b	Gastric Neoplasms	25537895	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-92b promotes the migration, adhesion and invasion of human gastric cancer cell line SGC7901 by mediating epithelial-mesenchymal transition,  and may accelerate tumor cell metastasis via signaling pathways other than PI3K/Akt pathway.
other	hsa-mir-93	Gastric Neoplasms	24643999	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study.
other	hsa-let-7a	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-101	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-106a	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-106a	Gastrointestinal Neoplasms	22994734			D37.9	D005770			Under these experimental conditions, MTg-AMOs demonstrated better suppression of the expression of miR-221, miR-106a, miR-21 in gastric cancer cells than that of single AMOs
other	hsa-mir-107	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-122	Gastrointestinal Neoplasms	19607815			D37.9	D005770			The down-regulation of miR-122a mediated by aberrant APC/beta-catenin signaling is important to the pathogenesis of gastrointestinal cancers.
other	hsa-mir-126	Gastrointestinal Neoplasms	19951901			D37.9	D005770			We have identified a seven-miRNA signature (miR-10b, miR-21, miR-223, miR-338, let-7a, miR-30a-5p, miR-126) for overall survival (p=0.0009) and relapse-free survival (p=0.0005) of gastric cancer patients. 
other	hsa-mir-126	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-133b	Gastrointestinal Neoplasms	23196799			D37.9	D005770			Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor
other	hsa-mir-143	Gastrointestinal Neoplasms	19439999			D37.9	D005770			Taken together, these findings suggest that miR-143 and miR-145 act as anti-oncomirs common to gastrointestinal tumors.
other	hsa-mir-143	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-145	Gastrointestinal Neoplasms	29459716			D37.9	D005770			miR-145, which blocked EGFR endocytosis, prolonged EGFR membrane signaling and altered responsiveness of colon cancer cells to EGFR-targeting drugs
other	hsa-mir-145	Gastrointestinal Neoplasms	19439999			D37.9	D005770			Taken together, these findings suggest that miR-143 and miR-145 act as anti-oncomirs common to gastrointestinal tumors.
other	hsa-mir-145	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-146a	Gastrointestinal Neoplasms	26211779			D37.9	D005770			miR-146a cancer susceptibility gene polymorphism is closely associated with gastrointestinal cancers.
other	hsa-mir-149	Gastrointestinal Neoplasms	24312386			D37.9	D005770			The present meta-analysis indicates that miR-499 may be associated with the risk to colorectal cancer. MiR-149 may confer a marginally increased risk of susceptibility to gastrointestinal cancer, especially for Asians.
other	hsa-mir-17	Gastrointestinal Neoplasms	29459716			D37.9	D005770			The regulation of EGF receptor (EGFR) endocytosis by two predicted miRNAs, namely miR-17 and miR-145, was confirmed experimentally
other	hsa-mir-17	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-17	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-18	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-181	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-192	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-194	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-195	Gastrointestinal Neoplasms	23212612			D37.9	D005770			We demonstrated that miR-195-5p is a novel tumor suppressor miRNA and may contribute to gastric carcinogenesis.
other	hsa-mir-196a-1	Gastrointestinal Neoplasms	22258453			D37.9	D005770			Upregulation of miR-196a and HOTAIR Drive Malignant Character in Gastrointestinal Stromal Tumors.
other	hsa-mir-196a-2	Gastrointestinal Neoplasms	22258453			D37.9	D005770			Upregulation of miR-196a and HOTAIR Drive Malignant Character in Gastrointestinal Stromal Tumors.
other	hsa-mir-19a	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-19b-1	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-20a	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-21	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-21	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-21	Gastrointestinal Neoplasms	22994734			D37.9	D005770			Under these experimental conditions, MTg-AMOs demonstrated better suppression of the expression of miR-221, miR-106a, miR-21 in gastric cancer cells than that of single AMOs
other	hsa-mir-215	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-218	Gastrointestinal Neoplasms	28024574			D37.9	D005770			miRNA-218-loaded carboxymethyl chitosan - Tocopherol nanoparticle to suppress the proliferation of gastrointestinal stromal tumor growth.
other	hsa-mir-221	Gastrointestinal Neoplasms	22994734			D37.9	D005770			Under these experimental conditions, MTg-AMOs demonstrated better suppression of the expression of miR-221, miR-106a, miR-21 in gastric cancer cells than that of single AMOs
other	hsa-mir-30e	Gastrointestinal Neoplasms	24312366			D37.9	D005770			Identification of miR-30e* regulation of Bmi1 expression mediated by tumor-associated macrophages in gastrointestinal cancer.
other	hsa-mir-34	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-421	Gastrointestinal Neoplasms	19802518			D37.9	D005770			miR-421 may involve in the early stage of stomach carcinogenesis and could be used as an efficient diagnostic biomarker.
other	hsa-mir-449	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-451a	Gastrointestinal Neoplasms	19318487			D37.9	D005770			miR-451: microRNA-451 Regulates Macrophage Migration Inhibitory Factor Proliferation of Gastrointestinal Cancer Cells Production
other	hsa-mir-486	Gastrointestinal Neoplasms	22168593			D37.9	D005770			The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR-21, miR-106a and miR-17), tumor suppressor miR (e.g. miR-101, miR-181, miR-449, miR-486, let-7a) and controversial roles of miR (e.g. miR-107, miR-126) for gastric cancer.
other	hsa-mir-499	Gastrointestinal Neoplasms	24312386			D37.9	D005770			The present meta-analysis indicates that miR-499 may be associated with the risk to colorectal cancer. MiR-149 may confer a marginally increased risk of susceptibility to gastrointestinal cancer, especially for Asians.
other	hsa-mir-7	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-92-1	Gastrointestinal Neoplasms	21219233			D37.9	D005770			The review focuses on the role of specific miRNAs (miR-192/194/215 and miR-7) in the differentiation of gastrointestinal epithelium and on the role of tumor-suppressive (miR-34, miR-143, miR-145) and oncogenic miRNAs (miR-21,miR-17-92 cluster) in gastrointestinal tumors.
other	hsa-mir-218	Gastrointestinal Stromal Tumor	24706111	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.
other	hsa-mir-221	Gastrointestinal Stromal Tumor	25898773	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours.
other	hsa-mir-222	Gastrointestinal Stromal Tumor	25898773	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours.
other	hsa-mir-320a	Gastrointestinal Stromal Tumor	24217767	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
other	hsa-mir-221	Gastrointestinal Stromal Tumor	24674454	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		Multiple sporadic gastrointestinal stromal tumors concomitant with ampullary adenocarcinoma: a case report with KIT and PDGFRA mutational analysis and miR-221/222 expression profile.
other	hsa-mir-222	Gastrointestinal Stromal Tumor	24674454	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		Multiple sporadic gastrointestinal stromal tumors concomitant with ampullary adenocarcinoma: a case report with KIT and PDGFRA mutational analysis and miR-221/222 expression profile.
other	hsa-mir-372	Germ Cell And Embryonal Neoplasms	17695719			D49.9	D009373	273300		we identified miR-372 and miR-373, each permitting proliferation and tumorigenesis of primary human cells that harbor both oncogenic RAS and active wild-type p53.
other	hsa-mir-373	Germ Cell And Embryonal Neoplasms	17695719			D49.9	D009373	273300		we identified miR-372 and miR-373, each permitting proliferation and tumorigenesis of primary human cells that harbor both oncogenic RAS and active wild-type p53.
other	hsa-mir-107	Glaucoma	26149270	nervous system disease	DOID:1686	H40	D005901	137750		Experimental evidences indicate that the uveoscleral pathway, via suprachoroidal space, can provide a potential route of access from the anterior region to the posterior segment of the eye and could represent the path followed  by biologic mediators to reach the inner layer of the peripapillary retina and transmit damage signals from the anterior to posterior segment during glaucoma course.
other	hsa-mir-143	Glaucoma	28424493	nervous system disease	DOID:1686	H40	D005901	137750		Regulation of intraocular pressure by microRNA cluster miR-143/145.
other	hsa-mir-145	Glaucoma	28424493	nervous system disease	DOID:1686	H40	D005901	137750		Regulation of intraocular pressure by microRNA cluster miR-143/145.
other	hsa-mir-149	Glaucoma	26149270	nervous system disease	DOID:1686	H40	D005901	137750		Experimental evidences indicate that the uveoscleral pathway, via suprachoroidal space, can provide a potential route of access from the anterior region to the posterior segment of the eye and could represent the path followed  by biologic mediators to reach the inner layer of the peripapillary retina and transmit damage signals from the anterior to posterior segment during glaucoma course.
other	hsa-mir-21	Glaucoma	26149270	nervous system disease	DOID:1686	H40	D005901	137750		Experimental evidences indicate that the uveoscleral pathway, via suprachoroidal space, can provide a potential route of access from the anterior region to the posterior segment of the eye and could represent the path followed  by biologic mediators to reach the inner layer of the peripapillary retina and transmit damage signals from the anterior to posterior segment during glaucoma course.
other	hsa-mir-450	Glaucoma	26149270	nervous system disease	DOID:1686	H40	D005901	137750		Experimental evidences indicate that the uveoscleral pathway, via suprachoroidal space, can provide a potential route of access from the anterior region to the posterior segment of the eye and could represent the path followed  by biologic mediators to reach the inner layer of the peripapillary retina and transmit damage signals from the anterior to posterior segment during glaucoma course.
other	hsa-let-7a	Glioblastoma	28494471				D005909		HP:0100843	Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma.
other	hsa-let-7b	Glioblastoma	28677425				D005909		HP:0100843	IKBKE promotes glioblastoma progression by establishing the regulatory feedback loop of IKBKE/YAP1/miR-Let-7b/i.
other	hsa-let-7d	Glioblastoma	25212824				D005909		HP:0100843	the current study is the first to demonstrate the effect of FCL on modulation of let-7d expression
other	hsa-let-7i	Glioblastoma	25869098				D005909		HP:0100843	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
other	hsa-mir-1	Glioblastoma	24310399				D005909		HP:0100843	Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1.
other	hsa-mir-1	Glioblastoma	25374033				D005909		HP:0100843	Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells.
other	hsa-mir-103	Glioblastoma	25903655				D005909		HP:0100843	CSF exosomes were enriched for miRNAs relative to CSF microvesicles. In CSF, there is an average of one molecule of miRNA per 150-25,000 EVs. Most EVs derived from clinical biofluids are devoid of miRNA content.
other	hsa-mir-106a	Glioblastoma	23416698				D005909		HP:0100843	MiR-106a is an independent prognostic marker in patients with glioblastoma
other	hsa-mir-10a	Glioblastoma	20444541				D005909		HP:0100843	miR-10a:miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells
other	hsa-mir-10b	Glioblastoma	21471404				D005909		HP:0100843	Human glioma growth is controlled by microRNA-10b
other	hsa-mir-10b	Glioblastoma	23307328				D005909		HP:0100843	Inhibition of miR-10b strongly reduced cell invasion and migration in glioblastoma cell and stem cell lines while overexpression of miR-10b induced cell migration and invasion
other	hsa-mir-10b	Glioblastoma	25738367				D005909		HP:0100843	MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma.
other	hsa-mir-10b	Glioblastoma	27467502				D005909		HP:0100843	Regulation of Cell Proliferation and Migration by miR-203 via GAS41/miR-10b Axis  in Human Glioblastoma Cells.
other	hsa-mir-10b	Glioblastoma	28153089				D005909		HP:0100843	Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b.
other	hsa-mir-1238	Glioblastoma	25869098				D005909		HP:0100843	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
other	hsa-mir-124	Glioblastoma	24954504				D005909		HP:0100843	MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma.
other	hsa-mir-124	Glioblastoma	25753094				D005909		HP:0100843	Gap Junctions Enhance the Antiproliferative Effect of MicroRNA-124-3p in Glioblastoma Cells.
other	hsa-mir-124	Glioblastoma	22701651				D005909		HP:0100843	Significantly, REST is highly expressed in self-renewing tumorigenic-competent GBM cells and its knock down strongly reduces their self-renewal in vitro and tumor-initiating capacity in vivo and affects levels of miR-124 and its downstream targets.
other	hsa-mir-124	Glioblastoma	22829753				D005909		HP:0100843	Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies.
other	hsa-mir-124-1	Glioblastoma	18577219				D005909		HP:0100843	miR-124: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
other	hsa-mir-124-2	Glioblastoma	18577219				D005909		HP:0100843	miR-124: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
other	hsa-mir-124-3	Glioblastoma	18577219				D005909		HP:0100843	miR-124: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
other	hsa-mir-125	Glioblastoma	23835866				D005909		HP:0100843	MicroRNA-125b inhibitor sensitizes human primary glioblastoma cells to chemotherapeutic drug temozolomide on invasion.
other	hsa-mir-125	Glioblastoma	25903655				D005909		HP:0100843	CSF exosomes were enriched for miRNAs relative to CSF microvesicles. In CSF, there is an average of one molecule of miRNA per 150-25,000 EVs. Most EVs derived from clinical biofluids are devoid of miRNA content.
other	hsa-mir-125a	Glioblastoma	25542152				D005909		HP:0100843	TAZ deregulation in glioma cells, and also demonstrated a tumor suppressor role of miR-125a-5p in glioblastoma cells.
other	hsa-mir-125b	Glioblastoma	24817689				D005909		HP:0100843	MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme
other	hsa-mir-125b-1	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-125b-1	Glioblastoma	22711523				D005909		HP:0100843	miR-125b expression plays an essential role in the invasion of glioblastoma CD133-positive cells but not CD133-negative cells.
other	hsa-mir-125b-2	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-125b-2	Glioblastoma	22711523				D005909		HP:0100843	miR-125b expression plays an essential role in the invasion of glioblastoma CD133-positive cells but not CD133-negative cells.
other	hsa-mir-128	Glioblastoma	25017996				D005909		HP:0100843	miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
other	hsa-mir-128	Glioblastoma	27893811				D005909		HP:0100843	The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
other	hsa-mir-128	Glioblastoma	28591575				D005909		HP:0100843	MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells.
other	hsa-mir-1280	Glioblastoma	25869098				D005909		HP:0100843	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
other	hsa-mir-128-1	Glioblastoma	21874051				D005909		HP:0100843	Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases.
other	hsa-mir-128-1	Glioblastoma	23482671				D005909		HP:0100843	NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200
other	hsa-mir-128-2	Glioblastoma	21874051				D005909		HP:0100843	Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases.
other	hsa-mir-128-2	Glioblastoma	23482671				D005909		HP:0100843	NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200
other	hsa-mir-130a	Glioblastoma	23302469				D005909		HP:0100843	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
other	hsa-mir-133	Glioblastoma	26138587				D005909		HP:0100843	Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression.
other	hsa-mir-137	Glioblastoma	18577219				D005909		HP:0100843	miR-137: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells
other	hsa-mir-137	Glioblastoma	24465609				D005909		HP:0100843	Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells.
other	hsa-mir-137	Glioblastoma	22829753				D005909		HP:0100843	Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies.
other	hsa-mir-137	Glioblastoma	25232498				D005909		HP:0100843	OLE significantly induced the expression of miR-153, miR-145, and miR-137 and decreased the expression of the target genes of these miRNAs in GSCs
other	hsa-mir-137	Glioblastoma	27448441				D005909		HP:0100843	Furthermore, combining miR-137 and antimiR-10b synergizes with the receptor inhibitory function of aptamer carriers and prevents GSC expansion.
other	hsa-mir-137	Glioblastoma	27649660				D005909		HP:0100843	Circulating microRNA-137 is a potential biomarker for human glioblastoma.
other	hsa-mir-142	Glioblastoma	22570537				D005909		HP:0100843	Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature.
other	hsa-mir-143	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-143	Glioblastoma	22490015				D005909		HP:0100843	Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines.
other	hsa-mir-143	Glioblastoma	23376635				D005909		HP:0100843	miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells
other	hsa-mir-145	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-145	Glioblastoma	22490015				D005909		HP:0100843	Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines.
other	hsa-mir-145	Glioblastoma	23814265				D005909		HP:0100843	Our study demonstrates that miR-145 has a tumor-suppressive function in glioblastoma in that it reduces proliferation, adhesion, and invasion of glioblastoma cells, apparently by suppressing the activity of oncogenic proteins Sox9 and ADD3. Reduced levels of miR-145 may lead to neoplastic transformation and malignant progression in glioma due to unregulated activity of these proteins.
other	hsa-mir-145	Glioblastoma	25232498				D005909		HP:0100843	OLE significantly induced the expression of miR-153, miR-145, and miR-137 and decreased the expression of the target genes of these miRNAs in GSCs
other	hsa-mir-145	Glioblastoma	25564360				D005909		HP:0100843	Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug  Sunitinib in Glioblastoma.
other	hsa-mir-145	Glioblastoma	29521593				D005909		HP:0100843	Inhibition of glioblastoma cell invasion by hsa-miR-145-5p and hsa-miR-31-5p co-overexpression in human mesenchymal stem cells
other	hsa-mir-146a	Glioblastoma	25326894				D005909		HP:0100843	The Downregulation of MicroRNA-146a Modulates TGF-β Signaling Pathways Activityin Glioblastoma.
other	hsa-mir-146a	Glioblastoma	26239619				D005909		HP:0100843	Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma.
other	hsa-mir-146b	Glioblastoma	21266476				D005909		HP:0100843	Induction of miR-146b by PDGF-BB is modulated via MAPK-dependent induction of c-fos.
other	hsa-mir-149	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-149	Glioblastoma	25017996				D005909		HP:0100843	miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
other	hsa-mir-15	Glioblastoma	25738367				D005909		HP:0100843	MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma.
other	hsa-mir-151	Glioblastoma	25869098				D005909		HP:0100843	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
other	hsa-mir-151a	Glioblastoma	20305651				D005909		HP:0100843	significantly increases HCC cell migration and invasion in vitro and in vivo, mainly through miR-151-5p, but not through miR-151-3p
other	hsa-mir-153-1	Glioblastoma	21213215				D005909		HP:0100843	Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines
other	hsa-mir-155	Glioblastoma	23302469				D005909		HP:0100843	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
other	hsa-mir-155	Glioblastoma	22834637				D005909		HP:0100843	A relationship between knock-down of miR-155 and re-expression of GABRA 1 protein in vivo was recently individuated.
other	hsa-mir-155	Glioblastoma	23512614				D005909		HP:0100843	Cytokines (IL-1β and TNFα) also induce the expression of miR-155 and miR-155*, the microRNAs crucial in immunity and inflammation-induced oncogenesis and this is dose-dependently suppressed by IRF3. 
other	hsa-mir-16	Glioblastoma	24418124				D005909		HP:0100843	MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-κB1/MMP9 signaling pathway.
other	hsa-mir-16	Glioblastoma	25738367				D005909		HP:0100843	MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity in glioblastoma.
other	hsa-mir-16-1	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-16-2	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-17	Glioblastoma	20305691				D005909		HP:0100843	De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures
other	hsa-mir-17	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-17	Glioblastoma	25677619				D005909		HP:0100843	Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy.
other	hsa-mir-17	Glioblastoma	20940405				D005909		HP:0100843	Together, our results define a pathway in which c-Myc activation of miR-17∼92 attenuates the TGFβ signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth.
other	hsa-mir-17	Glioblastoma	28903422				D005909		HP:0100843	The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines
other	hsa-mir-18	Glioblastoma	25677619				D005909		HP:0100843	Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy.
other	hsa-mir-18	Glioblastoma	20940405				D005909		HP:0100843	Together, our results define a pathway in which c-Myc activation of miR-17∼92 attenuates the TGFβ signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth.
other	hsa-mir-18	Glioblastoma	28903422				D005909		HP:0100843	The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines
other	hsa-mir-181a	Glioblastoma	27633853				D005909		HP:0100843	MicroRNA-181a promotes proliferation and inhibits apoptosis by suppressing CFIm25 in osteosarcoma.
other	hsa-mir-181a-2	Glioblastoma	20353279				D005909		HP:0100843	MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
other	hsa-mir-181a-2	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-181b	Glioblastoma	25633526				D005909		HP:0100843	NF-κB activation by DNA damage in GBM cells confers resistance to radiation-induced death.
other	hsa-mir-181b-1	Glioblastoma	20353279				D005909		HP:0100843	MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
other	hsa-mir-181b-2	Glioblastoma	20353279				D005909		HP:0100843	MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
other	hsa-mir-181c	Glioblastoma	20353279				D005909		HP:0100843	MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
other	hsa-mir-181c	Glioblastoma	21895872				D005909		HP:0100843	Evaluation of the miR-181c in combination with miR-21 predicted time to progression within six months from diagnosis with 92% sensitivity and 81% specificity (p < 0.0001). The combination of miR-181c and miR-21 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery.
other	hsa-mir-181d	Glioblastoma	20353279				D005909		HP:0100843	MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
other	hsa-mir-182	Glioblastoma	25838542				D005909		HP:0100843	miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.
other	hsa-mir-183	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-18a	Glioblastoma	20305691				D005909		HP:0100843	De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures
other	hsa-mir-1908	Glioblastoma	26265437				D005909		HP:0100843	miRNA-1908 functions as an oncogene in glioblastoma by repressing the PTEN pathway. MiR-1908 is a potential new molecular marker for predicting the risk of recurrence and prognosis of glioblastoma.
other	hsa-mir-191	Glioblastoma	28178667				D005909		HP:0100843	Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
other	hsa-mir-195	Glioblastoma	20444541				D005909		HP:0100843	miR-195:miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells
other	hsa-mir-195	Glioblastoma	21895872				D005909		HP:0100843	miR-195 (P=0.0124; log-rank test) has positively correlated with overall survival.
other	hsa-mir-196b	Glioblastoma	21895872				D005909		HP:0100843	miR-196b (P=0.0492; log-rank test) has positively correlated with overall survival.
other	hsa-mir-196b	Glioblastoma	22723849				D005909		HP:0100843	Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype.
other	hsa-mir-19a	Glioblastoma	25677619				D005909		HP:0100843	Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy.
other	hsa-mir-19a	Glioblastoma	20305691				D005909		HP:0100843	De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures
other	hsa-mir-19a	Glioblastoma	20940405				D005909		HP:0100843	Together, our results define a pathway in which c-Myc activation of miR-17∼92 attenuates the TGFβ signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth.
other	hsa-mir-19a	Glioblastoma	28903422				D005909		HP:0100843	The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines
other	hsa-mir-19b-1	Glioblastoma	25677619				D005909		HP:0100843	Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy.
other	hsa-mir-19b-1	Glioblastoma	20305691				D005909		HP:0100843	De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures
other	hsa-mir-19b-1	Glioblastoma	20940405				D005909		HP:0100843	Together, our results define a pathway in which c-Myc activation of miR-17∼92 attenuates the TGFβ signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth.
other	hsa-mir-19b-1	Glioblastoma	28903422				D005909		HP:0100843	The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines
other	hsa-mir-19b-2	Glioblastoma	20305691				D005909		HP:0100843	De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures
other	hsa-mir-200	Glioblastoma	23482671				D005909		HP:0100843	NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200
other	hsa-mir-200c	Glioblastoma	25058589				D005909		HP:0100843	Correlation between EGFR amplification and the expression of microRNA-200c in primary glioblastoma multiforme.
other	hsa-mir-205	Glioblastoma	25736407				D005909		HP:0100843	Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis.
other	hsa-mir-206	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-206	Glioblastoma	27558109				D005909		HP:0100843	MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2.
other	hsa-mir-208a	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-208b	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-20a	Glioblastoma	25677619				D005909		HP:0100843	Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy.
other	hsa-mir-20a	Glioblastoma	20305691				D005909		HP:0100843	De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures
other	hsa-mir-20a	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-20a	Glioblastoma	20940405				D005909		HP:0100843	Together, our results define a pathway in which c-Myc activation of miR-17∼92 attenuates the TGFβ signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth.
other	hsa-mir-20a	Glioblastoma	28903422				D005909		HP:0100843	The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines
other	hsa-mir-20a	Glioblastoma	29625108				D005909		HP:0100843	The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1α expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment
other	hsa-mir-20b	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-21	Glioblastoma	18829576				D005909		HP:0100843	miR-21: MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma
other	hsa-mir-21	Glioblastoma	21618027				D005909		HP:0100843	A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells.
other	hsa-mir-21	Glioblastoma	21895872				D005909		HP:0100843	Evaluation of the miR-181c in combination with miR-21 predicted time to progression within six months from diagnosis with 92% sensitivity and 81% specificity (p < 0.0001). The combination of miR-181c and miR-21 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery.
other	hsa-mir-21	Glioblastoma	22528454				D005909		HP:0100843	MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
other	hsa-mir-21	Glioblastoma	22753745				D005909		HP:0100843	MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
other	hsa-mir-21	Glioblastoma	23201752				D005909		HP:0100843	MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma
other	hsa-mir-21	Glioblastoma	23482671				D005909		HP:0100843	NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200
other	hsa-mir-21	Glioblastoma	25582055				D005909		HP:0100843	ADAR2 is a key factor for maintaining edited-miRNA population and balancing the expression of several essential miRNAs involved in cancer.
other	hsa-mir-21	Glioblastoma	26559642				D005909		HP:0100843	Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
other	hsa-mir-21	Glioblastoma	24205116				D005909		HP:0100843	MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development.
other	hsa-mir-21	Glioblastoma	25903655				D005909		HP:0100843	CSF exosomes were enriched for miRNAs relative to CSF microvesicles. In CSF, there is an average of one molecule of miRNA per 150-25,000 EVs. Most EVs derived from clinical biofluids are devoid of miRNA content.
other	hsa-mir-21	Glioblastoma	26433199				D005909		HP:0100843	Dissociated microglia and monocytes/macrophages from tumor-bearing brains revealed increased levels of miR-21 and reduced levels  of c-Myc mRNA.
other	hsa-mir-21	Glioblastoma	27757032				D005909		HP:0100843	Pluronic-based micelle encapsulation potentiates myricetin-induced cytotoxicity in human glioblastoma cells.
other	hsa-mir-21	Glioblastoma	28727188				D005909		HP:0100843	we highlighted utilization of miR-21 as diagnostic and therapeutic biomarker for GBM patients
other	hsa-mir-21	Glioblastoma	29023168				D005909		HP:0100843	Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells.
other	hsa-mir-21	Glioblastoma	23907387				D005909		HP:0100843	Furthermore, several modules associated with less well-reported molecular aberrations-such as chromosome 11 CNVs, CD40, PLXNB1 and GSTM1 methylations, and mir-21 expressions-were also validated by external information. 
other	hsa-mir-21	Glioblastoma	25628933				D005909		HP:0100843	Dox and miR-21 inhibitor therapy can sensitize GBM resistant cells to anthracyclines by enhancing apoptosis.
other	hsa-mir-210	Glioblastoma	23302469				D005909		HP:0100843	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
other	hsa-mir-219	Glioblastoma	22829753				D005909		HP:0100843	Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies.
other	hsa-mir-22	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-221	Glioblastoma	25582055				D005909		HP:0100843	ADAR2 is a key factor for maintaining edited-miRNA population and balancing the expression of several essential miRNAs involved in cancer.
other	hsa-mir-221	Glioblastoma	18759060				D005909		HP:0100843	Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM).
other	hsa-mir-221	Glioblastoma	27837435				D005909		HP:0100843	Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
other	hsa-mir-222	Glioblastoma	25582055				D005909		HP:0100843	ADAR2 is a key factor for maintaining edited-miRNA population and balancing the expression of several essential miRNAs involved in cancer.
other	hsa-mir-222	Glioblastoma	19520829				D005909		HP:0100843	Immunohistochemical and in situ hybridization analyses of 30 primary glioblastoma tissues demonstrated that expression of Dicer, miR-222, or miR-339 was inversely associated with ICAM-1 expression.
other	hsa-mir-222	Glioblastoma	23099529				D005909		HP:0100843	Electrochemical detection of miRNA-222 by use of a magnetic bead-based bioassay.
other	hsa-mir-224	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-224	Glioblastoma	24785373				D005909		HP:0100843	MiR-224 expression increases radiation sensitivity of glioblastoma cells.
other	hsa-mir-24	Glioblastoma	25903655				D005909		HP:0100843	CSF exosomes were enriched for miRNAs relative to CSF microvesicles. In CSF, there is an average of one molecule of miRNA per 150-25,000 EVs. Most EVs derived from clinical biofluids are devoid of miRNA content.
other	hsa-mir-25	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-26a	Glioblastoma	24211747				D005909		HP:0100843	MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated.
other	hsa-mir-26a-1	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-26a-2	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-29a	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-29c	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-302	Glioblastoma	25991553				D005909		HP:0100843	Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes.
other	hsa-mir-30a	Glioblastoma	21178384				D005909		HP:0100843	the transcriptional BDNF inhibitor miR-30a-5p was also overexpressed at 6 and 12 h of paroxetine incubation
other	hsa-mir-30c-1	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-30c-2	Glioblastoma	21961478				D005909		HP:0100843	altered expression after Polyunsaturated fatty acids (PUFAs) treatment
other	hsa-mir-31	Glioblastoma	26164206				D005909		HP:0100843	Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma.
other	hsa-mir-31	Glioblastoma	29521593				D005909		HP:0100843	Inhibition of glioblastoma cell invasion by hsa-miR-145-5p and hsa-miR-31-6p co-overexpression in human mesenchymal stem cells
other	hsa-mir-3189	Glioblastoma	25645911				D005909		HP:0100843	Anti-tumoral effects of miR-3189-3p in glioblastoma.
other	hsa-mir-323a	Glioblastoma	23302469				D005909		HP:0100843	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
other	hsa-mir-323b	Glioblastoma	23302469				D005909		HP:0100843	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
other	hsa-mir-326	Glioblastoma	23302469				D005909		HP:0100843	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
other	hsa-mir-326	Glioblastoma	27871300				D005909		HP:0100843	PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
other	hsa-mir-329-1	Glioblastoma	23302469				D005909		HP:0100843	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
other	hsa-mir-329-2	Glioblastoma	23302469				D005909		HP:0100843	Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
other	hsa-mir-339	Glioblastoma	19520829				D005909		HP:0100843	Immunohistochemical and in situ hybridization analyses of 30 primary glioblastoma tissues demonstrated that expression of Dicer, miR-222, or miR-339 was inversely associated with ICAM-1 expression.
other	hsa-mir-340	Glioblastoma	25817794				D005909		HP:0100843	miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2.
other	hsa-mir-340	Glioblastoma	25831237				D005909		HP:0100843	miR-340 suppresses glioblastoma multiforme.
other	hsa-mir-34a	Glioblastoma	22829753				D005909		HP:0100843	Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies.
other	hsa-mir-367	Glioblastoma	25991553				D005909		HP:0100843	Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes.
other	hsa-mir-376a-1	Glioblastoma	23093778				D005909		HP:0100843	Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells
other	hsa-mir-376a-2	Glioblastoma	23093778				D005909		HP:0100843	Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells
other	hsa-mir-378	Glioblastoma	29081036				D005909		HP:0100843	MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma.
other	hsa-mir-381	Glioblastoma	21435336				D005909		HP:0100843	Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth.
other	hsa-mir-423	Glioblastoma	25869098				D005909		HP:0100843	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
other	hsa-mir-451	Glioblastoma	20816946				D005909		HP:0100843	MiRNA-451 plays a role as tumor suppressor in human glioma cells.
other	hsa-mir-451	Glioblastoma	22205943				D005909		HP:0100843	The model provides an explanation for the growth-invasion cycling patterns of glioma cells in response to high/low glucose uptake in microenvironment in vitro, and suggests new targets for drugs,associated with miR-451 upregulation.
other	hsa-mir-451	Glioblastoma	24899919				D005909		HP:0100843	Those parameters are primarily  linked to the reactions that involve the microRNA-451 and the thereof regulated protein MO25.
other	hsa-mir-451	Glioblastoma	25833239				D005909		HP:0100843	low levels of glucose affect metabolism and activate cell migration through the miR-451-AMPK control system
other	hsa-mir-451	Glioblastoma	28440461				D005909		HP:0100843	The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required.
other	hsa-mir-451	Glioblastoma	28629521				D005909		HP:0100843	Erythropoietin Promotes Glioblastoma via miR-451 Suppression.
other	hsa-mir-451a	Glioblastoma	23367447				D005909		HP:0100843	A computational multiscale model of glioblastoma growth: Regulation of cell migration and proliferation via microRNA-451, LKB1 and AMPK
other	hsa-mir-455	Glioblastoma	20444541				D005909		HP:0100843	miR-455-3p:miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells
other	hsa-mir-491	Glioblastoma	24747968				D005909		HP:0100843	Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma.
other	hsa-mir-494	Glioblastoma	25662849				D005909		HP:0100843	miR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells.
other	hsa-mir-504	Glioblastoma	28056026				D005909		HP:0100843	Integration of MicroRNA, mRNA, and Protein Expression Data for the Identification of Cancer-Related MicroRNAs.
other	hsa-mir-513c	Glioblastoma	26063413				D005909		HP:0100843	microRNA-513c suppresses the proliferation of human glioblastoma cells by repressing low-density lipoprotein receptor-related protein 6.
other	hsa-mir-577	Glioblastoma	25764520				D005909		HP:0100843	miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway.
other	hsa-mir-603	Glioblastoma	24994119				D005909		HP:0100843	A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas.
other	hsa-mir-613	Glioblastoma	28718378				D005909		HP:0100843	MicroRNA-613 is downregulated in HCMV-positive glioblastoma and inhibits tumour progression by targeting arginase-2.
other	hsa-mir-7	Glioblastoma	24603851				D005909		HP:0100843	miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways.
other	hsa-mir-7	Glioblastoma	25149532				D005909		HP:0100843	Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma.
other	hsa-mir-7	Glioblastoma	18483236				D005909		HP:0100843	microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma.
other	hsa-mir-7	Glioblastoma	28459998				D005909		HP:0100843	Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.
other	hsa-mir-708	Glioblastoma	23754151				D005909		HP:0100843	miR-708 acts as a tumor suppressor in human glioblastoma cells.
other	hsa-mir-9	Glioblastoma	22829753				D005909		HP:0100843	Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies.
other	hsa-mir-92-1	Glioblastoma	25677619				D005909		HP:0100843	Our findings suggest that engineering of tumor antigen-specific CD8(+) T-cells to express miR-17-92 may improve the potency of cancer immunotherapy.
other	hsa-mir-92-1	Glioblastoma	20940405				D005909		HP:0100843	Together, our results define a pathway in which c-Myc activation of miR-17∼92 attenuates the TGFβ signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth.
other	hsa-mir-92-1	Glioblastoma	28903422				D005909		HP:0100843	The E2F1-regulated miR-17/92 cluster and its analogs are shown to be highly expressed in proneural GBM and in GSC lines
other	hsa-mir-92b	Glioblastoma	22829753				D005909		HP:0100843	Our follow up topological and functional analyses of the subnetwork revealed that six miRNAs (miR-124, miR-137, miR-219-5p, miR-34a, miR-9, and miR-92b) might play important roles in GBM, including some results that are supported by previous studies.
other	hsa-mir-93	Glioblastoma	25869098				D005909		HP:0100843	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
other	hsa-mir-938	Glioblastoma	25869098				D005909		HP:0100843	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
other	hsa-mir-99a	Glioblastoma	23298836				D005909		HP:0100843	The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma
other	hsa-mir-99a	Glioblastoma	23409016				D005909		HP:0100843	Photofrin Based Photodynamic Therapy and miR-99a Transfection Inhibited FGFR3 and PI3K/Akt Signaling Mechanisms to Control Growth of Human Glioblastoma In Vitro and In Vivo
other	hsa-mir-106a	Glioma	25950430	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines.
other	hsa-mir-106b	Glioma	28431179	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications.
other	hsa-mir-107	Glioma	23572380	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-107 Inhibits U87 Glioma Stem Cells Growth and Invasion
other	hsa-mir-10b	Glioma	22766763	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells.
other	hsa-mir-1227	Glioma	28091986	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-1227 may be associated with increased migration and miR-32 and miR-222 with decreased migration
other	hsa-mir-122	Glioma	24863942	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-122/Wnt/β-catenin regulatory circuitry sustains glioma progression.
other	hsa-mir-124	Glioma	26269187	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our findings indicate a clear benefit in harnessing the wild-type virus replicative potency in development of next-generation oncolytic alphaviruses.
other	hsa-mir-124	Glioma	26530859	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In conclusion,miR-124 was found to suppress the migration and invasion of glioma cells in vitro via Capn4.
other	hsa-mir-124	Glioma	23338605	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Luciferase reporter assay confirmed that miR-124, miR-128, miR-146b and miR-218 conferred exogenous gene expression with glioma-specificity.
other	hsa-mir-124-1	Glioma	22918790	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma.
other	hsa-mir-124-2	Glioma	22918790	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma.
other	hsa-mir-124a	Glioma	25175832	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-124a restoration inhibits glioma cell proliferation and invasion by suppressing IQGAP1 and β-catenin.
other	hsa-mir-125b	Glioma	26170223	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.
other	hsa-mir-127	Glioma	26261488	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
other	hsa-mir-127	Glioma	29805677	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Tudor-staphylococcal nuclease regulates the expression and biological function of alkylglycerone phosphate synthase via nuclear factor-κB and microRNA-127 in human glioma U87MG cells.
other	hsa-mir-128	Glioma	23338605	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Luciferase reporter assay confirmed that miR-124, miR-128, miR-146b and miR-218 conferred exogenous gene expression with glioma-specificity.
other	hsa-mir-130b	Glioma	28107197	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MTDH promotes glioma invasion through regulating miR-130b-ceRNAs.
other	hsa-mir-132	Glioma	25983322	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	TGF-β induced miR-132 enhances the activation of TGF-β signaling through inhibiting SMAD7 expression in glioma cells.
other	hsa-mir-135a-1	Glioma	22139076	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-135a functions as a selective killer of malignant glioma.
other	hsa-mir-135a-2	Glioma	22139076	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-135a functions as a selective killer of malignant glioma.
other	hsa-mir-138-1	Glioma	22921398	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-138 has a critical role in promoting growth and survival of bona fide tumor-initiating cells with self-renewal potential.
other	hsa-mir-138-2	Glioma	22921398	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-138 has a critical role in promoting growth and survival of bona fide tumor-initiating cells with self-renewal potential.
other	hsa-mir-140	Glioma	28443475	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-140-5p inhibits cell proliferation and invasion by regulating VEGFA/MMP2 signaling in glioma.
other	hsa-mir-142	Glioma	24825189	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.
other	hsa-mir-142	Glioma	24974128	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These data indicate a unique role of miR-142-3p in glioma immunity by modulating M2 macrophages through the transforming growth factor beta signaling pathway.
other	hsa-mir-145	Glioma	22269208	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Over-expression of miR-145 enhances the effectiveness of HSVtk gene therapy for malignant glioma.
other	hsa-mir-146b	Glioma	26397753	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In conclusion, the inhibition of miR-146b may increase hypoxia-induced cardiomyocyte apoptosis.
other	hsa-mir-146b	Glioma	23338605	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Luciferase reporter assay confirmed that miR-124, miR-128, miR-146b and miR-218 conferred exogenous gene expression with glioma-specificity.
other	hsa-mir-146b	Glioma	23419525	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Intra-tumor injection of exosomes derived from miR-146-expressing MSCs significantly reduced glioma xenograft growth in a rat model of primary brain tumor.
other	hsa-mir-155	Glioma	25672607	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-155 contributes to the progression of glioma by enhancing Wnt/β-catenin pathway.
other	hsa-mir-155	Glioma	28724215	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Melatonin inhibits proliferation and invasion via repression of miRNA-155 in glioma cells.
other	hsa-mir-15b	Glioma	21937590	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-15b and miR-21 were differentially expressed in CSF (cerebrospinal fluid) samples from patients with gliomas, compared to control subjects with various neurologic disorders, including patients with primary CNS lymphoma and carcinomatous brain metastases.In conclusion, the results of this pilot study demonstrate that miR-15b and miR-21 are markers for gliomas, which can be assessed in the CSF by means of qRT-PCR.
other	hsa-mir-15b	Glioma	25811315	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Decreased Expression of miR-15b in Human Gliomas is Associated with Poor Prognosis.
other	hsa-mir-16	Glioma	25242314	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-16 suppresses epithelial-mesenchymal transition-related gene expression in human glioma.
other	hsa-mir-16	Glioma	27430517	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	apigenin inhibits glioma cell growth through promoting miR‑16 and suppression of BCL2 and NF-κB/MMP-9
other	hsa-mir-17	Glioma	29351283	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The reduced miR-17 levels in glioma cells increased cell viability and migration, which correlates with increased expression of Cyclin D1, p-Akt and Akt
other	hsa-mir-181a-2	Glioma	18710654	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-181a: mir suppressor
other	hsa-mir-181b	Glioma	23810250	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas.
other	hsa-mir-181b	Glioma	23554660	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells.
other	hsa-mir-181b-1	Glioma	18710654	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-181b: mir suppressor
other	hsa-mir-181b-2	Glioma	18710654	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-181b: mir suppressor
other	hsa-mir-182	Glioma	23252827	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
other	hsa-mir-182	Glioma	23006329	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	we found that TGF-β induced miR-182 expression, leading to prolonged NF-κB activation.
other	hsa-mir-182	Glioma	28956430	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The feasibility of the method for sensitive determination of miRNA-182 and miRNA-381 from serum samples of glioma patients at different stages was demonstrated
other	hsa-mir-183	Glioma	23252827	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
other	hsa-mir-183	Glioma	28184912	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Interaction between transcription factors PAX6/PAX6-5a and specific members of miR-183-96-182 cluster, may contribute to glioma progression in glioblastoma cell lines.
other	hsa-mir-184	Glioma	26464691	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Inhibitory effect of miR-184 on the potential of proliferation and invasion in human glioma and breast cancer cells in vitro.
other	hsa-mir-185	Glioma	22834685	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway.
other	hsa-mir-186	Glioma	28351322	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186.
other	hsa-mir-18a	Glioma	23533157	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Tumorigenic Potential of miR-18A* in Glioma Initiating Cells Requires NOTCH-1 Signaling
other	hsa-mir-192	Glioma	28039611	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Alternative new mesenchymal stem cell source exerts tumor tropism through ALCAM and N-cadherin via regulation of microRNA-192 and -218.
other	hsa-mir-195	Glioma	27574009	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	TGF-β1 regulating miR-205/miR-195 expression affects the TGF-β signal pathway by respectively targeting SMAD2/SMAD7.
other	hsa-mir-196a	Glioma	20601442	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our results suggest that miR-196 may play a role in the malignant progression of gliomas and may be a prognostic predictor in glioblastomas.
other	hsa-mir-196b	Glioma	23049982	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	We have provided the first evidence that expression of miR-196b was associated with the occurrence of pre-operative seizures in low-grade gliomas,and may predict seizure prognosis in patients without pre-operative seizures
other	hsa-mir-196b	Glioma	27821299	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Biomarkers related with seizure risk in glioma patients: A systematic review.
other	hsa-mir-200	Glioma	27041571	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	SHP-2 acts together with PI3K/AKT to regulate a ZEB1-miR-200 feedback loop in PDGFR伪-driven gliomas.
other	hsa-mir-203	Glioma	23813496	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our data validate an important clinical significance of miR-203 in gliomas, and reveal that it might be an intrinsic regulator of tumor progression and a potential prognostic factor for this dismal disease.
other	hsa-mir-204	Glioma	26134825	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Decreased Expression of MiRNA-204-5p Contributes to Glioma Progression and Promotes Glioma Cell Growth, Migration and Invasion.
other	hsa-mir-205	Glioma	27574009	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	TGF-β1 regulating miR-205/miR-195 expression affects the TGF-β signal pathway by respectively targeting SMAD2/SMAD7.
other	hsa-mir-20a	Glioma	27242439	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The expression levels of miR-20a decreased significantly after U-87 and U-251 cells were treated with EMAP-II.
other	hsa-mir-20a	Glioma	29625108	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma
other	hsa-mir-21	Glioma	20514462	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-21:Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3
other	hsa-mir-21	Glioma	21937590	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-15b and miR-21 were differentially expressed in CSF (cerebrospinal fluid) samples from patients with gliomas, compared to control subjects with various neurologic disorders, including patients with primary CNS lymphoma and carcinomatous brain metastases.In conclusion, the results of this pilot study demonstrate that miR-15b and miR-21 are markers for gliomas, which can be assessed in the CSF by means of qRT-PCR.
other	hsa-mir-21	Glioma	22766763	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells.
other	hsa-mir-21	Glioma	23104517	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas
other	hsa-mir-21	Glioma	26109525	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Tamoxifen-Induced Cell Death of Malignant Glioma Cells Is Brought About by Oxidative-Stress-Mediated Alterations in the Expression of BCL2 Family Members and Is Enhanced on miR-21 Inhibition.
other	hsa-mir-21	Glioma	26473373	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These results suggest that miR-21 is associated with regulation of the migratory ability and survival in human glioma cells. These findings suggest novel mechanisms of malignancy and new potential combinatorial strategies for the management of malignant glioma.
other	hsa-mir-21	Glioma	26121981	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis.
other	hsa-mir-21	Glioma	23810250	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas.
other	hsa-mir-21	Glioma	19934272	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	the results of our study show that the downregulation of miR-21 contributes to the antitumor effects of IFN-beta and that miR-21 expression is negatively regulated by STAT3 activation. These results highlight the importance of understanding the transcriptional regulation of the miRNAs involved in oncogenesis.
other	hsa-mir-21	Glioma	25510379	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	An independent meta-analysis of five included studies was conducted to evaluate the  diagnostic efficacy of miR-21 in patients with glioma
other	hsa-mir-21	Glioma	26433199	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Dissociated microglia and monocytes/macrophages from tumor-bearing brains revealed increased levels of miR-21 and reduced levels  of c-Myc mRNA.
other	hsa-mir-21	Glioma	27504157	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our data showed that in 1321N1 cells, E2-adrenergic-Epac pathway stimulation up and down-regulated Cx43 and miR-21 expression respectively.
other	hsa-mir-21	Glioma	27909726	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA‑21 promotes migration and invasion of glioma cells via activation of Sox2 and β‑catenin signaling.
other	hsa-mir-21	Glioma	28208619	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	AKT Axis, miR-21, and RECK Play Pivotal Roles in Dihydroartemisinin Killing Malignant Glioma Cells.
other	hsa-mir-21	Glioma	28431179	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications.
other	hsa-mir-214	Glioma	24277415	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Combined aberrant expression of microRNA-214 and UBC9 is an independent unfavorable prognostic factor for patients with gliomas.
other	hsa-mir-218	Glioma	26572167	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-218-5p inhibits the stem cell properties and invasive ability of the A2B5+CD133- subgroup of human glioma stem cells.
other	hsa-mir-218	Glioma	23338605	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Luciferase reporter assay confirmed that miR-124, miR-128, miR-146b and miR-218 conferred exogenous gene expression with glioma-specificity.
other	hsa-mir-218	Glioma	28039611	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Alternative new mesenchymal stem cell source exerts tumor tropism through ALCAM and N-cadherin via regulation of microRNA-192 and -218.
other	hsa-mir-219	Glioma	28431179	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications.
other	hsa-mir-222	Glioma	28091986	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-1227 may be associated with increased migration and miR-32 and miR-222 with decreased migration
other	hsa-mir-23b	Glioma	24503899	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo.
other	hsa-mir-26a	Glioma	19487573	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.
other	hsa-mir-26a	Glioma	28431179	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications.
other	hsa-mir-29c	Glioma	23943502	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-29c inhibits glioma cell proliferation, migration, invasion and angiogenesis.
other	hsa-mir-29c	Glioma	23744344	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Tumor-suppressive effects of miR-29c on gliomas.
other	hsa-mir-300	Glioma	24464870	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	mir-300 promotes self-renewal and inhibits the differentiation of glioma stem-like cells.
other	hsa-mir-30a	Glioma	26255203	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-30a-5p is induced by Wnt/β-catenin pathway and promotes glioma cell invasion by repressing NCAM.
other	hsa-mir-30a	Glioma	28192116	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	PRRT2 inhibits the proliferation of glioma cells by modulating unfolded protein response pathway.
other	hsa-mir-30e	Glioma	22156201	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-ж╩B/Iж╩Bж┿negative feedback loop.
other	hsa-mir-32	Glioma	28091986	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-1227 may be associated with increased migration and miR-32 and miR-222 with decreased migration
other	hsa-mir-323	Glioma	26656446	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiRNA-323-5p inhibited human cerebral glioma U373 cell proliferation and promoted its apoptosis by reducing IGF-1R.
other	hsa-mir-326	Glioma	26183397	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326.
other	hsa-mir-328	Glioma	24305703	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation.
other	hsa-mir-335	Glioma	22172575	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-335 is Required for Differentiation of Malignant Glioma Cells Induced by Activation of cAMP/PKA Pathway.
other	hsa-mir-338	Glioma	28431179	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications.
other	hsa-mir-33a	Glioma	25202981	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.
other	hsa-mir-342	Glioma	28112756	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Long noncoding RNA FTX is upregulated in gliomas and promotes proliferation and invasion of glioma cells by negatively regulating miR-342-3p.
other	hsa-mir-34a	Glioma	20190569	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
other	hsa-mir-34a	Glioma	22568628	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-34a Suppresses Cell Proliferation and Induces Apoptosis in U87 Glioma Stem Cells.
other	hsa-mir-34a	Glioma	23529798	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These findings indicate the role of miR-34a in tumor progression may be closely associated with p53 mutation and inversely correlated to Bcl-2 expression
other	hsa-mir-34a	Glioma	27268916	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-34a was downregulated under hypoxia but upregulated by resveratrol
other	hsa-mir-376	Glioma	26940843	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MIR376 as an important  microRNA family for cancer formation and progression
other	hsa-mir-381	Glioma	28956430	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The feasibility of the method for sensitive determination of miRNA-182 and miRNA-381 from serum samples of glioma patients at different stages was demonstrated
other	hsa-mir-429	Glioma	26272601	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our results indicated that BMK1 modulation by miR-429 has an important function in glioma invasion both in vitro and in vivo.
other	hsa-mir-451	Glioma	24714982	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Selective β2 adrenergic agonist increases Cx43 and miR-451 expression via cAMP-Epac.
other	hsa-mir-451a	Glioma	25629604	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Effective control of growing cells near BV sites in addition to relocalization of invisible migratory cells back to the resection site was suggested as a way of eradicating these migratory cells.
other	hsa-mir-451a	Glioma	20227367	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells
other	hsa-mir-508	Glioma	28121353	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-508-5p is a prognostic marker and inhibits cell proliferation and migration in glioma.
other	hsa-mir-524	Glioma	24194606	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression.
other	hsa-mir-603	Glioma	25681036	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-603 promotes glioma cell growth via Wnt/β-catenin pathway by inhibiting WIF1 and CTNNBIP1.
other	hsa-mir-628	Glioma	24194606	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression.
other	hsa-mir-637	Glioma	27840895	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Sevoflurane inhibits the migration and invasion of glioma cells by upregulating microRNA-637.
other	hsa-mir-7-1	Glioma	23373996	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Regulation of Epidermal Growth Factor Receptor Signaling by plasmid-based MicroRNA-7 inhibits human malignant gliomas growth and metastasis in vivo
other	hsa-mir-7-1	Glioma	23404538	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells
other	hsa-mir-7-2	Glioma	23373996	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Regulation of Epidermal Growth Factor Receptor Signaling by plasmid-based MicroRNA-7 inhibits human malignant gliomas growth and metastasis in vivo
other	hsa-mir-7-2	Glioma	23404538	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells
other	hsa-mir-7-3	Glioma	23373996	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Regulation of Epidermal Growth Factor Receptor Signaling by plasmid-based MicroRNA-7 inhibits human malignant gliomas growth and metastasis in vivo
other	hsa-mir-7-3	Glioma	23404538	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells
other	hsa-mir-9	Glioma	27975329	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Density-Dependent Regulation of Glioma Cell Proliferation and Invasion Mediated by miR-9.
other	hsa-mir-92a	Glioma	25342742	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	We conclude that glioma-derived miR-92a induces IL-6(+) IL-10(+) NKT  cells; this fraction of NKT cells can suppress cytotoxic CD8(+) T cells.
other	hsa-mir-93	Glioma	25823655	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway.
other	hsa-mir-96	Glioma	23252827	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
other	hsa-mir-21	Gliosis	20130193				D005911		HP:0002171	We find that the two receptors exert opposing effects on the posttranscriptional regulation of astrocytic microRNA-21.
other	hsa-mir-135	Glomerulonephritis	26134897	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	miR-135 family members mediate podocyte injury through the activation of Wnt/β-catenin signaling.
other	hsa-mir-148b	Glomerulonephritis	22362909	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	Abnormal miR-148b Expression Promotes Aberrant Glycosylation of IgA1 in IgA Nephropathy.
other	hsa-mir-30	Glomerulonephritis	24029422	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids.
other	hsa-mir-140	Gout	27727249	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	microRNA-140 Inhibits Inflammation and Stimulates Chondrogenesis in a Model of Interleukin 1β-induced Osteoarthritis.
other	hsa-mir-140	Gout	28647469	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	Intra-articular injection of microRNA-140 (miRNA-140) alleviates osteoarthritis (OA) progression by modulating extracellular matrix (ECM) homeostasis in rats.
other	hsa-mir-146a	Gout	25646371	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals.
other	hsa-mir-146a	Graft-Versus-Host Disease	28853768			D89.813	D006086	614395		Systemic Treatment with a miR-146a Mimic Suppresses Endotoxin Sensitivity and Partially Protects Mice from the Progression of Acute Graft-versus-Host Disease.
other	hsa-mir-155	Graft-Versus-Host Disease	28423578			D89.813	D006086	614395		Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
other	hsa-mir-21	Graft-Versus-Host Disease	26631756			D89.813	D006086	614395		MicroRNA-21 deficiency protects from lupus-like autoimmunity in the chronic graft-versus-host disease model of systemic lupus erythematosus.
other	hsa-mir-21	Graft-Versus-Host Disease	28396121			D89.813	D006086	614395		Antagonism of profibrotic microRNA-21 improves outcome of murine chronic renal allograft dysfunction.
other	hsa-mir-663	Graft-Versus-Host Disease	27063175			D89.813	D006086	614395		Role of miR-663 in acute renal graft rejection: an in vitro study.
other	hsa-mir-132	Granulosa Cell Tumor	26282993	disease of cellular proliferation	DOID:2999		D006106			Our findings suggest that miR-132 is involved in the cAMP signaling pathway and promotes estradiol synthesis via the translational repression of Nurr1 in ovarian GCs.
other	hsa-mir-21	Granulosa Cell Tumor	20357270	disease of cellular proliferation	DOID:2999		D006106			MicroRNA 21 Blocks Apoptosis in Mouse Periovulatory Granulosa Cells
other	hsa-mir-23a	Granulosa Cell Tumor	26400397	disease of cellular proliferation	DOID:2999		D006106			These findings provide an improved understanding of the mechanisms underlying granulosa cell apoptosis, which could potentially be used for future clinical applications.
other	hsa-mir-27a	Granulosa Cell Tumor	26400397	disease of cellular proliferation	DOID:2999		D006106			These findings provide an improved understanding of the mechanisms underlying granulosa cell apoptosis, which could potentially be used for future clinical applications.
other	hsa-mir-346	Graves Disease	28192819	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	MiR-346 and TRAb as Predicative Factors for Relapse in Graves' Disease Within One Year.
other	hsa-mir-101	Graves Disease	25871842	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD.
other	hsa-mir-146a	Graves Ophthalmopathy	24743332			E05.00	D049970			Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy.
other	hsa-mir-146a	Graves Ophthalmopathy	25100151			E05.00	D049970			Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy.
other	hsa-mir-155	Graves Ophthalmopathy	24743332			E05.00	D049970			Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy.
other	hsa-mir-122	Growth Disorders	26198739			M89.20	D006130			Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA
other	hsa-mir-15	Growth Disorders	26198739			M89.20	D006130			Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA
other	hsa-mir-16	Growth Disorders	26198739			M89.20	D006130			Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA
other	hsa-mir-21	Growth Disorders	26198739			M89.20	D006130			Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA
other	hsa-mir-503	Growth Disorders	26198739			M89.20	D006130			Why is microRNA action tissue specific. A putative defense mechanism against growth disorders, tumor development or progression mediated by circulating microRNA
other	hsa-mir-125b-1	Hailey-Hailey Disease	21913998	integumentary system disease	DOID:0050429	Q82.8	D016506	169600		Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation.
other	hsa-mir-140	Hand, Foot And Mouth Disease	22087245	disease by infectious agent	DOID:10881	B08.4	D006232			A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761.
other	hsa-mir-143	Hand, Foot And Mouth Disease	22087245	disease by infectious agent	DOID:10881	B08.4	D006232			A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761.
other	hsa-mir-148a	Hand, Foot And Mouth Disease	22087245	disease by infectious agent	DOID:10881	B08.4	D006232			A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761.
other	hsa-mir-324	Hand, Foot And Mouth Disease	22087245	disease by infectious agent	DOID:10881	B08.4	D006232			A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761.
other	hsa-mir-362	Hand, Foot And Mouth Disease	22087245	disease by infectious agent	DOID:10881	B08.4	D006232			A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761.
other	hsa-mir-545	Hand, Foot And Mouth Disease	22087245	disease by infectious agent	DOID:10881	B08.4	D006232			A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761.
other	hsa-mir-628	Hand, Foot And Mouth Disease	22087245	disease by infectious agent	DOID:10881	B08.4	D006232			A receiver operating characteristic (ROC) curve analysis revealed that six serum miRNAs (miR-148a, miR-143, miR-324-3p, miR-628-3p, miR-140-5p, and miR-362-3p) were able to discriminate patients with enterovirus infections from healthy controls with area under curve (AUC) values ranged from 0.828 to 0.934. The combined six miRNA using multiple logistic regression analysis provided not only a sensitivity of 97.1% and a specificity of 92.7% but also a unique profile that differentiated enterovirial infections from other microbial infections. Expression levels of five miRNAs (miR-148a, miR-143, miR-324-3p, miR-545, and miR-140-5p) were significantly increased in patients with CVA16 versus those with EV71 (p<0.05). Combination of miR-545, miR-324-3p, and miR-143 possessed a moderate ability to discrimination between CVA16 and EV71 with an AUC value of 0.761.
other	hsa-mir-151	Hantavirus Infection	24074584			B33.4	D018778			Our data suggest that differential immune responses following hantavirus infection may be regulated in part by cellular miRNA through dysregulation of genes critical to the inflammatory process.
other	hsa-mir-1973	Hantavirus Infection	24074584			B33.4	D018778			Our data suggest that differential immune responses following hantavirus infection may be regulated in part by cellular miRNA through dysregulation of genes critical to the inflammatory process.
other	hsa-let-7a-1	Head And Neck Neoplasms	21292542	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation.
other	hsa-let-7a-2	Head And Neck Neoplasms	21292542	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation.
other	hsa-let-7a-3	Head And Neck Neoplasms	21292542	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation.
other	hsa-mir-107	Head And Neck Neoplasms	22491216	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Lipid-based Nanoparticle Delivery of Pre-miR-107 Inhibits the Tumorigenicity of Head and Neck Squamous Cell Carcinoma.
other	hsa-mir-10b	Head And Neck Neoplasms	24209638	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	The study of microRNA alterations in HNSCC is an essential step to the mechanistic understanding of tumor formation and could lead to the discovery of clinically relevant biomarkers.
other	hsa-mir-138-1	Head And Neck Neoplasms	23445815	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Role of microRNA-138 as a Potential Tumor Suppressor in Head and Neck Squamous Cell Carcinoma
other	hsa-mir-138-2	Head And Neck Neoplasms	23445815	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Role of microRNA-138 as a Potential Tumor Suppressor in Head and Neck Squamous Cell Carcinoma
other	hsa-mir-196a	Head And Neck Neoplasms	24209638	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	The study of microRNA alterations in HNSCC is an essential step to the mechanistic understanding of tumor formation and could lead to the discovery of clinically relevant biomarkers.
other	hsa-mir-200c	Head And Neck Neoplasms	21294122	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells.
other	hsa-mir-204	Head And Neck Neoplasms	20369013	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis
other	hsa-mir-7-1	Head And Neck Neoplasms	23115635	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7
other	hsa-mir-7-2	Head And Neck Neoplasms	23115635	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7
other	hsa-mir-7-3	Head And Neck Neoplasms	23115635	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7
other	hsa-mir-9-1	Head And Neck Neoplasms	22664743	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	IRS-1 suppresses metastasis of head and neck cancer possibly through miR-9
other	hsa-mir-9-2	Head And Neck Neoplasms	22664743	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	IRS-1 suppresses metastasis of head and neck cancer possibly through miR-9
other	hsa-mir-9-3	Head And Neck Neoplasms	22664743	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	IRS-1 suppresses metastasis of head and neck cancer possibly through miR-9
other	hsa-mir-34a	Hearing Loss	28756190			H91.93	D034381			miR-34a/Bcl-2 signaling pathway contributes to age-related hearing loss by modulating hair cell apoptosis.
other	hsa-mir-1	Heart Diseases [unspecific]	25177824			I51.9	D006333			miRNA-1: functional roles and dysregulation in heart disease.
other	hsa-mir-122	Heart Diseases [unspecific]	28287427			I51.9	D006333			The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling.
other	hsa-mir-184	Heart Diseases [unspecific]	28287427			I51.9	D006333			The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling.
other	hsa-mir-21	Heart Diseases [unspecific]	17786230			I51.9	D006333			Another miRNA consistently induced by cardiac stress, miR-21, appears to function as a regulator of cardiac growth and fetal gene activation in primary cardiomyocytes in vitro although some confusion remains regarding its exact role.
other	hsa-mir-34a	Heart Diseases [unspecific]	23047694			I51.9	D006333			Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.
other	hsa-mir-34a	Heart Diseases [unspecific]	28287427			I51.9	D006333			The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling.
other	hsa-mir-1	Heart Failure	19149547			I50	D006331		HP:0001635	miR-133 and miR-1 are specifically expressed in cardiac and skeletal muscle and control myogenesis, cardiac development, cardiac performance and cardiomyocyte hypertrophy (mainly by tuning transcription factors and other growth-related targets).
other	hsa-mir-1	Heart Failure	19320780			I50	D006331		HP:0001635	The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia,miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy.
other	hsa-mir-1	Heart Failure	19519553			I50	D006331		HP:0001635	MiR-1 influences susceptibility to cardiac arrhythmias after myocardial infarction.
other	hsa-mir-1	Heart Failure	22110643			I50	D006331		HP:0001635	We conclude that miR-1 and -499 play differential roles in cardiac differentiation of hESCs in a context-dependent fashion. While miR-499 promotes ventricular specification of hESCs, miR-1 serves to facilitate electrophysiological maturation.
other	hsa-mir-1	Heart Failure	22326846			I50	D006331		HP:0001635	These findings demonstrate the importance of miR-1 in cardiac function and in the pathogenesis of heart failure via Sorcin-dependent calcium homeostasis.
other	hsa-mir-1	Heart Failure	29117535			I50	D006331		HP:0001635	Rescuing infusion of miRNA-1 prevents cardiac remodeling in a heart-selective miRNA deficient mouse.
other	hsa-mir-100	Heart Failure	18582896			I50	D006331		HP:0001635	To pursue the observation that changes in expression levels of individual miRNAs are functionally relevant, microRNA mimics and inhibitors to miR-92, miR-100 and miR-133b were expressed in primary cultures of neonatal rat cardiac myocytes.
other	hsa-mir-1-1	Heart Failure	22163007			I50	D006331		HP:0001635	MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex.
other	hsa-mir-1-1	Heart Failure	22362515			I50	D006331		HP:0001635	SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway.
other	hsa-mir-1-2	Heart Failure	22163007			I50	D006331		HP:0001635	MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex.
other	hsa-mir-1-2	Heart Failure	22362515			I50	D006331		HP:0001635	SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway.
other	hsa-mir-125b	Heart Failure	25763857			I50	D006331		HP:0001635	Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells.
other	hsa-mir-125b	Heart Failure	22545159			I50	D006331		HP:0001635	These studies identified miR-125b as an important regulator of hESC differentiation in general, and the development of hESC-derived mesoderm and cardiac muscle in particular.
other	hsa-mir-126	Heart Failure	26313139			I50	D006331		HP:0001635	Biological significance of miR-126 expression in atrial fibrillation and heart failure.
other	hsa-mir-126	Heart Failure	23465244			I50	D006331		HP:0001635	Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients
other	hsa-mir-126	Heart Failure	19320780			I50	D006331		HP:0001635	The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia,miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy.
other	hsa-mir-126	Heart Failure	27180261			I50	D006331		HP:0001635	miR-126 up-regulation activates EPCs and ECs and contributes to vascular healing and neovessel formation.
other	hsa-mir-132	Heart Failure	29027324			I50	D006331		HP:0001635	Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure.
other	hsa-mir-133	Heart Failure	19149547			I50	D006331		HP:0001635	miR-133 and miR-1 are specifically expressed in cardiac and skeletal muscle and control myogenesis, cardiac development, cardiac performance and cardiomyocyte hypertrophy (mainly by tuning transcription factors and other growth-related targets).
other	hsa-mir-133	Heart Failure	19320780			I50	D006331		HP:0001635	The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia,miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy.
other	hsa-mir-133a	Heart Failure	19056878			I50	D006331		HP:0001635	It will be interesting to see, if miR-133a is also involved in human heart diseases, especially VSD and dilated cardiomyopathy.
other	hsa-mir-133a	Heart Failure	28283551			I50	D006331		HP:0001635	A novel role for miR-133a in centrally mediated activation of the renin-angiotensin system in congestive heart failure.
other	hsa-mir-133a-1	Heart Failure	19096030			I50	D006331		HP:0001635	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-133a-1	Heart Failure	22163007			I50	D006331		HP:0001635	MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex.
other	hsa-mir-133a-2	Heart Failure	19096030			I50	D006331		HP:0001635	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-133a-2	Heart Failure	22163007			I50	D006331		HP:0001635	MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex.
other	hsa-mir-133b	Heart Failure	19096030			I50	D006331		HP:0001635	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-133b	Heart Failure	22163007			I50	D006331		HP:0001635	MicroRNA-1 and -133 Increase Arrhythmogenesis in Heart Failure by Dissociating Phosphatase Activity from RyR2 Complex.
other	hsa-mir-133b	Heart Failure	18582896			I50	D006331		HP:0001635	To pursue the observation that changes in expression levels of individual miRNAs are functionally relevant, microRNA mimics and inhibitors to miR-92, miR-100 and miR-133b were expressed in primary cultures of neonatal rat cardiac myocytes.
other	hsa-mir-135a	Heart Failure	21185128			I50	D006331		HP:0001635	Possible involvement of microRNAs (miR-135a∗) in heart failure associated with 25bp deletion in MYBPC3 (cardiac myosin binding protein C) gene.
other	hsa-mir-142	Heart Failure	26327117			I50	D006331		HP:0001635	miR-142-5p has been proposed to control adaptive growth in cardiomyocytes postnatally and its increase is associated with extensive apoptosis and cardiac dysfunction in a murine heart failure model.
other	hsa-mir-150	Heart Failure	24462065			I50	D006331		HP:0001635	Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in  patients with chronic systolic heart failure.
other	hsa-mir-16	Heart Failure	25763857			I50	D006331		HP:0001635	Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells.
other	hsa-mir-181c	Heart Failure	27742689			I50	D006331		HP:0001635	Role of microRNA in metabolic shift during heart failure.
other	hsa-mir-195	Heart Failure	22190509			I50	D006331		HP:0001635	microRNA-195(miR-195) is an important member of the micro-15/16/195/424/497 family, and which is activated in multiple diseases, such as cancers, heart failure, and schizophrenia.
other	hsa-mir-199a-1	Heart Failure	20965886			I50	D006331		HP:0001635	Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart
other	hsa-mir-199a-2	Heart Failure	20965886			I50	D006331		HP:0001635	Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart
other	hsa-mir-19b	Heart Failure	27805004			I50	D006331		HP:0001635	miR-19b Regulates Ventricular Action Potential Duration in Zebrafish.
other	hsa-mir-19b	Heart Failure	28091585			I50	D006331		HP:0001635	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure.
other	hsa-mir-205	Heart Failure	28849082			I50	D006331		HP:0001635	Short‑term vagus nerve stimulation reduces myocardial apoptosis by downregulating microRNA‑205 in rats with chronic heart failure.
other	hsa-mir-206	Heart Failure	24465270			I50	D006331		HP:0001635	Provide a complex overview of microRNA-206.
other	hsa-mir-206	Heart Failure	23242657			I50	D006331		HP:0001635	Recent data indicate that these miRNAs as well as miR-206 change their expression quickly in response to physical activity.
other	hsa-mir-208	Heart Failure	19519553			I50	D006331		HP:0001635	MiR-208 is involved in the shift toward a fetal gene expression pattern in contractile proteins in heart failure.
other	hsa-mir-208	Heart Failure	23839576			I50	D006331		HP:0001635	Heart function has been restored in rodents by reprogramming non-myocytes into cardiomyocytes, by expressing transcription factors (GATA4, HAND2, myocyte-specific enhancer factor 2C (MEF2C) and T-box 5 (TBX5)) and microRNAs (miR-1, miR-133, miR-208 and miR-499) that control cardiomyocyte identity.
other	hsa-mir-208	Heart Failure	25840809			I50	D006331		HP:0001635	miR-208 family is closely associated with the development of  cardiac diseases
other	hsa-mir-208b	Heart Failure	24714087			I50	D006331		HP:0001635	These results demonstrated that circulating miR-208b and miR-34a could be useful biomarkers for predicting left ventricular remodeling after AMI, and the miRNA levels are associated with increased risk of mortality or heart failure.
other	hsa-mir-21	Heart Failure	25763857			I50	D006331		HP:0001635	Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells.
other	hsa-mir-21	Heart Failure	19519553			I50	D006331		HP:0001635	MiR-29 is involved in fibrotic reaction after myocardial infarction while miR-21 may exert a fundamental role in post-angioplasty restenosis.
other	hsa-mir-21	Heart Failure	22529925			I50	D006331		HP:0001635	Transfection assay revealed that both Ago1 and Ago2 synergistically induced miR-21 and miR-21* when the mir-21 plasmid was co-transfected with either.
other	hsa-mir-21	Heart Failure	22842854			I50	D006331		HP:0001635	TMZ improved RV function (as indicated by an increase in tricuspid annular plane systolic excursion), and inhibited fibrosis. TMZ also protects RVMCs againts apoptosis and increases miR-21 expression.
other	hsa-mir-21	Heart Failure	24743143			I50	D006331		HP:0001635	In particular, a passenger strand miR, miR-21*, was identified as a potent paracrine factor that induces cardiomyocyte hypertrophy when shuttled through exosomes.
other	hsa-mir-21	Heart Failure	25903305			I50	D006331		HP:0001635	Downregulation of miR-21 and p-ERK/ERK were observed in myocardial fibroblasts treated with UA in a dose-dependent manner compared with the control group both in vitro and in vivo.
other	hsa-mir-21	Heart Failure	26047574			I50	D006331		HP:0001635	Torasemide but not furosemide inhibits CYP11B2 activity and reduces the expression of CTGF, LOX, and miR-21.
other	hsa-mir-21	Heart Failure	27292200			I50	D006331		HP:0001635	heart failure (miR-21 and miR-133a)
other	hsa-mir-210	Heart Failure	23302636			I50	D006331		HP:0001635	MicroRNA 210 as a Biomarker for Congestive Heart Failure
other	hsa-mir-210	Heart Failure	28249798			I50	D006331		HP:0001635	Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis.
other	hsa-mir-212	Heart Failure	21977024			I50	D006331		HP:0001635	Conversely, alcohol-mediated inhibition of mTOR/S6K1, down-regulation of INS receptor and growth-inhibitory mir-200 family, and upregulation of mir-212 that promotes fetal gene program may exacerbate CRS-related cardiomyopathy.
other	hsa-mir-214	Heart Failure	29584819			I50	D006331		HP:0001635	ROCR acted as a microRNA-214 sponge to release PTEN, which blocked activation of the PI3 kinase/Akt pathway to inhibit cardiomyocyte proliferation and ROCR may be a novel therapeutic target for preventing and treating heart failure
other	hsa-mir-22	Heart Failure	22570371			I50	D006331		HP:0001635	These data indicate that miR-22 functions as an integrator of Ca(2+) homeostasis and myofibrillar protein content during stress in the heart and shed light on the mechanisms that enhance propensity toward heart failure.
other	hsa-mir-22	Heart Failure	27687198			I50	D006331		HP:0001635	Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction.
other	hsa-mir-23a	Heart Failure	25829494			I50	D006331		HP:0001635	Heat shock inhibition of CDK5 increases NOXA levels through miR-23a repression.
other	hsa-mir-25	Heart Failure	24161931			I50	D006331		HP:0001635	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.
other	hsa-mir-25	Heart Failure	25214573			I50	D006331		HP:0001635	miR-25 in heart failure.
other	hsa-mir-29	Heart Failure	19320780			I50	D006331		HP:0001635	The implication of several miRNAs in cardiovascular diseases has been well documented such as miRNA-1 in arrhythmia,miRNA-29 in cardiac fibrosis, miRNA-126 in angiogenesis and miRNA-133 in cardiac hypertrophy.
other	hsa-mir-29a	Heart Failure	25464262			I50	D006331		HP:0001635	MicroRNA-29a (miR-29a), a  key regulator of tissue fibrosis, was highly expressed in the exosomes and the marginal area of the RIC group.
other	hsa-mir-30a	Heart Failure	19096030			I50	D006331		HP:0001635	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-30b	Heart Failure	19096030			I50	D006331		HP:0001635	miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling
other	hsa-mir-30b	Heart Failure	25301066			I50	D006331		HP:0001635	E2F1 transcriptionally represses miR-30b expression.
other	hsa-mir-30d	Heart Failure	26858295			I50	D006331		HP:0001635	Letter by Sardu et al Regarding Article, Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study.
other	hsa-mir-30d	Heart Failure	26858296			I50	D006331		HP:0001635	Response to Letter Regarding Article, Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study.
other	hsa-mir-34a	Heart Failure	24714087			I50	D006331		HP:0001635	These results demonstrated that circulating miR-208b and miR-34a could be useful biomarkers for predicting left ventricular remodeling after AMI, and the miRNA levels are associated with increased risk of mortality or heart failure.
other	hsa-mir-378	Heart Failure	27742689			I50	D006331		HP:0001635	Role of microRNA in metabolic shift during heart failure.
other	hsa-mir-423	Heart Failure	24506564			I50	D006331		HP:0001635	The difference in transcoronary gradients between HF outpatients and controls suggests that miR-423-5p has a cardiac origin. The positive correlation between miR-423-5p and BNP transcoronary gradients supports this hypothesis.
other	hsa-mir-451a	Heart Failure	25763857			I50	D006331		HP:0001635	Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells.
other	hsa-mir-499	Heart Failure	22110643			I50	D006331		HP:0001635	We conclude that miR-1 and -499 play differential roles in cardiac differentiation of hESCs in a context-dependent fashion. While miR-499 promotes ventricular specification of hESCs, miR-1 serves to facilitate electrophysiological maturation.
other	hsa-mir-499	Heart Failure	22752967			I50	D006331		HP:0001635	miR-499 is increased in human and murine cardiac hypertrophy and cardiomyopathy, is sufficient to cause murine heart failure, and accelerates maladaptation to pressure overloading. 
other	hsa-mir-508	Heart Failure	23465244			I50	D006331		HP:0001635	Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients
other	hsa-mir-665	Heart Failure	25111814			I50	D006331		HP:0001635	MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure.
other	hsa-mir-92	Heart Failure	18582896			I50	D006331		HP:0001635	To pursue the observation that changes in expression levels of individual miRNAs are functionally relevant, microRNA mimics and inhibitors to miR-92, miR-100 and miR-133b were expressed in primary cultures of neonatal rat cardiac myocytes.
other	hsa-mir-99	Heart Failure	25517466			I50	D006331		HP:0001635	concept for identifying and activating conserved molecular programs to regenerate the damaged heart.
other	hsa-mir-15a	Heart Valve Disease	28888871	cardiovascular system disease	DOID:4079	I39	D006349			Interplay of mitochondria apoptosis regulatory factors and microRNAs in valvular heart disease.
other	hsa-mir-29a	Heart Valve Disease	28888871	cardiovascular system disease	DOID:4079	I39	D006349			Interplay of mitochondria apoptosis regulatory factors and microRNAs in valvular heart disease.
other	hsa-mir-106a	Helicobacter pylori Infection	25307786			B96.81	D016480	600263	HP:0005202	A MDM2-dependent positive-feedback loop is involved in inhibition of miR-375 and miR-106b induced by Helicobacter pylori lipopolysaccharide.
other	hsa-mir-155	Helicobacter pylori Infection	26191144			B96.81	D016480	600263	HP:0005202	Inflammatory response of macrophages cultured with Helicobacter pylori strains was regulated by miR-155.
other	hsa-mir-375	Helicobacter pylori Infection	25307786			B96.81	D016480	600263	HP:0005202	A MDM2-dependent positive-feedback loop is involved in inhibition of miR-375 and miR-106b induced by Helicobacter pylori lipopolysaccharide.
other	hsa-mir-126	Hemangioma	28538565	disease of cellular proliferation	DOID:255	D18.0	D006391	602089		Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation.
other	hsa-mir-382	Hemangioma	28112362	disease of cellular proliferation	DOID:255	D18.0	D006391	602089		Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway.
other	hsa-let-7	Hematologic Neoplasms	26676759	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Taken together, our results reveal a previously unknown mechanism by which Myc induces apoptosis independent of the p53 pathway and as a response to HDACi in malignant hematopoietic cells.
other	hsa-mir-103	Hematologic Neoplasms	24921248	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor.
other	hsa-mir-124	Hematologic Neoplasms	27864740	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
other	hsa-mir-125b	Hematologic Neoplasms	27864740	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
other	hsa-mir-15	Hematologic Neoplasms	26676759	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Taken together, our results reveal a previously unknown mechanism by which Myc induces apoptosis independent of the p53 pathway and as a response to HDACi in malignant hematopoietic cells.
other	hsa-mir-155	Hematologic Neoplasms	23815946	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Relationship between microRNA-155 and hematological malignancies
other	hsa-mir-155	Hematologic Neoplasms	27864740	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
other	hsa-mir-155	Hematologic Neoplasms	23538486	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Transfection of Kasumi-1 cells with a new type of polymer carriers loaded with miR-155 and antago-miR-155.
other	hsa-mir-181a	Hematologic Neoplasms	16249029	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	The stress-induced modulation of hematopoietic miR-181a levels through AChE, PKC and PKA cascade(s) suggests using miRNA mimics for diverting the fate of hematopoietic tumor cells towards differentiation and/or apoptosis.
other	hsa-mir-21	Hematologic Neoplasms	24921248	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor.
other	hsa-mir-223	Hematologic Neoplasms	25753223	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	C/EBP伪 interacts with AP-1 proteins to bind hybrid DNA elements during monopoiesis, and induction of Gfi-1, C/EBP蔚, KLF5, and miR-223 by C/EBP伪 enables granulopoiesis.
other	hsa-mir-23b	Hematologic Neoplasms	27864740	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
other	hsa-mir-26a	Hematologic Neoplasms	27864740	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
other	hsa-mir-29b	Hematologic Neoplasms	25004911	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Recent research of miR-29 family in hematological malignancies has proven its oncogenic as well as tumor suppressive potential.
other	hsa-mir-31	Hematologic Neoplasms	24921248	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor.
other	hsa-mir-378	Hematologic Neoplasms	27864740	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
other	hsa-mir-566	Hematologic Neoplasms	24921248	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor.
other	hsa-mir-93	Hematologic Neoplasms	24921248	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor.
other	hsa-let-7	Hemoglobin Diseases	27861570			D58.2	D006450	141900		HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts.
other	hsa-mir-1246	Hemophilia A	26176629			D66	D006467	306700		Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene.
other	hsa-mir-122	Hepatitis [unspecific]	25973575	endocrine system disease	DOID:2237		D006521		HP:0012115	These results demonstrate that first, exosomes mediate communication between hepatocytes and monocytes/macrophages and second, hepatocyte-derived miRNA-122 can reprogram monocytes inducing sensitization to LPS.
other	hsa-mir-208b	Hepatitis [unspecific]	27841874	endocrine system disease	DOID:2237		D006521		HP:0012115	Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling.
other	hsa-mir-223	Hepatitis [unspecific]	29145157	endocrine system disease	DOID:2237		D006521		HP:0012115	BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis
other	hsa-mir-499a	Hepatitis [unspecific]	27841874	endocrine system disease	DOID:2237		D006521		HP:0012115	Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling.
other	hsa-mir-101-1	Hepatitis B Virus Infection	21876625	disease by infectious agent	DOID:2043	B16/18	D006509	610424		potential associated miRNA
other	hsa-mir-101-2	Hepatitis B Virus Infection	21876625	disease by infectious agent	DOID:2043	B16/18	D006509	610424		potential associated miRNA
other	hsa-mir-106a	Hepatitis B Virus Infection	21876625	disease by infectious agent	DOID:2043	B16/18	D006509	610424		potential associated miRNA
other	hsa-mir-106b	Hepatitis B Virus Infection	26456479	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-106b	Hepatitis B Virus Infection	21876625	disease by infectious agent	DOID:2043	B16/18	D006509	610424		potential associated miRNA
other	hsa-mir-1-1	Hepatitis B Virus Infection	21520166	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MiR-1 regulates the expression of several host genes to enhance HBV replication and reverse cancer cell phenotype, which is apparently beneficial for HBV replication.
other	hsa-mir-1-2	Hepatitis B Virus Infection	21520166	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MiR-1 regulates the expression of several host genes to enhance HBV replication and reverse cancer cell phenotype, which is apparently beneficial for HBV replication.
other	hsa-mir-122	Hepatitis B Virus Infection	26541590	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122.
other	hsa-mir-122	Hepatitis B Virus Infection	23508904	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B
other	hsa-mir-122	Hepatitis B Virus Infection	26456479	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-122	Hepatitis B Virus Infection	21902631	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Hybridization between the host-encoded, liver-specific microRNA (miR-122) and the 5'-untranslated region of HCV genome was shown to be required for effective viral RNA replication.
other	hsa-mir-122	Hepatitis B Virus Infection	21903935	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-122 may down-regulate HBV replication by binding to the viral target sequence, contributing to the persistent/chronic infection of HBV, and that HBV-induced modulation of miR-122 expression may represent a mechanism to facilitate viral pathogenesis.
other	hsa-mir-122	Hepatitis B Virus Infection	23055569	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Inhibition of Alpha Interferon (IFN-alpha)-Induced MicroRNA-122 Negatively Affects the Anti-Hepatitis B Virus Efficiency of IFN-ж┿
other	hsa-mir-122	Hepatitis B Virus Infection	24314655	disease by infectious agent	DOID:2043	B16/18	D006509	610424		microRNA expression in hepatitis B virus infected primary treeshrew hepatocytes and the independence of intracellular miR-122 level for de novo HBV infection in culture.
other	hsa-mir-122	Hepatitis B Virus Infection	25299106	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Expression and clinical significance of miR-122 and miR-29 in hepatitis B virus-related liver disease.
other	hsa-mir-125a	Hepatitis B Virus Infection	24824183	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection.
other	hsa-mir-125a	Hepatitis B Virus Infection	21317190	disease by infectious agent	DOID:2043	B16/18	D006509	610424		hsa-mir-125a-5p, was found to interact with the viral sequence and to suppress the reporter activity markedly.
other	hsa-mir-151a	Hepatitis B Virus Infection	26801621	disease by infectious agent	DOID:2043	B16/18	D006509	610424		We identified miR-24-3p, miR-151a-5p, and miR-425-5p as the most valid combination of reference genes for microRNA RT-qPCR studies in our hepatitis B virus replicating HepG2 cell model.
other	hsa-mir-181b	Hepatitis B Virus Infection	26456479	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-185	Hepatitis B Virus Infection	26456479	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-18a	Hepatitis B Virus Infection	26456479	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-18a	Hepatitis B Virus Infection	21876625	disease by infectious agent	DOID:2043	B16/18	D006509	610424		potential associated miRNA
other	hsa-mir-18b	Hepatitis B Virus Infection	21876625	disease by infectious agent	DOID:2043	B16/18	D006509	610424		potential associated miRNA
other	hsa-mir-197	Hepatitis B Virus Infection	23710316	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-197 Expression in Peripheral Blood Mononuclear Cells from Hepatitis B Virus-Infected Patients.
other	hsa-mir-21	Hepatitis B Virus Infection	26456479	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-215	Hepatitis B Virus Infection	24434140	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Hepatitis B virus X protein mutant HBxΔ127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT.
other	hsa-mir-22	Hepatitis B Virus Infection	23508904	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B
other	hsa-mir-24	Hepatitis B Virus Infection	26801621	disease by infectious agent	DOID:2043	B16/18	D006509	610424		We identified miR-24-3p, miR-151a-5p, and miR-425-5p as the most valid combination of reference genes for microRNA RT-qPCR studies in our hepatitis B virus replicating HepG2 cell model.
other	hsa-mir-29	Hepatitis B Virus Infection	25299106	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Expression and clinical significance of miR-122 and miR-29 in hepatitis B virus-related liver disease.
other	hsa-mir-29a	Hepatitis B Virus Infection	23285022	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNA-29a-5p Is a Novel Predictor for Early Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection
other	hsa-mir-29c	Hepatitis B Virus Infection	26456479	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-31	Hepatitis B Virus Infection	24824126	disease by infectious agent	DOID:2043	B16/18	D006509	610424		HBsAg regulation of miR-31 expression in HepG2 cells
other	hsa-mir-323b	Hepatitis B Virus Infection	24341744	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Association of a microRNA-323b polymorphism with the persistence of hepatitis B virus infection by the enhancement of viral replication.
other	hsa-mir-323b	Hepatitis B Virus Infection	26037063	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The association between microRNA-323b polymorphism and hepatitis B virus persistent infection - some problems should be addressed.
other	hsa-mir-323b	Hepatitis B Virus Infection	26037064	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The association between microRNA-323b polymorphism and hepatitis B virus persistent infection - some problems should be addressed.
other	hsa-mir-338	Hepatitis B Virus Infection	22912826	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The Effect of miR-338-3p on HBx Deletion-Mutant (HBx-d382) Mediated Liver-Cell Proliferation through CyclinD1 Regulation.
other	hsa-mir-425	Hepatitis B Virus Infection	26801621	disease by infectious agent	DOID:2043	B16/18	D006509	610424		We identified miR-24-3p, miR-151a-5p, and miR-425-5p as the most valid combination of reference genes for microRNA RT-qPCR studies in our hepatitis B virus replicating HepG2 cell model.
other	hsa-mir-5193	Hepatitis B Virus Infection	26456535	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Therefore, miR-5193 might be useful and have a vital role for inhibition of HBV replication in the future.
other	hsa-mir-520b	Hepatitis B Virus Infection	24886421	disease by infectious agent	DOID:2043	B16/18	D006509	610424		HBx accelerates hepatocarcinogenesis with partner survivin through modulating tumor suppressor miR-520b and oncoprotein HBXIP.
other	hsa-mir-99	Hepatitis B Virus Infection	27886437	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy.
other	hsa-let-7b	Hepatitis C Virus Infection	22391672	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Let-7b is a novel regulator of hepatitis C virus replication.
other	hsa-let-7f	Hepatitis C Virus Infection	27496568	disease by infectious agent	DOID:1883	B19.2	D006526	609532		these functional miRNAs, mainly represented by let-7f, miR-145, miR-199a, and miR-221 released from uMSC-Exo, largely contributed to the suppression of HCV RNA replication.
other	hsa-mir-1181	Hepatitis C Virus Infection	20006370	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation
other	hsa-mir-122	Hepatitis C Virus Infection	23537271	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Down-regulating miR-122 expression by HCV core protein may give a new insight into the interaction between HCV and miR-122 and chronic HCV infection
other	hsa-mir-122	Hepatitis C Virus Infection	25646812	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.
other	hsa-mir-122	Hepatitis C Virus Infection	16141076	disease by infectious agent	DOID:1883	B19.2	D006526	609532		interaction with non-coding regions of Hepatitis C help its replication
other	hsa-mir-122	Hepatitis C Virus Infection	18550664	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122: Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in  nonhepatic cells
other	hsa-mir-122	Hepatitis C Virus Infection	19020517	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122: microRNA-122 stimulates translation of hepatitis C virus RNA
other	hsa-mir-122	Hepatitis C Virus Infection	19122656	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122: Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy
other	hsa-mir-122	Hepatitis C Virus Infection	20371461	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, a major regulatory RNA in liver that fine-tunes the expression of over 100 cellular genes and enhances HCV replication
other	hsa-mir-122	Hepatitis C Virus Infection	20527935	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122:Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma
other	hsa-mir-122	Hepatitis C Virus Infection	21653556	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components.
other	hsa-mir-122	Hepatitis C Virus Infection	22189820	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Here we show that HCV IRES-dependent translation efficiency in the hepatoma cell line Huh7 is highest during the G 0 and G 1 phases of the cell cycle but significantly drops during the S phase and even more in the G 2/M phase. The superimposed stimulation of HCV translation by ectopic miR-122 works best during the G 0, G 1 and G 2/M phases but is lower during the S phase. However, the levels of Ago2 protein do not substantially change during cell cycle phases, indicating that other cellular factors involved in HCV translation stimulation by miR-122 may be differentially expressed in different cell cycle phases. Moreover, the levels of endogenously expressed miR-122 in Huh7 cells are lowest in the S phase, indicating that the predominant G 0/G 1 state of non-dividing hepatocytes in the liver facilitates high expression of the HCV genome and stimulation by miR-122, with yet unknown factors involved in the differential extent of stimulation by miR-122.
other	hsa-mir-122	Hepatitis C Virus Infection	22342424	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a.
other	hsa-mir-122	Hepatitis C Virus Infection	22593164	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Expression of MicroRNA miR-122 Facilitates an Efficient Replication in Nonhepatic Cells upon Infection with Hepatitis C Virus.
other	hsa-mir-122	Hepatitis C Virus Infection	23126531	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Alcohol Facilitates HCV RNA Replication Via Up-Regulation of miR-122 Expression and Inhibition of Cyclin G1 in Human Hepatoma Cells
other	hsa-mir-122	Hepatitis C Virus Infection	23218444	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Can tobacco use promote HCV-induced miR-122 hijacking and hepatocarcinogenesis
other	hsa-mir-122	Hepatitis C Virus Infection	23245472	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells
other	hsa-mir-122	Hepatitis C Virus Infection	23248316	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication
other	hsa-mir-122	Hepatitis C Virus Infection	23405269	disease by infectious agent	DOID:1883	B19.2	D006526	609532		microRNA-122 Dependent Binding of Ago2 Protein to Hepatitis C Virus RNA Is Associated with Enhanced RNA Stability and Translation Stimulation
other	hsa-mir-122	Hepatitis C Virus Infection	23770926	disease by infectious agent	DOID:1883	B19.2	D006526	609532		mir-122 and the Hepatitis C RNA genome: more than just stability.
other	hsa-mir-122	Hepatitis C Virus Infection	23793894	disease by infectious agent	DOID:1883	B19.2	D006526	609532		A miRNA-responsive cell-free translation system facilitates isolation of hepatitis C virus miRNP complexes.
other	hsa-mir-122	Hepatitis C Virus Infection	24141094	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The P body protein LSm1 contributes to stimulation of hepatitis C virus translation, but not replication, by microRNA-122.
other	hsa-mir-122	Hepatitis C Virus Infection	24106328	disease by infectious agent	DOID:1883	B19.2	D006526	609532		By use of duplex and precursor miR-122 mimetic molecules that carried mutations in the passenger strand of miR-122, the effects on viral and reporter gene expression could be pinpointed to the action of precursor miR-122 molecules.
other	hsa-mir-122	Hepatitis C Virus Infection	25836383	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The binding of p68 onto HCV RNA can be specifically inhibited by miR-122 via a competitive binding process.
other	hsa-mir-122	Hepatitis C Virus Infection	23881584	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122 promotion of the hepatitis C virus life cycle: sound in the silence.
other	hsa-mir-122	Hepatitis C Virus Infection	24721497	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C virus and human miR-122: insights from the bench to the clinic.
other	hsa-mir-122	Hepatitis C Virus Infection	24844965	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Different types of IFN increase the expression of miRNAs that inhibit HCV replication and decrease the expression of miRNA-122 that supports HCV replication. Thus the regulation of HCV replication-related miRNA expression is a general anti-HCV mechanism by different types of IFN. However, the regulation pattern by type II IFN is different from those by other types of IFNs,implying that type II IFN has different anti-HCV mechanisms from other types of IFN at miRNA level.
other	hsa-mir-122	Hepatitis C Virus Infection	25403145	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Our study provides insight into the interaction between miR-122 and HCV, including viral adaptation to reduced miR-122 bioavailability, and has implications for the development of anti-miR-122-based HCV drugs.
other	hsa-mir-122	Hepatitis C Virus Infection	25662750	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122 stimulates hepatitis C virus RNA synthesis by altering the balance of viral RNAs engaged in replication versus translation.
other	hsa-mir-122	Hepatitis C Virus Infection	25768906	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C virus RNA functionally sequesters miR-122.
other	hsa-mir-122	Hepatitis C Virus Infection	25855736	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Regulation of Hepatitis C Virus Genome Replication by Xrn1 and MicroRNA-122 Binding to Individual Sites in the 5' Untranslated Region.
other	hsa-mir-122	Hepatitis C Virus Infection	26096908	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C virus addiction to liver miR-122 takes its Toll on the host.
other	hsa-mir-122	Hepatitis C Virus Infection	23826300	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Modulation of hepatitis C virus RNA accumulation and translation by DDX6 and miR-122 are mediated by separate mechanisms.
other	hsa-mir-122	Hepatitis C Virus Infection	25963774	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The mechanism of HCV dyslipidemia is complex and could partly relate to the effect of miR-122 on lipid metabolism which requires further evaluation in a larger study.
other	hsa-mir-122	Hepatitis C Virus Infection	26330540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		These results show that hnRNP K is a cellular protein that binds and affects the accumulation of miR-122. Its ability to also bind HCV RNA near the miR-122 binding site suggests a role for miR-122 recognition of HCV RNA.
other	hsa-mir-122	Hepatitis C Virus Infection	26305877	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Supporting Role for GTPase Rab27a in Hepatitis C Virus RNA Replication through a Novel miR-122-Mediated Effect.
other	hsa-mir-122	Hepatitis C Virus Infection	19965718	disease by infectious agent	DOID:1883	B19.2	D006526	609532		a locked nucleic acid (LNA)-modified oligonucleotide (SPC3649) complementary to miR-122 leads to long-lasting suppression of HCV viremia
other	hsa-mir-122	Hepatitis C Virus Infection	26845923	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Mechanism of regulation of HCV replication by miR-122.
other	hsa-mir-122	Hepatitis C Virus Infection	22965312	disease by infectious agent	DOID:1883	B19.2	D006526	609532		these findings indicate that miR-122 and functional lipid metabolism are involved in the tissue tropism of HCV infection. In this review, we would like to focus on the role of miR-122 and lipid metabolism in the cell tropism of HCV.
other	hsa-mir-122	Hepatitis C Virus Infection	29549787	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1).
other	hsa-mir-122	Hepatitis C Virus Infection	24871972	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Representatively, miR-122 directly modulates the HCV life cycle by increasing HCV translation and genomic RNA stability.
other	hsa-mir-122	Hepatitis C Virus Infection	25275643	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Exosome-loading with a miR-122 inhibitor,  or inhibition of HSP90, vacuolar H+-ATPases, and proton pumps, significantly suppressed exosome-mediated HCV transmission to na茂ve cells.
other	hsa-mir-122	Hepatitis C Virus Infection	26587035	disease by infectious agent	DOID:1883	B19.2	D006526	609532		characteristics of the miR-122 and Let-7 families further highlight the suitability of tree shrew as the animal model in HCV research.
other	hsa-mir-122	Hepatitis C Virus Infection	26927063	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-125a-5p and miR-1231 have  been shown to directly target hepatitis B virus (HBV) transcripts
other	hsa-mir-122	Hepatitis C Virus Infection	27303683	disease by infectious agent	DOID:1883	B19.2	D006526	609532		HCV infection requires miR-122
other	hsa-mir-122	Hepatitis C Virus Infection	27366906	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C Virus Core Protein Promotes miR-122 Destabilization by Inhibiting GLD-2.
other	hsa-mir-122	Hepatitis C Virus Infection	27440892	disease by infectious agent	DOID:1883	B19.2	D006526	609532		the expression of CAMP in nonhepatic 293T cells expressing claudin 1 and microRNA miR-122 confers complete propagation of HCV.
other	hsa-mir-122	Hepatitis C Virus Infection	27578438	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Unraveling the Mysterious Interactions Between Hepatitis C Virus RNA and Liver-Specific MicroRNA-122.
other	hsa-mir-122	Hepatitis C Virus Infection	27641985	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
other	hsa-mir-122	Hepatitis C Virus Infection	27692039	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family.
other	hsa-mir-122	Hepatitis C Virus Infection	28475652	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
other	hsa-mir-122	Hepatitis C Virus Infection	29411512	disease by infectious agent	DOID:1883	B19.2	D006526	609532		This result along with the idea about the driver function of circulating miRNAs will promote  further investigations that eventually lead to the development of novel strategies to treat HCV infection-associated extrahepatic comorbidities
other	hsa-mir-122	Hepatitis C Virus Infection	29528577	disease by infectious agent	DOID:1883	B19.2	D006526	609532		microRNA-122 is a potential marker of progression of hepatocytes injury in patients infected with HCV but not a reliable marker for diagnosis of HCC
other	hsa-mir-130a	Hepatitis C Virus Infection	24383925	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-130a inhibits HCV replication by restoring the innate immune response.
other	hsa-mir-130a	Hepatitis C Virus Infection	26060358	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Vitamin D Potentiates the Inhibitory Effect of MicroRNA-130a in Hepatitis C Virus Replication Independent of Type I Interferon Signaling Pathway.
other	hsa-mir-130a	Hepatitis C Virus Infection	29321333	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway.
other	hsa-mir-142	Hepatitis C Virus Infection	21970718	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-128a, miR-196a and miR-142-3p were modulated in a concerted fashion in all three HCV clones
other	hsa-mir-143	Hepatitis C Virus Infection	17188425	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miRNA-143 and -145 levels increase as disease progresses from chronic hepatitis to cirrhosis, suggesting that they may turn on inflammatory or fibrosis related genes and/or turn off tumor suppressor genes.
other	hsa-mir-145	Hepatitis C Virus Infection	17188425	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miRNA-143 and -145 levels increase as disease progresses from chronic hepatitis to cirrhosis, suggesting that they may turn on inflammatory or fibrosis related genes and/or turn off tumor suppressor genes.
other	hsa-mir-145	Hepatitis C Virus Infection	27496568	disease by infectious agent	DOID:1883	B19.2	D006526	609532		these functional miRNAs, mainly represented by let-7f, miR-145, miR-199a, and miR-221 released from uMSC-Exo, largely contributed to the suppression of HCV RNA replication.
other	hsa-mir-148a	Hepatitis C Virus Infection	27591428	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models.
other	hsa-mir-149	Hepatitis C Virus Infection	20006370	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation
other	hsa-mir-155	Hepatitis C Virus Infection	24383923	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver.
other	hsa-mir-155	Hepatitis C Virus Infection	24591085	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-155 and microRNA-196b: promising biomarkers in hepatitis C virus infection
other	hsa-mir-17	Hepatitis C Virus Infection	25707620	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Our rule discovery method is useful for integrating binding information and expression profile for identifying HCV miRNA-mRNA regulatory modules and can be applied to the study of the expression profiles of other complex human diseases.
other	hsa-mir-196a-1	Hepatitis C Virus Infection	21970718	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-128a, miR-196a and miR-142-3p were modulated in a concerted fashion in all three HCV clones
other	hsa-mir-196b	Hepatitis C Virus Infection	24591085	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-155 and microRNA-196b: promising biomarkers in hepatitis C virus infection
other	hsa-mir-199a	Hepatitis C Virus Infection	27496568	disease by infectious agent	DOID:1883	B19.2	D006526	609532		these functional miRNAs, mainly represented by let-7f, miR-145, miR-199a, and miR-221 released from uMSC-Exo, largely contributed to the suppression of HCV RNA replication.
other	hsa-mir-199a-1	Hepatitis C Virus Infection	19144437	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-199a: Regulation of the hepatitis C virus genome replication
other	hsa-mir-199a-2	Hepatitis C Virus Infection	19144437	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-199a: Regulation of the hepatitis C virus genome replication
other	hsa-mir-19a	Hepatitis C Virus Infection	28077652	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Furthermore, we demonstrate the role of exosomal miR-19a in activation of the STAT3-TGF-β pathway in HSC
other	hsa-mir-221	Hepatitis C Virus Infection	26090579	disease by infectious agent	DOID:1883	B19.2	D006526	609532		IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment.
other	hsa-mir-221	Hepatitis C Virus Infection	27496568	disease by infectious agent	DOID:1883	B19.2	D006526	609532		these functional miRNAs, mainly represented by let-7f, miR-145, miR-199a, and miR-221 released from uMSC-Exo, largely contributed to the suppression of HCV RNA replication.
other	hsa-mir-23a	Hepatitis C Virus Infection	19578061	disease by infectious agent	DOID:1883	B19.2	D006526	609532		virus specific, miR-122-sensitive double-helical switch element in the 5' region--a new mechanism of action of micro-RNAs
other	hsa-mir-24-1	Hepatitis C Virus Infection	20006370	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation
other	hsa-mir-24-2	Hepatitis C Virus Infection	20006370	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation
other	hsa-mir-27a	Hepatitis C Virus Infection	24824429	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-27a modulates HCV infection in differentiated hepatocyte-like cells from adipose tissue-derived mesenchymal stem cells.
other	hsa-mir-27b	Hepatitis C Virus Infection	27665576	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Lipoprotein lipase liberates free fatty acids to inhibit HCV infection and prevent hepatic lipid accumulation.
other	hsa-mir-29a	Hepatitis C Virus Infection	26429314	disease by infectious agent	DOID:1883	B19.2	D006526	609532		This study showed that HCV infection might abrogate NK cytotoxic potential through altering PU.1, NKG2D receptor and perforin molecules.
other	hsa-mir-29a	Hepatitis C Virus Infection	21606534	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture.
other	hsa-mir-29b-1	Hepatitis C Virus Infection	21606534	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture.
other	hsa-mir-29b-2	Hepatitis C Virus Infection	21606534	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture.
other	hsa-mir-29c	Hepatitis C Virus Infection	21606534	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C Virus Infection and Hepatic Stellate Cell Activation Downregulate miR-29: miR-29 Overexpression Reduces Hepatitis C Viral Abundance in Culture.
other	hsa-mir-449a	Hepatitis C Virus Infection	23226395	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C Virus Mediated Changes in miRNA-449a Modulates Inflammatory Biomarker YKL40 through Components of the NOTCH Signaling Pathway
other	hsa-mir-503	Hepatitis C Virus Infection	28343379	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C Virus Nonstructural 5A Protein (HCV-NS5A) Inhibits Hepatocyte Apoptosis through the NF-κb/miR-503/bcl-2 Pathway.
other	hsa-mir-557	Hepatitis C Virus Infection	25707620	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Our rule discovery method is useful for integrating binding information and expression profile for identifying HCV miRNA-mRNA regulatory modules and can be applied to the study of the expression profiles of other complex human diseases.
other	hsa-mir-638	Hepatitis C Virus Infection	20006370	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-24, miR-149, miR-638 and miR-1181 were identified to be involved in HCV entry, replication and propagation
other	hsa-mir-765	Hepatitis C Virus Infection	25707620	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Our rule discovery method is useful for integrating binding information and expression profile for identifying HCV miRNA-mRNA regulatory modules and can be applied to the study of the expression profiles of other complex human diseases.
other	hsa-mir-122	Hepatitis E Virus Infection	29540601	disease by infectious agent	DOID:4411	B17.2	D016751			Positive regulation of hepatitis E virus replication by microRNA-122
other	hsa-mir-221	Hepatitis E Virus Infection	23579640	disease by infectious agent	DOID:4411	B17.2	D016751			Identification of miR-221 and -222 as important regulators in genotype IV swine hepatitis E virus ORF3-expressing HEK 293 cells
other	hsa-mir-222	Hepatitis E Virus Infection	23579640	disease by infectious agent	DOID:4411	B17.2	D016751			Identification of miR-221 and -222 as important regulators in genotype IV swine hepatitis E virus ORF3-expressing HEK 293 cells
other	hsa-mir-184	Hepatoblastoma	26081234	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	miRNA-184 lentivirus-mediated human lens epithelial cells (HLEC) can inhibit the occurrence of epithelial-mesenchymal transition (EMT).
other	hsa-mir-199a	Hepatoblastoma	25673149	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	The miR-199a/Brm/EGR1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines.
other	hsa-mir-34a	Hepatoblastoma	28277300	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma.
other	hsa-mir-34b	Hepatoblastoma	28277300	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma.
other	hsa-mir-34c	Hepatoblastoma	28277300	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma.
other	hsa-mir-15a	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-16	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-15b	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-195	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-29a	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-29b	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-29c	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-30a	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-30b	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-30c	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-30d	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-30e	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-200a	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-200b	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-200c	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-141	Hereditary Breast Carcinoma	24104964			D05	D001943	114480		Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
other	hsa-mir-218-1	Hirschsprung Disease	25786906	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	SLIT2/ROBO1-miR-218-1-RET/PLAG1: a new disease pathway involved in Hirschsprung's disease.
other	hsa-mir-34a	Holt-Oram Syndrome	27471727	genetic disease	DOID:0060468	Q87.2	C535326	142900		This approach allowed to discover complex regulatory circuits involving novel miRNAs and protein coding genes not considered before in the HOS such as miR-34a and miR-30 and their targets.
other	hsa-mir-155	Human Cytomegalovirus Infection	28642130			B25	D003586	609889		mir-155 expression is downregulated in kidney transplant patients with human cytomegalovirus infection.
other	hsa-mir-21	Human Cytomegalovirus Infection	28589873			B25	D003586	609889		Human cytomegalovirus microRNAs are carried by virions and dense bodies and are delivered to target cells.
other	hsa-mir-218	Human Cytomegalovirus Infection	28589873			B25	D003586	609889		Human cytomegalovirus microRNAs are carried by virions and dense bodies and are delivered to target cells.
other	hsa-let-7c	Human Immunodeficiency Virus Infection	25717002			B20	D015658	609423		Our data suggest that HIV-1 exploits the host miRNA cellular systems in order to block the innate inhibition mechanism, allowing a more efficient infection process.
other	hsa-mir-101-1	Human Immunodeficiency Virus Infection	23554480			B20	D015658	609423		HIV-1 Tat C Modulates Expression of miRNA-101 to Suppress VE-Cadherin in Human Brain Microvascular Endothelial Cells
other	hsa-mir-101-2	Human Immunodeficiency Virus Infection	23554480			B20	D015658	609423		HIV-1 Tat C Modulates Expression of miRNA-101 to Suppress VE-Cadherin in Human Brain Microvascular Endothelial Cells
other	hsa-mir-124a	Human Immunodeficiency Virus Infection	25717002			B20	D015658	609423		Our data suggest that HIV-1 exploits the host miRNA cellular systems in order to block the innate inhibition mechanism, allowing a more efficient infection process.
other	hsa-mir-125b	Human Immunodeficiency Virus Infection	24434277			B20	D015658	609423		Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.
other	hsa-mir-125b	Human Immunodeficiency Virus Infection	22527633			B20	D015658	609423		Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection.
other	hsa-mir-125b-1	Human Immunodeficiency Virus Infection	23251514			B20	D015658	609423		Cocaine Enhances HIV-1 Replication in CD4+ T Cells by Down-Regulating MiR-125b
other	hsa-mir-125b-2	Human Immunodeficiency Virus Infection	23251514			B20	D015658	609423		Cocaine Enhances HIV-1 Replication in CD4+ T Cells by Down-Regulating MiR-125b
other	hsa-mir-126	Human Immunodeficiency Virus Infection	28250134			B20	D015658	609423		MicroRNA miR-126-5p Enhances the Inflammatory Responses of Monocytes to Lipopolysaccharide Stimulation by Suppressing Cylindromatosis in Chronic HIV-1 Infection.
other	hsa-mir-1290	Human Immunodeficiency Virus Infection	26469550			B20	D015658	609423		Our study emphasizes the role of cellular miRNAs in HIV-1 latency regulation, and it suggests that inhibitors of miR-196b and miR-1290 could be used to activate latent HIV-1.
other	hsa-mir-132	Human Immunodeficiency Virus Infection	23357732			B20	D015658	609423		miR-132 enhances HIV-1 replication
other	hsa-mir-150	Human Immunodeficiency Virus Infection	24434277			B20	D015658	609423		Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.
other	hsa-mir-150	Human Immunodeficiency Virus Infection	22527633			B20	D015658	609423		Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection.
other	hsa-mir-150	Human Immunodeficiency Virus Infection	23094138			B20	D015658	609423		Here, we observed that the expression levels of the cellular factors Trim5α, CypA, APOBEC3G, SAMHD-1, Trim22, tetherin and TREX-1, and the anti-HIV miRNAs miR-28, miR-150, miR-223 and miR-382 was upregulated by IFN-α and IFN-β in macrophages, which may account for the inhibiting effect on viral replication and the antiviral state of these cells.
other	hsa-mir-155	Human Immunodeficiency Virus Infection	25873391			B20	D015658	609423		we demonstrate that TRIM32, an E3 ubiquitin ligase, promotes reactivation from latency by directly modifying IκBα, leading to a novel mechanism of NF-κB induction not involving IκB kinase activation.
other	hsa-mir-155	Human Immunodeficiency Virus Infection	24391808			B20	D015658	609423		Cocaine enhances HIV-1 infectivity in monocyte derived dendritic cells by suppressing microRNA-155.
other	hsa-mir-155	Human Immunodeficiency Virus Infection	26181817			B20	D015658	609423		Levels of miR-155 and miR-223 but not miR-92 were strongly correlated negatively with EV abundance and size in ART-naive patients.
other	hsa-mir-155	Human Immunodeficiency Virus Infection	27981723			B20	D015658	609423		MicroRNA-155 is a biomarker of T-cell activation and immune dysfunction in HIV-1-infected patients.
other	hsa-mir-196a	Human Immunodeficiency Virus Infection	24872081			B20	D015658	609423		Involvement of miR-196a in HIV-associated neurocognitive disorders.
other	hsa-mir-196b	Human Immunodeficiency Virus Infection	26469550			B20	D015658	609423		Our study emphasizes the role of cellular miRNAs in HIV-1 latency regulation, and it suggests that inhibitors of miR-196b and miR-1290 could be used to activate latent HIV-1.
other	hsa-mir-21	Human Immunodeficiency Virus Infection	24961346			B20	D015658	609423		Relevance of miR-21 in HIV and non-HIV-related lymphomas.
other	hsa-mir-21	Human Immunodeficiency Virus Infection	26473639			B20	D015658	609423		These data reveal specific regulation of plasma miR-21 in HIV,HIV/HCV coinfection, and PAH and suggest that miR-21 may integrate complex disease-specific signaling in the setting of HIV infection.
other	hsa-mir-221	Human Immunodeficiency Virus Infection	23555914			B20	D015658	609423		HIV Tat Induces Expression of ICAM-1 in HUVECs: Implications for miR-221/-222 in HIV-Associated Cardiomyopathy
other	hsa-mir-222	Human Immunodeficiency Virus Infection	23555914			B20	D015658	609423		HIV Tat Induces Expression of ICAM-1 in HUVECs: Implications for miR-221/-222 in HIV-Associated Cardiomyopathy
other	hsa-mir-223	Human Immunodeficiency Virus Infection	26181817			B20	D015658	609423		Levels of miR-155 and miR-223 but not miR-92 were strongly correlated negatively with EV abundance and size in ART-naive patients.
other	hsa-mir-223	Human Immunodeficiency Virus Infection	22527633			B20	D015658	609423		Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection.
other	hsa-mir-223	Human Immunodeficiency Virus Infection	23094138			B20	D015658	609423		Here, we observed that the expression levels of the cellular factors Trim5α, CypA, APOBEC3G, SAMHD-1, Trim22, tetherin and TREX-1, and the anti-HIV miRNAs miR-28, miR-150, miR-223 and miR-382 was upregulated by IFN-α and IFN-β in macrophages, which may account for the inhibiting effect on viral replication and the antiviral state of these cells.
other	hsa-mir-28	Human Immunodeficiency Virus Infection	24434277			B20	D015658	609423		Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.
other	hsa-mir-28	Human Immunodeficiency Virus Infection	22527633			B20	D015658	609423		Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection.
other	hsa-mir-28	Human Immunodeficiency Virus Infection	23094138			B20	D015658	609423		Here, we observed that the expression levels of the cellular factors Trim5α, CypA, APOBEC3G, SAMHD-1, Trim22, tetherin and TREX-1, and the anti-HIV miRNAs miR-28, miR-150, miR-223 and miR-382 was upregulated by IFN-α and IFN-β in macrophages, which may account for the inhibiting effect on viral replication and the antiviral state of these cells.
other	hsa-mir-29	Human Immunodeficiency Virus Infection	25808800			B20	D015658	609423		The miRNA-29 family could influence the clinical progression of HIV-1 infection, the HIV-1 proviral load and the innate immune response against HIV-1.
other	hsa-mir-29a	Human Immunodeficiency Virus Infection	25486977			B20	D015658	609423		links miR-29a to viral latency and suggests another approach to activate and destroy latent HIV-1 reservoirs.
other	hsa-mir-29a	Human Immunodeficiency Virus Infection	24103357			B20	D015658	609423		The lack of significant negative correlation of miR-29a and TTP expression levels suggests that while miR-29a may contribute to TTP regulation, additional factors are involved. Reduced TTP expression during acute infection is consistent with increased cytokine production during this phase of infection, but the increases in TTP observed during late-stage infection were insufficient to halt runaway cytokine levels.
other	hsa-mir-34a	Human Immunodeficiency Virus Infection	25717002			B20	D015658	609423		Our data suggest that HIV-1 exploits the host miRNA cellular systems in order to block the innate inhibition mechanism, allowing a more efficient infection process.
other	hsa-mir-34c	Human Immunodeficiency Virus Infection	27993935			B20	D015658	609423		miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication.
other	hsa-mir-382	Human Immunodeficiency Virus Infection	22527633			B20	D015658	609423		Researchers have recently demonstrated the presence of anti-HIV-1 microRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382) in monocytes, macrophages, and CD4+ T cells, which are the primary targets of HIV infection.
other	hsa-mir-382	Human Immunodeficiency Virus Infection	23094138			B20	D015658	609423		Here, we observed that the expression levels of the cellular factors Trim5α, CypA, APOBEC3G, SAMHD-1, Trim22, tetherin and TREX-1, and the anti-HIV miRNAs miR-28, miR-150, miR-223 and miR-382 was upregulated by IFN-α and IFN-β in macrophages, which may account for the inhibiting effect on viral replication and the antiviral state of these cells.
other	hsa-mir-500	Human Immunodeficiency Virus Infection	28594894			B20	D015658	609423		MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology.
other	hsa-mir-9	Human Immunodeficiency Virus Infection	29497921			B20	D015658	609423		Exosomal miR-9 Released from HIV Tat Stimulated Astrocytes Mediates Microglial Migration
other	hsa-mir-9-1	Human Immunodeficiency Virus Infection	23129528			B20	D015658	609423		The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection
other	hsa-mir-9-1	Human Immunodeficiency Virus Infection	23508624			B20	D015658	609423		Modulation of BK Channel by MicroRNA-9 in Neurons After Exposure to HIV and Methamphetamine
other	hsa-mir-9-2	Human Immunodeficiency Virus Infection	23129528			B20	D015658	609423		The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection
other	hsa-mir-93	Human Immunodeficiency Virus Infection	28594894			B20	D015658	609423		MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology.
other	hsa-let-7a	Human Papilloma Virus Infection	21442230			B97.7	D027383			HPV-38 was predicted to express an miRNA conserved to human let-7a and the expression of let-7a, in HPV-38-positive non-melanoma skin cancer (NMSC) biopsies was 10-fold higher than those with HPV-positive (for other types except HPV-38) and HPV-negative NMSCs, suggesting that let-7a expression might be related to HPV-38 infection.
other	hsa-mir-125b	Human Papilloma Virus Infection	26180794			B97.7	D027383			miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development.
other	hsa-mir-146a	Human Papilloma Virus Infection	28551628			B97.7	D027383			Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice.
other	hsa-mir-146a	Human Papilloma Virus Infection	29181576			B97.7	D027383			HPV16 induces the overexpression of miR-146a in the initial stages of carcinogenesis (hyperplasia and dysplasia), whereas decreases its expression at later stages (CIS)
other	hsa-mir-150	Human Papilloma Virus Infection	28551628			B97.7	D027383			Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice.
other	hsa-mir-205	Human Papilloma Virus Infection	24314651			B97.7	D027383			miR-24 and miR-205 expression is dependent on HPV onco-protein expression in keratinocytes.
other	hsa-mir-24	Human Papilloma Virus Infection	24314651			B97.7	D027383			miR-24 and miR-205 expression is dependent on HPV onco-protein expression in keratinocytes.
other	hsa-mir-34a	Human Papilloma Virus Infection	26180794			B97.7	D027383			miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development.
other	hsa-mir-137	Huntington Disease	23965969	nervous system disease	DOID:12858	G10	D006816	143100		Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs.
other	hsa-mir-137	Huntington Disease	23145961	nervous system disease	DOID:12858	G10	D006816	143100		We also identified several microRNAs (miRNAs) whose aberrant repression is directly mediated by REST, including miR-137, which has not previously been shown to be a direct REST target in mouse.
other	hsa-mir-148a	Huntington Disease	23965969	nervous system disease	DOID:12858	G10	D006816	143100		Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs.
other	hsa-mir-196a	Huntington Disease	23810380	nervous system disease	DOID:12858	G10	D006816	143100		miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models.
other	hsa-mir-196a	Huntington Disease	27631085	nervous system disease	DOID:12858	G10	D006816	143100		miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington's Disease Monkey Neural Cells.
other	hsa-mir-214	Huntington Disease	23965969	nervous system disease	DOID:12858	G10	D006816	143100		Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs.
other	hsa-mir-126	Hyperglycemia	27673690	disease of metabolism	DOID:4195	E78.1	D006943		HP:0003074	Hyperglycemia and Advanced Glycation End Products Regulate miR-126 Expression in Endothelial Progenitor Cells.
other	hsa-mir-221	Hyperglycemia	19351599	disease of metabolism	DOID:4195	E78.1	D006943		HP:0003074	miR-221: induced expression
other	hsa-mir-24	Hyperglycemia	26022048	disease of metabolism	DOID:4195	E78.1	D006943		HP:0003074	In this issue of Blood, Xiang et al identify a novel mechanism, involving activation of the polyol pathway and repression of microRNA-24 (miR-24), through which hyperglycemia augments von Willebrand factor (VWF) expression and secretion.
other	hsa-mir-24	Hyperlipidemia	24677249			E78.4	D006949		HP:0003077	Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
other	hsa-mir-33a	Hyperlipidemia	24928089			E78.4	D006949		HP:0003077	all selected miRNAs were detected in 伪-lipoprotein fraction from sera, and miR-33a was also present in 尾-lipoprotein fraction;
other	hsa-mir-103a-1	Hypertension	21753805	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MicroRNA-130a Mediates Proliferation of Vascular Smooth Muscle Cells in Hypertension.
other	hsa-mir-103a-2	Hypertension	21753805	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MicroRNA-130a Mediates Proliferation of Vascular Smooth Muscle Cells in Hypertension.
other	hsa-mir-126	Hypertension	21946298	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-133a	Hypertension	24937684	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	These results suggest that high salt intervention could down-regulate the expression of myocardial microRNA-133a, which may be one  of the mechanisms involved in myocardial fibrosis in salt-sensitive hypertension.
other	hsa-mir-155	Hypertension	27683672	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging.
other	hsa-mir-155	Hypertension	28360962	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Novel Immune Mechanisms in Hypertension and Cardiovascular Risk.
other	hsa-mir-155	Hypertension	21946298	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-17	Hypertension	22161164	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Inhibition of microRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension.
other	hsa-mir-17	Hypertension	21946298	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-204	Hypertension	21890685	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	These effects were associated with the inhibition of Src, STAT3, Pim1, NFATc2, and Survivin and the upregulation of BMPR2 and miR-204.
other	hsa-mir-204	Hypertension	22534459	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	This correlates with a down-regulation of miR-204 as well as an up-regulation of miR-21 in PLs, which in turn corresponds to enhanced cell proliferation.
other	hsa-mir-204	Hypertension	27438705	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Its pathological functions have been observed in a few diseases including pulmonary arterial hypertension, diabetes, and various types of cancers.
other	hsa-mir-204	Hypertension	28473439	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension.
other	hsa-mir-204	Hypertension	28565757	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	An exploratory study into the role of miR-204-5p in pregnancy-induced hypertension.
other	hsa-mir-204	Hypertension	29196166	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	1,25(OH)2D3 was a promising therapeutic modality for treatment of PAH, function of which was exerted through miR-204 mediated Tgfbr2 signaling
other	hsa-mir-208a	Hypertension	22666483	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	this work reveals an original aldosterone-dependent inhibition of miR-208a in hypertension, resulting in the inhibition of β-myosin heavy chain expression through the induction of its transcriptional repressor Sox6.
other	hsa-mir-208b	Hypertension	22666483	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Besides, the AH-induced increase of ßMyHC and its intronic miRNA-208b was prevented in AS-Ren.
other	hsa-mir-208b	Hypertension	29506053	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-26b, miR-208b and miR-499 show a distinct in profile in hypertensive patients with HFpEF that is related with functional capacity
other	hsa-mir-20a	Hypertension	22450430	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension.
other	hsa-mir-21	Hypertension	22371328	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension
other	hsa-mir-21	Hypertension	22534459	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	This correlates with a down-regulation of miR-204 as well as an up-regulation of miR-21 in PLs, which in turn corresponds to enhanced cell proliferation.
other	hsa-mir-21	Hypertension	28360962	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Novel Immune Mechanisms in Hypertension and Cardiovascular Risk.
other	hsa-mir-221	Hypertension	21946298	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-222	Hypertension	21946298	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-223	Hypertension	28473439	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension.
other	hsa-mir-24	Hypertension	23836801	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex.
other	hsa-mir-26b	Hypertension	29506053	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-26b, miR-208b and miR-499 show a distinct in profile in hypertensive patients with HFpEF that is related with functional capacity
other	hsa-mir-30a	Hypertension	23817492	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-30a regulates endothelial tip cell formation and arteriolar branching.
other	hsa-mir-31	Hypertension	21946298	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Other known miRNAs,including miR-31, miR17-3p, miR-155, miR-221, miR-222, and miR-126, are important factors in the regulation of vascular inflammation.
other	hsa-mir-425	Hypertension	27132035	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	After NaAsO2 treatment, we found the expression of microRNA-425-5p (miR-425-5p) was reduced in vitro and in vivo
other	hsa-mir-499	Hypertension	29506053	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-26b, miR-208b and miR-499 show a distinct in profile in hypertensive patients with HFpEF that is related with functional capacity
other	hsa-mir-1-1	Hypertrophy	20619221				D006984			miR-1:have a profound influence on multiple myopathies
other	hsa-mir-1-2	Hypertrophy	20619221				D006984			miR-1:have a profound influence on multiple myopathies
other	hsa-mir-133a-1	Hypertrophy	20619221				D006984			miR-133:have a profound influence on multiple myopathies
other	hsa-mir-133a-2	Hypertrophy	20619221				D006984			miR-133:have a profound influence on multiple myopathies
other	hsa-mir-142	Hypertrophy	22367739				D006984			Repression of miR-142 by p300 and MAPK is required for survival signaling via gp130 during adaptive hypertrophy.
other	hsa-mir-206	Hypertrophy	20619221				D006984			miR-206:have a profound influence on multiple myopathies
other	hsa-mir-208a	Hypertrophy	17786230				D006984			Clearly, miR-208 is also essential for expression of the genes involved in cardiac fibrosis and hypertrophic growth.
other	hsa-mir-21	Hypertrophy	22879939				D006984			TGFbeta-Stimulated MicroRNA-21 Utilizes PTEN to Orchestrate AKT/mTORC1 Signaling for Mesangial Cell Hypertrophy and Matrix Expansion.
other	hsa-mir-23a	Hypertrophy	22084234				D006984			Cardiac hypertrophy is positively regulated by miR-23a.
other	hsa-mir-26a-1	Hypertrophy	20525681				D006984			MiR-26a:stretch or enforced expression of miR-26a induces HASMC hypertrophy
other	hsa-mir-26a-2	Hypertrophy	20525681				D006984			MiR-26a:stretch or enforced expression of miR-26a induces HASMC hypertrophy
other	hsa-mir-26b	Hypertrophy	22219180				D006984			GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy.
other	hsa-mir-375	Hypogonadism	26219823	endocrine system disease	DOID:1924		D007006	241100		we identified miR-375 as an androgen regulated microRNA, which could play an important role for understanding the mechanism of the increase in visceral fat mass and the associated insulin resistance caused by testosterone deficiency.
other	hsa-mir-676	Hypohidrotic Ectodermal Dysplasia	29106399	musculoskeletal system disease	DOID:14793		D053358	PS305100	HP:0007607	A microRNA screen reveals that elevated hepatic ectodysplasin A expression contributes to obesity-induced insulin resistance in skeletal muscle.
other	hsa-mir-155	Hypoxia	27587248				D000860			Effect of miR- 155 on immune- factors and its mechanism in mesenchymal stem cells under hypoxic environment.
other	hsa-mir-18a	Hypoxia	29363860				D000860			ACE-EPCs-EXs  have better protective effects on H/R injury in ageing ECs which could be through their carried miR-18a and subsequently down-regulating the Nox2/ROS pathway
other	hsa-mir-34a	Hypoxia	29581146				D000860			Inhibition of miR-34a-5p alleviates hypoxia-reoxygenation injury by enhancing autophagy in steatotic hepatocytes
other	hsa-mir-34b	Hypoxia	25982511				D000860			Sevoflurane preconditioning-inhibited apoptosis and preconditioning-enhanced cell viability of PC12 cells were significantly attenuated by transfection of miR-101a mimetic or miR-34b inhibitors, but were significantly enhanced by transfection of miR-34b mimetic.
other	hsa-mir-17	Hypoxic-Ischemic Encephalopathy	29394934			P91.60	D020925			IRE1α inhibition decreased TXNIP/NLRP3 inflammasome activation through miR-17-5p after neonatal hypoxic-ischemic brain injury in rats
other	hsa-let-7d	Idiopathic Pulmonary Fibrosis	20395557	respiratory system disease	DOID:0050156	J84.112	D054990	178500		The down-regulation of let-7d in IPF and the profibrotic effects of this down-regulation in vitro and in vivo suggest a key regulatory role for this microRNA in preventing lung fibrosis.
other	hsa-let-7d	Idiopathic Pulmonary Fibrosis	26787543	respiratory system disease	DOID:0050156	J84.112	D054990	178500		Lin28B causes epithelial-mesenchymal transition (EMT) by inhibition of let-7d.
other	hsa-mir-26a	Idiopathic Pulmonary Fibrosis	24853416	respiratory system disease	DOID:0050156	J84.112	D054990	178500		Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis.
other	hsa-mir-155	IgA Nephropathy	27796698	urinary system disease	DOID:2986	N02.8	D005922	161950	HP:0000794	MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy.
other	hsa-mir-21	IgA Nephropathy	24468088	urinary system disease	DOID:2986	N02.8	D005922	161950	HP:0000794	Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy.
other	hsa-let-7i	Immune System Disease [unspecific]	21742974	immune system disease	DOID:2914	D89.9	D007154			Dynamic regulation of let-7i may fine-tune immune responses by inducing Ag-specific immune tolerance.
other	hsa-mir-146	Immune System Disease [unspecific]	26400897	immune system disease	DOID:2914	D89.9	D007154			Present review is focused on the current knowledge about the action of medicaments,microRNA molecules, exosomes and related vesicles on macrophages leading to modulation of their biological activity.
other	hsa-mir-146a	Immune System Disease [unspecific]	19965651	immune system disease	DOID:2914	D89.9	D007154			Our results demonstrate that several signaling pathways, other than inflammation, are influenced by miR-146a. In particular, we provide experimental evidence that miR-146a modulates activation-induced cell death (AICD), acting as an antiapoptotic factor, and that Fas-associated death domain (FADD) is a target of miR-146a.
other	hsa-mir-150	Immune System Disease [unspecific]	25690461	immune system disease	DOID:2914	D89.9	D007154			Our current studies characterized TsF as regulatory miRNA-150 carried by T suppressor cell-derived exosomes that are antigen specific due to a surface coat of IgM antibody light chains produced by B1a cells.
other	hsa-mir-155	Immune System Disease [unspecific]	24303979	immune system disease	DOID:2914	D89.9	D007154			Role of miR-155 in the regulation of lymphocyte immune function and disease.
other	hsa-mir-155	Immune System Disease [unspecific]	23949802	immune system disease	DOID:2914	D89.9	D007154			MicroRNA-155 drives TH17 immune response and tissue injury in experimental crescentic GN.
other	hsa-mir-15a	Immune System Disease [unspecific]	22578383	immune system disease	DOID:2914	D89.9	D007154			In conclusion, our data support the involvement of elevated miR-15a in autoimmune disease development in B/W mice and suggest that decreasing this microRNA might be beneficial in B/W mice.
other	hsa-mir-2909	Immune System Disease [unspecific]	25500259	immune system disease	DOID:2914	D89.9	D007154			a mechanistic-pathway is proposed that links the epigenomic-interplay between MALT1 and miR-2909.
other	hsa-mir-9	Immune System Disease [unspecific]	22585398	immune system disease	DOID:2914	D89.9	D007154			Using microarray and deep sequencing approaches, we detected an increase in the abundance of miR-9 in activated human CD4(+) T cells.
other	hsa-mir-92a	Immune System Disease [unspecific]	23355465	immune system disease	DOID:2914	D89.9	D007154			we have demonstrated that TLR-mediated miR-92a reduction feedback enhances TLR-triggered production of inflammatory cytokines in macrophages, thus outlining new mechanisms for fine-tuning the TLR-triggered inflammatory response.
other	hsa-let-7	Infection [unspecific]	19592657				D007239			Our data suggest that miR-98 and let-7 confer cholangiocyte expression of CIS in response to microbial challenge, a process that may be relevant to the regulation of TLR-mediated epithelial innate immune response.
other	hsa-let-7i	Infection [unspecific]	29069656				D007239			Cyclosporine A Induces MicroRNAs Controlling Innate Immunity during Renal Bacterial Infection.
other	hsa-mir-100	Infection [unspecific]	28181552				D007239			MicroRNA-100 is involved in shrimp immune response to white spot syndrome virus (WSSV) and Vibrio alginolyticus infection.
other	hsa-mir-132	Infection [unspecific]	29467760				D007239			MicroRNA Regulation of Host Immune Responses following Fungal Exposure
other	hsa-mir-140	Infection [unspecific]	27749761				D007239			Microrna Expression Profiling of Macrophage Line Raw264.7 Infected by Candida Albicans.
other	hsa-mir-143	Infection [unspecific]	28870451				D007239			MicroRNA-based transcriptomic responses of Atlantic salmon during infection by the intracellular bacterium Piscirickettsia salmonis.
other	hsa-mir-146a	Infection [unspecific]	29467760				D007239			MicroRNA Regulation of Host Immune Responses following Fungal Exposure
other	hsa-mir-146a	Infection [unspecific]	27297392				D007239			miR-146a was found to be differentially regulated in THP-1 cells between probiotic and pathogenic bacteria.
other	hsa-mir-146a	Infection [unspecific]	28319200				D007239			Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera.
other	hsa-mir-155	Infection [unspecific]	26072128				D007239			An update on the role of miRNA-155 in pathogenic microbial infections.
other	hsa-mir-155	Infection [unspecific]	28319200				D007239			Induction of immunomodulatory miR-146a and miR-155 in small intestinal epithelium of Vibrio cholerae infected patients at acute stage of cholera.
other	hsa-mir-15a	Infection [unspecific]	22953717				D007239			Moreover, miR-664-5p, miR-451 and miR-15a appear as very promising candidates for microRNAs involved in response to pathogen infection.
other	hsa-mir-181	Infection [unspecific]	28870451				D007239			MicroRNA-based transcriptomic responses of Atlantic salmon during infection by the intracellular bacterium Piscirickettsia salmonis.
other	hsa-mir-21	Infection [unspecific]	28870451				D007239			MicroRNA-based transcriptomic responses of Atlantic salmon during infection by the intracellular bacterium Piscirickettsia salmonis.
other	hsa-mir-21	Infection [unspecific]	28589100				D007239			MicroRNA-21 Limits Uptake of Listeria monocytogenes by Macrophages to Reduce the Intracellular Niche and Control Infection.
other	hsa-mir-21	Infection [unspecific]	28083515				D007239			Genome-Wide Transcriptional and Post-transcriptional Regulation of Innate Immune and Defense Responses of Bovine Mammary Gland to Staphylococcus aureus.
other	hsa-mir-221	Infection [unspecific]	29698854				D007239			Avian leukosis virus subgroup J promotes cell proliferation and cell cycle progression through miR-221 by targeting CDKN1B.
other	hsa-mir-223	Infection [unspecific]	28083515				D007239			Genome-Wide Transcriptional and Post-transcriptional Regulation of Innate Immune and Defense Responses of Bovine Mammary Gland to Staphylococcus aureus.
other	hsa-mir-29b	Infection [unspecific]	28394930				D007239			Analysis of host microRNA function uncovers a role for miR-29b-2-5p in Shigella capture by filopodia.
other	hsa-mir-451	Infection [unspecific]	28378118				D007239			miR-451 limits CD4+ T cell proliferative responses to infection in mice.
other	hsa-mir-451	Infection [unspecific]	22953717				D007239			Moreover, miR-664-5p, miR-451 and miR-15a appear as very promising candidates for microRNAs involved in response to pathogen infection.
other	hsa-mir-664	Infection [unspecific]	22953717				D007239			Moreover, miR-664-5p, miR-451 and miR-15a appear as very promising candidates for microRNAs involved in response to pathogen infection.
other	hsa-mir-9	Infection [unspecific]	28031262				D007239			Pseudomonas aeruginosa GroEL Stimulates Production of PTX3 by Activating the NF-κB Pathway and Simultaneously Downregulating MicroRNA-9.
other	hsa-mir-98	Infection [unspecific]	19592657				D007239			Our data suggest that miR-98 and let-7 confer cholangiocyte expression of CIS in response to microbial challenge, a process that may be relevant to the regulation of TLR-mediated epithelial innate immune response.
other	hsa-mir-155	Infectious Bursal Disease Virus	29564226				D007243			gga-miR-155 plays a critical role in cell response to IBDV infection
other	hsa-mir-122	Infertility	26648257	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Altered miRNA Signature of Developing Germ-cells in Infertile Patients Relates to the Severity of Spermatogenic Failure and Persists in Spermatozoa.
other	hsa-mir-17	Infertility	29402772	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice
other	hsa-mir-18	Infertility	29402772	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice
other	hsa-mir-19a	Infertility	29402772	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice
other	hsa-mir-19b-1	Infertility	29402772	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice
other	hsa-mir-20a	Infertility	29402772	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice
other	hsa-mir-34c	Infertility	26648257	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Altered miRNA Signature of Developing Germ-cells in Infertile Patients Relates to the Severity of Spermatogenic Failure and Persists in Spermatozoa.
other	hsa-mir-449a	Infertility	26648257	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Altered miRNA Signature of Developing Germ-cells in Infertile Patients Relates to the Severity of Spermatogenic Failure and Persists in Spermatozoa.
other	hsa-mir-92-1	Infertility	29402772	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Ablation of the MiR-17-92 MicroRNA Cluster in Germ Cells Causes Subfertility in Female Mice
other	hsa-mir-1	Inflammation	21385380				D007249			Acute noxious stimulation with capsaicin also increased the expression of miR-1 and -16 in DRG cells but, on the other hand, in the spinal dorsal horn only a high dose of capsaicin was able to downregulate miR-206 expression.
other	hsa-mir-101	Inflammation	26087518				D007249			Advances in understanding the roles of microRNA-101 in inflammation, fibrosis and cancer
other	hsa-mir-122	Inflammation	26657215				D007249			In addition to the classical Jak-Stat antiviral signaling pathway,IFN-λ1 inhibits HCV replication through the suppression of miRNA-122 transcription via an inflammatory Stat 3-HNF4α feedback loop. Inflammatory feedback circuits activated by IFNs during chronic inflammation expose non-responders to the risk of hepatocellular carcinoma.
other	hsa-mir-125b	Inflammation	20435889				D007249			The process required to disrupt protein synthesis followed Toll-like receptor 4 (TLR4)-dependent induction of microRNA (miR)-221, miR-579, and miR-125b, which coupled with RNA-binding proteins TTP, AUF1, and TIAR at the 3'-untranslated region to arrest protein synthesis.
other	hsa-mir-125b	Inflammation	22456625				D007249			Targets of miR-125b include key proteins regulating apoptosis, innate immunity, inflammation and hematopoietic differentiation.
other	hsa-mir-125b	Inflammation	29354323				D007249			Up-Regulation of the Pro-Inflammatory Cytokines IL-6 and TNFα, C-Reactive Protein (CRP) and miRNA-146a in Blood Serum
other	hsa-mir-126	Inflammation	22419694				D007249			MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation.
other	hsa-mir-126	Inflammation	25300227				D007249			Polyphenolic extracts from cowpea (Vigna unguiculata) protect colonic myofibroblasts (CCD18Co cells) from lipopolysaccharide (LPS)-induced inflammation--modulation of microRNA 126.
other	hsa-mir-132	Inflammation	20005135				D007249			MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase
other	hsa-mir-132	Inflammation	20064444				D007249			Boosting the brain's ability to block inflammation via microRNA-132.
other	hsa-mir-132	Inflammation	22362752				D007249			we propose an outline of the current knowledge about miR-132 and miR-212 functions in neurons and immune cells
other	hsa-mir-132	Inflammation	28209997				D007249			Antisense miR-132 blockade via the AChE-R splice variant mitigates cortical inflammation.
other	hsa-mir-132	Inflammation	27378528				D007249			LPS down-regulated the expression of miRNA-132.
other	hsa-mir-143	Inflammation	26739093				D007249			Staphylococcal LTA-Induced miR-143 Inhibits Propionibacterium acnes-Mediated Inflammatory Response in Skin
other	hsa-mir-146	Inflammation	24035832				D007249			Our findings reveal a novel regulatory module of two miRNA-mediated negative feedback loops that allows for the fine-tuning of the dynamics of key mediators in inflammation.
other	hsa-mir-146	Inflammation	29601548				D007249			the NF-κB-miR-146 and NF-κB-miR-155 networks fine-tune the activity, intensity, and duration of inflammation, while the NF-κB-miR-21 and NF-κB-miR-181b-1 amplifying loops link inflammation to cancer
other	hsa-mir-146a	Inflammation	20214679				D007249			miR-146a in reactive astrocytes supports the possible involvement of miRNAs in the modulation of the astroglial inflammatory response
other	hsa-mir-146a	Inflammation	20384865				D007249			functional role of miR-146a in innate immune, inflammatory response, virus infection and human diseases
other	hsa-mir-146a	Inflammation	25805648				D007249			the model of endotoxin tolerance is suitable for the antagonistic effects on the dysregulation of ABCA1/G1 induced by high dose of P.g LPS.Conversely, low-dose AGEs did not induce the model of P.g LPS-mediated tolerance.
other	hsa-mir-146a	Inflammation	26956852				D007249			Effect of High MiR-146a Expression on the Inflammatory Reaction in BV2 Cells.
other	hsa-mir-146a	Inflammation	22371089				D007249			miR-146a and miR-147 are involved in the resolution phase of inflammation.
other	hsa-mir-146a	Inflammation	27256622				D007249			These effects were partially mediated through RvD2 induction of microRNA-146a
other	hsa-mir-146a	Inflammation	27998828				D007249			we reported an anti-inflammatory effect of resveratrol and hydroxytyrosol at low, nutritionally  relevant concentrations, involving the inhibition of granulocytes and monocytes activation, the modulation of miR-146a expression and the activation of Nrf2
other	hsa-mir-146a	Inflammation	26718614				D007249			miR-146a inhibits inflammatory activation.
other	hsa-mir-146b	Inflammation	18390754				D007249			Overall, these studies indicate that rapid increase in miRNA-146a expression provides a novel mechanism for the negative regulation of severe inflammation during the innate immune response.
other	hsa-mir-147	Inflammation	22371089				D007249			miR-146a and miR-147 are involved in the resolution phase of inflammation.
other	hsa-mir-155	Inflammation	21282106				D007249			Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyper-expression of interleukin-8.
other	hsa-mir-155	Inflammation	18940871				D007249			Finally, we demonstrate that LMP1-mediated activation of miR-155 in an EBV-negative background correlates with reduction of protein PU.1, which is a possible miR target.
other	hsa-mir-155	Inflammation	27981414				D007249			MicroRNA-155: a Novel Armamentarium Against Inflammatory Diseases.
other	hsa-mir-155	Inflammation	29601548				D007249			the NF-κB-miR-146 and NF-κB-miR-155 networks fine-tune the activity, intensity, and duration of inflammation, while the NF-κB-miR-21 and NF-κB-miR-181b-1 amplifying loops link inflammation to cancer
other	hsa-mir-16	Inflammation	21385380				D007249			Acute noxious stimulation with capsaicin also increased the expression of miR-1 and -16 in DRG cells but, on the other hand, in the spinal dorsal horn only a high dose of capsaicin was able to downregulate miR-206 expression.
other	hsa-mir-181a	Inflammation	18291670				D007249			MiRNAs are implicated in establishing and maintaining the cell fate of immune cells (e.g. miR-181a and miR-223), and they are involved in innate immunity by regulating Toll-like receptor signaling and ensuing cytokine response (e.g. miR-146).
other	hsa-mir-181a	Inflammation	29535629				D007249			we provide the first evidence for the negative regulation of miR-181a in LPS-induced inflammation via the suppression of ROS generation and TLR4-NF-κB pathway
other	hsa-mir-181a-2	Inflammation	23220232				D007249			miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo
other	hsa-mir-182	Inflammation	28045967				D007249			Induction of Multiple miR-200/182 Members in the Brains of Mice Are Associated with Acute Herpes Simplex Virus 1 Encephalitis.
other	hsa-mir-183	Inflammation	28045967				D007249			Induction of Multiple miR-200/182 Members in the Brains of Mice Are Associated with Acute Herpes Simplex Virus 1 Encephalitis.
other	hsa-mir-203	Inflammation	18291670				D007249			MiRNAs are implicated in establishing and maintaining the cell fate of immune cells (e.g. miR-181a and miR-223), and they are involved in innate immunity by regulating Toll-like receptor signaling and ensuing cytokine response (e.g. miR-146).
other	hsa-mir-206	Inflammation	21385380				D007249			Acute noxious stimulation with capsaicin also increased the expression of miR-1 and -16 in DRG cells but, on the other hand, in the spinal dorsal horn only a high dose of capsaicin was able to downregulate miR-206 expression.
other	hsa-mir-21	Inflammation	24035832				D007249			Our findings reveal a novel regulatory module of two miRNA-mediated negative feedback loops that allows for the fine-tuning of the dynamics of key mediators in inflammation.
other	hsa-mir-210	Inflammation	20237418				D007249			miR-210 appears to function as a master microRNA relevant for the control of diverse functions in the hypoxic state
other	hsa-mir-210	Inflammation	21467158				D007249			miRNA-210 is a good example in this category that impairs wound closure.
other	hsa-mir-210	Inflammation	27983913				D007249			Precise Regulation of miR-210 Is Critical for the Cellular Homeostasis Maintenance and Transplantation Efficacy Enhancement of Mesenchymal Stem Cells in Acute Liver Failure Therapy.
other	hsa-mir-210	Inflammation	28188219				D007249			Distinct Effects of miR-210 Reduction on Neurogenesis: Increased Neuronal Survival of Inflammation But Reduced Proliferation Associated with Mitochondrial Enhancement.
other	hsa-mir-212	Inflammation	22362752				D007249			we propose an outline of the current knowledge about miR-132 and miR-212 functions in neurons and immune cells
other	hsa-mir-219-2	Inflammation	22957142				D007249			Delayed resolution undermines endogenous resolution programs, altering miR-219-2 expression, increasing pro-inflammatory mediators and compromising SPM production that contribute to failed catabasis and homeostasis.
other	hsa-mir-22	Inflammation	26088024				D007249			extracellular Adenosine and uridine triphosphate (ATP and UTP) can attenuate ICAM-1 expression and leukocyte adhesion in endothelial cells through miR-22.
other	hsa-mir-221	Inflammation	20110463				D007249			Functional inhibition of miR-221 with anti-miR-221 induced ICAM-1 protein expression. Moreover, IFN-gamma stimulation decreased miR-221 expression in cholangiocytes in a signal transducer and activator of transcription 1-dependent manner.
other	hsa-mir-221	Inflammation	20435889				D007249			The process required to disrupt protein synthesis followed Toll-like receptor 4 (TLR4)-dependent induction of microRNA (miR)-221, miR-579, and miR-125b, which coupled with RNA-binding proteins TTP, AUF1, and TIAR at the 3'-untranslated region to arrest protein synthesis.
other	hsa-mir-221	Inflammation	27731391				D007249			Epithelial cell-derived microvesicles activate macrophages and promote inflammation via microvesicle-containing microRNAs.
other	hsa-mir-222	Inflammation	26081516				D007249			In pathological hyperglycaemic conditions, EMP-mediated miR-222-dependent anti-inflammatory effects are reduced.
other	hsa-mir-223	Inflammation	25997943				D007249			we found that different doses of acute aerobic exercise induced a distinct and specific c-inflammamiR response, which may be associated with control of the exercise-induced inflammatory cascade. Our  findings point to c-inflammamiRs as potential biomarkers of exercise-induced inflammation, and hence, exercise dose.
other	hsa-mir-223	Inflammation	27999792				D007249			Inflammation Related MicroRNAs Are Modulated in Total Plasma and in Extracellular Vesicles from Rats with Chronic Ingestion of Sucrose.
other	hsa-mir-223	Inflammation	29444433				D007249			MicroRNA-223 Suppresses the Canonical NF-κB Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation
other	hsa-mir-24-1	Inflammation	21282569				D007249			Role of miR-204 in the regulation of apoptosis, ER stress response, and inflammation in human trabecular meshwork cells.
other	hsa-mir-24-2	Inflammation	21282569				D007249			Role of miR-204 in the regulation of apoptosis, ER stress response, and inflammation in human trabecular meshwork cells.
other	hsa-mir-27b	Inflammation	20164187				D007249			We provide evidence that LPS-induced miR-27b contributes to destabilization of PPARgamma1 mRNA. Understanding molecular mechanisms decreasing PPARgamma might help to better appreciate inflammatory diseases.
other	hsa-mir-29a	Inflammation	25997943				D007249			we found that different doses of acute aerobic exercise induced a distinct and specific c-inflammamiR response, which may be associated with control of the exercise-induced inflammatory cascade. Our  findings point to c-inflammamiRs as potential biomarkers of exercise-induced inflammation, and hence, exercise dose.
other	hsa-mir-33a	Inflammation	21285396				D007249			miR-33 reduces RIP140 coactivator activity for NF-kB, which is supported by the reduction in NF-kB reporter activity and the inflammatory potential in macrophages.
other	hsa-mir-33b	Inflammation	21285396				D007249			miR-33 reduces RIP140 coactivator activity for NF-kB, which is supported by the reduction in NF-kB reporter activity and the inflammatory potential in macrophages.
other	hsa-mir-34a	Inflammation	25997943				D007249			we found that different doses of acute aerobic exercise induced a distinct and specific c-inflammamiR response, which may be associated with control of the exercise-induced inflammatory cascade. Our  findings point to c-inflammamiRs as potential biomarkers of exercise-induced inflammation, and hence, exercise dose.
other	hsa-mir-424	Inflammation	25997943				D007249			we found that different doses of acute aerobic exercise induced a distinct and specific c-inflammamiR response, which may be associated with control of the exercise-induced inflammatory cascade. Our  findings point to c-inflammamiRs as potential biomarkers of exercise-induced inflammation, and hence, exercise dose.
other	hsa-mir-4661	Inflammation	24238336				D007249			The bipolar role of miR-4661 in inflammation.
other	hsa-mir-579	Inflammation	20435889				D007249			The process required to disrupt protein synthesis followed Toll-like receptor 4 (TLR4)-dependent induction of microRNA (miR)-221, miR-579, and miR-125b, which coupled with RNA-binding proteins TTP, AUF1, and TIAR at the 3'-untranslated region to arrest protein synthesis.
other	hsa-mir-93	Inflammation	24433094				D007249			Expression of microRNA-93 and Interleukin-8 during Pseudomonas aeruginosa-mediated induction of proinflammatory responses.
other	hsa-mir-98	Inflammation	27913008				D007249			MicroRNA-98 plays a critical role in experimental myocarditis.
other	hsa-mir-100	Inflammation	26209130				D007249			Such delicately counterbalanced systems are a hallmark of immune plasticity and we propose that miR-100 editing is a novel mechanism toward this end.
other	hsa-mir-125b	Inflammation	26954942				D007249			MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response.
other	hsa-mir-1270	Inflammation	25746225				D007249			This coordinated regulatory architecture suggests a vital function for the innate immune system in maintaining precise physiological type I IFN levels via post-transcriptional regulatory mechanisms.
other	hsa-mir-146a	Inflammation	24607549				D007249			In conclusion several aging-related mitomiRs may play a direct role in controlling mitochondrial function by regulating mitochondrial protein expression. Their modulation could thus mediate the loss of mitochondrial integrity and function in aging cells, inducing or contributing to the inflammatory response and to age-related diseases.
other	hsa-mir-17	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-18	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-19a	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-19b	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-19b-1	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-20a	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-21	Inflammation	27075111				D007249			Extracellular microRNA-21 and microRNA-26a increase in body fluids from rats with antigen induced pulmonary inflammation and children with recurrent wheezing.
other	hsa-mir-24	Inflammation	25358394				D007249			miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development.
other	hsa-mir-26a	Inflammation	27075111				D007249			Extracellular microRNA-21 and microRNA-26a increase in body fluids from rats with antigen induced pulmonary inflammation and children with recurrent wheezing.
other	hsa-mir-33a	Inflammation	25329888				D007249			Effects of miR-33a-5P on ABCA1/G1-mediated cholesterol efflux under inflammatory stress in THP-1 macrophages.
other	hsa-mir-34a	Inflammation	24607549				D007249			In conclusion several aging-related mitomiRs may play a direct role in controlling mitochondrial function by regulating mitochondrial protein expression. Their modulation could thus mediate the loss of mitochondrial integrity and function in aging cells, inducing or contributing to the inflammatory response and to age-related diseases.
other	hsa-mir-449c	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-455	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-92-1	Inflammation	25979460				D007249			Our finding that certain miRNAs may de-repress critical acute phase proteins within acute timeframes has important biological and clinical implications.
other	hsa-mir-129	Inflammatory Bowel Diseases	26003847	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	TLR9 aptamers may hence potentiate miRNA regulation that enhances cholinergic signaling and the resolution of inflammation, which opens new venues for manipulating bowel diseases.
other	hsa-mir-133a	Inflammatory Bowel Diseases	28104982	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	miRNA-133a-UCP2 pathway regulates inflammatory bowel disease progress by influencing inflammation, oxidative stress and energy metabolism.
other	hsa-mir-155	Inflammatory Bowel Diseases	23288924	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	OVER EXPRESSION OF MICRORNAS-155 AND 21 TARGETING MISMATCH REPAIR PROTEINS IN INFLAMMATORY BOWEL DISEASES
other	hsa-mir-186	Inflammatory Bowel Diseases	26003847	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	TLR9 aptamers may hence potentiate miRNA regulation that enhances cholinergic signaling and the resolution of inflammation, which opens new venues for manipulating bowel diseases.
other	hsa-mir-200c	Inflammatory Bowel Diseases	26003847	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	TLR9 aptamers may hence potentiate miRNA regulation that enhances cholinergic signaling and the resolution of inflammation, which opens new venues for manipulating bowel diseases.
other	hsa-mir-21	Inflammatory Bowel Diseases	23224068	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis
other	hsa-mir-21	Inflammatory Bowel Diseases	23288924	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	OVER EXPRESSION OF MICRORNAS-155 AND 21 TARGETING MISMATCH REPAIR PROTEINS IN INFLAMMATORY BOWEL DISEASES
other	hsa-mir-31	Inflammatory Bowel Diseases	25665881	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Differential expression of miR-31 between inflammatory bowel disease and microscopic colitis.
other	hsa-let-7b	Influenza	25788763	respiratory system disease	DOID:8469	J09-J11	D007251	614680		This approach provides an additional layer of biosafety and thus has great potential for the application in the rational development of safer and more effective influenza viral vaccines.
other	hsa-let-7b	Influenza	26163223	respiratory system disease	DOID:8469	J09-J11	D007251	614680		These results indicate that the influenza virus containing microRNA response elements (MREs) is attenuated in vivo and can be used to design a live attenuated vaccine.
other	hsa-let-7c	Influenza	22452878	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Cellular MicroRNA let-7c Inhibits M1 Protein Expression of the H1N1 Influenza A Virus in Infected Human Lung Epithelial Cells.
other	hsa-mir-126	Influenza	28282445	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Endothelial cell tropism is a determinant of H5N1 pathogenesis in mammalian species.
other	hsa-mir-146a	Influenza	23343627	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a
other	hsa-mir-148a	Influenza	23731466	respiratory system disease	DOID:8469	J09-J11	D007251	614680		QRT-PCR assay and ROC curve analyses revealed that miR-31, miR-29a and miR-148a all had significant potential diagnostic value for critically ill patients infected with H1N1 influenza virus
other	hsa-mir-150	Influenza	26148929	respiratory system disease	DOID:8469	J09-J11	D007251	614680		The up-regulation of miR-150 is associated with poorer outcomes of A/H1N1 infection. The differential expression of miRNAs related with immune processes in severe A/H1N1 disease supports the potential role of these miRNAs as biomarkers of disease progression.
other	hsa-mir-155	Influenza	28392443	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome.
other	hsa-mir-15b	Influenza	21872652	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Ginsenoside metabolite protopanaxatriol showed significant suppression effect on IP-10 production upon H9N2/G1 infection through up-regulation of miR-15b expression.
other	hsa-mir-192	Influenza	23934176	respiratory system disease	DOID:8469	J09-J11	D007251	614680		MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies.
other	hsa-mir-29a	Influenza	26000345	respiratory system disease	DOID:8469	J09-J11	D007251	614680		With assay optimization, the detection limit of our MARS assay for miR-29a-3p was found to be 1 nM, and this new assay could be completed within 1 hour without thermal cycling. This non-PCR assay with high selectivity for mature microRNA provides a new platform for rapid disease diagnosis, quarantine and disease control.
other	hsa-mir-29a	Influenza	23731466	respiratory system disease	DOID:8469	J09-J11	D007251	614680		QRT-PCR assay and ROC curve analyses revealed that miR-31, miR-29a and miR-148a all had significant potential diagnostic value for critically ill patients infected with H1N1 influenza virus
other	hsa-mir-29c	Influenza	24953694	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA.
other	hsa-mir-30	Influenza	26296570	respiratory system disease	DOID:8469	J09-J11	D007251	614680		RNA interference of influenza A virus replication by microRNA-adapted lentiviral loop short hairpin RNA.
other	hsa-mir-31	Influenza	23731466	respiratory system disease	DOID:8469	J09-J11	D007251	614680		QRT-PCR assay and ROC curve analyses revealed that miR-31, miR-29a and miR-148a all had significant potential diagnostic value for critically ill patients infected with H1N1 influenza virus
other	hsa-mir-33a	Influenza	26498766	respiratory system disease	DOID:8469	J09-J11	D007251	614680		In conclusion, we found that miR-33a is a novel inhibitory factor for influenza A virus replication.
other	hsa-mir-548a	Influenza	24210102	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Expression of non-structural-1A binding protein in lung epithelial cells is modulated by miRNA-548an on exposure to influenza A virus.
other	hsa-mir-590	Influenza	29677213	respiratory system disease	DOID:8469	J09-J11	D007251	614680		IFN-λ and microRNAs are important modulators of the pulmonary innate immune response against influenza A (H1N2) infection in pigs
other	hsa-mir-650	Influenza	26460926	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Together these findings reveal a novel link between miR-650 and the innate immune response in human MDDCs.
other	hsa-mir-137	Intellectual Disability	26095359	disease of mental health	DOID:1059	F79	D008607	617991		Our findings suggest that miR-137 is a key factor in the control of synaptic efficacy and mGluR-dependent synaptic plasticity, supporting the notion that glutamatergic dysfunction contributes to the pathogenesis of miR-137-linked cognitive impairments.
other	hsa-mir-199a-1	Interstitial Cystitis	23201090	urinary system disease	DOID:13949	N30.10-.11	D018856			miR-199a-5p Regulates Urothelial Permeability and May Play a Role in Bladder Pain Syndrome
other	hsa-mir-199a-2	Interstitial Cystitis	23201090	urinary system disease	DOID:13949	N30.10-.11	D018856			miR-199a-5p Regulates Urothelial Permeability and May Play a Role in Bladder Pain Syndrome
other	hsa-mir-222	Intervertebral Disc Degeneration	26134418	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	a comprehensive microRNA-222 and microRNA-589 gene regulatory network was constructed, which was found to be important in IDD progression.
other	hsa-mir-589	Intervertebral Disc Degeneration	26134418	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	a comprehensive microRNA-222 and microRNA-589 gene regulatory network was constructed, which was found to be important in IDD progression.
other	hsa-mir-31	Intestinal Schistosomiasis	19997615	disease by infectious agent	DOID:0050597	B65.1	D012554	181460		some nucleotides at many positions of Schistosoma miRNAs, such as miR-8, let-7, miR-10, miR-31, miR-92, miR-124, and miR-125, are indeed significantly distinct from other bilaterian orthologs
other	hsa-mir-155	Intracerebral Hemorrhage	19724284			I60.1	D002543		HP:0001342	correlate
other	hsa-mir-298	Intracerebral Hemorrhage	19724284			I60.1	D002543		HP:0001342	correlate
other	hsa-mir-362	Intracerebral Hemorrhage	19724284			I60.1	D002543		HP:0001342	correlate
other	hsa-mir-126	Intracerebral Hemorrhage	28112373			I60.1	D002543		HP:0001342	Protective role of microRNA-126 in intracerebral hemorrhage.
other	hsa-mir-132	Intracerebral Hemorrhage	27940326			I60.1	D002543		HP:0001342	MicroRNA-132 attenuates neurobehavioral and neuropathological changes associated with intracerebral hemorrhage in mice.
other	hsa-mir-195	Intrahepatic Cholangiocarcinoma	27474881	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and  improve survival in a rat model.
other	hsa-mir-221	Intrahepatic Cholangiocarcinoma	27280413	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		no correlation was found between the expression levels of these molecular markers and histopathological differentiation grade.
other	hsa-mir-29a	Irritable Bowel Syndrome	19951903	syndrome	DOID:9778	K58	D043183			miR-29a:MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome
other	hsa-mir-126	Ischemia	21856785	cardiovascular system disease	DOID:326		D007511	601367		MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1+/Lin- progenitor cells in ischemia.
other	hsa-mir-126	Ischemia	29242072	cardiovascular system disease	DOID:326		D007511	601367		Therapeutic angiogenesis by local sustained release of microRNA-126 using poly lactic-co-glycolic acid nanoparticles in murine hindlimb ischemia
other	hsa-mir-155	Ischemia	22052914	cardiovascular system disease	DOID:326		D007511	601367		Inhibition of miR-15 Protects Against Cardiac Ischemic Injury.
other	hsa-mir-210	Ischemia	20237418	cardiovascular system disease	DOID:326		D007511	601367		miR-210 appears to function as a master microRNA relevant for the control of diverse functions in the hypoxic state
other	hsa-mir-592	Ischemia	29402808	cardiovascular system disease	DOID:326		D007511	601367		Effects of MicroRNA-592-5p on Hippocampal Neuron Injury Following Hypoxic-Ischemic Brain Damage in Neonatal Mice - Involvement of PGD2/DP and PTGDR.
other	hsa-mir-146a	Ischemia-Reperfusion Injury	28771774				D015427			MiR-146a protects small intestine against ischemia/reperfusion injury by down-regulating TLR4/TRAF6/NF-κB pathway.
other	hsa-mir-155	Ischemia-Reperfusion Injury	25916938				D015427			MicroRNA-155 aggravates ischemia-reperfusion injury by modulation of inflammatory cell recruitment and the respiratory oxidative burst.
other	hsa-mir-155	Ischemia-Reperfusion Injury	28640790				D015427			MicroRNA-155 Deficiency in Kupffer Cells Ameliorates Liver Ischemia-Reperfusion Injury in Mice.
other	hsa-mir-192	Ischemia-Reperfusion Injury	27870736				D015427			Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia-Reperfusion Injury.
other	hsa-mir-192	Ischemia-Reperfusion Injury	28035621				D015427			Implications of dynamic changes in miR-192 expression in ischemic acute kidney injury.
other	hsa-mir-204	Ischemia-Reperfusion Injury	28714326				D015427			miR-204 inhibitor upregulated the activity and expression of RAP2C, while miR-204 mimic played the opposite role
other	hsa-mir-21	Ischemia-Reperfusion Injury	25159851				D015427			miR-21 in ischemia/reperfusion injury: a double-edged sword
other	hsa-mir-21	Ischemia-Reperfusion Injury	24676391				D015427			microRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/Akt-dependent mechanism.
other	hsa-mir-21	Ischemia-Reperfusion Injury	26168042				D015427			losartan treatment significantly increased microRNA (miR)-1, -15b, -92a, -133a, -133b, -210, and -499 expression but decreased miR-21 in the left ventricle.
other	hsa-mir-21	Ischemia-Reperfusion Injury	22785173				D015427			Thus, upregulation of miR-21 contributes to the protective effect of delayed ischemic preconditioning against subsequent renal ischemia-reperfusion injury.
other	hsa-mir-21	Ischemia-Reperfusion Injury	23719532				D015427			MiR-21 expression is down-regulated and cell apoptosis is increased in rat myocardium during early ischemia-reperfusion injury. 
other	hsa-mir-21	Ischemia-Reperfusion Injury	25536091				D015427			isoflurane mediates  protection of cardiomyocytes against oxidative stress via an miR-21/programmed cell death protein 4 pathway.
other	hsa-mir-21	Ischemia-Reperfusion Injury	26259139				D015427			Isoflurane protects mouse hearts from ischemia-reperfusion injury by a microRNA-21-dependent mechanism.
other	hsa-mir-21	Ischemia-Reperfusion Injury	27804287				D015427			Fluorescent Nanocomposite for Visualizing Cross-Talk between MicroRNA-21 and Hydrogen Peroxide in Ischemia-Reperfusion Injury in Live Cells and In Vivo.
other	hsa-mir-21	Ischemia-Reperfusion Injury	29170412				D015427			Ischemic Postconditioning Protects Against Intestinal Ischemia/Reperfusion Injury via the HIF-1α/miR-21 Axis
other	hsa-mir-21	Ischemia-Reperfusion Injury	29187695				D015427			the activation of the Akt pathway regulated by miR-21 participates in the protective effects of H2S against I/R-induced liver injury
other	hsa-mir-21	Ischemia-Reperfusion Injury	29506703				D015427			Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction
other	hsa-mir-223	Ischemia-Reperfusion Injury	27635859				D015427			Neuroprotective effect of ischemic preconditioning via modulating the expression of cerebral miRNAs against transient cerebral ischemia in diabetic rats.
other	hsa-mir-24	Ischemia-Reperfusion Injury	24854275				D015427			MicroRNA-24 antagonism prevents renal ischemia reperfusion injury.
other	hsa-mir-27a	Ischemia-Reperfusion Injury	24009229				D015427			Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27.
other	hsa-mir-34a	Ischemia-Reperfusion Injury	28599575				D015427			Suppression of miR-34a Expression in the Myocardium Protects Against Ischemia-Reperfusion Injury Through SIRT1 Protective Pathway.
other	hsa-mir-34a	Ischemia-Reperfusion Injury	28709867				D015427			Attenuation of the hypoxia-induced miR-34a protects cardiomyocytes through maintenance of glucose metabolism.
other	hsa-mir-92a	Ischemia-Reperfusion Injury	23897866				D015427			Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model.
other	hsa-mir-144	Ischemic Diseases [unspecific]	25060662				D007511	601367		MicroRNA-144 is a circulating effector of remote ischemic preconditioning.
other	hsa-mir-199a	Ischemic Diseases [unspecific]	21464712				D007511	601367		On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia.
other	hsa-mir-21	Ischemic Diseases [unspecific]	21464712				D007511	601367		On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia.
other	hsa-mir-210	Ischemic Diseases [unspecific]	22833359				D007511	601367		miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia.
other	hsa-mir-210	Ischemic Diseases [unspecific]	21464712				D007511	601367		On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia.
other	hsa-mir-210	Ischemic Diseases [unspecific]	22123256				D007511	601367		Upregulation of microRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro.
other	hsa-mir-221	Ischemic Diseases [unspecific]	25796380				D007511	601367		Moreover, exosomes from MSCs and MSCs treated by BYHWD induced elevated microRNA (miRNA)-126 expression and reduced miR-221 and miR-222 expression.
other	hsa-mir-222	Ischemic Diseases [unspecific]	25796380				D007511	601367		Moreover, exosomes from MSCs and MSCs treated by BYHWD induced elevated microRNA (miRNA)-126 expression and reduced miR-221 and miR-222 expression.
other	hsa-mir-487b	Ischemic Diseases [unspecific]	25085941				D007511	601367		The 14q32 microRNA gene cluster is highly involved in neovascularization.
other	hsa-mir-494	Ischemic Diseases [unspecific]	25085941				D007511	601367		The 14q32 microRNA gene cluster is highly involved in neovascularization.
other	hsa-mir-494	Ischemic Diseases [unspecific]	21464712				D007511	601367		On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia.
other	hsa-mir-494	Ischemic Diseases [unspecific]	28624225				D007511	601367		Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494.
other	hsa-mir-494	Ischemic Diseases [unspecific]	28880896				D007511	601367		Extract of Spatholobus suberctus Dunn ameliorates ischemia-induced injury by targeting miR-494.
other	hsa-mir-495	Ischemic Diseases [unspecific]	25085941				D007511	601367		The 14q32 microRNA gene cluster is highly involved in neovascularization.
other	hsa-let-7	Ischemic Heart Disease	26588727			I25.9/I24.9	D017202			Computational Model of MicroRNA Control of HIF-VEGF Pathway: Insights into the Pathophysiology of Ischemic Vascular Disease and Cancer.
other	hsa-mir-18a	Ischemic Heart Disease	24903055			I25.9/I24.9	D017202			PNS treatment resulted in reduced expression of miR-18a in tumor and upregulated expression of miR-18a in heart.
other	hsa-mir-21	Ischemic Heart Disease	29444190			I25.9/I24.9	D017202			Bone marrow mesenchymal stem cell-derived exosomal miR-21 protects C-kit+ cardiac stem cells from oxidative injury through the PTEN/PI3K/Akt axis
other	hsa-mir-146a	Japanese Encephalitis Virus Infection	25889446			A83.0	D018349			Upregulation of miR-146a by JEV JaOArS982 strain leads to suppression of NF-κB activity and disruption of antiviral Jak-STAT signaling which helps the virus to evade the cellular immune response. This effect of JEV infection on miR-146a expression was found to be strain specific.
other	hsa-mir-146a	Kaposi Sarcoma	20023696	disease of cellular proliferation	DOID:8632	C46	D012514			Our results show that K13-induced NF-kappaB activity suppresses CXCR4 through upregulation of miR-146a.
other	hsa-mir-155	Kaposi Sarcoma	17881434	disease of cellular proliferation	DOID:8632	C46	D012514			Together, these findings indicate that KSHV miR-K12-11 is an ortholog of miR-155.
other	hsa-mir-155	Kaposi Sarcoma	18191785	disease of cellular proliferation	DOID:8632	C46	D012514			Two new papers provide strong evidence that a KSHV-encoded microRNA and mir-155 share a common set of mRNA targets and binding sites, implying a possible link between viral- and non-viral-mediated tumorigenesis.
other	hsa-mir-17	Kaposi Sarcoma	27512057	disease of cellular proliferation	DOID:8632	C46	D012514			Here, we provide the first experimental evidence of JMRV miRNAs in  vitro and demonstrate that one of these viral miRNAs can mimic the activity of the cellular miR-17/20/106 family.
other	hsa-mir-21	Kaposi Sarcoma	18971265	disease of cellular proliferation	DOID:8632	C46	D012514			Therefore, K15M may contribute to KSHV-mediated tumor metastasis and angiogenesis via regulation of miR-21 and miR-31, which we show here for the first time to be a specific regulator of cell migration.
other	hsa-mir-23	Kaposi Sarcoma	23986579	disease of cellular proliferation	DOID:8632	C46	D012514			Kaposi's sarcoma-associated herpesvirus encodes a mimic of cellular miR-23.
other	hsa-mir-31	Kaposi Sarcoma	18971265	disease of cellular proliferation	DOID:8632	C46	D012514			Therefore, K15M may contribute to KSHV-mediated tumor metastasis and angiogenesis via regulation of miR-21 and miR-31, which we show here for the first time to be a specific regulator of cell migration.
other	hsa-mir-409	Kaposi Sarcoma	25942495	disease of cellular proliferation	DOID:8632	C46	D012514			our data provide a more detailed understanding of KSHV latency and guide further studies of the biological significance of these changes.
other	hsa-mir-708	Kaposi Sarcoma	25942495	disease of cellular proliferation	DOID:8632	C46	D012514			our data provide a more detailed understanding of KSHV latency and guide further studies of the biological significance of these changes.
other	hsa-mir-196a-1	Keloid	22358059			L91.0	D007627	148100	HP:0010562	miR-196a Downregulation Increases the Expression of Type I and III Collagens in Keloid Fibroblasts.
other	hsa-mir-196a-2	Keloid	22358059			L91.0	D007627	148100	HP:0010562	miR-196a Downregulation Increases the Expression of Type I and III Collagens in Keloid Fibroblasts.
other	hsa-mir-205	Keloid	27651436			L91.0	D007627	148100	HP:0010562	Upregulation of microRNA-205 suppresses vascular endothelial growth factor expression-mediated PI3K/Akt signaling transduction in human keloid fibroblasts.
other	hsa-mir-146a	Keratitis	24996260	nervous system disease	DOID:4677	H16	D007634	148190	HP:0000491	Our data demonstrate that miR-146a controls nuclear factor kappa B-dependent inflammatory responses in keratinocytes and chronic skin inflammation in AD.
other	hsa-mir-155	Keratitis	25700796	nervous system disease	DOID:4677	H16	D007634	148190	HP:0000491	Role of miR-155 in the pathogenesis of herpetic stromal keratitis.
other	hsa-mir-182	Keratitis	27035623	nervous system disease	DOID:4677	H16	D007634	148190	HP:0000491	Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis.
other	hsa-mir-183	Keratitis	27035623	nervous system disease	DOID:4677	H16	D007634	148190	HP:0000491	Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis.
other	hsa-mir-96	Keratitis	27035623	nervous system disease	DOID:4677	H16	D007634	148190	HP:0000491	Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis.
other	hsa-mir-338	Kideny Transplant Rejection	25769569			T86.11	D006084			miR-338-5p is closely correlated with the procedure of renal allograft antibody-mediated rejection.
other	hsa-mir-107	Kidney Diseases [unspecific]	25392232			N18.9	D007674			new strategies for probing autonomic circulatory control and ultimately, susceptibility to hypertensive renal sequelae.
other	hsa-mir-107	Kidney Diseases [unspecific]	24597825			N18.9	D007674			This review was performed to sum up the role of miR-107 and its signaling pathways in renal diseases.
other	hsa-mir-155	Kidney Diseases [unspecific]	17965831			N18.9	D007674			miR-155 was shown to decrease the expression of angiotensin II type 1 receptor in human primary fibroblasts [175]. This suggests that miR-155 may regulate a diverse set of physiological functions including fluid homeostasis and renal function.
other	hsa-mir-192	Kidney Diseases [unspecific]	24508230			N18.9	D007674			miR-192 induces G2/M growth arrest in aristolochic acid nephropathy.
other	hsa-mir-21	Kidney Diseases [unspecific]	24576069			N18.9	D007674			This review was performed to sum up the role of miR-21 and its signaling pathways in renal diseases.
other	hsa-mir-122	Kidney Injury	26489516			S37.0	D058186			In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury.
other	hsa-mir-151a	Kidney Injury	26489516			S37.0	D058186			In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury.
other	hsa-mir-182	Kidney Injury	27870928			S37.0	D058186			miR-182-5p Inhibition Ameliorates Ischemic Acute Kidney Injury.
other	hsa-mir-200c	Kidney Injury	27431456			S37.0	D058186			Chromium upper tertile was also associated with higher urinary  miR-200c (500 copies/渭l) and miR-423 (189 copies/渭L).
other	hsa-mir-21	Kidney Injury	25145934			S37.0	D058186			MicroRNA-21 in glomerular injury.
other	hsa-mir-382	Kidney Injury	26489516			S37.0	D058186			In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury.
other	hsa-mir-423	Kidney Injury	27431456			S37.0	D058186			Chromium upper tertile was also associated with higher urinary  miR-200c (500 copies/渭l) and miR-423 (189 copies/渭L).
other	hsa-mir-1236	Kidney Neoplasms	26481573	disease of cellular proliferation	DOID:263	C64	D007680			Kidney cancer: RNA activation in RCC: p21 and miR-1236 are a promising pair.
other	hsa-mir-141	Kidney Neoplasms	27358122	disease of cellular proliferation	DOID:263	C64	D007680			Invasion and metastasis ability of renal cancer cell strains 786-0: under the influence of miR-141.
other	hsa-mir-148b	Kidney Neoplasms	26573018	disease of cellular proliferation	DOID:263	C64	D007680			The present study therefore suggested that miR-148b exerts an oncogenic function by enhancing the proliferation and apoptosis of renal cancer cells by inhibiting the MAPK/JNK pathway.
other	hsa-mir-199a	Kidney Neoplasms	24609899	disease of cellular proliferation	DOID:263	C64	D007680			miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma.
other	hsa-mir-21	Kidney Neoplasms	22347428	disease of cellular proliferation	DOID:263	C64	D007680			Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival.
other	hsa-mir-21	Kidney Neoplasms	23981302	disease of cellular proliferation	DOID:263	C64	D007680			NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation.
other	hsa-mir-27a	Kidney Neoplasms	24173369	disease of cellular proliferation	DOID:263	C64	D007680			Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a.
other	hsa-mir-302	Kidney Neoplasms	26363379	disease of cellular proliferation	DOID:263	C64	D007680			Evolutionary conservation and function of the human embryonic stem cell specific miR-302/367 cluster.
other	hsa-mir-367	Kidney Neoplasms	26363379	disease of cellular proliferation	DOID:263	C64	D007680			Evolutionary conservation and function of the human embryonic stem cell specific miR-302/367 cluster.
other	hsa-mir-381	Kidney Neoplasms	23816136	disease of cellular proliferation	DOID:263	C64	D007680			miR-381 increases sensitivity of 786-O cells to 5-FU by inhibitory WEE1 and increase of Cdc2 activity.
other	hsa-let-7a	Laryngeal Neoplasms	19787239			C32.3	D007822			Thus, we propose that let-7a may be a tumor suppressor in laryngeal cancer by inhibiting cell growth, inducing cell apoptosis and downregulating the oncogenes expression.
other	hsa-mir-15a	Laryngeal Neoplasms	29085504			C32.3	D007822			Curcumin inhibits cell proliferation and promotes apoptosis of laryngeal cancer cells through Bcl-2 and PI3K/Akt, and by upregulating miR-15a.
other	hsa-mir-193b	Laryngeal Neoplasms	25517434			C32.3	D007822			Culturing the IL-10(+) Mos with effector CD8(+) T cells resulted in the suppression of CD8(+) T-cell activitie
other	hsa-mir-373	Laryngeal Neoplasms	26688807			C32.3	D007822			Association of Polymorphic Variants of miRNA Processing Genes with Larynx Cancer Risk in a Polish Population.
other	hsa-mir-152	Leiomyosarcoma	27900663			C55	D007890		HP:0100243	miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
other	hsa-mir-210	Leishmaniasis	24098824	disease by infectious agent	DOID:9065	B55	D007896	602068		MicroRNA expression profile in human macrophages in response to Leishmania major  infection.
other	hsa-mir-21	Lepromatous Leprosy	23134990	disease by infectious agent	DOID:10887	A30.5	D015440			miR-21 and STAT3 are increased in LL lesions with PEH, given their association with epithelial hyperproliferation; and Cbl-b is diminished in LL lesions with PEH compared to classic LL lesions.
other	hsa-mir-17	Lesch-Nyhan Syndrome	23804752	disease of metabolism	DOID:1919	E79.1	D007926	300322		Deficiency of the purine metabolic gene HPRT dysregulates microRNA-17 family cluster and guanine-based cellular functions: a role for EPAC in Lesch-Nyhan syndrome.
other	hsa-mir-1224	Leukemia	28977780			C95	D007938	613065	HP:0001909	a similar expression pattern of hsa-miR-1224-3p and hsa-miR-21 were observed in urine samples collected from human leukemia patients preconditioned with TBI
other	hsa-mir-125	Leukemia	22504525			C95	D007938	613065	HP:0001909	Here we discuss new findings concerning PU.1-controlled microRNAs and miR-125-regulated networks in normal and malignant myelopoiesis.
other	hsa-mir-125a	Leukemia	24216483			C95	D007938	613065	HP:0001909	ASXL1-MT resulted in derepression of homeobox A9 (Hoxa9) and microRNA-125a (miR-125a) expression through inhibition of polycomb repressive complex 2–mediated (PRC2-mediated) methylation of histone H3K27.
other	hsa-mir-125a	Leukemia	28381182			C95	D007938	613065	HP:0001909	Involvement of miR-125a in resistance to daunorubicin by inhibiting apoptosis in leukemia cell lines.
other	hsa-mir-125b	Leukemia	25915540			C95	D007938	613065	HP:0001909	The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.
other	hsa-mir-126	Leukemia	26859449			C95	D007938	613065	HP:0001909	miR-126 Drives Quiescence and Self-Renewal in Leukemic Stem Cells.
other	hsa-mir-128a	Leukemia	21455993			C95	D007938	613065	HP:0001909	we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)
other	hsa-mir-138-1	Leukemia	19896708			C95	D007938	613065	HP:0001909	miR-138:miR-138 might reverse multidrug resistance of leukemia cells
other	hsa-mir-138-2	Leukemia	19896708			C95	D007938	613065	HP:0001909	miR-138:miR-138 might reverse multidrug resistance of leukemia cells
other	hsa-mir-145	Leukemia	20962326			C95	D007938	613065	HP:0001909	As evidence that this subset of miRNAs is relevant to leukemia, we show that loss of 2 miRNAs identified in our analysis, miR-145 and miR-146a, results in leukemia in a mouse model.
other	hsa-mir-145	Leukemia	21455993			C95	D007938	613065	HP:0001909	we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)
other	hsa-mir-146	Leukemia	21455993			C95	D007938	613065	HP:0001909	we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)
other	hsa-mir-146a	Leukemia	26487345			C95	D007938	613065	HP:0001909	Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell.
other	hsa-mir-146a	Leukemia	18568019			C95	D007938	613065	HP:0001909	In leukaemic cell lines PLZF overexpression downmodulated miR-146a and upregulated CXCR4 protein, whereas PLZF knockdown induced the opposite effects.
other	hsa-mir-146a	Leukemia	20962326			C95	D007938	613065	HP:0001909	As evidence that this subset of miRNAs is relevant to leukemia, we show that loss of 2 miRNAs identified in our analysis, miR-145 and miR-146a, results in leukemia in a mouse model.
other	hsa-mir-150	Leukemia	17923094			C95	D007938	613065	HP:0001909	Combining loss- and gain-of-function gene targeting approaches for miR-150 with conditional and partial ablation of c-Myb, we show that miR-150 indeed controls c-Myb expression in vivo in a dose-dependent manner over a narrow range of miRNA and c-Myb concentrations and that this dramatically affects lymphocyte development and response.
other	hsa-mir-150	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-150	Leukemia	18667440			C95	D007938	613065	HP:0001909	Our findings suggest that c-Myb is an evolutionally conserved target of miR-150 and miR-150/c-Myb interaction is important for embryonic development and possibly oncogenesis.
other	hsa-mir-150	Leukemia	27899822			C95	D007938	613065	HP:0001909	miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways.
other	hsa-mir-155	Leukemia	26337206			C95	D007938	613065	HP:0001909	Altogether, these data implicate QKI in the pathophysiology of inflammation and oncogenesis where miR-155 is involved.
other	hsa-mir-155	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-155	Leukemia	21455993			C95	D007938	613065	HP:0001909	we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)
other	hsa-mir-15a	Leukemia	21838537			C95	D007938	613065	HP:0001909	These data indicate that miR-15a/16-1 plays an important role in the ATRA-induced differentiation of leukemic and primary AML cells.
other	hsa-mir-16	Leukemia	17683260			C95	D007938	613065	HP:0001909	several confirmed miRNA targets appear in our high-confidence set, such as the interactions between miR-92 and the signal transduction gene MAP2K4, as well as the relationship between miR-16 and BCL2, an anti-apoptotic gene which has been implicated in chronic lymphocytic leukemia.
other	hsa-mir-16	Leukemia	20839343			C95	D007938	613065	HP:0001909	The murine disease is linked to a genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-15a/16.
other	hsa-mir-17	Leukemia	26041742			C95	D007938	613065	HP:0001909	Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.
other	hsa-mir-17	Leukemia	25130806			C95	D007938	613065	HP:0001909	Anti-leukemia mechanism of miR-17 and miR-20a silencing mediated by miRNA sponge.
other	hsa-mir-17	Leukemia	24872388			C95	D007938	613065	HP:0001909	Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S.
other	hsa-mir-17	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-17	Leukemia	27123834			C95	D007938	613065	HP:0001909	Combinatorial treatment against miR-17-5p and miR-19a-3p of the miR-17-92 cluster dramatically reduces colony forming ability of MLL-fusion containing cell lines relative to non-MLL acute myeloid leukemia (AML) controls.
other	hsa-mir-17	Leukemia	28247308			C95	D007938	613065	HP:0001909	Differential Maturation of miR-17 ~ 92 Cluster Members in Human Cancer Cell Lines.
other	hsa-mir-18	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-181	Leukemia	23550642			C95	D007938	613065	HP:0001909	We also present observations based on analyzes of miR-181 family genes that indicate the potential functions of primary and/or precursor miRNAs in target recognition and explore the impact of these findings on target identification. 
other	hsa-mir-181	Leukemia	28072759			C95	D007938	613065	HP:0001909	Induction of K562 Cell Apoptosis by As4S4 via Down-Regulating miR181.
other	hsa-mir-181a	Leukemia	21455993			C95	D007938	613065	HP:0001909	we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)
other	hsa-mir-181a-2	Leukemia	23393335			C95	D007938	613065	HP:0001909	MicroRNA 181a Influences the Expression of HMGB1 and CD4 in Acute Leukemias
other	hsa-mir-181b	Leukemia	21455993			C95	D007938	613065	HP:0001909	we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)
other	hsa-mir-18a	Leukemia	27888798			C95	D007938	613065	HP:0001909	miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis.
other	hsa-mir-196a	Leukemia	20570349			C95	D007938	613065	HP:0001909	our results identify miR-196a and miR-196b as ERG regulators and implicate a potential role for these miRNAs in acute leukemia.
other	hsa-mir-196b	Leukemia	19188669			C95	D007938	613065	HP:0001909	miR-196b: MLL normally regulates expression of mir-196b
other	hsa-mir-196b	Leukemia	25475721			C95	D007938	613065	HP:0001909	miRNA-196b may play an essential role in the development of MLL-associated leukemias through inhibiting cell differentiation and apoptosis, while promoting cell proliferation.
other	hsa-mir-196b	Leukemia	20570349			C95	D007938	613065	HP:0001909	our results identify miR-196a and miR-196b as ERG regulators and implicate a potential role for these miRNAs in acute leukemia.
other	hsa-mir-199a-1	Leukemia	22285730			C95	D007938	613065	HP:0001909	Low microRNA-199a expression in human amniotic epithelial cell feeder layers maintains human-induced pluripotent stem cell pluripotency via increased leukemia inhibitory factor expression.
other	hsa-mir-199a-2	Leukemia	22285730			C95	D007938	613065	HP:0001909	Low microRNA-199a expression in human amniotic epithelial cell feeder layers maintains human-induced pluripotent stem cell pluripotency via increased leukemia inhibitory factor expression.
other	hsa-mir-19a	Leukemia	26041742			C95	D007938	613065	HP:0001909	Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.
other	hsa-mir-19a	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-19b-1	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-20	Leukemia	26487345			C95	D007938	613065	HP:0001909	Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell.
other	hsa-mir-20a	Leukemia	25130806			C95	D007938	613065	HP:0001909	Anti-leukemia mechanism of miR-17 and miR-20a silencing mediated by miRNA sponge.
other	hsa-mir-20a	Leukemia	24872388			C95	D007938	613065	HP:0001909	Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S.
other	hsa-mir-20a	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-20a	Leukemia	23114118			C95	D007938	613065	HP:0001909	It is concluded that the miR-20a sponge is constructed successfully, and Jurkat-S stable cell line is established, in which the expression of miR-20a is inhibited stably.
other	hsa-mir-20a	Leukemia	27010069			C95	D007938	613065	HP:0001909	Mechanistic study further shows that induction of SIRP伪 protein in APL cells by ATO is mediated through suppression of c-Myc, resulting in reduction of three SIRP伪-targeting microRNAs: miR-17, miR-20a and miR-106a.
other	hsa-mir-20a	Leukemia	27888798			C95	D007938	613065	HP:0001909	miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis.
other	hsa-mir-20a	Leukemia	28247308			C95	D007938	613065	HP:0001909	Differential Maturation of miR-17 ~ 92 Cluster Members in Human Cancer Cell Lines.
other	hsa-mir-21	Leukemia	26294715			C95	D007938	613065	HP:0001909	In this issue of Blood, Junker et al delineate a novel signaling axis involving miR-21 and the tumor suppressor Pdcd4 that is essential for Notch-mediated induction of T-cell acute lymphoblastic leukemia (T-ALL).
other	hsa-mir-21	Leukemia	27895788			C95	D007938	613065	HP:0001909	Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia.
other	hsa-mir-21	Leukemia	27995885			C95	D007938	613065	HP:0001909	Targeted suppression of miRNA-21 inhibit K562 cells growth through PTEN-PI3K/AKT signaling pathway.
other	hsa-mir-21	Leukemia	28218044			C95	D007938	613065	HP:0001909	Leukemia microvesicles affect healthy hematopoietic stem cells.
other	hsa-mir-21	Leukemia	28977780			C95	D007938	613065	HP:0001909	a similar expression pattern of hsa-miR-1224-3p and hsa-miR-21 were observed in urine samples collected from human leukemia patients preconditioned with TBI
other	hsa-mir-217	Leukemia	24350829			C95	D007938	613065	HP:0001909	Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. miR-#-5p,miR-#-3p
other	hsa-mir-221	Leukemia	29156756			C95	D007938	613065	HP:0001909	Increasing knowledge of biological changes, due to altered miRNA dynamics, is expected to have relevant translational implications for leukemia detection and treatment
other	hsa-mir-223	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-23a	Leukemia	21455993			C95	D007938	613065	HP:0001909	we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)
other	hsa-mir-26a	Leukemia	21455993			C95	D007938	613065	HP:0001909	we observed a negative correlation between miR-181a and miR-181b, miR-155, and miR-146 expression with that of genes involved in immunity and inflammation (eg, IRF7 and TLR4) and a positive correlation between miR-23a, miR-26a, miR-128a, and miR-145 expression with that of proapoptotic genes (eg, BIM and PTEN)
other	hsa-mir-29a	Leukemia	28218044			C95	D007938	613065	HP:0001909	Leukemia microvesicles affect healthy hematopoietic stem cells.
other	hsa-mir-376	Leukemia	26940843			C95	D007938	613065	HP:0001909	MIR376 as an important  microRNA family for cancer formation and progression
other	hsa-mir-548f	Leukemia	28698179			C95	D007938	613065	HP:0001909	A Novel Regulatory Mechanism of Smooth Muscle α-Actin Expression by NRG-1/circACTA2/miR-548f-5p Axis.
other	hsa-mir-9-1	Leukemia	23509296			C95	D007938	613065	HP:0001909	a unique role of miR-9 in myelopoiesis and in the pathogenesis of EVI1-induced myeloid neoplasms and provide insights into the epigenetic regulation of miR9 in tumorigenesis
other	hsa-mir-92	Leukemia	17683260			C95	D007938	613065	HP:0001909	several confirmed miRNA targets appear in our high-confidence set, such as the interactions between miR-92 and the signal transduction gene MAP2K4, as well as the relationship between miR-16 and BCL2, an anti-apoptotic gene which has been implicated in chronic lymphocytic leukemia.
other	hsa-mir-9-2	Leukemia	23509296			C95	D007938	613065	HP:0001909	a unique role of miR-9 in myelopoiesis and in the pathogenesis of EVI1-induced myeloid neoplasms and provide insights into the epigenetic regulation of miR9 in tumorigenesis
other	hsa-mir-92-1	Leukemia	18536574			C95	D007938	613065	HP:0001909	Using animal models engineered to overexpress miR-150, miR-17 approximately 92 and miR-155 or to be deficient for miR-223, miR-155 and miR-17 approximately 92 expression, several groups have now shown that miRNAs are critical for B-lymphocyte development (miR-150 and miR-17 approximately 92), granulopoiesis (miR-223), immune function (miR-155) and B-lymphoproliferative disorders (miR-155 and miR-17 approximately 92).
other	hsa-mir-92a	Leukemia	28247308			C95	D007938	613065	HP:0001909	Differential Maturation of miR-17 ~ 92 Cluster Members in Human Cancer Cell Lines.
other	hsa-mir-92a	Leukemia	28358188			C95	D007938	613065	HP:0001909	Effective Integration of Targeted Tumor Imaging and Therapy Using Functionalized InP QDs with VEGFR2 Monoclonal Antibody and miR-92a Inhibitor.
other	hsa-mir-9-3	Leukemia	23509296			C95	D007938	613065	HP:0001909	a unique role of miR-9 in myelopoiesis and in the pathogenesis of EVI1-induced myeloid neoplasms and provide insights into the epigenetic regulation of miR9 in tumorigenesis
other	hsa-mir-150	Leukemia, Acute	24086639	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	miR-150 promotes myeloid differentiation, a previously uncharacterized role for this miRNA, and that absent or low miR-150 expression contributes to blocked myeloid differentiation in acute leukemia cells.
other	hsa-mir-222	Leukemia, Acute	23522449	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia
other	hsa-mir-142	Leukemia, B-Cell	12007417			C91.31	D015448	151430		A translocation that make MYC overexpression
other	hsa-mir-15a	Leukemia, B-Cell	23551855			C91.31	D015448	151430		DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas.
other	hsa-mir-16-1	Leukemia, B-Cell	23551855			C91.31	D015448	151430		DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas.
other	hsa-mir-17	Leukemia, B-Cell	17940623			C91.31	D015448	151430		These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1.
other	hsa-mir-17	Leukemia, B-Cell	17989227			C91.31	D015448	151430		the miR-17 cluster (8, 9) synergizes with MYC to induce B cell lymphoma.
other	hsa-mir-17	Leukemia, B-Cell	23551855			C91.31	D015448	151430		DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas.
other	hsa-mir-18	Leukemia, B-Cell	23551855			C91.31	D015448	151430		DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas.
other	hsa-mir-18a	Leukemia, B-Cell	17940623			C91.31	D015448	151430		These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1.
other	hsa-mir-19a	Leukemia, B-Cell	17940623			C91.31	D015448	151430		These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1.
other	hsa-mir-19a	Leukemia, B-Cell	23551855			C91.31	D015448	151430		DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas.
other	hsa-mir-19b	Leukemia, B-Cell	23551855			C91.31	D015448	151430		DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas.
other	hsa-mir-19b-1	Leukemia, B-Cell	17940623			C91.31	D015448	151430		These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1.
other	hsa-mir-20a	Leukemia, B-Cell	17940623			C91.31	D015448	151430		These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1.
other	hsa-mir-20a	Leukemia, B-Cell	23551855			C91.31	D015448	151430		DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas.
other	hsa-mir-92a	Leukemia, B-Cell	23551855			C91.31	D015448	151430		DLEU2, which encodes miR-15a and miR-16-1, was discovered from 13q14 deletion in chronic lymphocytic leukemia, while C13orf25, which encodes six mature miRNA (miR-17, miR-18, miR-19a, miR-19b, miR-20a and miR-92a), was identified from 13q31 amplification in aggressive B-cell lymphomas.
other	hsa-mir-92a-1	Leukemia, B-Cell	17940623			C91.31	D015448	151430		These data suggested a direct involvement of this miRNA cluster in tumorigenesis. The miR-17-92 cluster encompassing six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92-1.
other	hsa-mir-29b	Leukemia, Biphenotypic, Acute	27775550	disease of cellular proliferation	DOID:9953	C95.0	D015456		HP:0005531	MicroRNA-29b mediates altered innate immune development in acute leukemia.
other	hsa-mir-126	Leukemia, Lymphoblastic	19760605	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions.
other	hsa-mir-126	Leukemia, Lymphoblastic	27535859	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Bioinformatics analysis of microRNA comprehensive regulatory network in B- cell acute lymphoblastic leukemia.
other	hsa-mir-128	Leukemia, Lymphoblastic	19760605	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions.
other	hsa-mir-146b	Leukemia, Lymphoblastic	19760605	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions.
other	hsa-mir-17	Leukemia, Lymphoblastic	20855495	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92.
other	hsa-mir-18	Leukemia, Lymphoblastic	20855495	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92.
other	hsa-mir-191	Leukemia, Lymphoblastic	19760605	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions.
other	hsa-mir-19a	Leukemia, Lymphoblastic	20855495	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92.
other	hsa-mir-19b-1	Leukemia, Lymphoblastic	20855495	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92.
other	hsa-mir-20a	Leukemia, Lymphoblastic	20855495	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92.
other	hsa-mir-223	Leukemia, Lymphoblastic	23815897	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Expression of microRNA-223 in lymphocytic leukemia cells and its action mechanism
other	hsa-mir-425	Leukemia, Lymphoblastic	19760605	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions.
other	hsa-mir-509	Leukemia, Lymphoblastic	25368993	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia.
other	hsa-mir-629	Leukemia, Lymphoblastic	19760605	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		ANOVA highlighted a set of six miRNAs-namely miR-425-5p, miR-191, miR-146b, miR-128, miR-629, and miR-126-that can discriminate B-lineage ALL subgroups harboring specific molecular lesions.
other	hsa-mir-92-1	Leukemia, Lymphoblastic	20855495	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92.
other	hsa-mir-100	Leukemia, Lymphoblastic, Acute	23915977	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.
other	hsa-mir-125b	Leukemia, Lymphoblastic, Acute	23915977	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.
other	hsa-mir-146a	Leukemia, Lymphoblastic, Acute	23888320	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report.
other	hsa-mir-149	Leukemia, Lymphoblastic, Acute	26725775	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia.
other	hsa-mir-150	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-15a	Leukemia, Lymphoblastic, Acute	27281445	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Prednisolone in concentration of 700 µM was significantly increased the expression of miR 16-1 and miR 15a after 24 h and 48 h treatment
other	hsa-mir-16	Leukemia, Lymphoblastic, Acute	27281445	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Prednisolone in concentration of 700 µM was significantly increased the expression of miR 16-1 and miR 15a after 24 h and 48 h treatment
other	hsa-mir-17	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-18	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-181a	Leukemia, Lymphoblastic, Acute	28184923	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	miR-181a-5p, an inducer of Wnt-signaling, facilitates cell proliferation in acute lymphoblastic leukemia.
other	hsa-mir-18a	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-196a-2	Leukemia, Lymphoblastic, Acute	24291415	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Hsa-miR-196a2 polymorphism increases the risk of acute lymphoblastic leukemia in Chinese children.
other	hsa-mir-19a	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-19b-1	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-20a	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-222	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-29a	Leukemia, Lymphoblastic, Acute	26251039	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia.
other	hsa-mir-34a	Leukemia, Lymphoblastic, Acute	27150988	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Expression of miR-34a in Bone Marrow of Adult Acute Lymphoblastic Leukemia and Its Significance in Cell Drug Resistance.
other	hsa-mir-92-1	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-92a	Leukemia, Lymphoblastic, Acute	25796601	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study not only identifies differences in the pathways and networks of acute lymphocytic leukemia (ALL) relative to normal lymphocytes, but also identifies unique functional characteristics of lymphoid cells and distinct gene expression patterns during lymphoid development. The discovery of leukemia-related miRNAs may provide meaningful insights into the biology of the disease.
other	hsa-mir-99a	Leukemia, Lymphoblastic, Acute	23915977	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.
other	hsa-mir-323b	Leukemia, Lymphoblastic, Acute, B-Cell	27649261	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.
other	hsa-mir-196b	Leukemia, Lymphoblastic, Acute, Childhood	20494936	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
other	hsa-mir-210	Leukemia, Lymphoblastic, Acute, Childhood	24720529	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.
other	hsa-mir-146b	Leukemia, Lymphoblastic, Acute, T-Cell	27550837	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	MiR-146b negatively regulates migration and delays progression of T-cell acute lymphoblastic leukemia.
other	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	23525797	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients
other	hsa-mir-107	Leukemia, Lymphocytic, Chronic, B-Cell	19692702	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	regulation of PLAG1 by miR-181a, miR-181b, miR-107, and miR-424
other	hsa-mir-122	Leukemia, Lymphocytic, Chronic, B-Cell	24047131	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Four-way junction formation promoting ultrasensitive electrochemical detection of microRNA.
other	hsa-mir-146a	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-146b	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-148a	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	25833959	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile.
other	hsa-mir-151a	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	24914134	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.
other	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	25833959	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile.
other	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	25886051	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of microRNA in chronic lymphocytic leukemia onset and progression.
other	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	23821659	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.
other	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	24136167	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-β1/SMAD5 signaling module.
other	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	24392455	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia.
other	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	24971479	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of miR-15/16 in CLL.
other	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	16885332	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The finding that essentially all indolent CLLs have lost miR-15a/miR-16-1 expression suggests that this event is the initiating event in the pathogenesis of the indolent form of CLL.
other	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	25886051	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of microRNA in chronic lymphocytic leukemia onset and progression.
other	hsa-mir-15b	Leukemia, Lymphocytic, Chronic, B-Cell	26324892	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	These results are the first, to our knowledge, to suggest an important role of miR-15b/16-2 loss in the pathogenesis of B-cell chronic lymphocytic leukemia.
other	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	24392455	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia.
other	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	24971479	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of miR-15/16 in CLL.
other	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	25886051	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of microRNA in chronic lymphocytic leukemia onset and progression.
other	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	16885332	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The finding that essentially all indolent CLLs have lost miR-15a/miR-16-1 expression suggests that this event is the initiating event in the pathogenesis of the indolent form of CLL.
other	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	26324892	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	These results are the first, to our knowledge, to suggest an important role of miR-15b/16-2 loss in the pathogenesis of B-cell chronic lymphocytic leukemia.
other	hsa-mir-17	Leukemia, Lymphocytic, Chronic, B-Cell	25886051	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of microRNA in chronic lymphocytic leukemia onset and progression.
other	hsa-mir-181b	Leukemia, Lymphocytic, Chronic, B-Cell	25886051	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of microRNA in chronic lymphocytic leukemia onset and progression.
other	hsa-mir-196b	Leukemia, Lymphocytic, Chronic, B-Cell	20549547	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-196b:Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia
other	hsa-mir-22	Leukemia, Lymphocytic, Chronic, B-Cell	24825182	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.
other	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	25833959	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile.
other	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	20862275	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-223:ZAP70, LPL, CLLU1, microRNA-29c and microRNA-223 were measured by real time PCR in a cohort of 170 patients
other	hsa-mir-29	Leukemia, Lymphocytic, Chronic, B-Cell	25833959	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	this study successfully characterized CLL exosomes, demonstrated the control of BCR signaling in the release of CLL exosomes, and uncovered a disease-relevant exosome microRNA profile.
other	hsa-mir-29	Leukemia, Lymphocytic, Chronic, B-Cell	25886051	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of microRNA in chronic lymphocytic leukemia onset and progression.
other	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	20566844	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-29:dysregulation of miR-29 can contribute to the pathogenesis of indolent B-CLL
other	hsa-mir-29b-1	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	25860243	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Our data identify biological characteristics associated with subset #4 patients, providing further evidence for the putative role of BCR in shaping the features of the tumor cells in CLL.
other	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	20862275	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-29c:ZAP70, LPL, CLLU1, microRNA-29c and microRNA-223 were measured by real time PCR in a cohort of 170 patients
other	hsa-mir-34	Leukemia, Lymphocytic, Chronic, B-Cell	25886051	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of microRNA in chronic lymphocytic leukemia onset and progression.
other	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-497	Leukemia, Lymphocytic, Chronic, B-Cell	25860243	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Our data identify biological characteristics associated with subset #4 patients, providing further evidence for the putative role of BCR in shaping the features of the tumor cells in CLL.
other	hsa-mir-640	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	correlated with assessment of biological impact on Chronic Lymphocytic Leukemia
other	hsa-mir-650	Leukemia, Lymphocytic, Chronic, B-Cell	22234685	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia.
other	hsa-mir-663b	Leukemia, Lymphocytic, Chronic, B-Cell	26305332	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells.
other	hsa-mir-708	Leukemia, Lymphocytic, Chronic, B-Cell	25704289	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia.
other	hsa-mir-92	Leukemia, Lymphocytic, Chronic, B-Cell	25886051	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Role of microRNA in chronic lymphocytic leukemia onset and progression.
other	hsa-mir-125b	Leukemia, Lymphocytic, Chronic, B-Cell	28126961	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
other	hsa-mir-146b	Leukemia, Lymphocytic, Chronic, B-Cell	27431016	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	When evaluated in CLL cells from 38 patients pre and post treatment with ibrutinib, a subset of these miRNAs (miR-22, miR-34a, miR-146b and miR-181b) was significantly decreased in response to ibrutinib.
other	hsa-mir-15	Leukemia, Lymphocytic, Chronic, B-Cell	26010203	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A rare but recurrent t(8;13)(q24;q14) translocation in B-cell chronic lymphocytic leukaemia causing MYC up-regulation and concomitant loss of PVT1, miR-15/16 and DLEU7.
other	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	28783166	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.
other	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	21881595	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia.
other	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	23608884	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells.
other	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	26010203	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A rare but recurrent t(8;13)(q24;q14) translocation in B-cell chronic lymphocytic leukaemia causing MYC up-regulation and concomitant loss of PVT1, miR-15/16 and DLEU7.
other	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	21881595	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia.
other	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	23608884	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells.
other	hsa-mir-17	Leukemia, Lymphocytic, Chronic, B-Cell	27059597	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Interestingly, TLR1/2 triggering restored BCR functionality, likely breaching the anergic state, and this was accompanied by induction of the miR-17鈭?2 cluster
other	hsa-mir-181b	Leukemia, Lymphocytic, Chronic, B-Cell	27431016	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	When evaluated in CLL cells from 38 patients pre and post treatment with ibrutinib, a subset of these miRNAs (miR-22, miR-34a, miR-146b and miR-181b) was significantly decreased in response to ibrutinib.
other	hsa-mir-22	Leukemia, Lymphocytic, Chronic, B-Cell	27431016	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	When evaluated in CLL cells from 38 patients pre and post treatment with ibrutinib, a subset of these miRNAs (miR-22, miR-34a, miR-146b and miR-181b) was significantly decreased in response to ibrutinib.
other	hsa-mir-222	Leukemia, Lymphocytic, Chronic, B-Cell	28824233	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia
other	hsa-mir-26a	Leukemia, Lymphocytic, Chronic, B-Cell	28783166	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.
other	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	27431016	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	When evaluated in CLL cells from 38 patients pre and post treatment with ibrutinib, a subset of these miRNAs (miR-22, miR-34a, miR-146b and miR-181b) was significantly decreased in response to ibrutinib.
other	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	18818704	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
other	hsa-mir-363	Leukemia, Lymphocytic, Chronic, B-Cell	27118451	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Our results reveal an enrichment of specific cellular miRNAs including miR-363 within EVs derived from CD40/IL-4-stimulated CLL cells compared with parental cell miRNA content and control EVs from unstimulated CLL cells.
other	hsa-mir-532	Leukemia, Lymphocytic, Chronic, B-Cell	28126961	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
other	hsa-mir-126	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	29505034			C92.1	D015464			Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia
other	hsa-mir-155	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	26548770			C92.1	D015464			Analysis of microRNA and gene networks in human chronic myelogenous leukemia.
other	hsa-mir-21	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	26116834			C92.1	D015464			Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth:a possible role for exosomal disposal of miR-21.
other	hsa-mir-21	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	27050372			C92.1	D015464			Exosomes released by CML cells treated with Curcumin contain a high amount of miR-21
other	hsa-mir-10	Leukemia, Myeloid	21455993	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	Our analysis identified a strong positive correlation between HOX-related genes and miR-10 and miR-20a.
other	hsa-mir-125b	Leukemia, Myeloid	25006123	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias.
other	hsa-mir-125b-1	Leukemia, Myeloid	25316507	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation.
other	hsa-mir-130a	Leukemia, Myeloid	21638198	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML (Chronic Myeloid Leukaemia).
other	hsa-mir-130b	Leukemia, Myeloid	21638198	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML (Chronic Myeloid Leukaemia).
other	hsa-mir-139	Leukemia, Myeloid	26165837	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-139-5p controls translation in myeloid leukemia through EIF4G2.
other	hsa-mir-188	Leukemia, Myeloid	25646775	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
other	hsa-mir-20a	Leukemia, Myeloid	21455993	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	Our analysis identified a strong positive correlation between HOX-related genes and miR-10 and miR-20a.
other	hsa-mir-210	Leukemia, Myeloid	25579461	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	The suitability of the method for  biological samples was tested by detecting microRNA-210 from transfected K562 cells. 
other	hsa-mir-27b	Leukemia, Myeloid	24378438	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	(6)-Gingerolinduced myeloid leukemia cell death is initiated by reactive oxygen species and activation of miR-27b expression.
other	hsa-mir-486	Leukemia, Myeloid	25533034	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-486-5p cooperates with GATA1s in supporting the growth and survival, and the aberrant erythroid phenotype of the megakaryocytic leukemias of DS.
other	hsa-mir-92a	Leukemia, Myeloid	26866730	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	The human myeloid leukemia cell line K562 secretes exosomes containing a large amount of miR-92a that enhances angiogenesis under normoxic and hypoxic conditions.
other	hsa-let-7a-1	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7a:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7a-2	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7a:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7a-3	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7a:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7b	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7b:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7c	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7c:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7c	Leukemia, Myeloid, Acute	22964640	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia.
other	hsa-let-7d	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7d:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7e	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7e:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7f-1	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7f:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7f-2	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7f:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7g	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7g:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7i	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-let-7i:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-mir-1	Leukemia, Myeloid, Acute	20842122	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our data showed that EVI1 controls proliferation in AML through modulation of miR-1-2. This study contributes to further understand the transcriptional networks involving transcription factors and miRNAs in AML.
other	hsa-mir-1	Leukemia, Myeloid, Acute	28042875	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	the PI3K/mTOR dual inhibitor BEZ235 effectively chemosensitizes AML cells via increasing miR-1-3p and subsequently down-regulating BAG4, EDN1 and ABCB1
other	hsa-mir-10	Leukemia, Myeloid, Acute	24596420	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.
other	hsa-mir-125a	Leukemia, Myeloid, Acute	28053194	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism.
other	hsa-mir-125b	Leukemia, Myeloid, Acute	28053194	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism.
other	hsa-mir-125b-1	Leukemia, Myeloid, Acute	18936236	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-125b-1: Myeloid cell differentiation arrest by miR-125b-1
other	hsa-mir-126	Leukemia, Myeloid, Acute	26832662	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells.
other	hsa-mir-126	Leukemia, Myeloid, Acute	18832181	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-126: discriminate CBF, t(15;17), and MLL-rearrangement AMLs
other	hsa-mir-126	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-126:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-mir-128	Leukemia, Myeloid, Acute	24846063	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Effect of miR-128 in DNA damage of HL-60 acute myeloid leukemia cells.
other	hsa-mir-142	Leukemia, Myeloid, Acute	24858343	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
other	hsa-mir-142	Leukemia, Myeloid, Acute	22493297	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia.
other	hsa-mir-146a	Leukemia, Myeloid, Acute	20110180	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-146a	Leukemia, Myeloid, Acute	29657293	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-146 (146a and 146b) and miR-155  are among the first and most studied miRs for their multiple roles in the control of the innate and adaptive immune processes and for their deregulation and oncogenic role in some tumors
other	hsa-mir-146a	Leukemia, Myeloid, Acute	28399410	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.
other	hsa-mir-146b	Leukemia, Myeloid, Acute	29657293	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-146 (146a and 146b) and miR-155  are among the first and most studied miRs for their multiple roles in the control of the innate and adaptive immune processes and for their deregulation and oncogenic role in some tumors
other	hsa-mir-155	Leukemia, Myeloid, Acute	25428263	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	this 3-microRNA scoring system is simple and powerful for risk stratification of de novo AML patients.
other	hsa-mir-155	Leukemia, Myeloid, Acute	24708856	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	This study provides evidence for an anti-leukaemic role for miR-155 in human FLT3-wildtype AML, by inducing cell apoptosis and myelomonocytic differentiation, which is in contrast to its previously hypothesized role as an oncogene. This highlights the complexity of gene regulation by microRNAs that may have tumour repressor or oncogenic effects depending on disease context or tissue type.
other	hsa-mir-155	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-155:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-mir-155	Leukemia, Myeloid, Acute	22681934	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status.
other	hsa-mir-155	Leukemia, Myeloid, Acute	23497456	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
other	hsa-mir-155	Leukemia, Myeloid, Acute	24263100	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The silencing of Ago2 impairs the D3-dependent miR-17-5p/20a/106a, miR-125b and miR-155 downregulation, the accumulation of their translational targets AML1, VDR and C/EBP尾 and monocytic cell differentiation.
other	hsa-mir-155	Leukemia, Myeloid, Acute	28432220	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
other	hsa-mir-15a	Leukemia, Myeloid, Acute	19883312	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-15a in BM ( p = 0.034) and miR-16 in PB ( p = 0.005) were differentially expressed between low-risk and high-risk groups
other	hsa-mir-15b	Leukemia, Myeloid, Acute	22015065	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.
other	hsa-mir-17	Leukemia, Myeloid, Acute	18832181	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-17-5p: discriminate CBF, t(15;17), and MLL-rearrangement AMLs
other	hsa-mir-17	Leukemia, Myeloid, Acute	24263100	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The silencing of Ago2 impairs the D3-dependent miR-17-5p/20a/106a, miR-125b and miR-155 downregulation, the accumulation of their translational targets AML1, VDR and C/EBP尾 and monocytic cell differentiation.
other	hsa-mir-17	Leukemia, Myeloid, Acute	26038136	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	CDK inhibitor SNS-032 can induce apoptosis of AML HL-60 cells, which  is associated with the inhibition of MCL-1,C-MYC and JAK2/STAT3, and down-regulation of miR-17-92 family.
other	hsa-mir-182	Leukemia, Myeloid, Acute	28663557	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Disruption of the C/EBPα-miR-182 balance impairs granulocytic differentiation.
other	hsa-mir-186	Leukemia, Myeloid, Acute	27012040	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia.
other	hsa-mir-191	Leukemia, Myeloid, Acute	24858343	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
other	hsa-mir-196b	Leukemia, Myeloid, Acute	26436590	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
other	hsa-mir-196b	Leukemia, Myeloid, Acute	20110180	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-196b	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-196b:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-mir-19a	Leukemia, Myeloid, Acute	24349422	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.
other	hsa-mir-19b	Leukemia, Myeloid, Acute	24349422	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.
other	hsa-mir-203	Leukemia, Myeloid, Acute	25428263	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	this 3-microRNA scoring system is simple and powerful for risk stratification of de novo AML patients.
other	hsa-mir-20a	Leukemia, Myeloid, Acute	18832181	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-20a: discriminate CBF, t(15;17), and MLL-rearrangement AMLs
other	hsa-mir-20a	Leukemia, Myeloid, Acute	23515710	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
other	hsa-mir-21	Leukemia, Myeloid, Acute	25543261	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulated miR-21 expression may contribute to disease pathogenesis in NPM1-mutated AMLs
other	hsa-mir-21	Leukemia, Myeloid, Acute	26344648	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	GRh2 may be an effective treatment for pediatric leukemia, and GRh2 may induce apoptosis of leukemia cells through miR-21-modulated suppression of Bcl-2.
other	hsa-mir-219-1	Leukemia, Myeloid, Acute	22015065	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.
other	hsa-mir-219	Leukemia, Myeloid, Acute	22015065	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.
other	hsa-mir-22	Leukemia, Myeloid, Acute	27617961	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia.
other	hsa-mir-221	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-221:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-mir-222	Leukemia, Myeloid, Acute	19883312	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-222 ( p = 0.0023) and miR-181a ( p = 0.014) expression was higher in AML than in MDS
other	hsa-mir-223	Leukemia, Myeloid, Acute	25710580	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	De Novo Acute Myeloid Leukemia in Adults: Suppression of MicroRNA-223 is Independent of LMO2 Protein Expression BUT Associate With Adverse Cytogenetic Profile and Undifferentiated Blast Morphology.
other	hsa-mir-223	Leukemia, Myeloid, Acute	26163797	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia.
other	hsa-mir-223	Leukemia, Myeloid, Acute	20029046	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our study supports a molecular network involving miR-223, C/EBPalpha, and E2F1 as major components of the granulocyte differentiation program, which is deregulated in AML.
other	hsa-mir-224	Leukemia, Myeloid, Acute	18832181	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-224: discriminate CBF, t(15;17), and MLL-rearrangement AMLs
other	hsa-mir-25	Leukemia, Myeloid, Acute	20110180	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-25	Leukemia, Myeloid, Acute	26744876	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Moreover, miR-155 level was positively associated with the white  blood cell (WBC) count, serum lactate dehydrogenase (LDH) and C-reaction protein  (CRP) value in peripheral blood (PB), as well as miR-25/miR-196b expression levels.
other	hsa-mir-26a-1	Leukemia, Myeloid, Acute	20110180	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-26a-1	Leukemia, Myeloid, Acute	21901171	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2.
other	hsa-mir-26a-2	Leukemia, Myeloid, Acute	20110180	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-26a-2	Leukemia, Myeloid, Acute	21901171	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2.
other	hsa-mir-29a	Leukemia, Myeloid, Acute	21880628	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29a and miR-30c might contribute to the sensitivity to cytarabine
other	hsa-mir-29a	Leukemia, Myeloid, Acute	22493297	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia.
other	hsa-mir-29b-1	Leukemia, Myeloid, Acute	20110180	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-29b-2	Leukemia, Myeloid, Acute	20110180	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-30	Leukemia, Myeloid, Acute	24199710	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.
other	hsa-mir-30c-1	Leukemia, Myeloid, Acute	21880628	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29a and miR-30c might contribute to the sensitivity to cytarabine
other	hsa-mir-30c-2	Leukemia, Myeloid, Acute	21880628	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29a and miR-30c might contribute to the sensitivity to cytarabine
other	hsa-mir-335	Leukemia, Myeloid, Acute	26287405	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our finding suggests that bone marrow miR-335 level may be used as a marker to predict the chemotherapy response and prognosis in adult AML patients.
other	hsa-mir-34a	Leukemia, Myeloid, Acute	22810507	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Clinically, low miR-34a expression and TP53 alterations predicted for chemotherapy resistance and inferior outcome. Notably, in TP53(unaltered) CK-AML, high miR-34a expression predicted for inferior overall survival (OS), whereas in TP53(biallelic altered) CK-AML, high miR-34a expression pointed to better OS.
other	hsa-mir-378	Leukemia, Myeloid, Acute	23582927	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia.
other	hsa-mir-382	Leukemia, Myeloid, Acute	18832181	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-382: discriminate CBF, t(15;17), and MLL-rearrangement AMLs
other	hsa-mir-424	Leukemia, Myeloid, Acute	22681934	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status.
other	hsa-mir-494	Leukemia, Myeloid, Acute	27696394	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells.
other	hsa-mir-590	Leukemia, Myeloid, Acute	22015065	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.
other	hsa-mir-628	Leukemia, Myeloid, Acute	22015065	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.
other	hsa-mir-7	Leukemia, Myeloid, Acute	27784745	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.
other	hsa-mir-9	Leukemia, Myeloid, Acute	25428263	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	this 3-microRNA scoring system is simple and powerful for risk stratification of de novo AML patients.
other	hsa-mir-9	Leukemia, Myeloid, Acute	24270738	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-9 is a tumor suppressor in pediatric AML
other	hsa-mir-9	Leukemia, Myeloid, Acute	26464168	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.
other	hsa-mir-9	Leukemia, Myeloid, Acute	27770540	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
other	hsa-mir-9	Leukemia, Myeloid, Acute	28272704	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
other	hsa-mir-98	Leukemia, Myeloid, Acute	20425795	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	hsa-mir-98:miR-155, miR-221, let-7, miR-126 and miR-196b appear to be associated with particular subtypes.
other	hsa-let-7	Leukemia, Myeloid, Chronic	27494666	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	ADAR1 restores expression of let-7 and efficiently kills LSCs, providing an innovative therapeutic target in CML.
other	hsa-mir-130a	Leukemia, Myeloid, Chronic	26494558	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.
other	hsa-mir-130a	Leukemia, Myeloid, Chronic	27421670	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells.
other	hsa-mir-142	Leukemia, Myeloid, Chronic	27421670	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells.
other	hsa-mir-144	Leukemia, Myeloid, Chronic	22842456	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.
other	hsa-mir-145	Leukemia, Myeloid, Chronic	27421670	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells.
other	hsa-mir-146a	Leukemia, Myeloid, Chronic	27421670	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells.
other	hsa-mir-15a	Leukemia, Myeloid, Chronic	24629639	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	We found that dasatinib (DAS) modulated miR-let-7d, miR-let-7e, miR-15a, miR-16, miR-21, miR-130a and miR-142-3p expressions while IM modulated miR-15a and miR-130a levels. miR-16, miR-130a and miR-145 expressions were modulated by nilotinib (NIL).
other	hsa-mir-21	Leukemia, Myeloid, Chronic	25964959	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	we demonstrate that in two CML cell lines exhibiting different biological characteristics, LQB-118 modulates NFκB subcellular localization, apparently independently of the AKT and MAPK pathways, partially inhibits proteasome activity, and alters the expression  of microRNAs -9 and -21.
other	hsa-mir-21	Leukemia, Myeloid, Chronic	27421670	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells.
other	hsa-mir-26a	Leukemia, Myeloid, Chronic	27421670	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Here, the L-amino acid oxidase from Calloselasma rhodostoma (CR-LAAO) venom altered the apoptotic machinery regulation by modulating the expression of the miR-145, miR-26a, miR-142-3p, miR-21, miR-130a, and miR-146a, and of the apoptosis-related proteins Bid, Bim, Bcl-2, Ciap-2, c-Flip, and Mcl-1 in Bcr-Abl(+) cells.
other	hsa-mir-30a	Leukemia, Myeloid, Chronic	22617440	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	microRNA 30A promotes autophagy in response to cancer therapy.
other	hsa-mir-451a	Leukemia, Myeloid, Chronic	21944890	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miRNA-451 is a putative predictor marker of Imatinib therapy response in chronic myeloid leukemia.
other	hsa-mir-451a	Leukemia, Myeloid, Chronic	22842456	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.
other	hsa-mir-451b	Leukemia, Myeloid, Chronic	22842456	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.
other	hsa-mir-7	Leukemia, Myeloid, Chronic	28986256	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro.
other	hsa-mir-9	Leukemia, Myeloid, Chronic	25964959	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	we demonstrate that in two CML cell lines exhibiting different biological characteristics, LQB-118 modulates NFκB subcellular localization, apparently independently of the AKT and MAPK pathways, partially inhibits proteasome activity, and alters the expression  of microRNAs -9 and -21.
other	hsa-mir-125b	Leukemia, Promyelocytic, Acute	27613090	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Identification of miR-125b targets involved in acute promyelocytic leukemia cell proliferation.
other	hsa-mir-125b-1	Leukemia, Promyelocytic, Acute	21880154	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia.
other	hsa-mir-142	Leukemia, Promyelocytic, Acute	27480083	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Our results suggest the existence of a Vav1/PU.1/miR-142-3p network  that supports ATRA-induced differentiation in APL-derived cells
other	hsa-mir-223	Leukemia, Promyelocytic, Acute	17217039	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	The activation of both pathways of transcriptional regulation by the myeloid lineage-specific transcription factor C/EBPalpha (CCAAT/enhancer-binding protein-alpha), and posttranscriptional regulation by miR-223 appears essential for granulocytic differentiation and clinical response of acute promyelocytic leukemia (APL) blasts to all-trans retinoic acid (ATRA).
other	hsa-mir-34a	Leukemia, Promyelocytic, Acute	19151778	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-34: that enforced expression of miR-342 in APL cells stimulated ATRA-induced differentiation
other	hsa-mir-34b	Leukemia, Promyelocytic, Acute	19151778	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-34: that enforced expression of miR-342 in APL cells stimulated ATRA-induced differentiation
other	hsa-mir-34c	Leukemia, Promyelocytic, Acute	19151778	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-34: that enforced expression of miR-342 in APL cells stimulated ATRA-induced differentiation
other	hsa-mir-28	Leukemia, T-Cell	25568327	disease of cellular proliferation	DOID:715	C91.5	D015458			miR-28 may play an important role in HTLV-1 transmission.
other	hsa-mir-155	Leukemia-Lymphoma, Adult T-Cell	23762762			C91.51	D015459		HP:0005517	Cellular MicroRNA miR-155 has Important Roles in Leukemogenesis by Human T-Cell Leukemia Virus Type 1 Infection.
other	hsa-mir-203	Leukemia-Lymphoma, Adult T-Cell	21865341			C91.51	D015459		HP:0005517	repressed
other	hsa-mir-205	Leukemia-Lymphoma, Adult T-Cell	21865341			C91.51	D015459		HP:0005517	repressed
other	hsa-mir-326	Leukemia-Lymphoma, Adult T-Cell	21865341			C91.51	D015459		HP:0005517	induced
other	hsa-mir-663a	Leukemia-Lymphoma, Adult T-Cell	21865341			C91.51	D015459		HP:0005517	induced
other	hsa-mir-711	Leukemia-Lymphoma, Adult T-Cell	21865341			C91.51	D015459		HP:0005517	induced
other	hsa-mir-125b	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	21738213	disease of cellular proliferation	DOID:7061	C83.5	D015452			Our results provide direct evidence that miR-125b has important roles in the tumorigenesis of precursor B cells.
other	hsa-mir-146a	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	20110180	disease of cellular proliferation	DOID:5599	C83.5	D054218			Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-181a-2	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	20110180	disease of cellular proliferation	DOID:5599	C83.5	D054218			Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-181c	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	20110180	disease of cellular proliferation	DOID:5599	C83.5	D054218			Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-191	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	27093985	disease of cellular proliferation	DOID:5599	C83.5	D054218			Expression of microRNA-191 in T lymphoblastic leukemia/lymphoma and its underlying mechanism.
other	hsa-mir-221	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	20110180	disease of cellular proliferation	DOID:5599	C83.5	D054218			Of them, three (i.e., miR-146a, miR-181a/c, and miR-221), five (i.e., miR-25, miR-26a, miR-29b, miR-146a, and miR-196b), and three (i.e.,miR-26a, miR-29b, and miR-146a) miRNAs are significantly associated with overall survival (P<0.05) of the 32 ALL, 53 AML, and 40 non-M3 AML patients,
other	hsa-mir-223	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	19148136	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-223: regulated by Glucocorticoids (GCs)
other	hsa-mir-223	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22424712	disease of cellular proliferation	DOID:5599	C83.5	D054218			Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL.
other	hsa-mir-708	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21926415	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-708 was also found to be associated with the in vivo glucocorticoid therapy response and with disease risk stratification.
other	hsa-mir-122	Lipid Metabolism Disorder	17965831	disease of metabolism	DOID:3146	E75	D008052			Inhibition of miR-122 resulted in decreased levels of cholesterol in the plasma and improved liver function in obese mice.
other	hsa-mir-122	Lipid Metabolism Disorder	20880716	disease of metabolism	DOID:3146	E75	D008052			In addition to miR-33, miR-122 and miR-370 have been shown to play important roles in regulating cholesterol and fatty acid metabolism.
other	hsa-mir-33	Lipid Metabolism Disorder	20880716	disease of metabolism	DOID:3146	E75	D008052			In addition to miR-33, miR-122 and miR-370 have been shown to play important roles in regulating cholesterol and fatty acid metabolism.
other	hsa-mir-33a	Lipid Metabolism Disorder	25744742	disease of metabolism	DOID:3146	E75	D008052			we describe the current understanding of the function of miR-33a/b in lipid homeostasis, focusing on the thrifty aspect.
other	hsa-mir-33b	Lipid Metabolism Disorder	25744742	disease of metabolism	DOID:3146	E75	D008052			we describe the current understanding of the function of miR-33a/b in lipid homeostasis, focusing on the thrifty aspect.
other	hsa-mir-370	Lipid Metabolism Disorder	20880716	disease of metabolism	DOID:3146	E75	D008052			In addition to miR-33, miR-122 and miR-370 have been shown to play important roles in regulating cholesterol and fatty acid metabolism.
other	hsa-mir-92a	Lipid Metabolism Disorder	24481837	disease of metabolism	DOID:3146	E75	D008052			MiR-92a: at the heart of lipid-driven endothelial dysfunction.
other	hsa-let-7b	Liposarcoma	21412931	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	Let-7 MicroRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: Analysis of 56 lipomas and liposarcomas with molecular cytogenetic data.
other	hsa-let-7g	Liposarcoma	21412931	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	Let-7 MicroRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: Analysis of 56 lipomas and liposarcomas with molecular cytogenetic data.
other	hsa-mir-143	Liposarcoma	21693658	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	microRNA-143 is a tumor suppressor activity in liposarcoma
other	hsa-mir-193b	Liposarcoma	28882999	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	miR-193b-Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells.
other	hsa-let-7a	Liver Cirrhosis	27115285	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	There was decreased expression of let-7a in BDL and Mdr2(-/-) cholangiocytes that was associated with increased NGF expression.
other	hsa-mir-106b	Liver Cirrhosis	26456479	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-122	Liver Cirrhosis	26456479	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-122	Liver Cirrhosis	27391076	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	we showed that the isomiR profiles of liver specific MiR122, and a few other miRNAs, correlated with MC-LR treatment.
other	hsa-mir-181b	Liver Cirrhosis	26456479	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-185	Liver Cirrhosis	26456479	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-18a	Liver Cirrhosis	26456479	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-199a	Liver Cirrhosis	22942713	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	This review provides a comprehensive survey of the literature on miR-199a as an example of the complexity of miRNA biology and suggests future directions for miRNA research.
other	hsa-mir-199a-1	Liver Cirrhosis	21283674	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	In both the mouse and human studies, the expression levels of miR-199a, 199a*, 200a, and 200b were positively and significantly correlated to the progressed liver fibrosis.
other	hsa-mir-199a-2	Liver Cirrhosis	21283674	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	In both the mouse and human studies, the expression levels of miR-199a, 199a*, 200a, and 200b were positively and significantly correlated to the progressed liver fibrosis.
other	hsa-mir-200a	Liver Cirrhosis	21283674	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	In both the mouse and human studies, the expression levels of miR-199a, 199a*, 200a, and 200b were positively and significantly correlated to the progressed liver fibrosis.
other	hsa-mir-200a	Liver Cirrhosis	28025657	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-200a controls hepatic stellate cell activation and fibrosis via SIRT1/Notch1 signal pathway.
other	hsa-mir-200b	Liver Cirrhosis	21283674	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	In both the mouse and human studies, the expression levels of miR-199a, 199a*, 200a, and 200b were positively and significantly correlated to the progressed liver fibrosis.
other	hsa-mir-200b	Liver Cirrhosis	28502477	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b.
other	hsa-mir-203	Liver Cirrhosis	28355233	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis.
other	hsa-mir-21	Liver Cirrhosis	26456479	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-21	Liver Cirrhosis	19203462	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-21: n/a
other	hsa-mir-21	Liver Cirrhosis	26946098	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	increasing concentrations of Corilagin improved the quality of life, inhibited the mRNA expression of miR-21,  promoted smad7 protein expression, and inhibited CTGF protein expression (p<0.05  or 0.01).
other	hsa-mir-219	Liver Cirrhosis	27855391	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Suppression of MicroRNA-219-5p Activates Keratinocyte Growth Factor to Mitigate Severity of Experimental Cirrhosis.
other	hsa-mir-219	Liver Cirrhosis	28355233	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis.
other	hsa-mir-22	Liver Cirrhosis	26112332	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-22 promotes the development of cirrhosis through BMP7 suppression.
other	hsa-mir-221	Liver Cirrhosis	27935974	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Epigallocatechin-3-Gallate Upregulates miR-221 to Inhibit Osteopontin-Dependent Hepatic Fibrosis.
other	hsa-mir-29a	Liver Cirrhosis	27480597	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29a exhibited anti-fibrotic effect without cell toxicity in vivo and directly suppressed the expression of PDGF-related genes as well as COL1A1 and induced apoptosis of LX-2 cells.
other	hsa-mir-29c	Liver Cirrhosis	26456479	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Our results provide important information for developing novel diagnostic tools for distinguishing chronic HBV hepatitis and their corresponding cirrhosis.
other	hsa-mir-34a	Liver Cirrhosis	25068403	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	This study demonstrates for the first time, that miRNA-34a mayoriginate to a large extent from the liver. Even though higher levels ofmiRNA-34a are possibly associated with better survival at long-term follow-up in cirrhotic patients with severe portal hypertension receiving TIPS, classical prognostic parameters predict the survival better.
other	hsa-mir-92a	Liver Cirrhosis	27246196	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-92a expression closely correlated with the frequency of a subset of IL-17-producing T helper cells (Th17)
other	hsa-mir-122	Liver Diseases [unspecific]	24354366			K76.9	D008107			Roadmap of miR-122-related clinical application from bench to bedside.
other	hsa-mir-122	Liver Diseases [unspecific]	26574140			K76.9	D008107			miR-122 increased with moderate ethanol consumption, but the fold change was modest. As increases with acetaminophen toxicity are 100- to 10000-fold, moderate ethanol intoxication is unlikely to confound the use of this biomarker of hepatotoxicity.
other	hsa-mir-122	Liver Diseases [unspecific]	24121065			K76.9	D008107			miR-122 is a liver-specific microRNA associated with many liver diseases
other	hsa-mir-122	Liver Diseases [unspecific]	26669080			K76.9	D008107			Biological function of miR-122 and its relationship with liver diseases.
other	hsa-mir-122	Liver Diseases [unspecific]	27391076			K76.9	D008107			we showed that the isomiR profiles of liver specific MiR122, and a few other miRNAs, correlated with MC-LR treatment.
other	hsa-mir-146a	Liver Diseases [unspecific]	25562147			K76.9	D008107			a critical role for miRNAs in the pathogenesis of NAFLD.
other	hsa-mir-146b	Liver Diseases [unspecific]	25562147			K76.9	D008107			a critical role for miRNAs in the pathogenesis of NAFLD.
other	hsa-mir-152	Liver Diseases [unspecific]	25562147			K76.9	D008107			a critical role for miRNAs in the pathogenesis of NAFLD.
other	hsa-mir-183	Liver Diseases [unspecific]	25963660			K76.9	D008107			These results indicate that the modulation of miRNA processing by COX-2 is a key event in insulin signaling in liver and has potential clinical implications for the management of various hepatic dysfunctions.
other	hsa-mir-19b	Liver Diseases [unspecific]	28083843			K76.9	D008107			MicroRNA-19b Expression in Human Biliary Atresia Specimens and Its Role in BA-Related Fibrosis.
other	hsa-mir-200a	Liver Diseases [unspecific]	25562147			K76.9	D008107			a critical role for miRNAs in the pathogenesis of NAFLD.
other	hsa-mir-200b	Liver Diseases [unspecific]	25562147			K76.9	D008107			a critical role for miRNAs in the pathogenesis of NAFLD.
other	hsa-mir-200c	Liver Diseases [unspecific]	25562147			K76.9	D008107			a critical role for miRNAs in the pathogenesis of NAFLD.
other	hsa-mir-21	Liver Diseases [unspecific]	27107786			K76.9	D008107			In  L-02 cells exposed to arsenite, microRNA-21 (miRNA-21) is over-expressed
other	hsa-mir-214	Liver Diseases [unspecific]	28438567			K76.9	D008107			A systematic evaluation of microRNAs in regulating human hepatic CYP2E1.
other	hsa-mir-27a	Liver Diseases [unspecific]	25716995			K76.9	D008107			our study demonstrates the regulatory role of miR-27a in alcohol-induced monocyte activation and polarization.
other	hsa-mir-29a	Liver Diseases [unspecific]	22469499			K76.9	D008107			Hepatic miR-29ab1 expression modulates chronic hepatic injury.
other	hsa-mir-29b-1	Liver Diseases [unspecific]	22469499			K76.9	D008107			Hepatic miR-29ab1 expression modulates chronic hepatic injury.
other	hsa-mir-29b-2	Liver Diseases [unspecific]	22469499			K76.9	D008107			Hepatic miR-29ab1 expression modulates chronic hepatic injury.
other	hsa-mir-34a	Liver Diseases [unspecific]	29391755			K76.9	D008107			After normalization of the steatosis-related circRNA by expression vector, analysis of miR-34a activity, peroxisome proliferator-activated receptor  (PPAR)α level, and expression of downstream genes were carried out so as to reveal its impact on the miR-34a/PPARα regulatory system
other	hsa-mir-942	Liver Diseases [unspecific]	28438567			K76.9	D008107			A systematic evaluation of microRNAs in regulating human hepatic CYP2E1.
other	hsa-mir-223	Liver Failure	25562161			K72	D017093	613070	HP:0001399	miR-223 acted to inhibit IL-1β production via AIM2 pathway, suppressing Kupffer cells pro-inflammatory activation at the early stage of ALF. Thus, it played an important role in the pathogenesis of ALF.
other	hsa-mir-24	Liver Fibrosis	28602220			K74	D008103			Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2-/- mice.
other	hsa-mir-33a	Liver Fibrosis	24100264			K74	D008103			the expression of miR-33a increased with the progression of liver fibrosis. These results suggested that anti-miR-33a inhibit activation and extracellular matrix production, at least in part, via the activation of PI3K/Akt pathway and PPAR-α and anti sense of miR-33a may be a novel potential therapeutic approach for treating hepatic fibrosis in the future.
other	hsa-mir-122	Liver Injury	26489516			S36.11	D056486			In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury.
other	hsa-mir-122	Liver Injury	24118944			S36.11	D056486			M65 and microRNA-122 are potential biomarkers of DILI superior to ALT with respect to sensitivity and specificity.
other	hsa-mir-122	Liver Injury	25039534			S36.11	D056486			In mice and humans, miR-122 levels represent an independent and potent marker of ongoing liver injury and hepatic cell death regardless of the underlying disease.
other	hsa-mir-122	Liver Injury	28341748			S36.11	D056486			Drug-induced liver injury: recent advances in diagnosis and risk assessment.
other	hsa-mir-151a	Liver Injury	26489516			S36.11	D056486			In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury.
other	hsa-mir-155	Liver Injury	26844784			S36.11	D056486			Role of miR-155 in fluorooctane sulfonate-induced oxidative hepatic damage via the Nrf2-dependent pathway.
other	hsa-mir-200a	Liver Injury	25789565			S36.11	D056486			our data indicate that the p53-dependent expression of miR-200a-3p promotes cell death by inhibiting a p38/p53/miR-200 feedback loop.
other	hsa-mir-21	Liver Injury	29229992			S36.11	D056486			miRNA-21 ablation protects against liver injury and necroptosis in cholestasis
other	hsa-mir-223	Liver Injury	27679493			S36.11	D056486			MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils.
other	hsa-mir-223	Liver Injury	28295449			S36.11	D056486			Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice.
other	hsa-mir-29	Liver Injury	24052410			S36.11	D056486			Our results indicate that miR-29a decreases cholestatic liver injury and fibrosis after BDL, at least partially, by modulating the extrinsic rather than intrinsic pathway of apoptosis.
other	hsa-mir-31	Liver Injury	25706292			S36.11	D056486			Both compounds also down-regulated miR-31, which directly targets caspase-2 and influences apoptosis  in SEB-activated cells.
other	hsa-mir-382	Liver Injury	26489516			S36.11	D056486			In mice,miR-122-5p, miR-151a-3p and miR-382-5p specifically reported APAP toxicity -being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced kidney injury.
other	hsa-mir-877	Liver Injury	27713024			S36.11	D056486			MicroRNA-877-5p is involved in the trovafloxacin-induced liver injury.
other	hsa-mir-101	Liver Neoplasms	24123132	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Another myc in the wall: microRNA-101 controls important functions in liver cancer formation.
other	hsa-mir-122	Liver Neoplasms	24386085	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers.
other	hsa-mir-1307	Liver Neoplasms	26646011	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs.
other	hsa-mir-142	Liver Neoplasms	25015418	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133.
other	hsa-mir-143	Liver Neoplasms	29844837	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	The mechanism of miR-143 inducing apoptosis of liver carcinoma cells through regulation of the NF-κB pathway.
other	hsa-mir-199	Liver Neoplasms	24069256	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	We exploited this miR-199 differential expression to develop a conditionally replication-competent oncolytic adenovirus, Ad-199T, and achieve tumor-specific viral expression and replication. 
other	hsa-mir-200a	Liver Neoplasms	25203708	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MiR-200a may play an important role in liver cancer development and may have diagnostic value for indicating early liver cancer. 
other	hsa-mir-21	Liver Neoplasms	26646011	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs.
other	hsa-mir-21	Liver Neoplasms	29091291	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Genetic and pharmacologic manipulation of miR-21 does not inhibit the development of liver fibrosis and liver cancer
other	hsa-mir-214	Liver Neoplasms	24386085	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers.
other	hsa-mir-22	Liver Neoplasms	25596928	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	bile acid-activated FXR stimulates miR-22-silenced CCNA2, a novel pathway for FXR to exert its protective effect in the gastrointestinal tract.
other	hsa-mir-224	Liver Neoplasms	26646011	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs.
other	hsa-mir-23a	Liver Neoplasms	26439986	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	we found expression of miR-23a was related  to p53 functional status in the male-derived liver cell-lines
other	hsa-mir-24	Liver Neoplasms	23382622	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	This feedback loop, governed by miR-24 and miR-629, promotes a hepatocyte nuclear factor-4α transient inhibition resulting in miR-124 induction and signal transducer and activator of transcription 3 activation.
other	hsa-mir-27	Liver Neoplasms	26646011	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs.
other	hsa-mir-33	Liver Neoplasms	26646011	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs.
other	hsa-mir-433	Liver Neoplasms	23979134	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein.
other	hsa-mir-612	Liver Neoplasms	24704424	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MiR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling.
other	hsa-mir-629	Liver Neoplasms	23382622	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	This feedback loop, governed by miR-24 and miR-629, promotes a hepatocyte nuclear factor-4α transient inhibition resulting in miR-124 induction and signal transducer and activator of transcription 3 activation.
other	hsa-let-7i	Liver Neoplasms	21176238	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	let-7i* is overexpressed in side population of HCC cells compared to fetal liver cells
other	hsa-mir-122	Liver Neoplasms	20371461	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-122, a major regulatory RNA in liver that fine-tunes the expression of over 100 cellular genes and enhances HCV replication
other	hsa-mir-124	Liver Neoplasms	22153071	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	we show that transient inhibition of HNF4α initiates hepatocellular transformation through a microRNA-inflammatory feedback loop circuit consisting of miR-124, IL6R, STAT3, miR-24, and miR-629.
other	hsa-mir-200c	Liver Neoplasms	24647918	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer.
other	hsa-mir-24	Liver Neoplasms	22153071	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	we show that transient inhibition of HNF4α initiates hepatocellular transformation through a microRNA-inflammatory feedback loop circuit consisting of miR-124, IL6R, STAT3, miR-24, and miR-629.
other	hsa-mir-27b	Liver Neoplasms	25698578	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	we propose that miR-27b synergizes with anticancer drugs in a defined subgroup of liver and kidney cancer patients.
other	hsa-mir-629	Liver Neoplasms	22153071	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	we show that transient inhibition of HNF4α initiates hepatocellular transformation through a microRNA-inflammatory feedback loop circuit consisting of miR-124, IL6R, STAT3, miR-24, and miR-629.
other	hsa-mir-133a	Long QT Syndrome	24809446	cardiovascular system disease	DOID:2843	I45.81	D008133	192500	HP:0001657	MicroRNAs in cardiac arrhythmia: DNA sequence variation of MiR-1 and MiR-133A in  long QT syndrome.
other	hsa-mir-210	Lung Disease [unspecific]	26079696	respiratory system disease	DOID:850	J98.4	D008171	606963		this study demonstrates the added value of an integrated miRNA-mRNA approach for identifying molecular events altered by environmental pollutants in an in vitro human model.
other	hsa-let-7d	Lung Fibrosis	28385811	respiratory system disease	DOID:3770	J84.10	D011658	178500		Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model.
other	hsa-mir-153	Lung Fibrosis	26216407	respiratory system disease	DOID:3770	J84.10	D011658	178500		These data suggest that miR-153 disturbs TGF-β1 signal transduction and its effects on fibroblast activation, acting as an anti-fibrotic element in the development of pulmonary fibrosis.
other	hsa-mir-154	Lung Fibrosis	28385811	respiratory system disease	DOID:3770	J84.10	D011658	178500		Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model.
other	hsa-mir-200c	Lung Fibrosis	28255128	respiratory system disease	DOID:3770	J84.10	D011658	178500		Recent advances in miR-200c and fibrosis in organs.
other	hsa-mir-21	Lung Fibrosis	20643828	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-21:These experiments demonstrate an important role for miR-21 in fibrotic lung diseases
other	hsa-mir-218	Lung Fibrosis	24298938	respiratory system disease	DOID:3770	J84.10	D011658	178500		Andrographolide antagonizes cigarette smoke extract-induced inflammatory response and oxidative stress in human alveolar epithelial A549 cells through induction of microRNA-218.
other	hsa-mir-29c	Lung Fibrosis	28799781	respiratory system disease	DOID:3770	J84.10	D011658	178500		MicroRNA-29c Prevents Pulmonary Fibrosis by Regulating Epithelial Cell Renewal and Apoptosis.
other	hsa-mir-31	Lung Fibrosis	22661007	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis.
other	hsa-mir-34a	Lung Fibrosis	27635790	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence.
other	hsa-mir-34a	Lung Fibrosis	28273432	respiratory system disease	DOID:3770	J84.10	D011658	178500		p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis.
other	hsa-mir-486	Lung Fibrosis	26370615	respiratory system disease	DOID:3770	J84.10	D011658	178500		The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis.
other	hsa-mir-223	Lung Injury [unspecific]	28931657			S27.309D	D055370			Neutrophil transfer of miR-223 to lung epithelial cells dampens acute lung injury in mice.
other	hsa-let-7	Lung Neoplasms	24505620	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Mechanistic links between COPD and lung cancer: a role of microRNA let-7
other	hsa-let-7	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-let-7a	Lung Neoplasms	24293999	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.
other	hsa-let-7a	Lung Neoplasms	26026830	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	According to our literature survey and database validation, many of these results are biologically meaningful for understanding the mechanism of the complex post-transcriptional regulations in lung cancer.
other	hsa-let-7a	Lung Neoplasms	26962302	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The present study reveals that decreased C/EBP伪 contributes to the down-regulation of miRNA let-7a-1 in lung cancer cells.
other	hsa-let-7a	Lung Neoplasms	21097396	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Construction of let-7a expression plasmid and its inhibitory effect on k-Ras protein in A549 lung cancer cells
other	hsa-let-7a-1	Lung Neoplasms	20097187	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	inhibition of proliferation in non-small cell lung cancer
other	hsa-let-7a-1	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7a-2	Lung Neoplasms	20097187	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	inhibition of proliferation in non-small cell lung cancer
other	hsa-let-7a-2	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7a-3	Lung Neoplasms	20097187	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	inhibition of proliferation in non-small cell lung cancer
other	hsa-let-7a-3	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7b	Lung Neoplasms	26026830	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	According to our literature survey and database validation, many of these results are biologically meaningful for understanding the mechanism of the complex post-transcriptional regulations in lung cancer.
other	hsa-let-7b	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7c	Lung Neoplasms	26026830	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	According to our literature survey and database validation, many of these results are biologically meaningful for understanding the mechanism of the complex post-transcriptional regulations in lung cancer.
other	hsa-let-7c	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7c	Lung Neoplasms	23880305	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Additionally, antrocin increased microRNA let-7c expression and suppressed STAT signaling.
other	hsa-let-7d	Lung Neoplasms	26627242	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
other	hsa-let-7d	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7e	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7f	Lung Neoplasms	26026830	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	According to our literature survey and database validation, many of these results are biologically meaningful for understanding the mechanism of the complex post-transcriptional regulations in lung cancer.
other	hsa-let-7f-1	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7f-2	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7g	Lung Neoplasms	21472347	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Precursor let-7g microRNA can supress A549 lung cancer cell migration.
other	hsa-let-7g	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-let-7i	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-mir-101	Lung Neoplasms	24958470	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	IL-1β-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis.
other	hsa-mir-106a	Lung Neoplasms	26451608	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer.
other	hsa-mir-106a	Lung Neoplasms	19209007	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	High levels of miR-106a were associated with small-cell lung cancer (p = 0.031), and high levels of miR-19a with advanced NSCLC (p = 0.008).
other	hsa-mir-122	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-1226	Lung Neoplasms	25519225	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the screening approach used in this study can identify clinically relevant synthetic lethal interactions and that vitamin D receptor agonists may show enhanced efficacy in p53-negative lung cancer patients.
other	hsa-mir-125a	Lung Neoplasms	24044511	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells.
other	hsa-mir-125a	Lung Neoplasms	19702827	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Taken together, our results provide compelling evidence that miR-125a-5p, an epidermal growth factor-signaling-regulated miRNA, may function as a metastatic suppressor.
other	hsa-mir-125b	Lung Neoplasms	25573191	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-125b may function as an oncogene in lung cancer.
other	hsa-mir-126	Lung Neoplasms	18602365	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-126: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines
other	hsa-mir-126	Lung Neoplasms	19223090	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-126: inhibit the growth
other	hsa-mir-126	Lung Neoplasms	20097187	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	inhibition of proliferation in non-small cell lung cancer
other	hsa-mir-126	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-126	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	most analyzed miRNA genes undergo substantial copy number alteration in lung cancer.
other	hsa-mir-128b	Lung Neoplasms	22352917	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Among them, 11 miRNAs including miR-7 and miR-128b were confirmed by published experimental data or literatures.
other	hsa-mir-1323	Lung Neoplasms	25823795	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells.
other	hsa-mir-133a	Lung Neoplasms	24157646	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.
other	hsa-mir-133a-1	Lung Neoplasms	22089643	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma.
other	hsa-mir-133b	Lung Neoplasms	24157646	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.
other	hsa-mir-137	Lung Neoplasms	25498886	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-137 may be an independent favorable prognostic factor in NSCLC patients.
other	hsa-mir-138	Lung Neoplasms	24691972	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells.
other	hsa-mir-138	Lung Neoplasms	25994569	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells.
other	hsa-mir-141	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-145	Lung Neoplasms	20097187	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	inhibition of proliferation in non-small cell lung cancer
other	hsa-mir-146	Lung Neoplasms	23035181	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Other significantly differentiated miR families included carcinogenesis-related miR-146, miR-26, and miR-17 (P (FCS) < 0.05).
other	hsa-mir-146a	Lung Neoplasms	23555954	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells
other	hsa-mir-150	Lung Neoplasms	21935578	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Anti-miR-150 vector can regress A549 lung cancer tumors.
other	hsa-mir-153	Lung Neoplasms	25475731	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	significance of miR-153 and ADAM19 in the development and progression of NSCLC.
other	hsa-mir-154	Lung Neoplasms	25846246	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-154 suppresses non-small cell lung cancer growth in vitro and in vivo.
other	hsa-mir-155	Lung Neoplasms	25230125	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Chitosan combined with molecular beacon for mir-155 detection and imaging in lung cancer.
other	hsa-mir-155	Lung Neoplasms	26467212	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway.
other	hsa-mir-155	Lung Neoplasms	17965831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-155 has also been implicated in a number of cancers including Burkitt_s lymphoma, Hodgkin lymphoma and lung cancer.
other	hsa-mir-155	Lung Neoplasms	21762626	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-155 could significantly inhibit the growth of human lung cancer 95D cells in vitro, which might be closely related to miR-155 induced G0/G1 phase arrest.
other	hsa-mir-155	Lung Neoplasms	24528019	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	As Hsa-miR-155 (miR-155) can  be used as a diagnostic marker for non-small cell lung cancer (NSCLC), a smart molecular beacon of miR-155 was designed to image the expression of miR-155 in NSCLC cases.
other	hsa-mir-155	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	most analyzed miRNA genes undergo substantial copy number alteration in lung cancer.
other	hsa-mir-155	Lung Neoplasms	28315615	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MIR155 Regulation of Ubiquilin1 and Ubiquilin2: Implications in Cellular Protection and Tumorigenesis.
other	hsa-mir-155	Lung Neoplasms	22796123	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The present study demonstrated that intracellular miR-155 could be successfully and quickly detected by novel miR-155 MBs. As a noninvasive monitoring approach, MBs could be used to diagnose lung cancer at early stage through molecular imaging.
other	hsa-mir-16	Lung Neoplasms	25912305	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16.
other	hsa-mir-17	Lung Neoplasms	26451608	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer.
other	hsa-mir-17	Lung Neoplasms	23263848	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-17-5p may be potential biomarker for prediction the prognosis in patients with lung cancer.
other	hsa-mir-17	Lung Neoplasms	23035181	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Other significantly differentiated miR families included carcinogenesis-related miR-146, miR-26, and miR-17 (P (FCS) < 0.05).
other	hsa-mir-17	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	most analyzed miRNA genes undergo substantial copy number alteration in lung cancer.
other	hsa-mir-17	Lung Neoplasms	17384677	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth.
other	hsa-mir-18	Lung Neoplasms	17384677	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth.
other	hsa-mir-182	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-183	Lung Neoplasms	24586048	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells.
other	hsa-mir-183	Lung Neoplasms	25983004	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition.
other	hsa-mir-183	Lung Neoplasms	18840437	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-183: a potential metastasis-inhibitor
other	hsa-mir-183	Lung Neoplasms	21503569	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	microRNA-182 inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on human cortical actin-associated protein.
other	hsa-mir-183	Lung Neoplasms	27593936	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation.
other	hsa-mir-185	Lung Neoplasms	19688090	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	cell cycle arrest
other	hsa-mir-18a	Lung Neoplasms	19688090	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	cell cycle arrest
other	hsa-mir-18a	Lung Neoplasms	17384677	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth.
other	hsa-mir-19	Lung Neoplasms	26098000	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition.
other	hsa-mir-191	Lung Neoplasms	25252218	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-191, by promoting the EMT and increasing CSC-like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells.
other	hsa-mir-192	Lung Neoplasms	28067164	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	pharmacological effects of curcumin in lung cancer are also mediated by modulation of several miRNAs, such as downregulation of oncogenic miR-21 and upregulation of oncosuppressive miR-192-5p and miR-215
other	hsa-mir-193a	Lung Neoplasms	25391651	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	our findings provide the first clues regarding the role of miR-193a-3p as a tumor suppressor in lung cancer through the inhibition of ERBB4 translation.
other	hsa-mir-196a	Lung Neoplasms	27880728	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells.
other	hsa-mir-196a-2	Lung Neoplasms	19293314	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-196a-2: Susceptibility of Lung Cancer in Chinese
other	hsa-mir-197	Lung Neoplasms	25451482	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	ER stress plays a major role in STAT6-induced apoptosis.
other	hsa-mir-197	Lung Neoplasms	26451608	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer.
other	hsa-mir-19a	Lung Neoplasms	17384677	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth.
other	hsa-mir-19b	Lung Neoplasms	26451608	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer.
other	hsa-mir-19b-1	Lung Neoplasms	17384677	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth.
other	hsa-mir-200	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-200b	Lung Neoplasms	26012256	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Nobiletin inhibited hypoxia-induced epithelial-mesenchymal transition of lung cancer cells by inactivating of Notch-1 signaling and switching on miR-200b.
other	hsa-mir-200b	Lung Neoplasms	21954225	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Stably expressing microRNA-200b in As-p53lowHBECs (human bronchial epithelial cell) abolished Akt and Erk1/2 activation, and completely suppressed cell migration and invasion.
other	hsa-mir-200c	Lung Neoplasms	23824089	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	NF-κB-mediated inflammation leading to EMT via miR-200c is involved in cell transformation induced by cigarette smoke extract.
other	hsa-mir-200c	Lung Neoplasms	24791940	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.
other	hsa-mir-200c	Lung Neoplasms	24468793	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent studies suggest that epithelial-mesenchymal transition (EMT) is the most important contributor to cancer metastasis. Induction of this complex process requires endogenously produced microRNAs; specifically, downregulation of the miRNA-200c causes an induction of EMT.
other	hsa-mir-200c	Lung Neoplasms	28675952	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A novel fine tuning scheme of miR-200c in modulating lung cell redox homeostasis.
other	hsa-mir-205	Lung Neoplasms	24434435	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We have demonstrated for the first time a new molecular pathway that connects TMPRSS4 and integrin α5 through miR-205 to regulate cancer cell invasion and metastasis.
other	hsa-mir-205	Lung Neoplasms	25695220	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.
other	hsa-mir-205	Lung Neoplasms	26001155	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reply to MiR-205 and miR-375 microRNA Assays to Distinguish Squamous Cell Carcinoma From Adenocarcinoma in Lung Cancer Biopsies.
other	hsa-mir-205	Lung Neoplasms	19273703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-205: hsa-miR-205 as a highly specific marker for squamous cell lung carcinoma
other	hsa-mir-205	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-205	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	most analyzed miRNA genes undergo substantial copy number alteration in lung cancer.
other	hsa-mir-206	Lung Neoplasms	24390363	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Quantitative proteomics and protein network analysis of A549 lung cancer cells affected by miR-206.
other	hsa-mir-206	Lung Neoplasms	26075299	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis.
other	hsa-mir-206	Lung Neoplasms	21157919	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-206 Is Associated With Invasion and Metastasis of Lung Cancer.
other	hsa-mir-20a	Lung Neoplasms	17384677	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth.
other	hsa-mir-21	Lung Neoplasms	23857284	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression and significance of miRNA-21 and BTG2 in lung cancer.
other	hsa-mir-21	Lung Neoplasms	24012885	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Angiogenesis, mediated by miR-21, is involved arsenite-induced carcinogenesis.
other	hsa-mir-21	Lung Neoplasms	25323306	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.
other	hsa-mir-21	Lung Neoplasms	25831148	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Abnormal Expression of miR-21 and miR-95 in Cancer Stem-Like Cells is Associated  with Radioresistance of Lung Cancer.
other	hsa-mir-21	Lung Neoplasms	25901472	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The present study reports that DEPs increased miR-21 expression and then activated the PTEN/PI3K/AKT pathway in human bronchial epithelial (HBE) cells, which may serve as an important carcinogenic mechanism. However, the data revealed that short-term exposure to a high DEP concentration did not cause evident cell carcinogenesis in HBE cells.
other	hsa-mir-21	Lung Neoplasms	26026961	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR-mutated lung cancer via nickel-induced microRNA-21 expression.
other	hsa-mir-21	Lung Neoplasms	26134223	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A prognostic classifier comprising three types of genomic and epigenomic data may help guide the postoperative management of stage I lung cancer patients at high risk of recurrence.
other	hsa-mir-21	Lung Neoplasms	26525579	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results, demonstrating the function of exosomal miR-21 from transformed HBE cells, provide a new perspective for intervention strategies to prevent carcinogenesis of lung cancer.
other	hsa-mir-21	Lung Neoplasms	27266356	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain.
other	hsa-mir-21	Lung Neoplasms	22866162	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The detection of miR-21 expression yielded 78.80% sensitivity and 100.00% specificity in the diagnosis of lung cancer.
other	hsa-mir-21	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-21	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The most frequently amplified miRNA genes include the following: miR-30d, miR-21, miR-17 and miR-155.
other	hsa-mir-21	Lung Neoplasms	28067164	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	pharmacological effects of curcumin in lung cancer are also mediated by modulation of several miRNAs, such as downregulation of oncogenic miR-21 and upregulation of oncosuppressive miR-192-5p and miR-215
other	hsa-mir-210	Lung Neoplasms	23492775	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines
other	hsa-mir-215	Lung Neoplasms	28067164	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	pharmacological effects of curcumin in lung cancer are also mediated by modulation of several miRNAs, such as downregulation of oncogenic miR-21 and upregulation of oncosuppressive miR-192-5p and miR-215
other	hsa-mir-217	Lung Neoplasms	25234467	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.
other	hsa-mir-218	Lung Neoplasms	26553452	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our findings revealed an integrative tumor suppressor function of miR-218 in lung carcinogenesis and metastasis.
other	hsa-mir-221	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-222	Lung Neoplasms	23974492	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Metformin inhibits lung cancer cells proliferation through repressing microRNA-222.
other	hsa-mir-222	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-26	Lung Neoplasms	23035181	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Other significantly differentiated miR families included carcinogenesis-related miR-146, miR-26, and miR-17 (P (FCS) < 0.05).
other	hsa-mir-26a	Lung Neoplasms	24788552	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-26a involved in Toll-like receptor 9-mediated lung cancer growth and migration.
other	hsa-mir-27a	Lung Neoplasms	27602162	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling.
other	hsa-mir-29	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-29b	Lung Neoplasms	28164574	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression and Function Analysis of MicroRNA-29b in Xuanwei Lung Cancer.
other	hsa-mir-29b	Lung Neoplasms	28869603	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	DNMT1 and KIT form a positive regulatory loop, in which ectopic DNMT1 expression increases, whereas targeted DNMT1 depletion abrogates KIT signaling cascade through Sp1/miR-29b network
other	hsa-mir-30a	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The most frequently amplified miRNA genes include the following: miR-30d, miR-21, miR-17 and miR-155.
other	hsa-mir-30c	Lung Neoplasms	25340791	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, miR-30c, a FHIT-upregulated microRNA, contributes to FHIT function in suppression of EMT and metastasis
other	hsa-mir-30d	Lung Neoplasms	20194856	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	levels of four miRNAs (ie, miR-486, miR-30d, miR-1 and miR-499) were significantly associated with overall survival
other	hsa-mir-30d	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The most frequently amplified miRNA genes include the following: miR-30d, miR-21, miR-17 and miR-155.
other	hsa-mir-31	Lung Neoplasms	24978700	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Allelic imbalance in the miR-31 host gene locus in lung cancer--its potential role in carcinogenesis.
other	hsa-mir-31	Lung Neoplasms	22301433	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells.
other	hsa-mir-31	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	most analyzed miRNA genes undergo substantial copy number alteration in lung cancer.
other	hsa-mir-31	Lung Neoplasms	28197369	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome.
other	hsa-mir-326	Lung Neoplasms	23142363	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis
other	hsa-mir-328	Lung Neoplasms	25646356	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer.
other	hsa-mir-33a	Lung Neoplasms	25544258	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the treatment of lung cancer and clarify the mechanism of its progression.
other	hsa-mir-33a	Lung Neoplasms	27593936	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation.
other	hsa-mir-34	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-346	Lung Neoplasms	24157646	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.
other	hsa-mir-34a	Lung Neoplasms	24019906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the highly tumorigenic CD44(hi) cells are enriched for cells in the G2 phase of cell cycle.
other	hsa-mir-34a	Lung Neoplasms	25909221	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1).
other	hsa-mir-34a	Lung Neoplasms	19736307	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	relevant to the diagnosis
other	hsa-mir-34a	Lung Neoplasms	19921694	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-34a:MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells
other	hsa-mir-34a	Lung Neoplasms	23036084	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	microRNA-34a Sensitizes Lung Cancer Cell Lines to DDP Treatment Independent of p53 Status.
other	hsa-mir-361	Lung Neoplasms	24157646	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.
other	hsa-mir-375	Lung Neoplasms	25695220	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.
other	hsa-mir-375	Lung Neoplasms	26001155	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Reply to MiR-205 and miR-375 microRNA Assays to Distinguish Squamous Cell Carcinoma From Adenocarcinoma in Lung Cancer Biopsies.
other	hsa-mir-378	Lung Neoplasms	25646356	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer.
other	hsa-mir-4423	Lung Neoplasms	24191054	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A primate-specific microRNA enters the lung cancer landscape.
other	hsa-mir-451	Lung Neoplasms	25150396	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells.
other	hsa-mir-486	Lung Neoplasms	23980150	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer.
other	hsa-mir-486	Lung Neoplasms	26451608	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer.
other	hsa-mir-486	Lung Neoplasms	20194856	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	levels of four miRNAs (ie, miR-486, miR-30d, miR-1 and miR-499) were significantly associated with overall survival
other	hsa-mir-486	Lung Neoplasms	28124991	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis.
other	hsa-mir-487b	Lung Neoplasms	23426183	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis
other	hsa-mir-494	Lung Neoplasms	25226615	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494.
other	hsa-mir-494	Lung Neoplasms	26040900	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer.
other	hsa-mir-494	Lung Neoplasms	22151897	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells.
other	hsa-mir-497	Lung Neoplasms	25909221	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1).
other	hsa-mir-499a	Lung Neoplasms	20194856	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	levels of four miRNAs (ie, miR-486, miR-30d, miR-1 and miR-499) were significantly associated with overall survival
other	hsa-mir-503	Lung Neoplasms	24398307	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-503 was able to reverse the cisplatin resistance of A549/DDP.MiR-503 processed this kind of effect by inhibiting the drug efflux,downregulating the expression of drug-resistant related proteins and promoting cell apoptosis.
other	hsa-mir-522	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-5481	Lung Neoplasms	25245053	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results suggested that miR-548l may play a causal role through AKT1 in NSCLC invasion and metastasis.
other	hsa-mir-592	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-638	Lung Neoplasms	25952770	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
other	hsa-mir-660	Lung Neoplasms	28124991	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis.
other	hsa-mir-7	Lung Neoplasms	26108539	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1.
other	hsa-mir-7	Lung Neoplasms	25910758	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA as tools and therapeutics in lung cancer.
other	hsa-mir-7	Lung Neoplasms	22352917	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Among them, 11 miRNAs including miR-7 and miR-128b were confirmed by published experimental data or literatures.
other	hsa-mir-720	Lung Neoplasms	25286763	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Evaluation of miR-720 prognostic significance in patients with colorectal cancer.
other	hsa-mir-768	Lung Neoplasms	23928793	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis.
other	hsa-mir-769	Lung Neoplasms	26627242	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
other	hsa-mir-92	Lung Neoplasms	26156018	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	most analyzed miRNA genes undergo substantial copy number alteration in lung cancer.
other	hsa-mir-92-1	Lung Neoplasms	17384677	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In marked contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth.
other	hsa-mir-92a	Lung Neoplasms	25519225	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the screening approach used in this study can identify clinically relevant synthetic lethal interactions and that vitamin D receptor agonists may show enhanced efficacy in p53-negative lung cancer patients.
other	hsa-mir-92a	Lung Neoplasms	26451608	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results encourage exploiting the MSC test for lung cancer monitoring in LDCT screening for lung cancer.
other	hsa-mir-95	Lung Neoplasms	25831148	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Abnormal Expression of miR-21 and miR-95 in Cancer Stem-Like Cells is Associated  with Radioresistance of Lung Cancer.
other	hsa-mir-146a	Lupus Vulgaris	19333922			A18.4	D008177			miR-146a: miR-146a contributes to abnormal activation of the type i interferon pathway in human lupus by targeting the key signaling proteins
other	hsa-let-7d	Lymphoma	27300436	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	螖Np63 inhibition decreases the levels of its transcriptional target, DGCR8, and the maturation of  let-7d and miR-128
other	hsa-mir-10b	Lymphoma	27611973	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Profile of Exosomal and Intracellular microRNA in Gamma-Herpesvirus-Infected Lymphoma Cell Lines.
other	hsa-mir-127	Lymphoma	26640803	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The result of cross validation indicates that MiRNAClassify significantly outperforms other methods and models. In addition, the newly added pre-miRNAs are used to further evaluate the ability of these methods to discover novel pre-miRNAs. MiRNAClassify still achieves consistently superior performance and can discover more pre-miRNAs.
other	hsa-mir-128	Lymphoma	27300436	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	螖Np63 inhibition decreases the levels of its transcriptional target, DGCR8, and the maturation of  let-7d and miR-128
other	hsa-mir-143	Lymphoma	27611973	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Profile of Exosomal and Intracellular microRNA in Gamma-Herpesvirus-Infected Lymphoma Cell Lines.
other	hsa-mir-146a	Lymphoma	28918474	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium.
other	hsa-mir-146a	Lymphoma	21416002	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	In addition, LMP1 can also modulate cellular gene expression programs by affecting, via the NF-κB pathway, levels of cellular microRNAs miR-146a and miR-155
other	hsa-mir-150	Lymphoma	21502955	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	microRNA-150 is a tumor suppressor in malignant lymphoma
other	hsa-mir-150	Lymphoma	24633319	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The previously reported up-regulation of miR-150 in marginal zone lymphoma of MALT type was verified in an independent cohort of lymphoma samples employing a modified methodology. This further substantiates the role of miR-150 as a potential oncomiR in MALT lymphoma.
other	hsa-mir-155	Lymphoma	22096245	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-155 regulates HGAL expression and increases lymphoma cell motility.
other	hsa-mir-155	Lymphoma	22268450	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.
other	hsa-mir-155	Lymphoma	23815945	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Influence of miRNA-155 on lymphoma.
other	hsa-mir-155	Lymphoma	24345320	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary vitreoretinal B-cell lymphoma and uveitis might be characterized by distinct microRNA signatures. Quantification of ocular microRNA-155 might be helpful in the differential diagnosis of these 2 diseases.
other	hsa-mir-155	Lymphoma	25645925	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-155 controls the outcome of the GC reaction by modulating its initiation (Aicda) and termination (Socs1/p53 response)
other	hsa-mir-155	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-155	Lymphoma	20133617	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Together, our data helped explain miR-155 function, highlighted a hitherto unappreciated role of SMAD5 in lymphoma biology, and defined a unique mechanism used by cancer cells to escape TGF-beta's growth-inhibitory effects.
other	hsa-mir-155	Lymphoma	29228427	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway
other	hsa-mir-155	Lymphoma	21416002	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	In addition, LMP1 can also modulate cellular gene expression programs by affecting, via the NF-κB pathway, levels of cellular microRNAs miR-146a and miR-155
other	hsa-mir-15a	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-16	Lymphoma	23686310	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
other	hsa-mir-16	Lymphoma	28976967	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A viral Sm-class RNA base-pairs with mRNAs and recruits microRNAs to inhibit apoptosis.
other	hsa-mir-16-1	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-17	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-17	Lymphoma	19933089	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-17-5p can induce tumorigenesis, such as lymphoma and vascularized tumor as an oncogene
other	hsa-mir-17	Lymphoma	25870038	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation.
other	hsa-mir-17	Lymphoma	16096373	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Herein, we propose a model in which the mir-17 cluster prevents excessive E2F1 activity, and thereby apoptosis, in response to activation of c-Myc.
other	hsa-mir-17	Lymphoma	17608773	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron.
other	hsa-mir-17	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-17	Lymphoma	18329372	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development.
other	hsa-mir-18	Lymphoma	25870038	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation.
other	hsa-mir-18	Lymphoma	17608773	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron.
other	hsa-mir-18	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-18	Lymphoma	18329372	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development.
other	hsa-mir-181a	Lymphoma	21525173	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A multivariate Cox regression analysis including the IPI, the 6-gene model-derived mortality predictor score and expression of the miR-18a, miR-181a, and miR-222, revealed that all variables were independent predictors of survival except the expression of miR-222 for OS and the expression of miR-18a for PFS.
other	hsa-mir-18a	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-18a	Lymphoma	19933089	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	it can induce tumorigenesis, such as lymphoma and vascularized tumor as an oncogene
other	hsa-mir-18a	Lymphoma	21525173	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A multivariate Cox regression analysis including the IPI, the 6-gene model-derived mortality predictor score and expression of the miR-18a, miR-181a, and miR-222, revealed that all variables were independent predictors of survival except the expression of miR-222 for OS and the expression of miR-18a for PFS.
other	hsa-mir-18b	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-193b	Lymphoma	23288923	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Interestingly, down-regulation of micro-RNAs mmu-miR-30a and mmu-miR-141 as well as hsa-miR-193b clearly contributes to enhance the expression of this gene in mouse and human lymphomas
other	hsa-mir-194	Lymphoma	26147452	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	modulation of microRNA-194 may constitute a novel approach to inhibiting proliferation of EBV(+) B cell lymphomas in PTLD.
other	hsa-mir-199a	Lymphoma	26251897	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
other	hsa-mir-19a	Lymphoma	25870038	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation.
other	hsa-mir-19a	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-19a	Lymphoma	19933089	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	it can induce tumorigenesis, such as lymphoma and vascularized tumor as an oncogene
other	hsa-mir-19a	Lymphoma	17608773	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron.
other	hsa-mir-19a	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-19a	Lymphoma	18329372	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development.
other	hsa-mir-19b-1	Lymphoma	25870038	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation.
other	hsa-mir-19b-1	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-19b-1	Lymphoma	17608773	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron.
other	hsa-mir-19b-1	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-19b-1	Lymphoma	18329372	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development.
other	hsa-mir-19b-2	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-200c	Lymphoma	26639163	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.
other	hsa-mir-203	Lymphoma	26639163	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.
other	hsa-mir-20a	Lymphoma	25870038	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation.
other	hsa-mir-20a	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-20a	Lymphoma	19933089	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	it can induce tumorigenesis, such as lymphoma and vascularized tumor as an oncogene
other	hsa-mir-20a	Lymphoma	17608773	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron.
other	hsa-mir-20a	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-20a	Lymphoma	18329372	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development.
other	hsa-mir-20a	Lymphoma	21114763	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The pro-senescence role of miR-20a and miR-290 in MEF is apparently in contrast with their proliferative role in tumour and ES cells.
other	hsa-mir-20b	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-21	Lymphoma	26116372	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-21: an environmental driver of malignant melanoma
other	hsa-mir-21	Lymphoma	26150475	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Expression and clinicopathological significance of microRNA-21 and programmed cell death 4 in malignant melanoma.
other	hsa-mir-222	Lymphoma	21525173	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A multivariate Cox regression analysis including the IPI, the 6-gene model-derived mortality predictor score and expression of the miR-18a, miR-181a, and miR-222, revealed that all variables were independent predictors of survival except the expression of miR-222 for OS and the expression of miR-18a for PFS.
other	hsa-mir-26a	Lymphoma	23338972	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Our investigation of the mechanisms underlying the decrease in miR-26a in this lymphoma revealed novel evidence that STAT3, a major downstream substrate of NPM-ALK tyrosine kinase activity,suppresses MIR26A1 gene expression.
other	hsa-mir-26a	Lymphoma	23538750	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Loss- or gain-of-function approaches revealed that miR-26a functioned as a tumor suppressor miRNA and mediated the combinatorial effects of JQ1 and DZNep.
other	hsa-mir-31	Lymphoma	26639163	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.
other	hsa-mir-497	Lymphoma	26251897	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
other	hsa-mir-92-1	Lymphoma	25870038	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation.
other	hsa-mir-92-1	Lymphoma	17608773	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The c13orf25/miR-17 cluster, which is responsible for 13q31-q32 amplification in malignant lymphoma, contains the microRNA-17-18-19-20-92 polycistron.
other	hsa-mir-92-1	Lymphoma	17727326	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
other	hsa-mir-92-1	Lymphoma	18329372	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These results provide key insights into the physiologic functions of this family of microRNAs and suggest a link between the oncogenic properties of miR-17 approximately 92 and its functionsduring B lymphopoiesis and lung development.
other	hsa-mir-92a-1	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-92a-2	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-92b	Lymphoma	17093929	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	These data demonstrate that OncomiR-1 accelerates lymphoma and promotes a more disseminated disease.
other	hsa-mir-146a	Lymphoma, B-Cell	25906746	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Together our findings illuminate a bona fide role for miR-146a in the modulation of B-cell oncogenesis and reveal the importance of understanding microRNA function in a cell- and disease-specific context.
other	hsa-mir-155	Lymphoma, B-Cell	25541152	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Importantly, the targeting of miRNAs (like use of anti-miR-155 or miR-34a mimic)  could provide a novel therapeutic approach as evidenced by tumour regression in xenograft mouse models and initial promising data from clinical trials.
other	hsa-mir-17	Lymphoma, B-Cell	20008931	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	The miR-17 approximately 92 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA)
other	hsa-mir-18	Lymphoma, B-Cell	20008931	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	The miR-17 approximately 93 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA)
other	hsa-mir-19a	Lymphoma, B-Cell	21200023	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	diffuse large B-cell lymphoma
other	hsa-mir-19a	Lymphoma, B-Cell	20008931	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	The miR-17 approximately 94 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA)
other	hsa-mir-19b-1	Lymphoma, B-Cell	21200023	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	diffuse large B-cell lymphoma
other	hsa-mir-19b-1	Lymphoma, B-Cell	20008931	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	The miR-17 approximately 95 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA)
other	hsa-mir-19b-2	Lymphoma, B-Cell	21200023	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	diffuse large B-cell lymphoma
other	hsa-mir-20a	Lymphoma, B-Cell	20008931	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	The miR-17 approximately 96 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA)
other	hsa-mir-21	Lymphoma, B-Cell	20693987	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-21:OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
other	hsa-mir-21	Lymphoma, B-Cell	21200023	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	diffuse large B-cell lymphoma
other	hsa-mir-21	Lymphoma, B-Cell	23548551	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Inhibition of miR-21 Induces Biological and Behavioral Alterations in Diffuse Large B-Cell Lymphoma
other	hsa-mir-29a	Lymphoma, B-Cell	20086245	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	our results in primary MCL cells indicate that down-regulation of miR-29 could cooperate with cyclin D1 in MCL pathogenesis. Thus, our findings provide not only miRNA expression signature but also a novel prognostic marker and pathogenetic factor for this malignancy.
other	hsa-mir-34a	Lymphoma, B-Cell	25541152	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Importantly, the targeting of miRNAs (like use of anti-miR-155 or miR-34a mimic)  could provide a novel therapeutic approach as evidenced by tumour regression in xenograft mouse models and initial promising data from clinical trials.
other	hsa-mir-92-1	Lymphoma, B-Cell	20008931	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	The miR-17 approximately 96 cluster is frequently amplified or overexpressed in human cancers and has emerged as the prototypical oncogenic polycistron microRNA (miRNA)
other	hsa-mir-92a-1	Lymphoma, B-Cell	21200023	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	diffuse large B-cell lymphoma
other	hsa-mir-92a-2	Lymphoma, B-Cell	21200023	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	diffuse large B-cell lymphoma
other	hsa-mir-101	Lymphoma, Burkitt	24577510	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
other	hsa-mir-10a	Lymphoma, Burkitt	28400759	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma.
other	hsa-mir-127	Lymphoma, Burkitt	22941339	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells.
other	hsa-mir-142	Lymphoma, Burkitt	27796281	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Epstein-Barr Virus (EBV)-BamHI-A Rightward Transcript (BART)-6 and Cellular MicroRNA-142 Synergistically Compromise Immune Defense of Host Cells in EBV-Positive Burkitt Lymphoma.
other	hsa-mir-143	Lymphoma, Burkitt	24577510	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
other	hsa-mir-145	Lymphoma, Burkitt	24577510	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
other	hsa-mir-146a	Lymphoma, Burkitt	18347435	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	induced by EBV-encoded latent membrane protein 1 (LMP1)
other	hsa-mir-155	Lymphoma, Burkitt	17965831	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	miR-155 has also been implicated in a number of cancers including Burkitt_s lymphoma, Hodgkin lymphoma and lung cancer.
other	hsa-mir-155	Lymphoma, Burkitt	18347435	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	induced by EBV-encoded latent membrane protein 1 (LMP1)
other	hsa-mir-155	Lymphoma, Burkitt	18354490	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	process BIC
other	hsa-mir-155	Lymphoma, Burkitt	21831295	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	miR-93 repressed human activation induced cytidine deaminase.
other	hsa-mir-155	Lymphoma, Burkitt	17173072	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Our data provide evidence for two levels of regulation for mature miR-155 expression: one at the transcriptional level involving PKC and NF-kappaB, and one at the processing level. Burkitt lymphoma cells not only express low levels of BIC, but also prevent processing of BIC via an, as yet, unknown mechanism.
other	hsa-mir-15a	Lymphoma, Burkitt	26893685	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs
other	hsa-mir-17	Lymphoma, Burkitt	17135268	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma.
other	hsa-mir-18	Lymphoma, Burkitt	17135268	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma.
other	hsa-mir-197	Lymphoma, Burkitt	28259992	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	EBV‑BART‑6‑3p and cellular microRNA‑197 compromise the immune defense of host cells in EBV‑positive Burkitt lymphoma.
other	hsa-mir-19a	Lymphoma, Burkitt	17135268	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma.
other	hsa-mir-19b-1	Lymphoma, Burkitt	17135268	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma.
other	hsa-mir-20a	Lymphoma, Burkitt	17135268	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma.
other	hsa-mir-29a	Lymphoma, Burkitt	25746661	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.
other	hsa-mir-29b	Lymphoma, Burkitt	25746661	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.
other	hsa-mir-29c	Lymphoma, Burkitt	25746661	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.
other	hsa-mir-34b	Lymphoma, Burkitt	18802929	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	These results indicate for the first time that hsa-mir-34b may influence c-Myc expression in Burkitt lymphoma as the more common aberrant control exercised by the immunoglobulin enhancer locus.
other	hsa-mir-92-1	Lymphoma, Burkitt	17135268	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We recently demonstrated that a polycistronic cluster of miRNAs, miR-17-92, is oncogenic in a mouse model for Burkitt's lymphoma.
other	hsa-mir-92a	Lymphoma, Burkitt	27044389	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Our results describe for the first time miR-17, miR-19a, miR-19b, miR-20a, and miR-92a expression profiles in pBL.
other	hsa-mir-93	Lymphoma, Burkitt	21831295	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	miR-93 repressed human activation induced cytidine deaminase.
other	hsa-mir-17	Lymphoma, Follicular	26997445	disease of cellular proliferation	DOID:0050873	C82	D008224	613024		miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.
other	hsa-mir-31	Lymphoma, Follicular	26997445	disease of cellular proliferation	DOID:0050873	C82	D008224	613024		miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.
other	hsa-mir-155	Lymphoma, Hodgkin	17965831	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-155 has also been implicated in a number of cancers including Burkitt_s lymphoma, Hodgkin lymphoma and lung cancer.
other	hsa-mir-196a-1	Lymphoma, Hodgkin	24145479	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	MicroRNA and gene networks in human Hodgkin's lymphoma.
other	hsa-mir-9	Lymphoma, Hodgkin	26089393	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	We report a high-resolution time series study of transcriptome dynamics following antimiR-mediated inhibition of miR-9 in a Hodgkin lymphoma cell-line-the first such dynamic study of the microRNA inhibition response-revealing both general and specific aspects of the physiological response.
other	hsa-mir-9	Lymphoma, Hodgkin	24145479	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	MicroRNA and gene networks in human Hodgkin's lymphoma.
other	hsa-mir-1234	Lymphoma, Large B-Cell, Diffuse	23841503	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas.
other	hsa-mir-150	Lymphoma, Large B-Cell, Diffuse	25866097	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses.
other	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	24989312	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Role of miR-155 in pathogenesis of diffuse large B cell lymphoma and its possible mechanism
other	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	25866097	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses.
other	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	22609116	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-155 Regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma.
other	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	28281962	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		MicroRNA-155 Downregulation Promotes Cell Cycle Arrest and Apoptosis in Diffuse Large B-Cell Lymphoma.
other	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	26523117	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		In particular, it has been strongly implicated in the causation of diffuse large B-cell lymphomas.
other	hsa-mir-18a	Lymphoma, Large B-Cell, Diffuse	25866097	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses.
other	hsa-mir-200	Lymphoma, Large B-Cell, Diffuse	24390222	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior.
other	hsa-mir-20a	Lymphoma, Large B-Cell, Diffuse	29156774	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma
other	hsa-mir-221	Lymphoma, Large B-Cell, Diffuse	25866097	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses.
other	hsa-mir-222	Lymphoma, Large B-Cell, Diffuse	25866097	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses.
other	hsa-mir-342	Lymphoma, Large B-Cell, Diffuse	25866097	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR signature from DLBCL biopsies can discriminate between patients with favorable and poor prognoses.
other	hsa-mir-34a	Lymphoma, Large B-Cell, Diffuse	22522790	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo.
other	hsa-mir-155	Lymphoma, Large-Cell, Anaplastic	25820993	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
other	hsa-mir-17	Lymphoma, Large-Cell, Anaplastic	23975180	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	The microRNA-17~92 cluster is involved in lymphomagenesis of STAT3(+) ALCL and that its inhibition might represent an alternative avenue to interfere with ALK signaling in anaplastic large cell lymphomas.
other	hsa-mir-15a	Lymphoma, Mantle-Cell	22002311			C83.10	D020522			Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
other	hsa-mir-16-1	Lymphoma, Mantle-Cell	22002311			C83.10	D020522			Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
other	hsa-mir-20b	Lymphoma, Mantle-Cell	20485376			C83.10	D020522			miR-20b:miR-20b, whose lack of expression distinguished cases with a survival probability of 56% at 60 months
other	hsa-mir-26a-1	Lymphoma, Mantle-Cell	20485376			C83.10	D020522			miR-26a:NF-kappaB subunit nuclear translocation to be regulated by the expression of miR-26a
other	hsa-mir-26a-2	Lymphoma, Mantle-Cell	20485376			C83.10	D020522			miR-26a:NF-kappaB subunit nuclear translocation to be regulated by the expression of miR-26a
other	hsa-let-7a	Lymphoma, Non-Hodgkin	24648290	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Accordingly, c-Myc-targeting microRNAs let-7a and miR-26a were induced in all treated lymphomas and the cap-dependent translation machinery components 4E-BP1, eIF4E and eIF4G, as well as their upstream regulators, Akt and PIM kinases, were inhibited in function of the cell sensitivity to ITF2357, and, in turn, c-Myc downregulation.
other	hsa-mir-148b	Lymphoma, Non-Hodgkin	22843616	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	MicroRNA-148b enhances the radiosensitivity of non-Hodgkin's Lymphoma cells by promoting radiation-induced apoptosis.
other	hsa-mir-26a	Lymphoma, Non-Hodgkin	24648290	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Accordingly, c-Myc-targeting microRNAs let-7a and miR-26a were induced in all treated lymphomas and the cap-dependent translation machinery components 4E-BP1, eIF4E and eIF4G, as well as their upstream regulators, Akt and PIM kinases, were inhibited in function of the cell sensitivity to ITF2357, and, in turn, c-Myc downregulation.
other	hsa-mir-26b	Lymphoma, Non-Hodgkin	23978716	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Hepatitis C-associated B-cell non-Hodgkin lymphomas: the emerging role of miRNA-26b.
other	hsa-mir-126	Lymphoma, T-Cell, Cutaneous	24033365	disease of cellular proliferation	DOID:0060061	C84.A0	D016410	608856	HP:0012192	Taken together, our findings suggest that both malignant and non-malignant T cells express miR-155 in situ in CTCL. Moreover, they indicate heterogeneity in miR-155 expression among malignant T cells.
other	hsa-mir-150	Lymphoma, T-Cell, Cutaneous	24627548	disease of cellular proliferation	DOID:0060061	C84.A0	D016410	608856	HP:0012192	In this issue of Blood, Ito et al demonstrate pathogenic implications of microRNA-150 (miR-150) repression in an aggressive form of cutaneous T-cell lymphoma (CTCL).
other	hsa-mir-155	Lymphoma, T-Cell, Cutaneous	24033365	disease of cellular proliferation	DOID:0060061	C84.A0	D016410	608856	HP:0012192	Taken together, our findings suggest that both malignant and non-malignant T cells express miR-155 in situ in CTCL. Moreover, they indicate heterogeneity in miR-155 expression among malignant T cells.
other	hsa-mir-21	Lymphoma, T-Cell, Cutaneous	27422033	disease of cellular proliferation	DOID:0060061	C84.A0	D016410	608856	HP:0012192	Our findings not only demonstrate a critical role for IL15-mediated inflammation in cutaneous  T-cell lymphomagenesis, but also uncover a new oncogenic regulatory loop in CTCL  involving IL15, HDAC1, HDAC6, and miR-21 that shows differential sensitivity to isotype-specific HDAC inhibitors.
other	hsa-mir-181a	Machado-Joseph Disease	28236575	nervous system disease	DOID:1440	G11.1	D017827	109150		Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
other	hsa-mir-494	Machado-Joseph Disease	28236575	nervous system disease	DOID:1440	G11.1	D017827	109150		Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
other	hsa-mir-9	Machado-Joseph Disease	28236575	nervous system disease	DOID:1440	G11.1	D017827	109150		Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
other	hsa-let-7	Malignant Neoplasms [unspecific]	26285684			C80.1	D009369			and messenger RNAs and microRNAs miR-21, miR-27a, let-7, miR-451, among others.
other	hsa-mir-125	Malignant Neoplasms [unspecific]	26731991			C80.1	D009369			These results suggest that different members of the miR-125 family may have different functions in various cancers. Furthermore, miR-125a or miR-125b may be important clinical prognostic biomarkers for cancer patients.
other	hsa-mir-126	Malignant Neoplasms [unspecific]	26351404			C80.1	D009369			Our results indicated that miR-126 could act as a significant biomarker in the prognosis of various cancers.
other	hsa-mir-15	Malignant Neoplasms [unspecific]	28032148			C80.1	D009369			The relationship between platinum drug resistance and epithelial-mesenchymal transition.
other	hsa-mir-186	Malignant Neoplasms [unspecific]	28032148			C80.1	D009369			The relationship between platinum drug resistance and epithelial-mesenchymal transition.
other	hsa-mir-200b	Malignant Neoplasms [unspecific]	25644713			C80.1	D009369			YY1 acts as novel critical interface between epigenetic code and miRNAs machinery under chronic hypoxia in malignancy.
other	hsa-mir-200c	Malignant Neoplasms [unspecific]	25644713			C80.1	D009369			YY1 acts as novel critical interface between epigenetic code and miRNAs machinery under chronic hypoxia in malignancy.
other	hsa-mir-205	Malignant Neoplasms [unspecific]	25613953			C80.1	D009369			miRNA-205 is a promising biomarker for predicting the recurrence and progression of patients with adenocarcinomas or breast cancer. Owing to its complex roles, further relevant studies are warranted.
other	hsa-mir-21	Malignant Neoplasms [unspecific]	26320972			C80.1	D009369			Toehold-mediated nonenzymatic amplification circuit on graphene oxide fluorescence switching platform for sensitive and homogeneous microRNA detection.
other	hsa-mir-21	Malignant Neoplasms [unspecific]	26285684			C80.1	D009369			and messenger RNAs and microRNAs miR-21, miR-27a, let-7, miR-451, among others.
other	hsa-mir-22	Malignant Neoplasms [unspecific]	28000852			C80.1	D009369			Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer
other	hsa-mir-27a	Malignant Neoplasms [unspecific]	26285684			C80.1	D009369			and messenger RNAs and microRNAs miR-21, miR-27a, let-7, miR-451, among others.
other	hsa-mir-34a	Malignant Neoplasms [unspecific]	24091633			C80.1	D009369			miR-34a can potentially be exploited for DNA damage-effecting therapies of malignancies.
other	hsa-mir-451	Malignant Neoplasms [unspecific]	26285684			C80.1	D009369			and messenger RNAs and microRNAs miR-21, miR-27a, let-7, miR-451, among others.
other	hsa-mir-1202	Mandibular Prognathism	26025627			M26.19		176700		Our results indicated a possible association between the differentially expressed miRNAs and MP pathogenesis, and the precise mechanisms are needed to be further validated.
other	hsa-mir-629	Mandibular Prognathism	26025627			M26.19		176700		Our results indicated a possible association between the differentially expressed miRNAs and MP pathogenesis, and the precise mechanisms are needed to be further validated.
other	hsa-mir-638	Mandibular Prognathism	26025627			M26.19		176700		Our results indicated a possible association between the differentially expressed miRNAs and MP pathogenesis, and the precise mechanisms are needed to be further validated.
other	hsa-mir-125a	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-125a: promote growth arrest and apoptosis of MB cells
other	hsa-mir-17	Medulloblastoma	19196975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-17: collaborates with the Sonic Hedgehog pathway
other	hsa-mir-17	Medulloblastoma	27600805	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members
other	hsa-mir-18	Medulloblastoma	27600805	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members
other	hsa-mir-182	Medulloblastoma	22134538	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma.
other	hsa-mir-18a	Medulloblastoma	19196975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-18a: collaborates with the Sonic Hedgehog pathway
other	hsa-mir-199b	Medulloblastoma	19308264	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-199b-5p: MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma
other	hsa-mir-19a	Medulloblastoma	19196975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-19a: collaborates with the Sonic Hedgehog pathway
other	hsa-mir-19a	Medulloblastoma	27600805	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members
other	hsa-mir-19b-1	Medulloblastoma	19196975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-19b: collaborates with the Sonic Hedgehog pathway
other	hsa-mir-19b-1	Medulloblastoma	27600805	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members
other	hsa-mir-19b-2	Medulloblastoma	19196975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-19b: collaborates with the Sonic Hedgehog pathway
other	hsa-mir-20a	Medulloblastoma	19196975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-20a: collaborates with the Sonic Hedgehog pathway
other	hsa-mir-20a	Medulloblastoma	27600805	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members
other	hsa-mir-21	Medulloblastoma	21775132	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MicroRNA-21 suppression impedes medulloblastoma cell migration.
other	hsa-mir-30a	Medulloblastoma	21177782	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma.
other	hsa-mir-30a	Medulloblastoma	28757413	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Restoration of miR-30a expression inhibits growth, tumorigenicity of medulloblastoma cells accompanied by autophagy inhibition.
other	hsa-mir-31	Medulloblastoma	24970811	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MicroRNA-31 suppresses medulloblastoma cell growth by inhibiting DNA replication through minichromosome maintenance 2.
other	hsa-mir-31	Medulloblastoma	29377269	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Ginsenoside Rh2 inhibits proliferation and migration of medulloblastoma Daoy by down-regulation of microRNA-31
other	hsa-mir-34a	Medulloblastoma	25348795	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MiR-34a deficiency accelerates medulloblastoma formation in vivo.
other	hsa-mir-367	Medulloblastoma	26250335	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-367 promotes proliferation and stem-like traits in medulloblastoma cells.
other	hsa-mir-9-1	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-9: promote growth arrest and apoptosis of MB cells
other	hsa-mir-9-2	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-9: promote growth arrest and apoptosis of MB cells
other	hsa-mir-92-1	Medulloblastoma	27600805	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Dicer1 ablation impairs Shh-induced GNP proliferation by disrupting the expression of distinct cell cycle regulator genes that are targets of miR-17/92 cluster members
other	hsa-mir-92a-1	Medulloblastoma	19196975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-92a: collaborates with the Sonic Hedgehog pathway
other	hsa-mir-92a-2	Medulloblastoma	19196975	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-92a: collaborates with the Sonic Hedgehog pathway
other	hsa-mir-9-3	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-9: promote growth arrest and apoptosis of MB cells
other	hsa-let-7	Melanoma	28482074	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The overexpression of Lin28B reduced mature let-7 microRNA expression in melanoma cell lines
other	hsa-let-7a	Melanoma	26693896	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Aberrant activation of some known miRNAs, e.g. let-7a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR-214, miR-221 and 222, has been recognised to be linked with melanoma-associated genes
other	hsa-let-7a	Melanoma	27063098	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	two other miRNA modulators of EMT (miR-191 and let-7a) in serum exosomes
other	hsa-let-7b	Melanoma	25868368	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The concomitant inhibition of MMP-9 and MMP-13 affects prognosis and survival in skin melanoma.
other	hsa-let-7b	Melanoma	21087605	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Taken together, the present study identifies let-7b as a tumor suppressor that represses cancer cell proliferation and migration as well as tumor metastasis in mouse melanoma cells.
other	hsa-let-7b	Melanoma	26754091	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	EGCG up-regulated miRNA-let-7b expression through 67LR in melanoma cells.
other	hsa-let-7i	Melanoma	27063098	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	two other miRNA modulators of EMT (miR-191 and let-7a) in serum exosomes
other	hsa-mir-106a	Melanoma	23217102	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy. Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b, but not after dacarbazine.
other	hsa-mir-106b	Melanoma	25361006	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Down-regulation of miRNA-106b inhibits growth of melanoma cells by promoting G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1 protein.
other	hsa-mir-124-1	Melanoma	23404119	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-124a could function as a potent tumor suppressor in the development of uveal melanoma
other	hsa-mir-124-2	Melanoma	23404119	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-124a could function as a potent tumor suppressor in the development of uveal melanoma
other	hsa-mir-124-3	Melanoma	23404119	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-124a could function as a potent tumor suppressor in the development of uveal melanoma
other	hsa-mir-125a	Melanoma	28140520	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
other	hsa-mir-125b	Melanoma	28614272	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
other	hsa-mir-125b-1	Melanoma	20153427	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-125b:miRNA125b may be involved in the regulation of VDR expression and in the resistance against 1,25(OH)(2)D(3) in melanoma cells
other	hsa-mir-125b-1	Melanoma	22213330	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)(2)D(3)-responsive and -resistant melanoma cell lines and in the NHM.
other	hsa-mir-125b-2	Melanoma	20153427	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-125b:miRNA125b may be involved in the regulation of VDR expression and in the resistance against 1,25(OH)(2)D(3) in melanoma cells
other	hsa-mir-125b-2	Melanoma	22213330	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)(2)D(3)-responsive and -resistant melanoma cell lines and in the NHM.
other	hsa-mir-126	Melanoma	23217102	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy. Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b, but not after dacarbazine.
other	hsa-mir-1280	Melanoma	25195599	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Antitumor activity of miR-1280 in melanoma by regulation of Src.
other	hsa-mir-137	Melanoma	18316599	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines.
other	hsa-mir-141	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-141	Melanoma	20957176	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members.
other	hsa-mir-141	Melanoma	27616325	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Trans-nonachlor decreases miR-141-3p levels in human melanocytes in vitro promoting melanoma cell characteristics and shows a multigenerational impact on miR-8 levels in Drosophila.
other	hsa-mir-142	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04).
other	hsa-mir-142	Melanoma	26763444	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
other	hsa-mir-144	Melanoma	29260980	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Baohuoside-I suppresses cell proliferation and migration by up-regulating miR-144 in melanoma
other	hsa-mir-146b	Melanoma	26763444	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
other	hsa-mir-149	Melanoma	21896753	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	p53 directly up-regulates microRNA-149* (miR-149*) that in turn targets glycogen synthase kinase-3ж┿ resulting in increased expression of Mcl-1 and resistance to apoptosis in melanoma cells. Although deficiency in miR-149* undermined survival of melanoma cells and inhibited melanoma growth in a mouse xenograft model, elevated expression of miR-149* was found in fresh human metastatic melanoma isolates, which was associated with decreased glycogen synthase kinase-3ж┿and increased Mcl-1.
other	hsa-mir-150	Melanoma	25054912	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Role of microRNA-150 and glycoprotein nonmetastatic melanoma protein B in angiogenesis during hyperoxia-induced neonatal lung injury.
other	hsa-mir-150	Melanoma	26763444	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
other	hsa-mir-155	Melanoma	26176991	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	hsa-mir-214-3p, hsa-miR-199a-3p,hsa-miR-155-5p in subsets of EVs released by melanoma cells, with significant similarities to clinical melanoma tissue, and provides unique insights into the contribution of EV associated extracellular RNA in cancer.
other	hsa-mir-155	Melanoma	26763444	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
other	hsa-mir-15a	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-15b	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-16	Melanoma	23217102	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy. Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b, but not after dacarbazine.
other	hsa-mir-16-1	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-16-2	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-17	Melanoma	24920276	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex.
other	hsa-mir-18	Melanoma	24920276	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex.
other	hsa-mir-181a	Melanoma	29041990	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Piceatannol induced apoptosis through up-regulation of microRNA-181a in melanoma cells.
other	hsa-mir-182	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-182	Melanoma	28412746	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Krüppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions.
other	hsa-mir-183	Melanoma	28412746	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Krüppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions.
other	hsa-mir-18b	Melanoma	23365201	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The Role of miR-18b in MDM2-p53 Pathway Signaling and Melanoma Progression
other	hsa-mir-18b	Melanoma	24303553	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Role of miR-18b/MDM2/p53 circuitry in melanoma progression.
other	hsa-mir-191	Melanoma	27063098	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	two other miRNA modulators of EMT (miR-191 and let-7a) in serum exosomes
other	hsa-mir-193b	Melanoma	22665054	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Taken together, our study suggests that downregulation of miR-193b may contribute to increased STMN1 expression in melanoma, which consequently promotes migration and proliferation of tumor cells.
other	hsa-mir-194	Melanoma	27573550	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-194 is a negative regulator of GEF-H1 pathway in melanoma.
other	hsa-mir-196a-1	Melanoma	20480203	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-196a:MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma
other	hsa-mir-196a-2	Melanoma	20480203	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-196a:MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma
other	hsa-mir-199a	Melanoma	26176991	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	hsa-mir-214-3p, hsa-miR-199a-3p,hsa-miR-155-5p in subsets of EVs released by melanoma cells, with significant similarities to clinical melanoma tissue, and provides unique insights into the contribution of EV associated extracellular RNA in cancer.
other	hsa-mir-199a	Melanoma	23217102	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy. Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b, but not after dacarbazine.
other	hsa-mir-199a-1	Melanoma	23162627	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Let-7b and microRNA-199a inhibit the proliferation of B16F10 melanoma cells
other	hsa-mir-199a-2	Melanoma	23162627	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Let-7b and microRNA-199a inhibit the proliferation of B16F10 melanoma cells
other	hsa-mir-19a	Melanoma	24920276	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex.
other	hsa-mir-19b-1	Melanoma	24920276	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex.
other	hsa-mir-200a	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-200a	Melanoma	20957176	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members.
other	hsa-mir-200b	Melanoma	20957176	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members.
other	hsa-mir-200c	Melanoma	20957176	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members.
other	hsa-mir-203	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-204	Melanoma	29523154	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS
other	hsa-mir-205	Melanoma	22890556	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-205 is a tumor suppressor microRNAin malignant melanoma.
other	hsa-mir-205	Melanoma	28614272	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
other	hsa-mir-206	Melanoma	24289491	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.
other	hsa-mir-20a	Melanoma	24920276	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex.
other	hsa-mir-21	Melanoma	21940630	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-21 regulates the metastatic behavior of B16 melanoma cells.
other	hsa-mir-21	Melanoma	25868368	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The concomitant inhibition of MMP-9 and MMP-13 affects prognosis and survival in skin melanoma.
other	hsa-mir-21	Melanoma	29058784	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin
other	hsa-mir-210	Melanoma	22962263	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our findings show how miR-210 induction links hypoxia to immune escape from CTL-mediated lysis, by providing a mechanistic understanding of how this miRNA mediates immunosuppression in oxygen-deprived regions of tumors where cancer stem-like cells and metastatic cellular behaviors are known to evolve.
other	hsa-mir-210	Melanoma	26536104	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	methyl sulfone decreased expression of the master regulator of hypoxia, HIF-1伪, and reduced levels of the  glycolytic enzymes, PKM2, LDHA, GLUT1, the pro-angiogenic protein, VEGF, and the  iron-sulfur metabolism molecules, miR-210 and transferrin, all of which promote metastasis.
other	hsa-mir-211	Melanoma	21435193	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.
other	hsa-mir-211	Melanoma	27548915	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Melanoma miRNA trafficking controls tumour primary niche formation.
other	hsa-mir-211	Melanoma	27571736	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Pigmented melanosomes are now shown to have a relevant role in establishing a tumour niche in primary melanoma by reprogramming dermal fibroblasts into cancer-associated fibroblasts through the transfer of miR-211
other	hsa-mir-214	Melanoma	26176991	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	hsa-mir-214-3p, hsa-miR-199a-3p,hsa-miR-155-5p in subsets of EVs released by melanoma cells, with significant similarities to clinical melanoma tissue, and provides unique insights into the contribution of EV associated extracellular RNA in cancer.
other	hsa-mir-214	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04).
other	hsa-mir-214	Melanoma	21593728	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-214 drives melanoma metastasis.
other	hsa-mir-218-1	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04).
other	hsa-mir-218-2	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04).
other	hsa-mir-221	Melanoma	20547861	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	microRNA-221:Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells
other	hsa-mir-221	Melanoma	25492219	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The hair shaft miR-221 levels were significantly higher in patients with MM than controls.
other	hsa-mir-221	Melanoma	24035906	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we report the production of circular microRNA sponges against miR-21 or miR-221 in cell lines using the self-splicing permuted intron-exon sequences derived from T4 bacteriophage gene td.
other	hsa-mir-221	Melanoma	26693896	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Aberrant activation of some known miRNAs, e.g. let-7a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR-214, miR-221 and 222, has been recognised to be linked with melanoma-associated genes
other	hsa-mir-221	Melanoma	28936555	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Resveratrol suppresses melanoma by inhibiting NF-κB/miR-221 and inducing TFG expression.
other	hsa-mir-222	Melanoma	26338962	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-222 could function as a biomarker for the prediction of response to ipilimumab
other	hsa-mir-222	Melanoma	26912358	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	vesicles released by miR-222-overexpressing cells were able to transfer miR-222-dependent malignancy when taken-up by recipient primary  melanomas.
other	hsa-mir-222	Melanoma	28858076	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	KIT and mir-222 might be key genomic contributors toward the clinical differences observed
other	hsa-mir-26b	Melanoma	26872428	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-26b inhibits melanoma cell proliferation and enhances apoptosis by suppressing TRAF5-mediated MAPK activation.
other	hsa-mir-27b	Melanoma	22213330	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Treatment with 1,25(OH)(2)D(3) and/or epigenetic drugs (5-Aza, TSA) reduced the miR-27b expression in three out of four melanoma cell lines.
other	hsa-mir-27b	Melanoma	20495621	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we identified miRNAs that are up- and down-regulated in melanoma cells exposed to a hESC microenvironment, such as miR-302a and miR-27b, respectively.
other	hsa-mir-29b	Melanoma	27852308	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Systems analysis identifies miR-29b regulation of invasiveness in melanoma.
other	hsa-mir-302a	Melanoma	20495621	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we identified miRNAs that are up- and down-regulated in melanoma cells exposed to a hESC microenvironment, such as miR-302a and miR-27b, respectively.
other	hsa-mir-31	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04).
other	hsa-mir-320	Melanoma	27816966	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	HUR protects NONO from degradation by mir320, which is induced by p53 upon UV irradiation.
other	hsa-mir-340	Melanoma	25043973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma.
other	hsa-mir-340	Melanoma	26554847	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This is the first study showing the relationship between miR-340-5p and expression of ABCB5, a transmembrane transporter involved in drug resistance considered as a marker of melanoma stem-like cells.
other	hsa-mir-342	Melanoma	26763444	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
other	hsa-mir-34a	Melanoma	22102694	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress induced ligand of the natural killer cell receptor NKG2D.
other	hsa-mir-34a	Melanoma	21051724	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The authors' previous studies on miR-34a showed that miRNA can influence the growth of uveal melanoma cells.
other	hsa-mir-34a	Melanoma	21541354	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-34a and miR-185 were further shown to inhibit the growth of melanoma xenografts when implanted in SCID-NOD mice.
other	hsa-mir-34a	Melanoma	22198089	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our preliminary study suggests that miR-34a, although having a role in late tumorigenesis, does not contribute to the inherited susceptibility to cutaneous melanoma. 
other	hsa-mir-34a	Melanoma	28759238	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Ternary Nanoparticles with a Sheddable Shell Efficiently Deliver MicroRNA-34a against CD44-Positive Melanoma.
other	hsa-mir-34b	Melanoma	21949788	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Expression of miR-34b reduced cell invasion and motility rates of both WM1552C and A375, suggesting that the enhanced cell invasiveness and motility observed in metastatic melanoma cells may be related to their reduced expression of miR-34b.
other	hsa-mir-34b	Melanoma	28194372	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-34b-5p Suppresses Melanoma Differentiation-Associated Gene 5 (MDA5) Signaling Pathway to Promote Avian Leukosis Virus Subgroup J (ALV-J)-Infected Cells Proliferaction and ALV-J Replication.
other	hsa-mir-34c	Melanoma	22102694	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress induced ligand of the natural killer cell receptor NKG2D.
other	hsa-mir-362	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04).
other	hsa-mir-375	Melanoma	21723283	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Ectopic expression of miR-375 inhibited melanoma cell proliferation, invasion, and cell motility, and induced cell shape changes, strongly suggesting that miR-375 may have an important function in the development and progression of human melanomas.
other	hsa-mir-378	Melanoma	28513838	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The emerging role of NPNT in tissue injury repair and bone homeostasis.
other	hsa-mir-4286	Melanoma	28005927	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells.
other	hsa-mir-429	Melanoma	20957176	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overall our findings call into question the general role of miR-200 in suppressing invasion and metastasis, and highlight novel distinguishing characteristics of individual miR-200 family members.
other	hsa-mir-451a	Melanoma	25237911	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion.
other	hsa-mir-455	Melanoma	25686251	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.
other	hsa-mir-486	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04).
other	hsa-mir-625	Melanoma	28129648	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma.
other	hsa-mir-650	Melanoma	21543894	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31, were significantly correlated with acral as compared to non-acral melanomas (p < 0.04).
other	hsa-mir-768	Melanoma	23770856	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.
other	hsa-mir-9-1	Melanoma	22825752	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kB1 pathway.
other	hsa-mir-9-2	Melanoma	22825752	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kB1 pathway.
other	hsa-mir-92-1	Melanoma	24920276	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex.
other	hsa-mir-92a	Melanoma	27620505	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells.
other	hsa-mir-9-3	Melanoma	22825752	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kB1 pathway.
other	hsa-mir-96	Melanoma	22927992	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203.
other	hsa-mir-96	Melanoma	28412746	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Krüppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions.
other	hsa-mir-200a	Meningioma	19703647	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Down-regulation Promotes Tumor Growth by reducing E-cadherin and Activating the Wnt/{beta} catenin Signaling Pathway
other	hsa-mir-200a	Meningioma	24858044	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo.
other	hsa-mir-200a	Meningioma	19703993	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas.
other	hsa-mir-21	Meningioma	26242334	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Increased miR-21 and nestin mRNA levels were found in anaplastic meningiomas, in which recurrence is common, and the role of miR-21 and Nestin in meningiomas therefore warrants further investigation.
other	hsa-mir-29c	Meningioma	28327132	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c.
other	hsa-mir-146a	Meningitis	24442429	nervous system disease	DOID:9471	G03	D008581			Induction of endotoxin tolerance by pathogenic Neisseria is correlated with the inflammatory potential of lipooligosaccharides and regulated by microRNA-146a.
other	hsa-mir-204	Mesial Temporal Lobe Epilepsy	25410734			G40.209	D004833	608096		miR-204 and miR-218 are developmentally regulated in the hippocampus and may contribute to the molecular mechanisms underlying the pathogenesis of MTLE and HS.
other	hsa-mir-218	Mesial Temporal Lobe Epilepsy	25410734			G40.209	D004833	608096		miR-204 and miR-218 are developmentally regulated in the hippocampus and may contribute to the molecular mechanisms underlying the pathogenesis of MTLE and HS.
other	hsa-mir-1	Mesothelioma	23828229	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR-1 induces growth arrest and apoptosis in malignant mesothelioma.
other	hsa-mir-106a	Mesothelioma	19502386	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype
other	hsa-mir-143	Mesothelioma	19502386	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype
other	hsa-mir-17	Mesothelioma	19502386	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype
other	hsa-mir-205	Mesothelioma	21983934	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	our findings indicate that epithelial-mesenchymal transition has a significant part in the morphological features of malignant mesothelioma. In particular, miR-205 down-regulation correlated ignificantly with both a mesenchymal phenotype and a more aggressive behavior.
other	hsa-mir-21	Mesothelioma	19502386	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype
other	hsa-mir-29a	Mesothelioma	19502386	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype
other	hsa-mir-30c-1	Mesothelioma	19502386	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype
other	hsa-mir-30c-2	Mesothelioma	19502386	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype
other	hsa-mir-30d	Mesothelioma	28979837	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR-30d is related to asbestos exposure and inhibits migration and invasion in NCI-H2452 cells.
other	hsa-mir-30e	Mesothelioma	19502386	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	The expression of miR-17-5p, miR-21, miR-29a, miR-30c, miR-30e-5p, miR-106a, and miR-143 was significantly associated with the histopathological subtype
other	hsa-mir-31	Mesothelioma	28918032	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.
other	hsa-mir-34b	Mesothelioma	23155254	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells
other	hsa-mir-34c	Mesothelioma	23155254	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells
other	hsa-mir-103	Metabolic Syndrome	20886002	disease of metabolism	DOID:14221	E88.81	D024821	605552		Interestingly, a strong correlation was observed between miR-103 and -107 expression, as well as miR-221 and -222 in both experiments.
other	hsa-mir-103	Metabolic Syndrome	22436747	disease of metabolism	DOID:14221	E88.81	D024821	605552		Other metabolic miRNAs, such as miR-103 and miR-107, regulate insulin and glucose homeostasis, whereas miRNAs such as miR-34a are emerging as key regulators of hepatic lipid homeostasis.
other	hsa-mir-107	Metabolic Syndrome	22436747	disease of metabolism	DOID:14221	E88.81	D024821	605552		Other metabolic miRNAs, such as miR-103 and miR-107, regulate insulin and glucose homeostasis, whereas miRNAs such as miR-34a are emerging as key regulators of hepatic lipid homeostasis.
other	hsa-mir-122	Metabolic Syndrome	22965541	disease of metabolism	DOID:14221	E88.81	D024821	605552		These results suggest that proanthocyanidin treatment increased hepatic cholesterol efflux to produce new HDL particles by repressing miR-33, and it reduced lipogenesis by repressing miR-122.
other	hsa-mir-143	Metabolic Syndrome	20886002	disease of metabolism	DOID:14221	E88.81	D024821	605552		Interestingly, a strong correlation was observed between miR-103 and -107 expression, as well as miR-221 and -222 in both experiments.
other	hsa-mir-143	Metabolic Syndrome	28088407	disease of metabolism	DOID:14221	E88.81	D024821	605552		Far-off and close-up dry matter intake modulate indicators of immunometabolic adaptations to lactation in subcutaneous adipose tissue of pasture-based transition dairy cows.
other	hsa-mir-221	Metabolic Syndrome	20886002	disease of metabolism	DOID:14221	E88.81	D024821	605552		Interestingly, a strong correlation was observed between miR-103 and -107 expression, as well as miR-221 and -222 in both experiments.
other	hsa-mir-222	Metabolic Syndrome	20886002	disease of metabolism	DOID:14221	E88.81	D024821	605552		Interestingly, a strong correlation was observed between miR-103 and -107 expression, as well as miR-221 and -222 in both experiments.
other	hsa-mir-27b	Metabolic Syndrome	22893262	disease of metabolism	DOID:14221	E88.81	D024821	605552		we thus speculate that Rb1 may act though PPARγ to downregulate mir-27b gene transcription and mature miR-27b activity, which in turn promotes PPARγ expression and adipogenesis.
other	hsa-mir-33	Metabolic Syndrome	22965541	disease of metabolism	DOID:14221	E88.81	D024821	605552		These results suggest that proanthocyanidin treatment increased hepatic cholesterol efflux to produce new HDL particles by repressing miR-33, and it reduced lipogenesis by repressing miR-122.
other	hsa-mir-33a	Metabolic Syndrome	22436747	disease of metabolism	DOID:14221	E88.81	D024821	605552		miR-33a and miR-33b have a crucial role in controlling cholesterol and lipid metabolism in concert with their host genes, the sterol-regulatory element-binding protein (SREBP) transcription factors.
other	hsa-mir-33b	Metabolic Syndrome	22436747	disease of metabolism	DOID:14221	E88.81	D024821	605552		miR-33a and miR-33b have a crucial role in controlling cholesterol and lipid metabolism in concert with their host genes, the sterol-regulatory element-binding protein (SREBP) transcription factors.
other	hsa-mir-34a	Metabolic Syndrome	22436747	disease of metabolism	DOID:14221	E88.81	D024821	605552		Other metabolic miRNAs, such as miR-103 and miR-107, regulate insulin and glucose homeostasis, whereas miRNAs such as miR-34a are emerging as key regulators of hepatic lipid homeostasis.
other	hsa-mir-9-1	Methylmalonic Acidemia	24390963	disease of metabolism	DOID:14749	E71.120	C537358	309541		A Primary Study on Down-Regulated miR-9-1 and Its Biological Significances in Methylmalonic Acidemia.
other	hsa-mir-145	Microvascular Disease	23875242							The role of miR-145 in microvasculature.
other	hsa-mir-15a	Mitochondrial Metabolism Disease	29322081	disease of metabolism	DOID:700	E88.40	D028361			Data of expression status of miR-29a and its putative target mitochondrial apoptosis regulatory gene DRP1 upon miR-15a and miR-214 inhibition
other	hsa-mir-210	Mitochondrial Metabolism Disease	29621777	disease of metabolism	DOID:700	E88.40	D028361			Loading MiR-210 in Endothelial Progenitor Cells Derived Exosomes Boosts Their Beneficial Effects on Hypoxia/Reoxygeneation-Injured Human Endothelial Cells via Protecting Mitochondrial Function
other	hsa-mir-214	Mitochondrial Metabolism Disease	29322081	disease of metabolism	DOID:700	E88.40	D028361			Data of expression status of miR-29a and its putative target mitochondrial apoptosis regulatory gene DRP1 upon miR-15a and miR-214 inhibition
other	hsa-mir-30c	Mitochondrial Metabolism Disease	28330939	disease of metabolism	DOID:700	E88.40	D028361			Chlamydia preserves the mitochondrial network necessary for replication via microRNA-dependent inhibition of fission.
other	hsa-mir-33	Mitochondrial Metabolism Disease	26185207	disease of metabolism	DOID:700	E88.40	D028361			Novel Role of miR-33 in Regulating of Mitochondrial Function.
other	hsa-let-7a	Monocytic Leukemia	29599918	disease of cellular proliferation	DOID:8527	C93.Z		151380	HP:0004845	FC-99 ameliorates sepsis-induced liver dysfunction by modulating monocyte/macrophage differentiation via Let-7a related monocytes apoptosis.
other	hsa-let-7b	Monocytic Leukemia	29790117	disease of cellular proliferation	DOID:8527	C93.Z		151380	HP:0004845	Regulatory roles of miR-155 and let-7b on the expression of inflammation-related genes in THP-1 cells: effects of fatty acids.
other	hsa-mir-155	Monocytic Leukemia	29790117	disease of cellular proliferation	DOID:8527	C93.Z		151380	HP:0004845	Regulatory roles of miR-155 and let-7b on the expression of inflammation-related genes in THP-1 cells: effects of fatty acids.
other	hsa-let-7	Multiple Myeloma	25925570	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Our study establishes that the ribonuclease DIS3, targeting LIN28B, sustains the maturation of let-7 miRNAs and suggests the increased translation of critical oncogenes as one of the biological outcomes of DIS3 inactivation.
other	hsa-let-7a	Multiple Myeloma	28808676	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	a thymidine-kinase-deleted let-7a-regulated vaccinia virus was safe and effective for mice, warranting clinical trials in humans
other	hsa-mir-106b	Multiple Myeloma	27647143	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells.
other	hsa-mir-125a	Multiple Myeloma	24819167	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
other	hsa-mir-125a	Multiple Myeloma	26496024	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Members of the miR-99b/let-7e/miR-125a cluster, or of its paralog, upregulated in t(4;14), were  connected with the specific transcription factors PBX1 and CEBPA and several target genes.
other	hsa-mir-125b-1	Multiple Myeloma	23759586	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression.
other	hsa-mir-125b-2	Multiple Myeloma	23759586	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression.
other	hsa-mir-1271	Multiple Myeloma	27959416	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MicroRNA-1271 inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting smoothened-mediated Hedgehog signaling pathway.
other	hsa-mir-130b	Multiple Myeloma	21761344	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines.
other	hsa-mir-135b	Multiple Myeloma	24223191	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.
other	hsa-mir-135b	Multiple Myeloma	28245421	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Compared with those of the normal ones, exosomes in MM have less miR-15a and/or more miR-135b and miR-21
other	hsa-mir-135b	Multiple Myeloma	28316065	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.
other	hsa-mir-145	Multiple Myeloma	25369735	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo.
other	hsa-mir-146a	Multiple Myeloma	29333170	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a
other	hsa-mir-148a	Multiple Myeloma	28316065	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.
other	hsa-mir-15a	Multiple Myeloma	21936961	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells.
other	hsa-mir-15a	Multiple Myeloma	21534877	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.
other	hsa-mir-15a	Multiple Myeloma	22781767	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	BMSCs suppress the proliferation of myeloma cells and regulate the drug sensitivity of myeloma cells through the inhibited expression of miRNA-15a/-16. IL-6 plays a pivotal role in the occurrence of drug resistance.
other	hsa-mir-15a	Multiple Myeloma	28245421	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Compared with those of the normal ones, exosomes in MM have less miR-15a and/or more miR-135b and miR-21
other	hsa-mir-16	Multiple Myeloma	22781767	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	BMSCs suppress the proliferation of myeloma cells and regulate the drug sensitivity of myeloma cells through the inhibited expression of miRNA-15a/-16. IL-6 plays a pivotal role in the occurrence of drug resistance.
other	hsa-mir-16-1	Multiple Myeloma	21936961	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells.
other	hsa-mir-17	Multiple Myeloma	21664042	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
other	hsa-mir-181a-1	Multiple Myeloma	21761344	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines.
other	hsa-mir-181a-2	Multiple Myeloma	21761344	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines.
other	hsa-mir-18a	Multiple Myeloma	21664042	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
other	hsa-mir-192	Multiple Myeloma	20951946	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
other	hsa-mir-194-1	Multiple Myeloma	20951946	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
other	hsa-mir-194-2	Multiple Myeloma	20951946	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
other	hsa-mir-19a	Multiple Myeloma	21664042	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
other	hsa-mir-19b-1	Multiple Myeloma	21664042	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
other	hsa-mir-202	Multiple Myeloma	26689580	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-202 over-expression sensitized MM cells to bortezomib (Bort) but  less to Thalidomide (Thal) and dexamethasone (Dex).
other	hsa-mir-20a	Multiple Myeloma	21664042	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
other	hsa-mir-20a	Multiple Myeloma	26032093	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma.
other	hsa-mir-20a	Multiple Myeloma	27129167	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Moreover, nano-sized exosomes were isolated with significantly increasing internal RNAs and down-regulation of exosomal miR-16-5p, miR-15a-5p and miR-20a-5p, miR-17-5p was revealed in the patients resistant to Bz.
other	hsa-mir-21	Multiple Myeloma	20302778	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-21 acts as an oncogene and miR-30b a tumor suppressor gene in MM
other	hsa-mir-21	Multiple Myeloma	21718132	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
other	hsa-mir-21	Multiple Myeloma	23247593	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Set9, NF-kB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells
other	hsa-mir-21	Multiple Myeloma	24981236	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MicroRNA-21 and multiple myeloma: small molecule and big function.
other	hsa-mir-21	Multiple Myeloma	25656574	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling.
other	hsa-mir-21	Multiple Myeloma	17496199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Ectopically raising miR-21 expression in myeloma cells in the absence of IL-6 significantly reduced their apoptosis levels. These data provide strong evidence that miR-21 induction contributes to the oncogenic potential of Stat3.
other	hsa-mir-21	Multiple Myeloma	27494872	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-21 and miR-221/222 could negatively modulate drug sensitivity of MM cells.
other	hsa-mir-21	Multiple Myeloma	28245421	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Compared with those of the normal ones, exosomes in MM have less miR-15a and/or more miR-135b and miR-21
other	hsa-mir-21	Multiple Myeloma	29158801	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Gambogenic Acid Exerts Antitumor Activity in Hypoxic Multiple Myeloma Cells by Regulation of miR-21
other	hsa-mir-21	Multiple Myeloma	29320977	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3
other	hsa-mir-21	Multiple Myeloma	29333170	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a
other	hsa-mir-215	Multiple Myeloma	20951946	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
other	hsa-mir-221	Multiple Myeloma	23479461	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
other	hsa-mir-222	Multiple Myeloma	23479461	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
other	hsa-mir-223	Multiple Myeloma	21401705	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma.
other	hsa-mir-24	Multiple Myeloma	23934711	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Contribution of microRNA 24-3p and Erk1/2 to interleukin-6 mediated plasma cell survival.
other	hsa-mir-25	Multiple Myeloma	27647143	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells.
other	hsa-mir-29b	Multiple Myeloma	24091729	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-29b is endowed with epigenetic activity and mediates previously unknown functions of bortezomib in MM cells.
other	hsa-mir-29b	Multiple Myeloma	24189534	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-29b: a new demethylator in multiple myeloma.
other	hsa-mir-29b	Multiple Myeloma	26718793	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	genistein could suppress the protein level of NF-魏B and promote the expression of miR-29b in U266 cells.
other	hsa-mir-29b	Multiple Myeloma	27430753	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNA鈥?9b and matrix metalloproteinase鈥?.
other	hsa-mir-29b-1	Multiple Myeloma	23254643	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease
other	hsa-mir-29b-2	Multiple Myeloma	23254643	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease
other	hsa-mir-30b	Multiple Myeloma	20302778	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-21 acts as an oncogene and miR-30b a tumor suppressor gene in MM
other	hsa-mir-34a	Multiple Myeloma	24587182	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.
other	hsa-mir-636	Multiple Myeloma	21761344	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-130b, miR-181a, and miR-636 to be differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines.
other	hsa-mir-92a-1	Multiple Myeloma	21664042	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
other	hsa-mir-122	Multiple Sclerosis	28411393	nervous system disease	DOID:2377	G35	D009103	PS126200		Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis.
other	hsa-mir-126	Multiple Sclerosis	24598267	nervous system disease	DOID:2377	G35	D009103	PS126200		Our findings provided deeper insight into the mode of action of natalizumab, with possible implications for understanding both the effects of natalizumab on MS activity and its specific adverse event profile.
other	hsa-mir-126	Multiple Sclerosis	28358058	nervous system disease	DOID:2377	G35	D009103	PS126200		MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium.
other	hsa-mir-141	Multiple Sclerosis	25938517	nervous system disease	DOID:2377	G35	D009103	PS126200		According to our results, miR-141 and miR-200a may be key miRNAs in progression of symptoms of MS through inducing differentiation of Th17 cells and inhibiting differentiation to Treg cells. Our data suggest that these miRNAs may probably inhibit negative regulators of Th17 cell differentiation, thus promoting its differentiation.
other	hsa-mir-142	Multiple Sclerosis	25486582	nervous system disease	DOID:2377	G35	D009103	PS126200		AHSCT normalizes microRNA and gene expression, thereby improving the immunoregulatory network. These mechanisms may be important for disease control in the early periods after AHSCT.
other	hsa-mir-142	Multiple Sclerosis	28100738	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation.
other	hsa-mir-145	Multiple Sclerosis	27752929	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.
other	hsa-mir-155	Multiple Sclerosis	21908875	nervous system disease	DOID:2377	G35	D009103	PS126200		Expression of three neurosteroid synthesis enzyme-specific micro-RNAs (miR-338, miR-155 and miR-491) showed a bias towards induction in patients with multiple sclerosis (P < 0.05).
other	hsa-mir-155	Multiple Sclerosis	25486582	nervous system disease	DOID:2377	G35	D009103	PS126200		AHSCT normalizes microRNA and gene expression, thereby improving the immunoregulatory network. These mechanisms may be important for disease control in the early periods after AHSCT.
other	hsa-mir-16	Multiple Sclerosis	25486582	nervous system disease	DOID:2377	G35	D009103	PS126200		AHSCT normalizes microRNA and gene expression, thereby improving the immunoregulatory network. These mechanisms may be important for disease control in the early periods after AHSCT.
other	hsa-mir-16	Multiple Sclerosis	24898268	nervous system disease	DOID:2377	G35	D009103	PS126200		Further evidence indicated that DIM treatment significantly upregulated several miRNAs (miR-200c, miR-146a, miR-16, miR-93, and miR-22) in brain CD4(+) T cells during EAE while suppressing  their associated target genes.
other	hsa-mir-17	Multiple Sclerosis	20201009	nervous system disease	DOID:2377	G35	D009103	PS126200		Specifically, miR-17-5p, which is involved in autoimmunity, is upregulated in CD4(+) cells from MS patients
other	hsa-mir-17	Multiple Sclerosis	24901013	nervous system disease	DOID:2377	G35	D009103	PS126200		Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.
other	hsa-mir-17	Multiple Sclerosis	27512057	nervous system disease	DOID:2377	G35	D009103	PS126200		Here, we provide the first experimental evidence of JMRV miRNAs in  vitro and demonstrate that one of these viral miRNAs can mimic the activity of the cellular miR-17/20/106 family.
other	hsa-mir-200a	Multiple Sclerosis	25938517	nervous system disease	DOID:2377	G35	D009103	PS126200		According to our results, miR-141 and miR-200a may be key miRNAs in progression of symptoms of MS through inducing differentiation of Th17 cells and inhibiting differentiation to Treg cells. Our data suggest that these miRNAs may probably inhibit negative regulators of Th17 cell differentiation, thus promoting its differentiation.
other	hsa-mir-20a	Multiple Sclerosis	27752929	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.
other	hsa-mir-214	Multiple Sclerosis	26563334	nervous system disease	DOID:2377	G35	D009103	PS126200		Our data suggest that miR-27a may probably inhibit negative regulators of Th17 cell differentiation, thus promoting its differentiation while miR-214 has an adverse effect.
other	hsa-mir-223	Multiple Sclerosis	26305248	nervous system disease	DOID:2377	G35	D009103	PS126200		Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity.
other	hsa-mir-27a	Multiple Sclerosis	26563334	nervous system disease	DOID:2377	G35	D009103	PS126200		Our data suggest that miR-27a may probably inhibit negative regulators of Th17 cell differentiation, thus promoting its differentiation while miR-214 has an adverse effect.
other	hsa-mir-29c	Multiple Sclerosis	23946286	nervous system disease	DOID:2377	G35	D009103	PS126200		MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis.
other	hsa-mir-30a	Multiple Sclerosis	27581464	nervous system disease	DOID:2377	G35	D009103	PS126200		Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation.
other	hsa-mir-326	Multiple Sclerosis	19838199	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis
other	hsa-mir-326	Multiple Sclerosis	29043654	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of Selected MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to Cognition, Depression, and Disability.
other	hsa-mir-338	Multiple Sclerosis	21908875	nervous system disease	DOID:2377	G35	D009103	PS126200		Expression of three neurosteroid synthesis enzyme-specific micro-RNAs (miR-338, miR-155 and miR-491) showed a bias towards induction in patients with multiple sclerosis (P < 0.05).
other	hsa-mir-491	Multiple Sclerosis	21908875	nervous system disease	DOID:2377	G35	D009103	PS126200		Expression of three neurosteroid synthesis enzyme-specific micro-RNAs (miR-338, miR-155 and miR-491) showed a bias towards induction in patients with multiple sclerosis (P < 0.05).
other	hsa-mir-499a	Multiple Sclerosis	26305248	nervous system disease	DOID:2377	G35	D009103	PS126200		Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity.
other	hsa-mir-599	Multiple Sclerosis	19617918	nervous system disease	DOID:2377	G35	D009103	PS126200		relevant at the time of relapse
other	hsa-mir-96	Multiple Sclerosis	19617918	nervous system disease	DOID:2377	G35	D009103	PS126200		relevant at the time of relapse
other	hsa-mir-133a	Muscle Diseases [unspecific]	25146754			M63.80	D009135			These miRNAs are potential biomarkers of muscle damage or adaptation to exercise.
other	hsa-mir-133a	Muscle Diseases [unspecific]	23858090			M63.80	D009135			miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle.
other	hsa-mir-133a	Muscle Diseases [unspecific]	25547110			M63.80	D009135			human skeletal muscle differentiation and development in healthy and disease states.
other	hsa-mir-133b	Muscle Diseases [unspecific]	23858090			M63.80	D009135			miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle.
other	hsa-mir-133b	Muscle Diseases [unspecific]	25547110			M63.80	D009135			human skeletal muscle differentiation and development in healthy and disease states.
other	hsa-mir-144	Muscle Diseases [unspecific]	24036467			M63.80	D009135			Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype.
other	hsa-mir-15a	Muscle Diseases [unspecific]	24036467			M63.80	D009135			Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype.
other	hsa-mir-181b	Muscle Diseases [unspecific]	24036467			M63.80	D009135			Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype.
other	hsa-mir-18a	Muscle Diseases [unspecific]	24036467			M63.80	D009135			Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype.
other	hsa-mir-206	Muscle Diseases [unspecific]	25146754			M63.80	D009135			These miRNAs are potential biomarkers of muscle damage or adaptation to exercise.
other	hsa-mir-206	Muscle Diseases [unspecific]	23858090			M63.80	D009135			miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle.
other	hsa-mir-206	Muscle Diseases [unspecific]	25547110			M63.80	D009135			human skeletal muscle differentiation and development in healthy and disease states.
other	hsa-mir-206	Muscle Diseases [unspecific]	25678853			M63.80	D009135			MiR-206, a key modulator of skeletal muscle development and disease.
other	hsa-mir-20a	Muscle Diseases [unspecific]	25547110			M63.80	D009135			human skeletal muscle differentiation and development in healthy and disease states.
other	hsa-mir-26	Muscle Diseases [unspecific]	25547110			M63.80	D009135			human skeletal muscle differentiation and development in healthy and disease states.
other	hsa-mir-30	Muscle Diseases [unspecific]	25689854			M63.80	D009135			These findings indicate that the miR-30 family may be an interesting biomarker of perturbed muscle homeostasis and muscle disease.
other	hsa-mir-30	Muscle Diseases [unspecific]	25547110			M63.80	D009135			human skeletal muscle differentiation and development in healthy and disease states.
other	hsa-mir-431	Muscle Diseases [unspecific]	26215566			M63.80	D009135			our results suggest that the age-associated miR-431 plays a key role in maintaining the myogenic ability of skeletal muscle with age.
other	hsa-mir-451	Muscle Diseases [unspecific]	24036467			M63.80	D009135			Our results reveal that there are changes in expression of known and novel miRNAs with skeletal muscle aging and that CR may reverse some of these changes to a younger phenotype.
other	hsa-mir-494	Muscle Diseases [unspecific]	27181718			M63.80	D009135			Effects of microRNA-494 on the fiber type-specific skeletal myogenesis in human induced pluripotent stem cells.
other	hsa-mir-499	Muscle Diseases [unspecific]	23858090			M63.80	D009135			miRNA analysis for the assessment of exercise and amino acid effects on human skeletal muscle.
other	hsa-mir-608	Muscle Diseases [unspecific]	28358823			M63.80	D009135			Genome-wide association screens for Achilles tendon and ACL tears and tendinopathy.
other	hsa-let-7	Muscular Dystrophy	26272747			G71.0	D009136	310200	HP:0003560	Our study therefore introduces additional biological players in the regulation of skeletal muscle structure and myogenesis that may contribute to unexplained disorders of MD.
other	hsa-let-7e	Muscular Dystrophy	26272747			G71.0	D009136	310200	HP:0003560	Our study therefore introduces additional biological players in the regulation of skeletal muscle structure and myogenesis that may contribute to unexplained disorders of MD.
other	hsa-mir-125a	Muscular Dystrophy	19690046			G71.0	D009136	310200	HP:0003560	regulation of ж┿myosin heavy chain gene
other	hsa-mir-146a	Muscular Dystrophy	27671199			G71.0	D009136	310200	HP:0003560	Chronic alcohol exposure induces muscle atrophy (myopathy) in zebrafish and alters the expression of microRNAs targeting the Notch pathway in skeletal muscle.
other	hsa-mir-146a	Muscular Dystrophy	28637335			G71.0	D009136	310200	HP:0003560	Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy.
other	hsa-mir-208b	Muscular Dystrophy	19690046			G71.0	D009136	310200	HP:0003560	regulation of ж┿myosin heavy chain gene
other	hsa-mir-21	Muscular Dystrophy	25892183			G71.0	D009136	310200	HP:0003560	Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy.
other	hsa-mir-29	Muscular Dystrophy	25892183			G71.0	D009136	310200	HP:0003560	Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy.
other	hsa-mir-486	Muscular Dystrophy	24789910			G71.0	D009136	310200	HP:0003560	MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms.
other	hsa-mir-98	Muscular Dystrophy	26272747			G71.0	D009136	310200	HP:0003560	Our study therefore introduces additional biological players in the regulation of skeletal muscle structure and myogenesis that may contribute to unexplained disorders of MD.
other	hsa-mir-206	Muscular Dystrophy, Duchenne	25999854	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		In contrast, local expression of mIGF-1 promotes the modulation of other microRNAs, such as miR-206 and miR-24, along with the modulation of muscle specific genes
other	hsa-mir-21	Muscular Dystrophy, Duchenne	22213800	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy.
other	hsa-mir-1	Muscular Dystrophy, Facioscapulohumeral	29741619	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures.
other	hsa-mir-133a	Muscular Dystrophy, Facioscapulohumeral	29741619	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures.
other	hsa-mir-206	Muscular Dystrophy, Facioscapulohumeral	29741619	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures.
other	hsa-mir-146a	Myasthenia Gravis	24036458	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		We conclude that abnormal expression/regulation of miR-146a may play an important role in the regulation of AchR specific B cells and contribute to the pathogenesis of MG.
other	hsa-mir-150	Myasthenia Gravis	26095457	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		The immuno-microRNAs miR-150-5p and miR-21-5p show a disease specific signature, which suggests these microRNAs as possible biological autoimmune markers of myasthenia gravis (MG).
other	hsa-mir-20b	Myasthenia Gravis	27833920	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		miR-20b Inhibits T Cell Proliferation and Activation via NFAT Signaling Pathway in Thymoma-Associated Myasthenia Gravis.
other	hsa-mir-21	Myasthenia Gravis	26095457	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		The immuno-microRNAs miR-150-5p and miR-21-5p show a disease specific signature, which suggests these microRNAs as possible biological autoimmune markers of myasthenia gravis (MG).
other	hsa-mir-132	Mycobacterium tuberculosis Infection	25252958			A18	D014376	607948		Mycobacterium tuberculosis decreases human macrophage IFN-γ responsiveness through miR-132 and miR-26a.
other	hsa-mir-26a	Mycobacterium tuberculosis Infection	25252958			A18	D014376	607948		Mycobacterium tuberculosis decreases human macrophage IFN-γ responsiveness through miR-132 and miR-26a.
other	hsa-mir-124	Myelodysplastic Syndromes	28024498	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Reactivated Expression of MicroRNA-124 in Patients with Myelodysplastic Syndromes after Demethylating Therapy.
other	hsa-mir-125a	Myelodysplastic Syndromes	19615744	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome
other	hsa-mir-125a	Myelodysplastic Syndromes	25976472	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	In fact, regulatory factors have also been considered as miR-143/miR-145, miR-146a, miR-125a and MiR-21.
other	hsa-mir-125b-1	Myelodysplastic Syndromes	22944560	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Myelodysplastic syndrome with a t(2;11)(p21;q23-24) and translocation breakpoint close to miR-125b-1.
other	hsa-mir-143	Myelodysplastic Syndromes	22929976	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Lenalidomide selectively abrogated progenitor activity in cells depleted of miR-143 and miR-145 supporting a key role for miR-143/145 in the sensitivity to lenalidomide of del(5q) myelodysplastic syndrome patients.
other	hsa-mir-145	Myelodysplastic Syndromes	19898489	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	5q- syndrome deleted,Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype
other	hsa-mir-145	Myelodysplastic Syndromes	22929976	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Lenalidomide selectively abrogated progenitor activity in cells depleted of miR-143 and miR-145 supporting a key role for miR-143/145 in the sensitivity to lenalidomide of del(5q) myelodysplastic syndrome patients.
other	hsa-mir-145	Myelodysplastic Syndromes	20733155	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Other mouse modeling data suggest that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome. Lenalidomide has become an established therapy for the 5q- syndrome, although its precise mode of action remains uncertain.
other	hsa-mir-145	Myelodysplastic Syndromes	24507813	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Other genes, as well as miR-145 and miR-146a, contribute to aberrant megakaryopoiesis and a selective advantage for the del(5q) clone.
other	hsa-mir-146a	Myelodysplastic Syndromes	19898489	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	5q- syndrome deleted,Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype
other	hsa-mir-146a	Myelodysplastic Syndromes	20733155	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Other mouse modeling data suggest that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome. Lenalidomide has become an established therapy for the 5q- syndrome, although its precise mode of action remains uncertain.
other	hsa-mir-146a	Myelodysplastic Syndromes	25071842	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-146a is also implicated in the pathogenesis of human myelodysplastic syndromes (MDSs) as it is located within a commonly deleted region on chromosome 5, and miR-146a-deficient mice exhibit features of an MDS-like disease.
other	hsa-mir-155	Myelodysplastic Syndromes	22249254	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155.
other	hsa-mir-155	Myelodysplastic Syndromes	27513856	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	In the current study, we identified overexpression of c-Fos-targeting miR-34a and miR-155 as the cause of impairment.
other	hsa-mir-155	Myelodysplastic Syndromes	28130497	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Mechanisms of Impaired Neutrophil Migration by MicroRNAs in Myelodysplastic Syndromes.
other	hsa-mir-15a	Myelodysplastic Syndromes	19702585	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	differentially expressed between low-risk and high-risk
other	hsa-mir-210	Myelodysplastic Syndromes	22249254	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155.
other	hsa-mir-221	Myelodysplastic Syndromes	19615744	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome
other	hsa-mir-222	Myelodysplastic Syndromes	19615744	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome
other	hsa-mir-34a	Myelodysplastic Syndromes	27513856	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	In the current study, we identified overexpression of c-Fos-targeting miR-34a and miR-155 as the cause of impairment.
other	hsa-mir-34a	Myelodysplastic Syndromes	28130497	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Mechanisms of Impaired Neutrophil Migration by MicroRNAs in Myelodysplastic Syndromes.
other	hsa-mir-378	Myelodysplastic Syndromes	27633496	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-378 inhibits cell growth and enhances apoptosis in human myelodysplastic syndromes.
other	hsa-mir-378a	Myelodysplastic Syndromes	21703983	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	hsa-mir-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls.
other	hsa-mir-632	Myelodysplastic Syndromes	21703983	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	hsa-mir-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls.
other	hsa-mir-636	Myelodysplastic Syndromes	21703983	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	hsa-mir-378, hsa-miR-632, and hsa-miR-636 demonstrated particularly high discrimination between MDS and normal controls.
other	hsa-mir-34a	Myelofibrosis	28098757	disease of cellular proliferation	DOID:4971	D47.4	D055728	254450	HP:0011974	the increased expression of miR-34a-5p in PMF HPCs could be important for the skewing of megakaryopoiesis and the production of monocytes, that are key players in BM fibrosis in PMF patients
other	hsa-mir-130a	Myeloma	26389804			C90.0	D009101	254500		Together, our data suggest connection between lower level of microRNA-130a and extramedullary disease and prompt further work to evaluate this miRNA as a marker of extramedullary disease in multiple myeloma.
other	hsa-mir-19a	Myeloma	27830963			C90.0	D009101	254500		MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.
other	hsa-mir-143	Myeloproliferative Neoplasms	25527813	disease of cellular proliferation	DOID:2226	D47.1		616871		Our findings of aberrant miR-143 expression support the concept that factors other than JAK2 V617F mutation may contribute to the pathogenesis and some clinical signs of MPNs.
other	hsa-mir-15a	Myeloproliferative Neoplasms	20008792	disease of cellular proliferation	DOID:2226	D47.1		616871		STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.
other	hsa-mir-15b	Myeloproliferative Neoplasms	20008792	disease of cellular proliferation	DOID:2226	D47.1		616871		STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.
other	hsa-mir-16	Myeloproliferative Neoplasms	20008792	disease of cellular proliferation	DOID:2226	D47.1		616871		STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.
other	hsa-mir-433	Myeloproliferative Neoplasms	22864358	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.
other	hsa-let-7b	Myocardial Infarction	28062497	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased Proangiogenic Activity of Mobilized CD34+ Progenitor Cells of Patients With Acute ST-Segment-Elevation Myocardial Infarction: Role of Differential MicroRNA-378 Expression.
other	hsa-mir-1	Myocardial Infarction	20163779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	We conclude that miR-1 and miR-133 seem to be important regulators of heart adaptation after ischaemic stress.
other	hsa-mir-1	Myocardial Infarction	20959496	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.
other	hsa-mir-1	Myocardial Infarction	23625462	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-1 enhances the angiogenic differentiation of human cardiomyocyte progenitor cells.
other	hsa-mir-1	Myocardial Infarction	25588055	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Downregulation of IGF1 specific miRNA-1 and -133 but not miR-145 expression was also confirmed.
other	hsa-mir-1	Myocardial Infarction	26065643	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	spironolactone could increase miRNA-1  expression in ischemic rat myocardium after MI
other	hsa-mir-1	Myocardial Infarction	27056419	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1/133a control cardiac conductance and automaticity by regulating all phases of the cardiac action potential
other	hsa-mir-1	Myocardial Infarction	28894747	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	regulatory effects on miR-1, miR-133, Cx43, and Cx45 might be a possible mechanism of WXKL in the treatment of MI at the gene level
other	hsa-mir-1	Myocardial Infarction	29094045	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Effect of Wenxin Granules on Gap Junction and MiR-1 in Rats with Myocardial Infarction.
other	hsa-mir-1	Myocardial Infarction	29212255	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice
other	hsa-mir-1	Myocardial Infarction	29324314	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	up-regulation of miR-1 and miR-208 in remote myocardium might play a role in cardiac remodeling after MI, at least to certain degree
other	hsa-mir-103	Myocardial Infarction	25867756	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	This study provides more details on gene expression regulation and regulators involved in MI progression and recurrence. It also linked up and interpreted many previous results.
other	hsa-mir-106b	Myocardial Infarction	22613985	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiR-106b and MiR-15b modulate apoptosis and angiogenesis in myocardial infarction.
other	hsa-mir-126	Myocardial Infarction	21949332	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-223 and miR-197 showed positive associations (multivariable HR 2.19 [95% CI 1.26 to 3.83], p=0.006, and 1.79 [95% CI 1.00 to 3.20], p=0.049) while miR-126 was inversely correlated with disease risk (multivariable HR 0.40 [95% CI 0.22 to 0.73], p=0.003).
other	hsa-mir-126	Myocardial Infarction	18694565	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	We show that an endothelial cell-restricted microRNA (miR-126) mediates developmental angiogenesis in vivo.
other	hsa-mir-126	Myocardial Infarction	22113756	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Transplantation of MSCs transfected with miR-126 can improve angiogenesis and cardiac function in the infarcted area of the hearts of mice, which may be due to stimulation of the AKT/ERK-related pathway.
other	hsa-mir-126	Myocardial Infarction	25200057	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Exosomes purified from endothelial cells overexpressing HIF1 had  higher contents of miR-126 and miR-210.
other	hsa-mir-126	Myocardial Infarction	27180261	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-126 up-regulation activates EPCs and ECs and contributes to vascular healing and neovessel formation.
other	hsa-mir-130a	Myocardial Infarction	27789328	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Resveratrol increases microRNA-130a expression to promote angiogenesis and improve heart functions in mice after myocardial infarction.
other	hsa-mir-133	Myocardial Infarction	20959496	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.
other	hsa-mir-133	Myocardial Infarction	28894747	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	regulatory effects on miR-1, miR-133, Cx43, and Cx45 might be a possible mechanism of WXKL in the treatment of MI at the gene level
other	hsa-mir-133b	Myocardial Infarction	20163779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	We conclude that miR-1 and miR-133 seem to be important regulators of heart adaptation after ischaemic stress.
other	hsa-mir-145	Myocardial Infarction	28980287	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Inducible miR-145 expression by HIF-1a protects cardiomyocytes against apoptosis via regulating SGK1 in simulated myocardial infarction hypoxic microenvironment.
other	hsa-mir-150	Myocardial Infarction	23547171	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-150: A Novel Marker of Left Ventricular Remodeling After Acute Myocardial Infarction
other	hsa-mir-151	Myocardial Infarction	24039836	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Downregulation of miR-151-5p contributes to increased susceptibility to arrhythmogenesis during myocardial infarction with estrogen deprivation.
other	hsa-mir-155	Myocardial Infarction	28129114	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Macrophage-Derived mir-155-Containing Exosomes Suppress Fibroblast Proliferation and Promote Fibroblast Inflammation during Cardiac Injury.
other	hsa-mir-16	Myocardial Infarction	25867756	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	This study provides more details on gene expression regulation and regulators involved in MI progression and recurrence. It also linked up and interpreted many previous results.
other	hsa-mir-197	Myocardial Infarction	21949332	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-223 and miR-197 showed positive associations (multivariable HR 2.19 [95% CI 1.26 to 3.83], p=0.006, and 1.79 [95% CI 1.00 to 3.20], p=0.049) while miR-126 was inversely correlated with disease risk (multivariable HR 0.40 [95% CI 0.22 to 0.73], p=0.003).
other	hsa-mir-199a	Myocardial Infarction	20959496	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.
other	hsa-mir-206	Myocardial Infarction	27103465	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In an acute model of myocardial infarction, transplanted hypoxic MSCs showed a significantly  improved survival as compared with hypoxic MSCs overexpressing miR-206.
other	hsa-mir-206	Myocardial Infarction	29055786	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Carbon monoxide releasing molecule improves structural and functional cardiac recovery after myocardial injury.
other	hsa-mir-208	Myocardial Infarction	29324314	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	up-regulation of miR-1 and miR-208 in remote myocardium might play a role in cardiac remodeling after MI, at least to certain degree
other	hsa-mir-208a	Myocardial Infarction	25828373	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Targeting MicroRNA-208a to Suppress Adverse Postmyocardial Infarction Remodelling Related to RNA Activation of Endoglin Gene Expression.
other	hsa-mir-208a	Myocardial Infarction	29506703	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction
other	hsa-mir-208b	Myocardial Infarction	23448306	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	During surgery miR-208b and miR-499-5p was released in the coronary sinus after cardioplegia-reperfusion to markedly higher levels than in a peripheral vein.
other	hsa-mir-21	Myocardial Infarction	19147588	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-21: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue
other	hsa-mir-21	Myocardial Infarction	20959496	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.
other	hsa-mir-21	Myocardial Infarction	22760500	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Activation of Rac1 by angiotensin II leads to a CTGF- and lysyl oxidase-mediated increase of miR-21 expression contributing to structural remodelling of the atrial myocardium.
other	hsa-mir-21	Myocardial Infarction	26168042	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	losartan treatment significantly increased microRNA (miR)-1, -15b, -92a, -133a, -133b, -210, and -499 expression but decreased miR-21 in the left ventricle.
other	hsa-mir-21	Myocardial Infarction	27708252	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Effects of mir-21 on Cardiac Microvascular Endothelial Cells After Acute Myocardial Infarction in Rats: Role of Phosphatase and Tensin Homolog (PTEN)/Vascular Endothelial Growth Factor (VEGF) Signal Pathway.
other	hsa-mir-21	Myocardial Infarction	28170197	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Enhanced Cardioprotection by Human Endometrium Mesenchymal Stem Cells Driven by Exosomal MicroRNA-21.
other	hsa-mir-21	Myocardial Infarction	28699517	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circadian MicroRNAs in Cardioprotection.
other	hsa-mir-21	Myocardial Infarction	29506703	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction
other	hsa-mir-210	Myocardial Infarction	20837903	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-210:MicroRNA-210 can improve angiogenesis, inhibit apoptosis, and improve cardiac function in a murine model of myocardial infarction.
other	hsa-mir-210	Myocardial Infarction	23388440	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	These data demonstrated that a positive feedback loop involving miR-210 and HIF-1α was important for MSC survival under hypoxic conditions.
other	hsa-mir-210	Myocardial Infarction	25016614	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNAs most highly enriched in EVs secreted by CPCs compared with fibroblasts  included miR-210, miR-132, and miR-146a-3p.
other	hsa-mir-210	Myocardial Infarction	28948298	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-210-mediated proliferation, survival, and angiogenesis promote cardiac repair post myocardial infarction in rodents.
other	hsa-mir-210	Myocardial Infarction	29484401	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-210 promotes angiogenesis in acute myocardial infarction
other	hsa-mir-22	Myocardial Infarction	29063105	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-22 plays critical roles in MI and subsequent cardiac remodeling
other	hsa-mir-223	Myocardial Infarction	21949332	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-223 and miR-197 showed positive associations (multivariable HR 2.19 [95% CI 1.26 to 3.83], p=0.006, and 1.79 [95% CI 1.00 to 3.20], p=0.049) while miR-126 was inversely correlated with disease risk (multivariable HR 0.40 [95% CI 0.22 to 0.73], p=0.003).
other	hsa-mir-23	Myocardial Infarction	24864093	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA--a new diagnostic tool in coronary artery disease and myocardial infarction.
other	hsa-mir-23a	Myocardial Infarction	24269648	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-23a is involved in tumor necrosis factor-α induced apoptosis in mesenchymal stem cells and myocardial infarction.
other	hsa-mir-24-1	Myocardial Infarction	21788589	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-24 Regulates Vascularity After Myocardial Infarction
other	hsa-mir-24-1	Myocardial Infarction	22260784	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-24 Regulates Cardiac Fibrosis after Myocardial Infarction.
other	hsa-mir-24-2	Myocardial Infarction	21788589	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-24 Regulates Vascularity After Myocardial Infarction
other	hsa-mir-24-2	Myocardial Infarction	22260784	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-24 Regulates Cardiac Fibrosis after Myocardial Infarction.
other	hsa-mir-26	Myocardial Infarction	25867756	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	This study provides more details on gene expression regulation and regulators involved in MI progression and recurrence. It also linked up and interpreted many previous results.
other	hsa-mir-29	Myocardial Infarction	20959496	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.
other	hsa-mir-29b	Myocardial Infarction	28722488	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Berberine promotes ischemia-induced angiogenesis in mice heart via upregulation of microRNA-29b.
other	hsa-mir-31	Myocardial Infarction	28865712	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease.
other	hsa-mir-320	Myocardial Infarction	25867756	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	This study provides more details on gene expression regulation and regulators involved in MI progression and recurrence. It also linked up and interpreted many previous results.
other	hsa-mir-320	Myocardial Infarction	20959496	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.
other	hsa-mir-322	Myocardial Infarction	20972335	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	These results suggest that miR-322/424 plays an important physiological role in post-ischemic vascular remodeling and angiogenesis.
other	hsa-mir-34a	Myocardial Infarction	29559958	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-34a, a microRNA known to promote pro-apoptotic role in myocardial infarction during degenerative process of cardiac injuries thus indicating intrinsic differences in the nature of the mechanisms underlying the heart failure triggered by Trypanosoma cruzi infection.
other	hsa-mir-377	Myocardial Infarction	26564601	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The present study is timely because the field is eagerly awaiting the results of the large phase III BAMI (Bone Marrow-Derived Mononuclear Cells on All-Cause Mortality in Myocardial Infarction; NCT01569178) clinical trial. If this clinical trial turns out positively, approaches such as the one developed by Joladarashi et al.  will have additional relevance to the field.
other	hsa-mir-378	Myocardial Infarction	28062497	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased Proangiogenic Activity of Mobilized CD34+ Progenitor Cells of Patients With Acute ST-Segment-Elevation Myocardial Infarction: Role of Differential MicroRNA-378 Expression.
other	hsa-mir-424	Myocardial Infarction	20972335	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	These results suggest that miR-322/424 plays an important physiological role in post-ischemic vascular remodeling and angiogenesis.
other	hsa-mir-499	Myocardial Infarction	25111390	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our results demonstrate that circulating miR-499 is a novel, early biomarker for identifying perioperative myocardial infarction in cardiac surgery.
other	hsa-mir-499	Myocardial Infarction	21186368	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Here we report that modulation of microRNA-499 (miR-499) levels affects apoptosis and the severity of myocardial infarction and cardiac dysfunction induced by ischemia-reperfusion.
other	hsa-mir-499	Myocardial Infarction	23448306	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	During surgery miR-208b and miR-499-5p was released in the coronary sinus after cardioplegia-reperfusion to markedly higher levels than in a peripheral vein.
other	hsa-mir-499	Myocardial Infarction	24363996	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Treatment with cLA and nitrite  significantly induced levels of miRNA-499 compared to untreated MI mice.
other	hsa-mir-499	Myocardial Infarction	27056419	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-208/499 located in introns of the heavy chain myosin genes regulate expression of sarcomeric contractile proteins.
other	hsa-mir-499	Myocardial Infarction	29506703	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Droplet digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction
other	hsa-mir-92a	Myocardial Infarction	20959496	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a,miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.
other	hsa-mir-103	Myocardial Infarction	26038570	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our results reveal a novel myocardial necrosis regulation model,which is composed of H19, miR-103/107, and FADD. Modulation of their levels may provide a new approach for preventing myocardial necrosis.
other	hsa-mir-107	Myocardial Infarction	26038570	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our results reveal a novel myocardial necrosis regulation model,which is composed of H19, miR-103/107, and FADD. Modulation of their levels may provide a new approach for preventing myocardial necrosis.
other	hsa-mir-1	Myocardial Ischemic-Reperfusion Injury	29505745				D015428			Cardioprotective effect of paeonol against epirubicin-induced heart injury via regulating miR-1 and PI3K/AKT pathway
other	hsa-mir-146a	Myocardial Ischemic-Reperfusion Injury	23208587				D015428			Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury
other	hsa-mir-21	Myocardial Ischemic-Reperfusion Injury	24825878				D015428			Na2S induces cardioprotective effects through miR-21-dependent attenuation of ischemic and inflammatory injury in cardiomyocytes.
other	hsa-mir-29a	Myocardial Ischemic-Reperfusion Injury	26844226				D015428			After Myocardial Ischemia-Reperfusion, miR-29a, and Let7 Could Affect Apoptosis through Regulating IGF-1.
other	hsa-mir-376b	Myocardial Ischemic-Reperfusion Injury	22396777				D015428			M(3) Subtype of Muscarinic Acetylcholine Receptor Promotes Cardioprotection via the Suppression of miR-376b-5p.
other	hsa-mir-125b	Narcolepsy	26028057	disease of mental health	DOID:8986	G47.41	D009290	PS161400	HP:0030050	we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy.
other	hsa-mir-130a	Narcolepsy	26028057	disease of mental health	DOID:8986	G47.41	D009290	PS161400	HP:0030050	we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy.
other	hsa-mir-155	Narcolepsy	26028057	disease of mental health	DOID:8986	G47.41	D009290	PS161400	HP:0030050	we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy.
other	hsa-mir-26a	Narcolepsy	26028057	disease of mental health	DOID:8986	G47.41	D009290	PS161400	HP:0030050	we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy.
other	hsa-mir-30c	Narcolepsy	26028057	disease of mental health	DOID:8986	G47.41	D009290	PS161400	HP:0030050	we would suggest the possible overexpression of these miRNAs subtypes in N1 patients close to disease onset. Yet, larger investigations are needed in the future to better determine if there is a causal association among inflammation, miRNAs, and narcolepsy.
other	hsa-mir-296	Nasal Cavity Inverting Papilloma	28693263	disease of cellular proliferation	DOID:4633					Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma.
other	hsa-mir-149	Nasopharyngeal Neoplasms	21873783			C11.9	D009303	607107	HP:0100630	miR-149 promotes epithelial-mesenchymal transition and invasion in nasopharyngeal carcinoma cells.
other	hsa-mir-155	Nasopharyngeal Neoplasms	21541331			C11.9	D009303	607107	HP:0100630	Upregulation of MiR-155 in Nasopharyngeal Carcinoma is Partly Driven by LMP1 and LMP2A and Downregulates a Negative Prognostic Marker JMJD1A.
other	hsa-mir-18a	Nasopharyngeal Neoplasms	23097559			C11.9	D009303	607107	HP:0100630	miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma
other	hsa-mir-18b	Nasopharyngeal Neoplasms	23764853			C11.9	D009303	607107	HP:0100630	Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma.
other	hsa-mir-29c	Nasopharyngeal Neoplasms	23142283			C11.9	D009303	607107	HP:0100630	MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy
other	hsa-let-7	Neoplasms [unspecific]	24703842			C80.1	D009369			We conclude that IMP3 RNPs may function as cytoplasmic safe houses and prevent miRNA-directed mRNA decay of oncogenes during tumor progression.
other	hsa-let-7	Neoplasms [unspecific]	26080928			C80.1	D009369			these results suggest that cytoplasmic uridylation pathway actively participates in blockade of let-7 biogenesis by Lin28B.
other	hsa-let-7	Neoplasms [unspecific]	26187994			C80.1	D009369			Our data reveal an unexpected role of Rho-associated, coiled-coil-containing protein kinase (ROCK1) as a cofactor of HNF4A in enhancing PAIP2 transcription. Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitors may be useful for the various pathologies associated with the impairment of global miRNA function.
other	hsa-let-7	Neoplasms [unspecific]	27097729			C80.1	D009369			The insights of Let-7 miRNAs in oncogenesis and stem cell potency.
other	hsa-let-7	Neoplasms [unspecific]	27659051			C80.1	D009369			Several proteins known to bind immature forms of these let-7 miRNAs were identified, but with an improved coverage compared to previous studies
other	hsa-let-7	Neoplasms [unspecific]	28004230			C80.1	D009369			In Silico Mining of Conserved miRNAs of Indian Catfish Clarias batrachus (Linnaeus, 1758) from the Contigs, ESTs, and BAC End Sequences.
other	hsa-let-7	Neoplasms [unspecific]	28070818			C80.1	D009369			Entangling Relation of Micro RNA-let7, miRNA-200 and miRNA-125 with Various Cancers.
other	hsa-let-7	Neoplasms [unspecific]	28446596			C80.1	D009369			Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family.
other	hsa-let-7	Neoplasms [unspecific]	29644076			C80.1	D009369			These observations emphasize the central importance of IGF signaling pathways in the mediation of intragenomic conflicts over embryonic growth and identify possible targets for therapeutic interventions in cancer
other	hsa-let-7a	Neoplasms [unspecific]	26420675			C80.1	D009369			Target-Catalyzed DNA Four-Way Junctions for CRET Imaging of MicroRNA,Concatenated Logic Operations, and Self-Assembly of DNA Nanohydrogels for Targeted Drug Delivery.
other	hsa-let-7a	Neoplasms [unspecific]	25759134			C80.1	D009369			we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-let-7a	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-let-7a	Neoplasms [unspecific]	17554199			C80.1	D009369			Other p53-induced miRNAs identified here may also have tumor suppressive potential as they are known to suppress the anti-apoptotic factor Bcl2 (miR-15a/16) and the oncogenes RAS and HMGA2 (let-7a).
other	hsa-let-7a	Neoplasms [unspecific]	27659051			C80.1	D009369			Several proteins known to bind immature forms of these let-7 miRNAs were identified, but with an improved coverage compared to previous studies
other	hsa-let-7a-1	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7a: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7a-1	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7a: guardians against pluripotency and cancer progression
other	hsa-let-7a-2	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7a: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7a-2	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7a: guardians against pluripotency and cancer progression
other	hsa-let-7a-3	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7a: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7a-3	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7a: guardians against pluripotency and cancer progression
other	hsa-let-7b	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7b: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7b	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7b: guardians against pluripotency and cancer progression
other	hsa-let-7b	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-let-7b	Neoplasms [unspecific]	25946136			C80.1	D009369			Let-7 may represent a new class of chemosensitizer for the treatment of KRAS mutant tumors.
other	hsa-let-7c	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7c: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7c	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7c: guardians against pluripotency and cancer progression
other	hsa-let-7c	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-let-7c	Neoplasms [unspecific]	27087117			C80.1	D009369			microRNA let-7c (let-7c) contributed to the anisomycin-induced apoptosis
other	hsa-let-7d	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7d: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7d	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7d: guardians against pluripotency and cancer progression
other	hsa-let-7d	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-let-7e	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7e: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7e	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7e: guardians against pluripotency and cancer progression
other	hsa-let-7e	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-let-7f	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-let-7f-1	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7f: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7f-1	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7f: guardians against pluripotency and cancer progression
other	hsa-let-7f-2	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7f: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7f-2	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7f: guardians against pluripotency and cancer progression
other	hsa-let-7g	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7g: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7g	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7g: guardians against pluripotency and cancer progression
other	hsa-let-7g	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-let-7g	Neoplasms [unspecific]	27659051			C80.1	D009369			Several proteins known to bind immature forms of these let-7 miRNAs were identified, but with an improved coverage compared to previous studies
other	hsa-let-7i	Neoplasms [unspecific]	18560417			C80.1	D009369			let-7i: A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication
other	hsa-let-7i	Neoplasms [unspecific]	19221491			C80.1	D009369			let-7i: guardians against pluripotency and cancer progression
other	hsa-let-7i	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-mir-1	Neoplasms [unspecific]	25899823			C80.1	D009369			Our results suggest that the degradation status of ribosomal RNA is not always applicable to mRNA and microRNA. In fact, the stabilities of these RNA classes to exposure to ribonucleases are independent from each other, with microRNA being more stable than mRNA. The relative stability of microRNAs supports their potential and further development as biomarkers in a range of applications.
other	hsa-mir-1	Neoplasms [unspecific]	29642568			C80.1	D009369			A single sub-lethal dose of irradiation has been shown to result in compensatory up-regulation of the myocardial connexin-43 (Cx43), activation of the protein kinase C (PKC) signaling along with the decline of microRNA (miR)-1 and an increase of miR-21 levels in the left ventricle (LV)
other	hsa-mir-1	Neoplasms [unspecific]	27286699			C80.1	D009369			miR-1 is classified to be a tumor suppressor
other	hsa-mir-100	Neoplasms [unspecific]	24258109			C80.1	D009369			Prognostic role of microRNA-100 in various carcinomas: evidence from six studies.
other	hsa-mir-100	Neoplasms [unspecific]	24903380			C80.1	D009369			the prognostic role of miR-100 in human cancers, and thus, much more works are needed in this field.
other	hsa-mir-101	Neoplasms [unspecific]	26145175			C80.1	D009369			MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
other	hsa-mir-101	Neoplasms [unspecific]	20617180			C80.1	D009369			Up-regulating miR-101 efficiently reduced the protein levels of DNA-PKcs and ATM in these tumor cells and most importantly, sensitized the tumor cells to radiation in vitro and in vivo.
other	hsa-mir-101	Neoplasms [unspecific]	26005707			C80.1	D009369			eight miRNAs including miR-17-5p, miR-20a, miR-223, miR-21, miR-155, miR-494, miR-690 and miR-101 are of particular interest regarding MDSC accumulation and function.
other	hsa-mir-105	Neoplasms [unspecific]	23950948			C80.1	D009369			miR-105 inhibits prostate tumour growth by suppressing CDK6 levels.
other	hsa-mir-106a	Neoplasms [unspecific]	20878079			C80.1	D009369			The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy.
other	hsa-mir-106a	Neoplasms [unspecific]	27780637			C80.1	D009369			MiR-106a: Promising biomarker for cancer.
other	hsa-mir-106b	Neoplasms [unspecific]	25286029			C80.1	D009369			miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells.
other	hsa-mir-106b	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-106b: key modulators of TGFbeta signaling
other	hsa-mir-106b	Neoplasms [unspecific]	20878079			C80.1	D009369			The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy.
other	hsa-mir-107	Neoplasms [unspecific]	20833636			C80.1	D009369			p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins.
other	hsa-mir-10b	Neoplasms [unspecific]	24503738			C80.1	D009369			Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor.
other	hsa-mir-10b	Neoplasms [unspecific]	25426550			C80.1	D009369			miR-520d-5p leads to reduced proliferation of tumor cells, and that high levels of miR-520d-5p correlate with higher survival rates of cancer patients.
other	hsa-mir-10b	Neoplasms [unspecific]	20444703			C80.1	D009369			miR-10b:miR-10b targets Tiam1: implications for Rac activation and carcinoma migration
other	hsa-mir-10b	Neoplasms [unspecific]	18256538			C80.1	D009369			pro-metastatic
other	hsa-mir-10b	Neoplasms [unspecific]	20351690			C80.1	D009369			Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model
other	hsa-mir-10b	Neoplasms [unspecific]	28989695			C80.1	D009369			Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy.
other	hsa-mir-122	Neoplasms [unspecific]	26360933			C80.1	D009369			In conclusion, administration of TSA in hepatogenic differentiation of hAT-MSCs resulted in higher expression levels of miR-122,facilitation of differentiation, and subsequently attenuation of AFP levels.
other	hsa-mir-122	Neoplasms [unspecific]	26187994			C80.1	D009369			Our data reveal an unexpected role of Rho-associated, coiled-coil-containing protein kinase (ROCK1) as a cofactor of HNF4A in enhancing PAIP2 transcription. Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitors may be useful for the various pathologies associated with the impairment of global miRNA function.
other	hsa-mir-1224	Neoplasms [unspecific]	21320120			C80.1	D009369			Lipopolysaccharide-induced miR-1224 negatively regulates tumour necrosis factor-alpha gene expression by modulating Sp1.
other	hsa-mir-1228	Neoplasms [unspecific]	24488924			C80.1	D009369			Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients.
other	hsa-mir-125a	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-125a	Neoplasms [unspecific]	28197019			C80.1	D009369			Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters.
other	hsa-mir-125b	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-125b	Neoplasms [unspecific]	23800395			C80.1	D009369			The expression and regulation of microRNA-125b in cancers.
other	hsa-mir-125b	Neoplasms [unspecific]	26138442			C80.1	D009369			MAP3K11 might function as an important tumor suppressor neutralized by oncomiR-125b in B-cell leukemia.
other	hsa-mir-125b	Neoplasms [unspecific]	25403182			C80.1	D009369			these findings illuminate miR-125b as an important microRNA regulator that is shared between normal skin progenitors and their early malignant counterparts.
other	hsa-mir-125b	Neoplasms [unspecific]	27500388			C80.1	D009369			along with modulation of wt-p53  and miR-125b expression, we also show that the exosomes (i.e., wt-p53/exo, miR-125b/exo and combination/exo) have a reprogramed global miRNA profile.
other	hsa-mir-125b	Neoplasms [unspecific]	27321180			C80.1	D009369			Forced expression of hsa-miR-125b in these cells resulted in radiosensitivity
other	hsa-mir-125b-1	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-125b:in macrophages, miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs
other	hsa-mir-125b-1	Neoplasms [unspecific]	22268450			C80.1	D009369			Camptothecin Induces Apoptosis in Cancer Cells via miR-125b Mediated Mitochondrial Pathways.
other	hsa-mir-125b-1	Neoplasms [unspecific]	23437196			C80.1	D009369			Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis responses and Akt/p70S6K1/HIF-1ж┿pathway.
other	hsa-mir-125b-1	Neoplasms [unspecific]	23497288			C80.1	D009369			miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor
other	hsa-mir-125b-2	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-125b:in macrophages, miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs
other	hsa-mir-125b-2	Neoplasms [unspecific]	22268450			C80.1	D009369			Camptothecin Induces Apoptosis in Cancer Cells via miR-125b Mediated Mitochondrial Pathways.
other	hsa-mir-125b-2	Neoplasms [unspecific]	23437196			C80.1	D009369			Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis responses and Akt/p70S6K1/HIF-1ж┿pathway.
other	hsa-mir-125b-2	Neoplasms [unspecific]	23497288			C80.1	D009369			miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor
other	hsa-mir-126	Neoplasms [unspecific]	24368110			C80.1	D009369			miR-126 in human cancers: clinical roles and current perspectives.
other	hsa-mir-126	Neoplasms [unspecific]	25999416			C80.1	D009369			This pioneering work was followed by studies that reported intercellular exchange of miRs-143/145 and miR-21* within the vascular wall and the myocardium, respectively.
other	hsa-mir-126	Neoplasms [unspecific]	27583885			C80.1	D009369			Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis.
other	hsa-mir-130	Neoplasms [unspecific]	24220575			C80.1	D009369			Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif.
other	hsa-mir-132	Neoplasms [unspecific]	20676106			C80.1	D009369			miR-132:miR-132 was highly expressed in the endothelium of human tumors and hemangiomas
other	hsa-mir-132	Neoplasms [unspecific]	18075311			C80.1	D009369			In this review, we will discuss the specific roles of miRNA-(miR-)132 and miR-219 in the SCN, as well as a more general outlook on this newly elucidated layer of circadian clock regulation: inducible translation control via miRNAs.
other	hsa-mir-133	Neoplasms [unspecific]	28004230			C80.1	D009369			In Silico Mining of Conserved miRNAs of Indian Catfish Clarias batrachus (Linnaeus, 1758) from the Contigs, ESTs, and BAC End Sequences.
other	hsa-mir-137	Neoplasms [unspecific]	28004230			C80.1	D009369			In Silico Mining of Conserved miRNAs of Indian Catfish Clarias batrachus (Linnaeus, 1758) from the Contigs, ESTs, and BAC End Sequences.
other	hsa-mir-138	Neoplasms [unspecific]	26138095			C80.1	D009369			These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-138-1	Neoplasms [unspecific]	23300839			C80.1	D009369			MicroRNA-138 Suppresses Neutrophil Gelatinase-Associated Lipocalin Expression and Inhibits Tumorigenicity
other	hsa-mir-138-2	Neoplasms [unspecific]	23300839			C80.1	D009369			MicroRNA-138 Suppresses Neutrophil Gelatinase-Associated Lipocalin Expression and Inhibits Tumorigenicity
other	hsa-mir-139	Neoplasms [unspecific]	25691250			C80.1	D009369			MiR-139-5p: promising biomarker for cancer.
other	hsa-mir-139	Neoplasms [unspecific]	27022656			C80.1	D009369			The loss of MiR-139-5p promotes colitis-associated tumorigenesis by mediating PI3K/AKT/Wnt signaling.
other	hsa-mir-139	Neoplasms [unspecific]	28119089			C80.1	D009369			The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses.
other	hsa-mir-141	Neoplasms [unspecific]	25403569			C80.1	D009369			our comprehensive pan-cancer analysis provided not only biological insights into metastasis but also brought to bear the clinical relevance of the proposed recurrent miRNA-gene associations.
other	hsa-mir-141	Neoplasms [unspecific]	25889350			C80.1	D009369			The DNA tweezers also show high selectivity toward the fuel strand and can be used to monitor miR-141 expression in cancer cells, which provides new opportunities for the application of the dynamic DNA devices in clinical diagnostics.
other	hsa-mir-141	Neoplasms [unspecific]	26439017			C80.1	D009369			Coupling hybridization chain reaction with catalytic hairpin assembly enables non-enzymatic and sensitive fluorescent detection of microRNA cancer biomarkers.
other	hsa-mir-141	Neoplasms [unspecific]	19593777			C80.1	D009369			association with cancer progression
other	hsa-mir-141	Neoplasms [unspecific]	18829540			C80.1	D009369			These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression.
other	hsa-mir-141	Neoplasms [unspecific]	18927505			C80.1	D009369			Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype.
other	hsa-mir-142	Neoplasms [unspecific]	24227773			C80.1	D009369			Two specific miRNAs transferred efficiently between these cells--miR-142 and miR-223--and both were endogenously expressed in macrophages and not in HCCs.
other	hsa-mir-143	Neoplasms [unspecific]	25486198			C80.1	D009369			identify new molecules and mechanisms involved in the DDR, and to examine their role in tumor suppression and the clinical outcome of cancer patients.
other	hsa-mir-143	Neoplasms [unspecific]	25999416			C80.1	D009369			This pioneering work was followed by studies that reported intercellular exchange of miRs-143/145 and miR-21* within the vascular wall and the myocardium, respectively.
other	hsa-mir-143	Neoplasms [unspecific]	25477374			C80.1	D009369			differences in these tumor suppressors might contribute to regional differences in normal colonic gene expression and modulate site-specific differences in malignant predisposition.
other	hsa-mir-143	Neoplasms [unspecific]	26988859			C80.1	D009369			The miR-143/miR-145 cluster and the tumor microenvironment: unexpected roles.
other	hsa-mir-143	Neoplasms [unspecific]	28038917			C80.1	D009369			A positive feedback loop between GRP78 and VPS34 is critical for GRP78-mediated autophagy in cancer cells.
other	hsa-mir-143	Neoplasms [unspecific]	28119089			C80.1	D009369			The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses.
other	hsa-mir-145	Neoplasms [unspecific]	25999416			C80.1	D009369			This pioneering work was followed by studies that reported intercellular exchange of miRs-143/145 and miR-21* within the vascular wall and the myocardium, respectively.
other	hsa-mir-145	Neoplasms [unspecific]	25476854			C80.1	D009369			large-scale prospective studies and additional improvements are urgently needed to confirm our findings and its utilization for routine clinical diagnosis in future.
other	hsa-mir-145	Neoplasms [unspecific]	24657914			C80.1	D009369			miR-145 and its influence on tumor growth in systemic malignancies.
other	hsa-mir-145	Neoplasms [unspecific]	25477374			C80.1	D009369			differences in these tumor suppressors might contribute to regional differences in normal colonic gene expression and modulate site-specific differences in malignant predisposition.
other	hsa-mir-145	Neoplasms [unspecific]	26988859			C80.1	D009369			The miR-143/miR-145 cluster and the tumor microenvironment: unexpected roles.
other	hsa-mir-145	Neoplasms [unspecific]	26168819			C80.1	D009369			Treatments of T-CIN+ cells with senescence-conditioned  media induce sphere formation exclusively in cells with senescence-associated tumorigenicity, a capacity that depends on miR-145 repression.
other	hsa-mir-145	Neoplasms [unspecific]	28119089			C80.1	D009369			The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses.
other	hsa-mir-146a	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-146:in macrophages, miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs
other	hsa-mir-146a	Neoplasms [unspecific]	23200854			C80.1	D009369			Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity
other	hsa-mir-146a	Neoplasms [unspecific]	23796062			C80.1	D009369			Our results indicated that ectopic expression of miR-146a could not independently induce differentiation in lymphoblastic cells. However, the expression of multiple genes involved in T-cell differentiation and T-cell CD markers were found to be affected. These results have suggested a potential tumor suppressive, immunomodulatory and cell activator role for miR146-a.
other	hsa-mir-146a	Neoplasms [unspecific]	26549232			C80.1	D009369			Together our results uncover miRNAs as yet another negative mechanism controlling Merlin tumor suppressor functions.
other	hsa-mir-146a	Neoplasms [unspecific]	21555486			C80.1	D009369			miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice.
other	hsa-mir-146a	Neoplasms [unspecific]	22453030			C80.1	D009369			In this review we focus on recent progress in analyzing the functional role of miR-146a in the control of normal and malignant hematopoiesis.
other	hsa-mir-146a	Neoplasms [unspecific]	19021527			C80.1	D009369			In the present article, we review the evidence for a role of miR-146a in innate immunity and cancer and assess whether changes in miR-146a might link these two biological responses.
other	hsa-mir-146a	Neoplasms [unspecific]	28197019			C80.1	D009369			Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters.
other	hsa-mir-146b	Neoplasms [unspecific]	20406109			C80.1	D009369			miR-146b:potential importance of miR-221, miR-222, and miR-146b in determining the aggressive properties of PTCs
other	hsa-mir-147	Neoplasms [unspecific]	24454732			C80.1	D009369			MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance.
other	hsa-mir-148a	Neoplasms [unspecific]	26124099			C80.1	D009369			MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC.
other	hsa-mir-149	Neoplasms [unspecific]	25916550			C80.1	D009369			Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment.
other	hsa-mir-150	Neoplasms [unspecific]	26170969			C80.1	D009369			iR-150 may be a potential biomarker and therapeutic target in the diagnosis and treatment of various malignancies.
other	hsa-mir-152	Neoplasms [unspecific]	25578780			C80.1	D009369			XIST in GSCs and important clues for understanding the key roles of lncRNA-miRNA functionalnetwork in human glioma.
other	hsa-mir-155	Neoplasms [unspecific]	24122356			C80.1	D009369			microRNA-155 has functions in the control of various cancers
other	hsa-mir-155	Neoplasms [unspecific]	24716910			C80.1	D009369			MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis.
other	hsa-mir-155	Neoplasms [unspecific]	25486872			C80.1	D009369			miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
other	hsa-mir-155	Neoplasms [unspecific]	25548153			C80.1	D009369			overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers.
other	hsa-mir-155	Neoplasms [unspecific]	26317550			C80.1	D009369			Our results demonstrate that miR-155 inhibits the ability of cancer cells to extravasate and/or colonize at distant organs and brings additional insight into the complexity of miR-155 regulation in metastatic seeding.
other	hsa-mir-155	Neoplasms [unspecific]	25918453			C80.1	D009369			Our data suggest that single miR-155 profiling has a potential to be used as a screening test for various carcinomas, and parallel testing of miR-155 confers an improved specificity compared to single miR-155 analysis.
other	hsa-mir-155	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-155:in macrophages, miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs
other	hsa-mir-155	Neoplasms [unspecific]	23200854			C80.1	D009369			Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity
other	hsa-mir-155	Neoplasms [unspecific]	24687397			C80.1	D009369			In HepG2 cells, exogenous NO increases miR-155 expression, but endogenous basal NO inhibits it. Both effects are mediated via cGMP/PKG signaling. The upregulation of miR-155 by NO provides a new link between NO, inflammation, and cancer.
other	hsa-mir-155	Neoplasms [unspecific]	26771315			C80.1	D009369			Screening of Pre-miRNA-155 Binding Peptides for Apoptosis Inducing Activity Using Peptide Microarrays.
other	hsa-mir-155	Neoplasms [unspecific]	27602769			C80.1	D009369			MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/β-catenin signaling pathways.
other	hsa-mir-155	Neoplasms [unspecific]	28162271			C80.1	D009369			Nitric Oxide: Genomic Instability And Synthetic Lethality.
other	hsa-mir-155	Neoplasms [unspecific]	28197019			C80.1	D009369			Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters.
other	hsa-mir-155	Neoplasms [unspecific]	28256712			C80.1	D009369			Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study.
other	hsa-mir-155	Neoplasms [unspecific]	28912267			C80.1	D009369			Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
other	hsa-mir-155	Neoplasms [unspecific]	29366836			C80.1	D009369			Increased miR-155 expression was associated with poorer survival in human carcinoma and as such may be valuable in predicting outcome
other	hsa-mir-15a	Neoplasms [unspecific]	25945419			C80.1	D009369			these data demonstrate that miR-15a/16 induced autophagy contribute partly to their inhibition of cell proliferation and enhanced chemotherapeutic efficacy of camptothecin(CPT).
other	hsa-mir-15a	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-15a	Neoplasms [unspecific]	23353574			C80.1	D009369			Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines
other	hsa-mir-15a	Neoplasms [unspecific]	25540364			C80.1	D009369			viral RNAs can exert their functions as competing endogenous RNAs (ceRNAs) toward microRNA and participate in important cellular processes.
other	hsa-mir-15a	Neoplasms [unspecific]	26260813			C80.1	D009369			miRNA-15a/16: as tumor suppressors and more.
other	hsa-mir-16	Neoplasms [unspecific]	26031775			C80.1	D009369			Our findings provide the first clues regarding the role of miR-16 as a tumor suppressor in cancer cells through the inhibition of FEAT translation.
other	hsa-mir-16	Neoplasms [unspecific]	25486198			C80.1	D009369			identify new molecules and mechanisms involved in the DDR, and to examine their role in tumor suppression and the clinical outcome of cancer patients.
other	hsa-mir-16	Neoplasms [unspecific]	25945419			C80.1	D009369			these data demonstrate that miR-15a/16 induced autophagy contribute partly to their inhibition of cell proliferation and enhanced chemotherapeutic efficacy of camptothecin(CPT).
other	hsa-mir-16	Neoplasms [unspecific]	26260813			C80.1	D009369			miRNA-15a/16: as tumor suppressors and more.
other	hsa-mir-16	Neoplasms [unspecific]	25787082			C80.1	D009369			In addition, we observed significantly reduced expression of microRNAs (miRNAs) including miR-16 and miR-19b, which are known to be significantly reduced in the  semen of infertile men.
other	hsa-mir-16	Neoplasms [unspecific]	28670496			C80.1	D009369			Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.
other	hsa-mir-16-1	Neoplasms [unspecific]	19269153			C80.1	D009369			miR-16: can be upregulated by Epigallocatechin gallate
other	hsa-mir-16-1	Neoplasms [unspecific]	20668064			C80.1	D009369			miR-16:miR-16 in the regulation of Wip1 phosphatase in the DNA damage response and mammary tumorigenesis
other	hsa-mir-16-1	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-16-2	Neoplasms [unspecific]	19269153			C80.1	D009369			miR-16: can be upregulated by Epigallocatechin gallate
other	hsa-mir-16-2	Neoplasms [unspecific]	20668064			C80.1	D009369			miR-16:miR-16 in the regulation of Wip1 phosphatase in the DNA damage response and mammary tumorigenesis
other	hsa-mir-17	Neoplasms [unspecific]	24598644			C80.1	D009369			Effect of microRNA-17-92 cluster on the biological characteristics of K562 cells and its mechanisms.
other	hsa-mir-17	Neoplasms [unspecific]	26255770			C80.1	D009369			developmentally regulated pro-miRNA processing is a key step controlling miRNA expression and explains the posttranscriptional control of miR-17-92 expression in development.
other	hsa-mir-17	Neoplasms [unspecific]	26479035			C80.1	D009369			Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients
other	hsa-mir-17	Neoplasms [unspecific]	24220575			C80.1	D009369			Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif.
other	hsa-mir-17	Neoplasms [unspecific]	18700987			C80.1	D009369			miR-17-5p: The miR-17-5p microRNA is able to act as both an oncogene and a tumor suppressor in different cellular contexts
other	hsa-mir-17	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-17: key modulators of TGFbeta signaling
other	hsa-mir-17	Neoplasms [unspecific]	19887902			C80.1	D009369			miR-17-5p has initially been linked to tumorigenesis
other	hsa-mir-17	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-17:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-17	Neoplasms [unspecific]	20227518			C80.1	D009369			mir-17-92, a cluster of miRNAs in the midst of the cancer network
other	hsa-mir-17	Neoplasms [unspecific]	26117336			C80.1	D009369			Oncogenic miR-17/20a Forms a Positive Feed-forward Loop with the p53 Kinase DAPK3 to Promote Tumorigenesis.
other	hsa-mir-17	Neoplasms [unspecific]	25887381			C80.1	D009369			Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs.
other	hsa-mir-17	Neoplasms [unspecific]	26545119			C80.1	D009369			In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-β signaling pathway. Manipulation of the TGF-β pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS.
other	hsa-mir-17	Neoplasms [unspecific]	20878079			C80.1	D009369			The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy.
other	hsa-mir-17	Neoplasms [unspecific]	23550645			C80.1	D009369			Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease.
other	hsa-mir-17	Neoplasms [unspecific]	19066217			C80.1	D009369			Using the concept and model prediction of a "cancer zone," the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc.
other	hsa-mir-17	Neoplasms [unspecific]	27577994			C80.1	D009369			miR-17-5p is at the crossroads of aging, longevity and cancer and might represent a promising biomarker or even therapeutic tool and target in this context
other	hsa-mir-17	Neoplasms [unspecific]	27780637			C80.1	D009369			MiR-106a: Promising biomarker for cancer.
other	hsa-mir-18	Neoplasms [unspecific]	25887381			C80.1	D009369			Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs.
other	hsa-mir-18	Neoplasms [unspecific]	26479035			C80.1	D009369			Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients
other	hsa-mir-18	Neoplasms [unspecific]	26545119			C80.1	D009369			In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-β signaling pathway. Manipulation of the TGF-β pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS.
other	hsa-mir-18	Neoplasms [unspecific]	23550645			C80.1	D009369			Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease.
other	hsa-mir-18	Neoplasms [unspecific]	19066217			C80.1	D009369			Using the concept and model prediction of a "cancer zone," the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc.
other	hsa-mir-181a-1	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-181a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-181a-2	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-181a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-181b	Neoplasms [unspecific]	29601548			C80.1	D009369			the NF-κB-miR-146 and NF-κB-miR-155 networks fine-tune the activity, intensity, and duration of inflammation, while the NF-κB-miR-21 and NF-κB-miR-181b-2 amplifying loops link inflammation to cancer
other	hsa-mir-183	Neoplasms [unspecific]	25856466			C80.1	D009369			Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected].
other	hsa-mir-184	Neoplasms [unspecific]	19546886			C80.1	D009369			laryngeal carcinoma, upregulated; control of the G1-S phase transition;regulate BTG2, a cell cycle gene
other	hsa-mir-18a	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-18a: key modulators of TGFbeta signaling
other	hsa-mir-18a	Neoplasms [unspecific]	19887902			C80.1	D009369			has initially been linked to tumorigenesis
other	hsa-mir-18a	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-18a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-18a	Neoplasms [unspecific]	20227518			C80.1	D009369			mir-17-92, a cluster of miRNAs in the midst of the cancer network
other	hsa-mir-19	Neoplasms [unspecific]	24220575			C80.1	D009369			Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif.
other	hsa-mir-190	Neoplasms [unspecific]	23863200			C80.1	D009369			Transcriptional changes induced by the tumor dormancy-associated microRNA-190.
other	hsa-mir-192	Neoplasms [unspecific]	21128228			C80.1	D009369			The meta-analysis also revealed some novel tumor-related miRNAs such as hsa-miR-144, hsa-miR-130b, hsa-miR-132, hsa-miR-154, hsa-miR-192 and hsa-miR-345
other	hsa-mir-193a	Neoplasms [unspecific]	25826780			C80.1	D009369			Our findings have provided new insights into mechanisms of CIK cells production and tumor cytotoxic function, and shed light on their safety for clinical trial.
other	hsa-mir-195	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-195	Neoplasms [unspecific]	27572273			C80.1	D009369			MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways.
other	hsa-mir-199a-1	Neoplasms [unspecific]	23354452			C80.1	D009369			MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines
other	hsa-mir-199a-1	Neoplasms [unspecific]	23437196			C80.1	D009369			Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis responses and Akt/p70S6K1/HIF-1ж┿pathway.
other	hsa-mir-199a-2	Neoplasms [unspecific]	23354452			C80.1	D009369			MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines
other	hsa-mir-199a-2	Neoplasms [unspecific]	23437196			C80.1	D009369			Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis responses and Akt/p70S6K1/HIF-1ж┿pathway.
other	hsa-mir-199b	Neoplasms [unspecific]	23354452			C80.1	D009369			MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines
other	hsa-mir-19a	Neoplasms [unspecific]	25887381			C80.1	D009369			Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs.
other	hsa-mir-19a	Neoplasms [unspecific]	26479035			C80.1	D009369			Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients
other	hsa-mir-19a	Neoplasms [unspecific]	26545119			C80.1	D009369			In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-β signaling pathway. Manipulation of the TGF-β pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS.
other	hsa-mir-19a	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-19a: key modulators of TGFbeta signaling
other	hsa-mir-19a	Neoplasms [unspecific]	19887902			C80.1	D009369			has initially been linked to tumorigenesis
other	hsa-mir-19a	Neoplasms [unspecific]	20008935			C80.1	D009369			miR-19 is a key oncogenic component of mir-17-92
other	hsa-mir-19a	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-19a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-19a	Neoplasms [unspecific]	20227518			C80.1	D009369			mir-17-92, a cluster of miRNAs in the midst of the cancer network
other	hsa-mir-19a	Neoplasms [unspecific]	23550645			C80.1	D009369			Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease.
other	hsa-mir-19a	Neoplasms [unspecific]	19066217			C80.1	D009369			Using the concept and model prediction of a "cancer zone," the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc.
other	hsa-mir-19b	Neoplasms [unspecific]	26479035			C80.1	D009369			Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients
other	hsa-mir-19b-1	Neoplasms [unspecific]	25887381			C80.1	D009369			Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs.
other	hsa-mir-19b-1	Neoplasms [unspecific]	26479035			C80.1	D009369			Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients
other	hsa-mir-19b-1	Neoplasms [unspecific]	26545119			C80.1	D009369			In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-β signaling pathway. Manipulation of the TGF-β pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS.
other	hsa-mir-19b-1	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-19b: key modulators of TGFbeta signaling
other	hsa-mir-19b-1	Neoplasms [unspecific]	20008935			C80.1	D009369			miR-19 is a key oncogenic component of mir-17-92
other	hsa-mir-19b-1	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-19b:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-19b-1	Neoplasms [unspecific]	20227518			C80.1	D009369			mir-17-92, a cluster of miRNAs in the midst of the cancer network
other	hsa-mir-19b-1	Neoplasms [unspecific]	23550645			C80.1	D009369			Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease.
other	hsa-mir-19b-1	Neoplasms [unspecific]	19066217			C80.1	D009369			Using the concept and model prediction of a "cancer zone," the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc.
other	hsa-mir-19b-2	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-19b: key modulators of TGFbeta signaling
other	hsa-mir-19b-2	Neoplasms [unspecific]	20008935			C80.1	D009369			miR-19 is a key oncogenic component of mir-17-92
other	hsa-mir-19b-2	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-19b:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-19b-2	Neoplasms [unspecific]	20227518			C80.1	D009369			mir-17-92, a cluster of miRNAs in the midst of the cancer network
other	hsa-mir-200	Neoplasms [unspecific]	25403569			C80.1	D009369			our comprehensive pan-cancer analysis provided not only biological insights into metastasis but also brought to bear the clinical relevance of the proposed recurrent miRNA-gene associations.
other	hsa-mir-200	Neoplasms [unspecific]	26069247			C80.1	D009369			Network-Based Approaches to Understand the Roles of miR-200 and Other microRNAs in Cancer.
other	hsa-mir-200	Neoplasms [unspecific]	26547426			C80.1	D009369			On the basis of these findings,we believe that this method has great potential for quantitative detection of miRNA in biomedical research and early clinical diagnostics.
other	hsa-mir-200	Neoplasms [unspecific]	24018975			C80.1	D009369			The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent.
other	hsa-mir-200	Neoplasms [unspecific]	27837593			C80.1	D009369			the full role of the miR-200 family in cancer progression and metastasis is not completely understood and seems to differ between different tumour types and different cellular backgrounds
other	hsa-mir-200a	Neoplasms [unspecific]	21237487			C80.1	D009369			Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition.
other	hsa-mir-200a	Neoplasms [unspecific]	18381893			C80.1	D009369			the epithelial-to-mesenchymal transition
other	hsa-mir-200a	Neoplasms [unspecific]	19221491			C80.1	D009369			miR-200: guardians against pluripotency and cancer progression
other	hsa-mir-200a	Neoplasms [unspecific]	25586904			C80.1	D009369			exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of\ arsenic exposure as well as a maker of early urothelial carcinoma detection.
other	hsa-mir-200a	Neoplasms [unspecific]	18829540			C80.1	D009369			These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression.
other	hsa-mir-200a	Neoplasms [unspecific]	18927505			C80.1	D009369			Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype.
other	hsa-mir-200a	Neoplasms [unspecific]	27497669			C80.1	D009369			In conclusion, LEFTY2 down-regulates MKi67 expression and FAK activity, up-regulates miR-200a and E-cadherin, and is thus a powerful negative regulator of endometrial cell proliferation and migration.
other	hsa-mir-200b	Neoplasms [unspecific]	21237487			C80.1	D009369			Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition.
other	hsa-mir-200b	Neoplasms [unspecific]	18381893			C80.1	D009369			the epithelial-to-mesenchymal transition
other	hsa-mir-200b	Neoplasms [unspecific]	19221491			C80.1	D009369			miR-200: guardians against pluripotency and cancer progression
other	hsa-mir-200b	Neoplasms [unspecific]	19593777			C80.1	D009369			association with cancer progression
other	hsa-mir-200b	Neoplasms [unspecific]	25586904			C80.1	D009369			exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of\ arsenic exposure as well as a maker of early urothelial carcinoma detection.
other	hsa-mir-200b	Neoplasms [unspecific]	18829540			C80.1	D009369			These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression.
other	hsa-mir-200b	Neoplasms [unspecific]	18927505			C80.1	D009369			Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype.
other	hsa-mir-200c	Neoplasms [unspecific]	25808651			C80.1	D009369			A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential.
other	hsa-mir-200c	Neoplasms [unspecific]	26334100			C80.1	D009369			In summary, TKS5 and MYLK represent two mediators of invasive behavior of cancer cells that are regulated by the ZEB1/miR-200 feedback loop.
other	hsa-mir-200c	Neoplasms [unspecific]	25759134			C80.1	D009369			we demonstrate in detail the power of DNA/RNA chimera/AgNC probes in detecting two human miRNAs,let-7a and miR-200c. The DNA/RNA chimera-based probes are highly efficient to determine the level of miRNAs in several human cell lines.
other	hsa-mir-200c	Neoplasms [unspecific]	21237487			C80.1	D009369			Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition.
other	hsa-mir-200c	Neoplasms [unspecific]	23806972			C80.1	D009369			Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles.
other	hsa-mir-200c	Neoplasms [unspecific]	18381893			C80.1	D009369			the epithelial-to-mesenchymal transition
other	hsa-mir-200c	Neoplasms [unspecific]	19221491			C80.1	D009369			miR-200: guardians against pluripotency and cancer progression
other	hsa-mir-200c	Neoplasms [unspecific]	19593777			C80.1	D009369			association with cancer progression
other	hsa-mir-200c	Neoplasms [unspecific]	25586904			C80.1	D009369			exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of\ arsenic exposure as well as a maker of early urothelial carcinoma detection.
other	hsa-mir-200c	Neoplasms [unspecific]	27094812			C80.1	D009369			miR-200c,  an illustrious tumor suppressor, is one of the highly studied miRNAs in terms of  development, stemness, proliferation, epithelial-mesenchymal transition (EMT), therapy resistance, and metastasis.
other	hsa-mir-200c	Neoplasms [unspecific]	18829540			C80.1	D009369			These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression.
other	hsa-mir-200c	Neoplasms [unspecific]	18927505			C80.1	D009369			Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype.
other	hsa-mir-200c	Neoplasms [unspecific]	29029445			C80.1	D009369			MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling.
other	hsa-mir-202	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-mir-205	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-205	Neoplasms [unspecific]	21237487			C80.1	D009369			Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition.
other	hsa-mir-205	Neoplasms [unspecific]	19593777			C80.1	D009369			association with cancer progression
other	hsa-mir-205	Neoplasms [unspecific]	25586904			C80.1	D009369			exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of\ arsenic exposure as well as a maker of early urothelial carcinoma detection.
other	hsa-mir-205	Neoplasms [unspecific]	18927505			C80.1	D009369			Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype.
other	hsa-mir-206	Neoplasms [unspecific]	26138095			C80.1	D009369			These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-208	Neoplasms [unspecific]	25899823			C80.1	D009369			Our results suggest that the degradation status of ribosomal RNA is not always applicable to mRNA and microRNA. In fact, the stabilities of these RNA classes to exposure to ribonucleases are independent from each other, with microRNA being more stable than mRNA. The relative stability of microRNAs supports their potential and further development as biomarkers in a range of applications.
other	hsa-mir-20a	Neoplasms [unspecific]	25887381			C80.1	D009369			Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs.
other	hsa-mir-20a	Neoplasms [unspecific]	26479035			C80.1	D009369			Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients
other	hsa-mir-20a	Neoplasms [unspecific]	26545119			C80.1	D009369			In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-β signaling pathway. Manipulation of the TGF-β pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS.
other	hsa-mir-20a	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-20a: key modulators of TGFbeta signaling
other	hsa-mir-20a	Neoplasms [unspecific]	19887902			C80.1	D009369			has initially been linked to tumorigenesis
other	hsa-mir-20a	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-20a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-20a	Neoplasms [unspecific]	20227518			C80.1	D009369			mir-17-92, a cluster of miRNAs in the midst of the cancer network
other	hsa-mir-20a	Neoplasms [unspecific]	26117336			C80.1	D009369			Oncogenic miR-17/20a Forms a Positive Feed-forward Loop with the p53 Kinase DAPK3 to Promote Tumorigenesis.
other	hsa-mir-20a	Neoplasms [unspecific]	20878079			C80.1	D009369			The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy.
other	hsa-mir-20a	Neoplasms [unspecific]	23550645			C80.1	D009369			Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease.
other	hsa-mir-20a	Neoplasms [unspecific]	24732804			C80.1	D009369			Decreased expression of miR-27a/miR-20a:miR-17-5p by PEITC-induced ROS is  a key step in triggering the miR-ZBTB Sp cascade leading to downregulation of Sp  TFs, and this is due to ROS-dependent epigenetic effects associated with genome-wide shifts in repressor complexes, resulting in decreased expression of Myc and the Myc-regulated miRs.
other	hsa-mir-20a	Neoplasms [unspecific]	24969314			C80.1	D009369			Furthermore, we  demonstrated that upregulation of the miR-17-92 cluster (miR-20a/miR-17-5p) is involved in the regulation of E2F1-mediated negative feedback of the c-Myc/hTERT  pathway.
other	hsa-mir-20a	Neoplasms [unspecific]	19066217			C80.1	D009369			Using the concept and model prediction of a "cancer zone," the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc.
other	hsa-mir-20b	Neoplasms [unspecific]	20878079			C80.1	D009369			The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy.
other	hsa-mir-21	Neoplasms [unspecific]	24912785			C80.1	D009369			Exosomal miR-21 derived from arsenite-transformed human bronchial epithelial cells promotes cell proliferation associated with arsenite carcinogenesis.
other	hsa-mir-21	Neoplasms [unspecific]	25049417			C80.1	D009369			PAPD5 and PARN mediate degradation of oncogenic miRNA miR-21 through a tailing and trimming process, and that this pathway is disrupted in cancer and other proliferative diseases.
other	hsa-mir-21	Neoplasms [unspecific]	25550434			C80.1	D009369			ESCRT-I complex in the regulation of productive free uptake of anti-miRs and reveal potential avenues for improving oligonucleotide free uptake by cancer cells.
other	hsa-mir-21	Neoplasms [unspecific]	25943710			C80.1	D009369			We believe that this proposed sensitive and specific assay has great potential as a quantification method for miRNA detection in biomedical research and clinical diagnosis.
other	hsa-mir-21	Neoplasms [unspecific]	26156753			C80.1	D009369			This is the first study to demonstrate that kallistatin's heparin-binding site is crucial for preventing TGF-β-induced miR-21 and oxidative stress, while its active site is key for stimulating the expression of antioxidant genes via interaction with an endothelial surface tyrosine kinase.These findings reveal novel mechanisms of kallistatin in protection against fibrosis and cancer by suppressing EndMT.
other	hsa-mir-21	Neoplasms [unspecific]	26191606			C80.1	D009369			The activated single-stranded DC can project the LAA headgroup into the hCA-II active site and is a robust hCA-II inhibitor (K(i) of 3.12 μM). This work may spur research into developing new classes of cancer selective protein inhibitors.
other	hsa-mir-21	Neoplasms [unspecific]	26220158			C80.1	D009369			preliminary mechanism of action studies propose a different mode of action compared to previously reported miR-21 inhibitors, thus affording a new chemical probe for future studies.
other	hsa-mir-21	Neoplasms [unspecific]	20219416			C80.1	D009369			miR-21 serves as a chemosensitive miRNA, while miR-214 and -23a serve as chemoresistant miRNAs in the tongue squamous cell carcinoma  lines
other	hsa-mir-21	Neoplasms [unspecific]	20335152			C80.1	D009369			Expression of microRNA-21 in ovarian epithelial carcinoma and its clinical significance
other	hsa-mir-21	Neoplasms [unspecific]	23784029			C80.1	D009369			MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation.
other	hsa-mir-21	Neoplasms [unspecific]	25149066			C80.1	D009369			miR-21-3p is a positive regulator of L1CAM in several human carcinomas.
other	hsa-mir-21	Neoplasms [unspecific]	25376700			C80.1	D009369			MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis.
other	hsa-mir-21	Neoplasms [unspecific]	26271820			C80.1	D009369			MicroRNA-Responsive Cancer Cell Imaging and Therapy with Functionalized Gold Nanoprobe.
other	hsa-mir-21	Neoplasms [unspecific]	19073608			C80.1	D009369			miR-21: coordinately regulate EGFR signaling in multiple human cancer cell types
other	hsa-mir-21	Neoplasms [unspecific]	19593777			C80.1	D009369			association with cancer progression
other	hsa-mir-21	Neoplasms [unspecific]	20404348			C80.1	D009369			miR-21:function of AKT by which it inhibits apoptosis through miR-21-dependent suppression of FasL
other	hsa-mir-21	Neoplasms [unspecific]	26101800			C80.1	D009369			The IL-6/STAT3 pathway via miR-21 is involved in the neoplastic and metastatic properties of arsenite-transformed human keratinocytes.
other	hsa-mir-21	Neoplasms [unspecific]	24041029			C80.1	D009369			Here we summarize current knowledge on miR-21 functions in human cancers and discuss how this finding provides insight into the role of miR-21 as an oncogenic regulator in stem/progenitor cell populations of human cancers.
other	hsa-mir-21	Neoplasms [unspecific]	23811941			C80.1	D009369			AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression.
other	hsa-mir-21	Neoplasms [unspecific]	25979949			C80.1	D009369			Dicer1 imparts essential survival cues in Notch-driven T-ALL via miR-21-mediated  tumor suppressor Pdcd4 repression.
other	hsa-mir-21	Neoplasms [unspecific]	26189797			C80.1	D009369			RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4.
other	hsa-mir-21	Neoplasms [unspecific]	26503645			C80.1	D009369			Therefore,this study presents an improved method with shorten time to prepare a (99m)Tc radiolabeled AMO. In addition, it supports the role of (99m)Tc-AMO for noninvasive visualization of miR-21 in malignant tumors.
other	hsa-mir-21	Neoplasms [unspecific]	25445583			C80.1	D009369			Further, during the transformation of HBE cells, inhibition of miR-21 with an miR-21 inhibitor increased levels of PDCD4, an inhibitor of neoplastic transformation;
other	hsa-mir-21	Neoplasms [unspecific]	26610525			C80.1	D009369			induction of miR-21 by type I IFN
other	hsa-mir-21	Neoplasms [unspecific]	24507038			C80.1	D009369			Our results demonstrated that HIF-1伪 could significantly upregulate 伪-smooth muscle actin expression, and reduced the E-cadherin expression in HK-2 cells during I/R injury. Moreover, miR-21 expression had a positive correlation with HIF-1伪 in this process.
other	hsa-mir-21	Neoplasms [unspecific]	26716902			C80.1	D009369			LIF induces miR-21 expression through the activation of STAT3.
other	hsa-mir-21	Neoplasms [unspecific]	18384814			C80.1	D009369			Since exogenous miR-21 expression moderately induced endogenous miR-21, an evolutionarily conserved double-negative feedback regulation would be operating as a mechanism to sustain miR-21 expression.
other	hsa-mir-21	Neoplasms [unspecific]	27992999			C80.1	D009369			Systematic Evaluation of Biophysical and Functional Characteristics of Selenomethylene-Locked Nucleic Acid-Mediated Inhibition of miR-21.
other	hsa-mir-21	Neoplasms [unspecific]	28302473			C80.1	D009369			Quantitative relationship between chemical properties and bioactivities of anti-microRNA oligonucleotides targeted to tumor-associated microRNA-21.
other	hsa-mir-21	Neoplasms [unspecific]	28346427			C80.1	D009369			MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.
other	hsa-mir-21	Neoplasms [unspecific]	28427524			C80.1	D009369			Kallistatin suppresses cancer development by multi-factorial actions.
other	hsa-mir-21	Neoplasms [unspecific]	29601548			C80.1	D009369			the NF-κB-miR-146 and NF-κB-miR-155 networks fine-tune the activity, intensity, and duration of inflammation, while the NF-κB-miR-21 and NF-κB-miR-181b-3 amplifying loops link inflammation to cancer
other	hsa-mir-21	Neoplasms [unspecific]	29642568			C80.1	D009369			Irradiation-Induced Cardiac Connexin-43 and miR-21 Responses Are Hampered by Treatment with Atorvastatin and Aspirin
other	hsa-mir-210	Neoplasms [unspecific]	24909053			C80.1	D009369			Multiple functions of hypoxia-regulated miR-210 in cancer.
other	hsa-mir-210	Neoplasms [unspecific]	25809609			C80.1	D009369			The role of hypoxia-induced miR-210 in cancer progression.
other	hsa-mir-210	Neoplasms [unspecific]	24098326			C80.1	D009369			hypoxia related mir-210 and apoptosis-related mir-296-5p in the cancer mechanisms
other	hsa-mir-210	Neoplasms [unspecific]	24220575			C80.1	D009369			Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif.
other	hsa-mir-210	Neoplasms [unspecific]	26446394			C80.1	D009369			Potential Role of MicroRNA-210 as Biomarker in Human Cancers Detection: A Meta-Analysis.
other	hsa-mir-210	Neoplasms [unspecific]	20237418			C80.1	D009369			miR-210 appears to function as a master microRNA relevant for the control of diverse functions in the hypoxic state
other	hsa-mir-210	Neoplasms [unspecific]	23173806			C80.1	D009369			Considering that the exact function of miR-210 is still not well characterized and understood, more investigations should be performed to promote the success of therapeutic-clinical use of miR-210 in cancer
other	hsa-mir-210	Neoplasms [unspecific]	24586608			C80.1	D009369			This systematic review and meta-analysis suggests that miR-210 has a predictive effect on survival of patients with studied cancer types as indexed by disease-free survival, progression-free survival and relapse-free survival. While the predictive effect on overall survival, breast cancer overall survival, breast cancer disease-free survival, sarcoma overall survival and renal cancer overall survival was not statistically significant.
other	hsa-mir-210	Neoplasms [unspecific]	28036268			C80.1	D009369			Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.
other	hsa-mir-210	Neoplasms [unspecific]	28046107			C80.1	D009369			RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature.
other	hsa-mir-210	Neoplasms [unspecific]	28240549			C80.1	D009369			Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit.
other	hsa-mir-214	Neoplasms [unspecific]	25223704			C80.1	D009369			Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth.
other	hsa-mir-214	Neoplasms [unspecific]	20219416			C80.1	D009369			miR-21 serves as a chemosensitive miRNA, while miR-214 and -23a serve as chemoresistant miRNAs in the tongue squamous cell carcinoma  lines
other	hsa-mir-214	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-214:miR-34C and miR-214 as Damage Associated Molecular Pattern Molecules-associated miRs
other	hsa-mir-214	Neoplasms [unspecific]	25364765			C80.1	D009369			By contrast, miR-24, miR-125b, miR-195, and miR-214 function as oncogenic or tumor suppressor miRNAs in a cancer (sub)type-dependent manner.
other	hsa-mir-215	Neoplasms [unspecific]	25984907			C80.1	D009369			This potential path highlights the crucial role of BMP2,hsa-miR-24, AP2 and MYC as the up-stream regulators of the path and hsa-miR-215 and TYMS as potential indicator of chemotherapeutic benefit in STS metastasis.
other	hsa-mir-218	Neoplasms [unspecific]	25940608			C80.1	D009369			A feedback loop between c-Src and miR-218 was revealed where c-Src inhibits transcription of SLIT2, which intronically hosts miR-218. These results show a novel regulatory pathway for RPTPα-c-Src signalling.
other	hsa-mir-218	Neoplasms [unspecific]	26111662			C80.1	D009369			Opposite effects of two estrogen receptors on tau phosphorylation through disparate effects on the miR-218/PTPA pathway.
other	hsa-mir-218-1	Neoplasms [unspecific]	23060446			C80.1	D009369			miR-218 Directs a Wnt Signaling Circuit to Promote Differentiation of Osteoblasts and Osteomimicry of Metastatic Cancer Cells
other	hsa-mir-218-2	Neoplasms [unspecific]	23060446			C80.1	D009369			miR-218 Directs a Wnt Signaling Circuit to Promote Differentiation of Osteoblasts and Osteomimicry of Metastatic Cancer Cells
other	hsa-mir-219	Neoplasms [unspecific]	18075311			C80.1	D009369			In this review, we will discuss the specific roles of miRNA-(miR-)132 and miR-219 in the SCN, as well as a more general outlook on this newly elucidated layer of circadian clock regulation: inducible translation control via miRNAs.
other	hsa-mir-22	Neoplasms [unspecific]	21502362			C80.1	D009369			miR-22 represses cancer progression by inducing cellular senescence.
other	hsa-mir-22	Neoplasms [unspecific]	20523723			C80.1	D009369			Our results suggest that miR-22 acts to fine-tune the dynamics of PTEN/AKT/FoxO1 pathway.
other	hsa-mir-221	Neoplasms [unspecific]	20406109			C80.1	D009369			miR-221:potential importance of miR-221, miR-222, and miR-146b in determining the aggressive properties of PTCs
other	hsa-mir-221	Neoplasms [unspecific]	20461750			C80.1	D009369			MiR-221:MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma
other	hsa-mir-221	Neoplasms [unspecific]	21481725			C80.1	D009369			miRNA-221/-222 control radiation sensitivity by regulating the PTEN/AKT pathway and can be explored as novel targets for radiosensitization.
other	hsa-mir-221	Neoplasms [unspecific]	26959615			C80.1	D009369			biological significance of miR-221/222 in a variety of malignancies indicates that they will play a crucial role in the future of innovative therapeutic strategies
other	hsa-mir-222	Neoplasms [unspecific]	20406109			C80.1	D009369			miR-222:potential importance of miR-221, miR-222, and miR-146b in determining the aggressive properties of PTCs
other	hsa-mir-222	Neoplasms [unspecific]	20461750			C80.1	D009369			MiR-222:MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma
other	hsa-mir-222	Neoplasms [unspecific]	20525881			C80.1	D009369			miR-222:five miRNAs that negatively control cell proliferation, including miRNA-34a
other	hsa-mir-222	Neoplasms [unspecific]	21481725			C80.1	D009369			miRNA-221/-222 control radiation sensitivity by regulating the PTEN/AKT pathway and can be explored as novel targets for radiosensitization.
other	hsa-mir-222	Neoplasms [unspecific]	26959615			C80.1	D009369			biological significance of miR-221/222 in a variety of malignancies indicates that they will play a crucial role in the future of innovative therapeutic strategies
other	hsa-mir-223	Neoplasms [unspecific]	23772809			C80.1	D009369			mir-223: infection, inflammation and cancer.
other	hsa-mir-223	Neoplasms [unspecific]	28197019			C80.1	D009369			Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters.
other	hsa-mir-224	Neoplasms [unspecific]	20525881			C80.1	D009369			miR-224:five miRNAs that negatively control cell proliferation, including miRNA-34a
other	hsa-mir-23a	Neoplasms [unspecific]	25347474			C80.1	D009369			Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.
other	hsa-mir-23a	Neoplasms [unspecific]	25429623			C80.1	D009369			HSP70 could be beneficial to tumor cells by helping to maintain the expression of oncogenic miRNAs under conditions of cellular stress.
other	hsa-mir-23a	Neoplasms [unspecific]	20219416			C80.1	D009369			miR-21 serves as a chemosensitive miRNA, while miR-214 and -23a serve as chemoresistant miRNAs in the tongue squamous cell carcinoma  lines
other	hsa-mir-23a	Neoplasms [unspecific]	20086171			C80.1	D009369			In addition to its known function in regulating the cell cycle and glucose metabolism, recent studies document a role for Myc in stimulating glutamine catabolism, in part through the repression of miRNAs miR-23a and miR-23b.
other	hsa-mir-23a	Neoplasms [unspecific]	29387410			C80.1	D009369			the miR-23a/24-2/27a cluster may be a useful marker for predicting cancer prognosis and tumor progression
other	hsa-mir-23b	Neoplasms [unspecific]	24755453			C80.1	D009369			Regulation of miR-23b expression and its dual role on ROS production and tumour development.
other	hsa-mir-23b	Neoplasms [unspecific]	27040799			C80.1	D009369			Among down-regulators of PRODH/POX is an oncogenic transcription factor c-MYC and miR-23b*.
other	hsa-mir-23b	Neoplasms [unspecific]	20086171			C80.1	D009369			In addition to its known function in regulating the cell cycle and glucose metabolism, recent studies document a role for Myc in stimulating glutamine catabolism, in part through the repression of miRNAs miR-23a and miR-23b.
other	hsa-mir-24	Neoplasms [unspecific]	25984907			C80.1	D009369			This potential path highlights the crucial role of BMP2,hsa-miR-24, AP2 and MYC as the up-stream regulators of the path and hsa-miR-215 and TYMS as potential indicator of chemotherapeutic benefit in STS metastasis.
other	hsa-mir-24	Neoplasms [unspecific]	25364765			C80.1	D009369			By contrast, miR-24, miR-125b, miR-195, and miR-214 function as oncogenic or tumor suppressor miRNAs in a cancer (sub)type-dependent manner.
other	hsa-mir-24	Neoplasms [unspecific]	28500171			C80.1	D009369			Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth.
other	hsa-mir-24	Neoplasms [unspecific]	26967561			C80.1	D009369			melatonin can inhibit cell proliferation and migration, at least in part, by downregulating miR-24.
other	hsa-mir-24-2	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-24-2	Neoplasms [unspecific]	29387410			C80.1	D009369			the miR-23a/24-2/27a cluster may be a useful marker for predicting cancer prognosis and tumor progression
other	hsa-mir-25	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-25: key modulators of TGFbeta signaling
other	hsa-mir-25	Neoplasms [unspecific]	23246404			C80.1	D009369			Downregulation of the Mitochondrial Calcium Uniporter by Cancer-Related miR-25
other	hsa-mir-25	Neoplasms [unspecific]	25672882			C80.1	D009369			miR-25 is suggested to be important in TNF-α-induced abnormal proliferation of vascular smooth muscle cells (VSMCs).
other	hsa-mir-27a	Neoplasms [unspecific]	29387410			C80.1	D009369			the miR-23a/24-2/27a cluster may be a useful marker for predicting cancer prognosis and tumor progression
other	hsa-mir-27b	Neoplasms [unspecific]	26473412			C80.1	D009369			These findings show that miR-27b functions as a tumor suppressor by controlling ARFGEF1 and the paxillin/c-Src circuit at focal adhesions.
other	hsa-mir-28	Neoplasms [unspecific]	25617309			C80.1	D009369			miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation.
other	hsa-mir-29	Neoplasms [unspecific]	24573597			C80.1	D009369			Our review highlights the diverse relationship between miR-29 and cancer (particularly digestive system neoplasms).
other	hsa-mir-29	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-29	Neoplasms [unspecific]	23857059			C80.1	D009369			miR-29 represses the activities of DNA methyltransferases and DNA demethylases.
other	hsa-mir-29	Neoplasms [unspecific]	23901138			C80.1	D009369			miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.
other	hsa-mir-296	Neoplasms [unspecific]	24098326			C80.1	D009369			hypoxia related mir-210 and apoptosis-related mir-296-5p in the cancer mechanisms
other	hsa-mir-29a	Neoplasms [unspecific]	23401122			C80.1	D009369			miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer
other	hsa-mir-29a	Neoplasms [unspecific]	29217524			C80.1	D009369			we discussed the functions of miR-29a and its potential application in the diagnosis, treatment and stages of carcinoma, which could provide additional insight to develop a novel therapeutic strategy
other	hsa-mir-29b	Neoplasms [unspecific]	28185889			C80.1	D009369			MicroRNA hsa-miR-29b potentiates etoposide toxicity in HeLa cells via down-regulation of Mcl-1.
other	hsa-mir-29b-1	Neoplasms [unspecific]	20525881			C80.1	D009369			miR-29b:five miRNAs that negatively control cell proliferation, including miRNA-34a
other	hsa-mir-29b-1	Neoplasms [unspecific]	23354167			C80.1	D009369			GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression
other	hsa-mir-29b-2	Neoplasms [unspecific]	20525881			C80.1	D009369			miR-29b:five miRNAs that negatively control cell proliferation, including miRNA-34a
other	hsa-mir-29b-2	Neoplasms [unspecific]	23354167			C80.1	D009369			GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression
other	hsa-mir-29c	Neoplasms [unspecific]	23175151			C80.1	D009369			MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression
other	hsa-mir-302	Neoplasms [unspecific]	24705778			C80.1	D009369			In conclusion, the controversial role of miR-302-367 in different cell types may provide better understanding for its role in stemness level and its antitumorigenicity potential in different contexts.
other	hsa-mir-302c	Neoplasms [unspecific]	23820258			C80.1	D009369			1,25(OH)2D3 facilitates the immuno-attack of NK cells against malignant cells partly through downregulation of miR-302c and miR-520c and hence upregulation of the NKG2D ligands MICA/B and ULBP2.
other	hsa-mir-30a	Neoplasms [unspecific]	19593777			C80.1	D009369			association with cancer progression
other	hsa-mir-30d	Neoplasms [unspecific]	23274497			C80.1	D009369			mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells
other	hsa-mir-30e	Neoplasms [unspecific]	19593777			C80.1	D009369			association with cancer progression
other	hsa-mir-31	Neoplasms [unspecific]	25139099			C80.1	D009369			Prognostic role of microRNA-31 in various cancers: a meta-analysis.
other	hsa-mir-31	Neoplasms [unspecific]	20145132			C80.1	D009369			miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma
other	hsa-mir-31	Neoplasms [unspecific]	20530680			C80.1	D009369			miR-31:Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis
other	hsa-mir-31	Neoplasms [unspecific]	21875932			C80.1	D009369			miR-31 is a master regulator of integrins. The expression of miR-31 in cancer cells resulted in a significant repression of these integrin subunits both at the mRNA and protein levels.
other	hsa-mir-3158	Neoplasms [unspecific]	27919789			C80.1	D009369			Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness.
other	hsa-mir-330	Neoplasms [unspecific]	26138095			C80.1	D009369			These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-335	Neoplasms [unspecific]	20713524			C80.1	D009369			miR-335:miR-335 activates the p53 tumor suppressor pathway to limit cell proliferation and neoplastic cell transformation
other	hsa-mir-335	Neoplasms [unspecific]	28932769			C80.1	D009369			MicroRNA expression in a phosphaturic mesenchymal tumour.
other	hsa-mir-34	Neoplasms [unspecific]	24532687			C80.1	D009369			Taken together, our results elucidated the intricate cross-talk between p53 and miR-34 miRNAs and revealed an important tumor suppressor effect generated by this positive feedback loop.
other	hsa-mir-34	Neoplasms [unspecific]	25486198			C80.1	D009369			identify new molecules and mechanisms involved in the DDR, and to examine their role in tumor suppression and the clinical outcome of cancer patients.
other	hsa-mir-34	Neoplasms [unspecific]	25102298			C80.1	D009369			Role of microRNA-34 family in cancer with particular reference to cancer angiogenesis.
other	hsa-mir-34	Neoplasms [unspecific]	23834144			C80.1	D009369			Functional role of miR-34 family in human cancer.
other	hsa-mir-342	Neoplasms [unspecific]	26138095			C80.1	D009369			These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-34a	Neoplasms [unspecific]	24583844			C80.1	D009369			miR-34a/SIRT6 in squamous differentiation and cancer.
other	hsa-mir-34a	Neoplasms [unspecific]	25052958			C80.1	D009369			The well-formulated LPEI-CaPs with lc-miRNA-d have the potential to provide superior miRNA transfection efficiency and inhibition of cancer proliferation.
other	hsa-mir-34a	Neoplasms [unspecific]	25896587			C80.1	D009369			miR-34a plays an important role in the anti-tumor effects of querctin in HCC, miR-34a may be a tiemolecule between the p53 and SIRT1 and is composed of a p53/miR-34a/SIRT1 signal feedback loop, which could enhance apoptosis signal and significantly promote cell apoptosis.
other	hsa-mir-34a	Neoplasms [unspecific]	25939820			C80.1	D009369			Multivalent aptamer-RNA based fluorescent probes for carrier-free detection of cellular microRNA-34a in mucin1-expressing cancer cells.
other	hsa-mir-34a	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-34a	Neoplasms [unspecific]	24438466			C80.1	D009369			MicroRNA-34a: role in cancer and cardiovascular disease.
other	hsa-mir-34a	Neoplasms [unspecific]	23836017			C80.1	D009369			TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.).
other	hsa-mir-34a	Neoplasms [unspecific]	26718338			C80.1	D009369			MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1.
other	hsa-mir-34a	Neoplasms [unspecific]	20525881			C80.1	D009369			miR-34a:five miRNAs that negatively control cell proliferation, including miRNA-34a
other	hsa-mir-34a	Neoplasms [unspecific]	23292172			C80.1	D009369			Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model
other	hsa-mir-34a	Neoplasms [unspecific]	25579512			C80.1	D009369			Regulatory mechanisms and clinical perspectives of miR-34a in cancer.
other	hsa-mir-34a	Neoplasms [unspecific]	25220161			C80.1	D009369			Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.
other	hsa-mir-34a	Neoplasms [unspecific]	19074875			C80.1	D009369			Accordingly, the tumor suppressor p53 up-regulates miR-34a, a microRNA that contributes to apoptosis and acute senescence. 
other	hsa-mir-34a	Neoplasms [unspecific]	26648462			C80.1	D009369			MiR-34a is associated with G1 cell cycle arrest, senescence and apoptosis, thereby possessing a tumor suppressor activity.
other	hsa-mir-34a	Neoplasms [unspecific]	17656095			C80.1	D009369			Taken together, the data suggest the miRNA34s might be key effectors of p53 tumor-suppressor function, and their inactivation might contribute to certain cancers.
other	hsa-mir-34a	Neoplasms [unspecific]	28119089			C80.1	D009369			The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses.
other	hsa-mir-34a	Neoplasms [unspecific]	28511876			C80.1	D009369			Chondroitin sulfate-functionalized polyamidoamine as a tumor-targeted carrier for miR-34a delivery.
other	hsa-mir-34a	Neoplasms [unspecific]	28657476			C80.1	D009369			Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells.
other	hsa-mir-34b	Neoplasms [unspecific]	25227823			C80.1	D009369			Association between a polymorphism in miR-34b/c and susceptibility to cancer--a meta-analysis.
other	hsa-mir-34b	Neoplasms [unspecific]	23314612			C80.1	D009369			MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met
other	hsa-mir-34b	Neoplasms [unspecific]	17656095			C80.1	D009369			Taken together, the data suggest the miRNA34s might be key effectors of p53 tumor-suppressor function, and their inactivation might contribute to certain cancers.
other	hsa-mir-34c	Neoplasms [unspecific]	25227823			C80.1	D009369			Association between a polymorphism in miR-34b/c and susceptibility to cancer--a meta-analysis.
other	hsa-mir-34c	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-34c:miR-34C and miR-214 as Damage Associated Molecular Pattern Molecules-associated miRs
other	hsa-mir-34c	Neoplasms [unspecific]	23922103			C80.1	D009369			These findings provide a novel molecular mechanism of MET regulation in PCa and contribute to the increasing evidence that miR-34c has a key tumour suppressive role in PCa.
other	hsa-mir-34c	Neoplasms [unspecific]	17656095			C80.1	D009369			Taken together, the data suggest the miRNA34s might be key effectors of p53 tumor-suppressor function, and their inactivation might contribute to certain cancers.
other	hsa-mir-365-2	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-370	Neoplasms [unspecific]	17621267			C80.1	D009369			Thus, IL-6 may contribute to tumor growth by modulation of expression of selected miRNAs, such as miR-370. These studies define a mechanism by which inflammation-associated cytokines can epigenetically modulate gene expression and directly contribute to tumor biology.
other	hsa-mir-371	Neoplasms [unspecific]	25941115			C80.1	D009369			MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells.
other	hsa-mir-372	Neoplasms [unspecific]	17028596			C80.1	D009369			mir-372/373 shown to be oncogenes cooperating with Ras (Voorhoeve et al., 2006)
other	hsa-mir-372	Neoplasms [unspecific]	29374231			C80.1	D009369			Modulation of oncogenic miRNA biogenesis using functionalized polyamines
other	hsa-mir-373	Neoplasms [unspecific]	25941115			C80.1	D009369			MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells.
other	hsa-mir-373	Neoplasms [unspecific]	17028596			C80.1	D009369			mir-372/373 shown to be oncogenes cooperating with Ras (Voorhoeve et al., 2006)
other	hsa-mir-375	Neoplasms [unspecific]	24166096			C80.1	D009369			The emerging role of miR-375 in cancer.
other	hsa-mir-375	Neoplasms [unspecific]	24708873			C80.1	D009369			Taken together, miR-375-mediated suppression of multiple oncogenic components in HPV-associated carcinogenesis generates a cumulative biological response to rescue key tumor suppressors and diminish telomerase activity, which results in cell cycle arrest and cell proliferation inhibition.
other	hsa-mir-375	Neoplasms [unspecific]	25195536			C80.1	D009369			The CMAP database is a useful tool for identifying compounds affecting the same molecular pathways, particularly products that are difficult to apply via practical approaches, such as microRNAs.
other	hsa-mir-375	Neoplasms [unspecific]	27844328			C80.1	D009369			Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.
other	hsa-mir-378a	Neoplasms [unspecific]	21242960			C80.1	D009369			Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation.
other	hsa-mir-378a	Neoplasms [unspecific]	24651706			C80.1	D009369			A screen identifies the oncogenic micro-RNA miR-378a-5p as a negative regulator of oncogene-induced senescence.
other	hsa-mir-381	Neoplasms [unspecific]	24303078			C80.1	D009369			Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.
other	hsa-mir-421	Neoplasms [unspecific]	24716910			C80.1	D009369			MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis.
other	hsa-mir-424	Neoplasms [unspecific]	24967963			C80.1	D009369			Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis.
other	hsa-mir-424	Neoplasms [unspecific]	25716682			C80.1	D009369			TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation.
other	hsa-mir-429	Neoplasms [unspecific]	25403569			C80.1	D009369			our comprehensive pan-cancer analysis provided not only biological insights into metastasis but also brought to bear the clinical relevance of the proposed recurrent miRNA-gene associations.
other	hsa-mir-429	Neoplasms [unspecific]	18829540			C80.1	D009369			These findings establish a double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression that regulates cellular phenotype and has direct relevance to the role of these factors in tumor progression.
other	hsa-mir-429	Neoplasms [unspecific]	18927505			C80.1	D009369			Several recent studies have identified the miR-200 family and miR-205 as key regulators of EMT and enforcers of the epithelial phenotype.
other	hsa-mir-449a	Neoplasms [unspecific]	25760387			C80.1	D009369			microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.
other	hsa-mir-451	Neoplasms [unspecific]	26257001			C80.1	D009369			Both, energy-conserving metabolic shift and resource-seeking behavioral change require brain tumor cell to shut down miR-451, while forced expression of miR-451 during stress leads to cytotoxicity [3]. The AMPK-dependent inactivation of the OCT1 transcriptional activator of miR-451 helps brain tumor cells to escape from metabolically stressful events/locations. MiR-451 thus provides an example of a molecule that is not deregulated in brain tumor cells, but is instead finely regulated by promoting or suppressing brain tumor cell phenotypes based on microenvironmental contexts.
other	hsa-mir-455	Neoplasms [unspecific]	24220575			C80.1	D009369			Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif.
other	hsa-mir-455	Neoplasms [unspecific]	28004230			C80.1	D009369			In Silico Mining of Conserved miRNAs of Indian Catfish Clarias batrachus (Linnaeus, 1758) from the Contigs, ESTs, and BAC End Sequences.
other	hsa-mir-4728	Neoplasms [unspecific]	25950472			C80.1	D009369			ErbB2-intronic microRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling.
other	hsa-mir-483	Neoplasms [unspecific]	24298054			C80.1	D009369			The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis.
other	hsa-mir-493	Neoplasms [unspecific]	27956702			C80.1	D009369			Snail-Modulated MicroRNA 493 Forms a Negative Feedback Loop with the Insulin-Like Growth Factor 1 Receptor Pathway and Blocks Tumorigenesis.
other	hsa-mir-494	Neoplasms [unspecific]	25781916			C80.1	D009369			Specifically we have linked miR-134, miR-145, miR-146b-5p, miR-432 and miR-494 to the regulation of both apoptotic and anti-apoptotic genes expressed as a function of EGF treatment.
other	hsa-mir-495	Neoplasms [unspecific]	24303078			C80.1	D009369			Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistance.
other	hsa-mir-498	Neoplasms [unspecific]	23055531			C80.1	D009369			1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498
other	hsa-mir-499	Neoplasms [unspecific]	24593893			C80.1	D009369			These results suggest that miR-499 delivered by the present system has excellent potency to treat cancer via integrative anticancer actions.
other	hsa-mir-501	Neoplasms [unspecific]	25899823			C80.1	D009369			Our results suggest that the degradation status of ribosomal RNA is not always applicable to mRNA and microRNA. In fact, the stabilities of these RNA classes to exposure to ribonucleases are independent from each other, with microRNA being more stable than mRNA. The relative stability of microRNAs supports their potential and further development as biomarkers in a range of applications.
other	hsa-mir-503	Neoplasms [unspecific]	26999740			C80.1	D009369			miRNA-503 Promotes Tumor Progression and Is Associated with Early Recurrence and Poor Prognosis in Human Colorectal Cancer.
other	hsa-mir-504	Neoplasms [unspecific]	26625740			C80.1	D009369			This review covers roles of microRNAs and chemopreventive agents and makes an attempt at outlining possible partnerships in maximizing cancer cell death with minimal normal cell damage.
other	hsa-mir-511	Neoplasms [unspecific]	28197019			C80.1	D009369			Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters.
other	hsa-mir-520b	Neoplasms [unspecific]	19109132			C80.1	D009369			miR-520b: miR-520b was induced by IFN-gamma, leading to a reduction in MICA surface protein levels
other	hsa-mir-520c	Neoplasms [unspecific]	23820258			C80.1	D009369			1,25(OH)2D3 facilitates the immuno-attack of NK cells against malignant cells partly through downregulation of miR-302c and miR-520c and hence upregulation of the NKG2D ligands MICA/B and ULBP2.
other	hsa-mir-520d	Neoplasms [unspecific]	25426550			C80.1	D009369			miR-520d-5p leads to reduced proliferation of tumor cells, and that high levels of miR-520d-5p correlate with higher survival rates of cancer patients.
other	hsa-mir-520h	Neoplasms [unspecific]	20501832			C80.1	D009369			miR-520h:Downregulation of microRNA miR-520h by E1A contributes to anticancer activity
other	hsa-mir-520h	Neoplasms [unspecific]	25169894			C80.1	D009369			PD-miRNAs that are currently implicated as cancer biomarkers or diagnostics: hsa-mir-202, hsa-mir-423, hsa-mir-196a-2, hsa-mir-520h, hsa-mir-647, hsa-mir-943, and hsa-mir-1908.
other	hsa-mir-532	Neoplasms [unspecific]	20525881			C80.1	D009369			miR-532:five miRNAs that negatively control cell proliferation, including miRNA-34a
other	hsa-mir-542	Neoplasms [unspecific]	21756784			C80.1	D009369			miR-542-3p affects carcinogenesis induced by anti-benzo(a) pyrene-7,8-diol-9,10-epoxide
other	hsa-mir-548	Neoplasms [unspecific]	24556720			C80.1	D009369			Identification of a tumor-suppressive human-specific microRNA within the FHIT tumor-suppressor gene.
other	hsa-mir-630	Neoplasms [unspecific]	24909689			C80.1	D009369			E2F1-regulated DROSHA promotes miR-630 biosynthesis in cisplatin-exposed cancer cells.
other	hsa-mir-638	Neoplasms [unspecific]	23155245			C80.1	D009369			Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells
other	hsa-mir-650	Neoplasms [unspecific]	24716910			C80.1	D009369			MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis.
other	hsa-mir-663a	Neoplasms [unspecific]	23155245			C80.1	D009369			Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells
other	hsa-mir-663b	Neoplasms [unspecific]	23155245			C80.1	D009369			Expression of human endogenous retrovirus-K coincides with that of micro-RNA-663 and -638 in germ-cell tumor cells
other	hsa-mir-7	Neoplasms [unspecific]	24014594			C80.1	D009369			we review the current knowledge about the ciRS-7/miR-7 axis in cancer-related pathways and discuss possible models explaining the relevance of coexpressing miR-7 along with a circRNA inhibitor. c-mir-221-3p,c-mir-223-3p
other	hsa-mir-7-1	Neoplasms [unspecific]	19073608			C80.1	D009369			miR-7: coordinately regulate EGFR signaling in multiple human cancer cell types
other	hsa-mir-7-1	Neoplasms [unspecific]	21592959			C80.1	D009369			USP18 regulates EGF receptor expression and cancer cell survival via microrna-7.
other	hsa-mir-7-2	Neoplasms [unspecific]	19073608			C80.1	D009369			miR-7: coordinately regulate EGFR signaling in multiple human cancer cell types
other	hsa-mir-7-2	Neoplasms [unspecific]	21592959			C80.1	D009369			USP18 regulates EGF receptor expression and cancer cell survival via microrna-7.
other	hsa-mir-7-3	Neoplasms [unspecific]	19073608			C80.1	D009369			miR-7: coordinately regulate EGFR signaling in multiple human cancer cell types
other	hsa-mir-7-3	Neoplasms [unspecific]	21592959			C80.1	D009369			USP18 regulates EGF receptor expression and cancer cell survival via microrna-7.
other	hsa-mir-9	Neoplasms [unspecific]	25375090			C80.1	D009369			MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma.
other	hsa-mir-92	Neoplasms [unspecific]	26479035			C80.1	D009369			Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients
other	hsa-mir-92-1	Neoplasms [unspecific]	25887381			C80.1	D009369			Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs.
other	hsa-mir-92-1	Neoplasms [unspecific]	26479035			C80.1	D009369			Our findings signify the dynamic and reciprocal cross-talk between tumour cells and the metastatic niche; importantly, they provide new opportunities for effective anti-metastasis therapies, especially of consequence for brain metastasis patients
other	hsa-mir-92-1	Neoplasms [unspecific]	26545119			C80.1	D009369			In summary, our data demonstrate that vFLIP and vCyclin induce the oncogenic miR-17-92 cluster in endothelial cells and thereby interfere with the TGF-β signaling pathway. Manipulation of the TGF-β pathway via host miRNAs represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS.
other	hsa-mir-92-1	Neoplasms [unspecific]	23550645			C80.1	D009369			Recent functional dissection of mir-17-92 indicates that individual mir-17-92 components perform distinct biological functions, which collectively regulate multiple related cellular processes during development and disease.
other	hsa-mir-92-1	Neoplasms [unspecific]	19066217			C80.1	D009369			Using the concept and model prediction of a "cancer zone," the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc.
other	hsa-mir-92a	Neoplasms [unspecific]	29574928			C80.1	D009369			Our results show that miR-92a possesses a cell-type dependent function
other	hsa-mir-92a-1	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-92a: key modulators of TGFbeta signaling
other	hsa-mir-92a-1	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-92a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-92a-1	Neoplasms [unspecific]	20227518			C80.1	D009369			miR-92a:mir-17-92, a cluster of miRNAs in the midst of the cancer network
other	hsa-mir-92a-2	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-92a: key modulators of TGFbeta signaling
other	hsa-mir-92a-2	Neoplasms [unspecific]	20144731			C80.1	D009369			miR-92a:Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a
other	hsa-mir-92a-2	Neoplasms [unspecific]	20227518			C80.1	D009369			miR-92a:mir-17-92, a cluster of miRNAs in the midst of the cancer network
other	hsa-mir-93	Neoplasms [unspecific]	24220575			C80.1	D009369			Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif.
other	hsa-mir-93	Neoplasms [unspecific]	18922889			C80.1	D009369			miR-93: key modulators of TGFbeta signaling
other	hsa-mir-93	Neoplasms [unspecific]	20878079			C80.1	D009369			The miR-17 family, composed of miR-17-5p, miR-20a/b, miR-106a/b and miR-93, has been demonstrated to take part in critical pathways that regulate cellular life and death decisions during normal development and in malignancy.
other	hsa-mir-940	Neoplasms [unspecific]	24675421			C80.1	D009369			Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition.
other	hsa-mir-98	Neoplasms [unspecific]	25856466			C80.1	D009369			Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected].
other	hsa-mir-98	Neoplasms [unspecific]	22129484			C80.1	D009369			The let-7 family of microRNAs has cancer suppressor activity, and recent evidence suggests that markedly reduced levels of let-7 are not only a typical feature of cancer stem cells, but may be largely responsible for cancer stemness.
other	hsa-mir-99b	Neoplasms [unspecific]	26138095			C80.1	D009369			These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore,they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
other	hsa-mir-30a	Nephrotic Syndrome	26345917	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Analysis of the expression of HMGB-1, CXCL16, miRNA-30a, and TGF-β1 in primary nephritic syndrome patients and its significance.
other	hsa-let-7f	Nervous System Diseases [unspecific]	25406171			C72.9	D009422			EW-induced mitochondrial respiratory suppression was exacerbated by TSA treatment in a manner that was attenuated by let-7f antagomir cotreatment.
other	hsa-mir-124	Nervous System Diseases [unspecific]	26041995			C72.9	D009422			the link between dysregulation of miR-124 and CNS disorders, such as neurodegeneration, CNS stress, neuroimmune disorders, stroke,  and brain tumors, has become evident
other	hsa-mir-132	Nervous System Diseases [unspecific]	25351997			C72.9	D009422			Chronic infection of Toxoplasma gondii downregulates miR-132 expression in multiple brain regions in a sex-dependent manner.
other	hsa-mir-138	Nervous System Diseases [unspecific]	26026282			C72.9	D009422			Many studies have emerged which link miRNAs with OL and myelin pathology in various central nervous system (CNS) diseases including multiple sclerosis (MS), ischemic stroke,spinal cord injury, and adult-onset autosomal dominant leukodystrophy (ADLD).
other	hsa-mir-219	Nervous System Diseases [unspecific]	26026282			C72.9	D009422			Many studies have emerged which link miRNAs with OL and myelin pathology in various central nervous system (CNS) diseases including multiple sclerosis (MS), ischemic stroke,spinal cord injury, and adult-onset autosomal dominant leukodystrophy (ADLD).
other	hsa-mir-219	Nervous System Diseases [unspecific]	19196972			C72.9	D009422			miR-219: MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction
other	hsa-mir-302	Nervous System Diseases [unspecific]	26030913			C72.9	D009422			These results show that neuroblasts can be generated directly from adult human and mouse astrocytes by miR-302/367-driven induction. This approach seems promising for converting glial scar cells into neuroblasts in a wide range of neurological diseases.
other	hsa-mir-338	Nervous System Diseases [unspecific]	26026282			C72.9	D009422			Many studies have emerged which link miRNAs with OL and myelin pathology in various central nervous system (CNS) diseases including multiple sclerosis (MS), ischemic stroke,spinal cord injury, and adult-onset autosomal dominant leukodystrophy (ADLD).
other	hsa-mir-367	Nervous System Diseases [unspecific]	26030913			C72.9	D009422			These results show that neuroblasts can be generated directly from adult human and mouse astrocytes by miR-302/367-driven induction. This approach seems promising for converting glial scar cells into neuroblasts in a wide range of neurological diseases.
other	hsa-mir-9	Nervous System Diseases [unspecific]	26026282			C72.9	D009422			Many studies have emerged which link miRNAs with OL and myelin pathology in various central nervous system (CNS) diseases including multiple sclerosis (MS), ischemic stroke,spinal cord injury, and adult-onset autosomal dominant leukodystrophy (ADLD).
other	hsa-mir-21	Neurilemmoma	29298734	disease of cellular proliferation	DOID:3192	D36.10	D009442			Ailanthone promotes human vestibular schwannoma cells apoptosis and autophagy by down-regulation of miR-21
other	hsa-let-7	Neuroblastoma	27383785	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.
other	hsa-let-7b	Neuroblastoma	25779425	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Enterovirus 71 induces apoptosis of SH-SY5Y human neuroblastoma cells through stimulation of endogenous microRNA let-7b expression.
other	hsa-mir-1	Neuroblastoma	23022474	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	FOXP1 is upregulated as a result of gene fusion or amplification in DLBCL and MALT lymphoma and also repression of miRNAs, such as miR-1, miR-34a and miR-504.
other	hsa-mir-106a	Neuroblastoma	17943719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma.
other	hsa-mir-124	Neuroblastoma	29073265	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiRNA-124 is a link between measles virus persistent infection and cell division of human neuroblastoma cells.
other	hsa-mir-125b-1	Neuroblastoma	26480000	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Identification of linc-NeD125, a novel long non coding RNA that hosts miR-125b-1 and negatively controls proliferation of human neuroblastoma cells.
other	hsa-mir-128	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-128-1	Neuroblastoma	19713529	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	reduce cell motility and invasiveness
other	hsa-mir-128-2	Neuroblastoma	19713529	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	reduce cell motility and invasiveness
other	hsa-mir-130a	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-132	Neuroblastoma	27374124	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	New perspectives for multi-level regulations of neuronal acetylcholinesterase by  dioxins.
other	hsa-mir-137	Neuroblastoma	28223126	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137.
other	hsa-mir-17	Neuroblastoma	17943719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma.
other	hsa-mir-17	Neuroblastoma	20980091	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Mir-21, an established oncomir in a variety of cancer types, became strongly up-regulated upon MYCN knockdown and the subsequent differentiation.
other	hsa-mir-17	Neuroblastoma	27396325	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Here, we demonstrate that this microRNA (miRNA) cluster selectively targets several members of the nuclear hormone receptor (NHR) superfamily, and we present a unique NHR signature associated with the survival of neuroblastoma patients.
other	hsa-mir-18	Neuroblastoma	17943719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma.
other	hsa-mir-181a	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-181a	Neuroblastoma	28365714	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-181a Regulates Apoptosis and Autophagy Process in Parkinson's Disease by Inhibiting p38 Mitogen-Activated Protein Kinase (MAPK)/c-Jun N-Terminal Kinases (JNK) Signaling Pathways.
other	hsa-mir-181a	Neuroblastoma	29426375	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Triptolide inhibits proliferation and migration of human neuroblastoma SH-SY5Y cells by up-regulating microRNA-181a
other	hsa-mir-183	Neuroblastoma	23625969	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
other	hsa-mir-18a	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-18a	Neuroblastoma	27895778	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Regulatory network analysis of genes and microRNAs in human hepatoblastoma.
other	hsa-mir-190a	Neuroblastoma	23245204	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiR-190 leads to aggressive phenotype of neuroblastoma through indirect activation of TrkB pathway
other	hsa-mir-190b	Neuroblastoma	23245204	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiR-190 leads to aggressive phenotype of neuroblastoma through indirect activation of TrkB pathway
other	hsa-mir-19a	Neuroblastoma	17943719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma.
other	hsa-mir-19b	Neuroblastoma	27492819	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Suppression of miR-19b may enhance the cytotoxic effects of mTOR inhibitors in neuroblastoma cells
other	hsa-mir-19b-1	Neuroblastoma	17943719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma.
other	hsa-mir-204	Neuroblastoma	22892391	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.
other	hsa-mir-20a	Neuroblastoma	17943719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma.
other	hsa-mir-21	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-21	Neuroblastoma	28599474	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Reduction of miR-21 induces SK-N-SH cell apoptosis and inhibits proliferation via PTEN/PDCD4.
other	hsa-mir-21	Neuroblastoma	29635890	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiR-21 attenuates apoptosis-triggered by amyloid-β via modulating PDCD4/PI3K/AKT/GSK-3β pathway in SH-SY5Y cells
other	hsa-mir-212	Neuroblastoma	27374124	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	New perspectives for multi-level regulations of neuronal acetylcholinesterase by  dioxins.
other	hsa-mir-218	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-221	Neuroblastoma	17943719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma.
other	hsa-mir-25	Neuroblastoma	27374124	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	New perspectives for multi-level regulations of neuronal acetylcholinesterase by  dioxins.
other	hsa-mir-30a	Neuroblastoma	25149854	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Lithium/Valproic acid combination and L-glutamate induce similar pattern of changes in the expression of miR-30a-5p in SH-SY5Y neuroblastoma cells.
other	hsa-mir-335	Neuroblastoma	23806264	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	We report, for the first time, that GRP-R-mediated tumorigenicity and increased metastatic potential in neuroblastoma are regulated, in part, by miR-335 and miR-363. A better understanding of the anti-tumor functions of miRNAs could provide valuable insights to discerning molecular mechanisms responsible for neuroblastoma metastasis.
other	hsa-mir-337	Neuroblastoma	26084291	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miRNA-337-3p suppresses neuroblastoma progression by repressing the transcription of matrix metalloproteinase 14.
other	hsa-mir-34a	Neuroblastoma	21266077	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	This microRNA is a potent tumor suppressor molecule in vivo in neuroblastoma.
other	hsa-mir-34a	Neuroblastoma	17297439	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.
other	hsa-mir-34a	Neuroblastoma	19373781	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Neuroblastoma (NB) is the most common extracranial solid tumor in children below the age of 5 years. miR-34a, located in chromosome band 1p36, has been recently implicated as a tumor suppressor gene in NB.
other	hsa-mir-34a	Neuroblastoma	19461653	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	In this review, the evidence for a role of miR-34a and miR-34b/c in the apoptotic response of normal and tumor cells is surveyed.
other	hsa-mir-34a	Neuroblastoma	22662276	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.
other	hsa-mir-34a	Neuroblastoma	23022474	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	FOXP1 is upregulated as a result of gene fusion or amplification in DLBCL and MALT lymphoma and also repression of miRNAs, such as miR-1, miR-34a and miR-504.
other	hsa-mir-34a	Neuroblastoma	23647235	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	using the TANA modified antisense oligonucleotide against miR-34a, intracellular levels of miR-34 can be reduced, and consequently, the expression of its target oncogene V-myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN) is enhanced. 
other	hsa-mir-34a	Neuroblastoma	28145567	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	nanoparticles encapsulating miR‐34a and conjugated to a GD2 antibody facilitated tumor‐specific delivery following systemic administration into tumor bearing mice
other	hsa-mir-363	Neuroblastoma	23806264	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	We report, for the first time, that GRP-R-mediated tumorigenicity and increased metastatic potential in neuroblastoma are regulated, in part, by miR-335 and miR-363. A better understanding of the anti-tumor functions of miRNAs could provide valuable insights to discerning molecular mechanisms responsible for neuroblastoma metastasis.
other	hsa-mir-380	Neuroblastoma	20871609	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	In vivo delivery of a miR-380-5p antagonist decreases tumor size in an orthotopic mouse model of neuroblastoma.
other	hsa-mir-380	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-410	Neuroblastoma	27498840	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	In conclusion, the present study demonstrates that the overexpression of SPARC in combination with radiation reduced tumor angiogenesis by downregulating VEGF-A via miR-410.
other	hsa-mir-424	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-451	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-504	Neuroblastoma	23022474	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	FOXP1 is upregulated as a result of gene fusion or amplification in DLBCL and MALT lymphoma and also repression of miRNAs, such as miR-1, miR-34a and miR-504.
other	hsa-mir-542	Neuroblastoma	20466808	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-542-5p:the putative tumor suppressive microRNAs, miR-542-5p and miR-628, were expressed in favorable NBs and virtually absent in unfavorable NBs
other	hsa-mir-542	Neuroblastoma	21310526	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma.
other	hsa-mir-558	Neuroblastoma	25616966	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-558 induces the transcriptional activation of HPSE via the binding site within promoter, thus facilitating the tumorigenesis and aggressiveness of NB.
other	hsa-mir-558	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-572	Neuroblastoma	27716787	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines.
other	hsa-mir-628	Neuroblastoma	20466808	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-628:the putative tumor suppressive microRNAs, miR-542-5p and miR-628, were expressed in favorable NBs and virtually absent in unfavorable NBs
other	hsa-mir-659	Neuroblastoma	25980492	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients.
other	hsa-mir-663a	Neuroblastoma	27716787	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines.
other	hsa-mir-7	Neuroblastoma	26258008	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Such miRNAs regulate genes involved in cellular processes
other	hsa-mir-7-1	Neuroblastoma	23192662	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Overexpression of miR-7-1 Increases Efficacy of Green Tea Polyphenols for Induction of Apoptosis in Human Malignant Neuroblastoma SH-SY5Y and SK-N-DZ Cells
other	hsa-mir-7-2	Neuroblastoma	23192662	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Overexpression of miR-7-1 Increases Efficacy of Green Tea Polyphenols for Induction of Apoptosis in Human Malignant Neuroblastoma SH-SY5Y and SK-N-DZ Cells
other	hsa-mir-92-1	Neuroblastoma	17943719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 polycistron also acts as an oncogene in haematopoietic progenitor cells. We show here that miR-221 is also induced by MYCN in neuroblastoma.
other	hsa-mir-92a-1	Neuroblastoma	21572098	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MYCN-regulated miRNA-92 Inhibits Secretion of the Tumor Suppressor DICKKOPF-3 (DKK3) in Neuroblastoma.
other	hsa-mir-92a-2	Neuroblastoma	21572098	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MYCN-regulated miRNA-92 Inhibits Secretion of the Tumor Suppressor DICKKOPF-3 (DKK3) in Neuroblastoma.
other	hsa-mir-92b	Neuroblastoma	21572098	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MYCN-regulated miRNA-92 Inhibits Secretion of the Tumor Suppressor DICKKOPF-3 (DKK3) in Neuroblastoma.
other	hsa-let-7b	Neurodegenerative Diseases [unspecific]	20423455				D019636		HP:0002180	Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663).
other	hsa-mir-124	Neurodegenerative Diseases [unspecific]	27117821				D019636		HP:0002180	MicroRNAs underlying memory deficits in neurodegenerative disorders.
other	hsa-mir-132	Neurodegenerative Diseases [unspecific]	27117821				D019636		HP:0002180	MicroRNAs underlying memory deficits in neurodegenerative disorders.
other	hsa-mir-146a	Neurodegenerative Diseases [unspecific]	24917789				D019636		HP:0002180	These findings together with the reduced expression of microRNA (miR)-124, and miR-155, decreased autophagy, enhanced senescence associated beta-galactosidase activity and elevated miR-146a expression, are suggestive that 16 DIV cells mainly correspond  to irresponsive/senescent microglia.
other	hsa-mir-146a	Neurodegenerative Diseases [unspecific]	25484882				D019636		HP:0002180	We particularly focus on  the role played by miR-146a in the regulation and signaling mediated by one of the main pattern recognition receptors, toll/IL-1 receptors (TLRs).
other	hsa-mir-328	Neurodegenerative Diseases [unspecific]	26900752				D019636		HP:0002180	These experiments reveal Dicer1-miR-328-Bace1  signalling as a determinant of BAT function, and highlight the potential of Bace1 inhibition as a therapeutic approach to improve not only neurodegenerative diseases
other	hsa-mir-338	Neurodegenerative Diseases [unspecific]	23979835				D019636		HP:0002180	The EnSCs can differentiate to oligodendrocyte cells by the overexpression of miR-338, and these cells can be used as a unique source for cell therapy of neurodegenerative disease.
other	hsa-mir-34	Neurodegenerative Diseases [unspecific]	27117821				D019636		HP:0002180	MicroRNAs underlying memory deficits in neurodegenerative disorders.
other	hsa-mir-4306	Neurodegenerative Diseases [unspecific]	28302480				D019636		HP:0002180	Comprehensive investigation of aberrant microRNAs expression in cells culture model of MnCl2-induced neurodegenerative disease.
other	hsa-mir-663	Neurodegenerative Diseases [unspecific]	20423455				D019636		HP:0002180	Interestingly, both miRNAs are capable of binding directly to TDP-43 in different positions: within the miRNA sequence itself (let-7b) or in the hairpin precursor (miR-663).
other	hsa-mir-96	Neurodegenerative Diseases [unspecific]	24304186				D019636		HP:0002180	Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96.
other	hsa-mir-196a	Neuroendocrine Tumors	26052033	disease of cellular proliferation	DOID:169	C7A	D018358			Roles of miR-196a on gene regulation of neuroendocrine tumor cells.
other	hsa-mir-296	Neurofibromatosis type 2	26923924	genetic disease	DOID:8712	Q85.02	C537392	101000		Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p.
other	hsa-mir-155	Neuroinflammation	24604078							MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation.
other	hsa-mir-155	Neuroinflammation	28139244							MicroRNA 155 and viral-induced neuroinflammation.
other	hsa-mir-155	Neuroinflammation	29079998							Role of 3-Acetyl-11-Keto-Beta-Boswellic Acid in Counteracting LPS-Induced Neuroinflammation via Modulation of miRNA-155.
other	hsa-mir-608	Neuroinflammation	28326544							Personalized genetics of the cholinergic blockade of neuroinflammation.
other	hsa-mir-155	Neuronal Apoptosis-Related Diseases	28831740							Expression of miR-155 associated with Toll-like receptors 3, 7, and 9 transcription in the olfactory bulbs of cattle naturally infected with BHV5.
other	hsa-mir-124a	Neuropathic Pain	27646435				D009437			miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain.
other	hsa-mir-155	Neuropathic Pain	27646435				D009437			miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain.
other	hsa-mir-183	Neuropathic Pain	28572455				D009437			miR-183 cluster scales mechanical pain sensitivity by regulating basal and neuropathic pain genes.
other	hsa-mir-196b	Neutropenia	19278956	hematopoietic system disease	DOID:1227	D70.9	D009503	PS202700	HP:0001875	miR-196b: regulated by Gfi1
other	hsa-mir-21	Neutropenia	19278956	hematopoietic system disease	DOID:1227	D70.9	D009503	PS202700	HP:0001875	miR-21: regulated by Gfi1
other	hsa-mir-183	Non-Sensory Diseases	26170234							the genomic organization and seeming redundancy of the miR-183 family cluster was conserved through 600 million years of evolution
other	hsa-mir-146a	Non-Syndromic Orofacial Clefts	29484780					PS119530		A functional polymorphism in the pre-miR-146a gene is associated with the risk of nonsyndromic orofacial cleft.
other	hsa-let-7d	Obesity	25704235	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Nonivamide enhances miRNA let-7d expression and decreases adipogenesis PPAR纬 expression in 3T3-L1 cells.
other	hsa-let-7f	Obesity	25710930	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	genes modulated in RO-treated cells were found to be validated miRNAs targets, such as let-7f-1, miR-17, and miR-143.
other	hsa-let-7g	Obesity	22614057	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Maternal obesity downregulates microRNA let-7g expression, a possible mechanism for enhanced adipogenesis during ovine fetal skeletal muscle development.
other	hsa-mir-107	Obesity	22645244	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-107: a Toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes.
other	hsa-mir-122	Obesity	25515554	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Elevated circulating miR-122 is positively associated with obesity and insulin resistance in young adults. These findings provide a better understanding regarding the role of miRNAs in adiposity and insulin sensitivity.
other	hsa-mir-122	Obesity	24165878	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Resveratrol and EGCG bind directly and distinctively to miR-33a and miR-122 and modulate divergently their levels in hepatic cells.
other	hsa-mir-125a	Obesity	24901105	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our results support the involvement of miR-125a-3p in regulating the insulin signalling pathway and imply that increased miR- 125a-3p expression in omental adipose tissues may be a characteristic feature of insulin resistance in obese men.
other	hsa-mir-125a	Obesity	26148871	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-125a-3p and miR-483-5p promote adipogenesis via suppressing the RhoA/ROCK1/ERK1/2 pathway in multiple symmetric lipomatosis.
other	hsa-mir-126	Obesity	25701361	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our study provides a bioinformatic basis for further research of molecular mechanism in obesity.
other	hsa-mir-143	Obesity	19188425	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our results provide the first experimental evidence for miR-103 function in adipose biology.
other	hsa-mir-146b	Obesity	24931160	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	MiR-146b is a regulator of human visceral preadipocyte proliferation and differentiation and its expression is altered in human obesity.
other	hsa-mir-146b	Obesity	22393448	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Decrease of miR-146b-5p in Monocytes during Obesity Is Associated with Loss of the Anti-Inflammatory but Not Insulin Signaling Action of Adiponectin.
other	hsa-mir-148a	Obesity	27878286	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Obesity‑associated miR‑148a is regulated by cytokines and adipokines via a transcriptional mechanism.
other	hsa-mir-16	Obesity	25701361	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our study provides a bioinformatic basis for further research of molecular mechanism in obesity.
other	hsa-mir-221	Obesity	23867206	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our results support the link between miR-221 and obesity development as well as obesity related inflammatory status.
other	hsa-mir-223	Obesity	26962854	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	High-Density Lipoprotein-Associated miR-223 Is Altered after Diet-Induced Weight Loss in Overweight and Obese Males.
other	hsa-mir-26a	Obesity	26107166	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	These results unravel a new mechanism by which bile acid receptor TGR5 activates a miRNA gene expression.
other	hsa-mir-27a	Obesity	25510894	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Correspondingly, the expression of miR-27a and miR-27b  were up-regulated by persimmon tannin from Day 2 to Day 8 significantly.
other	hsa-mir-27b	Obesity	25510894	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Correspondingly, the expression of miR-27a and miR-27b  were up-regulated by persimmon tannin from Day 2 to Day 8 significantly.
other	hsa-mir-33	Obesity	24165878	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Resveratrol and EGCG bind directly and distinctively to miR-33a and miR-122 and modulate divergently their levels in hepatic cells.
other	hsa-mir-33a	Obesity	25769350	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Deregulation of miR-33 and miR-122, as major regulators of lipid metabolism in liver, has been related to obesity and metabolic syndrome.
other	hsa-mir-375	Obesity	21291493	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Taken together, these data suggest that miR-375 promotes 3T3-L1 adipocyte differentiation, possibly through modulating the ERK-PPARγ2-aP2 pathway.
other	hsa-mir-378	Obesity	24923530	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Insight into the effects of adipose tissue inflammation factors on miR-378 expression and the underlying mechanism.
other	hsa-mir-378	Obesity	27721392	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	DNA methylation landscape of fat deposits and fatty acid composition in obese and lean pigs.
other	hsa-mir-425	Obesity	25701361	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our study provides a bioinformatic basis for further research of molecular mechanism in obesity.
other	hsa-mir-483	Obesity	26148871	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-125a-3p and miR-483-5p promote adipogenesis via suppressing the RhoA/ROCK1/ERK1/2 pathway in multiple symmetric lipomatosis.
other	hsa-mir-634	Obesity	25701361	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our study provides a bioinformatic basis for further research of molecular mechanism in obesity.
other	hsa-mir-129	Oral Leukoplakia	25576219	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	a miRNA-mRNA regulatory network associated with the malignant transformation of OLK, and screened out some miRNAs and transcription factors that may have prominent roles during OLK malignant progression.
other	hsa-mir-205	Oral Leukoplakia	26064958	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia.
other	hsa-mir-21	Oral Leukoplakia	26064958	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia.
other	hsa-mir-31	Oral Leukoplakia	25576219	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	a miRNA-mRNA regulatory network associated with the malignant transformation of OLK, and screened out some miRNAs and transcription factors that may have prominent roles during OLK malignant progression.
other	hsa-mir-31	Oral Leukoplakia	22719913	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Upregulation of miR-31* is negatively associated with recurrent/newly formed oral leukoplakia.
other	hsa-mir-323	Oral Leukoplakia	26064958	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia.
other	hsa-mir-339	Oral Leukoplakia	25576219	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	a miRNA-mRNA regulatory network associated with the malignant transformation of OLK, and screened out some miRNAs and transcription factors that may have prominent roles during OLK malignant progression.
other	hsa-mir-423	Oral Leukoplakia	26064958	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia.
other	hsa-mir-491	Oral Leukoplakia	26064958	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia.
other	hsa-mir-499	Oral Leukoplakia	26064958	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia.
other	hsa-mir-525	Oral Leukoplakia	26064958	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia.
other	hsa-mir-549	Oral Leukoplakia	26064958	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	Identification of Gene and MicroRNA Signatures for Oral Cancer Developed from Oral Leukoplakia.
other	hsa-mir-146a	Oral Lichen Planus	27063128			L43.9	D017676		HP:0031453	Detection of miR-155, miR-146a in PBNCs and tissues from patients with oral lichen planus.
other	hsa-mir-146b	Oral Lichen Planus	26064947			L43.9	D017676		HP:0031453	The TF-miRNA Coregulation Network in Oral Lichen Planus.
other	hsa-mir-155	Oral Lichen Planus	27063128			L43.9	D017676		HP:0031453	Detection of miR-155, miR-146a in PBNCs and tissues from patients with oral lichen planus.
other	hsa-mir-190	Oral Lichen Planus	26064947			L43.9	D017676		HP:0031453	The TF-miRNA Coregulation Network in Oral Lichen Planus.
other	hsa-mir-26b	Oral Lichen Planus	26064947			L43.9	D017676		HP:0031453	The TF-miRNA Coregulation Network in Oral Lichen Planus.
other	hsa-mir-29a	Oral Lichen Planus	26064947			L43.9	D017676		HP:0031453	The TF-miRNA Coregulation Network in Oral Lichen Planus.
other	hsa-mir-595	Oral Lichen Planus	26064947			L43.9	D017676		HP:0031453	The TF-miRNA Coregulation Network in Oral Lichen Planus.
other	hsa-mir-628	Oral Lichen Planus	26064947			L43.9	D017676		HP:0031453	The TF-miRNA Coregulation Network in Oral Lichen Planus.
other	hsa-mir-34a	Oral Neoplasms	25973020			C06.9	D009062		HP:0100649	MiR-34a inhibits oral cancer progression partially by repression of interleukin-6-receptor.
other	hsa-mir-375	Oral Neoplasms	28713923			C06.9	D009062		HP:0100649	The differential regulation of microRNAs is associated with oral cancer
other	hsa-mir-4505	Oral Neoplasms	27207653			C06.9	D009062		HP:0100649	a microRNA (miR) analysis revealed that LCN2 can suppress CAIX expression and cell migration through miR-4505 induction.
other	hsa-mir-494	Oral Neoplasms	25500095			C06.9	D009062		HP:0100649	the role of miR-494 as a tumor suppressor miRNA in oral cancer.
other	hsa-mir-122	Osteoarthritis	26239639	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	An insertion/deletion polymorphism at the microRNA-122 binding site in the interleukin-1α 3'-untranslated region is associated with a risk for osteoarthritis.
other	hsa-mir-130a	Osteoarthritis	29532889	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MicroRNA-130a regulates chondrocyte proliferation and alleviates osteoarthritis through PTEN/PI3K/Akt signaling pathway
other	hsa-mir-140	Osteoarthritis	20516192	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-140:miR-140 has a critical and nonredundant role in cartilage development and homeostasis
other	hsa-mir-140	Osteoarthritis	23281373	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Detection of the expression level of miR-140 using realtime fluorescent quantitative PCR in knee synovial fluid of osteoarthritis patients
other	hsa-mir-140	Osteoarthritis	23942573	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Molecular mechanisms of the cartilage-specific microRNA-140 in osteoarthritis.
other	hsa-mir-140	Osteoarthritis	19948051	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	We investigated whether two highly predicted microRNAs (miRNAs), miR-140 and miR-27a, regulate these two genes in human OA chondrocytes.
other	hsa-mir-140	Osteoarthritis	20466812	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	We show that miR-140 regulates cartilage development and homeostasis, and its loss contributes to the development of age-related OA-like changes.
other	hsa-mir-140	Osteoarthritis	22273691	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Expression of miRNA-140 and MMP-13 was elevated in IL-1β-stimulated C28/I2 cells. 
other	hsa-mir-140	Osteoarthritis	23291479	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MiR-146a and -155 were mainly reported for RA, miR-140 was mainly reported for OA including cartilage development.
other	hsa-mir-140	Osteoarthritis	27165343	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	estrogen acts via ER and miR-140 to inhibit the catabolic activity of proteases within the chondrocyte extracellular matrix.
other	hsa-mir-140	Osteoarthritis	29095952	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Computer simulation models as a tool to investigate the role of microRNAs in osteoarthritis.
other	hsa-mir-146a	Osteoarthritis	24939082	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Role of miR-146a in human chondrocyte apoptosis in response to mechanical pressure injury in vitro.
other	hsa-mir-146a	Osteoarthritis	18438844	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	This study shows that miR-146 is expressed in RA synovial tissue and that its expression is induced by stimulation with TNFalpha and IL-1beta. Further studies are required to elucidate the function of miR-146 in these tissues.
other	hsa-mir-146a	Osteoarthritis	25052989	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	The mechanism underlying the inhibitory effects of denbinobin involved miR-146a induction, which in turn inhibited NF-魏B signaling.
other	hsa-mir-146a	Osteoarthritis	29292727	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	the modification of miR-146a and miR-34a in OA chondrocytes subjected to H2O2 stimulus and we confirmed the antioxidant effect of taurine
other	hsa-mir-146a	Osteoarthritis	29449647	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	they express a remarkably high basal level of miR-147a, a microRNA known to negatively regulate the TLR pathway
other	hsa-mir-146a	Osteoarthritis	29575548	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-146a may be used to counter both aging-associated OA and mechanical injury-/inflammation-induced PTOA
other	hsa-mir-148a	Osteoarthritis	24269634	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Overexpression of hsa-miR-148a inhibits hypertrophic differentiation and increases the production and deposition of type II collagen by OA chondrocytes, which is accompanied by an increased retention of proteoglycans.Hsa-miR-148a might be a potential disease-modifying compound in OA, as it promotes hyaline cartilage production.
other	hsa-mir-188	Osteoarthritis	24928913	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	In IL-1尾-stimulated human chondrocytes, chosen as a model of differentiated phenotype loss implicating the PPi transporter ANK, miR-9, miR-188 and let7e levels increased.
other	hsa-mir-27a	Osteoarthritis	19948051	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	We investigated whether two highly predicted microRNAs (miRNAs), miR-140 and miR-27a, regulate these two genes in human OA chondrocytes.
other	hsa-mir-27b	Osteoarthritis	20131257	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-27b:MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes
other	hsa-mir-335	Osteoarthritis	26243143	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Signature of microRNA expression during osteogenic differentiation of bone marrow MSCs reveals a putative role of miR-335-5p in osteoarthritis.
other	hsa-mir-34a	Osteoarthritis	29292727	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	the modification of miR-146a and miR-34a in OA chondrocytes subjected to H2O2 stimulus and we confirmed the antioxidant effect of taurine
other	hsa-mir-483	Osteoarthritis	28139355	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Intra-articular Delivery of Antago-miR-483-5p Inhibits Osteoarthritis by Modulating Matrilin 3 and Tissue Inhibitor of Metalloproteinase 2.
other	hsa-mir-519b	Osteoarthritis	28423042	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Transforming growth factor β1 enhances heme oxygenase 1 expression in human synovial fibroblasts by inhibiting microRNA 519b synthesis.
other	hsa-mir-9	Osteoarthritis	27404795	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	IL-6 expression is achieved through increased recruitment of CEBP伪 to the MCPIP1 promoter and by relieving the miR-9-mediated inhibition of MCPIP1 expression in OA chondrocytes.
other	hsa-mir-145	Osteogenesis Imperfecta	27551756	musculoskeletal system disease	DOID:12347	Q78.0	D010013	PS166200		Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145.
other	hsa-let-7g	Osteoporosis	27665867	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	An insertion/deletion polymorphism within the 3'‑untranslated region of COL1A2 confers susceptibility to osteoporosis.
other	hsa-mir-210	Osteoporosis	25503465	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-210 played an important role in ameliorating the estrogen deficiency caused-postmenopausal osteoporosis through promotion the VEGF expression and osteoblast differentiation.
other	hsa-mir-34	Osteoporosis	24815299	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-34 has also been implicated in various non-cancerous diseases, such as brain disorders, osteoporosis, and cardiovascular complications.
other	hsa-mir-422a	Osteoporosis	24820117	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	MiR-422a as a potential cellular microRNA biomarker for postmenopausal osteoporosis.
other	hsa-mir-637	Osteoporosis	21880893	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-637 suppressed the growth of hMSCs and induced S-phase arrest. Expression of miR-637 was increased during adipocyte differentiation (AD) whereas it was decreased during osteoblast differentiation (OS), which suggests that miR-637 could act as a mediator of adipo-osteogenic differentiation. Disruption of this differentiation balance leads to various bone-related metabolic diseases, including osteoporosis. Therefore, miR-637 could contributes to osteoporosis.
other	hsa-mir-145	Osteoporosis, Postmenopausal	28260003			M81.0	D015663			Estrogen stimulates osteoprotegerin expression via the suppression of miR-145 expression in MG-63 cells.
other	hsa-let-7	Osteosarcoma	24457375	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	the involvement of let-7 family miRNA in regulation of the cell proliferation as well as epithelial-mesenchymal transition of OS.
other	hsa-let-7d	Osteosarcoma	26679758	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.
other	hsa-mir-101	Osteosarcoma	25013866	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-101 blocks autophagy during the chemotherapy in osteosarcoma cells and enhances chemosensitivity in vitro.
other	hsa-mir-1-1	Osteosarcoma	23229283	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control
other	hsa-mir-1-2	Osteosarcoma	23229283	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control
other	hsa-mir-122	Osteosarcoma	25269820	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA sponge blocks the tumor-suppressing functions of microRNA-122 in human hepatoma and osteosarcoma cells.
other	hsa-mir-124	Osteosarcoma	24971902	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The tumor suppressor role of miR-124 in osteosarcoma.
other	hsa-mir-125b	Osteosarcoma	27990096	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma.
other	hsa-mir-130b	Osteosarcoma	26446495	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, our data indicated that high miR-130b level and low level of miR-218 are associated with poor clinicopathological characteristics.Furthermore, miR-130b may play a key role in the progression of osteosarcoma.
other	hsa-mir-133b	Osteosarcoma	23229283	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control
other	hsa-mir-140	Osteosarcoma	19734943	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	high-throughput microRNA (miRNA) expression analysis revealed that the expression of miR-140 was associated with chemosensitivity in osteosarcoma tumor xenografts
other	hsa-mir-141	Osteosarcoma	24307282	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Tumor-suppressing effects of miR-141 in human osteosarcoma.
other	hsa-mir-143	Osteosarcoma	21427707	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression.
other	hsa-mir-143	Osteosarcoma	24525123	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration.
other	hsa-mir-143	Osteosarcoma	24762226	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression.
other	hsa-mir-143	Osteosarcoma	25227664	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion.
other	hsa-mir-143	Osteosarcoma	23430952	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. 
other	hsa-mir-144	Osteosarcoma	25854173	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-144 inhibits the proliferation, apoptosis, invasion, and migration of osteosarcoma cell line F5M2.
other	hsa-mir-145	Osteosarcoma	23430952	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. 
other	hsa-mir-148a	Osteosarcoma	26111756	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Bufalin Inhibits the Differentiation and Proliferation of Cancer Stem Cells Derived from Primary Osteosarcoma Cells through Mir-148a.
other	hsa-mir-155	Osteosarcoma	25666090	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-155 promotes the growth of osteosarcoma in a HBP1-dependent mechanism.
other	hsa-mir-16	Osteosarcoma	27460987	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Moreover, GLIPR1 overexpression upregulated miR-16 in osteosarcoma cells.
other	hsa-mir-181a-1	Osteosarcoma	23740615	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell.
other	hsa-mir-181a-2	Osteosarcoma	23740615	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell.
other	hsa-mir-181c	Osteosarcoma	26062442	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-181c associates with tumor relapse of high grade osteosarcoma.
other	hsa-mir-199a	Osteosarcoma	24957404	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells.
other	hsa-mir-199a	Osteosarcoma	25931818	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells.
other	hsa-mir-19b-1	Osteosarcoma	23574781	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma
other	hsa-mir-19b-2	Osteosarcoma	23574781	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma
other	hsa-mir-200	Osteosarcoma	24815002	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo.
other	hsa-mir-200b	Osteosarcoma	23430952	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. 
other	hsa-mir-200c	Osteosarcoma	23430952	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. 
other	hsa-mir-210	Osteosarcoma	28032372	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line.
other	hsa-mir-212	Osteosarcoma	25562164	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The miR-212/Sox4 interaction plays an important role of in the osteosarcoma progression.
other	hsa-mir-214	Osteosarcoma	27840941	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Deregulated WWOX is involved in a negative feedback loop with microRNA-214-3p in osteosarcoma.
other	hsa-mir-217	Osteosarcoma	26062553	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Quercetin Enhances Cisplatin Sensitivity of Human Osteosarcoma Cells by Modulating microRNA-217-KRAS Axis.
other	hsa-mir-218	Osteosarcoma	26446495	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, our data indicated that high miR-130b level and low level of miR-218 are associated with poor clinicopathological characteristics.Furthermore, miR-130b may play a key role in the progression of osteosarcoma.
other	hsa-mir-221	Osteosarcoma	23372675	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma
other	hsa-mir-221	Osteosarcoma	26397386	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, our results suggest that miR-221 enhances the proliferation,invasion and migration ability of osteosarcoma cells partly by suppressing PTEN.
other	hsa-mir-221	Osteosarcoma	28074104	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Bufalin Inhibits Proliferation and Induces Apoptosis in Osteosarcoma Cells by Downregulating MicroRNA-221.
other	hsa-mir-223	Osteosarcoma	24784921	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma.
other	hsa-mir-23a	Osteosarcoma	26160225	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma.
other	hsa-mir-24	Osteosarcoma	25142229	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a.
other	hsa-mir-27a	Osteosarcoma	25749032	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells.
other	hsa-mir-27a	Osteosarcoma	27429847	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Moreover, our findings suggested that the modulatory effects of PG on EMMPRIN were due, at least in part, to regulation of an ROS-miR-27a/ZBTB10-Sp1 transcription factor pathway.
other	hsa-mir-29a	Osteosarcoma	25142229	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a.
other	hsa-mir-29a	Osteosarcoma	25015394	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Prognostic value of the microRNA-29 family in patients with primary osteosarcomas.
other	hsa-mir-29b	Osteosarcoma	25015394	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Prognostic value of the microRNA-29 family in patients with primary osteosarcomas.
other	hsa-mir-29b	Osteosarcoma	25337211	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF.
other	hsa-mir-29b-1	Osteosarcoma	25174983	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.
other	hsa-mir-29c	Osteosarcoma	25015394	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Prognostic value of the microRNA-29 family in patients with primary osteosarcomas.
other	hsa-mir-302b	Osteosarcoma	23845851	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis  and cell cycle regulation.
other	hsa-mir-34a	Osteosarcoma	22457788	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-34a Inhibits the Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo.
other	hsa-mir-34a	Osteosarcoma	24957404	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells.
other	hsa-mir-34a	Osteosarcoma	25490093	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	cell response to etoposide-induced DNA damage was not compromised in cells with dominant-negative p53 expression.
other	hsa-mir-34a	Osteosarcoma	23430952	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These effects were associated with decreased expression of Notch-1 and its downstream genes, such as vascular endothelial growth factor and matrix metalloproteinases, as well as increased expression of a panel of tumor-suppressive microRNAs (miRNAs), including miR-34a, miR-143, miR-145 and miR-200b/c that are typically lost in osteosarcoma. 
other	hsa-mir-34a	Osteosarcoma	28635396	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2.
other	hsa-mir-34c	Osteosarcoma	23720736	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma.
other	hsa-mir-34c	Osteosarcoma	24802328	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-34c inhibits osteosarcoma metastasis and chemoresistance.
other	hsa-mir-375	Osteosarcoma	26381132	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Formononetin has inhibitory effects on the proliferation of U2SO cells, both in vitro and in vivo. This antitumor effect is directly correlated with formononetin concentration.
other	hsa-mir-382	Osteosarcoma	25344865	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma.
other	hsa-mir-410	Osteosarcoma	25385479	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	VEGF-mediated suppression of cell proliferation and invasion by miR-410 in osteosarcoma.
other	hsa-mir-451	Osteosarcoma	25391425	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-451 may play an important role in tumor growth and metastasis in osteosarcoma.
other	hsa-mir-451	Osteosarcoma	25869073	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Suppression of liver receptor homolog-1 by microRNA-451 represses the proliferation of osteosarcoma cells.
other	hsa-mir-486	Osteosarcoma	28339053	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-486 suppresses the development of osteosarcoma by regulating PKC-δ pathway.
other	hsa-mir-497	Osteosarcoma	26202364	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, our results suggest that miR-497 modulates the sensitivity to cisplatin at least in part through PI3K/Akt pathway in osteosarcoma cells.
other	hsa-mir-10a	Ovarian Disease	26979400	endocrine system disease	DOID:1100	E28.9	D010049			AFSC-derived exosomes prevent ovarian follicular atresia in CTx-treated mice via the delivery of microRNAs in which both miR-146a  and miR-10a are highly enriched and their potential target genes are critical to  apoptosis.
other	hsa-let-7	Ovarian Neoplasms	24393345	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200.
other	hsa-let-7	Ovarian Neoplasms	29658612	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer
other	hsa-let-7	Ovarian Neoplasms	21618519	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.
other	hsa-let-7a	Ovarian Neoplasms	24643702	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	E(2) + P4 significantly inhibited the cell survival, promoted the cell apoptosis, induced the expression of let-7a and miR-34b, and reduced the expression of Bcl-2 in ovarian cancer cells.
other	hsa-let-7a	Ovarian Neoplasms	19477633	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our study also suggests that lin-28B may promote ovarian cancer progression and serve as an unfavourable prognostic marker for the disease. 
other	hsa-let-7a	Ovarian Neoplasms	21122376	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis.
other	hsa-let-7e	Ovarian Neoplasms	21122376	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis.
other	hsa-let-7f	Ovarian Neoplasms	21122376	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis.
other	hsa-let-7i	Ovarian Neoplasms	22812695	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our study indicated that this MUC1/let-7i chimera can specifically reverse chemoresistance to paclitaxel.
other	hsa-mir-1	Ovarian Neoplasms	27354590	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	loss of growth-inhibitory functionality of miR-1
other	hsa-mir-100	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	normal
other	hsa-mir-101-1	Ovarian Neoplasms	21818714	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21(waf1/cip1).
other	hsa-mir-101-2	Ovarian Neoplasms	21818714	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21(waf1/cip1).
other	hsa-mir-1181	Ovarian Neoplasms	26151663	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer.
other	hsa-mir-124	Ovarian Neoplasms	26655797	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
other	hsa-mir-125a	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	normal
other	hsa-mir-129	Ovarian Neoplasms	25895125	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
other	hsa-mir-1307	Ovarian Neoplasms	25887170	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our results suggest that miRNA-1307 may play a role in the development of chemoresistance in ovarian cancer.
other	hsa-mir-130a	Ovarian Neoplasms	20083225	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	we discuss several other microRNAs that have been associated with chemotherapy resistance, such as miR-214, miR-130a, miR-27a and miR-451. In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools.
other	hsa-mir-130b	Ovarian Neoplasms	25155039	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA 130b enhances drug resistance in human ovarian cancer cells.
other	hsa-mir-141	Ovarian Neoplasms	26725650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These mechanisms have significant relevance in ovarian cancers and stress response, pathophysiological conditions in which miR-200c/141 exert key functions.
other	hsa-mir-141	Ovarian Neoplasms	22101765	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response.
other	hsa-mir-141	Ovarian Neoplasms	22897840	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Some genes involved in EMT, such as BMP and activin membrane-bound inhibitor (BAMBI), and mir-141 resulted in association with overall or progression free survival.
other	hsa-mir-141	Ovarian Neoplasms	21051560	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final β-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients.
other	hsa-mir-145	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	normal
other	hsa-mir-146a	Ovarian Neoplasms	25537514	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	a proportion of patients with wild-type BRCA1/2 ovarian cancers benefit from platinum-based chemotherapy and that the patients who benefit could be predicted from BRCA1/2-directed miRNA signature.
other	hsa-mir-146a	Ovarian Neoplasms	20810544	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients.
other	hsa-mir-146a	Ovarian Neoplasms	21591024	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In conclusion, the polymorphism in the miR-146a gene is unlikely to be of substantial significance regarding breast cancer risk.
other	hsa-mir-146b	Ovarian Neoplasms	21266476	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Induction of miR-146b by PDGF-BB is modulated via MAPK-dependent induction of c-fos.
other	hsa-mir-148a	Ovarian Neoplasms	25537514	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	a proportion of patients with wild-type BRCA1/2 ovarian cancers benefit from platinum-based chemotherapy and that the patients who benefit could be predicted from BRCA1/2-directed miRNA signature.
other	hsa-mir-148a	Ovarian Neoplasms	21971665	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ovarian Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation.
other	hsa-mir-148a	Ovarian Neoplasms	29069830	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The selected signature composed by VAT1L, CALR, LINC01456, RP11-484L8.1, MIR196A1 and MIR148A, separated the training group patients into high-risk or low-risk subgroup with significantly different survival time
other	hsa-mir-152	Ovarian Neoplasms	21971665	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ovarian Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation.
other	hsa-mir-155	Ovarian Neoplasms	26655797	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
other	hsa-mir-181a	Ovarian Neoplasms	27249598	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-181a overexpression decreased the PTX sensitivity of SKOV3 cells and while miR-181a inhibition increased the sensitivity of SKOV3/PTX cells.
other	hsa-mir-181b	Ovarian Neoplasms	26655797	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
other	hsa-mir-196a-1	Ovarian Neoplasms	29069830	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The selected signature composed by VAT1L, CALR, LINC01456, RP11-484L8.1, MIR196A1 and MIR148A, separated the training group patients into high-risk or low-risk subgroup with significantly different survival time
other	hsa-mir-199	Ovarian Neoplasms	26819477	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-199a-5p and miR-34a-5p showed specific association with the disease, including molecular and cellular functions
other	hsa-mir-199a-1	Ovarian Neoplasms	20400975	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-199a:TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214
other	hsa-mir-199a-2	Ovarian Neoplasms	20400975	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-199a:TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214
other	hsa-mir-19a	Ovarian Neoplasms	24929208	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-19a was also transported via TnTs connecting transfected K7M2 cells and nontransfected stromal MC3T3 murine osteoblast cells.
other	hsa-mir-200	Ovarian Neoplasms	24393345	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200.
other	hsa-mir-200	Ovarian Neoplasms	24447705	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells.
other	hsa-mir-200	Ovarian Neoplasms	24966949	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
other	hsa-mir-200	Ovarian Neoplasms	26910180	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The prognostic value of the miR-200 family in ovarian cancer: a meta-analysis.
other	hsa-mir-200a	Ovarian Neoplasms	25327865	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Involvement of miR-200a in chemosensitivity regulation of ovarian cancer.
other	hsa-mir-200a	Ovarian Neoplasms	23888941	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features.
other	hsa-mir-200a	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200a:involved in epithelial-to-mesenchymal transition (EMT)
other	hsa-mir-200a	Ovarian Neoplasms	22101765	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response.
other	hsa-mir-200a	Ovarian Neoplasms	21051560	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final β-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients.
other	hsa-mir-200b	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200b:involved in epithelial-to-mesenchymal transition (EMT)
other	hsa-mir-200b	Ovarian Neoplasms	28399108	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
other	hsa-mir-200b	Ovarian Neoplasms	21051560	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final β-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients.
other	hsa-mir-200c	Ovarian Neoplasms	26725650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These mechanisms have significant relevance in ovarian cancers and stress response, pathophysiological conditions in which miR-200c/141 exert key functions.
other	hsa-mir-200c	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200c:involved in epithelial-to-mesenchymal transition (EMT)
other	hsa-mir-200c	Ovarian Neoplasms	23074172	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
other	hsa-mir-200c	Ovarian Neoplasms	23394580	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	a model for the combined regulatory activity of miR-200c and HuR on TUBB3 expression in ovarian cancer
other	hsa-mir-200c	Ovarian Neoplasms	27601996	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition.
other	hsa-mir-200c	Ovarian Neoplasms	28399108	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
other	hsa-mir-200c	Ovarian Neoplasms	21051560	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final β-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients.
other	hsa-mir-20a	Ovarian Neoplasms	28789409	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line.
other	hsa-mir-21	Ovarian Neoplasms	24865582	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.
other	hsa-mir-21	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	normal
other	hsa-mir-210	Ovarian Neoplasms	26640557	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-923, miR-1246, miR-149*, miR-638 and miR-210 were upregulated and miR-99a, miR-181a-2* and miR-339-5p were downregulated following  bafilomycin A1 treatment.
other	hsa-mir-214	Ovarian Neoplasms	20400975	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-214:TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214
other	hsa-mir-214	Ovarian Neoplasms	18199536	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway.
other	hsa-mir-214	Ovarian Neoplasms	20083225	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	we discuss several other microRNAs that have been associated with chemotherapy resistance, such as miR-214, miR-130a, miR-27a and miR-451. In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools.
other	hsa-mir-22	Ovarian Neoplasms	20869762	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-22:miR-22 might be involved in inhibiting ovarian cancer metastasis
other	hsa-mir-22	Ovarian Neoplasms	21122376	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis.
other	hsa-mir-24	Ovarian Neoplasms	26296081	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Enrichment Analysis Identifies Functional MicroRNA-Disease Associations in Humans.
other	hsa-mir-26a	Ovarian Neoplasms	24466274	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-26a promotes ovarian cancer proliferation and tumorigenesis.
other	hsa-mir-27a	Ovarian Neoplasms	23254909	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells
other	hsa-mir-27a	Ovarian Neoplasms	20083225	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	we discuss several other microRNAs that have been associated with chemotherapy resistance, such as miR-214, miR-130a, miR-27a and miR-451. In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools.
other	hsa-mir-27b	Ovarian Neoplasms	28396577	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression.
other	hsa-mir-29	Ovarian Neoplasms	23904094	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.
other	hsa-mir-302a	Ovarian Neoplasms	26191180	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-302a inhibits the tumorigenicity of ovarian cancer cells by suppression of SDC1.
other	hsa-mir-30d	Ovarian Neoplasms	22058146	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	A combined array-based comparative genomic hybridization (aCGH) and functional library screening approach identifies mir-30d as an oncomir in cancer.
other	hsa-mir-31	Ovarian Neoplasms	23552883	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET
other	hsa-mir-34a	Ovarian Neoplasms	26819477	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-199a-5p and miR-34a-5p showed specific association with the disease, including molecular and cellular functions
other	hsa-mir-34a	Ovarian Neoplasms	21423204	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We propose that elevated TRP53 and miR-34a-c may  exert negatively regulatory effects that reduce the proliferative potential of OSE cells leading to the low-grade serous adenocarcinoma phenotype.
other	hsa-mir-34a	Ovarian Neoplasms	21516127	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiRIDIAN-based knockdown and induction of miR-34a evidenced a direct regulatory link between miR-34a and E2F3a, and the tumor-suppressive character of miR-34a was documented by its association with improved survival.
other	hsa-mir-34b	Ovarian Neoplasms	24643702	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	E(2) + P4 significantly inhibited the cell survival, promoted the cell apoptosis, induced the expression of let-7a and miR-34b, and reduced the expression of Bcl-2 in ovarian cancer cells.
other	hsa-mir-34c	Ovarian Neoplasms	25273528	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
other	hsa-mir-367	Ovarian Neoplasms	24220856	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of miR-367 in the paclitaxel-sensitive cells [PA1; IC₅₀, 1.69 nM, high miR-367 (2.997), low miR-30a-5p (-0.323)] further increased paclitaxel sensitivity, whereas miR-367 depletion decreased paclitaxel sensitivity.
other	hsa-mir-370	Ovarian Neoplasms	29403287	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Long noncoding RNA H19 promotes transforming growth factor-β-induced epithelial-mesenchymal transition by acting as a competing endogenous RNA of miR-370-3p in ovarian cancer cells
other	hsa-mir-375	Ovarian Neoplasms	23696927	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer.
other	hsa-mir-376	Ovarian Neoplasms	26940843	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MIR376 as an important  microRNA family for cancer formation and progression
other	hsa-mir-429	Ovarian Neoplasms	21277012	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells.
other	hsa-mir-429	Ovarian Neoplasms	21051560	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In conclusion, miR-200 family members(200a,200b,200c,141,429) affect the final β-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients.
other	hsa-mir-451	Ovarian Neoplasms	20083225	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	we discuss several other microRNAs that have been associated with chemotherapy resistance, such as miR-214, miR-130a, miR-27a and miR-451. In the final section, we speculate on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools.
other	hsa-mir-490	Ovarian Neoplasms	25297343	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells.
other	hsa-mir-517a	Ovarian Neoplasms	26655797	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
other	hsa-mir-545	Ovarian Neoplasms	25537514	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	a proportion of patients with wild-type BRCA1/2 ovarian cancers benefit from platinum-based chemotherapy and that the patients who benefit could be predicted from BRCA1/2-directed miRNA signature.
other	hsa-mir-630	Ovarian Neoplasms	29452092	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
other	hsa-mir-7	Ovarian Neoplasms	29411964	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with  MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy
other	hsa-mir-718	Ovarian Neoplasms	24815691	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-718 represses VEGF and inhibits ovarian cancer cell progression.
other	hsa-mir-886	Ovarian Neoplasms	21122376	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Bioinformatic analysis indicated that let-7a, let-7e, let-7f, miR-22 and miR-886-5p may be involved in cancer invasion and metastasis.
other	hsa-mir-92a-1	Ovarian Neoplasms	23499550	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-92a Inhibits Peritoneal Dissemination of Ovarian Cancer Cells by Inhibiting Integrin  Expression.
other	hsa-mir-92a-2	Ovarian Neoplasms	23499550	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-92a Inhibits Peritoneal Dissemination of Ovarian Cancer Cells by Inhibiting Integrin α5 Expression.
other	hsa-mir-92b	Ovarian Neoplasms	28693226	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis.
other	hsa-mir-940	Ovarian Neoplasms	28423620	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.
other	hsa-mir-99a	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	normal
other	hsa-mir-106b	Ovary Mixed Epithelial Carcinoma	25933027	endocrine system disease	DOID:6898					Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
other	hsa-mir-135a	Pain	26498117			R52	D010146			These results show that circulating miRNA predict persistent severe axial pain after MVC and suggest that they may be involved in the pathogenesis of post-traumatic musculoskeletal pain. However, further studies are needed to determine if these miRNA play a direct causal role.
other	hsa-mir-182	Pain	19699278			R52	D010146			association with  chronic neuropathic pain, mechanical hypersensitivity
other	hsa-mir-183	Pain	19699278			R52	D010146			association with  chronic neuropathic pain, mechanical hypersensitivity
other	hsa-mir-34a	Pain	19699278			R52	D010146			association with  chronic neuropathic pain, mechanical hypersensitivity
other	hsa-mir-34a	Pain	27917453			R52	D010146			Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
other	hsa-mir-3613	Pain	26498117			R52	D010146			These results show that circulating miRNA predict persistent severe axial pain after MVC and suggest that they may be involved in the pathogenesis of post-traumatic musculoskeletal pain. However, further studies are needed to determine if these miRNA play a direct causal role.
other	hsa-mir-96	Pain	19699278			R52	D010146			association with  chronic neuropathic pain, mechanical hypersensitivity
other	hsa-mir-145	Pancreatic Adenocarcinoma	27765914	disease of cellular proliferation	DOID:4074	C25.3				MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
other	hsa-mir-155	Pancreatic Adenocarcinoma	20332664	disease of cellular proliferation	DOID:4074	C25.3				Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma
other	hsa-mir-155	Pancreatic Adenocarcinoma	27456015	disease of cellular proliferation	DOID:4074	C25.3				whereas miRNA-30c, miRNA-21, and miRNA-155 levels and CK19 mRNA levels in station 8 nodes were variable and did not correlate with RFS or OS.
other	hsa-mir-206	Pancreatic Adenocarcinoma	25500542	disease of cellular proliferation	DOID:4074	C25.3				miR-206 as a pleiotropic modulator of different hallmarks of cancer, and as such raising the intriguing possibility that miR-206 may be an attractive candidate for miRNA-based anticancer therapies.
other	hsa-mir-21	Pancreatic Adenocarcinoma	19730150	disease of cellular proliferation	DOID:4074	C25.3				Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma.
other	hsa-mir-221	Pancreatic Adenocarcinoma	19730150	disease of cellular proliferation	DOID:4074	C25.3				Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma.
other	hsa-mir-23b	Pancreatic Adenocarcinoma	24070722	disease of cellular proliferation	DOID:4074	C25.3				Mir-23B might be used as a biomarker for PDAC resistance to radiotherapy or chemotherapy. Or, patients with low tumor levels of Mir-23B might benefit from pharmacologic inhibitors of autophagy.
other	hsa-let-7a	Pancreatic Neoplasms	24040120	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.
other	hsa-let-7a	Pancreatic Neoplasms	23335963	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These data demonstrate an intricate post-transcriptional regulation of RRM2 and chemosensitivity by let-7a and that the manipulation of regulatory proteins involved in let-7a transcription/processing may provide a mechanism for improving chemotherapeutic and/or tumor growth control responses in pancreatic cancer.
other	hsa-let-7a-1	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7a: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7a-1	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-let-7a-2	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7a: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7a-2	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-let-7a-3	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7a: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7a-3	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-let-7b	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7b: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7b	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-let-7c	Pancreatic Neoplasms	26121640	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer.
other	hsa-let-7c	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7c: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7c	Pancreatic Neoplasms	22245693	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner.
other	hsa-let-7d	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7d: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7e	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7e: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7f-1	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7f: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7f-2	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7f: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7g	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7g: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-let-7i	Pancreatic Neoplasms	19323605	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Let-7i: inhibits in vitro cell proliferation but fails to alter tumor progression
other	hsa-mir-100	Pancreatic Neoplasms	25607660	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions.
other	hsa-mir-101	Pancreatic Neoplasms	26828016	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
other	hsa-mir-101-1	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-mir-101-1	Pancreatic Neoplasms	22943841	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101.
other	hsa-mir-101-1	Pancreatic Neoplasms	23139258	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
other	hsa-mir-101-2	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-mir-101-2	Pancreatic Neoplasms	22943841	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101.
other	hsa-mir-101-2	Pancreatic Neoplasms	23139258	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
other	hsa-mir-103	Pancreatic Neoplasms	23674172	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our study demonstrates that the pathophysiology of HNF1A-MODY is associated with the overexpression of miR-103 and miR-224.
other	hsa-mir-103a-1	Pancreatic Neoplasms	22479426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers.
other	hsa-mir-103a-2	Pancreatic Neoplasms	22479426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers.
other	hsa-mir-103b-1	Pancreatic Neoplasms	22479426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers.
other	hsa-mir-103b-2	Pancreatic Neoplasms	22479426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers.
other	hsa-mir-106a	Pancreatic Neoplasms	24444603	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Upregulated miR-106a plays an oncogenic role in pancreatic cancer.
other	hsa-mir-10a	Pancreatic Neoplasms	19747919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Inhibition of miR-10a expression (with retinoic acid receptor antagonists) or function (with specific inhibitors) is a promising starting point for antimetastatic therapies.
other	hsa-mir-10b	Pancreatic Neoplasms	26444644	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our findings suggest that this unique technique can be used to design novel diagnostic strategies for pancreatic and other cancers based on the direct quantitative measurement of plasma and exosome microRNAs, and can be readily extended to other diseases with identifiable microRNA signatures.
other	hsa-mir-10b	Pancreatic Neoplasms	21652542	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		microRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma.
other	hsa-mir-1181	Pancreatic Neoplasms	25444909	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-1181 plays a vital role in inhibiting the CSCs-like phenotypes in pancreatic cancer and might represent a potential target for anti-pancreatic cancer.
other	hsa-mir-126	Pancreatic Neoplasms	25607660	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions.
other	hsa-mir-130a	Pancreatic Neoplasms	25607660	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions.
other	hsa-mir-132	Pancreatic Neoplasms	25840985	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Xenograft tumors treated with ormeloxifene in combination  with gemcitabine restored the tumor-suppressor miR-132 and inhibited stromal cell infiltration into the tumor tissues.
other	hsa-mir-135b	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Using relative qRT-PCR to measure miR-135b normalized to miR-24 in 75 FFPE specimens (42 PDAC and 33 CP) covering a broad range of tumor content, the authors discriminated CP from PDAC with a sensitivity and specificity of 92.9% [95%CI=(80.5,98.5)] and 93.4% [95%CI=(79.8,99.3)], respectively. Therefore, miR-135b could be a novel biomarker for pancreatic ductal adenocarcinoma.
other	hsa-mir-143	Pancreatic Neoplasms	21159815	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.
other	hsa-mir-143	Pancreatic Neoplasms	23070684	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway
other	hsa-mir-143	Pancreatic Neoplasms	21159816	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Additionally, KRAS and RREB1 are targets of miR-143/miR-145, revealing a feed-forward mechanism that potentiates Ras signaling.
other	hsa-mir-145	Pancreatic Neoplasms	24040120	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.
other	hsa-mir-145	Pancreatic Neoplasms	21159815	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.
other	hsa-mir-145	Pancreatic Neoplasms	29464032	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Selective packaging of miRNAs into EVs led to enrichment of stromal specific miR-145 in EVs secreted by TAS cells
other	hsa-mir-145	Pancreatic Neoplasms	21159816	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Additionally, KRAS and RREB1 are targets of miR-143/miR-145, revealing a feed-forward mechanism that potentiates Ras signaling.
other	hsa-mir-145	Pancreatic Neoplasms	23834149	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		insulingrowth factor-1 receptor expression (miR-7, miR-139, miR-145, miR-1); 
other	hsa-mir-146a	Pancreatic Neoplasms	22311263	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation.
other	hsa-mir-146a	Pancreatic Neoplasms	20124483	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-146a suppresses invasion of pancreatic cancer cells.
other	hsa-mir-148a	Pancreatic Neoplasms	25950085	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy.
other	hsa-mir-148a	Pancreatic Neoplasms	24895996	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity.
other	hsa-mir-155	Pancreatic Neoplasms	23776656	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		It is possible that mirNA participates in the pathophysiology of pancreatic cancer, but the current popular methods do not accurately reveal the real-time mirNA function. Thus, this report provided a convenient, accurate, and sensitive approach to mirNA research.
other	hsa-mir-155	Pancreatic Neoplasms	23817566	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1.
other	hsa-mir-155	Pancreatic Neoplasms	26195069	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts.
other	hsa-mir-155	Pancreatic Neoplasms	21826251	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		preferential expression in holoclones
other	hsa-mir-155	Pancreatic Neoplasms	23139258	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
other	hsa-mir-155	Pancreatic Neoplasms	27060060	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A vast number of miRNAs, including the well-studied miR-21, miR-155 and miR-34, has been shown to regulate PDAC growth, invasion and metastasis
other	hsa-mir-15b	Pancreatic Neoplasms	26166038	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer.
other	hsa-mir-15b	Pancreatic Neoplasms	22479426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers.
other	hsa-mir-15b	Pancreatic Neoplasms	26314585	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic tumours are usually very aggressive cancer with a poor prognosis. 
other	hsa-mir-16	Pancreatic Neoplasms	24600978	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The combination of miR-16 and CA19-9 detections boosted the diagnostic performance in pancreatic cancer detection.
other	hsa-mir-16-1	Pancreatic Neoplasms	21913185	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-16 and miR-196a possessed an independent role in discriminating PCa (pancreatic cancer) from normal and CP.
other	hsa-mir-16-2	Pancreatic Neoplasms	21913185	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-16 and miR-196a possessed an independent role in discriminating PCa (pancreatic cancer) from normal and CP.
other	hsa-mir-17	Pancreatic Neoplasms	27400681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Mechanically, we discovered that high GFR伪2 expression level leads to  PTEN inactivation via enhancing Mir-17-5p level.
other	hsa-mir-181b	Pancreatic Neoplasms	25126577	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Some miRNAs were found  to be specifically expressed in some ZHENGs, for instance, miR-17, miR-21, and miR-181b in Shi-Re ZHENG and miR-196a in Pi-Xu ZHENG.
other	hsa-mir-181b	Pancreatic Neoplasms	22504911	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-181b and miR-210 discriminatedPCa from normal individuals with receiver operating characteristic (ROC) curves and area under curve (AUC-ROC) of 0.745 and 0.772, respectively.
other	hsa-mir-186	Pancreatic Neoplasms	26314585	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic tumours are usually very aggressive cancer with a poor prognosis. 
other	hsa-mir-18a	Pancreatic Neoplasms	28822990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		αM and γM can induce apoptosis and autophagy in pancreatic cancer cells and that their anti-cancer effect is likely to be associated with miR-18a
other	hsa-mir-190	Pancreatic Neoplasms	26314585	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic tumours are usually very aggressive cancer with a poor prognosis. 
other	hsa-mir-192	Pancreatic Neoplasms	22245693	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner.
other	hsa-mir-196a-1	Pancreatic Neoplasms	21913185	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-16 and miR-196a possessed an independent role in discriminating PCa (pancreatic cancer) from normal and CP.
other	hsa-mir-196a-2	Pancreatic Neoplasms	21913185	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-16 and miR-196a possessed an independent role in discriminating PCa (pancreatic cancer) from normal and CP.
other	hsa-mir-196b	Pancreatic Neoplasms	28186267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer.
other	hsa-mir-200	Pancreatic Neoplasms	24040120	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.
other	hsa-mir-200a	Pancreatic Neoplasms	24521357	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell.
other	hsa-mir-200a	Pancreatic Neoplasms	20388782	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-200:Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF
other	hsa-mir-200a	Pancreatic Neoplasms	21285251	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism.
other	hsa-mir-200a	Pancreatic Neoplasms	21408027	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer.
other	hsa-mir-200b	Pancreatic Neoplasms	23776656	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		It is possible that mirNA participates in the pathophysiology of pancreatic cancer, but the current popular methods do not accurately reveal the real-time mirNA function. Thus, this report provided a convenient, accurate, and sensitive approach to mirNA research.
other	hsa-mir-200b	Pancreatic Neoplasms	21408027	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		in gemcitabine-resistant (MIAPaCa-2) PC cells containing high proportion of CSCs consistent with increased miR-21 and decreased miR-200.
other	hsa-mir-200b	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-mir-200b	Pancreatic Neoplasms	26314585	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic tumours are usually very aggressive cancer with a poor prognosis. 
other	hsa-mir-200c	Pancreatic Neoplasms	21408027	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		in gemcitabine-resistant (MIAPaCa-2) PC cells containing high proportion of CSCs consistent with increased miR-21 and decreased miR-200.
other	hsa-mir-200c	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-mir-200c	Pancreatic Neoplasms	19112422	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Expression of microRNA was determined with microRNA array. Expression of miR-200c and miR-21 was detected by Northern blotting.
other	hsa-mir-203	Pancreatic Neoplasms	25872941	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This led to the identification of both its target gene miR-203 as a major drug sensitizer
other	hsa-mir-203	Pancreatic Neoplasms	28382422	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The Role of Exosomes in Pancreatic Cancer Microenvironment.
other	hsa-mir-204	Pancreatic Neoplasms	24025188	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Triptolide mediated miR-204 increase causes pancreatic cancer cell death via loss of Mcl-1.
other	hsa-mir-208	Pancreatic Neoplasms	24604208	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-208-induced epithelial to mesenchymal transition of pancreatic cancer cells promotes cell metastasis and invasion.
other	hsa-mir-21	Pancreatic Neoplasms	26121640	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer.
other	hsa-mir-21	Pancreatic Neoplasms	20388782	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21:Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF
other	hsa-mir-21	Pancreatic Neoplasms	20498843	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		microRNA-21:Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer
other	hsa-mir-21	Pancreatic Neoplasms	21408027	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer.
other	hsa-mir-21	Pancreatic Neoplasms	21826251	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		preferential expression in holoclones
other	hsa-mir-21	Pancreatic Neoplasms	23139258	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
other	hsa-mir-21	Pancreatic Neoplasms	23752880	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Endoscopically Acquired Pancreatic Cyst Fluid MicroRNA 21 and 221 Are Associated With Invasive Cancer.
other	hsa-mir-21	Pancreatic Neoplasms	27060060	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A vast number of miRNAs, including the well-studied miR-21, miR-155 and miR-34, has been shown to regulate PDAC growth, invasion and metastasis
other	hsa-mir-21	Pancreatic Neoplasms	28304379	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing.
other	hsa-mir-21	Pancreatic Neoplasms	28382422	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The Role of Exosomes in Pancreatic Cancer Microenvironment.
other	hsa-mir-21	Pancreatic Neoplasms	28438662	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer.
other	hsa-mir-210	Pancreatic Neoplasms	26121640	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer.
other	hsa-mir-210	Pancreatic Neoplasms	24395300	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response.
other	hsa-mir-210	Pancreatic Neoplasms	22672828	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-210 expression in PC cells is induced by hypoxia through a HIF-1alpha-dependent pathway, but does not influence PC cell proliferation.
other	hsa-mir-210	Pancreatic Neoplasms	19782034	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		When human head and neck or pancreatic tumor cells ectopically expressing mir-210 were implanted into immunodeficient mice, mir-210 repressed initiation of tumor growth.
other	hsa-mir-211	Pancreatic Neoplasms	23155457	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer
other	hsa-mir-214	Pancreatic Neoplasms	21826251	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		preferential expression in holoclones
other	hsa-mir-216	Pancreatic Neoplasms	26121640	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer.
other	hsa-mir-216a	Pancreatic Neoplasms	26134156	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-216a enhances the radiosensitivity of pancreatic cancer cells by inhibiting beclin-1-mediated autophagy.
other	hsa-mir-216a	Pancreatic Neoplasms	24895996	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity.
other	hsa-mir-221	Pancreatic Neoplasms	25955843	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
other	hsa-mir-221	Pancreatic Neoplasms	21779484	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miRNA is Potentially Associated with Antiproliferative Activity of Benzyl Isothiocyanate in Pancreatic Cancer
other	hsa-mir-221	Pancreatic Neoplasms	21826251	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		preferential expression in holoclones
other	hsa-mir-221	Pancreatic Neoplasms	23752880	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Endoscopically Acquired Pancreatic Cyst Fluid MicroRNA 21 and 221 Are Associated With Invasive Cancer.
other	hsa-mir-221	Pancreatic Neoplasms	26314585	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic tumours are usually very aggressive cancer with a poor prognosis. 
other	hsa-mir-222	Pancreatic Neoplasms	24026657	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This study provides the first evidence of a potential link between Ki67 and micro-RNA-222, which are both relevant to cell proliferation. Our data suggest the potential of micro-RNA-222 as a prognostic biomarker for the pancreatic cancer.
other	hsa-mir-222	Pancreatic Neoplasms	21826251	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		preferential expression in holoclones
other	hsa-mir-222	Pancreatic Neoplasms	26314585	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic tumours are usually very aggressive cancer with a poor prognosis. 
other	hsa-mir-224	Pancreatic Neoplasms	19475450	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-224 and miR-486 are associated with the progression of pancreatic ductal adenocarcinomas
other	hsa-mir-224	Pancreatic Neoplasms	23674172	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our study demonstrates that the pathophysiology of HNF1A-MODY is associated with the overexpression of miR-103 and miR-224.
other	hsa-mir-23a	Pancreatic Neoplasms	26121640	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer.
other	hsa-mir-23a	Pancreatic Neoplasms	22479426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The driving miRNAs were miR-103, miR-23a and miR-15b in pancreatic cancers.
other	hsa-mir-23b	Pancreatic Neoplasms	26121640	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer.
other	hsa-mir-24	Pancreatic Neoplasms	24895587	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miR-24 was the most significantly powerful miRNA that regulated series of important genes.
other	hsa-mir-24-1	Pancreatic Neoplasms	22761894	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We investigated this possibility by analysis of miR-24-1 expression profiles in parathyroid adenomatous tissues from MEN1 gene mutation carriers, in their sporadic non-MEN1 counterparts, and in normal parathyroid tissue.
other	hsa-mir-26a	Pancreatic Neoplasms	26189069	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer.
other	hsa-mir-26a-1	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-mir-26a-1	Pancreatic Neoplasms	22245693	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner. Forced expression of miR-26a significantly inhibited cell proliferation, invasion, migration and increased cell apoptosis, whereas knockdown of miR-26a obtained the opposite effect.
other	hsa-mir-26a-2	Pancreatic Neoplasms	22086681	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found that metformin significantly decreased cell survival, clonogenicity, wound healing capacity, sphere-forming capacity (pancreatospheres), and increased disintegration of pancreatospheres in both gemcitabine-sensitive and gemcitabine-resistant PC cells. Metformin also decreased the expression of CSC markers, CD44, EpCAM, EZH2, Notch-1, Nanog and Oct4, and caused re-expression of miRNAs (let-7a, b, miR-26a, miR-101, and miR-200b, c) that are typically lost in PC and especially in pancreatospheres. We also found that re-expression of miR-26a by transfection led to decreased expression of EZH2 and EpCAM in PC cells.
other	hsa-mir-26a-2	Pancreatic Neoplasms	22245693	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Metformin up-regulated the expression of miR-26a, miR-192 and let-7c in a dose-dependent manner. Forced expression of miR-26a significantly inhibited cell proliferation, invasion, migration and increased cell apoptosis, whereas knockdown of miR-26a obtained the opposite effect.
other	hsa-mir-27a	Pancreatic Neoplasms	24479798	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our findings demonstrated that genistein plays a tumor suppressor role in part through inhibition of miR-27a in pancreatic cancer cells.
other	hsa-mir-29	Pancreatic Neoplasms	26095125	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
other	hsa-mir-29a	Pancreatic Neoplasms	23900458	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.
other	hsa-mir-29c	Pancreatic Neoplasms	25863127	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients.
other	hsa-mir-29c	Pancreatic Neoplasms	26121640	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer.
other	hsa-mir-31	Pancreatic Neoplasms	22344632	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells.
other	hsa-mir-34	Pancreatic Neoplasms	27060060	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A vast number of miRNAs, including the well-studied miR-21, miR-155 and miR-34, has been shown to regulate PDAC growth, invasion and metastasis
other	hsa-mir-342	Pancreatic Neoplasms	25607660	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions.
other	hsa-mir-34a	Pancreatic Neoplasms	19714243	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		inhibits tumor-initiating cells.
other	hsa-mir-34a	Pancreatic Neoplasms	23140286	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Genistein Inhibits Cell Growth and Induces Apoptosis Through Up-regulation of miR-34a in Pancreatic Cancer Cell
other	hsa-mir-34a	Pancreatic Neoplasms	29295989	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer
other	hsa-mir-34a	Pancreatic Neoplasms	17540599	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Therefore, it is likely that an important function of miR-34a is the modulation and fine-tuning of the gene expression program initiated by p53.
other	hsa-mir-34a	Pancreatic Neoplasms	21622730	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1).
other	hsa-mir-34b	Pancreatic Neoplasms	19714243	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		inhibits tumor-initiating cells.
other	hsa-mir-34c	Pancreatic Neoplasms	19714243	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		inhibits tumor-initiating cells.
other	hsa-mir-375	Pancreatic Neoplasms	21779484	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miRNA is Potentially Associated with Antiproliferative Activity of Benzyl Isothiocyanate in Pancreatic Cancer
other	hsa-mir-486	Pancreatic Neoplasms	19475450	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-224 and miR-486 are associated with the progression of pancreatic ductal adenocarcinomas
other	hsa-mir-548d-1	Pancreatic Neoplasms	21946813	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA miR-548d Is a Superior Regulator in Pancreatic Cancer.
other	hsa-mir-548d-2	Pancreatic Neoplasms	21946813	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA miR-548d Is a Superior Regulator in Pancreatic Cancer.
other	hsa-mir-92a	Pancreatic Neoplasms	24332650	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-92a/DUSP10/JNK signalling axis promotes human pancreatic cancer cells proliferation.
other	hsa-mir-95	Pancreatic Neoplasms	26314585	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic tumours are usually very aggressive cancer with a poor prognosis. 
other	hsa-mir-96	Pancreatic Neoplasms	23752186	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
other	hsa-mir-99a	Pancreatic Neoplasms	25607660	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions.
other	hsa-mir-99b	Pancreatic Neoplasms	25607660	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This pilot study highlights miRNAs that may aid in preoperative risk stratification of IPMNs and provides novel insights into miRNA-mediated progression to pancreatic malignancy. The miRNAs identified here and in other recent investigations warrant evaluation in biofluids in a well-powered prospective cohort of individuals newly-diagnosed with IPMNs and other pancreatic cysts and those at increased genetic risk for these lesions.
other	hsa-mir-155	Pancreatic Serous Cystic Neoplasm	23638815	disease of cellular proliferation	DOID:3919					Upregulation of miR-21, miR-155 and miR-708 was found to occur during IPMN malignant transformation.
other	hsa-mir-21	Pancreatic Serous Cystic Neoplasm	23638815	disease of cellular proliferation	DOID:3919					Upregulation of miR-21, miR-155 and miR-708 was found to occur during IPMN malignant transformation.
other	hsa-mir-708	Pancreatic Serous Cystic Neoplasm	23638815	disease of cellular proliferation	DOID:3919					Upregulation of miR-21, miR-155 and miR-708 was found to occur during IPMN malignant transformation.
other	hsa-mir-138-2	Panic Disorder	21168126	disease of mental health	DOID:594	F41.0	D016584	167870		Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 Are Associated with Panic Disorder and Regulate Several Anxiety Candidate Genes and Related Pathways.
other	hsa-mir-148a	Panic Disorder	21168126	disease of mental health	DOID:594	F41.0	D016584	167870		Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 Are Associated with Panic Disorder and Regulate Several Anxiety Candidate Genes and Related Pathways.
other	hsa-mir-22	Panic Disorder	21168126	disease of mental health	DOID:594	F41.0	D016584	167870		Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 Are Associated with Panic Disorder and Regulate Several Anxiety Candidate Genes and Related Pathways.
other	hsa-mir-22	Panic Disorder	26361067	disease of mental health	DOID:594	F41.0	D016584	167870		This is the first report to show possible associations of miR-22 and miR-491 with genetic susceptibility to PD in a Korean population.
other	hsa-mir-488	Panic Disorder	21168126	disease of mental health	DOID:594	F41.0	D016584	167870		Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 Are Associated with Panic Disorder and Regulate Several Anxiety Candidate Genes and Related Pathways.
other	hsa-mir-491	Panic Disorder	26361067	disease of mental health	DOID:594	F41.0	D016584	167870		This is the first report to show possible associations of miR-22 and miR-491 with genetic susceptibility to PD in a Korean population.
other	hsa-let-7a	Parkinson Disease	23600457	nervous system disease	DOID:14330	G20	D010300	PS168600		Furthermore, the lack of LRRK2 leads to an up-regulation of neuronal differentiation-inducing processes, including the Let-7a pathway.
other	hsa-mir-106a	Parkinson Disease	28260060	nervous system disease	DOID:14330	G20	D010300	PS168600		Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
other	hsa-mir-126	Parkinson Disease	26047984	nervous system disease	DOID:14330	G20	D010300	PS168600		Our study provides evidence for a general association of miRNAs with the cellular function and identity of SN DA neurons, and with deregulated gene expression networks and signaling pathways related to PD pathogenesis that may be sex-specific.
other	hsa-mir-133b	Parkinson Disease	17761882	nervous system disease	DOID:14330	G20	D010300	PS168600		Expression of one of these precursor miRNAs, miR-133b, was specifically enriched in the midbrain and deficient in the context of Parkinson's disease patient samples, as determined by ribonuclease (RNase) protection assays, qPCR, and Northern blotting for mature miR-133b.
other	hsa-mir-133b	Parkinson Disease	24742361	nervous system disease	DOID:14330	G20	D010300	PS168600		Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease.
other	hsa-mir-133b	Parkinson Disease	25218846	nervous system disease	DOID:14330	G20	D010300	PS168600		Our observations suggest that miR-133b might be involved in ceruloplasmin dysmetabolism in PD patients and a further investigation is warranted to confirm this hypothesis.
other	hsa-mir-133b	Parkinson Disease	22245218	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-133b is deficient in the PD midbrain as well as in mouse models, and miR-34b/34c are decreased in several affected brain regions in PD and incidental Lewy body disease.
other	hsa-mir-135a	Parkinson Disease	27842305	nervous system disease	DOID:14330	G20	D010300	PS168600		Involvement of microRNA-135a-5p in the Protective Effects of Hydrogen Sulfide Against Parkinson's Disease.
other	hsa-mir-153	Parkinson Disease	26116522	nervous system disease	DOID:14330	G20	D010300	PS168600		Tanshinone IIA protects dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity through miR-153/NF-E2-related factor 2/antioxidant response element signaling pathway.
other	hsa-mir-203	Parkinson Disease	28260060	nervous system disease	DOID:14330	G20	D010300	PS168600		Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
other	hsa-mir-34a	Parkinson Disease	28259991	nervous system disease	DOID:14330	G20	D010300	PS168600		The involvement of Eag1 potassium channels and miR-34a in rotenone-induced death of dopaminergic SH-SY5Y cells.
other	hsa-mir-376a	Parkinson Disease	28260060	nervous system disease	DOID:14330	G20	D010300	PS168600		Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
other	hsa-mir-382	Parkinson Disease	28260060	nervous system disease	DOID:14330	G20	D010300	PS168600		Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
other	hsa-mir-433	Parkinson Disease	26070653	nervous system disease	DOID:14330	G20	D010300	PS168600		Variation in the miRNA-433 binding site of FGF20 is a risk factor for Parkinson's disease in Iranian population.
other	hsa-mir-433	Parkinson Disease	28986288	nervous system disease	DOID:14330	G20	D010300	PS168600		 Linking down-regulation of miRNA-7 and miRNA-433 with α-synuclein overexpression and risk of idiopathic Parkinson's disease.
other	hsa-mir-4697	Parkinson Disease	27653855	nervous system disease	DOID:14330	G20	D010300	PS168600		SIPA1L2, MIR4697, GCH1 and VPS13C loci and risk of Parkinson's diseases in Iranian population: A case-control study.
other	hsa-mir-495	Parkinson Disease	28260060	nervous system disease	DOID:14330	G20	D010300	PS168600		Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
other	hsa-mir-543	Parkinson Disease	28260060	nervous system disease	DOID:14330	G20	D010300	PS168600		Bioinformatics analysis on the differentiation of bone mesenchymal stem cells into osteoblasts and adipocytes.
other	hsa-mir-7	Parkinson Disease	28986288	nervous system disease	DOID:14330	G20	D010300	PS168600		 Linking down-regulation of miRNA-7 and miRNA-433 with α-synuclein overexpression and risk of idiopathic Parkinson's disease.
other	hsa-mir-7-1	Parkinson Disease	23281385	nervous system disease	DOID:14330	G20	D010300	PS168600		MiR-7 variation is not associated with PD in Chinese patients
other	hsa-mir-7-2	Parkinson Disease	23281385	nervous system disease	DOID:14330	G20	D010300	PS168600		MiR-7 variation is not associated with PD in Chinese patients
other	hsa-mir-7-3	Parkinson Disease	23281385	nervous system disease	DOID:14330	G20	D010300	PS168600		MiR-7 variation is not associated with PD in Chinese patients
other	hsa-mir-124	Pediatric Ependymoma	29383182	disease of cellular proliferation	DOID:5509					The tumor suppressor, hsa-miR-124, was down regulated in pediatric SEPN and it normally represses genes involved in cell-cell communication and metabolic processes
other	hsa-mir-1321	Pediatric Glioma	24053158							In the present study we identified the changed expression pattern of microRNAs in pediatric gliamas. Our study also provides a better understanding of pediatric brain tumor biology and may assist in the development of less toxic therapies and in the search for better markers for disease stratification.
other	hsa-mir-17	Pediatric Glioma	24305714							Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG.
other	hsa-mir-18	Pediatric Glioma	24305714							Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG.
other	hsa-mir-19a	Pediatric Glioma	24305714							Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG.
other	hsa-mir-19b-1	Pediatric Glioma	24305714							Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG.
other	hsa-mir-20a	Pediatric Glioma	24305714							Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG.
other	hsa-mir-513b	Pediatric Glioma	24053158							In the present study we identified the changed expression pattern of microRNAs in pediatric gliamas. Our study also provides a better understanding of pediatric brain tumor biology and may assist in the development of less toxic therapies and in the search for better markers for disease stratification.
other	hsa-mir-769	Pediatric Glioma	24053158							In the present study we identified the changed expression pattern of microRNAs in pediatric gliamas. Our study also provides a better understanding of pediatric brain tumor biology and may assist in the development of less toxic therapies and in the search for better markers for disease stratification.
other	hsa-mir-92-1	Pediatric Glioma	24305714							Our results suggest that microRNA profiling represents a tool to distinguishing pediatric from adult HGG and that miR-17-92 cluster sustains pHGG.
other	hsa-mir-340	Pediatric Osteosarcoma	24398981	disease of cellular proliferation	DOID:3361					Combined microRNA-340 and ROCK1 mRNA profiling predicts tumor progression and prognosis in pediatric osteosarcoma.
other	hsa-mir-142	Periodontal Diseases	27429973	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression  in saliva and their importance as noninvasive markers are questionable.
other	hsa-mir-146a	Periodontal Diseases	21263019	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	Polymicrobial Infection with Periodontal Pathogens Specifically enhances miR-146a in ApoE-/- Mice during Experimental Periodontal Disease.
other	hsa-mir-146a	Periodontal Diseases	27429973	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression  in saliva and their importance as noninvasive markers are questionable.
other	hsa-mir-155	Periodontal Diseases	27429973	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression  in saliva and their importance as noninvasive markers are questionable.
other	hsa-mir-203	Periodontal Diseases	27429973	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression  in saliva and their importance as noninvasive markers are questionable.
other	hsa-mir-21	Periodontal Diseases	25203845	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	microRNA-21 mediates stretch-induced osteogenic differentiation in human periodontal ligament stem cells.
other	hsa-mir-223	Periodontal Diseases	27429973	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	In conclusion, five miRNAs have consistently been reported for periodontitis; however, their disease specificity, detectability, and expression  in saliva and their importance as noninvasive markers are questionable.
other	hsa-mir-17	Periodontitis	21898695	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	MiR-17 Modulates Osteogenic Differentiation Through a Coherent Feed-Forward Loop in Mesenchymal Stem Cells Isolated from Periodontal Ligaments of Patients With Periodontitis.
other	hsa-mir-21	Peripheral Nerve Injury	25484256				D059348			miR-21 and miR-222 inhibited neuronal apoptosis at least partially through suppressing TIMP3 after peripheral nerve injury.
other	hsa-mir-222	Peripheral Nerve Injury	25484256				D059348			miR-21 and miR-222 inhibited neuronal apoptosis at least partially through suppressing TIMP3 after peripheral nerve injury.
other	hsa-mir-425	Peripheral Vascular Disease	27132035	cardiovascular system disease	DOID:341	I73.9	D016491			After NaAsO2 treatment, we found the expression of microRNA-425-5p (miR-425-5p) was reduced in vitro and in vivo
other	hsa-let-7d	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-100	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-107	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-129	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-132	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-136	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-146b	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-148a	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-152	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-15a	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-15b	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-160	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-192	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-193a	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-193b	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-194	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-200a	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-200b	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-203	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-205	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-21	Peritoneal Dialysis Failure	28495592			T85.71				miR-21 Promotes Fibrogenesis in Peritoneal Dialysis.
other	hsa-mir-26b	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-29b	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-30a	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-30b	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-31	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-335	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-497	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-664	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-703	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-709	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-801	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-923	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-mir-93	Peritoneal Dialysis Failure	26495316			T85.71				microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.
other	hsa-let-7	Perlman Syndrome	24141620	syndrome	DOID:0060476		C536399	267000		Mammalian DIS3L2 exoribonuclease targets the uridylated precursors of let-7 miRNAs.
other	hsa-let-7	Perlman Syndrome	27498873	syndrome	DOID:0060476		C536399	267000		we found that Dis3l2 specifically recognizes and degrades uridylated pre-let-7 microRNA
other	hsa-mir-17	Perlman Syndrome	26598317	syndrome	DOID:0060476		C536399	267000		Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia.
other	hsa-mir-18	Perlman Syndrome	26598317	syndrome	DOID:0060476		C536399	267000		Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia.
other	hsa-mir-19a	Perlman Syndrome	26598317	syndrome	DOID:0060476		C536399	267000		Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia.
other	hsa-mir-19b-1	Perlman Syndrome	26598317	syndrome	DOID:0060476		C536399	267000		Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia.
other	hsa-mir-20a	Perlman Syndrome	26598317	syndrome	DOID:0060476		C536399	267000		Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia.
other	hsa-mir-92-1	Perlman Syndrome	26598317	syndrome	DOID:0060476		C536399	267000		Our findings not only provide a novel insight into the molecular mechanisms of macrosomia, but also the clinical value of miR-17-92 cluster as a predictive biomarker for macrosomia.
other	hsa-mir-126a	Persistent Fetal Circulation Syndrome	28148930	cardiovascular system disease	DOID:13042	P29.3	D010547	265380	HP:0011726	MiR-126a-5p is involved in the hypoxia-induced endothelial-to-mesenchymal transition of neonatal pulmonary hypertension.
other	hsa-mir-101	Pheochromocytoma	25973039			C74.10	D010673	171300	HP:0002666	Role of miR-101 in pheochromocytoma patients with SDHD mutation.
other	hsa-mir-183	Pheochromocytoma	23660872			C74.10	D010673	171300	HP:0002666	We demonstrated that miR-183 and/or miR-96 impede NGF-induced differentiation in PC12 cells.
other	hsa-mir-96	Pheochromocytoma	23660872			C74.10	D010673	171300	HP:0002666	We demonstrated that miR-183 and/or miR-96 impede NGF-induced differentiation in PC12 cells.
other	hsa-mir-106b	Pituitary Adenoma	28288092	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT.
other	hsa-mir-185	Pituitary Adenoma	26036598	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	MiR-185 enhanced the cell proliferation and inhibited the apoptosis of GH3 cells.
other	hsa-mir-21	Pituitary Adenoma	22222153	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	We speculated the mechanism of miR-21 is involved in tumorigenesis, leading to improvements in therapies and prevention of metastasis.
other	hsa-mir-26a-1	Pituitary Adenoma	23525216	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-26a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase C
other	hsa-mir-26a-2	Pituitary Adenoma	23525216	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-26a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase C
other	hsa-let-7a-1	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7a: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7a-2	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7a: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7a-3	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7a: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7b	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7b: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7c	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7c: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7d	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7d: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7e	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7e: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7f-1	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7f: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7f-2	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7f: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7g	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7g: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-let-7i	Pituitary Neoplasms	19136928	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	let-7i: Overexpression of HMGA2 relates to reduction of the let-7
other	hsa-mir-106b	Pituitary Neoplasms	25862551	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Our results suggest microRNA involvement in malignant pituitary progression, whereby increased miR-20a, miR-106b and miR-17-5p promote metastasis by attenuating PTEN and TIMP2 in pituitary carcinoma.
other	hsa-mir-17	Pituitary Neoplasms	25862551	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Our results suggest microRNA involvement in malignant pituitary progression, whereby increased miR-20a, miR-106b and miR-17-5p promote metastasis by attenuating PTEN and TIMP2 in pituitary carcinoma.
other	hsa-mir-20a	Pituitary Neoplasms	25862551	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Our results suggest microRNA involvement in malignant pituitary progression, whereby increased miR-20a, miR-106b and miR-17-5p promote metastasis by attenuating PTEN and TIMP2 in pituitary carcinoma.
other	hsa-let-7a	Pleural Mesothelioma	25756049	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma.
other	hsa-mir-125a	Pleural Mesothelioma	25756049	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma.
other	hsa-mir-145	Pleural Mesothelioma	24240684	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
other	hsa-mir-193a	Pleural Mesothelioma	26125439	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
other	hsa-mir-21	Pleural Mesothelioma	25497279	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients.
other	hsa-mir-21	Pleural Mesothelioma	28125734	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	MiR-21-5p is suggested as novel regulator of MSLN with a possible functional role in cellular growth
other	hsa-mir-221	Pleural Mesothelioma	25497279	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients.
other	hsa-mir-222	Pleural Mesothelioma	25497279	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients.
other	hsa-mir-223	Pleural Mesothelioma	25824152	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.
other	hsa-mir-23a	Pleural Mesothelioma	25497279	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients.
other	hsa-mir-30e	Pleural Mesothelioma	25497279	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients.
other	hsa-mir-31	Pleural Mesothelioma	25497279	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	a novel 6-microRNA signature (miR-Score) that can accurately predict prognosis of MPM patients.
other	hsa-mir-320	Pleural Mesothelioma	25756049	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma.
other	hsa-mir-34b	Pleural Mesothelioma	24553485	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
other	hsa-mir-34c	Pleural Mesothelioma	24553485	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
other	hsa-mir-484	Pleural Mesothelioma	25756049	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion. These studies may be particularly helpful in patients who reside in a region with a high incidence of mesothelioma.
other	hsa-mir-146a	Pneumonia	26984146	respiratory system disease	DOID:552	J18.9	D011014		HP:0002090	pneumococci recognition induces  a negative feedback loop, preventing excessive inflammation via miR-146a and potentially other miRNAs.
other	hsa-mir-17	Polycystic Kidney Disease	23759744			Q61.19	D007690	PS173900	HP:0000113	miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease.
other	hsa-mir-17	Polycystic Kidney Disease	27512774			Q61.19	D007690	PS173900	HP:0000113	One of the mechanisms through which the miR-17~92 cluster aggravates to cyst growth is by promoting proliferation of the cyst epithelial cells.
other	hsa-mir-18a	Polycystic Kidney Disease	23759744			Q61.19	D007690	PS173900	HP:0000113	miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease.
other	hsa-mir-193b	Polycystic Kidney Disease	28077374			Q61.19	D007690	PS173900	HP:0000113	Expression of ErbB4 in vivo was increased in human ADPKD and Pkd1 cystic kidneys, both transcriptionally and posttranscriptionally by mir-193b-3p
other	hsa-mir-19a	Polycystic Kidney Disease	23759744			Q61.19	D007690	PS173900	HP:0000113	miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease.
other	hsa-mir-19b-1	Polycystic Kidney Disease	23759744			Q61.19	D007690	PS173900	HP:0000113	miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease.
other	hsa-mir-20a	Polycystic Kidney Disease	23759744			Q61.19	D007690	PS173900	HP:0000113	miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease.
other	hsa-mir-92a-1	Polycystic Kidney Disease	23759744			Q61.19	D007690	PS173900	HP:0000113	miR-17-92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease.
other	hsa-mir-103	Polycystic Ovarian Syndrome	24037889	syndrome	DOID:11612	E28.2	D011085	184700		The present results suggest that miRNAs that play an important role in metabolic and immune system processes are influenced by obesity and circulating androgen concentrations.
other	hsa-mir-155	Polycystic Ovarian Syndrome	24037889	syndrome	DOID:11612	E28.2	D011085	184700		The present results suggest that miRNAs that play an important role in metabolic and immune system processes are influenced by obesity and circulating androgen concentrations.
other	hsa-mir-21	Polycystic Ovarian Syndrome	24037889	syndrome	DOID:11612	E28.2	D011085	184700		The present results suggest that miRNAs that play an important role in metabolic and immune system processes are influenced by obesity and circulating androgen concentrations.
other	hsa-mir-27b	Polycystic Ovarian Syndrome	24037889	syndrome	DOID:11612	E28.2	D011085	184700		The present results suggest that miRNAs that play an important role in metabolic and immune system processes are influenced by obesity and circulating androgen concentrations.
other	hsa-mir-21	Polycythemia Vera	28522758	hematopoietic system disease	DOID:8997	D45	D011087	263300		Decreased CAT results from hypoxia-induced miR-21 that downregulates CAT
other	hsa-mir-222	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
other	hsa-mir-339	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		biphasic regulation
other	hsa-mir-378a	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
other	hsa-mir-181	Porcine Reproductive and Respiratory Syndrome Virus Infection	23152505							As expected, miR-181 and other potential PRRSV-targeting miRNAs (such as miR-206) are expressed much more abundantly in minimally permissive cells or tissues than in highly permissive cells or tissues.
other	hsa-mir-26b	Posterior Capsule Opacification	25063219			H26.40	D058442			MiRNA-26b inhibits the proliferation, migration, and epithelial-mesenchymal transition of lens epithelial cells.
other	hsa-mir-1	Preeclampsia	28466998	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Cardiac remodelling and preeclampsia: an overview of overlapping miRNAs.
other	hsa-mir-155	Preeclampsia	28471953	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Association of microRNA-155, interleukin 17A, and proteinuria in preeclampsia.
other	hsa-mir-195	Preeclampsia	28466998	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Cardiac remodelling and preeclampsia: an overview of overlapping miRNAs.
other	hsa-mir-210	Preeclampsia	21388516	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Elevated levels of hypoxia-inducible microRNA-210 in preeclampsia.
other	hsa-mir-210	Preeclampsia	22840297	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MIR-210 modulates mitochondrial respiration in placenta with preeclampsia.
other	hsa-mir-210	Preeclampsia	27529341	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Some of the most frequently differentially expressed miRs in PE include  miR-210, miR-223 and miR-126/126* which associate strongly with the etiological domains of hypoxia, immunology and angiogenesis.
other	hsa-mir-210	Preeclampsia	27683514	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Predictive value of miR-210 as a novel biomarker for pre-eclampsia: a systematic review protocol.
other	hsa-mir-210	Preeclampsia	27746364	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Evaluation of MicroRNA-210 and Protein tyrosine phosphatase, non-receptor type 2 in Pre-eclampsia.
other	hsa-mir-22	Preeclampsia	28193709	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Testosterone Represses Estrogen Signaling by Upregulating miR-22: A Mechanism for Imbalanced Steroid Hormone Production in Preeclampsia.
other	hsa-mir-29b	Preeclampsia	28466998	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Cardiac remodelling and preeclampsia: an overview of overlapping miRNAs.
other	hsa-mir-29b-1	Preeclampsia	22716646	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MicroRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells.
other	hsa-mir-29b-2	Preeclampsia	22716646	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MicroRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells.
other	hsa-mir-34a	Preeclampsia	24081307	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The results support a role for miR-34a in the pathophysiology of preeclampsia, through deregulation of the pri-miRNA expression and its altered maturation.
other	hsa-mir-494	Preeclampsia	25660325	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	we report an unrecognized mechanism of miR-494 affecting dMSC proliferation and function in the pathology of PE.
other	hsa-mir-942	Preeclampsia	28287888	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MiR-942 decreased before 20 weeks gestation in women with preeclampsia and was associated with the pathophysiology of preeclampsia in vitro.
other	hsa-let-7a	Pregnancy Complications [unspecific]	25965838				D011248			For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays.
other	hsa-mir-132	Pregnancy Complications [unspecific]	25965838				D011248			For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays.
other	hsa-mir-146a	Pregnancy Complications [unspecific]	25965838				D011248			For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays.
other	hsa-mir-155	Pregnancy Complications [unspecific]	25965838				D011248			For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays.
other	hsa-mir-16	Pregnancy Complications [unspecific]	25965838				D011248			For samples measured preconception, ROC curve analysis demonstrated AUC 0.81 for adverse pregnancy outcome. Maternal PBMC microRNA can identify high-risk patients likely to benefit from immunotherapy with improved sensitivity and specificity compared with standard immune assays.
other	hsa-mir-4286	Pregnancy Complications [unspecific]	26418635				D011248			The findings highlight miRNAs in the human cervix as novel responders to maternal chemical exposure during pregnancy.
other	hsa-mir-575	Pregnancy Complications [unspecific]	26418635				D011248			The findings highlight miRNAs in the human cervix as novel responders to maternal chemical exposure during pregnancy.
other	hsa-mir-133a	Preterm Labor	27452435			O60	D007752			IAI is associated with a transcriptional signature consistent with acute inflammation in the villous trophoblast.
other	hsa-mir-143	Preterm Labor	28596604			O60	D007752			miR-143 and miR-145 disrupt the cervical epithelial barrier through dysregulation of cell adhesion, apoptosis and proliferation.
other	hsa-mir-145	Preterm Labor	28596604			O60	D007752			miR-143 and miR-145 disrupt the cervical epithelial barrier through dysregulation of cell adhesion, apoptosis and proliferation.
other	hsa-mir-18a	Preterm Labor	27452440			O60	D007752			MALP-2 did not cause apoptosis but did lead to significant secretion of IL-4, IL-6, and IL-8 (P < 0.05, 0.01, 0.001, respectively) and significant changes in miRNA-320a and miRNA-18a (P < 0.05).
other	hsa-mir-139	Primary Biliary Cirrhosis	27668889	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis.
other	hsa-mir-146a	Prion Diseases	22363497	nervous system disease	DOID:649	A81.9	D017096			MicroRNA 146a (miR-146a) Is Over-Expressed during Prion Disease and Modulates the Innate Immune Response and the Microglial Activation State.
other	hsa-let-7a	Prostate Neoplasms	26415820	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
other	hsa-let-7a-1	Prostate Neoplasms	21148031	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	RPS2 control let-7a expression in human prostate cancer.
other	hsa-let-7c	Prostate Neoplasms	19372056	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We hypothesize that miR-let7c, miR-100, and miR-218 may be involved in the process of metastasization of PC, and their role as controllers of the expression of RAS, c-myc, Laminin 5 β3, THAP2, SMARCA5, and BAZ2A should be matter of additional studies.
other	hsa-let-7d	Prostate Neoplasms	21548940	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	PBX3 is up-regulated in prostate cancer and post- transcriptionally regulated by androgen through Let-7d.
other	hsa-mir-1	Prostate Neoplasms	24222130	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In 22Rv1 cells, all AR isoforms were co-regulated by the cytoprotective factor HSPB1 and the tumor suppressor miR-1. Notably, our data provide evidence that HSPB1 inhibition is able to target expression of long as well as of short AR isoforms.
other	hsa-mir-1	Prostate Neoplasms	24391925	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Coordinate microRNA-mediated regulation of protein complexes in prostate cancer.
other	hsa-mir-1	Prostate Neoplasms	24982356	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Heat-shock protein HSPB1 attenuates microRNA miR-1 expression thereby restoring oncogenic pathways in prostate cancer cells.
other	hsa-mir-100	Prostate Neoplasms	21212412	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-99 family of microRNAs suppresses the expression of prostate specific antigen and prostate cancer cell proliferation.
other	hsa-mir-100	Prostate Neoplasms	19372056	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We hypothesize that miR-let7c, miR-100, and miR-218 may be involved in the process of metastasization of PC, and their role as controllers of the expression of RAS, c-myc, Laminin 5 β3, THAP2, SMARCA5, and BAZ2A should be matter of additional studies.
other	hsa-mir-100	Prostate Neoplasms	23503652	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.
other	hsa-mir-101	Prostate Neoplasms	26067553	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	RLIP76-dependent suppression of PI3K/AKT/Bcl-2 pathway by miR-101 induces apoptosis in prostate cancer.
other	hsa-mir-101-1	Prostate Neoplasms	19285253	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-101: decrease of miR-101 leads to the overexpression of EZH2
other	hsa-mir-101-1	Prostate Neoplasms	21430074	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Enforced Expression of miR-101 inhibits prostate cancer cell growth by modulating cyclooxygenase-2 pathway in vivo.
other	hsa-mir-101-2	Prostate Neoplasms	19285253	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-101: decrease of miR-101 leads to the overexpression of EZH2
other	hsa-mir-101-2	Prostate Neoplasms	21430074	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Enforced Expression of miR-101 inhibits prostate cancer cell growth by modulating cyclooxygenase-2 pathway in vivo.
other	hsa-mir-106b	Prostate Neoplasms	24135225	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25.
other	hsa-mir-1227	Prostate Neoplasms	24091630	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Large oncosomes enhanced migration of cancer-associated fibroblasts (CAFs), an effect that was increased by miR-1227, a miRNA abundant in large oncosomes produced by RWPE-2 cells. 
other	hsa-mir-124	Prostate Neoplasms	25115393	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.
other	hsa-mir-124	Prostate Neoplasms	24913567	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	It was clear that PACE4 level was closely associated with malignancy and invasiveness of PCa in vivo or in vitro MiR-124, played a crucial role inhibiting PACE4 transcription thus exhibiting obvious effects of antiproliferation and antiaggression of PCa.
other	hsa-mir-125b	Prostate Neoplasms	25597828	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies.
other	hsa-mir-125b	Prostate Neoplasms	26544868	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Thus, the dual action of hsa-miR-125b as a tumor suppressor and hsa-miR-22 as an oncomiR contributed to prostate tumorigenesis by modulations in PI3K/AKT and MAPK/ERK signaling pathways, key pathways known to influence prostate cancer progression.
other	hsa-mir-125b	Prostate Neoplasms	27305142	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles.
other	hsa-mir-125b	Prostate Neoplasms	18056640	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results suggest that miR-125b acts as an oncogene, contributing to the pathogenesis of CaP.
other	hsa-mir-125b	Prostate Neoplasms	23503652	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.
other	hsa-mir-126	Prostate Neoplasms	25462564	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The regulation of these factors by miR-126 and miR-149 is essential for syndecan-1-mediated development of androgen-refractory prostate cancer.
other	hsa-mir-126	Prostate Neoplasms	21980368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis
other	hsa-mir-1290	Prostate Neoplasms	25129854	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
other	hsa-mir-1296	Prostate Neoplasms	20332239	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer
other	hsa-mir-130b	Prostate Neoplasms	20875868	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-130b:The hsa-miR-130b also shows a high variance between samples.
other	hsa-mir-130b	Prostate Neoplasms	24715691	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition to downregulation of the large tumor suppressor homolog2 and the programmed cell death protein 4, a neoplastic transformation inhibitor, the tumorigenic reprogramming of pASCs was associated with trafficking by PC cell-derived exosomes of oncogenic factors, including H-ras and K-ras transcripts, oncomiRNAs  miR-125b, miR-130b, and miR-155 as well as the Ras superfamily of GTPases Rab1a,  Rab1b, and Rab11a.
other	hsa-mir-130b	Prostate Neoplasms	20890088	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We recommend using hsa-miR-130b or the geometric mean of hsa-miR-130b and small RNA RNU6-2 for normalization in miRNA expression studies of prostate cancer.
other	hsa-mir-133a	Prostate Neoplasms	26089375	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer.
other	hsa-mir-133b	Prostate Neoplasms	24610824	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-133b might enhance tumor-promoting properties in less aggressive LNCaP cells, whereas this miR may act as a tumor suppressor in more aggressive PC-3 cells. miR-133b and RB1CC1 were independent prognostic indicators for prostate cancer.
other	hsa-mir-138	Prostate Neoplasms	25116803	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	伪-solanine downregulates oncogenic microRNA-21 (miR-21) and upregulates tumor suppressor miR-138 expression.
other	hsa-mir-141	Prostate Neoplasms	24195675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Sensitive detection of microRNA in complex biological samples via enzymatic signal amplification using DNA polymerase coupled with nicking endonuclease.
other	hsa-mir-141	Prostate Neoplasms	21723797	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-141 demonstrated high correlation with changes of the other biomarkers.
other	hsa-mir-141	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-143	Prostate Neoplasms	21647377	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRs-143 and -145 are associated with bone metastasis of prostate cancer and involved in the regulation of EMT.
other	hsa-mir-143	Prostate Neoplasms	22505520	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The authors experientially validated the miRNA-KLK interaction by transfecting miR-331-3p and miR-143 into a PCa cell line.
other	hsa-mir-143	Prostate Neoplasms	22948942	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells.
other	hsa-mir-143	Prostate Neoplasms	23321517	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer
other	hsa-mir-143	Prostate Neoplasms	22929553	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Several miRNAs such as miR-96, miR-182, and miR-143 demonstrated high influence on their target protein complexes and could explain most of the gene expression changes in our analyzed prostate cancer data set.
other	hsa-mir-145	Prostate Neoplasms	25969144	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.
other	hsa-mir-145	Prostate Neoplasms	26089375	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer.
other	hsa-mir-145	Prostate Neoplasms	26415820	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
other	hsa-mir-145	Prostate Neoplasms	26582710	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Re: A Feedback Regulation between miR-145 and DNA Methyltransferase 3b in Prostate Cancer Cell and Their Responses to Irradiation.
other	hsa-mir-145	Prostate Neoplasms	19996289	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-145 and miR-331-3p are predicted to target 3 of the 20 hub genes
other	hsa-mir-145	Prostate Neoplasms	21360565	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer.
other	hsa-mir-145	Prostate Neoplasms	21647377	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRs-143 and -145 are associated with bone metastasis of prostate cancer and involved in the regulation of EMT.
other	hsa-mir-145	Prostate Neoplasms	21980368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis
other	hsa-mir-145	Prostate Neoplasms	22948942	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells.
other	hsa-mir-145	Prostate Neoplasms	23404342	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR-145
other	hsa-mir-145	Prostate Neoplasms	28641312	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
other	hsa-mir-145	Prostate Neoplasms	28843521	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Curcumin suppresses proliferation and in vitro invasion of human prostate cancer stem cells by ceRNA effect of miR-145 and lncRNA-ROR.
other	hsa-mir-146a	Prostate Neoplasms	21980038	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Microdissected epithelial structures with CgA-positive cell clusters exhibited a more than 5- and 7-fold lower expression of miR-146a and miR-146b-5p than their CgA-negative counterparts. As focal basal cell layer disruptions and the reduction or loss of miR-146a and miR-146b-5p has been documented to correlate with prostate tumor invasion and hormone refractoriness, our findings suggest that aberrant CgA expression in epithelial structures with FBCLD may represent an early sign of these events.
other	hsa-mir-146b	Prostate Neoplasms	27273955	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-146b acts as a potential tumor suppressor in human prostate cancer.
other	hsa-mir-146b	Prostate Neoplasms	24301753	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	After Gene Set Functional Similarity analysis, we obtained 20 abnormal PC-related candidate miRNAs, including hsa-miR-26a, hsa-miR-152, hsa-miR-19a, hsa-miR-30c, hsa-miR-19b, and hsa-miR-146b-5p, among others.
other	hsa-mir-148a	Prostate Neoplasms	24337069	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing.
other	hsa-mir-148a	Prostate Neoplasms	26843836	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	decreased expressions of tumor suppressors: miR-34a, miR-143, miR-148a and miR-200 family are involved in  resistance of anti-cancer drugs
other	hsa-mir-149	Prostate Neoplasms	25462564	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The regulation of these factors by miR-126 and miR-149 is essential for syndecan-1-mediated development of androgen-refractory prostate cancer.
other	hsa-mir-150	Prostate Neoplasms	25778313	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-150 is a factor of survival in prostate cancer patients.
other	hsa-mir-151a	Prostate Neoplasms	22928040	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Genistein Suppresses Prostate Cancer Growth through Inhibition of Oncogenic MicroRNA-151.
other	hsa-mir-151b	Prostate Neoplasms	22928040	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Genistein Suppresses Prostate Cancer Growth through Inhibition of Oncogenic MicroRNA-151.
other	hsa-mir-152	Prostate Neoplasms	25004396	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1.
other	hsa-mir-154	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-155	Prostate Neoplasms	25283513	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer.
other	hsa-mir-16	Prostate Neoplasms	24391925	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Coordinate microRNA-mediated regulation of protein complexes in prostate cancer.
other	hsa-mir-16	Prostate Neoplasms	25750034	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	This study highlights that commonly used endogenous controls can be responsive to radiation and validation is required prior to gene/miRNAs expression studies.
other	hsa-mir-16	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-16	Prostate Neoplasms	27305142	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles.
other	hsa-mir-16-1	Prostate Neoplasms	21539977	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score.
other	hsa-mir-16-1	Prostate Neoplasms	21980368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis
other	hsa-mir-16-2	Prostate Neoplasms	21539977	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score.
other	hsa-mir-16-2	Prostate Neoplasms	21980368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis
other	hsa-mir-17	Prostate Neoplasms	21203553	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-17* Suppresses Tumorigenicity of Prostate Cancer by Inhibiting Mitochondrial Antioxidant Enzymes.
other	hsa-mir-17	Prostate Neoplasms	19771525	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection.
other	hsa-mir-182	Prostate Neoplasms	19267923	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-182: with high analytical sensitivity and specificity
other	hsa-mir-182	Prostate Neoplasms	26870290	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	mangiferin inhibited proliferation and induced apoptosis in PC3 human prostate cancer cells, and this effect was correlated with downregulation of Bcl-2 and upregulation of miR-182.
other	hsa-mir-182	Prostate Neoplasms	22929553	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Several miRNAs such as miR-96, miR-182, and miR-143 demonstrated high influence on their target protein complexes and could explain most of the gene expression changes in our analyzed prostate cancer data set.
other	hsa-mir-183	Prostate Neoplasms	25409297	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers.
other	hsa-mir-183	Prostate Neoplasms	25556023	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the regulation of prostate-specific antigen and may eventually affect clinical decision making in prostate cancer.
other	hsa-mir-185	Prostate Neoplasms	23951060	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.
other	hsa-mir-18a	Prostate Neoplasms	26415820	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
other	hsa-mir-191	Prostate Neoplasms	26078486	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results proved miR-191 to be the most stable gene, showing the lowest degree of variation and the highest stability value.miR-25 and SNORD48 values fell beyond the cutoff of acceptability. In conclusion,we recommend the use of miR-191 for normalization purposes in post-DRE urine sediments.
other	hsa-mir-193a	Prostate Neoplasms	22438885	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-193a-3p and miRPlus-E1245 observed to be specific to XMRV infection in all 4 cell types (Two prostate cell lines (LNCaP and DU145) and two primary cells).
other	hsa-mir-193a	Prostate Neoplasms	29216925	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
other	hsa-mir-195	Prostate Neoplasms	21539977	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score.
other	hsa-mir-19b	Prostate Neoplasms	27305142	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles.
other	hsa-mir-200	Prostate Neoplasms	24193225	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model.
other	hsa-mir-200b	Prostate Neoplasms	24391862	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-200b inhibits prostate cancer EMT, growth and metastasis.
other	hsa-mir-200b	Prostate Neoplasms	25597828	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies.
other	hsa-mir-200b	Prostate Neoplasms	24337069	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing.
other	hsa-mir-200b	Prostate Neoplasms	23389960	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Down-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells
other	hsa-mir-200c	Prostate Neoplasms	25363395	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism.
other	hsa-mir-200c	Prostate Neoplasms	25597828	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies.
other	hsa-mir-200c	Prostate Neoplasms	24646496	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Words of wisdom: Re: TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c.
other	hsa-mir-200c	Prostate Neoplasms	21431706	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Differentially expressed between androgen-dependent and androgen-independent metastatic prostate cancer cells
other	hsa-mir-200c	Prostate Neoplasms	23041061	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205
other	hsa-mir-203	Prostate Neoplasms	25004126	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.
other	hsa-mir-203	Prostate Neoplasms	25409297	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers.
other	hsa-mir-203	Prostate Neoplasms	21159887	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-203 expression is specifically attenuated in bone metastatic prostate cancer suggesting a fundamental anti-metastatic role for this miRNA
other	hsa-mir-203	Prostate Neoplasms	21368580	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines.
other	hsa-mir-203	Prostate Neoplasms	26976978	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	increase of miR-203 expression after ZA exposure
other	hsa-mir-204	Prostate Neoplasms	27438705	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	It is believed that miR-204 acts as a tumor-suppressor via promoting apoptosis, conferring the resistance of cancer cells to chemotherapy, and suppressing the self-renewal of cancer stem cells (CSCs) and the epithelial to mesenchymal transition (EMT).
other	hsa-mir-204	Prostate Neoplasms	29228612	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway
other	hsa-mir-205	Prostate Neoplasms	24370341	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells.
other	hsa-mir-205	Prostate Neoplasms	25409297	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers.
other	hsa-mir-205	Prostate Neoplasms	19244118	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-205: miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon
other	hsa-mir-205	Prostate Neoplasms	21431706	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Differentially expressed between androgen-dependent and androgen-independent metastatic prostate cancer cells
other	hsa-mir-205	Prostate Neoplasms	21980368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis
other	hsa-mir-205	Prostate Neoplasms	23041061	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205
other	hsa-mir-205	Prostate Neoplasms	27305142	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles.
other	hsa-mir-205	Prostate Neoplasms	20737563	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer.
other	hsa-mir-205	Prostate Neoplasms	21368878	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.
other	hsa-mir-205	Prostate Neoplasms	22815235	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Additionally, for two genes that are deregulated in PCa (heterogeneous nuclear ribonucleoprotein K, hnRNP-K, and vascular endothelial growth factor A, VEGF-A), we identified two regulatory miRNAs, miR-205 and miR-29b.
other	hsa-mir-208	Prostate Neoplasms	26032092	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation.
other	hsa-mir-20a	Prostate Neoplasms	24337069	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing.
other	hsa-mir-21	Prostate Neoplasms	25409297	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers.
other	hsa-mir-21	Prostate Neoplasms	19267923	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-21: with high analytical sensitivity and specificity
other	hsa-mir-21	Prostate Neoplasms	19597470	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	acts as tumor suppressor and induces apoptosis of tumor cells through E2F1-mediated suppression of Akt phosphorylation
other	hsa-mir-21	Prostate Neoplasms	20092645	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	oncogenic properties of miR-21 could be cell and tissue dependent
other	hsa-mir-21	Prostate Neoplasms	20160498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer
other	hsa-mir-21	Prostate Neoplasms	23272133	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Resveratrol Reduces Prostate Cancer Growth and Metastasis by Inhibiting the Akt/MicroRNA-21 Pathway
other	hsa-mir-21	Prostate Neoplasms	23353719	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases
other	hsa-mir-21	Prostate Neoplasms	25116803	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	伪-solanine downregulates oncogenic microRNA-21 (miR-21) and upregulates tumor suppressor miR-138 expression.
other	hsa-mir-21	Prostate Neoplasms	28467474	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.
other	hsa-mir-210	Prostate Neoplasms	25091736	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Senescent stroma promotes prostate cancer progression: the role of miR-210.
other	hsa-mir-210	Prostate Neoplasms	28693582	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
other	hsa-mir-212	Prostate Neoplasms	26439987	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In conclusion, our study indicates a functional role of miR-212 in PCa and suggests the development of miR-212 based therapies.
other	hsa-mir-218	Prostate Neoplasms	26415820	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
other	hsa-mir-218	Prostate Neoplasms	19372056	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We hypothesize that miR-let7c, miR-100, and miR-218 may be involved in the process of metastasization of PC, and their role as controllers of the expression of RAS, c-myc, Laminin 5 β3, THAP2, SMARCA5, and BAZ2A should be matter of additional studies.
other	hsa-mir-22	Prostate Neoplasms	26052614	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.
other	hsa-mir-210	Prostate Neoplasms	25846647	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Treatment with MIB led to an induction of miR-210 expression, a hypoxia-related miRNA
other	hsa-mir-221	Prostate Neoplasms	26164758	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells.
other	hsa-mir-221	Prostate Neoplasms	25846647	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	This observation indicates that this miRNA may have a more complex role in prostate cancer development than considered previously.Thus examining the effect of androgen receptor (AR) agonists and antagonists on miRNA expression can provide novel insights into the response of cells to androgen receptor (AR) ligands and subsequent downstream events.
other	hsa-mir-221	Prostate Neoplasms	19267923	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221: with high analytical sensitivity and specificity
other	hsa-mir-221	Prostate Neoplasms	23353719	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases
other	hsa-mir-221	Prostate Neoplasms	29281088	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Combining radiation dose parameters with microRNA expression in PBLs  may be useful for predicting acute gastrointestinal toxicity of radiation therapy, thus contributing to personalized treatment of prostate cancer
other	hsa-mir-222	Prostate Neoplasms	26164758	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells.
other	hsa-mir-222	Prostate Neoplasms	19267923	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-222: with high analytical sensitivity and specificity
other	hsa-mir-222	Prostate Neoplasms	23353719	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases
other	hsa-mir-223	Prostate Neoplasms	26552919	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells, and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines. We thus provide a novel way to increase celastrol's anti-cancer effects.
other	hsa-mir-23a	Prostate Neoplasms	26110567	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	By inhibiting snail signaling and miR-23a-3p, osthole suppresses the EMT-mediated metastatic ability in prostate cancer.
other	hsa-mir-23b	Prostate Neoplasms	25115396	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer.
other	hsa-mir-23b	Prostate Neoplasms	26415820	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
other	hsa-mir-23b	Prostate Neoplasms	23300597	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The microRNA -23b/-27b Cluster Suppresses the Metastatic Phenotype of Castration-Resistant Prostate Cancer Cells
other	hsa-mir-23c	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-24-1	Prostate Neoplasms	25115396	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer.
other	hsa-mir-25	Prostate Neoplasms	26078486	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results proved miR-191 to be the most stable gene, showing the lowest degree of variation and the highest stability value.miR-25 and SNORD48 values fell beyond the cutoff of acceptability. In conclusion,we recommend the use of miR-191 for normalization purposes in post-DRE urine sediments.
other	hsa-mir-25	Prostate Neoplasms	25372501	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These effects were strongly associated with changes in reduced expression of the miR-106b cluster (miR-106b, miR-93, and miR-25)
other	hsa-mir-25	Prostate Neoplasms	27305142	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiRNAs were shown to be differently distributed between different fractions of extracellular vesicles.
other	hsa-mir-26a-1	Prostate Neoplasms	21539977	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score.
other	hsa-mir-26a-2	Prostate Neoplasms	21539977	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We observed correlations with clinical-pathologic parameters: miR-16, miR-195, and miR-26a were significantly correlated with surgical margin positivity; miR-195 and miR-let7i were significantly correlated with the Gleason score.
other	hsa-mir-27b	Prostate Neoplasms	25115396	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer.
other	hsa-mir-27b	Prostate Neoplasms	23300597	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The microRNA -23b/-27b Cluster Suppresses the Metastatic Phenotype of Castration-Resistant Prostate Cancer Cells
other	hsa-mir-296	Prostate Neoplasms	26415820	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
other	hsa-mir-299	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-29a	Prostate Neoplasms	26052614	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.
other	hsa-mir-29b	Prostate Neoplasms	22815235	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Additionally, for two genes that are deregulated in PCa (heterogeneous nuclear ribonucleoprotein K, hnRNP-K, and vascular endothelial growth factor A, VEGF-A), we identified two regulatory miRNAs, miR-205 and miR-29b.
other	hsa-mir-29b-1	Prostate Neoplasms	22402125	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition Signaling.
other	hsa-mir-29b-2	Prostate Neoplasms	22402125	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition Signaling.
other	hsa-mir-301a	Prostate Neoplasms	25940439	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-β1/Smad/MMP9 signals.
other	hsa-mir-301a	Prostate Neoplasms	26813459	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Taken together, we demonstrated that miR-301a/b-NDRG2 might be an important axis modulating autophagy and viability of prostate cancer cells under hypoxia.
other	hsa-mir-301b	Prostate Neoplasms	26813459	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Taken together, we demonstrated that miR-301a/b-NDRG2 might be an important axis modulating autophagy and viability of prostate cancer cells under hypoxia.
other	hsa-mir-302a	Prostate Neoplasms	25922934	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.
other	hsa-mir-30c	Prostate Neoplasms	24452717	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
other	hsa-mir-30c	Prostate Neoplasms	24301753	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	After Gene Set Functional Similarity analysis, we obtained 20 abnormal PC-related candidate miRNAs, including hsa-miR-26a, hsa-miR-152, hsa-miR-19a, hsa-miR-30c, hsa-miR-19b, and hsa-miR-146b-5p, among others.
other	hsa-mir-30d	Prostate Neoplasms	23231923	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Identification of miR-30d as a novel prognostic maker of prostate cancer
other	hsa-mir-31	Prostate Neoplasms	29364469	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels
other	hsa-mir-31	Prostate Neoplasms	21368878	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.
other	hsa-mir-3176	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-32	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-323	Prostate Neoplasms	26160610	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data demonstrate that miR-323 may increase VEGF-A-mediated cancer vascularization in PC cells through AdipoR1 suppression.
other	hsa-mir-330	Prostate Neoplasms	19597470	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation
other	hsa-mir-331	Prostate Neoplasms	19996289	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-145 and miR-331-3p are predicted to target 3 of the 20 hub genes
other	hsa-mir-331	Prostate Neoplasms	21971048	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The RNA-binding protein HuR opposes the repression of ERBB-2 expression by miR-331-3p in prostate cancer cells.
other	hsa-mir-331	Prostate Neoplasms	22505520	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The authors experientially validated the miRNA-KLK interaction by transfecting miR-331-3p and miR-143 into a PCa cell line.
other	hsa-mir-335	Prostate Neoplasms	26647850	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These findings suggested that miR-335 and -543 are associated with bone metastasis of PCa and indicated that they may have important roles in the bone metastasis, which may also be clinically used as novel biomarkers in discriminating the different stages of human PCa and predicting bone metastasis.
other	hsa-mir-335	Prostate Neoplasms	23456549	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data demonstrated for the first time the inhibitory effect of miR-335 on cell proliferation and invasion for PCa cells
other	hsa-mir-342	Prostate Neoplasms	23951060	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.
other	hsa-mir-34a	Prostate Neoplasms	25053345	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	This study supports the extracellular environment as an important source of minimally invasive predictive biomarkers representing their cellular origin. Using miR-34a as example, we showed that biomarkers identified in this manner may also hold functional relevance.
other	hsa-mir-34a	Prostate Neoplasms	26089375	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer.
other	hsa-mir-34a	Prostate Neoplasms	26231042	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
other	hsa-mir-34a	Prostate Neoplasms	20687223	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-34a:MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms
other	hsa-mir-34a	Prostate Neoplasms	21980368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-16, miR-34a, miR-126*, miR-145, miR-205 have been linked to prostate cancer metastasis
other	hsa-mir-34a	Prostate Neoplasms	22235332	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells.
other	hsa-mir-3654	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-3673	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-373	Prostate Neoplasms	25409297	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs 200b, 30a, 1, and 183 and the genes Twist1 and Vimentin might play important roles in the progression of prostate cancer and may eventually become important prognostic markers.
other	hsa-mir-373	Prostate Neoplasms	25980442	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals.
other	hsa-mir-373	Prostate Neoplasms	21139802	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The oncogenic mi-croRNAs, miR-373 and miR-520c interact with CD44 in Prostate Cancer
other	hsa-mir-373	Prostate Neoplasms	18193036	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Taken together, our findings indicate that miRNAs are involved in tumour migration and invasion, and implicate miR-373 and miR-520c as metastasis-promoting miRNAs.
other	hsa-mir-375	Prostate Neoplasms	25129854	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
other	hsa-mir-375	Prostate Neoplasms	25597828	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	use of a combination of different types of genetic markers in ejaculate together with serum PSA are at least as sensitive as those reported in DRE urine. Furthermore, a combination of serum PSA and selected miRNAs improved prediction of prostate cancer status. This approach may be helpful in triaging patients for MRI and biopsy, when confirmed by larger studies.
other	hsa-mir-375	Prostate Neoplasms	24337069	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing.
other	hsa-mir-375	Prostate Neoplasms	28282880	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice.
other	hsa-mir-376a	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-376c	Prostate Neoplasms	26163549	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.
other	hsa-mir-376c	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-377	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-381	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-381	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-3915	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-409	Prostate Neoplasms	25065597	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis.
other	hsa-mir-424	Prostate Neoplasms	24193225	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model.
other	hsa-mir-424	Prostate Neoplasms	27820701	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression.
other	hsa-mir-429	Prostate Neoplasms	26415820	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
other	hsa-mir-429	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-449a	Prostate Neoplasms	26081756	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Capsaicin causes inactivation and degradation of the androgen receptor by inducing the restoration of miR-449a in prostate cancer.
other	hsa-mir-449a	Prostate Neoplasms	27250340	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Overexpression of miR-449a or knockdown of c-Myc promoted the sensitivity of LNCaP cells to IR.
other	hsa-mir-449b	Prostate Neoplasms	25416653	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	High miR-449b expression was shown to be an independent predictor of biochemical recurrence after radical prostatectomy.
other	hsa-mir-4723	Prostate Neoplasms	24223753	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases.
other	hsa-mir-485	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-487b	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-487b	Prostate Neoplasms	28282880	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice.
other	hsa-mir-488	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-497	Prostate Neoplasms	23886135	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-497 suppresses proliferation and induces apoptosis in prostate cancer cells.
other	hsa-mir-497	Prostate Neoplasms	26415820	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In this review, we focus on the regulation of miRNAs in prostate cancer and their mechanisms which contribute to prostate carcinogenesis. The relation of miRNAs with androgen signaling is highlighted and the prospects of miRNAs for clinical therapies are discussed.
other	hsa-mir-5004	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-513c	Prostate Neoplasms	26089375	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer.
other	hsa-mir-519d	Prostate Neoplasms	21703393	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-519d,and miR-647 could be used to separate patients with and without biochemical recurrence
other	hsa-mir-520c	Prostate Neoplasms	21139802	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The oncogenic mi-croRNAs, miR-373 and miR-520c interact with CD44 in Prostate Cancer
other	hsa-mir-541	Prostate Neoplasms	25135278	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.
other	hsa-mir-543	Prostate Neoplasms	26647850	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These findings suggested that miR-335 and -543 are associated with bone metastasis of PCa and indicated that they may have important roles in the bone metastasis, which may also be clinically used as novel biomarkers in discriminating the different stages of human PCa and predicting bone metastasis.
other	hsa-mir-574	Prostate Neoplasms	23554959	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Genistein Up-Regulates Tumor Suppressor MicroRNA-574-3p in Prostate Cancer
other	hsa-mir-606	Prostate Neoplasms	27278879	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hub hsa-miR3176, -141-3p, -5004-5p, -16-5p, -3915, -488鈥?p, -23c, -3673 and -3654 were potential targets to hub gene androgen receptor (AR) and phosphatase and tensin homolog (PTEN).
other	hsa-mir-630	Prostate Neoplasms	24971999	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
other	hsa-mir-647	Prostate Neoplasms	21703393	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-519d,and miR-647 could be used to separate patients with and without biochemical recurrence
other	hsa-mir-648	Prostate Neoplasms	24618011	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our analysis revealed the scale-free features of the human miRNA-mRNA interaction network and showed the distinctive topological features of existing cancer miRNA biomarkers from previously published studies. A novel cancer miRNA biomarker prediction framework was designed based on these observations and applied to prostate cancer study. This method could be applied for miRNA biomarker prediction in other cancers.
other	hsa-mir-650	Prostate Neoplasms	25956032	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression.
other	hsa-mir-654	Prostate Neoplasms	24166498	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b,miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
other	hsa-mir-663	Prostate Neoplasms	24243035	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence.
other	hsa-mir-708	Prostate Neoplasms	22552290	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNA-708 control of CD44+ prostate cancer initiating cells.
other	hsa-mir-765	Prostate Neoplasms	24837491	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer.
other	hsa-mir-888	Prostate Neoplasms	24200968	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration.
other	hsa-mir-888	Prostate Neoplasms	24457835	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration.
other	hsa-mir-93	Prostate Neoplasms	25372501	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These effects were strongly associated with changes in reduced expression of the miR-106b cluster (miR-106b, miR-93, and miR-25)
other	hsa-mir-96	Prostate Neoplasms	25333253	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Biphasic regulation of autophagy by miR-96 in prostate cancer cells under hypoxia.
other	hsa-mir-96	Prostate Neoplasms	26089375	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that AA-specific/-enriched miRNA-mRNA pairings may play a critical role in the activation of oncogenic pathways in AA prostate cancer. Our findings also suggest that miR-133a/MCL1, miR-513c/STAT1, and miR-96/FOXO3A may have clinical significance in the development of novel strategies for treating aggressive prostate cancer.
other	hsa-mir-96	Prostate Neoplasms	22929553	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Several miRNAs such as miR-96, miR-182, and miR-143 demonstrated high influence on their target protein complexes and could explain most of the gene expression changes in our analyzed prostate cancer data set.
other	hsa-mir-99a	Prostate Neoplasms	25937401	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	A combination of low Ku80 expression and highly-induced miR-99a expression could be a promising marker for predicting rectal bleeding after radiotherapy.
other	hsa-mir-99a	Prostate Neoplasms	21212412	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-99 family of microRNAs suppresses the expression of prostate specific antigen and prostate cancer cell proliferation.
other	hsa-mir-99b	Prostate Neoplasms	21212412	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-99 family of microRNAs suppresses the expression of prostate specific antigen and prostate cancer cell proliferation.
other	hsa-mir-125b	Psoriasis	18853072	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin)
other	hsa-mir-125b	Psoriasis	27479112	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Based on our bioinformatical pipeline, ubiquitin-specific peptidase 2 was selected as a likely candidate for a mechanistic explanation for psoriasis association.
other	hsa-mir-146a	Psoriasis	18853072	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin)
other	hsa-mir-146a	Psoriasis	26559308	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	It is found that genetic polymorphisms related to some of specific miRNAs, miR-146a for example, are associated with psoriasis susceptibility.
other	hsa-mir-146a	Psoriasis	27568078	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis.
other	hsa-mir-146a	Psoriasis	28595995	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in Psoriasis.
other	hsa-mir-146b	Psoriasis	28595995	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in Psoriasis.
other	hsa-mir-155	Psoriasis	28402921	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MiR-155 promotes cell proliferation and inhibits apoptosis by PTEN signaling pathway in the psoriasis.
other	hsa-mir-17	Psoriasis	27579777	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice.
other	hsa-mir-18	Psoriasis	27579777	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice.
other	hsa-mir-193b	Psoriasis	25431026	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	the altered local miRNA changes seen in the RD are reflected in the circulating immune cells, suggesting  that miRNAs may contribute to the pathogenesis of psoriasis.
other	hsa-mir-19a	Psoriasis	24192448	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Our results indicated hair root miR-19a levels are effective as a disease marker.
other	hsa-mir-19a	Psoriasis	27579777	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice.
other	hsa-mir-19b-1	Psoriasis	27579777	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice.
other	hsa-mir-203	Psoriasis	18853072	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin)
other	hsa-mir-20a	Psoriasis	27579777	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice.
other	hsa-mir-21	Psoriasis	18853072	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Recent findings report their involvement in hair follicle morphogenesis (ablation of miRNAs from keratinocytes causes several defects, such as evagination instead of invagination), in psoriasis (skin-specific expression of miR-203 and psoriasisspecific expression of miR-146a, miR-21 and miR-125b in the skin)
other	hsa-mir-21	Psoriasis	23479230	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Mechanistic studies revealed a P2X7R-dependent mir-21 angiogenesis pathway that leads to the expression of vascular endothelial growth factor and IL-6 and that may be involved in the development of psoriatic lesions.
other	hsa-mir-21	Psoriasis	27586798	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	the activation of S100A8/A9-dependent C3 complement as well as a miR-21-dependent TIMP-3/TACE pathway leading to TNF-α shedding
other	hsa-mir-223	Psoriasis	25431026	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	the altered local miRNA changes seen in the RD are reflected in the circulating immune cells, suggesting  that miRNAs may contribute to the pathogenesis of psoriasis.
other	hsa-mir-31	Psoriasis	26138368	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	NF-κB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis.
other	hsa-mir-31	Psoriasis	27405090	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Its own regulation is disrupted during the onset and progression of cancer and autoimmune disorders such as psoriasis and systemic lupus erythematosus.
other	hsa-mir-92-1	Psoriasis	27579777	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice.
other	hsa-mir-424	Psoriatic Arthritis	24628460	syndrome	DOID:9008	L40.5	D015535	607507		miR-424 levels in hair shaft are increased in psoriatic patients.
other	hsa-mir-146a	Psychotic Disorders	23295264			F24	D011618			Down-regulation of inflammation-protective microRNAs 146a and 212 in monocytes of patients with postpartum psychosis
other	hsa-mir-212	Psychotic Disorders	23295264			F24	D011618			Down-regulation of inflammation-protective microRNAs 146a and 212 in monocytes of patients with postpartum psychosis
other	hsa-mir-130	Pulmonary Hypertension	26565914	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.
other	hsa-mir-130	Pulmonary Hypertension	25505270	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	olecular cross-talk among the diverse cellular populations involved in PH.
other	hsa-mir-130a	Pulmonary Hypertension	25681685	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	These data suggest that miRNA family miR-130 plays an important role in the repression of CDKN1A by hypoxia.miR-130 enhances hypoxia-induced smooth muscle proliferation and might be involved in the development of right ventricular hypertrophy and vascular remodeling in pulmonary hypertension.
other	hsa-mir-145	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. 
other	hsa-mir-17	Pulmonary Hypertension	23114789	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	MEX suppressed the hypoxic activation of signal transducer and activator of transcription 3 (STAT3) and the upregulation of the miR-17 superfamily of microRNA clusters, whereas it increased lung levels of miR-204, a key microRNA, the expression of which is decreased in human pulmonary hypertension.
other	hsa-mir-17	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. 
other	hsa-mir-18	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. 
other	hsa-mir-19a	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. 
other	hsa-mir-19b-1	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. 
other	hsa-mir-204	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. 
other	hsa-mir-204	Pulmonary Hypertension	24270264	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	We also showed that PARP-1 activation accounts for miR-204 downregulation (quantitative reverse transcription polymerase chain reaction) and the subsequent activation of the transcription factors nuclear factor of activated T cells and hypoxia-inducible factor 1-伪 in PAH-PASMCs, previously shown to be critical for PAH in several models.
other	hsa-mir-204	Pulmonary Hypertension	25006436	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Novel research shows that miR-204, a microRNA recently found to be notably downregulated through induction  of PARP-1 (poly [ADP-ribose] polymerase 1) by excessive DNA damage in PAH, inhibits activation of STAT3.
other	hsa-mir-204	Pulmonary Hypertension	27438705	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Its pathological functions have been observed in a few diseases including pulmonary arterial hypertension, diabetes, and various types of cancers.
other	hsa-mir-206	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Recent studies demonstrated the role of miR-204 and miR- 206 in pulmonary artery smooth muscle cell (PASMC) proliferation. 
other	hsa-mir-20a	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. 
other	hsa-mir-21	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. 
other	hsa-mir-21	Pulmonary Hypertension	28522568	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Peroxisome proliferator-activated receptor-γ enhances human pulmonary artery smooth muscle cell apoptosis through microRNA-21 and programmed cell death 4.
other	hsa-mir-210	Pulmonary Hypertension	25825391	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension.
other	hsa-mir-223	Pulmonary Hypertension	26084306	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miR-223 reverses experimental pulmonary arterial hypertension.
other	hsa-mir-223	Pulmonary Hypertension	26201953	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	MicroRNAs and PARP: co-conspirators with ROS in pulmonary hypertension. Focus on miR-223 reverses experimental pulmonary arterial hypertension.
other	hsa-mir-223	Pulmonary Hypertension	26815432	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Inhibition of miR-223 did not attenuate MCT PAH, whereas human prostacyclin synthase overexpression restored miRNA levels in MCT PAH to levels detected in naive rats. These data may establish a paradigm linking attenuation of PAH to restoration of BMPR2 signaling.
other	hsa-mir-26a	Pulmonary Hypertension	24328779	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miR-26a linked to pulmonary hypertension by global assessment of circulating extracellular microRNAs.
other	hsa-mir-27a	Pulmonary Hypertension	27612006	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Peroxisome Proliferator-Activated Receptor γ Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung.
other	hsa-mir-301	Pulmonary Hypertension	26565914	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.
other	hsa-mir-301	Pulmonary Hypertension	25505270	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	olecular cross-talk among the diverse cellular populations involved in PH.
other	hsa-mir-451	Pulmonary Hypertension	25006399	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	In conclusion, transient inhibition of miR-451 attenuated the development of PAH in hypoxia-exposed rats.
other	hsa-mir-92-1	Pulmonary Hypertension	23713859	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Other microRNAs, such as miR-145, miR-21 and the miR17/92 cluster, have been associated with the disrupted BMPR2 pathway. 
other	hsa-mir-96	Pulmonary Hypertension	25871906	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Increased 5-HT1BR expression may be a consequence of decreased miRNA-96 expression in female patient human pulmonary artery smooth muscle cell(PASMCs), and this may contribute to the development of pulmonary arterial hypertension (PAH).
other	hsa-mir-143	Rectal Neoplasms	21567082	disease of cellular proliferation	DOID:1984		D012004			Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
other	hsa-mir-145	Rectal Neoplasms	21567082	disease of cellular proliferation	DOID:1984		D012004			Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
other	hsa-mir-153-1	Rectal Neoplasms	22903298	disease of cellular proliferation	DOID:1984		D012004			These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %.
other	hsa-mir-153-2	Rectal Neoplasms	22903298	disease of cellular proliferation	DOID:1984		D012004			These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %.
other	hsa-mir-16-1	Rectal Neoplasms	22903298	disease of cellular proliferation	DOID:1984		D012004			These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %.
other	hsa-mir-16-2	Rectal Neoplasms	22903298	disease of cellular proliferation	DOID:1984		D012004			These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %.
other	hsa-mir-21	Rectal Neoplasms	25496125	disease of cellular proliferation	DOID:1984		D012004			miR-21-5p as a promising predictive biomarker, which should aid in the selection of patients with cCR to nCRT that potentially could be spared from radical surgery.
other	hsa-mir-21	Rectal Neoplasms	21567082	disease of cellular proliferation	DOID:1984		D012004			Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
other	hsa-mir-519c	Rectal Neoplasms	22903298	disease of cellular proliferation	DOID:1984		D012004			These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %.
other	hsa-mir-561	Rectal Neoplasms	22903298	disease of cellular proliferation	DOID:1984		D012004			These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %.
other	hsa-mir-590	Rectal Neoplasms	22903298	disease of cellular proliferation	DOID:1984		D012004			These signatures consisted of three miRNA transcripts (miR-16, miR-590-5p and miR-153) to predict complete vs. incomplete response and two miRNA transcript (miR-519c-3p and miR-561) to predict good vs. poor response with a median accuracy of 100 %.
other	hsa-mir-194	Rectum Adenocarcinoma	28870889	disease of cellular proliferation	DOID:1996	C20				miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.
other	hsa-mir-155	Recurrent Spontaneous Abortion	24739646			O03	D000022			The expression of miR-155 and HIF-1α is topically stimulated by oxygen signal.HIF-1α adjusts the transcription and translation of VEGF, which together involved in placental trophoblast invasion and placental angiogenesis.The low expression of miR-155 could interfere with expression of HIF-1α and VEGF,which might be involved in villous vascular dysplasia in URSA.
other	hsa-mir-106b	Renal Fibrosis	25094038	urinary system disease	DOID:0050855	N26.9			HP:0030760	Expression of miR-106b-25 induced by salvianolic acid B inhibits epithelial-to-mesenchymal transition in HK-2 cells.
other	hsa-mir-21	Renal Fibrosis	21852586	urinary system disease	DOID:0050855	N26.9			HP:0030760	Smad3-Mediated Upregulation of miR-21 Promotes Renal Fibrosis.
other	hsa-mir-21	Renal Fibrosis	22344686	urinary system disease	DOID:0050855	N26.9			HP:0030760	MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways.
other	hsa-mir-21	Renal Fibrosis	26415649	urinary system disease	DOID:0050855	N26.9			HP:0030760	Collectively, these data present a unified model for a key role for miR-21 in the regulation of renal tubular extracellular matrix (ECM) synthesis and accumulation and provide important insights into the molecular pathways implicated in the progression of DN.
other	hsa-mir-21	Renal Fibrosis	23978520	urinary system disease	DOID:0050855	N26.9			HP:0030760	Microvesicle-mediated delivery of miR-21 among tubular epithelial cells might shed new light on the mechanism of progressive renal fibrosis.
other	hsa-mir-214	Renal Fibrosis	24158985	urinary system disease	DOID:0050855	N26.9			HP:0030760	MicroRNA-214 antagonism protects against renal fibrosis.
other	hsa-mir-215	Renal Fibrosis	25565137	urinary system disease	DOID:0050855	N26.9			HP:0030760	MicroRNA-215 Regulates Fibroblast Function: Insights from a Human Fibrotic Disease.
other	hsa-mir-29a	Renal Fibrosis	21784902	urinary system disease	DOID:0050855	N26.9			HP:0030760	TGF-{beta}/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29.
other	hsa-mir-29b-1	Renal Fibrosis	21784902	urinary system disease	DOID:0050855	N26.9			HP:0030760	TGF-{beta}/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29.
other	hsa-mir-29b-2	Renal Fibrosis	21784902	urinary system disease	DOID:0050855	N26.9			HP:0030760	TGF-{beta}/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29.
other	hsa-mir-29c	Renal Fibrosis	26040904	urinary system disease	DOID:0050855	N26.9			HP:0030760	Overall, miR-29c correlated with the degree of renal chronicity but not with renal function, suggesting it could be used as a novel non-invasive marker of early progression to fibrosis in patients with LN.
other	hsa-mir-29c	Renal Fibrosis	21784902	urinary system disease	DOID:0050855	N26.9			HP:0030760	TGF-{beta}/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29.
other	hsa-mir-378	Renal Fibrosis	28053239	urinary system disease	DOID:0050855	N26.9			HP:0030760	miR-378 reduces mesangial hypertrophy and kidney tubular fibrosis via MAPK signalling.
other	hsa-mir-382	Renal Fibrosis	20716515	urinary system disease	DOID:0050855	N26.9			HP:0030760	The study provided experimental evidence in the form of reciprocal expression at the protein level for a large number of predicted miRNA-target pairs and discovered a novel role of miR-382 and SOD2 in the loss of epithelial characteristics induced by TGFβ1.
other	hsa-let-7i	Respiratory Syncytial Virus Pneumonia	23249809	disease by infectious agent	DOID:1273	J12.1	D018357			we found that the RSV nonstructural genes NS1 and NS2 antagonized the upregulation of let-7i and miR-30b
other	hsa-mir-24	Respiratory Syncytial Virus Pneumonia	26253191	disease by infectious agent	DOID:1273	J12.1	D018357			Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β.
other	hsa-mir-30b	Respiratory Syncytial Virus Pneumonia	23249809	disease by infectious agent	DOID:1273	J12.1	D018357			we found that the RSV nonstructural genes NS1 and NS2 antagonized the upregulation of let-7i and miR-30b
other	hsa-mir-425	Respiratory System Disease	29535266	respiratory system disease	DOID:1579	J98				Prader-Willi region non-protein coding RNA 1 suppressed gastric cancer growth as a competing endogenous RNA of miR-425-5p.
other	hsa-mir-200b	Retinal Degeneration	27113191	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	Effect of MiR-200b on retinal endothelial cell function in high-glucose condition and the mechanism.
other	hsa-mir-200b	Retinal Vascular Disease	28882646	nervous system disease	DOID:2462	H35.06			HP:0012841	Protective effect of miR-200b/c by inhibiting vasohibin-2 in human retinal microvascular endothelial cells.
other	hsa-mir-200c	Retinal Vascular Disease	28882646	nervous system disease	DOID:2462	H35.06			HP:0012841	Protective effect of miR-200b/c by inhibiting vasohibin-2 in human retinal microvascular endothelial cells.
other	hsa-let-7a	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-let-7a	Retinoblastoma	21247883	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	E2F4 binding sites also occurred near regulatory elements for miRNAs such as let-7a and mir-17, suggestive of regulation of miRNAs by E2F4. Taken together, our genome-wide analysis provided evidence of versatile roles of E2F4 and insights into its functions.
other	hsa-let-7a-1	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7a-2	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7a-3	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7b	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7b	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-let-7c	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7c	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-let-7d	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7d	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-let-7e	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7e	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-let-7f	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-let-7f-1	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7f-2	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7g	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7g	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-let-7i	Retinoblastoma	20004941	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation,invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
other	hsa-let-7i	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-mir-15a	Retinoblastoma	21454377	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death.
other	hsa-mir-15b	Retinoblastoma	21454377	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death.
other	hsa-mir-16-1	Retinoblastoma	21454377	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death.
other	hsa-mir-16-2	Retinoblastoma	21454377	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	In particular, miRs encoded by the miR-15a, miR-16-1 cluster seem to act as tumor suppressors. Here, we evidence that the miR-15a, miR-16-1 cluster and related miR-15b, miR-16-2 cluster comprise miRs regulated by E2F1, a pivotal transcription factor that can induce both proliferation and cell death.
other	hsa-mir-17	Retinoblastoma	21816922	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.
other	hsa-mir-17	Retinoblastoma	22864477	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.
other	hsa-mir-17	Retinoblastoma	25513843	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells.
other	hsa-mir-17	Retinoblastoma	21247883	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	E2F4 binding sites also occurred near regulatory elements for miRNAs such as let-7a and mir-17, suggestive of regulation of miRNAs by E2F4. Taken together, our genome-wide analysis provided evidence of versatile roles of E2F4 and insights into its functions.
other	hsa-mir-18a	Retinoblastoma	21816922	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.
other	hsa-mir-18a	Retinoblastoma	22864477	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.
other	hsa-mir-18a	Retinoblastoma	25513843	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells.
other	hsa-mir-18a	Retinoblastoma	28481041	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Reduction of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase signaling and miR-18a regulation.
other	hsa-mir-192	Retinoblastoma	21511813	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells.
other	hsa-mir-19a	Retinoblastoma	21816922	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.
other	hsa-mir-19b	Retinoblastoma	25513843	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells.
other	hsa-mir-19b-1	Retinoblastoma	21816922	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.
other	hsa-mir-19b-1	Retinoblastoma	22864477	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.
other	hsa-mir-200a	Retinoblastoma	26379276	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Novel miRNA-31 and miRNA-200a-Mediated Regulation of Retinoblastoma Proliferation.
other	hsa-mir-202	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-mir-20a	Retinoblastoma	21816922	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.
other	hsa-mir-20a	Retinoblastoma	22864477	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.
other	hsa-mir-20a	Retinoblastoma	17135249	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Altogether, these results suggest that the autoregulation between E2F1-3 and miR-20a is important for preventing an abnormal accumulation of E2F1-3 and may play a role in the regulation of cellular proliferation and apoptosis.
other	hsa-mir-21	Retinoblastoma	24607444	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Seed-targeting anti-miR-21 inhibiting malignant progression of retinoblastoma and analysis of their phosphorylation signaling pathways.
other	hsa-mir-21	Retinoblastoma	27600360	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	MiR-21 inhibitor suppressed the progression of retinoblastoma via the modulation of PTEN/PI3K/AKT pathway.
other	hsa-mir-221	Retinoblastoma	29843209	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Upregulated miR-221/222 promotes cell proliferation and invasion and is associated with invasive features in retinoblastoma.
other	hsa-mir-222	Retinoblastoma	29843209	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Upregulated miR-221/222 promotes cell proliferation and invasion and is associated with invasive features in retinoblastoma.
other	hsa-mir-31	Retinoblastoma	26379276	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Novel miRNA-31 and miRNA-200a-Mediated Regulation of Retinoblastoma Proliferation.
other	hsa-mir-34b	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-mir-34c	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-mir-376a-1	Retinoblastoma	23373993	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a
other	hsa-mir-376a-2	Retinoblastoma	23373993	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a
other	hsa-mir-494	Retinoblastoma	27399693	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	The overexpression of miR-494-3p in SAS cells increased the population of senescence-associated 尾-galactosidase positive cells, the expression of p16(INK4a) and retinoblastoma 1 (RB1), as well as downregulated Bmi1.
other	hsa-mir-92a-1	Retinoblastoma	21816922	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.
other	hsa-mir-92a-1	Retinoblastoma	22864477	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.
other	hsa-mir-98	Retinoblastoma	20019750	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miRNA profiling of these tumors identified members of the let-7 and miR-34(34b,34c) families as candidate tumor suppressors in retinoblastoma.
other	hsa-mir-133a	Rhabdomyosarcoma	26153023	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	ARS treatment in ERMS cells ROS-dependently induces the expression of the myo-miRs, miR-133a and miR-206, which are down-regulated in RMS, and reduces PAX7 protein levels.
other	hsa-mir-206	Rhabdomyosarcoma	19620785	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-1 was barely detectable in primary RMS
other	hsa-mir-206	Rhabdomyosarcoma	20502458	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	MicroRNA-206:MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas
other	hsa-mir-206	Rhabdomyosarcoma	22541669	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells.
other	hsa-mir-206	Rhabdomyosarcoma	25644430	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
other	hsa-mir-206	Rhabdomyosarcoma	27488535	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Heme Oxygenase-1 Controls an HDAC4-miR-206 Pathway of Oxidative Stress in Rhabdomyosarcoma.
other	hsa-mir-206	Rhabdomyosarcoma	29844345	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	SNAIL silencing induces myogenic differentiation by upregulation of myogenic factors and muscle-specific microRNAs, such as miR-206.
other	hsa-mir-34c	Rhabdomyosarcoma	19620785	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	The muscle-specific microRNA miR-206, blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation
other	hsa-mir-9	Rhabdomyosarcoma	27984116	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.
other	hsa-mir-16	Rheumatic Myocarditis	29845432	disease by infectious agent	DOID:8481	I01.9				significant downregulation of hsa-miR-16-5p, hsa-miR-223-3p and hsa-miR-92a-3p in children with rheumatic carditis
other	hsa-mir-223	Rheumatic Myocarditis	29845432	disease by infectious agent	DOID:8481	I01.9				significant downregulation of hsa-miR-16-5p, hsa-miR-223-3p and hsa-miR-92a-3p in children with rheumatic carditis
other	hsa-mir-92a	Rheumatic Myocarditis	29845432	disease by infectious agent	DOID:8481	I01.9				significant downregulation of hsa-miR-16-5p, hsa-miR-223-3p and hsa-miR-92a-3p in children with rheumatic carditis
other	hsa-mir-124a	Rheumatoid Arthritis	19404929	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The results of this study suggest that miR-124a is a key miRNA in the posttranscriptional regulatory mechanisms of RA synoviocytes.
other	hsa-mir-125b	Rheumatoid Arthritis	24778468	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis.
other	hsa-mir-126	Rheumatoid Arthritis	27465842	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	CCN1 induced VEGF expression in osteoblasts and increased endothelial progenitor cells (EPCs) angiogenesis by inhibiting miR-126 via the protein kinase C-alpha (PKC-伪) signaling pathway.
other	hsa-mir-146a	Rheumatoid Arthritis	25630616	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	the miRNA-146 GG genotype might increase the risk of RA in females, and CC genotype may influence disease activity when evaluated with DAS28 score.
other	hsa-mir-146a	Rheumatoid Arthritis	20840794	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	These results indicated that miR-146a was associated with IL-17 expression in the PBMC and synovium in RA patients. There is the possibility that miR-146a participates in the IL-17 expression.
other	hsa-mir-146a	Rheumatoid Arthritis	22374446	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In 2008, miR-146a and miR-155 were reported to be involved in the pathology of rheumatoid arthritis.
other	hsa-mir-146a	Rheumatoid Arthritis	23291479	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiR-146a and -155 were mainly reported for RA, miR-140 was mainly reported for OA including cartilage development.
other	hsa-mir-146a	Rheumatoid Arthritis	28514293	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The role of circulating miR-146a in patients with rheumatoid arthritis treated by Tripterygium wilfordii Hook F.
other	hsa-mir-155	Rheumatoid Arthritis	22374446	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In 2008, miR-146a and miR-155 were reported to be involved in the pathology of rheumatoid arthritis.
other	hsa-mir-155	Rheumatoid Arthritis	23291479	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiR-146a and -155 were mainly reported for RA, miR-140 was mainly reported for OA including cartilage development.
other	hsa-mir-155	Rheumatoid Arthritis	26950427	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	epigenetic regulators such as micro-RNAs (i.e. miR-155) are key regulators of myeloid cells activation in RA
other	hsa-mir-155	Rheumatoid Arthritis	28118944	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MicroRNA-155 contributes to enhanced resistance to apoptosis in monocytes from patients with rheumatoid arthritis.
other	hsa-mir-155	Rheumatoid Arthritis	29575671	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Rituximab may cause increased hepatitis C virus viremia in rheumatoid arthritis patients through declining exosomal microRNA-155
other	hsa-mir-17	Rheumatoid Arthritis	23516027	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The miR-17 ∼ 92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis.
other	hsa-mir-18	Rheumatoid Arthritis	23516027	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The miR-17 ∼ 92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis.
other	hsa-mir-188	Rheumatoid Arthritis	26191188	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts.
other	hsa-mir-18a	Rheumatoid Arthritis	23280137	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The TNFa-induced miR-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-ж╩B signaling
other	hsa-mir-19a	Rheumatoid Arthritis	23516027	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The miR-17 ∼ 92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis.
other	hsa-mir-19b-1	Rheumatoid Arthritis	23516027	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The miR-17 ∼ 92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis.
other	hsa-mir-203	Rheumatoid Arthritis	21279994	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	elevated levels of miR-203 lead to increased secretion of MMP-1 and IL-6 via the NF-kB pathway and thereby contribute to the activated phenotype of synovial fibroblasts in RA.
other	hsa-mir-20a	Rheumatoid Arthritis	23516027	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The miR-17 ∼ 92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis.
other	hsa-mir-223	Rheumatoid Arthritis	24816316	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production.
other	hsa-mir-346	Rheumatoid Arthritis	21611196	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-346 Controls Release of TNF-a Protein and Stability of Its mRNA in Rheumatoid Arthritis via Tristetraprolin Stabilization.
other	hsa-mir-451	Rheumatoid Arthritis	24401767	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs.
other	hsa-mir-92-1	Rheumatoid Arthritis	23516027	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The miR-17 ∼ 92 Cluster: A Key Player in the Control of Inflammation during Rheumatoid Arthritis.
other	hsa-mir-124	Rhinosinusitis	26413631			B48.1				The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps.
other	hsa-mir-125b	Rhinosinusitis	26413631			B48.1				The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps.
other	hsa-mir-146a	Rhinosinusitis	26413631			B48.1				The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps.
other	hsa-mir-155	Rhinosinusitis	26413631			B48.1				The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps.
other	hsa-mir-181b	Rhinosinusitis	26413631			B48.1				The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps.
other	hsa-mir-26b	Rhinosinusitis	26413631			B48.1				The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps.
other	hsa-mir-92a	Rhinosinusitis	26413631			B48.1				The results from this study may further reveal the relationship between miRNA expressions and inflammation. These results can also provide an important mechanism (primitive data) on the occurrence of chronic sinusitis and nasal polyps.
other	hsa-mir-21	Salivary Gland Disease	29154818	gastrointestinal system disease	DOID:10854	K11.9				MicroRNA-21 promotes wound healing via the Smad7-Smad2/3-Elastin pathway.
other	hsa-let-7	Salivary Gland Neoplasms	23774803	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas
other	hsa-let-7a	Salivary Gland Neoplasms	24853424	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Furthermore, WIF1 significantly increased the expression of microRNAs pri-let-7a and pri-miR-200c, negative regulators of stemness and cancer progression.
other	hsa-mir-132	Salivary Gland Neoplasms	29108921	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors
other	hsa-mir-17	Salivary Gland Neoplasms	29108921	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors
other	hsa-mir-181a-2	Salivary Gland Neoplasms	23774803	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas
other	hsa-mir-195	Salivary Gland Neoplasms	29108921	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors
other	hsa-mir-221	Salivary Gland Neoplasms	29108921	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-17, miR-132, miR-195 and miR-221 seem to play an important role as tumor suppressor in salivary gland tumors
other	hsa-mir-24	Salivary Gland Neoplasms	23774803	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas
other	hsa-mir-15	Salmonellosis	25146723	disease by infectious agent	DOID:0060859	A02.0	D012480			Functional high-throughput screening identifies the miR-15 microRNA family as cellular restriction factors for Salmonella infection.
other	hsa-mir-29a	Salmonellosis	23826261	disease by infectious agent	DOID:0060859	A02.0	D012480			Our study outlines for the first time important regulation pathways in intestinal Salmonella infection pointing out that focal adhesion and organisation of actin cytoskeleton are regulated by microRNAs. Functional relevance is shown by miR-29a mediated Caveolin 2 regulation, modulating the activation state of CDC42. Further analysis of examined interactions may support the discovery of novel strategies impairing the uptake of intracellular pathogens.
other	hsa-mir-103-1	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-122	Schizophrenia	26575446	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Circulating miRNA biomarkers for schizophrenia
other	hsa-mir-124	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-130	Schizophrenia	26575446	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Circulating miRNA biomarkers for schizophrenia
other	hsa-mir-132	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-137	Schizophrenia	24556472	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells.
other	hsa-mir-137	Schizophrenia	24566148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-137: a new player in schizophrenia.
other	hsa-mir-137	Schizophrenia	25250332	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Association of a miRNA-137 polymorphism with schizophrenia in a Southern Chinese Han population.
other	hsa-mir-137	Schizophrenia	26005852	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The schizophrenia risk gene product miR-137 alters presynaptic plasticity.
other	hsa-mir-137	Schizophrenia	27650867	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	MicroRNA-137 Inhibits EFNB2 Expression Affected by a Genetic Variant and Is Expressed Aberrantly in Peripheral Blood of Schizophrenia Patients.
other	hsa-mir-137	Schizophrenia	27706734	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Association between miR-137 polymorphism and risk of schizophrenia: a meta-analysis.
other	hsa-mir-138	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-144	Schizophrenia	19849891	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder.
other	hsa-mir-181	Schizophrenia	19849891	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder.
other	hsa-mir-19	Schizophrenia	27387650	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our study demonstrates the significance of posttranscriptional gene regulation by miR-19 in preventing the irregular migration of adult-born neurons  that may contribute to the etiology of schizophrenia.
other	hsa-mir-195	Schizophrenia	19121517	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Using a postmortem case-control design, the association between BDNF protein, NPY/SST/PV mRNAs, and two BDNF-regulating microRNAs (miR-195 and miR-30a-5p) was determined in samples from the PFC of 20 schizophrenia and 20 control subjects.
other	hsa-mir-195	Schizophrenia	19849891	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder.
other	hsa-mir-195	Schizophrenia	22190509	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	microRNA-195(miR-195) is an important member of the micro-15/16/195/424/497 family, and which is activated in multiple diseases, such as cancers, heart failure, and schizophrenia.
other	hsa-mir-198	Schizophrenia	18552348	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Human microRNAs (Hsa-mir-198 and Hsa-mir-206) are predicted to bind to influenza, rubella, or poliovirus genes. Certain genes associated with schizophrenia, including those also concerned with neurophysiology, are intimately related to the life cycles of the  pathogens implicated in the disease.
other	hsa-mir-206	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-206	Schizophrenia	18552348	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Human microRNAs (Hsa-mir-198 and Hsa-mir-206) are predicted to bind to influenza, rubella, or poliovirus genes. Certain genes associated with schizophrenia, including those also concerned with neurophysiology, are intimately related to the life cycles of the  pathogens implicated in the disease.
other	hsa-mir-218-1	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-26b	Schizophrenia	26450699	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	the notion that microRNAs fine-tune the amount of proteins acting in the same biological pathways in schizophrenia, giving further support to the emerging theory of competing endogenous RNAs.
other	hsa-mir-29b	Schizophrenia	27613806	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Epistatic and Independent Effects on Schizophrenia-Related Phenotypes Following Co-disruption of the Risk Factors Neuregulin-1 × DISC1.
other	hsa-mir-30a	Schizophrenia	19121517	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Using a postmortem case-control design, the association between BDNF protein, NPY/SST/PV mRNAs, and two BDNF-regulating microRNAs (miR-195 and miR-30a-5p) was determined in samples from the PFC of 20 schizophrenia and 20 control subjects.
other	hsa-mir-30b	Schizophrenia	20732949	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	These preliminary findings point to the possibility that disease-related changes in the expression of small noncoding RNAs such as miR-30b in schizophrenia could be influenced by gender and potentially regulated by estrogen signaling.
other	hsa-mir-30e	Schizophrenia	27258654	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA-30e is associated with cognitive impairment in schizophrenia and depression.
other	hsa-mir-335	Schizophrenia	26450699	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	the notion that microRNAs fine-tune the amount of proteins acting in the same biological pathways in schizophrenia, giving further support to the emerging theory of competing endogenous RNAs.
other	hsa-mir-338	Schizophrenia	27892953	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Thalamic miR-338-3p mediates auditory thalamocortical disruption and its late onset in models of 22q11.2 microdeletion.
other	hsa-mir-346	Schizophrenia	19849891	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder.
other	hsa-mir-34a	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-34a	Schizophrenia	19849891	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The most promising miRNAs so far identified include miR-181, miR-346 and miR-195 in schizophrenia and miR-34a and miR-144 in bipolar disorder.
other	hsa-mir-365	Schizophrenia	23876895	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	This study analyzed possible circulating miRNAs in response to antipsychotic monotherapy for schizophrenia, the further mechanism need to be confirmed.
other	hsa-mir-449a	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-652	Schizophrenia	26575446	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Circulating miRNA biomarkers for schizophrenia
other	hsa-mir-7	Schizophrenia	25882257	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	MicroRNA-7/Shank3 axis involved in schizophrenia pathogenesis.
other	hsa-mir-9-3	Schizophrenia	25817407	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Our approach of integrating PGC findings with eQTL results can be used to generate specific hypotheses regarding the role of miRNAs in SZ and BD.
other	hsa-mir-21	Scleroderma, Systemic	27637490	musculoskeletal system disease	DOID:418	M34	D012595	181750		Inhibition of MicroRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis.
other	hsa-mir-29a	Scleroderma, Systemic	24107002	musculoskeletal system disease	DOID:418	M34	D012595	181750		Hair miR-29a levels are decreased in patients with scleroderma.
other	hsa-mir-29a	Scleroderma, Systemic	25857445	musculoskeletal system disease	DOID:418	M34	D012595	181750		MicroRNA-29a induces apoptosis via increasing the Bax:Bcl-2 ratio in dermal fibroblasts of patients with systemic sclerosis.
other	hsa-mir-30b	Scleroderma, Systemic	23893664	musculoskeletal system disease	DOID:418	M34	D012595	181750		Down-regulation of miR-30b might be involved in the pathogenesis of SSc.
other	hsa-mir-155	Selective IgE Deficiency Disease	24734904	immune system disease	DOID:6024					miRNA-155 controls mast cell activation by regulating the PI3Kγ pathway and anaphylaxis in a mouse model.
other	hsa-mir-182	Sensorineural Hearing Loss	29476110	nervous system disease	DOID:10003	H90.5	D006313	304400		A mouse model of miR-96, miR-182 and miR-183 misexpression implicates miRNAs in cochlear cell fate and homeostasis
other	hsa-mir-183	Sensorineural Hearing Loss	29476110	nervous system disease	DOID:10003	H90.5	D006313	304400		A mouse model of miR-96, miR-182 and miR-183 misexpression implicates miRNAs in cochlear cell fate and homeostasis
other	hsa-mir-96	Sensorineural Hearing Loss	29476110	nervous system disease	DOID:10003	H90.5	D006313	304400		A mouse model of miR-96, miR-182 and miR-183 misexpression implicates miRNAs in cochlear cell fate and homeostasis
other	hsa-mir-1	Sepsis	28673002			A41.9	D018805		HP:0100806	IGF-1 may predict the severity and outcome of patients with sepsis and be associated with microRNA-1 level changes.
other	hsa-mir-124	Sepsis	28342874			A41.9	D018805		HP:0100806	Activation of PPARγ inhibits pro-inflammatory cytokines production by upregulation of miR-124 in vitro and in vivo.
other	hsa-mir-135a	Sepsis	28147298			A41.9	D018805		HP:0100806	MicroRNA-135a is up-regulated and aggravates myocardial depression in sepsis via regulating p38 MAPK/NF-κB pathway.
other	hsa-mir-143	Sepsis	24105952			A41.9	D018805		HP:0100806	The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143.
other	hsa-mir-146a	Sepsis	23756365			A41.9	D018805		HP:0100806	Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a.
other	hsa-mir-146a	Sepsis	27596437			A41.9	D018805		HP:0100806	systemic inflammation induced an increase in EVs and associated pro-inflammatory miRNAs, including miR-146a and miR-155, in the CSF Interestingly, this was associated with an increase in amount of multivesicular bodies (MVBs) and exosomes per MVB in the CPE cells
other	hsa-mir-146a	Sepsis	28090688			A41.9	D018805		HP:0100806	Exosomal miR-146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin-1β-Primed Mesenchymal Stem Cells Against Sepsis.
other	hsa-mir-150	Sepsis	26822049			A41.9	D018805		HP:0100806	Lower microRNA-150 may indicate a poor prognosis, and Picco monitoring combined with microRNA 150 detection may improve the prognostic efficiency in septic shock patients.
other	hsa-mir-155	Sepsis	24598292			A41.9	D018805		HP:0100806	The result of this study suggest that miR-155 is involved in the cell proliferation regulation of CD4(+)CD25(+) Treg cells, and play some role in the immunological dissonance in sepsis.
other	hsa-mir-155	Sepsis	26433115			A41.9	D018805		HP:0100806	A higher level of miR-155 indicated a more severe condition and poorer prognosis in sepsis patients. The possible underlying mechanism could be that miR-155 induces an increased percentage of CD39(+) Tregs and thus immunosuppression.
other	hsa-mir-155	Sepsis	27596437			A41.9	D018805		HP:0100806	systemic inflammation induced an increase in EVs and associated pro-inflammatory miRNAs, including miR-146a and miR-155, in the CSF Interestingly, this was associated with an increase in amount of multivesicular bodies (MVBs) and exosomes per MVB in the CPE cells
other	hsa-mir-181b	Sepsis	28934717			A41.9	D018805		HP:0100806	the CCAAT enhancer-binding protein C/EBPβ activates microRNA (miR)-21 and miR-181b expressions
other	hsa-mir-21	Sepsis	28006751			A41.9	D018805		HP:0100806	miR-375 ameliorates sepsis by downregulating miR-21 level via inhibiting JAK2-STAT3 signaling.
other	hsa-mir-21	Sepsis	28437377			A41.9	D018805		HP:0100806	MicroRNA-21 Is Required for Local and Remote Ischemic Preconditioning in Multiple Organ Protection Against Sepsis.
other	hsa-mir-21	Sepsis	28934717			A41.9	D018805		HP:0100806	the CCAAT enhancer-binding protein C/EBPβ activates microRNA (miR)-21 and miR-181b expressions
other	hsa-mir-223	Sepsis	26348153			A41.9	D018805		HP:0100806	Exosomal miR-223 Contributes to Mesenchymal Stem Cell-Elicited Cardioprotection in Polymicrobial Sepsis.
other	hsa-mir-223	Sepsis	28515178			A41.9	D018805		HP:0100806	A model-specific role of microRNA-223 as a mediator of kidney injury during experimental sepsis.
other	hsa-mir-27a	Sepsis	26171875			A41.9	D018805		HP:0100806	RhTNFR:Fc improved cardiac function of sepsis mice, and markedly decreased miR-27a but increased Nrf2 expression level of myocardium in LPS treated mice.
other	hsa-mir-375	Sepsis	28006751			A41.9	D018805		HP:0100806	miR-375 ameliorates sepsis by downregulating miR-21 level via inhibiting JAK2-STAT3 signaling.
other	hsa-mir-17	Severe Acute Respiratory Syndrome Virus Infection	19915717	disease by infectious agent	DOID:2945	B97.21	D045169			Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to suppress its own replication and evade immune elimination
other	hsa-mir-214	Severe Acute Respiratory Syndrome Virus Infection	19915717	disease by infectious agent	DOID:2945	B97.21	D045169			Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to suppress its own replication and evade immune elimination
other	hsa-mir-574	Severe Acute Respiratory Syndrome Virus Infection	19915717	disease by infectious agent	DOID:2945	B97.21	D045169			Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to suppress its own replication and evade immune elimination
other	hsa-mir-199a-2	Sezary Disease	22336940	disease of cellular proliferation	DOID:8541	C84.1	D012751			Deep-Sequencing Analysis Reveals that the miR-199a2/214 Cluster within DNM3os Represents the Vast Majority of Aberrantly Expressed MicroRNAs in Sижzary Syndrome.
other	hsa-mir-214	Sezary Disease	22336940	disease of cellular proliferation	DOID:8541	C84.1	D012751			Deep-Sequencing Analysis Reveals that the miR-199a2/214 Cluster within DNM3os Represents the Vast Majority of Aberrantly Expressed MicroRNAs in Sижzary Syndrome.
other	hsa-mir-214	Sezary Disease	27766406	disease of cellular proliferation	DOID:8541	C84.1	D012751			CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.
other	hsa-mir-199a-2	Sickle Cell Disease	27573019			D57	D000755	603903		Activated Transcription Factor 3 in Association with Histone Deacetylase 6 Negatively Regulates MicroRNA 199a2 Transcription by Chromatin Remodeling and Reduces Endothelin-1 Expression.
other	hsa-mir-126	Sjogren Syndrome	28339625	immune system disease	DOID:12894	M35.00	D012859	270150		Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sjögren's syndrome.
other	hsa-mir-146a	Sjogren Syndrome	26505653	immune system disease	DOID:12894	M35.00	D012859	270150		Dysregulated co-stimulatory molecule expression in a Sjögren's syndrome mouse model with potential implications by microRNA-146a.
other	hsa-mir-335	Sjogren Syndrome	28339625	immune system disease	DOID:12894	M35.00	D012859	270150		Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sjögren's syndrome.
other	hsa-mir-150	Skin Disease [unspecific]	24530178	integumentary system disease	DOID:37	L98.9	D012871			miR-150 levels were significantly decreased in sera of scleroderma patients, and were inversely correlated with the prevalence of pitting scars/ulcers and the incidence of anti-topoisomerase I antibody.
other	hsa-mir-23b	Skin Neoplasms	24391759	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	UVA and UVB irradiation differentially regulate microRNA expression in human primary keratinocytes.
other	hsa-mir-302a	Skin Neoplasms	18755840	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	miR-302: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state
other	hsa-mir-302b	Skin Neoplasms	18755840	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	miR-302: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state
other	hsa-mir-302c	Skin Neoplasms	18755840	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	miR-302: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state
other	hsa-mir-302d	Skin Neoplasms	18755840	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	miR-302: Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state
other	hsa-mir-125b	Spinal Cord Injuries	29461585			S34.139A	D013119			MicroRNA-125b promotes the regeneration and repair of spinal cord injury through regulation of JAK/STAT pathway
other	hsa-mir-145	Spinal Cord Injuries	27907012			S34.139A	D013119			The Signature of MicroRNA Dysregulation in Muscle Paralyzed by Spinal Cord Injury Includes Downregulation of MicroRNAs that Target Myostatin Signaling.
other	hsa-mir-182	Spinal Cord Injuries	28552531			S34.139A	D013119			A causal relationship between the neurotherapeutic effects of miR182/7a and decreased expression of PRDM5.
other	hsa-mir-21	Spinal Cord Injuries	23238710			S34.139A	D013119			microRNA-21 Regulates Astrocytic Response Following Spinal Cord Injury
other	hsa-mir-210	Spinal Cord Injuries	27847197			S34.139A	D013119			Synchrotron radiation micro-CT as a novel tool to evaluate the effect of agomir-210 in a rat spinal cord injury model.
other	hsa-mir-223	Spinal Cord Injuries	27432064			S34.139A	D013119			Naringenin inhibits spinal cord injury-induced activation of neutrophils through  miR-223.
other	hsa-mir-23a	Spinal Cord Injuries	27907012			S34.139A	D013119			The Signature of MicroRNA Dysregulation in Muscle Paralyzed by Spinal Cord Injury Includes Downregulation of MicroRNAs that Target Myostatin Signaling.
other	hsa-mir-29b	Spinal Cord Injuries	26097563			S34.139A	D013119			Combinatorial effects of miR-20a and miR-29b on neuronal apoptosis induced by spinal cord injury.
other	hsa-mir-494	Spinal Cord Injuries	28601045			S34.139A	D013119			MicroRNA-494 improves functional recovery and inhibits apoptosis by modulating PTEN/AKT/mTOR pathway in rats after spinal cord injury.
other	hsa-let-7a	Spinal Cord Injuries	28552531			S34.139A	D013119			A causal relationship between the neurotherapeutic effects of miR182/7a and decreased expression of PRDM5.
other	hsa-let-7	Squamous Cell Carcinoma	24070899	disease of cellular proliferation	DOID:1749		D002294			Phospho-ΔNp63α regulates AQP3, ALOX12B, CASP14 and CLDN1 expression through transcription and microRNA modulation.
other	hsa-mir-193a	Squamous Cell Carcinoma	21436470	disease of cellular proliferation	DOID:1749		D002294			The resulting feed-forward circuit involving p63, miR-193a-5p and p73 controls p73 levels, cell viability and DNA damage susceptibility in certain cancers including squamous cell carcinoma.
other	hsa-mir-203	Squamous Cell Carcinoma	25284788	disease of cellular proliferation	DOID:1749		D002294			Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis.
other	hsa-mir-21	Squamous Cell Carcinoma	27371785	disease of cellular proliferation	DOID:1749		D002294			Blueberry also modulated the expression of the oncomiR miR-21 and the tumor suppressor let-7.
other	hsa-mir-106a	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-143	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-143	Squamous Cell Carcinoma, Cerevial	26252302	endocrine system disease	DOID:5531					A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study.
other	hsa-mir-145	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-145	Squamous Cell Carcinoma, Cerevial	26252302	endocrine system disease	DOID:5531					A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study.
other	hsa-mir-15a	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-16-1	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-16-2	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-18b	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-195	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-19b-2	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-205	Squamous Cell Carcinoma, Cerevial	26864590	endocrine system disease	DOID:5531					螖Np63伪 attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma.
other	hsa-mir-20b	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-363	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-497	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-92a-2	Squamous Cell Carcinoma, Cerevial	22472886	endocrine system disease	DOID:5531					The miR-15a/miR-16/miR195/miR-497 family, miR-143/miR-145 and the miR-106-363 cluster appear to be important within the known HPV pathogenesis.
other	hsa-mir-96	Squamous Cell Carcinoma, Cerevial	24791792	endocrine system disease	DOID:5531					Expressions of MicroRNA-96 before and after chemotherapy and its relationship with chemosensitivity in cervical squamous cell carcinoma.
other	hsa-let-7e	Squamous Cell Carcinoma, Esophageal	28408353	disease of cellular proliferation	DOID:3748		C562729			ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma.
other	hsa-mir-100	Squamous Cell Carcinoma, Esophageal	25109390	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-100 promotes migration and invasion through mammalian target of rapamycin in esophageal squamous cell carcinoma.
other	hsa-mir-106b	Squamous Cell Carcinoma, Esophageal	29552108	disease of cellular proliferation	DOID:3748		C562729			miR-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC
other	hsa-mir-1179	Squamous Cell Carcinoma, Esophageal	25755718	disease of cellular proliferation	DOID:3748		C562729			miR-1179 promotes cell invasion through SLIT2/ROBO1 axis in esophageal squamous cell carcinoma.
other	hsa-mir-125a	Squamous Cell Carcinoma, Esophageal	28408353	disease of cellular proliferation	DOID:3748		C562729			ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma.
other	hsa-mir-1290	Squamous Cell Carcinoma, Esophageal	25805931	disease of cellular proliferation	DOID:3748		C562729			Our findings suggested that miR-1290 may play an oncogenic role in cellular processes of ESCC.
other	hsa-mir-133b	Squamous Cell Carcinoma, Esophageal	28069586	disease of cellular proliferation	DOID:3748		C562729			SQLE induces epithelial-to-mesenchymal transition by regulating of miR-133b in esophageal squamous cell carcinoma.
other	hsa-mir-139	Squamous Cell Carcinoma, Esophageal	24204738	disease of cellular proliferation	DOID:3748		C562729			Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma.
other	hsa-mir-148a	Squamous Cell Carcinoma, Esophageal	21246413	disease of cellular proliferation	DOID:3748		C562729			Mir-148a Improves Response to Chemotherapy in Sensitive and Resistant Oesophageal Adenocarcinoma and Squamous Cell Carcinoma Cells.
other	hsa-mir-150	Squamous Cell Carcinoma, Esophageal	26606907	disease of cellular proliferation	DOID:3748		C562729			Taken together, our results highlight the involvement of miRNAs in ribosomal regulation during tumorigenesis.
other	hsa-mir-200b	Squamous Cell Carcinoma, Esophageal	26334393	disease of cellular proliferation	DOID:3748		C562729			These data highlight that suppression of the Kindlin-2-integrin β1-AKT regulatory axis is an alternative mechanism underlying the tumor suppressor function of miR-200b in ESCC.
other	hsa-mir-203	Squamous Cell Carcinoma, Esophageal	24692008	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-203 inhibits the progression of esophageal squamous cell carcinoma with restored epithelial tissue architecture in vivo.
other	hsa-mir-203	Squamous Cell Carcinoma, Esophageal	24519530	disease of cellular proliferation	DOID:3748		C562729			Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray.
other	hsa-mir-205	Squamous Cell Carcinoma, Esophageal	27974696	disease of cellular proliferation	DOID:3748		C562729			Sp1-mediated transcriptional activation of miR-205 promotes radioresistance in esophageal squamous cell carcinoma.
other	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	24039846	disease of cellular proliferation	DOID:3748		C562729			MiR-21 expression is mostly confined to the SCC stroma and its release from fibroblasts influences the migration and invasion capacity of SCC cells. Moreover, miR-21 may be an important factor in activating fibroblasts to CAFs. These findings provide new insights into the role of CAFs and the extracellular matrix in tumor microenvironment formation and in tumor cell maintenance, and suggest miR-21 may contribute to cellular crosstalk in the tumor microenvironment.
other	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	24519530	disease of cellular proliferation	DOID:3748		C562729			Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray.
other	hsa-mir-210	Squamous Cell Carcinoma, Esophageal	21044961	disease of cellular proliferation	DOID:3748		C562729			Taken together, our findings show an important role for miR-210 as a tumor-suppressive microRNA with effects on cancer cell proliferation.
other	hsa-mir-26a	Squamous Cell Carcinoma, Esophageal	28476684	disease of cellular proliferation	DOID:3748		C562729			miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway.
other	hsa-mir-26b	Squamous Cell Carcinoma, Esophageal	28476684	disease of cellular proliferation	DOID:3748		C562729			miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway.
other	hsa-mir-27a	Squamous Cell Carcinoma, Esophageal	19960259	disease of cellular proliferation	DOID:3748		C562729			miR-27a:Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma
other	hsa-mir-30a	Squamous Cell Carcinoma, Esophageal	29259372	disease of cellular proliferation	DOID:3748		C562729			Down-regulation of miR-30a-3p/5p promotes esophageal squamous cell carcinoma cell proliferation by activating the Wnt signaling pathway
other	hsa-mir-31	Squamous Cell Carcinoma, Esophageal	24039884	disease of cellular proliferation	DOID:3748		C562729			Dissection of miRNA-miRNA interaction in esophageal squamous cell carcinoma.
other	hsa-mir-338	Squamous Cell Carcinoma, Esophageal	24039884	disease of cellular proliferation	DOID:3748		C562729			Dissection of miRNA-miRNA interaction in esophageal squamous cell carcinoma.
other	hsa-mir-338	Squamous Cell Carcinoma, Esophageal	26004521	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-338-3p suppresses tumor growth of esophageal squamous cell carcinoma in vitro and in vivo.
other	hsa-mir-34a	Squamous Cell Carcinoma, Esophageal	26782413	disease of cellular proliferation	DOID:3748		C562729			Clinical significance of microRNA-34a in esophageal squamous cell carcinoma.
other	hsa-mir-3651	Squamous Cell Carcinoma, Esophageal	26210449	disease of cellular proliferation	DOID:3748		C562729			Clinical potential of miR-3651 as a novel prognostic biomarker for esophageal squamous cell cancer.
other	hsa-mir-383	Squamous Cell Carcinoma, Esophageal	26606907	disease of cellular proliferation	DOID:3748		C562729			Taken together, our results highlight the involvement of miRNAs in ribosomal regulation during tumorigenesis.
other	hsa-mir-424	Squamous Cell Carcinoma, Esophageal	27628042	disease of cellular proliferation	DOID:3748		C562729			MiR-424-5p participates in esophageal squamous cell carcinoma invasion and metastasis via SMAD7 pathway mediated EMT.
other	hsa-mir-498	Squamous Cell Carcinoma, Esophageal	28188753	disease of cellular proliferation	DOID:3748		C562729			MiR-498 in esophageal squamous cell carcinoma: clinicopathological impacts and functional interactions.
other	hsa-mir-508	Squamous Cell Carcinoma, Esophageal	25099196	disease of cellular proliferation	DOID:3748		C562729			miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma.
other	hsa-mir-630	Squamous Cell Carcinoma, Esophageal	27563011	disease of cellular proliferation	DOID:3748		C562729			MiR-630 inhibits invasion and metastasis in esophageal squamous cell carcinoma.
other	hsa-mir-7	Squamous Cell Carcinoma, Esophageal	28314263	disease of cellular proliferation	DOID:3748		C562729			Significance and Function of MicroRNA-7 in Oesophageal Squamous Cell Carcinoma.
other	hsa-mir-889	Squamous Cell Carcinoma, Esophageal	25841337	disease of cellular proliferation	DOID:3748		C562729			miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP.
other	hsa-mir-939	Squamous Cell Carcinoma, Esophageal	25346128	disease of cellular proliferation	DOID:3748		C562729			Expression of microRNA-939 and its correlation with prognosis in esophageal squamous cell carcinoma.
other	hsa-mir-942	Squamous Cell Carcinoma, Esophageal	25844602	disease of cellular proliferation	DOID:3748		C562729			miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/β-catenin signalling pathway.
other	hsa-mir-98	Squamous Cell Carcinoma, Esophageal	27422937	disease of cellular proliferation	DOID:3748		C562729			AmiR-98 mimic enforced the expression of miRNA-98 and made ESCC cells sensitive to radiotherapy, while anti-miR-98 reversed this process.
other	hsa-mir-99b	Squamous Cell Carcinoma, Esophageal	28408353	disease of cellular proliferation	DOID:3748		C562729			ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma.
other	hsa-let-7i	Squamous Cell Carcinoma, Head and Neck	26257063	disease of cellular proliferation	DOID:5520	C76.0	C535575			IB suppresses EMT and stemness of HNSCC cells through inhibition of Twist1-mediated let-7i downregulation and Rac1 activation and the EMT signalling.
other	hsa-mir-124	Squamous Cell Carcinoma, Head and Neck	26227488	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
other	hsa-mir-1254	Squamous Cell Carcinoma, Head and Neck	26452218	disease of cellular proliferation	DOID:5520	C76.0	C535575			Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy.
other	hsa-mir-128	Squamous Cell Carcinoma, Head and Neck	25764126	disease of cellular proliferation	DOID:5520	C76.0	C535575			Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis.
other	hsa-mir-138-1	Squamous Cell Carcinoma, Head and Neck	21770894	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines.
other	hsa-mir-138-2	Squamous Cell Carcinoma, Head and Neck	21770894	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines.
other	hsa-mir-141	Squamous Cell Carcinoma, Head and Neck	24424572	disease of cellular proliferation	DOID:5520	C76.0	C535575			Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma.
other	hsa-mir-146a	Squamous Cell Carcinoma, Head and Neck	26621153	disease of cellular proliferation	DOID:5520	C76.0	C535575			Characterizing the expression of miR-146a and miR-155 and their functional role in tumor biology underlined significantly their proliferation and migration potential suggesting relevance as potential prognostic markers in HNSCC.
other	hsa-mir-150	Squamous Cell Carcinoma, Head and Neck	26452218	disease of cellular proliferation	DOID:5520	C76.0	C535575			Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy.
other	hsa-mir-155	Squamous Cell Carcinoma, Head and Neck	26621153	disease of cellular proliferation	DOID:5520	C76.0	C535575			Characterizing the expression of miR-146a and miR-155 and their functional role in tumor biology underlined significantly their proliferation and migration potential suggesting relevance as potential prognostic markers in HNSCC.
other	hsa-mir-16	Squamous Cell Carcinoma, Head and Neck	26452218	disease of cellular proliferation	DOID:5520	C76.0	C535575			Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy.
other	hsa-mir-193a	Squamous Cell Carcinoma, Head and Neck	21293058	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-193a-5p, expression of which was repressed by p63, was activated by proapoptotic p73 isoforms in both normal cells and tumor cells in vivo.
other	hsa-mir-193b	Squamous Cell Carcinoma, Head and Neck	25677760	disease of cellular proliferation	DOID:5520	C76.0	C535575			Alteration in miR-193b expression level does not  show any significant association with cancer survival.
other	hsa-mir-200a	Squamous Cell Carcinoma, Head and Neck	28677748	disease of cellular proliferation	DOID:5520	C76.0	C535575			Salivary miR-93 and miR-200a as post-radiotherapy biomarkers in head and neck squamous cell carcinoma.
other	hsa-mir-200c	Squamous Cell Carcinoma, Head and Neck	21294122	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells.
other	hsa-mir-200c	Squamous Cell Carcinoma, Head and Neck	24424572	disease of cellular proliferation	DOID:5520	C76.0	C535575			Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma.
other	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	21685938	disease of cellular proliferation	DOID:5520	C76.0	C535575			Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and  chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells.
other	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	25175929	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-21 increases the programmed cell death 4 gene-regulated cell proliferation in head and neck squamous carcinoma cell lines.
other	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	26452218	disease of cellular proliferation	DOID:5520	C76.0	C535575			Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy.
other	hsa-mir-210	Squamous Cell Carcinoma, Head and Neck	26452218	disease of cellular proliferation	DOID:5520	C76.0	C535575			Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy.
other	hsa-mir-29	Squamous Cell Carcinoma, Head and Neck	26452218	disease of cellular proliferation	DOID:5520	C76.0	C535575			Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy.
other	hsa-mir-34a	Squamous Cell Carcinoma, Head and Neck	25762634	disease of cellular proliferation	DOID:5520	C76.0	C535575			MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).
other	hsa-mir-372	Squamous Cell Carcinoma, Head and Neck	25714028	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo.
other	hsa-mir-373	Squamous Cell Carcinoma, Head and Neck	26452218	disease of cellular proliferation	DOID:5520	C76.0	C535575			Together, we demonstrate the feasibility of using a miRNA signature to predict the clinical responsiveness of HNSCC radiotherapy.
other	hsa-mir-375	Squamous Cell Carcinoma, Head and Neck	26172508	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma.
other	hsa-mir-376c	Squamous Cell Carcinoma, Head and Neck	27760788	disease of cellular proliferation	DOID:5520	C76.0	C535575			Dysregulation of RUNX2/Activin-A Axis upon miR-376c Downregulation Promotes Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma.
other	hsa-mir-93	Squamous Cell Carcinoma, Head and Neck	25578493	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-93 may be a valuable marker for the prediction of metastasis and prognosis in HNSCC.
other	hsa-mir-93	Squamous Cell Carcinoma, Head and Neck	28677748	disease of cellular proliferation	DOID:5520	C76.0	C535575			Salivary miR-93 and miR-200a as post-radiotherapy biomarkers in head and neck squamous cell carcinoma.
other	hsa-mir-106b	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24846066	disease of cellular proliferation	DOID:2876					miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma.
other	hsa-mir-125b	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	28693195	disease of cellular proliferation	DOID:2876					MicroRNA-125b targeted STAT3 to inhibit laryngeal squamous cell carcinoma cell growth and motility.
other	hsa-mir-148a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27859417	disease of cellular proliferation	DOID:2876					RUNX3 inhibits laryngeal squamous cell carcinoma malignancy under the regulation of miR-148a-3p/DNMT1 axis.
other	hsa-mir-203	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	25840888	disease of cellular proliferation	DOID:2876					Effect of microRNA-203 on tumor growth in human hypopharyngeal squamous cell carcinoma.
other	hsa-mir-203	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24682952	disease of cellular proliferation	DOID:2876					MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours.
other	hsa-mir-205	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24297308	disease of cellular proliferation	DOID:2876					MicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma.
other	hsa-mir-205	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	28078305	disease of cellular proliferation	DOID:2876					miR-375 and miR-205 Regulate the Invasion and Migration of Laryngeal Squamous Cell Carcinoma Synergistically via AKT-Mediated EMT.
other	hsa-mir-206	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27279635	disease of cellular proliferation	DOID:2876					co-transfection of miR-375 and miR-206 exhibited a less effective inhibitory effect
other	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24846066	disease of cellular proliferation	DOID:2876					miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma.
other	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27545281	disease of cellular proliferation	DOID:2876					MicroRNA-21 in laryngeal squamous cell carcinoma: Diagnostic and prognostic features.
other	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27688683	disease of cellular proliferation	DOID:2876					Metformin significantly inhibited FaDu cell proliferation , possibly via downregulation of miR-21-5p and upregulation of PDCD4
other	hsa-mir-23a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	25879432	disease of cellular proliferation	DOID:2876					miR-23a, an independent prognostic factor for laryngeal cancer,participates in the onset and progression of laryngeal cancer.
other	hsa-mir-375	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24846066	disease of cellular proliferation	DOID:2876					miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma.
other	hsa-mir-375	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	28078305	disease of cellular proliferation	DOID:2876					miR-375 and miR-205 Regulate the Invasion and Migration of Laryngeal Squamous Cell Carcinoma Synergistically via AKT-Mediated EMT.
other	hsa-let-7a	Squamous Cell Carcinoma, Lung	25802847	disease of cellular proliferation	DOID:3907	C34.91				The novel candidate key drivers in this refined subnetwork, such as the methylation of ARHGDIB and HOXD3, microRNA let-7a and miR-31, and the CNV of AGAP2, were identified and analyzed.
other	hsa-let-7i	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				let-7i:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC
other	hsa-mir-126	Squamous Cell Carcinoma, Lung	25521201	disease of cellular proliferation	DOID:3907	C34.91				rule discovery followed by distance separation is a powerful computational method to identify reliable miRNA biomarkers. The visualization of the rules and the clear separation between the normal and cancer samples by our rules will help biology experts for their analysis and biological interpretation.
other	hsa-mir-133a	Squamous Cell Carcinoma, Lung	25518741	disease of cellular proliferation	DOID:3907	C34.91				Further analysis of novel cancer signaling pathways modulated by the tumor-suppressive cluster miR-1/133a will provide insights into the molecular mechanisms of lung-SCC oncogenesis and metastasis
other	hsa-mir-141	Squamous Cell Carcinoma, Lung	25746592	disease of cellular proliferation	DOID:3907	C34.91				MicroRNA-141 is a biomarker for progression of squamous cell carcinoma and adenocarcinoma of the lung: clinical analysis of 125 patients.
other	hsa-mir-145	Squamous Cell Carcinoma, Lung	27765924	disease of cellular proliferation	DOID:3907	C34.91				Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma.
other	hsa-mir-192	Squamous Cell Carcinoma, Lung	29571988	disease of cellular proliferation	DOID:3907	C34.91				MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma
other	hsa-mir-205	Squamous Cell Carcinoma, Lung	25521201	disease of cellular proliferation	DOID:3907	C34.91				rule discovery followed by distance separation is a powerful computational method to identify reliable miRNA biomarkers. The visualization of the rules and the clear separation between the normal and cancer samples by our rules will help biology experts for their analysis and biological interpretation.
other	hsa-mir-375	Squamous Cell Carcinoma, Lung	28214218	disease of cellular proliferation	DOID:3907	C34.91				Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma.
other	hsa-mir-661	Squamous Cell Carcinoma, Lung	19584273	disease of cellular proliferation	DOID:3907	C34.91				miR-146b alone have the strongest prediction accuracy for stratifying prognostic groups;
other	hsa-mir-662	Squamous Cell Carcinoma, Lung	29571988	disease of cellular proliferation	DOID:3907	C34.91				MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma
other	hsa-mir-98	Squamous Cell Carcinoma, Lung	25521201	disease of cellular proliferation	DOID:3907	C34.91				rule discovery followed by distance separation is a powerful computational method to identify reliable miRNA biomarkers. The visualization of the rules and the clear separation between the normal and cancer samples by our rules will help biology experts for their analysis and biological interpretation.
other	hsa-mir-375	Squamous Cell Carcinoma, Maxillary Sinus	21922130	disease of cellular proliferation	DOID:7910	C31.0				Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma.
other	hsa-mir-874	Squamous Cell Carcinoma, Maxillary Sinus	21847129	disease of cellular proliferation	DOID:7910	C31.0				Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma.
other	hsa-let-7d	Squamous Cell Carcinoma, Oral	21725603	disease of cellular proliferation	DOID:0050866					Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer.
other	hsa-mir-10b	Squamous Cell Carcinoma, Oral	26544609	disease of cellular proliferation	DOID:0050866					Results from both patient groups together stress the importance of miR196a-5p in OSCC malignancy in both never and ever smokers, and emphasize the overall similarity of miRNA expression in OSCCs in these two risk groups. It implies that there may be great similarity in etiology of OSCC in never and ever smokers and that classifying OSCC based on tobacco exposure may not be helpful in the clinic.
other	hsa-mir-124	Squamous Cell Carcinoma, Oral	27889233	disease of cellular proliferation	DOID:0050866					Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells.
other	hsa-mir-126	Squamous Cell Carcinoma, Oral	24789258	disease of cellular proliferation	DOID:0050866					Suppressive effect of microRNA-126 on oral squamous cell carcinoma in vitro.
other	hsa-mir-138	Squamous Cell Carcinoma, Oral	28962163	disease of cellular proliferation	DOID:0050866					miR-138 is able to inhibit the proliferation, migration and invasion of OSCC cell lines
other	hsa-mir-138	Squamous Cell Carcinoma, Oral	29088820	disease of cellular proliferation	DOID:0050866					Knockdown of fascin in OSCC cells promoted cell adhesion and inhibited migration, invasion and EMT, and forced expression of miR-138 in OSCC cells significantly decreased the expression of fascin
other	hsa-mir-145	Squamous Cell Carcinoma, Oral	27557511	disease of cellular proliferation	DOID:0050866					Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
other	hsa-mir-146a	Squamous Cell Carcinoma, Oral	26159827	disease of cellular proliferation	DOID:0050866					Decrease of miR-146a is associated with the aggressiveness of human oral squamous cell carcinoma.
other	hsa-mir-146a	Squamous Cell Carcinoma, Oral	29269299	disease of cellular proliferation	DOID:0050866					the activation of TLR2 by bacterial components can enhance the progression of OSCC and may be implicated in acquired resistance to cisplatin-induced apoptosis through regulation of the miR-146a pathway
other	hsa-mir-17	Squamous Cell Carcinoma, Oral	23602254	disease of cellular proliferation	DOID:0050866					MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma.
other	hsa-mir-194	Squamous Cell Carcinoma, Oral	25960215	disease of cellular proliferation	DOID:0050866					miR-194 regulated AGK and inhibited cell proliferation of oral squamous cell carcinoma by reducing PI3K-Akt-FoxO3a signaling.
other	hsa-mir-196a	Squamous Cell Carcinoma, Oral	26544609	disease of cellular proliferation	DOID:0050866					Results from both patient groups together stress the importance of miR196a-5p in OSCC malignancy in both never and ever smokers, and emphasize the overall similarity of miRNA expression in OSCCs in these two risk groups. It implies that there may be great similarity in etiology of OSCC in never and ever smokers and that classifying OSCC based on tobacco exposure may not be helpful in the clinic.
other	hsa-mir-200c	Squamous Cell Carcinoma, Oral	26839311	disease of cellular proliferation	DOID:0050866					suppression of the anti-inflammatory tumor suppressor microRNAs let-7d, miR-23b, and miR-200c was observed following PAR-2 stimulation.
other	hsa-mir-200c	Squamous Cell Carcinoma, Oral	26879838	disease of cellular proliferation	DOID:0050866					Sulforaphane treatment resulted in a dose-dependent increase in the  levels of tumor suppressive miR200c.
other	hsa-mir-20a	Squamous Cell Carcinoma, Oral	23602254	disease of cellular proliferation	DOID:0050866					MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma.
other	hsa-mir-21	Squamous Cell Carcinoma, Oral	24676554	disease of cellular proliferation	DOID:0050866					STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo.
other	hsa-mir-21	Squamous Cell Carcinoma, Oral	25236707	disease of cellular proliferation	DOID:0050866					Human papillomavirus-stratified analysis of the prognostic role of miR-21 in oral cavity and oropharyngeal squamous cell carcinoma.
other	hsa-mir-21	Squamous Cell Carcinoma, Oral	28314265	disease of cellular proliferation	DOID:0050866					Next-generation Sequencing for microRNA Profiling: MicroRNA-21-3p Promotes Oral Cancer Metastasis.
other	hsa-mir-210	Squamous Cell Carcinoma, Oral	28459203	disease of cellular proliferation	DOID:0050866					Leptin acts on neoplastic behavior and expression levels of genes related to hypoxia, angiogenesis, and invasiveness in oral squamous cell carcinoma.
other	hsa-mir-221	Squamous Cell Carcinoma, Oral	21226887	disease of cellular proliferation	DOID:0050866					miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells.
other	hsa-mir-221	Squamous Cell Carcinoma, Oral	26796268	disease of cellular proliferation	DOID:0050866					depleting cells of miR-221 increases the sensitivity of the cells to Adriamycin.
other	hsa-mir-222	Squamous Cell Carcinoma, Oral	21226887	disease of cellular proliferation	DOID:0050866					miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells.
other	hsa-mir-31	Squamous Cell Carcinoma, Oral	26544609	disease of cellular proliferation	DOID:0050866					Results from both patient groups together stress the importance of miR196a-5p in OSCC malignancy in both never and ever smokers, and emphasize the overall similarity of miRNA expression in OSCCs in these two risk groups. It implies that there may be great similarity in etiology of OSCC in never and ever smokers and that classifying OSCC based on tobacco exposure may not be helpful in the clinic.
other	hsa-mir-378	Squamous Cell Carcinoma, Oral	24120010	disease of cellular proliferation	DOID:0050866					MicroRNA in oral squamous cell carcinoma
other	hsa-mir-491	Squamous Cell Carcinoma, Oral	24335959	disease of cellular proliferation	DOID:0050866					miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis.
other	hsa-mir-494	Squamous Cell Carcinoma, Oral	27399693	disease of cellular proliferation	DOID:0050866					The overexpression of miR-494-3p in SAS cells increased the population of senescence-associated 尾-galactosidase positive cells, the expression of p16(INK4a) and retinoblastoma 1 (RB1), as well as downregulated Bmi1.
other	hsa-mir-9	Squamous Cell Carcinoma, Oral	29073835	disease of cellular proliferation	DOID:0050866					miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway.
other	hsa-mir-135b	Squamous Cell Carcinoma, Skin or Unspecific	25938461	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma.
other	hsa-mir-148a	Squamous Cell Carcinoma, Skin or Unspecific	26253263	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Role of miR-148a in cutaneous squamous cell carcinoma by repression of MAPK pathway.
other	hsa-mir-193b	Squamous Cell Carcinoma, Skin or Unspecific	24374827	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma.
other	hsa-mir-205	Squamous Cell Carcinoma, Skin or Unspecific	28013372	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MiR-21 and miR-205 are induced in invasive cutaneous squamous cell carcinomas.
other	hsa-mir-21	Squamous Cell Carcinoma, Skin or Unspecific	26029210	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Conversely, small HA-CD44 interaction stimulates RhoA activation, NF魏B/Stat-3 signaling, and miR-21 production, resulting in inflammation and proliferation as well as SCC progression.
other	hsa-mir-21	Squamous Cell Carcinoma, Skin or Unspecific	22614019	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	These findings indicate that decreased Grhl3 expression contributes to tumor progression and upregulation of the oncomir miR-21 in squamous cell carcinoma of the skin.
other	hsa-mir-21	Squamous Cell Carcinoma, Skin or Unspecific	28013372	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MiR-21 and miR-205 are induced in invasive cutaneous squamous cell carcinomas.
other	hsa-mir-222	Squamous Cell Carcinoma, Skin or Unspecific	28925390	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes.
other	hsa-mir-365a	Squamous Cell Carcinoma, Skin or Unspecific	24374827	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma.
other	hsa-mir-490	Squamous Cell Carcinoma, Skin or Unspecific	27629145	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Poly r(C) binding protein is post-transcriptionally repressed by MiR-490-3p to potentiate squamous cell carcinoma.
other	hsa-mir-137	Squamous Cell Carcinoma, Tongue	27571935	disease of cellular proliferation	DOID:0050865	C02.9				MicroRNA-137 suppresses tongue squamous carcinoma cell proliferation, migration and invasion.
other	hsa-mir-149	Squamous Cell Carcinoma, Tongue	28356969	disease of cellular proliferation	DOID:0050865	C02.9				MicroRNA-149 targets specificity protein 1 to suppress human tongue squamous cell carcinoma cell proliferation and motility.
other	hsa-mir-183	Squamous Cell Carcinoma, Tongue	28281960	disease of cellular proliferation	DOID:0050865	C02.9				miR-183 Modulates Cell Apoptosis and Proliferation in Tongue Squamous Cell Carcinoma SCC25 Cell Line.
other	hsa-mir-203	Squamous Cell Carcinoma, Tongue	26946357	disease of cellular proliferation	DOID:0050865	C02.9				miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer.
other	hsa-mir-21	Squamous Cell Carcinoma, Tongue	21426775	disease of cellular proliferation	DOID:0050865	C02.9				Anti-sense miRNA-21 oligonucleotide inhibits Tb 3.1 human tongue squamous cell carcinoma growth in vitro.]
other	hsa-mir-21	Squamous Cell Carcinoma, Tongue	26191145	disease of cellular proliferation	DOID:0050865	C02.9				The role of miR-21 in proliferation and invasion capacity of human tongue squamous cell carcinoma in vitro.
other	hsa-mir-214	Squamous Cell Carcinoma, Tongue	25962755	disease of cellular proliferation	DOID:0050865	C02.9				Cantharidin inhibits cell proliferation and promotes apoptosis in tongue squamous cell carcinoma through suppression of miR-214 and regulation of p53 and Bcl-2/Bax.
other	hsa-mir-23a	Squamous Cell Carcinoma, Tongue	25501015	disease of cellular proliferation	DOID:0050865	C02.9				the molecular mechanisms underlying TSCC chemoresistance.
other	hsa-mir-24	Squamous Cell Carcinoma, Tongue	28413152	disease of cellular proliferation	DOID:0050865	C02.9				Loss of PTEN Expression Is Associated With High MicroRNA 24 Level and Poor Prognosis in Patients With Tongue Squamous Cell Carcinoma.
other	hsa-mir-25	Squamous Cell Carcinoma, Tongue	23827155	disease of cellular proliferation	DOID:0050865	C02.9				MiR-25-3p attenuates the proliferation of tongue squamous cell carcinoma cell line Tca8113.
other	hsa-mir-26a	Squamous Cell Carcinoma, Tongue	24343426	disease of cellular proliferation	DOID:0050865	C02.9				Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma.
other	hsa-mir-375	Squamous Cell Carcinoma, Tongue	27878285	disease of cellular proliferation	DOID:0050865	C02.9				Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miR‑375.
other	hsa-mir-424	Squamous Cell Carcinoma, Tongue	25965165	disease of cellular proliferation	DOID:0050865	C02.9				Our patient data show that microRNA-424 alterations are a marker of field cancerisation specific for tongue tumourigenesis, which also could have a role in development of tongue squamous cell carcinoma.
other	hsa-mir-126	Status Epilepticus	29468563	nervous system disease	DOID:1824		D013226		HP:0002133	the analysis of miRNA levels in serum could provide clinicians with a tool to evaluate disease evolution and the efficacy of α-T therapy in SE
other	hsa-mir-146a	Status Epilepticus	29144992	nervous system disease	DOID:1824		D013226		HP:0002133	Intracerebroventricular injection of miR-146a relieves seizures in an immature rat model of lithium-pilocarpine induced status epilepticus.
other	hsa-let-7f-1	Stroke	23745809			I64	D020521	601367	HP:0001297	antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo.
other	hsa-let-7f-2	Stroke	23745809			I64	D020521	601367	HP:0001297	antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo.
other	hsa-mir-1-1	Stroke	23745809			I64	D020521	601367	HP:0001297	antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo.
other	hsa-mir-1-2	Stroke	23745809			I64	D020521	601367	HP:0001297	antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo.
other	hsa-mir-124	Stroke	23696548			I64	D020521	601367	HP:0001297	These data demonstrate that p53-mediated neuronal cell death after stroke can be nontranscriptionally regulated by a novel mechanism involving suppression of endogenous cell death inhibitors by miR-124.
other	hsa-mir-124	Stroke	23860031			I64	D020521	601367	HP:0001297	We highlight interactions between the miR-124 and the miR17-92 cluster and the Notch and Sonic hedgehog signaling pathways in mediating stroke-induced neurogenesis.
other	hsa-mir-124	Stroke	24244499			I64	D020521	601367	HP:0001297	miR-689, miR-124, and miR-155 were the most strongly associated miRNAs predicted to mediate pro-inflammatory pathways and M1-like activation phenotype.
other	hsa-mir-124	Stroke	27126323			I64	D020521	601367	HP:0001297	lithium increased miR-124 expression
other	hsa-mir-124	Stroke	27539642			I64	D020521	601367	HP:0001297	Dynamic Modulation of Microglia/Macrophage Polarization by miR-124 after Focal Cerebral Ischemia.
other	hsa-mir-124	Stroke	28624203			I64	D020521	601367	HP:0001297	Exosome Mediated Delivery of miR-124 Promotes Neurogenesis after Ischemia.
other	hsa-mir-124	Stroke	29221142			I64	D020521	601367	HP:0001297	D-4F increases microRNA-124a and reduces neuroinflammation in diabetic stroke rats
other	hsa-mir-124	Stroke	29494665			I64	D020521	601367	HP:0001297	MicroRNA-124-loaded nanoparticles increase survival and neuronal differentiation of neural stem cells in vitro but do not contribute to stroke outcome in vivo
other	hsa-mir-124	Stroke	29524052			I64	D020521	601367	HP:0001297	this network-based approach to delineate miRNA, TF, and gene interactions might promote the development of effective therapeutics against ischemic stroke
other	hsa-mir-126	Stroke	28101763			I64	D020521	601367	HP:0001297	MiR-126 Affects Brain-Heart Interaction after Cerebral Ischemic Stroke.
other	hsa-mir-145	Stroke	23745809			I64	D020521	601367	HP:0001297	antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo.
other	hsa-mir-150	Stroke	26922365			I64	D020521	601367	HP:0001297	Upregulation of miR-150  expression could decrease vascular density of infarct border zone in rat after MCAO and decrease tube formation, proliferation, and migration of BMVECs.
other	hsa-mir-155	Stroke	24244499			I64	D020521	601367	HP:0001297	miR-155, the most strongly up-regulated miRNA,regulates the signal transducer and activator of transcription 3 signaling pathway enabling the late phase response to M1-skewing stimulation. 
other	hsa-mir-155	Stroke	27829437			I64	D020521	601367	HP:0001297	In vivo inhibition of miR-155 significantly alters post-stroke inflammatory response.
other	hsa-mir-155	Stroke	28025572			I64	D020521	601367	HP:0001297	Influence of miR-155 on Cell Apoptosis in Rats with Ischemic Stroke: Role of the Ras Homolog Enriched in Brain (Rheb)/mTOR Pathway.
other	hsa-mir-155	Stroke	29527155			I64	D020521	601367	HP:0001297	the functions of the miRNA miR-155 and the effect of its in vivo inhibition on brain recovery following experimental cerebral ischemia
other	hsa-mir-181a-1	Stroke	23745809			I64	D020521	601367	HP:0001297	antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo.
other	hsa-mir-181a-2	Stroke	23745809			I64	D020521	601367	HP:0001297	antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo.
other	hsa-mir-185	Stroke	28199366			I64	D020521	601367	HP:0001297	MicroRNAs regulating cluster of differentiation 46 (CD46) in cardioembolic and non-cardioembolic stroke.
other	hsa-mir-19a	Stroke	28199366			I64	D020521	601367	HP:0001297	MicroRNAs regulating cluster of differentiation 46 (CD46) in cardioembolic and non-cardioembolic stroke.
other	hsa-mir-20a	Stroke	28199366			I64	D020521	601367	HP:0001297	MicroRNAs regulating cluster of differentiation 46 (CD46) in cardioembolic and non-cardioembolic stroke.
other	hsa-mir-210	Stroke	29111308			I64	D020521	601367	HP:0001297	Inhibition of microRNA-210 suppresses pro-inflammatory response and reduces acute brain injury of ischemic stroke in mice.
other	hsa-mir-30a	Stroke	28854438			I64	D020521	601367	HP:0001297	Down-Regulation of Lncrna MALAT1 Attenuates Neuronal Cell Death Through Suppressing Beclin1-Dependent Autophagy by Regulating Mir-30a in Cerebral Ischemic Stroke.
other	hsa-mir-374b	Stroke	28199366			I64	D020521	601367	HP:0001297	MicroRNAs regulating cluster of differentiation 46 (CD46) in cardioembolic and non-cardioembolic stroke.
other	hsa-mir-497	Stroke	23745809			I64	D020521	601367	HP:0001297	antagomirs to miR-145, -497, -181a, -1 and let-7f have been found to be neuroprotective in vivo.
other	hsa-mir-107	Stroke, Ischemic	24943094			I63.9			HP:0002140	Up-regulation of brain-enriched miR-107 promotes excitatory neurotoxicity through down-regulation of glutamate transporter-1 expression following ischaemic stroke.
other	hsa-mir-149	Stroke, Ischemic	25867405			I63.9			HP:0002140	Effect of a pre-microRNA-149 (miR-149) genetic variation on the risk of ischemic stroke in a Chinese Han population.
other	hsa-mir-17	Synovial Sarcoma	24989082	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.
other	hsa-let-7e	Systemic Lupus Erythematosus	25912736	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	These data suggest that 17β-estradiol amplifies the activation of IFN-α signaling in B cells via IKKε by down-regulating the expression of let-7e-5p, miR-98-5p and miR-145a-5p. Our findings may provide a new perspective for understanding the mechanism underlying the gender difference in the prevalence of SLE.
other	hsa-mir-101-1	Systemic Lupus Erythematosus	23139385	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-101, mitogen-activated protein kinases and mitogen-activated protein kinases phosphatase-1 in systemic lupus erythematosus
other	hsa-mir-101-2	Systemic Lupus Erythematosus	23139385	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-101, mitogen-activated protein kinases and mitogen-activated protein kinases phosphatase-1 in systemic lupus erythematosus
other	hsa-mir-142	Systemic Lupus Erythematosus	22549634	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Decreased miR-142-3p/5p expression causes CD4(+) T cell activation and B cell hyperstimulation in systemic lupus erythematosus.
other	hsa-mir-145a	Systemic Lupus Erythematosus	25912736	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	These data suggest that 17β-estradiol amplifies the activation of IFN-α signaling in B cells via IKKε by down-regulating the expression of let-7e-5p, miR-98-5p and miR-145a-5p. Our findings may provide a new perspective for understanding the mechanism underlying the gender difference in the prevalence of SLE.
other	hsa-mir-146a	Systemic Lupus Erythematosus	21952984	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-146a has a role in the pathogenesis of systemic lupus erythematosus with atherosclerosis.
other	hsa-mir-146a	Systemic Lupus Erythematosus	24292724	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	STAT1 and miR-146a may be upregulated during inflammation and via proinflammatory cytokines and chemokines in SLE. Prolonged upregulation of STAT1 and miR-146a appears to play an important role in anemia in SLE patients.
other	hsa-mir-146a	Systemic Lupus Erythematosus	25349113	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The miR-146a polymorphism and susceptibility to systemic lupus erythematosus and rheumatoid arthritis : a meta-analysis.
other	hsa-mir-155	Systemic Lupus Erythematosus	26055806	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	We demonstrate that SLE patients have reduced IL-21 signaling capacity, decreased miR-155 levels, and increased SOCS1 levels compared to HCs.The reduced IL-21 signaling in SLE could be rescued by overexpression of miR-155,suggesting an important role for miR-155 in the reduced IL-21 signaling observed in SLE.
other	hsa-mir-155	Systemic Lupus Erythematosus	25929465	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	These findings provide new insight into the mechanism underlying decreased CD1d expression on B cells in SLE, suggesting that inhibition of inflammation may increase CD1d expression in B cells to ameliorate SLE via modulating iNKT cells.
other	hsa-mir-155	Systemic Lupus Erythematosus	27697141	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Follicular T helper cells and IL-21 in rheumatic diseases.
other	hsa-mir-155	Systemic Lupus Erythematosus	28665018	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MiR-155*, miR-34b and miR-34a levels in T lymphocytes and corresponding MVs were deregulated in SLE when compared to healthy individuals
other	hsa-mir-19b-1	Systemic Lupus Erythematosus	21794077	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Down-regulation of miR-19b and miR-20a observed in patients with SLE and SAF could contribute to increase TF expression and thus provoke the hypercoagulable state characteristic of these patients.
other	hsa-mir-20a	Systemic Lupus Erythematosus	21794077	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Down-regulation of miR-19b and miR-20a observed in patients with SLE and SAF could contribute to increase TF expression and thus provoke the hypercoagulable state characteristic of these patients.
other	hsa-mir-21	Systemic Lupus Erythematosus	27697141	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Follicular T helper cells and IL-21 in rheumatic diseases.
other	hsa-mir-21	Systemic Lupus Erythematosus	28039018	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Estrogen-regulated STAT1 activation promotes TLR8 expression to facilitate signaling via microRNA-21 in systemic lupus erythematosus.
other	hsa-mir-31	Systemic Lupus Erythematosus	22736314	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	microRNA-31 is a novel regulator contributing to impaired IL-2 production in T cells from patients with systemic lupus erythematosus.
other	hsa-mir-31	Systemic Lupus Erythematosus	27405090	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Its own regulation is disrupted during the onset and progression of cancer and autoimmune disorders such as psoriasis and systemic lupus erythematosus.
other	hsa-mir-34a	Systemic Lupus Erythematosus	28665018	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MiR-155*, miR-34b and miR-34a levels in T lymphocytes and corresponding MVs were deregulated in SLE when compared to healthy individuals
other	hsa-mir-34b	Systemic Lupus Erythematosus	28665018	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MiR-155*, miR-34b and miR-34a levels in T lymphocytes and corresponding MVs were deregulated in SLE when compared to healthy individuals
other	hsa-mir-7	Systemic Lupus Erythematosus	27450756	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The clearest case is one circRNA CDR1as that serves as sponge of miR-7.
other	hsa-mir-98	Systemic Lupus Erythematosus	25912736	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	These data suggest that 17β-estradiol amplifies the activation of IFN-α signaling in B cells via IKKε by down-regulating the expression of let-7e-5p, miR-98-5p and miR-145a-5p. Our findings may provide a new perspective for understanding the mechanism underlying the gender difference in the prevalence of SLE.
other	hsa-mir-142	Systemic Mastocytosis	24361879	hematopoietic system disease	DOID:349	D47.2	D034721	154800		miR-142-3p enhances FcεRI-mediated degranulation in mast cells.
other	hsa-mir-124a	Teratocarcinoma	17716626	disease of cellular proliferation	DOID:3305		D018243			Based on these observations, it is suggested that the miR-302 cluster and miR-124a may be useful molecular indicators in the assessmentof degree of undifferentiation and/or differentiation in the course of neuronal differentiation.
other	hsa-mir-142	Testicular Germ Cell Tumor	23843459	disease of cellular proliferation	DOID:5557		C563236	273300		Tumor-suppressive function of protein-tyrosine phosphatase non-receptor type 23 in testicular germ cell tumors is lost upon overexpression of miR142-3p microRNA.
other	hsa-mir-302a	Testicular Germ Cell Tumor	23625774	disease of cellular proliferation	DOID:5557		C563236	273300		Up-regulation of miR-302a significantly increased the sensitivity of NT2 cells to cisplatin by enhancing cisplatin-induced G2/M phase arrest and the subsequent progression to apoptosis.MiR-302a also increased the killing effects of cisplatin by lowering the apoptotic threshold; the same result was also observed in another TGCT-derived cell line, NCCIT.
other	hsa-mir-371a	Testicular Germ Cell Tumor	28612337	disease of cellular proliferation	DOID:5557		C563236	273300		microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
other	hsa-mir-133b	Testicular Neoplasms	28126411	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	Perfluorooctanoic acid affects endocytosis involving clathrin light chain A and microRNA-133b-3p in mouse testes.
other	hsa-mir-372	Testicular Neoplasms	17965831	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	miR-372 and miR-373 have been implicated in testicular germ cell tumours.
other	hsa-mir-373	Testicular Neoplasms	17965831	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	miR-372 and miR-373 have been implicated in testicular germ cell tumours.
other	hsa-mir-940	Tetralogy Of Fallot	24889693	cardiovascular system disease	DOID:6419	Q21.3	D013771	187500		miRNA-940 reduction contributes to human Tetralogy of Fallot development.
other	hsa-mir-145	Thrombocytosis	22571696	hematopoietic system disease	DOID:2228	D69.6	D013922		HP:0001894	Recent evidence suggests that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome.
other	hsa-mir-146a	Thrombocytosis	22571696	hematopoietic system disease	DOID:2228	D69.6	D013922		HP:0001894	Recent evidence suggests that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the thrombocytosis seen in the 5q- syndrome.
other	hsa-mir-326	Thrombosis	25875481	cardiovascular system disease	DOID:0060903		D013927			The effect of miR-326 appeared to be limited to apoptosis,with no significant effect on platelet activation. These results provide new insight into the molecular mechanisms affecting differential platelet gene regulation, which may increase understanding of the role of platelet apoptosis in multiple diseases.
other	hsa-mir-101	Thyroid Adenomas	25916957	disease of cellular proliferation	DOID:2891		D013964	611800	HP:0000854	These results support a role for miRNA in the regulation of extracellular matrix proteins and tissue remodeling occurring during tumor development, and in the important negative feedback of the cAMP pathway, which limits the consequences of its constitutive activation in these tumors.
other	hsa-mir-144	Thyroid Adenomas	25916957	disease of cellular proliferation	DOID:2891		D013964	611800	HP:0000854	These results support a role for miRNA in the regulation of extracellular matrix proteins and tissue remodeling occurring during tumor development, and in the important negative feedback of the cAMP pathway, which limits the consequences of its constitutive activation in these tumors.
other	hsa-mir-126	Thyroid Neoplasms	26244545	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	To our knowledge, this is the first study to demonstrate that miR-126-3p has a tumor-suppressive function in thyroid cancer cells, and is associated with aggressive disease phenotype.
other	hsa-mir-126	Thyroid Neoplasms	27067785	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma.
other	hsa-mir-144	Thyroid Neoplasms	23783103	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis.
other	hsa-mir-146b	Thyroid Neoplasms	23264400	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Prognostic Implications of miR-146b Expression and Its Functional Role in Papillary Thyroid Carcinoma
other	hsa-mir-146b	Thyroid Neoplasms	23783103	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis.
other	hsa-mir-197	Thyroid Neoplasms	22351693	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	A SVM model with 4 miRNAs (miR-222, miR-328, miR-197 and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation to differentiate Malignant from Benign.
other	hsa-mir-205	Thyroid Neoplasms	26342107	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The angiogenic and tumour-suppressive roles of miRNA-205 were demonstrated for the first time in thyroid cancer. The current experiments provided specific information on the functional consequences of VEGF manipulation via miRNA on cancer.
other	hsa-mir-206	Thyroid Neoplasms	25955685	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-206 inhibits metastasis-relevant traits by degrading MRTF-A in anaplastic thyroid cancer.
other	hsa-mir-21	Thyroid Neoplasms	22351693	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	A SVM model with 4 miRNAs (miR-222, miR-328, miR-197 and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation to differentiate Malignant from Benign.
other	hsa-mir-221	Thyroid Neoplasms	23783103	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis.
other	hsa-mir-221	Thyroid Neoplasms	22771635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	While a combination of miR-221 and 222 when used in a diagnostic panel could provide fairly good accuracy additional markers may need to be investigated to augment their diagnostic utility.
other	hsa-mir-222	Thyroid Neoplasms	22351693	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	A SVM model with 4 miRNAs (miR-222, miR-328, miR-197 and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation to differentiate Malignant from Benign.
other	hsa-mir-222	Thyroid Neoplasms	22771635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	While a combination of miR-221 and 222 when used in a diagnostic panel could provide fairly good accuracy additional markers may need to be investigated to augment their diagnostic utility.
other	hsa-mir-25	Thyroid Neoplasms	26437444	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Together, our data suggest that IL-23 induces migration and invasion in thyroid cancer cells by mediating the miR-25/SOCS4 signaling pathway.
other	hsa-mir-30d	Thyroid Neoplasms	24345332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin.
other	hsa-mir-328	Thyroid Neoplasms	22351693	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	A SVM model with 4 miRNAs (miR-222, miR-328, miR-197 and miR-21) was initially estimated to have 86% predictive accuracy using cross-validation to differentiate Malignant from Benign.
other	hsa-mir-371a	Thyroid Neoplasms	23062364	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Activation of the two microRNA clusters C19MC and miR-371-3 does not play prominent role in thyroid cancer
other	hsa-mir-4295	Thyroid Neoplasms	26231799	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-4295 promotes cell proliferation and invasion in anaplastic thyroid carcinoma via CDKN1A.
other	hsa-mir-486	Thyroid Neoplasms	23783103	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis.
other	hsa-mir-551b	Thyroid Neoplasms	23783103	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis.
other	hsa-mir-618	Thyroid Neoplasms	25145559	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MiR-618 inhibits anaplastic thyroid cancer by repressing XIAP in one ATC cell line.
other	hsa-mir-7	Thyroid Neoplasms	23783103	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis.
other	hsa-mir-210	Tibial Meniscus Injuries	25430980				D000070600			An intra-articular injection of ds miR-210 was effective in the healing of the damaged white zone meniscus through promotion of the collagen type 2 production from meniscus cells and through upregulated of VEGF and FGF2 from synovial cells.
other	hsa-mir-195	Tongue Neoplasms	23451060	gastrointestinal system disease	DOID:8649	C01	D014062		HP:0100648	Prognostic Implications of MicoRNA miR-195 Expression in Human Tongue Squamous Cell Carcinoma
other	hsa-mir-375	Tongue Neoplasms	25521291	gastrointestinal system disease	DOID:8649	C01	D014062		HP:0100648	the four anti-cancer drugs examined in this study induce the expression of tumor suppressor miR-375 in tongue cancer.
other	hsa-mir-34a	Toxic Encephalopathy	26091620	nervous system disease	DOID:3602	G92	D020258			We also found that inhibition of astrocytic miR-34a after Lipopolysaccharide(LPS) stimulation can postpone dopaminergic neuron loss under neurotoxin stress.
other	hsa-mir-34a	Toxic Encephalopathy	29578002	nervous system disease	DOID:3602	G92	D020258			microRNA-34a could improve anesthesia-induced cognitive dysfunction by suppressing cell apoptosis and recovering the expression of genes associated with the MAPK/ERK signaling pathway
other	hsa-mir-106b	Toxoplasma gondii Infection	20090903	disease by infectious agent	DOID:9965	B58	D014123			play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases
other	hsa-mir-132	Toxoplasma gondii Infection	24657774	disease by infectious agent	DOID:9965	B58	D014123			MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway.
other	hsa-mir-146a	Toxoplasma gondii Infection	24582962	disease by infectious agent	DOID:9965	B58	D014123			miR-146a and miR-155 delineate a MicroRNA fingerprint associated with Toxoplasma  persistence in the host brain.
other	hsa-mir-155	Toxoplasma gondii Infection	24582962	disease by infectious agent	DOID:9965	B58	D014123			miR-146a and miR-155 delineate a MicroRNA fingerprint associated with Toxoplasma  persistence in the host brain.
other	hsa-mir-17	Toxoplasma gondii Infection	20090903	disease by infectious agent	DOID:9965	B58	D014123			play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases
other	hsa-mir-17	Toxoplasma gondii Infection	24583285	disease by infectious agent	DOID:9965	B58	D014123			Taken together, we describe a novel STAT3-miR-17-92-Bim pathway, thus providing a mechanistic explanation for inhibition of apoptosis of host cells following Toxoplasma infection.
other	hsa-mir-17	Toxoplasma gondii Infection	24341525	disease by infectious agent	DOID:9965	B58	D014123			We demonstrated that miR-30c-1, miR-125b-2, miR-23b-27b-24-1 and miR-17鈥墌鈥?2 cluster genes were transactivated through promoter binding of the STAT3 following T. gondii infection.
other	hsa-mir-18a	Toxoplasma gondii Infection	20090903	disease by infectious agent	DOID:9965	B58	D014123			play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases
other	hsa-mir-19a	Toxoplasma gondii Infection	20090903	disease by infectious agent	DOID:9965	B58	D014123			play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases
other	hsa-mir-19b-1	Toxoplasma gondii Infection	20090903	disease by infectious agent	DOID:9965	B58	D014123			play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases
other	hsa-mir-19b-2	Toxoplasma gondii Infection	20090903	disease by infectious agent	DOID:9965	B58	D014123			play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases
other	hsa-mir-20a	Toxoplasma gondii Infection	20090903	disease by infectious agent	DOID:9965	B58	D014123			play crucial roles in mammalian cell regulation and have been implicated in numerous hyperproliferative diseases
other	hsa-mir-223	Traumatic Brain Injury	28804446			S06.2	D000070642			Induction of miR-155 after Brain Injury Promotes Type 1 Interferon and has a Neuroprotective Effect.
other	hsa-mir-125b	Tuberculosis	27789724	disease by infectious agent	DOID:399	A15-A19	D014376			Downregulation of hsa-miR-337-3p and hsa-miR-125b-5p by miRNA sponges improved IL-23-mediated expansion of Vγ2Vδ2 T cells and restored the ability of these cells to produce anti-tuberculosis cytokines
other	hsa-mir-337	Tuberculosis	27789724	disease by infectious agent	DOID:399	A15-A19	D014376			Downregulation of hsa-miR-337-3p and hsa-miR-125b-5p by miRNA sponges improved IL-23-mediated expansion of Vγ2Vδ2 T cells and restored the ability of these cells to produce anti-tuberculosis cytokines
other	hsa-mir-144	Tuberculosis, Pulmonary	21367459	disease by infectious agent	DOID:2957	A15	D014397			Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis.
other	hsa-mir-29a	Tuberculosis, Pulmonary	24981709	disease by infectious agent	DOID:2957	A15	D014397			Dynamics of T-cell IFN-γ and miR-29a expression during active pulmonary tuberculosis.
other	hsa-mir-100	Urinary Bladder Cancer	25071007	urinary system disease	DOID:11054	C67	D001749	109800		microRNAs-99a/100 mediate a direct relationship between FGFR3 and FOXA1 and potentially facilitate cross talk between these pathways in UCC.
other	hsa-mir-133a-1	Urinary Bladder Cancer	23410519	urinary system disease	DOID:11054	C67	D001749	109800		A Common microRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ With Normal Umbrella Cells
other	hsa-mir-133b	Urinary Bladder Cancer	22179829	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways.
other	hsa-mir-138-1	Urinary Bladder Cancer	22954303	urinary system disease	DOID:11054	C67	D001749	109800		Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity.
other	hsa-mir-138-2	Urinary Bladder Cancer	22954303	urinary system disease	DOID:11054	C67	D001749	109800		Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity.
other	hsa-mir-139	Urinary Bladder Cancer	23410519	urinary system disease	DOID:11054	C67	D001749	109800		A Common microRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ With Normal Umbrella Cells
other	hsa-mir-142	Urinary Bladder Cancer	23410519	urinary system disease	DOID:11054	C67	D001749	109800		A Common microRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ With Normal Umbrella Cells
other	hsa-mir-143	Urinary Bladder Cancer	19157460	urinary system disease	DOID:11054	C67	D001749	109800		miR-143: a tumor suppressor
other	hsa-mir-143	Urinary Bladder Cancer	21550168	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells
other	hsa-mir-145	Urinary Bladder Cancer	22287315	urinary system disease	DOID:11054	C67	D001749	109800		Glucocorticoid regulation of a novel HPV E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells.
other	hsa-mir-182	Urinary Bladder Cancer	25676538	urinary system disease	DOID:11054	C67	D001749	109800		This study shows that the level of miR-182 is higher in cytology specimens from high-grade UCC patients as compared to normal controls.Measuring miR-182 may provide a potential alternative or adjunct approach for screening high-grade UCC.
other	hsa-mir-182	Urinary Bladder Cancer	23313739	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-182 plays an onco-miRNA role in cervical cancer
other	hsa-mir-194-1	Urinary Bladder Cancer	17470785	urinary system disease	DOID:11054	C67	D001749	109800		The list of miRNAs at or near sites commonly altered in human cancers includes mir-215 and mir-194-1, which are <0.17 kb from D1Mit208, a marker that defines the peak of the colon Scc3 locus on Chr 1. Homologous human miRNAs are located inside the FRA1H at Chr 1q42.1; this fragile site is an HPV16 integration site involved in cervical cancer.
other	hsa-mir-200a	Urinary Bladder Cancer	20124485	urinary system disease	DOID:11054	C67	D001749	109800		play important regulatory roles in cervical cancer control
other	hsa-mir-203	Urinary Bladder Cancer	21836020	urinary system disease	DOID:11054	C67	D001749	109800		Curcumin modulates microRNA-203 mediated regulation of the Src-Akt axis in bladder cancer.
other	hsa-mir-205	Urinary Bladder Cancer	23056551	urinary system disease	DOID:11054	C67	D001749	109800		miR-205 expression promotes cell proliferation and migration of human cervical cancer cells
other	hsa-mir-21	Urinary Bladder Cancer	21468550	urinary system disease	DOID:11054	C67	D001749	109800		microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells
other	hsa-mir-215	Urinary Bladder Cancer	17470785	urinary system disease	DOID:11054	C67	D001749	109800		The list of miRNAs at or near sites commonly altered in human cancers includes mir-215 and mir-194-1, which are <0.17 kb from D1Mit208, a marker that defines the peak of the colon Scc3 locus on Chr 1. Homologous human miRNAs are located inside the FRA1H at Chr 1q42.1; this fragile site is an HPV16 integration site involved in cervical cancer.
other	hsa-mir-218-1	Urinary Bladder Cancer	23443110	urinary system disease	DOID:11054	C67	D001749	109800		MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer
other	hsa-mir-218-2	Urinary Bladder Cancer	23443110	urinary system disease	DOID:11054	C67	D001749	109800		MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer
other	hsa-mir-23b	Urinary Bladder Cancer	21242962	urinary system disease	DOID:11054	C67	D001749	109800		Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway.
other	hsa-mir-27	Urinary Bladder Cancer	24821854	urinary system disease	DOID:11054	C67	D001749	109800		3'-Biotin-tagged microRNA-27 does not associate with Argonaute proteins in cells.
other	hsa-mir-27a	Urinary Bladder Cancer	22954303	urinary system disease	DOID:11054	C67	D001749	109800		Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity.
other	hsa-mir-34a	Urinary Bladder Cancer	21702042	urinary system disease	DOID:11054	C67	D001749	109800		MiR-34a chemo-sensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status.
other	hsa-mir-34a	Urinary Bladder Cancer	19258450	urinary system disease	DOID:11054	C67	D001749	109800		miR-34a: Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6
other	hsa-mir-517a	Urinary Bladder Cancer	21479368	urinary system disease	DOID:11054	C67	D001749	109800		Restoration of miR-517a expression induces cell apoptosis in bladder cancer cell lines.
other	hsa-mir-574	Urinary Bladder Cancer	22179486	urinary system disease	DOID:11054	C67	D001749	109800		Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines.
other	hsa-mir-642a	Urinary Bladder Cancer	22954303	urinary system disease	DOID:11054	C67	D001749	109800		Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity.
other	hsa-mir-642b	Urinary Bladder Cancer	22954303	urinary system disease	DOID:11054	C67	D001749	109800		Decreasing miR-138 increased the cisplatin sensitivity in half of the cell lines and increasing miR-27a and miR-642 generally increased cisplatin sensitivity.
other	hsa-mir-93	Urinary Bladder Cancer	19671845	urinary system disease	DOID:11054	C67	D001749	109800		control the EMT process and sensitivity to EGFR therapy
other	hsa-mir-944	Urinary Bladder Cancer	22954303	urinary system disease	DOID:11054	C67	D001749	109800		Three miRNAs were associated with both response (to chemotherapy) and survival (886-3p, 923, 944).
other	hsa-mir-99a	Urinary Bladder Cancer	25071007	urinary system disease	DOID:11054	C67	D001749	109800		microRNAs-99a/100 mediate a direct relationship between FGFR3 and FOXA1 and potentially facilitate cross talk between these pathways in UCC.
other	hsa-mir-29b	Uterine Corpus Choriocarcinoma	25738313	disease of cellular proliferation	DOID:8188	C54.9				BAG3 increases the invasiveness of uterine corpus carcinoma cells by suppressing miR-29b and enhancing MMP2 expression.
other	hsa-mir-182	Uterine Leiomyoma	24476133			D25.9	D007889	150699	HP:0000131	We observed that administration of MK-2206, an allosteric AKT inhibitor, increased levels of reactive oxygen species, up-regulated the microRNA miR-182 and several senescence-associated genes (including p16, p53, p21, and 尾-galactosidase), and drove leiomyoma cells into stress-induced premature senescence (SIPS).
other	hsa-mir-29b	Uterine Leiomyoma	24424054			D25.9	D007889	150699	HP:0000131	Down-regulation of miR-29b is essential for pathogenesis of uterine leiomyoma.
other	hsa-mir-144	Uveal Melanoma	25961751				C536494	155720	HP:0007716	MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression.
other	hsa-mir-454	Uveal Melanoma	26296312				C536494	155720	HP:0007716	Our data revealed that ectopic expression of PTEN restored the effects of miR-454 on cell proliferation and invasion in uveal melanoma cells. These findings support an oncogene role of miR-454 in development of uveal melanoma.
other	hsa-let-7f	Vascular Disease [unspecific]	18550634	cardiovascular system disease	DOID:178	I72.9	D000783			Meanwhile, a few specific miRNAs that regulate endothelial cell functions and angiogenesis have been described. Let7-f, miR-27b, and mir-130a were identified as pro-angiogenic miRNAs
other	hsa-mir-125a	Vascular Disease [unspecific]	25854878	cardiovascular system disease	DOID:178	I72.9	D000783			These translational data emphasize the pathogenetic role of miR-125a in pulmonary vascular remodeling.
other	hsa-mir-126	Vascular Disease [unspecific]	19917099	cardiovascular system disease	DOID:178	I72.9	D000783			miR-126, miR-24 and miR-23a are selectively expressed in microvascular endothelial cells in vivo
other	hsa-mir-126	Vascular Disease [unspecific]	20364122	cardiovascular system disease	DOID:178	I72.9	D000783			We further find that angiogenic sprouting of AA vessels requires a flow-induced genetic pathway in which the mechano-sensitive zinc finger transcription factor klf2a induces expression of an endothelial-specific microRNA, mir-126, to activate Vegf signalling.
other	hsa-mir-126	Vascular Disease [unspecific]	27780851	cardiovascular system disease	DOID:178	I72.9	D000783			GATA2-mediated regulation of miR-126 and miR-221 has an important impact on endothelial biology. Hence, modulation of GATA2 and its targets miR-126 and miR-221 is a promising therapeutic strategy for treatment of many vascular diseases
other	hsa-mir-130a	Vascular Disease [unspecific]	18550634	cardiovascular system disease	DOID:178	I72.9	D000783			Meanwhile, a few specific miRNAs that regulate endothelial cell functions and angiogenesis have been described. Let7-f, miR-27b, and mir-130a were identified as pro-angiogenic miRNAs
other	hsa-mir-143	Vascular Disease [unspecific]	25655189	cardiovascular system disease	DOID:178	I72.9	D000783			Myocyte Enhancer Factor 2A Regulates Hydrogen Peroxide-Induced Senescence of Vascular Smooth Muscle Cells Via microRNA-143.
other	hsa-mir-145	Vascular Disease [unspecific]	19917099	cardiovascular system disease	DOID:178	I72.9	D000783			elevated levels of miR-145 reduced migration of microvascular cells in response to growth factor gradients in vitro
other	hsa-mir-145	Vascular Disease [unspecific]	25655189	cardiovascular system disease	DOID:178	I72.9	D000783			Myocyte Enhancer Factor 2A Regulates Hydrogen Peroxide-Induced Senescence of Vascular Smooth Muscle Cells Via microRNA-143.
other	hsa-mir-145	Vascular Disease [unspecific]	27186305	cardiovascular system disease	DOID:178	I72.9	D000783			MicroRNA-145 regulates platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration by targeting CD40
other	hsa-mir-15b	Vascular Disease [unspecific]	25665638	cardiovascular system disease	DOID:178	I72.9	D000783			We focus on the diverse roles of miR-15b in the occurrence, progression and prognosis of vascular diseases,with particular emphasis on preeclampsia, a hypertensive disorder related to endovascular dysfunction in the placenta.
other	hsa-mir-16	Vascular Disease [unspecific]	29402872	cardiovascular system disease	DOID:178	I72.9	D000783			This revascularization is associated with a decrease in miRNA-16 expression permissive for increased VEGF protein expression, suggesting a mechanism for potential therapeutic application in vascular diseases
other	hsa-mir-181a	Vascular Disease [unspecific]	27911586	cardiovascular system disease	DOID:178	I72.9	D000783			miRNA-181a/b Regulates Phenotypes of Vessel Smooth Muscle Cells Through Serum Response Factor.
other	hsa-mir-181b	Vascular Disease [unspecific]	27911586	cardiovascular system disease	DOID:178	I72.9	D000783			miRNA-181a/b Regulates Phenotypes of Vessel Smooth Muscle Cells Through Serum Response Factor.
other	hsa-mir-22	Vascular Disease [unspecific]	25530680	cardiovascular system disease	DOID:178	I72.9	D000783			Mox-LDL interferes with parameters associated with angiogenesis. They suggest that high LDL levels in patients would impair their endothelial cell capacity to cope with a damaged endothelium contributing negatively to the progression of the atheroma plaque.
other	hsa-mir-221	Vascular Disease [unspecific]	27780851	cardiovascular system disease	DOID:178	I72.9	D000783			GATA2-mediated regulation of miR-126 and miR-221 has an important impact on endothelial biology. Hence, modulation of GATA2 and its targets miR-126 and miR-221 is a promising therapeutic strategy for treatment of many vascular diseases
other	hsa-mir-23a	Vascular Disease [unspecific]	19917099	cardiovascular system disease	DOID:178	I72.9	D000783			miR-126, miR-24 and miR-23a are selectively expressed in microvascular endothelial cells in vivo
other	hsa-mir-24	Vascular Disease [unspecific]	20019669	cardiovascular system disease	DOID:178	I72.9	D000783			Inhibition of miR-24 by antisense oligonuclotides abrogates the downregulation of Trb3 as well as pro-synthetic activity of the PDGF-signalling pathway.
other	hsa-mir-27b	Vascular Disease [unspecific]	18550634	cardiovascular system disease	DOID:178	I72.9	D000783			Meanwhile, a few specific miRNAs that regulate endothelial cell functions and angiogenesis have been described. Let7-f, miR-27b, and mir-130a were identified as pro-angiogenic miRNAs
other	hsa-mir-29a	Vascular Disease [unspecific]	27752152	cardiovascular system disease	DOID:178	I72.9	D000783			Dynamic alteration of microRNA in high phosphorus induced calcification of vascular smooth muscle cell.
other	hsa-mir-30b	Vascular Disease [unspecific]	23316327	cardiovascular system disease	DOID:178	I72.9	D000783			Bone Morphogenetic Protein-2 Decreases MicroRNA-30b and MicroRNA-30c to Promote Vascular Smooth Muscle Cell Calcification
other	hsa-mir-30c-1	Vascular Disease [unspecific]	23316327	cardiovascular system disease	DOID:178	I72.9	D000783			Bone Morphogenetic Protein-2 Decreases MicroRNA-30b and MicroRNA-30c to Promote Vascular Smooth Muscle Cell Calcification
other	hsa-mir-30c-2	Vascular Disease [unspecific]	23316327	cardiovascular system disease	DOID:178	I72.9	D000783			Bone Morphogenetic Protein-2 Decreases MicroRNA-30b and MicroRNA-30c to Promote Vascular Smooth Muscle Cell Calcification
other	hsa-mir-34a	Vascular Disease [unspecific]	26582729	cardiovascular system disease	DOID:178	I72.9	D000783			overexpression of a miR-34a mimic  prevents metformin-mediated protection.
other	hsa-mir-483	Vascular Disease [unspecific]	24976017	cardiovascular system disease	DOID:178	I72.9	D000783			Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system.
other	hsa-let-7a	Vascular Disease [unspecific]	17540974	cardiovascular system disease	DOID:178	I72.9	D000783			The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis.
other	hsa-let-7b	Vascular Disease [unspecific]	17540974	cardiovascular system disease	DOID:178	I72.9	D000783			The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis.
other	hsa-let-7b	Vascular Disease [unspecific]	26348824	cardiovascular system disease	DOID:178	I72.9	D000783			only let-7b and miR-133a were markedly upregulated.
other	hsa-let-7c	Vascular Disease [unspecific]	17540974	cardiovascular system disease	DOID:178	I72.9	D000783			The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis.
other	hsa-let-7d	Vascular Disease [unspecific]	17540974	cardiovascular system disease	DOID:178	I72.9	D000783			The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis.
other	hsa-let-7e	Vascular Disease [unspecific]	17540974	cardiovascular system disease	DOID:178	I72.9	D000783			The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis.
other	hsa-let-7f	Vascular Disease [unspecific]	17540974	cardiovascular system disease	DOID:178	I72.9	D000783			The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis.
other	hsa-let-7g	Vascular Disease [unspecific]	17540974	cardiovascular system disease	DOID:178	I72.9	D000783			The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis.
other	hsa-let-7i	Vascular Disease [unspecific]	17540974	cardiovascular system disease	DOID:178	I72.9	D000783			The let-7 family and mir-27b appear to be attractive targets for modulating angiogenesis.
other	hsa-mir-126	Vascular Disease [unspecific]	27789478	cardiovascular system disease	DOID:178	I72.9	D000783			MicroRNA-126a Directs Lymphangiogenesis Through Interacting With Chemokine and Flt4 Signaling in Zebrafish.
other	hsa-mir-155	Vascular Disease [unspecific]	17293455	cardiovascular system disease	DOID:178	I72.9	D000783			As predicted, miRNA-155 transduction greatly reduced both myeloid and erythroid colony formation of normal human HSPCs.
other	hsa-mir-21	Vascular Disease [unspecific]	28707876	cardiovascular system disease	DOID:178	I72.9	D000783			Fluorescence Light-Up Biosensor for MicroRNA Based on the Distance-Dependent Photoinduced Electron Transfer.
other	hsa-mir-21	Vascular Disease [unspecific]	29456377	cardiovascular system disease	DOID:178	I72.9	D000783			the stability of both DIM and pre-miR-22 was found to be inversely correlated to each other in binding condition
other	hsa-mir-21	Vascular Disease [unspecific]	29659130	cardiovascular system disease	DOID:178	I72.9	D000783			MicroRNA-21 (miR-21) is a short, non-coding RNA that has been implicated in cardiovascular diseases including proliferative vascular disease and ischaemic heart disease
other	hsa-mir-221	Vascular Disease [unspecific]	19351599	cardiovascular system disease	DOID:178	I72.9	D000783			MicroRNA-221 regulates high glucose-induced endothelial dysfunction
other	hsa-mir-23a	Vascular Disease [unspecific]	28662151	cardiovascular system disease	DOID:178	I72.9	D000783			Bone marrow mesenchymal stem cell-derived vascular endothelial growth factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a and miRNA-92a in a rat model of myocardial infarction.
other	hsa-mir-92a	Vascular Disease [unspecific]	28662151	cardiovascular system disease	DOID:178	I72.9	D000783			Bone marrow mesenchymal stem cell-derived vascular endothelial growth factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a and miRNA-92a in a rat model of myocardial infarction.
other	hsa-let-7a	Vascular Hypertrophy	28187784							Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
other	hsa-mir-1	Vascular Hypertrophy	23711953							the muscle-specific miR-1 and miR-133 are involved in cardiac development and hypertrophy
other	hsa-mir-1	Vascular Hypertrophy	23859766							In addition, microRNAs (miR) -133a, miR-208 and miR-1 which were elevated following high-fat feeding were attenuated by apelin treatment.
other	hsa-mir-1	Vascular Hypertrophy	27056419							miR-1/133a control cardiac conductance and automaticity by regulating all phases of the cardiac action potential
other	hsa-mir-1	Vascular Hypertrophy	28114137							Hydrogen Sulfide Protects Cardiomyocytes against Apoptosis in Ischemia/Reperfusion through MiR-1-Regulated Histone Deacetylase 4 Pathway.
other	hsa-mir-1	Vascular Hypertrophy	23691029							The synergistic effect of miR-21 and miR-1 were functionally validated for their significant influences on myocardial apoptosis, cardiac hypertrophy and fibrosis.
other	hsa-mir-133a	Vascular Hypertrophy	23493786							Our study unraveled for the first time the cardioprotection of choline against cardiac hypertrophy, with correction of expression of miR-133a and calcineurin as a possible mechanism. 
other	hsa-mir-133a	Vascular Hypertrophy	27056419							miR-1/133a control cardiac conductance and automaticity by regulating all phases of the cardiac action potential.
other	hsa-mir-133a	Vascular Hypertrophy	28526870							these c-miRNAs may serve as markers for monitoring the RT responses
other	hsa-mir-206	Vascular Hypertrophy	18381085							The review is also intended to serve as a comprehensive resource for miR-206 with the hope of encouraging further research on the role of miR-206 in skeletal muscle.
other	hsa-mir-206	Vascular Hypertrophy	27789288							Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor.
other	hsa-mir-208	Vascular Hypertrophy	23859766							In addition, microRNAs (miR) -133a, miR-208 and miR-1 which were elevated following high-fat feeding were attenuated by apelin treatment.
other	hsa-mir-208	Vascular Hypertrophy	25840809							miR-208 family is closely associated with the development of  cardiac diseases
other	hsa-mir-208	Vascular Hypertrophy	27056419							miR-208/499 located in introns of the heavy chain myosin genes regulate expression of sarcomeric contractile proteins.
other	hsa-mir-21	Vascular Hypertrophy	25689721							Ursolic acid down-regulated miRNA-21 expression and up-regulated PTEN protein and mRNA expression.
other	hsa-mir-21	Vascular Hypertrophy	25903305							Downregulation of miR-21 and p-ERK/ERK were observed in myocardial fibroblasts treated with UA in a dose-dependent manner compared with the control group both in vitro and in vivo.
other	hsa-mir-21	Vascular Hypertrophy	27160852							Celastrol also inhibited the miR-21/ERK signalling pathway.
other	hsa-mir-21	Vascular Hypertrophy	27542393							MicroRNA-21 Lowers Blood Pressure in Spontaneous Hypertensive Rats by Upregulating Mitochondrial Translation.
other	hsa-mir-21	Vascular Hypertrophy	28368454							Role and Regulation of MicroRNAs in Aldosterone-Mediated Cardiac Injury and Dysfunction in Male Rats.
other	hsa-mir-21	Vascular Hypertrophy	28465975							Review in Translational Cardiology: MicroRNAs and Myocardial Fibrosis in Aortic Valve Stenosis, a Deep Insight on Left Ventricular Remodeling.
other	hsa-mir-21	Vascular Hypertrophy	28526870							these c-miRNAs may serve as markers for monitoring the RT responses
other	hsa-mir-21	Vascular Hypertrophy	23691029							The synergistic effect of miR-21 and miR-1 were functionally validated for their significant influences on myocardial apoptosis, cardiac hypertrophy and fibrosis.
other	hsa-mir-29a	Vascular Hypertrophy	25308856							Effect of miR-29a inhibition on ventricular hypertrophy induced by pressure overload.
other	hsa-mir-100	Vascular Injuries	27622243				D057772			Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair.
other	hsa-mir-147	Vascular Injuries	27622243				D057772			Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair.
other	hsa-mir-181	Vascular Injuries	28316180				D057772			Effect and related mechanism of microRNA-181 attenuates oxidized low density lipoprotein induced vascular endothelial cell injury.
other	hsa-mir-21	Vascular Injuries	27622243				D057772			Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair.
other	hsa-mir-222	Vascular Injuries	27622243				D057772			Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair.
other	hsa-mir-27a	Vascular Injuries	27622243				D057772			Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair.
other	hsa-mir-122	Viral Infectious Disease	25265013	disease by infectious agent	DOID:934	A94	D001102			MiR-122 directly inhibits human papillomavirus E6 gene and enhances interferon signaling through blocking suppressor of cytokine signaling 1 in SiHa cells.
other	hsa-mir-200	Viral Infectious Disease	24599990	disease by infectious agent	DOID:934	A94	D001102			Host microRNA regulation of human cytomegalovirus immediate early protein translation promotes viral latency.
other	hsa-mir-2909	Viral Infectious Disease	24361962	disease by infectious agent	DOID:934	A94	D001102			Arsenic programmes cellular genomic-immunity through miR-2909 RNomics.
other	hsa-mir-32	Viral Infectious Disease	17096367	disease by infectious agent	DOID:934	A94	D001102			The authors found that a cellular miRNA, miR-32, mediated antiviral defense in human cells, and regulated primate foamy virus type I (PFV-1) proliferation.
other	hsa-mir-376a	Viral Infectious Disease	24586166	disease by infectious agent	DOID:934	A94	D001102			MicroRNA editing facilitates immune elimination of HCMV infected cells.
other	hsa-mir-485	Viral Infectious Disease	26645583	disease by infectious agent	DOID:934	A94	D001102			These findings highlight the dual role of miR-485 in preventing spurious activation of antiviral signaling and restricting influenza virus infection.
other	hsa-mir-7	Viral Infectious Disease	26067353	disease by infectious agent	DOID:934	A94	D001102			Results of this study identify a molecular mechanism of RNAi for antiviral defense, and extend our knowledge of the complex interplay between host and PV, which will provide a basis for the development of effective RNAi-based therapies designed to inhibit PV replication and protect host cells.
other	hsa-mir-9	Viral Infectious Disease	24109243	disease by infectious agent	DOID:934	A94	D001102			Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-κB activation.
other	hsa-mir-92a	Viral Infectious Disease	24518554	disease by infectious agent	DOID:934	A94	D001102			Reply to Shin and Bayry on An age-related decline of CD62L and vaccine response: a role of microRNA 92a.
other	hsa-mir-93	Viral Infectious Disease	25858415	disease by infectious agent	DOID:934	A94	D001102			Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA.
other	hsa-mir-1	Viral Myocarditis	27997912			B33.2	D009205			Analysis of the Indicating Value of Cardiac Troponin I, Tumor Necrosis Factor-α, Interleukin-18, Mir-1 and Mir-146b for Viral Myocarditis among Children.
other	hsa-mir-146b	Viral Myocarditis	27997912			B33.2	D009205			Analysis of the Indicating Value of Cardiac Troponin I, Tumor Necrosis Factor-α, Interleukin-18, Mir-1 and Mir-146b for Viral Myocarditis among Children.
other	hsa-mir-221	Viral Myocarditis	26206211			B33.2	D009205			The miR-221/-222 cluster orchestrates the antiviral and inflammatory immune response to viral infection of the heart. Its inhibition increases viral load, inflammation, and overall cardiac injury upon VM.
other	hsa-mir-222	Viral Myocarditis	26206211			B33.2	D009205			The miR-221/-222 cluster orchestrates the antiviral and inflammatory immune response to viral infection of the heart. Its inhibition increases viral load, inflammation, and overall cardiac injury upon VM.
other	hsa-mir-100	Vulvar Squamous Cell Carcinoma	24048714	disease of cellular proliferation	DOID:2101					In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer.
other	hsa-mir-133a	Vulvar Squamous Cell Carcinoma	24048714	disease of cellular proliferation	DOID:2101					In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer.
other	hsa-mir-19b-1	Vulvar Squamous Cell Carcinoma	24048714	disease of cellular proliferation	DOID:2101					In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer.
other	hsa-mir-223	Vulvar Squamous Cell Carcinoma	24048714	disease of cellular proliferation	DOID:2101					In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer.
other	hsa-mir-519b	Vulvar Squamous Cell Carcinoma	24048714	disease of cellular proliferation	DOID:2101					In conclusion, our study demonstrates that microRNAs may be clinically important in vulvar carcinomas and our findings may help for further studies on functional implications of miRNA deregulation in this type of cancer.
other	hsa-mir-155	Waldenstrom Macroglobulinemia	22122052			C88.0	D008258	153600	HP:0005508	Among deregulated miRNAs, miR-155 and miR-9* play a pivotal role in the pathogenesis of this disease.
other	hsa-mir-155	Waldenstrom Macroglobulinemia	23048077			C88.0	D008258	153600	HP:0005508	Importantly, everolimus targeted Waldenstrom macroglobulinemia cells even in the context of bone marrow milieu, where it affected migration, adhesion, and angiogenesis.Everolimus-dependent anti-Waldenstrom macroglobulinemia activity was partially driven by miRNA-155.
other	hsa-mir-9	Waldenstrom Macroglobulinemia	22122052			C88.0	D008258	153600	HP:0005508	Among deregulated miRNAs, miR-155 and miR-9* play a pivotal role in the pathogenesis of this disease.
other	hsa-mir-126	White Spot Syndrome Virus Infection	27825947				D046848			Characterization of microRNAs by deep sequencing in red claw crayfish Cherax quadricarinatus haematopoietic tissue cells after white spot syndrome virus infection.
other	hsa-mir-184	White Spot Syndrome Virus Infection	27825947				D046848			Characterization of microRNAs by deep sequencing in red claw crayfish Cherax quadricarinatus haematopoietic tissue cells after white spot syndrome virus infection.
other	hsa-mir-7	White Spot Syndrome Virus Infection	27825947				D046848			Characterization of microRNAs by deep sequencing in red claw crayfish Cherax quadricarinatus haematopoietic tissue cells after white spot syndrome virus infection.
other	hsa-let-7	Wilms Tumor	27647875			C64.2	D009396	PS194070	HP:0002667	uridylated pre-let-7 miRNAs and mRNAs are targeted by the 3' to 5' exoribonuclease DIS3L2
other	hsa-mir-193a	Wilms Tumor	29357419			C64.2	D009396	PS194070	HP:0002667	Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu.
other	hsa-mir-19b	Wilms Tumor	28322459			C64.2	D009396	PS194070	HP:0002667	Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway.
other	hsa-mir-743a	Wilms Tumor	27667021			C64.2	D009396	PS194070	HP:0002667	Proliferation of metanephric mesenchymal cells is inhibited by miR-743a-mediated WT1 suppression in vitro.
other	hsa-mir-125b	Wound Healing	27388239				D014945		HP:0001058	the uMSC-exosomal microRNAs were examined by high-throughput sequencing, with a group of specific microRNAs (miR-21, miR-23a, miR-125b, and miR-145) found to play key roles in suppressing myofibroblast formation by inhibiting excess 伪-smooth muscle actin and collagen deposition associated with activity of the transforming growth factor-尾/SMAD2 signaling pathway.
other	hsa-mir-1285	Wound Healing	28175294				D014945		HP:0001058	miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease.
other	hsa-mir-142	Wound Healing	27894934				D014945		HP:0001058	MiR-142 Is Required for Staphylococcus aureus Clearance at Skin Wound Sites via Small GTPase-Mediated Regulation of the Neutrophil Actin Cytoskeleton.
other	hsa-mir-145	Wound Healing	27388239				D014945		HP:0001058	the uMSC-exosomal microRNAs were examined by high-throughput sequencing, with a group of specific microRNAs (miR-21, miR-23a, miR-125b, and miR-145) found to play key roles in suppressing myofibroblast formation by inhibiting excess 伪-smooth muscle actin and collagen deposition associated with activity of the transforming growth factor-尾/SMAD2 signaling pathway.
other	hsa-mir-147b	Wound Healing	28175294				D014945		HP:0001058	miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease.
other	hsa-mir-155	Wound Healing	28175294				D014945		HP:0001058	miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease.
other	hsa-mir-184	Wound Healing	28175294				D014945		HP:0001058	miRNAs that associate with conjunctival inflammation and ocular Chlamydia trachomatis infection do not predict progressive disease.
other	hsa-mir-18a	Wound Healing	27390086				D014945		HP:0001058	We found miR-18a was most susceptible to SH treatment, the target prediction of which were enriched in a bunch of pathways implicated in corneal wound healing.
other	hsa-mir-21	Wound Healing	27388239				D014945		HP:0001058	the uMSC-exosomal microRNAs were examined by high-throughput sequencing, with a group of specific microRNAs (miR-21, miR-23a, miR-125b, and miR-145) found to play key roles in suppressing myofibroblast formation by inhibiting excess 伪-smooth muscle actin and collagen deposition associated with activity of the transforming growth factor-尾/SMAD2 signaling pathway.
other	hsa-mir-23a	Wound Healing	27388239				D014945		HP:0001058	the uMSC-exosomal microRNAs were examined by high-throughput sequencing, with a group of specific microRNAs (miR-21, miR-23a, miR-125b, and miR-145) found to play key roles in suppressing myofibroblast formation by inhibiting excess 伪-smooth muscle actin and collagen deposition associated with activity of the transforming growth factor-尾/SMAD2 signaling pathway.
other	hsa-mir-29b	Wound Healing	28092445				D014945		HP:0001058	miR-29b promotes skin wound healing and reduces excessive scar formation by inhibition of the TGF-β1/Smad/CTGF signaling pathway.
other	hsa-mir-31	Wound Healing	29605672				D014945		HP:0001058	these findings identify miR-31 as an important cell-autonomous mediator during the transition from inflammation to re-epithelialization phases of wound healing, suggesting a therapeutic potential for miR-31 in skin injury repair
other	hsa-mir-146a	Wound Inflammation	27864711							Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation.
other	hsa-mir-181	Wound Inflammation	27864711							Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation.
other	hsa-mir-21	Wound Inflammation	24391209							Engulfment of apoptotic cells by macrophages: a role of microRNA-21 in the resolution of wound inflammation.
other	hsa-mir-21	Wound Inflammation	27864711							Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation.
other	hsa-mir-132	Wounds and Injuries [unspecific]	26121747				D014947			MicroRNA-132 enhances transition from inflammation to proliferation during wound healing.
other	hsa-mir-21	Wounds and Injuries [unspecific]	21647251				D014947			miR-21 promotes keratinocyte migration and re-epithelialization during wound healing.
other	hsa-mir-31	Wounds and Injuries [unspecific]	25685928				D014947			MicroRNA-31 Promotes Skin Wound Healing by Enhancing Keratinocyte Proliferation and Migration.
other	hsa-mir-483	Wounds and Injuries [unspecific]	21676945				D014947			miR-483-3p controls proliferation in wounded epithelial cells.
target gene	hsa-mir-21	Acute Cerebral Infarction	28389999	cardiovascular system disease	DOID:3526	I63	D002544			Effects of microRNA-21 on Nerve Cell Regeneration and Neural Function Recovery in Diabetes Mellitus Combined with Cerebral Infarction Rats by Targeting PDCD4.
target gene	hsa-mir-491	Acute Cerebral Infarction	23257658	cardiovascular system disease	DOID:3526	I63	D002544			A functional polymorphism at miR-491-5p binding site in the 3'-UTR of MMP-9 gene confers increased risk for atherosclerotic cerebral infarction in a Chinese population
target gene	hsa-mir-15a	Acute Coronary Syndrome	24530761			I24.9	D054058			The present study demonstrated that CARM1 targeted by miR-15a played an important role in chemokine activation in the pathogenesis of ACS.
target gene	hsa-mir-122	Acute Ischemic Stroke	24911610	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis.
target gene	hsa-mir-148a	Acute Ischemic Stroke	24911610	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis.
target gene	hsa-mir-19a	Acute Ischemic Stroke	24911610	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis.
target gene	hsa-mir-223	Acute Ischemic Stroke	24708646	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Our results suggest that microRNA-223 is associated with acute ischemic stroke and possibly plays a role in stroke through up-regulating growth factor such as insulin-like growth factor-1 gene.
target gene	hsa-mir-320d	Acute Ischemic Stroke	24911610	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis.
target gene	hsa-mir-4429	Acute Ischemic Stroke	24911610	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis.
target gene	hsa-mir-487b	Acute Ischemic Stroke	24911610	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation,leukocyte extravasation and thrombosis.
target gene	hsa-mir-107	Acute Kidney Failure	28063928	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	MiR-107 induces TNF-α secretion in endothelial cells causing tubular cell injury in patients with septic acute kidney injury.
target gene	hsa-mir-181a	Acute Lung Injury	27802900			S27	D055371			Downregulation of miR-181a protects mice from LPS-induced acute lung injury by targeting Bcl-2.
target gene	hsa-mir-181b	Acute Lung Injury	26622531			S27	D055371			he overexpression of miR-181b resulted in the induction of an increment in interleukin (IL)-6 levels.
target gene	hsa-mir-125b	Acute Megakaryoblastic Leukemia	25571789	disease of cellular proliferation	DOID:8761	C94.2	D007947	606078		MiR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukemia.
target gene	hsa-mir-99a	Acute Megakaryoblastic Leukemia	25571789	disease of cellular proliferation	DOID:8761	C94.2	D007947	606078		MiR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukemia.
target gene	hsa-mir-106b	Acute Myocardial Infarction	28235791	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction.
target gene	hsa-mir-148b	Acute Myocardial Infarction	28235791	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction.
target gene	hsa-mir-204	Acute Myocardial Infarction	28235791	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	High-throughput screening identifies microRNAs that target Nox2 and improve function after acute myocardial infarction.
target gene	hsa-mir-34a	Acute Myocardial Infarction	23426265	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	these results identify age-induced expression of miR-34a and inhibition of its target PNUTS as a key mechanism that regulates cardiac contractile function during ageing and after acute myocardial infarction, by inducing DNA damage responses and telomere attrition.
target gene	hsa-mir-135a	Acute Pancreatitis	24710937	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	It was concluded that the expression levels of miR-22 and miR-135a were elevated in AEP. Up-regulating the expression of miR-22 and miR-135a may promote the apoptosis of pancreatic acinar cells by repressing ErbB3 and Ptk2 expression in AEP.
target gene	hsa-mir-22	Acute Pancreatitis	24710937	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	It was concluded that the expression levels of miR-22 and miR-135a were elevated in AEP. Up-regulating the expression of miR-22 and miR-135a may promote the apoptosis of pancreatic acinar cells by repressing ErbB3 and Ptk2 expression in AEP.
target gene	hsa-mir-199a	Acute Respiratory Distress Syndrome	29351405	respiratory system disease	DOID:11394	J80	D012128			Acute downregulation of miR-199a attenuates sepsis-induced acute lung injury by targeting SIRT1
target gene	hsa-mir-18a	Adenocarcinoma, Colon	19372139	disease of cellular proliferation	DOID:234	C18			HP:0040276	The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras
target gene	hsa-mir-18a	Adenocarcinoma, Colon	28408657	disease of cellular proliferation	DOID:234	C18			HP:0040276	Negative Regulation of Human Pregnane X Receptor by MicroRNA-18a-5p: Evidence for Suppression of MicroRNA-18a-5p Expression by Rifampin and Rilpivirine.
target gene	hsa-mir-223	Adenocarcinoma, Colon	29660302	disease of cellular proliferation	DOID:234	C18			HP:0040276	miR-223-RhoB signaling pathway regulates the proliferation and apoptosis of colon adenocarcinoma
target gene	hsa-mir-145	Adenocarcinoma, Endometrial	21365617	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells.
target gene	hsa-mir-182	Adenocarcinoma, Endometrial	26847831	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-182 expression is epigenetically increased leading to decreased CUL5 expression and increased cellular proliferation.
target gene	hsa-mir-200a	Adenocarcinoma, Endometrial	24413994	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	MiR-200a is involved in proliferation and apoptosis in the human endometrial adenocarcinoma cell line HEC-1B by targeting the tumor suppressor PTEN.
target gene	hsa-mir-196a	Adenocarcinoma, Esophageal	19773200	disease of cellular proliferation	DOID:4914		C562730	133239		Recent findings include the following: firstly, miRNA expression profiles can distinguish between BE and EAC; secondly, miR-196a is upregulated in EAC tissues targeting annexin A1, thereby exerting antiapoptotic effects and contributing to EAC cell survival
target gene	hsa-mir-107	Adenocarcinoma, Gastric	25824045	disease of cellular proliferation	DOID:3717	D37.1	D013274			miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells.
target gene	hsa-mir-194	Adenocarcinoma, Gastric	25800782	disease of cellular proliferation	DOID:3717	D37.1	D013274			We showed evidence that HNF4纬 (upregulated in intestinal metaplasia) is targeted by miR-30 and that miR-194 targets a known co-regulator of HNF4 activity, NR2F2 (downregulated in intestinal metaplasia).
target gene	hsa-mir-23a	Adenocarcinoma, Gastric	23785404	disease of cellular proliferation	DOID:3717	D37.1	D013274			miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells.
target gene	hsa-mir-25	Adenocarcinoma, Gastric	25824045	disease of cellular proliferation	DOID:3717	D37.1	D013274			miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells.
target gene	hsa-mir-30a	Adenocarcinoma, Gastric	25800782	disease of cellular proliferation	DOID:3717	D37.1	D013274			We showed evidence that HNF4纬 (upregulated in intestinal metaplasia) is targeted by miR-30 and that miR-194 targets a known co-regulator of HNF4 activity, NR2F2 (downregulated in intestinal metaplasia).
target gene	hsa-mir-31	Adenocarcinoma, Gastric	28836853	disease of cellular proliferation	DOID:3717	D37.1	D013274			MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells.
target gene	hsa-mir-645	Adenocarcinoma, Gastric-Esophageal Junction	25174799	disease of cellular proliferation	DOID:4944					Our data suggest that miR-645 functions as an oncogene in human AGEJ by, at least partially through, targeting IFIT2.
target gene	hsa-mir-126	Adenocarcinoma, Lung	26035298	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	These DEGs, and DEG-related histone modifications, TFs and miRNAs may be important in the pathogenesis of lung adenocarcinoma. The present results may indicate directions for the next step in the study of the further elucidation and targeted prevention of lung adenocarcinoma.
target gene	hsa-mir-133	Adenocarcinoma, Lung	25868726	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Metastasis-associated lung adenocarcinoma transcript 1 (Malat1) regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis.
target gene	hsa-mir-134	Adenocarcinoma, Lung	24258346	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
target gene	hsa-mir-135a	Adenocarcinoma, Lung	25230140	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-135a inhibition protects A549 cells from LPS-induced apoptosis by targeting Bcl-2.
target gene	hsa-mir-136	Adenocarcinoma, Lung	25198664	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-136 directly targeted Smad2 and Smad3, leading to reduced migration and invasiveness of lung adenocarcinoma (ADC) cell lines
target gene	hsa-mir-145	Adenocarcinoma, Lung	24903381	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells.
target gene	hsa-mir-145	Adenocarcinoma, Lung	28120164	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiRNA-145 suppresses lung adenocarcinoma cell invasion and migration by targeting N-cadherin.
target gene	hsa-mir-15b	Adenocarcinoma, Lung	25721211	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.
target gene	hsa-mir-16	Adenocarcinoma, Lung	26061016	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Quercetin Decreases Claudin-2 Expression Mediated by Up-Regulation of microRNA miR-16 in Lung Adenocarcinoma A549 Cells.
target gene	hsa-mir-182	Adenocarcinoma, Lung	23877371	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells.
target gene	hsa-mir-1827	Adenocarcinoma, Lung	29344280	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-378 and MiR-1827 Regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, Respectively
target gene	hsa-mir-183	Adenocarcinoma, Lung	26951513	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	overexpression of miR-183 in CSLCs decreased PTPN4 protein levels while inhibition of miR-183 increased PTPN4 protein levels.
target gene	hsa-mir-200a	Adenocarcinoma, Lung	23938385	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-200a enhances the migrations of A549 and SK-MES-1 cells by regulating the expression of TSPAN1.
target gene	hsa-mir-202	Adenocarcinoma, Lung	27887846	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression.
target gene	hsa-mir-203	Adenocarcinoma, Lung	27733346	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Direct interaction between miR-203 and ZEB2 suppresses epithelial-mesenchymal transition signaling and reduces lung adenocarcinoma chemoresistance.
target gene	hsa-mir-21	Adenocarcinoma, Lung	29663730	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-21 improves invasion and migration of drug-resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1
target gene	hsa-mir-222	Adenocarcinoma, Lung	28617551	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-222 promotes proliferation, migration and invasion of lung adenocarcinoma cells by targeting ETS1.
target gene	hsa-mir-224	Adenocarcinoma, Lung	24921914	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Our findings shed novel light on the roles of miR-224/p21(WAF1/CIP1) signalling in the DDP resistance of LA cells, and targeting it will be a potential strategic approach for reversing the DDP resistance in human LAs.
target gene	hsa-mir-23a	Adenocarcinoma, Lung	23437179	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Among them, we confirmed TGF-β-mediated induction of miR-23a in lung epithelial cell lines,target genes of which were further identified by gene expression profiling.
target gene	hsa-mir-26a	Adenocarcinoma, Lung	28000891	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Expression of miR‑26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells.
target gene	hsa-mir-26a	Adenocarcinoma, Lung	28214878	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
target gene	hsa-mir-27a	Adenocarcinoma, Lung	25128483	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Our results suggest that up-regulation of miR-27a could suppress RKIP expression and in turn contribute to chemoresistance of lung adenocarcinoma cells to cisplatin.
target gene	hsa-mir-297	Adenocarcinoma, Lung	27554041	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma.
target gene	hsa-mir-29a	Adenocarcinoma, Lung	25171863	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6.
target gene	hsa-mir-29c	Adenocarcinoma, Lung	28241836	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma.
target gene	hsa-mir-30c-2	Adenocarcinoma, Lung	26035298	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	These DEGs, and DEG-related histone modifications, TFs and miRNAs may be important in the pathogenesis of lung adenocarcinoma. The present results may indicate directions for the next step in the study of the further elucidation and targeted prevention of lung adenocarcinoma.
target gene	hsa-mir-31	Adenocarcinoma, Lung	27215092	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-31 Functions as a Tumor Suppressor in Lung Adenocarcinoma Mainly by Targeting HuR.
target gene	hsa-mir-326	Adenocarcinoma, Lung	26111641	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma.
target gene	hsa-mir-378	Adenocarcinoma, Lung	29344280	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-378 and MiR-1827 Regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, Respectively
target gene	hsa-mir-3941	Adenocarcinoma, Lung	28012229	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.
target gene	hsa-mir-409	Adenocarcinoma, Lung	25278243	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-409-3p was an independent prognostic factor and functioned as a tumor suppressor in LAD via regulation of Akt signaling by targeting c-Met.
target gene	hsa-mir-451	Adenocarcinoma, Lung	25310895	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.
target gene	hsa-mir-483	Adenocarcinoma, Lung	24710410	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM.
target gene	hsa-mir-487b	Adenocarcinoma, Lung	24258346	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
target gene	hsa-mir-590	Adenocarcinoma, Lung	28012926	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-590 accelerates lung adenocarcinoma migration and invasion through directly suppressing functional target OLFM4.
target gene	hsa-mir-620	Adenocarcinoma, Lung	24682381	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	GPC5, a tumor suppressor, is regulated by miR-620 in lung adenocarcinoma.
target gene	hsa-mir-655	Adenocarcinoma, Lung	24258346	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
target gene	hsa-mir-9	Adenocarcinoma, Lung	23985560	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus.
target gene	hsa-let-7d	Adenocarcinoma, Pancreatic Ductal	29137251	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		selinexor induced the expression of two important tumor suppressive miRNAs miR-34c and let-7d leading to the up-regulation of p21WAF1
target gene	hsa-mir-107	Adenocarcinoma, Pancreatic Ductal	29111166	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN.
target gene	hsa-mir-10b	Adenocarcinoma, Pancreatic Ductal	24096486	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.
target gene	hsa-mir-135a	Adenocarcinoma, Pancreatic Ductal	25013381	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma.
target gene	hsa-mir-143	Adenocarcinoma, Pancreatic Ductal	28194669	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro.
target gene	hsa-mir-143	Adenocarcinoma, Pancreatic Ductal	23661430	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		SEL1L mRNA expression levels were found to correlate inversely with the expression of hsa-mir-143, hsa-mir-155, and hsa-mir-223 (P < 0.0001, P < 0.0001, and P = 0.002,srespectively). 
target gene	hsa-mir-153	Adenocarcinoma, Pancreatic Ductal	26062664	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma.
target gene	hsa-mir-155	Adenocarcinoma, Pancreatic Ductal	23661430	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.
target gene	hsa-mir-17	Adenocarcinoma, Pancreatic Ductal	28987387	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes.
target gene	hsa-mir-181b	Adenocarcinoma, Pancreatic Ductal	23440261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
target gene	hsa-mir-183	Adenocarcinoma, Pancreatic Ductal	25109303	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1.
target gene	hsa-mir-200b	Adenocarcinoma, Pancreatic Ductal	19569050	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;
target gene	hsa-mir-200c	Adenocarcinoma, Pancreatic Ductal	19569050	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;
target gene	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26077422	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors
target gene	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	25846727	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our results demonstrate that p85α expression is a determinant of chemosensitivity in PDAC. Additionally, we provide novel evidence that miR-21 can influence PI3K-AKT signaling via its direct regulation of p85α. These data provide insight into potential mechanisms for the known relationship between increased p85α expression and improved survival in PDAC.
target gene	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	23991015	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-21 expression in PDAC TAFs is associated with decreased overall survival and promotes TC invasion. Anti-miR-21 may represent a novel therapeutic strategy for dual targeting of both tumor and stroma in PDAC.
target gene	hsa-mir-211	Adenocarcinoma, Pancreatic Ductal	26077422	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors
target gene	hsa-mir-212	Adenocarcinoma, Pancreatic Ductal	24961235	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		These data suggest that miR-212 could facilitate PDAC progression and metastasis through targeting PTCH1, implicating a novel mechanism for the progression of PDAC.
target gene	hsa-mir-223	Adenocarcinoma, Pancreatic Ductal	23661430	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		SEL1L mRNA expression levels were found to correlate inversely with the expression of hsa-mir-143, hsa-mir-155, and hsa-mir-223 (P < 0.0001, P < 0.0001, and P = 0.002,srespectively). 
target gene	hsa-mir-34c	Adenocarcinoma, Pancreatic Ductal	29137251	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		selinexor induced the expression of two important tumor suppressive miRNAs miR-34c and let-7d leading to the up-regulation of p21WAF1
target gene	hsa-mir-429	Adenocarcinoma, Pancreatic Ductal	19569050	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		regulate EP300, a metastasis suppressor gene; these miRs are related to reduced EP300 mRNA and protein;
target gene	hsa-mir-429	Adenocarcinoma, Pancreatic Ductal	25833382	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Low level of miR-429 and high level of TBK1 in PDAC promoted PDAC cells growth which might be related to the low survival rate of PDAC patients.MiR-429 play its role in PDAC by targeting TBK1.
target gene	hsa-mir-545	Adenocarcinoma, Pancreatic Ductal	25315416	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I.
target gene	hsa-mir-940	Adenocarcinoma, Pancreatic Ductal	25766528	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Low level of miR-940 and high level of MyD88 in PDAC promoted PDAC cells growth which might be related to the low survival rate of PDAC patients.MiR-940 exerted its effect by targeting MyD88.
target gene	hsa-mir-103	Adenovirus Infection	26000071			B34.0	D000257			miR-103 Regulates Oxidative Stress by Targeting the BCL2/Adenovirus E1B 19kDa Interacting Protein 3 in HUVECs.
target gene	hsa-mir-150	Adenovirus Infection	22595456			B34.0	D000257			Our study demonstrates that miR-150 regulates surfactant secretion through P2X7R.
target gene	hsa-mir-27	Adenovirus Infection	28356525			B34.0	D000257			MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2.
target gene	hsa-mir-27a	Adenovirus Infection	28356525			B34.0	D000257			MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2.
target gene	hsa-mir-27b	Adenovirus Infection	28356525			B34.0	D000257			MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2.
target gene	hsa-mir-466	Adenovirus Infection	25497012			B34.0	D000257			Coxsackie virus and Adenovirus Receptor (CAR), a cellular receptor, was one of the rno-miR-466d targets involved in viral entry. Subsequent experiments also proved that both the rno-miR-466d and the human hsa-miR-466, which are orthologs of the miR-467 gene family, could effectively down-regulate the levels of rat and human CAR protein expression, respectively.
target gene	hsa-mir-33a	Alcoholic Hepatitis	26945479	endocrine system disease	DOID:12351	K70.1	D006519			The relative expression of miR-33a  and miR-144 correlated inversely with ABCA1 but not with ABCG1 protein levels.
target gene	hsa-let-7a	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-let-7g	Allergic Asthma	24610935	immune system disease	DOID:9415	J45.909	C564133	600807		HDM exposure in WT mice and primary lung epithelial cells resulted in striking decreases in let-7g miRNA that were not observed in mice or primary lung epithelial cells lacking JNK1-/- mice.
target gene	hsa-mir-106a	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-124	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-126	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-135	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-142	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-143	Allergic Asthma	23965966	immune system disease	DOID:9415	J45.909	C564133	600807		It indicates that miR-143 directly targets IL-13Rα1 and suppresses IL-13Rα1 expression in HMC-1 cells. Therefore, miR-143 may be associated with allergic reaction in human mast cells.
target gene	hsa-mir-145	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-146	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-150	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-155	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-193	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-21	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-221	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-223	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-29	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-365	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-375	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-452	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-615	Allergic Asthma	26253882	immune system disease	DOID:9415	J45.909	C564133	600807		miRNAs are important post-transcriptional regulators of gene expression and have a role in allergic type 2 immune responses through their activity in multiple immune and non-immune cell subsets. Detailed mechanistic studies are critically needed to understand and leverage miRNAs to advance the field and inform clinical investigation. miRNAs act through multiple direct targets to regulate networks of genes, and their specificity and potency depends on the dynamics of individual miRNA-target interactions. Identifying which miRNAs and which targets are important for promoting or restraining allergy will help to identify vulnerable nodes in allergic inflammation, enhancing our mechanistic understanding of miRNA in the immune system and providing novel, possibly druggable, targets for these increasingly prevalent diseases.
target gene	hsa-mir-143	Allergic Rhinitis	25529447	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	the IL13Rα1 signaling pathway may be a potential target for the prevention and treatment of AR by miR-143.
target gene	hsa-mir-181a	Allergy	25202021	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	miR-218 and miR-181a formed a negative feedback loop with TGaseII and regulated the in vitro  and in vivo allergic inflammation.
target gene	hsa-mir-218	Allergy	25202021	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	miR-218 and miR-181a formed a negative feedback loop with TGaseII and regulated the in vitro  and in vivo allergic inflammation.
target gene	hsa-mir-100	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-101	Alzheimer Disease	20395292	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Thus, miR-101 is a negative regulator of APP expression and affects the accumulation of Abeta, suggesting a possible role  for miR-101 in neuropathological conditions.
target gene	hsa-mir-101	Alzheimer Disease	24592211	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Importantly, silencing of endogenous RanBP9 reduced sAPP尾 levels in miR-101 sponge-containing hippocampal cultures, indicating that miR-101 inhibition may increase amyloidogenic processing of APP by RanBP9.
target gene	hsa-mir-101	Alzheimer Disease	28202389	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
target gene	hsa-mir-103	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-103	Alzheimer Disease	27343180	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-103 and miR-107, regulate CDK5R1 expression and affect the levels of p35
target gene	hsa-mir-103a-1	Alzheimer Disease	21179570	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD
target gene	hsa-mir-103a-2	Alzheimer Disease	21179570	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD
target gene	hsa-mir-106b	Alzheimer Disease	20709030	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.
target gene	hsa-mir-106b	Alzheimer Disease	27520374	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-106b inhibits Aβ1-42-induced tau phosphorylation at Tyr18 by targeting Fyn.
target gene	hsa-mir-107	Alzheimer Disease	21179570	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	microRNAs 103 and 107 repress translation of cofilin, and that reduced levels of miR-103 or miR-107 are associated with elevated cofilin protein levels and formation of rod-like structures in a transgenic mouse model of AD
target gene	hsa-mir-124	Alzheimer Disease	26592243	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	our study indicates that miR-124 plays neuroprotective roles in AD Drosophila by targeting Delta in Notch signaling pathway, which helps further our understanding of miRNAs in the molecular pathology of AD.
target gene	hsa-mir-124	Alzheimer Disease	26984601	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The activation of EPAC-Rap1 pathway was involved in the inhibition of miR-124 in hippocampus under hypoxia or A尾 insult.
target gene	hsa-mir-124-1	Alzheimer Disease	22178568	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease.
target gene	hsa-mir-124-2	Alzheimer Disease	22178568	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease.
target gene	hsa-mir-124-3	Alzheimer Disease	22178568	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The miR-124 regulates the expression of BACE1/-secretase correlated with cell death in Alzheimer's disease.
target gene	hsa-mir-125b	Alzheimer Disease	17629564	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The main finding was that these ROS-generating neurotoxic metal sulfates also up-regulate a specific set of miRNAs that includes miR-9, miR-125b and miR-128. Notably, these same miRNAs are up-regulated in AD brain.
target gene	hsa-mir-125b-1	Alzheimer Disease	22302353	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain.
target gene	hsa-mir-125b-2	Alzheimer Disease	22302353	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain.
target gene	hsa-mir-132	Alzheimer Disease	24014289	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-132-3p may contribute to disease progression through aberrant regulation of mRNA targets in the Tau network. The transcription factor (TF) FOXO1a appears to be a key target of miR-132-3p in this pathway.
target gene	hsa-mir-138	Alzheimer Disease	25680531	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	our data suggest that miR-138 promotes tau phosphorylation by targeting the RARA/GSK-3β pathway.
target gene	hsa-mir-139	Alzheimer Disease	28218780	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-139 modulates Alzheimer's-associated pathogenesis in SAMP8 mice by targeting cannabinoid receptor type 2.
target gene	hsa-mir-146a	Alzheimer Disease	18801740	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	An NF-kB-sensitive microRNA-146a-mediated inflammatory circuit in Alzheimer's disease and in stressed human brain cells.
target gene	hsa-mir-146a	Alzheimer Disease	22302353	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-125b and miR-146a regulate Complement Factor H (CFH) in Alzheimer's Disease (AD) Brain.
target gene	hsa-mir-146a	Alzheimer Disease	23990414	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The pathway hsa-miR-146a→STAT1→MYC, which is the source of all nine significantly active pathways, may play an important role in AD progression, which should be further validated by biological experiments
target gene	hsa-mir-153-1	Alzheimer Disease	22733824	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients.
target gene	hsa-mir-153-2	Alzheimer Disease	22733824	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients.
target gene	hsa-mir-181c	Alzheimer Disease	21720722	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis.
target gene	hsa-mir-18a	Alzheimer Disease	28956815	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	hsa-mir-18a, having common key targets in the BARHL1-ESR1 network and AD pathway
target gene	hsa-mir-195	Alzheimer Disease	22721728	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-195 downregulates Alzheimer's disease amyloid-beta production by targeting BACE1.
target gene	hsa-mir-21	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-219	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-222	Alzheimer Disease	26398571	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	In conclusion, these results suggest that the abnormal expression of miR-222 may contribute to dysregulation of the cell-cycle in AD, at least in part by affecting the expression of p27Kip1.
target gene	hsa-mir-296	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-29a	Alzheimer Disease	20202123	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-29a decreased in Alzheimer disease brains targets neuron navigator-3
target gene	hsa-mir-29c	Alzheimer Disease	26212654	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-29c regulates NAV3 protein expression in a transgenic mouse model of Alzheimer's disease.
target gene	hsa-mir-339	Alzheimer Disease	24352696	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects.
target gene	hsa-mir-34c	Alzheimer Disease	26402112	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-34c Downregulation Ameliorates Amyloid-β-Induced Synaptic Failure and Memory Deficits by Targeting VAMP2.
target gene	hsa-mir-3622b	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-375	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-4467	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-505	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-511	Alzheimer Disease	27334923	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-511 is a functional regulator of FKBP5 and can contribute to neuronal differentiation.
target gene	hsa-mir-512	Alzheimer Disease	26258756	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.
target gene	hsa-mir-613	Alzheimer Disease	27545218	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-613 regulates the expression of brain-derived neurotrophic factor in Alzheimer's disease.
target gene	hsa-mir-708	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-766	Alzheimer Disease	25992776	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.
target gene	hsa-mir-9	Alzheimer Disease	21720722	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Taken together, our study identifies putative target genes of miRNAs miR-9 and 181c, which may function in brain homeostasis and disease pathogenesis.
target gene	hsa-mir-922	Alzheimer Disease	24950120	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-922 increasing the levels of phosphorylated tau by regulating UCHL1 levels contributed to the pathogenesis of AD. Our study partly explained one of the mechanisms underlying the downregulation of UCHL1 levels in AD patients and could enrich the content of tau pathology in the pathogenesis of AD.
target gene	hsa-mir-92a	Alzheimer Disease	28129110	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	the AD-like tau accumulation induces anxiety through disrupting miR92a-vGAT-GABA signaling, which reveals molecular mechanisms underlying the anxiety behavior in AD patients and potentially leads to the development of new therapeutics for tauopathies
target gene	hsa-mir-98	Alzheimer Disease	27541017	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-98-5p Acts as a Target for Alzheimer's Disease by Regulating Aβ Production Through Modulating SNX6 Expression.
target gene	hsa-mir-21	Anaplastic Astrocytoma	27347075	disease of cellular proliferation	DOID:3078		D001254			PTEN and miR-21 have been observed to form feedback loops.
target gene	hsa-mir-25	Anaplastic Astrocytoma	27347075	disease of cellular proliferation	DOID:3078		D001254			PTEN which is targeted by miR-21 and miR-106b, regulates miR-25 which in turn targets TP53
target gene	hsa-mir-329	Angiosarcoma	23878390	disease of cellular proliferation	DOID:0001816	C49.9	D006394		HP:0200058	MicroRNA 329 suppresses angiogenesis by targeting CD146.
target gene	hsa-mir-10b	Ankylosing Spondylitis	28039186	musculoskeletal system disease	DOID:7147	M45.9	D013167			miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis.
target gene	hsa-mir-124	Ankylosing Spondylitis	25736362	musculoskeletal system disease	DOID:7147	M45.9	D013167			Our results suggested that miR-124 might induce autophagy to participate in AS by targeting ANTXR2, which might be implicated in pathological process of AS.
target gene	hsa-mir-146a	Ankylosing Spondylitis	29145150	musculoskeletal system disease	DOID:7147	M45.9	D013167			MicroRNA-146a knockdown suppresses the progression of ankylosing spondylitis by targeting dickkopf 1
target gene	hsa-mir-19b	Antiphospholipid Syndrome	28028298	immune system disease	DOID:2988	D68.61	D016736	107320		MicroRNA expression in antiphospholipid syndrome: a systematic review and microRNA target genes analysis.
target gene	hsa-mir-20a	Antiphospholipid Syndrome	28028298	immune system disease	DOID:2988	D68.61	D016736	107320		MicroRNA expression in antiphospholipid syndrome: a systematic review and microRNA target genes analysis.
target gene	hsa-mir-608	Anxiety	24722204	disease of mental health	DOID:14320	F41.1	D001007	607834	HP:0000739	Competing targets of microRNA-608 affect anxiety and hypertension.
target gene	hsa-mir-4717	Anxiety Disorders	25847876	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	data indicate that MIR4717 regulates human RGS2 and contributes to the genetic risk towards anxiety-related traits.
target gene	hsa-mir-103a	Aortic Aneurysm, Abdominal	28357407	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Role of MicroRNA-103a Targeting ADAM10 in Abdominal Aortic Aneurysm.
target gene	hsa-mir-15a	Aortic Aneurysm, Abdominal	25993295	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology.
target gene	hsa-mir-15a	Aortic Aneurysm, Abdominal	28214350	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Upregulation of MicroRNA-15a Contributes to Pathogenesis of Abdominal Aortic Aneurysm (AAA) by Modulating the Expression of Cyclin-Dependent Kinase Inhibitor 2B (CDKN2B).
target gene	hsa-mir-205	Aortic Aneurysm, Abdominal	26781079	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		a significant downregulation of LRP1 protein expression was shown in miR-205-overexpressing VSMCs
target gene	hsa-mir-30a	Aortic Aneurysm, Abdominal	25993295	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology.
target gene	hsa-mir-489	Aortic Aneurysm, Abdominal	25993295	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Our data emphasize the potential of miR-15a-3p and miR-30a-5p as biomarkers of AAA but also as triggers of ATLO evolution. Further investigations will be required to evaluate their targets in order to better understand AAA pathophysiology.
target gene	hsa-mir-98	Aortic Aneurysm, Abdominal	26045772	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		our data provide compelling evidence on the association between hypoxia and inflammation triggered by hypoxia and then mediated by MCP-1/miR-98/IL-6/p38 regulatory loop, which leads to hASMCs apoptosis via Stat1 activation to contribute to AAA formation and progression.
target gene	hsa-mir-30b	Aortic Insufficiency	23968872	cardiovascular system disease	DOID:57	I35.1	D001022		HP:0001659	We demonstrated a remarkable role of miRNA-30b in calcific aortic valve disease as a regulator of human aortic valvular calcification and apoptosis through direct targeting of Runx2, Smad1, and caspase-3. Targeting of miRNA-30b could serve as a novel therapeutic strategy to limit progressive calcification in aortic stenosis.
target gene	hsa-mir-141	Aortic Stenosis	22336757	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis.
target gene	hsa-mir-181b	Aortic Valve Disease	28236165	cardiovascular system disease	DOID:62			PS109730		Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3.
target gene	hsa-mir-486	Aortic Valve Disease	28377507	cardiovascular system disease	DOID:62			PS109730		miR-486 inhibits Smurf2 expression to augment the miR-204 down-regulation
target gene	hsa-mir-204	Aplastic Anemia	25187411	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	Arsenic trioxide and microRNA-204 display contrary effects on regulating adipogenic and osteogenic differentiation of mesenchymal stem cells in aplastic anemia.
target gene	hsa-mir-1	Arrhythmia	17516552			I49.9	D001145	600919	HP:0011675	we also designed the microRNA-masking antisense based on the miR-1 and miR-133 target sites in the 3'UTRs of HCN2 and HCN4 and found that these antisense oligodeoxynucleotides markedly enhanced HCN2/HCN4 expression and function, as reflected by increased protein levels of HCN2/HCN4 and If conductance, by removing the repression of HCN2/HCN4 expression induced by endogenous miR-1/miR-133.
target gene	hsa-mir-1-1	Arrhythmia	19131648			I49.9	D001145	600919	HP:0011675	miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2
target gene	hsa-mir-1-2	Arrhythmia	19131648			I49.9	D001145	600919	HP:0011675	miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2
target gene	hsa-mir-133	Arrhythmia	17516552			I49.9	D001145	600919	HP:0011675	we also designed the microRNA-masking antisense based on the miR-1 and miR-133 target sites in the 3'UTRs of HCN2 and HCN4 and found that these antisense oligodeoxynucleotides markedly enhanced HCN2/HCN4 expression and function, as reflected by increased protein levels of HCN2/HCN4 and If conductance, by removing the repression of HCN2/HCN4 expression induced by endogenous miR-1/miR-133.
target gene	hsa-mir-133a-1	Arrhythmia	17965831			I49.9	D001145	600919	HP:0011675	miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model.
target gene	hsa-mir-133a-2	Arrhythmia	17965831			I49.9	D001145	600919	HP:0011675	miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model.
target gene	hsa-mir-3144	Arrhythmia	28796037			I49.9	D001145	600919	HP:0011675	miR-3144-5p overexpression plays a role  in HCMs by regulating these genes and TF
target gene	hsa-mir-125b	Arteriosclerosis Obliterans	25738314	cardiovascular system disease	DOID:5160		D001162		HP:0002634	MicroRNA-125b is involved in atherosclerosis obliterans in vitro by targeting podocalyxin.
target gene	hsa-mir-125b	Arteriosclerosis Obliterans	29689557	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Exogenous miR-125b expression modulated SRF expression and inhibited vascular neointimal formation in balloon-injured rat carotid arteries
target gene	hsa-mir-21	Arteriosclerosis Obliterans	27765464	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease.
target gene	hsa-mir-22	Arteriosclerosis Obliterans	28848136	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Our results indicate that miR-22-3p is a key molecule in regulating HASMC proliferation and migration by targeting HMGB1 and that miR-22-3p and HMGB1 may be therapeutic targets in the treatment of human ASO.
target gene	hsa-mir-31	Arteriosclerosis Obliterans	29403548	cardiovascular system disease	DOID:5160		D001162		HP:0002634	MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie
target gene	hsa-mir-15a	Arthritis	19714650	musculoskeletal system disease	DOID:848	M19.90	D001168			induction of apoptosis in the synovium of mice,suppresses apoptosis through inhibition of Bcl-2
target gene	hsa-mir-15a	Arthritis	28877850	musculoskeletal system disease	DOID:848	M19.90	D001168			Gabapentin regulates expression of FGF2 and FGFR1 in dorsal root ganglia via microRNA-15a in the arthritis rat model.
target gene	hsa-mir-151a	Asthenozoospermia	26626315			R86.9	D053627			These results indicate that miR-151a-5p may participate in the regulation of cellular respiration and ATP production through targeting Cytb.
target gene	hsa-mir-27b	Asthenozoospermia	25505194			R86.9	D053627			reduced CRISP2 expression in asthenozoospermia, offering a potential therapeutic target for treating male infertility or for male contraception.
target gene	hsa-mir-145	Asthma	27902892	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MicroRNA-145 influences the balance of Th1/Th2 via regulating RUNX3 in asthma patients.
target gene	hsa-mir-146a	Asthma	29101850	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MicroRNA-146a promotes IgE class switch in B cells via upregulating 14-3-3σ expression.
target gene	hsa-mir-148a	Asthma	23534973	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype.
target gene	hsa-mir-148b	Asthma	23534973	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype.
target gene	hsa-mir-152	Asthma	23534973	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype.
target gene	hsa-mir-155	Asthma	26693910	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MicroRNA Expression Is Altered in an Ovalbumin-Induced Asthma Model and Targeting miR-155 with Antagomirs Reveals Cellular Specificity.
target gene	hsa-mir-15a	Asthma	23954351	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Lower levels of hsa-mir-15a, which decreases VEGFA, in the CD4+ T cells of pediatric patients with asthma.
target gene	hsa-mir-21	Asthma	29334241	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS
target gene	hsa-mir-3162	Asthma	26959414	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MiR-3162-3p Is a Novel MicroRNA That Exacerbates Asthma by Regulating β-Catenin.
target gene	hsa-mir-92a	Asthma	29334241	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS
target gene	hsa-mir-93	Asthma	29334241	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS
target gene	hsa-mir-106a	Astrocytoma	24013584	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-106a-5p functions as a tumor suppressor during the development of astrocytomas by targeting FASTK.
target gene	hsa-mir-124	Astrocytoma	27088547	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	We showed that the repression of PIM1 in astrocytoma cancer cells by miR-124-3p suppressed proliferation, invasion, and aerobic glycolysis and promoted apoptosis.
target gene	hsa-mir-137	Astrocytoma	26440052	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1.
target gene	hsa-mir-22	Astrocytoma	27834627	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Promotion of astrocytoma cell invasion by micro RNA-22 targeting of tissue inhibitor of matrix metalloproteinase-2.
target gene	hsa-let-7c	Atherosclerosis	22917031	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Our data suggest that let-7c contributes to endothelial apoptosis through suppression of Bcl-xl
target gene	hsa-let-7g	Atherosclerosis	29254143	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Let-7g suppresses both canonical and non-canonical NF-κB pathways in macrophages leading to anti-atherosclerosis
target gene	hsa-mir-101	Atherosclerosis	26033364	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-101 promotes intracellular cholesterol retention under inflammatory conditions through suppressing ABCA1 expression and suggests that the miR-101-ABCA1 axis may play an intermediary role in the development of NAFLD and vascular atherosclerosis.
target gene	hsa-mir-103	Atherosclerosis	26837267	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4.
target gene	hsa-mir-10a	Atherosclerosis	20624982	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-10a:miR-10a contributes to the regulation of proinflammatory endothelial phenotypes in athero-susceptible regions in vivo
target gene	hsa-mir-1185	Atherosclerosis	28441650	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-1185 Induces Endothelial Cell Apoptosis by Targeting UVRAG and KRIT1.
target gene	hsa-mir-1185	Atherosclerosis	28441665	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-1185 Promotes Arterial Stiffness though Modulating VCAM-1 and E-Selectin Expression.
target gene	hsa-mir-122	Atherosclerosis	23260873	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Several miRNAs have been described to finely regulate lipid metabolism and the progression and regression of atherosclerosis including, miR-33, miR-122.
target gene	hsa-mir-126	Atherosclerosis	24140891	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Expression of miR-126 was markedly increased and expression of protein targets VCAM-1 and SDF-1 was altered during the course of CKD
target gene	hsa-mir-126	Atherosclerosis	27993686	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-126 suppresses inflammation in endothelial cells under hyperglycemic condition by targeting HMGB1.
target gene	hsa-mir-126	Atherosclerosis	28425867	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-126 activates the endothelial production of a chemokine CXCL12 via self-multiplying feedback loop to promote re-endothelialization and support lesion stability
target gene	hsa-mir-133a	Atherosclerosis	28257760	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Induction of MiR133a expression by IL-19 targets LDLRAP1 and reduces oxLDL uptake in VSMC.
target gene	hsa-mir-135b	Atherosclerosis	26184978	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-135b-5p and MiR-499a-3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C.
target gene	hsa-mir-145	Atherosclerosis	20415654	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNAs also regulate smooth muscle cell phenotypes and control neointima formation and atherosclerosis. In this respect, miR-143 and miR-145 have been shown to play a crucial role.
target gene	hsa-mir-145	Atherosclerosis	21945499	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	We showed that miR-145 can regulate the fate and phenotype of human ES-pre-SMCs as they become fully differentiated SMCs.
target gene	hsa-mir-145	Atherosclerosis	24140891	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Both vascular smooth muscle-specific miR-143 and miR-145 expressions were decreased in states of atherosclerosis and/or CKD or both, and the expression level of protein target Myocardin was increased.
target gene	hsa-mir-145	Atherosclerosis	26992033	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-145 modulates the phenotypic switch of VSMCs from a contractile to a proliferative state via KLF5 and MYOCD in atherosclerosis.
target gene	hsa-mir-145	Atherosclerosis	27731400	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miRNA-145 inhibits VSMC proliferation by targeting CD40.
target gene	hsa-mir-145	Atherosclerosis	29324316	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-145 alleviates high glucose-induced proliferation and migration of vascular smooth muscle cells through targeting ROCK1
target gene	hsa-mir-146a	Atherosclerosis	25523239	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-146a and miR-21 were significantly upregulated in atherosclerotic plaque, and cooperated to accelerate VSMC growth and cell cycle progression by targeting Notch2 and Jag1.
target gene	hsa-mir-146a	Atherosclerosis	21236257	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Our study clearly revealed that miRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion in DCs by targeting CD40L in ox-LDL-stimulated DCs.
target gene	hsa-mir-146a	Atherosclerosis	23784108	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiRNA-146a regulates the maturation and differentiation of vascular smooth muscle cells by targeting NF-κB expression.
target gene	hsa-mir-146a	Atherosclerosis	24022569	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-146a interacted with the 3' untranslated region of the TRAF6 gene, reducing its expression.
target gene	hsa-mir-150	Atherosclerosis	28110404	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-150 targets ELK1 and modulates the apoptosis induced by ox-LDL in endothelial cells.
target gene	hsa-mir-150	Atherosclerosis	29463607	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	the decreases in phosphorylated p65 expression and inflammatory cytokine secretion induced by miR-150 ablation were reversed by PDLIM1 knockdown
target gene	hsa-mir-152	Atherosclerosis	24813629	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17.
target gene	hsa-mir-155	Atherosclerosis	23041630	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages
target gene	hsa-mir-155	Atherosclerosis	26159489	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	microRNA-155 works as a promoter in the atherosclerotic procession. Its mechanism may include enhancing inflammatory response in atherosclerosis by increasing STAT3 and NF-κB signaling via targeting SOCS1.
target gene	hsa-mir-155	Atherosclerosis	24905663	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Regulation of microRNA-155 in endothelial inflammation by targeting nuclear factor (NF)-κB P65.
target gene	hsa-mir-16	Atherosclerosis	26936421	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR鈥?6 is a direct negative regulator of PDCD4 in atherosclerosis.
target gene	hsa-mir-17	Atherosclerosis	25785043	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-93 and miR-17 repress ABCA1 expression through directly targeting 3'UTR.
target gene	hsa-mir-181a	Atherosclerosis	22956783	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Thus, abundance of miR-181a reduced c-Fos protein, whereas inhibition of miR-181a increased c-Fos protein in BMDCs. We therefore suggest that miR-181a attenuates ox-LDL-stimulated immune inflammation responses by targeting c-Fos in DCs.
target gene	hsa-mir-182	Atherosclerosis	28855441	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice.
target gene	hsa-mir-19a	Atherosclerosis	26483345	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Endothelial Hypoxia-Inducible Factor-1α Promotes Atherosclerosis and Monocyte Recruitment by Upregulating MicroRNA-19a.
target gene	hsa-mir-19b	Atherosclerosis	26117405	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Taken together, these results demonstrate that PGC-1α plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1α by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function.
target gene	hsa-mir-206	Atherosclerosis	28342807	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Myocardin inhibited the gap protein connexin 43 via promoted miR-206 to regulate vascular smooth muscle cell phenotypic switch.
target gene	hsa-mir-21	Atherosclerosis	25523239	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-146a and miR-21 were significantly upregulated in atherosclerotic plaque, and cooperated to accelerate VSMC growth and cell cycle progression by targeting Notch2 and Jag1.
target gene	hsa-mir-21	Atherosclerosis	28460288	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response.
target gene	hsa-mir-21	Atherosclerosis	28823833	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-21 suppresses ox-LDL-induced human aortic endothelial cells injuries in atherosclerosis through enhancement of autophagic flux: Involvement in promotion of lysosomal function.
target gene	hsa-mir-210	Atherosclerosis	28536634	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-210 induces endothelial cell apoptosis by directly targeting PDK1 in the setting of atherosclerosis.
target gene	hsa-mir-216a	Atherosclerosis	24481443	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In conclusion, mir-216a controls ox-LDL induced autophagy in HUVECs by regulating intracellular levels of BECN1 and may have a relevant role in the pathogenesis of cardiovascular disorders and atherosclerosis.
target gene	hsa-mir-221	Atherosclerosis	26117405	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Taken together, these results demonstrate that PGC-1α plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1α by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function.
target gene	hsa-mir-222	Atherosclerosis	26117405	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Taken together, these results demonstrate that PGC-1α plays a protective role against the vascular complications of atherosclerosis. Moreover, the posttranscriptional regulation of PGC-1α by miR-19b/221/222 was unveiled,which provides a novel mechanism in which a panel of microRNAs can modulate endothelial cell apoptosis via the regulation mitochondrial function.
target gene	hsa-mir-223	Atherosclerosis	28460288	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response.
target gene	hsa-mir-24	Atherosclerosis	29250154	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-α3 and regulating inflammatory responses
target gene	hsa-mir-26a	Atherosclerosis	25613580	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The role of miR-26a in atherosclerosis is mediated by its target EphA2 via a mechanism involving the p38 MAPK/VEGF pathway.
target gene	hsa-mir-26a	Atherosclerosis	25801675	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis.
target gene	hsa-mir-27b	Atherosclerosis	26520906	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The results presented here provide evidence that short-term modulation of miR-27b expression in wild-type mice regulates hepatic LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels.
target gene	hsa-mir-27b	Atherosclerosis	27755984	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miRNA-27b modulates endothelial cell angiogenesis by directly targeting Naa15 in atherogenesis.
target gene	hsa-mir-29a	Atherosclerosis	26056009	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	our study demonstrates that miR-29a inhibits QKI, which in turn results in upregulation of scavenger receptor A (SRA) and lipid uptake.
target gene	hsa-mir-30	Atherosclerosis	26488467	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Upregulation of miR-30 by HFD may impair the protective effects of endothelial cell autophagy against development of atherosclerosis through suppressing protein translation of ATG6.
target gene	hsa-mir-320a	Atherosclerosis	25728840	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF.
target gene	hsa-mir-33	Atherosclerosis	23260873	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Several miRNAs have been described to finely regulate lipid metabolism and the progression and regression of atherosclerosis including, miR-33, miR-122.
target gene	hsa-mir-33a	Atherosclerosis	24499083	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Dialysis method alters the expression of microRNA-33a and its target genes ABCA1,ABCG1 in THP-1 macrophages.
target gene	hsa-mir-34a	Atherosclerosis	28485501	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-34a Targets HDAC1-Regulated H3K9 Acetylation on Lipid Accumulation Induced by Homocysteine in Foam Cells.
target gene	hsa-mir-34a	Atherosclerosis	28688900	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-34a/sirtuin-1/foxo3a is involved in genistein protecting against ox-LDL-induced oxidative damage in HUVECs.
target gene	hsa-mir-365	Atherosclerosis	28051250	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-365 participates in coronary atherosclerosis through regulating IL-6.
target gene	hsa-mir-370	Atherosclerosis	29663491	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-370 can reduce inflammatory reaction and inhibit the ROS production by targeting TLR4 in THP-1 cells
target gene	hsa-mir-490	Atherosclerosis	23821525	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Ox-LDL could inhibit the expression of miR-490-3p and IGF1, whereas increase IGF2 expression. The inhibition of miR0-490-3p up-regulated its target gene PAPP-A and then increased the proteolysis of IGFBP-4. The increased expression of IGF2 and proteolysis of IGFBP-4 might activate pathways independent or dependent on IGF axis by autocrine and paracrine mechanisms and resulted in the VSMC proliferation. Our results could help us to understand the mechanisms of the pro-atherogenic effects of ox-LDL and the effects of PAPP-A on atherosclerosis development.
target gene	hsa-mir-495	Atherosclerosis	25466836	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-495 could affect HUVECs proliferation and apoptosis by directly  targeting CCL2. This is the first report to disclose the roles and mechanisms of  miR-495 on HUVECs proliferation and apoptosis, which may provide a theoretical basis for clarifying the mechanisms of atherosclerosis.
target gene	hsa-mir-499a	Atherosclerosis	26184978	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-135b-5p and MiR-499a-3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C.
target gene	hsa-mir-503	Atherosclerosis	27829550	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-503 inhibits platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration through targeting the insulin receptor.
target gene	hsa-mir-590	Atherosclerosis	25149060	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-590 attenuates lipid accumulation and pro-inflammatory cytokine secretion by targeting LPL gene in human THP-1 macrophages. Therefore, targeting miR-590 may offer a promising strategy to treat atherosclerotic cardiovascular diseases.
target gene	hsa-mir-712	Atherosclerosis	26308181	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE(-/-) Mice.
target gene	hsa-mir-9	Atherosclerosis	28334721	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MicroRNA-9 Inhibits NLRP3 Inflammasome Activation in Human Atherosclerosis Inflammation Cell Models through the JAK1/STAT Signaling Pathway.
target gene	hsa-mir-99a	Atherosclerosis	27403035	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	MiR-99a inhibited the LPS-induced HUVECs inflammation via inhibition of the mTOR/NF-魏B signal.
target gene	hsa-mir-143	Atopic Dermatitis	27048505	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	The forced expression of microRNA-143 mimic  blocked the IL-13-induced downregulation of filaggrin, loricrin, and involucrin in epidermal keratinocytes.
target gene	hsa-mir-223	Atopic Dermatitis	29506638	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	miR-223 participates in AD through upregulating HNMT indirectly to degrade the excessive histamine
target gene	hsa-mir-199a	Atrial Fibrillation	26888839	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future.
target gene	hsa-mir-199b	Atrial Fibrillation	26888839	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future.
target gene	hsa-mir-21	Atrial Fibrillation	28495464	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MicroRNA-21 via Dysregulation of WW Domain-Containing Protein 1 Regulate Atrial Fibrosis in Atrial Fibrillation.
target gene	hsa-mir-30b	Atrial Fibrillation	26888839	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future.
target gene	hsa-mir-377	Atrial Fibrillation	26888839	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miRNAs regulate the occurrence and development of AF. RFA can change the expression of miRNAs in AF patients, which may be important for reversing the electrical and structural remodeling and maintaining sinus rhythm after RFA.miRNAs, such as miR-30b-5p, miR-377-5p and miR-199a-3p/miR-199b-3p etc., might become the target markers for early diagnosis and intervention of AF in future.
target gene	hsa-mir-132	Autism Spectrum Disorder	25885346	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	We found that through p-CREB/miR-132 signaling cascade is involved in MeCP2-mediated pain transduction.
target gene	hsa-mir-21	Autism Spectrum Disorder	29334241	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS
target gene	hsa-mir-92a	Autism Spectrum Disorder	29334241	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS
target gene	hsa-mir-93	Autism Spectrum Disorder	29334241	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	Disordered expression of genes under the regulation of miRNAs may play an important role in CARAS
target gene	hsa-mir-93	Barrett Esophagus	19422085	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim
target gene	hsa-mir-106b	Barrett Esophagus	19422085	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim
target gene	hsa-mir-25	Barrett Esophagus	19422085	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MiRs-93 and -106b targeted and inhibited p21, whereas miR-25 targeted and inhibited Bim
target gene	hsa-mir-145	Barrett Esophagus	22504665	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	microRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6.
target gene	hsa-mir-21	Barrett Esophagus	20702469	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	These data support a significant role for PDCD4 downregulation in the progression of BM to BAc, and confirm miR-21 as a negative regulator of PDCD4 in vivo. Further efforts are needed to validate PDCD4 as a potential prognostic marker in patients with Barrett's oesophagus.
target gene	hsa-mir-223	Barrett Esophagus	23757351	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MicroRNA 223 is Up-regulated in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARP1.
target gene	hsa-mir-155	Biliary Atresia	28355202	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		MicroRNA-155 modulates bile duct inflammation by targeting the suppressor of cytokine signaling 1 in biliary atresia.
target gene	hsa-mir-200b	Biliary Atresia	24412919	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		Up-regulation of miR-200b in biliary atresia patients accelerates proliferation and migration of hepatic stallate cells by activating PI3K/Akt signaling.
target gene	hsa-mir-222	Biliary Atresia	25238119	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		Our results show that miR-222 overexpression is common in BA and contributes to LX-2 cell proliferation by targeting protein phosphatase 2A subunit B and Akt signaling.
target gene	hsa-mir-421	Biliary Tract Neoplasms	22146319	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression.
target gene	hsa-let-7c	Bladder Neoplasms	23013190			C67	D001749	109800	HP:0009725	Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay.
target gene	hsa-mir-1	Bladder Neoplasms	20843712			C67	D001749	109800	HP:0009725	Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC.
target gene	hsa-mir-1	Bladder Neoplasms	22378464			C67	D001749	109800	HP:0009725	Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer.
target gene	hsa-mir-100	Bladder Neoplasms	23778527			C67	D001749	109800	HP:0009725	Hypoxia, in part via suppression of miR-100, induces FGFR3 expression in bladder cancer, both of which have an important role in maintaining cell viability under conditions of stress.
target gene	hsa-mir-101	Bladder Neoplasms	23618864			C67	D001749	109800	HP:0009725	MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met.
target gene	hsa-mir-103b	Bladder Neoplasms	23013190			C67	D001749	109800	HP:0009725	Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay.
target gene	hsa-mir-106b	Bladder Neoplasms	23013190			C67	D001749	109800	HP:0009725	Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay.
target gene	hsa-mir-10b	Bladder Neoplasms	24573354			C67	D001749	109800	HP:0009725	MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer.
target gene	hsa-mir-124	Bladder Neoplasms	24180482			C67	D001749	109800	HP:0009725	miR-124-3p can repress the migration and invasion of bladder cancer cells via regulating ROCK1. Our data indicate that miR-124-3p could be a tumor suppressor and may have a potential to be a diagnostics or predictive biomarker in bladder cancer.
target gene	hsa-mir-124	Bladder Neoplasms	25348738			C67	D001749	109800	HP:0009725	MiR-124 retards bladder cancer growth by directly targeting CDK4.
target gene	hsa-mir-125b	Bladder Neoplasms	24396870			C67	D001749	109800	HP:0009725	Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1.
target gene	hsa-mir-126	Bladder Neoplasms	24823697			C67	D001749	109800	HP:0009725	MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9.
target gene	hsa-mir-127	Bladder Neoplasms	24004856			C67	D001749	109800	HP:0009725	These findings provide new insights into the role of miRNAs in the pathway of cancer and give us a hypothesis that miR-127 might play a similar rolein regulation and control of PIK3R1.
target gene	hsa-mir-133a	Bladder Neoplasms	20843712			C67	D001749	109800	HP:0009725	Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC.
target gene	hsa-mir-133a	Bladder Neoplasms	22378464			C67	D001749	109800	HP:0009725	Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer.
target gene	hsa-mir-144	Bladder Neoplasms	23815091			C67	D001749	109800	HP:0009725	miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling.
target gene	hsa-mir-144	Bladder Neoplasms	26057453			C67	D001749	109800	HP:0009725	miR-144-5p functions as tumour suppressor in BC cells. CCNE1 and CCNE2 were directly regulated by miR-144-5p and might be good prognostic markers for survival of BC patients.
target gene	hsa-mir-145	Bladder Neoplasms	24999188			C67	D001749	109800	HP:0009725	MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells.
target gene	hsa-mir-145	Bladder Neoplasms	29693148			C67	D001749	109800	HP:0009725	microRNA‑145 modulates migration and invasion of bladder cancer cells by targeting N‑cadherin.
target gene	hsa-mir-145	Bladder Neoplasms	20843712			C67	D001749	109800	HP:0009725	Our data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in BC.
target gene	hsa-mir-16	Bladder Neoplasms	25196524			C67	D001749	109800	HP:0009725	Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression.
target gene	hsa-mir-16	Bladder Neoplasms	23013190			C67	D001749	109800	HP:0009725	Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay.
target gene	hsa-mir-193a	Bladder Neoplasms	25311867			C67	D001749	109800	HP:0009725	In addition to a new mechanistic insight, our results provide a set of the essential genes in this newly identified miR-193a-3p/LOXL4/Oxidative Stress axis as the diagnostic targets for a guided anti-bladder cancer chemotherapy.
target gene	hsa-mir-193a	Bladder Neoplasms	25991669			C67	D001749	109800	HP:0009725	The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer.
target gene	hsa-mir-193a	Bladder Neoplasms	25444900			C67	D001749	109800	HP:0009725	a set of the essential genes in the miR-193a-3p/HOXC9/DNA damage response/oxidative stress pathway axis as the diagnostic targets for the guided anti-bladder cancer chemotherapy.
target gene	hsa-mir-19a	Bladder Neoplasms	24122582			C67	D001749	109800	HP:0009725	Expression of miR-21, miR-19a and miR-222, known to regulate PTEN expression, was also evaluated
target gene	hsa-mir-203	Bladder Neoplasms	26599571			C67	D001749	109800	HP:0009725	In conclusion, decreased miR-203 predicts progression and poor prognosis for BC patients treated with cisplatin-based chemotherapy while miR-203 overexpression can enhance cisplatin sensitization by promoting apoptosis via directly targeting Bcl-w and Survivin.
target gene	hsa-mir-206	Bladder Neoplasms	27904673			C67	D001749	109800	HP:0009725	MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC.
target gene	hsa-mir-20b	Bladder Neoplasms	26166554			C67	D001749	109800	HP:0009725	MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression.
target gene	hsa-mir-21	Bladder Neoplasms	26230405			C67	D001749	109800	HP:0009725	microRNA-21 Regulates Cell Proliferation and Migration and Cross Talk with PTEN and p53 in Bladder Cancer.
target gene	hsa-mir-214	Bladder Neoplasms	25706919			C67	D001749	109800	HP:0009725	MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer.
target gene	hsa-mir-216	Bladder Neoplasms	27578985			C67	D001749	109800	HP:0009725	MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway.
target gene	hsa-mir-218	Bladder Neoplasms	25967457			C67	D001749	109800	HP:0009725	MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion  by targeting BMI-1.
target gene	hsa-mir-222	Bladder Neoplasms	24122582			C67	D001749	109800	HP:0009725	Expression of miR-21, miR-19a and miR-222, known to regulate PTEN expression, was also evaluated
target gene	hsa-mir-23b	Bladder Neoplasms	23844063			C67	D001749	109800	HP:0009725	MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer.
target gene	hsa-mir-24	Bladder Neoplasms	26252200			C67	D001749	109800	HP:0009725	MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3.
target gene	hsa-mir-24-1	Bladder Neoplasms	24999187			C67	D001749	109800	HP:0009725	Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer.
target gene	hsa-mir-26a	Bladder Neoplasms	23796420			C67	D001749	109800	HP:0009725	miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1.
target gene	hsa-mir-27a	Bladder Neoplasms	25656571			C67	D001749	109800	HP:0009725	rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.
target gene	hsa-mir-29b-1	Bladder Neoplasms	24265332			C67	D001749	109800	HP:0009725	Both miR-29b-1* and miR-29c regulate cell growth in BUC. The targets of miR-29b-1* and miR-29c may be functionally associated with proliferation, cell cycle and apoptosis.
target gene	hsa-mir-29c	Bladder Neoplasms	24265332			C67	D001749	109800	HP:0009725	Both miR-29b-1* and miR-29c regulate cell growth in BUC. The targets of miR-29b-1* and miR-29c may be functionally associated with proliferation, cell cycle and apoptosis.
target gene	hsa-mir-320a	Bladder Neoplasms	24443232			C67	D001749	109800	HP:0009725	MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3.
target gene	hsa-mir-34a	Bladder Neoplasms	25878394			C67	D001749	109800	HP:0009725	miR-34a inhibits proliferation and invasion of bladder cancer cells by targeting orphan nuclear receptor HNF4G.
target gene	hsa-mir-34a	Bladder Neoplasms	26198939			C67	D001749	109800	HP:0009725	MicroRNA-34a regulates cell cycle by targeting CD44 in human bladder carcinoma cells.
target gene	hsa-mir-34a	Bladder Neoplasms	23013190			C67	D001749	109800	HP:0009725	Expression of 5 miRNAs (miR-34a, let-7c, miR-16, miR-103b, and miR-106b) that target p53, Rb, or Bcl-2 protein pathways was determined for bladder samples and cells via quantitative real-time PCR assay.
target gene	hsa-mir-409	Bladder Neoplasms	23820886			C67	D001749	109800	HP:0009725	MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met.
target gene	hsa-mir-490	Bladder Neoplasms	24220339			C67	D001749	109800	HP:0009725	MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos.
target gene	hsa-mir-576	Bladder Neoplasms	25556372			C67	D001749	109800	HP:0009725	miR-576-3p might be a novel suppressor of bladder cancer cell proliferation through targeting cyclin D1.
target gene	hsa-mir-9	Bladder Neoplasms	26150338			C67	D001749	109800	HP:0009725	miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.
target gene	hsa-mir-96	Bladder Neoplasms	29467898			C67	D001749	109800	HP:0009725	HERG1 was an important target of miR-96
target gene	hsa-mir-127	Bone Cancer	28866093	musculoskeletal system disease	DOID:184	C79.51	D001859			MiR-127 and miR-376a act as tumor suppressors by in vivo targeting of COA1 and PDIA6 in giant cell tumor of bone.
target gene	hsa-mir-376a	Bone Cancer	28866093	musculoskeletal system disease	DOID:184	C79.51	D001859			MiR-127 and miR-376a act as tumor suppressors by in vivo targeting of COA1 and PDIA6 in giant cell tumor of bone.
target gene	hsa-mir-214	Bone Disease [unspecific]	28109866	musculoskeletal system disease	DOID:0080001	M89.9	D001847			miR-214 suppresses osteogenesis by targeting BIRC7, providing a possible therapeutic target for bone degenerative diseases
target gene	hsa-mir-221	Bone Disease [unspecific]	26062554	musculoskeletal system disease	DOID:0080001	M89.9	D001847			Intercellular adhesion molecule-1 was upregulated by microRNA-221 in mesenchymal stem cells because microRNAs are key regulators of various biological functions via gene expression.
target gene	hsa-mir-93	Bone Disease [unspecific]	28186136	musculoskeletal system disease	DOID:0080001	M89.9	D001847			FOXO1-suppressed miR-424 regulates the proliferation and osteogenic differentiation of MSCs by targeting FGF2 under oxidative stress.
target gene	hsa-mir-128	Borjeson-Forssman-Lehmann Syndrome	25556700	disease of mental health	DOID:0050681		C536575	301900		miR-128 regulates neuronal migration, outgrowth and intrinsic excitability via the intellectual disability gene Phf6.
target gene	hsa-mir-21	Brain Neoplasms	17965831	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The overexpression of miR-21 was recognized in malignant brain tumours, and knockdown of this miRNA in cultured glioblastoma cells resulted in caspase activation and apoptosis. The tumour suppressor tropomyosin 1 (TPM1) was demonstrated to be a target for miR-21, explaining why inhibition of miR-21 results in reduced tumour growth.
target gene	hsa-mir-296	Brain Neoplasms	18977327	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	Growth factor-induced miR-296 contributes significantly to angiogenesis by directly targeting the hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) mRNA, leading to decreased levels of HGS and thereby reducing HGS-mediated degradation of the growth factor receptors VEGFR2 and PDGFRbeta.
target gene	hsa-mir-7	Brain Neoplasms	29016934	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
target gene	hsa-mir-143	Breast Adenocarcinoma	28511343	thoracic disease	DOID:3458					Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors.
target gene	hsa-let-7a	Breast Neoplasms	26460550	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our research revealed the mechanisms through which miR-208a functioned in breast cancer and BrCSCs, and identified the miR-208a-SOX2/β-catenin-LIN28-let-7a-DICER1 regulatory feedback loop in regulations of stem cells renewal.
target gene	hsa-let-7a	Breast Neoplasms	27345399	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization
target gene	hsa-let-7a-1	Breast Neoplasms	22251626	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7.
target gene	hsa-let-7a-2	Breast Neoplasms	22251626	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7.
target gene	hsa-let-7a-3	Breast Neoplasms	22251626	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7.
target gene	hsa-let-7b	Breast Neoplasms	27345399	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization
target gene	hsa-let-7c	Breast Neoplasms	28731186	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Let-7c-5p inhibits cell proliferation and induces cell apoptosis by targeting ERCC6 in breast cancer
target gene	hsa-let-7f-1	Breast Neoplasms	22407818	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
target gene	hsa-mir-1	Breast Neoplasms	28159933	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes.
target gene	hsa-mir-100	Breast Neoplasms	26130569	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The role of miR-100 in regulating apoptosis of breast cancer cells.
target gene	hsa-mir-100	Breast Neoplasms	21634028	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	micro-RNA 100 Regulated beta-tubulin isotypes  in MCF7 breast cancer cells.
target gene	hsa-mir-100	Breast Neoplasms	22926517	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling.
target gene	hsa-mir-101	Breast Neoplasms	26927545	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3a.
target gene	hsa-mir-101-1	Breast Neoplasms	23071542	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1
target gene	hsa-mir-101-2	Breast Neoplasms	23071542	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1
target gene	hsa-mir-106a	Breast Neoplasms	21765466	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression.
target gene	hsa-mir-106b	Breast Neoplasms	24270410	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300.
target gene	hsa-mir-106b	Breast Neoplasms	22286770	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer.
target gene	hsa-mir-106b	Breast Neoplasms	28518139	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer.
target gene	hsa-mir-106b	Breast Neoplasms	21765466	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression.
target gene	hsa-mir-107	Breast Neoplasms	21841313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans.
target gene	hsa-mir-10a	Breast Neoplasms	19232136	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-10a: miR-10a inhibits transcriptional of Hoxd4
target gene	hsa-mir-10b	Breast Neoplasms	23839045	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination
target gene	hsa-mir-10b	Breast Neoplasms	26359455	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.
target gene	hsa-mir-10b	Breast Neoplasms	26392359	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression.
target gene	hsa-mir-10b	Breast Neoplasms	22573479	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.
target gene	hsa-mir-10b	Breast Neoplasms	22847191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis.
target gene	hsa-mir-122	Breast Neoplasms	25318895	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer.
target gene	hsa-mir-122	Breast Neoplasms	23056576	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R
target gene	hsa-mir-1225	Breast Neoplasms	25961594	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.
target gene	hsa-mir-124	Breast Neoplasms	23816858	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124 plays a critical role in inhibiting the invasive and metastatic potential of breast cancer cells, probably by directly targeting the CD151 genes. Our findings highlight an important role of miR-124 in the regulation of invasion and metastasis by breast cancer cells and suggest a potential application for miR-124 in breast cancer treatment.
target gene	hsa-mir-124	Breast Neoplasms	24330780	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our study demonstrated that miR-124 might be a tumor suppressor in breast cancer via the regulation of FLOT1. This microRNA could serve as a potential diagnostic marker and therapeutic target for breast cancer.
target gene	hsa-mir-124	Breast Neoplasms	25085587	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer.
target gene	hsa-mir-124	Breast Neoplasms	27468577	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Decreased miR-124-3p Expression Prompted Breast Cancer Cell Progression Mainly by Targeting Beclin-1. 
target gene	hsa-mir-124	Breast Neoplasms	27842510	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL.
target gene	hsa-mir-124-1	Breast Neoplasms	22085528	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro.
target gene	hsa-mir-124-1	Breast Neoplasms	22333974	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer.
target gene	hsa-mir-124-1	Breast Neoplasms	23250910	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer
target gene	hsa-mir-124-2	Breast Neoplasms	22085528	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro.
target gene	hsa-mir-124-2	Breast Neoplasms	22333974	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer.
target gene	hsa-mir-124-2	Breast Neoplasms	23250910	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer
target gene	hsa-mir-124-3	Breast Neoplasms	22085528	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro.
target gene	hsa-mir-124-3	Breast Neoplasms	22333974	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer.
target gene	hsa-mir-124-3	Breast Neoplasms	23250910	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer
target gene	hsa-mir-1245a	Breast Neoplasms	22158906	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair.
target gene	hsa-mir-1245b	Breast Neoplasms	22158906	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair.
target gene	hsa-mir-125a	Breast Neoplasms	25961594	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.
target gene	hsa-mir-125a	Breast Neoplasms	25962054	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the Hippo signaling pathway.
target gene	hsa-mir-125a	Breast Neoplasms	19875930	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-125a represses cell growth by targeting HuR in breast cancer
target gene	hsa-mir-125a	Breast Neoplasms	25504437	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	serum miR-125a-5p level in breast cancer may be a useful prognostic biomarker and offer a novel therapeutic avenue by targeting HDAC4 in breast cancer.
target gene	hsa-mir-125b	Breast Neoplasms	26531722	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125a-5p/miR-125b suppress the expression of TSTA3
target gene	hsa-mir-125b	Breast Neoplasms	29434858	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1
target gene	hsa-mir-125b	Breast Neoplasms	19570947	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, this study clearly demonstrates that miR-125b post-transcriptionally regulates the CYP24, which serves as a possible mechanism for the high CYP24 expression in cancer tissues.
target gene	hsa-mir-125b	Breast Neoplasms	19825990	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Thus, the short hairpin-looped ODN-Raf, targeting the same region of c-raf-1 as miR-125b, is a multifunctional molecule reducing the expression of oncoproteins and stimulating cell death. Both features may be useful to interfere with tumor growth.
target gene	hsa-mir-125b-1	Breast Neoplasms	19738052	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	hsa-mir-125b binding site in BMPR1B is Associated with Breast cancer pathogenesis
target gene	hsa-mir-125b-1	Breast Neoplasms	20460378	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-125b:MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression
target gene	hsa-mir-125b-1	Breast Neoplasms	21444677	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b is Methylated and Functions as A Tumor Suppressor by Regulating the ETS1 proto-oncogene in Human Invasive Breast Cancer.
target gene	hsa-mir-125b-1	Breast Neoplasms	22307404	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b targets ARID3B in breast cancer cells.
target gene	hsa-mir-125b-1	Breast Neoplasms	22693547	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells.
target gene	hsa-mir-125b-2	Breast Neoplasms	19738052	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	hsa-mir-125b binding site in BMPR1B is Associated with Breast cancer pathogenesis
target gene	hsa-mir-125b-2	Breast Neoplasms	20460378	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-125b:MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression
target gene	hsa-mir-125b-2	Breast Neoplasms	21444677	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b is Methylated and Functions as A Tumor Suppressor by Regulating the ETS1 proto-oncogene in Human Invasive Breast Cancer.
target gene	hsa-mir-125b-2	Breast Neoplasms	22307404	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b targets ARID3B in breast cancer cells.
target gene	hsa-mir-125b-2	Breast Neoplasms	22693547	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells.
target gene	hsa-mir-126	Breast Neoplasms	26261534	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Thus, our study revealed that miR-126 may act as a tumor suppressor via inhibition of cell invasion by downregulating ADAM9 in breast cancer development.
target gene	hsa-mir-126	Breast Neoplasms	21249429	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2.
target gene	hsa-mir-127	Breast Neoplasms	21343399	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Analyses of miRNA expression profiles identified numerous miRNAs implicated in cell proliferation including miR-127, -197, -222, and -223 targeting CXCL12.
target gene	hsa-mir-128	Breast Neoplasms	27341528	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	AurkA suppressed the expression of miR-128
target gene	hsa-mir-128-1	Breast Neoplasms	21953503	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.
target gene	hsa-mir-128-1	Breast Neoplasms	23526655	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miRNA-128 sensitizes breast cancer cell to chemodrugs by targeting Bax
target gene	hsa-mir-128-2	Breast Neoplasms	23526655	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miRNA-128 sensitizes breast cancer cell to chemodrugs by targeting Bax
target gene	hsa-mir-129	Breast Neoplasms	26720492	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-129-5p/HMGB1 axis can regulate irradiation-induced autophagy in breast cancer and might be an important pathway in regulating radiosensitivity of breast cancer cells.
target gene	hsa-mir-1290	Breast Neoplasms	25528056	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-1290 directly targets the NAT1 3'-UTR and that NAT1 protein expression is correlated with improved OS of breast cancer patients. NAT1 is a possible prognostic biomarker for lymph node-positive breast cancer. Thus, miR-1290 and its target NAT1 are associated with important characteristics of breast cancer.
target gene	hsa-mir-1290	Breast Neoplasms	23183268	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer
target gene	hsa-mir-130a	Breast Neoplasms	25755726	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A.
target gene	hsa-mir-132	Breast Neoplasms	25450365	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a critical role of miR-132 in prohibiting cell proliferation, invasion, migration and metastasis in breast cancer through direct suppression of HN1, supporting the potential utility of miR-132 as a novel therapeutic strategy against breast cancer.
target gene	hsa-mir-133a	Breast Neoplasms	23786162	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway.
target gene	hsa-mir-133b	Breast Neoplasms	24935473	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Correlations of common polymorphism of EVI-1 gene targeted by miRNA-206/133b with the pathogenesis of breast cancer.
target gene	hsa-mir-134	Breast Neoplasms	26318721	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-134 modulates resistance to doxorubicin in breast cancer cells by downregulating the expression of ABCC1 which is known to encode the multidrug resistance-associated protein 1.
target gene	hsa-mir-135a-1	Breast Neoplasms	22439757	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10.
target gene	hsa-mir-135a-2	Breast Neoplasms	22439757	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10.
target gene	hsa-mir-135b	Breast Neoplasms	23623609	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2.
target gene	hsa-mir-137	Breast Neoplasms	22723937	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.
target gene	hsa-mir-137	Breast Neoplasms	28407692	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-137 inhibits BMP7 to enhance the epithelial-mesenchymal transition of breast cancer cells.
target gene	hsa-mir-138	Breast Neoplasms	27155849	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Only 8 APOBEC3B targeting miRNAs were observed to regulate the fusion transcript of which miR-34b-3p and miR-138-5p were found to be frequently  downregulated in cancers suggesting miRNA-mediated deregulation of APOBEC3A expression in cancer patients harbouring this particular deletion polymorphism.
target gene	hsa-mir-139	Breast Neoplasms	26079880	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha.
target gene	hsa-mir-139	Breast Neoplasms	26299922	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-139-5p not only attenuated the development of breast cancer cells but also mediated drug-resistance by regulating the expression of the downstream target gene Notch1.
target gene	hsa-mir-141	Breast Neoplasms	25813250	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression.
target gene	hsa-mir-141	Breast Neoplasms	18376396	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
target gene	hsa-mir-142	Breast Neoplasms	25406066	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	in some tumors, miR-142 regulates the properties of BCSCs at least in part by activating the WNT signaling pathway and miR-150 expression.
target gene	hsa-mir-143	Breast Neoplasms	25248370	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, our findings provide the first clues regarding the role of the miR-143/145 cluster as a tumor suppressor in breast cancer through the inhibition of ERBB3 translation. These results also support the idea that different miRNAs in a cluster can synergistically repress a given target mRNA.
target gene	hsa-mir-143	Breast Neoplasms	22354042	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells.
target gene	hsa-mir-143	Breast Neoplasms	28559978	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells.
target gene	hsa-mir-145	Breast Neoplasms	25248370	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, our findings provide the first clues regarding the role of the miR-143/145 cluster as a tumor suppressor in breast cancer through the inhibition of ERBB3 translation. These results also support the idea that different miRNAs in a cluster can synergistically repress a given target mRNA.
target gene	hsa-mir-145	Breast Neoplasms	25253741	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	lincRNA-RoR and miR-145 regulate invasion in triple negative breast cancer via targeting ARF6.
target gene	hsa-mir-145	Breast Neoplasms	25450545	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the expression of an miRNA 145 target protein, c-myc, was determined by Western blotting after intracellular delivery of PSMT/miRNA 145 nanoparticle (NP).
target gene	hsa-mir-145	Breast Neoplasms	22592534	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF.
target gene	hsa-mir-145	Breast Neoplasms	23049906	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-145 regulates epithelial to mesenchymal transition of breast cancer cells by targeting Oct4
target gene	hsa-mir-145	Breast Neoplasms	29565493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-145 affects breast cancer BS524 cell proliferation, infiltration, and migration via positively regulating OCT4 gene expression
target gene	hsa-mir-145	Breast Neoplasms	19360360	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-145 inhibits breast cancer cell growth through RTKN.
target gene	hsa-mir-146	Breast Neoplasms	28128741	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-146a and miR-146-5p silencing BRCA1 may trigger formation of triple-negative and basal-like sporadic BC cases
target gene	hsa-mir-146a	Breast Neoplasms	26392359	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression.
target gene	hsa-mir-146a	Breast Neoplasms	27175941	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	invasion activity in MDA-MB-231 breast cancer cells could be directly influenced by altering miR-146a expression.
target gene	hsa-mir-147a	Breast Neoplasms	22333974	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer.
target gene	hsa-mir-148a	Breast Neoplasms	22935141	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of miR-148a or miR-152 significantly inhibits BC cell proliferation, colony formation and tumor angiogenesis via targeting IGF-IR and IRS1 and suppressing their downstream AKT and MAPK/ERK signaling pathways.
target gene	hsa-mir-148a	Breast Neoplasms	28430743	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-148a promotes apoptosis and suppresses growth of breast cancer cells by targeting B-cell lymphoma 2.
target gene	hsa-mir-148b	Breast Neoplasms	23233531	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS,and CSF1
target gene	hsa-mir-149	Breast Neoplasms	24608434	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis.
target gene	hsa-mir-150	Breast Neoplasms	24312495	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor.
target gene	hsa-mir-152	Breast Neoplasms	22935141	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of miR-148a or miR-152 significantly inhibits BC cell proliferation, colony formation and tumor angiogenesis via targeting IGF-IR and IRS1 and suppressing their downstream AKT and MAPK/ERK signaling pathways.
target gene	hsa-mir-153	Breast Neoplasms	25794773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer.
target gene	hsa-mir-153	Breast Neoplasms	26392359	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression.
target gene	hsa-mir-155	Breast Neoplasms	24152184	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	TP53INP1 is the direct target of miR-155. MiR-155, which is overexpressed in MCF-7 cells, contributes to proliferation of MCF-7 cells possibly through down-regulating target TP53INP1.
target gene	hsa-mir-155	Breast Neoplasms	24616504	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.
target gene	hsa-mir-155	Breast Neoplasms	24876105	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-155 drives telomere fragility in human breast cancer by targeting TRF1.
target gene	hsa-mir-155	Breast Neoplasms	20354188	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene
target gene	hsa-mir-155	Breast Neoplasms	20371610	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancer
target gene	hsa-mir-155	Breast Neoplasms	22354042	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells.
target gene	hsa-mir-155	Breast Neoplasms	23353819	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cance
target gene	hsa-mir-155	Breast Neoplasms	18794355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These data suggest that miR-155 may play an important role in TGF-beta-induced EMT and cell migration and invasion by targeting RhoA and indicate that it is a potential therapeutic target for breast cancer intervention.
target gene	hsa-mir-155	Breast Neoplasms	22736789	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This is the first review examining the role of miR-155 in breast cancer progression. The collated data of target genes and biologic pathways of miR-155 identified in this review suggest new avenues of research for this oncogenic miRNA.
target gene	hsa-mir-155	Breast Neoplasms	27065318	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-155 potently suppresses ErbB2 in breast cancer cells.
target gene	hsa-mir-15a	Breast Neoplasms	23900351	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.
target gene	hsa-mir-15a	Breast Neoplasms	25169552	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-15a has a critical role in mediating cell cycle arrest and promoting cell apoptosis of BC, probably by directly targeting SNCG. Thus, it may be involved in development and progression of BC.
target gene	hsa-mir-15a	Breast Neoplasms	27713175	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer.
target gene	hsa-mir-15b	Breast Neoplasms	25783158	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer.
target gene	hsa-mir-16	Breast Neoplasms	25830480	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells.
target gene	hsa-mir-16	Breast Neoplasms	26993770	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-16 sensitizes breast cancer cells to Taxol through the suppression of IKBKB expression
target gene	hsa-mir-16	Breast Neoplasms	27713175	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer.
target gene	hsa-mir-16-1	Breast Neoplasms	19250063	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation
target gene	hsa-mir-16-2	Breast Neoplasms	19250063	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation
target gene	hsa-mir-17	Breast Neoplasms	18695042	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.
target gene	hsa-mir-17	Breast Neoplasms	20505989	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These findings suggest that miR-17-5p plays an important role in breast cancer cell invasion and migration by suppressing HBP1 and subsequent activation of Wnt/β-catenin.
target gene	hsa-mir-17	Breast Neoplasms	21765466	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression.
target gene	hsa-mir-181a	Breast Neoplasms	27033456	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-181a, already demonstrated to inhibit ABCG2 translation, was down-regulated by GNT, explaining translational induction.
target gene	hsa-mir-181b	Breast Neoplasms	26572075	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the results of the present study suggest that miR-181b functions as an oncogene during breast cancer development, and the miR-181b/Bim pathway may be a novel target used to overcome the chemoresistance in breast cancer.
target gene	hsa-mir-181b	Breast Neoplasms	27102539	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-181b-3p promotes epithelial-mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG.
target gene	hsa-mir-181c	Breast Neoplasms	25695913	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-181c promotes proliferation via suppressing PTEN expression in inflammatory breast cancer.
target gene	hsa-mir-182	Breast Neoplasms	19574223	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells
target gene	hsa-mir-182	Breast Neoplasms	23333633	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Up-regulation of miR-182 by beta-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK
target gene	hsa-mir-182	Breast Neoplasms	23430586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1
target gene	hsa-mir-182	Breast Neoplasms	23474751	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis
target gene	hsa-mir-182	Breast Neoplasms	28546132	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
target gene	hsa-mir-183	Breast Neoplasms	27155522	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	among MTUS1 targeting miRNAs, miR-183-5p was identified to be overexpressed in breast cancer and down-regulated in fibroadenoma tissues.
target gene	hsa-mir-185	Breast Neoplasms	25319390	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.
target gene	hsa-mir-185	Breast Neoplasms	25448984	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Vegfa expression was found to be high in human breast cancer tissues. Thus, miR-185-mediated Vegfa targeting may be involved in breast cancer formation.
target gene	hsa-mir-18a	Breast Neoplasms	25069832	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The results of this study reveal a novel role for miR-18a in targeting HIF1A and repressing metastasis of basal-like breast tumors.
target gene	hsa-mir-190a	Breast Neoplasms	24009311	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis.
target gene	hsa-mir-192	Breast Neoplasms	24012720	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer.
target gene	hsa-mir-193	Breast Neoplasms	25961594	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.
target gene	hsa-mir-193a	Breast Neoplasms	22333974	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124, miR-147 and miR-193a-3p are three novel tumor suppressors that co-target EGFR-driven cell-cycle network proteins and inhibit cell-cycle progression and proliferation in breast cancer.
target gene	hsa-mir-193b	Breast Neoplasms	19701247	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
target gene	hsa-mir-194	Breast Neoplasms	27221739	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These findings demonstrate that nucleolin expression is down-regulated by miR-194 and miR-206 and upregulated by HuR
target gene	hsa-mir-194-1	Breast Neoplasms	22829924	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer.
target gene	hsa-mir-194-2	Breast Neoplasms	22829924	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer.
target gene	hsa-mir-195	Breast Neoplasms	22328513	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap
target gene	hsa-mir-195	Breast Neoplasms	23760062	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
target gene	hsa-mir-199b	Breast Neoplasms	23296799	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-199b-5p targets HER2 in breast cancer cells
target gene	hsa-mir-19a	Breast Neoplasms	22952885	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results suggest that the IMPDH1 and NPEPL1 genes are direct targets of miR-19a in breast cancer, while the exogenous expression of these genes is not associated with the growth suppression of MCF-7 cells.
target gene	hsa-mir-19b	Breast Neoplasms	25552929	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7f inhibition induced an increased expression of THBS1 mRNA and TSP-1 protein, but did not affect the proliferation and apoptosis of MCF-7 cells.
target gene	hsa-mir-19b	Breast Neoplasms	27602768	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-19b suppresses PTPRG to promote breast tumorigenesis.
target gene	hsa-mir-200	Breast Neoplasms	25886595	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The ADAM12-L 3'UTR is a direct target of miR-29 and miR-200 family members. Since the miR-29 and miR-200 families play important roles in breast cancer progression, these results may help explain the different prognostic and chemopredictive values of ADAM12-L and ADAM12-S in breast cancer.
target gene	hsa-mir-200a	Breast Neoplasms	24684598	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA-200a inhibits cell proliferation by targeting mitochondrial transcription factor A in breast cancer.
target gene	hsa-mir-200a	Breast Neoplasms	18376396	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
target gene	hsa-mir-200a	Breast Neoplasms	20514023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200a:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion
target gene	hsa-mir-200a	Breast Neoplasms	21224848	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
target gene	hsa-mir-200a	Breast Neoplasms	21926171	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.
target gene	hsa-mir-200a	Breast Neoplasms	23209748	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression
target gene	hsa-mir-200a	Breast Neoplasms	23340296	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer
target gene	hsa-mir-200a	Breast Neoplasms	29329575	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer
target gene	hsa-mir-200b	Breast Neoplasms	24447584	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family.
target gene	hsa-mir-200b	Breast Neoplasms	26011542	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
target gene	hsa-mir-200b	Breast Neoplasms	18376396	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
target gene	hsa-mir-200b	Breast Neoplasms	19665978	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulated, modulate Expression of BMI1, suppressed tumor formation of normal stem cell
target gene	hsa-mir-200b	Breast Neoplasms	20514023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200b:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion
target gene	hsa-mir-200b	Breast Neoplasms	21224848	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
target gene	hsa-mir-200b	Breast Neoplasms	23209748	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression
target gene	hsa-mir-200b	Breast Neoplasms	23975428	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200b directly inhibits expression of lysyl oxidase (LOX), leading to decreased invasion.
target gene	hsa-mir-200c	Breast Neoplasms	24615544	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
target gene	hsa-mir-200c	Breast Neoplasms	24710933	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1.
target gene	hsa-mir-200c	Breast Neoplasms	25044403	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1.
target gene	hsa-mir-200c	Breast Neoplasms	26400441	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	PDCD10 is a target gene of miR-200c and also a possible mechanism by which miR-200c plays a role in regulating the stemness of BCSCs and MaSCs.
target gene	hsa-mir-200c	Breast Neoplasms	18376396	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
target gene	hsa-mir-200c	Breast Neoplasms	20514023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-200c:Our results suggest that the miR-200 family has a tumor-suppressor function by negatively regulating EGF-driven cell invasion
target gene	hsa-mir-200c	Breast Neoplasms	21224848	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
target gene	hsa-mir-200c	Breast Neoplasms	22144583	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.
target gene	hsa-mir-200c	Breast Neoplasms	23209748	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression
target gene	hsa-mir-200c	Breast Neoplasms	28933253	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells.
target gene	hsa-mir-200c	Breast Neoplasms	21682933	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Decreased expression of miRNAs of the miR-200 family has been implicated in the growth and metastasis of breast cancer cells. Of this family, miR-200c has garnered particular attention as a consequence of its ability to target ZEB1 and ZEB2, mediators of epithelial- mesenchymal transition.
target gene	hsa-mir-200c	Breast Neoplasms	28829888	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-200c inhibits metastasis of breast tumor via the downregulation of Foxf2.
target gene	hsa-mir-203	Breast Neoplasms	22207897	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity.
target gene	hsa-mir-203	Breast Neoplasms	22713668	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.
target gene	hsa-mir-204	Breast Neoplasms	26191195	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway.
target gene	hsa-mir-204	Breast Neoplasms	28534958	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1.
target gene	hsa-mir-205	Breast Neoplasms	24098490	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Regulation of HMGB3 by miR-205 reduced both proliferation and invasion of breast cancer cells. Our findings suggest that modulating miR-205 and/or targeting HMGB3 are potential therapies for advanced breast cancer.
target gene	hsa-mir-205	Breast Neoplasms	24129185	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-205 is a tumor suppressor in human breast cancer by post-transcriptional inhibition of HER3 expression.
target gene	hsa-mir-205	Breast Neoplasms	26239614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-205 inhibits the proliferation and invasion of breast cancer by regulating AMOT expression.
target gene	hsa-mir-205	Breast Neoplasms	18376396	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
target gene	hsa-mir-205	Breast Neoplasms	19276373	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-205: a new oncosuppressor regulates HER3
target gene	hsa-mir-206	Breast Neoplasms	24373402	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Hsa-miR-206 has negative controls of proliferation, migration and invasion of breast cancer cell by targeting Cx43.
target gene	hsa-mir-206	Breast Neoplasms	24935473	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Correlations of common polymorphism of EVI-1 gene targeted by miRNA-206/133b with the pathogenesis of breast cancer.
target gene	hsa-mir-206	Breast Neoplasms	26093295	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting.
target gene	hsa-mir-206	Breast Neoplasms	26125274	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results suggest hsa-miR-206 may repress the tumor proliferation and invasion in breast cancer by targeting Cx43.
target gene	hsa-mir-206	Breast Neoplasms	17312270	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.
target gene	hsa-mir-206	Breast Neoplasms	18593897	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.
target gene	hsa-mir-206	Breast Neoplasms	25202123	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Antisense-mediated knockdown (anti-miR) revealed that miR-206/21 coordinately promote RAS-ERK signaling and the corresponding cell phenotypes by inhibiting translation of the  pathway suppressors RASA1 and SPRED1.
target gene	hsa-mir-206	Breast Neoplasms	26879016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly negative correlation between miR-206 and Cx43 expression
target gene	hsa-mir-206	Breast Neoplasms	27100732	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Tbx3 is directly repressed by miR-206
target gene	hsa-mir-208a	Breast Neoplasms	26460550	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our research revealed the mechanisms through which miR-208a functioned in breast cancer and BrCSCs, and identified the miR-208a-SOX2/β-catenin-LIN28-let-7a-DICER1 regulatory feedback loop in regulations of stem cells renewal.
target gene	hsa-mir-20a	Breast Neoplasms	26829385	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells.
target gene	hsa-mir-20a	Breast Neoplasms	17011485	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	TGF-b-2 receptor is expressed in the epithelium of breast cancer and can be regulated by miR-20a, which is down- regulated in breast cancer.
target gene	hsa-mir-20a	Breast Neoplasms	18695042	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.
target gene	hsa-mir-20a	Breast Neoplasms	21765466	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression.
target gene	hsa-mir-20b	Breast Neoplasms	26829385	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells.
target gene	hsa-mir-20b	Breast Neoplasms	20232316	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-20b modulates VEGF expression by targeting HIF-1alpha and STAT3 in MCF-7 breast cancer cells
target gene	hsa-mir-21	Breast Neoplasms	26098771	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.
target gene	hsa-mir-21	Breast Neoplasms	23936642	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data suggest that miR-21 could promote metastasis in breast cancer via the regulation of TIMP3 translation, and there was consistency between miR-21 of serum and miR-21 in tissue.
target gene	hsa-mir-21	Breast Neoplasms	24710931	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 targets Fas ligand-mediated apoptosis in breast cancer cell line MCF-7.
target gene	hsa-mir-21	Breast Neoplasms	25647415	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer.
target gene	hsa-mir-21	Breast Neoplasms	26363493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	An immobilization-free electrochemical impedance biosensor based on duplex-specific nuclease assisted target recycling for amplified detection of microRNA.
target gene	hsa-mir-21	Breast Neoplasms	26549725	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data suggest that miR-21 expression is increased in breast cancer and plays an important role as a tumor gene by targeting STAT3, which may act as a double-response controller in breast cancer.
target gene	hsa-mir-21	Breast Neoplasms	26531758	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, our results demonstrated that plasma miR-21 levels may serve as a diagnostic marker in breast cancers, whereas miR-21 promotes breast cancer cell proliferation and invasion by suppressing smad7, which enhances EGF and TGF-β pathways.
target gene	hsa-mir-21	Breast Neoplasms	20346171	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our data suggests that miR-21 could promote invasion in breast cancer cells via its regulation of TIMP3
target gene	hsa-mir-21	Breast Neoplasms	21761201	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	3,3'-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation.
target gene	hsa-mir-21	Breast Neoplasms	21820606	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN.
target gene	hsa-mir-21	Breast Neoplasms	22435731	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-21 regulates EMT phenotype and HIF-1ж┿expression in third-sphereforming breast cancer stem cell-like cells.
target gene	hsa-mir-21	Breast Neoplasms	22678116	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression.
target gene	hsa-mir-21	Breast Neoplasms	22832383	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Matrine Inhibits Breast Cancer Growth Via miR-21/PTEN/Akt Pathway in MCF-7 Cells.
target gene	hsa-mir-21	Breast Neoplasms	25202123	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Antisense-mediated knockdown (anti-miR) revealed that miR-206/21 coordinately promote RAS-ERK signaling and the corresponding cell phenotypes by inhibiting translation of the  pathway suppressors RASA1 and SPRED1.
target gene	hsa-mir-21	Breast Neoplasms	28935174	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC.
target gene	hsa-mir-210	Breast Neoplasms	25961594	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.
target gene	hsa-mir-214	Breast Neoplasms	25738546	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53.
target gene	hsa-mir-218	Breast Neoplasms	25900794	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
target gene	hsa-mir-22	Breast Neoplasms	23830207	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling.
target gene	hsa-mir-22	Breast Neoplasms	24906624	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis.
target gene	hsa-mir-22	Breast Neoplasms	25304371	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer.
target gene	hsa-mir-22	Breast Neoplasms	19414598	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA.
target gene	hsa-mir-221	Breast Neoplasms	23776679	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.
target gene	hsa-mir-221	Breast Neoplasms	23801152	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221.
target gene	hsa-mir-221	Breast Neoplasms	23939688	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review).
target gene	hsa-mir-221	Breast Neoplasms	24736554	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221/222 control luminal breast cancer tumor progression by regulating different targets.
target gene	hsa-mir-221	Breast Neoplasms	24924200	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.
target gene	hsa-mir-221	Breast Neoplasms	18708351	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
target gene	hsa-mir-221	Breast Neoplasms	21868360	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer.
target gene	hsa-mir-221	Breast Neoplasms	26503209	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a pro-apoptotic Bcl-2 family protein, was up-regulated by the knockdown of miR-221.
target gene	hsa-mir-222	Breast Neoplasms	23776679	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.
target gene	hsa-mir-222	Breast Neoplasms	24736554	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221/222 control luminal breast cancer tumor progression by regulating different targets.
target gene	hsa-mir-222	Breast Neoplasms	24924200	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.
target gene	hsa-mir-222	Breast Neoplasms	18708351	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-222: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
target gene	hsa-mir-222	Breast Neoplasms	21868360	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer.
target gene	hsa-mir-223	Breast Neoplasms	23953883	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Caprin-1 is a novel microRNA-223 target for regulating the proliferation and invasion of human breast cancer cells.
target gene	hsa-mir-224	Breast Neoplasms	22809510	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells.
target gene	hsa-mir-24	Breast Neoplasms	26044523	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA-24-3p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting p27Kip1.
target gene	hsa-mir-24	Breast Neoplasms	23359482	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of HR genes correlated with increased levels of their predicted microRNAs (miRNAs), miR-183 (predicted target RAD50) and miR-24 (predicted target BRCA1), suggesting that PE may regulate miRNAs involved in DNA repair processes.
target gene	hsa-mir-24-1	Breast Neoplasms	21986943	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-24 was found to be implicated in the regulation of the EMT program in response to TGF-beta and was shown to be directly involved in the TGF-ж┿induced breast cancer cell invasiveness through Net1A regulation.
target gene	hsa-mir-24-2	Breast Neoplasms	21463514	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting anti-apoptotic gene BCL-2: a potential for therapeutic intervention.
target gene	hsa-mir-24-2	Breast Neoplasms	21986943	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-24 was found to be implicated in the regulation of the EMT program in response to TGF-beta and was shown to be directly involved in the TGF-ж┿induced breast cancer cell invasiveness through Net1A regulation.
target gene	hsa-mir-24-2	Breast Neoplasms	22328513	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap
target gene	hsa-mir-24-2	Breast Neoplasms	22911661	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells.
target gene	hsa-mir-25	Breast Neoplasms	25026296	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin.
target gene	hsa-mir-25	Breast Neoplasms	22286770	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer.
target gene	hsa-mir-26a	Breast Neoplasms	25755724	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The results of the present study indicate that miR-26a may be associated with human breast carcinogenesis, which inhibits tumor cell proliferation by targeting HMGA1.
target gene	hsa-mir-26a	Breast Neoplasms	26392359	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our work provides evidence for the involvement of specific miRNAs in triple-negative breast cancer development through regulating BRCA1 expression.
target gene	hsa-mir-26a-1	Breast Neoplasms	23750239	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1.
target gene	hsa-mir-26a-2	Breast Neoplasms	23750239	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1.
target gene	hsa-mir-26b	Breast Neoplasms	21510944	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11.
target gene	hsa-mir-26b	Breast Neoplasms	23374284	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer
target gene	hsa-mir-26b	Breast Neoplasms	28944451	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer.
target gene	hsa-mir-27a	Breast Neoplasms	25223182	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Cinnamaldehyde could inhibit invasive capabilities of human breast cancer cell line MDA-MB-435S. The over-expression of miR-27a played an important role in the invasive capability of MDA-MB-435S. The inhibition of cinnamaldehyde on invasive capabilities of MDA-MB-435S cells was correlated with down-regulating the expression of miR-27a.
target gene	hsa-mir-27a	Breast Neoplasms	18006846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells.
target gene	hsa-mir-27a	Breast Neoplasms	19574223	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells.
target gene	hsa-mir-27a	Breast Neoplasms	22407812	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10.BA induced cell cycle arrest in the G2/M phase and increased Myt-1 mRNA (a microRNA-27a target gene), which causes inhibition in G2/M by phosphorylation of cdc2.
target gene	hsa-mir-27a	Breast Neoplasms	22553354	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer.
target gene	hsa-mir-29	Breast Neoplasms	25886595	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The ADAM12-L 3'UTR is a direct target of miR-29 and miR-200 family members. Since the miR-29 and miR-200 families play important roles in breast cancer progression, these results may help explain the different prognostic and chemopredictive values of ADAM12-L and ADAM12-S in breast cancer.
target gene	hsa-mir-296	Breast Neoplasms	24527800	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo.
target gene	hsa-mir-298	Breast Neoplasms	22521303	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.
target gene	hsa-mir-29a	Breast Neoplasms	25955714	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-29a inhibits cell migration and invasion by targeting Roundabout 1 in breast cancer cells.
target gene	hsa-mir-29a	Breast Neoplasms	25961594	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.
target gene	hsa-mir-29a	Breast Neoplasms	22330642	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
target gene	hsa-mir-29a	Breast Neoplasms	22751119	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.
target gene	hsa-mir-29a	Breast Neoplasms	28222663	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1.
target gene	hsa-mir-29b	Breast Neoplasms	25622979	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The distinct modulations of the NF-κB - miR-29b - p53 pathway make S100A7 an oncogene in ER-negative and a cancer-suppressing gene in ER-positive breast cancer cells, with miR-29b being the determining regulatory factor.
target gene	hsa-mir-29b	Breast Neoplasms	28365400	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3.
target gene	hsa-mir-29b	Breast Neoplasms	29256222	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiRNA-29b can inhibit the proliferation, invasion and metastasis of  breast cancer cells by inhibiting the expression of RTKN
target gene	hsa-mir-29b-1	Breast Neoplasms	22330642	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
target gene	hsa-mir-29b-1	Breast Neoplasms	22751119	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.
target gene	hsa-mir-29b-1	Breast Neoplasms	22864815	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
target gene	hsa-mir-29b-2	Breast Neoplasms	22330642	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
target gene	hsa-mir-29b-2	Breast Neoplasms	22751119	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.
target gene	hsa-mir-29b-2	Breast Neoplasms	22864815	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Three mRNAs (C1QTNF6, SPARC, and COL4A2) that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
target gene	hsa-mir-29c	Breast Neoplasms	24577056	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified miRNAs efficiently downregulating B7-H3 expression.The expression of miR-29c correlated with survival in breast cancer patients,suggesting a tumour suppressive role for this miRNA.
target gene	hsa-mir-29c	Breast Neoplasms	22330642	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
target gene	hsa-mir-29c	Breast Neoplasms	22751119	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.
target gene	hsa-mir-29c	Breast Neoplasms	27994679	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Brown Seaweed Fucoidan Inhibits Cancer Progression by Dual Regulation of mir-29c/ADAM12 and miR-17-5p/PTEN Axes in Human Breast Cancer Cells.
target gene	hsa-mir-301a	Breast Neoplasms	24315818	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling.
target gene	hsa-mir-302a	Breast Neoplasms	26842910	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer.
target gene	hsa-mir-302b	Breast Neoplasms	26842910	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer.
target gene	hsa-mir-302c	Breast Neoplasms	26842910	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer.
target gene	hsa-mir-302d	Breast Neoplasms	26842910	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target for reversing P-gp-mediated chemoresistance in breast cancer.
target gene	hsa-mir-30a	Breast Neoplasms	24508260	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2.
target gene	hsa-mir-30a	Breast Neoplasms	22157765	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy.
target gene	hsa-mir-30a	Breast Neoplasms	22476851	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.
target gene	hsa-mir-30a	Breast Neoplasms	23445407	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells
target gene	hsa-mir-30a	Breast Neoplasms	23851509	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. breast tumorigenesis
target gene	hsa-mir-30a	Breast Neoplasms	26918943	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we linked miR-30a to increased expression of claudins
target gene	hsa-mir-30c	Breast Neoplasms	24519092	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells.
target gene	hsa-mir-30c-1	Breast Neoplasms	22701724	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-30c overexpression inhibited proliferation of breast cancer cells.miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein.
target gene	hsa-mir-30c-1	Breast Neoplasms	23224145	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.
target gene	hsa-mir-30c-1	Breast Neoplasms	23340433	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
target gene	hsa-mir-30c-2	Breast Neoplasms	22701724	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-30c overexpression inhibited proliferation of breast cancer cells.miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein.
target gene	hsa-mir-30c-2	Breast Neoplasms	23224145	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.
target gene	hsa-mir-30c-2	Breast Neoplasms	23340433	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
target gene	hsa-mir-31	Breast Neoplasms	25889182	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These data provide strong evidence that GNA13 expression in breast cancer cells is regulated by post-transcriptional mechanisms involving miR-31.Additionally our data shows that miR-31 regulates breast cancer cell invasion partially via targeting GNA13 expression in breast cancer cells. Loss of miR-31 expression and increased GNA13 expression could be used as biomarkers of breast cancer progression.
target gene	hsa-mir-31	Breast Neoplasms	19574223	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells
target gene	hsa-mir-31	Breast Neoplasms	23364795	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon
target gene	hsa-mir-32	Breast Neoplasms	29661250	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	oncogenic miR-32 and miR-92b were identified to suppress IDH1 expression, leading to the inhibition of cell migration and invasion
target gene	hsa-mir-320a	Breast Neoplasms	25736597	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
target gene	hsa-mir-320a	Breast Neoplasms	22179046	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
target gene	hsa-mir-320b-1	Breast Neoplasms	22179046	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
target gene	hsa-mir-320b-2	Breast Neoplasms	22179046	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
target gene	hsa-mir-320c-1	Breast Neoplasms	22179046	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
target gene	hsa-mir-320c-2	Breast Neoplasms	22179046	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
target gene	hsa-mir-320d-1	Breast Neoplasms	22179046	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
target gene	hsa-mir-320d-2	Breast Neoplasms	22179046	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
target gene	hsa-mir-320e	Breast Neoplasms	22179046	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.
target gene	hsa-mir-328	Breast Neoplasms	21219875	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
target gene	hsa-mir-328	Breast Neoplasms	19270061	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells.
target gene	hsa-mir-335	Breast Neoplasms	25323813	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA-335 inhibits proliferation, cell-cycle progression, colony formation, and invasion via targeting PAX6 in breast cancer cells.
target gene	hsa-mir-335	Breast Neoplasms	25492484	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-335 suppresses breast cancer cell migration by negatively regulating the HGF/c-Met pathway.
target gene	hsa-mir-335	Breast Neoplasms	21618216	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Breast miR-335 regulates the known BRCA1 activators ERж┿ IGF1R, SP1 and the repressor ID4, including a feedback regulation of miR-335 expression by estrogens. Overexpression of miR-335 resulted in an upregulation of BRCA1 mRNA expression.miR-335 affects different targets in the upstream BRCA1-regulatory cascade with impact on key cellular functions such as proliferation and apoptosis.
target gene	hsa-mir-338	Breast Neoplasms	26252944	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-338-3p functions as tumor suppressor in breast cancer by targeting SOX4.
target gene	hsa-mir-33b	Breast Neoplasms	25919570	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1.
target gene	hsa-mir-340	Breast Neoplasms	21225860	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met
target gene	hsa-mir-340	Breast Neoplasms	21692045	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-340 inhibites breast cancer cell migration and invasion through targeting of oncoprotein c-Met.
target gene	hsa-mir-342	Breast Neoplasms	24475217	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
target gene	hsa-mir-342	Breast Neoplasms	24921394	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	TNBC with high expression of miR-342-3p are more sensitive to chemotherapy. miRNA-342-3p may regulate the sensitivity of breast cancer cell line MDA-MB-231 to chemotherapy drugs paclitaxel and cisplatin, but can not affect the chemotherapy sensitivity of doxorubicin.
target gene	hsa-mir-34a	Breast Neoplasms	24050776	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these results suggest that miR-34a inhibits breast cancer proliferation by targeting LMTK3 and might be used as an anti-ERα agent in breast cancer therapy.
target gene	hsa-mir-34a	Breast Neoplasms	25623761	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-34a negatively regulates the expression of Notch1 at both mRNA and protein levels. Overexpression of miR-34a may sensitize MCF-7/ADR cells to adriamycin.
target gene	hsa-mir-34a	Breast Neoplasms	25783790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway.
target gene	hsa-mir-34a	Breast Neoplasms	25826085	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness.
target gene	hsa-mir-34a	Breast Neoplasms	21814748	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
target gene	hsa-mir-34a	Breast Neoplasms	23085450	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1
target gene	hsa-mir-34a	Breast Neoplasms	23001043	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer.
target gene	hsa-mir-34a	Breast Neoplasms	26902416	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LDHA was a direct target of miR-34a
target gene	hsa-mir-34a	Breast Neoplasms	29689563	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-34a Inhibition of the TLR Signaling Pathway Via CXCL10 Suppresses Breast Cancer Cell Invasion and Migration
target gene	hsa-mir-34b	Breast Neoplasms	22113133	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In this study, we identified one such estrogen down-regulated microRNA, miR-34b, as an onco-suppressor that targets cyclin D1 and JAG-1 (jagged 1) in a ER-positive/wild-type p53 breast cancer cell line (MCF-7) as well as in ovarian and endometrial cells,
target gene	hsa-mir-34b	Breast Neoplasms	27155849	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Only 8 APOBEC3B targeting miRNAs were observed to regulate the fusion transcript of which miR-34b-3p and miR-138-5p were found to be frequently  downregulated in cancers suggesting miRNA-mediated deregulation of APOBEC3A expression in cancer patients harbouring this particular deletion polymorphism.
target gene	hsa-mir-34c	Breast Neoplasms	23001043	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results demonstrate that miR-34a/c functions as a metastasis suppressor to regulate breast cancer migration and invasion through targeting Fra-1 oncogene and suggest a therapeutic application of miR-34 in breast cancer.
target gene	hsa-mir-365b	Breast Neoplasms	22328513	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-195, miR-24-2 and miR-365-2 act as negative regulators of BCL2 through direct binding to their respective binding sites in the 3' UTR of human BCL2 gene.over expression of these miRNAs not only caused an increase in apoptosis but also augmented the ap
target gene	hsa-mir-372	Breast Neoplasms	29456685	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-372 functions as an oncogenic miRNA in breast cancer by targeting LATS2
target gene	hsa-mir-373	Breast Neoplasms	22158050	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways.
target gene	hsa-mir-375	Breast Neoplasms	24746361	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.
target gene	hsa-mir-378a	Breast Neoplasms	26255816	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
target gene	hsa-mir-379	Breast Neoplasms	23874748	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-379 regulates cyclin B1 expression and is decreased in breast cancer.
target gene	hsa-mir-429	Breast Neoplasms	26011542	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
target gene	hsa-mir-429	Breast Neoplasms	18376396	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
target gene	hsa-mir-448	Breast Neoplasms	29368542	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-448 inhibits cell migration, invasion, and EMT by targeting to the 3'UTR of ZEB1/2
target gene	hsa-mir-449a	Breast Neoplasms	29518546	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LINC0092 was co-expressed with SFRP1 and RGMA and regulated by hsa-miR-449a and hsa-miR-452-5p
target gene	hsa-mir-449a	Breast Neoplasms	29653747	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer
target gene	hsa-mir-450b	Breast Neoplasms	25046105	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.
target gene	hsa-mir-451	Breast Neoplasms	26516138	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression, followed by affecting the protein expression of caspase 3,and accelerate the apoptosis in breast cancer, indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line.
target gene	hsa-mir-451a	Breast Neoplasms	26896688	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy.
target gene	hsa-mir-452	Breast Neoplasms	29518546	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	LINC0092 was co-expressed with SFRP1 and RGMA and regulated by hsa-miR-449a and hsa-miR-452-5p
target gene	hsa-mir-486	Breast Neoplasms	25104088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells.
target gene	hsa-mir-489	Breast Neoplasms	24786471	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.
target gene	hsa-mir-489	Breast Neoplasms	26828271	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	GSE1 negative regulation by miR-489-5p promotes breast cancer cell proliferation  and invasion.
target gene	hsa-mir-491	Breast Neoplasms	25725194	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ERα-positive breast cancer.
target gene	hsa-mir-492	Breast Neoplasms	25407488	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-492 represents a potential onco-miR and participates in breast cancer carcinogenesis by suppressing SOX7 expression.
target gene	hsa-mir-494	Breast Neoplasms	25955111	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway.
target gene	hsa-mir-495	Breast Neoplasms	26020378	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulated miR-495 [Corrected] Inhibits the G1-S Phase Transition by Targeting Bmi-1 in Breast Cancer.
target gene	hsa-mir-502	Breast Neoplasms	24677135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Suppressive role of miR-502-5p in breast cancer via downregulation of TRAF2.
target gene	hsa-mir-513a-1	Breast Neoplasms	22330642	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
target gene	hsa-mir-513a-2	Breast Neoplasms	22330642	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progestin treatment decreases miR-29, thereby relieving repression of one of its direct targets, the gene encoding ATPase, Na(+)/K(+) transporting, beta 1 polypeptide (ATP1B1). ATP1B1 serves to limit migration and invasion in breast cancer cells. Lastly,
target gene	hsa-mir-519c	Breast Neoplasms	21219875	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
target gene	hsa-mir-520a	Breast Neoplasms	22158050	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways.
target gene	hsa-mir-520b	Breast Neoplasms	21343296	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-520b regulates migration of breast cancer cells through targeting hepatitis B X-interacting protein and interleukin-8.
target gene	hsa-mir-520b	Breast Neoplasms	22158050	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways.
target gene	hsa-mir-520c	Breast Neoplasms	22158050	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways.
target gene	hsa-mir-520d	Breast Neoplasms	22158050	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways.
target gene	hsa-mir-520h	Breast Neoplasms	21219875	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328; -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
target gene	hsa-mir-568	Breast Neoplasms	25311085	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study unravels a detailed role of NFAT5 in mediating metastatic signaling, and provides broad insights into the involvement of Hotair, in particular, by transcriptionally regulating the expression of microRNA(s), in the metastasis of breast cancers.
target gene	hsa-mir-575	Breast Neoplasms	25961594	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.
target gene	hsa-mir-625	Breast Neoplasms	26806308	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-625 suppresses cell proliferation and migration by targeting HMGA1 in breast cancer.
target gene	hsa-mir-630	Breast Neoplasms	24655723	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, our findings suggest miR-630 as a key regulator of cancer cell progression in HER2 over-expressing breast cancer, through targeting of IGF1R. This study supports miR-630 as a diagnostic and a predictive biomarker for response to HER-targeted drugs and indicates that the therapeutic addition of miR-630 may enhance and improve patients' response to HER-targeting drugs.
target gene	hsa-mir-632	Breast Neoplasms	22710984	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Micro-RNA-632 downregulates DNAJB6 in breast cancer.
target gene	hsa-mir-661	Breast Neoplasms	20543867	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-661:miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers
target gene	hsa-mir-675	Breast Neoplasms	26353930	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
target gene	hsa-mir-7	Breast Neoplasms	24931170	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression.
target gene	hsa-mir-7	Breast Neoplasms	28546132	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
target gene	hsa-mir-7	Breast Neoplasms	29614984	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data uncovered a crucial role of TINCR-miR-7-KLF4 axis in human breast cancer
target gene	hsa-mir-7-1	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1
target gene	hsa-mir-7-1	Breast Neoplasms	22876288	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression.
target gene	hsa-mir-7-1	Breast Neoplasms	23384942	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4
target gene	hsa-mir-7-1	Breast Neoplasms	23720754	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8.
target gene	hsa-mir-7-2	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1
target gene	hsa-mir-7-2	Breast Neoplasms	22876288	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression.
target gene	hsa-mir-7-2	Breast Neoplasms	23384942	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4
target gene	hsa-mir-7-2	Breast Neoplasms	23720754	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8.
target gene	hsa-mir-720	Breast Neoplasms	24085799	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1.
target gene	hsa-mir-7-3	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7:miR-345 and miR-7 target the human multidrug resistance-associated protein 1
target gene	hsa-mir-7-3	Breast Neoplasms	22876288	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression.
target gene	hsa-mir-7-3	Breast Neoplasms	23384942	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4
target gene	hsa-mir-7-3	Breast Neoplasms	23720754	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-7 Suppresses the Invasive Potential of Breast Cancer Cells and Sensitizes Cells to DNA Damages by Targeting Histone Methyltransferase SET8.
target gene	hsa-mir-762	Breast Neoplasms	26597380	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results demonstrate that miR-762 tumour effect was achieved by targeting IRF7 in human breast cancer specimens.
target gene	hsa-mir-874	Breast Neoplasms	25281924	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-874 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting CDK9.
target gene	hsa-mir-874	Breast Neoplasms	25961594	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.
target gene	hsa-mir-888	Breast Neoplasms	24845571	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-888 regulates side population properties and cancer metastasis in breast cancer cells.
target gene	hsa-mir-9	Breast Neoplasms	28546132	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
target gene	hsa-mir-9	Breast Neoplasms	20173740	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Here we show that miR-9, which is upregulated in breast cancer cells, directly targets CDH1, the E-cadherin-encoding messenger RNA, leading to increased cell motility and invasiveness. 
target gene	hsa-mir-9	Breast Neoplasms	28397066	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1.
target gene	hsa-mir-9-1	Breast Neoplasms	22761433	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells.
target gene	hsa-mir-9-1	Breast Neoplasms	23530058	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition
target gene	hsa-mir-92	Breast Neoplasms	26437339	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-92 is gradually lost in breast epithelial cells during cancer progression correlating with a shift in ERβ1 immunoreactivity from nuclei to the cytoplasm. Our data support a functional role in fibroblasts where modification of miR-92 expression can influence the invasive capacity of breast cancer epithelial cells. However in silico analysis suggests that ERβ1 may not be the most important miR-92 target in breast cancer.
target gene	hsa-mir-9-2	Breast Neoplasms	22761433	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells.
target gene	hsa-mir-9-2	Breast Neoplasms	23530058	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition
target gene	hsa-mir-92a-1	Breast Neoplasms	20484043	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-92:Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer
target gene	hsa-mir-92a-2	Breast Neoplasms	20484043	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-92:Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer
target gene	hsa-mir-92b	Breast Neoplasms	29661250	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	oncogenic miR-32 and miR-92b were identified to suppress IDH1 expression, leading to the inhibition of cell migration and invasion
target gene	hsa-mir-93	Breast Neoplasms	22685420	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells.
target gene	hsa-mir-93	Breast Neoplasms	21765466	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression.
target gene	hsa-mir-93	Breast Neoplasms	23492819	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis.
target gene	hsa-mir-9-3	Breast Neoplasms	22761433	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells.
target gene	hsa-mir-9-3	Breast Neoplasms	23530058	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9-3p targets integrin beta 1 to sensitize claudin-low breast cancer cells to MEK inhibition
target gene	hsa-mir-940	Breast Neoplasms	25673565	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A statistically inferred microRNA network identifies breast cancer target miR-940 as an actin cytoskeleton regulator.
target gene	hsa-mir-96	Breast Neoplasms	24366472	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer.
target gene	hsa-mir-96	Breast Neoplasms	19574223	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Coordinate Regulate FOXO1; highly expressed; a novel mechanism of FOXO1 regulation, and targeting of FOXO1 by microRNAs may contribute to transformation or maintenance of an oncogenic state in breast cancer cells
target gene	hsa-mir-96	Breast Neoplasms	21203424	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Unregulated miR-96 Induces Cell Proliferation in Human Breast Cancer by Downregulating Transcriptional Factor FOXO3a.
target gene	hsa-mir-96	Breast Neoplasms	28546132	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
target gene	hsa-mir-99a	Breast Neoplasms	25348507	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells. mir-23b,mir-27b,mir-24
target gene	hsa-mir-144	Bronchiolitis Obliterans Syndrome	25979625	respiratory system disease	DOID:2799	J42	D001989		HP:0011946	miR-144 is a critical regulator of the TGF-β signaling cascade and is over-expressed in lungs with BOS. Therefore, miR-144 is a potential target toward preventing fibrosis leading to BOS after lung transplant.
target gene	hsa-mir-206	Bronchopulmonary Dysplasia	24040336			P27.1	D001997			The expression of miR-206 and its target gene, fn 1, may contribute to the progression of BPD.
target gene	hsa-mir-205	Carcinoma, Adrenocortical	26397843	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	In conclusion, miR-205 suppresses the growth of ACC SW-13 cells via targeting the anti-apoptotic gene Bcl-2.
target gene	hsa-mir-21	Carcinoma, Basal Cell	27159391	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	Moreover, our results identify a miR21/GRHL3/D3  axis that reduces TH in the tumor microenvironment and has potential to be targeted as a therapeutic approach to BCC.
target gene	hsa-let-7	Carcinoma, Bladder	27620744	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
target gene	hsa-mir-1	Carcinoma, Bladder	28268231	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MiR-1-3p Suppresses the Proliferation, Invasion and Migration of Bladder Cancer Cells by Up-Regulating SFRP1 Expression.
target gene	hsa-mir-1	Carcinoma, Bladder	28618950	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MiR-1-3p inhibits the proliferation and invasion of bladder cancer cells by suppressing CCL2 expression.
target gene	hsa-mir-101	Carcinoma, Bladder	24490857	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MJ sensitizes bladder cancer cells to GA-induced apoptosis by down-regulating the expression of EZH2 induced by miR-101. Thus, the combination of selective anti-cancer agents MJ and GA could provide a novel strategy for treating human bladder cancer.
target gene	hsa-mir-130b	Carcinoma, Bladder	28042869	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin β1 Signaling Pathways in Bladder Carcinoma.
target gene	hsa-mir-135a	Carcinoma, Bladder	25888950	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Our study demonstrates that miR-135a promotes cell proliferation in bladder cancer by targeting PHLPP2 and FOXO1, and is performed as an onco-miR.
target gene	hsa-mir-138	Carcinoma, Bladder	27978829	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	miR-138-5p contributes to cell proliferation and invasion by targeting Survivin in bladder cancer cells.
target gene	hsa-mir-139	Carcinoma, Bladder	28720065	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene.
target gene	hsa-mir-199	Carcinoma, Bladder	28324890	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer.
target gene	hsa-mir-199a	Carcinoma, Bladder	27814720	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	miR-199a-5p suppresses human bladder cancer cell metastasis by targeting CCR7.
target gene	hsa-mir-218	Carcinoma, Bladder	28222430	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1.
target gene	hsa-mir-24	Carcinoma, Bladder	28000900	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	miR-24-3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD.
target gene	hsa-mir-294	Carcinoma, Bladder	28371605	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	MicroRNA-294 Promotes Cellular Proliferation and Motility through the PI3K/AKT and JAK/STAT Pathways by Upregulation of NRAS in Bladder Cancer.
target gene	hsa-mir-29c	Carcinoma, Bladder	24870742	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Human bladder cancer cells infected by microRNA- 29c adenovirus can transport microRNA-29c via exosomes. Moreover, exosome-derived microRNA29c induces apoptosis in bladder cancer cells by down-regulating BCL-2 and MCL-1.
target gene	hsa-mir-451	Carcinoma, Bladder	27571748	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	miR-451 suppresses bladder cancer cell migration and invasion via directly targeting c-Myc.
target gene	hsa-mir-495	Carcinoma, Bladder	28069380	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	microRNA-495 promotes bladder cancer cell growth and invasion by targeting phosphatase and tensin homolog.
target gene	hsa-mir-124	Carcinoma, Breast	27748910			D05	D001943	114480	HP:0003002	MicroRNA-124 inhibits cell proliferation and migration by regulating SNAI2 in breast cancer.
target gene	hsa-mir-124	Carcinoma, Breast	27815936			D05	D001943	114480	HP:0003002	MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3.
target gene	hsa-mir-125a	Carcinoma, Breast	27693788			D05	D001943	114480	HP:0003002	Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
target gene	hsa-mir-125a	Carcinoma, Breast	28188287			D05	D001943	114480	HP:0003002	A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
target gene	hsa-mir-129	Carcinoma, Breast	27831649			D05	D001943	114480	HP:0003002	MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance.
target gene	hsa-mir-130b	Carcinoma, Breast	28163094			D05	D001943	114480	HP:0003002	miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma.
target gene	hsa-mir-139	Carcinoma, Breast	27916718			D05	D001943	114480	HP:0003002	Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway.
target gene	hsa-mir-141	Carcinoma, Breast	27596953			D05	D001943	114480	HP:0003002	p16INK4A induces senescence and inhibits EMT through microRNA-141/microRNA-146b-5p-dependent repression of AUF1.
target gene	hsa-mir-142	Carcinoma, Breast	26657485			D05	D001943	114480	HP:0003002	microRNA miR-142-3p Inhibits Breast Cancer Cell Invasiveness by Synchronous Targeting of WASL, Integrin Alpha V, and Additional Cytoskeletal Elements. HrC-9698
target gene	hsa-mir-145	Carcinoma, Breast	28349828			D05	D001943	114480	HP:0003002	Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells.
target gene	hsa-mir-145	Carcinoma, Breast	28393176			D05	D001943	114480	HP:0003002	miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression.
target gene	hsa-mir-146b	Carcinoma, Breast	27596953			D05	D001943	114480	HP:0003002	p16INK4A induces senescence and inhibits EMT through microRNA-141/microRNA-146b-5p-dependent repression of AUF1.
target gene	hsa-mir-148a	Carcinoma, Breast	28063929			D05	D001943	114480	HP:0003002	MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
target gene	hsa-mir-151	Carcinoma, Breast	27930738			D05	D001943	114480	HP:0003002	miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells.
target gene	hsa-mir-152	Carcinoma, Breast	28063929			D05	D001943	114480	HP:0003002	MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
target gene	hsa-mir-15a	Carcinoma, Breast	27596816			D05	D001943	114480	HP:0003002	miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1.
target gene	hsa-mir-16	Carcinoma, Breast	27596816			D05	D001943	114480	HP:0003002	miR-15a/miR-16 induces mitochondrial dependent apoptosis in breast cancer cells by suppressing oncogene BMI1.
target gene	hsa-mir-17	Carcinoma, Breast	27831559			D05	D001943	114480	HP:0003002	Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.
target gene	hsa-mir-181	Carcinoma, Breast	28224609			D05	D001943	114480	HP:0003002	miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.
target gene	hsa-mir-181a	Carcinoma, Breast	28288641			D05	D001943	114480	HP:0003002	SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis.
target gene	hsa-mir-185	Carcinoma, Breast	27651238			D05	D001943	114480	HP:0003002	RKIP suppresses the proliferation and metastasis of breast cancer cell lines through up-regulation of miR-185 targeting HMGA2.
target gene	hsa-mir-199a	Carcinoma, Breast	28126676			D05	D001943	114480	HP:0003002	MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
target gene	hsa-mir-200a	Carcinoma, Breast	28440475			D05	D001943	114480	HP:0003002	A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases.
target gene	hsa-mir-200b	Carcinoma, Breast	28972876			D05	D001943	114480	HP:0003002	miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
target gene	hsa-mir-203	Carcinoma, Breast	28349828			D05	D001943	114480	HP:0003002	Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells.
target gene	hsa-mir-204	Carcinoma, Breast	28675122			D05	D001943	114480	HP:0003002	MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer.
target gene	hsa-mir-206	Carcinoma, Breast	28391353			D05	D001943	114480	HP:0003002	WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
target gene	hsa-mir-20b	Carcinoma, Breast	27831559			D05	D001943	114480	HP:0003002	Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.
target gene	hsa-mir-214	Carcinoma, Breast	27693451			D05	D001943	114480	HP:0003002	Crosstalk between the vitamin D receptor (VDR) and miR-214 in regulating SuFu, a hedgehog pathway inhibitor in breast cancer cells.
target gene	hsa-mir-216b	Carcinoma, Breast	27720715			D05	D001943	114480	HP:0003002	miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP.
target gene	hsa-mir-217	Carcinoma, Breast	27916422			D05	D001943	114480	HP:0003002	PGC-1 alpha interacts with microRNA-217 to functionally regulate breast cancer cell proliferation.
target gene	hsa-mir-221	Carcinoma, Breast	24286315			D05	D001943	114480	HP:0003002	MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN.
target gene	hsa-mir-25	Carcinoma, Breast	28188287			D05	D001943	114480	HP:0003002	A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
target gene	hsa-mir-26a	Carcinoma, Breast	28637868			D05	D001943	114480	HP:0003002	Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
target gene	hsa-mir-26b	Carcinoma, Breast	28637868			D05	D001943	114480	HP:0003002	Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
target gene	hsa-mir-27a	Carcinoma, Breast	28099945			D05	D001943	114480	HP:0003002	In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
target gene	hsa-mir-27b	Carcinoma, Breast	27809310			D05	D001943	114480	HP:0003002	Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
target gene	hsa-mir-29a	Carcinoma, Breast	26802653			D05	D001943	114480	HP:0003002	inhibitors of microRNA-29a promote apoptosis through upregulation of HSP60 level and downregulation of HSP27, HSP40, HSP70, and HSP90  levels
target gene	hsa-mir-30e	Carcinoma, Breast	28288641			D05	D001943	114480	HP:0003002	SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis.
target gene	hsa-mir-330	Carcinoma, Breast	28419078			D05	D001943	114480	HP:0003002	Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis.
target gene	hsa-mir-346	Carcinoma, Breast	27913185			D05	D001943	114480	HP:0003002	MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel.
target gene	hsa-mir-34a	Carcinoma, Breast	27813227			D05	D001943	114480	HP:0003002	MiR-34a modulates ErbB2 in breast cancer.
target gene	hsa-mir-375	Carcinoma, Breast	28075453			D05	D001943	114480	HP:0003002	miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.
target gene	hsa-mir-381	Carcinoma, Breast	28012397			D05	D001943	114480	HP:0003002	miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
target gene	hsa-mir-3908	Carcinoma, Breast	28327197			D05	D001943	114480	HP:0003002	Lipid raft-mediated miR-3908 inhibition of migration of breast cancer cell line MCF-7 by regulating the interactions between AdipoR1 and Flotillin-1.
target gene	hsa-mir-409	Carcinoma, Breast	28459205			D05	D001943	114480	HP:0003002	MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1.
target gene	hsa-mir-411	Carcinoma, Breast	27572271			D05	D001943	114480	HP:0003002	miRNA-411 acts as a potential tumor suppressor miRNA via the downregulation of specificity protein 1 in breast cancer.
target gene	hsa-mir-421	Carcinoma, Breast	27583980			D05	D001943	114480	HP:0003002	MicroRNA-421 inhibits breast cancer metastasis by targeting metastasis associated 1.
target gene	hsa-mir-4262	Carcinoma, Breast	27629257			D05	D001943	114480	HP:0003002	miR-4262 Promotes Proliferation and Invasion of Human Breast Cancer Cells Through Directly Targeting KLF6 and KLF15.
target gene	hsa-mir-503	Carcinoma, Breast	26047605			D05	D001943	114480	HP:0003002	MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression.
target gene	hsa-mir-519a	Carcinoma, Breast	24752803			D05	D001943	114480	HP:0003002	MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
target gene	hsa-mir-520c	Carcinoma, Breast	28112380			D05	D001943	114480	HP:0003002	miR520c blocks EMT progression of human breast cancer cells by repressing STAT3.
target gene	hsa-mir-542	Carcinoma, Breast	24403060			D05	D001943	114480	HP:0003002	MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2.
target gene	hsa-mir-542	Carcinoma, Breast	28121348			D05	D001943	114480	HP:0003002	miR-542-3p targets sphingosine-1-phosphate receptor 1 and regulates cell proliferation and invasion of breast cancer cells.
target gene	hsa-mir-590	Carcinoma, Breast	28121351			D05	D001943	114480	HP:0003002	MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2.
target gene	hsa-mir-590	Carcinoma, Breast	28443471			D05	D001943	114480	HP:0003002	Suppressing the molecular signaling pathways involved in inflammation and cancer in breast cancer cell lines MDA-MB-231 and MCF-7 by miR-590.
target gene	hsa-mir-597	Carcinoma, Breast	28393251			D05	D001943	114480	HP:0003002	miR-597 inhibits breast cancer cell proliferation, migration and invasion through FOSL2.
target gene	hsa-mir-9	Carcinoma, Breast	27520371			D05	D001943	114480	HP:0003002	CYP4Z1 3'UTR was the potential target of miR-9. CYP4Z1 3'UTR could inhibit the migration and EMT of breast cancer cells via acting as a ceRNA for E-cadherin.
target gene	hsa-mir-939	Carcinoma, Breast	27693459			D05	D001943	114480	HP:0003002	Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.
target gene	hsa-mir-99a	Carcinoma, Breast	24637915			D05	D001943	114480	HP:0003002	MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.
target gene	hsa-mir-101	Carcinoma, Breast, Triple Negative	26036638				D064726			MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
target gene	hsa-mir-107	Carcinoma, Breast, Triple Negative	25851994				D064726			MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer.
target gene	hsa-mir-135b	Carcinoma, Breast, Triple Negative	26711213				D064726			The expressions of miRNA-135b were higher in most triple-negative breast cancer cell lines than others. miRNA-135b could promote the proliferation,invasion and migration in triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-468, and APC was one of the target genes of miRNA- 135b by participating in the process of regulation.
target gene	hsa-mir-200a	Carcinoma, Breast, Triple Negative	29217458				D064726			The identified IMP2/3-miR-200a-PR axis represents a novel double-negative feedback loop and serves as a new potential therapeutic target for the treatment of TNBC
target gene	hsa-mir-200b	Carcinoma, Breast, Triple Negative	24925028				D064726			MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
target gene	hsa-mir-200b	Carcinoma, Breast, Triple Negative	26062653				D064726			Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
target gene	hsa-mir-206	Carcinoma, Breast, Triple Negative	25074552				D064726			miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer.
target gene	hsa-mir-206	Carcinoma, Breast, Triple Negative	26053033				D064726			Consistent with  increased levels of miR-206 in MaCSCs, the expression of both PDCD4 and CX43 was  suppressed in these cells relative to control cells.
target gene	hsa-mir-211	Carcinoma, Breast, Triple Negative	28571042				D064726			MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
target gene	hsa-mir-217	Carcinoma, Breast, Triple Negative	28437471				D064726			miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.
target gene	hsa-mir-223	Carcinoma, Breast, Triple Negative	27618431				D064726			MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1.
target gene	hsa-mir-30a	Carcinoma, Breast, Triple Negative	29666469				D064726			A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness
target gene	hsa-mir-31	Carcinoma, Breast, Triple Negative	27593563				D064726			MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer.
target gene	hsa-mir-603	Carcinoma, Breast, Triple Negative	28036267				D064726			MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
target gene	hsa-mir-7	Carcinoma, Breast, Triple Negative	26513016				D064726			Our results not only revealed IL-6 as a key regulator of lapatinib-induced metastasis, but also explored the requirement of miR7/Raf-1/MAPK/AP-1 axis in lapatinib-induced IL-6 expression.
target gene	hsa-mir-720	Carcinoma, Breast, Triple Negative	27039296				D064726			miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
target gene	hsa-mir-761	Carcinoma, Breast, Triple Negative	28054302				D064726			microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
target gene	hsa-mir-9	Carcinoma, Breast, Triple Negative	25963903				D064726			Overexpression of Notch signaling via Notch1 intracellular domain in MDA-MB-231 cell line was suppressed by lentiviruses expressing miR-9.
target gene	hsa-let-7	Carcinoma, Cervical	26051842	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Overall, our study suggests that the microRNAs, miR-21 and let-7a function as clinically relevant integral components of STAT3 signaling and are responsible for maintaining activated state of STAT3 in HPV-infected cells during cervical carcinogenesis.
target gene	hsa-mir-101	Carcinoma, Cervical	24289600	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells.
target gene	hsa-mir-107	Carcinoma, Cervical	25386925	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1.
target gene	hsa-mir-124	Carcinoma, Cervical	25218344	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells.
target gene	hsa-mir-124	Carcinoma, Cervical	27571703	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-124 inhibits proliferation, invasion, migration and epithelial-mesenchymal transition of cervical carcinoma cells by targeting astrocyte-elevated gene-1.
target gene	hsa-mir-129	Carcinoma, Cervical	24358111	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells.
target gene	hsa-mir-130a	Carcinoma, Cervical	24787017	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Prognostic significance of low DICER expression regulated by miR-130a in cervical cancer.
target gene	hsa-mir-130a	Carcinoma, Cervical	24885472	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	NF-κB-modulated miR-130a targets TNF-α in cervical cancer cells.
target gene	hsa-mir-133a	Carcinoma, Cervical	26134491	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-133a inhibits cervical cancer growth by targeting EGFR.
target gene	hsa-mir-135a	Carcinoma, Cervical	24503442	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-135a leads to cervical cancer cell transformation through regulation of β-catenin via a SIAH1-dependent ubiquitin proteosomal pathway.
target gene	hsa-mir-138	Carcinoma, Cervical	28385388	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-138 is a potential biomarker and tumor suppressor in human cervical carcinoma by reversely correlated with TCF3 gene.
target gene	hsa-mir-142	Carcinoma, Cervical	25976503	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7.
target gene	hsa-mir-143	Carcinoma, Cervical	27998464	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-143 inhibits cell proliferation through targeted regulating the expression of K-ras gene in HeLa cells.
target gene	hsa-mir-145	Carcinoma, Cervical	27933466	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells.
target gene	hsa-mir-150	Carcinoma, Cervical	26715362	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Taken together, our data demonstrated that elevated miR-150 targets FOXO4 expression and therefore regulates multiple genes expression, resulting in cervical cancer cell growth and survival.
target gene	hsa-mir-155	Carcinoma, Cervical	25155037	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Mir-155 promotes cervical cancer cell proliferation through suppression of its target gene LKB1.
target gene	hsa-mir-181b	Carcinoma, Cervical	24269684	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells.
target gene	hsa-mir-182	Carcinoma, Cervical	26191165	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-182 induces cervical cancer cell apoptosis through inhibiting the expression  of DNMT3a.
target gene	hsa-mir-187	Carcinoma, Cervical	28128400	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-187 induces apoptosis of SiHa cervical carcinoma cells by downregulating Bcl-2.
target gene	hsa-mir-196b	Carcinoma, Cervical	23861821	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer.
target gene	hsa-mir-203	Carcinoma, Cervical	25069511	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	the genes BIRC5, HOXA1 and RARB are critical targets that play an important regulatory role in cervical cancer pathogenesis.
target gene	hsa-mir-203	Carcinoma, Cervical	27466497	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Although preliminary, the expression levels of 螖Np63 mRNA and miR-203 seem to be promising for cervical cancer screening.
target gene	hsa-mir-205	Carcinoma, Cervical	28651495	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiR-205 serves as a prognostic factor and suppresses proliferation and invasion by targeting insulin-like growth factor receptor 1 in human cervical cancer.
target gene	hsa-mir-21	Carcinoma, Cervical	25769949	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-21 modulates resistance of HR-HPV positive cervical cancer cells to radiation through targeting LATS1.
target gene	hsa-mir-21	Carcinoma, Cervical	28495512	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
target gene	hsa-mir-211	Carcinoma, Cervical	27923652	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiR-211 inhibits invasion and epithelial-to-mesenchymal transition (EMT) of cervical cancer cells via targeting MUC4.
target gene	hsa-mir-212	Carcinoma, Cervical	28165569	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Effect of miR-212 targeting TCF7L2 on the proliferation and metastasis of cervical cancer.
target gene	hsa-mir-214	Carcinoma, Cervical	28137590	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells.
target gene	hsa-mir-218	Carcinoma, Cervical	25908215	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer.
target gene	hsa-mir-224	Carcinoma, Cervical	27626930	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Over-Expressed miR-224 Promotes the Progression of Cervical Cancer via Targeting RASSF8.
target gene	hsa-mir-25	Carcinoma, Cervical	25575057	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-25 could promote cell proliferation by targeting RECK in HeLa cells.
target gene	hsa-mir-25	Carcinoma, Cervical	27743413	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells.
target gene	hsa-mir-26a	Carcinoma, Cervical	24939702	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1
target gene	hsa-mir-30b	Carcinoma, Cervical	25069511	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	the genes BIRC5, HOXA1 and RARB are critical targets that play an important regulatory role in cervical cancer pathogenesis.
target gene	hsa-mir-31	Carcinoma, Cervical	24793973	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A.
target gene	hsa-mir-320a	Carcinoma, Cervical	26472185	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	CREB1-driven expression of miR-320a promotes mitophagy by down-regulating VDAC1 expression during serum starvation in cervical cancer cells.
target gene	hsa-mir-329	Carcinoma, Cervical	28393232	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer.
target gene	hsa-mir-331	Carcinoma, Cervical	27548144	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2.
target gene	hsa-mir-337	Carcinoma, Cervical	28641487	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-337 inhibits cell proliferation and invasion of cervical cancer through directly targeting specificity protein 1.
target gene	hsa-mir-33a	Carcinoma, Cervical	26541838	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Twist1 is critical for the invasiveness of cervical cancer cells;miR-33a, as a tumor suppressor gene, functions as an upstream regulator of Twist1 and is involved in the invasiveness of cervical cancer cell.
target gene	hsa-mir-342	Carcinoma, Cervical	25066298	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-342-3p suppresses proliferation, migration and invasion by targeting FOXM1 in human cervical cancer.
target gene	hsa-mir-346	Carcinoma, Cervical	26518874	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-346 Up-regulates Argonaute 2 (AGO2) Protein Expression to Augment the Activity of Other MicroRNAs (miRNAs) and Contributes to Cervical Cancer Cell Malignancy.
target gene	hsa-mir-362	Carcinoma, Cervical	27878258	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-362 is downregulated in cervical cancer and inhibits cell proliferation, migration and invasion by directly targeting SIX1.
target gene	hsa-mir-373	Carcinoma, Cervical	25747718	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer.
target gene	hsa-mir-375	Carcinoma, Cervical	26224081	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-375 Modulates Radiosensitivity of HR-HPV-Positive Cervical Cancer Cells by Targeting UBE3A through the p53 Pathway.
target gene	hsa-mir-421	Carcinoma, Cervical	27886335	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	microRNA 421 induces apoptosis of c-33a cervical cancer cells via down-regulation of Bcl-xL.
target gene	hsa-mir-424	Carcinoma, Cervical	28082020	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway.
target gene	hsa-mir-429	Carcinoma, Cervical	27883176	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-429 is involved in regulation of NF-κBactivity by targeting IKKβ and suppresses oncogenic activity in cervical cancer cells.
target gene	hsa-mir-432	Carcinoma, Cervical	25280995	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Heat shock factor 1 regulates hsa-miR-432 expression in human cervical cancer cell line.
target gene	hsa-mir-433	Carcinoma, Cervical	23915286	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The results indicate that miR-433 post-transcriptionally regulates the expression of TYMS mRNA and protein, and increases sensitivity to 5-FU in HeLa cells. This is the first report showing that a miRNA regulating TYMS expression has a significant impact on sensitivity to 5-FU treatment.
target gene	hsa-mir-491	Carcinoma, Cervical	26034994	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-491-5p suppresses cervical cancer cell growth by targeting hTERT.
target gene	hsa-mir-494	Carcinoma, Cervical	25738254	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-494 promotes cervical cancer proliferation through the regulation of PTEN.
target gene	hsa-mir-497	Carcinoma, Cervical	24909281	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Over-expressed miR-497 in HeLa cells could suppress cell proliferation by targeting CCNE1.
target gene	hsa-mir-506	Carcinoma, Cervical	24608427	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer.
target gene	hsa-mir-543	Carcinoma, Cervical	28231728	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-543 acts as a prognostic marker and promotes the cell proliferation in cervical cancer by BRCA1-interacting protein 1.
target gene	hsa-mir-590	Carcinoma, Cervical	24288179	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA-590 promotes cervical cancer cell growth and invasion by targeting CHL1.
target gene	hsa-mir-944	Carcinoma, Cervical	25156441	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Novel functions and targets of miR-944 in human cervical cancer cells.
target gene	hsa-mir-99a	Carcinoma, Cervical	24668416	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway.
target gene	hsa-mir-99b	Carcinoma, Cervical	24668416	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway.
target gene	hsa-mir-133a	Carcinoma, Colon	28466778	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-133a acts as a tumor suppressor in colorectal cancer by targeting eIF4A1.
target gene	hsa-mir-133b	Carcinoma, Colon	24870791	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-133b might act as a tumor suppressor and negatively regulate TBPL1 in CRC.
target gene	hsa-mir-137	Carcinoma, Colon	28035913	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1.
target gene	hsa-mir-139	Carcinoma, Colon	24885920	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-139-5p plays a pivotal role in colon cancer through inhibiting cell proliferation, metastasis, and promoting apoptosis and cell cycle arrest by targeting oncogenic NOTCH1.
target gene	hsa-mir-143	Carcinoma, Colon	27827523	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-143 inhibits colorectal cancer cell proliferation by targeting MMP7.
target gene	hsa-mir-143	Carcinoma, Colon	19062714	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The increased accumulation of miR-143 inhibits the proliferation of transfected cells, and results in down-regulation of K-ras protein in colorectal carcinoma.
target gene	hsa-mir-145	Carcinoma, Colon	25928322	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance.
target gene	hsa-mir-15a	Carcinoma, Colon	25623762	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-15a and miR-16 may reverse the drug resistance in human colon cancer cells. A possible mechanism is regulating the expression of bcl-2.
target gene	hsa-mir-16	Carcinoma, Colon	25623762	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-15a and miR-16 may reverse the drug resistance in human colon cancer cells. A possible mechanism is regulating the expression of bcl-2.
target gene	hsa-mir-182	Carcinoma, Colon	25695717	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells.
target gene	hsa-mir-183	Carcinoma, Colon	25695717	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells.
target gene	hsa-mir-18a	Carcinoma, Colon	24166503	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1.
target gene	hsa-mir-19a	Carcinoma, Colon	28257633	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1.
target gene	hsa-mir-200a	Carcinoma, Colon	27983967	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-200a acts as an oncogene in colorectal carcinoma by targeting PTEN.
target gene	hsa-mir-200c	Carcinoma, Colon	24682933	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	In conclusion, miR-200c functions as an oncogene in colon cancer cells through regulating tumor cell apoptosis, survival, invasion, and metastasis as well as xenograft tumor growth through inhibition of PTEN expression and p53 phosphorylation.
target gene	hsa-mir-21	Carcinoma, Colon	24275137	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.
target gene	hsa-mir-21	Carcinoma, Colon	25663768	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	RASA1 is a target gene of miR-21, which promotes malignant behaviors of RKO cells through regulation of RASA1 expression.
target gene	hsa-mir-21	Carcinoma, Colon	25928322	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our current observations suggest that miR-21, miR-145, and their networks play critical roles in regulating CSCs growth and/or differentiation in the colon cancer and progression of chemo-resistance.
target gene	hsa-mir-21	Carcinoma, Colon	26193421	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells.
target gene	hsa-mir-21	Carcinoma, Colon	26418978	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-21 can mediate the drug resistance to 5-FU by inhibiting its target PDCD4,which can regulate the expression of ABCC5 and CD44 genes.
target gene	hsa-mir-21	Carcinoma, Colon	20826792	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells.
target gene	hsa-mir-210	Carcinoma, Colon	25385144	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Hypoxia-induced autophagy reduces radiosensitivity by the HIF-1α/miR-210/Bcl-2 pathway in colon cancer cells.
target gene	hsa-mir-214	Carcinoma, Colon	27811858	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer.
target gene	hsa-mir-215	Carcinoma, Colon	27663660	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-215 suppresses cell proliferation, migration and invasion of colon cancer by repressing Yin-Yang 1.
target gene	hsa-mir-216a	Carcinoma, Colon	28213952	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer.
target gene	hsa-mir-218	Carcinoma, Colon	25760926	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
target gene	hsa-mir-218	Carcinoma, Colon	27773352	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	DCC Confers Susceptibility to Depression-like Behaviors in Humans and Mice and Is Regulated by miR-218.
target gene	hsa-mir-219	Carcinoma, Colon	26238082	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4.
target gene	hsa-mir-26b	Carcinoma, Colon	24785257	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression.
target gene	hsa-mir-29a	Carcinoma, Colon	27548517	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-29a Regulates Radiosensitivity in Human Intestinal Cells by Targeting PTEN Gene.
target gene	hsa-mir-29b	Carcinoma, Colon	24130681	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Since miR-29b plays a role in regulating the migration of cancer cells,we hypothesized that HAG induces miR-29b expression to target matrix metalloproteinase-2 (MMP-2) thereby suppressing the migration of colon cancer cells.
target gene	hsa-mir-300	Carcinoma, Colon	27779716	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-300 promotes proliferation and EMT-mediated colorectal cancer migration and invasion by targeting p53.
target gene	hsa-mir-31	Carcinoma, Colon	25362258	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-31 promotes proliferation of colon cancer cells by targeting E2F2.
target gene	hsa-mir-31	Carcinoma, Colon	20826792	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells.
target gene	hsa-mir-330	Carcinoma, Colon	27633518	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-330-5p negatively regulates ITGA5 expression in human colorectal cancer.
target gene	hsa-mir-34a	Carcinoma, Colon	26324236	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	These findings demonstrate that miR-34a may act as a negative regulator in colon cancer by targeting PDGFRA.
target gene	hsa-mir-34a	Carcinoma, Colon	28713966	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Spica Prunellae extract suppresses the growth of human colon carcinoma cells by targeting multiple oncogenes via activating miR-34a.
target gene	hsa-mir-374b	Carcinoma, Colon	28339062	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	p53/microRNA-374b/AKT1 regulates colorectal cancer cell apoptosis in response to DNA damage.
target gene	hsa-mir-429	Carcinoma, Colon	26058485	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-429 inhibits the migration and invasion of colon cancer cells by targeting PAK6/cofilin signaling.
target gene	hsa-mir-4458	Carcinoma, Colon	26607110	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	In conclusion, our findings suggested that miR-4458 inhibited the progression of colon cancer cells by inhibition of glycolysis and lactate production via directly targeting HK2 mRNA.
target gene	hsa-mir-492	Carcinoma, Colon	25862460	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147.
target gene	hsa-mir-494	Carcinoma, Colon	25873402	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.
target gene	hsa-mir-494	Carcinoma, Colon	27648301	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.
target gene	hsa-mir-506	Carcinoma, Colon	27993882	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-506 Inhibits Malignancy of Colorectal Carcinoma Cells by Targeting LAMC1.
target gene	hsa-mir-522	Carcinoma, Colon	26043974	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5.
target gene	hsa-mir-590	Carcinoma, Colon	27735951	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis.
target gene	hsa-mir-6734	Carcinoma, Colon	27509128	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Collectively, our results demonstrated that miR-6734 inhibits the growth of colon cancer cells by up-regulating p21 gene expression and subsequent induction of cell cycle arrest and apoptosis, suggesting its role as an important endogenous regulator of cancer cell proliferation and survival.
target gene	hsa-mir-675	Carcinoma, Colon	28189050	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through miR-675-5p in Colon Cancer Cells.
target gene	hsa-mir-885	Carcinoma, Colon	24882581	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling.
target gene	hsa-mir-96	Carcinoma, Colon	25695717	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells.
target gene	hsa-mir-98	Carcinoma, Colon	28025745	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-98 Suppress Warburg Effect by Targeting HK2 in Colon Cancer Cells.
target gene	hsa-mir-27	Carcinoma, Embryonal	25369332	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	miR-27 negatively regulates pluripotency-associated genes in human embryonal carcinoma cells.
target gene	hsa-mir-302b	Carcinoma, Embryonal	18930031	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	miR-302b: miR-302b maintains stemness of human embryonal carcinoma cells by post-transcriptional regulation of Cyclin D2 expression
target gene	hsa-mir-1	Carcinoma, Endometrial	25955017	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.
target gene	hsa-mir-101	Carcinoma, Endometrial	25153722	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and  stem cell-like phenotype of aggressive endometrial cancer cells.
target gene	hsa-mir-106b	Carcinoma, Endometrial	24002805	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines.
target gene	hsa-mir-124	Carcinoma, Endometrial	24287565	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	miR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3.
target gene	hsa-mir-133a	Carcinoma, Endometrial	25955017	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer.
target gene	hsa-mir-135b	Carcinoma, Endometrial	27222184	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MiR-135b promotes proliferation of endometrial carcinoma cells by targeting FOXO1.
target gene	hsa-mir-141	Carcinoma, Endometrial	24742567	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis.
target gene	hsa-mir-143	Carcinoma, Endometrial	24742567	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis.
target gene	hsa-mir-145	Carcinoma, Endometrial	24742567	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis.
target gene	hsa-mir-182	Carcinoma, Endometrial	24021963	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	miR-182 acts as an oncogenic miRNA in EC, promoting cell proliferation by targeting the tumor suppressor gene TCEAL7 and modulating the activity of its downstream effectors c-Myc, cyclin D1 and NFκB.
target gene	hsa-mir-199a	Carcinoma, Endometrial	23851675	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MiR-199a-3p inhibits tumor cell proliferation through negative regulation of mTOR expression. Restoration of intracellular miR-199a-3p levels may serve as a potential option for EEC treatment.
target gene	hsa-mir-200a	Carcinoma, Endometrial	24742567	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis.
target gene	hsa-mir-200b	Carcinoma, Endometrial	28529604	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	knockdown of DICER1 significantly downregulated miR-200b and let-7i, which may then regulate their targets SUZ12 and EZH2
target gene	hsa-mir-200c	Carcinoma, Endometrial	29080395	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MicroRNA-200c Inhibits Epithelial-Mesenchymal Transition by Targeting the BMI-1 Gene Through the Phospho-AKT Pathway in Endometrial Carcinoma Cells In Vitro.
target gene	hsa-mir-205	Carcinoma, Endometrial	24929707	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	For the first time, we demonstrate that the expression of PTEN is directly regulated by miR-205 in endometrial cancer cells and leads the inhibition of cellular apoptosis. This relationship could be targeted for new therapeutic strategies for endometrial cancer.
target gene	hsa-mir-205	Carcinoma, Endometrial	24742567	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	EC may have a unique miRNA expression profile. The expression levels of the five miRNAs (miR-141, miR-200a, miR-205, miR-143, miR-145) are significantly deregulated in typeIEC compared to normal control but not in typeIItumors. The findings suggest that the miRNAs related to type Iand typeIIEC might be different. PTEN might be a potential target of miR-141 and miR-200a in endometrial carcinogenesis.
target gene	hsa-mir-222	Carcinoma, Endometrial	24498137	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα.
target gene	hsa-mir-29b	Carcinoma, Endometrial	28222438	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
target gene	hsa-mir-34a	Carcinoma, Endometrial	24497324	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Our data suggest that miR-34a can regulate L1CAM expression by targeting L1CAM mRNA for degradation.These findings shed new light on the complex regulation of L1CAM in human tumors.
target gene	hsa-mir-34c	Carcinoma, Endometrial	25846116	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	our study demonstrated that miR-34c plays a role of tumor suppressor in HEC-1-B cells, and E2F3 protein may be a target of miR-34c.
target gene	hsa-mir-424	Carcinoma, Endometrial	25708247	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7.
target gene	hsa-mir-424	Carcinoma, Endometrial	29371986	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MicroRNA-424/E2F6 feedback loop modulates cell invasion, migration and EMT in endometrial carcinoma
target gene	hsa-mir-449a	Carcinoma, Endometrial	24993091	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A.
target gene	hsa-mir-505	Carcinoma, Endometrial	26832151	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Taken together, this study demonstrates that miR-505 acts as tumor suppressor in EC by regulating TGF-α.
target gene	hsa-mir-543	Carcinoma, Endometrial	24699721	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	MiR-543 expression is decreased in endometrial cancer and serves as a tumor suppressor by targeting FAK and TWIST1 expression.
target gene	hsa-mir-200a	Carcinoma, Endometrioid Endometrial	25750291			C54.1	D018269			miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma.
target gene	hsa-mir-200b	Carcinoma, Endometrioid Endometrial	25750291			C54.1	D018269			miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma.
target gene	hsa-mir-21	Carcinoma, Endometrioid Endometrial	23226804			C54.1	D018269			microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer
target gene	hsa-mir-23a	Carcinoma, Endometrioid Endometrial	27601936			C54.1	D018269			MicroRNA-23a regulates epithelial-to-mesenchymal transition in endometrial endometrioid adenocarcinoma by targeting SMAD3.
target gene	hsa-mir-429	Carcinoma, Endometrioid Endometrial	25750291			C54.1	D018269			miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma.
target gene	hsa-mir-503	Carcinoma, Endometrioid Endometrial	23731275			C54.1	D018269			MicroRNA-503 suppresses proliferation and cell cycle progression of endometrioid ndometrial cancer via negatively regulating cyclin D1.
target gene	hsa-mir-1207	Carcinoma, Esophageal	25695396	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miRNA-1207-5p is associated with cancer progression by targeting stomatin-like protein 2 in esophageal carcinoma.
target gene	hsa-mir-122	Carcinoma, Esophageal	24659424	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122.
target gene	hsa-mir-124	Carcinoma, Esophageal	25928665	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Collectively, these data suggest that miR-124 functions as a tumor suppressor in esophageal cancer through, at least partially, targeting STAT3 signaling pathway.
target gene	hsa-mir-126	Carcinoma, Esophageal	28536606	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A.
target gene	hsa-mir-133a	Carcinoma, Esophageal	24196787	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The combined expression of FSCN1 and MMP14 is associated with a poor prognosis, and miR-133a, which regulates their mRNAs, can serve as a strong tumour suppressor of ESCC.
target gene	hsa-mir-140	Carcinoma, Esophageal	25322669	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-140 may regulate the cell invasion of EC via controlling Slugexpression.
target gene	hsa-mir-141	Carcinoma, Esophageal	27644195	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.
target gene	hsa-mir-143	Carcinoma, Esophageal	24659424	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122.
target gene	hsa-mir-183	Carcinoma, Esophageal	25518924	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-183 might play an oncogenic role in ESCC by regulating  PDCD4 expression.
target gene	hsa-mir-193a	Carcinoma, Esophageal	26743123	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-193a-3p regulation of chemoradiation resistance in oesophageal cancer cells via the PSEN1 gene.
target gene	hsa-mir-195	Carcinoma, Esophageal	28487599	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-195 Regulates Proliferation and Apoptosis through Inhibiting the mTOR/p70s6k Signaling Pathway by Targeting HMGA2 in Esophageal Carcinoma Cells.
target gene	hsa-mir-203	Carcinoma, Esophageal	25216463	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells.
target gene	hsa-mir-204	Carcinoma, Esophageal	26722467	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer.
target gene	hsa-mir-21	Carcinoma, Esophageal	24221338	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Our findings suggest that miR-21 could be a potential oncomiR,probably by regulation of PTEN, and a novel prognostic factor for ESCC patients.
target gene	hsa-mir-21	Carcinoma, Esophageal	26345812	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Together,these results suggest that miR- 21 might be involved in the development and metastasis of esophageal cancer, through interaction with its PDCD4 and K-ras target genes.
target gene	hsa-mir-30b	Carcinoma, Esophageal	28189678	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-30b inhibits cancer cell growth, migration, and invasion by targeting homeobox A1 in esophageal cancer.
target gene	hsa-mir-328	Carcinoma, Esophageal	26773497	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	MiR-328 suppresses the survival of esophageal cancer cells by targeting PLCE1.
target gene	hsa-mir-340	Carcinoma, Esophageal	26316084	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	MiR-340 functions as a tumor suppressor by modulating the expression of PSAT1 and may contribute to the progression and invasiveness of ESCC.
target gene	hsa-mir-429	Carcinoma, Esophageal	23999873	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	In primary EC tissues miR-429 is expressed at low levels. Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1. Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429. This study paves the way for a better understanding of the mechanism underlying EC pathogenesis and the development of novel, targeted therapies.
target gene	hsa-mir-499	Carcinoma, Esophageal	26159783	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	MiR-499 Enhances the Cisplatin Sensitivity of Esophageal Carcinoma Cell Lines by  Targeting DNA Polymerase β.
target gene	hsa-mir-542	Carcinoma, Esophageal	26323919	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Taken together, our results indicated that miR-542-3p is a tumor suppressor of esophageal cancer acting at steps that regulate cell growth.
target gene	hsa-mir-96	Carcinoma, Esophageal	25465153	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-96 serves as an oncogene role in EC cells through downregulating RECK.
target gene	hsa-mir-135a	Carcinoma, Gallbladder	24903309	disease of cellular proliferation	DOID:4948	C23	D005706			MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer.
target gene	hsa-mir-143	Carcinoma, Gallbladder	29416013	disease of cellular proliferation	DOID:4948	C23	D005706			miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma.
target gene	hsa-mir-146b	Carcinoma, Gallbladder	25760482	disease of cellular proliferation	DOID:4948	C23	D005706			MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor.
target gene	hsa-mir-182	Carcinoma, Gallbladder	24445397	disease of cellular proliferation	DOID:4948	C23	D005706			TGF-β upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1.
target gene	hsa-mir-26a	Carcinoma, Gallbladder	24682444	disease of cellular proliferation	DOID:4948	C23	D005706			MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2.
target gene	hsa-mir-30a	Carcinoma, Gallbladder	29540696	disease of cellular proliferation	DOID:4948	C23	D005706			MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7.
target gene	hsa-mir-33a	Carcinoma, Gallbladder	27769047	disease of cellular proliferation	DOID:4948	C23	D005706			The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer.
target gene	hsa-mir-34	Carcinoma, Gallbladder	24078448	disease of cellular proliferation	DOID:4948	C23	D005706			Both low miR-34a expression and long telomere length are markers for poor prognosis of patients with gallbladder adenocarcinoma. Our study also suggests that the miR-34a gene could be a target for targeting therapy of GBC.
target gene	hsa-mir-663a	Carcinoma, Gallbladder	29778567	disease of cellular proliferation	DOID:4948	C23	D005706			EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway.
target gene	hsa-mir-103	Carcinoma, Gastric	25407491	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	caveolin-1(Cav-1), a critical component of lipid rafts, was a target of miR-103/107.
target gene	hsa-mir-107	Carcinoma, Gastric	25407491	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	caveolin-1(Cav-1), a critical component of lipid rafts, was a target of miR-103/107.
target gene	hsa-mir-10b	Carcinoma, Gastric	26191201	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Augmented miR-10b expression associated with depressed expression of its target gene KLF4 involved in gastric carcinoma.
target gene	hsa-mir-1228	Carcinoma, Gastric	28465246	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	microRNA-1228⁎ impairs the pro-angiogenic activity of gastric cancer cells by targeting macrophage migration inhibitory factor.
target gene	hsa-mir-124	Carcinoma, Gastric	24257299	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-124 can suppress the cell proliferation and invasion by targeting SPHK1 in gastric carcinoma.
target gene	hsa-mir-125a	Carcinoma, Gastric	25231560	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Reduced miR-125a-5p expression is associated with gastric carcinogenesis through the targeting of E2F3.
target gene	hsa-mir-126	Carcinoma, Gastric	27622325	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2.
target gene	hsa-mir-126	Carcinoma, Gastric	28260063	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126.
target gene	hsa-mir-129	Carcinoma, Gastric	28012924	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp.
target gene	hsa-mir-129	Carcinoma, Gastric	28653880	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-129-5p influences the progression of gastric cancer cells through interacting with SPOCK1.
target gene	hsa-mir-1296	Carcinoma, Gastric	28099468	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR 1296-5p Inhibits the Migration and Invasion of Gastric Cancer Cells by Repressing ERBB2 Expression.
target gene	hsa-mir-133a	Carcinoma, Gastric	25815687	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting fascin actin-bundling protein 1.
target gene	hsa-mir-134	Carcinoma, Gastric	28260021	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-134 suppresses cell proliferation in gastric cancer cells via targeting of GOLPH3.
target gene	hsa-mir-136	Carcinoma, Gastric	28656883	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-136 inhibits gastric cancer-specific peritoneal metastasis by targeting HOXC10.
target gene	hsa-mir-137	Carcinoma, Gastric	25064845	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway.
target gene	hsa-mir-137	Carcinoma, Gastric	26102366	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-137 Contributes to Dampened Tumorigenesis in Human Gastric Cancer by Targeting AKT2.
target gene	hsa-mir-141	Carcinoma, Gastric	28115163	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Lnc-ATB contributes to gastric cancer growth through a MiR-141-3p/TGFβ2 feedback loop.
target gene	hsa-mir-143	Carcinoma, Gastric	28718369	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer.
target gene	hsa-mir-144	Carcinoma, Gastric	28111340	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-144-3p suppresses gastric cancer progression by inhibiting epithelial-to-mesenchymal transition through targeting PBX3.
target gene	hsa-mir-155	Carcinoma, Gastric	24969405	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Downregulation of microRNA-155 accelerates cell growth and invasion by targeting c-myc in human gastric carcinoma cells.
target gene	hsa-mir-16	Carcinoma, Gastric	27683052	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer.
target gene	hsa-mir-181a	Carcinoma, Gastric	28043911	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation.
target gene	hsa-mir-185	Carcinoma, Gastric	23846337	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Our results show that GKN1 has an miR-185-dependent and -independent mechanism for chromatic and DNA epigenetic modification, thereby regulating the cell cycle. Thus, the loss of GKN1 function contributes to malignant transformation and proliferation of gastric epithelial cells in gastric carcinogenesis.
target gene	hsa-mir-187	Carcinoma, Gastric	27864146	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-187 regulates gastric cancer progression by targeting the tumor suppressor CRMP1.
target gene	hsa-mir-187	Carcinoma, Gastric	28098868	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-187 promotes growth and metastasis of gastric cancer by inhibiting FOXA2.
target gene	hsa-mir-194	Carcinoma, Gastric	27874950	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B.
target gene	hsa-mir-19b	Carcinoma, Gastric	27572553	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-19b inhibits proliferation of gastric cancer cells by targeting B-cell CLL/lymphoma 3.
target gene	hsa-mir-200a	Carcinoma, Gastric	27144885	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Depleting endogenous Bart9 of SNU-719 induced a surged expression of miR-200a and miR-141, accompanied by decreased proliferative and invasive ability.
target gene	hsa-mir-200c	Carcinoma, Gastric	29286062	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-200c regulates the proliferation, apoptosis and invasion of gastric carcinoma cells through the downregulation of EDNRA expression
target gene	hsa-mir-203	Carcinoma, Gastric	27542403	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM.
target gene	hsa-mir-218	Carcinoma, Gastric	27642088	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-218 Inhibits Proliferation, Migration, and EMT of Gastric Cancer Cells by Targeting WASF3.
target gene	hsa-mir-218	Carcinoma, Gastric	27696291	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-218 inhibits the proliferation, migration, and invasion and promotes apoptosis of gastric cancer cells by targeting LASP1.
target gene	hsa-mir-218	Carcinoma, Gastric	28323002	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-218 inhibited tumor angiogenesis by targeting ROBO1 in gastric cancer.
target gene	hsa-mir-221	Carcinoma, Gastric	28618968	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer.
target gene	hsa-mir-222	Carcinoma, Gastric	28618968	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer.
target gene	hsa-mir-223	Carcinoma, Gastric	25888377	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Our findings revealed the roles of miR-223/FBXW7 signaling in the DDP resistance of GC cells and targeting it will be a potential strategic approach for reversing the DDP resistance in human GC.
target gene	hsa-mir-224	Carcinoma, Gastric	28173803	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer.
target gene	hsa-mir-27b	Carcinoma, Gastric	27844448	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-27b inhibits gastric cancer metastasis by targeting NR2F2.
target gene	hsa-mir-320a	Carcinoma, Gastric	28008607	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting β-catenin and ATP-binding cassette, subfamily G, member 2.
target gene	hsa-mir-34	Carcinoma, Gastric	24970812	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis.
target gene	hsa-mir-34a	Carcinoma, Gastric	28399871	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis.
target gene	hsa-mir-34c	Carcinoma, Gastric	26097561	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	PABPC1 exerts carcinogenesis in gastric carcinoma by targeting miR-34c.
target gene	hsa-mir-363	Carcinoma, Gastric	23975832	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	These results suggest that miR-363 plays an important role in the increment of gastric carcinogenesis via targeting MBP-1.
target gene	hsa-mir-4496	Carcinoma, Gastric	28008607	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting β-catenin and ATP-binding cassette, subfamily G, member 2.
target gene	hsa-mir-494	Carcinoma, Gastric	24612089	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-494 is downregulated in human GC and acts as an anti-oncogene by targeting c-myc. miR-494 plays a role in the pathogenesis of gastric cancer in a recessive fashion.
target gene	hsa-mir-494	Carcinoma, Gastric	27735036	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-494 inhibits invasion and proliferation of gastric cancer by targeting IGF-1R.
target gene	hsa-mir-495	Carcinoma, Gastric	28159956	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-495 Inhibits Gastric Cancer Cell Migration and Invasion Possibly via Targeting High Mobility Group AT-Hook 2 (HMGA2).
target gene	hsa-mir-509	Carcinoma, Gastric	27697095	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-509-3p Inhibits Cancer Cell Proliferation and Migration via Upregulation of XIAP in Gastric Cancer Cells.
target gene	hsa-mir-520b	Carcinoma, Gastric	27997901	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer.
target gene	hsa-mir-520e	Carcinoma, Gastric	27997901	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer.
target gene	hsa-mir-532	Carcinoma, Gastric	28356225	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-532 promoted gastric cancer migration and invasion by targeting NKD1.
target gene	hsa-mir-630	Carcinoma, Gastric	28601080	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-630 Suppresses Epithelial-to-Mesenchymal Transition by Regulating FoxM1 in Gastric Cancer Cells.
target gene	hsa-mir-638	Carcinoma, Gastric	26250158	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma.
target gene	hsa-mir-646	Carcinoma, Gastric	28632723	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer.
target gene	hsa-mir-7	Carcinoma, Gastric	26261179	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-7/NF-κB signaling regulatory feedback circuit regulates gastric carcinogenesis.
target gene	hsa-mir-9	Carcinoma, Gastric	28127811	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-9 inhibits the gastric cancer cell proliferation by targeting TNFAIP8.
target gene	hsa-mir-935	Carcinoma, Gastric, Signet Ring Cell	26742429				D018279			miR-935 suppresses gastric signet ring cell carcinoma tumorigenesis by targeting Notch1 expression.
target gene	hsa-let-7a	Carcinoma, Hepatocellular	27932893	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression.
target gene	hsa-let-7a-1	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7a-2	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7a-3	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7a:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7b	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7b:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7b	Carcinoma, Hepatocellular	28671046	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Let7b modulates the Wnt/β-catenin pathway in liver cancer cells via downregulated Frizzled4.
target gene	hsa-let-7c	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7c:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7c	Carcinoma, Hepatocellular	22433309	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	let-7c can inhibit proliferation of HCCLM3 cells and increase the proportion of cells in G1 phase. The mechanism may be that let-7c represses the expressions of cyclin D1 at both protein and mRNA levels.
target gene	hsa-let-7c	Carcinoma, Hepatocellular	25909324	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA let-7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma.
target gene	hsa-let-7d	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7d:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7e	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7e:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7f-1	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7f:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7f-2	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7f:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7g	Carcinoma, Hepatocellular	20309945	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hsa-let-7g inhibits proliferation of hepatocellular carcinoma Cells by down-regulation of c-Myc and Up-regulation of p16(INK4A).
target gene	hsa-let-7g	Carcinoma, Hepatocellular	20338660	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma.
target gene	hsa-let-7g	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7g:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7g	Carcinoma, Hepatocellular	24724096	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Reexpression of Let-7g microRNA inhibits the proliferation and migration via K-Ras/HMGA2/snail axis in hepatocellular carcinoma.
target gene	hsa-let-7i	Carcinoma, Hepatocellular	20347499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-let-7i:The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
target gene	hsa-let-7i	Carcinoma, Hepatocellular	21665888	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In addition, we showed that HBx up-regulated CD59 by let-7i at post-transcriptional regulation level. 
target gene	hsa-mir-100	Carcinoma, Hepatocellular	25026290	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R.
target gene	hsa-mir-101	Carcinoma, Hepatocellular	26158762	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
target gene	hsa-mir-101	Carcinoma, Hepatocellular	24211739	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Tumor suppressor miR-101 represses HCC progression through directly targeting EZH2 oncogene and sensitizes liver cancer cells to chemotherapeutic treatment. Our findings provide significant insights into molecular mechanisms of hepatocarcinogenesis and may have clinical relevance for the development of novel targeted therapies for HCC.
target gene	hsa-mir-101	Carcinoma, Hepatocellular	25808945	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate that miR-101 regulates HCC cell phenotype by upregulating the epithelial marker genes and suppressing the mesenchymal ones.
target gene	hsa-mir-101	Carcinoma, Hepatocellular	25260594	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells.
target gene	hsa-mir-101	Carcinoma, Hepatocellular	27702662	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulation of SNHG6 regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma.
target gene	hsa-mir-101-1	Carcinoma, Hepatocellular	19133651	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-101: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene
target gene	hsa-mir-101-2	Carcinoma, Hepatocellular	19133651	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-101: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene
target gene	hsa-mir-106b	Carcinoma, Hepatocellular	28410209	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4.
target gene	hsa-mir-107	Carcinoma, Hepatocellular	27773820	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3'UTR.
target gene	hsa-mir-107	Carcinoma, Hepatocellular	28867541	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-107-mediated decrease of HMGCS2 indicates poor outcomes and promotes cell migration in hepatocellular carcinoma
target gene	hsa-mir-107	Carcinoma, Hepatocellular	26191213	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our observations suggested that miR-107 could promote HCC cells proliferation via targeting Axin2 and might represent a potential therapeutic target for HCC.
target gene	hsa-mir-10a	Carcinoma, Hepatocellular	22996586	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings highlight the importance of miR-10a in regulating the metastatic properties of HCC by directly targeting EphA4 and may provide new insights into the pathogenesis of HCC
target gene	hsa-mir-10b	Carcinoma, Hepatocellular	22528944	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells.
target gene	hsa-mir-10b	Carcinoma, Hepatocellular	27756250	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1).
target gene	hsa-mir-10b	Carcinoma, Hepatocellular	29375271	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma
target gene	hsa-mir-10b	Carcinoma, Hepatocellular	29506532	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma
target gene	hsa-mir-1-1	Carcinoma, Hepatocellular	22664953	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
target gene	hsa-mir-1-2	Carcinoma, Hepatocellular	22664953	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
target gene	hsa-mir-1202	Carcinoma, Hepatocellular	29217161	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14
target gene	hsa-mir-122	Carcinoma, Hepatocellular	16777601	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	inhibite CAT-1
target gene	hsa-mir-122	Carcinoma, Hepatocellular	17616664	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	18692484	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	19726678	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The liver specific miR-122 is frequently suppressed in primary hepatocellular carcinomas (HCCs). ADAM-10 (a distintegrin and metalloprotease family-10), SRF (serum response factor), and Igf1R (insulin like growth factor 1 receptor) that promote tumorigenesis were validated as targets of miR- 122 and were repressed by the microRNA.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	21725618	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	21802841	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	22276989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/ж┿catenin pathway.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	24244539	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	24466275	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	25422324	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our results reveal a novel Hnf4α/miR-122/GALNT10 regulatory pathway that facilitates EGF miR-122 activation and hepatoma growth in HBV-associated hepatocarcinogenesis.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	26252254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	24992599	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	27687586	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	WNT1 Gene from WNT Signaling Pathway Is a Direct Target of miR-122 in Hepatocellular Carcinoma.
target gene	hsa-mir-122	Carcinoma, Hepatocellular	27302319	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122*, the passenger strand of miR-122, regulates the activity of p53 by targeting Mdm2.
target gene	hsa-mir-122a	Carcinoma, Hepatocellular	26189916	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through miR-122a Regulation.
target gene	hsa-mir-1236	Carcinoma, Hepatocellular	25714026	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1236 down-regulates alpha-fetoprotein, thus causing PTEN accumulation, which inhibits the PI3K/Akt pathway and malignant phenotype in hepatoma cells.
target gene	hsa-mir-124	Carcinoma, Hepatocellular	24211205	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3.
target gene	hsa-mir-124-1	Carcinoma, Hepatocellular	21672940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
target gene	hsa-mir-124-1	Carcinoma, Hepatocellular	22940133	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
target gene	hsa-mir-124-2	Carcinoma, Hepatocellular	21672940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
target gene	hsa-mir-124-2	Carcinoma, Hepatocellular	22940133	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
target gene	hsa-mir-124-3	Carcinoma, Hepatocellular	21672940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
target gene	hsa-mir-1246	Carcinoma, Hepatocellular	25591821	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1246 is regulated by p53 and suppresses the growth of human HCC by targeting NFIB. Here, we propose a new p53-miR-1246-NFIB pathway in HCC.
target gene	hsa-mir-125a	Carcinoma, Hepatocellular	22768249	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF.
target gene	hsa-mir-125a	Carcinoma, Hepatocellular	23079745	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b
target gene	hsa-mir-125a	Carcinoma, Hepatocellular	28445974	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf.
target gene	hsa-mir-125b	Carcinoma, Hepatocellular	24811246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Prognostic marker microRNA-125b inhibits tumorigenic properties of carcinoma cells via suppressing tumorigenic molecule eIF5A2.
target gene	hsa-mir-125b	Carcinoma, Hepatocellular	24865963	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II.
target gene	hsa-mir-125b	Carcinoma, Hepatocellular	25424744	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HOTTIP is a novel oncogenic lncRNA, which negatively regulated by miR-125b. Overexpression of HOTTIP contributes to hepatocarcinogenesis by regulating the expression of its neighbouring protein-coding genes.
target gene	hsa-mir-125b	Carcinoma, Hepatocellular	26704017	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-125b has been reported to down-regulate SIRT7 by binding to its 3'UTR
target gene	hsa-mir-125b-1	Carcinoma, Hepatocellular	22293115	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression.
target gene	hsa-mir-125b-1	Carcinoma, Hepatocellular	23079745	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b
target gene	hsa-mir-125b-2	Carcinoma, Hepatocellular	22293115	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression.
target gene	hsa-mir-125b-2	Carcinoma, Hepatocellular	23079745	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b
target gene	hsa-mir-126	Carcinoma, Hepatocellular	28881749	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma
target gene	hsa-mir-1271	Carcinoma, Hepatocellular	22865282	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells.
target gene	hsa-mir-1275	Carcinoma, Hepatocellular	26160756	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma.
target gene	hsa-mir-128	Carcinoma, Hepatocellular	25962360	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients.
target gene	hsa-mir-1285	Carcinoma, Hepatocellular	25230788	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma.
target gene	hsa-mir-129	Carcinoma, Hepatocellular	26116538	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-129 suppresses tumor cell growth and invasion by targeting PAK5 in hepatocellular carcinoma.
target gene	hsa-mir-129	Carcinoma, Hepatocellular	25912876	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-129-5p inhibits hepatocellular carcinoma cell metastasis and invasion via targeting ETS1.
target gene	hsa-mir-129-1	Carcinoma, Hepatocellular	22865282	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells.
target gene	hsa-mir-129-2	Carcinoma, Hepatocellular	22865282	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells.
target gene	hsa-mir-1297	Carcinoma, Hepatocellular	26191190	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2.
target gene	hsa-mir-1303	Carcinoma, Hepatocellular	22865282	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells.
target gene	hsa-mir-130a	Carcinoma, Hepatocellular	22846564	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.
target gene	hsa-mir-130b	Carcinoma, Hepatocellular	25617495	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data collectively highlight a novel pathway interlinking T3/TR,  miR-130b, IRF1, the EMT-related genes, p-mTOR, p-STAT3 and the p-AKT cascade, which regulates the motility and invasion of hepatoma cells.
target gene	hsa-mir-132	Carcinoma, Hepatocellular	26252738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-132 inhibits cell proliferation, invasion and migration of hepatocellular carcinoma by targeting PIK3R3.
target gene	hsa-mir-133a	Carcinoma, Hepatocellular	26156803	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma.
target gene	hsa-mir-133a	Carcinoma, Hepatocellular	26173501	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-145 and MicroRNA-133a Inhibited Proliferation, Migration, and Invasion, While Promoted Apoptosis in Hepatocellular Carcinoma Cells Via Targeting FSCN1.
target gene	hsa-mir-134	Carcinoma, Hepatocellular	24498348	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Genome-wide screening identified that miR-134 acts as a metastasis suppressor by  targeting integrin β1 in hepatocellular carcinoma.
target gene	hsa-mir-135a	Carcinoma, Hepatocellular	27609066	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBXIP is able to depress the gluconeogenesis through suppressing PCK1 to promote hepatocarcinogenesis, involving miR-135a/FOXO1 axis and PI3K/Akt/p-FOXO1 pathway
target gene	hsa-mir-135a	Carcinoma, Hepatocellular	28389526	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells.
target gene	hsa-mir-135b	Carcinoma, Hepatocellular	24631529	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation.
target gene	hsa-mir-135b	Carcinoma, Hepatocellular	26429530	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-135b promotes the invasion and metastasis possibly by targeting the Hippo pathway genes.
target gene	hsa-mir-137	Carcinoma, Hepatocellular	24970808	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2.
target gene	hsa-mir-138	Carcinoma, Hepatocellular	28639887	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-138 enhances TRAIL-induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular carcinoma cells.
target gene	hsa-mir-138	Carcinoma, Hepatocellular	28677784	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-138 inhibits cell proliferation in hepatocellular carcinoma by targeting Sirt1.
target gene	hsa-mir-138	Carcinoma, Hepatocellular	29387246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	 miR-138 targeted SP1 to repress the growth, migration and invasion of HCC cells, and may therefore represent a therapeutic target in human HCC
target gene	hsa-mir-138-1	Carcinoma, Hepatocellular	22362728	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma.
target gene	hsa-mir-138-2	Carcinoma, Hepatocellular	22362728	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma.
target gene	hsa-mir-139	Carcinoma, Hepatocellular	26022123	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of  hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.
target gene	hsa-mir-140	Carcinoma, Hepatocellular	22898998	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiRNA-140 acts as a liver tumor suppressor by controlling NF-kB activity via directly targeting Dnmt1 expression.
target gene	hsa-mir-140	Carcinoma, Hepatocellular	23401231	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma
target gene	hsa-mir-141	Carcinoma, Hepatocellular	25008569	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-141 targets ZEB2 to suppress HCC progression.
target gene	hsa-mir-141	Carcinoma, Hepatocellular	25896253	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study showed that miR-141 plays a key role in 5-FU resistance by down-regulating Keap1 expression, thereby reactivating the Nrf2-dependent antioxidant pathway, which may serve as a potential target for overcoming 5-FU resistance in hepatocellular carcinoma cells.
target gene	hsa-mir-141	Carcinoma, Hepatocellular	26790956	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-141 suppression may cause aberrant expression of SPAG9 and promote HCC tumorigenesis via JNK pathway.
target gene	hsa-mir-142	Carcinoma, Hepatocellular	21482222	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells.
target gene	hsa-mir-143	Carcinoma, Hepatocellular	28765889	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of microRNA-143 promotes cell proliferation by regulating PKCε in hepatocellular carcinoma cells.
target gene	hsa-mir-144	Carcinoma, Hepatocellular	25073510	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-144 might suppress the growth and motility of HCC cells partially by targeting E2F3.
target gene	hsa-mir-144	Carcinoma, Hepatocellular	28229969	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-144 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by targeting ZFX.
target gene	hsa-mir-144	Carcinoma, Hepatocellular	27536132	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SMAD4.
target gene	hsa-mir-145	Carcinoma, Hepatocellular	23499894	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer
target gene	hsa-mir-145	Carcinoma, Hepatocellular	25174729	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma.
target gene	hsa-mir-145	Carcinoma, Hepatocellular	26068913	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-145 regulates chemoresistance in hepatocellular carcinoma via epithelial mesenchymal transition.
target gene	hsa-mir-145	Carcinoma, Hepatocellular	26173501	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-145 and MicroRNA-133a Inhibited Proliferation, Migration, and Invasion, While Promoted Apoptosis in Hepatocellular Carcinoma Cells Via Targeting FSCN1.
target gene	hsa-mir-145	Carcinoma, Hepatocellular	28104805	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-145 Modulates N6-Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the N6-Methyladenosine Binding YTH Domain Family 2 Protein.
target gene	hsa-mir-145	Carcinoma, Hepatocellular	23621665	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17.
target gene	hsa-mir-145	Carcinoma, Hepatocellular	29630879	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway
target gene	hsa-mir-146a	Carcinoma, Hepatocellular	22167321	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-ж╩B activity.
target gene	hsa-mir-146a	Carcinoma, Hepatocellular	23671131	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression.
target gene	hsa-mir-146a	Carcinoma, Hepatocellular	25608619	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This study identified a novel target of miR-146a and defined miR-146a as a crucial tumor suppressor in human HCC that acts through multiple pathways and mechanisms to suppress HCC invasion or metastasis.
target gene	hsa-mir-150	Carcinoma, Hepatocellular	22025269	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
target gene	hsa-mir-152	Carcinoma, Hepatocellular	27922690	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma.
target gene	hsa-mir-153	Carcinoma, Hepatocellular	26035427	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-153 inhibits epithelial-to-mesenchymal transition in hepatocellular carcinoma by targeting Snail.
target gene	hsa-mir-154	Carcinoma, Hepatocellular	26503460	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In conclusion, these results indicate that miR-154 functions as a tumor suppressor in HCC by suppressing ZEB2,suggesting that miR-154 may serve as a potential target for HCC.
target gene	hsa-mir-155	Carcinoma, Hepatocellular	21989846	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma.
target gene	hsa-mir-155	Carcinoma, Hepatocellular	29234238	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly  targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling
target gene	hsa-mir-155	Carcinoma, Hepatocellular	29565484	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-155 targeted and inhibited FoxO3a expression to suppress the BIM, depress caspase-3 and caspase-9 activities, therefore inhibiting the HCC cell apoptosis and facilitating proliferation
target gene	hsa-mir-141	Carcinoma, Hepatocellular	25142234	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3.
target gene	hsa-mir-15b	Carcinoma, Hepatocellular	28239814	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA15b induced SMCC7721 apoptosis via down-regulation of XIAP.
target gene	hsa-mir-16-1	Carcinoma, Hepatocellular	23226427	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells
target gene	hsa-mir-16-2	Carcinoma, Hepatocellular	23226427	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells
target gene	hsa-mir-26b	Carcinoma, Hepatocellular	26191168	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2.
target gene	hsa-mir-17	Carcinoma, Hepatocellular	23418359	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Mature MiR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7, and vimentin in different signal pathways
target gene	hsa-mir-17	Carcinoma, Hepatocellular	25686840	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma.
target gene	hsa-mir-181a	Carcinoma, Hepatocellular	28930552	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-181a inhibits autophagy by targeting Atg5 in hepatocellular carcinoma
target gene	hsa-mir-181b	Carcinoma, Hepatocellular	20023698	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3.
target gene	hsa-mir-182	Carcinoma, Hepatocellular	24447717	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
target gene	hsa-mir-182	Carcinoma, Hepatocellular	25663355	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA6 in hepatocellular carcinoma.
target gene	hsa-mir-184	Carcinoma, Hepatocellular	24558429	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Mir-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma.
target gene	hsa-mir-185	Carcinoma, Hepatocellular	24911372	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-185 inhibits hepatocellular carcinoma growth by targeting the DNMT1/PTEN/Akt pathway.
target gene	hsa-mir-185	Carcinoma, Hepatocellular	27643556	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our findings enlarged our knowledge about the roles of PLAC8 in HCC progression and miR-185-5p/PLAC8/β-catenin axis might be a novel pathway for HCC treatment
target gene	hsa-mir-187	Carcinoma, Hepatocellular	27544906	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4.
target gene	hsa-mir-18a	Carcinoma, Hepatocellular	19203451	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-18: target BTG2
target gene	hsa-mir-18a	Carcinoma, Hepatocellular	28399983	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-18a Promotes Cell Migration and Invasion Through Inhibiting Dicer l Expression in Hepatocellular Carcinoma In Vitro.
target gene	hsa-mir-18b	Carcinoma, Hepatocellular	19203451	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-18: target BTG2
target gene	hsa-mir-192	Carcinoma, Hepatocellular	21672525	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells.
target gene	hsa-mir-194	Carcinoma, Hepatocellular	24631529	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation.
target gene	hsa-mir-194	Carcinoma, Hepatocellular	26221053	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	NF-κB signaling relieves negative regulation by miR-194 in hepatocellular carcinoma by suppressing the transcription factor HNF-1α.
target gene	hsa-mir-194	Carcinoma, Hepatocellular	26722431	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4.
target gene	hsa-mir-195	Carcinoma, Hepatocellular	21947305	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w.
target gene	hsa-mir-195	Carcinoma, Hepatocellular	22888524	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2.
target gene	hsa-mir-195	Carcinoma, Hepatocellular	23468064	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2 and CDC42
target gene	hsa-mir-195	Carcinoma, Hepatocellular	23487264	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Genome-wide screening revealed that miR-195 targets the TNF-alpha/NF-kB pathway by downregulating IKK and TAB3 in hepatocellular carcinoma
target gene	hsa-mir-195	Carcinoma, Hepatocellular	23544130	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The Tumor-Suppressive miR-497-195 Cluster Targets Multiple Cell-Cycle Regulators in Hepatocellular Carcinoma
target gene	hsa-mir-195	Carcinoma, Hepatocellular	24740565	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells.
target gene	hsa-mir-195	Carcinoma, Hepatocellular	25119594	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span.
target gene	hsa-mir-195	Carcinoma, Hepatocellular	25174704	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-195 acts as a tumor suppressor by directly targeting Wnt3a in HepG2 hepatocellular carcinoma cells.
target gene	hsa-mir-195	Carcinoma, Hepatocellular	27574422	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
target gene	hsa-mir-195	Carcinoma, Hepatocellular	28529562	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma.
target gene	hsa-mir-198	Carcinoma, Hepatocellular	21658389	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
target gene	hsa-mir-199a	Carcinoma, Hepatocellular	25313882	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-199a regulates cell proliferation and survival by targeting FZD7.
target gene	hsa-mir-199a	Carcinoma, Hepatocellular	27599545	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Anti-invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151.
target gene	hsa-mir-199a	Carcinoma, Hepatocellular	27832779	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-199a-3p inhibits cell proliferation and induces apoptosis by targeting YAP1, suppressing Jagged1-Notch signaling in human hepatocellular carcinoma.
target gene	hsa-mir-199a	Carcinoma, Hepatocellular	28261837	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-199a-5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma.
target gene	hsa-mir-199a-1	Carcinoma, Hepatocellular	20501828	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-199a-3p:MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells
target gene	hsa-mir-199a-1	Carcinoma, Hepatocellular	21807947	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.
target gene	hsa-mir-199a-2	Carcinoma, Hepatocellular	20501828	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-199a-3p:MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells
target gene	hsa-mir-199a-2	Carcinoma, Hepatocellular	21807947	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.
target gene	hsa-mir-199b	Carcinoma, Hepatocellular	28588321	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-199b-5p attenuates TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.
target gene	hsa-mir-19a	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN.
target gene	hsa-mir-19a	Carcinoma, Hepatocellular	25985117	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma.
target gene	hsa-mir-19b	Carcinoma, Hepatocellular	26453548	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The overexpression of miR-19b was significantly correlated with better disease-free and overall survival in patients with HCC presenting with vascular invasion or multifocal disease after curative surgery. MiR-19b may influence the expression of NDRG1, EPCAM, HMGB2, HIF1A, and MAPK14.
target gene	hsa-mir-19b-1	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN.
target gene	hsa-mir-19b-2	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-19a/b activates PI3K by blocking expression of the tumor suppressor PTEN.
target gene	hsa-mir-200	Carcinoma, Hepatocellular	24895326	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-200 family members and their targets are significantly deregulated in HCC and liver cirrhosis. The miR-200 family is able to distinguish between cirrhotic and HCC tissue and could serve as an early marker for cirrhosis-associated HCC.
target gene	hsa-mir-200a	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Integration at FRA1A may silence expression of miRNA-200a, which is known to be decreased in HCC compared to nontumor [59] and [65]. Since most miRNAs suppress their target proteins, and miRNA-200a is known to regulate the expression of RAB30, a member of
target gene	hsa-mir-200a	Carcinoma, Hepatocellular	24009066	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6.
target gene	hsa-mir-200a	Carcinoma, Hepatocellular	28081727	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma.
target gene	hsa-mir-200a	Carcinoma, Hepatocellular	27542259	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a.
target gene	hsa-mir-200a	Carcinoma, Hepatocellular	28367241	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma.
target gene	hsa-mir-200a	Carcinoma, Hepatocellular	28440466	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-200a targets Gelsolin: A novel mechanism regulating secretion of microvesicles in hepatocellular carcinoma cells.
target gene	hsa-mir-200b	Carcinoma, Hepatocellular	25909223	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis.
target gene	hsa-mir-200b	Carcinoma, Hepatocellular	28695771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-200b suppresses the invasion and migration of hepatocellular carcinoma by downregulating RhoA and circRNA_000839.
target gene	hsa-mir-200b	Carcinoma, Hepatocellular	28383782	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma.
target gene	hsa-mir-200c	Carcinoma, Hepatocellular	25909223	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-200b/200c/428 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis.
target gene	hsa-mir-200c	Carcinoma, Hepatocellular	28609841	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1.
target gene	hsa-mir-202	Carcinoma, Hepatocellular	24704686	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally.
target gene	hsa-mir-203	Carcinoma, Hepatocellular	22886454	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-203 inhibits proliferation of hepatocellular carcinoma cells by targeting survivin.
target gene	hsa-mir-203	Carcinoma, Hepatocellular	28781949	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis.
target gene	hsa-mir-203a	Carcinoma, Hepatocellular	27780730	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-203a is involved in HBx-induced inflammation by targeting Rap1a.
target gene	hsa-mir-204	Carcinoma, Hepatocellular	24833879	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-204-3p acts on its potential target gene, FN1, and inhibits its expression, thus blocking the adhesion function of FN1 in promoting the growth of TECs.
target gene	hsa-mir-204	Carcinoma, Hepatocellular	27748572	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-204-5p targeting SIRT1 regulates hepatocellular carcinoma progression.
target gene	hsa-mir-205	Carcinoma, Hepatocellular	22167321	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-ж╩B activity.
target gene	hsa-mir-205	Carcinoma, Hepatocellular	26129839	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-205 regulates ubiquitin specific peptidase 7 protein expression in hepatocellular carcinoma cells.
target gene	hsa-mir-205	Carcinoma, Hepatocellular	24462768	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA.
target gene	hsa-mir-205	Carcinoma, Hepatocellular	24576478	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4.
target gene	hsa-mir-208	Carcinoma, Hepatocellular	26169693	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression.
target gene	hsa-mir-20a	Carcinoma, Hepatocellular	27748919	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-20a-5p targets RUNX3 to regulate proliferation and migration of human hepatocellular cancer cells.
target gene	hsa-mir-20a	Carcinoma, Hepatocellular	28378640	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma.
target gene	hsa-mir-20a	Carcinoma, Hepatocellular	28537677	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Targeting of miR-20a against CFLAR to potentiate TRAIL-induced apoptotic sensitivity in HepG2 cells.
target gene	hsa-mir-21	Carcinoma, Hepatocellular	22322403	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma.
target gene	hsa-mir-21	Carcinoma, Hepatocellular	24633222	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis B virus induces cell proliferation via HBx-induced microRNA-21 in hepatocellular carcinoma by targeting programmed cell death protein4 (PDCD4) and  phosphatase and tensin homologue (PTEN).
target gene	hsa-mir-21	Carcinoma, Hepatocellular	25687183	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1.
target gene	hsa-mir-21	Carcinoma, Hepatocellular	26210448	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3.
target gene	hsa-mir-21	Carcinoma, Hepatocellular	24098708	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our results demonstrate that miR-21-3p functions as a tumor suppressor by directly targeting both MAT2A and MAT2B, indicating its therapeutic potential in HCC.
target gene	hsa-mir-21	Carcinoma, Hepatocellular	27571873	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBx-induced miR-21 suppresses cell apoptosis in hepatocellular carcinoma by targeting interleukin-12.
target gene	hsa-mir-21	Carcinoma, Hepatocellular	23684551	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.
target gene	hsa-mir-21	Carcinoma, Hepatocellular	27261510	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Here, we demonstrated that TNF伪 stimulation induced transcriptional downregulation of MSH2, a member of the mismatch repair family, via NF-魏B-dependent miR-21 expression in hepatocytes.
target gene	hsa-mir-21	Carcinoma, Hepatocellular	29253196	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122 participates in the regulation of HCC cell apoptosis through modulating the miR-21-targeted programmed cell death 4 (PDCD4) signal pathway
target gene	hsa-mir-210	Carcinoma, Hepatocellular	22144109	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hypoxia-inducible MicroRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma.
target gene	hsa-mir-210	Carcinoma, Hepatocellular	27666683	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma.
target gene	hsa-mir-211	Carcinoma, Hepatocellular	25888635	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-211 suppresses hepatocellular carcinoma by downregulating SATB2.
target gene	hsa-mir-211	Carcinoma, Hepatocellular	26398845	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-211 promotes invasion of carcinoma cells by directly targeting ESR1.
target gene	hsa-mir-212	Carcinoma, Hepatocellular	23922798	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	RBP2 is overexpressed in HCC and negatively regulated by hsa-miR-212. The hsa-miR-212-RBP2-CDKI pathway may be important in the pathogenesis of HCC.
target gene	hsa-mir-212	Carcinoma, Hepatocellular	25965836	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1.
target gene	hsa-mir-214	Carcinoma, Hepatocellular	23068095	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin
target gene	hsa-mir-216a	Carcinoma, Hepatocellular	22392644	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The androgen pathway stimulates microRNA-216a transcription to suppress the TSLC1 tumor suppressor gene in early hepatocarcinogenesis.
target gene	hsa-mir-216a	Carcinoma, Hepatocellular	23471579	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer
target gene	hsa-mir-216b	Carcinoma, Hepatocellular	27474751	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines.
target gene	hsa-mir-216b	Carcinoma, Hepatocellular	27524242	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	this study firstly revealed that there is a HIF-2α-MALAT1-miR-216b axis regulating MDR of HCC cells via modulating autophagy.
target gene	hsa-mir-216b	Carcinoma, Hepatocellular	28389526	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells.
target gene	hsa-mir-217	Carcinoma, Hepatocellular	23471579	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer
target gene	hsa-mir-217	Carcinoma, Hepatocellular	24671492	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3.
target gene	hsa-mir-217	Carcinoma, Hepatocellular	28184926	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-217 suppresses proliferation, migration, and invasion promoting apoptosis via targeting MTDH in hepatocellular carcinoma.
target gene	hsa-mir-218	Carcinoma, Hepatocellular	23996750	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The low-expression of miR-218 is correlated with malignant clinicopathological characteristics of HCC, and miR-218 may inhibit cell proliferation and promote cell apoptosis by down-regulating Bmi-1 and CDK6 in HCC.
target gene	hsa-mir-218	Carcinoma, Hepatocellular	25816091	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma.
target gene	hsa-mir-219	Carcinoma, Hepatocellular	22449976	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3.
target gene	hsa-mir-221	Carcinoma, Hepatocellular	22152314	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-221 contributes to the growth of hepatocellular carcinoma cells and miR-221 inhibition can induce cell apoptosis. miR-221 has the potential to become one of the new molecular targets for liver cancer therapy.
target gene	hsa-mir-221	Carcinoma, Hepatocellular	22396537	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	SND1-induced activation of NF-kappaB resulted in induction of miR-221 and subsequent induction of angiogenic factors Angiogenin and CXCL16. Inhibition of either of these components resulted in significant inhibition of SND1-induced angiogenesis thus highlighting the importance of this molecular cascade in regulating SND1 function.
target gene	hsa-mir-221	Carcinoma, Hepatocellular	25019494	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-221 accentuates IFN׳s anti-HCV effect by downregulating SOCS1 and SOCS3.
target gene	hsa-mir-221	Carcinoma, Hepatocellular	26251599	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.
target gene	hsa-mir-221	Carcinoma, Hepatocellular	19671867	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.
target gene	hsa-mir-221	Carcinoma, Hepatocellular	28442344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway.
target gene	hsa-mir-221	Carcinoma, Hepatocellular	28539268	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-221 mediates the epithelial-mesenchymal transition of hepatocellular carcinoma by targeting AdipoR1.
target gene	hsa-mir-222	Carcinoma, Hepatocellular	24417222	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A highly sensitive target-primed rolling circle amplification (TPRCA) method for fluorescent in situ hybridization detection of microRNA in tumor cells.
target gene	hsa-mir-222	Carcinoma, Hepatocellular	26420065	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	all the four miRNAs synergistically target PBX3
target gene	hsa-mir-223	Carcinoma, Hepatocellular	21492514	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-223 and its target gene oncogene c-myc have roles in hepatocellular carcinoma pathogenesis.
target gene	hsa-mir-224	Carcinoma, Hepatocellular	18319255	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target.
target gene	hsa-mir-224	Carcinoma, Hepatocellular	23922662	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival.
target gene	hsa-mir-224	Carcinoma, Hepatocellular	24219032	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings suggest a previously undescribed regulatory pathway in which the miR-224/HOXD10/p-PAK4/MMP-9 signaling pathway contributes to the regulation of cell migration and invasion and provides a new biotarget for HCC treatment.
target gene	hsa-mir-23a	Carcinoma, Hepatocellular	22318941	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Stat3-mediated activation of miR-23a suppresses gluconeogenesis in hepatocellular carcinoma by downregulating G6PC and PGC-1ж┿
target gene	hsa-mir-23a	Carcinoma, Hepatocellular	24103454	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study sheds light on the role of miR-23a as a potential target in regulating chemosensitivity of HCC cells.
target gene	hsa-mir-23a	Carcinoma, Hepatocellular	24942805	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study reveals that miR-23a may be involved in regulating the anti-HCC effect of berberine by mediating the regulation of p53.
target gene	hsa-mir-23a	Carcinoma, Hepatocellular	27279136	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the miR-23a mimic downregulated IFN纬-induced IRF-1 protein expression, while the miR-23a inhibitor increased IRF-1.
target gene	hsa-mir-23a	Carcinoma, Hepatocellular	29176948	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The Oncogenic Role of Tribbles 1 in Hepatocellular Carcinoma Is Mediated by a Feedback Loop Involving microRNA-23a and p53
target gene	hsa-mir-23b	Carcinoma, Hepatocellular	28262617	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2.
target gene	hsa-mir-24	Carcinoma, Hepatocellular	25073511	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7.
target gene	hsa-mir-24	Carcinoma, Hepatocellular	27650047	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-24-3p enhances cell growth in hepatocellular carcinoma by targeting metallothionein 1M.
target gene	hsa-mir-24	Carcinoma, Hepatocellular	27780140	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-24 increases hepatocellular carcinoma cell metastasis and invasion by targeting p53: miR-24 targeted p53.
target gene	hsa-mir-26a	Carcinoma, Hepatocellular	24194905	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-26a modulated angiogenesis of HCC through the PIK3C2α/Akt/HIF-1α/VEGFA pathway. The expression of VEGFA was inversely correlated with miR-26a expression in HCC tumors.
target gene	hsa-mir-26a	Carcinoma, Hepatocellular	25494962	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-26a exerts growth inhibition in HCC and that its inhibitory effect is mediated briefly by blocking EZH2 expression.
target gene	hsa-mir-26a	Carcinoma, Hepatocellular	26021873	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-26a expression reduced M-CSF expression and recruitment of macrophages in hepatocellular carcinoma(HCC).
target gene	hsa-mir-26a-1	Carcinoma, Hepatocellular	23389848	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway
target gene	hsa-mir-26a-2	Carcinoma, Hepatocellular	23389848	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway
target gene	hsa-mir-26b	Carcinoma, Hepatocellular	24565101	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These data suggest that miR-26b suppresses NF-κB signaling and thereby sensitized HCC cells to the doxorubicin-induced apoptosis by inhibiting the expression of TAK1 and TAB3. Our findings highlight miR-26b as a potent inhibitor of the NF-κB pathway and an attractive target for cancer treatment.
target gene	hsa-mir-26b	Carcinoma, Hepatocellular	24890815	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X.
target gene	hsa-mir-26b	Carcinoma, Hepatocellular	26843134	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-26b Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells by Targeting EphA2.
target gene	hsa-mir-27a	Carcinoma, Hepatocellular	24018051	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-27a could function as a novel regulator to reverse MDR in hepatocellular carcinoma cells by inhibiting the FZD7/β-catenin pathway.
target gene	hsa-mir-27b	Carcinoma, Hepatocellular	27704356	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma.
target gene	hsa-mir-28	Carcinoma, Hepatocellular	26160280	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor  proliferation and migration by targeting insulin-like growth factor-1 (IGF-1).
target gene	hsa-mir-29	Carcinoma, Hepatocellular	27164857	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	SETDB1 is a target of miR-29, which is frequently downregulated in human HCCs.
target gene	hsa-mir-296	Carcinoma, Hepatocellular	27714806	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-296 inhibits proliferation and induces apoptosis by targeting FGFR1 in human hepatocellular carcinoma.
target gene	hsa-mir-29a	Carcinoma, Hepatocellular	21573166	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulated MicroRNA-29a by Hepatitis B Virus X Protein Enhances Hepatoma Cell Migration by Targeting PTEN in Cell Culture Model.
target gene	hsa-mir-29a	Carcinoma, Hepatocellular	21625215	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.
target gene	hsa-mir-29a	Carcinoma, Hepatocellular	28342862	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-29a suppresses growth and migration of hepatocellular carcinoma by regulating CLDN1.
target gene	hsa-mir-29b-1	Carcinoma, Hepatocellular	21625215	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.
target gene	hsa-mir-29b-1	Carcinoma, Hepatocellular	21793034	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression.
target gene	hsa-mir-29b-2	Carcinoma, Hepatocellular	21625215	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.
target gene	hsa-mir-29b-2	Carcinoma, Hepatocellular	21793034	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression.
target gene	hsa-mir-29c	Carcinoma, Hepatocellular	21625215	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.
target gene	hsa-mir-29c	Carcinoma, Hepatocellular	21763284	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.
target gene	hsa-mir-29c	Carcinoma, Hepatocellular	23728341	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma.
target gene	hsa-mir-29c	Carcinoma, Hepatocellular	25888625	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1.
target gene	hsa-mir-301a	Carcinoma, Hepatocellular	22373864	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-301a Is a Candidate Oncogene that Targets the Homeobox Gene Gax in Human Hepatocellular Carcinoma.
target gene	hsa-mir-302b	Carcinoma, Hepatocellular	24337067	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2.
target gene	hsa-mir-302b	Carcinoma, Hepatocellular	26457704	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This study showed that miR-302b could enhance the sensitivity to 5-FU in HCC cell lines and verified its two putative targeted genes responsible for its 5-FU sensitivity.
target gene	hsa-mir-302d	Carcinoma, Hepatocellular	28352351	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion.
target gene	hsa-mir-30a	Carcinoma, Hepatocellular	22157765	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy.
target gene	hsa-mir-30a	Carcinoma, Hepatocellular	24290372	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our data suggest that miR-30a-3p is downregulated in HCC and acts as a tumor suppressor in vitro. Regulation of vimentin, E-cadherin and MMP3 by miR-30a-3p suggests a useful therapeutic strategy for tumors with reduced miR-30a-3p expression.
target gene	hsa-mir-30a	Carcinoma, Hepatocellular	29108194	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-30a inhibits proliferation of hepatocellular carcinoma cells via targeted regulation of forkhead-box protein A1.
target gene	hsa-mir-30c-1	Carcinoma, Hepatocellular	22320217	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1.
target gene	hsa-mir-30c-2	Carcinoma, Hepatocellular	22320217	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1.
target gene	hsa-mir-30e	Carcinoma, Hepatocellular	26966067	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA.
target gene	hsa-mir-31	Carcinoma, Hepatocellular	28269758	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA31-NDRG3 regulation axes are essential for hepatocellular carcinoma survival and drug resistance.
target gene	hsa-mir-31	Carcinoma, Hepatocellular	28623129	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Increased expression of microRNA-31-5p inhibits cell proliferation, migration, and invasion via regulating Sp1 transcription factor in HepG2 hepatocellular carcinoma cell line.
target gene	hsa-mir-31	Carcinoma, Hepatocellular	29152108	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-31 suppresses the self-renewal capability of α2δ1+ liver tumor-initiating cells by targeting ISL1
target gene	hsa-mir-3117	Carcinoma, Hepatocellular	27822662	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL.
target gene	hsa-mir-3127	Carcinoma, Hepatocellular	25849943	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation.
target gene	hsa-mir-32	Carcinoma, Hepatocellular	25647261	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN.
target gene	hsa-mir-324	Carcinoma, Hepatocellular	26177288	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-324-5p Suppresses Hepatocellular Carcinoma Cell Invasion by Counteracting ECM Degradation through Post-Transcriptionally Downregulating ETS1 and SP1.
target gene	hsa-mir-325	Carcinoma, Hepatocellular	26194496	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings implied that miR-325 regulates cell invasion and proliferation via targeting HMGB1 and may be a potential prognostic marker for HCC.
target gene	hsa-mir-330	Carcinoma, Hepatocellular	28050784	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Roles of microRNA-330 and Its Target Gene ING4 in the Development of Aggressive Phenotype in Hepatocellular Carcinoma Cells.
target gene	hsa-mir-331	Carcinoma, Hepatocellular	24825302	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase.
target gene	hsa-mir-331	Carcinoma, Hepatocellular	26497554	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells,miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
target gene	hsa-mir-338	Carcinoma, Hepatocellular	21671467	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened.
target gene	hsa-mir-338	Carcinoma, Hepatocellular	25755720	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4).
target gene	hsa-mir-33b	Carcinoma, Hepatocellular	28026002	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression.
target gene	hsa-mir-340	Carcinoma, Hepatocellular	25556489	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway.
target gene	hsa-mir-340	Carcinoma, Hepatocellular	27998770	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-340 inhibits the proliferation and invasion of hepatocellular carcinoma cells by targeting JAK1.
target gene	hsa-mir-345	Carcinoma, Hepatocellular	28098858	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
target gene	hsa-mir-34a	Carcinoma, Hepatocellular	23862748	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
target gene	hsa-mir-34a	Carcinoma, Hepatocellular	25686834	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway.
target gene	hsa-mir-34a	Carcinoma, Hepatocellular	26385595	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-34a is Involved in the Decrease of ATP Contents Induced by Resistin Through Target on ATP5S in HepG2 Cells.
target gene	hsa-mir-34a	Carcinoma, Hepatocellular	28129650	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway.
target gene	hsa-mir-34a	Carcinoma, Hepatocellular	28667294	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop.
target gene	hsa-mir-34a	Carcinoma, Hepatocellular	28667334	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma.
target gene	hsa-mir-34a	Carcinoma, Hepatocellular	29298665	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results may lead researchers to understand the molecular mechanism of miR-34a in the diagnosis, prognosis and therapy of HCC
target gene	hsa-mir-34a	Carcinoma, Hepatocellular	29344126	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-34a overexpression inhibits cell migration and invasion via regulating SIRT1 in hepatocellular carcinoma
target gene	hsa-mir-34b	Carcinoma, Hepatocellular	28098861	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53.
target gene	hsa-mir-34c	Carcinoma, Hepatocellular	26722462	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS.
target gene	hsa-mir-34c	Carcinoma, Hepatocellular	27704267	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression.
target gene	hsa-mir-34c	Carcinoma, Hepatocellular	28098861	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53.
target gene	hsa-mir-361	Carcinoma, Hepatocellular	27641667	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-361-5p inhibits hepatocellular carcinoma cell proliferation and invasion by targeting VEGFA.
target gene	hsa-mir-362	Carcinoma, Hepatocellular	25649327	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulation of miR-362-3p Modulates Proliferation and Anchorage-Independent Growth by Directly Targeting Tob2 in Hepatocellular Carcinoma.
target gene	hsa-mir-363	Carcinoma, Hepatocellular	24631531	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells.
target gene	hsa-mir-3664	Carcinoma, Hepatocellular	28389526	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells.
target gene	hsa-mir-370	Carcinoma, Hepatocellular	28387905	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-370 acts as a tumor suppressor via the downregulation of PIM1 in hepatocellular carcinoma.
target gene	hsa-mir-372	Carcinoma, Hepatocellular	24552534	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The findings demonstrated that miR-372 suppressed the expression of ATAD2, which was highly expressed in HCC and exerted a proto-oncogene effect in hepatic carcinogenesis. In conclusion, ATAD2 may promote HCC progression.
target gene	hsa-mir-372	Carcinoma, Hepatocellular	25880458	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-372 may play an important role in hepatic carcinogenesis and may serve as a new target or method to detect and treat HCC in the future.
target gene	hsa-mir-373	Carcinoma, Hepatocellular	21481188	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-373 can regulate cell cycle progression by targeting PPP6C transcripts and promotes the growth activity of hepatocellular carcinoma cells in vitro. This miRNA functions as an oncogene in hepatocellular carcinoma.
target gene	hsa-mir-375	Carcinoma, Hepatocellular	22056881	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.
target gene	hsa-mir-375	Carcinoma, Hepatocellular	22504094	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-375 was down-regulated in HCC cells and tissues; it inhibited autophagy under hypoxic conditions by suppressing the conversion of LC3I to LC3II and thereby autophagic flux.
target gene	hsa-mir-376a	Carcinoma, Hepatocellular	25613642	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HDAC9 plays an important role both as effects and targets of miR-376a.
target gene	hsa-mir-377	Carcinoma, Hepatocellular	25739101	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-377 suppresses cell proliferation and invasion by inhibiting TIAM1 expression in hepatocellular carcinoma.
target gene	hsa-mir-377	Carcinoma, Hepatocellular	28081730	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-377 Downregulates Bcl-xL and Increases Apoptosis in Hepatocellular Carcinoma Cells.
target gene	hsa-mir-377	Carcinoma, Hepatocellular	27222047	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	IRX3 is a direct target of miR-377
target gene	hsa-mir-378	Carcinoma, Hepatocellular	24119742	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-378 may suppress growth characteristics of HBV-related HCC by directly targeting the IGF1R 3'-UTR and inhibiting its protein expression.
target gene	hsa-mir-379	Carcinoma, Hepatocellular	21540293	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulation of ABCC2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379.
target gene	hsa-mir-379	Carcinoma, Hepatocellular	26944318	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma.
target gene	hsa-mir-384	Carcinoma, Hepatocellular	27542674	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma.
target gene	hsa-mir-410	Carcinoma, Hepatocellular	28389526	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells.
target gene	hsa-mir-411	Carcinoma, Hepatocellular	25776495	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells.
target gene	hsa-mir-422a	Carcinoma, Hepatocellular	25251503	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis.
target gene	hsa-mir-423	Carcinoma, Hepatocellular	21890460	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-423 Promotes Cell Growth and Regulates G1/S Transition by Targeting p21Cip1/Waf1 in Hepatocellular Carcinoma
target gene	hsa-mir-423	Carcinoma, Hepatocellular	29312509	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1
target gene	hsa-mir-424	Carcinoma, Hepatocellular	25175916	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-424-5p reversed epithelial-mesenchymal transition of anchorage-independent HCC cells by directly targeting ICAT and suppressed HCC progression.
target gene	hsa-mir-429	Carcinoma, Hepatocellular	25909223	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-200b/200c/427 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis.
target gene	hsa-mir-429	Carcinoma, Hepatocellular	29403024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The newly identified miR-429-CRKL axis represents a novel potential therapeutic target for HCC treatment
target gene	hsa-mir-4417	Carcinoma, Hepatocellular	28394882	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells.
target gene	hsa-mir-448	Carcinoma, Hepatocellular	25969175	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-448 may contribute to the progression of HCC via regulating ROCK2 expression.
target gene	hsa-mir-451a	Carcinoma, Hepatocellular	23740840	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-451 Inhibits Cell Proliferation in Human Hepatocellular Carcinoma through Direct Suppression of IKK-beta
target gene	hsa-mir-452	Carcinoma, Hepatocellular	24381057	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B.
target gene	hsa-mir-455	Carcinoma, Hepatocellular	27748890	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-455 regulates migration and invasion of human hepatocellular carcinoma by targeting Runx2.
target gene	hsa-mir-485	Carcinoma, Hepatocellular	26054676	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Involvement of miR-485-5p in hepatocellular carcinoma progression targeting EMMPRIN.
target gene	hsa-mir-491	Carcinoma, Hepatocellular	25196641	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells.
target gene	hsa-mir-491	Carcinoma, Hepatocellular	27053618	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-491 inhibits the proliferation, invasion and migration of hepatocellular carcinoma cell via down-regulating TPX2 expression.
target gene	hsa-mir-494	Carcinoma, Hepatocellular	26045065	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
target gene	hsa-mir-494	Carcinoma, Hepatocellular	25820676	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors.
target gene	hsa-mir-497	Carcinoma, Hepatocellular	23544130	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The Tumor-Suppressive miR-497-195 Cluster Targets Multiple Cell-Cycle Regulators in Hepatocellular Carcinoma
target gene	hsa-mir-497	Carcinoma, Hepatocellular	24464213	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma.
target gene	hsa-mir-499a	Carcinoma, Hepatocellular	22311030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-499 (rs3746444; adenine to guanine [C-T]) .Significant differences were found in frequency and distribution of the genotypes of miRNA-499 between the HCC and the control group. Compared with miRNA-499 T/T, the odds ratio (OR) of patients with miRNA-499 C/C for developing HCC was 3.630 (95% CI: 1.545-8.532), and OR for developing HBV-related HCC was 3.133 (95% CI: 1.248-7.861).
target gene	hsa-mir-499a	Carcinoma, Hepatocellular	22664953	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
target gene	hsa-mir-499b	Carcinoma, Hepatocellular	22664953	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
target gene	hsa-mir-503	Carcinoma, Hepatocellular	24405610	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	an important role of miR-503 in inhibiting metastasis of HCC through deregulating ARHGEF19.
target gene	hsa-mir-503	Carcinoma, Hepatocellular	26163260	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1.
target gene	hsa-mir-503	Carcinoma, Hepatocellular	27840964	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5‑fluorouracil by targeting EIF4E.
target gene	hsa-mir-506	Carcinoma, Hepatocellular	25087998	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-506 suppresses the proliferation of hepatoma cells by targeting YAP mRNA.
target gene	hsa-mir-511	Carcinoma, Hepatocellular	25608840	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-511 inhibits growth and metastasis of human hepatocellular carcinoma cells by targeting PIK3R3.
target gene	hsa-mir-512-1	Carcinoma, Hepatocellular	20372864	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-512-3p:Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells
target gene	hsa-mir-512-2	Carcinoma, Hepatocellular	20372864	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-512-3p:Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells
target gene	hsa-mir-517a	Carcinoma, Hepatocellular	23142219	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2
target gene	hsa-mir-517c	Carcinoma, Hepatocellular	23142219	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2
target gene	hsa-mir-519d	Carcinoma, Hepatocellular	21524841	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703.
target gene	hsa-mir-520a	Carcinoma, Hepatocellular	25816091	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-218 and microRNA-520a inhibit cell proliferation by downregulating E2F2 in hepatocellular carcinoma.
target gene	hsa-mir-520b	Carcinoma, Hepatocellular	22319632	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1.
target gene	hsa-mir-520b	Carcinoma, Hepatocellular	25824049	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA.
target gene	hsa-mir-520e	Carcinoma, Hepatocellular	22105365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kB-inducing kinase (NIK).
target gene	hsa-mir-520g	Carcinoma, Hepatocellular	25436421	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	high miR-520g expression promotes HCC  cell mobility and EMT by targeting SMAD7, and this is correlated with reduced survival in HCC patients.
target gene	hsa-mir-539	Carcinoma, Hepatocellular	28393215	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion.
target gene	hsa-mir-542	Carcinoma, Hepatocellular	27815069	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway.
target gene	hsa-mir-550a-1	Carcinoma, Hepatocellular	23145039	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma
target gene	hsa-mir-550a-2	Carcinoma, Hepatocellular	23145039	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma
target gene	hsa-mir-550a-3	Carcinoma, Hepatocellular	23145039	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma
target gene	hsa-mir-570	Carcinoma, Hepatocellular	26084609	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma.
target gene	hsa-mir-582	Carcinoma, Hepatocellular	26002580	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3.
target gene	hsa-mir-590	Carcinoma, Hepatocellular	22684895	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-beta RII.
target gene	hsa-mir-590	Carcinoma, Hepatocellular	23803188	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-590 is an important tumorigenic factor for HCC, and its two arms can both promote tumorigenesis by regulating the expression of their target tumor suppressor gene, PDCD4 and PTEN, to promote HCC cell proliferation and survival and activate the core tumor signal pathway PI3K-AKT.
target gene	hsa-mir-590	Carcinoma, Hepatocellular	28349829	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-590-3p suppresses hepatocellular carcinoma growth by targeting TEAD1.
target gene	hsa-mir-592	Carcinoma, Hepatocellular	26722432	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-592 targets DEK oncogene and suppresses cell growth in the hepatocellular carcinoma cell line HepG2.
target gene	hsa-mir-602	Carcinoma, Hepatocellular	20364114	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma
target gene	hsa-mir-616	Carcinoma, Hepatocellular	26499912	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Based on these results, we conclude that miR-616 is a promising prognostic biomarker of HCC and targeting miR-616 may be a potential option to prevent the progression of HCC.
target gene	hsa-mir-625	Carcinoma, Hepatocellular	24632613	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma.
target gene	hsa-mir-636	Carcinoma, Hepatocellular	23306701	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma
target gene	hsa-mir-638	Carcinoma, Hepatocellular	27878280	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Loss of miR-638 promotes invasion and epithelial-mesenchymal transition by targeting SOX2 in hepatocellular carcinoma.
target gene	hsa-mir-657	Carcinoma, Hepatocellular	23175432	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-kB pathways
target gene	hsa-mir-7	Carcinoma, Hepatocellular	24370822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells.
target gene	hsa-mir-7	Carcinoma, Hepatocellular	26831666	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-7 suppressed the expression of VDAC1
target gene	hsa-mir-709	Carcinoma, Hepatocellular	25818666	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggest that miR-709 may positively regulate invasion  and metastasis of HCC through targeting GPC5.
target gene	hsa-mir-7-1	Carcinoma, Hepatocellular	22234835	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma.
target gene	hsa-mir-718	Carcinoma, Hepatocellular	28070994	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells.
target gene	hsa-mir-7-2	Carcinoma, Hepatocellular	22234835	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma.
target gene	hsa-mir-7-3	Carcinoma, Hepatocellular	22234835	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma.
target gene	hsa-mir-877	Carcinoma, Hepatocellular	25973036	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.
target gene	hsa-mir-9	Carcinoma, Hepatocellular	26125451	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-9-3p was identified as the tumour-suppressor miR targetting TAZ expression in HCC cells.
target gene	hsa-mir-9	Carcinoma, Hepatocellular	25592151	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HULC functions as an oncogene in hepatoma cells, acting mechanistically by deregulating lipid metabolism through a signaling pathway involving miR-9, PPARA, and ACSL1 that is reinforced by a feed-forward pathway involving cholesterol and  RXRA to drive HULC signaling.
target gene	hsa-mir-9	Carcinoma, Hepatocellular	29399149	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotypehepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2
target gene	hsa-mir-922	Carcinoma, Hepatocellular	28184924	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-922 regulates CYLD expression and promotes the cell proliferation of human hepatocellular carcinoma.
target gene	hsa-mir-935	Carcinoma, Hepatocellular	27697092	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-935 Promotes Liver Cancer Cell Proliferation and Migration by Targeting SOX7.
target gene	hsa-mir-940	Carcinoma, Hepatocellular	27807540	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-940 Suppresses Tumor Cell Invasion and Migration via Regulation of CXCR2 in Hepatocellular Carcinoma.
target gene	hsa-mir-96	Carcinoma, Hepatocellular	22865282	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-96, miR-129-1-3p, miR-1271, miR-1291 and miR-1303 differentially control GPC3 expression in HCC cells.
target gene	hsa-mir-96	Carcinoma, Hepatocellular	25663355	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma.
target gene	hsa-mir-98	Carcinoma, Hepatocellular	27890434	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway.
target gene	hsa-mir-98	Carcinoma, Hepatocellular	28244848	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-98-5p Inhibits Cell Proliferation and Induces Cell Apoptosis in Hepatocellular Carcinoma via Targeting IGF2BP1.
target gene	hsa-mir-99b	Carcinoma, Hepatocellular	22167321	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The authors demonstrate that miR-146a, miR-99b and miR-205, induced in HCC1937 BRCA1-expressing cells, bind and regulate TRAF2 gene. In addition, re-expression of miR-146a, miR-99b or miR-205 in HCC1937 BRCA1-null cells was sufficient to modulate NF-ж╩B activity.
target gene	hsa-mir-99b	Carcinoma, Hepatocellular	26134929	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-99b promotes metastasis of hepatocellular carcinoma through inhibition of claudin 11 expression and may serve as a prognostic marker.
target gene	hsa-mir-101	Carcinoma, Hepatocellular, HBV-Related	24788845							Downregulation of miR-101-3p by hepatitis B virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rab5a.
target gene	hsa-mir-191	Carcinoma, Hepatocellular, HBV-Related	25814782							These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC.
target gene	hsa-mir-221	Carcinoma, Hepatocellular, HBV-Related	25814782							These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC.
target gene	hsa-mir-26a	Carcinoma, Hepatocellular, HBV-Related	25814782							These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC.
target gene	hsa-mir-10b	Carcinoma, Laryngeal	25875782	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	MicroRNA-10b Triggers the Epithelial-Mesenchymal Transition (EMT) of Laryngeal Carcinoma Hep-2 Cells by Directly Targeting the E-cadherin.
target gene	hsa-mir-133a	Carcinoma, Laryngeal	27730543	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47.
target gene	hsa-mir-195	Carcinoma, Laryngeal	28791411	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	MicroRNA-195 inhibits growth and invasion of laryngeal carcinoma cells by directly targeting DCUN1D1.
target gene	hsa-mir-205	Carcinoma, Laryngeal	26281062	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	miRNA-205 might promote the proliferation of Hep-2 cells by regulating the expression of PTEN.
target gene	hsa-mir-9	Carcinoma, Laryngeal	27694005	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	Enhanced miR-9 promotes laryngocarcinoma cell survival via down-regulating PTEN.
target gene	hsa-mir-106b	Carcinoma, Lung	27797825	disease of cellular proliferation	DOID:3905	C34.90	D008175			MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.
target gene	hsa-mir-122	Carcinoma, Lung	25472877	disease of cellular proliferation	DOID:3905	C34.90	D008175			induce the expression of miR-122-regulating transcriptional factors in lung cancer cells. Collectively, OA induced cell cycle arrest in lung cancer cells through miR-122/Cyclin G1/MEF2D pathway. This finding may contribute to the understanding of the molecular mechanism of OA's anti-tumor activity.
target gene	hsa-mir-1236	Carcinoma, Lung	28631573	disease of cellular proliferation	DOID:3905	C34.90	D008175			Effects of miR-1236-3p and miR-370-5p on activation of p21 in various tumors and its inhibition on the growth of lung cancer cells.
target gene	hsa-mir-124	Carcinoma, Lung	27735038	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-124 suppresses Slug-mediated lung cancer metastasis.
target gene	hsa-mir-125a	Carcinoma, Lung	28631574	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-125a-5p plays a role as a tumor suppressor in lung carcinoma cells by directly targeting STAT3.
target gene	hsa-mir-133b	Carcinoma, Lung	28641694	disease of cellular proliferation	DOID:3905	C34.90	D008175			MiR-133b Affect the Proliferation and Drug Sensitivity in A549 Lung Cancer Stem Cells by Targeting PKM2.
target gene	hsa-mir-187	Carcinoma, Lung	27634346	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA‑187 is an independent prognostic factor in lung cancer and promotes lung cancer cell invasion via targeting of PTRF.
target gene	hsa-mir-199a	Carcinoma, Lung	28363780	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer.
target gene	hsa-mir-19a	Carcinoma, Lung	28364280	disease of cellular proliferation	DOID:3905	C34.90	D008175			Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer.
target gene	hsa-mir-19b	Carcinoma, Lung	28364280	disease of cellular proliferation	DOID:3905	C34.90	D008175			Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer.
target gene	hsa-mir-200c	Carcinoma, Lung	27666124	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1.
target gene	hsa-mir-214	Carcinoma, Lung	27494742	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-214 inhibits lung cancer progression by targeting CPD.
target gene	hsa-mir-218	Carcinoma, Lung	28192397	disease of cellular proliferation	DOID:3905	C34.90	D008175			Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling.
target gene	hsa-mir-25	Carcinoma, Lung	27797825	disease of cellular proliferation	DOID:3905	C34.90	D008175			MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.
target gene	hsa-mir-26a	Carcinoma, Lung	28237093	disease of cellular proliferation	DOID:3905	C34.90	D008175			MiR-26a enhances invasive capacity by suppressing GSK3β in human lung cancer cells.
target gene	hsa-mir-29c	Carcinoma, Lung	28345453	disease of cellular proliferation	DOID:3905	C34.90	D008175			Tumor suppressor miR-29c regulates radioresistance in lung cancer cells.
target gene	hsa-mir-302b	Carcinoma, Lung	28231299	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT2/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin
target gene	hsa-mir-31	Carcinoma, Lung	25050641	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-31 may be a suppressor that regulates an essential oncogenic pathway, the loss of which may promote lung carcinogenesis.
target gene	hsa-mir-338	Carcinoma, Lung	25374067	disease of cellular proliferation	DOID:3905	C34.90	D008175			microRNA-338-3p functions as a tumor suppressor in human non-small-cell lung carcinoma and targets Ras-related protein 14.
target gene	hsa-mir-33b	Carcinoma, Lung	27559850	disease of cellular proliferation	DOID:3905	C34.90	D008175			DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21WAF1/CIP1.
target gene	hsa-mir-34a	Carcinoma, Lung	27836543	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis.
target gene	hsa-mir-34a	Carcinoma, Lung	28231299	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT5/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin
target gene	hsa-mir-34c	Carcinoma, Lung	28231299	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-34a-5p/miR-34c-5p/miR-302b-3p-LEF1-CCND1/WNT6/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin
target gene	hsa-mir-370	Carcinoma, Lung	28631573	disease of cellular proliferation	DOID:3905	C34.90	D008175			Effects of miR-1236-3p and miR-370-5p on activation of p21 in various tumors and its inhibition on the growth of lung cancer cells.
target gene	hsa-mir-383	Carcinoma, Lung	27862077	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain-containing protein 1.
target gene	hsa-mir-451	Carcinoma, Lung	27686452	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1.
target gene	hsa-mir-490	Carcinoma, Lung	27683057	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-490 regulates lung cancer metastasis by targeting poly r(C)-binding protein 1.
target gene	hsa-mir-495	Carcinoma, Lung	28363780	disease of cellular proliferation	DOID:3905	C34.90	D008175			miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer.
target gene	hsa-mir-557	Carcinoma, Lung	28639890	disease of cellular proliferation	DOID:3905	C34.90	D008175			MiR-557 works as a tumor suppressor in human lung cancers by negatively regulating LEF1 expression.
target gene	hsa-mir-570	Carcinoma, Lung	26045791	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA-570 promotes lung carcinoma proliferation through targeting tumor suppressor KLF9.
target gene	hsa-mir-93	Carcinoma, Lung	27797825	disease of cellular proliferation	DOID:3905	C34.90	D008175			MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.
target gene	hsa-let-7	Carcinoma, Lung, Non-Small-Cell	28235063			C34.90	D002289		HP:0030358	Disturbance of the let-7/LIN28 double-negative feedback loop is associated with radio- and chemo-resistance in non-small cell lung cancer.
target gene	hsa-let-7c	Carcinoma, Lung, Non-Small-Cell	26945572			C34.90	D002289		HP:0030358	Also, let-7c directly targeted the 3'-untranslated regions of JMJD1A and EZH2.
target gene	hsa-mir-1207	Carcinoma, Lung, Non-Small-Cell	26338522			C34.90	D002289		HP:0030358	The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a  large number of genes.
target gene	hsa-mir-1228	Carcinoma, Lung, Non-Small-Cell	26338522			C34.90	D002289		HP:0030358	The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a  large number of genes.
target gene	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	27924500			C34.90	D002289		HP:0030358	miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
target gene	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	28488541			C34.90	D002289		HP:0030358	MicroRNA-124 suppresses proliferation and glycolysis in non-small cell lung cancer cells by targeting AKT-GLUT1/HKII.
target gene	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	29039564			C34.90	D002289		HP:0030358	Evaluation of microRNA-203 in bone metastasis of patients with non-small cell lung cancer through TGF-β/SMAD2 expression.
target gene	hsa-mir-1254	Carcinoma, Lung, Non-Small-Cell	28749936			C34.90	D002289		HP:0030358	MiR-1254 suppresses HO-1 expression through seed region-dependent silencing and non-seed interaction with TFAP2A transcript to attenuate NSCLC growth.
target gene	hsa-mir-125a	Carcinoma, Lung, Non-Small-Cell	20723344			C34.90	D002289		HP:0030358	hsa-miR-125a-5p could up-regulate Rock-1 and enhance invasion in lung cancer cells.
target gene	hsa-mir-125b	Carcinoma, Lung, Non-Small-Cell	28378642			C34.90	D002289		HP:0030358	Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer.
target gene	hsa-mir-125b	Carcinoma, Lung, Non-Small-Cell	28713974			C34.90	D002289		HP:0030358	miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway.
target gene	hsa-mir-1271	Carcinoma, Lung, Non-Small-Cell	28260088			C34.90	D002289		HP:0030358	Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes.
target gene	hsa-mir-1285	Carcinoma, Lung, Non-Small-Cell	28631567			C34.90	D002289		HP:0030358	MicroRNA-1285-5p influences the proliferation and metastasis of non-small-cell lung carcinoma cells via downregulating CDH1 and Smad4.
target gene	hsa-mir-1304	Carcinoma, Lung, Non-Small-Cell	27641735			C34.90	D002289		HP:0030358	MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1.
target gene	hsa-mir-132	Carcinoma, Lung, Non-Small-Cell	27735039			C34.90	D002289		HP:0030358	MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition by regulating TGFβ1/Smad2 in human non-small cell lung cancer.
target gene	hsa-mir-134	Carcinoma, Lung, Non-Small-Cell	28075475			C34.90	D002289		HP:0030358	miR-134 suppresses the migration and invasion of non‑small cell lung cancer by targeting ITGB1.
target gene	hsa-mir-135b	Carcinoma, Lung, Non-Small-Cell	27643554			C34.90	D002289		HP:0030358	miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1.
target gene	hsa-mir-137	Carcinoma, Lung, Non-Small-Cell	28239819			C34.90	D002289		HP:0030358	MiR-137 and its target TGFA modulate cell growth and tumorigenesis of non-small cell lung cancer.
target gene	hsa-mir-137	Carcinoma, Lung, Non-Small-Cell	28610956			C34.90	D002289		HP:0030358	Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C.
target gene	hsa-mir-138	Carcinoma, Lung, Non-Small-Cell	27665963			C34.90	D002289		HP:0030358	MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1.
target gene	hsa-mir-140	Carcinoma, Lung, Non-Small-Cell	29617683			C34.90	D002289		HP:0030358	MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
target gene	hsa-mir-141	Carcinoma, Lung, Non-Small-Cell	27840955			C34.90	D002289		HP:0030358	miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer.
target gene	hsa-mir-142	Carcinoma, Lung, Non-Small-Cell	28427045			C34.90	D002289		HP:0030358	MiR-142-3p Overexpression Increases Chemo-Sensitivity of NSCLC by Inhibiting HMGB1-Mediated Autophagy.
target gene	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	29541201			C34.90	D002289		HP:0030358	miR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX/BCL-2 ratio and the caspase-3 cascade
target gene	hsa-mir-146a	Carcinoma, Lung, Non-Small-Cell	28202053			C34.90	D002289		HP:0030358	Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
target gene	hsa-mir-146a	Carcinoma, Lung, Non-Small-Cell	29344219			C34.90	D002289		HP:0030358	Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2
target gene	hsa-mir-15	Carcinoma, Lung, Non-Small-Cell	28498424			C34.90	D002289		HP:0030358	MicroRNA-15b promotes proliferation and invasion of non‑small cell lung carcinoma cells by directly targeting TIMP2.
target gene	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	27811366			C34.90	D002289		HP:0030358	MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN.
target gene	hsa-mir-181a	Carcinoma, Lung, Non-Small-Cell	20145152			C34.90	D002289		HP:0030358	miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
target gene	hsa-mir-181a	Carcinoma, Lung, Non-Small-Cell	28946554			C34.90	D002289		HP:0030358	MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1.
target gene	hsa-mir-185	Carcinoma, Lung, Non-Small-Cell	27906433			C34.90	D002289		HP:0030358	MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
target gene	hsa-mir-186	Carcinoma, Lung, Non-Small-Cell	27714074			C34.90	D002289		HP:0030358	miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).
target gene	hsa-mir-186	Carcinoma, Lung, Non-Small-Cell	28317368			C34.90	D002289		HP:0030358	MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process.
target gene	hsa-mir-187	Carcinoma, Lung, Non-Small-Cell	28393200			C34.90	D002289		HP:0030358	MicroRNA-187 modulates epithelial-mesenchymal transition by targeting PTRF in non-small cell lung cancer.
target gene	hsa-mir-191	Carcinoma, Lung, Non-Small-Cell	28075452			C34.90	D002289		HP:0030358	A novel pathway in NSCLC cells: miR‑191, targeting NFIA, is induced by chronic hypoxia, and promotes cell proliferation and migration.
target gene	hsa-mir-195	Carcinoma, Lung, Non-Small-Cell	29416000			C34.90	D002289		HP:0030358	miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer
target gene	hsa-mir-196b	Carcinoma, Lung, Non-Small-Cell	26586336			C34.90	D002289		HP:0030358	homeobox A9 (HOXA9) as a target gene of miR-196b
target gene	hsa-mir-19b	Carcinoma, Lung, Non-Small-Cell	29455644			C34.90	D002289		HP:0030358	miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer
target gene	hsa-mir-200	Carcinoma, Lung, Non-Small-Cell	28405157			C34.90	D002289		HP:0030358	Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis.
target gene	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	27930974			C34.90	D002289		HP:0030358	miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
target gene	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	29557087			C34.90	D002289		HP:0030358	Anti-invasive effect of Cyclamen pseudibericum extract on A549 non-small cell lung carcinoma cells via inhibition of ZEB1 mediated by miR-200c
target gene	hsa-mir-203	Carcinoma, Lung, Non-Small-Cell	28350100			C34.90	D002289		HP:0030358	Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
target gene	hsa-mir-203	Carcinoma, Lung, Non-Small-Cell	27237033			C34.90	D002289		HP:0030358	Both miR-145 and miR-203 can directly target the 3'-untranslated region  (3'-UTR) of SMAD3
target gene	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	27279345			C34.90	D002289		HP:0030358	overexpression of miR鈥?05 suppressed the expression of Smad4
target gene	hsa-mir-20a	Carcinoma, Lung, Non-Small-Cell	29375712			C34.90	D002289		HP:0030358	MicroRNA-20a promotes proliferation and invasion by directly targeting early growth response 2 in non-small cell lung carcinoma
target gene	hsa-mir-214	Carcinoma, Lung, Non-Small-Cell	28076844			C34.90	D002289		HP:0030358	Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
target gene	hsa-mir-218	Carcinoma, Lung, Non-Small-Cell	28429357			C34.90	D002289		HP:0030358	Inhibition of pulmonary carcinoma proliferation or metastasis of miR-218 via down-regulating CDCP1 expression.
target gene	hsa-mir-219	Carcinoma, Lung, Non-Small-Cell	28714014			C34.90	D002289		HP:0030358	MicroRNA-219 is downregulated in non-small cell lung cancer and inhibits cell growth and metastasis by targeting HMGA2.
target gene	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	28392366			C34.90	D002289		HP:0030358	miRNA-221 acts as an oncogenic role by directly targeting TIMP2 in non-small-cell lung carcinoma.
target gene	hsa-mir-29a	Carcinoma, Lung, Non-Small-Cell	28521487			C34.90	D002289		HP:0030358	MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer.
target gene	hsa-mir-29c	Carcinoma, Lung, Non-Small-Cell	29512752			C34.90	D002289		HP:0030358	MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA
target gene	hsa-mir-30a	Carcinoma, Lung, Non-Small-Cell	28259977			C34.90	D002289		HP:0030358	miR-30a radiosensitizes non-small cell lung cancer by targeting ATF1 that is involved in the phosphorylation of ATM.
target gene	hsa-mir-30a	Carcinoma, Lung, Non-Small-Cell	28405690			C34.90	D002289		HP:0030358	MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines.
target gene	hsa-mir-30c	Carcinoma, Lung, Non-Small-Cell	28443468			C34.90	D002289		HP:0030358	Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction.
target gene	hsa-mir-330	Carcinoma, Lung, Non-Small-Cell	28629431			C34.90	D002289		HP:0030358	MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.
target gene	hsa-mir-33a	Carcinoma, Lung, Non-Small-Cell	27856248			C34.90	D002289		HP:0030358	MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA.
target gene	hsa-mir-3666	Carcinoma, Lung, Non-Small-Cell	27599551			C34.90	D002289		HP:0030358	MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of non-small cell lung cancer cells.
target gene	hsa-mir-367	Carcinoma, Lung, Non-Small-Cell	28000899			C34.90	D002289		HP:0030358	miR-367 promotes the proliferation and invasion of non-small cell lung cancer via targeting FBXW7.
target gene	hsa-mir-373	Carcinoma, Lung, Non-Small-Cell	29025258			C34.90	D002289		HP:0030358	MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line.
target gene	hsa-mir-375	Carcinoma, Lung, Non-Small-Cell	28098887			C34.90	D002289		HP:0030358	miRNA‑375 regulates the cell survival and apoptosis of human non‑small cell carcinoma by targeting HER2.
target gene	hsa-mir-377	Carcinoma, Lung, Non-Small-Cell	27874949			C34.90	D002289		HP:0030358	miR-377 inhibited tumorous behaviors of non-small cell lung cancer through directly targeting CDK6.
target gene	hsa-mir-379	Carcinoma, Lung, Non-Small-Cell	28117895			C34.90	D002289		HP:0030358	Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells.
target gene	hsa-mir-382	Carcinoma, Lung, Non-Small-Cell	28006750			C34.90	D002289		HP:0030358	miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer.
target gene	hsa-mir-424	Carcinoma, Lung, Non-Small-Cell	28535539			C34.90	D002289		HP:0030358	MiR-424 Promotes Non-Small Cell Lung Cancer Progression and Metastasis through Regulating the Tumor Suppressor Gene TNFAIP1.
target gene	hsa-mir-449a	Carcinoma, Lung, Non-Small-Cell	28800787			C34.90	D002289		HP:0030358	MiR-449a Suppresses LDHA-Mediated Glycolysis to Enhance the Sensitivity of Non-Small Cell Lung Cancer Cells to Ionizing Radiation.
target gene	hsa-mir-494	Carcinoma, Lung, Non-Small-Cell	23012423			C34.90	D002289		HP:0030358	MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation.
target gene	hsa-mir-509	Carcinoma, Lung, Non-Small-Cell	27894843			C34.90	D002289		HP:0030358	MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG.
target gene	hsa-mir-520a	Carcinoma, Lung, Non-Small-Cell	27748920			C34.90	D002289		HP:0030358	microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer.
target gene	hsa-mir-520e	Carcinoma, Lung, Non-Small-Cell	28242196			C34.90	D002289		HP:0030358	MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway.
target gene	hsa-mir-585	Carcinoma, Lung, Non-Small-Cell	27743168			C34.90	D002289		HP:0030358	MicroRNA-585 acts as a tumor suppressor in non-small-cell lung cancer by targeting hSMG-1.
target gene	hsa-mir-590	Carcinoma, Lung, Non-Small-Cell	27770372			C34.90	D002289		HP:0030358	microRNA-590 suppresses the tumorigenesis and invasiveness of non-small cell lung cancer cells by targeting ADAM9.
target gene	hsa-mir-592	Carcinoma, Lung, Non-Small-Cell	28004116			C34.90	D002289		HP:0030358	miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9.
target gene	hsa-mir-599	Carcinoma, Lung, Non-Small-Cell	28167280			C34.90	D002289		HP:0030358	The miR-599 promotes non-small cell lung cancer cell invasion via SATB2.
target gene	hsa-mir-630	Carcinoma, Lung, Non-Small-Cell	20145152			C34.90	D002289		HP:0030358	miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
target gene	hsa-mir-874	Carcinoma, Lung, Non-Small-Cell	28501870			C34.90	D002289		HP:0030358	Long Non-Coding RNA XLOC_008466 Functions as an Oncogene in Human Non-Small Cell Lung Cancer by Targeting miR-874.
target gene	hsa-mir-939	Carcinoma, Lung, Non-Small-Cell	26338522			C34.90	D002289		HP:0030358	The three miR-1207-5p, miR-1228* and miR-939 are the most connected miRNA that regulated a  large number of genes.
target gene	hsa-mir-96	Carcinoma, Lung, Non-Small-Cell	26893673			C34.90	D002289		HP:0030358	overexpression of miR-96 in  NSCLC cells markedly decreased SAMD9 expression and cisplatin-induced apoptosis,  and increased the cisplatin IC50
target gene	hsa-mir-98	Carcinoma, Lung, Non-Small-Cell	27938506			C34.90	D002289		HP:0030358	MicroRNA-98 Plays a Suppressive Role in Non-Small Cell Lung Cancer Through Inhibition of SALL4 Protein Expression.
target gene	hsa-mir-98	Carcinoma, Lung, Non-Small-Cell	28415380			C34.90	D002289		HP:0030358	miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers.
target gene	hsa-let-7c	Carcinoma, Lung, Non-Small-Cell	23981581			C34.90	D002289		HP:0030358	Our results suggest that let-7c,by degrading ITGB3 and MAP4K3, prevents NSCLC metastasis.
target gene	hsa-mir-101-1	Carcinoma, Lung, Non-Small-Cell	21270667			C34.90	D002289		HP:0030358	MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2.
target gene	hsa-mir-101-2	Carcinoma, Lung, Non-Small-Cell	21270667			C34.90	D002289		HP:0030358	MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2.
target gene	hsa-mir-10a	Carcinoma, Lung, Non-Small-Cell	26317552			C34.90	D002289		HP:0030358	We found that PTEN was a direct target of miR-10a in NSCLC. Also miR-10a activated the PTEN/AKT/ERK pathway. We suggest that miR-10a contributes to NSCLC by targeting PTEN.
target gene	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	25400731			C34.90	D002289		HP:0030358	miRNA-124 directly targeted and decreased SOX8 in NSCLC cell lines, suggesting smiRNA-124 may regulate NSCLC cell proliferation via decreasing SOX8 (oncogenicity of biomarker in NSCLC).
target gene	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	25749519			C34.90	D002289		HP:0030358	NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10.
target gene	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	25531908			C34.90	D002289		HP:0030358	miR-124 functions as a tumor suppressor by targeting STAT3, and that miR-124 may  potentially serve as a useful biomarker for the prognosis of NSCLC patients.
target gene	hsa-mir-1246	Carcinoma, Lung, Non-Small-Cell	26209100			C34.90	D002289		HP:0030358	These results suggested that the miR-1246 may promote cell metastasis by targeting CPEB4. Meanwhile, the level of CPEB4 could be used as a potential marker in NSCLC patients. Our findings unraveled novel functions of miR-1246 in lung cancer cells and shed light on NSCLC prognosis.
target gene	hsa-mir-1258	Carcinoma, Lung, Non-Small-Cell	22488243			C34.90	D002289		HP:0030358	The miR-1258 regulates the expression level of HPSE to influence the morbidity and metastasis of NSCLC.
target gene	hsa-mir-125a	Carcinoma, Lung, Non-Small-Cell	25998575			C34.90	D002289		HP:0030358	miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion.
target gene	hsa-mir-125b	Carcinoma, Lung, Non-Small-Cell	25668010			C34.90	D002289		HP:0030358	Kinesin-1 light chain-2 protein overexpression predicts poor survival in elderly NSCLC patients. Kinesin-1 light chain-2 acts as a proto-oncogene and a functional target of miR-125b in NSCLC cells.
target gene	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	21439283			C34.90	D002289		HP:0030358	miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5.
target gene	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	22510476			C34.90	D002289		HP:0030358	miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A.
target gene	hsa-mir-1271	Carcinoma, Lung, Non-Small-Cell	25686496			C34.90	D002289		HP:0030358	miR-1271 promotes non-small-cell lung cancer cell proliferation and invasion via targeting HOXA5.
target gene	hsa-mir-128	Carcinoma, Lung, Non-Small-Cell	25001183			C34.90	D002289		HP:0030358	microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.
target gene	hsa-mir-129	Carcinoma, Lung, Non-Small-Cell	25716201			C34.90	D002289		HP:0030358	MiR-129 regulates MMP9 to control metastasis of non-small cell lung cancer.
target gene	hsa-mir-130a	Carcinoma, Lung, Non-Small-Cell	21706050			C34.90	D002289		HP:0030358	miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222.
target gene	hsa-mir-130a	Carcinoma, Lung, Non-Small-Cell	24606471			C34.90	D002289		HP:0030358	MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
target gene	hsa-mir-132	Carcinoma, Lung, Non-Small-Cell	24158730			C34.90	D002289		HP:0030358	Hsa-miR-132 regulates apoptosis in non-small cell lung cancer independent of acetylcholinesterase.
target gene	hsa-mir-133b	Carcinoma, Lung, Non-Small-Cell	22883469			C34.90	D002289		HP:0030358	MicroRNA-133b Inhibits the Growth of Non-small Cell Lung Cancer by Targeting the Epidermal Growth Factor Receptor.
target gene	hsa-mir-137	Carcinoma, Lung, Non-Small-Cell	24243432			C34.90	D002289		HP:0030358	miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin.
target gene	hsa-mir-138	Carcinoma, Lung, Non-Small-Cell	24582749			C34.90	D002289		HP:0030358	miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via  negatively regulating G protein-coupled receptor 124.
target gene	hsa-mir-138	Carcinoma, Lung, Non-Small-Cell	25064732			C34.90	D002289		HP:0030358	Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer.
target gene	hsa-mir-140	Carcinoma, Lung, Non-Small-Cell	24039995			C34.90	D002289		HP:0030358	miR-140 suppresses tumor growth and metastasis of non-small cell lung cancer by targeting insulin-like growth factor 1 receptor.
target gene	hsa-mir-140	Carcinoma, Lung, Non-Small-Cell	24971538			C34.90	D002289		HP:0030358	Monocyte to macrophage differentiation-associated (MMD) targeted by miR-140-5p regulates tumor growth in non-small cell lung cancer.
target gene	hsa-mir-141	Carcinoma, Lung, Non-Small-Cell	24945731			C34.90	D002289		HP:0030358	MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2.
target gene	hsa-mir-142	Carcinoma, Lung, Non-Small-Cell	24558198			C34.90	D002289		HP:0030358	MiR-142-3p represses TGF-β-induced growth inhibition through repression of TGFβR1 in non-small cell lung cancer.
target gene	hsa-mir-143	Carcinoma, Lung, Non-Small-Cell	25003638			C34.90	D002289		HP:0030358	miR-143 inhibits NSCLC cell growth and metastasis by targeting Limk1.
target gene	hsa-mir-143	Carcinoma, Lung, Non-Small-Cell	24070896			C34.90	D002289		HP:0030358	Treatment with miR-143 inhibitor mimics cell proliferation and apoptosis imbalance in NSCLC, while inhibition of PKCε can reverse it. Our findings suggest that targeting PKCε overexpression in NSCLC should be beneficial for lung cancer therapy.
target gene	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	23876001			C34.90	D002289		HP:0030358	miRNA-145-regulated oncolytic HSV-1 is a promising agent for the treatment of NSCLC.
target gene	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	26238532			C34.90	D002289		HP:0030358	MicroRNA-145 inhibits migration and invasion via inhibition of fascin 1 protein expression in non-small-cell lung cancer cells.
target gene	hsa-mir-146a	Carcinoma, Lung, Non-Small-Cell	26238771			C34.90	D002289		HP:0030358	MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting insulin receptor substrate 2.
target gene	hsa-mir-148a	Carcinoma, Lung, Non-Small-Cell	23670799			C34.90	D002289		HP:0030358	MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells.
target gene	hsa-mir-148b	Carcinoma, Lung, Non-Small-Cell	25927928			C34.90	D002289		HP:0030358	miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNMT1 expression.
target gene	hsa-mir-149	Carcinoma, Lung, Non-Small-Cell	23762558			C34.90	D002289		HP:0030358	miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1.
target gene	hsa-mir-150	Carcinoma, Lung, Non-Small-Cell	24532468			C34.90	D002289		HP:0030358	Down-regulation of miR-150 induces cell proliferation inhibition and apoptosis in non-small-cell lung cancer by targeting BAK1 in vitro.
target gene	hsa-mir-152	Carcinoma, Lung, Non-Small-Cell	24780186			C34.90	D002289		HP:0030358	MicroRNA-152 targets ADAM17 to suppress NSCLC progression.
target gene	hsa-mir-15a	Carcinoma, Lung, Non-Small-Cell	25874488			C34.90	D002289		HP:0030358	MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer.
target gene	hsa-mir-16	Carcinoma, Lung, Non-Small-Cell	23954293			C34.90	D002289		HP:0030358	Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells.
target gene	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	24722426			C34.90	D002289		HP:0030358	MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.
target gene	hsa-mir-181b	Carcinoma, Lung, Non-Small-Cell	26620926			C34.90	D002289		HP:0030358	Consequently, miR-181b functions as a tumor suppressor and has an important role in proliferation, chemosensitivity to DDP and metastasis of NSCLC by targeting TGFβR1/Smad signaling pathway.
target gene	hsa-mir-182	Carcinoma, Lung, Non-Small-Cell	25012722			C34.90	D002289		HP:0030358	MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4.
target gene	hsa-mir-184	Carcinoma, Lung, Non-Small-Cell	25990966			C34.90	D002289		HP:0030358	MiR-184 as a tumor suppressor miR inhibits cell proliferation and invasion capability via targeting CDC25A and c-Myc. Low miR-184 level may predict worse prognosis in NSCLC patients.
target gene	hsa-mir-184	Carcinoma, Lung, Non-Small-Cell	24976536			C34.90	D002289		HP:0030358	Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers.
target gene	hsa-mir-186	Carcinoma, Lung, Non-Small-Cell	24894676			C34.90	D002289		HP:0030358	MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells.
target gene	hsa-mir-193a	Carcinoma, Lung, Non-Small-Cell	25833338			C34.90	D002289		HP:0030358	miR-193a-3p inhibited the metastasis of lung cancer cells by deregulating the expression of tumor-related proteins. These findings may improve the understanding of the molecular mechanisms underlying the metastatic-inhibitory effect of miR-193a-3p on lung cancer cells.
target gene	hsa-mir-195	Carcinoma, Lung, Non-Small-Cell	24486218			C34.90	D002289		HP:0030358	MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB.
target gene	hsa-mir-195	Carcinoma, Lung, Non-Small-Cell	24874051			C34.90	D002289		HP:0030358	MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R.
target gene	hsa-mir-195	Carcinoma, Lung, Non-Small-Cell	24891187			C34.90	D002289		HP:0030358	MiR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells.
target gene	hsa-mir-195	Carcinoma, Lung, Non-Small-Cell	25840419			C34.90	D002289		HP:0030358	MiR-195 suppresses non-small cell lung cancer by targeting CHEK1.
target gene	hsa-mir-196a-1	Carcinoma, Lung, Non-Small-Cell	22876840			C34.90	D002289		HP:0030358	MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.
target gene	hsa-mir-196a-2	Carcinoma, Lung, Non-Small-Cell	22876840			C34.90	D002289		HP:0030358	MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.
target gene	hsa-mir-200b	Carcinoma, Lung, Non-Small-Cell	21993663			C34.90	D002289		HP:0030358	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
target gene	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	21993663			C34.90	D002289		HP:0030358	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
target gene	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	24205206			C34.90	D002289		HP:0030358	MiR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway.
target gene	hsa-mir-204	Carcinoma, Lung, Non-Small-Cell	25157435			C34.90	D002289		HP:0030358	miR-204 functions as a tumor suppressor by regulating SIX1 in NSCLC.
target gene	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	23856247			C34.90	D002289		HP:0030358	miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.
target gene	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	24084898			C34.90	D002289		HP:0030358	miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN.
target gene	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	22956424			C34.90	D002289		HP:0030358	MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN.
target gene	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	24331411			C34.90	D002289		HP:0030358	miR-21 is involved in acquired resistance of EGFR-TKI in NSCLC, which is mediated by down-regulating PTEN and PDCD4 and activating PI3K/Akt pathway.
target gene	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	25058005			C34.90	D002289		HP:0030358	Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
target gene	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	25990966			C34.90	D002289		HP:0030358	MiR-184 as a tumor suppressor miR inhibits cell proliferation and invasion capability via targeting CDC25A and c-Myc. Low miR-184 level may predict worse prognosis in NSCLC patients.
target gene	hsa-mir-212	Carcinoma, Lung, Non-Small-Cell	20388802			C34.90	D002289		HP:0030358	miR-212:miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED
target gene	hsa-mir-212	Carcinoma, Lung, Non-Small-Cell	22357618			C34.90	D002289		HP:0030358	MiR-212 displays Tumor Promoting properties in NSCLC Cells and targets the Hedgehog Pathway Receptor PTCH1.
target gene	hsa-mir-212	Carcinoma, Lung, Non-Small-Cell	23974008			C34.90	D002289		HP:0030358	Synaptic acetylcholinesterase targeted by microRNA-212 functions as a tumor suppressor in non-small cell lung cancer.
target gene	hsa-mir-214	Carcinoma, Lung, Non-Small-Cell	22929890			C34.90	D002289		HP:0030358	miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence.
target gene	hsa-mir-214	Carcinoma, Lung, Non-Small-Cell	23929716			C34.90	D002289		HP:0030358	miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.
target gene	hsa-mir-218	Carcinoma, Lung, Non-Small-Cell	24247270			C34.90	D002289		HP:0030358	MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer.
target gene	hsa-mir-218-1	Carcinoma, Lung, Non-Small-Cell	21159652			C34.90	D002289		HP:0030358	Paxillin Predicts Survival and Relapse in Non-Small Cell Lung Cancer by MicroRNA-218 Targeting.
target gene	hsa-mir-218-2	Carcinoma, Lung, Non-Small-Cell	21159652			C34.90	D002289		HP:0030358	Paxillin Predicts Survival and Relapse in Non-Small Cell Lung Cancer by MicroRNA-218 Targeting.
target gene	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	21706050			C34.90	D002289		HP:0030358	miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222.
target gene	hsa-mir-222	Carcinoma, Lung, Non-Small-Cell	21706050			C34.90	D002289		HP:0030358	miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222.
target gene	hsa-mir-24	Carcinoma, Lung, Non-Small-Cell	25725584			C34.90	D002289		HP:0030358	Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer.
target gene	hsa-mir-25	Carcinoma, Lung, Non-Small-Cell	25576360			C34.90	D002289		HP:0030358	miR-25-BTG2 axis could directly regulated BTG2 expression and affect radiotherapy sensitivity of NSCLC cells.
target gene	hsa-mir-26b	Carcinoma, Lung, Non-Small-Cell	26827826			C34.90	D002289		HP:0030358	MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways.
target gene	hsa-mir-27b	Carcinoma, Lung, Non-Small-Cell	24390089			C34.90	D002289		HP:0030358	MiR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells.
target gene	hsa-mir-27b	Carcinoma, Lung, Non-Small-Cell	25012245			C34.90	D002289		HP:0030358	MicroRNA-27b suppresses growth and invasion of NSCLC cells by targeting Sp1.
target gene	hsa-mir-29b-1	Carcinoma, Lung, Non-Small-Cell	22290228			C34.90	D002289		HP:0030358	miR-29b is an upstream molecule of PTEN. miR-29b regulates PTEN gene expression through downregulating Dnmts expression and subsequently induces hypomethylation in PTEN promoter.
target gene	hsa-mir-29b-2	Carcinoma, Lung, Non-Small-Cell	22290228			C34.90	D002289		HP:0030358	miR-29b is an upstream molecule of PTEN. miR-29b regulates PTEN gene expression through downregulating Dnmts expression and subsequently induces hypomethylation in PTEN promoter.
target gene	hsa-mir-30a	Carcinoma, Lung, Non-Small-Cell	23758992			C34.90	D002289		HP:0030358	BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification.
target gene	hsa-mir-30c	Carcinoma, Lung, Non-Small-Cell	23988701			C34.90	D002289		HP:0030358	Down-regulation of miR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1.
target gene	hsa-mir-30d	Carcinoma, Lung, Non-Small-Cell	25843294			C34.90	D002289		HP:0030358	MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer.
target gene	hsa-mir-31	Carcinoma, Lung, Non-Small-Cell	24099915			C34.90	D002289		HP:0030358	The data demonstrate that miR-31 exerts an anti-apoptotic effect most likely through the inhibition of ABCB9 and thus provide a novel strategy involving the use of miR-31 as a potential target in NSCLC chemotherapy.
target gene	hsa-mir-325	Carcinoma, Lung, Non-Small-Cell	25776482			C34.90	D002289		HP:0030358	Expression of MicroRNA-325-3p and its potential functions by targeting HMGB1 in non-small cell lung cancer.
target gene	hsa-mir-330	Carcinoma, Lung, Non-Small-Cell	25935837			C34.90	D002289		HP:0030358	miR-330-3p controls cell proliferation by targeting early growth response 2 in non-small-cell lung cancer.
target gene	hsa-mir-337	Carcinoma, Lung, Non-Small-Cell	22723956			C34.90	D002289		HP:0030358	miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.
target gene	hsa-mir-342	Carcinoma, Lung, Non-Small-Cell	25663460			C34.90	D002289		HP:0030358	miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells.
target gene	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	23902763			C34.90	D002289		HP:0030358	Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.
target gene	hsa-mir-34c	Carcinoma, Lung, Non-Small-Cell	22370637			C34.90	D002289		HP:0030358	The authors found a number of miRNAs (miR-17, miR-135, miR-520, miR-124-1, and miR-34c) that may rescue cell viability from caspase-8 activation. miR-34c-5p markedly increased resistance to paclitaxel-induced apoptosis. We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation.
target gene	hsa-mir-34c	Carcinoma, Lung, Non-Small-Cell	26250586			C34.90	D002289		HP:0030358	miR-34c-3p directly targeted eIF4E and reduced miR-34c-3p expression in NSCLC, promoting cell cycle progression, proliferation, migration and invasion.
target gene	hsa-mir-370	Carcinoma, Lung, Non-Small-Cell	25976502			C34.90	D002289		HP:0030358	MicroRNA-370 inhibits the progression of non-small cell lung cancer by downregulating oncogene TRAF4.
target gene	hsa-mir-373	Carcinoma, Lung, Non-Small-Cell	25063738			C34.90	D002289		HP:0030358	miR-373 is silenced by histone modification in lung cancer cells and identified its function as a tumor suppressor and negative regulator of the mesenchymal phenotype through downstream IRAK2 and LAMP1 target genes.
target gene	hsa-mir-375	Carcinoma, Lung, Non-Small-Cell	25001509			C34.90	D002289		HP:0030358	CLDN1 is a novel target of miR-375, and high miR-375 expression shortens survival in NSCLC.
target gene	hsa-mir-429	Carcinoma, Lung, Non-Small-Cell	21993663			C34.90	D002289		HP:0030358	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
target gene	hsa-mir-429	Carcinoma, Lung, Non-Small-Cell	24866238			C34.90	D002289		HP:0030358	MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes.
target gene	hsa-mir-451a	Carcinoma, Lung, Non-Small-Cell	21358675			C34.90	D002289		HP:0030358	MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14).
target gene	hsa-mir-4782	Carcinoma, Lung, Non-Small-Cell	24556800			C34.90	D002289		HP:0030358	High expression of miR-4782-3p was associated with favorable prognosis in NSCLC patients. MiR-4782-3p inhibited cell proliferation in NSCLC by targeting USP14, ZEB2 and XIAP.
target gene	hsa-mir-489	Carcinoma, Lung, Non-Small-Cell	25833694			C34.90	D002289		HP:0030358	Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.
target gene	hsa-mir-495	Carcinoma, Lung, Non-Small-Cell	24293376			C34.90	D002289		HP:0030358	MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3.
target gene	hsa-mir-497	Carcinoma, Lung, Non-Small-Cell	23673296			C34.90	D002289		HP:0030358	Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer.
target gene	hsa-mir-503	Carcinoma, Lung, Non-Small-Cell	23856992			C34.90	D002289		HP:0030358	miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
target gene	hsa-mir-503	Carcinoma, Lung, Non-Small-Cell	24486548			C34.90	D002289		HP:0030358	Epigenetic silencing of MicroRNA-503 regulates FANCA expression in non-small cell lung cancer cell.
target gene	hsa-mir-503	Carcinoma, Lung, Non-Small-Cell	24550137			C34.90	D002289		HP:0030358	MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.
target gene	hsa-mir-512	Carcinoma, Lung, Non-Small-Cell	26648284			C34.90	D002289		HP:0030358	In conclusion, our present study revealed miR-512-5p was able to target p21 to induce apoptosis and inhibit glycolysis in A549 and H1299 cell lines.
target gene	hsa-mir-575	Carcinoma, Lung, Non-Small-Cell	25728273			C34.90	D002289		HP:0030358	MicroRNA-575 targets BLID to promote growth and invasion of non-small cell lung cancer cells.
target gene	hsa-mir-7	Carcinoma, Lung, Non-Small-Cell	24281003			C34.90	D002289		HP:0030358	All these findings strongly imply that the overexpression of PA28gamma resulted from miR-7 downexpression in NSCLC has an important role in promoting cancer cell progress and consequently results in NSCLC growth. Thus, strategies targeting PA28gamma and/or miR-7 may become promising molecular therapies in NSCLC treatment.
target gene	hsa-mir-7	Carcinoma, Lung, Non-Small-Cell	26464649			C34.90	D002289		HP:0030358	This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells.
target gene	hsa-mir-7-1	Carcinoma, Lung, Non-Small-Cell	21750649			C34.90	D002289		HP:0030358	MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2.
target gene	hsa-mir-7-2	Carcinoma, Lung, Non-Small-Cell	21750649			C34.90	D002289		HP:0030358	MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2.
target gene	hsa-mir-7-3	Carcinoma, Lung, Non-Small-Cell	21750649			C34.90	D002289		HP:0030358	MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2.
target gene	hsa-mir-761	Carcinoma, Lung, Non-Small-Cell	26278569			C34.90	D002289		HP:0030358	miR-761 promotes progression and metastasis of NSCLC by targeting ING4 and TIMP2.
target gene	hsa-mir-92b	Carcinoma, Lung, Non-Small-Cell	24162673			C34.90	D002289		HP:0030358	Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK.
target gene	hsa-mir-95	Carcinoma, Lung, Non-Small-Cell	24835695			C34.90	D002289		HP:0030358	MiR-95 induces proliferation and chemo- or radioresistance through directly targeting sorting nexin1 (SNX1) in non-small cell lung cancer.
target gene	hsa-mir-98	Carcinoma, Lung, Non-Small-Cell	21880462			C34.90	D002289		HP:0030358	miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway.
target gene	hsa-mir-98	Carcinoma, Lung, Non-Small-Cell	24712372			C34.90	D002289		HP:0030358	EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells.
target gene	hsa-mir-125a	Carcinoma, Lung, Small-Cell	25833836			C34.90	D055752	182280	HP:0030357	Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
target gene	hsa-mir-138	Carcinoma, Lung, Small-Cell	25699650			C34.90	D055752	182280	HP:0030357	MicroRNA-138 Regulates DNA Damage Response in Small Cell Lung Cancer Cells by Directly Targeting H2AX.
target gene	hsa-mir-181a	Carcinoma, Lung, Small-Cell	28535543			C34.90	D055752	182280	HP:0030357	MicroRNA-181a-5p Impedes IL-17-Induced Nonsmall Cell Lung Cancer Proliferation and Migration through Targeting VCAM-1.
target gene	hsa-mir-24	Carcinoma, Lung, Small-Cell	25426560			C34.90	D055752	182280	HP:0030357	miR-24-3p regulates autophagy by targeting ATG4A. Inhibition of autophagy by increasing miR-24-3p could be the basis of a strategy to prevent and treat SCLC with combination chemotherapy, particularly in chemoresistant disease.
target gene	hsa-mir-335	Carcinoma, Lung, Small-Cell	23966614			C34.90	D055752	182280	HP:0030357	miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways.
target gene	hsa-mir-335	Carcinoma, Lung, Small-Cell	27871924			C34.90	D055752	182280	HP:0030357	MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1.
target gene	hsa-mir-335	Carcinoma, Lung, Small-Cell	27336605			C34.90	D055752	182280	HP:0030357	miR-335 negatively regulated the MDR of WBP5 by targeting its 3'UTR
target gene	hsa-mir-495	Carcinoma, Lung, Small-Cell	28302484			C34.90	D055752	182280	HP:0030357	TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.
target gene	hsa-mir-203	Carcinoma, Merkel Cell	23962809	disease of cellular proliferation	DOID:3965	C4A.9	D015266		HP:0030447	Functionally, overexpression of miR-203 was found to inhibit cell growth, induce cell cycle arrest, and regulate survivin expression in MCV- MCC cells, but not in MCV+ MCC cells.  bovine
target gene	hsa-let-7	Carcinoma, Nasopharyngeal	26125802	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	The let-7 and miR-29 families may be related to the development of NPC by regulating the genes involved in cell cycle and ECM-receptor interaction.
target gene	hsa-mir-1	Carcinoma, Nasopharyngeal	26852690	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K-ras in nasopharyngeal carcinoma.
target gene	hsa-mir-10b	Carcinoma, Nasopharyngeal	25597482	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	hsa-mir-10b gene regulation through LMP1/Twist1 in NPC malignancy.
target gene	hsa-mir-124	Carcinoma, Nasopharyngeal	25098939	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our results demonstrate that miR-124 functions as a tumor-suppressive microRNA in NPC, and that its suppressive effects are mediated  chiefly by repressing Foxq1 expression. MiR-124 could serve as an independent biomarker to identify patients with different clinical characteristics.Therefore, our findings provide valuable clues toward the understanding the of mechanisms of NPC pathogenesis and provide an opportunity to develop new effective clinical therapies in the future.
target gene	hsa-mir-124	Carcinoma, Nasopharyngeal	28579809	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-124 suppresses proliferation and invasion of nasopharyngeal carcinoma cells through the Wnt/β-catenin signaling pathway by targeting Capn4.
target gene	hsa-mir-125b	Carcinoma, Nasopharyngeal	28260044	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2.
target gene	hsa-mir-125b	Carcinoma, Nasopharyngeal	28569771	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-125b regulates proliferation and apoptosis of nasopharyngeal carcinoma by targeting A20/NF-κB signaling pathway.
target gene	hsa-mir-125b	Carcinoma, Nasopharyngeal	28698199	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-125b Increases Nasopharyngeal Carcinoma Radioresistance by Targeting A20/NF-κB Signaling Pathway.
target gene	hsa-mir-138	Carcinoma, Nasopharyngeal	28075468	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1.
target gene	hsa-mir-143	Carcinoma, Nasopharyngeal	23895853	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-143 can inhibit the invasion of NPC cells by negative regulation of GLI3 gene, which sheds light on the role of miR-143 and Hh pathway in NPC.
target gene	hsa-mir-152	Carcinoma, Nasopharyngeal	28000885	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA‑152 inhibits cell proliferation, migration and invasion by directly targeting MAFB in nasopharyngeal carcinoma.
target gene	hsa-mir-155	Carcinoma, Nasopharyngeal	26698246	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	This study found that aberrant miR-155 expression driven by LMP1 can modulate radio-sensitivity of the NPC cell at least partly through targeting UBQLN1.
target gene	hsa-mir-15a	Carcinoma, Nasopharyngeal	24016566	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	inhibit the proliferation of CNE-2Z cells, promote apoptosis and enhance the sensitivity of the cells to radiotherapy probably by inhibiting bcl-2 expression, activating Caspase-2 and Caspase-3.
target gene	hsa-mir-15a	Carcinoma, Nasopharyngeal	25405832	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-15a/16-1 could inhibit cell proliferation and increase the apoptosis and radiosensitivity of CNE-2 cells, by regulating the bcl-2 gene at post-transcriptional level and by increasing the activation of caspase-2 and caspase-3.
target gene	hsa-mir-15a	Carcinoma, Nasopharyngeal	19144710	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	We found that the tumor suppressor BRCA-1 is a target of miR-15a as well as miR-16, suggesting a miRNA role in NPC pathogenesis.
target gene	hsa-mir-16	Carcinoma, Nasopharyngeal	25405832	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-15a/16-1 could inhibit cell proliferation and increase the apoptosis and radiosensitivity of CNE-2 cells, by regulating the bcl-2 gene at post-transcriptional level and by increasing the activation of caspase-2 and caspase-3.
target gene	hsa-mir-16-1	Carcinoma, Nasopharyngeal	24016566	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	inhibit the proliferation of CNE-2Z cells, promote apoptosis and enhance the sensitivity of the cells to radiotherapy probably by inhibiting bcl-2 expression, activating Caspase-2 and Caspase-3.
target gene	hsa-mir-185	Carcinoma, Nasopharyngeal	25297925	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-185-3p regulates nasopharyngeal carcinoma radioresistance by targeting WNT2B in vitro.
target gene	hsa-mir-185	Carcinoma, Nasopharyngeal	26390174	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Combined low miR-185-3p and miR-324-3p might be important markers for prediction of low response to RT/CRT and poor overall survival and recurrence-free survival.MiR-185-3p and miR-324-3p can modulate NPC cell growth and apoptosis, at least partly through targeting SMAD7.
target gene	hsa-mir-200a	Carcinoma, Nasopharyngeal	24190575	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Furthermore, overexpression of EBNA1 inhibited the expression of microRNA 200a (miR-200a) and miR-200b and, in turn, up-regulated expression of their target genes, zinc finger E-box binding homeobox 1 ( ZEB1) and ZEB2, which are well known mediators of EMT.
target gene	hsa-mir-200b	Carcinoma, Nasopharyngeal	24190575	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Furthermore, overexpression of EBNA1 inhibited the expression of microRNA 200a (miR-200a) and miR-200b and, in turn, up-regulated expression of their target genes, zinc finger E-box binding homeobox 1 ( ZEB1) and ZEB2, which are well known mediators of EMT.
target gene	hsa-mir-200c	Carcinoma, Nasopharyngeal	28459373	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA-200c plays an oncogenic role in nasopharyngeal carcinoma by targeting PTEN.
target gene	hsa-mir-203	Carcinoma, Nasopharyngeal	26304234	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling.
target gene	hsa-mir-205	Carcinoma, Nasopharyngeal	23564023	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our research group established the radioresistant NPC cell line CNE2R derived from the CNE2 cell line, and demonstrated that irradiation-induced miR-205 determined the resistance of NPC through directly targeting PTEN.
target gene	hsa-mir-21	Carcinoma, Nasopharyngeal	24194922	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Epstein-Barr Virus_Encoded LMP1 upregulates microRNA-21 to promote the resistance of nasopharyngeal carcinoma cells to cisplatin-induced Apoptosis by suppressing PDCD4 and Fas-L.
target gene	hsa-mir-21	Carcinoma, Nasopharyngeal	25365510	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Activation of miR-21 by STAT3 induces proliferation and suppresses apoptosis in nasopharyngeal carcinoma by targeting PTEN gene.
target gene	hsa-mir-216b	Carcinoma, Nasopharyngeal	24332049	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-216b suppresses cell proliferation and invasion by targeting PKCα in nasopharyngeal carcinoma cells
target gene	hsa-mir-222	Carcinoma, Nasopharyngeal	29115464	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	microRNA-222 promotes tumor growth and confers radioresistance in nasopharyngeal carcinoma by targeting PTEN.
target gene	hsa-mir-223	Carcinoma, Nasopharyngeal	26055874	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-223 negatively regulates the growth and migration of NPC cells via reducing MAFB expression, and this finding provides a novel insight into understanding miR-223 regulation mechanism in nasopharyngeal carcinoma tumorigenesis.
target gene	hsa-mir-23a	Carcinoma, Nasopharyngeal	26314966	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathway.
target gene	hsa-mir-23a	Carcinoma, Nasopharyngeal	29520105	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10
target gene	hsa-mir-24	Carcinoma, Nasopharyngeal	27538493	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma.
target gene	hsa-mir-27a	Carcinoma, Nasopharyngeal	28393229	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Dysregulated miR-27a-3p promotes nasopharyngeal carcinoma cell proliferation and migration by targeting Mapk10.
target gene	hsa-mir-29	Carcinoma, Nasopharyngeal	26125802	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	The let-7 and miR-29 families may be related to the development of NPC by regulating the genes involved in cell cycle and ECM-receptor interaction.
target gene	hsa-mir-29a	Carcinoma, Nasopharyngeal	25786138	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression.
target gene	hsa-mir-29b	Carcinoma, Nasopharyngeal	25786138	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression.
target gene	hsa-mir-30a	Carcinoma, Nasopharyngeal	27656832	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	IGF-I Induces Epithelial-to-Mesenchymal Transition via the IGF-IR-Src-MicroRNA-30a-E-Cadherin Pathway in Nasopharyngeal Carcinoma Cells.
target gene	hsa-mir-3188	Carcinoma, Nasopharyngeal	27095304	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN.
target gene	hsa-mir-320a	Carcinoma, Nasopharyngeal	25171860	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA-320a inhibits cell proliferation, migration and invasion by targeting BMI-1 in nasopharyngeal carcinoma.
target gene	hsa-mir-324	Carcinoma, Nasopharyngeal	26390174	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Combined low miR-185-3p and miR-324-3p might be important markers for prediction of low response to RT/CRT and poor overall survival and recurrence-free survival.MiR-185-3p and miR-324-3p can modulate NPC cell growth and apoptosis, at least partly through targeting SMAD7.
target gene	hsa-mir-338	Carcinoma, Nasopharyngeal	26260688	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA-338 inhibits migration and proliferation by targeting hypoxia-induced factor 1α in nasopharyngeal carcinoma.
target gene	hsa-mir-374a	Carcinoma, Nasopharyngeal	27270423	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-374a direct targeting of CCND1 is modulated by tumor suppressor PDCD4 via suppressing pPI3K/pAKT/c-JUN signaling.
target gene	hsa-mir-378	Carcinoma, Nasopharyngeal	24481647	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA-378 functions as an onco-miR in nasopharyngeal carcinoma by repressing TOB2 expression.
target gene	hsa-mir-451	Carcinoma, Nasopharyngeal	25201065	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-451 increases radiosensitivity of nasopharyngeal carcinoma cells by targeting ras-related protein 14 (RAB14).
target gene	hsa-mir-4649	Carcinoma, Nasopharyngeal	26081980	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA-4649-3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells.
target gene	hsa-mir-506	Carcinoma, Nasopharyngeal	25856555	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MiR-506 suppresses tumor proliferation and invasion by targeting FOXQ1 in nasopharyngeal carcinoma.
target gene	hsa-mir-519	Carcinoma, Nasopharyngeal	28315691	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP.
target gene	hsa-mir-9	Carcinoma, Nasopharyngeal	24170200	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-9 targets CXCR4 and functions as a potential tumor suppressor in nasopharyngeal carcinoma.
target gene	hsa-mir-9	Carcinoma, Nasopharyngeal	25891118	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	These data demonstrated that miR-9 did not modulate the sensitivity of the CNE2 cells to UV radiation through E-cadherin, but suggested that miR-9 regulated radiosensitivity through its effects on glutathione. These findings suggest that miR-9 may be a potential target for modulating the radiosensitivity of NPC cells.
target gene	hsa-mir-93	Carcinoma, Nasopharyngeal	25892549	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting disabled homolog-2.
target gene	hsa-mir-940	Carcinoma, Nasopharyngeal	25118937	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Depletion of intermediate filament protein Nestin, a target of microRNA-940, suppresses tumorigenesis by inducing spontaneous DNA damage accumulation in human nasopharyngeal carcinoma.
target gene	hsa-mir-125b-1	Carcinoma, Oral	23230394	gastrointestinal system disease	DOID:0050610					Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins
target gene	hsa-mir-125b-2	Carcinoma, Oral	23230394	gastrointestinal system disease	DOID:0050610					Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins
target gene	hsa-mir-126	Carcinoma, Oral	22836510	gastrointestinal system disease	DOID:0050610					Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer.
target gene	hsa-mir-146a	Carcinoma, Oral	24302991	gastrointestinal system disease	DOID:0050610					miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes.
target gene	hsa-mir-203	Carcinoma, Oral	23230394	gastrointestinal system disease	DOID:0050610					Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins
target gene	hsa-mir-205	Carcinoma, Oral	23212344	gastrointestinal system disease	DOID:0050610					MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells
target gene	hsa-mir-205	Carcinoma, Oral	24166197	gastrointestinal system disease	DOID:0050610					MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell.
target gene	hsa-mir-21	Carcinoma, Oral	23230394	gastrointestinal system disease	DOID:0050610					Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins
target gene	hsa-mir-214	Carcinoma, Oral	28290615	gastrointestinal system disease	DOID:0050610					MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5.
target gene	hsa-mir-31	Carcinoma, Oral	22854067	gastrointestinal system disease	DOID:0050610					Passenger strand miRNA miR-31* regulates the phenotypes of oral cancer cells by targeting RhoA.
target gene	hsa-mir-34a	Carcinoma, Oral	27612478	gastrointestinal system disease	DOID:0050610					miR5423p and miR34a targets the CD44v6-Nanog-PTEN axis, thus playing a vital role in regulating the CSC properties
target gene	hsa-mir-370	Carcinoma, Oral	23231387	gastrointestinal system disease	DOID:0050610					miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma
target gene	hsa-mir-542	Carcinoma, Oral	27612478	gastrointestinal system disease	DOID:0050610					miR5423p and miR34a targets the CD44v6-Nanog-PTEN axis, thus playing a vital role in regulating the CSC properties
target gene	hsa-mir-596	Carcinoma, Oral	23233740	gastrointestinal system disease	DOID:0050610					Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer
target gene	hsa-let-7a	Carcinoma, Ovarian	25630839	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA let-7a modifies the effect of self-renewal gene HIWI on patient survival of epithelial ovarian cancer.
target gene	hsa-let-7e	Carcinoma, Ovarian	28376831	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
target gene	hsa-mir-101	Carcinoma, Ovarian	25260883	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer.
target gene	hsa-mir-101	Carcinoma, Ovarian	24677166	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.
target gene	hsa-mir-127	Carcinoma, Ovarian	27571744	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA-127-3p acts as a tumor suppressor in epithelial ovarian cancer by regulating the BAG5 gene.
target gene	hsa-mir-1307	Carcinoma, Ovarian	28086946	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
target gene	hsa-mir-133b	Carcinoma, Ovarian	27802259	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Down-Regulation of MicroRNA-133b Suppresses Apoptosis of Lens Epithelial Cell by Up-Regulating BCL2L2 in Age-Related Cataracts.
target gene	hsa-mir-134	Carcinoma, Ovarian	28043921	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A.
target gene	hsa-mir-135a	Carcinoma, Ovarian	24607788	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
target gene	hsa-mir-136	Carcinoma, Ovarian	27887917	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
target gene	hsa-mir-137	Carcinoma, Ovarian	27875524	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.
target gene	hsa-mir-141	Carcinoma, Ovarian	28095864	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis.
target gene	hsa-mir-145	Carcinoma, Ovarian	25333261	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma.
target gene	hsa-mir-145	Carcinoma, Ovarian	25444913	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-145 functions as a tumor suppressor in ovarian cancer and directly targets HMGA2 oncoprotein. Low miR-145 and high HMGA2 expressions are potential biomarkers of poor prognosis of ovarian carcinoma and miR-145 is the more powerful predictor of patient outcome.
target gene	hsa-mir-145	Carcinoma, Ovarian	25937243	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Quercetin induces the apoptosis of human ovarian carcinoma cells by upregulating the expression of microRNA-145.
target gene	hsa-mir-150	Carcinoma, Ovarian	25090005	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1.
target gene	hsa-mir-200	Carcinoma, Ovarian	24512620	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients.A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped.
target gene	hsa-mir-200	Carcinoma, Ovarian	26025631	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
target gene	hsa-mir-206	Carcinoma, Ovarian	29291022	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells
target gene	hsa-mir-21	Carcinoma, Ovarian	25845681	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2.
target gene	hsa-mir-214	Carcinoma, Ovarian	24033540	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer.
target gene	hsa-mir-224	Carcinoma, Ovarian	27663866	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN.
target gene	hsa-mir-23a	Carcinoma, Ovarian	27537390	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-23a promotes IKKα expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
target gene	hsa-mir-26b	Carcinoma, Ovarian	26204489	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4.
target gene	hsa-mir-489	Carcinoma, Ovarian	24686007	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
target gene	hsa-mir-494	Carcinoma, Ovarian	27983981	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	CUL4A functions as an oncogene in ovarian cancer and is directly regulated by miR-494.
target gene	hsa-mir-506	Carcinoma, Ovarian	25230372	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.
target gene	hsa-mir-509	Carcinoma, Ovarian	24512620	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients.A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped.
target gene	hsa-mir-509-3	Carcinoma, Ovarian	24512620	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients.A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped.
target gene	hsa-mir-551b	Carcinoma, Ovarian	27743201	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer.
target gene	hsa-mir-572	Carcinoma, Ovarian	25893382	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.
target gene	hsa-mir-7	Carcinoma, Ovarian	25862909	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	There is a link between miR-7 expression and TP53 status and tumour grade in serous OC. Molecular mechanisms of these relationships need to be elucidated. Of the two postulated miR-7 target genes we examined, BCL2, but not EGFR, seems to be a possible miR-7 target in OC.
target gene	hsa-mir-92a	Carcinoma, Ovarian	28209618	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.
target gene	hsa-mir-93	Carcinoma, Ovarian	25649143	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
target gene	hsa-mir-939	Carcinoma, Ovarian	25960217	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression.
target gene	hsa-mir-940	Carcinoma, Ovarian	28081739	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-940 Upregulation Suppresses Cell Proliferation and Induces Apoptosis by Targeting PKC-δ in Ovarian Cancer OVCAR3 Cells.
target gene	hsa-mir-99a	Carcinoma, Ovarian	24456664	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells.
target gene	hsa-let-7b	Carcinoma, Ovarian, Serous	24129674	endocrine system disease	DOID:0050933					These overwhelmingly observed oncogenic genes were further detected in a sub-network with 32 FFLs centered by miRNA let-7b and TF TCF7L1 to regulate cell differentiation.
target gene	hsa-mir-106a	Carcinoma, Ovarian, Serous	24045973	endocrine system disease	DOID:0050933					miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
target gene	hsa-mir-1236	Carcinoma, Ovarian, Serous	24573236	endocrine system disease	DOID:0050933					miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma.
target gene	hsa-mir-21	Carcinoma, Ovarian, Serous	24888238	endocrine system disease	DOID:0050933					PDCD4 and miR-21 are involved in OSC oncogenesis. The transfer of miR-21 by exosomes could promote oncogenic transformation in target cells distant from the primary tumor without direct colonization by cancer cells and could be used as a diagnostic tool.
target gene	hsa-mir-223	Carcinoma, Ovarian, Serous	29079174	endocrine system disease	DOID:0050933					miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.
target gene	hsa-mir-133a	Carcinoma, Pancreatic	28286270			C25.3	C562463	260350	HP:0002894	USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway.
target gene	hsa-mir-138	Carcinoma, Pancreatic	28052003			C25.3	C562463	260350	HP:0002894	miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1.
target gene	hsa-mir-155	Carcinoma, Pancreatic	28152544			C25.3	C562463	260350	HP:0002894	Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
target gene	hsa-mir-181d	Carcinoma, Pancreatic	28381166			C25.3	C562463	260350	HP:0002894	Downregulation of microRNA-181d had suppressive effect on pancreatic cancer development through inverse regulation of KNAIN2.
target gene	hsa-mir-182	Carcinoma, Pancreatic	24736782			C25.3	C562463	260350	HP:0002894	GPC1 regulated by miR-96-5p, rather than miR-182-5p, in inhibition of pancreatic  carcinoma cell proliferation.
target gene	hsa-mir-182	Carcinoma, Pancreatic	27797718			C25.3	C562463	260350	HP:0002894	MicroRNA-182 promotes pancreatic cancer cell proliferation and migration by targeting β-TrCP2.
target gene	hsa-mir-183	Carcinoma, Pancreatic	28506766			C25.3	C562463	260350	HP:0002894	Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW1900 cells by targeting MTA1.
target gene	hsa-mir-195	Carcinoma, Pancreatic	28639885			C25.3	C562463	260350	HP:0002894	MicroRNA-195 inhibits the proliferation and invasion of pancreatic cancer cells by targeting the fatty acid synthase/Wnt signaling pathway.
target gene	hsa-mir-200a	Carcinoma, Pancreatic	28349057			C25.3	C562463	260350	HP:0002894	Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis.
target gene	hsa-mir-200b	Carcinoma, Pancreatic	27878247			C25.3	C562463	260350	HP:0002894	Oridonin inhibition and miR‑200b‑3p/ZEB1 axis in human pancreatic cancer.
target gene	hsa-mir-200	Carcinoma, Pancreatic	28349057			C25.3	C562463	260350	HP:0002894	Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis.
target gene	hsa-mir-216a	Carcinoma, Pancreatic	28034748			C25.3	C562463	260350	HP:0002894	MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells.
target gene	hsa-mir-23a	Carcinoma, Pancreatic	29141872			C25.3	C562463	260350	HP:0002894	miR-23a acts as an oncogene in pancreatic carcinoma by targeting FOXP2.
target gene	hsa-mir-301b	Carcinoma, Pancreatic	24398967			C25.3	C562463	260350	HP:0002894	MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells.
target gene	hsa-mir-33a	Carcinoma, Pancreatic	25971209			C25.3	C562463	260350	HP:0002894	MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.
target gene	hsa-mir-375	Carcinoma, Pancreatic	24481267			C25.3	C562463	260350	HP:0002894	MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway.
target gene	hsa-mir-377	Carcinoma, Pancreatic	27638830			C25.3	C562463	260350	HP:0002894	MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.
target gene	hsa-mir-451	Carcinoma, Pancreatic	28197410			C25.3	C562463	260350	HP:0002894	MiR-451 Promotes Cell Proliferation and Metastasis in Pancreatic Cancer through Targeting CAB39.
target gene	hsa-mir-7	Carcinoma, Pancreatic	28259961			C25.3	C562463	260350	HP:0002894	MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma.
target gene	hsa-mir-874	Carcinoma, Pancreatic	28377226			C25.3	C562463	260350	HP:0002894	Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling.
target gene	hsa-mir-96	Carcinoma, Pancreatic	24736782			C25.3	C562463	260350	HP:0002894	GPC1 regulated by miR-96-5p, rather than miR-182-5p, in inhibition of pancreatic  carcinoma cell proliferation.
target gene	hsa-mir-1207	Carcinoma, Prostate	27693493	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin.
target gene	hsa-mir-1271	Carcinoma, Prostate	28153722	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Inhibition of DIXDC1 by microRNA-1271 suppresses the proliferation and invasion of prostate cancer cells.
target gene	hsa-mir-1297	Carcinoma, Prostate	27746178	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-1297 inhibits prostate cancer cell proliferation and invasion by targeting the AEG-1/Wnt signaling pathway.
target gene	hsa-mir-1307	Carcinoma, Prostate	28122308	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A.
target gene	hsa-mir-130a	Carcinoma, Prostate	27984115	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
target gene	hsa-mir-138	Carcinoma, Prostate	27562865	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
target gene	hsa-mir-141	Carcinoma, Prostate	26065649	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	The presence of the microRNA-141 target molecules activates the DNA molecular machine powered by the DNA fuel strands, leading to non-enzymatic target cyclic reuse of microRNA-141 and significantly amplified fluorescent signals for sensitive monitoring of microRNA-141 from low numbers of human prostate cancer cells.
target gene	hsa-mir-141	Carcinoma, Prostate	27956179	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression.
target gene	hsa-mir-143	Carcinoma, Prostate	28109198	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-143 Induces the Apoptosis of Prostate Cancer LNCap Cells by Suppressing Bcl-2 Expression.
target gene	hsa-mir-143	Carcinoma, Prostate	28391351	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis.
target gene	hsa-mir-193a	Carcinoma, Prostate	28422308	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
target gene	hsa-mir-194	Carcinoma, Prostate	27959429	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
target gene	hsa-mir-194	Carcinoma, Prostate	28011622	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.
target gene	hsa-mir-200b	Carcinoma, Prostate	28028835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	TIMP4 expression is regulated by miR-200b-3p in prostate cancer cells.
target gene	hsa-mir-204	Carcinoma, Prostate	27686228	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells.
target gene	hsa-mir-204	Carcinoma, Prostate	28050800	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
target gene	hsa-mir-22	Carcinoma, Prostate	28231399	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MTA1-activated Epi-microRNA-22 regulates E-cadherin and prostate cancer invasiveness.
target gene	hsa-mir-221	Carcinoma, Prostate	24607843	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Survival in patients with high-risk prostate cancer is predicted by miR-221,which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3.
target gene	hsa-mir-26a	Carcinoma, Prostate	27562865	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
target gene	hsa-mir-33a	Carcinoma, Prostate	27921232	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating Engrailed-2.
target gene	hsa-mir-34	Carcinoma, Prostate	28373004	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
target gene	hsa-mir-3619	Carcinoma, Prostate	27878260	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression.
target gene	hsa-mir-372	Carcinoma, Prostate	27673408	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	microRNA-372 Suppresses Migration and Invasion by Targeting p65 in Human Prostate Cancer Cells.
target gene	hsa-mir-375	Carcinoma, Prostate	27832783	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
target gene	hsa-mir-382	Carcinoma, Prostate	27748848	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-382 inhibits prostate cancer cell proliferation and metastasis through targeting COUP-TFII.
target gene	hsa-mir-383	Carcinoma, Prostate	27893706	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer.
target gene	hsa-mir-449	Carcinoma, Prostate	28373004	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
target gene	hsa-mir-455	Carcinoma, Prostate	28350134	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer.
target gene	hsa-mir-500	Carcinoma, Prostate	28631332	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
target gene	hsa-mir-543	Carcinoma, Prostate	28245474	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MiR-543 Promotes Proliferation and Epithelial-Mesenchymal Transition in Prostate Cancer via Targeting RKIP.
target gene	hsa-mir-574	Carcinoma, Prostate	27779701	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Downregulation of microRNA‑574 in cancer stem cells causes recurrence of prostate cancer via targeting REL.
target gene	hsa-mir-590	Carcinoma, Prostate	28345464	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-590-3p promotes cell proliferation and invasion by targeting inositol polyphosphate 4-phosphatase type II in human prostate cancer cells.
target gene	hsa-mir-875	Carcinoma, Prostate	28274892	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.
target gene	hsa-mir-96	Carcinoma, Prostate	27746161	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6.
target gene	hsa-mir-135a	Carcinoma, Rectal	21192341	disease of cellular proliferation	DOID:1993	C20	D012004			In this issue, Li and colleagues describe a novel way of targeting miRNA, by using a naturally occurring anti-cancer compound found in mistletoe which they showed to down-regulate miR-135a&b, which target the 3' untranslated region of adenomatous polyposis coli gene, the inactivation of which is a major initiating event in colorectal tumourigenesis.
target gene	hsa-mir-135a	Carcinoma, Rectal	23017832	disease of cellular proliferation	DOID:1993	C20	D012004			MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro.
target gene	hsa-mir-135b	Carcinoma, Rectal	21192341	disease of cellular proliferation	DOID:1993	C20	D012004			In this issue, Li and colleagues describe a novel way of targeting miRNA, by using a naturally occurring anti-cancer compound found in mistletoe which they showed to down-regulate miR-135a&b, which target the 3' untranslated region of adenomatous polyposis coli gene, the inactivation of which is a major initiating event in colorectal tumourigenesis.
target gene	hsa-mir-34a	Carcinoma, Rectal	26287733	disease of cellular proliferation	DOID:1993	C20	D012004			Although miR-34a and miR-34c can regulate Axl expression in vitro,our data indicates that the miR-34 family members are not the primary regulators of Axl expression in RCC.
target gene	hsa-mir-34a	Carcinoma, Rectal	21067862	disease of cellular proliferation	DOID:1993	C20	D012004			These findings suggest that miR-34a targeting the Sirt1 and E2F3 genes could negatively regulate, at least in part, the resistance to 5-FU in human colorectal cancer DLD-1 cells.
target gene	hsa-mir-92a	Carcinoma, Rectal	26865277	disease of cellular proliferation	DOID:1993	C20	D012004			Integrated genomic profiling identifies microRNA-92a regulation of IQGAP2 in locally advanced rectal cancer.
target gene	hsa-let-7a	Carcinoma, Renal Cell	22155254	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our results suggest for the first time that let-7a acts as a tumor suppressor in RCC cell lines by down-regulating c-myc and c-myc target genes.
target gene	hsa-let-7d	Carcinoma, Renal Cell	25686498	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Rab25 is a target gene of let-7d, and further suggested that Rab25 upregulation in RCC is due to diminished expression of let-7d.
target gene	hsa-mir-122	Carcinoma, Renal Cell	28231730	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-122 promotes renal cancer cell proliferation by targeting Sprouty2.
target gene	hsa-mir-124	Carcinoma, Renal Cell	25861751	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma.
target gene	hsa-mir-1285-1	Carcinoma, Renal Cell	22294552	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma.
target gene	hsa-mir-1285-2	Carcinoma, Renal Cell	22294552	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma.
target gene	hsa-mir-129	Carcinoma, Renal Cell	24802708	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes.
target gene	hsa-mir-1291	Carcinoma, Renal Cell	23889809	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma.
target gene	hsa-mir-134	Carcinoma, Renal Cell	25811077	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.
target gene	hsa-mir-135a-1	Carcinoma, Renal Cell	23176581	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma
target gene	hsa-mir-135a-2	Carcinoma, Renal Cell	23176581	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma
target gene	hsa-mir-138	Carcinoma, Renal Cell	29344205	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9
target gene	hsa-mir-138-1	Carcinoma, Renal Cell	22766839	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.
target gene	hsa-mir-138-2	Carcinoma, Renal Cell	22766839	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.
target gene	hsa-mir-143	Carcinoma, Renal Cell	24033605	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Thus, our data showed that loss of the tumor-suppressive miR-143/145 cluster enhanced RCC cell proliferation and invasion through targeting HK2.
target gene	hsa-mir-144	Carcinoma, Renal Cell	27717821	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8.
target gene	hsa-mir-145	Carcinoma, Renal Cell	23441135	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients
target gene	hsa-mir-145	Carcinoma, Renal Cell	24033605	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Thus, our data showed that loss of the tumor-suppressive miR-143/145 cluster enhanced RCC cell proliferation and invasion through targeting HK2.
target gene	hsa-mir-146	Carcinoma, Renal Cell	26859141	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	We identified novel target genes of dysregulated miRNAs, which are involved in the transition from primary RCC without metastases into tumors generating distant metastasis.
target gene	hsa-mir-146a	Carcinoma, Renal Cell	20709800	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Loss of inducible nitric oxide synthase expression in the mouse renal cell carcinoma cell line RENCA is mediated by microRNA miR-146a.
target gene	hsa-mir-148a	Carcinoma, Renal Cell	27878305	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2.
target gene	hsa-mir-148a	Carcinoma, Renal Cell	28098870	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells.
target gene	hsa-mir-149	Carcinoma, Renal Cell	28902136	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma.
target gene	hsa-mir-155	Carcinoma, Renal Cell	22307849	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells.
target gene	hsa-mir-15a	Carcinoma, Renal Cell	28849086	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E.
target gene	hsa-mir-181a	Carcinoma, Renal Cell	27664584	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells.
target gene	hsa-mir-183	Carcinoma, Renal Cell	29552228	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf-related protein 3
target gene	hsa-mir-193a	Carcinoma, Renal Cell	28639901	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN.
target gene	hsa-mir-199a-1	Carcinoma, Renal Cell	22093618	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3
target gene	hsa-mir-19a	Carcinoma, Renal Cell	26058752	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro.
target gene	hsa-mir-200a	Carcinoma, Renal Cell	25813153	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2.
target gene	hsa-mir-200a	Carcinoma, Renal Cell	26797273	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma.
target gene	hsa-mir-200a	Carcinoma, Renal Cell	28717923	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiRNA-200a induce cell apoptosis in renal cell carcinoma by directly targeting SIRT1.
target gene	hsa-mir-200c	Carcinoma, Renal Cell	25150313	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.
target gene	hsa-mir-200c	Carcinoma, Renal Cell	26248649	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma.
target gene	hsa-mir-203a	Carcinoma, Renal Cell	25123268	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-203a regulates proliferation, migration, and apoptosis by targeting glycogen synthase kinase-3β in human renal cell carcinoma.
target gene	hsa-mir-204	Carcinoma, Renal Cell	22516261	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	VHL-Regulated MiR-204 Suppresses Tumor Growth through Inhibition of LC3B-Mediated Autophagy in Renal Clear Cell Carcinoma.
target gene	hsa-mir-204	Carcinoma, Renal Cell	25517751	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	TRPM3 Ca(2+) and Zn(2+) fluxes inhibit miR-214, which directly targets LC3A and LC3B. The von Hippel-Lindau tumor suppressor (VHL) represses TRPM3 directly through miR-204 and indirectly through another miR-204 target, Caveolin 1 (CAV1).
target gene	hsa-mir-205	Carcinoma, Renal Cell	25427583	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-205 is a candidate tumor suppressor that targets ZEB2 in RCC.
target gene	hsa-mir-206	Carcinoma, Renal Cell	27924503	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-206 inhibits renal cell cancer growth by targeting GAK.
target gene	hsa-mir-21	Carcinoma, Renal Cell	21820586	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-21 Modulates Cell Apoptosis by Targeting Multiple Genes in Renal Cell Carcinoma.
target gene	hsa-mir-21	Carcinoma, Renal Cell	22685542	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion.
target gene	hsa-mir-21	Carcinoma, Renal Cell	23206776	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-21 Downregulated TCF21 to Inhibit KISS1 in Renal Cancer
target gene	hsa-mir-21	Carcinoma, Renal Cell	23558936	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-21 is overexpressed in RCC tissue and modulates the growth, apoptosis and cell cycle progression of RCC cells and regulates the expression of PDCD4 and TPM1
target gene	hsa-mir-21	Carcinoma, Renal Cell	27388719	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	in cells treated with AU-1, transient elevation of miR-34 leads to the downregulation of SIRT1, thereby miR-21 is freed from SIRT1-dependent suppression.
target gene	hsa-mir-21	Carcinoma, Renal Cell	27222255	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR鈥?1 was able to decrease the expression of CASC2 in 786鈥慜 and A498 cells.
target gene	hsa-mir-210	Carcinoma, Renal Cell	23449350	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis
target gene	hsa-mir-218-1	Carcinoma, Renal Cell	23454155	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway
target gene	hsa-mir-218-2	Carcinoma, Renal Cell	23454155	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway
target gene	hsa-mir-224	Carcinoma, Renal Cell	21912701	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-224 Targets the 3'UTR of Type 1 5'-Iodothyronine Deiodinase Possibly Contributing to Tissue Hypothyroidism in Renal Cancer.
target gene	hsa-mir-23b	Carcinoma, Renal Cell	23189187	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer
target gene	hsa-mir-26a	Carcinoma, Renal Cell	26983694	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	two genes promoting metastasis, LOXL2 and PLOD2, were epigenetically regulated by tumor-suppressive microRNAs, miR-26a and miR-26b
target gene	hsa-mir-302c	Carcinoma, Renal Cell	28412750	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2).
target gene	hsa-mir-30a	Carcinoma, Renal Cell	27664584	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNAs target SRSF7 splicing factor to modulate the expression of osteopontin splice variants in renal cancer cells.
target gene	hsa-mir-30a	Carcinoma, Renal Cell	29073630	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-30a-5p Inhibits the Growth of Renal Cell Carcinoma by Modulating GRP78 Expression.
target gene	hsa-mir-30b	Carcinoma, Renal Cell	28536082	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit α-13 in renal cell carcinoma.
target gene	hsa-mir-34	Carcinoma, Renal Cell	27388719	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	in cells treated with AU-1, transient elevation of miR-34 leads to the downregulation of SIRT1, thereby miR-21 is freed from SIRT1-dependent suppression. Then, elevated miR-21 upregulates p21/Cip1 protein, followed by the  suppression of miR-34 expression.
target gene	hsa-mir-34a	Carcinoma, Renal Cell	22159222	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma.
target gene	hsa-mir-372	Carcinoma, Renal Cell	26332146	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our data indicated that miR-372 seemed to function as a tumour suppressor in renal cell carcinoma progression by inhibiting the IGF2BP1 expression.
target gene	hsa-mir-381	Carcinoma, Renal Cell	23778472	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	These data clearly demonstrate that these two miRNAs might synergistically act as novel modulators of tumorigenesis by down-regulating WEE1  expression in renal cell cancer cells.
target gene	hsa-mir-424	Carcinoma, Renal Cell	23778472	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	These data clearly demonstrate that these two miRNAs might synergistically act as novel modulators of tumorigenesis by down-regulating WEE1  expression in renal cell cancer cells.
target gene	hsa-mir-429	Carcinoma, Renal Cell	25953723	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	These results revealed a tumor suppressive role for miR-429 in renal cell carcinoma through directly targeting BMI1 and E2F3.
target gene	hsa-mir-509	Carcinoma, Renal Cell	25815776	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.
target gene	hsa-mir-629	Carcinoma, Renal Cell	25381221	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-629 Targets TRIM33 to Promote TGFβ/Smad Signaling and Metastatic Phenotypes in ccRCC.
target gene	hsa-mir-646	Carcinoma, Renal Cell	25010867	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Downregulated miR-646 in ccRCC was associated with tumour metastasis through MAPK pathway by targeting NOB1. miR-646 and NOB1 may play an important role in the development of ccRCC.
target gene	hsa-mir-96	Carcinoma, Renal Cell	26419932	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	These results suggest that miR-96 suppresses RCC invasion by modulating Ezrin expression.
target gene	hsa-mir-101	Carcinoma, Renal Cell, Clear-Cell	28138701	disease of cellular proliferation	DOID:4467				HP:0006770	Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma.
target gene	hsa-mir-106b	Carcinoma, Renal Cell, Clear-Cell	25714014	disease of cellular proliferation	DOID:4467				HP:0006770	miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
target gene	hsa-mir-138	Carcinoma, Renal Cell, Clear-Cell	28861152	disease of cellular proliferation	DOID:4467				HP:0006770	MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma.
target gene	hsa-mir-140	Carcinoma, Renal Cell, Clear-Cell	29253611	disease of cellular proliferation	DOID:4467				HP:0006770	miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development
target gene	hsa-mir-142	Carcinoma, Renal Cell, Clear-Cell	29253611	disease of cellular proliferation	DOID:4467				HP:0006770	miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development
target gene	hsa-mir-155	Carcinoma, Renal Cell, Clear-Cell	28565840	disease of cellular proliferation	DOID:4467				HP:0006770	Overexpression of miR-155 in clear-cell renal cell carcinoma and its oncogenic effect through targeting FOXO3a.
target gene	hsa-mir-181a	Carcinoma, Renal Cell, Clear-Cell	29066014	disease of cellular proliferation	DOID:4467				HP:0006770	Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis.
target gene	hsa-mir-184	Carcinoma, Renal Cell, Clear-Cell	29253611	disease of cellular proliferation	DOID:4467				HP:0006770	miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development
target gene	hsa-mir-195	Carcinoma, Renal Cell, Clear-Cell	28089832	disease of cellular proliferation	DOID:4467				HP:0006770	Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals.
target gene	hsa-mir-19a	Carcinoma, Renal Cell, Clear-Cell	27779660	disease of cellular proliferation	DOID:4467				HP:0006770	miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression.
target gene	hsa-mir-200c	Carcinoma, Renal Cell, Clear-Cell	26941587	disease of cellular proliferation	DOID:4467				HP:0006770	miRNA-200c that could regulate COL5A2 and COL5A3, miRNA-15a that could regulate ATP6V0B and miRNA-155 may play key roles in ccRCC progression.
target gene	hsa-mir-206	Carcinoma, Renal Cell, Clear-Cell	29253611	disease of cellular proliferation	DOID:4467				HP:0006770	miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development
target gene	hsa-mir-23b	Carcinoma, Renal Cell, Clear-Cell	25014580	disease of cellular proliferation	DOID:4467				HP:0006770	Expression of the miR-23b/27b cluster was frequently decreased in clear cell renal cell carcinoma tissue. Reduced expression of these miRNAs increased the risk of disease progression and predicted poor survival. Thus,miR-23b and miR-27b function as tumor suppressors, targeting several oncogenic genes in clear cell renal cell carcinoma cells.
target gene	hsa-mir-27b	Carcinoma, Renal Cell, Clear-Cell	25014580	disease of cellular proliferation	DOID:4467				HP:0006770	Expression of the miR-23b/27b cluster was frequently decreased in clear cell renal cell carcinoma tissue. Reduced expression of these miRNAs increased the risk of disease progression and predicted poor survival. Thus,miR-23b and miR-27b function as tumor suppressors, targeting several oncogenic genes in clear cell renal cell carcinoma cells.
target gene	hsa-mir-29a	Carcinoma, Renal Cell, Clear-Cell	28089832	disease of cellular proliferation	DOID:4467				HP:0006770	Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals.
target gene	hsa-mir-29c	Carcinoma, Renal Cell, Clear-Cell	28089832	disease of cellular proliferation	DOID:4467				HP:0006770	Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals.
target gene	hsa-mir-30a	Carcinoma, Renal Cell, Clear-Cell	24189146	disease of cellular proliferation	DOID:4467				HP:0006770	Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
target gene	hsa-mir-30a	Carcinoma, Renal Cell, Clear-Cell	23826258	disease of cellular proliferation	DOID:4467				HP:0006770	Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4.
target gene	hsa-mir-30c-2	Carcinoma, Renal Cell, Clear-Cell	24189146	disease of cellular proliferation	DOID:4467				HP:0006770	Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
target gene	hsa-mir-377	Carcinoma, Renal Cell, Clear-Cell	25776481	disease of cellular proliferation	DOID:4467				HP:0006770	miR-377 functions as a tumor suppressor in human clear cell renal cell carcinoma by targeting ETS1.
target gene	hsa-mir-429	Carcinoma, Renal Cell, Clear-Cell	29253611	disease of cellular proliferation	DOID:4467				HP:0006770	miRNA-429, miRNA-206, and miRNA-184 and their target gene CCND1, as well as miRNA-140-3p and miRNA-142-5p and their target gene ATP1B1, might play key roles in ccRCC progression and could be useful biomarkers during ccRCC development
target gene	hsa-mir-155	Carcinoma, Salivary Adenoid Cystic	28668836	disease of cellular proliferation	DOID:4866	C08.9	D003528			MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma.
target gene	hsa-mir-17	Carcinoma, Salivary Adenoid Cystic	23825564	disease of cellular proliferation	DOID:4866	C08.9	D003528			Our study indicates that the upregulation of miR-17-92 may play a role in the biology of ACC and could be potentially targeted in future therapeutic studies.
target gene	hsa-mir-205	Carcinoma, Salivary Adenoid Cystic	28668836	disease of cellular proliferation	DOID:4866	C08.9	D003528			MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma.
target gene	hsa-mir-20a	Carcinoma, Salivary Adenoid Cystic	23825564	disease of cellular proliferation	DOID:4866	C08.9	D003528			Our study indicates that the upregulation of miR-17-92 may play a role in the biology of ACC and could be potentially targeted in future therapeutic studies.
target gene	hsa-mir-21	Carcinoma, Salivary Adenoid Cystic	29328455	disease of cellular proliferation	DOID:4866	C08.9	D003528			miR-21 may promote SACC progression via PDCD4, PTEN and Bcl-2
target gene	hsa-mir-26a	Carcinoma, Skin	28977801	disease of cellular proliferation	DOID:3451	D04.9	D018280		HP:0008069	MiR-26a Mediates Ultraviolet B-Induced Apoptosis by Targeting Histone Methyltransferase EZH2 Depending on Myc Expression.
target gene	hsa-mir-126	Carcinoma, Thyroid	26239517	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6.
target gene	hsa-mir-129	Carcinoma, Thyroid	24631532	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration  of medullary thyroid carcinoma cells through targeting RET.
target gene	hsa-mir-146b	Carcinoma, Thyroid	25960292	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression.
target gene	hsa-mir-148a	Carcinoma, Thyroid	27779717	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
target gene	hsa-mir-584	Carcinoma, Thyroid	26405762	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	These results indicate that miR-584 could inhibit the expression of ROCK1, and ROCK1 knockdown would further affect the migration ability of K1 cells.
target gene	hsa-mir-639	Carcinoma, Thyroid	27829546	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	MiR-639 promoted cell proliferation and cell cycle in human thyroid cancer by suppressing CDKN1A expression.
target gene	hsa-mir-125b	Carcinoma, Thyroid, Anaplastic	28122310			C73	D065646	188550	HP:0011779	MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD.
target gene	hsa-mir-200a	Carcinoma, Thyroid, Anaplastic	25542369			C73	D065646	188550	HP:0011779	Restoration of miR-200 expression by pre-miR-200a/c transfection reversed the process, including increased E-cadherin and decreased vimentin.
target gene	hsa-mir-99a	Carcinoma, Thyroid, Anaplastic	26163618			C73	D065646	188550	HP:0011779	MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer.
target gene	hsa-mir-10a	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-137	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-139	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-144	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-145	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-146b	Carcinoma, Thyroid, Follicular	28427206	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4.
target gene	hsa-mir-296	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-452	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-493	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-7	Carcinoma, Thyroid, Follicular	29344146	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Network analysis indicated a co-regulatory association between miR-296-5p, miR-10a, miR-139-5p, miR-452, miR-493, miR-7, miR-137, miR-144, miR-145 and corresponding targeted mRNAs, including TNF receptor superfamily member 11b, benzodiazepine receptor (peripheral) -associated protein 1, and transforming growth factor β receptor 2
target gene	hsa-mir-182	Carcinoma, Thyroid, Medullary	28122586	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
target gene	hsa-mir-200	Carcinoma, Thyroid, Medullary	24127332	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	The members of miR-200 family regulate the expression of E-cadherin by directly targeting ZEB1 and ZEB2 mRNA and through the enhanced expression of tumour growth factor β (TGFβ)-2 and TGFβ-1.The members of miR-200 family associated with metastatic MTC and distinct biological processes providing new potential insights into the mechanisms of MTC metastasis.
target gene	hsa-let-7a	Carcinoma, Thyroid, Papillary	29050238	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma.
target gene	hsa-mir-150	Carcinoma, Thyroid, Papillary	28656254	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma.
target gene	hsa-mir-155	Carcinoma, Thyroid, Papillary	23796566	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Our results indicate that miR-155 functions as an oncogene in PTC. By targeting APC, miR-155 efficiently regulates the Wnt/β-catenin signaling. And miR-155 may be a potential therapeutic or diagnostic/prognostic target for treating PTC.
target gene	hsa-mir-182	Carcinoma, Thyroid, Papillary	24971532	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma.
target gene	hsa-mir-183	Carcinoma, Thyroid, Papillary	26063221	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4.
target gene	hsa-mir-199a	Carcinoma, Thyroid, Papillary	29427661	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1.
target gene	hsa-mir-221	Carcinoma, Thyroid, Papillary	18794255	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Microarray analysis showed thousands of genes were directly and indirectly regulated by miR-221 and shifted the gene expression pattern of normal thyroid cells toward PTC.
target gene	hsa-mir-221	Carcinoma, Thyroid, Papillary	27077469	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-221 exacerbated PTC by downregulating the expression of TIMP3.
target gene	hsa-mir-26a	Carcinoma, Thyroid, Papillary	23861775	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Our data indicate that miR-26a functions as a growth suppressive miRNA in PTC, and that its suppressive effects are mediated mainly by repressing CKS2 expression.
target gene	hsa-mir-31	Carcinoma, Thyroid, Papillary	26731986	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Down regulation of miR-31 contributed to the malignant progression of papillary thyroid carcinoma cells by targeting HuR.
target gene	hsa-mir-34a	Carcinoma, Thyroid, Papillary	24220341	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
target gene	hsa-mir-7	Carcinoma, Thyroid, Papillary	27633373	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA-7 inhibits proliferation, migration and invasion of thyroid papillary cancer cells via targeting CKS2.
target gene	hsa-mir-27a	Carcinoma, Urothelial	24462738	disease of cellular proliferation	DOID:4006				HP:0030409	Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia  associated with high-grade bladder urothelial carcinoma.
target gene	hsa-mir-9	Cardiac Fibrosis	27756824							MicroRNA-9 inhibits high glucose-induced proliferation, differentiation and collagen accumulation of cardiac fibroblasts by down-regulation of TGFBR2.
target gene	hsa-mir-133a	Cardiac Myocyte Injury	23069713							We also discovered that luciferase activity is exclusively decreased by targeting EGFR in hMSCs transfected with miR-133a mimic. These results suggest that EGFR plays a key role in the regulation of cardiogenic differentiation in hMSCs.
target gene	hsa-mir-214	Cardiac Myocyte Injury	23904244							miR-214 protects cardiac myocytes against H2O2-induced injury via one of its targets, PTEN.
target gene	hsa-mir-217	Cardiac Myxoma	28642131			D15.1	D009232	255960	HP:0011672	miR-217 suppresses proliferation and promotes apoptosis in cardiac myxoma by targeting Interleukin-6.
target gene	hsa-mir-218	Cardiac Myxoma	25812649			D15.1	D009232	255960	HP:0011672	miR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D.
target gene	hsa-mir-19a	Cardiomegaly	24117217			I51.7	D006332		HP:0001640	The results of the present study demonstrate that the miR-19a/b family regulates phenotypes of cardiomyocytes via suppression of multiple direct target genes.
target gene	hsa-mir-19b	Cardiomegaly	24117217			I51.7	D006332		HP:0001640	The results of the present study demonstrate that the miR-19a/b family regulates phenotypes of cardiomyocytes via suppression of multiple direct target genes.
target gene	hsa-mir-21	Cardiomegaly	25504627			I51.7	D006332		HP:0001640	miR-21-3p in regulating HDAC8 expression and Akt/Gsk3β pathway, and suggest that modulation of miR-21-3p levels may provide a therapeutic approach for cardiac hypertrophy.
target gene	hsa-mir-214	Cardiomegaly	26572862			I51.7	D006332		HP:0001640	These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure.
target gene	hsa-mir-30	Cardiomegaly	26572862			I51.7	D006332		HP:0001640	These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure.
target gene	hsa-mir-489	Cardiomegaly	24557880			I51.7	D006332		HP:0001640	Our present study reveals a novel cardiac hypertrophy regulating model that is composed of CHRF, miR-489, and Myd88. The modulation of their levels may provide a new approach for tackling cardiac hypertrophy.
target gene	hsa-mir-96	Cardiomegaly	26782545			I51.7	D006332		HP:0001640	miR-96 inhibits cardiac hypertrophy by targeting growth factor receptor-bound 2.
target gene	hsa-mir-1	Cardiomegaly	26476318			I51.7	D006332		HP:0001640	Further findings indicated that miR-1, which was depressed by Nkx2.5, might play a fundamental role in mediating cardiac hypertrophy and arrhythmia via its target genes Mef2a and Irx5 after HBCD treatment.
target gene	hsa-mir-1	Cardiomegaly	20571053			I51.7	D006332		HP:0001640	Taken together, our results demonstrate that the cytoskeleton regulatory protein twinfilin-1 is a novel target of miR-1, and that reduction of miR-1 by hypertrophic stimuli induces the upregulation of twinfilin-1, which in turn evokes hypertrophy through the regulation of cardiac cytoskeleton.
target gene	hsa-mir-1-1	Cardiomegaly	19188439			I51.7	D006332		HP:0001640	miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes
target gene	hsa-mir-1-1	Cardiomegaly	23156720			I51.7	D006332		HP:0001640	Effects of microRNA-1 on negatively regulating L-type calcium channel beta2 subunit gene expression during cardiac hypertrophy
target gene	hsa-mir-1-2	Cardiomegaly	19188439			I51.7	D006332		HP:0001640	miR-1: MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes
target gene	hsa-mir-1-2	Cardiomegaly	23156720			I51.7	D006332		HP:0001640	Effects of microRNA-1 on negatively regulating L-type calcium channel beta2 subunit gene expression during cardiac hypertrophy
target gene	hsa-mir-133a	Cardiomegaly	20177001			I51.7	D006332		HP:0001640	Our data show that reciprocal repression between miR-133 and calcineurin regulates cardiac hypertrophy.
target gene	hsa-mir-133a-1	Cardiomegaly	23166348			I51.7	D006332		HP:0001640	Mutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophy
target gene	hsa-mir-133a-2	Cardiomegaly	23166348			I51.7	D006332		HP:0001640	Mutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophy
target gene	hsa-mir-133b	Cardiomegaly	20177001			I51.7	D006332		HP:0001640	Our data show that reciprocal repression between miR-133 and calcineurin regulates cardiac hypertrophy.
target gene	hsa-mir-150	Cardiomegaly	23211718			I51.7	D006332		HP:0001640	miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300
target gene	hsa-mir-378a	Cardiomegaly	23447532			I51.7	D006332		HP:0001640	A cardiac enriched microRNA, miR-378 blocks cardiac hypertrophy by targeting Ras-signaling
target gene	hsa-mir-216a	Cardiometabolic Disorders	24481443							In conclusion, mir-216a controls ox-LDL induced autophagy in HUVECs by regulating intracellular levels of BECN1 and may have a relevant role in the pathogenesis of cardiovascular disorders and atherosclerosis.
target gene	hsa-mir-199a-1	Cardiomyopathy	23360823	cardiovascular system disease	DOID:0050700	I42	D009202			TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy
target gene	hsa-mir-199a-2	Cardiomyopathy	23360823	cardiovascular system disease	DOID:0050700	I42	D009202			TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy
target gene	hsa-mir-199b	Cardiomyopathy	23360823	cardiovascular system disease	DOID:0050700	I42	D009202			TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy
target gene	hsa-mir-214	Cardiomyopathy	23360823	cardiovascular system disease	DOID:0050700	I42	D009202			TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy
target gene	hsa-mir-27a	Cardiomyopathy	23143062	cardiovascular system disease	DOID:0050700	I42	D009202			MicroRNA-27a regulates cardiomyocytic apoptosis during cardioplegia-induced cardiac arrest by targeting interleukin 10-related pathways
target gene	hsa-mir-451a	Cardiomyopathy	27974462	cardiovascular system disease	DOID:0050700	I42	D009202			Down-regulation of microRNA-451a facilitates the activation and proliferation of CD4+ T cells by targeting Myc in patients with dilated cardiomyopathy.
target gene	hsa-mir-1	Cardiomyopathy, Hypertrophic	25152367	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Our results show that p65 can upregulate the level of miR-1 and miR-1 can decrease protein expression of myocardin in cardiac myocytes.
target gene	hsa-mir-106a	Cardiomyopathy, Hypertrophic	27565029	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-106a promotes cardiac hypertrophy by targeting mitofusin 2.
target gene	hsa-mir-21	Cardiomyopathy, Hypertrophic	19336275	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-21: miR-21 can protect this by targeting PDCD4
target gene	hsa-mir-30a	Cardiomyopathy, Hypertrophic	23326547	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-30a induced alterations in beclin-1 gene expression and autophagy in cardiomyocytes.
target gene	hsa-mir-34a	Cardiomyopathy, Hypertrophic	24728149	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	This study indicates that miR-34a plays a role in regulation of Ang II-induced cardiomyocyte hypertrophy by inhibition of ATG9A expression and autophagic activity.
target gene	hsa-mir-154	Cardiomyopathy, Ischemic	27542661			I25.5				MiR-154 directly suppresses DKK2 to activate Wnt signaling pathway and enhance activation of cardiac fibroblasts.
target gene	hsa-mir-21	Cardio-Renal Syndrome	28760335				D059347			MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4.
target gene	hsa-mir-106a	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-106b	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-1248	Cardiovascular Diseases [unspecific]	24088671				D002318			In humans, miR-1248 was found to regulate the expression of mRNAs involved in inflammatory pathways and miR-181a was found to correlate negatively with the pro-inflammatory cytokines IL-6 and TNFα and to correlate positively with the anti-inflammatory cytokines TGFβ and IL-10.
target gene	hsa-mir-125	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-126	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-133a-1	Cardiovascular Diseases [unspecific]	19720047				D002318			MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes
target gene	hsa-mir-133a-2	Cardiovascular Diseases [unspecific]	19720047				D002318			MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes
target gene	hsa-mir-133b	Cardiovascular Diseases [unspecific]	19720047				D002318			MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes
target gene	hsa-mir-143	Cardiovascular Diseases [unspecific]	26221598				D002318			We discuss the potential role of miR-143/-145 as valuable biomarkers for cardiovascular diseases and explore the potential strategy of targeting miR-143 and miR-145.
target gene	hsa-mir-143	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-145	Cardiovascular Diseases [unspecific]	26221598				D002318			We discuss the potential role of miR-143/-145 as valuable biomarkers for cardiovascular diseases and explore the potential strategy of targeting miR-143 and miR-145.
target gene	hsa-mir-145	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-145	Cardiovascular Diseases [unspecific]	27412561				D002318			miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40.
target gene	hsa-mir-151a	Cardiovascular Diseases [unspecific]	24088671				D002318			In humans, miR-1248 was found to regulate the expression of mRNAs involved in inflammatory pathways and miR-181a was found to correlate negatively with the pro-inflammatory cytokines IL-6 and TNFα and to correlate positively with the anti-inflammatory cytokines TGFβ and IL-10.
target gene	hsa-mir-155	Cardiovascular Diseases [unspecific]	29686722				D002318			Analysis of microRNA-155 expression also suggests its intervention in the regulation of eNOS expression.
target gene	hsa-mir-155	Cardiovascular Diseases [unspecific]	20550618				D002318			MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1.
target gene	hsa-mir-17	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-18	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-181b	Cardiovascular Diseases [unspecific]	28323879				D002318			miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling.
target gene	hsa-mir-195	Cardiovascular Diseases [unspecific]	21622680				D002318			MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1.
target gene	hsa-mir-19a	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-19b-1	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-200c	Cardiovascular Diseases [unspecific]	25791170				D002318			These results demonstrate that induction of a miR-200c-SUMOylated KLF4 feedback loop is a significant aspect of the PDGF-BB proliferative response in VSMCs and that targeting Ubc9 represents a novel approach for the prevention of restenosis.
target gene	hsa-mir-20a	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-21	Cardiovascular Diseases [unspecific]	25898844				D002318			In cardiac fibrosis related to Ang II, miR-21 is transcriptionally activated and targets PTEN/SMAD7 resulting in increased fibroblast survival. OPN KO animals are protected from miR-21 increase and fibrosis development due to impaired AP-1 activation and fibroblast activation.
target gene	hsa-mir-21	Cardiovascular Diseases [unspecific]	27545313				D002318			Viral Vector-Based Targeting of miR-21 in Cardiac Nonmyocyte Cells Reduces Pathologic Remodeling of the Heart.
target gene	hsa-mir-21	Cardiovascular Diseases [unspecific]	27663503				D002318			DDAH1 3'-UTR as a target for miR-21, and endogenous miR-21 showed increased inhibitory effect on DDAH1-V3 transcript
target gene	hsa-mir-221	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-221	Cardiovascular Diseases [unspecific]	26461283				D002318			Among differentially-expressed miRNAs are those involved in the regulation of inflammation or cell adhesion, such as miR-221 and miR-181.
target gene	hsa-mir-222	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-223	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-2861	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-29b	Cardiovascular Diseases [unspecific]	28164126				D002318			The Involvement of miR-29b-3p in Arterial Calcification by Targeting Matrix Metalloproteinase-2.
target gene	hsa-mir-34a	Cardiovascular Diseases [unspecific]	27694688				D002318			it could be considered as a circulating biomarker for anthracycline-induced cardiac damage
target gene	hsa-mir-378a	Cardiovascular Diseases [unspecific]	22119805				D002318			Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes.
target gene	hsa-mir-3960	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-9-1	Cardiovascular Diseases [unspecific]	21684288				D002318			MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes.
target gene	hsa-mir-9-2	Cardiovascular Diseases [unspecific]	21684288				D002318			MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes.
target gene	hsa-mir-92-1	Cardiovascular Diseases [unspecific]	26266261				D002318			Our current special issue presents a series of original researches and reviews on recent advances in miRNAs regulating the pathophysiology aspects of CVD that will hopefully set the stage for future research initiatives aimed at expanding our understanding of these important mediators of cardiovascular function.
target gene	hsa-mir-9-3	Cardiovascular Diseases [unspecific]	21684288				D002318			MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes.
target gene	hsa-mir-99a	Cardiovascular Diseases [unspecific]	27403035				D002318			MiR-99a inhibited the LPS-induced HUVECs inflammation via inhibition of the mTOR/NF-魏B signal.
target gene	hsa-mir-140	Cartilage Disease [unspecific]	29067438	musculoskeletal system disease	DOID:1222	M94.9	D002357			miRNA-140 inhibits C3H10T1/2 mesenchymal stem cell proliferation by targeting CXCL12 during transforming growth factor-β3-induced chondrogenic differentiation.
target gene	hsa-mir-34a	Cataract	29299142	nervous system disease	DOID:83	H26.9	D002386	PS116200	HP:0000518	MicroRNA-34a promotes mitochondrial dysfunction-induced apoptosis in human lens epithelial cells by targeting Notch2
target gene	hsa-mir-34a	Cataract	27840975	nervous system disease	DOID:83	H26.9	D002386	PS116200	HP:0000518	miR‑34a suppresses proliferation and induces apoptosis of human lens epithelial cells by targeting E2F3.
target gene	hsa-mir-370	Cerebral Aneurysm	28338184	cardiovascular system disease	DOID:0060228	I67.1	D002532	PS105800	HP:0007029	MicroRNA-370-3p inhibits human vascular smooth muscle cell proliferation via targeting KDR/AKT signaling pathway in cerebral aneurysm.
target gene	hsa-let-7f	Cerebral Ischemia	27812761	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	Let-7f Regulates the Hypoxic Response in Cerebral Ischemia by Targeting NDRG3.
target gene	hsa-mir-134	Cerebral Ischemia	25316150	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	miR-134 regulates ischemia/reperfusion injury-induced neuronal cell death by regulating CREB signaling.
target gene	hsa-mir-138	Cerebral Ischemia	26998035	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	The expression of Lcn-2 was inhibited by miR-138 mimics and enhanced by miR-138 inhibitors
target gene	hsa-mir-210	Cerebral Ischemia	29478968	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	miR-210 promoted neovascularization and NPC migration via the SOCS1-STAT3-VEGF-C pathway
target gene	hsa-mir-376b	Cerebral Ischemia	24789343	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	miR-376b-5p regulates angiogenesis in cerebral ischemia.
target gene	hsa-mir-497	Cerebral Ischemia	20053374	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	Taken together, our data suggest that miR-497 promotes ischemic neuronal death by negatively regulating antiapoptotic proteins, bcl-2 and bcl-w.
target gene	hsa-mir-124	Cerebrovascular Disease	29530526	cardiovascular system disease	DOID:6713	I63.9	D002561	601367		Levels of tight junction protein CLDND1 are regulated by microRNA-124 in the cerebellum of stroke-prone spontaneously hypertensive rats
target gene	hsa-mir-107	Cervical Neoplasms	29073938	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.
target gene	hsa-mir-130a	Cervical Neoplasms	27040383	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR-130a accelerates cervical cancer cell proliferation by  targeting the phosphatase and tensin homolog on chromosome 10 (PTEN)
target gene	hsa-mir-130a	Cervical Neoplasms	29099271	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell.
target gene	hsa-mir-138	Cervical Neoplasms	27900047	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer.
target gene	hsa-mir-143	Cervical Neoplasms	27177038	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	upregulation of miR鈥?43 expression reduced Bcl鈥? expression and increased Bax expression in HeLa cells.
target gene	hsa-mir-143	Cervical Neoplasms	29073938	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.
target gene	hsa-mir-143	Cervical Neoplasms	29271989	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MicroRNA-143 regulates the proliferation and apoptosis of cervical cancer cells by targeting HIF-1α
target gene	hsa-mir-150	Cervical Neoplasms	29091902	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4.
target gene	hsa-mir-16	Cervical Neoplasms	26629104	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	CCNE1 gene is targeted by miR-16-1 in CC cells.
target gene	hsa-mir-200b	Cervical Neoplasms	26935796	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR鈥?00b was shown to inhibit the function  of RhoE and suppress the EMT of cervical cancer
target gene	hsa-mir-204	Cervical Neoplasms	28800788	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-204 Regulates Cell Proliferation and Invasion by Targeting EphB2 in Human Cervical Cancer
target gene	hsa-mir-205	Cervical Neoplasms	27929537	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2.
target gene	hsa-mir-21	Cervical Neoplasms	27220494	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-21 overexpression decreases PTEN, increases p-Akt, and subsequently increases HIF-1伪 expression
target gene	hsa-mir-21	Cervical Neoplasms	29177591	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3
target gene	hsa-mir-210	Cervical Neoplasms	28401751	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Down-Regulation of MicroRNA-210 Confers Sensitivity towards 1'S-1'-Acetoxychavicol Acetate (ACA) in Cervical Cancer Cells by Targeting SMAD4.
target gene	hsa-mir-214	Cervical Neoplasms	19859982	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	these results suggest that miR-214 negatively regulates HeLa cell proliferation by targeting the noncoding regions of MEK3 and JNK1 mRNAs.
target gene	hsa-mir-218	Cervical Neoplasms	17998940	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	We also show that LAMB3 expression is increased in the presence of the HPV-16 E6 oncogene and this effect is mediated through miR-218. These findings may contribute to a better understanding of the molecular mechanisms involved in cervical carcinogenesis.
target gene	hsa-mir-218-1	Cervical Neoplasms	23483249	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma
target gene	hsa-mir-218-2	Cervical Neoplasms	23483249	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma
target gene	hsa-mir-31	Cervical Neoplasms	29159179	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR-31 Functions as an Oncomir Which Promotes Epithelial-Mesenchymal Transition via Regulating BAP1 in Cervical Cancer
target gene	hsa-mir-34a	Cervical Neoplasms	25675046	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-34a Inhibits Viability and Invasion of Human Papillomavirus-Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin.
target gene	hsa-mir-483	Cervical Neoplasms	27693430	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR-483 is a self-regulating microRNA and can activate its own expression via USF1 in HeLa cells.
target gene	hsa-mir-219	Child Development Disorders, Pervasive	20374639			F84.9	D002659			Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays
target gene	hsa-mir-29b	Child Development Disorders, Pervasive	20374639			F84.9	D002659			Putative gene targets (ID3 and PLK2) of two RT-PCR-confirmed brain-specific miRNAs (hsa-miR-29b and hsa-miR-219-5p),were validated by miRNA overexpression or knockdown assays
target gene	hsa-mir-106b	Cholangiocarcinoma	28881782	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma
target gene	hsa-mir-144	Cholangiocarcinoma	25479763	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-144 was reduced in CCA tissues and suggested that miR-144 may be an essential suppresser of CCA cell proliferation and invasion through targeting LIS1.
target gene	hsa-mir-148a	Cholangiocarcinoma	20146264	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	These data indicate that IL-6 can regulate the activity of DNMT-1 and expression of methylation-dependent tumor suppressor genes by modulation of miR-148a and miR-152, and provide a link between this inflammation-associated cytokine and oncogenesis in cholangiocarcinoma.
target gene	hsa-mir-152	Cholangiocarcinoma	20146264	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	These data indicate that IL-6 can regulate the activity of DNMT-1 and expression of methylation-dependent tumor suppressor genes by modulation of miR-148a and miR-152, and provide a link between this inflammation-associated cytokine and oncogenesis in cholangiocarcinoma.
target gene	hsa-mir-16	Cholangiocarcinoma	28915618	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma.
target gene	hsa-mir-17	Cholangiocarcinoma	25239565	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
target gene	hsa-mir-18	Cholangiocarcinoma	25239565	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
target gene	hsa-mir-19a	Cholangiocarcinoma	25239565	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
target gene	hsa-mir-19b-1	Cholangiocarcinoma	25239565	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
target gene	hsa-mir-205	Cholangiocarcinoma	24147037	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miRNA expression profiling was used to identify key miRNAs that regulate Gem sensitivity in CCA cells, and software that predicts miRNA targets was used to identify promising target genes for anti-tumor therapies.
target gene	hsa-mir-20a	Cholangiocarcinoma	25239565	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
target gene	hsa-mir-21	Cholangiocarcinoma	22770403	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	PTEN and PDCD4 are bona fide targets of microRNA-21 in human cholangiocarcinoma.
target gene	hsa-mir-21	Cholangiocarcinoma	24699315	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth.
target gene	hsa-mir-21	Cholangiocarcinoma	25803229	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.
target gene	hsa-mir-21	Cholangiocarcinoma	26191158	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma.
target gene	hsa-mir-21	Cholangiocarcinoma	23254774	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	These data indicated that TPM1 is downregulated in HuCCT1 cells and that the Ras signaling pathway as well as DNA methylation, histone deacetylation and miR-21 upregulation play important roles in the suppression of TPM1 expression in HuCCT1 cells. Thus, compounds that inhibit genetic and epigenetic mechanisms may be promising agents in treating cholangiocarcinoma.
target gene	hsa-mir-21	Cholangiocarcinoma	23480766	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	The expression level of miR-21 had an inverse correlation with the mRNA level of its target RECK, a metastasis suppressor, in human CCA
target gene	hsa-mir-21	Cholangiocarcinoma	23621247	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis.
target gene	hsa-mir-214	Cholangiocarcinoma	22540680	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Downregulated miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist.
target gene	hsa-mir-221	Cholangiocarcinoma	24147037	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miRNA expression profiling was used to identify key miRNAs that regulate Gem sensitivity in CCA cells, and software that predicts miRNA targets was used to identify promising target genes for anti-tumor therapies.
target gene	hsa-mir-25	Cholangiocarcinoma	21953056	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-25 targets TRAIL death Receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.
target gene	hsa-mir-26a	Cholangiocarcinoma	25691459	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression.
target gene	hsa-mir-26a-1	Cholangiocarcinoma	22484120	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MicroRNA-26a Promotes Cholangiocarcinoma Growth by Activating beta-catenin.
target gene	hsa-mir-26a-2	Cholangiocarcinoma	22484120	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MicroRNA-26a Promotes Cholangiocarcinoma Growth by Activating beta-catenin.
target gene	hsa-mir-26b	Cholangiocarcinoma	25691459	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression.
target gene	hsa-mir-29b	Cholangiocarcinoma	24147037	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miRNA expression profiling was used to identify key miRNAs that regulate Gem sensitivity in CCA cells, and software that predicts miRNA targets was used to identify promising target genes for anti-tumor therapies.
target gene	hsa-mir-34a	Cholangiocarcinoma	26077733	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway.
target gene	hsa-mir-373	Cholangiocarcinoma	21086164	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-373 is one negative regulator of MBD2. In hilar cholangiocarcinoma, down-expression of miR-373 leads to increase of MBD2, which in turn suppresses the methylation-mediated gene such as RASSF1A.
target gene	hsa-mir-605	Cholangiocarcinoma	25131931	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
target gene	hsa-mir-92-1	Cholangiocarcinoma	25239565	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
target gene	hsa-mir-100	Chondrosarcoma	24568519	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR.
target gene	hsa-mir-126	Chondrosarcoma	24975661	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Naringin suppress chondrosarcoma migration through inhibition vascular adhesion molecule-1 expression by modulating miR-126.
target gene	hsa-mir-23b	Chondrosarcoma	28085008	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.
target gene	hsa-mir-30a	Chondrosarcoma	25572678	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	SOX4 was oncogenic in chondrosarcoma and negatively regulated by miR-30a in vitro. Importantly, SOX4 overexpression may serve as a prognostic marker for patients with low-histological-grade chondrosarcoma
target gene	hsa-mir-494	Chondrosarcoma	26317788	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9.
target gene	hsa-mir-1	Chordoma	24760686	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug.
target gene	hsa-mir-34a	Chordoma	24621885	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.
target gene	hsa-mir-608	Chordoma	24621885	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.
target gene	hsa-mir-145	Choriocarcinoma	23251245	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Cell proliferation and invasion ability of human choriocarcinoma cells lessened due to inhibition of Sox2 expression by microRNA-145
target gene	hsa-mir-183	Choriocarcinoma	26951513	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	overexpression of miR-183 in CSLCs decreased PTPN4 protein levels while inhibition of miR-183 increased PTPN4 protein levels.
target gene	hsa-mir-192	Choriocarcinoma	27079614	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	microRNA-192 suppresses the expression of FXR and FXR target genes in vitro and in vivo.
target gene	hsa-mir-21	Choriocarcinoma	27475963	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	We find various mechanisms of PTEN protein loss in the different tumour cell populations, including allelic PTEN deletions, gross chromosomal 10 aberrations and altered miR-21 expression.
target gene	hsa-mir-218	Choriocarcinoma	24973709	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	MicroRNA-218 inhibits the proliferation of human choriocarcinoma JEG-3 cell line by targeting Fbxw8.
target gene	hsa-mir-221	Choriocarcinoma	26501139	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	In conclusion, our results suggested that miR-221 promotes EMT through targeting PTEN and forms a positive feedback loop with β-catenin/c-Jun signaling pathway in EHCC.
target gene	hsa-mir-29	Choroidal Neovascularization	24886609			H44.2A9	D020256		HP:0011506	The results suggest that in CNV, NFκB activation inhibits miR-29s,which may contribute to angiogenesis by up-regulating the MMP-2 protein level in RPE cells. These observations may help in developing a strategy for resolving CNV by targeting miR-29s levels.
target gene	hsa-mir-96	Chromosome 22Q11.2 Deletion Syndrome, Distal	25556186	genetic disease	DOID:0060413			611867		Tbx1 regulates the proliferation of dental progenitor cells and craniofacial development through miR-96-5p and PITX2. Together, these data suggest a new molecular mechanism controlling pathogenesis of dental anomalies in human 22q11.2DS miR-7a
target gene	hsa-mir-146a	Chronic Heart Failure	20495188	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	These findings suggested that the up-regulation of miR-146a after Dox treatment is involved in acute Dox-induced cardiotoxicity by targeting ErbB4.
target gene	hsa-mir-423	Chronic Heart Failure	25776937	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	the results of the present study indicated that miR-423-5p was involved in CHF via the direct targeting of OGT and the induction of apoptosis in cardiomyocytes.
target gene	hsa-mir-720	Chronic Hepatitis B	26199080			B18.0-.1	D019694	610424		therapies targeting miR-720 may help restore impaired immunity in chronic HBV infection (CHB) patients.
target gene	hsa-mir-122	Chronic Hepatitis C	27677491			B18.2	D019698	609532		microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3' untranslated region: function in replication and influence of RNA secondary structure.
target gene	hsa-mir-122	Chronic Hepatitis C	29182758			B18.2	D019698	609532		miR-122 regulates ALDOB and PKM2 expression at the mRNA level
target gene	hsa-mir-122	Chronic Hepatitis C	29593672			B18.2	D019698	609532		the liver-specific microRNA-122 (miR-122) binds to two target sites at the 5' end of the viral RNA genome as well as to at least three additional target sites in the coding region and the 3' UTR
target gene	hsa-mir-122	Chronic Hepatitis C	29669014			B18.2	D019698	609532		miR-122 positively regulates HCV replication by a direct interaction with the 5' untranslated region (UTR) of the viral RNA
target gene	hsa-mir-155	Chronic Hepatitis C	25772938			B18.2	D019698	609532		MicroRNA-155 regulates interferon-γ production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection.
target gene	hsa-mir-448	Chronic Hepatitis C	24158346			B18.2	D019698	609532		Besides miR-122, let-7b, miR-196, miR-199a* and miR-448 have also been reported to interact directly with the HCV RNA.
target gene	hsa-mir-130a	Chronic Inflammation	26436920							Therefore,miR-142-5p and miR-130a-3p regulate macrophage profibrogenic gene expression in chronic inflammation.
target gene	hsa-mir-142	Chronic Inflammation	26436920							Therefore,miR-142-5p and miR-130a-3p regulate macrophage profibrogenic gene expression in chronic inflammation.
target gene	hsa-mir-16	Chronic Inflammatory Pain	27770129							MicroRNA-16 Alleviates Inflammatory Pain by Targeting Ras-Related Protein 23 (RAB23) and Inhibiting p38 MAPK Activation.
target gene	hsa-mir-1-1	Chronic Obstructive Pulmonary Disease	21998125	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients.
target gene	hsa-mir-1-2	Chronic Obstructive Pulmonary Disease	21998125	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients.
target gene	hsa-mir-133a-1	Chronic Obstructive Pulmonary Disease	21998125	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients.
target gene	hsa-mir-133a-2	Chronic Obstructive Pulmonary Disease	21998125	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients.
target gene	hsa-mir-133b	Chronic Obstructive Pulmonary Disease	21998125	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients.
target gene	hsa-mir-199a	Chronic Obstructive Pulmonary Disease	24634990	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Blunted expression of miR-199a-5p in regulatory T cells of patients with chronic  obstructive pulmonary disease compared to unaffected smokers.
target gene	hsa-mir-203	Chronic Obstructive Pulmonary Disease	26617776	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	miR-203 represses NF-κB signaling via targeting TAK1 and PI3KCA and miR-203 overexpression may contribute to the COPD initiation.
target gene	hsa-mir-206	Chronic Obstructive Pulmonary Disease	21998125	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	A reduction in expression of miR-1 (2.5-fold, p=0.01) and the myocardin-related transcription factors (MRTFs) A and B was observed in patients compared with controls (MRTF-A mRNA: twofold, p=0.028; MRTF-B mRNA: fourfold, p=0.011). miR-1 expression was associated with smoking history, lung function, fat-free mass index, 6 min walk distance and percentage of type 1 fibres. miR-133 and miR-206 were negatively correlated with daily physical activity. Insulin-like growth factor 1 mRNA was increased in the patients and miR-1 was negatively correlated with phosphorylation of the kinase Akt. Furthermore, the protein levels of histone deacetylase 4, another miR-1 target, were increased in the patients.
target gene	hsa-mir-34a	Chronic Obstructive Pulmonary Disease	29373969	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	miR-34a is involved in CSE-induced apoptosis of human pulmonary microvascular endothelial cells by targeting Notch-1 receptor protein
target gene	hsa-mir-185	Cleidocranial Dysplasia	29242628	musculoskeletal system disease	DOID:13994	Q74.0	D002973	119600		Mutant Runx2 regulates amelogenesis and osteogenesis through a miR-185-5p-Dlx2 axis.
target gene	hsa-let-7d	Cocaine Abuse	19703567	disease of mental health	DOID:809	F14.1	D019970			downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated
target gene	hsa-mir-124-1	Cocaine Abuse	19703567	disease of mental health	DOID:809	F14.1	D019970			downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated
target gene	hsa-mir-124-2	Cocaine Abuse	19703567	disease of mental health	DOID:809	F14.1	D019970			downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated
target gene	hsa-mir-124-3	Cocaine Abuse	19703567	disease of mental health	DOID:809	F14.1	D019970			downregulated;These miRNAs target many genes involved in cocaine addiction. Precursor and mature miRNA quantification by qRT-PCR showed that miR-124 and let-7d are significantly downregulated
target gene	hsa-mir-181a-2	Cocaine Abuse	19703567	disease of mental health	DOID:809	F14.1	D019970			miR-124, let-7d and miR-181a may be involved in a complex feedback loop with cocaine-responsive plasticity genes
target gene	hsa-mir-19a	Colitis	23795660	gastrointestinal system disease	DOID:0060180	K52.9	D003092	191390	HP:0002583	Taken together, this study determines the levels of miR-19a and TNF-α in both DSS-induced experimental murine colitis and human UC and further demonstrates that miR-19a might directly regulate TNF-α. The findings may provide a new insight in the clinical treatment of UC.
target gene	hsa-mir-31	Colitis	27901018	gastrointestinal system disease	DOID:0060180	K52.9	D003092	191390	HP:0002583	The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis.
target gene	hsa-mir-124	Colitis, Ulcerative	23856509	gastrointestinal system disease	DOID:8577	K51	D003093			miR-124 appears to regulate the expression of STAT3. Reduced levels of miR-124 in colon tissues of children with active UC appear to increase expression and activity of STAT3, which could promote inflammation and the pathogenesis of UC in children.
target gene	hsa-mir-126	Colitis, Ulcerative	23285182	gastrointestinal system disease	DOID:8577	K51	D003093			Up-Regulation of microRNA-126 May Contribute to Pathogenesis of Ulcerative Colitis via Regulating NF-kappaB Inhibitor Iж╩Bж┿
target gene	hsa-mir-155	Colitis, Ulcerative	24583476	gastrointestinal system disease	DOID:8577	K51	D003093			miR-155 appears to play a role in the intestinal inflammation of patients with active UC by downregulating the expression of FOXO3a. This process may activate the nuclear factor kappa B signaling pathway.
target gene	hsa-mir-155	Colitis, Ulcerative	25998827	gastrointestinal system disease	DOID:8577	K51	D003093			MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis.
target gene	hsa-mir-155	Colitis, Ulcerative	28461115	gastrointestinal system disease	DOID:8577	K51	D003093			MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2.
target gene	hsa-mir-195	Colitis, Ulcerative	26303523	gastrointestinal system disease	DOID:8577	K51	D003093			miR-195 plays a role in steroid resistance of ulcerative colitis by targeting Smad7.
target gene	hsa-mir-29a	Colitis, Ulcerative	25674218	gastrointestinal system disease	DOID:8577	K51	D003093			miR-29a is involved in the pathogenesis of UC by regulating intestinal epithelial apoptosis via Mcl-1.
target gene	hsa-mir-4284	Colitis, Ulcerative	25738378	gastrointestinal system disease	DOID:8577	K51	D003093			Our data reveal a novel microRNA pediatric UC signature and provide evidence that miR-4284 directly regulates CXCL5 and correlates with the disease activity.
target gene	hsa-mir-182	Colon Adenoma	25269767	disease of cellular proliferation	DOID:0050912					Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7,contributing to the malignant transformation of colon adenoma to adenocarcinoma.
target gene	hsa-mir-503	Colon Adenoma	25269767	disease of cellular proliferation	DOID:0050912					Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7,contributing to the malignant transformation of colon adenoma to adenocarcinoma.
target gene	hsa-mir-106a	Colon Neoplasms	18521848			D12.6	D003110		HP:0100273	Deregulated expression of miR-106a predicts survival in human colon cancer patients.
target gene	hsa-mir-126	Colon Neoplasms	23744532			D12.6	D003110		HP:0100273	Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4.
target gene	hsa-mir-133a	Colon Neoplasms	24464560			D12.6	D003110		HP:0100273	Overexpression of miR-223, one of the main miRNA showing strong upregulation during AOM/DSS tumor growth, inhibited Akt phosphorylation and IGF-1R expression in these cells.
target gene	hsa-mir-143	Colon Neoplasms	22691140			D12.6	D003110		HP:0100273	microRNA-143 down-regulates Hexokinase 2 in colon cancer cells.
target gene	hsa-mir-145	Colon Neoplasms	17827156			D12.6	D003110		HP:0100273	Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells.
target gene	hsa-mir-145	Colon Neoplasms	21917858			D12.6	D003110		HP:0100273	The expression of miR-145 is downregulated in colon and ovarian cancer tissues and cell lines. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis.
target gene	hsa-mir-145	Colon Neoplasms	22766504			D12.6	D003110		HP:0100273	MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells.
target gene	hsa-mir-145	Colon Neoplasms	20098684			D12.6	D003110		HP:0100273	MicroRNA-145 targets YES and STAT1 in colon cancer cells.
target gene	hsa-mir-145	Colon Neoplasms	20737575			D12.6	D003110		HP:0100273	Taken together, these results suggest that miR-145 functions as a tumor suppressor by down-regulating oncogenic FLI1 in colon cancer.
target gene	hsa-mir-155	Colon Neoplasms	29104623			D12.6	D003110		HP:0100273	MicroRNA-155 regulates the proliferation, cell cycle, apoptosis and migration of colon cancer cells and targets CBL.
target gene	hsa-mir-17	Colon Neoplasms	18521848			D12.6	D003110		HP:0100273	Deregulated expression of miR-106a predicts survival in human colon cancer patients.
target gene	hsa-mir-17	Colon Neoplasms	27278684			D12.6	D003110		HP:0100273	miR鈥?7 overexpression led to the degradation of CYP7B1 mRNA expression in DLD1 cells.
target gene	hsa-mir-204	Colon Neoplasms	29460671			D12.6	D003110		HP:0100273	Targeted delivery of miRNA-204-5p by PEGylated polymer nanoparticles for colon cancer therapy
target gene	hsa-mir-21	Colon Neoplasms	22072622			D12.6	D003110		HP:0100273	MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells.
target gene	hsa-mir-21	Colon Neoplasms	22322462			D12.6	D003110		HP:0100273	microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells.
target gene	hsa-mir-21	Colon Neoplasms	29564000			D12.6	D003110		HP:0100273	Berberine regulates the microRNA-21-ITGΒ4-PDCD4 axis and inhibits colon cancer viability
target gene	hsa-mir-218-1	Colon Neoplasms	23255074			D12.6	D003110		HP:0100273	MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1
target gene	hsa-mir-218-2	Colon Neoplasms	23255074			D12.6	D003110		HP:0100273	MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating oncogene BMI-1
target gene	hsa-mir-221	Colon Neoplasms	22126772			D12.6	D003110		HP:0100273	MicroRNA-221 promotes colon carcinoma cell proliferation in vitro by inhibiting CDKN1C/p57 expression.
target gene	hsa-mir-24	Colon Neoplasms	27888625			D12.6	D003110		HP:0100273	TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer.
target gene	hsa-mir-30a	Colon Neoplasms	22287560			D12.6	D003110		HP:0100273	MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.
target gene	hsa-mir-31	Colon Neoplasms	23258531			D12.6	D003110		HP:0100273	miR-31 acts as an oncogene in colon cancer and identified RhoBTB1 as a new target of miR-31 further study demonstrated that miR-31 contributed to the development of colon cancer at least partly by targeting RhoBTB1
target gene	hsa-mir-330	Colon Neoplasms	22132977			D12.6	D003110		HP:0100273	Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R = 0.82, p = 0.04). Exposure to gemcitabine also appeared to influence miR-330 levels in these cell lines. Furthermore, in our cell line panel, miR-330 expression negatively correlated with dCK mRNA expression (R = 0.74), suggesting a role of miR-330 in post-transcriptional regulation of dCK.
target gene	hsa-mir-339	Colon Neoplasms	25193859			D12.6	D003110		HP:0100273	MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling.
target gene	hsa-mir-34a	Colon Neoplasms	22198213			D12.6	D003110		HP:0100273	MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1.
target gene	hsa-mir-34a	Colon Neoplasms	22479251			D12.6	D003110		HP:0100273	miR-34a induces colon cancer apoptosis through SIRT1, and miR-34a also promotes senescence in endothelial cells via SIRT1.
target gene	hsa-mir-34a	Colon Neoplasms	26849305			D12.6	D003110		HP:0100273	miR-34a directly suppresses Numb in early-stage colon cancer stem cells (CCSCs)
target gene	hsa-mir-378	Colon Neoplasms	28725241			D12.6	D003110		HP:0100273	miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1.
target gene	hsa-mir-506	Colon Neoplasms	22036718			D12.6	D003110		HP:0100273	MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells.
target gene	hsa-mir-1	Colorectal Carcinoma	28471448	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-1 suppresses tumor cell proliferation in colorectal cancer by inhibition of Smad3-mediated tumor glycolysis.
target gene	hsa-mir-100	Colorectal Carcinoma	24626817	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-100 regulates SW620 colorectal cancer cell proliferation and invasion by targeting RAP1B.
target gene	hsa-mir-101	Colorectal Carcinoma	25057058	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We have successfully constructed a SW620 cell line stably overexpressing mir-101. mir-101 can suppress RAC1 gene expression by targeting the specific sequence of RAC1 3'UTR.
target gene	hsa-mir-101	Colorectal Carcinoma	28000868	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Methyl jasmonate induces the apoptosis of human colorectal cancer cells via downregulation of EZH2 expression by microRNA‑101.
target gene	hsa-mir-103	Colorectal Carcinoma	24393525	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		PER3, a novel target of miR-103, plays a suppressive role in colorectal cancer in vitro.
target gene	hsa-mir-103	Colorectal Carcinoma	24828205	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-103 promotes colorectal cancer by targeting tumor suppressor DICER and PTEN.
target gene	hsa-mir-124	Colorectal Carcinoma	23940556	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3.
target gene	hsa-mir-124	Colorectal Carcinoma	25081869	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4.
target gene	hsa-mir-124	Colorectal Carcinoma	26248089	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR124 inhibits DNA synthesis and proliferation by reducing levels of pentose phosphate pathway enzymes in CRC cells. Expression of miR124 and its targets correlate with survival times and might be used in prognosis.
target gene	hsa-mir-124	Colorectal Carcinoma	26497367	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In conclusion, our data showed that miR-124 and miR-506 inhibit progression and increase sensitivity to chemotherapy by targeting DNMT3B and DNMT1 in CRC. These findings may provide novel avenues for the development of targeted therapies.
target gene	hsa-mir-126	Colorectal Carcinoma	24189753	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-126 functions as a tumor suppressor in CRC cells by regulating CXCR4 expression via the AKT and ERK1/2 signaling pathways and might be a novel target for therapeutic strategies in CRC.
target gene	hsa-mir-126	Colorectal Carcinoma	24312276	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-126 may play roles in regulation of the biological behavior of CRC cells, at least in part, by targeting IRS-1 via AKT and ERK1/2 signaling pathways.
target gene	hsa-mir-126	Colorectal Carcinoma	23922111	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The results validate the previous findings on the prognostic value of miRNA-126 in mCRC and may suggest a relationship between treatment efficacy and EGFL7 expression. As miRNA 126 may target VEGF-A as well as EGFL7, the results may provide predictive information in relation to next-generation anti-angiogenetics.
target gene	hsa-mir-129	Colorectal Carcinoma	20404570	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		our data indicate that miR-129 plays an important role in regulating cell proliferation by downregulation of Cdk6.
target gene	hsa-mir-130a	Colorectal Carcinoma	28849155	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-130a is upregulated in colorectal cancer and promotes cell growth and motility by directly targeting forkhead box F2.
target gene	hsa-mir-130b	Colorectal Carcinoma	24468585	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer.
target gene	hsa-mir-130b	Colorectal Carcinoma	26873488	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		colorectal cancer
target gene	hsa-mir-133b	Colorectal Carcinoma	24330809	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study demonstrated that downregulated miR-133b contributed to increased cell invasion and migration in CRC by negatively regulating CXCR4.These findings may be significant for the development of therapy target for CRC.
target gene	hsa-mir-135b	Colorectal Carcinoma	24343340	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-135b regulates metastasis suppressor 1 expression and promotes migration and invasion in colorectal cancer.
target gene	hsa-mir-135b	Colorectal Carcinoma	26061281	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-135b Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer.
target gene	hsa-mir-137	Colorectal Carcinoma	25940441	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression.
target gene	hsa-mir-138	Colorectal Carcinoma	24171926	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These data highlight a pivotal role for miR-138 in the regulation of CRC metastasis by targeting TWIST2, and suggest a potential application of miR-138 in prognosis prediction and CRC treatment.
target gene	hsa-mir-138	Colorectal Carcinoma	28707774	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1.
target gene	hsa-mir-139	Colorectal Carcinoma	25149074	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1.
target gene	hsa-mir-140	Colorectal Carcinoma	26402430	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggested a tumor suppressive role of miR-140-5p in CRC tumorigenesis and progression by targeting VEGFA.
target gene	hsa-mir-140	Colorectal Carcinoma	29499953	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-140 might be a key suppressor of CRC progression and metastasis through inhibiting EMT process by targeting Smad3
target gene	hsa-mir-145	Colorectal Carcinoma	24642628	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-145 has a critical role in the inhibition of invasive and metastatic capacities of CRC, probably through directly targeting Fascin-1. This miRNA may be involved in the development and progression of CRC.
target gene	hsa-mir-145	Colorectal Carcinoma	25913620	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.
target gene	hsa-mir-145	Colorectal Carcinoma	27572146	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-145 suppresses colorectal cancer cell migration and invasion by targeting an ETS-related gene.
target gene	hsa-mir-145	Colorectal Carcinoma	28534337	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98.
target gene	hsa-mir-145	Colorectal Carcinoma	28802228	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma
target gene	hsa-mir-146	Colorectal Carcinoma	29722931	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-146b-5p was shown to increase EMT by targeting Smad4, and the miR-146b-5p-Smad4 cascade regulated EMT in CRC
target gene	hsa-mir-146b	Colorectal Carcinoma	28560062	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer.
target gene	hsa-mir-146b	Colorectal Carcinoma	29722931	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-146b-5p was shown to increase EMT by targeting Smad4, and the miR-146b-5p-Smad4 cascade regulated EMT in CRC
target gene	hsa-mir-149	Colorectal Carcinoma	25613903	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		mR-149 was an independent prognostic factor and could inhibit migration and invasion of CRC cells, at least partially by targeting FOXM1.
target gene	hsa-mir-150	Colorectal Carcinoma	25230975	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb.
target gene	hsa-mir-154	Colorectal Carcinoma	24242044	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2.
target gene	hsa-mir-155	Colorectal Carcinoma	29556299	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro
target gene	hsa-mir-155	Colorectal Carcinoma	24793496	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We validate, for the first  time, that E2F2 is a direct target of miR-155 using western blot and a luciferase reporter assay and that miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2 using siRNA technology.
target gene	hsa-mir-155	Colorectal Carcinoma	26340059	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We further showed that miR-155  acted to repress the Warburg effect through the mechanism of inactivating the IL-6/STAT3 pathway.
target gene	hsa-mir-16	Colorectal Carcinoma	27857191	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Deregulation of the miR-16-KRAS axis promotes colorectal cancer.
target gene	hsa-mir-17	Colorectal Carcinoma	24912422	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-17-5p is a predictive factor for chemotherapy response and a prognostic factor for overall survival in CRC, which is due to its regulation of PTEN expression.
target gene	hsa-mir-181b	Colorectal Carcinoma	27647131	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-181b functions as an oncomiR in colorectal cancer by targeting PDCD4.
target gene	hsa-mir-182	Colorectal Carcinoma	25738520	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-182 promotes cell growth and invasion by targeting forkhead box F2 transcription factor in colorectal cancer.
target gene	hsa-mir-182	Colorectal Carcinoma	28767179	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
target gene	hsa-mir-185	Colorectal Carcinoma	25531324	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		expression of STIM1 is regulated by a posttranscriptional regulatory mechanism mediated by a new EMT-related miRNA. This novel miR-185-STIM1 axis promotes CRC metastasis and may be a candidate biomarker for prognosis and a target for new therapies.
target gene	hsa-mir-187	Colorectal Carcinoma	26820227	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-187, a downstream effector of TGFβ pathway, suppresses Smad-mediated epithelial-mesenchymal transition in colorectal cancer.
target gene	hsa-mir-18a	Colorectal Carcinoma	26398009	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings demonstrate that miR-18a exhibits a protective role in CRC via inhibiting proliferation, invasion and migration of CRC cells by directly targeting the TBPL1 gene.
target gene	hsa-mir-191	Colorectal Carcinoma	25784653	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPβ.
target gene	hsa-mir-193b	Colorectal Carcinoma	22674437	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism.
target gene	hsa-mir-194	Colorectal Carcinoma	25285168	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-194 deregulation contributes to colorectal carcinogenesis via targeting AKT2 pathway.
target gene	hsa-mir-195	Colorectal Carcinoma	24787958	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3.
target gene	hsa-mir-195	Colorectal Carcinoma	28345460	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Coactivator-associated arginine methyltransferase 1 promotes cell growth and is targeted by microRNA-195-5p in human colorectal cancer.
target gene	hsa-mir-197	Colorectal Carcinoma	26055341	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-197 mediates the response of colorectal cancer cells to 5-FU by regulating TYMS expression.
target gene	hsa-mir-198	Colorectal Carcinoma	25174450	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8.
target gene	hsa-mir-199a	Colorectal Carcinoma	24972723	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer.
target gene	hsa-mir-199a	Colorectal Carcinoma	25772759	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer.
target gene	hsa-mir-199a-1	Colorectal Carcinoma	22674437	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism.
target gene	hsa-mir-199a-2	Colorectal Carcinoma	22674437	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism.
target gene	hsa-mir-200b	Colorectal Carcinoma	24151081	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-200b stimulates tumour growth in TGFBR2-null colorectal cancers by negatively regulating p27/kip1.
target gene	hsa-mir-200b	Colorectal Carcinoma	25826661	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs.
target gene	hsa-mir-200c	Colorectal Carcinoma	25826661	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs.
target gene	hsa-mir-200c	Colorectal Carcinoma	27315529	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		ZEB1 expression was seen in connection with decreased miR-200c expression
target gene	hsa-mir-200c	Colorectal Carcinoma	28543447	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Fas signaling induces stemness properties in colorectal cancer by regulation of Bmi1.
target gene	hsa-mir-203	Colorectal Carcinoma	24145123	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.
target gene	hsa-mir-204	Colorectal Carcinoma	29402343	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-204 inhibits the growth and motility of colorectal cancer cells by downregulation of CXCL8
target gene	hsa-mir-205	Colorectal Carcinoma	28990808	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-205 Mediates Proteinase-Activated Receptor 2 (PAR2) -Promoted Cancer Cell Migration.
target gene	hsa-mir-20a	Colorectal Carcinoma	28004114	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a-directed regulation of BID is associated with the TRAIL sensitivity in colorectal cancer.
target gene	hsa-mir-20b	Colorectal Carcinoma	24468585	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer.
target gene	hsa-mir-21	Colorectal Carcinoma	24468585	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer.
target gene	hsa-mir-21	Colorectal Carcinoma	26419959	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our data support a possible role of tumor epigenetic deregulation by noncoding RNA in suppressing the antitumor T-cell-mediated adaptive immune response and suggest MIR21 as a potential target for immunotherapy and prevention in colorectal cancer.
target gene	hsa-mir-21	Colorectal Carcinoma	26811607	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-21 increases the levels of IL-10 and prostaglandin E2, which suppress antitumor T-cell-mediated adaptive immunity
target gene	hsa-mir-21	Colorectal Carcinoma	27350731	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		PTEN is one of the direct target genes of miR-21.
target gene	hsa-mir-21	Colorectal Carcinoma	28347230	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4.
target gene	hsa-mir-21	Colorectal Carcinoma	28957811	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer.
target gene	hsa-mir-215	Colorectal Carcinoma	25775580	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The CDX1-microRNA-215 axis regulates colorectal cancer stem cell differentiation.
target gene	hsa-mir-215	Colorectal Carcinoma	26287603	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of miR-215 mediated targets/pathways via translational immunoprecipitation expression analysis (TrIP-chip).
target gene	hsa-mir-218	Colorectal Carcinoma	27779719	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy.
target gene	hsa-mir-22	Colorectal Carcinoma	28347238	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The predicted target gene validation, function, and prognosis studies of miRNA-22 in colorectal cancer tissue.
target gene	hsa-mir-221	Colorectal Carcinoma	24269686	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK.
target gene	hsa-mir-221	Colorectal Carcinoma	24931456	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In human CRC cells, miR-221 and miR-222 act in a positive feedback loop to increase expression levels of RelA and STAT3. Antagonism of miR-221 and miR-222 reduces growth of colon tumors in mice with colitis.
target gene	hsa-mir-221	Colorectal Carcinoma	29434757	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-221 inhibits autophagy and targets TP53INP1 in colorectal cancer cells
target gene	hsa-mir-221	Colorectal Carcinoma	23688995	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Anti-miR-221 can enhance the radiosensitivity of colorectal carcinoma cells by up-regulating the expression of PTEN
target gene	hsa-mir-222	Colorectal Carcinoma	24931456	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In human CRC cells, miR-221 and miR-222 act in a positive feedback loop to increase expression levels of RelA and STAT3. Antagonism of miR-221 and miR-222 reduces growth of colon tumors in mice with colitis.
target gene	hsa-mir-222	Colorectal Carcinoma	23173124	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		On the other hand, miR-222 targeting ADAM-17, a disintegrin and metalloproteinase, and miR-328 interacting with ABCG2, an ABC transporter, may overcome drug resistance of cancer cells.
target gene	hsa-mir-222	Colorectal Carcinoma	28855850	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-222 influences migration and invasion through MIA3 in colorectal cancer
target gene	hsa-mir-223	Colorectal Carcinoma	27916606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma.
target gene	hsa-mir-224	Colorectal Carcinoma	24817781	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42.
target gene	hsa-mir-23a	Colorectal Carcinoma	24992592	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The involvement of miR-23a/APAF1 regulation axis in colorectal cancer.
target gene	hsa-mir-23a	Colorectal Carcinoma	25929864	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1.
target gene	hsa-mir-23b	Colorectal Carcinoma	28487386	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		our results define a critical function for miR-23b, which, by targeting LGR5, contributes to overpopulation of ALDH+ CSCs and colorectal cancer
target gene	hsa-mir-25	Colorectal Carcinoma	25174582	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Angiopoietin-like protein 2 negatively regulated by microRNA-25 contributes to the malignant progression of colorectal cancer.
target gene	hsa-mir-26a	Colorectal Carcinoma	24935220	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-26a regulates glucose metabolism of colorectal cancer cells by direct targeting the PDHX, which inhibits the conversion of pyruvate to acetyl coenzyme A in the citric acid cycle.
target gene	hsa-mir-26a	Colorectal Carcinoma	28443472	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-26a downregulates retinoblastoma in colorectal cancer.
target gene	hsa-mir-26a	Colorectal Carcinoma	28640257	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer.
target gene	hsa-mir-26b	Colorectal Carcinoma	23922874	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells.
target gene	hsa-mir-26b	Colorectal Carcinoma	28640257	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer.
target gene	hsa-mir-27a	Colorectal Carcinoma	25166914	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2.
target gene	hsa-mir-27a	Colorectal Carcinoma	26913609	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-27a modulates a group of proteins involved in MHC class I cell surface exposure
target gene	hsa-mir-29a	Colorectal Carcinoma	24281002	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-29a promoted CRC metastasis by regulating MMP2/E-cad through direct targeting KLF4, which highlights the potential of the miR-29a inhibitor as a novel agent against CRC metastasis.
target gene	hsa-mir-29a	Colorectal Carcinoma	23173124	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA levels may serve as a predictive CRC marker, which was confirmed by the serum level of miR-29a targeting KLF4, a marker of cell stemness, and the plasma level of miR-221 down-regulating c-Kit, Stat5A and ETS1, which are signal transducers and transcription factor, respectively
target gene	hsa-mir-29b	Colorectal Carcinoma	24913975	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-29b downregulates canonical Wnt signaling by suppressing coactivators of β-catenin in human colorectal cancer cells.
target gene	hsa-mir-29b	Colorectal Carcinoma	25472644	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-29b may be a useful, novel,prognostic marker and may play important roles in regulating apoptosis and cell cycle in CRC.
target gene	hsa-mir-29b	Colorectal Carcinoma	25592039	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the potential signaling pathway,IFN-γ/IRF1/miR-29b/IGF1, and its implication for CRC tumorigenesis. A positive feedback loop between IRF1 and miR-29b may contribute to the sensitivity of CRC cells to IFN-γ. Targeting miR-29b may provide a strategy for blocking CRC growth  and metastasis.
target gene	hsa-mir-29b	Colorectal Carcinoma	25032858	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition.
target gene	hsa-mir-301a	Colorectal Carcinoma	25551793	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-301a correlated with the metastatic and invasive ability in human colorectal cancers and miR-301a exerted its role as oncogene by targeting TGFBR2.
target gene	hsa-mir-302a	Colorectal Carcinoma	26191138	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Up-regulation of microRNA-302a inhibited the proliferation and invasion of colorectal cancer cells by regulation of the MAPK and PI3K/Akt signaling pathways.
target gene	hsa-mir-30a	Colorectal Carcinoma	27576787	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-30a-5p Suppresses Tumor Metastasis of Human Colorectal Cancer by Targeting ITGB3.
target gene	hsa-mir-30b	Colorectal Carcinoma	24293274	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
target gene	hsa-mir-30b	Colorectal Carcinoma	24593661	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-30b regulates migration and invasion of human colorectal cancer via SIX1.
target gene	hsa-mir-30c	Colorectal Carcinoma	25799050	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Role of microRNA-30c targeting ADAM19 in colorectal cancer.
target gene	hsa-mir-31	Colorectal Carcinoma	24386467	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2.
target gene	hsa-mir-31	Colorectal Carcinoma	24521875	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1).
target gene	hsa-mir-31	Colorectal Carcinoma	29463215	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-31 down-regulated c-MET in DLD-1 colon cancer cells
target gene	hsa-mir-320a	Colorectal Carcinoma	24265291	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-320a suppresses colorectal cancer progression by targeting Rac1.
target gene	hsa-mir-320c-1	Colorectal Carcinoma	22674437	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism.
target gene	hsa-mir-320c-2	Colorectal Carcinoma	22674437	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism.
target gene	hsa-mir-331	Colorectal Carcinoma	26718987	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overall, we identified that miR-331-3p is underexpressed in CRC and contributes to cell growth regulation by targeting HER2 through activating the PI3K/Akt and ERK1/2 signaling pathways.
target gene	hsa-mir-34a	Colorectal Carcinoma	24370784	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-34a is frequently downregulated in CRC and modulates the phosphorylation of FAK by negatively regulating VEGF.
target gene	hsa-mir-34a	Colorectal Carcinoma	26103003	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer.
target gene	hsa-mir-34a	Colorectal Carcinoma	28348487	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway.
target gene	hsa-mir-34c	Colorectal Carcinoma	25213795	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells.
target gene	hsa-mir-375	Colorectal Carcinoma	24440701	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
target gene	hsa-mir-375	Colorectal Carcinoma	28374902	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Impact of microRNA-375 and its target gene SMAD-7 polymorphism on susceptibility of colorectal cancer.
target gene	hsa-mir-375	Colorectal Carcinoma	28802228	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma
target gene	hsa-mir-409	Colorectal Carcinoma	25991585	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression.
target gene	hsa-mir-451	Colorectal Carcinoma	27612504	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Expression pattern of miR-451 and its target MIF (macrophage migration inhibitory factor) in colorectal cancer.
target gene	hsa-mir-454	Colorectal Carcinoma	25824771	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression.
target gene	hsa-mir-455	Colorectal Carcinoma	25355599	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase.
target gene	hsa-mir-487b	Colorectal Carcinoma	28000854	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer.
target gene	hsa-mir-497	Colorectal Carcinoma	26840372	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Thus our results provide evidence that miR-497 might function as a metastasis suppressor in CRC. Targeting miR-497 may provide a strategy for blocking its metastasis.
target gene	hsa-mir-506	Colorectal Carcinoma	26497367	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In conclusion, our data showed that miR-124 and miR-506 inhibit progression and increase sensitivity to chemotherapy by targeting DNMT3B and DNMT1 in CRC. These findings may provide novel avenues for the development of targeted therapies.
target gene	hsa-mir-518a	Colorectal Carcinoma	24559209	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We have shown that miR-518a-5p functionally interacts with CCR6 and that transfection of CRC cells with miR-518a-5p leads to significant CCR6 down-regulation. Consequently, CCR6 expression is regulated by miR-518a-5p in CRC cells indicating that regulation of CCR6 expression by miR-518a-5p might be a regulatory mechanism involved in CRC pathogenesis.
target gene	hsa-mir-519c	Colorectal Carcinoma	26386386	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
target gene	hsa-mir-522	Colorectal Carcinoma	29386092	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-522-3p promotes tumorigenesis in human colorectal cancer via targeting bloom syndrome protein.
target gene	hsa-mir-587	Colorectal Carcinoma	26247730	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.
target gene	hsa-mir-590	Colorectal Carcinoma	28433598	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer.
target gene	hsa-mir-612	Colorectal Carcinoma	26158514	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2.
target gene	hsa-mir-622	Colorectal Carcinoma	25961730	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb.
target gene	hsa-mir-630	Colorectal Carcinoma	26263387	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		CREB-miR-630-BCL2L2 and TP53RK comprise a novel signaling cascade regulating radiosensitivity in CRC cell lines by inducing cell apoptosis and death.
target gene	hsa-mir-646	Colorectal Carcinoma	29391877	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Low-level miR-646 in colorectal cancer inhibits cell proliferation and migration by targeting NOB1 expression
target gene	hsa-mir-892a	Colorectal Carcinoma	26054685	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-892a regulated PPP2R2A expression and promoted cell proliferation of human colorectal cancer cells.
target gene	hsa-mir-96	Colorectal Carcinoma	25369914	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a.
target gene	hsa-mir-96	Colorectal Carcinoma	25502560	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism  under 3D conditions
target gene	hsa-mir-99b	Colorectal Carcinoma	26259252	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR.
target gene	hsa-let-7a-1	Colorectal Carcinoma	22018986	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA.
target gene	hsa-let-7a-2	Colorectal Carcinoma	22018986	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA.
target gene	hsa-let-7a-3	Colorectal Carcinoma	22018986	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA.
target gene	hsa-let-7c	Colorectal Carcinoma	21984339	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer.
target gene	hsa-mir-1	Colorectal Carcinoma	24244701	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miR-1-NOTCH3-Asef pathway is important for colorectal tumor cell migration.
target gene	hsa-mir-103a-1	Colorectal Carcinoma	22593189	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
target gene	hsa-mir-103a-2	Colorectal Carcinoma	22593189	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
target gene	hsa-mir-103b-1	Colorectal Carcinoma	22593189	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
target gene	hsa-mir-103b-2	Colorectal Carcinoma	22593189	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
target gene	hsa-mir-106a	Colorectal Carcinoma	22912877	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-106a inhibits the expression of transforming growth factor-beta receptor 2 (TGFBR2), leading to increased CRC cell migration and invasion. Importantly, miR-106a expression levels in primary CRCs are correlated with clinical cancer progression.
target gene	hsa-mir-107	Colorectal Carcinoma	22593189	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-103/107 Promote Metastasis of Colorectal Cancer by Targeting the Metastasis Suppressors DAPK and KLF4.
target gene	hsa-mir-124	Colorectal Carcinoma	24705396	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1.
target gene	hsa-mir-124-1	Colorectal Carcinoma	22895557	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect.
target gene	hsa-mir-124-2	Colorectal Carcinoma	22895557	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect.
target gene	hsa-mir-126	Colorectal Carcinoma	25245095	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells.
target gene	hsa-mir-128	Colorectal Carcinoma	26352220	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Taken together, these data suggested that miR-128 serves as a tumor suppressor and blocks CRC growth and metastasis by targeting IRS1.
target gene	hsa-mir-130a	Colorectal Carcinoma	23393589	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression
target gene	hsa-mir-133a-1	Colorectal Carcinoma	23723074	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-133a activates the p53/p21 pathway and functions as a tumor suppressor in colorectal cancer by repressing RFFL.
target gene	hsa-mir-133a-2	Colorectal Carcinoma	23723074	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-133a activates the p53/p21 pathway and functions as a tumor suppressor in colorectal cancer by repressing RFFL.
target gene	hsa-mir-135a-1	Colorectal Carcinoma	18632633	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-135a: miR-135 family: Regulation of the adenomatous polyposis coli gene
target gene	hsa-mir-135a-2	Colorectal Carcinoma	18632633	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-135a: miR-135 family: Regulation of the adenomatous polyposis coli gene
target gene	hsa-mir-135b	Colorectal Carcinoma	18632633	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-135b: miR-135 family: Regulation of the adenomatous polyposis coli gene
target gene	hsa-mir-135b	Colorectal Carcinoma	23143558	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-beta in colorectal cells
target gene	hsa-mir-137	Colorectal Carcinoma	22895557	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect.
target gene	hsa-mir-139	Colorectal Carcinoma	22580051	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor.
target gene	hsa-mir-139	Colorectal Carcinoma	22642900	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation.
target gene	hsa-mir-143	Colorectal Carcinoma	19137007	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-143 directly recognize the 3'-untranslated region of KRAS transcripts
target gene	hsa-mir-143	Colorectal Carcinoma	19638978	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer.
target gene	hsa-mir-143	Colorectal Carcinoma	22533346	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer.
target gene	hsa-mir-143	Colorectal Carcinoma	22549179	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
target gene	hsa-mir-145	Colorectal Carcinoma	23499891	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Tumor-suppressive microRNA-145 targets catenin to regulate Wnt/beta-catenin signaling in human colon cancer cells
target gene	hsa-mir-145	Colorectal Carcinoma	25973017	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells.
target gene	hsa-mir-148a	Colorectal Carcinoma	21455217	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer.
target gene	hsa-mir-148b	Colorectal Carcinoma	22020560	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer.
target gene	hsa-mir-155	Colorectal Carcinoma	26303353	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Thus, it is hypothesized that miR-155 may be a promising target for antagonizing COX-2 expression in colorectal and other cancers.
target gene	hsa-mir-16-1	Colorectal Carcinoma	23380758	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway
target gene	hsa-mir-16-2	Colorectal Carcinoma	23380758	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway
target gene	hsa-mir-17	Colorectal Carcinoma	22132820	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Up-regulated miR-17 promotes cell proliferation, tumor growth and cell cycle progression by targeting RND3 tumor suppressor gene in colorectal carcinoma.
target gene	hsa-mir-17	Colorectal Carcinoma	23250421	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130
target gene	hsa-mir-185	Colorectal Carcinoma	21186079	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells.miR-185 is a negative regulator of RhoA and Cdc42 and their cellular activities, and could inhibit proliferation and invasion of colorectal cancer
target gene	hsa-mir-186	Colorectal Carcinoma	23137536	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells
target gene	hsa-mir-191	Colorectal Carcinoma	24195505	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-191 correlates with poor prognosis of colorectal carcinoma and plays multiple roles by targeting tissue inhibitor of metalloprotease 3.
target gene	hsa-mir-1915	Colorectal Carcinoma	22121083	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells.
target gene	hsa-mir-194-1	Colorectal Carcinoma	22028325	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.
target gene	hsa-mir-194-2	Colorectal Carcinoma	22028325	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.
target gene	hsa-mir-195	Colorectal Carcinoma	23526568	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA
target gene	hsa-mir-196a-1	Colorectal Carcinoma	23138850	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells
target gene	hsa-mir-196a-2	Colorectal Carcinoma	23138850	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells
target gene	hsa-mir-200a	Colorectal Carcinoma	25818799	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-200a plays a role in regulating the invasiveness and metastasis of CRC, and overexpression of miR-200a causes a significant reduction of cell proliferation and migration and promotes apoptosis and cell-cell adhesion in LoVo cells.
target gene	hsa-mir-200c	Colorectal Carcinoma	24658157	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings indicate that miR-200c regulates Sox2 expression through a feedback loop and is associated with CRC stemness, growth, and metastasis.
target gene	hsa-mir-200c	Colorectal Carcinoma	22407310	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1.miR-200c inhibits metastatic ability by targeting ZEB1 in colon cancer cells SW480/620 and suggested that modulation of miR-200c could serve as therapeutic to
target gene	hsa-mir-202	Colorectal Carcinoma	24327274	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma.
target gene	hsa-mir-20a	Colorectal Carcinoma	21242194	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
target gene	hsa-mir-21	Colorectal Carcinoma	21546206	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		This study demonstrates the inverse relationship between miR-21 and PDCD4, thus suggesting that miR-21 post-transcriptionally modulates PDCD4 via mRNA degradation. Pharmacological manipulation of the miR-21/PDCD4 axis could represent a novel therapeutic strategy in the treatment of colorectal cancer.
target gene	hsa-mir-21	Colorectal Carcinoma	21872591	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells.
target gene	hsa-mir-21	Colorectal Carcinoma	22099878	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21 functionally interacts with the 3'UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells.
target gene	hsa-mir-21	Colorectal Carcinoma	22267128	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Significant inverse correlations were demonstrated between PDCD4 and miR-21.
target gene	hsa-mir-21	Colorectal Carcinoma	23174819	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells
target gene	hsa-mir-21	Colorectal Carcinoma	23817679	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: significance of their regulation.
target gene	hsa-mir-211	Colorectal Carcinoma	22235338	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5.
target gene	hsa-mir-216b	Colorectal Carcinoma	23137536	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells
target gene	hsa-mir-22	Colorectal Carcinoma	21594648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells.
target gene	hsa-mir-221	Colorectal Carcinoma	24409057	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Anti-miR-221 can enhance the radiosensitivity of CRC cells by upregulating PTEN.
target gene	hsa-mir-221	Colorectal Carcinoma	21278784	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma.
target gene	hsa-mir-221	Colorectal Carcinoma	21538272	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-221 controls CDKN1C/P57 expression in human colorectal carcinoma
target gene	hsa-mir-222	Colorectal Carcinoma	22677042	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17.
target gene	hsa-mir-23a	Colorectal Carcinoma	22455847	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-23a expression promotes colon carcinoma cell growth, invasion and metastasis through inhibition of MTSS gene.
target gene	hsa-mir-25	Colorectal Carcinoma	23435373	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7
target gene	hsa-mir-27a	Colorectal Carcinoma	23471840	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis
target gene	hsa-mir-297	Colorectal Carcinoma	22676135	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2.
target gene	hsa-mir-29c	Colorectal Carcinoma	25193986	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings highlight the important role of miR-29c in regulating CRC EMT via GSK-3β/β-catenin signaling by targeting GNA13 and PTP4A and provide new insights into the metastatic basis of CRC.
target gene	hsa-mir-301a	Colorectal Carcinoma	23393589	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression
target gene	hsa-mir-30a	Colorectal Carcinoma	23486085	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-30a Suppresses Cell Migration and Invasion Through Downregulation of PIK3CD in Colorectal Carcinoma
target gene	hsa-mir-31	Colorectal Carcinoma	23322774	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-31 activates the Ras pathway and functions as an oncogenic microRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1(RASA1).
target gene	hsa-mir-320a	Colorectal Carcinoma	22134529	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer.
target gene	hsa-mir-320a	Colorectal Carcinoma	22459450	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin.
target gene	hsa-mir-328	Colorectal Carcinoma	22453125	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer.
target gene	hsa-mir-330	Colorectal Carcinoma	23337504	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42
target gene	hsa-mir-337	Colorectal Carcinoma	23137536	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells
target gene	hsa-mir-339	Colorectal Carcinoma	23696794	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-339-5p Regulates the Growth, Colony Formation and Metastasis of Colorectal Cancer Cells by Targeting PRL-1.
target gene	hsa-mir-340	Colorectal Carcinoma	22895557	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect.
target gene	hsa-mir-342	Colorectal Carcinoma	21565830	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-342 Inhibits Colorectal Cancer Cell Proliferation and Invasion by Directly Targeting DNA Methyltransferase 1.
target gene	hsa-mir-34b	Colorectal Carcinoma	21329882	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MK5 regulates translation of Myc, since it is required for expression of miR-34b and miR-34c that bind to the 3'UTR of MYC. MK5 activates miR-34b/c expression via phosphorylation of FoxO3a, thereby promoting nuclear localization of FoxO3a and enabling it
target gene	hsa-mir-34c	Colorectal Carcinoma	21329882	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MK5 regulates translation of Myc, since it is required for expression of miR-34b and miR-34c that bind to the 3'UTR of MYC. MK5 activates miR-34b/c expression via phosphorylation of FoxO3a, thereby promoting nuclear localization of FoxO3a and enabling it
target gene	hsa-mir-361	Colorectal Carcinoma	25965817	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1.
target gene	hsa-mir-362	Colorectal Carcinoma	23280316	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer
target gene	hsa-mir-363	Colorectal Carcinoma	24452072	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miR-363-GATA6-Lgr5 pathway is critical for colorectal tumourigenesis.
target gene	hsa-mir-429	Colorectal Carcinoma	24402783	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma.
target gene	hsa-mir-429	Colorectal Carcinoma	23111103	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2
target gene	hsa-mir-454	Colorectal Carcinoma	23393589	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The Oncogenic Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting Smad4 Expression
target gene	hsa-mir-491	Colorectal Carcinoma	20039318	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-491:Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells
target gene	hsa-mir-497	Colorectal Carcinoma	22710713	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
target gene	hsa-mir-499a	Colorectal Carcinoma	21934092	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4.
target gene	hsa-mir-574	Colorectal Carcinoma	22490519	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-574-5p negatively regulates Qki6/7 to impact ж┿catenin/Wnt signalling and the development of colorectal cancer.
target gene	hsa-mir-638	Colorectal Carcinoma	24885288	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These results demonstrate that the loss of miR-638 promotes invasion and a mesenchymal-like transition by directly targeting SOX2 in vitro. These findings define miR-638 as a new,invasion-associated tumor suppressor of CRC.
target gene	hsa-mir-638	Colorectal Carcinoma	25301729	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma.
target gene	hsa-mir-7-1	Colorectal Carcinoma	23208495	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis
target gene	hsa-mir-7-2	Colorectal Carcinoma	23208495	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis
target gene	hsa-mir-7-3	Colorectal Carcinoma	23208495	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis
target gene	hsa-mir-760	Colorectal Carcinoma	23137536	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-186, miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular senescence by targeting alpha subunit of protein kinase CKII in human colorectal cancer cells
target gene	hsa-mir-93	Colorectal Carcinoma	22581829	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle.
target gene	hsa-mir-95	Colorectal Carcinoma	21427358	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-95 Promotes Cell Proliferation and Targets Sorting Nexin 1 in Human Colorectal Carcinoma.
target gene	hsa-mir-34a	Complex Regional Pain Syndrome	26940669	nervous system disease	DOID:3223	G90.50	D020918			We show that hsa-miR-34a is a negative regulator of CRHR1; overexpression of hsa-miR-34a in Jurkat cells resulted in reduction of CRH-mediated POMC expression.
target gene	hsa-mir-10a	Congenital Heart Diseases	24714979	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	In conclusion, the study results indicate that miR-10a and miR-10b inhibit TBX5 expression at the level of translation. Higher levels of miR-10a and miR-10b expression are associated with a higher risk of congenital heart defects.
target gene	hsa-mir-10b	Congenital Heart Diseases	24714979	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	In conclusion, the study results indicate that miR-10a and miR-10b inhibit TBX5 expression at the level of translation. Higher levels of miR-10a and miR-10b expression are associated with a higher risk of congenital heart defects.
target gene	hsa-mir-181a	Congenital Heart Diseases	20884876	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	We showed that Dicer loss of function was, at least in part, mediated by miRNA-21 (miR-21) and miRNA-181a (miR-181a), which in turn repressed the protein level of Sprouty 2, an inhibitor of Erk1/2 signaling.
target gene	hsa-mir-21	Congenital Heart Diseases	20884876	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	We showed that Dicer loss of function was, at least in part, mediated by miRNA-21 (miR-21) and miRNA-181a (miR-181a), which in turn repressed the protein level of Sprouty 2, an inhibitor of Erk1/2 signaling.
target gene	hsa-mir-34a	Congenital Heart Diseases	29175286	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	miR-34a increases the risk of CHD through its downregulation of NOTCH-1 by modulating the Notch signaling pathway
target gene	hsa-mir-124	Congenital Hypothyroidism	29805523	endocrine system disease	DOID:0050328	E00.1	D003409	PS275200	HP:0000851	microRNA-124-3p inhibits the progression of congenital hypothyroidism via targeting programmed cell death protein 6.
target gene	hsa-mir-185	Congenital Microtia	26282502			Q17.2	D065817	251800		The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear.
target gene	hsa-mir-200c	Congenital Microtia	26282502			Q17.2	D065817	251800		The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear.
target gene	hsa-mir-203	Congenital Microtia	26282502			Q17.2	D065817	251800		The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear.
target gene	hsa-mir-451	Congenital Microtia	26282502			Q17.2	D065817	251800		The expression of has-miR-203, has-miR-200c and has-miR-451 were significantly different in microtia. Target gene of SOCS3, TFs of STAT1 and STAT2, and lncRNA of MALAT1 may play important roles in the development of the external ear.
target gene	hsa-mir-206	Congenital Myasthenic Syndrome	25765662	musculoskeletal system disease	DOID:3635	G70.2	D020294	PS610542		Our data demonstrate that the c.*22C>A mutation in the GFPT1 gene leads to illegitimate binding of microRNA resulting in reduced protein expression. We confirm that c.*22C>A is a causative mutation and suggest that formation of microRNA target sites might be a relevant pathomechanism in Mendelian disorders. Variants in the 3'-UTRs should be considered in genetic diagnostic procedures.
target gene	hsa-mir-146a	Cor Pulmonale	29667303	cardiovascular system disease	DOID:8515	I27.81	D011660		HP:0001648	miR-146a can negatively feedback regulate PM1 -induced inflammation via NF-κB signaling pathway in BEAS-2B cells
target gene	hsa-let-7i	Coronary Artery Disease	21899916	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		This study suggests that atorvastatin down-regulates TLR4 signal via let-7i expression in CAD patients, possibly contributing to the beneficial effects of atorvastatin on let-7i-mediated TLR4 signal in this disorder.
target gene	hsa-mir-1	Coronary Artery Disease	22883088	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Association study on the microRNA-1 target gene polymorphism and the risk of premature coronary artery disease
target gene	hsa-mir-154	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-15b	Coronary Artery Disease	28254819	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-15b-5p Regulates Collateral Artery Formation by Targeting AKT3 (Protein Kinase B-3).
target gene	hsa-mir-17	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-199a	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-206	Coronary Artery Disease	26175229	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Role of the microRNA, miR-206, and its target PIK3C2α in endothelial progenitor cell function – potential link with coronary artery disease.
target gene	hsa-mir-21	Coronary Artery Disease	26383248	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Because the smad7 expression pattern was similar to that of TGF-β,our study suggests that miR-21 can negatively regulate the frequency of circulating Treg cells through a TGF-β1/smad-independent signaling pathway in PBMCs.
target gene	hsa-mir-22	Coronary Artery Disease	27537567	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-22 contributes to the pathogenesis of patients with coronary artery disease by targeting MCP-1: An observational study.
target gene	hsa-mir-221	Coronary Artery Disease	23333386	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Overall, these findings demonstrate that miR-221 affects the MEK/ERK pathway by targeting PAK1 to inhibit the proliferation of EPCs.
target gene	hsa-mir-221	Coronary Artery Disease	25236949	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Overexpression of miR-221 and miR-222 resulted in the reduction of genes involved in hypoxia response, metabolism, TGF-beta signalling, and cell motion.
target gene	hsa-mir-222	Coronary Artery Disease	25236949	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Overexpression of miR-221 and miR-222 resulted in the reduction of genes involved in hypoxia response, metabolism, TGF-beta signalling, and cell motion.
target gene	hsa-mir-223	Coronary Artery Disease	26221610	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		our recent data demonstrated that the level of both intraplatelet and circulating miR-223 is an independent predictor for HTPR, thus providing a link between miR-223 and MACE. These lines of evidence indicate that miR-223 may serve as a potential regulatory target for HTPR, as well as a diagnostic tool for identification of HTPR in clinical settings.
target gene	hsa-mir-339	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-340	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-34a	Coronary Artery Disease	22364258	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MicroRNA-34a regulates the longevity-associated protein, SIRT1, in coronary artery disease.
target gene	hsa-mir-451	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-454	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-526b	Coronary Artery Disease	24247647	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		The miRNA-526b is significantly upregulated in patients with CAD and the target gene of miRNA-526b participates in the VEGF signaling pathway. Whether or not the miRNA-526b can be used as a biomarker remains to be elucidated in a larger prospective study.
target gene	hsa-mir-545	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-585	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-624	Coronary Artery Disease	24913032	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-545-TFEC and miR-585-SPOCK1 were highly positively correlated (ρ = 0.808091264; ρ = 0.874680776) in CAD samples.Therefore, differentially expressed miRNAs might participate in the pathogenesis of CAD by regulating their target genes.
target gene	hsa-mir-939	Coronary Artery Disease	28115160	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MicroRNA-939 governs vascular integrity and angiogenesis through targeting γ-catenin in endothelial cells.
target gene	hsa-mir-125a	Coronary Atherosclerosis	24877885			I25.1	D003324		HP:0004929	We focused on the human coronary arteries with atherosclerotic plaques. The expression of ET-1, as well as its upstream miRNAs, was determined. Unlikeany of previous study regarding miRNAs expression, we could exclude the discrepancy of artery-bed-specific miRNA expression. Besides, our data indicated,to some degree, that ET-1 might play a more vital role than Ang II in coronary atherosclerosis.
target gene	hsa-mir-155	Coronary Atherosclerosis	24877885			I25.1	D003324		HP:0004929	We focused on the human coronary arteries with atherosclerotic plaques. The expression of ET-1, as well as its upstream miRNAs, was determined. Unlikeany of previous study regarding miRNAs expression, we could exclude the discrepancy of artery-bed-specific miRNA expression. Besides, our data indicated,to some degree, that ET-1 might play a more vital role than Ang II in coronary atherosclerosis.
target gene	hsa-mir-199a	Coronary Atherosclerosis	24877885			I25.1	D003324		HP:0004929	We focused on the human coronary arteries with atherosclerotic plaques. The expression of ET-1, as well as its upstream miRNAs, was determined. Unlikeany of previous study regarding miRNAs expression, we could exclude the discrepancy of artery-bed-specific miRNA expression. Besides, our data indicated,to some degree, that ET-1 might play a more vital role than Ang II in coronary atherosclerosis.
target gene	hsa-mir-199b	Coronary Atherosclerosis	24877885			I25.1	D003324		HP:0004929	We focused on the human coronary arteries with atherosclerotic plaques. The expression of ET-1, as well as its upstream miRNAs, was determined. Unlikeany of previous study regarding miRNAs expression, we could exclude the discrepancy of artery-bed-specific miRNA expression. Besides, our data indicated,to some degree, that ET-1 might play a more vital role than Ang II in coronary atherosclerosis.
target gene	hsa-mir-21	Coronary Atherosclerosis	24594117			I25.1	D003324		HP:0004929	miR-21 might be a biomarker for plaque instability by suppressing target gene RECK to promote the expression and secretion of MMP-9 in macrophages.
target gene	hsa-mir-146a	Coronavirus Infections	29702211			B34.2	D018352			miR-146a-5p promotes replication of infectious bronchitis virus by targeting IRAK2 and TNFRSF18.
target gene	hsa-mir-122	Crohn Disease	23872065	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn's disease.
target gene	hsa-mir-143	Crohn Disease	29562274	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	MicroRNA-143 Targets ATG2B to Inhibit Autophagy and Increase Inflammatory Responses in Crohn's Disease
target gene	hsa-mir-192	Crohn Disease	24297055	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Overexpression of miR-192, miR-495, miR-512, and miR-671 suppressed NOD2 expression, muramyl dipeptide-mediated NF-魏B activation, and messenger RNA expressions of interleukin-8 and CXCL3 in HCT116 cells.
target gene	hsa-mir-27b	Cryptosporidium infection	22615562	disease by infectious agent	DOID:1733	A07.2	D003457			miR-27b targets KSRP to coordinate TLR4-mediated epithelial defense against Cryptosporidium parvum infection.
target gene	hsa-mir-125b	Cutaneous Melanoma	24762088	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Our results confirm the theory that miR-125b functions as a tumour supressor in cutaneous malignant melanoma by regulating cellular senescence,which is one of the central mechanisms protecting against the development and progression of malignant melanoma.
target gene	hsa-mir-4262	Cutaneous Melanoma	27779691	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	miR-4262 promotes the proliferation of human cutaneous malignant melanoma cells through KLF6-mediated EGFR inactivation and p21 upregulation.
target gene	hsa-mir-132	Dementia	22895706	disease of mental health	DOID:1307	F03	D003704	127750	HP:0000726	TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways.
target gene	hsa-mir-21	Dementia	21170291	disease of mental health	DOID:1307	F03	D003704	127750	HP:0000726	MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease.
target gene	hsa-mir-212	Dementia	22895706	disease of mental health	DOID:1307	F03	D003704	127750	HP:0000726	TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways.
target gene	hsa-mir-301a	Demyelinating Diseases	22517757	nervous system disease	DOID:3213	G37.9	D003711	118200		Both in vivo and in vitro, myelin antigen stimulation resulted in significant up-regulation of miR-301a, miR-21, and miR-155. miR-301a has a role in regulating the function of myelin-reactive T-helper type 17 cells, supporting a role for miR-301a as candidate for therapeutic targets for controlling of autoimmune demyelination.
target gene	hsa-let-7e	Dengue Shock Syndrome	29768655	disease by infectious agent	DOID:0050125					Let-7e inhibits TNF-α expression by targeting the methyl transferase EZH2 in DENV2-infected THP-1 cells.
target gene	hsa-mir-133a	Dengue Virus Infection	26818704	disease by infectious agent	DOID:12205	A90	D003715	614371		miRNA-133a regulates DENV replication possibly through the modulation of a host factor such as PTB. Further investigations are needed to verify whether miRNA-133a has an anti-DENV effect in vivo.
target gene	hsa-mir-147	Dengue Virus Infection	21810247	disease by infectious agent	DOID:12205	A90	D003715	614371		a microRNA which may negatively regulate pro-inflammatory cytokines in dengue infected peripheral blood cells, mIR-147 (NMES1).
target gene	hsa-mir-146a	Dermatomyositis	27889748	integumentary system disease	DOID:10223	M33	D003882			MiR-146a Regulates Inflammatory Infiltration by Macrophages in Polymyositis/Dermatomyositis by Targeting TRAF6 and Affecting IL-17/ICAM-1 Pathway.
target gene	hsa-mir-205	Dermatomyositis	24525843	integumentary system disease	DOID:10223	M33	D003882			miR-205 down-regulation promotes proliferation of dermatofibrosarcoma protuberans tumor cells by regulating LRP-1 and ERK phosphorylation.
target gene	hsa-mir-1	Diabetes Mellitus	24394957	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miRNA-1 regulates endothelin-1 in diabetes.
target gene	hsa-mir-126	Diabetes Mellitus	22525256	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1.
target gene	hsa-mir-126	Diabetes Mellitus	27127202	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	low miR-126 levels to  be associated with markedly increased TF protein and TF-mediated thrombogenicity.
target gene	hsa-mir-126	Diabetes Mellitus	28598282	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNA-126 Regulates Inflammatory Cytokine Secretion in Human Gingival Fibroblasts Under High Glucose via Targeting Tumor Necrosis Factor Receptor Associated Factor 6.
target gene	hsa-mir-130a	Diabetes Mellitus	23874686	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3.
target gene	hsa-mir-133a	Diabetes Mellitus	27411382	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Our results revealed that miR-133a mimic treatment improved the contractility of the diabetic rat's heart concomitant with upregulation of TH, cardiac NE, 尾-AR, and downregulation of TAT  and plasma levels of NE.
target gene	hsa-mir-146a	Diabetes Mellitus	28301595	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-146a regulates glucose induced upregulation of inflammatory cytokines extracellular matrix proteins in the retina and kidney in diabetes.
target gene	hsa-mir-146b	Diabetes Mellitus	25815338	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes.
target gene	hsa-mir-17	Diabetes Mellitus	26858253	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	In fact, miR-17 knockdown was able to mimic the IFN纬 effects on TXNIP, whereas miR-17 overexpression blunted the cytokine effect.
target gene	hsa-mir-185	Diabetes Mellitus	25658748	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNA-185 targets SOCS3 to inhibit beta-cell dysfunction in diabetes.
target gene	hsa-mir-19a	Diabetes Mellitus	27666763	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNA-19a-3p enhances the proliferation and insulin secretion, while it inhibits the apoptosis of pancreatic β cells via the inhibition of SOCS3.
target gene	hsa-mir-200a	Diabetes Mellitus	27121251	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Transfection with an miR-200a inhibitor increased Rheb protein levels and enhanced the feedback action on insulin receptor substrate-dependent insulin signaling, whereas transfection with an miR-200a mimic produced the opposite effects.
target gene	hsa-mir-200b	Diabetes Mellitus	25884496	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells:potential relevance in diabetic retinopathy.
target gene	hsa-mir-204	Diabetes Mellitus	27384111	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Taken together, we have identified PERK as a novel target of miR-204 and show that miR-204 inhibits PERK signaling and increases ER stress-induced cell death, revealing for the first time a link between this miRNA and UPR.
target gene	hsa-mir-21	Diabetes Mellitus	28230206	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway.
target gene	hsa-mir-27a	Diabetes Mellitus	29462799	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-27a may contribute to detrusor fibrosis in STZ-induced diabetic rats by targeting PRKAA2 via the TGF-β1/Smad3 signaling pathway
target gene	hsa-mir-27a	Diabetes Mellitus	29100869	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Oxidative stress-induced miR-27a targets the redox gene nuclear factor erythroid 2-related factor 2 in diabetic embryopathy.
target gene	hsa-mir-29a	Diabetes Mellitus	25062042	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	insulin and mTORC1 regulate cardiac miR-29-MCL-1 axis and its dysregulation caused by reduced insulin and mTORC1 inhibition increases the vulnerability of a diabetic heart to structural damage.
target gene	hsa-mir-29a	Diabetes Mellitus	26199111	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Using gain- and loss-of-function studies, five of these genes were confirmed as endogenous targets of miR-29a
target gene	hsa-mir-29b	Diabetes Mellitus	25062042	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	insulin and mTORC1 regulate cardiac miR-29-MCL-1 axis and its dysregulation caused by reduced insulin and mTORC1 inhibition increases the vulnerability of a diabetic heart to structural damage.
target gene	hsa-mir-29c	Diabetes Mellitus	21310958	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNA-29c is a signature MicroRNA under high glucose conditions which targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy.
target gene	hsa-mir-29c	Diabetes Mellitus	25062042	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	insulin and mTORC1 regulate cardiac miR-29-MCL-1 axis and its dysregulation caused by reduced insulin and mTORC1 inhibition increases the vulnerability of a diabetic heart to structural damage.
target gene	hsa-mir-29c	Diabetes Mellitus	28539664	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin.
target gene	hsa-mir-34a	Diabetes Mellitus	27297797	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Subsequent overexpression of miR-34a inhibited Fndc5 expression, whereas blockade of miR-34a increased Fndc5 expression in myoblasts.
target gene	hsa-mir-375	Diabetes Mellitus	24120394	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Because of the special role of miR-375, it may be a potential target to treat diabetes. Antagonising miR-375 may enhance the effects of exendin-4 in patients, and controlling the expression of miR-375 could assist mature hESCs-derived β-cells.
target gene	hsa-mir-463	Diabetes Mellitus	27664094	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNA-463-3p/ABCG4: A new axis in glucose-stimulated insulin secretion.
target gene	hsa-mir-494	Diabetes Mellitus	29333131	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-494 protects pancreatic β-cell function by targeting PTEN in gestational diabetes mellitus
target gene	hsa-mir-92a	Diabetes Mellitus	29660330	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MiRNA-92a protects pancreatic B-cell function by targeting KLF2 in diabetes mellitus
target gene	hsa-mir-101	Diabetes Mellitus, Gestational	25614281	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	GDM impairs HUVEC function via miR-101 upregulation. EZH2 is both a transcriptional inhibitor and a target gene of miR-101 in HUVECs, and it contributes to some of the miR-101-induced defects of GDM-HUVECs.
target gene	hsa-mir-518d	Diabetes Mellitus, Gestational	24639097	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	MicroRNA-518d regulates PPARα protein expression in the placentas of females with gestational diabetes mellitus.
target gene	hsa-mir-149	Diabetes Mellitus, Type 1	27737950	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β-Cells.
target gene	hsa-mir-21	Diabetes Mellitus, Type 1	28280903	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells.
target gene	hsa-mir-23a	Diabetes Mellitus, Type 1	27737950	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β-Cells.
target gene	hsa-mir-23b	Diabetes Mellitus, Type 1	27737950	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β-Cells.
target gene	hsa-let-7d	Diabetes Mellitus, Type 2	24105413	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Expression of microRNA let-7a and let-7d, which are direct translational repressors of the IL-13 gene, was increased in skeletal muscle from T2DM patients. 
target gene	hsa-mir-124a	Diabetes Mellitus, Type 2	25408296	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	We uncovered a major hyperexpression of miR-124a in T2D islets, whose silencing resulted in increased expression of target genes of major importance for beta cell function and whose overexpression impaired glucose-stimulated insulin secretion, leading to the hypothesis that an altered miR-124a expression may contribute to beta cell dysfunction in type 2 diabetes.
target gene	hsa-mir-1271	Diabetes Mellitus, Type 2	27613089	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MiR-1271 upregulated by saturated fatty acid palmitate provokes impaired insulin signaling by repressing INSR and IRS-1 expression in HepG2 cells.
target gene	hsa-mir-144	Diabetes Mellitus, Type 2	21829658	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus.
target gene	hsa-mir-155	Diabetes Mellitus, Type 2	26125263	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	In type 2 diabetes mellitus (T2DM) retinopathy, miR-155 may play an important role in the pathogenesis of T2DM retinopathy by regulating the Treg cells with TGF-β.
target gene	hsa-mir-17	Diabetes Mellitus, Type 2	29477089	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-17 improved inflammation-induced insulin resistance by suppressing ASK1 expression in macrophages
target gene	hsa-mir-187	Diabetes Mellitus, Type 2	24149837	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Our findings suggest a role for miR-187 in the blunting of insulin secretion, potentially involving regulation of HIPK3, which occurs during the pathogenesis of type 2 diabetes.
target gene	hsa-mir-199a	Diabetes Mellitus, Type 2	25084986	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MiR-199a is overexpressed in plasma of type 2 diabetes patients which contributes to type 2 diabetes by targeting GLUT4.
target gene	hsa-mir-200	Diabetes Mellitus, Type 2	25985365	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes.
target gene	hsa-mir-200b	Diabetes Mellitus, Type 2	25814674	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study reports that (1) inflammation underlying nonhealing wounds in patients with type 2 diabetes mellitus influences plasma miRNA concentrations and (2) miR-191 modulates cellular migration and angiogenesis via paracrine regulation of zonula occludens-1 to delay the tissue repair process.
target gene	hsa-mir-223	Diabetes Mellitus, Type 2	20080987	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	These data demonstrate a role for miR-223 in Glut4 regulation and glucose metabolism in the heart, reveal the pleiotropic effects of miRNAs across tissues, and show that miRNAs can upregulate target genes in terminally differentiated cardiomyocytes.
target gene	hsa-mir-23b	Diabetes Mellitus, Type 2	27467285	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes.
target gene	hsa-mir-24	Diabetes Mellitus, Type 2	23761103	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MicroRNA-24/MODY gene regulatory pathway mediates pancreatic β-cell dysfunction.
target gene	hsa-mir-375	Diabetes Mellitus, Type 2	25408296	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	We uncovered a major hyperexpression of miR-124a in T2D islets, whose silencing resulted in increased expression of target genes of major importance for beta cell function and whose overexpression impaired glucose-stimulated insulin secretion, leading to the hypothesis that an altered miR-124a expression may contribute to beta cell dysfunction in type 2 diabetes.
target gene	hsa-mir-590	Diabetes Mellitus, Type 2	27467285	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Transcriptome analysis revealed reduced expression of TRAIL, TRAIL-R2, FAS and FASLG (members of the extrinsic apoptosis pathway) in patient-derived compared with healthy donor-derived T cells. This was mirrored by increased expression of microRNAs predicted to regulate these particular genes, namely miR-98, miR-23b and miR-590-5p.
target gene	hsa-mir-696	Diabetes Mellitus, Type 2	27432632	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Taken together, our findings demonstrate that miR-696 plays an important role in the development of hepatic gluconeogenesis and insulin resistance through the inhibition of PGC-1伪 translation in the liver.
target gene	hsa-mir-96	Diabetes Mellitus, Type 2	28036389	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Induction of miR-96 by Dietary Saturated Fatty Acids Exacerbates Hepatic Insulin Resistance through the Suppression of INSR and IRS-1.
target gene	hsa-mir-98	Diabetes Mellitus, Type 2	27467285	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Transcriptome analysis revealed reduced expression of TRAIL, TRAIL-R2, FAS and FASLG (members of the extrinsic apoptosis pathway) in patient-derived compared with healthy donor-derived T cells. This was mirrored by increased expression of microRNAs predicted to regulate these particular genes, namely miR-98, miR-23b and miR-590-5p.
target gene	hsa-mir-1	Diabetic Cardiomyopathies	29024600				D058065			Liver X receptor α is targeted by microRNA-1 to inhibit cardiomyocyte apoptosis through a ROS-mediated mitochondrial pathway.
target gene	hsa-mir-9	Diabetic Cardiomyopathies	26898797				D058065			Inhibition of miR-9  upregulates ELAVL1 expression and activates caspase-1.
target gene	hsa-mir-30a	Diabetic Cataract	28442786	nervous system disease	DOID:13328					MicroRNA-30a Regulation of Epithelial-Mesenchymal Transition in Diabetic Cataracts Through Targeting SNAI1.
target gene	hsa-mir-30a	Diabetic Cataract	29100392	nervous system disease	DOID:13328					MiR-30a inhibits BECN1-mediated autophagy in diabetic cataract.
target gene	hsa-mir-1207	Diabetic Nephropathy	24204837			E10-11.21	D003928			Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy.
target gene	hsa-mir-1227	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-1234	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-125b	Diabetic Nephropathy	27775793			E10-11.21	D003928			microRNA-125b contributes to high glucose-induced reactive oxygen species generation and apoptosis in HK-2 renal tubular epithelial cells by targeting angiotensin-converting enzyme 2.
target gene	hsa-mir-1915	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-21	Diabetic Nephropathy	24887517			E10-11.21	D003928			miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy.
target gene	hsa-mir-2861	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-30d	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-30e	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-320c	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-371b	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-4270	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-451a	Diabetic Nephropathy	21827757			E10-11.21	D003928			MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early Diabetic Nephropathies.
target gene	hsa-mir-4739	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-4778	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-572	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-6068	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-6126	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-6133	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-638	Diabetic Nephropathy	26930277			E10-11.21	D003928			In conclusion, urinary exosomal miRNA content is altered in type II diabetic patients with DN. Deregulated miR-320c, which might have an impact on the TGF-β-signaling pathway via targeting thrombospondin 1 (TSP-1) shows promise as a novel candidate marker for disease progression in type II DN that should be evaluated in future studies.
target gene	hsa-mir-155	Diabetic Peripheral Neuropathy	29545091			E11.40				MiR-155 targets PTCH1 to mediate endothelial progenitor cell dysfunction caused by high glucose.
target gene	hsa-mir-96	Diabetic Peripheral Neuropathy	29689688			E11.40				Swimming Exercise Induced Reversed Expression of miR-96 and Its Target Gene NaV1.3 in Diabetic Peripheral Neuropathy in Rats
target gene	hsa-mir-126	Diabetic Retinopathy	28943945	nervous system disease	DOID:8947	E10-11.31	D003930			MicroRNA-126 inhibits cell viability and invasion in a diabetic retinopathy model via targeting IRS-1.
target gene	hsa-mir-146a	Diabetic Retinopathy	28433754	nervous system disease	DOID:8947	E10-11.31	D003930			miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions.
target gene	hsa-mir-152	Diabetic Retinopathy	25802486	nervous system disease	DOID:8947	E10-11.31	D003930			We have demonstrated that miR-152 interacting with PRR regulates downstream VEGF, VRGFR-2, and TGFβ1 expressions in hRECs in HG conditions. These studies suggest miR-152 and PRR may play a role in the pathogenesis of diabetic retinopathy (DR).
target gene	hsa-mir-195	Diabetic Retinopathy	24570140	nervous system disease	DOID:8947	E10-11.31	D003930			These studies identified a novel mechanism whereby miR-195 regulates SIRT1-mediated tissue damage in diabetic retinopathy.
target gene	hsa-mir-20b	Diabetic Retinopathy	27421659	nervous system disease	DOID:8947	E10-11.31	D003930			Transfection of miR-20b mimic in high glucose (HG)-treated human retinal endothelial cells (HRECs) increased miR-20b expression and decreased the expression level of VEGF mRNA, while transfection of miR-20b inhibitor in control HRECs reduced the miR-20b expression with a corresponding increase of VEGF mRNA.
target gene	hsa-mir-27b	Diabetic Retinopathy	26696637	nervous system disease	DOID:8947	E10-11.31	D003930			The authors assessed 155 baseline or DR progressors and 145 control samples (selected from 3,326 study participants) for a panel of 29 candidate miRNAs that were based on previous studies related to diabetes and myocardial infarction. They identified miR-27b and miR-320a as being significantly and independently associated with high DR risk. Complementing this analysis, they also elucidated the potential mechanism using cultured human endothelial cells and identified antiangiogenic thrombospondin-1 as a common target of these two miRNAs.
target gene	hsa-mir-29a	Diabetic Retinopathy	28189547	nervous system disease	DOID:8947	E10-11.31	D003930			Role of microRNA-29a in the development of diabetic retinopathy by targeting AGT gene in a rat model.
target gene	hsa-mir-29a	Diabetic Retinopathy	29409329	nervous system disease	DOID:8947	E10-11.31	D003930			Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of Müller cells via Forkhead box protein O4.
target gene	hsa-mir-29b	Diabetic Retinopathy	29409329	nervous system disease	DOID:8947	E10-11.31	D003930			Downregulation of MicroRNA 29a/b exacerbated diabetic retinopathy by impairing the function of Müller cells via Forkhead box protein O4.
target gene	hsa-mir-320a	Diabetic Retinopathy	26696637	nervous system disease	DOID:8947	E10-11.31	D003930			The authors assessed 155 baseline or DR progressors and 145 control samples (selected from 3,326 study participants) for a panel of 29 candidate miRNAs that were based on previous studies related to diabetes and myocardial infarction. They identified miR-27b and miR-320a as being significantly and independently associated with high DR risk. Complementing this analysis, they also elucidated the potential mechanism using cultured human endothelial cells and identified antiangiogenic thrombospondin-1 as a common target of these two miRNAs.
target gene	hsa-mir-216b	Diabetic Vasculopathy	29477872	cardiovascular system disease	DOID:11713		D003925			MicroRNA-216b actively modulates diabetic angiopathy through inverse regulation on FZD5.
target gene	hsa-mir-194	Disease of Metabolism	25412310	disease of metabolism	DOID:0014667	E88.9	D008659			miR-194 and COUP-TFII may be good target molecules for controlling bone and metabolic diseases.
target gene	hsa-mir-155	Down Syndrome	25869329	genetic disease	DOID:14250	Q90	D004314	190685		These results suggest that regulation of TFAM by hsa-miR-155-5p impacts mitochondrial biogenesis in the diploid setting but not in the DS setting.
target gene	hsa-mir-383	Embryonal Testis Carcinoma	24462707	disease of cellular proliferation	DOID:5680	C62.00	C104948	273300		microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells.
target gene	hsa-mir-513b	Embryonal Testis Carcinoma	28512062	disease of cellular proliferation	DOID:5680	C62.00	C104948	273300		Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells.
target gene	hsa-mir-206	Encephalitis	28765968	disease by infectious agent	DOID:9588	G04.90	D004660		HP:0002383	Downregulation of CCL2 induced by the upregulation of microRNA-206 is associated with the severity of HEV71 encephalitis
target gene	hsa-mir-17	Encephalomyelitis	23858035	nervous system disease	DOID:640	B01.11	D004679			microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis.
target gene	hsa-mir-20b	Encephalomyelitis	24842756	nervous system disease	DOID:640	B01.11	D004679			miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORγt and STAT3.
target gene	hsa-let-7a-1	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7a-2	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7a-3	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7b	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7c	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7d	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7e	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7f-1	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7f-2	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7g	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-let-7i	Endometrial Neoplasms	22014978	reproductive system disease	DOID:1380	C54.1	D016889	608089		The activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells.
target gene	hsa-mir-100	Endometrial Neoplasms	21472251	reproductive system disease	DOID:1380	C54.1	D016889	608089		hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1.
target gene	hsa-mir-103a-1	Endometrial Neoplasms	22783422	reproductive system disease	DOID:1380	C54.1	D016889	608089		microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3.
target gene	hsa-mir-103a-2	Endometrial Neoplasms	22783422	reproductive system disease	DOID:1380	C54.1	D016889	608089		microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3.
target gene	hsa-mir-103b-1	Endometrial Neoplasms	22783422	reproductive system disease	DOID:1380	C54.1	D016889	608089		microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3.
target gene	hsa-mir-103b-2	Endometrial Neoplasms	22783422	reproductive system disease	DOID:1380	C54.1	D016889	608089		microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3.
target gene	hsa-mir-125b-1	Endometrial Neoplasms	21970405	reproductive system disease	DOID:1380	C54.1	D016889	608089		MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo.
target gene	hsa-mir-125b-1	Endometrial Neoplasms	22460089	reproductive system disease	DOID:1380	C54.1	D016889	608089		MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2.
target gene	hsa-mir-125b-2	Endometrial Neoplasms	21970405	reproductive system disease	DOID:1380	C54.1	D016889	608089		MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo.
target gene	hsa-mir-125b-2	Endometrial Neoplasms	22460089	reproductive system disease	DOID:1380	C54.1	D016889	608089		MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2.
target gene	hsa-mir-130b	Endometrial Neoplasms	23392577	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer
target gene	hsa-mir-193a	Endometrial Neoplasms	22907428	reproductive system disease	DOID:1380	C54.1	D016889	608089		YY1 overexpression was found to be a consequence of miR-193a-5p downregulation through direct miR-193a-5p-YY1 interplay.
target gene	hsa-mir-194-1	Endometrial Neoplasms	21851624	reproductive system disease	DOID:1380	C54.1	D016889	608089		MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.
target gene	hsa-mir-194-2	Endometrial Neoplasms	21851624	reproductive system disease	DOID:1380	C54.1	D016889	608089		MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.
target gene	hsa-mir-200a	Endometrial Neoplasms	29442045	reproductive system disease	DOID:1380	C54.1	D016889	608089		MiR-200a promotes epithelial-mesenchymal transition of endometrial cancer cells by negatively regulating FOXA2 expression
target gene	hsa-mir-200b	Endometrial Neoplasms	23205572	reproductive system disease	DOID:1380	C54.1	D016889	608089		MicroRNA-200b Is Overexpressed in Endometrial Adenocarcinomas and Enhances MMP2 Activity by Downregulating TIMP2 in Human Endometrial Cancer Cell Line HEC-1A Cells
target gene	hsa-mir-200c	Endometrial Neoplasms	22015043	reproductive system disease	DOID:1380	C54.1	D016889	608089		We found that miR-200c expression was increased in endometrial carcinoma compared with normal endometrial tissues. Anti-miR or pre-miR-200c could regulate cell survival, proliferation, and apoptosis and affect cytotoxicity in endometrial cancer cells. Through mRNA microarray analysis, we found that miR-200c inhibits the expression of BRD7, which was recently reported as a potential tumor suppressor gene. MiR-200c regulated the translocation of ж┿catenin from the cytoplasm to the nucleus via inhibition of BRD7, resulting in increased expression of its transcriptional target genes, cyclinD1 and c-myc.
target gene	hsa-mir-204	Endometrial Neoplasms	21400511	reproductive system disease	DOID:1380	C54.1	D016889	608089		Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1.
target gene	hsa-mir-205	Endometrial Neoplasms	28427207	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.
target gene	hsa-mir-31	Endometrial Neoplasms	20980827	reproductive system disease	DOID:1380	C54.1	D016889	608089		These findings provide new insights into tumor-stroma interaction and document that miR-31 and its target gene SATB2, are involved in regulation of tumor cell motility.
target gene	hsa-mir-34c	Endometrial Neoplasms	23412924	reproductive system disease	DOID:1380	C54.1	D016889	608089		Furthermore, miR-34c mimics significantly enhanced apoptosis in Ishikawa cells by inhibiting IL-6R expression. Therefore, a combination of miR-34c mimics and DDP could be an effective therapeutic strategy for controlling Ishikawa cell proliferation.
target gene	hsa-mir-378a	Endometrial Neoplasms	21472251	reproductive system disease	DOID:1380	C54.1	D016889	608089		hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1.
target gene	hsa-mir-99a	Endometrial Neoplasms	21472251	reproductive system disease	DOID:1380	C54.1	D016889	608089		hsa-mir-100 and hsa-miR-99a were predicted to target ESR1, and hsa-miR-378 and hsa-miR-768-3p to target PGR. Hsa-miR-100 was significantly down-regulated in the estrogen-dependent endometrial cancer samples as compared to the estrogen-independent samples and thus has the potential to target ESR1.
target gene	hsa-mir-10b	Endometriosis	23206733	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion
target gene	hsa-mir-126	Endometriosis	22012249	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The expression level of miR-126 was significantly downregulated in ECs versus EUs (p = 5.45E(-5)) in the experimental group and in EUs versus ENs (p = 0.019).miR-126 may play an initial role in the development and progression of EMs. Crk may be regulated by miR-126, and synergism between abnormal expressions may play an important role in the pathogenesis of EMs.
target gene	hsa-mir-135a-1	Endometriosis	21956427	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-135a Regulates HOXA10 Expression in Endometriosis.
target gene	hsa-mir-135a-2	Endometriosis	21956427	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-135a Regulates HOXA10 Expression in Endometriosis.
target gene	hsa-mir-135b	Endometriosis	21956427	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-135b Regulates HOXA10 Expression in Endometriosis.
target gene	hsa-mir-145	Endometriosis	23312222	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an in vitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors
target gene	hsa-mir-15a	Endometriosis	27608888	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miRNA-15a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis.
target gene	hsa-mir-17	Endometriosis	29042983	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MicroRNA-17 downregulates expression of the PTEN gene to promote the occurrence and development of adenomyosis.
target gene	hsa-mir-183	Endometriosis	26357653	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	These findings, together with the fact that ITGB1 is a critical factor for cell adhesion and invasiveness, suggest that miR-183 may be involved in the development of endometriosis by regulating ITGB1 in endometrial stromal cells.
target gene	hsa-mir-191	Endometriosis	25819812	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-191 can directly regulate TIMP3 expression, thereby affecting cell proliferation rate and invasion ability. The miR-191-TIMP3 axis might be critical in the malignant transformation of endometriosis to EAOC.
target gene	hsa-mir-191	Endometriosis	26191186	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MiR-191 inhibits TNF-α induced apoptosis of ovarian endometriosis and endometrioid carcinoma cells by targeting DAPK1.
target gene	hsa-mir-195	Endometriosis	24294368	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MiR-195 inhibits proliferation and growth and induces apoptosis of endometrial stromal cells by targeting FKN.
target gene	hsa-mir-196b	Endometriosis	23293219	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells
target gene	hsa-mir-199a	Endometriosis	24155090	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miRNA-199a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis.
target gene	hsa-mir-199a	Endometriosis	26191163	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway.
target gene	hsa-mir-199a-1	Endometriosis	21989168	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKK{beta}/NF-kB pathway and reduced interleukin-8 expression.
target gene	hsa-mir-199a-2	Endometriosis	21989168	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKK{beta}/NF-kB pathway and reduced interleukin-8 expression.
target gene	hsa-mir-200c	Endometriosis	29116025	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-200c suppresses endometriosis by targeting MALAT1 in vitro and in vivo.
target gene	hsa-mir-20a	Endometriosis	24972566	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-20a contributes to endometriosis by regulating NTN4 expression.
target gene	hsa-mir-23a	Endometriosis	23450049	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MicroRNA23a and MicroRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis
target gene	hsa-mir-23b	Endometriosis	23450049	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	MicroRNA23a and MicroRNA23b Deregulation Derepresses SF-1 and Upregulates Estrogen Signaling in Ovarian Endometriosis
target gene	hsa-mir-122	Endomyocardial Fibrosis	24168656	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation.
target gene	hsa-mir-21	Endomyocardial Fibrosis	26968995	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	miR-21 specific degradation of Smad7 may decrease the inhibitory feedback regulation of TGF-尾1/Smad signaling
target gene	hsa-mir-98	Endomyocardial Fibrosis	28251559	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	MicroRNA-98 inhibits TGF-β1-induced differentiation and collagen production of cardiac fibroblasts by targeting TGFBR1.
target gene	hsa-mir-197	Enterovirus Infection	26581983			B97.10	D004769			Host MicroRNA miR-197 Plays a Negative Regulatory Role in the Enterovirus 71 Infectious Cycle by Targeting the RAN Protein.
target gene	hsa-mir-27a	Enterovirus Infection	25212431			B97.10	D004769			miR-27a suppresses EV71 replication by directly targeting EGFR.
target gene	hsa-mir-30a	Enterovirus Infection	26515789			B97.10	D004769			We provided further evidence that by modulating cellular miR-30a level through either overexpression or inhibition, one can inhibit or promote EV71 replication, respectively, through regulating autophagic activity.
target gene	hsa-mir-29	Ependymoma	25958202	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma.
target gene	hsa-mir-139	Epilepsy	27731509	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	MicroRNA-139-5p negatively regulates NR2A-containing NMDA receptor in the rat pilocarpine model and patients with temporal lobe epilepsy.
target gene	hsa-mir-206	Epithelioid Sarcoma	24327545	disease of cellular proliferation	DOID:6193		D012509			SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels.
target gene	hsa-mir-381	Epithelioid Sarcoma	24327545	disease of cellular proliferation	DOID:6193		D012509			SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels.
target gene	hsa-mir-671	Epithelioid Sarcoma	24327545	disease of cellular proliferation	DOID:6193		D012509			SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels.
target gene	hsa-mir-221	Epstein-Barr Virus Infection	26153983			B27.90	D020031	300853		Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. ebv-miR-BART20-5p
target gene	hsa-mir-222	Epstein-Barr Virus Infection	26153983			B27.90	D020031	300853		Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. ebv-miR-BART20-5p
target gene	hsa-let-7a	Esophageal Neoplasms	21600139			C15.9	D004938	133239	HP:0100751	Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance.
target gene	hsa-mir-100	Esophageal Neoplasms	23292834			C15.9	D004938	133239	HP:0100751	MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma
target gene	hsa-mir-133a-1	Esophageal Neoplasms	22641236			C15.9	D004938	133239	HP:0100751	CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma.
target gene	hsa-mir-133a-2	Esophageal Neoplasms	22641236			C15.9	D004938	133239	HP:0100751	CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma.
target gene	hsa-mir-141	Esophageal Neoplasms	21289630			C15.9	D004938	133239	HP:0100751	MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.
target gene	hsa-mir-141	Esophageal Neoplasms	21600139			C15.9	D004938	133239	HP:0100751	Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance.
target gene	hsa-mir-143	Esophageal Neoplasms	22457808			C15.9	D004938	133239	HP:0100751	The Cluster of miR-143 and miR-145 Affects the Risk for Esophageal Squamous Cell Carcinoma through Co-Regulating Fascin Homolog 1.
target gene	hsa-mir-145	Esophageal Neoplasms	22457808			C15.9	D004938	133239	HP:0100751	The Cluster of miR-143 and miR-145 Affects the Risk for Esophageal Squamous Cell Carcinoma through Co-Regulating Fascin Homolog 1.
target gene	hsa-mir-150	Esophageal Neoplasms	23301507			C15.9	D004938	133239	HP:0100751	MiR-150 regulates the EMT-inducer ZEB1 in esophageal squamous cell carcinoma.Wound healing assays of premiR-150-treated esophageal squamous cell carcinoma TE-8 cells
target gene	hsa-mir-185	Esophageal Neoplasms	21600139			C15.9	D004938	133239	HP:0100751	Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance.
target gene	hsa-mir-192-2	Esophageal Neoplasms	23677061			C15.9	D004938	133239	HP:0100751	miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression.
target gene	hsa-mir-19a	Esophageal Neoplasms	21271217			C15.9	D004938	133239	HP:0100751	TNF-alpha is a novel target of miR-19a.
target gene	hsa-mir-203	Esophageal Neoplasms	21299870			C15.9	D004938	133239	HP:0100751	MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma.
target gene	hsa-mir-203	Esophageal Neoplasms	22940702			C15.9	D004938	133239	HP:0100751	miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1.
target gene	hsa-mir-205	Esophageal Neoplasms	21426561			C15.9	D004938	133239	HP:0100751	MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells.
target gene	hsa-mir-21	Esophageal Neoplasms	23504349			C15.9	D004938	133239	HP:0100751	miR-21 Down-Regulation Suppresses Cell Growth, Invasion and Induces Cell Apoptosis by Targeting FASL, TIMP3, and RECK Genes in Esophageal Carcinoma
target gene	hsa-mir-214	Esophageal Neoplasms	22867052			C15.9	D004938	133239	HP:0100751	microRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma.
target gene	hsa-mir-22	Esophageal Neoplasms	21600139			C15.9	D004938	133239	HP:0100751	Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance.
target gene	hsa-mir-26a-1	Esophageal Neoplasms	23108995			C15.9	D004938	133239	HP:0100751	MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway
target gene	hsa-mir-26a-2	Esophageal Neoplasms	23108995			C15.9	D004938	133239	HP:0100751	MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway
target gene	hsa-mir-29c	Esophageal Neoplasms	21551130			C15.9	D004938	133239	HP:0100751	miR-29c induces cell cycle arrest in Esophageal Squamous Cell Carcinoma by modulating Cyclin E expression.
target gene	hsa-mir-301a	Esophageal Neoplasms	21600139			C15.9	D004938	133239	HP:0100751	Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance.
target gene	hsa-mir-373	Esophageal Neoplasms	19501585			C15.9	D004938	133239	HP:0100751	we demonstrated that the direct inhibition of LATS2 protein was mediated by miR-373 and manipulated the expression of miR-373 to affect esophageal cancer cells growth.
target gene	hsa-mir-375	Esophageal Neoplasms	28599478			C15.9	D004938	133239	HP:0100751	MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expression.
target gene	hsa-mir-593	Esophageal Neoplasms	21170987			C15.9	D004938	133239	HP:0100751	Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
target gene	hsa-mir-92b	Esophageal Neoplasms	21600139			C15.9	D004938	133239	HP:0100751	Eighteen miRNAs had their target genes, 10 of them had the potential to individually target up to 200 mRNAs. Hsa-let-7a, hsa-miR-185, hsa-miR-141, hsa-miR-92b, hsa-miR-22 and hsa-miR-301a were known as important genes associated with radioresistance.
target gene	hsa-mir-98	Esophageal Neoplasms	22867052			C15.9	D004938	133239	HP:0100751	microRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma.
target gene	hsa-mir-99a	Esophageal Neoplasms	23292834			C15.9	D004938	133239	HP:0100751	MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma
target gene	hsa-mir-203	Essential Thrombocythemia	26990535	disease of cellular proliferation	DOID:2224	D47.3	D013920	PS187950		miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.
target gene	hsa-mir-221	Essential Thrombocythemia	26990535	disease of cellular proliferation	DOID:2224	D47.3	D013920	PS187950		miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.
target gene	hsa-let-7a-1	Ewing Sarcoma	21853155	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development.
target gene	hsa-let-7a-2	Ewing Sarcoma	21853155	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development.
target gene	hsa-let-7a-3	Ewing Sarcoma	21853155	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing's Sarcoma Development.
target gene	hsa-mir-708	Ewing Sarcoma	22723308	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	EWS/FLI1 Regulates EYA3 in Ewing Sarcoma via Modulation of miRNA-708, Resulting in Increased Cell Survival and Chemoresistance.
target gene	hsa-mir-10b	Fatty Liver, Non-Alcoholic	19780876	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD
target gene	hsa-mir-144	Fatty Liver, Non-Alcoholic	25534427	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Decreased miR-144 could enhance TNF-α and IFN-γ production by targeting TLR2 in vitro, and might contribute to TLR2 up-regulation and the progression of NASH in HFD-MetS E3 rats. This might offer a novel and potential target for NASH therapy.
target gene	hsa-mir-150	Fatty Liver, Non-Alcoholic	29107687	disease of metabolism	DOID:0080208	K75.81	D065626	613282		MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
target gene	hsa-mir-182	Fatty Liver, Non-Alcoholic	26001595	disease of metabolism	DOID:0080208	K75.81	D065626	613282		E3 ubiquitin protein ligase (FBXW7) as potential targets of miR-182
target gene	hsa-mir-27a	Fatty Liver, Non-Alcoholic	29101357	disease of metabolism	DOID:0080208	K75.81	D065626	613282		MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.
target gene	hsa-mir-29a	Fatty Liver, Non-Alcoholic	28454323	disease of metabolism	DOID:0080208	K75.81	D065626	613282		MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease.
target gene	hsa-mir-29b	Fatty Liver, Non-Alcoholic	28454323	disease of metabolism	DOID:0080208	K75.81	D065626	613282		MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease.
target gene	hsa-mir-29c	Fatty Liver, Non-Alcoholic	28454323	disease of metabolism	DOID:0080208	K75.81	D065626	613282		MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease.
target gene	hsa-mir-30c	Fatty Liver, Non-Alcoholic	28088781	disease of metabolism	DOID:0080208	K75.81	D065626	613282		MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN.
target gene	hsa-mir-34a	Fatty Liver, Non-Alcoholic	28899784	disease of metabolism	DOID:0080208	K75.81	D065626	613282		MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1.
target gene	hsa-mir-375	Fatty Liver, Non-Alcoholic	29569260	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease
target gene	hsa-mir-577	Fatty Liver, Non-Alcoholic	27179781	disease of metabolism	DOID:0080208	K75.81	D065626	613282		NS5ATP6 regulated  the expression of miR-577, which directly targeted and regulated FGF21.
target gene	hsa-mir-9	Fatty Liver, Non-Alcoholic	27756894	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Altered microRNA-9 Expression Level is Directly Correlated with Pathogenesis of Nonalcoholic Fatty Liver Disease by Targeting Onecut2 and SIRT1.
target gene	hsa-mir-142	Fever	26825461			R50.9	D005334			RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever.
target gene	hsa-mir-143	Fever	26825461			R50.9	D005334			RBM3 regulates temperature sensitive miR-142-5p and miR-143 (thermomiRs), which target immune genes and control fever.
target gene	hsa-mir-150	Fever	24907421			R50.9	D005334			We demonstrate for the first time that augmented miR-150 expression with depressed SOCS1 expression in CD14(+) cells are associated with the pathogenesis of DHF.
target gene	hsa-mir-373	Fibrosarcoma	21898400	disease of cellular proliferation	DOID:3355		D005354		HP:0100244	miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-ж╩B; and finally increasing the mRN
target gene	hsa-mir-429	Fibrosarcoma	28432002	disease of cellular proliferation	DOID:3355		D005354		HP:0100244	miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma.
target gene	hsa-mir-520c	Fibrosarcoma	21898400	disease of cellular proliferation	DOID:3355		D005354		HP:0100244	miR-520c and miR-373 increased the expression of MMP9 by directly targeting the 3'UTRs of mRNAs of mTOR and SIRT1 and suppressing their translation; resulting in activation of the Ras/Raf/MEK/Erk signaling pathway and NF-ж╩B; and finally increasing the mRN
target gene	hsa-mir-29a	Focal Segmental Glomerulosclerosis	27460630	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	We also demonstrated that miR-29a acts as a positive regulator of Wnt/尾-catenin signaling in cultured mesangial cells and functions to protect cell apoptosis and fibrosis.
target gene	hsa-let-7g	Follicular Atresia	25817543				D005496			let-7g regulates the apoptosis of GCs in the pig ovary by targeting TGFBR1 and down-regulating the TGF-尾 signaling pathway.
target gene	hsa-mir-134	Fragile X Syndrome	17982590	genetic disease	DOID:14261	Q99.2	D005600	300624		spine morphology in patients with Fragile-X mental retardation syndrome (FXS) is not dissimilar from the spine structure observed on miR-134 overexpression or in neurons deficient for the miR-134 target Limk1
target gene	hsa-mir-155	Fungal Keratitis	24403554			H15.8	D007634			miR-155 suppresses bacterial clearance in Pseudomonas aeruginosa-induced keratitis by targeting Rheb.
target gene	hsa-mir-141	Gastric Cardia Adenocarcinoma	29765447	disease of cellular proliferation	DOID:6271					MicroRNA-141 inhibits proliferation of gastric cardia adenocarcinoma by targeting MACC1.
target gene	hsa-let-7a	Gastric Neoplasms	18413822	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family.
target gene	hsa-let-7f-1	Gastric Neoplasms	21533124	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer.
target gene	hsa-let-7f-2	Gastric Neoplasms	21533124	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer.
target gene	hsa-let-7g	Gastric Neoplasms	25972194	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes.
target gene	hsa-mir-1	Gastric Neoplasms	25874496	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET.
target gene	hsa-mir-100	Gastric Neoplasms	26404754	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study demonstrated that miR-100 could be induced by C/EBPα and may act as a tumor suppressor gene by inhibiting ZBTB7A.
target gene	hsa-mir-101	Gastric Neoplasms	26573417	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, the results of the present study suggested that miR-101 inhibited the proliferation and promoted DDP-induced apoptosis of DDP-resistant gastric cancer cells, at least in part via targeting VEGF-C.
target gene	hsa-mir-101	Gastric Neoplasms	26460960	disease of cellular proliferation	DOID:10534	C16	D013274	137215		We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers.
target gene	hsa-mir-101	Gastric Neoplasms	25561270	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-101 functions as a growth-suppressive miRNA in H. pylori related GC, and that its suppressive effects are mediated mainly by repressing SOCS2 expression.
target gene	hsa-mir-101-1	Gastric Neoplasms	20712078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-101-3p: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion
target gene	hsa-mir-101-2	Gastric Neoplasms	20712078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-101-3p: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion
target gene	hsa-mir-103a	Gastric Neoplasms	25530421	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-103a functioned as a tumour suppressor by targeting c-Myb. These findings indicate that miR-103a might play a significant role in pathogenesis of GC
target gene	hsa-mir-106a	Gastric Neoplasms	23932924	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3.
target gene	hsa-mir-106a	Gastric Neoplasms	24108762	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells
target gene	hsa-mir-106a	Gastric Neoplasms	24440352	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-106a targets TIMP2 to regulate invasion and metastasis of gastric cancer.
target gene	hsa-mir-106b	Gastric Neoplasms	23803041	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106b may promote cell cycling of gastric cancer cells through regulation of p21 and E2F5 target gene expression.
target gene	hsa-mir-106b	Gastric Neoplasms	19153141	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106b: inhibite p21,p27, and p57
target gene	hsa-mir-106b	Gastric Neoplasms	28489839	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Deregulation of microRNAs in gastric cancer: up regulation by miR-21 and miR-106.
target gene	hsa-mir-107	Gastric Neoplasms	24374340	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1.
target gene	hsa-mir-10b	Gastric Neoplasms	22293682	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer.
target gene	hsa-mir-1182	Gastric Neoplasms	25662441	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-1182 attenuates gastric cancer proliferation and metastasis by targeting the open reading frame of hTERT.
target gene	hsa-mir-1207	Gastric Neoplasms	24481448	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase.
target gene	hsa-mir-122	Gastric Neoplasms	28337380	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-122 inhibits proliferation and invasion in gastric cancer by targeting CREB1.
target gene	hsa-mir-124	Gastric Neoplasms	24658854	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer.
target gene	hsa-mir-124	Gastric Neoplasms	25169484	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1.
target gene	hsa-mir-124	Gastric Neoplasms	28829503	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-124 inhibits cell invasion and epithelial-mesenchymal transition by directly repressing Snail2 in gastric cancer
target gene	hsa-mir-124	Gastric Neoplasms	28941308	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In vivo and in vitro effects of microRNA-124 on human gastric cancer by targeting JAG1 through the Notch signaling pathway.
target gene	hsa-mir-124	Gastric Neoplasms	29234151	disease of cellular proliferation	DOID:10534	C16	D013274	137215		SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis
target gene	hsa-mir-124-1	Gastric Neoplasms	22450659	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1.
target gene	hsa-mir-124-2	Gastric Neoplasms	22450659	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1.
target gene	hsa-mir-124-3	Gastric Neoplasms	22450659	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-124 Inhibits Cell Proliferation in Gastric Cancer through Downregulation of SPHK1.
target gene	hsa-mir-125a	Gastric Neoplasms	26398444	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Collectively, our results indicated that miR-125a regulated the paracrine of VEGF-A in gastric cancer and thereby controlled the angiogenesis of the tumor.
target gene	hsa-mir-125a	Gastric Neoplasms	21220473	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-125a-5p is an independent prognostic factor in gastric cancer,and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab.
target gene	hsa-mir-125b	Gastric Neoplasms	24846940	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Expression profiling and functional analysis of hsa-miR-125b and its target genes in drug-resistant cell line of human gastric cancer.
target gene	hsa-mir-125b	Gastric Neoplasms	26504803	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer.
target gene	hsa-mir-126	Gastric Neoplasms	24055140	disease of cellular proliferation	DOID:10534	C16	D013274	137215		CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126.
target gene	hsa-mir-126	Gastric Neoplasms	24969300	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2.
target gene	hsa-mir-126	Gastric Neoplasms	26054677	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-126 inhibits cell proliferation in gastric cancer by targeting LAT-1.
target gene	hsa-mir-1266	Gastric Neoplasms	24481448	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase.
target gene	hsa-mir-1271	Gastric Neoplasms	24875127	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
target gene	hsa-mir-1271	Gastric Neoplasms	26159618	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-1271 Inhibits Cell Proliferation, Invasion and EMT in Gastric Cancer by Targeting FOXQ1.
target gene	hsa-mir-1274a	Gastric Neoplasms	25753202	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The role of microRNA-1274a in the tumorigenesis of gastric cancer: accelerating cancer cell proliferation and migration via directly targeting FOXO4.
target gene	hsa-mir-128	Gastric Neoplasms	26460960	disease of cellular proliferation	DOID:10534	C16	D013274	137215		We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers.
target gene	hsa-mir-129-1	Gastric Neoplasms	25008064	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer.
target gene	hsa-mir-1303	Gastric Neoplasms	24647998	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Downregulation of miR-1303 can inhibit proliferation, migration and invasion of GC cells by targeting CLDN18.
target gene	hsa-mir-130a	Gastric Neoplasms	26134263	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3.
target gene	hsa-mir-130a	Gastric Neoplasms	28831264	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-130a is an oncomir suppressing the expression of CRMP4 in gastric cancer
target gene	hsa-mir-130b	Gastric Neoplasms	20176475	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-130b:MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer
target gene	hsa-mir-133	Gastric Neoplasms	25152372	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer.
target gene	hsa-mir-133a	Gastric Neoplasms	24613927	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer.
target gene	hsa-mir-133b	Gastric Neoplasms	24613927	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer.
target gene	hsa-mir-133b	Gastric Neoplasms	23296701	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer
target gene	hsa-mir-135a-1	Gastric Neoplasms	22310976	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation.
target gene	hsa-mir-135a-2	Gastric Neoplasms	22310976	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation.
target gene	hsa-mir-137	Gastric Neoplasms	21221794	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42.
target gene	hsa-mir-141	Gastric Neoplasms	24276755	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF.
target gene	hsa-mir-141	Gastric Neoplasms	24628843	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Altogether, these findings demonstrated that the H. pylori infection could modulate cisplatin sensitivity through miR-141-mediated regulation of KEAP1.
target gene	hsa-mir-141	Gastric Neoplasms	24732377	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-141 may play a pivotal role in controlling gastric cancer invasion through regulating STAT4 and maybe a potential target to treat gastric cancer.
target gene	hsa-mir-141	Gastric Neoplasms	25975736	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-141 inhibits migration of gastric cancer by targeting zinc finger E-box-binding homeobox 2.
target gene	hsa-mir-141	Gastric Neoplasms	26160158	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These results were the first to demonstrate that H19 and miR-141 could compete with each other and affect their target genes in gastric cancer,which provide important clues for understanding the key roles of lncRNA-miRNA functional network in cancer.
target gene	hsa-mir-143	Gastric Neoplasms	24283360	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer.
target gene	hsa-mir-143	Gastric Neoplasms	24616567	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Both miR-143-5p and miR-143-3p function as anti-oncomirs in gastric cancer. However, miR-143-5p alone directly targets COX-2, and it exhibits a stronger tumor suppressive effect than miR-143-3p.
target gene	hsa-mir-143	Gastric Neoplasms	25492481	disease of cellular proliferation	DOID:10534	C16	D013274	137215		hsa-mir-143 could modulate cisplatin resistance of human gastric cancer cell line at least in part by targeting IGF1R and BCL2.
target gene	hsa-mir-143	Gastric Neoplasms	29321084	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-143 inhibits cell proliferation of gastric cancer cells through targeting GATA6
target gene	hsa-mir-144	Gastric Neoplasms	25927670	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression.
target gene	hsa-mir-144	Gastric Neoplasms	29456712	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2
target gene	hsa-mir-145	Gastric Neoplasms	24613927	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer.
target gene	hsa-mir-145	Gastric Neoplasms	25051317	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-145 may contribute to the progression of scirrhous type GC by regulating activation of peri-tumoral fibroblasts
target gene	hsa-mir-145	Gastric Neoplasms	25470111	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-145 inhibits invasion of gastric cancer cells not only by down-regulating cytoplasmic CTNND1 expression but also by inducing the translocation of CTNND1 and E-cadherin from the cytoplasm to the cell membrane through down-regulating N-cadherin.
target gene	hsa-mir-145	Gastric Neoplasms	25762621	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells.
target gene	hsa-mir-145	Gastric Neoplasms	23233482	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis and angiogenesis of gastric cancer cells
target gene	hsa-mir-146a	Gastric Neoplasms	23982143	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis
target gene	hsa-mir-146a	Gastric Neoplasms	22020746	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis.
target gene	hsa-mir-146a	Gastric Neoplasms	22711166	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-146a targets the L1 cell adhesion molecule and suppresses the metastatic potential of gastric cancer.
target gene	hsa-mir-146a	Gastric Neoplasms	23435376	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2
target gene	hsa-mir-146a	Gastric Neoplasms	28560435	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-146a promotes gastric cancer cell apoptosis by targeting transforming growth factor β-activated kinase 1.
target gene	hsa-mir-146b	Gastric Neoplasms	23982143	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis
target gene	hsa-mir-148a	Gastric Neoplasms	25341915	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-148a expression is down-regulated in gastric cancer tissues and inhibits gastric cancer cell proliferation. CDC25B may be the target gene ofmiR-148a that plays a role in tumor suppressor.
target gene	hsa-mir-148a	Gastric Neoplasms	23549984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer
target gene	hsa-mir-148a	Gastric Neoplasms	21552422	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-148a Promoted Cell Proliferation by Targeting p27 in Gastric Cancer Cells.
target gene	hsa-mir-148a	Gastric Neoplasms	21994419	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer.
target gene	hsa-mir-149	Gastric Neoplasms	23144691	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer
target gene	hsa-mir-150	Gastric Neoplasms	20067763	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2
target gene	hsa-mir-152	Gastric Neoplasms	25119599	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151.
target gene	hsa-mir-155	Gastric Neoplasms	27113301	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Target research on tumor biology characteristics of mir-155-5p regulation on gastric cancer cell.
target gene	hsa-mir-15b	Gastric Neoplasms	18449891	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
target gene	hsa-mir-16	Gastric Neoplasms	28667493	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer.
target gene	hsa-mir-16-1	Gastric Neoplasms	18449891	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
target gene	hsa-mir-16-2	Gastric Neoplasms	18449891	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
target gene	hsa-mir-17	Gastric Neoplasms	24801601	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells.
target gene	hsa-mir-17	Gastric Neoplasms	25115392	disease of cellular proliferation	DOID:10534	C16	D013274	137215		F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a.
target gene	hsa-mir-17	Gastric Neoplasms	25760688	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression.
target gene	hsa-mir-181a	Gastric Neoplasms	28447759	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-181a modulates proliferation, migration and autophagy in AGS gastric cancer cells and downregulates MTMR3.
target gene	hsa-mir-181a-2	Gastric Neoplasms	22581522	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6.
target gene	hsa-mir-181b	Gastric Neoplasms	29113265	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The present study confirmed that CDX2 was suppressed by activation of the IL-6/STAT3 signaling pathway via miR-181b in vitro
target gene	hsa-mir-181b-1	Gastric Neoplasms	20162574	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines
target gene	hsa-mir-181b-1	Gastric Neoplasms	22539488	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas.
target gene	hsa-mir-181b-2	Gastric Neoplasms	20162574	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines
target gene	hsa-mir-181b-2	Gastric Neoplasms	22539488	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas.
target gene	hsa-mir-182	Gastric Neoplasms	25682742	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-182 inhibits proliferation through targeting oncogenic ANUBL1 in gastric cancer.
target gene	hsa-mir-182	Gastric Neoplasms	22325466	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma.
target gene	hsa-mir-183	Gastric Neoplasms	25337200	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-183 inhibits invasion of gastric cancer by targeting Ezrin.
target gene	hsa-mir-185	Gastric Neoplasms	24763054	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain.
target gene	hsa-mir-185	Gastric Neoplasms	26191199	disease of cellular proliferation	DOID:10534	C16	D013274	137215		TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.
target gene	hsa-mir-18a	Gastric Neoplasms	26173586	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients.
target gene	hsa-mir-18a	Gastric Neoplasms	23322197	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis
target gene	hsa-mir-19	Gastric Neoplasms	26762410	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MEF2D is a direct target of miR-19, which was found to be decreased in gastric cancer clinical specimens.
target gene	hsa-mir-191	Gastric Neoplasms	21947487	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-191 targets N-deacetylase/N-sulfotransferase 1 and promotes cell growth in human gastric carcinoma cell line MGC803.
target gene	hsa-mir-194	Gastric Neoplasms	24748184	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our study clearly demonstrates that miR-194 inhibits the acquisition of the EMT phenotype in gastric cancer cells by downregulating FoxM1, thereby inhibiting cell migration and invasion during cancer progression.
target gene	hsa-mir-196a	Gastric Neoplasms	24933454	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer.
target gene	hsa-mir-196a	Gastric Neoplasms	25773825	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of mir-196a-5p is associated with lymph node metastasis and clinical stage, and enriched KEGG pathway analyses showed that targeted genes regulated by mir-196a-5p may contribute to tumorgenesis,suggesting roles as an oncogenic miRNA biomarker in gastric cancer.
target gene	hsa-mir-196a-1	Gastric Neoplasms	22343731	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-196a Is Up-regulated in Gastric cancer and Promotes Cell proliferation by Down-regulating p27kip1.
target gene	hsa-mir-196a-2	Gastric Neoplasms	22343731	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-196a Is Up-regulated in Gastric cancer and Promotes Cell proliferation by Down-regulating p27kip1.
target gene	hsa-mir-196b	Gastric Neoplasms	24933454	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer.
target gene	hsa-mir-199a	Gastric Neoplasms	24655788	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our present study suggests that miR-199a-5p acts as an oncogene in gastric cancer and functions by targeting klotho.
target gene	hsa-mir-199a	Gastric Neoplasms	25448600	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-199a-3p may function as a novel tumor promoter in GC and its oncogenic activity may involve the direct targeting and inhibition of ZHX1.
target gene	hsa-mir-19a	Gastric Neoplasms	24675462	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1.
target gene	hsa-mir-19b	Gastric Neoplasms	24675462	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1.
target gene	hsa-mir-19b	Gastric Neoplasms	23868977	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells.
target gene	hsa-mir-200a	Gastric Neoplasms	23381389	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/beta-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma
target gene	hsa-mir-200b	Gastric Neoplasms	21993663	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
target gene	hsa-mir-200b	Gastric Neoplasms	22311119	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-200b Regulates Cell Proliferation, Invasion, and Migration by Directly Targeting ZEB2 in Gastric Carcinoma.
target gene	hsa-mir-200c	Gastric Neoplasms	23821457	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE.
target gene	hsa-mir-200c	Gastric Neoplasms	24885194	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Together, these findings demonstrate that the ubiquitin ligase Cbl-b represses IGF-I-induced EMT, likely through targeting IGF-IR for degradation and  further inhibiting the Akt/ERK-miR-200c-ZEB2 axis in gastric cancer cells.
target gene	hsa-mir-200c	Gastric Neoplasms	21993663	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
target gene	hsa-mir-200c	Gastric Neoplasms	29138864	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Expression level of microRNA-200c is associated with cell morphology in vitro and histological differentiation through regulation of ZEB1/2 and E-cadherin in gastric carcinoma.
target gene	hsa-mir-203	Gastric Neoplasms	25373785	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-regulation of miR-203 induced by Helicobacter pylori infection promotes the  proliferation and invasion of gastric cancer by targeting CASK.
target gene	hsa-mir-203	Gastric Neoplasms	26980572	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling.
target gene	hsa-mir-204	Gastric Neoplasms	23768087	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results suggest that down-regulation of mir-204 promotes gastric  cancer cell invasion by activating the SIRT1-LKB1 pathway. These data demonstrate that mir-204 plays an important role in regulating metastasis of gastric cancer, which is involved in post-transcriptional repression of SIRT1.
target gene	hsa-mir-204	Gastric Neoplasms	24984017	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, our findings demonstrated that miR-204 may act as a tumor suppressor in H. pylori induced gastric cancer by targeting SOX4.
target gene	hsa-mir-204	Gastric Neoplasms	25429829	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-204-5p acts as a tumor suppressor in GC through inhibiting USP47 and RAB22A.
target gene	hsa-mir-204	Gastric Neoplasms	21416062	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-204, which was predicted to target ezrin, was downregulated in gastric cancer cells and gastric carcinomas. MiR-204 inhibited ezrin expression, Ras activation, cell growth and cell migration
target gene	hsa-mir-204	Gastric Neoplasms	23152059	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer
target gene	hsa-mir-205	Gastric Neoplasms	27082508	disease of cellular proliferation	DOID:10534	C16	D013274	137215		transfection with miR鈥?05, the epithelial marker CDH1 (E鈥慶adherin) was upregulated, and the mesenchymal markers CDH2 (N鈥慶adherin) and vimentin were suppressed.
target gene	hsa-mir-205	Gastric Neoplasms	28987942	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-205 regulation of ICT1 has an oncogenic potential via promoting the migration and invasion of gastric cancer cells.
target gene	hsa-mir-206	Gastric Neoplasms	23348698	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-206 inhibits gastric cancer proliferation in part by repressing CyclinD2
target gene	hsa-mir-20a	Gastric Neoplasms	23924943	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2).
target gene	hsa-mir-20a	Gastric Neoplasms	25115392	disease of cellular proliferation	DOID:10534	C16	D013274	137215		F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a.
target gene	hsa-mir-20a	Gastric Neoplasms	25760688	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Inhibition of microRNA-17/20a suppresses cell proliferation in gastric cancer by modulating UBE2C expression.
target gene	hsa-mir-20a	Gastric Neoplasms	23868977	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells.
target gene	hsa-mir-21	Gastric Neoplasms	24659669	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 is overexpressed in gastric cancer and its aberrant expression may have important role in gastric cancer growth and dissemination by modulating the expression of the tumor suppressors PTEN and PDCD4, as well as by modulating the pathways involved in mediating cell growth, migration, invasion and apoptosis. Targeting miR-21 may help develop novel therapeutics for gastric cancer, once its pathophysiology is completely investigated.
target gene	hsa-mir-21	Gastric Neoplasms	24154840	disease of cellular proliferation	DOID:10534	C16	D013274	137215		To our knowledge, this study was the first reveal the miR-21/PTEN pathway regulated the sensitivity of HER2-positive GC cell lines to trastuzumab through modulation apoptosis. These findings suggest that this pathway may be crucial to the mechanism of resistance to trastuzumab in GC, which may lead to the development of individualized treatment in clinical practice.
target gene	hsa-mir-21	Gastric Neoplasms	24821435	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 regulates N-methyl-N-nitro-N'-nitrosoguanidine-induced gastric tumorigenesis by targeting FASLG and BTG2.
target gene	hsa-mir-21	Gastric Neoplasms	22267008	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN.
target gene	hsa-mir-21	Gastric Neoplasms	22464652	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer.
target gene	hsa-mir-21	Gastric Neoplasms	22792096	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer.
target gene	hsa-mir-21	Gastric Neoplasms	23466500	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN
target gene	hsa-mir-21	Gastric Neoplasms	27611950	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-21 promotes TGF-β1-induced epithelial-mesenchymal transition in gastric cancer through up-regulating PTEN expression.
target gene	hsa-mir-21	Gastric Neoplasms	29101039	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH.
target gene	hsa-mir-21	Gastric Neoplasms	29687845	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miRNA-21 may promote the growth of gastric cancer cells by adjusting and controlling PTEN/Akt signal passage mediated PEG2
target gene	hsa-mir-212	Gastric Neoplasms	23794145	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
target gene	hsa-mir-214	Gastric Neoplasms	21688200	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-Regulated miRNA-214 Induces a Cell Cycle G1 Arrest in Gastric Cancer Cells by Up-Regulating the PTEN Protein.
target gene	hsa-mir-217	Gastric Neoplasms	25869101	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
target gene	hsa-mir-217	Gastric Neoplasms	26098560	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The MicroRNA-217 Functions as a Potential Tumor Suppressor in Gastric Cancer by Targeting GPC5.
target gene	hsa-mir-218	Gastric Neoplasms	25170221	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results indicated that targeting miR-218 may provide a strategy for blocking the development of gastric cancer and reverse the multi-drug resistance of gastric cell lines.
target gene	hsa-mir-218	Gastric Neoplasms	26261515	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings suggest that miR-218 inhibits MDR of gastric cancer cells by down-regulating SMO expression.
target gene	hsa-mir-218-1	Gastric Neoplasms	20300657	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.
target gene	hsa-mir-218-2	Gastric Neoplasms	20300657	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.
target gene	hsa-mir-22	Gastric Neoplasms	24495805	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151.
target gene	hsa-mir-22	Gastric Neoplasms	25323629	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-22 acts as a metastasis suppressor by targeting metadherin in gastric cancer.
target gene	hsa-mir-22	Gastric Neoplasms	23529765	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1
target gene	hsa-mir-221	Gastric Neoplasms	19153141	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-221: inhibite p21,p27, and p57
target gene	hsa-mir-222	Gastric Neoplasms	19153141	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-222: inhibite p21,p27, and p57
target gene	hsa-mir-222	Gastric Neoplasms	22321642	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Increased miR-222 in H. pylori-associated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK.
target gene	hsa-mir-223	Gastric Neoplasms	25159729	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway.
target gene	hsa-mir-223	Gastric Neoplasms	21628394	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3.
target gene	hsa-mir-223	Gastric Neoplasms	22270966	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.
target gene	hsa-mir-223	Gastric Neoplasms	22470493	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer.
target gene	hsa-mir-23a	Gastric Neoplasms	24997345	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Downregulation of PPP2R5E expression by miR-23a suppresses apoptosis to facilitate the growth of gastric cancer cells.
target gene	hsa-mir-23a	Gastric Neoplasms	23553990	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-23a in Amplified 19p13.13 Loci Targets Metallothionein 2A and Promotes Growth in Gastric Cancer Cells
target gene	hsa-mir-23b	Gastric Neoplasms	25996293	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2.
target gene	hsa-mir-23b	Gastric Neoplasms	28981115	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-23a/b promote tumor growth and suppress apoptosis by targeting PDCD4 in gastric cancer.
target gene	hsa-mir-25	Gastric Neoplasms	25043310	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival.
target gene	hsa-mir-25	Gastric Neoplasms	25944166	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7.
target gene	hsa-mir-25	Gastric Neoplasms	24078004	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-25 promotes gastric cancer cells growth and motility by targeting RECK.
target gene	hsa-mir-25	Gastric Neoplasms	19153141	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-25: inhibite p21,p27, and p57
target gene	hsa-mir-26a	Gastric Neoplasms	26458859	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results suggest that miR-26a can improve the sensitivity of GC cells to cisplatin-based chemotherapies through targeting NRAS and E2F2, and provide the first evidence of the potential utility of miR-26a as a sensitizer in chemotherapy for GC.
target gene	hsa-mir-27a	Gastric Neoplasms	28327189	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2.
target gene	hsa-mir-27b	Gastric Neoplasms	26460960	disease of cellular proliferation	DOID:10534	C16	D013274	137215		We conclude that miR-27b,miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers.
target gene	hsa-mir-27b	Gastric Neoplasms	29393383	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-27b may act as a potential biomarker for differentiating patients with GC from healthy controls, and serve as a tumor suppressor in GC by targeting VEGFC
target gene	hsa-mir-296	Gastric Neoplasms	23353818	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1
target gene	hsa-mir-29a	Gastric Neoplasms	25997819	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-29a inhibits cell migration and invasion via targeting Roundabout homolog 1 in gastric cancer cells.
target gene	hsa-mir-29a	Gastric Neoplasms	24209632	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A.
target gene	hsa-mir-29a	Gastric Neoplasms	21998710	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-29a Inhibits Cell Proliferation and Induces Cell Cycle Arrest through the Downregulation of p42.3 in Human Gastric Cancer.
target gene	hsa-mir-29b	Gastric Neoplasms	26564501	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-29b can enhance the sensitivity of S gastric cancer cell by directly targeting PI3K/Akt pathway.
target gene	hsa-mir-29c	Gastric Neoplasms	24054006	disease of cellular proliferation	DOID:10534	C16	D013274	137215		There are special miRNA expression profile in gastric cancer. The expression of miR-29c is closely related to biological behavior of human gastric cancer. miR-29c is involved in targeted regulation of Mcl-1, and may be one of mechanisms of the carcinogenesis of gastric cancer.
target gene	hsa-mir-29c	Gastric Neoplasms	23442884	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2
target gene	hsa-mir-29c	Gastric Neoplasms	28173777	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-29c inhibits cell proliferation by targeting NASP in human gastric cancer.
target gene	hsa-mir-301a	Gastric Neoplasms	23338485	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer
target gene	hsa-mir-30a	Gastric Neoplasms	24447545	disease of cellular proliferation	DOID:10534	C16	D013274	137215		RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells.
target gene	hsa-mir-320	Gastric Neoplasms	28713899	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-320a serves as a negative regulator in the progression of gastric cancer by targeting RAB14.
target gene	hsa-mir-326	Gastric Neoplasms	26359764	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our study demonstrated that miR-326 overexpression was a poor prognostic marker for gastric cancer patients, and miR-326 served as a tumor suppressor in gastric cancer via directly regulating FSCN1.
target gene	hsa-mir-329	Gastric Neoplasms	25654811	disease of cellular proliferation	DOID:10534	C16	D013274	137215		By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth.
target gene	hsa-mir-331	Gastric Neoplasms	20510161	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miRNA-331-3p:miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer
target gene	hsa-mir-335	Gastric Neoplasms	21822301	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1.
target gene	hsa-mir-338	Gastric Neoplasms	23826132	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP.
target gene	hsa-mir-338	Gastric Neoplasms	24375644	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a.
target gene	hsa-mir-338	Gastric Neoplasms	24736504	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-338 inhibits growth, invasion and metastasis of gastric cancer by targeting NRP1 expression.
target gene	hsa-mir-338	Gastric Neoplasms	25945841	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling.
target gene	hsa-mir-340	Gastric Neoplasms	29234151	disease of cellular proliferation	DOID:10534	C16	D013274	137215		SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis
target gene	hsa-mir-34a	Gastric Neoplasms	24837198	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
target gene	hsa-mir-34a	Gastric Neoplasms	26035691	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway.
target gene	hsa-mir-34a	Gastric Neoplasms	23264087	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells
target gene	hsa-mir-34a	Gastric Neoplasms	27497057	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our NVs-mediated miR-34a delivery system specifically increased endogenous target miR levels, thereby attenuating proliferation and migration of  gastric cancer cells by repressing the expression of CD44 with decreased levels of Bcl-2, Oct 3/4 and Nanog genes.
target gene	hsa-mir-34a	Gastric Neoplasms	29581731	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-34a regulates proliferation and apoptosis of gastric cancer cells by targeting silent information regulator 1
target gene	hsa-mir-34c	Gastric Neoplasms	23423488	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel
target gene	hsa-mir-362	Gastric Neoplasms	24495516	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The results suggest that miR-362 plays an important role in repressing the tumor suppressor CYLD and present a novel mechanism of miRNA-mediated NF-κB activation in gastric cancer.
target gene	hsa-mir-362	Gastric Neoplasms	25652145	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Anti-miR-362-3p Inhibits Migration and Invasion of Human Gastric Cancer Cells by Its Target CD82.
target gene	hsa-mir-363	Gastric Neoplasms	26709677	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-363-3p showed low levels in GC tissues and cells. Enforced expression of miR-363-3p inhibited cell growth and migration of GC cells and vice versa. NOTCH1 is the targeted gene of miR-363-3p. CONCLUSIONS MiR-363-3p plays a tumor suppressor role in GC.
target gene	hsa-mir-370	Gastric Neoplasms	23576572	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Fork head box M1 is overexpressed in Helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by hsa-miR-370
target gene	hsa-mir-370	Gastric Neoplasms	23721824	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Upregulation of miR-370 contributes to the progression of gastric carcinoma via suppression of FOXO1.
target gene	hsa-mir-372	Gastric Neoplasms	23242208	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-372 maintains oncogene characteristics by targeting TNFAIP1 and affects NFkB signaling in human gastric carcinoma cells
target gene	hsa-mir-372	Gastric Neoplasms	19937137	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, these findings demonstrate an oncogenic role for miR-372 in controlling cell growth, cell cycle, and apoptosis through down-regulation of a tumor suppressor gene, LATS2.
target gene	hsa-mir-372	Gastric Neoplasms	24179536	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings demonstrate an oncogenic role for miR-373, similar to that of miR-372, in controlling cell growth through the downregulation of TNFAIP1.
target gene	hsa-mir-373	Gastric Neoplasms	24179536	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings demonstrate an oncogenic role for miR-373, similar to that of miR-372, in controlling cell growth through the downregulation of TNFAIP1.
target gene	hsa-mir-375	Gastric Neoplasms	25055044	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-375 may be negatively regulated by Snail and involved in gastric cancer cell migration and invasion potentially by targeting JAK2.
target gene	hsa-mir-375	Gastric Neoplasms	20548334	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-375:MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2
target gene	hsa-mir-377	Gastric Neoplasms	25998046	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-377 predicts poor clinical outcome of gastric cancer and induces tumorigenesis by targeting multiple tumor-suppressor genes.
target gene	hsa-mir-378	Gastric Neoplasms	24139413	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro.
target gene	hsa-mir-409	Gastric Neoplasms	22179828	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers.
target gene	hsa-mir-409	Gastric Neoplasms	22388101	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer.
target gene	hsa-mir-410	Gastric Neoplasms	25136862	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer.
target gene	hsa-mir-421	Gastric Neoplasms	25041019	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-421 regulates apoptosis of BGC-823 gastric cancer cells by targeting caspase-3.
target gene	hsa-mir-425	Gastric Neoplasms	24571667	disease of cellular proliferation	DOID:10534	C16	D013274	137215		NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction.
target gene	hsa-mir-429	Gastric Neoplasms	21993663	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
target gene	hsa-mir-449a	Gastric Neoplasms	24248414	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This is the first report to provide evidence that miR-449a could modulate cell cycle and apoptosis through regulating cyclin D1 and BCL2 expression in SGC7901 cells.
target gene	hsa-mir-491	Gastric Neoplasms	29569792	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Downregulation of miR-491-5p promotes gastric cancer metastasis by regulating SNAIL and FGFR4.
target gene	hsa-mir-495	Gastric Neoplasms	22469786	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
target gene	hsa-mir-503	Gastric Neoplasms	24931256	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our findings suggest that hsa-miR-503 modulates cisplatin resistance of human gastric cancer cells at least in part by targeting IGF1R and BCL2.
target gene	hsa-mir-506	Gastric Neoplasms	25846731	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1.
target gene	hsa-mir-506	Gastric Neoplasms	26362716	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, miR-506 was identified as an ETS1 targeting suppressor of metastatic invasion and angiogenesis in gastric cancer.
target gene	hsa-mir-508	Gastric Neoplasms	23893241	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1.
target gene	hsa-mir-513b	Gastric Neoplasms	25095979	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Upregulation of miR-513b inhibits cell proliferation, migration, and promotes apoptosis by targeting high mobility group-box 3 protein in gastric cancer.
target gene	hsa-mir-519	Gastric Neoplasms	26819420	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-may inhibit the gastric cancer cell activity through suppression of HuR expression.
target gene	hsa-mir-544a	Gastric Neoplasms	22934698	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer.
target gene	hsa-mir-544b	Gastric Neoplasms	22934698	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer.
target gene	hsa-mir-551a	Gastric Neoplasms	22469786	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
target gene	hsa-mir-570	Gastric Neoplasms	23430453	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
target gene	hsa-mir-622	Gastric Neoplasms	21528065	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene.
target gene	hsa-mir-625	Gastric Neoplasms	22677169	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK.
target gene	hsa-mir-7	Gastric Neoplasms	29467883	disease of cellular proliferation	DOID:10534	C16	D013274	137215		YCS inhibits proliferation and induces apoptosis of GC cells mediated by miR-7 targeting EGFR, which may be one of the mechanisms whereby YZSJD exerts its effects on GC
target gene	hsa-mir-7-1	Gastric Neoplasms	22614005	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor.
target gene	hsa-mir-7-2	Gastric Neoplasms	22614005	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor.
target gene	hsa-mir-7-3	Gastric Neoplasms	22614005	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor.
target gene	hsa-mir-9-1	Gastric Neoplasms	20102618	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth
target gene	hsa-mir-9-1	Gastric Neoplasms	21225631	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-9 down-regulates CDX2 expression in gastric cancer cells.
target gene	hsa-mir-9-1	Gastric Neoplasms	23383271	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
target gene	hsa-mir-92	Gastric Neoplasms	25095974	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-92 promotes gastric cancer cell proliferation and invasion through targeting FXR.
target gene	hsa-mir-9-2	Gastric Neoplasms	20102618	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth
target gene	hsa-mir-9-2	Gastric Neoplasms	21225631	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-9 down-regulates CDX2 expression in gastric cancer cells.
target gene	hsa-mir-9-2	Gastric Neoplasms	23383271	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
target gene	hsa-mir-92a	Gastric Neoplasms	23868977	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells.
target gene	hsa-mir-93	Gastric Neoplasms	19153141	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-93: inhibite p21,p27, and p57
target gene	hsa-mir-9-3	Gastric Neoplasms	20102618	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-9 targets NF-kappaB1 and regulates gastric cancer cell growth
target gene	hsa-mir-9-3	Gastric Neoplasms	21225631	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-9 down-regulates CDX2 expression in gastric cancer cells.
target gene	hsa-mir-9-3	Gastric Neoplasms	23383271	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1
target gene	hsa-mir-940	Gastric Neoplasms	26317898	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer.
target gene	hsa-let-7a-1	Gastrointestinal Neoplasms	21349817			D37.9	D005770			let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas
target gene	hsa-let-7a-2	Gastrointestinal Neoplasms	21349817			D37.9	D005770			let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas
target gene	hsa-let-7a-3	Gastrointestinal Neoplasms	21349817			D37.9	D005770			let-7a is significant in suppressing gastric cancer growth in vivo and in vitro and provided the first evidence that RAB40C is negatively regulated by let-7a at the post-transcriptional level via binding to the 3'-untranslated region of RAB40C mRNA in gas
target gene	hsa-mir-106b	Gastrointestinal Neoplasms	18328430			D37.9	D005770			Together, these results suggest that the miR-106b-25 cluster is involved in E2F1 posttranscriptional regulation and may play a key role in the development of TGFbeta resistance in gastric cancer.
target gene	hsa-mir-107	Gastrointestinal Neoplasms	21264532			D37.9	D005770			miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells.
target gene	hsa-mir-107	Gastrointestinal Neoplasms	21029372			D37.9	D005770			MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer.
target gene	hsa-mir-126	Gastrointestinal Neoplasms	21304604			D37.9	D005770			miR-126 is a novel miRNA that targets SOX2, and PLAC1 may be a novel downstream target gene of SOX2 in gastric cancer cells. These findings suggest that aberrant over-expression of miR-126 and consequent SOX2 down-regulation may contribute to gastric carc
target gene	hsa-mir-155	Gastrointestinal Neoplasms	22719182			D37.9	D005770			As a possible new mechanism underlying MSI, overexpression of miR-155 has been shown to downregulate expression of MLH1, MSH2, and MSH6. Thus, a subset of MSI-positive (MSI+) cancers without known MMR defects may result from miR-155 overexpression. 
target gene	hsa-mir-155	Gastrointestinal Neoplasms	16875667			D37.9	D005770			Therefore, we concluded that artificial miRNA can depress the expression of PRL-3, and that PRL-3 might be a potential therapeutic target for gastric cancer peritoneal metastasis.
target gene	hsa-mir-19a	Gastrointestinal Neoplasms	23603256			D37.9	D005770			MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN.
target gene	hsa-mir-19a	Gastrointestinal Neoplasms	23621248			D37.9	D005770			miR-19a promotes cell growth and tumorigenesis through targeting SOCS1 in gastric cancer.
target gene	hsa-mir-19b	Gastrointestinal Neoplasms	23603256			D37.9	D005770			MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN.
target gene	hsa-mir-24	Gastrointestinal Neoplasms	20062076			D37.9	D005770			These findings establish a novel regulation of miR-24-related AE1 expression in gastric carcinogenesis and erythropoiesis.
target gene	hsa-mir-24	Gastrointestinal Neoplasms	23688438			D37.9	D005770			Dual-luciferase reporter assays showed that miR-24 inhibited the expression of B7-H2 through binding with the B7-H2 3'-UTR, and this inhibitory role of miR-24 was impacted by rs4819388.
target gene	hsa-mir-375	Gastrointestinal Neoplasms	21557705			D37.9	D005770			The genes targeted by miR-375, including JAK2 and 3'-phosphoinositide dependent protein kinase-1(PDK1), are also candidates for gastric cancer therapy
target gene	hsa-mir-43c	Gastrointestinal Neoplasms	21156161			D37.9	D005770			Furthermore, a luciferase reporter assay demonstrates that miR-43c directly targets adherens junctions' transmembrane protein (VEZT) and suppresses VEZT protein expression.
target gene	hsa-mir-494	Gastrointestinal Neoplasms	22042971			D37.9	D005770			MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation.
target gene	hsa-mir-497	Gastrointestinal Neoplasms	21258880			D37.9	D005770			miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.
target gene	hsa-mir-137	Gastrointestinal Stromal Tumor	25027394	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor.
target gene	hsa-mir-17	Gastrointestinal Stromal Tumor	23969726	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
target gene	hsa-mir-18	Gastrointestinal Stromal Tumor	23969726	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
target gene	hsa-mir-19a	Gastrointestinal Stromal Tumor	23969726	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
target gene	hsa-mir-19b-1	Gastrointestinal Stromal Tumor	23969726	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
target gene	hsa-mir-20a	Gastrointestinal Stromal Tumor	23969726	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
target gene	hsa-mir-218	Gastrointestinal Stromal Tumor	24375253	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT.
target gene	hsa-mir-221	Gastrointestinal Stromal Tumor	23969726	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
target gene	hsa-mir-222	Gastrointestinal Stromal Tumor	23969726	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
target gene	hsa-mir-335	Gastrointestinal Stromal Tumor	26214687	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		Our results suggest that miR-34a and miR-335 are candidate tumor suppressive miRNAs in GISTs, and that they are frequent targets of epigenetic silencing in GISTs.
target gene	hsa-mir-34a	Gastrointestinal Stromal Tumor	26214687	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		Our results suggest that miR-34a and miR-335 are candidate tumor suppressive miRNAs in GISTs, and that they are frequent targets of epigenetic silencing in GISTs.
target gene	hsa-mir-92-1	Gastrointestinal Stromal Tumor	23969726	disease of cellular proliferation	DOID:9253	C49.A	D046152	606764		MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
target gene	hsa-mir-106b	Giant Cell Tumor of Bone	26053181	disease of cellular proliferation	DOID:4305		D018212		HP:0011847	MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.
target gene	hsa-mir-126	Giant Cell Tumor of Bone	24973691	disease of cellular proliferation	DOID:4305		D018212		HP:0011847	MiR-126-5p regulates osteolysis formation and stromal cell proliferation in giant cell tumor through inhibition of PTHrP.
target gene	hsa-let-7g	Glioblastoma	27634309				D005909		HP:0100843	Let-7g-5p inhibits epithelial-mesenchymal transition consistent with reduction of glioma stem cell phenotypes by targeting VSIG4 in glioblastoma.
target gene	hsa-mir-100	Glioblastoma	24244722				D005909		HP:0100843	microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models.
target gene	hsa-mir-101	Glioblastoma	21297974				D005909		HP:0100843	Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2.
target gene	hsa-mir-101	Glioblastoma	27792996				D005909		HP:0100843	MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
target gene	hsa-mir-101	Glioblastoma	27911279				D005909		HP:0100843	MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9.
target gene	hsa-mir-106a	Glioblastoma	21656380				D005909		HP:0100843	MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status.
target gene	hsa-mir-106a	Glioblastoma	27815074				D005909		HP:0100843	MicroRNA-106a-5p facilitates human glioblastoma cell proliferation and invasion by targeting adenomatosis polyposis coli protein.
target gene	hsa-mir-10a	Glioblastoma	22558405				D005909		HP:0100843	a tumor suppressor, CSMD1, as a downstream target of miR-10a and miR-10b, two of the up-regulated miRNAs.
target gene	hsa-mir-10b	Glioblastoma	21419107				D005909		HP:0100843	MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10.
target gene	hsa-mir-10b	Glioblastoma	22558405				D005909		HP:0100843	a tumor suppressor, CSMD1, as a downstream target of miR-10a and miR-10b, two of the up-regulated miRNAs.
target gene	hsa-mir-10b	Glioblastoma	28393237				D005909		HP:0100843	MicroRNA-10b mediates TGF-β1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition.
target gene	hsa-mir-124	Glioblastoma	23624869				D005909		HP:0100843	Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L.
target gene	hsa-mir-124	Glioblastoma	23636127				D005909		HP:0100843	miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma.
target gene	hsa-mir-124	Glioblastoma	28040710				D005909		HP:0100843	REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.
target gene	hsa-mir-124	Glioblastoma	28242198				D005909		HP:0100843	miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
target gene	hsa-mir-124a	Glioblastoma	24068568				D005909		HP:0100843	The result indicates that miR-124a expression may also be modulated through the upstream targeting of REST. Preclinical studies involving inhibitors of REST and treatment with demethylating agents with the intent to increase miR-124a levels could be interesting.
target gene	hsa-mir-125b	Glioblastoma	23857508				D005909		HP:0100843	miR-125b could play a role in the development of temozolomide resistance in GSCs. Inhibition of miR-125b expression may enhance sensitivity of GSCs to temozolomide by targeting PIAS3 on cell invasion.
target gene	hsa-mir-125b	Glioblastoma	24356103				D005909		HP:0100843	miR-125b promotes cell proliferation by directly targeting Lin28 in glioblastoma stem cells with low expression levels of miR-125b.
target gene	hsa-mir-125b	Glioblastoma	24643683				D005909		HP:0100843	miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1.
target gene	hsa-mir-125b	Glioblastoma	24901050				D005909		HP:0100843	miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.
target gene	hsa-mir-125b-1	Glioblastoma	22415301				D005909		HP:0100843	Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma.
target gene	hsa-mir-125b-2	Glioblastoma	22415301				D005909		HP:0100843	Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma.
target gene	hsa-mir-127	Glioblastoma	24517116				D005909		HP:0100843	Next generation sequencing analysis of miRNAs: MiR-127-3p inhibits glioblastoma proliferation and activates TGF-β signaling by targeting SKI.
target gene	hsa-mir-127	Glioblastoma	24604520				D005909		HP:0100843	MicroRNA-127-3p promotes glioblastoma cell migration and invasion by targeting the tumor-suppressor gene SEPT7.
target gene	hsa-mir-128	Glioblastoma	19010882				D005909		HP:0100843	This showed that miR-128 specifically blocked glioma self-renewal consistent with Bmi-1 down-regulation.
target gene	hsa-mir-128	Glioblastoma	27507538				D005909		HP:0100843	We demonstrated that miR-31 and miR-128 can bind to the 3'UTR of  PVRL4 and decrease PVRL4 levels while anti-miR-31/128 increase PVRL4 levels suggesting that PVRL4 is miRNA targeted.
target gene	hsa-mir-129	Glioblastoma	26180082				D005909		HP:0100843	Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating  c-Myc and inhibiting miR-29b-1 and miR-129-3p.
target gene	hsa-mir-129	Glioblastoma	28068630				D005909		HP:0100843	Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B.
target gene	hsa-mir-133b	Glioblastoma	26857280				D005909		HP:0100843	several miRNAs (miR-133b, miR-30b-3p, miR-145-5p,  and miR-146a-5p) targeting EGFR
target gene	hsa-mir-134	Glioblastoma	23467648				D005909		HP:0100843	MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression
target gene	hsa-mir-135b	Glioblastoma	25936394				D005909		HP:0100843	MicroRNA-135b exerts oncogenic activity in glioblastoma via the inhibition of glycerol kinase 5 expression.
target gene	hsa-mir-135b	Glioblastoma	25265336				D005909		HP:0100843	miR-135b contributes to the radioresistance by targeting GSK3β in human glioblastoma multiforme cells.
target gene	hsa-mir-137	Glioblastoma	23714687				D005909		HP:0100843	MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1.
target gene	hsa-mir-137	Glioblastoma	25939439				D005909		HP:0100843	MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2.
target gene	hsa-mir-137	Glioblastoma	28386374				D005909		HP:0100843	MicroRNA-137 inhibits growth of glioblastoma through EGFR suppression.
target gene	hsa-mir-139	Glioblastoma	26449464				D005909		HP:0100843	We concluded that ectopic expression of miR-139-5p in GBM cell lines significantly suppressed cell proliferation and inducing apoptosis. Bioinformatics coupled with luciferase and western blot assays also revealed that miR-139-5p suppresses glioma cell proliferation by targeting ELTD1 and regulating cell cycle.
target gene	hsa-mir-143	Glioblastoma	27081712				D005909		HP:0100843	miR鈥?43 inhibited the proliferation, migration and invasion of the glioblastoma cells.
target gene	hsa-mir-144	Glioblastoma	26250785				D005909		HP:0100843	miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
target gene	hsa-mir-145	Glioblastoma	22098779				D005909		HP:0100843	The expression of miR145 (a tumor-suppressive miRNA) is inversely correlated with the levels of Oct4 and Sox2 in GBM-CD133(+) cells and malignant glioma specimens.miR145 negatively regulates GBM tumorigenesis by targeting Oct4 and Sox2 in GBM-CD133(+). Using polyurethane-short branch polyethylenimine (PU-PEI) as a therapeutic-delivery vehicle, PU-PEI-mediated miR145 delivery to GBM-CD133(+) significantly inhibited their tumorigenic and CSC-like abilities and facilitated their differentiation into CD133(-)-non-CSCs. Furthermore, PU-PEI-miR145-treated GBM-CD133(+) effectively suppressed the expression of drug-resistance and anti-apoptotic genes and increased the sensitivity of the cells to radiation and temozolomide. Finally, the in vivo delivery of PU-PEI-miR145 alone significantly suppressed tumorigenesis with stemness, and synergistically improved the survival rate when used in combination with radiotherapy and temozolomide in orthotopic GBM-CD133(+)-transplanted immunocompromised mice. Therefore, PU-PEI-miR145 is a novel therapeutic approach for malignant brain tumors.
target gene	hsa-mir-145	Glioblastoma	22869051				D005909		HP:0100843	NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma.
target gene	hsa-mir-145	Glioblastoma	26681767				D005909		HP:0100843	ISO attenuated SOX2 expression by specific induction of miR-145
target gene	hsa-mir-145	Glioblastoma	26857280				D005909		HP:0100843	several miRNAs (miR-133b, miR-30b-3p, miR-145-5p,  and miR-146a-5p) targeting EGFR
target gene	hsa-mir-146a	Glioblastoma	26857280				D005909		HP:0100843	several miRNAs (miR-133b, miR-30b-3p, miR-145-5p,  and miR-146a-5p) targeting EGFR
target gene	hsa-mir-148a	Glioblastoma	24425048				D005909		HP:0100843	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.
target gene	hsa-mir-148a	Glioblastoma	25903473				D005909		HP:0100843	miR-31 and miR-148a regulate glioma growth by maintaining tumor stem cells and their niche, and providing the tumor a way to activate angiogenesis even in a normoxic  environment.This is the first study that demonstrates intratumoral uptake and growth-inhibiting effects of uncomplexed antagomirs in orthotopic glioma.
target gene	hsa-mir-148a	Glioblastoma	25971746				D005909		HP:0100843	These findings uncover a plausible mechanism for NF-κB-sustained TGF-β/Smad activation via miR-148a in glioblastoma, and may suggest a new target for clinical intervention in human cancer.
target gene	hsa-mir-152	Glioblastoma	25218589				D005909		HP:0100843	MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4.
target gene	hsa-mir-153	Glioblastoma	28218035				D005909		HP:0100843	MicroRNA-153 regulates glutamine metabolism in glioblastoma through targeting glutaminase.
target gene	hsa-mir-155	Glioblastoma	19559015				D005909		HP:0100843	overexpressed; contributes to tumor resistance to VM-26 chemotherapy; targets LRRFIP1;
target gene	hsa-mir-155	Glioblastoma	22470130				D005909		HP:0100843	miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors.
target gene	hsa-mir-15b	Glioblastoma	27896672				D005909		HP:0100843	miR-15b Inhibits the Progression of Glioblastoma Cells Through Targeting Insulin-like Growth Factor Receptor 1.
target gene	hsa-mir-16	Glioblastoma	28497156				D005909		HP:0100843	Tumor suppressors microRNA-302d and microRNA-16 inhibit human glioblastoma multiforme by targeting NF-κB and FGF2.
target gene	hsa-mir-17	Glioblastoma	19676043				D005909		HP:0100843	inhibite Bcl-2 and Mcl-1, induce apoptosis
target gene	hsa-mir-17	Glioblastoma	23391506				D005909		HP:0100843	Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2
target gene	hsa-mir-17	Glioblastoma	23792642				D005909		HP:0100843	microRNA-17 regulates the expression of ATG7 and modulates the autophagy process,improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.
target gene	hsa-mir-181a	Glioblastoma	20204284				D005909		HP:0100843	MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2.
target gene	hsa-mir-181a	Glioblastoma	28389242				D005909		HP:0100843	Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme.
target gene	hsa-mir-181b	Glioblastoma	28459461				D005909		HP:0100843	MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma.
target gene	hsa-mir-181b	Glioblastoma	28501897				D005909		HP:0100843	MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
target gene	hsa-mir-181d	Glioblastoma	22570426				D005909		HP:0100843	miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
target gene	hsa-mir-181d	Glioblastoma	28286260				D005909		HP:0100843	miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
target gene	hsa-mir-181d	Glioblastoma	28389653				D005909		HP:0100843	Identification of IGF-1-enhanced cytokine expressions targeted by miR-181d in glioblastomas via an integrative miRNA/mRNA regulatory network analysis.
target gene	hsa-mir-18a	Glioblastoma	19676043				D005909		HP:0100843	inhibite Bcl-2 and Mcl-1, induce apoptosis
target gene	hsa-mir-18a	Glioblastoma	23249750				D005909		HP:0100843	Targeting of TGFbeta signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma
target gene	hsa-mir-18a	Glioblastoma	24657544				D005909		HP:0100843	MiR-18a regulates the proliferation, migration and invasion of human glioblastoma cell by targeting neogenin.
target gene	hsa-mir-18a	Glioblastoma	28123848				D005909		HP:0100843	The malignancy of miR-18a in human glioblastoma via directly targeting CBX7.
target gene	hsa-mir-193b	Glioblastoma	26857280				D005909		HP:0100843	microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated
target gene	hsa-mir-195	Glioblastoma	22217655				D005909		HP:0100843	MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion.
target gene	hsa-mir-19a	Glioblastoma	19676043				D005909		HP:0100843	inhibite Bcl-2 and Mcl-1, induce apoptosis
target gene	hsa-mir-203	Glioblastoma	24270883				D005909		HP:0100843	the present study demonstrated the clinical significance of miR-203 in gliomas and suggested that miR-203 was able to inhibit the proliferation and invasion of glioma cells,partially at least via suppressing the protein expression of PLD2. Thus, miR-203 may be a novel candidate for the development of therapeutic strategies for gliomas.
target gene	hsa-mir-203	Glioblastoma	27820599				D005909		HP:0100843	Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression.
target gene	hsa-mir-203	Glioblastoma	28040710				D005909		HP:0100843	REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.
target gene	hsa-mir-205	Glioblastoma	22159356				D005909		HP:0100843	MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A.
target gene	hsa-mir-20a	Glioblastoma	25960225				D005909		HP:0100843	miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
target gene	hsa-mir-21	Glioblastoma	19013014				D005909		HP:0100843	miR-21: MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G
target gene	hsa-mir-21	Glioblastoma	21636706				D005909		HP:0100843	Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.
target gene	hsa-mir-21	Glioblastoma	22353043				D005909		HP:0100843	Ursolic Acid Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Cell Lines U251 by Suppressing TGF-beta1/miR-21 /PDCD4 Pathway.
target gene	hsa-mir-21	Glioblastoma	22709411				D005909		HP:0100843	MiR-21 Modulates hTERT Through a STAT3-Dependent Manner on Glioblastoma Cell Growth.
target gene	hsa-mir-21	Glioblastoma	23904372				D005909		HP:0100843	MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2.
target gene	hsa-mir-21	Glioblastoma	25394756				D005909		HP:0100843	FASLG was a specific and direct target gene of miR-21. The advanced effects of anti-miR-21 on GSCs apoptosis and proliferation were mediated by expression of silenced FASLG. In summary, aberrantly expressed miR-21 regulates GSCs apoptosis and proliferation partly through directly down-regulating FASLG protein expression in GSCs and this might offer a new potential therapeutic stratagem for glioblastoma.
target gene	hsa-mir-21	Glioblastoma	26142886				D005909		HP:0100843	Targeting strategies on miRNA-21 and PDCD4 for glioblastoma.
target gene	hsa-mir-21	Glioblastoma	26558781				D005909		HP:0100843	Further, analysis of the miR-21-Sox2 relationship in mouse neural stem cells and in the mouse brain at different developmental stages indicates that miR-21 and Sox2 are predominantly expressed in mutually exclusive patterns, suggesting a role in normal neural development.
target gene	hsa-mir-21	Glioblastoma	19559015				D005909		HP:0100843	MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.
target gene	hsa-mir-21	Glioblastoma	25059666				D005909		HP:0100843	MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3).
target gene	hsa-mir-21	Glioblastoma	24012640				D005909		HP:0100843	Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas.
target gene	hsa-mir-21	Glioblastoma	28410224				D005909		HP:0100843	Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal.
target gene	hsa-mir-21	Glioblastoma	29228449				D005909		HP:0100843	miR-21 enhances the resistance of human glioma cells to BCNU by decreasing the expression of Spry2 protein
target gene	hsa-mir-210	Glioblastoma	29226333				D005909		HP:0100843	p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment
target gene	hsa-mir-212	Glioblastoma	25720694				D005909		HP:0100843	MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3.
target gene	hsa-mir-218	Glioblastoma	26012781				D005909		HP:0100843	MiR-218 Inhibited Growth and Metabolism of Human Glioblastoma Cells by Directly Targeting E2F2.
target gene	hsa-mir-218	Glioblastoma	25042866				D005909		HP:0100843	The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness.
target gene	hsa-mir-218-1	Glioblastoma	22766851				D005909		HP:0100843	MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1.
target gene	hsa-mir-218-2	Glioblastoma	22766851				D005909		HP:0100843	MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1.
target gene	hsa-mir-219	Glioblastoma	26081620				D005909		HP:0100843	MicroRNA-219-5p exerts tumor suppressor function by targeting ROBO1 in glioblastoma.
target gene	hsa-mir-221	Glioblastoma	21743492				D005909		HP:0100843	miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu.
target gene	hsa-mir-221	Glioblastoma	22294051				D005909		HP:0100843	miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells.
target gene	hsa-mir-221	Glioblastoma	24780067				D005909		HP:0100843	MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma.
target gene	hsa-mir-221	Glioblastoma	19953484				D005909		HP:0100843	Up-regulation of p27(kip1) by miR-221/222 antisense oligonucleotides enhances the radiosensitivity of U251 glioblastoma]
target gene	hsa-mir-221	Glioblastoma	20813046				D005909		HP:0100843	To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma intervention.
target gene	hsa-mir-221	Glioblastoma	21109963				D005909		HP:0100843	These results were confirmed by the protein expression of p27kip1, the validated target of miR-221/222, the effect on cell cycle arrest in G1 phase, and the impact on cell apoptosis.
target gene	hsa-mir-222	Glioblastoma	21743492				D005909		HP:0100843	miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu.
target gene	hsa-mir-222	Glioblastoma	19953484				D005909		HP:0100843	Up-regulation of p27(kip1) by miR-221/222 antisense oligonucleotides enhances the radiosensitivity of U251 glioblastoma]
target gene	hsa-mir-222	Glioblastoma	20813046				D005909		HP:0100843	To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma intervention.
target gene	hsa-mir-222	Glioblastoma	21109963				D005909		HP:0100843	These results were confirmed by the protein expression of p27kip1, the validated target of miR-221/222, the effect on cell cycle arrest in G1 phase, and the impact on cell apoptosis.
target gene	hsa-mir-223	Glioblastoma	23970099				D005909		HP:0100843	microRNA-223 promotes the growth and invasion of glioblastoma cells by targeting tumor suppressor PAX6.
target gene	hsa-mir-23b	Glioblastoma	22745829				D005909		HP:0100843	miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2.
target gene	hsa-mir-24	Glioblastoma	28352781				D005909		HP:0100843	SOX7 inhibits tumor progression of glioblastoma and is regulated by miRNA-24.
target gene	hsa-mir-25	Glioblastoma	22431589				D005909		HP:0100843	In this study, two miRNAs, miR-25 and -32, are identified as p53-repressed miRNAs by p53-dependent negative regulation of their transcriptional regulators, E2F1 and MYC. However, miR-25 and -32 result in p53 accumulation by directly targeting Mdm2 and TSC1, which are negative regulators of p53.
target gene	hsa-mir-25	Glioblastoma	26209061				D005909		HP:0100843	miR-25 promotes glioblastoma cell proliferation and invasion by directly targeting NEFL.
target gene	hsa-mir-297	Glioblastoma	24158111				D005909		HP:0100843	This work shows miR-297 as a novel and physiologic regulator of cancer cell survival, largely through targeting of DGK-α, and also indicates that hypoxia ameliorates miR-297 toxicity to cancer cells.
target gene	hsa-mir-29b	Glioblastoma	26155940				D005909		HP:0100843	miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2.
target gene	hsa-mir-29b-1	Glioblastoma	26180082				D005909		HP:0100843	Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating  c-Myc and inhibiting miR-29b-1 and miR-129-3p.
target gene	hsa-mir-29b-2	Glioblastoma	26240386				D005909		HP:0100843	our findings reveal a novel function of YB-1 in regulating non-coding RNA expression, which has important implications in tumorigenesis.
target gene	hsa-mir-302a	Glioblastoma	21720384				D005909		HP:0100843	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
target gene	hsa-mir-302b	Glioblastoma	21720384				D005909		HP:0100843	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
target gene	hsa-mir-302c	Glioblastoma	21720384				D005909		HP:0100843	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
target gene	hsa-mir-302d	Glioblastoma	21720384				D005909		HP:0100843	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
target gene	hsa-mir-302d	Glioblastoma	28497156				D005909		HP:0100843	Tumor suppressors microRNA-302d and microRNA-16 inhibit human glioblastoma multiforme by targeting NF-κB and FGF2.
target gene	hsa-mir-30b	Glioblastoma	26857280				D005909		HP:0100843	miRNAs (miR-133b, miR-30b-3p, miR-145-5p,  and miR-146a-5p) targeting EGFR
target gene	hsa-mir-31	Glioblastoma	25903473				D005909		HP:0100843	miR-31 and miR-148a regulate glioma growth by maintaining tumor stem cells and their niche, and providing the tumor a way to activate angiogenesis even in a normoxic  environment.This is the first study that demonstrates intratumoral uptake and growth-inhibiting effects of uncomplexed antagomirs in orthotopic glioma.
target gene	hsa-mir-32	Glioblastoma	22431589				D005909		HP:0100843	In this study, two miRNAs, miR-25 and -32, are identified as p53-repressed miRNAs by p53-dependent negative regulation of their transcriptional regulators, E2F1 and MYC. However, miR-25 and -32 result in p53 accumulation by directly targeting Mdm2 and TSC1, which are negative regulators of p53.
target gene	hsa-mir-330	Glioblastoma	24736727				D005909		HP:0100843	MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways.
target gene	hsa-mir-331	Glioblastoma	24142150				D005909		HP:0100843	miR-331-3p regulates expression of neuropilin-2 in glioblastoma.
target gene	hsa-mir-34a	Glioblastoma	21743299				D005909		HP:0100843	MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme.
target gene	hsa-mir-34a	Glioblastoma	22580610				D005909		HP:0100843	miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
target gene	hsa-mir-34a	Glioblastoma	22750848				D005909		HP:0100843	microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-beta Signaling in Glioblastoma.
target gene	hsa-mir-34a	Glioblastoma	19773441				D005909		HP:0100843	MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
target gene	hsa-mir-367	Glioblastoma	21720384				D005909		HP:0100843	The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.
target gene	hsa-mir-429	Glioblastoma	28749077				D005909		HP:0100843	MiR-429 suppresses glioblastoma multiforme by targeting SOX2.
target gene	hsa-mir-431	Glioblastoma	24584142				D005909		HP:0100843	Downregulation of microRNA-431 by human interferon-β inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
target gene	hsa-mir-503	Glioblastoma	24378652				D005909		HP:0100843	MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R.
target gene	hsa-mir-506	Glioblastoma	26857280				D005909		HP:0100843	microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated
target gene	hsa-mir-518b	Glioblastoma	26857280				D005909		HP:0100843	microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated
target gene	hsa-mir-520f	Glioblastoma	26857280				D005909		HP:0100843	microRNAs (miRNAs) (miR-193b-3p, miR-518b, miR-520f-3p, and miR-506-5p) targeting PDGFRB were downregulated
target gene	hsa-mir-522	Glioblastoma	25776496				D005909		HP:0100843	MiR-522 contributes to cell proliferation of human glioblastoma cells by suppressing PHLPP1 expression.
target gene	hsa-mir-590	Glioblastoma	26556542				D005909		HP:0100843	miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2.
target gene	hsa-mir-663	Glioblastoma	26717894				D005909		HP:0100843	MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-β1.
target gene	hsa-mir-7-1	Glioblastoma	22040413				D005909		HP:0100843	MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression.
target gene	hsa-mir-7-2	Glioblastoma	22040413				D005909		HP:0100843	MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression.
target gene	hsa-mir-7-3	Glioblastoma	22040413				D005909		HP:0100843	MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression.
target gene	hsa-mir-873	Glioblastoma	25670861				D005909		HP:0100843	MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1.
target gene	hsa-mir-9	Glioblastoma	24436148				D005909		HP:0100843	Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.
target gene	hsa-mir-9-1	Glioblastoma	21385897				D005909		HP:0100843	miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3.
target gene	hsa-mir-9-1	Glioblastoma	21531766				D005909		HP:0100843	ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2.
target gene	hsa-mir-9-1	Glioblastoma	21857646				D005909		HP:0100843	CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells.
target gene	hsa-mir-9-2	Glioblastoma	21385897				D005909		HP:0100843	miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3.
target gene	hsa-mir-9-2	Glioblastoma	21531766				D005909		HP:0100843	ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2.
target gene	hsa-mir-9-2	Glioblastoma	21857646				D005909		HP:0100843	CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells.
target gene	hsa-mir-92a-1	Glioblastoma	22895567				D005909		HP:0100843	miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11.
target gene	hsa-mir-92a-2	Glioblastoma	22895567				D005909		HP:0100843	miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11.
target gene	hsa-mir-92b	Glioblastoma	23892108				D005909		HP:0100843	The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas.
target gene	hsa-mir-93	Glioblastoma	20956944				D005909		HP:0100843	MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8.
target gene	hsa-mir-9-3	Glioblastoma	21385897				D005909		HP:0100843	miR-9 suppresses mesenchymal differentiation in glioblastoma by downregulating expression of JAK kinases and inhibiting activation of STAT3.
target gene	hsa-mir-9-3	Glioblastoma	21531766				D005909		HP:0100843	ID4 Imparts Chemoresistance and Cancer Stemness to Glioma Cells by Derepressing miR-9*-Mediated Suppression of SOX2.
target gene	hsa-mir-9-3	Glioblastoma	21857646				D005909		HP:0100843	CAMTA1 is a novel tumour suppressor regulated by miR-9/9(*) in glioblastoma stem cells.
target gene	hsa-mir-218	Glioblastoma Mesenchymal Subtype	24368849	disease of cellular proliferation	DOID:0050805					miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.
target gene	hsa-let-7	Glioma	26028311	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MDM4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells.
target gene	hsa-mir-101	Glioma	23788032	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma.
target gene	hsa-mir-105	Glioma	27736002	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-105 targets SOX9 and inhibits human glioma cell progression.
target gene	hsa-mir-105	Glioma	28618952	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-105 inhibits human glioma cell malignancy by directly targeting SUZ12.
target gene	hsa-mir-106a	Glioma	24124917	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM.
target gene	hsa-mir-106a	Glioma	24704830	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2.
target gene	hsa-mir-106b	Glioma	23377830	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-106b facilitates glioma cell growth by promoting cell cycle progression through the negative regulation of RBL2
target gene	hsa-mir-106b	Glioma	24166509	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes.
target gene	hsa-mir-107	Glioma	23299462	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression
target gene	hsa-mir-107	Glioma	26084601	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Upregulation of miR-107 Inhibits Glioma Angiogenesis and VEGF Expression.
target gene	hsa-mir-10a	Glioma	25683004	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8.
target gene	hsa-mir-1202	Glioma	28443461	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-1202 functions as a tumor suppressor in glioma cells by targeting Rab1A.
target gene	hsa-mir-1224	Glioma	25648114	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-1224-5p acts as a tumor suppressor by targeting CREB1 in malignant gliomas.
target gene	hsa-mir-124	Glioma	23792158	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Circadian gene Clock contributes to cell proliferation and migration of glioma and is directly regulated by tumor-suppressive miR-124.
target gene	hsa-mir-124	Glioma	28791348	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-124 inhibits the proliferation of C6 glioma cells by targeting Smad4.
target gene	hsa-mir-124	Glioma	25348135	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-124 could simultaneously regulate up-regulated (ELAVL1 and EZH2) and down-regulated (BACE1) DEGs.
target gene	hsa-mir-124	Glioma	28272711	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Down-regulation of miR-124 target protein SCP-1 inhibits neuroglioma cell migration.
target gene	hsa-mir-124	Glioma	28393219	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Inhibition of the Hedgehog signaling pathway suppresses cell proliferation by regulating the Gli2/miR-124/AURKA axis in human glioma cells.
target gene	hsa-mir-124-1	Glioma	23761023	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-124 radiosensitizes human glioma cells by targeting CDK4.
target gene	hsa-mir-124-2	Glioma	23761023	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-124 radiosensitizes human glioma cells by targeting CDK4.
target gene	hsa-mir-125b	Glioma	24046143	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	We conclude that miR-125b regulates glioma growth partly through Connexin43 protein.
target gene	hsa-mir-128	Glioma	18810376	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a.
target gene	hsa-mir-128	Glioma	23835497	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-128 promotes cell-cell adhesion in U87 glioma cells via regulation of EphB2.
target gene	hsa-mir-128	Glioma	25781272	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Proteomic screening and identification of microRNA-128 targets in glioma cells.
target gene	hsa-mir-128-1	Glioma	22442669	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-128 expression levels were decreased in glioma. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1.
target gene	hsa-mir-128-1	Glioma	23733246	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells.
target gene	hsa-mir-128-2	Glioma	22442669	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-128 expression levels were decreased in glioma. MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1.
target gene	hsa-mir-128-2	Glioma	23733246	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells.
target gene	hsa-mir-130b	Glioma	26653558	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In conclusion, miR-130b is an independent prognostic biomarker for indicating survival of glioma patients and promotes glioma cell migration and invasion by targeting PPARγ.
target gene	hsa-mir-133b	Glioma	25355491	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel.
target gene	hsa-mir-136	Glioma	25139024	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells.
target gene	hsa-mir-139	Glioma	23551751	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-139 Inhibits Mcl-1 Expression and Potentiates TMZ-Induced Apoptosis in Glioma
target gene	hsa-mir-141	Glioma	27608897	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration.
target gene	hsa-mir-141	Glioma	28595907	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma.
target gene	hsa-mir-143	Glioma	23250070	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Rapamycin inhibits human glioma cell proliferation through down-regulating mammalian target of rapamycin pathway and up-regulating microRNA-143
target gene	hsa-mir-143	Glioma	24980823	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
target gene	hsa-mir-145	Glioma	23076445	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells
target gene	hsa-mir-145	Glioma	23390502	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-145 Is Downregulated in Glial Tumors and Regulates Glioma Cell Migration by Targeting Connective Tissue Growth Factor
target gene	hsa-mir-145	Glioma	24777293	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2.
target gene	hsa-mir-146b	Glioma	19265686	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs.
target gene	hsa-mir-146b	Glioma	23796692	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-146b-5p inhibits glioma migration and invasion by targeting MMP16.
target gene	hsa-mir-149	Glioma	23298478	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling
target gene	hsa-mir-152	Glioma	23142217	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3
target gene	hsa-mir-153	Glioma	26124081	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-153/Nrf-2/GPx1 pathway regulates radiosensitivity and stemness of glioma stem cells via reactive oxygen species.
target gene	hsa-mir-155	Glioma	23970205	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma.
target gene	hsa-mir-155	Glioma	24376632	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-155 promotes glioma cell proliferation via the regulation of MXI1.
target gene	hsa-mir-155	Glioma	25535908	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Knockdown of miR-155 enhanced the anticancer effect of TMZ on glioma by targeting the MAPK13 and MAPK14-mediated oxidative stress and apoptosis, but did not affect the secretion of MMP2 and MMP9.
target gene	hsa-mir-15b	Glioma	19135980	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells.
target gene	hsa-mir-15b	Glioma	23142217	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3
target gene	hsa-mir-15b	Glioma	25901555	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Mangiferin regulates proliferation and apoptosis in glioma cells by induction of microRNA-15b and inhibition of MMP-9 expression.
target gene	hsa-mir-15b	Glioma	29323737	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-15b/HOTAIR/p53 form a regulatory loop that affects the growth of glioma cells
target gene	hsa-mir-16	Glioma	27748823	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-16 inhibits the proliferation, migration and invasion of glioma cells by targeting Sal-like protein 4.
target gene	hsa-mir-16-1	Glioma	23175429	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Zyxin may be one of putative target genes of miR-16-1
target gene	hsa-mir-16-2	Glioma	23175429	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Zyxin may be one of putative target genes of miR-16-1
target gene	hsa-mir-17	Glioma	28081732	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Inhibition of Beclin-1-Mediated Autophagy by MicroRNA-17-5p Enhanced the Radiosensitivity of Glioma Cells.
target gene	hsa-mir-181b	Glioma	27938503	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-181b Inhibits Cellular Proliferation and Invasion of Glioma Cells via Targeting Sal-Like Protein 4.
target gene	hsa-mir-181b-1	Glioma	23431408	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas
target gene	hsa-mir-181b-2	Glioma	23431408	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas
target gene	hsa-mir-181d	Glioma	22207524	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2.
target gene	hsa-mir-182	Glioma	24404152	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Disturbing miR-182 and -381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4.
target gene	hsa-mir-182	Glioma	27246830	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-182-5p negatively regulated PCDH8 expression by directly  targeting its 3'-untranslated region.
target gene	hsa-mir-19	Glioma	29340016	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-19 regulates the proliferation and invasion of glioma by RUNX3 via β-catenin/Tcf-4 signaling
target gene	hsa-mir-193b	Glioma	24496888	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Thus, our study indicates that miR-193b promotes cell proliferation by targeting Smad3 in human glioma, which may serve as a potentially useful target for development of miRNA-based therapies in the future.
target gene	hsa-mir-194	Glioma	28098896	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-194 represses glioma cell epithelial‑to‑mesenchymal transition by targeting Bmi1.
target gene	hsa-mir-195	Glioma	23383003	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-195 Inhibits the Proliferation of Human Glioma Cells by Directly Targeting Cyclin D1 and Cyclin E1
target gene	hsa-mir-199a	Glioma	25854175	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway.
target gene	hsa-mir-200	Glioma	28362995	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells.
target gene	hsa-mir-200a	Glioma	24162743	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-200a impairs glioma cell growth, migration, and invasion by targeting SIM2-s.
target gene	hsa-mir-200b	Glioma	23543137	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-200b targets CREB1 and suppresses cell growth in human malignant glioma
target gene	hsa-mir-200b	Glioma	24477653	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-200b as a prognostic factor targets multiple members of RAB family in glioma.
target gene	hsa-mir-200b	Glioma	25877314	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-200b may suppress cell invasion by targeting PROM1 in glioma.
target gene	hsa-mir-200b	Glioma	26648487	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2.
target gene	hsa-mir-200b	Glioma	27545608	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-200b-3p suppresses epithelial-mesenchymal transition and inhibits tumor growth of glioma through down-regulation of ERK5.
target gene	hsa-mir-200b	Glioma	28362995	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells.
target gene	hsa-mir-200c	Glioma	27608897	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration.
target gene	hsa-mir-203	Glioma	26678661	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These data demonstrate that miR-203 potentially controls DNA damage repair via the PI3K/AKT and JAK/STAT3 pathways and may collectively contribute to the modulation of radiation sensitivity in MG cells by inhibiting DNA damage repair, prosurvival signaling, and epithelium-mesenchyme transition. Taken together, these findings demonstrate that miR-203 could be a target for overcoming the radiation resistance of GBM.
target gene	hsa-mir-204	Glioma	25055875	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-204, a direct negative regulator of ezrin gene expression, inhibits glioma cell migration and invasion.
target gene	hsa-mir-20a	Glioma	24704830	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2.
target gene	hsa-mir-21	Glioma	18591254	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators.
target gene	hsa-mir-21	Glioma	21278789	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas.
target gene	hsa-mir-21	Glioma	22630347	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-21 expression is regulated by ж┿catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK.
target gene	hsa-mir-21	Glioma	24161395	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Sirt2 suppresses glioma cell growth through targeting NF-κB-miR-21 axis.
target gene	hsa-mir-21	Glioma	26701969	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These findings suggest that miR-21 is linked to glioma angiogenesis,that miR-21 is unlikely to regulate PTEN, and that miR-21-positive tumor cells do not possess stem cell characteristics.
target gene	hsa-mir-21	Glioma	29228450	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression
target gene	hsa-mir-21	Glioma	29316313	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway
target gene	hsa-mir-214	Glioma	23187003	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	microRNA-214-mediated UBC9 expression in glioma
target gene	hsa-mir-214	Glioma	26722446	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In summary, our data indicate that miR-214 may function as tumor suppressor in glioma by targeting PCBP2.
target gene	hsa-mir-215	Glioma	18810376	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a.
target gene	hsa-mir-215	Glioma	26766590	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.
target gene	hsa-mir-215	Glioma	27837373	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in high-grade glioma.
target gene	hsa-mir-218	Glioma	23950210	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1.
target gene	hsa-mir-218-1	Glioma	23243056	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kB activity
target gene	hsa-mir-218-2	Glioma	23243056	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kB activity
target gene	hsa-mir-221	Glioma	19424584	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo.
target gene	hsa-mir-221	Glioma	22075712	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
target gene	hsa-mir-221	Glioma	24147153	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
target gene	hsa-mir-221	Glioma	24595467	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221.
target gene	hsa-mir-221	Glioma	25731730	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2.
target gene	hsa-mir-222	Glioma	19424584	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo.
target gene	hsa-mir-222	Glioma	22075712	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
target gene	hsa-mir-222	Glioma	24147153	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
target gene	hsa-mir-222	Glioma	25731730	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2.
target gene	hsa-mir-223	Glioma	23946414	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS.
target gene	hsa-mir-23a	Glioma	23865473	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Anti-miRNA-23a oligonucleotide suppresses glioma cells growth by targeting apoptotic protease activating factor-1.
target gene	hsa-mir-23a	Glioma	24305689	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Targeting microRNA-23a to inhibit glioma cell invasion via HOXD10.
target gene	hsa-mir-23b	Glioma	24002170	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	TFAM is directly regulated by miR-23b in glioma.
target gene	hsa-mir-24-1	Glioma	23142218	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling
target gene	hsa-mir-24-1	Glioma	23254855	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1
target gene	hsa-mir-24-2	Glioma	23142218	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling
target gene	hsa-mir-24-2	Glioma	23254855	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1
target gene	hsa-mir-25	Glioma	25960208	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-25 promotes glioma cell proliferation by targeting CDKN1C.
target gene	hsa-mir-26a	Glioma	23870455	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These results reveal that miR-26a regulates PHB and promotes glioma progression both in vitro and in vivo and that miR-26a and its target PHB are associated with glioma development, which can be helpful in developing microRNA-based treatment for glioma in the future.
target gene	hsa-mir-26b	Glioma	21264258	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	This study demonstrated that miR-26b may act as a tumor suppressor in glioma and it directly regulates EphA2 expression. EphA2 is a direct target of miR-26b, and the down-regulation of EphA2 mediated by miR-26b is dependent on the binding of miR-26b to a
target gene	hsa-mir-27a	Glioma	22614734	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Lentiviral expression of anti-microRNAs targeting miR-27a inhibits proliferation and invasiveness of U87 glioma cells.
target gene	hsa-mir-27a	Glioma	23254855	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1
target gene	hsa-mir-27a	Glioma	26164457	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-27a regulates Wnt/beta-catenin signaling through targeting SFRP1 in glioma.
target gene	hsa-mir-27a	Glioma	25777779	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Emerging role of microRNA-27a in human malignant glioma cell survival via targeting of prohibitin.
target gene	hsa-mir-29a	Glioma	24595468	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Heat shock protein 47 regulated by miR-29a to enhance glioma tumor growth and invasion.
target gene	hsa-mir-29a	Glioma	27543358	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a.
target gene	hsa-mir-30	Glioma	25840690	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway.
target gene	hsa-mir-302a	Glioma	28000880	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-302a targets GAB2 to suppress cell proliferation, migration and invasion of glioma.
target gene	hsa-mir-302b	Glioma	28323865	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The microRNA-302b-inhibited insulin-like growth factor-binding protein 2 signaling pathway induces glioma cell apoptosis by targeting nuclear factor IA.
target gene	hsa-mir-302c	Glioma	26176806	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-302c-3p suppresses invasion and proliferation of glioma cells via down-regulating metadherin (MTDH) expression.
target gene	hsa-mir-30a	Glioma	23348703	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	PRDM1 is directly targeted by miR-30a-5p and modulates the Wnt/beta-catenin pathway in a Dkk1-dependent manner during glioma growth
target gene	hsa-mir-30a	Glioma	23383034	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-30a-5p Antisense Oligonucleotide Suppresses Glioma Cell Growth by Targeting SEPT7
target gene	hsa-mir-30e	Glioma	25691332	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Ionizing radiation-inducible miR-30e promotes glioma cell invasion through EGFR stabilization by directly targeting CBL-B.
target gene	hsa-mir-31	Glioma	22089331	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Human miR-31 targets radixin and inhibits migration and invasion of glioma cells.
target gene	hsa-mir-31	Glioma	26801671	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	the suppressive effect of miR-31 on glioma cell migration and invasion is p21-dependent
target gene	hsa-mir-320	Glioma	25901521	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1.
target gene	hsa-mir-320	Glioma	28934982	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-320 inhibits the growth of glioma cells through downregulating PBX3.
target gene	hsa-mir-320a	Glioma	25117070	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R.
target gene	hsa-mir-320a	Glioma	28160566	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients.
target gene	hsa-mir-324	Glioma	24706306	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The miR-324-5p can inhibit proliferation of the glioma cells via the targeted regulation of the glioma-associated oncogene 1.
target gene	hsa-mir-326	Glioma	20667897	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells
target gene	hsa-mir-326	Glioma	23869222	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1).
target gene	hsa-mir-329	Glioma	23866847	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-329 may inhibit cell proliferation in human glioma cells through regulating E2F1-mediated suppression of Akt pathway.
target gene	hsa-mir-335	Glioma	24737483	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells.
target gene	hsa-mir-34a	Glioma	22479456	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes Tumorigenesis.
target gene	hsa-mir-34a	Glioma	22684560	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-34a inhibits human brain glioma cell growth by down-regulation of Notch1.
target gene	hsa-mir-34a	Glioma	24393844	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-34a serves as a tumor suppressor in human glioma mainly by decreasing NOX2 expression.
target gene	hsa-mir-34a	Glioma	20470934	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our results demonstrate that miR-34a acts as a tumor suppressor in p53-mutant glioma cells U251, partially through regulating SIRT1.
target gene	hsa-mir-34a	Glioma	28859546	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-34a induces transdifferentiation of glioma stem cells into vascular endothelial cells by targeting Notch pathway.
target gene	hsa-mir-361	Glioma	28184914	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-361-5p inhibits epithelial-to-mesenchymal transition of glioma cells through targeting Twist1.
target gene	hsa-mir-365	Glioma	28260020	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3.
target gene	hsa-mir-372	Glioma	25160587	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-372 regulates glioma cell proliferation and invasion by directly targeting PHLPP2.
target gene	hsa-mir-381	Glioma	24404152	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Disturbing miR-182 and -381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4.
target gene	hsa-mir-383	Glioma	23564324	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor
target gene	hsa-mir-383	Glioma	25450356	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-383 plays the role of tumor suppressor by targeting CCND1 in glioma cells, and may be useful for developing a new therapeutic strategy for gliomas.
target gene	hsa-mir-383	Glioma	25936342	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells.
target gene	hsa-mir-410	Glioma	22750473	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-410 regulates MET to influence the proliferation and invasion of glioma.
target gene	hsa-mir-422a	Glioma	28277190	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-422a Inhibits Glioma Proliferation and Invasion by Targeting IGF1 and IGF1R.
target gene	hsa-mir-449a	Glioma	26502848	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The expression of microRNA-449a is low in patients with glioma,which may inhibit the proliferation of glioma and promote its cell apoptosis via affecting the expression of PKCα.
target gene	hsa-mir-451a	Glioma	22179124	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma.
target gene	hsa-mir-483	Glioma	22465663	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1.
target gene	hsa-mir-491	Glioma	27905892	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-491 regulates glioma cells proliferation by targeting TRIM28 in vitro.
target gene	hsa-mir-494	Glioma	24316134	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Ionizing radiation-inducible miR-494 promotes glioma cell invasion through EGFR stabilization by targeting p190B rhoGAP.
target gene	hsa-mir-495	Glioma	25759932	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-495 mediates metabolic shift in glioma cells via targeting Glut1.
target gene	hsa-mir-504	Glioma	26854715	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A tumor-suppressive microRNA, miR-504, inhibits cell proliferation and promotes apoptosis by targeting FOXP1 in human glioma.
target gene	hsa-mir-520c	Glioma	28184932	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-520c inhibits glioma cell migration and invasion by the suppression of transforming growth factor-β receptor type 2.
target gene	hsa-mir-524	Glioma	28778566	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas.
target gene	hsa-mir-542	Glioma	22871495	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The Putative Tumor Suppressor miR-524-5p Directly Targets Jagged-1 and Hes-1 in Glioma.
target gene	hsa-mir-584	Glioma	25674221	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-584 functions as a tumor suppressor and targets PTTG1IP in glioma.
target gene	hsa-mir-592	Glioma	28718372	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-592 functions as a tumor suppressor in glioma by targeting IGFBP2.
target gene	hsa-mir-622	Glioma	25258251	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells.
target gene	hsa-mir-656	Glioma	24480809	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
target gene	hsa-mir-661	Glioma	26585488	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These results indicate that miR-661 can inhibit glioma cell proliferation,migration and invasion by targeting hTERT.
target gene	hsa-mir-873	Glioma	28583401	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-873 suppresses H9C2 cardiomyocyte proliferation by targeting GLI1.
target gene	hsa-mir-9	Glioma	28430789	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-9-3p augments apoptosis induced by H2O2 through down regulation of Herpud1 in glioma.
target gene	hsa-mir-92a	Glioma	27801803	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-92a-3p Exerts Various Effects in Glioma and Glioma Stem-Like Cells Specifically Targeting CDH1/β-Catenin and Notch-1/Akt Signaling Pathways.
target gene	hsa-mir-92b	Glioma	23416699	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase
target gene	hsa-mir-92b	Glioma	24325785	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The present data indicates that miR-92b directly regulate cell proliferation and apoptosis by targeting DKK3 and act as prognostic factors for glioma patients.
target gene	hsa-mir-93	Glioma	26449498	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In conclusion, our results suggest an increasing role of miR-93 in regulating the level of expression of several genes involved in the angiogenesis of gliomas.
target gene	hsa-mir-93	Glioma	25277195	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	LNA inhibitor-mediated miRNA silencing up-regulated cell surface NKG2DL expression, which translated into increased susceptibility to NK cell-mediated lysis.
target gene	hsa-mir-95	Glioma	26165303	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of miR-95-3p inhibits proliferation, and invasion promoting apoptosis of glioma cells by targeting CELF2.
target gene	hsa-mir-96	Glioma	24931370	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-96/HBP1/Wnt/β-catenin regulatory circuitry promotes glioma growth.
target gene	hsa-mir-148a	Glomerulonephritis	28637300	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	The type of diet intake also influenced cytokine production, fecal microbiota (increased Lachnospiraceae in mice fed on 2018), altered microRNAs (miRNAs; higher levels of lupus-associated miR-148a and miR-183 in mice fed on 7013 and/or 2018) and altered DNA methylation.
target gene	hsa-mir-183	Glomerulonephritis	28637300	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	The type of diet intake also influenced cytokine production, fecal microbiota (increased Lachnospiraceae in mice fed on 2018), altered microRNAs (miRNAs; higher levels of lupus-associated miR-148a and miR-183 in mice fed on 7013 and/or 2018) and altered DNA methylation.
target gene	hsa-mir-140	Gout	27906093	musculoskeletal system disease	DOID:13189	M10	D006073		HP:0001997	microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5.
target gene	hsa-mir-21	Granular Corneal Dystrophy	26915797	nervous system disease	DOID:12318	H18.53	D003317	121900	HP:0007802	TGF-β regulates TGFBIp expression in corneal fibroblasts via miR-21, miR-181a,and Smad signaling.
target gene	hsa-mir-320a	Granulosa Cell Tumor	24828505	disease of cellular proliferation	DOID:2999		D006106			Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins.
target gene	hsa-mir-383	Granulosa Cell Tumor	24828505	disease of cellular proliferation	DOID:2999		D006106			Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins.
target gene	hsa-mir-146a	Graves Disease	28278511	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	Mechanism of MicroRNA-146a/Notch2 Signaling Regulating IL-6 in Graves Ophthalmopathy.
target gene	hsa-mir-183	Graves Disease	25871842	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD.
target gene	hsa-mir-197	Graves Disease	25871842	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD.
target gene	hsa-mir-22	Graves Disease	25871842	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD.
target gene	hsa-mir-346	Graves Disease	25666935	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	MiR-346 regulates CD4(+)CXCR5(+) T cells by targeting Bcl-6, a positive regulator of Tfh cells, and might play an important role in the pathogenesis of Graves' disease.
target gene	hsa-mir-660	Graves Disease	25871842	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	Our study highlights the possibility that miRNA-target gene network may be involved in the pathogenesis of GD and could provide new insights into understanding the pathophysiological mechanisms of GD.
target gene	hsa-mir-21	Hand, Foot And Mouth Disease	28506791	disease by infectious agent	DOID:10881	B08.4	D006232			Enterovirus 71-induced has-miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1.
target gene	hsa-let-7a	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-let-7b	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-let-7c	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-let-7d	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-let-7e	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-let-7f	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-let-7g	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-let-7i	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-mir-10b	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-mir-1-1	Head And Neck Neoplasms	21378409	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
target gene	hsa-mir-1-2	Head And Neck Neoplasms	21378409	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
target gene	hsa-mir-125b-1	Head And Neck Neoplasms	23416980	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway
target gene	hsa-mir-125b-2	Head And Neck Neoplasms	23416980	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway
target gene	hsa-mir-133a	Head And Neck Neoplasms	22378351	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	The genome-wide gene expression analysis and bioinformatics study showed that actin-related protein 2/3 complex subunit 5 (ARPC5) is a candidate target of miR-133a.
target gene	hsa-mir-133a-1	Head And Neck Neoplasms	22266319	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Tumor suppressive microRNA-133a regulates novel targets: Moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma.
target gene	hsa-mir-134	Head And Neck Neoplasms	23824713	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene.
target gene	hsa-mir-143	Head And Neck Neoplasms	22469988	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-143 regulates hexokinase 2 expression in cancer cells.
target gene	hsa-mir-145	Head And Neck Neoplasms	23548270	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR145 targets the SOX9/ADAM17 axis to inhibit tumor initiating cells and IL-6-mediated paracrine effects in head and neck cancer
target gene	hsa-mir-15a	Head And Neck Neoplasms	19117988	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-15a: feed-forward loop: PKCalpha down-regulates miR-15a, which directly inhibits protein synthesis of cyclin E
target gene	hsa-mir-196a	Head And Neck Neoplasms	25523631	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-196a as a potential important biomarker of prognosis and response of HNSCC to radiotherapy. Furthermore, our data suggest that miR-196a and/or its target gene ANXA1 could represent important therapeutic targets in HNSCC.
target gene	hsa-mir-200c	Head And Neck Neoplasms	21899661	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	The expression of ZEB1, a target mRNA for miR-200c, was up-regulated 3 and 6 hours after HGF stimulation.
target gene	hsa-mir-21	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-mir-211	Head And Neck Neoplasms	23726841	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-211 promotes the progression of head and neck carcinomas by targeting TGFbeta R2.
target gene	hsa-mir-27b	Head And Neck Neoplasms	21899661	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	The expression of ST14/matriptase an enzyme for extracellular matrix (ECM) degradation and HGF activation and a target mRNA for miR-27b, was drastically up-regulated in protein level after HGF stimulation.
target gene	hsa-mir-31	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-mir-363	Head And Neck Neoplasms	23246488	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin
target gene	hsa-mir-375	Head And Neck Neoplasms	22031094	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	MiR-375 expression was significantly reduced (p=0.01), and conversely, MTDH was significantly increased (p=0.0001) in NPC samples. Quantitative RT-PCR, western blots and luciferase assays corroborated MTDH as a target of miR-375. Re-expression of miR-375 and siRNA knock-down of MTDH both decreased cell viability and clonogenic survival, cell migration/invasion, as well as in vivo tumour formation. NPC patients whose tumours expressed high levels of MTDH experienced significantly lower survival, and in particular, higher distant relapse rates (5-year distant relapse rates: 26% vs. 5%; p=0.005).
target gene	hsa-mir-504	Head And Neck Neoplasms	23340306	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21, miR-31, miR-504 and miR-10b are important oncogenic miRNAs that are involved in HNSCC and target tumour suppressor genes. The tumour suppressor roles of the let-7 family, the miR-99 family, miR-107, miR-133a, miR-137, miR-138 and miR-375 with respect to their targeting of oncogenes are unequivocal and have been confirmed by many studies.
target gene	hsa-mir-27a	Heart Diseases [unspecific]	29694513			I51.9	D006333			miR-27a protects human mitral valve interstitial cell from TNF-α-induced inflammatory injury via up-regulation of NELL-1.
target gene	hsa-let-7a	Heart Failure	28060734			I50	D006331		HP:0001635	Let-7a regulates expression of β1-adrenoceptors and forms a negative feedback circuit with the β1-adrenoceptor signaling pathway in chronic ischemic heart failure.
target gene	hsa-mir-1	Heart Failure	22045061			I50	D006331		HP:0001635	MicroRNA-1 represses Cx43 expression in viral myocarditis.
target gene	hsa-mir-1	Heart Failure	23024758			I50	D006331		HP:0001635	Time-course analysis revealed that decreased expression of miR-1 and miR-133a commences at a pre-disease stage, and precedes upregulation of target genes causal of cardiac hypertrophy and extracellular matrix remodelling, suggesting a role for miR-1 and miR-133a in early disease development.
target gene	hsa-mir-1	Heart Failure	23141496			I50	D006331		HP:0001635	Biochemical assays and an inducible cardiac-specific transgenic mouse model overexpressing miR-1 were used to demonstrate that heart-type fatty acid-binding protein-3 (FABP3) is a target of miR-1. 
target gene	hsa-mir-1	Heart Failure	23436819			I50	D006331		HP:0001635	The decrease of miR-1 and increase of AnxA5 appear as important modulators of NCX1 expression and activity during heart failure.
target gene	hsa-mir-1	Heart Failure	27213338			I50	D006331		HP:0001635	miR-1 repressed the expression of gap junction protein 伪1 (GJA1) in VMC
target gene	hsa-mir-105	Heart Failure	27185878			I50	D006331		HP:0001635	miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes
target gene	hsa-mir-125b	Heart Failure	27592695			I50	D006331		HP:0001635	MiR-125b regulates SFRP5 expression to promote growth and activation of cardiac fibroblasts.
target gene	hsa-mir-133a	Heart Failure	23024758			I50	D006331		HP:0001635	Time-course analysis revealed that decreased expression of miR-1 and miR-133a commences at a pre-disease stage, and precedes upregulation of target genes causal of cardiac hypertrophy and extracellular matrix remodelling, suggesting a role for miR-1 and miR-133a in early disease development.
target gene	hsa-mir-133a	Heart Failure	26440278			I50	D006331		HP:0001635	miR-133a acts  as a repressor of SRF and CTGF expression
target gene	hsa-mir-155	Heart Failure	23956210			I50	D006331		HP:0001635	Our findings reveal that microRNA-155 expression in macrophages promotes cardiac inflammation, hypertrophy, and failure in response to pressure overload. These data support the causative significance of inflammatory signaling in hypertrophic heart disease and demonstrate the feasibility of therapeutic microRNA targeting of inflammation in heart failure.
target gene	hsa-mir-155	Heart Failure	27185878			I50	D006331		HP:0001635	miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes
target gene	hsa-mir-182	Heart Failure	27763637			I50	D006331		HP:0001635	miR-182 negatively regulated Nogo-C expression and was downregulated during MI
target gene	hsa-mir-18a	Heart Failure	21501375			I50	D006331		HP:0001635	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
target gene	hsa-mir-18b	Heart Failure	21501375			I50	D006331		HP:0001635	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
target gene	hsa-mir-195	Heart Failure	29330215			I50	D006331		HP:0001635	increased levels of miR-195 in failing myocardium regulate a novel pathway that involves direct SIRT3 suppression and enzymatic inhibition via increased acetylation of PDH and ATP synthase that are essential for cardiac energy metabolism
target gene	hsa-mir-199a	Heart Failure	24011070			I50	D006331		HP:0001635	our data suggest a mechanism whereby miR-199a∼214 actively represses cardiac PPARδ expression, facilitating a metabolic shift from predominant reliance on fatty acid utilization in the healthy myocardium toward increased reliance on glucose metabolism at the onset of heart failure.
target gene	hsa-mir-19a	Heart Failure	21501375			I50	D006331		HP:0001635	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
target gene	hsa-mir-19b	Heart Failure	27213338			I50	D006331		HP:0001635	a miR-19b inhibitor increased, while its mimics suppressed the expression of GJA1 in HL-1 cells.
target gene	hsa-mir-19b-1	Heart Failure	21501375			I50	D006331		HP:0001635	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
target gene	hsa-mir-19b-2	Heart Failure	21501375			I50	D006331		HP:0001635	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
target gene	hsa-mir-21	Heart Failure	19336275			I50	D006331		HP:0001635	miR-21: miR-21 can protect this by targeting PDCD4
target gene	hsa-mir-214	Heart Failure	26572862			I50	D006331		HP:0001635	These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure.
target gene	hsa-mir-214	Heart Failure	25656649			I50	D006331		HP:0001635	MicroRNA-214 Is Upregulated in Heart Failure Patients and Suppresses XBP1-Mediated Endothelial Cells Angiogenesis.
target gene	hsa-mir-22	Heart Failure	27997889			I50	D006331		HP:0001635	MiR-22 may Suppress Fibrogenesis by Targeting TGFβR I in Cardiac Fibroblasts.
target gene	hsa-mir-22	Heart Failure	28112401			I50	D006331		HP:0001635	MicroRNA-22 regulates inflammation and angiogenesis via targeting VE-cadherin.
target gene	hsa-mir-24	Heart Failure	22891046			I50	D006331		HP:0001635	MiR-24-mediated suppression of JP2 expression provides a novel molecular mechanism for E-C coupling regulation in heart cells and suggests a new target against heart failure.
target gene	hsa-mir-24	Heart Failure	29457789			I50	D006331		HP:0001635	miR-24 potently suppresses SCN5A expression and that rs1805126 modulates this regulation
target gene	hsa-mir-26a	Heart Failure	22664106			I50	D006331		HP:0001635	Up-regulation of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes by repressing GSK-3β protein expression.
target gene	hsa-mir-26a	Heart Failure	25608527			I50	D006331		HP:0001635	MicroRNA-26a, which targets KCNJ2, was downregulated in CHF fibroblasts.
target gene	hsa-mir-30	Heart Failure	26572862			I50	D006331		HP:0001635	These results provide the first clear link between miRNAs and direct regulation of XBP1 in heart failure and reveal that miR-214 and miR-30* synergistically regulates cardiac VEGF expression and angiogenesis by targeting XBP1 in the progression from adaptive hypertrophy to heart failure.
target gene	hsa-mir-30c	Heart Failure	27633839			I50	D006331		HP:0001635	MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy.
target gene	hsa-mir-30e	Heart Failure	27633839			I50	D006331		HP:0001635	MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy.
target gene	hsa-mir-325	Heart Failure	24531537			I50	D006331		HP:0001635	Our present study reveals a novel autophagic regulating model that is composed of E2F1,miR-325 and ARC. Modulation of their levels may provide a new approach for tackling cardiac failure.
target gene	hsa-mir-340	Heart Failure	26084457			I50	D006331		HP:0001635	microRNA-340-5p Functions Downstream of Cardiotrophin-1 to Regulate Cardiac Eccentric Hypertrophy and Heart Failure via Target Gene Dystrophin.
target gene	hsa-mir-365	Heart Failure	28130111			I50	D006331		HP:0001635	MicroRNA-365 accelerates cardiac hypertrophy by inhibiting autophagy via the modulation of Skp2 expression.
target gene	hsa-mir-425	Heart Failure	23867623			I50	D006331		HP:0001635	Atrial natriuretic peptide is negatively regulated by microRNA-425.
target gene	hsa-mir-425	Heart Failure	27185878			I50	D006331		HP:0001635	microRNA 425 (miR-425) was found to regulate ANP production
target gene	hsa-mir-497	Heart Failure	27992564			I50	D006331		HP:0001635	MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4.
target gene	hsa-mir-539	Heart Failure	25183011			I50	D006331		HP:0001635	MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression.
target gene	hsa-mir-17	Hemangiosarcoma	22383169			D48.1	D006394			The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
target gene	hsa-mir-18a	Hemangiosarcoma	22383169			D48.1	D006394			The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
target gene	hsa-mir-19a	Hemangiosarcoma	22383169			D48.1	D006394			The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
target gene	hsa-mir-19b-1	Hemangiosarcoma	22383169			D48.1	D006394			The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
target gene	hsa-mir-20a	Hemangiosarcoma	22383169			D48.1	D006394			The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
target gene	hsa-mir-92a-1	Hemangiosarcoma	22383169			D48.1	D006394			The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.
target gene	hsa-mir-1226	Hematologic Neoplasms	20514397	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	These findings indicate that expression of the MUC1 oncoprotein is downregulated by miR-1226 and that miR-1226 thereby functions as a tumor suppressor by promoting the induction of cell death.
target gene	hsa-mir-210	Hemoglobin Diseases	25849663			D58.2	D006450	141900		microRNA-210 and raptor are involved in mithramycin-mediated erythroid differentiation of K562 cells and participate to the fine-tuning and control of γ-globin gene expression in erythroid precursor cells.
target gene	hsa-mir-124	Hepatic Ischemia-Reperfusion Injury	24875359							Many miRNAs are involved in hepatic IRI in rats, and miR-124 is significantly decreased in this model. MiR-124 significantly decreases the H2O2-induced apoptosis of human hepatic L02 cells by targeting the Rab38 gene and activating the AKT pathway.
target gene	hsa-mir-122	Hepatitis B Virus Infection	24667324	disease by infectious agent	DOID:2043	B16/18	D006509	610424		In conclusion, HBx is a critical protein derived from HBV,which regulates miR-122 via down-regulating Gld2.
target gene	hsa-mir-122	Hepatitis B Virus Infection	25766860	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus.
target gene	hsa-mir-1231	Hepatitis B Virus Infection	24835118	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.
target gene	hsa-mir-125a	Hepatitis B Virus Infection	23783428	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Biogenesis, evolution and functional targets of microRNA-125a.
target gene	hsa-mir-125b	Hepatitis B Virus Infection	25173609	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene.
target gene	hsa-mir-130a	Hepatitis B Virus Infection	25595716	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-130a could contribute to metabolic homeostasis by dual targeting PGC1α and PPARγ simultaneously.
target gene	hsa-mir-141	Hepatitis B Virus Infection	22479552	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNA-141 Represses HBV Replication by Targeting PPARA
target gene	hsa-mir-141	Hepatitis B Virus Infection	28135713	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNA-141 Targets Sirt1 and Inhibits Autophagy to Reduce HBV Replication.
target gene	hsa-mir-146a	Hepatitis B Virus Infection	23698745	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNA-146a Feedback Suppresses T Cell Immune Function by Targeting Stat1 in Patients with Chronic Hepatitis B.
target gene	hsa-mir-146a	Hepatitis B Virus Infection	25805734	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H.
target gene	hsa-mir-155	Hepatitis B Virus Infection	25720442	disease by infectious agent	DOID:2043	B16/18	D006509	610424		our study established a correlation between miR-155 and TLR7 during HBV infection and also demonstrated in vitro that increased miR-155 level could help to reduce HBV viral load by targeting C/EBP-β.
target gene	hsa-mir-15a	Hepatitis B Virus Infection	24089558	disease by infectious agent	DOID:2043	B16/18	D006509	610424		we identified a novel HBV mRNA-miR-15a/16-Bcl-2 regulatory pathway that is involved in inhibiting etoposide-induced apoptosis of hepatoma cells, which may contribute to facilitating chronic HBV infection and hepatoma development.
target gene	hsa-mir-16	Hepatitis B Virus Infection	24089558	disease by infectious agent	DOID:2043	B16/18	D006509	610424		we identified a novel HBV mRNA-miR-15a/16-Bcl-2 regulatory pathway that is involved in inhibiting etoposide-induced apoptosis of hepatoma cells, which may contribute to facilitating chronic HBV infection and hepatoma development.
target gene	hsa-mir-26b	Hepatitis B Virus Infection	25342750	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNA-26b inhibits hepatitis B virus transcription and replication by targeting the host factor CHORDC1 protein.
target gene	hsa-mir-338	Hepatitis B Virus Infection	22942717	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-338-3p Is Down-Regulated by Hepatitis B Virus X and Inhibits Cell Proliferation by Targeting the 3'-UTR Region of CyclinD1.
target gene	hsa-mir-370	Hepatitis B Virus Infection	27664977	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-370 suppresses HBV gene expression and replication by targeting nuclear factor IA.
target gene	hsa-mir-372	Hepatitis B Virus Infection	21608007	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNAs-372/373 promote the expression of hepatitis B Virus through the targeting of nuclear factor I/B.
target gene	hsa-mir-373	Hepatitis B Virus Infection	21608007	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNAs-372/373 promote the expression of hepatitis B Virus through the targeting of nuclear factor I/B.
target gene	hsa-mir-4717	Hepatitis B Virus Infection	25895129	disease by infectious agent	DOID:2043	B16/18	D006509	610424		microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases.
target gene	hsa-mir-501	Hepatitis B Virus Infection	23266610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNA-501 promotes HBV replication by targeting HBXIP
target gene	hsa-mir-602	Hepatitis B Virus Infection	20364114	disease by infectious agent	DOID:2043	B16/18	D006509	610424		MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma
target gene	hsa-mir-107	Hepatitis C Virus Infection	24429361	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. miR-122,miR-126,miR-136,hsa-mir-181a
target gene	hsa-mir-122	Hepatitis C Virus Infection	25302477	disease by infectious agent	DOID:1883	B19.2	D006526	609532		This study uncovers a novel antiviral effect of miR-122 on human liver cells and shows that over-expression of miR-122 can decrease HCV entry into hepatocytes through down-regulation of OCLN.
target gene	hsa-mir-122	Hepatitis C Virus Infection	17462786	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Although miRNA regulation of cellular target genes through 3'UTR binding seems to be only negative, the hepatitis C virus (HCV) has creatively made use of the liver-specific and abundantly expressed miR-122 to promote viral replication.
target gene	hsa-mir-122	Hepatitis C Virus Infection	22957141	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Silencing of microRNA-122 enhances interferon-alpha signaling in the liver through regulating SOCS3 promoter methylation.
target gene	hsa-mir-122	Hepatitis C Virus Infection	24068553	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MiR-122 is a liver-specific miRNA with an important role in the life cycle of hepatitis C virus (HCV). It is the target of miravirsen (SPC3649), an antimiR drug candidate currently in clinical testing for treatment of HCV infections.
target gene	hsa-mir-1273g	Hepatitis C Virus Infection	27423040	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Overexpression of miR-1273g-3p could inhibit translation of PTEN, increase the expression of 伪-SMA, Col1A1, and reduce apoptosis in HSCs.
target gene	hsa-mir-15b	Hepatitis C Virus Infection	24705650	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1α.
target gene	hsa-mir-182	Hepatitis C Virus Infection	26518141	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-182 was never investigated before, neither in HCV infection nor in NK cells, and we found it to have dysregulated expression in both liver tissues and NK cells of HCV-infected patients compared to control. In addition to that, miR-182 was found to have a contradicting effect in both effector cell and its HCV-infected target cell regarding HCV replication.
target gene	hsa-mir-185	Hepatitis C Virus Infection	25914460	disease by infectious agent	DOID:1883	B19.2	D006526	609532		HCV core protein disturbs the cholesterol homeostasis in HepG2 cells via the SREBP2 pathway; miR-185-5p is involved in the regulation of SREBP2 by the core protein.
target gene	hsa-mir-194	Hepatitis C Virus Infection	25218426	disease by infectious agent	DOID:1883	B19.2	D006526	609532		This study showed that mir-194 hinders HCV entry through targeting CD81 receptors.
target gene	hsa-mir-199a	Hepatitis C Virus Infection	26027911	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway.
target gene	hsa-mir-215	Hepatitis C Virus Infection	29749134	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling.
target gene	hsa-mir-224	Hepatitis C Virus Infection	17188425	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miRNA-224 regulates PDGFR expression, and decreases as disease progresses from chronic hepatitis to cirrhosis [59], suggesting that miRNA normally suppresses PDGFR in the liver until HBV integration and genetic instability upsets this balance. miRNA-224 a
target gene	hsa-mir-27a	Hepatitis C Virus Infection	23449803	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells
target gene	hsa-mir-373	Hepatitis C Virus Infection	25589644	disease by infectious agent	DOID:1883	B19.2	D006526	609532		the role of miR-373 in HCV infection and suggest a new potential target against HCV infection.
target gene	hsa-mir-449a	Hepatitis C Virus Infection	24429361	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. miR-122,miR-126,miR-136,hsa-mir-181a
target gene	hsa-mir-491	Hepatitis C Virus Infection	21802413	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-491 was involved in regulation of HCV replication via the PI3 kinase/Akt pathway.
target gene	hsa-mir-942	Hepatitis C Virus Infection	24727952	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a.
target gene	hsa-mir-143	Hepatoblastoma	19472311	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression.
target gene	hsa-mir-328	Hepatoblastoma	24318997	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation.
target gene	hsa-mir-424	Hepatoblastoma	25524739	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	miR-424 regulates the myofibroblast differentiation during EMT by potentiating the TGF-β  signaling pathway, likely through Smurf2
target gene	hsa-mir-492	Hepatoblastoma	29314711	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MiR-492 regulates metastatic properties of hepatoblastoma via CD44
target gene	hsa-mir-569	Hepatoblastoma	25490449	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	targeting miR569 could potentially benefit patients with the 3q26.2 amplicon and subsequent miR569 elevatio
target gene	hsa-mir-96	hepatocellular carcinoma	28892647							miR-96 targets SOX6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma
target gene	hsa-let-7a	Hirschsprung Disease	26991540	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	Our study demonstrates that the miR-24-1*/let-7a*-ARP2/3 complex-RAC isoforms pathway may represent a novel pathogenic mechanism for HSCR.
target gene	hsa-mir-141	Hirschsprung Disease	24334875	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	The present study demonstrates for the first time the role of miR-141 and its target genes in the occurrence of HSCR, and provides us a new direction for the study of the pathogenesis of Hirschsprung's disease.
target gene	hsa-mir-192	Hirschsprung Disease	25857602	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	Nidogen-1 is a common target of microRNAs MiR-192/215 in the pathogenesis of Hirschsprung's disease.
target gene	hsa-mir-200	Hirschsprung Disease	25116353	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	The miR-200 family may play a crucial role in the pathogenesis of HSCR by co-regulating PTEN.
target gene	hsa-mir-215	Hirschsprung Disease	25857602	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	Nidogen-1 is a common target of microRNAs MiR-192/215 in the pathogenesis of Hirschsprung's disease.
target gene	hsa-mir-215	Hirschsprung Disease	28006787	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	Role of MiR-215 in Hirschsprung's Disease Pathogenesis by Targeting SIGLEC-8.
target gene	hsa-mir-24	Hirschsprung Disease	26991540	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	Our study demonstrates that the miR-24-1*/let-7a*-ARP2/3 complex-RAC isoforms pathway may represent a novel pathogenic mechanism for HSCR.
target gene	hsa-mir-122	Human Immunodeficiency Virus Infection	24503097			B20	D015658	609423		Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection.
target gene	hsa-mir-1236	Human Immunodeficiency Virus Infection	24932481			B20	D015658	609423		miRNA-1236 inhibits HIV-1 infection of monocytes by repressing translation of cellular factor VprBP.
target gene	hsa-mir-125b	Human Immunodeficiency Virus Infection	17906637			B20	D015658	609423		We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells.
target gene	hsa-mir-146a	Human Immunodeficiency Virus Infection	20181935			B20	D015658	609423		mir-146a:CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells
target gene	hsa-mir-150	Human Immunodeficiency Virus Infection	17906637			B20	D015658	609423		We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells.
target gene	hsa-mir-155	Human Immunodeficiency Virus Infection	22080513			B20	D015658	609423		microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region.
target gene	hsa-mir-155	Human Immunodeficiency Virus Infection	28096489			B20	D015658	609423		miR-155 and miR-92a, were reported previously to at least weakly bind HIV-1 transcripts
target gene	hsa-mir-17	Human Immunodeficiency Virus Infection	25146963			B20	D015658	609423		HIV-1 Tat C modulates NOX2 and NOX4 expressions through miR-17 in a human microglial cell line.
target gene	hsa-mir-182	Human Immunodeficiency Virus Infection	23153509			B20	D015658	609423		Down-regulation of NAMPT expression by miR-182 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation
target gene	hsa-mir-21	Human Immunodeficiency Virus Infection	19560422			B20	D015658	609423		highly abundant; specifically targets the HIV-1 3'UTR region; Inhibiting miR-29a enhanced HIV-1 viral production and infectivity; specific miR-29a-HIV-1 mRNA interactions enhance viral mRNA association with RISC and P body proteins
target gene	hsa-mir-21	Human Immunodeficiency Virus Infection	22080513			B20	D015658	609423		microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region.
target gene	hsa-mir-223	Human Immunodeficiency Virus Infection	22080513			B20	D015658	609423		microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region.
target gene	hsa-mir-223	Human Immunodeficiency Virus Infection	17906637			B20	D015658	609423		We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells.
target gene	hsa-mir-28	Human Immunodeficiency Virus Infection	17906637			B20	D015658	609423		We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells.
target gene	hsa-mir-29a	Human Immunodeficiency Virus Infection	22080513			B20	D015658	609423		microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region.
target gene	hsa-mir-382	Human Immunodeficiency Virus Infection	17906637			B20	D015658	609423		We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells.
target gene	hsa-mir-34a	Human Immunodeficiency Virus Infection	26188041			B20	D015658	609423		The miRNA miR-34a enhances HIV-1 replication by targeting PNUTS/PPP1R10, which negatively regulates HIV-1 transcriptional complex formation.
target gene	hsa-mir-92a	Human Immunodeficiency Virus Infection	28096489			B20	D015658	609423		miR-155 and miR-92a, were reported previously to at least weakly bind HIV-1 transcripts
target gene	hsa-mir-145	Human Papilloma Virus Infection	27386862			B97.7	D027383			KLF4 levels are increased in HPV-positive cells through a post-transcriptional mechanism involving E7-mediated suppression of cellular miR-145
target gene	hsa-mir-15a	Human Papilloma Virus Infection	27573302			B97.7	D027383			miR-15a induces cell apoptosis by targeting BCL2L2 and BCL2 in HPV-positive hypopharyngeal squamous cell carcinoma.
target gene	hsa-mir-3144	Human Papilloma Virus Infection	25913515			B97.7	D027383			Two less common human microRNAs miR-875 and miR-3144 target a conserved site of E6 oncogene in most high-risk human papillomavirus subtypes.
target gene	hsa-mir-875	Human Papilloma Virus Infection	25913515			B97.7	D027383			Two less common human microRNAs miR-875 and miR-3144 target a conserved site of E6 oncogene in most high-risk human papillomavirus subtypes.
target gene	hsa-mir-125b-1	Huntington Disease	21887328	nervous system disease	DOID:12858	G10	D006816	143100		The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a.
target gene	hsa-mir-125b-1	Huntington Disease	22048026	nervous system disease	DOID:12858	G10	D006816	143100		Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
target gene	hsa-mir-125b-2	Huntington Disease	21887328	nervous system disease	DOID:12858	G10	D006816	143100		The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a.
target gene	hsa-mir-125b-2	Huntington Disease	22048026	nervous system disease	DOID:12858	G10	D006816	143100		Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
target gene	hsa-mir-146a	Huntington Disease	21887328	nervous system disease	DOID:12858	G10	D006816	143100		The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a.
target gene	hsa-mir-146a	Huntington Disease	22048026	nervous system disease	DOID:12858	G10	D006816	143100		Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
target gene	hsa-mir-150	Huntington Disease	21887328	nervous system disease	DOID:12858	G10	D006816	143100		The authors conclude that (i) miR-125b and miR-150 target p53, which in turn regulates RelA/NFkB and miR-146a expressions; (ii) reduced miR-125b and miR-150 expressions, increased p53 level and decreased RelA/NFkB and miR-146a expressions originate from mutant HTT (iii) p53 directly or indirectly regulates the expression of miR-146a.
target gene	hsa-mir-150	Huntington Disease	22048026	nervous system disease	DOID:12858	G10	D006816	143100		Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
target gene	hsa-mir-214	Huntington Disease	22048026	nervous system disease	DOID:12858	G10	D006816	143100		Micro RNA -214,-150,-146a and-125b target Huntingtin gene.
target gene	hsa-mir-214	Huntington Disease	26307536	nervous system disease	DOID:12858	G10	D006816	143100		In summary, we have shown that increased expression of miR-214 observed in HD cell model could target MFN2, altered mitochondrial morphology and deregulated cell cycle. Inhibition of miR-214 could be a possible target of intervention in HD pathogenesis.
target gene	hsa-mir-22	Huntington Disease	23349832	nervous system disease	DOID:12858	G10	D006816	143100		MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington's Disease-Related Mechanisms
target gene	hsa-mir-34a	Huntington Disease	29289683	nervous system disease	DOID:12858	G10	D006816	143100		Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington's disease model
target gene	hsa-mir-491	Hypercholesterolaemia	27575876			E78.3	D006937	143890		Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.
target gene	hsa-let-7b	Hypertension	27286171	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	micro-RNA Let-7b in post-transcriptional regulation
target gene	hsa-mir-105	Hypertension	27185878	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes
target gene	hsa-mir-1283	Hypertension	26149214	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	inhibition of miR-1283 in HA-VSMCs enhanced the expression of Activating transcription factor 1 mRNA as well as the ROS levels.
target gene	hsa-mir-133a-1	Hypertension	21769867	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-133a regulates collagen 1A1, which has potential role in myocardial fibrosis in angiotensin II dependent hypertension.
target gene	hsa-mir-133a-2	Hypertension	21769867	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-133a regulates collagen 1A1, which has potential role in myocardial fibrosis in angiotensin II dependent hypertension.
target gene	hsa-mir-155	Hypertension	17668390	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Since hsa-miR-155 is on chromosome 21, we hypothesize that the observed lower blood pressure in trisomy 21 is partially caused by the overexpression of hsa-miR-155 leading to allele-specific underexpression of AGTR1.
target gene	hsa-mir-155	Hypertension	27185878	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-155 and miR-105, were found to modulate ANP production in human cardiomyocytes
target gene	hsa-mir-16	Hypertension	28531963	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease.
target gene	hsa-mir-19b	Hypertension	28531963	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease.
target gene	hsa-mir-204	Hypertension	28839162	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MicroRNA-204 promotes vascular endoplasmic reticulum stress and endothelial dysfunction by targeting Sirtuin1.
target gene	hsa-mir-328	Hypertension	22392900	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The MicroRNA-328 Regulates Hypoxic Pulmonary Hypertension by Targeting at Insulin Growth Factor 1 Receptor and L-Type Calcium Channel-alpha1C.
target gene	hsa-mir-424	Hypertension	23263626	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension
target gene	hsa-mir-425	Hypertension	27185878	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	microRNA 425 (miR-425) was found to regulate ANP production
target gene	hsa-mir-503	Hypertension	23263626	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension
target gene	hsa-mir-608	Hypertension	24722204	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Competing targets of microRNA-608 affect anxiety and hypertension.
target gene	hsa-mir-10a	Hypertrophic Scar	25554417			L91.0	D017439			miR-181c-uPA and miR-10a-PAI-1 regulatory pathways have an integral role in HS pathogenesis.
target gene	hsa-mir-145	Hypertrophic Scar	25704091			L91.0	D017439			Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits collagen synthesis in human hypertrophic scar fibroblasts by targeting Smad3 via miR-145.
target gene	hsa-mir-181c	Hypertrophic Scar	25554417			L91.0	D017439			miR-181c-uPA and miR-10a-PAI-1 regulatory pathways have an integral role in HS pathogenesis.
target gene	hsa-mir-21	Hypertrophic Scar	24817011			L91.0	D017439			MicroRNA-21 regulates hTERT via PTEN in hypertrophic scar fibroblasts.
target gene	hsa-mir-222	Hypertrophic Scar	29658663			L91.0	D017439			microRNA-222 regulates proliferation and apoptosis of fibroblasts in hypertrophic scar via matrix metalloproteinase 1
target gene	hsa-mir-1	Hypertrophy	29073097				D006984			Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy.
target gene	hsa-mir-1-1	Hypertrophy	18458081				D006984			Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
target gene	hsa-mir-1-2	Hypertrophy	18458081				D006984			Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
target gene	hsa-mir-133a-1	Hypertrophy	18458081				D006984			Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
target gene	hsa-mir-133a-2	Hypertrophy	18458081				D006984			Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
target gene	hsa-mir-133b	Hypertrophy	18458081				D006984			Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
target gene	hsa-mir-221	Hypertrophy	22275134				D006984			MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression.
target gene	hsa-let-7b	Hypohidrotic Ectodermal Dysplasia	29344666	musculoskeletal system disease	DOID:14793		D053358	PS305100	HP:0007607	Let-7b regulates alpaca hair growth by downregulating ectodysplasin A.
target gene	hsa-let-7a	Hypoxic-Ischemic Encephalopathy	29562785			P91.60	D020925			The expression levels of the microRNAs (miRs) let-7a and let-7e, known regulators of Casp3, were inversely correlated to Casp3
target gene	hsa-let-7e	Hypoxic-Ischemic Encephalopathy	29562785			P91.60	D020925			The expression levels of the microRNAs (miRs) let-7a and let-7e, known regulators of Casp3, were inversely correlated to Casp3
target gene	hsa-mir-155	Idiopathic Pulmonary Fibrosis	27746237	respiratory system disease	DOID:0050156	J84.112	D054990	178500		The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis.
target gene	hsa-mir-29c	Idiopathic Pulmonary Fibrosis	27765762	respiratory system disease	DOID:0050156	J84.112	D054990	178500		MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts.
target gene	hsa-mir-30a	Idiopathic Pulmonary Fibrosis	28294974	respiratory system disease	DOID:0050156	J84.112	D054990	178500		miR-30a as Potential Therapeutics by Targeting TET1 through Regulation of Drp-1 Promoter Hydroxymethylation in Idiopathic Pulmonary Fibrosis.
target gene	hsa-mir-92a	Idiopathic Pulmonary Fibrosis	24953558	respiratory system disease	DOID:0050156	J84.112	D054990	178500		miR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis.
target gene	hsa-mir-100	IgA Nephropathy	27542871	urinary system disease	DOID:2986	N02.8	D005922	161950	HP:0000794	MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1β in mesangial cells activated by secretory IgA from IgA nephropathy patients.
target gene	hsa-mir-29a	IgA Nephropathy	25664031	urinary system disease	DOID:2986	N02.8	D005922	161950	HP:0000794	we found that miR-29b-3p down-regulation caused CDK6 overexpression can promote NF-魏B signal by phosphorylating p65 which may enhance inflammation during IgAN pathogenesis.
target gene	hsa-mir-877	IgA Nephropathy	27542871	urinary system disease	DOID:2986	N02.8	D005922	161950	HP:0000794	MiR-100-3p and miR-877-3p regulate overproduction of IL-8 and IL-1β in mesangial cells activated by secretory IgA from IgA nephropathy patients.
target gene	hsa-mir-19a	Ileus	28537131	gastrointestinal system disease	DOID:8440	K56.7	D045823		HP:0002595	Acupuncture Ameliorates Postoperative Ileus via IL-6-miR-19a-KIT Axis to Protect Interstitial Cells of Cajal.
target gene	hsa-let-7i	Immune System Disease [unspecific]	17660297	immune system disease	DOID:2914	D89.9	D007154			These results indicate that let-7i regulates TLR4 expression in cholangiocytes and contributes to epithelial immune responses against C. parvum infection.
target gene	hsa-mir-101	Immune System Disease [unspecific]	21068409	immune system disease	DOID:2914	D89.9	D007154			Together, these results indicate that miR-101 regulates the innate immune responses of macrophages to LPS through targeting MKP-1.
target gene	hsa-mir-126	Immune System Disease [unspecific]	20083669	immune system disease	DOID:2914	D89.9	D007154			These data show that miR-126 is differentially regulated in CF versus non-CF airway epithelial cells and that TOM1 is a miR-126 target that may have an important role in regulating innate immune responses in the CF lung.
target gene	hsa-mir-155	Immune System Disease [unspecific]	19144316	immune system disease	DOID:2914	D89.9	D007154			Our studies suggest that Foxp3-dependent regulation of miR155 maintains competitive fitness of Treg cell subsets by targeting SOCS1, and they provide experimental support for a proposed role for miRNAs in ensuring the robustness of cellular phenotypes.
target gene	hsa-mir-17	Immune System Disease [unspecific]	23812097	immune system disease	DOID:2914	D89.9	D007154			MicroRNAs of the miR-17~92 family are critical regulators of T(FH) differentiation.
target gene	hsa-mir-181a	Immune System Disease [unspecific]	18701320	immune system disease	DOID:2914	D89.9	D007154			In addition to facilitating cell fate decisions of immune cells (e.g. miR-181a and miR-223), miRs also regulate central elements of the adaptive immune response such as antigen presentation (e.g. miR-155) and T cell receptor signaling (mir-181a).
target gene	hsa-mir-199	Immune System Disease [unspecific]	24062059	immune system disease	DOID:2914	D89.9	D007154			We demonstrated for the first time that CD14 knockdown significantly changed the expression of 199a-3p, miR-199a-5p, and miR-21-5p in RAW264.7 cells, and significantly enriched GO terms in the predicted target genes of these miRNAs were apoptosis process, immune response, inflammatory response, innate immune response, anti-apoptosis, cytokine production, and cytokine-mediated signaling pathway.
target gene	hsa-mir-21	Immune System Disease [unspecific]	23998932	immune system disease	DOID:2914	D89.9	D007154			miRNA-21 inhibition enhances RANTES and IP-10 release in MCF-7 via PIAS3 and STAT3 signalling and causes increased lymphocyte migration.
target gene	hsa-mir-21	Immune System Disease [unspecific]	28129531	immune system disease	DOID:2914	D89.9	D007154			MicroRNA-21 contributes to suppress cytokines production by targeting TLR28 in teleost fish.
target gene	hsa-mir-146a	Infection [unspecific]	27156837				D007239			The in vitro study suggested that transfected mmu-miR-146a-5p inhibitor upregulated TNF-α and its target gene Traf6 in microglia following stimulation with A. cantonensis larval antigen.
target gene	hsa-mir-16	Infection [unspecific]	26184511				D007239			miR- 16 targeted the 3鈥?untranslated region of IL-6 and suppressed its translation in mesangial cells induced by SIgA.
target gene	hsa-mir-513	Infection [unspecific]	19916867				D007239			These data suggest a role of miR-513 in regulating B7-H1 expression by cholangiocytes in response to C. parvum infection.
target gene	hsa-mir-122	Infertility	23327642	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			MicroRNA-122 influences the development of sperm abnormalities from human induced pluripotent stem cells by regulating TNP2 expression.
target gene	hsa-let-7a-1	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7a-2	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7a-3	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7b	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7c	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7d	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7e	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7f-1	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7f-2	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7g	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-let-7i	Inflammation	21616524				D007249			Let-7 microRNAs inhibit IL-13 expression and represent a major regulatory mechanism for modulating IL-13 secretion in IL-13-producing cell types and thereby T(H)2 inflammation.
target gene	hsa-mir-105	Inflammation	19509287				D007249			We identified miRNA (miR)-105 as a modulator of TLR-2 protein translation in human gingival keratinocytes.
target gene	hsa-mir-1236	Inflammation	22223733				D007249			Mirtron MicroRNA-1236 Inhibits VEGFR-3 Signaling During Inflammatory Lymphangiogenesis.
target gene	hsa-mir-125a	Inflammation	27836539				D007249			these findings identify a PPARγ-miR-125a-NOD1 signaling axis in endothelial cells that is critical in the regulation of inflammation-mediated angiogenesis
target gene	hsa-mir-125b	Inflammation	25728278				D007249			MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes.
target gene	hsa-mir-125b	Inflammation	25620312				D007249			miR-125b is a negative regulator of CCL4 and its reduction is partially responsible for the age-related increase of CCL4.
target gene	hsa-mir-127	Inflammation	22287715				D007249			MicroRNA-127 Inhibits Lung Inflammation by Targeting IgG Fcgamma Receptor I.
target gene	hsa-mir-132	Inflammation	25728278				D007249			MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes.
target gene	hsa-mir-132	Inflammation	29377244				D007249			MicroRNA-132 attenuates LPS-induced inflammatory injury by targeting TRAF6 in neuronal cell line HT-22
target gene	hsa-mir-135a	Inflammation	20634564				D007249			Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression.
target gene	hsa-mir-142	Inflammation	28275790				D007249			MiR-142-3p inhibits lipopolysaccharide-induced inflammatory response in human periodontal ligament cells through targeting IRAK1.
target gene	hsa-mir-143	Inflammation	25728278				D007249			MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes.
target gene	hsa-mir-146	Inflammation	24112639				D007249			apolipoprotein-mediated lipid transport emerged as an infection-inducible pathway under miR-146 knockdown conditions, suggesting a possible function of miR-146 in regulating lipid metabolism during inflammation.
target gene	hsa-mir-146a	Inflammation	29288795				D007249			miR-146a inhibits inflammatory cytokine production in B cells through directly targeting IRAK1
target gene	hsa-mir-146a	Inflammation	29074132				D007249			MicroRNA-146a promotes red spotted grouper nervous necrosis virus (RGNNV) replication by targeting TRAF6 in orange spotted grouper, Epinephelus coioides.
target gene	hsa-mir-146b	Inflammation	20956612				D007249			e.g., miR-146b targeted NF-κB signaling, and miR-219 targeted 5-lipoxygenase and reduced leukotriene production.
target gene	hsa-mir-146b	Inflammation	23733368				D007249			We demonstrate that miR-146 negatively regulates inflammation. Over-expression of miR-146a blunts endothelial activation, while knock-down of miR-146a/b in vitro or deletion of miR-146a in mice has the opposite effect.
target gene	hsa-mir-148a	Inflammation	25728278				D007249			MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes.
target gene	hsa-mir-148a	Inflammation	25630970				D007249			cyclic stretch of human AVICs activates inflammatory genes in a tissue-autonomous manner via a microRNA that regulates a central inflammatory pathway.
target gene	hsa-mir-150	Inflammation	26549736				D007249			miR-150 can effectively prevent CD28/B7 co-stimulatory signaling transduction, decrease production of inflammatory cytokines, such as IL-2 and TNF, and elicit the induction of immune tolerance.
target gene	hsa-mir-155	Inflammation	21310411				D007249			HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and
target gene	hsa-mir-155	Inflammation	25892184				D007249			miR-155-dependent regulation of mammalian sterile 20-like kinase 2 (MST2) coordinates inflammation, oxidative stress and proliferation in vascular smooth muscle cells.
target gene	hsa-mir-17	Inflammation	19949084				D007249			In this study, we report that TNF-mediated induction of endothelial adhesion molecules can be regulated by miRNAs that are induced by TNF. Specifically, E-selectin and ICAM-1 are targets of TNF-induced miRNAs miR-31 and miR-17-3p, respectively.
target gene	hsa-mir-181a	Inflammation	20634564				D007249			Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression.
target gene	hsa-mir-181a	Inflammation	23516523				D007249			we provide the first evidence for anti-inflammatory effects of miR-181a mediated at least in part by down-regulating IL1a.
target gene	hsa-mir-181b	Inflammation	20634564				D007249			Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression.
target gene	hsa-mir-181b	Inflammation	22622040				D007249			MicroRNA-181b regulates NF-κB-mediated vascular inflammation.
target gene	hsa-mir-182	Inflammation	23825948				D007249			miR-182 and miR-10a are key regulators of Treg specialisation and stability during Schistosome and Leishmania-associated inflammation.
target gene	hsa-mir-192	Inflammation	18835392				D007249			Macrophage inflammatory peptide (MIP)-2 alpha, a chemokine expressed by epithelial cells, was identified as a target of miR-192.
target gene	hsa-mir-193b	Inflammation	25728278				D007249			MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes.
target gene	hsa-mir-194	Inflammation	25984739				D007249			We conclude that miR-194 negatively regulates the TLR4 signal pathway which is activated by PA through directly negative TRAF6 expression.
target gene	hsa-mir-199b	Inflammation	20634564				D007249			Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression.
target gene	hsa-mir-203	Inflammation	22679274				D007249			The top-ranked predicted target of the highly down-regulated miRNA-203 in asthmatic cells was the aquaporin gene AQP4.
target gene	hsa-mir-203	Inflammation	22846677				D007249			miR-203 may regulate expression of the novel nociceptive mediator PLAA after incision. Furthermore, the regulation of miR-203 and PLAA levels is reliant upon intact substance P signaling.
target gene	hsa-mir-203	Inflammation	29242191				D007249			The inducible microRNA-203 in fish represses the inflammatory responses to Gram-negative bacteria by targeting IL-1 receptor-associated kinase 4
target gene	hsa-mir-204	Inflammation	20634564				D007249			Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression.
target gene	hsa-mir-21	Inflammation	21636785				D007249			MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation.
target gene	hsa-mir-219	Inflammation	20956612				D007249			e.g., miR-146b targeted NF-κB signaling, and miR-219 targeted 5-lipoxygenase and reduced leukotriene production.
target gene	hsa-mir-221	Inflammation	21310411				D007249			HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and
target gene	hsa-mir-221	Inflammation	25865302				D007249			these results indicated that miR-221 targets AdipoR1 to regulate endothelial inflammatory response.
target gene	hsa-mir-221	Inflammation	25810396				D007249			Moreover, downregulation of KIT expression by miRNA-221 overexpression or the proteasome inhibitor bortezomib also reduced 3BP2 and MITF expression.
target gene	hsa-mir-222	Inflammation	21310411				D007249			HUVECs highly expressed miR-155 may co-target AT1R and Ets-1 while miR-221/222 targets Ets-1, which indirectly regulate the expression of several inflammatory molecules of ECs, and therefore attenuate the adhesion of Jurkat T cells to activated HUVECs and
target gene	hsa-mir-223	Inflammation	25728278				D007249			MiR-193b may inhibit early chondrogenesis by targeting TGFB2 and TGFBR3, and may regulate inflammation by repressing TNF-alpha expression in inflamed chondrocytes.
target gene	hsa-mir-223	Inflammation	18791161				D007249			miR-223, which is markedly enhanced by estrogen,regulates LPS-induced IFNgamma, but not iNOS or nitric oxide in splenic lymphocytes. Inhibition of miR-223 activity decreased LPS-induced IFNgamma in splenic lymphocytes from estrogen-treated mice.
target gene	hsa-mir-23b	Inflammation	22660635				D007249			The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-a.
target gene	hsa-mir-25	Inflammation	19541842				D007249			Our study demonstrates that inhibition of miR-25 in cytokine-stimulated ASM cells up-regulates KLF4 expression via a post-transcriptional mechanism.
target gene	hsa-mir-26a	Inflammation	29315680				D007249			the effect of bta-miR-26a in mastitis, mediated at least in part by enhancing FGA expression, involves host defense, inflammation and tissue damage
target gene	hsa-mir-29a	Inflammation	21276447				D007249			microRNA-29a could regulate pro-inflammatory cytokine secretion and scavenger receptor expression by targeting lipoprotein lipase in oxLDL-stimulated dendritic cells.
target gene	hsa-mir-29b	Inflammation	29665646				D007249			miR-29b could regulate LPS-induced  endothelial cells inflammatory injury through regulation of NF-κB and JNK signaling pathways
target gene	hsa-mir-31	Inflammation	19949084				D007249			In this study, we report that TNF-mediated induction of endothelial adhesion molecules can be regulated by miRNAs that are induced by TNF. Specifically, E-selectin and ICAM-1 are targets of TNF-induced miRNAs miR-31 and miR-17-3p, respectively.
target gene	hsa-mir-328	Inflammation	27573788				D007249			UPF1 regulates myeloid cell functions and S100A9 expression by the hnRNP E2/miRNA-328 balance.
target gene	hsa-mir-708	Inflammation	25175907				D007249			In human ASM cells, TNF-α-induced CD38 expression is regulated by miR-708 directly binding to 3'UTR and indirectly by regulating JNK MAPK and PI3K/AKT signaling and has the potential to control airway inflammation, ASM contractility and proliferation.
target gene	hsa-mir-9	Inflammation	20634564				D007249			Specifically, miR-181a and b, miR-9, miR-204, miR-199b, and miR-135a suppressed SIRT1 protein expression.
target gene	hsa-mir-9	Inflammation	23525285				D007249			MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor δ in human monocytes during the inflammatory response.
target gene	hsa-mir-142	Inflammation	25601927				D007249			miR-24,miR-30b, and miR-142-3p regulate phagocytosis and associated cytokine production in myeloid inflammatory cells through modulation of various genes involved in the pathway.
target gene	hsa-mir-146b	Inflammation	25824148				D007249			Ang-1 disrupts TLR4 signalling, resulting in inhibition of LPS-induced inflammatory responses in endothelial cells. This inhibition occurs through selective targeting of IRAK1 and TRAF6 proteins by miR-146b-5p.
target gene	hsa-mir-149	Inflammation	24375488				D007249			MicroRNA-149 negatively regulates TLR-triggered inflammatory response in macrophages by targeting MyD88.
target gene	hsa-mir-155	Inflammation	25231976				D007249			MicroRNA-155 potentiates the inflammatory response in hypothermia by suppressing IL-10 production.
target gene	hsa-mir-24	Inflammation	25601927				D007249			miR-24,miR-30b, and miR-142-3p regulate phagocytosis and associated cytokine production in myeloid inflammatory cells through modulation of various genes involved in the pathway.
target gene	hsa-mir-30b	Inflammation	25601927				D007249			miR-24,miR-30b, and miR-142-3p regulate phagocytosis and associated cytokine production in myeloid inflammatory cells through modulation of various genes involved in the pathway.
target gene	hsa-mir-744	Inflammation	26259828				D007249			our data indicate that by targeting PTP1B, miR-744 plays a feed-forward role in regulating type I IFN signaling pathway. These findings give us new insights into the functions of renal miRNAs in regulating important signaling pathways.
target gene	hsa-mir-124	Inflammatory Bowel Diseases	27977009	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Downregulated expression of microRNA-124 in pediatric intestinal failure patients modulates macrophages activation by inhibiting STAT3 and AChE.
target gene	hsa-mir-125b	Inflammatory Bowel Diseases	28082316	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea.
target gene	hsa-mir-150	Inflammatory Bowel Diseases	21590770	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Together, the present study presents the first evidence that miR-150 and its targeting of c-Myb may serve as a new mechanism underlying the colonic epithelial disruption in DSS-induced murine experimental colitis and in active human IBD.
target gene	hsa-mir-16	Inflammatory Bowel Diseases	28082316	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea.
target gene	hsa-mir-191a	Inflammatory Bowel Diseases	28111380	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Baicalin Protects against TNF-α-Induced Injury by Down-Regulating miR-191a That Targets the Tight Junction Protein ZO-1 in IEC-6 Cells.
target gene	hsa-mir-193a	Inflammatory Bowel Diseases	25931122	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	These findings suggest that miR-193a-3p regulation of PepT1 mediates the uptake of bacterial products and is a potent mechanism during the colonic inflammation process. Overall, we believe miR-193a-3p may be a potent regulator of colonic PepT1 for maintaining intestinal homeostasis.
target gene	hsa-mir-200b	Inflammatory Bowel Diseases	27979826	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	miR-200b inhibits TNF-α-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitro.
target gene	hsa-mir-223	Inflammatory Bowel Diseases	28487310	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome.
target gene	hsa-mir-224	Inflammatory Bowel Diseases	23399735	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	MicroRNA-224 Negatively Regulates p21 Expression During Late Neoplastic Progression in Inflammatory Bowel Disease
target gene	hsa-mir-320	Inflammatory Bowel Diseases	26752466	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Exogenous miR-320 transfection in HT29 cells leads to a significant decrease of NOD2 expression
target gene	hsa-mir-144	Influenza	28380049	respiratory system disease	DOID:8469	J09-J11	D007251	614680		miR-144 attenuates the host response to influenza virus by targeting the TRAF6-IRF7 signaling axis.
target gene	hsa-mir-146a	Influenza	28131813	respiratory system disease	DOID:8469	J09-J11	D007251	614680		MicroRNA-146a induction during influenza H3N2 virus infection targets and regulates TRAF6 levels in human nasal epithelial cells (hNECs).
target gene	hsa-mir-24	Influenza	25234642	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Human microRNA-24 modulates highly pathogenic avian-origin H5N1 influenza A virus infection in A549 cells by targeting secretory pathway furin.
target gene	hsa-mir-302c	Influenza	26602079	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Mir-302c mediates influenza A virus-induced IFNβ expression by targeting NF-κB inducing kinase.
target gene	hsa-mir-34a	Influenza	27610823	respiratory system disease	DOID:8469	J09-J11	D007251	614680		MicroRNA 34a contributes to virus-mediated apoptosis through binding to its target gene Bax in influenza A virus infection.
target gene	hsa-mir-449b	Influenza	24086750	respiratory system disease	DOID:8469	J09-J11	D007251	614680		These findings demonstrate miRNA induction by influenza A virus infection and elucidate an example of miRNA control of antiviral gene expression in human cells, defining a role for miR-449b in regulation of HDAC1 and antiviral cytokine signaling.
target gene	hsa-mir-224	Inner Ear Inflammation	24470395							microRNA-224 regulates Pentraxin 3, a component of the humoral arm of innate immunity, in inner ear inflammation.
target gene	hsa-mir-137	Intellectual Disability	22003227	disease of mental health	DOID:1059	F79	D008607	617991		The patients displayed a significantly decreased expression of both precursor and mature miR-137 levels, as well as significantly increased expression of the validated downstream targets microphthalmia-associated transcription factor (MITF) and Enhancer of Zeste, Drosophila, Homologue 2 (EZH2), and the newly identified target Kruppel-like factor 4 (KLF4). The study also demonstrated significant enrichment of miR-137 at the synapses of cortical and hippocampal neurons, suggesting a role of miR-137 in regulating local synaptic protein synthesis machinery.
target gene	hsa-mir-320a	Interstitial Cystitis	29531336	urinary system disease	DOID:13949	N30.10-.11	D018856			three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-320 family miRNAs
target gene	hsa-mir-320b	Interstitial Cystitis	29531336	urinary system disease	DOID:13949	N30.10-.11	D018856			three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-321 family miRNAs
target gene	hsa-mir-320c	Interstitial Cystitis	29531336	urinary system disease	DOID:13949	N30.10-.11	D018856			three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-322 family miRNAs
target gene	hsa-mir-320d	Interstitial Cystitis	29531336	urinary system disease	DOID:13949	N30.10-.11	D018856			three transcription factors, E2F-1, E2F-2 and TUB, are regulated by miR-323 family miRNAs
target gene	hsa-mir-10b	Intervertebral Disc Degeneration	24376640	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration.
target gene	hsa-mir-155	Intervertebral Disc Degeneration	21706480	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3.
target gene	hsa-mir-15a	Intervertebral Disc Degeneration	28081468	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	Role of miR-15a in intervertebral disc degeneration through targeting MAP3K9.
target gene	hsa-mir-494	Intervertebral Disc Degeneration	28427186	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	MicroRNA-494 promotes ECM degradation and apoptosis of degenerative human NP cells by directly targeting SOX9
target gene	hsa-mir-7	Intervertebral Disc Degeneration	27583982	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	MicroRNA-7 regulates IL-1β-induced extracellular matrix degeneration by targeting GDF5 in human nucleus pulposus cells.
target gene	hsa-mir-93	Intervertebral Disc Degeneration	25818544	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	Taken together, we demonstrated that miR-93 contributed to abnormal NP cell type II collagen expression by targeting MMP3, involved in intervertebral disc degeneration.
target gene	hsa-mir-92a	Intracranial Aneurysm	26718427	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		In conclusion, our research demonstrated that miR-92a and KLF2 were negative correlation in intracranial aneurysm model, and miR-92a could directly target KLF2 in endothelial cells through complementary sequence of 3'UTR region.
target gene	hsa-mir-145	Intrahepatic Cholangiocarcinoma	26255969	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma.
target gene	hsa-mir-204	Intrahepatic Cholangiocarcinoma	24280681	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		These findings suggest that miR-204 plays negative roles in the invasive and/or metastatic potential of ICC, and that its suppressive effects are mediated by repressing Slug expression.
target gene	hsa-mir-376c	Intrahepatic Cholangiocarcinoma	23922722	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		MiR-376c down-regulation accelerates EGF-dependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line.
target gene	hsa-mir-605	Intrahepatic Cholangiocarcinoma	25131931	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
target gene	hsa-mir-218	Iron Metabolism Disease	26703568	disease of metabolism	DOID:2351	E83.1	D019189			Taken together, our results show that miR-218 inhibits erythroid differentiation and alters iron metabolism by targeting ALAS2 in K562 cells.
target gene	hsa-mir-181a-2	Ischemia	21983159	cardiovascular system disease	DOID:326		D007511	601367		miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo.
target gene	hsa-mir-23a	Ischemia	21709246	cardiovascular system disease	DOID:326		D007511	601367		miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia.
target gene	hsa-mir-494	Ischemia	20837890	cardiovascular system disease	DOID:326		D007511	601367		miR-494:MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury
target gene	hsa-let-7b	Ischemia-Reperfusion Injury	26296645				D015427			we report that let-7b targets caspase-3 to regulate apoptosis and  autophagy in MSCs exposed to ROS.
target gene	hsa-let-7e	Ischemia-Reperfusion Injury	21827835				D015427			MicroRNA let-7e regulates the expression of caspase-3 during apoptosis of PC12 cells following anoxia/reoxygenation injury.
target gene	hsa-mir-133a	Ischemia-Reperfusion Injury	28198596				D015427			Propofol protects against hepatic ischemia/reperfusion injury via miR-133a-5p regulating the expression of MAPK6.
target gene	hsa-mir-133a	Ischemia-Reperfusion Injury	23102905				D015427			Therefore, targeting of microRNA-133a represents a potentially novel means for regulating the cascade of profibrotic events after ischemia-reperfusion.
target gene	hsa-mir-146a	Ischemia-Reperfusion Injury	23143987				D015427			MicroRNA-146a-mediated downregulation of IRAK1 protects mouse and human small intestine against ischemia/reperfusion injury.
target gene	hsa-mir-148a	Ischemia-Reperfusion Injury	27609576				D015427			The miR-148a alleviates hepatic ischemia/reperfusion injury in mice via targeting CaMKIIα.
target gene	hsa-mir-155	Ischemia-Reperfusion Injury	28006785				D015427			MiR-155 is Involved in Renal Ischemia-Reperfusion Injury via Direct Targeting of FoxO3a and Regulating Renal Tubular Cell Pyroptosis.
target gene	hsa-mir-15a	Ischemia-Reperfusion Injury	28440490				D015427			MicroRNA-15a inhibition protects against hypoxia/reoxygenation-induced apoptosis of cardiomyocytes by targeting mothers against decapentaplegic homolog 7.
target gene	hsa-mir-21	Ischemia-Reperfusion Injury	28737660				D015427			Renal Protection Mediated by Hypoxia Inducible Factor-1α Depends on Proangiogenesis Function of miR-21 by Targeting Thrombospondin 1.
target gene	hsa-mir-21	Ischemia-Reperfusion Injury	29674977				D015427			the programmed cell death 4 (PDCD4) expression was identified as a target gene of miR-21
target gene	hsa-mir-210	Ischemia-Reperfusion Injury	29461605				D015427			miR-210, as an upstream factor, plays a protective role in cardiomyocytes through directly inhibiting the protein expression of its target gene E2F3
target gene	hsa-mir-214	Ischemia-Reperfusion Injury	27894079				D015427			MicroRNA-214 protects against hypoxia/reoxygenation induced cell damage and myocardial ischemia/reperfusion injury via suppression of PTEN and Bim1 expression.
target gene	hsa-mir-29a	Ischemia-Reperfusion Injury	29238305				D015427			MiR-29a Suppresses Spermatogenic Cell Apoptosis in Testicular Ischemia-Reperfusion Injury by Targeting TRPV4 Channels
target gene	hsa-mir-320a	Ischemia-Reperfusion Injury	26850728				D015427			intrathecal infusion of miR-320a mimic attenuated IR-induced lower limb motor function deficits
target gene	hsa-mir-494	Ischemia-Reperfusion Injury	20837890				D015427			miR-494:MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury
target gene	hsa-mir-494	Ischemia-Reperfusion Injury	28842516				D015427			miR-494 up-regulates the PI3K/Akt pathway via targetting PTEN and attenuates hepatic ischemia/reperfusion injury in a rat model.
target gene	hsa-mir-874	Ischemia-Reperfusion Injury	24462679				D015427			MiR-874 promotes intestinal barrier dysfunction through targeting AQP3 following  intestinal ischemic injury.
target gene	hsa-mir-132	Ischemic Diseases [unspecific]	25945589				D007511	601367		The miR-132/212 cluster promotes arteriogenesis by modulating Ras-MAPK signalling via direct targeting of its inhibitors Rasa1 and Spred1.
target gene	hsa-mir-210	Ischemic Diseases [unspecific]	28661226				D007511	601367		MicroRNA-210 alleviates oxidative stress-associated cardiomyocyte apoptosis by regulating BNIP3.
target gene	hsa-mir-212	Ischemic Diseases [unspecific]	25945589				D007511	601367		The miR-132/212 cluster promotes arteriogenesis by modulating Ras-MAPK signalling via direct targeting of its inhibitors Rasa1 and Spred1.
target gene	hsa-mir-26a	Ischemic Diseases [unspecific]	24047927				D007511	601367		These findings establish miR-26a as a regulator of bone morphogenic protein/SMAD1-mediated EC angiogenic responses, and that manipulating miR-26a expression could provide a new target for rapid angiogenic therapy in ischemic disease states.
target gene	hsa-mir-28	Ischemic Diseases [unspecific]	25807426				D007511	601367		These findings suggest that miR-28 promotes myocardial ischemia through the inhibition of ALDH2 expression in mus. miRNAs is as a probable index in identification of myocardial ischemia after acute myocardial infarction.
target gene	hsa-mir-592	Ischemic Diseases [unspecific]	24573298				D007511	601367		Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury.
target gene	hsa-mir-139	Ischemic Heart Disease	26175501			I25.9/I24.9	D017202			Gene enrichment studies of hsa-miR-139-5p,hsa-miR-483-3p targets demonstrated an association with cardiovascular disease, cell death,and metabolism.
target gene	hsa-mir-141	Ischemic Heart Disease	26371161			I25.9/I24.9	D017202			MicroRNA-141 regulates the expression level of ICAM-1 on endothelium to decrease myocardial ischemia-reperfusion injury.
target gene	hsa-mir-377	Ischemic Heart Disease	25251394			I25.9/I24.9	D017202			MicroRNA-377 regulates mesenchymal stem cell-induced angiogenesis in ischemic hearts by targeting VEGF.
target gene	hsa-mir-483	Ischemic Heart Disease	26175501			I25.9/I24.9	D017202			Gene enrichment studies of hsa-miR-139-5p,hsa-miR-483-3p targets demonstrated an association with cardiovascular disease, cell death,and metabolism.
target gene	hsa-mir-155	Japanese Encephalitis Virus Infection	24885259			A83.0	D018349			Induction of miR-155 in human microglial cells may negatively modulate JEV-induced innate immune gene expression and may have a beneficial role in limiting JEV replication in human microglial cells.
target gene	hsa-mir-15b	Japanese Encephalitis Virus Infection	26202983			A83.0	D018349			MicroRNA-15b Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF125.
target gene	hsa-mir-19b	Japanese Encephalitis Virus Infection	26937036			A83.0	D018349			MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11.
target gene	hsa-mir-33a	Japanese Encephalitis Virus Infection	26819305			A83.0	D018349			MicroRNA-33a-5p Modulates Japanese Encephalitis Virus Replication by Targeting Eukaryotic Translation Elongation Factor 1A1.
target gene	hsa-mir-146a	Juvenile Rheumatoid Arthritis	24719227	musculoskeletal system disease	DOID:676	M08.4	D001171	604302		Association of microRNA-146a and its target gene IRAK1 polymorphism with enthesitis related arthritis category of juvenile idiopathic arthritis.
target gene	hsa-mir-146a	Juvenile Rheumatoid Arthritis	27541693	musculoskeletal system disease	DOID:676	M08.4	D001171	604302		MiR-146a modulates macrophage polarization in systemic juvenile idiopathic arthritis by targeting INHBA.
target gene	hsa-mir-100	Kaposi Sarcoma	24027049	disease of cellular proliferation	DOID:8632	C46	D012514			The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis.
target gene	hsa-mir-1258	Kaposi Sarcoma	24554664	disease of cellular proliferation	DOID:8632	C46	D012514			These results illustrate that, in addition to viral miRNAs,cellular miRNAs also play an important role in regulating the life cycle of KSHV.Overall, this is the first study to report the involvement of Nef in KSHV latency, implying its likely important role in the pathogenesis of AIDS-related malignancies.
target gene	hsa-mir-1293	Kaposi Sarcoma	21984125	disease of cellular proliferation	DOID:8632	C46	D012514			We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or
target gene	hsa-mir-199b	Kaposi Sarcoma	24027049	disease of cellular proliferation	DOID:8632	C46	D012514			The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis.
target gene	hsa-mir-200	Kaposi Sarcoma	24027049	disease of cellular proliferation	DOID:8632	C46	D012514			The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis.
target gene	hsa-mir-320d-1	Kaposi Sarcoma	23418466	disease of cellular proliferation	DOID:8632	C46	D012514			Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA
target gene	hsa-mir-320d-2	Kaposi Sarcoma	23418466	disease of cellular proliferation	DOID:8632	C46	D012514			Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA
target gene	hsa-mir-335	Kaposi Sarcoma	24027049	disease of cellular proliferation	DOID:8632	C46	D012514			The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis.
target gene	hsa-mir-498	Kaposi Sarcoma	23418466	disease of cellular proliferation	DOID:8632	C46	D012514			Cellular MicroRNAs 498 and 320d Regulate Herpes Simplex Virus 1 Induction of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Targeting RTA
target gene	hsa-mir-608	Kaposi Sarcoma	21984125	disease of cellular proliferation	DOID:8632	C46	D012514			We show a direct repression of vIL-6 by hsa-miR-1293 and hIL-6 by hsa-miR-608. The repression of vIL-6 by miR-1293 was reversed by disruption of the vIL-6 miR-1293 seed match through the introduction of point mutations. In addition, expression of vIL-6 or
target gene	hsa-mir-99a	Kaposi Sarcoma	24027049	disease of cellular proliferation	DOID:8632	C46	D012514			The predicted target genes for differentially expressed miRNAs included genes which are involved in a variety of cellular processes such as angiogenesis (i.e. THBS1) and apoptosis (i.e. CASP3, MCL1), suggesting a role for these miRNAs in Kaposi's sarcoma pathogenesis.
target gene	hsa-mir-483	Kawasaki Syndrome	27923814	immune system disease	DOID:13378	M30.3	D009080	611775		miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.
target gene	hsa-mir-181a	Keloid	27915346			L91.0	D007627	148100	HP:0010562	MiR-181a Targets PHLPP2 to Augment AKT Signaling and Regulate Proliferation and Apoptosis in Human Keloid Fibroblasts.
target gene	hsa-mir-185	Keloid	28259900			L91.0	D007627	148100	HP:0010562	MicroRNA‑185 regulates transforming growth factor‑β1 and collagen‑1 in hypertrophic scar fibroblasts.
target gene	hsa-mir-136	Keratitis	25654102	nervous system disease	DOID:4677	H16	D007634	148190	HP:0000491	miR-136 modulates TGF-β1-induced proliferation arrest by targeting PPP2R2A in keratinocytes.
target gene	hsa-mir-155	Kidney Diseases [unspecific]	25672593			N18.9	D007674			this study not only demonstrated that hypoxia-induced miR-155 was a pro-fibrotic cytokine which was positively regulated by HIF-1α, but also revealed that miR-155 promoted the fibrosis of proximal tubule cells by regulating both TGF-β1 and the process of epithelial-mesenchymal transition (EMT) under hypoxia.
target gene	hsa-mir-21	Kidney Diseases [unspecific]	28808068			N18.9	D007674			Overexpression of renal Smad7 protects against hypertensive nephropathy by inactivating angiotensin II-induced TGF-β/Smad3 and NF-κB pathways and by targeting the Smad3-dependent microRNA-21 axis
target gene	hsa-mir-324	Kidney Diseases [unspecific]	22822076			N18.9	D007674			MicroRNA-324-3p Promotes Renal Fibrosis and Is a Target of ACE Inhibition.
target gene	hsa-mir-20a	Kidney Injury	26165754			S37.0	D058186			MiR-20a-5p mediates hypoxia-induced autophagy by targeting ATG16L1 in ischemic kidney injury.
target gene	hsa-mir-210	Kidney Injury	29387863			S37.0	D058186			miR-210 protects renal cell against hypoxia-induced apoptosis by targeting HIF-1 alpha
target gene	hsa-mir-106a	Kidney Neoplasms	26018509	disease of cellular proliferation	DOID:263	C64	D007680			miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2.
target gene	hsa-mir-138	Kidney Neoplasms	24406044	disease of cellular proliferation	DOID:263	C64	D007680			MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma.
target gene	hsa-mir-141	Kidney Neoplasms	22431721	disease of cellular proliferation	DOID:263	C64	D007680			miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms.
target gene	hsa-mir-155	Kidney Neoplasms	29228417	disease of cellular proliferation	DOID:263	C64	D007680			Inhibition of miR-155 increased GSK-3β expression, attenuated Wnt/β-catenin signaling pathway, weakened proliferation and invasion, and facilitated apoptosis in renal carcinoma cells
target gene	hsa-mir-183	Kidney Neoplasms	25152390	disease of cellular proliferation	DOID:263	C64	D007680			microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells.
target gene	hsa-mir-192	Kidney Neoplasms	22431721	disease of cellular proliferation	DOID:263	C64	D007680			miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms.
target gene	hsa-mir-200c	Kidney Neoplasms	22431721	disease of cellular proliferation	DOID:263	C64	D007680			miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms.
target gene	hsa-mir-203	Kidney Neoplasms	25890121	disease of cellular proliferation	DOID:263	C64	D007680			Our study suggested that miR-203 could be a potential prognostic marker and functions as a tumor suppressor in human renal cancer by post-transcriptionally targeting FGF2.
target gene	hsa-mir-21	Kidney Neoplasms	25016284	disease of cellular proliferation	DOID:263	C64	D007680			microRNA-21-induced dissociation of PDCD4 from rictor contributes t Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion.
target gene	hsa-mir-215	Kidney Neoplasms	22431721	disease of cellular proliferation	DOID:263	C64	D007680			miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms.
target gene	hsa-mir-23b	Kidney Neoplasms	20562915	disease of cellular proliferation	DOID:263	C64	D007680			miR-23b:miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer
target gene	hsa-mir-27a	Kidney Neoplasms	25197360	disease of cellular proliferation	DOID:263	C64	D007680			Primary microcephaly gene MCPH1 shows a novel molecular biomarker of human renal carcinoma and is regulated by miR-27a.
target gene	hsa-mir-381	Kidney Neoplasms	26541837	disease of cellular proliferation	DOID:263	C64	D007680			MiRNA-381 can inhibit cell invasion in renal cancer by block the function of CBP, β-catenin and LEF-1.
target gene	hsa-mir-454	Kidney Neoplasms	25115181	disease of cellular proliferation	DOID:263	C64	D007680			Our results indicate that BTG1 is a direct target of miR-454-3p. Down-regulation of BTG1 by miR-454-3p renders tumor cells sensitive to radiation. These results may shed light on the potential application in tumor radiotherapy.
target gene	hsa-mir-590	Kidney Neoplasms	24063284	disease of cellular proliferation	DOID:263	C64	D007680			Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells.
target gene	hsa-mir-106a	Kidney Osteogenic Sarcoma	29072688	disease of cellular proliferation	DOID:5983					MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5.
target gene	hsa-mir-9	Knee Osteoarthritis	27603333			M17	D020370	165720	HP:0005086	MicroRNA-9 regulates the development of knee osteoarthritis through the NF-kappaB1 pathway in chondrocytes.
target gene	hsa-mir-106b	Laryngeal Neoplasms	21819631			C32.3	D007822			MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma.
target gene	hsa-mir-1-1	Laryngeal Neoplasms	21924268			C32.3	D007822			miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.
target gene	hsa-mir-1-2	Laryngeal Neoplasms	21924268			C32.3	D007822			miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.
target gene	hsa-mir-155	Laryngeal Neoplasms	23437123			C32.3	D007822			Overexpression of miR -155 Promotes Proliferation and Invasion of Human Laryngeal Squamous Cell Carcinoma via Targeting SOCS1 and STAT3
target gene	hsa-mir-16-1	Laryngeal Neoplasms	21360639			C32.3	D007822			MicroRNA-16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp-2.
target gene	hsa-mir-16-2	Laryngeal Neoplasms	21360639			C32.3	D007822			MicroRNA-16 targets zyxin and promotes cell motility in human laryngeal carcinoma cell line HEp-2.
target gene	hsa-mir-203	Laryngeal Neoplasms	22306317			C32.3	D007822			MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin.
target gene	hsa-mir-206	Laryngeal Neoplasms	22110210			C32.3	D007822			Down-regulation of MiR-206 Promotes Proliferation and Invasion of Laryngeal Cancer by Regulating VEGF Expression.
target gene	hsa-mir-21	Laryngeal Neoplasms	23104547			C32.3	D007822			Downregulation of miR-21 regulates MMP-2 expression and suppress migration of Laryngeal squamous cell carcinoma
target gene	hsa-mir-210	Laryngeal Neoplasms	25639884			C32.3	D007822			our findings reveal a new mechanism of adaptation to hypoxia that miR-210 inhibits the proliferation via inducing cell cycle arrest and apoptosis by the targeting of FGFRL1.
target gene	hsa-mir-24-1	Laryngeal Neoplasms	22139384			C32.3	D007822			miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 protein.
target gene	hsa-mir-24-2	Laryngeal Neoplasms	22139384			C32.3	D007822			miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 protein.
target gene	hsa-mir-34a	Laryngeal Neoplasms	22246523			C32.3	D007822			MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin.
target gene	hsa-mir-34c	Laryngeal Neoplasms	29435079			C32.3	D007822			miR-34c may be involved in the pathogenesis of laryngeal cancer, and BCL2 may be negatively regulated by miR-34c in M4e cell
target gene	hsa-mir-206	Legg-Calve-Perthes Disease	29387248	musculoskeletal system disease	DOID:14415	M91.2	D007873	150600		Downregulated SOX9 mediated by miR-206 promoted cell apoptosis in Legg-Calvé-Perthes disease.
target gene	hsa-let-7c	Leiomyoma	17243163	disease of cellular proliferation	DOID:127	D25	D007889	150699		HMGA2 was identified as one of target genes of the let-7 family of miRNAs and has been found to be suppressed by let-7 in vitro.
target gene	hsa-let-7c	Leiomyoma	18403645	disease of cellular proliferation	DOID:127	D25	D007889	150699		Our findings suggest that the Let-7-mediated repression of HMGA2 mechanism can be an important molecular event in leiomyoma growth.
target gene	hsa-mir-106b	Leiomyoma	22556343	disease of cellular proliferation	DOID:127	D25	D007889	150699		miR-93/106b and Their Host Gene, MCM7, Are Differentially Expressed in Leiomyomas and Functionally Target F3 and IL-8.
target gene	hsa-mir-200a	Leiomyoma	22685266	disease of cellular proliferation	DOID:127	D25	D007889	150699		miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.
target gene	hsa-mir-200c	Leiomyoma	22685266	disease of cellular proliferation	DOID:127	D25	D007889	150699		miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.
target gene	hsa-mir-200c	Leiomyoma	24755559	disease of cellular proliferation	DOID:127	D25	D007889	150699		miR-200c regulates IL8 expression by targeting IKBKB: a potential mediator of inflammation in leiomyoma pathogenesis.
target gene	hsa-mir-93	Leiomyoma	22556343	disease of cellular proliferation	DOID:127	D25	D007889	150699		miR-93/106b and Their Host Gene, MCM7, Are Differentially Expressed in Leiomyomas and Functionally Target F3 and IL-8.
target gene	hsa-mir-126	Leishmaniasis	26941729	disease by infectious agent	DOID:9065	B55	D007896	602068		Development of Th2 type specific immune response can be suppressed by binding of miR-135 and miR-126 miRNAs over the 3'-UTR region of GATA-3 transcription factor of Th2 specific CD4(+) T helper cells.
target gene	hsa-mir-21	Leprosy	22286305	disease by infectious agent	DOID:1024	A30.9	D007918	609888		MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy
target gene	hsa-mir-107	Leukemia	20884628			C95	D007938	613065	HP:0001909	Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. 
target gene	hsa-mir-122	Leukemia	23791922			C95	D007938	613065	HP:0001909	Hydroquinone-induced miR-122 down-regulation elicits ADAM17 up regulation,leading to increased soluble TNF-α production in human leukemia cells with expressed Bcr/Abl.
target gene	hsa-mir-125a	Leukemia	25961914			C95	D007938	613065	HP:0001909	microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR.
target gene	hsa-mir-125a	Leukemia	26713860			C95	D007938	613065	HP:0001909	miR-125a suppressed Zbtb7a expression through its direct binding to the Zbtb7a-3'UTR.
target gene	hsa-mir-125b	Leukemia	28389358			C95	D007938	613065	HP:0001909	MicroRNA-125b inhibits AML cells differentiation by directly targeting Fes.
target gene	hsa-mir-125b-1	Leukemia	22366319			C95	D007938	613065	HP:0001909	Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A.
target gene	hsa-mir-125b-2	Leukemia	22366319			C95	D007938	613065	HP:0001909	Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A.
target gene	hsa-mir-138	Leukemia	28153721			C95	D007938	613065	HP:0001909	MiR-138 indirectly regulates the MDR1 promoter by NF-κB/p65 silencing.
target gene	hsa-mir-139	Leukemia	27605510			C95	D007938	613065	HP:0001909	MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis.
target gene	hsa-mir-143	Leukemia	21518477			C95	D007938	613065	HP:0001909	the expression of miR-143 was negatively correlated with the expression of DNMT3A mRNA, a known target gene of miR-143.
target gene	hsa-mir-144	Leukemia	26078353			C95	D007938	613065	HP:0001909	The long noncoding RNA TUG1 regulates blood-tumor barrier permeability by targeting miR-144.
target gene	hsa-mir-15	Leukemia	20884628			C95	D007938	613065	HP:0001909	Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. 
target gene	hsa-mir-150	Leukemia	23604034			C95	D007938	613065	HP:0001909	In conclusion, we demonstrate that miR-150 is a potent leukemic tumor suppressor that regulates multiple oncogenes.
target gene	hsa-mir-15a	Leukemia	18818396			C95	D007938	613065	HP:0001909	Using a luciferase reporter assay, we found that miR-15a directly binds the 3'-UTR of c-myb mRNA. By transfecting K562 myeloid leukemia cells with a miR-15a mimic, functionality of binding was shown.
target gene	hsa-mir-15a	Leukemia	20068100			C95	D007938	613065	HP:0001909	Compared with M non-IGHV3-23 CLL, the gene expression profile of M IGHV3-23 CLL was deprived in genes, including the growth/tumor suppressor genes PDCD4, TIA1, and RASSF5, whose downregulation is under control of miR-15a and miR-16-1.
target gene	hsa-mir-15a	Leukemia	22856663			C95	D007938	613065	HP:0001909	we review the main achievements made on targeting of prosurvival Bcl-2 proteins through the use of different approaches, i.e. anti-sense methodology, small molecules that mimic the action of BH3 domain and microRNAs (mainly miRNA-15a and miRNA-16-1).
target gene	hsa-mir-15a	Leukemia	23551855			C95	D007938	613065	HP:0001909	miR-15a/16-1 is known to regulate Bcl2 in chronic lymphocytic leukemia
target gene	hsa-mir-16	Leukemia	20884628			C95	D007938	613065	HP:0001909	Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. 
target gene	hsa-mir-16-1	Leukemia	20068100			C95	D007938	613065	HP:0001909	Compared with M non-IGHV3-23 CLL, the gene expression profile of M IGHV3-23 CLL was deprived in genes, including the growth/tumor suppressor genes PDCD4, TIA1, and RASSF5, whose downregulation is under control of miR-15a and miR-16-1.
target gene	hsa-mir-16-1	Leukemia	23551855			C95	D007938	613065	HP:0001909	miR-15a/16-1 is known to regulate Bcl2 in chronic lymphocytic leukemia
target gene	hsa-mir-17	Leukemia	20406979			C95	D007938	613065	HP:0001909	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
target gene	hsa-mir-17	Leukemia	25732734			C95	D007938	613065	HP:0001909	WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.
target gene	hsa-mir-17	Leukemia	23056458			C95	D007938	613065	HP:0001909	we demonstrated that physiological re-expression of exogenous miR-17 and miR-20a are able to partially rescue the proliferation loss induced by Fli-1 knock-down and identified HBP1 as a target of these miRNA in erythroleukemic cells.
target gene	hsa-mir-18	Leukemia	25732734			C95	D007938	613065	HP:0001909	WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.
target gene	hsa-mir-181a-2	Leukemia	22285729			C95	D007938	613065	HP:0001909	miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.
target gene	hsa-mir-183	Leukemia	27307158			C95	D007938	613065	HP:0001909	FOXP3-induced miR-183 expression reduced 尾-TrCP mRNA stability and suppressed 尾-TrCP-mediated Sp1 degradation
target gene	hsa-mir-18a	Leukemia	20406979			C95	D007938	613065	HP:0001909	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
target gene	hsa-mir-18a	Leukemia	26314433			C95	D007938	613065	HP:0001909	The miR-18a can regulated the sensitivity of leukemia HL-60 cells to VP-16 and VCR by targeting ATM.
target gene	hsa-mir-195	Leukemia	20884628			C95	D007938	613065	HP:0001909	Recent findings indicate that GRN is regulated strongly by the microRNA miR-107, which functionally overlaps with miR-15, miR-16, and miR-195 due to a common 5' sequence critical for target specificity. 
target gene	hsa-mir-196b	Leukemia	22353710			C95	D007938	613065	HP:0001909	miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
target gene	hsa-mir-196b	Leukemia	28000876			C95	D007938	613065	HP:0001909	miR-196b/miR-1290 participate in the antitumor effect of resveratrol via regulation of IGFBP3 expression in acute lymphoblastic leukemia.
target gene	hsa-mir-19a	Leukemia	25732734			C95	D007938	613065	HP:0001909	WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.
target gene	hsa-mir-19a	Leukemia	20406979			C95	D007938	613065	HP:0001909	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
target gene	hsa-mir-19b-1	Leukemia	25732734			C95	D007938	613065	HP:0001909	WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.
target gene	hsa-mir-19b-1	Leukemia	20406979			C95	D007938	613065	HP:0001909	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
target gene	hsa-mir-19b-2	Leukemia	20406979			C95	D007938	613065	HP:0001909	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
target gene	hsa-mir-20a	Leukemia	25732734			C95	D007938	613065	HP:0001909	WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.
target gene	hsa-mir-20a	Leukemia	20406979			C95	D007938	613065	HP:0001909	The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
target gene	hsa-mir-20a	Leukemia	18596985			C95	D007938	613065	HP:0001909	Here we report, for the first time, that LRF is post-transcriptionally regulated by miR-20a. Using a gene reporter assay, direct interaction of miR-20a with the LRF 3'UTR is demonstrated.
target gene	hsa-mir-20a	Leukemia	23056458			C95	D007938	613065	HP:0001909	we demonstrated that physiological re-expression of exogenous miR-17 and miR-20a are able to partially rescue the proliferation loss induced by Fli-1 knock-down and identified HBP1 as a target of these miRNA in erythroleukemic cells.
target gene	hsa-mir-21	Leukemia	21187093			C95	D007938	613065	HP:0001909	Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line.
target gene	hsa-mir-21	Leukemia	23834154			C95	D007938	613065	HP:0001909	Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells.
target gene	hsa-mir-21	Leukemia	27644439			C95	D007938	613065	HP:0001909	Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs.
target gene	hsa-mir-21	Leukemia	28947822			C95	D007938	613065	HP:0001909	Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.
target gene	hsa-mir-223	Leukemia	19017354			C95	D007938	613065	HP:0001909	Thus,our results suggest that miR-223 reversibly regulates erythroid and megakaryocytic differentiation of K562 cells via down-modulation of LMO2.
target gene	hsa-mir-2278	Leukemia	25953263			C95	D007938	613065	HP:0001909	Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted hsa-miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
target gene	hsa-mir-27b	Leukemia	24974217			C95	D007938	613065	HP:0001909	Ionizing radiation-inducible miR-27b suppresses leukemia proliferation via targeting cyclin A2.
target gene	hsa-mir-31	Leukemia	22264793			C95	D007938	613065	HP:0001909	Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kB pathway in adult T cell leukemia and other cancers.
target gene	hsa-mir-3151	Leukemia	24736457			C95	D007938	613065	HP:0001909	Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.
target gene	hsa-mir-34a	Leukemia	25788289			C95	D007938	613065	HP:0001909	MiR-34a regulates blood-tumor barrier function by targeting protein kinase Cε.
target gene	hsa-mir-34a	Leukemia	21367750			C95	D007938	613065	HP:0001909	miR-34a induces the down-regulation of both E2F1 and B-Myb oncogenes in leukemic cells.
target gene	hsa-mir-34c	Leukemia	25201524			C95	D007938	613065	HP:0001909	miR-34c regulates the permeability of blood-tumor barrier via MAZ-mediated expression changes of ZO-1, occludin, and claudin-5.
target gene	hsa-mir-424	Leukemia	23801117			C95	D007938	613065	HP:0001909	MiR-424 regulates monocytic differentiation of human leukemia U937 cells by directly targeting CDX2.
target gene	hsa-mir-485	Leukemia	21252292			C95	D007938	613065	HP:0001909	Novel regulation of NF-YB by miR-485-3p affects expression of DNA topoisomerase II{alpha} and drug responsiveness in human lymphoblastic leukemia CEM cells.
target gene	hsa-mir-486	Leukemia	28043832			C95	D007938	613065	HP:0001909	Exosomal miR-486 regulates hypoxia-induced erythroid differentiation of erythroleukemia cells through targeting Sirt1.
target gene	hsa-mir-92-1	Leukemia	25732734			C95	D007938	613065	HP:0001909	WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.
target gene	hsa-mir-125b-1	Leukemia, B-Cell	22139839			C91.31	D015448	151430		MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells.
target gene	hsa-mir-125b-2	Leukemia, B-Cell	22139839			C91.31	D015448	151430		MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells.
target gene	hsa-mir-155	Leukemia, B-Cell	22139839			C91.31	D015448	151430		MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells.
target gene	hsa-mir-193b	Leukemia, Lymphoblastic	25231743	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.
target gene	hsa-mir-100	Leukemia, Lymphoblastic, Acute	24030073	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	MiR-100 and miR-99a have critical roles in altering cellular processes by targeting both the FKBP51 and IGF1R/mTOR signalling pathways in vitro and might represent a potential novel strategy for ALL treatment.
target gene	hsa-mir-101	Leukemia, Lymphoblastic, Acute	22677230	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	We also found that p23 was regulated by hsa-miR-101 which was down-regulated in childhood ALL cases.
target gene	hsa-mir-124	Leukemia, Lymphoblastic, Acute	28578002	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor.
target gene	hsa-mir-1290	Leukemia, Lymphoblastic, Acute	28000876	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	miR-196b/miR-1290 participate in the antitumor effect of resveratrol via regulation of IGFBP3 expression in acute lymphoblastic leukemia.
target gene	hsa-mir-142	Leukemia, Lymphoblastic, Acute	24057258	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene.
target gene	hsa-mir-181a	Leukemia, Lymphoblastic, Acute	26580398	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	ectopic expression of miR-181a also resulted in decreased CD10 hyperexpression in ETV6/RUNX1+ primary patient samples.
target gene	hsa-mir-181a	Leukemia, Lymphoblastic, Acute	28732737	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	MicroRNA-181a and its target Smad 7 as potential biomarkers for tracking child acute lymphoblastic leukemia
target gene	hsa-mir-196b	Leukemia, Lymphoblastic, Acute	20924650	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Results of the present study revealed that miR-196b becomes non-functional in T-cell ALL as a consequence of mutations in 3'-UTR of c-myc gene in T-cell ALL cellular models.
target gene	hsa-mir-2909	Leukemia, Lymphoblastic, Acute	25037230	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	This study identified a novel miR-2909-KLF4 molecular axis able to differentiate between the pathogeneses of pediatric B- and T-cell ALLs, and which may represent a new diagnostic/prognostic marker.
target gene	hsa-mir-339	Leukemia, Lymphoblastic, Acute	29735550	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes.
target gene	hsa-mir-520h	Leukemia, Lymphoblastic, Acute	29768346	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Additionally, POLD1 and MCM2 were found to be regulated by miR-520H via E2F1
target gene	hsa-mir-664	Leukemia, Lymphoblastic, Acute	25735976	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	miR-664 negatively regulates PLP2 and promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia.
target gene	hsa-mir-708	Leukemia, Lymphoblastic, Acute	23970374	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The expression level of miR-708 reflects differences among the clinical types of common-ALL, and CNTFR, NNAT, and GNG12 were identified as targets of miR-708.
target gene	hsa-mir-99a	Leukemia, Lymphoblastic, Acute	24030073	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	MiR-100 and miR-99a have critical roles in altering cellular processes by targeting both the FKBP51 and IGF1R/mTOR signalling pathways in vitro and might represent a potential novel strategy for ALL treatment.
target gene	hsa-mir-15a	Leukemia, Lymphoblastic, Acute, B-Cell	28101583	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	we proposed a cellular model to discuss MYC/miR-15a-5p/FLT3 feed-forward loop (FFL) with Jak-STAT signaling pathway in B-ALL
target gene	hsa-mir-101	Leukemia, Lymphoblastic, Acute, T-Cell	27666896	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1.
target gene	hsa-mir-128	Leukemia, Lymphoblastic, Acute, T-Cell	24895337	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia.
target gene	hsa-mir-223	Leukemia, Lymphoblastic, Acute, T-Cell	23857984	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
target gene	hsa-mir-106b	Leukemia, Lymphocytic, Chronic, B-Cell	19096009	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-106b: Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase, Itch for degradation
target gene	hsa-mir-130a	Leukemia, Lymphocytic, Chronic, B-Cell	22350415	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MicroRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells.
target gene	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	24787006	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.
target gene	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
target gene	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	22133358	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level.
target gene	hsa-mir-15b	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
target gene	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
target gene	hsa-mir-16-2	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
target gene	hsa-mir-17	Leukemia, Lymphocytic, Chronic, B-Cell	22343732	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
target gene	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	22610076	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
target gene	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	22610076	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
target gene	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	22610076	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
target gene	hsa-mir-18a	Leukemia, Lymphocytic, Chronic, B-Cell	22343732	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
target gene	hsa-mir-195	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
target gene	hsa-mir-19a	Leukemia, Lymphocytic, Chronic, B-Cell	22343732	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
target gene	hsa-mir-19b-1	Leukemia, Lymphocytic, Chronic, B-Cell	22343732	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
target gene	hsa-mir-20a	Leukemia, Lymphocytic, Chronic, B-Cell	22343732	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
target gene	hsa-mir-21	Leukemia, Lymphocytic, Chronic, B-Cell	25909590	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia.
target gene	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	24217154	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.
target gene	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	21565980	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
target gene	hsa-mir-34b	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
target gene	hsa-mir-34c	Leukemia, Lymphocytic, Chronic, B-Cell	21205967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
target gene	hsa-mir-3676	Leukemia, Lymphocytic, Chronic, B-Cell	25646413	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
target gene	hsa-mir-92a-1	Leukemia, Lymphocytic, Chronic, B-Cell	19336759	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-92-1: overexpressed, can target the VHL transcript
target gene	hsa-mir-92a-1	Leukemia, Lymphocytic, Chronic, B-Cell	22343732	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
target gene	hsa-mir-138	Leukemia, Lymphocytic, Chronic, B-Cell	25670628	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	2 new target genes, namely acyl protein thioesterase (APT) 1 and 2, which are under control of both miRs and thereby significantly overexpressed in CLL cells.
target gene	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	22797699	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	In the present study, we show that an 8-mer locked nucleic acid anti-miR-155 oligonucleotide targeting the seed region of miR-155 inhibits WM and chronic lymphocytic leukemia cell proliferation in vitro.
target gene	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	29658610	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia
target gene	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	19498445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A. Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma.
target gene	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	19498445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a and miR-16-1 function by targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A. Down-regulation of these miRNAs has been reported in chronic lymphocytic lymphoma (CLL), pituitary adenomas, and prostate carcinoma.
target gene	hsa-mir-17	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-18	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-181	Leukemia, Lymphocytic, Chronic, B-Cell	20357824	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	We recently reported that levels of TCL1 expression in B-CLL are regulated by miR-29 and miR-181 that target 3' UTR of TCL1.
target gene	hsa-mir-181	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-19a	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-19b-1	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-20a	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-21	Leukemia, Lymphocytic, Chronic, B-Cell	29658610	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia
target gene	hsa-mir-29	Leukemia, Lymphocytic, Chronic, B-Cell	20357824	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	We recently reported that levels of TCL1 expression in B-CLL are regulated by miR-29 and miR-181 that target 3' UTR of TCL1.
target gene	hsa-mir-29	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-34b	Leukemia, Lymphocytic, Chronic, B-Cell	19536169	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia
target gene	hsa-mir-34c	Leukemia, Lymphocytic, Chronic, B-Cell	19536169	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia
target gene	hsa-mir-92-1	Leukemia, Lymphocytic, Chronic, B-Cell	23597135	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Here we review studies that provide evidence suggesting that certain miRNAs (e.g. miR-155, miR-17-92, miR-181, miR-29) can regulate the activated phenotype of CLL cells and/or fitness of the surface-immunoglobulin (sIg) B cell receptor (BCR) complex expressed by CLL cells, thereby accounting for the differential leukemia-cell expression of these miRNAs in different CLL prognostic subgroups.
target gene	hsa-mir-126	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	25015105			C92.1	D015464			Our results show that the miR-126 shuttled by exosomes is biologically active in the target cells, and support the hypothesis that exosomal miRNAs have an important role in tumor-endothelial crosstalk occurring in the bone marrow microenvironment, potentially affecting disease progression.
target gene	hsa-mir-181a	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	28103766			C92.1	D015464			inhibition of miR-181a using a microRNA sponge inhibitor resulted in decreased transcription of SOX2 and SALL4
target gene	hsa-mir-17	Leukemia, Myeloid	23059786	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation
target gene	hsa-mir-20a	Leukemia, Myeloid	23059786	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	HIF-1a downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation
target gene	hsa-mir-100	Leukemia, Myeloid, Acute	21643017	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia.
target gene	hsa-mir-125a	Leukemia, Myeloid, Acute	24484870	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia.
target gene	hsa-mir-127	Leukemia, Myeloid, Acute	29402726	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers
target gene	hsa-mir-128	Leukemia, Myeloid, Acute	23022987	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195.
target gene	hsa-mir-146a	Leukemia, Myeloid, Acute	22829170	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-146a and AMD3100, acting through different mechanism, downmodulate CXCR4 protein levels, impair leukemic cell proliferation and then may be used in combination with anti-leukemia drugs, for development of new therapeutic strategies.
target gene	hsa-mir-149	Leukemia, Myeloid, Acute	28013316	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Inhibition of MicroRNA-149-5p Induces Apoptosis of Acute Myeloid Leukemia Cell Line THP-1 by Targeting Fas Ligand (FASLG).
target gene	hsa-mir-150	Leukemia, Myeloid, Acute	27601730	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB.
target gene	hsa-mir-155	Leukemia, Myeloid, Acute	25092144	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
target gene	hsa-mir-155	Leukemia, Myeloid, Acute	25175984	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	SHIP1 is targeted by miR-155 in acute myeloid leukemia.
target gene	hsa-mir-155	Leukemia, Myeloid, Acute	25971362	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
target gene	hsa-mir-155	Leukemia, Myeloid, Acute	27786352	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Targeting miR-155 suppresses proliferation and induces apoptosis of HL-60 cells by targeting Slug/PUMA signal.
target gene	hsa-mir-155	Leukemia, Myeloid, Acute	27601730	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB.
target gene	hsa-mir-155	Leukemia, Myeloid, Acute	27530922	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	our evidence show that IRF3 overexpression in AML promotes cell growth and survival, and miR-155 is involved, indicating that IRF3  may be a potential new biomarker and therapeutic target for AML.
target gene	hsa-mir-15a	Leukemia, Myeloid, Acute	22133358	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level.
target gene	hsa-mir-15a	Leukemia, Myeloid, Acute	23022987	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195.
target gene	hsa-mir-16	Leukemia, Myeloid, Acute	22970245	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	our data demonstrated that over-expression of miR-16 mimics suppressed Pim-1 expression in FD-FLT3/ITD cells suggesting that increased miR-16 expression contributes to depletion of Pim-1 after FLT3 inhibition and that miR-16 repression may be associated with up-regulated Pim-1 in FLT3/ITD expressing cells.
target gene	hsa-mir-17	Leukemia, Myeloid, Acute	20406979	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-17:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
target gene	hsa-mir-17	Leukemia, Myeloid, Acute	23872792	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	 Hoxb8 appears to promote miR-17∼92 expression through c-Myc, a known transcriptional regulator of the miR-17∼92 cluster.
target gene	hsa-mir-181a-2	Leukemia, Myeloid, Acute	23100311	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia
target gene	hsa-mir-181b	Leukemia, Myeloid, Acute	24756163	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
target gene	hsa-mir-18a	Leukemia, Myeloid, Acute	20406979	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-18a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
target gene	hsa-mir-193b	Leukemia, Myeloid, Acute	21724256	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia.
target gene	hsa-mir-195	Leukemia, Myeloid, Acute	23022987	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195.
target gene	hsa-mir-199b	Leukemia, Myeloid, Acute	22374871	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia.
target gene	hsa-mir-19a	Leukemia, Myeloid, Acute	20406979	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-19a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
target gene	hsa-mir-19b-1	Leukemia, Myeloid, Acute	20406979	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-19b:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
target gene	hsa-mir-19b-2	Leukemia, Myeloid, Acute	20406979	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-19b:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
target gene	hsa-mir-20a	Leukemia, Myeloid, Acute	20406979	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-20a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
target gene	hsa-mir-21	Leukemia, Myeloid, Acute	29100302	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells.
target gene	hsa-mir-21	Leukemia, Myeloid, Acute	29402726	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers
target gene	hsa-mir-218	Leukemia, Myeloid, Acute	23022987	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195.
target gene	hsa-mir-23a	Leukemia, Myeloid, Acute	27197200	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	overexpression of miR-23a decreased RKIP mRNA and protein expression
target gene	hsa-mir-26a-1	Leukemia, Myeloid, Acute	23096114	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells
target gene	hsa-mir-26a-2	Leukemia, Myeloid, Acute	23096114	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells
target gene	hsa-mir-27a	Leukemia, Myeloid, Acute	23236401	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MiR-27a Functions as a Tumor Suppressor in Acute Leukemia by Regulating 14-3-3
target gene	hsa-mir-27a	Leukemia, Myeloid, Acute	27013583	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Overexpression of miR-424&27a,  by targeting the 3'UTR of PLAG1, enhanced TRAIL sensitivity in AML cells.
target gene	hsa-mir-27b	Leukemia, Myeloid, Acute	23022987	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	A Renilla-luciferase assay and flow cytometry after transfection with pre-microRNAs confirmed that RET is regulated by miR-218, miR-128, miR-27b, miR-15a and miR-195.
target gene	hsa-mir-29a	Leukemia, Myeloid, Acute	20212066	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our data indicate that miR-29a regulates early hematopoiesis and suggest that miR-29a initiates AML by converting myeloid progenitors into self-renewing LSC.
target gene	hsa-mir-29b-1	Leukemia, Myeloid, Acute	23493348	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
target gene	hsa-mir-29b-2	Leukemia, Myeloid, Acute	23493348	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
target gene	hsa-mir-3151	Leukemia, Myeloid, Acute	22529287	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
target gene	hsa-mir-330	Leukemia, Myeloid, Acute	27341144	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-330-5p is able to strongly silence TIM-3 expression (98.15% silencing) in HL-60 cell line (p = 0.0001).
target gene	hsa-mir-34a	Leukemia, Myeloid, Acute	28478444	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MiR-34a Promotes Apoptosis and Inhibits Autophagy by Targeting HMGB1 in Acute Myeloid Leukemia Cells.
target gene	hsa-mir-34b	Leukemia, Myeloid, Acute	19258499	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-34b: miR-34b targets cyclic AMP-responsive element binding protein
target gene	hsa-mir-370	Leukemia, Myeloid, Acute	22900969	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia.
target gene	hsa-mir-451	Leukemia, Myeloid, Acute	27764807	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia.
target gene	hsa-mir-494	Leukemia, Myeloid, Acute	29402726	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers
target gene	hsa-mir-519	Leukemia, Myeloid, Acute	26499919	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The results of the present study indicate that miR-519 may contribute to HL60 cell apoptosis by regulating the expression of HuR.
target gene	hsa-mir-616	Leukemia, Myeloid, Acute	29402726	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	mRNA and miRNA integrative analyses showed aberrant expression of several hub oncogenes appear to be regulated by some miRNAs like miR-127-5p, miR-494, miR-21 and miR-616 in high TET1 expressers
target gene	hsa-mir-92a	Leukemia, Myeloid, Acute	28059050	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-92a Inhibits Proliferation and Induces Apoptosis by Regulating Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) Expression in Acute Myeloid Leukemia.
target gene	hsa-mir-92a-1	Leukemia, Myeloid, Acute	20406979	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-92a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
target gene	hsa-mir-92a-2	Leukemia, Myeloid, Acute	20406979	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-92a:The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression
target gene	hsa-mir-183	Leukemia, Myeloid, Acute, Pediatric	27738758			C92.0				MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia.
target gene	hsa-mir-502	Leukemia, Myeloid, Acute, Pediatric	25048968			C92.0				Association of functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report.
target gene	hsa-mir-138	Leukemia, Myeloid, Chronic	26967056	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miR-138 in BCR-ABL tyrosine kinase
target gene	hsa-mir-17	Leukemia, Myeloid, Chronic	26967056	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	and miR-17, miR-19a, miR-17-92 cluster with  MAPK/ERK proteins.
target gene	hsa-mir-181a	Leukemia, Myeloid, Chronic	26967056	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miR-155, miR-181a with SOS proteins;
target gene	hsa-mir-196b	Leukemia, Myeloid, Chronic	23894305	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.
target gene	hsa-mir-19a	Leukemia, Myeloid, Chronic	26967056	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miR-155, miR-19a, with KRAS proteins; miR-19a with RAF1 protein;
target gene	hsa-mir-19b	Leukemia, Myeloid, Chronic	28461114	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miR-17-92 promotes leukemogenesis in chronic myeloid leukemia via targeting A20 and activation of NF-κB signaling.
target gene	hsa-mir-212	Leukemia, Myeloid, Chronic	22241070	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	ABCG2 protein was 7.2-fold elevated after long-term treatment with imatinib and decreased gradually at higher concentrations. miRNAs miR-212 and miR-328 were identified to correlate inversely with ABCG2 expression under these conditions.
target gene	hsa-mir-22	Leukemia, Myeloid, Chronic	27889568	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	FosB regulates expression of miR-22 during PMA induced differentiation of K562 cells to megakaryocytes.
target gene	hsa-mir-23a	Leukemia, Myeloid, Chronic	25213664	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
target gene	hsa-mir-320a	Leukemia, Myeloid, Chronic	26228085	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia.
target gene	hsa-mir-328	Leukemia, Myeloid, Chronic	22241070	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	ABCG2 protein was 7.2-fold elevated after long-term treatment with imatinib and decreased gradually at higher concentrations. miRNAs miR-212 and miR-328 were identified to correlate inversely with ABCG2 expression under these conditions.
target gene	hsa-mir-34a	Leukemia, Myeloid, Chronic	28157629	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The epigenetically-regulated miR-34a targeting c-SRC suppresses RAF/MEK/ERK signaling pathway in K-562 cells.
target gene	hsa-mir-4701	Leukemia, Myeloid, Chronic	27088512	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miR-4701-5p directly targeted ST3GAL1 to reduce CML cells resistance to multiple chemotherapeutics in vitro and to convert tumor cells from adriamycin resistant to susceptible in vivo of mice.
target gene	hsa-mir-486	Leukemia, Myeloid, Chronic	25515961	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miR-486-5p in regulating normal hematopoiesis and of BCR-ABL-induced miR-486-5p overexpression in modulating CML progenitor growth, survival, and drug sensitivity.
target gene	hsa-mir-9	Leukemia, Myeloid, Chronic	28260112	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.
target gene	hsa-mir-29a	Leukemia, Myeloid, Chronic-Phase	23113544			C92.1	D015466			Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia
target gene	hsa-mir-29b-1	Leukemia, Myeloid, Chronic-Phase	23113544			C92.1	D015466			Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia
target gene	hsa-mir-29b-2	Leukemia, Myeloid, Chronic-Phase	23113544			C92.1	D015466			Regulation of Human RNase-L by the miR-29 Family Reveals a Novel Oncogenic Role in Chronic Myelogenous Leukemia
target gene	hsa-mir-30a	Leukemia, Myeloid, Chronic-Phase	22395361			C92.1	D015466			Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.
target gene	hsa-mir-126	Leukemia, Promyelocytic, Acute	26274316	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	These results demonstrate that ATO inhibits the growth of HUVECs and induces apoptosis by downregulating VEGFA. One mechanism by which this occurs is Ets-2 upregulation, which results in an increase in miR-126 levels and downregulation of VEGFA expression.
target gene	hsa-mir-182	Leukemia, Promyelocytic, Acute	28298075	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression.
target gene	hsa-mir-18b	Leukemia, Promyelocytic, Acute	26041820	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
target gene	hsa-mir-92a	Leukemia, Promyelocytic, Acute	24481878	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression.
target gene	hsa-mir-181	Leukemia, T-Cell	27889686	disease of cellular proliferation	DOID:715	C91.5	D015458			MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
target gene	hsa-mir-142	Leukemia-Lymphoma, Adult T-Cell	21979877			C91.51	D015459		HP:0005517	miR-142-3p plans an oncogenic role in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-ж┿and cAMP/PKA pathways.
target gene	hsa-mir-150	Leukemia-Lymphoma, Adult T-Cell	26025667			C91.51	D015459		HP:0005517	STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of  HTLV-I-Transformed and ATL Cells.
target gene	hsa-mir-19a	Leukemia-Lymphoma, Adult T-Cell	22362744			C91.51	D015459		HP:0005517	miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia.
target gene	hsa-mir-19b-1	Leukemia-Lymphoma, Adult T-Cell	22362744			C91.51	D015459		HP:0005517	miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia.
target gene	hsa-mir-19b-2	Leukemia-Lymphoma, Adult T-Cell	22362744			C91.51	D015459		HP:0005517	miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia.
target gene	hsa-mir-223	Leukemia-Lymphoma, Adult T-Cell	26025667			C91.51	D015459		HP:0005517	STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of  HTLV-I-Transformed and ATL Cells.
target gene	hsa-mir-125b-1	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22469780	disease of cellular proliferation	DOID:5599	C83.5	D054218			B-cell regulator of immunoglobulin heavy chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells.
target gene	hsa-mir-125b-2	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22469780	disease of cellular proliferation	DOID:5599	C83.5	D054218			B-cell regulator of immunoglobulin heavy chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells.
target gene	hsa-mir-155	Lichen Planus	29813046	integumentary system disease	DOID:9201	L43	D008010	151620		MicroRNA Microarray-Based Identification of Involvement of miR-155 and miR-19a in Development of Oral Lichen Planus (OLP) by Modulating Th1/Th2 Balance via Targeting eNOS and Toll-Like Receptor 2 (TLR2).
target gene	hsa-mir-19a	Lichen Planus	29813046	integumentary system disease	DOID:9201	L43	D008010	151620		MicroRNA Microarray-Based Identification of Involvement of miR-155 and miR-19a in Development of Oral Lichen Planus (OLP) by Modulating Th1/Th2 Balance via Targeting eNOS and Toll-Like Receptor 2 (TLR2).
target gene	hsa-mir-155	Liposarcoma	22350414	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	MiR-155 is a liposarcoma oncogene that targets casein kinase-1ж┿and enhances ж┿catenin signaling.
target gene	hsa-mir-122	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-125b	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-126	Liver Cirrhosis	25974152	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Further, miR-126 promoted TNF-a-induced TGF-β1 and collagen I mRNA expression in  LX-2 cells. miR-126 may play an important role in hepatic fibrosis by downregulating the expression of IκBα partly through the NF-κB signaling pathway.
target gene	hsa-mir-1273g	Liver Cirrhosis	27423040	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Overexpression of miR-1273g-3p could inhibit translation of PTEN, increase the expression of 伪-SMA, Col1A1, and reduce apoptosis in HSCs.
target gene	hsa-mir-133a-1	Liver Cirrhosis	23183523	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-133a mediates TGF-beta-dependent de-repression of collagen-synthesis in hepatic stellate cells during liver fibrosis
target gene	hsa-mir-133a-2	Liver Cirrhosis	23183523	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-133a mediates TGF-beta-dependent de-repression of collagen-synthesis in hepatic stellate cells during liver fibrosis
target gene	hsa-mir-155	Liver Cirrhosis	24058572	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	The strong association between certain miRNAs, notably miR-155, and lower hepatic CYP3A activity suggest that altered miRNA expression may regulate hepatic CYP3A activity.
target gene	hsa-mir-181a-2	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-181b-1	Liver Cirrhosis	22446332	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-181b Promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients.
target gene	hsa-mir-181b-2	Liver Cirrhosis	22446332	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-181b Promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients.
target gene	hsa-mir-194	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-195	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-199a	Liver Cirrhosis	27662798	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p.
target gene	hsa-mir-200a	Liver Cirrhosis	25049078	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	By using miRNA mimic, we observed miRNA-200a silencing in activated hepatic stellate cell and demonstrated that upon re-expression, miRNA-200a targets the Keap1, and leading to Keap1 mRNA  degradation.
target gene	hsa-mir-21	Liver Cirrhosis	25303175	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-21 modulates ERK1 signaling and EMT in liver fibrosis by regulating SPRY2 and HNF4α expression. MiR-21 may serve as a potentially biomarker as well as intervention target for hepatic cirrhosis.
target gene	hsa-mir-21	Liver Cirrhosis	24196965	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR 21/PDCD4/AP-1) as a driving force for hepatic fibrosis development.
target gene	hsa-mir-21	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-21	Liver Cirrhosis	23417858	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis
target gene	hsa-mir-21	Liver Cirrhosis	29250171	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	The miRNA-target regulatory network may provide additional insight into the current data regarding the role of miRNAs in liver cirrhosis
target gene	hsa-mir-217	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-221	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-224	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-23a	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-34a	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-378a	Liver Cirrhosis	27832641	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Activation of Hepatic Stellate Cells is Inhibited by microRNA-378a-3p via Wnt10a.
target gene	hsa-mir-506	Liver Cirrhosis	22383162	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Upregulation of mir-506 leads to decreased AE2 expression in biliary epithelium of patients with primary biliary cirrhosis
target gene	hsa-mir-9	Liver Cirrhosis	28098912	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1.
target gene	hsa-mir-96	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-99a	Liver Cirrhosis	24033414	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Samples at recurrence of HCV and after antiviral therapy revealed distinct HCV-related miR expression profiles, with significant dysregulation of those miRNAs potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might be involved in the regulation of HCV receptor proteins'expression during HCV infection and antiviral therapy.
target gene	hsa-mir-122	Liver Diseases [unspecific]	25537773			K76.9	D008107			Development of novel technologies for targeted delivery of miR-122 to tumor cells and for direct monitoring of miR-122 in biological fluids is urgently needed for translating the basic research to the bedside. This review focuses on  miR-122, the most abundant hepatic miRNA, in the context of liver health and diseases.
target gene	hsa-mir-125b	Liver Diseases [unspecific]	25968989			K76.9	D008107			Our data suggest a mechanism for the marked changes in hepatic gene expression between the fetal and pediatric developmental periods, and support a role for these age-dependent miRNAs in regulating drug disposition.
target gene	hsa-mir-185	Liver Diseases [unspecific]	25548489			K76.9	D008107			miR-185 plays an important role in regulating fatty-acid metabolism and cholesterol homeostasis in hepatocytes, as well as in improving insulin sensitivity, both in vitro and in vivo.
target gene	hsa-mir-34a	Liver Diseases [unspecific]	25968989			K76.9	D008107			Our data suggest a mechanism for the marked changes in hepatic gene expression between the fetal and pediatric developmental periods, and support a role for these age-dependent miRNAs in regulating drug disposition.
target gene	hsa-mir-34a	Liver Diseases [unspecific]	26100857			K76.9	D008107			miR-34a-HNF4α pathway is activated under common conditions of metabolic stress and may have a role in the pathogenesis of Non-alcoholic fatty liver disease(NAFLD) and in regulating plasma lipoprotein metabolism.
target gene	hsa-mir-34a	Liver Diseases [unspecific]	29018509			K76.9	D008107			These findings indicate a circRNA_0046367/miR-34a/PPARα regulatory system underlying hepatic steatosis
target gene	hsa-mir-15b	Liver Failure	22374434			K72	D017093	613070	HP:0001399	miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure.
target gene	hsa-mir-16-1	Liver Failure	22374434			K72	D017093	613070	HP:0001399	miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure.
target gene	hsa-mir-16-2	Liver Failure	22374434			K72	D017093	613070	HP:0001399	miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure.
target gene	hsa-mir-101	Liver Fibrosis	24817606			K74	D008103			MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway.
target gene	hsa-mir-130a	Liver Fibrosis	26255201			K74	D008103			These findings suggest that miR-130a and miR-130b are involved in downregulation of PPAR纬 in liver fibrosis.
target gene	hsa-mir-134	Liver Fibrosis	27321552			K74	D008103			Dieckol suppresses liver fibrosis via caspase activation and miR134  mediated JNK activation and NF-kB inhibition.
target gene	hsa-mir-144	Liver Fibrosis	26097586			K74	D008103			miR-144 regulates transforming growth factor-β1 iduced hepatic stellate cell activation in human fibrotic liver.
target gene	hsa-mir-193	Liver Fibrosis	26120970			K74	D008103			These results suggest that miR-30 and miR-193 are members of a network of miRNAs modifying the TGF-β-dependent regulation of extracellular matrix-related genes in HSCs in the manifestation and resolution of liver fibrosis.
target gene	hsa-mir-27b	Liver Fibrosis	26255201			K74	D008103			In carbon tetrachloride injection (CCl4) and common bile duct ligation (CBDL) liver  fibrosis models, miRNAs miR-130a, miR-130b, miR-301a, miR-27b and miR-340 levels  were found to be increased and PPAR纬 expression decreased.
target gene	hsa-mir-29b	Liver Fibrosis	25356754			K74	D008103			microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway.
target gene	hsa-mir-30	Liver Fibrosis	26120970			K74	D008103			These results suggest that miR-30 and miR-193 are members of a network of miRNAs modifying the TGF-β-dependent regulation of extracellular matrix-related genes in HSCs in the manifestation and resolution of liver fibrosis.
target gene	hsa-mir-30a	Liver Fibrosis	29587268			K74	D008103			miR-30a inhibits EMT process, at least in part, via reduction of Snai1, leading to the suppression of HSC activation in liver fibrosis
target gene	hsa-let-7	Liver Injury	28536261			S36.11	D056486			The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury.
target gene	hsa-mir-125b	Liver Injury	24176857			S36.11	D056486			miR-125b is transcriptionally activated by Nrf2 and serves as an inhibitor of AhRR, which contributes to protecting kidney from acute injury.
target gene	hsa-mir-221	Liver Injury	28232457			S36.11	D056486			Dicer-dependent production of microRNA221 in hepatocytes inhibits p27 and is required for liver regeneration in mice.
target gene	hsa-mir-27a	Liver Injury	29156532			S36.11	D056486			paclitaxel significantly attenuated septic induced liver injury through reducing inflammatory response via miR-27a/TAB3/NF-κB signaling pathway
target gene	hsa-mir-101	Liver Neoplasms	24189458	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	we suggest that miR-101 functions as a tumor suppressor by regulating abnormal NLK activity in liver.
target gene	hsa-mir-122	Liver Neoplasms	26987776	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis.
target gene	hsa-mir-124a	Liver Neoplasms	29286137	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MicroRNA-124a inhibits cell proliferation and migration in liver cancer by regulating interleukin-11
target gene	hsa-mir-125b	Liver Neoplasms	25953743	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4.
target gene	hsa-mir-126	Liver Neoplasms	25710939	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	this study demonstrates that human CYP2A6 is post-transcriptionally regulated by miR-126* and that CYP2A7 affects CYP2A6 expression by competing for miR-126* binding.
target gene	hsa-mir-132	Liver Neoplasms	26096363	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP.
target gene	hsa-mir-148b	Liver Neoplasms	25997710	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1.
target gene	hsa-mir-155	Liver Neoplasms	25601564	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-155 may play an important role in promoting the generation of stem cell-like cells and their self-renewal by targeting the gene TP53INP1.
target gene	hsa-mir-182	Liver Neoplasms	23874989	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Inferring potential microRNA-microRNA associations based on targeting propensity and connectivity in the context of protein interaction network.
target gene	hsa-mir-199a	Liver Neoplasms	26054020	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer.
target gene	hsa-mir-200a	Liver Neoplasms	25412960	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-200a played an important role in linking the characteristics of cancer stem cells with EMT phenotype in HCC, and targeting miR-200a might be an effective strategy to weaken the invasive behavior of LCSCs.
target gene	hsa-mir-218	Liver Neoplasms	25416134	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	THA might be a potential anti-cancer drug candidate, at least in part, through the activation of miR-218 and suppression of Bmi-1 expression.
target gene	hsa-mir-31	Liver Neoplasms	25797269	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer.
target gene	hsa-mir-378	Liver Neoplasms	25562172	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-378 enhanced cell migration and metastasis by down-regulating Fus expression.
target gene	hsa-mir-449a	Liver Neoplasms	28088579	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4.
target gene	hsa-mir-449b	Liver Neoplasms	28088579	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4.
target gene	hsa-mir-451	Liver Neoplasms	24968707	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration.
target gene	hsa-mir-506	Liver Neoplasms	26549227	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Thus, we conclude that miR-506 depresses the angiogenesis of liver cancer through targeting 3'UTR of SPHK1 mRNA. Our finding provides new insights into the mechanism of tumor angiogenesis.
target gene	hsa-mir-525	Liver Neoplasms	24599008	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MiR-525-3p enhances the migration and invasion of liver cancer cells by downregulating ZNF395.
target gene	hsa-mir-122	Liver Neoplasms	23373973	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis
target gene	hsa-mir-133b	Liver Neoplasms	26945106	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-133b regulation of CTGF is a novel mechanism critical for the proliferation and migration of HCC cells and OC response.
target gene	hsa-mir-24-1	Liver Neoplasms	28499244	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MicroRNA-24-1 suppresses mouse hepatoma cell invasion and metastasis via directly targeting O-GlcNAc transferase.
target gene	hsa-mir-375	Liver Neoplasms	20226166	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties
target gene	hsa-mir-9500	Liver Neoplasms	24658401	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1.
target gene	hsa-mir-106b	Liver Transplant Rejection	26707312			T86.41				These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection.
target gene	hsa-mir-18b	Liver Transplant Rejection	26707312			T86.41				These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection.
target gene	hsa-mir-340	Liver Transplant Rejection	26707312			T86.41				These results suggest that miR-18b, miR-340, and miR-106b, which regulate the expression of specific immunophenotypes, can be used as potential biomarkers to identify long-term stable liver transplant recipients from recipients with acute rejection.
target gene	hsa-mir-133a-1	Long QT Syndrome	17965831	cardiovascular system disease	DOID:2843	I45.81	D008133	192500	HP:0001657	miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model.
target gene	hsa-mir-133a-2	Long QT Syndrome	17965831	cardiovascular system disease	DOID:2843	I45.81	D008133	192500	HP:0001657	miR-133 was shown to inhibit the expression of ERG (ether-a-go-go-related gene) and cause depression of the potassium channel I(Kr). This inhibition contributed to long QT syndrome and arrhythmia in a diabetic rat model.
target gene	hsa-mir-130b	Lung Fibrosis	26953888	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-130b-3p Modulates Epithelial-Mesenchymal Crosstalk in Lung Fibrosis by Targeting IGF-1.
target gene	hsa-mir-18a	Lung Fibrosis	28131417	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II.
target gene	hsa-mir-21	Lung Fibrosis	27916096	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-21 promotes pulmonary fibrosis in rats via down-regulating the expression of ADAMTS-1.
target gene	hsa-mir-21	Lung Fibrosis	29084974	respiratory system disease	DOID:3770	J84.10	D011658	178500		Mir-21 Mediates the Inhibitory Effect of Ang (1-7) on AngII-induced NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts.
target gene	hsa-mir-326	Lung Fibrosis	24279830	respiratory system disease	DOID:3770	J84.10	D011658	178500		MicroRNA-326 regulates profibrotic functions of transforming growth factor-β in pulmonary fibrosis.
target gene	hsa-let-7a	Lung Neoplasms	22970031	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The upregulation of let-7a/7g repressed the expression of their targets,C-MYC and the regulatory protein of LIN-28, at the mRNA and protein levels.
target gene	hsa-let-7a-1	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7a-2	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7a-3	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7b	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7c	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7c	Lung Neoplasms	23850892	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our results demonstrate that, through regulating the expression of TRIB2 and its downstream factors, let-7c can effectively inhibit A549 cell proliferation in vitro and in vivo.
target gene	hsa-let-7d	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7e	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7f-1	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7f-2	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7g	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-let-7g	Lung Neoplasms	21464588	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1.
target gene	hsa-let-7g	Lung Neoplasms	22970031	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The upregulation of let-7a/7g repressed the expression of their targets,C-MYC and the regulatory protein of LIN-28, at the mRNA and protein levels.
target gene	hsa-let-7i	Lung Neoplasms	15172979	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	decreased abundance; negatively regulate the RAS gene.
target gene	hsa-mir-100	Lung Neoplasms	24559685	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100.
target gene	hsa-mir-100	Lung Neoplasms	22120675	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-100 Resensitizes Docetaxel-Resistant Human Lung Adenocarcinoma Cells (SPC-A1) to Docetaxel by Targeting Plk1.
target gene	hsa-mir-100	Lung Neoplasms	23151088	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1
target gene	hsa-mir-101	Lung Neoplasms	26349988	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-101 represses lung cancer by inhibiting interaction of fibroblasts and cancer cells by down-regulating CXCL12.
target gene	hsa-mir-101	Lung Neoplasms	22977606	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpression of miR-101 induced a marked reduction in EZH2 mRNA levels in several lung cancer cell lines
target gene	hsa-mir-103a-1	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-103a-2	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-103b-1	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-103b-2	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-106a	Lung Neoplasms	25339370	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
target gene	hsa-mir-106a	Lung Neoplasms	26097565	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN.
target gene	hsa-mir-106a	Lung Neoplasms	27372519	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	An inverse correlation of miR-106a and ULK1 expression was seen in lung adenocarcinoma.
target gene	hsa-mir-10a	Lung Neoplasms	25586740	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-10a may be a potential target for improving the effectiveness of lung cancer chemotherapy via regulation of the TGF-β/Smad2/STAT3/STAT5 pathway.
target gene	hsa-mir-10b	Lung Neoplasms	25063061	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-10b may promote proliferation and invasion of 95-C cells by down regulating the expression of KLF4 protein.
target gene	hsa-mir-10b	Lung Neoplasms	25214146	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our results indicated that miR-10b expression was an independent prognostic factor in NSCLC patients. Furthermore, miR-10b might be necessary for driving the expression of E-cad in NSCLC.
target gene	hsa-mir-1-1	Lung Neoplasms	23142026	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties
target gene	hsa-mir-1-2	Lung Neoplasms	23142026	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties
target gene	hsa-mir-1238	Lung Neoplasms	26189214	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-1238 inhibits cell proliferation by targeting LHX2 in non-small cell lung cancer.
target gene	hsa-mir-124	Lung Neoplasms	25550787	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-124 functions as a tumor suppressor in NSCLC. We also demonstrate miRNA-124 directly targeted and decreased SOX8 in NSCLC cell lines, suggesting smiRNA-124 may regulate NSCLC cell proliferation via decreasing SOX8 (oncogenicity of biomarker in NSCLC)
target gene	hsa-mir-124	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-1258	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-125a	Lung Neoplasms	21777146	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells.
target gene	hsa-mir-127	Lung Neoplasms	22349807	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells).
target gene	hsa-mir-129	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-129-1	Lung Neoplasms	25373388	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer.
target gene	hsa-mir-1297	Lung Neoplasms	23071539	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2
target gene	hsa-mir-1298	Lung Neoplasms	27698189	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.
target gene	hsa-mir-132	Lung Neoplasms	24626466	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2.
target gene	hsa-mir-132	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-134	Lung Neoplasms	26166818	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-134 regulates lung cancer cell H69 growth and apoptosis by targeting WWOX gene and suppressing the ERK1/2 signaling pathway.
target gene	hsa-mir-135a	Lung Neoplasms	26235874	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-135a inhibits migration and invasion and regulates EMT-related marker genes by targeting KLF8 in lung cancer cells.
target gene	hsa-mir-135a-1	Lung Neoplasms	23715500	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression.
target gene	hsa-mir-135a-2	Lung Neoplasms	23715500	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression.
target gene	hsa-mir-135b	Lung Neoplasms	23715500	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression.
target gene	hsa-mir-137	Lung Neoplasms	23178712	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6
target gene	hsa-mir-138-1	Lung Neoplasms	23343715	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer
target gene	hsa-mir-138-2	Lung Neoplasms	23343715	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer
target gene	hsa-mir-139	Lung Neoplasms	26097570	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our results indicated that miR-139-5p acts as a tumor suppressor in non-small cell lung cancer (NSCLC) partially via down-regulating IGF1R expression.
target gene	hsa-mir-139	Lung Neoplasms	26497851	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Taken together, our results demonstrated that miR-139-5p plays a pivotal role in lung cancer through inhibiting cell proliferation, metastasis, and promoting apoptosis by targeting oncogenic c-Met.
target gene	hsa-mir-140	Lung Neoplasms	26722475	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-140-3p inhibits proliferation, migration and invasion of lung cancer cells by targeting ATP6AP2.
target gene	hsa-mir-142	Lung Neoplasms	24338464	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MIR-142-5p and miR-9 may be involved in squamous lung cancer by regulating cell cycle related genes.
target gene	hsa-mir-143	Lung Neoplasms	25322940	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells.
target gene	hsa-mir-144	Lung Neoplasms	25660220	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	inhibits proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR.
target gene	hsa-mir-144	Lung Neoplasms	26191328	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression of miR-144 is reduced in malignant SPN tissues and peripheral blood, being of clinical value in the diagnosis of malignant SPN.miR-144 promotes the apoptosis of lung cancer cells, and inhibits the proliferation, invasion and migration of lung cancer by regulating ZEB1 gene.
target gene	hsa-mir-145	Lung Neoplasms	25483817	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-145 inhibited lung cancer cell metastasis and EMT via targeting the Oct4 mediated Wnt/β-catenin signaling pathway.
target gene	hsa-mir-145	Lung Neoplasms	26440147	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In aggregate, our results attribute to miR-145-5p and its direct targets pivotal roles in malignancy progression and in metastasis.
target gene	hsa-mir-145	Lung Neoplasms	21289483	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1.
target gene	hsa-mir-145	Lung Neoplasms	21479367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4.
target gene	hsa-mir-145	Lung Neoplasms	21496429	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-145 Inhibits Lung Adenocarcinoma Stem Cells Proliferation by Targeting OCT4  Gene.
target gene	hsa-mir-145	Lung Neoplasms	21092188	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc.
target gene	hsa-mir-145	Lung Neoplasms	23879998	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	EGFR-ERK signaling pathway down-regulates miRNA-145 in lung cancer cells
target gene	hsa-mir-146a	Lung Neoplasms	25047043	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Regulation of COX-2 expression by miR-146a in lung cancer cells.
target gene	hsa-mir-150	Lung Neoplasms	24456795	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1.
target gene	hsa-mir-150	Lung Neoplasms	23747308	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-150 promotes the proliferation of lung cancer cells by targeting P53.
target gene	hsa-mir-150	Lung Neoplasms	28891208	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1.
target gene	hsa-mir-150	Lung Neoplasms	28108217	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	CDK3 is a major target of miR-150 in cell proliferation and anti-cancer effect.
target gene	hsa-mir-153	Lung Neoplasms	25066607	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Suppression of AKT expression by miR-153 produced anti-tumor activity in lung cancer.
target gene	hsa-mir-155	Lung Neoplasms	22027557	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Hypoxic conditions induce miR-155 expression in lung cancer cells and trigger a corresponding decrease in a validated target, FOXO3A. Furthermore, we find that increased levels of miR-155 radioprotects lung cancer cells, while inhibition of miR-155 radiosensitizes these cells. Moreover, we reveal a therapeutically important link between miR-155 expression, hypoxia, and irradiation by demonstrating that anti-miR-155 molecules also sensitize hypoxic lung cancer cells to irradiation. Our study helps explain how miR-155 becomes elevated in lung cancers, which contain extensive hypoxic microenvironments, and demonstrates that inhibition of miR-155 may have important therapeutic potential as a means to radiosensitize hypoxic lung cancer cells.
target gene	hsa-mir-155	Lung Neoplasms	28688901	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-155 regulates arsenite-induced malignant transformation by targeting Nrf2-mediated oxidative damage in human bronchial epithelial cells.
target gene	hsa-mir-16	Lung Neoplasms	25435430	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	though miR-17 and miR-16 had no common target, both miR-16 and miR-17 jointly played roles in the development  of paclitaxel resistance in lung cancer. miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1, whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2.
target gene	hsa-mir-17	Lung Neoplasms	24755562	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression.
target gene	hsa-mir-17	Lung Neoplasms	25435430	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	though miR-17 and miR-16 had no common target, both miR-16 and miR-17 jointly played roles in the development  of paclitaxel resistance in lung cancer. miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1, whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2.
target gene	hsa-mir-17	Lung Neoplasms	22349807	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells).
target gene	hsa-mir-181b-1	Lung Neoplasms	20162574	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines
target gene	hsa-mir-181b-2	Lung Neoplasms	20162574	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines
target gene	hsa-mir-181c	Lung Neoplasms	28806967	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-181c inhibits cigarette smoke-induced chronic obstructive pulmonary disease by regulating CCN1 expression.
target gene	hsa-mir-182	Lung Neoplasms	24519909	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Sp1-mediated microRNA-182 expression regulates lung cancer progression.
target gene	hsa-mir-182	Lung Neoplasms	26338969	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results suggest that modulation of miR-182 and miR-185 and their target genes may contribute to lung carcinogenesis  attributable to PM2.5 exposure.
target gene	hsa-mir-182	Lung Neoplasms	20420807	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-182:Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro
target gene	hsa-mir-182	Lung Neoplasms	25798833	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers.
target gene	hsa-mir-182	Lung Neoplasms	27641336	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis.
target gene	hsa-mir-183	Lung Neoplasms	22349807	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells).
target gene	hsa-mir-183	Lung Neoplasms	25798833	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers.
target gene	hsa-mir-185	Lung Neoplasms	26338969	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results suggest that modulation of miR-182 and miR-185 and their target genes may contribute to lung carcinogenesis  attributable to PM2.5 exposure.
target gene	hsa-mir-192	Lung Neoplasms	24854555	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our data suggested that miR-192 induced Cisplatin-resistance and inhibited cell apoptosis in lung cancer via negative targeting Bim expression.
target gene	hsa-mir-193a	Lung Neoplasms	24469061	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.
target gene	hsa-mir-193a	Lung Neoplasms	26655272	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overall, we concluded that UCA1 functions as an oncogene in NSCLC, acting mechanistically by upregulating ERBB4 in part through 'spongeing' miR-193a-3p.
target gene	hsa-mir-193a	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-195	Lung Neoplasms	28752530	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	HMGA2 regulation by microRNA-195 (miR-195) was validated by real time-PCR, Western blotting, and luciferase reporter assays
target gene	hsa-mir-197	Lung Neoplasms	24488097	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Antitumor effect of miR-197 targeting in p53 wild-type lung cancer.
target gene	hsa-mir-197	Lung Neoplasms	19671678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	regulate  tumor suppressor gene FUS1
target gene	hsa-mir-1973	Lung Neoplasms	25962089	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity.
target gene	hsa-mir-198	Lung Neoplasms	24357456	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1.
target gene	hsa-mir-19a	Lung Neoplasms	26367773	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression.
target gene	hsa-mir-200	Lung Neoplasms	25798833	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers.
target gene	hsa-mir-200a	Lung Neoplasms	26184032	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
target gene	hsa-mir-200b	Lung Neoplasms	24769353	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer.
target gene	hsa-mir-200b	Lung Neoplasms	22139708	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.
target gene	hsa-mir-200c	Lung Neoplasms	28727734	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1.
target gene	hsa-mir-203	Lung Neoplasms	24040137	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα.
target gene	hsa-mir-203	Lung Neoplasms	25140799	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC.
target gene	hsa-mir-203	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-203	Lung Neoplasms	23073851	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-203 negatively regulates survivin protein expression and inhibits the proliferation and invasion of lung cancer cells
target gene	hsa-mir-203a	Lung Neoplasms	26177443	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	ERGIC3, which is regulated by miR-203a, is a potential biomarker for non-small cell lung cancer.
target gene	hsa-mir-205	Lung Neoplasms	27929537	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2.
target gene	hsa-mir-205	Lung Neoplasms	28199217	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-205 targets SMAD4 in non-small cell lung cancer and promotes lung cancer cell growth in vitro and in vivo.
target gene	hsa-mir-21	Lung Neoplasms	20223231	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC)
target gene	hsa-mir-21	Lung Neoplasms	22806311	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer.
target gene	hsa-mir-210	Lung Neoplasms	19654003	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	low expression, targets pro-survival molecules MCL-1 and BCL2L2
target gene	hsa-mir-212	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-217	Lung Neoplasms	26415832	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The results indicate that miR-217 regulation of EZH2/H3K27me3 via MALAT1 is involved in CSE-induced EMT and malignant transformation of HBE cells. The posttranscriptional silencing of MALAT1 by miR-217 provides a link, through EZH2,between ncRNAs and the EMT and establishes a mechanism for CSE-induced lung carcinogenesis.
target gene	hsa-mir-22	Lung Neoplasms	22484852	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3.
target gene	hsa-mir-221	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-222	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-223	Lung Neoplasms	25881295	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our study demonstrates for the first time that platelet-secreted miR-223 via P-MVs can promote lung cancer cell invasion via targeting tumor suppressor EPB41L3.
target gene	hsa-mir-23a	Lung Neoplasms	22752005	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.
target gene	hsa-mir-25	Lung Neoplasms	25550809	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-25 is overexpressed in SCLC and acting as oncogenic regulator by regulating cyclin E2.
target gene	hsa-mir-25	Lung Neoplasms	25998847	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-25 targets the modulator of apoptosis 1 gene in lung cancer.
target gene	hsa-mir-25	Lung Neoplasms	26416661	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3.
target gene	hsa-mir-26a	Lung Neoplasms	25100863	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-26a/b regulate DNA replication licensing, tumorigenesis, and prognosis by targeting CDC6 in lung cancer.
target gene	hsa-mir-26a-1	Lung Neoplasms	22469510	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
target gene	hsa-mir-26a-1	Lung Neoplasms	22885155	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN.
target gene	hsa-mir-26a-2	Lung Neoplasms	22469510	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
target gene	hsa-mir-26a-2	Lung Neoplasms	22885155	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN.
target gene	hsa-mir-26b	Lung Neoplasms	25100863	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-26a/b regulate DNA replication licensing, tumorigenesis, and prognosis by targeting CDC6 in lung cancer.
target gene	hsa-mir-26b	Lung Neoplasms	26068649	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Down-regulation of microRNA-26b modulates non-small cell lung cancer cells chemoresistance and migration through the association of PTEN.
target gene	hsa-mir-26b	Lung Neoplasms	21901137	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression of miR-26b was down regulated, and its target activating transcription factor 2 (ATF2) mRNA was up regulated in ж┿irradiated H1299 cells.
target gene	hsa-mir-27a	Lung Neoplasms	23117485	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-27a regulates the self renewal of the H446 small cell lung cancer cell line in vitro
target gene	hsa-mir-29a	Lung Neoplasms	22349807	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells).
target gene	hsa-mir-29b	Lung Neoplasms	25962089	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity.
target gene	hsa-mir-29b-1	Lung Neoplasms	22349807	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells).
target gene	hsa-mir-29b-2	Lung Neoplasms	22349807	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Bberrant expression of miRNAs such as miR-29ab, miR-183, miR-17-5p and miR-127-3P may play an important role in regulating the bio-behavior of TICs (tumor initiating cells).
target gene	hsa-mir-29c	Lung Neoplasms	23936390	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2).
target gene	hsa-mir-30a	Lung Neoplasms	26025408	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R.
target gene	hsa-mir-30a	Lung Neoplasms	28678320	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-30 suppresses lung cancer cell 95D epithelial mesenchymal transition and invasion through targeted regulating Snail.
target gene	hsa-mir-30b	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-30c-1	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-30c-2	Lung Neoplasms	22157681	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Here we report that miR-30b, miR-30c, miR-221 and miR-222 are modulated by both epidermal growth factor (EGF) and MET receptors, whereas miR-103 and miR-203 are controlled only by MET. We showed that these miRNAs have important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition of NSCLC cells in vitro and in vivo by inhibiting the expression of the genes encoding BCL2-like 11 (BIM), apoptotic peptidase activating factor 1 (APAF-1), protein kinase C ɛ (PKC-ɛ) and sarcoma viral oncogene homolog (SRC).
target gene	hsa-mir-31	Lung Neoplasms	26657862	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our study distinguishes miR-31 as a driver of lung tumorigenesis that promotes mutant KRAS-mediated oncogenesis and reveals that miR-31 directly targets and reduces expression of negative regulators of RAS/MAPK signaling.
target gene	hsa-mir-330	Lung Neoplasms	22132977	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression of miR-330 in various colon and lung cancer cell lines, as measured by QRT-PCR, varied five-fold between samples and correlated with in-vitro gemcitabine resistance (R = 0.82, p = 0.04). Exposure to gemcitabine also appeared to influence miR-330 levels in these cell lines. Furthermore, in our cell line panel, miR-330 expression negatively correlated with dCK mRNA expression (R = 0.74), suggesting a role of miR-330 in post-transcriptional regulation of dCK.
target gene	hsa-mir-335	Lung Neoplasms	23232114	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations
target gene	hsa-mir-340	Lung Neoplasms	25151966	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer.
target gene	hsa-mir-342	Lung Neoplasms	26483346	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer.
target gene	hsa-mir-34a	Lung Neoplasms	24983493	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
target gene	hsa-mir-34a	Lung Neoplasms	25038915	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
target gene	hsa-mir-34a	Lung Neoplasms	26667302	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Therefore, we propose that AXL is autoregulated by miR-34a in a feedback loop; this may provide a novel opportunity for developing AXL-targeted anticancer therapies.
target gene	hsa-mir-34a	Lung Neoplasms	23349340	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway
target gene	hsa-mir-34b	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-34c	Lung Neoplasms	24479666	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Differences in miRNA expression are associated with emphysema severity in COPD patients. MiR-34c modulates expression of its putative target gene, SERPINE1, in vitro in respiratory cell lines and ex vivo in emphysematous lung tissue.
target gene	hsa-mir-34c	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-365a	Lung Neoplasms	22185756	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1.
target gene	hsa-mir-365b	Lung Neoplasms	22185756	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1.
target gene	hsa-mir-372	Lung Neoplasms	22451061	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In addition, there is evidence that miR-372 posttranscriptionally downregulates large tumor suppressor, homolog 2 (Lats2), resulting in tumorigenesis and proliferation. 
target gene	hsa-mir-375	Lung Neoplasms	26642205	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Thus, our study demonstrates the differential expression profiles of miR-375 in 3 subtypes of lung carcinomas and finds thatmiR-375 directly targets ITPKB and promoted cell growth in SCLC cell line.
target gene	hsa-mir-375	Lung Neoplasms	21856745	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-375 is activated by ASH1 and inhibits YAP1 in a lineage dependent manner in lung cancer.
target gene	hsa-mir-375	Lung Neoplasms	23206448	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-375 is a novel prognostic indicator in NSCLC and might be a potential target for diagnosis and gene therapy
target gene	hsa-mir-375	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-381	Lung Neoplasms	22592211	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma.
target gene	hsa-mir-410	Lung Neoplasms	26149213	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-410 promotes cell proliferation by targeting BRD7 in non-small cell lung cancer.
target gene	hsa-mir-4286	Lung Neoplasms	25962089	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity.
target gene	hsa-mir-449a	Lung Neoplasms	24211326	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells.
target gene	hsa-mir-449a	Lung Neoplasms	25818739	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our data indicate that miR-449a may function as a suppressor of lung cancer, and affects the expression of NEAT1 in lung cancer cells.
target gene	hsa-mir-486	Lung Neoplasms	23474761	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer
target gene	hsa-mir-490	Lung Neoplasms	24440705	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-490-3p inhibits proliferation of A549 lung cancer cells by targeting CCND1.
target gene	hsa-mir-493	Lung Neoplasms	25105419	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1.
target gene	hsa-mir-494	Lung Neoplasms	25962089	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity.
target gene	hsa-mir-497	Lung Neoplasms	21258880	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.
target gene	hsa-mir-506	Lung Neoplasms	24469051	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation.
target gene	hsa-mir-5100	Lung Neoplasms	25754817	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-5100 promotes tumor growth in lung cancer by targeting Rab6.
target gene	hsa-mir-511	Lung Neoplasms	23071539	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-511 and miR-1297 inhibit human lung adenocarcinoma cell proliferation by targeting oncogene TRIB2
target gene	hsa-mir-513a-1	Lung Neoplasms	22749944	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1.
target gene	hsa-mir-513a-2	Lung Neoplasms	22749944	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1.
target gene	hsa-mir-517a	Lung Neoplasms	24846831	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This study demonstrated that miR-517a-3p promoted lung cancer cell proliferation and invasion by targeting of FOXJ3 expression.
target gene	hsa-mir-520h	Lung Neoplasms	22410781	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol.
target gene	hsa-mir-542	Lung Neoplasms	22426479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-542-5p targets EGFR and inhibited the growth of human lung cancer cells.
target gene	hsa-mir-545	Lung Neoplasms	24505359	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells.
target gene	hsa-mir-574	Lung Neoplasms	23133627	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer
target gene	hsa-mir-610	Lung Neoplasms	25241780	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-610 suppresses lung cancer cell proliferation and invasion by targeting GJA3 expression.
target gene	hsa-mir-614	Lung Neoplasms	25342037	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-614 inhibited cell invasion and proliferationa targeting PSA in lung cancer cells, PGCL3.
target gene	hsa-mir-630	Lung Neoplasms	25255219	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targetingmultiple modulators in human lung cancer A549 cells.
target gene	hsa-mir-638	Lung Neoplasms	24842609	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC.
target gene	hsa-mir-7	Lung Neoplasms	25880778	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	KCNJ2/Kir2.1 modulates cell growth and drug resistance by regulating MRP1/ABCC1 expression and is simultaneously regulated by the Ras/MAPK pathway and miR-7. KCNJ2/Kir2.1 may be a prognostic predictor and a potentially novel target for interfering with chemoresistance in SCLC.
target gene	hsa-mir-7	Lung Neoplasms	26135959	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-7 inhibits the malignant phenotypes of non-small cell lung cancer in vitro by targeting Pax6.
target gene	hsa-mir-7	Lung Neoplasms	24004462	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Moreover, overexpression of HuR could reduce the expression of miR-7 in lung cancer cells.
target gene	hsa-mir-7-1	Lung Neoplasms	23135998	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway
target gene	hsa-mir-7-2	Lung Neoplasms	23135998	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway
target gene	hsa-mir-7-3	Lung Neoplasms	23135998	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway
target gene	hsa-mir-9	Lung Neoplasms	25869366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Novel potential regulatory miRNAs for RHOA (miR-9-1/-3, -34b/c, -129-2, -125b-1, -375, -1258) and NKIRAS1 (miR-34b/c, -129-2, -125b-1, -193a, -124a-1/-2/-3, -212, -132) genes in lung cancer were identified.
target gene	hsa-mir-9-1	Lung Neoplasms	21464588	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1.
target gene	hsa-mir-9-2	Lung Neoplasms	21464588	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1.
target gene	hsa-mir-93	Lung Neoplasms	24037530	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer.
target gene	hsa-mir-93	Lung Neoplasms	19671678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	regulate  tumor suppressor gene FUS1
target gene	hsa-mir-9-3	Lung Neoplasms	21464588	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFKB1.
target gene	hsa-mir-96	Lung Neoplasms	25798833	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers.
target gene	hsa-mir-96	Lung Neoplasms	24338464	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MIR-142-5p and miR-9 may be involved in squamous lung cancer by regulating cell cycle related genes.
target gene	hsa-mir-96	Lung Neoplasms	24469470	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells.
target gene	hsa-mir-96	Lung Neoplasms	25286764	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression of microRNA-96 and its potential functions by targeting FOXO3 innon-small cell lung cancer.
target gene	hsa-mir-98	Lung Neoplasms	19671678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	regulate  tumor suppressor gene FUS1
target gene	hsa-mir-99a	Lung Neoplasms	25187230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. LC-related miRNAs 
target gene	hsa-mir-10a	Lupus Nephritis	29109423	urinary system disease	DOID:0080162	M32.14	D008181			Transcriptomic profiling in human mesangial cells using patient-derived lupus autoantibodies identified miR-10a as a potential regulator of IL8.
target gene	hsa-mir-130b	Lupus Nephritis	26316103	urinary system disease	DOID:0080162	M32.14	D008181			MiR-130b-3p negatively regulated ERBB2IP expression by directly targeting the 3'-UTR of ERBB2IP The circulating miR-130b-3p might serve as a biomarker and play an important role in renal damage in early stage LN patients.
target gene	hsa-mir-146a	Lupus Nephritis	28338190	urinary system disease	DOID:0080162	M32.14	D008181			The role of miR-146a in modulating TRAF6-induced inflammation during lupus nephritis.
target gene	hsa-mir-148a	Lupus Nephritis	26791485	urinary system disease	DOID:0080162	M32.14	D008181			miR-148a-3p overexpression contributes to glomerular cell proliferation by targeting PTEN in lupus nephritis.
target gene	hsa-mir-371	Lupus Nephritis	27878241	urinary system disease	DOID:0080162	M32.14	D008181			Hsa‑miR‑371‑5p inhibits human mesangial cell proliferation and promotes apoptosis in lupus nephritis by directly targeting hypoxia‑inducible factor 1α.
target gene	hsa-mir-155	Lymphocytic Choriomeningitis	29768211	disease by infectious agent	DOID:12155	A87.2	D008216			Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155.
target gene	hsa-mir-122	Lymphoma	22235305	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
target gene	hsa-mir-1275	Lymphoma	26705180	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1.
target gene	hsa-mir-143	Lymphoma	28736328	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Down regulation of miR-143 promotes radiation - Induced thymic lymphoma by targeting B7H1.
target gene	hsa-mir-146a	Lymphoma	21610143	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNA-146a downregulates NF{kappa}B activity via targeting TRAF6, and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma.
target gene	hsa-mir-150	Lymphoma	23521217	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Re-expression of miR-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro
target gene	hsa-mir-155	Lymphoma	25480585	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	reduction in miRNA-155 expression can inhibit the proliferation of SNK-6 lymphoma cells and promote their apoptosis, which may be associated with regulation of FOXO3a gene.
target gene	hsa-mir-155	Lymphoma	26261072	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas.
target gene	hsa-mir-155	Lymphoma	23852382	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	In experimental models, some lymphomas are considered to be addicted to  the sustained expression of targetable oncomiRs, such as miR-155 and miR-21.
target gene	hsa-mir-17	Lymphoma	19666108	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The expression of these genes was also reduced in response to miR-17 and miR-20a transfection, and more specifically they were also shown to contain functional miRNA recognition elements for members of the miR-17 family by reporter gene assay.
target gene	hsa-mir-17	Lymphoma	24169826	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.
target gene	hsa-mir-200a	Lymphoma	22183793	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.
target gene	hsa-mir-200b	Lymphoma	22183793	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.
target gene	hsa-mir-200c	Lymphoma	22183793	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2.
target gene	hsa-mir-20a	Lymphoma	19666108	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The expression of these genes was also reduced in response to miR-17 and miR-20a transfection, and more specifically they were also shown to contain functional miRNA recognition elements for members of the miR-17 family by reporter gene assay.
target gene	hsa-mir-26a	Lymphoma	20441582	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines.
target gene	hsa-mir-365	Lymphoma	26191184	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression.
target gene	hsa-mir-383	Lymphoma	29387204	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	western blot analysis identified zinc finger E-box binding homeobox 2 (ZEB2) as a direct target gene of miR-383
target gene	hsa-mir-4736	Lymphoma	26705180	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1.
target gene	hsa-mir-4739	Lymphoma	26705180	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1.
target gene	hsa-mir-504	Lymphoma	26705180	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1.
target gene	hsa-mir-664	Lymphoma	26287415	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Taken together, our results suggest that miR-664 may play an important role in suppressing proliferation of CMM cells and present a novel mechanism of miR-mediated direct suppression of PLP2 expression in cancer cells.
target gene	hsa-mir-664b	Lymphoma	26705180	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-664b-5p, miR-1275, miR-4739, miR-4736 and miR-504-5p may become an important indicator in the differentiation ALK-negative anaplastic large cell lymphoma from CD30-positive peripheral T cell lymphoma (not otherwise specified).MiR-4739, miR-4736 and miR-1275 may play important role in pathogenesis of negative-anaplastic large cell lymphoma by target genes: TNFRSF8 and TMOD1.
target gene	hsa-mir-92a	Lymphoma	24375836	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim.
target gene	hsa-mir-155	Lymphoma, B-Cell	26497687	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-155 targeting of DET1, NIAM, TRIM32, HOMEZ, PSIP1 and JARID2.
target gene	hsa-mir-17	Lymphoma, B-Cell	25634356	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	this molecular and bioinformatic study of 44 patient skin biopsy samples showed that the oncogenic miR-17-92 cluster and its paralogs were involved in cutaneous B-cell lymphoma progression, and that the downregulation of the target gene PTEN was associated with shorter DFS.
target gene	hsa-mir-204	Lymphoma, B-Cell	25651400	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	MicroRNA-204 targets signal transducer and activator of transcription 5 expression and inhibits proliferation of B-cell lymphoma cells.
target gene	hsa-mir-21	Lymphoma, B-Cell	25909227	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
target gene	hsa-mir-224	Lymphoma, B-Cell	25146331	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP.
target gene	hsa-mir-92	Lymphoma, B-Cell	25634356	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	this molecular and bioinformatic study of 44 patient skin biopsy samples showed that the oncogenic miR-17-92 cluster and its paralogs were involved in cutaneous B-cell lymphoma progression, and that the downregulation of the target gene PTEN was associated with shorter DFS.
target gene	hsa-mir-127	Lymphoma, Burkitt	19530237	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	B cell differentiation in EBV-positive Burkitt Lymphoma is impaired at post-transcriptional level by miRNA altered expression.
target gene	hsa-mir-17	Lymphoma, Burkitt	29458013	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	In contrast to normal B cells, miRNA target genes in BL were  enriched for targets of the oncogenic miR-17 to 92 cluster, and were involved mainly in cell cycle and cell death
target gene	hsa-mir-18	Lymphoma, Burkitt	29458013	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	In contrast to normal B cells, miRNA target genes in BL were  enriched for targets of the oncogenic miR-17 to 93 cluster, and were involved mainly in cell cycle and cell death
target gene	hsa-mir-19a	Lymphoma, Burkitt	29458013	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	In contrast to normal B cells, miRNA target genes in BL were  enriched for targets of the oncogenic miR-17 to 94 cluster, and were involved mainly in cell cycle and cell death
target gene	hsa-mir-19b-1	Lymphoma, Burkitt	29458013	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	In contrast to normal B cells, miRNA target genes in BL were  enriched for targets of the oncogenic miR-17 to 96 cluster, and were involved mainly in cell cycle and cell death
target gene	hsa-mir-20a	Lymphoma, Burkitt	29458013	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	In contrast to normal B cells, miRNA target genes in BL were  enriched for targets of the oncogenic miR-17 to 95 cluster, and were involved mainly in cell cycle and cell death
target gene	hsa-mir-92-1	Lymphoma, Burkitt	29458013	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	In contrast to normal B cells, miRNA target genes in BL were  enriched for targets of the oncogenic miR-17 to 97 cluster, and were involved mainly in cell cycle and cell death
target gene	hsa-mir-15a	Lymphoma, Extranodal NK-T-Cell	23963825			C86.0	D054391			miR-15a could be a potential target for antitumor therapy and a prognostic predictor for NNKTL.
target gene	hsa-mir-106a	Lymphoma, Hodgkin	21953646	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.
target gene	hsa-mir-106b	Lymphoma, Hodgkin	21953646	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.
target gene	hsa-mir-17	Lymphoma, Hodgkin	21953646	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.
target gene	hsa-mir-205	Lymphoma, Hodgkin	19666866	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Regulates JAK2, prognostic impact
target gene	hsa-mir-28	Lymphoma, Hodgkin	28188132	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma.
target gene	hsa-mir-9-1	Lymphoma, Hodgkin	22310293	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo.
target gene	hsa-mir-9-2	Lymphoma, Hodgkin	22310293	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo.
target gene	hsa-mir-9-3	Lymphoma, Hodgkin	22310293	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo.
target gene	hsa-mir-92a	Lymphoma, Large B-Cell	27806315			C83.3	D016403	109565		Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
target gene	hsa-mir-10a	Lymphoma, Large B-Cell, Diffuse	27815824	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
target gene	hsa-mir-17	Lymphoma, Large B-Cell, Diffuse	26305986	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.
target gene	hsa-mir-18	Lymphoma, Large B-Cell, Diffuse	26305986	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.
target gene	hsa-mir-19a	Lymphoma, Large B-Cell, Diffuse	26305986	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.
target gene	hsa-mir-19b-1	Lymphoma, Large B-Cell, Diffuse	26305986	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.
target gene	hsa-mir-20a	Lymphoma, Large B-Cell, Diffuse	26305986	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.
target gene	hsa-mir-21	Lymphoma, Large B-Cell, Diffuse	24763002	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		The expression of miR-21 is high in DLBCL and its overexpression may be related with poor prognosis of DLCBL. These findings suggest that PTEN is possibly one of the targets of miR-21 in DLBCL.
target gene	hsa-mir-21	Lymphoma, Large B-Cell, Diffuse	23275230	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen
target gene	hsa-mir-21	Lymphoma, Large B-Cell, Diffuse	29067124	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		MicroRNA-21 regulates the viability and apoptosis of diffuse large B-cell lymphoma cells by upregulating B cell lymphoma-2.
target gene	hsa-mir-26a	Lymphoma, Large B-Cell, Diffuse	28640256	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
target gene	hsa-mir-520c	Lymphoma, Large B-Cell, Diffuse	24497838	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development.
target gene	hsa-mir-92-1	Lymphoma, Large B-Cell, Diffuse	26305986	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.
target gene	hsa-mir-16-1	Lymphoma, Mantle-Cell	18483394			C83.10	D020522			Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.
target gene	hsa-mir-17	Lymphoma, Mantle-Cell	22116552			C83.10	D020522			The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
target gene	hsa-mir-18a	Lymphoma, Mantle-Cell	22116552			C83.10	D020522			The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
target gene	hsa-mir-19a	Lymphoma, Mantle-Cell	22116552			C83.10	D020522			The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
target gene	hsa-mir-19b-1	Lymphoma, Mantle-Cell	22116552			C83.10	D020522			The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
target gene	hsa-mir-20a	Lymphoma, Mantle-Cell	22116552			C83.10	D020522			The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
target gene	hsa-mir-92a-1	Lymphoma, Mantle-Cell	22116552			C83.10	D020522			The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
target gene	hsa-mir-1291	Lymphoma, T-Cell	24246916	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways
target gene	hsa-mir-223	Lymphoma, T-Cell	24438193	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Our findings reveal that the downregulation of the tumour suppressor PRDM1 in EN-NK/T-NT samples is mediated by miR-223 and that PRDM1-positive staining might have prognostic value for evaluating the clinical outcome of EN-NK/T-NT patients.
target gene	hsa-mir-223	Lymphoma, T-Cell	24304814	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
target gene	hsa-mir-25	Lymphoma, T-Cell	24246916	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways
target gene	hsa-mir-26a	Lymphoma, T-Cell	26314438	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	that abnormal expression of miR-26a may participate in genesis and development of ENKTCL through regulating the expression of its target gene CDK6.
target gene	hsa-mir-27a	Lymphoma, T-Cell	24246916	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways
target gene	hsa-mir-373	Lymphoma, T-Cell	27874957	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Restoration of microRNA-373 suppresses growth of human T-cell lymphoma cells by repressing CCND1.
target gene	hsa-mir-511	Lymphoma, T-Cell	24246916	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways
target gene	hsa-mir-572	Lymphoma, T-Cell	24246916	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways
target gene	hsa-mir-886	Lymphoma, T-Cell	24246916	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Eight miRNAs are aberrantly expressed in PTCL-NOS, which may be involved in molecular regulation during the development of PTCL-NOS. The underlying mechanism is also related to a number of target genes and signaling pathways
target gene	hsa-mir-150	Lymphoma, T-Cell, Cutaneous	24385540	disease of cellular proliferation	DOID:0060061	C84.A0	D016410	608856	HP:0012192	MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma.
target gene	hsa-mir-155	Lymphoma, T-Cell, Cutaneous	24106870	disease of cellular proliferation	DOID:0060061	C84.A0	D016410	608856	HP:0012192	Recent data show that miR-155 is expressed in situ by both malignant and non-malignant T cells, induced via the STAT5 signal pathway and IL-2Rbeta/gamma cytokines, and thus suggest the importance of miR-155 in malignant proliferation, clinical diagnosis, and prognosis in CTCL.
target gene	hsa-mir-155	Lynch Syndrome	25701956	genetic disease	DOID:3883		D003123	120435		overexpression of miR-155 or miR-21 has been shown to downregulate the expression of the MMR genes.
target gene	hsa-mir-4480	Macular Degeneration	26765636	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	Functional single nucleotide polymorphism in IL-17A 3' untranslated region is targeted by miR-4480 in vitro and may be associated with age-related macular degeneration.
target gene	hsa-mir-30c	Malignant Neoplasms [unspecific]	27085140			C80.1	D009369			miR-30c-1-3p altered basal and induced expression of cytochrome P450 3A4 (CYP3A4), a prototypical target gene of PXR.
target gene	hsa-mir-3151	Malignant Neoplasms [unspecific]	26582795			C80.1	D009369			In conclusion, we identify miR-3151 as a previously unidentified player in MM and PTC pathogenesis, which is driven by BRAF-dependent and BRAF-independent mechanisms. Characterization of TP53 as a downstream effector of miR-3151 provides evidence for a causal link between BRAF mutations and TP53 inactivation.
target gene	hsa-mir-210	Malignant Peripheral Nerve Sheath Tumor	24512729	disease of cellular proliferation	DOID:5940		D009442		HP:0100697	MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3.
target gene	hsa-mir-30d	Malignant Peripheral Nerve Sheath Tumor	24132643	disease of cellular proliferation	DOID:5940		D009442		HP:0100697	EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis.
target gene	hsa-mir-320a	MALT Lymphoma	29788729	disease of cellular proliferation	DOID:0050909	C88.4		137245		the TF MYC was a co-target of miR-320a, miR-622, and miR-429
target gene	hsa-mir-429	MALT Lymphoma	29788729	disease of cellular proliferation	DOID:0050909	C88.4		137245		the TF MYC was a co-target of miR-320a, miR-622, and miR-429
target gene	hsa-mir-622	MALT Lymphoma	29788729	disease of cellular proliferation	DOID:0050909	C88.4		137245		the TF MYC was a co-target of miR-320a, miR-622, and miR-429
target gene	hsa-mir-155	Marek Disease	28757026				D008380			Marek's disease virus type 1 encoded analog of miR-155 promotes proliferation of chicken embryo fibroblast and DF-1 cells by targeting hnRNPAB.
target gene	hsa-mir-221	Marek Disease	19264608				D008380			miR-221: miR-221/222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1
target gene	hsa-mir-222	Marek Disease	19264608				D008380			miR-222: miR-221/222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1
target gene	hsa-let-7f-1	Medulloblastoma	25014664	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells.
target gene	hsa-mir-124	Medulloblastoma	19427019	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1.
target gene	hsa-mir-124-1	Medulloblastoma	18607543	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-124: regulates cyclin dependent kinase 6
target gene	hsa-mir-124-1	Medulloblastoma	22249617	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-124a targeted 3'UTR of HMGA1 and negatively modulated the expression in MB cells.
target gene	hsa-mir-124-2	Medulloblastoma	18607543	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-124: regulates cyclin dependent kinase 6
target gene	hsa-mir-124-3	Medulloblastoma	18607543	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-124: regulates cyclin dependent kinase 6
target gene	hsa-mir-125b	Medulloblastoma	18756266	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1.
target gene	hsa-mir-182	Medulloblastoma	22402744	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.
target gene	hsa-mir-183	Medulloblastoma	22402744	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.
target gene	hsa-mir-218-1	Medulloblastoma	23212916	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype associated genes in medulloblastoma
target gene	hsa-mir-218-2	Medulloblastoma	23212916	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype associated genes in medulloblastoma
target gene	hsa-mir-219	Medulloblastoma	24756834	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-219 inhibits the proliferation, migration and invasion of medulloblastoma cells by targeting CD164.
target gene	hsa-mir-22	Medulloblastoma	24576181	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target PAPST1.
target gene	hsa-mir-324	Medulloblastoma	18756266	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1.
target gene	hsa-mir-326	Medulloblastoma	18756266	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Specifically, we identify miR-125b and miR-326 as suppressors of the pathway activator Smoothened together with miR-324-5p, which also targets the downstream transcription factor Gli1.
target gene	hsa-mir-34a	Medulloblastoma	21931765	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15/CD133 Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblastoma.
target gene	hsa-mir-383	Medulloblastoma	23227829	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	MiR-383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3)
target gene	hsa-mir-431	Medulloblastoma	24584142	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Downregulation of microRNA-431 by human interferon-β inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
target gene	hsa-mir-495	Medulloblastoma	26160158	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Our results suggest that miR-495 may be a prognostic predictor in medulloblastoma and that Gfi1 is a potential functional target of miR-495.
target gene	hsa-mir-96	Medulloblastoma	22402744	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.
target gene	hsa-let-7a	Melanoma	28698805	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene.
target gene	hsa-let-7a-1	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7a-2	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7a-3	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7a: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7b	Melanoma	18379589	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth.
target gene	hsa-let-7b	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7b: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7c	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7c: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7d	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7d: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7e	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7e: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7f-1	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7f: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7f-2	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7f: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7g	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7g: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-let-7i	Melanoma	18679415	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7i: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma
target gene	hsa-mir-101	Melanoma	23962556	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2.
target gene	hsa-mir-124	Melanoma	27657824	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Upregulation of miR-124 by physcion 8-O-β-glucopyranoside inhibits proliferation and invasion of malignant melanoma cells via repressing RLIP76.
target gene	hsa-mir-124	Melanoma	29042947	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican.
target gene	hsa-mir-125a	Melanoma	26071398	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we discovered that Lin28B, a well-characterized inhibitor of let-7 miRNA biogenesis, was a direct target of miR-125a-5p in melanoma.
target gene	hsa-mir-125b	Melanoma	28108732	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPARγ/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells.
target gene	hsa-mir-125b-1	Melanoma	22797068	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression.
target gene	hsa-mir-125b-2	Melanoma	22797068	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression.
target gene	hsa-mir-126	Melanoma	23437250	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma
target gene	hsa-mir-137	Melanoma	20644734	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-137:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells.
target gene	hsa-mir-137	Melanoma	21278922	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-137 Targets Carboxyl-terminal Binding Protein 1 in Melanoma Cell Lines.
target gene	hsa-mir-137	Melanoma	23151846	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-137 Inhibits the Invasion of Melanoma Cells through Downregulation of Multiple Oncogenic Target Genes
target gene	hsa-mir-137	Melanoma	21051724	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The results showed that miR-137 can act as a tumor suppressor in uveal melanoma cell proliferation through downregulation of the targets MITF and CDK6. miR-137 may be epigenetically silenced during uveal melanoma tumorigenesis.
target gene	hsa-mir-137	Melanoma	28757416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor.
target gene	hsa-mir-137	Melanoma	29097210	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase.
target gene	hsa-mir-137	Melanoma	29307109	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-137 inhibits melanoma cell proliferation through downregulation of GLO1
target gene	hsa-mir-137	Melanoma	29348676	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma
target gene	hsa-mir-143	Melanoma	19639204	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-27a and its target gene ZBTB10 significantly different based on the dose of genistein
target gene	hsa-mir-143	Melanoma	24722758	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-143 targets Syndecan-1 to repress cell growth in melanoma.
target gene	hsa-mir-143	Melanoma	29230879	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	These results support a functional role for miR-143-5p in regulating alpaca melanocyte migration, proliferation and melanogenesis through direct targeting of TAK1
target gene	hsa-mir-146a	Melanoma	24550252	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.
target gene	hsa-mir-148a	Melanoma	20644734	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-148:Our data show that miR-148 and miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells.
target gene	hsa-mir-148b	Melanoma	28656878	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b.
target gene	hsa-mir-150	Melanoma	29434838	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4
target gene	hsa-mir-155	Melanoma	21466664	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-155 Targets the SKI Gene in Human Melanoma Cell Lines
target gene	hsa-mir-155	Melanoma	25853464	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	microRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells.
target gene	hsa-mir-155	Melanoma	29333944	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-155 Promotes Uveal Melanoma Cell Proliferation and Invasion by Regulating NDFIP1 Expression
target gene	hsa-mir-16	Melanoma	28991221	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	TYRP1-dependent miR-16 sequestration can also be overcome in vivo by using small oligonucleotides that mask miR-16-binding sites on TYRP1 mRNA
target gene	hsa-mir-17	Melanoma	26158900	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1.
target gene	hsa-mir-17	Melanoma	23728176	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	We found that cancer cells silence ADAR1 by overexpressing miR-17 and miR-432, which both directly target the ADAR1 transcript.
target gene	hsa-mir-182	Melanoma	19188590	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-182: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor
target gene	hsa-mir-182	Melanoma	22848417	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-182, a p53 dependent miRNA, suppressed the expression of MITF, BCL2, cyclin D2 and functioned as a potent tumor suppressor in uveal melanoma cells.
target gene	hsa-mir-186	Melanoma	27698793	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-186 suppressed CYLD expression and promoted cell proliferation in human melanoma.
target gene	hsa-mir-193b	Melanoma	20304954	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-193b Represses Cell Proliferationand Regulates Cyclin D1 in Melanoma
target gene	hsa-mir-193b	Melanoma	21893020	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-193b is expressed at a significantly lower level in malignant melanoma than in benign nevi. In a survey of melanoma samples, the level of Mcl-1 is inversely correlated with the level of miR-193b. Overexpression of miR-193b in melanoma cells represses Mcl-1 expression. Furthermore, the effect of miR-193b on the expression of Mcl-1 seems to be mediated by direct interaction between miR-193b and seed and seedless pairing sequences in the 3' untranslated region of Mcl-1 mRNA.
target gene	hsa-mir-194	Melanoma	28358423	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.
target gene	hsa-mir-196a	Melanoma	21077158	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	As it was stated before that miR-196a might negatively regulate expression of the transcription factor HOX-C8, we analyzed HOX-C8 levels in NHEMs and melanoma cells and found a strong up-regulation of HOX-C8 expression in malignant melanoma cell lines and tissue samples compared with melanocytes.
target gene	hsa-mir-199a	Melanoma	25400815	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-199a-5p regulates melanoma metastasis-related genes, and may provide a basis for the development of novel, molecularly targeted drugs.
target gene	hsa-mir-19b	Melanoma	25643913	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-19b regulates hTERT mRNA expression through targeting PITX1 mRNA in melanoma cells.
target gene	hsa-mir-200a	Melanoma	28526299	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
target gene	hsa-mir-200b	Melanoma	28535666	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A miR-200b inhibitor induced the direct regulation of SOX-2 by DDX53
target gene	hsa-mir-200c	Melanoma	22982443	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.
target gene	hsa-mir-203	Melanoma	22354972	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Anti-oncogenic MicroRNA-203 Induces Senescence by Targeting E2F3 in Human Melanoma Cells.
target gene	hsa-mir-203	Melanoma	23884313	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-203 regulates melanosome transport and tyrosinase expression in melanoma cells by targeting kinesin superfamily protein 5b.
target gene	hsa-mir-203	Melanoma	25475727	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-203 regulated melanoma invasive and proliferative abilities in part by targeting BMI1, providing new insights into potential mechanisms of melanoma metastasis.
target gene	hsa-mir-204	Melanoma	29075789	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	BANCR contributes to the growth and invasion of melanoma by functioning as a competing endogenous RNA to upregulate Notch2 expression by sponging miR‑204.
target gene	hsa-mir-205	Melanoma	21454583	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1.
target gene	hsa-mir-205	Melanoma	22871739	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.
target gene	hsa-mir-205	Melanoma	23638671	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our data suggest that miR-203 is a new prognostic factor in canine oral MMs and that miR-205 functions as a tumour suppressor by targeting erbb3 in both canine and human MM cells.
target gene	hsa-mir-20b	Melanoma	24405508	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells.
target gene	hsa-mir-21	Melanoma	22130252	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Increased levels of microRNA-21 expression were shown from dysplastic nevi to primary cutaneous melanomas to melanoma metastases. Moreover, high miR-21 expression was found to be correlated with Breslow thickness and advanced clinical stage. Patients with high microRNA-21 expression showed shorter 5-year disease-free or overall survival than those with low microRNA-21 expression. Furthermore, multivariate regression analysis showed that the status of microRNA-21 expression was an independent prognostic factor for overall survival of patients. Antisense-mediated microRNA-21 inhibition could significantly suppress growth, increase apoptosis and enhance chemo- or radiosensitivity of human cutaneous melanoma cells by inducing the increased Bax/Bcl-2 ratio. Thus, the status of microRNA-21 might be an independent prognostic factor for patients with cutaneous melanoma, and microRNA-21 has the potential of being a novel molecular target for the treatment of human cutaneous melanoma.
target gene	hsa-mir-21	Melanoma	25587717	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	increased expression of miR-21 enhanced the invasive potential of melanoma cell lines through TIMP3 inhibition. Therefore, inhibition of miR-21 in melanoma may reduce melanoma invasiveness.
target gene	hsa-mir-211	Melanoma	24039954	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion.
target gene	hsa-mir-211	Melanoma	21072171	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	our findings that miR-211 is a direct posttranscriptional regulator of KCNMA1 expression as well as the dependence of this miRNA's expression on MITF activity, establishes miR-211 as an important regulatory agent in human melanoma.
target gene	hsa-mir-211	Melanoma	26599548	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Overexpression of mature miR-211 in Bcl-2 overexpressing cells rescued Bcl-2 ability to increase cell migration.
target gene	hsa-mir-214	Melanoma	21468029	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-214 is highly expressed in human melanomas and contributes to melanoma tumour progression through suppression of TFAP2C
target gene	hsa-mir-214	Melanoma	23667173	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation.
target gene	hsa-mir-216a	Melanoma	28225180	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	microRNA-216b inhibits cell proliferation and migration in human melanoma by targeting FOXM1 in vitro and in vivo.
target gene	hsa-mir-218	Melanoma	24839010	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma.
target gene	hsa-mir-221	Melanoma	19126397	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-221: mir-221 can directly interact with c-kit 3'UTR and inhibit cKit protein translation
target gene	hsa-mir-223	Melanoma	22356618	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiRTrail identified several deregulated miRNAs that target deregulated mRNAs including miRNAs hsa-miR-23b and hsa-miR-223, which target the highest numbers of deregulated mRNAs and regulate the pathway "basal cell carcinoma".
target gene	hsa-mir-23b	Melanoma	22356618	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiRTrail identified several deregulated miRNAs that target deregulated mRNAs including miRNAs hsa-miR-23b and hsa-miR-223, which target the highest numbers of deregulated mRNAs and regulate the pathway "basal cell carcinoma".
target gene	hsa-mir-25	Melanoma	27801786	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Upregulated MicroRNA-25 Mediates the Migration of Melanoma Cells by Targeting DKK3 through the WNT/β-Catenin Pathway.
target gene	hsa-mir-26a	Melanoma	28698805	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene.
target gene	hsa-mir-29a	Melanoma	23245396	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells
target gene	hsa-mir-29b-1	Melanoma	23245396	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells
target gene	hsa-mir-29b-2	Melanoma	23245396	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells
target gene	hsa-mir-328	Melanoma	25743834	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-328 inhibits proliferation of human melanoma cells by targeting TGFβ2.
target gene	hsa-mir-33b	Melanoma	25725129	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2.
target gene	hsa-mir-33b	Melanoma	25868853	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Cordycepin (3'-deoxyadenosine) suppressed HMGA2, Twist1 and ZEB1-dependent melanoma invasion and metastasis by targeting miR-33b.
target gene	hsa-mir-340	Melanoma	25414259	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	the RNA-binding protein, coding region determinant-binding protein, was shown to be highly expressed in melanoma, directly binds to the 3'-UTR of MITF mRNA, and prevents the binding of  miR-340 to its target sites, resulting in the stabilization of MITF transcripts, elevated expression, and transcriptional activity of MITF. This regulatory interplay between RNA-binding protein and miRNA highlights an important mechanism for the regulation of MITF in melanocytes and malignant melanomas.
target gene	hsa-mir-342	Melanoma	29495972	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-342 prohibits proliferation and invasion of melanoma cells by directly targeting Zinc-finger E-box binding homeobox 1
target gene	hsa-mir-34a	Melanoma	19029026	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-34a: MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met
target gene	hsa-mir-34b	Melanoma	22419847	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets.
target gene	hsa-mir-34c	Melanoma	22419847	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets.
target gene	hsa-mir-367	Melanoma	28829890	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN.
target gene	hsa-mir-375	Melanoma	28723760	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	CXCL8 interacted with STAT1, CCL27, and  IGF1R targeted by hsa-miR-375
target gene	hsa-mir-432	Melanoma	23728176	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	We found that cancer cells silence ADAR1 by overexpressing miR-17 and miR-432, which both directly target the ADAR1 transcript.
target gene	hsa-mir-488	Melanoma	28328082	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC.
target gene	hsa-mir-493	Melanoma	28475006	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Downregulation of miR-493 promoted melanoma proliferation by suppressing IRS4 expression.
target gene	hsa-mir-514a	Melanoma	25980496	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.
target gene	hsa-mir-524	Melanoma	25275294	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2.
target gene	hsa-mir-532	Melanoma	19336521	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-532-5p: miR-532-5p is a regulatory factor of RUNX3, which is down-regulated during melanoma progression
target gene	hsa-mir-675	Melanoma	24940649	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Cadherin 11, a miR-675 target, induces N-cadherin expression and epithelial-mesenchymal transition in melasma.
target gene	hsa-mir-7-1	Melanoma	23206698	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling
target gene	hsa-mir-7-2	Melanoma	23206698	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling
target gene	hsa-mir-7-3	Melanoma	23206698	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-7-5p may represent a novel tumor suppressor miRNA in melanoma, acting at least in part via its inhibition of IRS-2 expression and oncogenic Akt signaling
target gene	hsa-mir-767	Melanoma	29054757	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression.
target gene	hsa-mir-9	Melanoma	26104682	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	These results identify a novel YY1~miR-9~RYBP axis involved in melanoma tumorigenesis and reinforce the idea that regulatory circuitries involving miRNAs and TFs are prevalent mechanisms.
target gene	hsa-mir-9	Melanoma	27895497	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-9 suppresses the growth, migration, and invasion of malignant melanoma cells via targeting NRP1.
target gene	hsa-mir-9	Melanoma	28810544	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-9 inhibits the proliferation and migration of malignant melanoma cells via targeting sirituin 1.
target gene	hsa-mir-98	Melanoma	25277211	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-98 suppresses melanoma metastasis through a negative feedback loop with its target gene IL-6.
target gene	hsa-mir-675	Melasma	24335901				D008548			Reduced MiR-675 in exosome in H19 RNA-related melanogenesis via MITF as a direct target.
target gene	hsa-mir-224	Meningioma	25783051	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma.
target gene	hsa-mir-335	Meningioma	22886530	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas.
target gene	hsa-mir-125b	Meningitis, Pneumococcal	29611100			G00.1	D008586			hsa-miR-25-3p and hsa-miR-125b-5p target the transcription factor TEF-1, for which there are binding sites in Il-1β, Ccl 2 , and Ccl 3 genes
target gene	hsa-mir-25	Meningitis, Pneumococcal	29611100			G00.1	D008586			hsa-miR-25-3p and hsa-miR-125b-5p target the transcription factor TEF-1, for which there are binding sites in Il-1β, Ccl 2 , and Ccl 3 genes
target gene	hsa-mir-146a	Mesial Temporal Lobe Epilepsy	29590637			G40.209	D004833	608096		modulation of the miR-146a-CFH-IL-1β loop circuit could be a novel therapeutic target for TLE
target gene	hsa-let-7a-1	Mesothelioma	21869823	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs.
target gene	hsa-let-7a-3	Mesothelioma	21869823	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs.
target gene	hsa-let-7f-1	Mesothelioma	21869823	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs.
target gene	hsa-let-7f-2	Mesothelioma	21869823	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.EphrinA1 activation induced several fold increases in let-7a1, let-7a3, let-7f1 and let-7f2 miRNA expression in MMCs.
target gene	hsa-mir-126	Mesothelioma	24444362	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function.
target gene	hsa-mir-379	Mesothelioma	25231602	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
target gene	hsa-mir-411	Mesothelioma	25231602	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
target gene	hsa-mir-503	Microvascular Disease	26268439							Collectively, our data demonstrate that miR-503 regulates pericyte-endothelial crosstalk in microvascular diabetic complications.
target gene	hsa-mir-106b	Mitochondrial Metabolism Disease	25529328	disease of metabolism	DOID:700	E88.40	D028361			miR-106b negatively regulated skeletal muscle mitochondrial function and insulin sensitivity under PA-induced insulin resistance by targeting Mfn2, which may be associated with reduced ROS and upregulation of the ERR-α/PGC-1α/Mfn2 axis.
target gene	hsa-mir-29a	Mitochondrial Metabolism Disease	29322081	disease of metabolism	DOID:700	E88.40	D028361			Data of expression status of miR-29a and its putative target mitochondrial apoptosis regulatory gene DRP1 upon miR-15a and miR-214 inhibition
target gene	hsa-let-7c	Moyamoya Disease	26070522	cardiovascular system disease	DOID:13099	I67.5	D009072	PS252350	HP:0011834	Increased expression of let-7c in MMD patients may contribute to MMD pathogenesis by targeting RNF213. Thus, let-7c may be a potential biomarker for the diagnosis of MMD.
target gene	hsa-mir-137	Multiple Myeloma	25724519	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.
target gene	hsa-mir-137	Multiple Myeloma	27531781	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The miR137-MITF is an important index in judging the prognosis of multiple myeloma.
target gene	hsa-mir-148a	Multiple Myeloma	27842905	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MiR-148a participates in the growth of RPMI8226 multiple myeloma cells by regulating CDKN1B.
target gene	hsa-mir-15a	Multiple Myeloma	22133358	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level.
target gene	hsa-mir-15a	Multiple Myeloma	23104180	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF
target gene	hsa-mir-15a	Multiple Myeloma	26117022	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	High expression of miR-15a can induce cell cycle arrest and apoptosis of MM cells, then inhibit their growth. The mechanisms may be related with the negative regulation of BMI-1 and BCL-2 genes in post-transcription level caused by miR-15a.
target gene	hsa-mir-15a	Multiple Myeloma	19401561	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.
target gene	hsa-mir-16	Multiple Myeloma	19401561	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.
target gene	hsa-mir-16	Multiple Myeloma	20962322	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	We validated designated genes showing binding sites within the conserved 3'-UTR and also within the mRNA coding region as direct miR-16 targets, thus indicating that the miRNAs may have many more targets than anticipated by conventional prediction methods.
target gene	hsa-mir-16-1	Multiple Myeloma	23104180	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF
target gene	hsa-mir-16-2	Multiple Myeloma	23104180	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF
target gene	hsa-mir-197	Multiple Myeloma	25724519	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.
target gene	hsa-mir-199a	Multiple Myeloma	24839982	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.
target gene	hsa-mir-19a	Multiple Myeloma	29201171	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	the results of the present study indicate that targets genes of miR-19a are potential candidate biomarkers for MM
target gene	hsa-mir-202	Multiple Myeloma	24506956	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MiR-202 can inhibit the proliferation and induce apoptosis in MM cells via regulating BAFF. JNK/SAPK signaling pathway is involved in the regulation of BAFF by miR-202.
target gene	hsa-mir-21	Multiple Myeloma	23446999	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth
target gene	hsa-mir-21	Multiple Myeloma	25825239	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation,metastasis and invasion, however promotes the apoptosis of multiple myeloma cells.
target gene	hsa-mir-21	Multiple Myeloma	26687742	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	STAT3 and hsa-miR-125b, PIAS3 and hsa-miR-21 respectively formed self adaptation feedback regulations.
target gene	hsa-mir-221	Multiple Myeloma	26249174	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
target gene	hsa-mir-222	Multiple Myeloma	26249174	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
target gene	hsa-mir-29b-1	Multiple Myeloma	21951844	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1.
target gene	hsa-mir-451	Multiple Myeloma	25915427	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
target gene	hsa-mir-631	Multiple Myeloma	28000886	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
target gene	hsa-mir-122	Multiple Sclerosis	19617918	nervous system disease	DOID:2377	G35	D009103	PS126200		The genes targeted by hsa-miR-96 are involved inimmunological pathways as Interleukin signaling and in other pathways as wnt signaling
target gene	hsa-mir-132	Multiple Sclerosis	25136908	nervous system disease	DOID:2377	G35	D009103	PS126200		Over-expression of miR-132 in normal B cells significantly enhanced their production of lymphotoxin and tumor necrosis factor 伪. The over-expression of miR-132 also suppressed the miR-132 target, sirtuin-1.
target gene	hsa-mir-155	Multiple Sclerosis	23818336	nervous system disease	DOID:2377	G35	D009103	PS126200		Our results demonstrate that miR-155 regulates proinflammatory responses in both blood-derived and central nervous system (CNS)-resident myeloid cells, in addition to impacting subsequent adaptive immune responses.Differential miRNA expression may therefore provide insight into mechanisms responsible for distinct phenotypic and functional properties of myeloid cells,thus impacting their ability to influence CNS injury and repair.
target gene	hsa-mir-15b	Multiple Sclerosis	28228555	nervous system disease	DOID:2377	G35	D009103	PS126200		MicroRNA-15b Suppresses Th17 Differentiation and Is Associated with Pathogenesis of Multiple Sclerosis by Targeting O-GlcNAc Transferase.
target gene	hsa-mir-17	Multiple Sclerosis	20148420	nervous system disease	DOID:2377	G35	D009103	PS126200		Functional experiments with a synthetic inhibitor of miR-17 supported the link between miRNA expression and the altered target gene expression.
target gene	hsa-mir-197	Multiple Sclerosis	23895517	nervous system disease	DOID:2377	G35	D009103	PS126200		MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS).
target gene	hsa-mir-29a	Multiple Sclerosis	22772450	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis.
target gene	hsa-mir-29b-1	Multiple Sclerosis	22772450	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis.
target gene	hsa-mir-29b-2	Multiple Sclerosis	22772450	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-29ab Deficiency Identifies a Negative Feedback Loop Controlling Th1 Bias That Is Dysregulated in Multiple Sclerosis.
target gene	hsa-mir-326	Multiple Sclerosis	29181619	nervous system disease	DOID:2377	G35	D009103	PS126200		MicroRNA-326 contributes to autoimmune thyroiditis by targeting the Ets-1 protein
target gene	hsa-mir-448	Multiple Sclerosis	28342869	nervous system disease	DOID:2377	G35	D009103	PS126200		MicroRNA-448 promotes multiple sclerosis development through induction of Th17 response through targeting protein tyrosine phosphatase non-receptor type 2 (PTPN2).
target gene	hsa-mir-494	Multiple Sclerosis	23895517	nervous system disease	DOID:2377	G35	D009103	PS126200		MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS).
target gene	hsa-mir-18a	Muscle Atrophy	28782600			M62.5	D009133		HP:0100295	miR-18a induces myotubes atrophy by down-regulating IgfI.
target gene	hsa-mir-206	Muscle Diseases [unspecific]	24107628			M63.80	D009135			miR-206 directly targets cyclin D1 and contributes to the regulation of CCND1 gene expression in both myogenic and non-muscle, transformed cells.
target gene	hsa-mir-23a	Muscular Dystrophy	21926429			G71.0	D009136	310200	HP:0003560	miR-23a suppresses the translation of both MAFbx/atrogin-1 and MuRF1 in a 3UTR-dependent manner. Ectopic expression of miR-23a is sufficient to protect muscles from atrophy in vitro and in vivo.
target gene	hsa-mir-143	Muscular Dystrophy, Duchenne	27223470	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miRNA-143 as a direct regulator of 尾-dystrobrevin expression
target gene	hsa-mir-31	Muscular Dystrophy, Duchenne	21212803	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-31 represses dystrophin expression by targeting its 3' untranslated region.
target gene	hsa-mir-25	Muscular Dystrophy, Facioscapulohumeral	20519410	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		miR-25:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
target gene	hsa-mir-32	Muscular Dystrophy, Facioscapulohumeral	20519410	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		miR-32:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
target gene	hsa-mir-363	Muscular Dystrophy, Facioscapulohumeral	20519410	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		miR-363:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
target gene	hsa-mir-367	Muscular Dystrophy, Facioscapulohumeral	20519410	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		miR-367:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
target gene	hsa-mir-92a-1	Muscular Dystrophy, Facioscapulohumeral	20519410	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		miR-92:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
target gene	hsa-mir-92a-2	Muscular Dystrophy, Facioscapulohumeral	20519410	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		miR-92:We report for the first time that FXR1P is regulated through miRNA binding, with one site being the miR-25/32/92/363/367 seed sequence
target gene	hsa-mir-15a	Myasthenia Gravis	26845678	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10.
target gene	hsa-mir-15b	Myasthenia Gravis	26087886	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		This study is the first to report the miR-15b-IL-15 axis can directly regulate IL15 expression, which helps to further explain the abnormal IL-15 expression in MG patients and the pathogenesis of MG.
target gene	hsa-mir-320a	Myasthenia Gravis	23196978	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1
target gene	hsa-let-7	Mycobacterium tuberculosis Infection	25683052			A18	D014376	607948		MicroRNA let-7 modulates the immune response to Mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-κB pathway.
target gene	hsa-mir-26a	Mycobacterium tuberculosis Infection	28558034			A18	D014376	607948		MicroRNA 26a (miR-26a)/KLF4 and CREB-C/EBPβ regulate innate immune signaling, the polarization of macrophages and the trafficking of Mycobacterium tuberculosis to lysosomes during infection.
target gene	hsa-mir-27b	Mycobacterium tuberculosis Infection	29661829			A18	D014376	607948		we revealed a novel role of the miR-27b/Bag2 axis in the regulation of inflammatory response and apoptosis and provide a potential molecular host defense mechanism against mycobacteria
target gene	hsa-mir-32	Mycobacterium tuberculosis Infection	28215633			A18	D014376	607948		TLR-4/miRNA-32-5p/FSTL1 signaling regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages.
target gene	hsa-mir-17	Myelodysplastic Syndromes	23246221	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes
target gene	hsa-mir-20a	Myelodysplastic Syndromes	23246221	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes
target gene	hsa-mir-22	Myelodysplastic Syndromes	23827711	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.
target gene	hsa-mir-23a	Myelodysplastic Syndromes	24584347	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells.
target gene	hsa-mir-125b	Myeloma	25987254			C90.0	D009101	254500		Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
target gene	hsa-mir-125b	Myeloma	27903272			C90.0	D009101	254500		BETi-mediated inhibition of cMYC correlates with the upregulation of miR-125b-5p and the downregulation of the cMYC/miR-125b-5p target gene IRF4, a transcriptional repressor of MICA
target gene	hsa-mir-135b	Myeloma	25320245			C90.0	D009101	254500		Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
target gene	hsa-mir-15a	Myeloma	27596960			C90.0	D009101	254500		MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma.
target gene	hsa-mir-15a	Myeloma	29399181			C90.0	D009101	254500		Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression
target gene	hsa-mir-16	Myeloma	27596960			C90.0	D009101	254500		MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma.
target gene	hsa-mir-16	Myeloma	29399181			C90.0	D009101	254500		Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN2 expression
target gene	hsa-mir-203	Myeloma	27748826			C90.0	D009101	254500		miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myeloma cells.
target gene	hsa-mir-125a	Myeloproliferative Neoplasms	23012470	disease of cellular proliferation	DOID:2226	D47.1		616871		we demonstrate that miR-125a targets multiple protein phosphatases. Our data demonstrate that miR-125a-induced MPN is addicted to its sustained overexpression, and highlight the complex nature of oncogenic miRNA dependence in an early neoplastic state.
target gene	hsa-mir-1	Myocardial Infarction	25995211	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	These experiments revealed the role of inducible cAMP early repressor as a repressor of miR-1 and Ito
target gene	hsa-mir-107	Myocardial Infarction	22482882	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	IPC enhances stem cell survival via the combined participation of hypoxia responsive miRs miR-107 and miR-210 via their respective putative target genes Pdcd10 and Casp8ap2.
target gene	hsa-mir-149	Myocardial Infarction	23873935	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis.
target gene	hsa-mir-150	Myocardial Infarction	22039399	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4.
target gene	hsa-mir-150	Myocardial Infarction	28597963	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-181a and miR-150 regulate dendritic cell immune inflammatory responses and cardiomyocyte apoptosis via targeting JAK1-STAT1/c-Fos pathway.
target gene	hsa-mir-16	Myocardial Infarction	28423616	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Suppression of microRNA-16 protects against acute myocardial infarction by reversing beta2-adrenergic receptor down-regulation in rats.
target gene	hsa-mir-17	Myocardial Infarction	26265044	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The delivery of exogenous miR-17 suppressed Apaf-1  expression and consequently attenuated formation of the apoptosome complex containing caspase-9, as demonstrated by co-immunoprecipitation and immunocytochemistry.
target gene	hsa-mir-181a	Myocardial Infarction	28597963	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-181a and miR-150 regulate dendritic cell immune inflammatory responses and cardiomyocyte apoptosis via targeting JAK1-STAT1/c-Fos pathway.
target gene	hsa-mir-186	Myocardial Infarction	27205869	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-186 promotes macrophage lipid accumulation and pro-inflammatory cytokine secretion by targeting cystathionine 纬-lyase in THP-1 macrophages.
target gene	hsa-mir-206	Myocardial Infarction	21731608	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	HMGB1 injected into chronically failing hearts enhanced LV function and attenuated LV remodelling; these effects were associated with cardiac regeneration, increased collagenolytic activity, miR-206 overexpression and miR-206 -mediated inhibition of TIMP-3.
target gene	hsa-mir-208a	Myocardial Infarction	26861724	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-208a can promote Ang II-induced cardiomyocyte apoptosis via negatively regulating NLK expression
target gene	hsa-mir-21	Myocardial Infarction	19336275	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-21: miR-21 can protect this by targeting PDCD4
target gene	hsa-mir-21	Myocardial Infarction	28817807	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7.
target gene	hsa-mir-21	Myocardial Infarction	29674977	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	the programmed cell death 4 (PDCD4) expression was identified as a target gene of miR-21
target gene	hsa-mir-210	Myocardial Infarction	22482882	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	IPC enhances stem cell survival via the combined participation of hypoxia responsive miRs miR-107 and miR-210 via their respective putative target genes Pdcd10 and Casp8ap2.
target gene	hsa-let-7	Myocardial Ischemic-Reperfusion Injury	26844226				D015428			After Myocardial Ischemia-Reperfusion, miR-29a, and Let7 Could Affect Apoptosis through Regulating IGF-1.
target gene	hsa-mir-21	Myocardial Ischemic-Reperfusion Injury	19336275				D015428			miR-21: miR-21 can protect this by targeting PDCD4
target gene	hsa-mir-384	Myocardial Ischemic-Reperfusion Injury	23315007				D015428			MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3Kp110ж─)
target gene	hsa-mir-328	Myopia	22447870	nervous system disease	DOID:11830	H52.1	D009216	PS160700		MicroRNA-328 may influence myopia development by mediating the PAX6 gene.
target gene	hsa-mir-148a	Myositis Ossificans	22408438	musculoskeletal system disease	DOID:668		D009221			ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a.
target gene	hsa-mir-103a-1	Myotonic Muscular Dystrophy	17697356			G71.11	D009223	160900		These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK.
target gene	hsa-mir-103a-2	Myotonic Muscular Dystrophy	17697356			G71.11	D009223	160900		These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK.
target gene	hsa-mir-107	Myotonic Muscular Dystrophy	17697356			G71.11	D009223	160900		These results support a role for miRNAs in DM1 pathogenesis, and, in particular, highlight mir-107 and mir-103 as attractive candidates for binding to DMPK.
target gene	hsa-mir-135b	Myxoid Liposarcoma	27157622	disease of cellular proliferation	DOID:5363	C49.9	D018208	613488	HP:0012268	Decreased THBS2 expression by miR-135b increases the total amount of matrix metalloproteinase 2 (MMP2) and influences cellular density and an extracellular matrix structure, thereby resulting in morphological change in tumor.
target gene	hsa-mir-100	Nasopharyngeal Neoplasms	19739117			C11.9	D009303	607107	HP:0100630	miR-100 can directly target Plk1
target gene	hsa-mir-101-1	Nasopharyngeal Neoplasms	21368858			C11.9	D009303	607107	HP:0100630	Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.
target gene	hsa-mir-101-2	Nasopharyngeal Neoplasms	21368858			C11.9	D009303	607107	HP:0100630	Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.
target gene	hsa-mir-1-1	Nasopharyngeal Neoplasms	22059741			C11.9	D009303	607107	HP:0100630	MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells.
target gene	hsa-mir-1-2	Nasopharyngeal Neoplasms	22059741			C11.9	D009303	607107	HP:0100630	MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells.
target gene	hsa-mir-138-1	Nasopharyngeal Neoplasms	22739938			C11.9	D009303	607107	HP:0100630	MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene.
target gene	hsa-mir-138-2	Nasopharyngeal Neoplasms	22739938			C11.9	D009303	607107	HP:0100630	MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene.
target gene	hsa-mir-144	Nasopharyngeal Neoplasms	23125220			C11.9	D009303	607107	HP:0100630	MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN
target gene	hsa-mir-205	Nasopharyngeal Neoplasms	22306986			C11.9	D009303	607107	HP:0100630	MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN.
target gene	hsa-mir-205	Nasopharyngeal Neoplasms	22374676			C11.9	D009303	607107	HP:0100630	MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN.
target gene	hsa-mir-214	Nasopharyngeal Neoplasms	23479198			C11.9	D009303	607107	HP:0100630	miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma
target gene	hsa-mir-216b	Nasopharyngeal Neoplasms	21878506			C11.9	D009303	607107	HP:0100630	miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma.
target gene	hsa-mir-218-1	Nasopharyngeal Neoplasms	21385904			C11.9	D009303	607107	HP:0100630	miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway.
target gene	hsa-mir-218-2	Nasopharyngeal Neoplasms	21385904			C11.9	D009303	607107	HP:0100630	miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway.
target gene	hsa-mir-26a-1	Nasopharyngeal Neoplasms	21199804			C11.9	D009303	607107	HP:0100630	MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2
target gene	hsa-mir-26a-1	Nasopharyngeal Neoplasms	21368858			C11.9	D009303	607107	HP:0100630	Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.
target gene	hsa-mir-26a-2	Nasopharyngeal Neoplasms	21199804			C11.9	D009303	607107	HP:0100630	MiR-26a Inhibits Cell Growth and Tumorigenesis of Nasopharyngeal Carcinoma through Repression of EZH2
target gene	hsa-mir-26a-2	Nasopharyngeal Neoplasms	21368858			C11.9	D009303	607107	HP:0100630	Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.
target gene	hsa-mir-663a	Nasopharyngeal Neoplasms	22249270			C11.9	D009303	607107	HP:0100630	MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma.
target gene	hsa-mir-9-1	Nasopharyngeal Neoplasms	23291181			C11.9	D009303	607107	HP:0100630	miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells
target gene	hsa-mir-9-2	Nasopharyngeal Neoplasms	23291181			C11.9	D009303	607107	HP:0100630	miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells
target gene	hsa-mir-98	Nasopharyngeal Neoplasms	21368858			C11.9	D009303	607107	HP:0100630	Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.
target gene	hsa-let-7a	Neoplasms [unspecific]	28057739			C80.1	D009369			the let-7-HMGA2 axis plays a prominent role in the pathogenesis of the disease that leads to unique clinical phenotypes
target gene	hsa-let-7a-1	Neoplasms [unspecific]	20033209			C80.1	D009369			let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
target gene	hsa-let-7a-1	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7a-1	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7a-1	Neoplasms [unspecific]	18758960			C80.1	D009369			Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3
target gene	hsa-let-7a-2	Neoplasms [unspecific]	20033209			C80.1	D009369			let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
target gene	hsa-let-7a-2	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7a-2	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7a-2	Neoplasms [unspecific]	18758960			C80.1	D009369			Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3
target gene	hsa-let-7a-3	Neoplasms [unspecific]	20033209			C80.1	D009369			let-7a:The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice
target gene	hsa-let-7a-3	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7a-3	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7a-3	Neoplasms [unspecific]	18758960			C80.1	D009369			Let-7a: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3
target gene	hsa-let-7b	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7b	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7c	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7c	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7c	Neoplasms [unspecific]	18006822			C80.1	D009369			In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade.
target gene	hsa-let-7d	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7d	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7e	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7e	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7f-1	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7f-1	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7f-2	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7f-2	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7g	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7g	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7i	Neoplasms [unspecific]	17322030			C80.1	D009369			Disrupting the pairing between let-7 and Hmga2
target gene	hsa-let-7i	Neoplasms [unspecific]	17989227			C80.1	D009369			let-7 family members have been suggested to serve as tumor suppressors by directly inhibiting the Hmg2A and RAS protooncogenes
target gene	hsa-let-7i	Neoplasms [unspecific]	27770612			C80.1	D009369			Let-7i-Induced Atg4B Suppression Is Essential for Autophagy of Placental Trophoblast in Preeclampsia.
target gene	hsa-mir-1	Neoplasms [unspecific]	27819721			C80.1	D009369			miR-1 association with cell proliferation inhibition and apoptosis in vestibular schwannoma by targeting VEGFA.
target gene	hsa-mir-101	Neoplasms [unspecific]	18096665			C80.1	D009369			The most up-regulated miR-196b and its precursors are highly expressed in the skin and showed similar tissue-specific expression patterns after treatment, indicating a common pattern of regulation by E(2). MiR-196b was shown to fine-tune the expression of its target gene Hoxb8a after treatment in whole-body homogenates.
target gene	hsa-mir-101-1	Neoplasms [unspecific]	20586854			C80.1	D009369			miR-101:Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation
target gene	hsa-mir-101-1	Neoplasms [unspecific]	23178713			C80.1	D009369			MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma
target gene	hsa-mir-101-2	Neoplasms [unspecific]	20586854			C80.1	D009369			miR-101:Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation
target gene	hsa-mir-101-2	Neoplasms [unspecific]	23178713			C80.1	D009369			MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma
target gene	hsa-mir-106a	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-106:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
target gene	hsa-mir-107	Neoplasms [unspecific]	20308559			C80.1	D009369			Taken together these data suggest that miR-107 can mediate p53 regulation of hypoxic signaling and tumor angiogenesis.
target gene	hsa-mir-10a	Neoplasms [unspecific]	18006822			C80.1	D009369			In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade.
target gene	hsa-mir-10b	Neoplasms [unspecific]	22915757			C80.1	D009369			MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells.
target gene	hsa-mir-10b	Neoplasms [unspecific]	25074381			C80.1	D009369			3'LIFE is a rapid and sensitive method to detect miRNA targets in high-throughput
target gene	hsa-mir-122	Neoplasms [unspecific]	19584290			C80.1	D009369			down-regulated; modulates expression of immunoinhibitory molecule B7-H3;directly target B7-H3 3' untranslated region, and knock-in and knockdown of miR-29a led to down-regulation and up-regulation of B7-H3 protein expression; potential immune based therapy
target gene	hsa-mir-1248	Neoplasms [unspecific]	24088671			C80.1	D009369			In humans, miR-1248 was found to regulate the expression of mRNAs involved in inflammatory pathways and miR-181a was found to correlate negatively with the pro-inflammatory cytokines IL-6 and TNFα and to correlate positively with the anti-inflammatory cytokines TGFβ and IL-10.
target gene	hsa-mir-125a	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-125:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
target gene	hsa-mir-125a	Neoplasms [unspecific]	25725290			C80.1	D009369			our study has demonstrated that Egr1 is able to regulate miRNA activity of miR-125a-3p in human cells through binding TRBP, which highlights an unexpected function of Egr1 in miRNA pathway.
target gene	hsa-mir-125a	Neoplasms [unspecific]	26713860			C80.1	D009369			miR-125a suppressed Zbtb7a expression through its direct binding to the Zbtb7a-3'UTR.
target gene	hsa-mir-125b	Neoplasms [unspecific]	26966351			C80.1	D009369			miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism.
target gene	hsa-mir-125b	Neoplasms [unspecific]	20935678			C80.1	D009369			Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d.
target gene	hsa-mir-126	Neoplasms [unspecific]	24603804			C80.1	D009369			MicroRNA-126 modulates the tumor microenvironment by targeting calmodulin-regulated spectrin-associated protein 1 (Camsap1).
target gene	hsa-mir-126	Neoplasms [unspecific]	24274104			C80.1	D009369			Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126.
target gene	hsa-mir-126	Neoplasms [unspecific]	27611944			C80.1	D009369			MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression.
target gene	hsa-mir-127	Neoplasms [unspecific]	26655997			C80.1	D009369			Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6.
target gene	hsa-mir-127	Neoplasms [unspecific]	17012848			C80.1	D009369			For example, mir-127, which is generally expressed in normal cells but absent in cancer cells, was markedly induced after treatment. Intriguingly, a predicted target of mir-127, BCL6, was translationally downregulated after treatment.
target gene	hsa-mir-128	Neoplasms [unspecific]	23958464			C80.1	D009369			miR-128 and its target genes in tumorigenesis and metastasis.
target gene	hsa-mir-128	Neoplasms [unspecific]	29568354			C80.1	D009369			miR-128 inhibits telomerase activity by targeting TERT mRNA
target gene	hsa-mir-129	Neoplasms [unspecific]	28536635			C80.1	D009369			the regulation of NG2 expression underlies inflammation  and hypoxia and is mediated by methyltransferases, transcription factors, including Sp1, paired box (Pax) 3 and Egr-1, and the microRNA miR129-2
target gene	hsa-mir-1291	Neoplasms [unspecific]	25934574			C80.1	D009369			Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.
target gene	hsa-mir-130a	Neoplasms [unspecific]	17957028			C80.1	D009369			From these data, we conclude that miR-130a is a regulator of the angiogenic phenotype of vascular ECs largely through its ability to modulate the expression of GAX and HOXA5.
target gene	hsa-mir-130a	Neoplasms [unspecific]	28393235			C80.1	D009369			Epigenetic silencing of miR-130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling.
target gene	hsa-mir-130a	Neoplasms [unspecific]	28935812			C80.1	D009369			miR-130a Deregulates PTEN and Stimulates Tumor Growth.
target gene	hsa-mir-135a-1	Neoplasms [unspecific]	23438844			C80.1	D009369			MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
target gene	hsa-mir-135a-2	Neoplasms [unspecific]	23438844			C80.1	D009369			MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
target gene	hsa-mir-137	Neoplasms [unspecific]	23178914			C80.1	D009369			miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1
target gene	hsa-mir-138-1	Neoplasms [unspecific]	20232393			C80.1	D009369			we demonstrate that miR-138 suppresses TSCC cell migration and invasion by regulating two key genes in the Rho GTPase signaling pathway
target gene	hsa-mir-138-1	Neoplasms [unspecific]	23438844			C80.1	D009369			MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
target gene	hsa-mir-138-2	Neoplasms [unspecific]	20232393			C80.1	D009369			we demonstrate that miR-138 suppresses TSCC cell migration and invasion by regulating two key genes in the Rho GTPase signaling pathway
target gene	hsa-mir-138-2	Neoplasms [unspecific]	23438844			C80.1	D009369			MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
target gene	hsa-mir-139	Neoplasms [unspecific]	25833697			C80.1	D009369			miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM.
target gene	hsa-mir-141	Neoplasms [unspecific]	24616104			C80.1	D009369			Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells.
target gene	hsa-mir-141	Neoplasms [unspecific]	25505268			C80.1	D009369			PLK1 inhibition down-regulates BMI1 by upregulating the miRNA-200c/141 cluster, which encodes miR-200c and miR-141, both of which are known to post-transcriptionally downregulate BMI1 expression.
target gene	hsa-mir-141	Neoplasms [unspecific]	19182522			C80.1	D009369			miR-141: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
target gene	hsa-mir-142	Neoplasms [unspecific]	26805039			C80.1	D009369			Our observations suggest that miR-142-3p functioned as a tumor suppressor by targeting CDC25C.
target gene	hsa-mir-143	Neoplasms [unspecific]	23804075			C80.1	D009369			De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells.
target gene	hsa-mir-144	Neoplasms [unspecific]	25151965			C80.1	D009369			Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.
target gene	hsa-mir-144	Neoplasms [unspecific]	26169798			C80.1	D009369			Our approach provides important insights into miRNAs and their role in regulatory networks. The methodology can be applied to systematically investigate the differences in target genes and pathways of arbitrary miRNA sets.
target gene	hsa-mir-144	Neoplasms [unspecific]	25907866			C80.1	D009369			MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
target gene	hsa-mir-144	Neoplasms [unspecific]	18006822			C80.1	D009369			In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade.
target gene	hsa-mir-145	Neoplasms [unspecific]	24845504			C80.1	D009369			Differential expression of speckled POZ protein, SPOP: putative regulation by miR-145.
target gene	hsa-mir-145	Neoplasms [unspecific]	25124875			C80.1	D009369			MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways.
target gene	hsa-mir-145	Neoplasms [unspecific]	25445287			C80.1	D009369			miR-145 has the ability to regulate DDC mRNA expression and potentially this occurs by recognizing its mRNA as a target.
target gene	hsa-mir-145	Neoplasms [unspecific]	25069957			C80.1	D009369			Our network propagation based method takes advantage of the network effect of the miRNA perturbation on its target genes. It is a useful approach to infer the perturbed miRNAs and their key target genes associated with the studied biological processes using gene expression data.
target gene	hsa-mir-145	Neoplasms [unspecific]	23714355			C80.1	D009369			Insulin receptor substrate-1 (IRS1) was identified as a target gene of miR-145, by which miR-145 was able to suppress cell proliferation.
target gene	hsa-mir-146a	Neoplasms [unspecific]	28401709			C80.1	D009369			The role of microRNA-93 regulating angiopoietin2 in the formation of malignant pleural effusion.
target gene	hsa-mir-146b	Neoplasms [unspecific]	24473196			C80.1	D009369			STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes.
target gene	hsa-mir-148a	Neoplasms [unspecific]	24084367			C80.1	D009369			MicroRNA-148a (miR-148a) which suppresses tumor growth by directly decreasing DNMT1 expression has been demonstrated as an important role for cancer therapy. The mechanisms for miR-148a in cancer will become potential future researches.
target gene	hsa-mir-149	Neoplasms [unspecific]	20623644			C80.1	D009369			miR-149:miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells
target gene	hsa-mir-15	Neoplasms [unspecific]	24704828			C80.1	D009369			c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2α  and promotes tumor angiogenesis and metastasis by upregulating FGF2.
target gene	hsa-mir-15	Neoplasms [unspecific]	20385127			C80.1	D009369			Our data thus imply that miR-15a regulates cell size and proliferation by fine-tuning Dlk1 among others, and further emphasize miR-15a and DLK1 levels to play important roles in growth signaling networks.
target gene	hsa-mir-150	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-150:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
target gene	hsa-mir-150	Neoplasms [unspecific]	24203759			C80.1	D009369			Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development.
target gene	hsa-mir-150	Neoplasms [unspecific]	18006822			C80.1	D009369			In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade.
target gene	hsa-mir-151a	Neoplasms [unspecific]	24088671			C80.1	D009369			In humans, miR-1248 was found to regulate the expression of mRNAs involved in inflammatory pathways and miR-181a was found to correlate negatively with the pro-inflammatory cytokines IL-6 and TNFα and to correlate positively with the anti-inflammatory cytokines TGFβ and IL-10.
target gene	hsa-mir-151a	Neoplasms [unspecific]	20445018			C80.1	D009369			miR-151:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity
target gene	hsa-mir-152	Neoplasms [unspecific]	25311946			C80.1	D009369			Mir-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by targeting KIT.
target gene	hsa-mir-152	Neoplasms [unspecific]	25194984			C80.1	D009369			MicroRNA-152 modulates the canonical Wnt pathway activation by targeting DNA methyltransferase 1 in arthritic rat model.
target gene	hsa-mir-155	Neoplasms [unspecific]	25633840			C80.1	D009369			miR-155 regulates TP53INP1 expression, to induce the epithelial-mesenchymal transition and acquisition of a stem cell phenotype.
target gene	hsa-mir-155	Neoplasms [unspecific]	24177167			C80.1	D009369			TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth.
target gene	hsa-mir-155	Neoplasms [unspecific]	18006822			C80.1	D009369			In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade.
target gene	hsa-mir-155	Neoplasms [unspecific]	28338203			C80.1	D009369			MiR-155 regulates oral squamous cell carcinoma Tca8113 cell proliferation, cycle, and apoptosis via regulating p27Kip1.
target gene	hsa-mir-155	Neoplasms [unspecific]	29066622			C80.1	D009369			MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.
target gene	hsa-mir-15a	Neoplasms [unspecific]	26686086			C80.1	D009369			In vivo inhibition of a PPAR纬-regulated miR-15a/angiopoietin-1 pathway blocked increased angiogenesis and MSC expansion.
target gene	hsa-mir-15b	Neoplasms [unspecific]	20154725			C80.1	D009369			miR-15b:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
target gene	hsa-mir-16	Neoplasms [unspecific]	23941513			C80.1	D009369			In summary, the present study identifies several novel miR-16 targets and illustrates a novel function of miR-16 targeting MAP7 in modulating proliferation in cancer cells.
target gene	hsa-mir-16-1	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
target gene	hsa-mir-16-1	Neoplasms [unspecific]	20154725			C80.1	D009369			miR-16:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
target gene	hsa-mir-16-2	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-16:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
target gene	hsa-mir-16-2	Neoplasms [unspecific]	20154725			C80.1	D009369			miR-16:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
target gene	hsa-mir-17	Neoplasms [unspecific]	24194900			C80.1	D009369			MicroRNA-17, 20a regulates the proangiogenic function of tumor-associated macrophages via targeting hypoxia-inducible factor 2α.
target gene	hsa-mir-17	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-17:miR-16, miR-17, miR-34a-c, and miR-125 served as tumor suppressor miRNAs, while miR-20, miR-106, and miR-150 acted as oncogenic miRNAs
target gene	hsa-mir-17	Neoplasms [unspecific]	25069957			C80.1	D009369			Our network propagation based method takes advantage of the network effect of the miRNA perturbation on its target genes. It is a useful approach to infer the perturbed miRNAs and their key target genes associated with the studied biological processes using gene expression data.
target gene	hsa-mir-17	Neoplasms [unspecific]	20851997			C80.1	D009369			miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster
target gene	hsa-mir-17	Neoplasms [unspecific]	29574928			C80.1	D009369			The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways.
target gene	hsa-mir-18	Neoplasms [unspecific]	20851997			C80.1	D009369			miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster
target gene	hsa-mir-18	Neoplasms [unspecific]	29574928			C80.1	D009369			The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways.
target gene	hsa-mir-181a-1	Neoplasms [unspecific]	23085757			C80.1	D009369			miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer
target gene	hsa-mir-181a-2	Neoplasms [unspecific]	23085757			C80.1	D009369			miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer
target gene	hsa-mir-181b	Neoplasms [unspecific]	17965831			C80.1	D009369			Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163]
target gene	hsa-mir-181c	Neoplasms [unspecific]	26607087			C80.1	D009369			Transfection with miR-181 mimics can suppress glycolysis in CAFs by inhibiting HK2 expression.
target gene	hsa-mir-185	Neoplasms [unspecific]	20603620			C80.1	D009369			miRNA-185:MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers
target gene	hsa-mir-186	Neoplasms [unspecific]	24935378			C80.1	D009369			miR-186 regulates glycolysis through Glut1 during the formation of cancer-associated fibroblasts.
target gene	hsa-mir-18a	Neoplasms [unspecific]	25923049			C80.1	D009369			this probe can be used for cell-specific intracellular miRNA sensing with a confocal microscope. Using miRNA-18a as a target model, the dynamic changes of its expression level inside living cells can be monitored with the proposed method. This method possesses promising applications in the study of miRNA related bioprocesses and biomedicine.
target gene	hsa-mir-19	Neoplasms [unspecific]	25308476			C80.1	D009369			miR-19, a component of the oncogenic miR-17-92 cluster, targets the DNA-end resection factor CtIP.
target gene	hsa-mir-190	Neoplasms [unspecific]	24962367			C80.1	D009369			The synergistic regulation of VEGF-mediated angiogenesis through miR-190 and target genes.
target gene	hsa-mir-191	Neoplasms [unspecific]	25992613			C80.1	D009369			MiR-191 Regulates Primary Human Fibroblast Proliferation and Directly Targets Multiple Oncogenes.
target gene	hsa-mir-192	Neoplasms [unspecific]	27041221			C80.1	D009369			A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.
target gene	hsa-mir-193	Neoplasms [unspecific]	18006822			C80.1	D009369			In addition to known genes, siRNAs targeting CDK4, PTGS1, ALG2, CLCN3, IRAK4, and MAP3K8 altered TRAIL-induced caspase-3 activation responses. Introduction of the miRNAs let-7c, mir-10a, mir-144, mir-150, mir-155, and mir-193 also affected the activation of the caspase cascade.
target gene	hsa-mir-193a	Neoplasms [unspecific]	28449010			C80.1	D009369			Excess of a Rassf1-targeting microRNA, miR-193a-3p, perturbs cell division fidelity.
target gene	hsa-mir-193b	Neoplasms [unspecific]	23335975			C80.1	D009369			MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1
target gene	hsa-mir-195	Neoplasms [unspecific]	25047265			C80.1	D009369			Our findings taken together suggest that ZNF367 regulates cancer progression.
target gene	hsa-mir-196	Neoplasms [unspecific]	26141604			C80.1	D009369			The miR-196 miRNA gene family located within the Hox gene clusters hsa been shown to function during embryogenesis and to be aberrantly expressed in various malignancies
target gene	hsa-mir-196a	Neoplasms [unspecific]	24463357			C80.1	D009369			MiR-196a exerts its oncogenic effect in GBM by inhibiting IκBα both  in vitro and in vivo.
target gene	hsa-mir-196b	Neoplasms [unspecific]	18663355			C80.1	D009369			miR-196: MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers
target gene	hsa-mir-196b	Neoplasms [unspecific]	25889892			C80.1	D009369			we identified IGF2BP1 as a direct and functional target of miR-196b and showed that miR-196b overexpression reverses the chemoresistance induced by hypoxia. These results emphasize that the chemoresistance induced by hypoxia is a complex mechanism.
target gene	hsa-mir-198	Neoplasms [unspecific]	26225959			C80.1	D009369			we have identified that miR-198 inhibited HaCaT cell proliferation by directly targeting CCND2.
target gene	hsa-mir-199a	Neoplasms [unspecific]	24413338			C80.1	D009369			The findings establish critical roles of miR-199a-5p and its downstream targets HIF-1/COX-2 in arsenic-induced tumor growth and angiogenesis.
target gene	hsa-mir-199a-1	Neoplasms [unspecific]	21189327			C80.1	D009369			microRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers.
target gene	hsa-mir-199a-1	Neoplasms [unspecific]	23085757			C80.1	D009369			miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer
target gene	hsa-mir-199a-2	Neoplasms [unspecific]	21189327			C80.1	D009369			microRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers.
target gene	hsa-mir-199a-2	Neoplasms [unspecific]	23085757			C80.1	D009369			miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer
target gene	hsa-mir-19a	Neoplasms [unspecific]	20851997			C80.1	D009369			miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster
target gene	hsa-mir-19a	Neoplasms [unspecific]	29574928			C80.1	D009369			The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways.
target gene	hsa-mir-19b	Neoplasms [unspecific]	24742936			C80.1	D009369			miR-19b promotes tumor growth and metastasis via targeting TP53.
target gene	hsa-mir-19b-1	Neoplasms [unspecific]	20851997			C80.1	D009369			miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster
target gene	hsa-mir-19b-1	Neoplasms [unspecific]	29574928			C80.1	D009369			The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways.
target gene	hsa-mir-200	Neoplasms [unspecific]	25348003			C80.1	D009369			Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
target gene	hsa-mir-200a	Neoplasms [unspecific]	19182522			C80.1	D009369			miR-200a: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
target gene	hsa-mir-200a	Neoplasms [unspecific]	28817830			C80.1	D009369			MicroRNA-200a Inhibits Transforming Growth Factor β1-Induced Proximal Tubular Epithelial-Mesenchymal Transition by Targeting β-Catenin.
target gene	hsa-mir-200b	Neoplasms [unspecific]	24174534			C80.1	D009369			miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs.
target gene	hsa-mir-200b	Neoplasms [unspecific]	19182522			C80.1	D009369			miR-200b: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
target gene	hsa-mir-200c	Neoplasms [unspecific]	25505268			C80.1	D009369			PLK1 inhibition down-regulates BMI1 by upregulating the miRNA-200c/141 cluster, which encodes miR-200c and miR-141, both of which are known to post-transcriptionally downregulate BMI2 expression.
target gene	hsa-mir-200c	Neoplasms [unspecific]	26203557			C80.1	D009369			miR-200c dampens cancer cell migration via regulation of protein kinase A subunits.
target gene	hsa-mir-200c	Neoplasms [unspecific]	19182522			C80.1	D009369			miR-200c: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
target gene	hsa-mir-200c	Neoplasms [unspecific]	19665999			C80.1	D009369			inhibits through down-regulating LRP1
target gene	hsa-mir-200c	Neoplasms [unspecific]	24368337			C80.1	D009369			The proto-oncogene KRAS is targeted by miR-200c.
target gene	hsa-mir-200c	Neoplasms [unspecific]	28029649			C80.1	D009369			MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN.
target gene	hsa-mir-200b	Neoplasms [unspecific]	26079153			C80.1	D009369			Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene.
target gene	hsa-mir-200c	Neoplasms [unspecific]	26079153			C80.1	D009369			Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene.
target gene	hsa-mir-429	Neoplasms [unspecific]	26079153			C80.1	D009369			Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene.
target gene	hsa-mir-203	Neoplasms [unspecific]	23968727			C80.1	D009369			Hyper-methylated miR-203 dysregulates ABL1 and contributes to the nickel-induced  tumorigenesis.
target gene	hsa-mir-204	Neoplasms [unspecific]	25342468			C80.1	D009369			Transformer 2β and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA.
target gene	hsa-mir-205	Neoplasms [unspecific]	25973003			C80.1	D009369			These results indicate that miR-205 might inhibitor the proliferation of A549 cells by regulating the expression of PTEN.
target gene	hsa-mir-205	Neoplasms [unspecific]	24911147			C80.1	D009369			MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis.
target gene	hsa-mir-205	Neoplasms [unspecific]	23487795			C80.1	D009369			Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells
target gene	hsa-mir-205	Neoplasms [unspecific]	26586569			C80.1	D009369			miR-205 is upregulated upon NF-魏B activation and suppresses COMMD1 expression in stemness-enriched cancer cells.
target gene	hsa-mir-205	Neoplasms [unspecific]	26831618			C80.1	D009369			This alteration inverts relative expression levels of ZEB1 and its antagonizing microRNAs, miR-205 and miR-200c
target gene	hsa-mir-206	Neoplasms [unspecific]	19723635			C80.1	D009369			inhibits Notch3
target gene	hsa-mir-206	Neoplasms [unspecific]	26325180			C80.1	D009369			Taken together, our results demonstrated that miR-206 suppressed c-Met and Bcl2 expression in NSCLS and could function as a potent tumor suppressor in c-Met/Bcl2-over expressing tumors. Inhibition of miR-206 function could contribute to aberrant cell proliferation, migration, invasion and apoptosis,leading to NSCLS development.
target gene	hsa-mir-20a	Neoplasms [unspecific]	24194900			C80.1	D009369			MicroRNA-17, 20a regulates the proangiogenic function of tumor-associated macrophages via targeting hypoxia-inducible factor 2α.
target gene	hsa-mir-20a	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-20:miR-16, miR-17, miR-34a-c, and miR-125 served as tumor suppressor miRNAs, while miR-20, miR-106, and miR-150 acted as oncogenic miRNAs
target gene	hsa-mir-20a	Neoplasms [unspecific]	20851997			C80.1	D009369			miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster
target gene	hsa-mir-20a	Neoplasms [unspecific]	29574928			C80.1	D009369			The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways.
target gene	hsa-mir-21	Neoplasms [unspecific]	25242444			C80.1	D009369			By regulating the expression of its target gene PTEN, which subsequently affects the PI3K/AKT signalling pathway, miR-21 exerts its regulatory role on the radiation sensitivity of K562 cells. These results may help to provide the basis for microRNA-based targeted therapies to overcome radiation resistance in tumour cells.
target gene	hsa-mir-21	Neoplasms [unspecific]	26082192			C80.1	D009369			we describe the ever-expanding role of miR-21 and its target genes in different cancers, and provide insight into how this oncogenic miRNA regulates cancer cell proliferation, migration, and apoptosis by suppressing the expression of tumor suppressors.
target gene	hsa-mir-21	Neoplasms [unspecific]	26194786			C80.1	D009369			the miRNA-21 target is cyclically reused, and many MB-DNA fuel strands are attached to the sensor surface, leading to a significantly amplified current response for sensitive detection of miRNA-21 down to 1.4 fM. The developed sensor also shows high sequence discrimination capability and can be used to monitor miRNA-21 expression levels in cancer cells. Moreover, this sensor avoids the involvement of any enzymes for target recycling amplification and features with highly minimized background noise for miRNA detection, which makes this method hold great potential for convenient monitoring of different miRNA biomarkers for early diagnosis of various cancers.
target gene	hsa-mir-21	Neoplasms [unspecific]	20154725			C80.1	D009369			miR-21:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
target gene	hsa-mir-21	Neoplasms [unspecific]	21328460			C80.1	D009369			miR-21 downregulates the tumor suppressor P12(CDK2AP1) and Stimulates Cell Proliferation and Invasion.
target gene	hsa-mir-21	Neoplasms [unspecific]	23940701			C80.1	D009369			The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. aca-mir-146a
target gene	hsa-mir-21	Neoplasms [unspecific]	23890123			C80.1	D009369			MicroRNA-21 plays a significant role in cancer growth by regulating stemness in cancer cells.
target gene	hsa-mir-21	Neoplasms [unspecific]	23872064			C80.1	D009369			miR-21 coordinates tumor growth and modulates KRIT1 levels.
target gene	hsa-mir-21	Neoplasms [unspecific]	25589783			C80.1	D009369			the oncogenic miRNA miR-21 decreases the expression of FBXO11, which normally acts as a tumor suppressor, and thereby promotesz tumorigenesis.
target gene	hsa-mir-21	Neoplasms [unspecific]	25997617			C80.1	D009369			Our results suggest that miR-21 may regulate intestinal epithelial tight junction permeability through PTEN/PI3K/Akt signalling pathway. This promotes the feasibility of targeting miR-21 in the clinical to preserve the intestinal barrier.
target gene	hsa-mir-21	Neoplasms [unspecific]	18372920			C80.1	D009369			The demonstration that miR-21 promotes cell transformation supports the concept that mir-21 functions as an oncogene by a mechanism that involves translational repression of the tumor suppressor Pdcd4.
target gene	hsa-mir-21	Neoplasms [unspecific]	28571917			C80.1	D009369			Targeting miR-21 with Sophocarpine Inhibits Tumor Progression and Reverses Epithelial-Mesenchymal Transition in Head and Neck Cancer.
target gene	hsa-mir-211	Neoplasms [unspecific]	23934065			C80.1	D009369			Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1.
target gene	hsa-mir-216	Neoplasms [unspecific]	24384842			C80.1	D009369			miR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2.
target gene	hsa-mir-22	Neoplasms [unspecific]	25627978			C80.1	D009369			a central role of miR-22 in the physiologic regulation of MDC1-dependent DDR and suggest a molecular mechanism for how aberrant Akt1 activation and senescence lead to increased genomic instability, fostering an environment that promotes tumorigenesis.
target gene	hsa-mir-22	Neoplasms [unspecific]	20562918			C80.1	D009369			miR-22:miR-22 acts as a tumor suppressor through direct repression of MYCBP expression and subsequent reduction of oncogenic c-Myc activities.
target gene	hsa-mir-221	Neoplasms [unspecific]	24969479			C80.1	D009369			Expression patterns of miR-221 and its target Caspase-3 in different cancer cell lines.
target gene	hsa-mir-24-1	Neoplasms [unspecific]	23418360			C80.1	D009369			MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling
target gene	hsa-mir-24-2	Neoplasms [unspecific]	23418360			C80.1	D009369			MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling
target gene	hsa-mir-25	Neoplasms [unspecific]	20935678			C80.1	D009369			Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d.
target gene	hsa-mir-25	Neoplasms [unspecific]	28920955			C80.1	D009369			miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS.
target gene	hsa-mir-26	Neoplasms [unspecific]	25069957			C80.1	D009369			Our network propagation based method takes advantage of the network effect of the miRNA perturbation on its target genes. It is a useful approach to infer the perturbed miRNAs and their key target genes associated with the studied biological processes using gene expression data.
target gene	hsa-mir-26a	Neoplasms [unspecific]	24056962			C80.1	D009369			miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis.
target gene	hsa-mir-26a	Neoplasms [unspecific]	27613140			C80.1	D009369			MiR-26a inhibits proliferation and migration of HaCaT keratinocytes through regulating PTEN expression.
target gene	hsa-mir-26a	Neoplasms [unspecific]	28126920			C80.1	D009369			Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR.
target gene	hsa-mir-27a	Neoplasms [unspecific]	26687066			C80.1	D009369			Importantly, we find that Six1 expression leads to marked resistance to therapies targeting the p53-MDM2 interaction. Thus, we identify a competitive mechanism of p53 regulation, which may have consequences for drugs aimed at reinstating p53 function in tumours.
target gene	hsa-mir-27a	Neoplasms [unspecific]	18619946			C80.1	D009369			miR-27a: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein
target gene	hsa-mir-28	Neoplasms [unspecific]	20445018			C80.1	D009369			miR-28:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity
target gene	hsa-mir-28	Neoplasms [unspecific]	24491803			C80.1	D009369			miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation.
target gene	hsa-mir-29	Neoplasms [unspecific]	26470025			C80.1	D009369			MiR-29 restrained K562 cell growth and proliferation. MiR-29 induced K562 cell apoptosis through down-regulating FoxM1.
target gene	hsa-mir-299	Neoplasms [unspecific]	28426762			C80.1	D009369			Human microRNA-299-3p decreases invasive behavior of cancer cells by downregulation of Oct4 expression and causes apoptosis.
target gene	hsa-mir-29a	Neoplasms [unspecific]	17965831			C80.1	D009369			Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163], while miR-29b reduced Mcl-1 protein and rendered cholangiocarcinoma cells more susceptible to apoptosis.
target gene	hsa-mir-29a	Neoplasms [unspecific]	19079265			C80.1	D009369			miR-29a: miR-29 directly suppress p85 alpha and CDC42, both of which negatively regulate p53
target gene	hsa-mir-29b	Neoplasms [unspecific]	25422179			C80.1	D009369			Our review highlights the diverse relationships between miR-29b and its target genes in malignant tumors.
target gene	hsa-mir-29b-1	Neoplasms [unspecific]	17965831			C80.1	D009369			Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163], while miR-29b reduced Mcl-1 protein and rendered cholangiocarcinoma cells more susceptible to apoptosis.
target gene	hsa-mir-29b-2	Neoplasms [unspecific]	17965831			C80.1	D009369			Many miRNAs are located at chromosomal break points or fragile sites associated with cancer. Indeed miR-29a and miR-29b are associated with the fragile site FRA7H. In addition, miR-29b along with miR-181b may target the oncogene TCL1 in CLL patients [163]
target gene	hsa-mir-29a	Neoplasms [unspecific]	26096783			C80.1	D009369			Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma.
target gene	hsa-mir-29b	Neoplasms [unspecific]	26096783			C80.1	D009369			Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma.
target gene	hsa-mir-29c	Neoplasms [unspecific]	26096783			C80.1	D009369			Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma.
target gene	hsa-mir-30	Neoplasms [unspecific]	24599134			C80.1	D009369			miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.
target gene	hsa-mir-302	Neoplasms [unspecific]	27756792			C80.1	D009369			A MicroRNA302-367-Erk1/2-Klf2-S1pr1 Pathway Prevents Tumor Growth via Restricting Angiogenesis and Improving Vascular Stability.
target gene	hsa-mir-30a	Neoplasms [unspecific]	26473838			C80.1	D009369			In summary, we uncovered the protective function of miR30a targeting NFATc3 in the regulation of podocyte injury response to EMT.
target gene	hsa-mir-30b	Neoplasms [unspecific]	24898602			C80.1	D009369			Of the upregulated miRNAs, miR-30b expression demonstrated the greatest increase. The administration of miR-30b ASO for two weeks significantly reduced 伪-SMA excretion and upregulated E-cadherin and BMP-7 expression.
target gene	hsa-mir-30d	Neoplasms [unspecific]	23085757			C80.1	D009369			miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer
target gene	hsa-mir-30d	Neoplasms [unspecific]	20935678			C80.1	D009369			Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d.
target gene	hsa-mir-30e	Neoplasms [unspecific]	19223510			C80.1	D009369			miR-30e: directly targets Ubc9
target gene	hsa-mir-31	Neoplasms [unspecific]	23539435			C80.1	D009369			MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells
target gene	hsa-mir-31	Neoplasms [unspecific]	23999990			C80.1	D009369			The diverse role of miR-31 in regulating cancer associated phenotypes.
target gene	hsa-mir-31	Neoplasms [unspecific]	26663584			C80.1	D009369			We identified VAV3, a regulator of actin remodeling and MRTF-A activity, as a miR-31 target.
target gene	hsa-mir-32	Neoplasms [unspecific]	26394836			C80.1	D009369			SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes
target gene	hsa-mir-326	Neoplasms [unspecific]	25138213			C80.1	D009369			miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.
target gene	hsa-mir-326	Neoplasms [unspecific]	25760058			C80.1	D009369			MicroRNA-326 functions as a tumor suppressor in colorectal cancer by targeting the nin one binding protein.
target gene	hsa-mir-326	Neoplasms [unspecific]	27960279			C80.1	D009369			Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission.
target gene	hsa-mir-331	Neoplasms [unspecific]	19584269			C80.1	D009369			miR-331-3p; a c/EBPalpha target,; Inhibits metastatic tumor antigen 1
target gene	hsa-mir-335	Neoplasms [unspecific]	24223803			C80.1	D009369			Metastasis suppressor microRNA-335 targets the formin family of actin nucleators.
target gene	hsa-mir-335	Neoplasms [unspecific]	25997740			C80.1	D009369			miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing  the Expression of HDAC3.
target gene	hsa-mir-335	Neoplasms [unspecific]	26204513			C80.1	D009369			Our data suggest that differences in response to miR-335 by tumor cells may lie in part in the mechanism of regulation of MT1-MMP production.
target gene	hsa-mir-34	Neoplasms [unspecific]	19221490			C80.1	D009369			Based on this observation, we propose a positive feedback loop, in which p53 induces expression of miR-34a which suppresses SIRT1, increasing p53 activity.
target gene	hsa-mir-34a	Neoplasms [unspecific]	20351093			C80.1	D009369			miR-34a:MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells
target gene	hsa-mir-34a	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-34a:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
target gene	hsa-mir-34a	Neoplasms [unspecific]	23361983			C80.1	D009369			Modeling miRNA Regulation in Cancer Signaling Systems: miR-34a Regulation of the p53/Sirt1 Signaling Module
target gene	hsa-mir-34a	Neoplasms [unspecific]	23533633			C80.1	D009369			CD24 Induces Expression of the Oncomir miR-21 via Src, and CD24 and Src Are Both Post-Transcriptionally Downregulated by the Tumor Suppressor miR-34a
target gene	hsa-mir-34a	Neoplasms [unspecific]	24185900			C80.1	D009369			SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition.
target gene	hsa-mir-34a	Neoplasms [unspecific]	23860128			C80.1	D009369			A miR-34a-SIRT6 axis in the squamous cell differentiation network.
target gene	hsa-mir-34a	Neoplasms [unspecific]	24970682			C80.1	D009369			Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway,leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
target gene	hsa-mir-34a	Neoplasms [unspecific]	18755897			C80.1	D009369			Finally, miR-34a itself is a transcriptional target of p53, suggesting a positive feedback loop between p53 and miR-34a. Thus, miR-34a functions as a tumor suppressor, in part, through a SIRT1-p53 pathway.
target gene	hsa-mir-34a	Neoplasms [unspecific]	29285066			C80.1	D009369			miR-34a may serve an important role in hyperthermia-regulated apoptosis and proliferation in HCT116 cells by influencing the transcriptional activity of p53
target gene	hsa-mir-34b	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
target gene	hsa-mir-34c	Neoplasms [unspecific]	20049626			C80.1	D009369			miR-34c:Our results also indicated that miR-16/34a-c, miR-17-5p, miR-125, miR-106, and miR-150 were the upstream factors, which could regulate the expression of BCL-2, E2F1, E2F3, RB1, and P53
target gene	hsa-mir-34c	Neoplasms [unspecific]	28125315			C80.1	D009369			miRNA-34c inhibits myoblasts proliferation by targeting YY1.
target gene	hsa-mir-372	Neoplasms [unspecific]	17989227			C80.1	D009369			the related miR-372/373 miRNAs promote tumorigenesis in combination with oncogenic RAS, at least in part by directly inhibiting the tumor suppressor LATS2.
target gene	hsa-mir-372	Neoplasms [unspecific]	20154725			C80.1	D009369			miR-372:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
target gene	hsa-mir-373	Neoplasms [unspecific]	17989227			C80.1	D009369			the related miR-372/373 miRNAs promote tumorigenesis in combination with oncogenic RAS, at least in part by directly inhibiting the tumor suppressor LATS2.
target gene	hsa-mir-373	Neoplasms [unspecific]	20154725			C80.1	D009369			miR-373:RECK is a target of at least three groups of miRNAs (miR-15b/16, miR-21 and miR-372/373)
target gene	hsa-mir-376a	Neoplasms [unspecific]	26655997			C80.1	D009369			Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6.
target gene	hsa-mir-378	Neoplasms [unspecific]	18077375			C80.1	D009369			Our results suggest that miR-378 transfection enhanced cell survival, tumor growth, and angiogenesis through repression of the expression of two tumor suppressors, Sufu and Fus-1.
target gene	hsa-mir-378g	Neoplasms [unspecific]	26473472			C80.1	D009369			MiR-378g enhanced radiosensitivity partially by targeting SHP-1 in NPC cells. Cell invasion was also partially inhibited by miR-378g, but the effect was not mediated by SHP-1.
target gene	hsa-mir-382	Neoplasms [unspecific]	24914051			C80.1	D009369			miR-382 induced by hypoxia promotes angiogenesis and acts as an angiogenic oncogene by repressing PTEN.
target gene	hsa-mir-383	Neoplasms [unspecific]	25415264			C80.1	D009369			miR-383 can specifically regulates the expression of Gadd45g by directly targeting to the 3-UTR region of  Gadd45g mRNA, a regulatory process conserved in human tumor cells and mouse embryonic stem cells. These two compotents can be potentially used as antineoplastic agents in cancer chemotherapy.
target gene	hsa-mir-384	Neoplasms [unspecific]	24827165			C80.1	D009369			MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression  and is a potential biomarker for Alzheimer's disease.
target gene	hsa-mir-429	Neoplasms [unspecific]	19182522			C80.1	D009369			miR-429: miR-200 family:inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2
target gene	hsa-mir-449a	Neoplasms [unspecific]	19833767			C80.1	D009369			Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer.
target gene	hsa-mir-449b	Neoplasms [unspecific]	19833767			C80.1	D009369			Our study reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer.
target gene	hsa-mir-451	Neoplasms [unspecific]	25151965			C80.1	D009369			Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression.
target gene	hsa-mir-451	Neoplasms [unspecific]	24445140			C80.1	D009369			MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression.
target gene	hsa-mir-451a	Neoplasms [unspecific]	18619946			C80.1	D009369			miR-451: miR-27a and miR-451 regulate expression of MDR1/P-glycoprotein
target gene	hsa-mir-4732	Neoplasms [unspecific]	23886136			C80.1	D009369			From our findings we propose designing further studies focused on overexpression of miRNA-4732-5p and introducing different mutations in the overlapping region of wrap53 and p53 genes in order to study their effects on p53 and its δN isoform (δ40p53) expression. The results may provide new pieces in the p53 targeting puzzle for cancer therapy.
target gene	hsa-mir-494	Neoplasms [unspecific]	26686085			C80.1	D009369			the regulatory effect of p100 on PTEN expression is mediated by its downregulation of miR-494 as a result of the inactivation of extracellular signal-regulated kinase  2
target gene	hsa-mir-503	Neoplasms [unspecific]	25653011			C80.1	D009369			miR-503 represses human cell proliferation and directly targets the oncogene DDHD2 by non-canonical target pairing.
target gene	hsa-mir-504	Neoplasms [unspecific]	20935678			C80.1	D009369			Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d.
target gene	hsa-mir-509	Neoplasms [unspecific]	24802056			C80.1	D009369			Inhibition of cell proliferation and migration by miR-509-3p that targets CDK2, Rac1, and PIK3C2A.
target gene	hsa-mir-509	Neoplasms [unspecific]	25144722			C80.1	D009369			Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth.
target gene	hsa-mir-520f	Neoplasms [unspecific]	28209612			C80.1	D009369			miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2.
target gene	hsa-mir-526a	Neoplasms [unspecific]	26002288			C80.1	D009369			miR-526a regulates apoptotic cell growth in human carcinoma cells.
target gene	hsa-mir-542	Neoplasms [unspecific]	21860426			C80.1	D009369			downregulation of miR-542-3p is significantly correlated with the upregulation of c-Src and ILK. Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression.
target gene	hsa-mir-590	Neoplasms [unspecific]	26394836			C80.1	D009369			SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes
target gene	hsa-mir-620	Neoplasms [unspecific]	26068950			C80.1	D009369			miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD).
target gene	hsa-mir-638	Neoplasms [unspecific]	25088422			C80.1	D009369			Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus.
target gene	hsa-mir-7	Neoplasms [unspecific]	25181544			C80.1	D009369			MiR-7 promotes epithelial cell transformation by targeting the tumor suppressor KLF4.
target gene	hsa-mir-708	Neoplasms [unspecific]	20445018			C80.1	D009369			miR-708:down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity
target gene	hsa-mir-9	Neoplasms [unspecific]	26091714			C80.1	D009369			our findings have identified a critical role of miR-9 in regulating the differentiation and function of Myeloid-derived suppressor cells (MDSCs).
target gene	hsa-mir-92-1	Neoplasms [unspecific]	20851997			C80.1	D009369			miR-17-92 inhibits apoptosis by suppressing Pten via the miR-19 components, our results indicate that this miRNA cluster promotes tumorigenesis by antagonizing both tumor-suppressing mechanisms, apoptosis, and senescence, through the activities of different miRNA components encoded in this cluster
target gene	hsa-mir-92-1	Neoplasms [unspecific]	29574928			C80.1	D009369			The role of miR-17/92 family in development and progression of various cancers has been established. The members of this miRNA family have been shown to be over expressed and target various genes within proliferation, metastasis and angiogenesis pathways.
target gene	hsa-mir-92a	Neoplasms [unspecific]	26062558			C80.1	D009369			An In Vivo Method to Identify microRNA Targets Not Predicted by Computation Algorithms: p21 Targeting by miR-92a in Cancer.
target gene	hsa-mir-92a	Neoplasms [unspecific]	23820254			C80.1	D009369			The STAT3-induced miR-92a promotes cancer invasion by suppressing RECK and targeting of the STAT3/miR-92a axis may be helpful for cancer treatment.
target gene	hsa-mir-92a	Neoplasms [unspecific]	24394541			C80.1	D009369			miR-92a family and their target genes in tumorigenesis and metastasis.
target gene	hsa-mir-93	Neoplasms [unspecific]	28401709			C80.1	D009369			The role of microRNA-93 regulating angiopoietin2 in the formation of malignant pleural effusion.
target gene	hsa-mir-98	Neoplasms [unspecific]	23211491			C80.1	D009369			MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11
target gene	hsa-mir-99	Neoplasms [unspecific]	26608597			C80.1	D009369			We have developed an efficient SVM-based model for miRNA target prediction using recent CLIP-seq data, demonstrating superior performance, evaluated using ROC curves, specifically about 20 % better than the state-of-the-art, for different species (human or mouse), or different target types (canonical or non-canonical). To the best of our knowledge we provide the first distributed framework for microRNA target prediction based on Apache Hadoop and Spark.
target gene	hsa-mir-155	Nephrolithiasis	25197634	urinary system disease	DOID:585	N20.0	D053040	167030		Serum and urinary levels of miR-155 were significantly elevated in patients with nephrolithiasis, and the upregulation of miR-155 was correlated with decline of eGFR and elevation of CRP. Our results suggested that miR-155 might play important roles in the pathophysiology of nephrolithiasis via regulating inflammatory cytokines expression. Further study on the molecular pathogenic mechanism and larger scale of clinical trial are required.
target gene	hsa-mir-503	Nephrotic Syndrome	26882816	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	In this study, we determined that serum miR-503 was significantly decreased in NS children. MiR-503 contributes to the aberrant proliferation of RMCs by targeting cyclin E, which may represent potential diagnostic and prognostic biomarkers for idiopathic pediatric NS.
target gene	hsa-let-7b	Nervous System Diseases [unspecific]	28436683			C72.9	D009422			Dexmedetomidine Protects PC12 Cells from Lidocaine-Induced Cytotoxicity Through Downregulation of COL3A1 Mediated by miR-let-7b.
target gene	hsa-mir-204	Nervous System Diseases [unspecific]	22718995			C72.9	D009422			MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.
target gene	hsa-mir-210	Nervous System Diseases [unspecific]	24577088			C72.9	D009422			The gain-of-function and loss-of-dysfunction assays revealed that miR-210 mediated the ISCU1/2 suppression, energy metabolism alterations, and ISC-containing metabolic enzyme inactivation after nickel exposure.
target gene	hsa-mir-29b-1	Nervous System Diseases [unspecific]	22932723			C72.9	D009422			Exosome-mediated shuttling of microRNA-29b regulates HIV Tat and morphine-mediated Neuronal dysfunction.
target gene	hsa-mir-29b-2	Nervous System Diseases [unspecific]	22932723			C72.9	D009422			Exosome-mediated shuttling of microRNA-29b regulates HIV Tat and morphine-mediated Neuronal dysfunction.
target gene	hsa-mir-29a	Neurilemmoma	29023945	disease of cellular proliferation	DOID:3192	D36.10	D009442			MicroRNA-29a inhibits proliferation and motility of schwannoma cells by targeting CDK6.
target gene	hsa-mir-29c	Neurilemmoma	29023945	disease of cellular proliferation	DOID:3192	D36.10	D009442			MicroRNA-29a inhibits proliferation and motility of schwannoma cells by targeting CDK6.
target gene	hsa-mir-10a	Neuroblastoma	21212796	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2.
target gene	hsa-mir-10a	Neuroblastoma	21118818	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1
target gene	hsa-mir-10b	Neuroblastoma	21212796	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2.
target gene	hsa-mir-128-1	Neuroblastoma	21143953	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells.
target gene	hsa-mir-128-2	Neuroblastoma	21143953	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells.
target gene	hsa-mir-137	Neuroblastoma	23400681	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-137 directly targets KDM1A mRNA in neuroblastoma cells, and activates cell properties consistent with tumor suppression
target gene	hsa-mir-137	Neuroblastoma	23934188	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells.
target gene	hsa-mir-145	Neuroblastoma	23222716	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha
target gene	hsa-mir-145	Neuroblastoma	29619741	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Expression of miR-145 and Its Target Proteins Are Regulated by miR-29b in Differentiated Neurons
target gene	hsa-mir-153	Neuroblastoma	26633009	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells.
target gene	hsa-mir-15a	Neuroblastoma	23176145	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression
target gene	hsa-mir-17	Neuroblastoma	18493594	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM
target gene	hsa-mir-17	Neuroblastoma	21145484	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma.
target gene	hsa-mir-17	Neuroblastoma	21796614	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
target gene	hsa-mir-17	Neuroblastoma	17894887	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA.
target gene	hsa-mir-17	Neuroblastoma	28560387	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.
target gene	hsa-mir-18	Neuroblastoma	17894887	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA.
target gene	hsa-mir-181c	Neuroblastoma	24345480	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiR-181c modulates the proliferation, migration, and invasion of neuroblastoma cells by targeting Smad7.
target gene	hsa-mir-183	Neuroblastoma	27239679	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Our results reveal the MCM complex to be a critical and directly regulated node within the miR-183 signaling network in MYCN-amplified neuroblastoma cells.
target gene	hsa-mir-18a	Neuroblastoma	20080637	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1)
target gene	hsa-mir-18a	Neuroblastoma	21145484	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma.
target gene	hsa-mir-18a	Neuroblastoma	21796614	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
target gene	hsa-mir-192	Neuroblastoma	24223844	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiR-192 directly binds and regulates Dicer1 expression in neuroblastoma.
target gene	hsa-mir-19a	Neuroblastoma	20080637	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1)
target gene	hsa-mir-19a	Neuroblastoma	21145484	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma.
target gene	hsa-mir-19a	Neuroblastoma	21796614	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
target gene	hsa-mir-19a	Neuroblastoma	17894887	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA.
target gene	hsa-mir-19b-1	Neuroblastoma	21145484	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma.
target gene	hsa-mir-19b-1	Neuroblastoma	21796614	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
target gene	hsa-mir-19b-1	Neuroblastoma	17894887	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA.
target gene	hsa-mir-203	Neuroblastoma	26136151	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-203 inhibits the malignant progression of neuroblastoma by targeting Sam68.
target gene	hsa-mir-205	Neuroblastoma	26633009	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells.
target gene	hsa-mir-20a	Neuroblastoma	21145484	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma.
target gene	hsa-mir-20a	Neuroblastoma	21796614	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
target gene	hsa-mir-20a	Neuroblastoma	17894887	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA.
target gene	hsa-mir-20a	Neuroblastoma	28560387	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.
target gene	hsa-mir-21	Neuroblastoma	23084187	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells
target gene	hsa-mir-210	Neuroblastoma	23108914	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells
target gene	hsa-mir-221	Neuroblastoma	28003306	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
target gene	hsa-mir-27b	Neuroblastoma	22120719	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells.
target gene	hsa-mir-29b	Neuroblastoma	29619741	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Expression of miR-145 and Its Target Proteins Are Regulated by miR-29b in Differentiated Neurons
target gene	hsa-mir-29b	Neuroblastoma	29399057	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-29b alleviates oxygen and glucose deprivation/reperfusion-induced injury via inhibition of the p53-dependent apoptosis pathway in N2a neuroblastoma cells
target gene	hsa-mir-329	Neuroblastoma	24316513	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A.
target gene	hsa-mir-335	Neuroblastoma	22382496	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiRNA-335 Suppresses Neuroblastoma Cell Invasiveness By Direct Targeting of Multiple Genes from the non-Canonical TGF-ж┿Signalling Pathway.
target gene	hsa-mir-338	Neuroblastoma	24140344	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a.
target gene	hsa-mir-34a	Neuroblastoma	17965831	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-34a induces apoptosis in neuroblastoma cells, possibly by targeting the transcription factor E2F3. This p53-induced up-regulation of miR-34a results in an enhanced reduction in cell proliferation, strongly suggesting that miR-34a reinforces the tumour suppressor function of p53.
target gene	hsa-mir-34a	Neuroblastoma	18504438	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The MYCN oncogene is a direct target of miR-34a.
target gene	hsa-mir-34a	Neuroblastoma	18505919	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
target gene	hsa-mir-34a	Neuroblastoma	22703967	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
target gene	hsa-mir-34a	Neuroblastoma	17894887	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-34a acts as a suppressor of neuroblastoma tumorigenesis by targeting the mRNA encoding E2F3 and reducing E2F3 protein levels.
target gene	hsa-mir-34a	Neuroblastoma	21182263	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	YY1 is a negative regulator of p53, and it plays an essential role in cancer biology. Therefore, YY1 is another important direct target of miR-34a which closely regulates TP53 activities.
target gene	hsa-mir-34a	Neuroblastoma	22160687	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Notably, the axis TAp73/miR-34a/synaptotagmin-1 is conserved in brains from Alzheimer's patients. 
target gene	hsa-mir-34b	Neuroblastoma	28525978	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miRNA-34b is able to significantly downregulate DLL1 mRNA expression levels
target gene	hsa-mir-362	Neuroblastoma	26073258	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β.
target gene	hsa-mir-375	Neuroblastoma	25864587	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.
target gene	hsa-mir-421	Neuroblastoma	25012242	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-421 may promote neuroblastoma cell growth and motility partially by targeting menin.
target gene	hsa-mir-432	Neuroblastoma	24657437	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-432 contributes to dopamine cocktail and retinoic acid induced differentiation of human neuroblastoma cells by targeting NESTIN and RCOR1 genes.
target gene	hsa-mir-4487	Neuroblastoma	26183158	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	we identified that miR-4487 and miR-595 could target ULK1 and experimentally verified they could negatively or positively regulate ULK1-mediated autophagy
target gene	hsa-mir-497	Neuroblastoma	23531080	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1
target gene	hsa-mir-595	Neuroblastoma	26183158	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Identification of ULK1 as a novel biomarker involved in miR-4487 and miR-595 regulation in neuroblastoma SH-SY5Y cell autophagy.
target gene	hsa-mir-885	Neuroblastoma	21233845	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival.
target gene	hsa-mir-9-1	Neuroblastoma	22564723	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells.
target gene	hsa-mir-9-2	Neuroblastoma	22564723	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells.
target gene	hsa-mir-92-1	Neuroblastoma	17894887	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miRNAs from the miR-17-92 cluster modulate tumor formation and function as oncogenes by influencing the translation of E2F1 mRNA.
target gene	hsa-mir-92a-1	Neuroblastoma	21145484	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-beta Pathway in Neuroblastoma.
target gene	hsa-mir-92a-1	Neuroblastoma	21796614	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma
target gene	hsa-mir-9-3	Neuroblastoma	22564723	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells.
target gene	hsa-mir-144	Neurodegenerative Diseases [unspecific]	27370936				D019636		HP:0002180	the expression of 14-3-3纬 was upregulated following transfection with miR-7 and miR-144 mimics.
target gene	hsa-mir-203	Neurodegenerative Diseases [unspecific]	27370936				D019636		HP:0002180	miR-203 resulted  in a down-regulation of 14-3-3胃 transcript
target gene	hsa-mir-7	Neurodegenerative Diseases [unspecific]	27370936				D019636		HP:0002180	the expression of 14-3-3纬 was upregulated following transfection with miR-7 and miR-144 mimics.
target gene	hsa-mir-7-1	Neurofibromatosis type 2	21454924	genetic disease	DOID:8712	Q85.02	C537392	101000		We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1.
target gene	hsa-mir-7-2	Neurofibromatosis type 2	21454924	genetic disease	DOID:8712	Q85.02	C537392	101000		We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1.
target gene	hsa-mir-7-3	Neurofibromatosis type 2	21454924	genetic disease	DOID:8712	Q85.02	C537392	101000		We found that miR-7 functions as a tumor suppressor by targeting proteins in three major oncogenic pathways - EGFR, Pak1, and Ack1.
target gene	hsa-mir-124	Neuronal Apoptosis-Related Diseases	24166354							MicroRNA-124 (miR-124) regulates Ku70 expression and is correlated with neuronal death induced by ischemia/reperfusion.
target gene	hsa-mir-23a	Neuronal Apoptosis-Related Diseases	24651435							MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis.
target gene	hsa-mir-23b	Neuronal Apoptosis-Related Diseases	24651435							MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis.
target gene	hsa-mir-27a	Neuronal Apoptosis-Related Diseases	24651435							MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis.
target gene	hsa-mir-27b	Neuronal Apoptosis-Related Diseases	24651435							MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis.
target gene	hsa-mir-150	Neuropathic Pain	28685867				D009437			MiR-150 alleviates neuropathic pain via inhibiting toll-like receptor 5.
target gene	hsa-mir-150	Neuropathic Pain	29323698				D009437			It was revealed that XIST/miR-150/ZEB1 axis can be provided as a therapeutic target in neuropathic pain
target gene	hsa-mir-93	Neuropathic Pain	28284149				D009437			MicroRNA-93 alleviates neuropathic pain through targeting signal transducer and activator of transcription 3.
target gene	hsa-mir-17	Non-Syndromic Orofacial Clefts	24068957					PS119530		our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P.
target gene	hsa-mir-18	Non-Syndromic Orofacial Clefts	24068957					PS119530		our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P.
target gene	hsa-mir-19a	Non-Syndromic Orofacial Clefts	24068957					PS119530		our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P.
target gene	hsa-mir-19b-1	Non-Syndromic Orofacial Clefts	24068957					PS119530		our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P.
target gene	hsa-mir-20a	Non-Syndromic Orofacial Clefts	24068957					PS119530		our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P.
target gene	hsa-mir-92-1	Non-Syndromic Orofacial Clefts	24068957					PS119530		our data indicate that miR-17-92 modulates expression of critical T-box transcriptional regulators during midface development and is itself a target of Bmp-signaling and the craniofacial pioneer factor AP-2α. Our data are the first genetic evidence that an individual miR or miR cluster is functionally important in mammalian CL/P.
target gene	hsa-mir-17	Non-Traumatic Osteonecrosis	25060766			M90.5	D010020			MiR-17-5p modulates osteoblastic differentiation and cell proliferation by targeting SMAD7 in non-traumatic osteonecrosis.
target gene	hsa-mir-126	Obesity	25887648	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation.
target gene	hsa-mir-126	Obesity	28367267	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Obesity Downregulates MicroRNA-126 Inducing Capillary Rarefaction in Skeletal Muscle: Effects of Aerobic Exercise Training.
target gene	hsa-mir-130	Obesity	28242765	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	APCDD1 positively regulates adipogenic differentiation and that its  down-regulation by miR-130 during DIO may contribute to impaired adipogenic differentiation and obesity-related metabolic disease
target gene	hsa-mir-143	Obesity	16195701	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Modified oligonucleotide complementary to miR-143 effectively suppressed adipocyte differentiation by modulation of its putative target ERK5, a protein previously known to be implicated in MAP kinase signaling pathways.
target gene	hsa-mir-145	Obesity	25887648	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation.
target gene	hsa-mir-146b	Obesity	24428800	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	IL-6 and TNF-α induced obesity-related inflammatory response through transcriptional regulation of miR-146b.
target gene	hsa-mir-193b	Obesity	25887648	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation.
target gene	hsa-mir-21	Obesity	25887648	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation.
target gene	hsa-mir-26b	Obesity	26016996	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Obesity-associated microRNA-26b regulates the proliferation of human preadipocytes via arrest of the G1/S transition.
target gene	hsa-mir-27a	Obesity	20060380	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Together, these results suggest that miR-27a would suppress adipocyte differentiation through targeting PPARgamma and thereby down-regulation of miR-27a might be associated with adipose tissue dysregulation in obesity.
target gene	hsa-mir-29b	Obesity	25887648	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	We identified 23 active miRNA-TF-gene regulatory pathways that were significantly related to obesity-related inflammation.
target gene	hsa-mir-342	Obesity	25895816	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-342-3p is a powerful enhancer of the adipogenesis of human adipose-derived MSCs that acts by inhibiting CtBP2 and releasing the key adipogenic regulator C/EBPα from CtBP2 binding, subsequently activating the expression of adipogenic transcription factors and markers.
target gene	hsa-mir-145	Obstructive Sleep Apnea	28465478	disease of mental health	DOID:0050848	G47.33	D020181	107650	HP:0002870	Chronic obstructive sleep apnea promotes aortic remodeling in canines through miR-145/Smad3 signaling pathway.
target gene	hsa-mir-15a	Odontogenic Tumors	22684875				D009808		HP:0100612	miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors.
target gene	hsa-mir-16-1	Odontogenic Tumors	22684875				D009808		HP:0100612	miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors.
target gene	hsa-mir-16-2	Odontogenic Tumors	22684875				D009808		HP:0100612	miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors.
target gene	hsa-mir-137	Oligodendroglioma	23252729	disease of cellular proliferation	DOID:3181		D009837			MIR-137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets CSE1L
target gene	hsa-mir-139	Oral Neoplasms	26191149			C06.9	D009062		HP:0100649	MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt signaling pathway.
target gene	hsa-mir-21	Oral Neoplasms	23999978			C06.9	D009062		HP:0100649	MicroRNA-21 promotes oral cancer invasion via the Wnt/β-catenin pathway by targeting DKK2.
target gene	hsa-mir-320	Oral Neoplasms	24114198			C06.9	D009062		HP:0100649	miR-320 regulates the function of vascular endothelial cells by targeting NRP1 and has the potential to be developed as an anti-angiogenic or anti-cancer drug.
target gene	hsa-mir-499	Oral Neoplasms	26867589			C06.9	D009062		HP:0100649	This study describes the regulation of PDCD4 specifically in tonsil SCC by miR-499 and miR-21 and has documented the loss of PDCD4 in tonsil SCCs.These findings highlight the complex interplay between miRNAs and tumour suppressor gene regulation and suggest that PDCD4 loss may be an important step in tonsillar carcinogenesis.
target gene	hsa-mir-518c	Oral Neoplasms	25536052			C06.9	D009062		HP:0100649	miR-518c-5p regulates the growth and metastasis of oral cancer as a downstream target of the SDF-1/CXCR4 system.
target gene	hsa-mir-203	Oral Submucous Fibrosis	25872484	gastrointestinal system disease	DOID:5773	K13.5	D009914			Thus, we provide evidence to illustrate that miR-203 plays a role in the pathogenesis of OSF, which may be a target for OSF management.
target gene	hsa-mir-21	Oral Submucous Fibrosis	26943153	gastrointestinal system disease	DOID:5773	K13.5	D009914			PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21.
target gene	hsa-mir-125b	Osteoarthritis	28260078	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Upregulation of microRNA-125b-5p is involved in the pathogenesis of osteoarthritis by downregulating SYVN1.
target gene	hsa-mir-125b	Osteoarthritis	29550827	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-125b could play an important role in inflammatory injury of chondrogenic cells and miR-125b affected inflammatory injury of ATDC5 cells via regulating expression of MIP-1α and regulating NF-κB and JNK signaling pathways
target gene	hsa-mir-127	Osteoarthritis	24022470	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MicroRNA-127-5p is an important regulator of MMP-13 in human chondrocytes and may contribute to the development of OA.
target gene	hsa-mir-130a	Osteoarthritis	27999816	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-204, which targets RUNX2, and miR-130a, which inhibits PPARγ, were lower and higher, respectively, in F versus OA serum samples
target gene	hsa-mir-140	Osteoarthritis	21872590	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to target Sp1 in maintaining the chondrocyte proliferation.
target gene	hsa-mir-140	Osteoarthritis	24257415	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	This is the first study to provide evidence of a regulatory mechanism of miR-140 independent of WWP2, and new and differential roles for NFAT3 and SMAD3 in the OA process in the regulation of miR-140 transcription.Such knowledge could advance therapeutic strategies targeting OA.
target gene	hsa-mir-145	Osteoarthritis	27922673	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Effects of miR-145 on the inhibition of chondrocyte proliferation and fibrosis by targeting TNFRSF11B in human osteoarthritis.
target gene	hsa-mir-146a	Osteoarthritis	24107356	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Our study demonstrated that HDAC inhibitor treatment in OA-FLS significantly increased miR-146a expression and mediated markedly negative regulation to inhibit IL-1β-induced signaling and cytokine secretion. Our results indicate the potential rationale of anti-inflammatory effects for HDAC inhibitors.
target gene	hsa-mir-146a	Osteoarthritis	25311550	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Transfection of miR-146a decreases IL-1 induced mRNA levels of inflammatory genes and catabolic proteases in NP cells
target gene	hsa-mir-146a	Osteoarthritis	26492575	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Simply, hypoxia induced HIF-1伪, and HIF-1伪 increased miR-146a, but miR-146a suppressed Bcl-2, an autophagy inhibitor.
target gene	hsa-mir-146a	Osteoarthritis	27845876	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Hypoxia-induced microRNA-146a represses Bcl-2 through Traf6/IRAK1 but not Smad4 to promote chondrocyte autophagy.
target gene	hsa-mir-146a	Osteoarthritis	28314786	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Effects of microRNA-146a on the proliferation and apoptosis of human osteoarthritis chondrocytes by targeting TRAF6 through the NF-κB signalling pathway.
target gene	hsa-mir-146a	Osteoarthritis	28383548	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-146a facilitates osteoarthritis by regulating cartilage homeostasis via targeting Camk2d and Ppp3r2.
target gene	hsa-mir-146a	Osteoarthritis	28634214	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathway.
target gene	hsa-mir-146a	Osteoarthritis	29183039	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MiR-146a Aggravates LPS-Induced Inflammatory Injury by Targeting CXCR4 in the Articular Chondrocytes
target gene	hsa-mir-15a	Osteoarthritis	27916780	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MiR-15a-5p regulates viability and matrix degradation of human osteoarthritis chondrocytes via targeting VEGFA.
target gene	hsa-mir-16	Osteoarthritis	26350536	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Our results indicate that miR-16-5p is an important regulator of SMAD3 expression in human chondrocytes and may contribute to the development of OA.
target gene	hsa-mir-181	Osteoarthritis	28177757	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MicroRNA-181 inhibits proliferation and promotes apoptosis of chondrocytes in osteoarthritis by targeting PTEN.
target gene	hsa-mir-181a	Osteoarthritis	28280258	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-181a Modulates Chondrocyte Apoptosis by Targeting Glycerol-3-Phosphate Dehydrogenase 1-Like Protein (GPD1L) in Osteoarthritis.
target gene	hsa-mir-199a	Osteoarthritis	27515563	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Transfection of OA chondrocytes with anti-miR-199a-3p significantly enhanced COX-2 expression and PGE2 production (P < 0.001).
target gene	hsa-mir-19a	Osteoarthritis	29306212	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MicroRNA-19a promotes cell viability and migration of chondrocytes via up-regulating SOX9 through NF-κB pathway
target gene	hsa-mir-204	Osteoarthritis	27999816	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-204, which targets RUNX2, and miR-130a, which inhibits PPARγ, were lower and higher, respectively, in F versus OA serum samples
target gene	hsa-mir-21	Osteoarthritis	24577233	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MicroRNA-21 controls the development of osteoarthritis by targeting GDF-5 in chondrocytes.
target gene	hsa-mir-24	Osteoarthritis	24572376	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	We disclosed herein a new role of the senescence marker p16INK4a and its regulation by miR-24 during OA and terminal chondrogenesis.
target gene	hsa-mir-24	Osteoarthritis	29143973	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Effects of microRNA-24 targeting C-myc on apoptosis, proliferation and cytokine expressions in chondrocytes of rats with osteoarthritis via MAPK signaling pathway.
target gene	hsa-mir-26a	Osteoarthritis	26854724	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MicroRNA-26a-5p regulates the expression of inducible nitric oxide synthase via activation of NF-κB pathway in human osteoarthritis chondrocytes.
target gene	hsa-mir-26a	Osteoarthritis	29208566	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-26a/-26b/FUT4/NF-κB axis may serve as a predictive biomarker and a potential therapeutic target in OA treatment
target gene	hsa-mir-30b	Osteoarthritis	26653555	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	In conclusion, miR-30b was involved in the process of OA, and it probably functioned through its target gene ERG.
target gene	hsa-mir-33a	Osteoarthritis	25880168	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Our findings suggest, for the first time to our knowledge, that miR-33a regulates cholesterol synthesis through the TGF-β1/Akt/SREBP-2 pathway,as well as cholesterol efflux-related genes ABCA1 and ApoA1, in OA chondrocytes, pointing to its identification as a novel target for ameliorating the OA phenotype.
target gene	hsa-mir-370	Osteoarthritis	26103880	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-370 and miR-373 regulate the pathogenesis of osteoarthritis by modulating one-carbon metabolism via SHMT-2 and MECP-2, respectively.
target gene	hsa-mir-373	Osteoarthritis	26103880	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-370 and miR-373 regulate the pathogenesis of osteoarthritis by modulating one-carbon metabolism via SHMT-2 and MECP-2, respectively.
target gene	hsa-mir-373	Osteoarthritis	28343378	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Adipose-Derived Stem Cells Suppress Inflammation Induced by IL-1β through Down-Regulation of P2X7R Mediated by miR-373 in Chondrocytes of Osteoarthritis.
target gene	hsa-mir-9	Osteoarthritis	24928913	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	However, luciferase reporter assays and transient miR overexpression in the ATDC5 chondrogenic cell line only support that miR-9 was a  negative post-transcriptional regulator of PC-1, Pit-1 and TNAP mRNAs.
target gene	hsa-mir-92a	Osteoarthritis	29241192	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MiR-92a-3p is an important regulator of ADAMTS-4/5 in human chondrocytes and may contribute to the development of OA
target gene	hsa-mir-98	Osteoarthritis	27590063	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MiR-98 promotes chondrocyte apoptosis by decreasing Bcl-2 expression in a rat model of osteoarthritis.
target gene	hsa-mir-24	Osteomyelitis	25976273	musculoskeletal system disease	DOID:1019	M86	D010019	612852		The Role of MicroRNA, miR-24, and Its Target CHI3L1 in Osteomyelitis Caused by Staphylococcus aureus.
target gene	hsa-mir-320a	Osteopetrosis	24084574	musculoskeletal system disease	DOID:13533	Q78.2	D010022	259700		Collectively, the present study established a new system approach for the investigation of microRNAs, and the microRNA-target pairs, particular has-miR-320a and Arf1, may have important roles in osteopetrosis.
target gene	hsa-mir-548d	Osteopetrosis	24929254	musculoskeletal system disease	DOID:13533	Q78.2	D010022	259700		miR-548d-5p is downregulated during dexamethasone-induced adipogenic differentiation of hBMSCs. By directly targeting and downregulating PPARγ,miR-548d-5p suppresses the dexamethasone-induced adipogenic differentiation of hBMSCs and enhances their osteogenic potential. Our findings suggest that miR-548d-5p has potential in the treatment of corticosteroid-induced osteonecrosis of the femoral head.
target gene	hsa-mir-133	Osteoporosis	26013661	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	Estrogen deficiency is associated with miR-133 overexpression.MiR-133 can induce postmenopausal osteoporosis by weakening osteogenic differentiation of hMSCs, at least partly through repressing SLC39A1 expression.
target gene	hsa-mir-205	Osteoporosis	26170952	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	The miR-205 antisense largely abolished the inhibitory effect of STAT3 activation on the levels of CHOP protein.
target gene	hsa-mir-23b	Osteoporosis	29234953	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	Involvement of microRNA-23b in TNF-α-reduced BMSC osteogenic differentiation via targeting runx2
target gene	hsa-mir-705	Osteoporosis	26700816	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	Mechanistically, TNF-α activated NF-κB pathway to promote microRNA-705 expression, which function as a repressor of FoxO1 through post-transcriptional regulation.
target gene	hsa-mir-1	Osteosarcoma	24969180	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-1 functions as a potential tumor suppressor in osteosarcoma by targeting Med1 and Med31.
target gene	hsa-mir-1	Osteosarcoma	27777493	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-1 Inhibits Cell Growth, Migration, and Invasion by Targeting VEGFA in Osteosarcoma Cells.
target gene	hsa-mir-100	Osteosarcoma	24317814	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61.
target gene	hsa-mir-101	Osteosarcoma	25190211	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-101 inhibits the metastasis of osteosarcoma cells by downregulation of EZH2 expression.
target gene	hsa-mir-107	Osteosarcoma	28682874	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/β-catenin signaling pathway in osteosarcoma
target gene	hsa-mir-10b	Osteosarcoma	27764757	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-10b promotes invasion by targeting KLF4 in osteosarcoma cells.
target gene	hsa-mir-124	Osteosarcoma	26259653	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-124 suppresses the migration and invasion of osteosarcoma cells via targeting ROR2-mediated non-canonical Wnt signaling.
target gene	hsa-mir-124	Osteosarcoma	26339404	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS.
target gene	hsa-mir-124	Osteosarcoma	27644254	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.
target gene	hsa-mir-124	Osteosarcoma	27743351	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1.
target gene	hsa-mir-124	Osteosarcoma	29552134	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-124 acts as a tumor-suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma
target gene	hsa-mir-1247	Osteosarcoma	25973030	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiRNA profile of osteosarcoma with CD117 and stro-1 expression: miR-1247 functions as an onco-miRNA by targeting MAP3K9.
target gene	hsa-mir-125a	Osteosarcoma	28950256	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-125a Regulates Cell Proliferation Via Directly Targeting E2F2 in Osteosarcoma
target gene	hsa-mir-126	Osteosarcoma	23877372	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1.
target gene	hsa-mir-126	Osteosarcoma	25213697	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-126 inhibits cell growth, invasion, and migration of osteosarcoma cells by downregulating ADAM-9.
target gene	hsa-mir-128	Osteosarcoma	24132591	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN
target gene	hsa-mir-132	Osteosarcoma	24449507	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells.
target gene	hsa-mir-133a	Osteosarcoma	27794430	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma.
target gene	hsa-mir-133a-1	Osteosarcoma	23756231	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	microRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.
target gene	hsa-mir-133a-2	Osteosarcoma	23756231	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	microRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.
target gene	hsa-mir-135b	Osteosarcoma	25025684	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-135b may function as a tumor suppressor to regulate osteosarcoma cell proliferation and invasion through a mechanism that targets the c-Myc oncogene. These findings indicate that miR-135b may play a role in the pathogenesis of osteosarcoma.
target gene	hsa-mir-135b	Osteosarcoma	25190111	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-135b promotes proliferation, invasion and migration of osteosarcoma cells by degrading myocardin.
target gene	hsa-mir-135b	Osteosarcoma	25416447	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-135b functions as an onco-miRNA in OS to promote OS cells proliferation and invasion, and its oncogenic effects are mediated chiefly through targeting FOXO1.
target gene	hsa-mir-137	Osteosarcoma	26302771	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	We revealed novel functional role of miR-137 in osteosarcoma regulation, likely through FXYD6 binding.
target gene	hsa-mir-138	Osteosarcoma	27019355	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells.
target gene	hsa-mir-138	Osteosarcoma	29042962	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-138 directly targets TNFAIP8 and acts as a tumor suppressor in osteosarcoma.
target gene	hsa-mir-140	Osteosarcoma	28341864	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy.
target gene	hsa-mir-142	Osteosarcoma	24803022	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1.
target gene	hsa-mir-143	Osteosarcoma	28734729	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-143 regulates the proliferation and migration of osteosarcoma cells through targeting MAPK7.
target gene	hsa-mir-144	Osteosarcoma	26081423	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-144 acts as a tumor suppressor by targeting Rho-associated coiled-coil containing protein kinase 1 in osteosarcoma cells.
target gene	hsa-mir-144	Osteosarcoma	25912304	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-144 suppresses osteosarcoma growth and metastasis by targeting ROCK1 and ROCK2.
target gene	hsa-mir-144	Osteosarcoma	29387244	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-144 suppresses proliferation and induces apoptosis of osteosarcoma cells via direct regulation of mTOR expression.
target gene	hsa-mir-145	Osteosarcoma	22472569	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells.
target gene	hsa-mir-145	Osteosarcoma	24789502	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1.
target gene	hsa-mir-145	Osteosarcoma	24801908	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1.
target gene	hsa-mir-145	Osteosarcoma	28051259	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
target gene	hsa-mir-150	Osteosarcoma	27900020	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin.
target gene	hsa-mir-150	Osteosarcoma	28070040	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-150 inhibits osteosarcoma cell proliferation by targeting RUNX2 gene.
target gene	hsa-mir-150	Osteosarcoma	28454380	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1.
target gene	hsa-mir-150	Osteosarcoma	28547952	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Mir-150 Up-Regulates Glut1 and Increases Glycolysis in Osteosarcoma Cells
target gene	hsa-mir-153	Osteosarcoma	25793604	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-β2.
target gene	hsa-mir-155	Osteosarcoma	28214207	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth.
target gene	hsa-mir-15a	Osteosarcoma	22922827	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma.
target gene	hsa-mir-15a	Osteosarcoma	26261520	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in  human osteosarcoma cells.
target gene	hsa-mir-16-1	Osteosarcoma	22922827	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma.
target gene	hsa-mir-16-1	Osteosarcoma	23507142	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma
target gene	hsa-mir-16-2	Osteosarcoma	23507142	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma
target gene	hsa-mir-17	Osteosarcoma	24462867	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression.
target gene	hsa-mir-181a	Osteosarcoma	27600004	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A.
target gene	hsa-mir-181a	Osteosarcoma	28381158	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro.
target gene	hsa-mir-181b	Osteosarcoma	27063156	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	microRNA-181b promotes migration and invasion of osteosarcoma cells by targeting N-myc downstream regulated gene 2.
target gene	hsa-mir-182	Osteosarcoma	29254169	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-182 downregulates Wnt/β-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9
target gene	hsa-mir-183	Osteosarcoma	22525461	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin.
target gene	hsa-mir-183	Osteosarcoma	22922800	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells.
target gene	hsa-mir-183	Osteosarcoma	24352761	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.
target gene	hsa-mir-19	Osteosarcoma	29702193	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-19a-mediated downregulation of RhoB inhibits the dephosphorylation of AKT1 and induces osteosarcoma cell metastasis.
target gene	hsa-mir-1908	Osteosarcoma	26328886	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Collectively, the results showed that, miR-1908 promotes proliferation and invasion of osteosarcoma cells by repressing PTEN expression.
target gene	hsa-mir-191	Osteosarcoma	25773391	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2.
target gene	hsa-mir-192	Osteosarcoma	27683056	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Upregulation of miR-192 inhibits cell growth and invasion and induces cell apoptosis by targeting TCF7 in human osteosarcoma.
target gene	hsa-mir-193a	Osteosarcoma	26913720	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively.
target gene	hsa-mir-194	Osteosarcoma	25096247	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R.
target gene	hsa-mir-195	Osteosarcoma	23162665	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN
target gene	hsa-mir-195	Osteosarcoma	25823925	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1.
target gene	hsa-mir-195	Osteosarcoma	28032380	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-195-5p suppresses osteosarcoma cell proliferation and invasion by suppressing naked cuticle homolog 1.
target gene	hsa-mir-198	Osteosarcoma	26970302	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1.
target gene	hsa-mir-199a	Osteosarcoma	26079799	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.
target gene	hsa-mir-19a	Osteosarcoma	28475001	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN.
target gene	hsa-mir-19b	Osteosarcoma	24824927	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-19b targets Mfn1 to inhibit Mfn1-induced apoptosis in osteosarcoma cells.
target gene	hsa-mir-19b	Osteosarcoma	26339404	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS.
target gene	hsa-mir-200b	Osteosarcoma	27307751	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-200b inhibits the proliferation, migration, and invasion of osteosarcoma cells, probably via the inhibition of ZEB1 expression.
target gene	hsa-mir-202	Osteosarcoma	25156120	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-202 suppresses proliferation and induces apoptosis of osteosarcoma cells by downregulating Gli2.
target gene	hsa-mir-202	Osteosarcoma	26276504	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This study provides new insights into miRNA-202 in osteosarcoma as a potential molecular target for chemotherapy.
target gene	hsa-mir-203	Osteosarcoma	26382657	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Take together, our results demonstrated that miR-203 act as a tumor suppressor miRNA through regulating RAB22A expression and suggested its involvement in osteosarcoma progression and carcinogenesis.
target gene	hsa-mir-204	Osteosarcoma	25998694	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1.
target gene	hsa-mir-205	Osteosarcoma	26708425	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, our study suggested that miR-205 may function as a tumor suppressor via targeting TGF-α in OS, and the abnormal expression of miR-205 might be a key factor in OS progression.
target gene	hsa-mir-206	Osteosarcoma	23886177	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These findings indicate that miR-206 may have a key role in osteosarcoma pathogenesis and development. It could serve as a useful biomarker for prediction of osteosarcoma progression, and provide a potential target for gene therapy.
target gene	hsa-mir-206	Osteosarcoma	29462818	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Effects of MicroRNA-206 on Osteosarcoma Cell Proliferation, Apoptosis, Migration and Invasion by Targeting ANXA2 Through the AKT Signaling Pathway
target gene	hsa-mir-208b	Osteosarcoma	28618961	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2.
target gene	hsa-mir-20a	Osteosarcoma	22186140	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-20a increases the metastatic potential of osteosarcoma cells by regulating Fas expression.
target gene	hsa-mir-20a	Osteosarcoma	26339404	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our findings may help to understand the molecular mechanisms of OS and identify targets of effective targeted therapies for OS.
target gene	hsa-mir-21	Osteosarcoma	25381586	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line.
target gene	hsa-mir-21	Osteosarcoma	20480266	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-21 is involved in osteosarcoma cell invasion and migration.
target gene	hsa-mir-21	Osteosarcoma	28260111	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-21-5p may be associated with metastasis via target genes
target gene	hsa-mir-214	Osteosarcoma	24802407	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1.
target gene	hsa-mir-214	Osteosarcoma	25310480	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-214 regulates osteosarcoma survival and growth by directly targeting phosphatase and tensin homolog.
target gene	hsa-mir-214	Osteosarcoma	28081735	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-214-5p Targets ROCK1 and Suppresses Proliferation and Invasion of Human Osteosarcoma Cells.
target gene	hsa-mir-217	Osteosarcoma	25289936	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-217 regulates WASF3 expression and suppresses tumor growth and metastasis in osteosarcoma.
target gene	hsa-mir-217	Osteosarcoma	26054690	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor.
target gene	hsa-mir-218	Osteosarcoma	23886165	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9.
target gene	hsa-mir-22	Osteosarcoma	24609901	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy.
target gene	hsa-mir-22	Osteosarcoma	24752578	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy.
target gene	hsa-mir-223	Osteosarcoma	23208072	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Heat Shock Protein 90B1 Plays an Oncogenic Role and is a Target of microRNA-223 in Human Osteosarcoma
target gene	hsa-mir-24	Osteosarcoma	28189676	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT/MMPs pathway.
target gene	hsa-mir-24-1	Osteosarcoma	23578572	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-24 Inhibits Osteosarcoma Cell Proliferation Both In Vitro and In Vivo by Targeting LPAAT
target gene	hsa-mir-24-2	Osteosarcoma	23578572	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-24 Inhibits Osteosarcoma Cell Proliferation Both In Vitro and In Vivo by Targeting LPAAT
target gene	hsa-mir-25	Osteosarcoma	28705117	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-25 suppresses proliferation, migration, and invasion of osteosarcoma by targeting SOX4.
target gene	hsa-mir-26b	Osteosarcoma	25761878	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-26b inhibits metastasis of osteosarcoma via targeting CTGF and Smad1.
target gene	hsa-mir-26b	Osteosarcoma	26681033	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR- 26b may inhibit osteosarcoma cell proliferation, migration, and invasion by regulating PFKFB3 protein expression.miR-26b may have a tumor suppressor role in tumor occurrence and development.
target gene	hsa-mir-27a	Osteosarcoma	24556602	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This is the first study showing that miR-27a can function as an oncogene by targeting MAP2K4 in the osteosarcoma MG63 cell line. Inhibition of miR-27a increases MAP2K4 expression, which in turn inhibits cell proliferation and migration through the JNK/p38 signaling pathway in MG63 cells. These findings may help us understand the molecular mechanism of miR-27a in the tumorigenesis of osteosarcoma and may provide new diagnostic and therapeutic options for the treatment of this neoplasia.
target gene	hsa-mir-29	Osteosarcoma	27649654	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Targeting miR-29 induces apoptosis of osteosarcoma MG-63 cells via regulation of TGF-β1/PUMA signal.
target gene	hsa-mir-29a	Osteosarcoma	23113351	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	data obtained highlight the role of miRNA-29a in the regulation of osteoblastic cell apoptosis by silencing Bcl-2 and Mcl-1 and inducing E2F1 and E2F3 expression
target gene	hsa-mir-300	Osteosarcoma	26010572	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Up-Regulation of MiR-300 Promotes Proliferation and Invasion of Osteosarcoma by Targeting BRD7.
target gene	hsa-mir-301a	Osteosarcoma	25727016	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
target gene	hsa-mir-301a	Osteosarcoma	27323075	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Upregulated microRNA-301a in osteosarcoma promotes tumor progression by targeting CDC14A.
target gene	hsa-mir-302a	Osteosarcoma	29563995	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-302a inhibits osteosarcoma cell migration and invasion by directly targeting IGF-1R.
target gene	hsa-mir-30a	Osteosarcoma	25264196	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone.
target gene	hsa-mir-32	Osteosarcoma	24989927	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9.
target gene	hsa-mir-320	Osteosarcoma	24390663	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase.
target gene	hsa-mir-320	Osteosarcoma	27721258	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1.
target gene	hsa-mir-326	Osteosarcoma	27723574	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma.
target gene	hsa-mir-335	Osteosarcoma	23975506	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells
target gene	hsa-mir-33a	Osteosarcoma	24468065	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
target gene	hsa-mir-33b	Osteosarcoma	25546234	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-33b inhibits osteosarcoma cells migration and invasion by targeting the c-Myc gene, acting as tumor suppressor. The findings of this study contribute to current understanding of the functions of miR-33b in osteosarcoma.
target gene	hsa-mir-33b	Osteosarcoma	27662380	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-33b Inhibits the Proliferation and Migration of Osteosarcoma Cells via Targeting Hypoxia-Inducible Factor-1α.
target gene	hsa-mir-340	Osteosarcoma	23872151	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1.
target gene	hsa-mir-340	Osteosarcoma	28443990	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma.
target gene	hsa-mir-340	Osteosarcoma	29769415	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Upregulation of microRNA-340 promotes osteosarcoma cell apoptosis while suppressing proliferation, migration and invasion by inactivating the CTNNB1-mediated Notch signaling pathway.
target gene	hsa-mir-34a	Osteosarcoma	23314380	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44.
target gene	hsa-mir-34a	Osteosarcoma	23569431	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether go-go 1 Expression
target gene	hsa-mir-34a	Osteosarcoma	29312491	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma.
target gene	hsa-mir-34a	Osteosarcoma	28275089	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The miR-34a/STMN1/βIII-tubulin axis maintains the microtubule cytoskeleton in osteosarcoma, and combining miR-34a with microtubule inhibitors can be investigated as a novel therapeutic strategy
target gene	hsa-mir-34c	Osteosarcoma	28075441	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR‑34c‑3p acts as a tumor suppressor gene in osteosarcoma by targeting MARCKS.
target gene	hsa-mir-365	Osteosarcoma	26728377	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-365 could inhibit the proliferation and promote the apoptosis in SOSP-9607 osteosarcoma cells probably by mediating the expression of KRAS.
target gene	hsa-mir-375	Osteosarcoma	26036761	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.
target gene	hsa-mir-377	Osteosarcoma	25577249	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-377 can suppress proliferation in MG-63 cells in part by targeting CDK6.
target gene	hsa-mir-379	Osteosarcoma	27781416	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1.
target gene	hsa-mir-381	Osteosarcoma	28406476	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	WISP-1 enhances VEGF-A expression and angiogenesis through the FAK/JNK/HIF-1α signaling pathways, as well as via down-regulation of miR-381 expression
target gene	hsa-mir-382	Osteosarcoma	25292190	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1.
target gene	hsa-mir-3928	Osteosarcoma	24854843	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Down-expression of miR-3928 in osteosarcoma promoted tumor growth by targeting ERBB3, IL-6R and CDK6. MiR-3928 may be a potential therapy target worth further investigation.
target gene	hsa-mir-409	Osteosarcoma	26992637	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-409-3p inhibits osteosarcoma cell migration and invasion by targeting catenin-δ1.
target gene	hsa-mir-410	Osteosarcoma	28138700	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma.
target gene	hsa-mir-449a	Osteosarcoma	29117539	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Hsa_circ_0009910 promotes carcinogenesis by promoting the expression of miR-449a target IL6R in osteosarcoma.
target gene	hsa-mir-451	Osteosarcoma	24218283	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-451 played a tumor-suppressing role through modulating the expression of PGE2 and CCND1, suggesting a novel target for the diagnosis and treatment of osteosarcoma.
target gene	hsa-mir-451	Osteosarcoma	27908732	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-451 inhibits cell growth, migration and angiogenesis in human osteosarcoma via down-regulating IL 6R.
target gene	hsa-mir-451	Osteosarcoma	28086136	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor.
target gene	hsa-mir-491	Osteosarcoma	27704627	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma.
target gene	hsa-mir-542	Osteosarcoma	26498360	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, our results indicated that miR-542-5p plays a critical role in the proliferation of osteosarcoma and targets HUWE1.
target gene	hsa-mir-543	Osteosarcoma	28108312	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling.
target gene	hsa-mir-646	Osteosarcoma	25403884	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-646 might be a tumor suppressor in osteosarcoma via the regulation of FGF2, which provided a potential prognostic biomarker and therapeutic target.
target gene	hsa-mir-661	Osteosarcoma	28391262	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1.
target gene	hsa-mir-664a	Osteosarcoma	28669734	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Inhibition of miR-664a interferes with the migration of osteosarcoma cells via modulation of MEG3.
target gene	hsa-mir-675	Osteosarcoma	29626470	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1.
target gene	hsa-let-7a	Osteosarcoma	25647078	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells.
target gene	hsa-mir-802	Osteosarcoma	24460254	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27.
target gene	hsa-mir-9	Osteosarcoma	26107195	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-9 Modulates Osteosarcoma Cell Growth by Targeting the GCIP Tumor Suppressor.
target gene	hsa-mir-92a	Osteosarcoma	28260104	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-92a promotes tumor growth of osteosarcoma by targeting PTEN/AKT signaling pathway.
target gene	hsa-mir-93	Osteosarcoma	21959981	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Levels of miR-93 were significantly higher in metastases from osteosarcoma than in paired primary tumours. When 143B and MG-63 were transfected with miR-93, clones appeared to respond differently to microRNA overexpression. Ectopic expression of miR-93 more significantly increased cell proliferation and invasivity in 143B than in MG-63 clones. Furthermore, increased mRNA and protein levels of E2F1, one of the potential miR-93 targets, were seen in osteosarcoma cellular clones and its involvement in 143B cell proliferation was confirmed by E2F1 silencing.
target gene	hsa-mir-93	Osteosarcoma	28056303	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-93 targets NKD2 to promote proliferation and inhibit apoptosis of osteosarcoma cells
target gene	hsa-mir-96	Osteosarcoma	29656060	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	microRNA-96 acts as a tumor suppressor gene in human osteosarcoma via target regulation of EZRIN
target gene	hsa-let-7	Ovarian Neoplasms	21109987	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells.
target gene	hsa-let-7a	Ovarian Neoplasms	23136250	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The hsa-let-7 family member hsa-let-7a is a modulator of KLK6 protein expression that is independent of the KLK6 copy number status.
target gene	hsa-let-7d	Ovarian Neoplasms	23268403	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Construction of let-7d expression vector and its inhibitory effect on HMGA2 and ras expression in human ovarian cancer cells in vitro
target gene	hsa-let-7f-1	Ovarian Neoplasms	20354523	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can  target KLK10.
target gene	hsa-let-7f-2	Ovarian Neoplasms	20354523	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can  target KLK10.
target gene	hsa-mir-1	Ovarian Neoplasms	26117268	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The mRNA level of HOTAIR and MAPK1 in ovarian SKOV3 decreased when transected with miR-1, miR-214-3p, or miR-330-5p compared to negative control (p<0.05).
target gene	hsa-mir-106a	Ovarian Neoplasms	23807165	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-106a and miR-591 have important roles in conferring PTX resistance to ovarian cancer cells. Modulation of these microRNAs resensitizes PTX-resistant cancer cells by targeting BCL10, caspase-7,and ZEB1.
target gene	hsa-mir-106a	Ovarian Neoplasms	23904379	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
target gene	hsa-mir-124	Ovarian Neoplasms	29344168	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6
target gene	hsa-mir-125b-1	Ovarian Neoplasms	21823019	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1.
target gene	hsa-mir-125b-2	Ovarian Neoplasms	21823019	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1.
target gene	hsa-mir-1271	Ovarian Neoplasms	26477861	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Low levels of miR-1271 in ovarian cancer tissues promoted cancer cell growth. MiR-1271 may be a new predictor of prognosis in ovarian cancer.MiR-1271 exerted its role by targeting CCNG1.
target gene	hsa-mir-128-1	Ovarian Neoplasms	22909061	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic potential of cancer cells.
target gene	hsa-mir-128-2	Ovarian Neoplasms	22909061	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Both miR-128 and miR-152 down-regulate CSF-1 mRNA and protein expression in ovarian cancer cells leading to decreased cell motility and adhesion in vitro, two major aspects of the metastatic potential of cancer cells.
target gene	hsa-mir-130a	Ovarian Neoplasms	24490491	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-130a expression may be associated with cisplatin resistance of ovarian cancer cells. MiR-130a inhibitor can reverse the cisplatin resistance by upregulating the expression of PTEN proteins and down-regulating P-gp in A2780 cell lines. MiR-130 may become a new potential target of genetic therapy for cisplatin-resistant ovarian cancers.
target gene	hsa-mir-130a	Ovarian Neoplasms	26573160	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis.
target gene	hsa-mir-130a	Ovarian Neoplasms	24145606	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
target gene	hsa-mir-130b	Ovarian Neoplasms	26573160	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	NRP1 is targeted by miR-130a and miR-130b, and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis.
target gene	hsa-mir-133a	Ovarian Neoplasms	24127040	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor.
target gene	hsa-mir-133a-1	Ovarian Neoplasms	22452920	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC.
target gene	hsa-mir-133a-2	Ovarian Neoplasms	22452920	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC.
target gene	hsa-mir-133b	Ovarian Neoplasms	26396496	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-133b may reduce ovarian cancer drug resistance by silencing the expression of the drug-resistance-related proteins, GST-π and MDR1. In future, the combination of miR-133b with chemotherapy agents may prevent the development of drug resistance in ovarian cancers.
target gene	hsa-mir-133b	Ovarian Neoplasms	26617770	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Altogether, our results indicated that miR-133b overexpression was shown to inhibit proliferation and invasion of OC cells through suppression of the MAPK and PI3K/Akt signaling pathways by targeting EGFR.
target gene	hsa-mir-135a	Ovarian Neoplasms	24016480	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-135a may play an important role in cell proliferation and apoptosis of ovarian cancer cells by regulating HOXA10 and its downstream pathways.
target gene	hsa-mir-136	Ovarian Neoplasms	25482209	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-136 may function as an anti-oncogene and deficiency of miR-136 expression in ovarian cancer can induce chemoresistance at least in part by downregulating apoptosis and promoting the repair of cisplatin-induced DNA damage. Thus, miR-136 may provide a biomarker for predicting the chemosensitivity to cisplatin in patients with epithelial ovarian cancer.
target gene	hsa-mir-137	Ovarian Neoplasms	24144591	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-137 suppresses cell growth in ovarian cancer by targeting AEG-1.
target gene	hsa-mir-138	Ovarian Neoplasms	25190487	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Upregulation of Limk1 caused by microRNA-138 loss aggravates the metastasis of ovarian cancer by activation of Limk1/cofilin signaling.
target gene	hsa-mir-138-1	Ovarian Neoplasms	23389731	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting  SOX4 and HIF-1a
target gene	hsa-mir-138-2	Ovarian Neoplasms	23389731	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting  SOX4 and HIF-1a
target gene	hsa-mir-141	Ovarian Neoplasms	23045278	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
target gene	hsa-mir-145	Ovarian Neoplasms	23919393	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer.
target gene	hsa-mir-145	Ovarian Neoplasms	24510775	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
target gene	hsa-mir-145	Ovarian Neoplasms	24157791	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1.
target gene	hsa-mir-145	Ovarian Neoplasms	21917858	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The expression of miR-145 is downregulated in colon and ovarian cancer tissues and cell lines. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis.
target gene	hsa-mir-145	Ovarian Neoplasms	22452920	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Other pairs of potentially biological relevance include: hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC.
target gene	hsa-mir-148a	Ovarian Neoplasms	26004124	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3.
target gene	hsa-mir-148a	Ovarian Neoplasms	26004261	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1.
target gene	hsa-mir-149	Ovarian Neoplasms	26223974	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings suggest that miRNA-149 mediates the susceptibility of paclitaxel by regulating MyD88 expression in ovarian cancer cells.
target gene	hsa-mir-151	Ovarian Neoplasms	24188450	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	the up-regulated miR-151 and miR-672 can also target expression of TNFSF10 and FNDC1, which have been shown to positively regulate cell apoptosis.
target gene	hsa-mir-152	Ovarian Neoplasms	23318422	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine
target gene	hsa-mir-152	Ovarian Neoplasms	29434752	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.
target gene	hsa-mir-153	Ovarian Neoplasms	25954928	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells.
target gene	hsa-mir-155	Ovarian Neoplasms	26779627	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-155 mediates cisplatin-induced apoptosis by targeting XIAP in ovarian cancer
target gene	hsa-mir-16	Ovarian Neoplasms	23990444	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Two regulatory networks for miRNA target genes and TF target genes were established and then both were combined, in which E2F transcription factor 1, cyclin-dependent kinase inhibitor 1A, cyclin E1, and miR-16 were the hub genes. These genes may be potential biomarkers for ovarian cancer.
target gene	hsa-mir-16-1	Ovarian Neoplasms	23302126	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-16 regulates the proliferation, invasion and apoptosis of ovarian epithelial carcinoma cells in vitro
target gene	hsa-mir-16-2	Ovarian Neoplasms	23302126	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-16 regulates the proliferation, invasion and apoptosis of ovarian epithelial carcinoma cells in vitro
target gene	hsa-mir-17	Ovarian Neoplasms	25561420	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-17-5p might play a role in human ovarian cancer by up-regulating YES1 expression.
target gene	hsa-mir-17	Ovarian Neoplasms	23396109	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN
target gene	hsa-mir-181b	Ovarian Neoplasms	24735543	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2.
target gene	hsa-mir-182	Ovarian Neoplasms	23296900	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-182 promotes cell growth, invasion and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas
target gene	hsa-mir-182	Ovarian Neoplasms	26472020	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In normal FTSE cells, miR-182 overexpression  triggers cellular senescence by p53-mediated upregulation of p21.
target gene	hsa-mir-183	Ovarian Neoplasms	22469921	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells.
target gene	hsa-mir-185	Ovarian Neoplasms	23318422	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine
target gene	hsa-mir-186	Ovarian Neoplasms	25867064	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.
target gene	hsa-mir-186	Ovarian Neoplasms	26626440	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-π.
target gene	hsa-mir-187	Ovarian Neoplasms	21725366	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	microRNA-187 Regulates of ovarian cancer progression through targeting Disabled homolog-2.
target gene	hsa-mir-18a	Ovarian Neoplasms	28588697	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK.
target gene	hsa-mir-191	Ovarian Neoplasms	21084273	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We conclude that acquisition of an illegitimate miR-191 target site causes downregulation of MDM4 expression,thereby significantly delaying ovarian carcinoma progression and tumor-related death.
target gene	hsa-mir-193a	Ovarian Neoplasms	23588298	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We demonstrated that miR-193a decreased the amount of MCL1 protein by binding 3'UTR of its mRNA.
target gene	hsa-mir-197	Ovarian Neoplasms	25833695	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.
target gene	hsa-mir-199a	Ovarian Neoplasms	26711828	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-199a regulates the sensitivity of ovarian cancer cells to cisplatin through modulating expression of mTOR, and involves in the cisplatin resistance process of ovarian cancer cells.
target gene	hsa-mir-199a	Ovarian Neoplasms	24706848	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.
target gene	hsa-mir-199a	Ovarian Neoplasms	18408758	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Furthermore, we describe for the first time the identification of the microRNA hsa-miR-199a as a regulator of IKKbeta expression. Our study describes the property of ovarian cancer cells to enhance the inflammatory microenvironment as a result of the expression of an active IKKbeta pathway.
target gene	hsa-mir-199a-1	Ovarian Neoplasms	22498306	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells.
target gene	hsa-mir-199a-2	Ovarian Neoplasms	22498306	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi-drug resistance of ovarian cancer-initiating cells.
target gene	hsa-mir-200a	Ovarian Neoplasms	24503464	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our research demonstrates that VM, miR-200a and EphA2 play key roles in the progression and prognosis of ovarian cancer, and for the first time suggests that miR-200a inhibits VM by directly regulating EphA2. Therefore, we might have identified a genetic mechanism underlying the involvement of miR-200a in ovarian cancer VM.
target gene	hsa-mir-200a	Ovarian Neoplasms	21529905	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2.
target gene	hsa-mir-200c	Ovarian Neoplasms	25052237	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-box-binding homeobox 2 (ZEB2) expression.
target gene	hsa-mir-200c	Ovarian Neoplasms	25860109	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This network included four separate types of interactions among miRNAs and genes. Simply analyzing each interaction component in isolation, such as the eQTL associations, the miRNA-target interactions or the protein-protein interactions, would create a much more limited network than the integrated one.
target gene	hsa-mir-20a	Ovarian Neoplasms	24813230	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity  by downregulating MICA/B expression.
target gene	hsa-mir-20a	Ovarian Neoplasms	20458444	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-20a:miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells
target gene	hsa-mir-20a	Ovarian Neoplasms	23869765	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	transfection of miR-20a or miR-200c led to corresponding reduction in endogenous PTEN protein
target gene	hsa-mir-21	Ovarian Neoplasms	23824073	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.
target gene	hsa-mir-21	Ovarian Neoplasms	25579119	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-21-3p can induce cisplatin resistance in ovarian tumours, potentially by targeting the NAV3 gene.
target gene	hsa-mir-21	Ovarian Neoplasms	22176994	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-21 might play an important role in the proliferation and apoptosis of ovarian epithelial carcinoma cells through negatively control the expression of PDCD4.
target gene	hsa-mir-210	Ovarian Neoplasms	24549370	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Inactivation of von Hippel-Lindau increases ovarian cancer cell aggressiveness through the HIF1α/miR-210/VMP1 signaling pathway.
target gene	hsa-mir-212	Ovarian Neoplasms	25201063	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF.
target gene	hsa-mir-214	Ovarian Neoplasms	22927443	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-214 regulates ovarian cancer cell stemness by targeting p53/nanog.
target gene	hsa-mir-22	Ovarian Neoplasms	25860109	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This network included four separate types of interactions among miRNAs and genes. Simply analyzing each interaction component in isolation, such as the eQTL associations, the miRNA-target interactions or the protein-protein interactions, would create a much more limited network than the integrated one.
target gene	hsa-mir-22	Ovarian Neoplasms	22469921	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells.
target gene	hsa-mir-222	Ovarian Neoplasms	27811362	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
target gene	hsa-mir-224	Ovarian Neoplasms	25017423	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-224-5p may function as an oncogene and induce platinum resistance in OPSC at least in part by downregulating PRKCD, thereby providing a biomarker for predicting chemosensitivity to cisplatin in patients with ovarian cancer.
target gene	hsa-mir-224	Ovarian Neoplasms	20354523	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can  target KLK10.
target gene	hsa-mir-23a	Ovarian Neoplasms	25613625	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	nhibition of miR-23a expression increases the sensitivity of A2780 cells to cisplatin possibly by inhibiting the negative regulation by miR-23a target genes that causes inhibition of P-gp protein expression.
target gene	hsa-mir-23b	Ovarian Neoplasms	24613919	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2.
target gene	hsa-mir-23b	Ovarian Neoplasms	26872615	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings show that miR-23b may inhibit ovarian cancer tumorigenesis and progression by downregulating CCNG1 and the expression of the relevant genes. MiR-23b is a potentially novel application for regulating ovarian carcinoma progression.
target gene	hsa-mir-25	Ovarian Neoplasms	25179841	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2.
target gene	hsa-mir-25	Ovarian Neoplasms	22076535	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer.
target gene	hsa-mir-27a	Ovarian Neoplasms	20624637	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-27a:MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells
target gene	hsa-mir-27a	Ovarian Neoplasms	23438830	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
target gene	hsa-mir-27a	Ovarian Neoplasms	20646448	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The expression of miR-27a is upregulated in A2780/Taxol cells, which may regulate MDR1 and P-gp expression by targeting HIPK2.
target gene	hsa-mir-296	Ovarian Neoplasms	27186401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	deregulated miR-296/S100A4 promotes tumor progression
target gene	hsa-mir-29b	Ovarian Neoplasms	29050034	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Mir-29b Regulates Oxidative Stress by Targeting SIRT1 in Ovarian Cancer Cells.
target gene	hsa-mir-302b	Ovarian Neoplasms	25562167	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-302b functions as a tumor suppressor in EOC by targeting RUNX1 and modulating the activity of the STAT3 signaling pathway.
target gene	hsa-mir-30a	Ovarian Neoplasms	22157765	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy.
target gene	hsa-mir-30a	Ovarian Neoplasms	25621074	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-30a overexpression upregulates BCL2A1, IER3 and cyclin D2 expression by inhibiting FOXL2.
target gene	hsa-mir-30c-1	Ovarian Neoplasms	22024689	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor induced cellular proliferation and downregulates the oncogene BCL9.
target gene	hsa-mir-30c-2	Ovarian Neoplasms	22024689	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor induced cellular proliferation and downregulates the oncogene BCL9.
target gene	hsa-mir-31	Ovarian Neoplasms	22469921	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells.
target gene	hsa-mir-330	Ovarian Neoplasms	29485916	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
target gene	hsa-mir-335	Ovarian Neoplasms	23708561	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w.
target gene	hsa-mir-34a	Ovarian Neoplasms	25895459	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
target gene	hsa-mir-370	Ovarian Neoplasms	25063739	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-370 acts as a tumor suppressor in endometrioid ovarian cancer via ENG regulation.
target gene	hsa-mir-376c	Ovarian Neoplasms	21224400	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
target gene	hsa-mir-382	Ovarian Neoplasms	26575700	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	these findings revealed that miR-382 inhibits migration and invision by targeting ROR1 through regulating EMT in ovarian cancer, and might serve as a tumor suppressor in ovarian cancer.
target gene	hsa-mir-433	Ovarian Neoplasms	22069160	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MAD2 protein expression levels were downregulated in pre-miR-433 transfected A2780 cells. Secondly, Pre-miR-433 suppressed the activity of a reporter construct containing the 3'-UTR of MAD2. Thirdly, blocking miR-433 binding to the MAD2 3'UTR protected MAD2 from miR-433 induced protein downregulation. Importantly, reduced MAD2 protein expression in pre-miR-433 transfected A2780 cells rendered these cells less sensitive to paclitaxel. In conclusion, loss of MAD2 protein expression results in increased resistance to paclitaxel in EOC cells.
target gene	hsa-mir-448	Ovarian Neoplasms	26103953	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data indicate that miR-448 functions as a tumor suppressor in ovarian cancer, which exerts its activity by suppressing the expression of CXCL12.
target gene	hsa-mir-486	Ovarian Neoplasms	26871282	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	OLFM4 is downregulated by miR-486-5p, which contributes to ovarian cancer tumorigenesis.
target gene	hsa-mir-488	Ovarian Neoplasms	29113360	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function.
target gene	hsa-mir-497	Ovarian Neoplasms	24858688	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-497 inhibition of ovarian cancer cell migration and invasion through targeting of SMAD specific E3 ubiquitin protein ligase 1.
target gene	hsa-mir-497	Ovarian Neoplasms	25176450	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.
target gene	hsa-mir-497	Ovarian Neoplasms	26238185	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
target gene	hsa-mir-498	Ovarian Neoplasms	26054675	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells.
target gene	hsa-mir-506	Ovarian Neoplasms	24604117	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.
target gene	hsa-mir-516a-1	Ovarian Neoplasms	20354523	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can  target KLK10.
target gene	hsa-mir-516a-2	Ovarian Neoplasms	20354523	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	When we co-transfected cells with pMIR-KLK10 and either let-7f, miR-224, or mR-516a, we saw decreased luciferase signal, suggesting that these miRNAs can  target KLK10.
target gene	hsa-mir-532	Ovarian Neoplasms	29558748	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells.
target gene	hsa-mir-591	Ovarian Neoplasms	23807165	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-106a and miR-591 have important roles in conferring PTX resistance to ovarian cancer cells. Modulation of these microRNAs resensitizes PTX-resistant cancer cells by targeting BCL10, caspase-7,and ZEB1.
target gene	hsa-mir-629	Ovarian Neoplasms	28972400	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Knockdown of miR-629 Inhibits Ovarian Cancer Malignant Behaviors by Targeting Testis-Specific Y-Like Protein 5.
target gene	hsa-mir-873	Ovarian Neoplasms	26850595	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	overexpression of miR-873 increased  the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting  MDR1 expression.
target gene	hsa-mir-9	Ovarian Neoplasms	19702828	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Ovarian cancer tissues display significantly low expression of miR-9 and a high level of NF-kappaB1 compared with normal tissues, indicating that regulation of NF-kappaB1 by miR-9 is an important mechanism for miR-9 to inhibit ovarian cancer proliferation.
target gene	hsa-mir-9	Ovarian Neoplasms	23722670	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1.
target gene	hsa-mir-92a-1	Ovarian Neoplasms	23396109	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN
target gene	hsa-mir-92a-2	Ovarian Neoplasms	23396109	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Downregulation of miR-17~92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN
target gene	hsa-mir-93	Ovarian Neoplasms	22465665	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.
target gene	hsa-mir-93	Ovarian Neoplasms	24626475	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miRNA expression analysis determined that miR-93, miR-144 and miR-382 had significantly lower levels of expression in primary serous OvCa tumors than normal tissues; treatment of an OvCa cell line with miRNA mimics and inhibitors specifically modulated KIF14 mRNA levels, pointing to potential novel mechanisms of KIF14 overexpression in primary tumors.
target gene	hsa-mir-98	Ovarian Neoplasms	24771265	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway.
target gene	hsa-mir-98	Ovarian Neoplasms	21109987	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells.
target gene	hsa-mir-490	Ovary Mixed Epithelial Carcinoma	25819031	endocrine system disease	DOID:6898					MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression.
target gene	hsa-mir-183	Pain	28214854			R52	D010146			MicroRNA-183 Suppresses Neuropathic Pain and Expression of AMPA Receptors by Targeting mTOR/VEGF Signaling Pathway.
target gene	hsa-mir-23b	Pain	22149086			R52	D010146			MiR23b Ameliorates Neuropathic Pain in Spinal Cord by Silencing NOX4.
target gene	hsa-mir-96	Pain	24234845			R52	D010146			miR-96 participate in the regulation of neuropathic pain through inhibiting the expression of Nav1.3 in the DRG of CCI rats.
target gene	hsa-mir-372	Pancreatic Adenocarcinoma	28677209	disease of cellular proliferation	DOID:4074	C25.3				Downregulation of ULK1 by microRNA-372 inhibits the survival of human pancreatic adenocarcinoma cells.
target gene	hsa-let-7b	Pancreatic Diseases	23684747			K86.9	D010182			Let-7b, miR-495, and their targets constitute a gene network that is required to establish and maintain pancreatic acinar cell differentiation.
target gene	hsa-mir-495	Pancreatic Diseases	23684747			K86.9	D010182			Let-7b, miR-495, and their targets constitute a gene network that is required to establish and maintain pancreatic acinar cell differentiation.
target gene	hsa-let-7	Pancreatic Neoplasms	24491408	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression.
target gene	hsa-let-7d	Pancreatic Neoplasms	22384141	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miRNA is downregulated and regulate known PDAC oncogenes
target gene	hsa-let-7i	Pancreatic Neoplasms	22261338	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro.
target gene	hsa-mir-10	Pancreatic Neoplasms	21738581	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Predicted target mRNAs FGFR1 (miR-10) and MLH1 (miR-155) were found downregulated.
target gene	hsa-mir-100	Pancreatic Neoplasms	25344675	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3.
target gene	hsa-mir-100	Pancreatic Neoplasms	23373509	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells
target gene	hsa-mir-106b	Pancreatic Neoplasms	25807437	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies.
target gene	hsa-mir-10a	Pancreatic Neoplasms	22407312	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene.
target gene	hsa-mir-1178	Pancreatic Neoplasms	25635996	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-1178 acts as an oncomiR in pancreatic cancer cells by inhibiting CHIP expression.
target gene	hsa-mir-1247	Pancreatic Neoplasms	24588767	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins.
target gene	hsa-mir-124a	Pancreatic Neoplasms	17462994	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines.
target gene	hsa-mir-125a	Pancreatic Neoplasms	25807437	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies.
target gene	hsa-mir-126	Pancreatic Neoplasms	22064652	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9.
target gene	hsa-mir-126	Pancreatic Neoplasms	22384141	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miRNA is downregulated and regulate known PDAC oncogenes
target gene	hsa-mir-1271	Pancreatic Neoplasms	26940738	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-1271 inhibits migration, invasion and epithelial-mesenchymal transition by targeting ZEB1 and TWIST1 in pancreatic cancer cells.
target gene	hsa-mir-130b	Pancreatic Neoplasms	24040078	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3.
target gene	hsa-mir-132	Pancreatic Neoplasms	21329664	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor, rb1.
target gene	hsa-mir-139	Pancreatic Neoplasms	25955258	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis.
target gene	hsa-mir-141	Pancreatic Neoplasms	24013097	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-141 targets MAP4K4, acts as a tumor suppressor in pancreatic cancer cells, and may serve as a novel therapeutic agent for miRNA-based pancreatic cancer therapy.
target gene	hsa-mir-143	Pancreatic Neoplasms	23973710	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells.
target gene	hsa-mir-143	Pancreatic Neoplasms	22261338	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro.
target gene	hsa-mir-143	Pancreatic Neoplasms	21622730	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1).
target gene	hsa-mir-145	Pancreatic Neoplasms	25277192	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.
target gene	hsa-mir-145	Pancreatic Neoplasms	25354783	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Identification of miR-145 targets through an integrated omics analysis.
target gene	hsa-mir-145	Pancreatic Neoplasms	25646678	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9
target gene	hsa-mir-145	Pancreatic Neoplasms	21622730	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1).
target gene	hsa-mir-146b	Pancreatic Neoplasms	21823013	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-146b-5p has inhibitory effects of  on cell migration and invasion of pancreatic cancer by targeting MMP16.
target gene	hsa-mir-148a	Pancreatic Neoplasms	23975374	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2.
target gene	hsa-mir-148a	Pancreatic Neoplasms	21709669	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.
target gene	hsa-mir-148b	Pancreatic Neoplasms	24448385	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines.
target gene	hsa-mir-150	Pancreatic Neoplasms	25522282	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-150 is an important suppressor of pancreatic ductal carcinoma and acts as a regulator of c-Myb and MUC4 in aggressive progress.
target gene	hsa-mir-150	Pancreatic Neoplasms	21983127	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells.
target gene	hsa-mir-150	Pancreatic Neoplasms	23675407	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R.
target gene	hsa-mir-152	Pancreatic Neoplasms	24448385	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines.
target gene	hsa-mir-153	Pancreatic Neoplasms	25807437	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies.
target gene	hsa-mir-155	Pancreatic Neoplasms	17911264	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.
target gene	hsa-mir-155	Pancreatic Neoplasms	23715647	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MLH1 as a Direct Target of MiR-155 and a Potential Predictor of Favorable Prognosis in Pancreatic Cancer.
target gene	hsa-mir-155	Pancreatic Neoplasms	21738581	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Predicted target mRNAs FGFR1 (miR-10) and MLH1 (miR-155) were found downregulated.
target gene	hsa-mir-16-1	Pancreatic Neoplasms	22384141	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miRNA is downregulated and regulate known PDAC oncogenes
target gene	hsa-mir-16-2	Pancreatic Neoplasms	22384141	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miRNA is downregulated and regulate known PDAC oncogenes
target gene	hsa-mir-17	Pancreatic Neoplasms	22407312	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene.
target gene	hsa-mir-17	Pancreatic Neoplasms	23194063	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors.
target gene	hsa-mir-181b	Pancreatic Neoplasms	24075517	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The present study demonstrated that miR-181b was associated with the resistance of pancreatic cancer cells to gemcitabine, and verified that miR-181b enhances the activity of NF-κB by inhibiting CYLD, leading to the resistance to gemcitabine. Our results suggest that miR-181b is a potential target for decreasing gemcitabine resistance.
target gene	hsa-mir-181c	Pancreatic Neoplasms	25807437	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our findings may provide new insights into the knowledge of molecular mechanisms of pancreatic cancer and development of novel targeting therapies.
target gene	hsa-mir-183	Pancreatic Neoplasms	25776494	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-183 induces cell proliferation, migration, and invasion by regulating PDCD4 expression in the SW1990 pancreatic cancer cell line.
target gene	hsa-mir-19	Pancreatic Neoplasms	26531836	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A positive feedback loop of p53/miR-19/TP53INP1 modulates pancreatic cancer cell proliferation and apoptosis.
target gene	hsa-mir-191	Pancreatic Neoplasms	25168367	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-191 promotes pancreatic cancer progression by targeting USP10.
target gene	hsa-mir-193b	Pancreatic Neoplasms	25215905	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-193b directly targets STMN1 and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer.
target gene	hsa-mir-193b	Pancreatic Neoplasms	25905463	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer.
target gene	hsa-mir-196a	Pancreatic Neoplasms	24504166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha.
target gene	hsa-mir-197	Pancreatic Neoplasms	23139153	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin
target gene	hsa-mir-200a	Pancreatic Neoplasms	20551052	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-200a:The elevated serum levels of miR-200a and miR-200b in most patients with pancreatic cancer could have diagnostic utility
target gene	hsa-mir-200a	Pancreatic Neoplasms	21224848	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
target gene	hsa-mir-200a	Pancreatic Neoplasms	22637745	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.
target gene	hsa-mir-200a	Pancreatic Neoplasms	28281184	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		TGF-β1-miR-200a-PTEN induces epithelial-mesenchymal transition and fibrosis of pancreatic stellate cells.
target gene	hsa-mir-200b	Pancreatic Neoplasms	20551052	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-200b:The elevated serum levels of miR-200a and miR-200b in most patients with pancreatic cancer could have diagnostic utility
target gene	hsa-mir-200b	Pancreatic Neoplasms	21224848	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
target gene	hsa-mir-200b	Pancreatic Neoplasms	22637745	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.
target gene	hsa-mir-200c	Pancreatic Neoplasms	24204560	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer.
target gene	hsa-mir-200c	Pancreatic Neoplasms	25955258	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis.
target gene	hsa-mir-200c	Pancreatic Neoplasms	21224848	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
target gene	hsa-mir-200c	Pancreatic Neoplasms	22637745	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.
target gene	hsa-mir-200c	Pancreatic Neoplasms	26400206	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		More importantly, garcinol treatment led to the upregulation of several tumor suppressor microRNAs, and miR-200c increased by garcinol treatment was found to target and downregulate Notch1.
target gene	hsa-mir-200c	Pancreatic Neoplasms	26609108	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Paradoxically, targeting eIF4E, the best-characterized effector of MNKs, increases ZEB1 mRNA expression through repression of ZEB1-targeting miRNAs, miR-200c and miR-141.
target gene	hsa-mir-202	Pancreatic Neoplasms	25611699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		down regulation of miR-202 increased the expression of its target Mxd1, followed by Mxd1 recruitment to the Sin3A repressor complex and through its dimerization with Max, and increased repression of Myc-Max target proteins.
target gene	hsa-mir-203	Pancreatic Neoplasms	25290620	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203.
target gene	hsa-mir-203	Pancreatic Neoplasms	23732815	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Survivin.
target gene	hsa-mir-206	Pancreatic Neoplasms	27233476	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Mechanistically, the Nampt expression was independent of Kras and p16 status, but it was directly regulated by miR-206
target gene	hsa-mir-20a	Pancreatic Neoplasms	23194063	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors.
target gene	hsa-mir-21	Pancreatic Neoplasms	21376256	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Bcl-2 Upregulation Induced by miR-21 Via a Direct Interaction Is Associated with Apoptosis and Chemoresistance in MIA PaCa-2 Pancreatic Cancer Cells.
target gene	hsa-mir-21	Pancreatic Neoplasms	23177026	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL
target gene	hsa-mir-21	Pancreatic Neoplasms	23359184	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression
target gene	hsa-mir-21	Pancreatic Neoplasms	29464088	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the expression of two miRComb miR-21 predicted targets, PDCD4 and BTG2, was significantly upregulated in these cells in comparison to control PANC-1
target gene	hsa-mir-210	Pancreatic Neoplasms	23831622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-210 regulates the interaction between pancreatic cancer cells and stellate cells.
target gene	hsa-mir-211	Pancreatic Neoplasms	24940696	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
target gene	hsa-mir-212	Pancreatic Neoplasms	26337469	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p.
target gene	hsa-mir-212	Pancreatic Neoplasms	21329664	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor.
target gene	hsa-mir-216a	Pancreatic Neoplasms	25220761	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2.
target gene	hsa-mir-216a	Pancreatic Neoplasms	26149212	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-216a may inhibit pancreatic tumor growth by targeting JAK2.
target gene	hsa-mir-217	Pancreatic Neoplasms	25172416	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway.
target gene	hsa-mir-217	Pancreatic Neoplasms	20675343	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
target gene	hsa-mir-218	Pancreatic Neoplasms	25010661	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1.
target gene	hsa-mir-218-1	Pancreatic Neoplasms	23733161	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer.
target gene	hsa-mir-218-2	Pancreatic Neoplasms	23733161	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer.
target gene	hsa-mir-221	Pancreatic Neoplasms	23967190	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells.
target gene	hsa-mir-221	Pancreatic Neoplasms	25639539	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the inhibition of miR-21 and miR-221 appear particularly suitable to target stem-like subpopulations and address their specific biological function to promote tumor progression in pancreatic cancer
target gene	hsa-mir-221	Pancreatic Neoplasms	25883224	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases.
target gene	hsa-mir-221	Pancreatic Neoplasms	27726102	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1.
target gene	hsa-mir-222	Pancreatic Neoplasms	25883224	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases.
target gene	hsa-mir-223	Pancreatic Neoplasms	28423622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion.
target gene	hsa-mir-224	Pancreatic Neoplasms	28036293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition.
target gene	hsa-mir-23b	Pancreatic Neoplasms	23916944	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		In pancreatic cancer cells, reduced levels of the miRNA miR-23b increase levels of ATG12 and autophagy to promote radioresistance. miR-23b might be used to increase the sensitivity of pancreatic cancer cells to radiation therapy.
target gene	hsa-mir-27a	Pancreatic Neoplasms	24060073	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		PSMA1 is the direct target gene of miR-27a in pancreatic cancer.
target gene	hsa-mir-27a	Pancreatic Neoplasms	23194063	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors.
target gene	hsa-mir-29a	Pancreatic Neoplasms	26036346	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the  MUC1 mucin in pancreatic cancer cells.
target gene	hsa-mir-29c	Pancreatic Neoplasms	25605017	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Wnt hyperactivation in pancreatic cancer and may suggest a new target for clinical intervention in pancreatic cancer.
target gene	hsa-mir-30	Pancreatic Neoplasms	26965588	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		high expression of the miR-30 family modulated by CD133 promotes migratory and invasive abilities in CD133(+) pancreatic cancer cells.
target gene	hsa-mir-301a	Pancreatic Neoplasms	26019136	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-301a-3p functions as a novel oncogene in PDAC and the oncogenic activity may involve its inhibition of the target gene SMAD4.
target gene	hsa-mir-330	Pancreatic Neoplasms	26036346	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the  MUC1 mucin in pancreatic cancer cells.
target gene	hsa-mir-335	Pancreatic Neoplasms	24859837	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4.
target gene	hsa-mir-34b	Pancreatic Neoplasms	23305226	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3
target gene	hsa-mir-365	Pancreatic Neoplasms	24216611	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX.
target gene	hsa-mir-410	Pancreatic Neoplasms	25646808	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-410 functions as a tumor suppressor by targeting angiotensin II type 1 receptor in pancreatic cancer.
target gene	hsa-mir-494	Pancreatic Neoplasms	25965392	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc.
target gene	hsa-mir-497	Pancreatic Neoplasms	24667580	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma  IGF-1R levels associated with TNM stage of pancreatic cancer.
target gene	hsa-mir-630	Pancreatic Neoplasms	23675407	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R.
target gene	hsa-mir-652	Pancreatic Neoplasms	26498682	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
target gene	hsa-mir-92a-1	Pancreatic Neoplasms	22407312	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Based on the microarray data, the authors found frequent and marked overexpression of miR-10a, miR-92, and miR-17-5p in pancreatic cancer cell lines. MicroRNA-10a is Overexpressed in Human Pancreatic Cancer and Involved in Its Invasiveness Partially via Suppression of the HOXA1 Gene.
target gene	hsa-mir-96	Pancreatic Neoplasms	20610624	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miRNA-96:miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer
target gene	hsa-mir-96	Pancreatic Neoplasms	25242509	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-96 suppresses the expression of NUAK1  by targeting its 3' UTR.
target gene	hsa-mir-99a	Pancreatic Neoplasms	24461517	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Antagonism of microRNA-99a promotes cell invasion and down-regulates E-cadherin expression in pancreatic cancer cells by regulating mammalian target of rapamycin.
target gene	hsa-let-7d	Parkinson Disease	29082467	nervous system disease	DOID:14330	G20	D010300	PS168600		Let-7d microRNA Attenuates 6-OHDA-Induced Injury by Targeting Caspase-3 in MN9D Cells.
target gene	hsa-mir-126	Parkinson Disease	24559646	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling.
target gene	hsa-mir-133b	Parkinson Disease	20468068	nervous system disease	DOID:14330	G20	D010300	PS168600		MiR-133b has been implicated in Parkinson's disease (PD) by a mechanism that involves the regulation of the transcription factor PITX3.
target gene	hsa-mir-16-1	Parkinson Disease	25054189	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-16-1 promotes the aberrant α-synuclein accumulation in parkinson disease via targeting heat shock protein 70.
target gene	hsa-mir-205	Parkinson Disease	23125283	nervous system disease	DOID:14330	G20	D010300	PS168600		MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein
target gene	hsa-mir-22	Parkinson Disease	27631550	nervous system disease	DOID:14330	G20	D010300	PS168600		Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7.
target gene	hsa-mir-221	Parkinson Disease	24055409	nervous system disease	DOID:14330	G20	D010300	PS168600		Trasferrin receptor 2 gene regulation by microRNA 221 in SH-SY5Y cells treated with MPP as Parkinson's disease cellular model.
target gene	hsa-mir-30e	Parkinson Disease	29274035	nervous system disease	DOID:14330	G20	D010300	PS168600		MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3.
target gene	hsa-mir-34b	Parkinson Disease	24892887	nervous system disease	DOID:14330	G20	D010300	PS168600		Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b.
target gene	hsa-mir-4271	Parkinson Disease	27217159	nervous system disease	DOID:14330	G20	D010300	PS168600		hsa-miR-4271 was downregulated, which could influence EFNA3 translation
target gene	hsa-mir-433	Parkinson Disease	18252210	nervous system disease	DOID:14330	G20	D010300	PS168600		Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein.
target gene	hsa-mir-7	Parkinson Disease	25814668	nervous system disease	DOID:14330	G20	D010300	PS168600		microRNA-7, by down-regulating RelA,augments Glut3 expression, promotes glycolysis, and subsequently prevents MPP(+)-induced cell death. This protective effect of microRNA-7 could be exploited to correct the defects in oxidative phosphorylation in Parkinson disease.
target gene	hsa-mir-7	Parkinson Disease	27158385	nervous system disease	DOID:14330	G20	D010300	PS168600		The altered molecular expressions downstream  of Bax and Sirt2 are also involved in miR-7 regulation of the MPP(+)-triggered neuronal apoptosis.
target gene	hsa-mir-15a	Patau Syndrome	21205891	genetic disease	DOID:11665	Q91.7	D000073839			MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13.
target gene	hsa-mir-16-1	Patau Syndrome	21205891	genetic disease	DOID:11665	Q91.7	D000073839			MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13.
target gene	hsa-mir-16-2	Patau Syndrome	21205891	genetic disease	DOID:11665	Q91.7	D000073839			MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13.
target gene	hsa-mir-124	Pediatric Ependymoma	28437838	disease of cellular proliferation	DOID:5509					Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma.
target gene	hsa-mir-30c	Pediatric Osteosarcoma	29364496	disease of cellular proliferation	DOID:3361					Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis.
target gene	hsa-mir-182	Peripheral Nerve Injury	22917588				D059348			Our data indicate that nerve injury inhibits SC proliferation and migration through rapid regulation of miR-182 by targeting FGF9 and NTM, providing novel insights into the roles of miRNAs in nerve injury and repair.
target gene	hsa-mir-210	Pheochromocytoma	29018330			C74.10	D010673	171300	HP:0002666	MicroRNA-210 Protects PC-12 Cells Against Hypoxia-Induced Injury by Targeting BNIP3.
target gene	hsa-mir-16	Pineal Gland Cancer	29359963	disease of cellular proliferation	DOID:5032	C75.3	D010871			Melatonin Inhibits the Proliferation of Gastric Cancer Cells Through Regulating the miR-16-5p-Smad3 Pathway.
target gene	hsa-mir-145	Pituitary Adenoma	28352194	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro.
target gene	hsa-mir-200c	Pituitary Adenoma	24512727	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	MicroRNA-200c inhibits apoptosis in pituitary adenoma cells by targeting the PTEN/Akt signaling pathway.
target gene	hsa-mir-107	Pituitary Neoplasms	22811466	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	MicroRNA miR-107 is overexpressed in pituitary adenomas and in vitro inhibits the expression of aryl hydrocarbon receptor-interacting protein (AIP).
target gene	hsa-mir-132	Pituitary Neoplasms	25305447	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5.
target gene	hsa-mir-15a	Pituitary Neoplasms	25305447	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5.
target gene	hsa-mir-15a	Pituitary Neoplasms	26309203	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	GAA-induced decrease in cell proliferation is associated with decreased expression of Bcl-2 and increased miR-15a.
target gene	hsa-mir-16	Pituitary Neoplasms	25305447	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5.
target gene	hsa-mir-16	Pituitary Neoplasms	29399695	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	MicroRNA‑16/VEGFR2/p38/NF‑κB signaling pathway regulates cell growth of human pituitary neoplasms.
target gene	hsa-mir-21	Pituitary Neoplasms	28742208	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Effects of microRNA-21 targeting PITX2 on proliferation and apoptosis of pituitary tumor cells.
target gene	hsa-mir-410	Pituitary Neoplasms	26125663	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary  gonadotroph tumors.
target gene	hsa-mir-203	Pneumonia	24996183	respiratory system disease	DOID:552	J18.9	D011014		HP:0002090	MicroRNA-203 accelerates apoptosis in LPS-stimulated alveolar epithelial cells by targeting PIK3CA.
target gene	hsa-mir-15a	Polycystic Kidney Disease	18949056			Q61.19	D007690	PS173900	HP:0000113	miR-15a: MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis
target gene	hsa-mir-365a	Polycystic Kidney Disease	22411058			Q61.19	D007690	PS173900	HP:0000113	PKHD1 post-transcriptionally modulated by miR-365-1 inhibits cell-cell adhesion.
target gene	hsa-mir-145	Polycystic Ovarian Syndrome	27799458	syndrome	DOID:11612	E28.2	D011085	184700		MicroRNA-145 Negatively Regulates Cell Proliferation Through Targeting IRS1 in Isolated Ovarian Granulosa Cells From Patients With Polycystic Ovary Syndrome.
target gene	hsa-mir-21	Polycystic Ovarian Syndrome	26427146	syndrome	DOID:11612	E28.2	D011085	184700		In comparison with normal subjects, serum miR-21 is obviously increased in PCOS patients. Through targeting LATS1, miR-21 could prompt PCOS progression and could act as a novel non-invasive biomarker for diagnosis of PCOS.
target gene	hsa-mir-27a	Polycystic Ovarian Syndrome	29089199	syndrome	DOID:11612	E28.2	D011085	184700		MicroRNA-27a-3p affects estradiol and androgen imbalance by targeting Creb1 in the granulosa cells in mouse polycytic ovary syndrome model.
target gene	hsa-mir-320a	Polycystic Ovarian Syndrome	27965096	syndrome	DOID:11612	E28.2	D011085	184700		Deregulation of RUNX2 by miR-320a deficiency impairs steroidogenesis in cumulus granulosa cells from polycystic ovary syndrome (PCOS) patients.
target gene	hsa-mir-93	Polycystic Ovarian Syndrome	23493574	syndrome	DOID:11612	E28.2	D011085	184700		miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of Polycystic Ovary Syndrome patients and women with insulin resistance
target gene	hsa-mir-181a-1	Porcine Reproductive and Respiratory Syndrome Virus Infection	23740977							MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
target gene	hsa-mir-181a-2	Porcine Reproductive and Respiratory Syndrome Virus Infection	23740977							MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
target gene	hsa-mir-181b-1	Porcine Reproductive and Respiratory Syndrome Virus Infection	23740977							MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
target gene	hsa-mir-181b-2	Porcine Reproductive and Respiratory Syndrome Virus Infection	23740977							MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
target gene	hsa-mir-181c	Porcine Reproductive and Respiratory Syndrome Virus Infection	23740977							MicroRNA-181 suppresses PRRSV infection by targeting its receptor CD163.
target gene	hsa-mir-212	Post-Traumatic Stress Disorder	26632874	disease of mental health	DOID:2055	F43.1	D013313			DICER1 is an enzyme that generates mature microRNAs (miRNAs), which regulate gene expression post-transcriptionally in brain and other tissues and is involved in synaptic maturation and plasticity. Here, through genome-wide differential gene expression survey of post-traumatic stress disorder (PTSD) with comorbid depression (PTSD&Dep), we find that blood DICER1 expression is significantly reduced in cases versus controls, and replicate this in two independent cohorts. 
target gene	hsa-mir-3130	Post-Traumatic Stress Disorder	26632874	disease of mental health	DOID:2055	F43.1	D013313			DICER1 is an enzyme that generates mature microRNAs (miRNAs), which regulate gene expression post-transcriptionally in brain and other tissues and is involved in synaptic maturation and plasticity. Here, through genome-wide differential gene expression survey of post-traumatic stress disorder (PTSD) with comorbid depression (PTSD&Dep), we find that blood DICER1 expression is significantly reduced in cases versus controls, and replicate this in two independent cohorts. 
target gene	hsa-mir-106b	Preeclampsia	28545271	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Effect of microRNA-106b on the invasion and proliferation of trophoblasts through targeting MMP-2.
target gene	hsa-mir-125b	Preeclampsia	27935985	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-125b Enhances IL-8 Production in Early-Onset Severe Preeclampsia by Targeting Sphingosine-1-Phosphate Lyase 1.
target gene	hsa-mir-125b-1	Preeclampsia	25251470	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-125b-1-3p inhibits trophoblast cell invasion by targeting sphingosine-1-phosphate receptor 1 in preeclampsia.
target gene	hsa-mir-1324	Preeclampsia	25143393	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Susceptibility allele-specific loss of miR-1324-mediated silencing of the INO80B chromatin-assembly complex gene in pre-eclampsia.
target gene	hsa-mir-144	Preeclampsia	28772212	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-144 may regulate the proliferation, migration and invasion of trophoblastic cells through targeting PTEN in preeclampsia.
target gene	hsa-mir-155	Preeclampsia	24806148	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MicroRNA-155 inhibits migration of trophoblast cells and contributes to the pathogenesis of severe preeclampsia by regulating endothelial nitric oxide synthase.
target gene	hsa-mir-155	Preeclampsia	20452491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-155:MicroRNA-155 contributes to preeclampsia by down-regulating CYR61
target gene	hsa-mir-155	Preeclampsia	21234519	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women.
target gene	hsa-mir-155	Preeclampsia	27375191	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	These miRNAs have previously been linked to PE and are predicted to regulate members of the TGF-尾 pathway.
target gene	hsa-mir-16	Preeclampsia	25135655	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the physiological roles of miR-16 and miR-136 in the down-regulation of VEGFA and PPP2R2A, respectively, were confirmed through reporter assays.
target gene	hsa-mir-17	Preeclampsia	22438230	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
target gene	hsa-mir-181a	Preeclampsia	29339719	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-181a-5p suppresses invasion and migration of HTR-8/SVneo cells by directly targeting IGF2BP2.
target gene	hsa-mir-195	Preeclampsia	22723898	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Downregulated miR-195 detected in preeclamptic placenta affects trophoblast cell invasion via modulating ActRIIA expression.
target gene	hsa-mir-195	Preeclampsia	27176145	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-195 could directly target and suppress the expression of ActRIIB
target gene	hsa-mir-20a	Preeclampsia	22438230	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
target gene	hsa-mir-20b	Preeclampsia	22438230	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Preeclampsia Up-Regulates Angiogenesis-Associated MicroRNA (i.e., miR-17, -20a, and -20b) That Target Ephrin-B2 and EPHB4 in Human Placenta.
target gene	hsa-mir-210	Preeclampsia	24980667	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MicroRNA-210 contributes to preeclampsia by downregulating potassium channel modulatory factor 1.
target gene	hsa-mir-210	Preeclampsia	21801864	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-210 Targets Iron-Sulfur Cluster Scaffold Homologue
target gene	hsa-mir-210	Preeclampsia	22203747	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Hydroxysteroid (17-beta) Dehydrogenase 1 Is Dysregulated by Mir-210 and Mir-518c That Are Aberrantly Expressed in Preeclamptic Placentas.
target gene	hsa-mir-26a	Preeclampsia	27375191	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	These miRNAs have previously been linked to PE and are predicted to regulate members of the TGF-尾 pathway.
target gene	hsa-mir-30a	Preeclampsia	26555189	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MiR-30a attenuates immunosuppressive functions of IL-1β-elicited mesenchymal stem cells via targeting TAB3
target gene	hsa-mir-346	Preeclampsia	27619846	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9.
target gene	hsa-mir-34a	Preeclampsia	29022890	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Elevated microRNA-34a contributes to trophoblast cell apoptosis in preeclampsia by targeting BCL-2.
target gene	hsa-mir-495	Preeclampsia	28628915	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MiR-495 Promotes Senescence of Mesenchymal Stem Cells by Targeting Bmi-1.
target gene	hsa-mir-518c	Preeclampsia	22203747	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Hydroxysteroid (17-beta) Dehydrogenase 1 Is Dysregulated by Mir-210 and Mir-518c That Are Aberrantly Expressed in Preeclamptic Placentas.
target gene	hsa-mir-582	Preeclampsia	27619846	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9.
target gene	hsa-mir-18a	Pregnancy Complications [unspecific]	25955393				D011248			The results of the present study suggested that miR-18a expression suppression led to a decrease in JEG-3 cell invasion and an increase in JEG-3 cell apoptosis, by inducing ESRα expression. The present study provides evidence for the involvement of miR-18a in the pathogenesis of pre-eclamptic pregnancies.
target gene	hsa-mir-144	Premature Ovarian Failure	24188450	endocrine system disease	DOID:5426	E28.3	D016649	PS311360		miR-29a and miR-144 were down-regulated in POF tissues, which may target expression of PLA2G4A that is involved in prostaglandin biosynthesis
target gene	hsa-mir-29a	Premature Ovarian Failure	24188450	endocrine system disease	DOID:5426	E28.3	D016649	PS311360		miR-29a and miR-144 were down-regulated in POF tissues, which may target expression of PLA2G4A that is involved in prostaglandin biosynthesis
target gene	hsa-let-7b	Prostate Neoplasms	26540468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.
target gene	hsa-let-7c	Prostate Neoplasms	22128178	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.
target gene	hsa-mir-101	Prostate Neoplasms	22505648	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The repressing activity of EZH2 on RKIP expression was dependent on histone deacetylase promoter recruitment and was negatively regulated upstream by miR-101.
target gene	hsa-mir-101	Prostate Neoplasms	23739676	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In conclusion, EZH2 is essential for PCSC growth, partly through a negative regulation by miR-101 and positively regulating cyclin E2.
target gene	hsa-mir-106a	Prostate Neoplasms	28889725	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Oncogene miR-106a promotes proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro.
target gene	hsa-mir-106b	Prostate Neoplasms	26124181	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression.
target gene	hsa-mir-1-1	Prostate Neoplasms	22068816	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.
target gene	hsa-mir-1-1	Prostate Neoplasms	22370643	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
target gene	hsa-mir-1-2	Prostate Neoplasms	22068816	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.
target gene	hsa-mir-1-2	Prostate Neoplasms	22370643	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
target gene	hsa-mir-122	Prostate Neoplasms	26540468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.
target gene	hsa-mir-122	Prostate Neoplasms	22914437	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR122 regulation of Ad6 significantly improves its safety profile after systemic administration, which allows increasing therapeutic doses leading to improved anticancer efficacy of systemic treatment for castration-resistant prostate cancer.
target gene	hsa-mir-124	Prostate Neoplasms	24969691	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-124 regulates TGF-α-induced epithelial-mesenchymal transition in human prostate cancer cells.
target gene	hsa-mir-124	Prostate Neoplasms	26540468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.
target gene	hsa-mir-124	Prostate Neoplasms	25969668	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpression of miR-124 by transient transfection of  mimics led to a significant decrease in talin 1 levels.
target gene	hsa-mir-124-1	Prostate Neoplasms	23069658	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells
target gene	hsa-mir-124-2	Prostate Neoplasms	23069658	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells
target gene	hsa-mir-124-3	Prostate Neoplasms	23069658	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells
target gene	hsa-mir-1247	Prostate Neoplasms	25731699	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2.
target gene	hsa-mir-125b	Prostate Neoplasms	26540468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.
target gene	hsa-mir-125b-1	Prostate Neoplasms	21308711	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-125b suppresses MUC1 translation in LNCaP cells and that an anti-sense miR-125b upregulates expression of MUC1 protein. In addition, stable expression of miR-125b in DU145 cells resulted in decreases in MUC1 levels.
target gene	hsa-mir-125b-2	Prostate Neoplasms	21308711	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-125b suppresses MUC1 translation in LNCaP cells and that an anti-sense miR-125b upregulates expression of MUC1 protein. In addition, stable expression of miR-125b in DU145 cells resulted in decreases in MUC1 levels.
target gene	hsa-mir-128	Prostate Neoplasms	24859886	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of SNAIL inhibits cellular growth and metabolism through the miR-128-mediated RPS6KB1/HIF-1α/PKM2 signaling pathway in prostate cancer cells.
target gene	hsa-mir-128	Prostate Neoplasms	24903149	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells.
target gene	hsa-mir-1301	Prostate Neoplasms	28483517	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells.
target gene	hsa-mir-133a-1	Prostate Neoplasms	22068816	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.
target gene	hsa-mir-133a-1	Prostate Neoplasms	22407299	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor.
target gene	hsa-mir-133a-2	Prostate Neoplasms	22068816	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.
target gene	hsa-mir-133a-2	Prostate Neoplasms	22407299	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor.
target gene	hsa-mir-133b	Prostate Neoplasms	22407299	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor.
target gene	hsa-mir-133b	Prostate Neoplasms	23451058	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-133b is directly up-regulated by AR, and represses CDC2L5, PTPRK, RB1CC1, and CPNE3, respectively. Moreover, we found miR-133b is essential to PCa cell survival. 
target gene	hsa-mir-135a	Prostate Neoplasms	25065599	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2.
target gene	hsa-mir-135b	Prostate Neoplasms	25907805	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
target gene	hsa-mir-135b	Prostate Neoplasms	21343391	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	3'UTR-binding assays validated 13 miRNAs that are able to regulate this long AR 3'UTR (miR-135b, miR-185, miR-297, miR-299-3p, miR-34a, miR-34c, miR-371-3p, miR-421, miR-449a, miR-449b, miR-634, miR-654-5p, and miR-9).
target gene	hsa-mir-135b	Prostate Neoplasms	22473899	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The results show that MUC1-C activates a posttranscriptional mechanism involving miR-135b-mediated downregulation of AR mRNA levels.
target gene	hsa-mir-138	Prostate Neoplasms	26474967	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-138 specifically targeted K2 and inhibited its expression, thereby regulating a miR-138/K2/尾1-integrin signaling axis in mCRPC that is critical for the modulation of sensitivity to chemotherapeutics.
target gene	hsa-mir-141	Prostate Neoplasms	26062412	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-141-3p regulates the expression of androgen receptor by targeting its 3'UTR in prostate cancer LNCaP cells
target gene	hsa-mir-141	Prostate Neoplasms	22314666	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein.
target gene	hsa-mir-143	Prostate Neoplasms	24284362	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.
target gene	hsa-mir-143	Prostate Neoplasms	20353999	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data indicate that miR-143 and miR-145 are involved in the regulation of MYO6 expression and possibly in the development of prostate cancer
target gene	hsa-mir-143	Prostate Neoplasms	21197560	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS
target gene	hsa-mir-143	Prostate Neoplasms	23383988	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression
target gene	hsa-mir-143	Prostate Neoplasms	23732700	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer.
target gene	hsa-mir-145	Prostate Neoplasms	24284362	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.
target gene	hsa-mir-145	Prostate Neoplasms	24846918	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Effects of miR-145 on the migration and invasion of prostate cancer PC3 cells by targeting DAB2
target gene	hsa-mir-145	Prostate Neoplasms	25645686	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells.
target gene	hsa-mir-145	Prostate Neoplasms	26540468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.
target gene	hsa-mir-145	Prostate Neoplasms	25296715	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.
target gene	hsa-mir-145	Prostate Neoplasms	23480797	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer
target gene	hsa-mir-145	Prostate Neoplasms	19544444	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	regulates PDGF-D, which mediate epithelial-mesenchymal transition, adhesion, and invasion, which was associated with the downregulation of ZEB1, ZEB2,and Snail2 expression;
target gene	hsa-mir-145	Prostate Neoplasms	20332243	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA145 targets BNIP3 and suppresses prostate cancer progression.
target gene	hsa-mir-145	Prostate Neoplasms	20353999	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data indicate that miR-143 and miR-145 are involved in the regulation of MYO6 expression and possibly in the development of prostate cancer
target gene	hsa-mir-145	Prostate Neoplasms	21258769	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1.
target gene	hsa-mir-145	Prostate Neoplasms	23355420	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145
target gene	hsa-mir-146a	Prostate Neoplasms	22161865	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer.
target gene	hsa-mir-146a	Prostate Neoplasms	18174313	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Given that ROCK1 is one of the key kinases for the activation of hyaluronan (HA)-mediated HRPC transformation in vivo and in PC3 cells, mir-146a may function as a tumor-suppressor gene in modulating HA/ROCK1-mediated tumorigenecity in androgen-dependent prostate cancer.
target gene	hsa-mir-148a	Prostate Neoplasms	20406806	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-148a:MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression
target gene	hsa-mir-148a	Prostate Neoplasms	20820187	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression.
target gene	hsa-mir-149	Prostate Neoplasms	26540468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.
target gene	hsa-mir-150	Prostate Neoplasms	26636522	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Increased miR-150 expression might participate in the development and progression of human prostate CSC by suppressing p27. This supported our previous study which found miR-150 was positively correlated with prostate tumor recurrence or metastasis.
target gene	hsa-mir-150	Prostate Neoplasms	29441850	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-150 promotes the cell invasion of prostate cancer cells by directly regulating the expression of p53
target gene	hsa-mir-152	Prostate Neoplasms	23460133	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines
target gene	hsa-mir-153-1	Prostate Neoplasms	23060044	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer
target gene	hsa-mir-153-2	Prostate Neoplasms	23060044	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer
target gene	hsa-mir-154	Prostate Neoplasms	23428540	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-154 inhibits prostate cancer cell proliferation by targeting CCND2
target gene	hsa-mir-155	Prostate Neoplasms	25339368	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7.
target gene	hsa-mir-155	Prostate Neoplasms	28599307	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
target gene	hsa-mir-15a	Prostate Neoplasms	25761682	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1.
target gene	hsa-mir-15a	Prostate Neoplasms	18931683	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.
target gene	hsa-mir-15b	Prostate Neoplasms	29363862	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer
target gene	hsa-mir-16-1	Prostate Neoplasms	18931683	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.
target gene	hsa-mir-16-2	Prostate Neoplasms	18931683	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-16: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
target gene	hsa-mir-17	Prostate Neoplasms	23095762	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells
target gene	hsa-mir-182	Prostate Neoplasms	23874837	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1).
target gene	hsa-mir-182	Prostate Neoplasms	23329838	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-182 and microRNA-200a control G-protein subunit alpha-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells.
target gene	hsa-mir-182	Prostate Neoplasms	23383207	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-182-5p Promotes Cell Invasion and Proliferation by Down Regulating FOXF2, RECK and MTSS1 Genes in Human Prostate Cancer
target gene	hsa-mir-183	Prostate Neoplasms	23538390	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer
target gene	hsa-mir-185	Prostate Neoplasms	23417242	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor
target gene	hsa-mir-187	Prostate Neoplasms	25969992	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer.
target gene	hsa-mir-188	Prostate Neoplasms	25714029	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression.
target gene	hsa-mir-193b	Prostate Neoplasms	26129688	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.
target gene	hsa-mir-193b	Prostate Neoplasms	22797075	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
target gene	hsa-mir-195	Prostate Neoplasms	29665645	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer
target gene	hsa-mir-197	Prostate Neoplasms	26540468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.
target gene	hsa-mir-198	Prostate Neoplasms	23069480	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Livin expression may be regulated by miR-198 in human prostate cancer cell lines
target gene	hsa-mir-19a	Prostate Neoplasms	25936765	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-19a regulates proliferation and apoptosis of castration-resistant prostate cancer cells by targeting BTG1.
target gene	hsa-mir-19a	Prostate Neoplasms	23451058	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-19a is directly up-regulated by AR, and represses SUZ12, RAB13, SC4MOL, PSAP and ABCA1, respectively. 
target gene	hsa-mir-200a	Prostate Neoplasms	21224847	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells.
target gene	hsa-mir-200a	Prostate Neoplasms	22370643	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
target gene	hsa-mir-200a	Prostate Neoplasms	23329838	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-182 and microRNA-200a control G-protein subunit alpha-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells.
target gene	hsa-mir-200b	Prostate Neoplasms	24317363	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.
target gene	hsa-mir-200b	Prostate Neoplasms	21224847	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells.
target gene	hsa-mir-200b	Prostate Neoplasms	22370643	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
target gene	hsa-mir-200c	Prostate Neoplasms	25017995	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development.
target gene	hsa-mir-200c	Prostate Neoplasms	21224847	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells.
target gene	hsa-mir-200c	Prostate Neoplasms	22370643	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. The authors demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Th
target gene	hsa-mir-203a	Prostate Neoplasms	25636908	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	a crucial role for miR-203 in inhibiting metastasis of PCa through the suppression of Rap1A expression.
target gene	hsa-mir-204	Prostate Neoplasms	25797256	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells.
target gene	hsa-mir-204	Prostate Neoplasms	21446014	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	PDEF expression is regulated via a functional microRNA-204 (miR-204) binding site within the 3'UTR. Furthermore, we demonstrate the biologic significance of miR-204 expression and that miR-204 is over-expressed in human prostate cancer specimens.
target gene	hsa-mir-204	Prostate Neoplasms	28861151	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1).
target gene	hsa-mir-205	Prostate Neoplasms	26211479	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Editorial Comment to MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer.
target gene	hsa-mir-205	Prostate Neoplasms	22555458	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-205 regulates basement membrane deposition in human prostate.
target gene	hsa-mir-205	Prostate Neoplasms	22949650	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer.
target gene	hsa-mir-205	Prostate Neoplasms	23571738	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients
target gene	hsa-mir-20a	Prostate Neoplasms	24464651	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-20a promotes prostate cancer invasion and migration through targeting ABL2.
target gene	hsa-mir-20a	Prostate Neoplasms	22785209	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	CX43 expression is suppressed by miR-20a in the progression of human prostate cancer.
target gene	hsa-mir-20b	Prostate Neoplasms	29163708	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-20b promotes cellular proliferation and migration by directly regulating phosphatase and tensin homolog in prostate cancer
target gene	hsa-mir-21	Prostate Neoplasms	24037531	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer.
target gene	hsa-mir-21	Prostate Neoplasms	24106176	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The exosome-encased SNAs are secreted into the extracellular environment from which they can be isolated and selectively re-introduced into the cell type from which they were derived. In the context of anti-miR21 experiments, the exosome-encased SNAs knockdown miR-21 target by approximately 50%. Similar knockdown of miR-21 by free SNAs requires a ≈3000-fold higher concentration.
target gene	hsa-mir-21	Prostate Neoplasms	25890570	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer.
target gene	hsa-mir-21	Prostate Neoplasms	26252635	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	IL-6 Inhibits the Targeted Modulation of PDCD4 by miR-21 in Prostate Cancer.
target gene	hsa-mir-21	Prostate Neoplasms	19302977	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-21: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells
target gene	hsa-mir-21	Prostate Neoplasms	21317927	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4
target gene	hsa-mir-21	Prostate Neoplasms	21826097	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Spry1 is a target for miR-21-mediated gene silencing.
target gene	hsa-mir-21	Prostate Neoplasms	22642976	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer.
target gene	hsa-mir-218	Prostate Neoplasms	24815849	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer.
target gene	hsa-mir-218	Prostate Neoplasms	26540468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Finally, we hypothesized that miR-218, miR-145, miR-197, miR-149, miR-122, and let-7b may contribute to the development of CRPC through the influence of Ras, Rho proteins,and the SCF complex. Further investigation is needed to verify the functions of the identified novel pathways in CRPC development.
target gene	hsa-mir-218	Prostate Neoplasms	27278788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	ectopic expression of these miRNAs suppressed PCa cell aggressiveness
target gene	hsa-mir-221	Prostate Neoplasms	24892674	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1.
target gene	hsa-mir-221	Prostate Neoplasms	25761682	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1.
target gene	hsa-mir-221	Prostate Neoplasms	26325107	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of the tumour-suppressive miR-221/222 cluster enhanced migration and invasion in PCa cells. Our data describing targets regulated by the tumour-suppressive miR-221/222 cluster provide insights into the mechanisms of PCa and CRPC progression.
target gene	hsa-mir-221	Prostate Neoplasms	23770851	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	mir-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.
target gene	hsa-mir-221	Prostate Neoplasms	17569667	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.
target gene	hsa-mir-221	Prostate Neoplasms	21487968	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2.
target gene	hsa-mir-221	Prostate Neoplasms	21071579	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	This study demonstrates for the first time that prostate cancer cells have decreased level of ARHI which could be caused by direct targeting of 3'UTR of ARHI by miR221/222.
target gene	hsa-mir-222	Prostate Neoplasms	26325107	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Loss of the tumour-suppressive miR-221/222 cluster enhanced migration and invasion in PCa cells. Our data describing targets regulated by the tumour-suppressive miR-221/222 cluster provide insights into the mechanisms of PCa and CRPC progression.
target gene	hsa-mir-222	Prostate Neoplasms	24892674	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1.
target gene	hsa-mir-222	Prostate Neoplasms	17569667	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.
target gene	hsa-mir-222	Prostate Neoplasms	22854542	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer.
target gene	hsa-mir-223	Prostate Neoplasms	26509963	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer.
target gene	hsa-mir-224	Prostate Neoplasms	24382668	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.
target gene	hsa-mir-224	Prostate Neoplasms	24768995	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer.
target gene	hsa-mir-224	Prostate Neoplasms	25394900	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-224 and its target gene CAMKK2 may synergistically contribute to the malignant progression of PCa. Combined detection of miR-224 and CAMKK2 expressions represents an efficient predictor of patient prognosis and may be a novel marker which can provide additional prognostic information in PCa.
target gene	hsa-mir-224	Prostate Neoplasms	25532941	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the dysregulated miR-224/APLN axis may be associated with tumorigenesis and aggressive progression of PCa. More importantly, miR-224 down-regulation and APLN up-regulation may synergistically predict biochemical recurrence-free survival in patients with PCa.
target gene	hsa-mir-23a	Prostate Neoplasms	25714010	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation of microRNA-23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway.
target gene	hsa-mir-23b	Prostate Neoplasms	22710126	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer.
target gene	hsa-mir-26a	Prostate Neoplasms	24972966	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-26a inhibits prostate cancer progression by repression of Wnt5a.
target gene	hsa-mir-26a	Prostate Neoplasms	26063484	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer.
target gene	hsa-mir-26a	Prostate Neoplasms	24098737	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We here report that a combination of four microRNAs (miR-19b, miR-23b, miR-26a and miR-92a) promotes prostate cell proliferation by regulating PTEN and its downstream signals in vitro.
target gene	hsa-mir-26a	Prostate Neoplasms	27278788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs
target gene	hsa-mir-26a	Prostate Neoplasms	27900011	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2.
target gene	hsa-mir-26b	Prostate Neoplasms	26063484	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer.
target gene	hsa-mir-26b	Prostate Neoplasms	26920049	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-26b inhibits autophagy by targeting ULK2 in prostate cancer cells.
target gene	hsa-mir-26b	Prostate Neoplasms	27278788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs
target gene	hsa-mir-27a	Prostate Neoplasms	19584056	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	decreased in prostate cancer; Regulates ERBB-2 Expression; blocked downstream phosphatidylinositol 3-kinase/AKT signaling, reducing activity of an androgen-stimulated prostate-specific antigen promoter and blocking prostate-specific antigen expression
target gene	hsa-mir-27a	Prostate Neoplasms	22505583	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer.
target gene	hsa-mir-27a	Prostate Neoplasms	27594411	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
target gene	hsa-mir-27a	Prostate Neoplasms	23451058	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-27a is directly up-regulated by AR, and represses ABCA1 and PDS5B. 
target gene	hsa-mir-29	Prostate Neoplasms	24820027	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer.
target gene	hsa-mir-296	Prostate Neoplasms	24915000	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1.
target gene	hsa-mir-296	Prostate Neoplasms	21138859	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of HMGA1 expression by microRNA296 affects prostate cancer growth and invasion
target gene	hsa-mir-29a	Prostate Neoplasms	24100420	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the tumor suppressor microRNA, miR-29a, is one of the regulators of  TRAF4 expression in metastatic prostate cancer.
target gene	hsa-mir-29a	Prostate Neoplasms	27278788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs
target gene	hsa-mir-29b	Prostate Neoplasms	27278788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs
target gene	hsa-mir-29c	Prostate Neoplasms	27278788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the lysyl oxidase-like 2 (LOXL2) gene was directly controlled by these tumor-suppressive miRNAs
target gene	hsa-mir-301a	Prostate Neoplasms	29331421	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer.
target gene	hsa-mir-30d	Prostate Neoplasms	25761682	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1.
target gene	hsa-mir-31	Prostate Neoplasms	23984644	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Overexpression of hsa-mir-31 can be a significant marker to distinguish cancer tissues from benign tissues. The targets such as ITGA5 and RDX regulated by hsa-mir-31 are candidate genes of prostate cancer, which provide new treatment strategies for its gene therapy.
target gene	hsa-mir-31	Prostate Neoplasms	22854542	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer.
target gene	hsa-mir-32	Prostate Neoplasms	22266859	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
target gene	hsa-mir-320a	Prostate Neoplasms	23188675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway
target gene	hsa-mir-330	Prostate Neoplasms	23670210	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells.
target gene	hsa-mir-331	Prostate Neoplasms	19584056	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-311-3p regulate ERBB-2 expression and androgen receptor signaling in prostate cancer
target gene	hsa-mir-331	Prostate Neoplasms	22908221	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.
target gene	hsa-mir-34a	Prostate Neoplasms	26499184	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Collectively, miR-34a enhances chemosensitivity by directly downregulating ATG4B-induced autophagy through AMPK/mTOR pathway in PCa.
target gene	hsa-mir-34a	Prostate Neoplasms	21240262	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
target gene	hsa-mir-34b	Prostate Neoplasms	26107383	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression.
target gene	hsa-mir-34c	Prostate Neoplasms	26808578	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Functional analysis revealed that miR-34c and miR-297 overexpression down-regulated AR expression and inhibited the expression of downstream AR targets
target gene	hsa-mir-3607	Prostate Neoplasms	24817628	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer.
target gene	hsa-mir-361	Prostate Neoplasms	24491557	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6).
target gene	hsa-mir-375	Prostate Neoplasms	26124181	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression.
target gene	hsa-mir-375	Prostate Neoplasms	21593139	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNA-375 Downregulated Sec23A protein in prostate carcinoma.
target gene	hsa-mir-375	Prostate Neoplasms	27270433	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer.
target gene	hsa-mir-429	Prostate Neoplasms	25351256	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation of microRNA-429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells.
target gene	hsa-mir-449a	Prostate Neoplasms	19252524	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.
target gene	hsa-mir-483	Prostate Neoplasms	26020509	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Based on our findings, we suggest that blood-based miRNA expression profiling can be used in the diagnosis and maybe even prognosis of the disease.In the future, miRNA profiling could possibly be used in targeted screening,together with Prostate Specific Antigene (PSA) testing, to identify men with an elevated PrCa risk.
target gene	hsa-mir-488	Prostate Neoplasms	21710544	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR 488* inhibits androgen receptor expression in prostate carcinoma cells.
target gene	hsa-mir-493	Prostate Neoplasms	29423080	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels.
target gene	hsa-mir-495	Prostate Neoplasms	27031291	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling.
target gene	hsa-mir-503	Prostate Neoplasms	26231797	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-503 suppresses tumor cell proliferation and metastasis by directly targeting RNF31 in prostate cancer.
target gene	hsa-mir-616	Prostate Neoplasms	21224345	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA-616 Induces Androgen-Independent Growth of Prostate Cancer Cells by Suppressing Expression of Tissue Factor Pathway Inhibitor TFPI-2.
target gene	hsa-mir-631	Prostate Neoplasms	26620225	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In all, our study demonstrates that miR-631 decreases PCa cell migration and invasion by dampening ZAP70 expression.
target gene	hsa-mir-642a	Prostate Neoplasms	22908221	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.
target gene	hsa-mir-642b	Prostate Neoplasms	22908221	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.
target gene	hsa-mir-652	Prostate Neoplasms	29721191	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells.
target gene	hsa-mir-675	Prostate Neoplasms	24988946	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI.
target gene	hsa-mir-7	Prostate Neoplasms	26172296	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21 pathway.
target gene	hsa-mir-93	Prostate Neoplasms	26124181	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression.
target gene	hsa-mir-940	Prostate Neoplasms	25406943	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	implicate miR-940, a regulator of MIEN1, as a promising novel diagnostic and prognostic tool for prostate cancer.
target gene	hsa-mir-95	Prostate Neoplasms	24145350	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1.
target gene	hsa-mir-96	Prostate Neoplasms	23951320	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1.
target gene	hsa-mir-96	Prostate Neoplasms	24260486	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1.
target gene	hsa-mir-98	Prostate Neoplasms	23188821	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Identification of microRNA-98 as a Therapeutic Target Inhibiting Prostate Cancer Growth and a Biomarker Induced by Vitamin D
target gene	hsa-let-7a	Psoriasis	28494466	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Let-7a Inhibits T-Cell Proliferation and IFN-γ Secretion by Down-Regulating STAT3 Expression in Patients with Psoriasis.
target gene	hsa-mir-125b-1	Psoriasis	21412257	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2.
target gene	hsa-mir-125b-2	Psoriasis	21412257	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2.
target gene	hsa-mir-130a	Psoriasis	28085489	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	microRNA-130a Promotes Human Keratinocyte Viability and Migration and Inhibits Apoptosis Through Direct Regulation of STK40-Mediated NF-κB Pathway and Indirect Regulation of SOX9-Meditated JNK/MAPK Pathway: A Potential Role in Psoriasis.
target gene	hsa-mir-138	Psoriasis	26045321	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA-138 regulates the balance of Th1/Th2 via targeting RUNX3 in psoriasis.
target gene	hsa-mir-138	Psoriasis	27936398	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA138 regulates keratin 17 protein expression to affect HaCaT cell proliferation and apoptosis by targeting hTERT in psoriasis vulgaris.
target gene	hsa-mir-146a	Psoriasis	23018031	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Inability of miR-146a inhibiting target gene IRAK1 may contribute to the persistent inflammation in lesions of psoriasis.
target gene	hsa-mir-146b	Psoriasis	29279330	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2
target gene	hsa-mir-150	Psoriasis	28399173	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1α and VEGFA: Implications for psoriasis treatment.
target gene	hsa-mir-181b	Psoriasis	27641447	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA-181b negatively regulates the proliferation of human epidermal keratinocytes in psoriasis through targeting TLR4.
target gene	hsa-mir-194	Psoriasis	28040329	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA-194 regulates keratinocyte proliferation and differentiation by targeting Grainyhead-like 2 in psoriasis.
target gene	hsa-mir-203	Psoriasis	22917968	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Our findings suggest that miR-203 serves to fine-tune cytokine signaling and may dampen skin immune responses by repressing key pro-inflammatory cytokines.
target gene	hsa-mir-210	Psoriasis	24316592	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris.
target gene	hsa-mir-26b	Psoriasis	27015452	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis Skin Inflammation-Induced microRNA-26b Targets NCEH1 in Underlying Subcutaneous Adipose Tissue.
target gene	hsa-mir-31	Psoriasis	23233723	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA-31 Is Overexpressed in Psoriasis and Modulates Inflammatory Cytokine and Chemokine Production in Keratinocytes via Targeting Serine/Threonine Kinase 40
target gene	hsa-mir-99a	Psoriasis	21687694	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	differentially expressed.  miR-99a is one of the regulators of the IGF-1R signaling pathway in keratinocytes. Activation of IGF1 signaling results in elevation of miR-99a which represses the expression of IGF-1R.
target gene	hsa-mir-146a	Psoriatic Arthritis	20500689	syndrome	DOID:9008	L40.5	D015535	607507		miR-146a:The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility
target gene	hsa-mir-15a	Psoriatic Arthritis	19714650	syndrome	DOID:9008	L40.5	D015535	607507		suppresses apoptosis through inhibition of Bcl-2
target gene	hsa-mir-641	Psychotic Disorders	24391914			F24	D011618			Association of impulsivity and polymorphic microRNA-641 target sites in the SNAP-25 gene.
target gene	hsa-mir-200a	Pterygium	26995143	nervous system disease	DOID:0002116	H11.0	D011625	178200		Up-regulated miR-200a levels were positively correlated with and p53 protein expression
target gene	hsa-let-7g	Pulmonary Hypertension	27889560	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	MicroRNA let-7g inhibited hypoxia-induced proliferation of PASMCs via G0/G1 cell cycle arrest by targeting c-myc.
target gene	hsa-mir-124	Pulmonary Hypertension	28972001	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis.
target gene	hsa-mir-130a	Pulmonary Hypertension	28514291	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Role of microRNA-130a in the pathogeneses of obstructive sleep apnea hypopnea syndrome-associated pulmonary hypertension by targeting the GAX gene.
target gene	hsa-mir-138	Pulmonary Hypertension	27648837	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype.
target gene	hsa-mir-17	Pulmonary Hypertension	27640178	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Upregulated miR-17 Regulates Hypoxia-Mediated Human Pulmonary Artery Smooth Muscle Cell Proliferation and Apoptosis by Targeting Mitofusin 2.
target gene	hsa-mir-204	Pulmonary Hypertension	26224795	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	BRD4 expression in PAH is microRNA-204 dependent
target gene	hsa-mir-204	Pulmonary Hypertension	27149112	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miR-204 diminution promotes RUNX2 up-regulation
target gene	hsa-mir-21	Pulmonary Hypertension	26208095	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	these results demonstrate that PPARγ ligands regulate proliferative responses to hypoxia by preventing hypoxic increases in miR-21 and reductions in PTEN. These findings further clarify molecular mechanisms that support targeting PPARγ to attenuate pathogenic derangements in PH.
target gene	hsa-mir-25	Pulmonary Hypertension	27648837	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype.
target gene	hsa-mir-29b	Pulmonary Hypertension	29662889	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Effect of miR-29b on the Proliferation and Apoptosis of Pulmonary Artery Smooth Muscle Cells by Targeting Mcl-1 and CCND2
target gene	hsa-mir-637	Pulmonary Hypertension	27794186	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Downregulation of microRNA-637 Increases Risk of Hypoxia-Induced Pulmonary Hypertension by Modulating Expression of Cyclin Dependent Kinase 6 (CDK6) in Pulmonary Smooth Muscle Cells.
target gene	hsa-mir-21	Rectal Neoplasms	28927090	disease of cellular proliferation	DOID:1984		D012004			Downregulation of PDCD4 by miR-21 suppresses tumor transformation and proliferation in a nude mouse renal cancer model.
target gene	hsa-mir-21	Rectal Neoplasms	29085468	disease of cellular proliferation	DOID:1984		D012004			miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype.
target gene	hsa-mir-21	Rectal Neoplasms	29131259	disease of cellular proliferation	DOID:1984		D012004			MicroRNA-21 functions as an oncogene and promotes cell proliferation and invasion via TIMP3 in renal cancer.
target gene	hsa-mir-452	Rectal Neoplasms	24440748	disease of cellular proliferation	DOID:1984		D012004			Firstly, we found that miR-452 directly regulates the expression of thyroid hormone receptor TR尾1 in renal cancer cells. In turn, the expression of miR-224/452/GABRE cluster and other microRNAs targeting TR尾1 was influenced by T3 treatment and/or TR silencing.
target gene	hsa-mir-16	Recurrent Spontaneous Abortion	27748453			O03	D000022			MicroRNA-16 inhibits feto-maternal angiogenesis and causes recurrent spontaneous abortion by targeting vascular endothelial growth factor.
target gene	hsa-mir-1908	Renal Fibrosis	26648305	urinary system disease	DOID:0050855	N26.9			HP:0030760	miR-1908 could inhibit renal fibrosis through targeting TGF-β1.
target gene	hsa-mir-30e	Renal Fibrosis	23515048	urinary system disease	DOID:0050855	N26.9			HP:0030760	A microRNA-30e/mitochondrial uncoupling protein 2 axis mediates TGF-β1-induced tubular epithelial cell extracellular matrix production and kidney fibrosis.
target gene	hsa-mir-125a	Retinal Degeneration	27527066	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	Possibly more than 30 miRNAs interact with Rac1 in retina, targeting both UTRs and coding regions.
target gene	hsa-mir-142	Retinal Degeneration	27527066	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	Possibly more than 30 miRNAs interact with Rac1 in retina, targeting both UTRs and coding regions.
target gene	hsa-mir-146	Retinal Degeneration	24985472	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	We uncovered a novel negative feedback regulatory mechanism on thrombin-induced GPCR-mediated NF-κB activation by miR-146. In combination with the negative feedback regulation of miR-146 on the IL-1R/toll-like receptor (TLR)-mediated NF-κB activation in RECs that we reported previously, our results underscore a pivotal, negative regulatory role of miR-146 on multiple NF-κB activation pathways and related inflammatory processes in DR.
target gene	hsa-mir-200b	Retinal Degeneration	26617758	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	MiR-200b can regulate RECs growth and proliferation by changing VEGF and TGFβ1 expression to delay DR.
target gene	hsa-mir-410	Retinal Degeneration	25351180	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-410 Inhibition Induces RPE Differentiation of Amniotic Epithelial Stem Cells via Overexpression of OTX2 and RPE65.
target gene	hsa-mir-96	Retinal Degeneration	27527066	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	Validation of miRNA-target mRNA  interactions for miR-1, miR-96/182 and miR-96 targeting Ctbp2, Rac1 and Slc6a9, respectively, was demonstrated in vitro.
target gene	hsa-let-7b	Retinoblastoma	26730174	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1.
target gene	hsa-let-7b	Retinoblastoma	18026111	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We experimentally verified our predictions by investigating the result of let-7b downregulation in retinoblastoma using quantitative reverse transcriptase (RT)-PCR and microarray profiling: some of our verified let-7b targets include CDC25A and BCL7A.
target gene	hsa-mir-101	Retinoblastoma	24807198	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2.
target gene	hsa-mir-106b	Retinoblastoma	29085029	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	HBeAg-induced miR-106b promotes cell growth by targeting the retinoblastoma gene.
target gene	hsa-mir-125b	Retinoblastoma	26730174	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1.
target gene	hsa-mir-145	Retinoblastoma	28706438	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Genistein suppresses retinoblastoma cell viability and growth and induces apoptosis by upregulating miR-145 and inhibiting its target ABCE1.
target gene	hsa-mir-181b	Retinoblastoma	25872572	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Hypoxia-induced miR-181b enhances angiogenesis of retinoblastoma cells by targeting PDCD10 and GATA6.
target gene	hsa-mir-183	Retinoblastoma	24289859	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	MicroRNA-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6.
target gene	hsa-mir-18a	Retinoblastoma	26730174	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1.
target gene	hsa-mir-20a	Retinoblastoma	26730174	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1.
target gene	hsa-mir-24-1	Retinoblastoma	22336108	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development.
target gene	hsa-mir-24-2	Retinoblastoma	22336108	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development.
target gene	hsa-mir-25	Retinoblastoma	26730174	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1.
target gene	hsa-mir-26a	Retinoblastoma	27421000	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Beclin 1 is the target of miR-26a in human RB cell lines Y79 and WERi-RB-1, and miR-26a inhibits the expression of Beclin 1 by reducing its mRNA and protein levels.
target gene	hsa-mir-29a	Retinoblastoma	29251322	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-29a inhibits human retinoblastoma progression by targeting STAT3
target gene	hsa-mir-373	Retinoblastoma	26730174	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Several critical miRNAs were identified in RB progression.Hsa-miR-373 might regulate RB invasion and metastasis, hsa-miR-181a might involve in the CDKN1B-mediated cell cycle pathway, and hsa-miR-125b and hsa-let-7b might serve as tumor suppressors by coregulating CDK6, CDC25A, and LIN28A. The miRNAs hsa-miR-25, hsa-miR-18a, and hsa-miR-20a might exert their function by coregulating BCL2L1.
target gene	hsa-mir-613	Retinoblastoma	28351331	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5.
target gene	hsa-mir-193a	Rhabdoid Cancer	24287458	disease of cellular proliferation	DOID:3672		D018335			Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.
target gene	hsa-mir-1	Rhabdomyosarcoma	28981396	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-133b also knock downed PAX3-FOXO1
target gene	hsa-mir-106a	Rhabdomyosarcoma	22330340	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
target gene	hsa-mir-1-1	Rhabdomyosarcoma	19710019	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	inhibits rhabdomyosarcoma through downregulating c-Met
target gene	hsa-mir-1-1	Rhabdomyosarcoma	22330340	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
target gene	hsa-mir-1-2	Rhabdomyosarcoma	19710019	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	inhibits rhabdomyosarcoma through downregulating c-Met
target gene	hsa-mir-1-2	Rhabdomyosarcoma	22330340	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
target gene	hsa-mir-206	Rhabdomyosarcoma	19710019	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	inhibits rhabdomyosarcoma through downregulating c-Met
target gene	hsa-mir-29a	Rhabdomyosarcoma	22330340	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
target gene	hsa-mir-29b-1	Rhabdomyosarcoma	22330340	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
target gene	hsa-mir-29b-2	Rhabdomyosarcoma	22330340	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
target gene	hsa-mir-29c	Rhabdomyosarcoma	22330340	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
target gene	hsa-mir-411	Rhabdomyosarcoma	26291313	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	These results establish an autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK in RMS, which governs the switch between proliferation and differentiation.
target gene	hsa-mir-205	Rheumatic Heart Diseases	29548280	cardiovascular system disease	DOID:0050827	I09.9	D012214			Hsa miR-205-3p and hsa-miR-3909 were predicted to target the 3'UTR of IL-1β and IL1R1 respectively
target gene	hsa-mir-3909	Rheumatic Heart Diseases	29548280	cardiovascular system disease	DOID:0050827	I09.9	D012214			Hsa miR-205-3p and hsa-miR-3909 were predicted to target the 3'UTR of IL-1β and IL1R1 respectively
target gene	hsa-mir-101	Rheumatic Heart Diseases	26022377	cardiovascular system disease	DOID:0050827	I09.9	D012214			The present study confirmed that miR-101 targets TLR2 3'UTR and represses TLR2 expression. This work also found an association between down-regulated miR-101 and rheumatic heart disease.
target gene	hsa-mir-126	Rheumatoid Arthritis	27729613	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway.
target gene	hsa-mir-146a	Rheumatoid Arthritis	24562503	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Our results suggest that in RA miR-146a facilitates a pro-inflammatory phenotype of Tregs via increased STAT1 activation, and contributes thereby to RA pathogenesis.
target gene	hsa-mir-155	Rheumatoid Arthritis	24351865	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Rheumatoid arthritis-associated microRNA-155 targets SOCS1 and upregulates TNF-α and IL-1β in PBMCs.
target gene	hsa-mir-155	Rheumatoid Arthritis	24562503	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Our results suggest that in RA miR-146a facilitates a pro-inflammatory phenotype of Tregs via increased STAT1 activation, and contributes thereby to RA pathogenesis.
target gene	hsa-mir-19a	Rheumatoid Arthritis	22105995	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA.
target gene	hsa-mir-19b-1	Rheumatoid Arthritis	22105995	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA.
target gene	hsa-mir-19b-2	Rheumatoid Arthritis	22105995	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	TLR2 Expression Is Regulated by MicroRNA miR-19 in Rheumatoid Fibroblast-like Synoviocytes.Downregulation of miR-19b and miR-19a, which belongs to the same cluster, was confirmed by real-time quantitative PCR. Transfection of RA FLS with miR-19a/b mimics decreased TLR2 protein expression. In parallel, we found that both IL-6 and matrix metalloproteinase 3 secretion was significantly downregulated in activated FLS transfected with either mimic. Moreover, using a luciferase assay, we showed that miR-19a/b directly target Tlr2 mRNA.
target gene	hsa-mir-22	Rheumatoid Arthritis	24449575	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	A novel p53/microRNA-22/Cyr61 axis in synovial cells regulates inflammation in rheumatoid arthritis.
target gene	hsa-mir-223	Rheumatoid Arthritis	28056105	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-223-3p may contribute to the pathogenesis of RA by downregulating the expression of IL-17RD and upregulating that of IL-6 in synovial cells
target gene	hsa-mir-23a	Rheumatoid Arthritis	27936459	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiR-23a inhibited IL-17-mediated proinflammatory mediators expression via targeting IKKα in articular chondrocytes.
target gene	hsa-mir-26b	Rheumatoid Arthritis	26088648	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiR-26b regulates β-catenin and CyclinD1 levels by inhibiting GSK-3β expression, which in-turn alters the Wnt/GSK-3β/β-catenin pathway to lower RAFLS proliferation and elevate cell apoptosis and the secretion of TNF-α,IL-1β and IL-6 cytokines. Therefore, our results show that miR-26B plays a central role in inhibiting the inflammation associated with rheumatoid arthritis.
target gene	hsa-mir-29a	Rheumatoid Arthritis	28987940	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MicroRNA-29a inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes by repressing STAT3.
target gene	hsa-mir-363	Rheumatoid Arthritis	28376277	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Dendritic Cells from Rheumatoid Arthritis Patient Peripheral Blood Induce Th17 Cell Differentiation via miR-363/Integrin αv/TGF-β Axis.
target gene	hsa-mir-650	Rheumatoid Arthritis	28129626	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiR-650 inhibits proliferation, migration and invasion of rheumatoid arthritis synovial fibroblasts by targeting AKT2.
target gene	hsa-mir-133	Roberts Syndrome	26434741	genetic disease	DOID:5325		C535687	268300		miR-133-dependent cx43 overexpression rescues esco2-dependent growth defects
target gene	hsa-mir-17	Sarcoma [unspecific]	23128393	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	Interestingly, the levels of onco-miR-17 locus coded miRNAs (miR-17-5p and miR-20a) were decreased upon TAF15 depletion and shown to affect the post-transcriptional regulation of TAF15-dependent genes,such as CDKN1A/p21.
target gene	hsa-mir-182	Sarcoma [unspecific]	25180607	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes.
target gene	hsa-mir-20a	Sarcoma [unspecific]	23128393	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	Interestingly, the levels of onco-miR-17 locus coded miRNAs (miR-17-5p and miR-20a) were decreased upon TAF15 depletion and shown to affect the post-transcriptional regulation of TAF15-dependent genes,such as CDKN1A/p21.
target gene	hsa-mir-137	Schizophrenia	22182936	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 are miR-137 targets.
target gene	hsa-mir-137	Schizophrenia	22883350	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Candidate schizophrenia gene ZNF804A is a target for hsa-miR-137.
target gene	hsa-mir-137	Schizophrenia	24275578	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	MIR137 gene and target gene CACNA1C of miR-137 contribute to schizophrenia susceptibility in Han Chinese.
target gene	hsa-mir-137	Schizophrenia	26163462	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Experimental validation of candidate schizophrenia gene CALN1 as a target for microRNA-137.
target gene	hsa-mir-137	Schizophrenia	26925706	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	MicroRNA-137 (miR-137) is a brain-enriched RNA with a critical role in regulating brain development and in mediating synaptic plasticity.
target gene	hsa-mir-17	Schizophrenia	22228753	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Expression of NPAS3 in the Human Cortex is regulated by miR-17 During Development and has Implications for Schizophrenia.
target gene	hsa-mir-212	Schizophrenia	25392085	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	NMDA receptor, the molecular cascades controlled by these miRNAs and commonly predicted target genes of the two miRNAs.
target gene	hsa-mir-193b	Scleroderma, Systemic	25384965	musculoskeletal system disease	DOID:418	M34	D012595	181750		Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression.
target gene	hsa-mir-202	Scleroderma, Systemic	28068631	musculoskeletal system disease	DOID:418	M34	D012595	181750		MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1.
target gene	hsa-mir-29a	Scleroderma, Systemic	26335042	musculoskeletal system disease	DOID:418	M34	D012595	181750		miRNA-29a in systemic sclerosis: A valid target.
target gene	hsa-mir-30a	Scleroderma, Systemic	25360821	musculoskeletal system disease	DOID:418	M34	D012595	181750		MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts.
target gene	hsa-mir-183	Sensorineural Hearing Loss	23472202	nervous system disease	DOID:10003	H90.5	D006313	304400		The miR-183/Taok1 target pair is implicated in cochlear responses to acoustic trauma.
target gene	hsa-mir-122	Sepsis	26889043			A41.9	D018805		HP:0100806	These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling.
target gene	hsa-mir-125b	Sepsis	26482503			A41.9	D018805		HP:0100806	miR-125b modulates PCT expression by manipulating the amount and transcriptional activity of Stat3.
target gene	hsa-mir-145	Sepsis	26889043			A41.9	D018805		HP:0100806	These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling.
target gene	hsa-mir-146a	Sepsis	26889043			A41.9	D018805		HP:0100806	These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling.
target gene	hsa-mir-146a	Sepsis	21562054			A41.9	D018805		HP:0100806	MicroRNA-146a regulates both transcription silencing and translation disruption of TNF-α during TLR4-induced gene reprogramming.
target gene	hsa-mir-146a	Sepsis	23825193			A41.9	D018805		HP:0100806	We conclude that a TLR4-, miR-146a-, p38 MAPK-, and MKP-1-dependent autoregulatory pathway regulates the translation of proinflammatory genes during the acute inflammatory response by spatially and temporally modifying the phosphorylation state of RBM4 translational repressor protein.
target gene	hsa-mir-146a	Sepsis	28288804			A41.9	D018805		HP:0100806	MiR-146a potentially promotes IVIg-mediated inhibition of TLR4 signaling in LPS-activated human monocytes.
target gene	hsa-mir-146a	Sepsis	28662100			A41.9	D018805		HP:0100806	miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model.
target gene	hsa-mir-146b	Sepsis	28662100			A41.9	D018805		HP:0100806	miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model.
target gene	hsa-mir-155	Sepsis	28662100			A41.9	D018805		HP:0100806	miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an In vitro sepsis model.
target gene	hsa-mir-210	Sepsis	26889043			A41.9	D018805		HP:0100806	These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling.
target gene	hsa-mir-30a	Sepsis	24858600			A41.9	D018805		HP:0100806	STAT1 regulates MD-2 expression in monocytes of sepsis via miR-30a.
target gene	hsa-mir-31	Sepsis	26978146			A41.9	D018805		HP:0100806	Down-regulation of MicroRNA-31 in CD4+ T Cells Contributes to Immunosuppression in Human Sepsis by Promoting TH2 Skewing.
target gene	hsa-mir-34a	Sepsis	26889043			A41.9	D018805		HP:0100806	These findings demonstrate that host cellular RNA and specific miRNAs are released into the circulation during polymicrobial sepsis and may function as extracellular mediators capable of promoting cfB production and AP activation through specific TLR7 and MyD88 signaling.
target gene	hsa-mir-718	Sepsis	28209713			A41.9	D018805		HP:0100806	miR-718 represses proinflammatory cytokine production through targeting phosphatase and tensin homolog (PTEN).
target gene	hsa-mir-155	Sezary Disease	29582620	disease of cellular proliferation	DOID:8541	C84.1	D012751			HERV-K and HERV-W expression is regulated by mir-155 in Sézary syndrome
target gene	hsa-mir-486	Sezary Disease	24062018	disease of cellular proliferation	DOID:8541	C84.1	D012751			we demonstrate that PTEN level can be also reduced by a group of miRs previously found upregulated and of prognostic relevance in SS; particularly, miR-21, miR-106b, and miR-486 were able to control PTEN abundance either in vitro or in vivo
target gene	hsa-mir-34a	Sickle Cell Anemia	26940952	genetic disease	DOID:10923	D57.1	D000755	603903		miR-34a promoted cell differentiation supported by increased expression of KLF1, glycophorin A, and the erythropoietin  receptor.
target gene	hsa-mir-302c	Skin Neoplasms	22486352	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	Co-treatment with decitabine and doxorubicin results first in increased OCT4 and mir-145, then a decrease in both, suggesting that OCT4 and mir-145 regulate each other.
target gene	hsa-mir-34a	Somatotropinoma	25658813			F45.9	D049912			miR-34a is a negative regulator of AIP-protein expression and could be responsible for the low AIP expression observed in somatotropinomas with an invasive phenotype and resistance to SSA.
target gene	hsa-mir-574	Spinal Chordoma	29051990	musculoskeletal system disease	DOID:4153		D002817			Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients.
target gene	hsa-mir-140	Spinal Cord Injuries	28501777			S34.139A	D013119			MiR-140/BDNF axis regulates normal human astrocyte proliferation and LPS-induced IL-6 and TNF-α secretion.
target gene	hsa-mir-16	Spinal Cord Injuries	25936407			S34.139A	D013119			A number of microRNAs (e.g. miR210, miR-487b and miR-16) were observed to target cholesterol  metabolism-associated DGEs.
target gene	hsa-mir-34b	Spinal Cord Injuries	27780189			S34.139A	D013119			Changes in the Expression of miR-34a and its Target Genes Following Spinal Cord Injury In Rats.
target gene	hsa-mir-34c	Spinal Cord Injuries	27780189			S34.139A	D013119			Changes in the Expression of miR-34a and its Target Genes Following Spinal Cord Injury In Rats.
target gene	hsa-mir-494	Spinal Cord Injuries	28368292			S34.139A	D013119			Long Coding RNA XIST Contributes to Neuronal Apoptosis through the Downregulation of AKT Phosphorylation and Is Negatively Regulated by miR-494 in Rat Spinal Cord Injury.
target gene	hsa-mir-185	Squamous Cell Carcinoma	24070899	disease of cellular proliferation	DOID:1749		D002294			Phospho-ΔNp63α regulates AQP3, ALOX12B, CASP14 and CLDN1 expression through transcription and microRNA modulation.
target gene	hsa-mir-1246	Squamous Cell Carcinoma, Cerevial	24806621	endocrine system disease	DOID:5531					MiR-1246 promotes SiHa cervical cancer cell proliferation, invasion, and migration through suppression of its target gene thrombospondin 2.
target gene	hsa-mir-138	Squamous Cell Carcinoma, Cerevial	26267680	endocrine system disease	DOID:5531					miR-138 and miR-720 are the down-regulated target miRNAs in HPV16-positive squamous carcinoma of the cervix in the Uygur of southern Xinjiang. The common target gene for miR-138 and miR-720 is EZH2, which might be related to cervical squamous carcinoma invasion and metastasis.
target gene	hsa-mir-29a	Squamous Cell Carcinoma, Cerevial	24141696	endocrine system disease	DOID:5531					Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma.
target gene	hsa-mir-720	Squamous Cell Carcinoma, Cerevial	26267680	endocrine system disease	DOID:5531					miR-138 and miR-720 are the down-regulated target miRNAs in HPV16-positive squamous carcinoma of the cervix in the Uygur of southern Xinjiang. The common target gene for miR-138 and miR-720 is EZH2, which might be related to cervical squamous carcinoma invasion and metastasis.
target gene	hsa-let-7	Squamous Cell Carcinoma, Esophageal	24612219	disease of cellular proliferation	DOID:3748		C562729			Expression of let-7 can suppress cell proliferation by acting directly on regulation of HMGA2 in OSCC. High expression of Snail and its correlation with HMGA2 expression and tumour invasion suggest that HMGA2 may be involved in EMT in the OSCC of Kazakh patients.
target gene	hsa-mir-106b	Squamous Cell Carcinoma, Esophageal	27619676	disease of cellular proliferation	DOID:3748		C562729			MiR-106b promotes migration and invasion through enhancing EMT via downregulation of Smad 7 in Kazakh's esophageal squamous cell carcinoma.
target gene	hsa-mir-107	Squamous Cell Carcinoma, Esophageal	28393193	disease of cellular proliferation	DOID:3748		C562729			miR-107 functions as a tumor suppressor in human esophageal squamous cell carcinoma and targets Cdc42.
target gene	hsa-mir-126	Squamous Cell Carcinoma, Esophageal	26191164	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway.
target gene	hsa-mir-127	Squamous Cell Carcinoma, Esophageal	27645894	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-127 is a tumor suppressor in human esophageal squamous cell carcinoma through the regulation of oncogene FMNL3.
target gene	hsa-mir-1290	Squamous Cell Carcinoma, Esophageal	26653554	disease of cellular proliferation	DOID:3748		C562729			Taken together, our findings suggested that miR-1290 functions as a tumor oncogene in the progression of ESCC by targeting NFIX.
target gene	hsa-mir-133a-1	Squamous Cell Carcinoma, Esophageal	21351259	disease of cellular proliferation	DOID:3748		C562729			miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma.
target gene	hsa-mir-133a-2	Squamous Cell Carcinoma, Esophageal	21351259	disease of cellular proliferation	DOID:3748		C562729			miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma.
target gene	hsa-mir-133b	Squamous Cell Carcinoma, Esophageal	21351259	disease of cellular proliferation	DOID:3748		C562729			miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma.
target gene	hsa-mir-138	Squamous Cell Carcinoma, Esophageal	23319823	disease of cellular proliferation	DOID:3748		C562729			Downregulation of miR-138 sustains NF-κB activation and promotes lipid raft formation in esophageal squamous cell carcinoma.
target gene	hsa-mir-143	Squamous Cell Carcinoma, Esophageal	26806810	disease of cellular proliferation	DOID:3748		C562729			MiR-143 inhibits tumor cell proliferation and invasion by targeting STAT3 in esophageal squamous cell carcinoma.
target gene	hsa-mir-143	Squamous Cell Carcinoma, Esophageal	29137232	disease of cellular proliferation	DOID:3748		C562729			Integration of metabolomics, transcriptomics, and microRNA expression profiling reveals a miR-143-HK2-glucose network underlying zinc-deficiency-associated esophageal neoplasia.
target gene	hsa-mir-145	Squamous Cell Carcinoma, Esophageal	21351259	disease of cellular proliferation	DOID:3748		C562729			miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma.
target gene	hsa-mir-145	Squamous Cell Carcinoma, Esophageal	24356567	disease of cellular proliferation	DOID:3748		C562729			miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.
target gene	hsa-mir-145	Squamous Cell Carcinoma, Esophageal	27771733	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-145 Inhibits Cell Migration and Invasion and Regulates Epithelial-Mesenchymal Transition (EMT) by Targeting Connective Tissue Growth Factor (CTGF) in Esophageal Squamous Cell Carcinoma.
target gene	hsa-mir-145	Squamous Cell Carcinoma, Esophageal	29430188	disease of cellular proliferation	DOID:3748		C562729			The ROR/miR-145/FSCN1 pathway was shown to take part in the metastasis of ESCC. ROR is likely an oncogene biomarker for ESCC early diagnosis and prognosis
target gene	hsa-mir-146a	Squamous Cell Carcinoma, Esophageal	27832663	disease of cellular proliferation	DOID:3748		C562729			miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2.
target gene	hsa-mir-148a	Squamous Cell Carcinoma, Esophageal	29067119	disease of cellular proliferation	DOID:3748		C562729			MiR-148a modulates HLA-G expression and influences tumor apoptosis in esophageal squamous cell carcinoma.
target gene	hsa-mir-155	Squamous Cell Carcinoma, Esophageal	24551280	disease of cellular proliferation	DOID:3748		C562729			microRNA-155 acts as an oncogene by targeting the tumor protein 53-induced nuclear protein 1 in esophageal squamous cell carcinoma.
target gene	hsa-mir-155	Squamous Cell Carcinoma, Esophageal	25823933	disease of cellular proliferation	DOID:3748		C562729			a novel pattern of differential miRNA-target expression was constructed, which with further investigation, may provide novel targets for diagnosing and understanding the mechanism of ESCC.
target gene	hsa-mir-16	Squamous Cell Carcinoma, Esophageal	24852767	disease of cellular proliferation	DOID:3748		C562729			Aberrant increased level of miR-16 was detected in the ESCC tissues compared with the corresponding adjacent tumor tissues. MiR-16 could inhibit cell apoptosis while promote cell proliferation by down-regulating RECK and SOX6 in TE-1 and Eca-109 cell lines through binding the 3'UTR of both RECK and SOX6 mRNA. CONCLUSIONS: Aberrant expression level of miR-16 could suppress cell apoptosis while promote growth by regulating RECK and SOX6 which play important roles in the pathogenesis of ESCC.
target gene	hsa-mir-181d	Squamous Cell Carcinoma, Esophageal	27572270	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-181d is a tumor suppressor in human esophageal squamous cell carcinoma inversely regulating Derlin-1.
target gene	hsa-mir-183	Squamous Cell Carcinoma, Esophageal	25211657	disease of cellular proliferation	DOID:3748		C562729			MiR-183 promotes ESCC cell proliferation and invasion by directly targeting PDCD4, which suggests that it is involved in the pathogenesis of ESCC.
target gene	hsa-mir-195	Squamous Cell Carcinoma, Esophageal	25400770	disease of cellular proliferation	DOID:3748		C562729			The main findings of this study indicate the involvement of miR-195-Cdc42 axis in the progression of ESCC and suggest that the combined aberrant expression of miR-195 and Cdc42 mRNA can serve as a promising unfavorable prognostic biomarker in ESCC.
target gene	hsa-mir-195	Squamous Cell Carcinoma, Esophageal	24025765	disease of cellular proliferation	DOID:3748		C562729			miR-195 may act as a tumor suppressor in ESCC by targeting Cdc42.
target gene	hsa-mir-200a	Squamous Cell Carcinoma, Esophageal	26341629	disease of cellular proliferation	DOID:3748		C562729			These results reaffirm the potential role of MSA as a chemopreventive agent via the regulation of KLF4/miR-200a/Keap1/Nrf2 axis in ESCC cells.
target gene	hsa-mir-200b	Squamous Cell Carcinoma, Esophageal	24064224	disease of cellular proliferation	DOID:3748		C562729			miR-200b suppresses invasiveness and modulates the cytoskeletal and adhesive machinery in esophageal squamous cell carcinoma cells via targeting Kindlin-2.
target gene	hsa-mir-202	Squamous Cell Carcinoma, Esophageal	25823933	disease of cellular proliferation	DOID:3748		C562729			a novel pattern of differential miRNA-target expression was constructed, which with further investigation, may provide novel targets for diagnosing and understanding the mechanism of ESCC.
target gene	hsa-mir-202	Squamous Cell Carcinoma, Esophageal	28277193	disease of cellular proliferation	DOID:3748		C562729			miR-202 Promotes Cell Apoptosis in Esophageal Squamous Cell Carcinoma by Targeting HSF2.
target gene	hsa-mir-203	Squamous Cell Carcinoma, Esophageal	21299870	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma.
target gene	hsa-mir-205	Squamous Cell Carcinoma, Esophageal	21426561	disease of cellular proliferation	DOID:3748		C562729			MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells.
target gene	hsa-mir-208a	Squamous Cell Carcinoma, Esophageal	25023649	disease of cellular proliferation	DOID:3748		C562729			These results suggest that miR-208 represents a potential onco-miR and participates in ESCC carcinogenesis by suppressing SOX6 expression.
target gene	hsa-mir-214	Squamous Cell Carcinoma, Esophageal	26234674	disease of cellular proliferation	DOID:3748		C562729			Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1.
target gene	hsa-mir-214	Squamous Cell Carcinoma, Esophageal	27619677	disease of cellular proliferation	DOID:3748		C562729			miR-214 inhibits invasion and migration via downregulating GALNT7 in esophageal squamous cell cancer.
target gene	hsa-mir-214	Squamous Cell Carcinoma, Esophageal	28954387	disease of cellular proliferation	DOID:3748		C562729			MiR-214 inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by targeting CDC25B.
target gene	hsa-mir-218	Squamous Cell Carcinoma, Esophageal	25999024	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1.
target gene	hsa-mir-224	Squamous Cell Carcinoma, Esophageal	26245343	disease of cellular proliferation	DOID:3748		C562729			The current study demonstrated that miR-224 acts as an oncogenic miRNA in esophageal squamous cell carcinoma (ESCC), possibly by targeting PHLPP1 and PHLPP2.
target gene	hsa-mir-25	Squamous Cell Carcinoma, Esophageal	29250158	disease of cellular proliferation	DOID:3748		C562729			PTEN, TP53, MDM2, E2F1, PRMT5, MCM2, RB1, CDKN1A, SHAD7 and EZH2 may be targeted by the miR-106b-25 cluster, and act together to regulate the development of ESCC
target gene	hsa-mir-27a	Squamous Cell Carcinoma, Esophageal	24154848	disease of cellular proliferation	DOID:3748		C562729			microRNA-27a functions as a tumor suppressor in esophageal squamous cell carcinoma by targeting KRAS.
target gene	hsa-mir-29c	Squamous Cell Carcinoma, Esophageal	21551130	disease of cellular proliferation	DOID:3748		C562729			miR-29c induces cell cycle arrest in Esophageal Squamous Cell Carcinoma by modulating Cyclin E expression.
target gene	hsa-mir-302b	Squamous Cell Carcinoma, Esophageal	24438167	disease of cellular proliferation	DOID:3748		C562729			miR-302b is a potential molecular marker of ESCC and functions as a tumor suppressor by post-transcriptionally regulating ErbB4
target gene	hsa-mir-30d	Squamous Cell Carcinoma, Esophageal	28184915	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-30d inhibits the migration and invasion of human esophageal squamous cell carcinoma cells via the post‑transcriptional regulation of enhancer of zeste homolog 2.
target gene	hsa-mir-34a	Squamous Cell Carcinoma, Esophageal	25954903	disease of cellular proliferation	DOID:3748		C562729			miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1.
target gene	hsa-mir-34a	Squamous Cell Carcinoma, Esophageal	28534990	disease of cellular proliferation	DOID:3748		C562729			Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma.
target gene	hsa-mir-34a	Squamous Cell Carcinoma, Esophageal	29094237	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44.
target gene	hsa-mir-34a	Squamous Cell Carcinoma, Esophageal	29190930	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma
target gene	hsa-mir-367	Squamous Cell Carcinoma, Esophageal	26777997	disease of cellular proliferation	DOID:3748		C562729			MiR-367 is a potential biomarker for ESCC and may act as an oncogene in regulating ESCC development.
target gene	hsa-mir-375	Squamous Cell Carcinoma, Esophageal	21813472	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor.
target gene	hsa-mir-375	Squamous Cell Carcinoma, Esophageal	28069583	disease of cellular proliferation	DOID:3748		C562729			MiR-375 suppresses invasion and metastasis by direct targeting of SHOX2 in esophageal squamous cell carcinoma.
target gene	hsa-mir-375	Squamous Cell Carcinoma, Esophageal	27779648	disease of cellular proliferation	DOID:3748		C562729			Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma.
target gene	hsa-mir-518	Squamous Cell Carcinoma, Esophageal	28119087	disease of cellular proliferation	DOID:3748		C562729			miR-518 inhibited the proliferation and invasion of esophageal squamous cell carcinoma (ESCC) cells possibly by targeting RAP1B
target gene	hsa-mir-520a	Squamous Cell Carcinoma, Esophageal	24589589	disease of cellular proliferation	DOID:3748		C562729			miR-520a regulates the expression of ErbB4 and suppresses the proliferation and invasion of ESCC cells in vitro, suggesting its role as a tumor suppressor.
target gene	hsa-mir-577	Squamous Cell Carcinoma, Esophageal	24294352	disease of cellular proliferation	DOID:3748		C562729			Effects and interactions of MiR-577 and TSGA10 in regulating esophageal squamous cell carcinoma.
target gene	hsa-mir-7	Squamous Cell Carcinoma, Esophageal	27956498	disease of cellular proliferation	DOID:3748		C562729			In cytoplasm, CCAT1 regulates HOXB13 as a molecular decoy for miR-7, a microRNA that targets both CCAT1 and HOXB13, thus facilitating cell growth and migration
target gene	hsa-mir-92b	Squamous Cell Carcinoma, Esophageal	27659550	disease of cellular proliferation	DOID:3748		C562729			RAB23, regulated by miR-92b, promotes the progression of esophageal squamous cell carcinoma.
target gene	hsa-let-7i	Squamous Cell Carcinoma, Head and Neck	23454123	disease of cellular proliferation	DOID:5520	C76.0	C535575			In clinical HNSCC samples, let-7i expression was inversely correlated with BMP4 expression. Our results revealed that let-7i attenuates mesenchymal-mode migration of HNSCC cells through repression of a novel target, BMP4.
target gene	hsa-mir-101-1	Squamous Cell Carcinoma, Head and Neck	21532618	disease of cellular proliferation	DOID:5520	C76.0	C535575			The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.
target gene	hsa-mir-101-2	Squamous Cell Carcinoma, Head and Neck	21532618	disease of cellular proliferation	DOID:5520	C76.0	C535575			The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.
target gene	hsa-mir-106a	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-1-1	Squamous Cell Carcinoma, Head and Neck	21378409	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
target gene	hsa-mir-1-2	Squamous Cell Carcinoma, Head and Neck	21378409	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
target gene	hsa-mir-124	Squamous Cell Carcinoma, Head and Neck	28212569	disease of cellular proliferation	DOID:5520	C76.0	C535575			MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma.
target gene	hsa-mir-125b	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-138	Squamous Cell Carcinoma, Head and Neck	24565984	disease of cellular proliferation	DOID:5520	C76.0	C535575			These findings strongly suggest that the inhibition of RhoC can be achieved by over expressing miR-138, which further attenuates the downstream signaling cascade leading to cancer progression and survival. Moreover, this study for the first time shows that down regulation of FAK, Src and Erk(1/2) by miR-138 overexpression is due to inhibition of RhoC in HNSCC.
target gene	hsa-mir-155	Squamous Cell Carcinoma, Head and Neck	26694378	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-15b	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-182	Squamous Cell Carcinoma, Head and Neck	29356167	disease of cellular proliferation	DOID:5520	C76.0	C535575			there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb
target gene	hsa-mir-193b	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-200c	Squamous Cell Carcinoma, Head and Neck	21899661	disease of cellular proliferation	DOID:5520	C76.0	C535575			The expression of ZEB1, a target mRNA for miR-200c, was up-regulated 3 and 6 hours after HGF stimulation.
target gene	hsa-mir-203	Squamous Cell Carcinoma, Head and Neck	18483491	disease of cellular proliferation	DOID:5520	C76.0	C535575			we have shown that miR-203 can regulate DeltaNp63 levels upon genotoxic damage in head and neck squamous cell carcinoma cells, thus controlling cell survival.
target gene	hsa-mir-206	Squamous Cell Carcinoma, Head and Neck	28987947	disease of cellular proliferation	DOID:5520	C76.0	C535575			MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
target gene	hsa-mir-20b	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	28138036	disease of cellular proliferation	DOID:5520	C76.0	C535575			Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152.
target gene	hsa-mir-218-1	Squamous Cell Carcinoma, Head and Neck	23159910	disease of cellular proliferation	DOID:5520	C76.0	C535575			Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma
target gene	hsa-mir-218-2	Squamous Cell Carcinoma, Head and Neck	23159910	disease of cellular proliferation	DOID:5520	C76.0	C535575			Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma
target gene	hsa-mir-27b	Squamous Cell Carcinoma, Head and Neck	21899661	disease of cellular proliferation	DOID:5520	C76.0	C535575			The expression of ST14/matriptase an enzyme for extracellular matrix (ECM) degradation and HGF activation and a target mRNA for miR-27b, was drastically up-regulated in protein level after HGF stimulation.
target gene	hsa-mir-29a	Squamous Cell Carcinoma, Head and Neck	24091622	disease of cellular proliferation	DOID:5520	C76.0	C535575			Downregulation of miR-29s was a frequent event in HNSCC. The miR-29s acted as tumour suppressors and directly targeted laminin-integrin signalling. Recognition of tumour-suppressive miRNA-mediated cancer pathways provides new insights into the potential mechanisms of HNSCC oncogenesis and metastasis and suggests novel therapeutic strategies for the disease.
target gene	hsa-mir-29b	Squamous Cell Carcinoma, Head and Neck	24091622	disease of cellular proliferation	DOID:5520	C76.0	C535575			Downregulation of miR-29s was a frequent event in HNSCC. The miR-29s acted as tumour suppressors and directly targeted laminin-integrin signalling. Recognition of tumour-suppressive miRNA-mediated cancer pathways provides new insights into the potential mechanisms of HNSCC oncogenesis and metastasis and suggests novel therapeutic strategies for the disease.
target gene	hsa-mir-29c	Squamous Cell Carcinoma, Head and Neck	24091622	disease of cellular proliferation	DOID:5520	C76.0	C535575			Downregulation of miR-29s was a frequent event in HNSCC. The miR-29s acted as tumour suppressors and directly targeted laminin-integrin signalling. Recognition of tumour-suppressive miRNA-mediated cancer pathways provides new insights into the potential mechanisms of HNSCC oncogenesis and metastasis and suggests novel therapeutic strategies for the disease.
target gene	hsa-mir-31	Squamous Cell Carcinoma, Head and Neck	29356167	disease of cellular proliferation	DOID:5520	C76.0	C535575			there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb
target gene	hsa-mir-34a	Squamous Cell Carcinoma, Head and Neck	26323460	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro.
target gene	hsa-mir-375	Squamous Cell Carcinoma, Head and Neck	21753766	disease of cellular proliferation	DOID:5520	C76.0	C535575			Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC).
target gene	hsa-mir-375	Squamous Cell Carcinoma, Head and Neck	28499703	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin.
target gene	hsa-mir-512	Squamous Cell Carcinoma, Head and Neck	26258591	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-512-5p suppresses tumor growth by targeting hTERT in telomerase positive head and neck squamous cell carcinoma in vitro and in vivo.
target gene	hsa-mir-548b	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-582	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-874	Squamous Cell Carcinoma, Head and Neck	23558898	disease of cellular proliferation	DOID:5520	C76.0	C535575			Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma
target gene	hsa-mir-885	Squamous Cell Carcinoma, Head and Neck	22071691	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-885-3p modulated the cisplatin-induced TP53-dependent mitochondrial apoptosis by up regulation of MDM4 levels and down regulation of BCL2 levels in mitochondria. Altogether, our results support the notion that miR-885-3p might contribute in regulation of cell viability, apoptosis and/or autophagy in squamous cell carcinoma cells upon cisplatin exposure.
target gene	hsa-mir-9-1	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-9-2	Squamous Cell Carcinoma, Head and Neck	26694379	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-Target Network Inference and Local Network Enrichment Analysis Identify Two microRNA Clusters with Distinct Functions in Head and Neck Squamous Cell Carcinoma.
target gene	hsa-mir-96	Squamous Cell Carcinoma, Head and Neck	29356167	disease of cellular proliferation	DOID:5520	C76.0	C535575			there is frequent and concordant upregulation of miR-31, miR-96, and miR-182 during HNSCC and these miRNAs co-target Numb
target gene	hsa-mir-1-1	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	21924268	disease of cellular proliferation	DOID:2876					miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.
target gene	hsa-mir-1-2	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	21924268	disease of cellular proliferation	DOID:2876					miRNA-1 targets fibronectin1 and suppresses the migration and invasion of the HEp2 laryngeal squamous carcinoma cell line.
target gene	hsa-mir-132	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27751825	disease of cellular proliferation	DOID:2876					MiR-132 plays an oncogenic role in laryngeal squamous cell carcinoma by targeting FOXO1 and activating the PI3K/AKT pathway.
target gene	hsa-mir-138	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	28962111	disease of cellular proliferation	DOID:2876					MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting EZH2 and PI3K/AKT signaling.
target gene	hsa-mir-139	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24318902	disease of cellular proliferation	DOID:2876					MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells.
target gene	hsa-mir-140	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27033573	disease of cellular proliferation	DOID:2876					miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression.
target gene	hsa-mir-19a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26502748	disease of cellular proliferation	DOID:2876					Our preliminary outcomes suggest the utility of miR-19a in the challenging differential diagnosis of laryngeal VSCC. Although miR-19a has been found to regulate SOCS-1 expression, this evidence was not confirmed by this investigation.
target gene	hsa-mir-19a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24427326	disease of cellular proliferation	DOID:2876					MiR-19a is correlated with prognosis and apoptosis of laryngeal squamous cell carcinoma by regulating TIMP-2 expression.
target gene	hsa-mir-214	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	25623865	disease of cellular proliferation	DOID:2876					miR-214 is expressed at a low level in advanced hypopharyngeal carcinoma tissues, and can obviously inhibit the invasion and migration abilities of FaDu cells, possibly because of its inhibiting effect on Twist expression. Additionally, miR-214 plays no significant role in the proliferation of FaDu cells.
target gene	hsa-mir-373	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	29307338	disease of cellular proliferation	DOID:2876					Expression of miR-373 and its predicted target genes E-cadherin and CD44 in patients with laryngeal squamous cell carcinoma
target gene	hsa-mir-375	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	25184138	disease of cellular proliferation	DOID:2876					miR-375 suppresses IGF1R expression and contributes to inhibition of cell progression in laryngeal squamous cell carcinoma.
target gene	hsa-mir-4497	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	29843929	disease of cellular proliferation	DOID:2876					MicroRNA-4497 functions as a tumor suppressor in laryngeal squamous cell carcinoma via negatively modulation the GBX2.
target gene	hsa-mir-489	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	20700123	disease of cellular proliferation	DOID:2876					miR-489:miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma
target gene	hsa-mir-504	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24647829	disease of cellular proliferation	DOID:2876					microRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma.
target gene	hsa-mir-93	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	25309979	disease of cellular proliferation	DOID:2876					MicroRNA-93 regulates cyclin G2 expression and plays an oncogenic role in laryngeal squamous cell carcinoma.
target gene	hsa-mir-205	Squamous Cell Carcinoma, Lung	24438615	disease of cellular proliferation	DOID:3907	C34.91				We confirmed the high diagnostic accuracy of miR-205 in discriminating SQ from AC and SCLC in Chinese patients. Moreover, we identified 11 significant target genes of miR-205 which could be used for further functional studies as the basis for the development of SQ targeted therapies.
target gene	hsa-mir-21	Squamous Cell Carcinoma, Lung	25084400	disease of cellular proliferation	DOID:3907	C34.91				MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China.
target gene	hsa-mir-218	Squamous Cell Carcinoma, Lung	27633630	disease of cellular proliferation	DOID:3907	C34.91				Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma.
target gene	hsa-mir-24	Squamous Cell Carcinoma, Lung	27666488	disease of cellular proliferation	DOID:3907	C34.91				MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma.
target gene	hsa-mir-29	Squamous Cell Carcinoma, Lung	26676674	disease of cellular proliferation	DOID:3907	C34.91				Elucidation of the novel lung SCC molecular pathways and targets regulated by tumor-suppressive miR-29s will provide new insights into the potential mechanisms of oncogenesis and metastasis of the disease.
target gene	hsa-mir-588	Squamous Cell Carcinoma, Lung	27571908	disease of cellular proliferation	DOID:3907	C34.91				MicroRNA-588 suppresses tumor cell migration and invasion by targeting GRN in lung squamous cell carcinoma.
target gene	hsa-let-7a	Squamous Cell Carcinoma, Lung	27666488	disease of cellular proliferation	DOID:3907	C34.91				MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma.
target gene	hsa-mir-101	Squamous Cell Carcinoma, Oral	25762643	disease of cellular proliferation	DOID:0050866					Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma.
target gene	hsa-mir-101	Squamous Cell Carcinoma, Oral	27904690	disease of cellular proliferation	DOID:0050866					miRNA-101 acts as a tumor suppressor in oral squamous cell carcinoma by targeting CX chemokine receptor 7.
target gene	hsa-mir-125a	Squamous Cell Carcinoma, Oral	25266720	disease of cellular proliferation	DOID:0050866					MicroRNA-125a reduces proliferation and invasion of oral squamous cell carcinoma cells by targeting estrogen-related receptor α: implications for cancertherapeutics.
target gene	hsa-mir-138	Squamous Cell Carcinoma, Oral	26239136	disease of cellular proliferation	DOID:0050866					miR-138 suppresses the proliferation of oral squamous cell carcinoma cells by targeting Yes-associated protein 1.
target gene	hsa-mir-140	Squamous Cell Carcinoma, Oral	22470160	disease of cellular proliferation	DOID:0050866					miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes.
target gene	hsa-mir-143	Squamous Cell Carcinoma, Oral	26625772	disease of cellular proliferation	DOID:0050866					Low levels of miR-380-5p and miR-504 that directly target the 3'UTR of TP53 suggest that p53 may not be repressed by these two miRNAs in OSCC. On the other hand, low levels of miR-34a or miR-143 may relieve MDM4 and SIRT1 or MDM2 respectively, which will sequester p53 indicating an indirect mode of p53 suppression in oral tumors.
target gene	hsa-mir-143	Squamous Cell Carcinoma, Oral	28174335	disease of cellular proliferation	DOID:0050866					MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2.
target gene	hsa-mir-181a-1	Squamous Cell Carcinoma, Oral	21167132	disease of cellular proliferation	DOID:0050866					miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras
target gene	hsa-mir-181a-2	Squamous Cell Carcinoma, Oral	21167132	disease of cellular proliferation	DOID:0050866					miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras
target gene	hsa-mir-19a	Squamous Cell Carcinoma, Oral	27581787	disease of cellular proliferation	DOID:0050866					Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma.
target gene	hsa-mir-19b	Squamous Cell Carcinoma, Oral	27581787	disease of cellular proliferation	DOID:0050866					Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma.
target gene	hsa-mir-205	Squamous Cell Carcinoma, Oral	29150940	disease of cellular proliferation	DOID:0050866					Tumor-suppressive roles of ΔNp63β-miR-205 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2
target gene	hsa-mir-21	Squamous Cell Carcinoma, Oral	20831814	disease of cellular proliferation	DOID:0050866					Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma.
target gene	hsa-mir-216a	Squamous Cell Carcinoma, Oral	25955794	disease of cellular proliferation	DOID:0050866					MicroRNA-216a inhibits the growth and metastasis of oral squamous cell carcinoma by targeting eukaryotic translation initiation factor 4B.
target gene	hsa-mir-218	Squamous Cell Carcinoma, Oral	24894864	disease of cellular proliferation	DOID:0050866					Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting.
target gene	hsa-mir-218-1	Squamous Cell Carcinoma, Oral	21795477	disease of cellular proliferation	DOID:0050866					The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.
target gene	hsa-mir-218-2	Squamous Cell Carcinoma, Oral	21795477	disease of cellular proliferation	DOID:0050866					The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.
target gene	hsa-mir-221	Squamous Cell Carcinoma, Oral	28101204	disease of cellular proliferation	DOID:0050866					Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN.
target gene	hsa-mir-222	Squamous Cell Carcinoma, Oral	24452416	disease of cellular proliferation	DOID:0050866					miR-222 regulates the cell biological behavior of oral squamous cell carcinoma by targeting PUMA.
target gene	hsa-mir-222	Squamous Cell Carcinoma, Oral	28101204	disease of cellular proliferation	DOID:0050866					Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN.
target gene	hsa-mir-23b	Squamous Cell Carcinoma, Oral	27573718	disease of cellular proliferation	DOID:0050866					The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma.
target gene	hsa-mir-27b	Squamous Cell Carcinoma, Oral	28735227	disease of cellular proliferation	DOID:0050866					MicroRNA-27b inhibits cell proliferation in oral squamous cell carcinoma by targeting FZD7 and Wnt signaling pathway.
target gene	hsa-mir-27b	Squamous Cell Carcinoma, Oral	27573718	disease of cellular proliferation	DOID:0050866					The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma.
target gene	hsa-mir-29a	Squamous Cell Carcinoma, Oral	22470160	disease of cellular proliferation	DOID:0050866					miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes.
target gene	hsa-mir-29c	Squamous Cell Carcinoma, Oral	22470160	disease of cellular proliferation	DOID:0050866					miR-140-3p, miR-29c, and miR-29a were differentially expressed in metastasis versus nonmetastatic samples and had a strong positive correlation with their DNA copy numbers and a negative correlation with the expression of their target genes.
target gene	hsa-mir-338	Squamous Cell Carcinoma, Oral	25204970	disease of cellular proliferation	DOID:0050866					MiR-338 suppresses the growth and metastasis of OSCC cells by targeting NRP1.
target gene	hsa-mir-340	Squamous Cell Carcinoma, Oral	26541225	disease of cellular proliferation	DOID:0050866					The findings suggest that miR-340 might act as a molecular switch that contributes to the regulation of glycolysis in OSCC by regulating Glut1 expression.
target gene	hsa-mir-34a	Squamous Cell Carcinoma, Oral	26625772	disease of cellular proliferation	DOID:0050866					Low levels of miR-380-5p and miR-504 that directly target the 3'UTR of TP53 suggest that p53 may not be repressed by these two miRNAs in OSCC. On the other hand, low levels of miR-34a or miR-143 may relieve MDM4 and SIRT1 or MDM2 respectively, which will sequester p53 indicating an indirect mode of p53 suppression in oral tumors.
target gene	hsa-mir-375	Squamous Cell Carcinoma, Oral	28627030	disease of cellular proliferation	DOID:0050866					MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion.
target gene	hsa-mir-375	Squamous Cell Carcinoma, Oral	28810236	disease of cellular proliferation	DOID:0050866					MicroRNA-375 Inhibits Growth and Enhances Radiosensitivity in Oral Squamous Cell Carcinoma by Targeting Insulin Like Growth Factor 1 Receptor.
target gene	hsa-mir-375	Squamous Cell Carcinoma, Oral	28000902	disease of cellular proliferation	DOID:0050866					MicroRNA‑375 inhibits oral squamous cell carcinoma cell migration and invasion by targeting platelet‑derived growth factor‑A.
target gene	hsa-mir-377	Squamous Cell Carcinoma, Oral	28267394	disease of cellular proliferation	DOID:0050866					Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9.
target gene	hsa-mir-504	Squamous Cell Carcinoma, Oral	21927029	disease of cellular proliferation	DOID:0050866					Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling.
target gene	hsa-mir-9	Squamous Cell Carcinoma, Oral	24141785	disease of cellular proliferation	DOID:0050866					MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway.
target gene	hsa-mir-99a	Squamous Cell Carcinoma, Oral	24410957	disease of cellular proliferation	DOID:0050866					Overall, results indicate that miR-99a functions as a tumor metastasis suppressor in OSCC cells and mutually regulates IGF1R expression in a reciprocal regulation.
target gene	hsa-mir-99b	Squamous Cell Carcinoma, Oral	26315788	disease of cellular proliferation	DOID:0050866					miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3β in oral squamous cell carcinoma Tca-8113 cells.
target gene	hsa-mir-124-1	Squamous Cell Carcinoma, Skin or Unspecific	22828925	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK.
target gene	hsa-mir-124-2	Squamous Cell Carcinoma, Skin or Unspecific	22828925	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK.
target gene	hsa-mir-125b-1	Squamous Cell Carcinoma, Skin or Unspecific	22782903	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MicroRNA-125b Down-regulates Matrix Metallopeptidase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion.
target gene	hsa-mir-125b-2	Squamous Cell Carcinoma, Skin or Unspecific	22782903	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MicroRNA-125b Down-regulates Matrix Metallopeptidase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion.
target gene	hsa-mir-154	Squamous Cell Carcinoma, Skin or Unspecific	29727714	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Inhibitory effect of microRNA-154 targeting WHSC1 on cell proliferation of human skin squamous cell carcinoma through mediating the P53 signaling pathway.
target gene	hsa-mir-15b	Squamous Cell Carcinoma, Skin or Unspecific	28165568	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MicroRNA15b regulates apoptosis of cutaneous squamous cell carcinoma SCL-1 cell line: a mechanism study.
target gene	hsa-mir-181a	Squamous Cell Carcinoma, Skin or Unspecific	28931048	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS.
target gene	hsa-mir-199a	Squamous Cell Carcinoma, Skin or Unspecific	26026896	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	These results suggested that miR-199a-5p plays a role in pathogenesis of cSCC via inhibition of invasiveness through regulation of BCAM, FZD6 and DDR1 expression.
target gene	hsa-mir-214	Squamous Cell Carcinoma, Skin or Unspecific	22828925	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK.
target gene	hsa-mir-31	Squamous Cell Carcinoma, Skin or Unspecific	28454216	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MicroRNA-31 functions as an oncogenic microRNA in cutaneous squamous cell carcinoma cells by targeting RhoTBT1.
target gene	hsa-mir-34a	Squamous Cell Carcinoma, Skin or Unspecific	29285100	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma
target gene	hsa-mir-361	Squamous Cell Carcinoma, Skin or Unspecific	23166713	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma
target gene	hsa-mir-365	Squamous Cell Carcinoma, Skin or Unspecific	26072217	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma.
target gene	hsa-mir-365	Squamous Cell Carcinoma, Skin or Unspecific	24949940	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	miR-365 promotes cutaneous squamous cell carcinoma (CSCC) through targeting nuclear factor I/B (NFIB).
target gene	hsa-let-7a	Squamous Cell Carcinoma, Tongue	29523225	disease of cellular proliferation	DOID:0050865	C02.9				These findings revealed that H19/let-7a/HMGA2/EMT axis plays a critical role in the regulation of TSCC migration and invasion, which may provide a new therapeutic target for TSCC cancers
target gene	hsa-mir-138	Squamous Cell Carcinoma, Tongue	21079996	disease of cellular proliferation	DOID:0050865	C02.9				Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma.
target gene	hsa-mir-15b	Squamous Cell Carcinoma, Tongue	28350138	disease of cellular proliferation	DOID:0050865	C02.9				miR-15b inhibits cancer-initiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer.
target gene	hsa-mir-182	Squamous Cell Carcinoma, Tongue	27698823	disease of cellular proliferation	DOID:0050865	C02.9				miRNA-335 and miRNA-182 affect the occurrence of tongue squamous cell carcinoma by targeting survivin.
target gene	hsa-mir-183	Squamous Cell Carcinoma, Tongue	25760063	disease of cellular proliferation	DOID:0050865	C02.9				a novel differential miRNA-mRNA expression network was constructed, and further investigation may provide novel targets for the diagnosis of TSCC.
target gene	hsa-mir-195	Squamous Cell Carcinoma, Tongue	26885901	disease of cellular proliferation	DOID:0050865	C02.9				Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior.
target gene	hsa-mir-21	Squamous Cell Carcinoma, Tongue	26191167	disease of cellular proliferation	DOID:0050865	C02.9				Targeting miR-21 with AS-miR-21 suppresses aggressive growth of human tongue squamous cell carcinoma in vivo.
target gene	hsa-mir-21	Squamous Cell Carcinoma, Tongue	24609942	disease of cellular proliferation	DOID:0050865	C02.9				MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4.
target gene	hsa-mir-222	Squamous Cell Carcinoma, Tongue	19487542	disease of cellular proliferation	DOID:0050865	C02.9				MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1(MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cellcarcinoma cell lines.
target gene	hsa-mir-24-1	Squamous Cell Carcinoma, Tongue	20816961	disease of cellular proliferation	DOID:0050865	C02.9				miR-24:MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma
target gene	hsa-mir-24-2	Squamous Cell Carcinoma, Tongue	20816961	disease of cellular proliferation	DOID:0050865	C02.9				miR-24:MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma
target gene	hsa-mir-26a	Squamous Cell Carcinoma, Tongue	26885901	disease of cellular proliferation	DOID:0050865	C02.9				Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior.
target gene	hsa-mir-29b	Squamous Cell Carcinoma, Tongue	26885901	disease of cellular proliferation	DOID:0050865	C02.9				Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior.
target gene	hsa-mir-33a	Squamous Cell Carcinoma, Tongue	29804249	disease of cellular proliferation	DOID:0050865	C02.9				Long non-coding RNA CASC15 promotes tongue squamous carcinoma progression through targeting miR-33a-5p.
target gene	hsa-mir-34a	Squamous Cell Carcinoma, Tongue	26885901	disease of cellular proliferation	DOID:0050865	C02.9				Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior.
target gene	hsa-mir-373	Squamous Cell Carcinoma, Tongue	28337453	disease of cellular proliferation	DOID:0050865	C02.9				miR-373-3p Targets DKK1 to Promote EMT-Induced Metastasis via the Wnt/β-Catenin Pathway in Tongue Squamous Cell Carcinoma.
target gene	hsa-mir-375	Squamous Cell Carcinoma, Tongue	26885901	disease of cellular proliferation	DOID:0050865	C02.9				Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior.
target gene	hsa-mir-483	Squamous Cell Carcinoma, Tongue	25843291	disease of cellular proliferation	DOID:0050865	C02.9				miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1.
target gene	hsa-mir-494	Squamous Cell Carcinoma, Tongue	25760063	disease of cellular proliferation	DOID:0050865	C02.9				a novel differential miRNA-mRNA expression network was constructed, and further investigation may provide novel targets for the diagnosis of TSCC.
target gene	hsa-mir-96	Squamous Cell Carcinoma, Tongue	25760063	disease of cellular proliferation	DOID:0050865	C02.9				a novel differential miRNA-mRNA expression network was constructed, and further investigation may provide novel targets for the diagnosis of TSCC.
target gene	hsa-mir-96	Squamous Cell Carcinoma, Tongue	26629033	disease of cellular proliferation	DOID:0050865	C02.9				MiR-96 is confirmed to be a direct target of MTSS1 gene and could regulate MTSS1 mediated Tca8113 cells proliferation and metastasis.
target gene	hsa-mir-103	Stroke	24954474			I64	D020521	601367	HP:0001297	MicroRNA-103-1 selectively downregulates brain NCX1 and its inhibition by anti-miRNA ameliorates stroke damage and neurological deficits.
target gene	hsa-mir-122	Stroke	29715465			I64	D020521	601367	HP:0001297	Up-regulation of miR-122 protects against neuronal cell death in ischemic stroke through the heat shock protein 70-dependent NF-κB pathway by targeting FOXO3.
target gene	hsa-mir-145	Stroke	29057271			I64	D020521	601367	HP:0001297	Overexpression of MicroRNA-145 Ameliorates Astrocyte Injury by Targeting Aquaporin 4 in Cerebral Ischemic Stroke
target gene	hsa-mir-146a	Stroke	28202285			I64	D020521	601367	HP:0001297	Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis.
target gene	hsa-mir-155	Stroke	25811992			I64	D020521	601367	HP:0001297	miR-155 mediates inflammatory responses in ischemic cerebral tissue by modulating TLR4/MyD88 and SOCS1 expression
target gene	hsa-mir-181a	Stroke	28522364			I64	D020521	601367	HP:0001297	Inhibition of miR-181a protects female mice from transient focal cerebral ischemia by targeting astrocyte estrogen receptor-α.
target gene	hsa-mir-126	Systemic Lupus Erythematosus	26531267	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miRNA-126 expression is reduced in SLE patients. miRNA-126 may be involved in the initiation and development of SLE by inhibiting the production of IFN.
target gene	hsa-mir-150	Systemic Lupus Erythematosus	27940256	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Enhanced expression of TREM-1 in splenic cDCs in lupus prone mice and it was modulated by miRNA-150.
target gene	hsa-mir-155	Systemic Lupus Erythematosus	25775145	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-α mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE.
target gene	hsa-mir-17	Systemic Lupus Erythematosus	26175399	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Targeting E2F1 and c-Myc expression by microRNA-17-5p represses interferon-stimulated gene MxA in peripheral blood mononuclear cells of pediatric systemic lupus erythematosus patients.
target gene	hsa-mir-17	Systemic Lupus Erythematosus	25775145	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-α mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE.
target gene	hsa-mir-181b	Systemic Lupus Erythematosus	25775145	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The results of the present study demonstrated for the first time that there is a differential expression and inverse correlation between the levels the miR-155, miR-17, and miR-181b and target molecules, AID and IFN-α mRNAs, in PBMCs of untreated SLE patients. These alterations may contribute to the pathogenesis of SLE.
target gene	hsa-mir-21	Systemic Lupus Erythematosus	21602271	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression.Upregulated miR-21 affects PDCD4 expression and regulates aberrant T cell responses in human SLE.
target gene	hsa-mir-30a	Systemic Lupus Erythematosus	23450709	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-30a promotes B cell hyperactivity in patient with SLE by direct interaction with LYN
target gene	hsa-mir-3148	Systemic Lupus Erythematosus	23468661	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus
target gene	hsa-mir-381	Systemic Mastocytosis	21273305	hematopoietic system disease	DOID:349	D47.2	D034721	154800		We found that miR-539 and miR-381 are downregulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3' UTR.
target gene	hsa-mir-539	Systemic Mastocytosis	21273305	hematopoietic system disease	DOID:349	D47.2	D034721	154800		We found that miR-539 and miR-381 are downregulated by KIT signaling and they repressed MITF expression through conserved miRNA binding sites in the MITF 3' UTR.
target gene	hsa-mir-199a	Testicular Germ Cell Tumor	25231260	disease of cellular proliferation	DOID:5557		C563236	273300		A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor.
target gene	hsa-mir-214	Testicular Germ Cell Tumor	25231260	disease of cellular proliferation	DOID:5557		C563236	273300		A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor.
target gene	hsa-mir-223	Testicular Germ Cell Tumor	28000896	disease of cellular proliferation	DOID:5557		C563236	273300		miR‑223‑3p regulates cell growth and apoptosis via FBXW7 suggesting an oncogenic role in human testicular germ cell tumors.
target gene	hsa-mir-372	Testicular Neoplasms	16564011	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.
target gene	hsa-mir-373	Testicular Neoplasms	16564011	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.
target gene	hsa-mir-155	Thrombocytopenia	25413124	hematopoietic system disease	DOID:1588	D69.6	D013921	313900	HP:0001873	miR-155 might be involved in the pathogenesis of ITP by regulating cytokine  profiles, which may be mediated by miR-155 targeting SOCS1.
target gene	hsa-mir-99a	Thrombocytopenia	26055579	hematopoietic system disease	DOID:1588	D69.6	D013921	313900	HP:0001873	We believe that miR-99a regulates CTDSPL, which induces the G1/Stransition by increasing Cyclin expression and play a significant role in proliferation of CB-MKs.
target gene	hsa-mir-1-1	Thyroid Neoplasms	21752897	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}
target gene	hsa-mir-1-2	Thyroid Neoplasms	21752897	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MiR-1 suppress Thyroid Cancer by Targeting CCND2, CXCR4, and SDF-1{alpha}
target gene	hsa-mir-142	Thyroid Neoplasms	25238203	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	These data demonstrate that miR-142-3p downregulation has a role in thyroid tumorigenesis, by regulating ASH1L and MLL1.
target gene	hsa-mir-144	Thyroid Neoplasms	24968735	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2.
target gene	hsa-mir-144	Thyroid Neoplasms	27099512	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), as one of the key inducers of epithelial-mesenchymal transition, has been reported to be regulated by microRNA-144 and Bcl-2-associated athanogene 3
target gene	hsa-mir-145	Thyroid Neoplasms	24781864	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3.
target gene	hsa-mir-146a	Thyroid Neoplasms	17012848	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation.
target gene	hsa-mir-146a	Thyroid Neoplasms	21159845	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Papillary Thyroid Carcinoma (PTC). Direct interaction with THRB was shown for miR-21 and miR-146a.
target gene	hsa-mir-146a	Thyroid Neoplasms	23457043	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development
target gene	hsa-mir-146b	Thyroid Neoplasms	17012848	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation.
target gene	hsa-mir-146b	Thyroid Neoplasms	21874046	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer.
target gene	hsa-mir-150	Thyroid Neoplasms	29023429	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MiR-150 Inhibits Cell Growth In Vitro and In Vivo by Restraining the RAB11A/WNT/β-Catenin Pathway in Thyroid Cancer.
target gene	hsa-mir-181a	Thyroid Neoplasms	29271997	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MiR-181a promotes growth of thyroid cancer cells by targeting tumor suppressor RB1
target gene	hsa-mir-191	Thyroid Neoplasms	21956418	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-191 Down-Regulation Plays a Role in Thyroid Follicular Tumors through CDK6 Targeting.
target gene	hsa-mir-19a	Thyroid Neoplasms	23998804	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	High iodine abrogates BRAF(V600E)-induced activation of miR-19, a newly identified Smad4 regulator, through Notch pathway inhibition and restores responsiveness to TGFβ signaling.
target gene	hsa-mir-200a	Thyroid Neoplasms	22797360	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells.
target gene	hsa-mir-200b	Thyroid Neoplasms	22797360	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells.
target gene	hsa-mir-200c	Thyroid Neoplasms	22797360	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells.
target gene	hsa-mir-21	Thyroid Neoplasms	21159845	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Papillary Thyroid Carcinoma (PTC). Direct interaction with THRB was shown for miR-21 and miR-146a.
target gene	hsa-mir-218-2	Thyroid Neoplasms	23720784	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer.
target gene	hsa-mir-22	Thyroid Neoplasms	17012848	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation.
target gene	hsa-mir-221	Thyroid Neoplasms	17012848	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Mir-221, mir-22 and mir-146 are significantly upregulated in this disease, whereas the expression of their predicted target gene KIT is lost, concurrently with the miRNA upregulation.
target gene	hsa-mir-25	Thyroid Neoplasms	22399519	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2.
target gene	hsa-mir-29b	Thyroid Neoplasms	27125250	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Functional assays confirmed PATZ1 as a target of miR-29b
target gene	hsa-mir-302b	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Genetically PTC is defined by several alterations which cause abnormal activation of the mitogen-activated protein kinase (MAPK) pathway, the most prevalent being point mutations in the intracellular signalling kinase BRAF. Of particular interest in this study is the downregulation of miR-323 and miR-302b in BRAF mutated cell line. miRBASE target database predicted that the BRAF transcript has binding sites for miR-323 and miR-302b to potentially bind and down- regulate BRAF expression.
target gene	hsa-mir-30d	Thyroid Neoplasms	22399519	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2.
target gene	hsa-mir-323a	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Genetically PTC is defined by several alterations which cause abnormal activation of the mitogen-activated protein kinase (MAPK) pathway, the most prevalent being point mutations in the intracellular signalling kinase BRAF. Of particular interest in this study is the downregulation of miR-323 and miR-302b in BRAF mutated cell line. miRBASE target database predicted that the BRAF transcript has binding sites for miR-323 and miR-302b to potentially bind and down- regulate BRAF expression.
target gene	hsa-mir-539	Thyroid Neoplasms	26206083	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1.
target gene	hsa-mir-146a	Thyroid-Associated Ophthalmopathy	28485799				D049970			Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB.
target gene	hsa-mir-15b	Tongue Neoplasms	21725369	gastrointestinal system disease	DOID:8649	C01	D014062		HP:0100648	MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.
target gene	hsa-mir-200b	Tongue Neoplasms	21725369	gastrointestinal system disease	DOID:8649	C01	D014062		HP:0100648	MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.
target gene	hsa-mir-491	Tongue Neoplasms	25749387	gastrointestinal system disease	DOID:8649	C01	D014062		HP:0100648	The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer.
target gene	hsa-mir-639	Tongue Neoplasms	25130698	gastrointestinal system disease	DOID:8649	C01	D014062		HP:0100648	miR-639 regulates transforming growth factor beta-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting FOXC1.
target gene	hsa-mir-155	Tuberculosis	26324048	disease by infectious agent	DOID:399	A15-A19	D014376			From these results, it was concluded that mycobacteria can improve the level of miR-155, while BCG can induce apoptosis in THP-1 cells. The results suggested FOXO3 is a downstream target gene of miR-155, which combines 3'-UTRs to inhibit the expression of FOXO3.
target gene	hsa-mir-20a	Tuberculosis	27803889	disease by infectious agent	DOID:399	A15-A19	D014376			microRNA-20a Inhibits Autophagic Process by Targeting ATG7 and ATG16L1 and Favors Mycobacterial Survival in Macrophage Cells.
target gene	hsa-mir-223	Tuberculosis	24084739	disease by infectious agent	DOID:399	A15-A19	D014376			Our study not only reveals an essential role for a single miRNA in TB, it also identifies new targets for, and assigns biological functions to, miR-223. By regulating leukocyte chemotaxis via chemoattractants, miR-223 is critical for the control of TB and potentially other chronic inflammatory diseases.
target gene	hsa-mir-223	Tuberculosis	26296289	disease by infectious agent	DOID:399	A15-A19	D014376			It is concluded that miR-223 can regulate macrophage function by inhibition of cytokine production and NF-κB activation.
target gene	hsa-mir-223	Tuberculosis	26505221	disease by infectious agent	DOID:399	A15-A19	D014376			Our data provide new clues for the essential role of miR-223 in the regulation of anti-Mtb-directed immune responses, which relies on the regulation of FOXO3 expression.
target gene	hsa-mir-29	Tuberculosis	24304957	disease by infectious agent	DOID:399	A15-A19	D014376			The expression of miR-29 family was increased and target gene IFN-γ in CD4(+) T cells was decreased by latent and active pulmonary TB, which might play important role in alteration of signal pathway.
target gene	hsa-mir-381	Tuberculosis	27296666	disease by infectious agent	DOID:399	A15-A19	D014376			inhibition of miR-381-3p could reverse suppression of CD1c expression and promote T cell responses against BCG infection.
target gene	hsa-mir-582	Tuberculosis	24205217	disease by infectious agent	DOID:399	A15-A19	D014376			miR-582-5p is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO1.
target gene	hsa-mir-124	Tuberculosis, Pulmonary	24705038	disease by infectious agent	DOID:2957	A15	D014397			Mycobacterium bovis BCG triggered MyD88 induces miR-124 feedback negatively regulates immune response in alveolar epithelial cells.
target gene	hsa-mir-29a	Tuberculosis, Pulmonary	23856141	disease by infectious agent	DOID:2957	A15	D014397			Level of miR-29a was increased significantly in serum of patients with active pulmonary tuberculosis. Target genes of miR-29a were mainly involved in biological processes including cell adhesion, regulation of transcription and so on.
target gene	hsa-mir-618	Tuberculosis, Pulmonary	23948412	disease by infectious agent	DOID:2957	A15	D014397			Level of miR-618 in both sputa and sera was significantly lower in the tuberculosis group than that in the control group and predicted target genes  of miR-618 were mainly involved in biological processes such as regulation of transcription and RNA metabolism.
target gene	hsa-mir-155	Unstable Angina	25760478	cardiovascular system disease	DOID:8805	I20.0	D000789			Upregulation of miR-155 in CD4(+) T Cells Promoted Th1 Bias in Patients With Unstable Angina.
target gene	hsa-mir-100	Urinary Bladder Cancer	23270926	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR
target gene	hsa-mir-100	Urinary Bladder Cancer	21636267	urinary system disease	DOID:11054	C67	D001749	109800		Reduced expression and had carcinogenic effect through targeting PLK1 protein.
target gene	hsa-mir-101-1	Urinary Bladder Cancer	19258506	urinary system disease	DOID:11054	C67	D001749	109800		miR-101: putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2
target gene	hsa-mir-101-2	Urinary Bladder Cancer	19258506	urinary system disease	DOID:11054	C67	D001749	109800		miR-101: putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2
target gene	hsa-mir-10a	Urinary Bladder Cancer	22634495	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells.
target gene	hsa-mir-1-1	Urinary Bladder Cancer	21304530	urinary system disease	DOID:11054	C67	D001749	109800		The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.
target gene	hsa-mir-1-1	Urinary Bladder Cancer	22178073	urinary system disease	DOID:11054	C67	D001749	109800		Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer.
target gene	hsa-mir-1-2	Urinary Bladder Cancer	21304530	urinary system disease	DOID:11054	C67	D001749	109800		The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.
target gene	hsa-mir-1-2	Urinary Bladder Cancer	22178073	urinary system disease	DOID:11054	C67	D001749	109800		Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer.
target gene	hsa-mir-125b-1	Urinary Bladder Cancer	23425975	urinary system disease	DOID:11054	C67	D001749	109800		microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer
target gene	hsa-mir-125b-1	Urinary Bladder Cancer	23160634	urinary system disease	DOID:11054	C67	D001749	109800		MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta
target gene	hsa-mir-125b-2	Urinary Bladder Cancer	23425975	urinary system disease	DOID:11054	C67	D001749	109800		microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer
target gene	hsa-mir-125b-2	Urinary Bladder Cancer	23160634	urinary system disease	DOID:11054	C67	D001749	109800		MiR-125b Inhibits Tumor Growth and Promotes Apoptosis of Cervical Cancer Cells by Targeting Phosphoinositide 3-Kinase Catalytic Subunit Delta
target gene	hsa-mir-1280	Urinary Bladder Cancer	23056431	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer
target gene	hsa-mir-133a-1	Urinary Bladder Cancer	21304530	urinary system disease	DOID:11054	C67	D001749	109800		The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.
target gene	hsa-mir-133a-1	Urinary Bladder Cancer	21396852	urinary system disease	DOID:11054	C67	D001749	109800		MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines.
target gene	hsa-mir-133a-1	Urinary Bladder Cancer	23206218	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer
target gene	hsa-mir-133a-2	Urinary Bladder Cancer	21304530	urinary system disease	DOID:11054	C67	D001749	109800		The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.
target gene	hsa-mir-133a-2	Urinary Bladder Cancer	23206218	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer
target gene	hsa-mir-133b	Urinary Bladder Cancer	23206218	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer
target gene	hsa-mir-143	Urinary Bladder Cancer	21790228	urinary system disease	DOID:11054	C67	D001749	109800		Expression of miR-143 Reduces Growth and Migration of Human Bladder Carcinoma Cells by Targeting Cyclooxygenase-2.
target gene	hsa-mir-143	Urinary Bladder Cancer	22108519	urinary system disease	DOID:11054	C67	D001749	109800		The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer.
target gene	hsa-mir-143	Urinary Bladder Cancer	23104321	urinary system disease	DOID:11054	C67	D001749	109800		Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways
target gene	hsa-mir-143	Urinary Bladder Cancer	22160209	urinary system disease	DOID:11054	C67	D001749	109800		miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2.
target gene	hsa-mir-145	Urinary Bladder Cancer	22108519	urinary system disease	DOID:11054	C67	D001749	109800		The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer.
target gene	hsa-mir-145	Urinary Bladder Cancer	23104321	urinary system disease	DOID:11054	C67	D001749	109800		Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways
target gene	hsa-mir-145	Urinary Bladder Cancer	23392170	urinary system disease	DOID:11054	C67	D001749	109800		socs7, a target gene of microRNA-145, regulates interferon-alpha induction through STAT3 nuclear translocation in bladder cancer cells
target gene	hsa-mir-17	Urinary Bladder Cancer	22730212	urinary system disease	DOID:11054	C67	D001749	109800		MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells.
target gene	hsa-mir-181a-1	Urinary Bladder Cancer	22847611	urinary system disease	DOID:11054	C67	D001749	109800		MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene.
target gene	hsa-mir-181a-2	Urinary Bladder Cancer	22847611	urinary system disease	DOID:11054	C67	D001749	109800		MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene.
target gene	hsa-mir-182	Urinary Bladder Cancer	23226455	urinary system disease	DOID:11054	C67	D001749	109800		Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer
target gene	hsa-mir-182	Urinary Bladder Cancer	23284967	urinary system disease	DOID:11054	C67	D001749	109800		Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells
target gene	hsa-mir-183	Urinary Bladder Cancer	23284967	urinary system disease	DOID:11054	C67	D001749	109800		Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells
target gene	hsa-mir-18a	Urinary Bladder Cancer	21935572	urinary system disease	DOID:11054	C67	D001749	109800		microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells.
target gene	hsa-mir-195	Urinary Bladder Cancer	22265971	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression.
target gene	hsa-mir-195	Urinary Bladder Cancer	22289176	urinary system disease	DOID:11054	C67	D001749	109800		Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells.
target gene	hsa-mir-199a-1	Urinary Bladder Cancer	21807947	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.
target gene	hsa-mir-199a-2	Urinary Bladder Cancer	21807947	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2.
target gene	hsa-mir-19a	Urinary Bladder Cancer	22561557	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5.
target gene	hsa-mir-19b-1	Urinary Bladder Cancer	22561557	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5.
target gene	hsa-mir-19b-2	Urinary Bladder Cancer	22561557	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5.
target gene	hsa-mir-200c	Urinary Bladder Cancer	23159064	urinary system disease	DOID:11054	C67	D001749	109800		Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2,9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells
target gene	hsa-mir-203	Urinary Bladder Cancer	21205209	urinary system disease	DOID:11054	C67	D001749	109800		microRNA-203 suppresses bladder cancer development by repressing bcl-w expression.
target gene	hsa-mir-20a	Urinary Bladder Cancer	22449978	urinary system disease	DOID:11054	C67	D001749	109800		miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells.
target gene	hsa-mir-21	Urinary Bladder Cancer	22001440	urinary system disease	DOID:11054	C67	D001749	109800		MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20.
target gene	hsa-mir-210	Urinary Bladder Cancer	23284967	urinary system disease	DOID:11054	C67	D001749	109800		Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells
target gene	hsa-mir-214	Urinary Bladder Cancer	21216304	urinary system disease	DOID:11054	C67	D001749	109800		Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa Cells.
target gene	hsa-mir-214	Urinary Bladder Cancer	22399294	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-214 Suppresses The Growth and Invasiveness of Cervical Cancer Cells by Targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7.
target gene	hsa-mir-302a	Urinary Bladder Cancer	23185040	urinary system disease	DOID:11054	C67	D001749	109800		The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1
target gene	hsa-mir-34a	Urinary Bladder Cancer	22684561	urinary system disease	DOID:11054	C67	D001749	109800		microRNA-34a inhibit cell migration and invasion of invasive urothelial bladder carcinoma by targeting Notch1.
target gene	hsa-mir-367	Urinary Bladder Cancer	23185040	urinary system disease	DOID:11054	C67	D001749	109800		The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1
target gene	hsa-mir-372	Urinary Bladder Cancer	21646351	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis.
target gene	hsa-mir-375	Urinary Bladder Cancer	21945323	urinary system disease	DOID:11054	C67	D001749	109800		miR-375, Down-Regulated in Squamous Cervical Cancer, Inhibits Cell Migration and Invasion via Targeting Transcription Factor SP1.
target gene	hsa-mir-449a	Urinary Bladder Cancer	22266187	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins.
target gene	hsa-mir-493	Urinary Bladder Cancer	22057916	urinary system disease	DOID:11054	C67	D001749	109800		Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by down-regulating RhoC and FZD4.
target gene	hsa-mir-494	Urinary Bladder Cancer	21859890	urinary system disease	DOID:11054	C67	D001749	109800		miR-494 Competitively regulates Nucleolin expression with HuR.
target gene	hsa-mir-497	Urinary Bladder Cancer	23453369	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor
target gene	hsa-mir-7-1	Urinary Bladder Cancer	23742934	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells.
target gene	hsa-mir-7-2	Urinary Bladder Cancer	23742934	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells.
target gene	hsa-mir-7-3	Urinary Bladder Cancer	23742934	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells.
target gene	hsa-mir-96	Urinary Bladder Cancer	23284967	urinary system disease	DOID:11054	C67	D001749	109800		Synthetic miRNA-Mowers Targeting miR-183-96-182 Cluster or miR-210 Inhibit Growth and Migration and Induce Apoptosis in Bladder Cancer Cells
target gene	hsa-mir-96	Urinary Bladder Cancer	23741253	urinary system disease	DOID:11054	C67	D001749	109800		miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer.
target gene	hsa-mir-197	Uterine Leiomyoma	25990270			D25.9	D007889	150699	HP:0000131	Upregulation of miR-197 inhibits cell proliferation by directly targeting IGFBP5 in human uterine leiomyoma cells.
target gene	hsa-mir-29c	Uterine Leiomyoma	26453978			D25.9	D007889	150699	HP:0000131	MiR-29c expression is suppressed in leiomyoma, resulting in an increase in expression of its targets COL3A1 and DNMT3A. The suppression of miR-29c in LSMC is primarily mediated by SP1, NF-κB signaling, and epigenetic modification. Collectively, these results indicate a significant role for miR-29c in leiomyoma pathogenesis.
target gene	hsa-mir-15a	Varicocele	24481955	cardiovascular system disease	DOID:12337	I86.1	D014646			Expressions of miR-15a and its target gene HSPA1B in the spermatozoa of patients  with varicocele.
target gene	hsa-mir-142	Vascular Disease [unspecific]	25832008	cardiovascular system disease	DOID:178	I72.9	D000783			this study demonstrates that miR-142-3p is a key regulator of the TGFβ-mediated contractile phenotype of VSMCs that acts through inhibiting cell migration through targeting DOCK6.
target gene	hsa-mir-145	Vascular Disease [unspecific]	19690387	cardiovascular system disease	DOID:178	I72.9	D000783			MicroRNA-modulated targeting of vascular smooth muscle cells
target gene	hsa-mir-145	Vascular Disease [unspecific]	24848371	cardiovascular system disease	DOID:178	I72.9	D000783			Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype.
target gene	hsa-mir-146a	Vascular Disease [unspecific]	27908889	cardiovascular system disease	DOID:178	I72.9	D000783			MicroRNA-146a Induces Lineage-Negative Bone Marrow Cell Apoptosis and Senescence by Targeting Polo-Like Kinase 2 Expression.
target gene	hsa-mir-155	Vascular Disease [unspecific]	26012521	cardiovascular system disease	DOID:178	I72.9	D000783			knockdown of miR155 could modulate ROS production, NO generation, apoptosis and function of HBMECs via regulating diverse gene expression, such as caspase-3, ICAM-1 and EGFR/ERK/p38 MAPK and PI3K/Akt pathways.
target gene	hsa-mir-17	Vascular Disease [unspecific]	19690387	cardiovascular system disease	DOID:178	I72.9	D000783			miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells
target gene	hsa-mir-18a	Vascular Disease [unspecific]	19690387	cardiovascular system disease	DOID:178	I72.9	D000783			miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells
target gene	hsa-mir-19a	Vascular Disease [unspecific]	19690387	cardiovascular system disease	DOID:178	I72.9	D000783			miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells
target gene	hsa-mir-20a	Vascular Disease [unspecific]	19690387	cardiovascular system disease	DOID:178	I72.9	D000783			miR-17-92 and miR-17-5p/miR-20a; MicroRNA-modulated targeting of vascular smooth muscle cells
target gene	hsa-mir-22	Vascular Disease [unspecific]	27325558	cardiovascular system disease	DOID:178	I72.9	D000783			miR-22-3p, had its binding site on the 3' UTR of VASH1 mRNA
target gene	hsa-mir-221	Vascular Disease [unspecific]	19088079	cardiovascular system disease	DOID:178	I72.9	D000783			Our study demonstrates that PDGF signaling, by modulating the expression of miR-221, regulates two critical determinants of the vSMC phenotype; they are SMC gene expression and cell proliferation.
target gene	hsa-mir-221	Vascular Disease [unspecific]	18550634	cardiovascular system disease	DOID:178	I72.9	D000783			In contrast, miR-221 and miR-222 inhibit endothelial cell migration, proliferation, and angiogenesis in vitro by targeting the stem cell factor receptor c-kit and indirectly regulating endothelial nitric oxide synthase expression.
target gene	hsa-mir-222	Vascular Disease [unspecific]	18550634	cardiovascular system disease	DOID:178	I72.9	D000783			In contrast, miR-221 and miR-222 inhibit endothelial cell migration, proliferation, and angiogenesis in vitro by targeting the stem cell factor receptor c-kit and indirectly regulating endothelial nitric oxide synthase expression.
target gene	hsa-mir-663	Vascular Disease [unspecific]	24014830	cardiovascular system disease	DOID:178	I72.9	D000783			targeting miR-663 or its specific downstream targets in human VSMCs may represent an attractive approach for the treatment of proliferative vascular diseases.
target gene	hsa-mir-106b	Vascular Disease [unspecific]	26013412	cardiovascular system disease	DOID:178	I72.9	D000783			The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases.
target gene	hsa-mir-16	Vascular Disease [unspecific]	26013412	cardiovascular system disease	DOID:178	I72.9	D000783			The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases.
target gene	hsa-mir-221	Vascular Disease [unspecific]	18068232	cardiovascular system disease	DOID:178	I72.9	D000783			miR-221 and miR-222 block endothelial cell migration, proliferation and angiogenesis in vitro by targeting  the stem cell factor receptor c-Kit and indirectly regulating expression of endothelial nitric oxide synthase.
target gene	hsa-mir-222	Vascular Disease [unspecific]	18068232	cardiovascular system disease	DOID:178	I72.9	D000783			miR-221 and miR-222 block endothelial cell migration, proliferation and angiogenesis in vitro by targeting  the stem cell factor receptor c-Kit and indirectly regulating expression of endothelial nitric oxide synthase.
target gene	hsa-mir-23a	Vascular Disease [unspecific]	22038739	cardiovascular system disease	DOID:178	I72.9	D000783			Our results suggest that miR-23a may be involved in TNF-α-induced endothelial cell apoptosis through regulation of the caspase-7 and serine/threonine kinase 4-caspase-3 pathways.
target gene	hsa-mir-28	Vascular Disease [unspecific]	26013412	cardiovascular system disease	DOID:178	I72.9	D000783			The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases.
target gene	hsa-mir-376a	Vascular Disease [unspecific]	26013412	cardiovascular system disease	DOID:178	I72.9	D000783			The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases.
target gene	hsa-mir-886	Vascular Disease [unspecific]	26013412	cardiovascular system disease	DOID:178	I72.9	D000783			The knowledge of molecular targets that change during the senescence can ultimately contribute to a better understanding and prevention of age-related vascular diseases.
target gene	hsa-let-7a	Vascular Hypertrophy	28123343							Let-7a Is an Antihypertrophic Regulator in the Heart via Targeting Calmodulin.
target gene	hsa-mir-1	Vascular Hypertrophy	23922949							In conclusion, miR-1 regulates Cx43 expression and activity in hypertrophic cardiomyocytes in vitro and in vivo.
target gene	hsa-mir-1	Vascular Hypertrophy	25995211							These experiments revealed the role of inducible cAMP early repressor as a repressor of miR-1 and Ito
target gene	hsa-mir-133a	Vascular Hypertrophy	24113045							MiR-133a can negatively regulate the expression of L-type calcium α1C subunit, resulting in the decrease of intracellular Ca(2+) content and the attenuation of ISO-induced cardiomyocyte hypertrophy.
target gene	hsa-mir-133a	Vascular Hypertrophy	26553694							Of 37 direct targets of miR-133a defined in unstressed hearts
target gene	hsa-mir-133a	Vascular Hypertrophy	28795305							microRNA-133a attenuates cardiomyocyte hypertrophy by targeting PKCδ and Gq.
target gene	hsa-mir-200c	Vascular Hypertrophy	23020145							Increased miR-21 and miR-200c contents were associated with reduced expression of their targets, Sprouty-1 and ZEB2, respectively.
target gene	hsa-mir-206	Vascular Hypertrophy	24023888							we show that inhibition of the established pro-myogenic regulator miR-206 can promote hypertrophy and increased protein synthesis in post-mitotic cells of the myogenic lineage.
target gene	hsa-mir-206	Vascular Hypertrophy	28114137							MiR-206 affected the process of cardiomyocytes hypertrophy by regulating histone deacetylase 4 (HDAC4)
target gene	hsa-mir-21	Vascular Hypertrophy	23020145							Increased miR-21 and miR-200c contents were associated with reduced expression of their targets, Sprouty-1 and ZEB2, respectively.
target gene	hsa-mir-1283	Vascular Injuries	27537404				D057772			miRNA-1283 Regulates the PERK/ATF4 Pathway in Vascular Injury by Targeting ATF4.
target gene	hsa-mir-145	Vascular Injuries	20841497				D057772			In addition, specific miRNAs such as miR-145, miR-21, and miR-221 have been found to regulate neointimal hyperplasia following vascular injury, which provides interesting possibilities for future herapeutical targets against vascular disease.
target gene	hsa-mir-124	Viral Infectious Disease	26865716	disease by infectious agent	DOID:934	A94	D001102			Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform.
target gene	hsa-mir-125	Viral Infectious Disease	26865716	disease by infectious agent	DOID:934	A94	D001102			Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform.
target gene	hsa-mir-133	Viral Infectious Disease	26865716	disease by infectious agent	DOID:934	A94	D001102			Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform.
target gene	hsa-mir-138	Viral Infectious Disease	24721573	disease by infectious agent	DOID:934	A94	D001102			A neuron-specific host microRNA targets herpes simplex virus-1 ICP0 expression and promotes latency.
target gene	hsa-mir-142	Viral Infectious Disease	26865716	disease by infectious agent	DOID:934	A94	D001102			Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform.
target gene	hsa-mir-155	Viral Infectious Disease	23572582	disease by infectious agent	DOID:934	A94	D001102			NK cells constitutively expressing Noxa and SOCS1 exhibit profound defects in expansion during the response to MCMV infection, suggesting that their regulation by miR-155 promotes antiviral immunity.
target gene	hsa-mir-199a-1	Viral Infectious Disease	23760629	disease by infectious agent	DOID:934	A94	D001102			MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS.
target gene	hsa-mir-199a-2	Viral Infectious Disease	23760629	disease by infectious agent	DOID:934	A94	D001102			MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS.
target gene	hsa-mir-208	Viral Infectious Disease	26865716	disease by infectious agent	DOID:934	A94	D001102			Our data show that microRNA targeting can be used to further increase the safety of an attenuated mengovirus, providing a basis for its development as an oncolytic platform.
target gene	hsa-mir-26a	Viral Infectious Disease	25012295	disease by infectious agent	DOID:934	A94	D001102			EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells.
target gene	hsa-mir-29b	Viral Infectious Disease	25234643	disease by infectious agent	DOID:934	A94	D001102			Lentivirus-mediated Bos taurus bta-miR-29b overexpression interferes with bovine  viral diarrhoea virus replication and viral infection-related autophagy by directly targeting ATG14 and ATG9A in Madin-Darby bovine kidney cells.
target gene	hsa-mir-32	Viral Infectious Disease	17462786	disease by infectious agent	DOID:934	A94	D001102			This has been reported for the retrovirus primate foamy virus-1 (PFV-1), which can be targeted by the host miR-32 [150], which was suggested to restrict its infection.
target gene	hsa-mir-155	Viral Myocarditis	29136142			B33.2	D009205			The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis.
target gene	hsa-mir-20b	Viral Myocarditis	28247213			B33.2	D009205			MicroRNA-20b suppresses the expression of ZFP-148 in viral myocarditis.
target gene	hsa-mir-223	Viral Myocarditis	29524390			B33.2	D009205			the data suggest  that miR-223 protects against CVB3-induced inflammation and myocardial damage, which may partly attribute to the regulation of macrophage polarization via targeting Pknox1
target gene	hsa-mir-3147	Vulvar Squamous Cell Carcinoma	29512734	disease of cellular proliferation	DOID:2101					miR‑3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression.
target gene	hsa-mir-155	Wound Healing	28247149				D014945		HP:0001058	miR-155 promotes cutaneous wound healing through enhanced keratinocytes migration by MMP-2.
target gene	hsa-mir-21	Wound Healing	27735045				D014945		HP:0001058	microRNA-21 mediates the TGF-β1-induced migration of keratinocytes via targeting PTEN.
target gene	hsa-mir-205	Wounds and Injuries [unspecific]	23950153				D014947			miR-205 stimulates wound healing by inhibiting its target gene KCNJ10.
target gene	hsa-mir-21	Wounds and Injuries [unspecific]	23159215				D014947			miR-21 regulates skin wound healing by targeting multiple aspects of the healing process
target gene	hsa-mir-34	Wounds and Injuries [unspecific]	25978377				D014947			our results provide compelling evidence supporting the existence of 106 novel miRNAs and the dynamic expression of miRNAs that extensively targets the TGF-β pathway at different gestational ages in fetal KCs.MiRNAs showing altered expression at different gestational ages in fetal KCs may contribute to scarless wound healing in early- to mid-gestational fetal Keratinocytes (KCs), and thus may be new targets for potential scar prevention and reduction therapies.
therapeutic target	hsa-mir-155	Acute Coronary Syndrome	25319951			I24.9	D054058			Our study suggests that high loading dose rosuvastatin pretreatment may reduce the incidence of cardiovascular events and levels of inflammatory markers in patients with ACS receiving PCI, which may be explained at least in part, by mechanism involving suppression of miR-155/SHIP-1 signaling pathway.
therapeutic target	hsa-mir-23a	Acute Erythroid Leukemia	27086927			C94.0	D004915			indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment.
therapeutic target	hsa-mir-24	Acute Erythroid Leukemia	27086927			C94.0	D004915			indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment.
therapeutic target	hsa-mir-27a	Acute Erythroid Leukemia	27086927			C94.0	D004915			indicating the therapeutic significance of miR-23a, -27a and -24 for AEL treatment.
therapeutic target	hsa-mir-124	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-125	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-218	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-22	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-23	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-30	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-33	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-330	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-9	Acute Ischemic Stroke	26459744	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	The confirmed miRNA-targeted genes identified serve as potential therapeutic targets for acute ischemic stroke.
therapeutic target	hsa-mir-4262	Acute Lung Injury	26356266			S27	D055371			ACE2-induced suppression of miR-4262 partially contribute to the inhibition of the PEC apoptosis after ALI through Bcl-2. MiR-4262 may be a novel promising treatment target for ALI and ARDS.
therapeutic target	hsa-mir-210	Acute Myocardial Infarction	27392480	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	HAR could reduce the infarction area, alleviate the interstitial fibrosis and improve the cardiac function of AMI rats. Those effects could be related to promoting myocardium angiogenesis of HAR by up-regulating miR-210 and  VEGF.
therapeutic target	hsa-mir-203	Adenocarcinoma, Colon	23285092	disease of cellular proliferation	DOID:234	C18			HP:0040276	in situ hybridization showed that miR-203 expression is attenuated in colon tumour tissues compared to normal colon tissues, suggesting that miR-203 could be a potential new prognostic marker and therapeutic target to explore in colon cancer. 
therapeutic target	hsa-mir-1201	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-149	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-203	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-22	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-224	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-23b	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-27b	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-452	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-671	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-944	Adenocarcinoma, Esophageal	25631748	disease of cellular proliferation	DOID:4914		C562730	133239		The exosomal onco-miRs identified seem to play a major role and may be applied for noninvasive diagnosis and therapy monitoring of adenocarcinoma of the esophagus.
therapeutic target	hsa-mir-100	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-106a	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-125b	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-127	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-145	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-15a	Adenocarcinoma, Gastric	25743273	disease of cellular proliferation	DOID:3717	D37.1	D013274			In conclusion, targeting YAP1 by tumor suppressor miRNA miR-15a and miR-16-1 plays inhibitory effect and this might have a therapeutic potential in GAC.
therapeutic target	hsa-mir-16-1	Adenocarcinoma, Gastric	25743273	disease of cellular proliferation	DOID:3717	D37.1	D013274			In conclusion, targeting YAP1 by tumor suppressor miRNA miR-15a and miR-16-1 plays inhibitory effect and this might have a therapeutic potential in GAC.
therapeutic target	hsa-mir-17	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-193a	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-20a	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-20b	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-381	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-455	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-483	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-601	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-671	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-92a	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-mir-96	Adenocarcinoma, Gastric	26460735	disease of cellular proliferation	DOID:3717	D37.1	D013274			these results develop a comprehensive expression and functional profile of differentially expressed miRNAs related to gastric oncogenesis. This profile may serve as a potential tool for biomarker and therapeutic target identification in GC patients.
therapeutic target	hsa-let-7g	Adenocarcinoma, Lung	24441398	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.
therapeutic target	hsa-mir-106a	Adenocarcinoma, Lung	24743967	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes.
therapeutic target	hsa-mir-106b	Adenocarcinoma, Lung	24743967	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes.
therapeutic target	hsa-mir-132	Adenocarcinoma, Lung	24743967	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes.
therapeutic target	hsa-mir-145	Adenocarcinoma, Lung	26687391	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
therapeutic target	hsa-mir-17	Adenocarcinoma, Lung	24743967	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes.
therapeutic target	hsa-mir-192	Adenocarcinoma, Lung	24743967	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes.
therapeutic target	hsa-mir-200	Adenocarcinoma, Lung	26395571	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	BMP4 functions as a pro-tumorigenic factor in a murine lung cancer model, and its transcription is regulated by miR-200 and GATA4/6. Thus, we propose that BMP4 and its antagonists may be suitable therapeutic targets for the treatment of lung cancer.
therapeutic target	hsa-mir-204	Adenocarcinoma, Lung	29281186	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Clinically, the miR-204/JAK2/STAT3 signaling pathway is a putative therapeutic target in lung adenocarcinoma
therapeutic target	hsa-mir-210	Adenocarcinoma, Lung	26687391	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
therapeutic target	hsa-mir-25	Adenocarcinoma, Lung	26687391	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
therapeutic target	hsa-mir-33b	Adenocarcinoma, Lung	26459797	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	In conclusion, the present study provided novel insight into the molecular mechanism of lung adenocarcinoma progression. MicroRNA-33b should be further investigated as a potential therapeutic target in human lung adenocarcinoma.
therapeutic target	hsa-mir-100	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-106a	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets
therapeutic target	hsa-mir-10a	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets
therapeutic target	hsa-mir-10b	Adenocarcinoma, Pancreatic Ductal	21816909	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		microRNA-10b (miR-10b) expression in pancreatic ductal adenocarcinoma (PDAC), as identified by in situ hybridization, is highly correlated with cancer diagnosis, therapy response, and prognosis.
therapeutic target	hsa-mir-124	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets
therapeutic target	hsa-mir-125b	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-138	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-143	Adenocarcinoma, Pancreatic Ductal	26554910	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability.
therapeutic target	hsa-mir-145	Adenocarcinoma, Pancreatic Ductal	26554910	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability.
therapeutic target	hsa-mir-148a	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets
therapeutic target	hsa-mir-155	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets
therapeutic target	hsa-mir-194	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets
therapeutic target	hsa-mir-200b	Adenocarcinoma, Pancreatic Ductal	26345967	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our study screened out some target miRNAs and mRNAs for pancreatic ductal adenocarcinoma, which may be helpful in its diagnosis and treatment.
therapeutic target	hsa-mir-200b	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets
therapeutic target	hsa-mir-200c	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	25591761	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-21/FoxO1 axis as a novel therapeutic target for inhibiting the growth of PDAC.
therapeutic target	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	25623117	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-21/FoxO1 axis appears to be a novel therapeutic target for inhibiting the growth of PDAC.
therapeutic target	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-210	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-221	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-222	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-224	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-23a	Adenocarcinoma, Pancreatic Ductal	25701323	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		It is suggested that miR-23a, acting as an oncogenic regulator by directly targeting APAF 1 in pancreatic cancer, is a useful potential biomarker in diagnosis and treatment of pancreatic cancer.
therapeutic target	hsa-mir-27a	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-31	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-330	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-34	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-367	Adenocarcinoma, Pancreatic Ductal	25867271	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The present study identified and characterised a signalling pathway,the miR-367/Smad7-TGF-β pathway, which is involved in the invasion and metastasis of pancreatic cancer cells. Our results suggest that miR-367 may be a promising therapeutic target for the treatment of human pancreatic cancer.
therapeutic target	hsa-mir-367	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-378	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-429	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-486	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-494	Adenocarcinoma, Pancreatic Ductal	24859161	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Loss of SMAD4 in PDAC cells leads to reduced levels of miR-494,increased levels of FOXM1, and nuclear localization of β-catenin. miR-494 might be developed as a prognostic marker for patients with PDAC or a therapeutic target.
therapeutic target	hsa-mir-615	Adenocarcinoma, Pancreatic Ductal	25856297	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		These results show that miR-615-5p inhibits pancreatic cancer cell proliferation, migration, and invasion by targeting AKT2. The data implicate miR-615-5p in the prognosis and treatment of PDAC.
therapeutic target	hsa-mir-615	Adenocarcinoma, Pancreatic Ductal	26259238	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic target
therapeutic target	hsa-mir-96	Adenocarcinoma, Pancreatic Ductal	26554910	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miRNA expression profiles should be investigated to evaluate the potential function as biomarkers for early diagnosis, disease progression, response to therapy, and prognosis because of their characteristics of high stability, tissue specificity and ease of availability.
therapeutic target	hsa-mir-99a	Adenocarcinoma, Pancreatic Ductal	26606261	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Consistent miR expression profiles, in part regulated by mutant TP53 gene, were identified in gemcitabine-resistant PDAC with significant MRP-1 and Bcl-2 overexpression. These results provide a basis for further elucidation of chemoresistance mechanisms and therapeutic approaches to overcome chemoresistance in PDAC.
therapeutic target	hsa-mir-328	Adenovirus Infection	21098446			B34.0	D000257			The study therefore uncovered a novel molecular mechanism for AF and indicated miR-328 as a potential therapeutic target for AF.
therapeutic target	hsa-mir-93	Age-Related Macular Degeneration	27349759	nervous system disease	DOID:10871	H35.30	D008268	PS603075		these results highlight the therapeutic potential of miR-93
therapeutic target	hsa-mir-122	Alcoholic Hepatitis	26264599	endocrine system disease	DOID:12351	K70.1	D006519			Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH.
therapeutic target	hsa-mir-1246	Alcoholic Hepatitis	26264599	endocrine system disease	DOID:12351	K70.1	D006519			Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH.
therapeutic target	hsa-mir-130a	Alcoholic Hepatitis	26264599	endocrine system disease	DOID:12351	K70.1	D006519			Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH.
therapeutic target	hsa-mir-192	Alcoholic Hepatitis	26264599	endocrine system disease	DOID:12351	K70.1	D006519			Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH.
therapeutic target	hsa-mir-212	Alcoholic Hepatitis	26207424	endocrine system disease	DOID:12351	K70.1	D006519			These studies thus support a novel miR-212 mechanism for alcohol-induced gut leakiness and a potential target that could be exploited for therapeutic intervention to prevent leaky gut and liver injury in alcoholics.
therapeutic target	hsa-mir-30a	Alcoholic Hepatitis	26264599	endocrine system disease	DOID:12351	K70.1	D006519			Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH.
therapeutic target	hsa-mir-30b	Alcoholic Hepatitis	26264599	endocrine system disease	DOID:12351	K70.1	D006519			Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH.
therapeutic target	hsa-mir-744	Alcoholic Hepatitis	26264599	endocrine system disease	DOID:12351	K70.1	D006519			Elevated level of EVs/exosomes and exosome-associated miRNA signature could serve as potential diagnostic markers for AH. In addition to the biomarker diagnostic capabilities, these findings may facilitate development of novel strategies for diagnostics, monitoring, and therapeutics of AH.
therapeutic target	hsa-mir-155	Allergic Asthma	27783037	immune system disease	DOID:9415	J45.909	C564133	600807		miR-155: A Novel Target in Allergic Asthma.
therapeutic target	hsa-mir-146a	Allergic Rhinitis	26700406	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	miR-146a can enforce OVA-specific immunotherapy via inducing antigen-specific regulatory T cells. miR-146a may have therapeutic potential to be used in the immunotherapy of allergic diseases.
therapeutic target	hsa-mir-146a	Allergy	26663191	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions.
therapeutic target	hsa-mir-155	Allergy	26663191	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions.
therapeutic target	hsa-mir-21	Allergy	26663191	immune system disease	DOID:1205	T78.40	D006967		HP:0012393	Further characterization of microRNA functions is important, as similar to other conditions, the modulation of microRNA expression could potentially be used for therapeutic purposes in allergic diseases in the future. In addition, miRNAs could be implemented as biomarkers for endotyping complex allergic conditions.
therapeutic target	hsa-mir-575	Alopecia	25955790	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	these results indicated that ROS-mediated cellular damage was inhibited by troxerutin and suggested that the use of troxerutin may be an effective approach in the treatment of alopecia.
therapeutic target	hsa-mir-602	Alopecia	25955790	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	these results indicated that ROS-mediated cellular damage was inhibited by troxerutin and suggested that the use of troxerutin may be an effective approach in the treatment of alopecia.
therapeutic target	hsa-let-7d	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-let-7g	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-101	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-125b	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-132	Alzheimer Disease	26362250	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	These findings support a role for miR-132/212 in the regulation of tau pathology in mice and humans and provide new alternatives for therapeutic development.
therapeutic target	hsa-mir-137	Alzheimer Disease	21994399	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.
therapeutic target	hsa-mir-146a	Alzheimer Disease	20937840	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The combinatorial use of NF-κB inhibitors with miRNA-146a or antisense miRNA-146a may have potential as a bi-pronged therapeutic strategy directed against IRAK-2-driven pathogenic signaling.
therapeutic target	hsa-mir-155	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-15b	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-181c	Alzheimer Disease	21994399	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.
therapeutic target	hsa-mir-191	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-206	Alzheimer Disease	28123152	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-206-3p is involved in the anti-dementia effects  of donepezil, and could be a novel pharmacological target for treating AD
therapeutic target	hsa-mir-212	Alzheimer Disease	26362250	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	These findings support a role for miR-132/212 in the regulation of tau pathology in mice and humans and provide new alternatives for therapeutic development.
therapeutic target	hsa-mir-26b	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-29a	Alzheimer Disease	21994399	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.
therapeutic target	hsa-mir-29b	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-29b-1	Alzheimer Disease	21994399	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.
therapeutic target	hsa-mir-29c	Alzheimer Disease	25815896	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	the present study suggested that miR-29c may be a promising potential therapeutic target in the treatment of AD.
therapeutic target	hsa-mir-29c	Alzheimer Disease	25955795	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results demonstrated that the upregulation of miR-29c promoted learning and memory behaviors in SAMP8 mice, at least partially, by increasing the activity of protein kinase A/cAMP response element-binding protein, involved in neuroprotection. This evidence suggested that miR-29c may be a promising potential therapeutic target against AD.
therapeutic target	hsa-mir-33	Alzheimer Disease	26538644	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	we demonstrate that inhibition of microRNA-33 increases lipidation of brain ApoE and reduces Aβ levels by inducing ABCA1. We provide a unique approach for AD therapeutics to increase ApoE lipidation and reduce Aβ levels via pharmacological inhibition of microRNA in vivo.
therapeutic target	hsa-mir-342	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-34a	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-9	Alzheimer Disease	29543360	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The potential functions of these miRNAs as diagnostic and therapeutic targets of the AD were revealed by this study
therapeutic target	hsa-mir-9-1	Alzheimer Disease	21994399	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.
therapeutic target	hsa-mir-9-2	Alzheimer Disease	21994399	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.
therapeutic target	hsa-mir-9-3	Alzheimer Disease	21994399	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Abeta levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.
therapeutic target	hsa-mir-937	Alzheimer Disease	26316079	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Overexpression of as-miR-937 in MSCs may substantially improve the therapeutic effects of MSCs on AD, possibly through augmenting Brn-4 levels in MSCs.
therapeutic target	hsa-mir-141	Amyotrophic Lateral Sclerosis	25004804	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	Our results reveal a possible correlation between deregulation of this regulatory circuit and ALS pathogenesis, and open interesting perspectives in the treatment of these mutations through ad hoc-modified microRNAs.
therapeutic target	hsa-mir-200a	Amyotrophic Lateral Sclerosis	25004804	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	Our results reveal a possible correlation between deregulation of this regulatory circuit and ALS pathogenesis, and open interesting perspectives in the treatment of these mutations through ad hoc-modified microRNAs.
therapeutic target	hsa-mir-205	Aortic Aneurysm, Abdominal	24812324	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		miRNAs may be a novel therapeutic strategy to prevent AAA.
therapeutic target	hsa-mir-1	Arrhythmia	26671473			I49.9	D001145	600919	HP:0011675	We aim at emphasizing the relationship between miR-1 and ion channels and proteins involved in the process of arrhythmia. In addition, we will pay attention to its future therapeutic prospects.
therapeutic target	hsa-mir-1298	Arteriosclerosis Obliterans	26025955	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Our data demonstrate a specific role of the upstream DNA methylation/miR-1298/Cx43 pathway in regulating VSMC function and suggest that modulation of miR-1298 levels may offer a novel therapeutic approach for ASO.
therapeutic target	hsa-mir-133a	Arteriosclerosis Obliterans	25445891	cardiovascular system disease	DOID:5160		D001162		HP:0002634	miR-133a regulates the functions of HASMCs by targeting RhoA and may be involved in the pathogenesis of ASO. These findings may lead to the development of potential therapeutic targets for ASO of the lower extremities.
therapeutic target	hsa-mir-24	Arteriosclerosis Obliterans	26159387	cardiovascular system disease	DOID:5160		D001162		HP:0002634	The results suggest that miR-24-3p regulates the proliferation and migration of hsaMCs by targeting PDGFRB and c-Myc. The PDGF/miR-24-3p/PDGFRB and PDGF/miR-24-3p/c-Myc pathways may play critical roles in the pathogenesis of ASO.These findings highlight the potential for new therapeutic targets for ASO.
therapeutic target	hsa-mir-18a	Arteriovenous Malformation	24837588	disease of cellular proliferation	DOID:11294	I77.0	D001165	108010		Ago-2 facilitates miR-18a entry into brain endothelial cells in vitro and in vivo. This study highlights the clinical potential of Ago-2 as a miRNA delivery platform for the treatment of brain vascular diseases.
therapeutic target	hsa-mir-18a	Arteriovenous Malformation	24203843	disease of cellular proliferation	DOID:11294	I77.0	D001165	108010		We report VEGF-D overexpression in AVM and the capacity of miR-18a to induce AVM-BECs to function more normally. This highlights the clinical potential of microRNA as a treatment for AVM and other vascular diseases.
therapeutic target	hsa-mir-155	Arthritis	29354135	musculoskeletal system disease	DOID:848	M19.90	D001168			we review the evidence for the pathogenic role of miR-155 in driving aberrant activation of the immune system in rheumatoid arthritis, and its potential as a disease biomarker and therapeutic target
therapeutic target	hsa-mir-1	Asthma	24043765	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These experiments define a novel VEGF-miR-1-Mpl-P-selectin effector pathway in lung Th2 inflammation and herald the utility of miR-1 and Mpl as potential therapeutic targets for asthma.
therapeutic target	hsa-mir-1	Asthma	25961389	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Targeting of miRNA-1 and  miRNA-145 has been used to inhibit lung inflammation in mouse models of asthma.
therapeutic target	hsa-mir-122	Asthma	27485847	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases.
therapeutic target	hsa-mir-1260a	Asthma	26118177	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These results indicate that circulating miR-3162-3p and miR-1260a should be further evaluated as potential non-invasive biomarkers in diagnosis and treatment for childhood asthma.
therapeutic target	hsa-mir-155	Asthma	23967196	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Mechanical stretch modulates the homeostasis of the hBEC secretome involving miR-155 and that hMSCs can be used as a potential therapeutic approach to reverse bronchial epithelial inflammation in asthma.
therapeutic target	hsa-mir-21	Asthma	26874829	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	This study suggested that serum miRNA-21 is stable and detectable in serum of asthmatic children, which could promise potential biomarker in diagnosis as well as in response to therapy of asthma.
therapeutic target	hsa-mir-3162	Asthma	26118177	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These results indicate that circulating miR-3162-3p and miR-1260a should be further evaluated as potential non-invasive biomarkers in diagnosis and treatment for childhood asthma.
therapeutic target	hsa-mir-708	Asthma	26998837	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	These results demonstrate that miR-708 and miR-140-3p exert distinct effects on inflammation-associated gene expression and biological function of ASM cells. Targeting these miRNA networks may provide a novel therapeutic mechanism to down-regulate airway inflammation and ASM proliferation in asthma.
therapeutic target	hsa-mir-9	Asthma	25772595	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MiR-9 regulates GR signaling and steroid-resistant AHR. Targeting miR-9 function might be a novel approach for the treatment of steroid-resistant asthma.
therapeutic target	hsa-mir-146a	Astrocytoma	25873300	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	The current findings demonstrated that β2-AR signaling has growth inhibitory effects via modulation of the cAMP/PKA pathway in A-1321N1 cells through increasing the expression level of Cx43 and miR-146a as well as decreasing miR-155 and miR-27a levels. Thus, stimulation of the β2-AR and PKA signaling pathway may be a useful approach for astrocytoma therapy.
therapeutic target	hsa-mir-155	Astrocytoma	25873300	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	The current findings demonstrated that β2-AR signaling has growth inhibitory effects via modulation of the cAMP/PKA pathway in A-1321N1 cells through increasing the expression level of Cx43 and miR-146a as well as decreasing miR-155 and miR-27a levels. Thus, stimulation of the β2-AR and PKA signaling pathway may be a useful approach for astrocytoma therapy.
therapeutic target	hsa-mir-27a	Astrocytoma	25873300	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	The current findings demonstrated that β2-AR signaling has growth inhibitory effects via modulation of the cAMP/PKA pathway in A-1321N1 cells through increasing the expression level of Cx43 and miR-146a as well as decreasing miR-155 and miR-27a levels. Thus, stimulation of the β2-AR and PKA signaling pathway may be a useful approach for astrocytoma therapy.
therapeutic target	hsa-mir-542	Astrocytoma	26286747	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	These findings suggest that miR-542-3p acts as a negative regulator in astrocytoma progression and that miR-542-3p down-regulation contributes to aberrant activation of AKT signaling, leaving open the possibility that miR-542-3p may be a potential therapeutic target for high grade astrocytoma.
therapeutic target	hsa-mir-100	Atherosclerosis	29208678	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Our findings of miR-100 as a potential protective anti-athero-miR suggest that the therapeutic replacement of this microRNA could be a potential strategy for the treatment of chronic inflammatory diseases, such as atherosclerosis, in the future
therapeutic target	hsa-mir-107	Atherosclerosis	25522185	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Since chronodisruption has been linked to metabolic disorders such as type 2 diabetes, atherosclerosis, obesity, and CVD, our findings suggests that miR-107 could represent a new approach for pharmacological treatment of these diseases.
therapeutic target	hsa-mir-10a	Atherosclerosis	29459264	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	EC miR-10a induction by RARα/RXRα-specific agonists is a potential hemodynamics-based strategy for atherosclerosis treatment
therapeutic target	hsa-mir-10b	Atherosclerosis	25612666	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The modulation of miR-10b in VSMCs provides a potential target for the therapy of atherosclerosis.
therapeutic target	hsa-mir-126	Atherosclerosis	25450610	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	we will discuss novel aspects of miR-mediated regulatory mechanisms, namely the regulation by competing RNA targets, miRNA tandems, or complementary miR strand pairs, as well as their potential diagnostic and therapeutic value in atherosclerosis. This article is part of a Special Issue entitled 'Non-coding RNAs'.
therapeutic target	hsa-mir-127	Atherosclerosis	25411193	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases.
therapeutic target	hsa-mir-132	Atherosclerosis	24924687	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	SIRT1 mRNAs are direct targets of miR-132. miR-132 controls lipogenesis and cholesterogenesis in HUVECs by inhibiting SIRT1 and SREBP-1c expression and their downstream regulated genes, including FASN and HMGCR.Inhibition of SIRT1 by miR-132 was associated with lipid metabolism-dependent pro-inflammatory processes in HUVECs. The newly identified miRNA, miR-132 represents a novel targeting mechanism for AS therapy.
therapeutic target	hsa-mir-134	Atherosclerosis	26546816	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Collectively, our findings indicate that miR-134 may regulate lipid accumulation and proinfiammatory cytokine secretion in macrophages by targeting the ANGPTL4 gene. Our results have also suggested a promising and potential therapeutic target for atherosclerosis.
therapeutic target	hsa-mir-136	Atherosclerosis	25411193	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases.
therapeutic target	hsa-mir-144	Atherosclerosis	24733347	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Our findings clearly indicate that miR-144-3p is essential for the regulation of cholesterol homeostasis and inflammatory reactions, supporting its utility as a potential therapeutic target of atherosclerosis and a promising diagnostic biomarker of AMI.
therapeutic target	hsa-mir-145	Atherosclerosis	22965997	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	VSMC-specific overexpression of microRNA-145 is a novel in vivo therapeutic target to limit atherosclerotic plaque morphology and cellular composition, shifting the balance toward plaque stability vs plaque rupture.
therapeutic target	hsa-mir-146a	Atherosclerosis	21511256	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Finding important factors that regulate endothelial cell senescence, like miR-146a, will help provide novel therapeutic strategies for vascular disorders.
therapeutic target	hsa-mir-146a	Atherosclerosis	26956647	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	delivery of microRNA (miR)-146a and miR-181b with an E-selectin-targeting multistage vector (ESTA-MSV) to inflamed endothelium covering atherosclerotic plaques inhibits atherosclerosis
therapeutic target	hsa-mir-155	Atherosclerosis	24675724	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Our findings reveal a new regulatory pathway of YY1/HDACs/miR-155/HBP1 in macrophage-derived foam cell formation during early atherogenesis and suggest that miR-155 is a potential therapeutic target for atherosclerosis.
therapeutic target	hsa-mir-155	Atherosclerosis	25450610	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	we will discuss novel aspects of miR-mediated regulatory mechanisms, namely the regulation by competing RNA targets, miRNA tandems, or complementary miR strand pairs, as well as their potential diagnostic and therapeutic value in atherosclerosis. This article is part of a Special Issue entitled 'Non-coding RNAs'.
therapeutic target	hsa-mir-181b	Atherosclerosis	26956647	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	delivery of microRNA (miR)-146a and miR-181b with an E-selectin-targeting multistage vector (ESTA-MSV) to inflamed endothelium covering atherosclerotic plaques inhibits atherosclerosis
therapeutic target	hsa-mir-21	Atherosclerosis	25755729	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	These findings  may help the development of strategies to enhance the vitality of EPCs for therapeutic applications.
therapeutic target	hsa-mir-21	Atherosclerosis	29228671	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	our results demonstrated that metformin improved IRSM by inhibiting miR-21 expression, and that miR-21 may be one of the therapeutic targets for IR
therapeutic target	hsa-mir-221	Atherosclerosis	25893733	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	These findings suggest that manipulation of the miR-221/222-Ets-1-p21 pathway may offer a novel strategy for treatment of endothelial apoptosis and atherosclerosis.
therapeutic target	hsa-mir-221	Atherosclerosis	22138289	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The opposite cellular effects of miR-221/222 on VSMCs and ECs may have important therapeutic applications in many vascular diseases such as atherosclerosis and restenosis after angioplasty.
therapeutic target	hsa-mir-222	Atherosclerosis	25893733	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	These findings suggest that manipulation of the miR-221/222-Ets-1-p21 pathway may offer a novel strategy for treatment of endothelial apoptosis and atherosclerosis.
therapeutic target	hsa-mir-222	Atherosclerosis	22138289	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The opposite cellular effects of miR-221/222 on VSMCs and ECs may have important therapeutic applications in many vascular diseases such as atherosclerosis and restenosis after angioplasty.
therapeutic target	hsa-mir-24	Atherosclerosis	24990232	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Taken together, our data demonstrates that downregulation of microRNA-24 promotes an invasive macrophage subset and plays a novel regulatory role in MMP-14 proteolytic activity and, therefore, plaque stability,highlighting its therapeutic potential.
therapeutic target	hsa-mir-29b	Atherosclerosis	25131924	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The effect of miR-29b on endothelial permeability and apoptosis is mediated through the down-regulation of MT1. Thus, miR-29b may be a new therapeutic target for atherosclerosis.
therapeutic target	hsa-mir-302a	Atherosclerosis	25524771	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-302a as a novel modulator of cholesterol efflux and a potential therapeutic target for suppressing atherosclerosis.
therapeutic target	hsa-mir-33a	Atherosclerosis	26645139	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	This review summarizes the current understanding of the functions of miR-33a/b and the progress in miRNA therapeutics for treatment of various diseases, including atherosclerosis.
therapeutic target	hsa-mir-33b	Atherosclerosis	26645139	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	This review summarizes the current understanding of the functions of miR-33a/b and the progress in miRNA therapeutics for treatment of various diseases, including atherosclerosis.
therapeutic target	hsa-mir-378	Atherosclerosis	24675662	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	This study identified activator protein-1/miR-378/ATP-binding cassette transporter G1 as a novel cascade for CoQ10 in facilitating macrophage cholesterol efflux in vitro and in vivo. Our data thus imply that both CoQ10 and  miR-378 are promising candidates for atherosclerosis prevention and treatment.
therapeutic target	hsa-mir-382	Atherosclerosis	25265644	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Our findings indicated that the RP5-833A20.1/miR-382-5p/NFIA pathway was essential to the regulation of cholesterol homeostasis and inflammatory reactions and suggested that NFIA may represent a therapeutic target to ameliorate cardiovascular disease.
therapeutic target	hsa-mir-410	Atherosclerosis	25411193	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases.
therapeutic target	hsa-mir-431	Atherosclerosis	25411193	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases.
therapeutic target	hsa-mir-432	Atherosclerosis	25411193	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases.
therapeutic target	hsa-mir-433	Atherosclerosis	25411193	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Significant changes in genomic methylation were identified in atherosclerotic lesions. The most prominent gene cluster activated via hypomethylation was detected at imprinted chromosomal locus 14q32 with several clustered miRNAs that were up-regulated. These results suggest that epigenetic changes are involved in atherogenesis and may offer new potential therapeutic targets for vascular diseases.
therapeutic target	hsa-mir-106b	Atrial Fibrillation	25389315	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-106b-25 cluster-mediated post-transcriptional regulation of RyR2 is a potential molecular mechanism involved in paroxysmal AF pathogenesis. As such, the miR-106b-25 cluster could be a novel gene-therapy target in AF associated with enhanced RyR2 expression.
therapeutic target	hsa-mir-25	Atrial Fibrillation	25389315	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-106b-25 cluster-mediated post-transcriptional regulation of RyR2 is a potential molecular mechanism involved in paroxysmal AF pathogenesis. As such, the miR-106b-25 cluster could be a novel gene-therapy target in AF associated with enhanced RyR3 expression
therapeutic target	hsa-mir-93	Atrial Fibrillation	25389315	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-106b-25 cluster-mediated post-transcriptional regulation of RyR2 is a potential molecular mechanism involved in paroxysmal AF pathogenesis. As such, the miR-106b-25 cluster could be a novel gene-therapy target in AF associated with enhanced RyR4 expression
therapeutic target	hsa-mir-150	Autoimmune Diseases [unspecific]	26287504				D001327	607836	HP:0002960	Though much remains to be explored about the roles of miR-150 in pathogenic infection and autoimmune diseases, targeting miR-150 may serve as a promising therapy strategy.
therapeutic target	hsa-mir-30a	Autoimmune Diseases [unspecific]	26376209				D001327	607836	HP:0002960	Thus, we concluded that the downregulation of miR-30a in autoimmune diseases may exacerbate IL-17-mediated inflammation, which may serve as a potential target for the therapy of these diseases.
therapeutic target	hsa-mir-146a	Autoimmune Lymphoproliferative Syndrome	23645835	immune system disease	DOID:6688	D89.82	D056735	PS308240		These results indicate that miR-146a may be involved in the pathogenesis of ALPS by targeting Fas and may therefore serve as a novel therapeutic target.
therapeutic target	hsa-mir-21	Biliary Atresia	25487473	gastrointestinal system disease	DOID:13608	Q44.2	D001656	210500		The miRNA-21/PTEN/AKT axis promotes the fibrosis process in BA, which might be a potential therapeutic target to improve the prognosis of patients with BA.
therapeutic target	hsa-mir-132	Bipolar Disorder	25708817	disease of mental health	DOID:3312	F31	D001714		HP:0007302	our observation of altered miRNA expression in the blood prior to the onset of illness provides hope that one day blood-based tests may aid in the risk-stratification and treatment of BD.
therapeutic target	hsa-mir-134	Bipolar Disorder	20546789	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Plasma miRNA-134 in BD may be considered as a potential peripheral marker that can respond to acute manic episodes and associate with effective mood stabilizers treatment.
therapeutic target	hsa-mir-15b	Bipolar Disorder	25708817	disease of mental health	DOID:3312	F31	D001714		HP:0007302	our observation of altered miRNA expression in the blood prior to the onset of illness provides hope that one day blood-based tests may aid in the risk-stratification and treatment of BD.
therapeutic target	hsa-mir-206	Bipolar Disorder	24767015	disease of mental health	DOID:3312	F31	D001714		HP:0007302	Our findings provide initial evidence of the gene-to-gene interaction of MIR206 and BDNF in regards to the risk for BD-I as well as treatment response to mood stabilizers.
therapeutic target	hsa-mir-652	Bipolar Disorder	25708817	disease of mental health	DOID:3312	F31	D001714		HP:0007302	our observation of altered miRNA expression in the blood prior to the onset of illness provides hope that one day blood-based tests may aid in the risk-stratification and treatment of BD.
therapeutic target	hsa-mir-133	Bladder Fibrosis	25451078							A novel antifibrotic functional role for miR-133 is presented which may represent a potential target for diagnostic and therapeutic strategies in bladder fibrosis.
therapeutic target	hsa-mir-106b	Bladder Neoplasms	25955758			C67	D001749	109800	HP:0009725	DE-miRNAs in bladder cancer tissue samples and DE-targeted genes, such as miR-106b and CDKN2A, which were identified in the present study, may provide the basis for targeted therapy for breast cancer and enhance understanding of its pathogenesis.
therapeutic target	hsa-mir-1182	Bladder Neoplasms	26772886			C67	D001749	109800	HP:0009725	In conclusion, these results demonstrate that miR-1182 acts as a tumor suppressor and may be a potential biomarker for bladder cancer diagnosis and treatment.
therapeutic target	hsa-mir-125b	Bladder Neoplasms	25955758			C67	D001749	109800	HP:0009725	DE-miRNAs in bladder cancer tissue samples and DE-targeted genes, such as miR-106b and CDKN2A, which were identified in the present study, may provide the basis for targeted therapy for breast cancer and enhance understanding of its pathogenesis.
therapeutic target	hsa-mir-145	Bladder Neoplasms	24954107			C67	D001749	109800	HP:0009725	Our results indicate that miR-145 inhibits bladder cancer cell invasion, at least partly through targeting PAK1. Restoration or replacement of miR-145 could be an efficient approach to inhibit PAK1 and bladder cancer development in the tumor therapy.
therapeutic target	hsa-mir-145	Bladder Neoplasms	26318860			C67	D001749	109800	HP:0009725	In summary, our data indicated that blocking TUG1 function may be an effective anti-cancer therapy.
therapeutic target	hsa-mir-145	Bladder Neoplasms	26544536			C67	D001749	109800	HP:0009725	Taken together, our results identified that lncRNA-UCA1 enhances bladder cancer cell migration and invasion in part through the hsa-miR-145/ZEB1/2/FSCN1 pathway. Therefore, lncRNA-UCA1 might act as a promising therapeutic target for the invasion and metastasis of bladder cancer.
therapeutic target	hsa-mir-150	Bladder Neoplasms	25287716			C67	D001749	109800	HP:0009725	This study provides novel evidence that miR-150 functions as a tumor promoter in reducing chemosensitivity and promoting invasiveness of MIBC cells via targeting PDCD4. Thus, modulation of the miR-150-PDCD4 axis shows promise as a therapeutic strategy for MIBC.
therapeutic target	hsa-mir-186	Bladder Neoplasms	26290438			C67	D001749	109800	HP:0009725	Our data first time identified miR-186 as the upstream regulator of NSBP1 and also suggest miR-186-suppressed NSBP1 as a novel therapeutic approach for bladder cancer.
therapeutic target	hsa-mir-193a	Bladder Neoplasms	25542424			C67	D001749	109800	HP:0009725	the key players in this microRNA-193a-3p/PSEN1 axis are likely the diagnostic and/or therapeutic targets for an effective chemotherapy of bladder cancer.
therapeutic target	hsa-mir-19a	Bladder Neoplasms	20857258			C67	D001749	109800	HP:0009725	The synergy effect between miRNA-19a and arsenic trioxide that advocates targeting the mir-19a may represent a potential approach to enhance the efficacy and safety of ATO to treat bladder cancer by a decrease in dose.
therapeutic target	hsa-mir-205	Bladder Neoplasms	26469956			C67	D001749	109800	HP:0009725	This study elucidates an important role that miR-205 had in the regulation of proliferation,migration and invasion of bladder cancer cells, suggesting a potential therapeutic target for combating bladder cancer.
therapeutic target	hsa-mir-26a	Bladder Neoplasms	25455159			C67	D001749	109800	HP:0009725	Tumors with miR-26a downregulation in combination with high expression of HMGA1 showed a worse prognosis than the other tumors. Combined detection of their expression might be particularly helpful for  surveillance of disease progression and treatment stratification.
therapeutic target	hsa-mir-27a	Bladder Neoplasms	24516043			C67	D001749	109800	HP:0009725	Our findings indicate that miRNA-27a negatively regulates SLC7A11 in cisplatin-resistant bladder cancer, and shows promise as a marker for patients likely to benefit from cisplatin-based chemotherapy. SLC7A11 inhibition with sulfasalazine may be a promising therapeutic approach to the treatment of cisplatin-resistant disease.
therapeutic target	hsa-mir-29	Bladder Neoplasms	26471361			C67	D001749	109800	HP:0009725	Taken together, our findings established a role for ATDC as a robust pathogenic driver of bladder cancer identified downstream effector pathways, and implicated ATDC as a candidatedevelopment,biomarker and therapeutic target.
therapeutic target	hsa-mir-320c	Bladder Neoplasms	25178497			C67	D001749	109800	HP:0009725	miR-320c could inhibit the proliferation, migration and invasion of bladder cancer cells via regulating CDK6. Our study revealed that miR-320c could be a therapeutic biomarker of bladder cancer in the future.
therapeutic target	hsa-mir-34a	Bladder Neoplasms	25556547			C67	D001749	109800	HP:0009725	the need for further clinical studies of miR-34a as a guide for recurrence screening and as a possible candidate therapeutic target in the bladder.
therapeutic target	hsa-mir-34a	Bladder Neoplasms	25551284			C67	D001749	109800	HP:0009725	a major metastasis and angiogenesis suppressive role for mir-34a, a microRNA functions as a tumor suppressor in bladder cancer by directly targeting CD44, which would be helpful as a therapeutic approach to block bladder cancer metastasis.
therapeutic target	hsa-mir-542	Bladder Neoplasms	26723509			C67	D001749	109800	HP:0009725	MiR-542-3p and its target gene survivin may play crucial roles in the aggressive progression of human bladder cancer. More interestingly, miR-542-3p may function as a tumor suppressor and inhibit the proliferation of bladder cancer cells, implying that miR-542-3p-survivin signal axis might be a novel therapeutic target of this disease.
therapeutic target	hsa-mir-378	Bone Disease [unspecific]	29686962	musculoskeletal system disease	DOID:0080001	M89.9	D001847			miR378 was an ideal target to osteogenesis-angiogenesis coupling for bone regeneration, which provides a potential tool for the gene therapy of bone regeneration.
therapeutic target	hsa-let-7a	Brain Neoplasms	24947843	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells.
therapeutic target	hsa-mir-221	Brain Neoplasms	20012062	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	As anti-miR therapy was recently proposed as an alternative treatment for cancer, these findings suggest that anti-miR-221/222 therapy might have therapeutic potential in ATRT.
therapeutic target	hsa-mir-222	Brain Neoplasms	20012062	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	As anti-miR therapy was recently proposed as an alternative treatment for cancer, these findings suggest that anti-miR-221/222 therapy might have therapeutic potential in ATRT.
therapeutic target	hsa-mir-326	Brain Neoplasms	19955368	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors
therapeutic target	hsa-mir-34a	Brain Neoplasms	25250818	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	Mir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells.
therapeutic target	hsa-let-7	Breast Neoplasms	26717565	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.
therapeutic target	hsa-let-7	Breast Neoplasms	29336465	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the findings identified a biochemical and functional link between Let-7 and endocrine therapy in breast CSCs
therapeutic target	hsa-let-7e	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-100	Breast Neoplasms	25537513	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	aggressive breast cancers responsive to standard treatments.
therapeutic target	hsa-mir-103	Breast Neoplasms	25547678	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC.
therapeutic target	hsa-mir-106a	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-107	Breast Neoplasms	25547678	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC.
therapeutic target	hsa-mir-10b	Breast Neoplasms	25428807	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a set of specific microRNAs may play an important role in modulating tumor microenvironment through exosomes.Thus, a better understanding of this process may aid in the development of novel therapeutic agents.
therapeutic target	hsa-mir-10b	Breast Neoplasms	25596707	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA-10b and MCM5 mRNA as prognostic markers and potential therapeutic targets in breast cancer to be applied to other patient data sets.
therapeutic target	hsa-mir-10b	Breast Neoplasms	26206152	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We propose miR-10b-HDAC4 nexus as one of the molecular mechanism of tamoxifen resistance which can potentially be expolited as a novel targeted therapeutic approach for the clinical management of tamoxifen-resistant breast cancers.
therapeutic target	hsa-mir-10b	Breast Neoplasms	21067538	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In particular, recent studies provide the first functional evidence that overexpression of a specific miRNA, miR-10b, can contribute to the development of metastasis, which can be exploited herapeutically in treating breast cancer metastasis in mice.
therapeutic target	hsa-mir-1207	Breast Neoplasms	25047087	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.
therapeutic target	hsa-mir-1207	Breast Neoplasms	25954907	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA profile changes demonstrated in this study provide a data set regarding their effects on the pathways that regulate telomerase activity in MCF-7 breast cancer cells treated with G. lucidum. These data should aid the development of novel cancer treatment strategies.
therapeutic target	hsa-mir-1228	Breast Neoplasms	25047087	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.
therapeutic target	hsa-mir-1228	Breast Neoplasms	26261546	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, this study provides evidences that miR-1228 serves as an oncogene to promote breast cancer proliferation, invasion and migration, which may become a critical therapeutic target for breast cancer treatment.
therapeutic target	hsa-mir-124	Breast Neoplasms	27266580	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-124-M-Oba may have potential applications in breast cancer therapy.
therapeutic target	hsa-mir-125b	Breast Neoplasms	25633049	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b is a new biomarker of poor prognosis and a candidate therapeutic target in AI-resistant breast cancers.
therapeutic target	hsa-mir-125b	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-125b	Breast Neoplasms	25894378	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.
therapeutic target	hsa-mir-125b	Breast Neoplasms	26335100	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data suggest a mechanism by which CT-Cx43 may regulate cell proliferation. Targeting of CT-Cx43 and/or miR-125b may be instrumental for therapeutic intervention in human breast cancer.
therapeutic target	hsa-mir-125b-1	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-126	Breast Neoplasms	25844955	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The use of the TRA-miR-126 chimera or the combination of the delivery strategy with other endothelial or tumor specific aptamers may provide an interesting therapeutic option to treat vascular disease or cancers.
therapeutic target	hsa-mir-127	Breast Neoplasms	25477702	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	status of miR-127 was an independent prognostic factor for patients. Functional analyses showed that upregulation of miR-127 significantly inhibited growth, enhanced apoptosis, and reduced migration and invasion in BC cells by targeting the protooncogene BCL-6. Therefore, miR-127 may be a potential biomarker for predicting the survival of BC patients and might be a molecular target for treatment of human BCs.
therapeutic target	hsa-mir-1274a	Breast Neoplasms	26581147	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Biomarkers of DNA repair and cell cycle control can identify patients at high risk of treatment failure in those receiving radiation therapy for early breast cancer in independent cohorts. These should be further investigated prospectively, especially TOP2A and SKP2, for which targeted therapies are available.
therapeutic target	hsa-mir-1275	Breast Neoplasms	25047087	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.
therapeutic target	hsa-mir-1285	Breast Neoplasms	25954907	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA profile changes demonstrated in this study provide a data set regarding their effects on the pathways that regulate telomerase activity in MCF-7 breast cancer cells treated with G. lucidum. These data should aid the development of novel cancer treatment strategies.
therapeutic target	hsa-mir-129	Breast Neoplasms	26487539	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our findings suggest that miR-129-3p down-regulation potentially sensitizes breast cancer cells to docetaxel treatment.
therapeutic target	hsa-mir-135	Breast Neoplasms	25634212	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	aberrant expression of Runx2 in aggressive tumor cells is related to the loss of specific Runx2-targeting miRNAs and that a clinically relevant replacement strategy by delivery of synthetic miRNAs is a candidate for a therapeutic approach to prevent metastatic bone disease by this route.
therapeutic target	hsa-mir-135b	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-137	Breast Neoplasms	26337822	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Moreover, we also found that carboxyl-terminal binding protein 1 (CtBP1) was a putative target gene of miR-137 in MCF-7 cells, and might be involved in the suppressive effects, which might provide novel diagnostic and  therapeutic options for human breast cancer in the future.
therapeutic target	hsa-mir-139	Breast Neoplasms	25047087	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.
therapeutic target	hsa-mir-139	Breast Neoplasms	26581147	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Biomarkers of DNA repair and cell cycle control can identify patients at high risk of treatment failure in those receiving radiation therapy for early breast cancer in independent cohorts. These should be further investigated prospectively, especially TOP2A and SKP2, for which targeted therapies are available.
therapeutic target	hsa-mir-141	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-141	Breast Neoplasms	26095675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers.
therapeutic target	hsa-mir-143	Breast Neoplasms	26095675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers.
therapeutic target	hsa-mir-145	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-145	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-145	Breast Neoplasms	21723890	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Ad-miR-145 suppressed cell growth and motility in both the in vitro and in vivo systems. Furthermore, a treatment combining Ad-miR-145 with 5-FU significantly showed anti-tumor effects, compared to treating alone.
therapeutic target	hsa-mir-145	Breast Neoplasms	26095675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers.
therapeutic target	hsa-mir-146a	Breast Neoplasms	25417703	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a novel BRCA1miR-146aEGFR paradigm by which BRCA1 carries out an aspect of tumor suppressor function that is potentially amenable to therapeutic intervention.
therapeutic target	hsa-mir-146b	Breast Neoplasms	26338965	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results show that miR-146b-5p has non-cell-autonomous tumor suppressor function through inhibition of IL-6, suggesting that targeting this microRNA in breast stromal fibroblasts could be of great therapeutic value.
therapeutic target	hsa-mir-155	Breast Neoplasms	21946536	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Mechanistically, we found that BRCA1 epigenetically represses miR-155 expression via its association with HDAC2, which deacetylates histones H2A and H3 on the miR-155 promoter. We show that overexpression of miR-155 accelerates but the knockdown of miR-155 attenuates the growth of tumor cell lines in vivo. Our findings demonstrate a new mode of tumor suppression by BRCA1 and suggest that miR-155 is a potential therapeutic target for BRCA1-deficient tumors.
therapeutic target	hsa-mir-155	Breast Neoplasms	26095675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers.
therapeutic target	hsa-mir-155	Breast Neoplasms	22652783	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This review summarizes the signaling pathways that are regulated by miR-155 in breast cancer and discusses therapeutic possibilities related to miR-155.
therapeutic target	hsa-mir-15a	Breast Neoplasms	26397135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Together, our results suggest that overexpression of E2F7 represses miR-15a/16 and then increases Cyclin E1 and Bcl-2 that result in tamoxifen resistance. E2F7 may be a valuable prognostic marker and a therapeutic target of tamoxifen resistance in breast cancer.
therapeutic target	hsa-mir-15a	Breast Neoplasms	29394261	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	modulatingspecific miRNAs may serve as a therapeutic approach for the treatment of breast cancer
therapeutic target	hsa-mir-16	Breast Neoplasms	26397135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Together, our results suggest that overexpression of E2F7 represses miR-15a/16 and then increases Cyclin E1 and Bcl-2 that result in tamoxifen resistance. E2F7 may be a valuable prognostic marker and a therapeutic target of tamoxifen resistance in breast cancer.
therapeutic target	hsa-mir-182	Breast Neoplasms	26563369	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulation of miR-182 might find therapeutical value for overcoming trastuzumab resistance.
therapeutic target	hsa-mir-182	Breast Neoplasms	21195000	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Together these results suggest that miR-182-mediated downregulation of BRCA1 impedes DNA repair and may impact breast cancer therapy.
therapeutic target	hsa-mir-18a	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-18b	Breast Neoplasms	25547678	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC.
therapeutic target	hsa-mir-190b	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-193b	Breast Neoplasms	26526790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Together, our findings provide evidence that the modulation of miR-193b may represent a novel therapeutic target for the treatment of breast cancer.
therapeutic target	hsa-mir-195	Breast Neoplasms	24402230	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer.
therapeutic target	hsa-mir-195	Breast Neoplasms	21350001	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets.
therapeutic target	hsa-mir-196b	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-200a	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-200a	Breast Neoplasms	21389093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	these results suggest a role of miR-200s(miR-200a, miR-200b, and miR-200c) in PGI/AMF-induced EMT and thus approaches for upregulation of miR-200s could be a novel therapeutic strategy for the treatment of highly invasive breast cancer.
therapeutic target	hsa-mir-200b	Breast Neoplasms	25639535	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200b has potential to serve as prognostic biomarker and tumour suppressor for BC patients. As a direct and functional target of miR-200b, Sp1 and miR-200b both could be an exciting target for BC treatment strategy.
therapeutic target	hsa-mir-200b	Breast Neoplasms	21389093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	these results suggest a role of miR-200s(miR-200a, miR-200b, and miR-200c) in PGI/AMF-induced EMT and thus approaches for upregulation of miR-201s could be a novel therapeutic strategy for the treatment of highly invasive breast cancer.
therapeutic target	hsa-mir-200c	Breast Neoplasms	25445393	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA may provide novel therapeutic molecular targets for TNBC treatment and new directions for the development of anticancer drugs.
therapeutic target	hsa-mir-200c	Breast Neoplasms	26392416	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our findings provide clues regarding the role of miR-200c as a tumor suppressor in breast cancer through the inhibition of KRAS translation both in vitro and in vivo. miR-200c could be a potential therapeutic target in breast cancer.
therapeutic target	hsa-mir-200c	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-200c	Breast Neoplasms	21389093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	these results suggest a role of miR-200s(miR-200a, miR-200b, and miR-200c) in PGI/AMF-induced EMT and thus approaches for upregulation of miR-202s could be a novel therapeutic strategy for the treatment of highly invasive breast cancer.
therapeutic target	hsa-mir-203	Breast Neoplasms	25634212	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	aberrant expression of Runx2 in aggressive tumor cells is related to the loss of specific Runx2-targeting miRNAs and that a clinically relevant replacement strategy by delivery of synthetic miRNAs is a candidate for a therapeutic approach to prevent metastatic bone disease by this route.
therapeutic target	hsa-mir-203	Breast Neoplasms	26278219	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data thus highlight miR203 as a novel therapeutic target for breast cancer.
therapeutic target	hsa-mir-204	Breast Neoplasms	26656364	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our study reveals that Sam68 is regulated by miR-204 and may play an important role in the self-renewal of BCSCs via activating the Wnt/beta-catenin pathway. Sam68 may represent a novel therapeutic target for breast cancer.
therapeutic target	hsa-mir-205	Breast Neoplasms	25633049	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b is a new biomarker of poor prognosis and a candidate therapeutic target in AI-resistant breast cancers.
therapeutic target	hsa-mir-205	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-205	Breast Neoplasms	26181203	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
therapeutic target	hsa-mir-205	Breast Neoplasms	27064979	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes.
therapeutic target	hsa-mir-206	Breast Neoplasms	25202071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
therapeutic target	hsa-mir-20a	Breast Neoplasms	29179464	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Therapy directed at uPAR-induced miR-17/20a  is a potential option for breast cancer and TNBC
therapeutic target	hsa-mir-21	Breast Neoplasms	25958353	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	two miRNAs, miR-21 and miR-34, are discussed as the most promising targets for RNA-based therapy in non-invasive and invasive breast cancer, respectively.Finally, relevant and commercialized therapeutic strategies are highlighted.
therapeutic target	hsa-mir-21	Breast Neoplasms	26169933	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy.
therapeutic target	hsa-mir-21	Breast Neoplasms	26387181	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The regulation effects of DNA methylation by transient transfection of miR-21 in MCF-7 and MDA-MB-231 cells are almost opposite, whilst the expression of miR-21 in two cell lines were all upregulated by decreased DNA methylation level and our results may provide some experimental evidences for the future development of rational therapy for different breast cancer.
therapeutic target	hsa-mir-21	Breast Neoplasms	26452030	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Collectively, these data provide a rationale for using miR-21 expression as a biomarker to select trastuzumab-chemotherapy-resistant HER2-positive breast cancer patients who may benefit from treatments containing PI3K inhibitors or immunomodulatory drugs.
therapeutic target	hsa-mir-21	Breast Neoplasms	26676464	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, we provide novel evidence that miR-21 knockdown suppresses cell growth, migration and invasion partly by inhibiting PI3K/AKT activation via direct targeting PIK3R1 and reversing EMT in breast cancer. p85α downregulation defined a specific subgroup of breast cancer with shorter 5-year DFS and OS, which may require more aggressive treatment.
therapeutic target	hsa-mir-21	Breast Neoplasms	27064979	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes.
therapeutic target	hsa-mir-21	Breast Neoplasms	26095675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers.
therapeutic target	hsa-mir-21	Breast Neoplasms	29567152	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	chemically modified miRNA-21 inhibitor based on gold nanoparticles would be as a promising diagnostic and therapeutic platform for breast cancer clinically
therapeutic target	hsa-mir-210	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-214	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-214	Breast Neoplasms	26666173	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-214 increased the sensitivity of breast cancer cells to TAM and FUL through inhibition of autophagy by targeting UCP2. MiR-214 shows potential as a novel therapeutic strategy for overcoming endocrine resistance in ER(+) breast cancers.
therapeutic target	hsa-mir-214	Breast Neoplasms	27422604	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, miR-214 functions as a tumor suppressor by regulating  the RFWD2-p53 cascade, thus delivery of miR-214 analogs could be a potential adjunct therapy in breast cancer harboring wild type p53.
therapeutic target	hsa-mir-218	Breast Neoplasms	25394901	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-218 has a significant function in the development of cisplatin resistance in breast cancer. Restoring miR-218 expression may constitute a novel therapeutic approach by which to increase cisplatin sensitivity in breast cancer.
therapeutic target	hsa-mir-221	Breast Neoplasms	24129242	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy.
therapeutic target	hsa-mir-221	Breast Neoplasms	25797271	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results demonstrate a direct and positive regulation of the secreted uPAR isoform 2 by miR-221, increasing its protein expression, a prerequisite for malignancy, while the other uPAR isoforms (1, 3 and 4) are indirectly regulated through miR-10b and miR-221/-222. By targeting uPAR isoforms and/or miRNA-221/-222, the diagnosis and therapy of breast cancer, in particular in TNBC, could be significantly improved.
therapeutic target	hsa-mir-221	Breast Neoplasms	26253160	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221 is a potential biomarker for predicting the survival of BC patients and may be a molecular therapeutic target for BC.
therapeutic target	hsa-mir-222	Breast Neoplasms	24129242	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy.
therapeutic target	hsa-mir-222	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-222	Breast Neoplasms	27282281	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulation of miR-222 in MCF-7/Adr increased sensitivity  to Adr and Adr-induced apoptosis
therapeutic target	hsa-mir-224	Breast Neoplasms	26701615	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results indicate that FUT4 and miR-224-3p are crucial regulators of cancer response to chemotherapy, and may serve as therapeutic targets to reverse chemotherapy resistance in breast cancer.
therapeutic target	hsa-mir-23a	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-24	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-24-2	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-26b	Breast Neoplasms	25536365	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ANXA1-regulated miR26b* and miR562 may play a role in wound healing and tumor-induced endothelial cell tube formation by targeting NF-κB expression and point towards a potential therapeutic target for breast cancer.
therapeutic target	hsa-mir-27a	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-27a	Breast Neoplasms	25954907	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA profile changes demonstrated in this study provide a data set regarding their effects on the pathways that regulate telomerase activity in MCF-7 breast cancer cells treated with G. lucidum. These data should aid the development of novel cancer treatment strategies.
therapeutic target	hsa-mir-27a	Breast Neoplasms	26592661	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our findings provide a novel anti-tumor mechanism of ATO involved in miR-27a for the treatment of breast cancer.
therapeutic target	hsa-mir-301a	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-302a	Breast Neoplasms	25030358	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-302a mimics are potential therapeutic agents for breast cancer metastasis.
therapeutic target	hsa-mir-302b	Breast Neoplasms	26744520	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Collectively, our findings reveal new insights underlying increased breast cancer mortality in obese individuals and provide a novel preclinical rationale to test the efficacy of Src inhibitors for breast cancer treatment.
therapeutic target	hsa-mir-30b	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-30d	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-31	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-31	Breast Neoplasms	26095675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers.
therapeutic target	hsa-mir-3196	Breast Neoplasms	25047087	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.
therapeutic target	hsa-mir-3200	Breast Neoplasms	27064979	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes.
therapeutic target	hsa-mir-331	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-34	Breast Neoplasms	25958353	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	two miRNAs, miR-21 and miR-34, are discussed as the most promising targets for RNA-based therapy in non-invasive and invasive breast cancer, respectively.Finally, relevant and commercialized therapeutic strategies are highlighted.
therapeutic target	hsa-mir-34	Breast Neoplasms	19421141	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These observations confirm that mir-34 is required for a normal cellular response to DNA damage in vivo resulting in altered cellular survival post-irradiation, and point to a potential therapeutic use for anti-miR-34 as a radiosensitizing agent in p53-mutant breast cancer.
therapeutic target	hsa-mir-340	Breast Neoplasms	26573744	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In brief, miR-340 plays an important role in breast cancer progression. Thus, miR-340 may be further explored as a novel biomarker for breast cancer metastasis and prognosis,and potentially a therapeutic target.
therapeutic target	hsa-mir-342	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-345	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-34a	Breast Neoplasms	25173798	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
therapeutic target	hsa-mir-34a	Breast Neoplasms	25396727	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	DADS could be a promising anticancer agent for breast cancer. miR-34a may also demonstrate a potential gene therapy agent that could enhance the antitumor effects of DADS.
therapeutic target	hsa-mir-34a	Breast Neoplasms	26095675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers.
therapeutic target	hsa-mir-363	Breast Neoplasms	25416050	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-363 was a negative regulator of Mcl-1 expression, and the combination of miR-363 and cisplatin may be a novel approach in the treatment for breast cancer.
therapeutic target	hsa-mir-3648	Breast Neoplasms	26717565	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.
therapeutic target	hsa-mir-3687	Breast Neoplasms	25954907	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA profile changes demonstrated in this study provide a data set regarding their effects on the pathways that regulate telomerase activity in MCF-7 breast cancer cells treated with G. lucidum. These data should aid the development of novel cancer treatment strategies.
therapeutic target	hsa-mir-370	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-375	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-377	Breast Neoplasms	26717565	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.
therapeutic target	hsa-mir-378a	Breast Neoplasms	25268374	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of Aurora B by excess miR-378a-5p can explain the observed microtubule drug resistance and increased chromosomal imbalance in the microRNA overexpressing cells. The results suggest that breast tumours may deploy high miR-378a-5p levels to gain growth advantage and antagonise taxane therapy.
therapeutic target	hsa-mir-381	Breast Neoplasms	26450928	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Therefore we are the first to identify that miR-381 suppresses C/EBPα-dependent Cx43 expression in breast cancer cells. The miR-381-C/EBPα-Cx43 axis might be a useful diagnostic and therapeutic target of metastatic breast cancer.
therapeutic target	hsa-mir-409	Breast Neoplasms	26631969	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data collectively indicate that miR-409-3p functions as a tumor suppressor in BC through downregulating Akt1, supporting the targeting of the novel miR-409-3p/Akt1 axis as a potentially effective therapeutic approach for BC.
therapeutic target	hsa-mir-424	Breast Neoplasms	25633049	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b is a new biomarker of poor prognosis and a candidate therapeutic target in AI-resistant breast cancers.
therapeutic target	hsa-mir-429	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-448	Breast Neoplasms	20798686	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Disruption of the NF-κB-miR-448 feedback loop during clinical treatment may improve the chemotherapy response of human breast cancers in which EMT is a critical component.
therapeutic target	hsa-mir-451	Breast Neoplasms	27064979	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Variations in serum miRNA levels during NAC treatment may be therapeutically significant for predicting response and survival outcomes.
therapeutic target	hsa-mir-4521	Breast Neoplasms	24517586	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design of therapeutic interventions.
therapeutic target	hsa-mir-493	Breast Neoplasms	27375041	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-493-5p/FUT4 pathway has therapeutic potential in breast cancer.
therapeutic target	hsa-mir-495	Breast Neoplasms	25070379	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-495 could facilitate breast cancer progression through the repression of JAM-A, making this miRNA a potential therapeutic target.
therapeutic target	hsa-mir-497	Breast Neoplasms	21350001	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets.
therapeutic target	hsa-mir-499	Breast Neoplasms	25883093	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
therapeutic target	hsa-mir-503	Breast Neoplasms	25860935	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our data are the first to reveal the involvement of the endothelium in the modulation of tumor development via the secretion of circulating miR-503 in response to chemotherapy  treatment.
therapeutic target	hsa-mir-506	Breast Neoplasms	26398880	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, the present study is the first to provide evidence that miR-506 acts as a tumor suppressor, at least partially,by directly downregulating IQGAP1 in breast cancer cells. The miR-506/IQGAP1/ERK pathway may be a novel therapeutic target in breast cancer.
therapeutic target	hsa-mir-510	Breast Neoplasms	23971998	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these data support a pivotal role for miR-510 in breast cancer progression and suggest it as a potential therapeutic target in breast cancer patients.
therapeutic target	hsa-mir-548d	Breast Neoplasms	26663100	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our study showed that miR-548d-3p/TP53BP2 pathway is critically involved in the proliferation and apoptosis of breast cancer cells and may be new therapeutic target of breast cancer cells.
therapeutic target	hsa-mir-548t	Breast Neoplasms	26717565	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.
therapeutic target	hsa-mir-562	Breast Neoplasms	25536365	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ANXA1-regulated miR26b* and miR562 may play a role in wound healing and tumor-induced endothelial cell tube formation by targeting NF-κB expression and point towards a potential therapeutic target for breast cancer.
therapeutic target	hsa-mir-576	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-629	Breast Neoplasms	28629464	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
therapeutic target	hsa-mir-633b	Breast Neoplasms	26717565	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.
therapeutic target	hsa-mir-638	Breast Neoplasms	25228385	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our findings suggest that miR-638 plays an important role in TNBC progression via BRCA1 deregulation. Therefore, miR-638 might serve as a potential prognostic biomarker and therapeutic target for breast cancer.
therapeutic target	hsa-mir-652	Breast Neoplasms	25547678	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This signature may serve as a minimally invasive predictor of tumor relapse and overall survival for patients with TNBC. This prediction model may ultimately lead to better treatment options for patients with TNBC.
therapeutic target	hsa-mir-760	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-765	Breast Neoplasms	25451164	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues  could be useful for developing new strategies for targeted therapies in patients  with chemoresistant breast cancer.
therapeutic target	hsa-mir-873	Breast Neoplasms	25531331	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-873 is a novel tumor suppressor in ER-positive breast cancer and a potential therapeutic approach for treatment of tamoxifen-resistant breast cancer.
therapeutic target	hsa-mir-886	Breast Neoplasms	24641359	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data show that downregulation of miR-886-5p expression in MCF-7 cells could significantly inhibit cell growth and migration. This might imply that inhibiting miR-886-5p could be a therapeutic strategy in breast cancer.
therapeutic target	hsa-mir-9	Breast Neoplasms	26095675	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-155, miR-9, miR-34a, miR-143/145, and miR-31 were found to be altered in both CMTs and human breast cancer. These altered miRNAs might serve as potential targets for advancing the development of future therapeuticreagents. These findings further strengthen the validity and use of canine breast cancers as appropriate models for the study of human breast cancers.
therapeutic target	hsa-mir-92b	Breast Neoplasms	25047087	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.
therapeutic target	hsa-mir-99a	Breast Neoplasms	26417931	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Collectively, our data indicate that miR-99a plays a tumor-suppressor role in the development of breast cancer, and could serve as a potential therapeutic target for breast cancer treatment.
therapeutic target	hsa-mir-23b	Burns	26153982			M61.30	D002056			Our findings suggest that downregulation of miR-23b contributes to the recovery of denatured dermis, which may be valuable for treatment of skin burns.
therapeutic target	hsa-mir-143	Carcinoma, Bladder	26484567	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Our data suggest a promising therapeutic option to develop drugs targeting EZH2/miR-143 axis, such as honokiol, for bladder cancer treatment.
therapeutic target	hsa-mir-145	Carcinoma, Bladder	26036261	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft.
therapeutic target	hsa-mir-221	Carcinoma, Bladder	25928257	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Our study demonstrated that miR-221 facilitated TGFβ1-induced EMT in human bladder cancer cells by targeting STMN1 and represented a promising therapeutic target in the process of metastasis.
therapeutic target	hsa-mir-106a	Carcinoma, Breast	25499219			D05	D001943	114480	HP:0003002	EZH2 is reciprocally regulated by a novel signaling network consisting of Sp proteins, oncogenic miRs  and ZBTB4, and modulation of this gene network is a novel therapeutic approach for treatment of breast cancer and possibly other cancers.
therapeutic target	hsa-mir-106b	Carcinoma, Breast	25499219			D05	D001943	114480	HP:0003002	EZH2 is reciprocally regulated by a novel signaling network consisting of Sp proteins, oncogenic miRs  and ZBTB4, and modulation of this gene network is a novel therapeutic approach for treatment of breast cancer and possibly other cancers.
therapeutic target	hsa-mir-145	Carcinoma, Breast	25923846			D05	D001943	114480	HP:0003002	Inclusion of miR-145 target sequences into the 3'-UTR of the Renilla luciferase gene is a feasible strategy for restricting transgene expression in a breast cancer cell line while sparing a breast normal cell line.
therapeutic target	hsa-mir-146b	Carcinoma, Breast	24667374			D05	D001943	114480	HP:0003002	Overall, this study contributes to our understanding of how inflammation is involved in oncogenic transformation. Further studies could evaluate the therapeutic potential of targeting this circuit in estrogen receptor-negative breast cancers.
therapeutic target	hsa-mir-17	Carcinoma, Breast	25499219			D05	D001943	114480	HP:0003002	EZH2 is reciprocally regulated by a novel signaling network consisting of Sp proteins, oncogenic miRs  and ZBTB4, and modulation of this gene network is a novel therapeutic approach for treatment of breast cancer and possibly other cancers.
therapeutic target	hsa-mir-21	Carcinoma, Breast	28067096			D05	D001943	114480	HP:0003002	Differential response of normal and transformed mammary epithelial cells to combined treatment of anti-miR-21 and radiation.
therapeutic target	hsa-mir-7	Carcinoma, Breast	25070049			D05	D001943	114480	HP:0003002	the overexpression of miR-7 might serve as a good strategy for treating highly invasive breast cancer.
therapeutic target	hsa-mir-103a	Carcinoma, Breast, Triple Negative	24945253				D064726			This model based on miRNA and node status covariates may be used to stratify TNBC patients into different prognostic subgroups for potentially individualized therapy.
therapeutic target	hsa-mir-107	Carcinoma, Breast, Triple Negative	24945253				D064726			This model based on miRNA and node status covariates may be used to stratify TNBC patients into different prognostic subgroups for potentially individualized therapy.
therapeutic target	hsa-mir-143	Carcinoma, Breast, Triple Negative	28621239				D064726			A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
therapeutic target	hsa-mir-17	Carcinoma, Breast, Triple Negative	26629823				D064726			Our results imply that therapeutic antisense sequences against miRNAs should be designed to target the miRNA strand with the greatest number of putative binding sites in the target mRNAs, while minimizing affinity for the minor strand.
therapeutic target	hsa-mir-18a	Carcinoma, Breast, Triple Negative	27338043				D064726			MiR-18a overexpression significantly increased PTX IC50 and reduced PTX induced cell apoptosis
therapeutic target	hsa-mir-21	Carcinoma, Breast, Triple Negative	26387848				D064726			The results demonstrate the clinical potentials of RNA nanotechnology based platform to deliver miRNA based therapeutics for cancer treatment.
therapeutic target	hsa-mir-27a	Carcinoma, Breast, Triple Negative	25943633				D064726			The miR-27a-CDC27 axis might play an important role in modulating response to radiotherapy in TNBC cells. Testing miR-27a expression might be a useful way to identify a subgroup of patients who will benefit from an IR-based therapeutic approach.
therapeutic target	hsa-mir-27b	Carcinoma, Breast, Triple Negative	24945253				D064726			This model based on miRNA and node status covariates may be used to stratify TNBC patients into different prognostic subgroups for potentially individualized therapy.
therapeutic target	hsa-mir-30a	Carcinoma, Breast, Triple Negative	28621239				D064726			A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
therapeutic target	hsa-mir-34a	Carcinoma, Breast, Triple Negative	24565525				D064726			Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
therapeutic target	hsa-mir-34a	Carcinoma, Breast, Triple Negative	25044638				D064726			HP-IPECs have a great potential as a biodegradable vector for microRNA-based therapy against triple-negative breast cancer.
therapeutic target	hsa-mir-34a	Carcinoma, Breast, Triple Negative	26676753				D064726			Together, our results demonstrate that miR-34a exerts potent antitumorigenic effects in vitro and in vivo and suggests that miR-34a replacement therapy, which is currently being tested in human clinical trials, represents a promising therapeutic strategy for TNBC.
therapeutic target	hsa-mir-770	Carcinoma, Breast, Triple Negative	28621239				D064726			A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
therapeutic target	hsa-mir-9	Carcinoma, Breast, Triple Negative	28621239				D064726			A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
therapeutic target	hsa-mir-96	Carcinoma, Breast, Triple Negative	27170187				D064726			3 directly engages pri-miR-96 in breast cancer cells.
therapeutic target	hsa-mir-101	Carcinoma, Cervical	24987920	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	We concluded that by targeting the proto-oncogene Fos, miR-101 is involved in G1-to-S phase transition in cervical cancer cells in vitro and might provide a new approach for the pharmacological interference node in cervical cancer treatment.
therapeutic target	hsa-mir-101	Carcinoma, Cervical	26617722	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiR-101 likely acts as a tumor suppressor in cervical cancer.Overexpression of miR-101 decreased expression of its target gene Cox-2 and inhibited proliferation and invasion, and promoted apoptosis to suppress tumorigenicity. MiR-101 is a promising new target for the development of therapeutic strategies for the clinical treatment of cervical cancer.
therapeutic target	hsa-mir-125a	Carcinoma, Cervical	26389681	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	These data highlight the importance of miR-125a in the cell proliferation and progression of cervical cancer, and indicate that miR-125a may be a useful therapeutic target for cervical cancer.
therapeutic target	hsa-mir-125a	Carcinoma, Cervical	26766902	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The molecular pathway of miR-125a-5p/ABL2 plays an important role in human cervical carcinoma. Targeting miR-125a-5p/ABL2 pathway may provide a new treatment strategy for patients with cervical carcinoma.
therapeutic target	hsa-mir-126	Carcinoma, Cervical	24013227	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	the temporal, spatial and progressive nature of tumor-stroma interactions during carcinogenesis, while in turn suggesting therapeutic strategies.
therapeutic target	hsa-mir-126	Carcinoma, Cervical	24516357	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and  treatment.
therapeutic target	hsa-mir-143	Carcinoma, Cervical	24516357	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and  treatment.
therapeutic target	hsa-mir-183	Carcinoma, Cervical	26873866	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	In conclusion, our study revealed that miR-183 might be a tumor suppressor via inhibiting the invasion and metastasis of cervical cancer cells through targeting MMP-9, indicating that miR-183 may be a novel potential therapeutic target for cervical cancer.
therapeutic target	hsa-mir-196a	Carcinoma, Cervical	24120501	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The findings provide new insights about the functional role of miR-196a in cervical carcinogenesis and suggested a potential use of miR-196a for clinical diagnosis and as a therapeutic target.
therapeutic target	hsa-mir-196a	Carcinoma, Cervical	24423924	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-196a has an important role in promoting human cervical cancer cell proliferation and may represent a novel therapeutic target of microRNA-mediated suppression of cell proliferation in cervical cancer.
therapeutic target	hsa-mir-203	Carcinoma, Cervical	23867971	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Our collective findings indicate that miR-203 functions as a tumor suppressor by targeting VEGFA, resulting in the inhibition of tumor growth and angiogenesis. Thus, miR-203 may be a potential therapeutic target and prognostic marker in cervical cancer.
therapeutic target	hsa-mir-206	Carcinoma, Cervical	26775359	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-206 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of cervical cancer.
therapeutic target	hsa-mir-21	Carcinoma, Cervical	24516357	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and  treatment.
therapeutic target	hsa-mir-214	Carcinoma, Cervical	25556274	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA-214 and MTFA may become important candidates for developing promising therapeutic strategies for the treatment of cervical cancer.
therapeutic target	hsa-mir-218	Carcinoma, Cervical	25473903	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	the miR-218~survivin axis inhibits cervical cancer progression by regulating clonogenicity, migration, and invasion, and suggest that the inhibition of survivin could be a potential therapeutic strategy to improve outcome in this disease.
therapeutic target	hsa-mir-222	Carcinoma, Cervical	24895988	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiR-222 plays an important role in the tumorigenesis of CC, possibly by specifically down-regulating p27Kip1 and PTEN. Our findings suggest that miR-222 may serve as a new therapeutic target in CC.
therapeutic target	hsa-mir-224	Carcinoma, Cervical	26390698	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The results suggests that miR-224 might serve as a predictor for paclitaxel response or a therapeutic target in cervical cancer therapy.
therapeutic target	hsa-mir-375	Carcinoma, Cervical	23778521	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Collectively, our results suggest that miR-375 might be a therapeutic target in paclitaxel-resistant cervical cancer.
therapeutic target	hsa-mir-520h	Carcinoma, Cervical	25047463	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Our results indicate a functional link between ATO-mediated PP2A/C regulation, CXCR4 expression, and tumor-suppressing ability. This information will be critical in realizing the potential for synergy between ATO and other anti-cancer agents, thus providing enhanced benefit in cancer therapy.
therapeutic target	hsa-mir-92a	Carcinoma, Cervical	25623537	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-92a acts as an onco-miRNA and may contribute to the progression and invasion of cervical cancer, suggesting miR-92a as a potential novel diagnostic and therapeutic target of cervical cancer.
therapeutic target	hsa-mir-1	Carcinoma, Colon	26459459	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings demonstrated that miR-145 and miR-1 play a negative regulatory role in the proliferation of colon cancer by targeting NAIP; thus, miR-145 and miR-1 may prove to be novel therapeutic targets in the treatment of colon cancer.
therapeutic target	hsa-mir-100	Carcinoma, Colon	25483280	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	the results of the current study elucidate a novel regulatory pathway involving miR-100 and Lgr5 in colon cancer cells, which may present a potential therapeutic target.
therapeutic target	hsa-mir-126	Carcinoma, Colon	23981989	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-126 was able to inhibit the development of colon cancer and its level was closely related with the prognosis of patients with colon cancer. The potential target genes for miR-126 might include IRS1, SLC7A5 and TOM1. Therefore, miR-126 might be a therapeutic target for colon cancer diagnosis and treatment.
therapeutic target	hsa-mir-133b	Carcinoma, Colon	24594999	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	TAp63 and microRNA-133b were able to suppress the metastasis of colon cancer. Both TAp63 and microRNA-133b may be potential biomarkers for diagnosis in colon cancer metastasis and may provide unique therapeutic targets for this common malignancy.
therapeutic target	hsa-mir-141	Carcinoma, Colon	28112364	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-141 inhibits tumor growth and minimizes therapy resistance in colorectal cancer.
therapeutic target	hsa-mir-145	Carcinoma, Colon	26459459	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings demonstrated that miR-145 and miR-1 play a negative regulatory role in the proliferation of colon cancer by targeting NAIP; thus, miR-145 and miR-1 may prove to be novel therapeutic targets in the treatment of colon cancer.
therapeutic target	hsa-mir-145	Carcinoma, Colon	27482839	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The results in this work show  that miR-145 has been effectively delivered to colon carcinomas through a PLGA/PEI/HA vehicle, indicating a promising miRNA replacement therapy strategy.
therapeutic target	hsa-mir-146a	Carcinoma, Colon	24670457	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-146a may serve as a potential therapeutic target for colonic cancer for its role in inhibiting colonic cancer cell proliferation.
therapeutic target	hsa-mir-17	Carcinoma, Colon	26463716	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets.
therapeutic target	hsa-mir-18	Carcinoma, Colon	26463716	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets.
therapeutic target	hsa-mir-19a	Carcinoma, Colon	26463716	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets.
therapeutic target	hsa-mir-19b-1	Carcinoma, Colon	26463716	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets.
therapeutic target	hsa-mir-20a	Carcinoma, Colon	26463716	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets.
therapeutic target	hsa-mir-21	Carcinoma, Colon	25051407	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	This population-based study supports miRNA-21 as an additional prognostic biomarker in patients with stage II colon cancer. Furthermore, the introduction of a risk index may guide the use of postoperative adjuvant treatment in a more appropriate way compared with current practice. bta-hsa-mir-142-5p,hsa-mir-223
therapeutic target	hsa-mir-31	Carcinoma, Colon	28147317	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.
therapeutic target	hsa-mir-320	Carcinoma, Colon	25446103	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-320-FOXM1 axis may overcome chemo-resistance of colon cancer cells and provide a new therapeutic target for the treatment of colon cancer.
therapeutic target	hsa-mir-92-1	Carcinoma, Colon	26463716	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets.
therapeutic target	hsa-mir-92a	Carcinoma, Colon	26463716	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our findings identify a novel cellular mechanism whereby butyrate inhibits miR-92a transcription by reducing c-Myc, thus augmenting p57 levels.These actions diminish colon cancer cell proliferation and stimulate apoptosis.This newly described regulation of oncogenic miRNA biogenesis expands our understanding of colon cancer cell biology and identifies novel therapeutic targets.
therapeutic target	hsa-mir-34a	Carcinoma, Embryonal	25551588	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	Deeper understanding of the aberrant miRNA expression in pediatric embryonal brain tumors might aid in the development of tumor-specific miRNA signatures, which could potentially afford promising biomarkers related to diagnosis, prognosis and patient targeted therapy.
therapeutic target	hsa-mir-601	Carcinoma, Embryonal	25551588	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	Deeper understanding of the aberrant miRNA expression in pediatric embryonal brain tumors might aid in the development of tumor-specific miRNA signatures, which could potentially afford promising biomarkers related to diagnosis, prognosis and patient targeted therapy.
therapeutic target	hsa-mir-200	Carcinoma, Endometrial	25738863	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	These results suggest that acquirement of EXM-resistance in Ish/EXM cells induces up regulation of ZEB1 via suppression of the miR-200 family following suppression of E-cadherin. Since suppression of ZEB1 in Ish/EXM cells by treatment with its siRNA did not restore the miR-200 family expression,miR-200 family was placed upstream of ZEB1 to regulate the expression.
therapeutic target	hsa-mir-204	Carcinoma, Endometrial	24321270	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	This study uncovers a new regulatory loop involving TrkB/miR-204-5p that is critical to the tumorigenesis of EC and proposes that reestablishment of miR-204-5p expression could be explored as a potential new therapeutic target for this disease.
therapeutic target	hsa-mir-218	Carcinoma, Endometrial	26261543	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	These results reveal novel potential role of miR-218 against chemotherapy resistance during the treatment of endometrial carcinoma.
therapeutic target	hsa-mir-30c	Carcinoma, Endometrial	24595016	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Taken together, our results suggest that miR-30c is an important deregulated miRNA in EC and might serve as a potential biomarker and novel therapeutic target for EC.
therapeutic target	hsa-mir-424	Carcinoma, Endometrial	26638889	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Taken together, our study suggests that increased miR-424 suppresses E2-induced cell growth, and providing a potential therapeutic target for estrogen-associated endometrial carcinoma.
therapeutic target	hsa-mir-106a	Carcinoma, Esophageal	26314198	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Our data indicate that miR-106a* might play an anti-oncogenic role in EC by regulating CACUL1 expression, which suggest miR-106a* as a new potential diagnostic and therapeutic target for EC.
therapeutic target	hsa-mir-21	Carcinoma, Esophageal	24324076	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The effect of miR-21 on PTEN/AKT signaling pathway is abrogated by the novel arene Ru(II) drug Rawq01. Our data may be useful for the future development of a chemosensitizing strategies through manipulating microRNA expression for tumor treatment.
therapeutic target	hsa-mir-217	Carcinoma, Esophageal	25703328	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	these data demonstrate that epigenetic repression of miR-217 contributes to the pathogenesis of EAC via upregulation of KLK7 and suggest that restoration of miR-217 expression may be a novel treatment strategy for these malignancies.
therapeutic target	hsa-mir-34a	Carcinoma, Esophageal	24528540	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Our findings suggest that miR-34a is involved in the etiology of ESCC and that hypermethylated miR-34a is a potential biomarker for ESCC diagnosis and prognosis. Moreover, targeting miR-34a methylation by demethylating agents may offer a novel strategy for anticancer therapy of ESCC.
therapeutic target	hsa-mir-451	Carcinoma, Esophageal	26019450	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	These findings suggest that miR-451 might be a novel prognostic biomarker and a potential target for the treatment of esophageal squamous cell carcinoma in the future.
therapeutic target	hsa-mir-20a	Carcinoma, Gallbladder	23665284	disease of cellular proliferation	DOID:4948	C23	D005706			TGF-β1-mediated activation of the miR-20a/Smad7/β-catenin axis plays a pivotal role in the pathogenesis and worse prognosis of GBCs and may serve as a potential therapeutic target in the future.
therapeutic target	hsa-mir-27a	Carcinoma, Gallbladder	26288960	disease of cellular proliferation	DOID:4948	C23	D005706			In conclusion, the miRNA variants cumulatively influence GBC susceptibility and treatment outcomes.
therapeutic target	hsa-mir-570	Carcinoma, Gallbladder	26288960	disease of cellular proliferation	DOID:4948	C23	D005706			In conclusion, the miRNA variants cumulatively influence GBC susceptibility and treatment outcomes.
therapeutic target	hsa-mir-29c	Carcinoma, Gastric	24870620	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-29c acts as a tumour suppressor in GC by directly targeting ITGB1. Loss of miR-29c expression is an early event in the initiation of gastric carcinogenesis and may serve as a diagnostic and therapeutic biomarker for patients with GC.
therapeutic target	hsa-mir-31	Carcinoma, Gastric	26494556	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Therefore, miR-31 could be a useful biomarker for monitoring GC development and progression, and also could potential by targeting SGPP2, Smad4 and STAT3 for GC therapy.have a therapeutic
therapeutic target	hsa-mir-32	Carcinoma, Gastric	26471298	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	We conclude that miR-32 promotes GC cell proliferation,migration and invasion by targeting KLF4, suggesting that the miR-32-KLF4 pathway may be useful in clinical diagnosis and therapeutics.
therapeutic target	hsa-mir-339	Carcinoma, Gastric	26391641	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	These findings uncover a novel role for miR-339 in gastric carcinogenesis, and restoration of miR-339 could be considered as a potential therapeutic strategy for GC treatment.
therapeutic target	hsa-mir-508	Carcinoma, Gastric	26801246	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	All these findings supports that canonical NF-κB signaling pathway is activated in GC at least by the inactivation of miR-508-3p and this might have therapeutic potential in GC treatment.
therapeutic target	hsa-mir-647	Carcinoma, Gastric	28098914	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-647 exerts powerful antitumorigenic effects in vitro and in vivo, and may represent a promising therapeutic agent against GC
therapeutic target	hsa-let-7a	Carcinoma, Hepatocellular	26468984	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC.
therapeutic target	hsa-let-7a	Carcinoma, Hepatocellular	25429777	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Chol-let-7a inhibited the viability and mobility of HCC cells.
therapeutic target	hsa-mir-101	Carcinoma, Hepatocellular	24002871	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	c-Myc collaborates with EZH2-containing PRC2 complex in silencing tumor-suppressive miRNAs during hepatocarcinogenesis and provides promising therapeutic candidates for human HCC.
therapeutic target	hsa-mir-101	Carcinoma, Hepatocellular	25693145	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.
therapeutic target	hsa-mir-103	Carcinoma, Hepatocellular	26646106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings indicate that miR-103 potentially acts as an oncogene in HCC by inhibiting AKAP12 expression and raise the possibility that miR-103 increases telomerase activity by increasing PKCα activity. Thus, miR-103 may represent a new potential diagnostic and therapeutic target for HCC treatment.
therapeutic target	hsa-mir-106a	Carcinoma, Hepatocellular	25510666	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	upregulated expression of miR-106a by its promoter hypomethylation might contribute to the progression of HCC, which might be considered as a potentially effective biomarker and therapeutic approach in the future
therapeutic target	hsa-mir-106b	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-106b	Carcinoma, Hepatocellular	25393367	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The HDACi SAHA epigenetically upregulates MICA expression through regulating the expression of miR-17-92 cluster and MCM7 in hepatoma, thus enhancing the sensitivity of HCC to natural killer cell-mediated lysis. This novel mechanism of action provides promise for HDACi in therapy of HCC.
therapeutic target	hsa-mir-10b	Carcinoma, Hepatocellular	25236186	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results suggested that miR-10b was overexpressed in HCC and promoted HCC cell migration and invasion through the HOXD10/ RhoC/ uPAR/ MMPs pathway which may provide a novel bio-target for HCC therapy.
therapeutic target	hsa-mir-122	Carcinoma, Hepatocellular	26506419	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings suggest that enhanced glycolysis is associated with CD133 (+) stem-like characteristics and that metabolic reprogramming through miR-122 or PDK4 may represent a novel therapeutic approach for the treatment of hepatocellular cancer.
therapeutic target	hsa-mir-122	Carcinoma, Hepatocellular	26302777	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122 is a novel target gene of FXR, and the upregulation of miR-122 by FXR represses the growth of HCC cells, suggesting that FXR may serve as a key transcriptional regulator for manipulating miR-122 expression, and the FXR/miR-122 pathway may therefore be a novel target for the treatment of HCC.
therapeutic target	hsa-mir-122	Carcinoma, Hepatocellular	26151503	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggested that differential miRNA profiling in malignant hepatocytes may account for the variable pathophysiological manifestations associated with the HCV NS4 protein. These differentially expressed miRNAs may offer potential as candidates for the development of miRNA-based therapeutics.
therapeutic target	hsa-mir-122	Carcinoma, Hepatocellular	27059462	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners.
therapeutic target	hsa-mir-126	Carcinoma, Hepatocellular	23378255	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	down-regulation of miR-126 plays an important role in HCC metastasis, and suggest a potential application of miR-126 in prognosis prediction and HCC treatment
therapeutic target	hsa-mir-126	Carcinoma, Hepatocellular	25240815	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrates that deregulation of miR-126-3p contributes to metastasis and angiogenesis in HCC. The restoration of miR-126-3p expression may be a promising strategy for HCC therapy.
therapeutic target	hsa-mir-126	Carcinoma, Hepatocellular	25585946	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-126 as a tumor suppressor in HCC through, at least partially by targeting Sox2. This may provide novel diagnostic and therapeutic options for  human HCC in future.
therapeutic target	hsa-mir-126	Carcinoma, Hepatocellular	27059462	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners.
therapeutic target	hsa-mir-127	Carcinoma, Hepatocellular	26708147	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, we found that miR-127-5p suppressed NF-κB activity by directly targeting BLVRB in HCC cells, and this finding improves our understanding of the molecular mechanism of inflammation-induced HCC growth and proliferation and the successful inhibition of NF-κB activity by cancer treatment.
therapeutic target	hsa-mir-1297	Carcinoma, Hepatocellular	26398017	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Collectively,miR-1297 was revealed to regulate the proliferation, apoptosis and migration of hepatocellular carcinoma cells via acting on HMGA2. The finding provides a new target for the treatment of hepatocellular carcinoma.
therapeutic target	hsa-mir-130a	Carcinoma, Hepatocellular	26817584	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings provide a molecular insight on understanding drug resistance in HCC cells. Therefore, activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC.
therapeutic target	hsa-mir-130a	Carcinoma, Hepatocellular	26151503	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggested that differential miRNA profiling in malignant hepatocytes may account for the variable pathophysiological manifestations associated with the HCV NS3 protein. These differentially expressed miRNAs may offer potential as candidates for the development of miRNA-based therapeutics.
therapeutic target	hsa-mir-133a	Carcinoma, Hepatocellular	25607810	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MMP-9 may be used for the development of novel molecular markers and therapeutic approaches to inhibit hepatocellular carcinoma metastasis.
therapeutic target	hsa-mir-133b	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-135b	Carcinoma, Hepatocellular	25537516	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HSF1/miR-135b/RECK&EVI5 axis provides novel insight into the mechanisms of HCC metastasis, which may facilitate the development of new therapeutics against HCC
therapeutic target	hsa-mir-136	Carcinoma, Hepatocellular	25050974	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-375 and miR-137 may have the miRNA-based therapeutic potential in HBV-associated HCC.
therapeutic target	hsa-mir-137	Carcinoma, Hepatocellular	25739100	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Further knowledge obtained from this study may provide important evidence for the prevention and targeted therapy of HCC.
therapeutic target	hsa-mir-139	Carcinoma, Hepatocellular	24190507	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-139 downregulation is common in HCC and that overexpression of miR-139 expression inhibits cell proliferation and invasion, suggesting that miR-139 may provide a therapeutic strategy for the treatment of HCC patients.
therapeutic target	hsa-mir-141	Carcinoma, Hepatocellular	24551096	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings indicated that miR-141 functions as a tumor suppressor and inhibits the migration and invasion of HCC cells by targeting Tiam1, which may provide novel prognostic and treatment strategies for HCC patients.
therapeutic target	hsa-mir-143	Carcinoma, Hepatocellular	26468984	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC.
therapeutic target	hsa-mir-145	Carcinoma, Hepatocellular	26468984	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC.
therapeutic target	hsa-mir-145	Carcinoma, Hepatocellular	29156696	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The interaction between pSmad3C/3L and microRNA-145/21 regulates HCC progression and the switch of pSmad3C/3L may serve as an important target for HCC therapy
therapeutic target	hsa-mir-146a	Carcinoma, Hepatocellular	25607648	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the mechanism responsible for tumor-induced immune suppression highlights the potential application of miR-146a as a novel immunotherapeutic target for HCC.
therapeutic target	hsa-mir-146b	Carcinoma, Hepatocellular	19584283	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	a liver-specific miRNA; down-regulation in HCC; miR-122 can regulate the expression of cyclin G1; by modulating cyclin G1 with doxorubicin, miR-122 influences p53 protein stability and transcriptional activity and reduces invasion capability of HCC-derived cell lines; miR-122, as well as cyclin G1 silencing, increases sensitivity to doxorubicin challenge;  miR-122 levels were associated with a shorter TTR (time to recurrence); potential combined chemo- and miRNA-based therapeutic target
therapeutic target	hsa-mir-148a	Carcinoma, Hepatocellular	22496917	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-148a may play a central role in HBx/URG11 mediated HCC, and may be an early diagnostic marker and/or therapeutic target associated with this tumor type.
therapeutic target	hsa-mir-148a	Carcinoma, Hepatocellular	24013226	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings highlight the significance of miR-148a downregulation in tumor progression and implicate miR-148a as an attractive candidate for cancer therapy.
therapeutic target	hsa-mir-148a	Carcinoma, Hepatocellular	26599259	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-148a is an inhibitor of the IκB kinase alpha/NUMB/NOTCH pathway and an inducer of hepatocytic differentiation that when deregulated promotes HCC initiation and progression. Differentiation-targeted therapy may be a promising strategy to treat and prevent HCC.
therapeutic target	hsa-mir-148b	Carcinoma, Hepatocellular	25627001	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the frequently downregulated miR-148b can regulate WNT1/β-catenin signalling pathway and function as a tumor suppressor in HCC. These findings suggest that miR-148b may serve as a novel therapeutic target for HCC. 
therapeutic target	hsa-mir-148b	Carcinoma, Hepatocellular	26530325	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggested that miR-148 may represent a novel molecular marker and a potential molecular therapeutic for inhibiting metastasis of HCC.
therapeutic target	hsa-mir-149	Carcinoma, Hepatocellular	25424347	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The newly identified miR-149/AKT/mTOR axis might be a promising therapeutic target in the prevention and treatment of HCC.
therapeutic target	hsa-mir-149	Carcinoma, Hepatocellular	26498692	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Taken together, our findings indicates that miR-149 is a potential prognostic biomarker of HCC and that the miR-149/PPM1F regulatory axis represents a novel therapeutic target for HCC treatment.
therapeutic target	hsa-mir-152	Carcinoma, Hepatocellular	24998573	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Underexpression of miR-152 plays a vital role in hepatocarcinogenesis and lack of miR-152 is related to the progression of HCC through deregulation of cell proliferation, motility and apoptosis. miR-152 may act as a tumor suppressor miRNA by also targeting TNFRSF6B and is therefore a potential candidate biomarker for HCC diagnosis, prognosis and molecular therapy.
therapeutic target	hsa-mir-15a	Carcinoma, Hepatocellular	27059462	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners.
therapeutic target	hsa-mir-15b	Carcinoma, Hepatocellular	26259570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value.
therapeutic target	hsa-mir-15b	Carcinoma, Hepatocellular	19956871	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results indicate that miR-15b expression in HCC tissues may predict a low risk of HCC recurrence. In addition, the modulation of miR-15b expression may be useful as an apoptosis-sensitizing strategy for HCC treatment.
therapeutic target	hsa-mir-17	Carcinoma, Hepatocellular	25617127	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the molecular mechanisms of how PTENP1 repressed the tumorigenic properties of HCC cells and demonstrated the potential of the SB-BV hybrid vector for PTENP1 lncRNA modulation and HCC therapy.
therapeutic target	hsa-mir-17	Carcinoma, Hepatocellular	26233958	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy.
therapeutic target	hsa-mir-17	Carcinoma, Hepatocellular	29464015	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hence, anti-miR-17 is an effective therapy for MYC-driven HCC
therapeutic target	hsa-mir-18	Carcinoma, Hepatocellular	26233958	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy.
therapeutic target	hsa-mir-181c	Carcinoma, Hepatocellular	26259570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value.
therapeutic target	hsa-mir-188	Carcinoma, Hepatocellular	25998163	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings collectively demonstrate a tumor suppressor role of miR-188-5p in HCC progression via targeting FGF5, suggesting that miR-188-5p could serve as a potential prognostic biomarker and therapeutic target for HCC.
therapeutic target	hsa-mir-191	Carcinoma, Hepatocellular	20924108	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings offer a preclinical proof of concept for miR-191 targeting as a rational strategy to pursue for improving HCC treatment.
therapeutic target	hsa-mir-192	Carcinoma, Hepatocellular	26710269	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results elucidate that the miR-192/-204-HOTTIP axis might be an important molecular pathway during hepatic cell tumorigenesis. Our data in clinical HCC samples highlight miR-192, miR-204 and HOTTIP with prognostic and potentially therapeutic implications.
therapeutic target	hsa-mir-195	Carcinoma, Hepatocellular	25607636	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-195 acts as a tumor suppressor by directly targeting CBX4 in HCC. This finding suggests a potential novel strategy for therapeutic interventions of this disease.
therapeutic target	hsa-mir-195	Carcinoma, Hepatocellular	19441017	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data highlight an important role of miR-195 in cell cycle control and in the molecular etiology of HCC, and implicate the potential application of miR-195 in cancer therapy.
therapeutic target	hsa-mir-197	Carcinoma, Hepatocellular	24613834	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Taken together, these data suggest that anti-miR-197 suppresses HCC migration and invasion by targeting CD82. The regulation of the miR-197/CD82 axis could be a novel therapeutic target in future HCC effective therapy.
therapeutic target	hsa-mir-199	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-199a	Carcinoma, Hepatocellular	26346275	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These data reveal a novel mechanism of reprogramming of cancer energy metabolism in which HuR suppresses miR-199a maturation to link hypoxia to the Warburg effect and suggest a promising therapeutic strategy that targets miR-199a to interrupt cancerous aerobic glycolysis.
therapeutic target	hsa-mir-199a	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-199a-1	Carcinoma, Hepatocellular	21316602	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma
therapeutic target	hsa-mir-199a-2	Carcinoma, Hepatocellular	21316602	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma
therapeutic target	hsa-mir-199b	Carcinoma, Hepatocellular	21316602	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma
therapeutic target	hsa-mir-19a	Carcinoma, Hepatocellular	26233958	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy.
therapeutic target	hsa-mir-19a	Carcinoma, Hepatocellular	29393488	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR‑19a may have potential as a novel molecular marker for HCC and Pter may be a promising clinical target with the potential to be developed as a HCC therapy
therapeutic target	hsa-mir-19b-1	Carcinoma, Hepatocellular	26233958	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy.
therapeutic target	hsa-mir-200	Carcinoma, Hepatocellular	26468984	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings suggest that the detection of elevated plasma DCLK1 may provide a cost-effective, less invasive tool for confirmation of clinical signs of cirrhosis, and a potential companion diagnostic marker for patients with cirrhosis and HCC. Our results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC.
therapeutic target	hsa-mir-200a	Carcinoma, Hepatocellular	26617701	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study reveals an important role of miR-200a in inhibiting EMT,proliferation and migration in HCC cells, suggesting the possibility of miR-200a-based therapeutics in HCC.
therapeutic target	hsa-mir-200b	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-204	Carcinoma, Hepatocellular	26710269	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results elucidate that the miR-192/-204-HOTTIP axis might be an important molecular pathway during hepatic cell tumorigenesis. Our data in clinical HCC samples highlight miR-192, miR-203 and HOTTIP with prognostic and potentially therapeutic implications.
therapeutic target	hsa-mir-206	Carcinoma, Hepatocellular	25436301	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-206 could not only be useful as a novel biomarker but also serve as a potential target for gene therapy of HCC.
therapeutic target	hsa-mir-20a	Carcinoma, Hepatocellular	26233958	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy.
therapeutic target	hsa-mir-20a	Carcinoma, Hepatocellular	26031366	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-20a induces HCC cell radioresistance by activating the PTEN/PI3K/Akt pathway, which suggests that miR-20a/PTEN/PI3K/Akt might represent a target of investigation for developing effective therapeutic strategies against HCC.
therapeutic target	hsa-mir-20a	Carcinoma, Hepatocellular	25393367	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The HDACi SAHA epigenetically upregulates MICA expression through regulating the expression of miR-17-92 cluster and MCM7 in hepatoma, thus enhancing the sensitivity of HCC to natural killer cell-mediated lysis. This novel mechanism of action provides promise for HDACi in therapy of HCC.
therapeutic target	hsa-mir-20a	Carcinoma, Hepatocellular	23594563	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings suggest miR-20a may represent a novel potential therapeutic target and biomarker for survival of HCC patients
therapeutic target	hsa-mir-20b	Carcinoma, Hepatocellular	26612965	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The whole study suggests that miR-20b, HIF-1α, and VEGF serve as a potential therapeutic agent for hepatocellular carcinoma.
therapeutic target	hsa-mir-21	Carcinoma, Hepatocellular	25428915	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	targeting this signaling pathway would be helpful as a therapeutic strategy for the reversal of  chemoresistance in HCC.
therapeutic target	hsa-mir-21	Carcinoma, Hepatocellular	24939570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results provide new insights into the complexity of EPC-HCC interactions and indicate that anticancer therapies targeting either the MCP-1 released from angiogenic EPCs or the miR-21 biogenesis in HCC cells may prevent the malignant progression of primary tumours.
therapeutic target	hsa-mir-21	Carcinoma, Hepatocellular	25544773	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Targeting microRNA-21 enhances the effect of chemotherapeutic drugs, thereby suggesting that microRNA-21 suppression in combination with HAIC may be a novel approach for HCC treatment.
therapeutic target	hsa-mir-21	Carcinoma, Hepatocellular	26311740	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We conclude that miR-21 participates in the acquired resistance of sorafenib by suppresing autophagy through the Akt/PTEN pathway. MiR-21 could serve as a therapeutic target for overcoming sorafenib resistance in the treatment of HCC.
therapeutic target	hsa-mir-21	Carcinoma, Hepatocellular	26427512	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The results show that miR-21 degradation can decrease the viability of cells, mainly by induction of apoptosis and necrosis. These findings suggest that degradation of miR-21 could be used as a novel approach in treatment of HCC. 
therapeutic target	hsa-mir-215	Carcinoma, Hepatocellular	26135967	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues.
therapeutic target	hsa-mir-22	Carcinoma, Hepatocellular	27059462	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners.
therapeutic target	hsa-mir-221	Carcinoma, Hepatocellular	24324033	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
therapeutic target	hsa-mir-221	Carcinoma, Hepatocellular	25483016	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-221 has potential as an miRNA-based therapeutic target for HBV-related HCC.
therapeutic target	hsa-mir-222	Carcinoma, Hepatocellular	25444921	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the complex molecular mechanisms underlying the invasion and metastasis of HCC and may provide new therapeutic targets.
therapeutic target	hsa-mir-26a	Carcinoma, Hepatocellular	24259426	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-26a could suppress tumor angiogenesis of HCC through HGF-cMet signaling, and it is a new hopeful therapeutic target and prognostic marker for HCC.
therapeutic target	hsa-mir-26a	Carcinoma, Hepatocellular	25537511	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ITGA5 is a functional target of miR-26a-induced anoikis in HCC cells. Collectively, our findings reveal that miR-26a is a novel player during anoikis and a potential therapeutic target for the treatment of metastatic HCC.
therapeutic target	hsa-mir-26a	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-26b	Carcinoma, Hepatocellular	26078955	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study showed that miR-26b was a negative regulator of Mcl-1 gene and sensitized TRAIL-inducing apoptosis in HCC cells, suggesting that the miR-26b-Mcl-1 pathway might be a novel target for the treatment of HCC.
therapeutic target	hsa-mir-27a	Carcinoma, Hepatocellular	25836616	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings suggested that miRNA-27a promoted HCC cell proliferation by regulating PPAR-γ expression. MiR-27a may provide a potential therapeutic strategy for HCC treatment.
therapeutic target	hsa-mir-27a	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-27a	Carcinoma, Hepatocellular	23621256	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our results suggest that up-regulation of miR-27a may play an oncogenic role in the development of HCC and might thus be a new therapeutic target in HCC patients.
therapeutic target	hsa-mir-28	Carcinoma, Hepatocellular	26754294	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A miR-28-5p-IL-34-macrophage feedback loop modulates HCC metastasis and serves as a novel prognostic factor as well as a therapeutic target for HCC.
therapeutic target	hsa-mir-29	Carcinoma, Hepatocellular	25616722	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the roles of feedback of miR-29-TET1 downregulation in HCC development and suggested a potential target in identification of the prognosis and application of cancer therapy for HCC patients.
therapeutic target	hsa-mir-296	Carcinoma, Hepatocellular	26151503	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results suggested that differential miRNA profiling in malignant hepatocytes may account for the variable pathophysiological manifestations associated with the HCV NS5 protein. These differentially expressed miRNAs may offer potential as candidates for the development of miRNA-based therapeutics.
therapeutic target	hsa-mir-29b	Carcinoma, Hepatocellular	26404322	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results demonstrate the profound effect of fucoidan not only on the regulation of miR-29b-DNMT3B-MTSS1 axis but also on the inhibition of TGF-β signaling in HCC cells, suggesting the potential of using fucoidan as integrative therapeutics against invasion and metastasis of HCC.
therapeutic target	hsa-mir-29c	Carcinoma, Hepatocellular	26259570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value.
therapeutic target	hsa-mir-30a	Carcinoma, Hepatocellular	24954667	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30a as a novel regulator of EMT by targeting SNAI1, indicating its potential therapeutic value for reducing invasion and metastasis of HCC.
therapeutic target	hsa-mir-30a	Carcinoma, Hepatocellular	27059462	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute to liver transplant selection criteria for practitioners.
therapeutic target	hsa-mir-30c	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-30e	Carcinoma, Hepatocellular	25811030	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.
therapeutic target	hsa-mir-335	Carcinoma, Hepatocellular	25804796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data revealed that miR-335 could inhibit the proliferation and migration invasion of HCC cells via regulating ROCK1, suggesting that miR-335 could be a therapeutic biomarker of HCC in the future.
therapeutic target	hsa-mir-335	Carcinoma, Hepatocellular	26305026	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data suggest that serum miR-335 can be used as a molecular marker to predict the treatment response and clinical outcome in HCC patients receiving TACE.
therapeutic target	hsa-mir-338	Carcinoma, Hepatocellular	25531114	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-338-3p inhibits HCC tumor growth and sensitizes HCC cells to sorafenib by down-regulating HIF-1α. Our data indicate that miR-338-3p could be a potential candidate for HCC therapeutics.
therapeutic target	hsa-mir-338	Carcinoma, Hepatocellular	26259570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value.
therapeutic target	hsa-mir-342	Carcinoma, Hepatocellular	25580008	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-342-3p has a significant role in HCC cell proliferation and is suitable for investigation of therapeutic targets.
therapeutic target	hsa-mir-362	Carcinoma, Hepatocellular	25449782	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-362-5p may serve as a novel therapeutic target for miRNA based HCC therapy
therapeutic target	hsa-mir-363	Carcinoma, Hepatocellular	26143754	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the combination of miR-363 and cisplatin may represent a novel approach in treatment for HCC, thus offering a new target for chemotherapy of HCC.
therapeutic target	hsa-mir-367	Carcinoma, Hepatocellular	26772880	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This study indicated that miR-367 negatively regulates PTEN and promotes proliferation and invasion of HCC cells. Thus, miR-367 may represent a potential therapeutic target for HCC intervention.
therapeutic target	hsa-mir-375	Carcinoma, Hepatocellular	25050974	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-375 and miR-136 may have the miRNA-based therapeutic potential in HBV-associated HCC.
therapeutic target	hsa-mir-375	Carcinoma, Hepatocellular	28624193	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.
therapeutic target	hsa-mir-378	Carcinoma, Hepatocellular	26259570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value.
therapeutic target	hsa-mir-425	Carcinoma, Hepatocellular	25040368	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Assessment of miR-425-3p levels in liver biopsies could help in stratifying patients with advanced HCC for sorafenib treatment. These promising results need to be confirmed in a large prospective study.
therapeutic target	hsa-mir-433	Carcinoma, Hepatocellular	25410752	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the roles and mechanisms of miRNA-433 in regulating HCC proliferation, and may benefit future development of therapeutics  targeting miRNA-433 and PAK4 in HCC.
therapeutic target	hsa-mir-4458	Carcinoma, Hepatocellular	25833000	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-4458 or IKBKE may be potential predictors of HCC prognosis.Restoration of miR-4458 or inhibition of IKBKE could be a prospective therapeutic approach for HCC.
therapeutic target	hsa-mir-449a	Carcinoma, Hepatocellular	26471185	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data highlight an important role of miR-449a in the molecular etiology of HCC, and implicate the potential application of miR-449a in cancer therapy.
therapeutic target	hsa-mir-450b	Carcinoma, Hepatocellular	26259570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value.
therapeutic target	hsa-mir-494	Carcinoma, Hepatocellular	23913442	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings identify a new therapeutic target (miR-494) for the treatment of HCC.
therapeutic target	hsa-mir-501	Carcinoma, Hepatocellular	25917358	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This study suggests that miR-501-5p may play an important role in the development of hepatocellular carcinoma by promoting cell proliferation, and indicates that miR-501-5p may represent a novel therapeutic target for hepatocellular carcinoma.
therapeutic target	hsa-mir-506	Carcinoma, Hepatocellular	26474697	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, our findings collectively suggest that miR-506 acts as a tumor suppressor via regulation of ROCK1 expression and may thus be a promising therapeutic target for HCC.
therapeutic target	hsa-mir-517a	Carcinoma, Hepatocellular	21324318	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-517a is an oncogenic miRNA that promotes tumor progression. There is rationale for developing therapies that miRNA 517 for patients with HCC.
therapeutic target	hsa-mir-542	Carcinoma, Hepatocellular	20574436	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of the most significant TrkA-correlated miRNA, miR-542-5p, also discriminated between local and metastatic disease and was inversely correlated with MYCN amplification and event-free survival. miR-542-5p might be important in neuroblastoma tumour biology, and qualify as potential therapeutic targets.
therapeutic target	hsa-mir-622	Carcinoma, Hepatocellular	26467022	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Taken together, miR-622 acts as a tumor suppressor in HCC and restoration of miR-622 may provide therapeutic benefits in the treatment of HCC.
therapeutic target	hsa-mir-622	Carcinoma, Hepatocellular	26404566	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This study establishes EZH2/miR-622/CXCR4 as a potential adverse prognostic factor and therapeutic target for HCC patients.
therapeutic target	hsa-mir-760	Carcinoma, Hepatocellular	26259570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a molecular expression signature and pathway regulatory mechanisms in HCSCs with potential diagnostic and therapeutic value.
therapeutic target	hsa-mir-9	Carcinoma, Hepatocellular	26547929	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study suggests that miR-9 functions as a tumor suppressor in HCC progression by inhibiting a series of target genes, including the newly validated miR-9/IGF2BP1/AKT&ERK axis, thus providing potential therapeutic targets and novel prognostic biomarkers for HCC patients.
therapeutic target	hsa-mir-92-1	Carcinoma, Hepatocellular	26233958	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate an important role of the miR-17-92 cluster in hepatocarcinogenesis and suggest the possibility of targeting this pivotal miRNA cluster for potential therapy.
therapeutic target	hsa-mir-92a	Carcinoma, Hepatocellular	26323375	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In conclusion, the results of the present study suggested that miR-92a promotes the tumor growth of HCC by targeting FBXW7 and may serve as a novel prognostic biomarker and therapeutic target for HCC.
therapeutic target	hsa-mir-93	Carcinoma, Hepatocellular	25393367	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The HDACi SAHA epigenetically upregulates MICA expression through regulating the expression of miR-17-92 cluster and MCM7 in hepatoma, thus enhancing the sensitivity of HCC to natural killer cell-mediated lysis. This novel mechanism of action provides promise for HDACi in therapy of HCC.
therapeutic target	hsa-mir-145	Carcinoma, Hepatocellular, HBV-Related	25260533							Thus, HBx protein differentially modulated the expression of miRNAs. The study throws light into possible way by which HBx protein acts through microRNA and thereby regulates host functioning. It might suggest new therapeutic strategies against hepatic cancer.
therapeutic target	hsa-mir-15b	Carcinoma, Hepatocellular, HBV-Related	24122375							Downregulation of microRNA-15b by hepatitis B virus X enhances hepatoceThe newly identified HBX/miR-15b/FUT2/Globo H axis suggests one possible molecular mechanism of HCC cell proliferation and represents a new potential therapeutic target for HCC treatment.llular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression.
therapeutic target	hsa-mir-21	Carcinoma, Hepatocellular, HBV-Related	25260533							Thus, HBx protein differentially modulated the expression of miRNAs. The study throws light into possible way by which HBx protein acts through microRNA and thereby regulates host functioning. It might suggest new therapeutic strategies against hepatic cancer.
therapeutic target	hsa-mir-222	Carcinoma, Hepatocellular, HBV-Related	25260533							Thus, HBx protein differentially modulated the expression of miRNAs. The study throws light into possible way by which HBx protein acts through microRNA and thereby regulates host functioning. It might suggest new therapeutic strategies against hepatic cancer.
therapeutic target	hsa-mir-152	Carcinoma, Hepatocellular, HCV-Related	24416131							These findings provide important evidence that the reduced miR-152 expression by HCV core protein can indirectly lose an inhibitory effect on Wnt1, which might, at least partially lead to cell proliferation of liver cancer cells.MiR-152 may have a therapeutic potential to suppress liver cancer proliferation.
therapeutic target	hsa-mir-101	Carcinoma, Laryngeal	26286725	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	These results indicate that miR-101 is a potent tumour repressor that directly represses CDK8 expression. Thus, detection and targeting of miR-101 may represent a novel diagnostic and therapeutic strategy for LSCC patients.
therapeutic target	hsa-mir-296	Carcinoma, Laryngeal	26264462	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	This study indicates that miR-296-5p expression is associated with resistance to radiotherapy and tumor recurrence in early stage LSCC, showing the feasibility of this marker as a novel prognostic factor for this malignance.Furthermore, miR-296-5p expression could be helpful in the identification of tumors resistant to radiotherapy; thus aiding the clinicians in the choice of the best therapeutic scheme to be used in each case.
therapeutic target	hsa-mir-1244	Carcinoma, Lung	26355845	disease of cellular proliferation	DOID:3905	C34.90	D008175			These results suggested that there is an autoregulatory circuit consisting of miR-1244 and MEF2D, which contributes to the progression of lung cancer. Targeting this molecular loop may be a promising strategy for lung carcinoma treatment.
therapeutic target	hsa-mir-15b	Carcinoma, Lung	23517578	disease of cellular proliferation	DOID:3905	C34.90	D008175			Up-regulation of miRNA-15b in tumor environment might negatively regulate anti-tumor immunity through inhibiting function of CD8+ T cells.miRNA-15b might be a potential therapeutic target for immunotherapy.
therapeutic target	hsa-let-7b	Carcinoma, Lung, Non-Small-Cell	23029111			C34.90	D002289		HP:0030358	Moreover, the regulation of let-7b and miR-126 expression could have therapeutic potential because it could reduce tumor angiogenesis and therefore suppress tumor growth in lung cancer patients.
therapeutic target	hsa-let-7c	Carcinoma, Lung, Non-Small-Cell	23534758			C34.90	D002289		HP:0030358	these results demonstrate let-7c inhibits NSCLC cell proliferation and tumorigenesis by partial direct targeting of the HOXA1 pathway, which suggests that restoration of let-7c expression may thus offer a potential therapeutic intervention strategy for NSCLC.
therapeutic target	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	23029111			C34.90	D002289		HP:0030358	Moreover, the regulation of let-7b and miR-126 expression could have therapeutic potential because it could reduce tumor angiogenesis and therefore suppress tumor growth in lung cancer patients.
therapeutic target	hsa-mir-140	Carcinoma, Lung, Non-Small-Cell	28739724			C34.90	D002289		HP:0030358	Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
therapeutic target	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	22618509			C34.90	D002289		HP:0030358	we report that miR-93, miR-205, miR-221, and let-7e may represent novel biomarkers for differential diagnosis and prognosis of certain NSCLC subtypes or be new targets of histology-specific treatments.
therapeutic target	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	22618509			C34.90	D002289		HP:0030358	we report that miR-93, miR-205, miR-221, and let-7e may represent novel biomarkers for differential diagnosis and prognosis of certain NSCLC subtypes or be new targets of histology-specific treatments.
therapeutic target	hsa-mir-224	Carcinoma, Lung, Non-Small-Cell	29723992			C34.90	D002289		HP:0030358	MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy.
therapeutic target	hsa-mir-93	Carcinoma, Lung, Non-Small-Cell	22618509			C34.90	D002289		HP:0030358	we report that miR-93, miR-205, miR-221, and let-7e may represent novel biomarkers for differential diagnosis and prognosis of certain NSCLC subtypes or be new targets of histology-specific treatments.
therapeutic target	hsa-mir-1	Carcinoma, Lung, Non-Small-Cell	24486107			C34.90	D002289		HP:0030358	These findings indicate that miR-1 may play an important role in the pathogenesis of NSCLC by regulating PIK3CA through the PI3K/Akt pathway. Increasing miR-1 expression may provide a novel approach for NSCLC treatment.
therapeutic target	hsa-mir-107	Carcinoma, Lung, Non-Small-Cell	25400821			C34.90	D002289		HP:0030358	miR-107 can be used to predict a patient's response to chemotherapy as well as serve as a novel  potential maker for NSCLC therapy.
therapeutic target	hsa-mir-10b	Carcinoma, Lung, Non-Small-Cell	24216130			C34.90	D002289		HP:0030358	In this study, we found that miR-10b is a tumor enhancer in NSCLC.Thus, miR-10b may represent a potential therapeutic target for NSCLC intervention.
therapeutic target	hsa-mir-130a	Carcinoma, Lung, Non-Small-Cell	26398698			C34.90	D002289		HP:0030358	Taken together, the results established miR-130a as a molecular switch during macrophage development and as a potential target for the treatment of NSCLC.
therapeutic target	hsa-mir-137	Carcinoma, Lung, Non-Small-Cell	26617798			C34.90	D002289		HP:0030358	Taken together, our findings suggested that miR-137/BMP7 axis could contribute to the progression of NSCLC, suggesting miR-137 as a potential therapeutic target for the treatment of NSCLC.
therapeutic target	hsa-mir-138	Carcinoma, Lung, Non-Small-Cell	24405893			C34.90	D002289		HP:0030358	These findings suggest that miR-138 as a potential tumor suppressor could inhibit cell proliferation by targeting PDK1 in NSCLC cells, which could be employed as a potential therapeutic target for miRNA-based NSCLC therapy.
therapeutic target	hsa-mir-142	Carcinoma, Lung, Non-Small-Cell	26617792			C34.90	D002289		HP:0030358	These results suggest that miR-142-3p may be a tumor suppressor through the downregulation of HMGB1 in NSCLC. miR-142-3p may be a tumor suppressor and a potential therapeutic agent for patients with NSCLC.
therapeutic target	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	25961369			C34.90	D002289		HP:0030358	Our results indicate that low miR-145 expression, due to methylation, promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1. Therefore, miR-145 may be a valuable therapeutic target for NSCLC.
therapeutic target	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	25703099			C34.90	D002289		HP:0030358	we identified miRs differentially expressed in cisplatin-resistant cell lines, including miR-145. A predicted target of miR-145  is CDK6, and its expression was found to be downregulated in the resistant sublines, although not directly by miR-145. Inhibition of CDK6 antagonizes cisplatin-induced NSCLC cell cytotoxicity, suggesting that agents that inhibit CDK6 should be avoided during cisplatin therapy.
therapeutic target	hsa-mir-148a	Carcinoma, Lung, Non-Small-Cell	26584284			C34.90	D002289		HP:0030358	Evidence from this study demonstrated that miR-148a exerts tumor-suppressive effects in NSCLC and suggests a new therapeutic option for NSCLC.
therapeutic target	hsa-mir-149	Carcinoma, Lung, Non-Small-Cell	24625834			C34.90	D002289		HP:0030358	These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies.
therapeutic target	hsa-mir-185	Carcinoma, Lung, Non-Small-Cell	26617940			C34.90	D002289		HP:0030358	Collectively, we conclude that miR-185 has a critical function by blocking AKT1 in NSCLC cells, and it may be a novel therapeutic agent for miRNA based NSCLC therapy.
therapeutic target	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	24997798			C34.90	D002289		HP:0030358	These findings indicate that miR-200c exerts tumor-suppressive effects for NSCLC through the suppression of USP25 expression and suggests a new therapeutic application of miR-200c in the treatment of NSCLC.
therapeutic target	hsa-mir-204	Carcinoma, Lung, Non-Small-Cell	25412236			C34.90	D002289		HP:0030358	NUAK1 is excessively expressed in NSCLC and plays important roles in NSCLC invasion. The miR-204 acts as a tumour suppressor by inhibiting NUAK1 expression in NSCLC. Both NUAK1 and miR-204 may serve as potential targets of NSCLC therapy.
therapeutic target	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	24625834			C34.90	D002289		HP:0030358	These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies.
therapeutic target	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23777591			C34.90	D002289		HP:0030358	miRNA-21 may be considered as a potential novel target for future development of specific therapeutic interventions in NSCLC.
therapeutic target	hsa-mir-22	Carcinoma, Lung, Non-Small-Cell	25702651			C34.90	D002289		HP:0030358	Our study may provide the groundwork for further clinical molecular target therapy experiments in NSCLC.BAC
therapeutic target	hsa-mir-23b	Carcinoma, Lung, Non-Small-Cell	26314549			C34.90	D002289		HP:0030358	In summary, integration of genomic analysis and microRNA expression profiling could identify novel cancer-related microRNAs, and miR-23b could be a potential prognostic marker for early stage NSCLCs. Further biological studies of miR-23b are warranted for the potential development of targeted therapy.
therapeutic target	hsa-mir-25	Carcinoma, Lung, Non-Small-Cell	26464659			C34.90	D002289		HP:0030358	In conclusion, miR-25 is up-regulated in NSCLC and promotes NSCLC cells proliferation and motility partially by targeting FBXW7. Our data suggest that miR-25 might serve as a potential therapeutic target for NSCLC treatment in the future.
therapeutic target	hsa-mir-296	Carcinoma, Lung, Non-Small-Cell	26549165			C34.90	D002289		HP:0030358	Taken together, the present study indicated that miR-296-5p regulated PLK1 expression and could function as a tumor suppressor in NSCLC progression, which provides a potential target for gene therapy of NSCLC.
therapeutic target	hsa-mir-326	Carcinoma, Lung, Non-Small-Cell	26548724			C34.90	D002289		HP:0030358	Our study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells. Thus, miR-326-NSBP1 is a promising candidate target for developing novel anticancer therapeutics for NSCLC.
therapeutic target	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	24551227			C34.90	D002289		HP:0030358	The data suggest that a majority of NSCLC and other cancers previously not suited for erlotinib may prove sensitive to the drug when used in combination with a miR-34a-based therapy.
therapeutic target	hsa-mir-34c	Carcinoma, Lung, Non-Small-Cell	26261507			C34.90	D002289		HP:0030358	Taken together, our study implicates important roles of miR-34c-3p in NSCLC pathogenesis and implicates its potential application in cancer therapy.
therapeutic target	hsa-mir-365	Carcinoma, Lung, Non-Small-Cell	26045746			C34.90	D002289		HP:0030358	aberrant expression of mir-365/TTF-1 may be involved in the tumor development in patients with NSCLC. Moreover, mir-365 and TTF-1 could jointly predict the prognosis of patients and their combination may serve as a biomarker to predict risk of poor survival in NSCLC patients. Mir-365/TTF-1 might serve as a potential therapeutic target for clinical treatment of NSCLC.
therapeutic target	hsa-mir-374a	Carcinoma, Lung, Non-Small-Cell	21748820			C34.90	D002289		HP:0030358	The authors show that low expression of miR-374a in early-stage NSCLC is associated with poor patient survival. Theresults demonstrate that expression of miR-374a at early stages of NSCLC progression can serve as a prognostic marker for patient risk stratification and may be a promising therapeutic target for the treatment of lung cancer.
therapeutic target	hsa-mir-375	Carcinoma, Lung, Non-Small-Cell	24625834			C34.90	D002289		HP:0030358	These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies.
therapeutic target	hsa-mir-378	Carcinoma, Lung, Non-Small-Cell	24625834			C34.90	D002289		HP:0030358	These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies.
therapeutic target	hsa-mir-422a	Carcinoma, Lung, Non-Small-Cell	24625834			C34.90	D002289		HP:0030358	These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies.
therapeutic target	hsa-mir-452	Carcinoma, Lung, Non-Small-Cell	26316085			C34.90	D002289		HP:0030358	Our results suggest that miR-452 plays a vital role in development of NSCLC, and this miR-452-BMI1 pathway might generate a novel insight into the treatment of NSCLC.
therapeutic target	hsa-mir-497	Carcinoma, Lung, Non-Small-Cell	26316081			C34.90	D002289		HP:0030358	miR-497 plays an important role in inhibiting the proliferation of NSCLC by targeting YAP1. Our results suggest that miR-497 is a potential therapeutic target in treating patients with NSCLC.
therapeutic target	hsa-mir-675	Carcinoma, Lung, Non-Small-Cell	25889562			C34.90	D002289		HP:0030358	miR-675-5p functions as a novel tumor suppressor in NSCLC and the anti-oncogenic activity may involve its inhibition of the target gene GPR55.These findings suggest the possibility for miR-675-5p as a therapeutic target in NSCLC.
therapeutic target	hsa-mir-708	Carcinoma, Lung, Non-Small-Cell	24625834			C34.90	D002289		HP:0030358	These results suggest miRNA-dependent transcriptional regulation differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for personalized treatment strategies.
therapeutic target	hsa-mir-9	Carcinoma, Lung, Non-Small-Cell	26593208			C34.90	D002289		HP:0030358	These findings suggest that oncogenic miR-9 targeted FoxO1 to promote cell growth, and downregulation of this axis was involved in erlotinib's growth inhibitory effects. Clarifying the regulation of miRNAs by erlotinib may indicate novel strategies for enhancing EGFR-targeted cancer therapy.
therapeutic target	hsa-mir-101	Carcinoma, Nasopharyngeal	25607713	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	the identified miR-101/STMN1 pathway contributed to the elucidation of the mechanisms of radioresistance in human NPC and that it may represent a potential therapeutic target.
therapeutic target	hsa-mir-145	Carcinoma, Nasopharyngeal	26297956	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	This study reveals that miR-145 suppressed the invasion and migration of NPC cells by targeting ADAM17.Thus, miR-145 could be a therapeutic target for NPC.
therapeutic target	hsa-mir-145	Carcinoma, Nasopharyngeal	25816323	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our findings demonstrated that miR-145 function as a tumor suppressor in NPC development and progression via targeting FSCN1, which could sever as a potential novel therapeutic target for patients with NPC.
therapeutic target	hsa-mir-200b	Carcinoma, Nasopharyngeal	24281414	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	These results indicate that miR-200b exerts tumor-suppressive effects in NPC carcinogenesis through the suppression of Notch1 expression and suggest a therapeutic application of miR-200b in NPC.
therapeutic target	hsa-mir-24	Carcinoma, Nasopharyngeal	26503504	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Overall, miR-24 acts as a novel tumor suppressor in the development and progression of NPC through targeting FSCN1, which providing new insight into the mechanisms of NPC carcinogenesis and suggesting the possibility of miR-24 as a therapeutic target.
therapeutic target	hsa-mir-34c	Carcinoma, Nasopharyngeal	25611392	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	The newly identified miR-34c/MET pathway provides further insights into the development and progression of NPC, and may represent a novel therapeutic target for NPC treatment.
therapeutic target	hsa-mir-451	Carcinoma, Nasopharyngeal	24138931	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	The newly identified miR-451/MIF pathway provides insight into NPC initiation and progression, and may represent a novel therapeutic target.
therapeutic target	hsa-mir-4792	Carcinoma, Nasopharyngeal	26585487	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	These findings suggest that miR-4792 functions as a tumor suppressor in NPC development and progression by targeting FOXC1, which could act as a novel potential therapeutic target for NPC treatment,and miR-4792/FOXC1 pathway that we studied might be used for NPC treatment in future.
therapeutic target	hsa-mir-634	Carcinoma, Nasopharyngeal	25400759	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-634 inhibited tumor growth and enhanced paclitaxel sensitivity. Thus, our findings provide important information for the development of targeted gene therapy for reversing paclitaxel resistance in NPC.
therapeutic target	hsa-mir-93	Carcinoma, Nasopharyngeal	24606633	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	The present study reports an involvement of miR-93-mediated TGFβR2 down-regulation in NPC aggressiveness, thus giving extended insights into molecular mechanisms underlying cancer aggressiveness. Approaches aimed at blocking miR-93 may serve as a promising therapeutic strategy for treating NPC patients.
therapeutic target	hsa-mir-145	Carcinoma, Ovarian	26472353	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	These data confirmed the tumor-suppressing function of miR-145 in EOC and identified TRIM2 as a new miR-145 target. In vivo delivery of agomiR-145 might be a feasible approach for miRNA-directed cancer therapy.
therapeutic target	hsa-mir-145	Carcinoma, Ovarian	28804560	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Using miR-145 mimics may be a rational approach for therapeutic applications in ovarian carcinoma in the future
therapeutic target	hsa-mir-204	Carcinoma, Ovarian	25962115	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miR-204 up-regulation may be linked directly to the sensitivity of EOC cell anoikis by contributing to BDNF down-regulation. Our findings provide a novel mechanism for manipulating miR-204 levels therapeutically to restore anoikis sensitivity.
therapeutic target	hsa-mir-506	Carcinoma, Ovarian	26369335	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Therefore, miR-506 plays a functionally important role in homologous recombination and has important therapeutic value for sensitizing cancer cells to chemotherapy, especially in chemo-resistant patients with attenuated expression of miR-506.
therapeutic target	hsa-mir-9	Carcinoma, Ovarian	26152689	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Methylation-associated miR-9 down-regulation is probably one of the key mechanisms for paclitaxel resistance in EOC cells, via targeting CCNG1. Our findings may also provide a new potential therapeutic target to reversepaclitaxel resistance in EOC patients.
therapeutic target	hsa-mir-200c	Carcinoma, Pancreatic	26081037			C25.3	C562463	260350	HP:0002894	Our study demonstrated that miR-200c may become a new therapeutic target for gene therapy in patients suffered from pancreatic cancer.
therapeutic target	hsa-mir-195	Carcinoma, Prostate	26080838	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	The newly identified miR-195-RPS6KB1 axis partially illustrates the molecular mechanism of prostate cancer progression and represents a novel potential therapeutic target for prostate cancer treatment.
therapeutic target	hsa-mir-21	Carcinoma, Rectal	24039353	disease of cellular proliferation	DOID:1993	C20	D012004			In this review,we summarize the latest research findings of the clinicopathological relevance of miRNAs-21 in CRC initiation, development, and progress, highlighting its potential diagnostic, prognostic, and therapeutic application, as well as discussing future prospects.
therapeutic target	hsa-mir-221	Carcinoma, Rectal	21515467	disease of cellular proliferation	DOID:1993	C20	D012004			The miR-221-specific inhibitor shows potent inhibitory effect on the growth of CRC cells, suggesting its value as a potential anti-tumor candidate for treatment of CRC.
therapeutic target	hsa-mir-101-1	Carcinoma, Renal Cell	22609199	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
therapeutic target	hsa-mir-101-2	Carcinoma, Renal Cell	22609199	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
therapeutic target	hsa-mir-126	Carcinoma, Renal Cell	28257806	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.
therapeutic target	hsa-mir-145	Carcinoma, Renal Cell	24384875	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-145 functions as tumor suppressor in RCC, suggesting that miR-145 may be a potential therapeutic target for RCC.
therapeutic target	hsa-mir-182	Carcinoma, Renal Cell	24886554	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	These findings highlight an important role for miR-182-5p in the pathogenesis of RCC, and restoration of miR-182-5p could be considered as a potential therapeutic strategy for RCC therapy.
therapeutic target	hsa-mir-204	Carcinoma, Renal Cell	26323722	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	These results suggested that miR-204 may have value as a marker for the early detection of tumor metastasis and a therapeutic target preventing the invasion of renal cell carcinoma.
therapeutic target	hsa-mir-206	Carcinoma, Renal Cell	26808577	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	All these results suggested that miR-206 functioned as a novel cell cycle regulator and tumor suppressor in ccRCC and could be considered as a potential target for ccRCC therapy.
therapeutic target	hsa-mir-210	Carcinoma, Renal Cell	25555365	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	might be involved in carcinogenesis and aggressive tumor behavior were identified. miR-210 is a potential therapeutic target and independent marker of poor prognosis of ccRCC
therapeutic target	hsa-mir-22	Carcinoma, Renal Cell	26499759	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	These findings showed that miR-22 functioned as tumor suppressor in RCC and blocked RCC growth and metastasis by directly targeting SIRT1 in RCC, indicating a potential novel therapeutic role in RCC treatment.
therapeutic target	hsa-mir-221	Carcinoma, Renal Cell	26191221	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	These findings suggested that miR-221 play an oncogenic role in the renal cancer cell proliferation, migration and invasion by directly inhibiting the tumor suppressor TIMP2, indicating miR-221 act as a potential new therapeutic target for the treatment of ccRCC.
therapeutic target	hsa-mir-451	Carcinoma, Renal Cell	26779781	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-451 acts as an anti-oncogene in RCC. Our data offer a new therapeutic target for further research.
therapeutic target	hsa-mir-451a	Carcinoma, Renal Cell	25405789	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-451a may have an important role as a tumor enhancer in RCC. These results imply that miR-451a may be a promising therapeutic target for the treatment of RCC.
therapeutic target	hsa-mir-107	Carcinoma, Renal Cell, Clear-Cell	25758424	disease of cellular proliferation	DOID:4467				HP:0006770	In summary, our results showed that miR-107 can inhibit cell proliferation and invasiveness of renal cell carcinoma. Furthermore, this study may provide a potential therapeutic regimen for clear cell renal cell carcinoma treatment.
therapeutic target	hsa-mir-10b	Carcinoma, Renal Cell, Clear-Cell	26617769	disease of cellular proliferation	DOID:4467				HP:0006770	Our results suggest that miR-10b plays a tumor-suppressive role in ccRCC. Demethylation of miR-10b may be therapeutically beneficial for ccRCC treatment.
therapeutic target	hsa-mir-124	Carcinoma, Renal Cell, Clear-Cell	26002553	disease of cellular proliferation	DOID:4467				HP:0006770	We hypothesize that these three miRNAs are fundamentalcontributing to ccRCC aggressive/metastatic behavior; and miR-124-3p especially has a key role through regulating CAV1 and FLOT1 expression. Restoration of the levels of these miRNAs could be considered as a potential therapeutic strategy for ccRCC.
therapeutic target	hsa-mir-136	Carcinoma, Renal Cell, Clear-Cell	25450277	disease of cellular proliferation	DOID:4467				HP:0006770	This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment.
therapeutic target	hsa-mir-155	Carcinoma, Renal Cell, Clear-Cell	29534467	disease of cellular proliferation	DOID:4467				HP:0006770	Our results further support a role for miR-155 as a promising cancer classifier and potentially as a therapeutic target in ccRCC that merits further investigation
therapeutic target	hsa-mir-223	Carcinoma, Renal Cell, Clear-Cell	25818776	disease of cellular proliferation	DOID:4467				HP:0006770	miR-223 promotes renal cancer cell migration and proliferation and may serve as a potential therapeutic target for ccRcc.
therapeutic target	hsa-mir-320d	Carcinoma, Renal Cell, Clear-Cell	25450277	disease of cellular proliferation	DOID:4467				HP:0006770	This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment.
therapeutic target	hsa-mir-335	Carcinoma, Renal Cell, Clear-Cell	25450277	disease of cellular proliferation	DOID:4467				HP:0006770	This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment.
therapeutic target	hsa-mir-340	Carcinoma, Renal Cell, Clear-Cell	25450277	disease of cellular proliferation	DOID:4467				HP:0006770	This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment.
therapeutic target	hsa-mir-425	Carcinoma, Renal Cell, Clear-Cell	25450277	disease of cellular proliferation	DOID:4467				HP:0006770	This integrative network approach revealed important miRNAs in the ccRCC that can identify specific disease biomarkers, which can be used as targets for cancer treatment.
therapeutic target	hsa-mir-492	Carcinoma, Renal Cell, Clear-Cell	25815441	disease of cellular proliferation	DOID:4467				HP:0006770	Upregulation of microRNA-492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro.
therapeutic target	hsa-mir-506	Carcinoma, Renal Cell, Clear-Cell	25793370	disease of cellular proliferation	DOID:4467				HP:0006770	miR-506 exerts its anti-cancer function by directly targeting FLOT1 in renal cancer, indicating a potential novel therapeutic role in renal cancer treatment.
therapeutic target	hsa-mir-21	Carcinoma, Salivary Adenoid Cystic	26367487	disease of cellular proliferation	DOID:4866	C08.9	D003528			Therefore, suppression of miR-21 may provide a potential approach for the treatment of advanced SACC patients.
therapeutic target	hsa-mir-320a	Carcinoma, Salivary Adenoid Cystic	25924850	disease of cellular proliferation	DOID:4866	C08.9	D003528			MiR-320a inhibits metastasis in SACCs by targeting ITGB3 and may serve as a therapeutic target and prognostic marker in salivary cancers.
therapeutic target	hsa-mir-126	Carcinoma, Thyroid	26384552	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Expression of miR-126 was down-regulated in BRAF(V600E) mutated undifferentiated thyroid carcinoma. In addition, miR-126 was found to act as proliferation suppressor targeting PIK3R2 gene and reducing p85β (a regulatory subunit of PI3K kinase) protein translation and lower AKT kinase activity.Therefore, miR-126 could be a potential therapeutic tool in the treatment of undifferentiated thyroid carcinoma.
therapeutic target	hsa-mir-146b	Carcinoma, Thyroid	26282166	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	In conclusion, our study has uncovered the existence of a miR-146b-3p/PAX8/NIS regulatory circuit that may be exploited therapeutically to modulate thyroid cell differentiation and iodide uptake for improved treatment of advanced thyroid cancer.
therapeutic target	hsa-mir-204	Carcinoma, Thyroid	25603050	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	miR-204-5p acts as a tumor suppressor in PTC by regulating IGFBP5 expression and that miR-204-5p can potentially serve as an antitumorigenic agent in the treatment of  PTC.
therapeutic target	hsa-mir-221	Carcinoma, Thyroid	29351231	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers
therapeutic target	hsa-mir-222	Carcinoma, Thyroid	29351231	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers
therapeutic target	hsa-mir-34b	Carcinoma, Thyroid	28840508	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	It could be a target for developing treatment strategies of thyroid carcinoma with aggressive clinical behaviour
therapeutic target	hsa-mir-375	Carcinoma, Thyroid	29351231	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	These ceRNAs are critical in revealing the secrets behind thyroid cancer progression and may serve as future therapeutic biomarkers
therapeutic target	hsa-mir-122	Carcinoma, Thyroid, Anaplastic	23598436			C73	D065646	188550	HP:0011779	Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy.
therapeutic target	hsa-mir-17	Carcinoma, Thyroid, Anaplastic	18429962			C73	D065646	188550	HP:0011779	Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment.
therapeutic target	hsa-mir-18	Carcinoma, Thyroid, Anaplastic	18429962			C73	D065646	188550	HP:0011779	Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment.
therapeutic target	hsa-mir-19a	Carcinoma, Thyroid, Anaplastic	18429962			C73	D065646	188550	HP:0011779	Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment.
therapeutic target	hsa-mir-19b-1	Carcinoma, Thyroid, Anaplastic	18429962			C73	D065646	188550	HP:0011779	Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment.
therapeutic target	hsa-mir-205	Carcinoma, Thyroid, Anaplastic	29317480			C73	D065646	188550	HP:0011779	This may open avenues to exploit miR-205 as an alternative cancer therapeutic strategy in the future
therapeutic target	hsa-mir-20a	Carcinoma, Thyroid, Anaplastic	18429962			C73	D065646	188550	HP:0011779	Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment.
therapeutic target	hsa-mir-375	Carcinoma, Thyroid, Anaplastic	23598436			C73	D065646	188550	HP:0011779	Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy.
therapeutic target	hsa-mir-92-1	Carcinoma, Thyroid, Anaplastic	18429962			C73	D065646	188550	HP:0011779	Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment.
therapeutic target	hsa-mir-146a	Carcinoma, Thyroid, Papillary	29048684	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
therapeutic target	hsa-mir-146b	Carcinoma, Thyroid, Papillary	27533309	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	In conjunction with current therapeutic regimens, targeting the miR-146b-IRAK1 axis  may provide a potential approach for PTC management.
therapeutic target	hsa-mir-146b	Carcinoma, Thyroid, Papillary	28294980	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.
therapeutic target	hsa-mir-146b	Carcinoma, Thyroid, Papillary	29048684	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
therapeutic target	hsa-mir-181b	Carcinoma, Thyroid, Papillary	25550803	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	downregulation of miR-181b results in the upregulation of CYLD at protein levels. Taken together, downregulation of miR-181b expression causes cellular growth inhibition, promoting cellular apoptosis by targeting CYLD. These findings suggest that downregulation of the expression of miR-181b may be a therapeutic target for the treatment of human thyroid papillary cancer.
therapeutic target	hsa-mir-21	Carcinoma, Thyroid, Papillary	24650454	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	These data suggest that miRNA-21 may play an oncogenic role by directly targeting PDCD4 in the cellular processes of PTC. In addition, the findings in our present study also may represent new clues for the diagnostic and therapeutic strategies in the treatment of PTC.
therapeutic target	hsa-mir-96	Carcinoma, Thyroid, Papillary	26617698	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	The data from the present study demonstrated that miR-96 can promote proliferation, and inhibit apoptosis in PTC cell lines K1 and TPC1, thus miR-96 may play an oncogenic role in PTC by inhibiting the FOXO1 and regulating AKT/FOXO1/Bim pathway, and it may serve as a novel therapeutic target for miRNA-based PTC therapy.
therapeutic target	hsa-mir-17	Carcinoma, Vulvar	26297962	disease of cellular proliferation	DOID:1294	C51.9	D014846			Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma.
therapeutic target	hsa-mir-130a	Cardiac Fibrosis	29114000							MicroRNA-130a, a Potential Antifibrotic Target in Cardiac Fibrosis.
therapeutic target	hsa-mir-150	Cardiomegaly	25639779			I51.7	D006332		HP:0001640	miR-150 may be a new therapeutic target for cardiac hypertrophy.
therapeutic target	hsa-mir-33	Cardiometabolic Disorders	20466882							Our findings indicate that miR-33 acts in concert with the SREBP host genes to control cholesterol homeostasis and suggest that miR-33 may represent a therapeutic target for ameliorating cardiometabolic diseases.
therapeutic target	hsa-mir-1290	Cardiomyopathy	25761932	cardiovascular system disease	DOID:0050700	I42	D009202			An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
therapeutic target	hsa-mir-135b	Cardiomyopathy	25761932	cardiovascular system disease	DOID:0050700	I42	D009202			An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
therapeutic target	hsa-mir-155	Cardiomyopathy	25761932	cardiovascular system disease	DOID:0050700	I42	D009202			An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
therapeutic target	hsa-mir-190	Cardiomyopathy	25761932	cardiovascular system disease	DOID:0050700	I42	D009202			An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
therapeutic target	hsa-mir-422a	Cardiomyopathy	25761932	cardiovascular system disease	DOID:0050700	I42	D009202			An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
therapeutic target	hsa-mir-489	Cardiomyopathy	25761932	cardiovascular system disease	DOID:0050700	I42	D009202			An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
therapeutic target	hsa-mir-590	Cardiomyopathy	25761932	cardiovascular system disease	DOID:0050700	I42	D009202			An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
therapeutic target	hsa-mir-601	Cardiomyopathy	25761932	cardiovascular system disease	DOID:0050700	I42	D009202			An immediate clinical application of the data is cardiac miR profiling to assess the risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy. Patients at risk are eligible for immediate antiviral therapy to minimize irreversible cardiac damage.
therapeutic target	hsa-mir-195	Cardiomyopathy, Hypertrophic	22844503	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Elevated miR-195 targets the LKB1/AMPK signaling axis in HCM progression and implicates a functional role in HCM disease progression.MiR-195 may serve as potential therapeutics or therapeutic targets for heart disease.
therapeutic target	hsa-mir-21	Cardiomyopathy, Hypertrophic	20560046	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions
therapeutic target	hsa-mir-1	Cardiovascular Diseases [unspecific]	26431632				D002318			The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes.
therapeutic target	hsa-mir-133a	Cardiovascular Diseases [unspecific]	25421410				D002318			the roles of miR-133a in hypoxia-induced apoptotic and implicate its potential in cardiac dysfunctions therapy.
therapeutic target	hsa-mir-146	Cardiovascular Diseases [unspecific]	28407626				D002318			Exogenous miRNA-146a Enhances the Therapeutic Efficacy of Human Mesenchymal Stem Cells by Increasing Vascular Endothelial Growth Factor Secretion in the Ischemia/Reperfusion-Injured Heart.
therapeutic target	hsa-mir-146a	Cardiovascular Diseases [unspecific]	26112171				D002318			miR-146a might be a new and promising therapeutic tool for treating cardiac disorders associated with enhanced inflammation in the heart.
therapeutic target	hsa-mir-15	Cardiovascular Diseases [unspecific]	26431632				D002318			The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes.
therapeutic target	hsa-mir-16	Cardiovascular Diseases [unspecific]	29104843				D002318			miR-16 was a potential therapeutic target by participating in the Ang II-associated multiple signaling pathways in cardiovascular diseases
therapeutic target	hsa-mir-199a	Cardiovascular Diseases [unspecific]	26431632				D002318			The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes.
therapeutic target	hsa-mir-21	Cardiovascular Diseases [unspecific]	25738901				D002318			miR-21 is sensitive to high-concentration glucose treatment in macrophages, and appears to have a protective effect in macrophage apoptosis induced by high concentrations of glucose via programmed cell death 4 (PDCD4).
therapeutic target	hsa-mir-21	Cardiovascular Diseases [unspecific]	20560046				D002318			miR-21:miR-21 might be a novel therapeutic target in cardiovascular diseases
therapeutic target	hsa-mir-21	Cardiovascular Diseases [unspecific]	26048714				D002318			our study uncovers a novel regulatory mechanism of VSMC migration by kaempferol and suggests that miRNA modulation by kaempferol is a potential therapy for cardiovascular diseases.
therapeutic target	hsa-mir-21	Cardiovascular Diseases [unspecific]	25069679				D002318			MicroRNA-21 coordinates human multipotent cardiovascular progenitors therapeutic potential.
therapeutic target	hsa-mir-21	Cardiovascular Diseases [unspecific]	20649511				D002318			We here overview the current patent situation about the therapeutic use of miR-21 modulation in cancer and cardiovascular disease.
therapeutic target	hsa-mir-29b	Cardiovascular Diseases [unspecific]	24569834				D002318			In conclusion, miR-29b plays a protective role in AngII-mediated cardiac remodeling and may be a therapeutic agent for cardiac fibrosis by targeting the TGF-β/Smad3 pathway.
therapeutic target	hsa-mir-302	Cardiovascular Diseases [unspecific]	26431632				D002318			The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes.
therapeutic target	hsa-mir-324	Cardiovascular Diseases [unspecific]	26633713				D002318			Our study defines the NFAT4/ miR-324-5p/Mtfr1 axis, which participates in the regulation of mitochondrial fission and cardiomyocyte apoptosis, and suggests potential new treatment avenues for cardiac diseases.
therapeutic target	hsa-mir-367	Cardiovascular Diseases [unspecific]	26431632				D002318			The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes.
therapeutic target	hsa-mir-499	Cardiovascular Diseases [unspecific]	28627982				D002318			miRNAs as potential therapeutic targets and diagnostic biomarkers for cardiovascular disease with a particular focus on WO2010091204.
therapeutic target	hsa-mir-637	Cardiovascular Diseases [unspecific]	26438598				D002318			Taken together, we have uncovered an important posttranscriptional mechanism that modulates the expression of the inflammatory marker CRP, which may be utilized in the development of treatments for inflammatory processes that cause CVD and age-related diseases.
therapeutic target	hsa-mir-100	Carotid Atherosclerosis	26238333			I65.29	D002340			This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke.
therapeutic target	hsa-mir-125a	Carotid Atherosclerosis	26238333			I65.29	D002340			This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke.
therapeutic target	hsa-mir-127	Carotid Atherosclerosis	26238333			I65.29	D002340			This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke.
therapeutic target	hsa-mir-133a	Carotid Atherosclerosis	26238333			I65.29	D002340			This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke.
therapeutic target	hsa-mir-145	Carotid Atherosclerosis	26238333			I65.29	D002340			This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke.
therapeutic target	hsa-mir-221	Carotid Atherosclerosis	26238333			I65.29	D002340			This pilot study evaluated the expression of seven selected miRNAs in human carotid plaques from a small group of patients and suggested a potential regulatory role for these miRNAs in evolution of the plaque towards growth,instability and rupture. Studies based on larger sample sizes are required to determine the potential use of miR-100, miR-125a, miR-127, miR-133a, miR-145, and miR-221 as biomarkers or therapeutic targets for stroke.
therapeutic target	hsa-mir-29b	Cerebral Ischemia	26126866	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	MicroRNA-29b is a therapeutic target in cerebral ischemia associated with aquaporin 4.
therapeutic target	hsa-mir-19a	Cervical Neoplasms	29332345	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Overall, inhibiting miR-19a significantly improves the sensitivity of SiHa cells to radiotherapy, which could lead to new methods for the treatment of cervical cancer
therapeutic target	hsa-mir-215	Cervical Neoplasms	27295129	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	dysregulation of miR-29C, miR-34A, miR-98, and miR-215
therapeutic target	hsa-mir-29c	Cervical Neoplasms	27295129	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	dysregulation of miR-29C, miR-34A, miR-98, and miR-215
therapeutic target	hsa-mir-34a	Cervical Neoplasms	27295129	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	dysregulation of miR-29C, miR-34A, miR-98, and miR-215
therapeutic target	hsa-mir-98	Cervical Neoplasms	27295129	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	dysregulation of miR-29C, miR-34A, miR-98, and miR-215
therapeutic target	hsa-mir-122	Cholangiocarcinoma	26686459	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-122 expression was significantly weaker in CC tissues, and miR-122 overexpression might play pivotal roles in inhibiting proliferation, stimulating apoptosis and suppressing invasion of CC cells, suggesting a new target for CC diagnosis and treatment.
therapeutic target	hsa-mir-122	Cholangiocarcinoma	26825606	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	The results indicate that HNF6 may serve as a tumor suppressor by regulating miR-122, and its overexpression may represent a mechanism-based therapy for CCA.
therapeutic target	hsa-mir-122	Cholangiocarcinoma	28832247	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma.
therapeutic target	hsa-mir-200c	Cholangiocarcinoma	26855082	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	The ability of the combined PCX/miR-200c treatment to obstruct two migratory pathways represents a promising antimetastatic strategy in cholangiocarcinoma.
therapeutic target	hsa-mir-203	Cholangiocarcinoma	26464713	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Our findings suggest that miR-203 expression was an independent poor prognostic factor for CCA patient overall survival. Therefore, miR-203 may serve as a valuable prognostic marker and promising treatment target for CCA.
therapeutic target	hsa-mir-224	Cholangiocarcinoma	26573191	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	IL-6 may promote the invasive and metastatic properties of CCA through upregulated miR-224. Studies of the differentially expressed serum miRNAs in CCA may help to further elucidate the pathogenic processes of this disease and aid in the development of a novel and effective therapeutic strategy.
therapeutic target	hsa-mir-29a	Cholangiocarcinoma	26441331	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	TGF-β1/miR-29a/HDAC4 pathway contributes to the pathogenesis of cholangiocarcinoma and our data provide new therapeutic targets for cholangiocarcinoma.
therapeutic target	hsa-mir-371b	Chondrosarcoma	26214773	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	It has been proposed that miRNA expression studies might be used as diagnostic, prognostic marker in cancer. miRNA expression data produced in our study may contribute future chondrosarcoma diagnosis and therapy.
therapeutic target	hsa-mir-1	Chordoma	24501096	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	These results indicate that suppressed miR-1 expression in chordoma may in part be a driver for tumor growth, and that miR-1 has potential to serve as prognostic biomarker and therapeutic target for chordoma patients.
therapeutic target	hsa-mir-155	Chordoma	25823817	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	We have shown miR-155 expression to independently affect prognosis in chordoma. These results collectively indicate that miR-155 expression may serve not only as a prognostic marker, but also as a potential therapeutic target in chordoma.
therapeutic target	hsa-mir-200c	Chronic Hepatitis B	29593314			B18.0-.1	D019694	610424		an HBV-pSTAT3-SALL4-miR-200c axis regulates PD-L1. Therapeutic strategies to influence this axis might reverse virus-induced immune exhaustion
therapeutic target	hsa-mir-548	Chronic Hepatitis B	25196343			B18.0-.1	D019694	610424		The abnormal expression profiles of miRNA in PBMCs could be closely associated with immune activation of chronic HBV infection. miR-548, by targeting IFN-γR1, may represent a mechanism that can facilitate viral pathogenesis and help determine new therapeutic molecular targets.
therapeutic target	hsa-mir-122	Chronic Hepatitis C	27485847			B18.2	D019698	609532		First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases.
therapeutic target	hsa-mir-122	Chronic Hepatitis C	28993299			B18.2	D019698	609532		Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes.
therapeutic target	hsa-mir-17	Chronic Hepatitis C	24819603			B18.2	D019698	609532		Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C.
therapeutic target	hsa-mir-143	Chronic Inflammation	23811549							miR-143 can lead to increased expression of AIM2 and ASC mRNAs. Considering the significance of AIM2 and ASC in DNA sensing and inflammosome formation, it can be considered as a therapeutic agent for the treatment of chronic infectious diseases, especially viral infections.
therapeutic target	hsa-mir-155	Chronic Inflammation	19596814							Finally, we report for the first time on miR-155 silencing in vivo in a mouse inflammation model, which underscores the potential of miR-155 antagonists in the development of novel therapeutics for treatment of chronic inflammatory diseases.
therapeutic target	hsa-mir-150	Chronic Obstructive Pulmonary Disease	29205062	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Restoration of miR-150 expression may represent a potential therapeutic strategy for CS-related COPD
therapeutic target	hsa-mir-193	Chronic Obstructive Pulmonary Disease	24963038	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	These studies establish the importance of microRNAs as downstream effectors of an apolipoprotein A-I mimetic peptide in the rescue of PH and suggest that treatment with apolipoprotein A-I mimetic peptides or miR193 may have therapeutic value.
therapeutic target	hsa-mir-328	Chronic Obstructive Pulmonary Disease	25894560	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	inhibition of miR-328 in respiratory models of infection, steroid-induced immunosuppression, and smoke-induced emphysema enhances bacterial clearance.Thus, miRNA pathways can be targeted in the lung to enhance host defence against a clinically relevant microbial infection and offer a potential new anti-microbial approach for the treatment of respiratory diseases.
therapeutic target	hsa-mir-1288	Chronic Pain	26166255			G89.29	D059350		HP:0012532	These results suggest that miRNAs represent a valuable tool for differentiating VBD subtypes (localized pain with apparent peripheral neurosensory disruption vs widespread pain with a central sensory contribution) that may require different treatment approaches.
therapeutic target	hsa-mir-1294	Chronic Pain	26166255			G89.29	D059350		HP:0012532	These results suggest that miRNAs represent a valuable tool for differentiating VBD subtypes (localized pain with apparent peripheral neurosensory disruption vs widespread pain with a central sensory contribution) that may require different treatment approaches.
therapeutic target	hsa-mir-1825	Chronic Pain	26166255			G89.29	D059350		HP:0012532	These results suggest that miRNAs represent a valuable tool for differentiating VBD subtypes (localized pain with apparent peripheral neurosensory disruption vs widespread pain with a central sensory contribution) that may require different treatment approaches.
therapeutic target	hsa-mir-645	Chronic Pain	26166255			G89.29	D059350		HP:0012532	These results suggest that miRNAs represent a valuable tool for differentiating VBD subtypes (localized pain with apparent peripheral neurosensory disruption vs widespread pain with a central sensory contribution) that may require different treatment approaches.
therapeutic target	hsa-mir-155	Colitis	27395764	gastrointestinal system disease	DOID:0060180	K52.9	D003092	191390	HP:0002583	IL-10/miR-155/SHIP-1 pathways play a critical role in commensal bacteria induced  colitis and miR-15
therapeutic target	hsa-mir-200c	Colitis, Ulcerative	25546151	gastrointestinal system disease	DOID:8577	K51	D003093			Integrated analysis of miRNA and mRNA expression profiles revealed hsa-miR-200c-3p for use of miRNA mimics as therapeutics.
therapeutic target	hsa-mir-132	Colon Neoplasms	29017096			D12.6	D003110		HP:0100273	miR-132 as a promising therapeutic candidate to control autoimmune inflammation and tumorigenesis in CAC patients
therapeutic target	hsa-mir-143	Colon Neoplasms	17504027			D12.6	D003110		HP:0100273	Further, we discuss the expression of miRNA-143 and -145 in colon cancer and their roles in carcinogenesis. The available data suggest that miRNAs would be potentially useful as diagnostic and therapeutic tools.
therapeutic target	hsa-mir-143	Colon Neoplasms	19464056			D12.6	D003110		HP:0100273	On the contrary, an extracellular signal-regulated protein kinase 5 (ERK5), which was determined to be a target of miR-143 in colon cancer DLD-1 cells, was time-dependently down-regulated at the translational level after the treatment.
therapeutic target	hsa-mir-21	Colon Neoplasms	24039353			D12.6	D003110		HP:0100273	In this review,we summarize the latest research findings of the clinicopathological relevance of miRNAs-21 in CRC initiation, development, and progress, highlighting its potential diagnostic, prognostic, and therapeutic application, as well as discussing future prospects.
therapeutic target	hsa-let-7	Colorectal Carcinoma	26084510	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In summary,the results reveal that detailed molecular events can be combined with individual genetic data, including gene/miRNA expression data, to enhance in silico prediction of therapeutic response of individual CRC tumors.The study demonstrates that miRNA information can be applied as actionable information regarding individual therapeutic response.
therapeutic target	hsa-let-7a	Colorectal Carcinoma	27737877	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our data support the role of let-7a in suppressing antitumor immunity in colorectal cancer and suggest let-7a as a potential target of immunotherapy
therapeutic target	hsa-let-7c	Colorectal Carcinoma	24503111	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy.
therapeutic target	hsa-mir-106b	Colorectal Carcinoma	26223867	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings indicate that miR-106b promotes CRC cell migration and invasion by targeting DLC1. This miRNA may serve as a potential prognostic biomarker and therapeutic target for CRC.
therapeutic target	hsa-mir-124	Colorectal Carcinoma	24949825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer.
therapeutic target	hsa-mir-1246	Colorectal Carcinoma	26573378	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Consequently, these findings provided a molecular basis for the role of miR-1246/CCNG2 in the progression of human CRC and suggested a novel target for the treatment of CRC.
therapeutic target	hsa-mir-125b	Colorectal Carcinoma	24949825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer.
therapeutic target	hsa-mir-125b	Colorectal Carcinoma	24503111	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy.
therapeutic target	hsa-mir-126	Colorectal Carcinoma	25584492	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		changes in cir-miRNA-126 during treatment are related to the response to chemotherapy and bevacizumab in patients with mCRC, thus representing a possible biomarker for the resistance to anti-angiogenic containing treatments.
therapeutic target	hsa-mir-1269a	Colorectal Carcinoma	25872451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings suggest that miR-1269a is a potential marker to inform adjuvant chemotherapy decisions for CRC patients and a potential therapeutic target to deter metastasis.
therapeutic target	hsa-mir-128	Colorectal Carcinoma	24046120	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		NEK2 may be an independent prognostic factor for CRC and was regulated by miR-128, a microRNA that was subjected to epigenetic regulation.Thus, this miR-128/NEK2 pathway may be a prospective therapeutic target for patients with CRC.
therapeutic target	hsa-mir-1297	Colorectal Carcinoma	25422199	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-1297 has the potential to provide a new approach to colorectal cancer therapy by directly inhibiting Cox-2 expression.
therapeutic target	hsa-mir-140	Colorectal Carcinoma	25567303	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-140 regulates the Smad3 expression at the post-transcriptional level. miR-140 suppresses the migrating and invasive abilities of CRC cells, possibly through down-regulation of Smad3. The findings of this study suggest that miR-140 may have a unique potential as a possible biomarker candidate for diagnosis and therapy of tumor metastasis.
therapeutic target	hsa-mir-141	Colorectal Carcinoma	26125745	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Some of these TFs, mRNAs, or miRNAs have previously been identified as critical targets in colorectal cancer metastasis.Additionally, several new targets were identified in our study, which may be helpful to improve metastatic colorectal cancer treatment.
therapeutic target	hsa-mir-143	Colorectal Carcinoma	26266366	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC.
therapeutic target	hsa-mir-144	Colorectal Carcinoma	26349975	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings suggested that microRNA 144 might be an important element to control the status of colorectal cancer, which has provided a new insight into the mechanism of proliferation and migration and a new target in therapy against colorectal cancer.
therapeutic target	hsa-mir-146a	Colorectal Carcinoma	24949825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer.
therapeutic target	hsa-mir-149	Colorectal Carcinoma	28370854	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-149 may serve as a therapeutic target for colorectal cancer treatment
therapeutic target	hsa-mir-155	Colorectal Carcinoma	24949825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer.
therapeutic target	hsa-mir-17	Colorectal Carcinoma	26266366	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC.
therapeutic target	hsa-mir-18	Colorectal Carcinoma	26266366	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC.
therapeutic target	hsa-mir-1914	Colorectal Carcinoma	26695693	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miR-1914* and -1915 interact with NFIX RNA and reduce its level in chemoresistant CRC cells to first-line chemotherapy. Up-regulation of miR-1914* and -1915 decreased the chemoresistance abilities of chemoresistant CRC cells. The plasma miR-1914* and -1915 may play a role in colorectal cancer therapy and diagnosis.
therapeutic target	hsa-mir-1915	Colorectal Carcinoma	26695693	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miR-1914* and -1915 interact with NFIX RNA and reduce its level in chemoresistant CRC cells to first-line chemotherapy. Up-regulation of miR-1914* and -1915 decreased the chemoresistance abilities of chemoresistant CRC cells. The plasma miR-1914* and -1915 may play a role in colorectal cancer therapy and diagnosis.
therapeutic target	hsa-mir-194	Colorectal Carcinoma	25602366	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-194, regulating the MAP4K4/c-Jun/MDM2 signaling pathway, might act as a tumor suppressor and serve as a novel target for CRC prevention and therapy.
therapeutic target	hsa-mir-196b	Colorectal Carcinoma	25605245	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the up-regulation of MIR196B modulates apoptosis in colorectal cancer cells by partially repressing FAS expression and that anti-MIR196B could be a potential candidate as an anti-cancer drug in colorectal cancer therapy.
therapeutic target	hsa-mir-199a	Colorectal Carcinoma	23173124	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Pre-miR-34a and pre-miR-199a decreased the level of Axl, a tyrosine-protein kinase receptor, so they can be considered as drugs in antimetastatic therapy
therapeutic target	hsa-mir-19a	Colorectal Carcinoma	26266366	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC.
therapeutic target	hsa-mir-19b-1	Colorectal Carcinoma	26266366	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC.
therapeutic target	hsa-mir-200a	Colorectal Carcinoma	29388209	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miR200 family has potential for both prognostic and therapeutic management of CRC.
therapeutic target	hsa-mir-200c	Colorectal Carcinoma	29388209	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miR201 family has potential for both prognostic and therapeutic management of CRC.
therapeutic target	hsa-mir-203	Colorectal Carcinoma	25482885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-203 has the potential as a therapeutic strategy for 5-FU-resistant colorectal cancer
therapeutic target	hsa-mir-203	Colorectal Carcinoma	26361147	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Taken together, our findings imply that posttranscriptional deregulation of CPEB4 contributes to the inhibited cell proliferation and the enhanced cell apoptosis in colorectal cancer, and directly targeting CPEB4 by miR-203 might be a novel strategy in colorectal cancer treatment.
therapeutic target	hsa-mir-203	Colorectal Carcinoma	25621839	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		ZNF217 has an oncogenic role in CRC and is regulated by miR-203, and open up the possibility of ZNF217- and miR-203-targeted therapy for CRC.
therapeutic target	hsa-mir-206	Colorectal Carcinoma	25607234	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-206 as a tumor suppressor in CRC and suggest a potential therapeutic target for clinical intervention.
therapeutic target	hsa-mir-206	Colorectal Carcinoma	26406866	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings suggest that miR-206 may be useful as a new potential therapeutic target for CRC.
therapeutic target	hsa-mir-206	Colorectal Carcinoma	26515696	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		This study revealed functional and mechanistic links between miR-206 and oncogene FMNL2 and c-MET in the progression of CRC. miR-206 functioned as a tumor suppressor in the progression of CRC by targeting FMNL2 and c-MET.Restoration of miR-206 expression may represent a promising therapeutic approach for targeting malignant CRC.
therapeutic target	hsa-mir-20a	Colorectal Carcinoma	26266366	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC.
therapeutic target	hsa-mir-21	Colorectal Carcinoma	25603978	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miRNA-21 regulates hTERT expression via the PTEN/ERK1/2 signaling pathway, therefore controlling CRC cell line growth. MiRNA-21 may serve as a novel therapeutic target in CRC.
therapeutic target	hsa-mir-21	Colorectal Carcinoma	25609245	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Stromal miR-21 expression is related to the expression of E-cadherin and metastasis-associated protein1 in colorectal cancer. Stage II colorectal cancer patients with high levels of miR-21 are at higher risk for tumor recurrence and should be considered for more intensive treatment.
therapeutic target	hsa-mir-21	Colorectal Carcinoma	25769454	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		we will focus on the critical role of miR-21 in CRC. Hopefully, the information obtained may lead to a better understanding of the pathogenesis and development of novel therapeutic strategies for this disease.
therapeutic target	hsa-mir-21	Colorectal Carcinoma	26084510	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In summary,the results reveal that detailed molecular events can be combined with individual genetic data, including gene/miRNA expression data, to enhance in silico prediction of therapeutic response of individual CRC tumors.The study demonstrates that miRNA information can be applied as actionable information regarding individual therapeutic response.
therapeutic target	hsa-mir-217	Colorectal Carcinoma	26016795	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings suggest that miR-217 has considerable value as a prognostic marker and potential therapeutic target in CRC.
therapeutic target	hsa-mir-218	Colorectal Carcinoma	26442524	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These suggest the unique potential of miR-218 as a novel candidate for developing miR-218-based therapeutic strategies in CRC.
therapeutic target	hsa-mir-22	Colorectal Carcinoma	25449431	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-22 could be considered as both a predictor of 5-FU sensitivity for personalized treatment and a therapeutic target for colorectal cancer.
therapeutic target	hsa-mir-221	Colorectal Carcinoma	24949825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer.
therapeutic target	hsa-mir-222	Colorectal Carcinoma	24949825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer.
therapeutic target	hsa-mir-224	Colorectal Carcinoma	23846336	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		This study reveals functional and mechanistic links between miRNA-224 and the tumor suppressors PHLPP1 and PHLPP2 in the pathogenesis of colorectal cancer. miR-224 not only plays important roles in the regulation of cell proliferation and tumor growth in colorectal cancer, but also has potential as a prognostic marker or therapeutic target for colorectal cancer.
therapeutic target	hsa-mir-23b	Colorectal Carcinoma	26269151	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		To conclude, the miRNA/mRNA deregulations pairs identified in this study have high potentials to be further applied in diagnosis and treatment of CRC.
therapeutic target	hsa-mir-24	Colorectal Carcinoma	25502080	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-regulation of miR-24-3p contributes to the development and progression of CRC and may have a potential role in prognosis and therapy.
therapeutic target	hsa-mir-26b	Colorectal Carcinoma	20831567	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MetaCore network analysis further showed that the regulatory pathways of miR-26b were significantly associated with the invasiveness and metastasis of CRC cells. These data suggest that miR-26b might serve as a novel prognostic factor and a potential therapeutic target for CRC.
therapeutic target	hsa-mir-301a	Colorectal Carcinoma	25591765	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-301a promotes CRC progression by directly downregulating SOCS6 expression, and miR-301a may represent a novel biomarker for the prevention and treatment of CRC.
therapeutic target	hsa-mir-30a	Colorectal Carcinoma	26333808	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results identify a new miR-30a/HP1γ/p21 regulatory axis controlling colorectal cancer development, which may offer prognostic and therapeutic opportunities.
therapeutic target	hsa-mir-31	Colorectal Carcinoma	25472647	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		in CRCs carrying all wild-type genes, high miR-31-5p was associated with shorter PFS, suggesting that it may be a useful and additional prognostic biomarker for anti-EGFR therapy.
therapeutic target	hsa-mir-320b	Colorectal Carcinoma	26487644	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our identification of c-MYC as a target gene of miR-320b provides new insights into the pathophysiology of CRC proliferation, and identifies miR-320b as a novel therapeutic target for the treatment of CRC.
therapeutic target	hsa-mir-326	Colorectal Carcinoma	25412953	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNAs, such as miRNA-1, miRNA-338-5p, and miRNA-326 may be used as potential targets for CRC diagnosis and treatment.
therapeutic target	hsa-mir-335	Colorectal Carcinoma	24829139	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		our results demonstrate that miR-335 functions as a tumor suppressor and play a role in inhibiting metastasis of CRC cells through targeting ZEB2. These findings suggest that miR-335 may be useful as a new potential therapeutic target for CRC.
therapeutic target	hsa-mir-335	Colorectal Carcinoma	24949825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results make sense for the prevention and treatment of intestinal-related chronic inflammation or cancer.
therapeutic target	hsa-mir-338	Colorectal Carcinoma	25412953	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNAs, such as miRNA-1, miRNA-338-5p, and miRNA-326 may be used as potential targets for CRC diagnosis and treatment.
therapeutic target	hsa-mir-34a	Colorectal Carcinoma	23173124	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Pre-miR-34a and pre-miR-199a decreased the level of Axl, a tyrosine-protein kinase receptor, so they can be considered as drugs in antimetastatic therapy
therapeutic target	hsa-mir-365-1	Colorectal Carcinoma	26269151	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		To conclude, the miRNA/mRNA deregulations pairs identified in this study have high potentials to be further applied in diagnosis and treatment of CRC.
therapeutic target	hsa-mir-365-2	Colorectal Carcinoma	26269151	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		To conclude, the miRNA/mRNA deregulations pairs identified in this study have high potentials to be further applied in diagnosis and treatment of CRC.
therapeutic target	hsa-mir-376a	Colorectal Carcinoma	25422250	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-376a may be a meaningful prognostic biomarker and potential therapeutic target in colorectal cancer.
therapeutic target	hsa-mir-378	Colorectal Carcinoma	24555885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In conclusion, miR-378 may function as a tumor suppressor and plays an important role in inhibiting tumor growth and invasion. Our present results implicate the potential effects of miR-378 on prognosis and treatment of CRC cancer.
therapeutic target	hsa-mir-409	Colorectal Carcinoma	26084278	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggest that miR-409-3p functions as a tumor suppressor by inhibiting the development and metastasis of CRC, suggesting that miR-409-3p is expected to become a new diagnostic marker and a new target of the treatment of CRC.
therapeutic target	hsa-mir-451	Colorectal Carcinoma	26497997	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Taken together, these findings suggest that lncRNAs may be promising therapeutic molecules to eradicate CSCs and MREs of tumor-suppressor miRNAs, such as miR-451,may be exploited to ensure the specificity of CSC-targeting strategies.
therapeutic target	hsa-mir-490	Colorectal Carcinoma	25412953	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miRNAs, such as miRNA-1, miRNA-338-5p, and miRNA-326 may be used as potential targets for CRC diagnosis and treatment.
therapeutic target	hsa-mir-503	Colorectal Carcinoma	26722476	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-503 inhibits cell proliferation and induces apoptosis by directly targeting E2F3 in CRC cells, indicating its potential application in CRC diagnosis and therapy.
therapeutic target	hsa-mir-520g	Colorectal Carcinoma	25616665	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A major implication of our studies is that inhibition of miR-520g or restoration of p21 expression may have considerable therapeutic potential to overcome drug resistance in colorectal cancer patients, especially in those with mutant p53.
therapeutic target	hsa-mir-7	Colorectal Carcinoma	24185687	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study suggests that as a novel target of miR-7, PAX6 may serve as a promising therapeutic target for colorectal cancer.
therapeutic target	hsa-mir-7	Colorectal Carcinoma	25503932	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-7 is a meaningful prognostic marker. Furthermore, these data indicate that miR-7 precursor, alone or in combination with cetuximab, may be useful in therapy against CRC
therapeutic target	hsa-mir-7	Colorectal Carcinoma	29549306	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		therapeutic targeting of the c-Myb/circHIPK3/miR-7 axis may be a promising treatment approach for CRC patients
therapeutic target	hsa-mir-874	Colorectal Carcinoma	26875895	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These data demonstrate that miR-874 functions as a tumor suppressor by repression of STAT3, suggesting its potential therapeutic value in CRC treatment.
therapeutic target	hsa-mir-92-1	Colorectal Carcinoma	26266366	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC.
therapeutic target	hsa-mir-92a	Colorectal Carcinoma	24026406	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-92a induced EMT and regulated cell growth, migration and invasion in the SW480 cells, at least partially, via suppression of PTEN expression. MiR-92a may serve as a novel therapeutic target in colorectal cancer.
therapeutic target	hsa-mir-99a	Colorectal Carcinoma	24503111	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The MiR-99a/Let-7c/miR-125b signature may improve the selection of patients with KRAS wild-type mCRC as good candidates for anti-EGFR therapy.
therapeutic target	hsa-mir-1	Colorectal Carcinoma	23874421	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications.
therapeutic target	hsa-mir-129	Colorectal Carcinoma	23874421	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications.
therapeutic target	hsa-mir-145	Colorectal Carcinoma	21690566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The authors' findings show that chemically unmodified miRNAs complexed with PEI can be used in an efficient and biocompatible strategy of miRNA replacement therapy, as illustrated by efficacious delivery of PEI/miR-145 and PEI/miR-33a complexes in colon carcinoma.
therapeutic target	hsa-mir-182	Colorectal Carcinoma	24884732	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results illustrated that the up-regulation of miR-182 played a pivotal role in CRC tumorigenesis and metastasis, which suggesting a potential implication of miR-182 in the molecular therapy for CRC.
therapeutic target	hsa-mir-215	Colorectal Carcinoma	23874421	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications.
therapeutic target	hsa-mir-223	Colorectal Carcinoma	25867276	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These results identify that C/EBP-β-activated miR-223 contributes to tumour growth by targeting RASA1 in CRC and miR-223-targeted inhibitors may have clinical promise for CRC treatment via suppression of miR-223.
therapeutic target	hsa-mir-24	Colorectal Carcinoma	26297223	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant.
therapeutic target	hsa-mir-30a	Colorectal Carcinoma	25582198	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-30a might serve as a promising therapeutic  strategy for colon cancer treatment.
therapeutic target	hsa-mir-320a	Colorectal Carcinoma	26297223	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant.
therapeutic target	hsa-mir-33a	Colorectal Carcinoma	21690566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The authors' findings show that chemically unmodified miRNAs complexed with PEI can be used in an efficient and biocompatible strategy of miRNA replacement therapy, as illustrated by efficacious delivery of PEI/miR-145 and PEI/miR-33a complexes in colon carcinoma.
therapeutic target	hsa-mir-423	Colorectal Carcinoma	26297223	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant.
therapeutic target	hsa-mir-497	Colorectal Carcinoma	23874421	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications.
therapeutic target	hsa-mir-582	Colorectal Carcinoma	26384136	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our data suggest that miR-582-5p may function as a tumor suppressor in the development of CRC by targeting Rab27a, indicating a novel therapeutic strategy for patients with CRC.
therapeutic target	hsa-mir-625	Colorectal Carcinoma	26314959	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings indicate the pivotal role of miR-625-3p in invasion that warrants further exploration whether targeting miR-625-3p could be a promising approach for the treatment of CRC.
therapeutic target	hsa-mir-95	Colorectal Carcinoma	25871428	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		This study demonstrates that genistein has an inhibitory effect on CRC involved in reducing miR-95, Akt and SGK1, offering novel insights into the mechanisms of genistein therapeutic actions.
therapeutic target	hsa-mir-548d	Complex Regional Pain Syndrome	26072390	nervous system disease	DOID:3223	G90.50	D020918			This study suggests the usefulness of circulating miRNAs as potential biomarkers. Assessing miRNA signatures before and after treatment demonstrated miRNA alterations from therapy; differences in miRNA signature in responders and poor responders before therapy indicate prognostic value. Mechanistic studies on altered miRNAs can provide new insights into disease.
therapeutic target	hsa-mir-1246	Corneal Neovascularization	27625050	nervous system disease	DOID:11382	H16.4	D016510		HP:0011496	Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization.
therapeutic target	hsa-mir-1275	Corneal Neovascularization	27625050	nervous system disease	DOID:11382	H16.4	D016510		HP:0011496	Curcumin inhibits angiogenesis by up-regulation of microRNA-1275 and microRNA-1246: a promising therapy for treatment of corneal neovascularization.
therapeutic target	hsa-mir-223	Coronary Artery Disease	25350775	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
therapeutic target	hsa-mir-2909	Coronary Artery Disease	24634009	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Based upon these results, we propose that miR-2909 RNomics may be a step forward in understanding human CHD at the epigenomic level and can be exploited for designing new therapeutic strategies as well as diagnostic and prognostic markers for this disease in future.
therapeutic target	hsa-mir-31	Coronary Artery Disease	24558106	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Manipulating the expression of the miR-31-miR-720 pathway in malfunction EPCs should help develop novel therapeutic modalities.
therapeutic target	hsa-mir-361	Coronary Artery Disease	24865854	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-361-5p/VEGF-dependent regulation that could help to develop new therapeutic modalities not only for ischemia-related diseases but also for tumor angiogenesis.
therapeutic target	hsa-mir-720	Coronary Artery Disease	24558106	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Manipulating the expression of the miR-31-miR-720 pathway in malfunction EPCs should help develop novel therapeutic modalities.
therapeutic target	hsa-let-7d	Crohn Disease	24447044	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	let-7d and let-7e might be possible therapeutic biomarkers in patients with CD, who are treated by infliximab.
therapeutic target	hsa-let-7e	Crohn Disease	24447044	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	let-7d and let-7e might be possible therapeutic biomarkers in patients with CD, who are treated by infliximab.
therapeutic target	hsa-mir-16	Cystic Fibrosis	26133785	genetic disease	DOID:1485	E84	D003550	219700		We interpret these findings to suggest that these miRs may constitute novel targets for CF therapy.
therapeutic target	hsa-mir-17	Cystic Fibrosis	26160865	genetic disease	DOID:1485	E84	D003550	219700		Modulating miR-17 expression in cystic fibrosis bronchial epithelial cells may be a novel anti-inflammatory strategy for cystic fibrosis and other chronic inflammatory airway diseases.
therapeutic target	hsa-mir-31	Cystic Fibrosis	24940638	genetic disease	DOID:1485	E84	D003550	219700		The miR-31/IRF-1/CTSS pathway may play a functional role in the pathogenesis of CF lung disease and may open up new avenues for exploration in the search for an effective therapeutic target.
therapeutic target	hsa-mir-335	Depression Disorder	26314506	disease of mental health	DOID:1596	F32.9	D003866			These results suggest that miR-335 is associated with the pathophysiology of depression and is a potential target for new antidepressant treatments.
therapeutic target	hsa-mir-511	Depression Disorder	25689572	disease of mental health	DOID:1596	F32.9	D003866			these results suggest that microRNA-mediated reductions of GFRα1a in depression change the quality, rather than the quantity, of GDNF signalling.They also suggest that central GDNF signalling may represent a novel target for antidepressant treatment.
therapeutic target	hsa-mir-122	Diabetes Mellitus	27966196	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases.
therapeutic target	hsa-mir-126	Diabetes Mellitus	28440196	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	miR-126 as a Therapeutic Agent for Diabetes Mellitus.
therapeutic target	hsa-mir-19a	Diabetes Mellitus	25887942	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The five miRNAs that were differentially expressed in GDM could serve as noninvasive biomarkers. The results also provide insights into the molecular mechanisms that underlie GDM, thereby contributing to the diagnosis and treatment of this disease.
therapeutic target	hsa-mir-19b	Diabetes Mellitus	25887942	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The five miRNAs that were differentially expressed in GDM could serve as noninvasive biomarkers. The results also provide insights into the molecular mechanisms that underlie GDM, thereby contributing to the diagnosis and treatment of this disease.
therapeutic target	hsa-mir-208	Diabetes Mellitus	27966196	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases.
therapeutic target	hsa-mir-20a	Diabetes Mellitus	25887942	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The five miRNAs that were differentially expressed in GDM could serve as noninvasive biomarkers. The results also provide insights into the molecular mechanisms that underlie GDM, thereby contributing to the diagnosis and treatment of this disease.
therapeutic target	hsa-mir-21	Diabetes Mellitus	26655730	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	These results suggest that endogenous miRNAs involved in the formation of IPCs from PPCs should be considered in the development of an effective cell transplant therapy for diabetes.
therapeutic target	hsa-mir-223	Diabetes Mellitus	26273679	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	In conclusion, in AT miR-223 is an IR-related miRNA that may serve as a potential therapeutic target for the treatment of IR-related disorders.
therapeutic target	hsa-mir-29	Diabetes Mellitus	25689084	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	In light of increasing awareness of the interconnection of diabetes mellitus, CVD, and cancer, it is of utmost importance to understand the mechanism of action of current treatment options on all of the comorbidities and careful evaluation of cardiovascular toxicity must accompany any treatment paradigm that increases miR-29 levels.
therapeutic target	hsa-mir-320	Diabetes Mellitus	18986336	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Transfection of an miR-320 inhibitor may be a therapeutic approach for the treatment of impaired angiogenesis in diabetes.
therapeutic target	hsa-mir-320a	Diabetes Mellitus	26031505	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	This study is the first to report miRs associated with response to a pharmacologic intervention for insulin resistance. MiR-320a and miR-486-5p identified responders to thiazolidinedione therapy among the insulin resistant group.
therapeutic target	hsa-mir-33	Diabetes Mellitus	27966196	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases.
therapeutic target	hsa-mir-375	Diabetes Mellitus	26047014	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	These findings highlight miRNAs functions in stem cells differentiation and suggest that they could be used as therapeutic tools for gene-based therapy in diabetes mellitus.
therapeutic target	hsa-mir-375	Diabetes Mellitus	15538371	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Thus, miR-375 is a regulator of insulin secretion and may thereby constitute a novel pharmacological target for the treatment of diabetes.
therapeutic target	hsa-mir-486	Diabetes Mellitus	26031505	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	This study is the first to report miRs associated with response to a pharmacologic intervention for insulin resistance. MiR-320a and miR-486-5p identified responders to thiazolidinedione therapy among the insulin resistant group.
therapeutic target	hsa-mir-9	Diabetes Mellitus	26047014	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	These findings highlight miRNAs functions in stem cells differentiation and suggest that they could be used as therapeutic tools for gene-based therapy in diabetes mellitus.
therapeutic target	hsa-mir-92a	Diabetes Mellitus	28462946	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice.
therapeutic target	hsa-mir-21	Diabetes Mellitus, Type 1	23506112	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy
therapeutic target	hsa-mir-22	Diabetes Mellitus, Type 2	26193896	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Our results support a critical role for miR-22-3p and its target, Tcf7, in the pathogenesis of diabetes by upregulating gluconeogenesis. Moreover, targeting the miR-22/Tcf7/Wnt axis might hold therapeutic potential for the treatment of altered hepatic physiology during insulin resistance and type 2 diabetes.
therapeutic target	hsa-mir-26a	Diabetes Mellitus, Type 2	25961460	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	These findings reveal miR-26a as a regulator of liver metabolism and suggest miR-26a should be further explored as a potential target for the treatment of T2D.
therapeutic target	hsa-mir-135a	Diabetic Nephropathy	24908566			E10-11.21	D003928			These findings suggest an important role for miR-135a in renal fibrosis and inhibition of miR-135a might be an effective therapy for diabetic nephropathy.
therapeutic target	hsa-mir-21	Diabetic Nephropathy	28129112			E10-11.21	D003928			Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice.
therapeutic target	hsa-mir-23b	Diabetic Nephropathy	26646104			E10-11.21	D003928			Taken together, we showed for the first time that miR-23b acts as a suppressor of EMT in diabetic nephropathy through repressing PI3K-AKT signalling pathway activation by targeting HMGA2, which maybe a potential therapeutic target for diabetes-induced renal dysfunction.
therapeutic target	hsa-mir-26a	Diabetic Nephropathy	25797045			E10-11.21	D003928			Together our results provide the first evidence for the involvement of miR-26a in high glucose-induced mesangial cell hypertrophy and matrix protein expression. These data indicate the potential therapeutic utility of anti-miR-26a for the complications of diabetic kidney disease.
therapeutic target	hsa-mir-106a	Diabetic Retinopathy	24018047	nervous system disease	DOID:8947	E10-11.31	D003930			There is a cross-talk between HIF1α and VEGF through interactions with their common miRNAs. miRNA based therapy can affect the expression of both HIF1α and VEGF and may represent a therapeutic potential for the treatment of DR.
therapeutic target	hsa-mir-126	Diabetic Retinopathy	25616704	nervous system disease	DOID:8947	E10-11.31	D003930			The A allele of rs4636297, known to be the non-functional allele for post-translational regulation of miR-126, is associated with STDR. This finding suggests that this locus would be a potential therapeutic target for inhibiting the development of DR.
therapeutic target	hsa-mir-24	Diabetic Vasculopathy	27085480	cardiovascular system disease	DOID:11713		D003925			elevation of miR-24 in vascular system may  be a novel therapeutic strategy to prevent the development of diabetic atherosclerosis.
therapeutic target	hsa-mir-33	Disease of Metabolism	24591767	disease of metabolism	DOID:0014667	E88.9	D008659			In patients with low HDL-C levels, XZK therapy raised plasma levels of miR-33a and miR-33b, which may inhibit cellular cholesterol export and limit the HDL-raising effect of XZK.
therapeutic target	hsa-mir-9	Disease of Metabolism	26459099	disease of metabolism	DOID:0014667	E88.9	D008659			Therefore, these findings demonstrated that the inhibition of miRNA-9-3p reduced the proliferation of HepG2 cells and lipid accumulation by upregulating the expression of SIRT1, indicating its potential as a therapeutic target.
therapeutic target	hsa-mir-106a	Early-Stage Colon Carcinoma	24746948			C18.9				The present results implied that miR-106a and the miR-125b were associated with the formation and invasion of colorectal tumors. Thus, these miRNAs might be used as significant prognostic factors and indicators of early-stage CRC. Further studies and validations are required; these miRNAs may provide novel molecular targets for CRC treatment.
therapeutic target	hsa-mir-125b	Early-Stage Colon Carcinoma	24746948			C18.9				The present results implied that miR-106a and the miR-125b were associated with the formation and invasion of colorectal tumors. Thus, these miRNAs might be used as significant prognostic factors and indicators of early-stage CRC. Further studies and validations are required; these miRNAs may provide novel molecular targets for CRC treatment.
therapeutic target	hsa-mir-143	Endometrial Neoplasms	29661100	reproductive system disease	DOID:1380	C54.1	D016889	608089		these miRNAs are potential candidates for the diagnosis of endometrial cancer and therapeutic targets
therapeutic target	hsa-mir-145	Endometrial Neoplasms	29661100	reproductive system disease	DOID:1380	C54.1	D016889	608089		these miRNAs are potential candidates for the diagnosis of endometrial cancer and therapeutic targets
therapeutic target	hsa-mir-29c	Endometriosis	25625784	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-29c exerts its effects on endometrial cell proliferation, apoptosis and invasion by inhibiting the expression of c-Jun. Our data may provide a novel potential therapeutic target for the treatment of endometriosis
therapeutic target	hsa-mir-503	Endometriosis	28720098	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Arcyriaflavin a, a cyclin D1-cyclin-dependent kinase4 inhibitor, induces apoptosis and inhibits proliferation of human endometriotic stromal cells: a potential therapeutic agent in endometriosis
therapeutic target	hsa-mir-125b	Endomyocardial Fibrosis	26585673	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	In conclusion, miR-125b is critical for induction of cardiac fibrosis and acts as a potent repressor of multiple anti-fibrotic mechanisms.Inhibition of miR-125b may represent a novel therapeutic approach for the treatment of human cardiac fibrosis and other fibrotic diseases.
therapeutic target	hsa-mir-433	Endomyocardial Fibrosis	28740551	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	Modulating microRNAs as Novel Therapeutic Targets in Cardiac Fibrosis.
therapeutic target	hsa-mir-210	Enteropathy	24290534			B80	D007410			MiR-210: A potential therapeutic target against radiation-induced enteropathy.
therapeutic target	hsa-mir-134	Epilepsy	29069823	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	MicroRNA-134 plasma levels before and after treatment with valproic acid for epilepsy patients.
therapeutic target	hsa-mir-17	Epilepsy	26343596	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful.
therapeutic target	hsa-mir-223	Epilepsy	26343596	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful.
therapeutic target	hsa-mir-320a	Epilepsy	26343596	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful.
therapeutic target	hsa-mir-451a	Epilepsy	26343596	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Research should be performed on miR-320-related pathways and their relationship to depression. Additionally, miR-451a could serve as a candidate biomarker for depression based on the acting mechanism of ketamine. Studies targeting miR-451a levels before and after treatment could be helpful.
therapeutic target	hsa-mir-182	Epithelioid Sarcoma	26314219	disease of cellular proliferation	DOID:6193		D012509			Thus, our findings suggest that demethylating agents could potentially be used to modulate miR-182 levels as a therapeutic strategy.
therapeutic target	hsa-mir-192	Esophageal Neoplasms	23649428			C15.9	D004938	133239	HP:0100751	The expression of miR-192, miR-194 and miR-622 was significantly reduced after neoadjuvant therapy confirming the array profiling data.
therapeutic target	hsa-let-7a	Ewing Sarcoma	26393798	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	These findings suggests that the up-regulation of c-Myc inhibited the expression of let-7a, miR-16 and miR-29b subsequently induced CCND2 expression in ES cells. The present study might identify a novel oncogenic axis that c-Myc regulates the expression of CCND2 via let-7a, miR-16 and miR-29b,leading to the development new therapeutic targets for ES.
therapeutic target	hsa-mir-125b	Ewing Sarcoma	24517182	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	Collectively, these data suggest that miR-125b functions as a tumor suppressor by targeting the PI3K/Akt/mTOR signaling pathway, and may provide potential therapy strategy for ES patients by targeting miRNA expression.
therapeutic target	hsa-mir-16	Ewing Sarcoma	26393798	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	These findings suggests that the up-regulation of c-Myc inhibited the expression of let-7a, miR-16 and miR-29b subsequently induced CCND2 expression in ES cells. The present study might identify a novel oncogenic axis that c-Myc regulates the expression of CCND2 via let-7a, miR-16 and miR-29b,leading to the development new therapeutic targets for ES.
therapeutic target	hsa-mir-29b	Ewing Sarcoma	26393798	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	These findings suggests that the up-regulation of c-Myc inhibited the expression of let-7a, miR-16 and miR-29b subsequently induced CCND2 expression in ES cells. The present study might identify a novel oncogenic axis that c-Myc regulates the expression of CCND2 via let-7a, miR-16 and miR-29b,leading to the development new therapeutic targets for ES.
therapeutic target	hsa-mir-17	Fatty Liver, Non-Alcoholic	25896250	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Our studies show that miR-17-5p inhibitor and agents used in metabolic disorders may be applied in combination with Dexamethasone in the treatment of anti-inflammation, immunosuppression, and cancer patients.
therapeutic target	hsa-mir-34a	Fatty Liver, Non-Alcoholic	26330104	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Taken together, our data indicated that decreased expression of miR-34a potentially contributes to altered lipid metabolism in NAFLD. Downregulation of miR-34a may be a therapeutic strategy against NAFLD by regulating its target PPARα and SIRT1.
therapeutic target	hsa-mir-451	Fatty Liver, Non-Alcoholic	25957914	disease of metabolism	DOID:0080208	K75.81	D065626	613282		These results provide new insights into the negative regulation of miR-451 in fatty acid-induced inflammation via the AMPK/AKT pathway and demonstrate potential therapeutic applications for miR-451 in preventing the progression from simple steatosis to severely advanced liver disease.
therapeutic target	hsa-mir-130b	Fragile X Syndrome	24021279	genetic disease	DOID:14261	Q99.2	D005600	300624		antagonizing miR-130b may be a new therapeutic entry point for treating Fragile X syndrome.
therapeutic target	hsa-mir-142	Fungal Keratitis	26720440			H15.8	D007634			This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies.
therapeutic target	hsa-mir-155	Fungal Keratitis	26720440			H15.8	D007634			This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies.
therapeutic target	hsa-mir-451a	Fungal Keratitis	26720440			H15.8	D007634			This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies.
therapeutic target	hsa-mir-511	Fungal Keratitis	26720440			H15.8	D007634			This is, to our knowledge, the first report on comprehensive human corneal miRNA expression profile in fungal keratitis. Several miRNAs with high expression in fungal keratitis point toward their potential role in regulation of pathogenesis. Further insights in understanding their role in corneal wound inflammation may help design new therapeutic strategies.
therapeutic target	hsa-let-7	Gastric Neoplasms	25860484	disease of cellular proliferation	DOID:10534	C16	D013274	137215		these data provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion. Further study with a large sample size and more functional experiments is needed to confirm these data and contribute to diagnostic and treatment strategies for gastric cancer.
therapeutic target	hsa-let-7b	Gastric Neoplasms	25613480	disease of cellular proliferation	DOID:10534	C16	D013274	137215		the molecular mechanisms involved in gastric cancer metastasis and indicate that let-7b modulation may be a bona fide treatment of gastric cancer.
therapeutic target	hsa-let-7i	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-106a	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-106b	Gastric Neoplasms	24842611	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106b might be a novel candidate target for the treatment of gastric cancer.
therapeutic target	hsa-mir-10a	Gastric Neoplasms	24498243	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our data indicate that miR-10a acts as a tumor suppressor in GC cells and is partially silenced by DNA hypermethylation in GC,suggesting that miR-10a may serve as a potential diagnostic or therapeutic target of GC.
therapeutic target	hsa-mir-126	Gastric Neoplasms	25027343	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results demonstrated that overexpression of miR-126 inhibited GC cells invasion in part by targeting Crk. These findings suggested that miR-126 played major roles in the malignant behavior of GC and it might be a promising therapeutic target of GC.
therapeutic target	hsa-mir-126	Gastric Neoplasms	25428912	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-126 could suppress tumor growth and tumor angiogenesis of GC through VEGF-A signaling, and it is a novel potential therapeutic target for GC.
therapeutic target	hsa-mir-128	Gastric Neoplasms	26334097	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our data suggest that cMET, PIK3CA and target-related miRNAs play an important role in GC and may  serve as potential targets for therapy.
therapeutic target	hsa-mir-128b	Gastric Neoplasms	26478435	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, our results indicate that miR-128b could serve as a potential diagnostic biomarker and therapeutic option for human GC in the near future.
therapeutic target	hsa-mir-130a	Gastric Neoplasms	26375442	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, targeting miR-130a and miR-495 could be a potential therapeutics to recover RUNX3 expression under hypoxic conditions and in early tumorigenic progression.
therapeutic target	hsa-mir-132	Gastric Neoplasms	26324336	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Therefore, the present results indicate that the miR-132/RB1 regulatory axis may be a potential novel diagnostic and therapeutic target for the treatment of gastric cancer.
therapeutic target	hsa-mir-133a	Gastric Neoplasms	25620172	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-133a inhibits cell growth and invasion and induces cell apoptosis and cycle arrest through repressing TAGLN2 gene, suggesting that miR-133a might be used as a biomarker or therapeutic target for the treatment of gastric cancer.
therapeutic target	hsa-mir-133a	Gastric Neoplasms	26276722	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer.
therapeutic target	hsa-mir-133a	Gastric Neoplasms	26629938	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These outcomes might be secondary to the increased expression of miR-133a after the treatment with UA.
therapeutic target	hsa-mir-133b	Gastric Neoplasms	25433493	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-133b was significantly down-regulated in GC tissues and exerted its tumor suppressor role in GC cells.The investigation of the detailed mechanism showed that miR-133b directly targeted FSCN1 which functioned as an oncogenic gene in GC cells. These results suggested that miR-133b can be developed as a new diagnostic marker or therapeutic target for GC.
therapeutic target	hsa-mir-133b	Gastric Neoplasms	26276722	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Identification of miRNomes in human stomach and gastric carcinoma reveals miR-133b/a-3p as therapeutic target for gastric cancer.
therapeutic target	hsa-mir-137	Gastric Neoplasms	26545111	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, the results reinforced the critical role for the down-regulated miR-137 expression in gastric cancer and suggested that miR-137 expression could be a prognostic indicator for this disease. In addition, these patients with TNM stage III gastric cancer and low miR-137 expression might need more aggressive postoperative treatment and closer follow-up.
therapeutic target	hsa-mir-141	Gastric Neoplasms	26233544	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings together suggested that miR-141 could be interacting with MEG3 and targeting E2F3, and these factors may play important anti-tumor effects in GC pathogenesis and provide therapeutic targets in the clinics.
therapeutic target	hsa-mir-141	Gastric Neoplasms	25633292	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-141 might be employed as novel prognostic markers and therapeutic targets of GC.
therapeutic target	hsa-mir-142	Gastric Neoplasms	26232716	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings together suggested that miR-141 could be interacting with MEG3 and targeting E2F4, and these factors may play important anti-tumor effects in GC pathogenesis and provide therapeutic targets in the clinics.
therapeutic target	hsa-mir-143	Gastric Neoplasms	26231888	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings together suggested that miR-141 could be interacting with MEG3 and targeting E2F5, and these factors may play important anti-tumor effects in GC pathogenesis and provide therapeutic targets in the clinics.
therapeutic target	hsa-mir-143	Gastric Neoplasms	26349981	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we determined miR-143 as a potent inhibitor of autophagy via targeting GABARAPL1 and miR-143 could improve the efficacy of Quercetin though autophagy inhibition in GC cell lines, thus representing a novel potential therapeutic target for gastric cancer.
therapeutic target	hsa-mir-148a	Gastric Neoplasms	24659367	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-148a may serve as a novel biomarker for the diagnosis and as a new therapeutic target in gastric cancer.
therapeutic target	hsa-mir-152	Gastric Neoplasms	26627200	disease of cellular proliferation	DOID:10534	C16	D013274	137215		TGF-β could induce HLA-G expression in GC by inhibiting miR-152,involving its negative regulation on HLA-G. Since TGF-β induced HLA-G up-regulation plays important role in immune escape, a potential application of miR-152 was suggested in GC treatment, or miR-152 might be one potential biomarker for GC.
therapeutic target	hsa-mir-155	Gastric Neoplasms	26056431	disease of cellular proliferation	DOID:10534	C16	D013274	137215		rosmarinic acid (RA) might potentially be a therapeutic agent for suppressing the Warburg effect in gastric carcinoma.
therapeutic target	hsa-mir-15b	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-16	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-181b	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-18a	Gastric Neoplasms	24624454	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data highlighted an important role for miR-18a in controlling gastric cancer growth and angiogenesis, therefore offering a possible therapeutic strategy against this malignancy.
therapeutic target	hsa-mir-19a	Gastric Neoplasms	25400827	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-19a could be used as a promising therapeutic target in the treatment of GC.
therapeutic target	hsa-mir-19a	Gastric Neoplasms	26334097	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our data suggest that cMET, PIK3CA and target-related miRNAs play an important role in GC and may  serve as potential targets for therapy.
therapeutic target	hsa-mir-19a	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-19a	Gastric Neoplasms	25914465	disease of cellular proliferation	DOID:10534	C16	D013274	137215		All together, our results suggest that miR-19a could be used as a promising therapeutic target in the treatment of GC.
therapeutic target	hsa-mir-19b	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-200	Gastric Neoplasms	25595591	disease of cellular proliferation	DOID:10534	C16	D013274	137215		EZH2 and DNMT1-mediated epigenetic silencing contributed to the progression of gastric cancer and glioblastoma, and therefore represents a novel therapeutic target for malignant tumors.
therapeutic target	hsa-mir-200b	Gastric Neoplasms	23995857	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our findings suggest that miR-200b and miR-200c, as valuable markers of gastric cancer prognosis, may be a promising approach to human gastric cancer treatment.
therapeutic target	hsa-mir-200b	Gastric Neoplasms	25411357	disease of cellular proliferation	DOID:10534	C16	D013274	137215		CAFs reduce miR-200b expression and promote tumor invasion through epigenetic changes of miR-200b in gastric cancer. Thus, CAFs might be a therapeutic target for inhibition of gastric cancer.
therapeutic target	hsa-mir-200b	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-200c	Gastric Neoplasms	23995857	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our findings suggest that miR-200b and miR-200c, as valuable markers of gastric cancer prognosis, may be a promising approach to human gastric cancer treatment.
therapeutic target	hsa-mir-204	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-206	Gastric Neoplasms	25960238	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our data provide evidence that the dysregulation of miR-206-CCND2 axis may contribute to the aggressive progression and poor prognosis of human gastric cancer in clinical settings. Combined detection of their expression might be particularly helpful for surveillance of disease progression and treatment stratification.
therapeutic target	hsa-mir-20a	Gastric Neoplasms	27357419	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Altering miR鈥?0a expression may be  a potential therapeutic strategy for the treatment of chemoresistance in GC in the future.
therapeutic target	hsa-mir-21	Gastric Neoplasms	25041158	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Stromal miR-21 is closely related to tumour progression in GC.Stromal miR-21 of tumours might be a target of treatment.
therapeutic target	hsa-mir-21	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-22	Gastric Neoplasms	26610210	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings provide a better understanding of the development and progression of GC and may be an important implication for future therapy of the GC.
therapeutic target	hsa-mir-223	Gastric Neoplasms	26334097	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our data suggest that cMET, PIK3CA and target-related miRNAs play an important role in GC and may  serve as potential targets for therapy.
therapeutic target	hsa-mir-23b	Gastric Neoplasms	26835790	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results indicated that plasma miR-23b was overexpressed in GC patients and high plasma miR-23b expression was associated with poor clinical outcome. Thus, plasma miR-23b may serve as a potential diagnostic biomarker and therapeutic target for GC.
therapeutic target	hsa-mir-24	Gastric Neoplasms	24886316	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-24 functions as a novel tumor suppressor in GC and the anti-oncogenic activity may involve its inhibition of the target gene RegIV.These findings suggest the possibility for miR-24 as a therapeutic target in GC.
therapeutic target	hsa-mir-26a	Gastric Neoplasms	24015269	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-26a functions as a tumor suppressor in GC development and progression, and holds promise as a prognostic biomarker and potential therapeutic target for GC.
therapeutic target	hsa-mir-27a	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-27b	Gastric Neoplasms	26576539	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These results show that miR-27b-3p suppresses ROR1 expression through the binding site in the 3'UTR inhibiting the cell proliferation. These findings indicate that miR-27b-3p exerts tumor-suppressive effects in GC through the suppression of oncogene ROR1 expression and suggest a therapeutic application of miR-27b-3p in GC.
therapeutic target	hsa-mir-28	Gastric Neoplasms	25860484	disease of cellular proliferation	DOID:10534	C16	D013274	137215		these data provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion. Further study with a large sample size and more functional experiments is needed to confirm these data and contribute to diagnostic and treatment strategies for gastric cancer.
therapeutic target	hsa-mir-29	Gastric Neoplasms	24130168	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Take together, our finding characterized the expression properties of miR-29 family, contributed to the function and molecular mechanism of miR-29 family in GC and implied that miR-29 family might be employed as novel prognostic markers and therapeutic targets of GC.
therapeutic target	hsa-mir-30b	Gastric Neoplasms	25170877	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-30b may function as a novel tumor suppressor gene in gastric cancer by targeting PAI-1 and regulating the apoptosis of cancer cells. miR-30b could serve as a potential biomarker and therapeutic target against gastric cancer.
therapeutic target	hsa-mir-30e	Gastric Neoplasms	27372603	disease of cellular proliferation	DOID:10534	C16	D013274	137215		DIM may through the miR-30e-ATG5 modulating autophagy inhibit the proliferation of gastric cancer cells.
therapeutic target	hsa-mir-331	Gastric Neoplasms	24775712	disease of cellular proliferation	DOID:10534	C16	D013274	137215		HOTAIR overexpression represents a biomarker of poor prognosis in gastric cancer, and may confer malignant phenotype to tumor cells. The ceRNA regulatory network involving HOTAIR and the positive interaction between HOTAIR and HER2 may contribute to a better understanding of gastric cancer pathogenesis and facilitate the development of lncRNA-directed diagnostics and therapeutics against this disease.
therapeutic target	hsa-mir-338	Gastric Neoplasms	26617808	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our study suggested that miR-338-3p is significantly decreased in gastric cancer, and inhibits cell proliferation, migration and invasion partially via the downregulation of ADAM17. Thus, miR-338-3p may represent a potential therapeutic target for gastric cancer intervention.
therapeutic target	hsa-mir-34	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-34a	Gastric Neoplasms	26464633	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Therefore, we concluded that miR-34a could inhibit tumor invasion and metastasis in gastric cancer by targeting Tgif2 and may be a novel therapeutic candidate for gastric cancer.
therapeutic target	hsa-mir-34c	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-367	Gastric Neoplasms	25489984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-367 is a key negative regulator of the invasion and metastasis of gastric cancer and establishes a strong rationale for  developing miR-367 as a novel therapeutic agent against gastric cancer.
therapeutic target	hsa-mir-374a	Gastric Neoplasms	25554419	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-374a functions as a candidate oncogene in GC by directly targeting SRCIN1. miR-374a may therefore be useful as a promising therapeutic target for malignant  GC.
therapeutic target	hsa-mir-409	Gastric Neoplasms	25860484	disease of cellular proliferation	DOID:10534	C16	D013274	137215		these data provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion. Further study with a large sample size and more functional experiments is needed to confirm these data and contribute to diagnostic and treatment strategies for gastric cancer.
therapeutic target	hsa-mir-429	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-429	Gastric Neoplasms	23554776	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miRNA-429 may serve as a tumor suppressor during tumorigenesis of gastric cancer and may be a potential gastric cancer therapeutic target
therapeutic target	hsa-mir-449a	Gastric Neoplasms	25871967	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study indicates that the miR-449a/E2F3 axis plays an important role in proliferation and apoptosis in gastric cancer. Therefore, miR-449a represents a novel target for gastric cancer therapy.
therapeutic target	hsa-mir-449a	Gastric Neoplasms	26576674	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results demonstrated that miR-449a suppressed Flot2 expression results in decreased cell invasion through repressing TGF-β-mediated-EMT, and provides a new theoretical basis to further investigate miR-449a-regulated Flot2 as a potential biomarker and a promising approach for GC treatment.
therapeutic target	hsa-mir-451	Gastric Neoplasms	26464660	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our findings indicated that miR-451 may act as a novel prognostic marker and potential therapeutic target in human GC.
therapeutic target	hsa-mir-495	Gastric Neoplasms	26375442	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, targeting miR-130a and miR-495 could be a potential therapeutics to recover RUNX3 expression under hypoxic conditions and in early tumorigenic progression.
therapeutic target	hsa-mir-495	Gastric Neoplasms	25475733	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-495 have tumor suppressor properties and are partially silenced by DNA hypermethylation in GC, will provide new strategies for prevention and treatment  of GC peritoneal metastasis.
therapeutic target	hsa-mir-497	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-506	Gastric Neoplasms	25707493	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The EMT was directly suppressed by miR-506, and its low expression was an independent prognostic factor in gastric cancer patients. The data indicated that miR-506 may act as a tumor suppressor and could be a novel therapeutic agent.
therapeutic target	hsa-mir-508	Gastric Neoplasms	26349984	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
therapeutic target	hsa-mir-516a-1	Gastric Neoplasms	21169410	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The metastasis associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer.
therapeutic target	hsa-mir-516a-2	Gastric Neoplasms	21169410	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The metastasis associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer.
therapeutic target	hsa-mir-520d	Gastric Neoplasms	25063221	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-520d-3p appears to contribute to GC progression via the regulation of EphA2 and could serve as a novel prognostic and potential therapeutic marker.
therapeutic target	hsa-mir-542	Gastric Neoplasms	25432696	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-542-3p might function as a tumor suppressor in gastric cancer, potentially by targeting the oncogene AEG-1, implying a potential role for miR-542-3p in the development of therapeutic methods for gastric cancer.
therapeutic target	hsa-mir-543	Gastric Neoplasms	26612257	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results identify a new regulatory mechanism of miR-543 on SIRT1 expression in gastric cancer, and raise the possibility that the miR-543/SIRT1 pathway may serve as a potential target for the treatment of gastric cancer.
therapeutic target	hsa-mir-544a	Gastric Neoplasms	26264654	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our findings raise the possibility that inhibition of miR-544a may be a therapeutic target of metastatic GC.
therapeutic target	hsa-mir-625	Gastric Neoplasms	25860484	disease of cellular proliferation	DOID:10534	C16	D013274	137215		these data provided the first evidence to illustrate that altered gene network was associated with gastric cancer invasion. Further study with a large sample size and more functional experiments is needed to confirm these data and contribute to diagnostic and treatment strategies for gastric cancer.
therapeutic target	hsa-mir-638	Gastric Neoplasms	24623314	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results demonstrated that miR-638 suppressed GC cell proliferation by targeting Sp2 with influence on the expression of cyclin D1. We suggest that miR-638 might be a candidate predictor or an anticancer therapeutic target for GC patients.
therapeutic target	hsa-mir-874	Gastric Neoplasms	25596740	disease of cellular proliferation	DOID:10534	C16	D013274	137215		down-regulation of miR-874 contributes to tumor angiogenesis through STAT3 in GC, highlighting the potential of miR-874 as a target for human GC therapy.
therapeutic target	hsa-mir-106b	Gastrointestinal Neoplasms	23510949			D37.9	D005770			Focus on the essential role in tumorgenisis and extremely low expression of miRNA-106b ∼ 25 in normal tissues, it maybe an appropriate target of gastric cancer treatment and a novel biomarkers for detecting gastric cancer.
therapeutic target	hsa-mir-221	Gastrointestinal Neoplasms	20618998			D37.9	D005770			Our study suggests that inhibition of miR-221 and miR-222 might form a novel therapeutic strategy for human gastric cancer.
therapeutic target	hsa-mir-222	Gastrointestinal Neoplasms	20618998			D37.9	D005770			Our study suggests that inhibition of miR-221 and miR-222 might form a novel therapeutic strategy for human gastric cancer.
therapeutic target	hsa-mir-483	Glaucoma	26747772	nervous system disease	DOID:1686	H40	D005901	137750		MicroRNA-483-3p has an inhibitory effect on ECM production in HTMCs through downregulating Smad4, which indicates that miR-483-3p may serve as a potential therapeutic target in glaucoma.
therapeutic target	hsa-let-7a	Glioblastoma	26502847				D005909		HP:0100843	DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions.
therapeutic target	hsa-let-7c	Glioblastoma	26502847				D005909		HP:0100843	DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions.
therapeutic target	hsa-mir-101	Glioblastoma	25230316				D005909		HP:0100843	Our findings provided a comprehensive analysis of miR-101 and further defining it as a potential therapeutic candidate for GBM.
therapeutic target	hsa-mir-124	Glioblastoma	24519663				D005909		HP:0100843	Our results provide new clues for the potential mechanisms involved in the origin and development of glioma. Clinically, the altered miRNAs may serve as potential targets and diagnostic tools for novel therapeutic strategies of glioblastoma.
therapeutic target	hsa-mir-124	Glioblastoma	18577221				D005909		HP:0100843	In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.
therapeutic target	hsa-mir-124	Glioblastoma	25200130				D005909		HP:0100843	These results demonstrate that engineered miR-124 responsiveness can eliminate off-target replication by unattenuated oHSV without compromising oncolytic activity, thereby providing increased safety.
therapeutic target	hsa-mir-124	Glioblastoma	27765835				D005909		HP:0100843	Immune modulatory nanoparticle therapeutics for intracerebral glioma.
therapeutic target	hsa-mir-124	Glioblastoma	29185191				D005909		HP:0100843	MicroRNAs (miRs) are potential therapeutic targets in glioblastoma multiforme (GBM)
therapeutic target	hsa-mir-124a	Glioblastoma	29016843				D005909		HP:0100843	Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas.
therapeutic target	hsa-mir-128	Glioblastoma	26502847				D005909		HP:0100843	DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions.
therapeutic target	hsa-mir-128	Glioblastoma	25897645				D005909		HP:0100843	MicroRNA-128 (miR-128) is an attractive therapeutic molecule with powerful glioblastoma regulation properties
therapeutic target	hsa-mir-129-1	Glioblastoma	26510428				D005909		HP:0100843	This is the first study to propose miR129-1 as a negative regulator of IGF2BP3 and MAPK1 and also a cell cycle arrest inducer in GBM cells. Our data suggests miR-129-1 as a potential tumour suppressor and presents a rationale for the use of miR-129-1 as a novel strategy to improve treatment response in GBM.
therapeutic target	hsa-mir-130a	Glioblastoma	25890369				D005909		HP:0100843	Our data suggested that miR-130a could be a predictive marker for TMZ response in patients with GBM, independently of the mechanism by which MGMT acts as a biomarker. miR-130a could serve as a guide for treatment strategy selection in cases of GBM.
therapeutic target	hsa-mir-135b	Glioblastoma	26437223				D005909		HP:0100843	Our results identify a critical role of miR-135b in the regulation of GBM development, suggesting that miR-135b might act as a tumor-suppressor factor and thus providing a potential candidate for the treatment of GBM patients.
therapeutic target	hsa-mir-137	Glioblastoma	18577221				D005909		HP:0100843	In this commentary, we discuss the known functions of miRNAs in cancer and stem cells, their therapeutic potential and how the findings of Silber et al provide insight into the role of miR-124/miR-137 dysregulation in glioblastomas.
therapeutic target	hsa-mir-139	Glioblastoma	26502847				D005909		HP:0100843	DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions.
therapeutic target	hsa-mir-143	Glioblastoma	26541455				D005909		HP:0100843	Taken together, for the first time, our results demonstrate that miR-143 could enhance the antitumor activity of shikonin toward GSCs through reducing BAG3 expression, which may provide a novel therapeutic strategy for enhancing the treatment efficacy of shikonin toward GSCs.
therapeutic target	hsa-mir-146b	Glioblastoma	26502847				D005909		HP:0100843	DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions.
therapeutic target	hsa-mir-153-1	Glioblastoma	23397238				D005909		HP:0100843	reactivation of miR-153 expression suggests novel therapeutic strategies for GBM-SCs
therapeutic target	hsa-mir-153-2	Glioblastoma	23397238				D005909		HP:0100843	reactivation of miR-153 expression suggests novel therapeutic strategies for GBM-SCs
therapeutic target	hsa-mir-155	Glioblastoma	22276743				D005909		HP:0100843	The data suggest that miR-155 blockage increased the chemosensitivity to taxol in GBM cells, making combined treatment an effective therapeutic strategy for controlling the growth by inhibiting EAG1 expression.
therapeutic target	hsa-mir-181b	Glioblastoma	26283154				D005909		HP:0100843	Our results showed that miR-181 family expression was closely correlated with TCGA subtypes and patients' overall survival, indicating that miR-181b, a tumor-suppressive miRNA, could be a novel therapeutic candidate for treating gliomas.
therapeutic target	hsa-mir-181c	Glioblastoma	26682928				D005909		HP:0100843	our study found that miR-181c plays a key role in glioblastoma cell invasion, migration and mesenchymal transition suggesting potential therapeutic applications.
therapeutic target	hsa-mir-182	Glioblastoma	26506113				D005909		HP:0100843	Thus, miR-182-based SNAs represent a tool for systemic delivery of miRNAs and a novel approach for the precision treatment of malignant brain cancers.
therapeutic target	hsa-mir-195	Glioblastoma	26537083				D005909		HP:0100843	This study revealed a significant role of miR-195 in the molecular pathology of glioma cells which can also implicate potential application of miR-195 in cancer therapy. Rather than downregulation of miR-195 alone to exhibit cytotoxicity, treatment with CsA could be more effective especially on temozolomide-resistant cells.
therapeutic target	hsa-mir-198	Glioblastoma	24519663				D005909		HP:0100843	Our results provide new clues for the potential mechanisms involved in the origin and development of glioma. Clinically, the altered miRNAs may serve as potential targets and diagnostic tools for novel therapeutic strategies of glioblastoma.
therapeutic target	hsa-mir-21	Glioblastoma	25625875				D005909		HP:0100843	combining DOX and miR-21i is a new strategy for the therapy of GBM.
therapeutic target	hsa-mir-21	Glioblastoma	25572456				D005909		HP:0100843	the R3V6 peptide may be a useful carrier of antisense-ODN for glioblastoma gene therapy.
therapeutic target	hsa-mir-21	Glioblastoma	20048743				D005909		HP:0100843	Taken together, our studies provide evidence that miR-21 may serve as a novel therapeutic target for malignant gliomas independent of PTEN status.
therapeutic target	hsa-mir-21	Glioblastoma	25861727				D005909		HP:0100843	MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
therapeutic target	hsa-mir-21	Glioblastoma	27079911				D005909		HP:0100843	Here we show that rationally designed hammerhead ribozymes and DNAzymes can target miR-21 and/or its precursors.
therapeutic target	hsa-mir-21	Glioblastoma	27277750				D005909		HP:0100843	co-delivery of anti-miR-21 significantly improved accumulation of LPNs in the nucleus of U87MG cells.
therapeutic target	hsa-mir-21	Glioblastoma	27355932				D005909		HP:0100843	Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model.
therapeutic target	hsa-mir-21	Glioblastoma	27508339				D005909		HP:0100843	Coinhibition of miR-21 and miR-10b significantly reduced the number of viable cells (by 24%; p < 0.01) and increased (2.9-fold) cell cycle arrest at G2/M phase upon Temozolomide treatment in U87 MG cells.
therapeutic target	hsa-mir-21	Glioblastoma	28109960				D005909		HP:0100843	RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.
therapeutic target	hsa-mir-21	Glioblastoma	28840962				D005909		HP:0100843	Biomarkers and therapeutic advances in glioblastoma multiforme.
therapeutic target	hsa-mir-21	Glioblastoma	29340361				D005909		HP:0100843	DP-Cur is an efficient carrier of miR21ASO and the combined delivery of miR21ASO  and curcumin may be useful in the development of combination therapy for glioblastoma
therapeutic target	hsa-mir-29b	Glioblastoma	29176935				D005909		HP:0100843	miR-29b may serve as a putative therapeutic molecule when its expression is restored using a nanoparticle delivery system in GBM
therapeutic target	hsa-mir-29c	Glioblastoma	26450587				D005909		HP:0100843	Our findings suggest a rationale for targeting the c-Myc/miR-29c/REV3L signalling pathway as a promising therapeutic approach for glioblastoma, even in recurrent,treatment-refractory settings.
therapeutic target	hsa-mir-30e	Glioblastoma	27388765				D005909		HP:0100843	Collectively, combination of miR-30e and PAC is a promising therapeutic strategy  to inhibit autophagy and increase apoptosis in GSC and SNB19 cells.
therapeutic target	hsa-mir-31	Glioblastoma	26310668				D005909		HP:0100843	Taken together, our results indicate that miR-31 triggers mitochondrial apoptosis and potentiates TMZ cytotoxicity in GBM cells largely through the suppression of STAT3 activation.Thus, the restoration of miR-31 expression may be of therapeutic beenefit in the treatment of GBM.
therapeutic target	hsa-mir-320a	Glioblastoma	26502847				D005909		HP:0100843	DEMs like hsa-miR-320a, hsa-miR-139-5p, has-miR-128,hsa-miR-146b-5p, hsa-let-7c, hsa-miR-128, and hsa-let-7a might participate in recurrent GBM. These results would pave ways for further study of recurrent GBM mechanism, and for the prevention and treatment of recurrent GBM. However, more experimental verifications are required to prove these predictions.
therapeutic target	hsa-mir-34a	Glioblastoma	27569663				D005909		HP:0100843	Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy.
therapeutic target	hsa-mir-377	Glioblastoma	24951112				D005909		HP:0100843	These findings reveal that miR-377/Sp1 signaling that may be required for GBM development and may consequently serve as a therapeutic target for the treatment of GBM.
therapeutic target	hsa-mir-449a	Glioblastoma	25487955				D005909		HP:0100843	results elucidated a novel molecular mechanism of GBM progression, and may thus suggest a promising application for GBM treatment.
therapeutic target	hsa-mir-486	Glioblastoma	21737610				D005909		HP:0100843	Nineteen and 26 microRNAs exhibited cohort-dependent (including hsa-miR-10b with therapy and hsa-miR-486 with race) and independent associations with glioblastoma, respectively.
therapeutic target	hsa-mir-566	Glioblastoma	24650032				D005909		HP:0100843	miR-566 activated EGFR signaling and its inhibition sensitized glioblastoma cells to anti-EGFR therapy.
therapeutic target	hsa-mir-663	Glioblastoma	24523440				D005909		HP:0100843	miR-663 is a novel prognostic biomarker and a potential therapeutic candidate for glioblastoma.
therapeutic target	hsa-let-7	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-106a	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-10a	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-124	Glioma	24861879	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Taken together, these results revealed that miR-124 levels in tumor tissues are associated with glioma occurrence, angiogenesis, and chemoresistance and that miR-124 may be used as a new diagnostic marker and therapeutic target for glioma in the future.
therapeutic target	hsa-mir-124	Glioma	25051157	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	adenovirus-mediated TIKI2 therapy may be used for glioma treatment 
therapeutic target	hsa-mir-124	Glioma	24497408	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The findings indicate that miR-124-5p functions as a tumor suppressor and could serve as a molecular marker for glioma diagnosis and as a potential therapeutic target in GBM treatment.
therapeutic target	hsa-mir-125a	Glioma	25560389	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	potential target for diagnosis and treatment of malignant glioma.
therapeutic target	hsa-mir-125b	Glioma	24479808	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our present study suggests that As2O3 could be a potential therapeutic agent for treatment of human glioma.
therapeutic target	hsa-mir-125b-2	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-126	Glioma	26617742	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Taken together, these findings showed that miR-126 functions as a tumor suppressor in glioma cells by targeting IRS-1 expression via the PI3K/AKT signaling pathways, suggesting that miR-126 might be a novel target for therapeutic strategies in glioma.
therapeutic target	hsa-mir-128	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-129-2	Glioma	26320507	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These results reveal that miR-129-2 is epigenetically regulated and functions as a tumor suppressor gene in GBMs, suggesting it may serve as a potential therapeutic target for GBM treatment.
therapeutic target	hsa-mir-134	Glioma	25564273	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	the reduced expression of miR-134 may predict aggressive progression and poor prognosis in human gliomas. miR-134 may represent both a prognostic marker and a novel therapeutic target for this malignancy.
therapeutic target	hsa-mir-137	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-140	Glioma	26619802	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Taken together, we have demonstrated the fact that knockdown of MALAT1 resulted in the increased permeability of BTB, which might contribute to establishing potential therapeutic strategies for human gliomas.
therapeutic target	hsa-mir-145	Glioma	24573110	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In conclusion, this is the first study to report that ROCK1, as a novel target of miR-145, acts as a positive regulator of glioma cell invasion. Therefore, ROCK1 may constitute a promising target for glioma treatment.
therapeutic target	hsa-mir-146b	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-146b	Glioma	26320176	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our findings identify miR-146b-5p as a tumor suppressor and novel prognostic biomarker of gliomas, and suggest miR-146b-5p and TRAF6 as potential therapeutic candidates for malignant gliomas.
therapeutic target	hsa-mir-146b	Glioma	26983831	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	a novel treatment whereby mesenchymal stromal cells were  employed to package tumor-suppressing miR-146b into exosomes
therapeutic target	hsa-mir-148a	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-155	Glioma	24623016	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These findings reveal that miR-155 expression might be an independent prognostic factor and a therapeutic target for human glioma.
therapeutic target	hsa-mir-15b	Glioma	24995320	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our findings identified that miR-15b may function as a glioma suppressor by targeting the Cyclin D1, which may provide a novel therapeutic strategy for treatment of glioma.
therapeutic target	hsa-mir-15b	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-16	Glioma	26722459	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In conclusion, MiR-16 mediated temozolomide-resistance in glioma cells by modulation of apoptosis via targeting Bcl-2, which suggesting that miR-16 and Bcl-2 would be potential therapeutic targets for glioma therapy.
therapeutic target	hsa-mir-17	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-181b	Glioma	25151861	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-181b is an important positive regulator on glioma cell sensitivity to teniposide. It confers glioma cell sensitivity to teniposide through binding to the 3'-UTR region of MDM2 leading to its reduced expression. Our findings not only reveal the novel mechanism involved in teniposide resistance, but also shed light on the optimization of glioma treatment in the future.
therapeutic target	hsa-mir-181b	Glioma	23645289	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-181b independently predicted chemoresponse to temozolomide and enhanced temozolomide sensitivity via MEK1 downregulation. A combination of miR-181b and temozolomide may be an effective therapeutic strategy for gliomas.
therapeutic target	hsa-mir-181d	Glioma	25007077	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3.
therapeutic target	hsa-mir-181d	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-184	Glioma	25216670	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our study is the first to show a novel regulatory role of SND1, a direct target of miR-184, in glioma progression, suggesting that the miR-184/SND1 axis may be a useful diagnostic and therapeutic tool for malignant glioma.
therapeutic target	hsa-mir-184	Glioma	25888093	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-184 could regulate TNFAIP2 expression and affected its translation in glioma. miR-184 could also inhibit glioma progression and might serve as a novel therapeutic target in glioma.
therapeutic target	hsa-mir-18a	Glioma	25452107	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of tight junction related proteins ZO-1, occludin and claudin-5, which would attract more attention to miR-18a and RUNX1 as potential targets of drug delivery across BTB and provide novel strategies for glioma treatment.
therapeutic target	hsa-mir-18a	Glioma	26356851	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-18a should garner growing attention because it might serve as a potential target in opening the BTB and providing a new strategy for the treatment of gliomas.
therapeutic target	hsa-mir-193a	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-200b	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-203	Glioma	25515700	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-203 may function as a tumor suppressor in glioma progression and that the miR-203/E2F3 axis may be a novel candidate in the development of rational therapeutic strategies for glioma.
therapeutic target	hsa-mir-20a	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-21	Glioma	24326156	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our data show that miR-21 may be a candidate independent marker for gliomas, especially those with high pathological grades, and this could also be a potential therapeutic target for molecular glioma therapy.
therapeutic target	hsa-mir-21	Glioma	25007077	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3.
therapeutic target	hsa-mir-21	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-21	Glioma	25446261	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	CASC2 plays a tumor suppressive role in glioma via negative regulation of miR-21, which may be a novel therapeutic target for treating gliomas.
therapeutic target	hsa-mir-21	Glioma	27079911	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Here we show that rationally designed hammerhead ribozymes and DNAzymes can target miR-21 and/or its precursors.
therapeutic target	hsa-mir-210	Glioma	24930954	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-210 might be a potential therapeutic target to eliminate GSCs located in hypoxic niches.
therapeutic target	hsa-mir-210	Glioma	25481483	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Aberrantly expressed miR-210 regulates human U251 glioma cells apoptosis and proliferation partly through directly down-regulating SIN3A protein expression. This might offer a new potential therapeutic stratagem for glioma.
therapeutic target	hsa-mir-221	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-221	Glioma	26708164	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	increased pro-apoptotic effects were obtained with the co-administration of both anti-miR鈥?21 and anti-miR鈥?22 PNAs.
therapeutic target	hsa-mir-222	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-222	Glioma	26370254	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In summary, we show that Gas5 suppresses tumor malignancy by downregulating miR-222, which may serve as a promising therapy for glioma.
therapeutic target	hsa-mir-23a	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-23b	Glioma	25007077	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3.
therapeutic target	hsa-mir-30b	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-30c	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-31	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-326	Glioma	25173582	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	This work suggests a possible molecular mechanism of the miR-326/SMO axis, which can be a potential alternative therapeutic pathway for gliomas.
therapeutic target	hsa-mir-326	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-328	Glioma	25562367	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	loss of miR-328 expression may stimulate advanced tumor progression and adverse outcome via promoting cellular proliferation and invasion. We propose a tumor suppressive role of miR-328 and its potential therapeutic value in human glioma.
therapeutic target	hsa-mir-34a	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-373	Glioma	28617546	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target.
therapeutic target	hsa-mir-381	Glioma	25605243	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	the miR-381-NEFL axis is important for TMZ resistance in GBM and may potentially serve as a novel therapeutic target for glioma.
therapeutic target	hsa-mir-425	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-455	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-506	Glioma	26554866	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These results showed that miR-506 functions as a tumor suppressor in glioma by targeting STAT3, suggesting that miR-506 may serve as a potential target in the treatment of human glioma.
therapeutic target	hsa-mir-5096	Glioma	25978028	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our findings reveal the potential for therapeutic interventions based on abolishing alteration of stromal cells by tumor cells via manipulation of microRNA and gap junction channel activity.
therapeutic target	hsa-mir-548	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-637	Glioma	25597410	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	the role of miR-637 in the development of gliomas, and implicate the potential application of miR-637 in cancer therapy.
therapeutic target	hsa-mir-7	Glioma	25394492	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-7 inhibits cellular growth and glucose metabolism in gliomas, at least partially, by regulating the IGF-1R/Akt signaling pathway. Therefore, miR-7 is a promising molecular drug for  glioma treatment
therapeutic target	hsa-mir-7-1	Glioma	22120825	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The absence of miR-7 function could cause downstream molecules to switch on or off, resulting in glioma development, invasion, and metastases. MiR-7-based gene treatment may be a novel anti-invasion therapeutic strategy for malignant glioma.
therapeutic target	hsa-mir-7-2	Glioma	22120825	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The absence of miR-7 function could cause downstream molecules to switch on or off, resulting in glioma development, invasion, and metastases. MiR-7-based gene treatment may be a novel anti-invasion therapeutic strategy for malignant glioma.
therapeutic target	hsa-mir-7-3	Glioma	22120825	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The absence of miR-7 function could cause downstream molecules to switch on or off, resulting in glioma development, invasion, and metastases. MiR-7-based gene treatment may be a novel anti-invasion therapeutic strategy for malignant glioma.
therapeutic target	hsa-mir-873	Glioma	26323558	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Taken together, these data suggest that miR-873 might be a potential marker for cisplatin resistance and a promising sensitizer in cisplatin treatment.
therapeutic target	hsa-mir-93	Glioma	24721397	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-93 was aberrantly over-expressed in glioma tissues and cell lines. Transient transfection of microRNA-93 mimic led to increased proliferation, G1-to-S cell cycle progression and reduced apoptosis in A172 glioma cells, indicating that micro-RNA-93 might be a new target for the diagnosis and treatment of glioma.
therapeutic target	hsa-mir-93	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-95	Glioma	26307768	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNAs are then biological markers with possible diagnostic and prognostic potential. They could also serve as one of the promising treatment targets in human glioblastoma
therapeutic target	hsa-mir-98	Glioma	26502849	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These findings demonstrated that miR-98 functions as a tumor suppressor in gliomas. Furthermore, miR-98 may act as a potential therapeutic biomarker for glioma patients.
therapeutic target	hsa-mir-30	Glomerulosclerosis	24086574	urinary system disease	DOID:0050851		D005923	603278		The therapeutic replacement of miR-30 as a novel strategy to prevent the podocyte apoptosis that is characteristic of progressive glomerular diseases.
therapeutic target	hsa-mir-150	Graft-Versus-Host Disease	27329362			D89.813	D006086	614395		microRNA-150 (miR-150) induces immunological tolerance in CD4(+) T cells after transplantation
therapeutic target	hsa-mir-200b	Graft-Versus-Host Disease	25510861			D89.813	D006086	614395		miR-200b in the negative regulation of DC development and provide a potential form of miRNA-mediated cell therapy for diseases that range from auto-immunity to graft-versus-host disease.
therapeutic target	hsa-mir-212	Habitual Abortion	26722471			N96	D000026			In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor.
therapeutic target	hsa-mir-223	Habitual Abortion	26722471			N96	D000026			In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor.
therapeutic target	hsa-mir-5096	Habitual Abortion	26722471			N96	D000026			In summary, we describe a unique myometrial miRNA expression pattern in human spontaneous preterm labor and discuss their possible role by predicting the target genes of each miRNA. Our results suggest that miRNA play a critical role in the process of partuition in myometrium. The identification of myometrial miRNA profile throws a new light upon the molecule mechanism and provides an insight into the potential diagnosis and treatment of preterm labor.
therapeutic target	hsa-mir-203	Head And Neck Neoplasms	26265694	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	These findings indicate that EMT and low expression of EMT-inhibiting miRs, especially miR-203, measured in pretreatment material,causes intrinsic radioresistance of HNSCC, which could enable identification and treatment modification of radioresistant tumors.
therapeutic target	hsa-mir-205	Head And Neck Neoplasms	25422181	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	LNA-ISH revealed that miR-205 exhibited significant differential cytoplasmic and nuclear staining among inflammation, benign and malignant tumors of head and neck. miR-205 was not only exclusively expressed in squamous epithelial malignancy. This study offers information and a basis for a comprehensive study of the role of miR-205 that may be useful as a biomarker and/or therapeutic target in head and neck tumors.
therapeutic target	hsa-mir-100	Heart Diseases [unspecific]	25736855			I51.9	D006333			Results from this study point to a role for miR-100 in the regulation of Natriuretic peptide receptor 3 (NPR3) expression, and suggest a possible therapeutic target for modulation of Natriuretic peptide(NP) bioactivity in heart disease.
therapeutic target	hsa-mir-23a	Heart Diseases [unspecific]	22136461			I51.9	D006333			miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease
therapeutic target	hsa-mir-24-2	Heart Diseases [unspecific]	22136461			I51.9	D006333			miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease
therapeutic target	hsa-mir-27a	Heart Diseases [unspecific]	22136461			I51.9	D006333			miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease
therapeutic target	hsa-mir-34a	Heart Diseases [unspecific]	29302057			I51.9	D006333			inhibition of miR-34a activity has differential effects depending on the cell type, thereby warranting  the need to eliminate off-target effects when introducing miR-based therapy
therapeutic target	hsa-mir-1	Heart Failure	23612897			I50	D006331		HP:0001635	Taken together, our findings suggest that restoration of miR-1 gene expression is a potential novel therapeutic strategy to reverse pressure-induced cardiac hypertrophy and prevent maladaptive cardiac remodeling.
therapeutic target	hsa-mir-122	Heart Failure	27485847			I50	D006331		HP:0001635	First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases.
therapeutic target	hsa-mir-208a	Heart Failure	21900086			I50	D006331		HP:0001635	Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure.
therapeutic target	hsa-mir-21	Heart Failure	20560046			I50	D006331		HP:0001635	miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions
therapeutic target	hsa-mir-21	Heart Failure	20978356			I50	D006331		HP:0001635	recent reports have suggested that an miR-21 antagomir might be therapeutically useful in preventing heart failure in mice
therapeutic target	hsa-mir-22	Heart Failure	29486470			I50	D006331		HP:0001635	Our findings demonstrate that miR-22 accelerates cardiac fibrosis through the miR-22-Cav3-PKCε pathway, which, therefore, may represent a new therapeutic target for treatment of excessive fibrosis-associated cardiac diseases
therapeutic target	hsa-mir-340	Heart Failure	23998897			I50	D006331		HP:0001635	Our study provided a comprehensive miRNA expression profiling in the end-stage heart failure and identified miR-340 as a key miRNA contributing to the occurrence and progression of heart failure. Our discoveries provide novel therapeutic targets for patients with heart failure
therapeutic target	hsa-mir-499	Heart Failure	21403094			I50	D006331		HP:0001635	The recognition that miR-499 promotes the differentiation of hCSCs into mechanically integrated cardiomyocytes has important clinical implications for the treatment of human heart failure.
therapeutic target	hsa-let-7	Hemangioma	26772808	disease of cellular proliferation	DOID:255	D18.0	D006391	602089		microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma.
therapeutic target	hsa-mir-9	Hemangioma	26772808	disease of cellular proliferation	DOID:255	D18.0	D006391	602089		microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma.
therapeutic target	hsa-mir-939	Hemangioma	26772808	disease of cellular proliferation	DOID:255	D18.0	D006391	602089		microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma.
therapeutic target	hsa-mir-223	Hematologic Neoplasms	28322994	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	The role of miRNA-223 in cancer: Function, diagnosis and therapy.
therapeutic target	hsa-mir-29	Hematologic Neoplasms	24993745	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	MiR-29 family members appear to govern some general features in commonly heterogenous hematological malignancies and therefore form a potential target for treatment.
therapeutic target	hsa-mir-146a	Hemoglobin Diseases	21901398			D58.2	D006450	141900		We suggest that manipulation of miR-146a expression may represent a potential new therapy for several hematopoietic diseases, and may further serve as a biomarker for diagnosis,prevention, and treatment of such disease.
therapeutic target	hsa-mir-223	Hemoglobinopathy	26080908	hematopoietic system disease	DOID:2860	D58.2	D006453			These findings have important implications in future design of shRNA(miR)s for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences.
therapeutic target	hsa-mir-30	Hemoglobinopathy	26080908	hematopoietic system disease	DOID:2860	D58.2	D006453			These findings have important implications in future design of shRNA(miR)s for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences.
therapeutic target	hsa-mir-101	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-106b	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-142	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-143	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-144	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-16	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-19a	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-19b	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-21	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-223	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-423	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-451	Hemophagocytic Lymphohistiocytosis	26194545	immune system disease	DOID:0050120	D76.1	D051359	267700		MicroRNA activation signature in patients with hemophagocytic lymphohistiocytosis and reversibility with disease-specific therapy.
therapeutic target	hsa-mir-126	Hepatic Ischemia-Reperfusion Injury	24457599							Systemic delivery of miR-126 by miRNA-loaded Bubble liposomes for the treatment of hindlimb ischemia.
therapeutic target	hsa-mir-494	Hepatic Ischemia-Reperfusion Injury	24364919							miR-494 might be a target of therapy for hepatic hypoxia/ischemia injury.
therapeutic target	hsa-mir-132	Hepatitis B Virus Infection	23376496	disease by infectious agent	DOID:2043	B16/18	D006509	610424		serum;miR-132 may be a promising biochemical marker and may have therapeutic applications in HBV-related HCC
therapeutic target	hsa-mir-33a	Hepatitis B Virus Infection	25155445	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-33a may be a novel marker for HSC activation and hepatic fibrosis progress, suggesting a new therapeutic target in liver fibrosis.
therapeutic target	hsa-mir-122	Hepatitis C Virus Infection	24385319	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-targeting therapeutics for hepatitis C.
therapeutic target	hsa-mir-122	Hepatitis C Virus Infection	25385103	disease by infectious agent	DOID:1883	B19.2	D006526	609532		In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
therapeutic target	hsa-mir-122	Hepatitis C Virus Infection	25518710	disease by infectious agent	DOID:1883	B19.2	D006526	609532		targeting miR-122, using antisense oligonucleotides (ASOs), can be a new anti-HCV treatment.
therapeutic target	hsa-mir-122	Hepatitis C Virus Infection	22545703	disease by infectious agent	DOID:1883	B19.2	D006526	609532		In conclusion, the maximal inhibition of miR-122 was associated with limited phenotypic changes, indicating that the clinical assessment of miravirsen as host factor antagonist for treatment of HCV infections is warranted.
therapeutic target	hsa-mir-125b	Hepatitis C Virus Infection	29541414	disease by infectious agent	DOID:1883	B19.2	D006526	609532		This study elucidates a novel pathway for miR-125b in the pathogenesis of chronic HCV infection and suggests it as a possible target for treating HCV infection
therapeutic target	hsa-mir-34a	Hepatoblastoma	21553024	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	All these results suggest that miR-34a plays multiple tumor suppressive roles in murine hepatocarcinoma, not only inhibiting cell growth by cell cycle arrest, but also repressing metastasis, and may serve as a novel therapeutic target for hepatocarcinoma.
therapeutic target	hsa-let-7	Human Immunodeficiency Virus Infection	25023625			B20	D015658	609423		miRNAs have emerged as important players in the T cell dysfunction observed with HIV-1 infection. It is likely that they may emerge as novel markers of T cell dysfunction and provide potential targets for new therapeutics to reverse dysfunction.
therapeutic target	hsa-mir-146a	Human Immunodeficiency Virus Infection	25705792			B20	D015658	609423		Our findings improve the prospects of developing new therapeutic strategies to prevent HIV-1 entry via CXCR4 by using the PLZF/miR-146a axis.
therapeutic target	hsa-mir-146b	Human Immunodeficiency Virus Infection	24828336			B20	D015658	609423		We report for the first time that PBMC and plasma levels of miR-150 and miR-146b-5p are predictive of HIV/AIDS disease progression and therapy.
therapeutic target	hsa-mir-150	Human Immunodeficiency Virus Infection	24828336			B20	D015658	609423		We report for the first time that PBMC and plasma levels of miR-150 and miR-146b-5p are predictive of HIV/AIDS disease progression and therapy.
therapeutic target	hsa-mir-128	Huntington Disease	24929669	nervous system disease	DOID:12858	G10	D006816	143100		Our studies found that miR-128a may play a critical role in HD and could be a viable candidate as a therapeutic or biomarker of the disease.
therapeutic target	hsa-mir-200a	Huntington Disease	22906125	nervous system disease	DOID:12858	G10	D006816	143100		Altered expression of miR-200a and miR-200c may interrupt the production of proteins involved in neuronal plasticity and survival, and further investigation of the involvement of perturbed miRNA expression in HD pathogenesis is warranted, and may lead to reveal novel approaches for HD therapy.
therapeutic target	hsa-mir-200c	Huntington Disease	22906125	nervous system disease	DOID:12858	G10	D006816	143100		Altered expression of miR-200a and miR-200c may interrupt the production of proteins involved in neuronal plasticity and survival, and further investigation of the involvement of perturbed miRNA expression in HD pathogenesis is warranted, and may lead to reveal novel approaches for HD therapy.
therapeutic target	hsa-mir-30c	Hyperlipidemia	25692340			E78.4	D006949		HP:0003077	These studies highlight the important role miR-30c plays in lipid metabolism, adipogenesis, and cell proliferation and differentiation. Further,they point to pathologic outcomes associated with reduced expression in cancer and cardiac hypertrophy. Additionally, they suggest that increasing miR-30c expression in the liver and cancerous tissue might reduce hyperlipidemia and atherosclerosis, and cancer progression and metastasis, respectively. Studies are needed to evaluate the efficacy of miR-30c mimic in the treatment of these disorders.
therapeutic target	hsa-mir-145	Hypertension	29434681	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-145 is a potential target for the treatment of hypertension
therapeutic target	hsa-mir-204	Hypertension	21321078	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Reestablishing miR-204 expression should be explored as a potential new therapy for this disease
therapeutic target	hsa-mir-421	Hypertension	24564768	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	In conclusion, the present study is the first to demonstrate that ACE2 may be subject to post-transcriptional regulation and reveals a novel potential therapeutic target, miR-421, which could be exploited to modulate ACE2 expression in disease.
therapeutic target	hsa-mir-543	Hypertension	26562529	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	In summary, our study suggested that the downregulation of the miR-543 could alleviate the insulin resistance via the modulation of the SIRT1 expression, which might be a potential new strategy for treating insulin resistance and a promising therapeutic method for hypertension.
therapeutic target	hsa-mir-145	Hypertrophic Scar	25876136			L91.0	D017439			these results suggest that miR-145 is a promising therapeutic target to prevent or reduce hypertrophic scarring of the skin.
therapeutic target	hsa-mir-181b	Hypertrophic Scar	25837671			L91.0	D017439			MicroRNA 181b regulates decorin production by dermal fibroblasts and may be a potential therapy for hypertrophic scar.
therapeutic target	hsa-mir-21	Hypertrophic Scar	28075443			L91.0	D017439			MicroRNA expression signature and the therapeutic effect of the microRNA‑21 antagomir in hypertrophic scarring.
therapeutic target	hsa-mir-92a	Hyperuricemia	26299712	disease of metabolism	DOID:1920	E79.0	D033461	240000		This study reported that there is a novel pathway regulating angiogenesis under HUA conditions. In the presence of HUA, miR-92a downregulation increased KLF2 expression, subsequently inhibiting VEGFA, which resulted in decreased angiogenesis. Thus, this study reports a possible mechanism for cardiovascular injury caused by hyperuricemia and suggests that the miR-92a-KLF2-VEGFA axis may be a target for hyperuricemia treatment.
therapeutic target	hsa-mir-210	Hypoxic-Ischemic Encephalopathy	24089674			P91.60	D020925			Recent study demonstrated that microRNA-210 has neuroprotective effects through inhibiting apoptosis in a murine model of HIE. It represents a potential novel therapeutic approach for the treatment of HIE.
therapeutic target	hsa-mir-133b	Infertility	24959893	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			MiR-133b regulates the expression of the Actin protein TAGLN2 during oocyte growth and maturation: a potential target for infertility therapy.
therapeutic target	hsa-mir-155	Inflammation	23239035				D007249			microRNA-155 can be used as a potential biomarker or therapeutic in the autoimmune diseases,especially rheumatoid arthritis
therapeutic target	hsa-mir-21	Inflammation	29620442				D007249			It may provide a novel therapeutic strategy to regulate the odontoblast differentiation of DPSCs
therapeutic target	hsa-mir-710	Inflammation	20005208				D007249			Our findings demonstrate that CO treatment to MF increased FGF15 expression via inhibition of miR-710 and FGF15 enhanced colonic epithelial cell restitution.
therapeutic target	hsa-mir-124	Inflammation	23979021				D007249			miR-124 is a potential therapeutic target for the treatment of inflammatory diseases
therapeutic target	hsa-mir-142	Inflammation	26721185				D007249			These results suggest that PPARγ-mediated upregulation of miR-142-3p inhibits the HMGB1 expression, which,in turn, is a novel anti-inflammatory mechanism of PPARγ and has an important role in the treatment of inflammatory diseases.
therapeutic target	hsa-mir-146a	Inflammation	25896300				D007249			our studies showed that miR-146a was crucial for monocytic cell-based IL-1β tolerance and cross-tolerance, and thus opens the way for future research in the  development of therapeutics for inflammatory diseases.
therapeutic target	hsa-mir-155	Inflammation	26697483				D007249			Taken together, our results suggest that genome editing of miR-155 holds the potential as a therapeutic strategy in RA.
therapeutic target	hsa-mir-122	Inflammatory Bowel Diseases	27485847	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	First clinical trials using the blockade of liver specific miR-122 showed very promising results in the treatment of chronic hepatitis C virus infection. Results of preclinical and animal studies are also promising providing future rationale for the development of new therapeutics for various internal diseases including heart failure, bronchial asthma or inflammatory bowel diseases.
therapeutic target	hsa-mir-1246	Inflammatory Bowel Diseases	25628040	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	miR-595 and miR-1246 warrant testing as potential targets for therapeutic intervention in the treatment of inflammatory bowel disease.
therapeutic target	hsa-mir-133	Inflammatory Bowel Diseases	25112884	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	NT-associated colitis and inflammatory signalling are regulated by miR-133α-AFTPH interactions. Targeting of miR-133α or AFTPH may represent a novel therapeutic approach in inflammatory bowel disease.
therapeutic target	hsa-mir-595	Inflammatory Bowel Diseases	25628040	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	miR-595 and miR-1246 warrant testing as potential targets for therapeutic intervention in the treatment of inflammatory bowel disease.
therapeutic target	hsa-mir-494	Intervertebral Disc Degeneration	25906693	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	These results indicated that miR-494 is a novel regulator of HNPC apoptosis induced by TNF-α. The knock-out of miR-494 expression protected the HNPCs from apoptosis via the up-regulation of JunD, which was possibly mediated via cytochrome C apoptotic signaling. These findings suggest that the miR-494/JunD signaling pathway might represent a novel therapeutic target for the prevention of IVDD.
therapeutic target	hsa-let-7b	Intestinal Barrier Dysfunction	29402773							Let-7b was identified as a novel diagnosis biomarker or a potential treatment target for preventing intestinal barrier dysfunction
therapeutic target	hsa-mir-26a-1	Intracerebral Hemorrhage	21764522			I60.1	D002543		HP:0001342	Circulating miR-26a is a potential predictors and therapeutic targets for non-hypertensive ICH (intracerebral hemorrhage).
therapeutic target	hsa-mir-26a-2	Intracerebral Hemorrhage	21764522			I60.1	D002543		HP:0001342	Circulating miR-26a is a potential predictors and therapeutic targets for non-hypertensive ICH (intracerebral hemorrhage).
therapeutic target	hsa-mir-1	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-133a	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-133b	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-143	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-145	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-23b	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-24-1	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-29b-2	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-455	Intracranial Aneurysm	24079748	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		These data support common disease mechanisms that may be under miRNA control and provide exciting directions for further investigations aimed at elucidating the miRNA mechanisms and targets that may yield new therapies for IA.
therapeutic target	hsa-mir-155	Intraductal Papillary Mucinous Neoplasms	28938594			D01.7				these miRNAs might serve as new risk biomarkers of IPMN and could be useful for future targeted therapies
therapeutic target	hsa-mir-1	Intrahepatic Cholangiocarcinoma	28098904	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC
therapeutic target	hsa-mir-101	Intrahepatic Cholangiocarcinoma	26299768	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In conclusion, the present study identified important roles for miR-101 and VEGF-C in ICC, suggesting that miR-101/VEGF-C signaling may be a promising diagnostic and/or therapeutic target for ICC.
therapeutic target	hsa-mir-25	Intrahepatic Cholangiocarcinoma	28098904	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC
therapeutic target	hsa-mir-96	Intrahepatic Cholangiocarcinoma	28098904	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		has-miR-96, has-miR-1 and has-miR-25, may be potential therapeutic targets for the future treatment of ICC
therapeutic target	hsa-mir-320a	Ischemia	20628061	cardiovascular system disease	DOID:326		D007511	601367		MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia
therapeutic target	hsa-mir-483	Ischemia	21893058	cardiovascular system disease	DOID:326		D007511	601367		These findings indicated that the miR-483-5p-SRF pathway may offer a novel strategy for treatment with angiogenesis in ischemic heart disease patients.
therapeutic target	hsa-mir-126	Ischemia-Reperfusion Injury	26381870				D015427			UTMD of miR-126 results in improved tissue perfusion and vascular density in the setting of chronic ischemia by repressing sprouty-related protein-1 and phosphatidylinositol-3-kinase regulatory subunit 2 and enhancing vascular endothelial growth factor and angiopoietin-1 signaling, with no effect on miR-126-5p. UTMD is a promising platform for microRNA delivery, with applications for therapeutic angiogenesis.
therapeutic target	hsa-mir-145	Ischemia-Reperfusion Injury	23028672				D015427			MiR-145 may represent a potential therapeutic target for treatment of oxidative stress-associated cardiovascular diseases, such as myocardial ischemia/reperfusion injury.
therapeutic target	hsa-mir-146a	Ischemia-Reperfusion Injury	29505740				D015427			our findings demonstrate that the elevation of miR-146a may be one of the compensatory responses after the cerebral I/R injury and suggest miR-146a as a potential therapeutic target for cerebral I/R injury
therapeutic target	hsa-mir-7	Ischemia-Reperfusion Injury	24594984				D015427			miR-7a/b is sensitive to I/R injury and protects myocardial cells against I/R-induced apoptosis by negatively regulating PARP expression in vivo and in vitro. miR-7a/b may provide a new therapeutic approach for treatment of myocardial I/R injury. Poly(ADP-ribose) polymerase.
therapeutic target	hsa-mir-30	Ischemic Diseases [unspecific]	25203395				D007511	601367		Our findings reveal a novel molecular mechanism for endogenous H2S production in the heart at the miRNA level and demonstrate the therapeutic potential of miR-30 family inhibition for ischemic heart diseases by increasing H2S production.
therapeutic target	hsa-mir-92a	Ischemic Diseases [unspecific]	19460962				D007511	601367		Thus, miR-92a may serve as a valuable therapeutic target in the setting of ischemic disease.
therapeutic target	hsa-mir-144	Ischemic Heart Disease	20708014			I25.9/I24.9	D017202			Thus, both miR-144 and miR-451 may represent new therapeutic agents for the treatment of ischemic heart disease.
therapeutic target	hsa-mir-320	Ischemic Heart Disease	25724494			I25.9/I24.9	D017202			we conclude that PDGF enhances MSC-mediated cardioprotection via a c-Jun/miR-320 signaling mechanism and PDGF MSC preconditioning may be an effective therapeutic strategy for cardiac ischemia.
therapeutic target	hsa-mir-451	Ischemic Heart Disease	20708014			I25.9/I24.9	D017202			Thus, both miR-144 and miR-451 may represent new therapeutic agents for the treatment of ischemic heart disease.
therapeutic target	hsa-let-7a	Kaposi Sarcoma	26197270	disease of cellular proliferation	DOID:8632	C46	D012514			Our results establish that let-7a specifically suppresses MAP4K4 expression, and further inhibits KSHV reactivation by interfering with the function of MAP4K4 on the MAPK pathway, highlighting let-7a as a potential treatment for KS.
therapeutic target	hsa-mir-891a	Kaposi Sarcoma	26446987	disease of cellular proliferation	DOID:8632	C46	D012514			Our results illustrate that, by targeting IκBα to activate the NF-κB pathway, miR-891a-5p mediates Tat and K1 synergistic induction of angiogenesis. Therefore, the miR-891a-5p/NF-κB pathway is important in the pathogenesis of AIDS-KS, which could be an attractive therapeutic target for AIDS-KS.
therapeutic target	hsa-mir-21	Keloid	29190966			L91.0	D007627	148100	HP:0010562	inhibition of microRNA-21 induces mitochondrial-mediated apoptosis in keloid fibroblasts, proposing microRNA-21 as a potential therapeutic target in keloid fibroblasts
therapeutic target	hsa-mir-17	Kidney Diseases [unspecific]	28399020			N18.9	D007674			Therapeutic microRNAs in polycystic kidney disease.
therapeutic target	hsa-mir-126	Kidney Injury	27832640			S37.0	D058186			non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI
therapeutic target	hsa-mir-127	Kidney Injury	27832640			S37.0	D058186			non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI
therapeutic target	hsa-mir-150	Kidney Injury	27832640			S37.0	D058186			non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI
therapeutic target	hsa-mir-21	Kidney Injury	27832640			S37.0	D058186			non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI
therapeutic target	hsa-mir-24	Kidney Injury	27832640			S37.0	D058186			non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI
therapeutic target	hsa-mir-30	Kidney Injury	27832640			S37.0	D058186			non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI
therapeutic target	hsa-mir-494	Kidney Injury	27832640			S37.0	D058186			non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI
therapeutic target	hsa-mir-687	Kidney Injury	27832640			S37.0	D058186			non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have significant potential to aid the development of diagnostic and therapeutic strategies of AKI
therapeutic target	hsa-mir-34a	Kidney Neoplasms	24866595	disease of cellular proliferation	DOID:263	C64	D007680			Our findings indicate that miR-34a targets CD44 in renal cancer cells and suppresses renal cancer cell growth, tube formation and metastasis invitro and in vivo. Thus, miR-34a may be a potential molecular target for novel therapeutic strategies for clear cell renal carcinoma.
therapeutic target	hsa-mir-362	Kidney Neoplasms	26647877	disease of cellular proliferation	DOID:263	C64	D007680			These results suggested that miR-362-3p functions as a tumor suppressor in RCC, and may serve as a potential molecular target in the treatment of RCC.
therapeutic target	hsa-mir-497	Kidney Neoplasms	25755771	disease of cellular proliferation	DOID:263	C64	D007680			Our results demonstrated that miR-497 was decreased in ccRCC tissues and may provide a potential prognostic biomarker and a potential target for therapeutic intervention.
therapeutic target	hsa-mir-196a	Laryngeal Neoplasms	23967217			C32.3	D007822			Our study provided the possibilities that miR-196a might be very useful in diagnosing and treating laryngeal cancer.
therapeutic target	hsa-mir-221	Laryngeal Neoplasms	25586265			C32.3	D007822			miR-221 inhibition caused elevated expression levels of the Apaf-1 apoptotic pathway proteins caspase-3, -8 and -9. miR-221 may therefore be used as a novel therapeutic target for laryngeal cancer.
therapeutic target	hsa-mir-27a	Laryngeal Neoplasms	25239093			C32.3	D007822			miR-27a acts as an oncogene in laryngeal squamous cell carcinoma through down-regulation of PLK2 and may provide a novel clue into the potential mechanism of LSCC oncogenesis or serve as a useful biomarker in diagnosis and therapy in laryngeal cancer.
therapeutic target	hsa-mir-221	Laryngeal Neoplasms	25945817			C32.3	D007822			Plasma miR-221 may have a potential as a novel diagnostic/prognostic marker and might be considered as a therapeutic target in LCa.LEVEL OF EVIDENCE: N/A.
therapeutic target	hsa-mir-125b	Leukemia	24369155			C95	D007938	613065	HP:0001909	BAK1 was a downstream target gene of miR-125b, and miR-125b promoted proliferation in human AML cells at least partially by targeting Bak1, so we speculated that miR-125b as an oncogene could be a potential therapeutic target for treating AML.
therapeutic target	hsa-mir-15	Leukemia	16616063			C95	D007938	613065	HP:0001909	Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors.
therapeutic target	hsa-mir-155	Leukemia	25543473			C95	D007938	613065	HP:0001909	miR-155 inhibition may be a promising therapy strategy for treating acute myeloid leukemia (AML).
therapeutic target	hsa-mir-15a	Leukemia	21056550			C95	D007938	613065	HP:0001909	these findings suggested that the combined regiment of miR-15a/16-1 and ATO might be a potential therapeutic remedy for the treatment of leukemia.
therapeutic target	hsa-mir-16	Leukemia	16616063			C95	D007938	613065	HP:0001909	Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors.
therapeutic target	hsa-mir-16-1	Leukemia	21056550			C95	D007938	613065	HP:0001909	these findings suggested that the combined regiment of miR-15a/16-1 and ATO might be a potential therapeutic remedy for the treatment of leukemia.
therapeutic target	hsa-mir-17	Leukemia	21239610			C95	D007938	613065	HP:0001909	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-18	Leukemia	21239610			C95	D007938	613065	HP:0001909	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-181a	Leukemia	21079133			C95	D007938	613065	HP:0001909	Targeted treatments that increase endogenous levels of miR-181a might represent novel therapeutic strategies.
therapeutic target	hsa-mir-19a	Leukemia	21239610			C95	D007938	613065	HP:0001909	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-19b-1	Leukemia	21239610			C95	D007938	613065	HP:0001909	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-20a	Leukemia	21239610			C95	D007938	613065	HP:0001909	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-21	Leukemia	26248946			C95	D007938	613065	HP:0001909	These findings indicate that miR-21 is required for maintaining the imatinib-resistant phenotype of CML CD34+ cells through PI3K/AKT signaling pathway, thus providing the basis for a promising therapeutic approach to eliminate CML leukemia stem cells(LSCs).
therapeutic target	hsa-mir-223	Leukemia	17996649			C95	D007938	613065	HP:0001909	Ectopic miR-223 expression, RNAi against AML1/ETO, or demethylating treatment enhances miR-223 levels and restores cell differentiation. Here, we identify an additional action for a leukemia fusion protein linking the epigenetic silencing of a microRNA locus to the differentiation block of leukemia.
therapeutic target	hsa-mir-23a	Leukemia	26378023			C95	D007938	613065	HP:0001909	Our findings thus connect a novel regulation pathway of the p65/miR-23a-27a-24 cluster with the erythroid proteome and provide an applicable approach for treating leukemia.
therapeutic target	hsa-mir-24	Leukemia	26378023			C95	D007938	613065	HP:0001909	Our findings thus connect a novel regulation pathway of the p65/miR-23a-27a-24 cluster with the erythroid proteome and provide an applicable approach for treating leukemia.
therapeutic target	hsa-mir-27a	Leukemia	26378023			C95	D007938	613065	HP:0001909	Our findings thus connect a novel regulation pathway of the p65/miR-23a-27a-24 cluster with the erythroid proteome and provide an applicable approach for treating leukemia.
therapeutic target	hsa-mir-638	Leukemia	25451924			C95	D007938	613065	HP:0001909	miR-638 regulates proliferation and myeloid differentiation by targeting CDK2 and may serve as a novel target for leukemia therapy or marker  for AML diagnosis and prognosis.
therapeutic target	hsa-mir-92-1	Leukemia	21239610			C95	D007938	613065	HP:0001909	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-128b	Leukemia, Lymphoblastic	19749093	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		These results demonstrate that down-regulation of miR-128b and miR-221 is implicated in glucocorticoid resistance and that restoration of their levels is a potentially promising therapeutic in MLL-AF4 ALL.
therapeutic target	hsa-mir-221	Leukemia, Lymphoblastic	19749093	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		These results demonstrate that down-regulation of miR-128b and miR-221 is implicated in glucocorticoid resistance and that restoration of their levels is a potentially promising therapeutic in MLL-AF4 ALL.
therapeutic target	hsa-let-7b	Leukemia, Lymphoblastic, Acute	26708866	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	In the patients with ALL, the expression of microRNA let-7b is regulated by methylation of CpG islands in the region of genomic promoter. The microRNA let-7b may act as a tumor suppressor, whose low expression is involved in ALL development, indicating the microRNA let-7b may become a new therapeutic target for ALL.
therapeutic target	hsa-mir-126	Leukemia, Lymphoblastic, Acute	26361793	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Our data demonstrate that miR-126 plays a critical but 2-faceted role in leukemia and thereby uncover a new layer of miRNA regulation in cancer.Moreover, because miR-126 depletion can sensitize AML cells to standard chemotherapy, our data also suggest that miR-126 represents a promising therapeutic target.
therapeutic target	hsa-mir-17	Leukemia, Lymphoblastic, Acute	24280866	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.
therapeutic target	hsa-mir-221	Leukemia, Lymphoblastic, Acute	27358112	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Niche-influenced miR-221/222 may define a novel therapeutic target in ALL
therapeutic target	hsa-mir-222	Leukemia, Lymphoblastic, Acute	27358112	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Niche-influenced miR-221/222 may define a novel therapeutic target in ALL
therapeutic target	hsa-mir-1290	Leukemia, Lymphoblastic, Acute, B-Cell	26684414	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients.
therapeutic target	hsa-mir-151	Leukemia, Lymphoblastic, Acute, B-Cell	26684414	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients.
therapeutic target	hsa-mir-199a	Leukemia, Lymphoblastic, Acute, B-Cell	26406572	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL.
therapeutic target	hsa-mir-221	Leukemia, Lymphoblastic, Acute, B-Cell	26406572	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL.
therapeutic target	hsa-mir-223	Leukemia, Lymphoblastic, Acute, B-Cell	26406572	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL.
therapeutic target	hsa-mir-26a	Leukemia, Lymphoblastic, Acute, B-Cell	26406572	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL.
therapeutic target	hsa-mir-451	Leukemia, Lymphoblastic, Acute, B-Cell	26684414	disease of cellular proliferation	DOID:0060592	C91.0		613065	HP:0004812	Our results identify an expression profile of miR-151-5p, miR-451, and miR-1290 as a novel biomarker for outcome in pediatric precursor B-cell ALL patients, regardless of treatment protocol. The use of these markers may lead to improved risk stratification at diagnosis and allow early therapeutic interventions in an attempt to improve survival of high risk patients.
therapeutic target	hsa-mir-204	Leukemia, Lymphoblastic, Acute, T-Cell	26464665	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Our findings indicated that miR-204 negatively regulates SOX4 and inhibited proliferation, migration and invasion of T-ALL cell lines. Thus,miR-204 might represent a potential therapeutic target for T-ALL intervention.
therapeutic target	hsa-mir-15	Leukemia, Lymphocytic, Chronic, B-Cell	24014303	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	the role of microRNAs in CLL pathogenesis, and how this knowledge can be used to identify new approaches to treat CLL.
therapeutic target	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	23995789	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.
therapeutic target	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	19723889	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	a role for the mir-15a/16-1 cluster in cell cycle regulation and suggest that these mature microRNAs in both the New Zealand Black model and human CLL may be targets for therapeutic efficacy in this disease.
therapeutic target	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	24014303	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	the role of microRNAs in CLL pathogenesis, and how this knowledge can be used to identify new approaches to treat CLL.
therapeutic target	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	23995789	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.
therapeutic target	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	19723889	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	a role for the mir-15a/16-1 cluster in cell cycle regulation and suggest that these mature microRNAs in both the New Zealand Black model and human CLL may be targets for therapeutic efficacy in this disease.
therapeutic target	hsa-mir-16-2	Leukemia, Lymphocytic, Chronic, B-Cell	19723889	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	a role for the mir-15a/16-1 cluster in cell cycle regulation and suggest that these mature microRNAs in both the New Zealand Black model and human CLL may be targets for therapeutic efficacy in this disease.
therapeutic target	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	25880332	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	HSP90B1 is a direct target gene of miR-223. Our results provide a plausible explanation of why CLL patients harboring miR-223 downregulation are associated with a poor outcome, pointing out HSP90B1 as a new pathogenic mechanism in CLL and a promising therapeutic target.
therapeutic target	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	20089965	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression of miR-34a in primary B-CLL cells induced apoptosis
therapeutic target	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	28053325	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.
therapeutic target	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	28053325	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.
therapeutic target	hsa-mir-362	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	26545365			C92.1	D015464			miR-362-5p acts as an oncomiR that down-regulates GADD45α, which consequently activates the JNK1/2 and P38 signalling. This finding provides novel insights into CML leukaemogenesis and may help identify new diagnostic and therapeutic targets.
therapeutic target	hsa-mir-520a	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	24870597			C92.1	D015464			MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin.
therapeutic target	hsa-mir-150	Leukemia, Myeloid	26644403	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	Our findings indicate that decreased KLF4 expression mediates antileukemic effects through regulation of gene and microRNA networks,containing miR-150, CDKN1A, and MYC, and provide mechanistic support for therapeutic strategies increasing KLF4 expression.
therapeutic target	hsa-mir-122	Leukemia, Myeloid, Acute	28822593	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Decreased expression of microRNA-122 is associated with an unfavorable prognosis in childhood acute myeloid leukemia and function analysis indicates a therapeutic potential.
therapeutic target	hsa-mir-150	Leukemia, Myeloid, Acute	27280396	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects.
therapeutic target	hsa-mir-199b	Leukemia, Myeloid, Acute	26340914	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We detected a therapy sensitive miRNA signature in plasma of patients with AML.
therapeutic target	hsa-mir-24	Leukemia, Myeloid, Acute	25550847	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-24 high regulation is a common event in AML with t(8;21), and it might serve as a novel and selective therapeutic target for the treatment of AML with t(8;21).
therapeutic target	hsa-mir-29	Leukemia, Myeloid, Acute	24076586	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Taken together, our finding revealed a pivotal role of miR-29 family in AML development and rescue of miR-29 family expression in AML patients could provide a new therapeutic strategy.
therapeutic target	hsa-mir-301b	Leukemia, Myeloid, Acute	26340914	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We detected a therapy sensitive miRNA signature in plasma of patients with AML.
therapeutic target	hsa-mir-326	Leukemia, Myeloid, Acute	26340914	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We detected a therapy sensitive miRNA signature in plasma of patients with AML.
therapeutic target	hsa-mir-331	Leukemia, Myeloid, Acute	25620533	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	we showed for the first time that miR-331 higher expression appears to be correlated with worse response to therapy and shorter survival of AML patients.
therapeutic target	hsa-mir-34a	Leukemia, Myeloid, Acute	25499621	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	the complex regulation of PD-L1 in human tumors, and on miR-34a in cancer immuno-based therapy.
therapeutic target	hsa-mir-34a	Leukemia, Myeloid, Acute	20889924	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	These results define miR-34a as a novel therapeutic target in AML with CEBPA mutations.
therapeutic target	hsa-mir-361	Leukemia, Myeloid, Acute	26340914	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We detected a therapy sensitive miRNA signature in plasma of patients with AML.
therapeutic target	hsa-mir-378	Leukemia, Myeloid, Acute	26191124	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our findings suggest that miR-378 is reactivated by demethylation after 5-aza-dC treatment. 5'-flanking region of miR-378 is hypomethylated in AML especially in those with t(8;21).
therapeutic target	hsa-mir-511	Leukemia, Myeloid, Acute	26762252	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our study provides new insights into the understanding of miRNAs as functional mediators of the leukemogenic fusion gene MLL-AF9 and opens new opportunities to further investigate specific therapeutic options for AML via the miRNA level.
therapeutic target	hsa-mir-625	Leukemia, Myeloid, Acute	26340914	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We detected a therapy sensitive miRNA signature in plasma of patients with AML.
therapeutic target	hsa-mir-655	Leukemia, Myeloid, Acute	26340914	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We detected a therapy sensitive miRNA signature in plasma of patients with AML.
therapeutic target	hsa-mir-155	Leukemia, Myeloid, Acute, Pediatric	25730818			C92.0				This study may promote the development of a personalized effective antileukemia therapy, in particular for the patients exhibiting higher expression levels of G-CSFRIV, and further highlights the necessity of pre-screening the patients for G-CSFR isoforms expression patterns before G-CSF administration.
therapeutic target	hsa-mir-148b	Leukemia, Myeloid, Chronic	25187697	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulated miR-148 may contribute to immune surveillance in STOP-IM patients and may therefore have potential as additive information in managing CML patients undergoing treatment with IM.
therapeutic target	hsa-mir-17	Leukemia, Myeloid, Chronic	23818358	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	These results may imply that miR-17 can be used for diagnosis and treatment of CML.
therapeutic target	hsa-mir-30e	Leukemia, Myeloid, Chronic	25305453	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
therapeutic target	hsa-mir-424	Leukemia, Myeloid, Chronic	25697481	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	These findings strongly suggest that miR-424 acts as a tumor suppressor by downregulating BCR-ABL expression. Up-regulation of miR-424 in CML cells may therefore have a therapeutic effect against this disease.
therapeutic target	hsa-mir-17	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22475310	disease of cellular proliferation	DOID:5599	C83.5	D054218			Down-regulation of miR17 plays an important role in glucocorticoid-induced cell death suggesting that targeting miR17 may improve the current ALL combination therapy.
therapeutic target	hsa-mir-182	Light-Induced Retinal Injury	25955435							The present study suggests that BDNF is a target gene of the has-miR-183-96-182 cluster in RPE cells. The present study suggests an underlying protective mechanism against retinal light injury and may provide a novel target for the prevention and treatment of light-induced retinal injury.
therapeutic target	hsa-mir-183	Light-Induced Retinal Injury	25955435							The present study suggests that BDNF is a target gene of the has-miR-183-96-182 cluster in RPE cells. The present study suggests an underlying protective mechanism against retinal light injury and may provide a novel target for the prevention and treatment of light-induced retinal injury.
therapeutic target	hsa-mir-96	Light-Induced Retinal Injury	25955435							The present study suggests that BDNF is a target gene of the has-miR-183-96-182 cluster in RPE cells. The present study suggests an underlying protective mechanism against retinal light injury and may provide a novel target for the prevention and treatment of light-induced retinal injury.
therapeutic target	hsa-mir-33a	Lipid Metabolism Disorder	22012398	disease of metabolism	DOID:3146	E75	D008052			These data establish, in a model that is highly relevant to humans, that pharmacological inhibition of miR-33a and miR-33b is a promising therapeutic strategy to raise plasma HDL and lower VLDL triglyceride levels for the treatment of dyslipidaemias that increase cardiovascular disease risk.
therapeutic target	hsa-mir-33b	Lipid Metabolism Disorder	22012398	disease of metabolism	DOID:3146	E75	D008052			These data establish, in a model that is highly relevant to humans, that pharmacological inhibition of miR-33a and miR-33b is a promising therapeutic strategy to raise plasma HDL and lower VLDL triglyceride levels for the treatment of dyslipidaemias that increase cardiovascular disease risk.
therapeutic target	hsa-mir-122	Liver Cirrhosis	25909171	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	These findings disclose a novel TGF-β-miR-122-FN1/SRF signaling cascade and its implication in hepatic fibrogenesis, and suggest miR-122 as a promising molecular target for anti-fibrosis therapy.
therapeutic target	hsa-mir-21	Liver Cirrhosis	25661333	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	our results identify miR-21 as a key regulator of fibrogenic EMT in hepatocytes via PTEN/Akt pathway. Targeting miR-21 may provide a new therapeutic strategy against hepatic fibrosis.
therapeutic target	hsa-mir-34a	Liver Cirrhosis	26437572	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-34a appears to play an important role in the process of liver fibrosis by targeting ACSL1 and may show promise as a therapeutic molecular target for hepatic fibrosis.
therapeutic target	hsa-mir-370	Liver Cirrhosis	25686745	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Our study demonstrated that miR-370 plays an inhibitory role in hepatic fibrogenesis by targeting SMO. Restoration of miR-370 may have beneficial effects on the treatment of liver fibrosis.
therapeutic target	hsa-mir-103	Liver Diseases [unspecific]	25593466			K76.9	D008107			miR-103 is involved in insulin resistance and NAFLD, and may be a molecular link between insulin resistance and NAFLD and a therapeutic target for these disorders.
therapeutic target	hsa-mir-122	Liver Diseases [unspecific]	25308172			K76.9	D008107			miR-122--a key factor and therapeutic target in liver disease.
therapeutic target	hsa-mir-122	Liver Diseases [unspecific]	26636761			K76.9	D008107			Taken together, our study indicates that miR-122 may downregulate cytokine production in HSCs and macrophage chemotaxis and that the targeting of miR-122 may have therapeutic potential for preventing the progression of liver diseases.
therapeutic target	hsa-mir-122	Liver Diseases [unspecific]	26019030			K76.9	D008107			microRNAs are promising tools in the diagnosis and treatment of hepatitis B virus -related liver diseases.
therapeutic target	hsa-mir-21	Liver Diseases [unspecific]	25605429			K76.9	D008107			miR-21 may be a useful biomarker for the diagnosis and treatment of NAFLD.
therapeutic target	hsa-mir-221	Liver Failure	21400558			K72	D017093	613070	HP:0001399	We identified miR-221 as a potent posttranscriptional regulator of FAS-induced apoptosis. miR-221 may serve as a potential therapeutic target for the treatment of hepatitis and liver failure.
therapeutic target	hsa-mir-17	Liver Fibrosis	25915722			K74	D008103			Our results collectively indicate that miR-17-5p promotes HSC proliferation and activation, at least in part, via reduction of Smad7, supporting its potential utility as a novel therapeutic target for liver fibrosis.
therapeutic target	hsa-mir-454	Liver Fibrosis	24685242			K74	D008103			All the results suggested that miR-454 could provide a novel therapeutic approach for treating liver fibrosis, especially the liver fibrosis induced by Schistosoma japonicum.
therapeutic target	hsa-mir-155	Liver Injury	29420849			S36.11	D056486			maintaining miR-155 expression in inflammatory cells might be a potential strategy to modulate liver injury
therapeutic target	hsa-mir-122	Liver Neoplasms	25885701	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	In conclusion, our results collectively suggested that GGMPN could serve as a novel therapeutic approach to control tumor cell apoptosis and growth.
therapeutic target	hsa-mir-132	Liver Neoplasms	25676267	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-132 is down-regulated in human liver cancer tissues miR-132 transfection can effectively inhibit proliferation and promote apoptosis of MHCC97H cells in vitro and in vivo. Therefore, miR-132 may become a new target in liver cancer treatment.
therapeutic target	hsa-mir-216a	Liver Neoplasms	24322754	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	MicroRNA-216a: a potential therapeutic target for drug resistance and recurrent of liver cancer.
therapeutic target	hsa-mir-1343	Lung Fibrosis	26542979	respiratory system disease	DOID:3770	J84.10	D011658	178500		As a result, the abundance of fibrotic markers is reduced, cell migration into a scratch wound impaired and epithelial-to-mesenchymal transition (EMT) repressed. Mature miR-1343 is readily detected in human neutrophils and HL-60 cells and is activated in response to stress in A549 lung epithelial cells. miR-1343 may have direct therapeutic applications in fibrotic lung disease.
therapeutic target	hsa-mir-200	Lung Fibrosis	22189082	respiratory system disease	DOID:3770	J84.10	D011658	178500		Thus, the miR-200 family members participate importantly in fibrotic lung diseases and suggest that restoring miR-200 expression in the lungs may represent a novel therapeutic approach in treating pulmonary fibrotic diseases.
therapeutic target	hsa-mir-27b	Lung Fibrosis	26311239	respiratory system disease	DOID:3770	J84.10	D011658	178500		Taken together,these results suggest that 1,25(OH)2D3 inhibits lung fibroblast differentiation induced by TGF-β1 via miR-27b targeting VDR 3'UTR, which may be used as a novel treatment strategy in differentiation pathways.
therapeutic target	hsa-mir-29	Lung Fibrosis	25454218	respiratory system disease	DOID:3770	J84.10	D011658	178500		the antifibrotic activity of miR-29 in animal models of fibrosis and highlight miR-29 as a promising therapeutic reagent or target for the treatment of pulmonary fibrosis.
therapeutic target	hsa-let-7	Lung Injury [unspecific]	26318567			S27.309D	D055370			Taken together, the present results propose an involvement of let-7 microRNA and K-ras in radon induced lung damage both in vivo and in vitro, which may thus be of potential value in early diagnosis and therapy of radon-induced lung tumorgenesis.
therapeutic target	hsa-mir-20a	Lung Injury [unspecific]	26525353			S27.309D	D055370			Our findings may provide a differential diagnostic method that is effective for diagnosing lung diseases caused by SM exposure. Additionally, these miRNAs may be regarded as probable targets for treatment of lung injuries.
therapeutic target	hsa-mir-92a	Lung Injury [unspecific]	26525353			S27.309D	D055370			Our findings may provide a differential diagnostic method that is effective for diagnosing lung diseases caused by SM exposure. Additionally, these miRNAs may be regarded as probable targets for treatment of lung injuries.
therapeutic target	hsa-let-7	Lung Neoplasms	26323902	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In this review, we summarize the newest investigations on let-7 and LC, the regulation of let-7 and its targets gene have been discussed, and the attempts for new therapy for LC have also been summarized.
therapeutic target	hsa-mir-1	Lung Neoplasms	25342548	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Pim-1 kinase could be a critical survival signaling factor in NSCLC,and regulated by miR-486-5p and eIF4E. Pim-1 kinase may provide a potential target for diagnosis and treatment for lung cancer.
therapeutic target	hsa-mir-125b	Lung Neoplasms	26686386	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	these results show tremendous promise of wt-p53 and miR-125b gene therapy using dual CD44/EGFR-targeting HA NP vector for  effective treatment of lung cancer.
therapeutic target	hsa-mir-132	Lung Neoplasms	25435090	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-212/132 may mediate proliferation and cell cycle arrest through p21 and cyclin D1. Our study provides insight into the biological function of the miR-212/132 cluster in lung cancer. The present study may provide a potential therapeutic target for the treatment of lung cancer.
therapeutic target	hsa-mir-132	Lung Neoplasms	25607827	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-132 may be a novel diagnostic and prognostic marker, as well as a potential target for molecular therapy in NSCLC.
therapeutic target	hsa-mir-134	Lung Neoplasms	26642897	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Altogether, our data demonstrated an altered expression of two development-related miRNAs namely miR-134 and miR-187 in lung tumors for the first time. Moreover we have shown that miR-134 and miR-187 expression alternation were in accordance with their approved regulatory roles, therefore these miRNAs could serve as new biomarkers with potential usefulness in lung cancer diagnosis and treatments. In addition, miR-187 expression in tumor cells could perturb cell cycle which supported its possible role as tumor suppressor.
therapeutic target	hsa-mir-137	Lung Neoplasms	26101014	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-137 downregulation was related to its promoter hypermethylation in lung cancer. Further studies are needed to assess its value as a prognostic factor and potential therapeutic applications in lung cancer.
therapeutic target	hsa-mir-143	Lung Neoplasms	26586766	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This study shows that miR-143/145 expressed from the tumor microenvironment stimulates neoangiogenesis and supports tumor expansion in the lung, demonstrating a surprising role for the putative tumor suppressor miRNA cluster in promoting tumorigenesis. We propose inhibition of miR-143/145 as a therapeutic avenue to modulate tumor neoangiogenesis.
therapeutic target	hsa-mir-144	Lung Neoplasms	26395400	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These results indicate that down-regulation of miR-144 is critical for air pollution-related lung cancer, and the miR-144-Zeb1 signalling pathway could represent a potential therapeutic target.
therapeutic target	hsa-mir-145	Lung Neoplasms	25428378	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These findings provide novel insights with potential therapeutic applications for the treatment of NSCLC.
therapeutic target	hsa-mir-145	Lung Neoplasms	26586766	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This study shows that miR-143/145 expressed from the tumor microenvironment stimulates neoangiogenesis and supports tumor expansion in the lung, demonstrating a surprising role for the putative tumor suppressor miRNA cluster in promoting tumorigenesis. We propose inhibition of miR-143/145 as a therapeutic avenue to modulate tumor neoangiogenesis.
therapeutic target	hsa-mir-150	Lung Neoplasms	26498874	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Thus, our findings identified that JMJD2A played an oncogenic role in NSCLC via regulating miR-150. JMJD2A could possibly serve as a prognostic factor and potential target for NSCLC therapy.
therapeutic target	hsa-mir-155	Lung Neoplasms	26543233	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our findings suggested that rs767649 A > T might contribute to the increased risk and poor prognosis of NSCLC, highlighting the importance of rs767649 in the prevention and therapy of NSCLC.
therapeutic target	hsa-mir-155	Lung Neoplasms	27315591	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Inhibition of microRNA-155 sensitizes lung cancer cells to irradiation
therapeutic target	hsa-mir-15a	Lung Neoplasms	25442346	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-15a/16 can enhance radiation sensitivity by regulating the TLR1/NF-κB signaling pathway and act as a potential therapeutic approach to overcome radioresistance for lung cancer treatment.
therapeutic target	hsa-mir-16	Lung Neoplasms	25442346	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-15a/16 can enhance radiation sensitivity by regulating the TLR1/NF-κB signaling pathway and act as a potential therapeutic approach to overcome radioresistance for lung cancer treatment.
therapeutic target	hsa-mir-186	Lung Neoplasms	20627087	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-186:miR-186 * may serve as a potential gene therapy target for refractory lung cancer that is sensitive to curcumin
therapeutic target	hsa-mir-186	Lung Neoplasms	20878113	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-186* could serve as a potential gene therapy target in curcumin treatment. 
therapeutic target	hsa-mir-187	Lung Neoplasms	26642897	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Altogether, our data demonstrated an altered expression of two development-related miRNAs namely miR-134 and miR-187 in lung tumors for the first time. Moreover we have shown that miR-134 and miR-187 expression alternation were in accordance with their approved regulatory roles, therefore these miRNAs could serve as new biomarkers with potential usefulness in lung cancer diagnosis and treatments. In addition, miR-187 expression in tumor cells could perturb cell cycle which supported its possible role as tumor suppressor.
therapeutic target	hsa-mir-192	Lung Neoplasms	25444916	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the proapoptotic effects of curcumin depend on miR-192-5p/215 induction and the p53-miR-192-5p/215-XIAP pathway is an important therapeutic target for non-small cell lung cancer.
therapeutic target	hsa-mir-193a	Lung Neoplasms	24356455	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Methylation-silencing of miR-9-3 and miR-193a may be an important epigenetic mechanisms favoring NSCLC cell growth and survival for carcinogenesis and cancer progression, and demethylation to reactivate expression of miR-9-3 and miR-193a genes contributes, at least partially, to the anti-cancer properties of 5-AzaC and thereby may be worthy of future studies for the possibility of being a new therapeutic strategy for the treatment of human NSCLCs.
therapeutic target	hsa-mir-197	Lung Neoplasms	25597412	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the miR-197/CKS1B/STAT3-mediated network can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC.
therapeutic target	hsa-mir-19a	Lung Neoplasms	25604748	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mechanism of action of miR-19a in the development of NSCLC and suggest that miR-19a may be a novel and promising target for therapeutic intervention in NSCLC.
therapeutic target	hsa-mir-200	Lung Neoplasms	26314828	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our findings also provide evidence that increased miR-200 expression may contribute to early lung tumorigenesis and that AKT inhibitors may be useful for the treatment of miR-200-dependent tumor cell growth.
therapeutic target	hsa-mir-208a	Lung Neoplasms	26754670	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The present study provides evidence that miR-208a can affect the proliferation and radiosensitivity of human lung cancer cells by targeting p21 and can be transported by exosomes. Thus, miR-208a may serve as a potential therapeutic target for lung cancer patients.
therapeutic target	hsa-mir-21	Lung Neoplasms	24691929	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21: a non-invasive biomarker and potential therapeutic target for lung cancer
therapeutic target	hsa-mir-21	Lung Neoplasms	25477028	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21 is highly expressed in patients with NSCLC and inhibition of miR-21 expression reduces proliferation, migration, and invasion of A549 cells by upregulating PDCD4 expression. Modulation of miR-21 or PDCD4 expression may provide a potentially novel therapeutic approach for NSCLC.
therapeutic target	hsa-mir-21	Lung Neoplasms	25563770	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Inhibition of NADPH oxidase protected against metastasis of human lung cancer cells by decreasing miR-21 expression, which could facilitate the understanding of lung cancer pathogenesis and provided clues for the development of novel therapeutics for lung cancer patients.
therapeutic target	hsa-mir-21	Lung Neoplasms	20338946	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Aberrantly increased expression of miR-21 plays a significant role in lung carcinogenesis and is a potential therapeutic target in both epidermal growth factor receptor-mutant and wild-type cases.
therapeutic target	hsa-mir-212	Lung Neoplasms	25435090	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-212/132 may mediate proliferation and cell cycle arrest through p21 and cyclin D1. Our study provides insight into the biological function of the miR-212/132 cluster in lung cancer. The present study may provide a potential therapeutic target for the treatment of lung cancer.
therapeutic target	hsa-mir-215	Lung Neoplasms	25444916	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the proapoptotic effects of curcumin depend on miR-192-5p/215 induction and the p53-miR-192-5p/215-XIAP pathway is an important therapeutic target for non-small cell lung cancer.
therapeutic target	hsa-mir-224	Lung Neoplasms	25410592	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-224 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for miR-based therapy of NSCLC.
therapeutic target	hsa-mir-224	Lung Neoplasms	26307684	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our study provides new insight in understanding of oncogenic role of miR-224 in the lung cancer pathogenesis and suggests that NF-κB/miR-224/CASP3, 7 pathway could be a putative therapeutic target in lung cancer.
therapeutic target	hsa-mir-26b	Lung Neoplasms	26744864	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Taken together, our results demonstrate that miR-26b could suppress lung cancer cells proliferation, migration and invasion by directly negative regulation of COX-2. MiR-26b could serve as a novel potential marker for NSCLC therapy.
therapeutic target	hsa-mir-299	Lung Neoplasms	26617714	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Therefore, the disordered decreased of miR-299-3p and resulting ABCE1 up-expression may contribute to chemoresistance of lung cancer, and miR-299-3p-ABCE1 may represent a new potential therapeutic target for the treatment of chemoresistance of lung cancer.
therapeutic target	hsa-mir-29b	Lung Neoplasms	26063204	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Taken together, our results demonstrate that miR-29b serves as a tumor metastasis suppressor, which suppresses NSCLC cell metastasis by directly inhibiting MMP2 expression. The results show that miR-29b may be a novel therapeutic candidate target to slow NSCLC metastasis.
therapeutic target	hsa-mir-30a	Lung Neoplasms	25484183	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	a competitive endogenous RNAs regulatory network which will help understand the metastasis mechanisms of lung cancer and improve the prevention and treatment of lung cancer.
therapeutic target	hsa-mir-30a	Lung Neoplasms	26305739	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-30a may be regarded as a tumor suppressor in NSCLC, and it could become a prognostic marker and potential therapeutic target for NSCLC.
therapeutic target	hsa-mir-31	Lung Neoplasms	24726065	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our data may help researchers to predict the molecular mechanisms of miR-31 in the molecular mechanism of lung cancer comprehensively. Moreover, the present data indicate that the interaction of miR-31 targets may be promising candidates as biomarkers for the diagnosis, prognosis and personalized therapy of lung cancer.
therapeutic target	hsa-mir-34a	Lung Neoplasms	26022002	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These findings provoke a conversation on producing biologic miRNAs to perform miRNA actions, and point toward a new direction in developing miRNA-based therapies.
therapeutic target	hsa-mir-34a	Lung Neoplasms	20570894	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-34a:Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34
therapeutic target	hsa-mir-373	Lung Neoplasms	25591738	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-512 and miR-373 exert cell-autonomous and non-autonomous tumor-suppressive effects in lung cancer cells, where their re-expression may benefit epigenetic cancer therapy.
therapeutic target	hsa-mir-4500	Lung Neoplasms	25277326	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Low expression of miR-4500 in NSCLC promoted tumor growth by targeting LIN28B and NRAS. MiR-4500 may be a prognosis predictor and potential target for NSCLC therapy.
therapeutic target	hsa-mir-451	Lung Neoplasms	25812923	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Systemic delivery of synthetic microRNA-451 is an effective therapeutic strategy for the treatment of lung cancer.
therapeutic target	hsa-mir-487b	Lung Neoplasms	27097129	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-487b-5p inhibition can be further explored as a chemotherapy target in the treatment of TMZ-resistant lung carcinoma.
therapeutic target	hsa-mir-498	Lung Neoplasms	26323905	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Our data indicated that miR-498 is downregulated and correlated with tumor progression, which might be a putitive therapeutic target in NSCLC treatment.
therapeutic target	hsa-mir-512	Lung Neoplasms	25591738	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-512 and miR-373 exert cell-autonomous and non-autonomous tumor-suppressive effects in lung cancer cells, where their re-expression may benefit epigenetic cancer therapy.
therapeutic target	hsa-mir-520e	Lung Neoplasms	25661366	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Developing an effective therapeutic by delivery of synthetic microRNA-520e in lung cancer treatment.
therapeutic target	hsa-mir-526b	Lung Neoplasms	25596743	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	hsa-mir-526b overexpression or Ku80 knockdown increased p53 and p21CIP1/WAF1 expression. These findings reveal that hsa-miR-526b is a potential target in cancer therapy.
therapeutic target	hsa-mir-564	Lung Neoplasms	26498524	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Taken together, our present study revealed the tumor suppressor role of miR-564, indicating restoration of miR-564 as a potential therapeutic strategy for the treatment of lung cancer.
therapeutic target	hsa-mir-582	Lung Neoplasms	26468775	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These findings suggest that miR-582-3p mediates the constitutive activation of Wnt/β-catenin signalling, likely serving as a potential therapeutic target for NSCLC.
therapeutic target	hsa-mir-660	Lung Neoplasms	25501825	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-660 acts as a tumor suppressor miRNA and we suggest the replacement of mir-660 as a new therapeutic approach for p53 wild-type lung cancer treatment.
therapeutic target	hsa-mir-9-3	Lung Neoplasms	24356455	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Methylation-silencing of miR-9-3 and miR-193a may be an important epigenetic mechanisms favoring NSCLC cell growth and survival for carcinogenesis and cancer progression, and demethylation to reactivate expression of miR-9-3 and miR-193a genes contributes, at least partially, to the anti-cancer properties of 5-AzaC and thereby may be worthy of future studies for the possibility of being a new therapeutic strategy for the treatment of human NSCLCs.
therapeutic target	hsa-mir-15a	Lymphoma	23307249	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Our study implies that the combination of Bcl-2 siRNA and miR-15a may be a useful approach in treatment for lymphoma.
therapeutic target	hsa-mir-17	Lymphoma	21239610	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-18	Lymphoma	21239610	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-19a	Lymphoma	21239610	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-19b-1	Lymphoma	21239610	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-20a	Lymphoma	21239610	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-365	Lymphoma	26406949	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Our data suggest that miR-365 functions as a tumor suppressor in MM development and progression, and holds promise as a prognostic biomarker and potential therapeutic target for MM.
therapeutic target	hsa-mir-466	Lymphoma	25573115	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-446 may have a protective effect on transplanted corneas by suppressing Prox1 expression at the post-transcriptional level. The results of the current study may provide insights into the mechanisms of lymphangiogenesis resulting from corneal graft rejection and alkali-burn injuries, as well as into the development of new treatments for lymphangiogenic eye diseases.
therapeutic target	hsa-mir-92-1	Lymphoma	21239610	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	our work demonstrating that inhibition of miR-17∼92 increases lucocorticoid-induced apoptosis highlights the potential importance of miR-17∼92 as a therapeutic target in leukemias and lymphomas.
therapeutic target	hsa-mir-155	Lymphoma, B-Cell	25498913	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	high expression of miR-155 sensitizes cells to v-akt murine thymoma viral oncogene homolog-1 inhibitors in vitro, suggesting a novel treatment option for resistant DLBCL.
therapeutic target	hsa-mir-29a	Lymphoma, B-Cell	23079660	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas
therapeutic target	hsa-mir-29b-1	Lymphoma, B-Cell	23079660	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas
therapeutic target	hsa-mir-29b-2	Lymphoma, B-Cell	23079660	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas
therapeutic target	hsa-mir-34a	Lymphoma, B-Cell	21460242	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	our results elucidate a novel Myc- and FoxP1-dependent pathway of malignant transformation and suggest miR-34a replacement therapy as a promising strategy in lymphoma treatment.
therapeutic target	hsa-mir-150	Lymphoma, Burkitt	24613688	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Deregulation of miR-150 may be useful as a diagnostic tool in BL,based on miRNA profile screening, qRT-PCR and miRNA-ISH. miR-150 plays an important role in BL by targeting c-Myb and Survivin. Re-expression of miR-150 reduced the proliferation of Raji cells, which suggests it to be a promising novel candidate for tumor treatment.
therapeutic target	hsa-mir-155	Lymphoma, Extranodal NK-T-Cell	19641183			C86.0	D054391			miR-21 or miR-155 led to down-regulation of PTEN and PDCD4 or SHIP1 with up-regulation of phosphorylated AKT(ser473).
therapeutic target	hsa-mir-27a	Lymphoma, Extranodal NK-T-Cell	19641183			C86.0	D054391			miR-21 or miR-155 led to down-regulation of PTEN and PDCD4 or SHIP1 with up-regulation of phosphorylated AKT(ser473).
therapeutic target	hsa-mir-15a	Lymphoma, Follicular	28653191	disease of cellular proliferation	DOID:0050873	C82	D008224	613024		MicroRNA Dysregulation to Identify Novel Therapeutic Targets.
therapeutic target	hsa-mir-618	Lymphoma, Follicular	24503492	disease of cellular proliferation	DOID:0050873	C82	D008224	613024		Taken together, our findings implicate miR-618 in follicular lymphomagenesis, identify miR-618 as a potential risk biomarker for follicular lymphoma, and illuminate miR-618-regulated lymphomagenic pathways that can serve as therapeutic targets for follicular lymphoma.
therapeutic target	hsa-mir-1973	Lymphoma, Hodgkin	24222179	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced.
therapeutic target	hsa-mir-21	Lymphoma, Hodgkin	24222179	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced.
therapeutic target	hsa-mir-494	Lymphoma, Hodgkin	24222179	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Our results demonstrate that in patients with cHL, circulating cell-free miRNAs can reflect disease response once therapy has commenced.
therapeutic target	hsa-mir-124	Lymphoma, Large B-Cell	25576220			C83.3	D016403	109565		notion that miR-124 could be an attractive therapeutic target for overcoming GC resistance in DLBCL.
therapeutic target	hsa-mir-21	Lymphoma, Large B-Cell	25543482			C83.3	D016403	109565		the miR-21 can regulate proliferation, invasion, and apoptosis, so it has a potential therapeutic application in DLBCL.
therapeutic target	hsa-mir-138	Lymphoma, Large B-Cell, Diffuse	24914240	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers.
therapeutic target	hsa-mir-146b	Lymphoma, Large B-Cell, Diffuse	25544772	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		a miRNA signature for EBV+DLBCLe and our findings suggest that hsa-miR-146b and hsa-miR-222 could be biomarkers and therapeutic targets.
therapeutic target	hsa-mir-147a	Lymphoma, Large B-Cell, Diffuse	24914240	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers.
therapeutic target	hsa-mir-147b	Lymphoma, Large B-Cell, Diffuse	24914240	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers.
therapeutic target	hsa-mir-222	Lymphoma, Large B-Cell, Diffuse	25544772	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		a miRNA signature for EBV+DLBCLe and our findings suggest that hsa-miR-146b and hsa-miR-222 could be biomarkers and therapeutic targets.
therapeutic target	hsa-mir-511	Lymphoma, Large B-Cell, Diffuse	24914240	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers.
therapeutic target	hsa-mir-21	Lymphoma, Non-Hodgkin	26439034	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Overexpression of miR-21 is associated with disease stage and treatment outcome of B-NHL. This potentially involves negative modulation of PTEN.
therapeutic target	hsa-mir-374b	Lymphoma, Non-Hodgkin	26100275	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Our data highlight the molecular etiology and clinical significance of miR-374b in T-LBL. Targeting miR-374b may represent a new therapeutic strategy to improve therapy and survival for T-LBL patients.
therapeutic target	hsa-mir-1202	Major Depressive Disorder	24908571	disease of mental health	DOID:1470	F32	D003865	608520		miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment.
therapeutic target	hsa-mir-138	Malignant Neoplasms [unspecific]	28378633			C80.1	D009369			MiR-138: A promising therapeutic target for cancer.
therapeutic target	hsa-mir-221	Malignant Neoplasms [unspecific]	24475314			C80.1	D009369			Our findings demonstrate that miR-221 is more suitable to predict cancer prognosis in Asians, and it is a promising prognostic biomarker for HCC.The detection of miR-221 in serum or plasma samples may make it become an effective method for monitoring patients' prognosis and assessing therapeutic efficacy in the future.
therapeutic target	hsa-mir-29a	Malignant Neoplasms [unspecific]	25968566			C80.1	D009369			miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.
therapeutic target	hsa-mir-29b	Malignant Neoplasms [unspecific]	25968566			C80.1	D009369			miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.
therapeutic target	hsa-mir-29c	Malignant Neoplasms [unspecific]	25968566			C80.1	D009369			miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.
therapeutic target	hsa-mir-30a	Malignant Peripheral Nerve Sheath Tumor	25890085	disease of cellular proliferation	DOID:5940		D009442		HP:0100697	These findings demonstrated that DZNep, an inhibitor of S-adenosyl-methionine-dependent methyltransferase, suppressed EZH2/miR-30a,d/KPNB1 signaling and blocked MPNST tumor cell growth and survival in vitro and in vivo. More importantly, our study indicated that pharmacological interference of EZH2 is a potential therapeutic approach for MPNST.
therapeutic target	hsa-mir-9	Mast Cell Neoplasm	24517413	disease of cellular proliferation	DOID:3664	D47.0				Our findings demonstrate that unique miRNA expression profiles correlate with the biological behavior of canine MCTs. Furthermore, dysregulation of miR-9 is associated with MCT metastasis potentially through the induction of an invasive phenotype, identifying a potentially novel pathway for therapeutic intervention.
therapeutic target	hsa-mir-124	Medulloblastoma	26840408	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	In all, we have discovered miR-124 to be downregulated in instances of medulloblastoma in which Nur77 is upregulated, resulting in a proliferative state that abets cancer progression. This study provides evidence for increasing miR-124 expression as a potential therapy for cancers with elevated levels of Nur77.
therapeutic target	hsa-mir-1280	Medulloblastoma	25576913	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	the role of PDGFRs in MB and unveils JAG2 as a key downstream effector of a PDGFRβ-driven signaling cascade and a potential therapeutic target.
therapeutic target	hsa-let-7b	Melanoma	28167449	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Curcumin and treatment of melanoma: The potential role of microRNAs.
therapeutic target	hsa-mir-142	Melanoma	25490969	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Robust association of miR-150-5p and the miR-142 duplex with good prognosis and earlier stage metastatic melanoma supports their potential as biomarkers. miRNAs overexpressed in association with PP in an autoregulatory fashion will not be suitable therapeutic targets.
therapeutic target	hsa-mir-145	Melanoma	23404256	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-145 is an invasion suppressor in metastatic melanoma cells. Despite the fact that it remains unclear which genes or pathways are regulated by miR-145 in melanoma, miR-145 may serve as a useful therapeutic agent in melanoma when re-expressed in situ
therapeutic target	hsa-mir-146a	Melanoma	27059647	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	two miRNAs that are particularly relevant in human melanoma progression, miR-146a and miR-214.
therapeutic target	hsa-mir-150	Melanoma	25490969	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Robust association of miR-150-5p and the miR-142 duplex with good prognosis and earlier stage metastatic melanoma supports their potential as biomarkers. miRNAs overexpressed in association with PP in an autoregulatory fashion will not be suitable therapeutic targets.
therapeutic target	hsa-mir-150	Melanoma	26089374	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies.
therapeutic target	hsa-mir-15a	Melanoma	26631117	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our results support a key role of IL-10Rα in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment.
therapeutic target	hsa-mir-15b	Melanoma	26089374	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies.
therapeutic target	hsa-mir-16	Melanoma	26089374	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies.
therapeutic target	hsa-mir-182	Melanoma	21102518	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our results demonstrate that the use of anti-miR-182 is a promising therapeutic strategy for metastatic melanoma and provide a solid basis for testing similar strategies in human metastatic tumors.
therapeutic target	hsa-mir-185	Melanoma	26631117	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our results support a key role of IL-10Rα in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment.
therapeutic target	hsa-mir-186	Melanoma	29578151	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-186 exhibit an inhibitory effect on  CMM cell proliferation, migration, and invasion; thus, may serve as a potential therapeutic target for human CMM intervention
therapeutic target	hsa-mir-200c	Melanoma	25903073	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	our data identify miR-200c as a critical signaling node in BRAFi-resistant melanomas impacting the MAPK and PI3K/AKT pathways, suggesting miR-200c as a potential therapeutic target for overcoming acquired BRAFi resistance.
therapeutic target	hsa-mir-203	Melanoma	26722525	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This study for the first time provided evidence that miR-203 could be an independent potential prognostic marker for patients with melanoma, and might even become a new therapeutic target for the treatment of melanoma.
therapeutic target	hsa-mir-21	Melanoma	28167449	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Curcumin and treatment of melanoma: The potential role of microRNAs.
therapeutic target	hsa-mir-211	Melanoma	26631117	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our results support a key role of IL-10Rα in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment.
therapeutic target	hsa-mir-211	Melanoma	26787841	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	These findings highlight a novel mechanism of melanoma formation: miR-211 is a molecular switch that is turned off in melanoma cells, raising the hope that in the future we might be able to turn the switch back on, thus providing a better treatment option for melanoma.
therapeutic target	hsa-mir-221	Melanoma	18983236	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In particular, the inhibition of miRNA-221 and -222, which are abnormally expressed in melanoma and favor the induction of the malignant phenotype by downregulating c-KIT receptor and p27Kip, might in the future represent an efficient treatment for translation into the clinical setting.
therapeutic target	hsa-mir-222	Melanoma	18983236	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In particular, the inhibition of miRNA-221 and -222, which are abnormally expressed in melanoma and favor the induction of the malignant phenotype by downregulating c-KIT receptor and p27Kip, might in the future represent an efficient treatment for translation into the clinical setting.
therapeutic target	hsa-mir-33a	Melanoma	25891797	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The newly identified miR-33a/HIF-1α axis might provide a new strategy for the treatment of melanoma.
therapeutic target	hsa-mir-34a	Melanoma	25403318	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-34a is involved in the tumor inhibition of melanoma by directly targeting FLOT2 gene. This finding provides potential novel strategies for therapeutic interventions of melanoma.
therapeutic target	hsa-mir-374b	Melanoma	26089374	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies.
therapeutic target	hsa-mir-7	Melanoma	27448964	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Collectively, our study demonstrated that miR-7 could reverse the resistance to BRAF inhibitors in certain vemurafenib resistant melanoma cell lines.
therapeutic target	hsa-mir-34a	Metabolic Syndrome	20689156	disease of metabolism	DOID:14221	E88.81	D024821	605552		The FXR/miR-34a pathway and other miRs controlling SIRT1 may be useful therapeutic targets for age-related diseases, including metabolic disorders.
therapeutic target	hsa-mir-379	Metabolic Syndrome	25510864	disease of metabolism	DOID:14221	E88.81	D024821	605552		the identification of a GC/GR-controlled miRNA cluster not only defines a novel layer of hormone-dependent metabolic control but also paves the way to alternative miRNA-based therapeutic approaches in metabolic dysfunction.
therapeutic target	hsa-mir-499	Mitochondrial Encephalomyopathy	26535630	musculoskeletal system disease	DOID:890	G93.4	D017237			blood miRNAs are deregulated in the pathogenesis of MNGIE and these changes may have therapeutic implications. Further experimental studies will be required to elucidate the functional miRNA-mRNA interactions in MNGIE.
therapeutic target	hsa-mir-181a	Mitochondrial Metabolism Disease	27281615	disease of metabolism	DOID:700	E88.40	D028361			Knock down of endogenous miR-181a accelerates the autophagic degradation of damaged mitochondria.
therapeutic target	hsa-mir-95	Mucosulfatidosis	25524633	disease of metabolism	DOID:0050441		D052517	272200		this regulatory mechanism opens the opportunity for a unique therapeutic approach in MSD patients where the need for exogenous enzyme replacement is circumvented.
therapeutic target	hsa-mir-150	Multiple Myeloma	25474406	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Altogether GC-inducible mir-150-5p adds another level of regulation to GC specific therapeutic responses in multiple myeloma.
therapeutic target	hsa-mir-152	Multiple Myeloma	26400224	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Our study contributes better understanding of the regulation mechanism of DKK-1 in MM, and opens up the potential for developing newer therapeutic strategies in the MM treatment.
therapeutic target	hsa-mir-155	Multiple Myeloma	25185784	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-155 in RPMI-8266 cells is a critical oncomiR in multiple myeloma and seed-targeting t-anti-miR-155 might be a novel strategy for miR-155-based therapeutics.
therapeutic target	hsa-mir-182	Multiple Myeloma	25874214	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	These subtype specific MFRMs may aid in the further elucidation of the pathogenesis of each subtype and may serve to guide MM subtype diagnosis and treatment.
therapeutic target	hsa-mir-186	Multiple Myeloma	26679605	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Our collective results clearly indicate that miR-186 functions as a tumor suppressor in MM, supporting its potential as a therapeutic target for the disease.
therapeutic target	hsa-mir-192	Multiple Myeloma	25489847	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	the IL-17/miR-192/IL-17Rs regulatory feedback loop is manifest in MM and might represent a promising and efficient prognostic marker and therapeutic target for MM.
therapeutic target	hsa-mir-21	Multiple Myeloma	26160841	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-21 is an oncogenic microRNA (miRNA) with an emerging role as therapeutic target in human malignancies, including multiple myeloma (MM)
therapeutic target	hsa-mir-21	Multiple Myeloma	22316494	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	This elucidation of the role of PIAS3 in the miR-21-STAT3 positive regulatory loop not only may shed light on the molecular basis of the biological effects of miR-21 observed in MM cells but also has direct implications for the development of novel anti-MM therapeutic strategies.
therapeutic target	hsa-mir-215	Multiple Myeloma	25489847	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	the IL-17/miR-192/IL-17Rs regulatory feedback loop is manifest in MM and might represent a promising and efficient prognostic marker and therapeutic target for MM.
therapeutic target	hsa-mir-221	Multiple Myeloma	24586944	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	LNA-i-miR-221 is a highly stable, effective agent against t(4;14) MM cells, and is suitable for systemic use. These data provide the rationale for the clinical development of LNA-i-miR-221 for the treatment of MM.
therapeutic target	hsa-mir-221	Multiple Myeloma	26527748	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	LNA-i-miR-221 can reverse melphalan resistance in preclinical models of multiple  myeloma
therapeutic target	hsa-mir-29b	Multiple Myeloma	27196750	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-29b-based epi-therapeutic approaches in the treatment of this malignancy
therapeutic target	hsa-mir-301a	Multiple Myeloma	26464662	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	MiR-301a promotes cell proliferation and inhibits apoptosis by direct targeting TIMP2 in MM, and miR-301a might represent a novel molecular in MM and may provide helpful therapeutic strategies for MM treatment.
therapeutic target	hsa-mir-34a	Multiple Myeloma	24683542	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.
therapeutic target	hsa-mir-34a	Multiple Myeloma	26620594	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.
therapeutic target	hsa-mir-34a	Multiple Myeloma	29263373	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment
therapeutic target	hsa-mir-96	Multiple Myeloma	25874214	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	These subtype specific MFRMs may aid in the further elucidation of the pathogenesis of each subtype and may serve to guide MM subtype diagnosis and treatment.
therapeutic target	hsa-mir-99a	Multiple Myeloma	25826415	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	our results suggest that BBR suppresses multiple myeloma cells,partly by down-regulating the 3 miRNA clusters and many mRNAs, possibly through TP53, Erb and MAPK signaling pathways. The mir-99a/125b cluster might be a novel target for MM treatment. These findings provide new mechanistic insight into the anticancer effects of certain traditional Chinese herbal medicine compounds.
therapeutic target	hsa-mir-100	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-107	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-145	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-146b	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-21	Multiple Sclerosis	23506112	nervous system disease	DOID:2377	G35	D009103	PS126200		Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy
therapeutic target	hsa-mir-320	Multiple Sclerosis	24852919	nervous system disease	DOID:2377	G35	D009103	PS126200		Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment.
therapeutic target	hsa-mir-320b	Multiple Sclerosis	24852919	nervous system disease	DOID:2377	G35	D009103	PS126200		Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment.
therapeutic target	hsa-mir-323	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-3614	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-369	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-494	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-629	Multiple Sclerosis	24852919	nervous system disease	DOID:2377	G35	D009103	PS126200		Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment.
therapeutic target	hsa-mir-874	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-9	Multiple Sclerosis	26943961	nervous system disease	DOID:2377	G35	D009103	PS126200		Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
therapeutic target	hsa-mir-1	Muscle Diseases [unspecific]	19754672			M63.80	D009135			Local injection of miR-1, 133 and 206 could be a novel therapeutic strategy in the treatment of skeletal muscle injury.
therapeutic target	hsa-mir-133	Muscle Diseases [unspecific]	19754672			M63.80	D009135			Local injection of miR-1, 133 and 206 could be a novel therapeutic strategy in the treatment of skeletal muscle injury.
therapeutic target	hsa-mir-206	Muscle Diseases [unspecific]	19754672			M63.80	D009135			Local injection of miR-1, 133 and 206 could be a novel therapeutic strategy in the treatment of skeletal muscle injury.
therapeutic target	hsa-mir-30a	Mycobacterium tuberculosis Infection	25866116			A18	D014376	607948		Our results indicate that miR-30A plays a key role in immune response against MTB and, therefore, may serve as a potential target for future treatments of tuberculosis infection.
therapeutic target	hsa-mir-20a	Myeloma	28979138			C90.0	D009101	254500		miR-20a plays a crucial role in the biology of MM and represents a potential target for novel therapies for MM patients
therapeutic target	hsa-mir-1	Myocardial Infarction	29269324	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: An early targeting therapy for myocardial infarction in mice
therapeutic target	hsa-mir-130a	Myocardial Infarction	28498815	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The optimization of cell therapy by combinational application with apicidin-treated mesenchymal stem cells after myocardial infarction.
therapeutic target	hsa-mir-155	Myocardial Infarction	26258537	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our study will aid in  deciphering the complex regulatory mechanisms involved in MI and provide putative therapeutic targets for MI.
therapeutic target	hsa-mir-21	Myocardial Infarction	26258537	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our study will aid in  deciphering the complex regulatory mechanisms involved in MI and provide putative therapeutic targets for MI.
therapeutic target	hsa-mir-21	Myocardial Infarction	22960625	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we found a novel reciprocal loop between miR-21 and TGFβRIII in cardiac fibrosis caused by myocardial infarction in mice, and targeting this pathway could be a new strategy for the prevention and treatment of myocardial remodeling.
therapeutic target	hsa-mir-210	Myocardial Infarction	22171547	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Given the fact that miR-210 is aberrantly expressed in a number of diseases such as tumor progression, myocardial infarction and cutaneous ischemic wounds, miR-210 could serve as an excellent candidate for prognostic purposes and therapeutic intervention.
therapeutic target	hsa-mir-29	Myocardial Infarction	26258537	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our study will aid in  deciphering the complex regulatory mechanisms involved in MI and provide putative therapeutic targets for MI.
therapeutic target	hsa-mir-34a	Myocardial Infarction	25322725	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our findings provide evidence that miR-34a plays a critical role in the progression of cardiac tissue fibrosis by directly targeting Smad4, which suggests that miR-34a may be new marker for cardiac fibrosis progression and that inhibition of miR-34a may be a promising strategy in the treatment of cardiac fibrosis.
therapeutic target	hsa-mir-34c	Myocardial Infarction	26232617	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Involvement of miR-34c in high glucose-insulted mesenchymal stem cells leads to inefficient therapeutic effect on myocardial infarction.
therapeutic target	hsa-mir-145	Nasopharyngeal Neoplasms	25578496			C11.9	D009303	607107	HP:0100630	miR-145 overexpression might be a potential therapeutic strategy of NPC intervention.
therapeutic target	hsa-mir-21	Nasopharyngeal Neoplasms	25544502			C11.9	D009303	607107	HP:0100630	NPC-derived miR-21 induces IL-10(+) B cells; the latter is capable of suppressing CD8(+) T-cell activities. miR-21 may be a potential target in the treatment of NP EBV-hsa-mir-BArT10-3p
therapeutic target	hsa-let-7	Neoplasms [unspecific]	24816444			C80.1	D009369			Therapeutic potential of microRNA let-7: tumor suppression or impeding normal stemness.
therapeutic target	hsa-let-7	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-let-7	Neoplasms [unspecific]	26284568			C80.1	D009369			To this end, we discuss the potential for miR-based therapies focused on three prominent miRs including the pan-RAS regulator let-7 and the GAP regulator comprised of miR-206  and miR-21 (miR-206/21).
therapeutic target	hsa-let-7a	Neoplasms [unspecific]	26348204			C80.1	D009369			Overall, our study provides a novel rationale of targeting miR let-7a-USP35-ABIN-2 pathway for the therapy of cancer patients.
therapeutic target	hsa-let-7i	Neoplasms [unspecific]	27588466			C80.1	D009369			Involvement of let-7 microRNA for the therapeutic effects of Rhenium-188-embedded liposomal nanoparticles on orthotopic human head and neck cancer model.
therapeutic target	hsa-mir-1	Neoplasms [unspecific]	24949449			C80.1	D009369			Role of microRNA-1 in human cancer and its therapeutic potentials.
therapeutic target	hsa-mir-100	Neoplasms [unspecific]	25740059			C80.1	D009369			Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.
therapeutic target	hsa-mir-106b	Neoplasms [unspecific]	25692889			C80.1	D009369			These preliminary findings warrant testing in a larger cohort of relapse patients to confirm whether the miRNA based predictor can select the optimal second line treatment and increase survival.
therapeutic target	hsa-mir-122	Neoplasms [unspecific]	25687306			C80.1	D009369			This study demonstrates that ultrasound induced microbubble cavitation can be a useful tool for delivery of therapeutic miR loaded nanocarriers into cancer in vivo.
therapeutic target	hsa-mir-122	Neoplasms [unspecific]	25910843			C80.1	D009369			The other strategy is increasing miRNA aims at decreasing target genes using miRNA mimic. This thematic issue will spur the interest of developing novel microRNA therapeutics and enhance the enthusiasm for targeting miRNAs as a novel class of drugs. 
therapeutic target	hsa-mir-122	Neoplasms [unspecific]	25935978			C80.1	D009369			Glutathione-mediated release of functional miR-122 from gold nanoparticles for targeted induction of apoptosis in cancer treatment.
therapeutic target	hsa-mir-122	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-122	Neoplasms [unspecific]	28209991			C80.1	D009369			MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
therapeutic target	hsa-mir-124	Neoplasms [unspecific]	26115122			C80.1	D009369			miR-124 could potentially be used as a therapeutic agent to improve the efficacy of chemotherapy with DNA-damaging agents.
therapeutic target	hsa-mir-124	Neoplasms [unspecific]	29602831			C80.1	D009369			This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics
therapeutic target	hsa-mir-126	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-126	Neoplasms [unspecific]	25572155			C80.1	D009369			miR-126 has potential therapeutic applications.
therapeutic target	hsa-mir-1268a	Neoplasms [unspecific]	29435930			C80.1	D009369			Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729)
therapeutic target	hsa-mir-1268b	Neoplasms [unspecific]	29435930			C80.1	D009369			Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729)
therapeutic target	hsa-mir-128	Neoplasms [unspecific]	24555688			C80.1	D009369			Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128.
therapeutic target	hsa-mir-128	Neoplasms [unspecific]	25916109			C80.1	D009369			The use of miR-128 as a diagnostic and/or therapeutic tool may result in improvements in diagnosis, prognosis, and treatment of numerous cancers.
therapeutic target	hsa-mir-129	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-129	Neoplasms [unspecific]	24307696			C80.1	D009369			The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors.
therapeutic target	hsa-mir-129	Neoplasms [unspecific]	27802440			C80.1	D009369			we summarized the roles of miR-129 family members and their target genes in tumorigenesis and clinical treatment of human cancers
therapeutic target	hsa-mir-133	Neoplasms [unspecific]	24975488			C80.1	D009369			microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer.
therapeutic target	hsa-mir-133b	Neoplasms [unspecific]	25743594			C80.1	D009369			Our results hence attempt to explain why miR-133b is generally downregulated in tumours and lay out the potential for Nup214 as a therapeutic target in the treatment of cancer.
therapeutic target	hsa-mir-138	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-143	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-143	Neoplasms [unspecific]	28448866			C80.1	D009369			Function of microRNA-143 in different signal pathways in cancer: New insights into cancer therapy.
therapeutic target	hsa-mir-145	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-145	Neoplasms [unspecific]	20407606			C80.1	D009369			This unique feature of miR-145-mediaed gene silencing may suggest that miR-145 is a potential cancer biomarker and serves as a novel target for cancer therapy.
therapeutic target	hsa-mir-145	Neoplasms [unspecific]	27655328			C80.1	D009369			our results indicated that mir-145, through targeting its common potential targets, may significantly contribute to tumor pathogenesis in distinct cancer types and might serve as an important target for cancer therapy
therapeutic target	hsa-mir-146b	Neoplasms [unspecific]	27533309			C80.1	D009369			In conjunction with current therapeutic regimens, targeting the miR-146b-IRAK1 axis  may provide a potential approach for PTC management.
therapeutic target	hsa-mir-150	Neoplasms [unspecific]	24698324			C80.1	D009369			Our results indicate that miR-150 is a common posttranscriptional regulator for Prf1 in mouse and human NK cells that represses NK cell lytic activity. Thus the therapeutic control of miR-150 in NK cells could enhance NK cell-based immunotherapy against cancer, providing a better clinical outcome.
therapeutic target	hsa-mir-155	Neoplasms [unspecific]	25892205			C80.1	D009369			pHLIP-mediated tumor targeting and anti-miR-155 PNA therapy was also effective in other tumor types, providing a bright perspective for future anti-miR conjugate medicines.
therapeutic target	hsa-mir-155	Neoplasms [unspecific]	26284487			C80.1	D009369			Altogether, our study demonstrates the multi-potent miRNA sponge is a useful tool to examine the functional impact of simultaneous inhibition of multiple miRNAs and proposes a therapeutic potential.
therapeutic target	hsa-mir-155	Neoplasms [unspecific]	25401928			C80.1	D009369			These results tie ELK3 into the hypoxia response pathway through an oncogenic microRNA and into a circuit implicated in the dynamics of the hypoxic response. This crosstalk could  be important for the development of new treatments for a range of pathologies.
therapeutic target	hsa-mir-155	Neoplasms [unspecific]	19811312			C80.1	D009369			Therefore, designing miR-155 based therapies will require a better understanding of the molecular basis of its action as well as of how miR-155 levels are regulated in a cell-specific manner.
therapeutic target	hsa-mir-155	Neoplasms [unspecific]	29282605			C80.1	D009369			miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
therapeutic target	hsa-mir-15b	Neoplasms [unspecific]	25888955			C80.1	D009369			miR-15b and miR-16 play a role in the inhibition of insulin resistance via reduced TNFα and SOCS3 signaling and increased IGFBP-3 levels,resulting in REC protection from hyperglycemia-induced apoptosis. This outcome suggests that both miR-15b and miR-16 are potential therapeutic targets for therapeutics for the diabetic retina.
therapeutic target	hsa-mir-15b	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-16	Neoplasms [unspecific]	25888955			C80.1	D009369			miR-15b and miR-16 play a role in the inhibition of insulin resistance via reduced TNFα and SOCS3 signaling and increased IGFBP-3 levels,resulting in REC protection from hyperglycemia-induced apoptosis. This outcome suggests that both miR-15b and miR-16 are potential therapeutic targets for therapeutics for the diabetic retina.
therapeutic target	hsa-mir-16	Neoplasms [unspecific]	19944013			C80.1	D009369			Together, all these results demonstrate that miR-16-1 plays a vital role in modulating cellular process in human cancers and indicate the therapeutic potential of miR-16-1 in cancer therapy.
therapeutic target	hsa-mir-16-2	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-17	Neoplasms [unspecific]	24419145			C80.1	D009369			microRNA-17~92 is a powerful cancer driver and a therapeutic target.
therapeutic target	hsa-mir-17	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-18	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-193a	Neoplasms [unspecific]	27669434			C80.1	D009369			the broader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer
therapeutic target	hsa-mir-195	Neoplasms [unspecific]	24446485			C80.1	D009369			The results suggest that miRNA expression profiles can distinguish different subtypes of ACA, which may contribute to a deeper understanding of ACA development and potential therapeutics.
therapeutic target	hsa-mir-196a	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-19a	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-19b-1	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-200	Neoplasms [unspecific]	25762624			C80.1	D009369			The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy.
therapeutic target	hsa-mir-200	Neoplasms [unspecific]	23888967			C80.1	D009369			A family of pleiotropically acting microRNAs in cancer progression, miR-200: potential cancer therapeutic targets.
therapeutic target	hsa-mir-200	Neoplasms [unspecific]	25401465			C80.1	D009369			This study provides a strong rationale for detailed assessment of the prognostic and predictive value of circulating extracellular vesicle-bound miR-200s in breast cancer progression and treatment.
therapeutic target	hsa-mir-205	Neoplasms [unspecific]	25308719			C80.1	D009369			The important roles of miR-205 in normal physiology, cancers and as a potential therapeutic target.
therapeutic target	hsa-mir-205	Neoplasms [unspecific]	24568460			C80.1	D009369			The aim of this review is to discuss miR-205 roles in different types of cancers. Given the critical effects of deregulated miR-205 on processes involved in tumorigenesis, they hold potential as novel therapeutic targets and biomarkers.
therapeutic target	hsa-mir-205	Neoplasms [unspecific]	25476932			C80.1	D009369			miR-205 as a radiosensitizing miRNA and reveal a new therapeutic strategy for radioresistant tumours.
therapeutic target	hsa-mir-206	Neoplasms [unspecific]	26284568			C80.1	D009369			To this end, we discuss the potential for miR-based therapies focused on three prominent miRs including the pan-RAS regulator let-7 and the GAP regulator comprised of miR-206  and miR-21 (miR-206/21).
therapeutic target	hsa-mir-20a	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	25942410			C80.1	D009369			These findings highlight the promise of the highly versatile multifunctional nanocomposite in biomedical application of intracellular molecules analysis and clinical gene therapeutics.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	25991670			C80.1	D009369			these studies highlight a stronger role for miR-21 in the pathogenesis of multiple autoimmune and chronic inflammatory disorders. However, the complete molecular mechanisms by which miR-21 regulates these pathologies remains to be investigated. Thus, a better understanding of the role of miR-21 in the innate and adaptive immune systems, during healthy states as well as during infection, chronic inflammation, and autoimmunity, is required before we design any therapeutic strategies aimed at targeting miR-21.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	24446181			C80.1	D009369			MicroRNA-21 is a novel promising target in cancer radiation therapy.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	20560046			C80.1	D009369			miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	23865553			C80.1	D009369			MicroRNA-21: a therapeutic target for reversing drug resistance in cancer.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	26284487			C80.1	D009369			Altogether, our study demonstrates the multi-potent miRNA sponge is a useful tool to examine the functional impact of simultaneous inhibition of multiple miRNAs and proposes a therapeutic potential.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	25827073			C80.1	D009369			our work demonstrated that AC1MMYR2 appeared to be a promising strategy in combating taxol induced cancer metastasis by targeting miR-21/CDK5 axis, which highlighted the potential for development of therapeutic modalities for better clinic taxol application.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	26028073			C80.1	D009369			These findings contribute to our understanding of the functions of miR-21 and exosomes as a carrier for therapy of gastric cancer.
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	26284568			C80.1	D009369			To this end, we discuss the potential for miR-based therapies focused on three prominent miRs including the pan-RAS regulator let-7 and the GAP regulator comprised of miR-206  and miR-21 (miR-206/21).
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	27428511			C80.1	D009369			Targeted inhibition of oncogenic miR-21 maturation with designed RNA-binding proteins
therapeutic target	hsa-mir-21	Neoplasms [unspecific]	28096467			C80.1	D009369			Our results not only elucidate miR-21-mediated radioresistance, but also provide potential new targets for improving radiotherapy
therapeutic target	hsa-mir-214	Neoplasms [unspecific]	26108246			C80.1	D009369			miRNA-214: expression, therapeutic and diagnostic potential in cancer.
therapeutic target	hsa-mir-214	Neoplasms [unspecific]	25501033			C80.1	D009369			miR-214 is a molecular hub involved in the control of cancer networks and, as such, could be a potential diagnostic/prognostic biomarker and target for therapeutic intervention.
therapeutic target	hsa-mir-214	Neoplasms [unspecific]	25591843			C80.1	D009369			miR-214: a potential biomarker and therapeutic for different cancers.
therapeutic target	hsa-mir-218	Neoplasms [unspecific]	26407971			C80.1	D009369			This system offers an efficient approach to cancer therapy and holds significant potential to improve the treatment of cancer in the future.
therapeutic target	hsa-mir-218	Neoplasms [unspecific]	25857406			C80.1	D009369			we provide a complex overview of miR-218, including its regulatory mechanisms, known functions in cancer and future challenges as a potential therapeutic target in human cancers.
therapeutic target	hsa-mir-221	Neoplasms [unspecific]	24474451			C80.1	D009369			The meta-analysis demonstrates that the elevated expression of miR-221 and miR-222 is associated with poor OS in patients with cancer. The miR-221/222 cluster might be used as a potential therapeutic strategy in clinical practice. More work is required to fully elucidate the role of the miR-221/222 family in human tumors.
therapeutic target	hsa-mir-221	Neoplasms [unspecific]	25431954			C80.1	D009369			Notch3 silencing strongly increases the effects of Nutilin-3.With regard to therapeutic implications, Notch3-specific drugs could represent a valuable strategy to limit Notch signaling in the context of hepatocellular carcinoma over-expressing this receptor.
therapeutic target	hsa-mir-221	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-221	Neoplasms [unspecific]	26284487			C80.1	D009369			Altogether, our study demonstrates the multi-potent miRNA sponge is a useful tool to examine the functional impact of simultaneous inhibition of multiple miRNAs and proposes a therapeutic potential.
therapeutic target	hsa-mir-222	Neoplasms [unspecific]	24474451			C80.1	D009369			The meta-analysis demonstrates that the elevated expression of miR-221 and miR-222 is associated with poor OS in patients with cancer. The miR-221/222 cluster might be used as a potential therapeutic strategy in clinical practice. More work is required to fully elucidate the role of the miR-221/222 family in human tumors.
therapeutic target	hsa-mir-222	Neoplasms [unspecific]	26284487			C80.1	D009369			Altogether, our study demonstrates the multi-potent miRNA sponge is a useful tool to examine the functional impact of simultaneous inhibition of multiple miRNAs and proposes a therapeutic potential.
therapeutic target	hsa-mir-223	Neoplasms [unspecific]	24606854			C80.1	D009369			miR-223 overexpression downregulates ATM expression and sensitizes U87 cells to radiation in vitro and in vivo. MicroRNA-223 may be a novel cancer-targeting therapy, although its cancer- and patient-specific roles are currently undefined.
therapeutic target	hsa-mir-224	Neoplasms [unspecific]	26254100			C80.1	D009369			MicroRNA-224: as a potential target for miR-based therapy of cancer.
therapeutic target	hsa-mir-25	Neoplasms [unspecific]	25692889			C80.1	D009369			These preliminary findings warrant testing in a larger cohort of relapse patients to confirm whether the miRNA based predictor can select the optimal second line treatment and increase survival.
therapeutic target	hsa-mir-26a	Neoplasms [unspecific]	25395662			C80.1	D009369			These studies reveal a tumor suppressor role for miR-26 in intestinal cancer that overrides putative oncogenic activity, highlighting the therapeutic potential of miR-26 delivery to this tumor type.
therapeutic target	hsa-mir-26b	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-27b	Neoplasms [unspecific]	28351320			C80.1	D009369			Promising therapeutic role of miR-27b in tumor.
therapeutic target	hsa-mir-28	Neoplasms [unspecific]	26485640			C80.1	D009369			Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics.
therapeutic target	hsa-mir-296	Neoplasms [unspecific]	25577262			C80.1	D009369			miRNAs might provide new diagnostic markers and new therapeutic approaches by developing molecular miRNA-targeted therapies for the cure of parathyroid tumours, whose unique option is surgery.
therapeutic target	hsa-mir-29a	Neoplasms [unspecific]	25846459			C80.1	D009369			Our findings may provide new insight into the pathogenesis of the bone metabolism disorder in inflammation environment and provide promising therapeutic target.
therapeutic target	hsa-mir-30	Neoplasms [unspecific]	25810374			C80.1	D009369			These findings illuminate a novel mechanism for the modulation of premetastatic niches by miR-30s, which suggest that miR-30s represent not only promising targets for antimetastasis therapy but also indicators for metastasis.
therapeutic target	hsa-mir-300	Neoplasms [unspecific]	24885626			C80.1	D009369			Down-regulation of miR-300 is required for EMT initiation and maintenance. MiR-300 may negatively regulate EMT by direct targeting Twist and therefore inhibit cancer cell invasion and metastasis, which implicates miR-300 as an attractive candidate for cancer therapy.
therapeutic target	hsa-mir-30a	Neoplasms [unspecific]	28359057			C80.1	D009369			miR-30a may serve as a potential target in the diagnosis and therapy of human cancer
therapeutic target	hsa-mir-30e	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-31	Neoplasms [unspecific]	24771647			C80.1	D009369			Hsa-miR-31-3p seems to be a new mCRC biomarker whose expression level allows for the identification of patients with wild-type KRAS mCRC who are more likely to respond to anti-EGFR therapy.
therapeutic target	hsa-mir-3175	Neoplasms [unspecific]	26565624			C80.1	D009369			Our results suggest that HOXB1 functions as a tumor suppressor, regulated by miR-3175 in glioma. These results clarify the pathogenesis of glioma and offer a potential target for its treatment.
therapeutic target	hsa-mir-3189	Neoplasms [unspecific]	25698447			C80.1	D009369			our study identified miR-3189 as a novel, primate-specific miRNA whose effects are mediated by both p53-dependent and p53-independent mechanisms. miR-3189 may, therefore,represent a novel tool that can be utilized therapeutically to induce a potent proapoptotic effect even in p53-deficient tumors.
therapeutic target	hsa-mir-32	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-323	Neoplasms [unspecific]	26485640			C80.1	D009369			Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics.
therapeutic target	hsa-mir-323a	Neoplasms [unspecific]	25556445			C80.1	D009369			increased expression of miR-323-5p might be related to glioma progression, which indicates a potential role of miR-323-5p for clinical therapy.
therapeutic target	hsa-mir-34	Neoplasms [unspecific]	25892205			C80.1	D009369			pHLIP-mediated tumor targeting and anti-miR-155 PNA therapy was also effective in other tumor types, providing a bright perspective for future anti-miR conjugate medicines.
therapeutic target	hsa-mir-34	Neoplasms [unspecific]	24884974			C80.1	D009369			P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy.
therapeutic target	hsa-mir-34	Neoplasms [unspecific]	24657911			C80.1	D009369			we review the miR-34 family and their role in tumor biology, and discuss the potential therapeutic applications of miR-34a mimic.
therapeutic target	hsa-mir-34	Neoplasms [unspecific]	28209991			C80.1	D009369			MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
therapeutic target	hsa-mir-34a	Neoplasms [unspecific]	25032850			C80.1	D009369			MicroRNA-34a: a potential therapeutic target in human cancer.
therapeutic target	hsa-mir-34a	Neoplasms [unspecific]	25585539			C80.1	D009369			miR-34a regulates the expression of a number of critical proteins involved in apoptosis, proliferation and the response to chemotherapy. In summary, miR-34a increases the sensitivity of colon  cancer cells to 5-FU treatment through specific regulation of the SIRT1/p53 pathway.
therapeutic target	hsa-mir-34a	Neoplasms [unspecific]	26454548			C80.1	D009369			Overall,CS-PEI is potentially employed as a promising tumor-targeting system for miR-34a delivery in tumor gene therapy.
therapeutic target	hsa-mir-34a	Neoplasms [unspecific]	26580663			C80.1	D009369			microRNA-34a as a Therapeutic Agent against Human Cancer.
therapeutic target	hsa-mir-34a	Neoplasms [unspecific]	20883704			C80.1	D009369			This circuitry mechanism for p53 activation is of interest in understanding the tumor suppressive function of miR-34a in colon carcinogenesis. miRNA should also be considered as novel anti-cancer agents in tumor suppressive therapeutic applications.
therapeutic target	hsa-mir-34a	Neoplasms [unspecific]	28010900			C80.1	D009369			Emergence of miR-34a in radiation therapy.
therapeutic target	hsa-mir-34a	Neoplasms [unspecific]	29602831			C80.1	D009369			This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics
therapeutic target	hsa-mir-3656	Neoplasms [unspecific]	29435930			C80.1	D009369			Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729)
therapeutic target	hsa-mir-4466	Neoplasms [unspecific]	29435930			C80.1	D009369			Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729)
therapeutic target	hsa-mir-449a	Neoplasms [unspecific]	29023247			C80.1	D009369			miR-449a: a potential therapeutic agent for cancer.
therapeutic target	hsa-mir-450a	Neoplasms [unspecific]	24307696			C80.1	D009369			The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors.
therapeutic target	hsa-mir-451	Neoplasms [unspecific]	23814177			C80.1	D009369			The potential role of miR-451 in cancer diagnosis, prognosis, and therapy.
therapeutic target	hsa-mir-495	Neoplasms [unspecific]	27697751			C80.1	D009369			MiR-495 functions as an adjuvant to radiation therapy by reducing the radiation-induced bystander effect.
therapeutic target	hsa-mir-497	Neoplasms [unspecific]	26345385			C80.1	D009369			In summary, miR-497 inhibits tumor angiogenesis and growth via targeting VEGFR2, indicating miR-497 can be explored as a potential drug candidate for cancer therapy.
therapeutic target	hsa-mir-497	Neoplasms [unspecific]	24446485			C80.1	D009369			The results suggest that miRNA expression profiles can distinguish different subtypes of ACA, which may contribute to a deeper understanding of ACA development and potential therapeutics.
therapeutic target	hsa-mir-507	Neoplasms [unspecific]	24307696			C80.1	D009369			The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors.
therapeutic target	hsa-mir-510	Neoplasms [unspecific]	26485640			C80.1	D009369			Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics.
therapeutic target	hsa-mir-519d	Neoplasms [unspecific]	25404641			C80.1	D009369			resistin promotes chondrosarcoma metastasis and MMP-2 expression through activation of the AMPK/p38 signaling pathway and down-regulation of miR-519d expression. Therefore, resistin may represent a potential novel molecular therapeutic target in chondrosarcoma metastasis.
therapeutic target	hsa-mir-519e	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-520d	Neoplasms [unspecific]	25303886			C80.1	D009369			In vitro data indicate the potent usefulness of this small molecule as a therapeutic biomaterial in normal cells and cancer cells because CD105+ cells never converted to iPSCs despite repeated transfections and all types of transfectants lost their tumorigenicity. This maintenance of a benign state following miR-520d-5p transfection appears to be caused by p53 upregulation. We conclude that miR-520d-5p may be a useful biomaterial at an in vitro level.
therapeutic target	hsa-mir-532	Neoplasms [unspecific]	25766316			C80.1	D009369			the development of new therapeutic strategies based on caspase recruitment domain (ARC) and miR-532-3p is promising for overcoming the cardiotoxicity of chemotherapy for cancer therapy.
therapeutic target	hsa-mir-542	Neoplasms [unspecific]	24762395			C80.1	D009369			Our results define miR-542-3p as an important new positive regulator of p53 with potential applications in cancer treatment.
therapeutic target	hsa-mir-542	Neoplasms [unspecific]	26203762			C80.1	D009369			Our novel framework impartially identifies therapeutically relevant miRNA candidates from transcriptomic data sets.
therapeutic target	hsa-mir-542	Neoplasms [unspecific]	26272182			C80.1	D009369			Together, these findings reveal a novel regulatory pathway whereby tumor-derived angiogenin directly activates angiogenesis through inhibition of miR-542-3p, suggesting that angiogenin may represent a promising target for anti-angiogenic therapy and a potential marker for monitoring disease progression.
therapeutic target	hsa-mir-552	Neoplasms [unspecific]	26485640			C80.1	D009369			Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics.
therapeutic target	hsa-mir-590	Neoplasms [unspecific]	26052692			C80.1	D009369			We believe that analyzing the cooperative mechanism of the miRNAs in modules rather than focusing on only single miRNAs may help us know more about the complicated relationship between miRNAs and cancers and develop more effective treatment strategies for cancers.
therapeutic target	hsa-mir-608	Neoplasms [unspecific]	26485640			C80.1	D009369			Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics.
therapeutic target	hsa-mir-624	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-629	Neoplasms [unspecific]	26052692			C80.1	D009369			We believe that analyzing the cooperative mechanism of the miRNAs in modules rather than focusing on only single miRNAs may help us know more about the complicated relationship between miRNAs and cancers and develop more effective treatment strategies for cancers.
therapeutic target	hsa-mir-634	Neoplasms [unspecific]	26216549			C80.1	D009369			Our findings illustrate how reversing miR-634-mediated cytoprotective processes may offer a broadly useful approach to improving cancer therapy.
therapeutic target	hsa-mir-634	Neoplasms [unspecific]	24307696			C80.1	D009369			The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors.
therapeutic target	hsa-mir-6729	Neoplasms [unspecific]	29435930			C80.1	D009369			Quantum Language of MicroRNA: Application for New Cancer Therapeutic Targets(the top 5 of high DNS were in rmiRNAs, rmiR-4466 in 5′ETS, rmiR-3656 in 28S, rmiR-1268a and rmiR-1268b in 3′ETS, and rmiR-6729)
therapeutic target	hsa-mir-7	Neoplasms [unspecific]	24907395			C80.1	D009369			microRNA-7: a tumor suppressor miRNA with therapeutic potential.
therapeutic target	hsa-mir-7	Neoplasms [unspecific]	25434362			C80.1	D009369			With the increasing understanding of molecular mechanisms of miR-7-mediated regulatory networks and the advancement of miRNA-based therapeutics, targeting miR-7 may be a potential and promising strategy for cancer therapy.
therapeutic target	hsa-mir-885	Neoplasms [unspecific]	26554827			C80.1	D009369			Our work shows how DNp73 promotes cancer stem-like features and provides a mechanistic rationale to target the DNp73-IGF1R cascade as a therapeutic strategy to eradicate CSC.
therapeutic target	hsa-mir-9	Neoplasms [unspecific]	25571061			C80.1	D009369			miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.
therapeutic target	hsa-mir-9	Neoplasms [unspecific]	25596753			C80.1	D009369			Aberrantly expressed miR-9 contributes to T24 cells invasion, partly through directly down-regulating CBX7 protein expression in TCC. This miRNA signature offers a new potential therapeutic target for TCC.
therapeutic target	hsa-mir-92-1	Neoplasms [unspecific]	26256260			C80.1	D009369			Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
therapeutic target	hsa-mir-92a-1	Neoplasms [unspecific]	23239404			C80.1	D009369			Development of miR-92a delivery system for antiangiogenesis-based cancer therapy
therapeutic target	hsa-mir-92a-2	Neoplasms [unspecific]	23239404			C80.1	D009369			Development of miR-92a delivery system for antiangiogenesis-based cancer therapy
therapeutic target	hsa-mir-93	Neoplasms [unspecific]	25692889			C80.1	D009369			These preliminary findings warrant testing in a larger cohort of relapse patients to confirm whether the miRNA based predictor can select the optimal second line treatment and increase survival.
therapeutic target	hsa-mir-487b	Nervous System Diseases [unspecific]	25660232			C72.9	D009422			These results demonstrate that miR-487b regulates angiogenesis by directly targeting THBS1 in HUVECs, indicating that miR-487b may contribute to angiogenesis and the functional recovery from ischemic stroke. miR-487b could represent a potential therapeutic option for neurovascular disease.
therapeutic target	hsa-mir-210	Neurilemmoma	28440459	disease of cellular proliferation	DOID:3192	D36.10	D009442			miR-210 could be a potential marker for judging tumor malignancy and be taken as an effective target for clinical auxiliary treatment of neurilemmoma
therapeutic target	hsa-mir-200a	Neuroblastoma	24969902	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Our study revealed that miR-200a is a candidate tumor suppressor in neuroblastoma, through direct targeting of AP-2γ. These findings re-enforce the proposal of AP-2γ as a therapeutic target in neuroblastoma.
therapeutic target	hsa-mir-34a	Neuroblastoma	24912852	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	proteome analysis has here identified early targets of miR-34a with relevance to NBL tumorigenesis. Along with the results of previous studies, our data strongly suggest miR-34a as a useful tool for improving the chance of therapeutic success with NBL.
therapeutic target	hsa-mir-34a	Neuroblastoma	19199973	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	MiR-17-5p-92 family members act in an oncogenic manner while miR-34a has tumor suppressor functions. The evidence for the contribution of miRNAs in the aggressive neuroblastoma phenotype is reviewed in this article, along with exciting possibilities for miRNA mediated therapeutics.
therapeutic target	hsa-mir-542	Neuroblastoma	25046253	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-542-3p exerts its tumor suppressive function in neuroblastoma, at least in part, by targeting Survivin. Expression of miR-542-3p could be a promising therapeutic strategy for treating aggressive neuroblastoma.
therapeutic target	hsa-mir-302	Neurodegenerative Diseases [unspecific]	26414965				D019636		HP:0002180	The combination of the proved pluripotency-inducing miRNA-302/367 cluster and cell-specific miRNAs provides a unique strategy for one-step cellular conversion that could have important implications for studies of neuron development and neurological disease therapy.
therapeutic target	hsa-mir-367	Neurodegenerative Diseases [unspecific]	26414965				D019636		HP:0002180	The combination of the proved pluripotency-inducing miRNA-302/367 cluster and cell-specific miRNAs provides a unique strategy for one-step cellular conversion that could have important implications for studies of neuron development and neurological disease therapy.
therapeutic target	hsa-mir-23b	Neuropathic Pain	23152062				D009437			We finally suggest that infusion of miR23b and NOX4 antibody may provide attractive diagnostic and therapeutic resources for effective pain modulation in neuropathic pain.
therapeutic target	hsa-mir-126	Obesity	26122028	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	These results indicate that obesity impacts on EV pro-angiogenic potential and may raise concerns about the use of adipose tissue-derived EVs in cell-based therapy in the obese setting.
therapeutic target	hsa-mir-143	Obesity	27623943	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment.
therapeutic target	hsa-mir-1908	Obesity	26349979	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our findings demonstrated that miR-1908 has its own transcription unit, and revealed the transcriptional mechanisms of miR-1908 expression based on NF-kappaB signaling. This study offers a theoretical basis for understanding the transcriptional mechanism of miR-1908 expression and may provide a new strategy for obesity clinical therapy.
therapeutic target	hsa-mir-200a	Obesity	24394757	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	These findings link the alteration of leptin and insulin signaling to the up-regulation of hypothalamic miR-200a which could be a new target for treatment of obesity.
therapeutic target	hsa-mir-223	Obesity	25842981	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	The findings in this study suggest that miR-223 is a factor of obesity. The level of miR-223 in the serum can be used as a biomarker of obesity and therapeutic response.
therapeutic target	hsa-mir-101	Osteoarthritis	24018042	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	non-coding RNAs could be a potent predictive biomarker for OA as well as a therapeutic target for preventing cartilage-related diseases.
therapeutic target	hsa-mir-130a	Osteoarthritis	26045761	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Our results indicated that miR-130a played an important role in regulating the expression of TNF-α in human chondrocytes and identified miR-130a as a novel therapeutic target in OA.
therapeutic target	hsa-mir-139	Osteoarthritis	26450708	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	These results support our hypothesis that miR-139-mediated downregulation of MCPIP1 promotes IL-6 expression in OA. Therefore, targeting miR-139 could be therapeutically beneficial in the management of OA.
therapeutic target	hsa-mir-140	Osteoarthritis	26608362	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-29a and miR-140 combination treatment may be a possible treatment for OA
therapeutic target	hsa-mir-146a	Osteoarthritis	21397669	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-146a controls knee joint homeostasis and OA associated algesia by balancing inflammatory responses in cartilage and synovium with pain-related factors in glial cells. Hence, miR-146a may be useful for the treatment of both cartilage regeneration and pain symptoms caused by OA (osteoarthritis).
therapeutic target	hsa-mir-335	Osteoarthritis	24582835	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Given that miR-335 has the different genes involved in the Wnt signalling pathway as potential targets, the observed trend may help to ascertain, at least partially, some of the alterations which determine the onset or progression of osteoarthritis, and can therefore serve for the design of future therapeutic targets for the treatment of this disease.
therapeutic target	hsa-mir-150	Osteoporosis	26212040	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-150 may have potential therapeutic applications in promoting bone formation in certain disease settings, such as in osteoporosis and in elderly patients.
therapeutic target	hsa-mir-216a	Osteoporosis	26206089	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	our findings suggest that miR-216a may serve as a novel therapeutic agent for the prevention and treatment of osteoporosis and other bone metabolism-related diseases.
therapeutic target	hsa-mir-320a	Osteoporosis	26555194	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	We identified two osteoblast miRNAs over-expressed in osteoporotic fractures, which opens novel prospects for research and therapy.
therapeutic target	hsa-mir-483	Osteoporosis	26555194	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	We identified two osteoblast miRNAs over-expressed in osteoporotic fractures, which opens novel prospects for research and therapy.
therapeutic target	hsa-mir-101	Osteosarcoma	25480586	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-101 may act as a tumor suppressor, which is commonly downregulated in both osteosarcoma tissues and cells. mTOR plays an important role in mediating miR-101 dependent biological functions in osteosarcoma. Reintroduction of miR-101 may be a novel therapeutic strategy by down-regulating  mTOR expression.
therapeutic target	hsa-mir-127	Osteosarcoma	26707641	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Overall, the results revealed that miR-127-3p acts as a tumor suppressor and that its down-regulation in cancer may contribute to OS progression and metastasis, suggesting that miR-127-3p could be a potential therapeutic target in the treatment of OS.
therapeutic target	hsa-mir-129	Osteosarcoma	25566966	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	increased miR-129-5p may be mediated by demethylation and inhibit OS cell migration and invasion by targeting VCP in OS, and targeting miR-129-5p/VCP signaling pathway may serve as a therapeutic strategy for OS management, although further studies will be necessary.
therapeutic target	hsa-mir-133a	Osteosarcoma	24715690	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells.
therapeutic target	hsa-mir-134	Osteosarcoma	26681023	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These findings indicate that miR-134 may act as a tumor suppressor in osteosarcoma and could serve as a novel therapeutic agent for miRNA-based therapy.
therapeutic target	hsa-mir-142	Osteosarcoma	25530132	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	overexpression of miR-142 and/or knockdown of Rac1 would be a novel target for OS therapy in the future.
therapeutic target	hsa-mir-146b	Osteosarcoma	26549292	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. It also increased resistance to chemotherapy through the regulation of ZNRF3, and suggested novel potential therapeutic targets for the treatment of osteosarcoma.
therapeutic target	hsa-mir-150	Osteosarcoma	26361218	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, miR-150 inhibits cell proliferation, invasion, and metastasis and stimulates cell apoptosis by regulating the expression of Sp1. Therefore, miR-150 may be a potential clinical target for the treatment of OS patients.
therapeutic target	hsa-mir-182	Osteosarcoma	25973950	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Down-expression of miR-182 in osteosarcoma promoted tumor growth,migration and invasion by targeting TIAM1. MiR-182 might act as a tumor suppressor gene whose down-regulation contributes to the progression and metastasis of osteosarcoma, providing a potential therapy target for osteosarcoma patients.
therapeutic target	hsa-mir-195	Osteosarcoma	25498513	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Decreased expression of miR-195 in serum may be a novel biomarker for screening osteosarcoma and can predict poor prognosis. Detection of serum miR-195 expression may have potential applications for the diagnosis, prognosis,  and treatment of osteosarcoma.
therapeutic target	hsa-mir-203	Osteosarcoma	26584294	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, these findings suggest that miR-203 acts as a tumor suppressor via regulation of TBK1 expression in OS progression, and miR-203 may be a promising therapeutic target for OS.
therapeutic target	hsa-mir-205	Osteosarcoma	25784290	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This is the first study to identify plasma miRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients.
therapeutic target	hsa-mir-214	Osteosarcoma	25784290	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This is the first study to identify plasma miRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients.
therapeutic target	hsa-mir-217	Osteosarcoma	25960216	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These findings indicate that miR-217 may act as a tumor suppressor in osteosarcoma and would serve as a novel therapeutic agent for miRNA-based therapy.
therapeutic target	hsa-mir-335	Osteosarcoma	25784290	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This is the first study to identify plasma miRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients.
therapeutic target	hsa-mir-34a	Osteosarcoma	26518752	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
therapeutic target	hsa-mir-374a	Osteosarcoma	26617789	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our study suggested that miR-374a functions as an oncogene in OS, and the miR-374a/Axin2 axis might represent a potential therapeutic target for OS intervention.
therapeutic target	hsa-mir-429	Osteosarcoma	24633485	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, miR-429 serves as a tumor suppressor via interaction with ZEB1. Our finding may provide a new target for osteosarcoma therapy.
therapeutic target	hsa-mir-451	Osteosarcoma	25471786	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-451 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of osteosarcoma.
therapeutic target	hsa-mir-454	Osteosarcoma	25880599	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Reduced-expression of miR-454 in osteosarcoma cells promoted tumour growth by targeting c-Met, thus miR-454 may be a potential therapy target for this tumour.
therapeutic target	hsa-mir-490	Osteosarcoma	26341146	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Taken together, our results suggest that miR-490-3p functions as a potential tumor suppressor by down-regulating HMGA2 expression directly, and it may represent a potential therapeutic target for patients with osteosarcoma.
therapeutic target	hsa-mir-503	Osteosarcoma	25536034	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-503 in osteosarcoma pathogenesis, indicating its potential application in cancer therapy.
therapeutic target	hsa-mir-539	Osteosarcoma	26339374	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	These findings provide evidence that miR-539 plays a key role in inhibiting osteosarcoma cell invasion and migration and can regulating MMP8 expression in osteosarcoma cells. These strongly suggest that exogenous miR-539 may have therapeutic value in treating osteosarcoma.
therapeutic target	hsa-mir-574	Osteosarcoma	25784290	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	This is the first study to identify plasma miRNAs that could be used to prospectively identify disease, potentially monitor therapeutic efficacy and have prognostic implications for OS patients.
therapeutic target	hsa-mir-9	Osteosarcoma	25592968	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	the high dose of E2 treatment upregulated miR-9 thus posttranscriptionally regulated MALAT-1 RNA level in OS cells, and then the downregulation of MALAT-1 inhibited cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) processes in the E2-dose dependent and ER-independent ways. miR-143
therapeutic target	hsa-mir-93	Osteosarcoma	26243299	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Ectopic expression of miR-93 decreased PTEN protein levels.Furthermore, miR-93 increased proliferation and decreased apoptosis in OS cells, whereas its silencing in these cells inhibited such carcinogenic processes.Taking these observations together, miR-93 can be seen to play a critical role in carcinogenesis through suppression of PTEN, and may serve as a therapeutic target for the treatment of OS.
therapeutic target	hsa-let-7i	Ovarian Neoplasms	19074899	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	let-7i: a novel biomarker and therapeutic target
therapeutic target	hsa-mir-1	Ovarian Neoplasms	26247403	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	LAPTM4B-miRNA-transfected NIH:OVCAR3 cells exhibited significant decreases in cell motility and invasion.
therapeutic target	hsa-mir-128	Ovarian Neoplasms	25248111	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Taken together, our findings suggest that miR-128 may act as a promising therapeutic target for improvement of tumor sensitivity to cisplatin.
therapeutic target	hsa-mir-141	Ovarian Neoplasms	25872328	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The present results suggest that miR-141-3p might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to  predict chemotherapy response.
therapeutic target	hsa-mir-143	Ovarian Neoplasms	25485872	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Viral miRNAs can be useful to develop biomarkers for early diagnosis and as a potential therapeutic tool to reduce SEOC lethality.
therapeutic target	hsa-mir-16	Ovarian Neoplasms	26393886	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC.
therapeutic target	hsa-mir-16	Ovarian Neoplasms	19903841	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These findings suggest the development of therapeutic strategies by restoring miR-15a and miR-16 expression in ovarian cancer and in other cancers that involve upregulation of Bmi-1.
therapeutic target	hsa-mir-17	Ovarian Neoplasms	25510663	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	mature miR-17 expression may have an important role in the pathogenesis of human ovarian tumors through its interference with the LKB1-p53-p21/WAF1 pathway expression by epigenetic modification. These findings are of potential importance in the identification of novel therapeutic targets in human ovarian cancer.
therapeutic target	hsa-mir-182	Ovarian Neoplasms	26393886	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC.
therapeutic target	hsa-mir-184	Ovarian Neoplasms	26601424	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Altogether, our results suggest that miR-184 together with pathologic diagnosis is critical for prognosis determination in EOC patients and help select treatment strategy.
therapeutic target	hsa-mir-193a	Ovarian Neoplasms	25545504	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	a simultaneous EZH2 inhibition and anti-estrogen therapy can constitute an effective combine therapeutic strategy against ovarian cancer.
therapeutic target	hsa-mir-200	Ovarian Neoplasms	24952258	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
therapeutic target	hsa-mir-200c	Ovarian Neoplasms	26260454	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These data suggested that miR-200c and miR-31 may play roles in the SEOC metastasis biology and could be considered as promising targets for therapeutic purposes.
therapeutic target	hsa-mir-205	Ovarian Neoplasms	26275944	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-205, acting as an oncogenic miRNA, may promote the clinical progression of EOC patients and enhance the cellular motility in vitro by directly and negatively regulating ZEB1, providing a potential therapeutic strategy for suppression of EOC metastasis.
therapeutic target	hsa-mir-21	Ovarian Neoplasms	24472409	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data suggest that miR-21 regulates drug resistance via apoptosis and cellular survival pathways. Targeting miR-21 may have clinical utility in the treatment of resistant ovarian cancer.
therapeutic target	hsa-mir-214	Ovarian Neoplasms	24822185	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Application of microRNA in diagnosis and treatment of ovarian cancer.
therapeutic target	hsa-mir-25	Ovarian Neoplasms	26393886	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC.
therapeutic target	hsa-mir-29b	Ovarian Neoplasms	24662327	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Id-1, a protein repressed by miR-29b, facilitates TGFβ1-induced EMT in human ovarian cancer cells and represents a promising therapeutic target for treating ovarian cancer.
therapeutic target	hsa-mir-29b	Ovarian Neoplasms	26512921	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Taken together, our study suggests that miR-29b regulates the Warburg effect in EOC via AKT2/AKT3 and may provide novel options for future treatments for EOC.
therapeutic target	hsa-mir-30d	Ovarian Neoplasms	26501435	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our results revealed that miR-30d functioned as a suppressor of ovarian cancer progression by decreasing Snail expression and thus blocking TGF-β1-induced EMT process, suggesting the potentiality of miR-30d analogs to be used as therapeutics for ovarian cancer. 
therapeutic target	hsa-mir-31	Ovarian Neoplasms	24822185	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Application of microRNA in diagnosis and treatment of ovarian cancer.
therapeutic target	hsa-mir-31	Ovarian Neoplasms	26260454	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These data suggested that miR-200c and miR-31 may play roles in the SEOC metastasis biology and could be considered as promising targets for therapeutic purposes.
therapeutic target	hsa-mir-373	Ovarian Neoplasms	25460499	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-373 suppresses EOC invasion and metastasis by directly targeting Rab22a gene, a new potential therapeutic target in EOC.
therapeutic target	hsa-mir-376a	Ovarian Neoplasms	26393886	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC.
therapeutic target	hsa-mir-378	Ovarian Neoplasms	24680769	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data suggest that miR-378 is overexpressed in ovarian cancer cells and tumors vs. normal ovarian epithelial cells. MiR-378 and its downstream targets may serve as markers for response to anti-angiogenic therapy.
therapeutic target	hsa-mir-429	Ovarian Neoplasms	26393886	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC.
therapeutic target	hsa-mir-451	Ovarian Neoplasms	26390704	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-451 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of EOC.
therapeutic target	hsa-mir-506	Ovarian Neoplasms	25995442	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MiR-506 is a robust clinical marker for chemotherapy response and survival in serous ovarian cancers and has important therapeutic value in sensitizing cancer cells to chemotherapy.
therapeutic target	hsa-mir-509	Ovarian Neoplasms	26786897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data suggest that restoring certain dysregulated miRNAs to their normal levels could increase the therapeutic effects of anticancer drugs.
therapeutic target	hsa-mir-548c	Ovarian Neoplasms	26762267	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These findings suggest that miR-548c directly downregulates Twist,and provide a novel mechanism for Twist upregulation in both endometrial and ovarian cancers. The use of miR-548c may hold therapeutic potential for the treatment of Twist-overexpressing tumors.
therapeutic target	hsa-mir-634	Ovarian Neoplasms	26576679	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-634 levels determine chemosensitivity in ovarian cancer cells. We identify miR-634 as a therapeutic candidate to resensitize chemotherapy resistant ovarian tumors.
therapeutic target	hsa-mir-7	Ovarian Neoplasms	26393886	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC.
therapeutic target	hsa-mir-708	Ovarian Neoplasms	25569036	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	glucocorticoids and their downstream mediators, miR-708 or Rap1B, as therapeutic modalities against metastatic ovarian epithelial cancer.
therapeutic target	hsa-mir-93	Ovarian Neoplasms	26393886	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our data indicate the diagnostic potential of miR-7, miR-25, miR-93 and miR-429 in EOC and the prognostic potential of miR-429. This microRNA panel may be promising molecules to be targeted in the treatment of EOC.
therapeutic target	hsa-mir-103a-1	Pain	21804529			R52	D010146			knocking-down or over-expressing miR-103, respectively, up- or down-regulate the level of Cav1.2-LTC translation.miR-103 knockdown in naive rats results in hypersensitivity to pain. Moreover, we demonstrate that miR-103 is down-regulated in neuropathic animals and that miR-103 intrathecal applications successfully relieve pain, identifying miR-103 as a novel possible therapeutic target in neuropathic chronic pain.
therapeutic target	hsa-mir-103a-2	Pain	21804529			R52	D010146			knocking-down or over-expressing miR-103, respectively, up- or down-regulate the level of Cav1.2-LTC translation.miR-103 knockdown in naive rats results in hypersensitivity to pain. Moreover, we demonstrate that miR-103 is down-regulated in neuropathic animals and that miR-103 intrathecal applications successfully relieve pain, identifying miR-103 as a novel possible therapeutic target in neuropathic chronic pain.
therapeutic target	hsa-mir-126	Pancreatic Adenocarcinoma	29200874	disease of cellular proliferation	DOID:4074	C25.3				The therapeutic system co-expressing miR-126 and miR-34a mediated by oncolytic adenovirus is a promising system for PAC target therapy
therapeutic target	hsa-mir-34a	Pancreatic Adenocarcinoma	29200874	disease of cellular proliferation	DOID:4074	C25.3				The therapeutic system co-expressing miR-126 and miR-34a mediated by oncolytic adenovirus is a promising system for PAC target therapy
therapeutic target	hsa-let-7b	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-100	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-101	Pancreatic Neoplasms	25841339	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Two independent microRNA backgrounds showed promise in therapeutic intervention of gemcitabine sensitive, MIA PaCa-2 and resistant, PANC-1 pancreatic cancer cells, in combination with dietary agents and drug.
therapeutic target	hsa-mir-1261	Pancreatic Neoplasms	25722110	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance.
therapeutic target	hsa-mir-1273	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-138	Pancreatic Neoplasms	25875420	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our data indicate that miR-138-5p may play an important role in regulating pancreatic cancer cell growth, possibly through targeting FOXC1.Over-expression of miR-138-5p may serve as a novel approach for the treatment of patients with pancreatic cancer.
therapeutic target	hsa-mir-141	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-145	Pancreatic Neoplasms	27507554	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-145 re-expression resulted in downregulation of MUC13, HER2, pAKT, and inhibition of cell proliferation, clonogenicity, migration, and invasion of pancreatic cancer cells.
therapeutic target	hsa-mir-146b	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-150	Pancreatic Neoplasms	24971005	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy.
therapeutic target	hsa-mir-150	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-195	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-200c	Pancreatic Neoplasms	26261532	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our study demonstrated that miR-200c overexpression could decrease colony formation, invasion and chemoresistance of PCSCs. It may become a new therapeutic target for gene therapy in patients suffered from pancreatic cancer.
therapeutic target	hsa-mir-200c	Pancreatic Neoplasms	26493507	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of miR-200c may be an important prognosis factor in pancreatic cancer, and it could be a novel therapeutic target of pancreatic cancer.
therapeutic target	hsa-mir-205	Pancreatic Neoplasms	24836307	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
therapeutic target	hsa-mir-205	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-21	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-21	Pancreatic Neoplasms	28444967	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
therapeutic target	hsa-mir-215	Pancreatic Neoplasms	26662405	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These findings indicate that miR-215 may act as a tumor suppressor in pancreatic cancer cells, and could serve as a novel therapeutic target for miR-based therapy.
therapeutic target	hsa-mir-216	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-217	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-223	Pancreatic Neoplasms	25638153	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		down-regulation of miR-223 could be a novel therapy for pancreatic cancer.
therapeutic target	hsa-mir-223	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-24-2	Pancreatic Neoplasms	25841339	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Two independent microRNA backgrounds showed promise in therapeutic intervention of gemcitabine sensitive, MIA PaCa-2 and resistant, PANC-1 pancreatic cancer cells, in combination with dietary agents and drug.
therapeutic target	hsa-mir-26a	Pancreatic Neoplasms	24116110	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-26a is an important suppressor of pancreatic ductal carcinoma, and can prove to be a novel prognostic factor and therapeutic target for pancreatic cancer treatment.
therapeutic target	hsa-mir-26b	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-27a	Pancreatic Neoplasms	20638779	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		This suggests the potential for miR-27a to be used as a target in the diagnosis and treatment of pancreatic adenocarcinoma.
therapeutic target	hsa-mir-29a	Pancreatic Neoplasms	26356262	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our results suggest that miR-29a acts as an oncogene by down regulating TTP and provide the basis for further studies exploring the potential of miR-29a and TTP as biomarkers and targets for the treatment of pancreatic cancer.
therapeutic target	hsa-mir-320c	Pancreatic Neoplasms	23799850	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The results indicate that miR-320c regulates the resistance of pancreatic cancer cells to gemcitabine through SMARCC1, suggesting that miR-320c/SMARCC1 could be suitable for prediction of the clinical response and potential therapeutic target in pancreatic cancer patients on gemcitabine-based therapy.
therapeutic target	hsa-mir-345	Pancreatic Neoplasms	26247574	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-345 downregulation confers apoptosis resistance to PC cells, and its restoration could be exploited for therapeutic benefit.
therapeutic target	hsa-mir-345	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-34a	Pancreatic Neoplasms	21909380	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-34a is a critical regulator of pancreatic cancer progression by the regulating CSC characteristics. The restoration of its expression by 5-Aza-dC and SAHA in CSCs will not only provide mechanistic insight and therapeutic targets for pancreatic cancer but also promising reagents to boost patient response to existing chemotherapies or as a standalone cancer drug by eliminating the CSC characteristics.
therapeutic target	hsa-mir-34c	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-3676	Pancreatic Neoplasms	25722110	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance.
therapeutic target	hsa-mir-4455	Pancreatic Neoplasms	25722110	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance.
therapeutic target	hsa-mir-4644	Pancreatic Neoplasms	25722110	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance.
therapeutic target	hsa-mir-4650	Pancreatic Neoplasms	25722110	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance.
therapeutic target	hsa-mir-483	Pancreatic Neoplasms	26516699	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
therapeutic target	hsa-mir-643	Pancreatic Neoplasms	25722110	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		these data may be useful for the detection and treatment of drug resistance in pancreatic cancer patients, and the microRNA-mRNA network-based analysis is expected to be more effective and provides deep insights into the molecular mechanism of drug resistance.
therapeutic target	hsa-mir-663	Pancreatic Neoplasms	25744894	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-663 attenuated the proliferation and invasion of pancreatic cells both in vitro and in vivo by directly targeting eEF1A2. miR-663 and eEF1A2 might be potential targets for the treatment of pancreatic cancer in the future.
therapeutic target	hsa-mir-744	Pancreatic Neoplasms	26485754	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These findings suggest that miR-744 plays a vital role in promoting the stem cell-like phenotype of pancreatic cancer cells, and may represent a novel prognostic biomarker and therapeutic target.
therapeutic target	hsa-mir-96	Pancreatic Neoplasms	25071021	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-96 acts as a tumor suppressor in pancreatic cancer and may therefore serve as a useful therapeutic target for the development of new anticancer therapy.
therapeutic target	hsa-mir-129	Parkinson Disease	25465742	nervous system disease	DOID:14330	G20	D010300	PS168600		miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease.
therapeutic target	hsa-mir-132	Parkinson Disease	25465742	nervous system disease	DOID:14330	G20	D010300	PS168600		miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease.
therapeutic target	hsa-mir-221	Parkinson Disease	29405726	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-221 may serve as a potential therapeutic target for Parkinson's disease treatment
therapeutic target	hsa-mir-7	Parkinson Disease	25465742	nervous system disease	DOID:14330	G20	D010300	PS168600		miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease.
therapeutic target	hsa-mir-7-1	Parkinson Disease	19628698	nervous system disease	DOID:14330	G20	D010300	PS168600		expression decreases; miR-7 down-regulates of alpha-expression decreases synuclein, protects cells against oxidative stress
therapeutic target	hsa-mir-7-2	Parkinson Disease	19628698	nervous system disease	DOID:14330	G20	D010300	PS168600		expression decreases; miR-7 down-regulates of alpha-expression decreases synuclein, protects cells against oxidative stress
therapeutic target	hsa-mir-7-3	Parkinson Disease	19628698	nervous system disease	DOID:14330	G20	D010300	PS168600		expression decreases; miR-7 down-regulates of alpha-expression decreases synuclein, protects cells against oxidative stress
therapeutic target	hsa-mir-9	Parkinson Disease	25465742	nervous system disease	DOID:14330	G20	D010300	PS168600		miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes in patients with Parkinson's disease.
therapeutic target	hsa-mir-30d	Pelvic Organ Prolapse	25630974				D056887	176780		both miR-30d and 181a are important posttranscriptional regulators of HOXA11 in the USLs and could be a potential therapeutic target for POP.
therapeutic target	hsa-mir-138	Periodontal Diseases	26518300	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	Our data establish miR-138 inhibitor as a potential therapeutic agent for the prevention of the bone loss associated with advanced periodontal disease.
therapeutic target	hsa-mir-223	Periodontal Diseases	27552373	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	Knowledge gained from future studies will be beneficial in developing alternative therapeutic approaches, especially ones that use miRNA delivery systems to treat periodontal disease
therapeutic target	hsa-mir-200b	Periodontitis	25630869	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Functional studies to explore the role of miR-200b in the above processes may offer new insights on putative therapeutic targets for this group of patients.
therapeutic target	hsa-mir-142	Peritoneal Fibrosis	26616819				D056627			These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF.
therapeutic target	hsa-mir-21	Peritoneal Fibrosis	26616819				D056627			These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF.
therapeutic target	hsa-mir-221	Peritoneal Fibrosis	26616819				D056627			These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF.
therapeutic target	hsa-mir-223	Peritoneal Fibrosis	26616819				D056627			These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF.
therapeutic target	hsa-mir-34a	Peritoneal Fibrosis	26616819				D056627			These results suggest that several miRNAs are involved in PF and that they may be useful as novel diagnostic biomarkers and therapeutic targets for PF.
therapeutic target	hsa-mir-300	Pituitary Neoplasms	26320179	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment.
therapeutic target	hsa-mir-329	Pituitary Neoplasms	26320179	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment.
therapeutic target	hsa-mir-381	Pituitary Neoplasms	26320179	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment.
therapeutic target	hsa-mir-655	Pituitary Neoplasms	26320179	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Together, these findings suggest that these PTTG1-targeting miRNAs are important players in the regulation of pituitary tumorigenesis and that these miRNAs may serve as valuable therapeutic targets for cancer treatment.
therapeutic target	hsa-mir-126	Pleural Mesothelioma	26504055	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In MPM, DNA-hypermethylation down-regulates miR-126 and its host gene EGFL7, therefore is a poor prognostic factor, and may represent a future therapeutic target for de-methylating strategies re-establishing EGFL7 and miR-126 expression.
therapeutic target	hsa-mir-15	Pleural Mesothelioma	26075427	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	this proof-of-concept case illustrates the promise of this novel strategy using targeted EDV nanocells to restore the expression of down-regulated miRs in MPM. Such an approach, if supported by further evaluation, has the potential for a paradigm shift in the management of treatment-resistant tumors such as MPM. We are eagerly awaiting the determination of the maximum tolerated dose of TargomiRs and commencement of subsequent phase 2 studies to confirm the efficacy of this novel therapeutic approach.
therapeutic target	hsa-mir-16	Pleural Mesothelioma	26075427	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	this proof-of-concept case illustrates the promise of this novel strategy using targeted EDV nanocells to restore the expression of down-regulated miRs in MPM. Such an approach, if supported by further evaluation, has the potential for a paradigm shift in the management of treatment-resistant tumors such as MPM. We are eagerly awaiting the determination of the maximum tolerated dose of TargomiRs and commencement of subsequent phase 2 studies to confirm the efficacy of this novel therapeutic approach.
therapeutic target	hsa-mir-155	Pneumonia	26589478	respiratory system disease	DOID:552	J18.9	D011014		HP:0002090	Our findings suggest that antagonizing certain microRNA might serve as a potential therapeutic strategy against secondary bacterial infection.
therapeutic target	hsa-mir-199a	Polycystic Kidney Disease	25588980			Q61.19	D007690	PS173900	HP:0000113	Up-regulation of miR-199a-5p in ADPKD tissues might promote cell proliferation through suppressing CDKN1C, suggesting miR-199a-5p as a novel target for ADPKD treatment.
therapeutic target	hsa-mir-204	Preeclampsia	26003727	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	our study indicates that miR-204 may contribute to the development of preeclampsia by inhibiting trophoblastic invasion, and that MMP9 is involved in miR-204-mediated trophoblast cell invasion. Our study suggests miR-204 as a novel therapeutic target for preeclampsia.
therapeutic target	hsa-mir-519d	Preeclampsia	25803859	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Our present findings suggest that upregulation of miR-519d-3p may contribute to the development of PE by inhibiting trophoblast cell migration and invasion via targeting MMP-2; miR-519d-3p may represent a potential predictive and therapeutic target for PE.
therapeutic target	hsa-mir-375	Primary Aldosteronism	25944465	disease of cellular proliferation	DOID:12028	E26.0	D006929	615474		Our findings suggest that miR-375 exerts its tumour-suppressive function via targeting MTDH/Akt pathway and implicate a potential therapeutic target in PA.
therapeutic target	hsa-mir-5338	Prostate Disease	29382326	reproductive system disease	DOID:47	N42.9	D011469			Study on the inhibition of Mfn1 by plant-derived miR5338 mediating the treatment of BPH with rape bee pollen.
therapeutic target	hsa-let-7a	Prostate Neoplasms	24480926	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA let-7a: a novel therapeutic candidate in prostate cancer.
therapeutic target	hsa-let-7a	Prostate Neoplasms	29236328	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the therapeutic potential of Let-7a as an antitumor and antimetastatic manager in prostate cancer and CCR7 may be regarded as a therapeutic target for the prostate cancer treatment
therapeutic target	hsa-let-7a	Prostate Neoplasms	20418948	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Let-7a may also be novel therapeutic candidate for prostate cancer given its ability to induce cell-cycle arrest and inhibit cell growth, especially in hormone-refractory prostate cancer.
therapeutic target	hsa-let-7a-1	Prostate Neoplasms	23974362	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	let-7a may be novel therapeutic candidate for prostate cancer
therapeutic target	hsa-mir-100	Prostate Neoplasms	23778488	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We demonstrate that miR-100 is a context-dependent miRNA controlling BAZ2, mTOR, FGFR3, SMARCA5 and THAP2 that might be involved in PC progression. The elucidation of the roles of miRNAs in tumors is important because they can be used as therapeutic targets in the future.
therapeutic target	hsa-mir-101	Prostate Neoplasms	26242038	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNA-101, with its inhibitory effect on the expression of EZH2 in LNCaP cells, is a potential biotherapeutic for prostate cancer.
therapeutic target	hsa-mir-101	Prostate Neoplasms	26473737	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results demonstrate that AR inhibits autophagy via transactivation of miR-101, thus combination of miR-101 mimics with celastrol may represent a promising therapeutic approach for treating prostate cancer.
therapeutic target	hsa-mir-101-1	Prostate Neoplasms	20478051	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-101:miR-101 introduction is a potential therapeutic strategy to combat PCa
therapeutic target	hsa-mir-101-2	Prostate Neoplasms	20478051	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-101:miR-101 introduction is a potential therapeutic strategy to combat PCa
therapeutic target	hsa-mir-103	Prostate Neoplasms	26771762	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Therefore, our data collectively demonstrate that miR-103 is a proto-oncogene miRNA that can suppress prostate cancer proliferation and migration by down-regulating the oncogene PDCD10, indicating that miR-103 may represent a new potential diagnostic and therapeutic target for prostate cancer treatment.
therapeutic target	hsa-mir-122	Prostate Neoplasms	26186079	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to survey studies conducted on human prostate tissue and biofluids and to consolidate trustworthy data on the role of miRNA in the occurrence and progression of PCa,with a delineation of differentially expressed miRNAs and an analysis of their association with PCa prognosis, progression to CRPC and metastatic disease, as well as their correlation with response to chemotherapy and hormonal therapy. Changes in circulating miRNAs may represent potentially useful non-invasive biomarkers for PCa diagnosis, staging and prediction of outcome.
therapeutic target	hsa-mir-122	Prostate Neoplasms	24292881	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	we successfully generated an adenoviral vector that expresses TRAIL in miRNA-regulated mechanism. This miRNA-based gene therapy may be promising for prostate carcinoma treatment.
therapeutic target	hsa-mir-124	Prostate Neoplasms	26573802	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Taken together, our results offer a preclinical rationale to evaluate miR-124 for cancer treatment.
therapeutic target	hsa-mir-125b	Prostate Neoplasms	20886540	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Data obtained in this study demonstrate that miR-125b promotes growth of prostatic xenograft tumors by down-regulating three key pro-apoptotic genes.This suggests that miR-125b is oncogenic and makes it an attractive therapeutic target in CaP.
therapeutic target	hsa-mir-128	Prostate Neoplasms	25921099	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-128 functions as a potential cancer suppressor in prostate cancer progression and rational therapeutic strategies for prostate cancer would be developed based on miR-128/zinc-finger E-box-binding homeobox 1 axis.
therapeutic target	hsa-mir-143	Prostate Neoplasms	24292881	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	we successfully generated an adenoviral vector that expresses TRAIL in miRNA-regulated mechanism. This miRNA-based gene therapy may be promising for prostate carcinoma treatment.
therapeutic target	hsa-mir-143	Prostate Neoplasms	19855844	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-143 is as a new target for prostate cancer treatment.
therapeutic target	hsa-mir-145	Prostate Neoplasms	26054847	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	we establish a novel and prostate cancer-specific targeting system for the systemic in vivo application of microRNAs through R11-SSPEI complexation as a powerful tool for future therapeutic use.
therapeutic target	hsa-mir-145	Prostate Neoplasms	26632856	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	This novel study shows a role for miR-145 in modulating radiosensitivity in vivo and highlights the need for further study investigating the potential role of miR-145 as both a predictive marker of response and a novel therapeutic agent with which to enhance the efficacy of radiation therapy.
therapeutic target	hsa-mir-145	Prostate Neoplasms	24292881	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	we successfully generated an adenoviral vector that expresses TRAIL in miRNA-regulated mechanism. This miRNA-based gene therapy may be promising for prostate carcinoma treatment.
therapeutic target	hsa-mir-145	Prostate Neoplasms	20588276	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-145:modulation of miR-145 may be an important therapeutic approach for the management of prostate cancer
therapeutic target	hsa-mir-146a	Prostate Neoplasms	26306811	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-146a has a critical role in the process of AIPC prostate cancer cells apoptosis through regulation of ROCK/Caspase 3 pathway. Targeting this pathway may be a promising therapeutic strategy for future personalized anti-cancer treatment.
therapeutic target	hsa-mir-146b	Prostate Neoplasms	25214035	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that miR-146a plays a suppressive role in prostate cancer through down-regulation of Rac1. The miR-146a/Rac1 signaling axis may be a potential therapeutic target to prevent prostate cancer progression.
therapeutic target	hsa-mir-15	Prostate Neoplasms	26073083	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These findings establish a new molecular circuitry for prostate cancer metastasis that was validated in patients' cohorts. Our data indicate a network of biomarkers and druggable pathways to improve patient treatment.
therapeutic target	hsa-mir-16	Prostate Neoplasms	26073083	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These findings establish a new molecular circuitry for prostate cancer metastasis that was validated in patients' cohorts. Our data indicate a network of biomarkers and druggable pathways to improve patient treatment.
therapeutic target	hsa-mir-17	Prostate Neoplasms	26318586	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our findings implicate dietary stilbenes as an attractive miRNA-mediated chemopreventive and therapeutic strategy, and circulating miRNAs as potential chemopreventive and predictive biomarkers for clinical development in prostate cancer.
therapeutic target	hsa-mir-17	Prostate Neoplasms	27125502	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or anti-miR21 as therapeutic modules.
therapeutic target	hsa-mir-181b	Prostate Neoplasms	23613247	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	As miR-181b is over-expressed in prostate cancer, its down-regulation could have potential as gene therapy for prostate cancer by inducing apoptosis, inhibiting proliferation and depressing invasion by cancer cells.
therapeutic target	hsa-mir-195	Prostate Neoplasms	26337460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-195 can repress the migration and invasion of prostate cancer cells via regulating Fra-1. Our results indicate that miR-195 could be a tumor suppressor and may have a potential to be a diagnostics or therapeutic target in prostate cancer.
therapeutic target	hsa-mir-199a	Prostate Neoplasms	24631181	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment.
therapeutic target	hsa-mir-205	Prostate Neoplasms	26813458	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-205/TP53INP1 mediated autophagy pathway might be an important molecular mechanism regulating radiosensitivity of prostate cancer cells and represents a potential therapeutic target for prostate cancer.
therapeutic target	hsa-mir-21	Prostate Neoplasms	25401698	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	High stromal expression of miR-21 was associated with poor biochemical recurrence-free survival after RP. For patients with Gleason score 6, miR-21 may help predict the risk of future disease progression and thereby help select patients for potential adjuvant treatment or a more stringent follow-up.
therapeutic target	hsa-mir-21	Prostate Neoplasms	26073083	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These findings establish a new molecular circuitry for prostate cancer metastasis that was validated in patients' cohorts. Our data indicate a network of biomarkers and druggable pathways to improve patient treatment.
therapeutic target	hsa-mir-21	Prostate Neoplasms	22341810	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-21 is an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer.
therapeutic target	hsa-mir-21	Prostate Neoplasms	27125502	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or anti-miR21 as therapeutic modules.
therapeutic target	hsa-mir-218	Prostate Neoplasms	25511513	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Clearly understanding of oncogenic TPD52 pathways regulated by miR-218 might be elpful to reveal new therapeutic targets for PC.
therapeutic target	hsa-mir-223	Prostate Neoplasms	25519054	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	we found increasing SEPT6 expression might reverse the biological activity induced by miR-223-3p, which might be a potential therapeutic target for PCa.
therapeutic target	hsa-mir-23a	Prostate Neoplasms	25604141	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-23a and miR-23b in LNCAP and PC3 cell lines, and these two miRNAs decreased IL-6R expression which has a critical role in these pathways. These results suggest the probability of utilizing miR-23a and miR-23b as therapeutic targets for the treatment of prostate cancer.
therapeutic target	hsa-mir-23b	Prostate Neoplasms	25604141	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-23a and miR-23b in LNCAP and PC3 cell lines, and these two miRNAs decreased IL-6R expression which has a critical role in these pathways. These results suggest the probability of utilizing miR-23a and miR-23b as therapeutic targets for the treatment of prostate cancer.
therapeutic target	hsa-mir-24	Prostate Neoplasms	26847530	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	These findings provide evidence that miR-24 has a tumor suppressor role in prostate cancer and also targets p27 and p16 in prostate cancer cells. We propose that it may be a useful progression biomarker or focus of therapeutic intervention for this disease.
therapeutic target	hsa-mir-30a	Prostate Neoplasms	26074357	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results suggested that reduced expression of miR-130a may be involved in the paclitaxel-resistance and that miR-130a could be a therapeutic target for taxane-resistant prostate cancer patients.
therapeutic target	hsa-mir-340	Prostate Neoplasms	26394192	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In summary, this study suggests that miR-340 suppresses the tumorigenic potential of prostate cancer cells. Moreover, the decreased miR-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5. Thus, miR340 and its target gene HMGN5 can serve as potentially useful therapeutic candidates for prostate cancer treatment.
therapeutic target	hsa-mir-340	Prostate Neoplasms	26718483	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our findings suggest that miR-340 may function as a novel tumor suppressor in PCa through the MDM2-p53 pathway by directly targeting MDM2, which may be a promising miRNA-targeted therapy for PCa.
therapeutic target	hsa-mir-34a	Prostate Neoplasms	25587085	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-34a-LEF1 axis represents a potential molecular target for novel therapeutic strategies in prostate cancer.
therapeutic target	hsa-mir-34a	Prostate Neoplasms	26313360	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Together, these results provide a new understanding of the biological effects of miR-34a and highlight the clinical potential for miR-34a delivery as a treatment for bone metastatic prostate cancer.
therapeutic target	hsa-mir-409	Prostate Neoplasms	24963047	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-409-3p/-5p plays an important role in prostate cancer biology by facilitating tumor growth, EMT, and bone metastasis. This finding bears particular translational importance as miR-409-3p/-5p appears to be an attractive biomarker and/or possibly a therapeutic target to treat bone metastatic prostate cancer.
therapeutic target	hsa-mir-4516	Prostate Neoplasms	25760964	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	two novel miRNAs (miR-4516 and miR-601) were identified that significantly improve prediction of biochemical failure post-salvage radiation therapy compared to clinico-histopathological factors,supporting the use of miRNAs within clinically used predictive models. Both findings warrant further validation studies.
therapeutic target	hsa-mir-494	Prostate Neoplasms	24644030	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results suggested that miR-494-3p might play crucial role in prostate cancer by post-transcriptional regulation to CXCR4 mRNA.MiR-494-3p/CXCR4 pathway may be a potential therapeutic target to prevent prostate cancer progression and metastasis.
therapeutic target	hsa-mir-601	Prostate Neoplasms	25760964	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	two novel miRNAs (miR-4516 and miR-601) were identified that significantly improve prediction of biochemical failure post-salvage radiation therapy compared to clinico-histopathological factors,supporting the use of miRNAs within clinically used predictive models. Both findings warrant further validation studies.
therapeutic target	hsa-mir-613	Prostate Neoplasms	26703210	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In conclusion, our study suggests that miR-613 functions as a tumor suppressor, partially through targeting Fzd7, and is a potential therapeutic target for prostate cancer.
therapeutic target	hsa-mir-96	Prostate Neoplasms	24633705	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Inhibition of miR-96 caused expression increase of tumor suppressor gene FOXO1, thus manipulating miR-96 expression may be a promising approach in treatment of prostate cancer.
therapeutic target	hsa-mir-21	Psoriasis	24574341	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Targeting miR-21 may represent a potential therapeutic option for the treatment of psoriasis.
therapeutic target	hsa-mir-21	Psoriasis	23506112	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy
therapeutic target	hsa-mir-130b	Pulmonary Hypertension	25763574	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these  miRNAs.
therapeutic target	hsa-mir-145	Pulmonary Hypertension	25763574	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these  miRNAs.
therapeutic target	hsa-mir-145	Pulmonary Hypertension	25979327	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	AntimiR-145 reduced the degree of  pulmonary arteriopathy, reduced the severity of pulmonary hypertension, and reduced the degree of cardiac dysfunction.
therapeutic target	hsa-mir-17	Pulmonary Hypertension	25763574	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these  miRNAs.
therapeutic target	hsa-mir-199a-2	Pulmonary Hypertension	25389292	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	a potential therapeutic approach whereby fenofibrate-induced miR-199a2 expression can ameliorate PH by reduction of ET-1 levels.
therapeutic target	hsa-mir-204	Pulmonary Hypertension	25763574	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these  miRNAs.
therapeutic target	hsa-mir-21	Pulmonary Hypertension	25763574	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these  miRNAs.
therapeutic target	hsa-mir-210	Pulmonary Hypertension	25851536	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	Despite expanding treatment options to ameliorate patients' symptoms, PAH remains a devastating disease with a poor long-term prognosis.
therapeutic target	hsa-mir-27b	Pulmonary Hypertension	25795136	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	We showed that miR-27b plays a role endothelial function and NO release and elucidated a potential mechanism by which miR-27b regulates Hsp90-eNOS and NO signaling by modulating PPARγ expression, providing potential therapeutic targets for the treatment of PAH.
therapeutic target	hsa-mir-29	Pulmonary Hypertension	26487756	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	16αOHE promotes the development of HPAH via upregulation of miR-29, which alters molecular and functional indexes of energy metabolism. Antagonism of miR-29 improves in vivo and in vitro features of HPAH and reveals a possible novel therapeutic target.
therapeutic target	hsa-mir-30c	Pulmonary Hypertension	25882492	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	These data suggest that the down-regulation of miR-30c accounts for the up-regulation of PDGFRβ expression, and subsequent activation of PDGF signaling results in the hypoxia-induced PASMC proliferation and phenotype switching. Therefore,increasing miR-30c expression levels could be explored as a potential new therapy for hypoxia-induced PAH.
therapeutic target	hsa-mir-424	Pulmonary Hypertension	25763574	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these  miRNAs.
therapeutic target	hsa-mir-503	Pulmonary Hypertension	25763574	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	miRNAs with established etiologic roles in PH showed context-dependent changes in tissue and circulating levels, which were not consistent across rodent models and human PAH. This suggests different miRNA-dependent mechanisms may contribute to experimental and clinical PH,complicating potential diagnostic and therapeutic applications amenable to these  miRNAs.
therapeutic target	hsa-mir-98	Pulmonary Hypertension	26098770	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	The results of this study show that PPARγ regulates miR-98 to modulate ET-1 expression and PAEC proliferation. These results further clarify molecular mechanisms by which PPARγ participates in PH pathogenesis and therapy.
therapeutic target	hsa-mir-155	Rapidly Progressive Glomerulonephritis	24158984	urinary system disease	DOID:4776	N01	C538458			MicroRNA-155 a new therapeutic target in crescentic GN.
therapeutic target	hsa-mir-21	Renal Fibrosis	25541205	urinary system disease	DOID:0050855	N26.9			HP:0030760	miR-21 as a potential diagnostic and prognostic marker and therapeutic target for fibrosis diseases.
therapeutic target	hsa-mir-21	Renal Fibrosis	26376826	urinary system disease	DOID:0050855	N26.9			HP:0030760	In summary, our study demonstrates a link between SphK1/S1P and TGF-β-induced miR-21 in renal TECs and may represent a novel therapeutic target in renal fibrosis.
therapeutic target	hsa-mir-26b	Respiratory Syncytial Virus Pneumonia	26222045	disease by infectious agent	DOID:1273	J12.1	D018357			This study reveals that RSV infection inhibits TLR4 signaling via up-regulation of miR-26b, which provides a potential therapeutic target for preventing and treating RSV infection.
therapeutic target	hsa-mir-34a	Retinoblastoma	19443717	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-34a functions as a tumor suppressor in RB cells and is a potential therapeutic target.
therapeutic target	hsa-mir-22	Rhabdomyosarcoma	27569217	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma.
therapeutic target	hsa-mir-27a	Rhabdomyosarcoma	25915942	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Study results have demonstrated that miRNA expression signature profiling can be used to classify different RMS subtypes and suggest that miR-27a may have a therapeutic potential in RMS by modulating the expression of retinoic acid receptors.
therapeutic target	hsa-mir-378	Rhabdomyosarcoma	25427715	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	MiR-378a-3p may function as a tumour suppressor in RMS and the restoration of its expression would be of therapeutic benefit in RMS. Furthermore, the role of epigenetic modifications in RMS deserves further investigations.
therapeutic target	hsa-mir-378a	Rhabdomyosarcoma	25427715	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	MiR-378a-3p may function as a tumour suppressor in RMS and the restoration of its expression would be of therapeutic benefit in RMS. Furthermore, the role of epigenetic modifications in RMS deserves further investigations.
therapeutic target	hsa-mir-106a	Rheumatoid Arthritis	27834806	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention
therapeutic target	hsa-mir-124-1	Rheumatoid Arthritis	21339227	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-124a is a key miRNA in the post-transcriptional regulatory mechanisms of RA synoviocytes, and has a therapeutic potential.
therapeutic target	hsa-mir-124-2	Rheumatoid Arthritis	21339227	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-124a is a key miRNA in the post-transcriptional regulatory mechanisms of RA synoviocytes, and has a therapeutic potential.
therapeutic target	hsa-mir-124-3	Rheumatoid Arthritis	21339227	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-124a is a key miRNA in the post-transcriptional regulatory mechanisms of RA synoviocytes, and has a therapeutic potential.
therapeutic target	hsa-mir-126	Rheumatoid Arthritis	26723864	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Our study demonstrated that down-regulation of miR-126 may indirectly inhibit PI3K/AKT signaling pathway to disrupt the imbalance between growth and death of RASFs by targeting PIK3R2, which may be clinically helpful to find therapeutic strategies directed toward miR-126 function for RA patients.
therapeutic target	hsa-mir-155	Rheumatoid Arthritis	29105307	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Hopefully the information obtained will benefit the development of novel therapeutic strategies
therapeutic target	hsa-mir-221	Rheumatoid Arthritis	27834806	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention
therapeutic target	hsa-mir-222	Rheumatoid Arthritis	27834806	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention
therapeutic target	hsa-mir-451	Rheumatoid Arthritis	24574214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	These results suggest that miR-451 suppresses neutrophil chemotaxis via p38 MAPK and is a potential target in the treatment of RA.
therapeutic target	hsa-mir-532	Rheumatoid Arthritis	27834806	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention
therapeutic target	hsa-mir-92a	Rheumatoid Arthritis	27834806	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention
therapeutic target	hsa-mir-98	Rheumatoid Arthritis	27834806	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	X-linked miRNAs, in the context of sex differences, might provide novel insight into new molecular mechanisms and potential therapeutic targets in RA for disease treatment and prevention
therapeutic target	hsa-mir-1290	Rhinosinusitis	26337346			B48.1				By comparing miRNA gene expression patterns in 3 types of CRS patients, we have been able to identify candidate miRNAs that might mediate the core pathogenesis of CRS through regulating dendritic cells. These miRNAs could serve as potential therapeutic targets for CRS.
therapeutic target	hsa-mir-137	Schizophrenia	24866554	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	We have identified a miR-137-regulated protein network that contributes to our understanding of the molecular basis of schizophrenia and provides clues for future research into psychopharmacological treatments for schizophrenia.
therapeutic target	hsa-mir-181b	Schizophrenia	24694668	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment.
therapeutic target	hsa-mir-30a	Schizophrenia	28072411	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring.
therapeutic target	hsa-mir-130b	Scleroderma, Systemic	25547017	musculoskeletal system disease	DOID:418	M34	D012595	181750		miR-130b played important profibrotic roles in SSc fibrosis, and enhanced TGF-β signaling through negative regulation of PPARγ expression. MiR-130b may be a potential therapeutic target in SSc fibrosis.
therapeutic target	hsa-mir-21	Scleroderma, Systemic	23506112	musculoskeletal system disease	DOID:418	M34	D012595	181750		Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy
therapeutic target	hsa-mir-29a	Scleroderma, Systemic	25549087	musculoskeletal system disease	DOID:418	M34	D012595	181750		miR-29a repressed TAB1-mediated TIMP-1 production in dermal fibroblasts, demonstrating that miR-29a may be a therapeutic target in SSc.
therapeutic target	hsa-mir-29a	Scleroderma, Systemic	20201077	musculoskeletal system disease	DOID:418	M34	D012595	181750		These data add the posttranscriptional regulation of collagens by miR-29a as a novel aspect to the fibrogenesis of SSc and suggest miR-29a as a potential therapeutic target.
therapeutic target	hsa-mir-195	Sepsis	26704614			A41.9	D018805		HP:0100806	Silencing of miR-195 reduced multiple-organ injury and improved the survival in sepsis, and the protective effects of miR-195 inhibition were associated with upregulation of Bcl-2, Sirt1, and Pim-1. Thus, inhibition of miR-195 may represent a new therapeutic approach for sepsis.
therapeutic target	hsa-mir-19a	Sepsis	26017478			A41.9	D018805		HP:0100806	Our study demonstrated that miR-19a and CD22 comprised a feedback loop for B cell response in sepsis, providing a potential therapeutic target to recover the immune homeostasis.
therapeutic target	hsa-mir-16	Short Bowel Syndrome	29364022	gastrointestinal system disease	DOID:10605		D012778	615237		Modulation of these pathways may represent a new therapeutic option for the management of short bowel syndrome
therapeutic target	hsa-mir-301a	Sickle Cell Disease	26460070			D57	D000755	603903		Our studies provide a potential therapeutic approach whereby fenofibrate-induced miR-301a/miR-454 expression can ameliorate PH and lung fibrosis by reduction in ET-1 and PAI-1 levels in SCD.
therapeutic target	hsa-mir-454	Sickle Cell Disease	26460070			D57	D000755	603903		Our studies provide a potential therapeutic approach whereby fenofibrate-induced miR-301a/miR-454 expression can ameliorate PH and lung fibrosis by reduction in ET-1 and PAI-1 levels in SCD.
therapeutic target	hsa-mir-378b	Skin Injury	26313654							In conclusion, our results demonstrate miR-378b promote keratinocytes differentiation by targeting NKX3.1. Manipulation of miR-378b may afford a new strategy to clinic treatment of skin injury and repair.
therapeutic target	hsa-mir-383	Skin Neoplasms	26261078	disease of cellular proliferation	DOID:4159	C44.90	D012878		HP:0008069	these studies suggest that STAT3 may be a potential target for both the prevention and treatment of human skin cancer.
therapeutic target	hsa-mir-210	Soft Tissue Sarcoma	24927770			C49.9	D012509		HP:0030448	Here we provide evidence for the miRNA mediated regulation of HIF3α by hypoxia responsive miRNAs in STS, which may help to tightly regulate and fine-tune the hypoxic response. This provides a better insight into the mechanisms underlying the hypoxic response in STS and may ultimately yield information on novel prognostic and predictive markers or targets for treatment.
therapeutic target	hsa-mir-485	Soft Tissue Sarcoma	24927770			C49.9	D012509		HP:0030448	Here we provide evidence for the miRNA mediated regulation of HIF3α by hypoxia responsive miRNAs in STS, which may help to tightly regulate and fine-tune the hypoxic response. This provides a better insight into the mechanisms underlying the hypoxic response in STS and may ultimately yield information on novel prognostic and predictive markers or targets for treatment.
therapeutic target	hsa-mir-142	Spinal Cord Injuries	26318123			S34.139A	D013119			In this article we suggest, for the first time, imitating sciatic nerve conditioning injury, thereby enhancing central regeneration of primary sensory neurons via interfering with the congenerous upstream regulator AC9 of the 3 above-mentioned signal pathways. We hope to provide a new clinical treatment strategy for the recovery of sensory function in SCI patients.
therapeutic target	hsa-mir-210	Spinal Cord Injuries	24732841			S34.139A	D013119			The administration of miR-210 promoted angiogenesis and astrogliosis, and improved functional recovery after SCI compared with the noninjected controls.
therapeutic target	hsa-mir-383	Spinal Cord Injuries	28365701			S34.139A	D013119			Suppression of MicroRNA-383 Enhances Therapeutic Potential of Human Bone-Marrow-Derived Mesenchymal Stem Cells in Treating Spinal Cord Injury via GDNF.
therapeutic target	hsa-mir-486	Spinal Cord Injuries	22466292			S34.139A	D013119			MicroRNA 486 is a potentially novel target for the treatment of spinal cord injury.
therapeutic target	hsa-mir-206	Spinal Muscular Atrophy	26030275	nervous system disease	DOID:12377	G12.9	D009134	253300	HP:0007269	We speculate that early modulation of miRNA-206 expression might delay SMA neurodegenerative pathway and that miRNA-206 could be an innovative, still relatively unexplored,therapeutic target for SMA.
therapeutic target	hsa-mir-184	Squamous Cell Carcinoma	19033458	disease of cellular proliferation	DOID:1749		D002294			Blockage of miR-205 activity with an antagomir or via ectopic expression of miR-184 could be novel therapeutic approaches for treating aggressive SCCs.
therapeutic target	hsa-mir-205	Squamous Cell Carcinoma	19033458	disease of cellular proliferation	DOID:1749		D002294			Blockage of miR-205 activity with an antagomir or via ectopic expression of miR-184 could be novel therapeutic approaches for treating aggressive SCCs.
therapeutic target	hsa-mir-494	Squamous Cell Carcinoma	26090866	disease of cellular proliferation	DOID:1749		D002294			We conclude that the inhibition of tumor aggressiveness in HNC-TICs by SB was mediated by up-regulation miR-494, suggesting that SB would be a valuable anti-cancer drug for treatment of HNC.
therapeutic target	hsa-mir-126	Squamous Cell Carcinoma, Cerevial	24641388	endocrine system disease	DOID:5531					Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy.
therapeutic target	hsa-mir-144	Squamous Cell Carcinoma, Cerevial	24641388	endocrine system disease	DOID:5531					Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy.
therapeutic target	hsa-mir-323	Squamous Cell Carcinoma, Cerevial	24641388	endocrine system disease	DOID:5531					Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy.
therapeutic target	hsa-mir-490	Squamous Cell Carcinoma, Cerevial	24641388	endocrine system disease	DOID:5531					Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy.
therapeutic target	hsa-mir-657	Squamous Cell Carcinoma, Cerevial	24641388	endocrine system disease	DOID:5531					Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy.
therapeutic target	hsa-mir-96	Squamous Cell Carcinoma, Cerevial	24641388	endocrine system disease	DOID:5531					Six MiRNAs with predicted tumor-associated target genes encoding proteins that are known to be involved in cell adhesion, cytoskeletal remodeling,cell proliferation, cell migration, and apoptosis were identified. These findings suggest that a panel of miRNAs may regulate multiple and various steps of the metastasis cascade by targeting metastasis-associated genes. Since these six miRNAs are predicted to target tumor-associated genes, it is likely that they contribute to the metastatic potential of cervical cancer and may aid in prognosis or molecular therapy.
therapeutic target	hsa-mir-101	Squamous Cell Carcinoma, Esophageal	26556718	disease of cellular proliferation	DOID:3748		C562729			Overexpression of miR-101 in ESCC inhibits proliferation and metastasis. Therefore, the miR-101/COX-2 pathway might be a therapeutic target in ESCC.
therapeutic target	hsa-mir-101	Squamous Cell Carcinoma, Esophageal	26530100	disease of cellular proliferation	DOID:3748		C562729			Taken together, our findings revealed a new post-transcriptional mechanism by which CSE regulated COX-2 expression to favor cancer cell proliferation, suggesting miR-101-3p as a potential biomarker and therapeutic target for smoke-related ESCC.
therapeutic target	hsa-mir-1291	Squamous Cell Carcinoma, Esophageal	26324125	disease of cellular proliferation	DOID:3748		C562729			Our results demonstrated the importance of miR-1291 in targeting MUC1 for the regulation of esophagus cancer growth, invasion and apoptosis, and may be helpful for developing new targets for early diagnosis or new therapeutic  targets for ESCC.
therapeutic target	hsa-mir-1294	Squamous Cell Carcinoma, Esophageal	25925090	disease of cellular proliferation	DOID:3748		C562729			Down-regulation of miR-1294 correlates with poor prognosis of ESCC. It's partially due to the reduced function of c-MYC. This study may give insight into the understanding of pathogenesis of esophageal cancer and provide evidence for diagnosis and treatment of esophageal cancer.
therapeutic target	hsa-mir-130b	Squamous Cell Carcinoma, Esophageal	25637514	disease of cellular proliferation	DOID:3748		C562729			miR-130b plays an oncogenic role in ESCC cells by repressing PTEN expression and Akt phosphorylation, which would be helpful in developing miRNA-based treatments for ESCC.
therapeutic target	hsa-mir-145	Squamous Cell Carcinoma, Esophageal	26445467	disease of cellular proliferation	DOID:3748		C562729			Combined qPCR of the 4 miRNAs provides the possibility of ESCC neo-CRT response prediction, which may facilitate individualized ESCC treatment.Further prospective validation in larger independent cohorts is necessary to fully assess its predictive power.
therapeutic target	hsa-mir-152	Squamous Cell Carcinoma, Esophageal	26445467	disease of cellular proliferation	DOID:3748		C562729			Combined qPCR of the 4 miRNAs provides the possibility of ESCC neo-CRT response prediction, which may facilitate individualized ESCC treatment.Further prospective validation in larger independent cohorts is necessary to fully assess its predictive power.
therapeutic target	hsa-mir-186	Squamous Cell Carcinoma, Esophageal	26568291	disease of cellular proliferation	DOID:3748		C562729			Our findings established that the miR-186 has a suppressive role in ESCC progression via SKP2-mediated pathway, and this implies that miR-186 could be a potential therapeutic target for ESCC.
therapeutic target	hsa-mir-192	Squamous Cell Carcinoma, Esophageal	26339371	disease of cellular proliferation	DOID:3748		C562729			These data suggest an important role of miR-192 in the molecular etiology of ESCC and implicate the potential application of miR-192 in ESCC therapy.
therapeutic target	hsa-mir-193b	Squamous Cell Carcinoma, Esophageal	26445467	disease of cellular proliferation	DOID:3748		C562729			Combined qPCR of the 4 miRNAs provides the possibility of ESCC neo-CRT response prediction, which may facilitate individualized ESCC treatment.Further prospective validation in larger independent cohorts is necessary to fully assess its predictive power.
therapeutic target	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	25400316	disease of cellular proliferation	DOID:3748		C562729			miR-21 may be a potential therapeutic target in management of ESCC.
therapeutic target	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	29568234	disease of cellular proliferation	DOID:3748		C562729			MiR-21 is a potential novel target for developing specific treatment interventions in ESCC in future
therapeutic target	hsa-mir-218	Squamous Cell Carcinoma, Esophageal	25482044	disease of cellular proliferation	DOID:3748		C562729			miR-218 regulated the expression of phosphorylated PI3K, AKT and mTOR, which may contribute to suppressed tumor growth of ESCC and enhanced sensitivity of ESCC cells. These findings suggest that miR-218 is a potential therapeutic agent for the treatment of ESCC.
therapeutic target	hsa-mir-34a	Squamous Cell Carcinoma, Esophageal	26523671	disease of cellular proliferation	DOID:3748		C562729			In summary, our findings indicated that the intrinsic expression of miR-34a was relatively low and was expressed differently among different p53 backgrounds and ADR treatment times. The anti-tumor effect of miR-34a was primarily dependent on the regulation of SIRT1 and p53/p21 protein,not apoptosis-associated proteins.
therapeutic target	hsa-mir-376a	Squamous Cell Carcinoma, Esophageal	26445467	disease of cellular proliferation	DOID:3748		C562729			Combined qPCR of the 4 miRNAs provides the possibility of ESCC neo-CRT response prediction, which may facilitate individualized ESCC treatment.Further prospective validation in larger independent cohorts is necessary to fully assess its predictive power.
therapeutic target	hsa-mir-382	Squamous Cell Carcinoma, Esophageal	26078564	disease of cellular proliferation	DOID:3748		C562729			miR-382 levels are reverse-correlated with ESCC poor outcomes,suggesting that miR-382 could be a potential predictive biomarker for both prognosis and treatment of ESCC.
therapeutic target	hsa-let-7a	Squamous Cell Carcinoma, Head and Neck	26323893	disease of cellular proliferation	DOID:5520	C76.0	C535575			In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC.
therapeutic target	hsa-mir-10b	Squamous Cell Carcinoma, Head and Neck	19540661	disease of cellular proliferation	DOID:5520	C76.0	C535575			tumor suppresser; suppressed cell invasion and led to cell cycle arrest and apoptosis; potential theraeutic target
therapeutic target	hsa-mir-138	Squamous Cell Carcinoma, Head and Neck	24747032	disease of cellular proliferation	DOID:5520	C76.0	C535575			MicroRNA-138: a potential therapeutic target for head and neck squamous cell carcinoma (HNSCC).
therapeutic target	hsa-mir-147b	Squamous Cell Carcinoma, Head and Neck	26323893	disease of cellular proliferation	DOID:5520	C76.0	C535575			In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC.
therapeutic target	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	26690371	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-21 cooperates with CDK5 to promote EMT and invasion in HNSCC.This finding suggests that CDK5 may be an important cofactor for targeting when designing metastasis-blocking therapy by targeting STAT3/miR-21 axis with STAT3 inhibitor or miR-21 antisense oligonucleotide. This is the first demonstration of the novel role of STAT3/miR-21 axis and CDK5/CDK5R1 (p35) in metastasis of HNSCC.
therapeutic target	hsa-mir-221	Squamous Cell Carcinoma, Head and Neck	26464363	disease of cellular proliferation	DOID:5520	C76.0	C535575			Expression of mirR221/222 is correlated to cell cycle regulation,carcinogenesis, and chemoresistance. Detailed knowledge of the molecular mechanisms and effects ofmiRNAs is important for identifying miRNAs as cancermarkers, as well as for increasing the efficiency of cancer therapeutics.
therapeutic target	hsa-mir-222	Squamous Cell Carcinoma, Head and Neck	26464363	disease of cellular proliferation	DOID:5520	C76.0	C535575			Expression of mirR221/222 is correlated to cell cycle regulation,carcinogenesis, and chemoresistance. Detailed knowledge of the molecular mechanisms and effects ofmiRNAs is important for identifying miRNAs as cancermarkers, as well as for increasing the efficiency of cancer therapeutics.
therapeutic target	hsa-mir-30a	Squamous Cell Carcinoma, Head and Neck	26472042	disease of cellular proliferation	DOID:5520	C76.0	C535575			Alcohol induces the dysregulation of miR-30a and miR-934, which may play crucial roles in HNSCC pathogenesis and progression. Future investigation of the alcohol-mediated pathways effecting these transformations will prove valuable for furthering the understanding and treatment of alcohol-associated HNSCC.
therapeutic target	hsa-mir-424	Squamous Cell Carcinoma, Head and Neck	26323893	disease of cellular proliferation	DOID:5520	C76.0	C535575			In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC.
therapeutic target	hsa-mir-6836	Squamous Cell Carcinoma, Head and Neck	26323893	disease of cellular proliferation	DOID:5520	C76.0	C535575			In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC.
therapeutic target	hsa-mir-6873	Squamous Cell Carcinoma, Head and Neck	26323893	disease of cellular proliferation	DOID:5520	C76.0	C535575			In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC.
therapeutic target	hsa-mir-7152	Squamous Cell Carcinoma, Head and Neck	26323893	disease of cellular proliferation	DOID:5520	C76.0	C535575			In conclusion, we identified a subset of microRNAs that were differentially expressed in ALDH1-high subpopulation, providing new microRNA targets to study dysregulation of HNSCC-initiating cells and develop therapeutic strategies aimed at eradicating the tumorigenic stem cells in HNSCC.
therapeutic target	hsa-mir-934	Squamous Cell Carcinoma, Head and Neck	26472042	disease of cellular proliferation	DOID:5520	C76.0	C535575			Alcohol induces the dysregulation of miR-30a and miR-934, which may play crucial roles in HNSCC pathogenesis and progression. Future investigation of the alcohol-mediated pathways effecting these transformations will prove valuable for furthering the understanding and treatment of alcohol-associated HNSCC.
therapeutic target	hsa-mir-107	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26822763	disease of cellular proliferation	DOID:2876					NEAT1 plays an oncogenic role in the tumorigenesis of LSCC and may serve as a potential target for therapeutic intervention.
therapeutic target	hsa-mir-205	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26515287	disease of cellular proliferation	DOID:2876					These findings help us to better elucidate the molecular mechanisms of LSCC progression and provide a new theoretical basis to further investigate miR-205 as a potential biomarker and a promising approach for LSCC treatment.
therapeutic target	hsa-mir-206	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26221902	disease of cellular proliferation	DOID:2876					Altogether, our results identify a crucial tumour suppressive role of miR-206 in LSCC growth, at least partly via up-regulation of cyclinD2 protein  levels, and suggest that miR-206 might be a candidate prognostic predictor or an anticancer therapeutic target for LSCC patients.
therapeutic target	hsa-mir-340	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26656176	disease of cellular proliferation	DOID:2876					Taken together, these data suggest that miR-340 impedes LSCC progression by targeting EZH2 with the possible mechanism to enhance the expression of anti-oncogene p27 and suppress PI3K/Akt activation, providing a novel target and a potential therapeutic pathway against LSCC.
therapeutic target	hsa-mir-519a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24300127	disease of cellular proliferation	DOID:2876					MicroRNA-519a may function as a tumour suppressor by inhibiting HuR expression, and may serve as a therapeutic target for laryngeal squamous cell carcinoma.
therapeutic target	hsa-mir-183	Squamous Cell Carcinoma, Lung	25813410	disease of cellular proliferation	DOID:3907	C34.91				This study describes the use of deep sequencing for comprehensive profiling of microRNAs in lung squamous cell carcinoma. The identified microRNA signatures may provide biomarkers for early detection, subclassification, and potential therapeutic targets of lung squamous cell carcinoma. This study also provides some insights into the molecular mechanism underlying the development and progression of lung squamous cell carcinoma, which may prove helpful for early diagnosis and treatment of the disease.
therapeutic target	hsa-mir-206	Squamous Cell Carcinoma, Lung	25522678	disease of cellular proliferation	DOID:3907	C34.91				the novel molecular mechanisms of lung-SCC oncogenesis and new therapeutic approaches for the treatment of this disease.
therapeutic target	hsa-mir-218	Squamous Cell Carcinoma, Lung	25813410	disease of cellular proliferation	DOID:3907	C34.91				This study describes the use of deep sequencing for comprehensive profiling of microRNAs in lung squamous cell carcinoma. The identified microRNA signatures may provide biomarkers for early detection, subclassification, and potential therapeutic targets of lung squamous cell carcinoma. This study also provides some insights into the molecular mechanism underlying the development and progression of lung squamous cell carcinoma, which may prove helpful for early diagnosis and treatment of the disease.
therapeutic target	hsa-mir-425	Squamous Cell Carcinoma, Lung	25813410	disease of cellular proliferation	DOID:3907	C34.91				This study describes the use of deep sequencing for comprehensive profiling of microRNAs in lung squamous cell carcinoma. The identified microRNA signatures may provide biomarkers for early detection, subclassification, and potential therapeutic targets of lung squamous cell carcinoma. This study also provides some insights into the molecular mechanism underlying the development and progression of lung squamous cell carcinoma, which may prove helpful for early diagnosis and treatment of the disease.
therapeutic target	hsa-mir-1254	Squamous Cell Carcinoma, Oral	28161631	disease of cellular proliferation	DOID:0050866					miR-1254 is a potential target for the treatment of OSCCs
therapeutic target	hsa-mir-143	Squamous Cell Carcinoma, Oral	25953639	disease of cellular proliferation	DOID:0050866					miR-143 could exert significantly suppressive effects on the ability of migration and invasion in OSCC cell lines, and the mechanism of this might be related to the activity of phospho-c-met though the CD44 v3/HGF signal. miR-143 could thus provide new applications for the treatment of OSCC.
therapeutic target	hsa-mir-21	Squamous Cell Carcinoma, Oral	25514838	disease of cellular proliferation	DOID:0050866					STAT3/miR-21 axis could be a candidate therapeutic target for OSCC chemoresistance.
therapeutic target	hsa-mir-222	Squamous Cell Carcinoma, Oral	25474084	disease of cellular proliferation	DOID:0050866					down-regulation of miR-222 could enhance the chemosensitivity of human OSCC cells to CDDP, and that the combination of As-miR-222 and CDDP could be an effective therapeutic strategy by boosting the expression of PUMA for controlling the growth of OSCC.
therapeutic target	hsa-mir-29b	Squamous Cell Carcinoma, Oral	25435433	disease of cellular proliferation	DOID:0050866					MiR-29b acts as an oncomir, promoting cell migration through CX3CL1 suppression, and could be a potential therapeutic target for preventing OSCC progression.
therapeutic target	hsa-mir-32	Squamous Cell Carcinoma, Oral	25472588	disease of cellular proliferation	DOID:0050866					miR-32 may act as a tumor suppressor in OSCC and could serve as a novel therapeutic agent for miR-based therapy.
therapeutic target	hsa-mir-375	Squamous Cell Carcinoma, Oral	26474386	disease of cellular proliferation	DOID:0050866					Our findings provide novel insights into the involvement of microRNAs in progression of inflammation to carcinoma and suggest a potential early-stage biomarker or therapy target for oral carcinoma.
therapeutic target	hsa-mir-429	Squamous Cell Carcinoma, Oral	25640197	disease of cellular proliferation	DOID:0050866					the tumor suppressor role of miR-429 in OSCC,and may provide a potential therapeutic target that warrants further investigation.
therapeutic target	hsa-mir-433	Squamous Cell Carcinoma, Oral	25962939	disease of cellular proliferation	DOID:0050866					Our data suggest that miR-433 exerts its tumor suppressor function by targeting HDAC6, leading to the inhibition of OSCC cell growth, invasion and migration, which suggest that miR-433 may be potential target for diagnostic and therapeutic applications in OSCC.
therapeutic target	hsa-mir-199a	Squamous Cell Carcinoma, Skin or Unspecific	25400809	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	increased expression of endogenous mature miR-199a might prevent the growth and migration of human cSCC via decreasing the expression of CD44 and regulating the interaction between CD44 and Ezrin, which may provide a potentially important therapeutic target for human cSCC.
therapeutic target	hsa-mir-20a	Squamous Cell Carcinoma, Skin or Unspecific	25019203	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Our study demonstrated that miR-20a is involved in the tumor inhibition of CSCC by directly targeting LIMK1 gene. This finding provides potential novel strategies for therapeutic interventions of CSCC.
therapeutic target	hsa-mir-27a	Squamous Cell Carcinoma, Skin or Unspecific	23963114	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	These findings identify miR-27a* as a functional star sequence that exhibits novel coordinated regulation of the EGFR pathway in solid tumors and potentially represents a novel therapeutic option.
therapeutic target	hsa-mir-31	Squamous Cell Carcinoma, Skin or Unspecific	25068518	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	miR-31 regulates cancer-associated phenotypes of cSCC and identify miR-31 as a potential target for cSCC treatment.
therapeutic target	hsa-mir-26b	Squamous Cell Carcinoma, Tongue	25483152	disease of cellular proliferation	DOID:0050865	C02.9				miR-26b serves as a tumor suppressor by targeting COX-2 and calls for the use of miR-26b as a potential therapeutic tool for human tongue squamous cell carcinoma, where COX-2 is often hyperactivated.
therapeutic target	hsa-mir-29a	Squamous Cell Carcinoma, Tongue	25127200	disease of cellular proliferation	DOID:0050865	C02.9				miR-29b functions as a tumor suppressor in TSCC, and the miR-29b/Sp1/PTEN/AKT axis might represent a potential therapeutic target for TSCC intervention.
therapeutic target	hsa-mir-34a	Squamous Cell Carcinoma, Tongue	25268950	disease of cellular proliferation	DOID:0050865	C02.9				miR-34a plays an important role in lymph node metastases of TSCC through targeting MMP9 and MMP14 and may have potential applications in prognosis prediction and gene therapy for lymph node metastases of TSCC patients.
therapeutic target	hsa-mir-107	Stroke	26294080			I64	D020521	601367	HP:0001297	This process might be a protective mechanism for ischemia-induced cerebral injury and miR-107 might be used as a novel tool in stroke treatment.
therapeutic target	hsa-mir-124	Stroke	27031810			I64	D020521	601367	HP:0001297	These neuroprotective and anti-inflammatory effects of the early miR-124 treatment were pronounced during the first week with Arg-1.
therapeutic target	hsa-mir-181b	Stroke, Ischemic	23900885			I63.9			HP:0002140	These results suggest that the downregulated miR-181b induces neuroprotection against ischemic injury through negatively regulating HSPA5 and UCHL1 protein levels, providing a potential therapeutic target for ischemic stroke.
therapeutic target	hsa-mir-21	Systemic Lupus Erythematosus	23506112	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Though the exact roles of miR-21 in autoimmune diseases have not been fully elucidated, targeting miR-21 may serve as a promising therapy
therapeutic target	hsa-mir-219	Tauopathy	25574843	nervous system disease	DOID:680		D024801			silencing of tau by miR-219 is an ancient regulatory mechanism that may become perturbed during neurofibrillary degeneration and suggest that this regulatory pathway may  be useful for developing therapeutics for tauopathies.
therapeutic target	hsa-mir-367	Testicular Germ Cell Tumor	25046619	disease of cellular proliferation	DOID:5557		C563236	273300		miR-371a-3p allows for better identification of testicular germ cell tumor than α1-fetoprotein and human chorionic gonadotropin. It could be helpful for clinically managing testicular germ cell tumor, especially for monitoring surveillance therapy and residual disease after chemotherapy.
therapeutic target	hsa-mir-371a	Testicular Germ Cell Tumor	25046619	disease of cellular proliferation	DOID:5557		C563236	273300		miR-371a-3p allows for better identification of testicular germ cell tumor than α1-fetoprotein and human chorionic gonadotropin. It could be helpful for clinically managing testicular germ cell tumor, especially for monitoring surveillance therapy and residual disease after chemotherapy.
therapeutic target	hsa-mir-372	Testicular Germ Cell Tumor	25046619	disease of cellular proliferation	DOID:5557		C563236	273300		miR-371a-3p allows for better identification of testicular germ cell tumor than α1-fetoprotein and human chorionic gonadotropin. It could be helpful for clinically managing testicular germ cell tumor, especially for monitoring surveillance therapy and residual disease after chemotherapy.
therapeutic target	hsa-mir-373	Testicular Germ Cell Tumor	25046619	disease of cellular proliferation	DOID:5557		C563236	273300		miR-371a-3p allows for better identification of testicular germ cell tumor than α1-fetoprotein and human chorionic gonadotropin. It could be helpful for clinically managing testicular germ cell tumor, especially for monitoring surveillance therapy and residual disease after chemotherapy.
therapeutic target	hsa-mir-126	Thrombosis	26659078	cardiovascular system disease	DOID:0060903		D013927			Overexpressed miR-126 inhibits apoptosis of VECs and DVT through targeting the anti-apoptotic pathway PI3K/Akt via PIK3R2.GENERAL SIGNIFICANCE: These findings may provide a new target for the therapy of DVT.
therapeutic target	hsa-mir-148a	Thrombosis	26516227	cardiovascular system disease	DOID:0060903		D013927			Our work suggests that modulating miR-148a expression is a potential therapeutic approach for thrombosis.
therapeutic target	hsa-mir-483	Thrombosis	26801758	cardiovascular system disease	DOID:0060903		D013927			miR-483-3p is upregulated in EPCs from DVT patients, and it targets SRF to decrease EPCs migration and tube formation and increase apoptosis in vitro, while decrease EPCs homing and thrombus resolution in vivo. MiR-483-3p is a potential therapeutic target in DVT treatment.
therapeutic target	hsa-mir-100	Thyroid Neoplasms	24785011	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	(131)I treatment inhibited the expression of miR-100, which modulated RBSP3 in FTC cells. The new mechanism of suppression of the proliferation of FTC cells by I described here might occur through the downregulation of miR-100.
therapeutic target	hsa-mir-106b	Thyroid Neoplasms	26317551	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	In summary, our findings not only provide new insights into molecular mechanism associated with C1orf24 overexpression in thyroid carcinomas but also show that C1orf24 might increase proliferation and cell migration. Thus, decreasing C1orf24 levels, by restoring miR-106b function, may have therapeutic implications.
therapeutic target	hsa-mir-146b	Thyroid Neoplasms	25547151	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b-5p induces EMT and may promote PTC metastasis through the regulation of Wnt/β-catenin signaling, and suggest novel potential therapeutic targets for the treatment of PTC.
therapeutic target	hsa-mir-204	Thyroid Neoplasms	26406941	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Our findings suggest that miR-204 plays a protective role by inhibiting thyroid cancer cell proliferation, and may identify new targets for anti-cancer treatment.
therapeutic target	hsa-mir-20a	Thyroid Neoplasms	24858712	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	To our knowledge, this is the first study to demonstrate that miR-20a plays a role as a tumor suppressor in thyroid cancer cells and targets LIMK1. Our findings suggest the upregulated expression of miR-20a in anaplastic thyroid cancer counteracts thyroid cancer progression and may have therapeutic potential.
therapeutic target	hsa-mir-339	Thyroid Neoplasms	25404690	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	hNIS-mediated RAIU can be modulated by miRs, and that the same miRs may also play roles in the development or maintenance of thyroid malignancy. Accordingly, miRs may serve as emerging targets to halt the progression of thyroid cancer and to enhance the efficacy of radioiodine therapy.
therapeutic target	hsa-mir-21	Thyroid-Associated Ophthalmopathy	25873777				D049970			The present study shows that miR-21 regulates cell proliferation,apoptosis, and differentiation in orbital fibroblasts from TAO, and acts as amediator in TGF-β1-induced collagen production. These data predict a close association between miR-21 and orbital muscle fibrosis, and provide a novel therapeutic target for TAO.
therapeutic target	hsa-mir-155	Uremic Neuropathy	26267685	urinary system disease	DOID:4675					Serum miRNA-155 and IL-6 in uremic dialysis patients were remarkably increased compared to healthy objects. Serum miRNA-155 was positively correlated with the level of IL-6 as well as hs-CRP, while miR-155 was negatively correlated with HDL and albumin. Alprostadil could ameliorate the inflammatory conditions of uremic dialysis patients by inhibition of the IL-6 expression. Serum miRNA-155 may be a novel target for the treatment of uremic dialysis patients.
therapeutic target	hsa-mir-145	Urinary Bladder Cancer	29723992	urinary system disease	DOID:11054	C67	D001749	109800		MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy.
therapeutic target	hsa-mir-200c	Uterine Carcinosarcoma	28620240	disease of cellular proliferation	DOID:6171	D06.9			HP:0010784	miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.
therapeutic target	hsa-mir-197	Uterine Leiomyoma	25960207			D25.9	D007889	150699	HP:0000131	In this study, the data showed that miR-197 could play an anti-oncogenic role in human uterus leiomyoma cells, and cooperate with LNG on the cell proliferation and apoptosis, which suggested that miR-197 might be a potential target and provided database for clinical treatment.
therapeutic target	hsa-mir-15a	Uterine Leiomyosarcoma	26768834						HP:0002891	Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy.
therapeutic target	hsa-mir-31	Uterine Leiomyosarcoma	26768834						HP:0002891	Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy.
therapeutic target	hsa-mir-92a	Uterine Leiomyosarcoma	26768834						HP:0002891	Differential miRNA signatures of ESS and LMS provide novel data regarding transcriptional regulation in these cancers, based on which new potential diagnostic markers, prognostic biomarkers and therapeutic targets may be explored. Differences in miRNA profiles of primary and metastatic LMS may improve our understanding of disease progression in this aggressive malignancy.
therapeutic target	hsa-mir-106a	Vascular Disease [unspecific]	26004384	cardiovascular system disease	DOID:178	I72.9	D000783			The results of the present study suggest that miRNAs are vital in the process of endothelial dysfunction and are involved in the pathogenesis of VGF. Thus, using miRNAs as biomarkers and therapeutic targets has the potential to improve early diagnosis and prognosis of patients with VGF.
therapeutic target	hsa-mir-145	Vascular Disease [unspecific]	23611811	cardiovascular system disease	DOID:178	I72.9	D000783			Forced expression of miR-145 emerges as a promising strategy for reduction and stabilization of atherosclerotic plaques as well as for reducing neointimal hyperplasia.
therapeutic target	hsa-mir-204	Vascular Disease [unspecific]	25806689	cardiovascular system disease	DOID:178	I72.9	D000783			these data suggested miR-204 as a possible molecular switch inhibiting osteoblastic transdifferentiation of human aortic VICs and targeting miR-204 may have therapeutic potential for human aortic valve calcification.
therapeutic target	hsa-mir-21	Vascular Disease [unspecific]	20560046	cardiovascular system disease	DOID:178	I72.9	D000783			miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions
therapeutic target	hsa-mir-23a	Vascular Disease [unspecific]	22136461	cardiovascular system disease	DOID:178	I72.9	D000783			miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease
therapeutic target	hsa-mir-24-2	Vascular Disease [unspecific]	22136461	cardiovascular system disease	DOID:178	I72.9	D000783			miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease
therapeutic target	hsa-mir-27a	Vascular Disease [unspecific]	22136461	cardiovascular system disease	DOID:178	I72.9	D000783			miRNA-23/27/24 cluster has potential therapetic application in vascular disorders and ischemic heart disease
therapeutic target	hsa-mir-363	Vascular Disease [unspecific]	26004384	cardiovascular system disease	DOID:178	I72.9	D000783			The results of the present study suggest that miRNAs are vital in the process of endothelial dysfunction and are involved in the pathogenesis of VGF. Thus, using miRNAs as biomarkers and therapeutic targets has the potential to improve early diagnosis and prognosis of patients with VGF.
therapeutic target	hsa-mir-145	Vascular Disease [unspecific]	19542014	cardiovascular system disease	DOID:178	I72.9	D000783			We conclude that miR-145 is a novel VSMC phenotypic marker and modulator that is able of controlling vascular neointimal lesion formation. These novel findings may have extensive implications for the diagnosis and therapy of a variety of proliferative vascular diseases.
therapeutic target	hsa-mir-145	Vascular Disease [unspecific]	19829088	cardiovascular system disease	DOID:178	I72.9	D000783			This review article summarizes the current research progress regarding the roles of miR-145 in VSMC biology and discusses the potential therapeutic opportunities surrounding this miRNA in vascular disease.
therapeutic target	hsa-mir-27b	Vascular Disease [unspecific]	18068232	cardiovascular system disease	DOID:178	I72.9	D000783			Expression of let7-f and miR-27b contributes to in vitro angiogenesis. We review recent studies on the involvement of miRNA in angiogenesis and discuss their implications for miRNA-based therapeutic strategies targeting this process in disease.
therapeutic target	hsa-mir-21	Vascular Hypertrophy	22227207							Our data suggest that miR-21 plays an important role in the pathogenesis of chronic hypoxia-induced pulmonary vascular remodeling and also suggest that miR-21 is a potential target for novel therapeutics to treat chronic hypoxia associated pulmonary diseases.
therapeutic target	hsa-mir-23a	Viral Infectious Disease	25461762	disease by infectious agent	DOID:934	A94	D001102			miR-23a may represent a promising target for antiviral treatments.
therapeutic target	hsa-mir-555	Viral Infectious Disease	26683768	disease by infectious agent	DOID:934	A94	D001102			These findings provide the first evidence for the role of miR-555 in PV replication and reveal that miR-555 could contribute to the development of antiviral therapeutic strategies against PV.
therapeutic target	hsa-mir-155	Viral Myocarditis	25219837			B33.2	D009205			So, our study indicated that miR-155 is a potential therapeutic target for viral myocarditis.
therapeutic target	hsa-mir-155	Waldenstrom Macroglobulinemia	23474146			C88.0	D008258	153600	HP:0005508	Among deregulated miRNAs, miRNA-155 has been shown to play a pivotal role in the biological characteristics of this disease both in vitro and in vivo, thus providing the rationale for testing miRNA-based therapeutic approaches for the treatment of WM.
therapeutic target	hsa-mir-132	Wound Healing	28807666				D014945		HP:0001058	MicroRNA-132 with Therapeutic Potential in Chronic Wounds.
tissue_expression_down	hsa-mir-150	Acquired Immunodeficiency Syndrome	22205749	disease by infectious agent	DOID:635	B20	D000163	609423		we used microarray expression analysis to identify miRNAs miR-27b, miR-29b, miR-150, and miR-223 as being significantly downregulated upon CD4(+) T cell activation
tissue_expression_down	hsa-mir-223	Acquired Immunodeficiency Syndrome	22205749	disease by infectious agent	DOID:635	B20	D000163	609423		we used microarray expression analysis to identify miRNAs miR-27b, miR-29b, miR-150, and miR-223 as being significantly downregulated upon CD4(+) T cell activation
tissue_expression_down	hsa-mir-27b	Acquired Immunodeficiency Syndrome	22205749	disease by infectious agent	DOID:635	B20	D000163	609423		we used microarray expression analysis to identify miRNAs miR-27b, miR-29b, miR-150, and miR-223 as being significantly downregulated upon CD4(+) T cell activation
tissue_expression_down	hsa-mir-29b	Acquired Immunodeficiency Syndrome	22205749	disease by infectious agent	DOID:635	B20	D000163	609423		we used microarray expression analysis to identify miRNAs miR-27b, miR-29b, miR-150, and miR-223 as being significantly downregulated upon CD4(+) T cell activation
tissue_expression_down	hsa-mir-126	Acute Myocardial Infarction	27376405	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Down-regulated miR-126 and up-regulated VEGF-A were also observed in MI models
tissue_expression_down	hsa-mir-499a	Acute Myocardial Infarction	26046358	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination.
tissue_expression_down	hsa-mir-24	Acute Respiratory Distress Syndrome	25070658	respiratory system disease	DOID:11394	J80	D012128			The down-regulated miRNAs included miR-24, miR-26a, miR-126, and Let-7a, b, c, f. The up-regulated miRNAs were composed of miR-344, miR-346, miR-99a, miR-127, miR-128b, miR-135b, and miR-30a/b.
tissue_expression_down	hsa-mir-1268	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -326b (downregulated)
tissue_expression_down	hsa-mir-1275	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -326b (downregulated)
tissue_expression_down	hsa-mir-320b	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -326b (downregulated)
tissue_expression_down	hsa-mir-326b	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -326b (downregulated)
tissue_expression_down	hsa-mir-663	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -325b (downregulated)
tissue_expression_down	hsa-mir-10b	Adenocarcinoma, Endometrial	19891660	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	down-regulated
tissue_expression_down	hsa-mir-152	Adenocarcinoma, Endometrial	19891660	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	down-regulated
tissue_expression_down	hsa-mir-193b	Adenocarcinoma, Endometrial	19077565	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-193b: downregulated
tissue_expression_down	hsa-mir-204	Adenocarcinoma, Endometrial	19077565	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-204: downregulated
tissue_expression_down	hsa-mir-410	Adenocarcinoma, Endometrial	26842619	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	a lower expression of microRNA-410 in the  cancer zone compared with the healthy zone
tissue_expression_down	hsa-mir-99b	Adenocarcinoma, Endometrial	19077565	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-99b: downregulated
tissue_expression_down	hsa-mir-17	Adenocarcinoma, Esophageal	28002789	disease of cellular proliferation	DOID:4914		C562730	133239		MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype.
tissue_expression_down	hsa-mir-205	Adenocarcinoma, Esophageal	25746664	disease of cellular proliferation	DOID:4914		C562730	133239		miRs such as miR-192, miR-196 and miR-21 were frequently noted to up-regulated whereas miR-203, miR-205 and miR-let-7 were commonly down-regulated during the development of Barrett's oesophagus to oesophageal adenocarcinoma.
tissue_expression_down	hsa-mir-216b	Adenocarcinoma, Gastric	26408293	disease of cellular proliferation	DOID:3717	D37.1	D013274			We reported a significantly decreased expression of miR-216b in GC clinical specimens compared with paired non-cancerous tissues.
tissue_expression_down	hsa-mir-299	Adenocarcinoma, Gastric	27007598	disease of cellular proliferation	DOID:3717	D37.1	D013274			significant downregulation of miR-299-5p in intestinal-type gastric adenocarcinoma
tissue_expression_down	hsa-mir-302b	Adenocarcinoma, Gastric	23508453	disease of cellular proliferation	DOID:3717	D37.1	D013274			Down-regulation of miR-302b, an ESC-specific microRNA, in Gastric Adenocarcinoma.
tissue_expression_down	hsa-mir-375	Adenocarcinoma, Gastric	23461060	disease of cellular proliferation	DOID:3717	D37.1	D013274			In our study, the expression of a subset of microRNAs was altered in distal gastric adenocarcinoma compared to normal tissue, miR-375 was significantly downregulated in distal gastric adenocarcinoma tissues, to a level that was significantly lower than cardia adenocarcinoma (p < 0.05).
tissue_expression_down	hsa-mir-124	Adenocarcinoma, Lung	26935152	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-124 was significantly downregulated in the lung ADC tissues compared with that noted in the corresponding non-cancerous lung tissues
tissue_expression_down	hsa-mir-485	Adenocarcinoma, Lung	27262438	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	expression level of miR-485 was downregulated in four lung adenocarcinoma cell lines and tissue
tissue_expression_down	hsa-mir-124	Adenocarcinoma, Pancreatic Ductal	27922430	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
tissue_expression_down	hsa-mir-133a	Adenocarcinoma, Pancreatic Ductal	17237814	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The expression of miR-216 and -217 and lack of expression of miR-133a were identified as characteristic of pancreas tissue.
tissue_expression_down	hsa-mir-15a	Adenocarcinoma, Pancreatic Ductal	24252251	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-15a inhibits cell proliferation and EMT in PDAC via the down-regulation of Bmi-1 expression.
tissue_expression_down	hsa-mir-218	Adenocarcinoma, Pancreatic Ductal	24166773	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Reduced miR-218 in PDAC tissues was correlated with tumor progression, and might be an independent poor prognostic factor for patients.
tissue_expression_down	hsa-mir-301a	Adenocarcinoma, Pancreatic Ductal	26384137	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		We conclude that MnSOD expression is negatively associated with miR-301a levels in PDAC tissues, and lower miR-301a levels are associated with increased MnSOD expression and inhibition of PDAC growth.
tissue_expression_down	hsa-mir-337	Adenocarcinoma, Pancreatic Ductal	24641834	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The present study showed that HOXB7 was over-expressed and miR-337 was minimally expressed in PDAC tissues, and their levels were related to TNM stage and lymph node status. The levels of HOXB7 mRNA, HOXB7 protein, and miR-337 were associated with survival in PDAC patients. Results suggested that HOXB7 and miR-337 could be used as determinants of PDAC patient prognosis.
tissue_expression_down	hsa-let-7e	Adenovirus Infection	20634878			B34.0	D000257			let-7e:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-101-1	Adenovirus Infection	20634878			B34.0	D000257			miR-101-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-101-2	Adenovirus Infection	20634878			B34.0	D000257			miR-101-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-1180	Adenovirus Infection	20634878			B34.0	D000257			hsa-mir-1180:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-1184-1	Adenovirus Infection	20634878			B34.0	D000257			miR-1184:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-125b-1	Adenovirus Infection	20634878			B34.0	D000257			miR-125b-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-125b-2	Adenovirus Infection	20634878			B34.0	D000257			miR-125b-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-148a	Adenovirus Infection	20634878			B34.0	D000257			miR-148a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-148b	Adenovirus Infection	20634878			B34.0	D000257			miR-148b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-181b-1	Adenovirus Infection	20634878			B34.0	D000257			miR-181b-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-181b-2	Adenovirus Infection	20634878			B34.0	D000257			miR-181b-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-18b	Adenovirus Infection	20634878			B34.0	D000257			miR-18b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-196b	Adenovirus Infection	20634878			B34.0	D000257			miR-196b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-19b-1	Adenovirus Infection	20634878			B34.0	D000257			miR-19b-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-19b-2	Adenovirus Infection	20634878			B34.0	D000257			miR-19b-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-210	Adenovirus Infection	20634878			B34.0	D000257			miR-210:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-219-1	Adenovirus Infection	20634878			B34.0	D000257			miR-219-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-25	Adenovirus Infection	20634878			B34.0	D000257			miR-25:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-26b	Adenovirus Infection	20634878			B34.0	D000257			miR-26b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-27a	Adenovirus Infection	20634878			B34.0	D000257			miR-27a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-27b	Adenovirus Infection	20634878			B34.0	D000257			miR-27b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-30a	Adenovirus Infection	20634878			B34.0	D000257			miR-30a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-30b	Adenovirus Infection	20634878			B34.0	D000257			miR-30b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-30c-1	Adenovirus Infection	20634878			B34.0	D000257			miR-30c-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-30c-2	Adenovirus Infection	20634878			B34.0	D000257			miR-30c-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-338	Adenovirus Infection	20634878			B34.0	D000257			miR-338:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-33a	Adenovirus Infection	20634878			B34.0	D000257			miR-33a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-34a	Adenovirus Infection	20634878			B34.0	D000257			miR-34a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-362	Adenovirus Infection	20634878			B34.0	D000257			miR-362:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-374b	Adenovirus Infection	20634878			B34.0	D000257			miR-374b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-421	Adenovirus Infection	20634878			B34.0	D000257			miR-421:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-433	Adenovirus Infection	20634878			B34.0	D000257			miR-433:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-452	Adenovirus Infection	20634878			B34.0	D000257			miR-452:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-519a-1	Adenovirus Infection	20634878			B34.0	D000257			miR-519a-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-582	Adenovirus Infection	20634878			B34.0	D000257			miR-582:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-619	Adenovirus Infection	20634878			B34.0	D000257			miR-619:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-650	Adenovirus Infection	20634878			B34.0	D000257			miR-650:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-655	Adenovirus Infection	20634878			B34.0	D000257			miR-655:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-92a-2	Adenovirus Infection	20634878			B34.0	D000257			miR-92a-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_down	hsa-mir-200b	Adrenal Cortex Neoplasms	19849700	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	down-regulated
tissue_expression_down	hsa-mir-203	Adrenal Cortex Neoplasms	19849700	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	down-regulated
tissue_expression_down	hsa-mir-214	Adrenal Cortex Neoplasms	19546168	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	significantly lower expressed
tissue_expression_down	hsa-mir-195	Adrenal Cortex Neoplasms	19996210	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	miR-335 and miR-195 were significantly downregulated in adrenocortical carcinomas
tissue_expression_down	hsa-mir-483	Adrenal Cortex Neoplasms	19996210	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	miR-335 and miR-195 were significantly downregulated in adrenocortical carcinomas
tissue_expression_down	hsa-mir-21	Alcoholic Cardiomyopathy	29039471			I42.6	D002310			The present study confirmed that H2S relieves myocardial fibrosis in mice with ACM, and the underlying mechanism may involve the downregulation of autophagy and miR-21 and miR-211 expression levels.
tissue_expression_down	hsa-mir-221	Alcoholic Cardiomyopathy	29039471			I42.6	D002310			The present study confirmed that H2S relieves myocardial fibrosis in mice with ACM, and the underlying mechanism may involve the downregulation of autophagy and miR-21 and miR-211 expression levels.
tissue_expression_down	hsa-mir-3098	Alcoholic Cardiomyopathy	29734191			I42.6	D002310			The results demonstrated that miR-467d-3p and miR-491-5p were up-regulated and miR-3098-3p was down-regulated in the alcohol-exposed myocardial samples compared with the control samples (P < 0.05).
tissue_expression_down	hsa-let-7e	Allergic Rhinitis	23704072	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Subjects with current allergic rhinitis symptoms had increased levels of miR-155, miR-205, and miR-498, but reduced levels of let-7e.
tissue_expression_down	hsa-let-7e	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-126	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-155	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-18a	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-224	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-143	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		down-regulated
tissue_expression_down	hsa-mir-187	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		down-regulated
tissue_expression_down	hsa-mir-224	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		down-regulated
tissue_expression_down	hsa-mir-498	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		down-regulated
tissue_expression_down	hsa-mir-767	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		miR-767-5p: down-regulated
tissue_expression_down	hsa-mir-874	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		down-regulated
tissue_expression_down	hsa-mir-107	Alzheimer Disease	18234899	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	downregulated
tissue_expression_down	hsa-mir-128-1	Alzheimer Disease	21686130	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-128a/b levels were significantly reduced in the temporal cortex and miR-128b in the frontal cortex in AD.
tissue_expression_down	hsa-mir-128-2	Alzheimer Disease	21686130	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-128a/b levels were significantly reduced in the temporal cortex and miR-128b in the frontal cortex in AD.
tissue_expression_down	hsa-mir-181c	Alzheimer Disease	27423553	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Taken together, these findings suggested that crmp2 is a target of miR-181c and that the abnormally low expression of miR-181c in the hippocampus of SAMP8 mice could lead to an increase of the crmp2 protein level in AD mice, which might potentially play a role in the pathogenesis of Alzheimer's disease.
tissue_expression_down	hsa-mir-29c	Alzheimer Disease	25973041	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Present study indicated that miR-29c was downregulated in sporadic AD brains, and it targeted the 3' UTR of BACE1, reduced the BACE1 expression, and downregulated the APPβ accumulation in vitro.
tissue_expression_down	hsa-mir-1-1	Aortic Aneurysm, Thoracic	22010139	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;
tissue_expression_down	hsa-mir-1-2	Aortic Aneurysm, Thoracic	22010139	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;
tissue_expression_down	hsa-mir-133a-1	Aortic Aneurysm, Thoracic	22010139	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;
tissue_expression_down	hsa-mir-133a-2	Aortic Aneurysm, Thoracic	22010139	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;
tissue_expression_down	hsa-mir-21	Aortic Aneurysm, Thoracic	22010139	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;
tissue_expression_down	hsa-mir-29a	Aortic Aneurysm, Thoracic	22010139	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		miRs -1, -21, -29a, -133a, and -486 showed decreased expression in Thoracic Aortic Aneurysm compared to normal aortic specimens.A significant relationship between miR expression levels (miRs -1, -21, -29a, and -133a) and aortic diameter was identified;
tissue_expression_down	hsa-mir-195	Aortic Insufficiency	20845893	cardiovascular system disease	DOID:57	I35.1	D001022		HP:0001659	miR-195:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-26a-1	Aortic Insufficiency	20845893	cardiovascular system disease	DOID:57	I35.1	D001022		HP:0001659	MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-26a-2	Aortic Insufficiency	20845893	cardiovascular system disease	DOID:57	I35.1	D001022		HP:0001659	MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-30b	Aortic Insufficiency	20845893	cardiovascular system disease	DOID:57	I35.1	D001022		HP:0001659	MiR-30b:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-195	Aortic Stenosis	20845893	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	miR-195:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-26a-1	Aortic Stenosis	20845893	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-26a-2	Aortic Stenosis	20845893	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-30b	Aortic Stenosis	20845893	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MiR-30b:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-142	Arteriosclerosis Obliterans	24743945	cardiovascular system disease	DOID:5160		D001162		HP:0002634	The results suggest that the expression of miR-142-3p is down-regulated in CD4+ T cells from patients with ASO. The down-regulation of miR-142-3p could increase the migration of CD4+ T cells to the vascular walls by regulation of actin cytoskeleton via its target genes, RAC1 and ROCK2.
tissue_expression_down	hsa-mir-122	Asthenozoospermia	21933900			R86.9	D053627			miR-122 was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-146b	Asthenozoospermia	21933900			R86.9	D053627			miR-146b was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-181a-2	Asthenozoospermia	21933900			R86.9	D053627			miR-181a was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-34c	Asthenozoospermia	21933900			R86.9	D053627			miR-34c-5p was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-374b	Asthenozoospermia	21933900			R86.9	D053627			miR-374b was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-509-1	Asthenozoospermia	21933900			R86.9	D053627			miR-509-5p was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-509-2	Asthenozoospermia	21933900			R86.9	D053627			miR-509-5p was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-509-3	Asthenozoospermia	21933900			R86.9	D053627			miR-509-5p was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-513a-1	Asthenozoospermia	21933900			R86.9	D053627			miR-513a-5p was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-mir-513a-2	Asthenozoospermia	21933900			R86.9	D053627			miR-513a-5p was markedly decreased in azoospermia but increased in asthenozoospermia.
tissue_expression_down	hsa-let-7a	Asthma	25130484	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	We found significantly reduced expression of let-7a in bronchial biopsies from patients with severe asthma in comparison to patients with mild asthma as well as in comparison to the non-asthmatic controls.
tissue_expression_down	hsa-let-7e	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-125b	Asthma	27112664	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	miR-125b expression was  decreased in the sputum of the asthmatic patients especially in eosinophilic asthma.
tissue_expression_down	hsa-mir-126	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-146a	Asthma	21917308	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Measurement of the microRNA expression profile showed selective downregulation of miR-28-5p in CD8(+) T cells and reduction of miR-146a and miR-146b in both CD4(+) and CD8(+) T cells.
tissue_expression_down	hsa-mir-146b	Asthma	21917308	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Measurement of the microRNA expression profile showed selective downregulation of miR-28-5p in CD8(+) T cells and reduction of miR-146a and miR-146b in both CD4(+) and CD8(+) T cells.
tissue_expression_down	hsa-mir-155	Asthma	22558995	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	The decreased expression level of miR-155 is correlated to asthma disease severity.
tissue_expression_down	hsa-mir-155	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-18a	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-192	Asthma	23170939	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MiR-192 was technically validated using real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR) showing that the level in asthmatics (pre-challenge) was significantly lower than HCs and that post-challenge was significantly lower than pre-challenge.
tissue_expression_down	hsa-mir-22	Asthma	27277384	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	miR-22-3p, miR鈥?13a-5p and miR-625-5p - were significantly downregulated in the asthma group compared with the control group
tissue_expression_down	hsa-mir-224	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_down	hsa-mir-28	Asthma	21917308	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Measurement of the microRNA expression profile showed selective downregulation of miR-28-5p in CD8(+) T cells and reduction of miR-146a and miR-146b in both CD4(+) and CD8(+) T cells.
tissue_expression_down	hsa-mir-106a	Astrocytoma	20219352	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-106a:hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma
tissue_expression_down	hsa-mir-107	Astrocytoma	21978395	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration.
tissue_expression_down	hsa-mir-124	Astrocytoma	24718706	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	The low expression of these miRNAs may constitute a potential marker of astrocytomas that correlates with localization, possibly due to alterations in the maturation processes of these miRNAs that produced low mature forms in patients with recurrent pediatric astrocytomas.
tissue_expression_down	hsa-mir-124-1	Astrocytoma	21978395	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration.
tissue_expression_down	hsa-mir-124-2	Astrocytoma	21978395	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration.
tissue_expression_down	hsa-mir-124-3	Astrocytoma	21978395	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration.
tissue_expression_down	hsa-mir-128-1	Astrocytoma	24718706	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	The low expression of these miRNAs may constitute a potential marker of astrocytomas that correlates with localization, possibly due to alterations in the maturation processes of these miRNAs that produced low mature forms in patients with recurrent pediatric astrocytomas.
tissue_expression_down	hsa-mir-133a-1	Astrocytoma	22674182	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Significantly decreased in grades II-IV patients.
tissue_expression_down	hsa-mir-133a-2	Astrocytoma	22674182	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Significantly decreased in grades II-IV patients.
tissue_expression_down	hsa-mir-137	Astrocytoma	20219352	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-137:The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease
tissue_expression_down	hsa-mir-138-1	Astrocytoma	21978395	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration.
tissue_expression_down	hsa-mir-138-2	Astrocytoma	21978395	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration.
tissue_expression_down	hsa-mir-149	Astrocytoma	21978395	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-107, miR-124, miR-138, and miR-149 were downregulated significantly in grade I-IV astrocytomas, and overexpression of miR-124 and miR-149 inhibited glioblastoma cell proliferation and migration.
tissue_expression_down	hsa-mir-150	Astrocytoma	22674182	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-150*:Significantly decreased in grades II-IV patients.
tissue_expression_down	hsa-mir-15b	Astrocytoma	22674182	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-15b*: Significantly decreased in grades II-IV patients.
tissue_expression_down	hsa-mir-181b-1	Astrocytoma	19159078	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-181b: downregulation
tissue_expression_down	hsa-mir-181b-1	Astrocytoma	20219352	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-181b:hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma
tissue_expression_down	hsa-mir-181b-2	Astrocytoma	19159078	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-181b: downregulation
tissue_expression_down	hsa-mir-181b-2	Astrocytoma	20219352	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-181b:hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma
tissue_expression_down	hsa-mir-197	Astrocytoma	22674182	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Significantly decreased in grades II-IV patients.
tissue_expression_down	hsa-mir-206	Astrocytoma	24390803	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas.
tissue_expression_down	hsa-mir-218	Astrocytoma	20711171	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.
tissue_expression_down	hsa-mir-219	Astrocytoma	20711171	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.
tissue_expression_down	hsa-mir-221	Astrocytoma	24718706	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	The low expression of these miRNAs may constitute a potential marker of astrocytomas that correlates with localization, possibly due to alterations in the maturation processes of these miRNAs that produced low mature forms in patients with recurrent pediatric astrocytomas.
tissue_expression_down	hsa-mir-23a	Astrocytoma	22674182	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Significantly decreased in grades II-IV patients.
tissue_expression_down	hsa-mir-497	Astrocytoma	22674182	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Significantly decreased in grades II-IV patients.
tissue_expression_down	hsa-mir-548b	Astrocytoma	22674182	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-548b-5p: Significantly decreased in grades II-IV patients.
tissue_expression_down	hsa-mir-126	Atherosclerosis	26221595	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	our results suggest that miR-126 (i) is overexpressed by long-term LSS, (ii) has a role in up- and downregulation of genes involved in atherosclerosis, and (iii) affects SDC-4 expression.
tissue_expression_down	hsa-mir-126	Atherosclerosis	26886754	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-126 expression was significantly down-regulated
tissue_expression_down	hsa-mir-126	Atherosclerosis	29642385	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant
tissue_expression_down	hsa-mir-125b-1	Atopic Dermatitis	17622355	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	The level of this miRNA significantly (p<0.001 for both) decreased both in psoriasis and atopic eczema.
tissue_expression_down	hsa-mir-125b-2	Atopic Dermatitis	17622355	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	The level of this miRNA significantly (p<0.001 for both) decreased both in psoriasis and atopic eczema.
tissue_expression_down	hsa-mir-193a	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_down	hsa-mir-484	Autism Spectrum Disorder	27378146	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	A chromosome 16p13.11 microduplication causes hyperactivity through dysregulation of miR-484/protocadherin-19 signaling.
tissue_expression_down	hsa-mir-16-1	Autoimmune Diseases [unspecific]	17351108				D001327	607836	HP:0002960	New Zealand black (NZB) mice (NZB) tissue sourcesof RNA showed a decrease in miR-16 in the spleen; however, theNZB kidney was not decreased in miR-16 expression compared withthe control strain expression. In addition, the NZB-derivedmalignant B-cell line, LNC, had an even greater decreased expressionof miR-16 compared with C57Bl6 spleen.
tissue_expression_down	hsa-mir-16-2	Autoimmune Diseases [unspecific]	17351108				D001327	607836	HP:0002960	New Zealand black (NZB) mice (NZB) tissue sourcesof RNA showed a decrease in miR-16 in the spleen; however, theNZB kidney was not decreased in miR-16 expression compared withthe control strain expression. In addition, the NZB-derivedmalignant B-cell line, LNC, had an even greater decreased expressionof miR-16 compared with C57Bl6 spleen.
tissue_expression_down	hsa-mir-181a	Autoimmune Diseases [unspecific]	27909056				D001327	607836	HP:0002960	Interferons Induce Expression of SAMHD1 in Monocytes through Down-regulation of miR-181a and miR-30a.
tissue_expression_down	hsa-mir-30a	Autoimmune Diseases [unspecific]	27909056				D001327	607836	HP:0002960	Interferons Induce Expression of SAMHD1 in Monocytes through Down-regulation of miR-181a and miR-30a.
tissue_expression_down	hsa-mir-141	Barrett Esophagus	21448356	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
tissue_expression_down	hsa-mir-200a	Barrett Esophagus	21448356	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
tissue_expression_down	hsa-mir-200b	Barrett Esophagus	21448356	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
tissue_expression_down	hsa-mir-200c	Barrett Esophagus	21448356	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
tissue_expression_down	hsa-mir-203	Barrett Esophagus	22094011	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to adenocarcinoma compared to normal individuals.
tissue_expression_down	hsa-mir-203	Barrett Esophagus	27374102	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-203 and miR-205 were lower in BE tissues
tissue_expression_down	hsa-mir-205	Barrett Esophagus	27374102	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-203 and miR-205 were lower in BE tissues
tissue_expression_down	hsa-mir-429	Barrett Esophagus	21448356	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.
tissue_expression_down	hsa-mir-155	Behcet Disease	22815348	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		Decreased microRNA-155 Expression in Ocular Behcet's Disease but Not in Vogt Koyanagi Harada Syndrome.
tissue_expression_down	hsa-mir-155	Behcet Disease	28482290	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease
tissue_expression_down	hsa-mir-4488	Behcet Disease	28482290	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease
tissue_expression_down	hsa-mir-638	Behcet Disease	28482290	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease
tissue_expression_down	hsa-let-7c	Bladder Neoplasms	25991007			C67	D001749	109800	HP:0009725	The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
tissue_expression_down	hsa-mir-1	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	down-regulated (miR-133a-3p, miR-1-3p, miR-99a-5p, miR-490-5p, and miR-133b)
tissue_expression_down	hsa-mir-1	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-100	Bladder Neoplasms	22393979			C67	D001749	109800	HP:0009725	Differential miRNA expression profiles in bladder urothelial carcinomas identified miR-100 down-regulation and miR-708 up-regulation among the most common alterations
tissue_expression_down	hsa-mir-124	Bladder Neoplasms	26310391			C67	D001749	109800	HP:0009725	Collectively, our study demonstrates that miR-124 can impair the proliferation or metastasis of human bladder cancer cells by down-regulation of UHRF1.
tissue_expression_down	hsa-mir-125	Bladder Neoplasms	25991007			C67	D001749	109800	HP:0009725	The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
tissue_expression_down	hsa-mir-125b	Bladder Neoplasms	19378336			C67	D001749	109800	HP:0009725	We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs.
tissue_expression_down	hsa-mir-125b	Bladder Neoplasms	23712207			C67	D001749	109800	HP:0009725	miRNAs downregulated in bladder cancer, such as miR-145, miR-143 and miR125b, are known to be tumour suppressors
tissue_expression_down	hsa-mir-1281	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-133a	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	five down-regulated (miR-133a-3p, miR-1-3p, miR-99a-5p, miR-490-5p, and miR-133b)
tissue_expression_down	hsa-mir-133a	Bladder Neoplasms	19378336			C67	D001749	109800	HP:0009725	We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs.
tissue_expression_down	hsa-mir-133a	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-133b	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	five down-regulated (miR-133a-3p, miR-1-3p, miR-99a-5p, miR-490-5p, and miR-133b)
tissue_expression_down	hsa-mir-133b	Bladder Neoplasms	19378336			C67	D001749	109800	HP:0009725	We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs.
tissue_expression_down	hsa-mir-133b	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-143	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-143	Bladder Neoplasms	23712207			C67	D001749	109800	HP:0009725	miRNAs downregulated in bladder cancer, such as miR-145, miR-143 and miR125b, are known to be tumour suppressors
tissue_expression_down	hsa-mir-145	Bladder Neoplasms	25991007			C67	D001749	109800	HP:0009725	The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
tissue_expression_down	hsa-mir-145	Bladder Neoplasms	19915607			C67	D001749	109800	HP:0009725	Our data indicate that reduction in miR-145 expression may provide bladder cancer cells with a selective advantage by inhibition of cell death otherwise triggered in malignant cells.
tissue_expression_down	hsa-mir-145	Bladder Neoplasms	19378336			C67	D001749	109800	HP:0009725	We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs.
tissue_expression_down	hsa-mir-145	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-145	Bladder Neoplasms	23712207			C67	D001749	109800	HP:0009725	miRNAs downregulated in bladder cancer, such as miR-145, miR-143 and miR125b, are known to be tumour suppressors
tissue_expression_down	hsa-mir-148a	Bladder Neoplasms	26700670			C67	D001749	109800	HP:0009725	miR-148a expression was decreased in bladder cancer specimens and reduced miR-148a expression was associated with poorer survival time
tissue_expression_down	hsa-mir-195	Bladder Neoplasms	19378336			C67	D001749	109800	HP:0009725	We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs.
tissue_expression_down	hsa-mir-199a	Bladder Neoplasms	25991007			C67	D001749	109800	HP:0009725	The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
tissue_expression_down	hsa-mir-199a	Bladder Neoplasms	19378336			C67	D001749	109800	HP:0009725	We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs.
tissue_expression_down	hsa-mir-199a	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-199b	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-200c	Bladder Neoplasms	25367080			C67	D001749	109800	HP:0009725	miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3.
tissue_expression_down	hsa-mir-204	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-30a	Bladder Neoplasms	19378336			C67	D001749	109800	HP:0009725	We identified a subset of 7 miRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) that were significantly downregulated in BCs.
tissue_expression_down	hsa-mir-490	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	five down-regulated (miR-133a-3p, miR-1-3p, miR-99a-5p, miR-490-5p, and miR-133b)
tissue_expression_down	hsa-mir-921	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_down	hsa-mir-99a	Bladder Neoplasms	24957100			C67	D001749	109800	HP:0009725	Our data indicated that miR-99a might act as a tumor suppressor in bladder cancer and was significantly down-regulated in development of bladder cancer.
tissue_expression_down	hsa-mir-99a	Bladder Neoplasms	25991007			C67	D001749	109800	HP:0009725	The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
tissue_expression_down	hsa-mir-99a	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	five down-regulated (miR-133a-3p, miR-1-3p, miR-99a-5p, miR-490-5p, and miR-133b)
tissue_expression_down	hsa-let-7	Breast Neoplasms	27082076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Significant alterations of expression included upregulation of miR-21-5p and the miR-200 family and downregulation of let-7 family members in DCIS samples.
tissue_expression_down	hsa-let-7a-1	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7a-2	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a-2, 7a-3, 7d, 7f-2 downregulated in breast cancer
tissue_expression_down	hsa-let-7a-2	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7a-3	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a-2, 7a-3, 7d, 7f-2 downregulated in breast cancer
tissue_expression_down	hsa-let-7a-3	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7b	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7c	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7c	Breast Neoplasms	25122196	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Let-7c were among the identified downregulated epithelial  miRNAs and its functions were delineated in unique CCH derived cells and breast cancer cell line MCF-7 suggesting anti-proliferative traits potentially due to effects on Myb and ER伪.
tissue_expression_down	hsa-let-7d	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a-2, 7a-3, 7d, 7f-2 downregulated in breast cancer
tissue_expression_down	hsa-let-7d	Breast Neoplasms	22315424	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7d, miR-210, and -221 were down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an expression reversal along the cancer progression path.
tissue_expression_down	hsa-let-7d	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7e	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7f-1	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7f-2	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a-2, 7a-3, 7d, 7f-2 downregulated in breast cancer
tissue_expression_down	hsa-let-7f-2	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-let-7f-2	Breast Neoplasms	22407818	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
tissue_expression_down	hsa-let-7g	Breast Neoplasms	21868760	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with estrogen or EGF specifically reduced the expression of mature let-7g through activation of p44/42 MAPK and subsequently stimulated expression of GAB2 and FN1, which in turn promoted tumor invasion. We thus identify let-7g as a unique member of the let-7 miRNA family which can serve as a prognostic biomarker in breast cancer and also  propose a paradigm utilized by specific signaling molecules via let-7g to cooperatively promote breast cancer invasion and metastasis.
tissue_expression_down	hsa-let-7g	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_down	hsa-mir-101	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_down	hsa-mir-107	Breast Neoplasms	27813254	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-107 is downregulated and having tumor suppressive effect in breast cancer by negatively regulating brain-derived neurotrophic factor.
tissue_expression_down	hsa-mir-107	Breast Neoplasms	28128741	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy
tissue_expression_down	hsa-mir-10b	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-10b downregulated in breast cancer (Iorio et al., 2005);
tissue_expression_down	hsa-mir-10b	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-10b	Breast Neoplasms	23125021	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours
tissue_expression_down	hsa-mir-124	Breast Neoplasms	25731732	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4.
tissue_expression_down	hsa-mir-124	Breast Neoplasms	25924779	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These findings proved that the decreased expression of miR-124 might be associated with tumor progression and poor prognosis in patients with breast cancer.
tissue_expression_down	hsa-mir-124	Breast Neoplasms	26415857	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data suggested that decreased expression of miR-124 has prognostic value in breast cancer and may serve as a prognostic marker for breast cancer, and also downregulation of miR-124 was inversely associated with the lymph node metastasis in breast cancer.
tissue_expression_down	hsa-mir-125a	Breast Neoplasms	25531695	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	HDACi influence tumorigenesis and apoptosis via downregulation of miR-125a-5p expression. This study provides clinical implications in cancer chemotherapy using HDACi.
tissue_expression_down	hsa-mir-125a	Breast Neoplasms	26782438	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, these findings suggest that miR-125a-5p may play an important role in BC progression in an age-dependent manner, and that the down-regulation of miR-125a-5p and miR-125b may serve as independent predictors for breast cancer.
tissue_expression_down	hsa-mir-125a	Breast Neoplasms	16103053	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulation
tissue_expression_down	hsa-mir-125a	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-125a, b1, b2 downregulated in breast cancer (Iorio et al., 2005);
tissue_expression_down	hsa-mir-125b	Breast Neoplasms	19290006	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221.
tissue_expression_down	hsa-mir-125b-1	Breast Neoplasms	16103053	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulation
tissue_expression_down	hsa-mir-125b-1	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-125a, b1, b2 downregulated in breast cancer (Iorio et al., 2005);
tissue_expression_down	hsa-mir-125b-1	Breast Neoplasms	22898264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miR-21 and miR-191 and downregulation of miR-125b, was found in breast cancer tissue.
tissue_expression_down	hsa-mir-125b-2	Breast Neoplasms	16103053	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulation
tissue_expression_down	hsa-mir-125b-2	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-125a, b1, b2 downregulated in breast cancer (Iorio et al., 2005);
tissue_expression_down	hsa-mir-125b-2	Breast Neoplasms	22898264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miR-21 and miR-191 and downregulation of miR-125b, was found in breast cancer tissue.
tissue_expression_down	hsa-mir-126	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down regulation in mir-17p, mir-126, mir-335, mir-30b
tissue_expression_down	hsa-mir-126	Breast Neoplasms	20801493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05).
tissue_expression_down	hsa-mir-129-1	Breast Neoplasms	22907300	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-129 is found to significantly inhibit the migration of MDA-MB-231 both in Transwell migration assay and wound healing assay. Furthermore, miR-129 also shows great suppressive ability to cell mobility and migration in another two breast cancer cell lines BT549 and MDA-MB-435s. Most importantly, miR-129 is down-regulated both in breast cancer tissues compared with the paired adjacent normal breast tissues, and in breast cancer cell lines compared with normal breast epithelial cell MCF10A (P < 0.05).
tissue_expression_down	hsa-mir-129-2	Breast Neoplasms	22907300	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-129 is found to significantly inhibit the migration of MDA-MB-231 both in Transwell migration assay and wound healing assay. Furthermore, miR-129 also shows great suppressive ability to cell mobility and migration in another two breast cancer cell lines BT549 and MDA-MB-435s. Most importantly, miR-129 is down-regulated both in breast cancer tissues compared with the paired adjacent normal breast tissues, and in breast cancer cell lines compared with normal breast epithelial cell MCF10A (P < 0.05).
tissue_expression_down	hsa-mir-132	Breast Neoplasms	23399321	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation
tissue_expression_down	hsa-mir-133b	Breast Neoplasms	19946373	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulated
tissue_expression_down	hsa-mir-139	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-140	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-141	Breast Neoplasms	25241899	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.
tissue_expression_down	hsa-mir-141	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_down	hsa-mir-143	Breast Neoplasms	27236032	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression levels of miR-143, miR-663a and miR-668 were significantly reduced in FHIT downregulated tumors.
tissue_expression_down	hsa-mir-145	Breast Neoplasms	16103053	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulation
tissue_expression_down	hsa-mir-145	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-145 downregulated in breast cancer (Iorio et al., 2005) and lung cancer and deleted in prostate cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-145	Breast Neoplasms	20331864	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated in male breast cancer
tissue_expression_down	hsa-mir-145	Breast Neoplasms	27396353	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Loss of miR-145 expression is related to the development of breast cancer complicated by T2DM, and low miR-145 expression might be an adverse prognostic factor in patients with this disease.
tissue_expression_down	hsa-mir-146a	Breast Neoplasms	25596948	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	quercetin exhibited excellent effect on inhibiting cell proliferation in human breast cancer cells, which was performed by up-regulating miR-146a expression, then via inducing apoptosis through caspase-3 activation and mitochondrial-dependent pathways, and inhibiting invasion through down-regulating the expression of EGFR.
tissue_expression_down	hsa-mir-146a	Breast Neoplasms	26406414	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulations of miR-146a and miR-146b expression in breast tissues were related to development and deterioration of breast cancer. miR-146a and miR-146b might act as potential biomarkers for young women with breast cancer.
tissue_expression_down	hsa-mir-146a	Breast Neoplasms	26458573	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, catalpol suppresses proliferation and facilitates apoptosis of MCF-7 breast cancer cells through upregulating miR-146a and downregulating MMP-16 expression.
tissue_expression_down	hsa-mir-146b	Breast Neoplasms	26406414	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulations of miR-146a and miR-146b expression in breast tissues were related to development and deterioration of breast cancer. miR-146a and miR-146b might act as potential biomarkers for young women with breast cancer.
tissue_expression_down	hsa-mir-15	Breast Neoplasms	28128741	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy
tissue_expression_down	hsa-mir-16-1	Breast Neoplasms	22583478	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
tissue_expression_down	hsa-mir-17	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down regulation in mir-17p, mir-126, mir-335, mir-30b
tissue_expression_down	hsa-mir-182	Breast Neoplasms	19665978	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulated in human BCSCs
tissue_expression_down	hsa-mir-182	Breast Neoplasms	28128741	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy
tissue_expression_down	hsa-mir-183	Breast Neoplasms	19665978	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulated in human BCSCs
tissue_expression_down	hsa-mir-191	Breast Neoplasms	22898264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miR-21 and miR-191 and downregulation of miR-125b, was found in breast cancer tissue.
tissue_expression_down	hsa-mir-1915	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-mir-195	Breast Neoplasms	22800791	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The levels of miR-195 in the breast cancer with histological high grade, tumor size of T3-4, lymph nodal involvement or vessel invasion were significantly down-regulated, compared with those of patients with histological low grade (Z = -2.271, P = 0.023), tumor size of T1-2 (Z = -2.687, P = 0.007), no lymph node metastasis (Z = -1.967, P = 0.049) and vessel invasion (Z = -2.432, P = 0.015).
tissue_expression_down	hsa-mir-199a	Breast Neoplasms	20801493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05).
tissue_expression_down	hsa-mir-199b	Breast Neoplasms	27788476	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients.
tissue_expression_down	hsa-mir-19a	Breast Neoplasms	23831570	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene.
tissue_expression_down	hsa-mir-19a	Breast Neoplasms	26416600	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the expression levels of miR-19a-3p, miR-19b-3p and miR-130a-3p were much lower in the MCF-7 cells
tissue_expression_down	hsa-mir-200	Breast Neoplasms	27082076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNAs  included in the invasive signatures include downregulation of miR-139-5p in aggressive subtypes and upregulation of miR-29c-5p expression in the luminal subtypes.
tissue_expression_down	hsa-mir-200a	Breast Neoplasms	19665978	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulated in human BCSCs
tissue_expression_down	hsa-mir-200a	Breast Neoplasms	23626803	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
tissue_expression_down	hsa-mir-200b	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_down	hsa-mir-200b	Breast Neoplasms	23626803	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
tissue_expression_down	hsa-mir-200c	Breast Neoplasms	22101791	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer.Down-regulated miR-200c was observed in non-responders as compared to responders. In addition, miR-200c expression was observed to be down-regulated over 800-fold in human breast cancer cells resistant to doxorubicin MCF-7/ADR as compared to the parental MCF-7 cells. Up-regulation of miR-200c with transfection of miR-200c mimics in breast cancer cells could enhance the chemosensitivity to epirubicin and reduce expression of multidrug resistance 1 mRNA and P-glycoprotein. Moreover, our study demonstrated that restoration of miR-200c in MCF-7/ADR cells could increase intracellular doxorubicin accumulation determined by flow cytometry.
tissue_expression_down	hsa-mir-200c	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_down	hsa-mir-200c	Breast Neoplasms	23626803	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
tissue_expression_down	hsa-mir-203a	Breast Neoplasms	27431784	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Moreover, we found a significant downregulation of miR-203a with increased stage in invasive lobular carcinomas, suggesting that miR-203a could represent a potential marker to discriminate stages in invasive lobular carcinomas.
tissue_expression_down	hsa-mir-205	Breast Neoplasms	19238171	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-205: Suppress cell growth and invasion by target ErbB3 and VEGF-A
tissue_expression_down	hsa-mir-205	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_down	hsa-mir-206	Breast Neoplasms	23466356	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2
tissue_expression_down	hsa-mir-21	Breast Neoplasms	26555418	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The established MCF-7/PR and SKBR-3/PR breast cancer cells show typical multidrug resistance characteristics, which can be used as the model for drug resistance study. Down-regulated miR-21 expression in MCF-7/PR and SKBR-3/PR breast cancer cells can enhance cell sensitivity to paclitaxel.
tissue_expression_down	hsa-mir-21	Breast Neoplasms	22898264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miR-21 and miR-191 and downregulation of miR-125b, was found in breast cancer tissue.
tissue_expression_down	hsa-mir-210	Breast Neoplasms	22315424	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7d, miR-210, and -221 were down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an expression reversal along the cancer progression path.
tissue_expression_down	hsa-mir-214	Breast Neoplasms	21828058	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Decreased MicroRNA-214 Levels In Breast Cancer Cells Coincides with Increased Cell Proliferation, Invasion, and Accumulation of the Polycomb Ezh2 Methyltransferase.
tissue_expression_down	hsa-mir-221	Breast Neoplasms	22315424	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7d, miR-210, and -221 were down-regulated in the in situ and up-regulated in the invasive transition, thus featuring an expression reversal along the cancer progression path.
tissue_expression_down	hsa-mir-221	Breast Neoplasms	19290006	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221.
tissue_expression_down	hsa-mir-224	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-26b	Breast Neoplasms	23939832	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion.
tissue_expression_down	hsa-mir-26b	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_down	hsa-mir-27b	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_down	hsa-mir-29b	Breast Neoplasms	28465475	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer.
tissue_expression_down	hsa-mir-302b	Breast Neoplasms	26644266	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-302S family including miR-302a, miR-302b, miR-302c, and miR-302d was significantly down-regulated in BCRP-overexpressing MCF-7/MX cells.
tissue_expression_down	hsa-mir-302d	Breast Neoplasms	26644266	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-302S family including miR-302a, miR-302b, miR-302c, and miR-302d was significantly down-regulated in BCRP-overexpressing MCF-7/MX cells.
tissue_expression_down	hsa-mir-30b	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down regulation in mir-17p, mir-126, mir-335, mir-30b
tissue_expression_down	hsa-mir-30c-2	Breast Neoplasms	25732226	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer.
tissue_expression_down	hsa-mir-335	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down regulation in mir-17p, mir-126, mir-335, mir-30b
tissue_expression_down	hsa-mir-335	Breast Neoplasms	20801493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05).
tissue_expression_down	hsa-mir-342	Breast Neoplasms	21172025	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Downregulation of miR-342 is Associated with Tamoxifen Resistant Breast Tumors.
tissue_expression_down	hsa-mir-342	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_down	hsa-mir-34a	Breast Neoplasms	25771001	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we provide direct evidence that TQ-Nps showed more efficiency in killing cancer cells as well as proved to be less toxic to normal cells at a significantly lower dose than TQ.NPs mediated miR-34a up-regulation directly down-regulated Rac1 expression followed by actin depolymerisation thereby disrupting the actin cytoskeleton which leads to significant reduction in the lamellipodia and filopodia formation on cell surfaces thus retarding cell migration.
tissue_expression_down	hsa-mir-34a	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-34 downregulated in breast cancer (Iorio et al., 2005)
tissue_expression_down	hsa-mir-34a	Breast Neoplasms	22623155	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.
tissue_expression_down	hsa-mir-34a	Breast Neoplasms	26553365	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Here we show that SNAI2 down-regulates miR34a expression in hypoxic MCF7 cell-derived mammospheres.
tissue_expression_down	hsa-mir-34b	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-34 downregulated in breast cancer (Iorio et al., 2005)
tissue_expression_down	hsa-mir-34c	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-34 downregulated in breast cancer (Iorio et al., 2005)
tissue_expression_down	hsa-mir-365a	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-365b	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-429	Breast Neoplasms	19665978	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulated in human BCSCs
tissue_expression_down	hsa-mir-450a-1	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-450a-2	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-450b	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_down	hsa-mir-451a	Breast Neoplasms	21666713	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Tamoxifen downregulation of miR-451 increases 14-3-3 and promotes breast cancer cell survival and endocrine resistance.
tissue_expression_down	hsa-mir-486	Breast Neoplasms	19946373	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-486-5p: downregulated
tissue_expression_down	hsa-mir-497	Breast Neoplasms	24143964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulation of miR-497 was correlated with BC progression, and miR-497 might be a potential molecular biomarker for predicting the prognosis of patients.
tissue_expression_down	hsa-mir-497	Breast Neoplasms	20331864	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated in male breast cancer
tissue_expression_down	hsa-mir-519d	Breast Neoplasms	26238950	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression.
tissue_expression_down	hsa-mir-661	Breast Neoplasms	24141721	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-661 downregulates both Mdm2 and Mdm4 to activate p53.
tissue_expression_down	hsa-mir-663a	Breast Neoplasms	27236032	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression levels of miR-143, miR-663a and miR-668 were significantly reduced in FHIT downregulated tumors.
tissue_expression_down	hsa-mir-668	Breast Neoplasms	27236032	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression levels of miR-143, miR-663a and miR-668 were significantly reduced in FHIT downregulated tumors.
tissue_expression_down	hsa-mir-802	Breast Neoplasms	26080894	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1.
tissue_expression_down	hsa-mir-922	Breast Neoplasms	27236032	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression levels of  the miRNAs and FHIT were downregulated in breast cancer tissue.
tissue_expression_down	hsa-mir-96	Breast Neoplasms	19665978	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	downregulated in human BCSCs
tissue_expression_down	hsa-mir-16	Bronchiolitis Obliterans Syndrome	25941328	respiratory system disease	DOID:2799	J42	D001989		HP:0011946	The expression of miR-16 and miR-195 was significantly decreased  in lungs of OAD mice
tissue_expression_down	hsa-mir-203	Burns	22360957			M61.30	D002056			miR-203 was down-regulated in denatured dermis compared with those in normal skin.
tissue_expression_down	hsa-mir-222	Carcinoma, Adenoid Cystic	28277192	disease of cellular proliferation	DOID:0080202		D003528			Downregulation of miR-222 Induces Apoptosis and Cellular Migration in Adenoid Cystic Carcinoma Cells.
tissue_expression_down	hsa-mir-106b	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-106b: down-regulated
tissue_expression_down	hsa-mir-125b-1	Carcinoma, Adrenocortical	21472710	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors.
tissue_expression_down	hsa-mir-125b-2	Carcinoma, Adrenocortical	21472710	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors.
tissue_expression_down	hsa-mir-139	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-139: down-regulated
tissue_expression_down	hsa-mir-148a	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-148a: down-regulated
tissue_expression_down	hsa-mir-195	Carcinoma, Adrenocortical	21472710	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors.
tissue_expression_down	hsa-mir-195	Carcinoma, Adrenocortical	21859927	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. 
tissue_expression_down	hsa-mir-196a-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-196a: down-regulated
tissue_expression_down	hsa-mir-196a-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-196a: down-regulated
tissue_expression_down	hsa-mir-1974	Carcinoma, Adrenocortical	21859927	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. 
tissue_expression_down	hsa-mir-210	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-210: down-regulated
tissue_expression_down	hsa-mir-301a	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-301: down-regulated
tissue_expression_down	hsa-mir-301b	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-301: down-regulated
tissue_expression_down	hsa-mir-376a-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-376: down-regulated
tissue_expression_down	hsa-mir-376a-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-376: down-regulated
tissue_expression_down	hsa-mir-376b	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-376: down-regulated
tissue_expression_down	hsa-mir-376c	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-376: down-regulated
tissue_expression_down	hsa-mir-424	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-424: down-regulated
tissue_expression_down	hsa-mir-484	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-484: down-regulated
tissue_expression_down	hsa-mir-491	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-491: down-regulated
tissue_expression_down	hsa-mir-497	Carcinoma, Adrenocortical	21859927	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. 
tissue_expression_down	hsa-mir-139	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-139-5p is downregulated in the tumor center
tissue_expression_down	hsa-mir-140	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-140-3p is downregulated in the tumor center
tissue_expression_down	hsa-mir-145	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-183	Carcinoma, Basal Cell	22384406	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	The expression level of miR-183 was consistently lower in infiltrative than nodular tumors and could be one element underlying the difference in invasiveness.
tissue_expression_down	hsa-mir-2861	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-29c	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-29c and miR-29c* are downregulated in the tumor center
tissue_expression_down	hsa-mir-3196	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378a	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378b	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378c	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378d-1	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378d-2	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378e	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378f	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378g	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378h	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-378i	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-572	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-mir-638	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	downregulated in the tumor center
tissue_expression_down	hsa-let-7i	Carcinoma, Bladder	23946872	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Within this group, let-7b and let-7i exhibited decreased expression, while miR-1290 and miR-138 displayed increased expression levels in gemcitabine-resistant cells.
tissue_expression_down	hsa-mir-101	Carcinoma, Bladder	24834983	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Our results suggest that the expression of miR-101 is down-regulated in BTCC, which consequently favored tumor progression. MiR-101 may play an important role as a diagnostic and prognostic marker in BTCC.
tissue_expression_down	hsa-mir-205	Carcinoma, Breast	27278159			D05	D001943	114480	HP:0003002	miR-205 was a miR specific to BLBC which functioned as tumor suppressor gene through directly targeting and negatively regulating proto-oncogene KLF12.
tissue_expression_down	hsa-mir-409	Carcinoma, Breast	27735035			D05	D001943	114480	HP:0003002	Low expression of miR-409-3p is a prognostic marker for breast cancer.
tissue_expression_down	hsa-mir-136	Carcinoma, Breast, Triple Negative	27108696				D064726			miR-136 was downregulated in TNBC and negative correlated with the WHO grades
tissue_expression_down	hsa-mir-145	Carcinoma, Breast, Triple Negative	27404381				D064726			While miR-21, miR-221 and miR-210 showed  significant over-expression, miR-195 and miR-145 were downregulated and well correlated with various clinicopathological and demographic risk factors, tumor grade, clinical stage and hormone receptor status.
tissue_expression_down	hsa-mir-195	Carcinoma, Breast, Triple Negative	27404381				D064726			While miR-21, miR-221 and miR-210 showed  significant over-expression, miR-195 and miR-145 were downregulated and well correlated with various clinicopathological and demographic risk factors, tumor grade, clinical stage and hormone receptor status.
tissue_expression_down	hsa-mir-200c	Carcinoma, Breast, Triple Negative	24821285				D064726			microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells.
tissue_expression_down	hsa-mir-1246	Carcinoma, Cervical	26074491	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	The expression of miR-1246 is negatively correlated with cervical cancer procedure as well as HPV16E6 infection status and the miR-1246 may act as a diagnostic biomarker for cervical cancer. In addition, HPV16E6 infection may be a major reason leading to decrease the expression of miR-1246 in cervical cancer.This finding contributes to deep understanding of the miR-1246 function in cervical carcinogenesis.
tissue_expression_down	hsa-mir-126	Carcinoma, Cervical	25551621	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-126 expression level in human cervical cancer tissues was significantly lower than that in adjacent nontumorous tissues
tissue_expression_down	hsa-mir-132	Carcinoma, Cervical	25988335	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-212/132 downregulates SMAD2 expression to suppress the G1/S phase transition of the cell cycle and the epithelial to mesenchymal transition in cervical cancer cells.
tissue_expression_down	hsa-mir-135b	Carcinoma, Cervical	26617737	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	In conclusion, down-regulation of miR-135b inhibited cell growth in cervical cancer cells by up-regulation of FOXO1.
tissue_expression_down	hsa-mir-145	Carcinoma, Cervical	25560490	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	downregulation of miR-145 in cervical cancer is associated with aggressive progression and poor prognosis and that miR-145 may serve as a prognostic marker.
tissue_expression_down	hsa-mir-196a	Carcinoma, Cervical	25563170	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	HPV16 E5 specifically down-regulates miR196a upon infection of the human cervix and initiates the transformation of normal cervix cells to cervical carcinoma.
tissue_expression_down	hsa-mir-212	Carcinoma, Cervical	25988335	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-212/132 downregulates SMAD2 expression to suppress the G1/S phase transition of the cell cycle and the epithelial to mesenchymal transition in cervical cancer cells.
tissue_expression_down	hsa-mir-218-1	Carcinoma, Cervical	21309487	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	infection with high-risk HPV lowered the expression of miR-218 and that down-regulation of miR-218 was involved in the pathogenesis of cervical cancer
tissue_expression_down	hsa-mir-218-2	Carcinoma, Cervical	21309487	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	infection with high-risk HPV lowered the expression of miR-218 and that down-regulation of miR-218 was involved in the pathogenesis of cervical cancer
tissue_expression_down	hsa-mir-26b	Carcinoma, Cervical	26191262	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Our results showed that reduced miR-26b was correlated with tumor development and poor prognosis in human cervical cancer. The status of miR-26b expression may be a potential prognostic biomarker for cervical cancer patients.
tissue_expression_down	hsa-mir-3156	Carcinoma, Cervical	28160779	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miR-3156-3p is downregulated in HPV-positive cervical cancer and performs as a tumor-suppressive miRNA.
tissue_expression_down	hsa-mir-503	Carcinoma, Cervical	26592830	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Reduced expression of miR-503 is an independent prognostic factor in cervical cancer indicating poor prognosis.
tissue_expression_down	hsa-mir-1295	Carcinoma, Colon	28193082	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression Analysis of Previously Verified Fecal and Plasma Dow-regulated MicroRNAs (miR-4478, 1295-3p, 142-3p and 26a-5p), in FFPE Tissue Samples of CRC Patients.
tissue_expression_down	hsa-mir-142	Carcinoma, Colon	28193082	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression Analysis of Previously Verified Fecal and Plasma Dow-regulated MicroRNAs (miR-4478, 1295-3p, 142-3p and 26a-5p), in FFPE Tissue Samples of CRC Patients.
tissue_expression_down	hsa-mir-143	Carcinoma, Colon	27906435	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Down-regulation of microRNA-143 is associated with colorectal cancer progression.
tissue_expression_down	hsa-mir-21	Carcinoma, Colon	23894315	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21.
tissue_expression_down	hsa-mir-26a	Carcinoma, Colon	28193082	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression Analysis of Previously Verified Fecal and Plasma Dow-regulated MicroRNAs (miR-4478, 1295-3p, 142-3p and 26a-5p), in FFPE Tissue Samples of CRC Patients.
tissue_expression_down	hsa-mir-4478	Carcinoma, Colon	28193082	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression Analysis of Previously Verified Fecal and Plasma Dow-regulated MicroRNAs (miR-4478, 1295-3p, 142-3p and 26a-5p), in FFPE Tissue Samples of CRC Patients.
tissue_expression_down	hsa-mir-145	Carcinoma, Endometrioid Endometrial	29569698			C54.1	D018269			miRNA-145 expression was lower in DPEEOC endometrial tissues and higher in DPEEOC ovarian tissues compared to the corresponding normal tissues
tissue_expression_down	hsa-mir-197	Carcinoma, Esophageal	25117314	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Implications of microRNA-197 downregulated expression in esophageal cancer with poor prognosis.
tissue_expression_down	hsa-mir-203	Carcinoma, Esophageal	24001611	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer.
tissue_expression_down	hsa-mir-21	Carcinoma, Esophageal	24001611	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer.
tissue_expression_down	hsa-mir-625	Carcinoma, Esophageal	24508466	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-625 down-regulation promotes proliferation and invasion in esophageal cancer by targeting Sox2.
tissue_expression_down	hsa-mir-148a	Carcinoma, Gastric	28475823	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system.
tissue_expression_down	hsa-mir-199a	Carcinoma, Gastric	24065659	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MicroRNA-199a-3p is downregulated in gastric carcinomas and modulates cell proliferation.
tissue_expression_down	hsa-mir-204	Carcinoma, Gastric	28475823	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system.
tissue_expression_down	hsa-mir-224	Carcinoma, Gastric	25017365	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	the down-regulation of RKIP expression was observed in human gastric cell lines, and miR-224 could negatively regulate the expression and biological characteristics of RKIP, contributing to suppress the proliferation and invasion of gastric cells.
tissue_expression_down	hsa-mir-31	Carcinoma, Gastric	28475823	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system.
tissue_expression_down	hsa-mir-375	Carcinoma, Gastric	28475823	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system.
tissue_expression_down	hsa-mir-939	Carcinoma, Gastric	28114937	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway.
tissue_expression_down	hsa-mir-665	Carcinoma, Gastric, Signet Ring Cell	25964059				D018279			It was concluded that hsa-miR-665 and hsa-miR-95 were downregulated in GSRCC but upregulated in intestinal gastric adenocarcinoma, and the relatively differential expression of the miRNAs negatively controlling their target genes could be closely related to the high invasive metastasis and chemoresistance of GSRCC.
tissue_expression_down	hsa-mir-95	Carcinoma, Gastric, Signet Ring Cell	25964059				D018279			It was concluded that hsa-miR-665 and hsa-miR-95 were downregulated in GSRCC but upregulated in intestinal gastric adenocarcinoma, and the relatively differential expression of the miRNAs negatively controlling their target genes could be closely related to the high invasive metastasis and chemoresistance of GSRCC.
tissue_expression_down	hsa-let-7a	Carcinoma, Hepatocellular	29314614	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC
tissue_expression_down	hsa-let-7c	Carcinoma, Hepatocellular	22289550	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Levels of let-7c miRNA were significantly lower in HCC tissues than in corresponding normal adjacent tumour tissues and there was a correlation between the downregulation of let-7c and poor tissue differentiation in HCC.
tissue_expression_down	hsa-let-7c	Carcinoma, Hepatocellular	18006136	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These mice do not exhibit downregulation of let-7c gene expression thus forming the basis for the resistance to hepatocellular carcinogenesis.
tissue_expression_down	hsa-let-7g	Carcinoma, Hepatocellular	29314614	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC
tissue_expression_down	hsa-mir-1	Carcinoma, Hepatocellular	29314614	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC
tissue_expression_down	hsa-mir-106b	Carcinoma, Hepatocellular	23087084	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma
tissue_expression_down	hsa-mir-107	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-10a	Carcinoma, Hepatocellular	22976466	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Significant downregulation of miR-10a was observed in tumor compared with non-tumor tissues (0.50 vs. 1.73, p = 0.031).
tissue_expression_down	hsa-mir-122	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122: be decreased in HCC compared to non-tumoral tissue
tissue_expression_down	hsa-mir-122	Carcinoma, Hepatocellular	19711427	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	down-regulation at early stage
tissue_expression_down	hsa-mir-122	Carcinoma, Hepatocellular	20859956	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122a:microRNA-122a (miR-122a) is a liver-specific miRNA that is frequently downregulated in hepatocellular carcinoma (HCC)
tissue_expression_down	hsa-mir-122	Carcinoma, Hepatocellular	21750653	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The down-regulation of miR-122 activated the CDK4-PSMD10-UPR pathway to decrease tumor cell anticancer drug-mediated apoptosis.
tissue_expression_down	hsa-mir-122	Carcinoma, Hepatocellular	22174818	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p=0.043).
tissue_expression_down	hsa-mir-122	Carcinoma, Hepatocellular	22312705	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins.
tissue_expression_down	hsa-mir-122	Carcinoma, Hepatocellular	23727126	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122, a liver-specific tumor suppressor microRNA, is frequently down-regulated in hepatocellular carcinoma (HCC)
tissue_expression_down	hsa-mir-122	Carcinoma, Hepatocellular	29314614	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC
tissue_expression_down	hsa-mir-1228	Carcinoma, Hepatocellular	25422913	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1228 functions as an oncogene by promoting cell cycle progression and cell mobility and negatively regulates the expression of p53. p53 downregulation in turn leads to an increase in miR-1228 expression, thereby forming a positive feedback loop that contributes to cancerogenesis in HCC.
tissue_expression_down	hsa-mir-1228	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-1246	Carcinoma, Hepatocellular	25159494	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study showed that miR-1246, by down-regulation CADM1, enhances migration and invasion in HCC cells.
tissue_expression_down	hsa-mir-1249	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-125a	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	downregulated
tissue_expression_down	hsa-mir-125a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-125b-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-125b-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-1275	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-129	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-1290	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-1290 was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_down	hsa-mir-129-1	Carcinoma, Hepatocellular	22536440	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma.
tissue_expression_down	hsa-mir-129-2	Carcinoma, Hepatocellular	22536440	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma.
tissue_expression_down	hsa-mir-130a	Carcinoma, Hepatocellular	25218269	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis.
tissue_expression_down	hsa-mir-133b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-134	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-138	Carcinoma, Hepatocellular	25439221	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the combined expression of miR-138 and its direct target CCND3 may be correlated with significant characteristics of HCC. MiR-138 downregulation and CCND3 upregulation maybe concurrently associated with  prognosis in patients with HCC.
tissue_expression_down	hsa-mir-138	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-139	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-139	Carcinoma, Hepatocellular	24549282	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival.
tissue_expression_down	hsa-mir-142	Carcinoma, Hepatocellular	26293610	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility.
tissue_expression_down	hsa-mir-143	Carcinoma, Hepatocellular	25270212	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The miR-143 expression was low in hepatic carcinoma and its over-expression could down-regulate the expressions of TLR2, NF-κB, MMP-2 and MMP-9.
tissue_expression_down	hsa-mir-143	Carcinoma, Hepatocellular	26722463	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-143 down-regulates TLR2 expression in hepatoma cells and inhibits hepatoma cell proliferation and invasion.
tissue_expression_down	hsa-mir-144	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-145	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-145: be decreased in HCC compared to non-tumoral tissue
tissue_expression_down	hsa-mir-145	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	down-regulated in HCC tissues.
tissue_expression_down	hsa-mir-145	Carcinoma, Hepatocellular	26512974	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HBV infection promotes cell growth, at least partially, through the HBX-induced downregulation of miRNA-145 expression, which is responsible for the oncogenesis of HBV-associated HCC.
tissue_expression_down	hsa-mir-145	Carcinoma, Hepatocellular	18307259	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma.
tissue_expression_down	hsa-mir-146	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-146a	Carcinoma, Hepatocellular	21829663	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues.
tissue_expression_down	hsa-mir-146a	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	down-regulated in HCC tissues.
tissue_expression_down	hsa-mir-146a	Carcinoma, Hepatocellular	24172202	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulation of miR-146a is related to HCC carcinogenesis and deterioration of HCC. MicroRNA-146a may act as a suppressor miRNA of HCC, and it is therefore a potential prognostic biomarker for HCC patients.
tissue_expression_down	hsa-mir-148a	Carcinoma, Hepatocellular	25444499	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Underexpression of miR-148a might be associated with HCC tumorigenesis and deterioration of HCC. miR-148a might act as a suppressor miRNA  of HCC and it therefore has a potential role in prognosis of HCC patients.
tissue_expression_down	hsa-mir-148a	Carcinoma, Hepatocellular	26248880	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulation of miR-148a is related to HCC carcinogenesis and deterioration of HCC. MicroRNA-148a may act as a suppressor miRNA of HCC, and it is therefore a potential prognostic biomarker for HCC patients.
tissue_expression_down	hsa-mir-148b	Carcinoma, Hepatocellular	24805877	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated  with prognosis.
tissue_expression_down	hsa-mir-150	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-151a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-155	Carcinoma, Hepatocellular	19711427	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated up-regulation of oncogenic miR-155, miR-221/222, and miR-21 and down-regulation of the most abundant liver-specific miR-122 at early stages of hepatocarcinogenesis.
tissue_expression_down	hsa-mir-15a	Carcinoma, Hepatocellular	21629246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro.
tissue_expression_down	hsa-mir-15a	Carcinoma, Hepatocellular	22033921	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The microRNA 15/16 cluster downregulates protein repair isoaspartyl methyltransferase in hepatoma cells. The authors conclude that PCMT is effectively regulated by the miR15a-16-1 cluster and is involved in apoptosis by preserving the structural stability and biological function of BclxL from deamidation. Control of PCMT expression by snRNAs may thus represent a late check point in apoptosis regulation.
tissue_expression_down	hsa-mir-16-1	Carcinoma, Hepatocellular	21629246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro.
tissue_expression_down	hsa-mir-16-1	Carcinoma, Hepatocellular	22033921	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The microRNA 15/16 cluster downregulates protein repair isoaspartyl methyltransferase in hepatoma cells. The authors conclude that PCMT is effectively regulated by the miR15a-16-1 cluster and is involved in apoptosis by preserving the structural stability and biological function of BclxL from deamidation. Control of PCMT expression by snRNAs may thus represent a late check point in apoptosis regulation.
tissue_expression_down	hsa-mir-16-2	Carcinoma, Hepatocellular	21629246	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro.
tissue_expression_down	hsa-mir-181c	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-182	Carcinoma, Hepatocellular	22681717	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma.
tissue_expression_down	hsa-mir-187	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-187* was down-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract.
tissue_expression_down	hsa-mir-18a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-18b	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-190a	Carcinoma, Hepatocellular	21829663	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues.
tissue_expression_down	hsa-mir-193a	Carcinoma, Hepatocellular	26263159	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-193a-3p may be a tumor-suppressive miRNA which is down-regulated in HCC tissues. It could be regarded as a predictor for the deterioration of HCC patients.
tissue_expression_down	hsa-mir-195	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	downregulated
tissue_expression_down	hsa-mir-195	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-197	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-198	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-198: up to five-fold down-regulated in hepatic tumors compared to normal liver parenchyma
tissue_expression_down	hsa-mir-198	Carcinoma, Hepatocellular	18307259	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma.
tissue_expression_down	hsa-mir-199a	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-199a-1	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	downregulated
tissue_expression_down	hsa-mir-199a-1	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-199a: be decreased in HCC compared to non-tumoral tissue
tissue_expression_down	hsa-mir-199a-1	Carcinoma, Hepatocellular	22713463	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell.
tissue_expression_down	hsa-mir-199a-2	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	downregulated
tissue_expression_down	hsa-mir-199a-2	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-199a: be decreased in HCC compared to non-tumoral tissue
tissue_expression_down	hsa-mir-199a-2	Carcinoma, Hepatocellular	22713463	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell.
tissue_expression_down	hsa-mir-199b	Carcinoma, Hepatocellular	21557766	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-199b-5p: Patients with lower levels of miR-199b expression had poorer overall survival and progression-free survival rates, whereas patients with higher levels of miR-199b expression had better survival.
tissue_expression_down	hsa-mir-19a	Carcinoma, Hepatocellular	27012708	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
tissue_expression_down	hsa-mir-200a	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	downregulated
tissue_expression_down	hsa-mir-200a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-200c	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	down-regulated in HCC tissues.
tissue_expression_down	hsa-mir-200c	Carcinoma, Hepatocellular	26940140	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of miR-200c and  miR-34a in the RFA group was significantly lower than that in the non-RFA group
tissue_expression_down	hsa-mir-202	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-204	Carcinoma, Hepatocellular	25652855	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Growth inhibition of human hepatocellular carcinoma by miRNA-204 via down-regulation of Bcl-2 and Sirt1 expression.
tissue_expression_down	hsa-mir-208a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-208b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-21	Carcinoma, Hepatocellular	19711427	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated up-regulation of oncogenic miR-155, miR-221/222, and miR-21 and down-regulation of the most abundant liver-specific miR-122 at early stages of hepatocarcinogenesis.
tissue_expression_down	hsa-mir-21	Carcinoma, Hepatocellular	22174818	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p=0.043).
tissue_expression_down	hsa-mir-21	Carcinoma, Hepatocellular	26222667	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results demonstrated that p53 is responsible for the anti-tumor effect of BA through up-regulation of p66(shc) and miR-21 and down-regulation of Sod2 expression, leading to mitochondrial ROS accumulation and apoptosis. The p53-p66(shc)/miR-21-Sod2 signaling is critical for BA-inhibited tumor growth and cancer cell proliferation.
tissue_expression_down	hsa-mir-21	Carcinoma, Hepatocellular	25775917	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.
tissue_expression_down	hsa-mir-2110	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-2110 was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_down	hsa-mir-2116	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-212	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-214	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-214	Carcinoma, Hepatocellular	22613005	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma.
tissue_expression_down	hsa-mir-214	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-214	Carcinoma, Hepatocellular	24129885	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the upregulation of miR-130b and downregulation of miR-199a-5p, miR-199b-5p, and miR-214 were more significant in HCC cell lines
tissue_expression_down	hsa-mir-217	Carcinoma, Hepatocellular	27879964	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma.
tissue_expression_down	hsa-mir-22	Carcinoma, Hepatocellular	23766411	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-22 is downregulated in HCC and its expression is associated with the differentiation, metastasis and prognosis of the carcinoma. Ezrin is a potential regulatory protein of miR-22.
tissue_expression_down	hsa-mir-221	Carcinoma, Hepatocellular	19711427	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated up-regulation of oncogenic miR-155, miR-221/222, and miR-21 and down-regulation of the most abundant liver-specific miR-122 at early stages of hepatocarcinogenesis.
tissue_expression_down	hsa-mir-221	Carcinoma, Hepatocellular	21876625	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	downregulated in acute HBV infection, normally expressed in chronic HBV infection, and upregulated in HCC
tissue_expression_down	hsa-mir-221	Carcinoma, Hepatocellular	25775917	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.
tissue_expression_down	hsa-mir-222	Carcinoma, Hepatocellular	19711427	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated up-regulation of oncogenic miR-155, miR-221/222, and miR-21 and down-regulation of the most abundant liver-specific miR-122 at early stages of hepatocarcinogenesis.
tissue_expression_down	hsa-mir-222	Carcinoma, Hepatocellular	22174818	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p=0.043).
tissue_expression_down	hsa-mir-223	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-223	Carcinoma, Hepatocellular	22174818	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Although miR-222, miR-223 or miR-21 were significantly up- or down-regulated between HCC patients and healthy controls, no significant difference was observed in the levels of these miRNAs between HBV patients without and with HCC. MiR-122 in serum was significantly higher in HCC patients than healthy controls (p<0.001). More importantly, it was found that the levels of miR-122 were significantly reduced in the post-operative serum samples when compared to the pre-operative samples. Although serum miR-122 was also elevated in HBV patients with HCC comparing with those without HCC, the difference was at the border line (p=0.043).
tissue_expression_down	hsa-mir-223	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	down-regulated in HCC tissues.
tissue_expression_down	hsa-mir-223	Carcinoma, Hepatocellular	23925649	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.
tissue_expression_down	hsa-mir-224	Carcinoma, Hepatocellular	25775917	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.
tissue_expression_down	hsa-mir-24-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-24-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-26a-1	Carcinoma, Hepatocellular	21829663	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues.
tissue_expression_down	hsa-mir-26a-2	Carcinoma, Hepatocellular	21829663	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues.
tissue_expression_down	hsa-mir-296	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-296	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-29c	Carcinoma, Hepatocellular	21829663	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNAs miR-26a, -29c, -146a and -190 were significantly down-regulated in a subset of HCC tissues with carboxyl-terminal HBx truncation compared to their matching non-tumor tissues.
tissue_expression_down	hsa-mir-30b	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-30b* was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_down	hsa-mir-30d	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-320a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-320b-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-320b-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-320c-1	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-320c was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_down	hsa-mir-320c-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-320c-2	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-320c was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_down	hsa-mir-320d-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-320e	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-323b	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-453 (note: this miRNA was replaced by hsa-mir-323b) was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_down	hsa-mir-324	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-326	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-330	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-33a	Carcinoma, Hepatocellular	24015284	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-33a down-regulated β-catenin by directly binding to the 3'-UTR of β-catenin. These results suggested that AFB1 might down-regulate β-catenin by up-regulating miR-33a. This understanding opens new lines of thought in the potential role of miR-33a in the  clinical therapy of cancer.
tissue_expression_down	hsa-mir-33a	Carcinoma, Hepatocellular	27460728	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-33a downregulation in HCC cells is hypoxia-induced and is a result of HIFs upregulation. MiR-33a can modulate EMT and invasion of hepatocellular cancer cells at least partly via downregulating Twist1.
tissue_expression_down	hsa-mir-33a	Carcinoma, Hepatocellular	28291769	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
tissue_expression_down	hsa-mir-345	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-346	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-34a	Carcinoma, Hepatocellular	27879964	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma.
tissue_expression_down	hsa-mir-361	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-365a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-365b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-370	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-371	Carcinoma, Hepatocellular	23466643	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma cells
tissue_expression_down	hsa-mir-373	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-378a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-381	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-409	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-423	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-424	Carcinoma, Hepatocellular	24675898	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb.
tissue_expression_down	hsa-mir-431	Carcinoma, Hepatocellular	25775917	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.
tissue_expression_down	hsa-mir-433	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-448	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-483	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-483-5p was down-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_down	hsa-mir-483	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-483	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-484	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-485	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-486	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-486	Carcinoma, Hepatocellular	25475121	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-486-5p, which is frequently downregulated in HCC, inhibits HCC progression by targeting PIK3R1 and phosphatidylinositol 3-kinase-AKT activation.
tissue_expression_down	hsa-mir-489	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-490	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-492	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-497	Carcinoma, Hepatocellular	26336827	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In conclusion,our findings indicate that miR-497 downregulation contributes to angiogenesis and metastasis in HCC.
tissue_expression_down	hsa-mir-498	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-500a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-500b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-503	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-511	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-518b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-520d	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-520e	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-520e was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate.
tissue_expression_down	hsa-mir-526a-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-526a-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-526b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-527	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-542	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-557	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-581	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-592	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-608	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-608 was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate.
tissue_expression_down	hsa-mir-610	Carcinoma, Hepatocellular	25491321	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-610 downregulation plays essential roles in HCC progression and reduced miR-610 is correlated with Wnt/β-catenin signaling pathway.
tissue_expression_down	hsa-mir-625	Carcinoma, Hepatocellular	23205106	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The following miRNAs were downregulated in the tumor and non-tumor tissues, and thus could serve as novel biomarkers for chronic liver diseases: miR-18b*, miR-296-5p, miR-557, miR-581, miR-625*, miR-1228, miR-1249 and miR-2116*. Similarly, miR-129*, miR-146b-3p and miR-448 are novel candidates for HCC biomarkers regardless of virus infection.
tissue_expression_down	hsa-mir-629	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-629 was down-regulated in HepG2 cells after 5 hours of culture with epigallocatechin gallate.
tissue_expression_down	hsa-mir-650	Carcinoma, Hepatocellular	22767438	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma.
tissue_expression_down	hsa-mir-655	Carcinoma, Hepatocellular	28272708	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Down-regulation of miR-655-3p predicts worse clinical outcome in patients suffering from hepatocellular carcinoma.
tissue_expression_down	hsa-mir-694	Carcinoma, Hepatocellular	25333455	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Knockout of the HCC suppressor gene Lass2 downregulates the expression level of miR-694.
tissue_expression_down	hsa-mir-708	Carcinoma, Hepatocellular	26211597	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings support that miR-708, which is frequently down-regulated in HCC, may contribute to the aggressive progression of HCC and inhibit HCC cell mobility. Further studies on the identification of its target genes are required to be performed.
tissue_expression_down	hsa-mir-708	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_down	hsa-mir-744	Carcinoma, Hepatocellular	25543521	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results associate decreased miR-744  expression with HCC recurrence and prognosis, and also suggest that miR-744 is an independent predictor of survival in HCC patients after LT and may therefore be a potential biomarker for their prognosis.
tissue_expression_down	hsa-mir-765	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-765 was down-regulated in HepG2 cells after 5 hours of culture with cocoa proanthocyanidin extract.
tissue_expression_down	hsa-mir-92a-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-92a-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-92b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-93	Carcinoma, Hepatocellular	25775917	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.
tissue_expression_down	hsa-mir-942	Carcinoma, Hepatocellular	24970806	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT.
tissue_expression_down	hsa-mir-96	Carcinoma, Hepatocellular	27012708	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ANT2 shRNA downregulates miR-19a and miR-96 through the PI4K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
tissue_expression_down	hsa-mir-96	Carcinoma, Hepatocellular	18433021	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma.
tissue_expression_down	hsa-mir-99a	Carcinoma, Hepatocellular	21878637	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Lower miR-99a expression in HCC tissues significantly correlated with shorter survival of HCC patients, and miR-99a was identified to be an independent predictor for prognosis of HCC patients. Furthermore, restoration of miR-99a dramatically suppressed HCC cell growth in vitro by inducing G1 phase cell cycle arrest.
tissue_expression_down	hsa-mir-99b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was down-regulated in HepG2 cells treated with BJA32515.
tissue_expression_down	hsa-mir-143	Carcinoma, Hepatocellular, HBV-Related	29616093							These results indicated that the decreased expression of the miR-143/145 cluster and their host gene MIR143HG in HBV-associated HCC tissue was associated with prognosis, and each of  these miRNAs may serve as a valuable diagnostic biomarker for predicting HBV-associated HCC tumorigenesis
tissue_expression_down	hsa-mir-145	Carcinoma, Hepatocellular, HBV-Related	29616093							These results indicated that the decreased expression of the miR-143/145 cluster and their host gene MIR143HG in HBV-associated HCC tissue was associated with prognosis, and each of  these miRNAs may serve as a valuable diagnostic biomarker for predicting HBV-associated HCC tumorigenesis
tissue_expression_down	hsa-mir-1290	Carcinoma, Laryngeal	26694163	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	Taken together, we propose miR-1290 as the new oncomiR involved in LSCC pathogenesis. Additionally, we suggest that the oncogenic potential of miR-1290 might be expressed by the involvement in downregulation of its target genes MAF and ITPR2.
tissue_expression_down	hsa-mir-519b	Carcinoma, Laryngeal	24742516	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	The expression of MiR-519b-3p as carcinoma suppressor gene is low in laryngeal carcinoma. The cell cycle of Hep-2 cells was arrested in the G2/M phase by MiR-519b-3p.
tissue_expression_down	hsa-mir-200b	Carcinoma, Lung	27189341	disease of cellular proliferation	DOID:3905	C34.90	D008175			carcinomas exhibiting lymph vessel invasion had significantly lower expression of miR-200a (P=.0230) and miR-200b (P=.0168)
tissue_expression_down	hsa-let-7e	Carcinoma, Lung, Non-Small-Cell	22618509			C34.90	D002289		HP:0030358	We showed that, compared to adjacent non-neoplastic lung tissues, the expressions of miR-125a-5p and let-7e were decreased in AD and SCC samples
tissue_expression_down	hsa-mir-10a	Carcinoma, Lung, Non-Small-Cell	26870288			C34.90	D002289		HP:0030358	miR-10a and -26b were downregulated in FF NSCLC tissues
tissue_expression_down	hsa-mir-125a	Carcinoma, Lung, Non-Small-Cell	22618509			C34.90	D002289		HP:0030358	We showed that, compared to adjacent non-neoplastic lung tissues, the expressions of miR-125a-5p and let-7e were decreased in AD and SCC samples
tissue_expression_down	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	25384507			C34.90	D002289		HP:0030358	In tumor samples, we found downregulation of miR-15a/16 (50/83.3%), miR-34a (83.3%), miR-126 (70%), and miR-128 (63.3%).
tissue_expression_down	hsa-mir-133a	Carcinoma, Lung, Non-Small-Cell	27282282			C34.90	D002289		HP:0030358	miR-133a was down-regulated in NSCLC
tissue_expression_down	hsa-mir-141	Carcinoma, Lung, Non-Small-Cell	26783187			C34.90	D002289		HP:0030358	induction of miR-200b or miR-141 enhanced sensitivity to nintedanib in nintedanib-resistant A549 and PC1-R cells.
tissue_expression_down	hsa-mir-200a	Carcinoma, Lung, Non-Small-Cell	26783187			C34.90	D002289		HP:0030358	induction of miR-200b or miR-141 enhanced sensitivity to nintedanib in nintedanib-resistant A549 and PC1-R cells.
tissue_expression_down	hsa-mir-200b	Carcinoma, Lung, Non-Small-Cell	26783187			C34.90	D002289		HP:0030358	induction of miR-200b or miR-141 enhanced sensitivity to nintedanib in nintedanib-resistant A549 and PC1-R cells.
tissue_expression_down	hsa-mir-26a	Carcinoma, Lung, Non-Small-Cell	27447710			C34.90	D002289		HP:0030358	Additionally, statistically significant negative correlation was found between MMP-2 expression and its regulatory miR-26a.
tissue_expression_down	hsa-mir-26b	Carcinoma, Lung, Non-Small-Cell	23207443			C34.90	D002289		HP:0030358	SQCC was distinguished from normal tissue and ADC by high-level miR-205 expression and decreased miR-26b.
tissue_expression_down	hsa-mir-29b	Carcinoma, Lung, Non-Small-Cell	27447710			C34.90	D002289		HP:0030358	The decrease in miRNA-29b expression was statistically significant and differentiated NSCLC histopathological subtypes.
tissue_expression_down	hsa-mir-429	Carcinoma, Lung, Non-Small-Cell	26783187			C34.90	D002289		HP:0030358	Expression of miR-200b, miR-200a and miR-141 belonging to the miR-200 family which contributes to epithelial-mesenchymal transition (EMT), was significantly lower
tissue_expression_down	hsa-mir-451	Carcinoma, Lung, Non-Small-Cell	28704499			C34.90	D002289		HP:0030358	The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases.
tissue_expression_down	hsa-mir-486	Carcinoma, Lung, Non-Small-Cell	27291819			C34.90	D002289		HP:0030358	miR-486-5p was down-regulated in adenocarcinoma
tissue_expression_down	hsa-let-7a-1	Carcinoma, Lung, Non-Small-Cell	21468581			C34.90	D002289		HP:0030358	Let-7a miRNAs were under-expressed in the blood of NSCLC patients, as well as NSCLC cells and NSCLC tissues, compared to normal controls.
tissue_expression_down	hsa-let-7a-1	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
tissue_expression_down	hsa-let-7a-2	Carcinoma, Lung, Non-Small-Cell	21468581			C34.90	D002289		HP:0030358	Let-7a miRNAs were under-expressed in the blood of NSCLC patients, as well as NSCLC cells and NSCLC tissues, compared to normal controls.
tissue_expression_down	hsa-let-7a-2	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
tissue_expression_down	hsa-let-7a-3	Carcinoma, Lung, Non-Small-Cell	21468581			C34.90	D002289		HP:0030358	Let-7a miRNAs were under-expressed in the blood of NSCLC patients, as well as NSCLC cells and NSCLC tissues, compared to normal controls.
tissue_expression_down	hsa-let-7a-3	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
tissue_expression_down	hsa-let-7b	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	Reduced plasma expression of let-7b was modestly associated with worse cancer-specific mortality in all patients and reduced serum expression of miR-223 was modestly associated with cancer-specific mortality in stage IA/B patients.
tissue_expression_down	hsa-mir-1	Carcinoma, Lung, Non-Small-Cell	24328409			C34.90	D002289		HP:0030358	Low expression of miR-1 and overexpression of PIK3CA in NSCLC tissues may be useful predictors of lymph node metastasis and postoperative recurrence in patients with NSCLC.
tissue_expression_down	hsa-mir-125a	Carcinoma, Lung, Non-Small-Cell	20569443			C34.90	D002289		HP:0030358	miR-125a-3p:Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer
tissue_expression_down	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	27072269			C34.90	D002289		HP:0030358	miR-15a/16, miR-34a, miR-126 and miR-128 were down-regulated significantly.
tissue_expression_down	hsa-mir-133a	Carcinoma, Lung, Non-Small-Cell	25903369			C34.90	D002289		HP:0030358	MiR-133a serves as a tumor-suppressive miRNA in human NSCLC, and its downregulation suggests deterioration in NSCLC patients.
tissue_expression_down	hsa-mir-134	Carcinoma, Lung, Non-Small-Cell	22937028			C34.90	D002289		HP:0030358	High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort.
tissue_expression_down	hsa-mir-143	Carcinoma, Lung, Non-Small-Cell	20363096			C34.90	D002289		HP:0030358	miR-143:Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis
tissue_expression_down	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	22835608			C34.90	D002289		HP:0030358	Low miR-145 and high miR-367 are associated with unfavorable prognosis in resected NSCLC.
tissue_expression_down	hsa-mir-148b	Carcinoma, Lung, Non-Small-Cell	25755777			C34.90	D002289		HP:0030358	our data indicate that decreased expression of miR-148b in NSCLC tissues has prognostic value.
tissue_expression_down	hsa-mir-150	Carcinoma, Lung, Non-Small-Cell	23228962			C34.90	D002289		HP:0030358	Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features
tissue_expression_down	hsa-mir-151a	Carcinoma, Lung, Non-Small-Cell	22937028			C34.90	D002289		HP:0030358	High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort.
tissue_expression_down	hsa-mir-151b	Carcinoma, Lung, Non-Small-Cell	22937028			C34.90	D002289		HP:0030358	High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort.
tissue_expression_down	hsa-mir-15a	Carcinoma, Lung, Non-Small-Cell	24500260			C34.90	D002289		HP:0030358	These findings clearly suggest that the downregulation of miR-15a-16 with Cripto amplification may be involved in the development of NSCLC.
tissue_expression_down	hsa-mir-181a-2	Carcinoma, Lung, Non-Small-Cell	20363096			C34.90	D002289		HP:0030358	miR-181a:Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis
tissue_expression_down	hsa-mir-181b	Carcinoma, Lung, Non-Small-Cell	23827213			C34.90	D002289		HP:0030358	Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
tissue_expression_down	hsa-mir-187	Carcinoma, Lung, Non-Small-Cell	26845350			C34.90	D002289		HP:0030358	MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6.
tissue_expression_down	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	21622546			C34.90	D002289		HP:0030358	Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens
tissue_expression_down	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	20363096			C34.90	D002289		HP:0030358	miR-21:Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis
tissue_expression_down	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	24667259			C34.90	D002289		HP:0030358	Our results indicated that down-regulation of miRNA-221 was associated with poor prognosis of patients with NSCLC. MiRNA-221 may serve as a molecular prognosis marker for patients with NSCLC.
tissue_expression_down	hsa-mir-29	Carcinoma, Lung, Non-Small-Cell	24909176			C34.90	D002289		HP:0030358	the decrease in the expression of miR-29b by c-Myc may be responsible for FHIT loss-mediated tumor aggressiveness and for poor outcome in NSCLC. Therefore, we suggest that restoration of the miR-29b expression using the c-Myc inhibitor might be helpful in suppressing tumor aggressiveness mediated by FHIT loss and consequently improving outcomes in NSCLC patients with tumors with low expression of FHIT.
tissue_expression_down	hsa-mir-30a	Carcinoma, Lung, Non-Small-Cell	21633953			C34.90	D002289		HP:0030358	MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer.
tissue_expression_down	hsa-mir-30a	Carcinoma, Lung, Non-Small-Cell	26238736			C34.90	D002289		HP:0030358	Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer.
tissue_expression_down	hsa-mir-32	Carcinoma, Lung, Non-Small-Cell	25755781			C34.90	D002289		HP:0030358	Our results provided the first evidence that down-regulation of miR-32 was correlated with NSCLC progression, and miR-32 might be a potential molecular biomarker for predicting the prognosis of patients.
tissue_expression_down	hsa-mir-345	Carcinoma, Lung, Non-Small-Cell	22937028			C34.90	D002289		HP:0030358	High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort.
tissue_expression_down	hsa-mir-3940	Carcinoma, Lung, Non-Small-Cell	23228962			C34.90	D002289		HP:0030358	Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features
tissue_expression_down	hsa-mir-449a	Carcinoma, Lung, Non-Small-Cell	22078727			C34.90	D002289		HP:0030358	miR-449a/b was significantly down-regulated in lung cancer tissues compared with normal lung tissues, while HDAC1 was up-regulated in lung cancer tissues.Combined treatment with miR-449a and HDAC inhibitors (apicidin and TSA) in HCC95 cells showed a significant growth reduction compared to mono-treatment with HDAC inhibitors. Interestingly, combination treatment with TSA and miR-449a was had significant growth reduction than a combination with apicidin.
tissue_expression_down	hsa-mir-449b	Carcinoma, Lung, Non-Small-Cell	22078727			C34.90	D002289		HP:0030358	miR-449a/b was significantly down-regulated in lung cancer tissues compared with normal lung tissues, while HDAC1 was up-regulated in lung cancer tissues.Combined treatment with miR-449a and HDAC inhibitors (apicidin and TSA) in HCC95 cells showed a significant growth reduction compared to mono-treatment with HDAC inhibitors. Interestingly, combination treatment with TSA and miR-449a was had significant growth reduction than a combination with apicidin.
tissue_expression_down	hsa-mir-451a	Carcinoma, Lung, Non-Small-Cell	21875770			C34.90	D002289		HP:0030358	This study showed that miRNA-451 expression decreased in non-small cell lung cancer (NSCLC) tissues and that its expression was negatively associated with lymph node metastasis, the stage of TNM classification and poor prognosis of NSCLC patients. Moreover, significantly different miRNA-451 expression levels were found between smoking and non-smoking patients. The overexpression of miRNA-451 inhibited cell cycle progression, cellular migration and the invasive ability of NSCLC cells.Increased miRNA-451 expression also promoted anoikis of NSCLC cells.
tissue_expression_down	hsa-mir-486	Carcinoma, Lung, Non-Small-Cell	26238736			C34.90	D002289		HP:0030358	Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer.
tissue_expression_down	hsa-mir-503	Carcinoma, Lung, Non-Small-Cell	26191272			C34.90	D002289		HP:0030358	In patients with NSCLC, low miR-503 expression is an independent prognostic factor.
tissue_expression_down	hsa-mir-93	Carcinoma, Lung, Non-Small-Cell	22937028			C34.90	D002289		HP:0030358	High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort.
tissue_expression_down	hsa-let-7c	Carcinoma, Lung, Small-Cell	22438992			C34.90	D055752	182280	HP:0030357	Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix.
tissue_expression_down	hsa-mir-100	Carcinoma, Lung, Small-Cell	22438992			C34.90	D055752	182280	HP:0030357	Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix.
tissue_expression_down	hsa-mir-125b-1	Carcinoma, Lung, Small-Cell	22438992			C34.90	D055752	182280	HP:0030357	Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix.
tissue_expression_down	hsa-mir-125b-2	Carcinoma, Lung, Small-Cell	22438992			C34.90	D055752	182280	HP:0030357	Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix.
tissue_expression_down	hsa-mir-137	Carcinoma, Lung, Small-Cell	24412084			C34.90	D055752	182280	HP:0030357	MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation.
tissue_expression_down	hsa-mir-143	Carcinoma, Lung, Small-Cell	22438992			C34.90	D055752	182280	HP:0030357	Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix.
tissue_expression_down	hsa-mir-145	Carcinoma, Lung, Small-Cell	22438992			C34.90	D055752	182280	HP:0030357	Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix.
tissue_expression_down	hsa-mir-199a-1	Carcinoma, Lung, Small-Cell	22438992			C34.90	D055752	182280	HP:0030357	Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix.
tissue_expression_down	hsa-mir-199a-2	Carcinoma, Lung, Small-Cell	22438992			C34.90	D055752	182280	HP:0030357	Downregulation of Six MicroRNAs (has-let-7c, has-miR-100, has-miR-125b, has-miR-143, has-miR-145 and has-miR-199a-5p) Is Associated with Advanced Stage, Lymph Node Metastasis and Poor Prognosis in Small Cell Carcinoma of the Cervix.
tissue_expression_down	hsa-mir-21	Carcinoma, Lung, Small-Cell	21731696			C34.90	D055752	182280	HP:0030357	The authors observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines.
tissue_expression_down	hsa-mir-29b-1	Carcinoma, Lung, Small-Cell	21731696			C34.90	D055752	182280	HP:0030357	The authors observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines.
tissue_expression_down	hsa-mir-29b-2	Carcinoma, Lung, Small-Cell	21731696			C34.90	D055752	182280	HP:0030357	The authors observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines.
tissue_expression_down	hsa-mir-34a	Carcinoma, Lung, Small-Cell	21731696			C34.90	D055752	182280	HP:0030357	The authors observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines.
tissue_expression_down	hsa-mir-34a	Carcinoma, Merkel Cell	25491743	disease of cellular proliferation	DOID:3965	C4A.9	D015266		HP:0030447	slight underexpression was detectable in MCV-positive tumors of miR-181d. We confirmed the distinct expression of miRNAs in MCV-positive and MCV-negative tumors and confirmed statistically significant underexpression of miR-34a in MCV-negative tumors by both array analysis and qRT-PCR. Neither tumor location nor development of metastases affected miRNA expression.
tissue_expression_down	hsa-let-7c	Carcinoma, Nasopharyngeal	24751144	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	We found that  let-7c was markedly downregulated in NPC tissues compared to NPs and suppressed cell growth and cell cycle progression by modulating p15/p16/CDK4/E2F1 pathway.
tissue_expression_down	hsa-mir-199b	Carcinoma, Nasopharyngeal	27489139	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	In addition, the low expression levels of hsa-miR-4324, hsa-miR-203a and hsa-miR-199b-5p were further validated in stage I NPC by ISH.
tissue_expression_down	hsa-mir-203a	Carcinoma, Nasopharyngeal	27489139	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	In addition, the low expression levels of hsa-miR-4324, hsa-miR-203a and hsa-miR-199b-5p were further validated in stage I NPC by ISH.
tissue_expression_down	hsa-mir-21	Carcinoma, Nasopharyngeal	25031780	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-21 inhibitor suppresses proliferation and migration of nasopharyngeal carcinoma cells through down-regulation of BCL2 expression.
tissue_expression_down	hsa-mir-23a	Carcinoma, Nasopharyngeal	24498188	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	We identified fifteen differential miRNAs and 372 differential mRNAs in the radioresistant NPC cells, constructed a posttranscriptional regulatory network including 375 miRNA-target gene pairs, discovered the ten target genes coregulated by the six miRNAs, and validated that downregulated miRNA-23a was involved in NPC radioresistance through directly targeting IL-8. Our data form a basis for further investigating the mechanisms of NPC radioresistance.
tissue_expression_down	hsa-mir-24	Carcinoma, Nasopharyngeal	27157611	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-24 levels were significantly decreased in recurrent NPC
tissue_expression_down	hsa-mir-372	Carcinoma, Nasopharyngeal	25265349	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	This preliminary study indicated the tumor suppressing roles of miR-372 in cell cycle progression of TW01 cells, possibly via the down-regulation of CDK2 and CCNA1 as well as the up-regulation of CDKN1A and INCA1.Key Words: apoptosis, microRNA, nasopharyngeal carcinoma, miR-372, CDK2, CCNA1.
tissue_expression_down	hsa-mir-4324	Carcinoma, Nasopharyngeal	27489139	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	In addition, the low expression levels of hsa-miR-4324, hsa-miR-203a and hsa-miR-199b-5p were further validated in stage I NPC by ISH.
tissue_expression_down	hsa-mir-504	Carcinoma, Nasopharyngeal	26201446	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-504 mediated down-regulation of nuclear respiratory factor 1 leads to radio-resistance in nasopharyngeal carcinoma.
tissue_expression_down	hsa-let-7b	Carcinoma, Oral	20232482	gastrointestinal system disease	DOID:0050610					Together, these data demonstrate that elevated expression levels of Dicer in oral cancer cells correlate with downregulation of let-7b and  increased cell proliferation.
tissue_expression_down	hsa-mir-203	Carcinoma, Oral	25910964	gastrointestinal system disease	DOID:0050610					miR-203 downregulates Yes-1 and suppresses oncogenic activity in human oral cancer cells.
tissue_expression_down	hsa-mir-99a	Carcinoma, Oral	22751686	gastrointestinal system disease	DOID:0050610					Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells.
tissue_expression_down	hsa-mir-211	Carcinoma, Ovarian	25889927	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Our results demonstrate that miR-211 is a tumor suppressor that controls expression of Cyclin D1 and CDK6, and that its downregulation results in overexpression of Cyclin D1 and CDK6 which increases proliferation ability of EOC cells to proliferate compared to normal cells.
tissue_expression_down	hsa-mir-22	Carcinoma, Ovarian	25257702	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Our data demonstrated that the expression of miR-22 was downregulated in EOC, and associated with overall survival as well as progression-free survival, suggesting that miR-22 could serve as an efficient prognostic factor for EOC patients.
tissue_expression_down	hsa-mir-29a	Carcinoma, Ovarian	25556270	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	In SOC tissue, expression of miR-200a, miR-93, miR-146a, and miR-18a were up-regulated, while miR-145, miR-143, miR-29a were down-regulated.
tissue_expression_down	hsa-mir-630	Carcinoma, Ovarian	26345808	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	In conclusion, downregulation of miR-630 dramatically increased apoptotic cell death chemosensitivity to cisplatin and decreased the proliferation, invasion, and migration of EOC cells. MiR-630 may thus play an important role in the biological behaviors of EOC cells through negative control of the PTEN expression.
tissue_expression_down	hsa-mir-449	Carcinoma, Ovarian, Clear Cell	25238166	endocrine system disease	DOID:0050934					Low expression of miR-449 in gynecologic clear cell carcinoma.
tissue_expression_down	hsa-mir-127	Carcinoma, Pancreatic	27571739			C25.3	C562463	260350	HP:0002894	MicroRNA-127 is aberrantly downregulated and acted as a functional tumor suppressor in human pancreatic cancer.
tissue_expression_down	hsa-mir-15a	Carcinoma, Pancreatic	18665421			C25.3	C562463	260350	HP:0002894	In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas.
tissue_expression_down	hsa-mir-16	Carcinoma, Pancreatic	18665421			C25.3	C562463	260350	HP:0002894	In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas.
tissue_expression_down	hsa-mir-149	Carcinoma, Prostate	27573045	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Downregulated expression of miRNA-149 promotes apoptosis in side population cells sorted from the TSU prostate cancer cell line.
tissue_expression_down	hsa-mir-185	Carcinoma, Prostate	25673182	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MicroRNA-185 downregulates androgen receptor expression in the LNCaP prostate carcinoma cell line.
tissue_expression_down	hsa-mir-125a	Carcinoma, Rectal	21671476	disease of cellular proliferation	DOID:1993	C20	D012004			One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies.
tissue_expression_down	hsa-mir-133a	Carcinoma, Rectal	21671476	disease of cellular proliferation	DOID:1993	C20	D012004			One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies.
tissue_expression_down	hsa-mir-135a	Carcinoma, Rectal	20955366	disease of cellular proliferation	DOID:1993	C20	D012004			The miR-135a&b were the miRNAs most down-regulated by CM-1.
tissue_expression_down	hsa-mir-135b	Carcinoma, Rectal	20955366	disease of cellular proliferation	DOID:1993	C20	D012004			The miR-135a&b were the miRNAs most down-regulated by CM-1.
tissue_expression_down	hsa-mir-139	Carcinoma, Rectal	21671476	disease of cellular proliferation	DOID:1993	C20	D012004			One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies.
tissue_expression_down	hsa-mir-143	Carcinoma, Rectal	18196926	disease of cellular proliferation	DOID:1993	C20	D012004			Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors.
tissue_expression_down	hsa-mir-145	Carcinoma, Rectal	18196926	disease of cellular proliferation	DOID:1993	C20	D012004			Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors.
tissue_expression_down	hsa-mir-145	Carcinoma, Rectal	21671476	disease of cellular proliferation	DOID:1993	C20	D012004			One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies.
tissue_expression_down	hsa-mir-30a	Carcinoma, Rectal	21671476	disease of cellular proliferation	DOID:1993	C20	D012004			One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies.
tissue_expression_down	hsa-let-7b	Carcinoma, Renal Cell	25951903	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression of let-7b and let-7c was significantly decreased in 32 paired clear cell renal cell carcinoma tissue specimens
tissue_expression_down	hsa-let-7c	Carcinoma, Renal Cell	25951903	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression of let-7b and let-7c was significantly decreased in 32 paired clear cell renal cell carcinoma tissue specimens
tissue_expression_down	hsa-mir-1	Carcinoma, Renal Cell	21745735	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our data indicate that up-regulation of the oncogenic TAGLN2 was due to down-regulation of tumour-suppressive miR-1 and miR-133a in human RCC.
tissue_expression_down	hsa-mir-106b	Carcinoma, Renal Cell	20609231	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miRNA-106b:Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy
tissue_expression_down	hsa-mir-10b	Carcinoma, Renal Cell	22492545	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse.
tissue_expression_down	hsa-mir-126	Carcinoma, Renal Cell	22492545	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse.
tissue_expression_down	hsa-mir-133a	Carcinoma, Renal Cell	21745735	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our data indicate that up-regulation of the oncogenic TAGLN2 was due to down-regulation of tumour-suppressive miR-1 and miR-133a in human RCC.
tissue_expression_down	hsa-mir-133b	Carcinoma, Renal Cell	24714873	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	microRNA-133b downregulation and inhibition of cell proliferation, migration and  invasion by targeting matrix metallopeptidase-9 in renal cell carcinoma.
tissue_expression_down	hsa-mir-141	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-141: down-regulated in malignant cancer than non-malignant one
tissue_expression_down	hsa-mir-141	Carcinoma, Renal Cell	23206420	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A possible role for micro-RNA 141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance
tissue_expression_down	hsa-mir-143	Carcinoma, Renal Cell	22492545	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse.
tissue_expression_down	hsa-mir-145	Carcinoma, Renal Cell	22492545	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse.
tissue_expression_down	hsa-mir-149	Carcinoma, Renal Cell	24137408	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-141, miR-149 and miR-429 were downregulated in the ccRCC tissues
tissue_expression_down	hsa-mir-192	Carcinoma, Renal Cell	29440068	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-192 and miR-194 as downregulated
tissue_expression_down	hsa-mir-194	Carcinoma, Renal Cell	29440068	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-192 and miR-194 as downregulated
tissue_expression_down	hsa-mir-195	Carcinoma, Renal Cell	22492545	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse.
tissue_expression_down	hsa-mir-199a-1	Carcinoma, Renal Cell	23174576	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A decreased expression of miR-199a is significantly correlated with a higher tumor stage, a greater likeliness of tumor recurrence, and a poorer prognosis in RCC patients
tissue_expression_down	hsa-mir-199a-2	Carcinoma, Renal Cell	23174576	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A decreased expression of miR-199a is significantly correlated with a higher tumor stage, a greater likeliness of tumor recurrence, and a poorer prognosis in RCC patients
tissue_expression_down	hsa-mir-200b	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-200b: down-regulated in malignant cancer than non-malignant one
tissue_expression_down	hsa-mir-200c	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-200c: down-regulated in malignant cancer than non-malignant one
tissue_expression_down	hsa-mir-200c	Carcinoma, Renal Cell	21784468	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Underexpression
tissue_expression_down	hsa-mir-21	Carcinoma, Renal Cell	24902663	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-21 not only promoted cancer cell hyperplasia and contributed to tumor cell transformation and metastasis, but also post-transcriptionally downregulated PDCD4 protein expression. PDCD4 and miR-21 expression levels potentially play an important role in renal cell cancer.
tissue_expression_down	hsa-mir-218-1	Carcinoma, Renal Cell	21784468	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Underexpression
tissue_expression_down	hsa-mir-218-2	Carcinoma, Renal Cell	21784468	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Underexpression
tissue_expression_down	hsa-mir-26a-1	Carcinoma, Renal Cell	22492545	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse.
tissue_expression_down	hsa-mir-26a-2	Carcinoma, Renal Cell	22492545	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression levels of miR-143, miR-26a, miR-145, miR-10b, miR-195, and miR-126 are lower in the tumors of RCC patients who developed tumor relapse.
tissue_expression_down	hsa-mir-30c	Carcinoma, Renal Cell	24112779	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	hypoxia induces EMT in RCC cells through downregulation of miR-30c, which leads to subsequent increase of Slug expression and repression of E-cadherin production, and suggest a potential application of miR-30c in RCC treatment.
tissue_expression_down	hsa-mir-335	Carcinoma, Renal Cell	21784468	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Underexpression
tissue_expression_down	hsa-mir-363	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-363: down-regulated in malignant cancer than non-malignant one
tissue_expression_down	hsa-mir-429	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-429: down-regulated in malignant cancer than non-malignant one
tissue_expression_down	hsa-mir-510	Carcinoma, Renal Cell	25936999	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Downregulated microRNA-510-5p acts as a tumor suppressor in renal cell carcinoma.
tissue_expression_down	hsa-mir-514a-1	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-514: down-regulated in malignant cancer than non-malignant one
tissue_expression_down	hsa-mir-514a-2	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-514: down-regulated in malignant cancer than non-malignant one
tissue_expression_down	hsa-mir-514a-3	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-514: down-regulated in malignant cancer than non-malignant one
tissue_expression_down	hsa-mir-187	Carcinoma, Renal Cell, Clear-Cell	23916610	disease of cellular proliferation	DOID:4467				HP:0006770	MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3.
tissue_expression_down	hsa-mir-125b	Carcinoma, Thyroid, Anaplastic	17563749			C73	D065646	188550	HP:0011779	The overexpression of these four miRs in two human ATC-derived cell lines suggests a critical role of miR-125b and miR-26a downregulation in thyroid carcinogenesis, since a cell growth inhibition was achieved.
tissue_expression_down	hsa-mir-26a	Carcinoma, Thyroid, Anaplastic	17563749			C73	D065646	188550	HP:0011779	The overexpression of these four miRs in two human ATC-derived cell lines suggests a critical role of miR-125b and miR-26a downregulation in thyroid carcinogenesis, since a cell growth inhibition was achieved.
tissue_expression_down	hsa-mir-138	Carcinoma, Thyroid, Papillary	26380656	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-138 and miR-98 were down-regulated in tumors compared to normal tissues.
tissue_expression_down	hsa-mir-221	Carcinoma, Thyroid, Papillary	27162538	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	postoperative levels of miR-151-5p, miR-221 and miR-222 were significantly lower in patients with PTC.
tissue_expression_down	hsa-mir-222	Carcinoma, Thyroid, Papillary	27162538	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	postoperative levels of miR-151-5p, miR-221 and miR-222 were significantly lower in patients with PTC.
tissue_expression_down	hsa-mir-30c-2	Carcinoma, Thyroid, Papillary	26487287	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Our results showed that down-regulated microRNAs can be used as new potential common biomarkers of PTC and to distinguish main subtypes of PTC.MicroRNA expressions can be linked to the development of LNM of PTC. The bioinformatics framework that we have developed can be used as a starting point for the global analysis of any microRNA deep-sequencing data in an unbiased way.
tissue_expression_down	hsa-mir-7-2	Carcinoma, Thyroid, Papillary	26487287	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Our results showed that down-regulated microRNAs can be used as new potential common biomarkers of PTC and to distinguish main subtypes of PTC.MicroRNA expressions can be linked to the development of LNM of PTC. The bioinformatics framework that we have developed can be used as a starting point for the global analysis of any microRNA deep-sequencing data in an unbiased way.
tissue_expression_down	hsa-mir-133a	Cardiac Fibrosis	26371176							The results reveal that HDACs play a role in the regulation of pressure overload-induced miR-133a downregulation. This work is the first to provide insight into an epigenetic-miRNA regulatory pathway in pressure overload-induced cardiac fibrosis.
tissue_expression_down	hsa-mir-1	Cardiomegaly	26675618			I51.7	D006332		HP:0001640	mature miR-1 levels decrease with pressure-induced cardiac hypertrophy
tissue_expression_down	hsa-mir-448	Cardiomyopathy	26503985	cardiovascular system disease	DOID:0050700	I42	D009202			Our studies suggest that downregulation of miR-448-3p leads to the increase in the expression of Ncf1 gene and p47(phox) protein, as well as to the substantial increase in NOX2-derived ROS production. Cellular oxidative stress subsequently triggers events that finally culminate in cardiac tissue damage and development of cardiomyopathy.
tissue_expression_down	hsa-let-7i	Cardiomyopathy, Dilated	22041329	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	Levels of let-7i, miR-126, and miR-155 were lower in the DCM group than in the controls, whereas levels of miR-21 and TLR4 (both mRNA and protein) were higher in the DCM group than in the control group. Levels of let-7i were negatively correlated with TLR4 protein levels in all subjects. After a mean follow-up period of 509 days, 6 DCM patients (5.8%) had died due to a cardiac cause and 15 (14.6%) had developed heart failure. When patients with DCM were divided into tertiles according to let-7i levels, log-rank analysis showed that the DCM subgroup with low let-7i levels was associated with poor clinical outcomes (P = .02).
tissue_expression_down	hsa-mir-126	Cardiomyopathy, Dilated	22041329	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	Levels of let-7i, miR-126, and miR-155 were lower in the DCM group than in the controls, whereas levels of miR-21 and TLR4 (both mRNA and protein) were higher in the DCM group than in the control group. Levels of let-7i were negatively correlated with TLR4 protein levels in all subjects. After a mean follow-up period of 509 days, 6 DCM patients (5.8%) had died due to a cardiac cause and 15 (14.6%) had developed heart failure. When patients with DCM were divided into tertiles according to let-7i levels, log-rank analysis showed that the DCM subgroup with low let-7i levels was associated with poor clinical outcomes (P = .02).
tissue_expression_down	hsa-mir-155	Cardiomyopathy, Dilated	22041329	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	Levels of let-7i, miR-126, and miR-155 were lower in the DCM group than in the controls, whereas levels of miR-21 and TLR4 (both mRNA and protein) were higher in the DCM group than in the control group. Levels of let-7i were negatively correlated with TLR4 protein levels in all subjects. After a mean follow-up period of 509 days, 6 DCM patients (5.8%) had died due to a cardiac cause and 15 (14.6%) had developed heart failure. When patients with DCM were divided into tertiles according to let-7i levels, log-rank analysis showed that the DCM subgroup with low let-7i levels was associated with poor clinical outcomes (P = .02).
tissue_expression_down	hsa-mir-150	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulated
tissue_expression_down	hsa-mir-181b-1	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulated
tissue_expression_down	hsa-mir-181b-2	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulated
tissue_expression_down	hsa-mir-1303	Cardiotoxicity	26842497				D066126			early deregulation of miR-187-3p, miR-182-5p, miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-34c-3p, miR-34c-5p and miR-1303, and also the prolonged up-regulation of miR-182-5p, miR-4423-3p and miR-34c-5p.
tissue_expression_down	hsa-mir-182	Cardiotoxicity	26842497				D066126			early deregulation of miR-187-3p, miR-182-5p, miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-34c-3p, miR-34c-5p and miR-1303, and also the prolonged up-regulation of miR-182-5p, miR-4423-3p and miR-34c-5p.
tissue_expression_down	hsa-mir-187	Cardiotoxicity	26842497				D066126			early deregulation of miR-187-3p, miR-182-5p, miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-34c-3p, miR-34c-5p and miR-1303, and also the prolonged up-regulation of miR-182-5p, miR-4423-3p and miR-34c-5p.
tissue_expression_down	hsa-mir-34a	Cardiotoxicity	26842497				D066126			early deregulation of miR-187-3p, miR-182-5p, miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-34c-3p, miR-34c-5p and miR-1303, and also the prolonged up-regulation of miR-182-5p, miR-4423-3p and miR-34c-5p.
tissue_expression_down	hsa-mir-34c	Cardiotoxicity	26842497				D066126			early deregulation of miR-187-3p, miR-182-5p, miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-34c-3p, miR-34c-5p and miR-1303, and also the prolonged up-regulation of miR-182-5p, miR-4423-3p and miR-34c-5p.
tissue_expression_down	hsa-mir-486	Cardiotoxicity	26842497				D066126			early deregulation of miR-187-3p, miR-182-5p, miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-34c-3p, miR-34c-5p and miR-1303, and also the prolonged up-regulation of miR-182-5p, miR-4423-3p and miR-34c-5p.
tissue_expression_down	hsa-mir-133a-1	Cardiovascular Diseases [unspecific]	20173049				D002318			miR-133a:NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression
tissue_expression_down	hsa-mir-487b	Cardiovascular Diseases [unspecific]	24096771				D002318			Angiotensin II-induced hypertension leads to upregulation of miR-487b, which targets IRS1. Via downregulation of IRS1, miR-487b can contribute to cell death and loss of adventitial and medial integrity during hypertension-induced vascular pathology.
tissue_expression_down	hsa-let-7b	Cerebral Cavernous Malformations	28181149	disease of cellular proliferation	DOID:0060669	Q28.3	C566394	116860		Genome-Wide Sequencing Reveals MicroRNAs Downregulated in Cerebral Cavernous Malformations.
tissue_expression_down	hsa-mir-181a	Cerebral Cavernous Malformations	28181149	disease of cellular proliferation	DOID:0060669	Q28.3	C566394	116860		Genome-Wide Sequencing Reveals MicroRNAs Downregulated in Cerebral Cavernous Malformations.
tissue_expression_down	hsa-mir-361	Cerebral Cavernous Malformations	28181149	disease of cellular proliferation	DOID:0060669	Q28.3	C566394	116860		Genome-Wide Sequencing Reveals MicroRNAs Downregulated in Cerebral Cavernous Malformations.
tissue_expression_down	hsa-mir-370	Cerebral Cavernous Malformations	28181149	disease of cellular proliferation	DOID:0060669	Q28.3	C566394	116860		Genome-Wide Sequencing Reveals MicroRNAs Downregulated in Cerebral Cavernous Malformations.
tissue_expression_down	hsa-mir-95	Cerebral Cavernous Malformations	28181149	disease of cellular proliferation	DOID:0060669	Q28.3	C566394	116860		Genome-Wide Sequencing Reveals MicroRNAs Downregulated in Cerebral Cavernous Malformations.
tissue_expression_down	hsa-mir-143	Cervical Neoplasms	27278606	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	expression of miR-21 was upregulated and the expression of miR-143 was downregulated by the HPV16 E7 oncoprotein in vivo
tissue_expression_down	hsa-mir-143	Cervical Neoplasms	22997891	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The high expression of miR-21 in cervical cancer and Hela cell indicate that it may play a possible role of oncogenes, while miR-143 and miR-373 with low expression may play the role of tumor suppressor genes.
tissue_expression_down	hsa-mir-145	Cervical Neoplasms	27345415	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miRNA-145 and 9 may be as potential prognostic marker in patients suffering from cervical cancer.
tissue_expression_down	hsa-mir-34a	Cervical Neoplasms	29487007	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-21-5p upregulation, miR-34a downregulation, and hTERC amplification were associated with the aggressive progression of CC, which suggests that miR-21-5p, miR-34a and hTERC might serve as surrogate markers for CC progression and potential molecular targets for blockage of the development of CC
tissue_expression_down	hsa-mir-34a	Cervical Neoplasms	20442590	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection.
tissue_expression_down	hsa-mir-373	Cervical Neoplasms	22997891	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The high expression of miR-21 in cervical cancer and Hela cell indicate that it may play a possible role of oncogenes, while miR-143 and miR-373 with low expression may play the role of tumor suppressor genes.
tissue_expression_down	hsa-mir-200a	Cholangiocarcinoma	26586458	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-200a may suppress the proliferative and invasive ability of REB cells. The reduced miR-200a expression might be correlated with the development and progression of CCA.
tissue_expression_down	hsa-mir-494	Cholangiocarcinoma	21809359	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miRNA-494 downregulated in human cholangiocarcinoma controls cell cycle through multiple targets involved in the G1/S checkpoint.
tissue_expression_down	hsa-mir-200b	Chondrosarcoma	25301739	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells.
tissue_expression_down	hsa-mir-106a	Choriocarcinoma	27080237	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	low miR-106a expression was associated with hepatitis B virus infection in hepatocellular carcinoma.
tissue_expression_down	hsa-mir-155	Choriocarcinoma	24007214	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	There were low expressions of exosomal miR-155 and miR-196a in serum samples of PC patients when U-6 was used as a control. Serum exosomal miR-17-5p was higher in PC patients than in non-PC patients and healthy participants.
tissue_expression_down	hsa-mir-196a	Choriocarcinoma	24007214	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	There were low expressions of exosomal miR-155 and miR-196a in serum samples of PC patients when U-6 was used as a control. Serum exosomal miR-17-5p was higher in PC patients than in non-PC patients and healthy participants.
tissue_expression_down	hsa-mir-200b	Choriocarcinoma	27189341	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	carcinomas exhibiting lymph vessel invasion had significantly lower expression of miR-200a (P=.0230) and miR-200b (P=.0168)
tissue_expression_down	hsa-mir-34a	Choriocarcinoma	20351093	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	MicroRNA-34a suppresses invasion through down-regulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells
tissue_expression_down	hsa-mir-195	Chronic Heart Failure	20845893	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	miR-195:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-26a-1	Chronic Heart Failure	20845893	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-26a-2	Chronic Heart Failure	20845893	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	MiR-26a:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-30b	Chronic Heart Failure	20845893	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	MiR-30b:MiR-26a, miR-30b, and miR-195 were each decreased in the aortic valves of patients requiring AVR due to AS, compared to those requiring replacement due to AI.
tissue_expression_down	hsa-mir-106a	Chronic Hepatitis B	26265888			B18.0-.1	D019694	610424		This study suggested that miR-106a is downregulated in PBMCs of CHB patients and that miR-106a may play an important role in CHB by targeting IL-8.
tissue_expression_down	hsa-mir-130a	Chronic Hepatitis C	23418453			B18.2	D019698	609532		Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-α treatment (p<0.01)
tissue_expression_down	hsa-mir-192	Chronic Hepatitis C	23418453			B18.2	D019698	609532		Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-α treatment (p<0.01)
tissue_expression_down	hsa-mir-199a	Chronic Hepatitis C	27275163			B18.2	D019698	609532		17 miRNAs (including miR-21, miR-122, miR-199a-3p, and miR-223) showed down-regulation.
tissue_expression_down	hsa-mir-301	Chronic Hepatitis C	23418453			B18.2	D019698	609532		Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-α treatment (p<0.01)
tissue_expression_down	hsa-mir-30b	Chronic Hepatitis C	23418453			B18.2	D019698	609532		Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-α treatment (p<0.01)
tissue_expression_down	hsa-mir-30c	Chronic Hepatitis C	23418453			B18.2	D019698	609532		Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-α treatment (p<0.01)
tissue_expression_down	hsa-mir-324	Chronic Hepatitis C	23418453			B18.2	D019698	609532		Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-α treatment (p<0.01)
tissue_expression_down	hsa-mir-565	Chronic Hepatitis C	23418453			B18.2	D019698	609532		Seven miRNAs (miR-30b, miR-30c, miR-130a, miR-192, miR-301, miR-324-5p, and miR-565) were down-regulated in HCV-infected Huh7.5 cells (p<0.05) and subsequently up-regulated following interferon-α treatment (p<0.01)
tissue_expression_down	hsa-let-7e	Chronic Inflammation	27539004							PM2.5 decreased expression of miR-338-5p and let-7e-5p, both related to mental development
tissue_expression_down	hsa-mir-338	Chronic Inflammation	27539004							PM2.5 decreased expression of miR-338-5p and let-7e-5p, both related to mental development
tissue_expression_down	hsa-mir-92b	Chronic Inflammation	27539004							miR-99b-5p, miR-92b-5p, and miR-99a-5p were decreased, leading to reduced expression of Kbtbd8 and Adam11 which reduced cell mitosis, migration, and differentiation, and inhibited learning abilities and motor coordination of the fetus
tissue_expression_down	hsa-mir-99a	Chronic Inflammation	27539004							miR-99b-5p, miR-92b-5p, and miR-99a-5p were decreased, leading to reduced expression of Kbtbd8 and Adam11 which reduced cell mitosis, migration, and differentiation, and inhibited learning abilities and motor coordination of the fetus
tissue_expression_down	hsa-mir-99b	Chronic Inflammation	27539004							miR-99b-5p, miR-92b-5p, and miR-99a-5p were decreased, leading to reduced expression of Kbtbd8 and Adam11 which reduced cell mitosis, migration, and differentiation, and inhibited learning abilities and motor coordination of the fetus
tissue_expression_down	hsa-mir-133a	Chronic Kidney Disease	27419135	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miR-30b, -133a, and -143 were downregulated during the  time course of Pi-induced VC, whereas the addition of Mg(2+) restored (miR-30b) or improved (miR-133a, miR-143) their expression.
tissue_expression_down	hsa-mir-143	Chronic Kidney Disease	27419135	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miR-30b, -133a, and -143 were downregulated during the  time course of Pi-induced VC, whereas the addition of Mg(2+) restored (miR-30b) or improved (miR-133a, miR-143) their expression.
tissue_expression_down	hsa-mir-15	Chronic Kidney Disease	28771472	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension.
tissue_expression_down	hsa-mir-17	Chronic Kidney Disease	28771472	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension.
tissue_expression_down	hsa-mir-204	Chronic Kidney Disease	26707063	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miR-30d, miR-140-3p, miR-532-3p, miR-194, miR-190, miR-204 and miR-206 were downregulated in progressive cases.
tissue_expression_down	hsa-mir-100	Chronic Obstructive Pulmonary Disease	22686440	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls.
tissue_expression_down	hsa-mir-20a	Chronic Obstructive Pulmonary Disease	22686440	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls.
tissue_expression_down	hsa-mir-28	Chronic Obstructive Pulmonary Disease	22686440	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls.
tissue_expression_down	hsa-mir-34c	Chronic Obstructive Pulmonary Disease	22686440	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls.
tissue_expression_down	hsa-mir-7-1	Chronic Obstructive Pulmonary Disease	22686440	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls.
tissue_expression_down	hsa-mir-7-2	Chronic Obstructive Pulmonary Disease	22686440	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls.
tissue_expression_down	hsa-mir-7-3	Chronic Obstructive Pulmonary Disease	22686440	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	There was down-regulation of miR-20a, miR-28-3p, miR-34c-5p, and miR-100, and up-regulation of miR-7, compared with the controls.
tissue_expression_down	hsa-mir-429	Colitis	26818658	gastrointestinal system disease	DOID:0060180	K52.9	D003092	191390	HP:0002583	We investigated  MIR429 that is down-regulated in DSS-induced colitis, and identified 41 target genes of MIR429.
tissue_expression_down	hsa-mir-143	Colitis, Ulcerative	21557394	gastrointestinal system disease	DOID:8577	K51	D003093			miR-143 and miR-145 are downregulated in ulcerative colitis
tissue_expression_down	hsa-mir-145	Colitis, Ulcerative	21557394	gastrointestinal system disease	DOID:8577	K51	D003093			miR-143 and miR-145 are downregulated in ulcerative colitis
tissue_expression_down	hsa-mir-26b	Colitis, Ulcerative	26083618	gastrointestinal system disease	DOID:8577	K51	D003093			We suggest that miR-26b could serve as a biomarker for inflammation-associated processes in the gastrointestinal system. Because miR-26b expression is downregulated in sporadic colon cancer, it could discriminate between UCC and the sporadic cancer type.
tissue_expression_down	hsa-mir-1231	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_down	hsa-mir-126	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-126:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-127	Colon Neoplasms	26556872			D12.6	D003110		HP:0100273	highly up-regulated miRNAs, let-7f-5p, miR-455-3p, miR-98, miR-155-5p and the down-regulated miRNAs, miR-1, miR-127-5p, miR-142-5p, miR-202-5p were associated with colon cancer pathways
tissue_expression_down	hsa-mir-133b	Colon Neoplasms	19946373			D12.6	D003110		HP:0100273	downregulated
tissue_expression_down	hsa-mir-142	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-142-3p:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-142	Colon Neoplasms	26556872			D12.6	D003110		HP:0100273	highly up-regulated miRNAs, let-7f-5p, miR-455-3p, miR-98, miR-155-5p and the down-regulated miRNAs, miR-1, miR-127-5p, miR-142-5p, miR-202-5p were associated with colon cancer pathways
tissue_expression_down	hsa-mir-146a	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-146a:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-152	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-152:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-155	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-155:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-17	Colon Neoplasms	23436804			D12.6	D003110		HP:0100273	We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. 
tissue_expression_down	hsa-mir-18	Colon Neoplasms	23436804			D12.6	D003110		HP:0100273	We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. 
tissue_expression_down	hsa-mir-1826	Colon Neoplasms	19956872			D12.6	D003110		HP:0100273	The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated.
tissue_expression_down	hsa-mir-191	Colon Neoplasms	19956872			D12.6	D003110		HP:0100273	The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated.
tissue_expression_down	hsa-mir-197	Colon Neoplasms	19956872			D12.6	D003110		HP:0100273	The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated.
tissue_expression_down	hsa-mir-19a	Colon Neoplasms	23436804			D12.6	D003110		HP:0100273	We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. 
tissue_expression_down	hsa-mir-19b-1	Colon Neoplasms	23436804			D12.6	D003110		HP:0100273	We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. 
tissue_expression_down	hsa-mir-200a	Colon Neoplasms	23436804			D12.6	D003110		HP:0100273	We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. 
tissue_expression_down	hsa-mir-200b	Colon Neoplasms	23436804			D12.6	D003110		HP:0100273	We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. 
tissue_expression_down	hsa-mir-200b	Colon Neoplasms	25846512			D12.6	D003110		HP:0100273	The activation of PAR1 on the platelets led to the inhibition of miR-200b expression in the SW620 cells that were cultured in platelet-conditioned media.
tissue_expression_down	hsa-mir-200b	Colon Neoplasms	28552992			D12.6	D003110		HP:0100273	MicroRNA-200b is downregulated in colon cancer budding cells.
tissue_expression_down	hsa-mir-200b	Colon Neoplasms	28821160			D12.6	D003110		HP:0100273	downregulation of AKT, NF-κB, Bcl-XL expressions and some key oncomicroRNAs such as miRNA-21 and miRNA-200b significantly
tissue_expression_down	hsa-mir-205	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-205:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-20a	Colon Neoplasms	23436804			D12.6	D003110		HP:0100273	We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. 
tissue_expression_down	hsa-mir-21	Colon Neoplasms	28821160			D12.6	D003110		HP:0100273	downregulation of AKT, NF-κB, Bcl-XL expressions and some key oncomicroRNAs such as miRNA-21 and miRNA-200b significantly
tissue_expression_down	hsa-mir-222	Colon Neoplasms	19956872			D12.6	D003110		HP:0100273	The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated.
tissue_expression_down	hsa-mir-365a	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-365:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-365a	Colon Neoplasms	22072615			D12.6	D003110		HP:0100273	microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2.
tissue_expression_down	hsa-mir-365b	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-365:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-378	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_down	hsa-mir-449a	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-449:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-486	Colon Neoplasms	19946373			D12.6	D003110		HP:0100273	miR-486-5p: downregulated
tissue_expression_down	hsa-mir-518c	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-518c:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-524	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_down	hsa-mir-552	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-552:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-561	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_down	hsa-mir-584	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-584:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-615	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-615:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-622	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-622:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-630	Colon Neoplasms	20859756			D12.6	D003110		HP:0100273	miR-630:In particular, miR-126, miR-142-3p, miR-155, miR-552, and miR-630 were all upregulated, whereas miR-146a, miR-152, miR-205, miR-365, miR-449, miR-518c, miR-584, miR-615, and miR-622 were downregulated after NGX6 transfection.
tissue_expression_down	hsa-mir-886	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_down	hsa-mir-92-1	Colon Neoplasms	23436804			D12.6	D003110		HP:0100273	We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. 
tissue_expression_down	hsa-mir-92a	Colon Neoplasms	19956872			D12.6	D003110		HP:0100273	The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated.
tissue_expression_down	hsa-mir-93	Colon Neoplasms	19956872			D12.6	D003110		HP:0100273	The down-regulations of miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-1826, whose expression was significantly down-regulated in both cell lines after the treatment of one drug or in one cell line following exposure to either drug, were further validated.
tissue_expression_down	hsa-mir-93	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_down	hsa-let-7a-1	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		let-7a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-let-7a-2	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		let-7a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-let-7a-3	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		let-7a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-143	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-143:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-145	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-145:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-16-1	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-16:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-16-2	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-16:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-191	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-191:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-192	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-192:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-196a-1	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-196a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-196a-2	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-196a:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-215	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-215:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-mir-26b	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-26b:nine(miR-192, -215, -26b, -143, -145, -191, -196a, -16, and let-7a) were under-expressed in CRC
tissue_expression_down	hsa-let-7a	Colorectal Carcinoma	27262492	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		down-regulation of let-7a-5p in serums and tumour tissues of CRC patients could be used to predict lymph node metastasis and the disease prognosis.
tissue_expression_down	hsa-mir-100	Colorectal Carcinoma	25216869	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer.
tissue_expression_down	hsa-mir-100	Colorectal Carcinoma	28032929	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of microRNA-100/microRNA-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion.
tissue_expression_down	hsa-mir-124	Colorectal Carcinoma	25987767	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-124 promotes hyperplasia and contributes to invasion of CRC cells, but downregulates ROCK1. ROCK1 and miR-124 may play important roles in CRC.
tissue_expression_down	hsa-mir-125b	Colorectal Carcinoma	28032929	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of microRNA-100/microRNA-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion.
tissue_expression_down	hsa-mir-126	Colorectal Carcinoma	24532280	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer.
tissue_expression_down	hsa-mir-126	Colorectal Carcinoma	24994098	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Underexpression of miR-126 and miR-20b was observed in various types of colorectal cancer, and occurs as an early event of colorectal carcinogenesis in FAP tumors.
tissue_expression_down	hsa-mir-1295b	Colorectal Carcinoma	25519020	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of miR-4478 and miR-1295b-3p were significantly diminished in stool samples of CRC patients with early stage (I, II) in comparison with normal group. These miRNAs maybe use as potential non-invasive molecular markers for CRC diagnosis, but further studies are needed.
tissue_expression_down	hsa-mir-130b	Colorectal Carcinoma	24498407	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA- 130b suppresses migration and invasion of colorectal cancer cells through downregulation of integrin β1 [corrected].
tissue_expression_down	hsa-mir-133a	Colorectal Carcinoma	25170220	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The downregulation of miR-133a may play an important role in the progression of CRC and can be used as an independent factor to determine CRC prognosis.
tissue_expression_down	hsa-mir-143	Colorectal Carcinoma	24875473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		we discuss the early reports on the identification of dysregulated miR-143 and miR-145 expression in colorectal cancer and how lack of consideration of cellular composition of normal tissue led to the misconception that these miRNAs are downregulated in cancer. We evaluate mechanistic data from miR-143/145 studies in context of their cell type-restricted expression pattern and the potential of these miRNAs to be considered tumor suppressors.
tissue_expression_down	hsa-mir-143	Colorectal Carcinoma	21551242	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies.
tissue_expression_down	hsa-mir-145	Colorectal Carcinoma	24875473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		we discuss the early reports on the identification of dysregulated miR-143 and miR-145 expression in colorectal cancer and how lack of consideration of cellular composition of normal tissue led to the misconception that these miRNAs are downregulated in cancer. We evaluate mechanistic data from miR-143/145 studies in context of their cell type-restricted expression pattern and the potential of these miRNAs to be considered tumor suppressors.
tissue_expression_down	hsa-mir-145	Colorectal Carcinoma	21551242	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies.
tissue_expression_down	hsa-mir-145	Colorectal Carcinoma	25736690	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Significant downregulation of miR-145 in CRC group was reported at all levels
tissue_expression_down	hsa-mir-148a	Colorectal Carcinoma	28863773	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding.
tissue_expression_down	hsa-mir-193a	Colorectal Carcinoma	25232258	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of miR-193a-5p correlates with lymph node metastasis and poor survival of CRC. miR-193a-5p may be a useful biomarker for CRC diagnosis, metastasis and prognosis prediction.
tissue_expression_down	hsa-mir-200a	Colorectal Carcinoma	24504363	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In conclusion, our data suggest that low miR-200a expression is associated with poor prognosis in CRC patients. MiR-200a has a regulatory effect on EMT and is associated with cancer stem cell properties in CRC.
tissue_expression_down	hsa-mir-203	Colorectal Carcinoma	27253631	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-203 was found to be downregulated in all polyps and CRC specimens
tissue_expression_down	hsa-mir-20b	Colorectal Carcinoma	24994098	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Underexpression of miR-126 and miR-20b was observed in various types of colorectal cancer, and occurs as an early event of colorectal carcinogenesis in FAP tumors.
tissue_expression_down	hsa-mir-21	Colorectal Carcinoma	23773491	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In Taiwan, downregulation of the APC gene in CRC correlated with gene mutation and mir-21 upregulation. APC mutation and mir-21 expression could be used to predict the clinical outcome of CRC, especially in patients with advanced disease.
tissue_expression_down	hsa-mir-214	Colorectal Carcinoma	24760176	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of miR-214 is specific of liver metastasis in colorectal cancer and could play a role determining the metastatic niche.
tissue_expression_down	hsa-mir-218	Colorectal Carcinoma	24294377	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer.
tissue_expression_down	hsa-mir-27b	Colorectal Carcinoma	23593282	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		we demonstrated that miR-27b expression is decreased in most CRC tissues and determined that overexpression of miR-27b represses CRC cell proliferation, colony formation and tumor growth in vitro and in vivo.
tissue_expression_down	hsa-mir-29c	Colorectal Carcinoma	26187071	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-29c downregulation contributes to metastatic progression in colorectal cancer.
tissue_expression_down	hsa-mir-31	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_down	hsa-mir-340	Colorectal Carcinoma	24448820	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer.
tissue_expression_down	hsa-mir-34a	Colorectal Carcinoma	26091352	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the concentration of s-IL6R protein was decreased in conditioned media of CRC cell lines ectopically expressing miR-34a.
tissue_expression_down	hsa-mir-375	Colorectal Carcinoma	25255814	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results indicate that the down-regulation of miR-375 in plasma and tissue is matched in CRC. Moreover, bioinformatics prediction revealed miR-375 association with some critical signal pathways in the development and progression of CRC. Therefore, plasma miR-375 holds great promise to be an alternative tissue biomarker for CRC detection.
tissue_expression_down	hsa-mir-422a	Colorectal Carcinoma	27350737	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-regulation of miR-422a may serve as an independent prognosis factor in CRC.
tissue_expression_down	hsa-mir-4478	Colorectal Carcinoma	25519020	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of miR-4478 and miR-1295b-3p were significantly diminished in stool samples of CRC patients with early stage (I, II) in comparison with normal group. These miRNAs maybe use as potential non-invasive molecular markers for CRC diagnosis, but further studies are needed.
tissue_expression_down	hsa-mir-452	Colorectal Carcinoma	27706792	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Decreased miR-452 expression in human colorectal cancer and its tumor suppressive function
tissue_expression_down	hsa-mir-490	Colorectal Carcinoma	26714817	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-490-3p is downregulated during CRC malignant progression.miR-490-3p represses CRC cell migration and invasion abilities, partially by targeting to the TGF-β signaling pathway. Taken together, miR-490-3p is acting as a tumor suppressor in CRC.
tissue_expression_down	hsa-mir-498	Colorectal Carcinoma	25128149	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of microRNA-498 in colorectal cancers and its cellular effects.
tissue_expression_down	hsa-mir-625	Colorectal Carcinoma	28863773	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding.
tissue_expression_down	hsa-let-7e	Colorectal Carcinoma	22241525	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)
tissue_expression_down	hsa-mir-106a	Colorectal Carcinoma	23178825	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-106a overexpression and pRB downregulation in sporadic colorectal cancer
tissue_expression_down	hsa-mir-122	Colorectal Carcinoma	22241525	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)
tissue_expression_down	hsa-mir-127	Colorectal Carcinoma	21922590	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The presence of the KRAS mutation was associated with up-regulation of miR-127-3p, miR-92a, and miR-486-3p and down-regulation of miR-378.
tissue_expression_down	hsa-mir-133b	Colorectal Carcinoma	21573504	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High expression of miR-185 and low expression of miR-133b were correlated with poor survival (p=0.001 and 0.028, respectively) and metastasis (p=0.007 and 0.036, respectively) in colorectal cancer.
tissue_expression_down	hsa-mir-141	Colorectal Carcinoma	25757925	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.
tissue_expression_down	hsa-mir-143	Colorectal Carcinoma	19287964	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-143: down-regualted
tissue_expression_down	hsa-mir-143	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		downregulated in colon cancer compared to normal colonic mucosa
tissue_expression_down	hsa-mir-143	Colorectal Carcinoma	22241525	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)
tissue_expression_down	hsa-mir-143	Colorectal Carcinoma	22273643	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-regulation of fecal miR-143 and miR-145 are potential markers for colorectal cancer.
tissue_expression_down	hsa-mir-145	Colorectal Carcinoma	19287964	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-145: down-regulated
tissue_expression_down	hsa-mir-145	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		downregulated in colon cancer compared to normal colonic mucosa
tissue_expression_down	hsa-mir-145	Colorectal Carcinoma	22273643	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-regulation of fecal miR-143 and miR-145 are potential markers for colorectal cancer.
tissue_expression_down	hsa-mir-146b	Colorectal Carcinoma	22241525	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)
tissue_expression_down	hsa-mir-148a	Colorectal Carcinoma	26389729	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We showed the collaborative participation of miR-148a and MMP7 in CRC cell invasion. These results also demonstrate that the downregulation of miR-148a expression promotes CRC progression, especially carcinogenesis and cancer cell invasion.
tissue_expression_down	hsa-mir-154	Colorectal Carcinoma	26048406	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		These findings suggested that miR-154 downregulation may be associated with tumor progression of CRC, and that this miR may be an independent prognostic marker for CRC patients.
tissue_expression_down	hsa-mir-16	Colorectal Carcinoma	24045965	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Down-regulation of miR-16 plays critical roles in CRC progression.Low miR-16 expression is an independent factor predicting a poor prognosis for CRC patients.
tissue_expression_down	hsa-mir-17	Colorectal Carcinoma	22241525	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)
tissue_expression_down	hsa-mir-181a-2	Colorectal Carcinoma	22241525	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Six miRNAs were up-regulated from non-neoplastic tissue to dysplasia, but down-regulated from dysplasia to cancer (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143)
tissue_expression_down	hsa-mir-195	Colorectal Carcinoma	21390519	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer.
tissue_expression_down	hsa-mir-199a-1	Colorectal Carcinoma	22903020	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-199a-5p was expressed at a low level in human primary colonic epithelial cells treated with deoxycholic acid compared with control, and miR-199a-5p was significantly down-regulated in colorectal cancer tissues.CAC1 was a direct miR-199a-5p target.The high miR-199a-5p expression and low CAC1 protein expression reverse the tumor cell drug resistance.
tissue_expression_down	hsa-mir-199a-2	Colorectal Carcinoma	22903020	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-199a-5p was expressed at a low level in human primary colonic epithelial cells treated with deoxycholic acid compared with control, and miR-199a-5p was significantly down-regulated in colorectal cancer tissues.CAC1 was a direct miR-199a-5p target.The high miR-199a-5p expression and low CAC1 protein expression reverse the tumor cell drug resistance.
tissue_expression_down	hsa-mir-200c	Colorectal Carcinoma	25757925	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.
tissue_expression_down	hsa-mir-206	Colorectal Carcinoma	22120473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases.
tissue_expression_down	hsa-mir-21	Colorectal Carcinoma	25310697	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 incolorectal cancer.
tissue_expression_down	hsa-mir-215	Colorectal Carcinoma	22469014	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-215, miR-375, miR-378 and miR-422a were significantly decreased, whereas miR-135b was increased in CRC tumor tissues. Levels of miR-215 and miR-422a correlated with clinical stage.
tissue_expression_down	hsa-mir-22	Colorectal Carcinoma	22492279	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The relative expression levels of miR-22 were significantly lower in colorectal cancer tissues than those in the normal adjacent mucosa, and low expression of miR-22 correlated with liver metastasis. Kaplan-Meier analysis indicated that patients with reduced miR-22 had a poor overall survival.
tissue_expression_down	hsa-mir-224	Colorectal Carcinoma	21864507	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Underexpression in methotrexate resistant human colon cancer cells.
tissue_expression_down	hsa-mir-34a	Colorectal Carcinoma	23355243	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The down-regulated expression of miR-34a in colorectal cancer patients is associated with recurrence after radical operation
tissue_expression_down	hsa-mir-375	Colorectal Carcinoma	22377847	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-375 expression was frequently downregulated in the colorectal cancer tissues compared to the non-tumor counterparts
tissue_expression_down	hsa-mir-378a	Colorectal Carcinoma	22469014	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-215, miR-375, miR-378 and miR-422a were significantly decreased, whereas miR-135b was increased in CRC tumor tissues. Levels of miR-215 and miR-422a correlated with clinical stage.
tissue_expression_down	hsa-mir-422a	Colorectal Carcinoma	22469014	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-215, miR-375, miR-378 and miR-422a were significantly decreased, whereas miR-135b was increased in CRC tumor tissues. Levels of miR-215 and miR-422a correlated with clinical stage.
tissue_expression_down	hsa-mir-451	Colorectal Carcinoma	23886157	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-451 inhibits growth of human colorectal carcinoma cells via downregulation of Pi3k/Akt pathway.
tissue_expression_down	hsa-mir-486	Colorectal Carcinoma	21922590	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The presence of the KRAS mutation was associated with up-regulation of miR-127-3p, miR-92a, and miR-486-3p and down-regulation of miR-378.
tissue_expression_down	hsa-mir-92a-1	Colorectal Carcinoma	21922590	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The presence of the KRAS mutation was associated with up-regulation of miR-127-3p, miR-92a, and miR-486-3p and down-regulation of miR-378.
tissue_expression_down	hsa-mir-92a-2	Colorectal Carcinoma	21922590	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The presence of the KRAS mutation was associated with up-regulation of miR-127-3p, miR-92a, and miR-486-3p and down-regulation of miR-378.
tissue_expression_down	hsa-mir-93	Colorectal Carcinoma	23354160	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the downregulation of miR-93 was significantly correlated with unfavorable clinicopathologic features and short overall survival in patients with colon cancer, suggesting that decreased expression of miR-93 be used as a novel prognostic factor for this disease
tissue_expression_down	hsa-mir-451	Constriction, Pathologic	26573748				D003251			MiRNA array of 1416 genes showed that in stenosed grafts, mir-451, mir-338, and mir-466 were downregulated and mir-154 was upregulated.
tissue_expression_down	hsa-mir-181a-2	Coronary Artery Disease	22535975	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Decreased miR-181a Expression in Monocytes of Obese Patients Is Associated with the Occurrence of Metabolic Syndrome and Coronary Artery Disease.
tissue_expression_down	hsa-mir-147	Crohn Disease	25810742	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	miR-147 and miR-205 were significantly downregulated in colons of experimental CD rats and may be closely associated with the onset of experimental CD.
tissue_expression_down	hsa-mir-19b	Crohn Disease	25997679	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	miR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn's disease.
tissue_expression_down	hsa-mir-137	Cutaneous Melanoma	26763596	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	miR-137 expression was lower in CM tissues.
tissue_expression_down	hsa-mir-217	Cytomegalovirus Retinitis	24376725	nervous system disease	DOID:0080160	B25.9	D017726			MicroRNA-217 promotes angiogenesis of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and FOXO3A. hcmv-miR-UL112-3p
tissue_expression_down	hsa-mir-130a	Diabetes Mellitus	25999017	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Downregulation of miR-130a may underlie endothelial dysfunction in diabetes through the activation of JNK signal pathway.
tissue_expression_down	hsa-mir-146a	Diabetes Mellitus	21885871	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	A total of 25 mmol/L glucose decreased miR-146a expression and increased FN expression compared with 5 mmol/L glucose in both cell types. miR-146a mimic transfection prevented such change, whereas miR-146a antagomir transfection in the cells in 5 mmol/L glucose caused FN upregulation. A luciferase assay confirmed miR-146a's binding to FN 3'-UTR. miR-146a was localized in the retinal endothelial cells and was decreased in diabetes. Intravitreal miR-146a mimic injection restored retinal miR-146a and increased FN in diabetes. Additional experiments showed that p300 regulates miR-146a.
tissue_expression_down	hsa-mir-200	Diabetes Mellitus, Type 1	26244930	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	These data strongly associate miR200-mediated downregulation of the DNA damage checkpoint proteins with propensity for developing microvascular complications of T1D.
tissue_expression_down	hsa-mir-21	Diabetes Mellitus, Type 2	27370645	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-21 expression is decreased in PBMCs of obese subjects
tissue_expression_down	hsa-mir-23b	Diabetic Cardiomyopathies	24670789				D058065			CA-II was shown to be a direct target for repression by microRNA-23b, which was downregulated in myocardial samples from DM-T2 patients.
tissue_expression_down	hsa-mir-200a	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_down	hsa-mir-200b	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_down	hsa-mir-200c	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_down	hsa-mir-26a	Diabetic Nephropathy	26063197			E10-11.21	D003928			MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy.
tissue_expression_down	hsa-mir-29a	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_down	hsa-mir-29b-1	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_down	hsa-mir-29b-2	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_down	hsa-mir-29c	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_down	hsa-let-7a-1	Digestive System Neoplasms	19156147			D49.0	D004067			let-7a: downregulation
tissue_expression_down	hsa-let-7a-2	Digestive System Neoplasms	19156147			D49.0	D004067			let-7a: downregulation
tissue_expression_down	hsa-let-7a-3	Digestive System Neoplasms	19156147			D49.0	D004067			let-7a: downregulation
tissue_expression_down	hsa-let-7b	Digestive System Neoplasms	19156147			D49.0	D004067			let-7b: downregulation
tissue_expression_down	hsa-let-7c	Digestive System Neoplasms	19156147			D49.0	D004067			let-7c: downregulation
tissue_expression_down	hsa-let-7d	Digestive System Neoplasms	19156147			D49.0	D004067			let-7d: downregulation
tissue_expression_down	hsa-let-7e	Digestive System Neoplasms	19156147			D49.0	D004067			let-7e: downregulation
tissue_expression_down	hsa-let-7f-1	Digestive System Neoplasms	19156147			D49.0	D004067			let-7f: downregulation
tissue_expression_down	hsa-let-7f-2	Digestive System Neoplasms	19156147			D49.0	D004067			let-7f: downregulation
tissue_expression_down	hsa-let-7g	Digestive System Neoplasms	19156147			D49.0	D004067			let-7g: downregulation
tissue_expression_down	hsa-let-7i	Digestive System Neoplasms	19156147			D49.0	D004067			let-7i: downregulation
tissue_expression_down	hsa-mir-101	Early-Stage Cervical Squamous Cell Carcinoma	24528073							Use of down-regulation of miR-101 and up-regulation of Cox-2 as markers may play a role in early diagnosis of cervical cancer in Uygur women.
tissue_expression_down	hsa-mir-196	Ectopic Pregnancy	25013942	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Microarray studies showed that four miRNAs were differentially  downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to  control tissue samples.
tissue_expression_down	hsa-mir-196b	Ectopic Pregnancy	25013942	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Microarray studies showed that four miRNAs were differentially  downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to  control tissue samples.
tissue_expression_down	hsa-mir-30a	Ectopic Pregnancy	25013942	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Microarray studies showed that four miRNAs were differentially  downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to  control tissue samples.
tissue_expression_down	hsa-mir-337	Ectopic Pregnancy	25013942	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Microarray studies showed that four miRNAs were differentially  downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to  control tissue samples.
tissue_expression_down	hsa-mir-873	Ectopic Pregnancy	25013942	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Microarray studies showed that four miRNAs were differentially  downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to  control tissue samples.
tissue_expression_down	hsa-mir-101	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-126	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-137	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-195	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-200a	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-200b	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-200c	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-141	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-429	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-205	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-206	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-29a	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-30a	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-539	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-613	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-7	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-9	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_down	hsa-mir-100	Endometrial Neoplasms	22920721	reproductive system disease	DOID:1380	C54.1	D016889	608089		Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.
tissue_expression_down	hsa-mir-153-1	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-153-2	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-182	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-183	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-186	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-193b	Endometrial Neoplasms	22543862	reproductive system disease	DOID:1380	C54.1	D016889	608089		Decreased expression after Progesterone Treatment.
tissue_expression_down	hsa-mir-27a	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-27b	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-29c	Endometrial Neoplasms	22543862	reproductive system disease	DOID:1380	C54.1	D016889	608089		Decreased expression after Progesterone Treatment.
tissue_expression_down	hsa-mir-633	Endometrial Neoplasms	22543862	reproductive system disease	DOID:1380	C54.1	D016889	608089		Decreased expression after Progesterone Treatment.
tissue_expression_down	hsa-mir-9-1	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-9-2	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-9-3	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-96	Endometrial Neoplasms	20028871	reproductive system disease	DOID:1380	C54.1	D016889	608089		Expression of miR-9, miR-27, miR-96, miR-153, miR-182, miR-183, or miR-186, but not miR-29a, miR-128, miR-152, or miR-486 mimetics in HEC-1B cells was sufficient to significantly reduce the abundance of FOXO1
tissue_expression_down	hsa-mir-10a	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-141	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-141: downregulated
tissue_expression_down	hsa-mir-141	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-142	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-142-3p: downregulated
tissue_expression_down	hsa-mir-196b	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-196b: downregulated
tissue_expression_down	hsa-mir-200a	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-200a: downregulated
tissue_expression_down	hsa-mir-200a	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-200b	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-200b: downregulated
tissue_expression_down	hsa-mir-200b	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-200c	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-203	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-20a	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-20a: downregulated
tissue_expression_down	hsa-mir-34c	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-34c: downregulated
tissue_expression_down	hsa-mir-34c	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-34c-5p down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-375	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-424	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-424: downregulated
tissue_expression_down	hsa-mir-429	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-449b	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-504	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-mir-873	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	down-regulated in endometriomas compared with endometrium.
tissue_expression_down	hsa-let-7g	Endotoxemia	19284987				D019446			Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR.
tissue_expression_down	hsa-mir-146b	Endotoxemia	19284987				D019446			Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR.
tissue_expression_down	hsa-mir-150	Endotoxemia	19284987				D019446			Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR.
tissue_expression_down	hsa-mir-342	Endotoxemia	19284987				D019446			Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR.
tissue_expression_down	hsa-mir-10a	Ependymoma	29658967	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	low expression of miR-10a and over-expression of miR-10b and miR-29a in ependymoma
tissue_expression_down	hsa-mir-383	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	underexpression
tissue_expression_down	hsa-mir-485	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	miR-485-5p: underexpression
tissue_expression_down	hsa-mir-182	Epstein-Barr Virus Infection	26401047			B27.90	D020031	300853		Here, we show that EBV-encoded LMP-1 is also involved in the downregulation of a cluster of three miRNAs, miR-183,-96, and -182, which are known to be also repressed in several cancers. We therefore identify yet another potential player in EBV-induced oncogenesis.
tissue_expression_down	hsa-mir-183	Epstein-Barr Virus Infection	26401047			B27.90	D020031	300853		Here, we show that EBV-encoded LMP-1 is also involved in the downregulation of a cluster of three miRNAs, miR-183,-96, and -182, which are known to be also repressed in several cancers. We therefore identify yet another potential player in EBV-induced oncogenesis.
tissue_expression_down	hsa-mir-96	Epstein-Barr Virus Infection	26401047			B27.90	D020031	300853		Here, we show that EBV-encoded LMP-1 is also involved in the downregulation of a cluster of three miRNAs, miR-183,-96, and -182, which are known to be also repressed in several cancers. We therefore identify yet another potential player in EBV-induced oncogenesis.
tissue_expression_down	hsa-let-7b	Esophageal Neoplasms	22847808			C15.9	D004938	133239	HP:0100751	Low expression of let-7b and let-7c in before-treatment biopsies from 74 patients of the training set correlated significantly with poor response to chemotherapy, both clinically and histopathologically.
tissue_expression_down	hsa-let-7c	Esophageal Neoplasms	22847808			C15.9	D004938	133239	HP:0100751	Low expression of let-7b and let-7c in before-treatment biopsies from 74 patients of the training set correlated significantly with poor response to chemotherapy, both clinically and histopathologically.
tissue_expression_down	hsa-let-7c	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_down	hsa-mir-100	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_down	hsa-mir-125b	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_down	hsa-mir-126	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	downregulated
tissue_expression_down	hsa-mir-1322	Esophageal Neoplasms	22315007			C15.9	D004938	133239	HP:0100751	miR-1322 could significantly down-regulate the ECRG2 with TCA3 allele (P<0.01), but it could not down-regulate the ECRG2 with TCA4 allele significantly (P>0.05). MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma.
tissue_expression_down	hsa-mir-135b	Esophageal Neoplasms	23477513			C15.9	D004938	133239	HP:0100751	patients with either decreased miR-135b or increased miR-145 expression in cancer tissue had improved disease-free survival
tissue_expression_down	hsa-mir-141	Esophageal Neoplasms	24155113			C15.9	D004938	133239	HP:0100751	The statistical significance of downregulation in hsa-miR-301a, hsa-miR-141 and hsa-miR-18b expression (P < 0.05) were confirmed by qRT-PCR.
tissue_expression_down	hsa-mir-143	Esophageal Neoplasms	21218087			C15.9	D004938	133239	HP:0100751	MiRNA profile in esophageal squamous cell carcinoma: Downregulation of miR-143 and miR-145.
tissue_expression_down	hsa-mir-145	Esophageal Neoplasms	21218087			C15.9	D004938	133239	HP:0100751	MiRNA profile in esophageal squamous cell carcinoma: Downregulation of miR-143 and miR-145.
tissue_expression_down	hsa-mir-145	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_down	hsa-mir-203	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_down	hsa-mir-205	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_down	hsa-mir-21	Esophageal Neoplasms	22363450			C15.9	D004938	133239	HP:0100751	Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA.
tissue_expression_down	hsa-mir-223	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	downregulated
tissue_expression_down	hsa-mir-27b	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_down	hsa-mir-30b	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	downregulated
tissue_expression_down	hsa-mir-34a	Esophageal Neoplasms	22363450			C15.9	D004938	133239	HP:0100751	Curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA.
tissue_expression_down	hsa-mir-375	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_down	hsa-mir-454	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	downregulated
tissue_expression_down	hsa-mir-486	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	downregulated
tissue_expression_down	hsa-mir-518b	Esophageal Neoplasms	21269950			C15.9	D004938	133239	HP:0100751	hsa-mir-126 is upregulated and hsa-miR-518b is downregulated in esophageal squamous carcinoma
tissue_expression_down	hsa-mir-574	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	miR-574-3p:downregulated
tissue_expression_down	hsa-mir-1	Essential Thrombocythemia	19497108	disease of cellular proliferation	DOID:2224	D47.3	D013920	PS187950		Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a.
tissue_expression_down	hsa-mir-133a	Essential Thrombocythemia	19497108	disease of cellular proliferation	DOID:2224	D47.3	D013920	PS187950		Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a.
tissue_expression_down	hsa-mir-31	Ewing Sarcoma	24667836	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion.
tissue_expression_down	hsa-mir-183	Fatty Liver [unspecific]	19572984	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	down-regulated after Lieber-DeCarli ;
tissue_expression_down	hsa-mir-122	Fatty Liver, Non-Alcoholic	20956972	disease of metabolism	DOID:0080208	K75.81	D065626	613282		The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats
tissue_expression_down	hsa-mir-21	Fatty Liver, Non-Alcoholic	20956972	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Besides, miR-21 expression was significantly decreased only in fructose-enriched diets.
tissue_expression_down	hsa-mir-27	Fatty Liver, Non-Alcoholic	20956972	disease of metabolism	DOID:0080208	K75.81	D065626	613282		The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats
tissue_expression_down	hsa-mir-451	Fatty Liver, Non-Alcoholic	20956972	disease of metabolism	DOID:0080208	K75.81	D065626	613282		The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats
tissue_expression_down	hsa-mir-197	Fibromatosis, Aggressive	28418912				D018222			The correlation between sporadic DTs and miRNA expression showed that miR-21-3p increased in mutated versus wild-type DTs, while miR-197-3p was decreased
tissue_expression_down	hsa-mir-143	Fibromyalgia	25803872	musculoskeletal system disease	DOID:631	M79.7	D005356			We propose a signature of five strikingly downregulated miRNAs (hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p and hsa-miR145-5p) to be used as biomarkers of FM. Validation in larger study groups is required before the results can be transferred to the clinic.
tissue_expression_down	hsa-mir-145	Fibromyalgia	25803872	musculoskeletal system disease	DOID:631	M79.7	D005356			We propose a signature of five strikingly downregulated miRNAs (hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p and hsa-miR145-5p) to be used as biomarkers of FM. Validation in larger study groups is required before the results can be transferred to the clinic.
tissue_expression_down	hsa-mir-21	Fibromyalgia	25803872	musculoskeletal system disease	DOID:631	M79.7	D005356			We propose a signature of five strikingly downregulated miRNAs (hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p and hsa-miR145-5p) to be used as biomarkers of FM. Validation in larger study groups is required before the results can be transferred to the clinic.
tissue_expression_down	hsa-mir-223	Fibromyalgia	25803872	musculoskeletal system disease	DOID:631	M79.7	D005356			We propose a signature of five strikingly downregulated miRNAs (hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p and hsa-miR145-5p) to be used as biomarkers of FM. Validation in larger study groups is required before the results can be transferred to the clinic.
tissue_expression_down	hsa-mir-338	Fibromyalgia	25803872	musculoskeletal system disease	DOID:631	M79.7	D005356			We propose a signature of five strikingly downregulated miRNAs (hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p and hsa-miR145-5p) to be used as biomarkers of FM. Validation in larger study groups is required before the results can be transferred to the clinic.
tissue_expression_down	hsa-mir-451a	Fibromyalgia	25803872	musculoskeletal system disease	DOID:631	M79.7	D005356			We propose a signature of five strikingly downregulated miRNAs (hsa-miR223-3p, hsa-miR451a, hsa-miR338-3p, hsa-miR143-3p and hsa-miR145-5p) to be used as biomarkers of FM. Validation in larger study groups is required before the results can be transferred to the clinic.
tissue_expression_down	hsa-let-7a-1	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_down	hsa-let-7a-2	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_down	hsa-let-7a-3	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_down	hsa-let-7g	Gastric Neoplasms	20022810	disease of cellular proliferation	DOID:10534	C16	D013274	137215		low expression
tissue_expression_down	hsa-mir-124	Gastric Neoplasms	24805774	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.
tissue_expression_down	hsa-mir-124	Gastric Neoplasms	27041578	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In gastric adenocarcinoma cells harboring highly methylated and silenced mir-124 gene loci
tissue_expression_down	hsa-mir-125b	Gastric Neoplasms	25240408	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-125b functions as an oncogene by targeting downregulated PPP1CA and upregulated Rb phosphorylation in gastric cancer. MiR-125b not only promotes cellular proliferation, migration, and invasion in vitro, but also acts as an independent prognostic factor in gastric cancer.
tissue_expression_down	hsa-mir-126	Gastric Neoplasms	26464628	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our study showed that miR-126, by down-regulation CADM1, enhances migration and invasion in GC cells.
tissue_expression_down	hsa-mir-129-1	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-129: downregulated in undifferentiated gastric cancer
tissue_expression_down	hsa-mir-129-2	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-129: downregulated in undifferentiated gastric cancer
tissue_expression_down	hsa-mir-130a	Gastric Neoplasms	19948396	disease of cellular proliferation	DOID:10534	C16	D013274	137215		different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1
tissue_expression_down	hsa-mir-133b	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-133b: down-regulated
tissue_expression_down	hsa-mir-135a	Gastric Neoplasms	24465504	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer.
tissue_expression_down	hsa-mir-139	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-139-5p: down-regulated
tissue_expression_down	hsa-mir-141	Gastric Neoplasms	26681225	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our data provide evidence that the downregulation of miR-141 may contribute to the aggressive progression and poor prognosis of human gastric cancer.
tissue_expression_down	hsa-mir-141	Gastric Neoplasms	19363643	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-141: significantly down-regulated in gastric cancer
tissue_expression_down	hsa-mir-145	Gastric Neoplasms	22370644	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The authors demonstrate a stepwise downregulation of miR-145 level in nontumorous gastric mucosa, primary gastric cancers and their secondary metastases.N-cadherin (CDH2) was proved to be a direct target of miR-145
tissue_expression_down	hsa-mir-146a	Gastric Neoplasms	24805774	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.
tissue_expression_down	hsa-mir-148a	Gastric Neoplasms	24283384	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis.
tissue_expression_down	hsa-mir-148a	Gastric Neoplasms	24515776	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our results suggest that the suppression of miR-148a may contribute to the down-regulation of MEG3 in gastric cancer by modulation of DNMT-1.
tissue_expression_down	hsa-mir-148a	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-148: downregulated in undifferentiated gastric cancer
tissue_expression_down	hsa-mir-148b	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-148: downregulated in undifferentiated gastric cancer
tissue_expression_down	hsa-mir-148b	Gastric Neoplasms	21205300	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation.
tissue_expression_down	hsa-mir-155	Gastric Neoplasms	24805774	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.
tissue_expression_down	hsa-mir-155	Gastric Neoplasms	22426647	disease of cellular proliferation	DOID:10534	C16	D013274	137215		microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis.
tissue_expression_down	hsa-mir-17	Gastric Neoplasms	19598010	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-17-92a cluster; expression lwere significantly lower than non-cancer tissue; may help to clarify the molecular mechanisms; may be a novel diagnostic biomarker
tissue_expression_down	hsa-mir-18a	Gastric Neoplasms	19598010	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-17-92a cluster; expression lwere significantly lower than non-cancer tissue; may help to clarify the molecular mechanisms; may be a novel diagnostic biomarker
tissue_expression_down	hsa-mir-192	Gastric Neoplasms	22205577	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The down-regulation of miR-192 and -215 was demonstrated to be associated with increased tumor sizes and advanced Borrmann type tumors.
tissue_expression_down	hsa-mir-193b	Gastric Neoplasms	25374225	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features andprognosis in gastric cancer.
tissue_expression_down	hsa-mir-195	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-195: down-regulated
tissue_expression_down	hsa-mir-198	Gastric Neoplasms	26852230	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These findings suggested that miR-198 downregulation may be associated with progression of GC and that this miR may be an independent prognostic marker for GC patients.
tissue_expression_down	hsa-mir-19a	Gastric Neoplasms	19598010	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-17-92a cluster; expression lwere significantly lower than non-cancer tissue; may help to clarify the molecular mechanisms; may be a novel diagnostic biomarker
tissue_expression_down	hsa-mir-205	Gastric Neoplasms	24763883	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our data suggest that down-regulation of miR-205 may represent an important mechanism for the development of gastric cancer.
tissue_expression_down	hsa-mir-206	Gastric Neoplasms	23751352	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer.
tissue_expression_down	hsa-mir-221	Gastric Neoplasms	26214494	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Propofol suppresses proliferation and invasion of gastric cancer cells via downregulation of microRNA-221 expression.
tissue_expression_down	hsa-mir-30c	Gastric Neoplasms	19948396	disease of cellular proliferation	DOID:10534	C16	D013274	137215		different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1
tissue_expression_down	hsa-mir-31	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-31: down-regulated
tissue_expression_down	hsa-mir-328	Gastric Neoplasms	25479940	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-328 downregulation and de novo expression of CD44v9 occurred in H. pylori-infected gastric mucosa adjacent to gastric cancer compared with gastric mucosa not infected with H. pylori adjacent to gastric cancer. CD44v9-overexpressing cells are known to acquire reactive oxygen species resistance; thus, these cells may avoid cell death caused by various stress inducers, which may be linked to the origin of gastric cancer development.
tissue_expression_down	hsa-mir-335	Gastric Neoplasms	24805774	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.
tissue_expression_down	hsa-mir-335	Gastric Neoplasms	19948396	disease of cellular proliferation	DOID:10534	C16	D013274	137215		different miRNAs have been found to predict sensitivity to anticancer treatment: miR-30c, miR-130a and miR-335 are downregulated in various chemoresistant cell lines, hsa-Let-7g and hsa-miR-181b are strongly associated with response to 5-fluorouracil-based antimetabolite S-1
tissue_expression_down	hsa-mir-34a	Gastric Neoplasms	26415802	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The results reinforce the critical role for the down-regulated miR-34a expression in gastric cancer and suggest that miR-34a could be a prognostic indicator for this disease.
tissue_expression_down	hsa-mir-370	Gastric Neoplasms	21666718	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Overexpression of miR-370 and downregulation of its novel target TGFbeta-RII contribute to the progression of gastric carcinoma.
tissue_expression_down	hsa-mir-378a	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-378: down-regulated
tissue_expression_down	hsa-mir-433	Gastric Neoplasms	20022810	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Low expression
tissue_expression_down	hsa-mir-449a	Gastric Neoplasms	21418558	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-449 inhibits cell proliferation and is down-regulated in gastric cancer.
tissue_expression_down	hsa-mir-449b	Gastric Neoplasms	21418558	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-449 inhibits cell proliferation and is down-regulated in gastric cancer.
tissue_expression_down	hsa-mir-449c	Gastric Neoplasms	21418558	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-449 inhibits cell proliferation and is down-regulated in gastric cancer.
tissue_expression_down	hsa-mir-497	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-497: down-regulated
tissue_expression_down	hsa-mir-504	Gastric Neoplasms	25015107	disease of cellular proliferation	DOID:10534	C16	D013274	137215		TFF1 activates p53 through down-regulation of miR-504 in gastric cancer.
tissue_expression_down	hsa-mir-573	Gastric Neoplasms	26054975	disease of cellular proliferation	DOID:10534	C16	D013274	137215		TSPAN1 functions as an oncogene in gastric cancer and is downregulated by miR-573.
tissue_expression_down	hsa-mir-760	Gastric Neoplasms	24097871	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Histone mRNA was upregulated, whereas miR-760 was downregulated in the bone marrow and primary tumor of advanced gastric cancer patients, suggesting that the histone mRNA/miR-760 axis had a crucial role in the development of gastric cancer.
tissue_expression_down	hsa-let-7g	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-126	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-146a	Gastrointestinal Neoplasms	21347720			D37.9	D005770			MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis.
tissue_expression_down	hsa-mir-148a	Gastrointestinal Neoplasms	20422307			D37.9	D005770			MiR-148a:MiR-148a and miR-152 may be involved in the carcinogenesis of gastrointestinal cancers and might be potential biomarkers
tissue_expression_down	hsa-mir-152	Gastrointestinal Neoplasms	20422307			D37.9	D005770			MiR-152:MiR-148a and miR-152 may be involved in the carcinogenesis of gastrointestinal cancers and might be potential biomarkers
tissue_expression_down	hsa-mir-196a-1	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-196a-2	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-200a	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-200a	Gastrointestinal Neoplasms	23456798			D37.9	D005770			It was noteworthy that miR-200a was significantly down-regulated in gastric adenocarcinoma samples (P = .04) but was up-regulated in esophageal adenocarcinoma samples (P = .001). 
tissue_expression_down	hsa-mir-200b	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-200c	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-218	Gastrointestinal Neoplasms	19890957			D37.9	D005770			miR-218 expression was reduced significantly in gastric cancer tissues, in H. pylori-infected gastric mucosa, and in H. pylori-infected AGS cells.
tissue_expression_down	hsa-mir-218	Gastrointestinal Neoplasms	20510072			D37.9	D005770			miR-218 expression is reduced in gastric cancer. miR-218 may function as a tumor suppressor in gastric carcinoma.
tissue_expression_down	hsa-mir-221	Gastrointestinal Neoplasms	21132270			D37.9	D005770			Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors
tissue_expression_down	hsa-mir-222	Gastrointestinal Neoplasms	21132270			D37.9	D005770			Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors
tissue_expression_down	hsa-mir-31	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-338	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-433	Gastrointestinal Neoplasms	19531230			D37.9	D005770			Down-regulated miR-9 and miR-433 in human gastric carcinoma.
tissue_expression_down	hsa-mir-7-1	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-7-2	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-7-3	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-mir-9	Gastrointestinal Neoplasms	19531230			D37.9	D005770			Down-regulated miR-9 and miR-433 in human gastric carcinoma.
tissue_expression_down	hsa-mir-98	Gastrointestinal Neoplasms	21293479			D37.9	D005770			In the HCPT-resistant gastric cancer cells, the levels of 25 miRNAs were deregulated, including miR-196a, miR-200 family, miR-338, miR-126, miR-31, miR-98, let-7g, and miR-7.
tissue_expression_down	hsa-let-7a-1	Glioblastoma	22074483				D005909		HP:0100843	Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment.
tissue_expression_down	hsa-let-7a-2	Glioblastoma	22074483				D005909		HP:0100843	Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment.
tissue_expression_down	hsa-let-7a-3	Glioblastoma	22074483				D005909		HP:0100843	Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment.
tissue_expression_down	hsa-mir-124	Glioblastoma	23817964				D005909		HP:0100843	MiR-124 inhibits the growth of glioblastoma through the downregulation of SOS1.
tissue_expression_down	hsa-mir-124	Glioblastoma	22929615				D005909		HP:0100843	We tested two predicted proneural drivers, miR-124 and miR-132, both underexpressed in proneural tumors, by overexpression in neurospheres and observed a partial reversal of corresponding tumor expression changes.
tissue_expression_down	hsa-mir-124	Glioblastoma	29559295				D005909		HP:0100843	In our microarray data, lower expression of miR-219-5p, miR-124, and miR-128 and higher expression of miR-21 was observed in GBM compared with the peripheral region, similar to the results of previous reports
tissue_expression_down	hsa-mir-124-1	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-124-2	Glioblastoma	21196113				D005909		HP:0100843	miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion.
tissue_expression_down	hsa-mir-124-2	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-124-3	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-126	Glioblastoma	27920004				D005909		HP:0100843	Down-regulation of MicroRNA-126 in Glioblastoma and its Correlation with Patient Prognosis: A Pilot Study.
tissue_expression_down	hsa-mir-1260a	Glioblastoma	22074483				D005909		HP:0100843	Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment.
tissue_expression_down	hsa-mir-128	Glioblastoma	27526390				D005909		HP:0100843	The microRNA-128 expression levels were down-regulated in low-grade glioma tissue
tissue_expression_down	hsa-mir-128	Glioblastoma	29559295				D005909		HP:0100843	In our microarray data, lower expression of miR-219-5p, miR-124, and miR-128 and higher expression of miR-21 was observed in GBM compared with the peripheral region, similar to the results of previous reports
tissue_expression_down	hsa-mir-128-1	Glioblastoma	19941032				D005909		HP:0100843	miR-128:Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation
tissue_expression_down	hsa-mir-128-1	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-128-1	Glioblastoma	22922228				D005909		HP:0100843	Platelet-derived growth factor-B (PDGF-B), a potent angiogenic growth factor involved in GBM development and progression, promotes downregulation of pro-oncogenic (miR-21) and anti-oncogenic (miR-128) miRNAs in GBM pathology.
tissue_expression_down	hsa-mir-128-2	Glioblastoma	19941032				D005909		HP:0100843	miR-128:Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation
tissue_expression_down	hsa-mir-128-2	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-128-2	Glioblastoma	22922228				D005909		HP:0100843	Platelet-derived growth factor-B (PDGF-B), a potent angiogenic growth factor involved in GBM development and progression, promotes downregulation of pro-oncogenic (miR-21) and anti-oncogenic (miR-128) miRNAs in GBM pathology.
tissue_expression_down	hsa-mir-1305	Glioblastoma	22074483				D005909		HP:0100843	Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment.
tissue_expression_down	hsa-mir-132	Glioblastoma	22929615				D005909		HP:0100843	We tested two predicted proneural drivers, miR-124 and miR-132, both underexpressed in proneural tumors, by overexpression in neurospheres and observed a partial reversal of corresponding tumor expression changes.
tissue_expression_down	hsa-mir-137	Glioblastoma	22406049				D005909		HP:0100843	miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2.
tissue_expression_down	hsa-mir-137	Glioblastoma	24412320				D005909		HP:0100843	We found gradual increase in miR-21 and miR-23a levels in all tumor grades whereas miR-7 and miR-137 were significantly down-regulated depending on the glioma grade.
tissue_expression_down	hsa-mir-139	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-143	Glioblastoma	21211035				D005909		HP:0100843	down regulation of miR-143, -145, -253-5p and miR-452 by SOX2
tissue_expression_down	hsa-mir-145	Glioblastoma	21211035				D005909		HP:0100843	down regulation of miR-143, -145, -253-5p and miR-452 by SOX2
tissue_expression_down	hsa-mir-145	Glioblastoma	24531649				D005909		HP:0100843	Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells.
tissue_expression_down	hsa-mir-145	Glioblastoma	26026080				D005909		HP:0100843	The elevated miR-145 present in invasive glioblastoma cells (IM3 cells) targets and down-regulated srGAP1, thereby allowing downstream G-proteins to remain in their active state and promote the observed invasive phenotype.
tissue_expression_down	hsa-mir-181a	Glioblastoma	27176932				D005909		HP:0100843	miR-181a is down-regulated in GBM patients
tissue_expression_down	hsa-mir-181c	Glioblastoma	25494473				D005909		HP:0100843	miR-181c can be considered a valuable indicator for the outcome of GBM patients. miR-181c acts as a tumor suppressor that attenuates proliferation, invasion, and self-renewal capacities by downregulation of Notch2 in glioma cells.
tissue_expression_down	hsa-mir-203	Glioblastoma	25871397				D005909		HP:0100843	MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
tissue_expression_down	hsa-mir-20a	Glioblastoma	21483847				D005909		HP:0100843	miR-20a upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_down	hsa-mir-21	Glioblastoma	22922228				D005909		HP:0100843	Platelet-derived growth factor-B (PDGF-B), a potent angiogenic growth factor involved in GBM development and progression, promotes downregulation of pro-oncogenic (miR-21) and anti-oncogenic (miR-128) miRNAs in GBM pathology.
tissue_expression_down	hsa-mir-21	Glioblastoma	25991372				D005909		HP:0100843	Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
tissue_expression_down	hsa-mir-219	Glioblastoma	29559295				D005909		HP:0100843	In our microarray data, lower expression of miR-219-5p, miR-124, and miR-128 and higher expression of miR-21 was observed in GBM compared with the peripheral region, similar to the results of previous reports
tissue_expression_down	hsa-mir-221	Glioblastoma	21483847				D005909		HP:0100843	miR-221 downregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_down	hsa-mir-222	Glioblastoma	21483847				D005909		HP:0100843	miR-222 downregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_down	hsa-mir-222	Glioblastoma	24412053				D005909		HP:0100843	The analysis  of 14 validated miRNA expression in the 60 glioblastomas, using three different non-neoplastic references as controls, revealed a putative miRNA signature: mir-10b and miR-21 were up-regulated, while miR-7, miR-31, miR-101, miR-137, miR-222 and miR-330 were down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-31	Glioblastoma	21483847				D005909		HP:0100843	miR-31 downregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_down	hsa-mir-328	Glioblastoma	23077581				D005909		HP:0100843	MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma
tissue_expression_down	hsa-mir-34c	Glioblastoma	24179539				D005909		HP:0100843	It was demonstrated that miR-34c-3p and miR-34c-5p were downregulated in gliomas, by performing qPCR on tumor tissues from glioma patients and glioma cell lines, compared with normal brain tissues and a normal glial cell line.
tissue_expression_down	hsa-mir-451	Glioblastoma	20647762				D005909		HP:0100843	We initially identified miR-451 due to its downregulation in a glioma cell migration assay.
tissue_expression_down	hsa-mir-452	Glioblastoma	21211035				D005909		HP:0100843	down regulation of miR-143, -145, -253-5p and miR-452 by SOX2
tissue_expression_down	hsa-mir-539	Glioblastoma	22074483				D005909		HP:0100843	Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment.
tissue_expression_down	hsa-mir-7	Glioblastoma	25027403				D005909		HP:0100843	MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1.
tissue_expression_down	hsa-mir-7-1	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-7-2	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-7-3	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-873	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-95	Glioblastoma	21912681				D005909		HP:0100843	Significantly down-regulated in glioblastomas.
tissue_expression_down	hsa-mir-107	Glioma	23220650	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2
tissue_expression_down	hsa-mir-124	Glioma	25112530	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of microRNA-124 predicts poor prognosis in glioma patients.
tissue_expression_down	hsa-mir-124	Glioma	28060761	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma
tissue_expression_down	hsa-mir-132	Glioma	27522003	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The expression of miR-132 was low in human glioma tissues,  and the downregulated expression was associated with advanced glioma grades.
tissue_expression_down	hsa-mir-154	Glioma	27417886	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Conclusions These results suggest that miR-154 downregulation may be involved in glioma formation and progression, and that miR-154 might serve as a potential prognostic biomarker for patients with this disease.
tissue_expression_down	hsa-mir-16	Glioma	26082082	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Osthole suppresses the proliferation and accelerates the apoptosis of human glioma cells via the upregulation of microRNA-16 and downregulation of MMP-9.
tissue_expression_down	hsa-mir-16	Glioma	25954855	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Paeoniflorin inhibits proliferation and induces apoptosis of human glioma cells via microRNA-16 upregulation and matrix metalloproteinase-9 downregulation.
tissue_expression_down	hsa-mir-200b	Glioma	24559637	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These findings prove that the decreased expression of miR-200b may be associated with malignant tumor progression and poor prognosis in patients with gliomas, suggesting the potential role of miR-200b in glioma management. miR-200b may be a novel and valuable signature for predicting the clinical outcome of patients with gliomas.
tissue_expression_down	hsa-mir-200b	Glioma	27374173	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-200b was found to be down-regulated in glioma samples
tissue_expression_down	hsa-mir-218	Glioma	25773834	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our results indicate that miR-218 is downregulated in gliomas and that its status might be a potential valuable biomarker for glioma patients.
tissue_expression_down	hsa-mir-218-1	Glioma	22088371	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The expression level of miR-218 is an important reference indicator for the assessment of the grade of gliomas. An aberrant decrease of its expression may lead to an increase of the CDK6 expression and proliferative activity of giloma cells. Introducing exogenous miR-218 may effectively down-regulate the CDK6 expression, inhibit cell proliferation and induce apoptosis of malignant giloma cells.
tissue_expression_down	hsa-mir-218-2	Glioma	22088371	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The expression level of miR-218 is an important reference indicator for the assessment of the grade of gliomas. An aberrant decrease of its expression may lead to an increase of the CDK6 expression and proliferative activity of giloma cells. Introducing exogenous miR-218 may effectively down-regulate the CDK6 expression, inhibit cell proliferation and induce apoptosis of malignant giloma cells.
tissue_expression_down	hsa-mir-221	Glioma	24589600	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MiR-221 regulates the expression of EMT-related genes through down-regulation of PTEN and activation of PI3-K/Akt signaling.
tissue_expression_down	hsa-mir-26a	Glioma	29658967	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	low expression  of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-527 in low-grade glioma
tissue_expression_down	hsa-mir-31	Glioma	24380686	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Concomitant microRNA-31 downregulation and radixin upregulation predicts advanced tumor progression and unfavorable prognosis in patients with gliomas.
tissue_expression_down	hsa-mir-320d	Glioma	27862991	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of MicroRNA-320d predicts poor overall survival and promotes the growth and invasive abilities in glioma.
tissue_expression_down	hsa-mir-326	Glioma	23292865	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Down-regulation of miR-326 may have potential value for predicting clinical outcomes in glioma patients with high pathological grades, suggesting that miR-326 is an important candidate tumor suppressor, and its down-regulated expression may contribute to glioma progression
tissue_expression_down	hsa-mir-367	Glioma	26261539	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our results suggested that both high-miR-196a and low-miR-367 expression may be associated with aggressive progression and unfavorable clinical outcome in glioma patients. And combination of high-miR-196a and low-miR-367 expression may be a novel biomarker in identifying a poor prognosis group of high-grade glioma.
tissue_expression_down	hsa-mir-375	Glioma	23103713	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma
tissue_expression_down	hsa-mir-378	Glioma	26261592	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Decreased expression of miR-378 correlates with tumor invasiveness and poor prognosis of patients with glioma.
tissue_expression_down	hsa-mir-494	Glioma	26153143	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Compound 331 selectively induces glioma cell death by upregulating miR-494 and downregulating CDC20.
tissue_expression_down	hsa-mir-497	Glioma	27569294	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Reduced expression of microRNA-497 is associated with greater angiogenesis and poor prognosis in human gliomas.
tissue_expression_down	hsa-mir-504	Glioma	25755767	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma.
tissue_expression_down	hsa-mir-544a	Glioma	23205130	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma
tissue_expression_down	hsa-mir-544b	Glioma	23205130	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma
tissue_expression_down	hsa-mir-9	Glioma	26082082	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Osthole suppresses the proliferation and accelerates the apoptosis of human glioma cells via the upregulation of microRNA-16 and downregulation of MMP-9.
tissue_expression_down	hsa-mir-26a	Glomerulonephritis	25329154	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	Decreased miR-26a expression correlates with the progression of podocyte injury in autoimmune glomerulonephritis.
tissue_expression_down	hsa-mir-372	Habitual Abortion	26879955			N96	D000026			hsa-miR-1 and -372 were significantly lower compared to normal pregnancy.
tissue_expression_down	hsa-let-7d	Head And Neck Neoplasms	19179615	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7d: show lower expression levels relative to normal adjacent tissue
tissue_expression_down	hsa-mir-100	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_down	hsa-mir-100	Head And Neck Neoplasms	22425712	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	down-regulation
tissue_expression_down	hsa-mir-101-1	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-101 was downregulated compared with normal tissue.
tissue_expression_down	hsa-mir-101-2	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-101 was downregulated compared with normal tissue.
tissue_expression_down	hsa-mir-107	Head And Neck Neoplasms	22158047	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase C
tissue_expression_down	hsa-mir-1-1	Head And Neck Neoplasms	19179615	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-1: show lower expression levels relative to normal adjacent tissue
tissue_expression_down	hsa-mir-1-2	Head And Neck Neoplasms	19179615	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-1: show lower expression levels relative to normal adjacent tissue
tissue_expression_down	hsa-mir-130a	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_down	hsa-mir-133a-1	Head And Neck Neoplasms	19179615	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-133a: show lower expression levels relative to normal adjacent tissue
tissue_expression_down	hsa-mir-133a-2	Head And Neck Neoplasms	19179615	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-133a: show lower expression levels relative to normal adjacent tissue
tissue_expression_down	hsa-mir-141	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-141 was downregulated compared with normal tissue.
tissue_expression_down	hsa-mir-197	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_down	hsa-mir-205	Head And Neck Neoplasms	19179615	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-205: show lower expression levels relative to normal adjacent tissue
tissue_expression_down	hsa-mir-26b	Head And Neck Neoplasms	22811001	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	In addition, the expression levels of miR-21 and miR-26b were both reduced in post-operative HNSCC patients with good prognosis.
tissue_expression_down	hsa-mir-375	Head And Neck Neoplasms	22234174	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Low-Level Expression of miR-375 Correlates with Poor Outcome and Metastasis While Altering the Invasive Properties of Head and Neck Squamous Cell Carcinomas.
tissue_expression_down	hsa-mir-375	Head And Neck Neoplasms	22425712	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	down-regulation
tissue_expression_down	hsa-mir-499a	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-499: underexpressed
tissue_expression_down	hsa-mir-95	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-95 was downregulated compared with normal tissue.
tissue_expression_down	hsa-mir-99a	Head And Neck Neoplasms	22425712	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	down-regulation
tissue_expression_down	hsa-mir-107	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-107	Heart Failure	20484156			I50	D006331		HP:0001635	miR-107: downregulated
tissue_expression_down	hsa-mir-1-1	Heart Failure	19059107			I50	D006331		HP:0001635	miR-1: decreased expression
tissue_expression_down	hsa-mir-1-2	Heart Failure	19059107			I50	D006331		HP:0001635	miR-1: decreased expression
tissue_expression_down	hsa-mir-130b	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-133a-1	Heart Failure	19059107			I50	D006331		HP:0001635	miR-133a: decreased expression
tissue_expression_down	hsa-mir-133a-2	Heart Failure	19059107			I50	D006331		HP:0001635	miR-133a: decreased expression
tissue_expression_down	hsa-mir-133b	Heart Failure	19059107			I50	D006331		HP:0001635	miR-133b: decreased expression
tissue_expression_down	hsa-mir-135a-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-135a-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-136	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-139	Heart Failure	20484156			I50	D006331		HP:0001635	miR-139: downregulated
tissue_expression_down	hsa-mir-142	Heart Failure	20484156			I50	D006331		HP:0001635	miR-142-5p: downregulated
tissue_expression_down	hsa-mir-148a	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-150	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-15b	Heart Failure	22093502			I50	D006331		HP:0001635	The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent).
tissue_expression_down	hsa-mir-16-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-16-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-17	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-182	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-186	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-186	Heart Failure	28233577			I50	D006331		HP:0001635	TNFα-induced downregulation of microRNA-186 contributes to apoptosis in rat primary cardiomyocytes.
tissue_expression_down	hsa-mir-192	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-195	Heart Failure	22093502			I50	D006331		HP:0001635	The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent).
tissue_expression_down	hsa-mir-19b-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-19b-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-218-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-218-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-22	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-23a	Heart Failure	22093502			I50	D006331		HP:0001635	The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent).
tissue_expression_down	hsa-mir-23b	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-24-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-24-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-26a-1	Heart Failure	22093502			I50	D006331		HP:0001635	The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent).
tissue_expression_down	hsa-mir-26a-2	Heart Failure	22093502			I50	D006331		HP:0001635	The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent).
tissue_expression_down	hsa-mir-27a	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-296	Heart Failure	21690488			I50	D006331		HP:0001635	The absolute expression levels of hcmv-miR-UL112, miR-296-5p, and let-7e were further determined in 127 patients and 67 control subjects (fold changes are 2.5, 0.5, and 1.7 respectively; all P<0.0001).
tissue_expression_down	hsa-mir-299	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-302b	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-302c	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-30a	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-30b	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-30c-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-30c-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-30e	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-325	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-339	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-342	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-424	Heart Failure	27072074			I50	D006331		HP:0001635	In coronary sinus samples, the microRNAs miR-16-5p, miR-27a-3p, miR-27b-3p, miR-29b-3p, miR-29c-3p, miR-30e-5p, miR-92a-3p, miR-125b-5p, miR-140-5p, miR-195-5p, miR-424-5p, and miR-451a were significantly down-regulated, and let-7a-5p, let-7c-5p, let-7e-5p, miR-23b-3p, miR-107, miR-155-5p, miR-181a-5p, miR-181b-5p and miR-320a were up-regulated in heart failure.
tissue_expression_down	hsa-mir-452	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-494	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-497	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-499	Heart Failure	24495916			I50	D006331		HP:0001635	In HHcy, the expression of NMDAR1, DNMT1, and matrix metalloproteinase 9 increased with increase in H3K9 acetylation, while HDAC1, miR-133a, and miR-499 decreased in cardiomyocytes.
tissue_expression_down	hsa-mir-499a	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-507	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-512-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-512-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-515-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-515-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-520a	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-520b	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-520d	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-520e	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-520f	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-520g	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-520h	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-523	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-526a-1	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-526a-2	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-526b	Heart Failure	17606841			I50	D006331		HP:0001635	downregulated
tissue_expression_down	hsa-mir-15a	Hepatitis B Virus Infection	19187610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-15a: down-regulated
tissue_expression_down	hsa-mir-185	Hepatitis B Virus Infection	27190255	disease by infectious agent	DOID:2043	B16/18	D006509	610424		two down-regulated microRNAs including miR-185-5p and miR-186-5p were correlated in both in vitro and in vivo studies
tissue_expression_down	hsa-mir-186	Hepatitis B Virus Infection	27190255	disease by infectious agent	DOID:2043	B16/18	D006509	610424		two down-regulated microRNAs including miR-185-5p and miR-186-5p were correlated in both in vitro and in vivo studies.
tissue_expression_down	hsa-mir-221	Hepatitis B Virus Infection	21876625	disease by infectious agent	DOID:2043	B16/18	D006509	610424		downregulated in acute HBV infection, normally expressed in chronic HBV infection, and upregulated in HCC
tissue_expression_down	hsa-mir-1-1	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-1: down-regulated
tissue_expression_down	hsa-mir-1-2	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-1: down-regulated
tissue_expression_down	hsa-mir-124	Hepatitis C Virus Infection	27753084	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Decline of miR-124 in myeloid cells promotes regulatory T-cell development in hepatitis C virus infection.
tissue_expression_down	hsa-mir-126	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		downregulated
tissue_expression_down	hsa-mir-143	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		downregulated
tissue_expression_down	hsa-mir-16	Hepatitis C Virus Infection	26071245	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7.
tissue_expression_down	hsa-mir-196a-1	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-196: down-regulated
tissue_expression_down	hsa-mir-196a-2	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-196: down-regulated
tissue_expression_down	hsa-mir-196b	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-196: down-regulated
tissue_expression_down	hsa-mir-199a-1	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		downregulated
tissue_expression_down	hsa-mir-199a-2	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		downregulated
tissue_expression_down	hsa-mir-28	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		downregulated
tissue_expression_down	hsa-mir-296	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-296: down-regulated
tissue_expression_down	hsa-mir-30a	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-30: down-regulated
tissue_expression_down	hsa-mir-30b	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-30: down-regulated
tissue_expression_down	hsa-mir-30c-1	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-30: down-regulated
tissue_expression_down	hsa-mir-30c-2	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-30: down-regulated
tissue_expression_down	hsa-mir-30d	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-30: down-regulated
tissue_expression_down	hsa-mir-342	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		downregulated
tissue_expression_down	hsa-mir-372	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		downregulated
tissue_expression_down	hsa-mir-376c	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		downregulated
tissue_expression_down	hsa-mir-431	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-431: down-regulated
tissue_expression_down	hsa-mir-448	Hepatitis C Virus Infection	19360909	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-448: down-regulated
tissue_expression_down	hsa-let-7i	Hepatoblastoma	29404451	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Let-7i-3p, miR-449b-3p, miR-624-5p, and miR-885-5p were decreased in tumors compared to normal livers
tissue_expression_down	hsa-mir-145	Hepatoblastoma	21145831	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	downregulated in early stages of HBV-associated multistep hepatocarcinogenesis.
tissue_expression_down	hsa-mir-148a	Hepatoblastoma	19701500	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	downregulated
tissue_expression_down	hsa-mir-199b	Hepatoblastoma	21145831	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	downregulated in early stages of HBV-associated multistep hepatocarcinogenesis.
tissue_expression_down	hsa-mir-34a	Hepatoblastoma	27046304	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	miR-34s were deregulated in tumor tissues compared with corresponding noncancerous tissue samples
tissue_expression_down	hsa-mir-34b	Hepatoblastoma	27046304	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	miR-34s were deregulated in tumor tissues compared with corresponding noncancerous tissue samples
tissue_expression_down	hsa-mir-34c	Hepatoblastoma	27046304	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	miR-34s were deregulated in tumor tissues compared with corresponding noncancerous tissue samples
tissue_expression_down	hsa-mir-449b	Hepatoblastoma	29404451	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Let-7i-3p, miR-449b-3p, miR-624-5p, and miR-885-5p were decreased in tumors compared to normal livers
tissue_expression_down	hsa-mir-624	Hepatoblastoma	29404451	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Let-7i-3p, miR-449b-3p, miR-624-5p, and miR-885-5p were decreased in tumors compared to normal livers
tissue_expression_down	hsa-mir-885	Hepatoblastoma	29404451	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Let-7i-3p, miR-449b-3p, miR-624-5p, and miR-885-5p were decreased in tumors compared to normal livers
tissue_expression_down	hsa-mir-205	Hereditary Hemorrhagic Telangiectasia	23800974	genetic disease	DOID:1270	I78.0	D013683	PS187300		MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells.
tissue_expression_down	hsa-mir-195	Hirschsprung Disease	25007945	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	Aberrant expression of miR-195 may involved in the pathogenesis of HSCR by down-regulated the level of DIEXF.
tissue_expression_down	hsa-mir-206	Hirschsprung Disease	25792468	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	Down-regulation of miR-206 is associated with Hirschsprung disease and suppresses cell migration and proliferation in cell models.
tissue_expression_down	hsa-let-7i	Human Immunodeficiency Virus Infection	27145859			B20	D015658	609423		HIV-1 infection decreases the expression of let-7i in CD4(+) T cells by attenuating its promoter activity.
tissue_expression_down	hsa-mir-150	Human Immunodeficiency Virus Infection	26937033			B20	D015658	609423		the T-cell activation-associated miR-15b, miR-142-3p, miR-142-5p, and miR-150 expression was significantly downregulated
tissue_expression_down	hsa-mir-217	Human Immunodeficiency Virus Infection	22406815			B20	D015658	609423		MiR-217 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation by down-regulation of SIRT1.
tissue_expression_down	hsa-mir-146a	Human Papilloma Virus Infection	27818285			B97.7	D027383			Down-regulation of microRNA-146a is associated with high-risk human papillomavirus infection and epidermal growth factor receptor overexpression in penile squamous cell carcinoma.
tissue_expression_down	hsa-mir-146a	Huntington Disease	26165466	nervous system disease	DOID:12858	G10	D006816	143100		This increase in the expressions of PCNA, CHEK1 and  CCNA2 was found to be the result of decreased expressions of miR-432, miR-146a, and (miR-19a and miR-146a)
tissue_expression_down	hsa-mir-19a	Huntington Disease	26165466	nervous system disease	DOID:12858	G10	D006816	143100		This increase in the expressions of PCNA, CHEK1 and  CCNA2 was found to be the result of decreased expressions of miR-432, miR-146a, and (miR-19a and miR-146a)
tissue_expression_down	hsa-mir-135b	Hypertension	27176897	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	4 were upregulated (miR鈥?18a, miR鈥?27, miR鈥?18e and miR鈥?532) and 2 downregulated (miR鈥?8 and miR鈥?35b) in SPE placentas compared with controls.
tissue_expression_down	hsa-mir-98	Hypertension	27176897	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	4 were upregulated (miR鈥?18a, miR鈥?27, miR鈥?18e and miR鈥?532) and 2 downregulated (miR鈥?8 and miR鈥?35b) in SPE placentas compared with controls.
tissue_expression_down	hsa-mir-1-1	Hypertrophy	21418519				D006984			IGF-1 deficiency retards AAC-induced cardiac hypertrophic and contractile changes via alleviating downregulation of miR-1 and miR-133a in response to left ventricular pressure overload.
tissue_expression_down	hsa-mir-1-2	Hypertrophy	21418519				D006984			IGF-1 deficiency retards AAC-induced cardiac hypertrophic and contractile changes via alleviating downregulation of miR-1 and miR-133a in response to left ventricular pressure overload.
tissue_expression_down	hsa-mir-133a-1	Hypertrophy	21418519				D006984			IGF-1 deficiency retards AAC-induced cardiac hypertrophic and contractile changes via alleviating downregulation of miR-1 and miR-133a in response to left ventricular pressure overload.
tissue_expression_down	hsa-mir-133a-2	Hypertrophy	21418519				D006984			IGF-1 deficiency retards AAC-induced cardiac hypertrophic and contractile changes via alleviating downregulation of miR-1 and miR-133a in response to left ventricular pressure overload.
tissue_expression_down	hsa-mir-125	Infection [unspecific]	29391047				D007239			upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections
tissue_expression_down	hsa-mir-129	Infection [unspecific]	29425228				D007239			Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding
tissue_expression_down	hsa-mir-1295a	Infection [unspecific]	29425228				D007239			Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding
tissue_expression_down	hsa-mir-143	Infection [unspecific]	29391047				D007239			upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections
tissue_expression_down	hsa-mir-188	Infection [unspecific]	29425228				D007239			Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding
tissue_expression_down	hsa-mir-363	Infection [unspecific]	29425228				D007239			Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding
tissue_expression_down	hsa-mir-4443	Infection [unspecific]	29425228				D007239			Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding
tissue_expression_down	hsa-mir-6721	Infection [unspecific]	29425228				D007239			Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding
tissue_expression_down	hsa-mir-99b	Infection [unspecific]	29425228				D007239			Seven of the 26 miRNAs, miR-99b-5p, miR-129-3p, miR-188-5p, miR-363-3p, miR-1295a, miR-4443 and miR-6721-5p, showed significantly decreased expression in individuals with detectable oral shedding
tissue_expression_down	hsa-let-7i	Inflammation	23509825				D007249			This let-7i downregulation in dendritic cells constitutes a novel feature of the modulatory activity that helminth-derived antigens exert on their host.
tissue_expression_down	hsa-mir-1-1	Inflammation	20098732				D007249			Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206.
tissue_expression_down	hsa-mir-1-2	Inflammation	20098732				D007249			Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206.
tissue_expression_down	hsa-mir-125b	Inflammation	26319761				D007249			The lower expression of miR-155 and miR-125b in ORG calves indicated the potential for maternal organic trace minerals in regulating the PMNL inflammatory response at least via alterations in mRNA and miRNA expression.
tissue_expression_down	hsa-mir-133a	Inflammation	20098732				D007249			Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206.
tissue_expression_down	hsa-mir-133b	Inflammation	20098732				D007249			Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206.
tissue_expression_down	hsa-mir-155	Inflammation	22326887				D007249			Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155
tissue_expression_down	hsa-mir-206	Inflammation	20098732				D007249			Low density miR array demonstrated that TWEAK inhibits the expression of several miRs including muscle-specific miR-1-1, miR-1-2, miR-133a, miR-133b and miR-206.
tissue_expression_down	hsa-mir-223	Inflammation	22937006				D007249			Here we reported that the expression of microRNA-223 (miR-223) was significantly decreased in murine macrophages during activation by lipopolysaccharide (LPS) or poly (I∶C) stimulation.
tissue_expression_down	hsa-mir-145	Inflammation	23980205				D007249			We demonstrate that miR-145, downregulated by IFN-I,targets histone deacetylase 11 to promote innate IL-10 expression in macrophages.Our findings suggest a new IFN-I-mediated negative feedback loop in the fine-tuning of innate IL-10 production that creates precise coordination of innate immune responses.
tissue_expression_down	hsa-mir-155	Inflammation	25295729				D007249			Differential expression of microRNAs in Francisella tularensis-infected human macrophages: miR-155-dependent downregulation of MyD88 inhibits the inflammatory  response.
tissue_expression_down	hsa-mir-10a	Inflammatory Bowel Diseases	25281418	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Our data indicate that miR-10a is decreased in the inflamed mucosa of IBD and downregulates mucosal inflammatory response through inhibition of IL-12/IL-23p40 and NOD2 expression, and blockade of Th1/Th17 cell immune responses. Thus, miR-10a could play a role in the pathogenesis and progression of IBD.
tissue_expression_down	hsa-mir-200	Inflammatory Bowel Diseases	27113480	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Our finding of down-regulation of the miR-200 family  and up-regulation of transcription repressors Snail and Slug supports the postulated role of EMT in the pathogenesis of fibrosis in IBD.
tissue_expression_down	hsa-mir-346	Inflammatory Bowel Diseases	25192497	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	These data suggest that during mucosal inflammation TNF-α induces miR-346, which downregulates epithelial VDR. Mucosal VDR reduction in turn compromises the integrity of the mucosal epithelial barrier, further driving mucosal inflammation and colitis development.
tissue_expression_down	hsa-mir-320a	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-320b-1	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-320b-2	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-320c-1	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-320c-2	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-320d-1	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-320d-2	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-328	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-449b	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-mir-500a	Interstitial Cystitis	20008142	urinary system disease	DOID:13949	N30.10-.11	D018856			demonstrate a direct correlation between miR-449b, miR-500, miR-328, and miR-320 and a down-regulation of NK1R mRNA and/or protein levels
tissue_expression_down	hsa-let-7e	Interstitial Lung Disease	22782705	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	downregulated
tissue_expression_down	hsa-mir-142	Interstitial Lung Disease	22782705	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	miR-142-5p: downregulated
tissue_expression_down	hsa-mir-19a	Interstitial Lung Disease	22782705	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	downregulated
tissue_expression_down	hsa-mir-27a	Intervertebral Disc Degeneration	24086481	musculoskeletal system disease	DOID:90	M51	D055959	603932	HP:0008419	This present study revealed that downregulated miR-27a might develop a novel intervention for IDD treatment through the prevention of apoptosis in Nucleus pulposus Cells.
tissue_expression_down	hsa-let-7f	Ischemia	28345812	cardiovascular system disease	DOID:326		D007511	601367		Reduced expression of let-7f activates TGF-β/ALK5 pathway and leads to impaired ischaemia-induced neovascularization after cigarette smoke exposure.
tissue_expression_down	hsa-mir-122	Ischemia-Reperfusion Injury	27569279				D015427			Downregulation of miR-122 attenuates hypoxia/reoxygenation (H/R)-induced myocardial cell apoptosis by upregulating GATA-4.
tissue_expression_down	hsa-mir-146a	Ischemia-Reperfusion Injury	23498784				D015427			Down-regulation of microRNA-146a in the early stage of liver ischemia-reperfusion injury.
tissue_expression_down	hsa-mir-214	Ischemia-Reperfusion Injury	27530948				D015427			the expression of miR-214 of IR group was lower than that of control group
tissue_expression_down	hsa-let-7g	Ischemic Heart Disease	26655604			I25.9/I24.9	D017202			MiR-let-7a, -7c and -7g were downregulated in the adult mouse heart early after coronary occlusion
tissue_expression_down	hsa-mir-34a	Ischemic Heart Disease	24123326			I25.9/I24.9	D017202			miR-34a was downregulated in heat shocked Sca-11 stem cells (HSSca-11 cells),heat shock induces exosomal transfer of HSF1 from Sca-1(+) cells, which directs ischemic cardiomyocytes toward a prosurvival phenotype by epigenetic repression of miR-34a.
tissue_expression_down	hsa-let-7a-1	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7a: down-regulated
tissue_expression_down	hsa-let-7a-2	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7a: down-regulated
tissue_expression_down	hsa-let-7a-3	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7a: down-regulated
tissue_expression_down	hsa-let-7b	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7b: down-regulated
tissue_expression_down	hsa-let-7c	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7c: down-regulated
tissue_expression_down	hsa-let-7d	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7d: down-regulated
tissue_expression_down	hsa-let-7e	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7e: down-regulated
tissue_expression_down	hsa-let-7f-1	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7f: down-regulated
tissue_expression_down	hsa-let-7f-2	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7f: down-regulated
tissue_expression_down	hsa-let-7g	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7g: down-regulated
tissue_expression_down	hsa-let-7i	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			let-7i: down-regulated
tissue_expression_down	hsa-mir-221	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			miR-221: down-regulated
tissue_expression_down	hsa-mir-221	Kaposi Sarcoma	21715310	disease of cellular proliferation	DOID:8632	C46	D012514			In the present study, we show that Kaposi sarcoma-associated herpesvirus (KSHV), the etiological agent of KS, induces global miRNA changes in lymphatic endothelial cells (LECs). Specifically, the miR-221/miR-222 cluster is down-regulated, whereas miR-31 is up-regulated.
tissue_expression_down	hsa-mir-222	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			miR-222: down-regulated
tissue_expression_down	hsa-mir-222	Kaposi Sarcoma	21715310	disease of cellular proliferation	DOID:8632	C46	D012514			In the present study, we show that Kaposi sarcoma-associated herpesvirus (KSHV), the etiological agent of KS, induces global miRNA changes in lymphatic endothelial cells (LECs). Specifically, the miR-221/miR-222 cluster is down-regulated, whereas miR-31 is up-regulated.
tissue_expression_down	hsa-mir-98	Kaposi Sarcoma	19252139	disease of cellular proliferation	DOID:8632	C46	D012514			miR-98: down-regulated
tissue_expression_down	hsa-mir-155	Kawasaki Syndrome	25039241	immune system disease	DOID:13378	M30.3	D009080	611775		These results suggest that the decrease in FoxP3(+) Treg might be associated with decreased expression of miR-155, leading to aberrant SOCS1/STAT-5 signalling and overexpression of miR-31 in patients with acute KD.
tissue_expression_down	hsa-mir-142	Kideny Transplant Rejection	27323802			T86.11	D006084			miR-142-5p was significantly (p鈥?鈥?.01) underexpressed in patients with DSA.
tissue_expression_down	hsa-mir-133a	Kidney Diseases [unspecific]	25871823			N18.9	D007674			This is the first report to analyze the correlation between ET-1-induced miRNA 133a overexpression in proteinuria resulting in MRP2 downregulation, which is a contributing factor for renal cytotoxicity. The detection of the miRNA 133a in urine samples can be possibly used as a monitor for cytotoxicity.
tissue_expression_down	hsa-mir-93	Kidney Neoplasms	25183046	disease of cellular proliferation	DOID:263	C64	D007680			TGF-beta induced RBL2 expression through down-regulating miR-93 in renal cancer cells. The newly identified TGF-beta/miR-93/RBL2 signal pathway reveals a new mechanism of TGF-beta induced growth arrest in renal cancer.
tissue_expression_down	hsa-mir-10a	Laryngeal Neoplasms	26268753			C32.3	D007822			Down regulation of miR-10a may be a useful molecular marker for grading of LEPL and diagnosis of early laryngeal cancer.
tissue_expression_down	hsa-mir-1-1	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-1-2	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-125b-1	Laryngeal Neoplasms	22605671			C32.3	D007822			Downregulation
tissue_expression_down	hsa-mir-125b-2	Laryngeal Neoplasms	22605671			C32.3	D007822			Downregulation
tissue_expression_down	hsa-mir-133a-1	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-133a-2	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-144	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-145	Laryngeal Neoplasms	22605671			C32.3	D007822			Downregulation
tissue_expression_down	hsa-mir-206	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-375	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-378a	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-384	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-422a	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-486	Laryngeal Neoplasms	20806854			C32.3	D007822			miR-486-5p: downregulated by 5 multiple
tissue_expression_down	hsa-mir-487a	Laryngeal Neoplasms	20806854			C32.3	D007822			downregulated by 5 multiple
tissue_expression_down	hsa-mir-141	Learned Helplessness	21275079				D006380			mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain.
tissue_expression_down	hsa-mir-182	Learned Helplessness	21275079				D006380			mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain.
tissue_expression_down	hsa-mir-183	Learned Helplessness	21275079				D006380			mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain.
tissue_expression_down	hsa-mir-200a	Learned Helplessness	21275079				D006380			mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain.
tissue_expression_down	hsa-mir-200b	Learned Helplessness	21275079				D006380			mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain.
tissue_expression_down	hsa-mir-200c	Learned Helplessness	21275079				D006380			mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain.
tissue_expression_down	hsa-mir-429	Learned Helplessness	21275079				D006380			mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain.
tissue_expression_down	hsa-mir-96	Learned Helplessness	21275079				D006380			mir-96, 141, 182, 183, 183*, 298, 200a, 200a*, 200b, 200b*, 200c, 429 are significantly downregulated in non-learned helplessness relative to tested controls in rat brain.
tissue_expression_down	hsa-mir-29	Leiomyoma	27233758	disease of cellular proliferation	DOID:127	D25	D007889	150699		Members of the miRNA-29 family (29a, 29b, 29c) are all down-regulated  in leiomyoma
tissue_expression_down	hsa-mir-17	Leukemia	25140305			C95	D007938	613065	HP:0001909	The antileukemia activity of natural product HQ17(3) is possibly associated with downregulation of miR-17-92 cluster.
tissue_expression_down	hsa-mir-495	Leukemia	23132946			C95	D007938	613065	HP:0001909	MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia
tissue_expression_down	hsa-mir-92	Leukemia	25140305			C95	D007938	613065	HP:0001909	The antileukemia activity of natural product HQ17(3) is possibly associated with downregulation of miR-17-92 cluster.
tissue_expression_down	hsa-mir-22	Leukemia, Lymphoblastic	25430416	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		proliferation of this subset mainly depends on microRNA-22 overexpression, which induces phosphatase and tensin homolog (PTEN) down-regulation and phosphoinositide 3-kinase (PI3K)/AKT pathway activation. These results underline  the role of the PI3K/AKT pathway at the origin of this proliferative pool in patients with UM CLL and provide additional rationale for the use of PI3K inhibitors.
tissue_expression_down	hsa-mir-145	Leukemia, Lymphoblastic, Acute, T-Cell	24745613	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Prognostic impact of microRNA-145 down-regulation in adult T-cell leukemia/lymphoma.
tissue_expression_down	hsa-mir-125b-1	Leukemia, Lymphocytic, Chronic, B-Cell	22723551	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state.
tissue_expression_down	hsa-mir-125b-2	Leukemia, Lymphocytic, Chronic, B-Cell	22723551	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state.
tissue_expression_down	hsa-mir-15	Leukemia, Lymphocytic, Chronic, B-Cell	23974981	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia.
tissue_expression_down	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	23974981	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia.
tissue_expression_down	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	17351108	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	New Zealand black (NZB) mice (NZB) tissue sourcesof RNA showed a decrease in miR-16 in the spleen; however, theNZB kidney was not decreased in miR-16 expression compared withthe control strain expression. In addition, the NZB-derivedmalignant B-cell line, LNC, had an even greater decreased expressionof miR-16 compared with C57Bl6 spleen.
tissue_expression_down	hsa-mir-16-2	Leukemia, Lymphocytic, Chronic, B-Cell	17351108	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	New Zealand black (NZB) mice (NZB) tissue sourcesof RNA showed a decrease in miR-16 in the spleen; however, theNZB kidney was not decreased in miR-16 expression compared withthe control strain expression. In addition, the NZB-derivedmalignant B-cell line, LNC, had an even greater decreased expressionof miR-16 compared with C57Bl6 spleen.
tissue_expression_down	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	22321781	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The down-regulation of microRNA-223 was associated with disease aggressiveness in CLL.
tissue_expression_down	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	24138306	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	down-regulation of miR-29c is associated with higher tumor burden and significantly predicts short survival in Chinese patients with CLL
tissue_expression_down	hsa-mir-143	Leukemia, Lymphocytic, Chronic, B-Cell	27111859	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-143 was downregulated and miR-155 was overexpressed in 13q-H.
tissue_expression_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	19591824	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma.
tissue_expression_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	23615967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference.
tissue_expression_down	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	19591824	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The microRNAs miR-15a and miR-16-1 are downregulated in multiple tumor types and are frequently deleted in chronic lymphocytic leukemia (CLL), myeloma and mantle cell lymphoma.
tissue_expression_down	hsa-let-7f	Leukemia, Myeloid, Acute	24067109	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA let-7f is down-regulated in patients with refractory acute myeloid leukemia and is involved in chemotherapy resistance of adriamycin-resistant leukemic cells.
tissue_expression_down	hsa-mir-155	Leukemia, Myeloid, Acute	26055960	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our results suggest that activating mutation of FLT3 in AML can lead,through the induction of JUN, to an increased expression of miR-155, which then causes down-regulation of SPI1 and CEBPB and consequently may causes block of myeloid differentiation.
tissue_expression_down	hsa-mir-27a	Leukemia, Myeloid, Acute	27396688	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We observed decreased levels of miRNA-27a but of not miRNA-138  in SKM-1/AzaC cells compared with SKM-1 cells.
tissue_expression_down	hsa-mir-34c	Leukemia, Myeloid, Acute	27577964	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia.
tissue_expression_down	hsa-mir-155	Leukemia, Myeloid, Chronic	22511990	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of mir-31, mir-155, and mir-564 in chronic myeloid leukemia cells.
tissue_expression_down	hsa-mir-155	Leukemia, Myeloid, Chronic	25833191	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Some onco-miRNAs were found to be downregulated (miR-155 and miR-106), and some tumor suppressor miRs (miR-16-1, miR-15a, miR-101, miR-568) were upregulated.
tissue_expression_down	hsa-mir-31	Leukemia, Myeloid, Chronic	22511990	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of mir-31, mir-155, and mir-564 in chronic myeloid leukemia cells.
tissue_expression_down	hsa-mir-370	Leukemia, Myeloid, Chronic	24148180	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	MiR-370 sensitized K562 cells to HHT by inducing apoptosis in part by downregulation of FoxM1 expression. These findings may provide further information for CML treatment with HHT.
tissue_expression_down	hsa-mir-564	Leukemia, Myeloid, Chronic	22511990	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of mir-31, mir-155, and mir-564 in chronic myeloid leukemia cells.
tissue_expression_down	hsa-mir-181a	Leukemia, Promyelocytic, Acute	22967415	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05).
tissue_expression_down	hsa-mir-17	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	19347736	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-17-5p: down-regulated
tissue_expression_down	hsa-mir-29a	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	19347736	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-29: down-regulated
tissue_expression_down	hsa-mir-29b-1	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	19347736	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-29: down-regulated
tissue_expression_down	hsa-mir-29b-2	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	19347736	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-29: down-regulated
tissue_expression_down	hsa-mir-29c	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	19347736	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-29: down-regulated
tissue_expression_down	hsa-mir-34a	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	19347736	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-34a: down-regulated
tissue_expression_down	hsa-mir-125b-1	Lichen Planus	21943223	integumentary system disease	DOID:9201	L43	D008010	151620		Increased expression of miR-21 and miR-203, decreased expression of miR-125, and down-regulation of p53 and deltaNp63 RNA were seen in OLP compared to normal oral mucosa. When comparing microRNA expression to levels of p53 and p63 RNA, a significant negative correlation was seen between deltaNp63 and miR-203 and between miR-21 and p53, respectively.
tissue_expression_down	hsa-mir-125b-2	Lichen Planus	21943223	integumentary system disease	DOID:9201	L43	D008010	151620		Increased expression of miR-21 and miR-203, decreased expression of miR-125, and down-regulation of p53 and deltaNp63 RNA were seen in OLP compared to normal oral mucosa. When comparing microRNA expression to levels of p53 and p63 RNA, a significant negative correlation was seen between deltaNp63 and miR-203 and between miR-21 and p53, respectively.
tissue_expression_down	hsa-mir-26b	Lichen Planus	22017396	integumentary system disease	DOID:9201	L43	D008010	151620		Levels of COX-2 mRNA were significantly higher while levels of miR-26b were significantly lower in OLP lesions compared to controls. Increased expression of COX-2 and decreased expression of miR-26b in OLP suggests both to play a role in OLP.
tissue_expression_down	hsa-mir-27b	Lichen Planus	22077423	integumentary system disease	DOID:9201	L43	D008010	151620		miR-27b was significantly down-regulated in OLP tissue, and miR-27b expression was even more suppressed in atrophic-erosive OLP than in reticular OLP. In addition, miR-27b was found to be expressed in the epithelial keratinocyte layer of both normal and OLP tissues.
tissue_expression_down	hsa-mir-122	Liver Cirrhosis	26167081	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Reduced expression of miR-122 in advanced fibrosis and its correlation with fibrosis stage and LS values seem to be characteristic of hepatic fibrosis of various etiologies.
tissue_expression_down	hsa-mir-200b	Liver Cirrhosis	28634212	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
tissue_expression_down	hsa-mir-15a	Liver Diseases [unspecific]	19360909			K76.9	D008107			miR-15a: decreased
tissue_expression_down	hsa-mir-34a	Liver Diseases [unspecific]	26567713			K76.9	D008107			These results suggested that AFB1 might down-regulate Wnt/β-catenin signaling pathway in HepG2 cells by up-regulating miR-34a, which may involve in the mechanism of liver tumorigenesis.
tissue_expression_down	hsa-mir-370	Liver Diseases [unspecific]	26608583			K76.9	D008107			up-regulated de novo lipogenesis (DNL) related proteins expression (ACC, SCD1), and down-regulated expressions of miR-122, miR-370 and miR-33;
tissue_expression_down	hsa-mir-22	Liver Neoplasms	26239725	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	microRNA-22 downregulation of galectin-9 influences lymphocyte apoptosis and tumor cell proliferation in liver cancer.
tissue_expression_down	hsa-mir-133b	Liver Neoplasms	19946373	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	downregulated
tissue_expression_down	hsa-mir-148b	Liver Neoplasms	21176238	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	mir-148b* is underexpressed in side population of HCC cells compared to fetal liver cells
tissue_expression_down	hsa-mir-200a	Liver Neoplasms	21176238	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	mir-200a* is underexpressed in side population of HCC cells compared to fetal liver cells
tissue_expression_down	hsa-mir-486	Liver Neoplasms	19946373	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-486-5p: downregulated
tissue_expression_down	hsa-mir-21	Lung Fibrosis	25704671	respiratory system disease	DOID:3770	J84.10	D011658	178500		our results demonstrate that by decreasing IFN-γ-induced STAT3/p-STAT3 expression to down-regulate miR-21,sulindac could significantly reverse EMT in A549 cells and prevent BLM-induced PF.
tissue_expression_down	hsa-let-7a	Lung Neoplasms	28846189	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Let-7a, miR-16 and miR-34a, were found to be significantly downregulated by chronic PM2.5 exposure
tissue_expression_down	hsa-mir-1	Lung Neoplasms	19748927	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs.
tissue_expression_down	hsa-mir-100	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-101	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-101-1	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-107	Lung Neoplasms	25120851	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The expression of miR-107 was decreased in NSCLC. Low expression of miR-107 was significantly associated with tumor progression and decreased survival in patients with NSCLC, indicating that miR-107 may serve as a novel prognostic marker in NSCLC.
tissue_expression_down	hsa-mir-107	Lung Neoplasms	26722426	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer.
tissue_expression_down	hsa-mir-1-1	Lung Neoplasms	23761296	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Sustainable downregulation in the lung tissues in lung carcinogenesis induced by urethane.
tissue_expression_down	hsa-mir-1-2	Lung Neoplasms	23761296	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Sustainable downregulation in the lung tissues in lung carcinogenesis induced by urethane.
tissue_expression_down	hsa-mir-1224	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_down	hsa-mir-124	Lung Neoplasms	25973090	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Down-regulation of microRNA-124 is correlated with tumor metastasis and poor prognosis in patients with lung cancer.
tissue_expression_down	hsa-mir-124-1	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-124-2	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-124-3	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-125a	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-125b	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-125b-1	Lung Neoplasms	25120851	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The expression of miR-107 was decreased in NSCLC. Low expression of miR-107 was significantly associated with tumor progression and decreased survival in patients with NSCLC, indicating that miR-107 may serve as a novel prognostic marker in NSCLC.
tissue_expression_down	hsa-mir-126	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-126	Lung Neoplasms	22672859	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis
tissue_expression_down	hsa-mir-126	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_down	hsa-mir-126	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-130a	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-130b	Lung Neoplasms	25120851	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The expression of miR-107 was decreased in NSCLC. Low expression of miR-107 was significantly associated with tumor progression and decreased survival in patients with NSCLC, indicating that miR-107 may serve as a novel prognostic marker in NSCLC.
tissue_expression_down	hsa-mir-133b	Lung Neoplasms	19946373	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulated
tissue_expression_down	hsa-mir-134	Lung Neoplasms	22306127	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-27b and miR-134 levels were significantly lower in the tumors than normal tissue.
tissue_expression_down	hsa-mir-140	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-142	Lung Neoplasms	19618089	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer cell lines, clinical implications discussed
tissue_expression_down	hsa-mir-143	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-143	Lung Neoplasms	20363096	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulated; Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis
tissue_expression_down	hsa-mir-143	Lung Neoplasms	19748927	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs.
tissue_expression_down	hsa-mir-143	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_down	hsa-mir-143	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-145	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-145	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-145 downregulated in breast cancer (Iorio et al., 2005) and lung cancer and deleted in prostate cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-145	Lung Neoplasms	19618089	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer cell lines, clinical implications discussed
tissue_expression_down	hsa-mir-145	Lung Neoplasms	22672859	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis
tissue_expression_down	hsa-mir-145	Lung Neoplasms	26309531	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We have found that miR-145 is dramatically down-regulated in clinical specimen of lung cancer
tissue_expression_down	hsa-mir-145	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_down	hsa-mir-145	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-155	Lung Neoplasms	19597153	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	down-regulated miR
tissue_expression_down	hsa-mir-16	Lung Neoplasms	28846189	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Let-7a, miR-16 and miR-34a, were found to be significantly downregulated by chronic PM2.5 exposure
tissue_expression_down	hsa-mir-181a	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-181a-2	Lung Neoplasms	20363096	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulated; Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis
tissue_expression_down	hsa-mir-181c	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-181c	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-181c-prec downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-186	Lung Neoplasms	23204228	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-186 Downregulation Correlates with Poor Survival in Lung Adenocarcinoma,Where It Interferes with Cell-Cycle Regulation
tissue_expression_down	hsa-mir-18b	Lung Neoplasms	19618089	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer cell lines, clinical implications discussed
tissue_expression_down	hsa-mir-192	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-192-prec downregulation
tissue_expression_down	hsa-mir-193a	Lung Neoplasms	22325218	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-33a was down-regulated by 92.8% and mir-193a-3p by 86.5% in epithelial-mesenchymal transition (EMT) on the expression of microRNAs (miRNAs) in lung cancer A549 cells.
tissue_expression_down	hsa-mir-198	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-199a	Lung Neoplasms	24022342	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation of miR-199a is essential for hypoxia-induced proliferation through derepressing the expression of HIF1a expression and affecting HIF1a mediated glycolytic pathway in NSCLC progression.
tissue_expression_down	hsa-mir-199b	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-202	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_down	hsa-mir-216a	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-216b	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-218-2	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-218-2	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-218-2 downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-219-1	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-223	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-224	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-25	Lung Neoplasms	25432132	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	CDC42 was confirmed to be the directly regulated by miR-25 in A549 cells. Upregulation of CDC42 in A549 cells rescued the inhibitory effect on proliferation and the G1 cell cycle arrest induced by miR-25 downregulation. Our  study demonstrates miR-25, by targeting CDC42, is an important regulator in NSCLC.
tissue_expression_down	hsa-mir-26a	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-26a-1	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-26a-1	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-26a-1-prec downregulated in lung cancer, deleted in epithelial cancers (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-26b	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-27b	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-27b	Lung Neoplasms	22306127	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-27b and miR-134 levels were significantly lower in the tumors than normal tissue.
tissue_expression_down	hsa-mir-29a	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-29a	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-29b-1	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-29b-1	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-29b-2	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-29c	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-29c	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-30a	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-30a	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-30a	Lung Neoplasms	27374108	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-30a-3p and miR-30a-5p were significantly decreased in tumors
tissue_expression_down	hsa-mir-30a	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_down	hsa-mir-30a	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-30b	Lung Neoplasms	25249344	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We demonstrated that miR-30b/c was down-regulated in NSCLC specimens compared with adjacent non-tumor tissues. miR-30b/c directly targeted and down-regulated Rab18 expression and inhibited NSCLC cells proliferation. These data indicated that miR-30b/c could serve as a tumor suppressor gene involved in NSCLC pathogenesis.
tissue_expression_down	hsa-mir-30b	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-30b	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-30c	Lung Neoplasms	25119247	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Low expression of microRNA-30c promotes invasion by inducing epithelial mesenchymal transition in non-small cell lung cancer.
tissue_expression_down	hsa-mir-30c	Lung Neoplasms	25249344	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We demonstrated that miR-30b/c was down-regulated in NSCLC specimens compared with adjacent non-tumor tissues. miR-30b/c directly targeted and down-regulated Rab18 expression and inhibited NSCLC cells proliferation. These data indicated that miR-30b/c could serve as a tumor suppressor gene involved in NSCLC pathogenesis.
tissue_expression_down	hsa-mir-30c-1	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-30c-2	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-30d	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-30d	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_down	hsa-mir-30d	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-30e	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-30e	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-32	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-32	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-32 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-320	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-33a	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-33a	Lung Neoplasms	22325218	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-33a was down-regulated by 92.8% and mir-193a-3p by 86.5% in epithelial-mesenchymal transition (EMT) on the expression of microRNAs (miRNAs) in lung cancer A549 cells.
tissue_expression_down	hsa-mir-33b	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-34a	Lung Neoplasms	25501507	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-34a could inhibit the proliferation and promote the apoptosis of H1299 cells partially through the downregulation of its target gene TGFβR2.
tissue_expression_down	hsa-mir-34a	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-34a	Lung Neoplasms	28846189	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Let-7a, miR-16 and miR-34a, were found to be significantly downregulated by chronic PM2.5 exposure
tissue_expression_down	hsa-mir-34b	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-34b	Lung Neoplasms	21339737	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A microRNA, miR-34b, that suppresses the expression of alpha4 through specific binding to the 3'-untranslated region of alpha4 is downregulated in transformed or human lung tumors.
tissue_expression_down	hsa-mir-34c	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-30, mir-34 mir-30a-5p downregulated in lung cancer (Yanaihara et al., 2006)
tissue_expression_down	hsa-mir-34c	Lung Neoplasms	23805317	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-34a and miR-34c were downregulated in lung tumors compared to normal tissues.
tissue_expression_down	hsa-mir-451	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-451a	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_down	hsa-mir-486	Lung Neoplasms	19946373	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-486-5p: downregulated
tissue_expression_down	hsa-mir-486	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_down	hsa-mir-605	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_down	hsa-mir-652	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-663	Lung Neoplasms	25301444	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Waltonitone induces apoptosis through mir-663-induced Bcl-2 downregulation in non-small cell lung cancer.
tissue_expression_down	hsa-mir-671	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_down	hsa-mir-886	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-9-1	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-9-2	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-9-3	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-939	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_down	hsa-mir-95	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
tissue_expression_down	hsa-mir-99a	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_down	hsa-mir-101-1	Lymphoma	21960592	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset.
tissue_expression_down	hsa-mir-101-2	Lymphoma	21960592	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset.
tissue_expression_down	hsa-mir-125a	Lymphoma	22307176	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	significantly underexpressed in SMZL (splenic marginal zone lymphoma).
tissue_expression_down	hsa-mir-126	Lymphoma	22307176	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	significantly underexpressed in SMZL (splenic marginal zone lymphoma).
tissue_expression_down	hsa-mir-133b	Lymphoma	19946373	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	downregulated
tissue_expression_down	hsa-mir-138-1	Lymphoma	21960592	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset.
tissue_expression_down	hsa-mir-138-2	Lymphoma	21960592	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset.
tissue_expression_down	hsa-mir-139	Lymphoma	22307176	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	significantly underexpressed in SMZL (splenic marginal zone lymphoma).
tissue_expression_down	hsa-mir-146a	Lymphoma	22307176	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	significantly overexpressed in SMZL (splenic marginal zone lymphoma).
tissue_expression_down	hsa-mir-155	Lymphoma	22307176	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	significantly overexpressed in SMZL (splenic marginal zone lymphoma).
tissue_expression_down	hsa-mir-15a	Lymphoma	21118128	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Both decreased expression of miR-15a and miR-16-1 and increased nucleolin have been shown to be associated with increased Bcl2 expression and resistance to apoptosis in the common human disease, chronic lymphocytic leukaemia.
tissue_expression_down	hsa-mir-16-1	Lymphoma	21778999	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
tissue_expression_down	hsa-mir-16-1	Lymphoma	21960592	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset.
tissue_expression_down	hsa-mir-16-1	Lymphoma	21118128	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Both decreased expression of miR-15a and miR-16-1 and increased nucleolin have been shown to be associated with increased Bcl2 expression and resistance to apoptosis in the common human disease, chronic lymphocytic leukaemia.
tissue_expression_down	hsa-mir-16-2	Lymphoma	21778999	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
tissue_expression_down	hsa-mir-16-2	Lymphoma	21960592	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset.
tissue_expression_down	hsa-mir-21	Lymphoma	22307176	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	significantly overexpressed in SMZL (splenic marginal zone lymphoma).
tissue_expression_down	hsa-mir-29c	Lymphoma	21960592	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The down-regulation of miR-16, miR-26a, miR-101, miR-29c and miR138 in the t(14;18)-negative FL( follicular lymphoma ) subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis and B-cell differentiation. miR-16 target CHEK1 showed increased expression on the protein level in t(14;18)-negative FL, while TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset.
tissue_expression_down	hsa-mir-345	Lymphoma	22307176	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	significantly underexpressed in SMZL (splenic marginal zone lymphoma).
tissue_expression_down	hsa-mir-486	Lymphoma	19946373	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-486-5p: downregulated
tissue_expression_down	hsa-mir-499a	Lymphoma	19690137	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	deregulated, hypermutations
tissue_expression_down	hsa-mir-377	Lymphoma, B-Cell	26537004	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	These findings reveal a novel mechanism by which down-regulation of miR-377 increases BCL-xL expression, promoting chemotherapy resistance in B-cell lymphoid malignancies.
tissue_expression_down	hsa-let-7c	Lymphoma, Burkitt	18802929	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	In particular, down-regulation of hsa-let-7c was observed in BL cases, compared to normal controls.
tissue_expression_down	hsa-mir-17	Lymphoma, Large B-Cell, Diffuse	28817403	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		PB-DLBCL and DLBCL-GCB-CC also had much higher levels of miR-125a-3p, miR-34-3p, and miR-155-5p, and significantly lower levels of miR-17-5p and miR-17-3p
tissue_expression_down	hsa-mir-221	Lymphoma, Large B-Cell, Diffuse	26683099	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Among antiangiomiRs we found decreased expression of miR-16, miR-20b, miR-92a, miR-221 and miR-328
tissue_expression_down	hsa-mir-26b	Lymphoma, Non-Hodgkin	24651473	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	We propose that activation of both canonical and alternative NF-κB signalling pathways and down-regulation of miR-26b contribute to the development  of HCV-associated B-NHL.
tissue_expression_down	hsa-let-7a-1	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7a: down-regulated
tissue_expression_down	hsa-let-7a-2	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7a: down-regulated
tissue_expression_down	hsa-let-7a-3	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7a: down-regulated
tissue_expression_down	hsa-let-7b	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7b: down-regulated
tissue_expression_down	hsa-let-7c	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7c: down-regulated
tissue_expression_down	hsa-let-7d	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7d: down-regulated
tissue_expression_down	hsa-let-7e	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7e: down-regulated
tissue_expression_down	hsa-let-7f-1	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7f: down-regulated
tissue_expression_down	hsa-let-7f-2	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7f: down-regulated
tissue_expression_down	hsa-let-7g	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7g: down-regulated
tissue_expression_down	hsa-let-7i	Lymphoma, Primary Effusion	19252139			C83.8	D054685			let-7i: down-regulated
tissue_expression_down	hsa-mir-221	Lymphoma, Primary Effusion	19252139			C83.8	D054685			miR-221: down-regulated
tissue_expression_down	hsa-mir-222	Lymphoma, Primary Effusion	19252139			C83.8	D054685			miR-222: down-regulated
tissue_expression_down	hsa-mir-98	Lymphoma, Primary Effusion	19252139			C83.8	D054685			miR-98: down-regulated
tissue_expression_down	hsa-mir-101-1	Lymphoma, T-Cell	21921041	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes.
tissue_expression_down	hsa-mir-101-2	Lymphoma, T-Cell	21921041	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes.
tissue_expression_down	hsa-mir-17	Lymphoma, T-Cell	20448109	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	mir-17:down-regulation of the miR-17-92 cluster in malignancy
tissue_expression_down	hsa-mir-18a	Lymphoma, T-Cell	20448109	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	mir-18a:down-regulation of the miR-17-92 cluster in malignancy
tissue_expression_down	hsa-mir-19a	Lymphoma, T-Cell	20448109	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	mir-19a:down-regulation of the miR-17-92 cluster in malignancy
tissue_expression_down	hsa-mir-19b-1	Lymphoma, T-Cell	20448109	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	mir-19b:down-regulation of the miR-17-92 cluster in malignancy
tissue_expression_down	hsa-mir-19b-2	Lymphoma, T-Cell	20448109	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	mir-19b:down-regulation of the miR-17-92 cluster in malignancy
tissue_expression_down	hsa-mir-20a	Lymphoma, T-Cell	20448109	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	mir-20a:down-regulation of the miR-17-92 cluster in malignancy
tissue_expression_down	hsa-mir-26a-1	Lymphoma, T-Cell	21921041	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes.
tissue_expression_down	hsa-mir-26a-2	Lymphoma, T-Cell	21921041	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes.
tissue_expression_down	hsa-mir-26b	Lymphoma, T-Cell	21921041	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	Re-expression of downregulated miRNAs, such as mir-101, mir-26a, mir26b, mir-28-5 and mir-363, reduced the growth of NK cell line and modulated the expression of their predicted target genes.
tissue_expression_down	hsa-mir-92a-1	Lymphoma, T-Cell	20448109	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	mir-92a:down-regulation of the miR-17-92 cluster in malignancy
tissue_expression_down	hsa-mir-92a-2	Lymphoma, T-Cell	20448109	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	mir-92a:down-regulation of the miR-17-92 cluster in malignancy
tissue_expression_down	hsa-mir-200c	Malignant Neoplasms [unspecific]	25766530			C80.1	D009369			This systematic review and meta-analysis clarified that low expression of miR-200c in primary tissue was significantly associated with poor survival in cancer patients at early stage, whereas a high level of blood miR-200c predicted poor prognosis in patients with advanced tumors.
tissue_expression_down	hsa-mir-106a	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-106a* was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-10a	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-10a was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-181c	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_down	hsa-mir-181d	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_down	hsa-mir-218	Medulloblastoma	23970061	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma.
tissue_expression_down	hsa-mir-219-1	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-219-1-3p was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-219	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-219-5p was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-221	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_down	hsa-mir-302b	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-302b* was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-302d	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-302d* was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-31	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-31: downregulated in all MBs
tissue_expression_down	hsa-mir-373	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-373 was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-383	Medulloblastoma	23157748	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Compared with normal brain tissue, decreased expression of miR-383 but elevated expression of PRDX3 are medulloblastoma tumour and Daoy cell lines
tissue_expression_down	hsa-mir-483	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-483-5p was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-504	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-504 was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-9	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_down	hsa-mir-92b	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-92b* was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-935	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-935 was significantly down-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_down	hsa-mir-122	Melanoma	19578755	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	down-regulated
tissue_expression_down	hsa-mir-125b	Melanoma	20827223	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Downregulation of miR-125b in metastatic cutaneous malignant melanoma.
tissue_expression_down	hsa-mir-125b	Melanoma	24462553	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-125b is down-regulated and the target genes (ERBB3a and ERBB3b) are upregulated in fish melanomas
tissue_expression_down	hsa-mir-125b	Melanoma	27469124	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Benign Spitz lesions were characterized by decreased expression of miR-125b and miR-211, and upregulation of miR-22, compared with benign nevi (p < 0.05).
tissue_expression_down	hsa-mir-125b-1	Melanoma	21460750	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	the expression of miRNA-125b (miR-125b) was two-fold lower in malignant melanoma producing lymph node micrometastases than in nonmetastasizing tumors. MicroRNA miR-125b induces senescence in human melanoma cells.We propose that downregulation of miR-125b in an early cutaneous malignant melanoma can contribute to the increased metastatic capability of this tumor.
tissue_expression_down	hsa-mir-125b-2	Melanoma	21460750	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	the expression of miRNA-125b (miR-125b) was two-fold lower in malignant melanoma producing lymph node micrometastases than in nonmetastasizing tumors. MicroRNA miR-125b induces senescence in human melanoma cells.We propose that downregulation of miR-125b in an early cutaneous malignant melanoma can contribute to the increased metastatic capability of this tumor.
tissue_expression_down	hsa-mir-1308	Melanoma	22898827	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes.
tissue_expression_down	hsa-mir-134	Melanoma	26485753	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Altogether, our results suggest that HIFU down-regulates miR-134 to release the inhibition of miR-134 on CD86 in melanoma cells, thereby enhancing anti-tumor immune response.
tissue_expression_down	hsa-mir-137	Melanoma	24001901	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-34a, miR-137 and miR-182 all had lower expression levels in uveal melanoma cell lines, compared with normal cells
tissue_expression_down	hsa-mir-138-1	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-138-2	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-145	Melanoma	21509659	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	significantly down-regulated in uveal melanomas compared with normal uveal tissues
tissue_expression_down	hsa-mir-145	Melanoma	21836381	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-145 was significantly down-regulated in canine malignant melanoma tissues. The ectopic expression of miR-145 showed a significant growth inhibition in both canine and human melanoma cells tested, and the effect was achieved partly by suppressing c-MYC in canine melanoma LMeC, and human melanoma A2058 and Mewo cells.
tissue_expression_down	hsa-mir-146a	Melanoma	27149382	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Among the miRNAs that were commonly and significantly down-regulated in each of these women were miR-193b (P<0.003), miR-342-3p (P<0.003), miR186 (P<0.007), miR-130a (P<0.007), and miR-146a (P<0.007).
tissue_expression_down	hsa-mir-146b	Melanoma	19578755	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	down-regulated
tissue_expression_down	hsa-mir-155	Melanoma	19578755	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	down-regulated
tissue_expression_down	hsa-mir-155	Melanoma	21763111	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization.
tissue_expression_down	hsa-mir-15a	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-16-1	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-16-2	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-181a-1	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-181a-2	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-182	Melanoma	24001901	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-34a, miR-137 and miR-182 all had lower expression levels in uveal melanoma cell lines, compared with normal cells
tissue_expression_down	hsa-mir-191	Melanoma	20357817	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Furthermore, low expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survive
tissue_expression_down	hsa-mir-191	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-191	Melanoma	26156293	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In particular, miR-101, miR-221,miR-21, miR-338-3p and miR-191 resulted in significant downregulation inBRAF-mutated patients.
tissue_expression_down	hsa-mir-193a	Melanoma	20357817	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In melanomas, miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation.
tissue_expression_down	hsa-mir-193b	Melanoma	27149382	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Among the miRNAs that were commonly and significantly down-regulated in each of these women were miR-193b (P<0.003), miR-342-3p (P<0.003), miR186 (P<0.007), miR-130a (P<0.007), and miR-146a (P<0.007).
tissue_expression_down	hsa-mir-195	Melanoma	22847610	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-195-mediated downregulation of WEE1 in metastatic lesions may help to overcome cell cycle arrest under stress conditions in the local tissue microenvironment to allow unrestricted growth of tumour cells.
tissue_expression_down	hsa-mir-200c	Melanoma	20442294	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miRNA-200c:miRNA-200c to be consistently downregulated in melanocytes, melanoma cell lines, and patient samples, whereas miRNA-205 and miRNA-23b were markedly reduced only in patient samples
tissue_expression_down	hsa-mir-200c	Melanoma	22223089	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.
tissue_expression_down	hsa-mir-203	Melanoma	22235882	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A decreased expression of miR-203 was significantly associated with a shorter survival time. Also, miR-203 and -205 were markedly down-regulated in canine and human MM cell lines tested.
tissue_expression_down	hsa-mir-204	Melanoma	21509659	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	significantly down-regulated in uveal melanomas compared with normal uveal tissues
tissue_expression_down	hsa-mir-205	Melanoma	20442294	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miRNA-205:miRNA-200c to be consistently downregulated in melanocytes, melanoma cell lines, and patient samples, whereas miRNA-205 and miRNA-23b were markedly reduced only in patient samples
tissue_expression_down	hsa-mir-205	Melanoma	22223089	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.
tissue_expression_down	hsa-mir-205	Melanoma	22235882	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A decreased expression of miR-203 was significantly associated with a shorter survival time. Also, miR-203 and -205 were markedly down-regulated in canine and human MM cell lines tested.
tissue_expression_down	hsa-mir-205	Melanoma	23629002	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	microRNA (miR)-205 is downregulated and acts as a tumor suppressor in human melanoma cells.
tissue_expression_down	hsa-mir-206	Melanoma	21763111	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization.
tissue_expression_down	hsa-mir-211	Melanoma	21687938	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells.
tissue_expression_down	hsa-mir-211	Melanoma	22223089	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.
tissue_expression_down	hsa-mir-23b	Melanoma	20442294	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miRNA-23b:miRNA-200c to be consistently downregulated in melanocytes, melanoma cell lines, and patient samples, whereas miRNA-205 and miRNA-23b were markedly reduced only in patient samples
tissue_expression_down	hsa-mir-24-1	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_down	hsa-mir-26a	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_down	hsa-mir-26a-1	Melanoma	23190898	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains
tissue_expression_down	hsa-mir-26a-2	Melanoma	23190898	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains
tissue_expression_down	hsa-mir-338	Melanoma	20357817	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In melanomas, miR-193a, miR-338, and miR-565 were underexpressed in cases with a BRAF mutation.
tissue_expression_down	hsa-mir-34a	Melanoma	19830692	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-34a:MiR-15b and miR-210 were significantly upregulated, miR-34a was significantly downregulated in melanomas
tissue_expression_down	hsa-mir-34a	Melanoma	20606648	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-34a delivered by the GC4-targeted nanoparticles significantly downregulated the survivin expression in the metastatic tumor and reduced tumor load in the lung.
tissue_expression_down	hsa-mir-4291	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_down	hsa-mir-4317	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_down	hsa-mir-4324	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_down	hsa-mir-720	Melanoma	22898827	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes.
tissue_expression_down	hsa-mir-933	Melanoma	22551973	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The downregulation of this miRNA was associated with selective genomic loss in SSM cell lines and primary tumors.
tissue_expression_down	hsa-mir-145	Meningioma	23108408	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells
tissue_expression_down	hsa-mir-219	Meningioma	22674195	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Downregulation of miR-29c-3p and miR-219-5p were found to be associated with advanced clinical stages of meningioma. Kaplan-Meier analysis showed that high expression of miR-190a and low expression of miR-29c-3p and miR-219-5p correlated significantly with higher recurrence rates in meningioma patients.
tissue_expression_down	hsa-mir-29c	Meningioma	22674195	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Downregulation of miR-29c-3p and miR-219-5p were found to be associated with advanced clinical stages of meningioma. Kaplan-Meier analysis showed that high expression of miR-190a and low expression of miR-29c-3p and miR-219-5p correlated significantly with higher recurrence rates in meningioma patients.
tissue_expression_down	hsa-mir-30c-1	Mesothelioma	21317924	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines
tissue_expression_down	hsa-mir-30c-2	Mesothelioma	21317924	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines
tissue_expression_down	hsa-mir-144	Mitochondrial Metabolism Disease	27329039	disease of metabolism	DOID:700	E88.40	D028361			down-regulation of miR-144-3p expression
tissue_expression_down	hsa-mir-194	Multiple Myeloma	25092124	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	We determined that the relative expression levels of miR-15a/16, miR-34a, miR-194 in MM patients were significantly lower than those in the healthy controls
tissue_expression_down	hsa-mir-194	Multiple Myeloma	25778888	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The expression of miR-15a/16,miR-34a,miR-194-2-192 cluster in MM patients were significantly lower than those of the health controls, while miR-181a/b were exactly the reverse (P<0.05).
tissue_expression_down	hsa-mir-15a	Multiple Sclerosis	22463747	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-15a and 16-1 are downregulated in CD4(+) T cells of multiple sclerosis relapsing patients.
tissue_expression_down	hsa-mir-16-1	Multiple Sclerosis	22463747	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-15a and 16-1 are downregulated in CD4(+) T cells of multiple sclerosis relapsing patients.
tissue_expression_down	hsa-mir-17	Multiple Sclerosis	20711463	nervous system disease	DOID:2377	G35	D009103	PS126200		In all MS subtypes miR-17 and miR-20a were significantly under-expressed in MS, confirmed by RT-PCR. 
tissue_expression_down	hsa-mir-20a	Multiple Sclerosis	20711463	nervous system disease	DOID:2377	G35	D009103	PS126200		In all MS subtypes miR-17 and miR-20a were significantly under-expressed in MS, confirmed by RT-PCR. 
tissue_expression_down	hsa-mir-223	Muscular Dystrophy	26398013			G71.0	D009136	310200	HP:0003560	higher levels of cytokines appear to inhibit myogenic miRNAs in muscle and artificially reducing levels of miR-223 increases protein kinase C-epsilon (PKC蔚) levels in keratinocytes.
tissue_expression_down	hsa-mir-25	Muscular Dystrophy, Facioscapulohumeral	24145033	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		eight were down-regulated (miR-15b, miR-20b, miR-21, miR-25, miR-100, miR-155, miR-345, and miR-594)
tissue_expression_down	hsa-mir-1-1	Musculoskeletal Abnormalities [unspecific]	17917533				D009139			Studies performed to determine whether skeletal muscle hypertrophy affects miRNA expression showed that miR-1 and miR-133 were decreased, suggesting that these muscle-specific miRNAs may contribute to regulating the initial response of skeletal muscle to functional overload.
tissue_expression_down	hsa-mir-1-2	Musculoskeletal Abnormalities [unspecific]	17917533				D009139			Studies performed to determine whether skeletal muscle hypertrophy affects miRNA expression showed that miR-1 and miR-133 were decreased, suggesting that these muscle-specific miRNAs may contribute to regulating the initial response of skeletal muscle to functional overload.
tissue_expression_down	hsa-mir-133a-1	Musculoskeletal Abnormalities [unspecific]	17917533				D009139			Studies performed to determine whether skeletal muscle hypertrophy affects miRNA expression showed that miR-1 and miR-133 were decreased, suggesting that these muscle-specific miRNAs may contribute to regulating the initial response of skeletal muscle to functional overload.
tissue_expression_down	hsa-mir-133a-2	Musculoskeletal Abnormalities [unspecific]	17917533				D009139			Studies performed to determine whether skeletal muscle hypertrophy affects miRNA expression showed that miR-1 and miR-133 were decreased, suggesting that these muscle-specific miRNAs may contribute to regulating the initial response of skeletal muscle to functional overload.
tissue_expression_down	hsa-mir-206	Musculoskeletal Abnormalities [unspecific]	17917533				D009139			Studies to evaluate the role of miRNAs in muscular dystrophy showed a dramatic increase in miR-206 expression in the diaphragm of the mdx mouse.
tissue_expression_down	hsa-let-7a-1	Mycosis Fungoides	21966986			C84.00	D009182			MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin.
tissue_expression_down	hsa-let-7a-2	Mycosis Fungoides	21966986			C84.00	D009182			MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin.
tissue_expression_down	hsa-let-7a-3	Mycosis Fungoides	21966986			C84.00	D009182			MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin.
tissue_expression_down	hsa-let-7d	Mycosis Fungoides	21966986			C84.00	D009182			MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin.
tissue_expression_down	hsa-let-7f-1	Mycosis Fungoides	21966986			C84.00	D009182			MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin.
tissue_expression_down	hsa-let-7f-2	Mycosis Fungoides	21966986			C84.00	D009182			MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin.
tissue_expression_down	hsa-mir-145	Myelodysplastic Syndromes	24627193	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Other pathogenetic elements include protein phosphatase 2a and CDC25C haplodeficiency and decreased miR-145 and miR-146a expression.
tissue_expression_down	hsa-mir-146a	Myelodysplastic Syndromes	21211043	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-378 and miR-146a showed reduced gene expression in the patients.
tissue_expression_down	hsa-mir-146a	Myelodysplastic Syndromes	24627193	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Other pathogenetic elements include protein phosphatase 2a and CDC25C haplodeficiency and decreased miR-145 and miR-146a expression.
tissue_expression_down	hsa-mir-155	Myelodysplastic Syndromes	22371183	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Real-time PCR approach confirmed that mir-155, miR-181a and miR-222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients.
tissue_expression_down	hsa-mir-181a-1	Myelodysplastic Syndromes	22371183	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Real-time PCR approach confirmed that mir-155, miR-181a and miR-222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients.
tissue_expression_down	hsa-mir-181a-2	Myelodysplastic Syndromes	22371183	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Real-time PCR approach confirmed that mir-155, miR-181a and miR-222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients.
tissue_expression_down	hsa-mir-222	Myelodysplastic Syndromes	22371183	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Real-time PCR approach confirmed that mir-155, miR-181a and miR-222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients.
tissue_expression_down	hsa-mir-29b	Myelodysplastic Syndromes	27020498	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	MiR-29b expression was down-regulated in refractory anaemia and OL bone marrow as compared to that in control bone marrow.
tissue_expression_down	hsa-mir-378a	Myelodysplastic Syndromes	21211043	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-378 and miR-146a showed reduced gene expression in the patients.
tissue_expression_down	hsa-mir-21	Myeloma	25000828			C90.0	D009101	254500		Our results suggest that berberine suppresses multiple myeloma cell growth, at least in part, by down-regulating miR-21 levels possibly through IL6/STAT3. This led to increased PDCD4 expression, which is likely to result in suppression of the p53 signaling pathway. These findings may also provide new mechanistic insight into the anti-cancer effects of certain compounds in traditional Chinese herbal medicines.
tissue_expression_down	hsa-mir-1	Myocardial Infarction	26253453	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Compared with the CON group, miR-1 was downregulated, whereas miR-21 was upregulated, and BCL2 messenger RNA (mRNA) was upregulated, whereas BAX mRNA and  programmed cell death 4 mRNA remained unchanged in the IPO group.
tissue_expression_down	hsa-mir-1	Myocardial Infarction	26646371	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MicroRNA-1 and -214 expressions were, respectively, decreased (52 %) and increased (54 %) in the S-INF compared to the S-SHAM, while exercise training normalized the expression of these microRNAs.
tissue_expression_down	hsa-mir-1	Myocardial Infarction	29162889	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly
tissue_expression_down	hsa-mir-126	Myocardial Infarction	20187981	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we found that AMI is associated with altered miRNA expression level and the differentially expressed miRNAs may be novel biomarkers of AMI
tissue_expression_down	hsa-mir-126	Myocardial Infarction	25064220	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-126 expression in ischemia-reperfusion group was significantly lower than in sham operation group
tissue_expression_down	hsa-mir-126	Myocardial Infarction	29642385	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant
tissue_expression_down	hsa-mir-133b	Myocardial Infarction	20029200	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	downregulated
tissue_expression_down	hsa-mir-150	Myocardial Infarction	22048267	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Comparing MI patients with VR and those without VR, we found miR-146a up-regulation, and miR-150 and miR-155 down-regulation in patients with VR. In conclusion, our study demonstrated an altered expression of miR-146a, miR-150, and miR-155 in MI compared to the normal hearts.
tissue_expression_down	hsa-mir-150	Myocardial Infarction	23326587	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Adenosine increases the migration of EPC. The mechanism involves A(2B) receptor activation, decreased expression of miR-150 and increased expression of CXCR4.
tissue_expression_down	hsa-mir-150	Myocardial Infarction	27184887	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-150 is downregulated in cardiovascular diseases, such as acute myocardial infarction
tissue_expression_down	hsa-mir-155	Myocardial Infarction	22048267	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Comparing MI patients with VR and those without VR, we found miR-146a up-regulation, and miR-150 and miR-155 down-regulation in patients with VR. In conclusion, our study demonstrated an altered expression of miR-146a, miR-150, and miR-155 in MI compared to the normal hearts.
tissue_expression_down	hsa-mir-223	Myocardial Infarction	29162889	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly
tissue_expression_down	hsa-mir-31	Myocardial Infarction	20187981	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we found that AMI is associated with altered miRNA expression level and the differentially expressed miRNAs may be novel biomarkers of AMI
tissue_expression_down	hsa-mir-499a	Myocardial Infarction	20187981	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-499-5p; we found that AMI is associated with altered miRNA expression level and the differentially expressed miRNAs may be novel biomarkers of AMI
tissue_expression_down	hsa-mir-92a	Myocardial Infarction	29162889	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly
tissue_expression_down	hsa-mir-99a	Myocardial Infarction	29162889	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly
tissue_expression_down	hsa-mir-1	Myositis	24757153	musculoskeletal system disease	DOID:633	G72.49	D009220	160750	HP:0100614	We observed decreased expression of microRNA-1 (miR-1), miR-133a, and miR-133b in all of the inflammatory myopathy subtypes we evaluated, as well as decreased expression of miR-206 in DM;
tissue_expression_down	hsa-mir-125b-1	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-125b-5p: decreased levels compared to controls
tissue_expression_down	hsa-mir-193a	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-193a-3p: decreased levels compared to controls
tissue_expression_down	hsa-mir-193b	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-193b-3p: decreased levels compared to controls
tissue_expression_down	hsa-mir-29b-1	Myotonic Muscular Dystrophy	21169019			G71.11	D009223	160900		We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls.
tissue_expression_down	hsa-mir-29b-2	Myotonic Muscular Dystrophy	21169019			G71.11	D009223	160900		We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls.
tissue_expression_down	hsa-mir-29c	Myotonic Muscular Dystrophy	21169019			G71.11	D009223	160900		We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls.
tissue_expression_down	hsa-mir-33a	Myotonic Muscular Dystrophy	21169019			G71.11	D009223	160900		We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls.
tissue_expression_down	hsa-mir-33b	Myotonic Muscular Dystrophy	21169019			G71.11	D009223	160900		We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls.
tissue_expression_down	hsa-mir-378a	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-378a-3p: decreased levels compared to controls
tissue_expression_down	hsa-let-7a-1	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7a-2	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7a-3	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7b	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7c	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7d	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7e	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7f-1	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7f-2	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7g	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7i	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-mir-34b	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-mir-34c	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	underexpressed
tissue_expression_down	hsa-let-7a-1	Neoplasms [unspecific]	17028596			C80.1	D009369			let-7a-1 downregulated in six solid cancer types by PAM and SAM (Volinia et al., 2006);
tissue_expression_down	hsa-let-7a-2	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7a-3	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7b	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7c	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7d	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7e	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7f-1	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7f-2	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7g	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-let-7i	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-mir-103a-1	Neoplasms [unspecific]	20439436			C80.1	D009369			miR-103:hsa-miR-103/106 were downgraded in cancer, whereas hsa-miR-30 became most prominent
tissue_expression_down	hsa-mir-103a-2	Neoplasms [unspecific]	20439436			C80.1	D009369			miR-103:hsa-miR-103/106 were downgraded in cancer, whereas hsa-miR-30 became most prominent
tissue_expression_down	hsa-mir-106a	Neoplasms [unspecific]	20439436			C80.1	D009369			miR-106:hsa-miR-103/106 were downgraded in cancer, whereas hsa-miR-30 became most prominent
tissue_expression_down	hsa-mir-10a	Neoplasms [unspecific]	20145181			C80.1	D009369			downregulation
tissue_expression_down	hsa-mir-10b	Neoplasms [unspecific]	20145181			C80.1	D009369			downregulation
tissue_expression_down	hsa-mir-125b	Neoplasms [unspecific]	24774301			C80.1	D009369			Thus, in different tumor entities increased or decreased miR-125b expression may contribute to carcinogenesis.
tissue_expression_down	hsa-mir-125b-1	Neoplasms [unspecific]	20145181			C80.1	D009369			underexpression
tissue_expression_down	hsa-mir-125b-2	Neoplasms [unspecific]	20145181			C80.1	D009369			underexpression
tissue_expression_down	hsa-mir-138	Neoplasms [unspecific]	24057215			C80.1	D009369			MiR-138 downregulates miRNA processing in HeLa cells by targeting RMND5A and decreasing Exportin-5 stability.
tissue_expression_down	hsa-mir-143	Neoplasms [unspecific]	19175697			C80.1	D009369			The expression of a subset of miRs (e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g.miR-143 and miR-145) was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes whose deregulation may lead to tumourigenesis.
tissue_expression_down	hsa-mir-145	Neoplasms [unspecific]	19676045			C80.1	D009369			down-regulated
tissue_expression_down	hsa-mir-145	Neoplasms [unspecific]	20370992			C80.1	D009369			under-expressed
tissue_expression_down	hsa-mir-145	Neoplasms [unspecific]	19175697			C80.1	D009369			The expression of a subset of miRs (e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g.miR-143 and miR-145) was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes whose deregulation may lead to tumourigenesis.
tissue_expression_down	hsa-mir-149	Neoplasms [unspecific]	19676045			C80.1	D009369			down-regulated
tissue_expression_down	hsa-mir-153-1	Neoplasms [unspecific]	23188671			C80.1	D009369			Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer
tissue_expression_down	hsa-mir-153-2	Neoplasms [unspecific]	23188671			C80.1	D009369			Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer
tissue_expression_down	hsa-mir-155	Neoplasms [unspecific]	20370992			C80.1	D009369			under-expressed
tissue_expression_down	hsa-mir-182	Neoplasms [unspecific]	19676045			C80.1	D009369			down-regulated
tissue_expression_down	hsa-mir-184	Neoplasms [unspecific]	19676045			C80.1	D009369			down-regulated
tissue_expression_down	hsa-mir-192	Neoplasms [unspecific]	19074876			C80.1	D009369			Our results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors.
tissue_expression_down	hsa-mir-199a-1	Neoplasms [unspecific]	23060436			C80.1	D009369			The microRNA miR-199a-5p down-regulation switches on wound angiogenesis by derepressing the v-ets erythroblastosis virus E26 oncogene homolog 1-matrix metalloproteinase-1 pathway
tissue_expression_down	hsa-mir-199a-2	Neoplasms [unspecific]	23060436			C80.1	D009369			The microRNA miR-199a-5p down-regulation switches on wound angiogenesis by derepressing the v-ets erythroblastosis virus E26 oncogene homolog 1-matrix metalloproteinase-1 pathway
tissue_expression_down	hsa-mir-200	Neoplasms [unspecific]	24282096			C80.1	D009369			The EMT-suppressive miR-203 and miR-200 family were consistently but non-significantly downregulated in CUP with the EMT phenotype. A larger study is warranted to further explore the role of microRNAs in CUP.
tissue_expression_down	hsa-mir-200a	Neoplasms [unspecific]	20484038			C80.1	D009369			miR-200a:Downregulation of microRNA-200 in EBV-associated gastric carcinoma
tissue_expression_down	hsa-mir-200a	Neoplasms [unspecific]	26198058			C80.1	D009369			miR-23b, miR-199a, and miR-15a displayed increased expression during early AVC development whereas others such as miR-130a and miR-200a display decreased expression levels
tissue_expression_down	hsa-mir-200b	Neoplasms [unspecific]	20484038			C80.1	D009369			miR-200b:Downregulation of microRNA-200 in EBV-associated gastric carcinoma
tissue_expression_down	hsa-mir-200c	Neoplasms [unspecific]	20484038			C80.1	D009369			miR-200c:Downregulation of microRNA-200 in EBV-associated gastric carcinoma
tissue_expression_down	hsa-mir-203	Neoplasms [unspecific]	24282096			C80.1	D009369			The EMT-suppressive miR-203 and miR-200 family were consistently but non-significantly downregulated in CUP with the EMT phenotype. A larger study is warranted to further explore the role of microRNAs in CUP.
tissue_expression_down	hsa-mir-205	Neoplasms [unspecific]	19676045			C80.1	D009369			down-regulated
tissue_expression_down	hsa-mir-215	Neoplasms [unspecific]	19074876			C80.1	D009369			Our results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors.
tissue_expression_down	hsa-mir-221	Neoplasms [unspecific]	19676045			C80.1	D009369			down-regulated
tissue_expression_down	hsa-mir-222	Neoplasms [unspecific]	19676045			C80.1	D009369			down-regulated
tissue_expression_down	hsa-mir-30c-1	Neoplasms [unspecific]	23318178			C80.1	D009369			Sulfuretin-induced miR-30C selectively downregulates cyclin D1 and D2 and triggers cell death in human cancer cell lines
tissue_expression_down	hsa-mir-30c-2	Neoplasms [unspecific]	23318178			C80.1	D009369			Sulfuretin-induced miR-30C selectively downregulates cyclin D1 and D2 and triggers cell death in human cancer cell lines
tissue_expression_down	hsa-mir-30d	Neoplasms [unspecific]	17028596			C80.1	D009369			mir-30d downregulated in six solid cancer types by SAM (Volinia et al., 2006);
tissue_expression_down	hsa-mir-31	Neoplasms [unspecific]	19676045			C80.1	D009369			down-regulated
tissue_expression_down	hsa-mir-375	Neoplasms [unspecific]	20145181			C80.1	D009369			underexpression
tissue_expression_down	hsa-mir-375	Neoplasms [unspecific]	20215506			C80.1	D009369			MicroRNA-375 is downregulated in gastric carcinomas
tissue_expression_down	hsa-mir-452	Neoplasms [unspecific]	25040964			C80.1	D009369			Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells.
tissue_expression_down	hsa-mir-92a-1	Neoplasms [unspecific]	17028596			C80.1	D009369			mir-92 downregulated in six solid cancer types by PAM (Volinia et al., 2006)
tissue_expression_down	hsa-mir-92a-2	Neoplasms [unspecific]	17028596			C80.1	D009369			mir-92 downregulated in six solid cancer types by PAM (Volinia et al., 2006)
tissue_expression_down	hsa-mir-92b	Neoplasms [unspecific]	17028596			C80.1	D009369			mir-92 downregulated in six solid cancer types by PAM (Volinia et al., 2006)
tissue_expression_down	hsa-mir-98	Neoplasms [unspecific]	17028596			C80.1	D009369			Let-7/mir-98 expression is reduced in tumours, potentially contributing to elevated activity of the Ras pathway and effects on growth control.
tissue_expression_down	hsa-mir-99a	Neoplasms [unspecific]	21383697			C80.1	D009369			miR-99a-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
tissue_expression_down	hsa-mir-15a	Nephrotic Syndrome	28299339	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	low expression levels of miR-15a and miR-16-1 were found compared with  healthy controls, but only the miR-16-1 expression levels showed statistically significant decrease
tissue_expression_down	hsa-mir-16	Nephrotic Syndrome	28299339	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	low expression levels of miR-15a and miR-16-1 were found compared with  healthy controls, but only the miR-16-1 expression levels showed statistically significant decrease
tissue_expression_down	hsa-mir-7	Nervous System Diseases [unspecific]	26647301			C72.9	D009422			We showed, for the first time in LUHMES, down-regulation of mir-7, a miRNA known to target alpha-synuclein and to be involved in PD.
tissue_expression_down	hsa-mir-106b	Neuroblastoma	22498172	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)
tissue_expression_down	hsa-mir-146b	Neuroblastoma	22244746	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	under-expressed in mature neuron.
tissue_expression_down	hsa-mir-152	Neuroblastoma	22244746	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	under-expressed in mature neuron.
tissue_expression_down	hsa-mir-204	Neuroblastoma	26145533	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-204 mediates post-transcriptional down-regulation of PHOX2B gene expression in neuroblastoma cells.
tissue_expression_down	hsa-mir-29a	Neuroblastoma	24898736	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis.
tissue_expression_down	hsa-mir-339	Neuroblastoma	22244746	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	miR-339-5p: under-expressed in mature neuron.
tissue_expression_down	hsa-mir-370	Neuroblastoma	22244746	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	under-expressed in neuroblastoma.
tissue_expression_down	hsa-mir-410	Neuroblastoma	21970883	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Two, miR-487b and miR-410, were significantly downregulated in the high-risk group. Multivariable analyses showed miR-487b expression as associated with overall survival and disease-free survival in the whole cohort, independently of clinical covariates. Moreover, miR-487b and miR-410 expression was significantly associated with disease-free survival of the non-MYCN-amplified favourable neuroblastoma: localised (stage 1, 2 and 3) and stage 4 of infant <18 months.Conclusion:Expression of miR-487b and miR-410 shows predictive value beyond the classical high-/low-risk stratification and is a biomarker of relapse in favourable neuroblastoma.
tissue_expression_down	hsa-mir-487b	Neuroblastoma	21970883	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Two, miR-487b and miR-410, were significantly downregulated in the high-risk group. Multivariable analyses showed miR-487b expression as associated with overall survival and disease-free survival in the whole cohort, independently of clinical covariates. Moreover, miR-487b and miR-410 expression was significantly associated with disease-free survival of the non-MYCN-amplified favourable neuroblastoma: localised (stage 1, 2 and 3) and stage 4 of infant <18 months.Conclusion:Expression of miR-487b and miR-410 shows predictive value beyond the classical high-/low-risk stratification and is a biomarker of relapse in favourable neuroblastoma.
tissue_expression_down	hsa-mir-9-1	Neuroblastoma	22244746	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	under-expressed in neuroblastoma.
tissue_expression_down	hsa-mir-9-2	Neuroblastoma	22244746	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	under-expressed in neuroblastoma.
tissue_expression_down	hsa-mir-92a-1	Neuroblastoma	22498172	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)
tissue_expression_down	hsa-mir-92a-2	Neuroblastoma	22498172	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)
tissue_expression_down	hsa-mir-92b	Neuroblastoma	22498172	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)
tissue_expression_down	hsa-mir-93	Neuroblastoma	22498172	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)
tissue_expression_down	hsa-mir-9-3	Neuroblastoma	22244746	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	under-expressed in neuroblastoma.
tissue_expression_down	hsa-mir-19	Neurodegenerative Diseases [unspecific]	26836165				D019636		HP:0002180	along with downregulation of miR-19a/miR-19b,
tissue_expression_down	hsa-mir-21	Neuroma	20856158	disease of cellular proliferation	DOID:2001		D009463			miR-21:Elevated levels of hsa-microRNA-21 (miR-21) in vestibular schwannomas (VSs) may contribute to tumor growth by downregulating the tumor suppressor phosphatase and tensin homolog (PTEN) and consequent hyperactivation of protein kinase B
tissue_expression_down	hsa-mir-145	NUT Midline Carcinoma	29322795	disease of cellular proliferation	DOID:0060463					All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484
tissue_expression_down	hsa-mir-99a	NUT Midline Carcinoma	29322795	disease of cellular proliferation	DOID:0060463					All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484
tissue_expression_down	hsa-mir-146a	Obesity	28652200	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Down-regulation of miRNAs in the brain and development of diet-induced obesity
tissue_expression_down	hsa-mir-155	Obesity	28652200	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Down-regulation of miRNAs in the brain and development of diet-induced obesity.
tissue_expression_down	hsa-mir-26b	Obesity	25999046	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Decreased miR-26b expression in VAT may be involved in obesity-related IR by interrupting the PTEN/PI3K/AKT pathway.
tissue_expression_down	hsa-mir-125b	Oral Lichen Planus	27133077			L43.9	D017676		HP:0031453	MMP-2 expression was up-regulated and miR-125b expression was down-regulated in both OLP mucosa tissues and LPS-incubated HaCaT cells.
tissue_expression_down	hsa-mir-132	Osteoarthritis	20470394	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid miRNAs.
tissue_expression_down	hsa-mir-140	Osteoarthritis	19714579	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	down-regulated IL-1beta-induced ADAMTS5
tissue_expression_down	hsa-mir-146a	Osteoarthritis	20470394	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid miRNAs.
tissue_expression_down	hsa-mir-146a	Osteoarthritis	23744481	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	The downregulation of miR-146a and/or the miR-183 cluster in the central compartments (DRG and spinal cord) are closely associated with the upregulation of inflammatory pain mediators.
tissue_expression_down	hsa-mir-146a	Osteoarthritis	25598697	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	This miR is considered a biological marker for cartilage and its level significantly decreases in OA cartilage.
tissue_expression_down	hsa-mir-15a	Osteoarthritis	26707794	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	hsa鈥憁iR鈥?5a expression was downregulated
tissue_expression_down	hsa-mir-16	Osteoarthritis	20470394	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid miRNAs.
tissue_expression_down	hsa-mir-183	Osteoarthritis	23744481	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	The downregulation of miR-146a and/or the miR-183 cluster in the central compartments (DRG and spinal cord) are closely associated with the upregulation of inflammatory pain mediators.
tissue_expression_down	hsa-mir-223	Osteoarthritis	20470394	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	In RA and OA, synovial fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower than their plasma concentrations, and there were no correlation between plasma and synovial fluid miRNAs.
tissue_expression_down	hsa-mir-26a	Osteoarthritis	28000846	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Reduced miR‑26a and miR‑26b expression contributes to the pathogenesis of osteoarthritis via the promotion of p65 translocation.
tissue_expression_down	hsa-mir-26b	Osteoarthritis	28000846	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Reduced miR‑26a and miR‑26b expression contributes to the pathogenesis of osteoarthritis via the promotion of p65 translocation.
tissue_expression_down	hsa-mir-27b	Osteoarthritis	26505891	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-146a significantly up-regulated and  miR-27b significantly down-regulated at all time points
tissue_expression_down	hsa-mir-675	Osteoarthritis	22527881	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Proinflammatory cytokines IL-1beta and TNF-alpha downregulated COL2A1, H19, and miR-675 significantly without close statistical correlation.
tissue_expression_down	hsa-mir-29b	Osteogenesis Imperfecta	24767406	musculoskeletal system disease	DOID:12347	Q78.0	D010013	PS166200		COL1A1 and miR-29b show lower expression levels during osteoblast differentiation of bone marrow stromal cells from Osteogenesis Imperfecta patients.
tissue_expression_down	hsa-mir-27a	Osteoporosis	27337099	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-27a expression was significantly reduced in osteoporotic patients
tissue_expression_down	hsa-mir-132	Osteosarcoma	26352673	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, miR-132 inhibited cell growth and metastasis in osteosarcoma cells by downregulation of Sox4, and knockdown of Sox4 was essential for the miR-132-inhibited cell growth and metastasis in osteosarcoma cells.
tissue_expression_down	hsa-mir-133b	Osteosarcoma	24391788	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis.
tissue_expression_down	hsa-mir-142	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	reduced expression
tissue_expression_down	hsa-mir-142	Osteosarcoma	25034529	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN.
tissue_expression_down	hsa-mir-144	Osteosarcoma	25318625	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The downregulation of miR-144 is associated with the growth and invasion of osteosarcoma cells through the regulation of TAGLN expression.
tissue_expression_down	hsa-mir-16-1	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	reduced expression
tissue_expression_down	hsa-mir-16-2	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	reduced expression
tissue_expression_down	hsa-mir-199a-1	Osteosarcoma	21666078	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration.
tissue_expression_down	hsa-mir-199a-2	Osteosarcoma	21666078	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration.
tissue_expression_down	hsa-mir-210	Osteosarcoma	26044868	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Downregulation of microRNA-210 inhibits osteosarcoma growth in vitro and in vivo.
tissue_expression_down	hsa-mir-22	Osteosarcoma	25953260	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Downregulation of miR-22 acts as an unfavorable prognostic biomarker in osteosarcoma.
tissue_expression_down	hsa-mir-223	Osteosarcoma	23601845	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	we found that miRNA-223 was downregulated in both osteosarcoma patients' tumor tissues and osteosarcoma cell lines.
tissue_expression_down	hsa-mir-23a	Osteosarcoma	25619478	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-23a functions as a tumor suppressor in osteosarcoma, and its inhibitory effect on tumor are mediated chiefly through downregulation of SATB1.
tissue_expression_down	hsa-mir-26a	Osteosarcoma	24452597	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients.
tissue_expression_down	hsa-mir-26b	Osteosarcoma	25672572	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells.
tissue_expression_down	hsa-mir-29b-1	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	reduced expression
tissue_expression_down	hsa-mir-29b-2	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	reduced expression
tissue_expression_down	hsa-mir-34a	Osteosarcoma	28260055	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-34a is downregulated in human osteosarcoma stem-like cells and promotes invasion, tumorigenic ability and self-renewal capacity.
tissue_expression_down	hsa-mir-370	Osteosarcoma	26617733	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, miR-370 inhibited cell growth and metastasis in osteosarcoma cells by down-regulation of FOXM1.
tissue_expression_down	hsa-mir-449a	Osteosarcoma	26002578	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miRNA-449a is downregulated in osteosarcoma and promotes cell apoptosis by targeting BCL2.
tissue_expression_down	hsa-mir-490	Osteosarcoma	28165565	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Decreased expression of miR-490-3p in osteosarcoma and its clinical significance.
tissue_expression_down	hsa-mir-519d	Osteosarcoma	25003330	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d.
tissue_expression_down	hsa-mir-586	Osteosarcoma	26580004	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Downregulation of microRNA-586 Inhibits Proliferation, Invasion and Metastasis and Promotes Apoptosis in Human Osteosarcoma U2-OS Cell Line.
tissue_expression_down	hsa-mir-199a	Ovarian Germ Cell Cancer	29138809	endocrine system disease	DOID:2156			603737		Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs
tissue_expression_down	hsa-mir-202	Ovarian Germ Cell Cancer	29138809	endocrine system disease	DOID:2156			603737		Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs
tissue_expression_down	hsa-mir-214	Ovarian Germ Cell Cancer	29138809	endocrine system disease	DOID:2156			603737		Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs
tissue_expression_down	hsa-let-7a-1	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7a:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7a-2	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7a:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7a-3	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7a:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7b	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	lower
tissue_expression_down	hsa-let-7b	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7b:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7c	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7c:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7c	Ovarian Neoplasms	21939554	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The miRNA was downregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines.
tissue_expression_down	hsa-let-7d	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7d:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7e	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7e:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7f-1	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7f:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7f-2	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7f:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7g	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7g:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7i	Ovarian Neoplasms	20035894	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-let-7i:The most frequently deregulated miRNAs are members of the let-7 and miR-200 families
tissue_expression_down	hsa-let-7i	Ovarian Neoplasms	24479883	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Members of the miR-200 family, miR-182, miR-214 and miR-221 are frequently up-regulated, whereas miR-100, let-7i, miR-199a, miR-125b, mir-145 and miR-335 are often down-regulated in ovarian cancer compared with normal ovarian tissue.
tissue_expression_down	hsa-mir-100	Ovarian Neoplasms	22246341	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The level of miR-100 was significantly lower in EOC (epithelial ovarian cancer)  tissues compared to adjacent normal tissues. Low miR-100 expression was found to be closely correlated with advanced FIGO stage, higher serum CA125 expression level and lymph node involvement.
tissue_expression_down	hsa-mir-1202	Ovarian Neoplasms	22643117	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181.
tissue_expression_down	hsa-mir-125b	Ovarian Neoplasms	29307001	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-26a, miR-125b-5p, miR-17-5p and miR-221 downregulation could be related to poor EOC prognosis
tissue_expression_down	hsa-mir-125b-1	Ovarian Neoplasms	17875710	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs.
tissue_expression_down	hsa-mir-127	Ovarian Neoplasms	18954897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-127: under-expression
tissue_expression_down	hsa-mir-1281	Ovarian Neoplasms	22643117	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181.
tissue_expression_down	hsa-mir-133b	Ovarian Neoplasms	19946373	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	downregulated
tissue_expression_down	hsa-mir-140	Ovarian Neoplasms	22452920	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The expression level of RAD51AP1 was found to be strongly anti-correlated with the expression of hsa-miR-140-3p, which was significantly down-regulated in the tumour samples.
tissue_expression_down	hsa-mir-141	Ovarian Neoplasms	19501389	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival.
tissue_expression_down	hsa-mir-145	Ovarian Neoplasms	20716115	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets.
tissue_expression_down	hsa-mir-150	Ovarian Neoplasms	25986891	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miRNA-150 downregulation may contribute to the pertuzumab resistance in ovarian cancer via, at least in part, PI3K-akt pathway.
tissue_expression_down	hsa-mir-155	Ovarian Neoplasms	18954897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-155: under-expression
tissue_expression_down	hsa-mir-15b	Ovarian Neoplasms	27195958	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	WNT7A Regulation by miR-15b in Ovarian Cancer.
tissue_expression_down	hsa-mir-17	Ovarian Neoplasms	29307001	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-26a, miR-125b-5p, miR-17-5p and miR-221 downregulation could be related to poor EOC prognosis
tissue_expression_down	hsa-mir-193b	Ovarian Neoplasms	25798837	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis.
tissue_expression_down	hsa-mir-193b	Ovarian Neoplasms	26675282	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduction of miR-193b was found in ovarian cancer and its lower expression was associated with poorer prognosis. Tissue miR-193b showed potential as novel biomarker for ovarian cancer.
tissue_expression_down	hsa-mir-196b	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_down	hsa-mir-200	Ovarian Neoplasms	25347277	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Catalpol suppresses proliferation and facilitates apoptosis of OVCAR-3 ovariancancer cells through upregulating microRNA-200 and downregulating MMP-2expression.
tissue_expression_down	hsa-mir-200a	Ovarian Neoplasms	19501389	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival.
tissue_expression_down	hsa-mir-200b	Ovarian Neoplasms	19501389	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival.
tissue_expression_down	hsa-mir-200c	Ovarian Neoplasms	21345725	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC.
tissue_expression_down	hsa-mir-200c	Ovarian Neoplasms	19501389	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival.
tissue_expression_down	hsa-mir-205	Ovarian Neoplasms	24608381	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	VEGF is significantly expressed in the serum of epithelial ovarian cancer patients; and miR-205 is up-regulated in the epithelial ovarian cancer specimens. Ezrin and Lamin A/C are down-regulated in the epithelial ovarian cancer samples. VEGF, miR-205 and target protein may be associated with the invasion and metastasis of epithelial ovarian cancer.
tissue_expression_down	hsa-mir-205	Ovarian Neoplasms	25597268	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	VEGF promotes the invasion of ovarian cancer cells, partially via the down-regulation of Ezrin and Lamin A/C caused by increased expression of miR-205.
tissue_expression_down	hsa-mir-20b	Ovarian Neoplasms	21939554	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The miRNA was downregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines.
tissue_expression_down	hsa-mir-21	Ovarian Neoplasms	21968270	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-21 down-regulation promotes apoptosis and inhibits invasion and migration abilities of OVCAR3 (ovarian papillary adenocarcinoma cell lines) cells.
tissue_expression_down	hsa-mir-214	Ovarian Neoplasms	25483088	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	down-regulation of RNF8 mediated by miR-214 impedes DNA damage response to induce chromosomal instability in ovarian cancers, which may facilitate the understanding of mechanisms underlying chromosomal instability.
tissue_expression_down	hsa-mir-214	Ovarian Neoplasms	20716115	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets.
tissue_expression_down	hsa-mir-214	Ovarian Neoplasms	23171795	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found that in ovarian CAFs, miR-31 and miR-214 were downregulated, whereas miR-155 was upregulated when compared with normal or tumor-adjacent fibroblasts.
tissue_expression_down	hsa-mir-214	Ovarian Neoplasms	23230184	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	They found that decreased miR-31 and miR-214 and increased miR-155 expression can reprogram normal fibroblasts into tumor-promoting cancer-associated fibroblasts.
tissue_expression_down	hsa-mir-221	Ovarian Neoplasms	29307001	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-26a, miR-125b-5p, miR-17-5p and miR-221 downregulation could be related to poor EOC prognosis
tissue_expression_down	hsa-mir-221	Ovarian Neoplasms	18560586	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	we identify several miRNAs aberrantly expressed in human ovarian cancer tissues and cell lines. miR-221 stands out as a highly elevated miRNA in ovarian cancer, while miR-21 and several members of the let-7 family are found downregulated.
tissue_expression_down	hsa-mir-26a	Ovarian Neoplasms	29307001	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-26a, miR-125b-5p, miR-17-5p and miR-221 downregulation could be related to poor EOC prognosis
tissue_expression_down	hsa-mir-27b	Ovarian Neoplasms	25823356	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-27b was identified as the most highly down-regulated miRNA in DGCR8 knockdown cells and promoted cell proliferation in ovarian cancer cells.
tissue_expression_down	hsa-mir-29b	Ovarian Neoplasms	24992675	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer.
tissue_expression_down	hsa-mir-31	Ovarian Neoplasms	23171795	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found that in ovarian CAFs, miR-31 and miR-214 were downregulated, whereas miR-155 was upregulated when compared with normal or tumor-adjacent fibroblasts.
tissue_expression_down	hsa-mir-31	Ovarian Neoplasms	23230184	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	They found that decreased miR-31 and miR-214 and increased miR-155 expression can reprogram normal fibroblasts into tumor-promoting cancer-associated fibroblasts.
tissue_expression_down	hsa-mir-34b	Ovarian Neoplasms	20145172	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	reduced expression of miR-34b*/c may be particularly important for progression to the most advanced stages
tissue_expression_down	hsa-mir-34c	Ovarian Neoplasms	21321636	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-449b and miR-34c on inducing down-regulation of cell cycle-related proteins and cycle arrests in SKOV3-ipl cell, an ovarian cancer cell line.
tissue_expression_down	hsa-mir-34c	Ovarian Neoplasms	20145172	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	reduced expression of miR-34b*/c may be particularly important for progression to the most advanced stages
tissue_expression_down	hsa-mir-429	Ovarian Neoplasms	19501389	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200b-429 may be used as a prognostic marker for ovarian cancer outcome, and low-level expression of miR-200 miRNAs in this cluster predicts poor survival.
tissue_expression_down	hsa-mir-449a	Ovarian Neoplasms	25179844	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells.
tissue_expression_down	hsa-mir-486	Ovarian Neoplasms	19946373	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-486-5p: downregulated
tissue_expression_down	hsa-mir-498	Ovarian Neoplasms	26744867	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Decreased expression levels of miR-498 are associated with worse overall survival and poor prognosis in patients with ovarian cancer, highlighting potential usefulness of this miR for prognosis in patients with ovarian cancer.
tissue_expression_down	hsa-mir-499a	Ovarian Neoplasms	21321636	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-449b and miR-34c on inducing down-regulation of cell cycle-related proteins and cycle arrests in SKOV3-ipl cell, an ovarian cancer cell line.
tissue_expression_down	hsa-mir-532	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_down	hsa-mir-542	Ovarian Neoplasms	21939554	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The miRNA hsa-miR-542-3p was downregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines.
tissue_expression_down	hsa-mir-625	Ovarian Neoplasms	21939554	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The miRNA was downregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines.
tissue_expression_down	hsa-mir-886	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_down	hsa-mir-9	Ovarian Neoplasms	24168967	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-9 mediates the downregulation of BRCA1 and impedes DNA damage repair in ovarian cancer. miR-9 may improve chemotherapeutic efficacy by increasing the sensitivity of cancer cells to DNA damage and may impact ovarian cancer therapy.
tissue_expression_down	hsa-mir-99b	Ovarian Neoplasms	18954897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-99b: under-expression
tissue_expression_down	hsa-mir-99b	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_down	hsa-let-7	Pancreatic Neoplasms	23338123	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors.
tissue_expression_down	hsa-let-7a-1	Pancreatic Neoplasms	21463919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype
tissue_expression_down	hsa-let-7a-2	Pancreatic Neoplasms	21463919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype
tissue_expression_down	hsa-let-7a-3	Pancreatic Neoplasms	21463919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype
tissue_expression_down	hsa-let-7b	Pancreatic Neoplasms	21463919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype
tissue_expression_down	hsa-let-7c	Pancreatic Neoplasms	21463919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype
tissue_expression_down	hsa-let-7c	Pancreatic Neoplasms	22929886	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients.
tissue_expression_down	hsa-let-7f-1	Pancreatic Neoplasms	22929886	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients.
tissue_expression_down	hsa-let-7f-2	Pancreatic Neoplasms	22929886	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients.
tissue_expression_down	hsa-let-7i	Pancreatic Neoplasms	22820191	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression.
tissue_expression_down	hsa-mir-100	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly down-regulated in PDAC compared with normal ductal
tissue_expression_down	hsa-mir-107	Pancreatic Neoplasms	23338123	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors.
tissue_expression_down	hsa-mir-122	Pancreatic Neoplasms	22850622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed.
tissue_expression_down	hsa-mir-125	Pancreatic Neoplasms	23338123	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors.
tissue_expression_down	hsa-mir-128	Pancreatic Neoplasms	23338123	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors.
tissue_expression_down	hsa-mir-130	Pancreatic Neoplasms	23338123	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors.
tissue_expression_down	hsa-mir-132	Pancreatic Neoplasms	23338123	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors.
tissue_expression_down	hsa-mir-133b	Pancreatic Neoplasms	19654291	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		downregulated, Up-regulation leads to the reversal of EMT
tissue_expression_down	hsa-mir-141	Pancreatic Neoplasms	24285464	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		hsa-mir-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration.
tissue_expression_down	hsa-mir-141	Pancreatic Neoplasms	23338123	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors.
tissue_expression_down	hsa-mir-143	Pancreatic Neoplasms	22905187	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05).
tissue_expression_down	hsa-mir-143	Pancreatic Neoplasms	22820191	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression.
tissue_expression_down	hsa-mir-145	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly down-regulated in PDAC compared with normal ductal
tissue_expression_down	hsa-mir-145	Pancreatic Neoplasms	22850622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed.
tissue_expression_down	hsa-mir-146a	Pancreatic Neoplasms	22850622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed.
tissue_expression_down	hsa-mir-146a	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_down	hsa-mir-148a	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly down-regulated in PDAC compared with normal ductal
tissue_expression_down	hsa-mir-150	Pancreatic Neoplasms	24246865	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-150-5p is down-regulated in pancreatic cancer. Over-expression of miR-150-5p inhibits cell proliferation, blocked the cell cycle, but promotes cell apoptosis in pancreatic cancer cells
tissue_expression_down	hsa-mir-155	Pancreatic Neoplasms	22905187	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05).
tissue_expression_down	hsa-mir-196a-1	Pancreatic Neoplasms	22905187	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05).
tissue_expression_down	hsa-mir-196a-2	Pancreatic Neoplasms	22905187	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05).
tissue_expression_down	hsa-mir-199b	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-199b-5p: Highly down-regulated in PDAC compared with normal ductal
tissue_expression_down	hsa-mir-200b	Pancreatic Neoplasms	21463919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype
tissue_expression_down	hsa-mir-200b	Pancreatic Neoplasms	22821831	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Furthermore, MIF-overexpression significantly increased ZEB1/2 and decreased miR-200b expression, while shRNA-mediated inhibition of MIF increased E-cadherin and miR-200b expression, and reduced the expression of ZEB1/2 in Panc1 cells.
tissue_expression_down	hsa-mir-200c	Pancreatic Neoplasms	21463919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype
tissue_expression_down	hsa-mir-200c	Pancreatic Neoplasms	22929886	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients.
tissue_expression_down	hsa-mir-216a	Pancreatic Neoplasms	22905187	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-216a, -196a, -143 und -155) were detected at lower concentrations in feces of PCA patients when compared to controls (p<0.05).
tissue_expression_down	hsa-mir-216a	Pancreatic Neoplasms	23174591	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The down-regulated expression of miR-216a in pancreatic cancer suggests the involvement of miR-216a in the tumorigenesis and development of pancreatic cancer
tissue_expression_down	hsa-mir-216a	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_down	hsa-mir-216b	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_down	hsa-mir-217	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_down	hsa-mir-218	Pancreatic Neoplasms	26662432	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our findings suggested a significant downregulation in the expression of miR-218;this might have considerable potential value in the prognosis for pancreatic cancer.
tissue_expression_down	hsa-mir-22	Pancreatic Neoplasms	22820191	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression.
tissue_expression_down	hsa-mir-223	Pancreatic Neoplasms	23834147	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Genistein down-regulates miR-223 expression in pancreatic cancer cells.
tissue_expression_down	hsa-mir-23a	Pancreatic Neoplasms	25422915	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-23a and/or miR-24 overexpression leads to gene silencing of FZD5, TMEM92 and/or HNF1B. Their downregulation induces deregulated expression and degradation of E-cadherin and β-catenin causing destabilisation of the cadherin/catenin complex, and altered the expression of Wnt-related genes. We propose a molecular (epi)genetic mechanism by which increased EMT-like cell shape transformation and integration into mesothelial monolayers of PDAC cells can be observed.
tissue_expression_down	hsa-mir-24	Pancreatic Neoplasms	25422915	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-23a and/or miR-24 overexpression leads to gene silencing of FZD5, TMEM92 and/or HNF1B. Their downregulation induces deregulated expression and degradation of E-cadherin and β-catenin causing destabilisation of the cadherin/catenin complex, and altered the expression of Wnt-related genes. We propose a molecular (epi)genetic mechanism by which increased EMT-like cell shape transformation and integration into mesothelial monolayers of PDAC cells can be observed.
tissue_expression_down	hsa-mir-27a	Pancreatic Neoplasms	25652374	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Grape seed proanthocyanidins extract inhibits pancreatic cancer cell growth through down-regulation of miR-27a expression.
tissue_expression_down	hsa-mir-27a	Pancreatic Neoplasms	23803693	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		in Panc1 cells metformin decreased microRNA-27a and induced the Sp repressor, ZBTB10, and disruption of miR-27a:ZBTB10 by metformin was phosphatase dependent.
tissue_expression_down	hsa-mir-29b	Pancreatic Neoplasms	22820191	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Knockdown of Dicer 1 expression in BxPC-3 and Panc-1 cells resulted in significant increases in KRAS, p53, PTEN, and Dnmts protein levels and significant decreases in miR-22, miR-143, let-7i, and miR-29b expression.
tissue_expression_down	hsa-mir-31	Pancreatic Neoplasms	22850622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed.
tissue_expression_down	hsa-mir-34	Pancreatic Neoplasms	23338123	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The BxPC-3-LN cells expressed lower levels of let-7, miR-34, miR-107, miR-125, miR-128, miR-130, miR-132 and miR-141 than the parental BxPC-3 cells detected by microRNA PCR array, which were reported to have close relation to stem cell factors.
tissue_expression_down	hsa-mir-34a	Pancreatic Neoplasms	22114136	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		In the initial cohort of 48 PDAC (pancreatic ductal adenocarcinoma) patients, high expression of miR-21 (Hazard ratio (HR): 3.22, 95% Confidence Interval (CI):1.21-8.58) and reduced expression of miR-34a (HR 0.15, 95%CI: 0.06-0.37) and miR-30d (HR:0.30, 95%CI:0.12-0.79) were associated with poor overall survival following resection independent of clinical covariates. In a further validation set of 24 patients miR-21 and miR-34a expression again significantly correlated with overall survival (P = 0.031 and P = 0.001).
tissue_expression_down	hsa-mir-34a	Pancreatic Neoplasms	20037478	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Finally,restituted expression of miR-34a, a miRNA whose expression is frequently lost in PDAC cell lines, abrogates growth, demonstrating that the anti-proliferative activity of this miRNA is operative in PDAC.
tissue_expression_down	hsa-mir-451a	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly down-regulated in PDAC compared with normal ductal
tissue_expression_down	hsa-mir-497	Pancreatic Neoplasms	25149530	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.
tissue_expression_down	hsa-mir-520h	Pancreatic Neoplasms	20628378	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-520h:miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations
tissue_expression_down	hsa-mir-21	Parkinson Disease	27173998	nervous system disease	DOID:14330	G20	D010300	PS168600		GP significantly downregulated miR-21.
tissue_expression_down	hsa-mir-34b	Parkinson Disease	21558425	nervous system disease	DOID:14330	G20	D010300	PS168600		This miRNA was downregulated in brain areas with variable neuropathological affectation at clinical (motor) stages (Braak stages 4 and 5) of the disease,including the amygdala, frontal cortex, substantia nigra and cerebellum. This miRNA modulate mitochondrial function.
tissue_expression_down	hsa-mir-34b	Parkinson Disease	22245218	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-133b is deficient in the PD midbrain as well as in mouse models, and miR-34b/34c are decreased in several affected brain regions in PD and incidental Lewy body disease.
tissue_expression_down	hsa-mir-34c	Parkinson Disease	21558425	nervous system disease	DOID:14330	G20	D010300	PS168600		This miRNA was downregulated in brain areas with variable neuropathological affectation at clinical (motor) stages (Braak stages 4 and 5) of the disease,including the amygdala, frontal cortex, substantia nigra and cerebellum. This miRNA modulate mitochondrial function.
tissue_expression_down	hsa-mir-34c	Parkinson Disease	22245218	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-133b is deficient in the PD midbrain as well as in mouse models, and miR-34b/34c are decreased in several affected brain regions in PD and incidental Lewy body disease.
tissue_expression_down	hsa-mir-132	Periodontal Diseases	26481834	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	Furthermore, miRNA-132 and miRNA-146a were significantly decreased in the pancreas of infected rats.
tissue_expression_down	hsa-mir-146a	Periodontal Diseases	26481834	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	Furthermore, miRNA-132 and miRNA-146a were significantly decreased in the pancreas of infected rats.
tissue_expression_down	hsa-mir-495	Periodontitis	26987780	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Seven randomly selected up-regulated (miR-21-5p, 498, 548a-5p) and down-regulated (miR-495-3p, 539-5p, 34c-3p and 7a-2-3p) miRNAs were examined by qRT-PCR, and the results proved the accuracy of the miRNA
tissue_expression_down	hsa-mir-130b	Pituitary Adenoma	24681352	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Mir-23b and miR-130b expression is downregulated in pituitary adenomas.
tissue_expression_down	hsa-mir-23b	Pituitary Adenoma	24681352	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Mir-23b and miR-130b expression is downregulated in pituitary adenomas.
tissue_expression_down	hsa-mir-1	Pituitary Neoplasms	28577032	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Studies have shown that the levels of miR-1, miR-195, and miR-206 are downregulated in Pas
tissue_expression_down	hsa-mir-195	Pituitary Neoplasms	28577032	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Studies have shown that the levels of miR-1, miR-195, and miR-206 are downregulated in Pas
tissue_expression_down	hsa-mir-206	Pituitary Neoplasms	28577032	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Studies have shown that the levels of miR-1, miR-195, and miR-206 are downregulated in Pas
tissue_expression_down	hsa-mir-16	Pleural Mesothelioma	24148817	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	The miR-15/16 family is downregulated and has tumour suppressor function in MPM. Restoring miR-16 expression represents a novel therapeutic approach for MPM.
tissue_expression_down	hsa-mir-592	Polycystic Ovarian Syndrome	26679164	syndrome	DOID:11612	E28.2	D011085	184700		miRNA-592 is downregulated and may target LHCGR in polycystic ovary syndrome patients.
tissue_expression_down	hsa-mir-92b	Polycystic Ovarian Syndrome	25591557	syndrome	DOID:11612	E28.2	D011085	184700		two (miR-92a and miR-92b)  of them were significantly downregulated in PCOS women
tissue_expression_down	hsa-mir-150	Polycythemia Vera	20218812	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed that miR-451 up-regulation and miR-150 down-regulation are associated with progression of erythroid maturation in K562 cells.
tissue_expression_down	hsa-mir-125b	Preeclampsia	27412941	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Compared with 0 渭mol/L H2O2 group, miR-125b-5p significantly decreased in 100 渭mol/L H2O2 group, while Smad4 protein significantly increased.
tissue_expression_down	hsa-mir-126	Preeclampsia	25341970	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-126 was downregulated in placentas from patients with pre-eclampsia and this correlated with decreased VEGF expression. These findings indicate that miRNA-126 may be involved in pre-eclampsia pathogenesis and could be a potential biomarker for this disease.
tissue_expression_down	hsa-mir-20a	Preeclampsia	26992682	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The expression level of miR-200c,-20a and -20b as well as the level of CBS, CSE and VEGF were downregulated in preeclamptic placentas.
tissue_expression_down	hsa-mir-325	Preeclampsia	22710575	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The expression of hsa-miR-325 was downregulated in the case of PE. Changes in hsa-miR-325 expression in the case of pregnancy-related hypertensive disorders might affect the oxidative stress pathways and heat-shock protein production.
tissue_expression_down	hsa-mir-411	Preeclampsia	24664294	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	In this study, a total of 9 downregulated miRNAs (miR-195, miR-223, miR-218, miR-17, miR-18a, miR-19b1, miR-92a1, miR-379, and miR-411) and 7 upregulated miRNAs (miR-210, miR-30a-3p, miR-518b, miR-524, miR-17-3p, miR-151, and miR-193b) were identified in severe preeclampsia (sPE) placentas when compared with normal pregnant controls.
tissue_expression_down	hsa-let-7b	Primary Biliary Cirrhosis	24074714	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	Decreased expression of miR-let-7b may be associated with development and progression of PBC, and this miRNA may represent a novel target of improved diagnostic and preventive strategies for PBC.
tissue_expression_down	hsa-mir-122a	Primary Biliary Cirrhosis	19345069	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	A total of 35 independent miRNAs were found to be differentially expressed in PBC (p < 0.001).Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p.
tissue_expression_down	hsa-mir-26a	Primary Biliary Cirrhosis	19345069	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	A total of 35 independent miRNAs were found to be differentially expressed in PBC (p < 0.001).Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p.
tissue_expression_down	hsa-mir-146	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_down	hsa-mir-125b-1	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	down-regulated
tissue_expression_down	hsa-mir-125b-2	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	down-regulated
tissue_expression_down	hsa-mir-130a	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	down-regulated
tissue_expression_down	hsa-mir-199b	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-199b-3p: down-regulated
tissue_expression_down	hsa-mir-200b	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	down-regulated
tissue_expression_down	hsa-let-7	Prostate Neoplasms	27197175	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In cancer cells, reduced expression of ESE3/EHF upregulated  Lin28A and Lin28B and downregulated the let-7 microRNAs.
tissue_expression_down	hsa-let-7c	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-100	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-100	Prostate Neoplasms	22999546	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-100 and miR-10a showed under expression and over expression, respectively, in low grade pTa tumors.
tissue_expression_down	hsa-mir-106a	Prostate Neoplasms	22719071	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulated in prostate cancer stem/progenitor cell.
tissue_expression_down	hsa-mir-106a	Prostate Neoplasms	21714127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors
tissue_expression_down	hsa-mir-106b	Prostate Neoplasms	20878953	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells.
tissue_expression_down	hsa-mir-106b	Prostate Neoplasms	21714127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors
tissue_expression_down	hsa-mir-126	Prostate Neoplasms	25277191	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Osteoblast-derived WNT-induced secreted protein 1 increases VCAM-1 expression and enhances prostate cancer metastasis by down-regulating miR-126.
tissue_expression_down	hsa-mir-130a	Prostate Neoplasms	22391564	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma.
tissue_expression_down	hsa-mir-130b	Prostate Neoplasms	25154741	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-130b suppresses prostate cancer metastasis through down-regulation of MMP2.
tissue_expression_down	hsa-mir-133b	Prostate Neoplasms	19946373	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulated
tissue_expression_down	hsa-mir-133b	Prostate Neoplasms	22532850	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Expression of miR-133b in tumor specimens of prostate cancer patients was significantly downregulated in 75% of the cases, when compared with matched healthy tissue.
tissue_expression_down	hsa-mir-135b	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-491.
tissue_expression_down	hsa-mir-141	Prostate Neoplasms	22719071	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulated in prostate cancer stem/progenitor cell.
tissue_expression_down	hsa-mir-143	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-143	Prostate Neoplasms	19671871	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Although miR-143 and miR-145 are highly expressed in normal tissues, they are significantly down-regulated in prostate cancer cells. 
tissue_expression_down	hsa-mir-145	Prostate Neoplasms	17028596	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	mir-145 downregulated in breast cancer (Iorio et al., 2005) and lung cancer and deleted in prostate cancer (Yanaihara et al., 2006);
tissue_expression_down	hsa-mir-145	Prostate Neoplasms	18949015	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-145: down-regulated
tissue_expression_down	hsa-mir-145	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-145	Prostate Neoplasms	19671871	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Although miR-143 and miR-145 are highly expressed in normal tissues, they are significantly down-regulated in prostate cancer cells. 
tissue_expression_down	hsa-mir-146a	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-146a	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-492.
tissue_expression_down	hsa-mir-15a	Prostate Neoplasms	21532615	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed.
tissue_expression_down	hsa-mir-15a	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-15a	Prostate Neoplasms	27322147	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-15a and miR-186, associated with expression of VEGF and hypoxia inducible factor-1伪 (HIF-1伪), were down-regulated in mPGES-1+/+ cells.
tissue_expression_down	hsa-mir-15b	Prostate Neoplasms	21532615	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed.
tissue_expression_down	hsa-mir-16-1	Prostate Neoplasms	19738602	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo
tissue_expression_down	hsa-mir-16-1	Prostate Neoplasms	21532615	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed.
tissue_expression_down	hsa-mir-16-1	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-16-2	Prostate Neoplasms	19738602	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo
tissue_expression_down	hsa-mir-16-2	Prostate Neoplasms	21532615	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-15 and miR-16 are downregulated in fibroblasts surrounding the prostate tumors of the majority of 23 patients analyzed.
tissue_expression_down	hsa-mir-16-2	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-17	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_down	hsa-mir-17	Prostate Neoplasms	21714127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors
tissue_expression_down	hsa-mir-18	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_down	hsa-mir-18	Prostate Neoplasms	21714127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors
tissue_expression_down	hsa-mir-191	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-199a-1	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-199a-2	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-19a	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_down	hsa-mir-19a	Prostate Neoplasms	21714127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors
tissue_expression_down	hsa-mir-19b-1	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_down	hsa-mir-19b-1	Prostate Neoplasms	21714127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors
tissue_expression_down	hsa-mir-203	Prostate Neoplasms	22391564	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma.
tissue_expression_down	hsa-mir-205	Prostate Neoplasms	23974361	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth.
tissue_expression_down	hsa-mir-205	Prostate Neoplasms	24173237	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.
tissue_expression_down	hsa-mir-205	Prostate Neoplasms	22391564	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma.
tissue_expression_down	hsa-mir-20a	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_down	hsa-mir-20a	Prostate Neoplasms	21714127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors
tissue_expression_down	hsa-mir-21	Prostate Neoplasms	25216674	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results indicate that miR-21 is able to downregulate p57(Kip2) expression by targeting the coding region of the gene and is also able to attenuate p57(Kip2) mediated functional responses. This is the first report demonstrating that p57(Kip2) is a novel target of miR-21 in prostate cancer and revealing a novel oncogenic function of this microRNA.
tissue_expression_down	hsa-mir-21	Prostate Neoplasms	21177307	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We also observed a significant down-regulation of androgen-regulated miRNA-21 and up-regulation of a tumor suppressor, miRNA-330, in tumors of mice treated with EGCG
tissue_expression_down	hsa-mir-21	Prostate Neoplasms	21594291	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated.
tissue_expression_down	hsa-mir-218-1	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-22	Prostate Neoplasms	22815235	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We previously detected several miRNAs, for example, miR-24 and miR-22, as significantly downregulated in Pca
tissue_expression_down	hsa-mir-221	Prostate Neoplasms	18949015	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221: down-regulated
tissue_expression_down	hsa-mir-221	Prostate Neoplasms	19585579	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221:Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis
tissue_expression_down	hsa-mir-221	Prostate Neoplasms	21378318	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer.
tissue_expression_down	hsa-mir-221	Prostate Neoplasms	22127852	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer.
tissue_expression_down	hsa-mir-221	Prostate Neoplasms	28886115	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
tissue_expression_down	hsa-mir-222	Prostate Neoplasms	18949015	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-222: down-regulated
tissue_expression_down	hsa-mir-222	Prostate Neoplasms	21378318	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer.
tissue_expression_down	hsa-mir-222	Prostate Neoplasms	22127852	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer.
tissue_expression_down	hsa-mir-222	Prostate Neoplasms	28886115	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
tissue_expression_down	hsa-mir-222	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-491.
tissue_expression_down	hsa-mir-224	Prostate Neoplasms	23136246	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Downregulation and Prognostic Performance of MicroRNA 224 Expression in Prostate Cancer
tissue_expression_down	hsa-mir-23b	Prostate Neoplasms	18949015	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-23b: down-regulated
tissue_expression_down	hsa-mir-23b	Prostate Neoplasms	22127852	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer.
tissue_expression_down	hsa-mir-24	Prostate Neoplasms	22815235	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We previously detected several miRNAs, for example, miR-24 and miR-22, as significantly downregulated in Pca
tissue_expression_down	hsa-mir-25	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-27a	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-491.
tissue_expression_down	hsa-mir-27b	Prostate Neoplasms	22127852	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The altered expression of MiR-221/-222 (increased miR-221/-222 expression ) and MiR-23b/-27b (down-regulated ) is associated with the development of human castration resistant prostate cancer.
tissue_expression_down	hsa-mir-32	Prostate Neoplasms	21880514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	significantly changed during the progression of cancer
tissue_expression_down	hsa-mir-324	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-491.
tissue_expression_down	hsa-mir-345	Prostate Neoplasms	26227059	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Taken together, our data suggest that miR-345 exerts a suppressive effect on prostate cancer proliferation, invasion and migration through downregulation of Smad1.
tissue_expression_down	hsa-mir-34a	Prostate Neoplasms	23936419	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results indicated that genistein inhibited PCa cell growth through down-regulation of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a. These findings enhance understanding of how genistein regulates lncRNA HOTAIR and miR-34a in PCa.
tissue_expression_down	hsa-mir-34a	Prostate Neoplasms	22719071	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulated in prostate cancer stem/progenitor cell.
tissue_expression_down	hsa-mir-34c	Prostate Neoplasms	20162671	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions
tissue_expression_down	hsa-mir-34c	Prostate Neoplasms	21351256	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.
tissue_expression_down	hsa-mir-373	Prostate Neoplasms	19158933	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-373: MicroRNAs 373 and 520c Are Downregulated in Prostate Cancer, Suppress CD44
tissue_expression_down	hsa-mir-373	Prostate Neoplasms	21594291	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated.
tissue_expression_down	hsa-mir-486	Prostate Neoplasms	19946373	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-486-5p: downregulated
tissue_expression_down	hsa-mir-486	Prostate Neoplasms	25597612	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs (miR-125b-5p, miR-126-5p, miR-151a-5p, miR-221-3p, and miR-222-3p) were significantly upregulated with downregulation of miR-486-5p.
tissue_expression_down	hsa-mir-491	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-492.
tissue_expression_down	hsa-mir-502	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-491.
tissue_expression_down	hsa-mir-520c	Prostate Neoplasms	19158933	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-520c: MicroRNAs 373 and 520c Are Downregulated in Prostate Cancer, Suppress CD44
tissue_expression_down	hsa-mir-521	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-491.
tissue_expression_down	hsa-mir-579	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	top nine miRNA with significantly lower expression level in ExoHypoxic compared to ExoNormoxic were miR-521, miR-27a, miR-324, miR-579, miR-502, miR-222, miR-135b,  miR-146a and miR-491.
tissue_expression_down	hsa-mir-92-1	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_down	hsa-mir-92-1	Prostate Neoplasms	21714127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The down-regulated miRs included miR-17-92 and miR-106ab clusters with well recognized oncogenic properties while the up-regulated miRs included several tumor suppressors
tissue_expression_down	hsa-mir-92a-1	Prostate Neoplasms	22412975	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression.
tissue_expression_down	hsa-mir-92a-2	Prostate Neoplasms	22412975	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be associated with RANKL signaling, EMT and cancer progression.
tissue_expression_down	hsa-mir-125b	Psoriasis	27729619	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	upregulation of miR-31/miR-203 and downregulation of hsa-miR-99a/miR-125b work together in concert to facilitate the development of psoriasis pathogenesis
tissue_expression_down	hsa-mir-125b-1	Psoriasis	17622355	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	The level of this miRNA significantly (p<0.001 for both) decreased both in psoriasis and atopic eczema.
tissue_expression_down	hsa-mir-125b-2	Psoriasis	17622355	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	The level of this miRNA significantly (p<0.001 for both) decreased both in psoriasis and atopic eczema.
tissue_expression_down	hsa-mir-21	Psoriasis	21373745	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Real-time PCR and immunohistochemistry showed that p63 expression was not significantly affected, whereas NB-UVB phototherapy significantly decreased expression ofmiR-21 (p = 0.003) and increased miR-125b levels (p = 0.003). The results indicate that the unresolved p63 abnormality in treated epidermis may play a role in maintenance of this disease.
tissue_expression_down	hsa-mir-217	Psoriasis	26826389	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MiR-217 is down-regulated in psoriasis and promotes keratinocyte differentiation via targeting GRHL2.
tissue_expression_down	hsa-mir-99a	Psoriasis	27729619	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	upregulation of miR-31/miR-203 and downregulation of hsa-miR-99a/miR-125b work together in concert to facilitate the development of psoriasis pathogenesis
tissue_expression_down	hsa-mir-1246	Pulmonary Hypertension	23717609	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects.
tissue_expression_down	hsa-mir-204	Pulmonary Hypertension	23114789	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	MEX suppressed the hypoxic activation of signal transducer and activator of transcription 3 (STAT3) and the upregulation of the miR-17 superfamily of microRNA clusters, whereas it increased lung levels of miR-204, a key microRNA, the expression of which is decreased in human pulmonary hypertension.
tissue_expression_down	hsa-mir-451	Pulmonary Hypertension	23717609	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects.
tissue_expression_down	hsa-mir-720	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_down	hsa-mir-125a	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_down	hsa-mir-125b	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_down	hsa-mir-429	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_down	hsa-mir-106a	Retinal Neovascularization	18500251			H35.059	D015861		HP:0030666	decreased
tissue_expression_down	hsa-mir-214	Retinal Neovascularization	18500251			H35.059	D015861		HP:0030666	decreased
tissue_expression_down	hsa-mir-424	Retinal Neovascularization	18500251			H35.059	D015861		HP:0030666	decreased
tissue_expression_down	hsa-mir-1	Retinitis Pigmentosa	18034880	nervous system disease	DOID:10584	H35.52	D012174	PS268000	HP:0000510	Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P < 0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P < 0.001) in Pro347Ser retinas, as validated by qPCR.
tissue_expression_down	hsa-mir-133	Retinitis Pigmentosa	18034880	nervous system disease	DOID:10584	H35.52	D012174	PS268000	HP:0000510	Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P < 0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P < 0.001) in Pro347Ser retinas, as validated by qPCR.
tissue_expression_down	hsa-mir-17	Retinoblastoma	25359779	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters.
tissue_expression_down	hsa-mir-18	Retinoblastoma	25359779	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters.
tissue_expression_down	hsa-mir-19a	Retinoblastoma	25359779	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters.
tissue_expression_down	hsa-mir-19b-1	Retinoblastoma	25359779	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters.
tissue_expression_down	hsa-mir-204	Retinoblastoma	25647033	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	MiR-204, down-regulated in retinoblastoma, regulates proliferation and invasion of human retinoblastoma cells by targeting CyclinD2 and MMP-9.
tissue_expression_down	hsa-mir-20a	Retinoblastoma	25359779	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters.
tissue_expression_down	hsa-mir-433	Retinoblastoma	27470361	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We found that the expression levels of miR-433 were downregulated in RB  tissues.
tissue_expression_down	hsa-mir-513a-1	Retinoblastoma	22886978	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-513a-5p expression was decreased in Rb cells after etoposide treatment.
tissue_expression_down	hsa-mir-513a-2	Retinoblastoma	22886978	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-513a-5p expression was decreased in Rb cells after etoposide treatment.
tissue_expression_down	hsa-mir-513b	Retinoblastoma	22886978	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-513a-5p expression was decreased in Rb cells after etoposide treatment.
tissue_expression_down	hsa-mir-513c	Retinoblastoma	22886978	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	miR-513a-5p expression was decreased in Rb cells after etoposide treatment.
tissue_expression_down	hsa-mir-92-1	Retinoblastoma	25359779	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters.
tissue_expression_down	hsa-let-7a-1	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	let-7a: down-regulated
tissue_expression_down	hsa-let-7a-2	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	let-7a: down-regulated
tissue_expression_down	hsa-let-7a-3	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	let-7a: down-regulated
tissue_expression_down	hsa-mir-144	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-144: down-regulated
tissue_expression_down	hsa-mir-20b	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-20b: down-regulated
tissue_expression_down	hsa-mir-375	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-375: down-regulated
tissue_expression_down	hsa-mir-206	Sarcoma [unspecific]	26878133	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	miR-133, miR-1, and miR-206 was significantly underexpressed in well-differentiated liposarcoma and synovial sarcoma
tissue_expression_down	hsa-mir-132	Schizophrenia	22315408	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	MicroRNA-132 downregulation in schizophrenia has implications for both neurodevelopment and adult brain function.
tissue_expression_down	hsa-mir-195	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-20b	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-212	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-24-1	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-24-2	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-26b	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-29a	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-29b-1	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-29c	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-30a	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-30b	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-30d	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-30e	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-7-1	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-7-2	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-7-3	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-9-1	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-9-2	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-92a-1	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-92a-2	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-92b	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-9-3	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	downregulation
tissue_expression_down	hsa-mir-129-1	Scleroderma, Systemic	22403442	musculoskeletal system disease	DOID:418	M34	D012595	181750		IL-17A signaling, not IL-17F, has an antifibrogenic effect via the upregulation of miR-129-5p and the downregulation of connective tissue growth factor and ж┿(I) collagen.
tissue_expression_down	hsa-mir-129-2	Scleroderma, Systemic	22403442	musculoskeletal system disease	DOID:418	M34	D012595	181750		IL-17A signaling, not IL-17F, has an antifibrogenic effect via the upregulation of miR-129-5p and the downregulation of connective tissue growth factor and ж┿(I) collagen.
tissue_expression_down	hsa-mir-124-1	Sepsis	22846781			A41.9	D018805		HP:0100806	Corticosteroid resistance in sepsis is influenced by microRNA-124-induced downregulation of glucocorticoid receptor-alpha
tissue_expression_down	hsa-mir-124-2	Sepsis	22846781			A41.9	D018805		HP:0100806	Corticosteroid resistance in sepsis is influenced by microRNA-124-induced downregulation of glucocorticoid receptor-alpha
tissue_expression_down	hsa-mir-299	Sjogren Syndrome	26888739	immune system disease	DOID:12894	M35.00	D012859	270150		downregulation of miR-1207-5p and miR-4695-3p expression was further revealed in the minor salivary glands of primary SS (pSS) patients.
tissue_expression_down	hsa-mir-208b	Spinal Cord Injuries	26603456			S34.139A	D013119			A progressive decline in skeletal muscle microRNA-208b and microRNA-499-5p expression occurred in humans during the first year after spinal cord injury
tissue_expression_down	hsa-mir-21	Spinal Cord Injuries	20816819			S34.139A	D013119			spinal cord injury (SCI)results in increased expression of miR Let-7a and miR16 while exercise leads to elevated levels of miR21 and decreased levels of miR15b. These changes in miR expression are correlated with changes in expression of their target genes: pro-apoptotic (decreased PTEN, PDCD4, and RAS mRNA) and anti-apoptotic (increased Bcl-2 mRNA) target genes. This is accompanied by a down-regulation of mRNA for caspase-7 and caspase-9 and reduced levels of caspase-7 protein.
tissue_expression_down	hsa-mir-9	Spinal Muscular Atrophy	24751385	nervous system disease	DOID:12377	G12.9	D009134	253300	HP:0007269	Survival of motor neuron protein downregulates miR-9 expression in patients with  spinal muscular atrophy.
tissue_expression_down	hsa-mir-221	Spinal Stenosis	26571175	musculoskeletal system disease	DOID:6725	M48.0	D013130		HP:0005733	miR-221 was significantly lower in LF tissues of patients than controls.
tissue_expression_down	hsa-mir-142	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_down	hsa-mir-155	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_down	hsa-mir-181a	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_down	hsa-mir-181b	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_down	hsa-mir-203	Squamous Cell Carcinoma	19789312	disease of cellular proliferation	DOID:1749		D002294			In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue.
tissue_expression_down	hsa-mir-218	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_down	hsa-mir-221	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_down	hsa-mir-222	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_down	hsa-mir-29a	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_down	hsa-mir-143	Squamous Cell Carcinoma, Cerevial	24774218	endocrine system disease	DOID:5531					Down-regulated miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical SCC, but miR-143 does not participate in the Taxol sensitivity response.
tissue_expression_down	hsa-mir-100	Squamous Cell Carcinoma, Esophageal	25218280	disease of cellular proliferation	DOID:3748		C562729			These findings show the reduced expression of miR-100 in human ESCC tissues and suggest a crucial role of its downregulation in ESCC progression and prognosis. More interestingly, the detection of miR-100 expression may be used to efficiently screen those ESCC patients who would benefit from radiotherapy.
tissue_expression_down	hsa-mir-106a	Squamous Cell Carcinoma, Esophageal	24314216	disease of cellular proliferation	DOID:3748		C562729			In esophageal squamous cell carcinomas, the miRNA-106a gene is under-expressed, with tumor suppressor function, and may be regarded as a biological marker to assess the prognosis in patients with esophageal squamous cell carcinoma.
tissue_expression_down	hsa-mir-10a	Squamous Cell Carcinoma, Esophageal	22966337	disease of cellular proliferation	DOID:3748		C562729			Down-regulation of microRNA 10a expression in esophageal squamous cell carcinoma cells.
tissue_expression_down	hsa-mir-133a	Squamous Cell Carcinoma, Esophageal	25280517	disease of cellular proliferation	DOID:3748		C562729			Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.
tissue_expression_down	hsa-mir-133a	Squamous Cell Carcinoma, Esophageal	27735040	disease of cellular proliferation	DOID:3748		C562729			Low miR-133a expression is a predictor of outcome in patients with esophageal squamous cell cancer.
tissue_expression_down	hsa-mir-133b	Squamous Cell Carcinoma, Esophageal	25280517	disease of cellular proliferation	DOID:3748		C562729			Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.
tissue_expression_down	hsa-mir-138	Squamous Cell Carcinoma, Esophageal	28759955	disease of cellular proliferation	DOID:3748		C562729			Downregulation of miR-138 predicts poor prognosis in patients with esophageal squamous cell carcinoma
tissue_expression_down	hsa-mir-145	Squamous Cell Carcinoma, Esophageal	25773691	disease of cellular proliferation	DOID:3748		C562729			Our data revealed a significant down-regulation of miR-145 in ESCC tissue samples. Based on our ROC curve analysis data (AUC = 0.74, p < 0.001) miR-145 could be regarded as a potential tumor marker for diagnosis of esophageal cancer.
tissue_expression_down	hsa-mir-302b	Squamous Cell Carcinoma, Esophageal	25773691	disease of cellular proliferation	DOID:3748		C562729			Our data revealed a significant down-regulation of miR-145 in ESCC tissue samples. Based on our ROC curve analysis data (AUC = 0.74, p < 0.001) miR-145 could be regarded as a potential tumor marker for diagnosis of esophageal cancer.
tissue_expression_down	hsa-mir-494	Squamous Cell Carcinoma, Esophageal	25480402	disease of cellular proliferation	DOID:3748		C562729			The qRT-PCR assays showed significant downregulation of miR-494 (P <0.05) and upregulation of CLPTM1L mRNA (P < 0.05), both of which were significantly associated with lymph node metastases (P < 0.05). High expression of miR-494 inhibited cell proliferation and invasion and promoted cell apoptosis (P < 0.05). The results also showed that CLPTM1L was a target of miR-494. CONCLUSION: These results show that the expression of miR-494, which can regulate cell growth, invasion and apoptosis of ESCC cells by targeting CLPTM1L, is downregulated in ESCC tumor tissues. The miR-494-CLPTM1L pathway could be further exploited to develop a new approach to treat ESCC
tissue_expression_down	hsa-mir-100	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_down	hsa-mir-10a	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			downregulation
tissue_expression_down	hsa-mir-130a	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_down	hsa-mir-138-1	Squamous Cell Carcinoma, Head and Neck	21969367	disease of cellular proliferation	DOID:5520	C76.0	C535575			In this study, the authors first confirm the microRNA-138-mediated down-regulation of FOSL1 in squamous cell carcinoma (SCC) cell lines.
tissue_expression_down	hsa-mir-138-2	Squamous Cell Carcinoma, Head and Neck	21969367	disease of cellular proliferation	DOID:5520	C76.0	C535575			In this study, the authors first confirm the microRNA-138-mediated down-regulation of FOSL1 in squamous cell carcinoma (SCC) cell lines.
tissue_expression_down	hsa-mir-15a	Squamous Cell Carcinoma, Head and Neck	27896137	disease of cellular proliferation	DOID:5520	C76.0	C535575			Lymph node or perineural invasion is associated with low miR-15a, miR-34c and miR-199b levels in head and neck squamous cell carcinoma.
tissue_expression_down	hsa-mir-181a-1	Squamous Cell Carcinoma, Head and Neck	21274007	disease of cellular proliferation	DOID:5520	C76.0	C535575			deltaNp63alpha-dependent miRNA miR-181a, miR-519a, and miR-374a downregulation in HNSCC,miR-630 upregulation in HNSCC
tissue_expression_down	hsa-mir-181a-2	Squamous Cell Carcinoma, Head and Neck	21274007	disease of cellular proliferation	DOID:5520	C76.0	C535575			deltaNp63alpha-dependent miRNA miR-181a, miR-519a, and miR-374a downregulation in HNSCC,miR-630 upregulation in HNSCC
tissue_expression_down	hsa-mir-197	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_down	hsa-mir-199b	Squamous Cell Carcinoma, Head and Neck	27896137	disease of cellular proliferation	DOID:5520	C76.0	C535575			Lymph node or perineural invasion is associated with low miR-15a, miR-34c and miR-199b levels in head and neck squamous cell carcinoma.
tissue_expression_down	hsa-mir-200b	Squamous Cell Carcinoma, Head and Neck	27440205	disease of cellular proliferation	DOID:5520	C76.0	C535575			Additionally, a significant decrease of hsa-miR-200b-5p expression was revealed in tumour-adjacent tissue samples of patients with node positivity.
tissue_expression_down	hsa-mir-203	Squamous Cell Carcinoma, Head and Neck	29667275	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-26 and miR-125b may be associated with the progression and metastasis of HNSCC, and that miR-203 is associated with a more favourable prognosis.
tissue_expression_down	hsa-mir-29c	Squamous Cell Carcinoma, Head and Neck	27440205	disease of cellular proliferation	DOID:5520	C76.0	C535575			Lower expression of hsa-miR-200b-5p and hsa-miR-29c-3p in HNSCC tumour tissue was associated with  higher tumour grade.
tissue_expression_down	hsa-mir-34c	Squamous Cell Carcinoma, Head and Neck	27896137	disease of cellular proliferation	DOID:5520	C76.0	C535575			Lymph node or perineural invasion is associated with low miR-15a, miR-34c and miR-199b levels in head and neck squamous cell carcinoma.
tissue_expression_down	hsa-mir-375	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			underexpression
tissue_expression_down	hsa-mir-491	Squamous Cell Carcinoma, Head and Neck	25677760	disease of cellular proliferation	DOID:5520	C76.0	C535575			Conversely, decreased expressions of miR-153, miR-200c, miR-363, miR-203, miR-17, miR-205, miR-Let-7d, Let-7g, miR-34a, miR-126a, miR-375, miR-491-p5, miR 218, miR-451 and miR-125b were associated with poor prognosis.
tissue_expression_down	hsa-mir-519a-1	Squamous Cell Carcinoma, Head and Neck	21274007	disease of cellular proliferation	DOID:5520	C76.0	C535575			deltaNp63alpha-dependent miRNA miR-181a, miR-519a, and miR-374a downregulation in HNSCC,miR-630 upregulation in HNSCC
tissue_expression_down	hsa-mir-519a-2	Squamous Cell Carcinoma, Head and Neck	21274007	disease of cellular proliferation	DOID:5520	C76.0	C535575			deltaNp63alpha-dependent miRNA miR-181a, miR-519a, and miR-374a downregulation in HNSCC,miR-630 upregulation in HNSCC
tissue_expression_down	hsa-mir-300	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	28272707	disease of cellular proliferation	DOID:2876					Reduced miR-300 expression predicts poor prognosis in patients with laryngeal squamous cell carcinoma.
tissue_expression_down	hsa-mir-34c	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26153151	disease of cellular proliferation	DOID:2876					A downregulation of miR-34c-5p in LSCC is independently associated with unfavorable disease-free survival, suggesting that miR-34c-5p might be a promising marker for evaluating the risk of recurrences.
tissue_expression_down	hsa-mir-370	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	24055400	disease of cellular proliferation	DOID:2876					In conclusion, our results suggest that miR-370 may function as a tumor suppressor in LSCC through downregulation of FoxM1,suggesting that miR-370 could serve as a novel potential maker for LSCC therapy.
tissue_expression_down	hsa-mir-101-1	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-101:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC
tissue_expression_down	hsa-mir-101-2	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-101:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC
tissue_expression_down	hsa-mir-126	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-126:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC
tissue_expression_down	hsa-mir-15a	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-15a:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC
tissue_expression_down	hsa-mir-193a	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-193a-3p:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC
tissue_expression_down	hsa-mir-30a	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-30a:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC
tissue_expression_down	hsa-mir-30d	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-30d:Seven human miRNAs (miR-126, miR-193a-3p, miR-30d, miR-30a, miR-101, let-7i, and miR-15a) were found to be significantly downregulated in lung SCC
tissue_expression_down	hsa-let-7a	Squamous Cell Carcinoma, Oral	26841253	disease of cellular proliferation	DOID:0050866					Downregulation of let-7a was associated with perineural invasion.
tissue_expression_down	hsa-let-7a	Squamous Cell Carcinoma, Oral	25245141	disease of cellular proliferation	DOID:0050866					Comparative analyses showed down-regulation of mir-98 in human samples and up-regulation of let-7a and mir-98 in canine neoplastic samples.
tissue_expression_down	hsa-let-7a	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_down	hsa-let-7d	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_down	hsa-let-7f	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_down	hsa-mir-125a	Squamous Cell Carcinoma, Oral	29480379	disease of cellular proliferation	DOID:0050866					increased miR-21 levels in conjunction with decreased miR-125a levels in saliva of OLP patients may be indicative for a poor prognosis
tissue_expression_down	hsa-mir-125b-2	Squamous Cell Carcinoma, Oral	25482863	disease of cellular proliferation	DOID:0050866					Our results corroborate the previous findings on the overexpression  of mir-21 and downregulation of miR-138 in OSCC. As the expression of miR-184 is controversial in tongue/oral cancer, the downregulation may be specific to tumor anatomical localization. On the other hand, to the best of our knowledge, this is the first report to show the association of miR-155 with tobacco chewing and the downregulation of miR-125b-2* in OSCC. Computational predictions suggest that miR-125b-2* may have a role in alternative splicing.
tissue_expression_down	hsa-mir-135b	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_down	hsa-mir-138	Squamous Cell Carcinoma, Oral	25482863	disease of cellular proliferation	DOID:0050866					Our results corroborate the previous findings on the overexpression  of mir-21 and downregulation of miR-138 in OSCC. As the expression of miR-184 is controversial in tongue/oral cancer, the downregulation may be specific to tumor anatomical localization. On the other hand, to the best of our knowledge, this is the first report to show the association of miR-155 with tobacco chewing and the downregulation of miR-125b-2* in OSCC. Computational predictions suggest that miR-125b-2* may have a role in alternative splicing.
tissue_expression_down	hsa-mir-143	Squamous Cell Carcinoma, Oral	26125902	disease of cellular proliferation	DOID:0050866					Decreased microRNA-143 expression and its tumor suppressive function in human oral squamous cell carcinoma.
tissue_expression_down	hsa-mir-143	Squamous Cell Carcinoma, Oral	26317418	disease of cellular proliferation	DOID:0050866					Overexpression of activin A in OSCCs, which is controlled by downregulation of miR-143/miR-145 cluster, regulates apoptosis, proliferation and invasiveness, and it is clinically correlated with lymph node metastasis and poor survival.
tissue_expression_down	hsa-mir-145	Squamous Cell Carcinoma, Oral	23548968	disease of cellular proliferation	DOID:0050866					Downregulation of miR-145 Expression in Oral Squamous Cell Carcinomas and Its Clinical Significance
tissue_expression_down	hsa-mir-145	Squamous Cell Carcinoma, Oral	26317418	disease of cellular proliferation	DOID:0050866					Overexpression of activin A in OSCCs, which is controlled by downregulation of miR-143/miR-145 cluster, regulates apoptosis, proliferation and invasiveness, and it is clinically correlated with lymph node metastasis and poor survival.
tissue_expression_down	hsa-mir-155	Squamous Cell Carcinoma, Oral	25482863	disease of cellular proliferation	DOID:0050866					Our results corroborate the previous findings on the overexpression  of mir-21 and downregulation of miR-138 in OSCC. As the expression of miR-184 is controversial in tongue/oral cancer, the downregulation may be specific to tumor anatomical localization. On the other hand, to the best of our knowledge, this is the first report to show the association of miR-155 with tobacco chewing and the downregulation of miR-125b-2* in OSCC. Computational predictions suggest that miR-125b-2* may have a role in alternative splicing.
tissue_expression_down	hsa-mir-16	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_down	hsa-mir-17	Squamous Cell Carcinoma, Oral	23780339	disease of cellular proliferation	DOID:0050866					miR-17-5p is induced in irradiated OC3 cells and it downregulates p21 protein expression, contributing to the radioresistance of OC3 cells.
tissue_expression_down	hsa-mir-197	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_down	hsa-mir-200b	Squamous Cell Carcinoma, Oral	26841253	disease of cellular proliferation	DOID:0050866					We observed downregulation of miR-200b and miR-203 in 60.0% and 71.4% of the samples
tissue_expression_down	hsa-mir-204	Squamous Cell Carcinoma, Oral	27470356	disease of cellular proliferation	DOID:0050866					The results showed that the expression of miR-204-5p was lower in cancer tissues or cells.
tissue_expression_down	hsa-mir-221	Squamous Cell Carcinoma, Oral	26788506	disease of cellular proliferation	DOID:0050866					In conclusion, downregulation of miR-221 inhibits cell migration and invasion at least partially through targeting MBD2 in the human OSCC cell line UM1.
tissue_expression_down	hsa-mir-224	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_down	hsa-mir-27a	Squamous Cell Carcinoma, Oral	24789751	disease of cellular proliferation	DOID:0050866					A microRNA-27a mimic sensitizes human oral squamous cell carcinoma HSC-4 cells to hyperthermia through downregulation of Hsp110 and Hsp90.
tissue_expression_down	hsa-mir-34a	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_down	hsa-mir-34a	Squamous Cell Carcinoma, Oral	26027785	disease of cellular proliferation	DOID:0050866					We observed downregulation of miR-15a, miR-29a, and miR-34a in 50, 75, and 70% of samples,
tissue_expression_down	hsa-mir-378a	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_down	hsa-mir-520h	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_down	hsa-mir-596	Squamous Cell Carcinoma, Oral	26502662	disease of cellular proliferation	DOID:0050866					Thus, these findings may help clarify the molecular mechanism of the tumor-suppressive effect through down-regulation of LGALS3BP by miR-596 in OSCC cells.
tissue_expression_down	hsa-mir-9	Squamous Cell Carcinoma, Oral	26813876	disease of cellular proliferation	DOID:0050866					Serum miR-9 was downregulated in patients with OSCC and patients with OLK. In addition, low serum miR-9 was correlated with poor prognosis of OSCC, indicating miR-9 might play a tumor suppressive role in OSCC and can serve as a promising biomarker for this deadly disease.
tissue_expression_down	hsa-mir-34a	Squamous Cell Carcinoma, Sinonasal	22624980							miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis.
tissue_expression_down	hsa-mir-140	Squamous Cell Carcinoma, Skin or Unspecific	23026055	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Non-stringent filtering with a non-adjusted p ≤ 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC
tissue_expression_down	hsa-mir-145	Squamous Cell Carcinoma, Skin or Unspecific	23026055	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Non-stringent filtering with a non-adjusted p ≤ 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC
tissue_expression_down	hsa-mir-204	Squamous Cell Carcinoma, Skin or Unspecific	27457246	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	cSCCs display a marked downregulation of miR-204 expression when compared to AK.
tissue_expression_down	hsa-mir-20a	Squamous Cell Carcinoma, Skin or Unspecific	26617873	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	The expression of miR-20a was lower in CSCC tissues compared with adjacent normal tissues
tissue_expression_down	hsa-mir-26a	Squamous Cell Carcinoma, Skin or Unspecific	23026055	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Non-stringent filtering with a non-adjusted p ≤ 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC
tissue_expression_down	hsa-mir-30a	Squamous Cell Carcinoma, Skin or Unspecific	23026055	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Non-stringent filtering with a non-adjusted p ≤ 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC
tissue_expression_down	hsa-mir-378	Squamous Cell Carcinoma, Skin or Unspecific	23026055	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Non-stringent filtering with a non-adjusted p ≤ 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC
tissue_expression_down	hsa-mir-421	Squamous Cell Carcinoma, Skin or Unspecific	23199656	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma
tissue_expression_down	hsa-mir-122	Stroke	28751928			I64	D020521	601367	HP:0001297	A Decrease of Brain MicroRNA-122 Level Is an Early Marker of Cerebrovascular Disease in the Stroke-Prone Spontaneously Hypertensive Rat.
tissue_expression_down	hsa-mir-126	Stroke	29642385			I64	D020521	601367	HP:0001297	Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant
tissue_expression_down	hsa-mir-125b-1	Systemic Lupus Erythematosus	23305626	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Further analysis showed that the down-regulation of miR-125b, mainly in T cells, was negatively correlated with lupus nephritis
tissue_expression_down	hsa-mir-125b-2	Systemic Lupus Erythematosus	23305626	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Further analysis showed that the down-regulation of miR-125b, mainly in T cells, was negatively correlated with lupus nephritis
tissue_expression_down	hsa-mir-15b	Systemic Lupus Erythematosus	26144250	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Moreover, we determined that the expression level of CCND3 was higher, while miR-15b was significantly lower in the B cells from SLE patients and B6.
tissue_expression_down	hsa-mir-181a-1	Systemic Lupus Erythematosus	21385555	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-181-a was significantly downregulated in SLE pediatrics as compared to healthy controls.
tissue_expression_down	hsa-mir-181a-2	Systemic Lupus Erythematosus	21385555	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-181-a was significantly downregulated in SLE pediatrics as compared to healthy controls.
tissue_expression_down	hsa-mir-133b	Testicular Neoplasms	19946373	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	downregulated
tissue_expression_down	hsa-mir-486	Testicular Neoplasms	19946373	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	miR-486-5p: downregulated
tissue_expression_down	hsa-mir-1-1	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_down	hsa-mir-1-2	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_down	hsa-mir-133b	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_down	hsa-mir-138-1	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_down	hsa-mir-138-2	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_down	hsa-mir-34b	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_down	hsa-mir-7	Thyroid Neoplasms	27430434	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	In the present study, miR鈥? was significantly downregulated in thyroid cancer tissues and cells compared with normal thyroid tissue samples.
tissue_expression_down	hsa-mir-146a	Tuberculosis	22964481	disease by infectious agent	DOID:399	A15-A19	D014376			we observed that miR-146a expression is also down-regulated in tuberculosis patients, both in PBMCs and PFMCs while miR-424 levels are elevated only in the peripheral compartments.
tissue_expression_down	hsa-mir-17	Tuberculosis	26513648	disease by infectious agent	DOID:399	A15-A19	D014376			tuberculosis infection leads to downregulation of miR-17 and  concomitant upregulation of its targets Mcl-1 and STAT3
tissue_expression_down	hsa-mir-125b	Tuberculosis, Pulmonary	27363278	disease by infectious agent	DOID:2957	A15	D014397			In PBMCs of children with PTB, miR-125b level is low.
tissue_expression_down	hsa-mir-19b-2	Tuberculosis, Pulmonary	22900099	disease by infectious agent	DOID:2957	A15	D014397			miR-19b-2*: Underexpression
tissue_expression_down	hsa-mir-10b	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-126	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-126	Urinary Bladder Cancer	18596939	urinary system disease	DOID:11054	C67	D001749	109800		miR-126: downregulated
tissue_expression_down	hsa-mir-143	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, downregulated.
tissue_expression_down	hsa-mir-143	Urinary Bladder Cancer	18596939	urinary system disease	DOID:11054	C67	D001749	109800		miR-143: downregulated
tissue_expression_down	hsa-mir-143	Urinary Bladder Cancer	22194833	urinary system disease	DOID:11054	C67	D001749	109800		mir-21 expression increased with worsening clinical diagnosis but that mir-143 was not correlated with histology. These observations were in stark contrast to previous reports involving cervical cancer cell lines in which mir-143 was consistently down-regulated but mir-21 largely unaffected.
tissue_expression_down	hsa-mir-145	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, downregulated.
tissue_expression_down	hsa-mir-145	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-145	Urinary Bladder Cancer	18596939	urinary system disease	DOID:11054	C67	D001749	109800		miR-145: downregulated
tissue_expression_down	hsa-mir-17	Urinary Bladder Cancer	22334592	urinary system disease	DOID:11054	C67	D001749	109800		The anticancer activity of CSL in 253JB-V cells is due to induction of ROS and ROS-mediated induction of Sp repressors (ZBTB4/ZBTB10) through downregulation of miR-27a and miR-20a/17-5p.
tissue_expression_down	hsa-mir-192	Urinary Bladder Cancer	22386240	urinary system disease	DOID:11054	C67	D001749	109800		Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant.
tissue_expression_down	hsa-mir-19a	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-200a	Urinary Bladder Cancer	22386240	urinary system disease	DOID:11054	C67	D001749	109800		Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant.
tissue_expression_down	hsa-mir-200b	Urinary Bladder Cancer	22386240	urinary system disease	DOID:11054	C67	D001749	109800		Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant.
tissue_expression_down	hsa-mir-200c	Urinary Bladder Cancer	22386240	urinary system disease	DOID:11054	C67	D001749	109800		Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant.
tissue_expression_down	hsa-mir-20a	Urinary Bladder Cancer	22334592	urinary system disease	DOID:11054	C67	D001749	109800		The anticancer activity of CSL in 253JB-V cells is due to induction of ROS and ROS-mediated induction of Sp repressors (ZBTB4/ZBTB10) through downregulation of miR-27a and miR-20a/17-5p.
tissue_expression_down	hsa-mir-214	Urinary Bladder Cancer	23337879	urinary system disease	DOID:11054	C67	D001749	109800		MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells
tissue_expression_down	hsa-mir-221	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-27a	Urinary Bladder Cancer	22334592	urinary system disease	DOID:11054	C67	D001749	109800		The anticancer activity of CSL in 253JB-V cells is due to induction of ROS and ROS-mediated induction of Sp repressors (ZBTB4/ZBTB10) through downregulation of miR-27a and miR-20a/17-5p.
tissue_expression_down	hsa-mir-296	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-300	Urinary Bladder Cancer	21223810	urinary system disease	DOID:11054	C67	D001749	109800		In grade I, grade II, grade III, grade I + II + III, infiltrating and non-infiltrating groups, hsa-miR-29b-1* was up-regulated while hsa-miR-923 and hsa-miR-300 were down-regulated
tissue_expression_down	hsa-mir-31	Urinary Bladder Cancer	23408039	urinary system disease	DOID:11054	C67	D001749	109800		Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer
tissue_expression_down	hsa-mir-378a	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378b	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378c	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378d-1	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378d-2	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378e	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378f	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378g	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378h	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-378i	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		miR-10b, 19a, 126, 145, 221, 296-5p and 378 were significantly down-regulated in bladder cancer compared to adjacent normal urothelium.
tissue_expression_down	hsa-mir-145	Urinary System Cancer	29623292	disease of cellular proliferation	DOID:3996	C68.9				the decline of miR-145 expression level have been proved to be able to distinguish bladder cancer patients from non-cancer controls in cell-free urine samples; the elevation of miR-10a and miR-30d was also observed in urine samples from patients with focal segmental glomerulosclerosis
tissue_expression_down	hsa-mir-145	Uveal Melanoma	24762580				C536494	155720	HP:0007716	MiR-145 might act as a tumor suppressor in uveal melanoma, and downregulation of the target IRS-1 might be a potential mechanism.
tissue_expression_down	hsa-mir-145	Vascular Disease [unspecific]	28104472	cardiovascular system disease	DOID:178	I72.9	D000783			Downregulation of miR-145 in venous malformations: Its association with disorganized vessels and sclerotherapy.
tissue_expression_down	hsa-mir-1	Vascular Hypertrophy	17008435							MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy.
tissue_expression_down	hsa-mir-133a	Vascular Hypertrophy	17008435							MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy.
tissue_expression_down	hsa-mir-190b	Vasomotor Rhinitis	28787742	respiratory system disease	DOID:4730	J30.0	D012223			there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p.
tissue_expression_down	hsa-mir-2110	Vasomotor Rhinitis	28787742	respiratory system disease	DOID:4730	J30.0	D012223			there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p.
tissue_expression_down	hsa-mir-449b	Vasomotor Rhinitis	28787742	respiratory system disease	DOID:4730	J30.0	D012223			there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p.
tissue_expression_down	hsa-mir-449c	Vasomotor Rhinitis	28787742	respiratory system disease	DOID:4730	J30.0	D012223			there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p.
tissue_expression_down	hsa-mir-92b	Vasomotor Rhinitis	28787742	respiratory system disease	DOID:4730	J30.0	D012223			there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p.
tissue_expression_down	hsa-mir-27a	Viral Infectious Disease	26700765	disease by infectious agent	DOID:934	A94	D001102			Therefore,type I IFN-induced downregulation of miR-27a can upregulate Siglec1 and TRIM27 expression, feedback inhibiting type I IFN production in antiviral innate response.
tissue_expression_down	hsa-mir-145	Vitiligo	26941046	immune system disease	DOID:12306	L80	D014820		HP:0001045	miR-99b, miR-125b, miR-155 and miR-199a-3p were found to be increased and miR-145 was found to be decreased in the skin of patients with vitiligo.
tissue_expression_down	hsa-mir-9	Waldenstrom Macroglobulinemia	23301642			C88.0	D008258	153600	HP:0005508	The most important changes of microRNA are increased expression of miR-155 and decreased expression of miR-9*. 
tissue_expression_ns	hsa-mir-4793	Necrotizing Enterocolitis	26274503	gastrointestinal system disease	DOID:8677	K55.3	D020345			The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology.
tissue_expression_ns	hsa-mir-29a	Acquired Immunodeficiency Syndrome	28692540	disease by infectious agent	DOID:635	B20	D000163	609423		Unique microRNA expression in the colonic mucosa during chronic HIV-1 infection.
tissue_expression_ns	hsa-mir-221	Acute Liver Failure	24913549			K72	D017114	613070		In liver biopsies, miR-21 and miR-221 displayed a reciprocal expression pattern and were found at lower levels in the spontaneous survivors, whereas miR-122 was elevated  in both serum and liver tissue of those patients.
tissue_expression_ns	hsa-mir-191	Acute Myocardial Infarction	26046358	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination.
tissue_expression_ns	hsa-mir-26b	Acute Myocardial Infarction	26046358	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination.
tissue_expression_ns	hsa-mir-186	Acute Peritonitis	29360196	gastrointestinal system disease	DOID:8283	K65.0	D010538		HP:0002586	The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-21	Acute Peritonitis	29360196	gastrointestinal system disease	DOID:8283	K65.0	D010538		HP:0002586	The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-222	Acute Peritonitis	29360196	gastrointestinal system disease	DOID:8283	K65.0	D010538		HP:0002586	The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-223	Acute Peritonitis	29360196	gastrointestinal system disease	DOID:8283	K65.0	D010538		HP:0002586	The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-483	Acute Peritonitis	29360196	gastrointestinal system disease	DOID:8283	K65.0	D010538		HP:0002586	The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-18a	Acute Respiratory Distress Syndrome	25070658	respiratory system disease	DOID:11394	J80	D012128			miR-26a, miR-346, miR-135b, miR-30a/b, miR-344, and miR-18a targeted multiple altered mRNAs.
tissue_expression_ns	hsa-mir-135b	Adenocarcinoma, Cervical	25230213	disease of cellular proliferation	DOID:3702					MiR-135b, miR-192, and miR-194 are altered in uterine cervical ACA, and miR-363-3p is an independent favorable prognostic factor in ACA. These miRNAs could be of value as biomarkers for the diagnosis and prognosis of ACA.
tissue_expression_ns	hsa-mir-192	Adenocarcinoma, Cervical	25230213	disease of cellular proliferation	DOID:3702					MiR-135b, miR-192, and miR-194 are altered in uterine cervical ACA, and miR-363-3p is an independent favorable prognostic factor in ACA. These miRNAs could be of value as biomarkers for the diagnosis and prognosis of ACA.
tissue_expression_ns	hsa-mir-194	Adenocarcinoma, Cervical	25230213	disease of cellular proliferation	DOID:3702					MiR-135b, miR-192, and miR-194 are altered in uterine cervical ACA, and miR-363-3p is an independent favorable prognostic factor in ACA. These miRNAs could be of value as biomarkers for the diagnosis and prognosis of ACA.
tissue_expression_ns	hsa-mir-145	Adenocarcinoma, Colon	24791633	disease of cellular proliferation	DOID:234	C18			HP:0040276	Differential expression of microRNA-320a, -145, and-192 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum.
tissue_expression_ns	hsa-mir-192	Adenocarcinoma, Colon	24791633	disease of cellular proliferation	DOID:234	C18			HP:0040276	Differential expression of microRNA-320a, -145, and-193 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum.
tissue_expression_ns	hsa-mir-21	Adenocarcinoma, Colon	19547998	disease of cellular proliferation	DOID:234	C18			HP:0040276	differential expression, with highest expression levels in SSAs; Levels of miR-181b but not miR-21 differed in HPs and normal mucosa; SSAs exhibited both significantly higher miR-181b levels and miR-21 levels; discriminating potential diagnostic value HP from SSA
tissue_expression_ns	hsa-mir-320a	Adenocarcinoma, Colon	24791633	disease of cellular proliferation	DOID:234	C18			HP:0040276	Differential expression of microRNA-320a, -145, and-194 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum.
tissue_expression_ns	hsa-mir-148	Adenocarcinoma, Esophageal	25928282	disease of cellular proliferation	DOID:4914		C562730	133239		Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer.
tissue_expression_ns	hsa-mir-203	Adenocarcinoma, Esophageal	25928282	disease of cellular proliferation	DOID:4914		C562730	133239		Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer.
tissue_expression_ns	hsa-mir-203	Adenocarcinoma, Esophageal	25784377	disease of cellular proliferation	DOID:4914		C562730	133239		We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC.
tissue_expression_ns	hsa-mir-205	Adenocarcinoma, Esophageal	25784377	disease of cellular proliferation	DOID:4914		C562730	133239		We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC.
tissue_expression_ns	hsa-mir-21	Adenocarcinoma, Esophageal	25928282	disease of cellular proliferation	DOID:4914		C562730	133239		Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer.
tissue_expression_ns	hsa-mir-210	Adenocarcinoma, Esophageal	25784377	disease of cellular proliferation	DOID:4914		C562730	133239		We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC.
tissue_expression_ns	hsa-mir-29c	Adenocarcinoma, Esophageal	25928282	disease of cellular proliferation	DOID:4914		C562730	133239		Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer.
tissue_expression_ns	hsa-mir-378	Adenocarcinoma, Esophageal	25784377	disease of cellular proliferation	DOID:4914		C562730	133239		We suggest that miRNA expression profiling expands current knowledge in molecular pathology of Barrett's-based carcinogenesis and enables identification of molecular biomarkers for early detection of BE dysplasia and progression to EAC.
tissue_expression_ns	hsa-let-7	Adenocarcinoma, Gastric	27422560	disease of cellular proliferation	DOID:3717	D37.1	D013274			The integrated analysis of miRNA and gene expression profiles showed the let-7 miRNA family playing a central role in the regulatory relationships.
tissue_expression_ns	hsa-let-7c	Adenocarcinoma, Gastric	27422560	disease of cellular proliferation	DOID:3717	D37.1	D013274			The miRNAs 100, let-7c, 125b and 99a stood out for their association  with the diffuse histological subtype.
tissue_expression_ns	hsa-mir-372	Adenocarcinoma, Gastric	29135097	disease of cellular proliferation	DOID:3717	D37.1	D013274			Analysis of expression profile of miRNA in stomach adenocarcinoma.
tissue_expression_ns	hsa-mir-192	Adenocarcinoma, Gastric-Esophageal Junction	25429911	disease of cellular proliferation	DOID:4944					Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected.
tissue_expression_ns	hsa-mir-21	Adenocarcinoma, Gastric-Esophageal Junction	25429911	disease of cellular proliferation	DOID:4944					Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected.
tissue_expression_ns	hsa-mir-222	Adenocarcinoma, Gastric-Esophageal Junction	25429911	disease of cellular proliferation	DOID:4944					Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected.
tissue_expression_ns	hsa-mir-302c	Adenocarcinoma, Gastric-Esophageal Junction	25429911	disease of cellular proliferation	DOID:4944					Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected.
tissue_expression_ns	hsa-mir-381	Adenocarcinoma, Gastric-Esophageal Junction	25429911	disease of cellular proliferation	DOID:4944					Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected.
tissue_expression_ns	hsa-mir-549	Adenocarcinoma, Gastric-Esophageal Junction	25429911	disease of cellular proliferation	DOID:4944					Comprehensive miRNA profiling showed a differential microRNA expression pattern depending on the histomorphologic regression in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. Moreover, using single RT-PCR analyses a prognostic impact of miR-222 and miR-302c was detected.
tissue_expression_ns	hsa-let-7b	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-101-1	Adenocarcinoma, Lung	24893932	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.
tissue_expression_ns	hsa-mir-106b	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-126	Adenocarcinoma, Lung	27277197	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Low levels of miR-126-3p and miR-451a were associated with poor pathological stage, large tumor diameter and lymph node metastasis
tissue_expression_ns	hsa-mir-149	Adenocarcinoma, Lung	28345454	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
tissue_expression_ns	hsa-mir-151a	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-187	Adenocarcinoma, Lung	24893932	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.
tissue_expression_ns	hsa-mir-187	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-195	Adenocarcinoma, Lung	24903339	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features.
tissue_expression_ns	hsa-mir-196b	Adenocarcinoma, Lung	24893932	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.
tissue_expression_ns	hsa-mir-205	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-21	Adenocarcinoma, Lung	27081085	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified a regulatory network including miR-15b and miR-155, and transcription factors with prognostic value in lung cancer.
tissue_expression_ns	hsa-mir-215	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-25	Adenocarcinoma, Lung	24606441	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Tissue miR-25 expression may be associated with tumor progression and have prognostic implications in female lung ADC patients.
tissue_expression_ns	hsa-mir-30d	Adenocarcinoma, Lung	24903339	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features.
tissue_expression_ns	hsa-mir-31	Adenocarcinoma, Lung	24893932	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.
tissue_expression_ns	hsa-mir-31	Adenocarcinoma, Lung	27695346	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	MicroRNA expression profiles predict progression and clinical outcome in lung adenocarcinoma.
tissue_expression_ns	hsa-mir-331	Adenocarcinoma, Lung	24893932	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.
tissue_expression_ns	hsa-mir-34a	Adenocarcinoma, Lung	26104764	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients.
tissue_expression_ns	hsa-mir-370	Adenocarcinoma, Lung	24833665	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Different morphologic subtypes of lung AC have distinct miRNA expression profiles, and 3 miRNAs encoded at 14q32 (miR-411, miR-370, and miR-376a) were associated with poor survival after lung AC resection.
tissue_expression_ns	hsa-mir-375	Adenocarcinoma, Lung	24893932	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.
tissue_expression_ns	hsa-mir-376a	Adenocarcinoma, Lung	24833665	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Different morphologic subtypes of lung AC have distinct miRNA expression profiles, and 3 miRNAs encoded at 14q32 (miR-411, miR-370, and miR-376a) were associated with poor survival after lung AC resection.
tissue_expression_ns	hsa-mir-411	Adenocarcinoma, Lung	24833665	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Different morphologic subtypes of lung AC have distinct miRNA expression profiles, and 3 miRNAs encoded at 14q32 (miR-411, miR-370, and miR-376a) were associated with poor survival after lung AC resection.
tissue_expression_ns	hsa-mir-449b	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-451a	Adenocarcinoma, Lung	27277197	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Low levels of miR-126-3p and miR-451a were associated with poor pathological stage, large tumor diameter and lymph node metastasis
tissue_expression_ns	hsa-mir-452	Adenocarcinoma, Lung	28488527	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Clinical value of miR-452-5p expression in lung adenocarcinoma: A retrospective quantitative real-time polymerase chain reaction study and verification based on The Cancer Genome Atlas and Gene Expression Omnibus databases.
tissue_expression_ns	hsa-mir-512	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-519a-1	Adenocarcinoma, Lung	24893932	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.
tissue_expression_ns	hsa-mir-520b	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-650	Adenocarcinoma, Lung	23991130	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-650 is a novel prognostic marker in LAD and its expression is a potential indicator of chemosensitivity to docetaxel-based chemotherapy regimen.
tissue_expression_ns	hsa-mir-7	Adenocarcinoma, Lung	28618418	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Prognostic Significance of microRNA-7 and its Roles in the Regulation of Cisplatin Resistance in Lung Adenocarcinoma.
tissue_expression_ns	hsa-mir-766	Adenocarcinoma, Lung	24893932	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	We identified an eight-miRNA signature that is prognostic of LUAD.The miRNA signature, if validated in other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of patients with LUAD who are at high risk of mortality.
tissue_expression_ns	hsa-mir-774	Adenocarcinoma, Lung	25028925	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	The most significant differences in mRNA expression for recurrent tumors compared to non-recurrent tumors were decreases in miR-106b*, -187, -205, -449b,  -774* and increases in miR-151-3p, let-7b, miR-215, -520b, and -512-3p.
tissue_expression_ns	hsa-mir-1	Adenocarcinoma, Pancreatic Ductal	29085459	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Abnormal alterations of miR-1 and miR-214 are associated with clinicopathological features and prognosis of patients with PDAC.
tissue_expression_ns	hsa-mir-100	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-143	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-148a	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-155	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-155	Adenocarcinoma, Pancreatic Ductal	21068491	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA-21 and microRNA-155 in pancreatic juice have the potential of becoming biomarkers for diagnosing pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-192	Adenocarcinoma, Pancreatic Ductal	23612862	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miRNA expression profiling of human PDACs and adjacent normal pancreatic tissues identified 16 upregulated miRNAs including miR-192 and 8 downregulated miRNAs.
tissue_expression_ns	hsa-mir-198	Adenocarcinoma, Pancreatic Ductal	25908274	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	25908274	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	21068491	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		MicroRNA-21 and microRNA-155 in pancreatic juice have the potential of becoming biomarkers for diagnosing pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	27086919	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		We provide further evidence for using miRNAs as diagnostic biomarkers for pancreatic malignancy.
tissue_expression_ns	hsa-mir-214	Adenocarcinoma, Pancreatic Ductal	29085459	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Abnormal alterations of miR-1 and miR-214 are associated with clinicopathological features and prognosis of patients with PDAC.
tissue_expression_ns	hsa-mir-216	Adenocarcinoma, Pancreatic Ductal	17237814	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The expression of miR-216 and -217 and lack of expression of miR-133a were identified as characteristic of pancreas tissue.
tissue_expression_ns	hsa-mir-217	Adenocarcinoma, Pancreatic Ductal	25908274	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-217	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-217	Adenocarcinoma, Pancreatic Ductal	17237814	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The expression of miR-216 and -217 and lack of expression of miR-133a were identified as characteristic of pancreas tissue.
tissue_expression_ns	hsa-mir-217	Adenocarcinoma, Pancreatic Ductal	28539816	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.
tissue_expression_ns	hsa-mir-221	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-222	Adenocarcinoma, Pancreatic Ductal	26002251	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		we found significant adjusted HRs for poor OS for high miR-155, high miR-203, and low miR-34a; and unadjusted HRs for high miR-222 and high miR-10b.
tissue_expression_ns	hsa-mir-23a	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-31	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-34a	Adenocarcinoma, Pancreatic Ductal	25908274	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-375	Adenocarcinoma, Pancreatic Ductal	24575833	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A microRNA meta-signature for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-96	Adenocarcinoma, Pancreatic Ductal	28539816	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.
tissue_expression_ns	hsa-mir-141	Adenocarcinoma, Sebaceous	28119291	disease of cellular proliferation	DOID:4839	C44.99	D018266			miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma.
tissue_expression_ns	hsa-mir-200c	Adenocarcinoma, Sebaceous	28119291	disease of cellular proliferation	DOID:4839	C44.99	D018266			miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma.
tissue_expression_ns	hsa-mir-195	Adrenal Cortex Neoplasms	29429354	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were  found to be differentially expressed among benign and malignant adrenocortical tumours
tissue_expression_ns	hsa-mir-210	Adrenal Cortex Neoplasms	29429354	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were  found to be differentially expressed among benign and malignant adrenocortical tumours
tissue_expression_ns	hsa-mir-335	Adrenal Cortex Neoplasms	29429354	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were  found to be differentially expressed among benign and malignant adrenocortical tumours
tissue_expression_ns	hsa-mir-483	Adrenal Cortex Neoplasms	29429354	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were  found to be differentially expressed among benign and malignant adrenocortical tumours
tissue_expression_ns	hsa-mir-503	Adrenal Cortex Neoplasms	29429354	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	Several tissue microRNAs, such as miR-483-5p, miR-503, miR-210, miR-335 and miR-195 were  found to be differentially expressed among benign and malignant adrenocortical tumours
tissue_expression_ns	hsa-mir-181a	African Swine Fever	29041944				D000357			Differential expression of porcine microRNAs in African swine fever virus infected pigs: a proof-of-concept study.
tissue_expression_ns	hsa-let-7g	Alzheimer Disease	26497684	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
tissue_expression_ns	hsa-mir-10a	Alzheimer Disease	26497684	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
tissue_expression_ns	hsa-mir-153	Alzheimer Disease	26497684	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
tissue_expression_ns	hsa-mir-409	Alzheimer Disease	26497684	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
tissue_expression_ns	hsa-mir-129	Amyotrophic Lateral Sclerosis	27773796	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	MicroRNA expression profiles of multiple system atrophy from formalin-fixed paraffin-embedded samples.
tissue_expression_ns	hsa-mir-132	Amyotrophic Lateral Sclerosis	27773796	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	MicroRNA expression profiles of multiple system atrophy from formalin-fixed paraffin-embedded samples.
tissue_expression_ns	hsa-mir-1	Aortic Aneurysm	27939432	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization.
tissue_expression_ns	hsa-mir-143	Aortic Aneurysm	27939432	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization.
tissue_expression_ns	hsa-mir-145	Aortic Aneurysm	27939432	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization.
tissue_expression_ns	hsa-mir-22	Aortic Aneurysm	27939432	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization.
tissue_expression_ns	hsa-mir-378a	Aortic Aneurysm	27939432	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	Regulation of microRNA expression in vascular smooth muscle by MRTF-A and actin polymerization.
tissue_expression_ns	hsa-mir-29a	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-29b-1	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-29b-2	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-29c	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-30a	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-30b	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-30c-1	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-30c-2	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-30d	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-30e	Aortic Aneurysm, Thoracic	21334170	cardiovascular system disease	DOID:14004	I71.1-.2	D017545	607086		dysregulated
tissue_expression_ns	hsa-mir-146b	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-193a	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-194	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-1972	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-200b	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-21	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-29b	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-301a	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-3138	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-34a	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-3663	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-505	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-513a	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-516a	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-575	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-630	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-636	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-718	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-mir-99b	Aortic Stenosis	27579316	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	MicroRNA Expression Signature in Degenerative Aortic Stenosis.
tissue_expression_ns	hsa-let-7d	Asthma	23885321	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Differential expression of miR-1248, miR-26a, Let-7a, and Let-7d were observed in asthmatic patients compared to controls.
tissue_expression_ns	hsa-mir-146a	Asthma	25217662	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle.
tissue_expression_ns	hsa-mir-146b	Asthma	25217662	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle.
tissue_expression_ns	hsa-mir-155	Asthma	28199728	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Altered miR-155 Expression in Allergic Asthmatic Airways.
tissue_expression_ns	hsa-mir-210	Astrocytoma	24729345	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	MiR-210 levels can be potentially established as a biomarker for pathological diagnosis of malignant astrocytic tumour progression. In addition,the expression of miR-210 can be utilized as an additional identification measure of glioma tumour origin.
tissue_expression_ns	hsa-mir-10a	Atherosclerosis	28403739	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Hydrogen Peroxide and Lipopolysaccharide Differentially Affect the Expression of MicroRNAs 10a, 33a, 21, 221 in Endothelial Cells Before and After Coculture With Monocytes.
tissue_expression_ns	hsa-mir-143	Atherosclerosis	20351064	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Thus, dysregulation of the miR-143 and -145 genes is causally involved in the aberrant SMC plasticity encountered during vascular disease, in part through the up-regulation of an autoregulatory loop that promotes podosome formation.
tissue_expression_ns	hsa-mir-143	Atherosclerosis	27631489	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Differential Expression of MicroRNAs in Endarterectomy Specimens Taken from Patients with Asymptomatic and Symptomatic Carotid Plaques.
tissue_expression_ns	hsa-mir-145	Atherosclerosis	20351064	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Thus, dysregulation of the miR-143 and -145 genes is causally involved in the aberrant SMC plasticity encountered during vascular disease, in part through the up-regulation of an autoregulatory loop that promotes podosome formation.
tissue_expression_ns	hsa-mir-155	Atherosclerosis	28234622	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	CagA-positive and CagA-negative Helicobacter pylori strains differentially affect the expression of micro RNAs 21, 92a, 155 and 663 in human umbilical vein endothelial cells.
tissue_expression_ns	hsa-mir-21	Atherosclerosis	27631489	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Differential Expression of MicroRNAs in Endarterectomy Specimens Taken from Patients with Asymptomatic and Symptomatic Carotid Plaques.
tissue_expression_ns	hsa-mir-21	Atherosclerosis	28234622	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	CagA-positive and CagA-negative Helicobacter pylori strains differentially affect the expression of micro RNAs 21, 92a, 155 and 663 in human umbilical vein endothelial cells.
tissue_expression_ns	hsa-mir-21	Atherosclerosis	28403739	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Hydrogen Peroxide and Lipopolysaccharide Differentially Affect the Expression of MicroRNAs 10a, 33a, 21, 221 in Endothelial Cells Before and After Coculture With Monocytes.
tissue_expression_ns	hsa-mir-221	Atherosclerosis	28403739	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Hydrogen Peroxide and Lipopolysaccharide Differentially Affect the Expression of MicroRNAs 10a, 33a, 21, 221 in Endothelial Cells Before and After Coculture With Monocytes.
tissue_expression_ns	hsa-mir-33a	Atherosclerosis	28403739	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Hydrogen Peroxide and Lipopolysaccharide Differentially Affect the Expression of MicroRNAs 10a, 33a, 21, 221 in Endothelial Cells Before and After Coculture With Monocytes.
tissue_expression_ns	hsa-mir-663	Atherosclerosis	28234622	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	CagA-positive and CagA-negative Helicobacter pylori strains differentially affect the expression of micro RNAs 21, 92a, 155 and 663 in human umbilical vein endothelial cells.
tissue_expression_ns	hsa-mir-92a	Atherosclerosis	28234622	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	CagA-positive and CagA-negative Helicobacter pylori strains differentially affect the expression of micro RNAs 21, 92a, 155 and 663 in human umbilical vein endothelial cells.
tissue_expression_ns	hsa-mir-1	Atrial Fibrillation	24461008	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients.
tissue_expression_ns	hsa-mir-106a	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-106b	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-144	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-15b	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-19	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-208a	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-21	Atrial Fibrillation	24069193	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The expression of miRNA-21 in human atrial tissue was found to be related to atrial fibrosis and might affect AF occurrence, indicating its usefulness as a biomarker for cardiac surgery management.
tissue_expression_ns	hsa-mir-23a	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-25	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-26a	Atrial Fibrillation	24461008	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients.
tissue_expression_ns	hsa-mir-30a	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-3613	Atrial Fibrillation	24461008	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients.
tissue_expression_ns	hsa-mir-363	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-451	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-466	Atrial Fibrillation	24461008	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients.
tissue_expression_ns	hsa-mir-486	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-574	Atrial Fibrillation	24461008	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	AF alters the miRNA expression profiles of the left atria of MS patients. These findings may be useful for the biological understanding of AF in MS patients.
tissue_expression_ns	hsa-mir-590	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-93	Atrial Fibrillation	24824214	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation.
tissue_expression_ns	hsa-mir-146a	Autism Spectrum Disorder	26753090	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	We identified a signature of four miRNAs (miR-146a, miR-221, miR-654-5p, and miR-656) commonly deregulated in ASD.
tissue_expression_ns	hsa-mir-221	Autism Spectrum Disorder	26753090	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	We identified a signature of four miRNAs (miR-146a, miR-221, miR-654-5p, and miR-656) commonly deregulated in ASD.
tissue_expression_ns	hsa-mir-106a	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-106a: deregulation
tissue_expression_ns	hsa-mir-106b	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-106b: deregulation
tissue_expression_ns	hsa-mir-129-1	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-129: deregulation
tissue_expression_ns	hsa-mir-129-2	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-129: deregulation
tissue_expression_ns	hsa-mir-132	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-132: deregulation
tissue_expression_ns	hsa-mir-140	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-140: deregulation
tissue_expression_ns	hsa-mir-146b	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-146b: deregulation
tissue_expression_ns	hsa-mir-148b	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-148b: deregulation
tissue_expression_ns	hsa-mir-15a	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-15a: deregulation
tissue_expression_ns	hsa-mir-15b	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-15b: deregulation
tissue_expression_ns	hsa-mir-181d	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-181d: deregulation
tissue_expression_ns	hsa-mir-193b	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-193b: deregulation
tissue_expression_ns	hsa-mir-21	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-21: deregulation
tissue_expression_ns	hsa-mir-212	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-212: deregulation
tissue_expression_ns	hsa-mir-23a	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-23a: deregulation
tissue_expression_ns	hsa-mir-27a	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-27a: deregulation
tissue_expression_ns	hsa-mir-381	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-381: deregulation
tissue_expression_ns	hsa-mir-431	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-431: deregulation
tissue_expression_ns	hsa-mir-432	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-432: deregulation
tissue_expression_ns	hsa-mir-484	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-484: deregulation
tissue_expression_ns	hsa-mir-539	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-539: deregulation
tissue_expression_ns	hsa-mir-550a-1	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-550: deregulation
tissue_expression_ns	hsa-mir-550a-2	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-550: deregulation
tissue_expression_ns	hsa-mir-598	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-598: deregulation
tissue_expression_ns	hsa-mir-652	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-652: deregulation
tissue_expression_ns	hsa-mir-7-1	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-7: deregulation
tissue_expression_ns	hsa-mir-7-2	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-7: deregulation
tissue_expression_ns	hsa-mir-7-3	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-7: deregulation
tissue_expression_ns	hsa-mir-93	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-93: deregulation
tissue_expression_ns	hsa-mir-95	Autistic Disorder	18563458	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-95: deregulation
tissue_expression_ns	hsa-mir-199a	Autoimmune Diseases [unspecific]	27871116				D001327	607836	HP:0002960	Excess glucocorticoids have been shown to modulate the expression of miRNAs, including miR-29a, miR-34a-5p, and miR-199a-5p, which regulate the proliferation and differentiation of osteoblast lineage cells
tissue_expression_ns	hsa-mir-223	Autoimmune Diseases [unspecific]	26879236				D001327	607836	HP:0002960	using co-expression analysis of miRNA expression  levels we showed that multiple miRNA contribute to multiple pathways that might be involved in pathogenesis of autoimmune skin blistering disease.
tissue_expression_ns	hsa-mir-29a	Autoimmune Diseases [unspecific]	27871116				D001327	607836	HP:0002960	Excess glucocorticoids have been shown to modulate the expression of miRNAs, including miR-29a, miR-34a-5p, and miR-199a-5p, which regulate the proliferation and differentiation of osteoblast lineage cells
tissue_expression_ns	hsa-mir-34a	Autoimmune Diseases [unspecific]	27871116				D001327	607836	HP:0002960	Excess glucocorticoids have been shown to modulate the expression of miRNAs, including miR-29a, miR-34a-5p, and miR-199a-5p, which regulate the proliferation and differentiation of osteoblast lineage cells
tissue_expression_ns	hsa-mir-155	Autoimmune Thyroiditis	24554510	immune system disease	DOID:7188	E06.3	D013967	109100		microRNA expressions in CD4+ and CD8+ T-cell subsets in autoimmune thyroid diseases.
tissue_expression_ns	hsa-mir-200a	Autoimmune Thyroiditis	24554510	immune system disease	DOID:7188	E06.3	D013967	109100		microRNA expressions in CD4+ and CD8+ T-cell subsets in autoimmune thyroid diseases.
tissue_expression_ns	hsa-mir-17	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-17: deregulation
tissue_expression_ns	hsa-mir-18a	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-18a: deregulation
tissue_expression_ns	hsa-mir-19a	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-19a: deregulation
tissue_expression_ns	hsa-mir-19b-1	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-19b: deregulation
tissue_expression_ns	hsa-mir-19b-2	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-19b: deregulation
tissue_expression_ns	hsa-mir-20a	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-20a: deregulation
tissue_expression_ns	hsa-mir-302a	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-302a: deregulation
tissue_expression_ns	hsa-mir-371a	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	mir-371: deregulation
tissue_expression_ns	hsa-mir-372	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	mir-372: deregulation
tissue_expression_ns	hsa-mir-373	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	mir-373: deregulation
tissue_expression_ns	hsa-mir-383	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-383: deregulation
tissue_expression_ns	hsa-mir-491	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-491-3p: deregulation
tissue_expression_ns	hsa-mir-520d	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-520d-3p: deregulation
tissue_expression_ns	hsa-mir-92a-1	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-92a: deregulation
tissue_expression_ns	hsa-mir-92a-2	Azoospermia	19210773	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	miR-92a: deregulation
tissue_expression_ns	hsa-mir-127	Balkan Nephropathy	27218105	urinary system disease	DOID:3052	N15.0	D001449	124100		 Only three microRNAs (hsa-miR-127-3p, hsa-miR-154-5p, and hsa-miR-30a-5p) were downregulated among BEN-UTUC, and one microRNA (hsa-miR-663b) was downregulated among non-BEN-UTUC samples
tissue_expression_ns	hsa-mir-154	Balkan Nephropathy	27218105	urinary system disease	DOID:3052	N15.0	D001449	124100		 Only three microRNAs (hsa-miR-127-3p, hsa-miR-154-5p, and hsa-miR-30a-5p) were downregulated among BEN-UTUC, and one microRNA (hsa-miR-663b) was downregulated among non-BEN-UTUC samples
tissue_expression_ns	hsa-mir-30a	Balkan Nephropathy	27218105	urinary system disease	DOID:3052	N15.0	D001449	124100		 Only three microRNAs (hsa-miR-127-3p, hsa-miR-154-5p, and hsa-miR-30a-5p) were downregulated among BEN-UTUC, and one microRNA (hsa-miR-663b) was downregulated among non-BEN-UTUC samples
tissue_expression_ns	hsa-mir-663b	Balkan Nephropathy	27218105	urinary system disease	DOID:3052	N15.0	D001449	124100		 Only three microRNAs (hsa-miR-127-3p, hsa-miR-154-5p, and hsa-miR-30a-5p) were downregulated among BEN-UTUC, and one microRNA (hsa-miR-663b) was downregulated among non-BEN-UTUC samples
tissue_expression_ns	hsa-let-7a-1	Barrett Esophagus	21407181	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	differential expression between Barrett Esophagus patients with and without dysplasia.
tissue_expression_ns	hsa-let-7a-2	Barrett Esophagus	21407181	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	differential expression between Barrett Esophagus patients with and without dysplasia.
tissue_expression_ns	hsa-let-7a-3	Barrett Esophagus	21407181	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	differential expression between Barrett Esophagus patients with and without dysplasia.
tissue_expression_ns	hsa-mir-145	Barrett Esophagus	21407181	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	differential expression between Barrett Esophagus patients with and without dysplasia.
tissue_expression_ns	hsa-mir-15b	Barrett Esophagus	21407181	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	differential expression between Barrett Esophagus patients with and without dysplasia.
tissue_expression_ns	hsa-mir-192	Barrett Esophagus	26572780	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies.
tissue_expression_ns	hsa-mir-194	Barrett Esophagus	26572780	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies.
tissue_expression_ns	hsa-mir-196a-1	Barrett Esophagus	19342367	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-196a: Marker of Progression
tissue_expression_ns	hsa-mir-196a-2	Barrett Esophagus	19342367	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-196a: Marker of Progression
tissue_expression_ns	hsa-mir-203	Barrett Esophagus	21407181	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	differential expression between Barrett Esophagus patients with and without dysplasia.
tissue_expression_ns	hsa-mir-203	Barrett Esophagus	26572780	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies.
tissue_expression_ns	hsa-mir-205	Barrett Esophagus	26572780	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies.
tissue_expression_ns	hsa-mir-21	Barrett Esophagus	21407181	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	differential expression between Barrett Esophagus patients with and without dysplasia.
tissue_expression_ns	hsa-mir-215	Barrett Esophagus	26572780	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies.
tissue_expression_ns	hsa-mir-486	Barrett Esophagus	21407181	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	differential expression between Barrett Esophagus patients with and without dysplasia.
tissue_expression_ns	hsa-mir-100	Bladder Neoplasms	26489968			C67	D001749	109800	HP:0009725	MiRNAs detected in urine and serum/plasma will demonstrate their potentiality to describe the variegated scenario of BC and to become relevant clinical markers.
tissue_expression_ns	hsa-mir-106b	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-125b	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-125b	Bladder Neoplasms	25014919			C67	D001749	109800	HP:0009725	The results revealed a unique microRNA expression signature in the urine supernatants of UCB patients for the development of molecular diagnostic tests. An effective cell-free urinary microRNA-based model was developed using a combined index of the levels of microRNA-99a and microRNA-125b to detect UCB with good discriminating power, high sensitivity and high specificity.
tissue_expression_ns	hsa-mir-126	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-130a	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-130b	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-139	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-141	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-141	Bladder Neoplasms	27357429			C67	D001749	109800	HP:0009725	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-141	Bladder Neoplasms	19945312			C67	D001749	109800	HP:0009725	The diagnostic test, based on the three most discriminatory miRNAs in our panel (miR-200c, miR-141, and miR-30b), showed a sensitivity of 100% and a specificity of 96.2%. Such a panel of miRNAs has the potential to identify invasive bladder tumors misclassified in pathologic assessment of bladder biopsy specimens.
tissue_expression_ns	hsa-mir-145	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-145	Bladder Neoplasms	22961325			C67	D001749	109800	HP:0009725	Assessment of miR-145 levels was able to distinguish bladder cancer patients from non-cancer controls
tissue_expression_ns	hsa-mir-150	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-15b	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-195	Bladder Neoplasms	24520312			C67	D001749	109800	HP:0009725	The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster.
tissue_expression_ns	hsa-mir-199a	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-200	Bladder Neoplasms	27357429			C67	D001749	109800	HP:0009725	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-200a	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-200a	Bladder Neoplasms	27357429			C67	D001749	109800	HP:0009725	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-200b	Bladder Neoplasms	27357429			C67	D001749	109800	HP:0009725	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-200c	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-200c	Bladder Neoplasms	27357429			C67	D001749	109800	HP:0009725	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-200c	Bladder Neoplasms	19945312			C67	D001749	109800	HP:0009725	The diagnostic test, based on the three most discriminatory miRNAs in our panel (miR-200c, miR-141, and miR-30b), showed a sensitivity of 100% and a specificity of 96.2%. Such a panel of miRNAs has the potential to identify invasive bladder tumors misclassified in pathologic assessment of bladder biopsy specimens.
tissue_expression_ns	hsa-mir-205	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-205	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-20a	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-21	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-210	Bladder Neoplasms	27441495			C67	D001749	109800	HP:0009725	High miR-210 may reflect hypoxia in bladder cancer. However, its ability to predict benefit from hypoxia modification does not improve upon other  hypoxia markers. Investigation as part of a miRNA hypoxia signature may reveal the full potential of miR-210.
tissue_expression_ns	hsa-mir-214	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-222	Bladder Neoplasms	23945108			C67	D001749	109800	HP:0009725	miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
tissue_expression_ns	hsa-mir-29b	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-3007a	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-30b	Bladder Neoplasms	19945312			C67	D001749	109800	HP:0009725	The diagnostic test, based on the three most discriminatory miRNAs in our panel (miR-200c, miR-141, and miR-30b), showed a sensitivity of 100% and a specificity of 96.2%. Such a panel of miRNAs has the potential to identify invasive bladder tumors misclassified in pathologic assessment of bladder biopsy specimens.
tissue_expression_ns	hsa-mir-4454	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-497	Bladder Neoplasms	24520312			C67	D001749	109800	HP:0009725	The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster.
tissue_expression_ns	hsa-mir-720	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-93	Bladder Neoplasms	26576778			C67	D001749	109800	HP:0009725	MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma. This study demonstrated varying relationships between miRNA detected in biological media from the same patient, and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other malignancies.
tissue_expression_ns	hsa-mir-96	Bladder Neoplasms	25511320			C67	D001749	109800	HP:0009725	Urinary miRNA-96 is a good noninvasive diagnostic biomarker for bladder cancer.
tissue_expression_ns	hsa-mir-99a	Bladder Neoplasms	25014919			C67	D001749	109800	HP:0009725	The results revealed a unique microRNA expression signature in the urine supernatants of UCB patients for the development of molecular diagnostic tests. An effective cell-free urinary microRNA-based model was developed using a combined index of the levels of microRNA-99a and microRNA-125b to detect UCB with good discriminating power, high sensitivity and high specificity.
tissue_expression_ns	hsa-mir-133a	Bone Disease [unspecific]	21108928	musculoskeletal system disease	DOID:0080001	M89.9	D001847			The expression of miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, was significantly altered in the PDLSCs cultured with ibandronate.
tissue_expression_ns	hsa-mir-141	Bone Disease [unspecific]	21108928	musculoskeletal system disease	DOID:0080001	M89.9	D001847			The expression of miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, was significantly altered in the PDLSCs cultured with ibandronate.
tissue_expression_ns	hsa-mir-18a	Bone Disease [unspecific]	21108928	musculoskeletal system disease	DOID:0080001	M89.9	D001847			The expression of miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, was significantly altered in the PDLSCs cultured with ibandronate.
tissue_expression_ns	hsa-mir-19a	Bone Disease [unspecific]	21108928	musculoskeletal system disease	DOID:0080001	M89.9	D001847			The expression of miRNAs, including miR-18a, miR-133a, miR-141 and miR-19a, was significantly altered in the PDLSCs cultured with ibandronate.
tissue_expression_ns	hsa-mir-1244	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-1290	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-146a	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-1908	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-296	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-3676	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-424	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-4521	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-7	Borna Disease	27748825	disease by infectious agent	DOID:5154		D001890			Identification and bioinformatic analysis of dysregulated microRNAs in human oligodendroglial cells infected with borna disease virus.
tissue_expression_ns	hsa-mir-129-1	Brain Neoplasms	21157891	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	MicroRNA-129, miR-142-5p, and miR-25 were differ entially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray.
tissue_expression_ns	hsa-mir-129-2	Brain Neoplasms	21157891	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	MicroRNA-129, miR-142-5p, and miR-25 were differ entially expressed in every pediatric brain tumor type compared to normal tissue controls as measured by microarray.
tissue_expression_ns	hsa-mir-9-1	Brain Neoplasms	18624795	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	miR-9: Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors
tissue_expression_ns	hsa-mir-9-2	Brain Neoplasms	18624795	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	miR-9: Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors
tissue_expression_ns	hsa-mir-92b	Brain Neoplasms	18624795	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	miR-92b: Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors
tissue_expression_ns	hsa-mir-9-3	Brain Neoplasms	18624795	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	miR-9: Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors
tissue_expression_ns	hsa-mir-16	Breast Adenocarcinoma	20433153	thoracic disease	DOID:3458					Using isolated total RNA from human breast adenocarcinoma MCF-7 cells, the assay detected specifically miR-21 and miR-16 in parallel, and higher expression of oncogene miR-21 compared to miR-16 was demonstrated.
tissue_expression_ns	hsa-mir-21	Breast Adenocarcinoma	20433153	thoracic disease	DOID:3458					Using isolated total RNA from human breast adenocarcinoma MCF-7 cells, the assay detected specifically miR-21 and miR-16 in parallel, and higher expression of oncogene miR-21 compared to miR-16 was demonstrated.
tissue_expression_ns	hsa-let-7a	Breast Neoplasms	26130254	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
tissue_expression_ns	hsa-let-7b	Breast Neoplasms	22294324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7b expression was shown to be associated with luminal tumours, and to have an independent significant positive prognostic value in this group. miR-205 is associated with tumours of ductal morphology, and is of significant positive prognostic value within these tumours.
tissue_expression_ns	hsa-let-7b	Breast Neoplasms	22976804	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n = 22) and IDC-NSTs (n = 24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. 
tissue_expression_ns	hsa-let-7c	Breast Neoplasms	26982264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line.
tissue_expression_ns	hsa-let-7i	Breast Neoplasms	22315424	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Five noncoding genes were associated with both prognostic signatures-miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition.
tissue_expression_ns	hsa-mir-1	Breast Neoplasms	23797906	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers.
tissue_expression_ns	hsa-mir-106b	Breast Neoplasms	26684238	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes.
tissue_expression_ns	hsa-mir-106b	Breast Neoplasms	22315424	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Five noncoding genes were associated with both prognostic signatures-miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition.
tissue_expression_ns	hsa-mir-10a	Breast Neoplasms	24632820	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery.
tissue_expression_ns	hsa-mir-10a	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-10a:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c
tissue_expression_ns	hsa-mir-10a	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-10a	Breast Neoplasms	27433802	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression.
tissue_expression_ns	hsa-mir-10b	Breast Neoplasms	24196612	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA expression in breast development and breast cancer]
tissue_expression_ns	hsa-mir-10b	Breast Neoplasms	24440078	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Detection of miRNA expression in intact cells using activatable sensor oligonucleotides.
tissue_expression_ns	hsa-mir-10b	Breast Neoplasms	24440980	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer.
tissue_expression_ns	hsa-mir-10b	Breast Neoplasms	27433802	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression.
tissue_expression_ns	hsa-mir-10b	Breast Neoplasms	28101798	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
tissue_expression_ns	hsa-mir-10b	Breast Neoplasms	29113216	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-10b is a useful marker for predicting metastasis and angiogenesis in ANN breast cancer
tissue_expression_ns	hsa-mir-124	Breast Neoplasms	27433802	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression.
tissue_expression_ns	hsa-mir-1248	Breast Neoplasms	24917463	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers.
tissue_expression_ns	hsa-mir-124a	Breast Neoplasms	26897751	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM.
tissue_expression_ns	hsa-mir-125b	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-125b	Breast Neoplasms	27433802	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression.
tissue_expression_ns	hsa-mir-125b	Breast Neoplasms	29483949	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs provide insights of this uncommon but highly aggressive pathology
tissue_expression_ns	hsa-mir-125b-1	Breast Neoplasms	21375733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	dysregulated
tissue_expression_ns	hsa-mir-125b-1	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-125b-2	Breast Neoplasms	21375733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	dysregulated
tissue_expression_ns	hsa-mir-125b-2	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-126	Breast Neoplasms	27433802	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression.
tissue_expression_ns	hsa-mir-127	Breast Neoplasms	26982264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line.
tissue_expression_ns	hsa-mir-129	Breast Neoplasms	26982264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line.
tissue_expression_ns	hsa-mir-130b	Breast Neoplasms	26152113	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers
tissue_expression_ns	hsa-mir-133a	Breast Neoplasms	23797906	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers.
tissue_expression_ns	hsa-mir-133b	Breast Neoplasms	23797906	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers.
tissue_expression_ns	hsa-mir-139	Breast Neoplasms	27082076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNAs  included in the invasive signatures include downregulation of miR-139-5p in aggressive subtypes and upregulation of miR-29c-5p expression in the luminal subtypes.
tissue_expression_ns	hsa-mir-142	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-142	Breast Neoplasms	24917463	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers.
tissue_expression_ns	hsa-mir-143	Breast Neoplasms	29073169	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.
tissue_expression_ns	hsa-mir-145	Breast Neoplasms	27433802	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression.
tissue_expression_ns	hsa-mir-145	Breast Neoplasms	29073169	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.
tissue_expression_ns	hsa-mir-146a	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-146a:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c
tissue_expression_ns	hsa-mir-146a	Breast Neoplasms	26982264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line.
tissue_expression_ns	hsa-mir-146a	Breast Neoplasms	28101798	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
tissue_expression_ns	hsa-mir-148a	Breast Neoplasms	26199650	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Based on the results obtained in the last decade, some miRNAs are emerging as biomarkers of BC for diagnosis (i.e., miR-9, miR-10b, and miR-17-5p), prognosis (i.e., miR-148a and miR-335)
tissue_expression_ns	hsa-mir-148a	Breast Neoplasms	22976804	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n = 22) and IDC-NSTs (n = 24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. 
tissue_expression_ns	hsa-mir-149	Breast Neoplasms	24632820	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery.
tissue_expression_ns	hsa-mir-149	Breast Neoplasms	26152113	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comparative microRNA profiling of sporadic and BRCA2 associated basal-like breast cancers
tissue_expression_ns	hsa-mir-151	Breast Neoplasms	25339470	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Specific differentially expressed miRNAs of the three subtypes were identified, including hsa-miR-99a and hsa-miR-151-3p for DCIS breast cancer, hsa-miR-145 and hsa-miR-210 for invasive breast cancer, and has-miR-205 and has-miR-361-5p metastatic breast cancer.
tissue_expression_ns	hsa-mir-152	Breast Neoplasms	25393370	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	For the first time, a different microRNA expression pattern in male and female fBC has been shown. Moreover, the importance of RASSF1A pathway in male fBC carcinogenesis has been confirmed, highlighting a possible role for miR-152 and miR-497 in controlling MAPK and Hippo signalling pathways, regulated by RASSF1A.
tissue_expression_ns	hsa-mir-153	Breast Neoplasms	28101798	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
tissue_expression_ns	hsa-mir-155	Breast Neoplasms	24440980	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer.
tissue_expression_ns	hsa-mir-155	Breast Neoplasms	25157366	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-155 detection might have a diagnostic value in breast cancer patients. It might be used as an auxiliary biomarker for different clinicopathological breast cancer.
tissue_expression_ns	hsa-mir-155	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-155	Breast Neoplasms	20664596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-155:miR-155, is differentially expressed in ER- versus ER+ tumors
tissue_expression_ns	hsa-mir-155	Breast Neoplasms	23162645	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status
tissue_expression_ns	hsa-mir-155	Breast Neoplasms	28882698	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer
tissue_expression_ns	hsa-mir-15a	Breast Neoplasms	25550542	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-15a expression levels could be a promising biological and prognostic marker for overall survival especially in triple-negative BC cases.
tissue_expression_ns	hsa-mir-16	Breast Neoplasms	26684238	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes.
tissue_expression_ns	hsa-mir-17	Breast Neoplasms	24626680	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment.
tissue_expression_ns	hsa-mir-181a	Breast Neoplasms	22976804	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n = 22) and IDC-NSTs (n = 24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. 
tissue_expression_ns	hsa-mir-181a-2	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-181a-2	Breast Neoplasms	24917463	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers.
tissue_expression_ns	hsa-mir-181b	Breast Neoplasms	22976804	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n = 22) and IDC-NSTs (n = 24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. 
tissue_expression_ns	hsa-mir-181b-1	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-181b-2	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-182	Breast Neoplasms	21375733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	dysregulated
tissue_expression_ns	hsa-mir-183	Breast Neoplasms	21375733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	dysregulated
tissue_expression_ns	hsa-mir-185	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-18a	Breast Neoplasms	24626680	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment.
tissue_expression_ns	hsa-mir-190b	Breast Neoplasms	26152113	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comparative microRNA profiling of sporadic and BRCA3 associated basal-like breast cancers
tissue_expression_ns	hsa-mir-191	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-195	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-195	Breast Neoplasms	21375733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	dysregulated
tissue_expression_ns	hsa-mir-196a	Breast Neoplasms	21962133	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-196a has been reported to be aberrantly expressed in breast cancer tissue. 
tissue_expression_ns	hsa-mir-197	Breast Neoplasms	22315424	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Five noncoding genes were associated with both prognostic signatures-miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition.
tissue_expression_ns	hsa-mir-198	Breast Neoplasms	26152113	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comparative microRNA profiling of sporadic and BRCA4 associated basal-like breast cancers
tissue_expression_ns	hsa-mir-19a	Breast Neoplasms	24626680	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment.
tissue_expression_ns	hsa-mir-19b	Breast Neoplasms	24626680	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment.
tissue_expression_ns	hsa-mir-200a	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-200a	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-200b	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-200b	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-200b	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200b:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c
tissue_expression_ns	hsa-mir-200b	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-200c	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-200c	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200c:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c
tissue_expression_ns	hsa-mir-200c	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-204	Breast Neoplasms	25031750	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the miR-204 may be a potential diagnostic and prognostic biomarker of breast cancer.
tissue_expression_ns	hsa-mir-204	Breast Neoplasms	24191129	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression and the functional role of several miRNAs (miR-206, miR-31, miR-27a/b, miR-21, miR-92a, miR-205, miR-125a/b, miR-10b, miR-155, miR-146a/b, miR-335, miR-204, miR-211, miR-7, miR-22, miR-126, and miR-17) in breast cancer has been identified.
tissue_expression_ns	hsa-mir-205	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-205	Breast Neoplasms	22294324	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7b expression was shown to be associated with luminal tumours, and to have an independent significant positive prognostic value in this group. miR-205 is associated with tumours of ductal morphology, and is of significant positive prognostic value within these tumours.
tissue_expression_ns	hsa-mir-205	Breast Neoplasms	22631664	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-205 and miR-342 may be used as potential biomarkers for diagnosis of triple negative breast cancer.
tissue_expression_ns	hsa-mir-206	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-20a	Breast Neoplasms	24626680	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment.
tissue_expression_ns	hsa-mir-20b	Breast Neoplasms	24632820	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery.
tissue_expression_ns	hsa-mir-21	Breast Neoplasms	24440980	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer.
tissue_expression_ns	hsa-mir-21	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-21	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-21	Breast Neoplasms	22315424	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Five noncoding genes were associated with both prognostic signatures-miR-210, -21, -106b*, -197, and let-7i, with miR-210 the only one also involved in the invasive transition.
tissue_expression_ns	hsa-mir-21	Breast Neoplasms	26891730	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Analysis has shown that changes in miR-21 levels might be important for the later and/or late phases of breast cancerogenesis rather than for the initial early phases.
tissue_expression_ns	hsa-mir-21	Breast Neoplasms	27433802	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified eight microRNAs (miR-10a, miR-10b, miR-21, miR-124, miR-125b, miR-126, miR-145 and miR-200a) to be associated with DMBA-induced mammary tumor progression.
tissue_expression_ns	hsa-mir-210	Breast Neoplasms	24196612	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA expression in breast development and breast cancer]
tissue_expression_ns	hsa-mir-215	Breast Neoplasms	25270284	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients.
tissue_expression_ns	hsa-mir-218	Breast Neoplasms	26152113	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comparative microRNA profiling of sporadic and BRCA5 associated basal-like breast cancers
tissue_expression_ns	hsa-mir-22	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-221	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-221:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c
tissue_expression_ns	hsa-mir-221	Breast Neoplasms	27488105	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	An increase in miR-221/222 might be an important event for in situ carcinoma formation, and miR-221/222 may be important molecules that highlight potential differences between invasive breast carcinomas associated with non-invasive and pure invasive BCs.
tissue_expression_ns	hsa-mir-222	Breast Neoplasms	24440980	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-21, -155, -222 and -10b are reliable candidate biomarkers for detection of breast cancer.
tissue_expression_ns	hsa-mir-222	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-222:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c
tissue_expression_ns	hsa-mir-222	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells
tissue_expression_ns	hsa-mir-222	Breast Neoplasms	27488105	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	An increase in miR-221/222 might be an important event for in situ carcinoma formation, and miR-221/222 may be important molecules that highlight potential differences between invasive breast carcinomas associated with non-invasive and pure invasive BCs.
tissue_expression_ns	hsa-mir-222	Breast Neoplasms	27659519	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer.
tissue_expression_ns	hsa-mir-23a	Breast Neoplasms	26684238	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes.
tissue_expression_ns	hsa-mir-23b	Breast Neoplasms	26684238	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, we have for the first time characterized the BMP4-induced miRNA expression profiles in breast cancer cell lines, showing that induced miRNAs contribute to the fine-tuning of proliferation and migration phenotypes.
tissue_expression_ns	hsa-mir-25	Breast Neoplasms	24917463	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers.
tissue_expression_ns	hsa-mir-26a	Breast Neoplasms	28101798	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
tissue_expression_ns	hsa-mir-29a	Breast Neoplasms	20664596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-29a:We identified a set of 13 miRNAs of which expression differed between IBC and non-IBC, making these miRNAs candidate markers for the IBC subtype
tissue_expression_ns	hsa-mir-29a	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-29b	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-29c	Breast Neoplasms	27082076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	include downregulation of miR-139-5p in aggressive subtypes and upregulation of miR-29c-5p expression in the luminal subtypes.
tissue_expression_ns	hsa-mir-30a	Breast Neoplasms	24632820	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery.
tissue_expression_ns	hsa-mir-30b	Breast Neoplasms	20664596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-30b:We identified a set of 13 miRNAs of which expression differed between IBC and non-IBC, making these miRNAs candidate markers for the IBC subtype
tissue_expression_ns	hsa-mir-30c	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-30c	Breast Neoplasms	22976804	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	By means of RT-qPCR, we further investigated miRNA expression in more IMPC (n = 22) and IDC-NSTs (n = 24) FFPE samples and found let-7b, miR-30c, miR-148a, miR-181a, miR-181a*, and miR-181b were significantly differently expressed between the two groups. 
tissue_expression_ns	hsa-mir-30d	Breast Neoplasms	26897751	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM.
tissue_expression_ns	hsa-mir-31	Breast Neoplasms	24196612	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA expression in breast development and breast cancer]
tissue_expression_ns	hsa-mir-31	Breast Neoplasms	23162645	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status
tissue_expression_ns	hsa-mir-31	Breast Neoplasms	27659519	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer.
tissue_expression_ns	hsa-mir-3196	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-335	Breast Neoplasms	24196612	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	microRNA expression in breast development and breast cancer]
tissue_expression_ns	hsa-mir-339	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-340	Breast Neoplasms	24917463	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers.
tissue_expression_ns	hsa-mir-342	Breast Neoplasms	24632820	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, we have identified a set of recurrence-related microRNAs with potential prognostic value to identify patients who will likely develop metastasis early after primary breast surgery.
tissue_expression_ns	hsa-mir-342	Breast Neoplasms	20664596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-342-3p:We identified a set of 13 miRNAs of which expression differed between IBC and non-IBC, making these miRNAs candidate markers for the IBC subtype
tissue_expression_ns	hsa-mir-342	Breast Neoplasms	22631664	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-205 and miR-342 may be used as potential biomarkers for diagnosis of triple negative breast cancer.
tissue_expression_ns	hsa-mir-345	Breast Neoplasms	20099276	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-345:dysregulated miRNAs were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b and miR-200c
tissue_expression_ns	hsa-mir-34a	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-374b	Breast Neoplasms	26152113	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comparative microRNA profiling of sporadic and BRCA7 associated basal-like breast cancers
tissue_expression_ns	hsa-mir-375	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-3923	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-421	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-451	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-451	Breast Neoplasms	25886191	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a  specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
tissue_expression_ns	hsa-mir-497	Breast Neoplasms	25393370	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	For the first time, a different microRNA expression pattern in male and female fBC has been shown. Moreover, the importance of RASSF1A pathway in male fBC carcinogenesis has been confirmed, highlighting a possible role for miR-152 and miR-497 in controlling MAPK and Hippo signalling pathways, regulated by RASSF1A.
tissue_expression_ns	hsa-mir-503	Breast Neoplasms	29164842	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others
tissue_expression_ns	hsa-mir-505	Breast Neoplasms	24917463	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers.
tissue_expression_ns	hsa-mir-520a	Breast Neoplasms	20664596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-520a-5p:We identified a set of 13 miRNAs of which expression differed between IBC and non-IBC, making these miRNAs candidate markers for the IBC subtype
tissue_expression_ns	hsa-mir-542	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-564	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-590	Breast Neoplasms	26152113	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comparative microRNA profiling of sporadic and BRCA6 associated basal-like breast cancers
tissue_expression_ns	hsa-mir-892a	Breast Neoplasms	26152113	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Comparative microRNA profiling of sporadic and BRCA8 associated basal-like breast cancers
tissue_expression_ns	hsa-mir-9	Breast Neoplasms	26982264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line.
tissue_expression_ns	hsa-mir-9	Breast Neoplasms	28882698	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer
tissue_expression_ns	hsa-mir-92a	Breast Neoplasms	24626680	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA expression profiles in human breast cancer cells after multifraction and single-dose radiation treatment.
tissue_expression_ns	hsa-mir-92a	Breast Neoplasms	24846313	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
tissue_expression_ns	hsa-mir-92a	Breast Neoplasms	23797906	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers.
tissue_expression_ns	hsa-mir-93	Breast Neoplasms	21955614	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.
tissue_expression_ns	hsa-mir-99a	Breast Neoplasms	26982264	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line.
tissue_expression_ns	hsa-let-7f	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-130b	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-141	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-146b	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-150	Bronchopulmonary Dysplasia	27216745			P27.1	D001997			expression of miR-150 was altered in experimental BPD
tissue_expression_ns	hsa-mir-21	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-214	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-29a	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-34a	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-382	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-411	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-431	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-503	Bronchopulmonary Dysplasia	24301780			P27.1	D001997			MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-150	Burns	28404517			M61.30	D002056			Dysregulation of microRNA biogenesis in the small intestine after ethanol and burn injury.
tissue_expression_ns	hsa-mir-23b	Carcinoma, Adenoid Cystic	25240490	disease of cellular proliferation	DOID:0080202		D003528			9 microRNAs were downexpressed in sACC cases and overexpressed in bACC tissues (let-7e, miR-23b, miR-27b, miR-193b, miR-320a, miR-320c, miR-768-5p, miR-1280 and miR-1826) relative to their controls.
tissue_expression_ns	hsa-mir-23b	Carcinoma, Adenoid Cystic	26293217	disease of cellular proliferation	DOID:0080202		D003528			Expression of miR-23b and  miR-27b differed between normal breast and normal salivary gland tissue
tissue_expression_ns	hsa-mir-195	Carcinoma, Adrenocortical	24890943	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	In conclusion, (a) miR-483-3p, miR-483-5p, and miR-210 are differentially expressed in ACC variants, and (b) high miR-210 is associated with clinicopathologic parameters of aggressiveness and a poor prognosis.
tissue_expression_ns	hsa-mir-1974	Carcinoma, Adrenocortical	24890943	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	In conclusion, (a) miR-483-3p, miR-483-5p, and miR-210 are differentially expressed in ACC variants, and (b) high miR-210 is associated with clinicopathologic parameters of aggressiveness and a poor prognosis.
tissue_expression_ns	hsa-mir-210	Carcinoma, Adrenocortical	24890943	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	In conclusion, (a) miR-483-3p, miR-483-5p, and miR-210 are differentially expressed in ACC variants, and (b) high miR-210 is associated with clinicopathologic parameters of aggressiveness and a poor prognosis.
tissue_expression_ns	hsa-mir-483	Carcinoma, Adrenocortical	24890943	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	In conclusion, (a) miR-483-3p, miR-483-5p, and miR-210 are differentially expressed in ACC variants, and (b) high miR-210 is associated with clinicopathologic parameters of aggressiveness and a poor prognosis.
tissue_expression_ns	hsa-let-7c	Carcinoma, Bladder	25990459	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	this study identified the specific miRNAs associated with the progression and aggressiveness of MIBC and a four-miRNA signature as a promising prognostic parameter of MIBC.
tissue_expression_ns	hsa-mir-100	Carcinoma, Bladder	27586262	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
tissue_expression_ns	hsa-mir-100	Carcinoma, Bladder	27631180	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Evaluation of miR-182/miR-100 Ratio for Diagnosis and Survival Prediction in Bladder Cancer.
tissue_expression_ns	hsa-mir-125b-1	Carcinoma, Bladder	25990459	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	this study identified the specific miRNAs associated with the progression and aggressiveness of MIBC and a four-miRNA signature as a promising prognostic parameter of MIBC.
tissue_expression_ns	hsa-mir-146a	Carcinoma, Bladder	27751843	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Real-time PCR analysis pointed to miR-375 as a biomarker for high-grade bladder cancer while miR-146a could identify low-grade patients
tissue_expression_ns	hsa-mir-146b	Carcinoma, Bladder	27586262	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
tissue_expression_ns	hsa-mir-182	Carcinoma, Bladder	27631180	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Evaluation of miR-182/miR-100 Ratio for Diagnosis and Survival Prediction in Bladder Cancer.
tissue_expression_ns	hsa-mir-193a	Carcinoma, Bladder	25990459	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	this study identified the specific miRNAs associated with the progression and aggressiveness of MIBC and a four-miRNA signature as a promising prognostic parameter of MIBC.
tissue_expression_ns	hsa-mir-193a	Carcinoma, Bladder	27586262	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
tissue_expression_ns	hsa-mir-34	Carcinoma, Bladder	27586262	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
tissue_expression_ns	hsa-mir-375	Carcinoma, Bladder	27751843	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Real-time PCR analysis pointed to miR-375 as a biomarker for high-grade bladder cancer while miR-146a could identify low-grade patients
tissue_expression_ns	hsa-mir-9	Carcinoma, Bladder	27586262	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
tissue_expression_ns	hsa-mir-99a	Carcinoma, Bladder	25990459	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	this study identified the specific miRNAs associated with the progression and aggressiveness of MIBC and a four-miRNA signature as a promising prognostic parameter of MIBC.
tissue_expression_ns	hsa-mir-1	Carcinoma, Breast	26331797			D05	D001943	114480	HP:0003002	These findings suggest that abnormal miR-1 expression is associated with an aggressive phenotype of breast carcinoma and that miR-1 status is a potent prognostic factor in human breast cancer patients.
tissue_expression_ns	hsa-mir-1246	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-1268a	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-1303	Carcinoma, Breast	23526361			D05	D001943	114480	HP:0003002	Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. 
tissue_expression_ns	hsa-mir-130a	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-138	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-139	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-197	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-200b	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-210	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-3613	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-421	Carcinoma, Breast	23526361			D05	D001943	114480	HP:0003002	Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. 
tissue_expression_ns	hsa-mir-4258	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-4298	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-449a	Carcinoma, Breast	27748845			D05	D001943	114480	HP:0003002	MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
tissue_expression_ns	hsa-mir-449b	Carcinoma, Breast	27748845			D05	D001943	114480	HP:0003002	MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
tissue_expression_ns	hsa-mir-452	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-4644	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-486	Carcinoma, Breast	23526361			D05	D001943	114480	HP:0003002	Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. 
tissue_expression_ns	hsa-mir-494	Carcinoma, Breast	27748845			D05	D001943	114480	HP:0003002	MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
tissue_expression_ns	hsa-mir-503	Carcinoma, Breast	23526361			D05	D001943	114480	HP:0003002	Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. 
tissue_expression_ns	hsa-mir-671	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-7107	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-720	Carcinoma, Breast	23526361			D05	D001943	114480	HP:0003002	Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. 
tissue_expression_ns	hsa-mir-7847	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-886	Carcinoma, Breast	27748845			D05	D001943	114480	HP:0003002	MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
tissue_expression_ns	hsa-mir-90b	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	This study highlights the role of numerous miRNAs in prediction of therapeutic responses and suggests that specific miRNAs could serve as valuable sources for biomarker detections and optimal chemotherapeutic choices for breast cancer patients
tissue_expression_ns	hsa-mir-923	Carcinoma, Breast	27748845			D05	D001943	114480	HP:0003002	MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
tissue_expression_ns	hsa-mir-126	Carcinoma, Breast, Triple Negative	26062749				D064726			This study provides strong evidence that the expression levels of miR-374b-5p, miR-27b-3p, miR-126-3p, and miR-218-5p in tumor tissues predict TNBC outcomes.
tissue_expression_ns	hsa-mir-155	Carcinoma, Breast, Triple Negative	24632568				D064726			microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
tissue_expression_ns	hsa-mir-17	Carcinoma, Breast, Triple Negative	24810926				D064726			Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.
tissue_expression_ns	hsa-mir-18a	Carcinoma, Breast, Triple Negative	24810926				D064726			Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.
tissue_expression_ns	hsa-mir-20a	Carcinoma, Breast, Triple Negative	24810926				D064726			Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.
tissue_expression_ns	hsa-mir-21	Carcinoma, Breast, Triple Negative	27113307				D064726			The function of MiR-21 expression differences and pathogenesis on familial and triple negative breast Cancer serum.
tissue_expression_ns	hsa-mir-218	Carcinoma, Breast, Triple Negative	26062749				D064726			This study provides strong evidence that the expression levels of miR-374b-5p, miR-27b-3p, miR-126-3p, and miR-218-5p in tumor tissues predict TNBC outcomes.
tissue_expression_ns	hsa-mir-27a	Carcinoma, Breast, Triple Negative	24632568				D064726			microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
tissue_expression_ns	hsa-mir-27b	Carcinoma, Breast, Triple Negative	26062749				D064726			This study provides strong evidence that the expression levels of miR-374b-5p, miR-27b-3p, miR-126-3p, and miR-218-5p in tumor tissues predict TNBC outcomes.
tissue_expression_ns	hsa-mir-30e	Carcinoma, Breast, Triple Negative	24632568				D064726			microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
tissue_expression_ns	hsa-mir-374b	Carcinoma, Breast, Triple Negative	26062749				D064726			This study provides strong evidence that the expression levels of miR-374b-5p, miR-27b-3p, miR-126-3p, and miR-218-5p in tumor tissues predict TNBC outcomes.
tissue_expression_ns	hsa-mir-493	Carcinoma, Breast, Triple Negative	24632568				D064726			microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
tissue_expression_ns	hsa-mir-106b	Carcinoma, Cervical	27764149	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
tissue_expression_ns	hsa-mir-10a	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-141	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-143	Carcinoma, Cervical	24517947	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	It seemed that miR-143 play an important role in the processes of generation and progression of cervical cancer. However, there was no significant difference found between the different ethnic groups. The expression level of miR-143 might serve as a valuable adjuvant parameter for diagnosing and predicting the state of cervical cancer.
tissue_expression_ns	hsa-mir-143	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-145	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-15a	Carcinoma, Cervical	27764149	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
tissue_expression_ns	hsa-mir-15b	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-17	Carcinoma, Cervical	27764149	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
tissue_expression_ns	hsa-mir-200a	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-203	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-20a	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-20a	Carcinoma, Cervical	27764149	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
tissue_expression_ns	hsa-mir-20b	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-21	Carcinoma, Cervical	27764149	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
tissue_expression_ns	hsa-mir-215	Carcinoma, Cervical	24710934	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	It was concluded that the expression level of miR-215 is associated with cervical tumor progression and worse survival rate, suggesting that it may serve as a potential prognostic marker to identify patients at higher risk of recurrence.
tissue_expression_ns	hsa-mir-224	Carcinoma, Cervical	25920605	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	This meta-analysis has identified several miRNAs whose expression correlates reliably with cervical cancer. These should be probed in further studies to explore their potential as diagnostic biomarkers.
tissue_expression_ns	hsa-mir-3653	Carcinoma, Cervical	27764149	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
tissue_expression_ns	hsa-mir-497	Carcinoma, Cervical	27764149	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
tissue_expression_ns	hsa-mir-96	Carcinoma, Cervical	27764149	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	miRNA Expression Profiles of HPV-Infected Patients with Cervical Cancer in the Uyghur Population in China.
tissue_expression_ns	hsa-mir-106a	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-106b	Carcinoma, Colon	25755775	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	In situ hybridization analysis of the expression of miR-106b in colonic cancer.
tissue_expression_ns	hsa-mir-125b	Carcinoma, Colon	25421775	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-145 and other 16 miRNAs may be used as diagnostic molecular markers of colon cancer, and miR100, miR125a-5p, miR125b, miR145 and miR145* may  become the molecular markers of colon cancer lymph node metastasis.
tissue_expression_ns	hsa-mir-126	Carcinoma, Colon	28714375	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.
tissue_expression_ns	hsa-mir-145	Carcinoma, Colon	25421775	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-145 and other 16 miRNAs may be used as diagnostic molecular markers of colon cancer, and miR100, miR125a-5p, miR125b, miR145 and miR146* may  become the molecular markers of colon cancer lymph node metastasis.
tissue_expression_ns	hsa-mir-17	Carcinoma, Colon	26465597	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer.
tissue_expression_ns	hsa-mir-18	Carcinoma, Colon	26465597	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer.
tissue_expression_ns	hsa-mir-19a	Carcinoma, Colon	26465597	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer.
tissue_expression_ns	hsa-mir-19b-1	Carcinoma, Colon	26465597	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer.
tissue_expression_ns	hsa-mir-200c	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-205	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-20a	Carcinoma, Colon	26465597	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer.
tissue_expression_ns	hsa-mir-302d	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-324	Carcinoma, Colon	24882011	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Dysregulation of the miR-324-5p-CUEDC2 axis leads to macrophage dysfunction and is associated with colon cancer.
tissue_expression_ns	hsa-mir-373	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-4454	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-483	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-5000	Carcinoma, Colon	24898979	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer.
tissue_expression_ns	hsa-mir-5009	Carcinoma, Colon	24898979	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer.
tissue_expression_ns	hsa-mir-512	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-552	Carcinoma, Colon	24898979	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer.
tissue_expression_ns	hsa-mir-664	Carcinoma, Colon	28714375	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.
tissue_expression_ns	hsa-mir-92-1	Carcinoma, Colon	26465597	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	It is concluded that the expression of miR-17, miR-21, and miR-145 changes at early stages of the normal-adenoma-adenocarcinoma sequence. Thus, these microRNAs may play a role in the development of colon cancer.
tissue_expression_ns	hsa-mir-93	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-99b	Carcinoma, Colon	28571588	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Expression profiling indicating low selenium-sensitive microRNA levels linked to cell cycle and cell stress response pathways in the CaCo-2 cell line.
tissue_expression_ns	hsa-mir-372	Carcinoma, Embryonal	17011485	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	Expression of miR-372 and miR-373 seems to be specifically associated with germ cell tumors, as most somatic tumors do not express these miRNAs.
tissue_expression_ns	hsa-mir-373	Carcinoma, Embryonal	17011485	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	Expression of miR-372 and miR-373 seems to be specifically associated with germ cell tumors, as most somatic tumors do not express these miRNAs.
tissue_expression_ns	hsa-mir-141	Carcinoma, Endometrial	24363810	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues.
tissue_expression_ns	hsa-mir-182	Carcinoma, Endometrial	24363810	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues.
tissue_expression_ns	hsa-mir-200a	Carcinoma, Endometrial	24363810	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues.
tissue_expression_ns	hsa-mir-200b	Carcinoma, Endometrial	24363810	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues.
tissue_expression_ns	hsa-mir-205	Carcinoma, Endometrial	24363810	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues.
tissue_expression_ns	hsa-mir-106a	Carcinoma, Esophageal	20628822	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Furthermore, miR-106a and miR-148a expression correlates with disease recurrence and tumor-related mortality.
tissue_expression_ns	hsa-mir-143	Carcinoma, Esophageal	25667498	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma.
tissue_expression_ns	hsa-mir-148a	Carcinoma, Esophageal	20628822	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Furthermore, miR-106a and miR-148a expression correlates with disease recurrence and tumor-related mortality.
tissue_expression_ns	hsa-mir-203	Carcinoma, Esophageal	25667498	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma.
tissue_expression_ns	hsa-mir-205	Carcinoma, Esophageal	25667498	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma.
tissue_expression_ns	hsa-mir-205	Carcinoma, Esophageal	20628822	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The expression of miR-21, miR-106a, miR-148a, miR-205 in formalin-fixed paraffin-embedded specimens was evaluated by TaqMan qPCR assays. Expression was compared with clinicopathological features of the cancers and outcome.
tissue_expression_ns	hsa-mir-21	Carcinoma, Esophageal	24680681	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The expression of miR-21 and miR-375 predict prognosis of esophageal cancer.
tissue_expression_ns	hsa-mir-21	Carcinoma, Esophageal	25667498	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma.
tissue_expression_ns	hsa-mir-21	Carcinoma, Esophageal	20628822	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The expression of miR-21, miR-106a, miR-148a, miR-205 in formalin-fixed paraffin-embedded specimens was evaluated by TaqMan qPCR assays. Expression was compared with clinicopathological features of the cancers and outcome.
tissue_expression_ns	hsa-mir-221	Carcinoma, Esophageal	25667498	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Alterations of miRNA expression in ESCC can be correlated with the presence of common risk factors. The altered expression of certain miRNAs could be used as novel molecular markers of esophageal carcinoma.
tissue_expression_ns	hsa-mir-375	Carcinoma, Esophageal	24680681	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The expression of miR-21 and miR-375 predict prognosis of esophageal cancer.
tissue_expression_ns	hsa-mir-106b	Carcinoma, Gastric	24040025	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.
tissue_expression_ns	hsa-mir-17	Carcinoma, Gastric	24040025	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.
tissue_expression_ns	hsa-mir-18a	Carcinoma, Gastric	24040025	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.
tissue_expression_ns	hsa-mir-1914	Carcinoma, Gastric	25730011	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The miRNA expression patterns in different gastric adenocarcinoma subtypes may help discriminate between signet-ring cell and tubular gland cancer or other gastric cancer subtypes that would otherwise be difficult to identify using routine histological and immunohistochemical analyses. These preliminary data should be verified in further prospective studies.
tissue_expression_ns	hsa-mir-20a	Carcinoma, Gastric	24040025	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.
tissue_expression_ns	hsa-mir-21	Carcinoma, Gastric	24040025	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.
tissue_expression_ns	hsa-mir-378	Carcinoma, Gastric	24040025	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.
tissue_expression_ns	hsa-mir-499	Carcinoma, Gastric	25730011	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The miRNA expression patterns in different gastric adenocarcinoma subtypes may help discriminate between signet-ring cell and tubular gland cancer or other gastric cancer subtypes that would otherwise be difficult to identify using routine histological and immunohistochemical analyses. These preliminary data should be verified in further prospective studies.
tissue_expression_ns	hsa-mir-524	Carcinoma, Gastric	25730011	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The miRNA expression patterns in different gastric adenocarcinoma subtypes may help discriminate between signet-ring cell and tubular gland cancer or other gastric cancer subtypes that would otherwise be difficult to identify using routine histological and immunohistochemical analyses. These preliminary data should be verified in further prospective studies.
tissue_expression_ns	hsa-mir-628	Carcinoma, Gastric	25730011	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The miRNA expression patterns in different gastric adenocarcinoma subtypes may help discriminate between signet-ring cell and tubular gland cancer or other gastric cancer subtypes that would otherwise be difficult to identify using routine histological and immunohistochemical analyses. These preliminary data should be verified in further prospective studies.
tissue_expression_ns	hsa-mir-638	Carcinoma, Gastric	24040025	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study.
tissue_expression_ns	hsa-let-7a	Carcinoma, Hepatocellular	28440732	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of microRNA let-7a positively correlates with hepatitis B virus replication in hepatocellular carcinoma tissues.
tissue_expression_ns	hsa-mir-106a	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106a: involve
tissue_expression_ns	hsa-mir-106b	Carcinoma, Hepatocellular	25916067	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A total of 54 differentially expressed miRNAs were identified, in which there were 13 miRNAs published to be related to HCC.
tissue_expression_ns	hsa-mir-106b	Carcinoma, Hepatocellular	29179453	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis
tissue_expression_ns	hsa-mir-122	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-122	Carcinoma, Hepatocellular	27874954	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The anti-cancer effects of cisplatin on hepatic cancer are associated with modulation of miRNA-21 and miRNA-122 expression.
tissue_expression_ns	hsa-mir-122	Carcinoma, Hepatocellular	28272709	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features.
tissue_expression_ns	hsa-mir-125a	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-125a	Carcinoma, Hepatocellular	28878257	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Molecular mechanisms governing microRNA-125a expression in human hepatocellular carcinoma cells.
tissue_expression_ns	hsa-mir-125b	Carcinoma, Hepatocellular	21882851	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer).
tissue_expression_ns	hsa-mir-125b	Carcinoma, Hepatocellular	28984009	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection.
tissue_expression_ns	hsa-mir-1285	Carcinoma, Hepatocellular	27554417	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Diagnosis of HCC for patients with cirrhosis using miRNA profiles of the tumor-surrounding tissue - A statistical model based on stepwise penalized logistic regression.
tissue_expression_ns	hsa-mir-129	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-130a	Carcinoma, Hepatocellular	26231037	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Systematic and integrative analysis of published datesets that compared the miRNA expression profiles between hepatocellular carcinoma (HCC) tissue and paired adjacent noncancerous liver tissue was performed to determine candidate HCC associated miRNAs. 
tissue_expression_ns	hsa-mir-130b	Carcinoma, Hepatocellular	26927562	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The expression and clinopathological significance of miR-130b in human hepatocellular carcinoma
tissue_expression_ns	hsa-mir-132	Carcinoma, Hepatocellular	28430373	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A five-miRNA expression signature predicts survival in hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-133b	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-142	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-1468	Carcinoma, Hepatocellular	28430373	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A five-miRNA expression signature predicts survival in hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-148a	Carcinoma, Hepatocellular	24798342	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression.
tissue_expression_ns	hsa-mir-155	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-17	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-17-5p: involve
tissue_expression_ns	hsa-mir-182	Carcinoma, Hepatocellular	26728044	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease.
tissue_expression_ns	hsa-mir-192	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-194	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-195	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-198	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-199a	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-199a	Carcinoma, Hepatocellular	26998997	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miTALOS v2: Analyzing Tissue Specific microRNA Function.
tissue_expression_ns	hsa-mir-199a	Carcinoma, Hepatocellular	22714032	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the expression of miR-21, miR-221, miR-222 and miR-199a showing characteristic alterations in hepatocellular carcinoma also displayed deregulated expressions in these two early stages.
tissue_expression_ns	hsa-mir-199a	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-199b	Carcinoma, Hepatocellular	26998997	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miTALOS v3: Analyzing Tissue Specific microRNA Function.
tissue_expression_ns	hsa-mir-20	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-200	Carcinoma, Hepatocellular	26998997	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miTALOS v4: Analyzing Tissue Specific microRNA Function.
tissue_expression_ns	hsa-mir-200a	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-200a	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-203	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-204	Carcinoma, Hepatocellular	28746200	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Promising significance of the association of miR-204-5p expression with clinicopathological features of hepatocellular carcinoma
tissue_expression_ns	hsa-mir-20a	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-20: involve
tissue_expression_ns	hsa-mir-20b	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-20: involve
tissue_expression_ns	hsa-mir-21	Carcinoma, Hepatocellular	25150373	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The results of the present study suggested miR-21 expression level could be a novel potential biomarker for HCC prognosis.
tissue_expression_ns	hsa-mir-21	Carcinoma, Hepatocellular	26231037	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Systematic and integrative analysis of published datesets that compared the miRNA expression profiles between hepatocellular carcinoma (HCC) tissue and paired adjacent noncancerous liver tissue was performed to determine candidate HCC associated miRNAs. 
tissue_expression_ns	hsa-mir-21	Carcinoma, Hepatocellular	27874954	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The anti-cancer effects of cisplatin on hepatic cancer are associated with modulation of miRNA-21 and miRNA-122 expression.
tissue_expression_ns	hsa-mir-21	Carcinoma, Hepatocellular	19120703	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In some cases, aberrantly expressed miRNAs could be linked to cancer-associated pathways, indicating a direct role in liver tumourigenesis. For example, up-regulation of mir-221 and mir-21 could promote cell cycle progression, reduce cell death and favour angiogenesis and invasion.
tissue_expression_ns	hsa-mir-21	Carcinoma, Hepatocellular	22714032	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the expression of miR-21, miR-221, miR-222 and miR-199a showing characteristic alterations in hepatocellular carcinoma also displayed deregulated expressions in these two early stages.
tissue_expression_ns	hsa-mir-212	Carcinoma, Hepatocellular	28430373	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A five-miRNA expression signature predicts survival in hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-214	Carcinoma, Hepatocellular	26231037	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Systematic and integrative analysis of published datesets that compared the miRNA expression profiles between hepatocellular carcinoma (HCC) tissue and paired adjacent noncancerous liver tissue was performed to determine candidate HCC associated miRNAs. 
tissue_expression_ns	hsa-mir-214	Carcinoma, Hepatocellular	24804874	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Among the analysed miRNAs, high miR-214 expression was associated with smaller tumor size (p=0.019), whereas high miR-17-5p expression correlated with better Eastern Cooperative Oncology Group performance status (p=0.003).
tissue_expression_ns	hsa-mir-215	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-22	Carcinoma, Hepatocellular	28272709	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features.
tissue_expression_ns	hsa-mir-22	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-221	Carcinoma, Hepatocellular	26231037	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Systematic and integrative analysis of published datesets that compared the miRNA expression profiles between hepatocellular carcinoma (HCC) tissue and paired adjacent noncancerous liver tissue was performed to determine candidate HCC associated miRNAs. 
tissue_expression_ns	hsa-mir-221	Carcinoma, Hepatocellular	19120703	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In some cases, aberrantly expressed miRNAs could be linked to cancer-associated pathways, indicating a direct role in liver tumourigenesis. For example, up-regulation of mir-221 and mir-21 could promote cell cycle progression, reduce cell death and favour angiogenesis and invasion.
tissue_expression_ns	hsa-mir-221	Carcinoma, Hepatocellular	22714032	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the expression of miR-21, miR-221, miR-222 and miR-199a showing characteristic alterations in hepatocellular carcinoma also displayed deregulated expressions in these two early stages.
tissue_expression_ns	hsa-mir-221	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-222	Carcinoma, Hepatocellular	22714032	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the expression of miR-21, miR-221, miR-222 and miR-199a showing characteristic alterations in hepatocellular carcinoma also displayed deregulated expressions in these two early stages.
tissue_expression_ns	hsa-mir-223	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-224	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-24	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-24-1	Carcinoma, Hepatocellular	23229173	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC
tissue_expression_ns	hsa-mir-24-2	Carcinoma, Hepatocellular	23229173	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC
tissue_expression_ns	hsa-mir-25	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-26a	Carcinoma, Hepatocellular	28218742	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5.
tissue_expression_ns	hsa-mir-26b	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-27a	Carcinoma, Hepatocellular	23229173	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC
tissue_expression_ns	hsa-mir-27a	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-29a	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-29b	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-29b	Carcinoma, Hepatocellular	23863670	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The combined detection of miRNA-29b and AFP aids the diagnosis of PHC and the prediction of its prognosis.
tissue_expression_ns	hsa-mir-29c	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-301a	Carcinoma, Hepatocellular	28430373	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A five-miRNA expression signature predicts survival in hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-302b	Carcinoma, Hepatocellular	24083596	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-302b suppresses HCC growth may due to targeting the EGFR/AKT2/CCND1 pathway.
tissue_expression_ns	hsa-mir-320	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-340	Carcinoma, Hepatocellular	26728044	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease.
tissue_expression_ns	hsa-mir-34a	Carcinoma, Hepatocellular	28218742	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5.
tissue_expression_ns	hsa-mir-34a	Carcinoma, Hepatocellular	28950684	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Deregulation of miR-34a and Its Chaperon Hsp70 in Hepatitis C virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma Patients
tissue_expression_ns	hsa-mir-34a	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-34c	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-369	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-432	Carcinoma, Hepatocellular	24592541	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study firstly demonstrated that miRNAs were differentially expressed in HCC-MVs compared with CHB and normal controls. Aberrant HCC-MVs miRNAs may play important roles in the development of HCC.
tissue_expression_ns	hsa-mir-484	Carcinoma, Hepatocellular	26728044	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease.
tissue_expression_ns	hsa-mir-489	Carcinoma, Hepatocellular	28430373	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A five-miRNA expression signature predicts survival in hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-491	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-503	Carcinoma, Hepatocellular	29164842	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others
tissue_expression_ns	hsa-mir-512	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-522	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-542	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-548l	Carcinoma, Hepatocellular	28218742	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5.
tissue_expression_ns	hsa-mir-571	Carcinoma, Hepatocellular	26998997	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miTALOS v5: Analyzing Tissue Specific microRNA Function.
tissue_expression_ns	hsa-mir-574	Carcinoma, Hepatocellular	26728044	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease.
tissue_expression_ns	hsa-mir-576	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-651	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-671	Carcinoma, Hepatocellular	24592541	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our study firstly demonstrated that miRNAs were differentially expressed in HCC-MVs compared with CHB and normal controls. Aberrant HCC-MVs miRNAs may play important roles in the development of HCC.
tissue_expression_ns	hsa-mir-720	Carcinoma, Hepatocellular	26728044	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In this study, fifteen microRNAs which were modulated in hepatic tissues and in tumors during the transition NAFLD-NASH-HCC are reported. Besides some already described, new and early dysregulated miRNAs were identified.Functional analyses are needed to validate the results here obtained, and to better define the role of these molecules in the progression of the hepatic disease.
tissue_expression_ns	hsa-mir-9	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
tissue_expression_ns	hsa-mir-92	Carcinoma, Hepatocellular	26229398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In summary, all the reported results suggest that differences in miRNA expression exist between HCV-related and HCV-negative NHLs, and further studies will be useful to ascertain if miRNAs are involved in the pathogenesis of HCV-related lymphomas and whether they can be used as biomarkers.
tissue_expression_ns	hsa-mir-92a-1	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92: involve
tissue_expression_ns	hsa-mir-92a-1	Carcinoma, Hepatocellular	20518884	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92a:Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development
tissue_expression_ns	hsa-mir-92a-2	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92: involve
tissue_expression_ns	hsa-mir-92a-2	Carcinoma, Hepatocellular	20518884	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92a:Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development
tissue_expression_ns	hsa-mir-92b	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92: involve
tissue_expression_ns	hsa-mir-93	Carcinoma, Hepatocellular	25633810	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-93 stimulated cell proliferation,migration, and invasion through the oncogenic c-Met/PI3K/Akt pathway and also inhibited apoptosis by directly inhibiting PTEN and CDKN1A expression in human HCC.
tissue_expression_ns	hsa-mir-943	Carcinoma, Hepatocellular	27554417	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Diagnosis of HCC for patients with cirrhosis using miRNA profiles of the tumor-surrounding tissue - A statistical model based on stepwise penalized logistic regression.
tissue_expression_ns	hsa-let-7a	Carcinoma, Hepatocellular, HBV-Related	24273923							Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma.
tissue_expression_ns	hsa-let-7c	Carcinoma, Hepatocellular, HBV-Related	24273923							Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-138	Carcinoma, Hepatocellular, HBV-Related	24273923							Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-183	Carcinoma, Hepatocellular, HBV-Related	24273923							Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-196a	Carcinoma, Hepatocellular, HBV-Related	24273923							Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-96	Carcinoma, Hepatocellular, HBV-Related	24273923							Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-10a	Carcinoma, Laryngeal	25266939	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	MicroRNA-10a-5p and microRNA-34c-5p in laryngeal epithelial premalignant lesions:differential expression and clinicopathological correlation.
tissue_expression_ns	hsa-mir-1276	Carcinoma, Laryngeal	27916417	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1276 in laryngeal cancer tissues
tissue_expression_ns	hsa-mir-20a	Carcinoma, Laryngeal	27916417	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1277 in laryngeal cancer tissues
tissue_expression_ns	hsa-mir-29	Carcinoma, Laryngeal	27916417	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1278 in laryngeal cancer tissues
tissue_expression_ns	hsa-mir-34c	Carcinoma, Laryngeal	25266939	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	MicroRNA-10a-5p and microRNA-34c-5p in laryngeal epithelial premalignant lesions:differential expression and clinicopathological correlation.
tissue_expression_ns	hsa-mir-489	Carcinoma, Laryngeal	27916417	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1279 in laryngeal cancer tissues
tissue_expression_ns	hsa-mir-632	Carcinoma, Laryngeal	27916417	disease of cellular proliferation	DOID:2600	C32.3	D007822	21198	HP:0012118	CCR6 was positively associated with miR-20a-5p, miR-489 and negatively related to miR-29-3p, miR-632 and miR-1280 in laryngeal cancer tissues
tissue_expression_ns	hsa-mir-125a	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-mir-125b	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-mir-128	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-mir-149	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-mir-192	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-mir-203	Carcinoma, Lung	26397233	disease of cellular proliferation	DOID:3905	C34.90	D008175			Cumulatively,our data purport that p53 not only increased Puma expression directly, but that it may also do so through miR-203. Additionally, functional studies revealed that miR-203 overexpression induced apoptosis and inhibited cell invasiveness.
tissue_expression_ns	hsa-mir-27a	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-mir-328	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-mir-350	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-mir-486	Carcinoma, Lung	27748875	disease of cellular proliferation	DOID:3905	C34.90	D008175			MicroRNA expression profiles of granulocytic myeloid‑derived suppressor cells from mice bearing Lewis lung carcinoma.
tissue_expression_ns	hsa-let-7a	Carcinoma, Lung, Non-Small-Cell	20975375			C34.90	D002289		HP:0030358	In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC.
tissue_expression_ns	hsa-let-7a	Carcinoma, Lung, Non-Small-Cell	20978195			C34.90	D002289		HP:0030358	We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression.
tissue_expression_ns	hsa-let-7a	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-let-7a	Carcinoma, Lung, Non-Small-Cell	24802132			C34.90	D002289		HP:0030358	Before PRFA, tumor suppressor let-7a and miR-34a were downregulated whereas oncomiR miR-21 was upregulated in primary tumors, and let-7a and miR-126 levels were downregulated whereas oncomiRs miR-21, miR-155 and miR-17-5p/miR-20b levels were upregulated in secondary tumors.
tissue_expression_ns	hsa-let-7b	Carcinoma, Lung, Non-Small-Cell	28534369			C34.90	D002289		HP:0030358	The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
tissue_expression_ns	hsa-mir-10b	Carcinoma, Lung, Non-Small-Cell	24448358			C34.90	D002289		HP:0030358	Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC.
tissue_expression_ns	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	27665734			C34.90	D002289		HP:0030358	Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line.
tissue_expression_ns	hsa-mir-128	Carcinoma, Lung, Non-Small-Cell	24448358			C34.90	D002289		HP:0030358	Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC.
tissue_expression_ns	hsa-mir-130a	Carcinoma, Lung, Non-Small-Cell	20625274			C34.90	D002289		HP:0030358	Multivariate Cox regression analysis showed that miRNA-130a was an independent prognostic factor for patients with NSCLC.
tissue_expression_ns	hsa-mir-143	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	20975375			C34.90	D002289		HP:0030358	In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC.
tissue_expression_ns	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-15a	Carcinoma, Lung, Non-Small-Cell	28537679			C34.90	D002289		HP:0030358	MiR-15a expression analysis in non-small cell lung cancer A549 cells under local hypoxia microenvironment.
tissue_expression_ns	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	28534369			C34.90	D002289		HP:0030358	The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
tissue_expression_ns	hsa-mir-182	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-192	Carcinoma, Lung, Non-Small-Cell	24448358			C34.90	D002289		HP:0030358	Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC.
tissue_expression_ns	hsa-mir-200b	Carcinoma, Lung, Non-Small-Cell	27876017			C34.90	D002289		HP:0030358	miR-27b and miR-200b levels were determined in resected adenocarcinoma and squamous cell carcinoma samples by qRT-PCR
tissue_expression_ns	hsa-mir-203	Carcinoma, Lung, Non-Small-Cell	29088807			C34.90	D002289		HP:0030358	Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis.
tissue_expression_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	23759980			C34.90	D002289		HP:0030358	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma.
tissue_expression_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	29088807			C34.90	D002289		HP:0030358	Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis.
tissue_expression_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	20975375			C34.90	D002289		HP:0030358	In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC.
tissue_expression_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	20978195			C34.90	D002289		HP:0030358	We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression.
tissue_expression_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	28799568			C34.90	D002289		HP:0030358	Association of long non-coding RNA H19 and microRNA-21 expression with the biological features and prognosis of non-small cell lung cancer.
tissue_expression_ns	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	20975375			C34.90	D002289		HP:0030358	In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC.
tissue_expression_ns	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	20975375			C34.90	D002289		HP:0030358	In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC.
tissue_expression_ns	hsa-mir-27b	Carcinoma, Lung, Non-Small-Cell	27876017			C34.90	D002289		HP:0030358	miR-27b and miR-200b levels were determined in resected adenocarcinoma and squamous cell carcinoma samples by qRT-PCR
tissue_expression_ns	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	20978195			C34.90	D002289		HP:0030358	We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression.
tissue_expression_ns	hsa-mir-34b	Carcinoma, Lung, Non-Small-Cell	20978195			C34.90	D002289		HP:0030358	We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression.
tissue_expression_ns	hsa-mir-34c	Carcinoma, Lung, Non-Small-Cell	20978195			C34.90	D002289		HP:0030358	We also analyzed the association of TP53 mutation status and miR-34a/b/c expression, epidermal growth factor receptor and KRAS mutation status, and miR-21 and Let-7a expression.
tissue_expression_ns	hsa-mir-372	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-375	Carcinoma, Lung, Non-Small-Cell	29088807			C34.90	D002289		HP:0030358	Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis.
tissue_expression_ns	hsa-mir-502	Carcinoma, Lung, Non-Small-Cell	24448358			C34.90	D002289		HP:0030358	Expression of miR-128, -10b, -502-3p and -192 differed between SCC and AC, and miR-128 and -192 - between NLP and NSCLC.
tissue_expression_ns	hsa-mir-662	Carcinoma, Lung, Non-Small-Cell	24448358			C34.90	D002289		HP:0030358	Of these six miRNAs, miR-662, -192 and -192* were confirmed as  prognostic in the independent SCC cohort.
tissue_expression_ns	hsa-mir-7	Carcinoma, Lung, Non-Small-Cell	20975375			C34.90	D002289		HP:0030358	In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with resected stage I NSCLC.
tissue_expression_ns	hsa-mir-92	Carcinoma, Lung, Non-Small-Cell	23043708			C34.90	D002289		HP:0030358	The relative expressions of 11 miRNAs in sputum (miR-21, miR-145,miR-155, miR-205, miR-210, miR-92, miR-17-5p, miR-143, miR-182, miR-372, and let-7a) in addition to U6 were retrospectively assessed in four NSCLC-positive and four negative controls.
tissue_expression_ns	hsa-mir-92a	Carcinoma, Lung, Non-Small-Cell	28534369			C34.90	D002289		HP:0030358	The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
tissue_expression_ns	hsa-let-7d	Carcinoma, Lung, Non-Small-Cell	25873351			C34.90	D002289		HP:0030358	mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells.
tissue_expression_ns	hsa-let-7e	Carcinoma, Lung, Non-Small-Cell	24945821			C34.90	D002289		HP:0030358	Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer.
tissue_expression_ns	hsa-mir-124a	Carcinoma, Lung, Non-Small-Cell	24113142			C34.90	D002289		HP:0030358	The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice.
tissue_expression_ns	hsa-mir-125a	Carcinoma, Lung, Non-Small-Cell	24945821			C34.90	D002289		HP:0030358	Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer.
tissue_expression_ns	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	24113142			C34.90	D002289		HP:0030358	The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice.
tissue_expression_ns	hsa-mir-127	Carcinoma, Lung, Non-Small-Cell	25873351			C34.90	D002289		HP:0030358	mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells.
tissue_expression_ns	hsa-mir-143	Carcinoma, Lung, Non-Small-Cell	24286416			C34.90	D002289		HP:0030358	It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate  marker for differentiating adenocarcinoma from squamous cell carcinoma.
tissue_expression_ns	hsa-mir-143	Carcinoma, Lung, Non-Small-Cell	25862841			C34.90	D002289		HP:0030358	miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC.
tissue_expression_ns	hsa-mir-150	Carcinoma, Lung, Non-Small-Cell	24286416			C34.90	D002289		HP:0030358	It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate  marker for differentiating adenocarcinoma from squamous cell carcinoma.
tissue_expression_ns	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	25862841			C34.90	D002289		HP:0030358	miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC.
tissue_expression_ns	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	24460255			C34.90	D002289		HP:0030358	the miR-155 expression level plays a prognostic role in patients with cancer, especially NSCLCs and digestive system carcinomas.
tissue_expression_ns	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	25873351			C34.90	D002289		HP:0030358	mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells.
tissue_expression_ns	hsa-mir-15b	Carcinoma, Lung, Non-Small-Cell	22389695			C34.90	D002289		HP:0030358	A combination of two differentially expressed miRNAs miR-15b and miR-27b, was able to discriminate NSCLC from healthy controls with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 100% in the training set.
tissue_expression_ns	hsa-mir-197	Carcinoma, Lung, Non-Small-Cell	25867273			C34.90	D002289		HP:0030358	The cost-effective expression analysis of miR-197 could constitute a novel molecular tool for NSCLC management.
tissue_expression_ns	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	24113142			C34.90	D002289		HP:0030358	The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice.
tissue_expression_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	25862841			C34.90	D002289		HP:0030358	miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC.
tissue_expression_ns	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	25862841			C34.90	D002289		HP:0030358	miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC.
tissue_expression_ns	hsa-mir-27b	Carcinoma, Lung, Non-Small-Cell	22389695			C34.90	D002289		HP:0030358	A combination of two differentially expressed miRNAs miR-15b and miR-27b, was able to discriminate NSCLC from healthy controls with sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 100% in the training set.
tissue_expression_ns	hsa-mir-34	Carcinoma, Lung, Non-Small-Cell	24113142			C34.90	D002289		HP:0030358	The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice.
tissue_expression_ns	hsa-mir-372	Carcinoma, Lung, Non-Small-Cell	25862841			C34.90	D002289		HP:0030358	miRNA expression profiling of sputum and BAL fluids represent a potential means to detect early-stage NSCLC.
tissue_expression_ns	hsa-mir-9	Carcinoma, Lung, Non-Small-Cell	24113142			C34.90	D002289		HP:0030358	The developed prediction algorithm is a valuable potential biomarker for assisting lung cancer diagnosis in minimal biopsy material. A prospective validation is required to measure the enhancement of diagnostic accuracy of our current clinical practice.
tissue_expression_ns	hsa-mir-155	Carcinoma, Lung, Small-Cell	27682492			C34.90	D055752	182280	HP:0030357	Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes.
tissue_expression_ns	hsa-mir-28	Carcinoma, Lung, Small-Cell	27682492			C34.90	D055752	182280	HP:0030357	Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes.
tissue_expression_ns	hsa-mir-30	Carcinoma, Lung, Small-Cell	27682492			C34.90	D055752	182280	HP:0030357	Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes.
tissue_expression_ns	hsa-mir-324	Carcinoma, Lung, Small-Cell	27682492			C34.90	D055752	182280	HP:0030357	Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes.
tissue_expression_ns	hsa-mir-34c	Carcinoma, Lung, Small-Cell	27682492			C34.90	D055752	182280	HP:0030357	Changes of microRNAs profiling in mesothelial cells exposed to multi-walled carbon nanotubes.
tissue_expression_ns	hsa-mir-302a	Carcinoma, Mucoepidermoid	29095552	disease of cellular proliferation	DOID:4531		D018277			miRNA expression profile of mucoepidermoid carcinoma.
tissue_expression_ns	hsa-let-7i	Carcinoma, Nasopharyngeal	29455649	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-142, miR-26a, miR-141 and let-7i have significant prognostic power
tissue_expression_ns	hsa-mir-130a	Carcinoma, Nasopharyngeal	27350400	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma
tissue_expression_ns	hsa-mir-1323	Carcinoma, Nasopharyngeal	24367666	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing.
tissue_expression_ns	hsa-mir-141	Carcinoma, Nasopharyngeal	29455649	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-142, miR-26a, miR-141 and let-7i have significant prognostic power
tissue_expression_ns	hsa-mir-142	Carcinoma, Nasopharyngeal	29455649	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-142, miR-26a, miR-141 and let-7i have significant prognostic power
tissue_expression_ns	hsa-mir-18b	Carcinoma, Nasopharyngeal	27350400	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma
tissue_expression_ns	hsa-mir-205	Carcinoma, Nasopharyngeal	27350400	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma
tissue_expression_ns	hsa-mir-205	Carcinoma, Nasopharyngeal	28931826	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma
tissue_expression_ns	hsa-mir-26a	Carcinoma, Nasopharyngeal	29455649	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	miR-142, miR-26a, miR-141 and let-7i have significant prognostic power
tissue_expression_ns	hsa-mir-324	Carcinoma, Nasopharyngeal	24367666	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing.
tissue_expression_ns	hsa-mir-34b	Carcinoma, Nasopharyngeal	26330189	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non-cancerous nasopharyngeal tissues.
tissue_expression_ns	hsa-mir-34b	Carcinoma, Nasopharyngeal	27350400	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma
tissue_expression_ns	hsa-mir-34c	Carcinoma, Nasopharyngeal	24367666	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing.
tissue_expression_ns	hsa-mir-371a	Carcinoma, Nasopharyngeal	24367666	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing.
tissue_expression_ns	hsa-mir-4501	Carcinoma, Nasopharyngeal	24367666	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing.
tissue_expression_ns	hsa-mir-632	Carcinoma, Nasopharyngeal	27350400	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	hsa-miR-205, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, and hsa-miR-34b may be related to the development of nasopharyngeal carcinoma
tissue_expression_ns	hsa-mir-93	Carcinoma, Nasopharyngeal	24367666	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing.
tissue_expression_ns	hsa-mir-10b	Carcinoma, Oral	22318752	gastrointestinal system disease	DOID:0050610					hsa-mir-10b has the potential for Oncogenic Function and Early Detection in Oral Cancer as Identified by microRNA Profiling.
tissue_expression_ns	hsa-mir-1271	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-130b	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-135b	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-141	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-143	Carcinoma, Ovarian	27748916	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma.
tissue_expression_ns	hsa-mir-15b	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-182	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-183	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-196b	Carcinoma, Ovarian	25964536	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC.
tissue_expression_ns	hsa-mir-19b	Carcinoma, Ovarian	25964536	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC.
tissue_expression_ns	hsa-mir-3198	Carcinoma, Ovarian	25964536	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC.
tissue_expression_ns	hsa-mir-3201	Carcinoma, Ovarian	25964536	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC.
tissue_expression_ns	hsa-mir-3613	Carcinoma, Ovarian	25964536	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC.
tissue_expression_ns	hsa-mir-381	Carcinoma, Ovarian	27757782	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.
tissue_expression_ns	hsa-mir-424	Carcinoma, Ovarian	27757782	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.
tissue_expression_ns	hsa-mir-510	Carcinoma, Ovarian	26497752	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
tissue_expression_ns	hsa-mir-551b	Carcinoma, Ovarian	25964536	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC.
tissue_expression_ns	hsa-mir-574	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-7515	Carcinoma, Ovarian	25964536	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC.
tissue_expression_ns	hsa-mir-8084	Carcinoma, Ovarian	25964536	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Based on our data, dysregulation of microRNA expression was associated with the recurrence of EOC. Moreover, significantly over- and down-regulated microRNAs can be useful biomarkers for the prediction of recurrence in EOC.
tissue_expression_ns	hsa-mir-96	Carcinoma, Ovarian	24816756	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.
tissue_expression_ns	hsa-mir-29a	Carcinoma, Ovarian, Serous	27063471	endocrine system disease	DOID:0050933					miR-29a and its target DNMT3A are novel candidate biomarkers of longer and shorter survival, respectively, in metastatic high-grade serous carcinoma.
tissue_expression_ns	hsa-mir-30a	Carcinoma, Ovarian, Serous	24676806	endocrine system disease	DOID:0050933					The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma.
tissue_expression_ns	hsa-mir-30e	Carcinoma, Ovarian, Serous	24676806	endocrine system disease	DOID:0050933					The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma.
tissue_expression_ns	hsa-mir-483	Carcinoma, Ovarian, Serous	23836287	endocrine system disease	DOID:0050933					MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
tissue_expression_ns	hsa-mir-508	Carcinoma, Ovarian, Serous	23836287	endocrine system disease	DOID:0050933					MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
tissue_expression_ns	hsa-mir-509	Carcinoma, Ovarian, Serous	23836287	endocrine system disease	DOID:0050933					MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
tissue_expression_ns	hsa-mir-510	Carcinoma, Ovarian, Serous	23836287	endocrine system disease	DOID:0050933					MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
tissue_expression_ns	hsa-mir-1178	Carcinoma, Pancreatic	28592083			C25.3	C562463	260350	HP:0002894	Correlation between miR-1178 expression and clinicopathological significance in human pancreatic cancer.
tissue_expression_ns	hsa-mir-155	Carcinoma, Pancreatic	27840954			C25.3	C562463	260350	HP:0002894	Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
tissue_expression_ns	hsa-mir-15a	Carcinoma, Pancreatic	27840954			C25.3	C562463	260350	HP:0002894	Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
tissue_expression_ns	hsa-mir-16	Carcinoma, Pancreatic	27840954			C25.3	C562463	260350	HP:0002894	Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
tissue_expression_ns	hsa-mir-375	Carcinoma, Pancreatic	27840954			C25.3	C562463	260350	HP:0002894	Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
tissue_expression_ns	hsa-mir-429	Carcinoma, Pancreatic	27840954			C25.3	C562463	260350	HP:0002894	Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
tissue_expression_ns	hsa-mir-196a	Carcinoma, Periampullary	24555977	disease of cellular proliferation	DOID:8110					Differentially expressed common miRNA signatures identified in PAC subgroups may have a role in pathogenesis of PAC and miR-375, miR-31 and miR-196a expression patterns may differentiate PAC subtypes.
tissue_expression_ns	hsa-mir-31	Carcinoma, Periampullary	24555977	disease of cellular proliferation	DOID:8110					Differentially expressed common miRNA signatures identified in PAC subgroups may have a role in pathogenesis of PAC and miR-375, miR-31 and miR-196a expression patterns may differentiate PAC subtypes.
tissue_expression_ns	hsa-mir-375	Carcinoma, Periampullary	24555977	disease of cellular proliferation	DOID:8110					Differentially expressed common miRNA signatures identified in PAC subgroups may have a role in pathogenesis of PAC and miR-375, miR-31 and miR-196a expression patterns may differentiate PAC subtypes.
tissue_expression_ns	hsa-let-7b	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-1179	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-1184	Carcinoma, Prostate	28072703	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships.
tissue_expression_ns	hsa-mir-1207	Carcinoma, Prostate	28072703	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships.
tissue_expression_ns	hsa-mir-1299	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-130a	Carcinoma, Prostate	27915273	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Altered miRNA expression in high-fat diet-induced prostate cancer progression.
tissue_expression_ns	hsa-mir-145	Carcinoma, Prostate	28617988	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
tissue_expression_ns	hsa-mir-155	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-182	Carcinoma, Prostate	28072703	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships.
tissue_expression_ns	hsa-mir-183	Carcinoma, Prostate	28072703	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships.
tissue_expression_ns	hsa-mir-18a	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-19a	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-200a	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-21	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-221	Carcinoma, Prostate	27630329	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	to evaluate miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy
tissue_expression_ns	hsa-mir-23b	Carcinoma, Prostate	27630329	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	to evaluate miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy
tissue_expression_ns	hsa-mir-24	Carcinoma, Prostate	28072703	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Screening the key microRNAs and transcription factors in prostate cancer based on microRNA functional synergistic relationships.
tissue_expression_ns	hsa-mir-26a	Carcinoma, Prostate	27630329	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	to evaluate miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy
tissue_expression_ns	hsa-mir-30c	Carcinoma, Prostate	26499781	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	The average relative expressions of hsa-miR-203 and hsa-miR-30c in tumor tissues were significantly different from those in adjacent normal tissues
tissue_expression_ns	hsa-mir-3120	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-3149	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-3189	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-3622b	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-3677	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-3682	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-3689d	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-410	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-4469	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-4518	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-5189	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-639	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-92b	Carcinoma, Prostate	27903835	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	the outcome of the study has important clinical implications for the management of prostate cancer, including the use of miRNA(s) as biomarkers for early detection of prostate cancer
tissue_expression_ns	hsa-mir-133b	Carcinoma, Rectal	16854228	disease of cellular proliferation	DOID:1993	C20	D012004			The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183.
tissue_expression_ns	hsa-mir-135b	Carcinoma, Rectal	16854228	disease of cellular proliferation	DOID:1993	C20	D012004			The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183.
tissue_expression_ns	hsa-mir-145	Carcinoma, Rectal	16854228	disease of cellular proliferation	DOID:1993	C20	D012004			The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183.
tissue_expression_ns	hsa-mir-183	Carcinoma, Rectal	16854228	disease of cellular proliferation	DOID:1993	C20	D012004			The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183.
tissue_expression_ns	hsa-mir-203	Carcinoma, Rectal	28403349	disease of cellular proliferation	DOID:1993	C20	D012004			Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors.
tissue_expression_ns	hsa-mir-21	Carcinoma, Rectal	20682703	disease of cellular proliferation	DOID:1993	C20	D012004			Although altered expressions of miR-21 and miR-34a were manifested within cancer cells, those of miR-126 and miR-155 were predominantly confined to endothelial cells and immune cells, respectively.
tissue_expression_ns	hsa-mir-21	Carcinoma, Rectal	28403349	disease of cellular proliferation	DOID:1993	C20	D012004			Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors.
tissue_expression_ns	hsa-mir-31	Carcinoma, Rectal	16854228	disease of cellular proliferation	DOID:1993	C20	D012004			The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183.
tissue_expression_ns	hsa-mir-34a	Carcinoma, Rectal	20682703	disease of cellular proliferation	DOID:1993	C20	D012004			Although altered expressions of miR-21 and miR-34a were manifested within cancer cells, those of miR-126 and miR-155 were predominantly confined to endothelial cells and immune cells, respectively.
tissue_expression_ns	hsa-mir-92b	Carcinoma, Rectal	27601590	disease of cellular proliferation	DOID:1993	C20	D012004			Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
tissue_expression_ns	hsa-mir-96	Carcinoma, Rectal	16854228	disease of cellular proliferation	DOID:1993	C20	D012004			The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13 miRNA whose expression is significantly altered in this tumor. The most significantly deregulated miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183.
tissue_expression_ns	hsa-let-7c	Carcinoma, Renal Cell	23799849	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling.
tissue_expression_ns	hsa-mir-106a	Carcinoma, Renal Cell	24977165	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles.
tissue_expression_ns	hsa-mir-10b	Carcinoma, Renal Cell	22623952	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis.
tissue_expression_ns	hsa-mir-126	Carcinoma, Renal Cell	22033272	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression level of this miRNA was significantly altered in two independent cohorts of patients.
tissue_expression_ns	hsa-mir-126	Carcinoma, Renal Cell	24428907	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A combined expression level of miR-21 and miR-126 accurately predicted CSS in two independent RCC cohorts and seems feasible for clinical application in assessing prognosis.
tissue_expression_ns	hsa-mir-130b	Carcinoma, Renal Cell	22623952	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis.
tissue_expression_ns	hsa-mir-135a	Carcinoma, Renal Cell	24977165	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles.
tissue_expression_ns	hsa-mir-139	Carcinoma, Renal Cell	22623952	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis.
tissue_expression_ns	hsa-mir-141	Carcinoma, Renal Cell	24129247	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression analysis of miR-141 or miR-200b accurately distinguished RCTs from normal renal tissues, oncocytoma from RCC and chRCC from oncocytoma. The diagnostic performance was confirmed in the validation set. Interestingly,miR-21, miR-141 and miR-155 expression levels showed prognostic significance in a univariate analysis.
tissue_expression_ns	hsa-mir-141	Carcinoma, Renal Cell	23635949	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC.
tissue_expression_ns	hsa-mir-141	Carcinoma, Renal Cell	27357429	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-142	Carcinoma, Renal Cell	24977165	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles.
tissue_expression_ns	hsa-mir-145	Carcinoma, Renal Cell	23799849	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling.
tissue_expression_ns	hsa-mir-155	Carcinoma, Renal Cell	24129247	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression analysis of miR-141 or miR-200b accurately distinguished RCTs from normal renal tissues, oncocytoma from RCC and chRCC from oncocytoma. The diagnostic performance was confirmed in the validation set. Interestingly,miR-21, miR-141 and miR-155 expression levels showed prognostic significance in a univariate analysis.
tissue_expression_ns	hsa-mir-15a	Carcinoma, Renal Cell	29549624	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
tissue_expression_ns	hsa-mir-195	Carcinoma, Renal Cell	22623952	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis.
tissue_expression_ns	hsa-mir-196a-1	Carcinoma, Renal Cell	22033272	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression level of this miRNA was significantly altered in two independent cohorts of patients.
tissue_expression_ns	hsa-mir-199b	Carcinoma, Renal Cell	22623952	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression levels of miR-10b, miR-139-5p, miR-130b and miR-199b-5p could determine the status of ccRCC metastasis.
tissue_expression_ns	hsa-mir-200	Carcinoma, Renal Cell	27357429	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-200a	Carcinoma, Renal Cell	23074016	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney
tissue_expression_ns	hsa-mir-200a	Carcinoma, Renal Cell	23635949	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC.
tissue_expression_ns	hsa-mir-200a	Carcinoma, Renal Cell	27357429	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-200b	Carcinoma, Renal Cell	23074016	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney
tissue_expression_ns	hsa-mir-200b	Carcinoma, Renal Cell	23635949	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC.
tissue_expression_ns	hsa-mir-200b	Carcinoma, Renal Cell	27357429	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-200b	Carcinoma, Renal Cell	29416756	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-126, miR-222 and miR-200b were significantly differentially expressed between the subtypes by in situ hybridization
tissue_expression_ns	hsa-mir-200c	Carcinoma, Renal Cell	23074016	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney
tissue_expression_ns	hsa-mir-200c	Carcinoma, Renal Cell	23799849	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling.
tissue_expression_ns	hsa-mir-200c	Carcinoma, Renal Cell	23635949	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC.
tissue_expression_ns	hsa-mir-200c	Carcinoma, Renal Cell	27357429	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	two types of cancer showed opposite expression patterns for miR-200 family miRNAs
tissue_expression_ns	hsa-mir-204	Carcinoma, Renal Cell	22033272	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression level of this miRNA was significantly altered in two independent cohorts of patients.
tissue_expression_ns	hsa-mir-206	Carcinoma, Renal Cell	24977165	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles.
tissue_expression_ns	hsa-mir-21	Carcinoma, Renal Cell	24428907	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A combined expression level of miR-21 and miR-126 accurately predicted CSS in two independent RCC cohorts and seems feasible for clinical application in assessing prognosis.
tissue_expression_ns	hsa-mir-21	Carcinoma, Renal Cell	26729387	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol.
tissue_expression_ns	hsa-mir-21	Carcinoma, Renal Cell	24977165	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles.
tissue_expression_ns	hsa-mir-21	Carcinoma, Renal Cell	24129247	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Expression analysis of miR-141 or miR-200b accurately distinguished RCTs from normal renal tissues, oncocytoma from RCC and chRCC from oncocytoma. The diagnostic performance was confirmed in the validation set. Interestingly,miR-21, miR-141 and miR-155 expression levels showed prognostic significance in a univariate analysis.
tissue_expression_ns	hsa-mir-210	Carcinoma, Renal Cell	23150176	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma
tissue_expression_ns	hsa-mir-210	Carcinoma, Renal Cell	23799849	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling.
tissue_expression_ns	hsa-mir-215	Carcinoma, Renal Cell	22033272	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The expression level of this miRNA was significantly altered in two independent cohorts of patients. Overexpression of miR-215 decreased cellular migration and invasion in an RCC cell line model. In addition, through gene expression profiling, the authors identified direct and indirect targets of miR-215 that can contribute to tumour metastasis.
tissue_expression_ns	hsa-mir-216b	Carcinoma, Renal Cell	24977165	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles.
tissue_expression_ns	hsa-mir-221	Carcinoma, Renal Cell	29416756	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-126, miR-222 and miR-201b were significantly differentially expressed between the subtypes by in situ hybridization
tissue_expression_ns	hsa-mir-222	Carcinoma, Renal Cell	29416756	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-126, miR-222 and miR-202b were significantly differentially expressed between the subtypes by in situ hybridization
tissue_expression_ns	hsa-mir-2278	Carcinoma, Renal Cell	28099931	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A new semisynthetic cardenolide analog 3β-2-(1-amantadine)- 1-on-ethylamine-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines.
tissue_expression_ns	hsa-mir-3065	Carcinoma, Renal Cell	24977165	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles.
tissue_expression_ns	hsa-mir-363	Carcinoma, Renal Cell	24977165	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles.
tissue_expression_ns	hsa-mir-429	Carcinoma, Renal Cell	23635949	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial-mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC.
tissue_expression_ns	hsa-mir-489	Carcinoma, Renal Cell	24621579	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	New miRNA profiles accurately distinguish renal cell carcinomas and upper tract urothelial carcinomas from the normal kidney.
tissue_expression_ns	hsa-mir-502	Carcinoma, Renal Cell	23799849	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling.
tissue_expression_ns	hsa-mir-670	Carcinoma, Renal Cell	28099931	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	A new semisynthetic cardenolide analog 3β-2-(1-amantadine)- 1-on-ethylamine-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines.
tissue_expression_ns	hsa-mir-191	Carcinoma, Renal Cell, Chromophobe	25981392	disease of cellular proliferation	DOID:4471					mir-191, mir-19a, mir-210, and mir-425 miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC.
tissue_expression_ns	hsa-mir-19a	Carcinoma, Renal Cell, Chromophobe	25981392	disease of cellular proliferation	DOID:4471					mir-191, mir-19a, mir-210, and mir-425 miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC.
tissue_expression_ns	hsa-mir-210	Carcinoma, Renal Cell, Chromophobe	25981392	disease of cellular proliferation	DOID:4471					mir-191, mir-19a, mir-210, and mir-425 miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC.
tissue_expression_ns	hsa-mir-425	Carcinoma, Renal Cell, Chromophobe	25981392	disease of cellular proliferation	DOID:4471					mir-191, mir-19a, mir-210, and mir-425 miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC.
tissue_expression_ns	hsa-let-7a	Carcinoma, Renal Cell, Clear-Cell	28694731	disease of cellular proliferation	DOID:4467				HP:0006770	Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma.
tissue_expression_ns	hsa-let-7b	Carcinoma, Renal Cell, Clear-Cell	28694731	disease of cellular proliferation	DOID:4467				HP:0006770	Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma.
tissue_expression_ns	hsa-let-7d	Carcinoma, Renal Cell, Clear-Cell	28694731	disease of cellular proliferation	DOID:4467				HP:0006770	Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma.
tissue_expression_ns	hsa-let-7e	Carcinoma, Renal Cell, Clear-Cell	28694731	disease of cellular proliferation	DOID:4467				HP:0006770	Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma.
tissue_expression_ns	hsa-let-7g	Carcinoma, Renal Cell, Clear-Cell	24351440	disease of cellular proliferation	DOID:4467				HP:0006770	MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.
tissue_expression_ns	hsa-let-7g	Carcinoma, Renal Cell, Clear-Cell	28694731	disease of cellular proliferation	DOID:4467				HP:0006770	Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma.
tissue_expression_ns	hsa-mir-122	Carcinoma, Renal Cell, Clear-Cell	28184927	disease of cellular proliferation	DOID:4467				HP:0006770	miR-122 and miR-34a, respectively, may regulate their expression in this cancer
tissue_expression_ns	hsa-mir-126	Carcinoma, Renal Cell, Clear-Cell	29202733	disease of cellular proliferation	DOID:4467				HP:0006770	Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics
tissue_expression_ns	hsa-mir-142	Carcinoma, Renal Cell, Clear-Cell	24351440	disease of cellular proliferation	DOID:4467				HP:0006770	MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.
tissue_expression_ns	hsa-mir-200b	Carcinoma, Renal Cell, Clear-Cell	29202733	disease of cellular proliferation	DOID:4467				HP:0006770	Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics
tissue_expression_ns	hsa-mir-204	Carcinoma, Renal Cell, Clear-Cell	24351440	disease of cellular proliferation	DOID:4467				HP:0006770	MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.
tissue_expression_ns	hsa-mir-21	Carcinoma, Renal Cell, Clear-Cell	24351440	disease of cellular proliferation	DOID:4467				HP:0006770	MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.
tissue_expression_ns	hsa-mir-29a	Carcinoma, Renal Cell, Clear-Cell	25938468	disease of cellular proliferation	DOID:4467				HP:0006770	This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB.
tissue_expression_ns	hsa-mir-34a	Carcinoma, Renal Cell, Clear-Cell	28184927	disease of cellular proliferation	DOID:4467				HP:0006770	Downregulation of OCLN and GAS1 in clear cell renal cell carcinoma.
tissue_expression_ns	hsa-mir-378	Carcinoma, Renal Cell, Clear-Cell	25119741	disease of cellular proliferation	DOID:4467				HP:0006770	The tumors of patients with ccRCC had lower  expression of miR-126 and miR-378 during the early stages of disease (T1), but higher expression of these miRNAs during the later stages of disease (T2/T3).
tissue_expression_ns	hsa-mir-424	Carcinoma, Renal Cell, Clear-Cell	24351440	disease of cellular proliferation	DOID:4467				HP:0006770	MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.
tissue_expression_ns	hsa-mir-429	Carcinoma, Renal Cell, Clear-Cell	25938468	disease of cellular proliferation	DOID:4467				HP:0006770	This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB.
tissue_expression_ns	hsa-mir-452	Carcinoma, Renal Cell, Clear-Cell	25938468	disease of cellular proliferation	DOID:4467				HP:0006770	This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB.
tissue_expression_ns	hsa-mir-487a	Carcinoma, Renal Cell, Clear-Cell	25938468	disease of cellular proliferation	DOID:4467				HP:0006770	This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB.
tissue_expression_ns	hsa-mir-491	Carcinoma, Renal Cell, Clear-Cell	25938468	disease of cellular proliferation	DOID:4467				HP:0006770	This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB.
tissue_expression_ns	hsa-mir-532	Carcinoma, Renal Cell, Clear-Cell	25938468	disease of cellular proliferation	DOID:4467				HP:0006770	This study identified 11 commonly dysregulated miRNAs in ccRCC,three of which (miR-199a-5p, miR-22 and miR-429) may represent key miRNAs involved in the pathogenesis of ccRCC. Further studies suggested that miR-199a-5p plays an important role in inhibition of cell invasion of ccRCC cells by suppressing expression of TGFBR1 and JunB.
tissue_expression_ns	hsa-mir-1	Carcinoma, Skin	23646287	disease of cellular proliferation	DOID:3451	D04.9	D018280		HP:0008069	Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice.
tissue_expression_ns	hsa-mir-19a	Carcinoma, Supraglottic	24676647	disease of cellular proliferation	DOID:13476	C32.1	D059525			MicroRNA expression profiles in supraglottic carcinoma.
tissue_expression_ns	hsa-mir-206	Carcinoma, Supraglottic	24676647	disease of cellular proliferation	DOID:13476	C32.1	D059525			MicroRNA expression profiles in supraglottic carcinoma.
tissue_expression_ns	hsa-mir-21	Carcinoma, Supraglottic	24676647	disease of cellular proliferation	DOID:13476	C32.1	D059525			MicroRNA expression profiles in supraglottic carcinoma.
tissue_expression_ns	hsa-mir-33a	Carcinoma, Supraglottic	24676647	disease of cellular proliferation	DOID:13476	C32.1	D059525			MicroRNA expression profiles in supraglottic carcinoma.
tissue_expression_ns	hsa-mir-375	Carcinoma, Supraglottic	24676647	disease of cellular proliferation	DOID:13476	C32.1	D059525			MicroRNA expression profiles in supraglottic carcinoma.
tissue_expression_ns	hsa-let-7a	Carcinoma, Thyroid	28655518	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis.
tissue_expression_ns	hsa-mir-150	Carcinoma, Thyroid	24443580	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.
tissue_expression_ns	hsa-mir-23b	Carcinoma, Thyroid	24443580	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.
tissue_expression_ns	hsa-mir-10b	Carcinoma, Thyroid, Anaplastic	29397781			C73	D065646	188550	HP:0011779	These results demonstrate that IR deregulates microRNA expression, affecting the double-strand DNA breaks repair efficiency of irradiated thyroid cells, and suggest that miR-10b-5p overexpression may be an innovative approach for anaplastic thyroid cancer therapy by increasing cancer cell radiosensitivity.
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Follicular	24631480	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.
tissue_expression_ns	hsa-mir-183	Carcinoma, Thyroid, Follicular	24631480	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.
tissue_expression_ns	hsa-mir-199b	Carcinoma, Thyroid, Follicular	24631480	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.
tissue_expression_ns	hsa-mir-221	Carcinoma, Thyroid, Follicular	24631480	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.
tissue_expression_ns	hsa-mir-151a	Carcinoma, Thyroid, Medullary	27666315	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears.
tissue_expression_ns	hsa-mir-183	Carcinoma, Thyroid, Medullary	23072640	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	This further validates previously reported miRNA profile analyses and reiterates the potential significance of miR-9*, -183 and -375 in the pathophysiology of MTC.
tissue_expression_ns	hsa-mir-197	Carcinoma, Thyroid, Medullary	27666315	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears.
tissue_expression_ns	hsa-mir-214	Carcinoma, Thyroid, Medullary	27666315	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears.
tissue_expression_ns	hsa-mir-375	Carcinoma, Thyroid, Medullary	23072640	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	This further validates previously reported miRNA profile analyses and reiterates the potential significance of miR-9*, -183 and -375 in the pathophysiology of MTC.
tissue_expression_ns	hsa-mir-375	Carcinoma, Thyroid, Medullary	28861609	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome.
tissue_expression_ns	hsa-mir-9	Carcinoma, Thyroid, Medullary	23072640	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	This further validates previously reported miRNA profile analyses and reiterates the potential significance of miR-9*, -183 and -375 in the pathophysiology of MTC.
tissue_expression_ns	hsa-mir-99a	Carcinoma, Thyroid, Medullary	27666315	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears.
tissue_expression_ns	hsa-let-7a	Carcinoma, Thyroid, Papillary	25720323	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.
tissue_expression_ns	hsa-mir-1179	Carcinoma, Thyroid, Papillary	25720323	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.
tissue_expression_ns	hsa-mir-1179	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-1271	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-130b	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-135b	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-140	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-144	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	25771986	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Since miR-146b-5p was mainly expressed in PTC including FVPTC and was not expressed in most FTC, PDTC, or ATC, it may serve as a useful diagnostic  marker for PTC. ISH is a useful method to analyze microRNA expression in formalin-fixed paraffin-embedded thyroid tissues.
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	25720323	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	20459574	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	21842215	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	26321247	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miRNA-222 and miRNA-146b deregulation are commonly associated with cancer recurrence in patients with papillary thyroid carcinoma.
tissue_expression_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	28599426	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.
tissue_expression_ns	hsa-mir-151	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-15a	Carcinoma, Thyroid, Papillary	26252081	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	We found that the area under the curve (AUC) values of 8 miRNAs (miR-106a, miR-15a, miR-30a, miR-30b, miR-20a, miR-20b, miR-30d and miR-30e)
tissue_expression_ns	hsa-mir-181-2	Carcinoma, Thyroid, Papillary	23427895	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p).
tissue_expression_ns	hsa-mir-181b	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-181b	Carcinoma, Thyroid, Papillary	21842215	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma
tissue_expression_ns	hsa-mir-192	Carcinoma, Thyroid, Papillary	25720323	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.
tissue_expression_ns	hsa-mir-199b	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-204	Carcinoma, Thyroid, Papillary	25720323	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.
tissue_expression_ns	hsa-mir-204	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-20a	Carcinoma, Thyroid, Papillary	26252081	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	We found that the area under the curve (AUC) values of 8 miRNAs (miR-106a, miR-15a, miR-30a, miR-30b, miR-20a, miR-20b, miR-30d and miR-30e)
tissue_expression_ns	hsa-mir-21	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-21	Carcinoma, Thyroid, Papillary	25771986	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Since miR-146b-5p was mainly expressed in PTC including FVPTC and was not expressed in most FTC, PDTC, or ATC, it may serve as a useful diagnostic  marker for PTC. ISH is a useful method to analyze microRNA expression in formalin-fixed paraffin-embedded thyroid tissues.
tissue_expression_ns	hsa-mir-21	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-21	Carcinoma, Thyroid, Papillary	21842215	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma
tissue_expression_ns	hsa-mir-221	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-221	Carcinoma, Thyroid, Papillary	25720323	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.
tissue_expression_ns	hsa-mir-221	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-221	Carcinoma, Thyroid, Papillary	21842215	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma
tissue_expression_ns	hsa-mir-221	Carcinoma, Thyroid, Papillary	28599426	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.
tissue_expression_ns	hsa-mir-222	Carcinoma, Thyroid, Papillary	25720323	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.
tissue_expression_ns	hsa-mir-222	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-222	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-222	Carcinoma, Thyroid, Papillary	29435194	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: a systematic review and meta-analysis
tissue_expression_ns	hsa-mir-222	Carcinoma, Thyroid, Papillary	21842215	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miRNA profiling of hyalinizing trabecular tumours compared with benign thyroid lesions and papillary thyroid carcinoma failed to demonstrate the characteristic up-regulation found in papillary thyroid carcinoma
tissue_expression_ns	hsa-mir-222	Carcinoma, Thyroid, Papillary	26321247	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miRNA-222 and miRNA-146b deregulation are commonly associated with cancer recurrence in patients with papillary thyroid carcinoma.
tissue_expression_ns	hsa-mir-2861	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-30a	Carcinoma, Thyroid, Papillary	26047355	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	The results of this study suggest that miR-30a-5p might be a novel diagnostic marker candidate in PTC. Further studies are required to investigate this possibility.
tissue_expression_ns	hsa-mir-30e	Carcinoma, Thyroid, Papillary	26252081	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	We found that the area under the curve (AUC) values of 8 miRNAs (miR-106a, miR-15a, miR-30a, miR-30b, miR-20a, miR-20b, miR-30d and miR-30e)
tissue_expression_ns	hsa-mir-34b	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-375	Carcinoma, Thyroid, Papillary	23427895	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p).
tissue_expression_ns	hsa-mir-451	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-486	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-551b	Carcinoma, Thyroid, Papillary	23427895	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p).
tissue_expression_ns	hsa-mir-623	Carcinoma, Thyroid, Papillary	26414548	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Further studies are needed to investigate whether miRs are independent predictors of aggressive clinicopathologic features before it can be recommended that miR expression levels should be incorporated into the management algorithm for patients with PTC. A well-designed prospective study is needed to assess these potential associations.
tissue_expression_ns	hsa-mir-7	Carcinoma, Thyroid, Papillary	25720323	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This comprehensive study complements the existing knowledge about deregulated microRNAs in the development of well-differentiated thyroid cancer and identifies novel markers associated with recurrence-free survival.
tissue_expression_ns	hsa-mir-7	Carcinoma, Thyroid, Papillary	28393181	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence
tissue_expression_ns	hsa-mir-99b	Carcinoma, Thyroid, Papillary	23427895	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p).
tissue_expression_ns	hsa-mir-183	Carcinoma, Tounge	28616749							miR-183 and miR-21 expression as biomarkers of progression and survival in tongue carcinoma patients.
tissue_expression_ns	hsa-mir-21	Carcinoma, Tounge	28616749							miR-183 and miR-21 expression as biomarkers of progression and survival in tongue carcinoma patients.
tissue_expression_ns	hsa-mir-630	Carcinoma, Urothelial	27752905	disease of cellular proliferation	DOID:4006				HP:0030409	Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance.
tissue_expression_ns	hsa-mir-181c	Carcinoma, Urothelial, Upper Tract	26397152							Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo.
tissue_expression_ns	hsa-mir-330	Carcinoma, Urothelial, Upper Tract	26397152							Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo.
tissue_expression_ns	hsa-mir-3916	Carcinoma, Urothelial, Upper Tract	26397152							Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo.
tissue_expression_ns	hsa-mir-4274	Carcinoma, Urothelial, Upper Tract	26397152							Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo.
tissue_expression_ns	hsa-mir-4784	Carcinoma, Urothelial, Upper Tract	26397152							Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo.
tissue_expression_ns	hsa-mir-4795	Carcinoma, Urothelial, Upper Tract	26397152							Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo.
tissue_expression_ns	hsa-mir-488	Carcinoma, Urothelial, Upper Tract	26397152							Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo.
tissue_expression_ns	hsa-mir-1	Cardiomegaly	20015039			I51.7	D006332		HP:0001640	Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias.
tissue_expression_ns	hsa-mir-21	Cardiomegaly	20015039			I51.7	D006332		HP:0001640	Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias.
tissue_expression_ns	hsa-mir-200	Cardiomyopathy	27737314	cardiovascular system disease	DOID:0050700	I42	D009202			Analyzing gene expression profiles in dilated cardiomyopathy via bioinformatics methods.
tissue_expression_ns	hsa-mir-30	Cardiomyopathy	27737314	cardiovascular system disease	DOID:0050700	I42	D009202			Analyzing gene expression profiles in dilated cardiomyopathy via bioinformatics methods.
tissue_expression_ns	hsa-mir-9	Cardiomyopathy	27737314	cardiovascular system disease	DOID:0050700	I42	D009202			Analyzing gene expression profiles in dilated cardiomyopathy via bioinformatics methods.
tissue_expression_ns	hsa-mir-10a	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-10b	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-181a-2	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-184	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-204	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-222	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-34b	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-371	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-383	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-497	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-708	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-96	Cardiomyopathy, Hypertrophic	24083979	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	In silico identification of mRNA targets of differentially expressed miRNAs showed a large proportion of genes involved in cardiac hypertrophy and cardiac beta-adrenergic receptor signaling and we showed reduced phosphorylation of cardiac troponin I in the HCM myocardium when compared with donor. HCM patients with MYBPC3 mutations have a specific miRNA expression profile. Downstream mRNA targets reveal possible involvement in cardiac signaling pathways.
tissue_expression_ns	hsa-mir-130a	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-146a	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-15b	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-187	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-199a	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-199b	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-214	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-34a	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-34b	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-424	Cardiotoxicity	27033315				D066126			We report on several microRNAs, including miR-34a, miR-34b, miR-187, miR-199a, miR-199b, miR-146a, miR-15b, miR-130a, miR-214, and miR-424, that are differentially expressed upon, and after, treatment with doxorubicin.
tissue_expression_ns	hsa-mir-133a	Cardiovascular Diseases [unspecific]	27765794				D002318			Inhibition of Aberrant MicroRNA-133a Expression in Endothelial Cells by Statin Prevents Endothelial Dysfunction by Targeting GTP Cyclohydrolase 1 in Vivo.
tissue_expression_ns	hsa-mir-155	Cardiovascular Diseases [unspecific]	25978529				D002318			microRNA expression patterns have a low diagnostic potential clinically in discriminating DCD liver quality and outcome.
tissue_expression_ns	hsa-mir-21	Cardiovascular Diseases [unspecific]	28802862				D002318			MicroRNA-21: Expression in oligodendrocytes and correlation with low myelin mRNAs in depression and alcoholism.
tissue_expression_ns	hsa-mir-22	Cardiovascular Diseases [unspecific]	25978529				D002318			microRNA expression patterns have a low diagnostic potential clinically in discriminating DCD liver quality and outcome.
tissue_expression_ns	hsa-mir-24	Cardiovascular Diseases [unspecific]	27108908				D002318			The dysregulation of miR-24 is associated with dysfunction or even damage of VECs, and contributes to the development of cardiovascular disease.
tissue_expression_ns	hsa-mir-940	Cardiovascular Diseases [unspecific]	25978529				D002318			microRNA expression patterns have a low diagnostic potential clinically in discriminating DCD liver quality and outcome.
tissue_expression_ns	hsa-mir-9	Cerebral Aneurysm	27824808	cardiovascular system disease	DOID:0060228	I67.1	D002532	PS105800	HP:0007029	Aberrant Expression of microRNA-9 Contributes to Development of Intracranial Aneurysm by Suppressing Proliferation and Reducing Contractility of Smooth Muscle Cells.
tissue_expression_ns	hsa-let-7i	Cerebral Malaria	21422175	disease by infectious agent	DOID:14069	B50.0	D016779			We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.
tissue_expression_ns	hsa-mir-150	Cerebral Malaria	21422175	disease by infectious agent	DOID:14069	B50.0	D016779			We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.
tissue_expression_ns	hsa-mir-27a	Cerebral Malaria	21422175	disease by infectious agent	DOID:14069	B50.0	D016779			We identified three miRNAs that were differentially expressed in the brain of PbA-infected CBA mice: let7i, miR-27a, and miR-150.
tissue_expression_ns	hsa-mir-126	Cholangiocarcinoma	23458262	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma
tissue_expression_ns	hsa-mir-151	Cholangiocarcinoma	23458262	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma
tissue_expression_ns	hsa-mir-138	Chondrosarcoma	27267924	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	increased expression of two microRNAs, miRs-181a and -138, in low-grade chondrosarcomas compared with enchondromas
tissue_expression_ns	hsa-mir-149	Chordoma	23826111	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord.
tissue_expression_ns	hsa-mir-1908	Chordoma	23826111	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord.
tissue_expression_ns	hsa-mir-2861	Chordoma	23826111	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord.
tissue_expression_ns	hsa-mir-3185	Chordoma	23826111	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord.
tissue_expression_ns	hsa-mir-663a	Chordoma	23826111	musculoskeletal system disease	DOID:3302	C41.0	D002817	215400	HP:0010762	This study provides an integrated dataset of the miRNA and mRNA profiles in chordomas, and the results demonstrate that not only the MAPK pathway and its related miRNAs but also the Notch pathway may be involved in chordoma development. The occurrence of chordoma may be associated with dysfunctional calcification or ossification of the notochord.
tissue_expression_ns	hsa-mir-194	Choriocarcinoma	26578390	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	we found hsa-miR-194 and  hsa-miR-7 along with 7 transcription factors (TFs) such as SOX11, SMAD3 and SOX4  etc. could correctly differentiate SPN from PanNET
tissue_expression_ns	hsa-mir-203	Choriocarcinoma	20652642	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	miR-203 expression is a new prognostic marker in pancreatic adenocarcinoma patients.
tissue_expression_ns	hsa-mir-204	Choriocarcinoma	26578390	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	while hsa-miR-204 and 4 TFs such as SOX9, TCF7 and PPARD etc. were demonstrated as the potential markers for  SPN versus PDAC.
tissue_expression_ns	hsa-mir-21	Choriocarcinoma	26338526	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Statistical analysis of a Bayesian classifier based on the expression of miRNAs.
tissue_expression_ns	hsa-mir-1238	Chronic Brucellosis	27722176			A23	D002006			Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis.
tissue_expression_ns	hsa-mir-139	Chronic Brucellosis	27722176			A23	D002006			Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis.
tissue_expression_ns	hsa-mir-494	Chronic Brucellosis	27722176			A23	D002006			Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis.
tissue_expression_ns	hsa-mir-6069	Chronic Brucellosis	27722176			A23	D002006			Altered Expressions of miR-1238-3p, miR-494, miR-6069, and miR-139-3p in the Formation of Chronic Brucellosis.
tissue_expression_ns	hsa-mir-146a	Chronic Hepatitis C	27888401			B18.2	D019698	609532		The impact of chronic hepatitis C infection on cholesterol metabolism in PBMCs is associated with microRNA-146a expression.
tissue_expression_ns	hsa-mir-106b	Chronic Kidney Disease	28148896	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial.
tissue_expression_ns	hsa-mir-107	Chronic Kidney Disease	21794090	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05).
tissue_expression_ns	hsa-mir-142	Chronic Kidney Disease	21794090	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05). Furthermore, differential expression of miR-142-3p (p < 0.01), miR-204 (p < 0.01) and miR-211 (p < 0.05) was also observed between patient groups in urine samples.
tissue_expression_ns	hsa-mir-19a	Chronic Kidney Disease	28148896	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial.
tissue_expression_ns	hsa-mir-204	Chronic Kidney Disease	21794090	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05). Furthermore, differential expression of miR-142-3p (p < 0.01), miR-204 (p < 0.01) and miR-211 (p < 0.05) was also observed between patient groups in urine samples.
tissue_expression_ns	hsa-mir-20a	Chronic Kidney Disease	28148896	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial.
tissue_expression_ns	hsa-mir-211	Chronic Kidney Disease	21794090	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05). Furthermore, differential expression of miR-142-3p (p < 0.01), miR-204 (p < 0.01) and miR-211 (p < 0.05) was also observed between patient groups in urine samples.
tissue_expression_ns	hsa-mir-26b	Chronic Kidney Disease	28148896	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial.
tissue_expression_ns	hsa-mir-32	Chronic Kidney Disease	21794090	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Differential expression was detected for miR-142-3p, miR-204, miR-107 and miR-211 (p < 0.001) and miR-32 (p < 0.05).
tissue_expression_ns	hsa-mir-374a	Chronic Kidney Disease	28148896	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial.
tissue_expression_ns	hsa-let-7a	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-let-7c	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-126	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-155	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-200b	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-21	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-210	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-30a	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-451	Chronic Obstructive Pulmonary Disease	29371906	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-198	Chronic Pancreatitis	25908274			K86.1	D050500	167800	HP:0006280	Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-21	Chronic Pancreatitis	25908274			K86.1	D050500	167800	HP:0006280	Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-217	Chronic Pancreatitis	25908274			K86.1	D050500	167800	HP:0006280	Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-mir-34a	Chronic Pancreatitis	25908274			K86.1	D050500	167800	HP:0006280	Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
tissue_expression_ns	hsa-let-7e	Colitis, Ulcerative	23885139	gastrointestinal system disease	DOID:8577	K51	D003093			The present study provides the first evidence that miR-20b, miR-98, miR-125b-1*, and let-7e* are deregulated in patients with UC.
tissue_expression_ns	hsa-let-7c	Colon Neoplasms	29844680			D12.6	D003110		HP:0100273	five hub miRNAs were identified to be related to prognosis (hsa-miR-125b-5p, hsa-miR-145-5p, hsa-let-7c-5p, hsa-miR-218-5p and hsa-miR-125b-2-3p)
tissue_expression_ns	hsa-mir-125b	Colon Neoplasms	29844680			D12.6	D003110		HP:0100273	five hub miRNAs were identified to be related to prognosis (hsa-miR-125b-5p, hsa-miR-145-5p, hsa-let-7c-5p, hsa-miR-218-5p and hsa-miR-125b-2-3p)
tissue_expression_ns	hsa-mir-138	Colon Neoplasms	24941171			D12.6	D003110		HP:0100273	This is the first to reveal the importance of aberrant expression of miRNAs in dynamically transformation from chronic colitis to colitis-associated cancer. These findings shed light on revealing the mechanisms of chronic colitis malignant transformation.
tissue_expression_ns	hsa-mir-138	Colon Neoplasms	24732966			D12.6	D003110		HP:0100273	miRs including mir-425, mir-196, mir-155, mir-150, mir-351, mir-16, let-7, mir34, and  mir-138 were differentially expressed between the dietary groups.
tissue_expression_ns	hsa-mir-143	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-145	Colon Neoplasms	24941171			D12.6	D003110		HP:0100273	This is the first to reveal the importance of aberrant expression of miRNAs in dynamically transformation from chronic colitis to colitis-associated cancer. These findings shed light on revealing the mechanisms of chronic colitis malignant transformation.
tissue_expression_ns	hsa-mir-145	Colon Neoplasms	29844680			D12.6	D003110		HP:0100273	five hub miRNAs were identified to be related to prognosis (hsa-miR-125b-5p, hsa-miR-145-5p, hsa-let-7c-5p, hsa-miR-218-5p and hsa-miR-125b-2-3p)
tissue_expression_ns	hsa-mir-146a	Colon Neoplasms	24941171			D12.6	D003110		HP:0100273	This is the first to reveal the importance of aberrant expression of miRNAs in dynamically transformation from chronic colitis to colitis-associated cancer. These findings shed light on revealing the mechanisms of chronic colitis malignant transformation.
tissue_expression_ns	hsa-mir-146a	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-148a	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-150	Colon Neoplasms	24941171			D12.6	D003110		HP:0100273	This is the first to reveal the importance of aberrant expression of miRNAs in dynamically transformation from chronic colitis to colitis-associated cancer. These findings shed light on revealing the mechanisms of chronic colitis malignant transformation.
tissue_expression_ns	hsa-mir-150	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-181a	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-196a	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-203	Colon Neoplasms	26397233			D12.6	D003110		HP:0100273	Cumulatively,our data purport that p53 not only increased Puma expression directly, but that it may also do so through miR-203. Additionally, functional studies revealed that miR-203 overexpression induced apoptosis and inhibited cell invasiveness.
tissue_expression_ns	hsa-mir-210	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-218	Colon Neoplasms	29844680			D12.6	D003110		HP:0100273	five hub miRNAs were identified to be related to prognosis (hsa-miR-125b-5p, hsa-miR-145-5p, hsa-let-7c-5p, hsa-miR-218-5p and hsa-miR-125b-2-3p)
tissue_expression_ns	hsa-mir-221	Colon Neoplasms	25075256			D12.6	D003110		HP:0100273	Five miRNAs (miR-203-3p, miR-221-3p, miR-342-3p, miR-491-5p and miR-503-5p) were dysregulated in colon cancer tissue (P < 0.05).
tissue_expression_ns	hsa-mir-222	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-223	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-23a	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-25	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-27a	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-30b	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-30c	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-30d	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-31	Colon Neoplasms	29152124			D12.6	D003110		HP:0100273	The LASSO regression analysis identified a 16-miRNA signature including miR-143-5p, miR-27a-3p, miR-31-5p, miR-181a-5p, miR-30b-5p, miR-30d-5p, miR-146a-5p, miR-23a-3p, miR-150-5p, miR-210-3p, miR-25-3p, miR-196a-5p, miR-148a-3p, miR-222-3p, miR-30c-5p and miR-223-3p
tissue_expression_ns	hsa-mir-1	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-135b	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-145	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-3195	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-429	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-4469	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-4510	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-4770	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-549	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-552	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-96	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-99b	Colorectal Adenocarcinoma	25803870	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma.
tissue_expression_ns	hsa-mir-125a	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-mir-145	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-mir-15b	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-mir-16	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-mir-21	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-mir-24	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-mir-320	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-mir-320b	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-mir-378	Colorectal Adenoma	25586944	disease of cellular proliferation	DOID:0050860					several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that several miRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
tissue_expression_ns	hsa-let-7g	Colorectal Carcinoma	23932154	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
tissue_expression_ns	hsa-mir-1	Colorectal Carcinoma	26045793	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer.
tissue_expression_ns	hsa-mir-100	Colorectal Carcinoma	26714601	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of miR-100 is correlated with lymph node metastasis, TNM stage and differentiation grade, and may be a potential biomarker indicating the development of CRC.
tissue_expression_ns	hsa-mir-106	Colorectal Carcinoma	24078989	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC.
tissue_expression_ns	hsa-mir-106a	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-106b	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-10b	Colorectal Carcinoma	28289479	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens.
tissue_expression_ns	hsa-mir-1246	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-125	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-126	Colorectal Carcinoma	25592646	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The intra-tumoural expression of EGFL7 in early stages of CRC may influence the risk of post-surgical recurrence. Differential expression of miRNA-126 seems more pronounced in disseminated disease, which supports its role as a regulator in the metastatic process.
tissue_expression_ns	hsa-mir-126	Colorectal Carcinoma	26455548	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		To conclude, deregulation of miR-126 in colorectal cancer at the tissue and cellular levels as well as its correlation with various clinicopathological parameters confirm the cancer suppressive role of miR-126 in colorectal cancer.
tissue_expression_ns	hsa-mir-126	Colorectal Carcinoma	24078989	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC.
tissue_expression_ns	hsa-mir-127	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-127	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-1290	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-132	Colorectal Carcinoma	23932154	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
tissue_expression_ns	hsa-mir-133a	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-133a	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-133b	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-135b	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-135b	Colorectal Carcinoma	23568010	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC
tissue_expression_ns	hsa-mir-135b	Colorectal Carcinoma	27672263	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer.
tissue_expression_ns	hsa-mir-139	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-141	Colorectal Carcinoma	24510588	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy.
tissue_expression_ns	hsa-mir-143	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-143	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-143	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-145	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-145	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-145	Colorectal Carcinoma	26335822	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The analysis of microRNAs miR-200C and miR-145 expression in colorectal cancer of different molecular subtypes.
tissue_expression_ns	hsa-mir-145	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-145	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-152	Colorectal Carcinoma	27784461	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Expression of microRNA-152 in colorectal cancer and its relationship with prognosis.
tissue_expression_ns	hsa-mir-155	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-17	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-17	Colorectal Carcinoma	23568010	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC
tissue_expression_ns	hsa-mir-182	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-183	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-183	Colorectal Carcinoma	28289479	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens.
tissue_expression_ns	hsa-mir-18a	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-18a	Colorectal Carcinoma	27672263	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer.
tissue_expression_ns	hsa-mir-19	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-192	Colorectal Carcinoma	27747302	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		high miR-192 and miR-194 correlate with better overall survival in Stage II patients, but worse survival in more advanced Stage III/IV patients
tissue_expression_ns	hsa-mir-192	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-194	Colorectal Carcinoma	27747302	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		high miR-192 and miR-194 correlate with better overall survival in Stage II patients, but worse survival in more advanced Stage III/IV patients
tissue_expression_ns	hsa-mir-194	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-195	Colorectal Carcinoma	25027346	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The 15 differentially expressed miRNAs, especially hsa-miR-195 and hsa-miR-20a may be used as potential biomarkers for early detection and screening of colorectal cancer.
tissue_expression_ns	hsa-mir-195	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-199	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-200	Colorectal Carcinoma	27157610	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The miR-200 family presented as the most powerful determinant of CMS4-specific gene expression, tuning the majority of genes differentially expressed in the poor prognosis subtype,
tissue_expression_ns	hsa-mir-200a	Colorectal Carcinoma	24510588	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy.
tissue_expression_ns	hsa-mir-200a	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-200c	Colorectal Carcinoma	24510588	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-200a, miR-200c, miR-141, and miR-429 expression levels may identify CRC patients, including those with stage II disease, who are most likely to benefit from adjuvant chemotherapy.
tissue_expression_ns	hsa-mir-200c	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-200C	Colorectal Carcinoma	26335822	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The analysis of microRNAs miR-200C and miR-145 expression in colorectal cancer of different molecular subtypes.
tissue_expression_ns	hsa-mir-200c	Colorectal Carcinoma	27565378	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer.
tissue_expression_ns	hsa-mir-204	Colorectal Carcinoma	25209181	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-204-5p expression in colorectal cancer: an autophagy-associated gene.
tissue_expression_ns	hsa-mir-205	Colorectal Carcinoma	24935592	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Diagnostic and prognostic value of miR-205 in colorectal cancer.
tissue_expression_ns	hsa-mir-20a	Colorectal Carcinoma	25027346	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The 15 differentially expressed miRNAs, especially hsa-miR-195 and hsa-miR-20a may be used as potential biomarkers for early detection and screening of colorectal cancer.
tissue_expression_ns	hsa-mir-20a	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-20a	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-20a	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	25292032	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our findings suggest that miR-21 has a potential diagnostic value for CRC with a moderate level of overall diagnostic accuracy. Hence, it could be  used as auxiliary means for the initial screening of CRC and avoid unnecessary colonoscopy, which is an invasive and expensive procedure.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	25421755	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21 expression may be a valuable biomarker for prediction of poor prognosis in CRC patients with Dukes' stage B, C and D.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	24078989	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	27565378	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	27672263	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	28207045	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.
tissue_expression_ns	hsa-mir-210	Colorectal Carcinoma	28207045	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.
tissue_expression_ns	hsa-mir-215	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-224	Colorectal Carcinoma	23932154	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
tissue_expression_ns	hsa-mir-26a	Colorectal Carcinoma	25611389	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer.
tissue_expression_ns	hsa-mir-26b	Colorectal Carcinoma	24078989	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC.
tissue_expression_ns	hsa-mir-27a	Colorectal Carcinoma	26913599	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Low miR-27a-expressing cells displayed more ecto-calreticulin on the cell surface and increased ATP and HMGB1 secretion than  high miR-27a-expressing ones in time-course experiments upon drug exposure.
tissue_expression_ns	hsa-mir-29a	Colorectal Carcinoma	23568010	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC
tissue_expression_ns	hsa-mir-29a	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-30d	Colorectal Carcinoma	28207045	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.
tissue_expression_ns	hsa-mir-31	Colorectal Carcinoma	25232271	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-31 expression in colorectal serrated pathway progression.
tissue_expression_ns	hsa-mir-3142	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-3182	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-320a	Colorectal Carcinoma	23932154	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
tissue_expression_ns	hsa-mir-328	Colorectal Carcinoma	24078989	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC.
tissue_expression_ns	hsa-mir-345	Colorectal Carcinoma	24078989	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC.
tissue_expression_ns	hsa-mir-362	Colorectal Carcinoma	25773836	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our study revealed dysregulation of expression of ten miRNAs in Turkish colon cancer patients. These miRNAs may be used as potential biomarkers for early detection, screening and surveillance of colorectal cancer, with functional effects on tumor cell behavior.
tissue_expression_ns	hsa-mir-363	Colorectal Carcinoma	24519049	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression pattern in female is different from that in male.miR-363 and miR-490-5p possess the potential in screening colorectal cancer patients from healthy people.
tissue_expression_ns	hsa-mir-375	Colorectal Carcinoma	26681654	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While the intra-tumor variance of miR-92a, miR-375 and miR-424 is substantial, it only constitutes approximately 30% of the total variation. Functional deregulation between tumor zones might contribute to variations in measured expression levels, and thus knowledge of specific intra-tumor expression patterns is crucial in tissue sampling for research as well as in future diagnostics.
tissue_expression_ns	hsa-mir-375	Colorectal Carcinoma	28618945	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study.
tissue_expression_ns	hsa-mir-378a	Colorectal Carcinoma	26462034	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
tissue_expression_ns	hsa-mir-424	Colorectal Carcinoma	26681654	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While the intra-tumor variance of miR-92a, miR-375 and miR-424 is substantial, it only constitutes approximately 30% of the total variation. Functional deregulation between tumor zones might contribute to variations in measured expression levels, and thus knowledge of specific intra-tumor expression patterns is crucial in tissue sampling for research as well as in future diagnostics.
tissue_expression_ns	hsa-mir-4286	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-429	Colorectal Carcinoma	27775664	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.
tissue_expression_ns	hsa-mir-4301	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-490	Colorectal Carcinoma	24519049	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression pattern in female is different from that in male.miR-363 and miR-490-5p possess the potential in screening colorectal cancer patients from healthy people.
tissue_expression_ns	hsa-mir-503	Colorectal Carcinoma	29164842	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others
tissue_expression_ns	hsa-mir-597	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-601	Colorectal Carcinoma	27672263	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer.
tissue_expression_ns	hsa-mir-720	Colorectal Carcinoma	27916938	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
tissue_expression_ns	hsa-mir-760	Colorectal Carcinoma	27672263	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer.
tissue_expression_ns	hsa-mir-760	Colorectal Carcinoma	28618945	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study.
tissue_expression_ns	hsa-mir-92a	Colorectal Carcinoma	24551148	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-92a might be a novel potential biomarker in the diagnosis of colorectal cancer, and more studies are needed to highlight the theoretical strengths.
tissue_expression_ns	hsa-mir-92a	Colorectal Carcinoma	26681654	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		While the intra-tumor variance of miR-92a, miR-375 and miR-424 is substantial, it only constitutes approximately 30% of the total variation. Functional deregulation between tumor zones might contribute to variations in measured expression levels, and thus knowledge of specific intra-tumor expression patterns is crucial in tissue sampling for research as well as in future diagnostics.
tissue_expression_ns	hsa-mir-92a	Colorectal Carcinoma	24078989	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNAs might soon represent novel prognostic and diagnostic tools in patients at high risk of CRC or being diagnosed with CRC.
tissue_expression_ns	hsa-mir-92a	Colorectal Carcinoma	23568010	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC
tissue_expression_ns	hsa-mir-92a	Colorectal Carcinoma	23690963	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Nine of the twelve miRNAs (miR-18a, -20a, -21, -29a, -92a, -106b, -133a, -143, -145) were found to be differentially expressed in CRC patients and controls in the validation samples.
tissue_expression_ns	hsa-mir-92a	Colorectal Carcinoma	27565378	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer.
tissue_expression_ns	hsa-mir-92a	Colorectal Carcinoma	27672263	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA biomarkers predicting risk, initiation and progression of colorectal cancer.
tissue_expression_ns	hsa-mir-92a	Colorectal Carcinoma	28618945	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study.
tissue_expression_ns	hsa-mir-1-1	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-1-2	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-133a-1	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-133a-2	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-135a-1	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-135a-2	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-135b	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-135b	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-135b	Colorectal Carcinoma	22844381	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer.
tissue_expression_ns	hsa-mir-137	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-137	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-144	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-145	Colorectal Carcinoma	25896668	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNA-145 and miRNA-378* are potential biomarkers for early detection of CRC, which may help in diagnosing CRC in early period.
tissue_expression_ns	hsa-mir-147b	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-148a	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-190a	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-21	Colorectal Carcinoma	22844381	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer.
tissue_expression_ns	hsa-mir-2110	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-215	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-218-1	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-218-2	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-26a-1	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-26a-2	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-26b	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-31	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-31	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-31	Colorectal Carcinoma	22844381	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer.
tissue_expression_ns	hsa-mir-338	Colorectal Carcinoma	24824250	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Relationship between miRNA-338-3p expression and progression and prognosis of human colorectal carcinoma.
tissue_expression_ns	hsa-mir-338	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-338-3p: differentially expressed
tissue_expression_ns	hsa-mir-375	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-378	Colorectal Carcinoma	25896668	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiRNA-145 and miRNA-378* are potential biomarkers for early detection of CRC, which may help in diagnosing CRC in early period.
tissue_expression_ns	hsa-mir-483	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-483-5p: differentially expressed
tissue_expression_ns	hsa-mir-492	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-542	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-542-5p: differentially expressed
tissue_expression_ns	hsa-mir-584	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-652	Colorectal Carcinoma	22850566	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		differentially expressed
tissue_expression_ns	hsa-mir-708	Colorectal Carcinoma	21532750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215, miR-137, miR-708, miR-31,and miR-135b were differentially expressed in APC tumors and miR-215, miR-133a,miR-467d, miR-218, miR-708, miR-31, and miR-135b in colitis-associated tumors.
tissue_expression_ns	hsa-mir-9-1	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-9-2	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-9-3	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-96	Colorectal Carcinoma	22844381	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer.
tissue_expression_ns	hsa-mir-99a	Colorectal Carcinoma	21694772	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		deregulated
tissue_expression_ns	hsa-mir-126	Coronary Artery Disease	22925274	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-126 was not significantly down-regulated or up-regulated in CAD patients. Interestingly, the level of miR-126 was significantly decreased in patients with CAD and high low-density lipoprotein (LDL) cholesterol level. In contrast, the level of miR-126 was significantly increased when LDL cholesterol was high in patients who had risk factors for CAD but did not have angiographically significant CAD.
tissue_expression_ns	hsa-let-7b	Crohn Disease	27556489	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease.
tissue_expression_ns	hsa-mir-124	Crohn Disease	24910152	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD.
tissue_expression_ns	hsa-mir-124	Crohn Disease	27556489	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease.
tissue_expression_ns	hsa-mir-192	Crohn Disease	24910152	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD.
tissue_expression_ns	hsa-mir-192	Crohn Disease	27556489	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease.
tissue_expression_ns	hsa-mir-196b	Crohn Disease	26164662	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	We found a suite of miRNAs, including miR-31-5p, miR-215, miR-223-3p, miR-196b-5p, and miR-203 that stratify patients with CD according to disease behavior independent of the effect of inflammation.
tissue_expression_ns	hsa-mir-203	Crohn Disease	26164662	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	We found a suite of miRNAs, including miR-31-5p, miR-215, miR-223-3p, miR-196b-5p, and miR-203 that stratify patients with CD according to disease behavior independent of the effect of inflammation.
tissue_expression_ns	hsa-mir-301a	Crohn Disease	27556489	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease.
tissue_expression_ns	hsa-mir-361	Crohn Disease	24910152	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD.
tissue_expression_ns	hsa-mir-423	Crohn Disease	27556489	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease.
tissue_expression_ns	hsa-mir-495	Crohn Disease	24910152	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD.
tissue_expression_ns	hsa-mir-495	Crohn Disease	27556489	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease.
tissue_expression_ns	hsa-mir-99a	Crohn Disease	27556489	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease.
tissue_expression_ns	hsa-let-7a	Cutaneous Melanoma	28218741	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
tissue_expression_ns	hsa-let-7b	Cutaneous Melanoma	28218741	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
tissue_expression_ns	hsa-mir-182	Cutaneous Melanoma	28218741	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
tissue_expression_ns	hsa-mir-199b	Cutaneous Melanoma	28218741	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
tissue_expression_ns	hsa-mir-205	Cutaneous Melanoma	28218741	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
tissue_expression_ns	hsa-mir-21	Cutaneous Melanoma	28218741	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
tissue_expression_ns	hsa-mir-423	Cutaneous Melanoma	28218741	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
tissue_expression_ns	hsa-mir-424	Cutaneous Melanoma	28218741	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
tissue_expression_ns	hsa-mir-146a	Diabetes Mellitus	27743454	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	we present an overview of the roles of miRNAs in the islet β-cell development, focusing on the application of different miRNAs in the experimental protocols
tissue_expression_ns	hsa-mir-200	Diabetes Mellitus	27743454	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The role of microRNAs in islet β-cell development.
tissue_expression_ns	hsa-mir-29a	Diabetes Mellitus	28003969	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Expression and regulation of microRNA-29a and microRNA-29c in early diabetic rat cataract formation.
tissue_expression_ns	hsa-mir-29c	Diabetes Mellitus	28003969	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Expression and regulation of microRNA-29a and microRNA-29c in early diabetic rat cataract formation.
tissue_expression_ns	hsa-mir-30	Diabetes Mellitus	27743454	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The role of microRNAs in islet β-cell development.
tissue_expression_ns	hsa-mir-342	Diabetes Mellitus	27743454	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The role of microRNAs in islet β-cell development.
tissue_expression_ns	hsa-mir-34a	Diabetes Mellitus	27743454	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The role of microRNAs in islet β-cell development.
tissue_expression_ns	hsa-mir-375	Diabetes Mellitus	27743454	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The role of microRNAs in islet β-cell development.
tissue_expression_ns	hsa-mir-7	Diabetes Mellitus	27743454	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The role of microRNAs in islet β-cell development.
tissue_expression_ns	hsa-mir-222	Diabetes Mellitus, Gestational	24601884	disease of metabolism	DOID:11714	O24.4	D016640	606176	HP:0009800	Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERα expression in estrogen-induced insulin resistance.
tissue_expression_ns	hsa-mir-103	Diabetes Mellitus, Type 2	23389544	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The deregulation of miRNAs miR-143 (ref. 4), miR-181 (ref. 5), and miR-103 and miR-107 (ref. 6) alters hepatic insulin sensitivity.
tissue_expression_ns	hsa-mir-107	Diabetes Mellitus, Type 2	23389544	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The deregulation of miRNAs miR-143 (ref. 4), miR-181 (ref. 5), and miR-103 and miR-107 (ref. 6) alters hepatic insulin sensitivity.
tissue_expression_ns	hsa-mir-122	Diabetes Mellitus, Type 2	27681254	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction.
tissue_expression_ns	hsa-mir-124a	Diabetes Mellitus, Type 2	26897751	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM.
tissue_expression_ns	hsa-mir-133	Diabetes Mellitus, Type 2	27681254	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction.
tissue_expression_ns	hsa-mir-143	Diabetes Mellitus, Type 2	23389544	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The deregulation of miRNAs miR-143 (ref. 4), miR-181 (ref. 5), and miR-103 and miR-107 (ref. 6) alters hepatic insulin sensitivity.
tissue_expression_ns	hsa-mir-181	Diabetes Mellitus, Type 2	23389544	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The deregulation of miRNAs miR-143 (ref. 4), miR-181 (ref. 5), and miR-103 and miR-107 (ref. 6) alters hepatic insulin sensitivity.
tissue_expression_ns	hsa-mir-18a	Diabetes Mellitus, Type 2	27681254	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction.
tissue_expression_ns	hsa-mir-206	Diabetes Mellitus, Type 2	27681254	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction.
tissue_expression_ns	hsa-mir-30d	Diabetes Mellitus, Type 2	26897751	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MiR-124a and miR-30d were correlated with insulin resistance and development of BC with T2DM.
tissue_expression_ns	hsa-mir-199a	Diabetic Cardiomyopathies	26553540				D058065			A dysregulation of 316 out of 1008 total miRNAs was observed in the diabetic hearts when compared with controls.
tissue_expression_ns	hsa-mir-203	Diabetic Foot	26722550			E10-11.621	D017719			Our results demonstrated that expression profile of miR-203 in diabetic foot had a positive correlation with the severity of diabetic foot ulcers, which indicated that miR-203 can be served as a new, accurate and validated bio-marker for evaluating the severity of diabetic foot ulcers in clinic. The significant finding of the study: Quantification of miR-203 in different degrees of diabetic foot. This study adds a new bio-marker for evaluation and management of diabetic foot.
tissue_expression_ns	hsa-mir-146a	Diabetic Peripheral Neuropathy	29398906			E11.40				miR-146a is involved in the pathogenesis of DPN, and its expression level is closely related to the inflammatory responses that aggravate sciatic nerve injuries
tissue_expression_ns	hsa-mir-150	Digeorge Syndrome	25084529	genetic disease	DOID:11198	D82.1	D004062	188400		Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome.
tissue_expression_ns	hsa-mir-185	Digeorge Syndrome	25084529	genetic disease	DOID:11198	D82.1	D004062	188400		Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome.
tissue_expression_ns	hsa-mir-194	Digeorge Syndrome	25084529	genetic disease	DOID:11198	D82.1	D004062	188400		Decreased DGCR8 expression and miRNA dysregulation in individuals with 22q11.2 deletion syndrome.
tissue_expression_ns	hsa-let-7c	Down Syndrome	24071828	genetic disease	DOID:14250	Q90	D004314	190685		Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns.
tissue_expression_ns	hsa-mir-125b-2	Down Syndrome	24071828	genetic disease	DOID:14250	Q90	D004314	190685		Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns.
tissue_expression_ns	hsa-mir-138	Down Syndrome	27266699	genetic disease	DOID:14250	Q90	D004314	190685		The function of hsa-miR-138-5p and its target EZH2 was involved in hippocampus in DS patients.
tissue_expression_ns	hsa-mir-146a	Down Syndrome	28720071	genetic disease	DOID:14250	Q90	D004314	190685		Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease.
tissue_expression_ns	hsa-mir-155	Down Syndrome	24071828	genetic disease	DOID:14250	Q90	D004314	190685		Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns.
tissue_expression_ns	hsa-mir-155	Down Syndrome	28720071	genetic disease	DOID:14250	Q90	D004314	190685		Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease.
tissue_expression_ns	hsa-mir-27a	Down Syndrome	27666924	genetic disease	DOID:14250	Q90	D004314	190685		Integrated microRNA and protein expression analysis reveals novel microRNA regulation of targets in fetal down syndrome.
tissue_expression_ns	hsa-mir-27b	Down Syndrome	27666924	genetic disease	DOID:14250	Q90	D004314	190685		Integrated microRNA and protein expression analysis reveals novel microRNA regulation of targets in fetal down syndrome.
tissue_expression_ns	hsa-mir-329	Down Syndrome	27666924	genetic disease	DOID:14250	Q90	D004314	190685		Integrated microRNA and protein expression analysis reveals novel microRNA regulation of targets in fetal down syndrome.
tissue_expression_ns	hsa-mir-802	Down Syndrome	24071828	genetic disease	DOID:14250	Q90	D004314	190685		Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns.
tissue_expression_ns	hsa-mir-99a	Down Syndrome	24071828	genetic disease	DOID:14250	Q90	D004314	190685		Differentially expressed microRNAs may be involved in hemopoietic abnormalities and the immune defects of DS fetuses and newborns.
tissue_expression_ns	hsa-mir-103	Early-Stage Gastric Carcinoma	24577775					613659		Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer.
tissue_expression_ns	hsa-mir-141	Early-Stage Gastric Carcinoma	24577775					613659		Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer.
tissue_expression_ns	hsa-mir-142	Early-Stage Gastric Carcinoma	24577775					613659		Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer.
tissue_expression_ns	hsa-mir-196a	Early-Stage Gastric Carcinoma	24577775					613659		Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer.
tissue_expression_ns	hsa-mir-25	Early-Stage Gastric Carcinoma	24577775					613659		Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer.
tissue_expression_ns	hsa-mir-9-1	Early-Stage Gastric Carcinoma	24577775					613659		Abnormal mirna expression level in early gastric cancer tissues may be associated to the development of gastric cancer.
tissue_expression_ns	hsa-mir-16	Endometrial Neoplasms	28129244	reproductive system disease	DOID:1380	C54.1	D016889	608089		Aberrant MicroRNA Expression in Patients With Endometrial Cancer.
tissue_expression_ns	hsa-mir-1	Endometriosis	26819681	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The expression of miR-1, miR-133a, and miR-451 were reduced significantly (p<0.0001) in the OC patients compared to its associated endometriosis.
tissue_expression_ns	hsa-mir-125a	Endometriosis	21335415	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA.
tissue_expression_ns	hsa-mir-15b	Endometriosis	21335415	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA.
tissue_expression_ns	hsa-mir-16	Endometriosis	26307093	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
tissue_expression_ns	hsa-mir-16	Endometriosis	21335415	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA.
tissue_expression_ns	hsa-mir-17	Endometriosis	21335415	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA.
tissue_expression_ns	hsa-mir-202	Endometriosis	24608518	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites.
tissue_expression_ns	hsa-mir-20a	Endometriosis	21335415	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA.
tissue_expression_ns	hsa-mir-21	Endometriosis	21335415	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA.
tissue_expression_ns	hsa-mir-221	Endometriosis	21335415	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA.
tissue_expression_ns	hsa-mir-222	Endometriosis	21335415	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	TaqMan real-time PCR was used to assess the expression of the miRNAs (miR-15b, -16, -17-5p, -20a, -21, -125a, -221 and -222), while VEGF-A and TSP-1 mRNA were assessed by real-time PCR, with SYBR Green I and VEGF-A and TSP-1 protein levels were quantified by ELISA.
tissue_expression_ns	hsa-mir-29c	Endometriosis	26307093	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
tissue_expression_ns	hsa-mir-424	Endometriosis	24608518	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites.
tissue_expression_ns	hsa-mir-424	Endometriosis	26307093	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
tissue_expression_ns	hsa-mir-449b	Endometriosis	24608518	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites.
tissue_expression_ns	hsa-mir-451	Endometriosis	26370665	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Altered expression of microRNA-451 in eutopic endometrium of baboons (Papioanubis) with endometriosis.
tissue_expression_ns	hsa-mir-556	Endometriosis	24608518	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites.
tissue_expression_ns	hsa-mir-203	Endomyocardial Fibrosis	28272698	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	Effect of miR-203 expression on myocardial fibrosis.
tissue_expression_ns	hsa-mir-323a	Epilepsy	27824513	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Aberrant Expression of miR-323a-5p in Patients with Refractory Epilepsy Caused by Focal Cortical Dysplasia.
tissue_expression_ns	hsa-mir-143	Esophageal Neoplasms	23092342			C15.9	D004938	133239	HP:0100751	There are several microRNAs that have been consistently reported to be differentially expressed in esophageal squamous cell carcinoma vs. normal squamous tissue, with prognostic associations for miR-21 (invasion, positive nodes, decreased survival), miR-143 (disease recurrence, invasion depth), and miR-375 (inversely correlated with advanced stage, distant metastasis, poor overall survival, and disease-free survival).
tissue_expression_ns	hsa-mir-183	Esophageal Neoplasms	22891887			C15.9	D004938	133239	HP:0100751	The relative expressions of miR-155, miR-183, and miR-20a in esophageal tissue were found to be significantly associated with increased risk for esophageal cancer.
tissue_expression_ns	hsa-mir-20a	Esophageal Neoplasms	22891887			C15.9	D004938	133239	HP:0100751	The relative expressions of miR-155, miR-183, and miR-20a in esophageal tissue were found to be significantly associated with increased risk for esophageal cancer.
tissue_expression_ns	hsa-mir-21	Esophageal Neoplasms	23092342			C15.9	D004938	133239	HP:0100751	There are several microRNAs that have been consistently reported to be differentially expressed in esophageal squamous cell carcinoma vs. normal squamous tissue, with prognostic associations for miR-21 (invasion, positive nodes, decreased survival), miR-143 (disease recurrence, invasion depth), and miR-375 (inversely correlated with advanced stage, distant metastasis, poor overall survival, and disease-free survival).
tissue_expression_ns	hsa-mir-375	Esophageal Neoplasms	23092342			C15.9	D004938	133239	HP:0100751	There are several microRNAs that have been consistently reported to be differentially expressed in esophageal squamous cell carcinoma vs. normal squamous tissue, with prognostic associations for miR-21 (invasion, positive nodes, decreased survival), miR-143 (disease recurrence, invasion depth), and miR-375 (inversely correlated with advanced stage, distant metastasis, poor overall survival, and disease-free survival).
tissue_expression_ns	hsa-mir-106b	Ewing Sarcoma	22429812	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression.
tissue_expression_ns	hsa-mir-145	Ewing Sarcoma	22429812	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression.
tissue_expression_ns	hsa-mir-150	Ewing Sarcoma	22429812	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression.
tissue_expression_ns	hsa-mir-21	Ewing Sarcoma	22429812	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression.
tissue_expression_ns	hsa-mir-31	Ewing Sarcoma	22429812	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression.
tissue_expression_ns	hsa-mir-371a	Ewing Sarcoma	22429812	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression.
tissue_expression_ns	hsa-mir-557	Ewing Sarcoma	22429812	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression.
tissue_expression_ns	hsa-mir-598	Ewing Sarcoma	22429812	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MiR-21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered expression.
tissue_expression_ns	hsa-mir-216a	Fatty Liver [unspecific]	21764575	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	altered expression
tissue_expression_ns	hsa-mir-216b	Fatty Liver [unspecific]	21764575	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	altered expression
tissue_expression_ns	hsa-mir-302a	Fatty Liver [unspecific]	21764575	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	altered expression
tissue_expression_ns	hsa-mir-516a-1	Frontotemporal Lobar Degeneration	22032330	disease of mental health	DOID:0060672		D057174	607485		miR-516a-3p was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers.
tissue_expression_ns	hsa-mir-516a-2	Frontotemporal Lobar Degeneration	22032330	disease of mental health	DOID:0060672		D057174	607485		miR-516a-3p was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers.
tissue_expression_ns	hsa-mir-548b	Frontotemporal Lobar Degeneration	22032330	disease of mental health	DOID:0060672		D057174	607485		miR-548b-5p was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers.
tissue_expression_ns	hsa-mir-548c	Frontotemporal Lobar Degeneration	22032330	disease of mental health	DOID:0060672		D057174	607485		miR-548c-5p was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers.
tissue_expression_ns	hsa-mir-571	Frontotemporal Lobar Degeneration	22032330	disease of mental health	DOID:0060672		D057174	607485		miR-571 was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers.
tissue_expression_ns	hsa-mir-922	Frontotemporal Lobar Degeneration	22032330	disease of mental health	DOID:0060672		D057174	607485		miR-922 was significantly dysregulated in frontal cortex and cerebellar tissue samples of PGRN mutation carriers.
tissue_expression_ns	hsa-mir-1244	Gastric Cardia Adenocarcinoma	26781873	disease of cellular proliferation	DOID:6271					Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation.
tissue_expression_ns	hsa-mir-135b	Gastric Cardia Adenocarcinoma	26781873	disease of cellular proliferation	DOID:6271					Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation.
tissue_expression_ns	hsa-mir-196a	Gastric Cardia Adenocarcinoma	26781873	disease of cellular proliferation	DOID:6271					miR-196a-5p, was found to be associated with age of GCA onset.
tissue_expression_ns	hsa-mir-3196	Gastric Cardia Adenocarcinoma	26781873	disease of cellular proliferation	DOID:6271					Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation.
tissue_expression_ns	hsa-mir-628	Gastric Cardia Adenocarcinoma	26781873	disease of cellular proliferation	DOID:6271					Four miRNAs (miR-1244, miR-135b-5p, miR-3196, and miR-628-3p) were found to be associated with GCA differentiation.
tissue_expression_ns	hsa-let-7f-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-let-7f-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-let-7g	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-103	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-103a-1	Gastric Neoplasms	20726036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers
tissue_expression_ns	hsa-mir-103a-2	Gastric Neoplasms	20726036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers
tissue_expression_ns	hsa-mir-106b	Gastric Neoplasms	20726036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers
tissue_expression_ns	hsa-mir-107	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-1-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-1-2	Gastric Neoplasms	26168960	disease of cellular proliferation	DOID:10534	C16	D013274	137215		mir-17, mir-133b, mir-133a-2, and mir-1-2 appear to be a potential novel predictor of tumor stage and preoperative and intraoperative diagnosis.
tissue_expression_ns	hsa-mir-1-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-1207	Gastric Neoplasms	25688358	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Multivariate analysis showed that stromal reaction type, lymphovascular invasion, pathological T category and TNM stage, and expression of miR-1207-5p were independent risk factors of LNM. MiR-1207-5p could serve as a useful biomarker in the prediction of LNM in gastric cancer.
tissue_expression_ns	hsa-mir-122	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-125a	Gastric Neoplasms	21987613	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN.
tissue_expression_ns	hsa-mir-127	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-128-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-128-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-130a	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-132	Gastric Neoplasms	24621117	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-132 could serve as an efficient prognostic factor for gastric cancer patients.
tissue_expression_ns	hsa-mir-132	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-133a-2	Gastric Neoplasms	26168960	disease of cellular proliferation	DOID:10534	C16	D013274	137215		mir-17, mir-133b, mir-133a-2, and mir-1-2 appear to be a potential novel predictor of tumor stage and preoperative and intraoperative diagnosis.
tissue_expression_ns	hsa-mir-133b	Gastric Neoplasms	26168960	disease of cellular proliferation	DOID:10534	C16	D013274	137215		mir-17, mir-133b, mir-133a-2, and mir-1-2 appear to be a potential novel predictor of tumor stage and preoperative and intraoperative diagnosis.
tissue_expression_ns	hsa-mir-133b	Gastric Neoplasms	21987613	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN.
tissue_expression_ns	hsa-mir-140	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-143	Gastric Neoplasms	21874264	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-32,miR-182 and miR-143 dysregulated expression levels are related with different pathological stages of intestinal-type gastric cancers.
tissue_expression_ns	hsa-mir-143	Gastric Neoplasms	21987613	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN.
tissue_expression_ns	hsa-mir-145	Gastric Neoplasms	20726036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers
tissue_expression_ns	hsa-mir-145	Gastric Neoplasms	21874264	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-145, miR-27a, miR-494 are differently expressed between intestinal-type and diffuse-type gastric cancers.
tissue_expression_ns	hsa-mir-146a	Gastric Neoplasms	20726036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers
tissue_expression_ns	hsa-mir-146a	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-146b	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-148a	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-148a	Gastric Neoplasms	20726036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers
tissue_expression_ns	hsa-mir-155	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-15b	Gastric Neoplasms	23907579	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The modulation of miR-15b and miR-16 mediated the apoptosis effects of DHA in gastric cancer cells.
tissue_expression_ns	hsa-mir-16-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-16-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-17	Gastric Neoplasms	26168960	disease of cellular proliferation	DOID:10534	C16	D013274	137215		mir-17, mir-133b, mir-133a-2, and mir-1-2 appear to be a potential novel predictor of tumor stage and preoperative and intraoperative diagnosis.
tissue_expression_ns	hsa-mir-181b-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-181b-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-182	Gastric Neoplasms	21874264	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-32,miR-182 and miR-143 dysregulated expression levels are related with different pathological stages of intestinal-type gastric cancers.
tissue_expression_ns	hsa-mir-182	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-183	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-185	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-186	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-193b	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-195	Gastric Neoplasms	21987613	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN.
tissue_expression_ns	hsa-mir-195	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-199b	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-206	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-21	Gastric Neoplasms	24023850	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 has potential diagnostic value with a moderate sensitivity and specificity for GC. More prospective studies on the diagnostic value of miR-21 for GC are needed in the future.
tissue_expression_ns	hsa-mir-21	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-21	Gastric Neoplasms	20726036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-103, miR-21, miR-145, miR-106b, miR-146a, and miR-148a separated node-positive from node-negative gastric cancers
tissue_expression_ns	hsa-mir-21	Gastric Neoplasms	28628924	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Chrysin Alters microRNAs Expression Levels in Gastric Cancer Cells: Possible Molecular Mechanism.
tissue_expression_ns	hsa-mir-212	Gastric Neoplasms	21987613	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Five microRNAs (miR-125a-3p, miR-133b, miR-143, miR-195 and miR-212) were differently expressed between different metastatic groups in 30 gastric cancer biopsies (P < 0.05). Partial correlation analysis showed that hsa-mir-212 and hsa-mir-195 were correlated with the status of metastasis to LN in spite of age, gender, tumor location, tumor size, depth of invasion and cell differentiation. ROC analysis indicated that miR-212 and miR-195 have better sensitivities (84.6% and 69.2%, respectively) and specificities (both 100%) in distinguishing biopsies with metastasis to LN from biopsies without metastasis to LN.
tissue_expression_ns	hsa-mir-221	Gastric Neoplasms	28628924	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Chrysin Alters microRNAs Expression Levels in Gastric Cancer Cells: Possible Molecular Mechanism.
tissue_expression_ns	hsa-mir-223	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-223	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-224	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-23a	Gastric Neoplasms	25674252	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These results suggest that the dysregulation of miR-23a and miR-23b may be implicated in the progression of human GC. Combined expression of miR-23a and miR-23b appears to be a valuable marker for prognosis of this disease.
tissue_expression_ns	hsa-mir-23b	Gastric Neoplasms	25674252	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These results suggest that the dysregulation of miR-23a and miR-23b may be implicated in the progression of human GC. Combined expression of miR-23a and miR-23b appears to be a valuable marker for prognosis of this disease.
tissue_expression_ns	hsa-mir-25	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-26b	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-27a	Gastric Neoplasms	21874264	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-145, miR-27a, miR-494 are differently expressed between intestinal-type and diffuse-type gastric cancers.
tissue_expression_ns	hsa-mir-29a	Gastric Neoplasms	25889078	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Our preliminary results suggest that altered expression of miR-29a-3p is involved in gastric cancer process. The present study provides the first insight into the specific role of miR-29a-3p in gastric carcinogenesis.
tissue_expression_ns	hsa-mir-32	Gastric Neoplasms	21874264	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-32,miR-182 and miR-143 dysregulated expression levels are related with different pathological stages of intestinal-type gastric cancers.
tissue_expression_ns	hsa-mir-320a	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-328	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-340	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-342	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-34a	Gastric Neoplasms	28628924	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Chrysin Alters microRNAs Expression Levels in Gastric Cancer Cells: Possible Molecular Mechanism.
tissue_expression_ns	hsa-mir-34c	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-363	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-374a	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-374b	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-375	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-421	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-487b	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-494	Gastric Neoplasms	21874264	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-145, miR-27a, miR-494 are differently expressed between intestinal-type and diffuse-type gastric cancers.
tissue_expression_ns	hsa-mir-497	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-503	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-513a-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-513a-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-513b	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-513c	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-515-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-515-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-516a-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-516a-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-516b-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-516b-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-517a	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-518f	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-519a-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-519a-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-519c	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-519e	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-520a	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-520d	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-524	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-526a-1	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-526a-2	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-574	Gastric Neoplasms	22683180	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-574-3p: Aberrant expression
tissue_expression_ns	hsa-mir-577	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-591	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-595	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-601	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-629	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-638	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-640	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-658	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-661	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemoresistance
tissue_expression_ns	hsa-mir-92	Gastric Neoplasms	24902858	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This systematic review study of human GC microRNA expression profiling studies would provide information on microRNAs with potential role as the biomarkers in gastric cancer.
tissue_expression_ns	hsa-mir-95	Gastric Neoplasms	22112324	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A miRNA signature distinguishing gastric cancer from normal stomach epithelium was identified. 30 miRNAs were significantly inversely correlated with TTP whereas 28 miRNAs were significantly positively correlated with TTP of 82 cancer patients (P<0.05). This miRNA is associated with chemosensitivity
tissue_expression_ns	hsa-mir-146b	Gastrointestinal Neoplasms	23456798			D37.9	D005770			The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas.
tissue_expression_ns	hsa-mir-148a	Gastrointestinal Neoplasms	23456798			D37.9	D005770			The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas.
tissue_expression_ns	hsa-mir-200b	Gastrointestinal Neoplasms	28402940			D37.9	D005770			Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-200c	Gastrointestinal Neoplasms	28402940			D37.9	D005770			Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-31	Gastrointestinal Neoplasms	23456798			D37.9	D005770			The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas.
tissue_expression_ns	hsa-mir-375	Gastrointestinal Neoplasms	23456798			D37.9	D005770			The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas.
tissue_expression_ns	hsa-mir-451	Gastrointestinal Neoplasms	23456798			D37.9	D005770			The deregulation of miR-146b-5p, miR-375, miR-148a, miR-31, and miR-451 was associated significantly with gastric adenocarcinomas.
tissue_expression_ns	hsa-mir-516	Gestational Trophoblastic Disease	28381180			O01.9	D031901			Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences.
tissue_expression_ns	hsa-mir-517	Gestational Trophoblastic Disease	28381180			O01.9	D031901			Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences.
tissue_expression_ns	hsa-mir-518b	Gestational Trophoblastic Disease	28381180			O01.9	D031901			Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences.
tissue_expression_ns	hsa-mir-520a	Gestational Trophoblastic Disease	28381180			O01.9	D031901			Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences.
tissue_expression_ns	hsa-mir-520h	Gestational Trophoblastic Disease	28381180			O01.9	D031901			Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences.
tissue_expression_ns	hsa-mir-525	Gestational Trophoblastic Disease	28381180			O01.9	D031901			Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences.
tissue_expression_ns	hsa-mir-526a	Gestational Trophoblastic Disease	28381180			O01.9	D031901			Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences.
tissue_expression_ns	hsa-let-7d	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-10a	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-10b	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-1247	Glioblastoma	27572852				D005909		HP:0100843	Several crucial genes, TFs, miRNAs and small molecules in the different GBM subgroups were identified, which may be used as potential markers
tissue_expression_ns	hsa-mir-1275	Glioblastoma	25129238				D005909		HP:0100843	We show miR-210-3p, miR-1275, miR-376c-3p, miR-23b-3p, miR-193a-3p and miR-145-5p to be up-regulated, while miR-92b-3p, miR-20a-5p, miR-10b-5p, miR-181a-2-3p and miR-185-5p are down-regulated by hypoxia.
tissue_expression_ns	hsa-mir-128-1	Glioblastoma	22844109				D005909		HP:0100843	Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM.
tissue_expression_ns	hsa-mir-128-2	Glioblastoma	22844109				D005909		HP:0100843	Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM.
tissue_expression_ns	hsa-mir-137	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-145	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-147b	Glioblastoma	27572852				D005909		HP:0100843	Several crucial genes, TFs, miRNAs and small molecules in the different GBM subgroups were identified, which may be used as potential markers
tissue_expression_ns	hsa-mir-153	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-17	Glioblastoma	19775293				D005909		HP:0100843	Taken together, our results support an important role of altered miRNA expression in gliomas, and suggest miR-17 and miR-184 as interesting candidates contributing to glioma progression.
tissue_expression_ns	hsa-mir-181b	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-184	Glioblastoma	22844109				D005909		HP:0100843	Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM.
tissue_expression_ns	hsa-mir-184	Glioblastoma	19775293				D005909		HP:0100843	Taken together, our results support an important role of altered miRNA expression in gliomas, and suggest miR-17 and miR-184 as interesting candidates contributing to glioma progression.
tissue_expression_ns	hsa-mir-220a	Glioblastoma	27572852				D005909		HP:0100843	miR-147b, miR-770-5p, miR-220a and miR-1247 were the particular miRNAs in subgroups 1-4
tissue_expression_ns	hsa-mir-34a	Glioblastoma	24412053				D005909		HP:0100843	Comparing miRNA expression between glioblastoma group and gliomas of grades I-III, 3 miRNAs (miR-10b, mir-34a and miR-101) showed different regulation statuses between high-grade and low-grade tumors.
tissue_expression_ns	hsa-mir-455	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-503	Glioblastoma	29164842				D005909		HP:0100843	miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others
tissue_expression_ns	hsa-mir-504	Glioblastoma	22844109				D005909		HP:0100843	Expression of miR-128a, -504, -124a, and -184 each negatively correlated with the expression of mesenchymal markers in GBM.
tissue_expression_ns	hsa-mir-524	Glioblastoma	23924460				D005909		HP:0100843	The miRNA gene expression profiles correlate with several selected MRI features of patients with GBM. Further analysis of key imaging features of MRI with correlation with miRNA gene expression patterns may help to guide treatment decisions based on these unique correlative profiles of GBM.
tissue_expression_ns	hsa-mir-612	Glioblastoma	23924460				D005909		HP:0100843	The miRNA gene expression profiles correlate with several selected MRI features of patients with GBM. Further analysis of key imaging features of MRI with correlation with miRNA gene expression patterns may help to guide treatment decisions based on these unique correlative profiles of GBM.
tissue_expression_ns	hsa-mir-770	Glioblastoma	27572852				D005909		HP:0100843	Several crucial genes, TFs, miRNAs and small molecules in the different GBM subgroups were identified, which may be used as potential markers
tissue_expression_ns	hsa-mir-9	Glioblastoma	24691539				D005909		HP:0100843	microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
tissue_expression_ns	hsa-mir-105	Glioma	25415048	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas.
tissue_expression_ns	hsa-mir-107	Glioma	25596705	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	expression level of miR-107 may be a novel and valuable prognostic factor in glioma.
tissue_expression_ns	hsa-mir-107	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-126	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-135	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-137	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-138	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-145	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-149	Glioma	26617839	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our study thus demonstrates that miR-149 expression in glioma tissues is critically associated with the prognosis of patients,suggesting its potential clinical significance.
tissue_expression_ns	hsa-mir-150	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-155	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-181a	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-182	Glioma	20472885	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-182 as a prognostic marker for glioma progression and patient survival.
tissue_expression_ns	hsa-mir-184	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-186	Glioma	26231038	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186.
tissue_expression_ns	hsa-mir-196a	Glioma	25415048	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas.
tissue_expression_ns	hsa-mir-205	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-21	Glioma	25452796	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Among  the six identified differentially expressed miRNAs, hsa-miR-21 and hsa-miR-612 have been previously reported to be associated with glioma.
tissue_expression_ns	hsa-mir-21	Glioma	26799295	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	4 hypoxia-mediated microRNAs (miRNA)-miR-210, miR-21, miR-10b, and miR-196b-are upregulated in glioma
tissue_expression_ns	hsa-mir-21	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-21	Glioma	28547591	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-21 expression in the prognosis of low-grade gliomas: data from the cancer genome atlas (TCGA) project.
tissue_expression_ns	hsa-mir-218	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-296	Glioma	25415048	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas.
tissue_expression_ns	hsa-mir-34a	Glioma	25953448	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The top 20 potential miRNAs including MIR-124A, MIR-34A and MIR-34C were screened for a constructing gene-miRNA interaction network.
tissue_expression_ns	hsa-mir-4489	Glioma	25954994	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The dysregulated miRNAs identified in the present study contribute to the tumorigenesis and malignant progression of gliomas and may serve as useful markers for advanced glioma pathological grading and prognosis.
tissue_expression_ns	hsa-mir-584	Glioma	25415048	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas.
tissue_expression_ns	hsa-mir-650	Glioma	24062138	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-650 expression in glioma is associated with prognosis of patients.
tissue_expression_ns	hsa-mir-7	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-767	Glioma	25415048	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA expression patterns in the malignant progression of gliomas and a novel prognostic classifier, the five-miRNA signature, serve as a prognostic marker for patient risk stratification in anaplastic gliomas, Secondary and Proneural glioblastomas.
tissue_expression_ns	hsa-mir-9	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-98	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-99b	Glioma	27999452	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Deregulation of miRNAs is caused by viral infections, tumorigenesis, and so forth
tissue_expression_ns	hsa-mir-4717	Guillain-Barre Syndrome	27836180	immune system disease	DOID:12842	G61.0	D020275	139393		MicroRNA expression profiling in Guillain-Barré syndrome.
tissue_expression_ns	hsa-mir-642b	Guillain-Barre Syndrome	27836180	immune system disease	DOID:12842	G61.0	D020275	139393		MicroRNA expression profiling in Guillain-Barré syndrome.
tissue_expression_ns	hsa-mir-125a	Head And Neck Adenoid Cystic Carcinoma	25750274							Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review
tissue_expression_ns	hsa-mir-199a	Head And Neck Adenoid Cystic Carcinoma	25750274							Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review
tissue_expression_ns	hsa-mir-199b	Head And Neck Adenoid Cystic Carcinoma	25750274							Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review
tissue_expression_ns	hsa-mir-214	Head And Neck Adenoid Cystic Carcinoma	25750274							Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review
tissue_expression_ns	hsa-mir-574	Head And Neck Adenoid Cystic Carcinoma	25750274							Our data showed significantly different expression patterns of mircoRNA in HNACC and HNSCC supporting the theory of tumor-specific expression and giving hints for different clinical behavior. review
tissue_expression_ns	hsa-mir-125a	Head And Neck Neoplasms	22690848	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Differential expression
tissue_expression_ns	hsa-mir-125b-1	Head And Neck Neoplasms	22690848	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Differential expression
tissue_expression_ns	hsa-mir-125b-2	Head And Neck Neoplasms	22690848	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Differential expression
tissue_expression_ns	hsa-mir-203	Head And Neck Neoplasms	22690848	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Differential expression
tissue_expression_ns	hsa-mir-21	Head And Neck Neoplasms	22690848	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Differential expression
tissue_expression_ns	hsa-mir-31	Head And Neck Neoplasms	22690848	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Differential expression
tissue_expression_ns	hsa-mir-355	Hearing Disorders	29781875			H91.90	D006311			Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool
tissue_expression_ns	hsa-mir-509	Hearing Disorders	29781875			H91.90	D006311			Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool
tissue_expression_ns	hsa-mir-515	Hearing Disorders	29781875			H91.90	D006311			Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool
tissue_expression_ns	hsa-mir-616	Hearing Disorders	29781875			H91.90	D006311			Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool
tissue_expression_ns	hsa-mir-873	Hearing Disorders	29781875			H91.90	D006311			Most fluids showed expression of miR-355, miR-509p, miR-515p, miR-3p, miR-873, and miR-616, but also showed significant differences between the fluid types, suggesting that miRNA profiling may be used as a diagnostic tool
tissue_expression_ns	hsa-mir-1	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-126	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-133	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-195	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-199a	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-199b	Heart Failure	22427379			I50	D006331		HP:0001635	Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223.
tissue_expression_ns	hsa-mir-208	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-208	Heart Failure	25287062			I50	D006331		HP:0001635	miR-208, which was progressively downregulated as RV failure progressed
tissue_expression_ns	hsa-mir-210	Heart Failure	22427379			I50	D006331		HP:0001635	Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223.
tissue_expression_ns	hsa-mir-223	Heart Failure	22427379			I50	D006331		HP:0001635	Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223.
tissue_expression_ns	hsa-mir-24	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-29	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-29b	Heart Failure	28765595			I50	D006331		HP:0001635	Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia.
tissue_expression_ns	hsa-mir-320	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-34b	Heart Failure	22427379			I50	D006331		HP:0001635	Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223.
tissue_expression_ns	hsa-mir-34c	Heart Failure	22427379			I50	D006331		HP:0001635	Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223.
tissue_expression_ns	hsa-mir-650	Heart Failure	22427379			I50	D006331		HP:0001635	Six miRNAs were differently expressed when comparing D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients: miR-34b, miR-34c, miR-199b, miR-210, miR-650, and miR-223.
tissue_expression_ns	hsa-mir-92a	Heart Failure	21737570			I50	D006331		HP:0001635	In particular, miRNA-1, miRNA-21, miRNA-24, miRNA-29, miRNA-92a, miRNA-126, miRNA-133, miRNA-320, miRNA-199a, miRNA-208, and miRNA-195 have been shown to be regulated after I/R injury.
tissue_expression_ns	hsa-mir-31	Heart Transplant Rejection	25176944			T86.31				We identified seven miRNAs that were differentially expressed between normal and rejecting heart allografts: miR-10a, miR-21, miR-31, miR-92a, miR-142-3p miR-155, and miR-451
tissue_expression_ns	hsa-mir-101	Hepatitis B Virus Infection	24971953	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis,liver cirrhosis, and hepatocellular carcinoma.
tissue_expression_ns	hsa-mir-122	Hepatitis C Virus Infection	24696531	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The study thus unveiled the role of miR-122 as a plausible diagnostic biomarker during HCV genotype-3 infection in India.
tissue_expression_ns	hsa-mir-122	Hepatitis C Virus Infection	24612050	disease by infectious agent	DOID:1883	B19.2	D006526	609532		However, a significant difference was observed in miR-122 expression between patients who showed a sustained virological response (SVR) and those who did not (P鈥?鈥?.05).
tissue_expression_ns	hsa-mir-125b	Hepatitis C Virus Infection	24637254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC-miR-125b expression levels were inversely related to the achievement of an SVR in HCV-1 patients, independent of interleukin-28B genotype,and was the single predictor of SVR in non-RVR patients.
tissue_expression_ns	hsa-mir-224	Hepatitis C Virus Infection	25386083	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Differences in miRNA expression were observed between CHC and steatotic CHC, CHC and steatotic liver, but not between steatotic CHC and steatotic liver of metabolic origin.
tissue_expression_ns	hsa-mir-33a	Hepatitis C Virus Infection	25386083	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Differences in miRNA expression were observed between CHC and steatotic CHC, CHC and steatotic liver, but not between steatotic CHC and steatotic liver of metabolic origin.
tissue_expression_ns	hsa-mir-106b	Hepatoblastoma	26613016	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	These datasets provide a global landscape of miRNA expression for a rare childhood cancer that has not previously been well characterised. These data could serve as a resource for future studies aiming to make comparisons of HB miRNA profiles and to document aberrant miRNA expression in this type of cancer.
tissue_expression_ns	hsa-mir-122	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-140	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-17	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-17	Hepatoblastoma	26613016	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	These datasets provide a global landscape of miRNA expression for a rare childhood cancer that has not previously been well characterised. These data could serve as a resource for future studies aiming to make comparisons of HB miRNA profiles and to document aberrant miRNA expression in this type of cancer.
tissue_expression_ns	hsa-mir-18a	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-191	Hepatoblastoma	26613016	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	These datasets provide a global landscape of miRNA expression for a rare childhood cancer that has not previously been well characterised. These data could serve as a resource for future studies aiming to make comparisons of HB miRNA profiles and to document aberrant miRNA expression in this type of cancer.
tissue_expression_ns	hsa-mir-195	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-210	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-214	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-221	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-222	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-223	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-224	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-34a	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-95	Hepatoblastoma	26613016	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	These datasets provide a global landscape of miRNA expression for a rare childhood cancer that has not previously been well characterised. These data could serve as a resource for future studies aiming to make comparisons of HB miRNA profiles and to document aberrant miRNA expression in this type of cancer.
tissue_expression_ns	hsa-mir-96	Hepatoblastoma	24570391	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
tissue_expression_ns	hsa-mir-210	Human Immunodeficiency Virus Infection	27749601			B20	D015658	609423		MicroRNA-210, MicroRNA-331, and MicroRNA-7 Are Differentially Regulated in Treated HIV-1-Infected Individuals and Are Associated With Markers of Systemic Inflammation.
tissue_expression_ns	hsa-mir-331	Human Immunodeficiency Virus Infection	27749601			B20	D015658	609423		MicroRNA-210, MicroRNA-331, and MicroRNA-7 Are Differentially Regulated in Treated HIV-1-Infected Individuals and Are Associated With Markers of Systemic Inflammation.
tissue_expression_ns	hsa-mir-7	Human Immunodeficiency Virus Infection	27749601			B20	D015658	609423		MicroRNA-210, MicroRNA-331, and MicroRNA-7 Are Differentially Regulated in Treated HIV-1-Infected Individuals and Are Associated With Markers of Systemic Inflammation.
tissue_expression_ns	hsa-mir-150	Human Papilloma Virus Infection	28302562			B97.7	D027383			Dysregulated expression of microRNA-150 in human papillomavirus-induced lesions of K14-HPV16 transgenic mice.
tissue_expression_ns	hsa-mir-155	Human Papilloma Virus Infection	25550598			B97.7	D027383			Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule
tissue_expression_ns	hsa-mir-196a	Human Papilloma Virus Infection	25550598			B97.7	D027383			Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule
tissue_expression_ns	hsa-mir-203	Human Papilloma Virus Infection	25550598			B97.7	D027383			Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule
tissue_expression_ns	hsa-mir-27a	Human Papilloma Virus Infection	25550598			B97.7	D027383			Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule
tissue_expression_ns	hsa-mir-34a	Human Papilloma Virus Infection	25550598			B97.7	D027383			Evaluation of miRNA expression might be helpful to distinguish different cervical lesions and might be able to help in the prediction of HPV infection outcome. epithelial cell adhesion molecule
tissue_expression_ns	hsa-mir-155	Hypertension	25087597	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	In addition, exercise training in SHR increased levels of microRNA-27a (targeting ACE) and microRNA-155 (targeting AT1R) and decreased levels of microRNA-143 (targeting ACE2) in the aortas.
tissue_expression_ns	hsa-mir-200b	Hypertrophic Scar	26500110			L91.0	D017439			Aberrant miR-21 and miR-200b expression and its pro-fibrotic potential in hypertrophic scars.
tissue_expression_ns	hsa-mir-21	Hypertrophic Scar	26500110			L91.0	D017439			Aberrant miR-21 and miR-200b expression and its pro-fibrotic potential in hypertrophic scars.
tissue_expression_ns	hsa-mir-133a	Hypertrophy	25147795				D006984			Fifty-seven miRNAs were expressed differentially between transgenic and littermate controls, of which most abundant miRNAs, miR-133a and 378a, were significantly differentially expressed.
tissue_expression_ns	hsa-mir-126	Immune System Disease [unspecific]	20682703	immune system disease	DOID:2914	D89.9	D007154			Although altered expressions of miR-21 and miR-34a were manifested within cancer cells, those of miR-126 and miR-155 were predominantly confined to endothelial cells and immune cells, respectively.
tissue_expression_ns	hsa-mir-155	Immune System Disease [unspecific]	20682703	immune system disease	DOID:2914	D89.9	D007154			Although altered expressions of miR-21 and miR-34a were manifested within cancer cells, those of miR-126 and miR-155 were predominantly confined to endothelial cells and immune cells, respectively.
tissue_expression_ns	hsa-mir-31	Immune System Disease [unspecific]	23352895	immune system disease	DOID:2914	D89.9	D007154			Bantam, miR-276*, miR-10, miR-31 and miR-184 were detected as five most abundant miRNAs in both libraries and 96 miRNAs were identified that were differentially expressed after parasitization.
tissue_expression_ns	hsa-mir-21	Infection [unspecific]	28472924				D007239			Identification of differentially expressed Atlantic salmon miRNAs responding to salmonid alphavirus (SAV) infection.
tissue_expression_ns	hsa-mir-34c	Infertility	28886318	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			New insights into the expression profile of MicroRNA-34c and P53 in infertile men spermatozoa and testicular tissue.
tissue_expression_ns	hsa-mir-132	Inflammation	25564423				D007249			We assessed miRNA and mRNA expression in lung infiltrating mononuclear cells following exposure to SEB and found 89 miRNA that were dysregulated (>2-fold) compared with vehicle controls.
tissue_expression_ns	hsa-mir-143	Inflammation	27776879				D007249			Expression Profiles of Inflammation-associated microRNAs in Periapical Lesions and Human Periodontal Ligament Fibroblasts Inflammation.
tissue_expression_ns	hsa-mir-146	Inflammation	18291670				D007249			Recent evidence showing altered miRNA expression in chronic inflammatory diseases (e.g. miR-203 and miR-146) suggests their involvement in immune-mediated diseases.
tissue_expression_ns	hsa-mir-146a	Inflammation	16885212				D007249			Analysis of miR-146a and miR-146b gene expression unveiled a pattern of induction in response to a variety of microbial components and proinflammatory cytokines.
tissue_expression_ns	hsa-mir-146b	Inflammation	16885212				D007249			Analysis of miR-146a and miR-146b gene expression unveiled a pattern of induction in response to a variety of microbial components and proinflammatory cytokines.
tissue_expression_ns	hsa-mir-15b	Inflammation	20564181				D007249			Of note, differentially expressed miRNAs (hsa-miR-15b and 181b) may have a potential role in regulating these processes.
tissue_expression_ns	hsa-mir-181b	Inflammation	20564181				D007249			Of note, differentially expressed miRNAs (hsa-miR-15b and 181b) may have a potential role in regulating these processes.
tissue_expression_ns	hsa-mir-223	Inflammation	27129807				D007249			miR-223 that has been reported to be abnormally expressed in several diseases like diabetes-type2, sepsis, rheumatoid arthritis, viral infections likes' human immunodeficiency virus-1 (HIV-1) and inflammatory disorders.
tissue_expression_ns	hsa-mir-31	Inflammation	26303911				D007249			We identified three miRNAs, miR-497, miR-351 and miR-31, that are candidate master regulators of genes associated with neutrophil recruitment.
tissue_expression_ns	hsa-mir-106a	Inflammatory Bowel Diseases	22899284	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	A significant difference in expressions of miR-19b, miR-106a, and miR-629 was detected between ulcerative colitis and Crohns disease groups (P<0.05).
tissue_expression_ns	hsa-mir-146a	Inflammatory Bowel Diseases	24051693	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	In summary,we demonstrate that miR-31, miR-206, miR-424, and miR-146a are novel specific biomarkers of inflammatory bowel disease.
tissue_expression_ns	hsa-mir-19b-1	Inflammatory Bowel Diseases	22899284	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	A significant difference in expressions of miR-19b, miR-106a, and miR-629 was detected between ulcerative colitis and Crohns disease groups (P<0.05).
tissue_expression_ns	hsa-mir-19b-2	Inflammatory Bowel Diseases	22899284	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	A significant difference in expressions of miR-19b, miR-106a, and miR-629 was detected between ulcerative colitis and Crohns disease groups (P<0.05).
tissue_expression_ns	hsa-mir-206	Inflammatory Bowel Diseases	24051693	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	In summary,we demonstrate that miR-31, miR-206, miR-424, and miR-146a are novel specific biomarkers of inflammatory bowel disease.
tissue_expression_ns	hsa-mir-21	Inflammatory Bowel Diseases	25222661	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	MiRNAs are differentially expressed in both human IBD and murine colitis, with overlap of several IBD-associated miRNAs. The demonstration that miR-21-/- deletion exacerbated CD4+ T-cell-mediated models of colitis provide further evidence that miRNAs play significant roles in the pathogenesis of IBD.
tissue_expression_ns	hsa-mir-31	Inflammatory Bowel Diseases	24051693	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	In summary,we demonstrate that miR-31, miR-206, miR-424, and miR-146a are novel specific biomarkers of inflammatory bowel disease.
tissue_expression_ns	hsa-mir-31	Inflammatory Bowel Diseases	20848542	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation.
tissue_expression_ns	hsa-mir-424	Inflammatory Bowel Diseases	24051693	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	In summary,we demonstrate that miR-31, miR-206, miR-424, and miR-146a are novel specific biomarkers of inflammatory bowel disease.
tissue_expression_ns	hsa-mir-629	Inflammatory Bowel Diseases	22899284	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	A significant difference in expressions of miR-19b, miR-106a, and miR-629 was detected between ulcerative colitis and Crohns disease groups (P<0.05).
tissue_expression_ns	hsa-mir-99b	Inflammatory Bowel Diseases	26466382	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	These results suggest that the proposed miRNA signature is of relevance for the etiology of IBD. Its diagnostic value, however, should be further evaluated in large, independent, clinically well characterized cohorts.
tissue_expression_ns	hsa-mir-143	Intracranial Aneurysm	25300531	cardiovascular system disease	DOID:10941	I67.1	D002532	105800		As compared to normal arteries, we identified 157 microRNAs that were differentially expressed in the aneurysmal tissue (P鈥?鈥?.05 and fold change鈥夆墺鈥?), including 72 upregulated and 85 downregulated.
tissue_expression_ns	hsa-mir-103	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-146a	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-216a	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-216b	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-217	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-338	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-513	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-652	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-675	Intrahepatic Cholangiocarcinoma	25880914	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
tissue_expression_ns	hsa-mir-126	Ischemia	26672806	cardiovascular system disease	DOID:326		D007511	601367		ghrelin treatment activated proangiogenic (miR-126  and miR-132) and antifibrotic (miR-30a) microRNAs (miRs)
tissue_expression_ns	hsa-mir-206	Ischemia	26672806	cardiovascular system disease	DOID:326		D007511	601367		ghrelin treatment activated proangiogenic (miR-126  and miR-132) and antifibrotic (miR-30a) microRNAs (miRs)
tissue_expression_ns	hsa-mir-21	Ischemia	21373187	cardiovascular system disease	DOID:326		D007511	601367		deregulated
tissue_expression_ns	hsa-mir-210	Ischemia	23931770	cardiovascular system disease	DOID:326		D007511	601367		The physiopathological significance of miR-210 is context dependent. In the ischemic skeletal muscle it seems to be cytoprotective, regulating oxidative metabolism and oxidative stress.
tissue_expression_ns	hsa-mir-29b-1	Ischemia	21373187	cardiovascular system disease	DOID:326		D007511	601367		deregulated
tissue_expression_ns	hsa-mir-29b-2	Ischemia	21373187	cardiovascular system disease	DOID:326		D007511	601367		deregulated
tissue_expression_ns	hsa-mir-30b	Ischemia	21373187	cardiovascular system disease	DOID:326		D007511	601367		deregulated
tissue_expression_ns	hsa-mir-92a	Ischemia	26672806	cardiovascular system disease	DOID:326		D007511	601367		Further, ghrelin treatment activated proangiogenic (miR-126  and miR-132) and antifibrotic (miR-30a) microRNAs (miRs) while inhibiting antiangiogenic (miR-92a and miR-206) miRs.
tissue_expression_ns	hsa-mir-1	Ischemia-Reperfusion Injury	29642230				D015427			Most commonly reported miRNAs with differential expression between preconditioned and control groups include miR-1, miR-21 and miR-144
tissue_expression_ns	hsa-mir-144	Ischemia-Reperfusion Injury	29642230				D015427			Most commonly reported miRNAs with differential expression between preconditioned and control groups include miR-1, miR-21 and miR-144
tissue_expression_ns	hsa-mir-146a	Ischemia-Reperfusion Injury	20651252				D015427			miR-146a:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-187	Ischemia-Reperfusion Injury	20651252				D015427			miR-187:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-192	Ischemia-Reperfusion Injury	20651252				D015427			miR-192:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-194-1	Ischemia-Reperfusion Injury	20651252				D015427			miR-194:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-194-2	Ischemia-Reperfusion Injury	20651252				D015427			miR-194:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-199a-1	Ischemia-Reperfusion Injury	20651252				D015427			miR-199a-3p:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-199a-2	Ischemia-Reperfusion Injury	20651252				D015427			miR-199a-3p:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-20a	Ischemia-Reperfusion Injury	20651252				D015427			miR-20a:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-21	Ischemia-Reperfusion Injury	20651252				D015427			miR-21:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-21	Ischemia-Reperfusion Injury	29642230				D015427			Most commonly reported miRNAs with differential expression between preconditioned and control groups include miR-1, miR-21 and miR-144
tissue_expression_ns	hsa-mir-214	Ischemia-Reperfusion Injury	20651252				D015427			miR-214:nine miRNAs (miR-21, miR-20a,miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, miR-805, and miR-194) that are differentially expressed following IRI
tissue_expression_ns	hsa-mir-210	Ischemic Diseases [unspecific]	27750254				D007511	601367		Temporal Profile of Circulating microRNAs after Global Hypoxia-Ischemia in Newborn Piglets.
tissue_expression_ns	hsa-mir-24	Kaposi Sarcoma	19381257	disease of cellular proliferation	DOID:8632	C46	D012514			Mir-140 and Kaposi sarcoma-associated herpesvirus viral miRNAs increased linearly with the degree of transformation. Mir-24 emerged as a biomarker specific for KS.
tissue_expression_ns	hsa-mir-199a	Keloid	24782087			L91.0	D007627	148100	HP:0010562	Keloid microRNA expression analysis and the influence of miR-199a-5p on the proliferation of keloid fibroblasts.
tissue_expression_ns	hsa-let-7d	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-130	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-186	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-192	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-200	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-21	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-29	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-30	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-709	Kidney Diseases [unspecific]	28414804			N18.9	D007674			Cyclosporine A alters expression of renal microRNAs: New insights into calcineurin inhibitor nephrotoxicity.
tissue_expression_ns	hsa-mir-1264	Laryngeal Neoplasms	23826416			C32.3	D007822			Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.
tissue_expression_ns	hsa-mir-1265	Laryngeal Neoplasms	23826416			C32.3	D007822			Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.
tissue_expression_ns	hsa-mir-1277	Laryngeal Neoplasms	23826416			C32.3	D007822			Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.
tissue_expression_ns	hsa-mir-1291	Laryngeal Neoplasms	23826416			C32.3	D007822			Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.
tissue_expression_ns	hsa-mir-130a	Laryngeal Neoplasms	23826416			C32.3	D007822			Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.
tissue_expression_ns	hsa-mir-155	Laryngeal Neoplasms	27292022			C32.3	D007822			miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo.
tissue_expression_ns	hsa-mir-192	Laryngeal Neoplasms	27292022			C32.3	D007822			miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo.
tissue_expression_ns	hsa-mir-195	Laryngeal Neoplasms	23826416			C32.3	D007822			Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.
tissue_expression_ns	hsa-mir-21	Laryngeal Neoplasms	23259291			C32.3	D007822			Expression of mir-21 and mir-375 in laryngeal squamous cell carcinoma
tissue_expression_ns	hsa-mir-21	Laryngeal Neoplasms	27292022			C32.3	D007822			miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo.
tissue_expression_ns	hsa-mir-214	Laryngeal Neoplasms	23826416			C32.3	D007822			Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.
tissue_expression_ns	hsa-mir-27b	Laryngeal Neoplasms	23826416			C32.3	D007822			Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.
tissue_expression_ns	hsa-mir-375	Laryngeal Neoplasms	23259291			C32.3	D007822			Expression of mir-21 and mir-375 in laryngeal squamous cell carcinoma
tissue_expression_ns	hsa-mir-375	Laryngeal Neoplasms	27292022			C32.3	D007822			miR-21, miR-155, miR-192, and miR-375 Deregulations Related to NF-kappaB Activation in Gastroduodenal Fluid-Induced Early Preneoplastic Lesions of Laryngeal Mucosa In Vivo.
tissue_expression_ns	hsa-mir-1287	Laryngeal Neoplasms	24238754			C32.3	D007822			Identification of predictive biomarkers for early diagnosis of larynx carcinoma based on microRNA expression data.
tissue_expression_ns	hsa-mir-657	Laryngeal Neoplasms	24238754			C32.3	D007822			Identification of predictive biomarkers for early diagnosis of larynx carcinoma based on microRNA expression data.
tissue_expression_ns	hsa-mir-137	Leiomyoma	22446413	disease of cellular proliferation	DOID:127	D25	D007889	150699		deregulated
tissue_expression_ns	hsa-mir-217	Leiomyoma	22446413	disease of cellular proliferation	DOID:127	D25	D007889	150699		deregulated
tissue_expression_ns	hsa-mir-363	Leiomyoma	22446413	disease of cellular proliferation	DOID:127	D25	D007889	150699		deregulated
tissue_expression_ns	hsa-mir-4792	Leiomyoma	22446413	disease of cellular proliferation	DOID:127	D25	D007889	150699		deregulated
tissue_expression_ns	hsa-mir-490	Leiomyoma	22446413	disease of cellular proliferation	DOID:127	D25	D007889	150699		deregulated
tissue_expression_ns	hsa-mir-142	Leukemia	19246560			C95	D007938	613065	HP:0001909	Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells.
tissue_expression_ns	hsa-mir-150	Leukemia	19246560			C95	D007938	613065	HP:0001909	Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells.
tissue_expression_ns	hsa-mir-155	Leukemia	19246560			C95	D007938	613065	HP:0001909	Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells.
tissue_expression_ns	hsa-mir-17	Leukemia	24479800			C95	D007938	613065	HP:0001909	Aberrant expression of oncogenic miRNAs, including miR-155, miR-17-92, miR-21, miR-125b, miR-93, miR-143-p3, miR-196b, and miR-223 promotes leukemogenesis through increasing the  leukemic stem/progenitor cell population, promoting cell proliferation, blocking  cell differentiation, and diminishing cell apoptosis.
tissue_expression_ns	hsa-mir-17	Leukemia	28105201			C95	D007938	613065	HP:0001909	Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia.
tissue_expression_ns	hsa-mir-181a	Leukemia	19246560			C95	D007938	613065	HP:0001909	Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells.
tissue_expression_ns	hsa-mir-21	Leukemia	21882851			C95	D007938	613065	HP:0001909	Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer).
tissue_expression_ns	hsa-mir-223	Leukemia	19246560			C95	D007938	613065	HP:0001909	Here, we report aberrant expression of hematopoietic-specific miR-223, miR-181a, miR-150, miR-142.3p, and miR-155 in HTLV-I-infected cells in vitro and uncultured ex vivo ATL cells.
tissue_expression_ns	hsa-mir-34a	Leukemia	29780367			C95	D007938	613065	HP:0001909	Expression of miR-34a in T-Cells Infected by Human T-Lymphotropic Virus 1.
tissue_expression_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17941951	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	altered expression
tissue_expression_ns	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	17941951	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	altered expression
tissue_expression_ns	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	21882851	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer).
tissue_expression_ns	hsa-mir-221	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	20299489			C92.1	D015464			Among them, the expression of miR-34a, miR-221, and miR-222 was induced in the early stages and maintained throughout the late stages of differentiation.
tissue_expression_ns	hsa-mir-222	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	20299489			C92.1	D015464			Among them, the expression of miR-34a, miR-221, and miR-222 was induced in the early stages and maintained throughout the late stages of differentiation.
tissue_expression_ns	hsa-mir-34a	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	20299489			C92.1	D015464			Among them, the expression of miR-34a, miR-221, and miR-222 was induced in the early stages and maintained throughout the late stages of differentiation.
tissue_expression_ns	hsa-mir-182	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22582938	disease of cellular proliferation	DOID:5599	C83.5	D054218			Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies.
tissue_expression_ns	hsa-mir-145	Liposarcoma	24375455	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.
tissue_expression_ns	hsa-mir-155	Liposarcoma	25888631	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	Deregulation of dicer and mir-155 expression in liposarcoma.
tissue_expression_ns	hsa-mir-451	Liposarcoma	24375455	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.
tissue_expression_ns	hsa-mir-122	Liver Cirrhosis	27879410	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	We also detected expression of hsa-miR-122 in primitive ductular reactions expected for hepatocytic differentiation and hsa-miR-23b cluster expression that drives liver cell fate decisions in cells undergoing lineage commitment
tissue_expression_ns	hsa-mir-23b	Liver Cirrhosis	27879410	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	We also detected expression of hsa-miR-122 in primitive ductular reactions expected for hepatocytic differentiation and hsa-miR-23b cluster expression that drives liver cell fate decisions in cells undergoing lineage commitment
tissue_expression_ns	hsa-mir-378	Liver Diseases [unspecific]	23818290			K76.9	D008107			Dietary fisetin protects against hepatosteatosis in association with modulation of lipid metabolism genes and miR-378 in mice
tissue_expression_ns	hsa-mir-155	Liver Injury	27673475			S36.11	D056486			Fine-tuning the expression of microRNA-155 controls acetaminophen-induced liver inflammation.
tissue_expression_ns	hsa-mir-141	Liver Neoplasms	19167416	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis
tissue_expression_ns	hsa-mir-146a	Liver Neoplasms	24431000	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Aberrant miRNA expression response to UV irradiation in human liver cancer cells.
tissue_expression_ns	hsa-mir-18	Liver Neoplasms	19167416	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis
tissue_expression_ns	hsa-mir-182	Liver Neoplasms	19167416	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis
tissue_expression_ns	hsa-mir-200a	Liver Neoplasms	19167416	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis
tissue_expression_ns	hsa-mir-200b	Liver Neoplasms	19167416	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis
tissue_expression_ns	hsa-mir-200c	Liver Neoplasms	19167416	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis
tissue_expression_ns	hsa-mir-21	Liver Neoplasms	24431000	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Aberrant miRNA expression response to UV irradiation in human liver cancer cells.
tissue_expression_ns	hsa-mir-21	Liver Neoplasms	19167416	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis
tissue_expression_ns	hsa-mir-26a	Liver Neoplasms	24431000	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Aberrant miRNA expression response to UV irradiation in human liver cancer cells.
tissue_expression_ns	hsa-mir-34a	Liver Neoplasms	24431000	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Aberrant miRNA expression response to UV irradiation in human liver cancer cells.
tissue_expression_ns	hsa-mir-429	Liver Neoplasms	19167416	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	the livers of 2-AAF-exposed rats were characterized by the substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family, microRNAs involved in control of apoptosis/cell proliferation and cell-cell contact pathways, two major pathways disrupted during the promotion stage of hepatocarcinogenesis
tissue_expression_ns	hsa-mir-18a	Lung Fibrosis	27689473	respiratory system disease	DOID:3770	J84.10	D011658	178500		Altered microRNA expression profiles in lung damage induced by nanosized SiO2.
tissue_expression_ns	hsa-mir-212	Lung Fibrosis	27689473	respiratory system disease	DOID:3770	J84.10	D011658	178500		Altered microRNA expression profiles in lung damage induced by nanosized SiO2.
tissue_expression_ns	hsa-let-7a	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-let-7a	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-let-7a	Lung Neoplasms	23365639	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, let-7 and miR-9 are deregulated in both lung cancers and other solid malignancies.
tissue_expression_ns	hsa-let-7b	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-let-7c	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-let-7c	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-let-7d	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-let-7e	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-let-7f	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-let-7g	Lung Neoplasms	20818338	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. 
tissue_expression_ns	hsa-let-7g	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-let-7i	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-mir-103	Lung Neoplasms	22576802	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression.
tissue_expression_ns	hsa-mir-125b	Lung Neoplasms	22576802	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression.
tissue_expression_ns	hsa-mir-126	Lung Neoplasms	25124149	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer.
tissue_expression_ns	hsa-mir-126	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-mir-126	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-126	Lung Neoplasms	19493678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs.
tissue_expression_ns	hsa-mir-145	Lung Neoplasms	19493678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs.
tissue_expression_ns	hsa-mir-155	Lung Neoplasms	24574164	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Under clinical conditions, mRNA detection is likely unsuitable for improving sensitivity of EBUS-TBNA-facilitated cancer staging. In contrast,detection of miRNA combined with EBUS-TBNA cytology may improve staging sensitivity.
tissue_expression_ns	hsa-mir-155	Lung Neoplasms	20818338	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. 
tissue_expression_ns	hsa-mir-155	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-155	Lung Neoplasms	29437031	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Underexpression of miR-486-5p but not Overexpression of miR-156 is Associated with Lung Cancer Stages
tissue_expression_ns	hsa-mir-15a	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-mir-182	Lung Neoplasms	19493678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs.
tissue_expression_ns	hsa-mir-183	Lung Neoplasms	19493678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs.
tissue_expression_ns	hsa-mir-194	Lung Neoplasms	22576802	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression.
tissue_expression_ns	hsa-mir-200b	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-200c	Lung Neoplasms	24574164	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Under clinical conditions, mRNA detection is likely unsuitable for improving sensitivity of EBUS-TBNA-facilitated cancer staging. In contrast,detection of miRNA combined with EBUS-TBNA cytology may improve staging sensitivity.
tissue_expression_ns	hsa-mir-200c	Lung Neoplasms	25124150	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression of microRNA miR-126 and miR-201c is associated with prognosis in patients with non-small cell lung cancer.
tissue_expression_ns	hsa-mir-202	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-mir-205	Lung Neoplasms	25917317	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
tissue_expression_ns	hsa-mir-21	Lung Neoplasms	24574164	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Under clinical conditions, mRNA detection is likely unsuitable for improving sensitivity of EBUS-TBNA-facilitated cancer staging. In contrast,detection of miRNA combined with EBUS-TBNA cytology may improve staging sensitivity.
tissue_expression_ns	hsa-mir-21	Lung Neoplasms	24880588	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies.
tissue_expression_ns	hsa-mir-21	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-mir-21	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-21	Lung Neoplasms	19493678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs.
tissue_expression_ns	hsa-mir-210	Lung Neoplasms	20885442	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	These observations help explain contradictory data regarding miR-210 expression and its putative function in solid tumors.
tissue_expression_ns	hsa-mir-210	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-210	Lung Neoplasms	19493678	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs.
tissue_expression_ns	hsa-mir-210	Lung Neoplasms	22576802	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression.
tissue_expression_ns	hsa-mir-218	Lung Neoplasms	25917317	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
tissue_expression_ns	hsa-mir-25	Lung Neoplasms	20818338	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. 
tissue_expression_ns	hsa-mir-25	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-mir-30a	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-34a	Lung Neoplasms	24574164	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Under clinical conditions, mRNA detection is likely unsuitable for improving sensitivity of EBUS-TBNA-facilitated cancer staging. In contrast,detection of miRNA combined with EBUS-TBNA cytology may improve staging sensitivity.
tissue_expression_ns	hsa-mir-451	Lung Neoplasms	29371906	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
tissue_expression_ns	hsa-mir-486	Lung Neoplasms	29437031	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Underexpression of miR-486-5p but not Overexpression of miR-155 is Associated with Lung Cancer Stages
tissue_expression_ns	hsa-mir-495	Lung Neoplasms	20818338	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. 
tissue_expression_ns	hsa-mir-500	Lung Neoplasms	22576802	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Among them, some have a well-characterized association with cancer progression, e.g. miR-125b, miR-210, miR-103, miR-194 and miR-500. In summary, it is evident from our results that MTA1 functions in regulating the invasive phenotype of lung cancer cells and this regulation may be through altered miRNA expression.
tissue_expression_ns	hsa-mir-503	Lung Neoplasms	29164842	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others
tissue_expression_ns	hsa-mir-9	Lung Neoplasms	23365639	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, let-7 and miR-9 are deregulated in both lung cancers and other solid malignancies.
tissue_expression_ns	hsa-mir-98	Lung Neoplasms	21102586	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In AD cases,a SNP within the same haplotype was associated with reduced RNASEN mRNA expression (P=0.013) and with miR expression changes (global P=0.007) of miRs known to be associated with cancer(e.g.,let-7 family, miR-21, miR-25, miR-126 and miR15a).
tissue_expression_ns	hsa-mir-125a	Lupus Nephritis	26762103	urinary system disease	DOID:0080162	M32.14	D008181			Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity.
tissue_expression_ns	hsa-mir-127	Lupus Nephritis	26762103	urinary system disease	DOID:0080162	M32.14	D008181			Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity.
tissue_expression_ns	hsa-mir-145	Lupus Nephritis	26722454	urinary system disease	DOID:0080162	M32.14	D008181			Association of miRNA-145 expression in vascular smooth muscle cells with vascular damages in patients with lupus nephritis.
tissue_expression_ns	hsa-mir-146a	Lupus Nephritis	22295894	urinary system disease	DOID:0080162	M32.14	D008181			Intra-renal expression of miR-638, miR-198 and miR-146a are differentially expressed between LN patients and normal controls. Furthermore, the degree of change in glomerular miR-146a and tubulointerstitial miR-638 expression correlated with clinical disease severity.
tissue_expression_ns	hsa-mir-146a	Lupus Nephritis	26762103	urinary system disease	DOID:0080162	M32.14	D008181			Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity.
tissue_expression_ns	hsa-mir-150	Lupus Nephritis	26762103	urinary system disease	DOID:0080162	M32.14	D008181			Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity.
tissue_expression_ns	hsa-mir-155	Lupus Nephritis	26762103	urinary system disease	DOID:0080162	M32.14	D008181			Levels of cell-free miR-125a, miR-150, and miR-155 in the urine supernatant are associated with the expression of LN-Panel biomarkers and some LN measures. These miRNA's may complement, but are unlikely superior to the LN-Panel for estimating concurrent LN activity.
tissue_expression_ns	hsa-mir-198	Lupus Nephritis	22295894	urinary system disease	DOID:0080162	M32.14	D008181			Intra-renal expression of miR-638, miR-198 and miR-146a are differentially expressed between LN patients and normal controls. Furthermore, the degree of change in glomerular miR-146a and tubulointerstitial miR-638 expression correlated with clinical disease severity.
tissue_expression_ns	hsa-mir-638	Lupus Nephritis	22295894	urinary system disease	DOID:0080162	M32.14	D008181			Intra-renal expression of miR-638, miR-198 and miR-146a are differentially expressed between LN patients and normal controls. Furthermore, the degree of change in glomerular miR-146a and tubulointerstitial miR-638 expression correlated with clinical disease severity.
tissue_expression_ns	hsa-mir-223	Lyme Disease	28076897	disease by infectious agent	DOID:11729	A69.2	D008193			MicroRNA Expression Shows Inflammatory Dysregulation and Tumor-Like Proliferative Responses in Joints of Patients With Postinfectious Lyme Arthritis.
tissue_expression_ns	hsa-mir-124-1	Lymphoma	22395483	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma.
tissue_expression_ns	hsa-mir-135a-1	Lymphoma	22490335	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	different expression between small lymphocytic leukemia and lymphoma
tissue_expression_ns	hsa-mir-135a-2	Lymphoma	22490335	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	different expression between small lymphocytic leukemia and lymphoma
tissue_expression_ns	hsa-mir-142	Lymphoma	28031239	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis.
tissue_expression_ns	hsa-mir-150	Lymphoma	22395483	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma.
tissue_expression_ns	hsa-mir-150	Lymphoma	22490335	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	different expression between small lymphocytic leukemia and lymphoma
tissue_expression_ns	hsa-mir-155	Lymphoma	25265435	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Differential expression of miR-155 and miR-21 in tumor and stroma cells in diffuse large B-cell lymphoma.
tissue_expression_ns	hsa-mir-155	Lymphoma	23871213	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The expression ratio of miR-17-5p and miR-155 correlates with grading in canine splenic lymphoma.
tissue_expression_ns	hsa-mir-155	Lymphoma	22776000	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL.
tissue_expression_ns	hsa-mir-155	Lymphoma	28031239	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis.
tissue_expression_ns	hsa-mir-184	Lymphoma	22490335	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	different expression between small lymphocytic leukemia and lymphoma
tissue_expression_ns	hsa-mir-203	Lymphoma	28031239	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis.
tissue_expression_ns	hsa-mir-21	Lymphoma	25265435	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Differential expression of miR-155 and miR-21 in tumor and stroma cells in diffuse large B-cell lymphoma.
tissue_expression_ns	hsa-mir-27b	Lymphoma	22776000	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL.
tissue_expression_ns	hsa-mir-29b	Lymphoma	22776000	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL.
tissue_expression_ns	hsa-mir-342	Lymphoma	22490335	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	different expression between small lymphocytic leukemia and lymphoma
tissue_expression_ns	hsa-mir-363	Lymphoma	22490335	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	different expression between small lymphocytic leukemia and lymphoma
tissue_expression_ns	hsa-mir-518b	Lymphoma	22395483	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma.
tissue_expression_ns	hsa-mir-539	Lymphoma	22395483	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma.
tissue_expression_ns	hsa-mir-550a-1	Lymphoma	22395483	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma.
tissue_expression_ns	hsa-mir-550a-2	Lymphoma	22395483	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	A distinct set of five microRNAs (miR-150, miR-550, miR-124a, miR-518b and miR-539) was shown to be differentially expressed in gastritis as opposed to MALT lymphoma.
tissue_expression_ns	hsa-mir-708	Lymphoma	22490335	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	different expression between small lymphocytic leukemia and lymphoma
tissue_expression_ns	hsa-mir-92a	Lymphoma	22776000	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL.
tissue_expression_ns	hsa-mir-93	Lymphoma	22776000	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Although miRNA microarray analysis did not identify statistically significant differentially expressed miRNAs, miRNA-Q-PCR demonstrated statistically significantly differential expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a between tumor-stage MF and C-ALCL.
tissue_expression_ns	hsa-mir-155	Lymphoma, Burkitt	16235244	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Expression of BIC and miR-155 in 3 latency type III EBV-positive BL cell lines and in all primary PTLD cases suggests a possible role for EBV latency type III specific proteins in the induction of BIC expression.
tissue_expression_ns	hsa-mir-26a	Lymphoma, Burkitt	18713946	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Interestingly, miR-26a was also found to be deregulated in primary human Burkitt lymphoma samples, thereby probably being of clinical relevance.
tissue_expression_ns	hsa-mir-129-2	Lymphoma, Large B-Cell	24358187			C83.3	D016403	109565		MicroRNA profiling of primary cutaneous large B-cell lymphomas.
tissue_expression_ns	hsa-mir-135b	Lymphoma, Large B-Cell	23801630			C83.3	D016403	109565		MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
tissue_expression_ns	hsa-mir-146a	Lymphoma, Large B-Cell	23801630			C83.3	D016403	109565		MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
tissue_expression_ns	hsa-mir-155	Lymphoma, Large B-Cell	23801630			C83.3	D016403	109565		MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
tissue_expression_ns	hsa-mir-214	Lymphoma, Large B-Cell	24358187			C83.3	D016403	109565		MicroRNA profiling of primary cutaneous large B-cell lymphomas.
tissue_expression_ns	hsa-mir-31	Lymphoma, Large B-Cell	24358187			C83.3	D016403	109565		MicroRNA profiling of primary cutaneous large B-cell lymphomas.
tissue_expression_ns	hsa-mir-512	Lymphoma, Large B-Cell	23801630			C83.3	D016403	109565		MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
tissue_expression_ns	hsa-mir-708	Lymphoma, Large B-Cell	23801630			C83.3	D016403	109565		MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
tissue_expression_ns	hsa-mir-886	Lymphoma, Large B-Cell	23801630			C83.3	D016403	109565		MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
tissue_expression_ns	hsa-mir-9	Lymphoma, Large B-Cell	24358187			C83.3	D016403	109565		MicroRNA profiling of primary cutaneous large B-cell lymphomas.
tissue_expression_ns	hsa-mir-127	Lymphoma, Large B-Cell, Diffuse	19287466	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma.
tissue_expression_ns	hsa-mir-17	Lymphoma, Large B-Cell, Diffuse	19287466	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma.
tissue_expression_ns	hsa-mir-23a	Lymphoma, Large B-Cell, Diffuse	24659264	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma.
tissue_expression_ns	hsa-mir-17	Lymphoproliferative Disorders	25130212			D47.Z1	D008232			Unsupervised nonhierarchical clustering of the viral and cellular microRNAome distinguished non-EBV-associated from EBV-associated samples and identified a separate group of EBV-associated pCNS PTLD that displayed reduced levels of B cell lymphoma associated oncomiRs such as hsa-miR-155, -21, -221 and the hsa-miR-17-92 cluster.
tissue_expression_ns	hsa-mir-181b	Male Infertility	25141839	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	The expression of three out of five selected miRNAs, including miR-34a, miR-181b and miR-122a, showed some degrees of changes following exposure to oxidative stress.
tissue_expression_ns	hsa-mir-29	Malignant Neoplasms [unspecific]	28063172			C80.1	D009369			Prognostic value of the MicroRNA-29 family in multiple human cancers: A meta-analysis and systematic review.
tissue_expression_ns	hsa-mir-223	Mastitis	28831974	thoracic disease	DOID:10690		D008413			Expression profiles of miRNAs from bovine mammary glands in response to Streptococcus agalactiae-induced mastitis.
tissue_expression_ns	hsa-mir-10b	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-10b: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-125b-1	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-125b: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-125b-2	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-125b: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-135a-1	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-135a: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-135a-2	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-135a: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-135b	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-135b: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-153-1	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-153: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-153-2	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-153: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-181b-1	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-181b: different expression in tumors overexpression or not c-Myc
tissue_expression_ns	hsa-mir-181b-2	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-181b: different expression in tumors overexpression or not c-Myc
tissue_expression_ns	hsa-mir-199b	Medulloblastoma	18973228	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-199b: different expression in tumors overexpression or not ErbB2
tissue_expression_ns	hsa-mir-211	Medulloepithelioma	25807141	disease of cellular proliferation	DOID:4790		D018242		HP:0030071	We report significantly dysregulated miRNAs in intraocular ME tumors, which exhibited abnormal profiles in other cancers as well such as retinoblastoma and glioblastoma. Pathway analysis of all dysregulated miRNAs shared commonalities with other cancer pathways.
tissue_expression_ns	hsa-mir-509	Medulloepithelioma	25807141	disease of cellular proliferation	DOID:4790		D018242		HP:0030071	We report significantly dysregulated miRNAs in intraocular ME tumors, which exhibited abnormal profiles in other cancers as well such as retinoblastoma and glioblastoma. Pathway analysis of all dysregulated miRNAs shared commonalities with other cancer pathways.
tissue_expression_ns	hsa-let-7a	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-let-7b	Melanoma	18477892	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The most significant discriminators were let-7b and miR-199a, and the expression of these miRNAs was validated by quantitative PCR.
tissue_expression_ns	hsa-let-7b	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-125b	Melanoma	27566021	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA dysregulation in melanoma.
tissue_expression_ns	hsa-mir-146a	Melanoma	27311960	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-146a controls melanoma progression in a dual way, promoting growth and inhibiting dissemination
tissue_expression_ns	hsa-mir-148	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-150	Melanoma	27566021	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA dysregulation in melanoma.
tissue_expression_ns	hsa-mir-155	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-155	Melanoma	27565163	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells.
tissue_expression_ns	hsa-mir-155	Melanoma	27566021	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA dysregulation in melanoma.
tissue_expression_ns	hsa-mir-182	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-182	Melanoma	26273328	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Clinical analyses demonstrated the link of miR-182 expression to poor prognosis in cancer patients.
tissue_expression_ns	hsa-mir-199a	Melanoma	18477892	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The most significant discriminators were let-7b and miR-199a, and the expression of these miRNAs was validated by quantitative PCR.
tissue_expression_ns	hsa-mir-199a	Melanoma	26812476	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Five miRNAs (miR-214, miR146b, miR-143, miR-199a  and miR-134) were found to be differentially expressed in M3/ D3 UM tumors.
tissue_expression_ns	hsa-mir-200b	Melanoma	26743475	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-10b and miR-200b showed independent prognostic value (P=0.002 and 0.047, respectively) in multivariable analysis alongside known clinico-pathological prognostic features
tissue_expression_ns	hsa-mir-200c	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-200c	Melanoma	27469124	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR expression profiles can be measured in indeterminate Spitz tumors and correlate with markers of malignant potential.
tissue_expression_ns	hsa-mir-203	Melanoma	24023765	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics.
tissue_expression_ns	hsa-mir-204	Melanoma	24023765	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics.
tissue_expression_ns	hsa-mir-204	Melanoma	20302635	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Although the number of cases is small, positive lymph node status in the two age groups was characterized by the statistically significant expression of hsa-miR-30a* and hsa-miR-204 (F-test, p-value < 0.001).
tissue_expression_ns	hsa-mir-205	Melanoma	24023765	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics.
tissue_expression_ns	hsa-mir-205	Melanoma	27566021	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA dysregulation in melanoma.
tissue_expression_ns	hsa-mir-21	Melanoma	27566021	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA dysregulation in melanoma.
tissue_expression_ns	hsa-mir-211	Melanoma	24023765	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics.
tissue_expression_ns	hsa-mir-211	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-211	Melanoma	27566021	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA dysregulation in melanoma.
tissue_expression_ns	hsa-mir-214	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-221	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-222	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-23a	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-23b	Melanoma	24023765	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics.
tissue_expression_ns	hsa-mir-23b	Melanoma	23377970	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Detailed studies of different groups thereafter identified miRNAs with differential expression in benign melanocytes compared with melanoma cell lines or in benign melanocytic lesions compared with melanomas. Among these were let-7a and b, miR-23a and b, miR-148, miR-155, miR-182, miR-200c, miR-211, miR214, and miR-221 and 222.
tissue_expression_ns	hsa-mir-26a	Melanoma	24023765	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics.
tissue_expression_ns	hsa-mir-26b	Melanoma	24023765	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we found extensive sequence variations (isomiRs) and other non-coding small RNAs revealing a complex melanoma transcriptome. Deep-sequencing small RNAs directly from clinically defined specimens provides a robust strategy to improve melanoma diagnostics.
tissue_expression_ns	hsa-mir-301a	Melanoma	27855389	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Expression of MicroRNA-301a and its Functional Roles in Malignant Melanoma.
tissue_expression_ns	hsa-mir-30a	Melanoma	20302635	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Although the number of cases is small, positive lymph node status in the two age groups was characterized by the statistically significant expression of hsa-miR-30a* and hsa-miR-204 (F-test, p-value < 0.001).
tissue_expression_ns	hsa-mir-320	Melanoma	26264058	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	hsa-miR-519, "hsa-miR-431" and "hsa-miR-320c" are possible novel predictions for renal cancer, lung cancer and melanoma, respectively.
tissue_expression_ns	hsa-mir-107	Meningioma	28349893	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma.
tissue_expression_ns	hsa-mir-137	Meningioma	28349893	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma.
tissue_expression_ns	hsa-mir-21	Meningioma	28349893	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma.
tissue_expression_ns	hsa-mir-29b	Meningioma	28349893	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma.
tissue_expression_ns	hsa-mir-124	Mesial Temporal Lobe Epilepsy	23315173			G40.209	D004833	608096		Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy.
tissue_expression_ns	hsa-mir-128a	Mesial Temporal Lobe Epilepsy	27695061			G40.209	D004833	608096		Identification of microRNAs with Dysregulated Expression in Status Epilepticus Induced Epileptogenesis.
tissue_expression_ns	hsa-mir-132	Mesial Temporal Lobe Epilepsy	23315173			G40.209	D004833	608096		Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy.
tissue_expression_ns	hsa-mir-134	Mesial Temporal Lobe Epilepsy	23315173			G40.209	D004833	608096		Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy.
tissue_expression_ns	hsa-mir-196b	Mesial Temporal Lobe Epilepsy	27695061			G40.209	D004833	608096		Identification of microRNAs with Dysregulated Expression in Status Epilepticus Induced Epileptogenesis.
tissue_expression_ns	hsa-mir-21	Mesial Temporal Lobe Epilepsy	23315173			G40.209	D004833	608096		Expression patterns of miR-124, miR-134, miR-132, and miR-21 in an immature rat model and children with mesial temporal lobe epilepsy.
tissue_expression_ns	hsa-mir-352	Mesial Temporal Lobe Epilepsy	27695061			G40.209	D004833	608096		Identification of microRNAs with Dysregulated Expression in Status Epilepticus Induced Epileptogenesis.
tissue_expression_ns	hsa-mir-103a	Mesothelioma	25469901	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	the use of biomarkers of different molecular classes might be a reasonable approach to assemble a biomarker panel.
tissue_expression_ns	hsa-mir-126	Mesothelioma	26765063	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Subject to validation of the current results in further larger studies, miR-21 and miR-126 profiling could be an effective and reliable tool for the diagnosis of MM in pleural effusions complementary to cytology evaluation.
tissue_expression_ns	hsa-mir-182	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	dysregulated
tissue_expression_ns	hsa-mir-21	Mesothelioma	26765063	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Subject to validation of the current results in further larger studies, miR-21 and miR-126 profiling could be an effective and reliable tool for the diagnosis of MM in pleural effusions complementary to cytology evaluation.
tissue_expression_ns	hsa-mir-214	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	dysregulated
tissue_expression_ns	hsa-mir-497	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	dysregulated
tissue_expression_ns	hsa-mir-7-1	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	dysregulated
tissue_expression_ns	hsa-mir-7-2	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	dysregulated
tissue_expression_ns	hsa-mir-7-3	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	dysregulated
tissue_expression_ns	hsa-let-7c	Mitral Valve Disease	29315310			I05				Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d  in naturally occurring canine myxomatous mitral valve disease
tissue_expression_ns	hsa-mir-17	Mitral Valve Disease	29315310			I05				Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d  in naturally occurring canine myxomatous mitral valve disease
tissue_expression_ns	hsa-mir-20a	Mitral Valve Disease	29315310			I05				Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d  in naturally occurring canine myxomatous mitral valve disease
tissue_expression_ns	hsa-mir-30d	Mitral Valve Disease	29315310			I05				Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d  in naturally occurring canine myxomatous mitral valve disease
tissue_expression_ns	hsa-mir-223	Multiple Myeloma	27023728	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-223 expression in MM-BMMSCs was reduced by the presence of MM cells
tissue_expression_ns	hsa-let-7a	Multiple Sclerosis	25487315	nervous system disease	DOID:2377	G35	D009103	PS126200		some miRNA subsets may be potential biomarkers for MS activity.
tissue_expression_ns	hsa-mir-26a	Multiple Sclerosis	24792898	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
tissue_expression_ns	hsa-mir-26a	Multiple Sclerosis	27310932	nervous system disease	DOID:2377	G35	D009103	PS126200		down-regulation of miR-155 and miR-26a was seen in MS patients during and after natalizumab therapy.
tissue_expression_ns	hsa-mir-326	Multiple Sclerosis	24792898	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
tissue_expression_ns	hsa-mir-648a	Multiple Sclerosis	25487315	nervous system disease	DOID:2377	G35	D009103	PS126200		some miRNA subsets may be potential biomarkers for MS activity.
tissue_expression_ns	hsa-mir-92a	Multiple Sclerosis	25487315	nervous system disease	DOID:2377	G35	D009103	PS126200		some miRNA subsets may be potential biomarkers for MS activity.
tissue_expression_ns	hsa-mir-202	Multiple System Atrophy	24981430	nervous system disease	DOID:4752	G90.3	D019578	146500		Altered expression of miR-202 in cerebellum of multiple-system atrophy.
tissue_expression_ns	hsa-mir-21	Muscle Atrophy	24891504			M62.5	D009133		HP:0100295	Among the different miRNAs, microRNA-206 and -21 were the most induced in denervated muscles.
tissue_expression_ns	hsa-mir-206	Muscle Diseases [unspecific]	25703017			M63.80	D009135			Thirty-six miRNAs were differentially expressed between prenatal and postnatal stages of muscle development including several myomiRs (miR-1, miR-206 and let-7  families).
tissue_expression_ns	hsa-mir-1	Muscular Dystrophy	26398013			G71.0	D009136	310200	HP:0003560	whereas down-regulation of myogenic miRNAs, including miR-1 and miR-206, is associated with inhibition of muscle regeneration.
tissue_expression_ns	hsa-mir-195	Muscular Dystrophy	27651778			G71.0	D009136	310200	HP:0003560	At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles
tissue_expression_ns	hsa-mir-214	Muscular Dystrophy	27651778			G71.0	D009136	310200	HP:0003560	At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles
tissue_expression_ns	hsa-mir-221	Muscular Dystrophy	27651778			G71.0	D009136	310200	HP:0003560	At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles
tissue_expression_ns	hsa-mir-222	Muscular Dystrophy	27651778			G71.0	D009136	310200	HP:0003560	At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles
tissue_expression_ns	hsa-mir-320	Muscular Dystrophy	27651778			G71.0	D009136	310200	HP:0003560	At the epigenetic level, miRNAs are thought to be highly involved in the pathophysiological progress of denervated muscles
tissue_expression_ns	hsa-mir-330	Muscular Dystrophy, Facioscapulohumeral	25692472	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated.
tissue_expression_ns	hsa-mir-331	Muscular Dystrophy, Facioscapulohumeral	25692472	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated.
tissue_expression_ns	hsa-mir-34a	Muscular Dystrophy, Facioscapulohumeral	25692472	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated.
tissue_expression_ns	hsa-mir-380	Muscular Dystrophy, Facioscapulohumeral	25692472	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated.
tissue_expression_ns	hsa-mir-516b	Muscular Dystrophy, Facioscapulohumeral	25692472	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated.
tissue_expression_ns	hsa-mir-517	Muscular Dystrophy, Facioscapulohumeral	25692472	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated.
tissue_expression_ns	hsa-mir-582	Muscular Dystrophy, Facioscapulohumeral	25692472	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated.
tissue_expression_ns	hsa-mir-625	Muscular Dystrophy, Facioscapulohumeral	25692472	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		This work provides new candidate mechanisms potentially involved in the onset of FSHD pathology. Whether these FSHD specific miRNAs cause deregulations during fetal development, or protect against the appearance of the FSHD phenotype until the second decade of life still needs to be investigated.
tissue_expression_ns	hsa-mir-146a	Mycobacterium Avium Complex Disease	24462562	disease by infectious agent	DOID:2755	A31.2	D015270			Analysis of miRNA expression profiling in human macrophages responding to Mycobacterium infection: induction of the immune regulator miR-146a.
tissue_expression_ns	hsa-mir-155	Mycosis Fungoides	25698383			C84.00	D009182			These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF.
tissue_expression_ns	hsa-mir-181b	Mycosis Fungoides	25698383			C84.00	D009182			These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF.
tissue_expression_ns	hsa-mir-223	Mycosis Fungoides	25698383			C84.00	D009182			These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF.
tissue_expression_ns	hsa-mir-326	Mycosis Fungoides	25698383			C84.00	D009182			These results by identifying a number of differentially expressed microRNAs add further insight into the molecular pathogenesis of folliculotropic MF and large cell transformation of MF.
tissue_expression_ns	hsa-mir-150	Myeloma	28458781			C90.0	D009101	254500		MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy.
tissue_expression_ns	hsa-mir-150	Myeloproliferative Neoplasms	23343777	disease of cellular proliferation	DOID:2226	D47.1		616871		An aberrant expression of miRNAs 10a and 150 could be demonstrated for essential thrombocythemia and PMF as well as for polycythemia vera and PMF, respectively. The expression of miR-150 could further be shown to correlate with both JAK2 allele burden and peripheral blood counts.
tissue_expression_ns	hsa-mir-1-1	Myocardial Infarction	21386882	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1, miR-29b and miR-98 dysregulated.
tissue_expression_ns	hsa-mir-1-2	Myocardial Infarction	21386882	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1, miR-29b and miR-98 dysregulated.
tissue_expression_ns	hsa-mir-133b	Myocardial Infarction	20075508	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	dysregulation
tissue_expression_ns	hsa-mir-150	Myocardial Infarction	20075508	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	dysregulation
tissue_expression_ns	hsa-mir-186	Myocardial Infarction	20075508	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	dysregulation
tissue_expression_ns	hsa-mir-21	Myocardial Infarction	19706597	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	hsa-mir-21:a remarkable example of MicroRNA expression signature; downregulated in infarcted areas,  upregulated in border areas
tissue_expression_ns	hsa-mir-21	Myocardial Infarction	21956146	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	deregulated
tissue_expression_ns	hsa-mir-210	Myocardial Infarction	20075508	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	dysregulation
tissue_expression_ns	hsa-mir-29a	Myocardial Infarction	21956146	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	deregulated
tissue_expression_ns	hsa-mir-29b-1	Myocardial Infarction	21386882	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1, miR-29b and miR-98 dysregulated.
tissue_expression_ns	hsa-mir-29b-2	Myocardial Infarction	21386882	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1, miR-29b and miR-98 dysregulated.
tissue_expression_ns	hsa-mir-451a	Myocardial Infarction	20075508	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	dysregulation
tissue_expression_ns	hsa-mir-98	Myocardial Infarction	21386882	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1, miR-29b and miR-98 dysregulated.
tissue_expression_ns	hsa-mir-1	Myocardial Ischemic-Reperfusion Injury	26738985				D015428			Of the 17 miRs, 9 miRs, including miR-1, miR-21, miR-24, and miR-195, which are related to apoptosis, exhibited different expression patterns in the RIPerc group compared with the control.
tissue_expression_ns	hsa-mir-195	Myocardial Ischemic-Reperfusion Injury	26738985				D015428			Of the 17 miRs, 9 miRs, including miR-1, miR-21, miR-24, and miR-195, which are related to apoptosis, exhibited different expression patterns in the RIPerc group compared with the control.
tissue_expression_ns	hsa-mir-1	Myotonic Muscular Dystrophy	28078570			G71.11	D009223	160900		Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1.
tissue_expression_ns	hsa-mir-133a	Myotonic Muscular Dystrophy	28078570			G71.11	D009223	160900		Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1.
tissue_expression_ns	hsa-mir-133b	Myotonic Muscular Dystrophy	28078570			G71.11	D009223	160900		Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1.
tissue_expression_ns	hsa-mir-206	Myotonic Muscular Dystrophy	28078570			G71.11	D009223	160900		Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1.
tissue_expression_ns	hsa-mir-23b	Myotonic Muscular Dystrophy	24412363			G71.11	D009223	160900		The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue,dramatically altering miRNA and mRNA expression.
tissue_expression_ns	hsa-mir-1290	Necrotizing Enterocolitis	26274503	gastrointestinal system disease	DOID:8677	K55.3	D020345			The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology.
tissue_expression_ns	hsa-mir-194	Necrotizing Enterocolitis	26274503	gastrointestinal system disease	DOID:8677	K55.3	D020345			The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology.
tissue_expression_ns	hsa-mir-203	Necrotizing Enterocolitis	26274503	gastrointestinal system disease	DOID:8677	K55.3	D020345			The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology.
tissue_expression_ns	hsa-mir-21	Necrotizing Enterocolitis	26274503	gastrointestinal system disease	DOID:8677	K55.3	D020345			The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology.
tissue_expression_ns	hsa-mir-31	Necrotizing Enterocolitis	26274503	gastrointestinal system disease	DOID:8677	K55.3	D020345			The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology.
tissue_expression_ns	hsa-mir-431	Necrotizing Enterocolitis	26274503	gastrointestinal system disease	DOID:8677	K55.3	D020345			The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology.
tissue_expression_ns	hsa-mir-451	Necrotizing Enterocolitis	26274503	gastrointestinal system disease	DOID:8677	K55.3	D020345			The robust response of miRNA dysregulation in NEC and SIP, and concerted involvement of specific miRNAs in the molecular networks indicated their crucial roles in mucosa integrity and disease pathophysiology.
tissue_expression_ns	hsa-let-7	Neoplasms [unspecific]	25998712			C80.1	D009369			together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer.
tissue_expression_ns	hsa-let-7a	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-10b	Neoplasms [unspecific]	28864233			C80.1	D009369			MicroRNA-10b and the clinical outcomes of various cancers: A systematic review and meta-analysis.
tissue_expression_ns	hsa-mir-125b	Neoplasms [unspecific]	26407906			C80.1	D009369			The aberrant expression of miR-125 familyis tightly related to tumorigenesis and tumor development.
tissue_expression_ns	hsa-mir-126	Neoplasms [unspecific]	28536479			C80.1	D009369			Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease.
tissue_expression_ns	hsa-mir-1267	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-128	Neoplasms [unspecific]	24515752			C80.1	D009369			Microvesicle-associated microRNA expression is altered upon particulate matter exposure in healthy workers and in A549 cells.
tissue_expression_ns	hsa-mir-1280	Neoplasms [unspecific]	23936320			C80.1	D009369			Characterization of microRNA expression profiles and the discovery of novel microRNAs involved in cancer during human embryonic development.
tissue_expression_ns	hsa-mir-1282	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-133b	Neoplasms [unspecific]	25075017			C80.1	D009369			Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors.
tissue_expression_ns	hsa-mir-141	Neoplasms [unspecific]	25789530			C80.1	D009369			miR-141 as a prognostic and diagnostic biomarker in different types of cancer
tissue_expression_ns	hsa-mir-141	Neoplasms [unspecific]	26828359			C80.1	D009369			microRNA (miR)-141 is aberrantly expressed in many human malignant tumors
tissue_expression_ns	hsa-mir-143	Neoplasms [unspecific]	24974841			C80.1	D009369			Using microRNA expression profiles the authors were able to distinguish peritumoural tissues according to distance from the primary tumour site. Future application of the method may prove to be useful in early detection of the altered epigenetic regulation in tissue fields representing normal phenotype. This may be helpful in cancer risk assessment and prevention.
tissue_expression_ns	hsa-mir-143	Neoplasms [unspecific]	20064147			C80.1	D009369			Overall, the current study suggests that miR-143 is ubiquitously expressed among tissues and is likely to be involved in the regulation of cell proliferation and apoptosis.
tissue_expression_ns	hsa-mir-145	Neoplasms [unspecific]	24609385			C80.1	D009369			Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences.
tissue_expression_ns	hsa-mir-145	Neoplasms [unspecific]	25792469			C80.1	D009369			In conclusion, our findings suggest that miR-145 expression is associated with overall survival (OS) in cancer patients and can serve as a promising biomarker for monitoring prognosis.
tissue_expression_ns	hsa-mir-148a	Neoplasms [unspecific]	27390598			C80.1	D009369			Mir-148a  is aberrantly expressed in various cancers and has been identified as an oncogenic or tumor suppressor with crucial roles in the molecular mechanisms of oncogenesis.
tissue_expression_ns	hsa-mir-15	Neoplasms [unspecific]	25998712			C80.1	D009369			together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer.
tissue_expression_ns	hsa-mir-155	Neoplasms [unspecific]	24824925			C80.1	D009369			miR-155 as a diagnostic and prognostic marker in hematological and solid malignancies
tissue_expression_ns	hsa-mir-155	Neoplasms [unspecific]	24974841			C80.1	D009369			Using microRNA expression profiles the authors were able to distinguish peritumoural tissues according to distance from the primary tumour site. Future application of the method may prove to be useful in early detection of the altered epigenetic regulation in tissue fields representing normal phenotype. This may be helpful in cancer risk assessment and prevention.
tissue_expression_ns	hsa-mir-155	Neoplasms [unspecific]	24609385			C80.1	D009369			Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences.
tissue_expression_ns	hsa-mir-16	Neoplasms [unspecific]	25998712			C80.1	D009369			together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer.
tissue_expression_ns	hsa-mir-16	Neoplasms [unspecific]	26299954			C80.1	D009369			Genome-wide analysis of microRNA and mRNA expression signatures in cancer.
tissue_expression_ns	hsa-mir-17	Neoplasms [unspecific]	28222938			C80.1	D009369			The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells.
tissue_expression_ns	hsa-mir-182	Neoplasms [unspecific]	23791657			C80.1	D009369			Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues.
tissue_expression_ns	hsa-mir-183	Neoplasms [unspecific]	24609385			C80.1	D009369			Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences.
tissue_expression_ns	hsa-mir-183	Neoplasms [unspecific]	23791657			C80.1	D009369			Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues.
tissue_expression_ns	hsa-mir-18a	Neoplasms [unspecific]	28222938			C80.1	D009369			The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells.
tissue_expression_ns	hsa-mir-191	Neoplasms [unspecific]	26299954			C80.1	D009369			Genome-wide analysis of microRNA and mRNA expression signatures in cancer.
tissue_expression_ns	hsa-mir-19a	Neoplasms [unspecific]	28222938			C80.1	D009369			The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells.
tissue_expression_ns	hsa-mir-19b	Neoplasms [unspecific]	28222938			C80.1	D009369			The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells.
tissue_expression_ns	hsa-mir-200a	Neoplasms [unspecific]	20498632			C80.1	D009369			miR-200a:altered microRNA signatures as potent markers for ATCs
tissue_expression_ns	hsa-mir-200b	Neoplasms [unspecific]	20498632			C80.1	D009369			miR-200b:altered microRNA signatures as potent markers for ATCs
tissue_expression_ns	hsa-mir-200c	Neoplasms [unspecific]	20498632			C80.1	D009369			miR-200c:altered microRNA signatures as potent markers for ATCs
tissue_expression_ns	hsa-mir-200c	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-20a	Neoplasms [unspecific]	28222938			C80.1	D009369			The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells.
tissue_expression_ns	hsa-mir-21	Neoplasms [unspecific]	24974841			C80.1	D009369			Using microRNA expression profiles the authors were able to distinguish peritumoural tissues according to distance from the primary tumour site. Future application of the method may prove to be useful in early detection of the altered epigenetic regulation in tissue fields representing normal phenotype. This may be helpful in cancer risk assessment and prevention.
tissue_expression_ns	hsa-mir-21	Neoplasms [unspecific]	24609385			C80.1	D009369			Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences.
tissue_expression_ns	hsa-mir-21	Neoplasms [unspecific]	20498632			C80.1	D009369			miR-21:altered microRNA signatures as potent markers for ATCs
tissue_expression_ns	hsa-mir-210	Neoplasms [unspecific]	25075017			C80.1	D009369			Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors.
tissue_expression_ns	hsa-mir-210	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-214	Neoplasms [unspecific]	28536479			C80.1	D009369			Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease.
tissue_expression_ns	hsa-mir-22	Neoplasms [unspecific]	26295583			C80.1	D009369			Genome Wide Expression Profiling of Cancer Cell Lines Cultured in Microgravity Reveals Significant Dysregulation of Cell Cycle and MicroRNA Gene Networks.
tissue_expression_ns	hsa-mir-221	Neoplasms [unspecific]	24974841			C80.1	D009369			Using microRNA expression profiles the authors were able to distinguish peritumoural tissues according to distance from the primary tumour site. Future application of the method may prove to be useful in early detection of the altered epigenetic regulation in tissue fields representing normal phenotype. This may be helpful in cancer risk assessment and prevention.
tissue_expression_ns	hsa-mir-221	Neoplasms [unspecific]	24609385			C80.1	D009369			Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences.
tissue_expression_ns	hsa-mir-222	Neoplasms [unspecific]	24609385			C80.1	D009369			Together, our probabilistic approach of integrating expression and sequence scores establishes a functional link between the aberrant miRNA and mRNA expression, which was previously under-appreciated due to the methodological differences.
tissue_expression_ns	hsa-mir-29a	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-302c	Neoplasms [unspecific]	24515752			C80.1	D009369			Microvesicle-associated microRNA expression is altered upon particulate matter exposure in healthy workers and in A549 cells.
tissue_expression_ns	hsa-mir-30a	Neoplasms [unspecific]	20498632			C80.1	D009369			miR-30:altered microRNA signatures as potent markers for ATCs
tissue_expression_ns	hsa-mir-3177	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-330	Neoplasms [unspecific]	24278004			C80.1	D009369			MicroRNA-gene association as a prognostic biomarker in cancer exposes disease mechanisms.
tissue_expression_ns	hsa-mir-34	Neoplasms [unspecific]	25452192			C80.1	D009369			miR-34 family members could be expected to become potential diagnostic and prognostic biomarkers in some types of human cancers. Further well-designed and larger sample studies are surely warranted to identify the role of the miR-34 family in the occurrence and development of tumors.
tissue_expression_ns	hsa-mir-34a	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-373	Neoplasms [unspecific]	25990556			C80.1	D009369			Deregulation of miR-373 has been demonstrated in a number of cancers, whether it acts as an oncogene or a tumor suppressor, however, seems to be context dependent. In this review, we focus on the diverse functions of miR-373 and its implication in cancers.
tissue_expression_ns	hsa-mir-514b	Neoplasms [unspecific]	27623940			C80.1	D009369			Aberrant microRNA expression in tumor mycosis fungoides.
tissue_expression_ns	hsa-mir-638	Neoplasms [unspecific]	23936320			C80.1	D009369			Characterization of microRNA expression profiles and the discovery of novel microRNAs involved in cancer during human embryonic development.
tissue_expression_ns	hsa-mir-7	Neoplasms [unspecific]	26578390			C80.1	D009369			we found hsa-miR-194 and  hsa-miR-7 along with 7 transcription factors (TFs) such as SOX11, SMAD3 and SOX4  etc. could correctly differentiate SPN from PanNET
tissue_expression_ns	hsa-mir-720	Neoplasms [unspecific]	23936320			C80.1	D009369			Characterization of microRNA expression profiles and the discovery of novel microRNAs involved in cancer during human embryonic development.
tissue_expression_ns	hsa-mir-92a	Neoplasms [unspecific]	28222938			C80.1	D009369			The role of miR-17-92 cluster in the expression of tumor suppressor genes in unrestricted somatic stem cells.
tissue_expression_ns	hsa-mir-93	Neoplasms [unspecific]	26299954			C80.1	D009369			Genome-wide analysis of microRNA and mRNA expression signatures in cancer.
tissue_expression_ns	hsa-mir-96	Neoplasms [unspecific]	23791657			C80.1	D009369			Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues.
tissue_expression_ns	hsa-mir-147b	Neuroblastoma	23724168	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. 
tissue_expression_ns	hsa-mir-182	Neuroblastoma	23724168	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. 
tissue_expression_ns	hsa-mir-222	Neuroblastoma	23724168	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. 
tissue_expression_ns	hsa-mir-34a	Neuroblastoma	23724168	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. 
tissue_expression_ns	hsa-mir-34a	Neuroblastoma	25292042	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Hsa-miR-34a, for example, targets gene  MYC, which regulates hsa-miR-34a in turn.
tissue_expression_ns	hsa-mir-496	Neuroblastoma	23724168	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. 
tissue_expression_ns	hsa-mir-690	Neuroblastoma	23724168	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Numerous miRNAs were detected by microarrays to be regulated by the combined lithium and valproic acid treatment, and the following candidates were confirmed using real-time PCR: miR-34a, miR-147b, miR-182,miR-222, miR-495, and miR-690. 
tissue_expression_ns	hsa-mir-133a	Neuroendocrine Tumors	24535468	disease of cellular proliferation	DOID:169	C7A	D018358			Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas.
tissue_expression_ns	hsa-mir-191	Neuroendocrine Tumors	24535468	disease of cellular proliferation	DOID:169	C7A	D018358			Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas.
tissue_expression_ns	hsa-mir-93	Neuroendocrine Tumors	24535468	disease of cellular proliferation	DOID:169	C7A	D018358			Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas.
tissue_expression_ns	hsa-mir-1909	Neuroepithelial Tumors	26698155				D018302			Our findings indicated that miR-3138 might act as a tumor suppressor gene when down-regulated and miR-1909* as a putative oncogenic molecule when up-regulated in pediatric DNETs compared to the control cohort. Subsequently, both miRNA signatures might serve as putative diagnostic biomarkers for pediatric DNETs.
tissue_expression_ns	hsa-mir-3138	Neuroepithelial Tumors	26698155				D018302			Our findings indicated that miR-3138 might act as a tumor suppressor gene when down-regulated and miR-1909* as a putative oncogenic molecule when up-regulated in pediatric DNETs compared to the control cohort. Subsequently, both miRNA signatures might serve as putative diagnostic biomarkers for pediatric DNETs.
tissue_expression_ns	hsa-let-7c	Nevus	21166724			I78.1	D009506	162900	HP:0003764	The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c.
tissue_expression_ns	hsa-mir-125b-1	Nevus	21166724			I78.1	D009506	162900	HP:0003764	The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c.
tissue_expression_ns	hsa-mir-125b-2	Nevus	21166724			I78.1	D009506	162900	HP:0003764	The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c.
tissue_expression_ns	hsa-let-7c	Non-Traumatic Osteonecrosis	25863178			M90.5	D010020			Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH.
tissue_expression_ns	hsa-let-7i	Non-Traumatic Osteonecrosis	25863178			M90.5	D010020			Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH.
tissue_expression_ns	hsa-mir-146b	Non-Traumatic Osteonecrosis	25863178			M90.5	D010020			Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH.
tissue_expression_ns	hsa-mir-320e	Non-Traumatic Osteonecrosis	25863178			M90.5	D010020			Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH.
tissue_expression_ns	hsa-mir-335	Non-Traumatic Osteonecrosis	25863178			M90.5	D010020			Our data also manifests that the signaling pathways regulated by these differentially expressed miRNAs might be important in the pathogenesis of non-traumatic ONFH.
tissue_expression_ns	hsa-let-7f	Obesity	27049726	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our study shows that the first evidence of hsa-let-7 family, hsa-miR-15a-5p, hsa-miR-27a-3p, hsa-miR-106b-5p, hsa-miR-148a-3p and hsa-miR-26b-5p got a great weight in adipogenesis
tissue_expression_ns	hsa-mir-10b	Obesity	27682205	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Impact of endurance exercise training on adipocyte microRNA expression in overweight men.
tissue_expression_ns	hsa-mir-122	Obesity	25769350	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Deregulation of miR-33 and miR-122, as major regulators of lipid metabolism in liver, has been related to obesity and metabolic syndrome.
tissue_expression_ns	hsa-mir-125a	Obesity	24675842	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Adaptive expression of microRNA-125a in adipose tissue in response to obesity in mice and men.
tissue_expression_ns	hsa-mir-200a	Obesity	24758184	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT.
tissue_expression_ns	hsa-mir-200b	Obesity	24758184	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT.
tissue_expression_ns	hsa-mir-204	Obesity	27682205	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Impact of endurance exercise training on adipocyte microRNA expression in overweight men.
tissue_expression_ns	hsa-mir-219	Obesity	23817051	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases.
tissue_expression_ns	hsa-mir-335	Obesity	24758184	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT.
tissue_expression_ns	hsa-mir-342	Obesity	24758184	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT.
tissue_expression_ns	hsa-mir-3613	Obesity	27682205	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Impact of endurance exercise training on adipocyte microRNA expression in overweight men.
tissue_expression_ns	hsa-mir-370	Obesity	28386478	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Changes in the MicroRNA Profile Observed in the Subcutaneous Adipose Tissue of Obese Patients after Laparoscopic Adjustable Gastric Banding.
tissue_expression_ns	hsa-mir-422b	Obesity	23817051	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases.
tissue_expression_ns	hsa-mir-4532	Obesity	27682205	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Impact of endurance exercise training on adipocyte microRNA expression in overweight men.
tissue_expression_ns	hsa-mir-523	Obesity	23817051	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases.
tissue_expression_ns	hsa-mir-575	Obesity	23817051	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases.
tissue_expression_ns	hsa-mir-579	Obesity	23817051	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases.
tissue_expression_ns	hsa-mir-618	Obesity	23817051	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases.
tissue_expression_ns	hsa-mir-659	Obesity	23817051	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	the miRNA profile is altered in amnion during obesity and hypothesize that this could affect pathways important for placental growth and function, thereby contributing to an increase in the newborn's risk of future metabolic diseases.
tissue_expression_ns	hsa-mir-181b	Oral Leukoplakia	24020903	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	some cytological and histopathological parameters used to grade dysplasia are associated with altered  miRNA expression.
tissue_expression_ns	hsa-mir-21	Oral Leukoplakia	24020903	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	some cytological and histopathological parameters used to grade dysplasia are associated with altered  miRNA expression.
tissue_expression_ns	hsa-mir-345	Oral Leukoplakia	24020903	gastrointestinal system disease	DOID:9655	K13.21	D007972		HP:0002745	some cytological and histopathological parameters used to grade dysplasia are associated with altered  miRNA expression.
tissue_expression_ns	hsa-mir-125b	Oral Neoplasms	27208839			C06.9	D009062		HP:0100649	Differential expression of miR-21, miR-100, miR-125b and miR-375 was validated in oral cytology training sample set.
tissue_expression_ns	hsa-mir-140	Osteoarthritis	25785087	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	We verified that miR-140 and miR-455 were associated with cartilage development
tissue_expression_ns	hsa-mir-140	Osteoarthritis	28065216	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Expression of miRNA-140 in Chondrocytes and Synovial Fluid of Knee Joints in Patients with Osteoarthritis.
tissue_expression_ns	hsa-mir-140	Osteoarthritis	28085114	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway.
tissue_expression_ns	hsa-mir-146a	Osteoarthritis	28085114	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway.
tissue_expression_ns	hsa-mir-146b	Osteoarthritis	28085114	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway.
tissue_expression_ns	hsa-mir-27a	Osteoarthritis	28085114	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway.
tissue_expression_ns	hsa-mir-27b	Osteoarthritis	28085114	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway.
tissue_expression_ns	hsa-mir-365	Osteoarthritis	28085114	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway.
tissue_expression_ns	hsa-mir-9	Osteoarthritis	25785087	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-9 and miR-98 were involved in the endochondral ossification, suggesting they may be also the key regulators in the process of endochondral ossification.
tissue_expression_ns	hsa-mir-98	Osteoarthritis	25785087	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-9 and miR-98 were involved in the endochondral ossification, suggesting they may be also the key regulators in the process of endochondral ossification.
tissue_expression_ns	hsa-mir-106b	Osteosarcoma	28272712	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The expression and function of miRNA-106 in pediatric osteosarcoma.
tissue_expression_ns	hsa-mir-126	Osteosarcoma	25510179	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	expression of miR-126 increased the sensitivity of osteosarcoma cells to EGCG through induction of apoptosis.
tissue_expression_ns	hsa-mir-126	Osteosarcoma	26194657	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Tissue microRNA-126 expression level predicts outcome in human osteosarcoma.
tissue_expression_ns	hsa-mir-135b	Osteosarcoma	21789031	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	deregulated
tissue_expression_ns	hsa-mir-148a	Osteosarcoma	27041566	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS
tissue_expression_ns	hsa-mir-150	Osteosarcoma	21789031	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	deregulated
tissue_expression_ns	hsa-mir-155	Osteosarcoma	27041566	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS
tissue_expression_ns	hsa-mir-19a	Osteosarcoma	28214202	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Elevated expression of microRNA-19a predicts a poor prognosis in patients with osteosarcoma.
tissue_expression_ns	hsa-mir-23a	Osteosarcoma	25322765	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	We identified miR-23a as a tumor suppressor in osteosarcoma. Our data clarify the mechanism of osteosarcoma progression and demonstrated the potential  for exploiting miR-23a as a diagnostic marker for osteosarcoma.
tissue_expression_ns	hsa-mir-542	Osteosarcoma	21789031	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-542-5p: deregulated
tissue_expression_ns	hsa-mir-652	Osteosarcoma	21789031	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	deregulated
tissue_expression_ns	hsa-let-7i	Ovarian Disease	25451316	endocrine system disease	DOID:1100	E28.9	D010049			let-7i-5p, miR-122,miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.
tissue_expression_ns	hsa-mir-122	Ovarian Disease	25451316	endocrine system disease	DOID:1100	E28.9	D010049			let-7i-5p, miR-122,miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.
tissue_expression_ns	hsa-mir-152	Ovarian Disease	25451316	endocrine system disease	DOID:1100	E28.9	D010049			let-7i-5p, miR-122,miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.
tissue_expression_ns	hsa-mir-15b	Ovarian Disease	29377183	endocrine system disease	DOID:1100	E28.9	D010049			miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction
tissue_expression_ns	hsa-mir-1897	Ovarian Disease	29377183	endocrine system disease	DOID:1100	E28.9	D010049			miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction
tissue_expression_ns	hsa-mir-25	Ovarian Disease	25451316	endocrine system disease	DOID:1100	E28.9	D010049			let-7i-5p, miR-122,miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.
tissue_expression_ns	hsa-mir-379	Ovarian Disease	29377183	endocrine system disease	DOID:1100	E28.9	D010049			miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction
tissue_expression_ns	hsa-mir-691	Ovarian Disease	29377183	endocrine system disease	DOID:1100	E28.9	D010049			miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction
tissue_expression_ns	hsa-mir-872	Ovarian Disease	29377183	endocrine system disease	DOID:1100	E28.9	D010049			miR-379, miR-15b, miR-691, miR-872 and miR-1897-5p are potentially useful markers of ovarian toxicity and dysfunction
tissue_expression_ns	hsa-let-7	Ovarian Neoplasms	18199536	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster.
tissue_expression_ns	hsa-let-7a	Ovarian Neoplasms	28423547	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression.
tissue_expression_ns	hsa-let-7b	Ovarian Neoplasms	29385306	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	RT-PCR revealed a significantly increased expression of ovarian miRNAs (let-7b, miR-17-5p miR-181a, and miR-151), which inhibit follicular granulosa cell proliferation
tissue_expression_ns	hsa-mir-100	Ovarian Neoplasms	18199536	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster.
tissue_expression_ns	hsa-mir-106a	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-106b	Ovarian Neoplasms	24805828	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The results obtained by miRNA microarrays of differential expression with hsa-miR-106b-3p, hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 were confirmed by real-time PCR.
tissue_expression_ns	hsa-mir-107	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-125b	Ovarian Neoplasms	18199536	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster.
tissue_expression_ns	hsa-mir-125b	Ovarian Neoplasms	20658525	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our results suggest that aberrantly expressed miR-125b may contribute to OC development.
tissue_expression_ns	hsa-mir-141	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-142	Ovarian Neoplasms	18182067	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05).
tissue_expression_ns	hsa-mir-151	Ovarian Neoplasms	29385306	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	RT-PCR revealed a significantly increased expression of ovarian miRNAs (let-7b, miR-17-5p miR-181a, and miR-151), which inhibit follicular granulosa cell proliferation
tissue_expression_ns	hsa-mir-153	Ovarian Neoplasms	21083603	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours.
tissue_expression_ns	hsa-mir-17	Ovarian Neoplasms	29385306	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	RT-PCR revealed a significantly increased expression of ovarian miRNAs (let-7b, miR-17-5p miR-181a, and miR-151), which inhibit follicular granulosa cell proliferation
tissue_expression_ns	hsa-mir-181a	Ovarian Neoplasms	29385306	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	RT-PCR revealed a significantly increased expression of ovarian miRNAs (let-7b, miR-17-5p miR-181a, and miR-151), which inhibit follicular granulosa cell proliferation
tissue_expression_ns	hsa-mir-181a	Ovarian Neoplasms	18182067	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05).
tissue_expression_ns	hsa-mir-181d	Ovarian Neoplasms	22925189	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
tissue_expression_ns	hsa-mir-187	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-18a	Ovarian Neoplasms	18182067	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05).
tissue_expression_ns	hsa-mir-195	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-199a	Ovarian Neoplasms	18199536	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster.
tissue_expression_ns	hsa-mir-199a	Ovarian Neoplasms	21882851	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer).
tissue_expression_ns	hsa-mir-200a	Ovarian Neoplasms	18199536	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Here, we show that several miRNAs are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, miR-199a*, miR-200a, miR-100, miR-125b, and let-7 cluster.
tissue_expression_ns	hsa-mir-200c	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-206	Ovarian Neoplasms	18182067	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05).
tissue_expression_ns	hsa-mir-20a	Ovarian Neoplasms	18182067	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05).
tissue_expression_ns	hsa-mir-21	Ovarian Neoplasms	18182067	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05).
tissue_expression_ns	hsa-mir-221	Ovarian Neoplasms	23569131	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer
tissue_expression_ns	hsa-mir-26a	Ovarian Neoplasms	18182067	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We selected and validated the expression of miR-20a, miR-21, miR-26a, miR-18a, miR-206, miR-181a and miR-142-5p and found their differential expression in tissue and cell-specific manners (P<0.05).
tissue_expression_ns	hsa-mir-302b	Ovarian Neoplasms	23484053	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	hsa-miR-302b expression was significantly associated with time to relapse or overall survival in two data sets of platinum-treated ovarian cancer patients.
tissue_expression_ns	hsa-mir-30a	Ovarian Neoplasms	22925189	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
tissue_expression_ns	hsa-mir-30c	Ovarian Neoplasms	28423547	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression.
tissue_expression_ns	hsa-mir-30c-1	Ovarian Neoplasms	22925189	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
tissue_expression_ns	hsa-mir-30c-2	Ovarian Neoplasms	22925189	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
tissue_expression_ns	hsa-mir-30d	Ovarian Neoplasms	22925189	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
tissue_expression_ns	hsa-mir-30e	Ovarian Neoplasms	22925189	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
tissue_expression_ns	hsa-mir-34c	Ovarian Neoplasms	19798417	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	High grade serous carcinomas as a group exhibit significant miRNA dysregulation in comparison to tubal epithelium and the levels of miR-34c and miR-422b appear to be prognostically important.
tissue_expression_ns	hsa-mir-370	Ovarian Neoplasms	22925189	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
tissue_expression_ns	hsa-mir-378	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-409	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-411	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-422b	Ovarian Neoplasms	19798417	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	High grade serous carcinomas as a group exhibit significant miRNA dysregulation in comparison to tubal epithelium and the levels of miR-34c and miR-422b appear to be prognostically important.
tissue_expression_ns	hsa-mir-432	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-485	Ovarian Neoplasms	21083603	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours.
tissue_expression_ns	hsa-mir-494	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-497	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-519a	Ovarian Neoplasms	21083603	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours.
tissue_expression_ns	hsa-mir-532	Ovarian Neoplasms	22925189	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues.
tissue_expression_ns	hsa-mir-622	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-647	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-663	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-96	Ovarian Neoplasms	24591819	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
tissue_expression_ns	hsa-mir-1244	Pallister-Killian Syndrome	24981202				C538105	601803		12p microRNA expression in fibroblast cell lines from probands with Pallister-Killian syndrome.
tissue_expression_ns	hsa-mir-145	Pancreatic Adenocarcinoma	28903323	disease of cellular proliferation	DOID:4074	C25.3				The pancreatic tumor microenvironment drives changes in miRNA expression that promote cytokine production and inhibit migration by the tumor associated stroma.
tissue_expression_ns	hsa-mir-205	Pancreatic Adenocarcinoma	28903323	disease of cellular proliferation	DOID:4074	C25.3				The pancreatic tumor microenvironment drives changes in miRNA expression that promote cytokine production and inhibit migration by the tumor associated stroma.
tissue_expression_ns	hsa-mir-21	Pancreatic Adenocarcinoma	29069873	disease of cellular proliferation	DOID:4074	C25.3				These molecules are often aberrantly expressed and exhibit oncogenic and/or tumor suppressor functions in PDAC
tissue_expression_ns	hsa-mir-100	Pancreatic Neoplasms	21785383	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells.
tissue_expression_ns	hsa-mir-103	Pancreatic Neoplasms	16966691	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal
tissue_expression_ns	hsa-mir-107	Pancreatic Neoplasms	16966691	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal
tissue_expression_ns	hsa-mir-1246	Pancreatic Neoplasms	25117811	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-1246 expression was associated with chemoresistance and CSC-like properties via CCNG2, and could predict worse prognosis in pancreatic cancer patients.
tissue_expression_ns	hsa-mir-1246	Pancreatic Neoplasms	25388097	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the concomitant evaluation of PaCIC and PaCa-related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally-invasive PaCa diagnostics.
tissue_expression_ns	hsa-mir-125b-1	Pancreatic Neoplasms	21785383	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells.
tissue_expression_ns	hsa-mir-125b-1	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-125b-2	Pancreatic Neoplasms	21785383	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells.
tissue_expression_ns	hsa-mir-125b-2	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-130b	Pancreatic Neoplasms	24662333	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures.
tissue_expression_ns	hsa-mir-135b	Pancreatic Neoplasms	24662333	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures.
tissue_expression_ns	hsa-mir-143	Pancreatic Neoplasms	22836856	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Changes in miR-143 and miR-21 Expression are correlated with Clinicopathology in Pancreatic Cancers.
tissue_expression_ns	hsa-mir-146a	Pancreatic Neoplasms	24839931	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling.
tissue_expression_ns	hsa-mir-146a	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-148a	Pancreatic Neoplasms	24662333	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures.
tissue_expression_ns	hsa-mir-155	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-155	Pancreatic Neoplasms	26499892	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found miR-21, miR-155 or miR-217 expression values in tumors may differ up to several times
tissue_expression_ns	hsa-mir-155	Pancreatic Neoplasms	16966691	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal
tissue_expression_ns	hsa-mir-155	Pancreatic Neoplasms	17149698	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
tissue_expression_ns	hsa-mir-15a	Pancreatic Neoplasms	21106054	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Dysregulation of miR-15a and miR-214 in human pancreatic cancer.
tissue_expression_ns	hsa-mir-182	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-183	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-183*:altered expression
tissue_expression_ns	hsa-mir-192	Pancreatic Neoplasms	21785383	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells.
tissue_expression_ns	hsa-mir-196	Pancreatic Neoplasms	24662333	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures.
tissue_expression_ns	hsa-mir-196a	Pancreatic Neoplasms	24048456	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our results provide experimental evidence to support aberrant expression of miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells.
tissue_expression_ns	hsa-mir-196a	Pancreatic Neoplasms	26499892	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Moreover, different internal controls can produce controversial results for miR-96, miR-148a or miR-196a quantification.
tissue_expression_ns	hsa-mir-196a-1	Pancreatic Neoplasms	18719196	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-196a: biomarkers improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis
tissue_expression_ns	hsa-mir-196a-1	Pancreatic Neoplasms	21463235	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-196a-2	Pancreatic Neoplasms	18719196	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-196a: biomarkers improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis
tissue_expression_ns	hsa-mir-196a-2	Pancreatic Neoplasms	21463235	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-196b	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-200a	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-200b	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-200b	Pancreatic Neoplasms	28548126	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer.
tissue_expression_ns	hsa-mir-200c	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-200c	Pancreatic Neoplasms	28548126	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer.
tissue_expression_ns	hsa-mir-203	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-21	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-21	Pancreatic Neoplasms	22836856	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Changes in miR-143 and miR-21 Expression are correlated with Clinicopathology in Pancreatic Cancers.
tissue_expression_ns	hsa-mir-21	Pancreatic Neoplasms	28186267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We also examined miRNA expression [microRNA-21 (miR-21) and microRNA-31 (miR-31)] and epigenetic alterations, including CpG island methylator phenotype (CIMP), potentially associated with the identified miRNAs
tissue_expression_ns	hsa-mir-21	Pancreatic Neoplasms	28548126	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer.
tissue_expression_ns	hsa-mir-21	Pancreatic Neoplasms	17149698	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
tissue_expression_ns	hsa-mir-210	Pancreatic Neoplasms	28548126	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer.
tissue_expression_ns	hsa-mir-214	Pancreatic Neoplasms	21106054	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Dysregulation of miR-15a and miR-214 in human pancreatic cancer.
tissue_expression_ns	hsa-mir-216a	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-216b	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-217	Pancreatic Neoplasms	18719196	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-217: biomarkers improved the ability to distinguish between healthy tissue, PDAC, and chronic pancreatitis
tissue_expression_ns	hsa-mir-217	Pancreatic Neoplasms	21463235	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-217	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-221	Pancreatic Neoplasms	17149698	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
tissue_expression_ns	hsa-mir-222	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-222	Pancreatic Neoplasms	17149698	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
tissue_expression_ns	hsa-mir-24	Pancreatic Neoplasms	24662333	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We developed and validated a 5-miRNA classifier that can accurately predict which preoperative pancreatic EUS-FNA specimens contain PDAC. This test might aid in the diagnosis of pancreatic cancer by reducing the number of FNAs without a definitive adenocarcinoma diagnosis, thereby reducing the number of repeat EUS-FNA procedures.
tissue_expression_ns	hsa-mir-296	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-296-5p:altered expression
tissue_expression_ns	hsa-mir-301	Pancreatic Neoplasms	17149698	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
tissue_expression_ns	hsa-mir-31	Pancreatic Neoplasms	28186267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We also examined miRNA expression [microRNA-21 (miR-21) and microRNA-31 (miR-31)] and epigenetic alterations, including CpG island methylator phenotype (CIMP), potentially associated with the identified miRNAs
tissue_expression_ns	hsa-mir-338	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-338-3p;altered expression
tissue_expression_ns	hsa-mir-34a	Pancreatic Neoplasms	21882851	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer).
tissue_expression_ns	hsa-mir-376a	Pancreatic Neoplasms	17149698	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		One hundred microRNA precursors were aberrantly expressed in pancreatic cancer or desmoplasia (p < 0.01), including microRNAs previously reported as differentially expressed in other human cancers (miR-155, miR-21, miR-221 and miR-222) as well as those not previously reported in cancer (miR-376a and miR-301).
tissue_expression_ns	hsa-mir-3976	Pancreatic Neoplasms	25388097	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the concomitant evaluation of PaCIC and PaCa-related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally-invasive PaCa diagnostics.
tissue_expression_ns	hsa-mir-429	Pancreatic Neoplasms	21785383	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells.
tissue_expression_ns	hsa-mir-4306	Pancreatic Neoplasms	25388097	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the concomitant evaluation of PaCIC and PaCa-related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally-invasive PaCa diagnostics.
tissue_expression_ns	hsa-mir-4644	Pancreatic Neoplasms	25388097	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		the concomitant evaluation of PaCIC and PaCa-related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally-invasive PaCa diagnostics.
tissue_expression_ns	hsa-mir-486	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-486-3p:altered expression
tissue_expression_ns	hsa-mir-494	Pancreatic Neoplasms	26782462	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Correlation of miR-494 expression with tumor progression and patient survival in pancreatic cancer.
tissue_expression_ns	hsa-mir-603	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-625	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-625*:altered expression
tissue_expression_ns	hsa-mir-708	Pancreatic Neoplasms	22114139	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		altered expression
tissue_expression_ns	hsa-mir-99a	Pancreatic Neoplasms	21785383	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells.
tissue_expression_ns	hsa-mir-126	Parathyroid Carcinoma	29453660	endocrine system disease	DOID:1540	C75.0	D010282	608266	HP:0006780	miR-139, miR-222, miR-30b, miR-517c, and miR-126* were differentially expressed between PCa and PAd.
tissue_expression_ns	hsa-mir-139	Parathyroid Carcinoma	29453660	endocrine system disease	DOID:1540	C75.0	D010282	608266	HP:0006780	The combined analysis of miR-139 and miR-30b may be used as a potential diagnostic strategy for distinguishing Pca from PAd
tissue_expression_ns	hsa-mir-222	Parathyroid Carcinoma	29453660	endocrine system disease	DOID:1540	C75.0	D010282	608266	HP:0006780	miR-139, miR-222, miR-30b, miR-517c, and miR-126* were differentially expressed between PCa and PAd.
tissue_expression_ns	hsa-mir-30b	Parathyroid Carcinoma	29453660	endocrine system disease	DOID:1540	C75.0	D010282	608266	HP:0006780	The combined analysis of miR-139 and miR-31b may be used as a potential diagnostic strategy for distinguishing Pca from PAd
tissue_expression_ns	hsa-mir-517c	Parathyroid Carcinoma	29453660	endocrine system disease	DOID:1540	C75.0	D010282	608266	HP:0006780	miR-139, miR-222, miR-30b, miR-517c, and miR-126* were differentially expressed between PCa and PAd.
tissue_expression_ns	hsa-let-7g	Parkinson Disease	26497684	nervous system disease	DOID:14330	G20	D010300	PS168600		Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
tissue_expression_ns	hsa-mir-10a	Parkinson Disease	26497684	nervous system disease	DOID:14330	G20	D010300	PS168600		Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
tissue_expression_ns	hsa-mir-153	Parkinson Disease	26497684	nervous system disease	DOID:14330	G20	D010300	PS168600		Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
tissue_expression_ns	hsa-mir-16	Parkinson Disease	24427314	nervous system disease	DOID:14330	G20	D010300	PS168600		We identified a total of 761 genes and 24 miRNAs that were misregulated in the absence of LRRK2 when a false discovery rate of 0.2 was applied. Notably, most changes in gene expression were modest (i.e., <2 fold). By real-time quantitative RT-PCR, we confirmed the variations of selected genes (e.g., adra2, syt2, opalin) and miRNAs (e.g., miR-16, miR-25).
tissue_expression_ns	hsa-mir-19b	Parkinson Disease	25675938	nervous system disease	DOID:14330	G20	D010300	PS168600		Our findings indicate that dysregulation of the microRNA miR-19b occurs in the prodromal stage of synucleinopathies.
tissue_expression_ns	hsa-mir-29a	Parkinson Disease	25675938	nervous system disease	DOID:14330	G20	D010300	PS168600		Our findings indicate that dysregulation of the microRNA miR-19b occurs in the prodromal stage of synucleinopathies.
tissue_expression_ns	hsa-mir-29b	Parkinson Disease	28540642	nervous system disease	DOID:14330	G20	D010300	PS168600		Plasma and White Blood Cells Show Different miRNA Expression Profiles in Parkinson's Disease.
tissue_expression_ns	hsa-mir-29c	Parkinson Disease	25675938	nervous system disease	DOID:14330	G20	D010300	PS168600		Our findings indicate that dysregulation of the microRNA miR-19b occurs in the prodromal stage of synucleinopathies.
tissue_expression_ns	hsa-mir-30a	Parkinson Disease	28540642	nervous system disease	DOID:14330	G20	D010300	PS168600		Plasma and White Blood Cells Show Different miRNA Expression Profiles in Parkinson's Disease.
tissue_expression_ns	hsa-mir-409	Parkinson Disease	26497684	nervous system disease	DOID:14330	G20	D010300	PS168600		Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
tissue_expression_ns	hsa-mir-128	Pediatric Ependymoma	29704232	disease of cellular proliferation	DOID:5509					miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes
tissue_expression_ns	hsa-mir-139	Pediatric Ependymoma	29704232	disease of cellular proliferation	DOID:5509					miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes
tissue_expression_ns	hsa-mir-299	Pediatric Ependymoma	29704232	disease of cellular proliferation	DOID:5509					miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes
tissue_expression_ns	hsa-mir-495	Pediatric Ependymoma	29704232	disease of cellular proliferation	DOID:5509					miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes
tissue_expression_ns	hsa-mir-543	Pediatric Ependymoma	29704232	disease of cellular proliferation	DOID:5509					miR-543, miR-495-3p, miR-299-3p, miR-139-5p and miR-128-3p were identified to have CD44 positively co-regulated potential target oncogenes
tissue_expression_ns	hsa-mir-130b	Penis Carcinoma	28751665	reproductive system disease	DOID:3449	C60.9				hsa-miR-31, hsa-miR-34a and hsa-miR-130b, were significantly associated with over-represented pathways in cancer
tissue_expression_ns	hsa-mir-223	Penis Carcinoma	28122331	reproductive system disease	DOID:3449	C60.9				Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact.
tissue_expression_ns	hsa-mir-224	Penis Carcinoma	28122331	reproductive system disease	DOID:3449	C60.9				Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact.
tissue_expression_ns	hsa-mir-31	Penis Carcinoma	28122331	reproductive system disease	DOID:3449	C60.9				Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact.
tissue_expression_ns	hsa-mir-31	Penis Carcinoma	28751665	reproductive system disease	DOID:3449	C60.9				hsa-miR-31, hsa-miR-34a and hsa-miR-130b, were significantly associated with over-represented pathways in cancer
tissue_expression_ns	hsa-mir-34a	Penis Carcinoma	28751665	reproductive system disease	DOID:3449	C60.9				hsa-miR-31, hsa-miR-34a and hsa-miR-130b, were significantly associated with over-represented pathways in cancer
tissue_expression_ns	hsa-mir-146a	Periodontal Diseases	21789961	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	hsa-mirNA-146a, hsa-miRNA-146b, and hsa-miRNA-155, showed significant differences between inflamed and healthy gingiva.
tissue_expression_ns	hsa-mir-146b	Periodontal Diseases	21789961	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	hsa-mirNA-146a, hsa-miRNA-146b, and hsa-miRNA-155, showed significant differences between inflamed and healthy gingiva.
tissue_expression_ns	hsa-mir-155	Periodontal Diseases	21789961	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	hsa-mirNA-146a, hsa-miRNA-146b, and hsa-miRNA-155, showed significant differences between inflamed and healthy gingiva.
tissue_expression_ns	hsa-let-7a	Periodontitis	29226952	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Differential expression of microRNAs let-7a, miR-125b, miR-100, and miR-21 and interaction with NF-kB pathway genes in periodontitis pathogenesis
tissue_expression_ns	hsa-mir-100	Periodontitis	29226952	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Differential expression of microRNAs let-7a, miR-125b, miR-100, and miR-21 and interaction with NF-kB pathway genes in periodontitis pathogenesis
tissue_expression_ns	hsa-mir-125b	Periodontitis	29226952	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Differential expression of microRNAs let-7a, miR-125b, miR-100, and miR-21 and interaction with NF-kB pathway genes in periodontitis pathogenesis
tissue_expression_ns	hsa-mir-21	Periodontitis	29226952	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Differential expression of microRNAs let-7a, miR-125b, miR-100, and miR-21 and interaction with NF-kB pathway genes in periodontitis pathogenesis
tissue_expression_ns	hsa-mir-21	Peritoneal Dialysis Failure	27867039			T85.71				Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics.
tissue_expression_ns	hsa-mir-589	Peritoneal Dialysis Failure	27867039			T85.71				Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics.
tissue_expression_ns	hsa-mir-186	Peritoneal Neoplasms	29360196			C48.2	D010534			The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-21	Peritoneal Neoplasms	29360196			C48.2	D010534			The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-222	Peritoneal Neoplasms	29360196			C48.2	D010534			The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-223	Peritoneal Neoplasms	29360196			C48.2	D010534			The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-483	Peritoneal Neoplasms	29360196			C48.2	D010534			The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA
tissue_expression_ns	hsa-mir-21	Perlman Syndrome	24786382	syndrome	DOID:0060476		C536399	267000		Our study is the first to investigate the association between placental miRNA expression and macrosomia. Our results indicate that the expression level of miR-21 in placental tissue may be involved in the development of macrosomia.
tissue_expression_ns	hsa-let-7a-1	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	let-7a: deregulation
tissue_expression_ns	hsa-let-7a-2	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	let-7a: deregulation
tissue_expression_ns	hsa-let-7a-3	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	let-7a: deregulation
tissue_expression_ns	hsa-mir-10b	Pituitary Adenoma	24310454	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas.
tissue_expression_ns	hsa-mir-135a	Pituitary Adenoma	29374071	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)
tissue_expression_ns	hsa-mir-141	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-141: deregulation
tissue_expression_ns	hsa-mir-143	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-143: deregulation
tissue_expression_ns	hsa-mir-145	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-145: deregulation
tissue_expression_ns	hsa-mir-150	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-150: deregulation
tissue_expression_ns	hsa-mir-15a	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-15a: deregulation
tissue_expression_ns	hsa-mir-16-1	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-16: deregulation
tissue_expression_ns	hsa-mir-16-2	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-16: deregulation
tissue_expression_ns	hsa-mir-181a	Pituitary Adenoma	28315020	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
tissue_expression_ns	hsa-mir-181b	Pituitary Adenoma	28315020	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
tissue_expression_ns	hsa-mir-181d	Pituitary Adenoma	28315020	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
tissue_expression_ns	hsa-mir-191	Pituitary Adenoma	28315020	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
tissue_expression_ns	hsa-mir-192	Pituitary Adenoma	21882851	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Many aberrantly expressed miRNAs were related to various cancers (e.g., miR-125b, hepatocellular carcinoma; miR-21, leukemia; miR-16, chronic lymphocytic leukemia;miR-192, pituitary adenomas; miR-199a-3p, ovarian cancer; miR-34a, pancreatic cancer).
tissue_expression_ns	hsa-mir-204	Pituitary Adenoma	29374071	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)
tissue_expression_ns	hsa-mir-21	Pituitary Adenoma	18840638	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	miR-21: deregulation
tissue_expression_ns	hsa-mir-210	Pituitary Adenoma	29374071	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)
tissue_expression_ns	hsa-mir-2110	Pituitary Adenoma	29374071	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)
tissue_expression_ns	hsa-mir-23a	Pituitary Adenoma	29374071	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	elevant compensatory mechanisms were found through the changes in miR involved in osteoblastogenesis (miR-210-5p, miR-135a-5p, miR-211, miR-23a-3p, miR-204-5p)
tissue_expression_ns	hsa-mir-26a	Pituitary Adenoma	28012286	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma.
tissue_expression_ns	hsa-mir-3676	Pituitary Adenoma	28315020	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
tissue_expression_ns	hsa-mir-383	Pituitary Adenoma	28315020	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
tissue_expression_ns	hsa-mir-422a	Pituitary Adenoma	24310454	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas.
tissue_expression_ns	hsa-mir-422b	Pituitary Adenoma	24310454	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas.
tissue_expression_ns	hsa-mir-520b	Pituitary Adenoma	24310454	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas.
tissue_expression_ns	hsa-mir-523	Pituitary Adenoma	24310454	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	We established miRNA expression maps of non-functioning and gonadotropin-secreting pituitary adenomas. The most strongly differentially expressed genes were miR-124a and miR-31 in non-functioning pituitary adenomas, and miR-10b and miR-503 in gonadotropin-secreting pituitary adenomas.
tissue_expression_ns	hsa-mir-598	Pituitary Adenoma	28315020	disease of cellular proliferation	DOID:3829	D35.2	D010911	102200	HP:0002893	Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
tissue_expression_ns	hsa-let-7a	Pituitary Neoplasms	28300776	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream.
tissue_expression_ns	hsa-let-7b	Pituitary Neoplasms	28300776	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream.
tissue_expression_ns	hsa-let-7c	Pituitary Neoplasms	28300776	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream.
tissue_expression_ns	hsa-let-7d	Pituitary Neoplasms	28300776	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream.
tissue_expression_ns	hsa-let-7e	Pituitary Neoplasms	28300776	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream.
tissue_expression_ns	hsa-let-7f	Pituitary Neoplasms	28300776	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream.
tissue_expression_ns	hsa-let-7g	Pituitary Neoplasms	28300776	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream.
tissue_expression_ns	hsa-let-7i	Pituitary Neoplasms	28300776	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Evolution of Fish Let-7 MicroRNAs and Their Expression Correlated to Growth Development in Blunt Snout Bream.
tissue_expression_ns	hsa-mir-126	Pleural Mesothelioma	24912849	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
tissue_expression_ns	hsa-mir-941	Polyangiitis	27755585							MicroRNA-941 Expression in Polymorphonuclear Granulocytes Is Not Related to Granulomatosis with Polyangiitis.
tissue_expression_ns	hsa-mir-133	Polycystic Kidney Disease	24489795			Q61.19	D007690	PS173900	HP:0000113	We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis.
tissue_expression_ns	hsa-mir-143	Polycystic Kidney Disease	24489795			Q61.19	D007690	PS173900	HP:0000113	We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis.
tissue_expression_ns	hsa-mir-199	Polycystic Kidney Disease	24489795			Q61.19	D007690	PS173900	HP:0000113	We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis.
tissue_expression_ns	hsa-mir-205	Polycystic Kidney Disease	24489795			Q61.19	D007690	PS173900	HP:0000113	We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis.
tissue_expression_ns	hsa-mir-223	Polycystic Kidney Disease	24489795			Q61.19	D007690	PS173900	HP:0000113	We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis.
tissue_expression_ns	hsa-mir-135a	Polycystic Ovarian Syndrome	24390626	syndrome	DOID:11612	E28.2	D011085	184700		Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome.
tissue_expression_ns	hsa-mir-18b	Polycystic Ovarian Syndrome	24390626	syndrome	DOID:11612	E28.2	D011085	184700		Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome.
tissue_expression_ns	hsa-mir-223	Polycystic Ovarian Syndrome	27777110	syndrome	DOID:11612	E28.2	D011085	184700		Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model.
tissue_expression_ns	hsa-mir-32	Polycystic Ovarian Syndrome	24390626	syndrome	DOID:11612	E28.2	D011085	184700		Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome.
tissue_expression_ns	hsa-mir-324	Polycystic Ovarian Syndrome	27777110	syndrome	DOID:11612	E28.2	D011085	184700		Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model.
tissue_expression_ns	hsa-mir-34c	Polycystic Ovarian Syndrome	24390626	syndrome	DOID:11612	E28.2	D011085	184700		Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome.
tissue_expression_ns	hsa-mir-375	Polycystic Ovarian Syndrome	27777110	syndrome	DOID:11612	E28.2	D011085	184700		Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model.
tissue_expression_ns	hsa-mir-484	Polycystic Ovarian Syndrome	27777110	syndrome	DOID:11612	E28.2	D011085	184700		Altered expression of miRNAs in the uterus from a letrozole-induced rat PCOS model.
tissue_expression_ns	hsa-mir-9	Polycystic Ovarian Syndrome	24390626	syndrome	DOID:11612	E28.2	D011085	184700		Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome.
tissue_expression_ns	hsa-mir-155	Porphyromonas Gingivalis	28069815				D016966			Identification and Characterization of MicroRNA Differentially Expressed in Macrophages Exposed to Porphyromonas gingivalis Infection.
tissue_expression_ns	hsa-mir-125a	Post-Traumatic Stress Disorder	24759737	disease of mental health	DOID:2055	F43.1	D013313			Dysregulation in microRNA expression is associated with alterations in immune functions in combat veterans with post-traumatic stress disorder.
tissue_expression_ns	hsa-mir-106a	Preeclampsia	25499681	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	facilitate further investigation of aberrant expression of miRNAs in the pathology of preeclampsia.
tissue_expression_ns	hsa-mir-152	Preeclampsia	19285651	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-152: expressed differentially in preeclamptic placentas vs normal controls
tissue_expression_ns	hsa-mir-16	Preeclampsia	23083510	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Together, these data suggest that the alteration of miR-16 expression in decidua-derived mesenchymal stem cells may be involved in the development of pre-eclampsia.
tissue_expression_ns	hsa-mir-182	Preeclampsia	17346547	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Differential expression between preeclampsia and the control group (miR-210, miR-182) and between preeclampsia + SGA and the control group (miR-210, miR-182*, and others) was found.
tissue_expression_ns	hsa-mir-191	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-197	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-198	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-202	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-204	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-210	Preeclampsia	19285651	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-210: expressed differentially in preeclamptic placentas vs normal controls
tissue_expression_ns	hsa-mir-210	Preeclampsia	17346547	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Differential expression between preeclampsia and the control group (miR-210, miR-182) and between preeclampsia + SGA and the control group (miR-210, miR-182*, and others) was found.
tissue_expression_ns	hsa-mir-25	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-26a	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-26b	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-296	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-342	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-363	Preeclampsia	25499681	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	facilitate further investigation of aberrant expression of miRNAs in the pathology of preeclampsia.
tissue_expression_ns	hsa-mir-411	Preeclampsia	19285651	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-411: expressed differentially in preeclamptic placentas vs normal controls
tissue_expression_ns	hsa-mir-517a	Preeclampsia	25799546	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia.
tissue_expression_ns	hsa-mir-517b	Preeclampsia	25799546	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia.
tissue_expression_ns	hsa-mir-517c	Preeclampsia	25799546	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia.
tissue_expression_ns	hsa-mir-92b	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-95	Preeclampsia	23830491	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Several miRNAs are found to be dysregulated in placentas of PE patients and they seem to be closely associated with the early pathogenesis of PE. Further study is necessary to develop tools for early detection and management.
tissue_expression_ns	hsa-mir-126	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-136	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-142	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-144	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-17	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-22	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-30a	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-382	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-451	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-486	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-mir-92a	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	Hsa-mir-93	Prolactinoma	25064468	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma.
tissue_expression_ns	hsa-let-7	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-let-7	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-let-7a	Prostate Neoplasms	20944140	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa.
tissue_expression_ns	hsa-let-7c	Prostate Neoplasms	17891175	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We have analysed expression of 328 known and 152 novel human miRNAs in 10 benign peripheral zone tissues and 16 prostate cancer tissues using microarrays and found widespread, but not universal, downregulation of miRNAs in clinically localized prostate cancer relative to benign peripheral zone tissue.These findings have been verified by real-time RT-PCR assays on select miRNAs, including miR-125b, miR-145 and let-7c.
tissue_expression_ns	hsa-let-7d	Prostate Neoplasms	20873592	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer.
tissue_expression_ns	hsa-let-7g	Prostate Neoplasms	20873592	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer.
tissue_expression_ns	hsa-mir-1	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-mir-1	Prostate Neoplasms	24967583	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer.
tissue_expression_ns	hsa-mir-100	Prostate Neoplasms	23621234	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important.
tissue_expression_ns	hsa-mir-101	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-106b	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-mir-106b	Prostate Neoplasms	23621234	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important.
tissue_expression_ns	hsa-mir-1-1	Prostate Neoplasms	22210864	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.
tissue_expression_ns	hsa-mir-1-2	Prostate Neoplasms	22210864	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.
tissue_expression_ns	hsa-mir-125b	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-mir-125b	Prostate Neoplasms	17891175	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We have analysed expression of 328 known and 152 novel human miRNAs in 10 benign peripheral zone tissues and 16 prostate cancer tissues using microarrays and found widespread, but not universal, downregulation of miRNAs in clinically localized prostate cancer relative to benign peripheral zone tissue.These findings have been verified by real-time RT-PCR assays on select miRNAs, including miR-125b, miR-145 and let-7c.
tissue_expression_ns	hsa-mir-125b	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-125b	Prostate Neoplasms	20890088	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results.
tissue_expression_ns	hsa-mir-126	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-127	Prostate Neoplasms	28239051	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA expression profiling in canine prostate cancer.
tissue_expression_ns	hsa-mir-127	Prostate Neoplasms	28621736	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer.
tissue_expression_ns	hsa-mir-133b	Prostate Neoplasms	24967583	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer.
tissue_expression_ns	hsa-mir-134	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-135a	Prostate Neoplasms	18831788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, microRNA microarray data from other studies confirm that several predicted microRNAs, including miR-21, miR-135a, and miR-135b, demonstrate differential expression in prostate cancer cells, comparing with normal tissues.
tissue_expression_ns	hsa-mir-135b	Prostate Neoplasms	18831788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, microRNA microarray data from other studies confirm that several predicted microRNAs, including miR-21, miR-135a, and miR-135b, demonstrate differential expression in prostate cancer cells, comparing with normal tissues.
tissue_expression_ns	hsa-mir-138	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-141	Prostate Neoplasms	26751899	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs as novel biomarkers in the management of prostate cancer.
tissue_expression_ns	hsa-mir-141	Prostate Neoplasms	20014922	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Promising molecular markers identified from gene expression profiling studies include AMACR, EZH2, TMPRSS2-ERG, miR-221 and miR-141, which are described in more detail.
tissue_expression_ns	hsa-mir-141	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-143	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-143	Prostate Neoplasms	21400514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The differential expression of miRNAs miR-375, miR-143 and miR-145 was validated by quantitative PCR. MiRNA in situ hybridization revealed that the differential expression is cancer-cell associated.
tissue_expression_ns	hsa-mir-145	Prostate Neoplasms	17891175	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We have analysed expression of 328 known and 152 novel human miRNAs in 10 benign peripheral zone tissues and 16 prostate cancer tissues using microarrays and found widespread, but not universal, downregulation of miRNAs in clinically localized prostate cancer relative to benign peripheral zone tissue.These findings have been verified by real-time RT-PCR assays on select miRNAs, including miR-125b, miR-145 and let-7c.
tissue_expression_ns	hsa-mir-145	Prostate Neoplasms	21400514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The differential expression of miRNAs miR-375, miR-143 and miR-145 was validated by quantitative PCR. MiRNA in situ hybridization revealed that the differential expression is cancer-cell associated.
tissue_expression_ns	hsa-mir-146a	Prostate Neoplasms	23621234	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important.
tissue_expression_ns	hsa-mir-146a	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-155	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-15a	Prostate Neoplasms	20944140	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa.
tissue_expression_ns	hsa-mir-16	Prostate Neoplasms	20890088	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results.
tissue_expression_ns	hsa-mir-16	Prostate Neoplasms	20944140	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa.
tissue_expression_ns	hsa-mir-181c	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-181d	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-182	Prostate Neoplasms	24518785	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Results show that miR-182 and 187 are promising biomarkers for prostate cancer prognosis to identify patients at risk for progression and for diagnosis to improve the predictive capability of existing biomarkers.
tissue_expression_ns	hsa-mir-182	Prostate Neoplasms	26484677	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer.
tissue_expression_ns	hsa-mir-182	Prostate Neoplasms	23184537	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Expression of MicroRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer
tissue_expression_ns	hsa-mir-182	Prostate Neoplasms	20873592	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer.
tissue_expression_ns	hsa-mir-183	Prostate Neoplasms	25720086	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
tissue_expression_ns	hsa-mir-183	Prostate Neoplasms	20873592	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer.
tissue_expression_ns	hsa-mir-187	Prostate Neoplasms	24518785	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Results show that miR-182 and 187 are promising biomarkers for prostate cancer prognosis to identify patients at risk for progression and for diagnosis to improve the predictive capability of existing biomarkers.
tissue_expression_ns	hsa-mir-193a	Prostate Neoplasms	23621234	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important.
tissue_expression_ns	hsa-mir-200a	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-200b	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-200c	Prostate Neoplasms	26484677	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer.
tissue_expression_ns	hsa-mir-200c	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-205	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-205	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-mir-205	Prostate Neoplasms	25720086	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
tissue_expression_ns	hsa-mir-205	Prostate Neoplasms	24167554	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214.
tissue_expression_ns	hsa-mir-205	Prostate Neoplasms	20890088	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results.
tissue_expression_ns	hsa-mir-20a	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-mir-20a	Prostate Neoplasms	20944140	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa.
tissue_expression_ns	hsa-mir-21	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-mir-21	Prostate Neoplasms	26751899	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs as novel biomarkers in the management of prostate cancer.
tissue_expression_ns	hsa-mir-21	Prostate Neoplasms	18831788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, microRNA microarray data from other studies confirm that several predicted microRNAs, including miR-21, miR-135a, and miR-135b, demonstrate differential expression in prostate cancer cells, comparing with normal tissues.
tissue_expression_ns	hsa-mir-21	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-214	Prostate Neoplasms	24167554	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214.
tissue_expression_ns	hsa-mir-221	Prostate Neoplasms	26484677	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer.
tissue_expression_ns	hsa-mir-221	Prostate Neoplasms	20014922	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Promising molecular markers identified from gene expression profiling studies include AMACR, EZH2, TMPRSS2-ERG, miR-221 and miR-141, which are described in more detail.
tissue_expression_ns	hsa-mir-221	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-222	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-330	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-34	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-34a	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-mir-34b	Prostate Neoplasms	28039468	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians.
tissue_expression_ns	hsa-mir-34c	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-373	Prostate Neoplasms	24431212	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
tissue_expression_ns	hsa-mir-375	Prostate Neoplasms	26751899	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miRNAs as novel biomarkers in the management of prostate cancer.
tissue_expression_ns	hsa-mir-375	Prostate Neoplasms	20890088	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results.
tissue_expression_ns	hsa-mir-375	Prostate Neoplasms	21400514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The differential expression of miRNAs miR-375, miR-143 and miR-145 was validated by quantitative PCR. MiRNA in situ hybridization revealed that the differential expression is cancer-cell associated.
tissue_expression_ns	hsa-mir-425	Prostate Neoplasms	23621234	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important.
tissue_expression_ns	hsa-mir-429	Prostate Neoplasms	20539944	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa.
tissue_expression_ns	hsa-mir-503	Prostate Neoplasms	29164842	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-503 is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma andseveral others
tissue_expression_ns	hsa-mir-521	Prostate Neoplasms	24452514	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment.
tissue_expression_ns	hsa-mir-96	Prostate Neoplasms	20873592	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer.
tissue_expression_ns	hsa-mir-96	Prostate Neoplasms	20890088	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results.
tissue_expression_ns	hsa-mir-98	Prostate Neoplasms	20873592	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression profiles of the microRNAs let-7d, let-7g, miR-98, miR-96, miR-182 and miR-183 reflect the biological behavior of PCa to some extent, and might be important biomarkers for the early detection and prognostic assessment of prostate cancer.
tissue_expression_ns	hsa-mir-100	Psoriasis	21807764	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	deregulated
tissue_expression_ns	hsa-mir-106a	Psoriasis	28077577	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity.
tissue_expression_ns	hsa-mir-142	Psoriasis	21807764	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-142-3p: deregulated
tissue_expression_ns	hsa-mir-146a	Psoriasis	25662483	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	In the mouse model of Aldara-induced skin inflammation, the level of miR-146a increased
tissue_expression_ns	hsa-mir-146a	Psoriasis	27562321	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA-146a and miR-99a are potential biomarkers for disease activity and clinical efficacy assessment in psoriasis patients treated with traditional Chinese medicine.
tissue_expression_ns	hsa-mir-146a	Psoriasis	28077577	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity.
tissue_expression_ns	hsa-mir-150	Psoriasis	21687694	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	differentially expressed
tissue_expression_ns	hsa-mir-150	Psoriasis	28077577	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity.
tissue_expression_ns	hsa-mir-155	Psoriasis	28077577	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity.
tissue_expression_ns	hsa-mir-197	Psoriasis	21687694	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	differentially expressed
tissue_expression_ns	hsa-mir-19a	Psoriasis	28077577	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity.
tissue_expression_ns	hsa-mir-203	Psoriasis	26559308	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Key roles of several unique miRNAs, such as miR-203 and miR-125b, in inflammatory responses and immune dysfunction, as well as hyperproliferative disorders of psoriatic lesions have been revealed.
tissue_expression_ns	hsa-mir-21	Psoriasis	21807764	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	deregulated
tissue_expression_ns	hsa-mir-21	Psoriasis	28077577	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity.
tissue_expression_ns	hsa-mir-223	Psoriasis	21807764	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-223 and miR-223*: deregulated
tissue_expression_ns	hsa-mir-378a	Psoriasis	21807764	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	deregulated
tissue_expression_ns	hsa-mir-423	Psoriasis	21687694	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	differentially expressed
tissue_expression_ns	hsa-mir-99a	Psoriasis	27562321	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MicroRNA-146a and miR-99a are potential biomarkers for disease activity and clinical efficacy assessment in psoriasis patients treated with traditional Chinese medicine.
tissue_expression_ns	hsa-mir-129	Psychiatric Disorders	24246224				D001523	604363		Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts.
tissue_expression_ns	hsa-mir-146b	Psychiatric Disorders	24246224				D001523	604363		Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts.
tissue_expression_ns	hsa-mir-543	Psychiatric Disorders	24246224				D001523	604363		Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts.
tissue_expression_ns	hsa-mir-550a	Psychiatric Disorders	24246224				D001523	604363		Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts.
tissue_expression_ns	hsa-mir-1246	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-1308	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-141	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-143	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-18a	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-1972	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-1973	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-200a	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-200b	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-210	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-211	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-29b	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-31	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-3172	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-3175	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-375	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-451	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-486	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-663b	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-665	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-675	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-mir-934	Pterygium	23872359	nervous system disease	DOID:0002116	H11.0	D011625	178200		miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.
tissue_expression_ns	hsa-let-7f	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-128a	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-130a	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-15b	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-16	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-192	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-20a	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-221	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-222	Pulmonary Sarcoidosis	26768132	immune system disease	DOID:13406	D86.0	D017565			The obtained results suggest that the studied miRNAs play a role in the pathogenesis of sarcoidosis, and that some of them might have negative prognostic value.
tissue_expression_ns	hsa-mir-222	Pulmonary Sarcoidosis	26696750	immune system disease	DOID:13406	D86.0	D017565			miRNAs in sarcoid BAL cells detected deregulation of miR-146a, miR-150,  miR-202, miR-204, and miR-222 expression comparing to controls
tissue_expression_ns	hsa-let-7g	Rectal Neoplasms	26937645	disease of cellular proliferation	DOID:1984		D012004			We recommend the mean expression of miR-27a, miR-193a-5p and let-7g as normalisation factor, when performing miRNA expression analyses by RT-qPCR on rectal cancer tissue.
tissue_expression_ns	hsa-mir-193a	Rectal Neoplasms	26937645	disease of cellular proliferation	DOID:1984		D012004			We recommend the mean expression of miR-27a, miR-193a-5p and let-7g as normalisation factor, when performing miRNA expression analyses by RT-qPCR on rectal cancer tissue.
tissue_expression_ns	hsa-mir-21	Rectal Neoplasms	25953218	disease of cellular proliferation	DOID:1984		D012004			MicroRNA-21 expression efficiently predicts preoperative chemoradiotherapy pathological response in locally advanced rectal cancer.
tissue_expression_ns	hsa-mir-27a	Rectal Neoplasms	26937645	disease of cellular proliferation	DOID:1984		D012004			We recommend the mean expression of miR-27a, miR-193a-5p and let-7g as normalisation factor, when performing miRNA expression analyses by RT-qPCR on rectal cancer tissue.
tissue_expression_ns	hsa-mir-645	Rectal Neoplasms	26937645	disease of cellular proliferation	DOID:1984		D012004			We recommend the mean expression of miR-27a, miR-193a-5p and let-7g as normalisation factor, when performing miRNA expression analyses by RT-qPCR on rectal cancer tissue.
tissue_expression_ns	hsa-mir-630	Rectum Adenocarcinoma	27225591	disease of cellular proliferation	DOID:1996	C20				The miR-630 appeared only with the NR patients and was anti-correlated with a single transcript: RAB5B.
tissue_expression_ns	hsa-mir-125b-2	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-184	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-187	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-3175	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-4672	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-517c	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-519a-1	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-520f	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-520h	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-mir-522	Recurrent Spontaneous Abortion	24686457			O03	D000022			Genome-wide miRNA profiling of villus and decidua of recurrent spontaneous abortion patients.
tissue_expression_ns	hsa-let-7d	Reproductive System Disease	27789200	reproductive system disease	DOID:15					A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)
tissue_expression_ns	hsa-mir-103-2	Reproductive System Disease	27789200	reproductive system disease	DOID:15					A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)
tissue_expression_ns	hsa-mir-130b	Reproductive System Disease	27789200	reproductive system disease	DOID:15					A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)
tissue_expression_ns	hsa-mir-146b	Reproductive System Disease	27789200	reproductive system disease	DOID:15					A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)
tissue_expression_ns	hsa-mir-26b	Reproductive System Disease	27789200	reproductive system disease	DOID:15					A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)
tissue_expression_ns	hsa-mir-29c	Reproductive System Disease	27789200	reproductive system disease	DOID:15					A number of these differentially expressed miRNAs have previously been associated with adipogenesis(e.g. let-7d*, miR-103-2*, -130b, -146b-5-p, -29c, and -26b)
tissue_expression_ns	hsa-mir-155	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_ns	hsa-mir-16	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_ns	hsa-mir-203a	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_ns	hsa-mir-27b	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_ns	hsa-mir-29c	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_ns	hsa-mir-31	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_ns	hsa-mir-34b	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_ns	hsa-mir-34c	Respiratory Syncytial Virus Pneumonia	25884957	disease by infectious agent	DOID:1273	J12.1	D018357			microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct profile of immune-associated miRNA.miR-125a has important functions within NF-κB signaling and macrophage function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in disease manifestations on infection with RSV.
tissue_expression_ns	hsa-mir-124-1	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-124-2	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-124-3	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-132	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-146a	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-155	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-15a	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-16-1	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-16-2	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-203	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-223	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-346	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-363	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-mir-498	Rheumatoid Arthritis	22100329	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	deregulated
tissue_expression_ns	hsa-let-7a	Salivary Gland Neoplasms	28377929	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours.
tissue_expression_ns	hsa-mir-133b	Salivary Gland Neoplasms	28377929	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours.
tissue_expression_ns	hsa-mir-140	Salivary Gland Neoplasms	28377929	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours.
tissue_expression_ns	hsa-mir-15a	Salivary Gland Neoplasms	27981346	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis.
tissue_expression_ns	hsa-mir-16	Salivary Gland Neoplasms	27981346	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis.
tissue_expression_ns	hsa-mir-17	Salivary Gland Neoplasms	27981346	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis.
tissue_expression_ns	hsa-mir-20a	Salivary Gland Neoplasms	27981346	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis.
tissue_expression_ns	hsa-mir-21	Salivary Gland Neoplasms	27981346	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis.
tissue_expression_ns	hsa-mir-29	Salivary Gland Neoplasms	27981346	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis.
tissue_expression_ns	hsa-mir-34	Salivary Gland Neoplasms	27981346	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis.
tissue_expression_ns	hsa-mir-34a	Salivary Gland Neoplasms	27981346	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis.
tissue_expression_ns	hsa-mir-99b	Salivary Gland Neoplasms	28377929	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	Expression, Mutation, and Amplification Status of EGFR and Its Correlation with Five miRNAs in Salivary Gland Tumours.
tissue_expression_ns	hsa-let-7	Schizophrenia	27748930	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	the possible role of let-7, miR-98 and miR-183 as biomarkers for Ca and SZ was investigated in our previous research studies
tissue_expression_ns	hsa-mir-183	Schizophrenia	27748930	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	the possible role of let-7, miR-98 and miR-183 as biomarkers for Ca and SZ was investigated in our previous research studies
tissue_expression_ns	hsa-mir-212	Schizophrenia	27468165	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-132, miR-133a and  miR-212 were initially identified as differentially expressed in BP, miR-184 in MDD and miR-34a in both MDD and BP (although none survived multiple correction testing and must be considered preliminary).
tissue_expression_ns	hsa-mir-7	Schizophrenia	26572867	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Here we show post-transcriptional regulation of SHANK3 expression by three microRNAs (miRNAs), miR-7, miR-34a, and miR-504.
tissue_expression_ns	hsa-mir-98	Schizophrenia	27748930	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	the possible role of let-7, miR-98 and miR-183 as biomarkers for Ca and SZ was investigated in our previous research studies
tissue_expression_ns	hsa-mir-145	Scleroderma, Systemic	22307526	musculoskeletal system disease	DOID:418	M34	D012595	181750		The expression of the miRNA was correlated with Systemic Scleroderma fibrosis
tissue_expression_ns	hsa-mir-146a	Scleroderma, Systemic	22307526	musculoskeletal system disease	DOID:418	M34	D012595	181750		The expression of the miRNA was correlated with Systemic Scleroderma fibrosis
tissue_expression_ns	hsa-mir-146b	Scleroderma, Systemic	22307526	musculoskeletal system disease	DOID:418	M34	D012595	181750		The expression of the miRNA was correlated with Systemic Scleroderma fibrosis
tissue_expression_ns	hsa-mir-21	Scleroderma, Systemic	22307526	musculoskeletal system disease	DOID:418	M34	D012595	181750		The expression of the miRNA was correlated with Systemic Scleroderma fibrosis
tissue_expression_ns	hsa-mir-29b-1	Scleroderma, Systemic	22307526	musculoskeletal system disease	DOID:418	M34	D012595	181750		The expression of the miRNA was correlated with Systemic Scleroderma fibrosis
tissue_expression_ns	hsa-mir-29b-2	Scleroderma, Systemic	22307526	musculoskeletal system disease	DOID:418	M34	D012595	181750		The expression of the miRNA was correlated with Systemic Scleroderma fibrosis
tissue_expression_ns	hsa-mir-31	Scleroderma, Systemic	22307526	musculoskeletal system disease	DOID:418	M34	D012595	181750		The expression of the miRNA was correlated with Systemic Scleroderma fibrosis
tissue_expression_ns	hsa-mir-503	Scleroderma, Systemic	22307526	musculoskeletal system disease	DOID:418	M34	D012595	181750		The expression of the miRNA was correlated with Systemic Scleroderma fibrosis
tissue_expression_ns	hsa-mir-223	Sepsis	27129807			A41.9	D018805		HP:0100806	miR-223 that has been reported to be abnormally expressed in several diseases like diabetes-type2, sepsis, rheumatoid arthritis, viral infections likes' human immunodeficiency virus-1 (HIV-1) and inflammatory disorders.
tissue_expression_ns	hsa-mir-129	Sertoli Cell-Only Syndrome	28779347	reproductive system disease	DOID:0050457		D054331	305700		Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group 
tissue_expression_ns	hsa-mir-34b	Sertoli Cell-Only Syndrome	28779347	reproductive system disease	DOID:0050457		D054331	305700		Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group 
tissue_expression_ns	hsa-mir-34c	Sertoli Cell-Only Syndrome	28779347	reproductive system disease	DOID:0050457		D054331	305700		Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group 
tissue_expression_ns	hsa-mir-449a	Sertoli Cell-Only Syndrome	28779347	reproductive system disease	DOID:0050457		D054331	305700		Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group 
tissue_expression_ns	hsa-mir-449b	Sertoli Cell-Only Syndrome	28779347	reproductive system disease	DOID:0050457		D054331	305700		Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group 
tissue_expression_ns	hsa-mir-517b	Sertoli Cell-Only Syndrome	28779347	reproductive system disease	DOID:0050457		D054331	305700		Among the highest differentially expressed miRNAs only seven, hsa-miR-34b, hsa-miR-34b*, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b*, hsa-miR-517b, and hsa-miR-129-3p, were shared by the three histopathological conditions and were strongly downregulated compared to the normal group 
tissue_expression_ns	hsa-mir-182	Shock, Septic	22940033			R65.21	D012772			We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction.
tissue_expression_ns	hsa-mir-199a	Shock, Septic	22940033			R65.21	D012772			We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction.
tissue_expression_ns	hsa-mir-203	Shock, Septic	22940033			R65.21	D012772			We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction.
tissue_expression_ns	hsa-mir-211	Shock, Septic	22940033			R65.21	D012772			We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction.
tissue_expression_ns	hsa-mir-222	Shock, Septic	22940033			R65.21	D012772			We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction.
tissue_expression_ns	hsa-mir-29b	Shock, Septic	22940033			R65.21	D012772			We confirmed expression of select miRNAs (miR-182, -199a-5p, -203, -211, -222, and -29b) using quantitative reverse transcriptase-polymerase chain reaction.
tissue_expression_ns	hsa-mir-181c	Silicosis	26903263	respiratory system disease	DOID:10325	J62.8	D012829			The differential expression of two selected miRNAs hsa-miR-181c-5p and hsa-miR-29a-3p were confirmed by RT-qPCR.
tissue_expression_ns	hsa-mir-29a	Silicosis	26903263	respiratory system disease	DOID:10325	J62.8	D012829			The differential expression of two selected miRNAs hsa-miR-181c-5p and hsa-miR-29a-3p were confirmed by RT-qPCR.
tissue_expression_ns	hsa-mir-146a	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-148a	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-150	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-152	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-155	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-16	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-21	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-223	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-224	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-326	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-342	Sjogren Syndrome	28339495	immune system disease	DOID:12894	M35.00	D012859	270150		MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-424	Skin Hemangioma	28928430	disease of cellular proliferation	DOID:471	D18.01				The expression and function of miR-424 in infantile skin hemangioma and its mechanism.
tissue_expression_ns	hsa-mir-1203	Small Cell Carcinoma, Esophageal	25667451							The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE.
tissue_expression_ns	hsa-mir-1249	Small Cell Carcinoma, Esophageal	25667451							The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE.
tissue_expression_ns	hsa-mir-3619	Small Cell Carcinoma, Esophageal	25667451							The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE.
tissue_expression_ns	hsa-mir-4419b	Small Cell Carcinoma, Esophageal	25667451							The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE.
tissue_expression_ns	hsa-mir-4648	Small Cell Carcinoma, Esophageal	25667451							The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE.
tissue_expression_ns	hsa-mir-4664	Small Cell Carcinoma, Esophageal	25667451							The expression profiles of microRNAs in tumors may represent a novel predictor for postoperative outcomes in patients with SCCE.
tissue_expression_ns	hsa-mir-765	Soft Tissue Sarcoma	27223121			C49.9	D012509		HP:0030448	miR-765 could possibly be a diagnostic tool for ES because of its 97% specificity and 80% sensitivity.
tissue_expression_ns	hsa-mir-1237	Spinal Chordoma	25850393	musculoskeletal system disease	DOID:4153		D002817			The data from the current study identified a total of 29 differentially expressed miRNAs in chordoma tissues and reduced miR-1237-3p expression was associated with chordoma invasion and worse recurrence-free survival of the patients.
tissue_expression_ns	hsa-let-7a	Squamous Cell Carcinoma	27835588	disease of cellular proliferation	DOID:1749		D002294			Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva.
tissue_expression_ns	hsa-mir-101	Squamous Cell Carcinoma, Esophageal	25538231	disease of cellular proliferation	DOID:3748		C562729			A significant negative correlation exists between miR-101 or miR-217 and MALAT1 in 42 pairs of ESCC tissue samples and adjacent normal tissues. Mice xenograft data also support the tumor suppressor role of both miRNAs in ESCCs.
tissue_expression_ns	hsa-mir-106b	Squamous Cell Carcinoma, Esophageal	27998862	disease of cellular proliferation	DOID:3748		C562729			Expression of mir-106b in esophageal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-10a	Squamous Cell Carcinoma, Esophageal	20588024	disease of cellular proliferation	DOID:3748		C562729			We found that miR-205 and miR-10a were significantly altered in cellular expression, and might be specific for ESCC with potential roles in the pathogenesis. 
tissue_expression_ns	hsa-mir-146b	Squamous Cell Carcinoma, Esophageal	23175214	disease of cellular proliferation	DOID:3748		C562729			The expression levels of miR-21 (p = 0.027), miR-181b (p = 0.002) and miR-146b (p = 0.021) in tumor tissue and miR-21 (p = 0.003) in noncancerous tissue were associated with overall survival of patients. 
tissue_expression_ns	hsa-mir-148	Squamous Cell Carcinoma, Esophageal	25928282	disease of cellular proliferation	DOID:3748		C562729			Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer.
tissue_expression_ns	hsa-mir-17	Squamous Cell Carcinoma, Esophageal	24360091	disease of cellular proliferation	DOID:3748		C562729			miR-17, miR-18a, and miR-19a can serve as potential unfavorable prognostic biomarkers in ESCC which are associated with some clinicopathologic factors
tissue_expression_ns	hsa-mir-181b	Squamous Cell Carcinoma, Esophageal	23175214	disease of cellular proliferation	DOID:3748		C562729			The expression levels of miR-21 (p = 0.027), miR-181b (p = 0.002) and miR-146b (p = 0.021) in tumor tissue and miR-21 (p = 0.003) in noncancerous tissue were associated with overall survival of patients. 
tissue_expression_ns	hsa-mir-181c	Squamous Cell Carcinoma, Esophageal	26888510	disease of cellular proliferation	DOID:3748		C562729			There are significant correlation between miR-181c-3p/miR-5692b expression, clinicopathologic parameters and prognosis. They represent potential prognostic biomarkers in esophageal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-186	Squamous Cell Carcinoma, Esophageal	27889881	disease of cellular proliferation	DOID:3748		C562729			Identification of reference genes and miRNAs for qRT-PCR in human esophageal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-18a	Squamous Cell Carcinoma, Esophageal	24360091	disease of cellular proliferation	DOID:3748		C562729			miR-17, miR-18a, and miR-19a can serve as potential unfavorable prognostic biomarkers in ESCC which are associated with some clinicopathologic factors
tissue_expression_ns	hsa-mir-19a	Squamous Cell Carcinoma, Esophageal	24360091	disease of cellular proliferation	DOID:3748		C562729			miR-17, miR-18a, and miR-19a can serve as potential unfavorable prognostic biomarkers in ESCC which are associated with some clinicopathologic factors
tissue_expression_ns	hsa-mir-203	Squamous Cell Carcinoma, Esophageal	25928282	disease of cellular proliferation	DOID:3748		C562729			Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer.
tissue_expression_ns	hsa-mir-205	Squamous Cell Carcinoma, Esophageal	20588024	disease of cellular proliferation	DOID:3748		C562729			We found that miR-205 and miR-10a were significantly altered in cellular expression, and might be specific for ESCC with potential roles in the pathogenesis. 
tissue_expression_ns	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	25928282	disease of cellular proliferation	DOID:3748		C562729			Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer.
tissue_expression_ns	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	23175214	disease of cellular proliferation	DOID:3748		C562729			The expression levels of miR-21 (p = 0.027), miR-181b (p = 0.002) and miR-146b (p = 0.021) in tumor tissue and miR-21 (p = 0.003) in noncancerous tissue were associated with overall survival of patients. 
tissue_expression_ns	hsa-mir-217	Squamous Cell Carcinoma, Esophageal	25538231	disease of cellular proliferation	DOID:3748		C562729			A significant negative correlation exists between miR-101 or miR-217 and MALAT1 in 42 pairs of ESCC tissue samples and adjacent normal tissues. Mice xenograft data also support the tumor suppressor role of both miRNAs in ESCCs.
tissue_expression_ns	hsa-mir-28	Squamous Cell Carcinoma, Esophageal	27889881	disease of cellular proliferation	DOID:3748		C562729			Identification of reference genes and miRNAs for qRT-PCR in human esophageal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-29c	Squamous Cell Carcinoma, Esophageal	25928282	disease of cellular proliferation	DOID:3748		C562729			Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic and prognostic biomarkers in esophageal cancer.
tissue_expression_ns	hsa-mir-335	Squamous Cell Carcinoma, Esophageal	25337272	disease of cellular proliferation	DOID:3748		C562729			miR-335 expression isan independent prognostic factor for patients with esophageal cancer, which might be a potential valuable biomarker for ESCC.
tissue_expression_ns	hsa-mir-33b	Squamous Cell Carcinoma, Esophageal	27609581	disease of cellular proliferation	DOID:3748		C562729			The expression and significance of miR-33b and HMGA2 in esophageal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-34a	Squamous Cell Carcinoma, Esophageal	27889881	disease of cellular proliferation	DOID:3748		C562729			Identification of reference genes and miRNAs for qRT-PCR in human esophageal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-5692b	Squamous Cell Carcinoma, Esophageal	26888510	disease of cellular proliferation	DOID:3748		C562729			There are significant correlation between miR-181c-3p/miR-5692b expression, clinicopathologic parameters and prognosis. They represent potential prognostic biomarkers in esophageal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-574	Squamous Cell Carcinoma, Esophageal	27565418	disease of cellular proliferation	DOID:3748		C562729			The expression of microRNA 574-3p as a predictor of postoperative outcome in patients with esophageal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-638	Squamous Cell Carcinoma, Esophageal	28108314	disease of cellular proliferation	DOID:3748		C562729			MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3.
tissue_expression_ns	hsa-mir-10a	Squamous Cell Carcinoma, Head and Neck	28495058	disease of cellular proliferation	DOID:5520	C76.0	C535575			miRNA profiling of primary lung and head and neck squamous cell carcinomas: Addressing a diagnostic dilemma.
tissue_expression_ns	hsa-mir-10b	Squamous Cell Carcinoma, Head and Neck	28495058	disease of cellular proliferation	DOID:5520	C76.0	C535575			miRNA profiling of primary lung and head and neck squamous cell carcinomas: Addressing a diagnostic dilemma.
tissue_expression_ns	hsa-mir-155	Squamous Cell Carcinoma, Head and Neck	28347920	disease of cellular proliferation	DOID:5520	C76.0	C535575			MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.
tissue_expression_ns	hsa-mir-200b	Squamous Cell Carcinoma, Head and Neck	28347920	disease of cellular proliferation	DOID:5520	C76.0	C535575			MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.
tissue_expression_ns	hsa-mir-34a	Squamous Cell Carcinoma, Head and Neck	28495058	disease of cellular proliferation	DOID:5520	C76.0	C535575			miRNA profiling of primary lung and head and neck squamous cell carcinomas: Addressing a diagnostic dilemma.
tissue_expression_ns	hsa-mir-375	Squamous Cell Carcinoma, Head and Neck	27440205	disease of cellular proliferation	DOID:5520	C76.0	C535575			Primary HNSCC carcinoma tissues can be distinguished from histologically normal-matched noncancerous tumour-adjacent tissues based on hsa-miR-375-3p expression.
tissue_expression_ns	hsa-let-7a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	29082244	disease of cellular proliferation	DOID:2876					Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-106b	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	25189575	disease of cellular proliferation	DOID:2876					Guo investigated regulation and expression of three miRNAs; miR-21, miR-106b and miR-375. The paper reported these miRNAs as potential biomarkers for laryngeal squamous cell carcinoma diagnosis.
tissue_expression_ns	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	29082244	disease of cellular proliferation	DOID:2876					Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-23a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26175945	disease of cellular proliferation	DOID:2876					MiR-21/miR-375 ratio is an independent prognostic factor in patients with laryngeal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-34c	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	29082244	disease of cellular proliferation	DOID:2876					Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-140	Squamous Cell Carcinoma, Lung	21890451	disease of cellular proliferation	DOID:3907	C34.91				The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues.
tissue_expression_ns	hsa-mir-182	Squamous Cell Carcinoma, Lung	21890451	disease of cellular proliferation	DOID:3907	C34.91				The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues.
tissue_expression_ns	hsa-mir-182	Squamous Cell Carcinoma, Lung	24600991	disease of cellular proliferation	DOID:3907	C34.91				We provide first time evidence through tissue microarray and quantitative PCR validation of mir-182 in the expression of lung squamous cell carcinoma. Our data provide a possible mechanism for lung cancer cell proliferation in lung squamous cell cancer and may be helpful in discovering a new strategy to reveal lung squamous cell carcinoma progress.
tissue_expression_ns	hsa-mir-196a	Squamous Cell Carcinoma, Lung	23074073	disease of cellular proliferation	DOID:3907	C34.91				Validation of selected microRNAs by in situ hybridization demonstrated strong expression of hsa-miR-196a in the inner tumor; moderate expression of hsa-miR-224 in the inner tumor and tumor front, and strong expression of hsa-miR-650 in the adjacent lung tissue.
tissue_expression_ns	hsa-mir-210	Squamous Cell Carcinoma, Lung	21890451	disease of cellular proliferation	DOID:3907	C34.91				The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues.
tissue_expression_ns	hsa-mir-224	Squamous Cell Carcinoma, Lung	23074073	disease of cellular proliferation	DOID:3907	C34.91				Validation of selected microRNAs by in situ hybridization demonstrated strong expression of hsa-miR-196a in the inner tumor; moderate expression of hsa-miR-224 in the inner tumor and tumor front, and strong expression of hsa-miR-650 in the adjacent lung tissue.
tissue_expression_ns	hsa-mir-30a	Squamous Cell Carcinoma, Lung	21890451	disease of cellular proliferation	DOID:3907	C34.91				The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues.
tissue_expression_ns	hsa-mir-486	Squamous Cell Carcinoma, Lung	21890451	disease of cellular proliferation	DOID:3907	C34.91				The authors identified a five-microRNA classifier (hsa-miR-210, hsa-miR-182, hsa-miR-486-5p, hsa-miR-30a and hsa-miR-140-3p) that could distinguish SCC (Squamous cell carcinoma) from normal lung tissues.
tissue_expression_ns	hsa-mir-650	Squamous Cell Carcinoma, Lung	23074073	disease of cellular proliferation	DOID:3907	C34.91				Validation of selected microRNAs by in situ hybridization demonstrated strong expression of hsa-miR-196a in the inner tumor; moderate expression of hsa-miR-224 in the inner tumor and tumor front, and strong expression of hsa-miR-650 in the adjacent lung tissue.
tissue_expression_ns	hsa-let-7g	Squamous Cell Carcinoma, Oral	25050621	disease of cellular proliferation	DOID:0050866					MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma.
tissue_expression_ns	hsa-mir-125b	Squamous Cell Carcinoma, Oral	25050621	disease of cellular proliferation	DOID:0050866					MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma.
tissue_expression_ns	hsa-mir-125b	Squamous Cell Carcinoma, Oral	27935034	disease of cellular proliferation	DOID:0050866					Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-1275	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					the expression of miR-1275 was variable in tumours, with high levels associated to regional lymph node invasion;
tissue_expression_ns	hsa-mir-133a	Squamous Cell Carcinoma, Oral	27935034	disease of cellular proliferation	DOID:0050866					Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-133b	Squamous Cell Carcinoma, Oral	27935034	disease of cellular proliferation	DOID:0050866					Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-139	Squamous Cell Carcinoma, Oral	27935034	disease of cellular proliferation	DOID:0050866					Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-184	Squamous Cell Carcinoma, Oral	25482863	disease of cellular proliferation	DOID:0050866					Our results corroborate the previous findings on the overexpression  of mir-21 and downregulation of miR-138 in OSCC. As the expression of miR-184 is controversial in tongue/oral cancer, the downregulation may be specific to tumor anatomical localization. On the other hand, to the best of our knowledge, this is the first report to show the association of miR-155 with tobacco chewing and the downregulation of miR-125b-2* in OSCC. Computational predictions suggest that miR-125b-2* may have a role in alternative splicing.
tissue_expression_ns	hsa-mir-200	Squamous Cell Carcinoma, Oral	29375721	disease of cellular proliferation	DOID:0050866					Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma
tissue_expression_ns	hsa-mir-21	Squamous Cell Carcinoma, Oral	24755828	disease of cellular proliferation	DOID:0050866					MiR-21 expression in the tumor stroma of oral squamous cell carcinoma: an independent biomarker of disease free survival.
tissue_expression_ns	hsa-mir-21	Squamous Cell Carcinoma, Oral	27935034	disease of cellular proliferation	DOID:0050866					Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-218	Squamous Cell Carcinoma, Oral	25050621	disease of cellular proliferation	DOID:0050866					MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma.
tissue_expression_ns	hsa-mir-31	Squamous Cell Carcinoma, Oral	26104160	disease of cellular proliferation	DOID:0050866					MiR-31 and miR-130b, known to inhibit several steps in the metastatic process, were over-expressed in non-metastatic samples and the expression of miR-130b was confirmed in plasma of patients showing no metastasis.
tissue_expression_ns	hsa-mir-31	Squamous Cell Carcinoma, Oral	27935034	disease of cellular proliferation	DOID:0050866					Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-338	Squamous Cell Carcinoma, Oral	27935034	disease of cellular proliferation	DOID:0050866					Integrated Analysis and MicroRNA Expression Profiling Identified Seven miRNAs Associated With Progression of Oral Squamous Cell Carcinoma.
tissue_expression_ns	hsa-mir-542	Squamous Cell Carcinoma, Oral	28275798	disease of cellular proliferation	DOID:0050866					Expression and correlation of survivin and hsa-miR-542-3p in patients with oral squamous cell carcinoma.
tissue_expression_ns	hsa-mir-200c	Squamous Cell Carcinoma, Sinonasal	28960576							Deregulation of selected microRNAs in sinonasal carcinoma: Value of miR-21 as prognostic biomarker in sinonasal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-21	Squamous Cell Carcinoma, Sinonasal	28960576							Deregulation of selected microRNAs in sinonasal carcinoma: Value of miR-21 as prognostic biomarker in sinonasal squamous cell carcinoma.
tissue_expression_ns	hsa-mir-203	Squamous Cell Carcinoma, Skin or Unspecific	27943259	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma.
tissue_expression_ns	hsa-mir-205	Squamous Cell Carcinoma, Skin or Unspecific	27943259	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma.
tissue_expression_ns	hsa-mir-375	Squamous Cell Carcinoma, Tongue	25633534	disease of cellular proliferation	DOID:0050865	C02.9				miR-375 inhibits the cell growth, and its expression is correlated  with clinical outcomes in TSCC.
tissue_expression_ns	hsa-mir-498	Squamous Cell Carcinoma, Tongue	27773646	disease of cellular proliferation	DOID:0050865	C02.9				MicroRNA and protein profiles in invasive versus non-invasive oral tongue squamous cell carcinoma cells in vitro.
tissue_expression_ns	hsa-mir-940	Squamous Cell Carcinoma, Tongue	27773646	disease of cellular proliferation	DOID:0050865	C02.9				MicroRNA and protein profiles in invasive versus non-invasive oral tongue squamous cell carcinoma cells in vitro.
tissue_expression_ns	hsa-mir-155	Stroke	26663183			I64	D020521	601367	HP:0001297	we will provide insight into recent knowledge from animal and human studies concerning miRNA profiling in acute stroke and their expression dynamics in brain tissue and extracellular fluids (roles of, e.g. let-7 family, miR-21, miR-29 family, miR-124, miR-145, miR-181 family, miR-210 and miR-223)
tissue_expression_ns	hsa-mir-124	Stroke, Hemorrhagic	24650689			I61.9			HP:0001342	Both miR-124-3p and miR-16 are diagnostic markers to discriminate HS and IS.
tissue_expression_ns	hsa-mir-16	Stroke, Hemorrhagic	24650689			I61.9			HP:0001342	Both miR-124-3p and miR-16 are diagnostic markers to discriminate HS and IS.
tissue_expression_ns	hsa-mir-210	Stroke, Ischemic	27906445			I63.9			HP:0002140	The expression research of miR-210 in the elderly patients with COPD combined with ischemic stroke.
tissue_expression_ns	hsa-mir-146a	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-148a	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-150	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-152	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-155	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-16	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-21	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-223	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-224	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-326	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-342	Systemic Lupus Erythematosus	28339495	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren's syndrome.
tissue_expression_ns	hsa-mir-140	Thymoma	28517980	disease of cellular proliferation	DOID:3275		D013945	274230	HP:0100522	Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913–1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated
tissue_expression_ns	hsa-mir-1976	Thymoma	28517980	disease of cellular proliferation	DOID:3275		D013945	274230	HP:0100522	Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913–1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated
tissue_expression_ns	hsa-mir-3613	Thymoma	28517980	disease of cellular proliferation	DOID:3275		D013945	274230	HP:0100522	Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913–1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated
tissue_expression_ns	hsa-mir-3913	Thymoma	28517980	disease of cellular proliferation	DOID:3275		D013945	274230	HP:0100522	Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913–1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated
tissue_expression_ns	hsa-mir-450b	Thymoma	28517980	disease of cellular proliferation	DOID:3275		D013945	274230	HP:0100522	Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913–1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated
tissue_expression_ns	hsa-mir-542	Thymoma	28517980	disease of cellular proliferation	DOID:3275		D013945	274230	HP:0100522	Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913–1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated
tissue_expression_ns	hsa-mir-639	Thymoma	28517980	disease of cellular proliferation	DOID:3275		D013945	274230	HP:0100522	Among the seven significant miRNAs, six (mir-140, mir-450b, mir-542, mir-639, mir-3613 and mir-3913–1) were positively associated with OS, while the remaining one (mir-1976) was negatively correlated
tissue_expression_ns	hsa-mir-146b	Thyroid Lymphoma	24327568	disease of cellular proliferation	DOID:10011	C85.99				Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures.
tissue_expression_ns	hsa-mir-221	Thyroid Lymphoma	24327568	disease of cellular proliferation	DOID:10011	C85.99				Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures.
tissue_expression_ns	hsa-mir-222	Thyroid Lymphoma	24327568	disease of cellular proliferation	DOID:10011	C85.99				Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures.
tissue_expression_ns	hsa-mir-26a	Thyroid Lymphoma	24327568	disease of cellular proliferation	DOID:10011	C85.99				Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures.
tissue_expression_ns	hsa-mir-138	Thyroid Neoplasms	27547222	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Expression of miRNA and Occurrence of Distant Metastases in Patients with Hürthle Cell Carcinoma.
tissue_expression_ns	hsa-let-7b	Thyroid Neoplasms	29762469	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of miRNAs hsa-let-7f-5p, has-let-7b-5p hsa-miR-146b-5p and hsa-miR-146b-3p was modulated heterogeneously
tissue_expression_ns	hsa-let-7f	Thyroid Neoplasms	29762469	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of miRNAs hsa-let-7f-5p, has-let-7b-5p hsa-miR-146b-5p and hsa-miR-146b-3p was modulated heterogeneously
tissue_expression_ns	hsa-mir-146b	Thyroid Neoplasms	29762469	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of miRNAs hsa-let-7f-5p, has-let-7b-5p hsa-miR-146b-5p and hsa-miR-146b-3p was modulated heterogeneously
tissue_expression_ns	hsa-mir-146b	Thyroid Neoplasms	21778212	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland.
tissue_expression_ns	hsa-mir-200b	Thyroid Neoplasms	21778212	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland.
tissue_expression_ns	hsa-mir-221	Thyroid Neoplasms	21778212	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland.
tissue_expression_ns	hsa-mir-222	Thyroid Neoplasms	21778212	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland.
tissue_expression_ns	hsa-mir-7	Thyroid Neoplasms	21778212	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland.
tissue_expression_ns	hsa-mir-20a	Toxoplasma gondii Infection	28424428	disease by infectious agent	DOID:9965	B58	D014123			Global miRNA expression profiling of domestic cat livers following acute Toxoplasma gondii infection.
tissue_expression_ns	hsa-mir-126	Traumatic Brain Injury	27027233			S06.2	D000070642			Our results indicated that altered expression of miR-126-3p and miR-3610 may play an important role in the development of TBI-induced hypopituitarism.
tissue_expression_ns	hsa-mir-150	Traumatic Brain Injury	24108763			S06.2	D000070642			neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury.
tissue_expression_ns	hsa-mir-155	Traumatic Brain Injury	24108763			S06.2	D000070642			neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury.
tissue_expression_ns	hsa-mir-223	Traumatic Brain Injury	24108763			S06.2	D000070642			neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury.
tissue_expression_ns	hsa-mir-23a	Traumatic Brain Injury	24108763			S06.2	D000070642			neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury.
tissue_expression_ns	hsa-mir-30e	Traumatic Brain Injury	24108763			S06.2	D000070642			neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury.
tissue_expression_ns	hsa-mir-3610	Traumatic Brain Injury	27027233			S06.2	D000070642			Our results indicated that altered expression of miR-126-3p and miR-3610 may play an important role in the development of TBI-induced hypopituitarism.
tissue_expression_ns	hsa-mir-3945	Traumatic Brain Injury	24108763			S06.2	D000070642			neutrophils associated with traumatic injury were found to have a unique miRNA signature. Changes in signaling pathways due to deregulated miRNAs may be involved in the pathological processes of traumatic injury.
tissue_expression_ns	hsa-mir-196	Tuberculosis	27102525	disease by infectious agent	DOID:399	A15-A19	D014376			9鈥塵iRNAs were differentially expressed after MAP infection.
tissue_expression_ns	hsa-mir-196b	Tuberculosis	24586438	disease by infectious agent	DOID:399	A15-A19	D014376			The microRNA differential-expression profiles generated in this study provide a good foundation for the development of markers for TB diagnosis, and for investigations on the role of microRNAs in BCG-inoculated and latent-infected individuals.
tissue_expression_ns	hsa-mir-376c	Tuberculosis	24586438	disease by infectious agent	DOID:399	A15-A19	D014376			The microRNA differential-expression profiles generated in this study provide a good foundation for the development of markers for TB diagnosis, and for investigations on the role of microRNAs in BCG-inoculated and latent-infected individuals.
tissue_expression_ns	hsa-mir-130b	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-130b*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-144	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-144: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-155	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-155: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-181b-1	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-181b: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-181b-2	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-181b: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-21	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-21*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-223	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-223: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-302a	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-302a: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-329-1	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-329: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-329-2	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-329: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-342	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-342-5p: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-421	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-421: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-424	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-424: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-451a	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-451: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-486	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-486-5p: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-520d	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-520d-3p: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-548b	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-548b-3p: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-550a-1	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-550a-2	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-550a-3	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-550b-1	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-550b-2	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-550*: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-640	Tuberculosis, Pulmonary	22003408	disease by infectious agent	DOID:2957	A15	D014397			hsa-mir-640: differently expressed in the samples from study participants with active tuberculosis (TB) versus latent tuberculosis infection (LTBI).
tissue_expression_ns	hsa-mir-100	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-100	Urinary Bladder Cancer	22330141	urinary system disease	DOID:11054	C67	D001749	109800		Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations.
tissue_expression_ns	hsa-mir-10a	Urinary Bladder Cancer	24439061	urinary system disease	DOID:11054	C67	D001749	109800		The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer.
tissue_expression_ns	hsa-mir-10a	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-10a	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-1-1	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-1-1	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-1-2	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-1-2	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-1224	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-125b-1	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-125b-1	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-125b-1	Urinary Bladder Cancer	22330141	urinary system disease	DOID:11054	C67	D001749	109800		Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations.
tissue_expression_ns	hsa-mir-125b-2	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-125b-2	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-133a-1	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-133a-1	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-133a-2	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-133a-2	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-133b	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-133b	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-135b	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-143	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-143	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-143	Urinary Bladder Cancer	22426337	urinary system disease	DOID:11054	C67	D001749	109800		miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer.
tissue_expression_ns	hsa-mir-145	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-145	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-146a	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-155	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-15a	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-15b	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-15b	Urinary Bladder Cancer	22330141	urinary system disease	DOID:11054	C67	D001749	109800		Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations.
tissue_expression_ns	hsa-mir-182	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-183	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-193b	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-196a-1	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-196a-2	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-200b	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-203	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-203	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-203	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-203	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-20b	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-21	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-212	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-221	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-222	Urinary Bladder Cancer	22426337	urinary system disease	DOID:11054	C67	D001749	109800		miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer.
tissue_expression_ns	hsa-mir-224	Urinary Bladder Cancer	22140553	urinary system disease	DOID:11054	C67	D001749	109800		deregulated
tissue_expression_ns	hsa-mir-24-1	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-27a	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-27b	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-28	Urinary Bladder Cancer	22330141	urinary system disease	DOID:11054	C67	D001749	109800		Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations.
tissue_expression_ns	hsa-mir-31	Urinary Bladder Cancer	24439061	urinary system disease	DOID:11054	C67	D001749	109800		The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer.
tissue_expression_ns	hsa-mir-328	Urinary Bladder Cancer	22644299	urinary system disease	DOID:11054	C67	D001749	109800		differential expression in urinary samples
tissue_expression_ns	hsa-mir-338	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-345	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-34a	Urinary Bladder Cancer	23749909	urinary system disease	DOID:11054	C67	D001749	109800		altered expression
tissue_expression_ns	hsa-mir-34b	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-34c	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-424	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-452	Urinary Bladder Cancer	22426337	urinary system disease	DOID:11054	C67	D001749	109800		miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer.
tissue_expression_ns	hsa-mir-512-1	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-512-2	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-518a-1	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-518a-2	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-708	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-9-1	Urinary Bladder Cancer	22330141	urinary system disease	DOID:11054	C67	D001749	109800		Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations.
tissue_expression_ns	hsa-mir-9-1	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-9-2	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-9-3	Urinary Bladder Cancer	22801550	urinary system disease	DOID:11054	C67	D001749	109800		differentially expressed
tissue_expression_ns	hsa-mir-99a	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-99b	Urinary Bladder Cancer	21133599	urinary system disease	DOID:11054	C67	D001749	109800		dysregulated
tissue_expression_ns	hsa-mir-142	Uterine Corpus Endometrial Carcinoma	29567372	disease of cellular proliferation	DOID:0050939					A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma.
tissue_expression_ns	hsa-mir-146a	Uterine Corpus Endometrial Carcinoma	29567372	disease of cellular proliferation	DOID:0050939					A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma.
tissue_expression_ns	hsa-mir-15a	Uterine Corpus Endometrial Carcinoma	29567372	disease of cellular proliferation	DOID:0050939					A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma.
tissue_expression_ns	hsa-mir-1976	Uterine Corpus Endometrial Carcinoma	29567372	disease of cellular proliferation	DOID:0050939					A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma.
tissue_expression_ns	hsa-mir-3170	Uterine Corpus Endometrial Carcinoma	29567372	disease of cellular proliferation	DOID:0050939					A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma.
tissue_expression_ns	hsa-mir-200c	Uterine Corpus Myxoid Leiomyosarcoma	26307392	disease of cellular proliferation	DOID:6567					Malignant tumors of the uterine corpus: molecular background of their origin.
tissue_expression_ns	hsa-mir-21	Uterine Corpus Serous Adenocarcinoma	24748979	disease of cellular proliferation	DOID:5750					microRNA expression patterns across seven cancers are highly correlated and dominated by evolutionarily ancient families.
tissue_expression_ns	hsa-mir-146a	Uveal Melanoma	27565163				C536494	155720	HP:0007716	Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells.
tissue_expression_ns	hsa-mir-122	Varicella	24759212	disease by infectious agent	DOID:8659	B01	D002644			Dysregulated microRNA expression in serum of non-vaccinated children with varicella.
tissue_expression_ns	hsa-mir-132	Varicella	24759212	disease by infectious agent	DOID:8659	B01	D002644			Dysregulated microRNA expression in serum of non-vaccinated children with varicella.
tissue_expression_ns	hsa-mir-197	Varicella	24759212	disease by infectious agent	DOID:8659	B01	D002644			Dysregulated microRNA expression in serum of non-vaccinated children with varicella.
tissue_expression_ns	hsa-mir-363	Varicella	24759212	disease by infectious agent	DOID:8659	B01	D002644			Dysregulated microRNA expression in serum of non-vaccinated children with varicella.
tissue_expression_ns	hsa-mir-629	Varicella	24759212	disease by infectious agent	DOID:8659	B01	D002644			Dysregulated microRNA expression in serum of non-vaccinated children with varicella.
tissue_expression_ns	hsa-mir-126	Vascular Disease [unspecific]	28082910	cardiovascular system disease	DOID:178	I72.9	D000783			Acute Effects of Different Exercise Protocols on the Circulating Vascular microRNAs -16, -21, and -126 in Trained Subjects.
tissue_expression_ns	hsa-mir-143	Vascular Disease [unspecific]	24166492	cardiovascular system disease	DOID:178	I72.9	D000783			The flank sequences of miR-145 and miR-143 play a critical role in their aberrant expression in VSMCs and vascular walls. The genetically engineered smart miRNAs based on their flank sequences may have broadly therapeutic applications for many vascular diseases.
tissue_expression_ns	hsa-mir-145	Vascular Disease [unspecific]	24166492	cardiovascular system disease	DOID:178	I72.9	D000783			The flank sequences of miR-145 and miR-143 play a critical role in their aberrant expression in VSMCs and vascular walls. The genetically engineered smart miRNAs based on their flank sequences may have broadly therapeutic applications for many vascular diseases.
tissue_expression_ns	hsa-mir-16	Vascular Disease [unspecific]	28082910	cardiovascular system disease	DOID:178	I72.9	D000783			Acute Effects of Different Exercise Protocols on the Circulating Vascular microRNAs -16, -21, and -126 in Trained Subjects.
tissue_expression_ns	hsa-mir-21	Vascular Disease [unspecific]	28082910	cardiovascular system disease	DOID:178	I72.9	D000783			Acute Effects of Different Exercise Protocols on the Circulating Vascular microRNAs -16, -21, and -126 in Trained Subjects.
tissue_expression_ns	hsa-mir-1	Vascular Hypertrophy	27831640							Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4.
tissue_expression_ns	hsa-mir-133	Vascular Hypertrophy	20015039							Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias.
tissue_expression_ns	hsa-mir-206	Vascular Hypertrophy	23842077							 miR-206 was depressed in the hypertrophied RV of Hx rats but was increased in growth-retarded SM.
tissue_expression_ns	hsa-mir-208	Vascular Hypertrophy	20015039							Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias.
tissue_expression_ns	hsa-mir-21	Viral Myocarditis	23544605			B33.2	D009205			Myocardial miR-21 expression was negatively related to viral myocarditis severity.
tissue_expression_ns	hsa-mir-146a	Vogt-Koyanagi-Harada Disease	26818976	immune system disease	DOID:12297	H20.82	D014607			CNVs of miR-146a, miR-23a and miR-301a confer susceptibility to VKH syndrome, but not to BD.
tissue_expression_ns	hsa-mir-103a	Vulvar Squamous Tumor	29299981	disease of cellular proliferation	DOID:2072					Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples
tissue_expression_ns	hsa-mir-16	Vulvar Squamous Tumor	29299981	disease of cellular proliferation	DOID:2072					Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples
tissue_expression_ns	hsa-mir-191	Vulvar Squamous Tumor	29299981	disease of cellular proliferation	DOID:2072					Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples
tissue_expression_ns	hsa-mir-423	Vulvar Squamous Tumor	29299981	disease of cellular proliferation	DOID:2072					Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples
tissue_expression_ns	hsa-mir-425	Vulvar Squamous Tumor	29299981	disease of cellular proliferation	DOID:2072					Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples
tissue_expression_ns	hsa-mir-93	Vulvar Squamous Tumor	29299981	disease of cellular proliferation	DOID:2072					Expression levels of six microRNAs-hsa-miR-425-5p, hsa-miR-191-5p, hsa-miR-93-5p, hsa-miR-423-5p, hsa-miR-103a-3p, and hsa-miR-16-5p-were analyzed by quantitative reverse transcription polymerase chain reaction in plasma samples
tissue_expression_ns	hsa-mir-205	Wounds and Injuries [unspecific]	23861701				D014947			we predicted that topical treatment of shikonin in vivo affects epithelial-mesenchymal transition (EMT) and the expression of related microRNAs, including 200a, 200b, 200c, 141, 205, and 429 microRNAs, in mouse skin tissues.
tissue_expression_up	hsa-mir-1224	Acute Kidney Failure	24695114	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	Ischemia-reperfusion caused highly reproducible, progressive, concordant elevation of miR-714, miR-1188, miR-1897-3p, miR-877*, and miR-1224 in plasma and kidneys at 3, 6 and 24 hours after acute kidney injury compared to the sham-operated mice (n鈥?鈥?).
tissue_expression_up	hsa-mir-21	Acute Kidney Failure	26577279	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	A set of microRNAs was differentially expressed after renal damage, among them miR-21, which was up-regulated.
tissue_expression_up	hsa-mir-16-1	Acute Lung Injury	22940131			S27	D055371			miR-16 upregulates ENaC, a major sodium channel involved in resolution of pulmonary edema in acute lung injury.
tissue_expression_up	hsa-mir-16-2	Acute Lung Injury	22940131			S27	D055371			miR-16 upregulates ENaC, a major sodium channel involved in resolution of pulmonary edema in acute lung injury.
tissue_expression_up	hsa-mir-21	Acute Lung Injury	24736893			S27	D055371			miR-21 was upregulated in the OA group throughout the 24 h following OA challenge.
tissue_expression_up	hsa-mir-1	Acute Myocardial Infarction	26046358	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination.
tissue_expression_up	hsa-mir-208b	Acute Myocardial Infarction	26046358	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	This study highlights the stability of miRNAs after death and long-term fixation, validating their use as reliable biomarkers for AMI during postmortem examination.
tissue_expression_up	hsa-mir-29a	Acute Pancreatitis	27239114	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	The expression of miR-29a was much higher in the AEP group compared with the control group
tissue_expression_up	hsa-mir-125b	Acute Peritonitis	28074870	gastrointestinal system disease	DOID:8283	K65.0	D010538		HP:0002586	MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis.
tissue_expression_up	hsa-mir-107	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -322b (downregulated)
tissue_expression_up	hsa-mir-143	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -321b (downregulated)
tissue_expression_up	hsa-mir-145	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -320b (downregulated)
tissue_expression_up	hsa-mir-16	Adenocarcinoma, Colon	27930363	disease of cellular proliferation	DOID:234	C18			HP:0040276	Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients.
tissue_expression_up	hsa-mir-194	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -323b (downregulated)
tissue_expression_up	hsa-mir-21	Adenocarcinoma, Colon	19672269	disease of cellular proliferation	DOID:234	C18			HP:0040276	expression Increased
tissue_expression_up	hsa-mir-24	Adenocarcinoma, Colon	27939727	disease of cellular proliferation	DOID:234	C18			HP:0040276	Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma.
tissue_expression_up	hsa-mir-26a	Adenocarcinoma, Colon	27658891	disease of cellular proliferation	DOID:234	C18			HP:0040276	the top most upregulated and downregulated miRNAs in HPNM included miR-145, -143, -107, -194, and -26a (upregulated), and miR-663, -1268, -320b, -1275, and -324b (downregulated)
tissue_expression_up	hsa-mir-103a-1	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-103: upregulated
tissue_expression_up	hsa-mir-103a-2	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-103: upregulated
tissue_expression_up	hsa-mir-106a	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-106a: upregulated
tissue_expression_up	hsa-mir-151a	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-151: upregulated
tissue_expression_up	hsa-mir-155	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-155: upregulated
tissue_expression_up	hsa-mir-182	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-182: upregulated
tissue_expression_up	hsa-mir-183	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-183: upregulated
tissue_expression_up	hsa-mir-194-1	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-194: upregulated
tissue_expression_up	hsa-mir-194-2	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-194: upregulated
tissue_expression_up	hsa-mir-200a	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-200a: upregulated
tissue_expression_up	hsa-mir-200a	Adenocarcinoma, Endometrial	19891660	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	up-regulated
tissue_expression_up	hsa-mir-200b	Adenocarcinoma, Endometrial	19891660	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	up-regulated
tissue_expression_up	hsa-mir-200c	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-200c: upregulated
tissue_expression_up	hsa-mir-203	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-203: upregulated
tissue_expression_up	hsa-mir-205	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-205: upregulated
tissue_expression_up	hsa-mir-205	Adenocarcinoma, Endometrial	19077565	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-205: upregulated
tissue_expression_up	hsa-mir-205	Adenocarcinoma, Endometrial	19891660	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	up-regulated
tissue_expression_up	hsa-mir-210	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-210: upregulated
tissue_expression_up	hsa-mir-223	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-223: upregulated
tissue_expression_up	hsa-mir-429	Adenocarcinoma, Endometrial	19077565	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-429: upregulated
tissue_expression_up	hsa-mir-449a	Adenocarcinoma, Endometrial	19077565	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-449: upregulated
tissue_expression_up	hsa-mir-449b	Adenocarcinoma, Endometrial	19077565	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-449: upregulated
tissue_expression_up	hsa-mir-95	Adenocarcinoma, Endometrial	19065659	reproductive system disease	DOID:2870	C54.1	D018269	608089	HP:0012114	miR-95: upregulated
tissue_expression_up	hsa-mir-143	Adenocarcinoma, Esophageal	20301167	disease of cellular proliferation	DOID:4914		C562730	133239		upregulated
tissue_expression_up	hsa-mir-145	Adenocarcinoma, Esophageal	20301167	disease of cellular proliferation	DOID:4914		C562730	133239		upregulated
tissue_expression_up	hsa-mir-192	Adenocarcinoma, Esophageal	23724052	disease of cellular proliferation	DOID:4914		C562730	133239		6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC
tissue_expression_up	hsa-mir-194	Adenocarcinoma, Esophageal	23724052	disease of cellular proliferation	DOID:4914		C562730	133239		6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC
tissue_expression_up	hsa-mir-200a	Adenocarcinoma, Esophageal	23724052	disease of cellular proliferation	DOID:4914		C562730	133239		6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC
tissue_expression_up	hsa-mir-203	Adenocarcinoma, Esophageal	20301167	disease of cellular proliferation	DOID:4914		C562730	133239		miR-203:Levels of miR-203 and miR-205 were high in normal squamous epithelium and low in columnar epithelia
tissue_expression_up	hsa-mir-203	Adenocarcinoma, Esophageal	23724052	disease of cellular proliferation	DOID:4914		C562730	133239		6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC
tissue_expression_up	hsa-mir-205	Adenocarcinoma, Esophageal	20301167	disease of cellular proliferation	DOID:4914		C562730	133239		miR-205:Levels of miR-203 and miR-205 were high in normal squamous epithelium and low in columnar epithelia
tissue_expression_up	hsa-mir-205	Adenocarcinoma, Esophageal	23724052	disease of cellular proliferation	DOID:4914		C562730	133239		6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC
tissue_expression_up	hsa-mir-21	Adenocarcinoma, Esophageal	20301167	disease of cellular proliferation	DOID:4914		C562730	133239		upregulated
tissue_expression_up	hsa-mir-21	Adenocarcinoma, Esophageal	25950983	disease of cellular proliferation	DOID:4914		C562730	133239		microRNA-21 expression is elevated in esophageal adenocarcinoma after neoadjuvant chemotherapy.
tissue_expression_up	hsa-mir-21	Adenocarcinoma, Esophageal	25746664	disease of cellular proliferation	DOID:4914		C562730	133239		miRs such as miR-192, miR-196 and miR-21 were frequently noted to up-regulated whereas miR-203, miR-205 and miR-let-7 were commonly down-regulated during the development of Barrett's oesophagus to oesophageal adenocarcinoma.
tissue_expression_up	hsa-mir-210	Adenocarcinoma, Esophageal	28968550	disease of cellular proliferation	DOID:4914		C562730	133239		Expression levels of miR-25 and miR-210 were significantly higher, and  those of PTEN and AIFM3 significantly lower
tissue_expression_up	hsa-mir-215	Adenocarcinoma, Esophageal	20301167	disease of cellular proliferation	DOID:4914		C562730	133239		upregulated
tissue_expression_up	hsa-mir-221	Adenocarcinoma, Esophageal	27501171	disease of cellular proliferation	DOID:4914		C562730	133239		MiR-221 was overexpressed in 5-FU resistant EC cell lines as well as in  human EAC tissue.
tissue_expression_up	hsa-mir-25	Adenocarcinoma, Esophageal	28968550	disease of cellular proliferation	DOID:4914		C562730	133239		Expression levels of miR-25 and miR-210 were significantly higher, and  those of PTEN and AIFM3 significantly lower
tissue_expression_up	hsa-mir-31	Adenocarcinoma, Esophageal	23724052	disease of cellular proliferation	DOID:4914		C562730	133239		6 miRNAs (up-regulated: miR-194, miR-31, miR-192, and miR-200a; down-regulated: miR-203 and miR-205) in EAC
tissue_expression_up	hsa-mir-183	Adenocarcinoma, Lung	24805982	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers.
tissue_expression_up	hsa-mir-183	Adenocarcinoma, Lung	26170125	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	down-regulation of miR-34c and up-regulation of miR-183 and miR-210 were identified in caner groups
tissue_expression_up	hsa-mir-200c	Adenocarcinoma, Lung	20864637	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-200c:Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas
tissue_expression_up	hsa-mir-210	Adenocarcinoma, Lung	26170125	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	down-regulation of miR-34c and up-regulation of miR-183 and miR-210 were identified in caner groups
tissue_expression_up	hsa-mir-218	Adenocarcinoma, Lung	24705471	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells.
tissue_expression_up	hsa-mir-26b	Adenocarcinoma, Lung	24815696	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p.
tissue_expression_up	hsa-mir-196	Adenocarcinoma, Pancreatic Ductal	27267055	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The expressions of all microRNAs were 1.4-3.7 times higher (significantly) in the PAC group compared to non-cancer patients.
tissue_expression_up	hsa-mir-200	Adenocarcinoma, Pancreatic Ductal	27267055	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		The expressions of all microRNAs were 1.4-3.7 times higher (significantly) in the PAC group compared to non-cancer patients.
tissue_expression_up	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	21757972	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Elevated microRNA miR-21 Levels in Pancreatic Cyst Fluid Are Predictive of Mucinous Precursor Lesions of Ductal Adenocarcinoma.
tissue_expression_up	hsa-mir-506	Adenocarcinoma, Pancreatic Ductal	27371108	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		miR-506 expression was higher in PDAC
tissue_expression_up	hsa-mir-181a	Adenosquamous Pancreas Carcinoma	29221165	disease of cellular proliferation	DOID:5637					Furthermore, lower Ang-1 and Tie-2 transcript levels and higher increases of miR-21-5p, miR27a-3p and miR-181a-5p levels were found in the rarest form of pancreatic carcinoma.
tissue_expression_up	hsa-mir-21	Adenosquamous Pancreas Carcinoma	29221165	disease of cellular proliferation	DOID:5637					Furthermore, lower Ang-1 and Tie-2 transcript levels and higher increases of miR-21-5p, miR27a-3p and miR-181a-5p levels were found in the rarest form of pancreatic carcinoma.
tissue_expression_up	hsa-mir-27a	Adenosquamous Pancreas Carcinoma	29221165	disease of cellular proliferation	DOID:5637					Furthermore, lower Ang-1 and Tie-2 transcript levels and higher increases of miR-21-5p, miR27a-3p and miR-181a-5p levels were found in the rarest form of pancreatic carcinoma.
tissue_expression_up	hsa-mir-1246	Adenovirus Infection	20634878			B34.0	D000257			miR-1246:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1247	Adenovirus Infection	20634878			B34.0	D000257			miR-1247:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1273a	Adenovirus Infection	20634878			B34.0	D000257			miR-1273:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1302-1	Adenovirus Infection	20634878			B34.0	D000257			miR-1302-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1302-2	Adenovirus Infection	20634878			B34.0	D000257			miR-1302-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1302-3	Adenovirus Infection	20634878			B34.0	D000257			miR-1302-3:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1302-4	Adenovirus Infection	20634878			B34.0	D000257			miR-1302-4:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1302-5	Adenovirus Infection	20634878			B34.0	D000257			miR-1302-5:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1302-6	Adenovirus Infection	20634878			B34.0	D000257			miR-1302-6:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1302-7	Adenovirus Infection	20634878			B34.0	D000257			miR-1302-7:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-1302-8	Adenovirus Infection	20634878			B34.0	D000257			miR-1302-8:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-146b	Adenovirus Infection	20634878			B34.0	D000257			miR-146b:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-150	Adenovirus Infection	20634878			B34.0	D000257			miR-150:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-17	Adenovirus Infection	20634878			B34.0	D000257			miR-17:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-181b	Adenovirus Infection	25744056			B34.0	D000257			The expression patterns of these miRNAs changed dramatically during the course of the infection
tissue_expression_up	hsa-mir-18a	Adenovirus Infection	20634878			B34.0	D000257			miR-18a:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-191	Adenovirus Infection	20634878			B34.0	D000257			miR-191:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-191	Adenovirus Infection	25744056			B34.0	D000257			The expression patterns of these miRNAs changed dramatically during the course of the infection
tissue_expression_up	hsa-mir-1972-1	Adenovirus Infection	20634878			B34.0	D000257			miR-1972:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-320c-2	Adenovirus Infection	20634878			B34.0	D000257			miR-320c-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-324	Adenovirus Infection	20634878			B34.0	D000257			miR-324:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-342	Adenovirus Infection	20634878			B34.0	D000257			miR-342:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-345	Adenovirus Infection	20634878			B34.0	D000257			miR-345:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-378a	Adenovirus Infection	20634878			B34.0	D000257			miR-378:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-454	Adenovirus Infection	20634878			B34.0	D000257			miR-454:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-505	Adenovirus Infection	20634878			B34.0	D000257			miR-505:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-566	Adenovirus Infection	20634878			B34.0	D000257			miR-566:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-589	Adenovirus Infection	20634878			B34.0	D000257			miR-589:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-627	Adenovirus Infection	20634878			B34.0	D000257			miR-627:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-635	Adenovirus Infection	20634878			B34.0	D000257			miR-635:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-7-1	Adenovirus Infection	20634878			B34.0	D000257			miR-7-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-7-2	Adenovirus Infection	20634878			B34.0	D000257			miR-7-2:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-7-3	Adenovirus Infection	20634878			B34.0	D000257			miR-7-3:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-744	Adenovirus Infection	20634878			B34.0	D000257			miR-744:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-92a-1	Adenovirus Infection	20634878			B34.0	D000257			miR-92a-1:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-942	Adenovirus Infection	20634878			B34.0	D000257			miR-942:A total of 44 miRNAs demonstrated high expression and 36 miRNAs showed lower expression in the AD3 infected cells than control
tissue_expression_up	hsa-mir-210	Adrenal Cortex Neoplasms	19546168	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	significantly higher expressed
tissue_expression_up	hsa-mir-210	Adrenal Cortex Neoplasms	19849700	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	up-regulated
tissue_expression_up	hsa-mir-484	Adrenal Cortex Neoplasms	19849700	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	up-regulated
tissue_expression_up	hsa-mir-503	Adrenal Cortex Neoplasms	19546168	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	significantly higher expressed
tissue_expression_up	hsa-mir-467d	Alcoholic Cardiomyopathy	29734191			I42.6	D002310			The results demonstrated that miR-467d-3p and miR-491-5p were up-regulated and miR-3098-3p was down-regulated in the alcohol-exposed myocardial samples compared with the control samples (P < 0.05).
tissue_expression_up	hsa-mir-491	Alcoholic Cardiomyopathy	29734191			I42.6	D002310			The results demonstrated that miR-467d-3p and miR-491-5p were up-regulated and miR-3098-3p was down-regulated in the alcohol-exposed myocardial samples compared with the control samples (P < 0.05).
tissue_expression_up	hsa-mir-182	Alcoholic Hepatitis	27196584	endocrine system disease	DOID:12351	K70.1	D006519			miR-182 was the most highly expressed miRNA in AH
tissue_expression_up	hsa-mir-143	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-155	Allergic Rhinitis	23704072	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Subjects with current allergic rhinitis symptoms had increased levels of miR-155, miR-205, and miR-498, but reduced levels of let-7e.
tissue_expression_up	hsa-mir-187	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-205	Allergic Rhinitis	23704072	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Subjects with current allergic rhinitis symptoms had increased levels of miR-155, miR-205, and miR-498, but reduced levels of let-7e.
tissue_expression_up	hsa-mir-498	Allergic Rhinitis	23704072	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Subjects with current allergic rhinitis symptoms had increased levels of miR-155, miR-205, and miR-498, but reduced levels of let-7e.
tissue_expression_up	hsa-mir-498	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-874	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-886	Allergic Rhinitis	24513959	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-7-1	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		up-regulated
tissue_expression_up	hsa-mir-7-2	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		up-regulated
tissue_expression_up	hsa-mir-7-3	Allergic Rhinitis,Perennial	22185732			J30.89	D012221	607154		up-regulated
tissue_expression_up	hsa-mir-106a	Alopecia	21967250	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	We detected the significant upregulation of miR-221, miR-125b, miR-106a and miR-410 in balding papilla cells.
tissue_expression_up	hsa-mir-125b	Alopecia	21967250	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	We detected the significant upregulation of miR-221, miR-125b, miR-106a and miR-410 in balding papilla cells.
tissue_expression_up	hsa-mir-221	Alopecia	21967250	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	We detected the significant upregulation of miR-221, miR-125b, miR-106a and miR-410 in balding papilla cells.
tissue_expression_up	hsa-mir-410	Alopecia	21967250	integumentary system disease	DOID:987	L65.9	D000505	300042	HP:0001596	We detected the significant upregulation of miR-221, miR-125b, miR-106a and miR-410 in balding papilla cells.
tissue_expression_up	hsa-mir-148a	Alzheimer Disease	21834602	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	upregulated in bone marrow plasma cells from patients with immunoglobulin light chain (AL) amyloidosis compared with controls.
tissue_expression_up	hsa-mir-16-2	Alzheimer Disease	21834602	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	upregulated in bone marrow plasma cells from patients with immunoglobulin light chain (AL) amyloidosis compared with controls.
tissue_expression_up	hsa-mir-206	Alzheimer Disease	24604632	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We now report that miR-206 is upregulated in the hippocampal tissue, cerebrospinal fluid, and plasma of embryonic APP/PS1 transgenic mice.
tissue_expression_up	hsa-mir-21	Alzheimer Disease	19683563	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	up-regulated,  inhibits bcl2 translation
tissue_expression_up	hsa-mir-26a-1	Alzheimer Disease	21834602	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	upregulated in bone marrow plasma cells from patients with immunoglobulin light chain (AL) amyloidosis compared with controls.
tissue_expression_up	hsa-mir-26a-2	Alzheimer Disease	21834602	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	upregulated in bone marrow plasma cells from patients with immunoglobulin light chain (AL) amyloidosis compared with controls.
tissue_expression_up	hsa-mir-26b	Alzheimer Disease	24027266	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry,tau-phosphorylation, and apoptosis in postmitotic neurons.
tissue_expression_up	hsa-mir-34a	Alzheimer Disease	27235866	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	miR-34a over expression in patient's tissue
tissue_expression_up	hsa-mir-34c	Alzheimer Disease	21946562	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The authors identify miR-34c as a negative constraint of memory consolidation and show that miR-34c levels are elevated in the hippocampus of AD patients and corresponding mouse models.
tissue_expression_up	hsa-mir-34c	Alzheimer Disease	25052764	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	We have used an  in vivo neonatal mouse model to induce ketamine-related neurotoxicity in the hippocampus, and found that miR-34c, a microRNA associated with pathogenesis of Alzheimer's disease, was significantly upregulated during ketamine-induced hippocampal neurodegeneration.
tissue_expression_up	hsa-mir-125b	Amyotrophic Lateral Sclerosis	24336079	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We identified upregulation of selected immune-enriched miRNAs, recognizing miR-22, miR-155, miR-125b and miR-146b among the most highly modulated.
tissue_expression_up	hsa-mir-146b	Amyotrophic Lateral Sclerosis	24336079	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We identified upregulation of selected immune-enriched miRNAs, recognizing miR-22, miR-155, miR-125b and miR-146b among the most highly modulated.
tissue_expression_up	hsa-mir-132	Aneurysmal Subarachnoid Hemorrhage	26675167			I60	D013345		HP:0002138	Our study demonstrated that as compared to healthy control, miR-132 and miR-324 showed a upregulation in both SAH DCI and Non-DCI groups. However,the differences between the SAH DCI and non-DCI groups were not statistically significant.
tissue_expression_up	hsa-mir-324	Aneurysmal Subarachnoid Hemorrhage	26675167			I60	D013345		HP:0002138	Our study demonstrated that as compared to healthy control, miR-132 and miR-324 showed a upregulation in both SAH DCI and Non-DCI groups. However,the differences between the SAH DCI and non-DCI groups were not statistically significant.
tissue_expression_up	hsa-let-7i	Ankylosing Spondylitis	23607629	musculoskeletal system disease	DOID:7147	M45.9	D013167			In the functional studies, the increased let-7i expression facilitated the T helper type 1 (IFN-γ) immune response in T cells.
tissue_expression_up	hsa-mir-145	Aortic Aneurysm	25465469	cardiovascular system disease	DOID:3627	I71	D001014	100070	HP:0004942	The increased expression of microRNA-145 promotes media remodeling through TGF-b1 in the aortic aneurysm wall.
tissue_expression_up	hsa-mir-124a	Aortic Aneurysm, Abdominal	23316282	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. 
tissue_expression_up	hsa-mir-126	Aortic Aneurysm, Abdominal	23316282	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. 
tissue_expression_up	hsa-mir-146a	Aortic Aneurysm, Abdominal	23316282	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. 
tissue_expression_up	hsa-mir-155	Aortic Aneurysm, Abdominal	23316282	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. 
tissue_expression_up	hsa-mir-223	Aortic Aneurysm, Abdominal	23316282	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. 
tissue_expression_up	hsa-mir-29b	Aortic Aneurysm, Abdominal	23316282	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		MicroRNAs related to fibrosis (miR-29b),inflammation (miR-124a, miR-146a, miR-155, and miR-223), and endothelium(miR-126, let-7 family members, and miR-21) were significantly upregulated in AAA tissue. 
tissue_expression_up	hsa-mir-126	Asthma	21605405	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	upregulated compared with normal control
tissue_expression_up	hsa-mir-126	Asthma	24615202	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	In mice models of asthma it has been found that increased levels of miR-21 and miR-126
tissue_expression_up	hsa-mir-126	Asthma	24995087	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Compared to the normal group, miR-21 and miR-126 expression was significantly upregulated in asthma patients regardless of treatment.
tissue_expression_up	hsa-mir-126	Asthma	27247924	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Elevated levels of miRNA-126, IL-13 mRNA and pathological changes were observed in the sensitized group compared to the control group
tissue_expression_up	hsa-mir-143	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-15a	Asthma	25979194	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	miRNA regulation network demonstrated that miR-16 and miR-15a had higher degree.
tissue_expression_up	hsa-mir-16	Asthma	25979194	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	miRNA regulation network demonstrated that miR-16 and miR-15a had higher degree.
tissue_expression_up	hsa-mir-187	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-221	Asthma	22895815	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Upregulation of miRNA-221 and miRNA-485-3p in pediatric asthma.
tissue_expression_up	hsa-mir-485	Asthma	22895815	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Upregulation of miRNA-221 and miRNA-485-3p in pediatric asthma.
tissue_expression_up	hsa-mir-498	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-874	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-886	Asthma	24513959	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Downregulation of miR-18a, miR-126, let-7e, miR-155, and miR-224 and upregulation of miR-498, miR-187, miR-874, miR-143, and miR-886-3p were observed in asthmatic  patients in comparison to controls. The differences in miRNA expression were mainly similar in asthmatics with and without AR.
tissue_expression_up	hsa-mir-15a	Astrocytoma	26813564	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases
tissue_expression_up	hsa-mir-195	Astrocytoma	20976148	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	The observation that miR-34a and miR-195 levels were increased in the RISC of U-87 astrocytoma cells suggests an oncogenic role for these miRNAs.
tissue_expression_up	hsa-mir-21	Astrocytoma	19159078	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-21: upregulation
tissue_expression_up	hsa-mir-21	Astrocytoma	20219352	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-21:hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma
tissue_expression_up	hsa-mir-21	Astrocytoma	20711171	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.
tissue_expression_up	hsa-mir-221	Astrocytoma	19159078	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-221: upregulation
tissue_expression_up	hsa-mir-23a	Astrocytoma	20711171	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	Inhibition of two glioblastoma-upregulated miRNAs (miR-21 and miR-23a) and exogenous overexpression of two glioblastoma-downregulated miRNAs (miR-218 and miR-219-5p) resulted in reduced soft agar colony formation but showed varying effects on cell proliferation and chemosensitivity.
tissue_expression_up	hsa-mir-24	Astrocytoma	26813564	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases
tissue_expression_up	hsa-mir-34a	Astrocytoma	20976148	disease of cellular proliferation	DOID:3069	C72.9	D001254	155755	HP:0009592	The observation that miR-34a and miR-195 levels were increased in the RISC of U-87 astrocytoma cells suggests an oncogenic role for these miRNAs.
tissue_expression_up	hsa-mir-126	Atherosclerosis	27288564	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels.
tissue_expression_up	hsa-mir-142	Atherosclerosis	25586666	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	the upregulation of miR-142-5p expression may regulate apoptosis in human macrophages by targeting TGF-β2. This effect may have an important role in the progression of atherosclerosis.
tissue_expression_up	hsa-mir-146b	Atherosclerosis	25743474	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Aa challenge significantly increased the expression of miR-146b and miR-155 in the aorta.
tissue_expression_up	hsa-mir-155	Atherosclerosis	25872580	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	our data demonstrate that miR-155 is significantly upregulated in atherosclerotic plaque, functioning to accelerate the proliferation and migration of VSMCs by targeting eNOS.
tissue_expression_up	hsa-mir-155	Atherosclerosis	29642385	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Exposure to the high dose of CS also significantly upregulated the miRNA-155 level in the aortic tissues of ApoE KO mice
tissue_expression_up	hsa-mir-21	Atherosclerosis	27288564	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels.
tissue_expression_up	hsa-mir-21	Atherosclerosis	29642385	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant
tissue_expression_up	hsa-mir-221	Atherosclerosis	27288564	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels.
tissue_expression_up	hsa-mir-222	Atherosclerosis	27288564	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels.
tissue_expression_up	hsa-mir-223	Atherosclerosis	26492242	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	an obvious increase  of miR-223 was observed in aortic atherosclerotic lesions.
tissue_expression_up	hsa-mir-31	Atherosclerosis	27288564	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Aroclor 1260 increased miR-21, miR-31, miR-126, miR-221 and miR-222 expression levels.
tissue_expression_up	hsa-mir-142	Atopic Dermatitis	22594804	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	In humans sensitized with DPCP, we found significant upregulation of miR-21, miR-142-3p, miR-142-5p and miR-223 in challenged skin.
tissue_expression_up	hsa-mir-21	Atopic Dermatitis	17622355	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	miR-21 was significantly up-regulated both psoriasis (p<0.001) and atopic eczema (p<0.001) as compared with healthy skin.
tissue_expression_up	hsa-mir-21	Atopic Dermatitis	22594804	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	In humans sensitized with DPCP, we found significant upregulation of miR-21, miR-142-3p, miR-142-5p and miR-223 in challenged skin.
tissue_expression_up	hsa-mir-223	Atopic Dermatitis	22594804	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	In humans sensitized with DPCP, we found significant upregulation of miR-21, miR-142-3p, miR-142-5p and miR-223 in challenged skin.
tissue_expression_up	hsa-mir-142	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-146b	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-146b	Atrial Fibrillation	26319023	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Expression of inflammation-associated miRNAs is significantly up-regulated in the left atrial appendage of patients with non-valvular paroxysmal atrial fibrillation, which may play a significant role in electrical and structural remodeling.
tissue_expression_up	hsa-mir-155	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-155	Atrial Fibrillation	26319023	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Expression of inflammation-associated miRNAs is significantly up-regulated in the left atrial appendage of patients with non-valvular paroxysmal atrial fibrillation, which may play a significant role in electrical and structural remodeling.
tissue_expression_up	hsa-mir-193b	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-19a	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-19b	Atrial Fibrillation	26319023	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Expression of inflammation-associated miRNAs is significantly up-regulated in the left atrial appendage of patients with non-valvular paroxysmal atrial fibrillation, which may play a significant role in electrical and structural remodeling.
tissue_expression_up	hsa-mir-19b-1	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-19b-2	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-223	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-328	Atrial Fibrillation	23710743	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	miR-328 expression is significantly increased in patients with AF
tissue_expression_up	hsa-mir-483	Atrial Fibrillation	27422887	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Sixteen microRNAs were differentially expressed in the atrial myocardium of POAF patients when compared with those maintaining sinus rhythm. miR-208a was  the most underexpressed [fold change (FC) = 2.458] and miR-483-5p the most overexpressed (FC = 1.804).
tissue_expression_up	hsa-mir-486	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-519b	Atrial Fibrillation	22944230	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	MiR-155, miR-142-3p, miR-19b, miR-223, miR-146b-5p, miR-486-5p, miR-301b, miR-193b, miR-519b were found to be up-regulated by > 2 folds whereas miR-193a-5p was down-regulated  in left atrial appendage (LAA) in patients with atrial fibrillation.
tissue_expression_up	hsa-mir-125a	Autoimmune Thyroiditis	25863684	immune system disease	DOID:7188	E06.3	D013967	109100		Decreased expression of microRNA-125a-3p upregulates interleukin-23 receptor in patients with Hashimoto's thyroiditis.
tissue_expression_up	hsa-mir-141	Azoospermia	23559187	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p
tissue_expression_up	hsa-mir-429	Azoospermia	23559187	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p
tissue_expression_up	hsa-mir-7-1	Azoospermia	23559187	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p
tissue_expression_up	hsa-mir-7-2	Azoospermia	23559187	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p
tissue_expression_up	hsa-mir-7-3	Azoospermia	23559187	reproductive system disease	DOID:14227	N46.0	D053713		HP:0000027	Genome-wide microRNA expression profiling in idiopathic non-obstructive azoospermia: significant up-regulation of miR-141, miR-429 and miR-7-1-3p
tissue_expression_up	hsa-mir-143	Barrett Esophagus	27374102	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-143, miR-145, miR-194 and miR-215 levels were significantly higher
tissue_expression_up	hsa-mir-192	Barrett Esophagus	22094011	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to adenocarcinoma compared to normal individuals.
tissue_expression_up	hsa-mir-194	Barrett Esophagus	27374102	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-143, miR-145, miR-194 and miR-215 levels were significantly higher
tissue_expression_up	hsa-mir-196a-1	Barrett Esophagus	22094011	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to adenocarcinoma compared to normal individuals.
tissue_expression_up	hsa-mir-196a-2	Barrett Esophagus	22094011	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to adenocarcinoma compared to normal individuals.
tissue_expression_up	hsa-mir-205	Barrett Esophagus	26711784	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	we observed significantly higher levels of miR-205 in tumor tissue of esophageal squamous cell carcinoma
tissue_expression_up	hsa-mir-215	Barrett Esophagus	27374102	gastrointestinal system disease	DOID:9206	K22.7	D001471	614266	HP:0100580	miR-143, miR-145, miR-194 and miR-215 levels were significantly higher
tissue_expression_up	hsa-mir-155	Behcet Disease	27156371	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		The expression of miR-155 and IL-17 was significantly increased in CD4+  T cells of patients with active BD.
tissue_expression_up	hsa-mir-182	Behcet Disease	28482290	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease
tissue_expression_up	hsa-mir-3591	Behcet Disease	28482290	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		up regulation of miR-182 and miR-3591-3p; down regulation of miR-155, miR-638 and miR-4488 in the pathogenesis of the disease
tissue_expression_up	hsa-let-7f-2	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA let-7f-2* was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-let-7i	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA let-7i* was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-105-1	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-105-2	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-141	Biliary Tract Neoplasms	27172928	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	Overexpression of miRNA 141 is an indicator of a poor prognosis in patients with biliary tract cancer
tissue_expression_up	hsa-mir-145	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA miR-145* was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-147b	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-199a-1	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA miR-199a-3p was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-199a-2	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA miR-199a-3p was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-222	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA miR-222* was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-302c	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA miR-302c* was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-9-1	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-9-2	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-9-3	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-942	Biliary Tract Neoplasms	21858175	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	The miRNA was significantly more highly expressed in the malignant group than in the benign group.
tissue_expression_up	hsa-mir-100	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)
tissue_expression_up	hsa-mir-103	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-103-1	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-1233	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-130b	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-135b	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-137	Bladder Neoplasms	25330156			C67	D001749	109800	HP:0009725	MicroRNA-137 upregulation increases bladder cancer cell proliferation and invasion by targeting PAQR3.
tissue_expression_up	hsa-mir-138	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_up	hsa-mir-141	Bladder Neoplasms	25304156			C67	D001749	109800	HP:0009725	Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer.
tissue_expression_up	hsa-mir-141	Bladder Neoplasms	25703910			C67	D001749	109800	HP:0009725	There was a more expression rate of miR-200c, miR-141 and miR-30b in bladder cancer tissues than healthy adjacent control tissues. Further studies are needed to draw final conclusion.
tissue_expression_up	hsa-mir-141	Bladder Neoplasms	25991007			C67	D001749	109800	HP:0009725	The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
tissue_expression_up	hsa-mir-141	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-145	Bladder Neoplasms	26196183			C67	D001749	109800	HP:0009725	The most hypoxia-upregulated miRNA was miR-145.
tissue_expression_up	hsa-mir-146b	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	Except for two miRNAs, miR-146b and miR-9, which were specifically upregulated in MIBC, the majority of miRNAs (n = 13) were deregulated in the same way in the two types of bladder tumors
tissue_expression_up	hsa-mir-15a	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-17	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-182	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)
tissue_expression_up	hsa-mir-182	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_up	hsa-mir-182	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-183	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-185	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-18a	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-190	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-191	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-19a	Bladder Neoplasms	25107371			C67	D001749	109800	HP:0009725	Our data indicated that miR-19a might act as an oncogenic microRNA in bladder cancer and was significantly up-regulated in bladder cancer carcinogenesis. The oncogenic role of miR19a in bladder cancer was dependent on targeting PTEN.
tissue_expression_up	hsa-mir-200b	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	three miRNAs were upregulated (miR-200b, miR-182 and miR-138) and the other 10 miRNAs were downregulated (miR-1, miR-133a, miR-133b, miR-145, miR-143, miR-204, miR-921, miR-1281, miR-199a and miR-199b)
tissue_expression_up	hsa-mir-200b	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-200c	Bladder Neoplasms	25703910			C67	D001749	109800	HP:0009725	There was a more expression rate of miR-200c, miR-141 and miR-30b in bladder cancer tissues than healthy adjacent control tissues. Further studies are needed to draw final conclusion.
tissue_expression_up	hsa-mir-200c	Bladder Neoplasms	25991007			C67	D001749	109800	HP:0009725	The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
tissue_expression_up	hsa-mir-203	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-205	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-21	Bladder Neoplasms	25991007			C67	D001749	109800	HP:0009725	The present meta-analysis identified eight highly significant and consistently dysregulated miRNAs from 19 datasets. We also constructed an eight-miRNA signature which provided predictive and prognostic value that complements traditional clinicopathological risk factors.
tissue_expression_up	hsa-mir-21	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-221	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-222	Bladder Neoplasms	25078265			C67	D001749	109800	HP:0009725	Increased expression of miR-222 is associated with poor prognosis in bladder cancer.
tissue_expression_up	hsa-mir-223	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-23a	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-23b	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-26b	Bladder Neoplasms	17826655			C67	D001749	109800	HP:0009725	Human micro-RNAs miR-223, miR-26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and miR-205 were significantly up-regulated in bladder cancers (P < 0.05) compared to normal bladder mucosa.
tissue_expression_up	hsa-mir-30b	Bladder Neoplasms	25703910			C67	D001749	109800	HP:0009725	There was a more expression rate of miR-200c, miR-141 and miR-30b in bladder cancer tissues than healthy adjacent control tissues. Further studies are needed to draw final conclusion.
tissue_expression_up	hsa-mir-3171	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)
tissue_expression_up	hsa-mir-422b	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-425	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-449b	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-518e	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)
tissue_expression_up	hsa-mir-573	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)
tissue_expression_up	hsa-mir-601	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-639	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-644	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-649	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-708	Bladder Neoplasms	22393979			C67	D001749	109800	HP:0009725	Differential miRNA expression profiles in bladder urothelial carcinomas identified miR-100 down-regulation and miR-708 up-regulation among the most common alterations
tissue_expression_up	hsa-mir-9	Bladder Neoplasms	23169479			C67	D001749	109800	HP:0009725	Except for two miRNAs, miR-146b and miR-9, which were specifically upregulated in MIBC, the majority of miRNAs (n = 13) were deregulated in the same way in the two types of bladder tumors
tissue_expression_up	hsa-mir-93	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-935	Bladder Neoplasms	27350368			C67	D001749	109800	HP:0009725	six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171)
tissue_expression_up	hsa-mir-96	Bladder Neoplasms	23266581			C67	D001749	109800	HP:0009725	Quantitative real-time PCR was applied to measure the levels of 22 microRNAs upregulated in BCA tissue (miR-15a, miR-18a, miR-21, miR-93, miR-96, miR-103, miR-130b, miR-135b, miR-141, miR-182, miR-183, miR-190, miR-191, miR-200b, miR-422b, miR-425, miR-449b, miR-601, miR-639, miR-644, miR-649 and miR-1233) in the marker identification cohort
tissue_expression_up	hsa-mir-21	Breast Ductal Carcinoma	19080492	thoracic disease	DOID:3007	D05.10	D044584			miR-21: expression is significantly higher than the normal controls
tissue_expression_up	hsa-mir-103a-1	Breast Neoplasms	20603000	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-103:In human breast cancer, high levels of miR-103/107 are associated with metastasis and poor outcome
tissue_expression_up	hsa-mir-103a-2	Breast Neoplasms	20603000	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-103:In human breast cancer, high levels of miR-103/107 are associated with metastasis and poor outcome
tissue_expression_up	hsa-mir-106a	Breast Neoplasms	20801493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05).
tissue_expression_up	hsa-mir-107	Breast Neoplasms	20603000	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-107:In human breast cancer, high levels of miR-103/107 are associated with metastasis and poor outcome
tissue_expression_up	hsa-mir-10a	Breast Neoplasms	23968733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.
tissue_expression_up	hsa-mir-10a	Breast Neoplasms	25266482	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These findings indicate that higher expression of RUNX2 and miR-10a/b was associated with adverse outcome of breast cancer. Expression levels of RUNX2 and miR-10a/b individually or jointly are potential prognostic factors for predicting breast cancer recurrence. Data from in vitro studies support the notion that RUNX2 promoted cell motility by upregulating miR-10a/b.
tissue_expression_up	hsa-mir-10a	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)
tissue_expression_up	hsa-mir-10b	Breast Neoplasms	25266482	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These findings indicate that higher expression of RUNX2 and miR-10a/b was associated with adverse outcome of breast cancer. Expression levels of RUNX2 and miR-10a/b individually or jointly are potential prognostic factors for predicting breast cancer recurrence. Data from in vitro studies support the notion that RUNX2 promoted cell motility by upregulating miR-10a/b.
tissue_expression_up	hsa-mir-10b	Breast Neoplasms	22057972	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas.
tissue_expression_up	hsa-mir-10b	Breast Neoplasms	22492962	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions.
tissue_expression_up	hsa-mir-10b	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)
tissue_expression_up	hsa-mir-1-1	Breast Neoplasms	21931769	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ATF-126 and Maspin cDNA induction led to the re-activation of tumor suppressive miRNAs also expressed in neural cells, such as miR-1 and miR-34, and to the down-regulation of potential oncogenic miRNAs, such as miR-10b, miR-124, and miR-363.
tissue_expression_up	hsa-mir-1-2	Breast Neoplasms	21931769	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ATF-126 and Maspin cDNA induction led to the re-activation of tumor suppressive miRNAs also expressed in neural cells, such as miR-1 and miR-34, and to the down-regulation of potential oncogenic miRNAs, such as miR-10b, miR-124, and miR-363.
tissue_expression_up	hsa-mir-125b	Breast Neoplasms	25605244	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR-125b or targeting Sema4C could serve as novel approaches to reverse chemotherapy resistance in breast cancers.
tissue_expression_up	hsa-mir-125b-1	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-125b-1	Breast Neoplasms	22523546	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b was significantly associated with therapeutic response, exhibiting higher expression level in non-responsive patients.
tissue_expression_up	hsa-mir-125b-2	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-125b-2	Breast Neoplasms	22523546	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-125b was significantly associated with therapeutic response, exhibiting higher expression level in non-responsive patients.
tissue_expression_up	hsa-mir-126	Breast Neoplasms	23968733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.
tissue_expression_up	hsa-mir-126	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-127	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-139	Breast Neoplasms	25027758	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.
tissue_expression_up	hsa-mir-143	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-143	Breast Neoplasms	28588724	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1.
tissue_expression_up	hsa-mir-145	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-146a	Breast Neoplasms	16461460	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
tissue_expression_up	hsa-mir-146b	Breast Neoplasms	16461460	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
tissue_expression_up	hsa-mir-146b	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-151a	Breast Neoplasms	22489664	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-151-5p upregulation may suppress metastasis in primary breast tumors.
tissue_expression_up	hsa-mir-151b	Breast Neoplasms	22489664	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-151-5p upregulation may suppress metastasis in primary breast tumors.
tissue_expression_up	hsa-mir-155	Breast Neoplasms	16103053	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	upregulated
tissue_expression_up	hsa-mir-155	Breast Neoplasms	16461460	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
tissue_expression_up	hsa-mir-155	Breast Neoplasms	22105810	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The relative expression of miR-155 was significantly higher in breast cancer tissues than in corresponding nontumor tissues. High miR-155 expression was correlated with higher tumor grade, advanced tumor stage and lymph node metastasis (P=0.012, 0.001, and 0.003, respectively). Kaplan-Meier survival analysis indicated that the disease-free and overall survival rates of high miR-155 group were significantly lower than those of low miR-155 group (P=0.038 and 0.029, respectively). Multivariate analysis showed that high miR-155 expression was a poor prognostic factor (P=0.009). Furthermore, antisense targeting miR-155 could inhibit growth, induce cell arrest in G(0) /G(1) phase, enhance apoptosis, and increase radiosensitivity in breast cancer cells.
tissue_expression_up	hsa-mir-155	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)
tissue_expression_up	hsa-mir-155	Breast Neoplasms	23568502	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	17β-Estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells
tissue_expression_up	hsa-mir-155	Breast Neoplasms	26901459	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiRNA-155 was selected for being overexpressed in breast cancer
tissue_expression_up	hsa-mir-155	Breast Neoplasms	19290006	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221.
tissue_expression_up	hsa-mir-155	Breast Neoplasms	20388420	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression of miR-155 is up-regulated in primary breast cancer, especially in patients with positive estrogen and progesterone receptor.
tissue_expression_up	hsa-mir-155	Breast Neoplasms	20801493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05).
tissue_expression_up	hsa-mir-17	Breast Neoplasms	16461460	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
tissue_expression_up	hsa-mir-181a	Breast Neoplasms	23656790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers, and their expression correlates inversely with ATM levels.
tissue_expression_up	hsa-mir-181a-2	Breast Neoplasms	21271219	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased miR-21 and miR-181a levels were significantly associated with shortened
tissue_expression_up	hsa-mir-181a-2	Breast Neoplasms	23241956	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	TGF-beta upregulates miR-181a expression to promote breast cancer metastasis
tissue_expression_up	hsa-mir-181b	Breast Neoplasms	23656790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We report that miR-181a and miR-181b were overexpressed in more aggressive breast cancers, and their expression correlates inversely with ATM levels.
tissue_expression_up	hsa-mir-181b-1	Breast Neoplasms	16461460	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
tissue_expression_up	hsa-mir-182	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_up	hsa-mir-183	Breast Neoplasms	20331864	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulated in male breast cancer
tissue_expression_up	hsa-mir-183	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_up	hsa-mir-18a	Breast Neoplasms	19624877	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells: mir-18a and mir-195 were highly expressed in MCF-7 cells; target genes of mir-200b were predicted by informatics analysis.
tissue_expression_up	hsa-mir-18a	Breast Neoplasms	19684618	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	higher levels of expression in ERalpha-negative tumors
tissue_expression_up	hsa-mir-18b	Breast Neoplasms	23970382	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-18b is upregulated in breast cancer and modulates genes involved in cell migration.
tissue_expression_up	hsa-mir-190b	Breast Neoplasms	26141719	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study reveals miR-190b as the highest up-regulated miRNA in hormone-dependent breast cancers. Due to its specificity and high expression level, miR-190b could therefore represent a new biomarker in hormone-dependent breast cancers but its exact role carcinogenesis remains to elucidate.
tissue_expression_up	hsa-mir-191	Breast Neoplasms	19290006	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221.
tissue_expression_up	hsa-mir-196a	Breast Neoplasms	26062455	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer.
tissue_expression_up	hsa-mir-196a	Breast Neoplasms	19290006	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221.
tissue_expression_up	hsa-mir-197	Breast Neoplasms	20331864	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulated in male breast cancer
tissue_expression_up	hsa-mir-199a-1	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-199a-2	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR-145, miR-146b-5p, and miR-199a-3p), preferentially expressed in normal basal cells
tissue_expression_up	hsa-mir-200a	Breast Neoplasms	22294488	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer.
tissue_expression_up	hsa-mir-200b	Breast Neoplasms	19624877	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells: mir-18a and mir-195 were highly expressed in MCF-7 cells; target genes of mir-200b were predicted by informatics analysis.
tissue_expression_up	hsa-mir-200b	Breast Neoplasms	22294488	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer.
tissue_expression_up	hsa-mir-200c	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Both miR-200c and miR-429, two members of the miR-200 family were expressed in the luminal and basal type of breast cancer in contrast to malignant myoepithelioma.
tissue_expression_up	hsa-mir-200c	Breast Neoplasms	22294488	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer.
tissue_expression_up	hsa-mir-200c	Breast Neoplasms	23185507	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-200c targets a NF-kB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer
tissue_expression_up	hsa-mir-203	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_up	hsa-mir-204	Breast Neoplasms	18922924	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-204: upregulated
tissue_expression_up	hsa-mir-206	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-206 upregulated in breast cancer (Iorio et al., 2005).
tissue_expression_up	hsa-mir-20a	Breast Neoplasms	29617404	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our results suggest a role for miR-20a in the regulation of breast cancer angiogenesis, and raise the possibility of its use as an angiogenic biomarker
tissue_expression_up	hsa-mir-21	Breast Neoplasms	25027758	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	25337203	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	25440114	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the context of altered miR-21 expression provides clinically relevant information. Importantly, miR-21 expression was predominantly up-regulated and potentially prognostic in the tumor stroma of TNBC.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	16103053	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	upregulation
tissue_expression_up	hsa-mir-21	Breast Neoplasms	16461460	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
tissue_expression_up	hsa-mir-21	Breast Neoplasms	17531469	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-21 is found to be highly expressed in numerous cancers like breast cancer, and glioblastoma and pancreatic cancer.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	19212625	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21: upregulated, The expression levels of miR-21 were correlated with PTEN and commonly used clinicopathologic features of breast cancer
tissue_expression_up	hsa-mir-21	Breast Neoplasms	20331864	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulated in male breast cancer
tissue_expression_up	hsa-mir-21	Breast Neoplasms	21270527	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-210 and miR-221 were significantly overexpressed, whereas miR-10b, miR-145, miR-205, miR-122a were significantly underexpressed in the triple-negative primary breast cancers.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	21271219	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased miR-21 and miR-181a levels were significantly associated with shortened disease-free survival(DFS; p=0.0003, 0.0007) and overall survival (OS; p=0.0351, 0.0443), respectively. Accumulation of miR-21 and miR-181a in bone marrow appears to be associated with prognosis in breast cancer patients. The much higher significant correlation with microRNA levels and prognosis suggests epistatic effects on multiple target genes in the bone marrow of breast cancer patients.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	21326627	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 Expression in Pregnancy-Associated Breast Cancer: A Possible Marker of Poor Prognosis.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	22057972	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	22323912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High miR-21 expression was associated with mastectomy, larger tumor size, higher stage, higher grade, estrogen receptor (ER) negative, human epidermal growth factor receptor 2 (HER2) positive, HER2 positive breast cancer subtype, high Ki-67 expression, and death.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	22492962	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)
tissue_expression_up	hsa-mir-21	Breast Neoplasms	22638884	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	27082076	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	included upregulation of miR-21-5p and the miR-200 family and downregulation of let-7 family members in DCIS samples.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	19290006	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Compared with normal breast samples, a panel of miRs was consistently dysregulated in breast cancer, including earlier-reported breast cancer-related miRs, such as upregulated miR-21, miR-155, miR-191, and miR-196a, and downregulated miR-125b and miR-221.
tissue_expression_up	hsa-mir-21	Breast Neoplasms	20801493	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A high correlation of miRNA expression level was found between breast tumor tissues and sera. MiR-21, miR-106a and miR-155 were significantly over-expressed in the tumor specimens compared with those in normal controls (P < 0.05), whereas miR-126, miR-199a and miR-335 were significantly under-expressed (P < 0.05).
tissue_expression_up	hsa-mir-210	Breast Neoplasms	21270527	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-210 and miR-221 were significantly overexpressed, whereas miR-10b, miR-145, miR-205, miR-122a were significantly underexpressed in the triple-negative primary breast cancers.
tissue_expression_up	hsa-mir-210	Breast Neoplasms	22323552	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High Expression of MicroRNA-210 is an Independent Factor Indicating a Poor Prognosis in Japanese Triple-negative Breast Cancer Patients.
tissue_expression_up	hsa-mir-221	Breast Neoplasms	21270527	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21, miR-210 and miR-221 were significantly overexpressed, whereas miR-10b, miR-145, miR-205, miR-122a were significantly underexpressed in the triple-negative primary breast cancers.
tissue_expression_up	hsa-mir-221	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_up	hsa-mir-223	Breast Neoplasms	19624877	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells: mir-18a and mir-195 were highly expressed in MCF-7 cells; target genes of mir-200b were predicted by informatics analysis.
tissue_expression_up	hsa-mir-223	Breast Neoplasms	21939504	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-223, a miRNA specific for IL-4-activated macrophages, was detected within the exosomes released by macrophages and was significantly elevated in the co-cultivated SKBR3 and MDA-MB-231 cells.
tissue_expression_up	hsa-mir-24	Breast Neoplasms	25120807	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Over-expression of miR-24 and miR-378 in FFPE tissue of breast cancer patients might conduct as an ideal source for biomarker discovery and validation in breast cancer patients.
tissue_expression_up	hsa-mir-29b-1	Breast Neoplasms	16461460	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
tissue_expression_up	hsa-mir-301a	Breast Neoplasms	25311065	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer.
tissue_expression_up	hsa-mir-302f	Breast Neoplasms	24982406	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-337 and miR-302f were commonly overexpressed in HER2-postive breast  and gastric cancer. MiR-139 and miR-129 were commonly underexpressed in HER2-positive breast and gastric cancer.
tissue_expression_up	hsa-mir-31	Breast Neoplasms	22057972	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas.
tissue_expression_up	hsa-mir-31	Breast Neoplasms	22964023	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	We identified 11 dysregulated miRNAs in CAFs: three were up-regulated (miR-221-5p, miR-31-3p, miR-221-3p), while eight were down-regulated (miR-205, miR-200b, miR-200c, miR-141, miR-101,miR-342-3p, let-7g, miR-26b)
tissue_expression_up	hsa-mir-342	Breast Neoplasms	19432961	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-342 expression was highest in ER and HER2/neu-positive luminal B tumours and lowest in triple-negative tumours. MiR-520g expression was elevated in ER and PR-negative tumours.
tissue_expression_up	hsa-mir-34a	Breast Neoplasms	23771315	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of mir-34a.
tissue_expression_up	hsa-mir-34a	Breast Neoplasms	19684618	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	higher levels of expression in ERalpha-negative tumors
tissue_expression_up	hsa-mir-34a	Breast Neoplasms	21931769	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ATF-126 and Maspin cDNA induction led to the re-activation of tumor suppressive miRNAs also expressed in neural cells, such as miR-1 and miR-34, and to the down-regulation of potential oncogenic miRNAs, such as miR-10b, miR-124, and miR-363.
tissue_expression_up	hsa-mir-373	Breast Neoplasms	21271679	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-373 was found to be capable of promoting breast cancer invasion and metastasis
tissue_expression_up	hsa-mir-373	Breast Neoplasms	22524830	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The BC patients showed an up-regulation in miRNAs (mir-155, mir-10,mir-21 and mir-373)
tissue_expression_up	hsa-mir-375	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA was up-regulated during lobular neoplasia progression compared to normal epithelium. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.
tissue_expression_up	hsa-mir-378a	Breast Neoplasms	25120807	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Over-expression of miR-24 and miR-378 in FFPE tissue of breast cancer patients might conduct as an ideal source for biomarker discovery and validation in breast cancer patients.
tissue_expression_up	hsa-mir-425	Breast Neoplasms	21953071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-425-5p was up-regulated during lobular neoplasia progression compared to normal epithelium.
tissue_expression_up	hsa-mir-429	Breast Neoplasms	21409395	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Both miR-200c and miR-429, two members of the miR-200 family were expressed in the luminal and basal type of breast cancer in contrast to malignant myoepithelioma.
tissue_expression_up	hsa-mir-486	Breast Neoplasms	25027758	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.
tissue_expression_up	hsa-mir-493	Breast Neoplasms	20331864	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulated in male breast cancer
tissue_expression_up	hsa-mir-495	Breast Neoplasms	21258409	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1.
tissue_expression_up	hsa-mir-510	Breast Neoplasms	18922924	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-510: upregulated
tissue_expression_up	hsa-mir-519d	Breast Neoplasms	20331864	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulated in male breast cancer
tissue_expression_up	hsa-mir-520g	Breast Neoplasms	19432961	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-342 expression was highest in ER and HER2/neu-positive luminal B tumours and lowest in triple-negative tumours. MiR-520g expression was elevated in ER and PR-negative tumours.
tissue_expression_up	hsa-mir-629	Breast Neoplasms	19946373	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	upregulated
tissue_expression_up	hsa-mir-638	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_up	hsa-mir-663a	Breast Neoplasms	22403704	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Treatment with E2, BPA and DDT decreased (p<0.05) miR-21 expression. Several members of the let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e and let-7f), were downregulated (p<0.05) by all three treatments.and miR-15b (p<0.005) and miR-27b (p<0.01) were also downregulated by the three treatments.upregulation of miR-638 (P<0.005), miR-663 (P<0.005), and miR-1915 (P<0.005) was observed after treatment of MCF7 cells with E2, BPA or DDT
tissue_expression_up	hsa-mir-888	Breast Neoplasms	24480745	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	As a potential role in intercellular adhesiveness and maintenance of malignant tissue architecture, the results indicate that miR-888 is a repressor of the AJ pathway in MCF-7 cells and that up-regulation of miR-888 contributes to aggressiveness in MCF-7 SP cells.
tissue_expression_up	hsa-mir-9-1	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-9 increased in breast cancers (Iorio et al., 2005), but downregulated in lung cancers (Yanaihara et al., 2006)
tissue_expression_up	hsa-mir-9-1	Breast Neoplasms	22294488	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer.
tissue_expression_up	hsa-mir-9-2	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-9 increased in breast cancers (Iorio et al., 2005), but downregulated in lung cancers (Yanaihara et al., 2006)
tissue_expression_up	hsa-mir-9-2	Breast Neoplasms	22294488	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer.
tissue_expression_up	hsa-mir-93	Breast Neoplasms	24606013	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results suggest that overexpression of miR-93 in FFPE tissues may serve as an indispensable source for biomarker discovery and validation in breast cancer patients.
tissue_expression_up	hsa-mir-9-3	Breast Neoplasms	17028596	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	mir-9 increased in breast cancers (Iorio et al., 2005), but downregulated in lung cancers (Yanaihara et al., 2006)
tissue_expression_up	hsa-mir-9-3	Breast Neoplasms	22294488	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer.
tissue_expression_up	hsa-mir-98	Breast Neoplasms	24696733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients.
tissue_expression_up	hsa-mir-663a	Burns	22360957			M61.30	D002056			miR-663 was up-regulated in denatured dermis compared with those in normal skin.
tissue_expression_up	hsa-mir-181d	Carcinoma, Adenoid Cystic	29467480	disease of cellular proliferation	DOID:0080202		D003528			hsa-miR-455-5p and hsa-miR-181d-5p were upregulated in carcinomas of both salivary and lacrimal gland
tissue_expression_up	hsa-mir-20a	Carcinoma, Adenoid Cystic	26293217	disease of cellular proliferation	DOID:0080202		D003528			Increased expression of miR-17 and miR-20a was found in bACCs compared with bNs
tissue_expression_up	hsa-mir-455	Carcinoma, Adenoid Cystic	29467480	disease of cellular proliferation	DOID:0080202		D003528			hsa-miR-455-5p and hsa-miR-181d-5p were upregulated in carcinomas of both salivary and lacrimal gland
tissue_expression_up	hsa-let-7a-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	let-7a: upregulated
tissue_expression_up	hsa-let-7a-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	let-7a: upregulated
tissue_expression_up	hsa-let-7a-3	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	let-7a: upregulated
tissue_expression_up	hsa-let-7b	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	let-7b: upregulated
tissue_expression_up	hsa-let-7c	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	let-7c: upregulated
tissue_expression_up	hsa-let-7d	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	let-7d: upregulated
tissue_expression_up	hsa-mir-100	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-100: upregulated
tissue_expression_up	hsa-mir-1-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-1: upregulated
tissue_expression_up	hsa-mir-1-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-1: upregulated
tissue_expression_up	hsa-mir-125b-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-125b: upregulated
tissue_expression_up	hsa-mir-125b-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-125b: upregulated
tissue_expression_up	hsa-mir-126	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-126: upregulated
tissue_expression_up	hsa-mir-130a	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-130a: upregulated
tissue_expression_up	hsa-mir-132	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-132: upregulated
tissue_expression_up	hsa-mir-133a-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-133a: upregulated
tissue_expression_up	hsa-mir-133a-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-133a: upregulated
tissue_expression_up	hsa-mir-135a-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-135a: upregulated
tissue_expression_up	hsa-mir-135a-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-135a: upregulated
tissue_expression_up	hsa-mir-137	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-137: upregulated
tissue_expression_up	hsa-mir-139	Carcinoma, Adrenocortical	21471143	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	ACCs (adrenocortical carcinomas) exhibited significantly lower levels of miR-139-3p (up to 8.49-fold, p<0.001), miR-675 (up to 23.25-fold, p<0.001) and miR-335 (up to 5.25-fold, p<0.001).
tissue_expression_up	hsa-mir-143	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-143: upregulated
tissue_expression_up	hsa-mir-145	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-145: upregulated
tissue_expression_up	hsa-mir-146a	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-146a: upregulated
tissue_expression_up	hsa-mir-155	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-155: upregulated
tissue_expression_up	hsa-mir-15b	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-15b: upregulated
tissue_expression_up	hsa-mir-16-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-16: upregulated
tissue_expression_up	hsa-mir-16-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-16: upregulated
tissue_expression_up	hsa-mir-17	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-17-5p: upregulated
tissue_expression_up	hsa-mir-192	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-192: upregulated
tissue_expression_up	hsa-mir-194-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-194: upregulated
tissue_expression_up	hsa-mir-194-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-194: upregulated
tissue_expression_up	hsa-mir-200b	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-200b: upregulated
tissue_expression_up	hsa-mir-200c	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-200c: upregulated
tissue_expression_up	hsa-mir-203	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-203: upregulated
tissue_expression_up	hsa-mir-21	Carcinoma, Adrenocortical	21859927	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. 
tissue_expression_up	hsa-mir-210	Carcinoma, Adrenocortical	21859927	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. 
tissue_expression_up	hsa-mir-222	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-222: upregulated
tissue_expression_up	hsa-mir-23b	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-23b: upregulated
tissue_expression_up	hsa-mir-28	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-28: upregulated
tissue_expression_up	hsa-mir-30a	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-30a-3p: upregulated
tissue_expression_up	hsa-mir-335	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-335: upregulated
tissue_expression_up	hsa-mir-375	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-375: upregulated
tissue_expression_up	hsa-mir-375	Carcinoma, Adrenocortical	21471143	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	ACCs (adrenocortical carcinomas) exhibited significantly lower levels of miR-139-3p (up to 8.49-fold, p<0.001), miR-675 (up to 23.25-fold, p<0.001) and miR-335 (up to 5.25-fold, p<0.001).
tissue_expression_up	hsa-mir-449a	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-449: upregulated
tissue_expression_up	hsa-mir-449b	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-449: upregulated
tissue_expression_up	hsa-mir-483	Carcinoma, Adrenocortical	21472710	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors.
tissue_expression_up	hsa-mir-483	Carcinoma, Adrenocortical	21859927	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Among others, miR-483-3p, miR-483-5p, miR-210, and miR-21 were found overexpressed,while miR-195, miR-497, and miR-1974 were underexpressed in ACC. 
tissue_expression_up	hsa-mir-675	Carcinoma, Adrenocortical	21471143	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	ACCs (adrenocortical carcinomas) exhibited significantly lower levels of miR-139-3p (up to 8.49-fold, p<0.001), miR-675 (up to 23.25-fold, p<0.001) and miR-335 (up to 5.25-fold, p<0.001).
tissue_expression_up	hsa-mir-7-1	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-7: upregulated
tissue_expression_up	hsa-mir-7-2	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-7: upregulated
tissue_expression_up	hsa-mir-7-3	Carcinoma, Adrenocortical	19351815	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miR-7: upregulated
tissue_expression_up	hsa-mir-106b	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	upregulated in the tumor center
tissue_expression_up	hsa-mir-125a	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-125a-5p is upregulated in the tumor center
tissue_expression_up	hsa-mir-17	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	upregulated in the tumor center
tissue_expression_up	hsa-mir-181c	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-181c and miR-181c* are upregulated in the tumor center
tissue_expression_up	hsa-mir-181d	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	upregulated in the tumor center
tissue_expression_up	hsa-mir-182	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	upregulated in the tumor center
tissue_expression_up	hsa-mir-18a	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	upregulated in the tumor center
tissue_expression_up	hsa-mir-18b	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	upregulated in the tumor center
tissue_expression_up	hsa-mir-19b-1	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-19b is upregulated in the tumor center
tissue_expression_up	hsa-mir-19b-2	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-19b is upregulated in the tumor center
tissue_expression_up	hsa-mir-455	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-455-5p and miR-455-3p are upregulated in the tumor center
tissue_expression_up	hsa-mir-542	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	miR-542 is upregulated in the tumor center
tissue_expression_up	hsa-mir-93	Carcinoma, Basal Cell	22540308	disease of cellular proliferation	DOID:2513	C44.91	D002280	605462	HP:0002671	upregulated in the tumor center
tissue_expression_up	hsa-mir-138	Carcinoma, Bladder	23946872	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Within this group, let-7b and let-7i exhibited decreased expression, while miR-1290 and miR-138 displayed increased expression levels in gemcitabine-resistant cells.
tissue_expression_up	hsa-mir-140	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-mir-181b	Carcinoma, Breast	21779448			D05	D001943	114480	HP:0003002	we focused on miR-181b, which was overexpressed in several malignant neoplasias including breast carcinomas. 
tissue_expression_up	hsa-mir-20b	Carcinoma, Breast	25893380			D05	D001943	114480	HP:0003002	miR-20b is up-regulated in brain metastases from primary breast cancers.
tissue_expression_up	hsa-mir-21	Carcinoma, Breast	24781337			D05	D001943	114480	HP:0003002	Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia.
tissue_expression_up	hsa-mir-21	Carcinoma, Breast	26342497			D05	D001943	114480	HP:0003002	Chromosome 17 aneusomy and miR-21 expression are positively correlated and can potentially serve as prognostic markers in BC.
tissue_expression_up	hsa-mir-222	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-mir-222	Carcinoma, Breast	27746366			D05	D001943	114480	HP:0003002	MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
tissue_expression_up	hsa-mir-29a	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-mir-3178	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-mir-34a	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-mir-423	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-mir-574	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-mir-6780b	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-mir-744	Carcinoma, Breast	27746365			D05	D001943	114480	HP:0003002	MiR-222, miR-29a, miR-34a, miR-423, miR-140, miR-3178, miR-574, miR-6780b and miR-744 exhibited significantly higher expression levels in surgically-resected specimens compared with pre-neoadjuvant chemotherapy biopsies
tissue_expression_up	hsa-let-7a	Carcinoma, Breast, Triple Negative	27404381				D064726			Interestingly, despite being a known tumor suppressor, Let-7a showed a significant overexpression in TNBCs.
tissue_expression_up	hsa-mir-155	Carcinoma, Breast, Triple Negative	26398931				D064726			These results indicate that miR-155-5p antagonizes bufalin sensitivity in TNBC cells, and that downregulation of DNMT1 and DNMT3a may be responsible for the bufalin-induced upregulation of miR-155-5p.
tissue_expression_up	hsa-mir-21	Carcinoma, Breast, Triple Negative	24930006				D064726			High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation.
tissue_expression_up	hsa-mir-21	Carcinoma, Breast, Triple Negative	27404381				D064726			While miR-21, miR-221 and miR-210 showed  significant over-expression, miR-195 and miR-145 were downregulated and well correlated with various clinicopathological and demographic risk factors, tumor grade, clinical stage and hormone receptor status.
tissue_expression_up	hsa-mir-210	Carcinoma, Breast, Triple Negative	27404381				D064726			While miR-21, miR-221 and miR-210 showed  significant over-expression, miR-195 and miR-145 were downregulated and well correlated with various clinicopathological and demographic risk factors, tumor grade, clinical stage and hormone receptor status.
tissue_expression_up	hsa-mir-221	Carcinoma, Breast, Triple Negative	27404381				D064726			While miR-21, miR-221 and miR-210 showed  significant over-expression, miR-195 and miR-145 were downregulated and well correlated with various clinicopathological and demographic risk factors, tumor grade, clinical stage and hormone receptor status.
tissue_expression_up	hsa-mir-126	Carcinoma, Cervical	24037526	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer.
tissue_expression_up	hsa-mir-196a	Carcinoma, Cervical	24817935	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Heterogeneity of microRNAs expression in cervical cancer cells: over-expression of miR-196a.
tissue_expression_up	hsa-mir-21	Carcinoma, Cervical	26261606	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	MiR-21 upregulation is associated with aggressive progression and poor prognosis in cervical cancer, which suggests that miR-21 might be identified as an independent marker for predicting the clinical outcome of cervical cancer patients.
tissue_expression_up	hsa-mir-27a	Carcinoma, Cervical	26987623	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	B4GALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells.
tissue_expression_up	hsa-mir-27b	Carcinoma, Cervical	26397063	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	In summary, the present study revealed that miR-27b is upregulated by HPV16 E7 to inhibit PPARγ expression and promotes proliferation and invasion in cervical carcinoma cells.
tissue_expression_up	hsa-mir-155	Carcinoma, Colon	24888652	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of miR-155 is up-regulated in colon cancer tissue. A combination of miR-155 level assay in colon cancer tissue and the serum CEA level both pre- and postoperatively can afford more accurate information for diagnosis and prognosis, especially for predicting recurrence and metastasis postoperatively.
tissue_expression_up	hsa-mir-182	Carcinoma, Colon	24053448	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Our data suggest that miR-182 targets the anti-angiogenic factor TSP-1 and that anti-miR-182 determines an upregulation of TSP-1 expression in colon cancer cells. Moreover, anti-miR-182 exerts a transcriptional regulatory mechanism of tsp-1 modulating Egr-1 and Sp-1 function. Anti-miR-182 could be used to restore TSP-1 expression in order to contrast angiogenic and invasive events in CRC.
tissue_expression_up	hsa-mir-21	Carcinoma, Colon	24122631	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer.
tissue_expression_up	hsa-mir-21	Carcinoma, Colon	25569638	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	the primary tumor in colon cancer releases high concentrations of miR-21 in the MV but that these concentrations are later diluted in the circulatory system. MV expression of miR-21 may be a stronger prognostic marker than PV expression.
tissue_expression_up	hsa-mir-141	Carcinoma, Ehrlich Tumor	21899346	thoracic disease	DOID:5050		D002286			Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells.
tissue_expression_up	hsa-mir-182	Carcinoma, Ehrlich Tumor	21899346	thoracic disease	DOID:5050		D002286			Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells.
tissue_expression_up	hsa-mir-183	Carcinoma, Ehrlich Tumor	21899346	thoracic disease	DOID:5050		D002286			Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells.
tissue_expression_up	hsa-mir-200a	Carcinoma, Ehrlich Tumor	21899346	thoracic disease	DOID:5050		D002286			Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells.
tissue_expression_up	hsa-mir-200b	Carcinoma, Ehrlich Tumor	21899346	thoracic disease	DOID:5050		D002286			Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells.
tissue_expression_up	hsa-mir-429	Carcinoma, Ehrlich Tumor	21899346	thoracic disease	DOID:5050		D002286			Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells.
tissue_expression_up	hsa-mir-96	Carcinoma, Ehrlich Tumor	21899346	thoracic disease	DOID:5050		D002286			Two clusters miR-183~miR-96~miR-182 and miR-200b~miR-200a~miR-429 as well as miR-141 to be consistently up-regulated in the MDR (Multidrug resistance) cell lines, while miR-125b-5p and the two clusters miR-30d~miR-30b and miR-23b~miR-27b~miR-24-1 were down-regulated in most of the resistant EAT (Ehrlich ascites tumor) cells.
tissue_expression_up	hsa-mir-141	Carcinoma, Endometrial	26045795	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas.
tissue_expression_up	hsa-mir-155	Carcinoma, Endometrial	21125666	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Up-regulated miRNAs included miR-155, miR-369-5p, miR-370, miR-450a and miR-542-5p. These data suggest that in human ECS, the interplay between transcriptional repressors of E-cadherin and miRNAs provides a link between EMT-activation and the maintenance of stemness.
tissue_expression_up	hsa-mir-200a	Carcinoma, Endometrial	26045795	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas.
tissue_expression_up	hsa-mir-205	Carcinoma, Endometrial	26045795	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas.
tissue_expression_up	hsa-mir-369	Carcinoma, Endometrial	21125666	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Up-regulated miRNAs included miR-155, miR-369-5p, miR-370, miR-450a and miR-542-5p. These data suggest that in human ECS, the interplay between transcriptional repressors of E-cadherin and miRNAs provides a link between EMT-activation and the maintenance of stemness.
tissue_expression_up	hsa-mir-450a	Carcinoma, Endometrial	21125666	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Up-regulated miRNAs included miR-155, miR-369-5p, miR-370, miR-450a and miR-542-5p. These data suggest that in human ECS, the interplay between transcriptional repressors of E-cadherin and miRNAs provides a link between EMT-activation and the maintenance of stemness.
tissue_expression_up	hsa-mir-542	Carcinoma, Endometrial	21125666	reproductive system disease	DOID:2871	D07.0	D016889	608089	HP:0012114	Up-regulated miRNAs included miR-155, miR-369-5p, miR-370, miR-450a and miR-542-5p. These data suggest that in human ECS, the interplay between transcriptional repressors of E-cadherin and miRNAs provides a link between EMT-activation and the maintenance of stemness.
tissue_expression_up	hsa-mir-135b	Carcinoma, Endometrioid Endometrial	24491411			C54.1	D018269			Quantitative reverse-transcriptase PCR identified 8 EEC-associated miRNAs in tissue (upregulated: miR-499, miR-135b, miR-205, downregulated: miR-10b, miR-195, miR-30a-5p, miR-30a-3p and miR-21).
tissue_expression_up	hsa-mir-141	Carcinoma, Endometrioid Endometrial	21035172			C54.1	D018269			A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues.
tissue_expression_up	hsa-mir-200a	Carcinoma, Endometrioid Endometrial	21035172			C54.1	D018269			A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues.
tissue_expression_up	hsa-mir-200b	Carcinoma, Endometrioid Endometrial	21035172			C54.1	D018269			A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues.
tissue_expression_up	hsa-mir-200c	Carcinoma, Endometrioid Endometrial	21035172			C54.1	D018269			A miRNA microarray showed that the miR-200 family, including hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, and hsa-miR-429, was up-regulated in EECs as compared with that in normal endometrial tissues.
tissue_expression_up	hsa-mir-429	Carcinoma, Endometrioid Endometrial	21035172			C54.1	D018269			These results indicate that the miR-200 family is highly expressed in EECs compared with that of normal endometrial tissues and could play an important role in cancer growth. Specifically, anti-miR-429 could enhance the cytotoxic activity with cisplatin in EECs.
tissue_expression_up	hsa-mir-198	Carcinoma, Esophageal	24175778	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	miR-198 overexpression is involved in the poor prognosis of esophageal cancer and can be used as a biomarker for selection of cases requiring especial attention.
tissue_expression_up	hsa-mir-21	Carcinoma, Esophageal	24756761	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Nicotine upregulates microRNA-21 and promotes TGF-β-dependent epithelial-mesenchymal transition of esophageal cancer cells.
tissue_expression_up	hsa-mir-503	Carcinoma, Esophageal	25750296	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	High miR-503 expression was identified as an independent prognostic predictor in patients with EC according to multivariate analysis
tissue_expression_up	hsa-let-7a	Carcinoma, Gastric	28399984	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Up-regulation of Let-7a Expression Induces Gastric Carcinoma Cell Apoptosis In Vitro.
tissue_expression_up	hsa-mir-124	Carcinoma, Gastric	26109806	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling.
tissue_expression_up	hsa-mir-16	Carcinoma, Gastric	27605261	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer.
tissue_expression_up	hsa-mir-222	Carcinoma, Gastric	27994199	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Upregulation of miR-222 in both Helicobacter pylori- infected and noninfected gastric cancer patients.
tissue_expression_up	hsa-mir-451	Carcinoma, Gastric	27605261	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer.
tissue_expression_up	hsa-mir-223	Carcinoma, Gastrooesophageal	28395057							Early miR-223 Upregulation in Gastroesophageal Carcinogenesis.
tissue_expression_up	hsa-mir-31	Carcinoma, Gingival	25126847			D00.03				Expression of hsa-miR-31 was significantly up-regulated in both cancer and leukoplakia tissues and, thus, may  be one of the molecular markers of leukoplakia which may progress to gingivo-buccal cancer.
tissue_expression_up	hsa-let-7a-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-let-7a-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-let-7a-3	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-100	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-100: overexpressed In HCC patients with hepatitis C and liver cirrhosis
tissue_expression_up	hsa-mir-100	Carcinoma, Hepatocellular	18307259	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma.
tissue_expression_up	hsa-mir-105-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-105-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-106a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-106b	Carcinoma, Hepatocellular	25466449	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-106b expression was significantly upregulated in HCC and could serve as a potential unfavorable prognostic biomarker.
tissue_expression_up	hsa-mir-106b	Carcinoma, Hepatocellular	27298561	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The value of miR-106b expression in HBV-associated HCC patients was significantly higher
tissue_expression_up	hsa-mir-10a	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-10a: overexpressed In HCC patients with hepatitis C and liver cirrhosis
tissue_expression_up	hsa-mir-10a	Carcinoma, Hepatocellular	18307259	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma.
tissue_expression_up	hsa-mir-10b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-10b	Carcinoma, Hepatocellular	29314614	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC
tissue_expression_up	hsa-mir-122	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	up-regulated in HCC tissues.correlated with cirrhosis
tissue_expression_up	hsa-mir-122	Carcinoma, Hepatocellular	18307259	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma.
tissue_expression_up	hsa-mir-1224	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-1224-3p was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-1234	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-1234 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-1249	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-1249 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-126	Carcinoma, Hepatocellular	20619223	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-126:hsa-miR-126 showed higher expression levels in hepatocellular carcinomas
tissue_expression_up	hsa-mir-126	Carcinoma, Hepatocellular	18433021	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma.
tissue_expression_up	hsa-mir-128a	Carcinoma, Hepatocellular	25345933	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-128a is up-regulated in HCC and promotes HCC cell proliferation by targeting RND3.
tissue_expression_up	hsa-mir-137	Carcinoma, Hepatocellular	28350139	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
tissue_expression_up	hsa-mir-146a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-148b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-151a	Carcinoma, Hepatocellular	21319996	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30d and miR-151 were amplified in ~50% of Hepatitis B Virus-Associated HCC tumor tissues
tissue_expression_up	hsa-mir-155	Carcinoma, Hepatocellular	21762537	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ectopic expression of miR-155 upregulated the expression of several IFN-inducible antivirus genes in human hepatoma cells.
tissue_expression_up	hsa-mir-155	Carcinoma, Hepatocellular	22629365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free.
tissue_expression_up	hsa-mir-155	Carcinoma, Hepatocellular	23863669	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-155 is over-expressed in primary HCC with tumor recurrence and may serve as a novel biomarker for tumor recurrence and survival of HCC patients after LT. The detection of microRNA-155 is of clinical significance in HCC.
tissue_expression_up	hsa-mir-15a	Carcinoma, Hepatocellular	22629365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free.
tissue_expression_up	hsa-mir-15b	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-15b* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-15b	Carcinoma, Hepatocellular	22629365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free.
tissue_expression_up	hsa-mir-17	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-17	Carcinoma, Hepatocellular	22583011	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-17-5p was significantly upregulated in HCCs. HCC with metastasis had higher miR-17-5p levels than that without metastasis.
tissue_expression_up	hsa-mir-182	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-183	Carcinoma, Hepatocellular	20602797	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Among the 25 HCC samples analyzed, microRNA-183 was significantly up-regulated (twofold to 367-fold) in 17 samples compared with the matching nontumoral liver tissues.
tissue_expression_up	hsa-mir-183	Carcinoma, Hepatocellular	26640336	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miRNA-183 was the most up-regulated, followed by miRNA-373. miRNA-129 and miRNA-188 were both strongly down-regulated and miRNA-378 was down-regulated a small amount.
tissue_expression_up	hsa-mir-18a	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	upregulated
tissue_expression_up	hsa-mir-18b	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	upregulated
tissue_expression_up	hsa-mir-193a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-196a-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-196a-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-197	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-197 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-199a-1	Carcinoma, Hepatocellular	23319430	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Propofol induces apoptosis of hepatocellular carcinoma cells by upregulation of microRNA-199a expression
tissue_expression_up	hsa-mir-199a-2	Carcinoma, Hepatocellular	23319430	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Propofol induces apoptosis of hepatocellular carcinoma cells by upregulation of microRNA-199a expression
tissue_expression_up	hsa-mir-203	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-203: up-regulated in HCC compared to benign hepatocellular tumors
tissue_expression_up	hsa-mir-205	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-20a	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	overexpression
tissue_expression_up	hsa-mir-20b	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	overexpression
tissue_expression_up	hsa-mir-21	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-21: up-regulated in HCC compared to benign hepatocellular tumors
tissue_expression_up	hsa-mir-21	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-21	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	up-regulated in HCC tissues.correlated with cirrhosis;associated with tumor stage and poor prognosis.
tissue_expression_up	hsa-mir-21	Carcinoma, Hepatocellular	26436398	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We concluded that miR-21 might be complementary to alpha fetal protein in HCC diagnosis, and might serve as an attractive estimator of HCC. We also demonstrated that miR-21 overexpression was associated with HCC TNM stage and with poor survival.
tissue_expression_up	hsa-mir-21	Carcinoma, Hepatocellular	26261620	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results suggested that increased expression of miR-21 was significantly correlated with tumor progression and could be a novel potential biomarker for HCC prognosis.
tissue_expression_up	hsa-mir-21	Carcinoma, Hepatocellular	29314614	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC
tissue_expression_up	hsa-mir-210	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-214	Carcinoma, Hepatocellular	29088870	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	high miR-214 could be a promising biomarker for prognosis prediction of cancer
tissue_expression_up	hsa-mir-217	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-217	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-221	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-221: up-regulated in HCC compared to benign hepatocellular tumors
tissue_expression_up	hsa-mir-221	Carcinoma, Hepatocellular	19585654	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	critical player; up-regulated; could directly target hepatic transcriptional regulators of differentiation and an inhibitor of Wnt/beta-catenin signaling
tissue_expression_up	hsa-mir-221	Carcinoma, Hepatocellular	21458843	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma.
tissue_expression_up	hsa-mir-221	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	up-regulated in HCC tissues.correlated with cirrhosis;associated with tumor stage and poor prognosis.
tissue_expression_up	hsa-mir-221	Carcinoma, Hepatocellular	23320393	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro
tissue_expression_up	hsa-mir-221	Carcinoma, Hepatocellular	26258795	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MiR-221 and miR-222 (miR-221/222) are well-studied oncogenic microRNAs that are frequently upregulated in several types of human tumors
tissue_expression_up	hsa-mir-222	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-222: up-regulated in HCC compared to benign hepatocellular tumors
tissue_expression_up	hsa-mir-222	Carcinoma, Hepatocellular	20103675	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	overexpression
tissue_expression_up	hsa-mir-222	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-222	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	up-regulated in HCC tissues.
tissue_expression_up	hsa-mir-222	Carcinoma, Hepatocellular	24124720	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-222, upregulated in HCC, maybe helpful in prognosis of HCC patients.
tissue_expression_up	hsa-mir-224	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	upregulated
tissue_expression_up	hsa-mir-224	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-224: up-regulated in HCC compared to benign hepatocellular tumors
tissue_expression_up	hsa-mir-224	Carcinoma, Hepatocellular	24923856	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These results indicate for the first time that miR-224 upregulation and AKT activation may synergistically associate with tumor progression of HCC.The combined high expression of miR-224 and pAKT may be a potential indicator for predicting unfavorable prognosis in HCC patients.
tissue_expression_up	hsa-mir-25	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-25	Carcinoma, Hepatocellular	24593846	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data suggests that the overexpression of miR-25 in HCC tissues is of predictive value on poor prognosis.
tissue_expression_up	hsa-mir-29a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-302b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-302c	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-30a	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-30b	Carcinoma, Hepatocellular	22629365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free.
tissue_expression_up	hsa-mir-30d	Carcinoma, Hepatocellular	21319996	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30d and miR-151 were amplified in ~50% of Hepatitis B Virus-Associated HCC tumor tissues
tissue_expression_up	hsa-mir-31	Carcinoma, Hepatocellular	22213236	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	up-regulated in HCC tissues.correlated with cirrhosis
tissue_expression_up	hsa-mir-34a	Carcinoma, Hepatocellular	19360909	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-34a: up-regulated in HCC compared to benign hepatocellular tumors
tissue_expression_up	hsa-mir-34c	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-372	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-372	Carcinoma, Hepatocellular	23291979	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma
tissue_expression_up	hsa-mir-376a-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-376a-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-379	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-432	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-432	Carcinoma, Hepatocellular	22629365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free.
tissue_expression_up	hsa-mir-449b	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-449b* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-450a-1	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-450a-2	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-450b	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-486	Carcinoma, Hepatocellular	22629365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression levels of miR-155, miR-15a, miR-432, miR-486-3p, miR-15b and miR-30b were significantly associated with recurrence-free.
tissue_expression_up	hsa-mir-493	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-508	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-512	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-517c	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-517c	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-518a	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-518b	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-518e	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-519a	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-519e	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-520g	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-522	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-522 was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-522	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-525	Carcinoma, Hepatocellular	23082062	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Ten up-regulated miRNAs (miR-217, miR-518b, miR-517c, miR-520g, miR-519a, miR-522, miR-518e, miR-525-3p, miR-512-3p, and miR-518a-3p) and 11 down-regulated miRNAs (miR-138, miR-214, miR-214#, miR-199a-5p, miR-433, miR-511, miR-592, miR-483-3p, miR-483-5p, miR-708 and miR-1275) were identified by Taqman miRNAs array and confirmed quantitatively by reverse transcription polymerase chain reaction in HCC and adjacent non-tumor tissues. 
tissue_expression_up	hsa-mir-532	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-532-3p was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-675	Carcinoma, Hepatocellular	23864307	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of the miR-675 in hepatocellular carcinoma links a dramatic upregulation of proliferative and growth capacity with inhibition of motility in HCC cells.
tissue_expression_up	hsa-mir-744	Carcinoma, Hepatocellular	21998738	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	hsa-mir-744* was up-regulated in HepG2 cells after 5 hours of culture with grape seed proanthocyanidin extract.
tissue_expression_up	hsa-mir-761	Carcinoma, Hepatocellular	26845057	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin-2.
tissue_expression_up	hsa-mir-888	Carcinoma, Hepatocellular	28337887	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Up-regulation of miR-888-5p in hepatocellular carcinoma cell lines and its effect on malignant characteristics of cells.
tissue_expression_up	hsa-mir-9	Carcinoma, Hepatocellular	28774651	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	inhibition of hsa_circ_0071410 increased the expression of miR-9-5p, resulting in the attenuation of irradiation induced HSC activation
tissue_expression_up	hsa-mir-92a-1	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	overexpression
tissue_expression_up	hsa-mir-92a-2	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	overexpression
tissue_expression_up	hsa-mir-92b	Carcinoma, Hepatocellular	16331254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	overexpression
tissue_expression_up	hsa-mir-96	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-98	Carcinoma, Hepatocellular	22027761	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	This miRNA was up-regulated in HepG2 cells treated with BJA32515.
tissue_expression_up	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	23099007			C34.90	D002289		HP:0030358	High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer.
tissue_expression_up	hsa-mir-181b	Carcinoma, Lung, Non-Small-Cell	27291819			C34.90	D002289		HP:0030358	miR-181b-5p was up-regulated in squamous cell carcinoma
tissue_expression_up	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	20068099			C34.90	D002289		HP:0030358	hsa-miR-205 is a miRNA that is highly expressed in lung squamous cell carcinomas (SqCC) but not in lung adenocarcinomas.
tissue_expression_up	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	23207443			C34.90	D002289		HP:0030358	SQCC was distinguished from normal tissue and ADC by high-level miR-205 expression and decreased miR-26b.
tissue_expression_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	19446359			C34.90	D002289		HP:0030358	Mir-21 expression in the sputum specimens was significantly higher in cancer patients (76.32+/-9.79) than cancer-free individuals (62.24+/-3.82) (P<0.0001).
tissue_expression_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23099007			C34.90	D002289		HP:0030358	High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer.
tissue_expression_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	27072269			C34.90	D002289		HP:0030358	miR-15a/16, miR-34a, miR-126 and miR-128 were down-regulated significantly. (>2-fold change), while miR-21 and miR.210 were up-regulated in A549.
tissue_expression_up	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	25384507			C34.90	D002289		HP:0030358	At the same time, miR-21 and miR-210 were upregulated by 53.3 and 66.6% in cancer tissue versus matched adjacent normal tissues, respectively.
tissue_expression_up	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	27072269			C34.90	D002289		HP:0030358	miR-15a/16, miR-34a, miR-126 and miR-128 were down-regulated significantly. (>2-fold change), while miR-21 and miR.210 were up-regulated in A549.
tissue_expression_up	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	26831656			C34.90	D002289		HP:0030358	The relative expression levels of microRNA-221 in the pathological  tissues were remarkably higher than that in the corresponding normal tissues
tissue_expression_up	hsa-mir-543	Carcinoma, Lung, Non-Small-Cell	27769862			C34.90	D002289		HP:0030358	miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog.
tissue_expression_up	hsa-let-7b	Carcinoma, Lung, Non-Small-Cell	21622546			C34.90	D002289		HP:0030358	Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens
tissue_expression_up	hsa-let-7c	Carcinoma, Lung, Non-Small-Cell	21622546			C34.90	D002289		HP:0030358	Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens
tissue_expression_up	hsa-let-7f	Carcinoma, Lung, Non-Small-Cell	21622546			C34.90	D002289		HP:0030358	Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens
tissue_expression_up	hsa-let-7g	Carcinoma, Lung, Non-Small-Cell	21622546			C34.90	D002289		HP:0030358	Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens
tissue_expression_up	hsa-let-7i	Carcinoma, Lung, Non-Small-Cell	21622546			C34.90	D002289		HP:0030358	Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens
tissue_expression_up	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	21264844			C34.90	D002289		HP:0030358	Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: Coexpression with vascular endothelial growth factor-A predicts poor survival.
tissue_expression_up	hsa-mir-1280	Carcinoma, Lung, Non-Small-Cell	25698202			C34.90	D002289		HP:0030358	The miR-1280 expression was significantly higher in the NSCLC tissues than distal normal tissues
tissue_expression_up	hsa-mir-141	Carcinoma, Lung, Non-Small-Cell	25003366			C34.90	D002289		HP:0030358	High miR-141 and miR-200c expression are associated with shorter OS in NSCLC patients with adenocarcinoma through MET and angiogenesis.
tissue_expression_up	hsa-mir-146	Carcinoma, Lung, Non-Small-Cell	24448024			C34.90	D002289		HP:0030358	microRNA-146 up-regulation predicts the prognosis of non-small cell lung cancer by miRNA in situ hybridization.
tissue_expression_up	hsa-mir-150	Carcinoma, Lung, Non-Small-Cell	25755784			C34.90	D002289		HP:0030358	Our data indicated that overexpression of miR-150 in NSCLC tissues has prognostic value.
tissue_expression_up	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	24854560			C34.90	D002289		HP:0030358	High expression of miR-155 represents a valuable marker of poor clinical outcomes in patients with stage III NSCLC.
tissue_expression_up	hsa-mir-16-1	Carcinoma, Lung, Non-Small-Cell	21400525			C34.90	D002289		HP:0030358	miR-16 levels in tumor samples may be a prognostic marker in NSCLC.
tissue_expression_up	hsa-mir-16-2	Carcinoma, Lung, Non-Small-Cell	21400525			C34.90	D002289		HP:0030358	miR-16 levels in tumor samples may be a prognostic marker in NSCLC.
tissue_expression_up	hsa-mir-182	Carcinoma, Lung, Non-Small-Cell	24575749			C34.90	D002289		HP:0030358	In patients with SCC and in stage II patients, high tumor cell miR-182 expression is an independent positive prognostic factor.
tissue_expression_up	hsa-mir-200c	Carcinoma, Lung, Non-Small-Cell	25003366			C34.90	D002289		HP:0030358	High miR-141 and miR-200c expression are associated with shorter OS in NSCLC patients with adenocarcinoma through MET and angiogenesis.
tissue_expression_up	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	18719201			C34.90	D002289		HP:0030358	miR-205: overexpression
tissue_expression_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	18719201			C34.90	D002289		HP:0030358	miR-21: overexpression
tissue_expression_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	24293118			C34.90	D002289		HP:0030358	Our data suggest a novel molecular mechanism in which inhibition of microRNA-21 and upregulation of PTEN mediate the anticancer activities of curcumin in NSCLC cells. Suppression of microRNA-21 may thus have therapeutic benefits against this malignancy.
tissue_expression_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	26563758			C34.90	D002289		HP:0030358	Higher expression levels of miR-21, AmiR-27a, and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations. These findings need to be further confirmed in a study with a larger sample size.
tissue_expression_up	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	22438124			C34.90	D002289		HP:0030358	Delta-tocotrienol suppresses Notch-1 pathway by up-regulating miR-34a in non-small cell lung cancer cells.
tissue_expression_up	hsa-mir-708	Carcinoma, Lung, Non-Small-Cell	22573352			C34.90	D002289		HP:0030358	Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers.
tissue_expression_up	hsa-mir-96	Carcinoma, Lung, Non-Small-Cell	22046296			C34.90	D002289		HP:0030358	hsa-mir-96 is significantly and consistently up-regulated in all 6 NSCLCs.
tissue_expression_up	hsa-mir-98	Carcinoma, Lung, Non-Small-Cell	21622546			C34.90	D002289		HP:0030358	Eighteen cases were classified as AD and 13 as SCC by light microscopy and immunocytochemistry. miRNA expression profiles demonstrated considerable, statistically significant differences between AD and SCC, showing an upregulation of hsa-let-7a, hsa-let-7b, hsa-let-7c,hsa-let-7f, hsa-let-7g, hsa-let-7i, and hsa-miR-98 and a downregulation of hsa-miR-205 in AD specimens
tissue_expression_up	hsa-mir-375	Carcinoma, Lung, Small-Cell	22172490			C34.90	D055752	182280	HP:0030357	miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells.
tissue_expression_up	hsa-mir-10b	Carcinoma, Nasopharyngeal	27186392	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	we show that microRNA-10b (miR-10b) is up-regulated in HNE1/DDP cells
tissue_expression_up	hsa-mir-143	Carcinoma, Nasopharyngeal	28105209	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Upregulated microRNA-143 inhibits cell proliferation in human nasopharyngeal carcinoma.
tissue_expression_up	hsa-mir-155	Carcinoma, Neuroendocrine	22924844	disease of cellular proliferation	DOID:1800	C7A	D018278		HP:0100634	The expression levels of miR-21 and miR-155 were significantly higher in high-grade NE carcinomas (LCNECs and SCLCs) than in carcinoid tumors (TCs and ACs) (each P < 0.001). The expression level of miR-21 in carcinoid tumors with lymph node metastasis was significantly higher than in carcinoid tumors without lymph node metastasis (P= 0.010).
tissue_expression_up	hsa-mir-21	Carcinoma, Neuroendocrine	22924844	disease of cellular proliferation	DOID:1800	C7A	D018278		HP:0100634	The expression levels of miR-21 and miR-155 were significantly higher in high-grade NE carcinomas (LCNECs and SCLCs) than in carcinoid tumors (TCs and ACs) (each P < 0.001). The expression level of miR-21 in carcinoid tumors with lymph node metastasis was significantly higher than in carcinoid tumors without lymph node metastasis (P= 0.010).
tissue_expression_up	hsa-mir-31	Carcinoma, Oral	22083872	gastrointestinal system disease	DOID:0050610					Salivary miR-31 was significantly increased in patients with oral carcinoma at all clinical stages, including very small tumors. However, our preliminary analysis showed no increase of salivary miR-31in patients with oral verrucous leukoplakia relative to controls. The miR-31 was more abundant in saliva than in plasma, suggesting salivary miR-31 was a more sensitive marker for oral malignancy. After excision of oral carcinoma, salivary miR-31 was remarkably reduced, indicating that most of the upregulated salivary miR-31 came from tumor tissues.
tissue_expression_up	hsa-mir-372	Carcinoma, Oral	26152520	gastrointestinal system disease	DOID:0050610					Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas.
tissue_expression_up	hsa-mir-373	Carcinoma, Oral	26152520	gastrointestinal system disease	DOID:0050610					Upregulation of miR-372 and -373 associates with lymph node metastasis and poor prognosis of oral carcinomas.
tissue_expression_up	hsa-mir-145	Carcinoma, Ovarian	29569698	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	miRNA-145 expression was lower in DPEEOC endometrial tissues and higher in DPEEOC ovarian tissues compared to the corresponding normal tissues
tissue_expression_up	hsa-mir-25	Carcinoma, Ovarian	24696291	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	The increased expression of miR-25 is closely related to poor prognosis of EOC, indicating that miR-25 may serve as a predictive biomarker for the prognosis of EOC.
tissue_expression_up	hsa-mir-126	Carcinoma, Ovarian, Clear Cell	27612152	endocrine system disease	DOID:0050934					MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma.
tissue_expression_up	hsa-mir-9	Carcinoma, Ovarian, Clear Cell	27612152	endocrine system disease	DOID:0050934					MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma.
tissue_expression_up	hsa-let-7f	Carcinoma, Pancreatic	18665421			C25.3	C562463	260350	HP:0002894	In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas.
tissue_expression_up	hsa-mir-181b	Carcinoma, Pancreatic	18665421			C25.3	C562463	260350	HP:0002894	In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas.
tissue_expression_up	hsa-mir-21	Carcinoma, Pancreatic	18665421			C25.3	C562463	260350	HP:0002894	In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas.
tissue_expression_up	hsa-mir-29b	Carcinoma, Pancreatic	18665421			C25.3	C562463	260350	HP:0002894	In addition, when analyzed according to specific cancer phenotypes, miR-15a and miR-16 show a significant downregulation in canine ductal carcinomas while miRsR-181b, -21, -29b, and let-7f show a significant upregulation in canine tubular papillary carcinomas.
tissue_expression_up	hsa-mir-106a	Carcinoma, Rectal	21671476	disease of cellular proliferation	DOID:1993	C20	D012004			One of the most up-regulated miRNAs, miRNA-106a, was consistently reported to be differentially expressed in six studies and the five most down-regulated miRNAs, miR-30a-3p, miR-139, miR-145, miR-125a and miR-133a, were consistently reported to be differentially expressed in four studies.
tissue_expression_up	hsa-mir-143	Carcinoma, Rectal	17553685	disease of cellular proliferation	DOID:1993	C20	D012004			Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells.
tissue_expression_up	hsa-mir-21	Carcinoma, Rectal	18196926	disease of cellular proliferation	DOID:1993	C20	D012004			Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors.
tissue_expression_up	hsa-mir-21	Carcinoma, Rectal	20551304	disease of cellular proliferation	DOID:1993	C20	D012004			miRNA expression profiles from 29 patients showed higher expression of miR-21 and miR-106a in patients with adenomas and CRCs compared with individuals free of colorectal neoplasia.
tissue_expression_up	hsa-mir-31	Carcinoma, Rectal	18196926	disease of cellular proliferation	DOID:1993	C20	D012004			Expression levels of analyzed miRNAs significantly differed among tumors and adjacent non-tumor tissues: miR-21 (p = 0.0001) and miR-31 (p = 0.0006) were upregulated, and miR-143 (p = 0.011) and miR-145 (p = 0.003) were downregulated in tumors.
tissue_expression_up	hsa-mir-122	Carcinoma, Renal Cell	21784468	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Overexpression
tissue_expression_up	hsa-mir-122	Carcinoma, Renal Cell	24175769	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The up-regulation of miR-122 may play an important role in the progress of renal cancer through activating PI3K/Akt signal pathway and could be a potential molecular target for anti-cancer therapeutics.
tissue_expression_up	hsa-mir-142	Carcinoma, Renal Cell	29440068	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-21, miR-142-3p, miR-142-5p, miR-150, and miR-155 as significantly upregulated
tissue_expression_up	hsa-mir-150	Carcinoma, Renal Cell	29440068	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-21, miR-142-3p, miR-142-5p, miR-150, and miR-155 as significantly upregulated
tissue_expression_up	hsa-mir-155	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-155: overexpressed in malignant cancer than non-malignant one
tissue_expression_up	hsa-mir-155	Carcinoma, Renal Cell	21784468	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Overexpression
tissue_expression_up	hsa-mir-155	Carcinoma, Renal Cell	29440068	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-21, miR-142-3p, miR-142-5p, miR-150, and miR-155 as significantly upregulated
tissue_expression_up	hsa-mir-16-1	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-16: overexpressed in malignant cancer than non-malignant one
tissue_expression_up	hsa-mir-16-2	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-16: overexpressed in malignant cancer than non-malignant one
tissue_expression_up	hsa-mir-185	Carcinoma, Renal Cell	25217984	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Elevated microRNA-185 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in clear cell renal cell carcinoma.
tissue_expression_up	hsa-mir-200c	Carcinoma, Renal Cell	25860934	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.
tissue_expression_up	hsa-mir-21	Carcinoma, Renal Cell	28184919	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Upregulation of miR-21 expression is a valuable predicator of advanced clinicopathological features and poor prognosis in patients with renal cell carcinoma through the p53/p21‑cyclin E2‑Bax/caspase-3 signaling pathway.
tissue_expression_up	hsa-mir-21	Carcinoma, Renal Cell	29440068	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-21, miR-142-3p, miR-142-5p, miR-150, and miR-155 as significantly upregulated
tissue_expression_up	hsa-mir-210	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-210: overexpressed in malignant cancer than non-malignant one
tissue_expression_up	hsa-mir-210	Carcinoma, Renal Cell	21465485	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Overexpression of miR-210, a downstream target of HIF1, causes centrosome amplification in renal carcinoma cells.
tissue_expression_up	hsa-mir-210	Carcinoma, Renal Cell	21784468	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Overexpression
tissue_expression_up	hsa-mir-210	Carcinoma, Renal Cell	22043236	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	For miR-92a, and a striking inverse correlation with VHL mRNA levels was found. For the hypoxia-regulated miR-210, clear cell tumors showed significantly higher expression levels when compared to tumor of non-clear cell histology (9.90-fold vs. 1.36, p<0.001).
tissue_expression_up	hsa-mir-224	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-224: overexpressed in malignant cancer than non-malignant one
tissue_expression_up	hsa-mir-605	Carcinoma, Renal Cell	28222071	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-605 is elevated at baseline in the Responders and is downregulated with treatment in Responders as compared with Progressors
tissue_expression_up	hsa-mir-452	Carcinoma, Renal Cell	19228262	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-452*: overexpressed in malignant cancer than non-malignant one
tissue_expression_up	hsa-mir-92a-1	Carcinoma, Renal Cell	22043236	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	For miR-92a, and a striking inverse correlation with VHL mRNA levels was found. For the hypoxia-regulated miR-210, clear cell tumors showed significantly higher expression levels when compared to tumor of non-clear cell histology (9.90-fold vs. 1.36, p<0.001).
tissue_expression_up	hsa-mir-92a-2	Carcinoma, Renal Cell	22043236	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	For miR-92a, and a striking inverse correlation with VHL mRNA levels was found. For the hypoxia-regulated miR-210, clear cell tumors showed significantly higher expression levels when compared to tumor of non-clear cell histology (9.90-fold vs. 1.36, p<0.001).
tissue_expression_up	hsa-mir-210	Carcinoma, Renal Cell, Clear-Cell	26670229	disease of cellular proliferation	DOID:4467				HP:0006770	miR-21-5p and miR-210-3p resulted the most significantly up-regulated miRNAs in this patient cohort
tissue_expression_up	hsa-mir-221	Carcinoma, Renal Cell, Clear-Cell	27427222	disease of cellular proliferation	DOID:4467				HP:0006770	miRNA-21 and miRNA-221 expressions were significantly up-regulated in tumor specimens compared to normal tissue (P<0.05).
tissue_expression_up	hsa-mir-21	Carcinoma, Skin	28069514	disease of cellular proliferation	DOID:3451	D04.9	D018280		HP:0008069	Increased microRNA 21 expression contributes to arsenic induced skin lesions, skin cancers and respiratory distress in chronically exposed individuals.
tissue_expression_up	hsa-mir-146a	Carcinoma, Thyroid	25524940	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Up-regulation of miR-146a and miR-146b expression in tissues was related to carcinogenesis and deterioration of PTC. MicroRNA-146a and miR-146b expressed in thyroid tissue may act as potential biomarkers for PTC patients.
tissue_expression_up	hsa-mir-146b	Carcinoma, Thyroid	25524940	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	Up-regulation of miR-146a and miR-146b expression in tissues was related to carcinogenesis and deterioration of PTC. MicroRNA-146a and miR-146b expressed in thyroid tissue may act as potential biomarkers for PTC patients.
tissue_expression_up	hsa-mir-146b	Carcinoma, Thyroid	27347103	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	the expression levels of miR146b, miR221 and miR222 were significantly higher
tissue_expression_up	hsa-mir-221	Carcinoma, Thyroid	27347103	disease of cellular proliferation	DOID:3963	C73	D013964	188550	HP:0002890	the expression levels of miR146b, miR221 and miR222 were significantly higher
tissue_expression_up	hsa-mir-146a	Carcinoma, Thyroid, Anaplastic	20061417			C73	D065646	188550	HP:0011779	Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a.
tissue_expression_up	hsa-mir-375	Carcinoma, Thyroid, Follicular	26818914	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	Only miR-375 was over-expressed in the FNs diagnosed as carcinomas and in the PMs.
tissue_expression_up	hsa-mir-375	Carcinoma, Thyroid, Follicular	29683529	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	High expression values of MirR-375 provided 100% ROM
tissue_expression_up	hsa-mir-183	Carcinoma, Thyroid, Medullary	29388012	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	Tumour expression levels of miR-21 (p=0.0008) and miR-183 (p=0.0096) were higher in the LNI group
tissue_expression_up	hsa-mir-21	Carcinoma, Thyroid, Medullary	29107050	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
tissue_expression_up	hsa-mir-21	Carcinoma, Thyroid, Medullary	29388012	disease of cellular proliferation	DOID:3973	C73	C536914	155240	HP:0002865	Tumour expression levels of miR-21 (p=0.0008) and miR-183 (p=0.0097) were higher in the LNI group
tissue_expression_up	hsa-mir-146a	Carcinoma, Thyroid, Papillary	26003825	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Our results demonstrate that down-regulation of THRβ is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis.
tissue_expression_up	hsa-mir-146b	Carcinoma, Thyroid, Papillary	23427895	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p).
tissue_expression_up	hsa-mir-146b	Carcinoma, Thyroid, Papillary	23569392	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	In addition, the miR-146b expression level was significantly higher in the massive extrathyroidal invasion group than in the minimal extrathyroidal invasion group
tissue_expression_up	hsa-mir-21	Carcinoma, Thyroid, Papillary	26003825	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Our results demonstrate that down-regulation of THRβ is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis.
tissue_expression_up	hsa-mir-221	Carcinoma, Thyroid, Papillary	16365291	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	upregulation
tissue_expression_up	hsa-mir-221	Carcinoma, Thyroid, Papillary	16728577	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	upregulation
tissue_expression_up	hsa-mir-221	Carcinoma, Thyroid, Papillary	26003825	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Our results demonstrate that down-regulation of THRβ is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis.
tissue_expression_up	hsa-mir-221	Carcinoma, Thyroid, Papillary	19030936	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Primary or mature miR-221 were overexpressed in PTC as compared with HT-ori3.
tissue_expression_up	hsa-mir-221	Carcinoma, Thyroid, Papillary	23427895	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p).
tissue_expression_up	hsa-mir-222	Carcinoma, Thyroid, Papillary	16728577	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	upregulation
tissue_expression_up	hsa-mir-222	Carcinoma, Thyroid, Papillary	23427895	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p).
tissue_expression_up	hsa-mir-31	Carcinoma, Thyroid, Papillary	26380656	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	miR-21, miR-146b, miR-221, miR-222, miR-31, and miR-3613 were up-regulated
tissue_expression_up	hsa-mir-595	Carcinoma, Thyroid, Papillary	27022736	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Interestingly, in PTC cell lines and PTC tissues, expression of IL-22 and miR-595 was upregulated and Sox17  downregulated compared with normal thyroid
tissue_expression_up	hsa-mir-372	Carcinoma, Urothelial	27351382	disease of cellular proliferation	DOID:4006				HP:0030409	high primary tumour levels of E2F1, miR-21 and miR-372 are associated with poor PFS independent of clinical prognostic factors.
tissue_expression_up	hsa-mir-208a	Cardiomegaly	19726871			I51.7	D006332		HP:0001640	overexpression
tissue_expression_up	hsa-mir-133a	Cardiomyopathy, Dilated	27292200	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	Endomyocardial  expression of miR-155 and miR-133a, as quantified by reverse transcription-PCR (RT-PCR), was up-regulated in patients with iCMP as compared with patients with DCM.
tissue_expression_up	hsa-mir-208	Cardiomyopathy, Dilated	20447577	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	Levels of miR-208, miR-208b, and miR-499 were higher in DCM patients than in controls.
tissue_expression_up	hsa-mir-208b	Cardiomyopathy, Dilated	20447577	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	Levels of miR-208, miR-208b, and miR-499 were higher in DCM patients than in controls.
tissue_expression_up	hsa-mir-21	Cardiomyopathy, Dilated	22041329	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	Levels of let-7i, miR-126, and miR-155 were lower in the DCM group than in the controls, whereas levels of miR-21 and TLR4 (both mRNA and protein) were higher in the DCM group than in the control group. Levels of let-7i were negatively correlated with TLR4 protein levels in all subjects. After a mean follow-up period of 509 days, 6 DCM patients (5.8%) had died due to a cardiac cause and 15 (14.6%) had developed heart failure. When patients with DCM were divided into tertiles according to let-7i levels, log-rank analysis showed that the DCM subgroup with low let-7i levels was associated with poor clinical outcomes (P = .02).
tissue_expression_up	hsa-mir-499	Cardiomyopathy, Dilated	20447577	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	Levels of miR-208, miR-208b, and miR-499 were higher in DCM patients than in controls.
tissue_expression_up	hsa-mir-133a-1	Cardiomyopathy, Hypertrophic	21893044	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a.
tissue_expression_up	hsa-mir-133a-2	Cardiomyopathy, Hypertrophic	21893044	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a.
tissue_expression_up	hsa-mir-195	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro.
tissue_expression_up	hsa-mir-199a-1	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	overexpressed
tissue_expression_up	hsa-mir-199a-2	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	overexpressed
tissue_expression_up	hsa-mir-214	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	overexpressed
tissue_expression_up	hsa-mir-23a	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro.
tissue_expression_up	hsa-mir-23b	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro.
tissue_expression_up	hsa-mir-24-1	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro.
tissue_expression_up	hsa-mir-24-2	Cardiomyopathy, Hypertrophic	17108080	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-23a, miR-23b, miR-24, miR-195, and miR-214, all of which were up-regulated during cardiac hypertrophy, appeared to be capable of inducing hypertrophic growth in vitro.
tissue_expression_up	hsa-mir-4423	Cardiotoxicity	26842497				D066126			early deregulation of miR-187-3p, miR-182-5p, miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-34c-3p, miR-34c-5p and miR-1303, and also the prolonged up-regulation of miR-182-5p, miR-4423-3p and miR-34c-5p.
tissue_expression_up	hsa-mir-195	Cardiovascular Diseases [unspecific]	25339460				D002318			The cardiac dysfunction of the rat with selenium deficiency was mainly associated with five upregulated miRNAs, which were miR-374, miR-16, miR-199a-5p, miR-195 and miR-30e*, and three downregulated  miRNAs, which were miR-3571, miR-675 and miR-450a*.
tissue_expression_up	hsa-mir-21	Cardiovascular Diseases [unspecific]	26342092				D002318			MiR-146b-5p, -146a, -21, -150, -155, -299-5p are overexpressed in the presence of inflammation in TABs from patients with GCA.
tissue_expression_up	hsa-mir-34a	Cardiovascular Diseases [unspecific]	26446137				D002318			overexpression of miR-34a was significantly associated with increased apoptosis, impaired cell vitality and aggravated senescence.
tissue_expression_up	hsa-mir-15a	Cataract	25932180	nervous system disease	DOID:83	H26.9	D002386	PS116200	HP:0000518	hsa-miR-15a-5p, hsa-miR-15a-3p, and hsa-miR-16-1-5p were expressed at low levels  in normal lens epithelial cells but at significantly higher levels in corresponding cells of patients
tissue_expression_up	hsa-mir-210	Cerebral Ischemia	27386874	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	miR-210 expression in the hippocampus of the I/R group at 6, 24 and 96 h after reperfusion was significantly increased at each time point, while its  expression in the group treated with HRS was significantly decreased.
tissue_expression_up	hsa-mir-21	Cervical Neoplasms	27278606	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	the expression of miR-21 was upregulated and the expression of miR-143 was downregulated by the HPV16 E7 oncoprotein in vivo
tissue_expression_up	hsa-mir-21	Cervical Neoplasms	29487007	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-21-5p upregulation, miR-34a downregulation, and hTERC amplification were associated with the aggressive progression of CC, which suggests that miR-21-5p, miR-34a and hTERC might serve as surrogate markers for CC progression and potential molecular targets for blockage of the development of CC
tissue_expression_up	hsa-mir-21	Cervical Neoplasms	22997891	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The high expression of miR-21 in cervical cancer and Hela cell indicate that it may play a possible role of oncogenes, while miR-143 and miR-373 with low expression may play the role of tumor suppressor genes.
tissue_expression_up	hsa-mir-425	Cervical Neoplasms	27166306	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	miR-425-5p is up-regulated in cervical cancer and serum miR-425-5p may serve as a potential prognostic biomarker for cervical cancer.
tissue_expression_up	hsa-mir-9	Cervical Neoplasms	27345415	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-9 up-regulated in cervical cancer
tissue_expression_up	hsa-mir-141	Cholangiocarcinoma	16762633	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-21, miR-141, and miR-200b were highly over-expressed in malignant cholangiocytes.
tissue_expression_up	hsa-mir-200b	Cholangiocarcinoma	16762633	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-21, miR-141, and miR-200b were highly over-expressed in malignant cholangiocytes.
tissue_expression_up	hsa-mir-21	Cholangiocarcinoma	17531469	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Recently Meng et al. showed that miR-21 is also overexpressed in malignant cholangiocarcinomas, a highly chemoresistant cancer type, knockdown of miR-21 sensitised cholangiocarcinoma cell lines for treatment with gemcitabin, whereas transfection of non-malignant cholangiocytes with precursor miR-21 made cells more resistant to gemcitabin.
tissue_expression_up	hsa-mir-21	Cholangiocarcinoma	19296468	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-21: overexpressed
tissue_expression_up	hsa-mir-21	Cholangiocarcinoma	16762633	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-21, miR-141, and miR-200b were highly over-expressed in malignant cholangiocytes.
tissue_expression_up	hsa-let-7a-1	Cholesteatoma	22289526	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients.
tissue_expression_up	hsa-let-7a-2	Cholesteatoma	22289526	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients.
tissue_expression_up	hsa-let-7a-3	Cholesteatoma	22289526	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients.
tissue_expression_up	hsa-mir-21	Cholesteatoma	22289526	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients.
tissue_expression_up	hsa-mir-221	Cholesteatoma	19672202	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	up-regulated concurrent with down-regulation of PTEN
tissue_expression_up	hsa-mir-141	Chondrosarcoma	24992595	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Paeonol suppresses chondrosarcoma metastasis through up-regulation of miR-141 by modulating PKCδ and c-Src signaling pathway.
tissue_expression_up	hsa-mir-518b	Chondrosarcoma	24173143	disease of cellular proliferation	DOID:3371	M91-M94	D002813	215300	HP:0006765	Gallic acid induces apoptosis and inhibits cell migration by upregulating miR-518b in SW1353 human chondrosarcoma cells.
tissue_expression_up	hsa-mir-223	Chorioamnionitis	29083107	reproductive system disease	DOID:0050697	41.129	D002821			Increased miR-223 expression in foetal organs is a signature of acute chorioamnionitis with systemic consequences.
tissue_expression_up	hsa-mir-143	Choriocarcinoma	27374102	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	miR-143, miR-145, miR-194 and miR-215 levels were significantly higher
tissue_expression_up	hsa-mir-205	Choriocarcinoma	26711784	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	we observed significantly higher levels of miR-205 in tumor tissue of esophageal squamous cell carcinoma
tissue_expression_up	hsa-mir-21	Choriocarcinoma	26807210	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	the expression of miR-200b, miR-200c, miR-451, miR-223 and miR-21 were significantly upregulated in mucinous cystadenocarcinoma
tissue_expression_up	hsa-mir-221	Choriocarcinoma	26258795	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	MiR-221 and miR-222 (miR-221/222) are well-studied oncogenic microRNAs that are frequently upregulated in several types of human tumors
tissue_expression_up	hsa-mir-223	Choriocarcinoma	26807210	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	the expression of miR-200b, miR-200c, miR-451, miR-223 and miR-21 were significantly upregulated in mucinous cystadenocarcinoma
tissue_expression_up	hsa-mir-31	Choriocarcinoma	23946296	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.
tissue_expression_up	hsa-mir-130a	Chronic Alcohol-Induced Alveolar Macrophage Dysfunction	26677910							Alcohol increased levels of microRNA-130a/-301a, these findings demonstrate that targeting PPARγ provides a novel therapeutic approach for mitigating alcohol-induced AM derangements and susceptibility to lung infection
tissue_expression_up	hsa-mir-301a	Chronic Alcohol-Induced Alveolar Macrophage Dysfunction	26677910							Alcohol increased levels of microRNA-130a/-301a, these findings demonstrate that targeting PPARγ provides a novel therapeutic approach for mitigating alcohol-induced AM derangements and susceptibility to lung infection
tissue_expression_up	hsa-mir-150	Chronic Heart Failure	24239242	cardiovascular system disease	DOID:6000	I50	D006333		HP:0001635	MicroRNA-150 counteracts ADIPOR2 up-regulation in CHF and thus may contribute to adiponectin resistance. Targeting microRNA-150 may be a future strategy to restore cardioprotective adiponectin effects.
tissue_expression_up	hsa-mir-143	Chronic Hepatitis	24993656			K75.9	D006521		HP:0200123	In conclusion, the expression of miR-143 and miR-215 in serum were significantly up-regulated in patients with chronic hepatitis and HCC. Due to its reasonable sensitivity and specificity for both diseases, miR-143 and miR-215 could be as potential circulating biomarkers.
tissue_expression_up	hsa-mir-215	Chronic Hepatitis	24993656			K75.9	D006521		HP:0200123	In conclusion, the expression of miR-143 and miR-215 in serum were significantly up-regulated in patients with chronic hepatitis and HCC. Due to its reasonable sensitivity and specificity for both diseases, miR-143 and miR-215 could be as potential circulating biomarkers.
tissue_expression_up	hsa-let-7b	Chronic Inflammation	27539004							PM2.5 exposure increased miR-3560 and let-7b-5p in the hippocampus, two proteins that regulate genes Oxct1 and Lin28b that control ketogenesis and glycosylation, and neural cell differentiation, respectively
tissue_expression_up	hsa-mir-3560	Chronic Inflammation	27539004							PM2.5 exposure increased miR-3560 and let-7b-5p in the hippocampus, two proteins that regulate genes Oxct1 and Lin28b that control ketogenesis and glycosylation, and neural cell differentiation, respectively
tissue_expression_up	hsa-mir-3588	Chronic Inflammation	27539004							Expression levels of cortical miR-6315, miR-3588, and miR-466b-5p were upregulated
tissue_expression_up	hsa-mir-466b	Chronic Inflammation	27539004							Expression levels of cortical miR-6315, miR-3588, and miR-466b-5p were upregulated
tissue_expression_up	hsa-mir-6315	Chronic Inflammation	27539004							Expression levels of cortical miR-6315, miR-3588, and miR-466b-5p were upregulated
tissue_expression_up	hsa-mir-199a-1	Chronic Obstructive Pulmonary Disease	22383663	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	miR-34a and miR-199a-5p expression was increased and the phosphorylation of AKT was decreased in COPD lungs. The miR-199a-5p expression was correlated with HIF-1ж┿protein expression in COPD patient's lungs. Transfection of HPMVEC with the miR-199a-5p precursor gene decreased HIF-1ж┿protein expression, and transfection with the miR-34a precursor gene increased miR-199a-5p expression.
tissue_expression_up	hsa-mir-34a	Chronic Obstructive Pulmonary Disease	22383663	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	miR-34a and miR-199a-5p expression was increased and the phosphorylation of AKT was decreased in COPD lungs. The miR-199a-5p expression was correlated with HIF-1ж┿protein expression in COPD patient's lungs. Transfection of HPMVEC with the miR-199a-5p precursor gene decreased HIF-1ж┿protein expression, and transfection with the miR-34a precursor gene increased miR-199a-5p expression.
tissue_expression_up	hsa-mir-155	Colitis, Ulcerative	20586854	gastrointestinal system disease	DOID:8577	K51	D003093			miR-155:Upregulated miRNA may be responsible for the development of intestinal inflammation in UC
tissue_expression_up	hsa-mir-21	Colitis, Ulcerative	20586854	gastrointestinal system disease	DOID:8577	K51	D003093			miR-21:Upregulated miRNA may be responsible for the development of intestinal inflammation in UC
tissue_expression_up	hsa-let-7f	Colon Neoplasms	26556872			D12.6	D003110		HP:0100273	highly up-regulated miRNAs, let-7f-5p, miR-455-3p, miR-98, miR-155-5p and the down-regulated miRNAs, miR-1, miR-127-5p, miR-142-5p, miR-202-5p were associated with colon cancer pathways
tissue_expression_up	hsa-mir-101	Colon Neoplasms	28560419			D12.6	D003110		HP:0100273	Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation.
tissue_expression_up	hsa-mir-101	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-106a	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-106a	Colon Neoplasms	20551304			D12.6	D003110		HP:0100273	miRNA expression profiles from 29 patients showed higher expression of miR-21 and miR-106a in patients with adenomas and CRCs compared with individuals free of colorectal neoplasia.
tissue_expression_up	hsa-mir-106b	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-107	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-128-2	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-128a	Colon Neoplasms	22898888			D12.6	D003110		HP:0100273	in colonic fibroblasts p38 was only moderately activated, p53 as well as p16 expressions were upregulated in the presence of increased expression of miR-34a, miR-128a and miR-449a.
tissue_expression_up	hsa-mir-135b	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-137	Colon Neoplasms	19659786			D12.6	D003110		HP:0100273	expressed differently, miR-137 upregulated in non-cancerous colonic tissues from colon cancer patients with lymph node metastasis
tissue_expression_up	hsa-mir-142	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-146a	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-155	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-155	Colon Neoplasms	24989910			D12.6	D003110		HP:0100273	The level of miR-155 was gradually elevated with the formation of colitis-associated  colon cancer.
tissue_expression_up	hsa-mir-155	Colon Neoplasms	26556872			D12.6	D003110		HP:0100273	highly up-regulated miRNAs, let-7f-5p, miR-455-3p, miR-98, miR-155-5p and the down-regulated miRNAs, miR-1, miR-127-5p, miR-142-5p, miR-202-5p were associated with colon cancer pathways
tissue_expression_up	hsa-mir-155	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-17	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-18a	Colon Neoplasms	23229340			D12.6	D003110		HP:0100273	MicroRNA-18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells
tissue_expression_up	hsa-mir-18a	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-18b	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-191	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-192	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_up	hsa-mir-194	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_up	hsa-mir-196b	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-19a	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-19a	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-19b-1	Colon Neoplasms	22382630			D12.6	D003110		HP:0100273	In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells.
tissue_expression_up	hsa-mir-19b-2	Colon Neoplasms	22382630			D12.6	D003110		HP:0100273	In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells.
tissue_expression_up	hsa-mir-20a	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-20a	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-21	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-21	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-215	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_up	hsa-mir-221	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-221	Colon Neoplasms	25932237			D12.6	D003110		HP:0100273	high expression of miR-211 (HR=2.394, 95% CI: 1.210-4.910, P=0.006)  were identified as risk factors for colon cancer prognosis
tissue_expression_up	hsa-mir-223	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-223	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-224	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-24-1	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-24-2	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-29a	Colon Neoplasms	22426940			D12.6	D003110		HP:0100273	High expression of miR-29a was associated with a longer disease-free survival (DFS) for patients with stage 2 colon cancer, on both univariate and multivariate analyses.
tissue_expression_up	hsa-mir-29b	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_up	hsa-mir-29b-1	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-301b	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-30c-1	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-30c-2	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-31	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-32	Colon Neoplasms	16461460			D12.6	D003110		HP:0100273	overexpressed
tissue_expression_up	hsa-mir-32	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_up	hsa-mir-326	Colon Neoplasms	22043014			D12.6	D003110		HP:0100273	The development of colonic inflammation in IL-10(-/-) mice was accompanied by upregulation in the expression of 10 miRNAs (miR-19a, miR-21, miR-31, miR-101, miR-223, miR-326, miR-142-3p, miR-142-5p, miR-146a, and miR-155)
tissue_expression_up	hsa-mir-335	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-33a	Colon Neoplasms	22180714			D12.6	D003110		HP:0100273	Compared with expression in SW1116 cells, 35 miRNAs (including hsa-miR-192, hsa-miR-29b, hsa-miR-215, hsa-miR-194, hsa-miR-33a and hsa-miR-32) were upregulated more than 1.5-fold, and 11 miRNAs (including hsa-miR-93, hsa-miR-1231, hsa-miRPlus-F1080, hsa-miR-524-3p, hsa-miR-886-3p and hsa-miR-561) were downregulated in SW1116csc.
tissue_expression_up	hsa-mir-34a	Colon Neoplasms	17875987			D12.6	D003110		HP:0100273	highly upregulated
tissue_expression_up	hsa-mir-34a	Colon Neoplasms	22898888			D12.6	D003110		HP:0100273	in colonic fibroblasts p38 was only moderately activated, p53 as well as p16 expressions were upregulated in the presence of increased expression of miR-34a, miR-128a and miR-449a.
tissue_expression_up	hsa-mir-374a	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-424	Colon Neoplasms	20132431			D12.6	D003110		HP:0100273	A total of 14 miRNAs were found to be associated with colonic cancer, in which the expression of miR-106b, miR-135b, miR-18a, miR-18b, miR-196b, miR-19a, miR-224, miR-335, miR-424, miR-20a*, miR-301b and miR-374a were up-regulated and the expression of miR-378 and miR-378* were downregulated in colonic cancer tissues, compared with the para-cancerous control.
tissue_expression_up	hsa-mir-449a	Colon Neoplasms	22898888			D12.6	D003110		HP:0100273	in colonic fibroblasts p38 was only moderately activated, p53 as well as p16 expressions were upregulated in the presence of increased expression of miR-34a, miR-128a and miR-449a.
tissue_expression_up	hsa-mir-629	Colon Neoplasms	19946373			D12.6	D003110		HP:0100273	upregulated
tissue_expression_up	hsa-mir-133a-2	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-133b:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-135a-1	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-135a:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-135a-2	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-135a:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-17	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-17:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-183	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-183:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-203	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-203:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-20a	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-20:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-223	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-223:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-224	Colorectal Adenocarcinoma	25420464	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-224 is significantly upregulated in malignant colorectal tumors compared to adjacent non-cancer mucosae, and its enhanced expression constitutes an independent predictor of short-term relapse and poor overall survival in colorectal adenocarcinoma patients.
tissue_expression_up	hsa-mir-25	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-25:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-31	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-31:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-92a	Colorectal Adenocarcinoma	25663865	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		A statistically significant difference was observed between the expression levels of miR-92a in CA and the paralesional normal controls.
tissue_expression_up	hsa-mir-92a-1	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-92:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-92a-2	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-92:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-93	Colorectal Adenocarcinoma	20413677	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-93:eleven miRNAs (miR-183, -31, -20, -25, -92, -93, -17, -135a, -203,-133b, and -223) were over-expressed in CRC relative to mucosa,
tissue_expression_up	hsa-mir-106a	Colorectal Carcinoma	24670448	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		plasma miR-106a is up-regulated in CRC patients, suggesting its potential value for the diagnosis of CRC.
tissue_expression_up	hsa-mir-10b	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-125b	Colorectal Carcinoma	28881590	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Upregulation of microRNA-125b by G-CSF promotes metastasis in colorectal cancer
tissue_expression_up	hsa-mir-125b	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-126	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-1287	Colorectal Carcinoma	27251300	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-1287 was significantly upregulated in the group of CRC samples compared with matched noncancerous tissue samples.
tissue_expression_up	hsa-mir-129	Colorectal Carcinoma	25218158	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Piceatannol promotes apoptosis via up-regulation of microRNA-129 expression in colorectal cancer cell lines.
tissue_expression_up	hsa-mir-133a	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-133b	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-143	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-145	Colorectal Carcinoma	25019299	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Up-regulation of microRNA-145 associates with lymph node metastasis in colorectal cancer.
tissue_expression_up	hsa-mir-145	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-146a	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-181a	Colorectal Carcinoma	27264420	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		IL-1尾 induced the expression of miR-181a.
tissue_expression_up	hsa-mir-183	Colorectal Carcinoma	24150523	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The increased expression of miR-183 is closely related to advanced clinical stage, lymph node and distant metastases, and poor prognosis of CRC,indicating that miR-183 may serve as a predictive biomarker for the prognosis or the aggressiveness of CRC.
tissue_expression_up	hsa-mir-199a	Colorectal Carcinoma	24711074	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-199a-5p loss up-regulated DDR1 aggravated colorectal cancer by activating epithelial-to-mesenchymal transition related signaling.
tissue_expression_up	hsa-mir-199a	Colorectal Carcinoma	28639895	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells.
tissue_expression_up	hsa-mir-199a	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-199b	Colorectal Carcinoma	28639895	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1+ colorectal cancer stem cells.
tissue_expression_up	hsa-mir-199b	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-200a	Colorectal Carcinoma	26790446	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of MMP-2 and -9 was elevated, on the other hand, in cell lines derived from primary tumor cancer cells as well as the expression of miR-21, miR-29a, and miR-200a.
tissue_expression_up	hsa-mir-20a	Colorectal Carcinoma	21551242	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	24265822	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The present findings suggest that high expression of miR-21 might predict poor prognosis in patients with colorectal cancer.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	26790446	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of MMP-2 and -9 was elevated, on the other hand, in cell lines derived from primary tumor cancer cells as well as the expression of miR-21, miR-29a, and miR-200a.
tissue_expression_up	hsa-mir-211	Colorectal Carcinoma	26152286	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA 211 expression is upregulated and associated with poor prognosis in colorectal cancer: a case-control study.
tissue_expression_up	hsa-mir-22	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-25	Colorectal Carcinoma	24293092	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis.
tissue_expression_up	hsa-mir-28	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-mir-29a	Colorectal Carcinoma	26790446	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of MMP-2 and -9 was elevated, on the other hand, in cell lines derived from primary tumor cancer cells as well as the expression of miR-21, miR-29a, and miR-200a.
tissue_expression_up	hsa-mir-29b	Colorectal Carcinoma	27346400	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression level of miR-29b is reduced in colorectal cancer tissues compared with that in the adjacent colorectal tissues.
tissue_expression_up	hsa-mir-31	Colorectal Carcinoma	21551242	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies.
tissue_expression_up	hsa-mir-34a	Colorectal Carcinoma	21566225	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The gene encoding the miR-34a microRNA is a transcriptional target of the p53 tumor suppressor protein and subject to epigenetic inactivation in colorectal cancer and numerous other tumor types
tissue_expression_up	hsa-mir-576	Colorectal Carcinoma	22740910	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-145, miR-1, miR-146a, miR-576-5p, miR-126*, HS287, miR-28-5p, miR-143, miR-199b-5p, miR-199a-5p, miR-10b, miR-22, miR-133b, miR-145*, miR-199a, miR-133a, miR-125b and downregulation of miR-31 and HS170 were observed in brain-metastatic carcinomas.
tissue_expression_up	hsa-let-7a-1	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-let-7a-1	Colorectal Carcinoma	22120473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases.
tissue_expression_up	hsa-let-7a-2	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-let-7a-2	Colorectal Carcinoma	22120473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases.
tissue_expression_up	hsa-let-7a-3	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-let-7a-3	Colorectal Carcinoma	22120473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases.
tissue_expression_up	hsa-mir-106a	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-mir-1179	Colorectal Carcinoma	21174058	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis
tissue_expression_up	hsa-mir-125b-2	Colorectal Carcinoma	21174058	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis
tissue_expression_up	hsa-mir-126	Colorectal Carcinoma	22397399	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The median miRNA-126 expression level was significantly higher in patients responding to XELOX (capecitabine and oxaliplatin).
tissue_expression_up	hsa-mir-135a-1	Colorectal Carcinoma	22120473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases.
tissue_expression_up	hsa-mir-135a-2	Colorectal Carcinoma	22120473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases.
tissue_expression_up	hsa-mir-139	Colorectal Carcinoma	21174058	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis
tissue_expression_up	hsa-mir-141	Colorectal Carcinoma	25989926	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools.
tissue_expression_up	hsa-mir-144	Colorectal Carcinoma	21863218	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer.
tissue_expression_up	hsa-mir-150	Colorectal Carcinoma	21174058	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-150*, miR-125b-2*, miR-1179 and miR-139-3p were up-regulated in colorectal cancers with liver metastasis
tissue_expression_up	hsa-mir-155	Colorectal Carcinoma	26261588	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-155-5p expression is up-regulated in most CRC and promotes proliferation, invasion and metastasis of CRC cells. It may play an essential role in tumorigenesis and tumor progression of CRC.
tissue_expression_up	hsa-mir-155	Colorectal Carcinoma	21412018	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High miR-155 expression was significantly correlated with lymph node metastases. The overall (OS) and disease-free survival (DFS) rates of patients with high miR-155 expression were also significantly worse than those in patients with low miR-155 expression.
tissue_expression_up	hsa-mir-16	Colorectal Carcinoma	25989926	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools.
tissue_expression_up	hsa-mir-17	Colorectal Carcinoma	19201770	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-17-3p: up-regulated both in plasma and tissue samples
tissue_expression_up	hsa-mir-17	Colorectal Carcinoma	19287964	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-17-5p: up-regulated
tissue_expression_up	hsa-mir-17	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-mir-181a-2	Colorectal Carcinoma	22641662	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells.
tissue_expression_up	hsa-mir-182	Colorectal Carcinoma	25031782	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miRNA-182 in colorectal carcinoma: an independent and tissue-specific prognostic factor.
tissue_expression_up	hsa-mir-182	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-mir-182	Colorectal Carcinoma	23474644	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value
tissue_expression_up	hsa-mir-183	Colorectal Carcinoma	19287964	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-183: up-regulated
tissue_expression_up	hsa-mir-185	Colorectal Carcinoma	21573504	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High expression of miR-185 and low expression of miR-133b were correlated with poor survival (p=0.001 and 0.028, respectively) and metastasis (p=0.007 and 0.036, respectively) in colorectal cancer.
tissue_expression_up	hsa-mir-18a	Colorectal Carcinoma	19287964	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-18a: up-regulated
tissue_expression_up	hsa-mir-199a-1	Colorectal Carcinoma	23292866	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-199a-3p may serve as an efficient biomarker for diagnosis and novel prognostic indicator in colorectal cancer
tissue_expression_up	hsa-mir-199a-2	Colorectal Carcinoma	23292866	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-199a-3p may serve as an efficient biomarker for diagnosis and novel prognostic indicator in colorectal cancer
tissue_expression_up	hsa-mir-19b	Colorectal Carcinoma	25989926	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools.
tissue_expression_up	hsa-mir-200c	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-mir-200c	Colorectal Carcinoma	22641662	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells.
tissue_expression_up	hsa-mir-20a	Colorectal Carcinoma	25989926	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools.
tissue_expression_up	hsa-mir-20a	Colorectal Carcinoma	19287964	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a: up-regulated
tissue_expression_up	hsa-mir-20a	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	25989926	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	26845148	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In the context of previous studies demonstrating increased miRNA-21 expression in metastatic primary tumors, our findings raise the question whether miRNA-21 might be involved in the initiation but not in the perpetuation and growth of metastases.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	21412018	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High miR-21 expression was significantly associated with venous invasion, liver metastasis and tumor stage.The overall (OS) and disease-free survival (DFS) rates of patients with high miR-21 expression were significantly worse than those of patients with low miR-21 expression.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	21930727	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of miR-21 and miR-92a was significantly higher in CRC tissues compared with their adjacent normal tissues (p<0.0001). Patients with CRC had a significantly higher stool miR-21 level (p<0.01) and miR-92a level (p<0.0001) compared with normal controls. Stool miR-92a, but not miR-21, was significantly higher in patients with polyps than in controls (p<0.0001). At a cut-off value of 435 copies/ng of stool RNA, miR-92a had a sensitivity of 71.6% and 56.1% for CRC and polyp, respectively, and a specificity of 73.3%. In addition, the stool miR-92a level demonstrated a higher sensitivity for distal CRC than proximal CRC (p<0.05), and a higher sensitivity for advanced adenoma than minor polyps (p<0.05). Removal of tumour resulted in reduced stool miR-21 and miR-92a levels (p<0.01), and the removal of advanced adenoma resulted in a reduction of the stool miR-92a level (p<0.05).
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	22120473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	22289545	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		There was a significantly higher level of miR-21 in CRC tumour tissue than in NAT and high expression of miR-21 was significantly correlated with advanced clinical stage and poor cell differentiation.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	22382630	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In response to 5-FU, miR-19b and miR-21 were over-expressed in 5-FU-resistant cells.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	22476768	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Kaplan-Meier analysis proved that the miR-21 expression levels are correlated to shorter overall survival of CRC patients.
tissue_expression_up	hsa-mir-21	Colorectal Carcinoma	22638884	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers.
tissue_expression_up	hsa-mir-210	Colorectal Carcinoma	22641662	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells.
tissue_expression_up	hsa-mir-215	Colorectal Carcinoma	21752725	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-215 has a unique potential as a prognostic biomarker in stage II and III colon cancer.
tissue_expression_up	hsa-mir-31	Colorectal Carcinoma	19287964	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-31: up-regulated
tissue_expression_up	hsa-mir-335	Colorectal Carcinoma	22120473	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Increased expression of miR-21, mir-135a and miR-335 was associated with clinical progression of CRC (colorectal cancer), while miR-206 demonstrated an opposite trend. The levels of mir-21 did not associate with the expression of PTEN, an important tumour suppressor in CRC and one of many putative targets of miR-21, but interestingly was associated with stage of disease in the PTEN expressing tumours. Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors. Finally, a prognostic signature of miR 21,135a, 335, 206 and let-7a for detecting the presence of metastases had a specificity of 87% and sensitivity of 76% for the presence of metastases.
tissue_expression_up	hsa-mir-34a	Colorectal Carcinoma	22562822	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer.
tissue_expression_up	hsa-mir-625	Colorectal Carcinoma	23506979	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer
tissue_expression_up	hsa-mir-9-1	Colorectal Carcinoma	21562850	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility.
tissue_expression_up	hsa-mir-9-2	Colorectal Carcinoma	21562850	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility.
tissue_expression_up	hsa-mir-92a	Colorectal Carcinoma	25989926	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A set of three specific fecal miRNAs is overexpressed before surgery, and return within the normal range after cancer removal could be considered as an appealing opportunity for a new reliable tool for CRC secondary prevention. However, their role needs to be explored in large prospective trials and compared with the existing screening tools.
tissue_expression_up	hsa-mir-92a-1	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-mir-92a-1	Colorectal Carcinoma	21930727	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of miR-21 and miR-92a was significantly higher in CRC tissues compared with their adjacent normal tissues (p<0.0001). Patients with CRC had a significantly higher stool miR-21 level (p<0.01) and miR-92a level (p<0.0001) compared with normal controls. Stool miR-92a, but not miR-21, was significantly higher in patients with polyps than in controls (p<0.0001). At a cut-off value of 435 copies/ng of stool RNA, miR-92a had a sensitivity of 71.6% and 56.1% for CRC and polyp, respectively, and a specificity of 73.3%. In addition, the stool miR-92a level demonstrated a higher sensitivity for distal CRC than proximal CRC (p<0.05), and a higher sensitivity for advanced adenoma than minor polyps (p<0.05). Removal of tumour resulted in reduced stool miR-21 and miR-92a levels (p<0.01), and the removal of advanced adenoma resulted in a reduction of the stool miR-92a level (p<0.05).
tissue_expression_up	hsa-mir-92a-1	Colorectal Carcinoma	22772712	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer.
tissue_expression_up	hsa-mir-92a-2	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-mir-92a-2	Colorectal Carcinoma	21930727	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The expression of miR-21 and miR-92a was significantly higher in CRC tissues compared with their adjacent normal tissues (p<0.0001). Patients with CRC had a significantly higher stool miR-21 level (p<0.01) and miR-92a level (p<0.0001) compared with normal controls. Stool miR-92a, but not miR-21, was significantly higher in patients with polyps than in controls (p<0.0001). At a cut-off value of 435 copies/ng of stool RNA, miR-92a had a sensitivity of 71.6% and 56.1% for CRC and polyp, respectively, and a specificity of 73.3%. In addition, the stool miR-92a level demonstrated a higher sensitivity for distal CRC than proximal CRC (p<0.05), and a higher sensitivity for advanced adenoma than minor polyps (p<0.05). Removal of tumour resulted in reduced stool miR-21 and miR-92a levels (p<0.01), and the removal of advanced adenoma resulted in a reduction of the stool miR-92a level (p<0.05).
tissue_expression_up	hsa-mir-92b	Colorectal Carcinoma	19287964	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-92: up-regulated
tissue_expression_up	hsa-mir-93	Colorectal Carcinoma	21826996	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		upregulated in colon cancer compared to normal colonic mucosa
tissue_expression_up	hsa-mir-9-3	Colorectal Carcinoma	21562850	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility.
tissue_expression_up	hsa-mir-155	Congenital Heart Diseases	29281614	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	Mir-486-3p, mir-486-5p, and mir-155-5p increased in patients with cyanotic heart disease compared with those without heart disease
tissue_expression_up	hsa-mir-486	Congenital Heart Diseases	29281614	cardiovascular system disease	DOID:1682	Q24	D006330	617912	HP:0030680	Mir-486-3p, mir-486-5p, and mir-155-5p increased in patients with cyanotic heart disease compared with those without heart disease
tissue_expression_up	hsa-mir-1-1	Coronary Artery Disease	17401374	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		overexpressed
tissue_expression_up	hsa-mir-1-2	Coronary Artery Disease	17401374	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		overexpressed
tissue_expression_up	hsa-mir-21	Coronary Artery Disease	26183619	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-21 expression was increased in human tissue samples from patients with ISR compared with coronary artery disease specimen
tissue_expression_up	hsa-mir-23a	Coronary Artery Disease	27085964	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-23a was enriched in not only diseased endothelial progenitor cells (EPCs) but also in the plasma of patients with coronary artery disease (CAD).
tissue_expression_up	hsa-mir-146a	Creutzfeldt-Jakob Disease	22043907	nervous system disease	DOID:11949	A81.0	D007562	123400		Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome.
tissue_expression_up	hsa-mir-146a	Crohn Disease	27468194	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The elevated expression of miR-146a and -155 in the inflamed duodenal mucosa of CD patients suggests the role of these miRs in the pathomechanism of inflammatory bowel disease.
tissue_expression_up	hsa-mir-155	Crohn Disease	27468194	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The elevated expression of miR-146a and -155 in the inflamed duodenal mucosa of CD patients suggests the role of these miRs in the pathomechanism of inflammatory bowel disease.
tissue_expression_up	hsa-mir-106b	Cutaneous Melanoma	26662433	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	This study showed that miR-106b may contribute to the progression of cutaneous melanoma and its up-regulation may be independently associated with poor prognosis of cutaneous melanoma. This suggests that miR-106b might serve as a promising biological marker for further risk stratification in the management of cutaneous melanoma.
tissue_expression_up	hsa-mir-155	Demyelinating Diseases	22517757	nervous system disease	DOID:3213	G37.9	D003711	118200		Both in vivo and in vitro, myelin antigen stimulation resulted in significant up-regulation of miR-301a, miR-21, and miR-155.
tissue_expression_up	hsa-mir-21	Demyelinating Diseases	22517757	nervous system disease	DOID:3213	G37.9	D003711	118200		Both in vivo and in vitro, myelin antigen stimulation resulted in significant up-regulation of miR-301a, miR-21, and miR-155.
tissue_expression_up	hsa-mir-146a	Diabetes Mellitus	25490205	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	abnormal miR-146a upregulation may be an important mechanism of delayed wound healing in the diabetic cornea.
tissue_expression_up	hsa-mir-375	Diabetes Mellitus	25875172	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	These findings support an important role of miR-375 in regulation of human β-cell phenotype, and suggest that miR-375 upregulation may facilitate the generation of functional insulin-producing cells following ex-vivo expansion of human islet cells.
tissue_expression_up	hsa-mir-181a	Diabetes Mellitus, Type 1	26892629	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	miRNA-181a expression was significantly higher in diabetic children and  adolescents
tissue_expression_up	hsa-mir-107	Diabetes Mellitus, Type 2	19689793	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	over-expressed in insulin target tissues
tissue_expression_up	hsa-mir-143	Diabetes Mellitus, Type 2	21441927	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism.
tissue_expression_up	hsa-mir-143	Diabetes Mellitus, Type 2	24333576	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Adipocyte-derived factors impair insulin signaling in differentiated human vascular smooth muscle cells via the upregulation of miR-143.
tissue_expression_up	hsa-mir-192	Diabetes Mellitus, Type 2	23372846	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Several highly-expressed islet miRNAs, such as miR-375, have established roles in the regulation of islet function, but others (e.g. miR-27b-3p, miR-192-5p) have not previously been described in the context of islet biology.
tissue_expression_up	hsa-mir-27b	Diabetes Mellitus, Type 2	23372846	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Several highly-expressed islet miRNAs, such as miR-375, have established roles in the regulation of islet function, but others (e.g. miR-27b-3p, miR-192-5p) have not previously been described in the context of islet biology.
tissue_expression_up	hsa-mir-375	Diabetes Mellitus, Type 2	23372846	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Several highly-expressed islet miRNAs, such as miR-375, have established roles in the regulation of islet function, but others (e.g. miR-27b-3p, miR-192-5p) have not previously been described in the context of islet biology.
tissue_expression_up	hsa-mir-483	Diabetes Mellitus, Type 2	22223106	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Increased miR-483-3p expression in vivo, programmed by early-life nutrition, limits storage of lipids in adipose tissue, causing lipotoxicity and insulin resistance and thus increasing susceptibility to metabolic disease.
tissue_expression_up	hsa-mir-30d	Diabetic Cardiomyopathies	25341033				D058065			Our study revealed that mir-30d expression was substantially increased in streptozotocin (STZ)-induced diabetic rats and in high-glucose-treated cardiomyocytes as well.
tissue_expression_up	hsa-mir-146a	Diabetic Nephropathy	25182190			E10-11.21	D003928			Taken together, these findings indicate that the increased expression of miR-155 and miR-146a in the DN patients and in the experimental DN animal models was found to contribute to inflammation-mediated glomerular endothelial injury.
tissue_expression_up	hsa-mir-155	Diabetic Nephropathy	25182190			E10-11.21	D003928			Taken together, these findings indicate that the increased expression of miR-155 and miR-146a in the DN patients and in the experimental DN animal models was found to contribute to inflammation-mediated glomerular endothelial injury.
tissue_expression_up	hsa-mir-192	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_up	hsa-mir-21	Diabetic Nephropathy	22211842			E10-11.21	D003928			TGF-beta1 activates Smad3 to regulate microRNAs that mediate renal fibrosis. Of them, miR-21 and miR-192 are upregulated but miR-29 and miR-200 families are downregulated.
tissue_expression_up	hsa-mir-155	Down Syndrome	22182977	genetic disease	DOID:14250	Q90	D004314	190685		a screening of micro-RNA (miRNA) from Down's syndrome brain and peripheral tissues indicated an upregulation of a chromosome 21-encoded miRNA-155 and a decrease in the abundance of the miRNA-155 mRNA target complement factor H (CFH), an important repressor of the innate immune response.
tissue_expression_up	hsa-mir-155	Early-Stage Breast Carcinoma	24938880			D05.10	D001943	114480		OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.
tissue_expression_up	hsa-mir-181b	Early-Stage Breast Carcinoma	24938880			D05.10	D001943	114480		OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.
tissue_expression_up	hsa-mir-19a	Early-Stage Breast Carcinoma	24938880			D05.10	D001943	114480		OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.
tissue_expression_up	hsa-mir-24	Early-Stage Breast Carcinoma	24938880			D05.10	D001943	114480		OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.
tissue_expression_up	hsa-mir-195	Eclampsia	19642860	cardiovascular system disease	DOID:13593	O15.9	D004461	189800		increased in placenta
tissue_expression_up	hsa-mir-21	Eclampsia	19642860	cardiovascular system disease	DOID:13593	O15.9	D004461	189800		increased in placenta
tissue_expression_up	hsa-mir-222	Eclampsia	19642860	cardiovascular system disease	DOID:13593	O15.9	D004461	189800		increased in placenta
tissue_expression_up	hsa-mir-26b	Eclampsia	19642860	cardiovascular system disease	DOID:13593	O15.9	D004461	189800		increased in placenta
tissue_expression_up	hsa-mir-335	Eclampsia	19642860	cardiovascular system disease	DOID:13593	O15.9	D004461	189800		increased in placenta
tissue_expression_up	hsa-mir-1288	Ectopic Pregnancy	25013942	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Microarray studies showed that four miRNAs were differentially  downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to  control tissue samples.
tissue_expression_up	hsa-mir-223	Ectopic Pregnancy	25013942	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Microarray studies showed that four miRNAs were differentially  downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to  control tissue samples.
tissue_expression_up	hsa-mir-451	Ectopic Pregnancy	25013942	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Microarray studies showed that four miRNAs were differentially  downregulated (hsa-mir-196b, hsa-mir-30a, hsa-mir-873, and hsa-mir-337-3p) and three upregulated (hsa-mir-1288, hsa-mir-451, and hsa-mir-223) in EP compared to  control tissue samples.
tissue_expression_up	hsa-let-7b	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-146b	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-183	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-21	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-221	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-222	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-25	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-31	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-584	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-595	Endocrine Gland Neoplasms	28322989			D35.9	D004701			Several miRNAs show lowered expression in endocrine cancers (i.e. miR-200s, miR-126, miR-7, miR-29a, miR-30a, miR-137, miR-206, miR-101, miR-613, miR-539, miR-205, miR-9, miR-195), while others are commonly overexpressed (i.e. miR-21, miR-183, miR-31, miR-let7b, miR-584, miR-146b, miR-221, miR-222, miR-25, miR-595)
tissue_expression_up	hsa-mir-141	Endometrial Neoplasms	21897839	reproductive system disease	DOID:1380	C54.1	D016889	608089		The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma).
tissue_expression_up	hsa-mir-142	Endometrial Neoplasms	22543862	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-142-5p: Increased expression after Progesterone Treatment.
tissue_expression_up	hsa-mir-146b	Endometrial Neoplasms	22543862	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-146b-5p: Increased expression after Progesterone Treatment.
tissue_expression_up	hsa-mir-155	Endometrial Neoplasms	22525818	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-155 was over-expressed and AGTR1 was underexpressed in endometrial carcinoma tissues.
tissue_expression_up	hsa-mir-200a	Endometrial Neoplasms	21897839	reproductive system disease	DOID:1380	C54.1	D016889	608089		The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma).
tissue_expression_up	hsa-mir-200b	Endometrial Neoplasms	21897839	reproductive system disease	DOID:1380	C54.1	D016889	608089		The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma).
tissue_expression_up	hsa-mir-200b	Endometrial Neoplasms	22904162	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-200b and -210 were significantly up-regulated in the cancerous endometrium.
tissue_expression_up	hsa-mir-200c	Endometrial Neoplasms	21897839	reproductive system disease	DOID:1380	C54.1	D016889	608089		The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma).
tissue_expression_up	hsa-mir-200c	Endometrial Neoplasms	22514717	reproductive system disease	DOID:1380	C54.1	D016889	608089		The expression levels of miR-200c (P<0.0001) and miR-205 (P<0.0001) were significantly increased in endometrial tumors compared to normal tissues. Kaplan-Meier survival analysis revealed that high levels of miR-205 expression were associated with poor patient overall survival.
tissue_expression_up	hsa-mir-205	Endometrial Neoplasms	22514717	reproductive system disease	DOID:1380	C54.1	D016889	608089		The expression levels of miR-200c (P<0.0001) and miR-205 (P<0.0001) were significantly increased in endometrial tumors compared to normal tissues. Kaplan-Meier survival analysis revealed that high levels of miR-205 expression were associated with poor patient overall survival.
tissue_expression_up	hsa-mir-21	Endometrial Neoplasms	21330826	reproductive system disease	DOID:1380	C54.1	D016889	608089		Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer
tissue_expression_up	hsa-mir-21	Endometrial Neoplasms	22543862	reproductive system disease	DOID:1380	C54.1	D016889	608089		Increased expression after Progesterone Treatment.
tissue_expression_up	hsa-mir-210	Endometrial Neoplasms	22904162	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-200b and -210 were significantly up-regulated in the cancerous endometrium.
tissue_expression_up	hsa-mir-429	Endometrial Neoplasms	21897839	reproductive system disease	DOID:1380	C54.1	D016889	608089		The entire miR-200 family (miR-200a/b/c, miR-141, and miR-429) was up-regulated in cases of EEC (endometrioid endometrial adenocarcinoma).
tissue_expression_up	hsa-mir-625	Endometrial Neoplasms	22543862	reproductive system disease	DOID:1380	C54.1	D016889	608089		miR-625*: Increased expression after Progesterone Treatment.
tissue_expression_up	hsa-mir-100	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-100: upregulated
tissue_expression_up	hsa-mir-100	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-10b	Endometriosis	25896413	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-10b directly targets ZEB1 and PIK3CA to curb adenomyotic epithelial cell invasiveness via upregulation of E-Cadherin and inhibition of Akt phosphorylation.
tissue_expression_up	hsa-mir-1-1	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-1: upregulated
tissue_expression_up	hsa-mir-1-2	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-1: upregulated
tissue_expression_up	hsa-mir-125a	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-125a: upregulated
tissue_expression_up	hsa-mir-125b-1	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-125b: upregulated
tissue_expression_up	hsa-mir-125b-2	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-125b: upregulated
tissue_expression_up	hsa-mir-126	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-126: upregulated
tissue_expression_up	hsa-mir-141	Endometriosis	25386850	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	We found five miRNAs specific to epithelial cells--miR-34c, miR-449a, miR-200a, miR-200b and miR-141 showing significantly higher expression in peritoneal endometriotic lesions compared to healthy peritoneal tissues.
tissue_expression_up	hsa-mir-143	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-143: upregulated
tissue_expression_up	hsa-mir-143	Endometriosis	25408705	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-143 was up-regulated in EC (p=0.000) compared to EN.
tissue_expression_up	hsa-mir-145	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-145: upregulated
tissue_expression_up	hsa-mir-145	Endometriosis	24495683	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Up-regulation of mir-29c, mir-200a, mir-145 in the endometrial tissue might play a role in endometriosis associated infertility.
tissue_expression_up	hsa-mir-145	Endometriosis	25408705	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	The miR-145 was up-regulated in both EU (p=0.004) and EC (p=0.000) in compared to EN group.
tissue_expression_up	hsa-mir-150	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-150: upregulated
tissue_expression_up	hsa-mir-193a	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-193a-3p and miR-193a-5p up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-194-1	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-194: upregulated
tissue_expression_up	hsa-mir-194-2	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-194: upregulated
tissue_expression_up	hsa-mir-200a	Endometriosis	24495683	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Up-regulation of mir-29c, mir-200a, mir-145 in the endometrial tissue might play a role in endometriosis associated infertility.
tissue_expression_up	hsa-mir-200b	Endometriosis	25386850	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	We found five miRNAs specific to epithelial cells--miR-34c, miR-449a, miR-200a, miR-200b and miR-141 showing significantly higher expression in peritoneal endometriotic lesions compared to healthy peritoneal tissues.
tissue_expression_up	hsa-mir-202	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-223	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-223: upregulated
tissue_expression_up	hsa-mir-29c	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-29c: upregulated
tissue_expression_up	hsa-mir-29c	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-29c	Endometriosis	24495683	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Up-regulation of mir-29c, mir-200a, mir-145 in the endometrial tissue might play a role in endometriosis associated infertility.
tissue_expression_up	hsa-mir-365a	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-365: upregulated
tissue_expression_up	hsa-mir-365b	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-365: upregulated
tissue_expression_up	hsa-mir-485	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-485-3p up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-509-3	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-509-3-5p up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-574	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-574-3p up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-708	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-720	Endometriosis	21436257	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	up-regulated in endometriomas compared with endometrium.
tissue_expression_up	hsa-mir-99a	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-99a: upregulated
tissue_expression_up	hsa-mir-99b	Endometriosis	19074548	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-99b: upregulated
tissue_expression_up	hsa-mir-143	Endotoxemia	19284987				D019446			Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were down-regulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). The miR-150 and mir-342 response was confirmed by real-time PCR.
tissue_expression_up	hsa-mir-142	Eosinophilic Esophagitis	22815788	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated.
tissue_expression_up	hsa-mir-145	Eosinophilic Esophagitis	22815788	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated.
tissue_expression_up	hsa-mir-146a	Eosinophilic Esophagitis	22815788	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated.
tissue_expression_up	hsa-mir-146b	Eosinophilic Esophagitis	22815788	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated.
tissue_expression_up	hsa-mir-21	Eosinophilic Esophagitis	22815788	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Compared to the post-glucocorticoid treated esophageal mucosa,MiR-214, miR-146b-5b, 146a, 145, 142-3p and 21 were upregulated.
tissue_expression_up	hsa-mir-10b	Ependymoma	29658967	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	low expression of miR-10a and over-expression of miR-10b and miR-29a in ependymoma
tissue_expression_up	hsa-mir-135a-1	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	overexpression
tissue_expression_up	hsa-mir-135a-2	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	overexpression
tissue_expression_up	hsa-mir-15a	Ependymoma	26813564	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases
tissue_expression_up	hsa-mir-17	Ependymoma	22053178	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	miR-17-5p: overexpression
tissue_expression_up	hsa-mir-24	Ependymoma	26813564	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases
tissue_expression_up	hsa-mir-29a	Ependymoma	29658967	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	low expression of miR-10a and over-expression of miR-10b and miR-29a in ependymoma
tissue_expression_up	hsa-mir-190	Epstein-Barr Virus Infection	25086243			B27.90	D020031	300853		mir-190 is upregulated in Epstein-Barr Virus type I latency and modulates cellular mRNAs involved in cell survival and viral reactivation.
tissue_expression_up	hsa-mir-101-1	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-101-2	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-106	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-106b	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-10b	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-126	Esophageal Neoplasms	21269950			C15.9	D004938	133239	HP:0100751	hsa-mir-126 is upregulated and hsa-miR-518b is downregulated in esophageal squamous carcinoma
tissue_expression_up	hsa-mir-130a	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-130b	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-135b	Esophageal Neoplasms	22939244			C15.9	D004938	133239	HP:0100751	Patients with high levels of miR-135b or miR-145 in the posttreatment biopsy specimens had significantly shorter median disease-free survival (DFS) than did those with low levels.
tissue_expression_up	hsa-mir-143	Esophageal Neoplasms	21453382			C15.9	D004938	133239	HP:0100751	The high levels of expression of mature MIR143 and mature MIR145 were associated with recurrence of metastasis in ESCC patients.The high expression of mature MIR21 and mature MIR205 was associated with lymph node positivity in ESCC patients (P < 0.05).
tissue_expression_up	hsa-mir-143	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-145	Esophageal Neoplasms	21453382			C15.9	D004938	133239	HP:0100751	The high levels of expression of mature MIR143 and mature MIR145 were associated with recurrence of metastasis in ESCC patients.The high expression of mature MIR21 and mature MIR205 was associated with lymph node positivity in ESCC patients (P < 0.05).
tissue_expression_up	hsa-mir-145	Esophageal Neoplasms	23477513			C15.9	D004938	133239	HP:0100751	patients with either decreased miR-135b or increased miR-145 expression in cancer tissue had improved disease-free survival
tissue_expression_up	hsa-mir-151	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-15a	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-192	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-194	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-196b	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-200a	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-203	Esophageal Neoplasms	18242245			C15.9	D004938	133239	HP:0100751	Both mir_203 and mir_205 were expressed 2- to 10-fold lower in squamous cell carcinoma and adenocarcinomas than in normal epithelium.
tissue_expression_up	hsa-mir-205	Esophageal Neoplasms	21453382			C15.9	D004938	133239	HP:0100751	The high levels of expression of mature MIR143 and mature MIR145 were associated with recurrence of metastasis in ESCC patients.The high expression of mature MIR21 and mature MIR205 was associated with lymph node positivity in ESCC patients (P < 0.05).
tissue_expression_up	hsa-mir-205	Esophageal Neoplasms	18242245			C15.9	D004938	133239	HP:0100751	Both mir_203 and mir_205 were expressed 2- to 10-fold lower in squamous cell carcinoma and adenocarcinomas than in normal epithelium.
tissue_expression_up	hsa-mir-21	Esophageal Neoplasms	19276261			C15.9	D004938	133239	HP:0100751	miR-21: overexpressed compared with with matched normal epitheliums, regulates the proliferation and invasion
tissue_expression_up	hsa-mir-21	Esophageal Neoplasms	21453382			C15.9	D004938	133239	HP:0100751	The high levels of expression of mature MIR143 and mature MIR145 were associated with recurrence of metastasis in ESCC patients.The high expression of mature MIR21 and mature MIR205 was associated with lymph node positivity in ESCC patients (P < 0.05).
tissue_expression_up	hsa-mir-21	Esophageal Neoplasms	22638884			C15.9	D004938	133239	HP:0100751	miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers.
tissue_expression_up	hsa-mir-21	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-210	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-223	Esophageal Neoplasms	21453483			C15.9	D004938	133239	HP:0100751	miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma.
tissue_expression_up	hsa-mir-25	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-27a	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-28	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	miR-28-3p: upregulated
tissue_expression_up	hsa-mir-31	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-31	Esophageal Neoplasms	26918602			C15.9	D004938	133239	HP:0100751	miR-223, miR-21, and miR-31 as the top-up-regulated species
tissue_expression_up	hsa-mir-452	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-92a	Esophageal Neoplasms	26498375			C15.9	D004938	133239	HP:0100751	13 miRNAs were up-regulated including hsa-mir-153-2, hsa-mir-92a-1 and hsa-mir-182; while 27 miRNAs were down-regulated including hsa-mir comprising 29a, hsa-mir-100 and hsa-mir-139 and  so on.
tissue_expression_up	hsa-mir-93	Esophageal Neoplasms	23092349			C15.9	D004938	133239	HP:0100751	A number of consistently dysregulated miRNAs have been identified in EAC and/or ESCC, including upregulation of miR-21, miR-192, miR-194, miR-106-25 polycistron (miR-25, miR-93, and miR-106b), miR-10b, miR-151, and miR-93, and downregulation of miR-375, miR-203, miR-205, miR-145, miR- 27b,miR-100, miR-125b, let-7c, etc. 
tissue_expression_up	hsa-mir-99b	Esophageal Neoplasms	23761828			C15.9	D004938	133239	HP:0100751	upregulated
tissue_expression_up	hsa-mir-143	Esophagitis	23297865	gastrointestinal system disease	DOID:11963	K20	D004941		HP:0100633	Elevated miR-143, miR-145 and miR-205 expression was observed in oesophageal squamous mucosa of individuals with ulcerative oesophagitis.
tissue_expression_up	hsa-mir-145	Esophagitis	23297865	gastrointestinal system disease	DOID:11963	K20	D004941		HP:0100633	Elevated miR-143, miR-145 and miR-205 expression was observed in oesophageal squamous mucosa of individuals with ulcerative oesophagitis.
tissue_expression_up	hsa-mir-205	Esophagitis	23297865	gastrointestinal system disease	DOID:11963	K20	D004941		HP:0100633	Elevated miR-143, miR-145 and miR-205 expression was observed in oesophageal squamous mucosa of individuals with ulcerative oesophagitis.
tissue_expression_up	hsa-mir-1224	Fatty Liver [unspecific]	19572984	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	expression increased after Lieber-DeCarli or MCD;
tissue_expression_up	hsa-mir-182	Fatty Liver [unspecific]	19572984	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	expression increased after Lieber-DeCarli or MCD;
tissue_expression_up	hsa-mir-125b	Fatty Liver, Non-Alcoholic	26272872	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Our findings identify a novel mechanism by which estrogen protects against hepatic steatosis in female mice via upregulating miR-125b expression.
tissue_expression_up	hsa-mir-149	Fatty Liver, Non-Alcoholic	27061435	disease of metabolism	DOID:0080208	K75.81	D065626	613282		miR-149 was increased in HepG2 cells treated with long-chain fatty acid (FFA)
tissue_expression_up	hsa-mir-200a	Fatty Liver, Non-Alcoholic	20956972	disease of metabolism	DOID:0080208	K75.81	D065626	613282		The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats
tissue_expression_up	hsa-mir-200b	Fatty Liver, Non-Alcoholic	20956972	disease of metabolism	DOID:0080208	K75.81	D065626	613282		The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats
tissue_expression_up	hsa-mir-429	Fatty Liver, Non-Alcoholic	20956972	disease of metabolism	DOID:0080208	K75.81	D065626	613282		The miRNAs analysis showed the significant downregulation of three miRNAs (miR-122, miR-451 and miR-27) and the upregulation of miR-200a, miR-200b and miR-429 in HFD, SD-HF and HFD-HF rats
tissue_expression_up	hsa-mir-21	Fibromatosis, Aggressive	28418912				D018222			The correlation between sporadic DTs and miRNA expression showed that miR-21-3p increased in mutated versus wild-type DTs, while miR-197-3p was decreased
tissue_expression_up	hsa-let-7g	Follicular Atresia	25824548				D005496			let-7g was highly  expressed during follicle atresia
tissue_expression_up	hsa-mir-101-2	Gastric Neoplasms	22450781	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 upregulation in intestinal gastric cancer.
tissue_expression_up	hsa-mir-106a	Gastric Neoplasms	25115709	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Similarly up-regulated microRNA-106a in matched formalin-fixed paraffin-embedded and fresh frozen samples and the dynamic changes during gastric carcinogenesis and development.
tissue_expression_up	hsa-mir-106a	Gastric Neoplasms	18996365	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The level of miR-106a in cancer tissues was significantly higher than that in non-tumor tissues, with an average 1.625-fold increase. miR-106a level was significantly associated with tumor stage, size and differentiation; lymphatic and distant metastasis; and invasion (P<0.01).
tissue_expression_up	hsa-mir-106a	Gastric Neoplasms	22431000	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106a Is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS.
tissue_expression_up	hsa-mir-106b	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106b: overexpressed
tissue_expression_up	hsa-mir-107	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-107	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-129	Gastric Neoplasms	24969565	disease of cellular proliferation	DOID:10534	C16	D013274	137215		lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis.
tissue_expression_up	hsa-mir-142	Gastric Neoplasms	21343377	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A high frequency recurrence and poor survival were observed in gastric cancer cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001). The results indicate that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients.
tissue_expression_up	hsa-mir-142	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-148a	Gastric Neoplasms	21703006	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-148a could reduce the invasiveness, migratory and adhesive activities of gastric tumor cells. Most importantly, elevated miR-148a level in gastric cancer tissues was strongly correlated with distant metastasis, organ and peritoneal invasion and reduced survival rate.
tissue_expression_up	hsa-mir-150	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-150: patients with high expression levels have lower survival time
tissue_expression_up	hsa-mir-150	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-17	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-17: overexpressed
tissue_expression_up	hsa-mir-17	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-181b-1	Gastric Neoplasms	21876743	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues.
tissue_expression_up	hsa-mir-181b-1	Gastric Neoplasms	22901205	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The upregulation of miR-181b may play an important role in the progress of gastric cancer and miR-181b maybe a potential molecular target for anticancer therapeutics of gastric cancer.
tissue_expression_up	hsa-mir-181b-2	Gastric Neoplasms	21876743	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues.
tissue_expression_up	hsa-mir-181b-2	Gastric Neoplasms	22901205	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The upregulation of miR-181b may play an important role in the progress of gastric cancer and miR-181b maybe a potential molecular target for anticancer therapeutics of gastric cancer.
tissue_expression_up	hsa-mir-181c	Gastric Neoplasms	23803080	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The expression of miR-181c is upregulated in GC tissues and plasma, and the miR-181c expression level in GC plasma is positively correlated to that in the corresponding cancer tissues. Plasma miR-181c is possibly a new serological marker for GC diagnosis.
tissue_expression_up	hsa-mir-187	Gastric Neoplasms	22169097	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genome-wide miRNA expression profiles followed with Real-Time quantitative RT-PCR (qRT-PCR) assays revealed that miR-187(*), miR-371-5p and miR-378 were significantly elevated in GC patients. Further validation indicated that miR-378 alone could yields a ROC curve area of 0.861 with 87.5% sensitivity and 70.73% specificity in discriminating GC patients from healthy controls.
tissue_expression_up	hsa-mir-18a	Gastric Neoplasms	25416437	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-18a may be a promising biomarker for the detection of gastric cancer and its upregulation may be potentially associated with unfavorable prognosis of bladder cancer, suggesting that miR-18a might serve as a potential biological marker for further risk stratification in the management of gastric cancer.
tissue_expression_up	hsa-mir-18a	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-18a: overexpressed
tissue_expression_up	hsa-mir-18b	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-18b: overexpressed
tissue_expression_up	hsa-mir-191	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-191	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-192	Gastric Neoplasms	24981590	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data suggest that frequently up-regulated miR-215/192 in gastric cancer may participate in gastric cancer progression.
tissue_expression_up	hsa-mir-192	Gastric Neoplasms	21119604	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro.
tissue_expression_up	hsa-mir-194	Gastric Neoplasms	25412959	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-194 overexpression or RBX1 lowexpression was associated with prolonged survival of GC patients. In conclusion, upregulation of miR-194 can inhibit proliferation, migration, and invasion of GC cells, possibly by targeting RBX1. Aberrant expression of miR-194  and RBX1 is correlated to GC patient survival time.
tissue_expression_up	hsa-mir-195	Gastric Neoplasms	22046085	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13).
tissue_expression_up	hsa-mir-196a	Gastric Neoplasms	25374225	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features andprognosis in gastric cancer.
tissue_expression_up	hsa-mir-196a-1	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-196a-1	Gastric Neoplasms	22420029	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The expression level of miR-196a microRNA significantly increased in primary gastric cancer tissues versus adjacent normal tissues. In addition, extracellular miR-196a detected in conditioned medium was strongly correlated with its cellular expression status and increased circulating miR-196a in patient serum was associated with gastric cancer disease status and relapse.
tissue_expression_up	hsa-mir-196a-2	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-196a-2	Gastric Neoplasms	22420029	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The expression level of miR-196a microRNA significantly increased in primary gastric cancer tissues versus adjacent normal tissues. In addition, extracellular miR-196a detected in conditioned medium was strongly correlated with its cellular expression status and increased circulating miR-196a in patient serum was associated with gastric cancer disease status and relapse.
tissue_expression_up	hsa-mir-199a-1	Gastric Neoplasms	22046085	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13).
tissue_expression_up	hsa-mir-199a-2	Gastric Neoplasms	22046085	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13).
tissue_expression_up	hsa-mir-19a	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-19a: overexpressed
tissue_expression_up	hsa-mir-200b	Gastric Neoplasms	23851184	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22.
tissue_expression_up	hsa-mir-20a	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-20a: overexpressed
tissue_expression_up	hsa-mir-20b	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-20b: patients with high expression levels have lower survival time
tissue_expression_up	hsa-mir-20b	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-20b: overexpressed
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	23888942	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Oxidative stress upregulates PDCD4 expression in patients with gastric cancer via miR-21.
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	26209976	disease of cellular proliferation	DOID:10534	C16	D013274	137215		It seems that miR-21 and miR-221 expression pattern in Iranian patients with gastric cancer are similar to any other population. Considering the increased expression level of two miRNAs in cancerous tissue compared to normal tissue as well as the area under ROC curve, miR-21 and miR-221 can be used for early detection of gastric cancer.
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21: overexpressed
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	20372781	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Expression of miR-21 in cancer tissues was significantly higher than in non-cancer tissues
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	21876743	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Doxifluridine/Oxaliplatin treated advanced stage gastric cancer patients. The expression of miR-181b and miR-21 was significantly overexpressed in gastric tumors compared to normal gastric tissues.
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	22638884	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers.
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	26824898	disease of cellular proliferation	DOID:10534	C16	D013274	137215		hsa-miR-21-5p was more highly expressed in the recurrence group than in the nonrecurrence group
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	27179559	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-21 is overexpressed in tumour tissue
tissue_expression_up	hsa-mir-21	Gastric Neoplasms	29142602	disease of cellular proliferation	DOID:10534	C16	D013274	137215		there was a higher expression of VEGF and miR-21 in GC tissues compared with that in morphologically adjacent normal tissues whereas PPARα expression was decreased
tissue_expression_up	hsa-mir-214	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-214	Gastric Neoplasms	20022810	disease of cellular proliferation	DOID:10534	C16	D013274	137215		high expression
tissue_expression_up	hsa-mir-215	Gastric Neoplasms	23981575	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Frequently up-regulated miR-215 in gastric cancer may influence cell proliferation by targeting RB1.
tissue_expression_up	hsa-mir-215	Gastric Neoplasms	24981590	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These data suggest that frequently up-regulated miR-215/192 in gastric cancer may participate in gastric cancer progression.
tissue_expression_up	hsa-mir-215	Gastric Neoplasms	21119604	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro.
tissue_expression_up	hsa-mir-218	Gastric Neoplasms	25694126	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Thermo-chemotherapy Induced miR-218 upregulation inhibits the invasion of gastric cancer via targeting Gli2 and E-cadherin.
tissue_expression_up	hsa-mir-22	Gastric Neoplasms	23851184	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22.
tissue_expression_up	hsa-mir-221	Gastric Neoplasms	26209976	disease of cellular proliferation	DOID:10534	C16	D013274	137215		It seems that miR-21 and miR-221 expression pattern in Iranian patients with gastric cancer are similar to any other population. Considering the increased expression level of two miRNAs in cancerous tissue compared to normal tissue as well as the area under ROC curve, miR-21 and miR-221 can be used for early detection of gastric cancer.
tissue_expression_up	hsa-mir-221	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-221	Gastric Neoplasms	22613407	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-221 was up-regulated in 88% (81/92) of gastric cancer tissue samples compared with their paired adjacent nontumour tissue samples. High expression of miR-221 showed a significant correlation with advanced tumour-node-metastasis stage, local invasion and lymphatic metastasis.
tissue_expression_up	hsa-mir-223	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-24-1	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-24-2	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-25	Gastric Neoplasms	16461460	disease of cellular proliferation	DOID:10534	C16	D013274	137215		overexpressed
tissue_expression_up	hsa-mir-26b	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-301a	Gastric Neoplasms	23832550	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-301a overexpression correlated with TNM stage and prognosis,suggesting that miR-301a is involved in cellular clone formation, migration, and invasion in vitro and may play an important role in the clinical progression and prognosis of gastric cancer.
tissue_expression_up	hsa-mir-302a	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-302b	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-302c	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-302d	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-302e	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-302f	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-30b	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-340	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-340*: overexpressed
tissue_expression_up	hsa-mir-34b	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-34b: upregulated in undifferentiated gastric cancer
tissue_expression_up	hsa-mir-34c	Gastric Neoplasms	19148490	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-34c: upregulated in undifferentiated gastric cancer
tissue_expression_up	hsa-mir-371a	Gastric Neoplasms	22169097	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genome-wide miRNA expression profiles followed with Real-Time quantitative RT-PCR (qRT-PCR) assays revealed that miR-187(*), miR-371-5p and miR-378 were significantly elevated in GC patients. Further validation indicated that miR-378 alone could yields a ROC curve area of 0.861 with 87.5% sensitivity and 70.73% specificity in discriminating GC patients from healthy controls.
tissue_expression_up	hsa-mir-372	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-373	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-374b	Gastric Neoplasms	25516656	disease of cellular proliferation	DOID:10534	C16	D013274	137215		upregulation of miR-374b-5p contributes to gastric cancer cell metastasis and invasion through inhibition of RECK expression.
tissue_expression_up	hsa-mir-375	Gastric Neoplasms	21343377	disease of cellular proliferation	DOID:10534	C16	D013274	137215		A high frequency recurrence and poor survival were observed in gastric cancer cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001). The results indicate that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients.
tissue_expression_up	hsa-mir-378a	Gastric Neoplasms	22169097	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Genome-wide miRNA expression profiles followed with Real-Time quantitative RT-PCR (qRT-PCR) assays revealed that miR-187(*), miR-371-5p and miR-378 were significantly elevated in GC patients. Further validation indicated that miR-378 alone could yields a ROC curve area of 0.861 with 87.5% sensitivity and 70.73% specificity in discriminating GC patients from healthy controls.
tissue_expression_up	hsa-mir-421	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-421: overexpressed
tissue_expression_up	hsa-mir-451a	Gastric Neoplasms	22046085	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three miRs, miR-451, miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P < 0.0002, 0.0027 and 0.0046 respectively). High expression of each miR was associated with poorer prognosis for both recurrence and survival. Using miR-451, the positive predictive value for non-recurrence was 100% (13/13).
tissue_expression_up	hsa-mir-520c	Gastric Neoplasms	22374783	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Real-time RT-PCR analysis demonstrated an increase in mir-21 and mir-302 expression level in CSCs(cancer stem cells), relative to cancer cells, whereas let-7a expression level was decreased in CSC in comparison with cancer cells. mir-372, mir-373 and mir-520c-5p were markedly increased in cancer cells in comparison with CSCs.
tissue_expression_up	hsa-mir-630	Gastric Neoplasms	24621930	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Increased microRNA-630 expression in gastric cancer is associated with poor overall survival.
tissue_expression_up	hsa-mir-658	Gastric Neoplasms	19175831	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-658: overexpressed
tissue_expression_up	hsa-mir-874	Gastric Neoplasms	23800944	disease of cellular proliferation	DOID:10534	C16	D013274	137215		These results provide a mechanism by which AQP3 is upregulated, as well as highlight the importance of miR-874 in gastric cancer development and progression.
tissue_expression_up	hsa-mir-9-1	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-9-2	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-93	Gastric Neoplasms	22567743	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-93 is highly elevated in gastric cancer, especially in advanced and metastasized gastric cancer, suggesting miR-93 may play critical roles in carcinogenesis of gastric cancer. Overexpression of miR-93 can serve as a novel prognostic marker for gastric cancer.
tissue_expression_up	hsa-mir-9-3	Gastric Neoplasms	22407237	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In the analysis by real-time PCR-based miRNA arrays using pooled RNA samples from five gastric cancer patients, expression of miR-107, miR-21, miR-196a, miR-26b, miR-9, miR-142-3p, miR-30b, miR-150, miR-191 and miR-17 was found to be upregulation.miR-107 expression showed significant association with depth of tumor invasion, lymph node metastasis and stage. In Kaplan-Meier survival curve analysis, overall survival rates (OS) and disease-free survival rates (DFS) of patients with high miR-107 expression were significantly worse than those of patients with low miR-107 expression. In the Cox multivariate analysis, it was shown that miR-107 expression in gastric cancer tissues was an independent prognostic factor for OS and DFS. Significant inverse correlations were demonstrated between miR-107 and DICER1 mRNA. Our results indicate that miR-107 may be useful as an effective biomarker for prediction of a poor prognosis in gastric cancer patients.
tissue_expression_up	hsa-mir-146b	Gastroduodenal Ulcer	25753878			K28				This study indicated that the up-regulation of miR-155 and miR-146b decreases H. pylori (cagA+)-introduced IL6 overexpression, which might weaken the cleanup of H. pylori (cagA+) and contributes to ulcer.
tissue_expression_up	hsa-mir-155	Gastroduodenal Ulcer	25753878			K28				This study indicated that the up-regulation of miR-155 and miR-146b decreases H. pylori (cagA+)-introduced IL6 overexpression, which might weaken the cleanup of H. pylori (cagA+) and contributes to ulcer.
tissue_expression_up	hsa-mir-103	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis
tissue_expression_up	hsa-mir-106a	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis
tissue_expression_up	hsa-mir-106b	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis
tissue_expression_up	hsa-mir-130	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis
tissue_expression_up	hsa-mir-142	Gastrointestinal Neoplasms	21343377			D37.9	D005770			A high frequency recurrence and poor survival were observed in GC cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001),indicating that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients
tissue_expression_up	hsa-mir-17	Gastrointestinal Neoplasms	21743960			D37.9	D005770			Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients.
tissue_expression_up	hsa-mir-18	Gastrointestinal Neoplasms	21743960			D37.9	D005770			Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients.
tissue_expression_up	hsa-mir-19a	Gastrointestinal Neoplasms	21743960			D37.9	D005770			Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients.
tissue_expression_up	hsa-mir-19b-1	Gastrointestinal Neoplasms	21743960			D37.9	D005770			Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients.
tissue_expression_up	hsa-mir-20a	Gastrointestinal Neoplasms	21743960			D37.9	D005770			Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients.
tissue_expression_up	hsa-mir-20a	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis
tissue_expression_up	hsa-mir-221	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-222 and miR-221 showed correlation with shorter metastasis-free survival (P = 0.039 and 0.033,respectively), and miR-222 high expression was related to reduced overall survival (P = 0.012).
tissue_expression_up	hsa-mir-222	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-222 and miR-221 showed correlation with shorter metastasis-free survival (P = 0.039 and 0.033,respectively), and miR-222 high expression was related to reduced overall survival (P = 0.012).
tissue_expression_up	hsa-mir-223	Gastrointestinal Neoplasms	20802470			D37.9	D005770			Taken together, aberrant E2A expression is a diagnostic feature of a subtype of gastric MALT lymphoma with weaker plasmacytoid infiltrates and stronger miR-223 expression.
tissue_expression_up	hsa-mir-25	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis
tissue_expression_up	hsa-mir-375	Gastrointestinal Neoplasms	21343377			D37.9	D005770			A high frequency recurrence and poor survival were observed in GC cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001),indicating that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients
tissue_expression_up	hsa-mir-92-1	Gastrointestinal Neoplasms	21743960			D37.9	D005770			Our study suggests that the presence of BM-DTCs and the upregulation of the miR-17-92 cluster in tumors are both significant but independent prognostic markers in gastrointestinal cancer patients.
tissue_expression_up	hsa-mir-93	Gastrointestinal Neoplasms	22996433			D37.9	D005770			The high expression of miR-20a, miR-25, miR-93, miR-103, miR-106a, miR-106b, miR-130 was associated with lymph node metastasis
tissue_expression_up	hsa-mir-155	Gaucher Disease	26376862	disease of metabolism	DOID:1926	E75.22	D005776	230800		sustained up-regulation of miR-155
tissue_expression_up	hsa-mir-146a	Gerstmann-Straussler-Scheinker Syndrome	22043907	nervous system disease	DOID:4249	A81.82	D016098	137440		Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome.
tissue_expression_up	hsa-mir-27a	Glaucoma	26720444	nervous system disease	DOID:1686	H40	D005901	137750		miR-27a was significantly upregulated.
tissue_expression_up	hsa-mir-106a	Glioblastoma	21483847				D005909		HP:0100843	miR-106aa upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_up	hsa-mir-10b	Glioblastoma	22492962				D005909		HP:0100843	The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions.
tissue_expression_up	hsa-mir-125b	Glioblastoma	24169356				D005909		HP:0100843	High-level expression of miR-125b is associated with poor outcomes of GMB. MiR-125b may have an oncogenic role in GMB cells by promoting cell proliferation and inhibiting apoptosis.
tissue_expression_up	hsa-mir-125b	Glioblastoma	29538610				D005909		HP:0100843	Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients
tissue_expression_up	hsa-mir-128	Glioblastoma	27063952				D005909		HP:0100843	The three most over-expressed miRs in the non-differentiated GSCs compared to xenografts were miR-126, -137 and -128.
tissue_expression_up	hsa-mir-130b	Glioblastoma	26241672				D005909		HP:0100843	Upregulation of miR-130b enhances stem cell-like phenotype in glioblastoma by inactivating the Hippo signaling pathway.
tissue_expression_up	hsa-mir-137	Glioblastoma	22722712				D005909		HP:0100843	miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract).
tissue_expression_up	hsa-mir-142	Glioblastoma	20380575				D005909		HP:0100843	miR-142-3p:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells.
tissue_expression_up	hsa-mir-143	Glioblastoma	20380575				D005909		HP:0100843	miR-143:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K
tissue_expression_up	hsa-mir-145	Glioblastoma	22722712				D005909		HP:0100843	miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract).
tissue_expression_up	hsa-mir-145	Glioblastoma	23577178				D005909		HP:0100843	Most importantly, higher hsa-miR-145 expression in GBM tumors yielded significantly better survival (p<0.005) in a subset of patients thus validating it as a genuine tumor suppressor miRNA.
tissue_expression_up	hsa-mir-146b	Glioblastoma	21483847				D005909		HP:0100843	miR-146b upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_up	hsa-mir-148a	Glioblastoma	21483847				D005909		HP:0100843	miR-148a upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_up	hsa-mir-153-1	Glioblastoma	22722712				D005909		HP:0100843	miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract).
tissue_expression_up	hsa-mir-153-2	Glioblastoma	22722712				D005909		HP:0100843	miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract).
tissue_expression_up	hsa-mir-155	Glioblastoma	20380575				D005909		HP:0100843	miR-155:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K
tissue_expression_up	hsa-mir-15a	Glioblastoma	20380575				D005909		HP:0100843	miR-15a:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K
tissue_expression_up	hsa-mir-16	Glioblastoma	29110584				D005909		HP:0100843	Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)
tissue_expression_up	hsa-mir-16-1	Glioblastoma	20380575				D005909		HP:0100843	miR-16:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K
tissue_expression_up	hsa-mir-16-2	Glioblastoma	20380575				D005909		HP:0100843	miR-16:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K
tissue_expression_up	hsa-mir-17	Glioblastoma	20380575				D005909		HP:0100843	miR-17-3p:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells.
tissue_expression_up	hsa-mir-17	Glioblastoma	21483847				D005909		HP:0100843	miR-17-5p upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_up	hsa-mir-17	Glioblastoma	23497354				D005909		HP:0100843	In glioblastoma a high ratio of miR-17 to miR-221/222 was predictive of better overall survival suggesting that high miR-221/222 expression is more adverse for patients than high miR-17 expression.
tissue_expression_up	hsa-mir-17	Glioblastoma	29110584				D005909		HP:0100843	Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)
tissue_expression_up	hsa-mir-181b-1	Glioblastoma	22722712				D005909		HP:0100843	miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract).
tissue_expression_up	hsa-mir-181b-2	Glioblastoma	22722712				D005909		HP:0100843	miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract).
tissue_expression_up	hsa-mir-181d	Glioblastoma	29538610				D005909		HP:0100843	Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients
tissue_expression_up	hsa-mir-193a	Glioblastoma	21483847				D005909		HP:0100843	miR-193a upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_up	hsa-mir-197	Glioblastoma	26081814				D005909		HP:0100843	FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma.
tissue_expression_up	hsa-mir-19a	Glioblastoma	20380575				D005909		HP:0100843	miR-19a:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells.
tissue_expression_up	hsa-mir-19b-1	Glioblastoma	20380575				D005909		HP:0100843	miR-19b:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells.
tissue_expression_up	hsa-mir-19b-2	Glioblastoma	20380575				D005909		HP:0100843	miR-19b:The miR-17-3p, miR-17-5p, miR-19a, miR-19b, miR-142-3p, and miR-142-5p were upregulated in both M059K and M059J cells.
tissue_expression_up	hsa-mir-200b	Glioblastoma	21483847				D005909		HP:0100843	miR-200b upregulated in Glioblastoma vs Normal. Ten miRNAs (miR-20a, miR-106a, miR-17-5p, miR-31, miR-222, miR-148a, miR-221, miR-146b, miR-200b, and miR-193a) could be a signature predicding survival in Glioblastoma.
tissue_expression_up	hsa-mir-21	Glioblastoma	26344589				D005909		HP:0100843	The results indicate that compound 1j can enhance apoptosis, retard proliferation, and up-regulate PDCD4, a target protein of miR-21. In addition,the compound 1j does not influence the expression of multiple miRNAs and the genes that participate in miRNA universal biosynthesis pathway. These results strongly support the assumption that title compounds can serve as a small molecule inhibitor of miR-21.
tissue_expression_up	hsa-mir-21	Glioblastoma	16024602				D005909		HP:0100843	upregulated
tissue_expression_up	hsa-mir-21	Glioblastoma	16039986				D005909		HP:0100843	upregulated
tissue_expression_up	hsa-mir-21	Glioblastoma	17531469				D005909		HP:0100843	MiR-21 is found to be highly expressed in numerous cancers like breast cancer, and glioblastoma and pancreatic cancer.
tissue_expression_up	hsa-mir-21	Glioblastoma	20380575				D005909		HP:0100843	miR-21:The miR-15a, miR-16, miR-143, miR-155, and miR-21 were upregulated in M059K
tissue_expression_up	hsa-mir-21	Glioblastoma	22492962				D005909		HP:0100843	The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions.
tissue_expression_up	hsa-mir-21	Glioblastoma	29110584				D005909		HP:0100843	Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)
tissue_expression_up	hsa-mir-21	Glioblastoma	29559295				D005909		HP:0100843	In our microarray data, lower expression of miR-219-5p, miR-124, and miR-128 and higher expression of miR-21 was observed in GBM compared with the peripheral region, similar to the results of previous reports
tissue_expression_up	hsa-mir-210	Glioblastoma	25586423				D005909		HP:0100843	Acute hypoxia induces upregulation of microRNA-210 expression in glioblastoma spheroids.
tissue_expression_up	hsa-mir-221	Glioblastoma	20428775				D005909		HP:0100843	miR-221:STAT1/2 upregulation under the transcriptional control of INF-alpha signaling after knockdown of miR-221/222 cluster in U251 glioma cells
tissue_expression_up	hsa-mir-221	Glioblastoma	17627278				D005909		HP:0100843	Interestingly, high levels of miR-221&222 appear in glioblastomas and correlate with low levels of p27(Kip1) protein. Thus, deregulated expression of miR-221&222 promotes cancerous growth by inhibiting the expression of p27(Kip1).
tissue_expression_up	hsa-mir-221	Glioblastoma	23497354				D005909		HP:0100843	In glioblastoma a high ratio of miR-17 to miR-221/222 was predictive of better overall survival suggesting that high miR-221/222 expression is more adverse for patients than high miR-17 expression.
tissue_expression_up	hsa-mir-221	Glioblastoma	24155920				D005909		HP:0100843	A number of changes in the levels of microRNAs were detected in differentiating GICs, including over-expression of hsa-miR-21, hsa-miR-29a, hsa-miR-29b, hsa-miR-221 and hsa-miR-222, and down-regulation of hsa-miR-93 and hsa-miR-106a.
tissue_expression_up	hsa-mir-221	Glioblastoma	29110584				D005909		HP:0100843	Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)
tissue_expression_up	hsa-mir-221	Glioblastoma	29538610				D005909		HP:0100843	Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients
tissue_expression_up	hsa-mir-222	Glioblastoma	20428775				D005909		HP:0100843	miR-222:STAT1/2 upregulation under the transcriptional control of INF-alpha signaling after knockdown of miR-221/222 cluster in U251 glioma cells
tissue_expression_up	hsa-mir-222	Glioblastoma	17627278				D005909		HP:0100843	Interestingly, high levels of miR-221&222 appear in glioblastomas and correlate with low levels of p27(Kip1) protein. Thus, deregulated expression of miR-221&222 promotes cancerous growth by inhibiting the expression of p27(Kip1).
tissue_expression_up	hsa-mir-222	Glioblastoma	24155920				D005909		HP:0100843	A number of changes in the levels of microRNAs were detected in differentiating GICs, including over-expression of hsa-miR-21, hsa-miR-29a, hsa-miR-29b, hsa-miR-221 and hsa-miR-222, and down-regulation of hsa-miR-93 and hsa-miR-106a.
tissue_expression_up	hsa-mir-27b	Glioblastoma	21922148				D005909		HP:0100843	Real-time PCR showed that miR-27b was up-regulated in glioma samples and glioma cells. Down-regulation of miR-27b triggered growth inhibition, induced apoptosis and inhibited invasion in glioma cells. In addition, Western blot assay showed that STAT3, c-myc and cyclin D1 were knocked down after treatment with miR-27b inhibitor.
tissue_expression_up	hsa-mir-3163	Glioblastoma	22074483				D005909		HP:0100843	Significantly deregulated miRNAs were miR-3163 (fold change 2.0, p = 0.05), miR-539 (fold change 0.5, p = 0.001), miR-1305 (fold change 0.5, p = 0.05), miR-1260 (fold change 0.5, p = 0.03) and let-7a (fold change 0.3, p = 0.02) after temozolomide treatment.
tissue_expression_up	hsa-mir-375	Glioblastoma	29110584				D005909		HP:0100843	Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375)
tissue_expression_up	hsa-mir-4284	Glioblastoma	24732116				D005909		HP:0100843	A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling.
tissue_expression_up	hsa-mir-491	Glioblastoma	21831363				D005909		HP:0100843	miR-491-5p has high positive correlation with MMP-9 expression and its upregulation was demonstrated to reduce the levels of MMP-9 expression and inhibit cellular invasion in U251 and U87 glioma cells. Furthermore, miR-491-5p suppressed glioma cell invasion via targeting MMP-9 directly.
tissue_expression_up	hsa-mir-885	Glioblastoma	21831363				D005909		HP:0100843	miR-885-5p has high positive correlation with MMP-9 expression and its upregulation was demonstrated to reduce the levels of MMP-9 expression and inhibit cellular invasion in U251 and U87 glioma cells.
tissue_expression_up	hsa-mir-106a	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-106a	Glioma	26439036	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Elevated expression of miRNA-106a plays a crucial role in the development and progression of glioma, probably by promoting the proliferation and suppressing the apoptosis of glioma cells through the JNK/MAPK signaling pathway.
tissue_expression_up	hsa-mir-106b	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-106b	Glioma	22825541	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Upregulation of miR-20a and miR-106b is involved in the acquisition of malignancy of pediatric brainstem gliomas.
tissue_expression_up	hsa-mir-107	Glioma	23811124	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4.
tissue_expression_up	hsa-mir-10b	Glioma	25773393	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Correlation of microRNA-10b upregulation and poor prognosis in human gliomas.
tissue_expression_up	hsa-mir-10b	Glioma	26988656	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Expression levels of miR-10b in glioma tissue were significantly higher than in normal brain tissue
tissue_expression_up	hsa-mir-125b	Glioma	25502291	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Higher expressions of miR-125b and miR-222 have also been proved to be associated with glioma. Furthermore, glioma patients with higher miR-125b, miR-221, and miR-222 expression were manifested to have poorer prognostic status, which might be attributed to their attenuated sensitivity to chemotherapy and radiotherapy.
tissue_expression_up	hsa-mir-125b-1	Glioma	22360855	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The levels of miRNA-125b and MMP9 were significantly higher in SU3 and SU2, also a highly invasive GSCPs we established before, than in U251s.
tissue_expression_up	hsa-mir-132	Glioma	25234714	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Upregulation of miR-132 expression in glioma and its clinical significance.
tissue_expression_up	hsa-mir-15a	Glioma	28060761	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma
tissue_expression_up	hsa-mir-15b	Glioma	26191187	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma.
tissue_expression_up	hsa-mir-16	Glioma	28060761	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma
tissue_expression_up	hsa-mir-17	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-17	Glioma	23226946	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Increased Expression of microRNA-17 Predicts Poor Prognosis in Human Glioma
tissue_expression_up	hsa-mir-182	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-182	Glioma	22788545	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The concentration of miRNA-182 in glioma patients was found to be 3.1 times as high as that in healthy persons, a conclusion in excellent agreement with a separate qPCR measurement of the expression level.
tissue_expression_up	hsa-mir-183	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-183	Glioma	23263745	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-183 upregulates HIF-1a by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells
tissue_expression_up	hsa-mir-183	Glioma	27215622	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	In conclusion, our study indicated that miR-183 was upregulated in glioma, and that  it may be used as a potential biomarker of poor prognosis in patients with glioma.
tissue_expression_up	hsa-mir-184	Glioma	25277131	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-184 upregulation enhanced the malignant phenotype of human glioma cancer cells by reducing FIH-1 protein expression.
tissue_expression_up	hsa-mir-18a	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-18b	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-196a	Glioma	26261539	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our results suggested that both high-miR-196a and low-miR-367 expression may be associated with aggressive progression and unfavorable clinical outcome in glioma patients. And combination of high-miR-196a and low-miR-367 expression may be a novel biomarker in identifying a poor prognosis group of high-grade glioma.
tissue_expression_up	hsa-mir-19a	Glioma	23824915	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-19a and miR-19b overexpression in gliomas.
tissue_expression_up	hsa-mir-19a	Glioma	29658967	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	low expression  of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-528 in low-grade glioma
tissue_expression_up	hsa-mir-19b	Glioma	23824915	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-19a and miR-19b overexpression in gliomas.
tissue_expression_up	hsa-mir-19b	Glioma	29658967	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	low expression  of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-529 in low-grade glioma
tissue_expression_up	hsa-mir-20a	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-20a	Glioma	22381757	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The glioma tissues showed significantly up-regulated expression of miR-20a compared with normal brain tissues (P=0.035). The expression level of miR-20a was higher in high-grade than in low-grade gliomas. miR-20a mimics significantly enhanced the proliferation of U251 cells and the percentage of S-phase cells.
tissue_expression_up	hsa-mir-20a	Glioma	22825541	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Upregulation of miR-20a and miR-106b is involved in the acquisition of malignancy of pediatric brainstem gliomas.
tissue_expression_up	hsa-mir-20b	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-21	Glioma	22335906	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-21 was up-regulated 1.49-fold in SHG-44(R) cells (Radioresistant cell line) relative to the SHG-44 cells.
tissue_expression_up	hsa-mir-21	Glioma	28060761	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma
tissue_expression_up	hsa-mir-210	Glioma	24382515	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	MicroRNA-210 overexpression predicts poorer prognosis in glioma patients.
tissue_expression_up	hsa-mir-218	Glioma	26133092	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Propofol suppresses proliferation and invasion of glioma cells by upregulating microRNA-218 expression.
tissue_expression_up	hsa-mir-221	Glioma	22681957	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma.
tissue_expression_up	hsa-mir-221	Glioma	25428536	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	There are a series of abnormal miRNA expressions in glioma. Among them, miR-221 and miR -222 are clustered miR s with elevated expressions. The over-expressions of miR-221 and miR-222 can be considered as new molecular tags for human glioma (Tab. 5, Fig. 4, Ref. 30).
tissue_expression_up	hsa-mir-221	Glioma	25502291	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Higher expressions of miR-125b and miR-222 have also been proved to be associated with glioma. Furthermore, glioma patients with higher miR-125b, miR-221, and miR-222 expression were manifested to have poorer prognostic status, which might be attributed to their attenuated sensitivity to chemotherapy and radiotherapy.
tissue_expression_up	hsa-mir-222	Glioma	22681957	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma.
tissue_expression_up	hsa-mir-222	Glioma	25428536	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	There are a series of abnormal miRNA expressions in glioma. Among them, miR-221 and miR -222 are clustered miR s with elevated expressions. The over-expressions of miR-221 and miR-222 can be considered as new molecular tags for human glioma (Tab. 5, Fig. 4, Ref. 30).
tissue_expression_up	hsa-mir-222	Glioma	25502291	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Higher expressions of miR-125b and miR-222 have also been proved to be associated with glioma. Furthermore, glioma patients with higher miR-125b, miR-221, and miR-222 expression were manifested to have poorer prognostic status, which might be attributed to their attenuated sensitivity to chemotherapy and radiotherapy.
tissue_expression_up	hsa-mir-224	Glioma	23263909	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Upregulation of microRNA-224 confers a poor prognosis in glioma patients
tissue_expression_up	hsa-mir-23a	Glioma	28060761	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma
tissue_expression_up	hsa-mir-24	Glioma	29658967	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	low expression  of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-530 in low-grade glioma
tissue_expression_up	hsa-mir-27a	Glioma	29658967	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	low expression  of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-531 in low-grade glioma
tissue_expression_up	hsa-mir-27b	Glioma	21922148	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Real-time PCR showed that miR-27b was up-regulated in glioma samples and glioma cells.
tissue_expression_up	hsa-mir-302a	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-302b	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-302c	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-302d	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-335	Glioma	22644918	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Tumor microRNA-335 expression is associated with poor prognosis in human glioma.
tissue_expression_up	hsa-mir-367	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-371a	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-372	Glioma	23298385	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Correlation of microRNA-372 upregulation with poor prognosis in human glioma.
tissue_expression_up	hsa-mir-373	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-527	Glioma	29658967	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	low expression  of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-533 in low-grade glioma
tissue_expression_up	hsa-mir-584	Glioma	29658967	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	low expression  of miR-26a and overexpression of miR-19a/b, miR-24, miR-27a, miR- 584, and miR-532 in low-grade glioma
tissue_expression_up	hsa-mir-9	Glioma	24122417	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma.
tissue_expression_up	hsa-mir-9	Glioma	28060761	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma
tissue_expression_up	hsa-mir-93	Glioma	20406893	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR17 family, mir183-182, and the SC-specific clusters mir367-302 and mir371-373,which are upregulated in gliomas,
tissue_expression_up	hsa-mir-93	Glioma	27185265	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	the upregulated miR-93 level was significantly associated with the advanced malignancy.
tissue_expression_up	hsa-mir-93	Glioma	28440610	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Evaluation Expression of Microrna-93 and Integrin Β8 in Different Types of Glioma Tumors
tissue_expression_up	hsa-mir-98	Glioma	24392454	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Overexpression of RKIP inhibits cell invasion in glioma cell lines through upregulation of miR-98.
tissue_expression_up	hsa-mir-155	Graft-Versus-Host Disease	22408260			D89.813	D006086	614395		miR-155 up-regulation was shown in specimens from patients with pathological evidence of intestinal aGVHD (Acute graft-versus-host disease).
tissue_expression_up	hsa-let-7a-1	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7a: overexpressed
tissue_expression_up	hsa-let-7a-2	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7a: overexpressed
tissue_expression_up	hsa-let-7a-3	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7a: overexpressed
tissue_expression_up	hsa-let-7b	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7b: overexpressed
tissue_expression_up	hsa-let-7c	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7c: overexpressed
tissue_expression_up	hsa-let-7d	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7d: overexpressed
tissue_expression_up	hsa-let-7e	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7e: overexpressed
tissue_expression_up	hsa-let-7f-1	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7f: overexpressed
tissue_expression_up	hsa-let-7f-2	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7f: overexpressed
tissue_expression_up	hsa-let-7g	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7g: overexpressed
tissue_expression_up	hsa-let-7i	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	let-7i: overexpressed
tissue_expression_up	hsa-mir-101-1	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-101-2	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-1271	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-1271 was upregulated compared with normal tissue.
tissue_expression_up	hsa-mir-130b	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-130b: up-regulated
tissue_expression_up	hsa-mir-130b	Head And Neck Neoplasms	22425712	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	up-regulation
tissue_expression_up	hsa-mir-142	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-142-3p: overexpressed
tissue_expression_up	hsa-mir-146b	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-146b: overexpressed
tissue_expression_up	hsa-mir-155	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-155: overexpressed
tissue_expression_up	hsa-mir-155	Head And Neck Neoplasms	22425712	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	up-regulation
tissue_expression_up	hsa-mir-181a-2	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-181a: up-regulated
tissue_expression_up	hsa-mir-181a-2	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-181a-2* was upregulated compared with normal tissue.
tissue_expression_up	hsa-mir-181b-1	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-181b: up-regulated
tissue_expression_up	hsa-mir-181b-1	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-181b-1	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-181b was upregulated compared with normal tissue.
tissue_expression_up	hsa-mir-181b-2	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-181b: up-regulated
tissue_expression_up	hsa-mir-181b-2	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-181b-2	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-181b was upregulated compared with normal tissue.
tissue_expression_up	hsa-mir-181d	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-181d: up-regulated
tissue_expression_up	hsa-mir-181d	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-18a	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-18: overexpressed
tissue_expression_up	hsa-mir-18a	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-18a: up-regulated
tissue_expression_up	hsa-mir-18b	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-18: overexpressed
tissue_expression_up	hsa-mir-193b	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-193b: up-regulated
tissue_expression_up	hsa-mir-195	Head And Neck Neoplasms	21560177	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-200c	Head And Neck Neoplasms	23474763	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	expression of p21, miR-34a and miR-200c are increased, demonstrating functional p53 reactivation.
tissue_expression_up	hsa-mir-21	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21: overexpressed
tissue_expression_up	hsa-mir-21	Head And Neck Neoplasms	19179615	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21: is frequently overexpressed in human HNSCC
tissue_expression_up	hsa-mir-21	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-21: up-regulated
tissue_expression_up	hsa-mir-21	Head And Neck Neoplasms	22425712	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	up-regulation
tissue_expression_up	hsa-mir-21	Head And Neck Neoplasms	22811001	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	The expression level of miR-21 was significantly up-regulated in plasma samples obtained from HNSCC patients (p<0.01) than those from healthy subjects, which were in consistent with our finding in HNSCC tissues.
tissue_expression_up	hsa-mir-221	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-221: up-regulated
tissue_expression_up	hsa-mir-221	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-221* was upregulated compared with normal tissue.
tissue_expression_up	hsa-mir-223	Head And Neck Neoplasms	22425712	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	up-regulation
tissue_expression_up	hsa-mir-29c	Head And Neck Neoplasms	18798260	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-29c: overexpressed
tissue_expression_up	hsa-mir-31	Head And Neck Neoplasms	22425712	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	up-regulation
tissue_expression_up	hsa-mir-34a	Head And Neck Neoplasms	22629428	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis.
tissue_expression_up	hsa-mir-34a	Head And Neck Neoplasms	23474763	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	expression of p21, miR-34a and miR-200c are increased, demonstrating functional p53 reactivation.
tissue_expression_up	hsa-mir-455	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-455: up-regulated
tissue_expression_up	hsa-mir-491	Head And Neck Neoplasms	19351747	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	miR-491: up-regulated
tissue_expression_up	hsa-mir-744	Head And Neck Neoplasms	21637912	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	hsa-mir-744 was upregulated compared with normal tissue.
tissue_expression_up	hsa-let-7a-1	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-let-7a-2	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-let-7b	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-let-7c	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-let-7d	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-let-7e	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-let-7e	Heart Failure	21690488			I50	D006331		HP:0001635	The absolute expression levels of hcmv-miR-UL112, miR-296-5p, and let-7e were further determined in 127 patients and 67 control subjects (fold changes are 2.5, 0.5, and 1.7 respectively; all P<0.0001).
tissue_expression_up	hsa-let-7f-1	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-let-7f-2	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-1	Heart Failure	22735911			I50	D006331		HP:0001635	Some miRNAs highly expressed in the heart, such as miR-1,miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains  controversial.
tissue_expression_up	hsa-mir-106b	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-10b	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-1-1	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-1-2	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-124	Heart Failure	23307820			I50	D006331		HP:0001635	The significant upregulation of miR-124 and miR-134 in the seizure-related stages and children suggested that both can be potential targets for anticonvulsant drugs in the epileptic developing brains, while the different expression patterns of miR-132 and miR-21 may suggest different functions in MTLE pathogenesis.
tissue_expression_up	hsa-mir-125a	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-126	Heart Failure	26162916			I50	D006331		HP:0001635	RV failure in PAH is associated with a specific molecular signature within the RV, contributing to a decrease in RV vascular density and promoting the progression to RV failure. More importantly, miR-126 upregulation in the RV improves microvessel density and RV function in experimental PAH.
tissue_expression_up	hsa-mir-126	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-129-2	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-130a	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-132	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-133	Heart Failure	22735911			I50	D006331		HP:0001635	Some miRNAs highly expressed in the heart, such as miR-1,miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains  controversial.
tissue_expression_up	hsa-mir-134	Heart Failure	23307820			I50	D006331		HP:0001635	The significant upregulation of miR-124 and miR-134 in the seizure-related stages and children suggested that both can be potential targets for anticonvulsant drugs in the epileptic developing brains, while the different expression patterns of miR-132 and miR-21 may suggest different functions in MTLE pathogenesis.
tissue_expression_up	hsa-mir-181a	Heart Failure	27072074			I50	D006331		HP:0001635	In coronary sinus samples, the microRNAs miR-16-5p, miR-27a-3p, miR-27b-3p, miR-29b-3p, miR-29c-3p, miR-30e-5p, miR-92a-3p, miR-125b-5p, miR-140-5p, miR-195-5p, miR-424-5p, and miR-451a were significantly down-regulated, and let-7a-5p, let-7c-5p, let-7e-5p, miR-23b-3p, miR-107, miR-155-5p, miR-181a-5p, miR-181b-5p and miR-320a were up-regulated in heart failure.
tissue_expression_up	hsa-mir-195	Heart Failure	17108080			I50	D006331		HP:0001635	overexpressed
tissue_expression_up	hsa-mir-196a-1	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-196a-2	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-199b	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-200c	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-204	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-205	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-208	Heart Failure	22735911			I50	D006331		HP:0001635	Some miRNAs highly expressed in the heart, such as miR-1,miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains  controversial.
tissue_expression_up	hsa-mir-208a	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-208b	Heart Failure	22859947			I50	D006331		HP:0001635	Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. 
tissue_expression_up	hsa-mir-21	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-21	Heart Failure	22735911			I50	D006331		HP:0001635	Some miRNAs highly expressed in the heart, such as miR-1,miR-133 and miR-208, are strongly associated with the development of cardiac hypertrophy, while the exact role of miR-21 in the cardiovascular system remains  controversial.
tissue_expression_up	hsa-mir-210	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-210	Heart Failure	23660476			I50	D006331		HP:0001635	miR-210 and miR-30a were elevated in the HF and fetus groups.
tissue_expression_up	hsa-mir-211	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-212	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-215	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-215	Heart Failure	22859947			I50	D006331		HP:0001635	Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. 
tissue_expression_up	hsa-mir-216a	Heart Failure	22427379			I50	D006331		HP:0001635	miR-216a was strongly increased in both D-HF (diabetic HF) and ND-HF (nondiabetic HF) patients, negatively correlated with left ventricular ejection fraction.
tissue_expression_up	hsa-mir-216b	Heart Failure	22859947			I50	D006331		HP:0001635	Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. 
tissue_expression_up	hsa-mir-26a-1	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-26a-2	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-28	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-296	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-297	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-29a	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-29b-1	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-300	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-302a	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-30a	Heart Failure	23660476			I50	D006331		HP:0001635	miR-210 and miR-30a were elevated in the HF and fetus groups.
tissue_expression_up	hsa-mir-32	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-320a	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-330	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-340	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-34b	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-34c	Heart Failure	22859947			I50	D006331		HP:0001635	Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. 
tissue_expression_up	hsa-mir-365a	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-365b	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-367	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-367	Heart Failure	22859947			I50	D006331		HP:0001635	Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. 
tissue_expression_up	hsa-mir-372	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-373	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-377	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-381	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-382	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-423	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-424	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-429	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-429	Heart Failure	26408546			I50	D006331		HP:0001635	17 miRNAs exhibited particularly high increases in expression, including miR-598, miR-429, miR-224, miR-425, and miR-221.
tissue_expression_up	hsa-mir-432	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-500a	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-520c	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-525	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-98	Heart Failure	17606841			I50	D006331		HP:0001635	upregulated
tissue_expression_up	hsa-mir-103a	Helicobacter pylori Infection	26945693			B96.81	D016480	600263	HP:0005202	miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples
tissue_expression_up	hsa-mir-181c	Helicobacter pylori Infection	26945693			B96.81	D016480	600263	HP:0005202	miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples
tissue_expression_up	hsa-mir-223	Helicobacter pylori Infection	26945693			B96.81	D016480	600263	HP:0005202	miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples
tissue_expression_up	hsa-mir-370	Helicobacter pylori Infection	26945693			B96.81	D016480	600263	HP:0005202	miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples
tissue_expression_up	hsa-mir-375	Helicobacter pylori Infection	26945693			B96.81	D016480	600263	HP:0005202	miRNAs miR-103a-3p, miR-181c-5p, miR-370-3p, miR-375 and miR-223-3p were evaluated in tissue samples
tissue_expression_up	hsa-mir-193b	Hematologic Neoplasms	19883314	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	miR-193b-365 significantly up-regulated in MM
tissue_expression_up	hsa-mir-122	Hepatitis B Virus Infection	21692939	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Expression of the liver-specific miR-122 was significantly up-regulated in HBV-infected patients.
tissue_expression_up	hsa-mir-122	Hepatitis B Virus Infection	23221562	disease by infectious agent	DOID:2043	B16/18	D006509	610424		HBV mRNAs-mediated miR-122 inhibition up-regulates PTTG1-binding protein which promotes HCC tumor growth and cell invasion
tissue_expression_up	hsa-mir-130a	Hepatitis B Virus Infection	26871786	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Upregulation of miRNA-130a Represents Good Prognosis in Patients With HBV-Related Acute-on-Chronic Liver Failure: A Prospective Study.
tissue_expression_up	hsa-mir-146a	Hepatitis B Virus Infection	19187610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-146a: up-regulated
tissue_expression_up	hsa-mir-181a-2	Hepatitis B Virus Infection	19187610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-181a: up-regulated
tissue_expression_up	hsa-mir-181b-1	Hepatitis B Virus Infection	19187610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-181b: up-regulated
tissue_expression_up	hsa-mir-181b-2	Hepatitis B Virus Infection	19187610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-181b: up-regulated
tissue_expression_up	hsa-mir-200a	Hepatitis B Virus Infection	19187610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-200: up-regulated
tissue_expression_up	hsa-mir-200b	Hepatitis B Virus Infection	19187610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-200: up-regulated
tissue_expression_up	hsa-mir-200c	Hepatitis B Virus Infection	19187610	disease by infectious agent	DOID:2043	B16/18	D006509	610424		miR-200: up-regulated
tissue_expression_up	hsa-mir-122	Hepatitis C Virus Infection	22114337	disease by infectious agent	DOID:1883	B19.2	D006526	609532		A high level of miR122 was expressed by lentiviral vector into human liver cell lines at a level comparable to the endogenous level in Huh7 cells. Among the cell lines we examined, Hep3B cells stably expressing miR122 (Hep3B/miR122) exhibited a significant enhancement of HCVcc propagation. Surprisingly, the productions of infectious particles in Hep3B/miR122 cells upon infection with HCVcc were comparable to those in Huh7 cells. Furthermore, a line of cured cells established by elimination of HCV RNA from the Hep3B/miR122 replicon cells exhibited an enhanced expression of miR122 and a continuous increase of infectious titers of HCVcc in every passage.
tissue_expression_up	hsa-mir-122	Hepatitis C Virus Infection	26272127	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The levels  of miR-122 were higher in liver than those in blood from individuals infected with HCV genotypes 1 and 3
tissue_expression_up	hsa-mir-125b	Hepatitis C Virus Infection	27158204	disease by infectious agent	DOID:1883	B19.2	D006526	609532		In response to HCV core protein stimulation, cytokine production was up-regulated and miR-125b expression was down-regulated in THP-1 cells.
tissue_expression_up	hsa-mir-146a	Hepatitis C Virus Infection	27147737	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-146a-5p level was consistently increased in HCV-infected hepatocyte-like cells
tissue_expression_up	hsa-mir-15b	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		overexpression
tissue_expression_up	hsa-mir-182	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		overexpression
tissue_expression_up	hsa-mir-192	Hepatitis C Virus Infection	27350618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-192 expression was induced by HCV infection
tissue_expression_up	hsa-mir-199b	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		overexpression
tissue_expression_up	hsa-mir-224	Hepatitis C Virus Infection	16331254	disease by infectious agent	DOID:1883	B19.2	D006526	609532		overexpression
tissue_expression_up	hsa-mir-27	Hepatitis C Virus Infection	23897856	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis.
tissue_expression_up	hsa-mir-758	Hepatitis C Virus Infection	25008898	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758.
tissue_expression_up	hsa-mir-125a	Hepatoblastoma	19701500	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	upregulated
tissue_expression_up	hsa-mir-150	Hepatoblastoma	19701500	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	upregulated
tissue_expression_up	hsa-mir-214	Hepatoblastoma	19701500	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	upregulated
tissue_expression_up	hsa-mir-492	Hepatoblastoma	21319197	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma.
tissue_expression_up	hsa-let-7d	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-125	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-125a	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-149	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-186	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-191	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-196b	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-199a	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-214	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-218	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-24	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-30c	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-342	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-374a	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-374b	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-452	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-454	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Eleven other miRNAs (i.e. miR-let-7d, miR-24, miR-30c, miR-125a-3p, miR-149, miR-191, miR-196-b, miR-218, miR-342-3p, miR-452 and miR-454*) were 2- to 2.5-fold more expressed in HIV+ samples than in controls.
tissue_expression_up	hsa-mir-487b	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-532	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-628	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-874	HIV-Associated Lipodystrophy	25063777			E88.1	D039682			Ten of these (i.e. miR-186, miR-199a-3p, miR-214, miR-374a, miR-487b, miR-532-5p, miR-628-5p, miR-874, miR-125-b-1* and miR-374b*) were up-regulated to a significant degree
tissue_expression_up	hsa-mir-122	Human Immunodeficiency Virus Infection	25920531			B20	D015658	609423		our results revealed that the Vpr-upregulated expression of miR-122 is closely related to the stimulation of HCV 5' UTR activity and HCV replication by Vpr, providing new evidence for how HIV interacts with HCV during HIV/HCV co-infection.
tissue_expression_up	hsa-mir-24	Hyperglycemia	25814526	disease of metabolism	DOID:4195	E78.1	D006943		HP:0003074	Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor.
tissue_expression_up	hsa-mir-4532	Hypertension	27176897	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	4 were upregulated (miR鈥?18a, miR鈥?27, miR鈥?18e and miR鈥?532) and 2 downregulated (miR鈥?8 and miR鈥?35b) in SPE placentas compared with controls.
tissue_expression_up	hsa-mir-518a	Hypertension	27176897	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	4 were upregulated (miR鈥?18a, miR鈥?27, miR鈥?18e and miR鈥?532) and 2 downregulated (miR鈥?8 and miR鈥?35b) in SPE placentas compared with controls.
tissue_expression_up	hsa-mir-518e	Hypertension	27176897	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	4 were upregulated (miR鈥?18a, miR鈥?27, miR鈥?18e and miR鈥?532) and 2 downregulated (miR鈥?8 and miR鈥?35b) in SPE placentas compared with controls.
tissue_expression_up	hsa-mir-527	Hypertension	27176897	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	4 were upregulated (miR鈥?18a, miR鈥?27, miR鈥?18e and miR鈥?532) and 2 downregulated (miR鈥?8 and miR鈥?35b) in SPE placentas compared with controls.
tissue_expression_up	hsa-mir-133a-1	Hypertrophy	21893044				D006984			Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a
tissue_expression_up	hsa-mir-133a-2	Hypertrophy	21893044				D006984			Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a
tissue_expression_up	hsa-mir-182	Hypoxic-Ischemic Encephalopathy	26975828			P91.60	D020925			miRNA-182 was highly expressed in the pineal gland.
tissue_expression_up	hsa-mir-34	Idiopathic Pulmonary Fibrosis	27362652	respiratory system disease	DOID:0050156	J84.112	D054990	178500		miR-34a, miR-34b, and miR-34c, but not miR-20a, miR-29c, or miR-let-7f were significantly higher in type II AECs from IPF patients.
tissue_expression_up	hsa-mir-150	Infection [unspecific]	29391047				D007239			upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections
tissue_expression_up	hsa-mir-155	Infection [unspecific]	29391047				D007239			upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections
tissue_expression_up	hsa-mir-21	Infection [unspecific]	29391047				D007239			upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections
tissue_expression_up	hsa-mir-221	Infection [unspecific]	29391047				D007239			upregulated miR-21, miR-155, miR-150, and miR-221, as well as downregulated miR-143 and miR-125, all of them previously linked to other bacterial infections
tissue_expression_up	hsa-let-7b	Infertility	24711889	reproductive system disease	DOID:5223	N46.9/N97.9	D007246			Mir-100, let-7b levels were significantly higher than those in control group (P=0.008 and P=0.009, respectively).
tissue_expression_up	hsa-mir-130b	Inflammation	23733276				D007249			Statistical analysis considering liver donor meta-data including correction for multiple testing revealed strongly elevated levels of miR-21, miR-34a, miR-130b, and miR-132 in cholestatic liver and of miR-21 and miR-130b during inflammation, as indicated by elevated C-reactive protein levels in serum.
tissue_expression_up	hsa-mir-132	Inflammation	23733276				D007249			Statistical analysis considering liver donor meta-data including correction for multiple testing revealed strongly elevated levels of miR-21, miR-34a, miR-130b, and miR-132 in cholestatic liver and of miR-21 and miR-130b during inflammation, as indicated by elevated C-reactive protein levels in serum.
tissue_expression_up	hsa-mir-132	Inflammation	23951048				D007249			Chronic ethanol feeding up-regulated miR-155 and miR-132 expression in mouse cerebellum.
tissue_expression_up	hsa-mir-146a	Inflammation	20098732				D007249			The expression of a few miRs including miR-146a and miR-455 was found to be significantly increased in response to TWEAK treatment. 
tissue_expression_up	hsa-mir-150	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-150	Inflammation	22595106				D007249			Of the 335 human miRNAs identified in the pulp tissues, 3 miRNAs, miR-150, miR-584, and miR-766, were significantly up-regulated in inflamed pulps as compared with normal pulps
tissue_expression_up	hsa-mir-155	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-17	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-18	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-181	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-19a	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-19b-1	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-20a	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-21	Inflammation	23733276				D007249			Statistical analysis considering liver donor meta-data including correction for multiple testing revealed strongly elevated levels of miR-21, miR-34a, miR-130b, and miR-132 in cholestatic liver and of miR-21 and miR-130b during inflammation, as indicated by elevated C-reactive protein levels in serum.
tissue_expression_up	hsa-mir-221	Inflammation	25926893				D007249			Interestingly, miR-221  (2-fold, P鈥?鈥?.002), miR-222 (2.5-fold, P鈥?鈥?.04), and miR-155 (5-fold, P鈥?鈥?.015) were increased in inflamed adipocytes
tissue_expression_up	hsa-mir-222	Inflammation	25926893				D007249			Interestingly, miR-221  (2-fold, P鈥?鈥?.002), miR-222 (2.5-fold, P鈥?鈥?.04), and miR-155 (5-fold, P鈥?鈥?.015) were increased in inflamed adipocytes
tissue_expression_up	hsa-mir-223	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-34a	Inflammation	23733276				D007249			Statistical analysis considering liver donor meta-data including correction for multiple testing revealed strongly elevated levels of miR-21, miR-34a, miR-130b, and miR-132 in cholestatic liver and of miR-21 and miR-130b during inflammation, as indicated by elevated C-reactive protein levels in serum.
tissue_expression_up	hsa-mir-455	Inflammation	20098732				D007249			The expression of a few miRs including miR-146a and miR-455 was found to be significantly increased in response to TWEAK treatment. 
tissue_expression_up	hsa-mir-584	Inflammation	22595106				D007249			Of the 335 human miRNAs identified in the pulp tissues, 3 miRNAs, miR-150, miR-584, and miR-766, were significantly up-regulated in inflamed pulps as compared with normal pulps
tissue_expression_up	hsa-mir-766	Inflammation	22595106				D007249			Of the 335 human miRNAs identified in the pulp tissues, 3 miRNAs, miR-150, miR-584, and miR-766, were significantly up-regulated in inflamed pulps as compared with normal pulps
tissue_expression_up	hsa-mir-92-1	Inflammation	19525145				D007249			Specifically, recent studies indicate that those miRNAs that are selectively and/or highly expressed in immune cells including the miR-17-92 cluster, miR-150, miR-155, miR-181 and miR-223 have a 'permissive' function in the maturation, proliferation and differentiation of myeloid and lymphoid cells.
tissue_expression_up	hsa-mir-132	Inflammatory Bowel Diseases	23598815	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	MiR-132 levels are higher in inflamed compared with apparently quiescent intestinal biopsies from patients with IBD.
tissue_expression_up	hsa-mir-132	Inflammatory Bowel Diseases	26878986	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	significant upregulation of miR-132  and miR-223 was confirmed
tissue_expression_up	hsa-mir-146a	Inflammatory Bowel Diseases	26752469	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	Expression of miR-146a and -155 was higher in the inflamed mucosa of children with CD and UC than in the intact mucosa. Expression of miR-122 elevated in the macroscopically intact colonic regions of CD compared with controls and patients with UC.
tissue_expression_up	hsa-mir-223	Inflammatory Bowel Diseases	26878986	gastrointestinal system disease	DOID:0050589		D015212	PS266600	HP:0002037	significant upregulation of miR-132  and miR-223 was confirmed
tissue_expression_up	hsa-mir-200c	Interstitial Lung Disease	27309544	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	The miR-200c level in the SSc group was significantly higher than in the DM/PM, pSS, and RA groups
tissue_expression_up	hsa-mir-668	Interstitial Lung Disease	22782705	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	upregulated
tissue_expression_up	hsa-mir-92b	Interstitial Lung Disease	22782705	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	upregulated
tissue_expression_up	hsa-mir-146b	Intestinal Schistosomiasis	23825609	disease by infectious agent	DOID:0050597	B65.1	D012554	181460		miRNAs exhibiting a peak expression in the late phase of infection (dpi 45), such as mmu-miR-223, mmu-miR-146a/b, mmu-miR-155, mmu-miR-34c, mmu-miR-199, and mmu-miR-134, may represent a molecular ignature of the development of schistosomal hepatopathy.
tissue_expression_up	hsa-mir-199	Irritable Bowel Syndrome	25681400	syndrome	DOID:9778	K58	D043183			Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1.
tissue_expression_up	hsa-mir-15a	Ischemia-Reperfusion Injury	22783320				D015427			MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury.
tissue_expression_up	hsa-mir-15b	Ischemia-Reperfusion Injury	22783320				D015427			MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury.
tissue_expression_up	hsa-mir-21	Ischemia-Reperfusion Injury	25691473				D015427			miR-21 has been shown to be enriched in kidney tissue in mice and humans with acute kidney injury
tissue_expression_up	hsa-mir-21	Ischemia-Reperfusion Injury	23988020				D015427			Our results demonstrate that besides miR-21, miR-17-5p, and miR-106a are additionally activated during the maintenance and recovery phases of renal I/R injury.
tissue_expression_up	hsa-mir-21	Ischemia-Reperfusion Injury	26178499				D015427			Renal expressions of miR-21 and miR-106a were significantly elevated in ischemia 20 min and 30 min groups at  12 h and 24 h post-reperfusion
tissue_expression_up	hsa-mir-223	Ischemia-Reperfusion Injury	19104939				D015427			miR-223: miR-223 expression levels were greatly up-regulated in the livers after 75 min ischemia followed by 120 min reperfusion when compared to sham controls
tissue_expression_up	hsa-mir-31	Kaposi Sarcoma	21715310	disease of cellular proliferation	DOID:8632	C46	D012514			In the present study, we show that Kaposi sarcoma-associated herpesvirus (KSHV), the etiological agent of KS, induces global miRNA changes in lymphatic endothelial cells (LECs). Specifically, the miR-221/miR-222 cluster is down-regulated, whereas miR-31 is up-regulated.
tissue_expression_up	hsa-mir-31	Kawasaki Syndrome	25039241	immune system disease	DOID:13378	M30.3	D009080	611775		These results suggest that the decrease in FoxP3(+) Treg might be associated with decreased expression of miR-155, leading to aberrant SOCS1/STAT-5 signalling and overexpression of miR-31 in patients with acute KD.
tissue_expression_up	hsa-mir-486	Kideny Transplant Rejection	27323802			T86.11	D006084			iR-486-5p and its target PTEN/foxO3 mRNA were significantly overexpressed (p鈥?鈥?.01) and underexpressed (p鈥?鈥?.01)
tissue_expression_up	hsa-mir-630	Kidney Neoplasms	25031755	disease of cellular proliferation	DOID:263	C64	D007680			The study proves for the first time that miR-630 is upregulated in a majority of ccRCC patients. It also shows that miR-630 expression is an independent prognostic factor for patients with renal cancer, which might be a potential valuable biomarker for ccRCC.
tissue_expression_up	hsa-mir-223	Knee Osteoarthritis	24727161			M17	D020370	165720	HP:0005086	Peroxisomal dysfunction is associated with up-regulation of apoptotic cell death  via miR-223 induction in knee osteoarthritis patients with type 2 diabetes mellitus.
tissue_expression_up	hsa-mir-205	Laryngeal Neoplasms	22605671			C32.3	D007822			Upregulation
tissue_expression_up	hsa-mir-20b	Laryngeal Neoplasms	20806854			C32.3	D007822			upregulated by 3 multiple
tissue_expression_up	hsa-mir-21	Laryngeal Neoplasms	22320969			C32.3	D007822			Mir-21 was up-regulated in LSCCs and HSCCs compared to adjacent non-tumor tissues (P < 0.05), and the up-regulated expression of mir-21 was associated with clinical stage (P = 0.001), T classification (P = 0.007), pathologic differentiation (P = 0.025), and lymph node positivity (P = 0.002).
tissue_expression_up	hsa-mir-21	Laryngeal Neoplasms	22605671			C32.3	D007822			Upregulation
tissue_expression_up	hsa-mir-31	Laryngeal Neoplasms	20806854			C32.3	D007822			upregulated by 3 multiple
tissue_expression_up	hsa-mir-708	Laryngeal Neoplasms	22605671			C32.3	D007822			Upregulation
tissue_expression_up	hsa-mir-93	Laryngeal Neoplasms	20806854			C32.3	D007822			upregulated by 3 multiple
tissue_expression_up	hsa-mir-93	Laryngeal Neoplasms	22605671			C32.3	D007822			Upregulation
tissue_expression_up	hsa-mir-125b	Leukemia	23550646			C95	D007938	613065	HP:0001909	miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune  response or hypoxia are often overexpressed in cancers and leukemias
tissue_expression_up	hsa-mir-155	Leukemia	23550646			C95	D007938	613065	HP:0001909	miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune  response or hypoxia are often overexpressed in cancers and leukemias
tissue_expression_up	hsa-mir-15a	Leukemia	22449094			C95	D007938	613065	HP:0001909	Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells.
tissue_expression_up	hsa-mir-15a	Leukemia	26456833			C95	D007938	613065	HP:0001909	miR-223 and miR-15a were upregulated in 11/19 JMML bone marrow mononuclear cells harboring PTPN11 mutations
tissue_expression_up	hsa-mir-16-1	Leukemia	22449094			C95	D007938	613065	HP:0001909	Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells.
tissue_expression_up	hsa-mir-16-2	Leukemia	22449094			C95	D007938	613065	HP:0001909	Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells.
tissue_expression_up	hsa-mir-196	Leukemia	23550646			C95	D007938	613065	HP:0001909	miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune  response or hypoxia are often overexpressed in cancers and leukemias
tissue_expression_up	hsa-mir-21	Leukemia	23550646			C95	D007938	613065	HP:0001909	miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune  response or hypoxia are often overexpressed in cancers and leukemias
tissue_expression_up	hsa-mir-210	Leukemia	23550646			C95	D007938	613065	HP:0001909	miRNAs such as miR-21, miR-125b, miR-155, miR-196, and miR-210 that are critical for the immune  response or hypoxia are often overexpressed in cancers and leukemias
tissue_expression_up	hsa-mir-17	Leukemia, B-Cell	15944707			C91.31	D015448	151430		overexpression
tissue_expression_up	hsa-mir-18a	Leukemia, B-Cell	15944707			C91.31	D015448	151430		overexpression
tissue_expression_up	hsa-mir-19a	Leukemia, B-Cell	15944707			C91.31	D015448	151430		overexpression
tissue_expression_up	hsa-mir-19b-1	Leukemia, B-Cell	15944707			C91.31	D015448	151430		overexpression
tissue_expression_up	hsa-mir-20a	Leukemia, B-Cell	15944707			C91.31	D015448	151430		overexpression
tissue_expression_up	hsa-mir-92a-1	Leukemia, B-Cell	15944707			C91.31	D015448	151430		overexpression
tissue_expression_up	hsa-mir-182	Leukemia, Biphenotypic, Acute	20227111	disease of cellular proliferation	DOID:9953	C95.0	D015456		HP:0005531	miR-182:miR-584 and miR-182 upregulation in the CD34(+)CD38(-) fraction
tissue_expression_up	hsa-mir-584	Leukemia, Biphenotypic, Acute	20227111	disease of cellular proliferation	DOID:9953	C95.0	D015456		HP:0005531	miR-584:miR-584 and miR-182 upregulation in the CD34(+)CD38(-) fraction
tissue_expression_up	hsa-mir-132	Leukemia, Lymphocytic, Chronic, B-Cell	25645730	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.
tissue_expression_up	hsa-mir-132	Leukemia, Lymphocytic, Chronic, B-Cell	26036258	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
tissue_expression_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	22238073	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	SOCS1 is significantly up-regulated in Nutlin-3-treated p53(wild-type) B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
tissue_expression_up	hsa-mir-212	Leukemia, Lymphocytic, Chronic, B-Cell	25645730	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.
tissue_expression_up	hsa-mir-143	Leukemia, Lymphocytic, Chronic, B-Cell	23615967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference.
tissue_expression_up	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	23615967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference.
tissue_expression_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	27111859	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-143 was downregulated and miR-155 was overexpressed in 13q-H.
tissue_expression_up	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	23615967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference.
tissue_expression_up	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	23615967	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Significant upregulation of miR-150, miR-29c, miR-143 and miR-223 and downregulation of miR-15a was found in mutated versus unmutated CLL, with miR-15a showing the highest fold difference.
tissue_expression_up	hsa-mir-32	Leukemia, Myeloid	21816906	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.
tissue_expression_up	hsa-mir-155	Leukemia, Myeloid, Acute	19744129	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2. 
tissue_expression_up	hsa-mir-23b	Leukemia, Myeloid, Acute	24828865	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia.
tissue_expression_up	hsa-mir-26a	Leukemia, Myeloid, Acute	24828865	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia.
tissue_expression_up	hsa-mir-328	Leukemia, Myeloid, Chronic	25948184	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	miR-328 has been successfully constructed and transfected into K562 cells, miR-328 inhibits the proliferation of K562 cells by up-regulation of C/EBPα.
tissue_expression_up	hsa-mir-107	Leukemia, Promyelocytic, Acute	22967415	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05).
tissue_expression_up	hsa-mir-15b	Leukemia, Promyelocytic, Acute	22967415	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05).
tissue_expression_up	hsa-mir-16	Leukemia, Promyelocytic, Acute	22967415	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05).
tissue_expression_up	hsa-mir-223	Leukemia, Promyelocytic, Acute	22967415	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05).
tissue_expression_up	hsa-mir-342	Leukemia, Promyelocytic, Acute	22967415	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	The expression level of miR-15b, miR-16, miR-107, miR-223 and miR-342 in APL CR group were significantly upregulated compared with that of newly diagnosed APL groups (P < 0.05), while the expression level of miR-181a was significantly downregulated (P < 0.05).
tissue_expression_up	hsa-mir-17	Leukemia-Lymphoma, Adult T-Cell	26231295			C91.51	D015459		HP:0005517	Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma.
tissue_expression_up	hsa-mir-19	Leukemia-Lymphoma, Adult T-Cell	26231295			C91.51	D015459		HP:0005517	Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma.
tissue_expression_up	hsa-mir-126	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	17604727	disease of cellular proliferation	DOID:7061	C83.5	D015452			strongly expressed
tissue_expression_up	hsa-mir-146a	Lichen Planus	22139425	integumentary system disease	DOID:9201	L43	D008010	151620		Increased miRNA-146a and miRNA-155 expressions in oral lichen planus.
tissue_expression_up	hsa-mir-155	Lichen Planus	22139425	integumentary system disease	DOID:9201	L43	D008010	151620		Increased miRNA-146a and miRNA-155 expressions in oral lichen planus.
tissue_expression_up	hsa-mir-203	Lichen Planus	21943223	integumentary system disease	DOID:9201	L43	D008010	151620		Increased expression of miR-21 and miR-203, decreased expression of miR-125, and down-regulation of p53 and deltaNp63 RNA were seen in OLP compared to normal oral mucosa. When comparing microRNA expression to levels of p53 and p63 RNA, a significant negative correlation was seen between deltaNp63 and miR-203 and between miR-21 and p53, respectively.
tissue_expression_up	hsa-mir-21	Lichen Planus	21943223	integumentary system disease	DOID:9201	L43	D008010	151620		Increased expression of miR-21 and miR-203, decreased expression of miR-125, and down-regulation of p53 and deltaNp63 RNA were seen in OLP compared to normal oral mucosa. When comparing microRNA expression to levels of p53 and p63 RNA, a significant negative correlation was seen between deltaNp63 and miR-203 and between miR-21 and p53, respectively.
tissue_expression_up	hsa-mir-214	Liver Cirrhosis	22849305	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	miR-214-5p was upregulated in human and mouse livers in a fibrosis progression-dependent manner.
tissue_expression_up	hsa-mir-221	Liver Cirrhosis	22267590	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis.
tissue_expression_up	hsa-mir-222	Liver Cirrhosis	22267590	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis.
tissue_expression_up	hsa-mir-132	Liver Diseases, Alcoholic	22518321			K70.9	D008108			In this paper, we summarize the current knowledge of miRNAs in ALD and also report increased expression of miR-155 and miR-132 in the total liver as well as in isolated hepatocytes and KCs of alcohol-fed mice.
tissue_expression_up	hsa-mir-155	Liver Diseases, Alcoholic	22518321			K70.9	D008108			In this paper, we summarize the current knowledge of miRNAs in ALD and also report increased expression of miR-155 and miR-132 in the total liver as well as in isolated hepatocytes and KCs of alcohol-fed mice.
tissue_expression_up	hsa-mir-122	Liver Failure	21692939			K72	D017093	613070	HP:0001399	The expression levels of miR-122 and miR-194 correlated negatively with the age of patients with CHB (chronic hepatitis B) or ACLF (acute-on-chronic liver failure).
tissue_expression_up	hsa-mir-194-1	Liver Failure	21692939			K72	D017093	613070	HP:0001399	The expression levels of miR-122 and miR-194 correlated negatively with the age of patients with CHB (chronic hepatitis B) or ACLF (acute-on-chronic liver failure).
tissue_expression_up	hsa-mir-194-2	Liver Failure	21692939			K72	D017093	613070	HP:0001399	The expression levels of miR-122 and miR-194 correlated negatively with the age of patients with CHB (chronic hepatitis B) or ACLF (acute-on-chronic liver failure).
tissue_expression_up	hsa-mir-34	Liver Fibrosis	27387128			K74	D008103			Further studies showed that the miR-34a/SIRT1/p53 signaling pathway was  activated in hepatocytes but not in HSCs.
tissue_expression_up	hsa-mir-34a	Liver Fibrosis	27387128			K74	D008103			In the present study, using a CCl4-induced rat liver fibrosis model, we found that the miR-34a/SIRT1/p53 signaling pathway was activated and could be inhibited by SIRT1 activator SRT1720.
tissue_expression_up	hsa-mir-10b	Liver Neoplasms	21176238	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	overexpressed in side population of HCC cells compared to fetal liver cells
tissue_expression_up	hsa-mir-21	Liver Neoplasms	21176238	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	overexpressed in side population of HCC cells compared to fetal liver cells
tissue_expression_up	hsa-mir-210	Liver Neoplasms	21175813	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	upregulated after arsenic trioxide treatment in HepG-2 cells
tissue_expression_up	hsa-mir-24-1	Liver Neoplasms	21175813	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	upregulated after arsenic trioxide treatment in HepG-2 cells
tissue_expression_up	hsa-mir-24-2	Liver Neoplasms	21175813	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	upregulated after arsenic trioxide treatment in HepG-2 cells
tissue_expression_up	hsa-mir-29a	Liver Neoplasms	21175813	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	upregulated after arsenic trioxide treatment in HepG-2 cells miR-29a showed a positive therapeutic effect in liver cancer cells by inhibiting cell growth and inducing cell apoptosis, and PPM1D was confirmed to be the target gene of miR-29a.
tissue_expression_up	hsa-mir-30a	Liver Neoplasms	21175813	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	upregulated after arsenic trioxide treatment in HepG-2 cells
tissue_expression_up	hsa-mir-34c	Liver Neoplasms	21176238	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	miR-34c-3p is overexpressed in side population of HCC cells compared to fetal liver cells
tissue_expression_up	hsa-mir-372	Liver Neoplasms	20423907	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	microRNA-372:CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer
tissue_expression_up	hsa-mir-629	Liver Neoplasms	19946373	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	upregulated
tissue_expression_up	hsa-mir-149	Lung Fibrosis	24641842	respiratory system disease	DOID:3770	J84.10	D011658	178500		Down-regulation of miR-149 and up-regulation of IL-6 might be involved in the progression of silica-induced pulmonary fibrosis; miR-149 could negatively regulate IL-6 expression.
tissue_expression_up	hsa-mir-199b	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_up	hsa-let-7d	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_up	hsa-let-7e	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_up	hsa-mir-103a-1	Lung Neoplasms	20624269	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-103:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs
tissue_expression_up	hsa-mir-103a-2	Lung Neoplasms	20624269	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-103:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs
tissue_expression_up	hsa-mir-106a	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-107	Lung Neoplasms	20624269	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-107:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs
tissue_expression_up	hsa-mir-10b	Lung Neoplasms	22492962	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions.
tissue_expression_up	hsa-mir-126	Lung Neoplasms	20418022	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This set includes hsa-miR-182, which was most strongly over-expressed in the lung primary tumors, and hsa-miR-126, which was over-expressed in the metastatic tumors.
tissue_expression_up	hsa-mir-128-2	Lung Neoplasms	16461460	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
tissue_expression_up	hsa-mir-130a	Lung Neoplasms	19748927	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs.
tissue_expression_up	hsa-mir-133b	Lung Neoplasms	21648427	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Mice treated with pre-miR-133b containing lipoplexes had mature miR-133b expression in lung ~52-fold higher than untreated mice. 
tissue_expression_up	hsa-mir-136	Lung Neoplasms	20237410	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers.
tissue_expression_up	hsa-mir-143	Lung Neoplasms	23904792	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The up-regulated miR-143 in lung cancer could significantly inhibit  cell migration and invasion, and this might work through targeting CD44v3, which  was newly identified by us.
tissue_expression_up	hsa-mir-146a	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-146b	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-146b	Lung Neoplasms	19748927	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs.
tissue_expression_up	hsa-mir-148b	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_up	hsa-mir-150	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-155	Lung Neoplasms	25603615	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The current paper on Meta-analysis demonstrated a correlation between the high expression of miRNA-155 and the outcome of patients with non-small cell  lung cancer.
tissue_expression_up	hsa-mir-155	Lung Neoplasms	16461460	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
tissue_expression_up	hsa-mir-155	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-17	Lung Neoplasms	16461460	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
tissue_expression_up	hsa-mir-17	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-17	Lung Neoplasms	19597473	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-17-5p ; frequent overexpression
tissue_expression_up	hsa-mir-182	Lung Neoplasms	22672859	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis
tissue_expression_up	hsa-mir-182	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_up	hsa-mir-182	Lung Neoplasms	20418022	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	This set includes hsa-miR-182, which was most strongly over-expressed in the lung primary tumors, and hsa-miR-126, which was over-expressed in the metastatic tumors.
tissue_expression_up	hsa-mir-183	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	mir-124, mir-183, mir-223, mir-29 mir-124a-3 downregulated in lung cancer (Yanaihara et al., 2006);
tissue_expression_up	hsa-mir-183	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_up	hsa-mir-184	Lung Neoplasms	26199015	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-197 and miRNA-184 are overexpressed in EGFR-mutant patients with BM and they might be a new biomarker for stratifying the risk of BM in this  subpopulation.
tissue_expression_up	hsa-mir-18a	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_up	hsa-mir-191	Lung Neoplasms	16461460	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
tissue_expression_up	hsa-mir-191	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-192	Lung Neoplasms	26351877	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Collectively, our findings suggested that curcumin inhibited cell proliferation and induced apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of the PI3K/Akt signaling pathway.
tissue_expression_up	hsa-mir-197	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-199a-1	Lung Neoplasms	16461460	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
tissue_expression_up	hsa-mir-200b	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_up	hsa-mir-203	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-205	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-205	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_up	hsa-mir-20a	Lung Neoplasms	19597473	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-17-92 overexpression may serve as a fine-tuning influence to counterbalance the generation of DNA damage
tissue_expression_up	hsa-mir-20a	Lung Neoplasms	26560875	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	increased expression of miR-20 in lung cancer
tissue_expression_up	hsa-mir-21	Lung Neoplasms	16461460	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
tissue_expression_up	hsa-mir-21	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-21	Lung Neoplasms	20363096	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulated; Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis
tissue_expression_up	hsa-mir-21	Lung Neoplasms	22492962	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The levels of miR-10b and miR-21 are found significantly increased in the CSF (cerebrospinal fluid) of patients with glioblastoma and brain metastasis of breast and lung cancer, compared with tumors in remission and a variety of nonneoplastic conditions.
tissue_expression_up	hsa-mir-21	Lung Neoplasms	22638884	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21 was significantly overexpressed in human solid cancerous serum relative to normal control (P < 0.001), and its sensitivity and specificity were significantly higher than the currently used tumor markers.
tissue_expression_up	hsa-mir-21	Lung Neoplasms	19748927	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs.
tissue_expression_up	hsa-mir-21	Lung Neoplasms	22672859	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis
tissue_expression_up	hsa-mir-21	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_up	hsa-mir-21	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_up	hsa-mir-210	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-210	Lung Neoplasms	21965273	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1{alpha}
tissue_expression_up	hsa-mir-210	Lung Neoplasms	22672859	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis
tissue_expression_up	hsa-mir-210	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_up	hsa-mir-212	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-214	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-22	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_up	hsa-mir-24-1	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_up	hsa-mir-24-2	Lung Neoplasms	16530703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulation
tissue_expression_up	hsa-mir-29a	Lung Neoplasms	19818597	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiRNA expression profiling of human NSCLC cell lines indicated that miR-29a levels were reduced in more invasive cell lines. Exogenous overexpression of miR-29a in both lung and pancreatic cancer cell lines resulted in a significant reduction in the invasion phenotype, as well as in proliferation.
tissue_expression_up	hsa-mir-301a	Lung Neoplasms	20624269	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-301:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs
tissue_expression_up	hsa-mir-31	Lung Neoplasms	20237410	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers.
tissue_expression_up	hsa-mir-31	Lung Neoplasms	19748927	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs.
tissue_expression_up	hsa-mir-31	Lung Neoplasms	22672859	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Four up-regulated microRNAs (miR-210, miR-21, miR-31 and miR-182) and two down-regulated mcroiRNAs (miR-126 and miR-145) were consistently reported both in squamous carcinoma and adenocarcinoma-based subgroup analysis
tissue_expression_up	hsa-mir-31	Lung Neoplasms	29516903	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the authors identified a statistically significant miRNA meta-signature of seven upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, and miR-183) and eight downregulated (miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, and miR-145) miRNAs
tissue_expression_up	hsa-mir-31	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_up	hsa-mir-32	Lung Neoplasms	26036635	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer.
tissue_expression_up	hsa-mir-331	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_up	hsa-mir-338	Lung Neoplasms	20624269	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-338:we found significant overexpression of miR-103, miR-107, miR-301 and miR-338 in lung cancer cells as compared to HBECs
tissue_expression_up	hsa-mir-34a	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_up	hsa-mir-374a	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_up	hsa-mir-376a-1	Lung Neoplasms	20237410	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers.
tissue_expression_up	hsa-mir-376a-2	Lung Neoplasms	20237410	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers.
tissue_expression_up	hsa-mir-377	Lung Neoplasms	19748927	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-21, mir-31, miR-130a, miR-146b and miR-377 were consistently upregulated, whereas miR-1 and miR-143 were downregulated in lung tumors relative to normal lungs.
tissue_expression_up	hsa-mir-412	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_up	hsa-mir-504	Lung Neoplasms	20508945	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Seven miRNAs of hsa-miR-21, hsa-miR-31, hsa-miR-34a, hsa-miR-22*, hsa-miR-504, hsa-miR-18a, and hsa-miR-412 were observed to be upregulated greater than twofold in the squamous cell lung carcinoma tissues compared with normal tissues, whereas 23 miRNAs of hsa-miR-30a, hsa-miR-30d, hsa-miR-126, hsa-miR-652, hsa-miR-100, hsa-miR-143, hsa-miR-130a, hsa-miR-145, hsa-miR-30e, hsa-miR-126*, hsa-miR-181a, hsa-miR-125b, hsa-miR-886-3p, hsa-miR-451, hsa-miR-29c, hsa-miR-26b, hsa-miR-101, hsa-miR-320, hsa-miR-30b, hsa-miR-886-5p, hsa-miR-29a, hsa-miR-26a, and hsa-miR-99a were found to be downregulated greater than twofold.
tissue_expression_up	hsa-mir-629	Lung Neoplasms	19946373	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	upregulated
tissue_expression_up	hsa-mir-638	Lung Neoplasms	21303527	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	We found the upregulation of microRNA-638 and microRNA-923 in bostrycin-treated lung adenocarcinoma cells
tissue_expression_up	hsa-mir-9	Lung Neoplasms	24019037	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-9 was up-regulated in non-small cell lung cancer tissues and correlated with adverse clinical features and unfavorable survival, indicating that miR-9 might be involved in non-small lung cancer progression and could serve as a promising biomarker for further risk stratification in the treatment of this cancer.
tissue_expression_up	hsa-mir-96	Lung Neoplasms	21563230	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Specifically, thirteen novel asbestos-related miRNAs (over-expressed: miR-148b, miR-374a, miR-24-1*, Let-7d, Let-7e, miR-199b-5p, miR-331-3p, and miR-96 and under-expressed: miR-939, miR-671-5p, miR-605, miR-1224-5p and miR-202) and inversely correlated target genes (e.g., GADD45A, LTBP1, FOSB, NCALD, CACNA2D2, MTSS1, EPB41L3) were identified. 
tissue_expression_up	hsa-mir-150	Lupus Nephritis	26961386	urinary system disease	DOID:0080162	M32.14	D008181			Overexpression of miR-150 is observed in renal biopsies from patients with lupus  nephritis
tissue_expression_up	hsa-mir-155	Lymphoma	27473081	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p 鈮?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p 鈮?0.0360).
tissue_expression_up	hsa-mir-17	Lymphoma	27473081	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Furthermore, MF patients showed higher miRNA expression compared to controls (p 鈮?0.0223). T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p 鈮?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p 鈮?0.0360).
tissue_expression_up	hsa-mir-18a	Lymphoma	27473081	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Furthermore, MF patients showed higher miRNA expression compared to controls (p 鈮?0.0223). T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p 鈮?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p 鈮?0.0360).
tissue_expression_up	hsa-mir-19b	Lymphoma	27473081	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Furthermore, MF patients showed higher miRNA expression compared to controls (p 鈮?0.0223). T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p 鈮?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p 鈮?0.0360).
tissue_expression_up	hsa-mir-23b	Lymphoma	24356489	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	We found that miR-23a & miR-23b were up-regulated in radiation induced thymic lymphoma tissue samples.
tissue_expression_up	hsa-mir-629	Lymphoma	19946373	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	upregulated
tissue_expression_up	hsa-mir-92a	Lymphoma	27473081	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Furthermore, MF patients showed higher miRNA expression compared to controls (p 鈮?0.0223). T-MF showed higher miR17 and miR-18a expression compared to F-MF and TR-MF (p 鈮?0.0387) while miR19b, miR92a, and miR-155 showed increased levels in F-MF and TR-MF with respect to T-MF (p 鈮?0.0360).
tissue_expression_up	hsa-mir-145	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-9 is upregulated.
tissue_expression_up	hsa-mir-155	Lymphoma, B-Cell	21987025	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL (diffuse large B cell lymphoma) serum when compared with normal controls (P<0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P<0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%.
tissue_expression_up	hsa-mir-15a	Lymphoma, B-Cell	21987025	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL (diffuse large B cell lymphoma) serum when compared with normal controls (P<0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P<0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%.
tissue_expression_up	hsa-mir-16-1	Lymphoma, B-Cell	21987025	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL (diffuse large B cell lymphoma) serum when compared with normal controls (P<0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P<0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%.
tissue_expression_up	hsa-mir-17	Lymphoma, B-Cell	15944707	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	overexpressed
tissue_expression_up	hsa-mir-17	Lymphoma, B-Cell	19945163	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-17-5p:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively
tissue_expression_up	hsa-mir-17	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-17-5p is upregulated.
tissue_expression_up	hsa-mir-181a-1	Lymphoma, B-Cell	19945163	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-181a:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively
tissue_expression_up	hsa-mir-181a-2	Lymphoma, B-Cell	19945163	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-181a:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively
tissue_expression_up	hsa-mir-18a	Lymphoma, B-Cell	15944707	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	overexpressed
tissue_expression_up	hsa-mir-193b	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-9 is upregulated.
tissue_expression_up	hsa-mir-199a-1	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-9 is upregulated.
tissue_expression_up	hsa-mir-199a-2	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-9 is upregulated.
tissue_expression_up	hsa-mir-19a	Lymphoma, B-Cell	15944707	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	overexpressed
tissue_expression_up	hsa-mir-19b-1	Lymphoma, B-Cell	15944707	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	overexpressed
tissue_expression_up	hsa-mir-19b-2	Lymphoma, B-Cell	15944707	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	overexpressed
tissue_expression_up	hsa-mir-20a	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-20a is upregulated.
tissue_expression_up	hsa-mir-214	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-9 is upregulated.
tissue_expression_up	hsa-mir-29c	Lymphoma, B-Cell	21987025	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Four of miRNAs (miR-15a, miR-16-1, miR-29c, and miR-155) were significantly elevated in DLBCL (diffuse large B cell lymphoma) serum when compared with normal controls (P<0.05), while miR-34a was downregulated in DLBCL serum when compared with controls (P<0.05). Receiver operating characteristic analyses reflects strong discriminating DLBCL from controls, with area under the curves of 0.7722, 0.7002, 0.6672, 0.8538, and 0.7157 for miR-15a, miR-16-1, miR-29c, miR-34a, and miR-155, respectively. At the cut-off value of 0.0006 for miR-15a, the sensitivity was 80% and the specificity was 76%; at the cut-off value of 0.0886 for miR-16-1, the sensitivity was 94% and the specificity was 51%; at the cut-off value of 1.395 for miR-34a, the sensitivity was 100% and the specificity was 70%; at the cut-off value of 0.0022 for miR-155, the sensitivity was 83% and the specificity was 65%.
tissue_expression_up	hsa-mir-9-1	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-9 is upregulated.
tissue_expression_up	hsa-mir-9-2	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-9 is upregulated.
tissue_expression_up	hsa-mir-9-3	Lymphoma, B-Cell	21803762	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-9 is upregulated.
tissue_expression_up	hsa-mir-155	Lymphoma, Hodgkin	12661002	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	upregulated
tissue_expression_up	hsa-mir-182	Lymphoma, Hodgkin	22343918	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	In cHL cell lines FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183.
tissue_expression_up	hsa-mir-183	Lymphoma, Hodgkin	22343918	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	In cHL cell lines FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183.
tissue_expression_up	hsa-mir-20a	Lymphoma, Hodgkin	26951445	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-20a-5p were found to be increased in  cHL
tissue_expression_up	hsa-mir-96	Lymphoma, Hodgkin	22343918	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	In cHL cell lines FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183.
tissue_expression_up	hsa-mir-125a	Lymphoma, Large B-Cell, Diffuse	28817403	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		PB-DLBCL and DLBCL-GCB-CC also had much higher levels of miR-125a-3p, miR-34-3p, and miR-155-5p, and significantly lower levels of miR-17-5p and miR-17-3p
tissue_expression_up	hsa-mir-126	Lymphoma, Large B-Cell, Diffuse	26683099	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378
tissue_expression_up	hsa-mir-130a	Lymphoma, Large B-Cell, Diffuse	26683099	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378
tissue_expression_up	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	16041695	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		upregulated
tissue_expression_up	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	19744129	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2. 
tissue_expression_up	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	28817403	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		PB-DLBCL and DLBCL-GCB-CC also had much higher levels of miR-125a-3p, miR-34-3p, and miR-155-5p, and significantly lower levels of miR-17-5p and miR-17-3p
tissue_expression_up	hsa-mir-296	Lymphoma, Large B-Cell, Diffuse	26683099	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378
tissue_expression_up	hsa-mir-34	Lymphoma, Large B-Cell, Diffuse	28817403	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		PB-DLBCL and DLBCL-GCB-CC also had much higher levels of miR-125a-3p, miR-34-3p, and miR-155-5p, and significantly lower levels of miR-17-5p and miR-17-3p
tissue_expression_up	hsa-mir-378	Lymphoma, Large B-Cell, Diffuse	26683099	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378
tissue_expression_up	hsa-mir-15b	Lymphoma, Mantle-Cell	26676972			C83.10	D020522			Our present findings suggest that the upregulated expression of miR-15b is likely to play an important role in the trans-formation of cMCL to aMCL.
tissue_expression_up	hsa-mir-17	Lymphoma, T-Cell	19945163	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR-17-5p:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively
tissue_expression_up	hsa-mir-181a-1	Lymphoma, T-Cell	19945163	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR-181a:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively
tissue_expression_up	hsa-mir-181a-2	Lymphoma, T-Cell	19945163	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR-181a:the detection of upregulation of miR-17-5p and miR-181a in B- and T-cell lymphomas respectively
tissue_expression_up	hsa-mir-15a	Macular Degeneration	24970617	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye.
tissue_expression_up	hsa-mir-29a	Macular Degeneration	24970617	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye.
tissue_expression_up	hsa-mir-320a	Macular Degeneration	24970617	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye.
tissue_expression_up	hsa-mir-320b	Macular Degeneration	24970617	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye.
tissue_expression_up	hsa-mir-423	Macular Degeneration	24970617	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye.
tissue_expression_up	hsa-mir-93	Macular Degeneration	24970617	nervous system disease	DOID:4448	H35.30	D008268	PS603075	HP:0000608	The expression of several miRNAs related to angiogenesis and fibrosis was expressed significantly higher in the vitreous of eyes with PDR.Further studies are needed to understand the role played by the miRNAs in the biological function of the eye.
tissue_expression_up	hsa-mir-210	Male Infertility	27535712	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	 Compared with obstructive azoospermia (OA) as normal control, our results suggest that miR-210  was significantly up-regulated in testis of patients with NOA (P<0.05)
tissue_expression_up	hsa-mir-145	Malignant Neoplasms [unspecific]	25106061			C80.1	D009369			Our findings indicate that high miR-145 expression is better at predicting patient survival rather than disease progression for malignant tumors, especially for SCC and glioblastoma in Asians. Considering the insufficient evidence, further investigations and more studies are needed.
tissue_expression_up	hsa-mir-101	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_up	hsa-mir-106b	Medulloblastoma	25041637	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	These data suggested the upregulation of miR-106b in MB and the involvement of miR-106b in MB biology.
tissue_expression_up	hsa-mir-10b	Medulloblastoma	26394044	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	microRNA-10b Is Overexpressed and Critical for Cell Survival and Proliferation in Medulloblastoma.
tissue_expression_up	hsa-mir-126	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-126 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-127	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-127-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-139	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_up	hsa-mir-143	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-143 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-144	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-144* was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-145	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-145 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-146a	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-146a was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-1827	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_up	hsa-mir-193a	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-193a-5p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-203	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-203 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-21	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-21* was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-222	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_up	hsa-mir-223	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-223 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-323a	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-323-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-338	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-338-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-34c	Medulloblastoma	29658967	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	Low-expression of miR-221, miR-9, and miR-181c/d and over-expression of miR-101, miR-222, miR-139, miR-1827, and miR-34c was found in medulloblastoma
tissue_expression_up	hsa-mir-361	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-361-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-376a-1	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-376 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-376a-2	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-376 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-376c	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-376c was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-379	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-379 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-409	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-409-3p was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-494	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-494 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-495	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-495 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-539	Medulloblastoma	21931624	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	hsa-mir-539 was significantly up-regulated in primary Medulloblastoma specimens relative to CD133+ NSCs (Neural Stem Cells).
tissue_expression_up	hsa-mir-106a	Melanoma	21509659	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	significantly up-regulated in uveal melanomas compared with normal uveal tissues
tissue_expression_up	hsa-mir-106a	Melanoma	21763111	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization.
tissue_expression_up	hsa-mir-1225	Melanoma	22898827	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes.
tissue_expression_up	hsa-mir-125b	Melanoma	24635082	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MLK3 is upregulated in metastatic melanoma, and regulates cell proliferation and invasion in melanoma cells. MLK3 is a direct target of miR-125b.
tissue_expression_up	hsa-mir-125b	Melanoma	26684239	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-34a, miR-100 and miR-125b showed high expression in both resistant cells and in tumor biopsies
tissue_expression_up	hsa-mir-1260	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-1274a	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-1274b	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-130b	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-146a	Melanoma	19578755	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	overexpressed
tissue_expression_up	hsa-mir-146a	Melanoma	20442294	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-146a:miR-146a and miR-155 were upregulated in all analyzed patients but none of the cell lines
tissue_expression_up	hsa-mir-146a	Melanoma	23441115	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-146a and miR-26a were overexpressed more than threefold in VH from patients with uveal melanomas compared to the other pathological groups (Wilcoxon signed-rank test, p value <0.05).
tissue_expression_up	hsa-mir-146b	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-155	Melanoma	20442294	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-155:miR-146a and miR-155 were upregulated in all analyzed patients but none of the cell lines
tissue_expression_up	hsa-mir-155	Melanoma	21863027	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	PCR analysis revealed primary cutaneous melanomas had an 8.6-fold overexpression of miR-21 and a 7.5-fold overexpression of miR-155 compared with benign naevi (P<0.0001).
tissue_expression_up	hsa-mir-155	Melanoma	27469124	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A comparison of Spitzoid melanomas to benign nevi revealed overexpression of miR-21, miR-150, and miR-155 in the malignant primaries (p < 0.05).
tissue_expression_up	hsa-mir-15b	Melanoma	19830692	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-15b:MiR-15b and miR-210 were significantly upregulated, miR-34a was significantly downregulated in melanomas
tissue_expression_up	hsa-mir-17	Melanoma	19578755	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-17-5p; overexpressed
tissue_expression_up	hsa-mir-17	Melanoma	21509659	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	significantly up-regulated in uveal melanomas compared with normal uveal tissues
tissue_expression_up	hsa-mir-17	Melanoma	21763111	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization.
tissue_expression_up	hsa-mir-17	Melanoma	24462553	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	We show that miRNAs of the miR-17-92 cluster (miR-20a2, miR-92a1, miR-17 and miR-18a), miR-126, miR-182, miR-210 and miR-214 are upregulated and their respective target genes (RUNX1, HIF1A, TGFBR2, THBS1 and JAK2) are down-regulated in melanoma.
tissue_expression_up	hsa-mir-18a	Melanoma	19578755	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	overexpressed
tissue_expression_up	hsa-mir-193b	Melanoma	20357817	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Furthermore, low expression of miR-191 and high expression of miR-193b were associated with poor melanoma-specific survive
tissue_expression_up	hsa-mir-197	Melanoma	22898827	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes.
tissue_expression_up	hsa-mir-200a	Melanoma	27054085	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Among the up-regulated miRNAs, miR-21, miR-200a and miR-141, are well known to be involved in carcinogenesis.
tissue_expression_up	hsa-mir-20a	Melanoma	19578755	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	overexpressed
tissue_expression_up	hsa-mir-20a	Melanoma	21509659	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	significantly up-regulated in uveal melanomas compared with normal uveal tissues
tissue_expression_up	hsa-mir-21	Melanoma	21509659	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	significantly up-regulated in uveal melanomas compared with normal uveal tissues
tissue_expression_up	hsa-mir-21	Melanoma	21863027	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	PCR analysis revealed primary cutaneous melanomas had an 8.6-fold overexpression of miR-21 and a 7.5-fold overexpression of miR-155 compared with benign naevi (P<0.0001).
tissue_expression_up	hsa-mir-21	Melanoma	22716245	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells.
tissue_expression_up	hsa-mir-21	Melanoma	21763111	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Early steps in skin tumor formation in HPV8-CER mice were associated with an upregulation of the oncogenic miRNA-17-5p, -21 and -106a and a downregulation of the tumor-suppressive miRNA-155 and -206, which could be demonstrated by qPCR and in situ hybridization.
tissue_expression_up	hsa-mir-210	Melanoma	19830692	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-210:MiR-15b and miR-210 were significantly upregulated, miR-34a was significantly downregulated in melanomas
tissue_expression_up	hsa-mir-210	Melanoma	27009863	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Hypoxia-induced gene signatures and overexpression of the hypoxia-regulated miRNA hsa-miR-210 characterized CDXs.
tissue_expression_up	hsa-mir-214	Melanoma	24462553	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	We show that miRNAs of the miR-17-92 cluster (miR-20a2, miR-92a1, miR-17 and miR-18a), miR-126, miR-182, miR-210 and miR-214 are upregulated and their respective target genes (RUNX1, HIF1A, TGFBR2, THBS1 and JAK2) are down-regulated in melanoma.
tissue_expression_up	hsa-mir-22	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-221	Melanoma	21711453	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNAs-221 and -222 are highly upregulated in several solid tumors, including melanomas.
tissue_expression_up	hsa-mir-222	Melanoma	21711453	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNAs-221 and -222 are highly upregulated in several solid tumors, including melanomas.
tissue_expression_up	hsa-mir-223	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-26a	Melanoma	23441115	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MiR-146a and miR-26a were overexpressed more than threefold in VH from patients with uveal melanomas compared to the other pathological groups (Wilcoxon signed-rank test, p value <0.05).
tissue_expression_up	hsa-mir-301a	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-328	Melanoma	22898827	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes.
tissue_expression_up	hsa-mir-34a	Melanoma	21509659	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	significantly up-regulated in uveal melanomas compared with normal uveal tissues
tissue_expression_up	hsa-mir-34a	Melanoma	25982144	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Real-time PCR analysis showed 14-fold increase of miR-34a expression in the SDT group compared to the control group
tissue_expression_up	hsa-mir-3663	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-4281	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-4286	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-484	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-506	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-507	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-508	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-509-1	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-509-2	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-509-3	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-510	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-513a-1	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-513a-2	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-513b	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-513c	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-514a-1	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-514a-2	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-514a-3	Melanoma	21860416	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-506-514 cluster was consistently overexpressed in nearly all melanomas tested (30-60 fold, P<0.001), regardless of mutations in N-ras or B-raf.
tissue_expression_up	hsa-mir-574	Melanoma	22898827	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes.
tissue_expression_up	hsa-mir-634	Melanoma	22898827	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes.
tissue_expression_up	hsa-mir-663	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-720	Melanoma	23111773	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	In addition to several miRNAs previously known to be associated with CMM, 19 unidentified miRNA candidates were found to be dysregulated in CMM patient samples. Among the 19 novel miRNA candidates, the genes hsa-miR-22, hsa-miR-130b, hsa-miR-146b-5p,hsa-miR-223, hsa-miR-301a, hsa-miR-484, hsa-miR-663, hsa-miR-720, hsa-miR-1260,hsa-miR-1274a, hsa-miR-1274b, hsa-miR-3663-3p, hsa-miR-4281, and hsa-miR-4286 were upregulated, and the genes hsa-miR-24-1*, hsa-miR-26a, hsa-miR-4291, hsa-miR-4317, and hsa-miR-4324 were downregulated.
tissue_expression_up	hsa-mir-766	Melanoma	22898827	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	we assayed the MITF-KD miRNA profiles using a miRNA microarray and found that hsa-miR-1225-3p, hsa-miR-634, hsa-miR-197, hsa-miR-766, hsa-miR-574-5p and hsa-miR-328 were upregulated, and hsa-miR-720 and hsa-miR-1308 were downregulated in MITF knocked down melanocytes.
tissue_expression_up	hsa-mir-9-1	Melanoma	22131135	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kB1-Snail1 pathway in melanoma.
tissue_expression_up	hsa-mir-190a	Meningioma	22674195	disease of cellular proliferation	DOID:3565	D32.9	D008579	607174	HP:0002858	Downregulation of miR-29c-3p and miR-219-5p were found to be associated with advanced clinical stages of meningioma. Kaplan-Meier analysis showed that high expression of miR-190a and low expression of miR-29c-3p and miR-219-5p correlated significantly with higher recurrence rates in meningioma patients.
tissue_expression_up	hsa-mir-125b	Mesial Temporal Lobe Epilepsy	25801837			G40.209	D004833	608096		In TLE patients, miR-183, miR- 135a, miR-125b, miR-30c and miR-27a were upregulated, whereas miR-128 was downregulated.
tissue_expression_up	hsa-mir-183	Mesial Temporal Lobe Epilepsy	25801837			G40.209	D004833	608096		In TLE patients, miR-183, miR- 135a, miR-125b, miR-30c and miR-27a were upregulated, whereas miR-128 was downregulated.
tissue_expression_up	hsa-mir-106a	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-106b	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-17	Mesothelioma	21317924	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Hsa-miR-17* was significantly upregulated and hsa-miR-30c was significantly downregulated by Onconase treatment in all cell lines
tissue_expression_up	hsa-mir-17	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-18a	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-193a	Mesothelioma	20864637	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR-193-3p:Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas
tissue_expression_up	hsa-mir-19b-1	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-19b-2	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-20a	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-20b	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-25	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-92a-1	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-92a-2	Mesothelioma	21358347	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly upregulated
tissue_expression_up	hsa-mir-26a-1	Multiple Endocrine Neoplasia Type 1	22409234	genetic disease	DOID:10017	E31.21	D018761	PS131100		The authors found that in hADSCs the siRNA-induced silencing of MEN1 mRNA resulted in a down regulation of miR-26a, with a consequent up-regulation of SMAD1 protein.
tissue_expression_up	hsa-mir-26a-2	Multiple Endocrine Neoplasia Type 1	22409234	genetic disease	DOID:10017	E31.21	D018761	PS131100		The authors found that in hADSCs the siRNA-induced silencing of MEN1 mRNA resulted in a down regulation of miR-26a, with a consequent up-regulation of SMAD1 protein.
tissue_expression_up	hsa-mir-21	Multiple Myeloma	22739167	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	It is concluded that the expression levels of miR-21 in BMMNC of MM patients are significantly higher than in normal bone marrow, these data indicated that miR-21 may play an important role in the development of MM.
tissue_expression_up	hsa-mir-21	Multiple Myeloma	25704079	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	EBV could further exacerbate the disease by inducing miR-21
tissue_expression_up	hsa-mir-128-1	Multiple Sclerosis	22088562	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-128 and miR-27b were increased in naive and miR-340 in memory CD4(+) T cells from patients with multiple sclerosis, inhibiting Th2 cell development and favouring pro-inflammatory Th1 responses.
tissue_expression_up	hsa-mir-128-2	Multiple Sclerosis	22088562	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-128 and miR-27b were increased in naive and miR-340 in memory CD4(+) T cells from patients with multiple sclerosis, inhibiting Th2 cell development and favouring pro-inflammatory Th1 responses.
tissue_expression_up	hsa-mir-155	Multiple Sclerosis	21453702	nervous system disease	DOID:2377	G35	D009103	PS126200		Several miRNAs such as miR-155 or miR-326 are considerably overexpressed in active MS lesions versus controls
tissue_expression_up	hsa-mir-155	Multiple Sclerosis	27310932	nervous system disease	DOID:2377	G35	D009103	PS126200		up-regulation of miR-155 (p value = 0.009) and miR-132 (p value = 0.04) in MS patients
tissue_expression_up	hsa-mir-27b	Multiple Sclerosis	22088562	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-128 and miR-27b were increased in naive and miR-340 in memory CD4(+) T cells from patients with multiple sclerosis, inhibiting Th2 cell development and favouring pro-inflammatory Th1 responses.
tissue_expression_up	hsa-mir-326	Multiple Sclerosis	21453702	nervous system disease	DOID:2377	G35	D009103	PS126200		Several miRNAs such as miR-155 or miR-326 are considerably overexpressed in active MS lesions versus controls
tissue_expression_up	hsa-mir-326	Multiple Sclerosis	24936144	nervous system disease	DOID:2377	G35	D009103	PS126200		For instance, miR-21, miR-142-3p, miR-146a, miR-146b, miR-155 and miR-326 were up-regulated in both peripheral blood mononuclear cells (PBMCs) and brain white matter lesions from MS patients and mouse model as well.
tissue_expression_up	hsa-mir-23a	Muscle Atrophy	28000445			M62.5	D009133		HP:0100295	Delphinidin Prevents Muscle Atrophy and Upregulates miR-23a Expression.
tissue_expression_up	hsa-mir-100	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-127	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	miR-127-3p: highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-136	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	miR-136*: highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-148a	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-155	Muscular Dystrophy	26398013			G71.0	D009136	310200	HP:0003560	Up-regulation of immune-related miRNAs in muscle, for example, miR-155 and miR-146, is associated with autoimmunity
tissue_expression_up	hsa-mir-192	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-206	Muscular Dystrophy	22129894			G71.0	D009136	310200	HP:0003560	The expression of miR-206 is increased in muscular dystrophy.
tissue_expression_up	hsa-mir-335	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-376c	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-489	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-502	Muscular Dystrophy	21840938			G71.0	D009136	310200	HP:0003560	miR-502-3p: highly expressed in fetal muscle.
tissue_expression_up	hsa-mir-32	Muscular Dystrophy, Facioscapulohumeral	24145033	musculoskeletal system disease	DOID:11727	G71.0	D020391	158900		Twenty-one microRNAs (miR-1, miR-7, miR-15a, miR-22, miR-30e, miR-32, miR-107, miR-133a, miR-133b, miR-139, miR-152, miR-206, miR-223, miR-302b, miR-331, miR-362, miR-365, miR-382, miR-496, miR-532, miR-654, and miR-660) were up-regulated
tissue_expression_up	hsa-mir-155	Mycosis Fungoides	21406335			C84.00	D009182			upregulated in tumor stage MF compared to benign inflammatory dermatoses.
tissue_expression_up	hsa-mir-155	Mycosis Fungoides	21966986			C84.00	D009182			MiR-155 was only found to be slightly overexpressed in MF compared to healthy controls. Furthermore, metastatic MF demonstrated lower concentrations of let-7a, let-7d and let-7f when compared to MF limited to the skin.
tissue_expression_up	hsa-mir-92a-1	Mycosis Fungoides	21406335			C84.00	D009182			upregulated in tumor stage MF compared to benign inflammatory dermatoses.
tissue_expression_up	hsa-mir-92a-2	Mycosis Fungoides	21406335			C84.00	D009182			upregulated in tumor stage MF compared to benign inflammatory dermatoses.
tissue_expression_up	hsa-mir-93	Mycosis Fungoides	21406335			C84.00	D009182			upregulated in tumor stage MF compared to benign inflammatory dermatoses.
tissue_expression_up	hsa-mir-1-1	Myelodysplastic Syndromes	20627384	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-1:Evaluation in a larger cohort could confirm the up-regulation of the miR-1 in MDS
tissue_expression_up	hsa-mir-1-2	Myelodysplastic Syndromes	20627384	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-1:Evaluation in a larger cohort could confirm the up-regulation of the miR-1 in MDS
tissue_expression_up	hsa-mir-34a	Myelodysplastic Syndromes	21150891	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	In early MDS, we monitored upregulation of proapoptotic miR-34a
tissue_expression_up	hsa-mir-146b	Myeloproliferative Neoplasms	26116595	disease of cellular proliferation	DOID:2226	D47.1		616871		Up-regulation of MicroRNA 146b is Associated with Myelofibrosis in Myeloproliferative Neoplasms.
tissue_expression_up	hsa-mir-1	Myocardial Infarction	24046434	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Consistent with previous publications, cardiac specific miR-1 and miR-133a were up-regulated in STEMI patients compared with healthy controls (both, P < 0.0001)
tissue_expression_up	hsa-mir-1-1	Myocardial Infarction	22330002	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR.
tissue_expression_up	hsa-mir-1-2	Myocardial Infarction	22330002	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR.
tissue_expression_up	hsa-mir-133a-1	Myocardial Infarction	22330002	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR.
tissue_expression_up	hsa-mir-133a-2	Myocardial Infarction	22330002	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR.
tissue_expression_up	hsa-mir-143	Myocardial Infarction	29162889	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The expression level of miR-143 in monocytes from STEMI patients compared to healthy controls was increased, whereas the expression of miR-1, -92a, -99a, and -223 was reduced significantly
tissue_expression_up	hsa-mir-155	Myocardial Infarction	19581315	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Overexpressed; arrhythmogenic miR-1, contributing to ischaemic arrhythmogenesis stimulated by beta-adrenergic pathway; downregulatied by propranolol together with SRF
tissue_expression_up	hsa-mir-155	Myocardial Infarction	29642385	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Exposure to the high dose of CS also significantly upregulated the miRNA-155 level in the aortic tissues of ApoE KO mice
tissue_expression_up	hsa-mir-208a	Myocardial Infarction	27314868	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	over-expression of miR-208a in myocardial infarction tissue
tissue_expression_up	hsa-mir-21	Myocardial Infarction	22330002	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR.
tissue_expression_up	hsa-mir-21	Myocardial Infarction	25896982	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Compared to sham group, we found a twofold increase in the cardiac expression of microRNA-21 and 0.5-fold decrease in microRNA-29b in heart tissue from vehicle-treated MI.
tissue_expression_up	hsa-mir-21	Myocardial Infarction	26253453	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Compared with the CON group, miR-1 was downregulated, whereas miR-21 was upregulated, and BCL2 messenger RNA (mRNA) was upregulated, whereas BAX mRNA and  programmed cell death 4 mRNA remained unchanged in the IPO group.
tissue_expression_up	hsa-mir-21	Myocardial Infarction	29642385	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant
tissue_expression_up	hsa-mir-423	Myocardial Infarction	22330002	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiR-1, -21 -133a and -423-5p showed a 3- to 10-fold increase and miR-499-5p exhibited >80-fold increase in acute NSTEMI patient vs. CTR.
tissue_expression_up	hsa-mir-92a	Myocardial Infarction	25064220	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-92a expression in ischemia-reperfusion group was significantly higher than in sham operation group
tissue_expression_up	hsa-mir-125b-1	Myocardial Ischemic-Reperfusion Injury	23123599				D015428			SR-A deficiency reduces myocardial ischemia/reperfusion injury; involvement of increased microRNA-125b expression in macrophages
tissue_expression_up	hsa-mir-125b-2	Myocardial Ischemic-Reperfusion Injury	23123599				D015428			SR-A deficiency reduces myocardial ischemia/reperfusion injury; involvement of increased microRNA-125b expression in macrophages
tissue_expression_up	hsa-mir-15a	Myocardial Ischemic-Reperfusion Injury	22783320				D015428			MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury.
tissue_expression_up	hsa-mir-15b	Myocardial Ischemic-Reperfusion Injury	22783320				D015428			MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury.
tissue_expression_up	hsa-mir-21	Myocardial Ischemic-Reperfusion Injury	26097555				D015428			this study revealed the mechanism that TMZ up-regulated miR-21 expression, then miR-21 targeted PTEN increasing the PI3K pathway and finally the activation of this pathway counteracted the apoptotic effect of hypoxia/reperfusion.
tissue_expression_up	hsa-mir-1-1	Myotonic Muscular Dystrophy	21169019			G71.11	D009223	160900		We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls.
tissue_expression_up	hsa-mir-125b-2	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-125b-5p: decreased levels compared to controls
tissue_expression_up	hsa-mir-146b	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		higher levels compared to controls
tissue_expression_up	hsa-mir-206	Myotonic Muscular Dystrophy	20487562			G71.11	D009223	160900		microRNA-206:Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients
tissue_expression_up	hsa-mir-208a	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-146b-5p: higher levels compared to controls
tissue_expression_up	hsa-mir-221	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		higher levels compared to controls
tissue_expression_up	hsa-mir-335	Myotonic Muscular Dystrophy	21169019			G71.11	D009223	160900		We found that miR-1 and miR-335 were up-regulated, whereas miR-29b and c, and miR-33 were down-regulated in DM1 biopsies compared to controls.
tissue_expression_up	hsa-mir-34a	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-34a-5p: higher levels compared to controls
tissue_expression_up	hsa-mir-34b	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-34b-3p: higher levels compared to controls
tissue_expression_up	hsa-mir-34c	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		miR-34c-5p: higher levels compared to controls
tissue_expression_up	hsa-mir-381	Myotonic Muscular Dystrophy	22768114			G71.11	D009223	160900		higher levels compared to controls
tissue_expression_up	hsa-mir-146a	Nasopharyngeal Neoplasms	22843060			C11.9	D009303	607107	HP:0100630	Expression of miRNA-146a in nasopharyngeal carcinoma is upregulated by Epstein-Barr virus latent membrane protein 1.
tissue_expression_up	hsa-mir-18a	Nasopharyngeal Neoplasms	21373758			C11.9	D009303	607107	HP:0100630	overexpressed
tissue_expression_up	hsa-let-7a-1	Neoplasms [unspecific]	20370992			C80.1	D009369			over-expressed
tissue_expression_up	hsa-let-7a-2	Neoplasms [unspecific]	20370992			C80.1	D009369			over-expressed
tissue_expression_up	hsa-let-7a-3	Neoplasms [unspecific]	20370992			C80.1	D009369			over-expressed
tissue_expression_up	hsa-let-7i	Neoplasms [unspecific]	20145181			C80.1	D009369			overexpression
tissue_expression_up	hsa-let-7i	Neoplasms [unspecific]	18187804			C80.1	D009369			Changing the cellular levels of let-7i, mir-16, and mir-21 affected the potencies of a number of the anticancer agents by up to 4-fold.
tissue_expression_up	hsa-mir-106b	Neoplasms [unspecific]	20145181			C80.1	D009369			Upregulation
tissue_expression_up	hsa-mir-10b	Neoplasms [unspecific]	25510966			C80.1	D009369			high-expression of microRNA-10b can predict worse outcomes in some types of cancer and the regular monitoring of miR-10b expression might be useful in the clinical practice.
tissue_expression_up	hsa-mir-142	Neoplasms [unspecific]	20145181			C80.1	D009369			overexpression
tissue_expression_up	hsa-mir-142	Neoplasms [unspecific]	20178649			C80.1	D009369			Most of the differentially expressed miRNAs were downregulated in germinomas, but miR-142-5p and miR-146a were upregulated.
tissue_expression_up	hsa-mir-146a	Neoplasms [unspecific]	20178649			C80.1	D009369			Most of the differentially expressed miRNAs were downregulated in germinomas, but miR-142-5p and miR-146a were upregulated.
tissue_expression_up	hsa-mir-155	Neoplasms [unspecific]	20145181			C80.1	D009369			overexpression
tissue_expression_up	hsa-mir-155	Neoplasms [unspecific]	19652553			C80.1	D009369			overexpression, target MYC antagonist MNT
tissue_expression_up	hsa-mir-155	Neoplasms [unspecific]	26850462			C80.1	D009369			miR-155 is an oncogenic miRNA that is often overexpressed in cancer and is associated with poor prognosis.
tissue_expression_up	hsa-mir-155	Neoplasms [unspecific]	19175697			C80.1	D009369			The expression of a subset of miRs (e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g.miR-143 and miR-145) was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes whose deregulation may lead to tumourigenesis.
tissue_expression_up	hsa-mir-16	Neoplasms [unspecific]	18187804			C80.1	D009369			Changing the cellular levels of let-7i, mir-16, and mir-21 affected the potencies of a number of the anticancer agents by up to 4-fold.
tissue_expression_up	hsa-mir-16-1	Neoplasms [unspecific]	20145181			C80.1	D009369			Upregulation
tissue_expression_up	hsa-mir-16-2	Neoplasms [unspecific]	20145181			C80.1	D009369			Upregulation
tissue_expression_up	hsa-mir-17	Neoplasms [unspecific]	20299512			C80.1	D009369			The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia.
tissue_expression_up	hsa-mir-182	Neoplasms [unspecific]	26063957			C80.1	D009369			High miR-182 expression is associated with poor OS and DFS/RFS/RFI in some types of cancers, and miR-182 may be a useful prognostic biomarker for predicting cancer prognosis. However, given the current insufficient relevant data, further clinical studies are needed.
tissue_expression_up	hsa-mir-182	Neoplasms [unspecific]	20370992			C80.1	D009369			over-expressed
tissue_expression_up	hsa-mir-183	Neoplasms [unspecific]	19676045			C80.1	D009369			up-regulated
tissue_expression_up	hsa-mir-18a	Neoplasms [unspecific]	20299512			C80.1	D009369			The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia.
tissue_expression_up	hsa-mir-191	Neoplasms [unspecific]	18375788			C80.1	D009369			increased
tissue_expression_up	hsa-mir-192	Neoplasms [unspecific]	20864637			C80.1	D009369			miR-192:Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas
tissue_expression_up	hsa-mir-19a	Neoplasms [unspecific]	20299512			C80.1	D009369			The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia.
tissue_expression_up	hsa-mir-19b-1	Neoplasms [unspecific]	20299512			C80.1	D009369			The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia.
tissue_expression_up	hsa-mir-205	Neoplasms [unspecific]	26681200			C80.1	D009369			miR-9, mi-R-19a, miR-22 and miR-205 that promote EMT, fibrosis and tumorigenesis  were up-regulated.
tissue_expression_up	hsa-mir-20a	Neoplasms [unspecific]	20145181			C80.1	D009369			Upregulation
tissue_expression_up	hsa-mir-20a	Neoplasms [unspecific]	20299512			C80.1	D009369			The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia.
tissue_expression_up	hsa-mir-21	Neoplasms [unspecific]	20145181			C80.1	D009369			overexpression
tissue_expression_up	hsa-mir-21	Neoplasms [unspecific]	17028596			C80.1	D009369			mir-21 upregulated in glioblastoma and associated with antiapoptosis upregulated in breast cancer (Iorio et al., 2005), and in a signature for solid cancers (Volinia et al., 2006).
tissue_expression_up	hsa-mir-21	Neoplasms [unspecific]	20370992			C80.1	D009369			over-expressed
tissue_expression_up	hsa-mir-21	Neoplasms [unspecific]	26032086			C80.1	D009369			miR-21, miR-148a, miR-505, and miR-1207-5p were found to be upregulated in growth factors-induced EMT process
tissue_expression_up	hsa-mir-21	Neoplasms [unspecific]	18187804			C80.1	D009369			Changing the cellular levels of let-7i, mir-16, and mir-21 affected the potencies of a number of the anticancer agents by up to 4-fold.
tissue_expression_up	hsa-mir-21	Neoplasms [unspecific]	19175697			C80.1	D009369			The expression of a subset of miRs (e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g.miR-143 and miR-145) was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes whose deregulation may lead to tumourigenesis.
tissue_expression_up	hsa-mir-210	Neoplasms [unspecific]	26239498			C80.1	D009369			MicroRNA-210 is upregulated by hypoxia-inducible factor-1α in the stromal cells of giant cell tumors of bone.
tissue_expression_up	hsa-mir-210	Neoplasms [unspecific]	19141645			C80.1	D009369			two miRs, miR-210 and miR-373, are up-regulated in a hypoxia-inducible factor-1alpha-dependent manner in hypoxic cells
tissue_expression_up	hsa-mir-221	Neoplasms [unspecific]	18413744			C80.1	D009369			Thus, the physiologic up-regulation of miR-221 and miR-222 is tightly linked to a cell cycle checkpoint that ensures cell survival by coordinating competency for initiation of S phase with growth factor signaling pathways that stimulate cell proliferation.
tissue_expression_up	hsa-mir-222	Neoplasms [unspecific]	18413744			C80.1	D009369			Thus, the physiologic up-regulation of miR-221 and miR-222 is tightly linked to a cell cycle checkpoint that ensures cell survival by coordinating competency for initiation of S phase with growth factor signaling pathways that stimulate cell proliferation.
tissue_expression_up	hsa-mir-29a	Neoplasms [unspecific]	24210072			C80.1	D009369			MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis.
tissue_expression_up	hsa-mir-302a	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-302b	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-302c	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-302d	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-302e	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-302f	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-34	Neoplasms [unspecific]	26177460			C80.1	D009369			miR-34a overexpression leads to variable effects on p53 levels in p53-sufficient human cancer cell lines.
tissue_expression_up	hsa-mir-34a	Neoplasms [unspecific]	26177460			C80.1	D009369			miR-34a overexpression leads to variable effects on p53 levels in p53-sufficient human cancer cell lines.
tissue_expression_up	hsa-mir-371a	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-372	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-373	Neoplasms [unspecific]	20332240			C80.1	D009369			overexpressed
tissue_expression_up	hsa-mir-373	Neoplasms [unspecific]	19141645			C80.1	D009369			two miRs, miR-210 and miR-373, are up-regulated in a hypoxia-inducible factor-1alpha-dependent manner in hypoxic cells
tissue_expression_up	hsa-mir-381	Neoplasms [unspecific]	26688820			C80.1	D009369			Further study revealed that IκBα was a target gene of miR-381. The upregulation of miR-381 under LPS stimulation contributes to respiratory infections mainly by targeting IκBα.
tissue_expression_up	hsa-mir-423	Neoplasms [unspecific]	20145181			C80.1	D009369			Upregulation
tissue_expression_up	hsa-mir-525	Neoplasms [unspecific]	24147004			C80.1	D009369			The transient up-regulation of miR-525-3p, and the resultant repression of its direct targets ARRB1, TXN1 and HSPA9, is required for cell survival following irradiation. The conserved function of miR-525-3p across several cell types makes this microRNA pathway a promising target for modifying the efficacy of radiotherapy.
tissue_expression_up	hsa-mir-9	Neoplasms [unspecific]	27284255			C80.1	D009369			higher expression level of miR-9 significantly predicted worse  OS in various carcinomas
tissue_expression_up	hsa-mir-92a-1	Neoplasms [unspecific]	20299512			C80.1	D009369			The miR-17-92 cluster (encoding miR-17, -18a, -19a/b, -20a, and miR-92a) is highly expressed in tumor cells and is up-regulated by ischemia.
tissue_expression_up	hsa-mir-96	Neoplasms [unspecific]	19676045			C80.1	D009369			up-regulated
tissue_expression_up	hsa-mir-141	Nephrosclerosis	19910931	cardiovascular system disease	DOID:11664	N26.9	D009400		HP:0009741	significantly higher in patients with hypertensive nephrosclerosis than controls
tissue_expression_up	hsa-mir-192	Nephrosclerosis	19910931	cardiovascular system disease	DOID:11664	N26.9	D009400		HP:0009741	significantly higher in patients with hypertensive nephrosclerosis than controls
tissue_expression_up	hsa-mir-200a	Nephrosclerosis	19910931	cardiovascular system disease	DOID:11664	N26.9	D009400		HP:0009741	significantly higher in patients with hypertensive nephrosclerosis than controls
tissue_expression_up	hsa-mir-200b	Nephrosclerosis	19910931	cardiovascular system disease	DOID:11664	N26.9	D009400		HP:0009741	significantly higher in patients with hypertensive nephrosclerosis than controls
tissue_expression_up	hsa-mir-205	Nephrosclerosis	19910931	cardiovascular system disease	DOID:11664	N26.9	D009400		HP:0009741	significantly higher in patients with hypertensive nephrosclerosis than controls
tissue_expression_up	hsa-mir-429	Nephrosclerosis	19910931	cardiovascular system disease	DOID:11664	N26.9	D009400		HP:0009741	significantly higher in patients with hypertensive nephrosclerosis than controls
tissue_expression_up	hsa-mir-193a	Nephrotic Syndrome	28299339	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	The miR-193a expression levels only slightly increased in NS patients
tissue_expression_up	hsa-mir-7-1	Neurilemmoma	21156648	disease of cellular proliferation	DOID:3192	D36.10	D009442			miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.
tissue_expression_up	hsa-mir-7-2	Neurilemmoma	21156648	disease of cellular proliferation	DOID:3192	D36.10	D009442			miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.
tissue_expression_up	hsa-mir-7-3	Neurilemmoma	21156648	disease of cellular proliferation	DOID:3192	D36.10	D009442			miRNA-7 attenuation in schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.
tissue_expression_up	hsa-mir-1246	Neuroblastoma	24739954	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Parallel mRNA and microRNA profiling of HEV71-infected human neuroblastoma cells  reveal the up-regulation of miR-1246 in association with DLG3 repression.
tissue_expression_up	hsa-mir-34a	Neuroblastoma	22498172	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)
tissue_expression_up	hsa-mir-34a	Neuroblastoma	17888029	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	All of the Fe-NTA-induced rat renal carcinomas and an array of human cancers (151 positive cases of 177) showed high expression of miRNA-34a.
tissue_expression_up	hsa-mir-7-1	Neuroblastoma	22498172	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)
tissue_expression_up	hsa-mir-99a	Neuroblastoma	22498172	disease of cellular proliferation	DOID:769	C74.90	D009447	256700	HP:0003006	Combination of 4-HPR (N-(4-hydroxyphenyl) retinamide) and EGCG ((-)-epigallocatechin-3-gallate) most significantly decreased expression of OGmiRs (miR-92, miR-93, and miR-106b) and increased expression of TSmiRs (miR-7-1, miR-34a, and miR-99a) in both cell lines(SK-N-BE2 and IMR-32 cells)
tissue_expression_up	hsa-mir-196a	Niemann-Pick Disease, Type C	21075073	disease of metabolism	DOID:0070113	E75.2	D052556	257220		We found that three miRNAs, miR-196a, miR-196b and miR-296 were up-regulated (>3.5-fold increase, p<0.05) whereas 38 miRNAs were significantly down-regulated in NPC cells (>3.5-fold decrease, p<0.05).
tissue_expression_up	hsa-mir-196b	Niemann-Pick Disease, Type C	21075073	disease of metabolism	DOID:0070113	E75.2	D052556	257220		We found that three miRNAs, miR-196a, miR-196b and miR-296 were up-regulated (>3.5-fold increase, p<0.05) whereas 38 miRNAs were significantly down-regulated in NPC cells (>3.5-fold decrease, p<0.05).
tissue_expression_up	hsa-mir-296	Niemann-Pick Disease, Type C	21075073	disease of metabolism	DOID:0070113	E75.2	D052556	257220		We found that three miRNAs, miR-196a, miR-196b and miR-296 were up-regulated (>3.5-fold increase, p<0.05) whereas 38 miRNAs were significantly down-regulated in NPC cells (>3.5-fold decrease, p<0.05).
tissue_expression_up	hsa-mir-143	NUT Midline Carcinoma	29322795	disease of cellular proliferation	DOID:0060463					All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484
tissue_expression_up	hsa-mir-21	NUT Midline Carcinoma	29322795	disease of cellular proliferation	DOID:0060463					All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484
tissue_expression_up	hsa-mir-484	NUT Midline Carcinoma	29322795	disease of cellular proliferation	DOID:0060463					All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-484
tissue_expression_up	hsa-mir-9	NUT Midline Carcinoma	29322795	disease of cellular proliferation	DOID:0060463					All NMCs showed upregulation of miR-9 and downregulation of miR-99a and miR-145 and two cases featured also upregulation of miR-21, miR-143, and miR-485
tissue_expression_up	hsa-let-7b	Obesity	26258540	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Specifically, miR-28, miR-26, and let-7b previously shown to inhibit sex steroid production in human granulosa cells, were up-regulated.
tissue_expression_up	hsa-mir-143	Obesity	18809385	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR-143: Up-regulated expression of microRNA-143 in association with obesity in adipose
tissue_expression_up	hsa-mir-18a	Obesity	22043006	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Two microRNA species (miR-18a, miR-30e) were up-regulated among obese individuals with a healthy periodontium.
tissue_expression_up	hsa-mir-199a	Obesity	27279151	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	miR鈥?99a鈥?p may represent a factor in the modulation of obesity鈥慳ssociated IR
tissue_expression_up	hsa-mir-21	Obesity	21426570	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	mir-21 is up-regulated in subcutaneous adipose tissue in human obesity
tissue_expression_up	hsa-mir-221	Obesity	23756832	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-alpha
tissue_expression_up	hsa-mir-223	Obesity	27812198	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Visceral Adipose MicroRNA 223 Is Upregulated in Human and Murine Obesity and Modulates the Inflammatory Phenotype of Macrophages.
tissue_expression_up	hsa-mir-30e	Obesity	22043006	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Two microRNA species (miR-18a, miR-30e) were up-regulated among obese individuals with a healthy periodontium.
tissue_expression_up	hsa-mir-335	Obesity	19460359	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	These findings provide the first evidence that the up-regulated expressions of miR-335 in liver and WAT of obese mice might contribute to the pathophysiology of obesity.
tissue_expression_up	hsa-mir-378	Obesity	24771406	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	TNF-α, IL-6, and leptin upregulated miR-378 expression indicating that miR-378 probably is a novel mediator in the development of insulin resistance related to obesity.
tissue_expression_up	hsa-mir-31	Oral Neoplasms	24480806			C06.9	D009062		HP:0100649	miR-31 is upregulated in oral premalignant epithelium and contributes to the immortalization of normal oral keratinocytes.
tissue_expression_up	hsa-mir-146a	Osteoarthritis	22006119	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA.
tissue_expression_up	hsa-mir-146a	Osteoarthritis	22507670	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	IL-1β responsive miR-146a is overexpressed in an experimentally induced OA model, accompanied by upregulation of VEGF and downregulation of Smad4 in vivo.
tissue_expression_up	hsa-mir-146a	Osteoarthritis	26505891	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-146a significantly up-regulated and  miR-27b significantly down-regulated at all time points
tissue_expression_up	hsa-mir-155	Osteoarthritis	22006119	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA.
tissue_expression_up	hsa-mir-181a-1	Osteoarthritis	22006119	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA.
tissue_expression_up	hsa-mir-181a-2	Osteoarthritis	22006119	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA.
tissue_expression_up	hsa-mir-223	Osteoarthritis	22006119	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	The relative expression levels of miR-146a, 155, 181a, and 223 in the OA patients were significantly higher than those found in healthy controls. In the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages. There was a significant correlation between the expression of miR-223 and KS. This study demonstrated that high expression levels of miR-146a, 155, 181a, and 223 in the PBMCs of OA patients might be related to the pathogenesis of OA.
tissue_expression_up	hsa-mir-9	Osteoarthritis	25917063	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	These findings implicate miR-9-mediated suppression of MCPIP-1 in the pathogenesis of OA via up-regulation of IL-6 expression in IL-1β-stimulated human OA chondrocytes.
tissue_expression_up	hsa-mir-98	Osteoarthritis	27676099	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	Upregulation of miR-98 Inhibits Apoptosis in Cartilage Cells in Osteoarthritis.
tissue_expression_up	hsa-mir-34a	Osteonecrosis	25612520	musculoskeletal system disease	DOID:10159	M87	D010020			The expression of miR-34a and miR-146a and genes in the predict pathways were significantly up-regulated.
tissue_expression_up	hsa-mir-143	Osteosarcoma	25562163	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	TGF-β1 up-regulates versican expression bysuppressing miR-143, and this pathway is important for osteosarcoma cell migration and invasion.
tissue_expression_up	hsa-mir-17	Osteosarcoma	22682620	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	up-regulated in osteosarcoma.
tissue_expression_up	hsa-mir-17	Osteosarcoma	24645838	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Upregulation of microRNA-17-92 cluster associates with tumor progression and prognosis in osteosarcoma.
tissue_expression_up	hsa-mir-181a-1	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	high expression
tissue_expression_up	hsa-mir-181a-2	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	high expression
tissue_expression_up	hsa-mir-181b-1	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	high expression
tissue_expression_up	hsa-mir-181b-2	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	high expression
tissue_expression_up	hsa-mir-181c	Osteosarcoma	22350417	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	high expression
tissue_expression_up	hsa-mir-18a	Osteosarcoma	22682620	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	up-regulated in osteosarcoma.
tissue_expression_up	hsa-mir-196a	Osteosarcoma	24747591	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our present data indicate the involvement of miR-196a and miR-196b upregulation in the pathogenesis of osteosarcoma. More importantly, the altered levels of circulating miR-196a and miR-196b might have great potential to serve as novel and non-invasive prognostic factors for this malignancy.
tissue_expression_up	hsa-mir-196a	Osteosarcoma	25599934	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	the effects of miR-196a over-expression on tumour cell response may be strictly related to species and cell type. Further studies are needed to define the impact of miRNA deregulation on OS development.
tissue_expression_up	hsa-mir-196b	Osteosarcoma	24747591	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our present data indicate the involvement of miR-196a and miR-196b upregulation in the pathogenesis of osteosarcoma. More importantly, the altered levels of circulating miR-196a and miR-196b might have great potential to serve as novel and non-invasive prognostic factors for this malignancy.
tissue_expression_up	hsa-mir-19a	Osteosarcoma	22682620	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	up-regulated in osteosarcoma.
tissue_expression_up	hsa-mir-19b-1	Osteosarcoma	22682620	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	up-regulated in osteosarcoma.
tissue_expression_up	hsa-mir-20a	Osteosarcoma	22682620	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	up-regulated in osteosarcoma.
tissue_expression_up	hsa-mir-210	Osteosarcoma	23430441	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-210 upregulation showed a strong correlation with tumor aggressive progression of pediatric osteosarcoma and could help prognostic screening of patients with this malignancy
tissue_expression_up	hsa-mir-9	Osteosarcoma	27051003	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-9 was significantly upregulated in OS tissues and cell lines compared to the corresponding non-cancerous bone tissues
tissue_expression_up	hsa-mir-92a-1	Osteosarcoma	22682620	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	up-regulated in osteosarcoma.
tissue_expression_up	hsa-mir-146b	Otitis Media	27497395	nervous system disease	DOID:10754	H66.9	D010033	166760	HP:0000388	Middle ear miR-146a and miR-146b expression was elevated in otitis media patients relative to control subjects and correlated with middle ear epithelial thickness.
tissue_expression_up	hsa-mir-302c	Ovarian Germ Cell Cancer	29138809	endocrine system disease	DOID:2156			603737		Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs
tissue_expression_up	hsa-mir-372	Ovarian Germ Cell Cancer	29138809	endocrine system disease	DOID:2156			603737		Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs
tissue_expression_up	hsa-mir-373	Ovarian Germ Cell Cancer	29138809	endocrine system disease	DOID:2156			603737		Higher expression of miR-373-3p, miR-372-3p and miR-302c-3p and lower expression of miR-199a-5p, miR-214-5p and miR-202-3p were reproducibly observed in malignant OGCTs as compared to benign OGCTs or SCSTs
tissue_expression_up	hsa-let-7f	Ovarian Neoplasms	20716115	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets.
tissue_expression_up	hsa-mir-10b	Ovarian Neoplasms	23670532	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Loss of HOXD10 expression induced by upregulation of miR-10b accelerates the migration and invasion activities of ovarian cancer cells.
tissue_expression_up	hsa-mir-126	Ovarian Neoplasms	18954897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-126: over-expressed
tissue_expression_up	hsa-mir-1299	Ovarian Neoplasms	21939554	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines.
tissue_expression_up	hsa-mir-130a	Ovarian Neoplasms	22614869	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
tissue_expression_up	hsa-mir-134	Ovarian Neoplasms	26363097	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	In conclusion, our findings indicate that repression of miR-134 and consequent up-regulation of Pak2 might contribute to paclitaxel resistance.
tissue_expression_up	hsa-mir-140	Ovarian Neoplasms	17875710	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs.
tissue_expression_up	hsa-mir-141	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Higher
tissue_expression_up	hsa-mir-141	Ovarian Neoplasms	17875710	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs.
tissue_expression_up	hsa-mir-141	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_up	hsa-mir-145	Ovarian Neoplasms	17875710	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs.
tissue_expression_up	hsa-mir-146a	Ovarian Neoplasms	22643117	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181.
tissue_expression_up	hsa-mir-146a	Ovarian Neoplasms	23554878	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These observations suggest that at least two of the miRNAs, miR-146a and miR-150, up-regulated in omental lesions, stimulate survival and increase drug tolerance.
tissue_expression_up	hsa-mir-146b	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_up	hsa-mir-148b	Ovarian Neoplasms	22344713	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-148b was overexpressed in 92.21% (71/77) of the ovarian cancer samples examined, and overexpression of miR-148b in ovarian cancer tissues was not associated with any of the clinicopathological features of patients with ovarian cancer.
tissue_expression_up	hsa-mir-150	Ovarian Neoplasms	23554878	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	These observations suggest that at least two of the miRNAs, miR-146a and miR-150, up-regulated in omental lesions, stimulate survival and increase drug tolerance.
tissue_expression_up	hsa-mir-155	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_up	hsa-mir-155	Ovarian Neoplasms	23171795	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found that in ovarian CAFs, miR-31 and miR-214 were downregulated, whereas miR-155 was upregulated when compared with normal or tumor-adjacent fibroblasts.
tissue_expression_up	hsa-mir-155	Ovarian Neoplasms	23230184	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	They found that decreased miR-31 and miR-214 and increased miR-155 expression can reprogram normal fibroblasts into tumor-promoting cancer-associated fibroblasts.
tissue_expression_up	hsa-mir-182	Ovarian Neoplasms	23262295	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation
tissue_expression_up	hsa-mir-182	Ovarian Neoplasms	27295517	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-182 expression is significantly increased in EOC
tissue_expression_up	hsa-mir-182	Ovarian Neoplasms	20716115	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets.
tissue_expression_up	hsa-mir-183	Ovarian Neoplasms	21176563	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Increased expression of miR-183 and miR-22 may both repress the protein level of ezrin, indicating that miR-183 and miR-22 may bear a potential role in inhibiting ovarian cancer metastasis in a ezrin-mediated way
tissue_expression_up	hsa-mir-18a	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Higher
tissue_expression_up	hsa-mir-192	Ovarian Neoplasms	23766361	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a*, while mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified.
tissue_expression_up	hsa-mir-192	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_up	hsa-mir-193b	Ovarian Neoplasms	21939554	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines.
tissue_expression_up	hsa-mir-194-1	Ovarian Neoplasms	23766361	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a*, while mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified.
tissue_expression_up	hsa-mir-194-2	Ovarian Neoplasms	23766361	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a*, while mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified.
tissue_expression_up	hsa-mir-199a	Ovarian Neoplasms	17875710	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs.
tissue_expression_up	hsa-mir-200a	Ovarian Neoplasms	25374174	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200a overexpression in advanced ovarian carcinomas as a prognostic indicator.
tissue_expression_up	hsa-mir-200a	Ovarian Neoplasms	17875710	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs.
tissue_expression_up	hsa-mir-200a	Ovarian Neoplasms	22643117	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181.
tissue_expression_up	hsa-mir-200b	Ovarian Neoplasms	17875710	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs.
tissue_expression_up	hsa-mir-200b	Ovarian Neoplasms	22643117	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181.
tissue_expression_up	hsa-mir-200c	Ovarian Neoplasms	17875710	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The most significantly overexpressed miRNAs were miR-200a, miR-141, miR-200c, and miR-200b, whereas miR-199a, miR-140, miR-145, and miR-125b1 were among the most down-modulated miRNAs.
tissue_expression_up	hsa-mir-200c	Ovarian Neoplasms	20716115	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets.
tissue_expression_up	hsa-mir-203	Ovarian Neoplasms	23918241	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.
tissue_expression_up	hsa-mir-205	Ovarian Neoplasms	22643117	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181.
tissue_expression_up	hsa-mir-21	Ovarian Neoplasms	18954897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-21: over-expressed
tissue_expression_up	hsa-mir-21	Ovarian Neoplasms	18560586	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	we identify several miRNAs aberrantly expressed in human ovarian cancer tissues and cell lines. miR-221 stands out as a highly elevated miRNA in ovarian cancer, while miR-21 and several members of the let-7 family are found downregulated.
tissue_expression_up	hsa-mir-210	Ovarian Neoplasms	20716115	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets.
tissue_expression_up	hsa-mir-214	Ovarian Neoplasms	24479883	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Members of the miR-200 family, miR-182, miR-214 and miR-221 are frequently up-regulated, whereas miR-100, let-7i, miR-199a, miR-125b, mir-145 and miR-335 are often down-regulated in ovarian cancer compared with normal ovarian tissue.
tissue_expression_up	hsa-mir-22	Ovarian Neoplasms	21176563	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Increased expression of miR-183 and miR-22 may both repress the protein level of ezrin, indicating that miR-183 and miR-22 may bear a potential role in inhibiting ovarian cancer metastasis in a ezrin-mediated way
tissue_expression_up	hsa-mir-222	Ovarian Neoplasms	24137356	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1.
tissue_expression_up	hsa-mir-222	Ovarian Neoplasms	20716115	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets.
tissue_expression_up	hsa-mir-23a	Ovarian Neoplasms	20716115	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Reduced miR-145 and miR-214 and elevated let-7f, miR-182, miR-210, miR-200c, miR-222 and miR-23a levels were found in effusions in both sets.
tissue_expression_up	hsa-mir-27a	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_up	hsa-mir-27a	Ovarian Neoplasms	19446316	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	High expression of hsa-mir-27a identified a sub-group of patients with very poor prognosis.
tissue_expression_up	hsa-mir-29a	Ovarian Neoplasms	18954897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-29a: over-expressed
tissue_expression_up	hsa-mir-29c	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_up	hsa-mir-3	Ovarian Neoplasms	22643117	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	We found 37 differentially expressed miRNAs in the CD133(+) spheroid-forming subpopulation of OVCAR3 cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and 3 of which were significantly down-regulated, including miR-1202 and miR-1181.
tissue_expression_up	hsa-mir-300	Ovarian Neoplasms	21939554	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines.
tissue_expression_up	hsa-mir-30a	Ovarian Neoplasms	23766361	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The clear cell histotype is characterized by a five-fold (log scale) higher expression of miR-30a and miR-30a*, while mucinous histotype has five-fold (log scale) higher levels of miR-192/194. Furthermore a mucinous-specific regulatory loop involving miR-192/194 cluster and a differential regulation of E2F3 in clear cell histotype were identified.
tissue_expression_up	hsa-mir-30a	Ovarian Neoplasms	24479883	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Clear cell carcinoma has a significantly higher expression of miR-30a and miR-30a*, whereas mucinous histotype has elevated levels of miR-192/194.
tissue_expression_up	hsa-mir-34b	Ovarian Neoplasms	22340095	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin.
tissue_expression_up	hsa-mir-34c	Ovarian Neoplasms	22340095	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin.
tissue_expression_up	hsa-mir-429	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Higher
tissue_expression_up	hsa-mir-449a	Ovarian Neoplasms	22340095	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin.
tissue_expression_up	hsa-mir-449b	Ovarian Neoplasms	22340095	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The expressions of miR-449a/b, miR-34b and miR-34c were 19-fold to 21-fold elevated after p53 activation by genotoxic agent adriamycin.
tissue_expression_up	hsa-mir-454	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_up	hsa-mir-486	Ovarian Neoplasms	29518404	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Specifically, miR-196b, miR-532, miR-886-3b, and miR-99b exhibited lower levels in HGOSC compared with USC, whereas miR-29c, miR-155, miR-454, miR-146b-5p, miR-486-5p, miR-27a, miR-192, and miR-141 exhibited significantly higher expression in HGOSC samples
tissue_expression_up	hsa-mir-622	Ovarian Neoplasms	26774475	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
tissue_expression_up	hsa-mir-629	Ovarian Neoplasms	19946373	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	upregulated
tissue_expression_up	hsa-mir-642a	Ovarian Neoplasms	21939554	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The miRNA was upregulated in cis-platin resistant (A2780/CP70) vs. cis-platin sensitive (A2780) ovarian cancer cell lines.
tissue_expression_up	hsa-mir-9	Ovarian Neoplasms	24870723	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The present study provided evidence that curcumin exerts its cytotoxic effects against SKOV3 ovarian cancer cells largely through upregulation of miR-9 and subsequent modulation of Akt/FOXO1 axis. Further studies are needed to identify direct targets of miR-9 that mediate the anticancer effects of curcumin in ovarian cancer cells.
tissue_expression_up	hsa-mir-92b	Ovarian Neoplasms	18954897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-92: over-expressed
tissue_expression_up	hsa-mir-93	Ovarian Neoplasms	18451233	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Higher
tissue_expression_up	hsa-mir-93	Ovarian Neoplasms	18954897	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-93: over-expressed
tissue_expression_up	hsa-mir-96	Ovarian Neoplasms	23262295	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation
tissue_expression_up	hsa-mir-196a	Pancreatic Intraductal Papillary Mucinous Neoplasms	24622064	disease of cellular proliferation	DOID:7575					Elevated expression of miR-196a in pancreatic juice samples is predictive of intestinal-type IPMNs.
tissue_expression_up	hsa-let-7a	Pancreatic Neoplasms	29596326	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with increases in the expression of let-7a microRNA; suppression of K-Ras and survivin; and the elimination of drug-resistant cancer stem/tumor-initiating cells
tissue_expression_up	hsa-let-7a	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-let-7b	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-let-7c	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-let-7d	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-mir-100	Pancreatic Neoplasms	22466166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions.
tissue_expression_up	hsa-mir-101	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-mir-103a	Pancreatic Neoplasms	26714641	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We identified suitable reference miRNAs for future miRNA expression experiments using CRC- and PC FFPE tissue samples. Formalin fixation decreased miRNA expression considerably, while the effect of increasing sample age was estimated to be negligible in a clinical setting.
tissue_expression_up	hsa-mir-106a	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-107	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-10a	Pancreatic Neoplasms	29169171	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells
tissue_expression_up	hsa-mir-10b	Pancreatic Neoplasms	22117151	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-10b is upregulated in pancreatic ductal adenocarcinoma and can be used as a diagnostic marker in endoscopic ultrasound-guided fine-needle aspiration biopsies of suspicious pancreatic lesions. In addition, miR-10b may be able to guide neoadjuvant gemcitabine-based chemoradiotherapy and predict metastatic-free survival and overall survival.
tissue_expression_up	hsa-mir-10b	Pancreatic Neoplasms	22910491	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA-10b is overexpressed in pancreatic cancer.
tissue_expression_up	hsa-mir-10b	Pancreatic Neoplasms	29169171	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells
tissue_expression_up	hsa-mir-128-2	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-1300	Pancreatic Neoplasms	22042419	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold.
tissue_expression_up	hsa-mir-133a	Pancreatic Neoplasms	26214431	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Propofol suppresses proliferation and invasion of pancreatic cancer cells by upregulating microRNA-133a expression.
tissue_expression_up	hsa-mir-134	Pancreatic Neoplasms	22690071	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-95, miR-134 and miR-34c-3p are the top three miRNAs regulated by glargine (3.65-fold, 2.67-fold and 2.60-fold changes respectively, P < 0.01) in Sw1990 cells.
tissue_expression_up	hsa-mir-142	Pancreatic Neoplasms	21347785	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		patients with high miR-142-5p and miR-204 expression had significantly longer survival times than those with low miR-142-5p (P = 0.0077) and miR-204 (P = 0.0054) expression in the gemcitabine-treated group.
tissue_expression_up	hsa-mir-146a	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-146a	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-mir-146b	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-155	Pancreatic Neoplasms	22466166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions.
tissue_expression_up	hsa-mir-155	Pancreatic Neoplasms	22850622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed.
tissue_expression_up	hsa-mir-155	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_up	hsa-mir-15a	Pancreatic Neoplasms	19551852	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		differentially expressed; associates with poorer survival
tissue_expression_up	hsa-mir-15b	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-15b: upregulated
tissue_expression_up	hsa-mir-17	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-17	Pancreatic Neoplasms	20703102	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion
tissue_expression_up	hsa-mir-181b-1	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-181b-1	Pancreatic Neoplasms	22466166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions.
tissue_expression_up	hsa-mir-181b-2	Pancreatic Neoplasms	22466166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions.
tissue_expression_up	hsa-mir-182	Pancreatic Neoplasms	22042419	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold.
tissue_expression_up	hsa-mir-183	Pancreatic Neoplasms	22042419	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold.
tissue_expression_up	hsa-mir-186	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-186: upregulated
tissue_expression_up	hsa-mir-190a	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-190: upregulated
tissue_expression_up	hsa-mir-191	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-194-1	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly up-regulated in PDAC compared with normal ductal
tissue_expression_up	hsa-mir-194-2	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly up-regulated in PDAC compared with normal ductal
tissue_expression_up	hsa-mir-196a	Pancreatic Neoplasms	22042419	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold.
tissue_expression_up	hsa-mir-196a-1	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-196a: upregulated
tissue_expression_up	hsa-mir-196a-1	Pancreatic Neoplasms	22466166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions.
tissue_expression_up	hsa-mir-196a-2	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-196a: upregulated
tissue_expression_up	hsa-mir-196a-2	Pancreatic Neoplasms	22466166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions.
tissue_expression_up	hsa-mir-196a-2	Pancreatic Neoplasms	17473300	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Finally, high expression of miR-196a-2 was found to predict poor survival (median, 14.3 months [95% confidence interval, 12.4-16.2] vs 26.5 months [95% confidence interval, 23.4-29.6]; P = .009).
tissue_expression_up	hsa-mir-199a-1	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-200b	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-200b: upregulated
tissue_expression_up	hsa-mir-200b	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-mir-200c	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-mir-203	Pancreatic Neoplasms	19551852	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		differentially expressed; associates with poorer survival
tissue_expression_up	hsa-mir-204	Pancreatic Neoplasms	21347785	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		patients with high miR-142-5p and miR-204 expression had significantly longer survival times than those with low miR-142-5p (P = 0.0077) and miR-204 (P = 0.0054) expression in the gemcitabine-treated group.
tissue_expression_up	hsa-mir-20a	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	17531469	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MiR-21 is found to be highly expressed in numerous cancers like breast cancer, and glioblastoma and pancreatic cancer.
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	18642050	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	21463919	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		over-expression of Notch-1 leads to increased expression of miR-21, and decreased expression of miR-200b, miR-200c, let-7a, let-7b, and let-7c. over-expression of Notch-1 led to the induction of EMT phenotype
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	21983937	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miRNA-21 was the most significantly overexpressed miRNA in the pancreatic ductal adenocarcinomas analyzed, and was also highly expressed in 75% of the 65 pancreatic ductal adenocarcinomas examined by real-time RT-PCR. High miRNA-21 expression was correlated with a worse prognosis in the pancreatic ductal adenocarcinoma patients (P=0.045). The immunohistochemical expression patterns of PDCD4 (reduced nuclear staining pattern) and TIMP3 (downregulated expression) were significantly associated with both the upregulated miR-21 expression (P<0.05) and the poor survival of the patients (P<0.001 and P=0.001, respectively). Our data suggest that an overexpression of miRNA-21 is, therefore, associated with the biological behavior of pancreatic ductal adenocarcinoma via the downregulation of the expression of tumor suppressors, PDCD4 and TIMP3, thus resulting in tumor progression and the adverse clinical course of pancreatic ductal adenocarcinoma.
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	22114136	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		In the initial cohort of 48 PDAC (pancreatic ductal adenocarcinoma) patients, high expression of miR-21 (Hazard ratio (HR): 3.22, 95% Confidence Interval (CI):1.21-8.58) and reduced expression of miR-34a (HR 0.15, 95%CI: 0.06-0.37) and miR-30d (HR:0.30, 95%CI:0.12-0.79) were associated with poor overall survival following resection independent of clinical covariates. In a further validation set of 24 patients miR-21 and miR-34a expression again significantly correlated with overall survival (P = 0.031 and P = 0.001).
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	22466166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions.
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	22850622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed.
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	23272057	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Here, we show, for the first time, that hypoxia leads to increased expression of VEGF, IL-6, and CSC signature genes Nanog, Oct4 and EZH2 consistent with increased cell migration/invasion and angiogenesis, and the formation of pancreatospheres,concomitant with increased expression of miR-21 and miR-210 in human pancreatic cancer (PC) cells
tissue_expression_up	hsa-mir-21	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_up	hsa-mir-210	Pancreatic Neoplasms	19551852	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		differentially expressed; associates with poorer survival
tissue_expression_up	hsa-mir-210	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly up-regulated in PDAC compared with normal ductal
tissue_expression_up	hsa-mir-210	Pancreatic Neoplasms	22850622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed.
tissue_expression_up	hsa-mir-210	Pancreatic Neoplasms	23272057	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Here, we show, for the first time, that hypoxia leads to increased expression of VEGF, IL-6, and CSC signature genes Nanog, Oct4 and EZH2 consistent with increased cell migration/invasion and angiogenesis, and the formation of pancreatospheres,concomitant with increased expression of miR-21 and miR-210 in human pancreatic cancer (PC) cells
tissue_expression_up	hsa-mir-214	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-214	Pancreatic Neoplasms	25304377	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Thirteen miRNAs (miR-138, miR-195, miR-204, miR-216a, miR-217, miR-218, miR-802, miR-155, miR-214, miR-26a, miR-30b, miR-31, and miR-125) were enriched and two miRNAs (miR-451a and miR-4284) were depleted in the cyst fluids derived from invasive carcinomas.
tissue_expression_up	hsa-mir-218	Pancreatic Neoplasms	25304377	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Thirteen miRNAs (miR-138, miR-195, miR-204, miR-216a, miR-217, miR-218, miR-802, miR-155, miR-214, miR-26a, miR-30b, miR-31, and miR-125) were enriched and two miRNAs (miR-451a and miR-4284) were depleted in the cyst fluids derived from invasive carcinomas.
tissue_expression_up	hsa-mir-221	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-221	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-221: upregulated
tissue_expression_up	hsa-mir-221	Pancreatic Neoplasms	22466166	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Carcinomas showed higher expression of miR-21, miR-221, miR-155, miR-100, and miR-181b than benign lesions. Cellblocks containing carcinoma showed higher expression of miR-21, miR-221, and miR-196a than those from benign lesions.
tissue_expression_up	hsa-mir-221	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_up	hsa-mir-222	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-222: upregulated
tissue_expression_up	hsa-mir-222	Pancreatic Neoplasms	19551852	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		differentially expressed; associates with poorer survival
tissue_expression_up	hsa-mir-222	Pancreatic Neoplasms	22850622	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-21, miR-155, miR-210, miR-221, and miR-222, were overexpressed in diseased tissues than in the control samples, whereas miR-31, miR-122, miR-145, and miR-146a were underexpressed.
tissue_expression_up	hsa-mir-223	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-24-1	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-24-2	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-25	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-25	Pancreatic Neoplasms	22042419	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold.
tissue_expression_up	hsa-mir-26a	Pancreatic Neoplasms	22108826	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		These effects were associated with decreased expression of EZH2 and increased expression of a panel of tumor-suppressive microRNAs (miRNA), including let-7a, b, c, d, miR-26a, miR-101, miR-146a, andmiR-200b, c that are typically lost in pancreatic cancer.
tissue_expression_up	hsa-mir-27a	Pancreatic Neoplasms	29169171	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells
tissue_expression_up	hsa-mir-27a	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_up	hsa-mir-27b	Pancreatic Neoplasms	29169171	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells
tissue_expression_up	hsa-mir-27b	Pancreatic Neoplasms	22213426	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a,miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model
tissue_expression_up	hsa-mir-29b-1	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-301b	Pancreatic Neoplasms	27197190	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		PDAC tumors expressing high levels of MIF displayed elevated levels of miR-301b and reduced levels of NR3C2.
tissue_expression_up	hsa-mir-30b	Pancreatic Neoplasms	25304377	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Thirteen miRNAs (miR-138, miR-195, miR-204, miR-216a, miR-217, miR-218, miR-802, miR-155, miR-214, miR-26a, miR-30b, miR-31, and miR-125) were enriched and two miRNAs (miR-451a and miR-4284) were depleted in the cyst fluids derived from invasive carcinomas.
tissue_expression_up	hsa-mir-30c	Pancreatic Neoplasms	22042419	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold.
tissue_expression_up	hsa-mir-30c-1	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-30c-2	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-32	Pancreatic Neoplasms	16461460	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		overexpressed
tissue_expression_up	hsa-mir-34c	Pancreatic Neoplasms	22690071	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-95, miR-134 and miR-34c-3p are the top three miRNAs regulated by glargine (3.65-fold, 2.67-fold and 2.60-fold changes respectively, P < 0.01) in Sw1990 cells.
tissue_expression_up	hsa-mir-425	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly up-regulated in PDAC compared with normal ductal
tissue_expression_up	hsa-mir-429	Pancreatic Neoplasms	21953293	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Highly up-regulated in PDAC compared with normal ductal
tissue_expression_up	hsa-mir-451a	Pancreatic Neoplasms	22929886	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients.
tissue_expression_up	hsa-mir-451b	Pancreatic Neoplasms	22929886	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients.
tissue_expression_up	hsa-mir-486	Pancreatic Neoplasms	22929886	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of let-7c, let-7f, and miR-200c were significantly reduced in most patients whereas the expression of miR-486-5p and miR-451 were significantly elevated in all pancreas cancer patients.
tissue_expression_up	hsa-mir-552	Pancreatic Neoplasms	22042419	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold.
tissue_expression_up	hsa-mir-7	Pancreatic Neoplasms	25256401	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells.
tissue_expression_up	hsa-mir-9	Pancreatic Neoplasms	29169171	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-27a, miR-27b, miR-9, miR10a and miR-10b were up-regulated in PDAC cells compared to HPDE cells
tissue_expression_up	hsa-mir-95	Pancreatic Neoplasms	19030927	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-95: upregulated
tissue_expression_up	hsa-mir-95	Pancreatic Neoplasms	22690071	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-95, miR-134 and miR-34c-3p are the top three miRNAs regulated by glargine (3.65-fold, 2.67-fold and 2.60-fold changes respectively, P < 0.01) in Sw1990 cells.
tissue_expression_up	hsa-mir-214	Pediatric Osteosarcoma	24038809	disease of cellular proliferation	DOID:3361					Our data offer evidence that upregulated expression of miR-214 may be linked to tumor progression and adverse prognosis in pediatric osteosarcoma.Further investigation in prospective studies would appear warranted.
tissue_expression_up	hsa-mir-106b	Periodontal Diseases	22043006	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	Two microRNA species (miR-30e, miR-106b) were up-regulated in non-obese individuals with periodontal disease.
tissue_expression_up	hsa-mir-30e	Periodontal Diseases	22043006	gastrointestinal system disease	DOID:3388	K05.6	D010510		HP:0000704	Two microRNA species (miR-30e, miR-106b) were up-regulated in non-obese individuals with periodontal disease.
tissue_expression_up	hsa-let-7a-1	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-let-7a-2	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-let-7a-3	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-let-7c	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-130a	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-181b-1	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-181b-2	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-19b-1	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-19b-2	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-21	Periodontitis	26987780	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Seven randomly selected up-regulated (miR-21-5p, 498, 548a-5p) and down-regulated (miR-495-3p, 539-5p, 34c-3p and 7a-2-3p) miRNAs were examined by qRT-PCR, and the results proved the accuracy of the miRNA
tissue_expression_up	hsa-mir-23a	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-301a	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-30a	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-520d	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-548a-1	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-548a-2	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-548a-3	Periodontitis	22128589	gastrointestinal system disease	DOID:824	K05.4	D010518	260950	HP:0000704	Six miRNA genes, let-7a, let-7c, miR-130a, miR301a, miR-520d, and miR-548a, were up-regulated more than 8 fold compared to the healthy gingiva. miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a, and miR-301a, were amplified successfully and increased much more in periodontitis gingivae than in healthy ones.
tissue_expression_up	hsa-mir-101-1	Pheochromocytoma	22241719			C74.10	D010673	171300	HP:0002666	miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts.
tissue_expression_up	hsa-mir-101-2	Pheochromocytoma	22241719			C74.10	D010673	171300	HP:0002666	miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts.
tissue_expression_up	hsa-mir-183	Pheochromocytoma	22241719			C74.10	D010673	171300	HP:0002666	miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts.
tissue_expression_up	hsa-mir-483	Pheochromocytoma	22241719			C74.10	D010673	171300	HP:0002666	miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts.
tissue_expression_up	hsa-mir-451	Placenta Cancer	29805755	disease of cellular proliferation	DOID:2021	C58				The results showed that miR-451 and miR-720, highly expressed placental miRNAs, presented very low or undetectable expression in cancer cell lines compared to the normal placenta and healthy tissues
tissue_expression_up	hsa-mir-720	Placenta Cancer	29805755	disease of cellular proliferation	DOID:2021	C58				The results showed that miR-451 and miR-720, highly expressed placental miRNAs, presented very low or undetectable expression in cancer cell lines compared to the normal placenta and healthy tissues
tissue_expression_up	hsa-let-7b	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-let-7e	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-1228	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-144	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-195	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-203	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-30b	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-31	Pleural Mesothelioma	25358615	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
tissue_expression_up	hsa-mir-32	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-340	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-345	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-34a	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-423	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-483	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-582	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-584	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-595	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-615	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-7-1	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-885	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-9	Pleural Mesothelioma	29462963	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	They reported 12 over-expressed miRNAs (let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p) and nine sub-expressed (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1* and miR-9) in MPM tissue compared to the single control
tissue_expression_up	hsa-mir-451	Polycythemia Vera	20218812	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed that miR-451 up-regulation and miR-150 down-regulation are associated with progression of erythroid maturation in K562 cells.
tissue_expression_up	hsa-let-7b	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-128-1	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-128-2	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-128a	Preeclampsia	27261578	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-128a is an up-regulated miRNA in patient with PE.
tissue_expression_up	hsa-mir-133b	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-182	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-206	Preeclampsia	26213997	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Our pilot study has identified miRNA-206 as a novel factor upregulated in preeclampsia within the maternal circulation and in placental tissue.
tissue_expression_up	hsa-mir-21	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-21	Preeclampsia	26859593	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	we could observe a significant increase in gene expression of miR-155 (p<0.001), miR-21 (p<0.0001) and miR-122 (p<0.01) in preeclamptic placentas.
tissue_expression_up	hsa-mir-210	Preeclampsia	21388517	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Elevated levels of hypoxia-inducible microRNA-210 in pre-eclampsia: new insights into molecular mechanisms for the disease.
tissue_expression_up	hsa-mir-210	Preeclampsia	25015807	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	This increases the expression of miR-210 in the placenta causing repression of mitochondria-associated target genes, potentially leading to mitochondrial and placental dysfunction.
tissue_expression_up	hsa-mir-302a	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-302b	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-302c	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-302d	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-302e	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-302f	Preeclampsia	21309633	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Six miRNAs were more than 2-fold over-expressed in severe preeclampsia: let-7b, miRNA-302*, miRNA-104, miRNA-128a, miRNA-182* and miRNA-133b.
tissue_expression_up	hsa-mir-299	Primary Biliary Cirrhosis	19345069	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	A total of 35 independent miRNAs were found to be differentially expressed in PBC (p < 0.001).Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p.
tissue_expression_up	hsa-mir-328	Primary Biliary Cirrhosis	19345069	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	A total of 35 independent miRNAs were found to be differentially expressed in PBC (p < 0.001).Quantitative PCR was employed to validate down-regulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p.
tissue_expression_up	hsa-let-7b	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_up	hsa-let-7i	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_up	hsa-mir-128a	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_up	hsa-mir-21	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_up	hsa-mir-222	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_up	hsa-mir-29b	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_up	hsa-mir-342	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_up	hsa-mir-424	Prion Diseases	22965126	nervous system disease	DOID:649	A81.9	D017096			we show that exosomes released by prion-infected neuronal cells have increased let-7b, let-7i, miR-128a, miR-21, miR-222, miR-29b,miR-342-3p and miR-424 levels with decreased miR-146 a levels compared to non-infected exosomes.
tissue_expression_up	hsa-mir-206	Prolactinoma	22366961	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-206 was significantly up-regulated in prolactinomas following bromocriptine treatment.
tissue_expression_up	hsa-mir-23b	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	up-regulated
tissue_expression_up	hsa-mir-342	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-342-3p: up-regulated
tissue_expression_up	hsa-mir-432	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	up-regulated
tissue_expression_up	hsa-mir-493	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	up-regulated
tissue_expression_up	hsa-mir-516b-1	Prolactinoma	22366961	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-516b was significantly up-regulated in prolactinomas following bromocriptine treatment.
tissue_expression_up	hsa-mir-516b-2	Prolactinoma	22366961	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-516b was significantly up-regulated in prolactinomas following bromocriptine treatment.
tissue_expression_up	hsa-mir-550a-1	Prolactinoma	22366961	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-516b was significantly up-regulated in prolactinomas following bromocriptine treatment.
tissue_expression_up	hsa-mir-550a-2	Prolactinoma	22366961	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-550 was significantly up-regulated in prolactinomas following bromocriptine treatment.
tissue_expression_up	hsa-mir-664	Prolactinoma	22490835	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-664*: up-regulated
tissue_expression_up	hsa-mir-671	Prolactinoma	22366961	disease of cellular proliferation	DOID:5394		D015175	600634	HP:0040278	miR-671-5p was significantly up-regulated in prolactinomas following bromocriptine treatment.
tissue_expression_up	hsa-mir-21	Proliferative Vitreoretinal Disease	27351379			H35.23				miR-21 expression positively  correlates with disease progression
tissue_expression_up	hsa-let-7b	Prostate Neoplasms	27157642	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	up-regulation of let-7b is characteristic of prostatic TAMs
tissue_expression_up	hsa-let-7c	Prostate Neoplasms	21255804	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively.
tissue_expression_up	hsa-mir-100	Prostate Neoplasms	21255804	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively.
tissue_expression_up	hsa-mir-106a	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-106b	Prostate Neoplasms	18676839	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-106b: significantly higher expression
tissue_expression_up	hsa-mir-107	Prostate Neoplasms	22240788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-107 and miR-574-3p were quantified at significantly higher concentrations in the urine of men with prostate cancer compared with controls.
tissue_expression_up	hsa-mir-10a	Prostate Neoplasms	22999546	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-100 and miR-10a showed under expression and over expression, respectively, in low grade pTa tumors.
tissue_expression_up	hsa-mir-1207	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_up	hsa-mir-126	Prostate Neoplasms	21594291	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated.
tissue_expression_up	hsa-mir-127	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-186a
tissue_expression_up	hsa-mir-134	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_up	hsa-mir-135b	Prostate Neoplasms	18949015	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-135b: up-regulated
tissue_expression_up	hsa-mir-143	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-184a
tissue_expression_up	hsa-mir-145	Prostate Neoplasms	22298119	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Significantly increased miR-145 expression were observed for patients with intermediate or high risk D'Amico scores compared to patients with low risk scores
tissue_expression_up	hsa-mir-145	Prostate Neoplasms	21255804	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively.
tissue_expression_up	hsa-mir-146a	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-146b	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-155	Prostate Neoplasms	25938433	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hsa-miR-155, hsa-miR-141 and hsa-miR-21 gene expressions were significantly elevated (66-85%, P<0.05) in tumor specimens
tissue_expression_up	hsa-mir-17	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-181a	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-191a
tissue_expression_up	hsa-mir-181b-1	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-182	Prostate Neoplasms	22045813	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells.
tissue_expression_up	hsa-mir-182	Prostate Neoplasms	25977730	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MicroRNA expression profiling in primary PCa and morphological normal prostate (MNPT) tissues identified 17 miRNAs significantly overexpressed in PCa.
tissue_expression_up	hsa-mir-182	Prostate Neoplasms	23936432	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21.
tissue_expression_up	hsa-mir-183	Prostate Neoplasms	22045813	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells.
tissue_expression_up	hsa-mir-191	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-191	Prostate Neoplasms	21255804	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively.
tissue_expression_up	hsa-mir-194-1	Prostate Neoplasms	18949015	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-194: up-regulated
tissue_expression_up	hsa-mir-194-2	Prostate Neoplasms	18949015	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-194: up-regulated
tissue_expression_up	hsa-mir-195	Prostate Neoplasms	26338045	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Collectively,this is the first report unveils that loss of miR-195 expression and thus uncontrolled BCOX1 upregulation might drive PCa metastasis.
tissue_expression_up	hsa-mir-199a-1	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-200	Prostate Neoplasms	21594291	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated.
tissue_expression_up	hsa-mir-204	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-182a
tissue_expression_up	hsa-mir-205	Prostate Neoplasms	21594291	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated.
tissue_expression_up	hsa-mir-20a	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-20a	Prostate Neoplasms	22298119	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-20a was significantly overexpressed in plasma from patients with stage 3 tumors compared to stage 2 or below (P=0.03).
tissue_expression_up	hsa-mir-21	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-21	Prostate Neoplasms	22298119	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression levels for miR-20a and miR-21 were significantly increased in patients with high risk CAPRA scores
tissue_expression_up	hsa-mir-21	Prostate Neoplasms	27040772	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the expression level of miR-21 was significantly increased in PCa tissues
tissue_expression_up	hsa-mir-214	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-22	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_up	hsa-mir-221	Prostate Neoplasms	19351832	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-221: Overexpression
tissue_expression_up	hsa-mir-221	Prostate Neoplasms	22117988	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The level of ARHI mRNA was significantly lower in aggressive compared with non-aggressive prostate cancer tissue samples. In contrast, microRNA 221 and 222 levels were significantly higher in aggressive compared with non-aggressive prostate cancer tissue samples.
tissue_expression_up	hsa-mir-222	Prostate Neoplasms	19351832	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-222: Overexpression
tissue_expression_up	hsa-mir-222	Prostate Neoplasms	22117988	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The level of ARHI mRNA was significantly lower in aggressive compared with non-aggressive prostate cancer tissue samples. In contrast, microRNA 221 and 222 levels were significantly higher in aggressive compared with non-aggressive prostate cancer tissue samples.
tissue_expression_up	hsa-mir-223	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-25	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-25	Prostate Neoplasms	18676839	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-25: significantly higher expression
tissue_expression_up	hsa-mir-29a	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_up	hsa-mir-29b	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_up	hsa-mir-29b-1	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-301a	Prostate Neoplasms	22719071	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	upregulated in prostate cancer stem/progenitor cell.
tissue_expression_up	hsa-mir-301a	Prostate Neoplasms	26990571	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	High levels of miR-301a (above the median) were associated with an increased risk of biochemical recurrence
tissue_expression_up	hsa-mir-301a	Prostate Neoplasms	27327120	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-301a and miR-301b are 2 hypoxia responsive miRNAs that are significantly upregulated in hypoxia in prostate cancer cells.
tissue_expression_up	hsa-mir-301b	Prostate Neoplasms	22719071	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	upregulated in prostate cancer stem/progenitor cell.
tissue_expression_up	hsa-mir-301b	Prostate Neoplasms	27327120	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-301a and miR-301b are 2 hypoxia responsive miRNAs that are significantly upregulated in hypoxia in prostate cancer cells.
tissue_expression_up	hsa-mir-30c-1	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-30c-2	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-32	Prostate Neoplasms	16461460	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	overexpressed
tissue_expression_up	hsa-mir-32	Prostate Neoplasms	18676839	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-32: significantly higher expression
tissue_expression_up	hsa-mir-330	Prostate Neoplasms	21177307	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We also observed a significant down-regulation of androgen-regulated miRNA-21 and up-regulation of a tumor suppressor, miRNA-330, in tumors of mice treated with EGCG
tissue_expression_up	hsa-mir-335	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-185a
tissue_expression_up	hsa-mir-335	Prostate Neoplasms	21594291	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	In addition, anti-invasive microRNAs such as miR-335, miR-205, miR-200, and miR-126, were up-regulated, whereas pro-invasive microRNA such as miR-21 and miR-373, were down-regulated.
tissue_expression_up	hsa-mir-371	Prostate Neoplasms	21592394	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated.
tissue_expression_up	hsa-mir-424	Prostate Neoplasms	24244675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-424/503-mediated Rictor upregulation promotes tumor progression.
tissue_expression_up	hsa-mir-433	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-188a
tissue_expression_up	hsa-mir-451	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-189a
tissue_expression_up	hsa-mir-452	Prostate Neoplasms	22719071	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	upregulated in prostate cancer stem/progenitor cell.
tissue_expression_up	hsa-mir-503	Prostate Neoplasms	24244675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-424/503-mediated Rictor upregulation promotes tumor progression.
tissue_expression_up	hsa-mir-542	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-187a
tissue_expression_up	hsa-mir-517a	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-181a
tissue_expression_up	hsa-mir-574	Prostate Neoplasms	22240788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-107 and miR-574-3p were quantified at significantly higher concentrations in the urine of men with prostate cancer compared with controls.
tissue_expression_up	hsa-mir-582	Prostate Neoplasms	25176332	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results suggest that up-regulation of miR-582-5p contributes to an increase in the proliferation of prostate cancer cells under androgen deprived conditions.
tissue_expression_up	hsa-mir-629	Prostate Neoplasms	19946373	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	upregulated
tissue_expression_up	hsa-mir-885	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-183a
tissue_expression_up	hsa-mir-92a	Prostate Neoplasms	29568403	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The top 11 miRNAs with significantly higher level in ExoHypoxic compared to ExoNormoxic were miR-517a, miR-204, miR-885, miR-143, miR-335, miR-127, miR-542, miR-433, miR-451, miR-92a and miR-190a
tissue_expression_up	hsa-mir-93	Prostate Neoplasms	18676839	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-93: significantly higher expression
tissue_expression_up	hsa-mir-96	Prostate Neoplasms	22045813	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells.
tissue_expression_up	hsa-mir-125b	Psoriasis	21373745	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Real-time PCR and immunohistochemistry showed that p63 expression was not significantly affected, whereas NB-UVB phototherapy significantly decreased expression ofmiR-21 (p = 0.003) and increased miR-125b levels (p = 0.003). The results indicate that the unresolved p63 abnormality in treated epidermis may play a role in maintenance of this disease.
tissue_expression_up	hsa-mir-146a	Psoriasis	17622355	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-146a was significantly over-expressed in psoriatic lesional skin p<0.001) but not in atopic eczema lesions when compared with healthy skin.
tissue_expression_up	hsa-mir-155	Psoriasis	27706699	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Increased miR-155-5p expression in dermal mesenchymal stem cells of psoriatic patients: comparing the microRNA expression profile by microarray.
tissue_expression_up	hsa-mir-203	Psoriasis	17622355	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	upregulation (lead to downregulation of its target SOCS3)
tissue_expression_up	hsa-mir-203	Psoriasis	23608026	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MiR-203 is a miRNA preferentially expressed in the skin, and an important regulator of keratinocyte differentiation. MiR-203 has been implicated in skin diseases, in particular in psoriasis in which it is overexpressed, and in basal cell carcinoma where it acts as a tumor suppressor miRNA.
tissue_expression_up	hsa-mir-203	Psoriasis	27729619	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	upregulation of miR-31/miR-203 and downregulation of hsa-miR-99a/miR-125b work together in concert to facilitate the development of psoriasis pathogenesis
tissue_expression_up	hsa-mir-21	Psoriasis	17622355	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-21 was significantly up-regulated both psoriasis (p<0.001) and atopic eczema (p<0.001) as compared with healthy skin.
tissue_expression_up	hsa-mir-21	Psoriasis	22417311	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis.
tissue_expression_up	hsa-mir-31	Psoriasis	27729619	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	upregulation of miR-31/miR-203 and downregulation of hsa-miR-99a/miR-125b work together in concert to facilitate the development of psoriasis pathogenesis
tissue_expression_up	hsa-mir-130a	Pulmonary Hypertension	23717609	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects.
tissue_expression_up	hsa-mir-191	Pulmonary Hypertension	23717609	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects.
tissue_expression_up	hsa-mir-199a	Pulmonary Hypertension	27162619	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	All 4 miRNAs were upregulated in the lung and right ventricle
tissue_expression_up	hsa-mir-23b	Pulmonary Hypertension	23717609	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	We identified several novel downregulated miRNAs (miR-451, miR-1246) and upregulated miRNAs (miR-23b, miR-130a and miR-191) in the circulation of PH subjects.
tissue_expression_up	hsa-mir-1183	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-1224	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-125a	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-1471	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-155	Rectal Neoplasms	25261908	disease of cellular proliferation	DOID:1984		D012004			Increase in the expression of miR-155 might represent a potential valuable marker for rectal carcinoma N and combined tumor-node-metastasis staging.
tissue_expression_up	hsa-mir-188	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-1909	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-483	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-622	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-630	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-671	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-765	Rectal Neoplasms	22172905	disease of cellular proliferation	DOID:1984		D012004			Microarray analysis selected 14 miRNAs as being differentially expressed in TRG1 patients, and 13 were confirmed by qRT-PCR: 11 miRNAs (miR-1183, miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-188-5p, miR-1471, miR-671-5p, miR-1909, miR-630, miR-765) were significantly upregulated in TRG1 patients, 2 (miR-1274b, miR-720) were downexpressed. MiR-622 and miR-630 had a 100% sensitivity and specificity in selecting TRG1 cases.
tissue_expression_up	hsa-mir-155	Renal Fibrosis	27158339	urinary system disease	DOID:0050855	N26.9			HP:0030760	MiR-155 levels were higher in UUO mouse kidneys
tissue_expression_up	hsa-mir-21	Renal Fibrosis	21775484	urinary system disease	DOID:0050855	N26.9			HP:0030760	miR-21 expression was upregulated in response to treatment with TGF-beta1 or TNF-alpha in human renal tubular epithelial cells in vitro.
tissue_expression_up	hsa-mir-125a	Retinal Degeneration	20053268	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	Over-expression
tissue_expression_up	hsa-mir-204	Retinal Degeneration	20053268	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	Over-expression
tissue_expression_up	hsa-mir-150	Retinal Neovascularization	18500251			H35.059	D015861		HP:0030666	increased
tissue_expression_up	hsa-mir-184	Retinal Neovascularization	18500251			H35.059	D015861		HP:0030666	increased
tissue_expression_up	hsa-mir-31	Retinal Neovascularization	18500251			H35.059	D015861		HP:0030666	increased
tissue_expression_up	hsa-mir-451a	Retinal Neovascularization	18500251			H35.059	D015861		HP:0030666	increased
tissue_expression_up	hsa-mir-183	Retinitis Pigmentosa	18034880	nervous system disease	DOID:10584	H35.52	D012174	PS268000	HP:0000510	Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P < 0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P < 0.001) in Pro347Ser retinas, as validated by qPCR.
tissue_expression_up	hsa-mir-96	Retinitis Pigmentosa	18034880	nervous system disease	DOID:10584	H35.52	D012174	PS268000	HP:0000510	Expression of miR-1 and miR-133 decreased by more than 2.5-fold (P < 0.001), whereas expression of miR-96 and miR-183 increased by more than 3-fold (P < 0.001) in Pro347Ser retinas, as validated by qPCR.
tissue_expression_up	hsa-let-7c	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-let-7i	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-10b	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-124-1	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-124-2	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-124-3	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-125a	Retinoblastoma	21373755	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions.
tissue_expression_up	hsa-mir-135b	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-142	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	hsa-mir-142-5p: differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-181b-1	Retinoblastoma	21373755	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions.
tissue_expression_up	hsa-mir-181b-2	Retinoblastoma	21373755	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions.
tissue_expression_up	hsa-mir-29a	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-29b-1	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-29b-2	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-29c	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-30c-2	Retinoblastoma	21373755	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions.
tissue_expression_up	hsa-mir-34a	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-34c	Retinoblastoma	21941147	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	hsa-mir-34c-5p: differential expression between RB cell lines of different growth patterns: SNUOT-Rb1 with adherent and more rapid growth and Y79 with nonadherent and slower growth.
tissue_expression_up	hsa-mir-491	Retinoblastoma	21373755	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions.
tissue_expression_up	hsa-mir-497	Retinoblastoma	21373755	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	We identified a cluster of miRNAs that includes miR-181b, miR-125a-3p, miR-30c-2, miR-497 and miR-491-3p as hypoxia-regulated miRNAs (HRMs) in retinoblastoma cells, of which miR-181b was the most typically differentially expressed miRNA under hypoxic conditions.
tissue_expression_up	hsa-mir-1-1	Rhabdomyosarcoma	20466878	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-1:mRNA targets of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas
tissue_expression_up	hsa-mir-1-2	Rhabdomyosarcoma	20466878	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-1:mRNA targets of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas
tissue_expression_up	hsa-mir-133a-1	Rhabdomyosarcoma	20466878	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-133a:mRNA targets of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas
tissue_expression_up	hsa-mir-146a	Rheumatoid Arthritis	18759964	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-146a: Upregulated miR-146a expression in peripheral blood mononuclear cells
tissue_expression_up	hsa-mir-146a	Rheumatoid Arthritis	21810022	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miRNA 146a expression was significantly higher in patients with RA than in those with OA and in controls.In patients with RA, miRNA 146a positively correlated with TNF-a (p=0.0003), erythrocyte sedimentation rate (ESR)(p=0.022), and DAS 28 (p=0.009).
tissue_expression_up	hsa-mir-146a	Rheumatoid Arthritis	18383392	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	This study provides the first description of increased expression of miRNA miR-155 and miR-146a in RA.
tissue_expression_up	hsa-mir-146a	Rheumatoid Arthritis	27079198	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-146a, miR-155, and miR-223 were significantly elevated in RA compared to OA synovial tissues
tissue_expression_up	hsa-mir-155	Rheumatoid Arthritis	21690378	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-155 is up-regulated in synovial membrane and synovial fluid (SF) macrophages from patients with rheumatoid arthritis (RA). The increased expression of miR-155 in SF CD14(+) cells was associated with lower expression of the miR-155 target, Src homology 2-containing inositol phosphatase-1 (SHIP-1), an inhibitor of inflammation.
tissue_expression_up	hsa-mir-155	Rheumatoid Arthritis	24151514	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	An inflammatory milieu may alter miRNA expression profiles in rheumatoid arthritis. miR-155 is upregulated in RA-FLS, and it may be a protective factor against the inflammatory effect in part by attenuating expression of IKBKE.
tissue_expression_up	hsa-mir-155	Rheumatoid Arthritis	24909288	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	TPT suppressed the expression of miR-155 and up-regulated the release of SHIP-1, thus inhibiting the inflammatory response in the LPS-stimulated monocytes of RA patients.
tissue_expression_up	hsa-mir-155	Rheumatoid Arthritis	18383392	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	This study provides the first description of increased expression of miRNA miR-155 and miR-146a in RA.
tissue_expression_up	hsa-mir-155	Rheumatoid Arthritis	27079198	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-146a, miR-155, and miR-223 were significantly elevated in RA compared to OA synovial tissues
tissue_expression_up	hsa-mir-16	Rheumatoid Arthritis	27875659	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Upregulated Expression of microRNA-16 Correlates with Th17/Treg Cell Imbalance in Patients with Rheumatoid Arthritis.
tissue_expression_up	hsa-mir-223	Rheumatoid Arthritis	22032299	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-223 is overexpressed in T-lymphocytes of early rheumatoid arthritis patients.
tissue_expression_up	hsa-mir-223	Rheumatoid Arthritis	19931339	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis.
tissue_expression_up	hsa-mir-223	Rheumatoid Arthritis	27079198	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-146a, miR-155, and miR-223 were significantly elevated in RA compared to OA synovial tissues
tissue_expression_up	hsa-mir-140	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-140: up-regulated
tissue_expression_up	hsa-mir-154	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-154: up-regulated
tissue_expression_up	hsa-mir-188	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-188: up-regulated
tissue_expression_up	hsa-mir-21	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-21: up-regulated
tissue_expression_up	hsa-mir-21	Salivary Gland Neoplasms	27184509	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	tissue samples were studied miR-21, miR-31, miR-199a-5p, miR-146b, miR-345 were up-regulated
tissue_expression_up	hsa-mir-23b	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-23b: up-regulated
tissue_expression_up	hsa-mir-299	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-299-3p: up-regulated
tissue_expression_up	hsa-mir-29c	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-29c: up-regulated
tissue_expression_up	hsa-mir-301a	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-301: up-regulated
tissue_expression_up	hsa-mir-301b	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-301: up-regulated
tissue_expression_up	hsa-mir-302c	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-302c: up-regulated
tissue_expression_up	hsa-mir-337	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-337: up-regulated
tissue_expression_up	hsa-mir-376a-1	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-376a: up-regulated
tissue_expression_up	hsa-mir-376a-2	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-376a: up-regulated
tissue_expression_up	hsa-mir-409	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-409-3p: up-regulated
tissue_expression_up	hsa-mir-449a	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-449: up-regulated
tissue_expression_up	hsa-mir-449b	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-449: up-regulated
tissue_expression_up	hsa-mir-495	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-495: up-regulated
tissue_expression_up	hsa-mir-99b	Salivary Gland Neoplasms	19347935	gastrointestinal system disease	DOID:8850	C08	D012468	603641	HP:0100684	miR-99b: up-regulated
tissue_expression_up	hsa-mir-128	Salmonellosis	24415783	disease by infectious agent	DOID:0060859	A02.0	D012480			Salmonella can upregulate intestinal epithelial miR-128 expression,which, in turn, decreases levels of epithelial cell-secreted M-CSF and M-CSF-induced macrophage recruitment. mir-9-5p
tissue_expression_up	hsa-mir-200a	Sarcoma [unspecific]	27402864	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET.
tissue_expression_up	hsa-mir-200b	Sarcoma [unspecific]	27402864	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET.
tissue_expression_up	hsa-mir-200c	Sarcoma [unspecific]	27402864	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET.
tissue_expression_up	hsa-mir-141	Sarcoma [unspecific]	27402864	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET.
tissue_expression_up	hsa-mir-429	Sarcoma [unspecific]	27402864	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	combined expression of miR-200s and GRHL2 further upregulates epithelial genes to induce MET.
tissue_expression_up	hsa-mir-210	Sarcoma [unspecific]	21455991	disease of cellular proliferation	DOID:1115	C49	D012509		HP:0100242	Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients.
tissue_expression_up	hsa-let-7g	Schizophrenia	18184693	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	upregulated
tissue_expression_up	hsa-mir-106b	Schizophrenia	17326821	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	upregulation
tissue_expression_up	hsa-mir-29c	Schizophrenia	23382797	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	RT-PCR validation confirmed that two miRNAs, miR-497 in SZ samples and miR-29c in BD samples, have significantly increased expression when compared to control samples. These results warrant future studies to evaluate the potential of exosome-derived miRNAs to serve as biomarkers of SZ and BD.
tissue_expression_up	hsa-mir-497	Schizophrenia	23382797	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	RT-PCR validation confirmed that two miRNAs, miR-497 in SZ samples and miR-29c in BD samples, have significantly increased expression when compared to control samples. These results warrant future studies to evaluate the potential of exosome-derived miRNAs to serve as biomarkers of SZ and BD.
tissue_expression_up	hsa-mir-214	Scleroderma, Localized	26498408	musculoskeletal system disease	DOID:8472	L94.0	D012594			The levels of miR-214 in hair shafts of patients with dermatomyositis were significantly higher than those of normal subjects and patients with scleroderma.
tissue_expression_up	hsa-mir-155	Scleroderma, Systemic	29559981	musculoskeletal system disease	DOID:418	M34	D012595	181750		miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls
tissue_expression_up	hsa-mir-16	Scleroderma, Systemic	29559981	musculoskeletal system disease	DOID:418	M34	D012595	181750		miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls
tissue_expression_up	hsa-mir-21	Scleroderma, Systemic	29559981	musculoskeletal system disease	DOID:418	M34	D012595	181750		miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls
tissue_expression_up	hsa-mir-92a	Scleroderma, Systemic	29559981	musculoskeletal system disease	DOID:418	M34	D012595	181750		miR-21-5p, miR-92a-3p, miR-155-5p, and miR-16-5p expression was significantly higher in SSc sera compared to healthy controls
tissue_expression_up	hsa-mir-92a-1	Scleroderma, Systemic	22661558	musculoskeletal system disease	DOID:418	M34	D012595	181750		microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma.
tissue_expression_up	hsa-mir-92a-2	Scleroderma, Systemic	22661558	musculoskeletal system disease	DOID:418	M34	D012595	181750		microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma.
tissue_expression_up	hsa-mir-184	Sebaceous Carcinoma	26203913	disease of cellular proliferation	DOID:4840	C44			HP:0030410	Serial testing and validation confirmed overexpression of 2 miRNAs previously reported to be oncogenic, miR-486-5p (4.4-fold; P鈥?鈥?.4鈥壝椻€?0-8) and miR-184 (3.5-fold; P鈥?鈥?.7鈥壝椻€?0-6)
tissue_expression_up	hsa-mir-34b	Seizures	27514646			G40.89	D012640		HP:0001250	We discovered that miR-34b-5p, a member of the miR-34 family, increased  significantly in flurothyl-treated rat hippocampus tissue.
tissue_expression_up	hsa-mir-372	Seminoma	23064661	disease of cellular proliferation	DOID:4440	C62.90	D018239	273300	HP:0100617	Hsa-mir-372 was upregulated around 1,270-fold (95 % confidence interval (CI) 525.2-3,064.8; sp = 8.1e-5 by Mann-Whitney U test)
tissue_expression_up	hsa-mir-143	Sepsis	25043848			A41.9	D018805		HP:0100806	Through microRNA microarray and qRT-PCR we found that the levels of miR-27a, miR-153 and  miR-143 are up regulated, while let-7a, miR-218 and miR-129-5p are down regulated in lungs of septic mice.
tissue_expression_up	hsa-mir-146a	Sepsis	23596477			A41.9	D018805		HP:0100806	We observed a significant increase in miR-146a expression in the initial cohort of 6 non-sepsis-SIRS patients compared to the 4 sepsis patients(P=0.01) 
tissue_expression_up	hsa-mir-21	Sezary Disease	21525938	disease of cellular proliferation	DOID:8541	C84.1	D012751			MicroRNA profiling reveals that miR-21, miR-486 and miR-214 are upregulated and involved in cell survival in Sezary Syndrome.
tissue_expression_up	hsa-mir-214	Sezary Disease	21525938	disease of cellular proliferation	DOID:8541	C84.1	D012751			MicroRNA profiling reveals that miR-21, miR-486 and miR-214 are upregulated and involved in cell survival in Sezary Syndrome.
tissue_expression_up	hsa-mir-486	Sezary Disease	21525938	disease of cellular proliferation	DOID:8541	C84.1	D012751			MicroRNA profiling reveals that miR-21, miR-486 and miR-214 are upregulated and involved in cell survival in Sezary Syndrome.
tissue_expression_up	hsa-mir-126	Shock, Hemorrhagic	27345902				D012771			miR-29a and miR-126 were upregulated
tissue_expression_up	hsa-mir-29a	Shock, Hemorrhagic	27345902				D012771			miR-29a and miR-126 were upregulated
tissue_expression_up	hsa-mir-146a	Sjogren Syndrome	21469088	immune system disease	DOID:12894	M35.00	D012859	270150		Altered miR-146a expression in Sjogren's syndrome
tissue_expression_up	hsa-mir-146a	Sjogren Syndrome	22033216	immune system disease	DOID:12894	M35.00	D012859	270150		We found that both miR-146a and miR-146b, furthermore, the gene of TRAF6 were significantly overexpressed in the Sjogren's patients, whereas the expression of IRAK1 gene was significantly decreased.
tissue_expression_up	hsa-mir-146b	Sjogren Syndrome	22033216	immune system disease	DOID:12894	M35.00	D012859	270150		We found that both miR-146a and miR-146b, furthermore, the gene of TRAF6 were significantly overexpressed in the Sjogren's patients, whereas the expression of IRAK1 gene was significantly decreased.
tissue_expression_up	hsa-mir-206	Soft Tissue Sarcoma	27223121			C49.9	D012509		HP:0030448	At least threefold overexpression of one of miR-206,-381, and 671-5p  was detected in all MPNSTs, EMCSs, SSs and 7 MCs.
tissue_expression_up	hsa-mir-381	Soft Tissue Sarcoma	27223121			C49.9	D012509		HP:0030448	At least threefold overexpression of one of miR-206,-381, and 671-5p  was detected in all MPNSTs, EMCSs, SSs and 7 MCs.
tissue_expression_up	hsa-mir-671	Soft Tissue Sarcoma	27223121			C49.9	D012509		HP:0030448	At least threefold overexpression of one of miR-206,-381, and 671-5p  was detected in all MPNSTs, EMCSs, SSs and 7 MCs.
tissue_expression_up	hsa-mir-140	Spinal Chordoma	25197358	musculoskeletal system disease	DOID:4153		D002817			Over-expression of miR-140-3p is correlated with recurrence and tumor invasion, suggesting that miR-140-3p could be a new predictor for recurrence and prognosis in patients with spinal chordoma.
tissue_expression_up	hsa-let-7a-1	Spinal Cord Injuries	20816819			S34.139A	D013119			Let-7a:SCI results in increased expression of miR Let-7a and miR16
tissue_expression_up	hsa-let-7a-2	Spinal Cord Injuries	20816819			S34.139A	D013119			Let-7a:SCI results in increased expression of miR Let-7a and miR16
tissue_expression_up	hsa-let-7a-3	Spinal Cord Injuries	20816819			S34.139A	D013119			Let-7a:SCI results in increased expression of miR Let-7a and miR16
tissue_expression_up	hsa-mir-15b	Spinal Cord Injuries	20816819			S34.139A	D013119			spinal cord injury (SCI)results in increased expression of miR Let-7a and miR16 while exercise leads to elevated levels of miR21 and decreased levels of miR15b. These changes in miR expression are correlated with changes in expression of their target genes: pro-apoptotic (decreased PTEN, PDCD4, and RAS mRNA) and anti-apoptotic (increased Bcl-2 mRNA) target genes. This is accompanied by a down-regulation of mRNA for caspase-7 and caspase-9 and reduced levels of caspase-7 protein.
tissue_expression_up	hsa-mir-16-1	Spinal Cord Injuries	20816819			S34.139A	D013119			miR16:SCI results in increased expression of miR Let-7a and miR16
tissue_expression_up	hsa-mir-16-2	Spinal Cord Injuries	20816819			S34.139A	D013119			miR16:SCI results in increased expression of miR Let-7a and miR16
tissue_expression_up	hsa-mir-21	Spinal Cord Injuries	26323253			S34.139A	D013119			miR鈥?46a, miR鈥?1 and miR鈥?50 expression was upregulated during H2O2 treatment.
tissue_expression_up	hsa-mir-192	Squamous Cell Carcinoma	19789312	disease of cellular proliferation	DOID:1749		D002294			In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue.
tissue_expression_up	hsa-mir-194	Squamous Cell Carcinoma	19789312	disease of cellular proliferation	DOID:1749		D002294			In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue.
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma	19789312	disease of cellular proliferation	DOID:1749		D002294			In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue.
tissue_expression_up	hsa-mir-223	Squamous Cell Carcinoma	19789312	disease of cellular proliferation	DOID:1749		D002294			In adenocarcinoma patients, miR-21, miR-223, miR-192, and miR-194 expression was elevated, whereas miR-203 expression was reduced in cancerous compared with noncancerous tissue.
tissue_expression_up	hsa-mir-33	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_up	hsa-mir-363	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_up	hsa-mir-497	Squamous Cell Carcinoma	20652977	disease of cellular proliferation	DOID:1749		D002294			The miRNAs miR-363, miR-33, and miR-497 were upregulated, whereas miR-155, miR-181a, miR-181b, miR-29a, miR-218, miR-222, miR-221, and miR-142-5p were downregulated in HPV-positive cells compared to both HPV-negative SCCHN and normal oral keratinocytes.
tissue_expression_up	hsa-mir-31	Squamous Cell Carcinoma, Cerevial	21590768	endocrine system disease	DOID:5531					miR-31 up-regulation in Drosha-overexpressing samples/cell lines was the highest-ranked change (by adjusted p value) in both analyses, an observation validated by northern blotting.
tissue_expression_up	hsa-mir-142	Squamous Cell Carcinoma, Esophageal	21882196	disease of cellular proliferation	DOID:3748		C562729			MiR-31 and miR-142-3p expression were correlated to histological differentiation in ESCC (P<0.05, Student's t-test); high miR-142-3p expression was associated with a poor prognosis in all 91 ESCC patients (P=0.014, log-rank) and identified as an independent prognostic factor in ESCC (P=0.017, univariate Cox; P=0.022, multivariate Cox). More importantly, stratified analysis indicated that high miR-142-3p expression was correlated to a poor prognosis within good-prognosis groups comprised of ESCC patients with small tumor size, negative lymph node metastasis, or early stage (all P<0.05).
tissue_expression_up	hsa-mir-205	Squamous Cell Carcinoma, Esophageal	20428818	disease of cellular proliferation	DOID:3748		C562729			miR-205:miR-205 and miR-21 are specific markers for HNSCC and ESCC
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	21883657	disease of cellular proliferation	DOID:3748		C562729			miR-21 expression was significantly up-regulated in the whole spectrum of preneoplastic/neoplastic lesions considered.
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	20428818	disease of cellular proliferation	DOID:3748		C562729			miR-21:miR-205 and miR-21 are specific markers for HNSCC and ESCC
tissue_expression_up	hsa-mir-210	Squamous Cell Carcinoma, Esophageal	26851030	disease of cellular proliferation	DOID:3748		C562729			squamous cell carcinoma (9.26-fold, p<0.001) and adenocarcinoma cell lines (4.95-fold, p<0.001) and miR-27a-star was significantly up-regulated in adenocarcinoma cell lines (4.79-fold, p=0.04).
tissue_expression_up	hsa-mir-296	Squamous Cell Carcinoma, Esophageal	20485139	disease of cellular proliferation	DOID:3748		C562729			miR-296:MiR-296 might play important roles in the pathogenesis of esophageal cancer and considered as a potential target for this malignancy intervention
tissue_expression_up	hsa-mir-30a	Squamous Cell Carcinoma, Esophageal	19536617	disease of cellular proliferation	DOID:3748		C562729			high expression levels; might play a important role in the development of the cancer
tissue_expression_up	hsa-mir-31	Squamous Cell Carcinoma, Esophageal	21658006	disease of cellular proliferation	DOID:3748		C562729			miR-31 was up-regulated in 77.8% of the ESCC tissues. Serum miR-31 levels in ESCC patients were significantly higher than in normal controls (P<0.001).
tissue_expression_up	hsa-mir-31	Squamous Cell Carcinoma, Esophageal	21882196	disease of cellular proliferation	DOID:3748		C562729			MiR-31 and miR-142-3p expression were correlated to histological differentiation in ESCC (P<0.05, Student's t-test); high miR-142-3p expression was associated with a poor prognosis in all 91 ESCC patients (P=0.014, log-rank) and identified as an independent prognostic factor in ESCC (P=0.017, univariate Cox; P=0.022, multivariate Cox). More importantly, stratified analysis indicated that high miR-142-3p expression was correlated to a poor prognosis within good-prognosis groups comprised of ESCC patients with small tumor size, negative lymph node metastasis, or early stage (all P<0.05).
tissue_expression_up	hsa-mir-373	Squamous Cell Carcinoma, Esophageal	29578163	disease of cellular proliferation	DOID:3748		C562729			Upregulation of miR-371-373 cluster, a human embryonic stem cell specific microRNA cluster, in esophageal squamous cell carcinoma
tissue_expression_up	hsa-mir-655	Squamous Cell Carcinoma, Esophageal	24314023	disease of cellular proliferation	DOID:3748		C562729			Mir-655 up-regulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma.
tissue_expression_up	hsa-let-7a	Squamous Cell Carcinoma, Head and Neck	25862914	disease of cellular proliferation	DOID:5520	C76.0	C535575			The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted.
tissue_expression_up	hsa-let-7i	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			overexpression
tissue_expression_up	hsa-mir-101-1	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-101-2	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-106b	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			Upregulation
tissue_expression_up	hsa-mir-125b	Squamous Cell Carcinoma, Head and Neck	29667275	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-26 and miR-125b may be associated with the progression and metastasis of HNSCC, and that miR-203 is associated with a more favourable prognosis.
tissue_expression_up	hsa-mir-142	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-142-3p; overexpression
tissue_expression_up	hsa-mir-155	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			overexpression
tissue_expression_up	hsa-mir-181b-1	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-181b-2	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-181d	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-195	Squamous Cell Carcinoma, Head and Neck	21560177	disease of cellular proliferation	DOID:5520	C76.0	C535575			Docetaxel resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01).
tissue_expression_up	hsa-mir-200c	Squamous Cell Carcinoma, Head and Neck	25862914	disease of cellular proliferation	DOID:5520	C76.0	C535575			The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted.
tissue_expression_up	hsa-mir-205	Squamous Cell Carcinoma, Head and Neck	20428818	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-205:miR-205 and miR-21 are specific markers for HNSCC and ESCC
tissue_expression_up	hsa-mir-20a	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			Upregulation
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			overexpression
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	20428818	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-21:miR-205 and miR-21 are specific markers for HNSCC and ESCC
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	25862914	disease of cellular proliferation	DOID:5520	C76.0	C535575			The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted.
tissue_expression_up	hsa-mir-26	Squamous Cell Carcinoma, Head and Neck	29667275	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-26 and miR-125b may be associated with the progression and metastasis of HNSCC, and that miR-203 is associated with a more favourable prognosis.
tissue_expression_up	hsa-mir-34a	Squamous Cell Carcinoma, Head and Neck	25862914	disease of cellular proliferation	DOID:5520	C76.0	C535575			The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted.
tissue_expression_up	hsa-mir-375	Squamous Cell Carcinoma, Head and Neck	25862914	disease of cellular proliferation	DOID:5520	C76.0	C535575			The microRNA profile seems to play a potential role in the pathobiology of oropharyngeal and laryngeal HNSCC. Up-regulation of miR34a in p16-positive oropharyngeal cancer has not been so far described and additional studies are warranted.
tissue_expression_up	hsa-mir-423	Squamous Cell Carcinoma, Head and Neck	20145181	disease of cellular proliferation	DOID:5520	C76.0	C535575			Upregulation
tissue_expression_up	hsa-mir-155	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26847279	disease of cellular proliferation	DOID:2876					The expression of tissue and plasma miR-155 were significantly up-regulated in patients with LSCC. Our work will serve as a basis for further investigation, preferably large-scale validation in clinical trials.
tissue_expression_up	hsa-mir-15a	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	26497405	disease of cellular proliferation	DOID:2876					We detected miR-363 and miR-15a, and their expression levels were significantly increased in the HPV-16-positive patients and in FaDu cells expressing HPV-16 E6-E7.
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	22320969	disease of cellular proliferation	DOID:2876					Mir-21 was up-regulated in LSCCs (laryngeal squamous cell carcinomas) and HSCCs(hypopharyngeal squamous cell carcinomas) compared to adjacent non-tumor tissues (P < 0.05), and the up-regulated expression of mir-21 was associated with clinical stage (P = 0.001), T classification (P = 0.007), pathologic differentiation (P = 0.025), and lymph node positivity (P = 0.002).
tissue_expression_up	hsa-mir-375	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27446362	disease of cellular proliferation	DOID:2876					The results of the present study suggested that miR-148a and miR-375 were significantly upregulated in LSCC tissues, and increased expression of miR-375 was associated with a more aggressive phenotype of LSCC.
tissue_expression_up	hsa-mir-125a	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-125a-5p:The miRNAs miR-185 * and miR-125a-5p were significantly upregulated in lung SCC
tissue_expression_up	hsa-mir-185	Squamous Cell Carcinoma, Lung	20620595	disease of cellular proliferation	DOID:3907	C34.91				miR-185:The miRNAs miR-185 * and miR-125a-5p were significantly upregulated in lung SCC
tissue_expression_up	hsa-mir-1246	Squamous Cell Carcinoma, Oral	25791131	disease of cellular proliferation	DOID:0050866					High miR-1246 expression is associated with poor prognosis in OSCC and may serve as a novel prognostic marker in OSCC.
tissue_expression_up	hsa-mir-129-1	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-129-2	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-138	Squamous Cell Carcinoma, Oral	26841253	disease of cellular proliferation	DOID:0050866					Upregulation of miR-138 and miR-183 was observed in 50.0% of the samples
tissue_expression_up	hsa-mir-142	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_up	hsa-mir-144	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_up	hsa-mir-146b	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-155	Squamous Cell Carcinoma, Oral	24439918	disease of cellular proliferation	DOID:0050866					In OSSC, upregulation of miR-155 correlated with the histologic grade and can be used as a potential prognostic biomarker.
tissue_expression_up	hsa-mir-155	Squamous Cell Carcinoma, Oral	24692283	disease of cellular proliferation	DOID:0050866					MiRNA-155 was overexpressed in OSCC and it was located in the cancer nest, inflammatory area, and vascular endothelium of OSCC. High miRNA-155 expression level in ACF may predict poor prognosis in patients with OSCC.
tissue_expression_up	hsa-mir-181b	Squamous Cell Carcinoma, Oral	27509922	disease of cellular proliferation	DOID:0050866					he expression levels of miR鈥?81b and Bcl鈥? in OVC were significantly higher compared with normal mucosal tissue (NM);
tissue_expression_up	hsa-mir-183	Squamous Cell Carcinoma, Oral	26841253	disease of cellular proliferation	DOID:0050866					Upregulation of miR-138 and miR-183 was observed in 50.0% of the samples
tissue_expression_up	hsa-mir-203	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_up	hsa-mir-205	Squamous Cell Carcinoma, Oral	26841253	disease of cellular proliferation	DOID:0050866					Upregulation of miR-138, miRNA-145, and miR-205 was associated with advanced tumor stages, vascular invasion, and lymph node metastasis, respectively.
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Oral	25482863	disease of cellular proliferation	DOID:0050866					Our results corroborate the previous findings on the overexpression  of mir-21 and downregulation of miR-138 in OSCC. As the expression of miR-184 is controversial in tongue/oral cancer, the downregulation may be specific to tumor anatomical localization. On the other hand, to the best of our knowledge, this is the first report to show the association of miR-155 with tobacco chewing and the downregulation of miR-125b-2* in OSCC. Computational predictions suggest that miR-125b-2* may have a role in alternative splicing.
tissue_expression_up	hsa-mir-21	Squamous Cell Carcinoma, Oral	29480379	disease of cellular proliferation	DOID:0050866					increased miR-21 levels in conjunction with decreased miR-125a levels in saliva of OLP patients may be indicative for a poor prognosis
tissue_expression_up	hsa-mir-210	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-212	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-214	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-223	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_up	hsa-mir-23a	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-23b	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-25	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-29b	Squamous Cell Carcinoma, Oral	27056547	disease of cellular proliferation	DOID:0050866					let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC
tissue_expression_up	hsa-mir-30b	Squamous Cell Carcinoma, Oral	22542163	disease of cellular proliferation	DOID:0050866					Amplification and up-regulation of microRNA-30b in oral squamous cell cancers.
tissue_expression_up	hsa-mir-31	Squamous Cell Carcinoma, Oral	24238414	disease of cellular proliferation	DOID:0050866					The up-regulated level of microRNA-31 expression may be related to the pathogenesis of OSCC.
tissue_expression_up	hsa-mir-338	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-489	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-515-1	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-515-2	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-92a-1	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-92a-2	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-92b	Squamous Cell Carcinoma, Oral	21244772	disease of cellular proliferation	DOID:0050866					Thirteen miRNA were significantly overexpressed (miR-489, miR-129, miR-23a, miR-214, miR-23b, miR-92, miR-25, miR-210, miR-212, miR-515, miR-146b, miR-21, miR-338) and 6 miRNA were underexpressed (miR-520h, miR-197, miR-378, miR-135b, miR-224, miR-34a) in oral tumours. Underexpression of mir-155, let-7i, mir-146a was found to characterize progression to metastastatic tumours.
tissue_expression_up	hsa-mir-92b	Squamous Cell Carcinoma, Oral	26503628	disease of cellular proliferation	DOID:0050866					Taken together, our results indicate that miR-92b upregulation accelerates tumor growth and present a novel mechanism of miRNA-mediated NF-κB activation in OSCC.
tissue_expression_up	hsa-mir-124	Squamous Cell Carcinoma, Skin or Unspecific	27818465	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	The expression of miR-124 increases in aged skin to cause cell senescence and it decreases in squamous cell carcinoma.
tissue_expression_up	hsa-mir-135b	Squamous Cell Carcinoma, Skin or Unspecific	23026055	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Non-stringent filtering with a non-adjusted p ≤ 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC
tissue_expression_up	hsa-mir-424	Squamous Cell Carcinoma, Skin or Unspecific	23026055	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Non-stringent filtering with a non-adjusted p ≤ 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC
tissue_expression_up	hsa-mir-766	Squamous Cell Carcinoma, Skin or Unspecific	23026055	disease of cellular proliferation	DOID:3151	C44.92			HP:0006739	Non-stringent filtering with a non-adjusted p ≤ 0.01 revealed three up-regulated (hsa-miR-135b, hsa-miR-424 and hsa-miR-766) and six down-regulated (hsa-miR-30a*, hsa-miR-378, hsa-miR-145, hsa-miR-140-3p, hsa-miR-30a and hsa-miR-26a) miRNAs in cSCC
tissue_expression_up	hsa-mir-124	Stroke	23826665			I64	D020521	601367	HP:0001297	The level of miR-124 is significantly increased in ischemic penumbra as compared with that in nonischemic area of MACO mice.
tissue_expression_up	hsa-mir-146a	Stroke	26738853			I64	D020521	601367	HP:0001297	stroke considerably increased miR-146a density in the corpus callosum and subventricular zone (SVZ) of the lateral ventricle of the ischemic hemisphere.
tissue_expression_up	hsa-mir-155	Stroke	29642385			I64	D020521	601367	HP:0001297	Exposure to the high dose of CS also significantly upregulated the miRNA-155 level in the aortic tissues of ApoE KO mice
tissue_expression_up	hsa-mir-17	Stroke	23511639			I64	D020521	601367	HP:0001297	These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression.
tissue_expression_up	hsa-mir-18	Stroke	23511639			I64	D020521	601367	HP:0001297	These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression.
tissue_expression_up	hsa-mir-19a	Stroke	23511639			I64	D020521	601367	HP:0001297	These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression.
tissue_expression_up	hsa-mir-19b-1	Stroke	23511639			I64	D020521	601367	HP:0001297	These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression.
tissue_expression_up	hsa-mir-20a	Stroke	23511639			I64	D020521	601367	HP:0001297	These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression.
tissue_expression_up	hsa-mir-21	Stroke	29642385			I64	D020521	601367	HP:0001297	Moreover, the expression level of miR-126 tended to be downregulated and that of miR-21 tended to be upregulated in ApoE KO mice exposed to the high dose of CS, albeit statistically insignificant
tissue_expression_up	hsa-mir-92-1	Stroke	23511639			I64	D020521	601367	HP:0001297	These data indicate that the miR17-92 cluster plays an important role in mediating neural progenitor cell function and that the Shh signaling pathway is involved in up-regulating miR17-92 cluster expression.
tissue_expression_up	hsa-mir-34a	Stroke, Ischemic	27545688			I63.9			HP:0002140	Increased Expression of mir-34a-5p and Clinical Association in Acute Ischemic Stroke Patients and in a Rat Model.
tissue_expression_up	hsa-mir-9	Stroke, Ischemic	26718002			I63.9			HP:0002140	The expression of miR-9 in the peri-infarct cortex was increased in the EA group compared with the MCAO group
tissue_expression_up	hsa-let-7e	Synovial Sarcoma	21213367	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	upregulated
tissue_expression_up	hsa-mir-125a	Synovial Sarcoma	21213367	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	hsa-mir-125a-3p upregulated
tissue_expression_up	hsa-mir-99b	Synovial Sarcoma	21213367	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	upregulated
tissue_expression_up	hsa-mir-146a	Systemic Lupus Erythematosus	21987229	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The levels of urinary miR-146a and miR-155 in patients with SLE were significantly higher than that in healthy controls. Calcitriol treatment reduced the levels of urinary miR-155 in patients with SLE. The level of urinary miR-146a significantly correlated with estimated glomerular filtration rate. The level of urinary miR-155 significantly correlated with proteinuria  and systemic lupus erythematosus disease activity index (r=0.278, P=0.002). The level of urinary miR-146a reversely correlated with the urinary expression of TNF-a. Our results suggested that miR-146a and miR-155 might play important roles in the pathophysiology of SLE and the levels of urinary miR-146a and miR-155 could be used as potential markers for diagnosis, disease activity, and therapeutic response.
tissue_expression_up	hsa-mir-146a	Systemic Lupus Erythematosus	26315540	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Type I IFN inhibits the maturation of miR-146a through the up-regulation of MCPIP-1, and thus contributes to the uncontrolled inflammation and excessive inflammatory gene expression in SLE.
tissue_expression_up	hsa-mir-155	Systemic Lupus Erythematosus	21987229	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The levels of urinary miR-146a and miR-155 in patients with SLE were significantly higher than that in healthy controls. Calcitriol treatment reduced the levels of urinary miR-155 in patients with SLE. The level of urinary miR-146a significantly correlated with estimated glomerular filtration rate. The level of urinary miR-155 significantly correlated with proteinuria  and systemic lupus erythematosus disease activity index (r=0.278, P=0.002). The level of urinary miR-146a reversely correlated with the urinary expression of TNF-a. Our results suggested that miR-146a and miR-155 might play important roles in the pathophysiology of SLE and the levels of urinary miR-146a and miR-155 could be used as potential markers for diagnosis, disease activity, and therapeutic response.
tissue_expression_up	hsa-mir-155	Systemic Lupus Erythematosus	28779021	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	IFN-α impairs insulin-mediated NO production, and altered gene expression resulted from eNOS instability, possibly due to enhanced miR-155 expression
tissue_expression_up	hsa-mir-629	Testicular Neoplasms	19946373	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	upregulated
tissue_expression_up	hsa-mir-100	Thyroid Neoplasms	22006248	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P <0.001), and in Hurthle cell carcinoma samples alone (P < 0.01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05).
tissue_expression_up	hsa-mir-10b	Thyroid Neoplasms	23563786	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma
tissue_expression_up	hsa-mir-122	Thyroid Neoplasms	21779480	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miRNA increased 8.9-fold (P < 0.05) in all Thyroid Neoplasms versus normal.
tissue_expression_up	hsa-mir-125b-1	Thyroid Neoplasms	22006248	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P < .001), and in Hurthle cell carcinoma samples alone (P < .01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05).
tissue_expression_up	hsa-mir-125b-2	Thyroid Neoplasms	22006248	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P < .001), and in Hurthle cell carcinoma samples alone (P < .01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05).
tissue_expression_up	hsa-mir-126	Thyroid Neoplasms	21553140	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-7 and miR-126 could be candidate diagnostic microRNAs for thyroid histologic subtypes.
tissue_expression_up	hsa-mir-127	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-138-1	Thyroid Neoplasms	22006248	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P < .001), and in Hurthle cell carcinoma samples alone (P < .01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05).
tissue_expression_up	hsa-mir-138-2	Thyroid Neoplasms	22006248	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-100, miR-125b, miR-138, and miR-768-3p were overexpressed in malignant samples of follicular origin (P < .001), and in Hurthle cell carcinoma samples alone (P < .01). Only miR-125b was significantly overexpressed in follicular carcinoma samples (P < .05).
tissue_expression_up	hsa-mir-146b	Thyroid Neoplasms	18587330	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b: overexpressed
tissue_expression_up	hsa-mir-146b	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_up	hsa-mir-154	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-155	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_up	hsa-mir-183	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-21	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-21	Thyroid Neoplasms	23416953	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	there were significant associations (P<0.05) between BRAF(V600E) and a higher tumor-node-metastasis staging (III/IV), and between miR-21* over-expression and lymph node metastasis.
tissue_expression_up	hsa-mir-221	Thyroid Neoplasms	17028596	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Upregulated mir-221/222 in papillary thyroid cancer
tissue_expression_up	hsa-mir-221	Thyroid Neoplasms	18587330	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-221: overexpressed
tissue_expression_up	hsa-mir-221	Thyroid Neoplasms	21275764	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	mir-221 was overexpressed in 19 patients (p<0.0001) with a sensitive yield of 95%.
tissue_expression_up	hsa-mir-221	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_up	hsa-mir-221	Thyroid Neoplasms	23563786	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma
tissue_expression_up	hsa-mir-222	Thyroid Neoplasms	17028596	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Upregulated mir-221/222 in papillary thyroid cancer
tissue_expression_up	hsa-mir-222	Thyroid Neoplasms	18587330	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-222: overexpressed
tissue_expression_up	hsa-mir-222	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_up	hsa-mir-222	Thyroid Neoplasms	23563786	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma
tissue_expression_up	hsa-mir-222	Thyroid Neoplasms	27353001	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-25 and miR-222 expression was upregulated in 8505C
tissue_expression_up	hsa-mir-222	Thyroid Neoplasms	26745212	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-221 and miR-222 are consistently upregulated in different types of thyroid carcinomas
tissue_expression_up	hsa-mir-224	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-25	Thyroid Neoplasms	27353001	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-25 and miR-222 expression was upregulated in 8505C
tissue_expression_up	hsa-mir-31	Thyroid Neoplasms	21537871	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b, miR-221, miR-222, miR-155, miR-31 upregulation and miR-1, miR-34b, miR-130b, miR-138 downregulation in aggressive compared with nonaggressive PTC.
tissue_expression_up	hsa-mir-323	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-370	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-375	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-7-1	Thyroid Neoplasms	21553140	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-7 and miR-126 could be candidate diagnostic microRNAs for thyroid histologic subtypes.
tissue_expression_up	hsa-mir-7-2	Thyroid Neoplasms	21553140	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-7 and miR-126 could be candidate diagnostic microRNAs for thyroid histologic subtypes.
tissue_expression_up	hsa-mir-7-3	Thyroid Neoplasms	21553140	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-7 and miR-126 could be candidate diagnostic microRNAs for thyroid histologic subtypes.
tissue_expression_up	hsa-mir-9	Thyroid Neoplasms	22747440	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	MTC and CCH were both characterized by a significant overexpression of the whole set of miRNAs (the increase being 4.2-fold for miR-21, 6.7-fold for miR-127, 8.8-fold for miR-154, 6.6-fold for miR-224, 5.8-fold for miR-323, 6.1-fold for miR-370, 13-fold for miR-9*, 6.7-fold for miR-183, and 10.1 for miR-375, p<0.0001).
tissue_expression_up	hsa-mir-92a-1	Thyroid Neoplasms	23563786	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma
tissue_expression_up	hsa-mir-92a-2	Thyroid Neoplasms	23563786	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma
tissue_expression_up	hsa-mir-22	Toxic Encephalopathy	26649298	nervous system disease	DOID:3602	G92	D020258			Our results demonstrated that PFOS exposure decreased miR-16 expression and increased miR-22 expression, which may represent a possible mechanism by which PFOS decreases BDNF protein levels. PFOS may inhibit BDNF-ERK-CREB signalling by increasing miR-22 levels, which may, in part, explain the mechanism of PFOS neurotoxicity.
tissue_expression_up	hsa-mir-106a	Toxoplasma gondii Infection	20423977	disease by infectious agent	DOID:9965	B58	D014123			hsa-mir-106a:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii
tissue_expression_up	hsa-mir-106b	Toxoplasma gondii Infection	20423977	disease by infectious agent	DOID:9965	B58	D014123			hsa-mir-106b:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii
tissue_expression_up	hsa-mir-17	Toxoplasma gondii Infection	20423977	disease by infectious agent	DOID:9965	B58	D014123			hsa-mir-17:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii
tissue_expression_up	hsa-mir-18a	Toxoplasma gondii Infection	20423977	disease by infectious agent	DOID:9965	B58	D014123			hsa-mir-18a:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii
tissue_expression_up	hsa-mir-18b	Toxoplasma gondii Infection	20423977	disease by infectious agent	DOID:9965	B58	D014123			hsa-mir-18b:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii
tissue_expression_up	hsa-mir-20a	Toxoplasma gondii Infection	20423977	disease by infectious agent	DOID:9965	B58	D014123			hsa-mir-20a:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii
tissue_expression_up	hsa-mir-20b	Toxoplasma gondii Infection	20423977	disease by infectious agent	DOID:9965	B58	D014123			hsa-mir-20b:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii
tissue_expression_up	hsa-mir-93	Toxoplasma gondii Infection	20423977	disease by infectious agent	DOID:9965	B58	D014123			hsa-mir-93:human miR-17 family members that are increased by infection with the intracellular parasite Toxoplasma gondii
tissue_expression_up	hsa-mir-424	Tuberculosis	22964481	disease by infectious agent	DOID:399	A15-A19	D014376			we observed that miR-146a expression is also down-regulated in tuberculosis patients, both in PBMCs and PFMCs while miR-424 levels are elevated only in the peripheral compartments.
tissue_expression_up	hsa-mir-147a	Tuberculosis, Pulmonary	22900099	disease by infectious agent	DOID:2957	A15	D014397			Overexpression
tissue_expression_up	hsa-mir-147b	Tuberculosis, Pulmonary	22900099	disease by infectious agent	DOID:2957	A15	D014397			Overexpression
tissue_expression_up	hsa-mir-3179-1	Tuberculosis, Pulmonary	22900099	disease by infectious agent	DOID:2957	A15	D014397			Overexpression
tissue_expression_up	hsa-mir-3179-2	Tuberculosis, Pulmonary	22900099	disease by infectious agent	DOID:2957	A15	D014397			Overexpression
tissue_expression_up	hsa-mir-3179-3	Tuberculosis, Pulmonary	22900099	disease by infectious agent	DOID:2957	A15	D014397			Overexpression
tissue_expression_up	hsa-mir-141	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-141	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-145	Urinary Bladder Cancer	26514209	urinary system disease	DOID:11054	C67	D001749	109800		Results indicate that miR-145 suppresses syndecan-1 and, by this mechanism, up-regulates stem cell factors and induces cell senescence and differentiation. We propose that miR-145 may confer stem cell-like properties on urothelial carcinoma cells and thus facilitate differentiation into multiple cell types.
tissue_expression_up	hsa-mir-146a	Urinary Bladder Cancer	18596939	urinary system disease	DOID:11054	C67	D001749	109800		miR-146a: upregulated
tissue_expression_up	hsa-mir-155	Urinary Bladder Cancer	22386240	urinary system disease	DOID:11054	C67	D001749	109800		Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant.
tissue_expression_up	hsa-mir-155	Urinary Bladder Cancer	18596939	urinary system disease	DOID:11054	C67	D001749	109800		miR-155: upregulated
tissue_expression_up	hsa-mir-15b	Urinary Bladder Cancer	18596939	urinary system disease	DOID:11054	C67	D001749	109800		miR-15b: upregulated
tissue_expression_up	hsa-mir-16-1	Urinary Bladder Cancer	18596939	urinary system disease	DOID:11054	C67	D001749	109800		miR-16: upregulated
tissue_expression_up	hsa-mir-16-2	Urinary Bladder Cancer	18596939	urinary system disease	DOID:11054	C67	D001749	109800		miR-16: upregulated
tissue_expression_up	hsa-mir-17	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-183	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-18a	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-19a	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-19b-1	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-19b-2	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-200a	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-200a	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-200b	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-200c	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-200c	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-20a	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-21	Urinary Bladder Cancer	22133680	urinary system disease	DOID:11054	C67	D001749	109800		Nuclear and cytoplasmatic PDCD4 immunostaining decreased significantly with histopathological progression of the tumor (p<0001). Controls showed strong nuclear and cytoplasmatic immunohistochemical staining. MiR-21 up regulation in tissue corresponded to PDCD4 suppression.
tissue_expression_up	hsa-mir-21	Urinary Bladder Cancer	22704449	urinary system disease	DOID:11054	C67	D001749	109800		High miR-21 expression correlated with worse overall patient survival (p = 0.0099).
tissue_expression_up	hsa-mir-21	Urinary Bladder Cancer	22194833	urinary system disease	DOID:11054	C67	D001749	109800		mir-21 expression increased with worsening clinical diagnosis but that mir-143 was not correlated with histology. These observations were in stark contrast to previous reports involving cervical cancer cell lines in which mir-143 was consistently down-regulated but mir-21 largely unaffected.
tissue_expression_up	hsa-mir-29b-1	Urinary Bladder Cancer	21223810	urinary system disease	DOID:11054	C67	D001749	109800		In grade I, grade II, grade III, grade I + II + III, infiltrating and non-infiltrating groups, hsa-miR-29b-1* was up-regulated while hsa-miR-923 and hsa-miR-300 were down-regulated
tissue_expression_up	hsa-mir-29c	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378a	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378b	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378c	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378d-1	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378d-2	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378e	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378f	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378g	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378h	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-378i	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-424	Urinary Bladder Cancer	22469983	urinary system disease	DOID:11054	C67	D001749	109800		Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer.
tissue_expression_up	hsa-mir-429	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-429	Urinary Bladder Cancer	22886973	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated.
tissue_expression_up	hsa-mir-92a-1	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-92a-2	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-96	Urinary Bladder Cancer	21464941	urinary system disease	DOID:11054	C67	D001749	109800		Compared to matched histologically normal urothelium, upregulated.
tissue_expression_up	hsa-mir-96	Urinary Bladder Cancer	21993544	urinary system disease	DOID:11054	C67	D001749	109800		hsa-mir-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas.
tissue_expression_up	hsa-mir-10a	Urinary System Cancer	29623292	disease of cellular proliferation	DOID:3996	C68.9				the decline of miR-145 expression level have been proved to be able to distinguish bladder cancer patients from non-cancer controls in cell-free urine samples5; the elevation of miR-10a and miR-30d was also observed in urine samples from patients with focal segmental glomerulosclerosis
tissue_expression_up	hsa-mir-30d	Urinary System Cancer	29623292	disease of cellular proliferation	DOID:3996	C68.9				the decline of miR-145 expression level have been proved to be able to distinguish bladder cancer patients from non-cancer controls in cell-free urine samples5; the elevation of miR-10a and miR-30d was also observed in urine samples from patients with focal segmental glomerulosclerosis
tissue_expression_up	hsa-mir-1298	Vascular Disease [unspecific]	26199195	cardiovascular system disease	DOID:178	I72.9	D000783			Keep calm and carry on: miR-1298 prevents up-regulation of Cx43 and secures a quiescent vascular smooth muscle cell.
tissue_expression_up	hsa-mir-126	Vasomotor Rhinitis	28787742	respiratory system disease	DOID:4730	J30.0	D012223			there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p.
tissue_expression_up	hsa-mir-129	Vasomotor Rhinitis	28787742	respiratory system disease	DOID:4730	J30.0	D012223			there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p.
tissue_expression_up	hsa-mir-543	Vasomotor Rhinitis	28787742	respiratory system disease	DOID:4730	J30.0	D012223			there was significant overexpression of miR-543, miR-129-5p, and miR-126-3p, and under-expression of miR-2110, miR-449c-5p, miR-449b-5p, miR-190b, and miR-92b-5p.
tissue_expression_up	hsa-mir-155	Vitiligo	26941046	immune system disease	DOID:12306	L80	D014820		HP:0001045	miR-99b, miR-125b, miR-155 and miR-199a-3p were found to be increased and miR-145 was found to be decreased in the skin of patients with vitiligo.
tissue_expression_up	hsa-mir-590	Vulvar Squamous Cell Carcinoma	26498065	disease of cellular proliferation	DOID:2101					In conclusion, we present the miRNA expression profile in VSCC, and our findings suggest that the upregulation of miR-590-5p promotes cellular malignant behaviours via the target gene TGFβRII.
tissue_expression_up	hsa-mir-155	Waldenstrom Macroglobulinemia	23301642			C88.0	D008258	153600	HP:0005508	The most important changes of microRNA are increased expression of miR-155 and decreased expression of miR-9*. 
tissue_expression_up	hsa-mir-155	Waldenstrom Macroglobulinemia	25893290			C88.0	D008258	153600	HP:0005508	In two cell lines, miR-155 upregulation, which is common in WM, was responsible for the  inhibition of FOXO3a and Bim expression.
transcription factor target	hsa-mir-200b	Adenocarcinoma, Lung	24830600	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	the HDAC1/4/Sp1/miR-200b/E2F3 pathway is responsible for chemoresistance of docetaxel-resistant LAD cells.
transcription factor target	hsa-mir-200b	Adenocarcinoma, Lung	25279705	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma.
transcription factor target	hsa-mir-144	Alzheimer Disease	23546882	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-144 Is Regulated by Activator Protein-1 (AP-1) and Decreases Expression of Alzheimer's Disease-related A Disintegrin And Metalloprotease 10 (ADAM10)
transcription factor target	hsa-mir-188	Alzheimer Disease	25378159	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through  upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease.
transcription factor target	hsa-mir-222	Brain Neoplasms	19351827	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	miR-222: Overexpression
transcription factor target	hsa-let-7a-1	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7a-2	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7a-3	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7b	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7c	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7c	Breast Neoplasms	25388283	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients.
transcription factor target	hsa-let-7d	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7e	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7f-1	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7f-2	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7g	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-let-7i	Breast Neoplasms	22388088	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	SHP2 activated stemness-associated transcription factors, including v-myc myelocytomatosis viral oncogene homolog (c-Myc) and zinc finger E-box binding homeobox 1 (ZEB1), which resulted in the repression of let-7 microRNA and the expression of a set of 'SHP2 signature' genes.
transcription factor target	hsa-mir-106b	Breast Neoplasms	24292682	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	high level of miR-106b induced by TGF-β determines the tumor-promoting effects of TGF-β in breast cancer.
transcription factor target	hsa-mir-10b	Breast Neoplasms	22286762	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-125b	Breast Neoplasms	25388283	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients.
transcription factor target	hsa-mir-129	Breast Neoplasms	26460733	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Thus,miR-129-5p down-regulation fosters EMT in breast cancer by increasing Twist1-Snail and activating a negative feedback loop.
transcription factor target	hsa-mir-132	Breast Neoplasms	26377202	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, the findings provide the first evidences of the synergistic anti-metastatic properties of miR-212/132 cluster through suppression of SOX4. Also, current study suggest a new miRNA-based mechanism elucidating the anti-metastatic properties of Ahr agonists, suggesting possibility of using miR-212/132 to control metastasis in breast cancer patients.
transcription factor target	hsa-mir-141	Breast Neoplasms	23975430	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.
transcription factor target	hsa-mir-146	Breast Neoplasms	25712342	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	FOXP3 Controls an miR-146/NF-κB Negative Feedback Loop That Inhibits Apoptosis in Breast Cancer Cells.
transcription factor target	hsa-mir-146a	Breast Neoplasms	19190326	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-146: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis
transcription factor target	hsa-mir-146b	Breast Neoplasms	19190326	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-146: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis
transcription factor target	hsa-mir-155	Breast Neoplasms	24080728	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-155 broadly orchestrates inflammation-induced changes of microRNA expression in breast cancer
transcription factor target	hsa-mir-155	Breast Neoplasms	22797073	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.
transcription factor target	hsa-mir-17	Breast Neoplasms	22286762	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-182	Breast Neoplasms	25873390	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer.
transcription factor target	hsa-mir-182	Breast Neoplasms	25394902	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration.
transcription factor target	hsa-mir-183	Breast Neoplasms	25873390	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer.
transcription factor target	hsa-mir-183	Breast Neoplasms	25394902	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration.
transcription factor target	hsa-mir-191	Breast Neoplasms	25867965	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment.
transcription factor target	hsa-mir-191	Breast Neoplasms	23542418	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-191, an estrogen responsive microRNA, functions as an oncogenic regulator in human breast cancer
transcription factor target	hsa-mir-200a	Breast Neoplasms	23975430	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.
transcription factor target	hsa-mir-200a	Breast Neoplasms	25972084	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our results suggest that Restin inhibits EMT and tumor metastasis by controlling the expression of the tumor metastasis suppressor mir-200a/b via association with p73. Our findings not only establish a mechanistic link between Restin, EMT and tumor metastasis, but also provide strong evidence supporting the notion that MAGE Group II proteins may exert a tumor suppressive effect in vivo.
transcription factor target	hsa-mir-200b	Breast Neoplasms	25972084	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	our results suggest that Restin inhibits EMT and tumor metastasis by controlling the expression of the tumor metastasis suppressor mir-200a/b via association with p73. Our findings not only establish a mechanistic link between Restin, EMT and tumor metastasis, but also provide strong evidence supporting the notion that MAGE Group II proteins may exert a tumor suppressive effect in vivo.
transcription factor target	hsa-mir-203	Breast Neoplasms	23447531	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Signaling between TGF-beta and Transcription factor SNAI2 Represses Expression of microRNA miR-203 to Promote Epithelial-Mesenchymal Transition and Tumor Metastasis
transcription factor target	hsa-mir-20b	Breast Neoplasms	23945289	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer.
transcription factor target	hsa-mir-21	Breast Neoplasms	19264808	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21: Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.
transcription factor target	hsa-mir-21	Breast Neoplasms	19308091	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21: BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1
transcription factor target	hsa-mir-21	Breast Neoplasms	22286762	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-210	Breast Neoplasms	18316553	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	induced
transcription factor target	hsa-mir-212	Breast Neoplasms	26377202	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Taken together, the findings provide the first evidences of the synergistic anti-metastatic properties of miR-212/132 cluster through suppression of SOX4. Also, current study suggest a new miRNA-based mechanism elucidating the anti-metastatic properties of Ahr agonists, suggesting possibility of using miR-212/132 to control metastasis in breast cancer patients.
transcription factor target	hsa-mir-221	Breast Neoplasms	20388878	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors
transcription factor target	hsa-mir-222	Breast Neoplasms	20388878	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors
transcription factor target	hsa-mir-23b	Breast Neoplasms	22231442	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERж┿on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex.
transcription factor target	hsa-mir-24-1	Breast Neoplasms	22231442	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERж┿on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex.
transcription factor target	hsa-mir-27a	Breast Neoplasms	23752185	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-27a regulates endothelial differentiation of breast cancer stem like cells.
transcription factor target	hsa-mir-27b	Breast Neoplasms	22231442	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERж┿on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex.
transcription factor target	hsa-mir-30a	Breast Neoplasms	22231442	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	ERalpha downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERж┿on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex.
transcription factor target	hsa-mir-31	Breast Neoplasms	24582497	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31.
transcription factor target	hsa-mir-31	Breast Neoplasms	25927669	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.
transcription factor target	hsa-mir-373	Breast Neoplasms	26196741	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer.
transcription factor target	hsa-mir-506	Breast Neoplasms	23717581	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-506 Regulates Epithelial Mesenchymal Transition in Breast Cancer Cell Lines.
transcription factor target	hsa-mir-590	Breast Neoplasms	25150595	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A feedback expression of microRNA-590 and activating transcription factor-3 in human breast cancer cells.
transcription factor target	hsa-mir-9-1	Breast Neoplasms	22286762	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-9-2	Breast Neoplasms	22286762	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-9-3	Breast Neoplasms	22286762	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-96	Breast Neoplasms	25873390	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer.
transcription factor target	hsa-mir-96	Breast Neoplasms	25394902	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast cancer as it increases cell proliferation and migration.
transcription factor target	hsa-mir-99a	Breast Neoplasms	25388283	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	HER2 protein expression and activity are negatively correlated with let-7c expression in TCGA. In summary, we identified an ER-regulated miRNA cluster that regulates HER2, is lost with progression to estrogen independence, and may serve as a biomarker of poor outcome in ER(+) luminal A breast cancer patients.
transcription factor target	hsa-mir-31	Carcinoma, Breast	25737447			D05	D001943	114480	HP:0003002	These studies further suggest that manipulation of miR-31 expression can be used to modulate senescence-related pathological conditions such as cancer,and the aging process.
transcription factor target	hsa-mir-100	Carcinoma, Cervical	25757558	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma  HeLa cells.
transcription factor target	hsa-mir-125b	Carcinoma, Cervical	23928699	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway.
transcription factor target	hsa-mir-146a	Carcinoma, Cervical	25757558	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma  HeLa cells.
transcription factor target	hsa-mir-150	Carcinoma, Cervical	25757558	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma  HeLa cells.
transcription factor target	hsa-mir-203	Carcinoma, Cervical	25658920	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	BANF1 is downregulated by IRF1-regulated microRNA-203 in cervical cancer.
transcription factor target	hsa-mir-130b	Carcinoma, Colon	27082112	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks.
transcription factor target	hsa-mir-17	Carcinoma, Colon	27082112	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks.
transcription factor target	hsa-mir-181b	Carcinoma, Colon	27082112	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks.
transcription factor target	hsa-mir-200	Carcinoma, Colon	25371200	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells.
transcription factor target	hsa-mir-203	Carcinoma, Colon	24145190	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression.
transcription factor target	hsa-mir-21	Carcinoma, Colon	27082112	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks.
transcription factor target	hsa-mir-301b	Carcinoma, Colon	27082112	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The infinity software that we have developed is a powerful tool to underscore new TF/miRNA regulatory networks.
transcription factor target	hsa-mir-146b	Carcinoma, Esophageal	24589738	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Transcriptional regulation of miR-146b by C/EBPβ LAP2 in esophageal cancer cells.
transcription factor target	hsa-mir-31	Carcinoma, Esophageal	25644061	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
transcription factor target	hsa-mir-23b	Carcinoma, Gastric	26041881	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis.
transcription factor target	hsa-let-7a-1	Carcinoma, Hepatocellular	21903590	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box.
transcription factor target	hsa-let-7d	Carcinoma, Hepatocellular	21903590	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box.
transcription factor target	hsa-let-7f-1	Carcinoma, Hepatocellular	21903590	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	C-myc Inhibits the Transcription of the MicroRNA Cluster MC-let-7a-1~let-7d via a Non-Canonical E-box.
transcription factor target	hsa-mir-101	Carcinoma, Hepatocellular	26718325	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings show that elevated EZH2 contributes to miR-101 deregulation in HCC and highlight the coordinated role of miR-101 and EZH2 in hepatocarcinogenesis.
transcription factor target	hsa-mir-101-1	Carcinoma, Hepatocellular	26718325	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	These findings show that elevated EZH2 contributes to miR-101 deregulation in HCC and highlight the coordinated role of miR-101 and EZH2 in hepatocarcinogenesis.
transcription factor target	hsa-mir-122	Carcinoma, Hepatocellular	21654638	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma.
transcription factor target	hsa-mir-122	Carcinoma, Hepatocellular	24038073	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2.
transcription factor target	hsa-mir-127	Carcinoma, Hepatocellular	23762330	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A Feedback Inhibition between miRNA-127 and TGFbeta/c-Jun Cascade in HCC Cell Migration via MMP13.
transcription factor target	hsa-mir-134	Carcinoma, Hepatocellular	23775631	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatocyte nuclear factor-4α reverses malignancy of hepatocellular carcinoma through regulating mir-134 in the DLK1-DIO3 region.
transcription factor target	hsa-mir-135a-1	Carcinoma, Hepatocellular	21888875	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-135a Contributes to the Development of Portal Vein Tumor Thrombus by Promoting Metastasis in Hepatocellular Carcinoma.
transcription factor target	hsa-mir-135a-2	Carcinoma, Hepatocellular	21888875	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-135a Contributes to the Development of Portal Vein Tumor Thrombus by Promoting Metastasis in Hepatocellular Carcinoma.
transcription factor target	hsa-mir-181a-2	Carcinoma, Hepatocellular	21711587	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma.
transcription factor target	hsa-mir-181b-1	Carcinoma, Hepatocellular	21711587	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma.
transcription factor target	hsa-mir-181b-2	Carcinoma, Hepatocellular	21711587	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma.
transcription factor target	hsa-mir-181c	Carcinoma, Hepatocellular	21711587	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma.
transcription factor target	hsa-mir-181d	Carcinoma, Hepatocellular	21711587	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma.
transcription factor target	hsa-mir-182	Carcinoma, Hepatocellular	25813403	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion.
transcription factor target	hsa-mir-183	Carcinoma, Hepatocellular	25813403	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion.
transcription factor target	hsa-mir-195	Carcinoma, Hepatocellular	27179445	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells.
transcription factor target	hsa-mir-199a-1	Carcinoma, Hepatocellular	22359598	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer.
transcription factor target	hsa-mir-199a-2	Carcinoma, Hepatocellular	22359598	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer.
transcription factor target	hsa-mir-21	Carcinoma, Hepatocellular	25087183	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression.
transcription factor target	hsa-mir-214	Carcinoma, Hepatocellular	22359598	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	ER Stress Negatively Modulates the Expression of the miR-199a/214 Cluster to Regulates Tumor Survival and Progression in Human Hepatocellular Cancer.
transcription factor target	hsa-mir-224	Carcinoma, Hepatocellular	23988648	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells.
transcription factor target	hsa-mir-224	Carcinoma, Hepatocellular	22178270	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Transcriptional regulation of mir-224 upregulated in human HCCs by NFkB inflammatory pathways.
transcription factor target	hsa-mir-338	Carcinoma, Hepatocellular	26082033	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma.
transcription factor target	hsa-mir-370	Carcinoma, Hepatocellular	23728999	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Perturbation of miR-370-LIN28A-NF-κB regulatory circuit contributes to the development of hepatocellular carcinoma.
transcription factor target	hsa-mir-509	Carcinoma, Hepatocellular	24882622	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells.
transcription factor target	hsa-mir-615	Carcinoma, Hepatocellular	25987019	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	PU.1 Is Identified as a Novel Metastasis Suppressor in Hepatocellular Carcinoma Regulating the miR-615-5p/IGF2 Axis.
transcription factor target	hsa-mir-96	Carcinoma, Hepatocellular	25813403	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion.
transcription factor target	hsa-mir-124	Carcinoma, Lung, Non-Small-Cell	26818357			C34.90	D002289		HP:0030358	The feedback loop between miR-124 and TGF-β pathway plays a significant role in non-small cell lung cancer metastasis.
transcription factor target	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	25799148			C34.90	D002289		HP:0030358	Modulation of the NF-κB/miR-21/PTEN pathway in NSCLC showed that inhibition of this pathway may increase cisplatin sensitivity.
transcription factor target	hsa-mir-1	Carcinoma, Nasopharyngeal	25237831	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma.
transcription factor target	hsa-mir-184	Carcinoma, Nasopharyngeal	24157866	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma.
transcription factor target	hsa-mir-204	Carcinoma, Nasopharyngeal	24613926	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Down-regulation of miRNA-204 by LMP-1 enhances CDC42 activity and facilitates invasion of EBV-associated nasopharyngeal carcinoma cells.
transcription factor target	hsa-mir-31	Carcinoma, Oral	25229239	gastrointestinal system disease	DOID:0050610					EGF up-regulates miR-31 through the C/EBPβ signal cascade in oral carcinoma.
transcription factor target	hsa-mir-145	Carcinoma, Renal Cell	26304926	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.
transcription factor target	hsa-mir-30d	Carcinoma, Renal Cell	23416459	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma
transcription factor target	hsa-mir-23a	Cardiomyopathy, Hypertrophic	19574461	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy
transcription factor target	hsa-mir-17	Cardiovascular Diseases [unspecific]	24378993				D002318			Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis.
transcription factor target	hsa-mir-18	Cardiovascular Diseases [unspecific]	24378993				D002318			Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis.
transcription factor target	hsa-mir-19a	Cardiovascular Diseases [unspecific]	24378993				D002318			Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis.
transcription factor target	hsa-mir-19b-1	Cardiovascular Diseases [unspecific]	24378993				D002318			Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis.
transcription factor target	hsa-mir-20a	Cardiovascular Diseases [unspecific]	24378993				D002318			Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis.
transcription factor target	hsa-mir-92-1	Cardiovascular Diseases [unspecific]	24378993				D002318			Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis.
transcription factor target	hsa-mir-373	Cholangiocarcinoma	22876037	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma.
transcription factor target	hsa-mir-10b	Colon Neoplasms	22286762			D12.6	D003110		HP:0100273	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-17	Colon Neoplasms	22286762			D12.6	D003110		HP:0100273	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-192	Colon Neoplasms	19088023			D12.6	D003110		HP:0100273	miR-192: the effect of miR-192 on cellular proliferation is mainly p53 dependent
transcription factor target	hsa-mir-21	Colon Neoplasms	22286762			D12.6	D003110		HP:0100273	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-9-1	Colon Neoplasms	22286762			D12.6	D003110		HP:0100273	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-9-1	Colon Neoplasms	23045246			D12.6	D003110		HP:0100273	Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9
transcription factor target	hsa-mir-9-2	Colon Neoplasms	22286762			D12.6	D003110		HP:0100273	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-9-2	Colon Neoplasms	23045246			D12.6	D003110		HP:0100273	Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9
transcription factor target	hsa-mir-9-3	Colon Neoplasms	22286762			D12.6	D003110		HP:0100273	Sulindac inhibits tumor cell invasion by suppressing NF-kB-mediated transcription of microRNAs.
transcription factor target	hsa-mir-124	Colorectal Carcinoma	24619225	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The pro-apoptotic role of the regulatory feedback loop between miR-124 and PKM1/HNF4α in colorectal cancer cells.
transcription factor target	hsa-mir-145	Colorectal Carcinoma	24631504	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Peroxisome proliferator-activated receptor γ-mediated induction of microRNA-145 opposes tumor phenotype in colorectal cancer.
transcription factor target	hsa-mir-15a	Colorectal Carcinoma	24285725	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer.
transcription factor target	hsa-mir-16-1	Colorectal Carcinoma	24285725	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer.
transcription factor target	hsa-mir-320a	Colorectal Carcinoma	24454819	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		E2A predicts prognosis of colorectal cancer patients and regulates cancer cell growth by targeting miR-320a.
transcription factor target	hsa-mir-34a	Colorectal Carcinoma	24642471	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.
transcription factor target	hsa-mir-371	Colorectal Carcinoma	25868860	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer.
transcription factor target	hsa-mir-146a	Colorectal Carcinoma	24561623	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer  stem cells.
transcription factor target	hsa-mir-200a	Colorectal Carcinoma	22286765	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression.
transcription factor target	hsa-mir-200b	Colorectal Carcinoma	22286765	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression.
transcription factor target	hsa-mir-200c	Colorectal Carcinoma	22286765	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		SIX1-induced CDH1 repression and EMT in CRC cells were correlated at least in part with posttranscriptional ZEB1 activation and miR-200-family transcriptional repression.
transcription factor target	hsa-mir-204	Diabetes Mellitus	23975026	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The newly identified TXNIP-miR-204-MAFA-insulin pathway may contribute to diabetes progression and provides new insight into TXNIP function and microRNA biology in health and disease.
transcription factor target	hsa-mir-145	Diabetes Mellitus, Type 2	24548410	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-145 plays a role in the development of resistin-induced insulin resistance via the p65 pathway.
transcription factor target	hsa-mir-29	Diabetes Mellitus, Type 2	24722248	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes.
transcription factor target	hsa-mir-34a	Disease of Metabolism	20185821	disease of metabolism	DOID:0014667	E88.9	D008659			Our study demonstrates an unexpected role of the FXR/SHP pathway in controlling SIRT1 levels via miR-34a inhibition and that elevated miR-34a levels in obese mice contribute to decreased SIRT1 levels
transcription factor target	hsa-mir-22	Emphysema	26437241			J43	D004646	130700	HP:0002097	Thus, miR-22 is a critical regulator of both emphysema and T(H)17 responses.
transcription factor target	hsa-mir-34a	Esophageal Neoplasms	22292433			C15.9	D004938	133239	HP:0100751	Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells.
transcription factor target	hsa-mir-720	Esophageal Neoplasms	23154181			C15.9	D004938	133239	HP:0100751	SnoN/SKIL modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells
transcription factor target	hsa-mir-139	Gastric Neoplasms	25499265	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Given that miR-139 and Jun are deregulated in many cancers, our findings here might have broader implication in other types  of human cancers
transcription factor target	hsa-mir-183	Gastric Neoplasms	24335145	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells.
transcription factor target	hsa-mir-196b	Gastric Neoplasms	22298639	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-196b expression was significantly repressed by ETS2 during gastric cancer oncogenesis.
transcription factor target	hsa-mir-199a	Gastric Neoplasms	25080937	disease of cellular proliferation	DOID:10534	C16	D013274	137215		SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR-199a-5p expression in human gastric cancer.
transcription factor target	hsa-mir-27a	Gastric Neoplasms	26292288	disease of cellular proliferation	DOID:10534	C16	D013274	137215		HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a.
transcription factor target	hsa-mir-365	Gastric Neoplasms	24149576	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency.
transcription factor target	hsa-mir-425	Gastric Neoplasms	25154996	disease of cellular proliferation	DOID:10534	C16	D013274	137215		There is a critical role for NF-kappa B-dependent up-regulation of miR-425. And it represents a new pathway for the repression of phosphatase and tensin homolog activation and the promotion of cell survival upon IL-1β induction.
transcription factor target	hsa-mir-96	Gastric Neoplasms	24335145	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells.
transcription factor target	hsa-mir-23a	Gastrointestinal Neoplasms	23929433			D37.9	D005770			miR-23a inhibits E-cadherin expression and is regulated by AP-1 and NFAT4 complex during Fas-induced EMT in gastrointestinal cancer.
transcription factor target	hsa-mir-29b	Glaucoma	26191170	nervous system disease	DOID:1686	H40	D005901	137750		This study suggests that TGF-β2 has a time-effect relationship with Tenon's capsule fibroblasts proliferation from glaucoma patients, and it stimulates Tenon's capsule fibroblast proliferation via suppression of miR-29b expression regulated by Nrf2.
transcription factor target	hsa-mir-134	Glioblastoma	24440911				D005909		HP:0100843	Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS,STAT5B, and glioblastoma.
transcription factor target	hsa-mir-218	Glioblastoma	25943352				D005909		HP:0100843	Feedback circuitry between miR-218 repression and RTK activation in glioblastoma.
transcription factor target	hsa-mir-221	Glioblastoma	21245048				D005909		HP:0100843	NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells.
transcription factor target	hsa-mir-221	Glioblastoma	24295494				D005909		HP:0100843	miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status.
transcription factor target	hsa-mir-222	Glioblastoma	24295494				D005909		HP:0100843	miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status.
transcription factor target	hsa-mir-26a	Glioblastoma	24140063				D005909		HP:0100843	C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells.
transcription factor target	hsa-mir-425	Glioblastoma	18765229				D005909		HP:0100843	up-regulation in the CD133-cells
transcription factor target	hsa-mir-451	Glioblastoma	25937278				D005909		HP:0100843	These findings uncover miR-451 as a major effector of glucose-regulated AMPK signaling, allowing tumor cell adaptation to variations in nutrient availability in the tumor microenvironment.
transcription factor target	hsa-mir-451a	Glioblastoma	18765229				D005909		HP:0100843	miR-451: MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells
transcription factor target	hsa-mir-486	Glioblastoma	18765229				D005909		HP:0100843	up-regulation in the CD133-cells
transcription factor target	hsa-mir-128	Glioma	24959930	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	An axis involving SNAI1, microRNA-128 and SP1 modulates glioma progression.
transcription factor target	hsa-mir-128a	Glioma	26324126	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	IDH1R132H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
transcription factor target	hsa-mir-21	Glioma	25305446	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Krüppel-like factor 9 inhibits glioma cell proliferation and tumorigenicity via downregulation of miR-21.
transcription factor target	hsa-mir-9-1	Glioma	23185366	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells
transcription factor target	hsa-mir-9-2	Glioma	23185366	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells
transcription factor target	hsa-mir-302a	Head And Neck Neoplasms	22847005	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
transcription factor target	hsa-mir-302b	Head And Neck Neoplasms	22847005	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
transcription factor target	hsa-mir-302c	Head And Neck Neoplasms	22847005	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
transcription factor target	hsa-mir-302d	Head And Neck Neoplasms	22847005	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
transcription factor target	hsa-mir-302e	Head And Neck Neoplasms	22847005	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
transcription factor target	hsa-mir-302f	Head And Neck Neoplasms	22847005	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
transcription factor target	hsa-mir-199b	Heart Failure	21102440			I50	D006331		HP:0001635	miR-199b is a direct calcineurin/NFAT target gene that increases in expression in mouse and human heart failure, and targets the nuclear NFAT kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a (Dyrk1a)
transcription factor target	hsa-mir-21	Heart Failure	20546595			I50	D006331		HP:0001635	We show that the transcription factor p53 piggy-backs onto NF-kappaB/RELA and utilizes the kappaB-motif at a cis-regulatory region to control mir-21 expression.
transcription factor target	hsa-mir-30	Heart Failure	25950484			I50	D006331		HP:0001635	we describe that DOX causes acute and sustained miR-30 downregulation in cardiomyocytes via GATA-6. miR-30 overexpression protects cardiac cells from DOX-induced apoptosis, and its maintenance represents a potential cardioprotective and anti-tumorigenic strategy for anthracyclines.
transcription factor target	hsa-mir-203	Helicobacter pylori Infection	25689935			B96.81	D016480	600263	HP:0005202	Our results demonstrated that H. pylori infection induced hepatic insulin resistance by the c-Jun/miR-203/SOCS3 signaling pathway and provide possible implications with regard to resolving insulin resistance.
transcription factor target	hsa-mir-125b-1	Hematologic Neoplasms	21903586	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Mir-125b, a target of CDX2, regulates cell differentiation through the repression of the core binding factor in hematopoietic malignancies.
transcription factor target	hsa-mir-125b-2	Hematologic Neoplasms	21903586	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	Mir-125b, a target of CDX2, regulates cell differentiation through the repression of the core binding factor in hematopoietic malignancies.
transcription factor target	hsa-mir-181c	Hepatitis C Virus Infection	24789793	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression.
transcription factor target	hsa-mir-29	Human Immunodeficiency Virus Infection	26108174			B20	D015658	609423		IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection.
transcription factor target	hsa-mir-210	Idiopathic Pulmonary Fibrosis	24951777	respiratory system disease	DOID:0050156	J84.112	D054990	178500		miR-210 promotes IPF fibroblast proliferation in response to hypoxia.
transcription factor target	hsa-mir-26a	Idiopathic Pulmonary Fibrosis	24594795	respiratory system disease	DOID:0050156	J84.112	D054990	178500		The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis.
transcription factor target	hsa-mir-146a	Inflammation	26855180				D007249			Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation.
transcription factor target	hsa-mir-155	Inflammation	22170100				D007249			Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*.
transcription factor target	hsa-mir-155	Inflammation	26855180				D007249			Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation.
transcription factor target	hsa-mir-29c	Influenza	22850539	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Induction of the cellular microRNA-29c by influenza virus contributes to virus-mediated apoptosis through repression of antiapoptotic factors BCL2L2.
transcription factor target	hsa-mir-210	Ischemia	20308562	cardiovascular system disease	DOID:326		D007511	601367		demonstrated a key role of miR-210 in limiting keratinocyte proliferation
transcription factor target	hsa-mir-146a	Leukemia	26045293			C95	D007938	613065	HP:0001909	Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy.
transcription factor target	hsa-mir-223	Leukemia, Lymphoblastic, Acute, T-Cell	24727676	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia.
transcription factor target	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	21296997	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia.
transcription factor target	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	23750211	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Signal Transducer and Activator of Transcription-3 Induces MicroRNA-155 Expression in Chronic Lymphocytic Leukemia.
transcription factor target	hsa-mir-221	Leukemia, Lymphocytic, Chronic, B-Cell	20203269	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-221:miR-221/222 and p27 may represent a regulatory loop that helps maintaining CLL cells in a resting condition
transcription factor target	hsa-mir-222	Leukemia, Lymphocytic, Chronic, B-Cell	20203269	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-222:miR-221/222 and p27 may represent a regulatory loop that helps maintaining CLL cells in a resting condition
transcription factor target	hsa-mir-138-1	Leukemia, Myeloid	23208504	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia
transcription factor target	hsa-mir-138-2	Leukemia, Myeloid	23208504	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia
transcription factor target	hsa-mir-23a	Leukemia, Myeloid	20399246	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	the 23a cluster is the first downstream miRNA target implicated in regulating the development of myeloid versus lymphoid cells.
transcription factor target	hsa-mir-125b	Leukemia, Myeloid, Acute	25982911	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα.
transcription factor target	hsa-mir-125b-1	Leukemia, Myeloid, Acute	25323587	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival.
transcription factor target	hsa-mir-143	Leukemia, Myeloid, Acute	22093444	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-143 and miR-145 expression is significantly repressed in primary AML patient samples as compared to neutrophils of healthy donors. Further analysis revealed impaired neutrophil differentiation of APL cells upon inhibition of miR-145 expression. Lastly, we identified p73 as transcriptional regulator of miR-143/145 during neutrophil differentiation of APL cells. Our data suggest that low miR-145 levels in APL, possibly due to aberrant expression of p73 transcription factors, contribute to the differentiation block seen in this disease.
transcription factor target	hsa-mir-145	Leukemia, Myeloid, Acute	22093444	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-143 and miR-145 expression is significantly repressed in primary AML patient samples as compared to neutrophils of healthy donors. Further analysis revealed impaired neutrophil differentiation of APL cells upon inhibition of miR-145 expression. Lastly, we identified p73 as transcriptional regulator of miR-143/145 during neutrophil differentiation of APL cells. Our data suggest that low miR-145 levels in APL, possibly due to aberrant expression of p73 transcription factors, contribute to the differentiation block seen in this disease.
transcription factor target	hsa-mir-155	Leukemia, Myeloid, Acute	25092123	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	LIFRα-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK/STAT pathway.
transcription factor target	hsa-mir-17	Leukemia, Myeloid, Acute	25612891	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	the extent of KIT-induced proliferation itself can modulate myeloid differentiation of cells with wild type RUNX1 function.
transcription factor target	hsa-mir-223	Leukemia, Myeloid, Acute	20018373	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-223:miR-223 suppression in AML is caused by impaired miR-223 upstream factors
transcription factor target	hsa-mir-29b-1	Leukemia, Myeloid, Acute	25323587	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival.
transcription factor target	hsa-mir-30c	Leukemia, Myeloid, Acute	23974200	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.
transcription factor target	hsa-mir-17	Leukemia-Lymphoma, Adult T-Cell	19148830			C91.51	D015459		HP:0005517	miR-17: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia
transcription factor target	hsa-mir-18a	Leukemia-Lymphoma, Adult T-Cell	19148830			C91.51	D015459		HP:0005517	miR-18a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia
transcription factor target	hsa-mir-19a	Leukemia-Lymphoma, Adult T-Cell	19148830			C91.51	D015459		HP:0005517	miR-19a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia
transcription factor target	hsa-mir-19b-1	Leukemia-Lymphoma, Adult T-Cell	19148830			C91.51	D015459		HP:0005517	miR-19b: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia
transcription factor target	hsa-mir-19b-2	Leukemia-Lymphoma, Adult T-Cell	19148830			C91.51	D015459		HP:0005517	miR-19b: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia
transcription factor target	hsa-mir-20a	Leukemia-Lymphoma, Adult T-Cell	19148830			C91.51	D015459		HP:0005517	miR-20a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia
transcription factor target	hsa-mir-451a	Leukemia-Lymphoma, Adult T-Cell	21464222			C91.51	D015459		HP:0005517	Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL.
transcription factor target	hsa-mir-92a-1	Leukemia-Lymphoma, Adult T-Cell	19148830			C91.51	D015459		HP:0005517	miR-92a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia
transcription factor target	hsa-mir-92a-2	Leukemia-Lymphoma, Adult T-Cell	19148830			C91.51	D015459		HP:0005517	miR-92a: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia
transcription factor target	hsa-mir-214	Liver Fibrosis	26229009			K74	D008103			These findings reveal a unique function for cellular or exosomal Twist1 in CCN2-dependent fibrogenesis.
transcription factor target	hsa-mir-21	Liver Neoplasms	23355454	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	microRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation
transcription factor target	hsa-mir-140	Lung Fibrosis	26300493	respiratory system disease	DOID:3770	J84.10	D011658	178500		Using these models we showed that IR induces overexpression of Brca1, Nrf2 and miR-140 in lung tissue after irradiation. These data reveal a novel radioprotective mechanism in which IR promotes NRF2 nuclear translocation and subsequent activation of miR-140 transcription in HLFs.
transcription factor target	hsa-let-7a-2	Lung Neoplasms	21365266	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	9-cis-RA, all-trans-RA,lithium chloride and CEBP might play important regulatory roles in let-7a2 gene expression in A549 cells
transcription factor target	hsa-mir-1-1	Lung Neoplasms	18818206	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-1: Down-regulation
transcription factor target	hsa-mir-1-2	Lung Neoplasms	18818206	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-1: Down-regulation
transcription factor target	hsa-mir-200a	Lung Neoplasms	21403400	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice.
transcription factor target	hsa-mir-200b	Lung Neoplasms	21403400	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice.
transcription factor target	hsa-mir-200c	Lung Neoplasms	21403400	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice.
transcription factor target	hsa-mir-222	Lung Neoplasms	21656127	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells.
transcription factor target	hsa-mir-224	Lung Neoplasms	26187928	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer.
transcription factor target	hsa-mir-29b-1	Lung Neoplasms	22249264	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.
transcription factor target	hsa-mir-29b-2	Lung Neoplasms	22249264	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.
transcription factor target	hsa-mir-135b	Lymphoma	22042699	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
transcription factor target	hsa-mir-204	Lymphoma	26350953	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	This study demonstrated that HIF-1α-miR-204-BCL-2 pathway contributed to apoptosis of neuronal cells induced by hypoxia, which could potentially be exploited to prevent spinal cord ischemia-reperfusion injury.
transcription factor target	hsa-mir-22	Lymphoma	26244872	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
transcription factor target	hsa-mir-26a-1	Lymphoma	19197161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-26a: repressed by MYC
transcription factor target	hsa-mir-26a-2	Lymphoma	19197161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-26a: repressed by MYC
transcription factor target	hsa-mir-494	Lymphoma	25907832	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The PTEN-AKT-mTOR/RICTOR Pathway in Nasal Natural Killer Cell Lymphoma Is Activated by miR-494-3p via PTEN But Inhibited by miR-142-3p via RICTOR.
transcription factor target	hsa-mir-124	Lymphoma, B-Cell	25915824	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas.
transcription factor target	hsa-mir-146a	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-150	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-15a	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-195	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-22	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-26b	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-28	Lymphoma, B-Cell	24843176	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.
transcription factor target	hsa-mir-29a	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-29c	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-30e	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-34a	Lymphoma, B-Cell	18066065	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	c-Myc repressed this miRNA
transcription factor target	hsa-mir-150	Lymphoma, Large-Cell, Anaplastic	26258416	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	our results suggest that hypomethylating drugs,alone or in combination with other agents, may benefit ALK(+) patients harboring tumors resistant to crizotinib and other anti-ALK tyrosine kinase inhibitors (TKIs). Moreover, these results support further work on miR-150 in these and other ALK(+) malignancies.
transcription factor target	hsa-mir-548	Lymphoma, Non-Hodgkin	24216476	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
transcription factor target	hsa-mir-125b-1	Lymphoma, T-Cell	23527180	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas
transcription factor target	hsa-mir-125b-2	Lymphoma, T-Cell	23527180	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas
transcription factor target	hsa-mir-17	Medulloblastoma	19351822	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-17: the most highly up-regulated miRNAs in medulloblastoma
transcription factor target	hsa-mir-18a	Medulloblastoma	19351822	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-18a: the most highly up-regulated miRNAs in medulloblastoma
transcription factor target	hsa-mir-19a	Medulloblastoma	19351822	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-19a: the most highly up-regulated miRNAs in medulloblastoma
transcription factor target	hsa-mir-19b-1	Medulloblastoma	19351822	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-19b: the most highly up-regulated miRNAs in medulloblastoma
transcription factor target	hsa-mir-19b-2	Medulloblastoma	19351822	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-19b: the most highly up-regulated miRNAs in medulloblastoma
transcription factor target	hsa-mir-20a	Medulloblastoma	19351822	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-20a: the most highly up-regulated miRNAs in medulloblastoma
transcription factor target	hsa-mir-92a-1	Medulloblastoma	19351822	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-92a: the most highly up-regulated miRNAs in medulloblastoma
transcription factor target	hsa-mir-92a-2	Medulloblastoma	19351822	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	miR-92a: the most highly up-regulated miRNAs in medulloblastoma
transcription factor target	hsa-mir-210	Melanoma	24767210	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A.
transcription factor target	hsa-mir-218	Melanoma	24767210	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A.
transcription factor target	hsa-mir-221	Melanoma	18417445	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	suppressing
transcription factor target	hsa-mir-221	Melanoma	23400877	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway
transcription factor target	hsa-mir-222	Melanoma	18417445	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	suppressing
transcription factor target	hsa-mir-222	Melanoma	23400877	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway
transcription factor target	hsa-mir-224	Melanoma	25341426	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation.
transcription factor target	hsa-mir-224	Melanoma	24767210	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A.
transcription factor target	hsa-mir-452	Melanoma	25341426	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation.
transcription factor target	hsa-mir-452	Melanoma	24767210	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A.
transcription factor target	hsa-mir-638	Melanoma	25650662	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy.
transcription factor target	hsa-mir-9	MELAS Syndrome	25149473	musculoskeletal system disease	DOID:3687	E88.41	D017241	540000		The ROS-sensitive microRNA-9/9* controls the expression of mitochondrial tRNA-modifying enzymes and is involved in the molecular mechanism of MELAS syndrome.
transcription factor target	hsa-mir-23b	Multiple Myeloma	26771806	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.
transcription factor target	hsa-mir-29b-1	Multiple Myeloma	23190608	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
transcription factor target	hsa-mir-29b-2	Multiple Myeloma	23190608	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
transcription factor target	hsa-mir-206	Muscle Diseases [unspecific]	26272918			M63.80	D009135			MyoD transcription factor induces myogenesis by inhibiting Twist-1 through miR-206.
transcription factor target	hsa-mir-199a-1	Muscular Dystrophy, Duchenne	23764775	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation.
transcription factor target	hsa-mir-199a-2	Muscular Dystrophy, Duchenne	23764775	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation.
transcription factor target	hsa-mir-132	Myocardial Infarction	21868695	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Transplantation of Human Pericyte Progenitor Cells Improves the Repair of Infarcted Heart Through Activation of an Angiogenic Program Involving Micro-RNA-132.
transcription factor target	hsa-mir-21	Myocardial Ischemic-Reperfusion Injury	24983504				D015428			A feedback regulatory loop between HIF-1α and miR-21 in response to hypoxia in cardiomyocytes.
transcription factor target	hsa-mir-10b	Nasopharyngeal Neoplasms	20732742			C11.9	D009303	607107	HP:0100630	MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells
transcription factor target	hsa-let-7a-1	Neoplasms [unspecific]	20404092			C80.1	D009369			let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells
transcription factor target	hsa-let-7a-2	Neoplasms [unspecific]	20404092			C80.1	D009369			let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells
transcription factor target	hsa-let-7a-3	Neoplasms [unspecific]	20404092			C80.1	D009369			let-7a:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells
transcription factor target	hsa-let-7i	Neoplasms [unspecific]	20404092			C80.1	D009369			let-7i:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells
transcription factor target	hsa-mir-1	Neoplasms [unspecific]	23921124			C80.1	D009369			Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis.
transcription factor target	hsa-mir-100	Neoplasms [unspecific]	24586203			C80.1	D009369			miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion.
transcription factor target	hsa-mir-106b	Neoplasms [unspecific]	20404092			C80.1	D009369			mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells
transcription factor target	hsa-mir-130a	Neoplasms [unspecific]	26272168			C80.1	D009369			These findings reveal an evolutionarily conserved positive feedback mechanism underlying robustness of the Hippo pathway in size control and tumorigenesis.
transcription factor target	hsa-mir-143	Neoplasms [unspecific]	23932921			C80.1	D009369			DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.
transcription factor target	hsa-mir-145	Neoplasms [unspecific]	19202062			C80.1	D009369			miR-145: putative tumor suppressor, miR-145 provides a direct link between p53 and c-Myc in this gene regulatory network
transcription factor target	hsa-mir-145	Neoplasms [unspecific]	23932921			C80.1	D009369			DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.
transcription factor target	hsa-mir-148a	Neoplasms [unspecific]	25703326			C80.1	D009369			Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression.
transcription factor target	hsa-mir-152	Neoplasms [unspecific]	25703326			C80.1	D009369			Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression.
transcription factor target	hsa-mir-155	Neoplasms [unspecific]	26156524			C80.1	D009369			the losing equilibrium of the regulatory feedback loop between STAT1 and miR-155-5p influencing tumorigenesis.
transcription factor target	hsa-mir-15b	Neoplasms [unspecific]	20404092			C80.1	D009369			mir-15b-16-2:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells
transcription factor target	hsa-mir-183	Neoplasms [unspecific]	24277930			C80.1	D009369			A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster.
transcription factor target	hsa-mir-18a	Neoplasms [unspecific]	19706389			C80.1	D009369			significantly upregulated, downregulate Eralpha
transcription factor target	hsa-mir-200a	Neoplasms [unspecific]	23759590			C80.1	D009369			KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
transcription factor target	hsa-mir-200b	Neoplasms [unspecific]	23759590			C80.1	D009369			KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
transcription factor target	hsa-mir-200c	Neoplasms [unspecific]	23759590			C80.1	D009369			KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
transcription factor target	hsa-mir-206	Neoplasms [unspecific]	23921124			C80.1	D009369			Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis.
transcription factor target	hsa-mir-21	Neoplasms [unspecific]	18850008			C80.1	D009369			miR-21: oncomir, An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation
transcription factor target	hsa-mir-25	Neoplasms [unspecific]	20404092			C80.1	D009369			mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells
transcription factor target	hsa-mir-34a	Neoplasms [unspecific]	20185821			C80.1	D009369			Our study demonstrates an unexpected role of the FXR/SHP pathway in controlling SIRT1 levels via miR-34a inhibition and that elevated miR-34a levels in obese mice contribute to decreased SIRT1 levels
transcription factor target	hsa-mir-370	Neoplasms [unspecific]	23333300			C80.1	D009369			Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor
transcription factor target	hsa-mir-519c	Neoplasms [unspecific]	20233879			C80.1	D009369			MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis
transcription factor target	hsa-mir-93	Neoplasms [unspecific]	20404092			C80.1	D009369			mir-106b-25:let-7a-d, let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and E2F3 during G(1)/S and are repressed in E2F1/3-null cells
transcription factor target	hsa-mir-148a	Obesity	26001136	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	The results suggest that miR-148a is a biomarker of obesity in human subjects and mouse model, which represents a CREB-modulated miRNA that acts to repress Wnt1, thereby promoting adipocyte differentiation.
transcription factor target	hsa-mir-210	Obesity	25833255	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Our data suggest that the inflammatory intrauterine environment associated with maternal obesity induces an NFκB1-mediated increase in miR-210 in a fetal sex-dependent manner, leading to inhibition of mitochondrial respiration and placental dysfunction in the placentas of female fetuses.
transcription factor target	hsa-mir-34a	Obesity	26036628	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	These data provide first in vitro and in vivo evidence for the leptin-antagonist potential of honokiol (HNK) revealing a crosstalk between HNK and miR34a and Wnt1-MTA1-β-catenin axis.
transcription factor target	hsa-mir-146a	Osteoarthritis	19333945	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miR-146a: miR-146 is intensely expressed in low-grade OA cartilage and that its expression is induced by stimulation of IL-1beta
transcription factor target	hsa-mir-125b-1	Osteosarcoma	22093834	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3.
transcription factor target	hsa-mir-125b-2	Osteosarcoma	22093834	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3.
transcription factor target	hsa-mir-125b	Ovarian Neoplasms	25944662	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b.
transcription factor target	hsa-mir-155	Pancreatic Neoplasms	20871480	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-155:Human SMG-1 is Involved in Gemcitabine-Induced Primary microRNA-155/BIC Up-Regulation in Human Pancreatic Cancer PANC-1 Cells
transcription factor target	hsa-mir-191	Pancreatic Neoplasms	25119596	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer.
transcription factor target	hsa-mir-198	Pancreatic Neoplasms	23989979	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-198 acts as a central tumor suppressor and modulates the molecular makeup of a critical interactome in pancreatic cancer, indicating a potential prognostic marker signature and the therapeutic potential of attacking this tumorigenic network through a central vantage point.
transcription factor target	hsa-mir-19a	Pancreatic Neoplasms	26041879	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer.
transcription factor target	hsa-mir-373	Pancreatic Neoplasms	23857777	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth.
transcription factor target	hsa-mir-1	Prostate Neoplasms	26071255	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1.
transcription factor target	hsa-mir-106b	Prostate Neoplasms	20388916	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer
transcription factor target	hsa-mir-125b-1	Prostate Neoplasms	23503464	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells
transcription factor target	hsa-mir-125b-2	Prostate Neoplasms	23503464	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells
transcription factor target	hsa-mir-132	Prostate Neoplasms	22916239	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Luteolin Induces microRNA-132 Expression and Modulates Neurite Outgrowth in PC12 Cells.
transcription factor target	hsa-mir-190a	Prostate Neoplasms	26314494	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Taken together, our findings identified a biochemical and functional link between miR-190a with reduced expression in advanced prostate cancer, YB-1 and AR signaling in prostate cancer.
transcription factor target	hsa-mir-200c	Prostate Neoplasms	24186205	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c.
transcription factor target	hsa-mir-205	Prostate Neoplasms	23924028	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The evidence that miR-205 replacement in PCa cells is able not only to prevent but also to revert the oxidative/pro-inflammatory axis leading to EMT induced by CAFs sets the rationale for developing miRNA-based approaches to prevent and treat metastatic disease.
transcription factor target	hsa-mir-21	Prostate Neoplasms	19738047	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	hsa-mir-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth
transcription factor target	hsa-mir-22	Prostate Neoplasms	20388916	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer
transcription factor target	hsa-mir-221	Prostate Neoplasms	21245048	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells.
transcription factor target	hsa-mir-222	Prostate Neoplasms	19351827	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-222: Overexpression
transcription factor target	hsa-mir-25	Prostate Neoplasms	20388916	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer
transcription factor target	hsa-mir-31	Prostate Neoplasms	25341040	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
transcription factor target	hsa-mir-93	Prostate Neoplasms	20388916	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer
transcription factor target	hsa-mir-96	Prostate Neoplasms	25531317	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	a novel mechanism accounting for the TGFβ signaling and bone metastasis.
transcription factor target	hsa-mir-99a	Prostate Neoplasms	23503464	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells
transcription factor target	hsa-mir-19a	PTEN Hamartoma Tumor Tyndrome	18460397	syndrome	DOID:0080191	Q85.9	C566636			overexpressed
transcription factor target	hsa-mir-21	PTEN Hamartoma Tumor Tyndrome	18460397	syndrome	DOID:0080191	Q85.9	C566636			overexpressed
transcription factor target	hsa-mir-143	Pulmonary Hypertension	26311719	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	MiR-143-3p modulated both cellular and exosome-mediated responses in pulmonary vascular cells, whereas inhibition of miR-143-3p blocked experimental pulmonary hypertension. Taken together, these findings confirm an important role for the miR-143/145 cluster in PAH pathobiology.
transcription factor target	hsa-mir-648	Pulmonary Hypertension	25403488	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	These studies provide a novel link wherein PlGF-mediated downregulation of PAX5 attenuates miR-648 expression leading to increased ET-1 levels that are known to induce PHT in SCA.
transcription factor target	hsa-mir-192	Renal Fibrosis	20488955	urinary system disease	DOID:0050855	N26.9			HP:0030760	miR-192:miR-192 mediates TGF-beta/Smad3-driven renal fibrosis
transcription factor target	hsa-mir-29a	Rhabdomyosarcoma	18977326	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-29: NF-kappaB-YY1-miR-29 regulatory circuitry
transcription factor target	hsa-mir-195	Schizophrenia	20156358	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	EGR3 and hsa-miR-195 were core regulators
transcription factor target	hsa-mir-150	Scleroderma, Systemic	23159943	musculoskeletal system disease	DOID:418	M34	D012595	181750		miR-150 Down-Regulation Contributes to the Constitutive Type I Collagen Overexpression in Scleroderma Dermal Fibroblasts via the Induction of Integrin ж┿
transcription factor target	hsa-mir-214	Sickle Cell Disease	25876995			D57	D000755	603903		Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease.
transcription factor target	hsa-mir-182	Soft Tissue Sarcoma	26234681			C49.9	D012509		HP:0030448	these results suggest that sarcoma metastasis can be partially controlled through Pax7/MyoD-dependent activation of miR-182 and provide insight into the role that myogenic transcription factors have in sarcoma progression.
transcription factor target	hsa-mir-203	Squamous Cell Carcinoma, Esophageal	24994936	disease of cellular proliferation	DOID:3748		C562729			EGF-induced C/EBPβ participates in EMT by decreasing the expression of miR-203 in esophageal squamous cell carcinoma cells.
transcription factor target	hsa-mir-593	Squamous Cell Carcinoma, Tongue	25912308	disease of cellular proliferation	DOID:0050865	C02.9				Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis.
transcription factor target	hsa-mir-199a	Testicular Germ Cell Tumor	24391856	disease of cellular proliferation	DOID:5557		C563236	273300		Molecular mechanisms of regulation and action of microRNA-199a in testicular germ cell tumor and glioblastomas.
transcription factor target	hsa-mir-205	Urinary Bladder Cancer	23239884	urinary system disease	DOID:11054	C67	D001749	109800		The p63 isoform deltaNp63ж┿inhibits epithelial-mesenchymal transition in human bladder cancer cells: Role of miR205
transcription factor target	hsa-mir-143	Wounds and Injuries [unspecific]	19720868				D014947			modulate cytoskeletal dynamics and responsiveness
transcription factor target	hsa-mir-145	Wounds and Injuries [unspecific]	19720868				D014947			modulate cytoskeletal dynamics and responsiveness